Number [C]N [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
and [C]a [C]n [C]d O 
their [C]t [C]h [C]e [C]i [C]r O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
to [C]t [C]o O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e O 
action [C]a [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
study [C]s [C]t [C]u [C]d [C]y O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
a [C]a O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
( [C]( O 
GR [C]G [C]R S-protein 
) [C]) O 
in [C]i [C]n O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
hypercholesterolemic [C]h [C]y [C]p [C]e [C]r [C]c [C]h [C]o [C]l [C]e [C]s [C]t [C]e [C]r [C]o [C]l [C]e [C]m [C]i [C]c O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
an [C]a [C]n O 
elevated [C]e [C]l [C]e [C]v [C]a [C]t [C]e [C]d O 
level [C]l [C]e [C]v [C]e [C]l O 
in [C]i [C]n O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
acute [C]a [C]c [C]u [C]t [C]e O 
myocardial [C]m [C]y [C]o [C]c [C]a [C]r [C]d [C]i [C]a [C]l O 
infarction [C]i [C]n [C]f [C]a [C]r [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

In [C]I [C]n O 
the [C]t [C]h [C]e O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
high [C]h [C]i [C]g [C]h O 
GR [C]G [C]R S-protein 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
, [C], O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
-thymidine [C]- [C]t [C]h [C]y [C]m [C]i [C]d [C]i [C]n [C]e O 
and [C]a [C]n [C]d O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
-acetate [C]- [C]a [C]c [C]e [C]t [C]a [C]t [C]e O 
incorporation [C]i [C]n [C]c [C]o [C]r [C]p [C]o [C]r [C]a [C]t [C]i [C]o [C]n O 
into [C]i [C]n [C]t [C]o O 
DNA [C]D [C]N [C]A O 
and [C]a [C]n [C]d O 
cholesterol [C]c [C]h [C]o [C]l [C]e [C]s [C]t [C]e [C]r [C]o [C]l O 
, [C], O 
respectively [C]r [C]e [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
, [C], O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
manner [C]m [C]a [C]n [C]n [C]e [C]r O 
as [C]a [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

On [C]O [C]n O 
the [C]t [C]h [C]e O 
other [C]o [C]t [C]h [C]e [C]r O 
hand [C]h [C]a [C]n [C]d O 
, [C], O 
a [C]a O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
GR [C]G [C]R S-protein 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
a [C]a O 
less [C]l [C]e [C]s [C]s O 
efficient [C]e [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
incorporation [C]i [C]n [C]c [C]o [C]r [C]p [C]o [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
labeled [C]l [C]a [C]b [C]e [C]l [C]e [C]d O 
compounds [C]c [C]o [C]m [C]p [C]o [C]u [C]n [C]d [C]s O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
to [C]t [C]o O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
changed [C]c [C]h [C]a [C]n [C]g [C]e [C]d O 
only [C]o [C]n [C]l [C]y O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
of [C]o [C]f O 
GR [C]G [C]R S-protein 
level [C]l [C]e [C]v [C]e [C]l O 
. [C]. O 

[ [C][ O 
1 [C]1 B-protein 
, [C], I-protein 
25-Dihydroxyvitamin [C]2 [C]5 [C]- [C]D [C]i [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]v [C]i [C]t [C]a [C]m [C]i [C]n I-protein 
D3 [C]D [C]3 I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
and [C]a [C]n [C]d O 
T- [C]T [C]- B-cell_type 
and [C]a [C]n [C]d I-cell_type 
B-lymphocyte [C]B [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e E-cell_type 
count [C]c [C]o [C]u [C]n [C]t O 
in [C]i [C]n O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
glomerulonephritis [C]g [C]l [C]o [C]m [C]e [C]r [C]u [C]l [C]o [C]n [C]e [C]p [C]h [C]r [C]i [C]t [C]i [C]s O 
] [C]] O 

Content [C]C [C]o [C]n [C]t [C]e [C]n [C]t O 
of [C]o [C]f O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
to [C]t [C]o O 
hormonal [C]h [C]o [C]r [C]m [C]o [C]n [C]a [C]l O 
form [C]f [C]o [C]r [C]m O 
of [C]o [C]f O 
vitamin [C]v [C]i [C]t [C]a [C]m [C]i [C]n O 
D3 [C]D [C]3 O 
, [C], O 
1.25 [C]1 [C]. [C]2 [C]5 O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
, [C], O 
constituted [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]e [C]d O 
27.3 [C]2 [C]7 [C]. [C]3 O 
fmole/mg [C]f [C]m [C]o [C]l [C]e [C]/ [C]m [C]g O 
of [C]o [C]f O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
in [C]i [C]n O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
of [C]o [C]f O 
peripheric [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]i [C]c O 
blood [C]b [C]l [C]o [C]o [C]d O 
of [C]o [C]f O 
children [C]c [C]h [C]i [C]l [C]d [C]r [C]e [C]n O 
with [C]w [C]i [C]t [C]h O 
glomerulonephritis [C]g [C]l [C]o [C]m [C]e [C]r [C]u [C]l [C]o [C]n [C]e [C]p [C]h [C]r [C]i [C]t [C]i [C]s O 
. [C]. O 

In [C]I [C]n O 
the [C]t [C]h [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
total [C]t [C]o [C]t [C]a [C]l O 
and [C]a [C]n [C]d O 
ionized [C]i [C]o [C]n [C]i [C]z [C]e [C]d O 
form [C]f [C]o [C]r [C]m O 
of [C]o [C]f O 
Ca2+ [C]C [C]a [C]2 [C]+ O 
was [C]w [C]a [C]s O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
down [C]d [C]o [C]w [C]n O 
to [C]t [C]o O 
2.04 [C]2 [C]. [C]0 [C]4 O 
mmole/L [C]m [C]m [C]o [C]l [C]e [C]/ [C]L O 
and [C]a [C]n [C]d O 
1.09 [C]1 [C]. [C]0 [C]9 O 
mmole/L [C]m [C]m [C]o [C]l [C]e [C]/ [C]L O 
, [C], O 
respectively [C]r [C]e [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
, [C], O 
while [C]w [C]h [C]i [C]l [C]e O 
an [C]a [C]n O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
parathormone [C]p [C]a [C]r [C]a [C]t [C]h [C]o [C]r [C]m [C]o [C]n [C]e O 
( [C]( O 
PTH [C]P [C]T [C]H O 
) [C]) O 
by [C]b [C]y O 
36 [C]3 [C]6 O 
% [C]% O 
and [C]a [C]n [C]d O 
a [C]a O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
25 [C]2 [C]5 O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
D [C]D O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
( [C]( O 
lower [C]l [C]o [C]w [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
1.25 [C]1 [C]. [C]2 [C]5 O 
ng/ml [C]n [C]g [C]/ [C]m [C]l O 
) [C]) O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
blood [C]b [C]l [C]o [C]o [C]d O 
; [C]; O 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
of [C]o [C]f O 
cAMP [C]c [C]A [C]M [C]P O 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
in [C]i [C]n O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s O 
by [C]b [C]y O 
33 [C]3 [C]3 O 
% [C]% O 
. [C]. O 

At [C]A [C]t O 
the [C]t [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
time [C]t [C]i [C]m [C]e O 
, [C], O 
total [C]t [C]o [C]t [C]a [C]l O 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
of [C]o [C]f O 
T [C]T B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
was [C]w [C]a [C]s O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
1.5-fold [C]1 [C]. [C]5 [C]- [C]f [C]o [C]l [C]d O 
in [C]i [C]n O 
peripheric [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]i [C]c O 
blood [C]b [C]l [C]o [C]o [C]d O 
. [C]. O 

Treatment [C]T [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
I-hydroxyvitamin [C]I [C]- [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]v [C]i [C]t [C]a [C]m [C]i [C]n O 
D3 [C]D [C]3 O 
( [C]( O 
1-1.5 [C]1 [C]- [C]1 [C]. [C]5 O 
mg [C]m [C]g O 
daily [C]d [C]a [C]i [C]l [C]y O 
, [C], O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
4 [C]4 O 
weeks [C]w [C]e [C]e [C]k [C]s O 
) [C]) O 
led [C]l [C]e [C]d O 
to [C]t [C]o O 
normalization [C]n [C]o [C]r [C]m [C]a [C]l [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
total [C]t [C]o [C]t [C]a [C]l O 
and [C]a [C]n [C]d O 
ionized [C]i [C]o [C]n [C]i [C]z [C]e [C]d O 
form [C]f [C]o [C]r [C]m O 
of [C]o [C]f O 
Ca2+ [C]C [C]a [C]2 [C]+ O 
and [C]a [C]n [C]d O 
of [C]o [C]f O 
25 [C]2 [C]5 O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
D [C]D O 
, [C], O 
but [C]b [C]u [C]t O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
affect [C]a [C]f [C]f [C]e [C]c [C]t O 
the [C]t [C]h [C]e O 
PTH [C]P [C]T [C]H O 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
in [C]i [C]n O 
blood [C]b [C]l [C]o [C]o [C]d O 
. [C]. O 

Concentration [C]C [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s S-protein 
to [C]t [C]o O 
1.25 [C]1 [C]. [C]2 [C]5 O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
was [C]w [C]a [C]s O 
elevated [C]e [C]l [C]e [C]v [C]a [C]t [C]e [C]d O 
up [C]u [C]p O 
to [C]t [C]o O 
39.7 [C]3 [C]9 [C]. [C]7 O 
fmole/mg [C]f [C]m [C]o [C]l [C]e [C]/ [C]m [C]g O 
after [C]a [C]f [C]t [C]e [C]r O 
I [C]I O 
week [C]w [C]e [C]e [C]k O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
it [C]i [C]t O 
was [C]w [C]a [C]s O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
initial [C]i [C]n [C]i [C]t [C]i [C]a [C]l O 
level [C]l [C]e [C]v [C]e [C]l O 
24.8 [C]2 [C]4 [C]. [C]8 O 
fmole/mg [C]f [C]m [C]o [C]l [C]e [C]/ [C]m [C]g O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
4 [C]4 O 
weeks [C]w [C]e [C]e [C]k [C]s O 
; [C]; O 
simultaneous [C]s [C]i [C]m [C]u [C]l [C]t [C]a [C]n [C]e [C]o [C]u [C]s O 
alteration [C]a [C]l [C]t [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
cAMP [C]c [C]A [C]M [C]P O 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
. [C]. O 

Treatment [C]T [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
1- [C]1 [C]- O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
D3 [C]D [C]3 O 
normalized [C]n [C]o [C]r [C]m [C]a [C]l [C]i [C]z [C]e [C]d O 
also [C]a [C]l [C]s [C]o O 
the [C]t [C]h [C]e O 
T [C]T B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
in [C]i [C]n O 
peripheric [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]i [C]c O 
blood [C]b [C]l [C]o [C]o [C]d O 
. [C]. O 

The [C]T [C]h [C]e O 
data [C]d [C]a [C]t [C]a O 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
under [C]u [C]n [C]d [C]e [C]r O 
conditions [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
glomerulonephritis [C]g [C]l [C]o [C]m [C]e [C]r [C]u [C]l [C]o [C]n [C]e [C]p [C]h [C]r [C]i [C]t [C]i [C]s O 
only [C]o [C]n [C]l [C]y O 
high [C]h [C]i [C]g [C]h O 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
of [C]o [C]f O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s S-protein 
to [C]t [C]o O 
1.25 [C]1 [C]. [C]2 [C]5 O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
in [C]i [C]n O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
enabled [C]e [C]n [C]a [C]b [C]l [C]e [C]d O 
to [C]t [C]o O 
perform [C]p [C]e [C]r [C]f [C]o [C]r [C]m O 
the [C]t [C]h [C]e O 
cell [C]c [C]e [C]l [C]l O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
. [C]. O 

Tumor [C]T [C]u [C]m [C]o [C]r O 
and [C]a [C]n [C]d O 
serum [C]s [C]e [C]r [C]u [C]m O 
beta-2-microglobulin [C]b [C]e [C]t [C]a [C]- [C]2 [C]- [C]m [C]i [C]c [C]r [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
women [C]w [C]o [C]m [C]e [C]n O 
with [C]w [C]i [C]t [C]h O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
. [C]. O 

To [C]T [C]o O 
investigate [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
the [C]t [C]h [C]e O 
tumor [C]t [C]u [C]m [C]o [C]r S-cell_type 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
beta-2-microglobulin [C]b [C]e [C]t [C]a [C]- [C]2 [C]- [C]m [C]i [C]c [C]r [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n S-protein 
( [C]( O 
beta [C]b [C]e [C]t [C]a B-protein 
2-M [C]2 [C]- [C]M E-protein 
) [C]) O 
could [C]c [C]o [C]u [C]l [C]d O 
serve [C]s [C]e [C]r [C]v [C]e O 
as [C]a [C]s O 
a [C]a O 
marker [C]m [C]a [C]r [C]k [C]e [C]r O 
of [C]o [C]f O 
tumor [C]t [C]u [C]m [C]o [C]r O 
biologic [C]b [C]i [C]o [C]l [C]o [C]g [C]i [C]c O 
behavior [C]b [C]e [C]h [C]a [C]v [C]i [C]o [C]r O 
, [C], O 
the [C]t [C]h [C]e O 
authors [C]a [C]u [C]t [C]h [C]o [C]r [C]s O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
specimens [C]s [C]p [C]e [C]c [C]i [C]m [C]e [C]n [C]s O 
of [C]o [C]f O 
breast [C]b [C]r [C]e [C]a [C]s [C]t B-cell_type 
carcinomas [C]c [C]a [C]r [C]c [C]i [C]n [C]o [C]m [C]a [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
60 [C]6 [C]0 O 
consecutive [C]c [C]o [C]n [C]s [C]e [C]c [C]u [C]t [C]i [C]v [C]e O 
female [C]f [C]e [C]m [C]a [C]l [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

Presence [C]P [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
beta [C]b [C]e [C]t [C]a B-protein 
2-M [C]2 [C]- [C]M E-protein 
was [C]w [C]a [C]s O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
by [C]b [C]y O 
immunohistochemistry [C]i [C]m [C]m [C]u [C]n [C]o [C]h [C]i [C]s [C]t [C]o [C]c [C]h [C]e [C]m [C]i [C]s [C]t [C]r [C]y O 
. [C]. O 

No [C]N [C]o O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
correlations [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n [C]s O 
were [C]w [C]e [C]r [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
tumor [C]t [C]u [C]m [C]o [C]r B-protein 
beta [C]b [C]e [C]t [C]a I-protein 
2-M [C]2 [C]- [C]M E-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
histologic [C]h [C]i [C]s [C]t [C]o [C]l [C]o [C]g [C]i [C]c O 
attributes [C]a [C]t [C]t [C]r [C]i [C]b [C]u [C]t [C]e [C]s O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
type [C]t [C]y [C]p [C]e O 
, [C], O 
histologic [C]h [C]i [C]s [C]t [C]o [C]l [C]o [C]g [C]i [C]c O 
and [C]a [C]n [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
grades [C]g [C]r [C]a [C]d [C]e [C]s O 
, [C], O 
mitotic [C]m [C]i [C]t [C]o [C]t [C]i [C]c O 
index [C]i [C]n [C]d [C]e [C]x O 
, [C], O 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s O 
, [C], O 
vascular [C]v [C]a [C]s [C]c [C]u [C]l [C]a [C]r O 
invasion [C]i [C]n [C]v [C]a [C]s [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
lymphocytic [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]i [C]c O 
infiltration [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Likewise [C]L [C]i [C]k [C]e [C]w [C]i [C]s [C]e O 
, [C], O 
beta [C]b [C]e [C]t [C]a B-protein 
2-M [C]2 [C]- [C]M E-protein 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
markers [C]m [C]a [C]r [C]k [C]e [C]r [C]s O 
of [C]o [C]f O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
extension [C]e [C]x [C]t [C]e [C]n [C]s [C]i [C]o [C]n O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
TNM [C]T [C]N [C]M O 
, [C], O 
( [C]( O 
UICC [C]U [C]I [C]C [C]C O 
, [C], O 
classification [C]c [C]l [C]a [C]s [C]s [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
malignant [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]t B-cell_type 
tumors [C]t [C]u [C]m [C]o [C]r [C]s E-cell_type 
) [C]) O 
staging [C]s [C]t [C]a [C]g [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
axillary [C]a [C]x [C]i [C]l [C]l [C]a [C]r [C]y O 
lymph [C]l [C]y [C]m [C]p [C]h O 
node [C]n [C]o [C]d [C]e O 
involvement [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]m [C]e [C]n [C]t O 
or [C]o [C]r O 
with [C]w [C]i [C]t [C]h O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n O 
, [C], O 
progesterone [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
, [C], O 
and [C]a [C]n [C]d O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
there [C]t [C]h [C]e [C]r [C]e O 
was [C]w [C]a [C]s O 
a [C]a O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
association [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
tumor [C]t [C]u [C]m [C]o [C]r B-protein 
beta [C]b [C]e [C]t [C]a I-protein 
2-M [C]2 [C]- [C]M E-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
degree [C]d [C]e [C]g [C]r [C]e [C]e O 
of [C]o [C]f O 
lymphocytic [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]i [C]c O 
infiltration [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
tumor [C]t [C]u [C]m [C]o [C]r O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
. [C]. O 

Beta [C]B [C]e [C]t [C]a B-protein 
2-M [C]2 [C]- [C]M E-protein 
serum [C]s [C]e [C]r [C]u [C]m O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
were [C]w [C]e [C]r [C]e O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
an [C]a [C]n O 
enzyme-linked [C]e [C]n [C]z [C]y [C]m [C]e [C]- [C]l [C]i [C]n [C]k [C]e [C]d O 
immunosorbent [C]i [C]m [C]m [C]u [C]n [C]o [C]s [C]o [C]r [C]b [C]e [C]n [C]t O 
assay [C]a [C]s [C]s [C]a [C]y O 
in [C]i [C]n O 
samples [C]s [C]a [C]m [C]p [C]l [C]e [C]s O 
from [C]f [C]r [C]o [C]m O 
22 [C]2 [C]2 O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
above [C]a [C]b [C]o [C]v [C]e O 
women [C]w [C]o [C]m [C]e [C]n O 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
some [C]s [C]o [C]m [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
highest [C]h [C]i [C]g [C]h [C]e [C]s [C]t O 
values [C]v [C]a [C]l [C]u [C]e [C]s O 
had [C]h [C]a [C]d O 
been [C]b [C]e [C]e [C]n O 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
in [C]i [C]n O 
women [C]w [C]o [C]m [C]e [C]n O 
with [C]w [C]i [C]t [C]h O 
larger [C]l [C]a [C]r [C]g [C]e [C]r O 
( [C]( O 
T4 [C]T [C]4 O 
) [C]) O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y O 
tumors [C]t [C]u [C]m [C]o [C]r [C]s O 
, [C], O 
the [C]t [C]h [C]e O 
authors [C]a [C]u [C]t [C]h [C]o [C]r [C]s O 
failed [C]f [C]a [C]i [C]l [C]e [C]d O 
to [C]t [C]o O 
detect [C]d [C]e [C]t [C]e [C]c [C]t O 
any [C]a [C]n [C]y O 
statistical [C]s [C]t [C]a [C]t [C]i [C]s [C]t [C]i [C]c [C]a [C]l O 
relationship [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n [C]s [C]h [C]i [C]p O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
beta [C]b [C]e [C]t [C]a B-protein 
2-M [C]2 [C]- [C]M E-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
tumor [C]t [C]u [C]m [C]o [C]r O 
with [C]w [C]i [C]t [C]h O 
serum [C]s [C]e [C]r [C]u [C]m O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
or [C]o [C]r O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
serum [C]s [C]e [C]r [C]u [C]m B-protein 
beta [C]b [C]e [C]t [C]a I-protein 
2-M [C]2 [C]- [C]M E-protein 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
above [C]a [C]b [C]o [C]v [C]e O 
histologic [C]h [C]i [C]s [C]t [C]o [C]l [C]o [C]g [C]i [C]c O 
, [C], O 
laboratory [C]l [C]a [C]b [C]o [C]r [C]a [C]t [C]o [C]r [C]y O 
, [C], O 
and [C]a [C]n [C]d O 
clinical [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
. [C]. O 

[ [C][ O 
Preliminary [C]P [C]r [C]e [C]l [C]i [C]m [C]i [C]n [C]a [C]r [C]y O 
observation [C]o [C]b [C]s [C]e [C]r [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
level [C]l [C]e [C]v [C]e [C]l O 
free-form [C]f [C]r [C]e [C]e [C]- [C]f [C]o [C]r [C]m B-protein 
E [C]E I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
in [C]i [C]n O 
serum [C]s [C]e [C]r [C]u [C]m O 
of [C]o [C]f O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
childbearing-aged [C]c [C]h [C]i [C]l [C]d [C]b [C]e [C]a [C]r [C]i [C]n [C]g [C]- [C]a [C]g [C]e [C]d O 
and [C]a [C]n [C]d O 
pregnant [C]p [C]r [C]e [C]g [C]n [C]a [C]n [C]t O 
women [C]w [C]o [C]m [C]e [C]n O 
] [C]] O 

In [C]I [C]n O 
137 [C]1 [C]3 [C]7 O 
cases [C]c [C]a [C]s [C]e [C]s O 
of [C]o [C]f O 
childbearing-aged [C]c [C]h [C]i [C]l [C]d [C]b [C]e [C]a [C]r [C]i [C]n [C]g [C]- [C]a [C]g [C]e [C]d O 
and [C]a [C]n [C]d O 
pregnant [C]p [C]r [C]e [C]g [C]n [C]a [C]n [C]t O 
women [C]w [C]o [C]m [C]e [C]n O 
, [C], O 
free [C]f [C]r [C]e [C]e B-protein 
form [C]f [C]o [C]r [C]m I-protein 
E [C]E I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
( [C]( O 
sE [C]s [C]E S-protein 
) [C]) O 
in [C]i [C]n O 
serum [C]s [C]e [C]r [C]u [C]m O 
were [C]w [C]e [C]r [C]e O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
by [C]b [C]y O 
ELISA [C]E [C]L [C]I [C]S [C]A O 
. [C]. O 

The [C]T [C]h [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
sE [C]s [C]E S-protein 
was [C]w [C]a [C]s O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
first [C]f [C]i [C]r [C]s [C]t O 
trimester [C]t [C]r [C]i [C]m [C]e [C]s [C]t [C]e [C]r O 
, [C], O 
slightly [C]s [C]l [C]i [C]g [C]h [C]t [C]l [C]y O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
second [C]s [C]e [C]c [C]o [C]n [C]d O 
trimester [C]t [C]r [C]i [C]m [C]e [C]s [C]t [C]e [C]r O 
, [C], O 
and [C]a [C]n [C]d O 
recovered [C]r [C]e [C]c [C]o [C]v [C]e [C]r [C]e [C]d O 
to [C]t [C]o O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
third [C]t [C]h [C]i [C]r [C]d O 
trimester [C]t [C]r [C]i [C]m [C]e [C]s [C]t [C]e [C]r O 
. [C]. O 

The [C]T [C]h [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
remained [C]r [C]e [C]m [C]a [C]i [C]n [C]e [C]d O 
lower [C]l [C]o [C]w [C]e [C]r O 
in [C]i [C]n O 
29 [C]2 [C]9 O 
PIH [C]P [C]I [C]H O 
women [C]w [C]o [C]m [C]e [C]n O 
but [C]b [C]u [C]t O 
appeared [C]a [C]p [C]p [C]e [C]a [C]r [C]e [C]d O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
in [C]i [C]n O 
overdue [C]o [C]v [C]e [C]r [C]d [C]u [C]e O 
pregnancies [C]p [C]r [C]e [C]g [C]n [C]a [C]n [C]c [C]i [C]e [C]s O 
as [C]a [C]s O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
3rd [C]3 [C]r [C]d O 
trimester [C]t [C]r [C]i [C]m [C]e [C]s [C]t [C]e [C]r O 
range [C]r [C]a [C]n [C]g [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
there [C]t [C]h [C]e [C]r [C]e O 
is [C]i [C]s O 
a [C]a O 
relationship [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n [C]s [C]h [C]i [C]p O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
a [C]a O 
change [C]c [C]h [C]a [C]n [C]g [C]e O 
in [C]i [C]n O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
pregnancy [C]p [C]r [C]e [C]g [C]n [C]a [C]n [C]c [C]y O 
. [C]. O 

Kappa [C]K [C]a [C]p [C]p [C]a B-protein 
B-specific [C]B [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-protein 
DNA [C]D [C]N [C]A I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
: [C]: O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
interleukin-2 [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]2 I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Transcriptional [C]T [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
interleukin-2 [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]2 I-DNA 
( [C]( I-DNA 
IL-2 [C]I [C]L [C]- [C]2 I-DNA 
) [C]) I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
, [C], O 
like [C]l [C]i [C]k [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-DNA 
alpha [C]a [C]l [C]p [C]h [C]a I-DNA 
( [C]( I-DNA 
IL-2R [C]I [C]L [C]- [C]2 [C]R I-DNA 
alpha [C]a [C]l [C]p [C]h [C]a I-DNA 
) [C]) I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
type [C]t [C]y [C]p [C]e O 
1 [C]1 O 
human [C]h [C]u [C]m [C]a [C]n O 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
virus [C]v [C]i [C]r [C]u [C]s O 
( [C]( O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
) [C]) O 
, [C], O 
is [C]i [C]s O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
be [C]b [C]e O 
modulated [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
kappa [C]k [C]a [C]p [C]p [C]a B-protein 
B-like [C]B [C]- [C]l [C]i [C]k [C]e I-protein 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r I-protein 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-protein 
. [C]. O 

Mutation [C]M [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
kappa [C]k [C]a [C]p [C]p [C]a B-DNA 
B [C]B I-DNA 
core [C]c [C]o [C]r [C]e I-DNA 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e E-DNA 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
( [C]( O 
-206 [C]- [C]2 [C]0 [C]6 O 
to [C]t [C]o O 
-195 [C]- [C]1 [C]9 [C]5 O 
) [C]) O 
partially [C]p [C]a [C]r [C]t [C]i [C]a [C]l [C]l [C]y O 
inhibits [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]s O 
both [C]b [C]o [C]t [C]h O 
mitogen- [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- O 
and [C]a [C]n [C]d O 
HTLV-I [C]H [C]T [C]L [C]V [C]- [C]I O 
Tax-mediated [C]T [C]a [C]x [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
unit [C]u [C]n [C]i [C]t E-protein 
and [C]a [C]n [C]d O 
blocks [C]b [C]l [C]o [C]c [C]k [C]s O 
the [C]t [C]h [C]e O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
two [C]t [C]w [C]o O 
inducible [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e B-protein 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
kappa [C]k [C]a [C]p [C]p [C]a B-protein 
B-specific [C]B [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
( [C]( O 
80 [C]8 [C]0 O 
to [C]t [C]o O 
90 [C]9 [C]0 O 
and [C]a [C]n [C]d O 
50 [C]5 [C]0 O 
to [C]t [C]o O 
55 [C]5 [C]5 O 
kilodaltons [C]k [C]i [C]l [C]o [C]d [C]a [C]l [C]t [C]o [C]n [C]s O 
) [C]) O 
similarly [C]s [C]i [C]m [C]i [C]l [C]a [C]r [C]l [C]y O 
interact [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
kappa [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B I-protein 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r E-protein 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
IL-2R [C]I [C]L [C]- [C]2 [C]R B-DNA 
alpha [C]a [C]l [C]p [C]h [C]a I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
these [C]t [C]h [C]e [C]s [C]e O 
kappa [C]k [C]a [C]p [C]p [C]a B-protein 
B-specific [C]B [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
have [C]h [C]a [C]v [C]e O 
a [C]a O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
coordinate [C]c [C]o [C]o [C]r [C]d [C]i [C]n [C]a [C]t [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
factor-growth [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]g [C]r [C]o [C]w [C]t [C]h O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
gene [C]g [C]e [C]n [C]e O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
that [C]t [C]h [C]a [C]t O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Novel [C]N [C]o [C]v [C]e [C]l O 
region [C]r [C]e [C]g [C]i [C]o [C]n O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
the [C]t [C]h [C]e O 
V [C]V B-DNA 
kappa [C]k [C]a [C]p [C]p [C]a I-DNA 
gene [C]g [C]e [C]n [C]e I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
is [C]i [C]s O 
responsible [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]b [C]l [C]e O 
for [C]f [C]o [C]r O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
and [C]a [C]n [C]d O 
stage-specific [C]s [C]t [C]a [C]g [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d I-cell_type 
neoplasms [C]n [C]e [C]o [C]p [C]l [C]a [C]s [C]m [C]s E-cell_type 
. [C]. O 

Immunoglobulin [C]I [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n B-protein 
gene-specific [C]g [C]e [C]n [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-protein 
transacting [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]n [C]g I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
play [C]p [C]l [C]a [C]y O 
a [C]a O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d O 
tissue-specific [C]t [C]i [C]s [C]s [C]u [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
. [C]. O 

The [C]T [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
in [C]i [C]n O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l S-cell_type 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
stage-specific [C]s [C]t [C]a [C]g [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
genes [C]g [C]e [C]n [C]e [C]s O 
is [C]i [C]s O 
, [C], O 
however [C]h [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
not [C]n [C]o [C]t O 
fully [C]f [C]u [C]l [C]l [C]y O 
understood [C]u [C]n [C]d [C]e [C]r [C]s [C]t [C]o [C]o [C]d O 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
used [C]u [C]s [C]e [C]d O 
a [C]a O 
model [C]m [C]o [C]d [C]e [C]l O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d O 
neoplasia [C]n [C]e [C]o [C]p [C]l [C]a [C]s [C]i [C]a O 
to [C]t [C]o O 
address [C]a [C]d [C]d [C]r [C]e [C]s [C]s O 
this [C]t [C]h [C]i [C]s O 
question [C]q [C]u [C]e [C]s [C]t [C]i [C]o [C]n O 
. [C]. O 

Different [C]D [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
fragments [C]f [C]r [C]a [C]g [C]m [C]e [C]n [C]t [C]s O 
of [C]o [C]f O 
unrearranged [C]u [C]n [C]r [C]e [C]a [C]r [C]r [C]a [C]n [C]g [C]e [C]d B-DNA 
human [C]h [C]u [C]m [C]a [C]n I-DNA 
variable [C]v [C]a [C]r [C]i [C]a [C]b [C]l [C]e I-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
of [C]o [C]f O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n B-DNA 
kappa [C]k [C]a [C]p [C]p [C]a I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
( [C]( O 
V [C]V B-DNA 
kappa [C]k [C]a [C]p [C]p [C]a E-DNA 
) [C]) O 
were [C]w [C]e [C]r [C]e O 
used [C]u [C]s [C]e [C]d O 
for [C]f [C]o [C]r O 
cell-free [C]c [C]e [C]l [C]l [C]- [C]f [C]r [C]e [C]e O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
DNA [C]D [C]N [C]A O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
. [C]. O 

Previously [C]P [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
described [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
enhancement [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
that [C]t [C]h [C]a [C]t O 
was [C]w [C]a [C]s O 
only [C]o [C]n [C]l [C]y O 
seen [C]s [C]e [C]e [C]n O 
with [C]w [C]i [C]t [C]h O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
derived [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l B-cell_type 
neoplasms [C]n [C]e [C]o [C]p [C]l [C]a [C]s [C]m [C]s E-cell_type 
corresponding [C]c [C]o [C]r [C]r [C]e [C]s [C]p [C]o [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
late [C]l [C]a [C]t [C]e O 
stages [C]s [C]t [C]a [C]g [C]e [C]s O 
of [C]o [C]f O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l S-cell_type 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
be [C]b [C]e O 
dependent [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
actions [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
( [C]( O 
s [C]s O 
) [C]) O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
DNA [C]D [C]N [C]A O 
region [C]r [C]e [C]g [C]i [C]o [C]n O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
the [C]t [C]h [C]e O 
V [C]V B-DNA 
kappa [C]k [C]a [C]p [C]p [C]a I-DNA 
gene [C]g [C]e [C]n [C]e I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
region [C]r [C]e [C]g [C]i [C]o [C]n O 
is [C]i [C]s O 
located [C]l [C]o [C]c [C]a [C]t [C]e [C]d O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
the [C]t [C]h [C]e O 
920 [C]9 [C]2 [C]0 O 
bp [C]b [C]p O 
fragment [C]f [C]r [C]a [C]g [C]m [C]e [C]n [C]t O 
located [C]l [C]o [C]c [C]a [C]t [C]e [C]d O 
210 [C]2 [C]1 [C]0 O 
bp [C]b [C]p O 
upstream [C]u [C]p [C]s [C]t [C]r [C]e [C]a [C]m O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
coding [C]c [C]o [C]d [C]i [C]n [C]g O 
region [C]r [C]e [C]g [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
this [C]t [C]h [C]i [C]s O 
fragment [C]f [C]r [C]a [C]g [C]m [C]e [C]n [C]t O 
represents [C]r [C]e [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]s O 
a [C]a O 
possible [C]p [C]o [C]s [C]s [C]i [C]b [C]l [C]e O 
novel [C]n [C]o [C]v [C]e [C]l O 
DNA [C]D [C]N [C]A O 
region [C]r [C]e [C]g [C]i [C]o [C]n O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
plays [C]p [C]l [C]a [C]y [C]s O 
a [C]a O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
stage- [C]s [C]t [C]a [C]g [C]e [C]- O 
and [C]a [C]n [C]d O 
tissue-specific [C]t [C]i [C]s [C]s [C]u [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
. [C]. O 

[ [C][ O 
Determination [C]D [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
to [C]t [C]o O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s S-protein 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
] [C]] O 

A [C]A O 
modified [C]m [C]o [C]d [C]i [C]f [C]i [C]e [C]d O 
method [C]m [C]e [C]t [C]h [C]o [C]d O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
determination [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
is [C]i [C]s O 
suggested [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]e [C]d O 
. [C]. O 

The [C]T [C]h [C]e O 
principal [C]p [C]r [C]i [C]n [C]c [C]i [C]p [C]a [C]l O 
distinction [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
method [C]m [C]e [C]t [C]h [C]o [C]d O 
is [C]i [C]s O 
standardization [C]s [C]t [C]a [C]n [C]d [C]a [C]r [C]d [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e S-cell_type 
count [C]c [C]o [C]u [C]n [C]t O 
in [C]i [C]n O 
a [C]a O 
sample [C]s [C]a [C]m [C]p [C]l [C]e O 
( [C]( O 
1 [C]1 O 
mln [C]m [C]l [C]n O 
) [C]) O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
labeled [C]l [C]a [C]b [C]e [C]l [C]e [C]d O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e S-protein 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
modification [C]m [C]o [C]d [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
saves [C]s [C]a [C]v [C]e [C]s O 
time [C]t [C]i [C]m [C]e O 
and [C]a [C]n [C]d O 
money [C]m [C]o [C]n [C]e [C]y O 
, [C], O 
limits [C]l [C]i [C]m [C]i [C]t [C]s O 
the [C]t [C]h [C]e O 
range [C]r [C]a [C]n [C]g [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
data [C]d [C]a [C]t [C]a O 
variations [C]v [C]a [C]r [C]i [C]a [C]t [C]i [C]o [C]n [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
makes [C]m [C]a [C]k [C]e [C]s O 
use [C]u [C]s [C]e O 
of [C]o [C]f O 
a [C]a O 
lesser [C]l [C]e [C]s [C]s [C]e [C]r O 
volume [C]v [C]o [C]l [C]u [C]m [C]e O 
of [C]o [C]f O 
blood [C]b [C]l [C]o [C]o [C]d O 
. [C]. O 

Examinations [C]E [C]x [C]a [C]m [C]i [C]n [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
70 [C]7 [C]0 O 
children [C]c [C]h [C]i [C]l [C]d [C]r [C]e [C]n O 
aged [C]a [C]g [C]e [C]d O 
4 [C]4 O 
to [C]t [C]o O 
15 [C]1 [C]5 O 
suffering [C]s [C]u [C]f [C]f [C]e [C]r [C]i [C]n [C]g O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
nephrotic [C]n [C]e [C]p [C]h [C]r [C]o [C]t [C]i [C]c O 
form [C]f [C]o [C]r [C]m O 
of [C]o [C]f O 
glomerulonephritis [C]g [C]l [C]o [C]m [C]e [C]r [C]u [C]l [C]o [C]n [C]e [C]p [C]h [C]r [C]i [C]t [C]i [C]s O 
have [C]h [C]a [C]v [C]e O 
made [C]m [C]a [C]d [C]e O 
it [C]i [C]t O 
possible [C]p [C]o [C]s [C]s [C]i [C]b [C]l [C]e O 
to [C]t [C]o O 
distinguish [C]d [C]i [C]s [C]t [C]i [C]n [C]g [C]u [C]i [C]s [C]h O 
two [C]t [C]w [C]o O 
groups [C]g [C]r [C]o [C]u [C]p [C]s O 
of [C]o [C]f O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
: [C]: O 
with [C]w [C]i [C]t [C]h O 
relatively [C]r [C]e [C]l [C]a [C]t [C]i [C]v [C]e [C]l [C]y O 
high [C]h [C]i [C]g [C]h O 
values [C]v [C]a [C]l [C]u [C]e [C]s O 
of [C]o [C]f O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
X [C]X O 
= [C]= O 
6820.1 [C]6 [C]8 [C]2 [C]0 [C]. [C]1 O 
+/- [C]+ [C]/ [C]- O 
530.0 [C]5 [C]3 [C]0 [C]. [C]0 O 
( [C]( O 
n [C]n O 
= [C]= O 
30 [C]3 [C]0 O 
, [C], O 
p [C]p O 
= [C]= O 
0.95 [C]0 [C]. [C]9 [C]5 O 
, [C], O 
t [C]t O 
= [C]= O 
2.04 [C]2 [C]. [C]0 [C]4 O 
) [C]) O 
, [C], O 
this [C]t [C]h [C]i [C]s O 
corresponding [C]c [C]o [C]r [C]r [C]e [C]s [C]p [C]o [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
a [C]a O 
clinical [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
form [C]f [C]o [C]r [C]m O 
of [C]o [C]f O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e S-protein 
-sensitive [C]- [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
glomerulonephritis [C]g [C]l [C]o [C]m [C]e [C]r [C]u [C]l [C]o [C]n [C]e [C]p [C]h [C]r [C]i [C]t [C]i [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
with [C]w [C]i [C]t [C]h O 
relatively [C]r [C]e [C]l [C]a [C]t [C]i [C]v [C]e [C]l [C]y O 
low [C]l [C]o [C]w O 
values [C]v [C]a [C]l [C]u [C]e [C]s O 
of [C]o [C]f O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
X [C]X O 
= [C]= O 
1815.2 [C]1 [C]8 [C]1 [C]5 [C]. [C]2 O 
+/- [C]+ [C]/ [C]- O 
302.8 [C]3 [C]0 [C]2 [C]. [C]8 O 
( [C]( O 
n [C]n O 
= [C]= O 
40 [C]4 [C]0 O 
, [C], O 
p [C]p O 
= [C]= O 
0.95 [C]0 [C]. [C]9 [C]5 O 
, [C], O 
t [C]t O 
= [C]= O 
1.96 [C]1 [C]. [C]9 [C]6 O 
) [C]) O 
, [C], O 
that [C]t [C]h [C]a [C]t O 
corresponds [C]c [C]o [C]r [C]r [C]e [C]s [C]p [C]o [C]n [C]d [C]s O 
to [C]t [C]o O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e S-protein 
-resistant [C]- [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]t O 
glomerulonephritis [C]g [C]l [C]o [C]m [C]e [C]r [C]u [C]l [C]o [C]n [C]e [C]p [C]h [C]r [C]i [C]t [C]i [C]s O 
. [C]. O 

Dynamic [C]D [C]y [C]n [C]a [C]m [C]i [C]c O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
have [C]h [C]a [C]v [C]e O 
not [C]n [C]o [C]t O 
shown [C]s [C]h [C]o [C]w [C]n O 
any [C]a [C]n [C]y O 
statistically [C]s [C]t [C]a [C]t [C]i [C]s [C]t [C]i [C]c [C]a [C]l [C]l [C]y O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
values [C]v [C]a [C]l [C]u [C]e [C]s O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
permit [C]p [C]e [C]r [C]m [C]i [C]t O 
regarding [C]r [C]e [C]g [C]a [C]r [C]d [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
value [C]v [C]a [C]l [C]u [C]e O 
as [C]a [C]s O 
a [C]a O 
prognostic [C]p [C]r [C]o [C]g [C]n [C]o [C]s [C]t [C]i [C]c O 
criterion [C]c [C]r [C]i [C]t [C]e [C]r [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
assessment [C]a [C]s [C]s [C]e [C]s [C]s [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
corticosteroid [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]t [C]e [C]r [C]o [C]i [C]d S-protein 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
; [C]; O 
this [C]t [C]h [C]i [C]s O 
allows [C]a [C]l [C]l [C]o [C]w [C]s O 
a [C]a O 
wide [C]w [C]i [C]d [C]e O 
employment [C]e [C]m [C]p [C]l [C]o [C]y [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
described [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
method [C]m [C]e [C]t [C]h [C]o [C]d O 
in [C]i [C]n O 
practical [C]p [C]r [C]a [C]c [C]t [C]i [C]c [C]a [C]l O 
nephrology [C]n [C]e [C]p [C]h [C]r [C]o [C]l [C]o [C]g [C]y O 
. [C]. O 

Octamer-binding [C]O [C]c [C]t [C]a [C]m [C]e [C]r [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
from [C]f [C]r [C]o [C]m O 
B [C]B B-cell_line 
or [C]o [C]r I-cell_line 
HeLa [C]H [C]e [C]L [C]a I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
stimulate [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n B-DNA 
heavy-chain [C]h [C]e [C]a [C]v [C]y [C]- [C]c [C]h [C]a [C]i [C]n I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
. [C]. O 

The [C]T [C]h [C]e O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l S-cell_type 
-type [C]- [C]t [C]y [C]p [C]e O 
specificity [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n S-protein 
( [C]( O 
Ig [C]I [C]g S-protein 
) [C]) O 
heavy-chain [C]h [C]e [C]a [C]v [C]y [C]- [C]c [C]h [C]a [C]i [C]n O 
and [C]a [C]n [C]d O 
light-chain [C]l [C]i [C]g [C]h [C]t [C]- [C]c [C]h [C]a [C]i [C]n O 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s O 
is [C]i [C]s O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
an [C]a [C]n O 
octanucleotide [C]o [C]c [C]t [C]a [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e B-DNA 
( [C]( I-DNA 
OCTA [C]O [C]C [C]T [C]A I-DNA 
) [C]) I-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
, [C], O 
ATGCAAAT [C]A [C]T [C]G [C]C [C]A [C]A [C]A [C]T O 
, [C], O 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
also [C]a [C]l [C]s [C]o O 
a [C]a O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
component [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t O 
of [C]o [C]f O 
other [C]o [C]t [C]h [C]e [C]r O 
RNA [C]R [C]N [C]A B-DNA 
polymerase [C]p [C]o [C]l [C]y [C]m [C]e [C]r [C]a [C]s [C]e I-DNA 
II [C]I [C]I I-DNA 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s E-DNA 
, [C], O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
snRNA [C]s [C]n [C]R [C]N [C]A O 
and [C]a [C]n [C]d O 
histone [C]h [C]i [C]s [C]t [C]o [C]n [C]e O 
H2B [C]H [C]2 [C]B O 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s O 
. [C]. O 

Two [C]T [C]w [C]o O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
that [C]t [C]h [C]a [C]t O 
bind [C]b [C]i [C]n [C]d O 
specifically [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]a [C]l [C]l [C]y O 
and [C]a [C]n [C]d O 
with [C]w [C]i [C]t [C]h O 
high [C]h [C]i [C]g [C]h O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
OCTA [C]O [C]C [C]T [C]A B-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
. [C]. O 

NF-A1 [C]N [C]F [C]- [C]A [C]1 S-protein 
is [C]i [C]s O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
in [C]i [C]n O 
a [C]a O 
variety [C]v [C]a [C]r [C]i [C]e [C]t [C]y O 
of [C]o [C]f O 
cell [C]c [C]e [C]l [C]l O 
types [C]t [C]y [C]p [C]e [C]s O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
NF-A2 [C]N [C]F [C]- [C]A [C]2 S-protein 
is [C]i [C]s O 
essentially [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l [C]l [C]y O 
confined [C]c [C]o [C]n [C]f [C]i [C]n [C]e [C]d O 
to [C]t [C]o O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
leading [C]l [C]e [C]a [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
hypothesis [C]h [C]y [C]p [C]o [C]t [C]h [C]e [C]s [C]i [C]s O 
that [C]t [C]h [C]a [C]t O 
NF-A2 [C]N [C]F [C]- [C]A [C]2 S-protein 
activates [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]s O 
cell-type-specific [C]c [C]e [C]l [C]l [C]- [C]t [C]y [C]p [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Ig [C]I [C]g B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
and [C]a [C]n [C]d O 
NF-A1 [C]N [C]F [C]- [C]A [C]1 S-protein 
mediates [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]s O 
the [C]t [C]h [C]e O 
other [C]o [C]t [C]h [C]e [C]r O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
OCTA [C]O [C]C [C]T [C]A B-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
. [C]. O 

Extracts [C]E [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l B-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
, [C], O 
BJA-B [C]B [C]J [C]A [C]- [C]B S-cell_line 
, [C], O 
contain [C]c [C]o [C]n [C]t [C]a [C]i [C]n O 
high [C]h [C]i [C]g [C]h O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
NF-A2 [C]N [C]F [C]- [C]A [C]2 S-protein 
and [C]a [C]n [C]d O 
specifically [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]a [C]l [C]l [C]y O 
transcribe [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]b [C]e O 
Ig [C]I [C]g B-DNA 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s E-DNA 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
from [C]f [C]r [C]o [C]m O 
HeLa [C]H [C]e [C]L [C]a B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
transcribed [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
the [C]t [C]h [C]e O 
Ig [C]I [C]g B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
poorly [C]p [C]o [C]o [C]r [C]l [C]y O 
. [C]. O 

Surprisingly [C]S [C]u [C]r [C]p [C]r [C]i [C]s [C]i [C]n [C]g [C]l [C]y O 
, [C], O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
affinity-enriched [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y [C]- [C]e [C]n [C]r [C]i [C]c [C]h [C]e [C]d O 
NF-A2 [C]N [C]F [C]- [C]A [C]2 O 
or [C]o [C]r O 
NF-A1 [C]N [C]F [C]- [C]A [C]1 O 
to [C]t [C]o O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
a [C]a O 
HeLa [C]H [C]e [C]L [C]a O 
extract [C]e [C]x [C]t [C]r [C]a [C]c [C]t O 
or [C]o [C]r O 
a [C]a O 
partially [C]p [C]a [C]r [C]t [C]i [C]a [C]l [C]l [C]y O 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d O 
reaction [C]r [C]e [C]a [C]c [C]t [C]i [C]o [C]n O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
specifically [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]a [C]l [C]l [C]y O 
stimulates [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]s O 
the [C]t [C]h [C]e O 
Ig [C]I [C]g B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
suggests [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]s O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
constitutive [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
OCTA-binding [C]O [C]C [C]T [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
NF-A1 [C]N [C]F [C]- [C]A [C]1 E-protein 
can [C]c [C]a [C]n O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Ig [C]I [C]g B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
and [C]a [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l S-cell_type 
-specific [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
, [C], O 
at [C]a [C]t O 
least [C]l [C]e [C]a [C]s [C]t O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
, [C], O 
is [C]i [C]s O 
partially [C]p [C]a [C]r [C]t [C]i [C]a [C]l [C]l [C]y O 
due [C]d [C]u [C]e O 
to [C]t [C]o O 
a [C]a O 
quantitative [C]q [C]u [C]a [C]n [C]t [C]i [C]t [C]a [C]t [C]i [C]v [C]e O 
difference [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
amount [C]a [C]m [C]o [C]u [C]n [C]t O 
of [C]o [C]f O 
OCTA-binding [C]O [C]C [C]T [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
. [C]. O 

Because [C]B [C]e [C]c [C]a [C]u [C]s [C]e O 
NF-A1 [C]N [C]F [C]- [C]A [C]1 S-protein 
can [C]c [C]a [C]n O 
stimulate [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e O 
Ig [C]I [C]g S-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
, [C], O 
the [C]t [C]h [C]e O 
inability [C]i [C]n [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
to [C]t [C]o O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
the [C]t [C]h [C]e O 
Ig [C]I [C]g B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
degree [C]d [C]e [C]g [C]r [C]e [C]e O 
as [C]a [C]s O 
the [C]t [C]h [C]e O 
snRNA [C]s [C]n [C]R [C]N [C]A B-DNA 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s E-DNA 
probably [C]p [C]r [C]o [C]b [C]a [C]b [C]l [C]y O 
reflects [C]r [C]e [C]f [C]l [C]e [C]c [C]t [C]s O 
a [C]a O 
difference [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
context [C]c [C]o [C]n [C]t [C]e [C]x [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
OCTA [C]O [C]C [C]T [C]A B-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
in [C]i [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
two [C]t [C]w [C]o O 
types [C]t [C]y [C]p [C]e [C]s O 
of [C]o [C]f O 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s S-DNA 
. [C]. O 

Identification [C]I [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
putative [C]p [C]u [C]t [C]a [C]t [C]i [C]v [C]e O 
regulator [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r O 
of [C]o [C]f O 
early [C]e [C]a [C]r [C]l [C]y B-DNA 
T [C]T I-DNA 
cell [C]c [C]e [C]l [C]l I-DNA 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
. [C]. O 

Molecules [C]M [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]s O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n O 
receptor-dependent [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
early [C]e [C]a [C]r [C]l [C]y B-DNA 
T [C]T I-DNA 
cell [C]c [C]e [C]l [C]l I-DNA 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
were [C]w [C]e [C]r [C]e O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
use [C]u [C]s [C]e O 
of [C]o [C]f O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
sequences [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
T [C]T B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
activation-specific [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-protein 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r E-protein 
of [C]o [C]f O 
interleukin-2 [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]2 S-protein 
( [C]( O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
) [C]) O 
. [C]. O 

One [C]O [C]n [C]e O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
sequences [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s O 
forms [C]f [C]o [C]r [C]m [C]s O 
a [C]a O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
, [C], O 
NFAT-1 [C]N [C]F [C]A [C]T [C]- [C]1 S-protein 
, [C], O 
specifically [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]a [C]l [C]l [C]y O 
with [C]w [C]i [C]t [C]h O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
of [C]o [C]f O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
appeared [C]a [C]p [C]p [C]e [C]a [C]r [C]e [C]d O 
10 [C]1 [C]0 O 
to [C]t [C]o O 
25 [C]2 [C]5 O 
minutes [C]m [C]i [C]n [C]u [C]t [C]e [C]s O 
before [C]b [C]e [C]f [C]o [C]r [C]e O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
. [C]. O 

Studies [C]S [C]t [C]u [C]d [C]i [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
of [C]o [C]f O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
indicated [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
time [C]t [C]i [C]m [C]e O 
of [C]o [C]f O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
in [C]i [C]n O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_line 
T [C]T I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
corresponds [C]c [C]o [C]r [C]r [C]e [C]s [C]p [C]o [C]n [C]d [C]s O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
time [C]t [C]i [C]m [C]e O 
of [C]o [C]f O 
appearance [C]a [C]p [C]p [C]e [C]a [C]r [C]a [C]n [C]c [C]e O 
of [C]o [C]f O 
NFAT-1 [C]N [C]F [C]A [C]T [C]- [C]1 S-protein 
. [C]. O 

NFAT-1 [C]N [C]F [C]A [C]T [C]- [C]1 S-protein 
, [C], O 
or [C]o [C]r O 
a [C]a O 
very [C]v [C]e [C]r [C]y O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
, [C], O 
bound [C]b [C]o [C]u [C]n [C]d O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
sequences [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
long [C]l [C]o [C]n [C]g B-DNA 
terminal [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l I-DNA 
repeat [C]r [C]e [C]p [C]e [C]a [C]t E-DNA 
( [C]( O 
LTR [C]L [C]T [C]R S-DNA 
) [C]) O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n O 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
virus [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
1 [C]1 O 
; [C]; O 
the [C]t [C]h [C]e O 
LTR [C]L [C]T [C]R S-DNA 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
virus [C]v [C]i [C]r [C]u [C]s O 
is [C]i [C]s O 
known [C]k [C]n [C]o [C]w [C]n O 
to [C]t [C]o O 
be [C]b [C]e O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
early [C]e [C]a [C]r [C]l [C]y O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
for [C]f [C]o [C]r O 
this [C]t [C]h [C]i [C]s O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
a [C]a O 
linked [C]l [C]i [C]n [C]k [C]e [C]d O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
after [C]a [C]f [C]t [C]e [C]r O 
transfection [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
into [C]i [C]n [C]t [C]o O 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n B-cell_type 
receptor-activated [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
other [C]o [C]t [C]h [C]e [C]r O 
cell [C]c [C]e [C]l [C]l O 
types [C]t [C]y [C]p [C]e [C]s O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
characteristics [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]s [C]t [C]i [C]c [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
NFAT-1 [C]N [C]F [C]A [C]T [C]- [C]1 S-protein 
transmits [C]t [C]r [C]a [C]n [C]s [C]m [C]i [C]t [C]s O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
initiated [C]i [C]n [C]i [C]t [C]i [C]a [C]t [C]e [C]d O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
T [C]T B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
. [C]. O 

Characterization [C]C [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
thyroid [C]t [C]h [C]y [C]r [C]o [C]i [C]d B-protein 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
IM-9 [C]I [C]M [C]- [C]9 I-cell_line 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_line 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
putatively [C]p [C]u [C]t [C]a [C]t [C]i [C]v [C]e [C]l [C]y O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
more [C]m [C]o [C]r [C]e O 
than [C]t [C]h [C]a [C]n O 
10 [C]1 [C]0 O 
years [C]y [C]e [C]a [C]r [C]s O 
ago [C]a [C]g [C]o O 
, [C], O 
thyroid [C]t [C]h [C]y [C]r [C]o [C]i [C]d B-protein 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n O 
tissues [C]t [C]i [C]s [C]s [C]u [C]e [C]s O 
remain [C]r [C]e [C]m [C]a [C]i [C]n O 
poorly [C]p [C]o [C]o [C]r [C]l [C]y O 
characterized [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]d O 
. [C]. O 

As [C]A [C]s O 
a [C]a O 
first [C]f [C]i [C]r [C]s [C]t O 
step [C]s [C]t [C]e [C]p O 
towards [C]t [C]o [C]w [C]a [C]r [C]d [C]s O 
understanding [C]u [C]n [C]d [C]e [C]r [C]s [C]t [C]a [C]n [C]d [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
of [C]o [C]f O 
thyroid [C]t [C]h [C]y [C]r [C]o [C]i [C]d O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e O 
action [C]a [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
man [C]m [C]a [C]n O 
we [C]w [C]e O 
have [C]h [C]a [C]v [C]e O 
characterized [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]d O 
T3 [C]T [C]3 B-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
sites [C]s [C]i [C]t [C]e [C]s E-protein 
in [C]i [C]n O 
nuclei [C]n [C]u [C]c [C]l [C]e [C]i O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
lymphoblastoid [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]o [C]i [C]d I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
, [C], O 
IM-9 [C]I [C]M [C]- [C]9 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

In [C]I [C]n O 
whole [C]w [C]h [C]o [C]l [C]e O 
cell [C]c [C]e [C]l [C]l O 
experiments [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]s O 
at [C]a [C]t O 
37 [C]3 [C]7 O 
degrees [C]d [C]e [C]g [C]r [C]e [C]e [C]s O 
C [C]C O 
, [C], O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
[ [C][ B-protein 
125I [C]1 [C]2 [C]5 [C]I I-protein 
] [C]] I-protein 
T3 [C]T [C]3 E-protein 
was [C]w [C]a [C]s O 
saturable [C]s [C]a [C]t [C]u [C]r [C]a [C]b [C]l [C]e O 
( [C]( O 
Kd [C]K [C]d O 
34 [C]3 [C]4 O 
+/- [C]+ [C]/ [C]- O 
6 [C]6 O 
pmol/l [C]p [C]m [C]o [C]l [C]/ [C]l O 
) [C]) O 
and [C]a [C]n [C]d O 
of [C]o [C]f O 
finite [C]f [C]i [C]n [C]i [C]t [C]e O 
capacity [C]c [C]a [C]p [C]a [C]c [C]i [C]t [C]y O 
( [C]( O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
equal [C]e [C]q [C]u [C]a [C]l O 
to [C]t [C]o O 
350 [C]3 [C]5 [C]0 O 
sites/cell [C]s [C]i [C]t [C]e [C]s [C]/ [C]c [C]e [C]l [C]l O 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
sites [C]s [C]i [C]t [C]e [C]s E-protein 
were [C]w [C]e [C]r [C]e O 
extracted [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
a [C]a O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
pellet [C]p [C]e [C]l [C]l [C]e [C]t O 
by [C]b [C]y O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
0.4 [C]0 [C]. [C]4 O 
mol/l [C]m [C]o [C]l [C]/ [C]l O 
KCl [C]K [C]C [C]l O 
and [C]a [C]n [C]d O 
sonication [C]s [C]o [C]n [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Separation [C]S [C]e [C]p [C]a [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
bound [C]b [C]o [C]u [C]n [C]d O 
from [C]f [C]r [C]o [C]m O 
free [C]f [C]r [C]e [C]e O 
[ [C][ B-protein 
125I [C]1 [C]2 [C]5 [C]I I-protein 
] [C]] I-protein 
T3 [C]T [C]3 E-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
was [C]w [C]a [C]s O 
achieved [C]a [C]c [C]h [C]i [C]e [C]v [C]e [C]d O 
using [C]u [C]s [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
calcium [C]c [C]a [C]l [C]c [C]i [C]u [C]m O 
phosphate [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]e O 
matrix [C]m [C]a [C]t [C]r [C]i [C]x O 
, [C], O 
hydroxyapatite [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]a [C]p [C]a [C]t [C]i [C]t [C]e O 
at [C]a [C]t O 
a [C]a O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
0.3 [C]0 [C]. [C]3 O 
ml [C]m [C]l O 
of [C]o [C]f O 
a [C]a O 
150 [C]1 [C]5 [C]0 O 
g/l [C]g [C]/ [C]l O 
slurry [C]s [C]l [C]u [C]r [C]r [C]y O 
. [C]. O 

Rectilinear [C]R [C]e [C]c [C]t [C]i [C]l [C]i [C]n [C]e [C]a [C]r O 
Scatchard [C]S [C]c [C]a [C]t [C]c [C]h [C]a [C]r [C]d O 
plots [C]p [C]l [C]o [C]t [C]s O 
were [C]w [C]e [C]r [C]e O 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
only [C]o [C]n [C]l [C]y O 
when [C]w [C]h [C]e [C]n O 
the [C]t [C]h [C]e O 
hydroxyapatite [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]a [C]p [C]a [C]t [C]i [C]t [C]e O 
was [C]w [C]a [C]s O 
washed [C]w [C]a [C]s [C]h [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
buffer [C]b [C]u [C]f [C]f [C]e [C]r O 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
0.5 [C]0 [C]. [C]5 O 
% [C]% O 
Triton [C]T [C]r [C]i [C]t [C]o [C]n O 
X-100 [C]X [C]- [C]1 [C]0 [C]0 O 
. [C]. O 

Under [C]U [C]n [C]d [C]e [C]r O 
these [C]t [C]h [C]e [C]s [C]e O 
conditions [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n [C]s O 
T3 [C]T [C]3 B-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
sites [C]s [C]i [C]t [C]e [C]s E-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
were [C]w [C]e [C]r [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
at [C]a [C]t O 
a [C]a O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
22.4 [C]2 [C]2 [C]. [C]4 O 
+/- [C]+ [C]/ [C]- O 
8.6 [C]8 [C]. [C]6 O 
fmol/mg [C]f [C]m [C]o [C]l [C]/ [C]m [C]g O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
and [C]a [C]n [C]d O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
an [C]a [C]n O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
of [C]o [C]f O 
( [C]( O 
Kd [C]K [C]d O 
, [C], O 
room [C]r [C]o [C]o [C]m O 
temperature [C]t [C]e [C]m [C]p [C]e [C]r [C]a [C]t [C]u [C]r [C]e O 
) [C]) O 
140 [C]1 [C]4 [C]0 O 
+/- [C]+ [C]/ [C]- O 
10 [C]1 [C]0 O 
pmol/l [C]p [C]m [C]o [C]l [C]/ [C]l O 
. [C]. O 

The [C]T [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
assay [C]a [C]s [C]s [C]a [C]y O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
was [C]w [C]a [C]s O 
used [C]u [C]s [C]e [C]d O 
to [C]t [C]o O 
determine [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e O 
the [C]t [C]h [C]e O 
hierarchy [C]h [C]i [C]e [C]r [C]a [C]r [C]c [C]h [C]y O 
of [C]o [C]f O 
affinities [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]i [C]e [C]s O 
for [C]f [C]o [C]r O 
a [C]a O 
range [C]r [C]a [C]n [C]g [C]e O 
of [C]o [C]f O 
natural [C]n [C]a [C]t [C]u [C]r [C]a [C]l O 
and [C]a [C]n [C]d O 
synthetic [C]s [C]y [C]n [C]t [C]h [C]e [C]t [C]i [C]c O 
analogues [C]a [C]n [C]a [C]l [C]o [C]g [C]u [C]e [C]s O 
. [C]. O 

Calling [C]C [C]a [C]l [C]l [C]i [C]n [C]g O 
T3 [C]T [C]3 O 
100 [C]1 [C]0 [C]0 O 
, [C], O 
the [C]t [C]h [C]e O 
order [C]o [C]r [C]d [C]e [C]r O 
of [C]o [C]f O 
potencies [C]p [C]o [C]t [C]e [C]n [C]c [C]i [C]e [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
was [C]w [C]a [C]s O 
: [C]: O 
Triac [C]T [C]r [C]i [C]a [C]c O 
, [C], O 
500 [C]5 [C]0 [C]0 O 
; [C]; O 
3 [C]3 O 
, [C], O 
5-diiodo-3'-isopropylthyronine [C]5 [C]- [C]d [C]i [C]i [C]o [C]d [C]o [C]- [C]3 [C]' [C]- [C]i [C]s [C]o [C]p [C]r [C]o [C]p [C]y [C]l [C]t [C]h [C]y [C]r [C]o [C]n [C]i [C]n [C]e O 
, [C], O 
89 [C]8 [C]9 O 
; [C]; O 
T4 [C]T [C]4 O 
, [C], O 
32 [C]3 [C]2 O 
; [C]; O 
3 [C]3 O 
, [C], O 
5-dimethyl-3'isopropylthyronine [C]5 [C]- [C]d [C]i [C]m [C]e [C]t [C]h [C]y [C]l [C]- [C]3 [C]' [C]i [C]s [C]o [C]p [C]r [C]o [C]p [C]y [C]l [C]t [C]h [C]y [C]r [C]o [C]n [C]i [C]n [C]e O 
2 [C]2 O 
; [C]; O 
3 [C]3 O 
, [C], O 
5-T2 [C]5 [C]- [C]T [C]2 O 
, [C], O 
0.7 [C]0 [C]. [C]7 O 
, [C], O 
rT3 [C]r [C]T [C]3 O 
, [C], O 
0.4 [C]0 [C]. [C]4 O 
; [C]; O 
3'5'-T2 [C]3 [C]' [C]5 [C]' [C]- [C]T [C]2 O 
, [C], O 
less [C]l [C]e [C]s [C]s O 
than [C]t [C]h [C]a [C]n O 
0.01 [C]0 [C]. [C]0 [C]1 O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
T3 [C]T [C]3 B-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
sites [C]s [C]i [C]t [C]e [C]s E-protein 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
IM-9 [C]I [C]M [C]- [C]9 I-cell_line 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e E-cell_line 
nuclei [C]n [C]u [C]c [C]l [C]e [C]i O 
and [C]a [C]n [C]d O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
thereof [C]t [C]h [C]e [C]r [C]e [C]o [C]f O 
are [C]a [C]r [C]e O 
thyroid [C]t [C]h [C]y [C]r [C]o [C]i [C]d B-protein 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
a [C]a O 
useful [C]u [C]s [C]e [C]f [C]u [C]l O 
tool [C]t [C]o [C]o [C]l O 
to [C]t [C]o O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
our [C]o [C]u [C]r O 
understanding [C]u [C]n [C]d [C]e [C]r [C]s [C]t [C]a [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-protein 
T3 [C]T [C]3 I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 

Definition [C]D [C]e [C]f [C]i [C]n [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l B-protein 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-protein 
DNA-binding [C]D [C]N [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
that [C]t [C]h [C]a [C]t O 
interact [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
3'-silencer [C]3 [C]' [C]- [C]s [C]i [C]l [C]e [C]n [C]c [C]e [C]r S-DNA 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
CD4+ [C]C [C]D [C]4 [C]+ B-DNA 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l I-DNA 
gene [C]g [C]e [C]n [C]e I-DNA 
Rpt-1 [C]R [C]p [C]t [C]- [C]1 E-DNA 
. [C]. O 

Analysis [C]A [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
region [C]r [C]e [C]g [C]i [C]o [C]n O 
3 [C]3 O 
' [C]' O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
CD4+ [C]C [C]D [C]4 [C]+ B-DNA 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l I-DNA 
gene [C]g [C]e [C]n [C]e I-DNA 
Rpt-1 [C]R [C]p [C]t [C]- [C]1 E-DNA 
( [C]( O 
encoding [C]e [C]n [C]c [C]o [C]d [C]i [C]n [C]g O 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
T-lymphocyte [C]T [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e B-protein 
1 [C]1 E-protein 
) [C]) O 
led [C]l [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
definition [C]d [C]e [C]f [C]i [C]n [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
silencer [C]s [C]i [C]l [C]e [C]n [C]c [C]e [C]r B-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
that [C]t [C]h [C]a [C]t O 
inhibits [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]s O 
heterologous [C]h [C]e [C]t [C]e [C]r [C]o [C]l [C]o [C]g [C]o [C]u [C]s B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
certain [C]c [C]e [C]r [C]t [C]a [C]i [C]n O 
CD4+ [C]C [C]D [C]4 [C]+ B-cell_type 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l I-cell_type 
lines [C]l [C]i [C]n [C]e [C]s E-cell_type 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
in [C]i [C]n O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l S-cell_type 
or [C]o [C]r O 
non-lymphoid [C]n [C]o [C]n [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d B-cell_type 
cell [C]c [C]e [C]l [C]l I-cell_type 
lines [C]l [C]i [C]n [C]e [C]s E-cell_type 
. [C]. O 

Functional [C]F [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
silencer [C]s [C]i [C]l [C]e [C]n [C]c [C]e [C]r S-DNA 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
was [C]w [C]a [C]s O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
a [C]a O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
silencer-DNA-protein [C]s [C]i [C]l [C]e [C]n [C]c [C]e [C]r [C]- [C]D [C]N [C]A [C]- [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
in [C]i [C]n O 
electrophoretic [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
with [C]w [C]i [C]t [C]h O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l S-cell_type 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
. [C]. O 

Formation [C]F [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
was [C]w [C]a [C]s O 
selectively [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
region [C]r [C]e [C]g [C]i [C]o [C]n O 
in [C]i [C]n O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 S-DNA 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
a [C]a O 
silencer [C]s [C]i [C]l [C]e [C]n [C]c [C]e [C]r B-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
. [C]. O 

We [C]W [C]e O 
discuss [C]d [C]i [C]s [C]c [C]u [C]s [C]s O 
the [C]t [C]h [C]e O 
possibility [C]p [C]o [C]s [C]s [C]i [C]b [C]i [C]l [C]i [C]t [C]y O 
that [C]t [C]h [C]a [C]t O 
DNA-binding [C]D [C]N [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
may [C]m [C]a [C]y O 
coregulate [C]c [C]o [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
and [C]a [C]n [C]d O 
Rpt-1 [C]R [C]p [C]t [C]- [C]1 O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
a [C]a O 
common [C]c [C]o [C]m [C]m [C]o [C]n O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l B-DNA 
silencer [C]s [C]i [C]l [C]e [C]n [C]c [C]e [C]r I-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
. [C]. O 

Congenital [C]C [C]o [C]n [C]g [C]e [C]n [C]i [C]t [C]a [C]l O 
immunodeficiencies [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]i [C]e [C]s O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
HLA [C]H [C]L [C]A B-protein 
class [C]c [C]l [C]a [C]s [C]s I-protein 
II [C]I [C]I I-protein 
antigens [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]s E-protein 
on [C]o [C]n O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
result [C]r [C]e [C]s [C]u [C]l [C]t O 
from [C]f [C]r [C]o [C]m O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
trans-acting [C]t [C]r [C]a [C]n [C]s [C]- [C]a [C]c [C]t [C]i [C]n [C]g B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

Coordinate [C]C [C]o [C]o [C]r [C]d [C]i [C]n [C]a [C]t [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
HLA [C]H [C]L [C]A B-DNA 
class [C]c [C]l [C]a [C]s [C]s I-DNA 
II [C]I [C]I I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
coinduction [C]c [C]o [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
class [C]c [C]l [C]a [C]s [C]s B-DNA 
II [C]I [C]I I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
by [C]b [C]y O 
soluble [C]s [C]o [C]l [C]u [C]b [C]l [C]e B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
suggests [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]s O 
that [C]t [C]h [C]a [C]t O 
common [C]c [C]o [C]m [C]m [C]o [C]n O 
trans-acting [C]t [C]r [C]a [C]n [C]s [C]- [C]a [C]c [C]t [C]i [C]n [C]g B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
( [C]( O 
s [C]s O 
) [C]) O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
genes [C]g [C]e [C]n [C]e [C]s O 
. [C]. O 

In [C]I [C]n O 
B-lymphoblastoid [C]B [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]o [C]i [C]d B-cell_type 
cell [C]c [C]e [C]l [C]l I-cell_type 
lines [C]l [C]i [C]n [C]e [C]s E-cell_type 
derived [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
two [C]t [C]w [C]o O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
class [C]c [C]l [C]a [C]s [C]s O 
II-deficient [C]I [C]I [C]- [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
bare [C]b [C]a [C]r [C]e O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e O 
syndrome [C]s [C]y [C]n [C]d [C]r [C]o [C]m [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
, [C], O 
we [C]w [C]e O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
a [C]a O 
drastic [C]d [C]r [C]a [C]s [C]t [C]i [C]c O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
rates [C]r [C]a [C]t [C]e [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
class [C]c [C]l [C]a [C]s [C]s B-DNA 
II [C]I [C]I I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
. [C]. O 

When [C]W [C]h [C]e [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
cell [C]c [C]e [C]l [C]l O 
lines [C]l [C]i [C]n [C]e [C]s O 
are [C]a [C]r [C]e O 
fused [C]f [C]u [C]s [C]e [C]d O 
, [C], O 
class [C]c [C]l [C]a [C]s [C]s B-DNA 
II [C]I [C]I I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
are [C]a [C]r [C]e O 
reexpressed [C]r [C]e [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
, [C], O 
indicating [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
immunodeficiencies [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]i [C]e [C]s O 
in [C]i [C]n O 
bare [C]b [C]a [C]r [C]e O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e O 
syndrome [C]s [C]y [C]n [C]d [C]r [C]o [C]m [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
are [C]a [C]r [C]e O 
the [C]t [C]h [C]e O 
result [C]r [C]e [C]s [C]u [C]l [C]t O 
of [C]o [C]f O 
two [C]t [C]w [C]o O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

Further [C]F [C]u [C]r [C]t [C]h [C]e [C]r O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
genes [C]g [C]e [C]n [C]e [C]s O 
governing [C]g [C]o [C]v [C]e [C]r [C]n [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
class [C]c [C]l [C]a [C]s [C]s B-protein 
II [C]I [C]I I-protein 
antigens [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]s E-protein 
fall [C]f [C]a [C]l [C]l O 
into [C]i [C]n [C]t [C]o O 
at [C]a [C]t O 
least [C]l [C]e [C]a [C]s [C]t O 
three [C]t [C]h [C]r [C]e [C]e O 
complementation [C]c [C]o [C]m [C]p [C]l [C]e [C]m [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
groups [C]g [C]r [C]o [C]u [C]p [C]s O 
; [C]; O 
two [C]t [C]w [C]o O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
were [C]w [C]e [C]r [C]e O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
unidentified [C]u [C]n [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
in [C]i [C]n O 
mutant [C]m [C]u [C]t [C]a [C]n [C]t B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
generated [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
we [C]w [C]e O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
the [C]t [C]h [C]e O 
identification [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
two [C]t [C]w [C]o O 
discrete [C]d [C]i [C]s [C]c [C]r [C]e [C]t [C]e O 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s O 
, [C], O 
NFX1.1 [C]N [C]F [C]X [C]1 [C]. [C]1 S-protein 
and [C]a [C]n [C]d O 
NFX1.2 [C]N [C]F [C]X [C]1 [C]. [C]2 S-protein 
, [C], O 
that [C]t [C]h [C]a [C]t O 
bind [C]b [C]i [C]n [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
DRA [C]D [C]R [C]A B-DNA 
X [C]X I-DNA 
consensus [C]c [C]o [C]n [C]s [C]e [C]n [C]s [C]u [C]s I-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
. [C]. O 

Though [C]T [C]h [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
at [C]a [C]t O 
least [C]l [C]e [C]a [C]s [C]t O 
one [C]o [C]n [C]e O 
mutant [C]m [C]u [C]t [C]a [C]n [C]t B-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
generated [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
( [C]( O 
RJ2.2.5 [C]R [C]J [C]2 [C]. [C]2 [C]. [C]5 S-cell_line 
) [C]) O 
affects [C]a [C]f [C]f [C]e [C]c [C]t [C]s O 
products [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]s O 
functioning [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]i [C]n [C]g O 
via [C]v [C]i [C]a O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
X [C]X B-DNA 
box [C]b [C]o [C]x E-DNA 
, [C], O 
clear [C]c [C]l [C]e [C]a [C]r O 
alterations [C]a [C]l [C]t [C]e [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
NFX1.1 [C]N [C]F [C]X [C]1 [C]. [C]1 S-protein 
or [C]o [C]r O 
NFX1.2 [C]N [C]F [C]X [C]1 [C]. [C]2 S-protein 
are [C]a [C]r [C]e O 
not [C]n [C]o [C]t O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
any [C]a [C]n [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
mutant [C]m [C]u [C]t [C]a [C]n [C]t B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
. [C]. O 

In [C]I [C]n O 
vivo [C]v [C]i [C]v [C]o O 
responsiveness [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e [C]n [C]e [C]s [C]s O 
to [C]t [C]o O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
in [C]i [C]n O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
humans [C]h [C]u [C]m [C]a [C]n [C]s O 
. [C]. O 

Dexamethasone [C]D [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
loading [C]l [C]o [C]a [C]d [C]i [C]n [C]g O 
tests [C]t [C]e [C]s [C]t [C]s O 
( [C]( O 
0.1 [C]0 [C]. [C]1 O 
mg [C]m [C]g O 
dexamethasone/kg [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e [C]/ [C]k [C]g O 
, [C], O 
iv [C]i [C]v O 
) [C]) O 
were [C]w [C]e [C]r [C]e O 
performed [C]p [C]e [C]r [C]f [C]o [C]r [C]m [C]e [C]d O 
in [C]i [C]n O 
18 [C]1 [C]8 O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
males [C]m [C]a [C]l [C]e [C]s O 
to [C]t [C]o O 
evaluate [C]e [C]v [C]a [C]l [C]u [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
individual [C]i [C]n [C]d [C]i [C]v [C]i [C]d [C]u [C]a [C]l O 
responsiveness [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e [C]n [C]e [C]s [C]s O 
to [C]t [C]o O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
. [C]. O 

There [C]T [C]h [C]e [C]r [C]e O 
were [C]w [C]e [C]r [C]e O 
inter-individual [C]i [C]n [C]t [C]e [C]r [C]- [C]i [C]n [C]d [C]i [C]v [C]i [C]d [C]u [C]a [C]l O 
differences [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e [C]s O 
in [C]i [C]n O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
polymorphonuclear [C]p [C]o [C]l [C]y [C]m [C]o [C]r [C]p [C]h [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e E-cell_type 
count [C]c [C]o [C]u [C]n [C]t O 
, [C], O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e E-cell_type 
count [C]c [C]o [C]u [C]n [C]t O 
, [C], O 
and [C]a [C]n [C]d O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
plasma [C]p [C]l [C]a [C]s [C]m [C]a O 
free [C]f [C]r [C]e [C]e O 
fatty [C]f [C]a [C]t [C]t [C]y O 
acids [C]a [C]c [C]i [C]d [C]s O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
after [C]a [C]f [C]t [C]e [C]r O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
injection [C]i [C]n [C]j [C]e [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
there [C]t [C]h [C]e [C]r [C]e O 
was [C]w [C]a [C]s O 
a [C]a O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
maximum [C]m [C]a [C]x [C]i [C]m [C]u [C]m O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
polymorphonuclear [C]p [C]o [C]l [C]y [C]m [C]o [C]r [C]p [C]h [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_type 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
maximum [C]m [C]a [C]x [C]i [C]m [C]u [C]m O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
( [C]( O 
r [C]r O 
= [C]= O 
0.7514 [C]0 [C]. [C]7 [C]5 [C]1 [C]4 O 
, [C], O 
p [C]p O 
less [C]l [C]e [C]s [C]s O 
than [C]t [C]h [C]a [C]n O 
0.0003 [C]0 [C]. [C]0 [C]0 [C]0 [C]3 O 
) [C]) O 
. [C]. O 

Simultaneous [C]S [C]i [C]m [C]u [C]l [C]t [C]a [C]n [C]e [C]o [C]u [C]s O 
measurements [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]m [C]e [C]n [C]t [C]s O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
by [C]b [C]y O 
whole-cell [C]w [C]h [C]o [C]l [C]e [C]- [C]c [C]e [C]l [C]l O 
assay [C]a [C]s [C]s [C]a [C]y O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
in [C]i [C]n O 
polymorphonuclear [C]p [C]o [C]l [C]y [C]m [C]o [C]r [C]p [C]h [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_type 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
linearly [C]l [C]i [C]n [C]e [C]a [C]r [C]l [C]y O 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
that [C]t [C]h [C]a [C]t O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
corresponding [C]c [C]o [C]r [C]r [C]e [C]s [C]p [C]o [C]n [C]d [C]i [C]n [C]g O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
( [C]( O 
r [C]r O 
= [C]= O 
0.9482 [C]0 [C]. [C]9 [C]4 [C]8 [C]2 O 
, [C], O 
p [C]p O 
less [C]l [C]e [C]s [C]s O 
than [C]t [C]h [C]a [C]n O 
0.0001 [C]0 [C]. [C]0 [C]0 [C]0 [C]1 O 
) [C]) O 
. [C]. O 

There [C]T [C]h [C]e [C]r [C]e O 
were [C]w [C]e [C]r [C]e O 
also [C]a [C]l [C]s [C]o O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
correlations [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n [C]s O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
maximum [C]m [C]a [C]x [C]i [C]m [C]u [C]m O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
polymorphonuclear [C]p [C]o [C]l [C]y [C]m [C]o [C]r [C]p [C]h [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_type 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
in [C]i [C]n O 
polymorphonuclear [C]p [C]o [C]l [C]y [C]m [C]o [C]r [C]p [C]h [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_type 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
( [C]( O 
r [C]r O 
= [C]= O 
0.7239 [C]0 [C]. [C]7 [C]2 [C]3 [C]9 O 
, [C], O 
p [C]p O 
less [C]l [C]e [C]s [C]s O 
than [C]t [C]h [C]a [C]n O 
0.0007 [C]0 [C]. [C]0 [C]0 [C]0 [C]7 O 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
maximum [C]m [C]a [C]x [C]i [C]m [C]u [C]m O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
and [C]a [C]n [C]d O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
in [C]i [C]n O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
( [C]( O 
r [C]r O 
= [C]= O 
0.7703 [C]0 [C]. [C]7 [C]7 [C]0 [C]3 O 
, [C], O 
p [C]p O 
less [C]l [C]e [C]s [C]s O 
than [C]t [C]h [C]a [C]n O 
0.0002 [C]0 [C]. [C]0 [C]0 [C]0 [C]2 O 
) [C]) O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
individual [C]i [C]n [C]d [C]i [C]v [C]i [C]d [C]u [C]a [C]l O 
differences [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e [C]s O 
are [C]a [C]r [C]e O 
preserved [C]p [C]r [C]e [C]s [C]e [C]r [C]v [C]e [C]d O 
both [C]b [C]o [C]t [C]h O 
in [C]i [C]n O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
responsiveness [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e [C]n [C]e [C]s [C]s O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
in [C]i [C]n O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
humans [C]h [C]u [C]m [C]a [C]n [C]s O 
. [C]. O 

Estradiol [C]E [C]s [C]t [C]r [C]a [C]d [C]i [C]o [C]l O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
of [C]o [C]f O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
hepatitis [C]h [C]e [C]p [C]a [C]t [C]i [C]t [C]i [C]s O 
B [C]B O 
virus [C]v [C]i [C]r [C]u [C]s O 
carriers [C]c [C]a [C]r [C]r [C]i [C]e [C]r [C]s O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
interferon-alpha [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
. [C]. O 

Estradiol [C]E [C]s [C]t [C]r [C]a [C]d [C]i [C]o [C]l B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
of [C]o [C]f O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
interferon-alpha [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
( [C]( O 
IFN-alpha [C]I [C]F [C]N [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
) [C]) O 
on [C]o [C]n O 
estradiol [C]e [C]s [C]t [C]r [C]a [C]d [C]i [C]o [C]l B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
were [C]w [C]e [C]r [C]e O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
in [C]i [C]n O 
asymptomatic [C]a [C]s [C]y [C]m [C]p [C]t [C]o [C]m [C]a [C]t [C]i [C]c O 
hepatitis [C]h [C]e [C]p [C]a [C]t [C]i [C]t [C]i [C]s O 
B [C]B O 
virus [C]v [C]i [C]r [C]u [C]s O 
( [C]( O 
HBV [C]H [C]B [C]V O 
) [C]) O 
carriers [C]c [C]a [C]r [C]r [C]i [C]e [C]r [C]s O 
, [C], O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
hepatitis [C]h [C]e [C]p [C]a [C]t [C]i [C]t [C]i [C]s O 
B [C]B O 
and [C]a [C]n [C]d O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
estradiol [C]e [C]s [C]t [C]r [C]a [C]d [C]i [C]o [C]l B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
of [C]o [C]f O 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
was [C]w [C]a [C]s O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
lower [C]l [C]o [C]w [C]e [C]r O 
in [C]i [C]n O 
asymptomatic [C]a [C]s [C]y [C]m [C]p [C]t [C]o [C]m [C]a [C]t [C]i [C]c O 
HBV [C]H [C]B [C]V O 
carriers [C]c [C]a [C]r [C]r [C]i [C]e [C]r [C]s O 
and [C]a [C]n [C]d O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
hepatitis [C]h [C]e [C]p [C]a [C]t [C]i [C]t [C]i [C]s O 
B [C]B O 
, [C], O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
low [C]l [C]o [C]w O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
estradiol [C]e [C]s [C]t [C]r [C]a [C]d [C]i [C]o [C]l B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
hepatitis [C]h [C]e [C]p [C]a [C]t [C]i [C]t [C]i [C]s O 
B [C]B O 
was [C]w [C]a [C]s O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
administration [C]a [C]d [C]m [C]i [C]n [C]i [C]s [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IFN-alpha [C]I [C]F [C]N [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
when [C]w [C]h [C]e [C]n O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
hepatitis [C]h [C]e [C]p [C]a [C]t [C]i [C]t [C]i [C]s O 
B [C]B O 
were [C]w [C]e [C]r [C]e O 
incubated [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
IFN-alpha [C]I [C]F [C]N [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
, [C], O 
the [C]t [C]h [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
estradiol [C]e [C]s [C]t [C]r [C]a [C]d [C]i [C]o [C]l B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
also [C]a [C]l [C]s [C]o O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
by [C]b [C]y O 
increasing [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IFN-alpha [C]I [C]F [C]N [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
. [C]. O 

We [C]W [C]e O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
reported [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
of [C]o [C]f O 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
to [C]t [C]o O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n O 
is [C]i [C]s O 
impaired [C]i [C]m [C]p [C]a [C]i [C]r [C]e [C]d O 
in [C]i [C]n O 
HBV [C]H [C]B [C]V O 
carriers [C]c [C]a [C]r [C]r [C]i [C]e [C]r [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
our [C]o [C]u [C]r O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggested [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
this [C]t [C]h [C]i [C]s O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
due [C]d [C]u [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
low [C]l [C]o [C]w O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
estradiol [C]e [C]s [C]t [C]r [C]a [C]d [C]i [C]o [C]l B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
of [C]o [C]f O 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Association [C]A [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
lytic [C]l [C]y [C]t [C]i [C]c O 
effector [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r O 
cell [C]c [C]e [C]l [C]l O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
high [C]h [C]i [C]g [C]h O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
in [C]i [C]n O 
tumor-bearing [C]t [C]u [C]m [C]o [C]r [C]- [C]b [C]e [C]a [C]r [C]i [C]n [C]g O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
. [C]. O 

Tumor-bearing [C]T [C]u [C]m [C]o [C]r [C]- [C]b [C]e [C]a [C]r [C]i [C]n [C]g O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
were [C]w [C]e [C]r [C]e O 
assayed [C]a [C]s [C]s [C]a [C]y [C]e [C]d O 
for [C]f [C]o [C]r O 
their [C]t [C]h [C]e [C]i [C]r O 
natural [C]n [C]a [C]t [C]u [C]r [C]a [C]l B-cell_type 
killer [C]k [C]i [C]l [C]l [C]e [C]r I-cell_type 
( [C]( I-cell_type 
NK [C]N [C]K I-cell_type 
) [C]) I-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
cytotoxic [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c B-cell_type 
T-cells [C]T [C]- [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
as [C]a [C]s O 
assessed [C]a [C]s [C]s [C]e [C]s [C]s [C]e [C]d O 
by [C]b [C]y O 
lectin-dependent [C]l [C]e [C]c [C]t [C]i [C]n [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
cytotoxicity [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c [C]i [C]t [C]y O 
( [C]( O 
LDCC [C]L [C]D [C]C [C]C O 
) [C]) O 
. [C]. O 

Tumor-bearing [C]T [C]u [C]m [C]o [C]r [C]- [C]b [C]e [C]a [C]r [C]i [C]n [C]g O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
had [C]h [C]a [C]d O 
a [C]a O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
NK [C]N [C]K S-cell_type 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
LDCC [C]L [C]D [C]C [C]C O 
, [C], O 
as [C]a [C]s O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
healthy [C]h [C]e [C]a [C]l [C]t [C]h [C]y O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
individuals [C]i [C]n [C]d [C]i [C]v [C]i [C]d [C]u [C]a [C]l [C]s O 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
NK [C]N [C]K B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
LDCC [C]L [C]D [C]C [C]C O 
were [C]w [C]e [C]r [C]e O 
closely [C]c [C]l [C]o [C]s [C]e [C]l [C]y O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
high [C]h [C]i [C]g [C]h O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
( [C]( O 
greater [C]g [C]r [C]e [C]a [C]t [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
31 [C]3 [C]1 O 
fmol/mg [C]f [C]m [C]o [C]l [C]/ [C]m [C]g O 
) [C]) O 
of [C]o [C]f O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
( [C]( O 
ER [C]E [C]R S-protein 
) [C]) O 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y O 
tumor [C]t [C]u [C]m [C]o [C]r O 
, [C], O 
no [C]n [C]o O 
other [C]o [C]t [C]h [C]e [C]r O 
clinical [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
or [C]o [C]r O 
histologic [C]h [C]i [C]s [C]t [C]o [C]l [C]o [C]g [C]i [C]c O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
parameter [C]p [C]a [C]r [C]a [C]m [C]e [C]t [C]e [C]r O 
of [C]o [C]f O 
cytotoxic [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c B-cell_type 
effector [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r I-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
ER [C]E [C]R S-protein 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
greater [C]g [C]r [C]e [C]a [C]t [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
31 [C]3 [C]1 O 
fmol/mg [C]f [C]m [C]o [C]l [C]/ [C]m [C]g O 
might [C]m [C]i [C]g [C]h [C]t O 
be [C]b [C]e O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
cytotoxic [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c B-cell_type 
effector [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r I-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
tumor-bearing [C]t [C]u [C]m [C]o [C]r [C]- [C]b [C]e [C]a [C]r [C]i [C]n [C]g O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
. [C]. O 

Properties [C]P [C]r [C]o [C]p [C]e [C]r [C]t [C]i [C]e [C]s O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
Epstein-Barr [C]E [C]p [C]s [C]t [C]e [C]i [C]n [C]- [C]B [C]a [C]r [C]r B-cell_line 
virus-transformed [C]v [C]i [C]r [C]u [C]s [C]- [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]e [C]d I-cell_line 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_line 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
familial [C]f [C]a [C]m [C]i [C]l [C]i [C]a [C]l O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
. [C]. O 

In [C]I [C]n O 
a [C]a O 
previous [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
of [C]o [C]f O 
two [C]t [C]w [C]o O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
familial [C]f [C]a [C]m [C]i [C]l [C]i [C]a [C]l O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
due [C]d [C]u [C]e O 
to [C]t [C]o O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
numbers [C]n [C]u [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
( [C]( O 
GR [C]G [C]R S-protein 
) [C]) O 
, [C], O 
we [C]w [C]e O 
have [C]h [C]a [C]v [C]e O 
shown [C]s [C]h [C]o [C]w [C]n O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
numbers [C]n [C]u [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
GR [C]G [C]R S-protein 
in [C]i [C]n O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
cultured [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]d B-cell_line 
fibroblasts [C]f [C]i [C]b [C]r [C]o [C]b [C]l [C]a [C]s [C]t [C]s E-cell_line 
but [C]b [C]u [C]t O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
of [C]o [C]f O 
GR [C]G [C]R S-protein 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
, [C], O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
these [C]t [C]h [C]e [C]s [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
, [C], O 
one [C]o [C]n [C]e O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
's [C]' [C]s O 
son [C]s [C]o [C]n O 
and [C]a [C]n [C]d O 
daughter [C]d [C]a [C]u [C]g [C]h [C]t [C]e [C]r O 
, [C], O 
and [C]a [C]n [C]d O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
were [C]w [C]e [C]r [C]e O 
transformed [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
Epstein-Barr [C]E [C]p [C]s [C]t [C]e [C]i [C]n [C]- [C]B [C]a [C]r [C]r O 
virus [C]v [C]i [C]r [C]u [C]s O 
. [C]. O 

Reduced [C]R [C]e [C]d [C]u [C]c [C]e [C]d O 
numbers [C]n [C]u [C]m [C]b [C]e [C]r [C]s O 
and [C]a [C]n [C]d O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
of [C]o [C]f O 
GR [C]G [C]R S-protein 
were [C]w [C]e [C]r [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
Epstein-Barr [C]E [C]p [C]s [C]t [C]e [C]i [C]n [C]- [C]B [C]a [C]r [C]r B-cell_line 
virus-transformed [C]v [C]i [C]r [C]u [C]s [C]- [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]e [C]d I-cell_line 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_line 
from [C]f [C]r [C]o [C]m O 
both [C]b [C]o [C]t [C]h O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
while [C]w [C]h [C]i [C]l [C]e O 
the [C]t [C]h [C]e O 
son [C]s [C]o [C]n O 
and [C]a [C]n [C]d O 
daughter [C]d [C]a [C]u [C]g [C]h [C]t [C]e [C]r O 
had [C]h [C]a [C]d O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
numbers [C]n [C]u [C]m [C]b [C]e [C]r [C]s O 
and [C]a [C]n [C]d O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
of [C]o [C]f O 
GR [C]G [C]R S-protein 
. [C]. O 

The [C]T [C]h [C]e O 
thermal [C]t [C]h [C]e [C]r [C]m [C]a [C]l O 
stability [C]s [C]t [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
GR [C]G [C]R S-protein 
and [C]a [C]n [C]d O 
thermal [C]t [C]h [C]e [C]r [C]m [C]a [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cytosolic [C]c [C]y [C]t [C]o [C]s [C]o [C]l [C]i [C]c B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
were [C]w [C]e [C]r [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
percentages [C]p [C]e [C]r [C]c [C]e [C]n [C]t [C]a [C]g [C]e [C]s O 
of [C]o [C]f O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
bound [C]b [C]o [C]u [C]n [C]d O 
GR [C]G [C]R S-protein 
were [C]w [C]e [C]r [C]e O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
and [C]a [C]n [C]d O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
, [C], O 
the [C]t [C]h [C]e O 
absolute [C]a [C]b [C]s [C]o [C]l [C]u [C]t [C]e O 
amounts [C]a [C]m [C]o [C]u [C]n [C]t [C]s O 
of [C]o [C]f O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
bound [C]b [C]o [C]u [C]n [C]d O 
GR [C]G [C]R S-protein 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
were [C]w [C]e [C]r [C]e O 
about [C]a [C]b [C]o [C]u [C]t O 
one-half [C]o [C]n [C]e [C]- [C]h [C]a [C]l [C]f O 
that [C]t [C]h [C]a [C]t O 
of [C]o [C]f O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
abnormal [C]a [C]b [C]n [C]o [C]r [C]m [C]a [C]l O 
properties [C]p [C]r [C]o [C]p [C]e [C]r [C]t [C]i [C]e [C]s O 
of [C]o [C]f O 
GR [C]G [C]R S-protein 
( [C]( O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
numbers [C]n [C]u [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
GR [C]G [C]R S-protein 
) [C]) O 
were [C]w [C]e [C]r [C]e O 
preserved [C]p [C]r [C]e [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
transformed [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]e [C]d B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

Octamer [C]O [C]c [C]t [C]a [C]m [C]e [C]r O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
1 [C]1 O 
and [C]a [C]n [C]d O 
2 [C]2 O 
each [C]e [C]a [C]c [C]h O 
bind [C]b [C]i [C]n [C]d O 
to [C]t [C]o O 
two [C]t [C]w [C]o O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l B-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n B-DNA 
heavy-chain [C]h [C]e [C]a [C]v [C]y [C]- [C]c [C]h [C]a [C]i [C]n I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

Immunoglobulin [C]I [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n B-DNA 
heavy-chain [C]h [C]e [C]a [C]v [C]y [C]- [C]c [C]h [C]a [C]i [C]n I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
contain [C]c [C]o [C]n [C]t [C]a [C]i [C]n O 
two [C]t [C]w [C]o O 
conserved [C]c [C]o [C]n [C]s [C]e [C]r [C]v [C]e [C]d B-DNA 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e I-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
5 [C]5 O 
' [C]' O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
site [C]s [C]i [C]t [C]e O 
of [C]o [C]f O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
initiation [C]i [C]n [C]i [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
: [C]: O 
the [C]t [C]h [C]e O 
octamer [C]o [C]c [C]t [C]a [C]m [C]e [C]r O 
ATGCAAAT [C]A [C]T [C]G [C]C [C]A [C]A [C]A [C]T O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
heptamer [C]h [C]e [C]p [C]t [C]a [C]m [C]e [C]r O 
CTCATGA [C]C [C]T [C]C [C]A [C]T [C]G [C]A O 
. [C]. O 

Both [C]B [C]o [C]t [C]h O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s O 
are [C]a [C]r [C]e O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-DNA 
cell-specific [C]c [C]e [C]l [C]l [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
study [C]s [C]t [C]u [C]d [C]y O 
demonstrates [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]s O 
that [C]t [C]h [C]a [C]t O 
both [C]b [C]o [C]t [C]h O 
the [C]t [C]h [C]e O 
ubiquitous [C]u [C]b [C]i [C]q [C]u [C]i [C]t [C]o [C]u [C]s B-protein 
and [C]a [C]n [C]d I-protein 
lymphoid-cell-specific [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d [C]- [C]c [C]e [C]l [C]l [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-protein 
octamer [C]o [C]c [C]t [C]a [C]m [C]e [C]r I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
( [C]( O 
OTF-1 [C]O [C]T [C]F [C]- [C]1 S-protein 
and [C]a [C]n [C]d O 
OTF-2 [C]O [C]T [C]F [C]- [C]2 S-protein 
, [C], O 
respectively [C]r [C]e [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
) [C]) O 
interact [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t O 
specifically [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]a [C]l [C]l [C]y O 
with [C]w [C]i [C]t [C]h O 
each [C]e [C]a [C]c [C]h O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
two [C]t [C]w [C]o O 
conserved [C]c [C]o [C]n [C]s [C]e [C]r [C]v [C]e [C]d B-DNA 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e I-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
, [C], O 
forming [C]f [C]o [C]r [C]m [C]i [C]n [C]g O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
homo- [C]h [C]o [C]m [C]o [C]- B-protein 
or [C]o [C]r I-protein 
heterodimeric [C]h [C]e [C]t [C]e [C]r [C]o [C]d [C]i [C]m [C]e [C]r [C]i [C]c I-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
was [C]w [C]a [C]s O 
surprising [C]s [C]u [C]r [C]p [C]r [C]i [C]s [C]i [C]n [C]g O 
, [C], O 
since [C]s [C]i [C]n [C]c [C]e O 
the [C]t [C]h [C]e O 
heptamer [C]h [C]e [C]p [C]t [C]a [C]m [C]e [C]r O 
and [C]a [C]n [C]d O 
octamer [C]o [C]c [C]t [C]a [C]m [C]e [C]r O 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
motifs [C]m [C]o [C]t [C]i [C]f [C]s O 
bear [C]b [C]e [C]a [C]r O 
no [C]n [C]o O 
obvious [C]o [C]b [C]v [C]i [C]o [C]u [C]s O 
similarity [C]s [C]i [C]m [C]i [C]l [C]a [C]r [C]i [C]t [C]y O 
to [C]t [C]o O 
each [C]e [C]a [C]c [C]h O 
other [C]o [C]t [C]h [C]e [C]r O 
. [C]. O 

Binding [C]B [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
octamer [C]o [C]c [C]t [C]a [C]m [C]e [C]r B-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
occurred [C]o [C]c [C]c [C]u [C]r [C]r [C]e [C]d O 
independently [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t [C]l [C]y O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
OTF [C]O [C]T [C]F S-protein 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
heptamer [C]h [C]e [C]p [C]t [C]a [C]m [C]e [C]r B-DNA 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e E-DNA 
appeared [C]a [C]p [C]p [C]e [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
require [C]r [C]e [C]q [C]u [C]i [C]r [C]e O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
an [C]a [C]n O 
intact [C]i [C]n [C]t [C]a [C]c [C]t O 
octamer [C]o [C]c [C]t [C]a [C]m [C]e [C]r O 
motif [C]m [C]o [C]t [C]i [C]f O 
and [C]a [C]n [C]d O 
occurred [C]o [C]c [C]c [C]u [C]r [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
spacing [C]s [C]p [C]a [C]c [C]i [C]n [C]g O 
of [C]o [C]f O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
2 [C]2 B-DNA 
or [C]o [C]r I-DNA 
14 [C]1 [C]4 I-DNA 
base [C]b [C]a [C]s [C]e I-DNA 
pairs [C]p [C]a [C]i [C]r [C]s E-DNA 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
two [C]t [C]w [C]o O 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s O 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
coordinate [C]c [C]o [C]o [C]r [C]d [C]i [C]n [C]a [C]t [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
resulting [C]r [C]e [C]s [C]u [C]l [C]t [C]i [C]n [C]g O 
from [C]f [C]r [C]o [C]m O 
protein-protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
interactions [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
degeneracy [C]d [C]e [C]g [C]e [C]n [C]e [C]r [C]a [C]c [C]y O 
in [C]i [C]n O 
sequences [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s O 
recognized [C]r [C]e [C]c [C]o [C]g [C]n [C]i [C]z [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
OTFs [C]O [C]T [C]F [C]s S-protein 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
in [C]i [C]n O 
widening [C]w [C]i [C]d [C]e [C]n [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
range [C]r [C]a [C]n [C]g [C]e O 
over [C]o [C]v [C]e [C]r O 
which [C]w [C]h [C]i [C]c [C]h O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
can [C]c [C]a [C]n O 
be [C]b [C]e O 
modulated [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]e [C]d O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
establishing [C]e [C]s [C]t [C]a [C]b [C]l [C]i [C]s [C]h [C]i [C]n [C]g O 
cell [C]c [C]e [C]l [C]l O 
type [C]t [C]y [C]p [C]e O 
specificity [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]i [C]t [C]y O 
. [C]. O 

Identification [C]I [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d B-protein 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-protein 
octamer [C]o [C]c [C]t [C]a [C]m [C]e [C]r I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
( [C]( O 
OTF-2B [C]O [C]T [C]F [C]- [C]2 [C]B S-protein 
) [C]) O 
by [C]b [C]y O 
proteolytic [C]p [C]r [C]o [C]t [C]e [C]o [C]l [C]y [C]t [C]i [C]c O 
clipping [C]c [C]l [C]i [C]p [C]p [C]i [C]n [C]g O 
bandshift [C]b [C]a [C]n [C]d [C]s [C]h [C]i [C]f [C]t O 
assay [C]a [C]s [C]s [C]a [C]y O 
( [C]( O 
PCBA [C]P [C]C [C]B [C]A O 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
octamer [C]o [C]c [C]t [C]a [C]m [C]e [C]r O 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
ATGCAAAT [C]A [C]T [C]G [C]C [C]A [C]A [C]A [C]T O 
is [C]i [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s O 
of [C]o [C]f O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n B-DNA 
( [C]( I-DNA 
Ig [C]I [C]g I-DNA 
) [C]) I-DNA 
heavy [C]h [C]e [C]a [C]v [C]y I-DNA 
and [C]a [C]n [C]d I-DNA 
light [C]l [C]i [C]g [C]h [C]t I-DNA 
chain [C]c [C]h [C]a [C]i [C]n I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
heavy [C]h [C]e [C]a [C]v [C]y B-DNA 
chain [C]c [C]h [C]a [C]i [C]n I-DNA 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r E-DNA 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
a [C]a O 
major [C]m [C]a [C]j [C]o [C]r O 
determinant [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cell [C]c [C]e [C]l [C]l O 
type [C]t [C]y [C]p [C]e O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
Ig [C]I [C]g B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
in [C]i [C]n O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

An [C]A [C]n O 
apparent [C]a [C]p [C]p [C]a [C]r [C]e [C]n [C]t O 
paradox [C]p [C]a [C]r [C]a [C]d [C]o [C]x O 
is [C]i [C]s O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
serves [C]s [C]e [C]r [C]v [C]e [C]s O 
as [C]a [C]s O 
an [C]a [C]n O 
upstream [C]u [C]p [C]s [C]t [C]r [C]e [C]a [C]m B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r I-DNA 
or [C]o [C]r I-DNA 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r I-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
in [C]i [C]n O 
a [C]a O 
variety [C]v [C]a [C]r [C]i [C]e [C]t [C]y O 
of [C]o [C]f O 
housekeeping [C]h [C]o [C]u [C]s [C]e [C]k [C]e [C]e [C]p [C]i [C]n [C]g B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
the [C]t [C]h [C]e O 
histone [C]h [C]i [C]s [C]t [C]o [C]n [C]e B-DNA 
H2B [C]H [C]2 [C]B I-DNA 
and [C]a [C]n [C]d I-DNA 
U [C]U I-DNA 
snRNA [C]s [C]n [C]R [C]N [C]A I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
. [C]. O 

The [C]T [C]h [C]e O 
differential [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l O 
usage [C]u [C]s [C]a [C]g [C]e O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
motif [C]m [C]o [C]t [C]i [C]f O 
is [C]i [C]s O 
thought [C]t [C]h [C]o [C]u [C]g [C]h [C]t O 
to [C]t [C]o O 
be [C]b [C]e O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
species [C]s [C]p [C]e [C]c [C]i [C]e [C]s O 
of [C]o [C]f O 
octamer [C]o [C]c [C]t [C]a [C]m [C]e [C]r B-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
. [C]. O 

One [C]O [C]n [C]e O 
species [C]s [C]p [C]e [C]c [C]i [C]e [C]s O 
of [C]o [C]f O 
100 [C]1 [C]0 [C]0 O 
kd [C]k [C]d O 
, [C], O 
designated [C]d [C]e [C]s [C]i [C]g [C]n [C]a [C]t [C]e [C]d O 
OTF-1 [C]O [C]T [C]F [C]- [C]1 S-protein 
, [C], O 
is [C]i [C]s O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
in [C]i [C]n O 
all [C]a [C]l [C]l O 
cell [C]c [C]e [C]l [C]l O 
types [C]t [C]y [C]p [C]e [C]s O 
and [C]a [C]n [C]d O 
may [C]m [C]a [C]y O 
exert [C]e [C]x [C]e [C]r [C]t O 
its [C]i [C]t [C]s O 
activating [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]n [C]g O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
only [C]o [C]n [C]l [C]y O 
when [C]w [C]h [C]e [C]n O 
it [C]i [C]t O 
can [C]c [C]a [C]n O 
interact [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t O 
with [C]w [C]i [C]t [C]h O 
additional [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n [C]a [C]l O 
adjacent [C]a [C]d [C]j [C]a [C]c [C]e [C]n [C]t O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-protein 
octamer [C]o [C]c [C]t [C]a [C]m [C]e [C]r I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
of [C]o [C]f O 
60 [C]6 [C]0 O 
kd [C]k [C]d O 
( [C]( O 
OTF-2A [C]O [C]T [C]F [C]- [C]2 [C]A S-protein 
) [C]) O 
specifically [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]a [C]l [C]l [C]y O 
stimulates [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]s O 
Ig [C]I [C]g B-DNA 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s E-DNA 
which [C]w [C]h [C]i [C]c [C]h O 
consist [C]c [C]o [C]n [C]s [C]i [C]s [C]t O 
essentially [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l [C]l [C]y O 
of [C]o [C]f O 
a [C]a O 
TATA-box [C]T [C]A [C]T [C]A [C]- [C]b [C]o [C]x S-DNA 
and [C]a [C]n [C]d O 
an [C]a [C]n O 
octamer [C]o [C]c [C]t [C]a [C]m [C]e [C]r B-DNA 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e E-DNA 
upstream [C]u [C]p [C]s [C]t [C]r [C]e [C]a [C]m O 
of [C]o [C]f O 
it [C]i [C]t O 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
we [C]w [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
for [C]f [C]o [C]r O 
yet [C]y [C]e [C]t O 
another [C]a [C]n [C]o [C]t [C]h [C]e [C]r O 
B [C]B B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-protein 
octamer [C]o [C]c [C]t [C]a [C]m [C]e [C]r I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
of [C]o [C]f O 
75 [C]7 [C]5 O 
kd [C]k [C]d O 
( [C]( O 
OTF-2B [C]O [C]T [C]F [C]- [C]2 [C]B S-protein 
) [C]) O 
. [C]. O 

From [C]F [C]r [C]o [C]m O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
OTF-2B [C]O [C]T [C]F [C]- [C]2 [C]B S-protein 
( [C]( O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
OTF-2A [C]O [C]T [C]F [C]- [C]2 [C]A S-protein 
) [C]) O 
from [C]f [C]r [C]o [C]m O 
a [C]a O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e B-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
that [C]t [C]h [C]a [C]t O 
can [C]c [C]a [C]n O 
not [C]n [C]o [C]t O 
respond [C]r [C]e [C]s [C]p [C]o [C]n [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
IgH [C]I [C]g [C]H B-DNA 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r E-DNA 
, [C], O 
we [C]w [C]e O 
propose [C]p [C]r [C]o [C]p [C]o [C]s [C]e O 
a [C]a O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
novel [C]n [C]o [C]v [C]e [C]l B-protein 
octamer [C]o [C]c [C]t [C]a [C]m [C]e [C]r I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
long [C]l [C]o [C]n [C]g O 
range [C]r [C]a [C]n [C]g [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
IgH [C]I [C]g [C]H B-DNA 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r E-DNA 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
used [C]u [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
proteolytic [C]p [C]r [C]o [C]t [C]e [C]o [C]l [C]y [C]t [C]i [C]c O 
clipping [C]c [C]l [C]i [C]p [C]p [C]i [C]n [C]g O 
bandshift [C]b [C]a [C]n [C]d [C]s [C]h [C]i [C]f [C]t O 
assay [C]a [C]s [C]s [C]a [C]y O 
( [C]( O 
PCBA [C]P [C]C [C]B [C]A O 
) [C]) O 
technique [C]t [C]e [C]c [C]h [C]n [C]i [C]q [C]u [C]e O 
to [C]t [C]o O 
distinguish [C]d [C]i [C]s [C]t [C]i [C]n [C]g [C]u [C]i [C]s [C]h O 
the [C]t [C]h [C]e O 
three [C]t [C]h [C]r [C]e [C]e O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
forms [C]f [C]o [C]r [C]m [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
indicates [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e [C]s O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
75 [C]7 [C]5 O 
kd-species [C]k [C]d [C]- [C]s [C]p [C]e [C]c [C]i [C]e [C]s O 
OTF-2B [C]O [C]T [C]F [C]- [C]2 [C]B S-protein 
is [C]i [C]s O 
closely [C]c [C]l [C]o [C]s [C]e [C]l [C]y O 
related [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
60 [C]6 [C]0 B-protein 
kd [C]k [C]d I-protein 
species [C]s [C]p [C]e [C]c [C]i [C]e [C]s I-protein 
OTF-2A [C]O [C]T [C]F [C]- [C]2 [C]A E-protein 
. [C]. O 

Inhibition [C]I [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
interleukin [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n B-protein 
2 [C]2 E-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cloned [C]c [C]l [C]o [C]n [C]e [C]d B-cell_line 
murine [C]m [C]u [C]r [C]i [C]n [C]e I-cell_line 
T [C]T I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
by [C]b [C]y O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
. [C]. O 

Possible [C]P [C]o [C]s [C]s [C]i [C]b [C]l [C]e O 
involvement [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
an [C]a [C]n O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
to [C]t [C]o O 
inhibit [C]i [C]n [C]h [C]i [C]b [C]i [C]t O 
interleukin [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n B-protein 
2 [C]2 E-protein 
( [C]( O 
IL [C]I [C]L B-protein 
2 [C]2 E-protein 
) [C]) O 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
two [C]t [C]w [C]o O 
cytotoxic [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c B-cell_line 
T [C]T I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
( [C]( I-cell_line 
CTL [C]C [C]T [C]L I-cell_line 
) [C]) I-cell_line 
clones [C]c [C]l [C]o [C]n [C]e [C]s E-cell_line 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
. [C]. O 

A [C]A O 
complete [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
DNA [C]D [C]N [C]A O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
by [C]b [C]y O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
( [C]( O 
Dx [C]D [C]x O 
) [C]) O 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
when [C]w [C]h [C]e [C]n O 
IL [C]I [C]L B-cell_line 
2-depleted [C]2 [C]- [C]d [C]e [C]p [C]l [C]e [C]t [C]e [C]d I-cell_line 
cultures [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]s E-cell_line 
of [C]o [C]f O 
CTL [C]C [C]T [C]L S-cell_line 
were [C]w [C]e [C]r [C]e O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
incubated [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]e [C]d O 
for [C]f [C]o [C]r O 
6 [C]6 O 
h [C]h O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e S-protein 
prior [C]p [C]r [C]i [C]o [C]r O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL [C]I [C]L B-protein 
2 [C]2 E-protein 
or [C]o [C]r O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
simultaneously [C]s [C]i [C]m [C]u [C]l [C]t [C]a [C]n [C]e [C]o [C]u [C]s [C]l [C]y O 
with [C]w [C]i [C]t [C]h O 
Dx [C]D [C]x O 
and [C]a [C]n [C]d O 
a [C]a O 
low [C]l [C]o [C]w O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL [C]I [C]L B-protein 
2 [C]2 E-protein 
. [C]. O 

No [C]N [C]o O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
reduction [C]r [C]e [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
and [C]a [C]n [C]d O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
of [C]o [C]f O 
IL [C]I [C]L B-protein 
2 [C]2 I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
was [C]w [C]a [C]s O 
seen [C]s [C]e [C]e [C]n O 
after [C]a [C]f [C]t [C]e [C]r O 
6 [C]6 O 
h [C]h O 
incubation [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
Dx [C]D [C]x O 
. [C]. O 

The [C]T [C]h [C]e O 
order [C]o [C]r [C]d [C]e [C]r O 
of [C]o [C]f O 
potency [C]p [C]o [C]t [C]e [C]n [C]c [C]y O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
steroids [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]s O 
indicated [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
this [C]t [C]h [C]i [C]s O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
was [C]w [C]a [C]s O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
a [C]a O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
action [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
hormones [C]h [C]o [C]r [C]m [C]o [C]n [C]e [C]s S-protein 
possibly [C]p [C]o [C]s [C]s [C]i [C]b [C]l [C]y O 
involves [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]s O 
the [C]t [C]h [C]e O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
an [C]a [C]n O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
( [C]( O 
s [C]s O 
) [C]) O 
, [C], O 
since [C]s [C]i [C]n [C]c [C]e O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
cycloheximide [C]c [C]y [C]c [C]l [C]o [C]h [C]e [C]x [C]i [C]m [C]i [C]d [C]e O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
incubation [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
Dx [C]D [C]x O 
prevented [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
DNA [C]D [C]N [C]A O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
supernatant [C]s [C]u [C]p [C]e [C]r [C]n [C]a [C]t [C]a [C]n [C]t O 
from [C]f [C]r [C]o [C]m O 
Dx-treated [C]D [C]x [C]- [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
CTL [C]C [C]T [C]L S-cell_line 
contained [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]e [C]d O 
a [C]a O 
nondialyzable [C]n [C]o [C]n [C]d [C]i [C]a [C]l [C]y [C]z [C]a [C]b [C]l [C]e O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
which [C]w [C]h [C]i [C]c [C]h O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
DNA [C]D [C]N [C]A O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
cell [C]c [C]e [C]l [C]l O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
of [C]o [C]f O 
CTL [C]C [C]T [C]L B-cell_line 
clones [C]c [C]l [C]o [C]n [C]e [C]s E-cell_line 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
IL [C]I [C]L B-protein 
2 [C]2 E-protein 
. [C]. O 

Blocking [C]B [C]l [C]o [C]c [C]k [C]i [C]n [C]g O 
of [C]o [C]f O 
IL [C]I [C]L B-protein 
2 [C]2 E-protein 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
IL [C]I [C]L B-protein 
2 [C]2 I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
proposed [C]p [C]r [C]o [C]p [C]o [C]s [C]e [C]d O 
as [C]a [C]s O 
one [C]o [C]n [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
major [C]m [C]a [C]j [C]o [C]r O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
of [C]o [C]f O 
glucocorticoid-induced [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
immunosuppression [C]i [C]m [C]m [C]u [C]n [C]o [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Our [C]O [C]u [C]r O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
these [C]t [C]h [C]e [C]s [C]e O 
hormones [C]h [C]o [C]r [C]m [C]o [C]n [C]e [C]s S-protein 
may [C]m [C]a [C]y O 
also [C]a [C]l [C]s [C]o O 
affect [C]a [C]f [C]f [C]e [C]c [C]t O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
inhibiting [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]n [C]g O 
IL [C]I [C]L B-protein 
2 [C]2 E-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

Identification [C]I [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
purification [C]p [C]u [C]r [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
human [C]h [C]u [C]m [C]a [C]n B-protein 
immunoglobulin-enhancer-binding [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n [C]- [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
( [C]( O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
) [C]) O 
that [C]t [C]h [C]a [C]t O 
activates [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]s O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
from [C]f [C]r [C]o [C]m O 
a [C]a O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y I-DNA 
virus [C]v [C]i [C]r [C]u [C]s I-DNA 
type [C]t [C]y [C]p [C]e I-DNA 
1 [C]1 I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
. [C]. O 

The [C]T [C]h [C]e O 
enhancer-binding [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
only [C]o [C]n [C]l [C]y O 
in [C]i [C]n O 
cells [C]c [C]e [C]l [C]l [C]s O 
that [C]t [C]h [C]a [C]t O 
transcribe [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]b [C]e O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n B-DNA 
light [C]l [C]i [C]g [C]h [C]t I-DNA 
chain [C]c [C]h [C]a [C]i [C]n I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
, [C], O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
of [C]o [C]f O 
Namalwa [C]N [C]a [C]m [C]a [C]l [C]w [C]a B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
( [C]( O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
Burkitt [C]B [C]u [C]r [C]k [C]i [C]t [C]t I-cell_line 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
) [C]) O 
by [C]b [C]y O 
sequence-specific [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
DNA [C]D [C]N [C]A O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
chromatography [C]c [C]h [C]r [C]o [C]m [C]a [C]t [C]o [C]g [C]r [C]a [C]p [C]h [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
as [C]a [C]s O 
a [C]a O 
51-kDa [C]5 [C]1 [C]- [C]k [C]D [C]a B-protein 
polypeptide [C]p [C]o [C]l [C]y [C]p [C]e [C]p [C]t [C]i [C]d [C]e E-protein 
by [C]b [C]y O 
UV-crosslinking [C]U [C]V [C]- [C]c [C]r [C]o [C]s [C]s [C]l [C]i [C]n [C]k [C]i [C]n [C]g O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
. [C]. O 

`` [C]` [C]` O 
Footprint [C]F [C]o [C]o [C]t [C]p [C]r [C]i [C]n [C]t O 
'' [C]' [C]' O 
and [C]a [C]n [C]d O 
methylation-interference [C]m [C]e [C]t [C]h [C]y [C]l [C]a [C]t [C]i [C]o [C]n [C]- [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]e [C]n [C]c [C]e O 
analyses [C]a [C]n [C]a [C]l [C]y [C]s [C]e [C]s O 
have [C]h [C]a [C]v [C]e O 
shown [C]s [C]h [C]o [C]w [C]n O 
that [C]t [C]h [C]a [C]t O 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
has [C]h [C]a [C]s O 
a [C]a O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
kappa [C]k [C]a [C]p [C]p [C]a B-DNA 
light [C]l [C]i [C]g [C]h [C]t I-DNA 
chain [C]c [C]h [C]a [C]i [C]n I-DNA 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r I-DNA 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e E-DNA 
. [C]. O 

The [C]T [C]h [C]e O 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y I-DNA 
virus [C]v [C]i [C]r [C]u [C]s I-DNA 
type [C]t [C]y [C]p [C]e I-DNA 
I [C]I I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
by [C]b [C]y O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
an [C]a [C]n O 
upstream [C]u [C]p [C]s [C]t [C]r [C]e [C]a [C]m B-DNA 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a I-DNA 
B-binding [C]B [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 

Lymphocyte [C]L [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e S-cell_type 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
in [C]i [C]n O 
depression [C]d [C]e [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
: [C]: O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
values [C]v [C]a [C]l [C]u [C]e [C]s O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
recovery [C]r [C]e [C]c [C]o [C]v [C]e [C]r [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
sites [C]s [C]i [C]t [C]e [C]s O 
in [C]i [C]n O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
and [C]a [C]n [C]d O 
plasma [C]p [C]l [C]a [C]s [C]m [C]a O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
were [C]w [C]e [C]r [C]e O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
in [C]i [C]n O 
20 [C]2 [C]0 O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
who [C]w [C]h [C]o O 
had [C]h [C]a [C]d O 
recovered [C]r [C]e [C]c [C]o [C]v [C]e [C]r [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
major [C]m [C]a [C]j [C]o [C]r O 
depressive [C]d [C]e [C]p [C]r [C]e [C]s [C]s [C]i [C]v [C]e O 
disorder [C]d [C]i [C]s [C]o [C]r [C]d [C]e [C]r O 
and [C]a [C]n [C]d O 
20 [C]2 [C]0 O 
healthy [C]h [C]e [C]a [C]l [C]t [C]h [C]y O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
sites [C]s [C]i [C]t [C]e [C]s O 
in [C]i [C]n O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
recovered [C]r [C]e [C]c [C]o [C]v [C]e [C]r [C]e [C]d O 
depressed [C]d [C]e [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
group [C]g [C]r [C]o [C]u [C]p O 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
from [C]f [C]r [C]o [C]m O 
that [C]t [C]h [C]a [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
group [C]g [C]r [C]o [C]u [C]p O 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
mean [C]m [C]e [C]a [C]n O 
plasma [C]p [C]l [C]a [C]s [C]m [C]a O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
recovered [C]r [C]e [C]c [C]o [C]v [C]e [C]r [C]e [C]d O 
depressives [C]d [C]e [C]p [C]r [C]e [C]s [C]s [C]i [C]v [C]e [C]s O 
was [C]w [C]a [C]s O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
in [C]i [C]n O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
, [C], O 
the [C]t [C]h [C]e O 
difference [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e O 
only [C]o [C]n [C]l [C]y O 
just [C]j [C]u [C]s [C]t O 
reached [C]r [C]e [C]a [C]c [C]h [C]e [C]d O 
significance [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]c [C]e O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
shows [C]s [C]h [C]o [C]w [C]s O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
reduction [C]r [C]e [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
numbers [C]n [C]u [C]m [C]b [C]e [C]r [C]s O 
which [C]w [C]h [C]i [C]c [C]h O 
occurs [C]o [C]c [C]c [C]u [C]r [C]s O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
acute [C]a [C]c [C]u [C]t [C]e O 
depressive [C]d [C]e [C]p [C]r [C]e [C]s [C]s [C]i [C]v [C]e O 
illness [C]i [C]l [C]l [C]n [C]e [C]s [C]s O 
does [C]d [C]o [C]e [C]s O 
not [C]n [C]o [C]t O 
persist [C]p [C]e [C]r [C]s [C]i [C]s [C]t O 
on [C]o [C]n O 
recovery [C]r [C]e [C]c [C]o [C]v [C]e [C]r [C]y O 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
, [C], O 
therefore [C]t [C]h [C]e [C]r [C]e [C]f [C]o [C]r [C]e O 
, [C], O 
state-dependent [C]s [C]t [C]a [C]t [C]e [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
. [C]. O 

Identification [C]I [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
purification [C]p [C]u [C]r [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
human [C]h [C]u [C]m [C]a [C]n B-protein 
lymphoid-specific [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-protein 
octamer-binding [C]o [C]c [C]t [C]a [C]m [C]e [C]r [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
( [C]( O 
OTF-2 [C]O [C]T [C]F [C]- [C]2 S-protein 
) [C]) O 
that [C]t [C]h [C]a [C]t O 
activates [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]s O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
an [C]a [C]n O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
. [C]. O 

The [C]T [C]h [C]e O 
octamer [C]o [C]c [C]t [C]a [C]m [C]e [C]r O 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
5'-ATGCAAAT [C]5 [C]' [C]- [C]A [C]T [C]G [C]C [C]A [C]A [C]A [C]T O 
, [C], O 
in [C]i [C]n O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
orientation [C]o [C]r [C]i [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
serves [C]s [C]e [C]r [C]v [C]e [C]s O 
as [C]a [C]s O 
an [C]a [C]n O 
upstream [C]u [C]p [C]s [C]t [C]r [C]e [C]a [C]m B-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
in [C]i [C]n O 
a [C]a O 
variety [C]v [C]a [C]r [C]i [C]e [C]t [C]y O 
of [C]o [C]f O 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s S-DNA 
and [C]a [C]n [C]d O 
also [C]a [C]l [C]s [C]o O 
occurs [C]o [C]c [C]c [C]u [C]r [C]s O 
as [C]a [C]s O 
a [C]a O 
modular [C]m [C]o [C]d [C]u [C]l [C]a [C]r B-DNA 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r I-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
. [C]. O 

It [C]I [C]t O 
is [C]i [C]s O 
of [C]o [C]f O 
particular [C]p [C]a [C]r [C]t [C]i [C]c [C]u [C]l [C]a [C]r O 
interest [C]i [C]n [C]t [C]e [C]r [C]e [C]s [C]t O 
in [C]i [C]n O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
since [C]s [C]i [C]n [C]c [C]e O 
it [C]i [C]t O 
is [C]i [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
upstream [C]u [C]p [C]s [C]t [C]r [C]e [C]a [C]m B-DNA 
regions [C]r [C]e [C]g [C]i [C]o [C]n [C]s E-DNA 
of [C]o [C]f O 
all [C]a [C]l [C]l O 
heavy [C]h [C]e [C]a [C]v [C]y B-DNA 
and [C]a [C]n [C]d I-DNA 
light [C]l [C]i [C]g [C]h [C]t I-DNA 
chain [C]c [C]h [C]a [C]i [C]n I-DNA 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s E-DNA 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
heavy [C]h [C]e [C]a [C]v [C]y B-DNA 
chain [C]c [C]h [C]a [C]i [C]n I-DNA 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r E-DNA 
, [C], O 
both [C]b [C]o [C]t [C]h O 
of [C]o [C]f O 
which [C]w [C]h [C]i [C]c [C]h O 
are [C]a [C]r [C]e O 
known [C]k [C]n [C]o [C]w [C]n O 
to [C]t [C]o O 
be [C]b [C]e O 
necessary [C]n [C]e [C]c [C]e [C]s [C]s [C]a [C]r [C]y O 
for [C]f [C]o [C]r O 
cell-specific [C]c [C]e [C]l [C]l [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

We [C]W [C]e O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
here [C]h [C]e [C]r [C]e O 
the [C]t [C]h [C]e O 
chromatographic [C]c [C]h [C]r [C]o [C]m [C]a [C]t [C]o [C]g [C]r [C]a [C]p [C]h [C]i [C]c O 
separation [C]s [C]e [C]p [C]a [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
ubiquitous [C]u [C]b [C]i [C]q [C]u [C]i [C]t [C]o [C]u [C]s B-protein 
and [C]a [C]n [C]d I-protein 
B [C]B I-protein 
cell-specific [C]c [C]e [C]l [C]l [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-protein 
octamer-binding [C]o [C]c [C]t [C]a [C]m [C]e [C]r [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
B [C]B B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
was [C]w [C]a [C]s O 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d O 
to [C]t [C]o O 
homogeneity [C]h [C]o [C]m [C]o [C]g [C]e [C]n [C]e [C]i [C]t [C]y O 
using [C]u [C]s [C]i [C]n [C]g O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
chromatography [C]c [C]h [C]r [C]o [C]m [C]a [C]t [C]o [C]g [C]r [C]a [C]p [C]h [C]y O 
and [C]a [C]n [C]d O 
consists [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]s O 
of [C]o [C]f O 
three [C]t [C]h [C]r [C]e [C]e O 
peptides [C]p [C]e [C]p [C]t [C]i [C]d [C]e [C]s O 
of [C]o [C]f O 
62 [C]6 [C]2 O 
, [C], O 
61 [C]6 [C]1 O 
, [C], O 
and [C]a [C]n [C]d O 
58.5 [C]5 [C]8 [C]. [C]5 O 
+/- [C]+ [C]/ [C]- O 
1.5 [C]1 [C]. [C]5 O 
kd [C]k [C]d O 
. [C]. O 

Each [C]E [C]a [C]c [C]h O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
polypeptides [C]p [C]o [C]l [C]y [C]p [C]e [C]p [C]t [C]i [C]d [C]e [C]s O 
was [C]w [C]a [C]s O 
renatured [C]r [C]e [C]n [C]a [C]t [C]u [C]r [C]e [C]d O 
after [C]a [C]f [C]t [C]e [C]r O 
SDS-PAGE [C]S [C]D [C]S [C]- [C]P [C]A [C]G [C]E O 
and [C]a [C]n [C]d O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
bind [C]b [C]i [C]n [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
octamer [C]o [C]c [C]t [C]a [C]m [C]e [C]r O 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
pure [C]p [C]u [C]r [C]e O 
B [C]B B-protein 
cell-specific [C]c [C]e [C]l [C]l [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
was [C]w [C]a [C]s O 
indistinguishable [C]i [C]n [C]d [C]i [C]s [C]t [C]i [C]n [C]g [C]u [C]i [C]s [C]h [C]a [C]b [C]l [C]e O 
from [C]f [C]r [C]o [C]m O 
that [C]t [C]h [C]a [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
affinity-purified [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y [C]- [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d B-protein 
ubiquitous [C]u [C]b [C]i [C]q [C]u [C]i [C]t [C]o [C]u [C]s I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
B [C]B B-protein 
cell-specific [C]c [C]e [C]l [C]l [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-protein 
octamer-binding [C]o [C]c [C]t [C]a [C]m [C]e [C]r [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
, [C], O 
in [C]i [C]n O 
pure [C]p [C]u [C]r [C]e O 
form [C]f [C]o [C]r [C]m O 
, [C], O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
from [C]f [C]r [C]o [C]m O 
a [C]a O 
kappa [C]k [C]a [C]p [C]p [C]a B-DNA 
light [C]l [C]i [C]g [C]h [C]t I-DNA 
chain [C]c [C]h [C]a [C]i [C]n I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
, [C], O 
thus [C]t [C]h [C]u [C]s O 
demonstrating [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
it [C]i [C]t O 
is [C]i [C]s O 
indeed [C]i [C]n [C]d [C]e [C]e [C]d O 
a [C]a O 
B [C]B B-protein 
cell-specific [C]c [C]e [C]l [C]l [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
for [C]f [C]o [C]r O 
this [C]t [C]h [C]i [C]s O 
gene [C]g [C]e [C]n [C]e O 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
ubiquitous [C]u [C]b [C]i [C]q [C]u [C]i [C]t [C]o [C]u [C]s B-protein 
and [C]a [C]n [C]d I-protein 
B [C]B I-protein 
cell-specific [C]c [C]e [C]l [C]l [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-protein 
octamer-binding [C]o [C]c [C]t [C]a [C]m [C]e [C]r [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
, [C], O 
we [C]w [C]e O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
additional [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n [C]a [C]l O 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s O 
, [C], O 
one [C]o [C]n [C]e O 
of [C]o [C]f O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
B [C]B B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
-specific [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
, [C], O 
that [C]t [C]h [C]a [C]t O 
interact [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
kappa [C]k [C]a [C]p [C]p [C]a B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

Decreased [C]D [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
deoxyribonucleic [C]d [C]e [C]o [C]x [C]y [C]r [C]i [C]b [C]o [C]n [C]u [C]c [C]l [C]e [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
glucocorticoid-receptor [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r B-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
in [C]i [C]n O 
cultured [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]d O 
skin [C]s [C]k [C]i [C]n B-cell_line 
fibroblasts [C]f [C]i [C]b [C]r [C]o [C]b [C]l [C]a [C]s [C]t [C]s E-cell_line 
from [C]f [C]r [C]o [C]m O 
a [C]a O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
syndrome [C]s [C]y [C]n [C]d [C]r [C]o [C]m [C]e O 
. [C]. O 

A [C]A O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
syndrome [C]s [C]y [C]n [C]d [C]r [C]o [C]m [C]e O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
was [C]w [C]a [C]s O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
. [C]. O 

A [C]A O 
27-yr-old [C]2 [C]7 [C]- [C]y [C]r [C]- [C]o [C]l [C]d O 
woman [C]w [C]o [C]m [C]a [C]n O 
initially [C]i [C]n [C]i [C]t [C]i [C]a [C]l [C]l [C]y O 
was [C]w [C]a [C]s O 
diagnosed [C]d [C]i [C]a [C]g [C]n [C]o [C]s [C]e [C]d O 
as [C]a [C]s O 
having [C]h [C]a [C]v [C]i [C]n [C]g O 
Cushing [C]C [C]u [C]s [C]h [C]i [C]n [C]g O 
's [C]' [C]s O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
, [C], O 
based [C]b [C]a [C]s [C]e [C]d O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
of [C]o [C]f O 
high [C]h [C]i [C]g [C]h O 
plasma [C]p [C]l [C]a [C]s [C]m [C]a O 
ACTH [C]A [C]C [C]T [C]H O 
and [C]a [C]n [C]d O 
serum [C]s [C]e [C]r [C]u [C]m O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
, [C], O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
urinary [C]u [C]r [C]i [C]n [C]a [C]r [C]y O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
secretion [C]s [C]e [C]c [C]r [C]e [C]t [C]i [C]o [C]n O 
, [C], O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
to [C]t [C]o O 
adrenal [C]a [C]d [C]r [C]e [C]n [C]a [C]l O 
suppression [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
, [C], O 
and [C]a [C]n [C]d O 
bilateral [C]b [C]i [C]l [C]a [C]t [C]e [C]r [C]a [C]l O 
adrenal [C]a [C]d [C]r [C]e [C]n [C]a [C]l O 
hyperplasia [C]h [C]y [C]p [C]e [C]r [C]p [C]l [C]a [C]s [C]i [C]a O 
by [C]b [C]y O 
computed [C]c [C]o [C]m [C]p [C]u [C]t [C]e [C]d O 
tomography [C]t [C]o [C]m [C]o [C]g [C]r [C]a [C]p [C]h [C]y O 
and [C]a [C]n [C]d O 
scintigraphy [C]s [C]c [C]i [C]n [C]t [C]i [C]g [C]r [C]a [C]p [C]h [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
adrenal [C]a [C]d [C]r [C]e [C]n [C]a [C]l O 
glands [C]g [C]l [C]a [C]n [C]d [C]s O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
she [C]s [C]h [C]e O 
had [C]h [C]a [C]d O 
no [C]n [C]o O 
signs [C]s [C]i [C]g [C]n [C]s O 
or [C]o [C]r O 
symptoms [C]s [C]y [C]m [C]p [C]t [C]o [C]m [C]s O 
of [C]o [C]f O 
Cushing [C]C [C]u [C]s [C]h [C]i [C]n [C]g O 
's [C]' [C]s O 
syndrome [C]s [C]y [C]n [C]d [C]r [C]o [C]m [C]e O 
. [C]. O 

During [C]D [C]u [C]r [C]i [C]n [C]g O 
a [C]a O 
5-yr [C]5 [C]- [C]y [C]r O 
follow-up [C]f [C]o [C]l [C]l [C]o [C]w [C]- [C]u [C]p O 
, [C], O 
no [C]n [C]o O 
clinical [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
abnormalities [C]a [C]b [C]n [C]o [C]r [C]m [C]a [C]l [C]i [C]t [C]i [C]e [C]s O 
developed [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]e [C]d O 
, [C], O 
although [C]a [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
hypercortisolism [C]h [C]y [C]p [C]e [C]r [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l [C]i [C]s [C]m O 
persisted [C]p [C]e [C]r [C]s [C]i [C]s [C]t [C]e [C]d O 
. [C]. O 

End-organ [C]E [C]n [C]d [C]- [C]o [C]r [C]g [C]a [C]n O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
to [C]t [C]o O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
was [C]w [C]a [C]s O 
suspected [C]s [C]u [C]s [C]p [C]e [C]c [C]t [C]e [C]d O 
. [C]. O 

To [C]T [C]o O 
explain [C]e [C]x [C]p [C]l [C]a [C]i [C]n O 
the [C]t [C]h [C]e O 
end-organ [C]e [C]n [C]d [C]- [C]o [C]r [C]g [C]a [C]n O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
to [C]t [C]o O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
, [C], O 
the [C]t [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
( [C]( O 
GR [C]G [C]R S-protein 
) [C]) O 
in [C]i [C]n O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
cultured [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]d B-cell_line 
skin [C]s [C]k [C]i [C]n I-cell_line 
fibroblasts [C]f [C]i [C]b [C]r [C]o [C]b [C]l [C]a [C]s [C]t [C]s E-cell_line 
from [C]f [C]r [C]o [C]m O 
a [C]a O 
forearm [C]f [C]o [C]r [C]e [C]a [C]r [C]m O 
skin [C]s [C]k [C]i [C]n O 
biopsy [C]b [C]i [C]o [C]p [C]s [C]y O 
were [C]w [C]e [C]r [C]e O 
characterized [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]d O 
and [C]a [C]n [C]d O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
of [C]o [C]f O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
's [C]' [C]s O 
GR [C]G [C]R S-protein 
in [C]i [C]n O 
whole [C]w [C]h [C]o [C]l [C]e O 
cell [C]c [C]e [C]l [C]l O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
had [C]h [C]a [C]d O 
an [C]a [C]n O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
dissociation [C]d [C]i [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
constant [C]c [C]o [C]n [C]s [C]t [C]a [C]n [C]t O 
( [C]( O 
Kd [C]K [C]d O 
) [C]) O 
. [C]. O 

In [C]I [C]n O 
the [C]t [C]h [C]e O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
of [C]o [C]f O 
cultured [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]d B-cell_line 
skin [C]s [C]k [C]i [C]n I-cell_line 
fibroblasts [C]f [C]i [C]b [C]r [C]o [C]b [C]l [C]a [C]s [C]t [C]s E-cell_line 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
, [C], O 
there [C]t [C]h [C]e [C]r [C]e O 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
capacity [C]c [C]a [C]p [C]a [C]c [C]i [C]t [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
thermal [C]t [C]h [C]e [C]r [C]m [C]a [C]l O 
stability [C]s [C]t [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
sedimentation [C]s [C]e [C]d [C]i [C]m [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
coefficient [C]c [C]o [C]e [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
in [C]i [C]n O 
a [C]a O 
sucrose [C]s [C]u [C]c [C]r [C]o [C]s [C]e O 
density [C]d [C]e [C]n [C]s [C]i [C]t [C]y O 
gradient [C]g [C]r [C]a [C]d [C]i [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
of [C]o [C]f O 
cultured [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]d B-cell_line 
skin [C]s [C]k [C]i [C]n I-cell_line 
fibroblasts [C]f [C]i [C]b [C]r [C]o [C]b [C]l [C]a [C]s [C]t [C]s E-cell_line 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
were [C]w [C]e [C]r [C]e O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
. [C]. O 

GR [C]G [C]R B-cell_line 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x I-cell_line 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n E-cell_line 
, [C], O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
by [C]b [C]y O 
DEAE-cellulose [C]D [C]E [C]A [C]E [C]- [C]c [C]e [C]l [C]l [C]u [C]l [C]o [C]s [C]e B-cell_line 
chromatography [C]c [C]h [C]r [C]o [C]m [C]a [C]t [C]o [C]g [C]r [C]a [C]p [C]h [C]y E-cell_line 
, [C], O 
was [C]w [C]a [C]s O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
. [C]. O 

DNA [C]D [C]N [C]A S-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
GR [C]G [C]R B-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
after [C]a [C]f [C]t [C]e [C]r O 
temperature-induced [C]t [C]e [C]m [C]p [C]e [C]r [C]a [C]t [C]u [C]r [C]e [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
lower [C]l [C]o [C]w [C]e [C]r O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
than [C]t [C]h [C]a [C]n O 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
. [C]. O 

Nuclear [C]N [C]u [C]c [C]l [C]e [C]a [C]r O 
translocation [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
GR [C]G [C]R B-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
slightly [C]s [C]l [C]i [C]g [C]h [C]t [C]l [C]y O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
's [C]' [C]s O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
was [C]w [C]a [C]s O 
due [C]d [C]u [C]e O 
to [C]t [C]o O 
a [C]a O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
for [C]f [C]o [C]r O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
and [C]a [C]n [C]d O 
a [C]a O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
GR [C]G [C]R B-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
to [C]t [C]o O 
DNA [C]D [C]N [C]A S-DNA 
. [C]. O 

Granulocyte-macrophage [C]G [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e [C]- [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e B-protein 
colony-stimulating [C]c [C]o [C]l [C]o [C]n [C]y [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]n [C]g I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
. [C]. O 

Sensitive [C]S [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
and [C]a [C]n [C]d O 
receptor-mediated [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
1 [C]1 O 
, [C], O 
25-dihydroxyvitamin [C]2 [C]5 [C]- [C]d [C]i [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]v [C]i [C]t [C]a [C]m [C]i [C]n O 
D3 [C]D [C]3 O 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

We [C]W [C]e O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
1 [C]1 O 
, [C], O 
25-dihydroxyvitamin [C]2 [C]5 [C]- [C]d [C]i [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]v [C]i [C]t [C]a [C]m [C]i [C]n O 
D3 [C]D [C]3 O 
( [C]( O 
1 [C]1 O 
, [C], O 
25 [C]2 [C]5 O 
[ [C][ O 
OH [C]O [C]H O 
] [C]] O 
2D3 [C]2 [C]D [C]3 O 
) [C]) O 
, [C], O 
the [C]t [C]h [C]e O 
most [C]m [C]o [C]s [C]t O 
hormonally [C]h [C]o [C]r [C]m [C]o [C]n [C]a [C]l [C]l [C]y O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
metabolite [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]t [C]e O 
of [C]o [C]f O 
vitamin [C]v [C]i [C]t [C]a [C]m [C]i [C]n O 
D3 [C]D [C]3 O 
, [C], O 
modulates [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]e [C]s O 
sensitively [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e [C]l [C]y O 
and [C]a [C]n [C]d O 
specifically [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]a [C]l [C]l [C]y O 
both [C]b [C]o [C]t [C]h O 
the [C]t [C]h [C]e O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
and [C]a [C]n [C]d O 
messenger [C]m [C]e [C]s [C]s [C]e [C]n [C]g [C]e [C]r B-RNA 
RNA [C]R [C]N [C]A E-RNA 
accumulation [C]a [C]c [C]c [C]u [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
multilineage [C]m [C]u [C]l [C]t [C]i [C]l [C]i [C]n [C]e [C]a [C]g [C]e B-protein 
growth [C]g [C]r [C]o [C]w [C]t [C]h I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
granulocyte-macrophage [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e [C]- [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e B-protein 
colony-stimulating [C]c [C]o [C]l [C]o [C]n [C]y [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]n [C]g I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
( [C]( O 
GM-CSF [C]G [C]M [C]- [C]C [C]S [C]F S-protein 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
GM-CSF [C]G [C]M [C]- [C]C [C]S [C]F S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
is [C]i [C]s O 
seen [C]s [C]e [C]e [C]n O 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
mitogen-activated [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d I-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
T [C]T B-cell_line 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s I-cell_line 
from [C]f [C]r [C]o [C]m I-cell_line 
a [C]a I-cell_line 
line [C]l [C]i [C]n [C]e I-cell_line 
( [C]( I-cell_line 
S-LB1 [C]S [C]- [C]L [C]B [C]1 I-cell_line 
) [C]) I-cell_line 
transformed [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]e [C]d I-cell_line 
with [C]w [C]i [C]t [C]h I-cell_line 
human [C]h [C]u [C]m [C]a [C]n I-cell_line 
T [C]T I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lymphotropic [C]l [C]y [C]m [C]p [C]h [C]o [C]t [C]r [C]o [C]p [C]i [C]c I-cell_line 
virus [C]v [C]i [C]r [C]u [C]s I-cell_line 
1 [C]1 E-cell_line 
( [C]( O 
HTLV-1 [C]H [C]T [C]L [C]V [C]- [C]1 O 
) [C]) O 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
cells [C]c [C]e [C]l [C]l [C]s O 
from [C]f [C]r [C]o [C]m O 
a [C]a O 
HTLV-1 [C]H [C]T [C]L [C]V [C]- [C]1 B-cell_line 
transformed [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]e [C]d I-cell_line 
T [C]T I-cell_line 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
( [C]( O 
Ab-VDR [C]A [C]b [C]- [C]V [C]D [C]R S-cell_line 
) [C]) O 
established [C]e [C]s [C]t [C]a [C]b [C]l [C]i [C]s [C]h [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
a [C]a O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
vitamin [C]v [C]i [C]t [C]a [C]m [C]i [C]n O 
D-resistant [C]D [C]- [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]t O 
rickets [C]r [C]i [C]c [C]k [C]e [C]t [C]s O 
type [C]t [C]y [C]p [C]e O 
II [C]I [C]I O 
with [C]w [C]i [C]t [C]h O 
undetectable [C]u [C]n [C]d [C]e [C]t [C]e [C]c [C]t [C]a [C]b [C]l [C]e O 
1 [C]1 B-protein 
, [C], I-protein 
25 [C]2 [C]5 I-protein 
( [C]( I-protein 
OH [C]O [C]H I-protein 
) [C]) I-protein 
2D3 [C]2 [C]D [C]3 I-protein 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
are [C]a [C]r [C]e O 
resistant [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]t O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
action [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
1 [C]1 O 
, [C], O 
25 [C]2 [C]5 O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
. [C]. O 

Inhibition [C]I [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
GM-CSF [C]G [C]M [C]- [C]C [C]S [C]F S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
by [C]b [C]y O 
1 [C]1 O 
, [C], O 
25 [C]2 [C]5 O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
can [C]c [C]a [C]n O 
occur [C]o [C]c [C]c [C]u [C]r O 
independently [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t [C]l [C]y O 
of [C]o [C]f O 
interleukin [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n B-protein 
2 [C]2 E-protein 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
probably [C]p [C]r [C]o [C]b [C]a [C]b [C]l [C]y O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
1 [C]1 I-protein 
, [C], I-protein 
25 [C]2 [C]5 I-protein 
( [C]( I-protein 
OH [C]O [C]H I-protein 
) [C]) I-protein 
2D3 [C]2 [C]D [C]3 I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

We [C]W [C]e O 
conclude [C]c [C]o [C]n [C]c [C]l [C]u [C]d [C]e O 
that [C]t [C]h [C]a [C]t O 
1 [C]1 O 
, [C], O 
25 [C]2 [C]5 O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
physiology [C]p [C]h [C]y [C]s [C]i [C]o [C]l [C]o [C]g [C]y O 
of [C]o [C]f O 
hematopoiesis [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
. [C]. O 

Altered [C]A [C]l [C]t [C]e [C]r [C]e [C]d O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
triiodothyronine [C]t [C]r [C]i [C]i [C]o [C]d [C]o [C]t [C]h [C]y [C]r [C]o [C]n [C]i [C]n [C]e O 
and [C]a [C]n [C]d O 
its [C]i [C]t [C]s O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
: [C]: O 
a [C]a O 
proposed [C]p [C]r [C]o [C]p [C]o [C]s [C]e [C]d O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
for [C]f [C]o [C]r O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
thyrotropin [C]t [C]h [C]y [C]r [C]o [C]t [C]r [C]o [C]p [C]i [C]n O 
secretion [C]s [C]e [C]c [C]r [C]e [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
corticosteroid [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
deficiency [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
states [C]s [C]t [C]a [C]t [C]e [C]s O 
. [C]. O 

Thyroid [C]T [C]h [C]y [C]r [C]o [C]i [C]d O 
hormones [C]h [C]o [C]r [C]m [C]o [C]n [C]e [C]s O 
occasionally [C]o [C]c [C]c [C]a [C]s [C]i [C]o [C]n [C]a [C]l [C]l [C]y O 
appear [C]a [C]p [C]p [C]e [C]a [C]r O 
less [C]l [C]e [C]s [C]s O 
effective [C]e [C]f [C]f [C]e [C]c [C]t [C]i [C]v [C]e O 
when [C]w [C]h [C]e [C]n O 
administered [C]a [C]d [C]m [C]i [C]n [C]i [C]s [C]t [C]e [C]r [C]e [C]d O 
alone [C]a [C]l [C]o [C]n [C]e O 
to [C]t [C]o O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
panhypopituitarism [C]p [C]a [C]n [C]h [C]y [C]p [C]o [C]p [C]i [C]t [C]u [C]i [C]t [C]a [C]r [C]i [C]s [C]m O 
, [C], O 
and [C]a [C]n [C]d O 
manifestations [C]m [C]a [C]n [C]i [C]f [C]e [C]s [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
suggestive [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]v [C]e O 
of [C]o [C]f O 
hypothyroidism [C]h [C]y [C]p [C]o [C]t [C]h [C]y [C]r [C]o [C]i [C]d [C]i [C]s [C]m O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
reported [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]d O 
in [C]i [C]n O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
suffering [C]s [C]u [C]f [C]f [C]e [C]r [C]i [C]n [C]g O 
from [C]f [C]r [C]o [C]m O 
untreated [C]u [C]n [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
Addison [C]A [C]d [C]d [C]i [C]s [C]o [C]n O 
's [C]' [C]s O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
. [C]. O 

In [C]I [C]n O 
the [C]t [C]h [C]e O 
latter [C]l [C]a [C]t [C]t [C]e [C]r O 
condition [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
thyrotropin [C]t [C]h [C]y [C]r [C]o [C]t [C]r [C]o [C]p [C]i [C]n O 
secretion [C]s [C]e [C]c [C]r [C]e [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
: [C]: O 
this [C]t [C]h [C]i [C]s O 
occurs [C]o [C]c [C]c [C]u [C]r [C]s O 
already [C]a [C]l [C]r [C]e [C]a [C]d [C]y O 
after [C]a [C]f [C]t [C]e [C]r O 
as [C]a [C]s O 
little [C]l [C]i [C]t [C]t [C]l [C]e O 
as [C]a [C]s O 
2 [C]2 O 
days [C]d [C]a [C]y [C]s O 
of [C]o [C]f O 
temporary [C]t [C]e [C]m [C]p [C]o [C]r [C]a [C]r [C]y O 
withdrawal [C]w [C]i [C]t [C]h [C]d [C]r [C]a [C]w [C]a [C]l O 
of [C]o [C]f O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
with [C]w [C]i [C]t [C]h O 
substitution [C]s [C]u [C]b [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]o [C]n O 
doses [C]d [C]o [C]s [C]e [C]s O 
of [C]o [C]f O 
corticosteroids [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]s O 
while [C]w [C]h [C]i [C]l [C]e O 
circulating [C]c [C]i [C]r [C]c [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
thyroid [C]t [C]h [C]y [C]r [C]o [C]i [C]d O 
hormones [C]h [C]o [C]r [C]m [C]o [C]n [C]e [C]s O 
remain [C]r [C]e [C]m [C]a [C]i [C]n O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
limits [C]l [C]i [C]m [C]i [C]t [C]s O 
. [C]. O 

Therefore [C]T [C]h [C]e [C]r [C]e [C]f [C]o [C]r [C]e O 
, [C], O 
a [C]a O 
possible [C]p [C]o [C]s [C]s [C]i [C]b [C]l [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
in [C]i [C]n O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
triiodothyronine [C]t [C]r [C]i [C]i [C]o [C]d [C]o [C]t [C]h [C]y [C]r [C]o [C]n [C]i [C]n [C]e O 
and [C]a [C]n [C]d O 
its [C]i [C]t [C]s O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
was [C]w [C]a [C]s O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
circulating [C]c [C]i [C]r [C]c [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s O 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y O 
or [C]o [C]r O 
secondary [C]s [C]e [C]c [C]o [C]n [C]d [C]a [C]r [C]y O 
adrenocortical [C]a [C]d [C]r [C]e [C]n [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]a [C]l O 
failure [C]f [C]a [C]i [C]l [C]u [C]r [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
, [C], O 
by [C]b [C]y O 
more [C]m [C]o [C]r [C]e O 
than [C]t [C]h [C]a [C]n O 
50 [C]5 [C]0 O 
% [C]% O 
on [C]o [C]n O 
average [C]a [C]v [C]e [C]r [C]a [C]g [C]e O 
, [C], O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
treatments [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t [C]s O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
change [C]c [C]h [C]a [C]n [C]g [C]e O 
was [C]w [C]a [C]s O 
promptly [C]p [C]r [C]o [C]m [C]p [C]t [C]l [C]y O 
corrected [C]c [C]o [C]r [C]r [C]e [C]c [C]t [C]e [C]d O 
upon [C]u [C]p [C]o [C]n O 
resumption [C]r [C]e [C]s [C]u [C]m [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
sites [C]s [C]i [C]t [C]e [C]s O 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
modified [C]m [C]o [C]d [C]i [C]f [C]i [C]e [C]d O 
. [C]. O 

The [C]T [C]h [C]e O 
influence [C]i [C]n [C]f [C]l [C]u [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
on [C]o [C]n O 
thyroid [C]t [C]h [C]y [C]r [C]o [C]i [C]d B-protein 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
discussed [C]d [C]i [C]s [C]c [C]u [C]s [C]s [C]e [C]d O 
here [C]h [C]e [C]r [C]e O 
might [C]m [C]i [C]g [C]h [C]t O 
account [C]a [C]c [C]c [C]o [C]u [C]n [C]t O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
clinical [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
observations [C]o [C]b [C]s [C]e [C]r [C]v [C]a [C]t [C]i [C]o [C]n [C]s O 
mentioned [C]m [C]e [C]n [C]t [C]i [C]o [C]n [C]e [C]d O 
above [C]a [C]b [C]o [C]v [C]e O 
. [C]. O 

Inhibition [C]I [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
natural [C]n [C]a [C]t [C]u [C]r [C]a [C]l I-cell_type 
killer [C]k [C]i [C]l [C]l [C]e [C]r I-cell_type 
( [C]( I-cell_type 
NK [C]N [C]K I-cell_type 
) [C]) I-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
natural [C]n [C]a [C]t [C]u [C]r [C]a [C]l B-cell_type 
killer [C]k [C]i [C]l [C]l [C]e [C]r E-cell_type 
( [C]( O 
NK [C]N [C]K O 
) [C]) O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
( [C]( I-cell_type 
PBM [C]P [C]B [C]M I-cell_type 
) [C]) I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
using [C]u [C]s [C]i [C]n [C]g O 
a [C]a O 
direct [C]d [C]i [C]r [C]e [C]c [C]t O 
4-h [C]4 [C]- [C]h O 
51Cr-release [C]5 [C]1 [C]C [C]r [C]- [C]r [C]e [C]l [C]e [C]a [C]s [C]e O 
assay [C]a [C]s [C]s [C]a [C]y O 
and [C]a [C]n [C]d O 
K [C]K B-cell_line 
562 [C]5 [C]6 [C]2 I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
as [C]a [C]s O 
a [C]a O 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
. [C]. O 

Preincubation [C]P [C]r [C]e [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]i [C]o [C]n O 
for [C]f [C]o [C]r O 
20 [C]2 [C]0 O 
h [C]h O 
of [C]o [C]f O 
PBM [C]P [C]B [C]M B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
drawn [C]d [C]r [C]a [C]w [C]n O 
from [C]f [C]r [C]o [C]m O 
healthy [C]h [C]e [C]a [C]l [C]t [C]h [C]y O 
donors [C]d [C]o [C]n [C]o [C]r [C]s O 
with [C]w [C]i [C]t [C]h O 
1 [C]1 O 
X [C]X O 
10 [C]1 [C]0 O 
( [C]( O 
-8 [C]- [C]8 O 
) [C]) O 
to [C]t [C]o O 
1 [C]1 O 
X [C]X O 
10 [C]1 [C]0 O 
( [C]( O 
-5 [C]- [C]5 O 
) [C]) O 
M [C]M O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
a [C]a O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
of [C]o [C]f O 
NK [C]N [C]K B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
magnitude [C]m [C]a [C]g [C]n [C]i [C]t [C]u [C]d [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
suppression [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
directly [C]d [C]i [C]r [C]e [C]c [C]t [C]l [C]y O 
related [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
inversely [C]i [C]n [C]v [C]e [C]r [C]s [C]e [C]l [C]y O 
related [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
effector [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Cortisol [C]C [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
was [C]w [C]a [C]s O 
able [C]a [C]b [C]l [C]e O 
to [C]t [C]o O 
minimize [C]m [C]i [C]n [C]i [C]m [C]i [C]z [C]e O 
the [C]t [C]h [C]e O 
enhancement [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
NK [C]N [C]K O 
cytotoxicity [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c [C]i [C]t [C]y O 
obtainable [C]o [C]b [C]t [C]a [C]i [C]n [C]a [C]b [C]l [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
interferon [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n O 
( [C]( O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a O 
) [C]) O 
. [C]. O 

A [C]A O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
suppression [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
achieved [C]a [C]c [C]h [C]i [C]e [C]v [C]e [C]d O 
after [C]a [C]f [C]t [C]e [C]r O 
sequential [C]s [C]e [C]q [C]u [C]e [C]n [C]t [C]i [C]a [C]l O 
exposure [C]e [C]x [C]p [C]o [C]s [C]u [C]r [C]e O 
of [C]o [C]f O 
PBM [C]P [C]B [C]M B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
to [C]t [C]o O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
and [C]a [C]n [C]d O 
equimolar [C]e [C]q [C]u [C]i [C]m [C]o [C]l [C]a [C]r O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
prostaglandin [C]p [C]r [C]o [C]s [C]t [C]a [C]g [C]l [C]a [C]n [C]d [C]i [C]n O 
E2 [C]E [C]2 O 
( [C]( O 
PgE2 [C]P [C]g [C]E [C]2 O 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
concomitant [C]c [C]o [C]n [C]c [C]o [C]m [C]i [C]t [C]a [C]n [C]t O 
incubation [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
theophylline [C]t [C]h [C]e [C]o [C]p [C]h [C]y [C]l [C]l [C]i [C]n [C]e O 
and [C]a [C]n [C]d O 
isobutyl-methylxanthine [C]i [C]s [C]o [C]b [C]u [C]t [C]y [C]l [C]- [C]m [C]e [C]t [C]h [C]y [C]l [C]x [C]a [C]n [C]t [C]h [C]i [C]n [C]e O 
failed [C]f [C]a [C]i [C]l [C]e [C]d O 
to [C]t [C]o O 
enhance [C]e [C]n [C]h [C]a [C]n [C]c [C]e O 
the [C]t [C]h [C]e O 
cortisol-induced [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
suppression [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
PgE2-dependent [C]P [C]g [C]E [C]2 [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
after [C]a [C]f [C]t [C]e [C]r O 
exposure [C]e [C]x [C]p [C]o [C]s [C]u [C]r [C]e O 
of [C]o [C]f O 
PBM [C]P [C]B [C]M B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
to [C]t [C]o O 
methyl-xanthines [C]m [C]e [C]t [C]h [C]y [C]l [C]- [C]x [C]a [C]n [C]t [C]h [C]i [C]n [C]e [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
was [C]w [C]a [C]s O 
partially [C]p [C]a [C]r [C]t [C]i [C]a [C]l [C]l [C]y O 
or [C]o [C]r O 
totally [C]t [C]o [C]t [C]a [C]l [C]l [C]y O 
prevented [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
concomitant [C]c [C]o [C]n [C]c [C]o [C]m [C]i [C]t [C]a [C]n [C]t O 
incubation [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
equimolar [C]e [C]q [C]u [C]i [C]m [C]o [C]l [C]a [C]r O 
amounts [C]a [C]m [C]o [C]u [C]n [C]t [C]s O 
of [C]o [C]f O 
11-deoxycortisol [C]1 [C]1 [C]- [C]d [C]e [C]o [C]x [C]y [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
and [C]a [C]n [C]d O 
RU [C]R [C]U O 
486 [C]4 [C]8 [C]6 O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
of [C]o [C]f O 
progesterone [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
. [C]. O 

Treatment [C]T [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
NK [C]N [C]K B-cell_type 
effectors [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r [C]s E-cell_type 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
monoclonal [C]m [C]o [C]n [C]o [C]c [C]l [C]o [C]n [C]a [C]l B-protein 
anti-human [C]a [C]n [C]t [C]i [C]- [C]h [C]u [C]m [C]a [C]n I-protein 
corticosteroid-binding [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
globulin [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n I-protein 
( [C]( I-protein 
CBG [C]C [C]B [C]G I-protein 
) [C]) I-protein 
antibody [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y E-protein 
produced [C]p [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
an [C]a [C]n O 
enhancement [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
spontaneous [C]s [C]p [C]o [C]n [C]t [C]a [C]n [C]e [C]o [C]u [C]s O 
NK [C]N [C]K S-cell_type 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
a [C]a O 
partial [C]p [C]a [C]r [C]t [C]i [C]a [C]l O 
suppression [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
cortisol-mediated [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
. [C]. O 

Our [C]O [C]u [C]r O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
endogenous [C]e [C]n [C]d [C]o [C]g [C]e [C]n [C]o [C]u [C]s O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
play [C]p [C]l [C]a [C]y O 
a [C]a O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NK [C]N [C]K O 
cell-mediated [C]c [C]e [C]l [C]l [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
cytotoxicity [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c [C]i [C]t [C]y O 
. [C]. O 

Since [C]S [C]i [C]n [C]c [C]e O 
the [C]t [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
was [C]w [C]a [C]s O 
additive [C]a [C]d [C]d [C]i [C]t [C]i [C]v [C]e O 
to [C]t [C]o O 
that [C]t [C]h [C]a [C]t O 
of [C]o [C]f O 
PgE2 [C]P [C]g [C]E [C]2 O 
and [C]a [C]n [C]d O 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
changed [C]c [C]h [C]a [C]n [C]g [C]e [C]d O 
by [C]b [C]y O 
phosphodiesterase [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]d [C]i [C]e [C]s [C]t [C]e [C]r [C]a [C]s [C]e S-protein 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
, [C], O 
it [C]i [C]t O 
is [C]i [C]s O 
conceivable [C]c [C]o [C]n [C]c [C]e [C]i [C]v [C]a [C]b [C]l [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e O 
acts [C]a [C]c [C]t [C]s O 
at [C]a [C]t O 
a [C]a O 
level [C]l [C]e [C]v [C]e [C]l O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
adenylate [C]a [C]d [C]e [C]n [C]y [C]l [C]a [C]t [C]e B-protein 
cyclase [C]c [C]y [C]c [C]l [C]a [C]s [C]e E-protein 
- [C]- O 
phosphodiesterase [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]d [C]i [C]e [C]s [C]t [C]e [C]r [C]a [C]s [C]e S-protein 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
. [C]. O 

Data [C]D [C]a [C]t [C]a O 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
use [C]u [C]s [C]e O 
of [C]o [C]f O 
antiglucocorticoids [C]a [C]n [C]t [C]i [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
anti-CBG [C]a [C]n [C]t [C]i [C]- [C]C [C]B [C]G B-protein 
antibody [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y E-protein 
are [C]a [C]r [C]e O 
compatible [C]c [C]o [C]m [C]p [C]a [C]t [C]i [C]b [C]l [C]e O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
role [C]r [C]o [C]l [C]e O 
both [C]b [C]o [C]t [C]h O 
of [C]o [C]f O 
high-affinity [C]h [C]i [C]g [C]h [C]- [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
and [C]a [C]n [C]d O 
of [C]o [C]f O 
CBG [C]C [C]B [C]G S-protein 
in [C]i [C]n O 
mediating [C]m [C]e [C]d [C]i [C]a [C]t [C]i [C]n [C]g O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
action [C]a [C]c [C]t [C]i [C]o [C]n O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
NK [C]N [C]K I-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

Interaction [C]I [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cell-type-specific [C]c [C]e [C]l [C]l [C]- [C]t [C]y [C]p [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-protein 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
with [C]w [C]i [C]t [C]h O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n B-DNA 
VH [C]V [C]H I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r I-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n I-DNA 
sequences [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s E-DNA 
. [C]. O 

All [C]A [C]l [C]l O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
and [C]a [C]n [C]d I-DNA 
murine [C]m [C]u [C]r [C]i [C]n [C]e I-DNA 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n I-DNA 
heavy [C]h [C]e [C]a [C]v [C]y I-DNA 
chain [C]c [C]h [C]a [C]i [C]n I-DNA 
variable [C]v [C]a [C]r [C]i [C]a [C]b [C]l [C]e I-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n I-DNA 
( [C]( I-DNA 
VH [C]V [C]H I-DNA 
) [C]) I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
contain [C]c [C]o [C]n [C]t [C]a [C]i [C]n O 
the [C]t [C]h [C]e O 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
ATGCAAAT [C]A [C]T [C]G [C]C [C]A [C]A [C]A [C]T O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
70 [C]7 [C]0 O 
nucleotides [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e [C]s O 
5 [C]5 O 
' [C]' O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
site [C]s [C]i [C]t [C]e O 
of [C]o [C]f O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
initiation [C]i [C]n [C]i [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
octanucleotide [C]o [C]c [C]t [C]a [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e O 
, [C], O 
in [C]i [C]n O 
reverse [C]r [C]e [C]v [C]e [C]r [C]s [C]e O 
orientation [C]o [C]r [C]i [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
is [C]i [C]s O 
also [C]a [C]l [C]s [C]o O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
all [C]a [C]l [C]l O 
light [C]l [C]i [C]g [C]h [C]t B-DNA 
chain [C]c [C]h [C]a [C]i [C]n I-DNA 
variable [C]v [C]a [C]r [C]i [C]a [C]b [C]l [C]e I-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n I-DNA 
( [C]( I-DNA 
VL [C]V [C]L I-DNA 
) [C]) I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
, [C], O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n B-DNA 
heavy [C]h [C]e [C]a [C]v [C]y I-DNA 
chain [C]c [C]h [C]a [C]i [C]n I-DNA 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l I-DNA 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r E-DNA 
. [C]. O 

Transfection [C]T [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
have [C]h [C]a [C]v [C]e O 
established [C]e [C]s [C]t [C]a [C]b [C]l [C]i [C]s [C]h [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
this [C]t [C]h [C]i [C]s O 
octamer [C]o [C]c [C]t [C]a [C]m [C]e [C]r O 
is [C]i [C]s O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
lymphoid-specific [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
. [C]. O 

Octamer-containing [C]O [C]c [C]t [C]a [C]m [C]e [C]r [C]- [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g B-DNA 
fragments [C]f [C]r [C]a [C]g [C]m [C]e [C]n [C]t [C]s E-DNA 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
reported [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]d O 
to [C]t [C]o O 
bind [C]b [C]i [C]n [C]d O 
a [C]a O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
in [C]i [C]n O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
; [C]; O 
however [C]h [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
identical [C]i [C]d [C]e [C]n [C]t [C]i [C]c [C]a [C]l O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
was [C]w [C]a [C]s O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
B [C]B B-cell_line 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d I-cell_line 
and [C]a [C]n [C]d I-cell_line 
non-lymphoid [C]n [C]o [C]n [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
we [C]w [C]e O 
establish [C]e [C]s [C]t [C]a [C]b [C]l [C]i [C]s [C]h O 
that [C]t [C]h [C]a [C]t O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
from [C]f [C]r [C]o [C]m O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
cell [C]c [C]e [C]l [C]l O 
types [C]t [C]y [C]p [C]e [C]s O 
differ [C]d [C]i [C]f [C]f [C]e [C]r O 
in [C]i [C]n O 
their [C]t [C]h [C]e [C]i [C]r O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
to [C]t [C]o O 
interact [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t O 
with [C]w [C]i [C]t [C]h O 
octamer-containing [C]o [C]c [C]t [C]a [C]m [C]e [C]r [C]- [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g B-DNA 
fragments [C]f [C]r [C]a [C]g [C]m [C]e [C]n [C]t [C]s E-DNA 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
also [C]a [C]l [C]s [C]o O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
a [C]a O 
DNA-protein [C]D [C]N [C]A [C]- [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
that [C]t [C]h [C]a [C]t O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
cell-type [C]c [C]e [C]l [C]l [C]- [C]t [C]y [C]p [C]e O 
specificity [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]i [C]t [C]y O 
of [C]o [C]f O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
we [C]w [C]e O 
have [C]h [C]a [C]v [C]e O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
a [C]a O 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
upstream [C]u [C]p [C]s [C]t [C]r [C]e [C]a [C]m O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
octamer [C]o [C]c [C]t [C]a [C]m [C]e [C]r O 
participates [C]p [C]a [C]r [C]t [C]i [C]c [C]i [C]p [C]a [C]t [C]e [C]s O 
in [C]i [C]n O 
an [C]a [C]n O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
( [C]( O 
s [C]s O 
) [C]) O 
. [C]. O 

Preferential [C]P [C]r [C]e [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
HTLV-I [C]H [C]T [C]L [C]V [C]- [C]I B-DNA 
LTR [C]L [C]T [C]R E-DNA 
in [C]i [C]n O 
cell-free [C]c [C]e [C]l [C]l [C]- [C]f [C]r [C]e [C]e O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
producing [C]p [C]r [C]o [C]d [C]u [C]c [C]i [C]n [C]g O 
HTLV-I [C]H [C]T [C]L [C]V [C]- [C]I B-protein 
viral [C]v [C]i [C]r [C]a [C]l I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s S-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
adenovirus [C]a [C]d [C]e [C]n [C]o [C]v [C]i [C]r [C]u [C]s B-DNA 
2 [C]2 I-DNA 
major [C]m [C]a [C]j [C]o [C]r I-DNA 
late [C]l [C]a [C]t [C]e I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
, [C], O 
the [C]t [C]h [C]e O 
mouse [C]m [C]o [C]u [C]s [C]e B-DNA 
beta-globin [C]b [C]e [C]t [C]a [C]- [C]g [C]l [C]o [C]b [C]i [C]n I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
, [C], O 
the [C]t [C]h [C]e O 
mouse [C]m [C]o [C]u [C]s [C]e B-DNA 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n I-DNA 
VH [C]V [C]H I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
LTR [C]L [C]T [C]R S-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n O 
T-lymphotropic [C]T [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]t [C]r [C]o [C]p [C]i [C]c O 
retrovirus [C]r [C]e [C]t [C]r [C]o [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
I [C]I O 
were [C]w [C]e [C]r [C]e O 
tested [C]t [C]e [C]s [C]t [C]e [C]d O 
for [C]f [C]o [C]r O 
their [C]t [C]h [C]e [C]i [C]r O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
activities [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]i [C]e [C]s O 
in [C]i [C]n O 
cell-free [C]c [C]e [C]l [C]l [C]- [C]f [C]r [C]e [C]e O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
of [C]o [C]f O 
four [C]f [C]o [C]u [C]r O 
cell [C]c [C]e [C]l [C]l O 
lines [C]l [C]i [C]n [C]e [C]s O 
; [C]; O 
HeLa [C]H [C]e [C]L [C]a S-cell_line 
, [C], O 
CESS [C]C [C]E [C]S [C]S S-cell_line 
( [C]( O 
Epstein-Barr [C]E [C]p [C]s [C]t [C]e [C]i [C]n [C]- [C]B [C]a [C]r [C]r B-cell_line 
virus-transformed [C]v [C]i [C]r [C]u [C]s [C]- [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]e [C]d I-cell_line 
human [C]h [C]u [C]m [C]a [C]n I-cell_line 
B [C]B I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
) [C]) O 
, [C], O 
MT-1 [C]M [C]T [C]- [C]1 S-cell_line 
( [C]( O 
HTLV-I-infected [C]H [C]T [C]L [C]V [C]- [C]I [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d B-cell_line 
human [C]h [C]u [C]m [C]a [C]n I-cell_line 
T [C]T I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
without [C]w [C]i [C]t [C]h [C]o [C]u [C]t O 
viral [C]v [C]i [C]r [C]a [C]l O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
MT-2 [C]M [C]T [C]- [C]2 S-cell_line 
( [C]( O 
HTLV-I-infected [C]H [C]T [C]L [C]V [C]- [C]I [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d B-cell_line 
human [C]h [C]u [C]m [C]a [C]n I-cell_line 
T [C]T I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
producing [C]p [C]r [C]o [C]d [C]u [C]c [C]i [C]n [C]g O 
viral [C]v [C]i [C]r [C]a [C]l B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
) [C]) O 
. [C]. O 

LTR [C]L [C]T [C]R S-DNA 
was [C]w [C]a [C]s O 
preferentially [C]p [C]r [C]e [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l [C]l [C]y O 
transcribed [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
of [C]o [C]f O 
MT-2 [C]M [C]T [C]- [C]2 S-cell_line 
although [C]a [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
other [C]o [C]t [C]h [C]e [C]r O 
three [C]t [C]h [C]r [C]e [C]e O 
genes [C]g [C]e [C]n [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
transcribed [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
relatively [C]r [C]e [C]l [C]a [C]t [C]i [C]v [C]e [C]l [C]y O 
constant [C]c [C]o [C]n [C]s [C]t [C]a [C]n [C]t O 
efficiencies [C]e [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]i [C]e [C]s O 
in [C]i [C]n O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
agree [C]a [C]g [C]r [C]e [C]e O 
well [C]w [C]e [C]l [C]l O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
previous [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
HTLV-I [C]H [C]T [C]L [C]V [C]- [C]I B-DNA 
LTR [C]L [C]T [C]R E-DNA 
. [C]. O 

Mixing [C]M [C]i [C]x [C]i [C]n [C]g O 
of [C]o [C]f O 
HeLa [C]H [C]e [C]L [C]a O 
and [C]a [C]n [C]d O 
MT-2 [C]M [C]T [C]- [C]2 O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
a [C]a O 
LTR-specific [C]L [C]T [C]R [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
stimulating [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
MT-2 [C]M [C]T [C]- [C]2 O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
. [C]. O 

A [C]A O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
that [C]t [C]h [C]a [C]t O 
binds [C]b [C]i [C]n [C]d [C]s O 
to [C]t [C]o O 
a [C]a O 
conserved [C]c [C]o [C]n [C]s [C]e [C]r [C]v [C]e [C]d O 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
motif [C]m [C]o [C]t [C]i [C]f O 
in [C]i [C]n O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l B-DNA 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l I-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
of [C]o [C]f O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
. [C]. O 

Trans-acting [C]T [C]r [C]a [C]n [C]s [C]- [C]a [C]c [C]t [C]i [C]n [C]g B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
that [C]t [C]h [C]a [C]t O 
mediate [C]m [C]e [C]d [C]i [C]a [C]t [C]e O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
postulated [C]p [C]o [C]s [C]t [C]u [C]l [C]a [C]t [C]e [C]d O 
based [C]b [C]a [C]s [C]e [C]d O 
on [C]o [C]n O 
an [C]a [C]n O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
exogenously [C]e [C]x [C]o [C]g [C]e [C]n [C]o [C]u [C]s [C]l [C]y O 
introduced [C]i [C]n [C]t [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n B-DNA 
gene [C]g [C]e [C]n [C]e I-DNA 
recombinants [C]r [C]e [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]n [C]t [C]s E-DNA 
in [C]i [C]n O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d B-cell_type 
and [C]a [C]n [C]d I-cell_type 
non-lymphoid [C]n [C]o [C]n [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Two [C]T [C]w [C]o O 
B-cell-specific [C]B [C]- [C]c [C]e [C]l [C]l [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
, [C], O 
cis-acting [C]c [C]i [C]s [C]- [C]a [C]c [C]t [C]i [C]n [C]g B-DNA 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l I-DNA 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y I-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
. [C]. O 

One [C]O [C]n [C]e O 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t O 
is [C]i [C]s O 
located [C]l [C]o [C]c [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
intron [C]i [C]n [C]t [C]r [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
variable [C]v [C]a [C]r [C]i [C]a [C]b [C]l [C]e O 
( [C]( O 
V [C]V O 
) [C]) O 
and [C]a [C]n [C]d O 
constant [C]c [C]o [C]n [C]s [C]t [C]a [C]n [C]t O 
( [C]( O 
C [C]C O 
) [C]) O 
regions [C]r [C]e [C]g [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
heavy [C]h [C]e [C]a [C]v [C]y B-DNA 
and [C]a [C]n [C]d I-DNA 
kappa [C]k [C]a [C]p [C]p [C]a I-DNA 
light-chain [C]l [C]i [C]g [C]h [C]t [C]- [C]c [C]h [C]a [C]i [C]n I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
and [C]a [C]n [C]d O 
acts [C]a [C]c [C]t [C]s O 
as [C]a [C]s O 
a [C]a O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r O 
. [C]. O 

The [C]T [C]h [C]e O 
second [C]s [C]e [C]c [C]o [C]n [C]d O 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t S-DNA 
is [C]i [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
upstream [C]u [C]p [C]s [C]t [C]r [C]e [C]a [C]m O 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
heavy [C]h [C]e [C]a [C]v [C]y B-DNA 
and [C]a [C]n [C]d I-DNA 
kappa [C]k [C]a [C]p [C]p [C]a I-DNA 
light-chain [C]l [C]i [C]g [C]h [C]t [C]- [C]c [C]h [C]a [C]i [C]n I-DNA 
gene [C]g [C]e [C]n [C]e I-DNA 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s E-DNA 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t O 
directs [C]d [C]i [C]r [C]e [C]c [C]t [C]s O 
lymphoid-specific [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
even [C]e [C]v [C]e [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
viral [C]v [C]i [C]r [C]a [C]l B-DNA 
enhancers [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r [C]s E-DNA 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
sought [C]s [C]o [C]u [C]g [C]h [C]t O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
that [C]t [C]h [C]a [C]t O 
might [C]m [C]i [C]g [C]h [C]t O 
bind [C]b [C]i [C]n [C]d O 
specifically [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]a [C]l [C]l [C]y O 
to [C]t [C]o O 
these [C]t [C]h [C]e [C]s [C]e O 
two [C]t [C]w [C]o O 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y B-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
by [C]b [C]y O 
application [C]a [C]p [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
modified [C]m [C]o [C]d [C]i [C]f [C]i [C]e [C]d O 
gel [C]g [C]e [C]l O 
electrophoresis [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]s [C]i [C]s O 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
assay [C]a [C]s [C]s [C]a [C]y O 
. [C]. O 

We [C]W [C]e O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
here [C]h [C]e [C]r [C]e O 
the [C]t [C]h [C]e O 
identification [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
human [C]h [C]u [C]m [C]a [C]n B-protein 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l I-protein 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
( [C]( O 
IgNF-A [C]I [C]g [C]N [C]F [C]- [C]A S-protein 
) [C]) O 
that [C]t [C]h [C]a [C]t O 
binds [C]b [C]i [C]n [C]d [C]s O 
to [C]t [C]o O 
DNA [C]D [C]N [C]A B-DNA 
sequences [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s E-DNA 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
upstream [C]u [C]p [C]s [C]t [C]r [C]e [C]a [C]m B-DNA 
regions [C]r [C]e [C]g [C]i [C]o [C]n [C]s E-DNA 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
the [C]t [C]h [C]e O 
mouse [C]m [C]o [C]u [C]s [C]e B-DNA 
heavy [C]h [C]e [C]a [C]v [C]y I-DNA 
and [C]a [C]n [C]d I-DNA 
kappa [C]k [C]a [C]p [C]p [C]a I-DNA 
light-chain [C]l [C]i [C]g [C]h [C]t [C]- [C]c [C]h [C]a [C]i [C]n I-DNA 
gene [C]g [C]e [C]n [C]e I-DNA 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s E-DNA 
and [C]a [C]n [C]d O 
also [C]a [C]l [C]s [C]o O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
mouse [C]m [C]o [C]u [C]s [C]e B-DNA 
heavy-chain [C]h [C]e [C]a [C]v [C]y [C]- [C]c [C]h [C]a [C]i [C]n I-DNA 
gene [C]g [C]e [C]n [C]e I-DNA 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r E-DNA 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
sequence-specific [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
is [C]i [C]s O 
probably [C]p [C]r [C]o [C]b [C]a [C]b [C]l [C]y O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
highly [C]h [C]i [C]g [C]h [C]l [C]y O 
conserved [C]c [C]o [C]n [C]s [C]e [C]r [C]v [C]e [C]d O 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
motif [C]m [C]o [C]t [C]i [C]f O 
, [C], O 
ATTTGCAT [C]A [C]T [C]T [C]T [C]G [C]C [C]A [C]T O 
, [C], O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
in [C]i [C]n O 
all [C]a [C]l [C]l O 
three [C]t [C]h [C]r [C]e [C]e O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l B-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
. [C]. O 

Interestingly [C]I [C]n [C]t [C]e [C]r [C]e [C]s [C]t [C]i [C]n [C]g [C]l [C]y O 
, [C], O 
a [C]a O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
showing [C]s [C]h [C]o [C]w [C]i [C]n [C]g O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
specificity [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]i [C]t [C]y O 
to [C]t [C]o O 
IgNF-A [C]I [C]g [C]N [C]F [C]- [C]A S-DNA 
is [C]i [C]s O 
also [C]a [C]l [C]s [C]o O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
HeLa [C]H [C]e [C]L [C]a I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

The [C]T [C]h [C]e O 
new [C]n [C]e [C]w O 
world [C]w [C]o [C]r [C]l [C]d O 
primates [C]p [C]r [C]i [C]m [C]a [C]t [C]e [C]s O 
as [C]a [C]s O 
animal [C]a [C]n [C]i [C]m [C]a [C]l O 
models [C]m [C]o [C]d [C]e [C]l [C]s O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
. [C]. O 

Many [C]M [C]a [C]n [C]y O 
New [C]N [C]e [C]w O 
World [C]W [C]o [C]r [C]l [C]d O 
primate [C]p [C]r [C]i [C]m [C]a [C]t [C]e O 
species [C]s [C]p [C]e [C]c [C]i [C]e [C]s O 
have [C]h [C]a [C]v [C]e O 
greatly [C]g [C]r [C]e [C]a [C]t [C]l [C]y O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
plasma [C]p [C]l [C]a [C]s [C]m [C]a O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
, [C], O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
plasma [C]p [C]l [C]a [C]s [C]m [C]a O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
globulin [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n O 
capacity [C]c [C]a [C]p [C]a [C]c [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
, [C], O 
marked [C]m [C]a [C]r [C]k [C]e [C]d O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
hypothalamic-pituitary-adrenal [C]h [C]y [C]p [C]o [C]t [C]h [C]a [C]l [C]a [C]m [C]i [C]c [C]- [C]p [C]i [C]t [C]u [C]i [C]t [C]a [C]r [C]y [C]- [C]a [C]d [C]r [C]e [C]n [C]a [C]l O 
axis [C]a [C]x [C]i [C]s O 
to [C]t [C]o O 
suppression [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
by [C]b [C]y O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
, [C], O 
and [C]a [C]n [C]d O 
no [C]n [C]o O 
biological [C]b [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
excess [C]e [C]x [C]c [C]e [C]s [C]s O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
primates [C]p [C]r [C]i [C]m [C]a [C]t [C]e [C]s O 
also [C]a [C]l [C]s [C]o O 
have [C]h [C]a [C]v [C]e O 
high [C]h [C]i [C]g [C]h O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
circulating [C]c [C]i [C]r [C]c [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
progesterone [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
, [C], O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n O 
, [C], O 
mineralocorticoid [C]m [C]i [C]n [C]e [C]r [C]a [C]l [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
, [C], O 
androgen [C]a [C]n [C]d [C]r [C]o [C]g [C]e [C]n O 
and [C]a [C]n [C]d O 
vitamin [C]v [C]i [C]t [C]a [C]m [C]i [C]n O 
D [C]D O 
. [C]. O 

The [C]T [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
tissues [C]t [C]i [C]s [C]s [C]u [C]e [C]s O 
that [C]t [C]h [C]a [C]t O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
( [C]( O 
circulating [C]c [C]i [C]r [C]c [C]u [C]l [C]a [C]t [C]i [C]n [C]g B-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
cultured [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]d B-cell_line 
skin [C]s [C]k [C]i [C]n I-cell_line 
fibroblasts [C]f [C]i [C]b [C]r [C]o [C]b [C]l [C]a [C]s [C]t [C]s E-cell_line 
) [C]) O 
have [C]h [C]a [C]v [C]e O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
with [C]w [C]i [C]t [C]h O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
for [C]f [C]o [C]r O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
. [C]. O 

Transformation [C]T [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
B-lymphocytes [C]B [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
Epstein-Barr [C]E [C]p [C]s [C]t [C]e [C]i [C]n [C]- [C]B [C]a [C]r [C]r O 
virus [C]v [C]i [C]r [C]u [C]s O 
leads [C]l [C]e [C]a [C]d [C]s O 
to [C]t [C]o O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
less [C]l [C]e [C]s [C]s O 
than [C]t [C]h [C]a [C]n O 
that [C]t [C]h [C]a [C]t O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
cells [C]c [C]e [C]l [C]l [C]s O 
from [C]f [C]r [C]o [C]m O 
Old [C]O [C]l [C]d O 
World [C]W [C]o [C]r [C]l [C]d O 
primates [C]p [C]r [C]i [C]m [C]a [C]t [C]e [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
in [C]i [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
has [C]h [C]a [C]s O 
a [C]a O 
low [C]l [C]o [C]w O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
for [C]f [C]o [C]r O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
low [C]l [C]o [C]w O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
leads [C]l [C]e [C]a [C]d [C]s O 
to [C]t [C]o O 
an [C]a [C]n O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
loss [C]l [C]o [C]s [C]s O 
of [C]o [C]f O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
bound [C]b [C]o [C]u [C]n [C]d O 
ligand [C]l [C]i [C]g [C]a [C]n [C]d O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
thermal [C]t [C]h [C]e [C]r [C]m [C]a [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Meroreceptor [C]M [C]e [C]r [C]o [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
generation [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
. [C]. O 

The [C]T [C]h [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
weight [C]w [C]e [C]i [C]g [C]h [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
, [C], O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
SDS-PAGE [C]S [C]D [C]S [C]- [C]P [C]A [C]G [C]E O 
, [C], O 
is [C]i [C]s O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
to [C]t [C]o O 
that [C]t [C]h [C]a [C]t O 
of [C]o [C]f O 
Old [C]O [C]l [C]d O 
World [C]W [C]o [C]r [C]l [C]d O 
primates [C]p [C]r [C]i [C]m [C]a [C]t [C]e [C]s O 
( [C]( O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
92 [C]9 [C]2 O 
, [C], O 
000 [C]0 [C]0 [C]0 O 
) [C]) O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
pattern [C]p [C]a [C]t [C]t [C]e [C]r [C]n O 
per [C]p [C]e [C]r O 
se [C]s [C]e O 
, [C], O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
by [C]b [C]y O 
heating [C]h [C]e [C]a [C]t [C]i [C]n [C]g O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
and [C]a [C]n [C]d O 
performing [C]p [C]e [C]r [C]f [C]o [C]r [C]m [C]i [C]n [C]g O 
phosphocellulose [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]c [C]e [C]l [C]l [C]u [C]l [C]o [C]s [C]e O 
chromatography [C]c [C]h [C]r [C]o [C]m [C]a [C]t [C]o [C]g [C]r [C]a [C]p [C]h [C]y O 
, [C], O 
appears [C]a [C]p [C]p [C]e [C]a [C]r [C]s O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
to [C]t [C]o O 
that [C]t [C]h [C]a [C]t O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
ratios [C]r [C]a [C]t [C]i [C]o [C]s O 
of [C]o [C]f O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
to [C]t [C]o O 
cytosolic [C]c [C]y [C]t [C]o [C]s [C]o [C]l [C]i [C]c B-protein 
hormone-receptor-complexes [C]h [C]o [C]r [C]m [C]o [C]n [C]e [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]- [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
and [C]a [C]n [C]d O 
of [C]o [C]f O 
cytosolic [C]c [C]y [C]t [C]o [C]s [C]o [C]l [C]i [C]c O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
to [C]t [C]o O 
unactivated [C]u [C]n [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
in [C]i [C]n O 
intact [C]i [C]n [C]t [C]a [C]c [C]t O 
cells [C]c [C]e [C]l [C]l [C]s O 
are [C]a [C]r [C]e O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
to [C]t [C]o O 
Old [C]O [C]l [C]d O 
World [C]W [C]o [C]r [C]l [C]d O 
primates [C]p [C]r [C]i [C]m [C]a [C]t [C]e [C]s O 
. [C]. O 

Results [C]R [C]e [C]s [C]u [C]l [C]t [C]s O 
from [C]f [C]r [C]o [C]m O 
mixing [C]m [C]i [C]x [C]i [C]n [C]g O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
do [C]d [C]o O 
not [C]n [C]o [C]t O 
support [C]s [C]u [C]p [C]p [C]o [C]r [C]t O 
the [C]t [C]h [C]e O 
hypothesis [C]h [C]y [C]p [C]o [C]t [C]h [C]e [C]s [C]i [C]s O 
that [C]t [C]h [C]a [C]t O 
a [C]a O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
( [C]( O 
s [C]s O 
) [C]) O 
or [C]o [C]r O 
a [C]a O 
deficient [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
cytosolic [C]c [C]y [C]t [C]o [C]s [C]o [C]l [C]i [C]c O 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
modifier [C]m [C]o [C]d [C]i [C]f [C]i [C]e [C]r O 
( [C]( O 
s [C]s O 
) [C]) O 
of [C]o [C]f O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
underlies [C]u [C]n [C]d [C]e [C]r [C]l [C]i [C]e [C]s O 
the [C]t [C]h [C]e O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
in [C]i [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
primates [C]p [C]r [C]i [C]m [C]a [C]t [C]e [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
New [C]N [C]e [C]w O 
World [C]W [C]o [C]r [C]l [C]d O 
primates [C]p [C]r [C]i [C]m [C]a [C]t [C]e [C]s O 
, [C], O 
unlike [C]u [C]n [C]l [C]i [C]k [C]e O 
men [C]m [C]e [C]n O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
syndrome [C]s [C]y [C]n [C]d [C]r [C]o [C]m [C]e O 
of [C]o [C]f O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
, [C], O 
have [C]h [C]a [C]v [C]e O 
compensated [C]c [C]o [C]m [C]p [C]e [C]n [C]s [C]a [C]t [C]e [C]d O 
for [C]f [C]o [C]r O 
their [C]t [C]h [C]e [C]i [C]r O 
condition [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
intra-adrenal [C]i [C]n [C]t [C]r [C]a [C]- [C]a [C]d [C]r [C]e [C]n [C]a [C]l O 
and [C]a [C]n [C]d O 
mineralocorticoid [C]m [C]i [C]n [C]e [C]r [C]a [C]l [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
adaptations [C]a [C]d [C]a [C]p [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
unlike [C]u [C]n [C]l [C]i [C]k [C]e O 
Old [C]O [C]l [C]d O 
World [C]W [C]o [C]r [C]l [C]d O 
primates [C]p [C]r [C]i [C]m [C]a [C]t [C]e [C]s O 
, [C], O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
in [C]i [C]n O 
New [C]N [C]e [C]w O 
World [C]W [C]o [C]r [C]l [C]d O 
primates [C]p [C]r [C]i [C]m [C]a [C]t [C]e [C]s O 
has [C]h [C]a [C]s O 
only [C]o [C]n [C]l [C]y O 
weak [C]w [C]e [C]a [C]k O 
sodium-retaining [C]s [C]o [C]d [C]i [C]u [C]m [C]- [C]r [C]e [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
potency [C]p [C]o [C]t [C]e [C]n [C]c [C]y O 
because [C]b [C]e [C]c [C]a [C]u [C]s [C]e O 
the [C]t [C]h [C]e O 
aldosterone [C]a [C]l [C]d [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
has [C]h [C]a [C]s O 
a [C]a O 
low [C]l [C]o [C]w O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
for [C]f [C]o [C]r O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
. [C]. O 

The [C]T [C]h [C]e O 
common [C]c [C]o [C]m [C]m [C]o [C]n O 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t O 
that [C]t [C]h [C]a [C]t O 
would [C]w [C]o [C]u [C]l [C]d O 
explain [C]e [C]x [C]p [C]l [C]a [C]i [C]n O 
the [C]t [C]h [C]e O 
apparent [C]a [C]p [C]p [C]a [C]r [C]e [C]n [C]t O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
to [C]t [C]o O 
six [C]s [C]i [C]x O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
hormones [C]h [C]o [C]r [C]m [C]o [C]n [C]e [C]s O 
in [C]i [C]n O 
New [C]N [C]e [C]w O 
World [C]W [C]o [C]r [C]l [C]d O 
primates [C]p [C]r [C]i [C]m [C]a [C]t [C]e [C]s O 

Acetylation [C]A [C]c [C]e [C]t [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
modulation [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d B-protein 
Kruppel-like [C]K [C]r [C]u [C]p [C]p [C]e [C]l [C]- [C]l [C]i [C]k [C]e I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
( [C]( O 
EKLF [C]E [C]K [C]L [C]F S-protein 
) [C]) O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
by [C]b [C]y O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
histone [C]h [C]i [C]s [C]t [C]o [C]n [C]e B-protein 
acetyltransferases [C]a [C]c [C]e [C]t [C]y [C]l [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]r [C]a [C]s [C]e [C]s E-protein 
. [C]. O 

Erythroid [C]E [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d B-protein 
Kruppel-like [C]K [C]r [C]u [C]p [C]p [C]e [C]l [C]- [C]l [C]i [C]k [C]e I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
( [C]( O 
EKLF [C]E [C]K [C]L [C]F S-protein 
) [C]) O 
is [C]i [C]s O 
a [C]a O 
red [C]r [C]e [C]d B-protein 
cell-specific [C]c [C]e [C]l [C]l [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-protein 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l I-protein 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r E-protein 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
crucial [C]c [C]r [C]u [C]c [C]i [C]a [C]l O 
for [C]f [C]o [C]r O 
consolidating [C]c [C]o [C]n [C]s [C]o [C]l [C]i [C]d [C]a [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
switch [C]s [C]w [C]i [C]t [C]c [C]h O 
to [C]t [C]o O 
high [C]h [C]i [C]g [C]h O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
adult [C]a [C]d [C]u [C]l [C]t O 
beta-globin [C]b [C]e [C]t [C]a [C]- [C]g [C]l [C]o [C]b [C]i [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d O 
ontogeny [C]o [C]n [C]t [C]o [C]g [C]e [C]n [C]y O 
. [C]. O 

EKLF [C]E [C]K [C]L [C]F S-protein 
is [C]i [C]s O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
integrity [C]i [C]n [C]t [C]e [C]g [C]r [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
chromatin [C]c [C]h [C]r [C]o [C]m [C]a [C]t [C]i [C]n O 
structure [C]s [C]t [C]r [C]u [C]c [C]t [C]u [C]r [C]e O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
beta-like [C]b [C]e [C]t [C]a [C]- [C]l [C]i [C]k [C]e B-DNA 
globin [C]g [C]l [C]o [C]b [C]i [C]n I-DNA 
locus [C]l [C]o [C]c [C]u [C]s E-DNA 
, [C], O 
and [C]a [C]n [C]d O 
it [C]i [C]t O 
interacts [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
positive-acting [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e [C]- [C]a [C]c [C]t [C]i [C]n [C]g B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
. [C]. O 

We [C]W [C]e O 
find [C]f [C]i [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
EKLF [C]E [C]K [C]L [C]F S-protein 
is [C]i [C]s O 
an [C]a [C]n O 
acetylated [C]a [C]c [C]e [C]t [C]y [C]l [C]a [C]t [C]e [C]d B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
, [C], O 
and [C]a [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
it [C]i [C]t O 
interacts [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]s O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
with [C]w [C]i [C]t [C]h O 
CBP [C]C [C]B [C]P S-protein 
, [C], O 
p300 [C]p [C]3 [C]0 [C]0 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
P/CAF [C]P [C]/ [C]C [C]A [C]F S-protein 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
its [C]i [C]t [C]s O 
interactions [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
with [C]w [C]i [C]t [C]h O 
these [C]t [C]h [C]e [C]s [C]e O 
histone [C]h [C]i [C]s [C]t [C]o [C]n [C]e B-protein 
acetyltransferases [C]a [C]c [C]e [C]t [C]y [C]l [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]r [C]a [C]s [C]e [C]s E-protein 
are [C]a [C]r [C]e O 
not [C]n [C]o [C]t O 
equivalent [C]e [C]q [C]u [C]i [C]v [C]a [C]l [C]e [C]n [C]t O 
, [C], O 
as [C]a [C]s O 
CBP [C]C [C]B [C]P S-protein 
and [C]a [C]n [C]d O 
p300 [C]p [C]3 [C]0 [C]0 S-protein 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
P/CAF [C]P [C]/ [C]C [C]A [C]F S-protein 
, [C], O 
utilize [C]u [C]t [C]i [C]l [C]i [C]z [C]e O 
EKLF [C]E [C]K [C]L [C]F S-protein 
as [C]a [C]s O 
a [C]a O 
substrate [C]s [C]u [C]b [C]s [C]t [C]r [C]a [C]t [C]e O 
for [C]f [C]o [C]r O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
acetylation [C]a [C]c [C]e [C]t [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
its [C]i [C]t [C]s O 
trans-activation [C]t [C]r [C]a [C]n [C]s [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
region [C]r [C]e [C]g [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
interactions [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
are [C]a [C]r [C]e O 
that [C]t [C]h [C]a [C]t O 
CBP [C]C [C]B [C]P S-protein 
and [C]a [C]n [C]d O 
p300 [C]p [C]3 [C]0 [C]0 S-protein 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
P/CAF [C]P [C]/ [C]C [C]A [C]F S-protein 
, [C], O 
enhance [C]e [C]n [C]h [C]a [C]n [C]c [C]e O 
EKLF [C]E [C]K [C]L [C]F S-protein 
's [C]' [C]s O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
beta-globin [C]b [C]e [C]t [C]a [C]- [C]g [C]l [C]o [C]b [C]i [C]n B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
in [C]i [C]n O 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
establish [C]e [C]s [C]t [C]a [C]b [C]l [C]i [C]s [C]h O 
EKLF [C]E [C]K [C]L [C]F S-protein 
as [C]a [C]s O 
a [C]a O 
tissue-specific [C]t [C]i [C]s [C]s [C]u [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
that [C]t [C]h [C]a [C]t O 
undergoes [C]u [C]n [C]d [C]e [C]r [C]g [C]o [C]e [C]s O 
post-translational [C]p [C]o [C]s [C]t [C]- [C]t [C]r [C]a [C]n [C]s [C]l [C]a [C]t [C]i [C]o [C]n [C]a [C]l O 
acetylation [C]a [C]c [C]e [C]t [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
a [C]a O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
by [C]b [C]y O 
which [C]w [C]h [C]i [C]c [C]h O 
EKLF [C]E [C]K [C]L [C]F S-protein 
is [C]i [C]s O 
able [C]a [C]b [C]l [C]e O 
to [C]t [C]o O 
alter [C]a [C]l [C]t [C]e [C]r O 
chromatin [C]c [C]h [C]r [C]o [C]m [C]a [C]t [C]i [C]n O 
structure [C]s [C]t [C]r [C]u [C]c [C]t [C]u [C]r [C]e O 
and [C]a [C]n [C]d O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
beta-globin [C]b [C]e [C]t [C]a [C]- [C]g [C]l [C]o [C]b [C]i [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
the [C]t [C]h [C]e O 
beta-like [C]b [C]e [C]t [C]a [C]- [C]l [C]i [C]k [C]e B-DNA 
globin [C]g [C]l [C]o [C]b [C]i [C]n I-DNA 
cluster [C]c [C]l [C]u [C]s [C]t [C]e [C]r E-DNA 
. [C]. O 

Recognition [C]R [C]e [C]c [C]o [C]g [C]n [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
herpes [C]h [C]e [C]r [C]p [C]e [C]s B-protein 
simplex [C]s [C]i [C]m [C]p [C]l [C]e [C]x I-protein 
virus [C]v [C]i [C]r [C]u [C]s I-protein 
type [C]t [C]y [C]p [C]e I-protein 
2 [C]2 I-protein 
tegument [C]t [C]e [C]g [C]u [C]m [C]e [C]n [C]t I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
by [C]b [C]y O 
CD4 [C]C [C]D [C]4 B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
infiltrating [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]n [C]g O 
human [C]h [C]u [C]m [C]a [C]n O 
genital [C]g [C]e [C]n [C]i [C]t [C]a [C]l O 
herpes [C]h [C]e [C]r [C]p [C]e [C]s O 
lesions [C]l [C]e [C]s [C]i [C]o [C]n [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
local [C]l [C]o [C]c [C]a [C]l O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
herpes [C]h [C]e [C]r [C]p [C]e [C]s O 
simplex [C]s [C]i [C]m [C]p [C]l [C]e [C]x O 
virus [C]v [C]i [C]r [C]u [C]s O 
( [C]( O 
HSV [C]H [C]S [C]V O 
) [C]) O 
is [C]i [C]s O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
of [C]o [C]f O 
recurrent [C]r [C]e [C]c [C]u [C]r [C]r [C]e [C]n [C]t O 
HSV [C]H [C]S [C]V O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
antiviral [C]a [C]n [C]t [C]i [C]v [C]i [C]r [C]a [C]l O 
functions [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
infiltrating [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]n [C]g B-cell_type 
CD4-bearing [C]C [C]D [C]4 [C]- [C]b [C]e [C]a [C]r [C]i [C]n [C]g I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
may [C]m [C]a [C]y O 
include [C]i [C]n [C]c [C]l [C]u [C]d [C]e O 
cytotoxicity [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c [C]i [C]t [C]y O 
, [C], O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
viral [C]v [C]i [C]r [C]a [C]l O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
, [C], O 
lymphokine [C]l [C]y [C]m [C]p [C]h [C]o [C]k [C]i [C]n [C]e O 
secretion [C]s [C]e [C]c [C]r [C]e [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
support [C]s [C]u [C]p [C]p [C]o [C]r [C]t O 
of [C]o [C]f O 
humoral [C]h [C]u [C]m [C]o [C]r [C]a [C]l O 
and [C]a [C]n [C]d O 
CD8 [C]C [C]D [C]8 O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
antigens [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]s O 
recognized [C]r [C]e [C]c [C]o [C]g [C]n [C]i [C]z [C]e [C]d O 
by [C]b [C]y O 
many [C]m [C]a [C]n [C]y O 
HSV-specific [C]H [C]S [C]V [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-cell_type 
CD4 [C]C [C]D [C]4 I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
localizing [C]l [C]o [C]c [C]a [C]l [C]i [C]z [C]i [C]n [C]g O 
to [C]t [C]o O 
genital [C]g [C]e [C]n [C]i [C]t [C]a [C]l O 
HSV-2 [C]H [C]S [C]V [C]- [C]2 O 
lesions [C]l [C]e [C]s [C]i [C]o [C]n [C]s O 
are [C]a [C]r [C]e O 
unknown [C]u [C]n [C]k [C]n [C]o [C]w [C]n O 
. [C]. O 

T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
recognizing [C]r [C]e [C]c [C]o [C]g [C]n [C]i [C]z [C]i [C]n [C]g O 
antigens [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]s O 
encoded [C]e [C]n [C]c [C]o [C]d [C]e [C]d O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
map [C]m [C]a [C]p O 
units [C]u [C]n [C]i [C]t [C]s O 
0.67 [C]0 [C]. [C]6 [C]7 O 
to [C]t [C]o O 
0.73 [C]0 [C]. [C]7 [C]3 O 
of [C]o [C]f O 
HSV [C]H [C]S [C]V B-DNA 
DNA [C]D [C]N [C]A E-DNA 
are [C]a [C]r [C]e O 
frequently [C]f [C]r [C]e [C]q [C]u [C]e [C]n [C]t [C]l [C]y O 
recovered [C]r [C]e [C]c [C]o [C]v [C]e [C]r [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
herpetic [C]h [C]e [C]r [C]p [C]e [C]t [C]i [C]c O 
lesions [C]l [C]e [C]s [C]i [C]o [C]n [C]s O 
. [C]. O 

Expression [C]E [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
cloning [C]c [C]l [C]o [C]n [C]i [C]n [C]g O 
with [C]w [C]i [C]t [C]h O 
this [C]t [C]h [C]i [C]s O 
region [C]r [C]e [C]g [C]i [C]o [C]n O 
of [C]o [C]f O 
DNA [C]D [C]N [C]A O 
now [C]n [C]o [C]w O 
shows [C]s [C]h [C]o [C]w [C]s O 
that [C]t [C]h [C]a [C]t O 
tegument [C]t [C]e [C]g [C]u [C]m [C]e [C]n [C]t B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
VP22 [C]V [C]P [C]2 [C]2 S-protein 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
viral [C]v [C]i [C]r [C]a [C]l B-protein 
dUTPase [C]d [C]U [C]T [C]P [C]a [C]s [C]e E-protein 
, [C], O 
encoded [C]e [C]n [C]c [C]o [C]d [C]e [C]d O 
by [C]b [C]y O 
genes [C]g [C]e [C]n [C]e [C]s B-DNA 
UL49 [C]U [C]L [C]4 [C]9 I-DNA 
and [C]a [C]n [C]d I-DNA 
UL50 [C]U [C]L [C]5 [C]0 E-DNA 
, [C], O 
respectively [C]r [C]e [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
, [C], O 
are [C]a [C]r [C]e O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l B-protein 
antigens [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]s E-protein 
. [C]. O 

Separate [C]S [C]e [C]p [C]a [C]r [C]a [C]t [C]e O 
epitopes [C]e [C]p [C]i [C]t [C]o [C]p [C]e [C]s S-protein 
in [C]i [C]n O 
VP22 [C]V [C]P [C]2 [C]2 S-protein 
were [C]w [C]e [C]r [C]e O 
defined [C]d [C]e [C]f [C]i [C]n [C]e [C]d O 
for [C]f [C]o [C]r O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l B-cell_line 
clones [C]c [C]l [C]o [C]n [C]e [C]s E-cell_line 
from [C]f [C]r [C]o [C]m O 
each [C]e [C]a [C]c [C]h O 
of [C]o [C]f O 
three [C]t [C]h [C]r [C]e [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

Reactivity [C]R [C]e [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
tegument [C]t [C]e [C]g [C]u [C]m [C]e [C]n [C]t B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
encoded [C]e [C]n [C]c [C]o [C]d [C]e [C]d O 
by [C]b [C]y O 
UL21 [C]U [C]L [C]2 [C]1 S-DNA 
was [C]w [C]a [C]s O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
for [C]f [C]o [C]r O 
an [C]a [C]n O 
additional [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n [C]a [C]l O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
. [C]. O 

Three [C]T [C]h [C]r [C]e [C]e O 
new [C]n [C]e [C]w O 
epitopes [C]e [C]p [C]i [C]t [C]o [C]p [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
in [C]i [C]n O 
VP16 [C]V [C]P [C]1 [C]6 S-protein 
, [C], O 
a [C]a O 
tegument [C]t [C]e [C]g [C]u [C]m [C]e [C]n [C]t B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
VP22 [C]V [C]P [C]2 [C]2 S-protein 
. [C]. O 

Some [C]S [C]o [C]m [C]e O 
tegument-specific [C]t [C]e [C]g [C]u [C]m [C]e [C]n [C]t [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-cell_line 
CD4 [C]C [C]D [C]4 I-cell_line 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l I-cell_line 
clones [C]c [C]l [C]o [C]n [C]e [C]s E-cell_line 
exhibited [C]e [C]x [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
cytotoxic [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
HSV-infected [C]H [C]S [C]V [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
herpes [C]h [C]e [C]r [C]p [C]e [C]s B-protein 
simplex [C]s [C]i [C]m [C]p [C]l [C]e [C]x I-protein 
tegument [C]t [C]e [C]g [C]u [C]m [C]e [C]n [C]t I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
are [C]a [C]r [C]e O 
processed [C]p [C]r [C]o [C]c [C]e [C]s [C]s [C]e [C]d O 
for [C]f [C]o [C]r O 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n O 
presentation [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
and [C]a [C]n [C]d O 
are [C]a [C]r [C]e O 
possible [C]p [C]o [C]s [C]s [C]i [C]b [C]l [C]e O 
candidate [C]c [C]a [C]n [C]d [C]i [C]d [C]a [C]t [C]e O 
compounds [C]c [C]o [C]m [C]p [C]o [C]u [C]n [C]d [C]s O 
for [C]f [C]o [C]r O 
herpes [C]h [C]e [C]r [C]p [C]e [C]s O 
simplex [C]s [C]i [C]m [C]p [C]l [C]e [C]x O 
vaccines [C]v [C]a [C]c [C]c [C]i [C]n [C]e [C]s O 
. [C]. O 

Fibrinogen [C]F [C]i [C]b [C]r [C]i [C]n [C]o [C]g [C]e [C]n S-protein 
activates [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]s O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_type 
phagocytes [C]p [C]h [C]a [C]g [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

Adhesion [C]A [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
to [C]t [C]o O 
extracellular [C]e [C]x [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
matrices [C]m [C]a [C]t [C]r [C]i [C]c [C]e [C]s O 
is [C]i [C]s O 
known [C]k [C]n [C]o [C]w [C]n O 
to [C]t [C]o O 
modulate [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]e O 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
although [C]a [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
are [C]a [C]r [C]e O 
not [C]n [C]o [C]t O 
fully [C]f [C]u [C]l [C]l [C]y O 
understood [C]u [C]n [C]d [C]e [C]r [C]s [C]t [C]o [C]o [C]d O 
. [C]. O 

Mononuclear [C]M [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_type 
phagocytes [C]p [C]h [C]a [C]g [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
are [C]a [C]r [C]e O 
exposed [C]e [C]x [C]p [C]o [C]s [C]e [C]d O 
to [C]t [C]o O 
fibrinous [C]f [C]i [C]b [C]r [C]i [C]n [C]o [C]u [C]s O 
provisional [C]p [C]r [C]o [C]v [C]i [C]s [C]i [C]o [C]n [C]a [C]l O 
matrix [C]m [C]a [C]t [C]r [C]i [C]x O 
throughout [C]t [C]h [C]r [C]o [C]u [C]g [C]h [C]o [C]u [C]t O 
migration [C]m [C]i [C]g [C]r [C]a [C]t [C]i [C]o [C]n O 
into [C]i [C]n [C]t [C]o O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
foci [C]f [C]o [C]c [C]i O 
, [C], O 
so [C]s [C]o O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
was [C]w [C]a [C]s O 
undertaken [C]u [C]n [C]d [C]e [C]r [C]t [C]a [C]k [C]e [C]n O 
to [C]t [C]o O 
determine [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
fibrinogen [C]f [C]i [C]b [C]r [C]i [C]n [C]o [C]g [C]e [C]n O 
triggers [C]t [C]r [C]i [C]g [C]g [C]e [C]r [C]s O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

U937 [C]U [C]9 [C]3 [C]7 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
differentiated [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
PMA [C]P [C]M [C]A O 
in [C]i [C]n O 
nonadherent [C]n [C]o [C]n [C]a [C]d [C]h [C]e [C]r [C]e [C]n [C]t B-cell_line 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e E-cell_line 
were [C]w [C]e [C]r [C]e O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
two [C]t [C]w [C]o O 
fibrinogen-binding [C]f [C]i [C]b [C]r [C]i [C]n [C]o [C]g [C]e [C]n [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
integrins [C]i [C]n [C]t [C]e [C]g [C]r [C]i [C]n [C]s E-protein 
, [C], O 
predominately [C]p [C]r [C]e [C]d [C]o [C]m [C]i [C]n [C]a [C]t [C]e [C]l [C]y O 
CD11b/CD18 [C]C [C]D [C]1 [C]1 [C]b [C]/ [C]C [C]D [C]1 [C]8 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
to [C]t [C]o O 
a [C]a O 
lesser [C]l [C]e [C]s [C]s [C]e [C]r O 
extent [C]e [C]x [C]t [C]e [C]n [C]t O 
, [C], O 
CD11c/CD18 [C]C [C]D [C]1 [C]1 [C]c [C]/ [C]C [C]D [C]1 [C]8 S-protein 
. [C]. O 

Cells [C]C [C]e [C]l [C]l [C]s O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
fibrinogen [C]f [C]i [C]b [C]r [C]i [C]n [C]o [C]g [C]e [C]n S-protein 
( [C]( O 
10-100 [C]1 [C]0 [C]- [C]1 [C]0 [C]0 O 
microg/ml [C]m [C]i [C]c [C]r [C]o [C]g [C]/ [C]m [C]l O 
) [C]) O 
/Mn2+ [C]/ [C]M [C]n [C]2 [C]+ O 
( [C]( O 
50 [C]5 [C]0 O 
microM [C]m [C]i [C]c [C]r [C]o [C]M O 
) [C]) O 
for [C]f [C]o [C]r O 
2 [C]2 O 
h [C]h O 
were [C]w [C]e [C]r [C]e O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
electrophoretic [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
assay [C]a [C]s [C]s [C]a [C]y O 
. [C]. O 

NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
minimal [C]m [C]i [C]n [C]i [C]m [C]a [C]l O 
in [C]i [C]n O 
unstimulated [C]u [C]n [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
was [C]w [C]a [C]s O 
substantially [C]s [C]u [C]b [C]s [C]t [C]a [C]n [C]t [C]i [C]a [C]l [C]l [C]y O 
up-regulated [C]u [C]p [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
fibrinogen [C]f [C]i [C]b [C]r [C]i [C]n [C]o [C]g [C]e [C]n S-protein 
. [C]. O 

Fibrinogen [C]F [C]i [C]b [C]r [C]i [C]n [C]o [C]g [C]e [C]n S-protein 
also [C]a [C]l [C]s [C]o O 
caused [C]c [C]a [C]u [C]s [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
SP1 [C]S [C]P [C]1 S-protein 
or [C]o [C]r O 
cAMP [C]c [C]A [C]M [C]P B-protein 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e I-protein 
element-binding [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
( [C]( I-protein 
CREB [C]C [C]R [C]E [C]B I-protein 
) [C]) I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

Blocking [C]B [C]l [C]o [C]c [C]k [C]i [C]n [C]g O 
mAbs [C]m [C]A [C]b [C]s S-protein 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
CD18 [C]C [C]D [C]1 [C]8 S-protein 
and [C]a [C]n [C]d O 
CD11b [C]C [C]D [C]1 [C]1 [C]b S-protein 
abrogated [C]a [C]b [C]r [C]o [C]g [C]a [C]t [C]e [C]d O 
fibrinogen [C]f [C]i [C]b [C]r [C]i [C]n [C]o [C]g [C]e [C]n S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

To [C]T [C]o O 
determine [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e O 
the [C]t [C]h [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
on [C]o [C]n O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
U937 [C]U [C]9 [C]3 [C]7 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
were [C]w [C]e [C]r [C]e O 
transfected [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
plasmid [C]p [C]l [C]a [C]s [C]m [C]i [C]d O 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 B-DNA 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r E-DNA 
( [C]( O 
bearing [C]b [C]e [C]a [C]r [C]i [C]n [C]g O 
two [C]t [C]w [C]o O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-DNA 
B [C]B I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
) [C]) O 
coupled [C]c [C]o [C]u [C]p [C]l [C]e [C]d O 
to [C]t [C]o O 
a [C]a O 
chloramphenicol [C]c [C]h [C]l [C]o [C]r [C]a [C]m [C]p [C]h [C]e [C]n [C]i [C]c [C]o [C]l B-DNA 
acetyltransferase [C]a [C]c [C]e [C]t [C]y [C]l [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]r [C]a [C]s [C]e I-DNA 
( [C]( I-DNA 
CAT [C]C [C]A [C]T I-DNA 
) [C]) I-DNA 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r E-DNA 
. [C]. O 

Cells [C]C [C]e [C]l [C]l [C]s O 
were [C]w [C]e [C]r [C]e O 
subsequently [C]s [C]u [C]b [C]s [C]e [C]q [C]u [C]e [C]n [C]t [C]l [C]y O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
1 [C]1 O 
) [C]) O 
PMA [C]P [C]M [C]A O 
for [C]f [C]o [C]r O 
24 [C]2 [C]4 O 
h [C]h O 
, [C], O 
inducing [C]i [C]n [C]d [C]u [C]c [C]i [C]n [C]g O 
CAT [C]C [C]A [C]T O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
by [C]b [C]y O 
2.6-fold [C]2 [C]. [C]6 [C]- [C]f [C]o [C]l [C]d O 
, [C], O 
2 [C]2 O 
) [C]) O 
fibrinogen [C]f [C]i [C]b [C]r [C]i [C]n [C]o [C]g [C]e [C]n S-protein 
/Mn2+ [C]/ [C]M [C]n [C]2 [C]+ O 
for [C]f [C]o [C]r O 
2 [C]2 O 
h [C]h O 
, [C], O 
inducing [C]i [C]n [C]d [C]u [C]c [C]i [C]n [C]g O 
CAT [C]C [C]A [C]T O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
by [C]b [C]y O 
3.2-fold [C]3 [C]. [C]2 [C]- [C]f [C]o [C]l [C]d O 
, [C], O 
or [C]o [C]r O 
3 [C]3 O 
) [C]) O 
costimulation [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
fibrinogen [C]f [C]i [C]b [C]r [C]i [C]n [C]o [C]g [C]e [C]n S-protein 
and [C]a [C]n [C]d O 
PMA [C]P [C]M [C]A O 
, [C], O 
inducing [C]i [C]n [C]d [C]u [C]c [C]i [C]n [C]g O 
5.7-fold [C]5 [C]. [C]7 [C]- [C]f [C]o [C]l [C]d O 
the [C]t [C]h [C]e O 
CAT [C]C [C]A [C]T O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
PMA [C]P [C]M [C]A O 
alone [C]a [C]l [C]o [C]n [C]e O 
. [C]. O 

We [C]W [C]e O 
conclude [C]c [C]o [C]n [C]c [C]l [C]u [C]d [C]e O 
that [C]t [C]h [C]a [C]t O 
contact [C]c [C]o [C]n [C]t [C]a [C]c [C]t O 
with [C]w [C]i [C]t [C]h O 
fibrinogen-derived [C]f [C]i [C]b [C]r [C]i [C]n [C]o [C]g [C]e [C]n [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
may [C]m [C]a [C]y O 
contribute [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e O 
to [C]t [C]o O 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
phagocyte [C]p [C]h [C]a [C]g [C]o [C]c [C]y [C]t [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
CD11b/CD18 [C]C [C]D [C]1 [C]1 [C]b [C]/ [C]C [C]D [C]1 [C]8 S-protein 
, [C], O 
resulting [C]r [C]e [C]s [C]u [C]l [C]t [C]i [C]n [C]g O 
in [C]i [C]n O 
selective [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l B-protein 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
. [C]. O 

Peripheral [C]P [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s I-cell_type 
and [C]a [C]n [C]d I-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
B [C]B B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
derived [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
lupus [C]l [C]u [C]p [C]u [C]s O 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
transcripts [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]s O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
to [C]t [C]o O 
those [C]t [C]h [C]o [C]s [C]e O 
of [C]o [C]f O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

OBJECTIVE [C]O [C]B [C]J [C]E [C]C [C]T [C]I [C]V [C]E O 
: [C]: O 
To [C]T [C]o O 
identify [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]y O 
and [C]a [C]n [C]d O 
characterize [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n B-RNA 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-RNA 
( [C]( I-RNA 
ER [C]E [C]R I-RNA 
) [C]) I-RNA 
transcripts [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]s E-RNA 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
immune [C]i [C]m [C]m [C]u [C]n [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
of [C]o [C]f O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
systemic [C]s [C]y [C]s [C]t [C]e [C]m [C]i [C]c O 
lupus [C]l [C]u [C]p [C]u [C]s O 
erythematosus [C]e [C]r [C]y [C]t [C]h [C]e [C]m [C]a [C]t [C]o [C]s [C]u [C]s O 
( [C]( O 
SLE [C]S [C]L [C]E O 
) [C]) O 
and [C]a [C]n [C]d O 
healthy [C]h [C]e [C]a [C]l [C]t [C]h [C]y O 
donors [C]d [C]o [C]n [C]o [C]r [C]s O 
. [C]. O 

METHODS [C]M [C]E [C]T [C]H [C]O [C]D [C]S O 
: [C]: O 
Peripheral [C]P [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s I-cell_type 
and [C]a [C]n [C]d I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
prepared [C]p [C]r [C]e [C]p [C]a [C]r [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
SLE [C]S [C]L [C]E O 
( [C]( O 
n [C]n O 
= [C]= O 
6 [C]6 O 
) [C]) O 
and [C]a [C]n [C]d O 
healthy [C]h [C]e [C]a [C]l [C]t [C]h [C]y O 
donors [C]d [C]o [C]n [C]o [C]r [C]s O 
( [C]( O 
n [C]n O 
= [C]= O 
8 [C]8 O 
) [C]) O 
. [C]. O 

T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
separated [C]s [C]e [C]p [C]a [C]r [C]a [C]t [C]e [C]d O 
into [C]i [C]n [C]t [C]o O 
CD4 [C]C [C]D [C]4 S-cell_type 
and [C]a [C]n [C]d O 
CD8 [C]C [C]D [C]8 S-cell_type 
. [C]. O 

Some [C]S [C]o [C]m [C]e O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
and [C]a [C]n [C]d O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
estradiol [C]e [C]s [C]t [C]r [C]a [C]d [C]i [C]o [C]l O 
, [C], O 
PMA [C]P [C]M [C]A O 
, [C], O 
and [C]a [C]n [C]d O 
ionomycin [C]i [C]o [C]n [C]o [C]m [C]y [C]c [C]i [C]n O 
. [C]. O 

Epstein-Barr [C]E [C]p [C]s [C]t [C]e [C]i [C]n [C]- [C]B [C]a [C]r [C]r O 
virus-transformed [C]v [C]i [C]r [C]u [C]s [C]- [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]e [C]d O 
B [C]B B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
( [C]( O 
n [C]n O 
= [C]= O 
7 [C]7 O 
) [C]) O 
and [C]a [C]n [C]d O 
B [C]B B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
hybridomas [C]h [C]y [C]b [C]r [C]i [C]d [C]o [C]m [C]a [C]s E-cell_line 
( [C]( O 
n [C]n O 
= [C]= O 
2 [C]2 O 
) [C]) O 
established [C]e [C]s [C]t [C]a [C]b [C]l [C]i [C]s [C]h [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
SLE [C]S [C]L [C]E O 
and [C]a [C]n [C]d O 
a [C]a O 
healthy [C]h [C]e [C]a [C]l [C]t [C]h [C]y O 
individual [C]i [C]n [C]d [C]i [C]v [C]i [C]d [C]u [C]a [C]l O 
were [C]w [C]e [C]r [C]e O 
used [C]u [C]s [C]e [C]d O 
as [C]a [C]s O 
a [C]a O 
B [C]B O 
cell [C]c [C]e [C]l [C]l O 
source [C]s [C]o [C]u [C]r [C]c [C]e O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
were [C]w [C]e [C]r [C]e O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
for [C]f [C]o [C]r O 
ER [C]E [C]R B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
by [C]b [C]y O 
reverse [C]r [C]e [C]v [C]e [C]r [C]s [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
nested [C]n [C]e [C]s [C]t [C]e [C]d O 
polymerase [C]p [C]o [C]l [C]y [C]m [C]e [C]r [C]a [C]s [C]e O 
chain [C]c [C]h [C]a [C]i [C]n O 
reaction [C]r [C]e [C]a [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

Amplified [C]A [C]m [C]p [C]l [C]i [C]f [C]i [C]e [C]d O 
cDNA [C]c [C]D [C]N [C]A S-DNA 
were [C]w [C]e [C]r [C]e O 
sequenced [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]d O 
by [C]b [C]y O 
standard [C]s [C]t [C]a [C]n [C]d [C]a [C]r [C]d O 
methods [C]m [C]e [C]t [C]h [C]o [C]d [C]s O 
. [C]. O 

RESULTS [C]R [C]E [C]S [C]U [C]L [C]T [C]S O 
: [C]: O 
In [C]I [C]n O 
all [C]a [C]l [C]l O 
cells [C]c [C]e [C]l [C]l [C]s O 
tested [C]t [C]e [C]s [C]t [C]e [C]d O 
, [C], O 
ER [C]E [C]R B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
was [C]w [C]a [C]s O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
without [C]w [C]i [C]t [C]h [C]o [C]u [C]t O 
prior [C]p [C]r [C]i [C]o [C]r O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Partial [C]P [C]a [C]r [C]t [C]i [C]a [C]l O 
sequences [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s O 
from [C]f [C]r [C]o [C]m O 
exons [C]e [C]x [C]o [C]n [C]s B-DNA 
1-8 [C]1 [C]- [C]8 E-DNA 
were [C]w [C]e [C]r [C]e O 
nearly [C]n [C]e [C]a [C]r [C]l [C]y O 
identical [C]i [C]d [C]e [C]n [C]t [C]i [C]c [C]a [C]l O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
published [C]p [C]u [C]b [C]l [C]i [C]s [C]h [C]e [C]d O 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-RNA 
ER [C]E [C]R I-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
. [C]. O 

There [C]T [C]h [C]e [C]r [C]e O 
were [C]w [C]e [C]r [C]e O 
no [C]n [C]o O 
notable [C]n [C]o [C]t [C]a [C]b [C]l [C]e O 
differences [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
ER [C]E [C]R B-RNA 
transcripts [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]s E-RNA 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
and [C]a [C]n [C]d O 
healthy [C]h [C]e [C]a [C]l [C]t [C]h [C]y O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
. [C]. O 

Variant [C]V [C]a [C]r [C]i [C]a [C]n [C]t O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
transcripts [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]s O 
lacking [C]l [C]a [C]c [C]k [C]i [C]n [C]g O 
exon [C]e [C]x [C]o [C]n B-DNA 
5 [C]5 E-DNA 
or [C]o [C]r O 
exon [C]e [C]x [C]o [C]n B-DNA 
7 [C]7 E-DNA 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
encodes [C]e [C]n [C]c [C]o [C]d [C]e [C]s O 
the [C]t [C]h [C]e O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e B-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
, [C], O 
were [C]w [C]e [C]r [C]e O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
majority [C]m [C]a [C]j [C]o [C]r [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
. [C]. O 

Precise [C]P [C]r [C]e [C]c [C]i [C]s [C]e O 
deletion [C]d [C]e [C]l [C]e [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
exons [C]e [C]x [C]o [C]n [C]s O 
suggests [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]s O 
that [C]t [C]h [C]a [C]t O 
they [C]t [C]h [C]e [C]y O 
are [C]a [C]r [C]e O 
alternatively [C]a [C]l [C]t [C]e [C]r [C]n [C]a [C]t [C]i [C]v [C]e [C]l [C]y O 
spliced [C]s [C]p [C]l [C]i [C]c [C]e [C]d O 
transcripts [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]s O 
. [C]. O 

Whether [C]W [C]h [C]e [C]t [C]h [C]e [C]r O 
the [C]t [C]h [C]e O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
transcripts [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]s O 
are [C]a [C]r [C]e O 
translated [C]t [C]r [C]a [C]n [C]s [C]l [C]a [C]t [C]e [C]d O 
into [C]i [C]n [C]t [C]o O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
remains [C]r [C]e [C]m [C]a [C]i [C]n [C]s O 
to [C]t [C]o O 
be [C]b [C]e O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
. [C]. O 

In [C]I [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
affect [C]a [C]f [C]f [C]e [C]c [C]t O 
ER [C]E [C]R B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
variants [C]v [C]a [C]r [C]i [C]a [C]n [C]t [C]s O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
correlate [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e O 
with [C]w [C]i [C]t [C]h O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
or [C]o [C]r O 
medication [C]m [C]e [C]d [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

CONCLUSION [C]C [C]O [C]N [C]C [C]L [C]U [C]S [C]I [C]O [C]N O 
: [C]: O 
Monocytes [C]M [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
, [C], O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
and [C]a [C]n [C]d O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
transcripts [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
wild [C]w [C]i [C]l [C]d B-protein 
type [C]t [C]y [C]p [C]e I-protein 
ER [C]E [C]R E-protein 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e B-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n I-protein 
variants [C]v [C]a [C]r [C]i [C]a [C]n [C]t [C]s E-protein 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
. [C]. O 

DNA [C]D [C]N [C]A O 
damaging [C]d [C]a [C]m [C]a [C]g [C]i [C]n [C]g O 
agents [C]a [C]g [C]e [C]n [C]t [C]s O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
Fas [C]F [C]a [C]s B-protein 
ligand [C]l [C]i [C]g [C]a [C]n [C]d E-protein 
and [C]a [C]n [C]d O 
subsequent [C]s [C]u [C]b [C]s [C]e [C]q [C]u [C]e [C]n [C]t O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
T [C]T B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
via [C]v [C]i [C]a O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
and [C]a [C]n [C]d O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
. [C]. O 

Apoptosis [C]A [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
DNA [C]D [C]N [C]A O 
damage [C]d [C]a [C]m [C]a [C]g [C]e O 
and [C]a [C]n [C]d O 
other [C]o [C]t [C]h [C]e [C]r O 
stresses [C]s [C]t [C]r [C]e [C]s [C]s [C]e [C]s O 
can [C]c [C]a [C]n O 
proceed [C]p [C]r [C]o [C]c [C]e [C]e [C]d O 
via [C]v [C]i [C]a O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
Fas [C]F [C]a [C]s B-protein 
ligand [C]l [C]i [C]g [C]a [C]n [C]d E-protein 
( [C]( O 
FasL [C]F [C]a [C]s [C]L S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
ligation [C]l [C]i [C]g [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
its [C]i [C]t [C]s O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
, [C], O 
Fas [C]F [C]a [C]s O 
( [C]( O 
CD95 [C]C [C]D [C]9 [C]5 O 
) [C]) O 
. [C]. O 

We [C]W [C]e O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
that [C]t [C]h [C]a [C]t O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
two [C]t [C]w [C]o O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s I-protein 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B I-protein 
and [C]a [C]n [C]d I-protein 
AP-1 [C]A [C]P [C]- [C]1 E-protein 
is [C]i [C]s O 
crucially [C]c [C]r [C]u [C]c [C]i [C]a [C]l [C]l [C]y O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
FasL [C]F [C]a [C]s [C]L S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
etoposide [C]e [C]t [C]o [C]p [C]o [C]s [C]i [C]d [C]e O 
, [C], O 
teniposide [C]t [C]e [C]n [C]i [C]p [C]o [C]s [C]i [C]d [C]e O 
, [C], O 
and [C]a [C]n [C]d O 
UV [C]U [C]V O 
irradiation [C]i [C]r [C]r [C]a [C]d [C]i [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

A [C]A O 
nondegradable [C]n [C]o [C]n [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]b [C]l [C]e B-protein 
mutant [C]m [C]u [C]t [C]a [C]n [C]t E-protein 
of [C]o [C]f O 
I [C]I B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
both [C]b [C]o [C]t [C]h O 
FasL [C]F [C]a [C]s [C]L S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
DNA [C]D [C]N [C]A O 
damage [C]d [C]a [C]m [C]a [C]g [C]e O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
Fas [C]F [C]a [C]s O 
ligation [C]l [C]i [C]g [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
stimuli [C]s [C]t [C]i [C]m [C]u [C]l [C]i O 
also [C]a [C]l [C]s [C]o O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
the [C]t [C]h [C]e O 
stress-activated [C]s [C]t [C]r [C]e [C]s [C]s [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
( [C]( O 
SAPK/JNK [C]S [C]A [C]P [C]K [C]/ [C]J [C]N [C]K O 
) [C]) O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
was [C]w [C]a [C]s O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
maximal [C]m [C]a [C]x [C]i [C]m [C]a [C]l O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
. [C]. O 

A [C]A O 
1.2 [C]1 [C]. [C]2 O 
kb [C]k [C]b O 
FasL [C]F [C]a [C]s [C]L B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
responded [C]r [C]e [C]s [C]p [C]o [C]n [C]d [C]e [C]d O 
to [C]t [C]o O 
DNA [C]D [C]N [C]A O 
damage [C]d [C]a [C]m [C]a [C]g [C]e O 
, [C], O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
coexpression [C]c [C]o [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
p65 [C]p [C]6 [C]5 B-protein 
Rel [C]R [C]e [C]l E-protein 
or [C]o [C]r O 
Fos/Jun [C]F [C]o [C]s [C]/ [C]J [C]u [C]n S-protein 
. [C]. O 

Mutations [C]M [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
relevant [C]r [C]e [C]l [C]e [C]v [C]a [C]n [C]t O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-DNA 
B [C]B I-DNA 
and [C]a [C]n [C]d I-DNA 
AP-1 [C]A [C]P [C]- [C]1 I-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
eliminated [C]e [C]l [C]i [C]m [C]i [C]n [C]a [C]t [C]e [C]d O 
these [C]t [C]h [C]e [C]s [C]e O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
and [C]a [C]n [C]d O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
contributes [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e [C]s O 
to [C]t [C]o O 
stress-induced [C]s [C]t [C]r [C]e [C]s [C]s [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
via [C]v [C]i [C]a O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
FasL [C]F [C]a [C]s [C]L S-protein 
. [C]. O 

A [C]A O 
small [C]s [C]m [C]a [C]l [C]l O 
, [C], O 
nonpeptidyl [C]n [C]o [C]n [C]p [C]e [C]p [C]t [C]i [C]d [C]y [C]l O 
mimic [C]m [C]i [C]m [C]i [C]c O 
of [C]o [C]f O 
granulocyte-colony-stimulating [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e [C]- [C]c [C]o [C]l [C]o [C]n [C]y [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]n [C]g B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
[ [C][ O 
see [C]s [C]e [C]e O 
commetns [C]c [C]o [C]m [C]m [C]e [C]t [C]n [C]s O 
] [C]] O 

A [C]A O 
nonpeptidyl [C]n [C]o [C]n [C]p [C]e [C]p [C]t [C]i [C]d [C]y [C]l O 
small [C]s [C]m [C]a [C]l [C]l O 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e O 
SB [C]S [C]B O 
247464 [C]2 [C]4 [C]7 [C]4 [C]6 [C]4 O 
, [C], O 
capable [C]c [C]a [C]p [C]a [C]b [C]l [C]e O 
of [C]o [C]f O 
activating [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]n [C]g O 
granulocyte-colony-stimulating [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e [C]- [C]c [C]o [C]l [C]o [C]n [C]y [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]n [C]g B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
( [C]( O 
G-CSF [C]G [C]- [C]C [C]S [C]F S-protein 
) [C]) O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
, [C], O 
was [C]w [C]a [C]s O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
in [C]i [C]n O 
a [C]a O 
high-throughput [C]h [C]i [C]g [C]h [C]- [C]t [C]h [C]r [C]o [C]u [C]g [C]h [C]p [C]u [C]t O 
assay [C]a [C]s [C]s [C]a [C]y O 
in [C]i [C]n O 
cultured [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Like [C]L [C]i [C]k [C]e O 
G-CSF [C]G [C]- [C]C [C]S [C]F S-protein 
, [C], O 
SB [C]S [C]B O 
247464 [C]2 [C]4 [C]7 [C]4 [C]6 [C]4 O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
multiple [C]m [C]u [C]l [C]t [C]i [C]p [C]l [C]e B-protein 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
and [C]a [C]n [C]d O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y B-cell_type 
murine [C]m [C]u [C]r [C]i [C]n [C]e I-cell_type 
bone [C]b [C]o [C]n [C]e I-cell_type 
marrow [C]m [C]a [C]r [C]r [C]o [C]w I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
to [C]t [C]o O 
form [C]f [C]o [C]r [C]m O 
granulocytic [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]i [C]c B-cell_type 
colonies [C]c [C]o [C]l [C]o [C]n [C]i [C]e [C]s E-cell_type 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
. [C]. O 

It [C]I [C]t O 
also [C]a [C]l [C]s [C]o O 
elevated [C]e [C]l [C]e [C]v [C]a [C]t [C]e [C]d O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
neutrophil [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]h [C]i [C]l E-cell_type 
counts [C]c [C]o [C]u [C]n [C]t [C]s O 
in [C]i [C]n O 
mice [C]m [C]i [C]c [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
extracellular [C]e [C]x [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
domain [C]d [C]o [C]m [C]a [C]i [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
murine [C]m [C]u [C]r [C]i [C]n [C]e B-protein 
G-CSF [C]G [C]- [C]C [C]S [C]F I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
was [C]w [C]a [C]s O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
SB [C]S [C]B O 
247464 [C]2 [C]4 [C]7 [C]4 [C]6 [C]4 O 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
compound [C]c [C]o [C]m [C]p [C]o [C]u [C]n [C]d O 
acts [C]a [C]c [C]t [C]s O 
by [C]b [C]y O 
oligomerizing [C]o [C]l [C]i [C]g [C]o [C]m [C]e [C]r [C]i [C]z [C]i [C]n [C]g B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
chains [C]c [C]h [C]a [C]i [C]n [C]s E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
a [C]a O 
small [C]s [C]m [C]a [C]l [C]l O 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e O 
can [C]c [C]a [C]n O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
a [C]a O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
that [C]t [C]h [C]a [C]t O 
normally [C]n [C]o [C]r [C]m [C]a [C]l [C]l [C]y O 
binds [C]b [C]i [C]n [C]d [C]s O 
a [C]a O 
relatively [C]r [C]e [C]l [C]a [C]t [C]i [C]v [C]e [C]l [C]y O 
large [C]l [C]a [C]r [C]g [C]e O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
ligand [C]l [C]i [C]g [C]a [C]n [C]d O 
. [C]. O 

Minimal [C]M [C]i [C]n [C]i [C]m [C]a [C]l O 
residual [C]r [C]e [C]s [C]i [C]d [C]u [C]a [C]l O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
acute [C]a [C]c [C]u [C]t [C]e O 
myelogenous [C]m [C]y [C]e [C]l [C]o [C]g [C]e [C]n [C]o [C]u [C]s O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
with [C]w [C]i [C]t [C]h O 
PML/RAR [C]P [C]M [C]L [C]/ [C]R [C]A [C]R B-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
or [C]o [C]r O 
AML1/ETO [C]A [C]M [C]L [C]1 [C]/ [C]E [C]T [C]O B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
and [C]a [C]n [C]d O 
phenotypic [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]i [C]c O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
possible [C]p [C]o [C]s [C]s [C]i [C]b [C]l [C]e O 
T [C]T B-cell_type 
and [C]a [C]n [C]d I-cell_type 
natural [C]n [C]a [C]t [C]u [C]r [C]a [C]l I-cell_type 
killer [C]k [C]i [C]l [C]l [C]e [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
bone [C]b [C]o [C]n [C]e O 
marrow [C]m [C]a [C]r [C]r [C]o [C]w O 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
we [C]w [C]e O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
minimal [C]m [C]i [C]n [C]i [C]m [C]a [C]l O 
residual [C]r [C]e [C]s [C]i [C]d [C]u [C]a [C]l O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
( [C]( O 
MRD [C]M [C]R [C]D O 
) [C]) O 
of [C]o [C]f O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
acute [C]a [C]c [C]u [C]t [C]e O 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
( [C]( O 
AML [C]A [C]M [C]L O 
) [C]) O 
who [C]w [C]h [C]o O 
have [C]h [C]a [C]v [C]e O 
PML/RAR [C]P [C]M [C]L [C]/ [C]R [C]A [C]R B-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
or [C]o [C]r O 
AML1/ETO [C]A [C]M [C]L [C]1 [C]/ [C]E [C]T [C]O S-protein 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
the [C]t [C]h [C]e O 
phenotypic [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]i [C]c O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e B-cell_type 
subsets [C]s [C]u [C]b [C]s [C]e [C]t [C]s E-cell_type 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
antitumor [C]a [C]n [C]t [C]i [C]t [C]u [C]m [C]o [C]r O 
immunity [C]i [C]m [C]m [C]u [C]n [C]i [C]t [C]y O 
. [C]. O 

Eight [C]E [C]i [C]g [C]h [C]t O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
in [C]i [C]n O 
long-term [C]l [C]o [C]n [C]g [C]- [C]t [C]e [C]r [C]m O 
( [C]( O 
LT [C]L [C]T O 
; [C]; O 
3 [C]3 O 
to [C]t [C]o O 
15 [C]1 [C]5 O 
years [C]y [C]e [C]a [C]r [C]s O 
) [C]) O 
and [C]a [C]n [C]d O 
15 [C]1 [C]5 O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
in [C]i [C]n O 
short-term [C]s [C]h [C]o [C]r [C]t [C]- [C]t [C]e [C]r [C]m O 
( [C]( O 
ST [C]S [C]T O 
; [C]; O 
up [C]u [C]p O 
to [C]t [C]o O 
3 [C]3 O 
years [C]y [C]e [C]a [C]r [C]s O 
) [C]) O 
remission [C]r [C]e [C]m [C]i [C]s [C]s [C]i [C]o [C]n O 
were [C]w [C]e [C]r [C]e O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
. [C]. O 

Using [C]U [C]s [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
reverse [C]r [C]e [C]v [C]e [C]r [C]s [C]e O 
transcription-polymerase [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]- [C]p [C]o [C]l [C]y [C]m [C]e [C]r [C]a [C]s [C]e O 
chain [C]c [C]h [C]a [C]i [C]n O 
reaction [C]r [C]e [C]a [C]c [C]t [C]i [C]o [C]n O 
( [C]( O 
RT [C]R [C]T O 
) [C]) O 
assay [C]a [C]s [C]s [C]a [C]y O 
, [C], O 
the [C]t [C]h [C]e O 
limit [C]l [C]i [C]m [C]i [C]t O 
of [C]o [C]f O 
detection [C]d [C]e [C]t [C]e [C]c [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
10 [C]1 [C]0 O 
( [C]( O 
-5 [C]- [C]5 O 
) [C]) O 
to [C]t [C]o O 
10 [C]1 [C]0 O 
( [C]( O 
-6 [C]- [C]6 O 
) [C]) O 
for [C]f [C]o [C]r O 
PML/RAR [C]P [C]M [C]L [C]/ [C]R [C]A [C]R B-RNA 
alpha [C]a [C]l [C]p [C]h [C]a I-RNA 
transcript [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t E-RNA 
and [C]a [C]n [C]d O 
10 [C]1 [C]0 O 
( [C]( O 
-4 [C]- [C]4 O 
) [C]) O 
to [C]t [C]o O 
10 [C]1 [C]0 O 
( [C]( O 
-5 [C]- [C]5 O 
) [C]) O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
AML1/ETO [C]A [C]M [C]L [C]1 [C]/ [C]E [C]T [C]O B-RNA 
transcript [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t E-RNA 
. [C]. O 

Simultaneously [C]S [C]i [C]m [C]u [C]l [C]t [C]a [C]n [C]e [C]o [C]u [C]s [C]l [C]y O 
, [C], O 
T [C]T B-cell_type 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e I-cell_type 
subsets [C]s [C]u [C]b [C]s [C]e [C]t [C]s E-cell_type 
and [C]a [C]n [C]d O 
NK [C]N [C]K B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l O 
blood [C]b [C]l [C]o [C]o [C]d O 
( [C]( O 
PB [C]P [C]B O 
) [C]) O 
and [C]a [C]n [C]d O 
bone [C]b [C]o [C]n [C]e O 
marrow [C]m [C]a [C]r [C]r [C]o [C]w O 
( [C]( O 
BM [C]B [C]M O 
) [C]) O 
were [C]w [C]e [C]r [C]e O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
flow [C]f [C]l [C]o [C]w O 
cytometric [C]c [C]y [C]t [C]o [C]m [C]e [C]t [C]r [C]i [C]c O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
. [C]. O 

Four [C]F [C]o [C]u [C]r O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
eight [C]e [C]i [C]g [C]h [C]t O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
in [C]i [C]n O 
LT [C]L [C]T O 
and [C]a [C]n [C]d O 
7 [C]7 O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
15 [C]1 [C]5 O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
in [C]i [C]n O 
ST [C]S [C]T O 
remission [C]r [C]e [C]m [C]i [C]s [C]s [C]i [C]o [C]n O 
were [C]w [C]e [C]r [C]e O 
MRD-positive [C]M [C]R [C]D [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
all [C]a [C]l [C]l O 
MRD-positive [C]M [C]R [C]D [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
in [C]i [C]n O 
LT [C]L [C]T O 
remission [C]r [C]e [C]m [C]i [C]s [C]s [C]i [C]o [C]n O 
are [C]a [C]r [C]e O 
still [C]s [C]t [C]i [C]l [C]l O 
until [C]u [C]n [C]t [C]i [C]l O 
now [C]n [C]o [C]w O 
event-free [C]e [C]v [C]e [C]n [C]t [C]- [C]f [C]r [C]e [C]e O 
, [C], O 
3 [C]3 O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
7 [C]7 O 
MRD-positive [C]M [C]R [C]D [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
( [C]( O 
MRD+ [C]M [C]R [C]D [C]+ O 
) [C]) O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
in [C]i [C]n O 
ST [C]S [C]T O 
remission [C]r [C]e [C]m [C]i [C]s [C]s [C]i [C]o [C]n O 
soon [C]s [C]o [C]o [C]n O 
relapsed [C]r [C]e [C]l [C]a [C]p [C]s [C]e [C]d O 
. [C]. O 

The [C]T [C]h [C]e O 
total [C]t [C]o [C]t [C]a [C]l O 
populations [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
CD4 [C]C [C]D [C]4 S-protein 
+ [C]+ O 
, [C], O 
CD8 [C]C [C]D [C]8 S-protein 
+ [C]+ O 
and [C]a [C]n [C]d O 
CD56 [C]C [C]D [C]5 [C]6 S-protein 
+ [C]+ O 
[ [C][ O 
possible [C]p [C]o [C]s [C]s [C]i [C]b [C]l [C]e O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l B-cell_type 
and [C]a [C]n [C]d I-cell_type 
natural [C]n [C]a [C]t [C]u [C]r [C]a [C]l I-cell_type 
killer [C]k [C]i [C]l [C]l [C]e [C]r I-cell_type 
( [C]( I-cell_type 
T/NK [C]T [C]/ [C]N [C]K I-cell_type 
) [C]) I-cell_type 
populations [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n [C]s E-cell_type 
] [C]] O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
BM [C]B [C]M O 
of [C]o [C]f O 
ST [C]S [C]T O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
and [C]a [C]n [C]d O 
MRD+/LT [C]M [C]R [C]D [C]+ [C]/ [C]L [C]T O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
were [C]w [C]e [C]r [C]e O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
( [C]( O 
p [C]p O 
< [C]< O 
.01 [C]. [C]0 [C]1 O 
) [C]) O 
low [C]l [C]o [C]w O 
. [C]. O 

The [C]T [C]h [C]e O 
CD8+ [C]C [C]D [C]8 [C]+ B-cell_type 
CD28+ [C]C [C]D [C]2 [C]8 [C]+ I-cell_type 
population [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n E-cell_type 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
the [C]t [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
tendency [C]t [C]e [C]n [C]d [C]e [C]n [C]c [C]y O 
( [C]( O 
p [C]p O 
< [C]< O 
.01-.02 [C]. [C]0 [C]1 [C]- [C]. [C]0 [C]2 O 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
T/NK [C]T [C]/ [C]N [C]K B-cell_type 
subsets [C]s [C]u [C]b [C]s [C]e [C]t [C]s E-cell_type 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
BM [C]B [C]M O 
of [C]o [C]f O 
MRD-negative [C]M [C]R [C]D [C]- [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
( [C]( O 
MRD- [C]M [C]R [C]D [C]- O 
) [C]) O 
LT [C]L [C]T O 
( [C]( O 
MRD-/LT [C]M [C]R [C]D [C]- [C]/ [C]L [C]T O 
) [C]) O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
numbers [C]n [C]u [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
cells [C]c [C]e [C]l [C]l [C]s O 
as [C]a [C]s O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
volunteers [C]v [C]o [C]l [C]u [C]n [C]t [C]e [C]e [C]r [C]s O 
. [C]. O 

Basically [C]B [C]a [C]s [C]i [C]c [C]a [C]l [C]l [C]y O 
, [C], O 
the [C]t [C]h [C]e O 
total [C]t [C]o [C]t [C]a [C]l O 
percentage [C]p [C]e [C]r [C]c [C]e [C]n [C]t [C]a [C]g [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
CD4+ [C]C [C]D [C]4 [C]+ B-cell_type 
, [C], I-cell_type 
CD8+ [C]C [C]D [C]8 [C]+ I-cell_type 
and [C]a [C]n [C]d I-cell_type 
CD56+ [C]C [C]D [C]5 [C]6 [C]+ I-cell_type 
cell [C]c [C]e [C]l [C]l I-cell_type 
populations [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n [C]s E-cell_type 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
BM [C]B [C]M O 
was [C]w [C]a [C]s O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
order [C]o [C]r [C]d [C]e [C]r O 
: [C]: O 
MRD-/LT [C]M [C]R [C]D [C]- [C]/ [C]L [C]T O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
, [C], O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
volunteers [C]v [C]o [C]l [C]u [C]n [C]t [C]e [C]e [C]r [C]s O 
, [C], O 
MRD+/LT [C]M [C]R [C]D [C]+ [C]/ [C]L [C]T O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
and [C]a [C]n [C]d O 
MRD+ [C]M [C]R [C]D [C]+ O 
or [C]o [C]r O 
-/ST [C]- [C]/ [C]S [C]T O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
percentages [C]p [C]e [C]r [C]c [C]e [C]n [C]t [C]a [C]g [C]e [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
T/NK-cell [C]T [C]/ [C]N [C]K [C]- [C]c [C]e [C]l [C]l B-cell_type 
subsets [C]s [C]u [C]b [C]s [C]e [C]t [C]s E-cell_type 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
PB [C]P [C]B O 
were [C]w [C]e [C]r [C]e O 
not [C]n [C]o [C]t O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
among [C]a [C]m [C]o [C]n [C]g O 
these [C]t [C]h [C]e [C]s [C]e O 
groups [C]g [C]r [C]o [C]u [C]p [C]s O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
the [C]t [C]h [C]e O 
difference [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
possible [C]p [C]o [C]s [C]s [C]i [C]b [C]l [C]e O 
T/NK-cell [C]T [C]/ [C]N [C]K [C]- [C]c [C]e [C]l [C]l S-cell_type 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
BM [C]B [C]M O 
may [C]m [C]a [C]y O 
strongly [C]s [C]t [C]r [C]o [C]n [C]g [C]l [C]y O 
influence [C]i [C]n [C]f [C]l [C]u [C]e [C]n [C]c [C]e O 
clinical [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
and [C]a [C]n [C]d O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
remission [C]r [C]e [C]m [C]i [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
still [C]s [C]t [C]i [C]l [C]l O 
remain [C]r [C]e [C]m [C]a [C]i [C]n O 
to [C]t [C]o O 
be [C]b [C]e O 
confirmed [C]c [C]o [C]n [C]f [C]i [C]r [C]m [C]e [C]d O 
by [C]b [C]y O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
anti-tumor [C]a [C]n [C]t [C]i [C]- [C]t [C]u [C]m [C]o [C]r O 
immunity [C]i [C]m [C]m [C]u [C]n [C]i [C]t [C]y O 
of [C]o [C]f O 
T/NK [C]T [C]/ [C]N [C]K B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
of [C]o [C]f O 
AML [C]A [C]M [C]L S-cell_type 
in [C]i [C]n O 
remission [C]r [C]e [C]m [C]i [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Mycobacterium [C]M [C]y [C]c [C]o [C]b [C]a [C]c [C]t [C]e [C]r [C]i [C]u [C]m O 
tuberculosis [C]t [C]u [C]b [C]e [C]r [C]c [C]u [C]l [C]o [C]s [C]i [C]s O 
mannose-capped [C]m [C]a [C]n [C]n [C]o [C]s [C]e [C]- [C]c [C]a [C]p [C]p [C]e [C]d O 
lipoarabinomannan [C]l [C]i [C]p [C]o [C]a [C]r [C]a [C]b [C]i [C]n [C]o [C]m [C]a [C]n [C]n [C]a [C]n O 
can [C]c [C]a [C]n O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y I-DNA 
virus [C]v [C]i [C]r [C]u [C]s I-DNA 
type [C]t [C]y [C]p [C]e I-DNA 
1 [C]1 I-DNA 
long [C]l [C]o [C]n [C]g I-DNA 
terminal [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l I-DNA 
repeat [C]r [C]e [C]p [C]e [C]a [C]t E-DNA 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Tuberculosis [C]T [C]u [C]b [C]e [C]r [C]c [C]u [C]l [C]o [C]s [C]i [C]s O 
has [C]h [C]a [C]s O 
emerged [C]e [C]m [C]e [C]r [C]g [C]e [C]d O 
as [C]a [C]s O 
an [C]a [C]n O 
epidemic [C]e [C]p [C]i [C]d [C]e [C]m [C]i [C]c O 
, [C], O 
extended [C]e [C]x [C]t [C]e [C]n [C]d [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
large [C]l [C]a [C]r [C]g [C]e O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
individuals [C]i [C]n [C]d [C]i [C]v [C]i [C]d [C]u [C]a [C]l [C]s O 
infected [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
human [C]h [C]u [C]m [C]a [C]n O 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
virus [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
1 [C]1 O 
( [C]( O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
major [C]m [C]a [C]j [C]o [C]r O 
goal [C]g [C]o [C]a [C]l O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
was [C]w [C]a [C]s O 
to [C]t [C]o O 
determine [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
the [C]t [C]h [C]e O 
mycobacterial [C]m [C]y [C]c [C]o [C]b [C]a [C]c [C]t [C]e [C]r [C]i [C]a [C]l O 
cell [C]c [C]e [C]l [C]l O 
wall [C]w [C]a [C]l [C]l O 
component [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t O 
mannose-capped [C]m [C]a [C]n [C]n [C]o [C]s [C]e [C]- [C]c [C]a [C]p [C]p [C]e [C]d O 
lipoarabinomannan [C]l [C]i [C]p [C]o [C]a [C]r [C]a [C]b [C]i [C]n [C]o [C]m [C]a [C]n [C]n [C]a [C]n O 
( [C]( O 
ManLAM [C]M [C]a [C]n [C]L [C]A [C]M O 
) [C]) O 
of [C]o [C]f O 
Mycobacterium [C]M [C]y [C]c [C]o [C]b [C]a [C]c [C]t [C]e [C]r [C]i [C]u [C]m O 
tuberculosis [C]t [C]u [C]b [C]e [C]r [C]c [C]u [C]l [C]o [C]s [C]i [C]s O 
( [C]( O 
M. [C]M [C]. O 
tuberculosis [C]t [C]u [C]b [C]e [C]r [C]c [C]u [C]l [C]o [C]s [C]i [C]s O 
) [C]) O 
could [C]c [C]o [C]u [C]l [C]d O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
use [C]u [C]s [C]e O 
of [C]o [C]f O 
an [C]a [C]n O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
cell [C]c [C]e [C]l [C]l O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
experiments [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]s O 
are [C]a [C]r [C]e O 
of [C]o [C]f O 
prime [C]p [C]r [C]i [C]m [C]e O 
importance [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]c [C]e O 
considering [C]c [C]o [C]n [C]s [C]i [C]d [C]e [C]r [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
CD4 [C]C [C]D [C]4 S-protein 
-expressing [C]- [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]n [C]g O 
T [C]T B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
represent [C]r [C]e [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
the [C]t [C]h [C]e O 
major [C]m [C]a [C]j [C]o [C]r O 
virus [C]v [C]i [C]r [C]u [C]s O 
reservoir [C]r [C]e [C]s [C]e [C]r [C]v [C]o [C]i [C]r O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l O 
blood [C]b [C]l [C]o [C]o [C]d O 
of [C]o [C]f O 
infected [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
individuals [C]i [C]n [C]d [C]i [C]v [C]i [C]d [C]u [C]a [C]l [C]s O 
. [C]. O 

Using [C]U [C]s [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
1G5 [C]1 [C]G [C]5 B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
harbouring [C]h [C]a [C]r [C]b [C]o [C]u [C]r [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
luciferase [C]l [C]u [C]c [C]i [C]f [C]e [C]r [C]a [C]s [C]e O 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r O 
gene [C]g [C]e [C]n [C]e O 
under [C]u [C]n [C]d [C]e [C]r O 
the [C]t [C]h [C]e O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 B-DNA 
LTR [C]L [C]T [C]R E-DNA 
, [C], O 
it [C]i [C]t O 
was [C]w [C]a [C]s O 
first [C]f [C]i [C]r [C]s [C]t O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
filtrates [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]e [C]s O 
( [C]( O 
CFP [C]C [C]F [C]P O 
) [C]) O 
from [C]f [C]r [C]o [C]m O 
M. [C]M [C]. O 
tuberculosis [C]t [C]u [C]b [C]e [C]r [C]c [C]u [C]l [C]o [C]s [C]i [C]s O 
or [C]o [C]r O 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d O 
ManLAM [C]M [C]a [C]n [C]L [C]A [C]M O 
could [C]c [C]o [C]u [C]l [C]d O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 B-DNA 
LTR-dependent [C]L [C]T [C]R [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
unlike [C]u [C]n [C]l [C]i [C]k [C]e O 
similarly [C]s [C]i [C]m [C]i [C]l [C]a [C]r [C]l [C]y O 
prepared [C]p [C]r [C]e [C]p [C]a [C]r [C]e [C]d O 
CFP [C]C [C]F [C]P O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
devoid [C]d [C]e [C]v [C]o [C]i [C]d O 
of [C]o [C]f O 
ManLAM [C]M [C]a [C]n [C]L [C]A [C]M O 
. [C]. O 

The [C]T [C]h [C]e O 
implication [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
( [C]( I-protein 
s [C]s I-protein 
) [C]) E-protein 
, [C], O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
A [C]A E-protein 
and/or [C]a [C]n [C]d [C]/ [C]o [C]r O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
C [C]C E-protein 
was [C]w [C]a [C]s O 
highlighted [C]h [C]i [C]g [C]h [C]l [C]i [C]g [C]h [C]t [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
abrogation [C]a [C]b [C]r [C]o [C]g [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
ManLAM-mediated [C]M [C]a [C]n [C]L [C]A [C]M [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
LTR-driven [C]L [C]T [C]R [C]- [C]d [C]r [C]i [C]v [C]e [C]n O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
using [C]u [C]s [C]i [C]n [C]g O 
herbimycin [C]h [C]e [C]r [C]b [C]i [C]m [C]y [C]c [C]i [C]n O 
A [C]A O 
and [C]a [C]n [C]d O 
H7 [C]H [C]7 O 
. [C]. O 

It [C]I [C]t O 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
, [C], O 
using [C]u [C]s [C]i [C]n [C]g O 
electrophoresis [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]s [C]i [C]s O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
, [C], O 
that [C]t [C]h [C]a [C]t O 
M. [C]M [C]. O 
tuberculosis [C]t [C]u [C]b [C]e [C]r [C]c [C]u [C]l [C]o [C]s [C]i [C]s O 
ManLAM [C]M [C]a [C]n [C]L [C]A [C]M O 
led [C]l [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
translocation [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
. [C]. O 

M. [C]M [C]. O 
tuberculosis [C]t [C]u [C]b [C]e [C]r [C]c [C]u [C]l [C]o [C]s [C]i [C]s O 
ManLAM [C]M [C]a [C]n [C]L [C]A [C]M O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
clear [C]c [C]l [C]e [C]a [C]r O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
luciferase [C]l [C]u [C]c [C]i [C]f [C]e [C]r [C]a [C]s [C]e B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
placed [C]p [C]l [C]a [C]c [C]e [C]d O 
under [C]u [C]n [C]d [C]e [C]r O 
the [C]t [C]h [C]e O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
wild-type [C]w [C]i [C]l [C]d [C]- [C]t [C]y [C]p [C]e B-DNA 
, [C], I-DNA 
but [C]b [C]u [C]t I-DNA 
not [C]n [C]o [C]t I-DNA 
the [C]t [C]h [C]e I-DNA 
kappaB-mutated [C]k [C]a [C]p [C]p [C]a [C]B [C]- [C]m [C]u [C]t [C]a [C]t [C]e [C]d I-DNA 
, [C], I-DNA 
HIV-1 [C]H [C]I [C]V [C]- [C]1 I-DNA 
LTR [C]L [C]T [C]R I-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
. [C]. O 

Finally [C]F [C]i [C]n [C]a [C]l [C]l [C]y O 
, [C], O 
the [C]t [C]h [C]e O 
ManLAM-mediated [C]M [C]a [C]n [C]L [C]A [C]M [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
LTR [C]L [C]T [C]R O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
autocrine [C]a [C]u [C]t [C]o [C]c [C]r [C]i [C]n [C]e O 
or [C]o [C]r O 
paracrine [C]p [C]a [C]r [C]a [C]c [C]r [C]i [C]n [C]e O 
action [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
endogenous [C]e [C]n [C]d [C]o [C]g [C]e [C]n [C]o [C]u [C]s B-protein 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
M. [C]M [C]. O 
tuberculosis [C]t [C]u [C]b [C]e [C]r [C]c [C]u [C]l [C]o [C]s [C]i [C]s O 
can [C]c [C]a [C]n O 
upregulate [C]u [C]p [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
could [C]c [C]o [C]u [C]l [C]d O 
thus [C]t [C]h [C]u [C]s O 
have [C]h [C]a [C]v [C]e O 
the [C]t [C]h [C]e O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
to [C]t [C]o O 
influence [C]i [C]n [C]f [C]l [C]u [C]e [C]n [C]c [C]e O 
the [C]t [C]h [C]e O 
pathogenesis [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

Human [C]H [C]u [C]m [C]a [C]n B-DNA 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y I-DNA 
virus [C]v [C]i [C]r [C]u [C]s I-DNA 
type [C]t [C]y [C]p [C]e I-DNA 
1 [C]1 I-DNA 
long [C]l [C]o [C]n [C]g I-DNA 
terminal [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l I-DNA 
repeat [C]r [C]e [C]p [C]e [C]a [C]t E-DNA 
quasispecies [C]q [C]u [C]a [C]s [C]i [C]s [C]p [C]e [C]c [C]i [C]e [C]s O 
differ [C]d [C]i [C]f [C]f [C]e [C]r O 
in [C]i [C]n O 
basal [C]b [C]a [C]s [C]a [C]l O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
recruitment [C]r [C]e [C]c [C]r [C]u [C]i [C]t [C]m [C]e [C]n [C]t O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
glial [C]g [C]l [C]i [C]a [C]l I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s I-cell_type 
and [C]a [C]n [C]d I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
generation [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
genomic [C]g [C]e [C]n [C]o [C]m [C]i [C]c O 
diversity [C]d [C]i [C]v [C]e [C]r [C]s [C]i [C]t [C]y O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
course [C]c [C]o [C]u [C]r [C]s [C]e O 
of [C]o [C]f O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
has [C]h [C]a [C]s O 
the [C]t [C]h [C]e O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
to [C]t [C]o O 
affect [C]a [C]f [C]f [C]e [C]c [C]t O 
all [C]a [C]l [C]l O 
aspects [C]a [C]s [C]p [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
replication [C]r [C]e [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
proviral [C]p [C]r [C]o [C]v [C]i [C]r [C]a [C]l O 
genome [C]g [C]e [C]n [C]o [C]m [C]e O 
. [C]. O 

To [C]T [C]o O 
gain [C]g [C]a [C]i [C]n O 
a [C]a O 
better [C]b [C]e [C]t [C]t [C]e [C]r O 
understanding [C]u [C]n [C]d [C]e [C]r [C]s [C]t [C]a [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
impact [C]i [C]m [C]p [C]a [C]c [C]t O 
of [C]o [C]f O 
long [C]l [C]o [C]n [C]g B-DNA 
terminal [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l I-DNA 
repeat [C]r [C]e [C]p [C]e [C]a [C]t E-DNA 
( [C]( O 
LTR [C]L [C]T [C]R S-DNA 
) [C]) O 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
diversity [C]d [C]i [C]v [C]e [C]r [C]s [C]i [C]t [C]y O 
on [C]o [C]n O 
LTR-directed [C]L [C]T [C]R [C]- [C]d [C]i [C]r [C]e [C]c [C]t [C]e [C]d B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
cells [C]c [C]e [C]l [C]l [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
central [C]c [C]e [C]n [C]t [C]r [C]a [C]l O 
nervous [C]n [C]e [C]r [C]v [C]o [C]u [C]s O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
( [C]( O 
CNS [C]C [C]N [C]S O 
) [C]) O 
and [C]a [C]n [C]d O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
, [C], O 
we [C]w [C]e O 
amplified [C]a [C]m [C]p [C]l [C]i [C]f [C]i [C]e [C]d O 
and [C]a [C]n [C]d O 
cloned [C]c [C]l [C]o [C]n [C]e [C]d O 
LTRs [C]L [C]T [C]R [C]s S-DNA 
from [C]f [C]r [C]o [C]m O 
proviral [C]p [C]r [C]o [C]v [C]i [C]r [C]a [C]l O 
DNA [C]D [C]N [C]A O 
in [C]i [C]n O 
HIV-1-infected [C]H [C]I [C]V [C]- [C]1 [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l O 
blood [C]b [C]l [C]o [C]o [C]d O 
. [C]. O 

Sequence [C]S [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
nineteen [C]n [C]i [C]n [C]e [C]t [C]e [C]e [C]n O 
LTRs [C]L [C]T [C]R [C]s S-DNA 
cloned [C]c [C]l [C]o [C]n [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
2 [C]2 O 
adult [C]a [C]d [C]u [C]l [C]t O 
and [C]a [C]n [C]d O 
3 [C]3 O 
pediatric [C]p [C]e [C]d [C]i [C]a [C]t [C]r [C]i [C]c O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
an [C]a [C]n O 
average [C]a [C]v [C]e [C]r [C]a [C]g [C]e O 
of [C]o [C]f O 
33 [C]3 [C]3 O 
nucleotide [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
( [C]( O 
with [C]w [C]i [C]t [C]h O 
respect [C]r [C]e [C]s [C]p [C]e [C]c [C]t O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
LAI [C]L [C]A [C]I B-DNA 
LTR [C]L [C]T [C]R E-DNA 
) [C]) O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
the [C]t [C]h [C]e O 
455-bp [C]4 [C]5 [C]5 [C]- [C]b [C]p B-DNA 
U3 [C]U [C]3 I-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
. [C]. O 

Transient [C]T [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
analyses [C]a [C]n [C]a [C]l [C]y [C]s [C]e [C]s O 
in [C]i [C]n O 
cells [C]c [C]e [C]l [C]l [C]s O 
of [C]o [C]f O 
neuroglial [C]n [C]e [C]u [C]r [C]o [C]g [C]l [C]i [C]a [C]l O 
and [C]a [C]n [C]d O 
lymphocytic [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]i [C]c O 
origin [C]o [C]r [C]i [C]g [C]i [C]n O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
some [C]s [C]o [C]m [C]e O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
LTRs [C]L [C]T [C]R [C]s S-DNA 
had [C]h [C]a [C]d O 
activities [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]i [C]e [C]s O 
which [C]w [C]h [C]i [C]c [C]h O 
varied [C]v [C]a [C]r [C]i [C]e [C]d O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
LAI [C]L [C]A [C]I B-DNA 
LTR [C]L [C]T [C]R E-DNA 
in [C]i [C]n O 
U-373 [C]U [C]- [C]3 [C]7 [C]3 B-cell_line 
MG [C]M [C]G I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
( [C]( O 
an [C]a [C]n O 
astrocytoma [C]a [C]s [C]t [C]r [C]o [C]c [C]y [C]t [C]o [C]m [C]a B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
) [C]) O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
in [C]i [C]n O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
( [C]( O 
a [C]a O 
CD4-positive [C]C [C]D [C]4 [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e B-cell_line 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
) [C]) O 
. [C]. O 

While [C]W [C]h [C]i [C]l [C]e O 
LTRs [C]L [C]T [C]R [C]s S-DNA 
which [C]w [C]h [C]i [C]c [C]h O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
highest [C]h [C]i [C]g [C]h [C]e [C]s [C]t O 
activities [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]i [C]e [C]s O 
in [C]i [C]n O 
U-373 [C]U [C]- [C]3 [C]7 [C]3 B-cell_line 
MG [C]M [C]G I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
also [C]a [C]l [C]s [C]o O 
yielded [C]y [C]i [C]e [C]l [C]d [C]e [C]d O 
high [C]h [C]i [C]g [C]h O 
activities [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]i [C]e [C]s O 
in [C]i [C]n O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
, [C], O 
the [C]t [C]h [C]e O 
LTRs [C]L [C]T [C]R [C]s S-DNA 
were [C]w [C]e [C]r [C]e O 
generally [C]g [C]e [C]n [C]e [C]r [C]a [C]l [C]l [C]y O 
more [C]m [C]o [C]r [C]e O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
in [C]i [C]n O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
when [C]w [C]h [C]e [C]n O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
LAI [C]L [C]A [C]I B-DNA 
LTR [C]L [C]T [C]R E-DNA 
. [C]. O 

Differences [C]D [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e [C]s O 
in [C]i [C]n O 
LTR [C]L [C]T [C]R B-DNA 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e E-DNA 
also [C]a [C]l [C]s [C]o O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
differences [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e [C]s O 
in [C]i [C]n O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
recruitment [C]r [C]e [C]c [C]r [C]u [C]i [C]t [C]m [C]e [C]n [C]t O 
to [C]t [C]o O 
cis-acting [C]c [C]i [C]s [C]- [C]a [C]c [C]t [C]i [C]n [C]g B-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
the [C]t [C]h [C]e O 
U3 [C]U [C]3 B-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
LTR [C]L [C]T [C]R S-DNA 
, [C], O 
as [C]a [C]s O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
electrophoretic [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
. [C]. O 

In [C]I [C]n O 
particular [C]p [C]a [C]r [C]t [C]i [C]c [C]u [C]l [C]a [C]r O 
, [C], O 
naturally [C]n [C]a [C]t [C]u [C]r [C]a [C]l [C]l [C]y O 
occurring [C]o [C]c [C]c [C]u [C]r [C]r [C]i [C]n [C]g O 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
variation [C]v [C]a [C]r [C]i [C]a [C]t [C]i [C]o [C]n O 
impacted [C]i [C]m [C]p [C]a [C]c [C]t [C]e [C]d O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
an [C]a [C]n O 
activating [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]n [C]g B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
/ [C]/ O 
cAMP [C]c [C]A [C]M [C]P B-protein 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e I-protein 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g E-protein 
( [C]( O 
ATF [C]A [C]T [C]F S-protein 
/ [C]/ O 
CREB [C]C [C]R [C]E [C]B S-protein 
) [C]) O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
site [C]s [C]i [C]t [C]e O 
( [C]( O 
located [C]l [C]o [C]c [C]a [C]t [C]e [C]d O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
LEF-1 [C]L [C]E [C]F [C]- [C]1 B-DNA 
and [C]a [C]n [C]d I-DNA 
distal [C]d [C]i [C]s [C]t [C]a [C]l I-DNA 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B I-DNA 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-DNA 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
) [C]) O 
that [C]t [C]h [C]a [C]t O 
we [C]w [C]e O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
in [C]i [C]n O 
previous [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 B-DNA 
LTR [C]L [C]T [C]R E-DNA 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
LTR [C]L [C]T [C]R B-DNA 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e E-DNA 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
can [C]c [C]a [C]n O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
affect [C]a [C]f [C]f [C]e [C]c [C]t O 
basal [C]b [C]a [C]s [C]a [C]l O 
LTR [C]L [C]T [C]R O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
recruitment [C]r [C]e [C]c [C]r [C]u [C]i [C]t [C]m [C]e [C]n [C]t O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
may [C]m [C]a [C]y O 
, [C], O 
in [C]i [C]n O 
turn [C]t [C]u [C]r [C]n O 
, [C], O 
alter [C]a [C]l [C]t [C]e [C]r O 
the [C]t [C]h [C]e O 
course [C]c [C]o [C]u [C]r [C]s [C]e O 
of [C]o [C]f O 
viral [C]v [C]i [C]r [C]a [C]l O 
replication [C]r [C]e [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
cells [C]c [C]e [C]l [C]l [C]s O 
of [C]o [C]f O 
CNS [C]C [C]N [C]S O 
and [C]a [C]n [C]d O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
origin [C]o [C]r [C]i [C]g [C]i [C]n O 
. [C]. O 

HMG [C]H [C]M [C]G B-protein 
box [C]b [C]o [C]x I-protein 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e S-cell_type 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
identification [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
mammalian [C]m [C]a [C]m [C]m [C]a [C]l [C]i [C]a [C]n B-DNA 
sex-determining [C]s [C]e [C]x [C]- [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]i [C]n [C]g I-DNA 
gene [C]g [C]e [C]n [C]e I-DNA 
Sry [C]S [C]r [C]y E-DNA 
has [C]h [C]a [C]s O 
led [C]l [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
discovery [C]d [C]i [C]s [C]c [C]o [C]v [C]e [C]r [C]y O 
of [C]o [C]f O 
a [C]a O 
large [C]l [C]a [C]r [C]g [C]e O 
family [C]f [C]a [C]m [C]i [C]l [C]y O 
of [C]o [C]f O 
related [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
( [C]( O 
' [C]' O 
HMG [C]H [C]M [C]G B-protein 
box [C]b [C]o [C]x E-protein 
' [C]' O 
) [C]) O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
that [C]t [C]h [C]a [C]t O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
developmental [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t [C]a [C]l O 
events [C]e [C]v [C]e [C]n [C]t [C]s O 
in [C]i [C]n O 
yeast [C]y [C]e [C]a [C]s [C]t O 
, [C], O 
C. [C]C [C]. O 
elegans [C]e [C]l [C]e [C]g [C]a [C]n [C]s O 
, [C], O 
Drosophila [C]D [C]r [C]o [C]s [C]o [C]p [C]h [C]i [C]l [C]a O 
and [C]a [C]n [C]d O 
vertebrates [C]v [C]e [C]r [C]t [C]e [C]b [C]r [C]a [C]t [C]e [C]s O 
. [C]. O 

In [C]I [C]n O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e S-cell_type 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
HMG [C]H [C]M [C]G B-protein 
box [C]b [C]o [C]x I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
play [C]p [C]l [C]a [C]y O 
a [C]a O 
decisive [C]d [C]e [C]c [C]i [C]s [C]i [C]v [C]e O 
role [C]r [C]o [C]l [C]e O 
. [C]. O 

Sox-4 [C]S [C]o [C]x [C]- [C]4 S-protein 
is [C]i [C]s O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
for [C]f [C]o [C]r O 
very [C]v [C]e [C]r [C]y O 
early [C]e [C]a [C]r [C]l [C]y O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
while [C]w [C]h [C]i [C]l [C]e O 
TCF-1 [C]T [C]C [C]F [C]- [C]1 S-protein 
/ [C]/ O 
LEF-1 [C]L [C]E [C]F [C]- [C]1 S-protein 
play [C]p [C]l [C]a [C]y O 
a [C]a O 
crucial [C]c [C]r [C]u [C]c [C]i [C]a [C]l O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
early [C]e [C]a [C]r [C]l [C]y O 
thymocyte [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
. [C]. O 

TCF/LEF [C]T [C]C [C]F [C]/ [C]L [C]E [C]F B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
have [C]h [C]a [C]v [C]e O 
recently [C]r [C]e [C]c [C]e [C]n [C]t [C]l [C]y O 
been [C]b [C]e [C]e [C]n O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
constitute [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]e O 
a [C]a O 
downstream [C]d [C]o [C]w [C]n [C]s [C]t [C]r [C]e [C]a [C]m O 
component [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Wingless/Wnt [C]W [C]i [C]n [C]g [C]l [C]e [C]s [C]s [C]/ [C]W [C]n [C]t O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
. [C]. O 

In [C]I [C]n O 
flies [C]f [C]l [C]i [C]e [C]s O 
, [C], O 
this [C]t [C]h [C]i [C]s O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
segment [C]s [C]e [C]g [C]m [C]e [C]n [C]t O 
polarity [C]p [C]o [C]l [C]a [C]r [C]i [C]t [C]y O 
; [C]; O 
in [C]i [C]n O 
Xenopus [C]X [C]e [C]n [C]o [C]p [C]u [C]s O 
it [C]i [C]t O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
the [C]t [C]h [C]e O 
definition [C]d [C]e [C]f [C]i [C]n [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
body [C]b [C]o [C]d [C]y O 
axis [C]a [C]x [C]i [C]s O 
. [C]. O 

Deregulation [C]D [C]e [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
occurs [C]o [C]c [C]c [C]u [C]r [C]s O 
in [C]i [C]n O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
tumors [C]t [C]u [C]m [C]o [C]r [C]s E-cell_type 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
insights [C]i [C]n [C]s [C]i [C]g [C]h [C]t [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
events [C]e [C]v [C]e [C]n [C]t [C]s O 
that [C]t [C]h [C]a [C]t O 
are [C]a [C]r [C]e O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
TCF/LEF [C]T [C]C [C]F [C]/ [C]L [C]E [C]F S-protein 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
organisms [C]o [C]r [C]g [C]a [C]n [C]i [C]s [C]m [C]s O 
may [C]m [C]a [C]y O 
eventually [C]e [C]v [C]e [C]n [C]t [C]u [C]a [C]l [C]l [C]y O 
lead [C]l [C]e [C]a [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
understanding [C]u [C]n [C]d [C]e [C]r [C]s [C]t [C]a [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
HMG [C]H [C]M [C]G B-protein 
box [C]b [C]o [C]x I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
in [C]i [C]n O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 

Transcriptional [C]T [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
C/EBP [C]C [C]/ [C]E [C]B [C]P B-protein 
alpha [C]a [C]l [C]p [C]h [C]a I-protein 
and [C]a [C]n [C]d I-protein 
-beta [C]- [C]b [C]e [C]t [C]a E-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
gene [C]g [C]e [C]n [C]e O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
MRP14 [C]M [C]R [C]P [C]1 [C]4 B-protein 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d I-protein 
calcium [C]c [C]a [C]l [C]c [C]i [C]u [C]m I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
. [C]. O 

Transcriptional [C]T [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
gene [C]g [C]e [C]n [C]e O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d B-protein 
calcium [C]c [C]a [C]l [C]c [C]i [C]u [C]m I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
, [C], O 
MRP14 [C]M [C]R [C]P [C]1 [C]4 S-protein 
, [C], O 
was [C]w [C]a [C]s O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
monocytic [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]i [C]c I-cell_line 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
. [C]. O 

The [C]T [C]h [C]e O 
MRP14 [C]M [C]R [C]P [C]1 [C]4 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
monoblastic [C]m [C]o [C]n [C]o [C]b [C]l [C]a [C]s [C]t [C]i [C]c B-cell_line 
ML-1 [C]M [C]L [C]- [C]1 I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
, [C], O 
promonocytic [C]p [C]r [C]o [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]i [C]c B-cell_line 
U-937 [C]U [C]- [C]9 [C]3 [C]7 I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
, [C], O 
or [C]o [C]r O 
promyelocytic [C]p [C]r [C]o [C]m [C]y [C]e [C]l [C]o [C]c [C]y [C]t [C]i [C]c B-cell_line 
HL-60 [C]H [C]L [C]- [C]6 [C]0 I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

On [C]O [C]n O 
the [C]t [C]h [C]e O 
other [C]o [C]t [C]h [C]e [C]r O 
hand [C]h [C]a [C]n [C]d O 
, [C], O 
the [C]t [C]h [C]e O 
gene [C]g [C]e [C]n [C]e O 
was [C]w [C]a [C]s O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
monocytic [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]i [C]c B-cell_line 
THP-1 [C]T [C]H [C]P [C]- [C]1 I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
HL-60 [C]H [C]L [C]- [C]6 [C]0 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
1 [C]1 O 
, [C], O 
25-dihydroxyvitamin [C]2 [C]5 [C]- [C]d [C]i [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]v [C]i [C]t [C]a [C]m [C]i [C]n O 
D3 [C]D [C]3 O 
( [C]( O 
VD3 [C]V [C]D [C]3 O 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
MRP14 [C]M [C]R [C]P [C]1 [C]4 S-protein 
in [C]i [C]n O 
VD3-treated [C]V [C]D [C]3 [C]- [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
HL-60 [C]H [C]L [C]- [C]6 [C]0 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
was [C]w [C]a [C]s O 
two-fold [C]t [C]w [C]o [C]- [C]f [C]o [C]l [C]d O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
that [C]t [C]h [C]a [C]t O 
in [C]i [C]n O 
THP-1 [C]T [C]H [C]P [C]- [C]1 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

Among [C]A [C]m [C]o [C]n [C]g O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
known [C]k [C]n [C]o [C]w [C]n O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-DNA 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
motifs [C]m [C]o [C]t [C]i [C]f [C]s E-DNA 
, [C], O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
( [C]( I-protein 
s [C]s I-protein 
) [C]) E-protein 
of [C]o [C]f O 
VD3-treated [C]V [C]D [C]3 [C]- [C]t [C]r [C]e [C]a [C]t [C]e [C]d B-cell_line 
HL-60 [C]H [C]L [C]- [C]6 [C]0 I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s I-cell_line 
and [C]a [C]n [C]d I-cell_line 
THP-1 [C]T [C]H [C]P [C]- [C]1 I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
bound [C]b [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
CCAAT/enhancer [C]C [C]C [C]A [C]A [C]T [C]/ [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r B-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-DNA 
( [C]( I-DNA 
C/EBP [C]C [C]/ [C]E [C]B [C]P I-DNA 
) [C]) I-DNA 
-binding [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
motif [C]m [C]o [C]t [C]i [C]f E-DNA 
that [C]t [C]h [C]a [C]t O 
was [C]w [C]a [C]s O 
located [C]l [C]o [C]c [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
upstream [C]u [C]p [C]s [C]t [C]r [C]e [C]a [C]m B-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
MRP14 [C]M [C]R [C]P [C]1 [C]4 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
( [C]( O 
-81 [C]- [C]8 [C]1 O 
) [C]) O 
, [C], O 
as [C]a [C]s O 
evidenced [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
competitive [C]c [C]o [C]m [C]p [C]e [C]t [C]i [C]t [C]i [C]v [C]e O 
gel [C]g [C]e [C]l O 
mobility-shift [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y [C]- [C]s [C]h [C]i [C]f [C]t O 
assay [C]a [C]s [C]s [C]a [C]y O 
. [C]. O 

An [C]A [C]n O 
antibody [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y O 
for [C]f [C]o [C]r O 
C/EBP [C]C [C]/ [C]E [C]B [C]P B-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
super-shifted [C]s [C]u [C]p [C]e [C]r [C]- [C]s [C]h [C]i [C]f [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
nucleoprotein [C]n [C]u [C]c [C]l [C]e [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
in [C]i [C]n O 
THP-1 [C]T [C]H [C]P [C]- [C]1 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
VD3-treated [C]V [C]D [C]3 [C]- [C]t [C]r [C]e [C]a [C]t [C]e [C]d B-cell_line 
HL-60 [C]H [C]L [C]- [C]6 [C]0 I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
an [C]a [C]n O 
antibody [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y O 
for [C]f [C]o [C]r O 
C/EBP [C]C [C]/ [C]E [C]B [C]P B-protein 
beta [C]b [C]e [C]t [C]a E-protein 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
the [C]t [C]h [C]e O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
HL-60 [C]H [C]L [C]- [C]6 [C]0 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
with [C]w [C]i [C]t [C]h O 
that [C]t [C]h [C]a [C]t O 
of [C]o [C]f O 
THP-1 [C]T [C]H [C]P [C]- [C]1 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

An [C]A [C]n O 
anti-C/EBP [C]a [C]n [C]t [C]i [C]- [C]C [C]/ [C]E [C]B [C]P B-protein 
delta [C]d [C]e [C]l [C]t [C]a I-protein 
antibody [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y E-protein 
had [C]h [C]a [C]d O 
no [C]n [C]o O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
in [C]i [C]n O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
cell [C]c [C]e [C]l [C]l O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
it [C]i [C]t O 
was [C]w [C]a [C]s O 
concluded [C]c [C]o [C]n [C]c [C]l [C]u [C]d [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
C/EBP [C]C [C]/ [C]E [C]B [C]P B-protein 
alpha [C]a [C]l [C]p [C]h [C]a I-protein 
and [C]a [C]n [C]d I-protein 
-beta [C]- [C]b [C]e [C]t [C]a E-protein 
were [C]w [C]e [C]r [C]e O 
able [C]a [C]b [C]l [C]e O 
to [C]t [C]o O 
bind [C]b [C]i [C]n [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
C/EBP [C]C [C]/ [C]E [C]B [C]P B-protein 
motif [C]m [C]o [C]t [C]i [C]f E-protein 
, [C], O 
and [C]a [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
C/EBP [C]C [C]/ [C]E [C]B [C]P B-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
bound [C]b [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
motif [C]m [C]o [C]t [C]i [C]f O 
in [C]i [C]n O 
THP-1 [C]T [C]H [C]P [C]- [C]1 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
and [C]a [C]n [C]d O 
C/EBP [C]C [C]/ [C]E [C]B [C]P B-protein 
beta [C]b [C]e [C]t [C]a E-protein 
bound [C]b [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
that [C]t [C]h [C]a [C]t O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
VD3-treated [C]V [C]D [C]3 [C]- [C]t [C]r [C]e [C]a [C]t [C]e [C]d B-cell_line 
HL-60 [C]H [C]L [C]- [C]6 [C]0 I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
to [C]t [C]o O 
examine [C]e [C]x [C]a [C]m [C]i [C]n [C]e O 
the [C]t [C]h [C]e O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
C/EBP [C]C [C]/ [C]E [C]B [C]P B-protein 
motif [C]m [C]o [C]t [C]i [C]f E-protein 
, [C], O 
we [C]w [C]e O 
transfected [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]e [C]d O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
constructed [C]c [C]o [C]n [C]s [C]t [C]r [C]u [C]c [C]t [C]e [C]d O 
luciferase [C]l [C]u [C]c [C]i [C]f [C]e [C]r [C]a [C]s [C]e B-DNA 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r I-DNA 
DNAs [C]D [C]N [C]A [C]s E-DNA 
into [C]i [C]n [C]t [C]o O 
HL-60 [C]H [C]L [C]- [C]6 [C]0 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
and [C]a [C]n [C]d O 
THP-1 [C]T [C]H [C]P [C]- [C]1 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

The [C]T [C]h [C]e O 
luciferase [C]l [C]u [C]c [C]i [C]f [C]e [C]r [C]a [C]s [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
C/EBP [C]C [C]/ [C]E [C]B [C]P B-protein 
motif [C]m [C]o [C]t [C]i [C]f E-protein 
in [C]i [C]n O 
HL-60 [C]H [C]L [C]- [C]6 [C]0 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
was [C]w [C]a [C]s O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
by [C]b [C]y O 
VD3 [C]V [C]D [C]3 O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
. [C]. O 

The [C]T [C]h [C]e O 
C/EBP [C]C [C]/ [C]E [C]B [C]P B-protein 
motif [C]m [C]o [C]t [C]i [C]f E-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
MRP14 [C]M [C]R [C]P [C]1 [C]4 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
was [C]w [C]a [C]s O 
confirmed [C]c [C]o [C]n [C]f [C]i [C]r [C]m [C]e [C]d O 
to [C]t [C]o O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
as [C]a [C]s O 
a [C]a O 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
region [C]r [C]e [C]g [C]i [C]o [C]n O 
in [C]i [C]n O 
VD3-treated [C]V [C]D [C]3 [C]- [C]t [C]r [C]e [C]a [C]t [C]e [C]d B-cell_line 
HL-60 [C]H [C]L [C]- [C]6 [C]0 I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s I-cell_line 
and [C]a [C]n [C]d I-cell_line 
THP-1 [C]T [C]H [C]P [C]- [C]1 I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
assay [C]a [C]s [C]s [C]a [C]y O 
. [C]. O 

Since [C]S [C]i [C]n [C]c [C]e O 
C/EBP [C]C [C]/ [C]E [C]B [C]P B-protein 
beta [C]b [C]e [C]t [C]a E-protein 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
in [C]i [C]n O 
VD3-untreated [C]V [C]D [C]3 [C]- [C]u [C]n [C]t [C]r [C]e [C]a [C]t [C]e [C]d B-cell_line 
HL-60 [C]H [C]L [C]- [C]6 [C]0 I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
by [C]b [C]y O 
immunoblotting [C]i [C]m [C]m [C]u [C]n [C]o [C]b [C]l [C]o [C]t [C]t [C]i [C]n [C]g O 
, [C], O 
VD3 [C]V [C]D [C]3 O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
C/EBP [C]C [C]/ [C]E [C]B [C]P B-protein 
beta [C]b [C]e [C]t [C]a E-protein 
to [C]t [C]o O 
bind [C]b [C]i [C]n [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
motif [C]m [C]o [C]t [C]i [C]f O 
, [C], O 
probably [C]p [C]r [C]o [C]b [C]a [C]b [C]l [C]y O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
post-translational [C]p [C]o [C]s [C]t [C]- [C]t [C]r [C]a [C]n [C]s [C]l [C]a [C]t [C]i [C]o [C]n [C]a [C]l O 
modification [C]m [C]o [C]d [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Patients [C]P [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
high-risk [C]h [C]i [C]g [C]h [C]- [C]r [C]i [C]s [C]k O 
myelodysplastic [C]m [C]y [C]e [C]l [C]o [C]d [C]y [C]s [C]p [C]l [C]a [C]s [C]t [C]i [C]c O 
syndrome [C]s [C]y [C]n [C]d [C]r [C]o [C]m [C]e O 
can [C]c [C]a [C]n O 
have [C]h [C]a [C]v [C]e O 
polyclonal [C]p [C]o [C]l [C]y [C]c [C]l [C]o [C]n [C]a [C]l O 
or [C]o [C]r O 
clonal [C]c [C]l [C]o [C]n [C]a [C]l O 
haemopoiesis [C]h [C]a [C]e [C]m [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
in [C]i [C]n O 
complete [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e O 
haematological [C]h [C]a [C]e [C]m [C]a [C]t [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
remission [C]r [C]e [C]m [C]i [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
clonality [C]c [C]l [C]o [C]n [C]a [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
mature [C]m [C]a [C]t [C]u [C]r [C]e B-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
blood-derived [C]b [C]l [C]o [C]o [C]d [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d I-cell_type 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d I-cell_type 
and [C]a [C]n [C]d I-cell_type 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
bone [C]b [C]o [C]n [C]e B-cell_type 
marrow [C]m [C]a [C]r [C]r [C]o [C]w I-cell_type 
haemopoietic [C]h [C]a [C]e [C]m [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c I-cell_type 
progenitors [C]p [C]r [C]o [C]g [C]e [C]n [C]i [C]t [C]o [C]r [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
18 [C]1 [C]8 O 
females [C]f [C]e [C]m [C]a [C]l [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
myelodysplasia [C]m [C]y [C]e [C]l [C]o [C]d [C]y [C]s [C]p [C]l [C]a [C]s [C]i [C]a O 
( [C]( O 
MDS [C]M [C]D [C]S O 
) [C]) O 
( [C]( O 
five [C]f [C]i [C]v [C]e O 
refractory [C]r [C]e [C]f [C]r [C]a [C]c [C]t [C]o [C]r [C]y O 
anaemia [C]a [C]n [C]a [C]e [C]m [C]i [C]a O 
, [C], O 
RA [C]R [C]A O 
; [C]; O 
one [C]o [C]n [C]e O 
RA [C]R [C]A O 
with [C]w [C]i [C]t [C]h O 
ringed [C]r [C]i [C]n [C]g [C]e [C]d B-cell_type 
sideroblasts [C]s [C]i [C]d [C]e [C]r [C]o [C]b [C]l [C]a [C]s [C]t [C]s E-cell_type 
, [C], O 
RARS [C]R [C]A [C]R [C]S O 
; [C]; O 
three [C]t [C]h [C]r [C]e [C]e O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
myelomonocytic [C]m [C]y [C]e [C]l [C]o [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]i [C]c O 
leukaemia [C]l [C]e [C]u [C]k [C]a [C]e [C]m [C]i [C]a O 
, [C], O 
CMML [C]C [C]M [C]M [C]L O 
; [C]; O 
four [C]f [C]o [C]u [C]r O 
RA [C]R [C]A O 
with [C]w [C]i [C]t [C]h O 
excess [C]e [C]x [C]c [C]e [C]s [C]s O 
of [C]o [C]f O 
blasts [C]b [C]l [C]a [C]s [C]t [C]s O 
, [C], O 
RAEB [C]R [C]A [C]E [C]B O 
; [C]; O 
five [C]f [C]i [C]v [C]e O 
RAEB [C]R [C]A [C]E [C]B O 
in [C]i [C]n O 
transformation [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
RAEB-t [C]R [C]A [C]E [C]B [C]- [C]t O 
) [C]) O 
was [C]w [C]a [C]s O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
by [C]b [C]y O 
X-chromosome [C]X [C]- [C]c [C]h [C]r [C]o [C]m [C]o [C]s [C]o [C]m [C]e S-DNA 
inactivation [C]i [C]n [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
. [C]. O 

Using [C]U [C]s [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n O 
androgen-receptor [C]a [C]n [C]d [C]r [C]o [C]g [C]e [C]n [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
( [C]( O 
HUMARA [C]H [C]U [C]M [C]A [C]R [C]A O 
) [C]) O 
assay [C]a [C]s [C]s [C]a [C]y O 
, [C], O 
we [C]w [C]e O 
analysed [C]a [C]n [C]a [C]l [C]y [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
clonal [C]c [C]l [C]o [C]n [C]a [C]l O 
patterns [C]p [C]a [C]t [C]t [C]e [C]r [C]n [C]s O 
of [C]o [C]f O 
highly [C]h [C]i [C]g [C]h [C]l [C]y B-cell_type 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d I-cell_type 
immature [C]i [C]m [C]m [C]a [C]t [C]u [C]r [C]e I-cell_type 
CD34+ [C]C [C]D [C]3 [C]4 [C]+ I-cell_type 
38- [C]3 [C]8 [C]- I-cell_type 
and [C]a [C]n [C]d I-cell_type 
committed [C]c [C]o [C]m [C]m [C]i [C]t [C]t [C]e [C]d I-cell_type 
CD34+ [C]C [C]D [C]3 [C]4 [C]+ I-cell_type 
38+ [C]3 [C]8 [C]+ I-cell_type 
marrow-derived [C]m [C]a [C]r [C]r [C]o [C]w [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d I-cell_type 
progenitors [C]p [C]r [C]o [C]g [C]e [C]n [C]i [C]t [C]o [C]r [C]s E-cell_type 
, [C], O 
and [C]a [C]n [C]d O 
CD16+ [C]C [C]D [C]1 [C]6 [C]+ B-cell_type 
14- [C]1 [C]4 [C]- I-cell_type 
granulocytes [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
, [C], O 
CD14+ [C]C [C]D [C]1 [C]4 [C]+ B-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
, [C], O 
CD3+ [C]C [C]D [C]3 [C]+ B-cell_type 
T [C]T I-cell_type 
and [C]a [C]n [C]d I-cell_type 
CD19+ [C]C [C]D [C]1 [C]9 [C]+ I-cell_type 
B [C]B I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l O 
blood [C]b [C]l [C]o [C]o [C]d O 
. [C]. O 

In [C]I [C]n O 
high-risk [C]h [C]i [C]g [C]h [C]- [C]r [C]i [C]s [C]k O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
( [C]( O 
RAEB [C]R [C]A [C]E [C]B O 
, [C], O 
RAEB-t [C]R [C]A [C]E [C]B [C]- [C]t O 
) [C]) O 
, [C], O 
clonality [C]c [C]l [C]o [C]n [C]a [C]l [C]i [C]t [C]y O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
was [C]w [C]a [C]s O 
performed [C]p [C]e [C]r [C]f [C]o [C]r [C]m [C]e [C]d O 
before [C]b [C]e [C]f [C]o [C]r [C]e O 
and [C]a [C]n [C]d O 
after [C]a [C]f [C]t [C]e [C]r O 
intensive [C]i [C]n [C]t [C]e [C]n [C]s [C]i [C]v [C]e O 
remission-induction [C]r [C]e [C]m [C]i [C]s [C]s [C]i [C]o [C]n [C]- [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
. [C]. O 

All [C]A [C]l [C]l O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
, [C], O 
except [C]e [C]x [C]c [C]e [C]p [C]t O 
one [C]o [C]n [C]e O 
with [C]w [C]i [C]t [C]h O 
RA [C]R [C]A O 
, [C], O 
had [C]h [C]a [C]d O 
predominance [C]p [C]r [C]e [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]c [C]e O 
of [C]o [C]f O 
a [C]a O 
single [C]s [C]i [C]n [C]g [C]l [C]e O 
clone [C]c [C]l [C]o [C]n [C]e O 
in [C]i [C]n O 
their [C]t [C]h [C]e [C]i [C]r O 
granulocytes [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
and [C]a [C]n [C]d O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
clonal [C]c [C]l [C]o [C]n [C]a [C]l O 
pattern [C]p [C]a [C]t [C]t [C]e [C]r [C]n O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
CD34+ [C]C [C]D [C]3 [C]4 [C]+ B-cell_type 
progenitor [C]p [C]r [C]o [C]g [C]e [C]n [C]i [C]t [C]o [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
CD3+ [C]C [C]D [C]3 [C]+ B-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
polyclonal [C]p [C]o [C]l [C]y [C]c [C]l [C]o [C]n [C]a [C]l O 
or [C]o [C]r O 
oligoclonal [C]o [C]l [C]i [C]g [C]o [C]c [C]l [C]o [C]n [C]a [C]l O 
in [C]i [C]n O 
14/18 [C]1 [C]4 [C]/ [C]1 [C]8 O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

X-chromosome [C]X [C]- [C]c [C]h [C]r [C]o [C]m [C]o [C]s [C]o [C]m [C]e S-DNA 
inactivation [C]i [C]n [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
patterns [C]p [C]a [C]t [C]t [C]e [C]r [C]n [C]s O 
of [C]o [C]f O 
CD19+ [C]C [C]D [C]1 [C]9 [C]+ B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
highly [C]h [C]i [C]g [C]h [C]l [C]y O 
concordant [C]c [C]o [C]n [C]c [C]o [C]r [C]d [C]a [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
CD3+ [C]C [C]D [C]3 [C]+ B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
except [C]e [C]x [C]c [C]e [C]p [C]t O 
for [C]f [C]o [C]r O 
two [C]t [C]w [C]o O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
( [C]( O 
one [C]o [C]n [C]e O 
RA [C]R [C]A O 
, [C], O 
one [C]o [C]n [C]e O 
CMML [C]C [C]M [C]M [C]L O 
) [C]) O 
with [C]w [C]i [C]t [C]h O 
monoclonal [C]m [C]o [C]n [C]o [C]c [C]l [C]o [C]n [C]a [C]l B-cell_type 
B [C]B I-cell_type 
and [C]a [C]n [C]d I-cell_type 
polyclonal [C]p [C]o [C]l [C]y [C]c [C]l [C]o [C]n [C]a [C]l I-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
, [C], O 
therefore [C]t [C]h [C]e [C]r [C]e [C]f [C]o [C]r [C]e O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
a [C]a O 
clonal [C]c [C]l [C]o [C]n [C]a [C]l O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
a [C]a O 
progenitor [C]p [C]r [C]o [C]g [C]e [C]n [C]i [C]t [C]o [C]r S-cell_type 
common [C]c [C]o [C]m [C]m [C]o [C]n O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d B-cell_type 
and [C]a [C]n [C]d I-cell_type 
B-lymphoid [C]B [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d I-cell_type 
lineages [C]l [C]i [C]n [C]e [C]a [C]g [C]e [C]s E-cell_type 
or [C]o [C]r O 
the [C]t [C]h [C]e O 
coexistence [C]c [C]o [C]e [C]x [C]i [C]s [C]t [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
MDS [C]M [C]D [C]S O 
and [C]a [C]n [C]d O 
a [C]a O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l O 
disorder [C]d [C]i [C]s [C]o [C]r [C]d [C]e [C]r O 
in [C]i [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
particular [C]p [C]a [C]r [C]t [C]i [C]c [C]u [C]l [C]a [C]r O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

After [C]A [C]f [C]t [C]e [C]r O 
high-dose [C]h [C]i [C]g [C]h [C]- [C]d [C]o [C]s [C]e O 
non-myeloablative [C]n [C]o [C]n [C]- [C]m [C]y [C]e [C]l [C]o [C]a [C]b [C]l [C]a [C]t [C]i [C]v [C]e O 
chemotherapy [C]c [C]h [C]e [C]m [C]o [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
, [C], O 
polyclonal [C]p [C]o [C]l [C]y [C]c [C]l [C]o [C]n [C]a [C]l O 
haemopoiesis [C]h [C]a [C]e [C]m [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
was [C]w [C]a [C]s O 
reinstalled [C]r [C]e [C]i [C]n [C]s [C]t [C]a [C]l [C]l [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
mature [C]m [C]a [C]t [C]u [C]r [C]e B-cell_type 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
immature [C]i [C]m [C]m [C]a [C]t [C]u [C]r [C]e O 
and [C]a [C]n [C]d O 
committed [C]c [C]o [C]m [C]m [C]i [C]t [C]t [C]e [C]d B-cell_type 
marrow [C]m [C]a [C]r [C]r [C]o [C]w I-cell_type 
progenitors [C]p [C]r [C]o [C]g [C]e [C]n [C]i [C]t [C]o [C]r [C]s E-cell_type 
in [C]i [C]n O 
three [C]t [C]h [C]r [C]e [C]e O 
of [C]o [C]f O 
four [C]f [C]o [C]u [C]r O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
achieving [C]a [C]c [C]h [C]i [C]e [C]v [C]i [C]n [C]g O 
complete [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e O 
haematological [C]h [C]a [C]e [C]m [C]a [C]t [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
remission [C]r [C]e [C]m [C]i [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Therefore [C]T [C]h [C]e [C]r [C]e [C]f [C]o [C]r [C]e O 
we [C]w [C]e O 
conclude [C]c [C]o [C]n [C]c [C]l [C]u [C]d [C]e O 
that [C]t [C]h [C]a [C]t O 
most [C]m [C]o [C]s [C]t O 
haematological [C]h [C]a [C]e [C]m [C]a [C]t [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
remissions [C]r [C]e [C]m [C]i [C]s [C]s [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
MDS [C]M [C]D [C]S O 
are [C]a [C]r [C]e O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
restoration [C]r [C]e [C]s [C]t [C]o [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
polyclonal [C]p [C]o [C]l [C]y [C]c [C]l [C]o [C]n [C]a [C]l O 
haemopoiesis [C]h [C]a [C]e [C]m [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
. [C]. O 

Prominent [C]P [C]r [C]o [C]m [C]i [C]n [C]e [C]n [C]t O 
sex [C]s [C]e [C]x O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
metabolism [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]s [C]m O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

Steroid [C]S [C]t [C]e [C]r [C]o [C]i [C]d O 
metabolism [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]s [C]m O 
was [C]w [C]a [C]s O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
cultured [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]d B-cell_line 
human [C]h [C]u [C]m [C]a [C]n I-cell_line 
B-lymphoblastoid [C]B [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]o [C]i [C]d I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
( [C]( O 
B-LCL [C]B [C]- [C]L [C]C [C]L S-cell_line 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
T [C]T I-cell_type 
and [C]a [C]n [C]d I-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Gene [C]G [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
reverse-transcription [C]r [C]e [C]v [C]e [C]r [C]s [C]e [C]- [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
polymerase [C]p [C]o [C]l [C]y [C]m [C]e [C]r [C]a [C]s [C]e O 
chain [C]c [C]h [C]a [C]i [C]n O 
reaction [C]r [C]e [C]a [C]c [C]t [C]i [C]o [C]n O 
amplification [C]a [C]m [C]p [C]l [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
( [C]( O 
RT-PCR [C]R [C]T [C]- [C]P [C]C [C]R O 
) [C]) O 
. [C]. O 

Appropriate [C]A [C]p [C]p [C]r [C]o [C]p [C]r [C]i [C]a [C]t [C]e O 
sized [C]s [C]i [C]z [C]e [C]d O 
transcripts [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]s S-RNA 
were [C]w [C]e [C]r [C]e O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
cultured [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]d O 
and [C]a [C]n [C]d O 
fresh [C]f [C]r [C]e [C]s [C]h O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
for [C]f [C]o [C]r O 
CYP11A [C]C [C]Y [C]P [C]1 [C]1 [C]A S-protein 
, [C], O 
CYP17 [C]C [C]Y [C]P [C]1 [C]7 S-protein 
, [C], O 
HSD11L [C]H [C]S [C]D [C]1 [C]1 [C]L S-protein 
( [C]( O 
11beta-hydroxysteroid [C]1 [C]1 [C]b [C]e [C]t [C]a [C]- [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]s [C]t [C]e [C]r [C]o [C]i [C]d B-protein 
dehydrogenase [C]d [C]e [C]h [C]y [C]d [C]r [C]o [C]g [C]e [C]n [C]a [C]s [C]e I-protein 
I [C]I E-protein 
) [C]) O 
, [C], O 
HSD17B1 [C]H [C]S [C]D [C]1 [C]7 [C]B [C]1 S-protein 
( [C]( O 
17beta-hydroxysteroid [C]1 [C]7 [C]b [C]e [C]t [C]a [C]- [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]s [C]t [C]e [C]r [C]o [C]i [C]d B-protein 
dehydrogenase [C]d [C]e [C]h [C]y [C]d [C]r [C]o [C]g [C]e [C]n [C]a [C]s [C]e I-protein 
type [C]t [C]y [C]p [C]e I-protein 
I [C]I E-protein 
) [C]) O 
and [C]a [C]n [C]d O 
SRD5A1 [C]S [C]R [C]D [C]5 [C]A [C]1 S-protein 
( [C]( O 
5alpha-reductase [C]5 [C]a [C]l [C]p [C]h [C]a [C]- [C]r [C]e [C]d [C]u [C]c [C]t [C]a [C]s [C]e B-protein 
I [C]I E-protein 
) [C]) O 
. [C]. O 

B-LCL [C]B [C]- [C]L [C]C [C]L O 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
T [C]T B-cell_type 
and [C]a [C]n [C]d I-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
CYP11B [C]C [C]Y [C]P [C]1 [C]1 [C]B S-protein 
. [C]. O 

There [C]T [C]h [C]e [C]r [C]e O 
was [C]w [C]a [C]s O 
minimal [C]m [C]i [C]n [C]i [C]m [C]a [C]l O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
HSD3B1 [C]H [C]S [C]D [C]3 [C]B [C]1 S-protein 
and [C]a [C]n [C]d O 
HSD3B2 [C]H [C]S [C]D [C]3 [C]B [C]2 S-protein 
( [C]( O 
3beta-hydroxysteroid [C]3 [C]b [C]e [C]t [C]a [C]- [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]s [C]t [C]e [C]r [C]o [C]i [C]d B-protein 
dehydrogenase [C]d [C]e [C]h [C]y [C]d [C]r [C]o [C]g [C]e [C]n [C]a [C]s [C]e I-protein 
I [C]I I-protein 
and [C]a [C]n [C]d I-protein 
II [C]I [C]I E-protein 
) [C]) O 
in [C]i [C]n O 
B-LCL [C]B [C]- [C]L [C]C [C]L S-cell_line 
and [C]a [C]n [C]d O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Transcripts [C]T [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]s O 
for [C]f [C]o [C]r O 
CYP19 [C]C [C]Y [C]P [C]1 [C]9 S-protein 
and [C]a [C]n [C]d O 
HSD11K [C]H [C]S [C]D [C]1 [C]1 [C]K S-protein 
were [C]w [C]e [C]r [C]e O 
not [C]n [C]o [C]t O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
. [C]. O 

Corresponding [C]C [C]o [C]r [C]r [C]e [C]s [C]p [C]o [C]n [C]d [C]i [C]n [C]g O 
enzymatic [C]e [C]n [C]z [C]y [C]m [C]a [C]t [C]i [C]c O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
was [C]w [C]a [C]s O 
detectable [C]d [C]e [C]t [C]e [C]c [C]t [C]a [C]b [C]l [C]e O 
only [C]o [C]n [C]l [C]y O 
for [C]f [C]o [C]r O 
17-hydroxysteroid [C]1 [C]7 [C]- [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]s [C]t [C]e [C]r [C]o [C]i [C]d B-protein 
dehydrogenase [C]d [C]e [C]h [C]y [C]d [C]r [C]o [C]g [C]e [C]n [C]a [C]s [C]e E-protein 
and [C]a [C]n [C]d O 
5alpha-reductase [C]5 [C]a [C]l [C]p [C]h [C]a [C]- [C]r [C]e [C]d [C]u [C]c [C]t [C]a [C]s [C]e S-protein 
, [C], O 
respectively [C]r [C]e [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
producing [C]p [C]r [C]o [C]d [C]u [C]c [C]i [C]n [C]g O 
testosterone [C]t [C]e [C]s [C]t [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
and [C]a [C]n [C]d O 
5alpha-dihydrotestosterone [C]5 [C]a [C]l [C]p [C]h [C]a [C]- [C]d [C]i [C]h [C]y [C]d [C]r [C]o [C]t [C]e [C]s [C]t [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
. [C]. O 

Steroid [C]S [C]t [C]e [C]r [C]o [C]i [C]d O 
identities [C]i [C]d [C]e [C]n [C]t [C]i [C]t [C]i [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
confirmed [C]c [C]o [C]n [C]f [C]i [C]r [C]m [C]e [C]d O 
by [C]b [C]y O 
gas [C]g [C]a [C]s O 
chromatography/mass [C]c [C]h [C]r [C]o [C]m [C]a [C]t [C]o [C]g [C]r [C]a [C]p [C]h [C]y [C]/ [C]m [C]a [C]s [C]s O 
spectrometry [C]s [C]p [C]e [C]c [C]t [C]r [C]o [C]m [C]e [C]t [C]r [C]y O 
( [C]( O 
GC/MS [C]G [C]C [C]/ [C]M [C]S O 
) [C]) O 
. [C]. O 

One [C]O [C]n [C]e O 
metabolite [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]t [C]e O 
thought [C]t [C]h [C]o [C]u [C]g [C]h [C]t O 
to [C]t [C]o O 
be [C]b [C]e O 
deoxycorticosterone [C]d [C]e [C]o [C]x [C]y [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
was [C]w [C]a [C]s O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
by [C]b [C]y O 
GC/MS [C]G [C]C [C]/ [C]M [C]S O 
as [C]a [C]s O 
6alpha-hydroxypregnanolone [C]6 [C]a [C]l [C]p [C]h [C]a [C]- [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]p [C]r [C]e [C]g [C]n [C]a [C]n [C]o [C]l [C]o [C]n [C]e O 
. [C]. O 

It [C]I [C]t O 
was [C]w [C]a [C]s O 
concluded [C]c [C]o [C]n [C]c [C]l [C]u [C]d [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
sex [C]s [C]e [C]x O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e O 
metabolism [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]s [C]m O 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
androgen [C]a [C]n [C]d [C]r [C]o [C]g [C]e [C]n O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
, [C], O 
occurs [C]o [C]c [C]c [C]u [C]r [C]s O 
in [C]i [C]n O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
may [C]m [C]a [C]y O 
modulate [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]e O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
. [C]. O 

Human [C]H [C]u [C]m [C]a [C]n B-cell_type 
white [C]w [C]h [C]i [C]t [C]e I-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
hair [C]h [C]a [C]i [C]r O 
follicles [C]f [C]o [C]l [C]l [C]i [C]c [C]l [C]e [C]s O 
are [C]a [C]r [C]e O 
good [C]g [C]o [C]o [C]d O 
sources [C]s [C]o [C]u [C]r [C]c [C]e [C]s O 
of [C]o [C]f O 
mRNA [C]m [C]R [C]N [C]A S-RNA 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
pterin [C]p [C]t [C]e [C]r [C]i [C]n B-protein 
carbinolamine [C]c [C]a [C]r [C]b [C]i [C]n [C]o [C]l [C]a [C]m [C]i [C]n [C]e I-protein 
dehydratase/dimerization [C]d [C]e [C]h [C]y [C]d [C]r [C]a [C]t [C]a [C]s [C]e [C]/ [C]d [C]i [C]m [C]e [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n I-protein 
cofactor [C]c [C]o [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
of [C]o [C]f O 
HNF1 [C]H [C]N [C]F [C]1 S-protein 
for [C]f [C]o [C]r O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
detection [C]d [C]e [C]t [C]e [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

Pterin [C]P [C]t [C]e [C]r [C]i [C]n B-protein 
carbinolamine [C]c [C]a [C]r [C]b [C]i [C]n [C]o [C]l [C]a [C]m [C]i [C]n [C]e I-protein 
dehydratase/dimerization [C]d [C]e [C]h [C]y [C]d [C]r [C]a [C]t [C]a [C]s [C]e [C]/ [C]d [C]i [C]m [C]e [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n I-protein 
cofactor [C]c [C]o [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
of [C]o [C]f O 
HNF1 [C]H [C]N [C]F [C]1 S-protein 
( [C]( O 
PCD/DCoH [C]P [C]C [C]D [C]/ [C]D [C]C [C]o [C]H S-protein 
) [C]) O 
is [C]i [C]s O 
a [C]a O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
that [C]t [C]h [C]a [C]t O 
has [C]h [C]a [C]s O 
a [C]a O 
dual [C]d [C]u [C]a [C]l O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

It [C]I [C]t O 
is [C]i [C]s O 
a [C]a O 
pterin [C]p [C]t [C]e [C]r [C]i [C]n B-protein 
4alpha-carbinolamine [C]4 [C]a [C]l [C]p [C]h [C]a [C]- [C]c [C]a [C]r [C]b [C]i [C]n [C]o [C]l [C]a [C]m [C]i [C]n [C]e I-protein 
dehydratase [C]d [C]e [C]h [C]y [C]d [C]r [C]a [C]t [C]a [C]s [C]e E-protein 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
regeneration [C]r [C]e [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cofactor [C]c [C]o [C]f [C]a [C]c [C]t [C]o [C]r B-protein 
tetrahydrobiopterin [C]t [C]e [C]t [C]r [C]a [C]h [C]y [C]d [C]r [C]o [C]b [C]i [C]o [C]p [C]t [C]e [C]r [C]i [C]n E-protein 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
phenylalanine [C]p [C]h [C]e [C]n [C]y [C]l [C]a [C]l [C]a [C]n [C]i [C]n [C]e O 
hydroxylase- [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]l [C]a [C]s [C]e [C]- O 
catalyzed [C]c [C]a [C]t [C]a [C]l [C]y [C]z [C]e [C]d O 
hydroxylation [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
phenylalanine [C]p [C]h [C]e [C]n [C]y [C]l [C]a [C]l [C]a [C]n [C]i [C]n [C]e O 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
it [C]i [C]t O 
is [C]i [C]s O 
the [C]t [C]h [C]e O 
dimerization [C]d [C]i [C]m [C]e [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
cofactor [C]c [C]o [C]f [C]a [C]c [C]t [C]o [C]r O 
of [C]o [C]f O 
HNF1 [C]H [C]N [C]F [C]1 S-protein 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
able [C]a [C]b [C]l [C]e O 
to [C]t [C]o O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
HNF1 [C]H [C]N [C]F [C]1 S-protein 
. [C]. O 

Deficiencies [C]D [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]i [C]e [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
gene [C]g [C]e [C]n [C]e O 
for [C]f [C]o [C]r O 
this [C]t [C]h [C]i [C]s O 
dual [C]d [C]u [C]a [C]l B-protein 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
result [C]r [C]e [C]s [C]u [C]l [C]t O 
in [C]i [C]n O 
hyperphenylalaninemia [C]h [C]y [C]p [C]e [C]r [C]p [C]h [C]e [C]n [C]y [C]l [C]a [C]l [C]a [C]n [C]i [C]n [C]e [C]m [C]i [C]a O 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
we [C]w [C]e O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
first [C]f [C]i [C]r [C]s [C]t O 
time [C]t [C]i [C]m [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
PCD/DCoH [C]P [C]C [C]D [C]/ [C]D [C]C [C]o [C]H B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
is [C]i [C]s O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
white [C]w [C]h [C]i [C]t [C]e I-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
hair [C]h [C]a [C]i [C]r O 
follicles [C]f [C]o [C]l [C]l [C]i [C]c [C]l [C]e [C]s O 
. [C]. O 

Taking [C]T [C]a [C]k [C]i [C]n [C]g O 
advantage [C]a [C]d [C]v [C]a [C]n [C]t [C]a [C]g [C]e O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
finding [C]f [C]i [C]n [C]d [C]i [C]n [C]g O 
, [C], O 
a [C]a O 
sensitive [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
, [C], O 
rapid [C]r [C]a [C]p [C]i [C]d O 
and [C]a [C]n [C]d O 
convenient [C]c [C]o [C]n [C]v [C]e [C]n [C]i [C]e [C]n [C]t O 
method [C]m [C]e [C]t [C]h [C]o [C]d O 
for [C]f [C]o [C]r O 
screening [C]s [C]c [C]r [C]e [C]e [C]n [C]i [C]n [C]g O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
occurring [C]o [C]c [C]c [C]u [C]r [C]r [C]i [C]n [C]g O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
coding [C]c [C]o [C]d [C]i [C]n [C]g O 
region [C]r [C]e [C]g [C]i [C]o [C]n O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
gene [C]g [C]e [C]n [C]e O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
described [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
. [C]. O 

Copyright [C]C [C]o [C]p [C]y [C]r [C]i [C]g [C]h [C]t O 
1998 [C]1 [C]9 [C]9 [C]8 O 
Academic [C]A [C]c [C]a [C]d [C]e [C]m [C]i [C]c O 
Press [C]P [C]r [C]e [C]s [C]s O 
. [C]. O 

Biochemical [C]B [C]i [C]o [C]c [C]h [C]e [C]m [C]i [C]c [C]a [C]l O 
characterization [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
NF-Y [C]N [C]F [C]- [C]Y B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
B [C]B O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
. [C]. O 

The [C]T [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
, [C], O 
NF-Y [C]N [C]F [C]- [C]Y S-protein 
, [C], O 
plays [C]p [C]l [C]a [C]y [C]s O 
a [C]a O 
critical [C]c [C]r [C]i [C]t [C]i [C]c [C]a [C]l O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
tissue-specific [C]t [C]i [C]s [C]s [C]u [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
major [C]m [C]a [C]j [C]o [C]r B-DNA 
histocompatibility [C]h [C]i [C]s [C]t [C]o [C]c [C]o [C]m [C]p [C]a [C]t [C]i [C]b [C]i [C]l [C]i [C]t [C]y I-DNA 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x I-DNA 
class [C]c [C]l [C]a [C]s [C]s I-DNA 
II [C]I [C]I I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
the [C]t [C]h [C]e O 
biochemical [C]b [C]i [C]o [C]c [C]h [C]e [C]m [C]i [C]c [C]a [C]l O 
properties [C]p [C]r [C]o [C]p [C]e [C]r [C]t [C]i [C]e [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
heterotrimeric [C]h [C]e [C]t [C]e [C]r [C]o [C]t [C]r [C]i [C]m [C]e [C]r [C]i [C]c B-protein 
NF-Y [C]N [C]F [C]- [C]Y I-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
characterized [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]d O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
stage-specific [C]s [C]t [C]a [C]g [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
, [C], O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
class [C]c [C]l [C]a [C]s [C]s B-cell_line 
II- [C]I [C]I [C]- I-cell_line 
mutant [C]m [C]u [C]t [C]a [C]n [C]t I-cell_line 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
represent [C]r [C]e [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
bare [C]b [C]a [C]r [C]e O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e O 
syndrome [C]s [C]y [C]n [C]d [C]r [C]o [C]m [C]e O 
class [C]c [C]l [C]a [C]s [C]s O 
II [C]I [C]I O 
genetic [C]g [C]e [C]n [C]e [C]t [C]i [C]c O 
complementation [C]c [C]o [C]m [C]p [C]l [C]e [C]m [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
groups [C]g [C]r [C]o [C]u [C]p [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
NF-Y [C]N [C]F [C]- [C]Y B-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
derived [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
class [C]c [C]l [C]a [C]s [C]s B-cell_type 
II+ [C]I [C]I [C]+ I-cell_type 
mature [C]m [C]a [C]t [C]u [C]r [C]e I-cell_type 
B-cells [C]B [C]- [C]c [C]e [C]l [C]l [C]s E-cell_type 
bound [C]b [C]o [C]u [C]n [C]d O 
with [C]w [C]i [C]t [C]h O 
high [C]h [C]i [C]g [C]h O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
to [C]t [C]o O 
anion [C]a [C]n [C]i [C]o [C]n B-protein 
exchangers [C]e [C]x [C]c [C]h [C]a [C]n [C]g [C]e [C]r [C]s E-protein 
, [C], O 
and [C]a [C]n [C]d O 
eluted [C]e [C]l [C]u [C]t [C]e [C]d O 
as [C]a [C]s O 
an [C]a [C]n O 
intact [C]i [C]n [C]t [C]a [C]c [C]t O 
trimeric [C]t [C]r [C]i [C]m [C]e [C]r [C]i [C]c B-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
, [C], O 
NF-Y [C]N [C]F [C]- [C]Y S-protein 
derived [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
class [C]c [C]l [C]a [C]s [C]s B-cell_type 
II- [C]I [C]I [C]- I-cell_type 
plasma [C]p [C]l [C]a [C]s [C]m [C]a I-cell_type 
B-cells [C]B [C]- [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
and [C]a [C]n [C]d O 
from [C]f [C]r [C]o [C]m O 
bare [C]b [C]a [C]r [C]e B-cell_line 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e I-cell_line 
syndrome [C]s [C]y [C]n [C]d [C]r [C]o [C]m [C]e I-cell_line 
group [C]g [C]r [C]o [C]u [C]p I-cell_line 
II [C]I [C]I I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
, [C], O 
RJ2.2.5 [C]R [C]J [C]2 [C]. [C]2 [C]. [C]5 S-cell_line 
and [C]a [C]n [C]d O 
RM3 [C]R [C]M [C]3 S-cell_line 
, [C], O 
dissociated [C]d [C]i [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
into [C]i [C]n [C]t [C]o O 
discrete [C]d [C]i [C]s [C]c [C]r [C]e [C]t [C]e O 
NF-YA [C]N [C]F [C]- [C]Y [C]A S-protein 
and [C]a [C]n [C]d O 
NF-YB [C]N [C]F [C]- [C]Y [C]B B-protein 
: [C]: I-protein 
C [C]C E-protein 
subunit [C]s [C]u [C]b [C]u [C]n [C]i [C]t B-protein 
fractions [C]f [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s E-protein 
. [C]. O 

Recombination [C]R [C]e [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
MPC11 [C]M [C]P [C]C [C]1 [C]1 B-protein 
plasma [C]p [C]l [C]a [C]s [C]m [C]a I-protein 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l I-protein 
derived [C]d [C]e [C]r [C]i [C]v [C]e [C]d I-protein 
NF-Y [C]N [C]F [C]- [C]Y I-protein 
A [C]A I-protein 
: [C]: I-protein 
B [C]B I-protein 
: [C]: I-protein 
C [C]C I-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
low [C]l [C]o [C]w O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
mass [C]m [C]a [C]s [C]s O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
fraction [C]f [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
, [C], O 
NF-Y-associated [C]N [C]F [C]- [C]Y [C]- [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
( [C]( O 
YAFs [C]Y [C]A [C]F [C]s S-protein 
) [C]) O 
, [C], O 
derived [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
mature [C]m [C]a [C]t [C]u [C]r [C]e O 
A20 [C]A [C]2 [C]0 O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l O 
nuclei [C]n [C]u [C]c [C]l [C]e [C]i O 
, [C], O 
conferred [C]c [C]o [C]n [C]f [C]e [C]r [C]r [C]e [C]d O 
high [C]h [C]i [C]g [C]h O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
anion [C]a [C]n [C]i [C]o [C]n O 
exchange [C]e [C]x [C]c [C]h [C]a [C]n [C]g [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
NF-Y [C]N [C]F [C]- [C]Y S-protein 
as [C]a [C]s O 
an [C]a [C]n O 
intact [C]i [C]n [C]t [C]a [C]c [C]t B-protein 
trimeric [C]t [C]r [C]i [C]m [C]e [C]r [C]i [C]c I-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
. [C]. O 

Recombination [C]R [C]e [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
native [C]n [C]a [C]t [C]i [C]v [C]e B-protein 
NF-YA [C]N [C]F [C]- [C]Y [C]A I-protein 
: [C]: I-protein 
B [C]B I-protein 
: [C]: I-protein 
C [C]C I-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l B-protein 
cofactor [C]c [C]o [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
, [C], O 
PC4 [C]P [C]C [C]4 S-protein 
, [C], O 
likewise [C]l [C]i [C]k [C]e [C]w [C]i [C]s [C]e O 
conferred [C]c [C]o [C]n [C]f [C]e [C]r [C]r [C]e [C]d O 
high [C]h [C]i [C]g [C]h B-protein 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y I-protein 
NF-Y [C]N [C]F [C]- [C]Y E-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
anion [C]a [C]n [C]i [C]o [C]n B-protein 
exchangers [C]e [C]x [C]c [C]h [C]a [C]n [C]g [C]e [C]r [C]s E-protein 
, [C], O 
and [C]a [C]n [C]d O 
stabilized [C]s [C]t [C]a [C]b [C]i [C]l [C]i [C]z [C]e [C]d O 
NF-Y [C]N [C]F [C]- [C]Y S-protein 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
CCAAT-box [C]C [C]C [C]A [C]A [C]T [C]- [C]b [C]o [C]x B-DNA 
DNA [C]D [C]N [C]A I-DNA 
motifs [C]m [C]o [C]t [C]i [C]f [C]s E-DNA 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
. [C]. O 

Interaction [C]I [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
PC4 [C]P [C]C [C]4 S-protein 
and [C]a [C]n [C]d O 
NF-Y [C]N [C]F [C]- [C]Y S-protein 
was [C]w [C]a [C]s O 
mapped [C]m [C]a [C]p [C]p [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
C-terminal [C]C [C]- [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l B-protein 
region [C]r [C]e [C]g [C]i [C]o [C]n E-protein 
of [C]o [C]f O 
PC4 [C]P [C]C [C]4 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
subunit [C]s [C]u [C]b [C]u [C]n [C]i [C]t B-protein 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n I-protein 
subdomain [C]s [C]u [C]b [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
highly [C]h [C]i [C]g [C]h [C]l [C]y B-protein 
conserved [C]c [C]o [C]n [C]s [C]e [C]r [C]v [C]e [C]d I-protein 
DNA [C]D [C]N [C]A I-protein 
binding-subunit [C]b [C]i [C]n [C]d [C]i [C]n [C]g [C]- [C]s [C]u [C]b [C]u [C]n [C]i [C]t I-protein 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n I-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
( [C]( O 
DBD [C]D [C]B [C]D S-protein 
) [C]) O 
of [C]o [C]f O 
NF-YA [C]N [C]F [C]- [C]Y [C]A S-protein 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
in [C]i [C]n O 
class [C]c [C]l [C]a [C]s [C]s B-cell_type 
II+ [C]I [C]I [C]+ I-cell_type 
mature [C]m [C]a [C]t [C]u [C]r [C]e I-cell_type 
B-cells [C]B [C]- [C]c [C]e [C]l [C]l [C]s E-cell_type 
NF-Y [C]N [C]F [C]- [C]Y S-protein 
is [C]i [C]s O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
cofactor [C]c [C]o [C]f [C]a [C]c [C]t [C]o [C]r O 
, [C], O 
PC4 [C]P [C]C [C]4 S-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
may [C]m [C]a [C]y O 
play [C]p [C]l [C]a [C]y O 
an [C]a [C]n O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
NF-Y-mediated [C]N [C]F [C]- [C]Y [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
of [C]o [C]f O 
class [C]c [C]l [C]a [C]s [C]s B-DNA 
II [C]I [C]I I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
. [C]. O 

Arrest [C]A [C]r [C]r [C]e [C]s [C]t O 
of [C]o [C]f O 
B [C]B O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e O 
terminal [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
CD40 [C]C [C]D [C]4 [C]0 O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
: [C]: O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
for [C]f [C]o [C]r O 
lack [C]l [C]a [C]c [C]k O 
of [C]o [C]f O 
antibody-secreting [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y [C]- [C]s [C]e [C]c [C]r [C]e [C]t [C]i [C]n [C]g B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
germinal [C]g [C]e [C]r [C]m [C]i [C]n [C]a [C]l O 
centers [C]c [C]e [C]n [C]t [C]e [C]r [C]s O 
. [C]. O 

Despite [C]D [C]e [C]s [C]p [C]i [C]t [C]e O 
extensive [C]e [C]x [C]t [C]e [C]n [C]s [C]i [C]v [C]e O 
research [C]r [C]e [C]s [C]e [C]a [C]r [C]c [C]h O 
, [C], O 
the [C]t [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
CD40 [C]C [C]D [C]4 [C]0 S-protein 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
in [C]i [C]n O 
B [C]B O 
cell [C]c [C]e [C]l [C]l O 
terminal [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
remains [C]r [C]e [C]m [C]a [C]i [C]n [C]s O 
controversial [C]c [C]o [C]n [C]t [C]r [C]o [C]v [C]e [C]r [C]s [C]i [C]a [C]l O 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
we [C]w [C]e O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
CD40 [C]C [C]D [C]4 [C]0 S-protein 
engagement [C]e [C]n [C]g [C]a [C]g [C]e [C]m [C]e [C]n [C]t O 
arrests [C]a [C]r [C]r [C]e [C]s [C]t [C]s O 
B [C]B O 
cell [C]c [C]e [C]l [C]l O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
prior [C]p [C]r [C]i [C]o [C]r O 
to [C]t [C]o O 
plasma [C]p [C]l [C]a [C]s [C]m [C]a O 
cell [C]c [C]e [C]l [C]l O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
arrest [C]a [C]r [C]r [C]e [C]s [C]t O 
is [C]i [C]s O 
manifested [C]m [C]a [C]n [C]i [C]f [C]e [C]s [C]t [C]e [C]d O 
at [C]a [C]t O 
a [C]a O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
level [C]l [C]e [C]v [C]e [C]l O 
as [C]a [C]s O 
a [C]a O 
reduction [C]r [C]e [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
mRNA [C]m [C]R [C]N [C]A O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
secretory [C]s [C]e [C]c [C]r [C]e [C]t [C]o [C]r [C]y O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n O 
gene [C]g [C]e [C]n [C]e O 
products [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]s O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
mu [C]m [C]u O 
( [C]( O 
s [C]s O 
) [C]) O 
and [C]a [C]n [C]d O 
J [C]J O 
chain [C]c [C]h [C]a [C]i [C]n O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
the [C]t [C]h [C]e O 
loss [C]l [C]o [C]s [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l B-protein 
regulator [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r E-protein 
BLIMP-1 [C]B [C]L [C]I [C]M [C]P [C]- [C]1 S-protein 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
the [C]t [C]h [C]e O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
B [C]B O 
cell [C]c [C]e [C]l [C]l O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
CD40 [C]C [C]D [C]4 [C]0 S-protein 
engagement [C]e [C]n [C]g [C]a [C]g [C]e [C]m [C]e [C]n [C]t O 
could [C]c [C]o [C]u [C]l [C]d O 
not [C]n [C]o [C]t O 
be [C]b [C]e O 
overcome [C]o [C]v [C]e [C]r [C]c [C]o [C]m [C]e O 
by [C]b [C]y O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
mitogens [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]s S-protein 
or [C]o [C]r O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
, [C], O 
but [C]b [C]u [C]t O 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
reversed [C]r [C]e [C]v [C]e [C]r [C]s [C]e [C]d O 
by [C]b [C]y O 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s O 
that [C]t [C]h [C]a [C]t O 
interfere [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]e O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
CD40 [C]C [C]D [C]4 [C]0 S-protein 
/ [C]/ O 
gp39 [C]g [C]p [C]3 [C]9 S-protein 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
secretory [C]s [C]e [C]c [C]r [C]e [C]t [C]o [C]r [C]y O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n O 
is [C]i [C]s O 
not [C]n [C]o [C]t O 
produced [C]p [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
that [C]t [C]h [C]a [C]t O 
are [C]a [C]r [C]e O 
actively [C]a [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
engaged [C]e [C]n [C]g [C]a [C]g [C]e [C]d O 
by [C]b [C]y O 
gp39-expressing [C]g [C]p [C]3 [C]9 [C]- [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]n [C]g B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

A [C]A O 
positively [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e [C]l [C]y O 
charged [C]c [C]h [C]a [C]r [C]g [C]e [C]d O 
alpha-lipoic [C]a [C]l [C]p [C]h [C]a [C]- [C]l [C]i [C]p [C]o [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
analogue [C]a [C]n [C]a [C]l [C]o [C]g [C]u [C]e O 
with [C]w [C]i [C]t [C]h O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
uptake [C]u [C]p [C]t [C]a [C]k [C]e O 
and [C]a [C]n [C]d O 
more [C]m [C]o [C]r [C]e O 
potent [C]p [C]o [C]t [C]e [C]n [C]t O 
immunomodulatory [C]i [C]m [C]m [C]u [C]n [C]o [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

alpha-Lipoic [C]a [C]l [C]p [C]h [C]a [C]- [C]L [C]i [C]p [C]o [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
( [C]( O 
LA [C]L [C]A O 
) [C]) O 
is [C]i [C]s O 
taken [C]t [C]a [C]k [C]e [C]n O 
up [C]u [C]p O 
by [C]b [C]y O 
cells [C]c [C]e [C]l [C]l [C]s O 
and [C]a [C]n [C]d O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
to [C]t [C]o O 
its [C]i [C]t [C]s O 
potent [C]p [C]o [C]t [C]e [C]n [C]t O 
dithiol [C]d [C]i [C]t [C]h [C]i [C]o [C]l O 
form [C]f [C]o [C]r [C]m O 
, [C], O 
dihydrolipoate [C]d [C]i [C]h [C]y [C]d [C]r [C]o [C]l [C]i [C]p [C]o [C]a [C]t [C]e O 
( [C]( O 
DHLA [C]D [C]H [C]L [C]A O 
) [C]) O 
, [C], O 
much [C]m [C]u [C]c [C]h O 
of [C]o [C]f O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
rapidly [C]r [C]a [C]p [C]i [C]d [C]l [C]y O 
effluxed [C]e [C]f [C]f [C]l [C]u [C]x [C]e [C]d O 
out [C]o [C]u [C]t O 
from [C]f [C]r [C]o [C]m O 
cells [C]c [C]e [C]l [C]l [C]s O 
. [C]. O 

To [C]T [C]o O 
improve [C]i [C]m [C]p [C]r [C]o [C]v [C]e O 
retention [C]r [C]e [C]t [C]e [C]n [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
cells [C]c [C]e [C]l [C]l [C]s O 
, [C], O 
the [C]t [C]h [C]e O 
LA [C]L [C]A O 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e O 
was [C]w [C]a [C]s O 
modified [C]m [C]o [C]d [C]i [C]f [C]i [C]e [C]d O 
to [C]t [C]o O 
confer [C]c [C]o [C]n [C]f [C]e [C]r O 
a [C]a O 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
charge [C]c [C]h [C]a [C]r [C]g [C]e O 
at [C]a [C]t O 
physiological [C]p [C]h [C]y [C]s [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
pH [C]p [C]H O 
. [C]. O 

N [C]N O 
, [C], O 
N-dimethyl [C]N [C]- [C]d [C]i [C]m [C]e [C]t [C]h [C]y [C]l O 
, [C], O 
N'-2-amidoethyl-lipoate [C]N [C]' [C]- [C]2 [C]- [C]a [C]m [C]i [C]d [C]o [C]e [C]t [C]h [C]y [C]l [C]- [C]l [C]i [C]p [C]o [C]a [C]t [C]e O 
was [C]w [C]a [C]s O 
synthesized [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]z [C]e [C]d O 
. [C]. O 

The [C]T [C]h [C]e O 
protonated [C]p [C]r [C]o [C]t [C]o [C]n [C]a [C]t [C]e [C]d O 
form [C]f [C]o [C]r [C]m O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
new [C]n [C]e [C]w O 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e O 
is [C]i [C]s O 
referred [C]r [C]e [C]f [C]e [C]r [C]r [C]e [C]d O 
to [C]t [C]o O 
as [C]a [C]s O 
LA-Plus [C]L [C]A [C]- [C]P [C]l [C]u [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
uptake [C]u [C]p [C]t [C]a [C]k [C]e O 
of [C]o [C]f O 
LA-Plus [C]L [C]A [C]- [C]P [C]l [C]u [C]s O 
by [C]b [C]y O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
Wurzburg [C]W [C]u [C]r [C]z [C]b [C]u [C]r [C]g I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
was [C]w [C]a [C]s O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
that [C]t [C]h [C]a [C]t O 
of [C]o [C]f O 
LA [C]L [C]A O 
. [C]. O 

Several-fold [C]S [C]e [C]v [C]e [C]r [C]a [C]l [C]- [C]f [C]o [C]l [C]d O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
amounts [C]a [C]m [C]o [C]u [C]n [C]t [C]s O 
of [C]o [C]f O 
DHLA-Plus [C]D [C]H [C]L [C]A [C]- [C]P [C]l [C]u [C]s O 
, [C], O 
the [C]t [C]h [C]e O 
corresponding [C]c [C]o [C]r [C]r [C]e [C]s [C]p [C]o [C]n [C]d [C]i [C]n [C]g O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
form [C]f [C]o [C]r [C]m O 
of [C]o [C]f O 
LA-Plus [C]L [C]A [C]- [C]P [C]l [C]u [C]s O 
, [C], O 
were [C]w [C]e [C]r [C]e O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
in [C]i [C]n O 
LA-Plus [C]L [C]A [C]- [C]P [C]l [C]u [C]s O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
cells [C]c [C]e [C]l [C]l [C]s O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
amount [C]a [C]m [C]o [C]u [C]n [C]t O 
of [C]o [C]f O 
DHLA [C]D [C]H [C]L [C]A O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
cells [C]c [C]e [C]l [C]l [C]s O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
LA [C]L [C]A O 
. [C]. O 

At [C]A [C]t O 
100 [C]1 [C]0 [C]0 O 
microM [C]m [C]i [C]c [C]r [C]o [C]M O 
, [C], O 
LA [C]L [C]A O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
but [C]b [C]u [C]t O 
LA-Plus [C]L [C]A [C]- [C]P [C]l [C]u [C]s O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
H2O2 [C]H [C]2 [C]O [C]2 O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
directed [C]d [C]i [C]r [C]e [C]c [C]t [C]e [C]d O 
IL-2 [C]I [C]L [C]- [C]2 B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Both [C]B [C]o [C]t [C]h O 
LA [C]L [C]A O 
and [C]a [C]n [C]d O 
LA-Plus [C]L [C]A [C]- [C]P [C]l [C]u [C]s O 
synergised [C]s [C]y [C]n [C]e [C]r [C]g [C]i [C]s [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
selenium [C]s [C]e [C]l [C]e [C]n [C]i [C]u [C]m O 
in [C]i [C]n O 
inhibiting [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]n [C]g O 
H2O2 [C]H [C]2 [C]O [C]2 O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

At [C]A [C]t O 
150 [C]1 [C]5 [C]0 O 
microM [C]m [C]i [C]c [C]r [C]o [C]M O 
LA-Plus [C]L [C]A [C]- [C]P [C]l [C]u [C]s O 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
LA [C]L [C]A O 
, [C], O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
TNFalpha [C]T [C]N [C]F [C]a [C]l [C]p [C]h [C]a S-protein 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

At [C]A [C]t O 
5 [C]5 O 
microM [C]m [C]i [C]c [C]r [C]o [C]M O 
LA-Plus [C]L [C]A [C]- [C]P [C]l [C]u [C]s O 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
LA [C]L [C]A O 
, [C], O 
protected [C]p [C]r [C]o [C]t [C]e [C]c [C]t [C]e [C]d O 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
both [C]b [C]o [C]t [C]h O 
spontaneous [C]s [C]p [C]o [C]n [C]t [C]a [C]n [C]e [C]o [C]u [C]s O 
and [C]a [C]n [C]d O 
etoposide [C]e [C]t [C]o [C]p [C]o [C]s [C]i [C]d [C]e O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
rat [C]r [C]a [C]t B-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

LA-Plus [C]L [C]A [C]- [C]P [C]l [C]u [C]s O 
is [C]i [C]s O 
thus [C]t [C]h [C]u [C]s O 
an [C]a [C]n O 
improved [C]i [C]m [C]p [C]r [C]o [C]v [C]e [C]d O 
form [C]f [C]o [C]r [C]m O 
of [C]o [C]f O 
LA [C]L [C]A O 
with [C]w [C]i [C]t [C]h O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
therapeutic [C]t [C]h [C]e [C]r [C]a [C]p [C]e [C]u [C]t [C]i [C]c O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
. [C]. O 

Copyright [C]C [C]o [C]p [C]y [C]r [C]i [C]g [C]h [C]t O 
1998 [C]1 [C]9 [C]9 [C]8 O 
Academic [C]A [C]c [C]a [C]d [C]e [C]m [C]i [C]c O 
Press [C]P [C]r [C]e [C]s [C]s O 
. [C]. O 

Carrier [C]C [C]a [C]r [C]r [C]i [C]e [C]r O 
identification [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
X-linked [C]X [C]- [C]l [C]i [C]n [C]k [C]e [C]d O 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
diseases [C]d [C]i [C]s [C]e [C]a [C]s [C]e [C]s O 
. [C]. O 

OBJECTIVE [C]O [C]B [C]J [C]E [C]C [C]T [C]I [C]V [C]E O 
: [C]: O 
Carrier [C]C [C]a [C]r [C]r [C]i [C]e [C]r O 
identification [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
X-linked [C]X [C]- [C]l [C]i [C]n [C]k [C]e [C]d O 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
disorders [C]d [C]i [C]s [C]o [C]r [C]d [C]e [C]r [C]s O 
can [C]c [C]a [C]n O 
be [C]b [C]e O 
based [C]b [C]a [C]s [C]e [C]d O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
demonstration [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
non-random [C]n [C]o [C]n [C]- [C]r [C]a [C]n [C]d [C]o [C]m O 
X [C]X O 
inactivation [C]i [C]n [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
( [C]( O 
NRXI [C]N [C]R [C]X [C]I O 
) [C]) O 
in [C]i [C]n O 
affected [C]a [C]f [C]f [C]e [C]c [C]t [C]e [C]d B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
cell [C]c [C]e [C]l [C]l I-cell_type 
lineages [C]l [C]i [C]n [C]e [C]a [C]g [C]e [C]s E-cell_type 
when [C]w [C]h [C]e [C]n O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
is [C]i [C]s O 
impaired [C]i [C]m [C]p [C]a [C]i [C]r [C]e [C]d O 
in [C]i [C]n O 
cells [C]c [C]e [C]l [C]l [C]s O 
expressing [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
abnormal [C]a [C]b [C]n [C]o [C]r [C]m [C]a [C]l B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
. [C]. O 

We [C]W [C]e O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
the [C]t [C]h [C]e O 
utility [C]u [C]t [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
seeking [C]s [C]e [C]e [C]k [C]i [C]n [C]g O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
NRXI [C]N [C]R [C]X [C]I O 
to [C]t [C]o O 
test [C]t [C]e [C]s [C]t O 
the [C]t [C]h [C]e O 
carrier [C]c [C]a [C]r [C]r [C]i [C]e [C]r O 
status [C]s [C]t [C]a [C]t [C]u [C]s O 
of [C]o [C]f O 
women [C]w [C]o [C]m [C]e [C]n O 
in [C]i [C]n O 
families [C]f [C]a [C]m [C]i [C]l [C]i [C]e [C]s O 
affected [C]a [C]f [C]f [C]e [C]c [C]t [C]e [C]d O 
by [C]b [C]y O 
X-linked [C]X [C]- [C]l [C]i [C]n [C]k [C]e [C]d O 
severe [C]s [C]e [C]v [C]e [C]r [C]e O 
combined [C]c [C]o [C]m [C]b [C]i [C]n [C]e [C]d O 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
( [C]( O 
XSCID [C]X [C]S [C]C [C]I [C]D O 
) [C]) O 
and [C]a [C]n [C]d O 
X-linked [C]X [C]- [C]l [C]i [C]n [C]k [C]e [C]d O 
hypogammaglobulinaemia [C]h [C]y [C]p [C]o [C]g [C]a [C]m [C]m [C]a [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n [C]a [C]e [C]m [C]i [C]a O 
( [C]( O 
XLH [C]X [C]L [C]H O 
) [C]) O 
, [C], O 
to [C]t [C]o O 
identify [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]y O 
as [C]a [C]s O 
carriers [C]c [C]a [C]r [C]r [C]i [C]e [C]r [C]s O 
the [C]t [C]h [C]e O 
mothers [C]m [C]o [C]t [C]h [C]e [C]r [C]s O 
of [C]o [C]f O 
boys [C]b [C]o [C]y [C]s O 
with [C]w [C]i [C]t [C]h O 
SCID [C]S [C]C [C]I [C]D O 
or [C]o [C]r O 
hypogammaglobulinaemia [C]h [C]y [C]p [C]o [C]g [C]a [C]m [C]m [C]a [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n [C]a [C]e [C]m [C]i [C]a O 
whose [C]w [C]h [C]o [C]s [C]e O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
suggested [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]e [C]d O 
X-linkage [C]X [C]- [C]l [C]i [C]n [C]k [C]a [C]g [C]e O 
and [C]a [C]n [C]d O 
to [C]t [C]o O 
infer [C]i [C]n [C]f [C]e [C]r O 
X-linkage [C]X [C]- [C]l [C]i [C]n [C]k [C]a [C]g [C]e O 
in [C]i [C]n O 
boys [C]b [C]o [C]y [C]s O 
with [C]w [C]i [C]t [C]h O 
SCID [C]S [C]C [C]I [C]D O 
or [C]o [C]r O 
hypogammaglobulinaemia [C]h [C]y [C]p [C]o [C]g [C]a [C]m [C]m [C]a [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n [C]a [C]e [C]m [C]i [C]a O 
whose [C]w [C]h [C]o [C]s [C]e O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
clearly [C]c [C]l [C]e [C]a [C]r [C]l [C]y O 
X-linked [C]X [C]- [C]l [C]i [C]n [C]k [C]e [C]d O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
basis [C]b [C]a [C]s [C]i [C]s O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
of [C]o [C]f O 
family [C]f [C]a [C]m [C]i [C]l [C]y O 
history [C]h [C]i [C]s [C]t [C]o [C]r [C]y O 
or [C]o [C]r O 
clinical [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
and [C]a [C]n [C]d O 
immunological [C]i [C]m [C]m [C]u [C]n [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
characteristics [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]s [C]t [C]i [C]c [C]s O 
. [C]. O 

METHODOLOGY [C]M [C]E [C]T [C]H [C]O [C]D [C]O [C]L [C]O [C]G [C]Y O 
: [C]: O 
A [C]A O 
polymerase [C]p [C]o [C]l [C]y [C]m [C]e [C]r [C]a [C]s [C]e O 
chain [C]c [C]h [C]a [C]i [C]n O 
reaction-based [C]r [C]e [C]a [C]c [C]t [C]i [C]o [C]n [C]- [C]b [C]a [C]s [C]e [C]d O 
method [C]m [C]e [C]t [C]h [C]o [C]d O 
was [C]w [C]a [C]s O 
used [C]u [C]s [C]e [C]d O 
to [C]t [C]o O 
amplify [C]a [C]m [C]p [C]l [C]i [C]f [C]y O 
a [C]a O 
polymorphic [C]p [C]o [C]l [C]y [C]m [C]o [C]r [C]p [C]h [C]i [C]c O 
CAG [C]C [C]A [C]G B-DNA 
repeat [C]r [C]e [C]p [C]e [C]a [C]t E-DNA 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
first [C]f [C]i [C]r [C]s [C]t B-DNA 
exon [C]e [C]x [C]o [C]n E-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
androgen [C]a [C]n [C]d [C]r [C]o [C]g [C]e [C]n B-DNA 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
after [C]a [C]f [C]t [C]e [C]r O 
selective [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e O 
digestion [C]d [C]i [C]g [C]e [C]s [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
active [C]a [C]c [C]t [C]i [C]v [C]e B-DNA 
X [C]X I-DNA 
chromosome [C]c [C]h [C]r [C]o [C]m [C]o [C]s [C]o [C]m [C]e E-DNA 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
methylation-sensitive [C]m [C]e [C]t [C]h [C]y [C]l [C]a [C]t [C]i [C]o [C]n [C]- [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e B-protein 
enzyme [C]e [C]n [C]z [C]y [C]m [C]e E-protein 
, [C], O 
HpaII [C]H [C]p [C]a [C]I [C]I S-protein 
to [C]t [C]o O 
distinguish [C]d [C]i [C]s [C]t [C]i [C]n [C]g [C]u [C]i [C]s [C]h O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
paternal [C]p [C]a [C]t [C]e [C]r [C]n [C]a [C]l B-DNA 
and [C]a [C]n [C]d I-DNA 
maternal [C]m [C]a [C]t [C]e [C]r [C]n [C]a [C]l I-DNA 
alleles [C]a [C]l [C]l [C]e [C]l [C]e [C]s E-DNA 
and [C]a [C]n [C]d O 
to [C]t [C]o O 
identify [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]y O 
their [C]t [C]h [C]e [C]i [C]r O 
methylation [C]m [C]e [C]t [C]h [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
status [C]s [C]t [C]a [C]t [C]u [C]s O 
. [C]. O 

RESULTS [C]R [C]E [C]S [C]U [C]L [C]T [C]S O 
: [C]: O 
Heterozygosity [C]H [C]e [C]t [C]e [C]r [C]o [C]z [C]y [C]g [C]o [C]s [C]i [C]t [C]y O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
24 [C]2 [C]4 O 
of [C]o [C]f O 
31 [C]3 [C]1 O 
female [C]f [C]e [C]m [C]a [C]l [C]e O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
( [C]( O 
77 [C]7 [C]7 O 
% [C]% O 
) [C]) O 
. [C]. O 

As [C]A [C]s O 
anticipated [C]a [C]n [C]t [C]i [C]c [C]i [C]p [C]a [C]t [C]e [C]d O 
, [C], O 
NRXI [C]N [C]R [C]X [C]I O 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
all [C]a [C]l [C]l O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
obligate [C]o [C]b [C]l [C]i [C]g [C]a [C]t [C]e O 
carriers [C]c [C]a [C]r [C]r [C]i [C]e [C]r [C]s O 
of [C]o [C]f O 
XSCID [C]X [C]S [C]C [C]I [C]D O 
and [C]a [C]n [C]d O 
an [C]a [C]n O 
obligate [C]o [C]b [C]l [C]i [C]g [C]a [C]t [C]e O 
carrier [C]c [C]a [C]r [C]r [C]i [C]e [C]r O 
of [C]o [C]f O 
XLH [C]X [C]L [C]H O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
on [C]o [C]n O 
a [C]a O 
carrier [C]c [C]a [C]r [C]r [C]i [C]e [C]r O 
of [C]o [C]f O 
X-linked [C]X [C]- [C]l [C]i [C]n [C]k [C]e [C]d O 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
with [C]w [C]i [C]t [C]h O 
hyper-IgM [C]h [C]y [C]p [C]e [C]r [C]- [C]I [C]g [C]M S-protein 
. [C]. O 

The [C]T [C]h [C]e O 
finding [C]f [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
NRXI [C]N [C]R [C]X [C]I O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
mother [C]m [C]o [C]t [C]h [C]e [C]r O 
of [C]o [C]f O 
a [C]a O 
boy [C]b [C]o [C]y O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
SCID [C]S [C]C [C]I [C]D O 
variant [C]v [C]a [C]r [C]i [C]a [C]n [C]t O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
her [C]h [C]e [C]r O 
to [C]t [C]o O 
be [C]b [C]e O 
a [C]a O 
carrier [C]c [C]a [C]r [C]r [C]i [C]e [C]r O 
of [C]o [C]f O 
XSCID [C]X [C]S [C]C [C]I [C]D O 
and [C]a [C]n [C]d O 
establishes [C]e [C]s [C]t [C]a [C]b [C]l [C]i [C]s [C]h [C]e [C]s O 
that [C]t [C]h [C]a [C]t O 
her [C]h [C]e [C]r O 
son [C]s [C]o [C]n O 
has [C]h [C]a [C]s O 
XSCID [C]X [C]S [C]C [C]I [C]D O 
, [C], O 
not [C]n [C]o [C]t O 
otherwise [C]o [C]t [C]h [C]e [C]r [C]w [C]i [C]s [C]e O 
evident [C]e [C]v [C]i [C]d [C]e [C]n [C]t O 
from [C]f [C]r [C]o [C]m O 
available [C]a [C]v [C]a [C]i [C]l [C]a [C]b [C]l [C]e O 
data [C]d [C]a [C]t [C]a O 
. [C]. O 

CONCLUSIONS [C]C [C]O [C]N [C]C [C]L [C]U [C]S [C]I [C]O [C]N [C]S O 
: [C]: O 
This [C]T [C]h [C]i [C]s O 
PCR [C]P [C]C [C]R O 
assay [C]a [C]s [C]s [C]a [C]y O 
provides [C]p [C]r [C]o [C]v [C]i [C]d [C]e [C]s O 
a [C]a O 
rapid [C]r [C]a [C]p [C]i [C]d O 
method [C]m [C]e [C]t [C]h [C]o [C]d O 
for [C]f [C]o [C]r O 
carrier [C]c [C]a [C]r [C]r [C]i [C]e [C]r O 
detection [C]d [C]e [C]t [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
X-linked [C]X [C]- [C]l [C]i [C]n [C]k [C]e [C]d O 
immunodeficiencies [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]i [C]e [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
has [C]h [C]a [C]s O 
allowed [C]a [C]l [C]l [C]o [C]w [C]e [C]d O 
us [C]u [C]s O 
to [C]t [C]o O 
expand [C]e [C]x [C]p [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
of [C]o [C]f O 
XSCID [C]X [C]S [C]C [C]I [C]D O 

Leukocyte-endothelial [C]L [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]- [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
augmented [C]a [C]u [C]g [C]m [C]e [C]n [C]t [C]e [C]d O 
by [C]b [C]y O 
high [C]h [C]i [C]g [C]h O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
and [C]a [C]n [C]d O 
hyperglycemia [C]h [C]y [C]p [C]e [C]r [C]g [C]l [C]y [C]c [C]e [C]m [C]i [C]a O 
in [C]i [C]n O 
a [C]a O 
NF-kB-dependent [C]N [C]F [C]- [C]k [C]B [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
fashion [C]f [C]a [C]s [C]h [C]i [C]o [C]n O 
. [C]. O 

We [C]W [C]e O 
addressed [C]a [C]d [C]d [C]r [C]e [C]s [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
hyperglycemia [C]h [C]y [C]p [C]e [C]r [C]g [C]l [C]y [C]c [C]e [C]m [C]i [C]a O 
in [C]i [C]n O 
leukocyte-endothelium [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]- [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]u [C]m O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
under [C]u [C]n [C]d [C]e [C]r O 
flow [C]f [C]l [C]o [C]w O 
conditions [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n [C]s O 
by [C]b [C]y O 
exposing [C]e [C]x [C]p [C]o [C]s [C]i [C]n [C]g O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
umbilical [C]u [C]m [C]b [C]i [C]l [C]i [C]c [C]a [C]l I-cell_type 
vein [C]v [C]e [C]i [C]n I-cell_type 
endothelial [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
for [C]f [C]o [C]r O 
24 [C]2 [C]4 O 
h [C]h O 
to [C]t [C]o O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
( [C]( O 
5 [C]5 O 
mM [C]m [C]M O 
) [C]) O 
, [C], O 
high [C]h [C]i [C]g [C]h O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
( [C]( O 
30 [C]3 [C]0 O 
mM [C]m [C]M O 
) [C]) O 
, [C], O 
advanced [C]a [C]d [C]v [C]a [C]n [C]c [C]e [C]d O 
glycosylation [C]g [C]l [C]y [C]c [C]o [C]s [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
end [C]e [C]n [C]d O 
product-albumin [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]- [C]a [C]l [C]b [C]u [C]m [C]i [C]n S-protein 
( [C]( O 
100 [C]1 [C]0 [C]0 O 
microg/ml [C]m [C]i [C]c [C]r [C]o [C]g [C]/ [C]m [C]l O 
) [C]) O 
, [C], O 
or [C]o [C]r O 
hyperglycemic [C]h [C]y [C]p [C]e [C]r [C]g [C]l [C]y [C]c [C]e [C]m [C]i [C]c O 
( [C]( O 
174-316 [C]1 [C]7 [C]4 [C]- [C]3 [C]1 [C]6 O 
mg/dl [C]m [C]g [C]/ [C]d [C]l O 
) [C]) O 
sera [C]s [C]e [C]r [C]a O 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
diabetes [C]d [C]i [C]a [C]b [C]e [C]t [C]e [C]s O 
and [C]a [C]n [C]d O 
abnormal [C]a [C]b [C]n [C]o [C]r [C]m [C]a [C]l O 
hemoglobin [C]h [C]e [C]m [C]o [C]g [C]l [C]o [C]b [C]i [C]n O 
A1c [C]A [C]1 [C]c O 
( [C]( O 
8.1+/-1.4 [C]8 [C]. [C]1 [C]+ [C]/ [C]- [C]1 [C]. [C]4 O 
% [C]% O 
) [C]) O 
. [C]. O 

At [C]A [C]t O 
the [C]t [C]h [C]e O 
end [C]e [C]n [C]d O 
of [C]o [C]f O 
incubation [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]i [C]o [C]n O 
endothelial [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
perfused [C]p [C]e [C]r [C]f [C]u [C]s [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
total [C]t [C]o [C]t [C]a [C]l O 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e O 
suspension [C]s [C]u [C]s [C]p [C]e [C]n [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
a [C]a O 
parallel [C]p [C]a [C]r [C]a [C]l [C]l [C]e [C]l O 
plate [C]p [C]l [C]a [C]t [C]e O 
flow [C]f [C]l [C]o [C]w O 
chamber [C]c [C]h [C]a [C]m [C]b [C]e [C]r O 
under [C]u [C]n [C]d [C]e [C]r O 
laminar [C]l [C]a [C]m [C]i [C]n [C]a [C]r O 
flow [C]f [C]l [C]o [C]w O 
( [C]( O 
1.5 [C]1 [C]. [C]5 O 
dyn/cm2 [C]d [C]y [C]n [C]/ [C]c [C]m [C]2 O 
) [C]) O 
. [C]. O 

Rolling [C]R [C]o [C]l [C]l [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
adherent [C]a [C]d [C]h [C]e [C]r [C]e [C]n [C]t B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
evaluated [C]e [C]v [C]a [C]l [C]u [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
digital [C]d [C]i [C]g [C]i [C]t [C]a [C]l O 
image [C]i [C]m [C]a [C]g [C]e O 
processing [C]p [C]r [C]o [C]c [C]e [C]s [C]s [C]i [C]n [C]g O 
. [C]. O 

Results [C]R [C]e [C]s [C]u [C]l [C]t [C]s O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
30 [C]3 [C]0 O 
mM [C]m [C]M O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
( [C]( O 
P [C]P O 
< [C]< O 
0.01 [C]0 [C]. [C]0 [C]1 O 
) [C]) O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
adherent [C]a [C]d [C]h [C]e [C]r [C]e [C]n [C]t B-cell_type 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
to [C]t [C]o O 
endothelial [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
respect [C]r [C]e [C]s [C]p [C]e [C]c [C]t O 
to [C]t [C]o O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
( [C]( O 
5 [C]5 O 
mM [C]m [C]M O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
; [C]; O 
151+/-19 [C]1 [C]5 [C]1 [C]+ [C]/ [C]- [C]1 [C]9 O 
versus [C]v [C]e [C]r [C]s [C]u [C]s O 
33+/-8 [C]3 [C]3 [C]+ [C]/ [C]- [C]8 O 
cells/mm2 [C]c [C]e [C]l [C]l [C]s [C]/ [C]m [C]m [C]2 O 
) [C]) O 
. [C]. O 

A [C]A O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
was [C]w [C]a [C]s O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
endothelial [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
IL-1beta [C]I [C]L [C]- [C]1 [C]b [C]e [C]t [C]a S-protein 
, [C], O 
here [C]h [C]e [C]r [C]e O 
used [C]u [C]s [C]e [C]d O 
as [C]a [C]s O 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
( [C]( O 
195+/-20 [C]1 [C]9 [C]5 [C]+ [C]/ [C]- [C]2 [C]0 O 
cells/mm2 [C]c [C]e [C]l [C]l [C]s [C]/ [C]m [C]m [C]2 O 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
rolling [C]r [C]o [C]l [C]l [C]i [C]n [C]g B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
on [C]o [C]n O 
endothelial [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
affected [C]a [C]f [C]f [C]e [C]c [C]t [C]e [C]d O 
by [C]b [C]y O 
high [C]h [C]i [C]g [C]h O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
. [C]. O 

Stable [C]S [C]t [C]a [C]b [C]l [C]e O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
to [C]t [C]o O 
glucose-treated [C]g [C]l [C]u [C]c [C]o [C]s [C]e [C]- [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
to [C]t [C]o O 
IL-1beta-stimulated [C]I [C]L [C]- [C]1 [C]b [C]e [C]t [C]a [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_type 
endothelial [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
was [C]w [C]a [C]s O 
preceded [C]p [C]r [C]e [C]c [C]e [C]d [C]e [C]d O 
by [C]b [C]y O 
short [C]s [C]h [C]o [C]r [C]t O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
endothelial [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
distance [C]d [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
travelled [C]t [C]r [C]a [C]v [C]e [C]l [C]l [C]e [C]d O 
by [C]b [C]y O 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
before [C]b [C]e [C]f [C]o [C]r [C]e O 
arrest [C]a [C]r [C]r [C]e [C]s [C]t O 
on [C]o [C]n O 
30 [C]3 [C]0 O 
mM [C]m [C]M O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
, [C], O 
or [C]o [C]r O 
on [C]o [C]n O 
IL-1beta-treated [C]I [C]L [C]- [C]1 [C]b [C]e [C]t [C]a [C]- [C]t [C]r [C]e [C]a [C]t [C]e [C]d B-cell_type 
endothelial [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
was [C]w [C]a [C]s O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
( [C]( O 
P [C]P O 
< [C]< O 
0.01 [C]0 [C]. [C]0 [C]1 O 
) [C]) O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
that [C]t [C]h [C]a [C]t O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
for [C]f [C]o [C]r O 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
adhering [C]a [C]d [C]h [C]e [C]r [C]i [C]n [C]g O 
on [C]o [C]n O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
endothelium [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]u [C]m O 
( [C]( O 
30 [C]3 [C]0 O 
mM [C]m [C]M O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
: [C]: O 
76.7+/-3.5 [C]7 [C]6 [C]. [C]7 [C]+ [C]/ [C]- [C]3 [C]. [C]5 O 
; [C]; O 
IL1beta [C]I [C]L [C]1 [C]b [C]e [C]t [C]a O 
: [C]: O 
69.7+/-4 [C]6 [C]9 [C]. [C]7 [C]+ [C]/ [C]- [C]4 O 
versus [C]v [C]e [C]r [C]s [C]u [C]s O 
5 [C]5 O 
mM [C]m [C]M O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
: [C]: O 
21.5+/-5 [C]2 [C]1 [C]. [C]5 [C]+ [C]/ [C]- [C]5 O 
microm [C]m [C]i [C]c [C]r [C]o [C]m O 
) [C]) O 
. [C]. O 

Functional [C]F [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
blocking [C]b [C]l [C]o [C]c [C]k [C]i [C]n [C]g O 
of [C]o [C]f O 
E-selectin [C]E [C]- [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]n S-protein 
, [C], O 
intercellular [C]i [C]n [C]t [C]e [C]r [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n I-protein 
molecule-1 [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]- [C]1 E-protein 
, [C], O 
and [C]a [C]n [C]d O 
vascular [C]v [C]a [C]s [C]c [C]u [C]l [C]a [C]r B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n I-protein 
molecule-1 [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]- [C]1 E-protein 
on [C]o [C]n O 
endothelial [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
corresponding [C]c [C]o [C]r [C]r [C]e [C]s [C]p [C]o [C]n [C]d [C]i [C]n [C]g O 
mouse [C]m [C]o [C]u [C]s [C]e B-protein 
mAb [C]m [C]A [C]b E-protein 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
glucose-induced [C]g [C]l [C]u [C]c [C]o [C]s [C]e [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
( [C]( O 
67+/-16 [C]6 [C]7 [C]+ [C]/ [C]- [C]1 [C]6 O 
, [C], O 
83+/-12 [C]8 [C]3 [C]+ [C]/ [C]- [C]1 [C]2 O 
, [C], O 
62+/-8 [C]6 [C]2 [C]+ [C]/ [C]- [C]8 O 
versus [C]v [C]e [C]r [C]s [C]u [C]s O 
144+/-21 [C]1 [C]4 [C]4 [C]+ [C]/ [C]- [C]2 [C]1 O 
cells/ [C]c [C]e [C]l [C]l [C]s [C]/ O 
mm2 [C]m [C]m [C]2 O 
) [C]) O 
. [C]. O 

Confocal [C]C [C]o [C]n [C]f [C]o [C]c [C]a [C]l O 
fluorescence [C]f [C]l [C]u [C]o [C]r [C]e [C]s [C]c [C]e [C]n [C]c [C]e O 
microscopy [C]m [C]i [C]c [C]r [C]o [C]s [C]c [C]o [C]p [C]y O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
30 [C]3 [C]0 O 
mM [C]m [C]M O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
an [C]a [C]n O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
endothelial [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
E-selectin [C]E [C]- [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]n S-protein 
, [C], O 
intercellular [C]i [C]n [C]t [C]e [C]r [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n I-protein 
molecule-1 [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]- [C]1 E-protein 
, [C], O 
and [C]a [C]n [C]d O 
vascular [C]v [C]a [C]s [C]c [C]u [C]l [C]a [C]r B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n I-protein 
molecule-1 [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]- [C]1 E-protein 
. [C]. O 

Electrophoretic [C]E [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
assay [C]a [C]s [C]s [C]a [C]y O 
of [C]o [C]f O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
umbilical [C]u [C]m [C]b [C]i [C]l [C]i [C]c [C]a [C]l I-cell_type 
vein [C]v [C]e [C]i [C]n I-cell_type 
endothelial [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
HUVEC [C]H [C]U [C]V [C]E [C]C O 
) [C]) O 
exposed [C]e [C]x [C]p [C]o [C]s [C]e [C]d O 
for [C]f [C]o [C]r O 
1 [C]1 O 
h [C]h O 
to [C]t [C]o O 
30 [C]3 [C]0 O 
mM [C]m [C]M O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
an [C]a [C]n O 
intense [C]i [C]n [C]t [C]e [C]n [C]s [C]e O 
NF-kB [C]N [C]F [C]- [C]k [C]B S-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Treatment [C]T [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
HUVEC [C]H [C]U [C]V [C]E [C]C O 
exposed [C]e [C]x [C]p [C]o [C]s [C]e [C]d O 
to [C]t [C]o O 
high [C]h [C]i [C]g [C]h O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
NF-kB [C]N [C]F [C]- [C]k [C]B B-protein 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s E-protein 
pyrrolidinedithiocarbamate [C]p [C]y [C]r [C]r [C]o [C]l [C]i [C]d [C]i [C]n [C]e [C]d [C]i [C]t [C]h [C]i [C]o [C]c [C]a [C]r [C]b [C]a [C]m [C]a [C]t [C]e O 
( [C]( O 
100 [C]1 [C]0 [C]0 O 
microM [C]m [C]i [C]c [C]r [C]o [C]M O 
) [C]) O 
and [C]a [C]n [C]d O 
tosyl-phe-chloromethylketone [C]t [C]o [C]s [C]y [C]l [C]- [C]p [C]h [C]e [C]- [C]c [C]h [C]l [C]o [C]r [C]o [C]m [C]e [C]t [C]h [C]y [C]l [C]k [C]e [C]t [C]o [C]n [C]e O 
( [C]( O 
25 [C]2 [C]5 O 
microM [C]m [C]i [C]c [C]r [C]o [C]M O 
) [C]) O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
( [C]( O 
P [C]P O 
< [C]< O 
0.05 [C]0 [C]. [C]0 [C]5 O 
) [C]) O 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
respect [C]r [C]e [C]s [C]p [C]e [C]c [C]t O 
to [C]t [C]o O 
HUVEC [C]H [C]U [C]V [C]E [C]C O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
alone [C]a [C]l [C]o [C]n [C]e O 
. [C]. O 

A [C]A O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
( [C]( O 
P [C]P O 
< [C]< O 
0.01 [C]0 [C]. [C]0 [C]1 O 
) [C]) O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
glucose-induced [C]g [C]l [C]u [C]c [C]o [C]s [C]e [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
after [C]a [C]f [C]t [C]e [C]r O 
blocking [C]b [C]l [C]o [C]c [C]k [C]i [C]n [C]g O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
C [C]C E-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
with [C]w [C]i [C]t [C]h O 
staurosporine [C]s [C]t [C]a [C]u [C]r [C]o [C]s [C]p [C]o [C]r [C]i [C]n [C]e O 
( [C]( O 
5 [C]5 O 
nM [C]n [C]M O 
) [C]) O 
. [C]. O 

When [C]W [C]h [C]e [C]n O 
HUVEC [C]H [C]U [C]V [C]E [C]C O 
were [C]w [C]e [C]r [C]e O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
antisense [C]a [C]n [C]t [C]i [C]s [C]e [C]n [C]s [C]e O 
oligodesoxynucleotides [C]o [C]l [C]i [C]g [C]o [C]d [C]e [C]s [C]o [C]x [C]y [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e [C]s O 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
PKCalpha [C]P [C]K [C]C [C]a [C]l [C]p [C]h [C]a B-protein 
and [C]a [C]n [C]d I-protein 
PKCepsilon [C]P [C]K [C]C [C]e [C]p [C]s [C]i [C]l [C]o [C]n I-protein 
isoforms [C]i [C]s [C]o [C]f [C]o [C]r [C]m [C]s E-protein 
before [C]b [C]e [C]f [C]o [C]r [C]e O 
the [C]t [C]h [C]e O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
30 [C]3 [C]0 O 
mM [C]m [C]M O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
, [C], O 
a [C]a O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
( [C]( O 
P [C]P O 
< [C]< O 
0.05 [C]0 [C]. [C]0 [C]5 O 
) [C]) O 
reduction [C]r [C]e [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
seen [C]s [C]e [C]e [C]n O 
. [C]. O 

Advanced [C]A [C]d [C]v [C]a [C]n [C]c [C]e [C]d O 
glycosylation [C]g [C]l [C]y [C]c [C]o [C]s [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
end [C]e [C]n [C]d O 
product-albumin [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]- [C]a [C]l [C]b [C]u [C]m [C]i [C]n S-protein 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
adhering [C]a [C]d [C]h [C]e [C]r [C]i [C]n [C]g B-cell_type 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
in [C]i [C]n O 
respect [C]r [C]e [C]s [C]p [C]e [C]c [C]t O 
to [C]t [C]o O 
native [C]n [C]a [C]t [C]i [C]v [C]e B-protein 
albumin [C]a [C]l [C]b [C]u [C]m [C]i [C]n E-protein 
used [C]u [C]s [C]e [C]d O 
as [C]a [C]s O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
( [C]( O 
110+/-16 [C]1 [C]1 [C]0 [C]+ [C]/ [C]- [C]1 [C]6 O 
versus [C]v [C]e [C]r [C]s [C]u [C]s O 
66+/-7 [C]6 [C]6 [C]+ [C]/ [C]- [C]7 O 
, [C], O 
P [C]P O 
< [C]< O 
0.01 [C]0 [C]. [C]0 [C]1 O 
) [C]) O 
. [C]. O 

Sera [C]S [C]e [C]r [C]a O 
from [C]f [C]r [C]o [C]m O 
diabetic [C]d [C]i [C]a [C]b [C]e [C]t [C]i [C]c O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
( [C]( O 
P [C]P O 
< [C]< O 
0.01 [C]0 [C]. [C]0 [C]1 O 
) [C]) O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
as [C]a [C]s O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
, [C], O 
despite [C]d [C]e [C]s [C]p [C]i [C]t [C]e O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
IL-1beta [C]I [C]L [C]- [C]1 [C]b [C]e [C]t [C]a S-protein 
and [C]a [C]n [C]d O 
TNFalpha [C]T [C]N [C]F [C]a [C]l [C]p [C]h [C]a S-protein 
in [C]i [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
sera [C]s [C]e [C]r [C]a O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
high [C]h [C]i [C]g [C]h O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
hyperglycemia [C]h [C]y [C]p [C]e [C]r [C]g [C]l [C]y [C]c [C]e [C]m [C]i [C]a O 
promote [C]p [C]r [C]o [C]m [C]o [C]t [C]e O 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
endothelium [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]u [C]m O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
upregulation [C]u [C]p [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cell [C]c [C]e [C]l [C]l O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
adhesive [C]a [C]d [C]h [C]e [C]s [C]i [C]v [C]e O 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s O 
, [C], O 
possibly [C]p [C]o [C]s [C]s [C]i [C]b [C]l [C]y O 
depending [C]d [C]e [C]p [C]e [C]n [C]d [C]i [C]n [C]g O 
on [C]o [C]n O 
NF-kB [C]N [C]F [C]- [C]k [C]B S-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Ikaros [C]I [C]k [C]a [C]r [C]o [C]s S-protein 
in [C]i [C]n O 
hemopoietic [C]h [C]e [C]m [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c O 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e O 
determination [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
homeostasis [C]h [C]o [C]m [C]e [C]o [C]s [C]t [C]a [C]s [C]i [C]s O 
. [C]. O 

Studies [C]S [C]t [C]u [C]d [C]i [C]e [C]s O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
that [C]t [C]h [C]a [C]t O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
hemopoietic [C]h [C]e [C]m [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
have [C]h [C]a [C]v [C]e O 
focused [C]f [C]o [C]c [C]u [C]s [C]e [C]d O 
on [C]o [C]n O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
cascades [C]c [C]a [C]s [C]c [C]a [C]d [C]e [C]s O 
and [C]a [C]n [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
effectors [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r [C]s O 
that [C]t [C]h [C]a [C]t O 
drive [C]d [C]r [C]i [C]v [C]e O 
this [C]t [C]h [C]i [C]s O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
developmental [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t [C]a [C]l O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
in [C]i [C]n O 
a [C]a O 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
fashion [C]f [C]a [C]s [C]h [C]i [C]o [C]n O 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
we [C]w [C]e O 
review [C]r [C]e [C]v [C]i [C]e [C]w O 
the [C]t [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
Ikaros [C]I [C]k [C]a [C]r [C]o [C]s S-protein 
, [C], O 
the [C]t [C]h [C]e O 
founding [C]f [C]o [C]u [C]n [C]d [C]i [C]n [C]g O 
member [C]m [C]e [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
a [C]a O 
unique [C]u [C]n [C]i [C]q [C]u [C]e O 
family [C]f [C]a [C]m [C]i [C]l [C]y O 
of [C]o [C]f O 
zinc [C]z [C]i [C]n [C]c B-protein 
finger [C]f [C]i [C]n [C]g [C]e [C]r I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
this [C]t [C]h [C]i [C]s O 
developmental [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t [C]a [C]l O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
. [C]. O 

Studies [C]S [C]t [C]u [C]d [C]i [C]e [C]s O 
on [C]o [C]n O 
an [C]a [C]n O 
Ikaros [C]I [C]k [C]a [C]r [C]o [C]s S-protein 
null [C]n [C]u [C]l [C]l O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
have [C]h [C]a [C]v [C]e O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
an [C]a [C]n O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
role [C]r [C]o [C]l [C]e O 
for [C]f [C]o [C]r O 
this [C]t [C]h [C]i [C]s O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
in [C]i [C]n O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d O 
cell [C]c [C]e [C]l [C]l O 
fate [C]f [C]a [C]t [C]e O 
determination [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
at [C]a [C]t O 
subsequent [C]s [C]u [C]b [C]s [C]e [C]q [C]u [C]e [C]n [C]t O 
branch [C]b [C]r [C]a [C]n [C]c [C]h O 
points [C]p [C]o [C]i [C]n [C]t [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
. [C]. O 

Differences [C]D [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
phenotypes [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e [C]s O 
of [C]o [C]f O 
a [C]a O 
null [C]n [C]u [C]l [C]l O 
and [C]a [C]n [C]d O 
a [C]a O 
dominant [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t B-DNA 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e I-DNA 
( [C]( I-DNA 
DN [C]D [C]N I-DNA 
) [C]) I-DNA 
Ikaros [C]I [C]k [C]a [C]r [C]o [C]s I-DNA 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n E-DNA 
provide [C]p [C]r [C]o [C]v [C]i [C]d [C]e O 
insight [C]i [C]n [C]s [C]i [C]g [C]h [C]t O 
into [C]i [C]n [C]t [C]o O 
a [C]a O 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
network [C]n [C]e [C]t [C]w [C]o [C]r [C]k O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
which [C]w [C]h [C]i [C]c [C]h O 
Ikaros [C]I [C]k [C]a [C]r [C]o [C]s B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
exert [C]e [C]x [C]e [C]r [C]t O 
their [C]t [C]h [C]e [C]i [C]r O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
in [C]i [C]n O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
a [C]a O 
comparative [C]c [C]o [C]m [C]p [C]a [C]r [C]a [C]t [C]i [C]v [C]e O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
hemopoietic [C]h [C]e [C]m [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c B-cell_type 
stem [C]s [C]t [C]e [C]m I-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
and [C]a [C]n [C]d O 
precursor [C]p [C]r [C]e [C]c [C]u [C]r [C]s [C]o [C]r O 
compartment [C]c [C]o [C]m [C]p [C]a [C]r [C]t [C]m [C]e [C]n [C]t O 
resulting [C]r [C]e [C]s [C]u [C]l [C]t [C]i [C]n [C]g O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
two [C]t [C]w [C]o O 
Ikaros [C]I [C]k [C]a [C]r [C]o [C]s B-DNA 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s E-DNA 
reveals [C]r [C]e [C]v [C]e [C]a [C]l [C]s O 
a [C]a O 
profound [C]p [C]r [C]o [C]f [C]o [C]u [C]n [C]d O 
yet [C]y [C]e [C]t O 
not [C]n [C]o [C]t O 
absolute [C]a [C]b [C]s [C]o [C]l [C]u [C]t [C]e O 
requirement [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]m [C]e [C]n [C]t O 
for [C]f [C]o [C]r O 
Ikaros [C]I [C]k [C]a [C]r [C]o [C]s S-protein 

Induction [C]I [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
early [C]e [C]a [C]r [C]l [C]y B-protein 
B [C]B I-protein 
cell [C]c [C]e [C]l [C]l I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
( [C]( O 
EBF [C]E [C]B [C]F S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
multiple [C]m [C]u [C]l [C]t [C]i [C]p [C]l [C]e B-DNA 
B [C]B I-DNA 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
basic [C]b [C]a [C]s [C]i [C]c B-protein 
helix-loop-helix [C]h [C]e [C]l [C]i [C]x [C]- [C]l [C]o [C]o [C]p [C]- [C]h [C]e [C]l [C]i [C]x I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
E12 [C]E [C]1 [C]2 S-protein 
. [C]. O 

The [C]T [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
encoded [C]e [C]n [C]c [C]o [C]d [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
E2A [C]E [C]2 [C]A S-protein 
and [C]a [C]n [C]d O 
early [C]e [C]a [C]r [C]l [C]y B-protein 
B [C]B I-protein 
cell [C]c [C]e [C]l [C]l I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
( [C]( O 
EBF [C]E [C]B [C]F S-protein 
) [C]) O 
genes [C]g [C]e [C]n [C]e [C]s O 
are [C]a [C]r [C]e O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
proper [C]p [C]r [C]o [C]p [C]e [C]r O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
B [C]B B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
the [C]t [C]h [C]e O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
B [C]B B-cell_type 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
E2A- [C]E [C]2 [C]A [C]- O 
and [C]a [C]n [C]d O 
EBF-deficient [C]E [C]B [C]F [C]- [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
mice [C]m [C]i [C]c [C]e O 
has [C]h [C]a [C]s O 
made [C]m [C]a [C]d [C]e O 
it [C]i [C]t O 
difficult [C]d [C]i [C]f [C]f [C]i [C]c [C]u [C]l [C]t O 
to [C]t [C]o O 
determine [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e O 
the [C]t [C]h [C]e O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
or [C]o [C]r O 
relationship [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n [C]s [C]h [C]i [C]p O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s O 
. [C]. O 

We [C]W [C]e O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
the [C]t [C]h [C]e O 
identification [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
model [C]m [C]o [C]d [C]e [C]l O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
in [C]i [C]n O 
which [C]w [C]h [C]i [C]c [C]h O 
the [C]t [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
E2A [C]E [C]2 [C]A S-protein 
and [C]a [C]n [C]d O 
EBF [C]E [C]B [C]F S-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
multiple [C]m [C]u [C]l [C]t [C]i [C]p [C]l [C]e O 
B [C]B O 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e O 
traits [C]t [C]r [C]a [C]i [C]t [C]s O 
can [C]c [C]a [C]n O 
be [C]b [C]e O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
. [C]. O 

We [C]W [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
conversion [C]c [C]o [C]n [C]v [C]e [C]r [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
70Z/3 [C]7 [C]0 [C]Z [C]/ [C]3 B-cell_line 
pre-B [C]p [C]r [C]e [C]- [C]B I-cell_line 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_line 
to [C]t [C]o O 
cells [C]c [C]e [C]l [C]l [C]s O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
macrophage-like [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]- [C]l [C]i [C]k [C]e O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
is [C]i [C]s O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
loss [C]l [C]o [C]s [C]s O 
of [C]o [C]f O 
E2A [C]E [C]2 [C]A S-protein 
and [C]a [C]n [C]d O 
EBF [C]E [C]B [C]F S-protein 
. [C]. O 

Moreover [C]M [C]o [C]r [C]e [C]o [C]v [C]e [C]r O 
, [C], O 
we [C]w [C]e O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
ectopic [C]e [C]c [C]t [C]o [C]p [C]i [C]c O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
E2A [C]E [C]2 [C]A S-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
E12 [C]E [C]1 [C]2 S-protein 
in [C]i [C]n O 
this [C]t [C]h [C]i [C]s O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e B-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
many [C]m [C]a [C]n [C]y B-DNA 
B [C]B I-DNA 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
EBF [C]E [C]B [C]F S-protein 
, [C], O 
IL7Ralpha [C]I [C]L [C]7 [C]R [C]a [C]l [C]p [C]h [C]a S-protein 
, [C], O 
lambda5 [C]l [C]a [C]m [C]b [C]d [C]a [C]5 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
Rag-1 [C]R [C]a [C]g [C]- [C]1 O 
, [C], O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
to [C]t [C]o O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
kappa [C]k [C]a [C]p [C]p [C]a B-protein 
light [C]l [C]i [C]g [C]h [C]t I-protein 
chain [C]c [C]h [C]a [C]i [C]n E-protein 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
mitogen [C]m [C]i [C]t [C]o [C]g [C]e [C]n O 
. [C]. O 

Activation [C]A [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
EBF [C]E [C]B [C]F S-protein 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
one [C]o [C]n [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
critical [C]c [C]r [C]i [C]t [C]i [C]c [C]a [C]l O 
functions [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
E12 [C]E [C]1 [C]2 S-protein 
in [C]i [C]n O 
regulating [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
B [C]B O 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
since [C]s [C]i [C]n [C]c [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
EBF [C]E [C]B [C]F S-protein 
alone [C]a [C]l [C]o [C]n [C]e O 
leads [C]l [C]e [C]a [C]d [C]s O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
subset [C]s [C]u [C]b [C]s [C]e [C]t O 
of [C]o [C]f O 
E12 [C]E [C]1 [C]2 S-protein 
-inducible [C]- [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
traits [C]t [C]r [C]a [C]i [C]t [C]s O 
. [C]. O 

Our [C]O [C]u [C]r O 
data [C]d [C]a [C]t [C]a O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
, [C], O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
context [C]c [C]o [C]n [C]t [C]e [C]x [C]t O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e B-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
, [C], O 
E12 [C]E [C]1 [C]2 S-protein 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
EBF [C]E [C]B [C]F S-protein 
and [C]a [C]n [C]d O 
together [C]t [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
these [C]t [C]h [C]e [C]s [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
coordinately [C]c [C]o [C]o [C]r [C]d [C]i [C]n [C]a [C]t [C]e [C]l [C]y O 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
numerous [C]n [C]u [C]m [C]e [C]r [C]o [C]u [C]s O 
B [C]B B-DNA 
lineage-associated [C]l [C]i [C]n [C]e [C]a [C]g [C]e [C]- [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
. [C]. O 

Activation-induced [C]A [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
down-regulation [C]d [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
retinoid [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
RXRalpha [C]R [C]X [C]R [C]a [C]l [C]p [C]h [C]a E-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

Role [C]R [C]o [C]l [C]e O 
of [C]o [C]f O 
cell [C]c [C]e [C]l [C]l O 
cycle [C]c [C]y [C]c [C]l [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

A [C]A O 
5.4-kilobase [C]5 [C]. [C]4 [C]- [C]k [C]i [C]l [C]o [C]b [C]a [C]s [C]e B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
, [C], O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
down-regulated [C]d [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
after [C]a [C]f [C]t [C]e [C]r O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
PBMCs [C]P [C]B [C]M [C]C [C]s S-cell_type 
) [C]) O 
with [C]w [C]i [C]t [C]h O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
T [C]T O 
cell-activating [C]c [C]e [C]l [C]l [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]n [C]g O 
agents [C]a [C]g [C]e [C]n [C]t [C]s O 
, [C], O 
was [C]w [C]a [C]s O 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d O 
using [C]u [C]s [C]i [C]n [C]g O 
an [C]a [C]n O 
mRNA [C]m [C]R [C]N [C]A O 
differential [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l O 
display [C]d [C]i [C]s [C]p [C]l [C]a [C]y O 
method [C]m [C]e [C]t [C]h [C]o [C]d O 
. [C]. O 

Nucleotide [C]N [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e O 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
the [C]t [C]h [C]e O 
5 [C]5 B-RNA 
' [C]' I-RNA 
end [C]e [C]n [C]d E-RNA 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
RNA [C]R [C]N [C]A S-RNA 
as [C]a [C]s O 
human [C]h [C]u [C]m [C]a [C]n B-RNA 
retinoid [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]d I-RNA 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-RNA 
RXRalpha [C]R [C]X [C]R [C]a [C]l [C]p [C]h [C]a I-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
, [C], O 
we [C]w [C]e O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
the [C]t [C]h [C]e O 
nucleotide [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e O 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
3.6 [C]3 [C]. [C]6 B-DNA 
kilobases [C]k [C]i [C]l [C]o [C]b [C]a [C]s [C]e [C]s E-DNA 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
RNA [C]R [C]N [C]A O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
represents [C]r [C]e [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]s O 
the [C]t [C]h [C]e O 
3 [C]3 B-RNA 
' [C]' I-RNA 
end [C]e [C]n [C]d E-RNA 
of [C]o [C]f O 
RXRalpha [C]R [C]X [C]R [C]a [C]l [C]p [C]h [C]a B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
, [C], O 
the [C]t [C]h [C]e O 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
which [C]w [C]h [C]i [C]c [C]h O 
has [C]h [C]a [C]s O 
not [C]n [C]o [C]t O 
been [C]b [C]e [C]e [C]n O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
described [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
. [C]. O 

Activated [C]A [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
PBMCs [C]P [C]B [C]M [C]C [C]s S-cell_type 
also [C]a [C]l [C]s [C]o O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
lower [C]l [C]o [C]w [C]e [C]r O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
RXRalpha [C]R [C]X [C]R [C]a [C]l [C]p [C]h [C]a S-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
a [C]a O 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
assay [C]a [C]s [C]s [C]a [C]y O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
activation-induced [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
loss [C]l [C]o [C]s [C]s O 
of [C]o [C]f O 
RXRalpha [C]R [C]X [C]R [C]a [C]l [C]p [C]h [C]a B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
and [C]a [C]n [C]d O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
loss [C]l [C]o [C]s [C]s O 
of [C]o [C]f O 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
. [C]. O 

We [C]W [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
transition [C]t [C]r [C]a [C]n [C]s [C]i [C]t [C]i [C]o [C]n O 
from [C]f [C]r [C]o [C]m O 
G0/G1 [C]G [C]0 [C]/ [C]G [C]1 O 
to [C]t [C]o O 
S [C]S O 
phase [C]p [C]h [C]a [C]s [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cell [C]c [C]e [C]l [C]l O 
cycle [C]c [C]y [C]c [C]l [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
down-regulation [C]d [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
RXRalpha [C]R [C]X [C]R [C]a [C]l [C]p [C]h [C]a S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
cell [C]c [C]e [C]l [C]l O 
cycle [C]c [C]y [C]c [C]l [C]e O 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
block [C]b [C]l [C]o [C]c [C]k O 
the [C]t [C]h [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
in [C]i [C]n O 
G1 [C]G [C]1 O 
phase [C]p [C]h [C]a [C]s [C]e O 
, [C], O 
prevent [C]p [C]r [C]e [C]v [C]e [C]n [C]t O 
this [C]t [C]h [C]i [C]s O 
down-regulation [C]d [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
RXRalpha [C]R [C]X [C]R [C]a [C]l [C]p [C]h [C]a B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
post-transcriptional [C]p [C]o [C]s [C]t [C]- [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
level [C]l [C]e [C]v [C]e [C]l O 
and [C]a [C]n [C]d O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
new [C]n [C]e [C]w O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
observations [C]o [C]b [C]s [C]e [C]r [C]v [C]a [C]t [C]i [C]o [C]n [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
RXRalpha [C]R [C]X [C]R [C]a [C]l [C]p [C]h [C]a S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
T [C]T O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s O 
are [C]a [C]r [C]e O 
coupled [C]c [C]o [C]u [C]p [C]l [C]e [C]d O 
to [C]t [C]o O 
cell [C]c [C]e [C]l [C]l O 
cycle [C]c [C]y [C]c [C]l [C]e O 
progression [C]p [C]r [C]o [C]g [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
there [C]t [C]h [C]e [C]r [C]e O 
is [C]i [C]s O 
tight [C]t [C]i [C]g [C]h [C]t O 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
of [C]o [C]f O 
RXRalpha [C]R [C]X [C]R [C]a [C]l [C]p [C]h [C]a S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
transition [C]t [C]r [C]a [C]n [C]s [C]i [C]t [C]i [C]o [C]n O 
from [C]f [C]r [C]o [C]m O 
G0/G1 [C]G [C]0 [C]/ [C]G [C]1 O 
to [C]t [C]o O 
S [C]S O 
phase [C]p [C]h [C]a [C]s [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cell [C]c [C]e [C]l [C]l O 
cycle [C]c [C]y [C]c [C]l [C]e O 
. [C]. O 

Epidemiology [C]E [C]p [C]i [C]d [C]e [C]m [C]i [C]o [C]l [C]o [C]g [C]y O 
and [C]a [C]n [C]d O 
pathogenesis [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
AIDS-related [C]A [C]I [C]D [C]S [C]- [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
lymphomas [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a [C]s O 
. [C]. O 

Among [C]A [C]m [C]o [C]n [C]g O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
congenital [C]c [C]o [C]n [C]g [C]e [C]n [C]i [C]t [C]a [C]l O 
and [C]a [C]n [C]d O 
acquired [C]a [C]c [C]q [C]u [C]i [C]r [C]e [C]d O 
immunodeficiencies [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]i [C]e [C]s O 
, [C], O 
non-Hodgkin [C]n [C]o [C]n [C]- [C]H [C]o [C]d [C]g [C]k [C]i [C]n O 
's [C]' [C]s O 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a O 
( [C]( O 
NHLs [C]N [C]H [C]L [C]s O 
) [C]) O 
are [C]a [C]r [C]e O 
the [C]t [C]h [C]e O 
most [C]m [C]o [C]s [C]t O 
common [C]c [C]o [C]m [C]m [C]o [C]n O 
tumors [C]t [C]u [C]m [C]o [C]r [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
. [C]. O 

In [C]I [C]n O 
the [C]t [C]h [C]e O 
setting [C]s [C]e [C]t [C]t [C]i [C]n [C]g O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n O 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
virus [C]v [C]i [C]r [C]u [C]s O 
( [C]( O 
HIV [C]H [C]I [C]V O 
) [C]) O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
, [C], O 
as [C]a [C]s O 
many [C]m [C]a [C]n [C]y O 
as [C]a [C]s O 
10 [C]1 [C]0 O 
% [C]% O 
to [C]t [C]o O 
20 [C]2 [C]0 O 
% [C]% O 
of [C]o [C]f O 
people [C]p [C]e [C]o [C]p [C]l [C]e O 
ultimately [C]u [C]l [C]t [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
developed [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]e [C]d O 
NHLs [C]N [C]H [C]L [C]s O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
tumors [C]t [C]u [C]m [C]o [C]r [C]s O 
are [C]a [C]r [C]e O 
clinically [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l [C]l [C]y O 
aggressive [C]a [C]g [C]g [C]r [C]e [C]s [C]s [C]i [C]v [C]e O 
, [C], O 
frequently [C]f [C]r [C]e [C]q [C]u [C]e [C]n [C]t [C]l [C]y O 
involve [C]i [C]n [C]v [C]o [C]l [C]v [C]e O 
extranodal [C]e [C]x [C]t [C]r [C]a [C]n [C]o [C]d [C]a [C]l O 
sites [C]s [C]i [C]t [C]e [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
often [C]o [C]f [C]t [C]e [C]n O 
exhibit [C]e [C]x [C]h [C]i [C]b [C]i [C]t O 
unique [C]u [C]n [C]i [C]q [C]u [C]e O 
features [C]f [C]e [C]a [C]t [C]u [C]r [C]e [C]s O 
that [C]t [C]h [C]a [C]t O 
distinguish [C]d [C]i [C]s [C]t [C]i [C]n [C]g [C]u [C]i [C]s [C]h O 
them [C]t [C]h [C]e [C]m O 
from [C]f [C]r [C]o [C]m O 
NHL [C]N [C]H [C]L O 
arising [C]a [C]r [C]i [C]s [C]i [C]n [C]g O 
in [C]i [C]n O 
individuals [C]i [C]n [C]d [C]i [C]v [C]i [C]d [C]u [C]a [C]l [C]s O 
with [C]w [C]i [C]t [C]h O 
other [C]o [C]t [C]h [C]e [C]r O 
forms [C]f [C]o [C]r [C]m [C]s O 
of [C]o [C]f O 
immunosuppression [C]i [C]m [C]m [C]u [C]n [C]o [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Important [C]I [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
HIV-associated [C]H [C]I [C]V [C]- [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
NHL [C]N [C]H [C]L O 
are [C]a [C]r [C]e O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
and [C]a [C]n [C]d O 
other [C]o [C]t [C]h [C]e [C]r O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
that [C]t [C]h [C]a [C]t O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
the [C]t [C]h [C]e O 
likelihood [C]l [C]i [C]k [C]e [C]l [C]i [C]h [C]o [C]o [C]d O 
of [C]o [C]f O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
c-myc [C]c [C]- [C]m [C]y [C]c S-DNA 
, [C], O 
bcl-6 [C]b [C]c [C]l [C]- [C]6 S-DNA 
, [C], O 
and [C]a [C]n [C]d O 
other [C]o [C]t [C]h [C]e [C]r O 
tumor-suppressor [C]t [C]u [C]m [C]o [C]r [C]- [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]o [C]r B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
with [C]w [C]i [C]t [C]h O 
carcinogenic [C]c [C]a [C]r [C]c [C]i [C]n [C]o [C]g [C]e [C]n [C]i [C]c O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
. [C]. O 

Specific [C]S [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
forms [C]f [C]o [C]r [C]m [C]s O 
of [C]o [C]f O 
HIV-associated [C]H [C]I [C]V [C]- [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
NHL [C]N [C]H [C]L O 
are [C]a [C]r [C]e O 
linked [C]l [C]i [C]n [C]k [C]e [C]d O 
to [C]t [C]o O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
Epstein-Barr [C]E [C]p [C]s [C]t [C]e [C]i [C]n [C]- [C]B [C]a [C]r [C]r B-protein 
virus [C]v [C]i [C]r [C]u [C]s I-protein 
( [C]( I-protein 
EBV [C]E [C]B [C]V I-protein 
) [C]) I-protein 
-latent [C]- [C]l [C]a [C]t [C]e [C]n [C]t I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
; [C]; O 
the [C]t [C]h [C]e O 
newly [C]n [C]e [C]w [C]l [C]y O 
described [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
DNA [C]D [C]N [C]A O 
virus [C]v [C]i [C]r [C]u [C]s O 
, [C], O 
Karposi [C]K [C]a [C]r [C]p [C]o [C]s [C]i O 
's [C]' [C]s O 
sarcoma-associated [C]s [C]a [C]r [C]c [C]o [C]m [C]a [C]- [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
herpesvirus/human [C]h [C]e [C]r [C]p [C]e [C]s [C]v [C]i [C]r [C]u [C]s [C]/ [C]h [C]u [C]m [C]a [C]n O 
herpesvirus-8 [C]h [C]e [C]r [C]p [C]e [C]s [C]v [C]i [C]r [C]u [C]s [C]- [C]8 O 
( [C]( O 
KSHV/HHV-8 [C]K [C]S [C]H [C]V [C]/ [C]H [C]H [C]V [C]- [C]8 O 
) [C]) O 
; [C]; O 
and [C]a [C]n [C]d O 
perhaps [C]p [C]e [C]r [C]h [C]a [C]p [C]s O 
HIV [C]H [C]I [C]V O 
. [C]. O 

Elucidation [C]E [C]l [C]u [C]c [C]i [C]d [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
that [C]t [C]h [C]a [C]t O 
contribute [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
high [C]h [C]i [C]g [C]h O 
incidence [C]i [C]n [C]c [C]i [C]d [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
NHL [C]N [C]H [C]L O 
among [C]a [C]m [C]o [C]n [C]g O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
infected [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
HIV [C]H [C]I [C]V O 
provides [C]p [C]r [C]o [C]v [C]i [C]d [C]e [C]s O 
insights [C]i [C]n [C]s [C]i [C]g [C]h [C]t [C]s O 
into [C]i [C]n [C]t [C]o O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s O 
of [C]o [C]f O 
lymphomagenesis [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
. [C]. O 

Matrix [C]M [C]a [C]t [C]r [C]i [C]x B-protein 
metalloproteinase [C]m [C]e [C]t [C]a [C]l [C]l [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]a [C]s [C]e E-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
: [C]: O 
an [C]a [C]n O 
immunohistochemical [C]i [C]m [C]m [C]u [C]n [C]o [C]h [C]i [C]s [C]t [C]o [C]c [C]h [C]e [C]m [C]i [C]c [C]a [C]l O 
study [C]s [C]t [C]u [C]d [C]y O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
cathepsin [C]c [C]a [C]t [C]h [C]e [C]p [C]s [C]i [C]n B-protein 
D [C]D E-protein 
, [C], O 
type [C]t [C]y [C]p [C]e B-protein 
IV [C]I [C]V I-protein 
collagen [C]c [C]o [C]l [C]l [C]a [C]g [C]e [C]n E-protein 
, [C], O 
laminin [C]l [C]a [C]m [C]i [C]n [C]i [C]n S-protein 
, [C], O 
fibronectin [C]f [C]i [C]b [C]r [C]o [C]n [C]e [C]c [C]t [C]i [C]n S-protein 
, [C], O 
EGFR [C]E [C]G [C]F [C]R S-protein 
, [C], O 
c-erbB-2 [C]c [C]- [C]e [C]r [C]b [C]B [C]- [C]2 B-protein 
oncoprotein [C]o [C]n [C]c [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
, [C], O 
p53 [C]p [C]5 [C]3 S-protein 
, [C], O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
status [C]s [C]t [C]a [C]t [C]u [C]s O 
and [C]a [C]n [C]d O 
proliferative [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
indices [C]i [C]n [C]d [C]i [C]c [C]e [C]s O 
. [C]. O 

Matrix [C]M [C]a [C]t [C]r [C]i [C]x B-protein 
metalloproteinase [C]m [C]e [C]t [C]a [C]l [C]l [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]a [C]s [C]e E-protein 
s [C]s O 
( [C]( O 
MMPs [C]M [C]M [C]P [C]s S-protein 
) [C]) O 
are [C]a [C]r [C]e O 
a [C]a O 
group [C]g [C]r [C]o [C]u [C]p O 
of [C]o [C]f O 
enzymes [C]e [C]n [C]z [C]y [C]m [C]e [C]s O 
thought [C]t [C]h [C]o [C]u [C]g [C]h [C]t O 
to [C]t [C]o O 
be [C]b [C]e O 
responsible [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]b [C]l [C]e O 
for [C]f [C]o [C]r O 
both [C]b [C]o [C]t [C]h O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
connective [C]c [C]o [C]n [C]n [C]e [C]c [C]t [C]i [C]v [C]e O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
matrix [C]m [C]a [C]t [C]r [C]i [C]x O 
remodelling [C]r [C]e [C]m [C]o [C]d [C]e [C]l [C]l [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
accelerated [C]a [C]c [C]c [C]e [C]l [C]e [C]r [C]a [C]t [C]e [C]d O 
breakdown [C]b [C]r [C]e [C]a [C]k [C]d [C]o [C]w [C]n O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
tumour [C]t [C]u [C]m [C]o [C]u [C]r O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
. [C]. O 

The [C]T [C]h [C]e O 
current [C]c [C]u [C]r [C]r [C]e [C]n [C]t O 
study [C]s [C]t [C]u [C]d [C]y O 
aimed [C]a [C]i [C]m [C]e [C]d O 
to [C]t [C]o O 
investigate [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
immunohistochemical [C]i [C]m [C]m [C]u [C]n [C]o [C]h [C]i [C]s [C]t [C]o [C]c [C]h [C]e [C]m [C]i [C]c [C]a [C]l O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
matrix [C]m [C]a [C]t [C]r [C]i [C]x B-protein 
metalloproteinase [C]m [C]e [C]t [C]a [C]l [C]l [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]a [C]s [C]e I-protein 
3 [C]3 E-protein 
( [C]( O 
MMP-3 [C]M [C]M [C]P [C]- [C]3 S-protein 
, [C], O 
stromelysin-1 [C]s [C]t [C]r [C]o [C]m [C]e [C]l [C]y [C]s [C]i [C]n [C]- [C]1 S-protein 
) [C]) O 
in [C]i [C]n O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
Basement [C]B [C]a [C]s [C]e [C]m [C]e [C]n [C]t B-protein 
Membrane [C]M [C]e [C]m [C]b [C]r [C]a [C]n [C]e I-protein 
( [C]( I-protein 
BM [C]B [C]M I-protein 
) [C]) I-protein 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n E-protein 
( [C]( O 
type [C]t [C]y [C]p [C]e B-protein 
IV [C]I [C]V I-protein 
collagen [C]c [C]o [C]l [C]l [C]a [C]g [C]e [C]n E-protein 
, [C], O 
laminin [C]l [C]a [C]m [C]i [C]n [C]i [C]n S-protein 
) [C]) O 
, [C], O 
fibronectin [C]f [C]i [C]b [C]r [C]o [C]n [C]e [C]c [C]t [C]i [C]n S-protein 
, [C], O 
cathepsin [C]c [C]a [C]t [C]h [C]e [C]p [C]s [C]i [C]n B-protein 
D [C]D E-protein 
, [C], O 
p53 [C]p [C]5 [C]3 S-protein 
, [C], O 
c-erbB-2 [C]c [C]- [C]e [C]r [C]b [C]B [C]- [C]2 S-protein 
, [C], O 
proliferative [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
( [C]( O 
Ki-67 [C]K [C]i [C]- [C]6 [C]7 S-protein 
, [C], O 
PCNA [C]P [C]C [C]N [C]A S-protein 
) [C]) O 
, [C], O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
other [C]o [C]t [C]h [C]e [C]r O 
conventional [C]c [C]o [C]n [C]v [C]e [C]n [C]t [C]i [C]o [C]n [C]a [C]l O 
clinicopathological [C]c [C]l [C]i [C]n [C]i [C]c [C]o [C]p [C]a [C]t [C]h [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
parameters [C]p [C]a [C]r [C]a [C]m [C]e [C]t [C]e [C]r [C]s O 
in [C]i [C]n O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
was [C]w [C]a [C]s O 
performed [C]p [C]e [C]r [C]f [C]o [C]r [C]m [C]e [C]d O 
on [C]o [C]n O 
a [C]a O 
series [C]s [C]e [C]r [C]i [C]e [C]s O 
of [C]o [C]f O 
frozen [C]f [C]r [C]o [C]z [C]e [C]n O 
and [C]a [C]n [C]d O 
paraffin [C]p [C]a [C]r [C]a [C]f [C]f [C]i [C]n O 
sections [C]s [C]e [C]c [C]t [C]i [C]o [C]n [C]s O 
from [C]f [C]r [C]o [C]m O 
84 [C]8 [C]4 O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
specimens [C]s [C]p [C]e [C]c [C]i [C]m [C]e [C]n [C]s O 
by [C]b [C]y O 
immunohistochemistry [C]i [C]m [C]m [C]u [C]n [C]o [C]h [C]i [C]s [C]t [C]o [C]c [C]h [C]e [C]m [C]i [C]s [C]t [C]r [C]y O 
using [C]u [C]s [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
monoclonal [C]m [C]o [C]n [C]o [C]c [C]l [C]o [C]n [C]a [C]l B-protein 
antibody [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y I-protein 
MMP-3 [C]M [C]M [C]P [C]- [C]3 E-protein 
( [C]( O 
Ab-1 [C]A [C]b [C]- [C]1 S-protein 
) [C]) O 
. [C]. O 

Stromelysin-1 [C]S [C]t [C]r [C]o [C]m [C]e [C]l [C]y [C]s [C]i [C]n [C]- [C]1 S-protein 
( [C]( O 
ST1 [C]S [C]T [C]1 S-protein 
) [C]) O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
about [C]a [C]b [C]o [C]u [C]t O 
10 [C]1 [C]0 O 
% [C]% O 
of [C]o [C]f O 
epithelial [C]e [C]p [C]i [C]t [C]h [C]e [C]l [C]i [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
groups [C]g [C]r [C]o [C]u [C]p [C]s O 
( [C]( O 
cases [C]c [C]a [C]s [C]e [C]s O 
of [C]o [C]f O 
fibrocystic [C]f [C]i [C]b [C]r [C]o [C]c [C]y [C]s [C]t [C]i [C]c O 
and [C]a [C]n [C]d O 
benign [C]b [C]e [C]n [C]i [C]g [C]n O 
proliferative [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
) [C]) O 
, [C], O 
while [C]w [C]h [C]i [C]l [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
( [C]( O 
> [C]> O 
10 [C]1 [C]0 O 
% [C]% O 
of [C]o [C]f O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
) [C]) O 
was [C]w [C]a [C]s O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
in [C]i [C]n O 
89.7 [C]8 [C]9 [C]. [C]7 O 
% [C]% O 
of [C]o [C]f O 
tumours [C]t [C]u [C]m [C]o [C]u [C]r [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
ST1 [C]S [C]T [C]1 S-protein 
in [C]i [C]n O 
carcinoma [C]c [C]a [C]r [C]c [C]i [C]n [C]o [C]m [C]a O 
cells [C]c [C]e [C]l [C]l [C]s O 
was [C]w [C]a [C]s O 
strongly [C]s [C]t [C]r [C]o [C]n [C]g [C]l [C]y O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
its [C]i [C]t [C]s O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
stroma [C]s [C]t [C]r [C]o [C]m [C]a O 
( [C]( O 
p [C]p O 
< [C]< O 
0.001 [C]0 [C]. [C]0 [C]0 [C]1 O 
) [C]) O 
. [C]. O 

A [C]A O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
ST1 [C]S [C]T [C]1 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
p53 [C]p [C]5 [C]3 S-protein 
tumour [C]t [C]u [C]m [C]o [C]u [C]r O 
suppressor [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]o [C]r O 
gene [C]g [C]e [C]n [C]e O 
product [C]p [C]r [C]o [C]d [C]u [C]c [C]t O 
( [C]( O 
p [C]p O 
= [C]= O 
0.004 [C]0 [C]. [C]0 [C]0 [C]4 O 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
a [C]a O 
relationship [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n [C]s [C]h [C]i [C]p O 
with [C]w [C]i [C]t [C]h O 
c-erbB-2 [C]c [C]- [C]e [C]r [C]b [C]B [C]- [C]2 S-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
and [C]a [C]n [C]d O 
progesterone [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
status [C]s [C]t [C]a [C]t [C]u [C]s O 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
indicated [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e [C]d O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
ST1 [C]S [C]T [C]1 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
is [C]i [C]s O 
irrespective [C]i [C]r [C]r [C]e [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
extracellular [C]e [C]x [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
matrix [C]m [C]a [C]t [C]r [C]i [C]x O 
component [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t O 
, [C], O 
the [C]t [C]h [C]e O 
proteolytic [C]p [C]r [C]o [C]t [C]e [C]o [C]l [C]y [C]t [C]i [C]c B-protein 
enzyme [C]e [C]n [C]z [C]y [C]m [C]e E-protein 
cathepsin [C]c [C]a [C]t [C]h [C]e [C]p [C]s [C]i [C]n B-protein 
D [C]D E-protein 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
fraction [C]f [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
tumour [C]t [C]u [C]m [C]o [C]u [C]r O 
, [C], O 
and [C]a [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
it [C]i [C]t O 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
a [C]a O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
new [C]n [C]e [C]w O 
prognostic [C]p [C]r [C]o [C]g [C]n [C]o [C]s [C]t [C]i [C]c O 
marker [C]m [C]a [C]r [C]k [C]e [C]r O 
in [C]i [C]n O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
. [C]. O 

Use [C]U [C]s [C]e O 
of [C]o [C]f O 
transfected [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]e [C]d B-cell_line 
liver [C]l [C]i [C]v [C]e [C]r I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
to [C]t [C]o O 
evaluate [C]e [C]v [C]a [C]l [C]u [C]a [C]t [C]e O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
of [C]o [C]f O 
alcohol-induced [C]a [C]l [C]c [C]o [C]h [C]o [C]l [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
liver [C]l [C]i [C]v [C]e [C]r O 
injury [C]i [C]n [C]j [C]u [C]r [C]y O 
[ [C][ O 
see [C]s [C]e [C]e O 
comments [C]c [C]o [C]m [C]m [C]e [C]n [C]t [C]s O 
] [C]] O 

There [C]T [C]h [C]e [C]r [C]e O 
is [C]i [C]s O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
proinflammatory [C]p [C]r [C]o [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y B-protein 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e E-protein 
, [C], O 
tumor [C]t [C]u [C]m [C]o [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
( [C]( O 
TNF [C]T [C]N [C]F S-protein 
) [C]) O 
in [C]i [C]n O 
alcoholic [C]a [C]l [C]c [C]o [C]h [C]o [C]l [C]i [C]c O 
liver [C]l [C]i [C]v [C]e [C]r O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
( [C]( O 
ALD [C]A [C]L [C]D O 
) [C]) O 
. [C]. O 

Hepatic [C]H [C]e [C]p [C]a [C]t [C]i [C]c O 
neutrophil [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]h [C]i [C]l O 
infiltration [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
a [C]a O 
principal [C]p [C]r [C]i [C]n [C]c [C]i [C]p [C]a [C]l O 
injurious [C]i [C]n [C]j [C]u [C]r [C]i [C]o [C]u [C]s O 
manifestation [C]m [C]a [C]n [C]i [C]f [C]e [C]s [C]t [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
ALD [C]A [C]L [C]D O 
. [C]. O 

TNF [C]T [C]N [C]F S-protein 
can [C]c [C]a [C]n O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
oxidative [C]o [C]x [C]i [C]d [C]a [C]t [C]i [C]v [C]e O 
injury [C]i [C]n [C]j [C]u [C]r [C]y O 
directly [C]d [C]i [C]r [C]e [C]c [C]t [C]l [C]y O 
, [C], O 
and [C]a [C]n [C]d O 
indirectly [C]i [C]n [C]d [C]i [C]r [C]e [C]c [C]t [C]l [C]y O 
by [C]b [C]y O 
inducing [C]i [C]n [C]d [C]u [C]c [C]i [C]n [C]g O 
neutrophil [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]h [C]i [C]l O 
chemotactic [C]c [C]h [C]e [C]m [C]o [C]t [C]a [C]c [C]t [C]i [C]c O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
( [C]( O 
IL-8 [C]I [C]L [C]- [C]8 S-protein 
) [C]) O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
hepatocytes [C]h [C]e [C]p [C]a [C]t [C]o [C]c [C]y [C]t [C]e [C]s O 
. [C]. O 

IL-8 [C]I [C]L [C]- [C]8 S-protein 
activates [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]s O 
and [C]a [C]n [C]d O 
chemotactically [C]c [C]h [C]e [C]m [C]o [C]t [C]a [C]c [C]t [C]i [C]c [C]a [C]l [C]l [C]y O 
attracts [C]a [C]t [C]t [C]r [C]a [C]c [C]t [C]s O 
neutrophils [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]h [C]i [C]l [C]s O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
liver [C]l [C]i [C]v [C]e [C]r O 
where [C]w [C]h [C]e [C]r [C]e O 
they [C]t [C]h [C]e [C]y O 
release [C]r [C]e [C]l [C]e [C]a [C]s [C]e O 
oxidizing [C]o [C]x [C]i [C]d [C]i [C]z [C]i [C]n [C]g O 
substances [C]s [C]u [C]b [C]s [C]t [C]a [C]n [C]c [C]e [C]s O 
. [C]. O 

Patients [C]P [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
ALD [C]A [C]L [C]D O 
also [C]a [C]l [C]s [C]o O 
have [C]h [C]a [C]v [C]e O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
protective [C]p [C]r [C]o [C]t [C]e [C]c [C]t [C]i [C]v [C]e B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
for [C]f [C]o [C]r O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
oxidative [C]o [C]x [C]i [C]d [C]a [C]t [C]i [C]v [C]e O 
injury [C]i [C]n [C]j [C]u [C]r [C]y O 
. [C]. O 

Manganous [C]M [C]a [C]n [C]g [C]a [C]n [C]o [C]u [C]s B-protein 
superoxide [C]s [C]u [C]p [C]e [C]r [C]o [C]x [C]i [C]d [C]e I-protein 
dismutase [C]d [C]i [C]s [C]m [C]u [C]t [C]a [C]s [C]e E-protein 
( [C]( O 
MnSOD [C]M [C]n [C]S [C]O [C]D S-protein 
) [C]) O 
is [C]i [C]s O 
an [C]a [C]n O 
antioxidant [C]a [C]n [C]t [C]i [C]o [C]x [C]i [C]d [C]a [C]n [C]t B-protein 
protective [C]p [C]r [C]o [C]t [C]e [C]c [C]t [C]i [C]v [C]e I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
objectives [C]o [C]b [C]j [C]e [C]c [C]t [C]i [C]v [C]e [C]s O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
to [C]t [C]o O 
investigate [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
for [C]f [C]o [C]r O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
an [C]a [C]n O 
injurious [C]i [C]n [C]j [C]u [C]r [C]i [C]o [C]u [C]s B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
( [C]( O 
IL-8 [C]I [C]L [C]- [C]8 S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
a [C]a O 
protective [C]p [C]r [C]o [C]t [C]e [C]c [C]t [C]i [C]v [C]e B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
( [C]( O 
MnSOD [C]M [C]n [C]S [C]O [C]D S-protein 
) [C]) O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
HepG2 [C]H [C]e [C]p [C]G [C]2 B-cell_line 
human [C]h [C]u [C]m [C]a [C]n I-cell_line 
hepatoma [C]h [C]e [C]p [C]a [C]t [C]o [C]m [C]a I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
. [C]. O 

In [C]I [C]n O 
the [C]t [C]h [C]e O 
first [C]f [C]i [C]r [C]s [C]t O 
set [C]s [C]e [C]t O 
of [C]o [C]f O 
experiments [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]s O 
, [C], O 
IL-8 [C]I [C]L [C]- [C]8 B-DNA 
gene [C]g [C]e [C]n [C]e I-DNA 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r I-DNA 
constructs [C]c [C]o [C]n [C]s [C]t [C]r [C]u [C]c [C]t [C]s E-DNA 
were [C]w [C]e [C]r [C]e O 
used [C]u [C]s [C]e [C]d O 
to [C]t [C]o O 
transiently [C]t [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t [C]l [C]y O 
transfect [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t O 
a [C]a O 
derivative [C]d [C]e [C]r [C]i [C]v [C]a [C]t [C]i [C]v [C]e O 
( [C]( O 
MVh2E1-9 [C]M [C]V [C]h [C]2 [C]E [C]1 [C]- [C]9 S-cell_line 
) [C]) O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
HepG2 [C]H [C]e [C]p [C]G [C]2 B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
which [C]w [C]h [C]i [C]c [C]h O 
expresses [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]s O 
P-4502E1 [C]P [C]- [C]4 [C]5 [C]0 [C]2 [C]E [C]1 S-protein 
and [C]a [C]n [C]d O 
metabolizes [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]z [C]e [C]s O 
ethanol [C]e [C]t [C]h [C]a [C]n [C]o [C]l O 
. [C]. O 

Inactivation [C]I [C]n [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B B-DNA 
and [C]a [C]n [C]d I-DNA 
3'NF-IL-6 [C]3 [C]' [C]N [C]F [C]- [C]I [C]L [C]- [C]6 I-DNA 
DNA [C]D [C]N [C]A I-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
IL-8 [C]I [C]L [C]- [C]8 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
TNF [C]T [C]N [C]F S-protein 
while [C]w [C]h [C]i [C]l [C]e O 
inactivation [C]i [C]n [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
5'NF-IL-6 [C]5 [C]' [C]N [C]F [C]- [C]I [C]L [C]- [C]6 B-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
IL-8 [C]I [C]L [C]- [C]8 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
TNF [C]T [C]N [C]F S-protein 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
useful [C]u [C]s [C]e [C]f [C]u [C]l O 
to [C]t [C]o O 
assess [C]a [C]s [C]s [C]e [C]s [C]s O 
the [C]t [C]h [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
ethanol [C]e [C]t [C]h [C]a [C]n [C]o [C]l O 
on [C]o [C]n O 
TNF [C]T [C]N [C]F S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
hepatocyte [C]h [C]e [C]p [C]a [C]t [C]o [C]c [C]y [C]t [C]e O 
IL-8 [C]I [C]L [C]- [C]8 S-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

In [C]I [C]n O 
the [C]t [C]h [C]e O 
second [C]s [C]e [C]c [C]o [C]n [C]d O 
set [C]s [C]e [C]t O 
of [C]o [C]f O 
experiments [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]s O 
, [C], O 
HepG2 [C]H [C]e [C]p [C]G [C]2 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
were [C]w [C]e [C]r [C]e O 
cultured [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]d O 
in [C]i [C]n O 
25 [C]2 [C]5 O 
to [C]t [C]o O 
100 [C]1 [C]0 [C]0 O 
mmol [C]m [C]m [C]o [C]l O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
ethanol [C]e [C]t [C]h [C]a [C]n [C]o [C]l O 
. [C]. O 

Both [C]B [C]o [C]t [C]h O 
TNF [C]T [C]N [C]F S-protein 
and [C]a [C]n [C]d O 
ethanol [C]e [C]t [C]h [C]a [C]n [C]o [C]l O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
HepG2 [C]H [C]e [C]p [C]G [C]2 B-cell_line 
cell [C]c [C]e [C]l [C]l E-cell_line 
MnSOD [C]M [C]n [C]S [C]O [C]D S-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
short-term [C]s [C]h [C]o [C]r [C]t [C]- [C]t [C]e [C]r [C]m O 
( [C]( O 
72 [C]7 [C]2 O 
hr [C]h [C]r O 
) [C]) O 
cultures [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
ethanol [C]e [C]t [C]h [C]a [C]n [C]o [C]l O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
after [C]a [C]f [C]t [C]e [C]r O 
long-term [C]l [C]o [C]n [C]g [C]- [C]t [C]e [C]r [C]m O 
( [C]( O 
10 [C]1 [C]0 O 
weeks [C]w [C]e [C]e [C]k [C]s O 
) [C]) O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
with [C]w [C]i [C]t [C]h O 
ethanol [C]e [C]t [C]h [C]a [C]n [C]o [C]l O 
, [C], O 
there [C]t [C]h [C]e [C]r [C]e O 
was [C]w [C]a [C]s O 
no [C]n [C]o O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
MnSOD [C]M [C]n [C]S [C]O [C]D S-protein 
by [C]b [C]y O 
ethanol [C]e [C]t [C]h [C]a [C]n [C]o [C]l O 
and [C]a [C]n [C]d O 
there [C]t [C]h [C]e [C]r [C]e O 
was [C]w [C]a [C]s O 
a [C]a O 
diminished [C]d [C]i [C]m [C]i [C]n [C]i [C]s [C]h [C]e [C]d O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
MnSOD [C]M [C]n [C]S [C]O [C]D S-protein 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
TNF [C]T [C]N [C]F S-protein 
. [C]. O 

Further [C]F [C]u [C]r [C]t [C]h [C]e [C]r O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
are [C]a [C]r [C]e O 
needed [C]n [C]e [C]e [C]d [C]e [C]d O 
to [C]t [C]o O 
assess [C]a [C]s [C]s [C]e [C]s [C]s O 
the [C]t [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
diminished [C]d [C]i [C]m [C]i [C]n [C]i [C]s [C]h [C]e [C]d O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
MnSOD [C]M [C]n [C]S [C]O [C]D S-protein 
with [C]w [C]i [C]t [C]h O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
ethanol [C]e [C]t [C]h [C]a [C]n [C]o [C]l O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
on [C]o [C]n O 
HepG2 [C]H [C]e [C]p [C]G [C]2 B-cell_line 
cell [C]c [C]e [C]l [C]l E-cell_line 
susceptibility [C]s [C]u [C]s [C]c [C]e [C]p [C]t [C]i [C]b [C]i [C]l [C]i [C]t [C]y O 
to [C]t [C]o O 
TNF [C]T [C]N [C]F B-cell_line 
cytotoxicity [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c [C]i [C]t [C]y E-cell_line 
. [C]. O 

We [C]W [C]e O 
conclude [C]c [C]o [C]n [C]c [C]l [C]u [C]d [C]e O 
that [C]t [C]h [C]a [C]t O 
transfected [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]e [C]d O 
liver [C]l [C]i [C]v [C]e [C]r B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
can [C]c [C]a [C]n O 
be [C]b [C]e O 
used [C]u [C]s [C]e [C]d O 
to [C]t [C]o O 
evaluate [C]e [C]v [C]a [C]l [C]u [C]a [C]t [C]e O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
for [C]f [C]o [C]r O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
injurious [C]i [C]n [C]j [C]u [C]r [C]i [C]o [C]u [C]s B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
and [C]a [C]n [C]d O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
protective [C]p [C]r [C]o [C]t [C]e [C]c [C]t [C]i [C]v [C]e B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
alcoholic [C]a [C]l [C]c [C]o [C]h [C]o [C]l [C]i [C]c O 
liver [C]l [C]i [C]v [C]e [C]r O 
injury [C]i [C]n [C]j [C]u [C]r [C]y O 
. [C]. O 

Tissue [C]T [C]i [C]s [C]s [C]u [C]e O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
driven [C]d [C]r [C]i [C]v [C]e [C]n O 
by [C]b [C]y O 
Egr-1 [C]E [C]g [C]r [C]- [C]1 S-protein 
is [C]i [C]s O 
a [C]a O 
critical [C]c [C]r [C]i [C]t [C]i [C]c [C]a [C]l O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
of [C]o [C]f O 
murine [C]m [C]u [C]r [C]i [C]n [C]e B-protein 
pulmonary [C]p [C]u [C]l [C]m [C]o [C]n [C]a [C]r [C]y I-protein 
fibrin [C]f [C]i [C]b [C]r [C]i [C]n E-protein 
deposition [C]d [C]e [C]p [C]o [C]s [C]i [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
hypoxia [C]h [C]y [C]p [C]o [C]x [C]i [C]a O 
. [C]. O 

Local [C]L [C]o [C]c [C]a [C]l O 
hypoxemia [C]h [C]y [C]p [C]o [C]x [C]e [C]m [C]i [C]a O 
and [C]a [C]n [C]d O 
stasis [C]s [C]t [C]a [C]s [C]i [C]s O 
trigger [C]t [C]r [C]i [C]g [C]g [C]e [C]r O 
thrombosis [C]t [C]h [C]r [C]o [C]m [C]b [C]o [C]s [C]i [C]s O 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
that [C]t [C]h [C]a [C]t O 
in [C]i [C]n O 
a [C]a O 
murine [C]m [C]u [C]r [C]i [C]n [C]e O 
model [C]m [C]o [C]d [C]e [C]l O 
of [C]o [C]f O 
normobaric [C]n [C]o [C]r [C]m [C]o [C]b [C]a [C]r [C]i [C]c O 
hypoxia [C]h [C]y [C]p [C]o [C]x [C]i [C]a O 
pulmonary [C]p [C]u [C]l [C]m [C]o [C]n [C]a [C]r [C]y O 
fibrin [C]f [C]i [C]b [C]r [C]i [C]n S-protein 
deposition [C]d [C]e [C]p [C]o [C]s [C]i [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
a [C]a O 
result [C]r [C]e [C]s [C]u [C]l [C]t O 
of [C]o [C]f O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
, [C], O 
especially [C]e [C]s [C]p [C]e [C]c [C]i [C]a [C]l [C]l [C]y O 
in [C]i [C]n O 
oxygen-deprived [C]o [C]x [C]y [C]g [C]e [C]n [C]- [C]d [C]e [C]p [C]r [C]i [C]v [C]e [C]d B-protein 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-protein 
phagocytes [C]p [C]h [C]a [C]g [C]o [C]c [C]y [C]t [C]e [C]s E-protein 
( [C]( O 
MPs [C]M [C]P [C]s S-protein 
) [C]) O 
. [C]. O 

We [C]W [C]e O 
now [C]n [C]o [C]w O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
early-growth-response [C]e [C]a [C]r [C]l [C]y [C]- [C]g [C]r [C]o [C]w [C]t [C]h [C]- [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e I-protein 
gene [C]g [C]e [C]n [C]e I-protein 
product [C]p [C]r [C]o [C]d [C]u [C]c [C]t E-protein 
( [C]( O 
Egr-1 [C]E [C]g [C]r [C]- [C]1 S-protein 
) [C]) O 
is [C]i [C]s O 
rapidly [C]r [C]a [C]p [C]i [C]d [C]l [C]y O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
hypoxia [C]h [C]y [C]p [C]o [C]x [C]i [C]a O 
, [C], O 
both [C]b [C]o [C]t [C]h O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
, [C], O 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
responsible [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]b [C]l [C]e O 
for [C]f [C]o [C]r O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
in [C]i [C]n O 
hypoxic [C]h [C]y [C]p [C]o [C]x [C]i [C]c O 
lung [C]l [C]u [C]n [C]g O 
. [C]. O 

MPs [C]M [C]P [C]s S-protein 
and [C]a [C]n [C]d O 
HeLa [C]H [C]e [C]L [C]a B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
subjected [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]e [C]d O 
to [C]t [C]o O 
hypoxia [C]h [C]y [C]p [C]o [C]x [C]i [C]a O 
( [C]( O 
pO2 [C]p [C]O [C]2 O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
13 [C]1 [C]3 O 
torr [C]t [C]o [C]r [C]r O 
) [C]) O 
had [C]h [C]a [C]d O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e B-RNA 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-RNA 
transcripts [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]s E-RNA 
( [C]( O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
18-fold [C]1 [C]8 [C]- [C]f [C]o [C]l [C]d O 
) [C]) O 
and [C]a [C]n [C]d O 
an [C]a [C]n O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
rate [C]r [C]a [C]t [C]e O 
of [C]o [C]f O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
( [C]( O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
15-fold [C]1 [C]5 [C]- [C]f [C]o [C]l [C]d O 
) [C]) O 
, [C], O 
based [C]b [C]a [C]s [C]e [C]d O 
on [C]o [C]n O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
run-on [C]r [C]u [C]n [C]- [C]o [C]n O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
. [C]. O 

Gel-shift [C]G [C]e [C]l [C]- [C]s [C]h [C]i [C]f [C]t O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
from [C]f [C]r [C]o [C]m O 
hypoxic [C]h [C]y [C]p [C]o [C]x [C]i [C]c B-protein 
MPs [C]M [C]P [C]s E-protein 
and [C]a [C]n [C]d O 
HeLa [C]H [C]e [C]L [C]a B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
DNA-binding [C]D [C]N [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
serum [C]s [C]e [C]r [C]u [C]m B-DNA 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e I-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
( [C]( O 
SRR [C]S [C]R [C]R O 
; [C]; O 
-111/+14 [C]- [C]1 [C]1 [C]1 [C]/ [C]+ [C]1 [C]4 O 
bp [C]b [C]p O 
) [C]) O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e B-DNA 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
at [C]a [C]t O 
Egr-1 [C]E [C]g [C]r [C]- [C]1 B-DNA 
motifs [C]m [C]o [C]t [C]i [C]f [C]s E-DNA 
. [C]. O 

Using [C]U [C]s [C]i [C]n [C]g O 
32P-labeled [C]3 [C]2 [C]P [C]- [C]l [C]a [C]b [C]e [C]l [C]e [C]d O 
Egr [C]E [C]g [C]r O 
consensus [C]c [C]o [C]n [C]s [C]e [C]n [C]s [C]u [C]s O 
oligonucleotide [C]o [C]l [C]i [C]g [C]o [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e O 
, [C], O 
we [C]w [C]e O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
DNA-binding [C]D [C]N [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
from [C]f [C]r [C]o [C]m O 
hypoxic [C]h [C]y [C]p [C]o [C]x [C]i [C]c O 
lung [C]l [C]u [C]n [C]g O 
and [C]a [C]n [C]d O 
HeLa [C]H [C]e [C]L [C]a B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
because [C]b [C]e [C]c [C]a [C]u [C]s [C]e O 
of [C]o [C]f O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Egr-1 [C]E [C]g [C]r [C]- [C]1 S-protein 
, [C], O 
by [C]b [C]y O 
means [C]m [C]e [C]a [C]n [C]s O 
of [C]o [C]f O 
supershift [C]s [C]u [C]p [C]e [C]r [C]s [C]h [C]i [C]f [C]t O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
. [C]. O 

Transient [C]T [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t O 
transfection [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
HeLa [C]H [C]e [C]L [C]a B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
with [C]w [C]i [C]t [C]h O 
chimeric [C]c [C]h [C]i [C]m [C]e [C]r [C]i [C]c B-DNA 
plasmids [C]p [C]l [C]a [C]s [C]m [C]i [C]d [C]s E-DNA 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
wild-type [C]w [C]i [C]l [C]d [C]- [C]t [C]y [C]p [C]e B-protein 
or [C]o [C]r I-protein 
mutant [C]m [C]u [C]t [C]a [C]n [C]t I-protein 
SRR [C]S [C]R [C]R E-protein 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e B-DNA 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
intact [C]i [C]n [C]t [C]a [C]c [C]t B-DNA 
Sp1 [C]S [C]p [C]1 I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
are [C]a [C]r [C]e O 
necessary [C]n [C]e [C]c [C]e [C]s [C]s [C]a [C]r [C]y O 
for [C]f [C]o [C]r O 
basal [C]b [C]a [C]s [C]a [C]l O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
the [C]t [C]h [C]e O 
integrity [C]i [C]n [C]t [C]e [C]g [C]r [C]i [C]t [C]y O 
of [C]o [C]f O 
Egr-1 [C]E [C]g [C]r [C]- [C]1 B-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
was [C]w [C]a [C]s O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
hypoxia-enhanced [C]h [C]y [C]p [C]o [C]x [C]i [C]a [C]- [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

A [C]A O 
central [C]c [C]e [C]n [C]t [C]r [C]a [C]l O 
role [C]r [C]o [C]l [C]e O 
for [C]f [C]o [C]r O 
Egr-1 [C]E [C]g [C]r [C]- [C]1 S-protein 
in [C]i [C]n O 
hypoxia-mediated [C]h [C]y [C]p [C]o [C]x [C]i [C]a [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
confirmed [C]c [C]o [C]n [C]f [C]i [C]r [C]m [C]e [C]d O 
by [C]b [C]y O 
experiments [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
homozygous [C]h [C]o [C]m [C]o [C]z [C]y [C]g [C]o [C]u [C]s O 
Egr-1 [C]E [C]g [C]r [C]- [C]1 S-protein 
null [C]n [C]u [C]l [C]l O 
mice [C]m [C]i [C]c [C]e O 
; [C]; O 
wild-type [C]w [C]i [C]l [C]d [C]- [C]t [C]y [C]p [C]e O 
mice [C]m [C]i [C]c [C]e O 
subjected [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]e [C]d O 
to [C]t [C]o O 
oxygen [C]o [C]x [C]y [C]g [C]e [C]n B-protein 
deprivation [C]d [C]e [C]p [C]r [C]i [C]v [C]a [C]t [C]i [C]o [C]n I-protein 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d I-protein 
tissue [C]t [C]i [C]s [C]s [C]u [C]e I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
and [C]a [C]n [C]d O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
fibrin [C]f [C]i [C]b [C]r [C]i [C]n S-protein 
deposition [C]d [C]e [C]p [C]o [C]s [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
but [C]b [C]u [C]t O 
hypoxic [C]h [C]y [C]p [C]o [C]x [C]i [C]c O 
homozygous [C]h [C]o [C]m [C]o [C]z [C]y [C]g [C]o [C]u [C]s O 
Egr-1 [C]E [C]g [C]r [C]- [C]1 S-protein 
null [C]n [C]u [C]l [C]l O 
mice [C]m [C]i [C]c [C]e O 
displayed [C]d [C]i [C]s [C]p [C]l [C]a [C]y [C]e [C]d O 
neither [C]n [C]e [C]i [C]t [C]h [C]e [C]r O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
nor [C]n [C]o [C]r O 
fibrin [C]f [C]i [C]b [C]r [C]i [C]n S-protein 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
delineate [C]d [C]e [C]l [C]i [C]n [C]e [C]a [C]t [C]e O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
biology [C]b [C]i [C]o [C]l [C]o [C]g [C]y O 
for [C]f [C]o [C]r O 
hypoxia-induced [C]h [C]y [C]p [C]o [C]x [C]i [C]a [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
fibrin [C]f [C]i [C]b [C]r [C]i [C]n S-protein 
deposition [C]d [C]e [C]p [C]o [C]s [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
in [C]i [C]n O 
which [C]w [C]h [C]i [C]c [C]h O 
oxygen [C]o [C]x [C]y [C]g [C]e [C]n O 
deprivation-induced [C]d [C]e [C]p [C]r [C]i [C]v [C]a [C]t [C]i [C]o [C]n [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Egr-1 [C]E [C]g [C]r [C]- [C]1 S-protein 
, [C], O 
resulting [C]r [C]e [C]s [C]u [C]l [C]t [C]i [C]n [C]g O 
in [C]i [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
, [C], O 
has [C]h [C]a [C]s O 
an [C]a [C]n O 
unexpected [C]u [C]n [C]e [C]x [C]p [C]e [C]c [C]t [C]e [C]d O 
and [C]a [C]n [C]d O 
central [C]c [C]e [C]n [C]t [C]r [C]a [C]l O 
role [C]r [C]o [C]l [C]e O 
. [C]. O 

Kinetics [C]K [C]i [C]n [C]e [C]t [C]i [C]c [C]s O 
of [C]o [C]f O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
and [C]a [C]n [C]d O 
NFAT [C]N [C]F [C]A [C]T O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
interleukin-2-dependent [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]2 [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t I-cell_line 
T [C]T I-cell_line 
lymphoblasts [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]s E-cell_line 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
via [C]v [C]i [C]a O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
. [C]. O 

T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
respond [C]r [C]e [C]s [C]p [C]o [C]n [C]d O 
to [C]t [C]o O 
mitogenic [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]i [C]c O 
or [C]o [C]r O 
antigenic [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]i [C]c O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
by [C]b [C]y O 
turning [C]t [C]u [C]r [C]n [C]i [C]n [C]g O 
on [C]o [C]n O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
we [C]w [C]e O 
have [C]h [C]a [C]v [C]e O 
analysed [C]a [C]n [C]a [C]l [C]y [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
kinetics [C]k [C]i [C]n [C]e [C]t [C]i [C]c [C]s O 
and [C]a [C]n [C]d O 
nature [C]n [C]a [C]t [C]u [C]r [C]e O 
of [C]o [C]f O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
blood-derived [C]b [C]l [C]o [C]o [C]d [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d I-cell_type 
T [C]T I-cell_type 
lymphoblasts [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]s E-cell_type 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
anti-CD3 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]3 B-protein 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s E-protein 
or [C]o [C]r O 
Lens [C]L [C]e [C]n [C]s B-protein 
culinaris [C]c [C]u [C]l [C]i [C]n [C]a [C]r [C]i [C]s I-protein 
lectin [C]l [C]e [C]c [C]t [C]i [C]n E-protein 
( [C]( O 
LCL [C]L [C]C [C]L S-protein 
) [C]) O 
. [C]. O 

T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
PBMC [C]P [C]B [C]M [C]C S-cell_type 
) [C]) O 
and [C]a [C]n [C]d O 
primarily [C]p [C]r [C]i [C]m [C]a [C]r [C]i [C]l [C]y O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
anti-CD3 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]3 B-protein 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s E-protein 
and [C]a [C]n [C]d O 
cultured [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
interleukin-2 [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]2 S-protein 
( [C]( O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
) [C]) O 
. [C]. O 

Anti-CD3-restimulated [C]A [C]n [C]t [C]i [C]- [C]C [C]D [C]3 [C]- [C]r [C]e [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
mainly [C]m [C]a [C]i [C]n [C]l [C]y O 
CD8+ [C]C [C]D [C]8 [C]+ O 
) [C]) O 
produced [C]p [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
, [C], O 
interferon-gamma [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
( [C]( O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
tumour [C]t [C]u [C]m [C]o [C]u [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor-alpha [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]a [C]l [C]p [C]h [C]a E-protein 
( [C]( O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
low [C]l [C]o [C]w O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
IL-4 [C]I [C]L [C]- [C]4 B-RNA 
and [C]a [C]n [C]d I-RNA 
IL-10 [C]I [C]L [C]- [C]1 [C]0 I-RNA 
transcripts [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]s E-RNA 
and [C]a [C]n [C]d O 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s O 
. [C]. O 

No [C]N [C]o O 
IL-6 [C]I [C]L [C]- [C]6 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
. [C]. O 

In [C]I [C]n O 
LCL-stimulated [C]L [C]C [C]L [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
the [C]t [C]h [C]e O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
pattern [C]p [C]a [C]t [C]t [C]e [C]r [C]n O 
was [C]w [C]a [C]s O 
very [C]v [C]e [C]r [C]y O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
. [C]. O 

Steady-state [C]S [C]t [C]e [C]a [C]d [C]y [C]- [C]s [C]t [C]a [C]t [C]e O 
mRNA [C]m [C]R [C]N [C]A O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
, [C], O 
IL-10 [C]I [C]L [C]- [C]1 [C]0 S-protein 
and [C]a [C]n [C]d O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
peaked [C]p [C]e [C]a [C]k [C]e [C]d O 
at [C]a [C]t O 
3 [C]3 O 
hr [C]h [C]r O 
after [C]a [C]f [C]t [C]e [C]r O 
anti-CD3 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]3 O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
declined [C]d [C]e [C]c [C]l [C]i [C]n [C]e [C]d O 
rapidly [C]r [C]a [C]p [C]i [C]d [C]l [C]y O 
thereafter [C]t [C]h [C]e [C]r [C]e [C]a [C]f [C]t [C]e [C]r O 
. [C]. O 

The [C]T [C]h [C]e O 
kinetics [C]k [C]i [C]n [C]e [C]t [C]i [C]c [C]s O 
of [C]o [C]f O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
faster [C]f [C]a [C]s [C]t [C]e [C]r O 
, [C], O 
being [C]b [C]e [C]i [C]n [C]g O 
at [C]a [C]t O 
its [C]i [C]t [C]s O 
peak [C]p [C]e [C]a [C]k O 
level [C]l [C]e [C]v [C]e [C]l O 
1 [C]1 O 
hr [C]h [C]r O 
after [C]a [C]f [C]t [C]e [C]r O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Anti-CD3-stimulated [C]A [C]n [C]t [C]i [C]- [C]C [C]D [C]3 [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
down-regulated [C]d [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
IL-10 [C]I [C]L [C]- [C]1 [C]0 B-DNA 
, [C], I-DNA 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a I-DNA 
and [C]a [C]n [C]d I-DNA 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
were [C]w [C]e [C]r [C]e O 
readily [C]r [C]e [C]a [C]d [C]i [C]l [C]y O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
of [C]o [C]f O 
ongoing [C]o [C]n [C]g [C]o [C]i [C]n [C]g O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
. [C]. O 

T-cell [C]T [C]- [C]c [C]e [C]l [C]l B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
also [C]a [C]l [C]s [C]o O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
a [C]a O 
very [C]v [C]e [C]r [C]y O 
rapid [C]r [C]a [C]p [C]i [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
c-jun [C]c [C]- [C]j [C]u [C]n B-DNA 
, [C], I-DNA 
c-fos [C]c [C]- [C]f [C]o [C]s I-DNA 
and [C]a [C]n [C]d I-DNA 
NFATc1 [C]N [C]F [C]A [C]T [C]c [C]1 I-DNA 
( [C]( I-DNA 
NFATc [C]N [C]F [C]A [C]T [C]c I-DNA 
) [C]) I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
, [C], O 
the [C]t [C]h [C]e O 
gene [C]g [C]e [C]n [C]e O 
products [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]s O 
of [C]o [C]f O 
which [C]w [C]h [C]i [C]c [C]h O 
are [C]a [C]r [C]e O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

In [C]I [C]n O 
conclusion [C]c [C]o [C]n [C]c [C]l [C]u [C]s [C]i [C]o [C]n O 
, [C], O 
the [C]t [C]h [C]e O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
synthesized [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]z [C]e [C]d O 
by [C]b [C]y O 
IL-2-dependent [C]I [C]L [C]- [C]2 [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
predominantly [C]p [C]r [C]e [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t [C]l [C]y O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
, [C], O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
and [C]a [C]n [C]d O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
. [C]. O 

An [C]A [C]n O 
animal [C]a [C]n [C]i [C]m [C]a [C]l O 
model [C]m [C]o [C]d [C]e [C]l O 
to [C]t [C]o O 
study [C]s [C]t [C]u [C]d [C]y O 
local [C]l [C]o [C]c [C]a [C]l O 
oxidation [C]o [C]x [C]i [C]d [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
LDL [C]L [C]D [C]L O 
and [C]a [C]n [C]d O 
its [C]i [C]t [C]s O 
biological [C]b [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
arterial [C]a [C]r [C]t [C]e [C]r [C]i [C]a [C]l O 
wall [C]w [C]a [C]l [C]l O 
. [C]. O 

Oxidized [C]O [C]x [C]i [C]d [C]i [C]z [C]e [C]d O 
LDL [C]L [C]D [C]L O 
( [C]( O 
oxLDL [C]o [C]x [C]L [C]D [C]L O 
) [C]) O 
is [C]i [C]s O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
in [C]i [C]n O 
atherosclerotic [C]a [C]t [C]h [C]e [C]r [C]o [C]s [C]c [C]l [C]e [C]r [C]o [C]t [C]i [C]c O 
lesions [C]l [C]e [C]s [C]i [C]o [C]n [C]s O 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
believed [C]b [C]e [C]l [C]i [C]e [C]v [C]e [C]d O 
to [C]t [C]o O 
play [C]p [C]l [C]a [C]y O 
a [C]a O 
key [C]k [C]e [C]y O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
atherogenesis [C]a [C]t [C]h [C]e [C]r [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
. [C]. O 

Mainly [C]M [C]a [C]i [C]n [C]l [C]y O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
basis [C]b [C]a [C]s [C]i [C]s O 
of [C]o [C]f O 
cell [C]c [C]e [C]l [C]l O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
, [C], O 
oxLDL [C]o [C]x [C]L [C]D [C]L O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
produce [C]p [C]r [C]o [C]d [C]u [C]c [C]e O 
many [C]m [C]a [C]n [C]y O 
biological [C]b [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
that [C]t [C]h [C]a [C]t O 
influence [C]i [C]n [C]f [C]l [C]u [C]e [C]n [C]c [C]e O 
the [C]t [C]h [C]e O 
atherosclerotic [C]a [C]t [C]h [C]e [C]r [C]o [C]s [C]c [C]l [C]e [C]r [C]o [C]t [C]i [C]c O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
. [C]. O 

To [C]T [C]o O 
study [C]s [C]t [C]u [C]d [C]y O 
LDL [C]L [C]D [C]L O 
oxidation [C]o [C]x [C]i [C]d [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
, [C], O 
we [C]w [C]e O 
have [C]h [C]a [C]v [C]e O 
established [C]e [C]s [C]t [C]a [C]b [C]l [C]i [C]s [C]h [C]e [C]d O 
a [C]a O 
model [C]m [C]o [C]d [C]e [C]l O 
in [C]i [C]n O 
which [C]w [C]h [C]i [C]c [C]h O 
Sprague-Dawley [C]S [C]p [C]r [C]a [C]g [C]u [C]e [C]- [C]D [C]a [C]w [C]l [C]e [C]y O 
rats [C]r [C]a [C]t [C]s O 
are [C]a [C]r [C]e O 
given [C]g [C]i [C]v [C]e [C]n O 
a [C]a O 
single [C]s [C]i [C]n [C]g [C]l [C]e O 
injection [C]i [C]n [C]j [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
unmodified [C]u [C]n [C]m [C]o [C]d [C]i [C]f [C]i [C]e [C]d O 
human [C]h [C]u [C]m [C]a [C]n O 
LDL [C]L [C]D [C]L O 
( [C]( O 
> [C]> O 
or [C]o [C]r O 
= [C]= O 
4 [C]4 O 
mg/kg [C]m [C]g [C]/ [C]k [C]g O 
body [C]b [C]o [C]d [C]y O 
weight [C]w [C]e [C]i [C]g [C]h [C]t O 
) [C]) O 
. [C]. O 

Within [C]W [C]i [C]t [C]h [C]i [C]n O 
6 [C]6 O 
hours [C]h [C]o [C]u [C]r [C]s O 
, [C], O 
an [C]a [C]n O 
accumulation [C]a [C]c [C]c [C]u [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
apolipoprotein [C]a [C]p [C]o [C]l [C]i [C]p [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
B [C]B O 
and [C]a [C]n [C]d O 
epitopes [C]e [C]p [C]i [C]t [C]o [C]p [C]e [C]s S-protein 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
on [C]o [C]n O 
oxLDL [C]o [C]x [C]L [C]D [C]L O 
are [C]a [C]r [C]e O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
arterial [C]a [C]r [C]t [C]e [C]r [C]i [C]a [C]l O 
endothelium [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]u [C]m O 
and [C]a [C]n [C]d O 
media [C]m [C]e [C]d [C]i [C]a O 
. [C]. O 

The [C]T [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
oxLDL [C]o [C]x [C]L [C]D [C]L O 
is [C]i [C]s O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor-kappaB [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
endothelium [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]u [C]m O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
endothelial [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
intercellular [C]i [C]n [C]t [C]e [C]r [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n I-protein 
molecule-1 [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]- [C]1 E-protein 
. [C]. O 

Injection [C]I [C]n [C]j [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
LDL [C]L [C]D [C]L O 
enriched [C]e [C]n [C]r [C]i [C]c [C]h [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
antioxidant [C]a [C]n [C]t [C]i [C]o [C]x [C]i [C]d [C]a [C]n [C]t O 
probucol [C]p [C]r [C]o [C]b [C]u [C]c [C]o [C]l O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
arterial [C]a [C]r [C]t [C]e [C]r [C]i [C]a [C]l O 
accumulation [C]a [C]c [C]c [C]u [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
apolipoprotein [C]a [C]p [C]o [C]l [C]i [C]p [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
B [C]B O 
, [C], O 
but [C]b [C]u [C]t O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
oxLDL-specific [C]o [C]x [C]L [C]D [C]L [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
epitopes [C]e [C]p [C]i [C]t [C]o [C]p [C]e [C]s O 
was [C]w [C]a [C]s O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
at [C]a [C]t O 
24 [C]2 [C]4 O 
hours [C]h [C]o [C]u [C]r [C]s O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
this [C]t [C]h [C]i [C]s O 
simple [C]s [C]i [C]m [C]p [C]l [C]e O 
model [C]m [C]o [C]d [C]e [C]l O 
has [C]h [C]a [C]s O 
the [C]t [C]h [C]e O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
to [C]t [C]o O 
analyze [C]a [C]n [C]a [C]l [C]y [C]z [C]e O 
the [C]t [C]h [C]e O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
behind [C]b [C]e [C]h [C]i [C]n [C]d O 
and [C]a [C]n [C]d O 
biological [C]b [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
LDL [C]L [C]D [C]L O 
oxidation [C]o [C]x [C]i [C]d [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
. [C]. O 

Molecular [C]M [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
of [C]o [C]f O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
gp34 [C]g [C]p [C]3 [C]4 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
trans-activated [C]t [C]r [C]a [C]n [C]s [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
an [C]a [C]n O 
oncoprotein [C]o [C]n [C]c [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
Tax [C]T [C]a [C]x E-protein 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
virus [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
I [C]I O 
. [C]. O 

We [C]W [C]e O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
of [C]o [C]f O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
gp34 [C]g [C]p [C]3 [C]4 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
Tax [C]T [C]a [C]x B-protein 
oncoprotein [C]o [C]n [C]c [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
virus [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
I [C]I O 
( [C]( O 
HTLV-I [C]H [C]T [C]L [C]V [C]- [C]I O 
) [C]) O 
. [C]. O 

gp34 [C]g [C]p [C]3 [C]4 S-protein 
is [C]i [C]s O 
a [C]a O 
type [C]t [C]y [C]p [C]e B-protein 
II [C]I [C]I I-protein 
transmembrane [C]t [C]r [C]a [C]n [C]s [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e I-protein 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e E-protein 
belonging [C]b [C]e [C]l [C]o [C]n [C]g [C]i [C]n [C]g O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
tumor [C]t [C]u [C]m [C]o [C]r O 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
family [C]f [C]a [C]m [C]i [C]l [C]y O 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
constitutively [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
on [C]o [C]n O 
HTLV-I-producing [C]H [C]T [C]L [C]V [C]- [C]I [C]- [C]p [C]r [C]o [C]d [C]u [C]c [C]i [C]n [C]g B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
resting [C]r [C]e [C]s [C]t [C]i [C]n [C]g I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
region [C]r [C]e [C]g [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
gp34 [C]g [C]p [C]3 [C]4 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
was [C]w [C]a [C]s O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
HTLV-I [C]H [C]T [C]L [C]V [C]- [C]I O 
Tax [C]T [C]a [C]x S-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
T [C]T I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e I-cell_line 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t E-cell_line 
, [C], O 
in [C]i [C]n O 
which [C]w [C]h [C]i [C]c [C]h O 
endogenous [C]e [C]n [C]d [C]o [C]g [C]e [C]n [C]o [C]u [C]s O 
gp34 [C]g [C]p [C]3 [C]4 S-protein 
is [C]i [C]s O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
Tax [C]T [C]a [C]x S-protein 
. [C]. O 

Sequence [C]S [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
two [C]t [C]w [C]o O 
NF-kappaB-like [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B [C]- [C]l [C]i [C]k [C]e B-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
( [C]( O 
1 [C]1 O 
and [C]a [C]n [C]d O 
2 [C]2 O 
) [C]) O 
were [C]w [C]e [C]r [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y B-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
. [C]. O 

Both [C]B [C]o [C]t [C]h O 
NF-kappaB-like [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B [C]- [C]l [C]i [C]k [C]e B-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
were [C]w [C]e [C]r [C]e O 
able [C]a [C]b [C]l [C]e O 
to [C]t [C]o O 
bind [C]b [C]i [C]n [C]d O 
to [C]t [C]o O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
or [C]o [C]r O 
its [C]i [C]t [C]s O 
related [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
( [C]( O 
s [C]s O 
) [C]) O 
in [C]i [C]n O 
a [C]a O 
Tax [C]T [C]a [C]x S-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
manner [C]m [C]a [C]n [C]n [C]e [C]r O 
. [C]. O 

Chloramphenicol [C]C [C]h [C]l [C]o [C]r [C]a [C]m [C]p [C]h [C]e [C]n [C]i [C]c [C]o [C]l B-protein 
acetyltransferase [C]a [C]c [C]e [C]t [C]y [C]l [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]r [C]a [C]s [C]e E-protein 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
indicated [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
NF-kappaB-like [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B [C]- [C]l [C]i [C]k [C]e B-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t I-DNA 
1 [C]1 E-DNA 
was [C]w [C]a [C]s O 
Tax [C]T [C]a [C]x S-protein 
-responsive [C]- [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e O 
, [C], O 
although [C]a [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
was [C]w [C]a [C]s O 
lower [C]l [C]o [C]w [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
native [C]n [C]a [C]t [C]i [C]v [C]e B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
-like [C]- [C]l [C]i [C]k [C]e O 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t O 
2 [C]2 O 
elevated [C]e [C]l [C]e [C]v [C]a [C]t [C]e [C]d O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
when [C]w [C]h [C]e [C]n O 
combined [C]c [C]o [C]m [C]b [C]i [C]n [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
NF-kappaB-like [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B [C]- [C]l [C]i [C]k [C]e B-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t I-DNA 
1 [C]1 E-DNA 
, [C], O 
indicating [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]i [C]n [C]g O 
cooperative [C]c [C]o [C]o [C]p [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s O 
for [C]f [C]o [C]r O 
maximum [C]m [C]a [C]x [C]i [C]m [C]u [C]m O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

Unlike [C]U [C]n [C]l [C]i [C]k [C]e O 
typical [C]t [C]y [C]p [C]i [C]c [C]a [C]l O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B B-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
, [C], O 
the [C]t [C]h [C]e O 
NF-kappaB-like [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B [C]- [C]l [C]i [C]k [C]e B-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
in [C]i [C]n O 
gp34 [C]g [C]p [C]3 [C]4 S-protein 
were [C]w [C]e [C]r [C]e O 
not [C]n [C]o [C]t O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
with [C]w [C]i [C]t [C]h O 
phorbol [C]p [C]h [C]o [C]r [C]b [C]o [C]l O 
ester [C]e [C]s [C]t [C]e [C]r O 
despite [C]d [C]e [C]s [C]p [C]i [C]t [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
-like [C]- [C]l [C]i [C]k [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

Chloramphenicol [C]C [C]h [C]l [C]o [C]r [C]a [C]m [C]p [C]h [C]e [C]n [C]i [C]c [C]o [C]l B-protein 
acetyltransferase [C]a [C]c [C]e [C]t [C]y [C]l [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]r [C]a [C]s [C]e E-protein 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
using [C]u [C]s [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
region [C]r [C]e [C]g [C]i [C]o [C]n O 
upstream [C]u [C]p [C]s [C]t [C]r [C]e [C]a [C]m O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
NF-kappaB-like [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B [C]- [C]l [C]i [C]k [C]e B-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
an [C]a [C]n O 
upstream [C]u [C]p [C]s [C]t [C]r [C]e [C]a [C]m O 
region [C]r [C]e [C]g [C]i [C]o [C]n O 
that [C]t [C]h [C]a [C]t O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
from [C]f [C]r [C]o [C]m O 
cognate [C]c [C]o [C]g [C]n [C]a [C]t [C]e B-DNA 
and [C]a [C]n [C]d I-DNA 
noncognate [C]n [C]o [C]n [C]c [C]o [C]g [C]n [C]a [C]t [C]e I-DNA 
core [C]c [C]o [C]r [C]e I-DNA 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s E-DNA 
in [C]i [C]n O 
a [C]a O 
Tax-independent [C]T [C]a [C]x [C]- [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
manner [C]m [C]a [C]n [C]n [C]e [C]r O 
. [C]. O 

Our [C]O [C]u [C]r O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
imply [C]i [C]m [C]p [C]l [C]y O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
gp34 [C]g [C]p [C]3 [C]4 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
and [C]a [C]n [C]d O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
implication [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
gp34 [C]g [C]p [C]3 [C]4 S-protein 
in [C]i [C]n O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
HTLV-I [C]H [C]T [C]L [C]V [C]- [C]I O 
infected [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
T [C]T O 
cells [C]c [C]e [C]l [C]l [C]s O 
. [C]. O 

beta-Amyloid [C]b [C]e [C]t [C]a [C]- [C]A [C]m [C]y [C]l [C]o [C]i [C]d B-protein 
fibrils [C]f [C]i [C]b [C]r [C]i [C]l [C]s E-protein 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
parallel [C]p [C]a [C]r [C]a [C]l [C]l [C]e [C]l O 
mitogen-activated [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
in [C]i [C]n O 
microglia [C]m [C]i [C]c [C]r [C]o [C]g [C]l [C]i [C]a S-cell_type 
and [C]a [C]n [C]d O 
THP1 [C]T [C]H [C]P [C]1 B-cell_line 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_line 
. [C]. O 

The [C]T [C]h [C]e O 
senile [C]s [C]e [C]n [C]i [C]l [C]e O 
plaques [C]p [C]l [C]a [C]q [C]u [C]e [C]s O 
of [C]o [C]f O 
Alzheimer [C]A [C]l [C]z [C]h [C]e [C]i [C]m [C]e [C]r O 
's [C]' [C]s O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
are [C]a [C]r [C]e O 
foci [C]f [C]o [C]c [C]i O 
of [C]o [C]f O 
local [C]l [C]o [C]c [C]a [C]l O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
, [C], O 
as [C]a [C]s O 
evidenced [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
acute [C]a [C]c [C]u [C]t [C]e B-protein 
phase [C]p [C]h [C]a [C]s [C]e I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
and [C]a [C]n [C]d O 
oxidative [C]o [C]x [C]i [C]d [C]a [C]t [C]i [C]v [C]e O 
damage [C]d [C]a [C]m [C]a [C]g [C]e O 
. [C]. O 

Fibrillar [C]F [C]i [C]b [C]r [C]i [C]l [C]l [C]a [C]r B-protein 
forms [C]f [C]o [C]r [C]m [C]s E-protein 
of [C]o [C]f O 
beta-amyloid [C]b [C]e [C]t [C]a [C]- [C]a [C]m [C]y [C]l [C]o [C]i [C]d S-protein 
( [C]( O 
Abeta [C]A [C]b [C]e [C]t [C]a S-protein 
) [C]) O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
are [C]a [C]r [C]e O 
the [C]t [C]h [C]e O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y O 
constituents [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]e [C]n [C]t [C]s O 
of [C]o [C]f O 
senile [C]s [C]e [C]n [C]i [C]l [C]e O 
plaques [C]p [C]l [C]a [C]q [C]u [C]e [C]s O 
, [C], O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
kinase-dependent [C]k [C]i [C]n [C]a [C]s [C]e [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
cascades [C]c [C]a [C]s [C]c [C]a [C]d [C]e [C]s O 
, [C], O 
resulting [C]r [C]e [C]s [C]u [C]l [C]t [C]i [C]n [C]g O 
in [C]i [C]n O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
in [C]i [C]n O 
microglia [C]m [C]i [C]c [C]r [C]o [C]g [C]l [C]i [C]a S-cell_type 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
the [C]t [C]h [C]e O 
downstream [C]d [C]o [C]w [C]n [C]s [C]t [C]r [C]e [C]a [C]m O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
mediating [C]m [C]e [C]d [C]i [C]a [C]t [C]i [C]n [C]g O 
Abeta [C]A [C]b [C]e [C]t [C]a S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
events [C]e [C]v [C]e [C]n [C]t [C]s O 
are [C]a [C]r [C]e O 
not [C]n [C]o [C]t O 
well [C]w [C]e [C]l [C]l O 
characterized [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]d O 
. [C]. O 

We [C]W [C]e O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
that [C]t [C]h [C]a [C]t O 
exposure [C]e [C]x [C]p [C]o [C]s [C]u [C]r [C]e O 
of [C]o [C]f O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y B-cell_type 
rat [C]r [C]a [C]t I-cell_type 
microglia [C]m [C]i [C]c [C]r [C]o [C]g [C]l [C]i [C]a E-cell_type 
and [C]a [C]n [C]d O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
THP1 [C]T [C]H [C]P [C]1 I-cell_line 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_line 
to [C]t [C]o O 
fibrillar [C]f [C]i [C]b [C]r [C]i [C]l [C]l [C]a [C]r B-protein 
Abeta [C]A [C]b [C]e [C]t [C]a E-protein 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
two [C]t [C]w [C]o O 
parallel [C]p [C]a [C]r [C]a [C]l [C]l [C]e [C]l O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
cascades [C]c [C]a [C]s [C]c [C]a [C]d [C]e [C]s O 
involving [C]i [C]n [C]v [C]o [C]l [C]v [C]i [C]n [C]g O 
members [C]m [C]e [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
mitogen-activated [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
( [C]( I-protein 
MAPK [C]M [C]A [C]P [C]K I-protein 
) [C]) I-protein 
superfamily [C]s [C]u [C]p [C]e [C]r [C]f [C]a [C]m [C]i [C]l [C]y E-protein 
. [C]. O 

Abeta [C]A [C]b [C]e [C]t [C]a S-protein 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
rapid [C]r [C]a [C]p [C]i [C]d O 
, [C], O 
transient [C]t [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
extracellular [C]e [C]x [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
signal-regulated [C]s [C]i [C]g [C]n [C]a [C]l [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
1 [C]1 E-protein 
( [C]( O 
ERK1 [C]E [C]R [C]K [C]1 S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
ERK2 [C]E [C]R [C]K [C]2 S-protein 
in [C]i [C]n O 
microglia [C]m [C]i [C]c [C]r [C]o [C]g [C]l [C]i [C]a S-cell_type 
and [C]a [C]n [C]d O 
ERK2 [C]E [C]R [C]K [C]2 S-protein 
in [C]i [C]n O 
THP1 [C]T [C]H [C]P [C]1 B-cell_line 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_line 
. [C]. O 

A [C]A O 
second [C]s [C]e [C]c [C]o [C]n [C]d O 
superfamily [C]s [C]u [C]p [C]e [C]r [C]f [C]a [C]m [C]i [C]l [C]y B-protein 
member [C]m [C]e [C]m [C]b [C]e [C]r E-protein 
, [C], O 
p38 [C]p [C]3 [C]8 B-protein 
MAPK [C]M [C]A [C]P [C]K E-protein 
, [C], O 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
kinetics [C]k [C]i [C]n [C]e [C]t [C]i [C]c [C]s O 
. [C]. O 

Scavenger [C]S [C]c [C]a [C]v [C]e [C]n [C]g [C]e [C]r B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
and [C]a [C]n [C]d O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r B-protein 
for [C]f [C]o [C]r I-protein 
advanced [C]a [C]d [C]v [C]a [C]n [C]c [C]e [C]d I-protein 
glycated [C]g [C]l [C]y [C]c [C]a [C]t [C]e [C]d I-protein 
end [C]e [C]n [C]d I-protein 
products [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]s E-protein 
( [C]( O 
RAGE [C]R [C]A [C]G [C]E S-protein 
) [C]) O 
ligands [C]l [C]i [C]g [C]a [C]n [C]d [C]s O 
failed [C]f [C]a [C]i [C]l [C]e [C]d O 
to [C]t [C]o O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
ERK [C]E [C]R [C]K S-protein 
and [C]a [C]n [C]d O 
p38 [C]p [C]3 [C]8 B-protein 
MAPK [C]M [C]A [C]P [C]K E-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
increases [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
in [C]i [C]n O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
demonstrating [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
scavenger [C]s [C]c [C]a [C]v [C]e [C]n [C]g [C]e [C]r B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
and [C]a [C]n [C]d O 
RAGE [C]R [C]A [C]G [C]E S-protein 
are [C]a [C]r [C]e O 
not [C]n [C]o [C]t O 
linked [C]l [C]i [C]n [C]k [C]e [C]d O 
to [C]t [C]o O 
these [C]t [C]h [C]e [C]s [C]e O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
. [C]. O 

Importantly [C]I [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t [C]l [C]y O 
, [C], O 
the [C]t [C]h [C]e O 
stress-activated [C]s [C]t [C]r [C]e [C]s [C]s [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
kinases [C]k [C]i [C]n [C]a [C]s [C]e [C]s E-protein 
( [C]( O 
SAPKs [C]S [C]A [C]P [C]K [C]s S-protein 
) [C]) O 
were [C]w [C]e [C]r [C]e O 
not [C]n [C]o [C]t O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
Abeta [C]A [C]b [C]e [C]t [C]a S-protein 
. [C]. O 

Downstream [C]D [C]o [C]w [C]n [C]s [C]t [C]r [C]e [C]a [C]m O 
effectors [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
MAPK [C]M [C]A [C]P [C]K O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
cascades [C]c [C]a [C]s [C]c [C]a [C]d [C]e [C]s O 
include [C]i [C]n [C]c [C]l [C]u [C]d [C]e O 
MAPKAP [C]M [C]A [C]P [C]K [C]A [C]P B-protein 
kinases [C]k [C]i [C]n [C]a [C]s [C]e [C]s E-protein 
, [C], O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
RSK1 [C]R [C]S [C]K [C]1 S-protein 
and [C]a [C]n [C]d O 
RSK2 [C]R [C]S [C]K [C]2 S-protein 
, [C], O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

Exposure [C]E [C]x [C]p [C]o [C]s [C]u [C]r [C]e O 
of [C]o [C]f O 
microglia [C]m [C]i [C]c [C]r [C]o [C]g [C]l [C]i [C]a S-cell_type 
and [C]a [C]n [C]d O 
THP1 [C]T [C]H [C]P [C]1 B-cell_line 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_line 
to [C]t [C]o O 
Abeta [C]A [C]b [C]e [C]t [C]a S-protein 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
RSK1 [C]R [C]S [C]K [C]1 S-protein 
and [C]a [C]n [C]d O 
RSK2 [C]R [C]S [C]K [C]2 S-protein 
and [C]a [C]n [C]d O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cAMP [C]c [C]A [C]M [C]P B-protein 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e I-protein 
element-binding [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
at [C]a [C]t O 
Ser133 [C]S [C]e [C]r [C]1 [C]3 [C]3 O 
, [C], O 
providing [C]p [C]r [C]o [C]v [C]i [C]d [C]i [C]n [C]g O 
a [C]a O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
for [C]f [C]o [C]r O 
Abeta [C]A [C]b [C]e [C]t [C]a S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
in [C]i [C]n O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 

Regulation [C]R [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
retinoic [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]c I-protein 
acid [C]a [C]c [C]i [C]d I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
( [C]( O 
CRABP [C]C [C]R [C]A [C]B [C]P B-protein 
II [C]I [C]I E-protein 
) [C]) O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
monocyte [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e E-cell_type 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
. [C]. O 

Cellular [C]C [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
retinoic [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]c I-protein 
acid [C]a [C]c [C]i [C]d I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
( [C]( O 
CRABP [C]C [C]R [C]A [C]B [C]P S-protein 
) [C]) O 
are [C]a [C]r [C]e O 
low [C]l [C]o [C]w B-protein 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r I-protein 
weight [C]w [C]e [C]i [C]g [C]h [C]t I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
whose [C]w [C]h [C]o [C]s [C]e O 
precise [C]p [C]r [C]e [C]c [C]i [C]s [C]e O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
remains [C]r [C]e [C]m [C]a [C]i [C]n [C]s O 
unknown [C]u [C]n [C]k [C]n [C]o [C]w [C]n O 
. [C]. O 

They [C]T [C]h [C]e [C]y O 
bind [C]b [C]i [C]n [C]d O 
retinoids [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]d [C]s O 
and [C]a [C]n [C]d O 
may [C]m [C]a [C]y O 
thereby [C]t [C]h [C]e [C]r [C]e [C]b [C]y O 
modulate [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
steady-state [C]s [C]t [C]e [C]a [C]d [C]y [C]- [C]s [C]t [C]a [C]t [C]e O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
retinoids [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]d [C]s O 
. [C]. O 

Whereas [C]W [C]h [C]e [C]r [C]e [C]a [C]s O 
CRABP [C]C [C]R [C]A [C]B [C]P B-protein 
I [C]I E-protein 
is [C]i [C]s O 
ubiquitously [C]u [C]b [C]i [C]q [C]u [C]i [C]t [C]o [C]u [C]s [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
, [C], O 
CRABP [C]C [C]R [C]A [C]B [C]P B-protein 
II [C]I [C]I E-protein 
is [C]i [C]s O 
mainly [C]m [C]a [C]i [C]n [C]l [C]y O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
in [C]i [C]n O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
cell [C]c [C]e [C]l [C]l O 
types [C]t [C]y [C]p [C]e [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
skin [C]s [C]k [C]i [C]n O 
. [C]. O 

By [C]B [C]y O 
representative [C]r [C]e [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]a [C]t [C]i [C]v [C]e O 
difference [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
we [C]w [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
CRABP [C]C [C]R [C]A [C]B [C]P B-protein 
II [C]I [C]I E-protein 
is [C]i [C]s O 
also [C]a [C]l [C]s [C]o O 
strongly [C]s [C]t [C]r [C]o [C]n [C]g [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
monocyte-derived [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d I-cell_type 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s E-cell_type 
( [C]( O 
MAC [C]M [C]A [C]C S-cell_type 
) [C]) O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
in [C]i [C]n O 
freshly [C]f [C]r [C]e [C]s [C]h [C]l [C]y B-cell_type 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d I-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
( [C]( O 
MO [C]M [C]O S-cell_type 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
CRABP [C]C [C]R [C]A [C]B [C]P B-RNA 
II [C]I [C]I I-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
was [C]w [C]a [C]s O 
gradually [C]g [C]r [C]a [C]d [C]u [C]a [C]l [C]l [C]y O 
upregulated [C]u [C]p [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
from [C]f [C]r [C]o [C]m O 
MO [C]M [C]O S-cell_type 
to [C]t [C]o O 
MAC [C]M [C]A [C]C S-cell_type 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
2 [C]2 O 
% [C]% O 
serum [C]s [C]e [C]r [C]u [C]m O 
. [C]. O 

Adherence [C]A [C]d [C]h [C]e [C]r [C]e [C]n [C]c [C]e O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
for [C]f [C]o [C]r O 
MO [C]M [C]O S-cell_type 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
CRABP [C]C [C]R [C]A [C]B [C]P B-protein 
II [C]I [C]I E-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
but [C]b [C]u [C]t O 
the [C]t [C]h [C]e O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
10 [C]1 [C]0 O 
( [C]( O 
-7 [C]- [C]7 O 
) [C]) O 
M [C]M O 
retinoic [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
upregulation [C]u [C]p [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CRABP [C]C [C]R [C]A [C]B [C]P B-protein 
II [C]I [C]I E-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
MO/MAC [C]M [C]O [C]/ [C]M [C]A [C]C O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

As [C]A [C]s O 
MO [C]M [C]O S-cell_type 
can [C]c [C]a [C]n O 
differentiate [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]e O 
along [C]a [C]l [C]o [C]n [C]g O 
the [C]t [C]h [C]e O 
classical [C]c [C]l [C]a [C]s [C]s [C]i [C]c [C]a [C]l O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
not [C]n [C]o [C]t O 
only [C]o [C]n [C]l [C]y O 
to [C]t [C]o O 
MAC [C]M [C]A [C]C S-cell_type 
but [C]b [C]u [C]t O 
also [C]a [C]l [C]s [C]o O 
to [C]t [C]o O 
dendritic [C]d [C]e [C]n [C]d [C]r [C]i [C]t [C]i [C]c O 
cells [C]c [C]e [C]l [C]l [C]s O 
we [C]w [C]e O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
CRABP [C]C [C]R [C]A [C]B [C]P B-protein 
II [C]I [C]I E-protein 
in [C]i [C]n O 
MO-derived [C]M [C]O [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d B-cell_type 
dendritic [C]d [C]e [C]n [C]d [C]r [C]i [C]t [C]i [C]c I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
cultured [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
10 [C]1 [C]0 O 
% [C]% O 
FCS [C]F [C]C [C]S S-protein 
, [C], O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
GM-CSF [C]G [C]M [C]- [C]C [C]S [C]F S-protein 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
to [C]t [C]o O 
MAC [C]M [C]A [C]C S-cell_type 
, [C], O 
MO-derived [C]M [C]O [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d B-cell_type 
dendritic [C]d [C]e [C]n [C]d [C]r [C]i [C]t [C]i [C]c I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
an [C]a [C]n O 
extremely [C]e [C]x [C]t [C]r [C]e [C]m [C]e [C]l [C]y O 
low [C]l [C]o [C]w O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
CRABP [C]C [C]R [C]A [C]B [C]P B-protein 
II [C]I [C]I E-protein 
. [C]. O 

From [C]F [C]r [C]o [C]m O 
these [C]t [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
we [C]w [C]e O 
conclude [C]c [C]o [C]n [C]c [C]l [C]u [C]d [C]e O 
( [C]( O 
1 [C]1 O 
) [C]) O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
availability [C]a [C]v [C]a [C]i [C]l [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
metabolism [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]s [C]m O 
of [C]o [C]f O 
retinoids [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]d [C]s O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
in [C]i [C]n O 
MAC [C]M [C]A [C]C S-cell_type 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
MO [C]M [C]O S-cell_type 
and [C]a [C]n [C]d O 
dendritic [C]d [C]e [C]n [C]d [C]r [C]i [C]t [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
( [C]( O 
2 [C]2 O 
) [C]) O 
that [C]t [C]h [C]a [C]t O 
this [C]t [C]h [C]i [C]s O 
may [C]m [C]a [C]y O 
influence [C]i [C]n [C]f [C]l [C]u [C]e [C]n [C]c [C]e O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
those [C]t [C]h [C]o [C]s [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
. [C]. O 

Transcription [C]T [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
B-cell-specific [C]B [C]- [C]c [C]e [C]l [C]l [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-protein 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
( [C]( O 
BSAP [C]B [C]S [C]A [C]P S-protein 
) [C]) O 
is [C]i [C]s O 
differentially [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
subsets [C]s [C]u [C]b [C]s [C]e [C]t [C]s O 
of [C]o [C]f O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l O 
lymphomas [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
paired [C]p [C]a [C]i [C]r [C]e [C]d B-DNA 
box [C]b [C]o [C]x I-DNA 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
PAX-5 [C]P [C]A [C]X [C]- [C]5 S-DNA 
encodes [C]e [C]n [C]c [C]o [C]d [C]e [C]s O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
BSAP [C]B [C]S [C]A [C]P S-protein 
( [C]( O 
B-cell-specific [C]B [C]- [C]c [C]e [C]l [C]l [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-protein 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
) [C]) O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
plays [C]p [C]l [C]a [C]y [C]s O 
a [C]a O 
key [C]k [C]e [C]y O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
B-lymphocyte [C]B [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
. [C]. O 

Despite [C]D [C]e [C]s [C]p [C]i [C]t [C]e O 
its [C]i [C]t [C]s O 
known [C]k [C]n [C]o [C]w [C]n O 
involvement [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]m [C]e [C]n [C]t O 
in [C]i [C]n O 
a [C]a O 
rare [C]r [C]a [C]r [C]e O 
subtype [C]s [C]u [C]b [C]t [C]y [C]p [C]e O 
of [C]o [C]f O 
non-Hodgkin [C]n [C]o [C]n [C]- [C]H [C]o [C]d [C]g [C]k [C]i [C]n O 
's [C]' [C]s O 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a O 
( [C]( O 
NHL [C]N [C]H [C]L O 
) [C]) O 
, [C], O 
a [C]a O 
detailed [C]d [C]e [C]t [C]a [C]i [C]l [C]e [C]d O 
examination [C]e [C]x [C]a [C]m [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
BSAP [C]B [C]S [C]A [C]P S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
NHL [C]N [C]H [C]L O 
has [C]h [C]a [C]s O 
not [C]n [C]o [C]t O 
been [C]b [C]e [C]e [C]n O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
reported [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]d O 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
, [C], O 
we [C]w [C]e O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
and [C]a [C]n [C]d O 
malignant [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]t O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d O 
tissues [C]t [C]i [C]s [C]s [C]u [C]e [C]s O 
and [C]a [C]n [C]d O 
cell [C]c [C]e [C]l [C]l B-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
102 [C]1 [C]0 [C]2 O 
cases [C]c [C]a [C]s [C]e [C]s O 
of [C]o [C]f O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l O 
NHL [C]N [C]H [C]L O 
, [C], O 
23 [C]2 [C]3 O 
cases [C]c [C]a [C]s [C]e [C]s O 
of [C]o [C]f O 
T- [C]T [C]- O 
and [C]a [C]n [C]d O 
null-cell [C]n [C]u [C]l [C]l [C]- [C]c [C]e [C]l [C]l O 
NHL [C]N [C]H [C]L O 
, [C], O 
and [C]a [C]n [C]d O 
18 [C]1 [C]8 O 
cases [C]c [C]a [C]s [C]e [C]s O 
of [C]o [C]f O 
Hodgkin [C]H [C]o [C]d [C]g [C]k [C]i [C]n O 
's [C]' [C]s O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
. [C]. O 

Normal [C]N [C]o [C]r [C]m [C]a [C]l O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d O 
tissues [C]t [C]i [C]s [C]s [C]u [C]e [C]s O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
strong [C]s [C]t [C]r [C]o [C]n [C]g O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
BSAP [C]B [C]S [C]A [C]P S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
mantle [C]m [C]a [C]n [C]t [C]l [C]e B-cell_type 
zone [C]z [C]o [C]n [C]e I-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
less [C]l [C]e [C]s [C]s O 
intense [C]i [C]n [C]t [C]e [C]n [C]s [C]e O 
reactivity [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
follicular [C]f [C]o [C]l [C]l [C]i [C]c [C]u [C]l [C]a [C]r B-cell_type 
center [C]c [C]e [C]n [C]t [C]e [C]r I-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
and [C]a [C]n [C]d O 
no [C]n [C]o O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
cells [C]c [C]e [C]l [C]l [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
T-cell-rich [C]T [C]- [C]c [C]e [C]l [C]l [C]- [C]r [C]i [C]c [C]h O 
zones [C]z [C]o [C]n [C]e [C]s O 
. [C]. O 

Monocytoid [C]M [C]o [C]n [C]o [C]c [C]y [C]t [C]o [C]i [C]d B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
weak [C]w [C]e [C]a [C]k O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
plasma [C]p [C]l [C]a [C]s [C]m [C]a B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
extrafollicular [C]e [C]x [C]t [C]r [C]a [C]f [C]o [C]l [C]l [C]i [C]c [C]u [C]l [C]a [C]r B-cell_type 
large [C]l [C]a [C]r [C]g [C]e I-cell_type 
transformed [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]e [C]d I-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
. [C]. O 

Of [C]O [C]f O 
the [C]t [C]h [C]e O 
102 [C]1 [C]0 [C]2 O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l O 
NHLs [C]N [C]H [C]L [C]s O 
, [C], O 
83 [C]8 [C]3 O 
( [C]( O 
81 [C]8 [C]1 O 
% [C]% O 
) [C]) O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
BSAP [C]B [C]S [C]A [C]P S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

All [C]A [C]l [C]l O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
13 [C]1 [C]3 O 
( [C]( O 
100 [C]1 [C]0 [C]0 O 
% [C]% O 
) [C]) O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
lymphocytic [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]i [C]c O 
leukemias [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a [C]s O 
( [C]( O 
B-CLLs [C]B [C]- [C]C [C]L [C]L [C]s O 
) [C]) O 
, [C], O 
21 [C]2 [C]1 O 
of [C]o [C]f O 
( [C]( O 
100 [C]1 [C]0 [C]0 O 
% [C]% O 
) [C]) O 
mantle [C]m [C]a [C]n [C]t [C]l [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
MCLs [C]M [C]C [C]L [C]s S-cell_type 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
20 [C]2 [C]0 O 
of [C]o [C]f O 
21 [C]2 [C]1 O 
( [C]( O 
95 [C]9 [C]5 O 
% [C]% O 
) [C]) O 
follicular [C]f [C]o [C]l [C]l [C]i [C]c [C]u [C]l [C]a [C]r O 
lymphomas [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a [C]s O 
( [C]( O 
FLs [C]F [C]L [C]s O 
) [C]) O 
were [C]w [C]e [C]r [C]e O 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
. [C]. O 

Moderate [C]M [C]o [C]d [C]e [C]r [C]a [C]t [C]e O 
staining [C]s [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
intensities [C]i [C]n [C]t [C]e [C]n [C]s [C]i [C]t [C]i [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
most [C]m [C]o [C]s [C]t O 
B-CLL [C]B [C]- [C]C [C]L [C]L O 
and [C]a [C]n [C]d O 
FL [C]F [C]L O 
cases [C]c [C]a [C]s [C]e [C]s O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
most [C]m [C]o [C]s [C]t O 
MCLs [C]M [C]C [C]L [C]s S-cell_type 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
strong [C]s [C]t [C]r [C]o [C]n [C]g O 
reactions [C]r [C]e [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
, [C], O 
paralleling [C]p [C]a [C]r [C]a [C]l [C]l [C]e [C]l [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
strong [C]s [C]t [C]r [C]o [C]n [C]g O 
reactivity [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
nonmalignant [C]n [C]o [C]n [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]t B-cell_type 
mantle [C]m [C]a [C]n [C]t [C]l [C]e I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Eight [C]E [C]i [C]g [C]h [C]t O 
of [C]o [C]f O 
12 [C]1 [C]2 O 
( [C]( O 
67 [C]6 [C]7 O 
% [C]% O 
) [C]) O 
marginal [C]m [C]a [C]r [C]g [C]i [C]n [C]a [C]l O 
zone [C]z [C]o [C]n [C]e O 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a O 
cases [C]c [C]a [C]s [C]e [C]s O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
or [C]o [C]r O 
low [C]l [C]o [C]w O 
BSAP [C]B [C]S [C]A [C]P S-protein 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
17 [C]1 [C]7 O 
of [C]o [C]f O 
24 [C]2 [C]4 O 
( [C]( O 
71 [C]7 [C]1 O 
% [C]% O 
) [C]) O 
large [C]l [C]a [C]r [C]g [C]e O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l O 
lymphomas [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a [C]s O 
displayed [C]d [C]i [C]s [C]p [C]l [C]a [C]y [C]e [C]d O 
moderate [C]m [C]o [C]d [C]e [C]r [C]a [C]t [C]e O 
to [C]t [C]o O 
strong [C]s [C]t [C]r [C]o [C]n [C]g O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

None [C]N [C]o [C]n [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
23 [C]2 [C]3 O 
T- [C]T [C]- O 
and [C]a [C]n [C]d O 
null-cell [C]n [C]u [C]l [C]l [C]- [C]c [C]e [C]l [C]l O 
lymphomas [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a [C]s O 
reacted [C]r [C]e [C]a [C]c [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
BSAP [C]B [C]S [C]A [C]P S-protein 
antisera [C]a [C]n [C]t [C]i [C]s [C]e [C]r [C]a O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
in [C]i [C]n O 
Hodgkin [C]H [C]o [C]d [C]g [C]k [C]i [C]n O 
's [C]' [C]s O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
, [C], O 
2 [C]2 O 
of [C]o [C]f O 
4 [C]4 O 
( [C]( O 
50 [C]5 [C]0 O 
% [C]% O 
) [C]) O 
nodular [C]n [C]o [C]d [C]u [C]l [C]a [C]r O 
lymphocytic [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]i [C]c O 
predominance [C]p [C]r [C]e [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]c [C]e O 
and [C]a [C]n [C]d O 
5 [C]5 O 
of [C]o [C]f O 
14 [C]1 [C]4 O 
( [C]( O 
36 [C]3 [C]6 O 
% [C]% O 
) [C]) O 
classical [C]c [C]l [C]a [C]s [C]s [C]i [C]c [C]a [C]l O 
cases [C]c [C]a [C]s [C]e [C]s O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
weak [C]w [C]e [C]a [C]k O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
or [C]o [C]r O 
nucleolar [C]n [C]u [C]c [C]l [C]e [C]o [C]l [C]a [C]r O 
BSAP [C]B [C]S [C]A [C]P S-protein 
reactions [C]r [C]e [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
a [C]a O 
fraction [C]f [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
tumor [C]t [C]u [C]m [C]o [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Western [C]W [C]e [C]s [C]t [C]e [C]r [C]n O 
blot [C]b [C]l [C]o [C]t O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
a [C]a O 
52-kD [C]5 [C]2 [C]- [C]k [C]D O 
BSAP [C]B [C]S [C]A [C]P S-protein 
band [C]b [C]a [C]n [C]d O 
in [C]i [C]n O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l B-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
in [C]i [C]n O 
non-B-cell [C]n [C]o [C]n [C]- [C]B [C]- [C]c [C]e [C]l [C]l B-cell_line 
or [C]o [C]r I-cell_line 
plasma [C]p [C]l [C]a [C]s [C]m [C]a I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
. [C]. O 

We [C]W [C]e O 
conclude [C]c [C]o [C]n [C]c [C]l [C]u [C]d [C]e O 
that [C]t [C]h [C]a [C]t O 
BSAP [C]B [C]S [C]A [C]P S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
is [C]i [C]s O 
largely [C]l [C]a [C]r [C]g [C]e [C]l [C]y O 
restricted [C]r [C]e [C]s [C]t [C]r [C]i [C]c [C]t [C]e [C]d O 
to [C]t [C]o O 
lymphomas [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a [C]s O 
of [C]o [C]f O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l B-cell_type 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e E-cell_type 
and [C]a [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
BSAP [C]B [C]S [C]A [C]P S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
varies [C]v [C]a [C]r [C]i [C]e [C]s O 
in [C]i [C]n O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l B-cell_type 
subsets [C]s [C]u [C]b [C]s [C]e [C]t [C]s E-cell_type 
and [C]a [C]n [C]d O 
subtypes [C]s [C]u [C]b [C]t [C]y [C]p [C]e [C]s O 
of [C]o [C]f O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l O 
NHL [C]N [C]H [C]L O 
. [C]. O 

The [C]T [C]h [C]e O 
high [C]h [C]i [C]g [C]h O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
BSAP [C]B [C]S [C]A [C]P S-protein 
, [C], O 
especially [C]e [C]s [C]p [C]e [C]c [C]i [C]a [C]l [C]l [C]y O 
those [C]t [C]h [C]o [C]s [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
large-cell [C]l [C]a [C]r [C]g [C]e [C]- [C]c [C]e [C]l [C]l B-cell_type 
lymphomas [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a [C]s E-cell_type 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
some [C]s [C]o [C]m [C]e O 
follicular [C]f [C]o [C]l [C]l [C]i [C]c [C]u [C]l [C]a [C]r B-cell_type 
lymphomas [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a [C]s E-cell_type 
, [C], O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
a [C]a O 
consequence [C]c [C]o [C]n [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
deregulated [C]d [C]e [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
a [C]a O 
possible [C]p [C]o [C]s [C]s [C]i [C]b [C]l [C]e O 
involvement [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
PAX-5 [C]P [C]A [C]X [C]- [C]5 S-DNA 
in [C]i [C]n O 
certain [C]c [C]e [C]r [C]t [C]a [C]i [C]n O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l O 
malignancies [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]c [C]i [C]e [C]s O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
is [C]i [C]s O 
a [C]a O 
US [C]U [C]S O 
government [C]g [C]o [C]v [C]e [C]r [C]n [C]m [C]e [C]n [C]t O 
work [C]w [C]o [C]r [C]k O 
. [C]. O 

There [C]T [C]h [C]e [C]r [C]e O 
are [C]a [C]r [C]e O 
no [C]n [C]o O 
restrictions [C]r [C]e [C]s [C]t [C]r [C]i [C]c [C]t [C]i [C]o [C]n [C]s O 
on [C]o [C]n O 
its [C]i [C]t [C]s O 
use [C]u [C]s [C]e O 
. [C]. O 

Mitogen [C]M [C]i [C]t [C]o [C]g [C]e [C]n O 
and [C]a [C]n [C]d O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
factor-induced [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
STAT-like [C]S [C]T [C]A [C]T [C]- [C]l [C]i [C]k [C]e B-protein 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e E-protein 
in [C]i [C]n O 
channel [C]c [C]h [C]a [C]n [C]n [C]e [C]l B-cell_type 
catfish [C]c [C]a [C]t [C]f [C]i [C]s [C]h I-cell_type 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
article [C]a [C]r [C]t [C]i [C]c [C]l [C]e O 
describes [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e [C]s O 
the [C]t [C]h [C]e O 
identification [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
putative [C]p [C]u [C]t [C]a [C]t [C]i [C]v [C]e B-protein 
STAT [C]S [C]T [C]A [C]T I-protein 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e E-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
channel [C]c [C]h [C]a [C]n [C]n [C]e [C]l O 
catfish [C]c [C]a [C]t [C]f [C]i [C]s [C]h O 
( [C]( O 
Ictalurus [C]I [C]c [C]t [C]a [C]l [C]u [C]r [C]u [C]s O 
punctatus [C]p [C]u [C]n [C]c [C]t [C]a [C]t [C]u [C]s O 
) [C]) O 
, [C], O 
the [C]t [C]h [C]e O 
first [C]f [C]i [C]r [C]s [C]t O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
of [C]o [C]f O 
such [C]s [C]u [C]c [C]h O 
a [C]a O 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e O 
in [C]i [C]n O 
a [C]a O 
'lower [C]' [C]l [C]o [C]w [C]e [C]r O 
' [C]' O 
vertebrate [C]v [C]e [C]r [C]t [C]e [C]b [C]r [C]a [C]t [C]e O 
. [C]. O 

A [C]A O 
monoclonal [C]m [C]o [C]n [C]o [C]c [C]l [C]o [C]n [C]a [C]l B-protein 
antibody [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y E-protein 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
human [C]h [C]u [C]m [C]a [C]n B-protein 
STAT6 [C]S [C]T [C]A [C]T [C]6 E-protein 
recognizes [C]r [C]e [C]c [C]o [C]g [C]n [C]i [C]z [C]e [C]s O 
an [C]a [C]n O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
100 [C]1 [C]0 [C]0 B-protein 
kDa [C]k [C]D [C]a I-protein 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e E-protein 
that [C]t [C]h [C]a [C]t O 
becomes [C]b [C]e [C]c [C]o [C]m [C]e [C]s O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
and [C]a [C]n [C]d O 
translocates [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]e [C]s O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
nucleus [C]n [C]u [C]c [C]l [C]e [C]u [C]s O 
upon [C]u [C]p [C]o [C]n O 
both [C]b [C]o [C]t [C]h O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
and [C]a [C]n [C]d O 
mitogen [C]m [C]i [C]t [C]o [C]g [C]e [C]n O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
catfish [C]c [C]a [C]t [C]f [C]i [C]s [C]h O 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
presumed [C]p [C]r [C]e [C]s [C]u [C]m [C]e [C]d O 
catfish [C]c [C]a [C]t [C]f [C]i [C]s [C]h B-protein 
STAT [C]S [C]T [C]A [C]T E-protein 
binds [C]b [C]i [C]n [C]d [C]s O 
the [C]t [C]h [C]e O 
mammalian [C]m [C]a [C]m [C]m [C]a [C]l [C]i [C]a [C]n B-DNA 
interferon-gamma [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n [C]- [C]g [C]a [C]m [C]m [C]a I-DNA 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
, [C], O 
a [C]a O 
known [C]k [C]n [C]o [C]w [C]n O 
motif [C]m [C]o [C]t [C]i [C]f O 
of [C]o [C]f O 
mammalian [C]m [C]a [C]m [C]m [C]a [C]l [C]i [C]a [C]n O 
STAT [C]S [C]T [C]A [C]T O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
, [C], O 
as [C]a [C]s O 
shown [C]s [C]h [C]o [C]w [C]n O 
by [C]b [C]y O 
electromobility [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
. [C]. O 

Purification [C]P [C]u [C]r [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
in [C]i [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
DNA [C]D [C]N [C]A B-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
confirms [C]c [C]o [C]n [C]f [C]i [C]r [C]m [C]s O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
catfish [C]c [C]a [C]t [C]f [C]i [C]s [C]h O 
reactive [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]e O 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e O 
binds [C]b [C]i [C]n [C]d [C]s O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
interferon-gamma [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n [C]- [C]g [C]a [C]m [C]m [C]a B-DNA 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n I-DNA 
site [C]s [C]i [C]t [C]e I-DNA 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e E-DNA 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
STAT [C]S [C]T [C]A [C]T B-protein 
molecules [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]s E-protein 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
highly [C]h [C]i [C]g [C]h [C]l [C]y O 
conserved [C]c [C]o [C]n [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
vertebrate [C]v [C]e [C]r [C]t [C]e [C]b [C]r [C]a [C]t [C]e O 
evolution [C]e [C]v [C]o [C]l [C]u [C]t [C]i [C]o [C]n O 
. [C]. O 

Isolation [C]I [C]s [C]o [C]l [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
a [C]a O 
T [C]T B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
clone [C]c [C]l [C]o [C]n [C]e I-cell_line 
variant [C]v [C]a [C]r [C]i [C]a [C]n [C]t E-cell_line 
exhibiting [C]e [C]x [C]h [C]i [C]b [C]i [C]t [C]i [C]n [C]g O 
constitutively [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y O 
phosphorylated [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]e [C]d B-protein 
Ser133 [C]S [C]e [C]r [C]1 [C]3 [C]3 I-protein 
cAMP [C]c [C]A [C]M [C]P I-protein 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e I-protein 
element-binding [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
. [C]. O 

In [C]I [C]n O 
driving [C]d [C]r [C]i [C]v [C]i [C]n [C]g O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
stimulates [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]s O 
a [C]a O 
new [C]n [C]e [C]w O 
program [C]p [C]r [C]o [C]g [C]r [C]a [C]m O 
of [C]o [C]f O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
that [C]t [C]h [C]a [C]t O 
includes [C]i [C]n [C]c [C]l [C]u [C]d [C]e [C]s O 
proliferating [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]n [C]g B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-protein 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n E-protein 
( [C]( O 
PCNA [C]P [C]C [C]N [C]A S-protein 
) [C]) O 
, [C], O 
a [C]a O 
requisite [C]r [C]e [C]q [C]u [C]i [C]s [C]i [C]t [C]e O 
processivity [C]p [C]r [C]o [C]c [C]e [C]s [C]s [C]i [C]v [C]i [C]t [C]y O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
for [C]f [C]o [C]r O 
DNA [C]D [C]N [C]A B-protein 
polymerase [C]p [C]o [C]l [C]y [C]m [C]e [C]r [C]a [C]s [C]e I-protein 
delta [C]d [C]e [C]l [C]t [C]a E-protein 
. [C]. O 

PCNA [C]P [C]C [C]N [C]A S-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
part [C]p [C]a [C]r [C]t O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
tandem [C]t [C]a [C]n [C]d [C]e [C]m O 
CRE [C]C [C]R [C]E B-DNA 
sequences [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s E-DNA 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r B-protein 
and [C]a [C]n [C]d I-protein 
CRE [C]C [C]R [C]E I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
; [C]; O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
stimulates [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]s O 
CREB [C]C [C]R [C]E [C]B O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
resting [C]r [C]e [C]s [C]t [C]i [C]n [C]g B-cell_line 
cloned [C]c [C]l [C]o [C]n [C]e [C]d I-cell_line 
T [C]T I-cell_line 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e E-cell_line 
, [C], O 
L2 [C]L [C]2 S-cell_line 
. [C]. O 

After [C]A [C]f [C]t [C]e [C]r O 
culturing [C]c [C]u [C]l [C]t [C]u [C]r [C]i [C]n [C]g O 
L2 [C]L [C]2 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
for [C]f [C]o [C]r O 
greater [C]g [C]r [C]e [C]a [C]t [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
91 [C]9 [C]1 O 
days [C]d [C]a [C]y [C]s O 
, [C], O 
we [C]w [C]e O 
consistently [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]t [C]l [C]y O 
isolate [C]i [C]s [C]o [C]l [C]a [C]t [C]e O 
a [C]a O 
stable [C]s [C]t [C]a [C]b [C]l [C]e O 
variant [C]v [C]a [C]r [C]i [C]a [C]n [C]t O 
that [C]t [C]h [C]a [C]t O 
exhibits [C]e [C]x [C]h [C]i [C]b [C]i [C]t [C]s O 
constitutive [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
CREB [C]C [C]R [C]E [C]B O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

L2 [C]L [C]2 B-cell_line 
and [C]a [C]n [C]d I-cell_line 
L2 [C]L [C]2 I-cell_line 
variant [C]v [C]a [C]r [C]i [C]a [C]n [C]t I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
were [C]w [C]e [C]r [C]e O 
tested [C]t [C]e [C]s [C]t [C]e [C]d O 
for [C]f [C]o [C]r O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
responsiveness [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e [C]n [C]e [C]s [C]s O 
and [C]a [C]n [C]d O 
rapamycin [C]r [C]a [C]p [C]a [C]m [C]y [C]c [C]i [C]n O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
with [C]w [C]i [C]t [C]h O 
respect [C]r [C]e [C]s [C]p [C]e [C]c [C]t O 
to [C]t [C]o O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
, [C], O 
PCNA [C]P [C]C [C]N [C]A O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

In [C]I [C]n O 
L2 [C]L [C]2 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
, [C], O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
and [C]a [C]n [C]d O 
rapamycin [C]r [C]a [C]p [C]a [C]m [C]y [C]c [C]i [C]n O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
: [C]: O 
cAMP-independent [C]c [C]A [C]M [C]P [C]- [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
CREB [C]C [C]R [C]E [C]B B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
, [C], O 
PCNA [C]P [C]C [C]N [C]A O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

In [C]I [C]n O 
L2 [C]L [C]2 B-cell_line 
variant [C]v [C]a [C]r [C]i [C]a [C]n [C]t I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
, [C], O 
CREB [C]C [C]R [C]E [C]B B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
was [C]w [C]a [C]s O 
constitutively [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y O 
high [C]h [C]i [C]g [C]h O 
; [C]; O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
and [C]a [C]n [C]d O 
rapamycin [C]r [C]a [C]p [C]a [C]m [C]y [C]c [C]i [C]n O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
PCNA [C]P [C]C [C]N [C]A O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
a [C]a O 
rapamycin-sensitive [C]r [C]a [C]p [C]a [C]m [C]y [C]c [C]i [C]n [C]- [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
, [C], O 
cAMP-independent [C]c [C]A [C]M [C]P [C]- [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
CREB [C]C [C]R [C]E [C]B B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
L2 [C]L [C]2 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CREB [C]C [C]R [C]E [C]B S-protein 
alone [C]a [C]l [C]o [C]n [C]e O 
is [C]i [C]s O 
not [C]n [C]o [C]t O 
sufficient [C]s [C]u [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
to [C]t [C]o O 
drive [C]d [C]r [C]i [C]v [C]e O 
PCNA [C]P [C]C [C]N [C]A S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
L2 [C]L [C]2 O 
cell [C]c [C]e [C]l [C]l O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
. [C]. O 

Serotonin [C]S [C]e [C]r [C]o [C]t [C]o [C]n [C]i [C]n O 
derivative [C]d [C]e [C]r [C]i [C]v [C]a [C]t [C]i [C]v [C]e O 
, [C], O 
N- [C]N [C]- O 
( [C]( O 
p-coumaroyl [C]p [C]- [C]c [C]o [C]u [C]m [C]a [C]r [C]o [C]y [C]l O 
) [C]) O 
serotonin [C]s [C]e [C]r [C]o [C]t [C]o [C]n [C]i [C]n O 
, [C], O 
inhibits [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]s O 
the [C]t [C]h [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
, [C], O 
IL-1alpha [C]I [C]L [C]- [C]1 [C]a [C]l [C]p [C]h [C]a S-protein 
, [C], O 
IL-1beta [C]I [C]L [C]- [C]1 [C]b [C]e [C]t [C]a S-protein 
, [C], O 
and [C]a [C]n [C]d O 
IL-6 [C]I [C]L [C]- [C]6 S-protein 
by [C]b [C]y O 
endotoxin-stimulated [C]e [C]n [C]d [C]o [C]t [C]o [C]x [C]i [C]n [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
reported [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
N- [C]N [C]- O 
( [C]( O 
p-coumaroyl [C]p [C]- [C]c [C]o [C]u [C]m [C]a [C]r [C]o [C]y [C]l O 
) [C]) O 
serotonin [C]s [C]e [C]r [C]o [C]t [C]o [C]n [C]i [C]n O 
( [C]( O 
CS [C]C [C]S O 
) [C]) O 
and [C]a [C]n [C]d O 
its [C]i [C]t [C]s O 
derivatives [C]d [C]e [C]r [C]i [C]v [C]a [C]t [C]i [C]v [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
antioxidative [C]a [C]n [C]t [C]i [C]o [C]x [C]i [C]d [C]a [C]t [C]i [C]v [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
are [C]a [C]r [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
in [C]i [C]n O 
safflower [C]s [C]a [C]f [C]f [C]l [C]o [C]w [C]e [C]r O 
seeds [C]s [C]e [C]e [C]d [C]s O 
. [C]. O 

As [C]A [C]s O 
reactive [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]e O 
oxygen [C]o [C]x [C]y [C]g [C]e [C]n O 
species [C]s [C]p [C]e [C]c [C]i [C]e [C]s O 
( [C]( O 
ROS [C]R [C]O [C]S O 
) [C]) O 
are [C]a [C]r [C]e O 
implicated [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
of [C]o [C]f O 
lipopolysaccharide [C]l [C]i [C]p [C]o [C]p [C]o [C]l [C]y [C]s [C]a [C]c [C]c [C]h [C]a [C]r [C]i [C]d [C]e O 
( [C]( O 
LPS [C]L [C]P [C]S O 
) [C]) O 
, [C], O 
we [C]w [C]e O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
CS [C]C [C]S O 
has [C]h [C]a [C]s O 
a [C]a O 
suppressive [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]v [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y B-protein 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e E-protein 
generation [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
from [C]f [C]r [C]o [C]m O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
monocyte [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e E-cell_type 
s [C]s O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
. [C]. O 

CS [C]C [C]S O 
at [C]a [C]t O 
50-200 [C]5 [C]0 [C]- [C]2 [C]0 [C]0 O 
microM [C]m [C]i [C]c [C]r [C]o [C]M O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
tumor [C]t [C]u [C]m [C]o [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
( [C]( O 
TNF [C]T [C]N [C]F S-protein 
) [C]) O 
, [C], O 
interleukin-1 [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]1 S-protein 
( [C]( O 
IL-1 [C]I [C]L [C]- [C]1 S-protein 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
IL-6 [C]I [C]L [C]- [C]6 S-protein 
activities [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]i [C]e [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
supernatants [C]s [C]u [C]p [C]e [C]r [C]n [C]a [C]t [C]a [C]n [C]t [C]s O 
from [C]f [C]r [C]o [C]m O 
LPS-stimulated [C]L [C]P [C]S [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_line 
human [C]h [C]u [C]m [C]a [C]n I-cell_line 
blood [C]b [C]l [C]o [C]o [C]d I-cell_line 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_line 
without [C]w [C]i [C]t [C]h [C]o [C]u [C]t O 
cytotoxicity [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c [C]i [C]t [C]y O 
. [C]. O 

ELISA [C]E [C]L [C]I [C]S [C]A O 
assay [C]a [C]s [C]s [C]a [C]y O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
, [C], O 
IL-1alpha [C]I [C]L [C]- [C]1 [C]a [C]l [C]p [C]h [C]a S-protein 
, [C], O 
IL-1beta [C]I [C]L [C]- [C]1 [C]b [C]e [C]t [C]a S-protein 
, [C], O 
and [C]a [C]n [C]d O 
IL-6 [C]I [C]L [C]- [C]6 S-protein 
was [C]w [C]a [C]s O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
by [C]b [C]y O 
CS [C]C [C]S O 
. [C]. O 

Northern [C]N [C]o [C]r [C]t [C]h [C]e [C]r [C]n O 
blot [C]b [C]l [C]o [C]t O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
LPS-induced [C]L [C]P [C]S [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
in [C]i [C]n O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
was [C]w [C]a [C]s O 
suppressed [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
by [C]b [C]y O 
CS [C]C [C]S O 
. [C]. O 

NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
by [C]b [C]y O 
CS [C]C [C]S O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
CS [C]C [C]S O 
has [C]h [C]a [C]s O 
a [C]a O 
suppressive [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]v [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
proinflammatory [C]p [C]r [C]o [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
from [C]f [C]r [C]o [C]m O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
, [C], O 
and [C]a [C]n [C]d O 
this [C]t [C]h [C]i [C]s O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
is [C]i [C]s O 
based [C]b [C]a [C]s [C]e [C]d O 
in [C]i [C]n O 
part [C]p [C]a [C]r [C]t O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
suppression [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Elevated [C]E [C]l [C]e [C]v [C]a [C]t [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n B-RNA 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y I-RNA 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-RNA 
nm23 [C]n [C]m [C]2 [C]3 I-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
in [C]i [C]n O 
monoblastic [C]m [C]o [C]n [C]o [C]b [C]l [C]a [C]s [C]t [C]i [C]c O 
crisis [C]c [C]r [C]i [C]s [C]i [C]s O 
of [C]o [C]f O 
a [C]a O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
myelogenous [C]m [C]y [C]e [C]l [C]o [C]g [C]e [C]n [C]o [C]u [C]s O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
. [C]. O 

Differentiation [C]D [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n B-protein 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
nm23 [C]n [C]m [C]2 [C]3 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
high [C]h [C]i [C]g [C]h O 
quantities [C]q [C]u [C]a [C]n [C]t [C]i [C]t [C]i [C]e [C]s O 
in [C]i [C]n O 
acute [C]a [C]c [C]u [C]t [C]e O 
myelogenous [C]m [C]y [C]e [C]l [C]o [C]g [C]e [C]n [C]o [C]u [C]s O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
( [C]( O 
AML [C]A [C]M [C]L O 
) [C]) O 
, [C], O 
especially [C]e [C]s [C]p [C]e [C]c [C]i [C]a [C]l [C]l [C]y O 
in [C]i [C]n O 
acute [C]a [C]c [C]u [C]t [C]e O 
monocytic [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
( [C]( O 
AML-M5 [C]A [C]M [C]L [C]- [C]M [C]5 O 
) [C]) O 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
suggested [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]e [C]d O 
as [C]a [C]s O 
a [C]a O 
new [C]n [C]e [C]w O 
prognostic [C]p [C]r [C]o [C]g [C]n [C]o [C]s [C]t [C]i [C]c O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
in [C]i [C]n O 
AML-M5 [C]A [C]M [C]L [C]- [C]M [C]5 O 
. [C]. O 

We [C]W [C]e O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
an [C]a [C]n O 
example [C]e [C]x [C]a [C]m [C]p [C]l [C]e O 
of [C]o [C]f O 
elevated [C]e [C]l [C]e [C]v [C]a [C]t [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
nm23 [C]n [C]m [C]2 [C]3 B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
in [C]i [C]n O 
a [C]a O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
myelogenous [C]m [C]y [C]e [C]l [C]o [C]g [C]e [C]n [C]o [C]u [C]s O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
( [C]( O 
CML [C]C [C]M [C]L O 
) [C]) O 
who [C]w [C]h [C]o O 
developed [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]e [C]d O 
monoblastic [C]m [C]o [C]n [C]o [C]b [C]l [C]a [C]s [C]t [C]i [C]c O 
crisis [C]c [C]r [C]i [C]s [C]i [C]s O 
. [C]. O 

Relative [C]R [C]e [C]l [C]a [C]t [C]i [C]v [C]e O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
nm23-H1 [C]n [C]m [C]2 [C]3 [C]- [C]H [C]1 B-RNA 
and [C]a [C]n [C]d I-RNA 
-H2 [C]- [C]H [C]2 I-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
extracted [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
's [C]' [C]s O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
bone [C]b [C]o [C]n [C]e B-cell_type 
marrow [C]m [C]a [C]r [C]r [C]o [C]w I-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
by [C]b [C]y O 
quantitative [C]q [C]u [C]a [C]n [C]t [C]i [C]t [C]a [C]t [C]i [C]v [C]e O 
reverse [C]r [C]e [C]v [C]e [C]r [C]s [C]e O 
transcriptase [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]a [C]s [C]e O 
polymerase [C]p [C]o [C]l [C]y [C]m [C]e [C]r [C]a [C]s [C]e O 
chain [C]c [C]h [C]a [C]i [C]n O 
reaction [C]r [C]e [C]a [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
nm23-H1 [C]n [C]m [C]2 [C]3 [C]- [C]H [C]1 B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
in [C]i [C]n O 
CML [C]C [C]M [C]L B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
phase [C]p [C]h [C]a [C]s [C]e O 
was [C]w [C]a [C]s O 
as [C]a [C]s O 
high [C]h [C]i [C]g [C]h O 
as [C]a [C]s O 
that [C]t [C]h [C]a [C]t O 
in [C]i [C]n O 
bone [C]b [C]o [C]n [C]e B-cell_type 
marrow [C]m [C]a [C]r [C]r [C]o [C]w I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
healthy [C]h [C]e [C]a [C]l [C]t [C]h [C]y O 
volunteers [C]v [C]o [C]l [C]u [C]n [C]t [C]e [C]e [C]r [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
mRNA [C]m [C]R [C]N [C]A O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
nm23-H2 [C]n [C]m [C]2 [C]3 [C]- [C]H [C]2 S-protein 
was [C]w [C]a [C]s O 
slightly [C]s [C]l [C]i [C]g [C]h [C]t [C]l [C]y O 
below [C]b [C]e [C]l [C]o [C]w O 
the [C]t [C]h [C]e O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
level [C]l [C]e [C]v [C]e [C]l O 
. [C]. O 

At [C]A [C]t O 
blastic [C]b [C]l [C]a [C]s [C]t [C]i [C]c O 
crisis [C]c [C]r [C]i [C]s [C]i [C]s O 
, [C], O 
however [C]h [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
nm23-H1 [C]n [C]m [C]2 [C]3 [C]- [C]H [C]1 B-RNA 
and [C]a [C]n [C]d I-RNA 
-H2 [C]- [C]H [C]2 I-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
was [C]w [C]a [C]s O 
elevated [C]e [C]l [C]e [C]v [C]a [C]t [C]e [C]d O 
to [C]t [C]o O 
about [C]a [C]b [C]o [C]u [C]t O 
three [C]t [C]h [C]r [C]e [C]e O 
to [C]t [C]o O 
nine [C]n [C]i [C]n [C]e O 
times [C]t [C]i [C]m [C]e [C]s O 
of [C]o [C]f O 
that [C]t [C]h [C]a [C]t O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
phase [C]p [C]h [C]a [C]s [C]e O 
. [C]. O 

Proliferated [C]P [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]e [C]d B-cell_type 
blastic [C]b [C]l [C]a [C]s [C]t [C]i [C]c I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
for [C]f [C]o [C]r O 
non-specific [C]n [C]o [C]n [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-protein 
esterase [C]e [C]s [C]t [C]e [C]r [C]a [C]s [C]e E-protein 
, [C], O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
serum [C]s [C]e [C]r [C]u [C]m O 
lysozyme [C]l [C]y [C]s [C]o [C]z [C]y [C]m [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
was [C]w [C]a [C]s O 
elevated [C]e [C]l [C]e [C]v [C]a [C]t [C]e [C]d O 
and [C]a [C]n [C]d O 
diagnosed [C]d [C]i [C]a [C]g [C]n [C]o [C]s [C]e [C]d O 
as [C]a [C]s O 
monoblastic [C]m [C]o [C]n [C]o [C]b [C]l [C]a [C]s [C]t [C]i [C]c O 
crisis [C]c [C]r [C]i [C]s [C]i [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
received [C]r [C]e [C]c [C]e [C]i [C]v [C]e [C]d O 
combined [C]c [C]o [C]m [C]b [C]i [C]n [C]e [C]d O 
chemotherapy [C]c [C]h [C]e [C]m [C]o [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
but [C]b [C]u [C]t O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
was [C]w [C]a [C]s O 
partial [C]p [C]a [C]r [C]t [C]i [C]a [C]l O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
are [C]a [C]r [C]e O 
compatible [C]c [C]o [C]m [C]p [C]a [C]t [C]i [C]b [C]l [C]e O 
with [C]w [C]i [C]t [C]h O 
our [C]o [C]u [C]r O 
previous [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
that [C]t [C]h [C]a [C]t O 
nm23 [C]n [C]m [C]2 [C]3 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
is [C]i [C]s O 
overexpressed [C]o [C]v [C]e [C]r [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
monocytic [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
. [C]. O 

Increased [C]I [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
decreases [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
the [C]t [C]h [C]e O 
spontaneous [C]s [C]p [C]o [C]n [C]t [C]a [C]n [C]e [C]o [C]u [C]s O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
rate [C]r [C]a [C]t [C]e O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
thymidine [C]t [C]h [C]y [C]m [C]i [C]d [C]i [C]n [C]e B-DNA 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-DNA 
locus [C]l [C]o [C]c [C]u [C]s E-DNA 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Transcription [C]T [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
increases [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
DNA [C]D [C]N [C]A O 
repair [C]r [C]e [C]p [C]a [C]i [C]r O 
efficiency [C]e [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
and [C]a [C]n [C]d O 
modulates [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]e [C]s O 
the [C]t [C]h [C]e O 
distribution [C]d [C]i [C]s [C]t [C]r [C]i [C]b [C]u [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
certain [C]c [C]e [C]r [C]t [C]a [C]i [C]n O 
types [C]t [C]y [C]p [C]e [C]s O 
of [C]o [C]f O 
DNA [C]D [C]N [C]A O 
damage [C]d [C]a [C]m [C]a [C]g [C]e O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
level [C]l [C]e [C]v [C]e [C]l O 
stimulates [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]s O 
spontaneous [C]s [C]p [C]o [C]n [C]t [C]a [C]n [C]e [C]o [C]u [C]s O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
rate [C]r [C]a [C]t [C]e O 
in [C]i [C]n O 
yeast [C]y [C]e [C]a [C]s [C]t O 
. [C]. O 

We [C]W [C]e O 
explored [C]e [C]x [C]p [C]l [C]o [C]r [C]e [C]d O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
level [C]l [C]e [C]v [C]e [C]l O 
affects [C]a [C]f [C]f [C]e [C]c [C]t [C]s O 
spontaneous [C]s [C]p [C]o [C]n [C]t [C]a [C]n [C]e [C]o [C]u [C]s O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
rate [C]r [C]a [C]t [C]e O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

We [C]W [C]e O 
first [C]f [C]i [C]r [C]s [C]t O 
developed [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]e [C]d O 
two [C]t [C]w [C]o O 
thymidine [C]t [C]h [C]y [C]m [C]i [C]d [C]i [C]n [C]e B-cell_line 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-cell_line 
( [C]( I-cell_line 
tk [C]t [C]k I-cell_line 
) [C]) I-cell_line 
inducible [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e I-cell_line 
human [C]h [C]u [C]m [C]a [C]n I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
using [C]u [C]s [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
Gal4-Estrogen [C]G [C]a [C]l [C]4 [C]- [C]E [C]s [C]t [C]r [C]o [C]g [C]e [C]n O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
. [C]. O 

In [C]I [C]n O 
our [C]o [C]u [C]r O 
TK6i-G3 [C]T [C]K [C]6 [C]i [C]- [C]G [C]3 B-cell_line 
and [C]a [C]n [C]d I-cell_line 
G9 [C]G [C]9 I-cell_line 
tk [C]t [C]k I-cell_line 
heterozygous [C]h [C]e [C]t [C]e [C]r [C]o [C]z [C]y [C]g [C]o [C]u [C]s I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
, [C], O 
the [C]t [C]h [C]e O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
tk [C]t [C]k B-DNA 
allele [C]a [C]l [C]l [C]e [C]l [C]e E-DNA 
is [C]i [C]s O 
linked [C]l [C]i [C]n [C]k [C]e [C]d O 
to [C]t [C]o O 
an [C]a [C]n O 
inducible [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r B-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
. [C]. O 

Tk [C]T [C]k B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
is [C]i [C]s O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n O 
. [C]. O 

Spontaneous [C]S [C]p [C]o [C]n [C]t [C]a [C]n [C]e [C]o [C]u [C]s O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
rate [C]r [C]a [C]t [C]e O 
was [C]w [C]a [C]s O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
after [C]a [C]f [C]t [C]e [C]r O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
in [C]i [C]n O 
yeast [C]y [C]e [C]a [C]s [C]t O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
humans [C]h [C]u [C]m [C]a [C]n [C]s O 
may [C]m [C]a [C]y O 
have [C]h [C]a [C]v [C]e O 
evolved [C]e [C]v [C]o [C]l [C]v [C]e [C]d O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
or [C]o [C]r O 
additional [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n [C]a [C]l O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
to [C]t [C]o O 
deal [C]d [C]e [C]a [C]l O 
with [C]w [C]i [C]t [C]h O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
related [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
spontaneous [C]s [C]p [C]o [C]n [C]t [C]a [C]n [C]e [C]o [C]u [C]s O 
mutagenesis [C]m [C]u [C]t [C]a [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
. [C]. O 

Copyright [C]C [C]o [C]p [C]y [C]r [C]i [C]g [C]h [C]t O 
1998 [C]1 [C]9 [C]9 [C]8 O 
Elsevier [C]E [C]l [C]s [C]e [C]v [C]i [C]e [C]r O 
Science [C]S [C]c [C]i [C]e [C]n [C]c [C]e O 
B.V [C]B [C]. [C]V O 
. [C]. O 

All [C]A [C]l [C]l O 
rights [C]r [C]i [C]g [C]h [C]t [C]s O 
reserved [C]r [C]e [C]s [C]e [C]r [C]v [C]e [C]d O 
. [C]. O 

Mutation [C]M [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
BCL-6 [C]B [C]C [C]L [C]- [C]6 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
of [C]o [C]f O 
somatic [C]s [C]o [C]m [C]a [C]t [C]i [C]c O 
hypermutation [C]h [C]y [C]p [C]e [C]r [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Ig [C]I [C]g B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
. [C]. O 

Immunoglobulin [C]I [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n B-DNA 
( [C]( I-DNA 
Ig [C]I [C]g I-DNA 
) [C]) I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
are [C]a [C]r [C]e O 
hypermutated [C]h [C]y [C]p [C]e [C]r [C]m [C]u [C]t [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
B [C]B B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
that [C]t [C]h [C]a [C]t O 
are [C]a [C]r [C]e O 
the [C]t [C]h [C]e O 
precursors [C]p [C]r [C]e [C]c [C]u [C]r [C]s [C]o [C]r [C]s O 
to [C]t [C]o O 
memory [C]m [C]e [C]m [C]o [C]r [C]y B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
are [C]a [C]r [C]e O 
linked [C]l [C]i [C]n [C]k [C]e [C]d O 
to [C]t [C]o O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
initiation [C]i [C]n [C]i [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
but [C]b [C]u [C]t O 
non-Ig [C]n [C]o [C]n [C]- [C]I [C]g B-DNA 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s E-DNA 
are [C]a [C]r [C]e O 
permissible [C]p [C]e [C]r [C]m [C]i [C]s [C]s [C]i [C]b [C]l [C]e O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
; [C]; O 
thus [C]t [C]h [C]u [C]s O 
, [C], O 
other [C]o [C]t [C]h [C]e [C]r O 
genes [C]g [C]e [C]n [C]e [C]s O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
mutating [C]m [C]u [C]t [C]a [C]t [C]i [C]n [C]g O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
may [C]m [C]a [C]y O 
also [C]a [C]l [C]s [C]o O 
be [C]b [C]e O 
subject [C]s [C]u [C]b [C]j [C]e [C]c [C]t O 
to [C]t [C]o O 
somatic [C]s [C]o [C]m [C]a [C]t [C]i [C]c O 
hypermutation [C]h [C]y [C]p [C]e [C]r [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Significant [C]S [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
were [C]w [C]e [C]r [C]e O 
not [C]n [C]o [C]t O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
c-MYC [C]c [C]- [C]M [C]Y [C]C B-DNA 
, [C], I-DNA 
S14 [C]S [C]1 [C]4 I-DNA 
, [C], I-DNA 
or [C]o [C]r I-DNA 
alpha-fetoprotein [C]a [C]l [C]p [C]h [C]a [C]- [C]f [C]e [C]t [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-DNA 
( [C]( I-DNA 
AFP [C]A [C]F [C]P I-DNA 
) [C]) I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
, [C], O 
but [C]b [C]u [C]t O 
BCL-6 [C]B [C]C [C]L [C]- [C]6 S-protein 
was [C]w [C]a [C]s O 
highly [C]h [C]i [C]g [C]h [C]l [C]y O 
mutated [C]m [C]u [C]t [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
a [C]a O 
large [C]l [C]a [C]r [C]g [C]e O 
proportion [C]p [C]r [C]o [C]p [C]o [C]r [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
memory [C]m [C]e [C]m [C]o [C]r [C]y B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
of [C]o [C]f O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
individuals [C]i [C]n [C]d [C]i [C]v [C]i [C]d [C]u [C]a [C]l [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
pattern [C]p [C]a [C]t [C]t [C]e [C]r [C]n O 
was [C]w [C]a [C]s O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
to [C]t [C]o O 
that [C]t [C]h [C]a [C]t O 
of [C]o [C]f O 
Ig [C]I [C]g B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
. [C]. O 

CD28-mediated [C]C [C]D [C]2 [C]8 [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
CD45RA+ [C]C [C]D [C]4 [C]5 [C]R [C]A [C]+ B-cell_type 
and [C]a [C]n [C]d I-cell_type 
CD45RO+ [C]C [C]D [C]4 [C]5 [C]R [C]O [C]+ I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
: [C]: O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
reactive [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]e O 
oxygen [C]o [C]x [C]y [C]g [C]e [C]n O 
intermediates [C]i [C]n [C]t [C]e [C]r [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]s O 
and [C]a [C]n [C]d O 
c-Rel [C]c [C]- [C]R [C]e [C]l O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
translocation [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
CD45RA+ [C]C [C]D [C]4 [C]5 [C]R [C]A [C]+ B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
the [C]t [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
complete [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
( [C]( O 
anti-CD3 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]3 O 
plus [C]p [C]l [C]u [C]s O 
anti-CD28 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]2 [C]8 O 
) [C]) O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
in [C]i [C]n O 
CD45RA+ [C]C [C]D [C]4 [C]5 [C]R [C]A [C]+ B-cell_type 
( [C]( I-cell_type 
naive [C]n [C]a [C]i [C]v [C]e I-cell_type 
) [C]) I-cell_type 
and [C]a [C]n [C]d I-cell_type 
CD45RO+ [C]C [C]D [C]4 [C]5 [C]R [C]O [C]+ I-cell_type 
( [C]( I-cell_type 
memory/effector [C]m [C]e [C]m [C]o [C]r [C]y [C]/ [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r I-cell_type 
) [C]) I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Long [C]L [C]o [C]n [C]g O 
exposure [C]e [C]x [C]p [C]o [C]s [C]u [C]r [C]e O 
( [C]( O 
24 [C]2 [C]4 O 
h [C]h O 
) [C]) O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
stronger [C]s [C]t [C]r [C]o [C]n [C]g [C]e [C]r O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
in [C]i [C]n O 
CD45RA+ [C]C [C]D [C]4 [C]5 [C]R [C]A [C]+ B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
than [C]t [C]h [C]a [C]n O 
in [C]i [C]n O 
CD45RO+ [C]C [C]D [C]4 [C]5 [C]R [C]O [C]+ B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Analysis [C]A [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
c-Rel [C]c [C]- [C]R [C]e [C]l I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
indicated [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
after [C]a [C]f [C]t [C]e [C]r O 
anti-CD3+anti-CD28 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]3 [C]+ [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]2 [C]8 O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
the [C]t [C]h [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
c-Rel [C]c [C]- [C]R [C]e [C]l S-protein 
was [C]w [C]a [C]s O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
in [C]i [C]n O 
CD45RA+ [C]C [C]D [C]4 [C]5 [C]R [C]A [C]+ B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Analysis [C]A [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c B-protein 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r E-protein 
IkappaBalpha [C]I [C]k [C]a [C]p [C]p [C]a [C]B [C]a [C]l [C]p [C]h [C]a S-protein 
indicated [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
anti-CD3+anti-CD28 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]3 [C]+ [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]2 [C]8 O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
a [C]a O 
long-lasting [C]l [C]o [C]n [C]g [C]- [C]l [C]a [C]s [C]t [C]i [C]n [C]g O 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
CD45RA+ [C]C [C]D [C]4 [C]5 [C]R [C]A [C]+ B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
but [C]b [C]u [C]t O 
in [C]i [C]n O 
CD45RO+ [C]C [C]D [C]4 [C]5 [C]R [C]O [C]+ B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
the [C]t [C]h [C]e O 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
was [C]w [C]a [C]s O 
more [C]m [C]o [C]r [C]e O 
rapid [C]r [C]a [C]p [C]i [C]d O 
. [C]. O 

Because [C]B [C]e [C]c [C]a [C]u [C]s [C]e O 
the [C]t [C]h [C]e O 
CD28 [C]C [C]D [C]2 [C]8 S-protein 
costimulus [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]u [C]s O 
is [C]i [C]s O 
known [C]k [C]n [C]o [C]w [C]n O 
to [C]t [C]o O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
the [C]t [C]h [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
reactive [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]e O 
oxygen [C]o [C]x [C]y [C]g [C]e [C]n O 
intermediates [C]i [C]n [C]t [C]e [C]r [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]s O 
( [C]( O 
ROIs [C]R [C]O [C]I [C]s O 
) [C]) O 
, [C], O 
the [C]t [C]h [C]e O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
ROI [C]R [C]O [C]I O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
in [C]i [C]n O 
CD45RA+ [C]C [C]D [C]4 [C]5 [C]R [C]A [C]+ B-cell_type 
and [C]a [C]n [C]d I-cell_type 
CD45RO+ [C]C [C]D [C]4 [C]5 [C]R [C]O [C]+ I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
by [C]b [C]y O 
flow [C]f [C]l [C]o [C]w O 
cytometry [C]c [C]y [C]t [C]o [C]m [C]e [C]t [C]r [C]y O 
. [C]. O 

ROIs [C]R [C]O [C]I [C]s O 
were [C]w [C]e [C]r [C]e O 
produced [C]p [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
cell [C]c [C]e [C]l [C]l O 
types [C]t [C]y [C]p [C]e [C]s O 
, [C], O 
but [C]b [C]u [C]t O 
more [C]m [C]o [C]r [C]e O 
strongly [C]s [C]t [C]r [C]o [C]n [C]g [C]l [C]y O 
in [C]i [C]n O 
CD45RA+ [C]C [C]D [C]4 [C]5 [C]R [C]A [C]+ B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
data [C]d [C]a [C]t [C]a O 
presented [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]e [C]d O 
in [C]i [C]n O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
emphasize [C]e [C]m [C]p [C]h [C]a [C]s [C]i [C]z [C]e O 
the [C]t [C]h [C]e O 
differences [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e [C]s O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
CD45RA+ [C]C [C]D [C]4 [C]5 [C]R [C]A [C]+ B-cell_type 
and [C]a [C]n [C]d I-cell_type 
CD45RO+ [C]C [C]D [C]4 [C]5 [C]R [C]O [C]+ I-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
in [C]i [C]n O 
ROI-dependent [C]R [C]O [C]I [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
. [C]. O 

Non-Hodgkin [C]N [C]o [C]n [C]- [C]H [C]o [C]d [C]g [C]k [C]i [C]n O 
's [C]' [C]s O 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a O 
involving [C]i [C]n [C]v [C]o [C]l [C]v [C]i [C]n [C]g O 
bilateral [C]b [C]i [C]l [C]a [C]t [C]e [C]r [C]a [C]l O 
breasts [C]b [C]r [C]e [C]a [C]s [C]t [C]s O 
[ [C][ O 
see [C]s [C]e [C]e O 
comments [C]c [C]o [C]m [C]m [C]e [C]n [C]t [C]s O 
] [C]] O 

We [C]W [C]e O 
describe [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e O 
here [C]h [C]e [C]r [C]e O 
two [C]t [C]w [C]o O 
cases [C]c [C]a [C]s [C]e [C]s O 
of [C]o [C]f O 
diffuse [C]d [C]i [C]f [C]f [C]u [C]s [C]e O 
large [C]l [C]a [C]r [C]g [C]e O 
cell [C]c [C]e [C]l [C]l O 
type [C]t [C]y [C]p [C]e O 
non-Hodgkin [C]n [C]o [C]n [C]- [C]H [C]o [C]d [C]g [C]k [C]i [C]n O 
's [C]' [C]s O 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a O 
affecting [C]a [C]f [C]f [C]e [C]c [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
bilateral [C]b [C]i [C]l [C]a [C]t [C]e [C]r [C]a [C]l O 
breasts [C]b [C]r [C]e [C]a [C]s [C]t [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
contralateral [C]c [C]o [C]n [C]t [C]r [C]a [C]l [C]a [C]t [C]e [C]r [C]a [C]l O 
tumor [C]t [C]u [C]m [C]o [C]r O 
in [C]i [C]n O 
one [C]o [C]n [C]e O 
case [C]c [C]a [C]s [C]e O 
appeared [C]a [C]p [C]p [C]e [C]a [C]r [C]e [C]d O 
17 [C]1 [C]7 O 
months [C]m [C]o [C]n [C]t [C]h [C]s O 
after [C]a [C]f [C]t [C]e [C]r O 
the [C]t [C]h [C]e O 
first [C]f [C]i [C]r [C]s [C]t O 
mastectomy [C]m [C]a [C]s [C]t [C]e [C]c [C]t [C]o [C]m [C]y O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
the [C]t [C]h [C]e O 
bilateral [C]b [C]i [C]l [C]a [C]t [C]e [C]r [C]a [C]l O 
tumors [C]t [C]u [C]m [C]o [C]r [C]s O 
occurred [C]o [C]c [C]c [C]u [C]r [C]r [C]e [C]d O 
concurrently [C]c [C]o [C]n [C]c [C]u [C]r [C]r [C]e [C]n [C]t [C]l [C]y O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
other [C]o [C]t [C]h [C]e [C]r O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
who [C]w [C]h [C]o O 
was [C]w [C]a [C]s O 
pregnant [C]p [C]r [C]e [C]g [C]n [C]a [C]n [C]t O 
and [C]a [C]n [C]d O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
widespread [C]w [C]i [C]d [C]e [C]s [C]p [C]r [C]e [C]a [C]d O 
dissemination [C]d [C]i [C]s [C]s [C]e [C]m [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
at [C]a [C]t O 
initial [C]i [C]n [C]i [C]t [C]i [C]a [C]l O 
presentation [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Lymphoma [C]L [C]y [C]m [C]p [C]h [C]o [C]m [C]a B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
both [C]b [C]o [C]t [C]h O 
cases [C]c [C]a [C]s [C]e [C]s O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
the [C]t [C]h [C]e O 
mature [C]m [C]a [C]t [C]u [C]r [C]e O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l O 
immunophenotype [C]i [C]m [C]m [C]u [C]n [C]o [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
and [C]a [C]n [C]d O 
had [C]h [C]a [C]d O 
rearrangements [C]r [C]e [C]a [C]r [C]r [C]a [C]n [C]g [C]e [C]m [C]e [C]n [C]t [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
BCL6 [C]B [C]C [C]L [C]6 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
. [C]. O 

Both [C]B [C]o [C]t [C]h O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
developed [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]e [C]d O 
progressive [C]p [C]r [C]o [C]g [C]r [C]e [C]s [C]s [C]i [C]v [C]e O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
despite [C]d [C]e [C]s [C]p [C]i [C]t [C]e O 
chemo-radiotherapy [C]c [C]h [C]e [C]m [C]o [C]- [C]r [C]a [C]d [C]i [C]o [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
and [C]a [C]n [C]d O 
died [C]d [C]i [C]e [C]d O 
of [C]o [C]f O 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c O 
manifestations [C]m [C]a [C]n [C]i [C]f [C]e [C]s [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

There [C]T [C]h [C]e [C]r [C]e O 
were [C]w [C]e [C]r [C]e O 
no [C]n [C]o O 
apparent [C]a [C]p [C]p [C]a [C]r [C]e [C]n [C]t O 
pathological [C]p [C]a [C]t [C]h [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
features [C]f [C]e [C]a [C]t [C]u [C]r [C]e [C]s O 
of [C]o [C]f O 
lymphomas [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a [C]s O 
of [C]o [C]f O 
mucosa-associated [C]m [C]u [C]c [C]o [C]s [C]a [C]- [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
origin [C]o [C]r [C]i [C]g [C]i [C]n O 

Biochemical [C]B [C]i [C]o [C]c [C]h [C]e [C]m [C]i [C]c [C]a [C]l O 
characterization [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
MIP-1 [C]M [C]I [C]P [C]- [C]1 B-protein 
alpha [C]a [C]l [C]p [C]h [C]a I-protein 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
. [C]. O 

A [C]A O 
family [C]f [C]a [C]m [C]i [C]l [C]y O 
of [C]o [C]f O 
hematopoietic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c B-protein 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
, [C], O 
MIP-1 [C]M [C]I [C]P [C]- [C]1 B-protein 
alpha [C]a [C]l [C]p [C]h [C]a I-protein 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
( [C]( I-protein 
MNP [C]M [C]N [C]P I-protein 
) [C]) I-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y E-protein 
, [C], O 
has [C]h [C]a [C]s O 
recently [C]r [C]e [C]c [C]e [C]n [C]t [C]l [C]y O 
been [C]b [C]e [C]e [C]n O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
. [C]. O 

They [C]T [C]h [C]e [C]y O 
are [C]a [C]r [C]e O 
intimately [C]i [C]n [C]t [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
regulating [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
huMIP-1 [C]h [C]u [C]M [C]I [C]P [C]- [C]1 B-DNA 
alpha [C]a [C]l [C]p [C]h [C]a I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
in [C]i [C]n O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
, [C], O 
T-cells [C]T [C]- [C]c [C]e [C]l [C]l [C]s S-cell_type 
, [C], O 
and [C]a [C]n [C]d O 
transformed [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]e [C]d B-cell_type 
B-cells [C]B [C]- [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

One [C]O [C]n [C]e O 
member [C]m [C]e [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
family [C]f [C]a [C]m [C]i [C]l [C]y O 
( [C]( O 
MNP-1 [C]M [C]N [C]P [C]- [C]1 S-protein 
) [C]) O 
is [C]i [C]s O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
for [C]f [C]o [C]r O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
and [C]a [C]n [C]d O 
B-cells [C]B [C]- [C]c [C]e [C]l [C]l [C]s S-cell_type 
, [C], O 
while [C]w [C]h [C]i [C]l [C]e O 
another [C]a [C]n [C]o [C]t [C]h [C]e [C]r O 
( [C]( O 
MNP-2 [C]M [C]N [C]P [C]- [C]2 S-protein 
) [C]) O 
is [C]i [C]s O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
full [C]f [C]u [C]l [C]l O 
promotor [C]p [C]r [C]o [C]m [C]o [C]t [C]o [C]r O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
T-cells [C]T [C]- [C]c [C]e [C]l [C]l [C]s S-cell_type 
. [C]. O 

A [C]A O 
third [C]t [C]h [C]i [C]r [C]d O 
member [C]m [C]e [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
family [C]f [C]a [C]m [C]i [C]l [C]y O 
( [C]( O 
MNP-3 [C]M [C]N [C]P [C]- [C]3 S-protein 
) [C]) O 
is [C]i [C]s O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
PMA [C]P [C]M [C]A B-cell_line 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d I-cell_line 
HL60 [C]H [C]L [C]6 [C]0 I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
and [C]a [C]n [C]d O 
probably [C]p [C]r [C]o [C]b [C]a [C]b [C]l [C]y O 
has [C]h [C]a [C]s O 
a [C]a O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
monocyte [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
communication [C]c [C]o [C]m [C]m [C]u [C]n [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
we [C]w [C]e O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
by [C]b [C]y O 
two [C]t [C]w [C]o O 
techniques [C]t [C]e [C]c [C]h [C]n [C]i [C]q [C]u [C]e [C]s O 
that [C]t [C]h [C]a [C]t O 
MNP-1 [C]M [C]N [C]P [C]- [C]1 S-protein 
and [C]a [C]n [C]d O 
MNP-2 [C]M [C]N [C]P [C]- [C]2 S-protein 
are [C]a [C]r [C]e O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
but [C]b [C]u [C]t O 
related [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
we [C]w [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
to [C]t [C]o O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
MNP-1 [C]M [C]N [C]P [C]- [C]1 S-protein 
acts [C]a [C]c [C]t [C]s O 
as [C]a [C]s O 
a [C]a O 
heterodimer [C]h [C]e [C]t [C]e [C]r [C]o [C]d [C]i [C]m [C]e [C]r S-protein 
. [C]. O 

Bcl-3 [C]B [C]c [C]l [C]- [C]3 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
translocation [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
are [C]a [C]r [C]e O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
granulocyte-macrophage [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e [C]- [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e B-protein 
colony-stimulating [C]c [C]o [C]l [C]o [C]n [C]y [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]n [C]g I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
and [C]a [C]n [C]d O 
erythropoietin [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]n S-protein 
in [C]i [C]n O 
proliferating [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]n [C]g B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d I-cell_type 
precursors [C]p [C]r [C]e [C]c [C]u [C]r [C]s [C]o [C]r [C]s E-cell_type 
. [C]. O 

Bcl-3 [C]B [C]c [C]l [C]- [C]3 S-protein 
is [C]i [C]s O 
a [C]a O 
proto-oncogene [C]p [C]r [C]o [C]t [C]o [C]- [C]o [C]n [C]c [C]o [C]g [C]e [C]n [C]e S-DNA 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
chromosomal [C]c [C]h [C]r [C]o [C]m [C]o [C]s [C]o [C]m [C]a [C]l O 
translocation [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
t [C]t B-DNA 
( [C]( I-DNA 
14 [C]1 [C]4 I-DNA 
; [C]; I-DNA 
19 [C]1 [C]9 I-DNA 
) [C]) E-DNA 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
some [C]s [C]o [C]m [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
lymphocytic [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
. [C]. O 

It [C]I [C]t O 
shares [C]s [C]h [C]a [C]r [C]e [C]s O 
structural [C]s [C]t [C]r [C]u [C]c [C]t [C]u [C]r [C]a [C]l O 
similarities [C]s [C]i [C]m [C]i [C]l [C]a [C]r [C]i [C]t [C]i [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
a [C]a O 
member [C]m [C]e [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IkappaB [C]I [C]k [C]a [C]p [C]p [C]a [C]B B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y E-protein 
of [C]o [C]f O 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s O 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
, [C], O 
involvement [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
Bcl-3 [C]B [C]c [C]l [C]- [C]3 S-protein 
in [C]i [C]n O 
hematopoietic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
factor-stimulated [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
. [C]. O 

In [C]I [C]n O 
TF-1 [C]T [C]F [C]- [C]1 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
, [C], O 
an [C]a [C]n O 
erythroleukemia [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
, [C], O 
granulocyte-macrophage [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e [C]- [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e B-protein 
colony-stimulating [C]c [C]o [C]l [C]o [C]n [C]y [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]n [C]g I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
( [C]( O 
GM-CSF [C]G [C]M [C]- [C]C [C]S [C]F S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
erythropoietin [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]n S-protein 
( [C]( O 
Epo [C]E [C]p [C]o S-protein 
) [C]) O 
greatly [C]g [C]r [C]e [C]a [C]t [C]l [C]y O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
Bcl-3 [C]B [C]c [C]l [C]- [C]3 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
at [C]a [C]t O 
both [C]b [C]o [C]t [C]h O 
the [C]t [C]h [C]e O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
and [C]a [C]n [C]d O 
mRNA [C]m [C]R [C]N [C]A O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
in [C]i [C]n O 
association [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Bcl-3 [C]B [C]c [C]l [C]- [C]3 S-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
highly [C]h [C]i [C]g [C]h [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
early [C]e [C]a [C]r [C]l [C]y B-cell_type 
burst-forming [C]b [C]u [C]r [C]s [C]t [C]- [C]f [C]o [C]r [C]m [C]i [C]n [C]g I-cell_type 
unit-erythroid [C]u [C]n [C]i [C]t [C]- [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d I-cell_type 
( [C]( I-cell_type 
BFU-E [C]B [C]F [C]U [C]- [C]E I-cell_type 
) [C]) I-cell_type 
-derived [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d I-cell_type 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d I-cell_type 
precursors [C]p [C]r [C]e [C]c [C]u [C]r [C]s [C]o [C]r [C]s E-cell_type 
( [C]( O 
day [C]d [C]a [C]y O 
7 [C]7 O 
) [C]) O 
and [C]a [C]n [C]d O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
maturation [C]m [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
( [C]( O 
days [C]d [C]a [C]y [C]s O 
10 [C]1 [C]0 O 
and [C]a [C]n [C]d O 
14 [C]1 [C]4 O 
) [C]) O 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
Bcl-3 [C]B [C]c [C]l [C]- [C]3 S-protein 
is [C]i [C]s O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

In [C]I [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
hematopoietic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
Bcl-3 [C]B [C]c [C]l [C]- [C]3 S-protein 
was [C]w [C]a [C]s O 
hyperphosphorylated [C]h [C]y [C]p [C]e [C]r [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]e [C]d O 
. [C]. O 

GM-CSF [C]G [C]M [C]- [C]C [C]S [C]F S-protein 
and [C]a [C]n [C]d O 
Epo [C]E [C]p [C]o S-protein 
modulated [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
subcellular [C]s [C]u [C]b [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
localization [C]l [C]o [C]c [C]a [C]l [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Bcl-3 [C]B [C]c [C]l [C]- [C]3 S-protein 
. [C]. O 

Upon [C]U [C]p [C]o [C]n O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
TF-1 [C]T [C]F [C]- [C]1 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
with [C]w [C]i [C]t [C]h O 
GM-CSF [C]G [C]M [C]- [C]C [C]S [C]F S-protein 
or [C]o [C]r O 
Epo [C]E [C]p [C]o S-protein 
, [C], O 
the [C]t [C]h [C]e O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
translocation [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Bcl-3 [C]B [C]c [C]l [C]- [C]3 S-protein 
was [C]w [C]a [C]s O 
dramatically [C]d [C]r [C]a [C]m [C]a [C]t [C]i [C]c [C]a [C]l [C]l [C]y O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
. [C]. O 

Overexpression [C]O [C]v [C]e [C]r [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
Bcl-3 [C]B [C]c [C]l [C]- [C]3 S-protein 
in [C]i [C]n O 
TF-1 [C]T [C]F [C]- [C]1 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
by [C]b [C]y O 
transient [C]t [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t O 
transfection [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
along [C]a [C]l [C]o [C]n [C]g O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s I-protein 
p50 [C]p [C]5 [C]0 I-protein 
or [C]o [C]r I-protein 
p52 [C]p [C]5 [C]2 E-protein 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
an [C]a [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y I-DNA 
virus-type [C]v [C]i [C]r [C]u [C]s [C]- [C]t [C]y [C]p [C]e I-DNA 
1 [C]1 I-DNA 
( [C]( I-DNA 
HIV-1 [C]H [C]I [C]V [C]- [C]1 I-DNA 
) [C]) I-DNA 
kappaB-TATA-luceriferase [C]k [C]a [C]p [C]p [C]a [C]B [C]- [C]T [C]A [C]T [C]A [C]- [C]l [C]u [C]c [C]e [C]r [C]i [C]f [C]e [C]r [C]a [C]s [C]e I-DNA 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r I-DNA 
plasmid [C]p [C]l [C]a [C]s [C]m [C]i [C]d E-DNA 
, [C], O 
demonstrating [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
Bcl-3 [C]B [C]c [C]l [C]- [C]3 S-protein 
has [C]h [C]a [C]s O 
a [C]a O 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
transactivation [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
kappaB-containing [C]k [C]a [C]p [C]p [C]a [C]B [C]- [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
in [C]i [C]n O 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Stimulation [C]S [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
GM-CSF [C]G [C]M [C]- [C]C [C]S [C]F S-protein 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
c-myb [C]c [C]- [C]m [C]y [C]b B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
. [C]. O 

Bcl-3 [C]B [C]c [C]l [C]- [C]3 S-protein 
in [C]i [C]n O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
of [C]o [C]f O 
TF-1 [C]T [C]F [C]- [C]1 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
bound [C]b [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
a [C]a O 
kappaB [C]k [C]a [C]p [C]p [C]a [C]B B-DNA 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r E-DNA 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
c-myb [C]c [C]- [C]m [C]y [C]b B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
together [C]t [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
with [C]w [C]i [C]t [C]h O 
NF-kappaB2/p52 [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B [C]2 [C]/ [C]p [C]5 [C]2 S-protein 
and [C]a [C]n [C]d O 
this [C]t [C]h [C]i [C]s O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
was [C]w [C]a [C]s O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
by [C]b [C]y O 
GM-CSF [C]G [C]M [C]- [C]C [C]S [C]F S-protein 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
cotransfection [C]c [C]o [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Bcl-3 [C]B [C]c [C]l [C]- [C]3 S-protein 
with [C]w [C]i [C]t [C]h O 
p52 [C]p [C]5 [C]2 S-protein 
or [C]o [C]r O 
p50 [C]p [C]5 [C]0 S-protein 
in [C]i [C]n O 
TF-1 [C]T [C]F [C]- [C]1 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
c-myb [C]c [C]- [C]m [C]y [C]b B-DNA 
kappaB-TATA-luceriferase [C]k [C]a [C]p [C]p [C]a [C]B [C]- [C]T [C]A [C]T [C]A [C]- [C]l [C]u [C]c [C]e [C]r [C]i [C]f [C]e [C]r [C]a [C]s [C]e I-DNA 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r I-DNA 
plasmid [C]p [C]l [C]a [C]s [C]m [C]i [C]d E-DNA 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
Bcl-3 [C]B [C]c [C]l [C]- [C]3 S-protein 
may [C]m [C]a [C]y O 
participate [C]p [C]a [C]r [C]t [C]i [C]c [C]i [C]p [C]a [C]t [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
certain [C]c [C]e [C]r [C]t [C]a [C]i [C]n O 
kappaB-containing [C]k [C]a [C]p [C]p [C]a [C]B [C]- [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
hematopoiesis [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
c-myb [C]c [C]- [C]m [C]y [C]b S-DNA 
. [C]. O 

Copyright [C]C [C]o [C]p [C]y [C]r [C]i [C]g [C]h [C]t O 
1998 [C]1 [C]9 [C]9 [C]8 O 
by [C]b [C]y O 
The [C]T [C]h [C]e O 
American [C]A [C]m [C]e [C]r [C]i [C]c [C]a [C]n O 
Society [C]S [C]o [C]c [C]i [C]e [C]t [C]y O 
of [C]o [C]f O 
Hematology [C]H [C]e [C]m [C]a [C]t [C]o [C]l [C]o [C]g [C]y O 
. [C]. O 

5-Lipoxygenase [C]5 [C]- [C]L [C]i [C]p [C]o [C]x [C]y [C]g [C]e [C]n [C]a [C]s [C]e S-protein 
compartmentalization [C]c [C]o [C]m [C]p [C]a [C]r [C]t [C]m [C]e [C]n [C]t [C]a [C]l [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
granulocytic [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]i [C]c O 
cells [C]c [C]e [C]l [C]l [C]s O 
is [C]i [C]s O 
modulated [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
an [C]a [C]n O 
internal [C]i [C]n [C]t [C]e [C]r [C]n [C]a [C]l B-protein 
bipartite [C]b [C]i [C]p [C]a [C]r [C]t [C]i [C]t [C]e I-protein 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-protein 
localizing [C]l [C]o [C]c [C]a [C]l [C]i [C]z [C]i [C]n [C]g I-protein 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e E-protein 
and [C]a [C]n [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B I-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

A [C]A O 
region [C]r [C]e [C]g [C]i [C]o [C]n O 
of [C]o [C]f O 
basic [C]b [C]a [C]s [C]i [C]c O 
amino [C]a [C]m [C]i [C]n [C]o O 
acids [C]a [C]c [C]i [C]d [C]s O 
spanning [C]s [C]p [C]a [C]n [C]n [C]i [C]n [C]g O 
residues [C]r [C]e [C]s [C]i [C]d [C]u [C]e [C]s B-protein 
639-656 [C]6 [C]3 [C]9 [C]- [C]6 [C]5 [C]6 E-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-protein 
5-lipoxygenase [C]5 [C]- [C]l [C]i [C]p [C]o [C]x [C]y [C]g [C]e [C]n [C]a [C]s [C]e I-protein 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e E-protein 
resembles [C]r [C]e [C]s [C]e [C]m [C]b [C]l [C]e [C]s O 
a [C]a O 
consensus [C]c [C]o [C]n [C]s [C]e [C]n [C]s [C]u [C]s B-protein 
bipartite [C]b [C]i [C]p [C]a [C]r [C]t [C]i [C]t [C]e I-protein 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-protein 
localizing [C]l [C]o [C]c [C]a [C]l [C]i [C]z [C]i [C]n [C]g I-protein 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e E-protein 
. [C]. O 

A [C]A O 
synthetic [C]s [C]y [C]n [C]t [C]h [C]e [C]t [C]i [C]c O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
consisting [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]i [C]n [C]g O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Kaposi [C]K [C]a [C]p [C]o [C]s [C]i B-protein 
fibroblast [C]f [C]i [C]b [C]r [C]o [C]b [C]l [C]a [C]s [C]t I-protein 
growth [C]g [C]r [C]o [C]w [C]t [C]h I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
signal [C]s [C]i [C]g [C]n [C]a [C]l I-protein 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e E-protein 
fused [C]f [C]u [C]s [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
5-lipoxygenase639-656 [C]5 [C]- [C]l [C]i [C]p [C]o [C]x [C]y [C]g [C]e [C]n [C]a [C]s [C]e [C]6 [C]3 [C]9 [C]- [C]6 [C]5 [C]6 B-protein 
bipartite [C]b [C]i [C]p [C]a [C]r [C]t [C]i [C]t [C]e I-protein 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-protein 
localizing [C]l [C]o [C]c [C]a [C]l [C]i [C]z [C]i [C]n [C]g I-protein 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e E-protein 
has [C]h [C]a [C]s O 
a [C]a O 
prominent [C]p [C]r [C]o [C]m [C]i [C]n [C]e [C]n [C]t O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
5-lipoxygenase [C]5 [C]- [C]l [C]i [C]p [C]o [C]x [C]y [C]g [C]e [C]n [C]a [C]s [C]e S-protein 
catalysis [C]c [C]a [C]t [C]a [C]l [C]y [C]s [C]i [C]s O 
in [C]i [C]n O 
granulocytic [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]i [C]c O 
HL-60 [C]H [C]L [C]- [C]6 [C]0 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
calcium [C]c [C]a [C]l [C]c [C]i [C]u [C]m O 
ionophor [C]i [C]o [C]n [C]o [C]p [C]h [C]o [C]r O 
A23187 [C]A [C]2 [C]3 [C]1 [C]8 [C]7 O 
. [C]. O 

Recombinant [C]R [C]e [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]n [C]t O 
5-lipoxygenase [C]5 [C]- [C]l [C]i [C]p [C]o [C]x [C]y [C]g [C]e [C]n [C]a [C]s [C]e S-protein 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
affected [C]a [C]f [C]f [C]e [C]c [C]t [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
also [C]a [C]l [C]s [C]o O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
redistribution [C]r [C]e [C]d [C]i [C]s [C]t [C]r [C]i [C]b [C]u [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
5-lipoxygenase [C]5 [C]- [C]l [C]i [C]p [C]o [C]x [C]y [C]g [C]e [C]n [C]a [C]s [C]e S-protein 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
of [C]o [C]f O 
HL-60 [C]H [C]L [C]- [C]6 [C]0 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
A23187 [C]A [C]2 [C]3 [C]1 [C]8 [C]7 O 
. [C]. O 

5-Lipoxygenase [C]5 [C]- [C]L [C]i [C]p [C]o [C]x [C]y [C]g [C]e [C]n [C]a [C]s [C]e B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
was [C]w [C]a [C]s O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
in [C]i [C]n O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
kappaB [C]k [C]a [C]p [C]p [C]a [C]B I-protein 
( [C]( I-protein 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B I-protein 
) [C]) I-protein 
p65 [C]p [C]6 [C]5 I-protein 
subunit [C]s [C]u [C]b [C]u [C]n [C]i [C]t E-protein 
immunoprecipitate [C]i [C]m [C]m [C]u [C]n [C]o [C]p [C]r [C]e [C]c [C]i [C]p [C]i [C]t [C]a [C]t [C]e O 
fractions [C]f [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
prepared [C]p [C]r [C]e [C]p [C]a [C]r [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
HL-60 [C]H [C]L [C]- [C]6 [C]0 B-cell_line 
cell [C]c [C]e [C]l [C]l E-cell_line 
lysates [C]l [C]y [C]s [C]a [C]t [C]e [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
amount [C]a [C]m [C]o [C]u [C]n [C]t O 
of [C]o [C]f O 
5-lipoxygenase [C]5 [C]- [C]l [C]i [C]p [C]o [C]x [C]y [C]g [C]e [C]n [C]a [C]s [C]e B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
coimmunoprecipitated [C]c [C]o [C]i [C]m [C]m [C]u [C]n [C]o [C]p [C]r [C]e [C]c [C]i [C]p [C]i [C]t [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B O 
antiserum [C]a [C]n [C]t [C]i [C]s [C]e [C]r [C]u [C]m O 
was [C]w [C]a [C]s O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
A23187 [C]A [C]2 [C]3 [C]1 [C]8 [C]7 O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

In [C]I [C]n O 
cells [C]c [C]e [C]l [C]l [C]s O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
agents [C]a [C]g [C]e [C]n [C]t [C]s O 
that [C]t [C]h [C]a [C]t O 
block [C]b [C]l [C]o [C]c [C]k O 
5-lipoxygenase [C]5 [C]- [C]l [C]i [C]p [C]o [C]x [C]y [C]g [C]e [C]n [C]a [C]s [C]e S-protein 
translocation [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
nucleus [C]n [C]u [C]c [C]l [C]e [C]u [C]s O 
, [C], O 
5-lipoxygenase [C]5 [C]- [C]l [C]i [C]p [C]o [C]x [C]y [C]g [C]e [C]n [C]a [C]s [C]e S-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
appearing [C]a [C]p [C]p [C]e [C]a [C]r [C]i [C]n [C]g O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
immunoprecipitate [C]i [C]m [C]m [C]u [C]n [C]o [C]p [C]r [C]e [C]c [C]i [C]p [C]i [C]t [C]a [C]t [C]e O 
was [C]w [C]a [C]s O 
diminished [C]d [C]i [C]m [C]i [C]n [C]i [C]s [C]h [C]e [C]d O 
. [C]. O 

Our [C]O [C]u [C]r O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
implicate [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]e O 
an [C]a [C]n O 
internal [C]i [C]n [C]t [C]e [C]r [C]n [C]a [C]l B-protein 
bipartite [C]b [C]i [C]p [C]a [C]r [C]t [C]i [C]t [C]e I-protein 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-protein 
localizing [C]l [C]o [C]c [C]a [C]l [C]i [C]z [C]i [C]n [C]g I-protein 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e E-protein 
as [C]a [C]s O 
a [C]a O 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
domain [C]d [C]o [C]m [C]a [C]i [C]n O 
that [C]t [C]h [C]a [C]t O 
modulates [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]e [C]s O 
5-lipoxygenase [C]5 [C]- [C]l [C]i [C]p [C]o [C]x [C]y [C]g [C]e [C]n [C]a [C]s [C]e S-protein 
redistribution [C]r [C]e [C]d [C]i [C]s [C]t [C]r [C]i [C]b [C]u [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
catalysis [C]c [C]a [C]t [C]a [C]l [C]y [C]s [C]i [C]s O 
in [C]i [C]n O 
granulocytic [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Additionally [C]A [C]d [C]d [C]i [C]t [C]i [C]o [C]n [C]a [C]l [C]l [C]y O 
, [C], O 
our [C]o [C]u [C]r O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
determinants [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]n [C]t [C]s O 
which [C]w [C]h [C]i [C]c [C]h O 
govern [C]g [C]o [C]v [C]e [C]r [C]n O 
5-lipoxygenase [C]5 [C]- [C]l [C]i [C]p [C]o [C]x [C]y [C]g [C]e [C]n [C]a [C]s [C]e O 
and [C]a [C]n [C]d O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B O 
redistribution [C]r [C]e [C]d [C]i [C]s [C]t [C]r [C]i [C]b [C]u [C]t [C]i [C]o [C]n O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
nucleus [C]n [C]u [C]c [C]l [C]e [C]u [C]s O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
coordinately [C]c [C]o [C]o [C]r [C]d [C]i [C]n [C]a [C]t [C]e [C]l [C]y O 
controlled [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]l [C]e [C]d O 
in [C]i [C]n O 
granulocytic [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Copyright [C]C [C]o [C]p [C]y [C]r [C]i [C]g [C]h [C]t O 
1998 [C]1 [C]9 [C]9 [C]8 O 
Academic [C]A [C]c [C]a [C]d [C]e [C]m [C]i [C]c O 
Press [C]P [C]r [C]e [C]s [C]s O 
. [C]. O 

Inhibition [C]I [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CD28/CD3-mediated [C]C [C]D [C]2 [C]8 [C]/ [C]C [C]D [C]3 [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
costimulation [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
naive [C]n [C]a [C]i [C]v [C]e B-cell_type 
and [C]a [C]n [C]d I-cell_type 
memory [C]m [C]e [C]m [C]o [C]r [C]y I-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
by [C]b [C]y O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
incorporation [C]i [C]n [C]c [C]o [C]r [C]p [C]o [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
polyclonal [C]p [C]o [C]l [C]y [C]c [C]l [C]o [C]n [C]a [C]l B-protein 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s E-protein 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r B-protein 
protein-1 [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]1 I-protein 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l I-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
. [C]. O 

A [C]A O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
indirect [C]i [C]n [C]d [C]i [C]r [C]e [C]c [C]t O 
methods [C]m [C]e [C]t [C]h [C]o [C]d [C]s O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
utilized [C]u [C]t [C]i [C]l [C]i [C]z [C]e [C]d O 
in [C]i [C]n O 
demonstrating [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]i [C]n [C]g O 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r B-protein 
protein-1 [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]1 E-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
IL-2 [C]I [C]L [C]- [C]2 O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
there [C]t [C]h [C]e [C]r [C]e O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
no [C]n [C]o O 
direct [C]d [C]i [C]r [C]e [C]c [C]t O 
demonstration [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
that [C]t [C]h [C]a [C]t O 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r B-protein 
protein-1 [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]1 E-protein 
is [C]i [C]s O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
CD28-dependent [C]C [C]D [C]2 [C]8 [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
costimulation [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
freshly [C]f [C]r [C]e [C]s [C]h [C]l [C]y O 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d O 
naive [C]n [C]a [C]i [C]v [C]e B-cell_type 
and [C]a [C]n [C]d I-cell_type 
memory [C]m [C]e [C]m [C]o [C]r [C]y I-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

To [C]T [C]o O 
address [C]a [C]d [C]d [C]r [C]e [C]s [C]s O 
this [C]t [C]h [C]i [C]s O 
issue [C]i [C]s [C]s [C]u [C]e O 
, [C], O 
the [C]t [C]h [C]e O 
method [C]m [C]e [C]t [C]h [C]o [C]d O 
of [C]o [C]f O 
scrape [C]s [C]c [C]r [C]a [C]p [C]e O 
loading [C]l [C]o [C]a [C]d [C]i [C]n [C]g O 
was [C]w [C]a [C]s O 
applied [C]a [C]p [C]p [C]l [C]i [C]e [C]d O 
to [C]t [C]o O 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d B-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

Since [C]S [C]i [C]n [C]c [C]e O 
scrape [C]s [C]c [C]r [C]a [C]p [C]e O 
loading [C]l [C]o [C]a [C]d [C]i [C]n [C]g O 
relies [C]r [C]e [C]l [C]i [C]e [C]s O 
on [C]o [C]n O 
adherent [C]a [C]d [C]h [C]e [C]r [C]e [C]n [C]t B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
T [C]T I-cell_type 
( [C]( I-cell_type 
PB-T [C]P [C]B [C]- [C]T I-cell_type 
) [C]) I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
immobilized [C]i [C]m [C]m [C]o [C]b [C]i [C]l [C]i [C]z [C]e [C]d O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
nonspecific [C]n [C]o [C]n [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
cell [C]c [C]e [C]l [C]l O 
attachment [C]a [C]t [C]t [C]a [C]c [C]h [C]m [C]e [C]n [C]t O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
poly-L-lysine [C]p [C]o [C]l [C]y [C]- [C]L [C]- [C]l [C]y [C]s [C]i [C]n [C]e O 
. [C]. O 

Cells [C]C [C]e [C]l [C]l [C]s O 
scraped [C]s [C]c [C]r [C]a [C]p [C]e [C]d O 
off [C]o [C]f [C]f O 
poly-L-lysine [C]p [C]o [C]l [C]y [C]- [C]L [C]- [C]l [C]y [C]s [C]i [C]n [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
Ig [C]I [C]g B-protein 
FITC [C]F [C]I [C]T [C]C E-protein 
efficiently [C]e [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t [C]l [C]y O 
incorporated [C]i [C]n [C]c [C]o [C]r [C]p [C]o [C]r [C]a [C]t [C]e [C]d O 
Ig [C]I [C]g O 
, [C], O 
with [C]w [C]i [C]t [C]h O 
relatively [C]r [C]e [C]l [C]a [C]t [C]i [C]v [C]e [C]l [C]y O 
uniform [C]u [C]n [C]i [C]f [C]o [C]r [C]m O 
fluorescence [C]f [C]l [C]u [C]o [C]r [C]e [C]s [C]c [C]e [C]n [C]c [C]e O 
. [C]. O 

T [C]T O 
cells [C]c [C]e [C]l [C]l [C]s O 
retained [C]r [C]e [C]t [C]a [C]i [C]n [C]e [C]d O 
their [C]t [C]h [C]e [C]i [C]r O 
physical [C]p [C]h [C]y [C]s [C]i [C]c [C]a [C]l O 
parameters [C]p [C]a [C]r [C]a [C]m [C]e [C]t [C]e [C]r [C]s O 
as [C]a [C]s O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
by [C]b [C]y O 
forward [C]f [C]o [C]r [C]w [C]a [C]r [C]d O 
and [C]a [C]n [C]d O 
side [C]s [C]i [C]d [C]e O 
light [C]l [C]i [C]g [C]h [C]t O 
scatter [C]s [C]c [C]a [C]t [C]t [C]e [C]r O 
, [C], O 
and [C]a [C]n [C]d O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
as [C]a [C]s O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
by [C]b [C]y O 
costimulation [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
after [C]a [C]f [C]t [C]e [C]r O 
being [C]b [C]e [C]i [C]n [C]g O 
scraped [C]s [C]c [C]r [C]a [C]p [C]e [C]d O 
off [C]o [C]f [C]f O 
this [C]t [C]h [C]i [C]s O 
substrate [C]s [C]u [C]b [C]s [C]t [C]r [C]a [C]t [C]e O 
. [C]. O 

CD28/CD3-costimulated [C]C [C]D [C]2 [C]8 [C]/ [C]C [C]D [C]3 [C]- [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
produced [C]p [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
from [C]f [C]r [C]o [C]m O 
all [C]a [C]l [C]l O 
subsets [C]s [C]u [C]b [C]s [C]e [C]t [C]s O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
( [C]( O 
CD4+ [C]C [C]D [C]4 [C]+ S-cell_type 
, [C], O 
CD4- [C]C [C]D [C]4 [C]- S-cell_type 
, [C], O 
CD45RO+ [C]C [C]D [C]4 [C]5 [C]R [C]O [C]+ S-cell_type 
, [C], O 
and [C]a [C]n [C]d O 
CD45RO- [C]C [C]D [C]4 [C]5 [C]R [C]O [C]- S-cell_type 
) [C]) O 
. [C]. O 

IL-2 [C]I [C]L [C]- [C]2 S-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
accumulation [C]a [C]c [C]c [C]u [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
nonscraped [C]n [C]o [C]n [C]s [C]c [C]r [C]a [C]p [C]e [C]d O 
PB-T [C]P [C]B [C]- [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
CD28/CD3 [C]C [C]D [C]2 [C]8 [C]/ [C]C [C]D [C]3 O 
coligation [C]c [C]o [C]l [C]i [C]g [C]a [C]t [C]i [C]o [C]n O 
were [C]w [C]e [C]r [C]e O 
skewed [C]s [C]k [C]e [C]w [C]e [C]d O 
favoring [C]f [C]a [C]v [C]o [C]r [C]i [C]n [C]g O 
CD45RO+ [C]C [C]D [C]4 [C]5 [C]R [C]O [C]+ B-cell_type 
and [C]a [C]n [C]d I-cell_type 
CD4+ [C]C [C]D [C]4 [C]+ I-cell_type 
subsets [C]s [C]u [C]b [C]s [C]e [C]t [C]s E-cell_type 
, [C], O 
as [C]a [C]s O 
was [C]w [C]a [C]s O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
scraped [C]s [C]c [C]r [C]a [C]p [C]e [C]d O 
PB-T [C]P [C]B [C]- [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
incorporation [C]i [C]n [C]c [C]o [C]r [C]p [C]o [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Abs [C]A [C]b [C]s O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
for [C]f [C]o [C]r O 
c-Fos [C]c [C]- [C]F [C]o [C]s B-protein 
and [C]a [C]n [C]d I-protein 
c-Jun [C]c [C]- [C]J [C]u [C]n I-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y I-protein 
members [C]m [C]e [C]m [C]b [C]e [C]r [C]s E-protein 
by [C]b [C]y O 
scrape [C]s [C]c [C]r [C]a [C]p [C]e O 
loading [C]l [C]o [C]a [C]d [C]i [C]n [C]g O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
accumulation [C]a [C]c [C]c [C]u [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
6 [C]6 O 
h [C]h O 
of [C]o [C]f O 
costimulation [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
PMA/ionomycin [C]P [C]M [C]A [C]/ [C]i [C]o [C]n [C]o [C]m [C]y [C]c [C]i [C]n O 
, [C], O 
or [C]o [C]r O 
costimulation [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
CD28 [C]C [C]D [C]2 [C]8 O 
and [C]a [C]n [C]d O 
CD3 [C]C [C]D [C]3 O 
ligation [C]l [C]i [C]g [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Scrape [C]S [C]c [C]r [C]a [C]p [C]e O 
loading [C]l [C]o [C]a [C]d [C]i [C]n [C]g O 
thus [C]t [C]h [C]u [C]s O 
provides [C]p [C]r [C]o [C]v [C]i [C]d [C]e [C]s O 
an [C]a [C]n O 
efficient [C]e [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
for [C]f [C]o [C]r O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
incorporation [C]i [C]n [C]c [C]o [C]r [C]p [C]o [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
macromolecules [C]m [C]a [C]c [C]r [C]o [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
first [C]f [C]i [C]r [C]s [C]t O 
direct [C]d [C]i [C]r [C]e [C]c [C]t O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
that [C]t [C]h [C]a [C]t O 
c-Fos [C]c [C]- [C]F [C]o [C]s S-protein 
and [C]a [C]n [C]d O 
c-Jun [C]c [C]- [C]J [C]u [C]n S-protein 
are [C]a [C]r [C]e O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
its [C]i [C]t [C]s O 
correct [C]c [C]o [C]r [C]r [C]e [C]c [C]t O 
chromosomal [C]c [C]h [C]r [C]o [C]m [C]o [C]s [C]o [C]m [C]a [C]l O 
context [C]c [C]o [C]n [C]t [C]e [C]x [C]t O 
, [C], O 
in [C]i [C]n O 
resting [C]r [C]e [C]s [C]t [C]i [C]n [C]g O 
human [C]h [C]u [C]m [C]a [C]n O 
T [C]T O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e O 
subpopulations [C]s [C]u [C]b [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

Differential [C]D [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
Nur77 [C]N [C]u [C]r [C]7 [C]7 B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y I-protein 
members [C]m [C]e [C]m [C]b [C]e [C]r [C]s E-protein 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
T-lymphotropic [C]T [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]t [C]r [C]o [C]p [C]i [C]c I-cell_type 
virus [C]v [C]i [C]r [C]u [C]s I-cell_type 
type [C]t [C]y [C]p [C]e I-cell_type 
1-infected [C]1 [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
: [C]: O 
transactivation [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
TR3/nur77 [C]T [C]R [C]3 [C]/ [C]n [C]u [C]r [C]7 [C]7 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
by [C]b [C]y O 
Tax [C]T [C]a [C]x B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
. [C]. O 

We [C]W [C]e O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
the [C]t [C]h [C]e O 
differential [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
three [C]t [C]h [C]r [C]e [C]e O 
members [C]m [C]e [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Nur77 [C]N [C]u [C]r [C]7 [C]7 B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y E-protein 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n O 
T-lymphotropic [C]T [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]t [C]r [C]o [C]p [C]i [C]c O 
virus [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
1 [C]1 O 
( [C]( O 
HTLV-1 [C]H [C]T [C]L [C]V [C]- [C]1 O 
) [C]) O 
Tax [C]T [C]a [C]x B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
HTLV-1-infected [C]H [C]T [C]L [C]V [C]- [C]1 [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
Tax-expressing [C]T [C]a [C]x [C]- [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]n [C]g B-cell_line 
JPX-9 [C]J [C]P [C]X [C]- [C]9 I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
, [C], O 
TR3/nur77 [C]T [C]R [C]3 [C]/ [C]n [C]u [C]r [C]7 [C]7 S-protein 
is [C]i [C]s O 
highly [C]h [C]i [C]g [C]h [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
neither [C]n [C]e [C]i [C]t [C]h [C]e [C]r O 
NOR-1 [C]N [C]O [C]R [C]- [C]1 O 
nor [C]n [C]o [C]r O 
NOT [C]N [C]O [C]T O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
is [C]i [C]s O 
detectable [C]d [C]e [C]t [C]e [C]c [C]t [C]a [C]b [C]l [C]e O 
. [C]. O 

Transient [C]T [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t O 
transfection [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
confirmed [C]c [C]o [C]n [C]f [C]i [C]r [C]m [C]e [C]d O 
the [C]t [C]h [C]e O 
Tax [C]T [C]a [C]x S-protein 
transactivation [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
TR3/nur77 [C]T [C]R [C]3 [C]/ [C]n [C]u [C]r [C]7 [C]7 S-protein 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
the [C]t [C]h [C]e O 
NOR-1 [C]N [C]O [C]R [C]- [C]1 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
in [C]i [C]n O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
cell [C]c [C]e [C]l [C]l O 
types [C]t [C]y [C]p [C]e [C]s O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
luciferase [C]l [C]u [C]c [C]i [C]f [C]e [C]r [C]a [C]s [C]e B-DNA 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
driven [C]d [C]r [C]i [C]v [C]e [C]n O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
NGFI-B [C]N [C]G [C]F [C]I [C]- [C]B B-DNA 
( [C]( I-DNA 
rat [C]r [C]a [C]t I-DNA 
homolog [C]h [C]o [C]m [C]o [C]l [C]o [C]g I-DNA 
of [C]o [C]f I-DNA 
TR3/Nur77 [C]T [C]R [C]3 [C]/ [C]N [C]u [C]r [C]7 [C]7 I-DNA 
) [C]) I-DNA 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e I-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
( [C]( O 
NBRE [C]N [C]B [C]R [C]E S-DNA 
) [C]) O 
provided [C]p [C]r [C]o [C]v [C]i [C]d [C]e [C]d O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
that [C]t [C]h [C]a [C]t O 
Tax [C]T [C]a [C]x S-protein 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
transactivation [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
. [C]. O 

Cotransfection [C]C [C]o [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
TR3/nur77 [C]T [C]R [C]3 [C]/ [C]n [C]u [C]r [C]7 [C]7 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r I-DNA 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e E-DNA 
or [C]o [C]r O 
the [C]t [C]h [C]e O 
NBRE [C]N [C]B [C]R [C]E S-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
motif [C]m [C]o [C]t [C]i [C]f O 
together [C]t [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
series [C]s [C]e [C]r [C]i [C]e [C]s O 
of [C]o [C]f O 
Tax [C]T [C]a [C]x S-protein 
mutants [C]m [C]u [C]t [C]a [C]n [C]t [C]s O 
have [C]h [C]a [C]v [C]e O 
shown [C]s [C]h [C]o [C]w [C]n O 
that [C]t [C]h [C]a [C]t O 
Tax [C]T [C]a [C]x S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
TR3/nur77 [C]T [C]R [C]3 [C]/ [C]n [C]u [C]r [C]7 [C]7 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
is [C]i [C]s O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
CREB/ATF-related [C]C [C]R [C]E [C]B [C]/ [C]A [C]T [C]F [C]- [C]r [C]e [C]l [C]a [C]t [C]e [C]d B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

Negative [C]N [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
heat [C]h [C]e [C]a [C]t O 
shock [C]s [C]h [C]o [C]c [C]k O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
by [C]b [C]y O 
HSBP1 [C]H [C]S [C]B [C]P [C]1 S-protein 
. [C]. O 

In [C]I [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
stress [C]s [C]t [C]r [C]e [C]s [C]s O 
, [C], O 
heat [C]h [C]e [C]a [C]t B-protein 
shock [C]s [C]h [C]o [C]c [C]k I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
1 [C]1 E-protein 
( [C]( O 
HSF1 [C]H [C]S [C]F [C]1 S-protein 
) [C]) O 
acquires [C]a [C]c [C]q [C]u [C]i [C]r [C]e [C]s O 
rapid [C]r [C]a [C]p [C]i [C]d O 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
transient [C]t [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
while [C]w [C]h [C]i [C]l [C]e O 
undergoing [C]u [C]n [C]d [C]e [C]r [C]g [C]o [C]i [C]n [C]g O 
conformational [C]c [C]o [C]n [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n [C]a [C]l O 
transition [C]t [C]r [C]a [C]n [C]s [C]i [C]t [C]i [C]o [C]n O 
from [C]f [C]r [C]o [C]m O 
an [C]a [C]n O 
inert [C]i [C]n [C]e [C]r [C]t O 
non-DNA-binding [C]n [C]o [C]n [C]- [C]D [C]N [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
monomer [C]m [C]o [C]n [C]o [C]m [C]e [C]r E-protein 
to [C]t [C]o O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
trimers [C]t [C]r [C]i [C]m [C]e [C]r [C]s O 
. [C]. O 

Attenuation [C]A [C]t [C]t [C]e [C]n [C]u [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
inducible [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
occurs [C]o [C]c [C]c [C]u [C]r [C]s O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
heat [C]h [C]e [C]a [C]t O 
shock [C]s [C]h [C]o [C]c [C]k O 
or [C]o [C]r O 
upon [C]u [C]p [C]o [C]n O 
recovery [C]r [C]e [C]c [C]o [C]v [C]e [C]r [C]y O 
at [C]a [C]t O 
non-stress [C]n [C]o [C]n [C]- [C]s [C]t [C]r [C]e [C]s [C]s O 
conditions [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n [C]s O 
and [C]a [C]n [C]d O 
involves [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]s O 
dissociation [C]d [C]i [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
HSF1 [C]H [C]S [C]F [C]1 B-protein 
trimer [C]t [C]r [C]i [C]m [C]e [C]r E-protein 
and [C]a [C]n [C]d O 
loss [C]l [C]o [C]s [C]s O 
of [C]o [C]f O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
used [C]u [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
hydrophobic [C]h [C]y [C]d [C]r [C]o [C]p [C]h [C]o [C]b [C]i [C]c B-protein 
repeats [C]r [C]e [C]p [C]e [C]a [C]t [C]s E-protein 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
HSF1 [C]H [C]S [C]F [C]1 S-protein 
trimerization [C]t [C]r [C]i [C]m [C]e [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
domain [C]d [C]o [C]m [C]a [C]i [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
yeast [C]y [C]e [C]a [C]s [C]t O 
two-hybrid [C]t [C]w [C]o [C]- [C]h [C]y [C]b [C]r [C]i [C]d O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
assay [C]a [C]s [C]s [C]a [C]y O 
to [C]t [C]o O 
identify [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]y O 
heat [C]h [C]e [C]a [C]t B-protein 
shock [C]s [C]h [C]o [C]c [C]k I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
1 [C]1 E-protein 
( [C]( O 
HSBP1 [C]H [C]S [C]B [C]P [C]1 S-protein 
) [C]) O 
, [C], O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
, [C], O 
conserved [C]c [C]o [C]n [C]s [C]e [C]r [C]v [C]e [C]d O 
, [C], O 
76-amino-acid [C]7 [C]6 [C]- [C]a [C]m [C]i [C]n [C]o [C]- [C]a [C]c [C]i [C]d B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
that [C]t [C]h [C]a [C]t O 
contains [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]s O 
two [C]t [C]w [C]o O 
extended [C]e [C]x [C]t [C]e [C]n [C]d [C]e [C]d O 
arrays [C]a [C]r [C]r [C]a [C]y [C]s O 
of [C]o [C]f O 
hydrophobic [C]h [C]y [C]d [C]r [C]o [C]p [C]h [C]o [C]b [C]i [C]c B-protein 
repeats [C]r [C]e [C]p [C]e [C]a [C]t [C]s E-protein 
that [C]t [C]h [C]a [C]t O 
interact [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
HSF1 [C]H [C]S [C]F [C]1 B-protein 
heptad [C]h [C]e [C]p [C]t [C]a [C]d I-protein 
repeats [C]r [C]e [C]p [C]e [C]a [C]t [C]s E-protein 
. [C]. O 

HSBP1 [C]H [C]S [C]B [C]P [C]1 S-protein 
is [C]i [C]s O 
nuclear-localized [C]n [C]u [C]c [C]l [C]e [C]a [C]r [C]- [C]l [C]o [C]c [C]a [C]l [C]i [C]z [C]e [C]d O 
and [C]a [C]n [C]d O 
interacts [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]s O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
trimeric [C]t [C]r [C]i [C]m [C]e [C]r [C]i [C]c O 
state [C]s [C]t [C]a [C]t [C]e O 
of [C]o [C]f O 
HSF1 [C]H [C]S [C]F [C]1 S-protein 
that [C]t [C]h [C]a [C]t O 
appears [C]a [C]p [C]p [C]e [C]a [C]r [C]s O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
heat [C]h [C]e [C]a [C]t O 
shock [C]s [C]h [C]o [C]c [C]k O 
. [C]. O 

During [C]D [C]u [C]r [C]i [C]n [C]g O 
attenuation [C]a [C]t [C]t [C]e [C]n [C]u [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
HSF1 [C]H [C]S [C]F [C]1 S-protein 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
inert [C]i [C]n [C]e [C]r [C]t O 
monomer [C]m [C]o [C]n [C]o [C]m [C]e [C]r O 
, [C], O 
HSBP1 [C]H [C]S [C]B [C]P [C]1 S-protein 
associates [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
Hsp70 [C]H [C]s [C]p [C]7 [C]0 O 
. [C]. O 

HSBP1 [C]H [C]S [C]B [C]P [C]1 S-protein 
negatively [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e [C]l [C]y O 
affects [C]a [C]f [C]f [C]e [C]c [C]t [C]s O 
HSF1 [C]H [C]S [C]F [C]1 S-protein 
DNA-binding [C]D [C]N [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
, [C], O 
and [C]a [C]n [C]d O 
overexpression [C]o [C]v [C]e [C]r [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
HSBP1 [C]H [C]S [C]B [C]P [C]1 S-protein 
in [C]i [C]n O 
mammalian [C]m [C]a [C]m [C]m [C]a [C]l [C]i [C]a [C]n B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
represses [C]r [C]e [C]p [C]r [C]e [C]s [C]s [C]e [C]s O 
the [C]t [C]h [C]e O 
transactivation [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
HSF1 [C]H [C]S [C]F [C]1 S-protein 
. [C]. O 

To [C]T [C]o O 
establish [C]e [C]s [C]t [C]a [C]b [C]l [C]i [C]s [C]h O 
a [C]a O 
biological [C]b [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
role [C]r [C]o [C]l [C]e O 
for [C]f [C]o [C]r O 
HSBP1 [C]H [C]S [C]B [C]P [C]1 S-protein 
, [C], O 
the [C]t [C]h [C]e O 
homologous [C]h [C]o [C]m [C]o [C]l [C]o [C]g [C]o [C]u [C]s O 
Caenorhabditis [C]C [C]a [C]e [C]n [C]o [C]r [C]h [C]a [C]b [C]d [C]i [C]t [C]i [C]s B-protein 
elegans [C]e [C]l [C]e [C]g [C]a [C]n [C]s I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
was [C]w [C]a [C]s O 
overexpressed [C]o [C]v [C]e [C]r [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
body [C]b [C]o [C]d [C]y B-cell_type 
wall [C]w [C]a [C]l [C]l I-cell_type 
muscle [C]m [C]u [C]s [C]c [C]l [C]e I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
was [C]w [C]a [C]s O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
block [C]b [C]l [C]o [C]c [C]k O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
heat [C]h [C]e [C]a [C]t O 
shock [C]s [C]h [C]o [C]c [C]k O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
from [C]f [C]r [C]o [C]m O 
a [C]a O 
heat [C]h [C]e [C]a [C]t B-DNA 
shock [C]s [C]h [C]o [C]c [C]k I-DNA 
promoter-reporter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]- [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r I-DNA 
construct [C]c [C]o [C]n [C]s [C]t [C]r [C]u [C]c [C]t E-DNA 
. [C]. O 

Alteration [C]A [C]l [C]t [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
HSBP1 [C]H [C]S [C]B [C]P [C]1 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
C. [C]C [C]. O 
elegans [C]e [C]l [C]e [C]g [C]a [C]n [C]s O 
has [C]h [C]a [C]s O 
severe [C]s [C]e [C]v [C]e [C]r [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
on [C]o [C]n O 
survival [C]s [C]u [C]r [C]v [C]i [C]v [C]a [C]l O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
animals [C]a [C]n [C]i [C]m [C]a [C]l [C]s O 
after [C]a [C]f [C]t [C]e [C]r O 
thermal [C]t [C]h [C]e [C]r [C]m [C]a [C]l O 
and [C]a [C]n [C]d O 
chemical [C]c [C]h [C]e [C]m [C]i [C]c [C]a [C]l O 
stress [C]s [C]t [C]r [C]e [C]s [C]s O 
, [C], O 
consistent [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
role [C]r [C]o [C]l [C]e O 
for [C]f [C]o [C]r O 
HSBP1 [C]H [C]S [C]B [C]P [C]1 S-protein 
as [C]a [C]s O 
a [C]a O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
regulator [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
heat [C]h [C]e [C]a [C]t O 
shock [C]s [C]h [C]o [C]c [C]k O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
. [C]. O 

Long-range [C]L [C]o [C]n [C]g [C]- [C]r [C]a [C]n [C]g [C]e O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Most [C]M [C]o [C]s [C]t O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
of [C]o [C]f O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
have [C]h [C]a [C]v [C]e O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
the [C]t [C]h [C]e O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
proximal [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]l B-DNA 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s E-DNA 
. [C]. O 

Recent [C]R [C]e [C]c [C]e [C]n [C]t O 
work [C]w [C]o [C]r [C]k O 
has [C]h [C]a [C]s O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
distal [C]d [C]i [C]s [C]t [C]a [C]l B-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
that [C]t [C]h [C]a [C]t O 
mediate [C]m [C]e [C]d [C]i [C]a [C]t [C]e O 
long-range [C]l [C]o [C]n [C]g [C]- [C]r [C]a [C]n [C]g [C]e O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
gene [C]g [C]e [C]n [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
has [C]h [C]a [C]s O 
implicated [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]e [C]d O 
chromatin [C]c [C]h [C]r [C]o [C]m [C]a [C]t [C]i [C]n O 
reorganization [C]r [C]e [C]o [C]r [C]g [C]a [C]n [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e B-DNA 
gene [C]g [C]e [C]n [C]e I-DNA 
loci [C]l [C]o [C]c [C]i E-DNA 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
have [C]h [C]a [C]v [C]e O 
begun [C]b [C]e [C]g [C]u [C]n O 
to [C]t [C]o O 
elucidate [C]e [C]l [C]u [C]c [C]i [C]d [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
basis [C]b [C]a [C]s [C]i [C]s O 
for [C]f [C]o [C]r O 
cell-specificity [C]c [C]e [C]l [C]l [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
high-level [C]h [C]i [C]g [C]h [C]- [C]l [C]e [C]v [C]e [C]l O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
. [C]. O 

A [C]A O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
of [C]o [C]f O 
Ca2+-calmodulin-dependent [C]C [C]a [C]2 [C]+ [C]- [C]c [C]a [C]l [C]m [C]o [C]d [C]u [C]l [C]i [C]n [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
IV [C]I [C]V E-protein 
and [C]a [C]n [C]d O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
phosphatase [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]a [C]s [C]e I-protein 
2A [C]2 [C]A E-protein 
[ [C][ O 
see [C]s [C]e [C]e O 
comments [C]c [C]o [C]m [C]m [C]e [C]n [C]t [C]s O 
] [C]] O 

Stimulation [C]S [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
T [C]T B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
in [C]i [C]n O 
a [C]a O 
rapid [C]r [C]a [C]p [C]i [C]d O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
calcium [C]c [C]a [C]l [C]c [C]i [C]u [C]m O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
( [C]( O 
[ [C][ O 
Ca2+ [C]C [C]a [C]2 [C]+ O 
] [C]] O 
i [C]i O 
) [C]) O 
that [C]t [C]h [C]a [C]t O 
parallels [C]p [C]a [C]r [C]a [C]l [C]l [C]e [C]l [C]s O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Ca2+-calmodulin-dependent [C]C [C]a [C]2 [C]+ [C]- [C]c [C]a [C]l [C]m [C]o [C]d [C]u [C]l [C]i [C]n [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
IV [C]I [C]V E-protein 
( [C]( O 
CaMKIV [C]C [C]a [C]M [C]K [C]I [C]V S-protein 
) [C]) O 
, [C], O 
a [C]a O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
enzyme [C]e [C]n [C]z [C]y [C]m [C]e E-protein 
that [C]t [C]h [C]a [C]t O 
can [C]c [C]a [C]n O 
phosphorylate [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]e O 
and [C]a [C]n [C]d O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
cyclic [C]c [C]y [C]c [C]l [C]i [C]c B-protein 
adenosine [C]a [C]d [C]e [C]n [C]o [C]s [C]i [C]n [C]e I-protein 
monophosphate [C]m [C]o [C]n [C]o [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]e I-protein 
( [C]( I-protein 
cAMP [C]c [C]A [C]M [C]P I-protein 
) [C]) I-protein 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e I-protein 
element-binding [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
( [C]( O 
CREB [C]C [C]R [C]E [C]B S-protein 
) [C]) O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
inactivation [C]i [C]n [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CaMKIV [C]C [C]a [C]M [C]K [C]I [C]V S-protein 
occurs [C]o [C]c [C]c [C]u [C]r [C]s O 
despite [C]d [C]e [C]s [C]p [C]i [C]t [C]e O 
the [C]t [C]h [C]e O 
sustained [C]s [C]u [C]s [C]t [C]a [C]i [C]n [C]e [C]d O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
[ [C][ O 
Ca2+ [C]C [C]a [C]2 [C]+ O 
] [C]] O 
i [C]i O 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

A [C]A O 
stable [C]s [C]t [C]a [C]b [C]l [C]e O 
and [C]a [C]n [C]d O 
stoichiometric [C]s [C]t [C]o [C]i [C]c [C]h [C]i [C]o [C]m [C]e [C]t [C]r [C]i [C]c O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
of [C]o [C]f O 
CaMKIV [C]C [C]a [C]M [C]K [C]I [C]V S-protein 
with [C]w [C]i [C]t [C]h O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
serine-threonine [C]s [C]e [C]r [C]i [C]n [C]e [C]- [C]t [C]h [C]r [C]e [C]o [C]n [C]i [C]n [C]e I-protein 
phosphatase [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]a [C]s [C]e I-protein 
2A [C]2 [C]A E-protein 
( [C]( O 
PP2A [C]P [C]P [C]2 [C]A S-protein 
) [C]) O 
was [C]w [C]a [C]s O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
in [C]i [C]n O 
which [C]w [C]h [C]i [C]c [C]h O 
PP2A [C]P [C]P [C]2 [C]A S-protein 
dephosphorylates [C]d [C]e [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]e [C]s O 
CaMKIV [C]C [C]a [C]M [C]K [C]I [C]V S-protein 
and [C]a [C]n [C]d O 
functions [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]s O 
as [C]a [C]s O 
a [C]a O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
regulator [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r O 
of [C]o [C]f O 
CaMKIV [C]C [C]a [C]M [C]K [C]I [C]V S-protein 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
. [C]. O 

In [C]I [C]n O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_line 
T [C]T I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
, [C], O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
PP2A [C]P [C]P [C]2 [C]A S-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
by [C]b [C]y O 
small [C]s [C]m [C]a [C]l [C]l O 
t [C]t O 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CREB [C]C [C]R [C]E [C]B S-protein 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
CaMKIV [C]C [C]a [C]M [C]K [C]I [C]V S-protein 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
reveal [C]r [C]e [C]v [C]e [C]a [C]l O 
an [C]a [C]n O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
whereby [C]w [C]h [C]e [C]r [C]e [C]b [C]y O 
a [C]a O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
serine-threonine [C]s [C]e [C]r [C]i [C]n [C]e [C]- [C]t [C]h [C]r [C]e [C]o [C]n [C]i [C]n [C]e I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
( [C]( O 
CaMKIV [C]C [C]a [C]M [C]K [C]I [C]V S-protein 
) [C]) O 
is [C]i [C]s O 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
tightly [C]t [C]i [C]g [C]h [C]t [C]l [C]y O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
serine-threonine [C]s [C]e [C]r [C]i [C]n [C]e [C]- [C]t [C]h [C]r [C]e [C]o [C]n [C]i [C]n [C]e I-protein 
phosphatase [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]a [C]s [C]e E-protein 
( [C]( O 
PP2A [C]P [C]P [C]2 [C]A S-protein 
) [C]) O 
. [C]. O 

Hypoxia [C]H [C]y [C]p [C]o [C]x [C]i [C]a O 
down-regulates [C]d [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]s O 
MCP-1 [C]M [C]C [C]P [C]- [C]1 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
: [C]: O 
implications [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n [C]s O 
for [C]f [C]o [C]r O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e O 
distribution [C]d [C]i [C]s [C]t [C]r [C]i [C]b [C]u [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
tumors [C]t [C]u [C]m [C]o [C]r [C]s O 
. [C]. O 

Monocyte [C]M [C]o [C]n [C]o [C]c [C]y [C]t [C]e B-protein 
chemoattractant [C]c [C]h [C]e [C]m [C]o [C]a [C]t [C]t [C]r [C]a [C]c [C]t [C]a [C]n [C]t I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
1 [C]1 E-protein 
( [C]( O 
MCP-1 [C]M [C]C [C]P [C]- [C]1 S-protein 
) [C]) O 
is [C]i [C]s O 
likely [C]l [C]i [C]k [C]e [C]l [C]y O 
to [C]t [C]o O 
contribute [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e B-cell_type 
infiltrate [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]e E-cell_type 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n O 
ovarian [C]o [C]v [C]a [C]r [C]i [C]a [C]n O 
carcinomas [C]c [C]a [C]r [C]c [C]i [C]n [C]o [C]m [C]a [C]s O 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
MCP-1 [C]M [C]C [C]P [C]- [C]1 S-protein 
is [C]i [C]s O 
predominantly [C]p [C]r [C]e [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
tumor [C]t [C]u [C]m [C]o [C]r O 
parenchyma [C]p [C]a [C]r [C]e [C]n [C]c [C]h [C]y [C]m [C]a O 
, [C], O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s O 
accumulate [C]a [C]c [C]c [C]u [C]m [C]u [C]l [C]a [C]t [C]e O 
at [C]a [C]t O 
highest [C]h [C]i [C]g [C]h [C]e [C]s [C]t O 
density [C]d [C]e [C]n [C]s [C]i [C]t [C]y O 
in [C]i [C]n O 
necrotic [C]n [C]e [C]c [C]r [C]o [C]t [C]i [C]c O 
regions [C]r [C]e [C]g [C]i [C]o [C]n [C]s O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
are [C]a [C]r [C]e O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
low [C]l [C]o [C]w O 
oxygen [C]o [C]x [C]y [C]g [C]e [C]n O 
tensions [C]t [C]e [C]n [C]s [C]i [C]o [C]n [C]s O 
. [C]. O 

Tumor [C]T [C]u [C]m [C]o [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
( [C]( O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
) [C]) O 
can [C]c [C]a [C]n O 
stimulate [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e O 
MCP-1 [C]M [C]C [C]P [C]- [C]1 S-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
also [C]a [C]l [C]s [C]o O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
ovarian [C]o [C]v [C]a [C]r [C]i [C]a [C]n O 
carcinomas [C]c [C]a [C]r [C]c [C]i [C]n [C]o [C]m [C]a [C]s O 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
hypoxia [C]h [C]y [C]p [C]o [C]x [C]i [C]a O 
both [C]b [C]o [C]t [C]h O 
on [C]o [C]n O 
MCP-1 [C]M [C]C [C]P [C]- [C]1 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
ovarian [C]o [C]v [C]a [C]r [C]i [C]a [C]n B-cell_line 
cancer [C]c [C]a [C]n [C]c [C]e [C]r I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
and [C]a [C]n [C]d O 
monocyte [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e O 
migration [C]m [C]i [C]g [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Hypoxia [C]H [C]y [C]p [C]o [C]x [C]i [C]a O 
down-regulated [C]d [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
TNF-alpha-induced [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d B-RNA 
MCP-1 [C]M [C]C [C]P [C]- [C]1 I-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
and [C]a [C]n [C]d O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
ovarian [C]o [C]v [C]a [C]r [C]i [C]a [C]n B-cell_type 
cancer [C]c [C]a [C]n [C]c [C]e [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
was [C]w [C]a [C]s O 
mimicked [C]m [C]i [C]m [C]i [C]c [C]k [C]e [C]d O 
by [C]b [C]y O 
cobalt [C]c [C]o [C]b [C]a [C]l [C]t O 
chloride [C]c [C]h [C]l [C]o [C]r [C]i [C]d [C]e O 
and [C]a [C]n [C]d O 
desferrioxamine [C]d [C]e [C]s [C]f [C]e [C]r [C]r [C]i [C]o [C]x [C]a [C]m [C]i [C]n [C]e O 
, [C], O 
consistent [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
oxygen-sensing [C]o [C]x [C]y [C]g [C]e [C]n [C]- [C]s [C]e [C]n [C]s [C]i [C]n [C]g O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
. [C]. O 

Unlike [C]U [C]n [C]l [C]i [C]k [C]e O 
antioxidants [C]a [C]n [C]t [C]i [C]o [C]x [C]i [C]d [C]a [C]n [C]t [C]s O 
, [C], O 
hypoxia [C]h [C]y [C]p [C]o [C]x [C]i [C]a O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
inhibit [C]i [C]n [C]h [C]i [C]b [C]i [C]t O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
KB [C]K [C]B O 
mobilization [C]m [C]o [C]b [C]i [C]l [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Monocyte [C]M [C]o [C]n [C]o [C]c [C]y [C]t [C]e O 
migration [C]m [C]i [C]g [C]r [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
MCP-1 [C]M [C]C [C]P [C]- [C]1 S-protein 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
diminished [C]d [C]i [C]m [C]i [C]n [C]i [C]s [C]h [C]e [C]d O 
under [C]u [C]n [C]d [C]e [C]r O 
hypoxic [C]h [C]y [C]p [C]o [C]x [C]i [C]c O 
conditions [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

Down-regulation [C]D [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
MCP-1 [C]M [C]C [C]P [C]- [C]1 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
monocyte [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e O 
migration [C]m [C]i [C]g [C]r [C]a [C]t [C]i [C]o [C]n O 
are [C]a [C]r [C]e O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
hypoxia [C]h [C]y [C]p [C]o [C]x [C]i [C]a O 
that [C]t [C]h [C]a [C]t O 
may [C]m [C]a [C]y O 
contribute [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
distribution [C]d [C]i [C]s [C]t [C]r [C]i [C]b [C]u [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_type 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
ovarian [C]o [C]v [C]a [C]r [C]i [C]a [C]n O 
tumors [C]t [C]u [C]m [C]o [C]r [C]s O 
. [C]. O 

Activation [C]A [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
bowel [C]b [C]o [C]w [C]e [C]l O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
[ [C][ O 
see [C]s [C]e [C]e O 
comments [C]c [C]o [C]m [C]m [C]e [C]n [C]t [C]s O 
] [C]] O 

BACKGROUND [C]B [C]A [C]C [C]K [C]G [C]R [C]O [C]U [C]N [C]D O 
: [C]: O 
Expression [C]E [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
pro-inflammatory [C]p [C]r [C]o [C]- [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y B-protein 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s E-protein 
is [C]i [C]s O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
intestinal [C]i [C]n [C]t [C]e [C]s [C]t [C]i [C]n [C]a [C]l O 
lamina [C]l [C]a [C]m [C]i [C]n [C]a O 
propria [C]p [C]r [C]o [C]p [C]r [C]i [C]a O 
of [C]o [C]f O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
bowel [C]b [C]o [C]w [C]e [C]l O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
( [C]( O 
IBD [C]I [C]B [C]D O 
) [C]) O 
. [C]. O 

Nuclear [C]N [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
( [C]( O 
NF [C]N [C]F B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
) [C]) O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
inflammation [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]i [C]o [C]n B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
. [C]. O 

On [C]O [C]n O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
NF [C]N [C]F B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
is [C]i [C]s O 
rapidly [C]r [C]a [C]p [C]i [C]d [C]l [C]y O 
released [C]r [C]e [C]l [C]e [C]a [C]s [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
its [C]i [C]t [C]s O 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c B-protein 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r E-protein 
( [C]( O 
I [C]I B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
) [C]) O 
, [C], O 
transmigrates [C]t [C]r [C]a [C]n [C]s [C]m [C]i [C]g [C]r [C]a [C]t [C]e [C]s O 
into [C]i [C]n [C]t [C]o O 
the [C]t [C]h [C]e O 
nucleus [C]n [C]u [C]c [C]l [C]e [C]u [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
binds [C]b [C]i [C]n [C]d [C]s O 
to [C]t [C]o O 
DNA [C]D [C]N [C]A B-DNA 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e I-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
in [C]i [C]n O 
gene [C]g [C]e [C]n [C]e O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
regions [C]r [C]e [C]g [C]i [C]o [C]n [C]s O 
. [C]. O 

AIMS [C]A [C]I [C]M [C]S O 
: [C]: O 
To [C]T [C]o O 
investigate [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF [C]N [C]F B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
is [C]i [C]s O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
in [C]i [C]n O 
IBD [C]I [C]B [C]D O 
and [C]a [C]n [C]d O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
down-regulated [C]d [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
anti-inflammatory [C]a [C]n [C]t [C]i [C]- [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
. [C]. O 

METHODS [C]M [C]E [C]T [C]H [C]O [C]D [C]S O 
: [C]: O 
Activation [C]A [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF [C]N [C]F B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
was [C]w [C]a [C]s O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
western [C]w [C]e [C]s [C]t [C]e [C]r [C]n O 
blot [C]b [C]l [C]o [C]t O 
assessment [C]a [C]s [C]s [C]e [C]s [C]s [C]m [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
electrophoretic [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
assay [C]a [C]s [C]s [C]a [C]y O 
in [C]i [C]n O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
of [C]o [C]f O 
colonic [C]c [C]o [C]l [C]o [C]n [C]i [C]c O 
biopsy [C]b [C]i [C]o [C]p [C]s [C]y O 
samples [C]s [C]a [C]m [C]p [C]l [C]e [C]s O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
lamina [C]l [C]a [C]m [C]i [C]n [C]a B-cell_type 
propria [C]p [C]r [C]o [C]p [C]r [C]i [C]a I-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

RESULTS [C]R [C]E [C]S [C]U [C]L [C]T [C]S O 
: [C]: O 
Nuclear [C]N [C]u [C]c [C]l [C]e [C]a [C]r O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
NF [C]N [C]F B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
p65 [C]p [C]6 [C]5 S-protein 
are [C]a [C]r [C]e O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
in [C]i [C]n O 
lamina [C]l [C]a [C]m [C]i [C]n [C]a O 
propria [C]p [C]r [C]o [C]p [C]r [C]i [C]a O 
biopsy [C]b [C]i [C]o [C]p [C]s [C]y O 
specimens [C]s [C]p [C]e [C]c [C]i [C]m [C]e [C]n [C]s O 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
Crohn [C]C [C]r [C]o [C]h [C]n O 
's [C]' [C]s O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
comparison [C]c [C]o [C]m [C]p [C]a [C]r [C]i [C]s [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
ulcerative [C]u [C]l [C]c [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
colitis [C]c [C]o [C]l [C]i [C]t [C]i [C]s O 
and [C]a [C]n [C]d O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
. [C]. O 

Increased [C]I [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF [C]N [C]F B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
was [C]w [C]a [C]s O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
in [C]i [C]n O 
lamina [C]l [C]a [C]m [C]i [C]n [C]a B-cell_type 
propria [C]p [C]r [C]o [C]p [C]r [C]i [C]a I-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
IBD [C]I [C]B [C]D O 
. [C]. O 

Corticosteroids [C]C [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]s O 
strongly [C]s [C]t [C]r [C]o [C]n [C]g [C]l [C]y O 
inhibit [C]i [C]n [C]h [C]i [C]b [C]i [C]t O 
intestinal [C]i [C]n [C]t [C]e [C]s [C]t [C]i [C]n [C]a [C]l O 
NF [C]N [C]F B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
IBD [C]I [C]B [C]D O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
by [C]b [C]y O 
stabilising [C]s [C]t [C]a [C]b [C]i [C]l [C]i [C]s [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
cytosolic [C]c [C]y [C]t [C]o [C]s [C]o [C]l [C]i [C]c B-protein 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r E-protein 
I [C]I B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
alpha [C]a [C]l [C]p [C]h [C]a O 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

CONCLUSIONS [C]C [C]O [C]N [C]C [C]L [C]U [C]S [C]I [C]O [C]N [C]S O 
: [C]: O 
In [C]I [C]n O 
both [C]b [C]o [C]t [C]h O 
IBDs [C]I [C]B [C]D [C]s O 
, [C], O 
but [C]b [C]u [C]t O 
particularly [C]p [C]a [C]r [C]t [C]i [C]c [C]u [C]l [C]a [C]r [C]l [C]y O 
Crohn [C]C [C]r [C]o [C]h [C]n O 
's [C]' [C]s O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
, [C], O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF [C]N [C]F B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
. [C]. O 

Inhibition [C]I [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF [C]N [C]F B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
may [C]m [C]a [C]y O 
represent [C]r [C]e [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
a [C]a O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
by [C]b [C]y O 
which [C]w [C]h [C]i [C]c [C]h O 
steroids [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]s O 
exert [C]e [C]x [C]e [C]r [C]t O 
an [C]a [C]n O 
anti-inflammatory [C]a [C]n [C]t [C]i [C]- [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
in [C]i [C]n O 
IBD [C]I [C]B [C]D O 

Insufficient [C]I [C]n [C]s [C]u [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
glycemic [C]g [C]l [C]y [C]c [C]e [C]m [C]i [C]c O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
increases [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor-kappa [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
type [C]t [C]y [C]p [C]e O 
1 [C]1 O 
diabetes [C]d [C]i [C]a [C]b [C]e [C]t [C]e [C]s O 
. [C]. O 

OBJECTIVE [C]O [C]B [C]J [C]E [C]C [C]T [C]I [C]V [C]E O 
: [C]: O 
The [C]T [C]h [C]e O 
redox-sensitive [C]r [C]e [C]d [C]o [C]x [C]- [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-protein 
factor-kappa [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
( [C]( O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
) [C]) O 
is [C]i [C]s O 
believed [C]b [C]e [C]l [C]i [C]e [C]v [C]e [C]d O 
to [C]t [C]o O 
contribute [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e O 
to [C]t [C]o O 
late [C]l [C]a [C]t [C]e O 
diabetic [C]d [C]i [C]a [C]b [C]e [C]t [C]i [C]c O 
complications [C]c [C]o [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

It [C]I [C]t O 
is [C]i [C]s O 
unknown [C]u [C]n [C]k [C]n [C]o [C]w [C]n O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
is [C]i [C]s O 
influenced [C]i [C]n [C]f [C]l [C]u [C]e [C]n [C]c [C]e [C]d O 
by [C]b [C]y O 
glycemic [C]g [C]l [C]y [C]c [C]e [C]m [C]i [C]c O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
. [C]. O 

RESEARCH [C]R [C]E [C]S [C]E [C]A [C]R [C]C [C]H O 
DESIGN [C]D [C]E [C]S [C]I [C]G [C]N O 
AND [C]A [C]N [C]D O 
METHODS [C]M [C]E [C]T [C]H [C]O [C]D [C]S O 
: [C]: O 
To [C]T [C]o O 
determine [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
is [C]i [C]s O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
insufficient [C]i [C]n [C]s [C]u [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
glycemic [C]g [C]l [C]y [C]c [C]e [C]m [C]i [C]c O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
( [C]( O 
HbA1c [C]H [C]b [C]A [C]1 [C]c O 
> [C]> O 
10 [C]1 [C]0 O 
% [C]% O 
) [C]) O 
, [C], O 
we [C]w [C]e O 
developed [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]e [C]d O 
a [C]a O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
culture-independent [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]- [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
electrophoretic [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
assay [C]a [C]s [C]s [C]a [C]y O 
( [C]( O 
EMSA [C]E [C]M [C]S [C]A O 
) [C]) O 
-based [C]- [C]b [C]a [C]s [C]e [C]d O 
semiquantitative [C]s [C]e [C]m [C]i [C]q [C]u [C]a [C]n [C]t [C]i [C]t [C]a [C]t [C]i [C]v [C]e O 
detection [C]d [C]e [C]t [C]e [C]c [C]t [C]i [C]o [C]n O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
that [C]t [C]h [C]a [C]t O 
allowed [C]a [C]l [C]l [C]o [C]w [C]e [C]d O 
us [C]u [C]s O 
to [C]t [C]o O 
determine [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
ex [C]e [C]x O 
vivo-isolated [C]v [C]i [C]v [C]o [C]- [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
PBMCs [C]P [C]B [C]M [C]C [C]s S-cell_type 
) [C]) O 
. [C]. O 

We [C]W [C]e O 
included [C]i [C]n [C]c [C]l [C]u [C]d [C]e [C]d O 
43 [C]4 [C]3 O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
type [C]t [C]y [C]p [C]e O 
1 [C]1 O 
diabetes [C]d [C]i [C]a [C]b [C]e [C]t [C]e [C]s O 
in [C]i [C]n O 
this [C]t [C]h [C]i [C]s O 
cross-sectional [C]c [C]r [C]o [C]s [C]s [C]- [C]s [C]e [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
study [C]s [C]t [C]u [C]d [C]y O 
. [C]. O 

10 [C]1 [C]0 O 
of [C]o [C]f O 
those [C]t [C]h [C]o [C]s [C]e O 
received [C]r [C]e [C]c [C]e [C]i [C]v [C]e [C]d O 
the [C]t [C]h [C]e O 
antioxidant [C]a [C]n [C]t [C]i [C]o [C]x [C]i [C]d [C]a [C]n [C]t O 
thioctic [C]t [C]h [C]i [C]o [C]c [C]t [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
( [C]( O 
600 [C]6 [C]0 [C]0 O 
mg/day [C]m [C]g [C]/ [C]d [C]a [C]y O 
p.o. [C]p [C]. [C]o [C]. O 
) [C]) O 
for [C]f [C]o [C]r O 
2 [C]2 O 
weeks [C]w [C]e [C]e [C]k [C]s O 
. [C]. O 

RESULTS [C]R [C]E [C]S [C]U [C]L [C]T [C]S O 
: [C]: O 
Monocytes [C]M [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s O 
of [C]o [C]f O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
HbA1c [C]H [C]b [C]A [C]1 [C]c O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
> [C]> O 
10 [C]1 [C]0 O 
% [C]% O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
an [C]a [C]n O 
EMSA [C]E [C]M [C]S [C]A O 
and [C]a [C]n [C]d O 
a [C]a O 
stronger [C]s [C]t [C]r [C]o [C]n [C]g [C]e [C]r O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
staining [C]s [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
in [C]i [C]n O 
immunohistochemistry [C]i [C]m [C]m [C]u [C]n [C]o [C]h [C]i [C]s [C]t [C]o [C]c [C]h [C]e [C]m [C]i [C]s [C]t [C]r [C]y O 
than [C]t [C]h [C]a [C]n O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
of [C]o [C]f O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
HbA1c [C]H [C]b [C]A [C]1 [C]c O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
6-8 [C]6 [C]- [C]8 O 
% [C]% O 
. [C]. O 

The [C]T [C]h [C]e O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
an [C]a [C]n O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
plasmatic [C]p [C]l [C]a [C]s [C]m [C]a [C]t [C]i [C]c O 
markers [C]m [C]a [C]r [C]k [C]e [C]r [C]s O 
of [C]o [C]f O 
lipid [C]l [C]i [C]p [C]i [C]d O 
peroxidation [C]p [C]e [C]r [C]o [C]x [C]i [C]d [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Treatment [C]T [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
antioxidant [C]a [C]n [C]t [C]i [C]o [C]x [C]i [C]d [C]a [C]n [C]t O 
thioctic [C]t [C]h [C]i [C]o [C]c [C]t [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

CONCLUSIONS [C]C [C]O [C]N [C]C [C]L [C]U [C]S [C]I [C]O [C]N [C]S O 
: [C]: O 
Hyperglycemia [C]H [C]y [C]p [C]e [C]r [C]g [C]l [C]y [C]c [C]e [C]m [C]i [C]a O 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
in [C]i [C]n O 
ex [C]e [C]x O 
vivo-isolated [C]v [C]i [C]v [C]o [C]- [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d O 
PBMCs [C]P [C]B [C]M [C]C [C]s S-cell_type 
of [C]o [C]f O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
type [C]t [C]y [C]p [C]e O 
1 [C]1 O 
diabetes [C]d [C]i [C]a [C]b [C]e [C]t [C]e [C]s O 
. [C]. O 

NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
at [C]a [C]t O 
least [C]l [C]e [C]a [C]s [C]t O 
partially [C]p [C]a [C]r [C]t [C]i [C]a [C]l [C]l [C]y O 
dependent [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
on [C]o [C]n O 
oxidative [C]o [C]x [C]i [C]d [C]a [C]t [C]i [C]v [C]e O 
stress [C]s [C]t [C]r [C]e [C]s [C]s O 
, [C], O 
since [C]s [C]i [C]n [C]c [C]e O 
the [C]t [C]h [C]e O 
antioxidant [C]a [C]n [C]t [C]i [C]o [C]x [C]i [C]d [C]a [C]n [C]t O 
thioctic [C]t [C]h [C]i [C]o [C]c [C]t [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
lowered [C]l [C]o [C]w [C]e [C]r [C]e [C]d O 
the [C]t [C]h [C]e O 
extent [C]e [C]x [C]t [C]e [C]n [C]t O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

Synergistic [C]S [C]y [C]n [C]e [C]r [C]g [C]i [C]s [C]t [C]i [C]c O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
MAP [C]M [C]A [C]P B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
( [C]( O 
ERK1/2 [C]E [C]R [C]K [C]1 [C]/ [C]2 S-protein 
) [C]) O 
by [C]b [C]y O 
erythropoietin [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]n S-protein 
and [C]a [C]n [C]d O 
stem [C]s [C]t [C]e [C]m B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
is [C]i [C]s O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
for [C]f [C]o [C]r O 
expanded [C]e [C]x [C]p [C]a [C]n [C]d [C]e [C]d O 
erythropoiesis [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
. [C]. O 

Stem [C]S [C]t [C]e [C]m B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
( [C]( O 
SCF [C]S [C]C [C]F S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
erythropoietin [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]n S-protein 
( [C]( O 
EPO [C]E [C]P [C]O S-protein 
) [C]) O 
work [C]w [C]o [C]r [C]k O 
synergistically [C]s [C]y [C]n [C]e [C]r [C]g [C]i [C]s [C]t [C]i [C]c [C]a [C]l [C]l [C]y O 
to [C]t [C]o O 
support [C]s [C]u [C]p [C]p [C]o [C]r [C]t O 
erythropoiesis [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
, [C], O 
but [C]b [C]u [C]t O 
the [C]t [C]h [C]e O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
for [C]f [C]o [C]r O 
this [C]t [C]h [C]i [C]s O 
synergism [C]s [C]y [C]n [C]e [C]r [C]g [C]i [C]s [C]m O 
is [C]i [C]s O 
unknown [C]u [C]n [C]k [C]n [C]o [C]w [C]n O 
. [C]. O 

By [C]B [C]y O 
using [C]u [C]s [C]i [C]n [C]g O 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d B-cell_line 
human [C]h [C]u [C]m [C]a [C]n I-cell_line 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d I-cell_line 
colony-forming [C]c [C]o [C]l [C]o [C]n [C]y [C]- [C]f [C]o [C]r [C]m [C]i [C]n [C]g I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
( [C]( O 
ECFC [C]E [C]C [C]F [C]C S-cell_line 
) [C]) O 
, [C], O 
we [C]w [C]e O 
have [C]h [C]a [C]v [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
SCF [C]S [C]C [C]F S-protein 
and [C]a [C]n [C]d O 
EPO [C]E [C]P [C]O S-protein 
synergistically [C]s [C]y [C]n [C]e [C]r [C]g [C]i [C]s [C]t [C]i [C]c [C]a [C]l [C]l [C]y O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
MAP [C]M [C]A [C]P B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
( [C]( O 
MAPK [C]M [C]A [C]P [C]K S-protein 
, [C], O 
ERK1/2 [C]E [C]R [C]K [C]1 [C]/ [C]2 S-protein 
) [C]) O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
correlates [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
cell [C]c [C]e [C]l [C]l O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
and [C]a [C]n [C]d O 
thus [C]t [C]h [C]u [C]s O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
responsible [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]b [C]l [C]e O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
synergistic [C]s [C]y [C]n [C]e [C]r [C]g [C]i [C]s [C]t [C]i [C]c O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
. [C]. O 

Treatment [C]T [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
with [C]w [C]i [C]t [C]h O 
PD98059 [C]P [C]D [C]9 [C]8 [C]0 [C]5 [C]9 O 
and [C]a [C]n [C]d O 
wortmannin [C]w [C]o [C]r [C]t [C]m [C]a [C]n [C]n [C]i [C]n O 
, [C], O 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
of [C]o [C]f O 
MEK [C]M [C]E [C]K S-protein 
and [C]a [C]n [C]d O 
PI-3 [C]P [C]I [C]- [C]3 B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
, [C], O 
respectively [C]r [C]e [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
, [C], O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
synergistic [C]s [C]y [C]n [C]e [C]r [C]g [C]i [C]s [C]t [C]i [C]c O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
MAPK [C]M [C]A [C]P [C]K S-protein 
and [C]a [C]n [C]d O 
also [C]a [C]l [C]s [C]o O 
the [C]t [C]h [C]e O 
cell [C]c [C]e [C]l [C]l O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
, [C], O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
supporting [C]s [C]u [C]p [C]p [C]o [C]r [C]t [C]i [C]n [C]g O 
this [C]t [C]h [C]i [C]s O 
conclusion [C]c [C]o [C]n [C]c [C]l [C]u [C]s [C]i [C]o [C]n O 
. [C]. O 

Wortmannin [C]W [C]o [C]r [C]t [C]m [C]a [C]n [C]n [C]i [C]n O 
only [C]o [C]n [C]l [C]y O 
inhibits [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]s O 
MAPK [C]M [C]A [C]P [C]K S-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
EPO [C]E [C]P [C]O S-protein 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
that [C]t [C]h [C]a [C]t O 
by [C]b [C]y O 
SCF [C]S [C]C [C]F S-protein 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
SCF [C]S [C]C [C]F S-protein 
and [C]a [C]n [C]d O 
EPO [C]E [C]P [C]O S-protein 
may [C]m [C]a [C]y O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
MAPK [C]M [C]A [C]P [C]K S-protein 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
would [C]w [C]o [C]u [C]l [C]d O 
facilitate [C]f [C]a [C]c [C]i [C]l [C]i [C]t [C]a [C]t [C]e O 
synergy [C]s [C]y [C]n [C]e [C]r [C]g [C]y O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
EPO [C]E [C]P [C]O S-protein 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
SCF [C]S [C]C [C]F S-protein 
, [C], O 
led [C]l [C]e [C]d O 
to [C]t [C]o O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
STAT5 [C]S [C]T [C]A [C]T [C]5 S-protein 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
SCF [C]S [C]C [C]F S-protein 
and [C]a [C]n [C]d O 
wortmannin [C]w [C]o [C]r [C]t [C]m [C]a [C]n [C]n [C]i [C]n O 
had [C]h [C]a [C]d O 
no [C]n [C]o O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
EPO [C]E [C]P [C]O S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
STAT5 [C]S [C]T [C]A [C]T [C]5 S-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
STAT5 [C]S [C]T [C]A [C]T [C]5 S-protein 
is [C]i [C]s O 
not [C]n [C]o [C]t O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
synergistic [C]s [C]y [C]n [C]e [C]r [C]g [C]i [C]s [C]t [C]i [C]c O 
action [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
SCF [C]S [C]C [C]F S-protein 
and [C]a [C]n [C]d O 
EPO [C]E [C]P [C]O S-protein 
. [C]. O 

Together [C]T [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
, [C], O 
the [C]t [C]h [C]e O 
data [C]d [C]a [C]t [C]a O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
synergistic [C]s [C]y [C]n [C]e [C]r [C]g [C]i [C]s [C]t [C]i [C]c O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
MAPK [C]M [C]A [C]P [C]K S-protein 
by [C]b [C]y O 
SCF [C]S [C]C [C]F S-protein 
and [C]a [C]n [C]d O 
EPO [C]E [C]P [C]O S-protein 
is [C]i [C]s O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
for [C]f [C]o [C]r O 
expanded [C]e [C]x [C]p [C]a [C]n [C]d [C]e [C]d O 
erythropoiesis [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
. [C]. O 

Copyright [C]C [C]o [C]p [C]y [C]r [C]i [C]g [C]h [C]t O 
1998 [C]1 [C]9 [C]9 [C]8 O 
by [C]b [C]y O 
The [C]T [C]h [C]e O 
American [C]A [C]m [C]e [C]r [C]i [C]c [C]a [C]n O 
Society [C]S [C]o [C]c [C]i [C]e [C]t [C]y O 
of [C]o [C]f O 
Hematology [C]H [C]e [C]m [C]a [C]t [C]o [C]l [C]o [C]g [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
and [C]a [C]n [C]d O 
phenotypic [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]i [C]c O 
profile [C]p [C]r [C]o [C]f [C]i [C]l [C]e O 
of [C]o [C]f O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y O 
central [C]c [C]e [C]n [C]t [C]r [C]a [C]l O 
nervous [C]n [C]e [C]r [C]v [C]o [C]u [C]s O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a O 
identifies [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]s O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
categories [C]c [C]a [C]t [C]e [C]g [C]o [C]r [C]i [C]e [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
consistent [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
histogenetic [C]h [C]i [C]s [C]t [C]o [C]g [C]e [C]n [C]e [C]t [C]i [C]c O 
derivation [C]d [C]e [C]r [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
from [C]f [C]r [C]o [C]m O 
germinal [C]g [C]e [C]r [C]m [C]i [C]n [C]a [C]l B-cell_type 
center-related [C]c [C]e [C]n [C]t [C]e [C]r [C]- [C]r [C]e [C]l [C]a [C]t [C]e [C]d I-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Primary [C]P [C]r [C]i [C]m [C]a [C]r [C]y O 
central [C]c [C]e [C]n [C]t [C]r [C]a [C]l O 
nervous [C]n [C]e [C]r [C]v [C]o [C]u [C]s O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a O 
( [C]( O 
PCNSL [C]P [C]C [C]N [C]S [C]L O 
) [C]) O 
is [C]i [C]s O 
a [C]a O 
major [C]m [C]a [C]j [C]o [C]r O 
cause [C]c [C]a [C]u [C]s [C]e O 
of [C]o [C]f O 
morbidity [C]m [C]o [C]r [C]b [C]i [C]d [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
mortality [C]m [C]o [C]r [C]t [C]a [C]l [C]i [C]t [C]y O 
among [C]a [C]m [C]o [C]n [C]g O 
human [C]h [C]u [C]m [C]a [C]n O 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
virus [C]v [C]i [C]r [C]u [C]s O 
( [C]( O 
HIV [C]H [C]I [C]V O 
) [C]) O 
-infected [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
individuals [C]i [C]n [C]d [C]i [C]v [C]i [C]d [C]u [C]a [C]l [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
precise [C]p [C]r [C]e [C]c [C]i [C]s [C]e O 
histogenetic [C]h [C]i [C]s [C]t [C]o [C]g [C]e [C]n [C]e [C]t [C]i [C]c O 
derivation [C]d [C]e [C]r [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
pathogenesis [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
PCNSL [C]P [C]C [C]N [C]S [C]L O 
is [C]i [C]s O 
poorly [C]p [C]o [C]o [C]r [C]l [C]y O 
understood [C]u [C]n [C]d [C]e [C]r [C]s [C]t [C]o [C]o [C]d O 
. [C]. O 

In [C]I [C]n O 
an [C]a [C]n O 
attempt [C]a [C]t [C]t [C]e [C]m [C]p [C]t O 
to [C]t [C]o O 
clarify [C]c [C]l [C]a [C]r [C]i [C]f [C]y O 
the [C]t [C]h [C]e O 
histogenesis [C]h [C]i [C]s [C]t [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
pathogenesis [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
lymphomas [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a [C]s O 
, [C], O 
49 [C]4 [C]9 O 
PCNSL [C]P [C]C [C]N [C]S [C]L O 
( [C]( O 
26 [C]2 [C]6 O 
acquired [C]a [C]c [C]q [C]u [C]i [C]r [C]e [C]d O 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
syndrome [C]s [C]y [C]n [C]d [C]r [C]o [C]m [C]e O 
[ [C][ O 
AIDS [C]A [C]I [C]D [C]S O 
] [C]] O 
-related [C]- [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
and [C]a [C]n [C]d O 
23 [C]2 [C]3 O 
AIDS-unrelated [C]A [C]I [C]D [C]S [C]- [C]u [C]n [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
) [C]) O 
were [C]w [C]e [C]r [C]e O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
for [C]f [C]o [C]r O 
multiple [C]m [C]u [C]l [C]t [C]i [C]p [C]l [C]e O 
biologic [C]b [C]i [C]o [C]l [C]o [C]g [C]i [C]c O 
markers [C]m [C]a [C]r [C]k [C]e [C]r [C]s O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
are [C]a [C]r [C]e O 
known [C]k [C]n [C]o [C]w [C]n O 
to [C]t [C]o O 
bear [C]b [C]e [C]a [C]r O 
histogenetic [C]h [C]i [C]s [C]t [C]o [C]g [C]e [C]n [C]e [C]t [C]i [C]c O 
and [C]a [C]n [C]d O 
pathogenetic [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]e [C]t [C]i [C]c O 
significance [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]c [C]e O 
for [C]f [C]o [C]r O 
mature [C]m [C]a [C]t [C]u [C]r [C]e O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l O 
neoplasms [C]n [C]e [C]o [C]p [C]l [C]a [C]s [C]m [C]s O 
. [C]. O 

PCNSL [C]P [C]C [C]N [C]S [C]L O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
frequently [C]f [C]r [C]e [C]q [C]u [C]e [C]n [C]t [C]l [C]y O 
( [C]( O 
50.0 [C]5 [C]0 [C]. [C]0 O 
% [C]% O 
) [C]) O 
with [C]w [C]i [C]t [C]h O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
BCL-6 [C]B [C]C [C]L [C]- [C]6 B-DNA 
5 [C]5 I-DNA 
' [C]' I-DNA 
noncoding [C]n [C]o [C]n [C]c [C]o [C]d [C]i [C]n [C]g I-DNA 
regions [C]r [C]e [C]g [C]i [C]o [C]n [C]s E-DNA 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
are [C]a [C]r [C]e O 
regarded [C]r [C]e [C]g [C]a [C]r [C]d [C]e [C]d O 
as [C]a [C]s O 
a [C]a O 
marker [C]m [C]a [C]r [C]k [C]e [C]r O 
of [C]o [C]f O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l O 
transition [C]t [C]r [C]a [C]n [C]s [C]i [C]t [C]i [C]o [C]n O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
germinal [C]g [C]e [C]r [C]m [C]i [C]n [C]a [C]l O 
center [C]c [C]e [C]n [C]t [C]e [C]r O 
( [C]( O 
GC [C]G [C]C O 
) [C]) O 
. [C]. O 

Expression [C]E [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
BCL-6 [C]B [C]C [C]L [C]- [C]6 B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
restricted [C]r [C]e [C]s [C]t [C]r [C]i [C]c [C]t [C]e [C]d O 
to [C]t [C]o O 
GC [C]G [C]C B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
throughout [C]t [C]h [C]r [C]o [C]u [C]g [C]h [C]o [C]u [C]t O 
physiologic [C]p [C]h [C]y [C]s [C]i [C]o [C]l [C]o [C]g [C]i [C]c O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l O 
maturation [C]m [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
was [C]w [C]a [C]s O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
in [C]i [C]n O 
100 [C]1 [C]0 [C]0 O 
% [C]% O 
AIDS-unrelated [C]A [C]I [C]D [C]S [C]- [C]u [C]n [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
PCNSL [C]P [C]C [C]N [C]S [C]L O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
56.2 [C]5 [C]6 [C]. [C]2 O 
% [C]% O 
AIDS-related [C]A [C]I [C]D [C]S [C]- [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
cases [C]c [C]a [C]s [C]e [C]s O 
. [C]. O 

Notably [C]N [C]o [C]t [C]a [C]b [C]l [C]y O 
, [C], O 
among [C]a [C]m [C]o [C]n [C]g O 
AIDS-related [C]A [C]I [C]D [C]S [C]- [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
PCNSL [C]P [C]C [C]N [C]S [C]L O 
, [C], O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
BCL-6 [C]B [C]C [C]L [C]- [C]6 S-protein 
was [C]w [C]a [C]s O 
mutually [C]m [C]u [C]t [C]u [C]a [C]l [C]l [C]y O 
exclusive [C]e [C]x [C]c [C]l [C]u [C]s [C]i [C]v [C]e O 
with [C]w [C]i [C]t [C]h O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
Epstein-Barr [C]E [C]p [C]s [C]t [C]e [C]i [C]n [C]- [C]B [C]a [C]r [C]r B-protein 
virus [C]v [C]i [C]r [C]u [C]s I-protein 
( [C]( I-protein 
EBV [C]E [C]B [C]V I-protein 
) [C]) I-protein 
-encoded [C]- [C]e [C]n [C]c [C]o [C]d [C]e [C]d I-protein 
latent [C]l [C]a [C]t [C]e [C]n [C]t I-protein 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
( [C]( I-protein 
LMP [C]L [C]M [C]P I-protein 
) [C]) I-protein 
-1 [C]- [C]1 E-protein 
and [C]a [C]n [C]d O 
, [C], O 
with [C]w [C]i [C]t [C]h O 
few [C]f [C]e [C]w O 
exceptions [C]e [C]x [C]c [C]e [C]p [C]t [C]i [C]o [C]n [C]s O 
, [C], O 
also [C]a [C]l [C]s [C]o O 
of [C]o [C]f O 
BCL-2 [C]B [C]C [C]L [C]- [C]2 S-protein 
. [C]. O 

All [C]A [C]l [C]l O 
but [C]b [C]u [C]t O 
one [C]o [C]n [C]e O 
PCNSL [C]P [C]C [C]N [C]S [C]L O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
hMSH2 [C]h [C]M [C]S [C]H [C]2 O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
among [C]a [C]m [C]o [C]n [C]g O 
mature [C]m [C]a [C]t [C]u [C]r [C]e B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
selectively [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
stains [C]s [C]t [C]a [C]i [C]n [C]s O 
GC [C]G [C]C B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
PCNSL [C]P [C]C [C]N [C]S [C]L O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
frequently [C]f [C]r [C]e [C]q [C]u [C]e [C]n [C]t [C]l [C]y O 
related [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
to [C]t [C]o O 
GC [C]G [C]C B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
segregated [C]s [C]e [C]g [C]r [C]e [C]g [C]a [C]t [C]e [C]d O 
into [C]i [C]n [C]t [C]o O 
two [C]t [C]w [C]o O 
major [C]m [C]a [C]j [C]o [C]r O 
biologic [C]b [C]i [C]o [C]l [C]o [C]g [C]i [C]c O 
categories [C]c [C]a [C]t [C]e [C]g [C]o [C]r [C]i [C]e [C]s O 
based [C]b [C]a [C]s [C]e [C]d O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
pattern [C]p [C]a [C]t [C]t [C]e [C]r [C]n O 
of [C]o [C]f O 
BCL-6 [C]B [C]C [C]L [C]- [C]6 S-protein 
, [C], O 
LMP-1 [C]L [C]M [C]P [C]- [C]1 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
BCL-2 [C]B [C]C [C]L [C]- [C]2 S-protein 
. [C]. O 

BCL-6 [C]B [C]C [C]L [C]- [C]6 S-protein 
( [C]( O 
+ [C]+ O 
) [C]) O 
/ [C]/ O 
LMP-1 [C]L [C]M [C]P [C]- [C]1 S-protein 
( [C]( O 
- [C]- O 
) [C]) O 
/ [C]/ O 
BCL-2 [C]B [C]C [C]L [C]- [C]2 S-protein 
( [C]( O 
- [C]- O 
) [C]) O 
PCNSL [C]P [C]C [C]N [C]S [C]L O 
occur [C]o [C]c [C]c [C]u [C]r O 
both [C]b [C]o [C]t [C]h O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
HIV [C]H [C]I [C]V O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
consistently [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]t [C]l [C]y O 
display [C]d [C]i [C]s [C]p [C]l [C]a [C]y O 
a [C]a O 
large [C]l [C]a [C]r [C]g [C]e O 
noncleaved [C]n [C]o [C]n [C]c [C]l [C]e [C]a [C]v [C]e [C]d O 
cell [C]c [C]e [C]l [C]l O 
morphology [C]m [C]o [C]r [C]p [C]h [C]o [C]l [C]o [C]g [C]y O 
. [C]. O 

Conversely [C]C [C]o [C]n [C]v [C]e [C]r [C]s [C]e [C]l [C]y O 
, [C], O 
BCL-6 [C]B [C]C [C]L [C]- [C]6 S-protein 
( [C]( O 
- [C]- O 
) [C]) O 
/ [C]/ O 
LMP-1 [C]L [C]M [C]P [C]- [C]1 S-protein 
( [C]( O 
+ [C]+ O 
) [C]) O 
/ [C]/ O 
BCL-2 [C]B [C]C [C]L [C]- [C]2 S-protein 
( [C]( O 
+ [C]+ O 
) [C]) O 
PCNSL [C]P [C]C [C]N [C]S [C]L O 
are [C]a [C]r [C]e O 
restricted [C]r [C]e [C]s [C]t [C]r [C]i [C]c [C]t [C]e [C]d O 
to [C]t [C]o O 
HIV-infected [C]H [C]I [C]V [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
hosts [C]h [C]o [C]s [C]t [C]s O 
and [C]a [C]n [C]d O 
are [C]a [C]r [C]e O 
represented [C]r [C]e [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]e [C]d O 
by [C]b [C]y O 
lymphomas [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a [C]s O 
with [C]w [C]i [C]t [C]h O 
immunoblastic [C]i [C]m [C]m [C]u [C]n [C]o [C]b [C]l [C]a [C]s [C]t [C]i [C]c O 
features [C]f [C]e [C]a [C]t [C]u [C]r [C]e [C]s O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
are [C]a [C]r [C]e O 
relevant [C]r [C]e [C]l [C]e [C]v [C]a [C]n [C]t O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
pathogenesis [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
histogenesis [C]h [C]i [C]s [C]t [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
PCNSL [C]P [C]C [C]N [C]S [C]L O 
and [C]a [C]n [C]d O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
helpful [C]h [C]e [C]l [C]p [C]f [C]u [C]l O 
to [C]t [C]o O 
segregate [C]s [C]e [C]g [C]r [C]e [C]g [C]a [C]t [C]e O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
biologic [C]b [C]i [C]o [C]l [C]o [C]g [C]i [C]c O 
and [C]a [C]n [C]d O 
prognostic [C]p [C]r [C]o [C]g [C]n [C]o [C]s [C]t [C]i [C]c O 
categories [C]c [C]a [C]t [C]e [C]g [C]o [C]r [C]i [C]e [C]s O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
lymphomas [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a [C]s O 
. [C]. O 

Copyright [C]C [C]o [C]p [C]y [C]r [C]i [C]g [C]h [C]t O 
1998 [C]1 [C]9 [C]9 [C]8 O 
by [C]b [C]y O 
The [C]T [C]h [C]e O 
American [C]A [C]m [C]e [C]r [C]i [C]c [C]a [C]n O 
Society [C]S [C]o [C]c [C]i [C]e [C]t [C]y O 
of [C]o [C]f O 
Hematology [C]H [C]e [C]m [C]a [C]t [C]o [C]l [C]o [C]g [C]y O 
. [C]. O 

Antioxidant [C]A [C]n [C]t [C]i [C]o [C]x [C]i [C]d [C]a [C]n [C]t O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
phorbol [C]p [C]h [C]o [C]r [C]b [C]o [C]l O 
ester-induced [C]e [C]s [C]t [C]e [C]r [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t I-cell_line 
T-cells [C]T [C]- [C]c [C]e [C]l [C]l [C]s E-cell_line 
to [C]t [C]o O 
endothelial [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Regulation [C]R [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
reactive [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]e O 
oxygen [C]o [C]x [C]y [C]g [C]e [C]n O 
species [C]s [C]p [C]e [C]c [C]i [C]e [C]s O 
via [C]v [C]i [C]a O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
redox [C]r [C]e [C]d [C]o [C]x O 
sensitive [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
reported [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]d O 
. [C]. O 

The [C]T [C]h [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
clinically [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l [C]l [C]y O 
safe [C]s [C]a [C]f [C]e O 
antioxidants [C]a [C]n [C]t [C]i [C]o [C]x [C]i [C]d [C]a [C]n [C]t [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
endothelial [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
ECV [C]E [C]C [C]V O 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
adherence [C]a [C]d [C]h [C]e [C]r [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t I-cell_line 
T [C]T I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
to [C]t [C]o O 
ECV [C]E [C]C [C]V B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
. [C]. O 

The [C]T [C]h [C]e O 
thiol [C]t [C]h [C]i [C]o [C]l O 
antioxidant [C]a [C]n [C]t [C]i [C]o [C]x [C]i [C]d [C]a [C]n [C]t O 
, [C], O 
alpha-lipoate [C]a [C]l [C]p [C]h [C]a [C]- [C]l [C]i [C]p [C]o [C]a [C]t [C]e O 
, [C], O 
at [C]a [C]t O 
clinically [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l [C]l [C]y O 
relevant [C]r [C]e [C]l [C]e [C]v [C]a [C]n [C]t O 
doses [C]d [C]o [C]s [C]e [C]s O 
down-regulated [C]d [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
phorbol [C]p [C]h [C]o [C]r [C]b [C]o [C]l O 
12-myristate [C]1 [C]2 [C]- [C]m [C]y [C]r [C]i [C]s [C]t [C]a [C]t [C]e O 
13-acetate [C]1 [C]3 [C]- [C]a [C]c [C]e [C]t [C]a [C]t [C]e O 
( [C]( O 
PMA [C]P [C]M [C]A O 
) [C]) O 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
cell-cell [C]c [C]e [C]l [C]l [C]- [C]c [C]e [C]l [C]l O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
. [C]. O 

Inhibition [C]I [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
PMA-induced [C]P [C]M [C]A [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
ICAM-1 [C]I [C]C [C]A [C]M [C]- [C]1 O 
and [C]a [C]n [C]d O 
VCAM-1 [C]V [C]C [C]A [C]M [C]- [C]1 O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
PMA-induced [C]P [C]M [C]A [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_line 
T-cells [C]T [C]- [C]c [C]e [C]l [C]l [C]s E-cell_line 
to [C]t [C]o O 
ECV [C]E [C]C [C]V B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
by [C]b [C]y O 
alpha-lipoate [C]a [C]l [C]p [C]h [C]a [C]- [C]l [C]i [C]p [C]o [C]a [C]t [C]e O 
was [C]w [C]a [C]s O 
dose [C]d [C]o [C]s [C]e O 
dependent [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
( [C]( O 
50-250 [C]5 [C]0 [C]- [C]2 [C]5 [C]0 O 
microM [C]m [C]i [C]c [C]r [C]o [C]M O 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
was [C]w [C]a [C]s O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
for [C]f [C]o [C]r O 
ICAM-1 [C]I [C]C [C]A [C]M [C]- [C]1 S-protein 
( [C]( O 
p [C]p O 
< [C]< O 
.01 [C]. [C]0 [C]1 O 
) [C]) O 
and [C]a [C]n [C]d O 
VCAM-1 [C]V [C]C [C]A [C]M [C]- [C]1 S-protein 
( [C]( O 
p [C]p O 
< [C]< O 
.01 [C]. [C]0 [C]1 O 
) [C]) O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
cells [C]c [C]e [C]l [C]l [C]s O 
pretreated [C]p [C]r [C]e [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
100 [C]1 [C]0 [C]0 O 
microM [C]m [C]i [C]c [C]r [C]o [C]M O 
alpha-lipoate [C]a [C]l [C]p [C]h [C]a [C]- [C]l [C]i [C]p [C]o [C]a [C]t [C]e O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
PMA-activated [C]P [C]M [C]A [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-cell_type 
untreated [C]u [C]n [C]t [C]r [C]e [C]a [C]t [C]e [C]d I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Inhibition [C]I [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
PMA-induced [C]P [C]M [C]A [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
cell-cell [C]c [C]e [C]l [C]l [C]- [C]c [C]e [C]l [C]l O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
more [C]m [C]o [C]r [C]e O 
pronounced [C]p [C]r [C]o [C]n [C]o [C]u [C]n [C]c [C]e [C]d O 
when [C]w [C]h [C]e [C]n O 
a [C]a O 
combination [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
antioxidants [C]a [C]n [C]t [C]i [C]o [C]x [C]i [C]d [C]a [C]n [C]t [C]s O 
, [C], O 
alpha-lipoate [C]a [C]l [C]p [C]h [C]a [C]- [C]l [C]i [C]p [C]o [C]a [C]t [C]e O 
and [C]a [C]n [C]d O 
alpha-tocopherol [C]a [C]l [C]p [C]h [C]a [C]- [C]t [C]o [C]c [C]o [C]p [C]h [C]e [C]r [C]o [C]l O 
, [C], O 
were [C]w [C]e [C]r [C]e O 
used [C]u [C]s [C]e [C]d O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
use [C]u [C]s [C]e O 
of [C]o [C]f O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
antioxidant [C]a [C]n [C]t [C]i [C]o [C]x [C]i [C]d [C]a [C]n [C]t O 
alone [C]a [C]l [C]o [C]n [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
low [C]l [C]o [C]w O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
antioxidants [C]a [C]n [C]t [C]i [C]o [C]x [C]i [C]d [C]a [C]n [C]t [C]s O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
does [C]d [C]o [C]e [C]s O 
not [C]n [C]o [C]t O 
appear [C]a [C]p [C]p [C]e [C]a [C]r O 
to [C]t [C]o O 
be [C]b [C]e O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
or [C]o [C]r O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
dependent [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
because [C]b [C]e [C]c [C]a [C]u [C]s [C]e O 
no [C]n [C]o O 
change [C]c [C]h [C]a [C]n [C]g [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
mRNA [C]m [C]R [C]N [C]A O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
. [C]. O 

Protein [C]P [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
C [C]C E-protein 
( [C]( O 
PKC [C]P [C]K [C]C S-protein 
) [C]) O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
suggested [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]e [C]d O 
to [C]t [C]o O 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
PMA-induced [C]P [C]M [C]A [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
by [C]b [C]y O 
post-transcriptional [C]p [C]o [C]s [C]t [C]- [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
stabilization [C]s [C]t [C]a [C]b [C]i [C]l [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n B-RNA 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e I-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
. [C]. O 

Alpha-lipoate [C]A [C]l [C]p [C]h [C]a [C]- [C]l [C]i [C]p [C]o [C]a [C]t [C]e O 
pretreatment [C]p [C]r [C]e [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
influence [C]i [C]n [C]f [C]l [C]u [C]e [C]n [C]c [C]e O 
the [C]t [C]h [C]e O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
of [C]o [C]f O 
PKC [C]P [C]K [C]C S-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
to [C]t [C]o O 
PMA [C]P [C]M [C]A O 
. [C]. O 

Oxidants [C]O [C]x [C]i [C]d [C]a [C]n [C]t [C]s O 
are [C]a [C]r [C]e O 
known [C]k [C]n [C]o [C]w [C]n O 
to [C]t [C]o O 
be [C]b [C]e O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cell [C]c [C]e [C]l [C]l O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
processes [C]p [C]r [C]o [C]c [C]e [C]s [C]s [C]e [C]s O 
. [C]. O 

Treatment [C]T [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
ECV [C]E [C]C [C]V B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
with [C]w [C]i [C]t [C]h O 
PMA [C]P [C]M [C]A O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
generation [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
oxidants [C]o [C]x [C]i [C]d [C]a [C]n [C]t [C]s O 
. [C]. O 

Alpha-lipoate [C]A [C]l [C]p [C]h [C]a [C]- [C]l [C]i [C]p [C]o [C]a [C]t [C]e O 
( [C]( O 
100 [C]1 [C]0 [C]0 O 
or [C]o [C]r O 
250 [C]2 [C]5 [C]0 O 
microM [C]m [C]i [C]c [C]r [C]o [C]M O 
) [C]) O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
PMA-induced [C]P [C]M [C]A [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
generation [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
oxidants [C]o [C]x [C]i [C]d [C]a [C]n [C]t [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
low [C]l [C]o [C]w O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
alpha-lipaote [C]a [C]l [C]p [C]h [C]a [C]- [C]l [C]i [C]p [C]a [C]o [C]t [C]e O 
alone [C]a [C]l [C]o [C]n [C]e O 
or [C]o [C]r O 
in [C]i [C]n O 
combination [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
alpha-tocopherol [C]a [C]l [C]p [C]h [C]a [C]- [C]t [C]o [C]c [C]o [C]p [C]h [C]e [C]r [C]o [C]l O 
on [C]o [C]n O 
agonist-induced [C]a [C]g [C]o [C]n [C]i [C]s [C]t [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
processes [C]p [C]r [C]o [C]c [C]e [C]s [C]s [C]e [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
of [C]o [C]f O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
therapeutic [C]t [C]h [C]e [C]r [C]a [C]p [C]e [C]u [C]t [C]i [C]c O 
value [C]v [C]a [C]l [C]u [C]e O 
. [C]. O 

Binding [C]B [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n O 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
virus [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
1 [C]1 O 
to [C]t [C]o O 
CD4 [C]C [C]D [C]4 B-protein 
and [C]a [C]n [C]d I-protein 
CXCR4 [C]C [C]X [C]C [C]R [C]4 I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
differentially [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l [C]l [C]y O 
regulates [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]s O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
and [C]a [C]n [C]d O 
activates [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]s O 
the [C]t [C]h [C]e O 
MEK [C]M [C]E [C]K S-protein 
/ERK [C]/ [C]E [C]R [C]K O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
shown [C]s [C]h [C]o [C]w [C]n O 
that [C]t [C]h [C]a [C]t O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n O 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
virus [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
1 [C]1 O 
( [C]( O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
) [C]) O 
virions [C]v [C]i [C]r [C]i [C]o [C]n [C]s O 
to [C]t [C]o O 
CD4 [C]C [C]D [C]4 B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
stimulates [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]s O 
association [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Lck [C]L [C]c [C]k S-protein 
with [C]w [C]i [C]t [C]h O 
Raf-1 [C]R [C]a [C]f [C]- [C]1 S-protein 
and [C]a [C]n [C]d O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Raf-1 [C]R [C]a [C]f [C]- [C]1 S-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
in [C]i [C]n O 
a [C]a O 
Ras-independent [C]R [C]a [C]s [C]- [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
manner [C]m [C]a [C]n [C]n [C]e [C]r O 
. [C]. O 

In [C]I [C]n O 
the [C]t [C]h [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
study [C]s [C]t [C]u [C]d [C]y O 
, [C], O 
we [C]w [C]e O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 B-protein 
envelope [C]e [C]n [C]v [C]e [C]l [C]o [C]p [C]e I-protein 
glycoproteins [C]g [C]l [C]y [C]c [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
T-cell-tropic [C]T [C]- [C]c [C]e [C]l [C]l [C]- [C]t [C]r [C]o [C]p [C]i [C]c O 
and [C]a [C]n [C]d O 
macrophagetropic [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]t [C]r [C]o [C]p [C]i [C]c O 
strains [C]s [C]t [C]r [C]a [C]i [C]n [C]s O 
rapidly [C]r [C]a [C]p [C]i [C]d [C]l [C]y O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
ERK/mitogen-activated [C]E [C]R [C]K [C]/ [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
( [C]( O 
MAP [C]M [C]A [C]P O 
) [C]) O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
( [C]( O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
, [C], O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
, [C], O 
and [C]a [C]n [C]d O 
C/EBP [C]C [C]/ [C]E [C]B [C]P S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
stimulate [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e B-DNA 
and [C]a [C]n [C]d I-DNA 
chemokine [C]c [C]h [C]e [C]m [C]o [C]k [C]i [C]n [C]e I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
. [C]. O 

The [C]T [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
requires [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]s O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
CD4 [C]C [C]D [C]4 B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
of [C]o [C]f O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
CXCR4 [C]C [C]X [C]C [C]R [C]4 S-protein 
. [C]. O 

Binding [C]B [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
natural [C]n [C]a [C]t [C]u [C]r [C]a [C]l O 
ligand [C]l [C]i [C]g [C]a [C]n [C]d O 
stromal [C]s [C]t [C]r [C]o [C]m [C]a [C]l B-protein 
cell-derived [C]c [C]e [C]l [C]l [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
1 [C]1 E-protein 
( [C]( O 
SDF-1 [C]S [C]D [C]F [C]- [C]1 S-protein 
) [C]) O 
to [C]t [C]o O 
CXCR4 [C]C [C]X [C]C [C]R [C]4 S-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
inhibits [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]s O 
entry [C]e [C]n [C]t [C]r [C]y O 
of [C]o [C]f O 
T-cell-tropic [C]T [C]- [C]c [C]e [C]l [C]l [C]- [C]t [C]r [C]o [C]p [C]i [C]c O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
, [C], O 
activates [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]s O 
also [C]a [C]l [C]s [C]o O 
the [C]t [C]h [C]e O 
ERK/ [C]E [C]R [C]K [C]/ O 
MAP [C]M [C]A [C]P B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
SDF-1 [C]S [C]D [C]F [C]- [C]1 S-protein 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
affect [C]a [C]f [C]f [C]e [C]c [C]t O 
the [C]t [C]h [C]e O 
CD4-mediated [C]C [C]D [C]4 [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e B-DNA 
and [C]a [C]n [C]d I-DNA 
chemokine [C]c [C]h [C]e [C]m [C]o [C]k [C]i [C]n [C]e I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
provide [C]p [C]r [C]o [C]v [C]i [C]d [C]e O 
firm [C]f [C]i [C]r [C]m O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
that [C]t [C]h [C]a [C]t O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 B-protein 
envelope [C]e [C]n [C]v [C]e [C]l [C]o [C]p [C]e I-protein 
glycoproteins [C]g [C]l [C]y [C]c [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
to [C]t [C]o O 
CD4 [C]C [C]D [C]4 B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
initiates [C]i [C]n [C]i [C]t [C]i [C]a [C]t [C]e [C]s O 
a [C]a O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
( [C]( O 
s [C]s O 
) [C]) O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
chemokine [C]c [C]h [C]e [C]m [C]o [C]k [C]i [C]n [C]e B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
that [C]t [C]h [C]a [C]t O 
leads [C]l [C]e [C]a [C]d [C]s O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
aberrant [C]a [C]b [C]e [C]r [C]r [C]a [C]n [C]t O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
and [C]a [C]n [C]d O 
may [C]m [C]a [C]y O 
contribute [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
to [C]t [C]o O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
replication [C]r [C]e [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
to [C]t [C]o O 
deregulation [C]d [C]e [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
. [C]. O 

Antigen [C]A [C]n [C]t [C]i [C]g [C]e [C]n O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
MAP [C]M [C]A [C]P O 
kinase-mediated [C]k [C]i [C]n [C]a [C]s [C]e [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
BCL-6 [C]B [C]C [C]L [C]- [C]6 S-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
bcl-6 [C]b [C]c [C]l [C]- [C]6 B-DNA 
proto-oncogene [C]p [C]r [C]o [C]t [C]o [C]- [C]o [C]n [C]c [C]o [C]g [C]e [C]n [C]e E-DNA 
encodes [C]e [C]n [C]c [C]o [C]d [C]e [C]s O 
a [C]a O 
POZ/zinc [C]P [C]O [C]Z [C]/ [C]z [C]i [C]n [C]c B-protein 
finger [C]f [C]i [C]n [C]g [C]e [C]r I-protein 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l I-protein 
repressor [C]r [C]e [C]p [C]r [C]e [C]s [C]s [C]o [C]r E-protein 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
germinal [C]g [C]e [C]r [C]m [C]i [C]n [C]a [C]l B-cell_type 
center [C]c [C]e [C]n [C]t [C]e [C]r I-cell_type 
( [C]( I-cell_type 
GC [C]G [C]C I-cell_type 
) [C]) I-cell_type 
B [C]B I-cell_type 
and [C]a [C]n [C]d I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
GC [C]G [C]C O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
antibody [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
maturation [C]m [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Deregulation [C]D [C]e [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
bcl-6 [C]b [C]c [C]l [C]- [C]6 S-DNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
by [C]b [C]y O 
chromosomal [C]c [C]h [C]r [C]o [C]m [C]o [C]s [C]o [C]m [C]a [C]l O 
rearrangements [C]r [C]e [C]a [C]r [C]r [C]a [C]n [C]g [C]e [C]m [C]e [C]n [C]t [C]s O 
and [C]a [C]n [C]d O 
point [C]p [C]o [C]i [C]n [C]t O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
bcl-6 [C]b [C]c [C]l [C]- [C]6 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r I-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
are [C]a [C]r [C]e O 
implicated [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
pathogenesis [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l O 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a O 
. [C]. O 

The [C]T [C]h [C]e O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
regulating [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
bcl-6 [C]b [C]c [C]l [C]- [C]6 S-DNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
are [C]a [C]r [C]e O 
not [C]n [C]o [C]t O 
known [C]k [C]n [C]o [C]w [C]n O 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
we [C]w [C]e O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
leads [C]l [C]e [C]a [C]d [C]s O 
to [C]t [C]o O 
BCL-6 [C]B [C]C [C]L [C]- [C]6 S-protein 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
mitogen-activated [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
( [C]( O 
MAPK [C]M [C]A [C]P [C]K S-protein 
) [C]) O 
. [C]. O 

Phosphorylation [C]P [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
in [C]i [C]n O 
turn [C]t [C]u [C]r [C]n O 
, [C], O 
targets [C]t [C]a [C]r [C]g [C]e [C]t [C]s O 
BCL-6 [C]B [C]C [C]L [C]- [C]6 S-protein 
for [C]f [C]o [C]r O 
rapid [C]r [C]a [C]p [C]i [C]d O 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
ubiquitin [C]u [C]b [C]i [C]q [C]u [C]i [C]t [C]i [C]n S-protein 
/ [C]/ O 
proteasome [C]p [C]r [C]o [C]t [C]e [C]a [C]s [C]o [C]m [C]e S-protein 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
BCL-6 [C]B [C]C [C]L [C]- [C]6 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
is [C]i [C]s O 
directly [C]d [C]i [C]r [C]e [C]c [C]t [C]l [C]y O 
controlled [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]l [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
via [C]v [C]i [C]a O 
MAPK [C]M [C]A [C]P [C]K S-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
crucial [C]c [C]r [C]u [C]c [C]i [C]a [C]l O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
of [C]o [C]f O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
antibody [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
and [C]a [C]n [C]d O 
has [C]h [C]a [C]s O 
implications [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n [C]s O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
other [C]o [C]t [C]h [C]e [C]r O 
POZ/zinc [C]P [C]O [C]Z [C]/ [C]z [C]i [C]n [C]c B-protein 
finger [C]f [C]i [C]n [C]g [C]e [C]r I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
other [C]o [C]t [C]h [C]e [C]r O 
tissues [C]t [C]i [C]s [C]s [C]u [C]e [C]s O 
. [C]. O 

Glucocorticoid [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
are [C]a [C]r [C]e O 
differentially [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
and [C]a [C]n [C]d O 
tissues [C]t [C]i [C]s [C]s [C]u [C]e [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
. [C]. O 

Cytosolic [C]C [C]y [C]t [C]o [C]s [C]o [C]l [C]i [C]c B-protein 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
( [C]( O 
GR [C]G [C]R S-protein 
) [C]) O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
on [C]o [C]n O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
tissues [C]t [C]i [C]s [C]s [C]u [C]e [C]s O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
thymus [C]t [C]h [C]y [C]m [C]u [C]s O 
exhibits [C]e [C]x [C]h [C]i [C]b [C]i [C]t [C]s O 
three [C]t [C]h [C]r [C]e [C]e O 
to [C]t [C]o O 
four [C]f [C]o [C]u [C]r O 
times [C]t [C]i [C]m [C]e [C]s O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
GR [C]G [C]R B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
than [C]t [C]h [C]a [C]n O 
the [C]t [C]h [C]e O 
spleen [C]s [C]p [C]l [C]e [C]e [C]n O 
. [C]. O 

High [C]H [C]i [C]g [C]h O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
GR [C]G [C]R S-protein 
are [C]a [C]r [C]e O 
consistent [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
exquisite [C]e [C]x [C]q [C]u [C]i [C]s [C]i [C]t [C]e O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
thymus [C]t [C]h [C]y [C]m [C]u [C]s O 
to [C]t [C]o O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
exposure [C]e [C]x [C]p [C]o [C]s [C]u [C]r [C]e O 
. [C]. O 

Nevertheless [C]N [C]e [C]v [C]e [C]r [C]t [C]h [C]e [C]l [C]e [C]s [C]s O 
, [C], O 
whole [C]w [C]h [C]o [C]l [C]e O 
cell [C]c [C]e [C]l [C]l O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
reveal [C]r [C]e [C]v [C]e [C]a [C]l O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
GR [C]G [C]R S-protein 
in [C]i [C]n O 
immature [C]i [C]m [C]m [C]a [C]t [C]u [C]r [C]e B-cell_type 
thymic [C]t [C]h [C]y [C]m [C]i [C]c I-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
more [C]m [C]o [C]r [C]e O 
mature [C]m [C]a [C]t [C]u [C]r [C]e O 
, [C], O 
splenic [C]s [C]p [C]l [C]e [C]n [C]i [C]c B-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

Moreover [C]M [C]o [C]r [C]e [C]o [C]v [C]e [C]r O 
, [C], O 
whole [C]w [C]h [C]o [C]l [C]e O 
cell [C]c [C]e [C]l [C]l O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
techniques [C]t [C]e [C]c [C]h [C]n [C]i [C]q [C]u [C]e [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
neutrophils [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]h [C]i [C]l [C]s S-cell_type 
( [C]( O 
which [C]w [C]h [C]i [C]c [C]h O 
represent [C]r [C]e [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
roughly [C]r [C]o [C]u [C]g [C]h [C]l [C]y O 
30 [C]3 [C]0 O 
% [C]% O 
of [C]o [C]f O 
splenic [C]s [C]p [C]l [C]e [C]n [C]i [C]c B-cell_type 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
) [C]) O 
exhibit [C]e [C]x [C]h [C]i [C]b [C]i [C]t O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
GR [C]G [C]R S-protein 
than [C]t [C]h [C]a [C]n O 
both [C]b [C]o [C]t [C]h O 
T [C]T B-cell_type 
and [C]a [C]n [C]d I-cell_type 
B [C]B I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
, [C], O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
contradicting [C]c [C]o [C]n [C]t [C]r [C]a [C]d [C]i [C]c [C]t [C]i [C]n [C]g O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
from [C]f [C]r [C]o [C]m O 
cytosolic [C]c [C]y [C]t [C]o [C]s [C]o [C]l [C]i [C]c O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
. [C]. O 

To [C]T [C]o O 
address [C]a [C]d [C]d [C]r [C]e [C]s [C]s O 
these [C]t [C]h [C]e [C]s [C]e O 
inconsistencies [C]i [C]n [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]c [C]i [C]e [C]s O 
, [C], O 
GR [C]G [C]R B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
was [C]w [C]a [C]s O 
assessed [C]a [C]s [C]s [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
immune [C]i [C]m [C]m [C]u [C]n [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s I-cell_type 
and [C]a [C]n [C]d I-cell_type 
tissues [C]t [C]i [C]s [C]s [C]u [C]e [C]s E-cell_type 
using [C]u [C]s [C]i [C]n [C]g O 
cytosolic [C]c [C]y [C]t [C]o [C]s [C]o [C]l [C]i [C]c O 
radioligand [C]r [C]a [C]d [C]i [C]o [C]l [C]i [C]g [C]a [C]n [C]d O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
. [C]. O 

Western [C]W [C]e [C]s [C]t [C]e [C]r [C]n O 
blot [C]b [C]l [C]o [C]t O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
immunocytochemistry [C]i [C]m [C]m [C]u [C]n [C]o [C]c [C]y [C]t [C]o [C]c [C]h [C]e [C]m [C]i [C]s [C]t [C]r [C]y O 
. [C]. O 

Consistent [C]C [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
previous [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s O 
cytosolic [C]c [C]y [C]t [C]o [C]s [C]o [C]l [C]i [C]c O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
on [C]o [C]n O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
homogenates [C]h [C]o [C]m [C]o [C]g [C]e [C]n [C]a [C]t [C]e [C]s O 
, [C], O 
thymic [C]t [C]h [C]y [C]m [C]i [C]c O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
have [C]h [C]a [C]v [C]e O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
GR [C]G [C]R S-protein 
than [C]t [C]h [C]a [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
spleen [C]s [C]p [C]l [C]e [C]e [C]n O 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
neutrophils [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]h [C]i [C]l [C]s O 
were [C]w [C]e [C]r [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
have [C]h [C]a [C]v [C]e O 
fewer [C]f [C]e [C]w [C]e [C]r O 
GR [C]G [C]R S-protein 
than [C]t [C]h [C]a [C]n O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
and [C]a [C]n [C]d O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
a [C]a O 
meaningful [C]m [C]e [C]a [C]n [C]i [C]n [C]g [C]f [C]u [C]l O 
relationship [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n [C]s [C]h [C]i [C]p O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
known [C]k [C]n [C]o [C]w [C]n O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
to [C]t [C]o O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
. [C]. O 

Functional [C]F [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
replacement [C]r [C]e [C]p [C]l [C]a [C]c [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
mouse [C]m [C]o [C]u [C]s [C]e B-DNA 
E2A [C]E [C]2 [C]A I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
HEB [C]H [C]E [C]B I-DNA 
cDNA [C]c [C]D [C]N [C]A E-DNA 
. [C]. O 

The [C]T [C]h [C]e O 
mammalian [C]m [C]a [C]m [C]m [C]a [C]l [C]i [C]a [C]n B-DNA 
E2A [C]E [C]2 [C]A I-DNA 
, [C], I-DNA 
HEB [C]H [C]E [C]B I-DNA 
, [C], I-DNA 
and [C]a [C]n [C]d I-DNA 
E2-2 [C]E [C]2 [C]- [C]2 I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
encode [C]e [C]n [C]c [C]o [C]d [C]e O 
a [C]a O 
unique [C]u [C]n [C]i [C]q [C]u [C]e O 
class [C]c [C]l [C]a [C]s [C]s O 
of [C]o [C]f O 
basic [C]b [C]a [C]s [C]i [C]c B-protein 
helix-loop-helix [C]h [C]e [C]l [C]i [C]x [C]- [C]l [C]o [C]o [C]p [C]- [C]h [C]e [C]l [C]i [C]x I-protein 
( [C]( I-protein 
bHLH [C]b [C]H [C]L [C]H I-protein 
) [C]) I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
that [C]t [C]h [C]a [C]t O 
are [C]a [C]r [C]e O 
evolutionarily [C]e [C]v [C]o [C]l [C]u [C]t [C]i [C]o [C]n [C]a [C]r [C]i [C]l [C]y O 
conserved [C]c [C]o [C]n [C]s [C]e [C]r [C]v [C]e [C]d O 
and [C]a [C]n [C]d O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
for [C]f [C]o [C]r O 
embryonic [C]e [C]m [C]b [C]r [C]y [C]o [C]n [C]i [C]c O 
and [C]a [C]n [C]d O 
postnatal [C]p [C]o [C]s [C]t [C]n [C]a [C]t [C]a [C]l O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
. [C]. O 

While [C]W [C]h [C]i [C]l [C]e O 
the [C]t [C]h [C]e O 
structural [C]s [C]t [C]r [C]u [C]c [C]t [C]u [C]r [C]a [C]l O 
and [C]a [C]n [C]d O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
similarities [C]s [C]i [C]m [C]i [C]l [C]a [C]r [C]i [C]t [C]i [C]e [C]s O 
among [C]a [C]m [C]o [C]n [C]g O 
the [C]t [C]h [C]e O 
gene [C]g [C]e [C]n [C]e B-protein 
products [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]s E-protein 
are [C]a [C]r [C]e O 
well [C]w [C]e [C]l [C]l O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
, [C], O 
it [C]i [C]t O 
is [C]i [C]s O 
not [C]n [C]o [C]t O 
clear [C]c [C]l [C]e [C]a [C]r O 
why [C]w [C]h [C]y O 
deletion [C]d [C]e [C]l [C]e [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
E2A [C]E [C]2 [C]A S-DNA 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
HEB [C]H [C]E [C]B S-DNA 
or [C]o [C]r O 
E2-2 [C]E [C]2 [C]- [C]2 S-DNA 
, [C], O 
leads [C]l [C]e [C]a [C]d [C]s O 
to [C]t [C]o O 
a [C]a O 
complete [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e O 
arrest [C]a [C]r [C]r [C]e [C]s [C]t O 
in [C]i [C]n O 
B-lymphocyte [C]B [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
. [C]. O 

To [C]T [C]o O 
understand [C]u [C]n [C]d [C]e [C]r [C]s [C]t [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
basis [C]b [C]a [C]s [C]i [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
specificity [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]i [C]t [C]y O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
E2A [C]E [C]2 [C]A S-DNA 
and [C]a [C]n [C]d O 
HEB [C]H [C]E [C]B S-DNA 
/ [C]/ O 
E2-2 [C]E [C]2 [C]- [C]2 S-DNA 
in [C]i [C]n O 
mammalian [C]m [C]a [C]m [C]m [C]a [C]l [C]i [C]a [C]n O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
, [C], O 
we [C]w [C]e O 
generated [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]e [C]d O 
and [C]a [C]n [C]d O 
tested [C]t [C]e [C]s [C]t [C]e [C]d O 
a [C]a O 
panel [C]p [C]a [C]n [C]e [C]l O 
of [C]o [C]f O 
E2A [C]E [C]2 [C]A S-DNA 
knockin [C]k [C]n [C]o [C]c [C]k [C]i [C]n O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
subtle [C]s [C]u [C]b [C]t [C]l [C]e O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
E12 [C]E [C]1 [C]2 B-DNA 
and [C]a [C]n [C]d I-DNA 
E47 [C]E [C]4 [C]7 I-DNA 
exons [C]e [C]x [C]o [C]n [C]s E-DNA 
and [C]a [C]n [C]d O 
substitution [C]s [C]u [C]b [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
E12 [C]E [C]1 [C]2 B-DNA 
and [C]a [C]n [C]d I-DNA 
E47 [C]E [C]4 [C]7 I-DNA 
exons [C]e [C]x [C]o [C]n [C]s E-DNA 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
HEB [C]H [C]E [C]B I-DNA 
cDNA [C]c [C]D [C]N [C]A E-DNA 
. [C]. O 

We [C]W [C]e O 
find [C]f [C]i [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
alternatively [C]a [C]l [C]t [C]e [C]r [C]n [C]a [C]t [C]i [C]v [C]e [C]l [C]y O 
spliced [C]s [C]p [C]l [C]i [C]c [C]e [C]d O 
E12 [C]E [C]1 [C]2 B-protein 
and [C]a [C]n [C]d I-protein 
E47 [C]E [C]4 [C]7 I-protein 
bHLH [C]b [C]H [C]L [C]H I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
E2A [C]E [C]2 [C]A B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
play [C]p [C]l [C]a [C]y O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
and [C]a [C]n [C]d O 
additive [C]a [C]d [C]d [C]i [C]t [C]i [C]v [C]e O 
roles [C]r [C]o [C]l [C]e [C]s O 
in [C]i [C]n O 
supporting [C]s [C]u [C]p [C]p [C]o [C]r [C]t [C]i [C]n [C]g O 
B [C]B B-cell_type 
lymphopoiesis [C]l [C]y [C]m [C]p [C]h [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s E-cell_type 
. [C]. O 

Further [C]F [C]u [C]r [C]t [C]h [C]e [C]r O 
, [C], O 
we [C]w [C]e O 
find [C]f [C]i [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
HEB [C]H [C]E [C]B S-DNA 
driven [C]d [C]r [C]i [C]v [C]e [C]n O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
endogenous [C]e [C]n [C]d [C]o [C]g [C]e [C]n [C]o [C]u [C]s B-DNA 
E2A [C]E [C]2 [C]A I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
can [C]c [C]a [C]n O 
functionally [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l [C]l [C]y O 
replace [C]r [C]e [C]p [C]l [C]a [C]c [C]e O 
E2A [C]E [C]2 [C]A S-DNA 
in [C]i [C]n O 
supporting [C]s [C]u [C]p [C]p [C]o [C]r [C]t [C]i [C]n [C]g O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l O 
commitment [C]c [C]o [C]m [C]m [C]i [C]t [C]m [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
toward [C]t [C]o [C]w [C]a [C]r [C]d O 
completion [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]i [C]o [C]n O 
. [C]. O 

Finally [C]F [C]i [C]n [C]a [C]l [C]l [C]y O 
, [C], O 
the [C]t [C]h [C]e O 
postnatal [C]p [C]o [C]s [C]t [C]n [C]a [C]t [C]a [C]l O 
lethality [C]l [C]e [C]t [C]h [C]a [C]l [C]i [C]t [C]y O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
E2A [C]E [C]2 [C]A S-DNA 
disruption [C]d [C]i [C]s [C]r [C]u [C]p [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
fully [C]f [C]u [C]l [C]l [C]y O 
rescued [C]r [C]e [C]s [C]c [C]u [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
HEB [C]H [C]E [C]B S-DNA 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
suggests [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]s O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
divergence [C]d [C]i [C]v [C]e [C]r [C]g [C]e [C]n [C]c [C]e O 
among [C]a [C]m [C]o [C]n [C]g O 
E12 [C]E [C]1 [C]2 S-DNA 
, [C], O 
E47 [C]E [C]4 [C]7 S-DNA 
, [C], O 
and [C]a [C]n [C]d O 
HEB [C]H [C]E [C]B S-DNA 
in [C]i [C]n O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
cell [C]c [C]e [C]l [C]l O 
types [C]t [C]y [C]p [C]e [C]s O 
is [C]i [C]s O 
partially [C]p [C]a [C]r [C]t [C]i [C]a [C]l [C]l [C]y O 
defined [C]d [C]e [C]f [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
context [C]c [C]o [C]n [C]t [C]e [C]x [C]t O 
of [C]o [C]f O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Biased [C]B [C]i [C]a [C]s [C]e [C]d O 
dependency [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]c [C]y O 
of [C]o [C]f O 
CD80 [C]C [C]D [C]8 [C]0 S-protein 
versus [C]v [C]e [C]r [C]s [C]u [C]s O 
CD86 [C]C [C]D [C]8 [C]6 S-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
regulating [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
IL-2 [C]I [C]L [C]- [C]2 I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
ligation [C]l [C]i [C]g [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
TCR [C]T [C]C [C]R O 
, [C], O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
need [C]n [C]e [C]e [C]d O 
additional [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n [C]a [C]l O 
, [C], O 
co-stimulatory [C]c [C]o [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
to [C]t [C]o O 
be [C]b [C]e O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
. [C]. O 

One [C]O [C]n [C]e O 
such [C]s [C]u [C]c [C]h O 
co-stimulatory [C]c [C]o [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
is [C]i [C]s O 
delivered [C]d [C]e [C]l [C]i [C]v [C]e [C]r [C]e [C]d O 
when [C]w [C]h [C]e [C]n O 
CD28 [C]C [C]D [C]2 [C]8 S-protein 
on [C]o [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
binds [C]b [C]i [C]n [C]d [C]s O 
to [C]t [C]o O 
CD80 [C]C [C]D [C]8 [C]0 S-protein 
or [C]o [C]r O 
CD86 [C]C [C]D [C]8 [C]6 S-protein 
on [C]o [C]n O 
antigen-presenting [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]- [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]i [C]n [C]g B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
APC [C]A [C]P [C]C S-cell_type 
) [C]) O 
. [C]. O 

In [C]I [C]n O 
the [C]t [C]h [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
study [C]s [C]t [C]u [C]d [C]y O 
, [C], O 
we [C]w [C]e O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
the [C]t [C]h [C]e O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
CD80 [C]C [C]D [C]8 [C]0 S-protein 
and [C]a [C]n [C]d O 
CD86 [C]C [C]D [C]8 [C]6 S-protein 
to [C]t [C]o O 
co-stimulate [C]c [C]o [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
superantigen [C]s [C]u [C]p [C]e [C]r [C]a [C]n [C]t [C]i [C]g [C]e [C]n O 
. [C]. O 

Using [C]U [C]s [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
Raji [C]R [C]a [C]j [C]i B-cell_line 
B [C]B I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a E-cell_line 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
CD80 [C]C [C]D [C]8 [C]0 S-protein 
and [C]a [C]n [C]d O 
CD86 [C]C [C]D [C]8 [C]6 S-protein 
, [C], O 
it [C]i [C]t O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
mainly [C]m [C]a [C]i [C]n [C]l [C]y O 
co-stimulated [C]c [C]o [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
CD80 [C]C [C]D [C]8 [C]0 S-protein 
. [C]. O 

To [C]T [C]o O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
characterize [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e O 
the [C]t [C]h [C]e O 
consequences [C]c [C]o [C]n [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
biased [C]b [C]i [C]a [C]s [C]e [C]d O 
co-stimulatory [C]c [C]o [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
dependency [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]c [C]y O 
, [C], O 
we [C]w [C]e O 
employed [C]e [C]m [C]p [C]l [C]o [C]y [C]e [C]d O 
a [C]a O 
well-defined [C]w [C]e [C]l [C]l [C]- [C]d [C]e [C]f [C]i [C]n [C]e [C]d O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
of [C]o [C]f O 
transfected [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]e [C]d O 
CHO [C]C [C]H [C]O B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
expressing [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]n [C]g O 
human [C]h [C]u [C]m [C]a [C]n B-protein 
MHC [C]M [C]H [C]C I-protein 
class [C]c [C]l [C]a [C]s [C]s I-protein 
II [C]I [C]I E-protein 
together [C]t [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
with [C]w [C]i [C]t [C]h O 
CD80 [C]C [C]D [C]8 [C]0 S-protein 
, [C], O 
CD86 [C]C [C]D [C]8 [C]6 S-protein 
or [C]o [C]r O 
CD80 [C]C [C]D [C]8 [C]0 S-protein 
and [C]a [C]n [C]d O 
CD86 [C]C [C]D [C]8 [C]6 S-protein 
. [C]. O 

Proliferation [C]P [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
freshly [C]f [C]r [C]e [C]s [C]h [C]l [C]y O 
prepared [C]p [C]r [C]e [C]p [C]a [C]r [C]e [C]d O 
CD4+ [C]C [C]D [C]4 [C]+ B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
CD80 [C]C [C]D [C]8 [C]0 S-protein 
or [C]o [C]r O 
CD86 [C]C [C]D [C]8 [C]6 S-protein 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
reached [C]r [C]e [C]a [C]c [C]h [C]e [C]d O 
only [C]o [C]n [C]l [C]y O 
suboptimal [C]s [C]u [C]b [C]o [C]p [C]t [C]i [C]m [C]a [C]l O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
CD86 [C]C [C]D [C]8 [C]6 S-protein 
but [C]b [C]u [C]t O 
optimal [C]o [C]p [C]t [C]i [C]m [C]a [C]l O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
with [C]w [C]i [C]t [C]h O 
CD80 [C]C [C]D [C]8 [C]0 S-protein 
. [C]. O 

To [C]T [C]o O 
analyze [C]a [C]n [C]a [C]l [C]y [C]z [C]e O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
CD80 [C]C [C]D [C]8 [C]0 S-protein 
and [C]a [C]n [C]d O 
CD86 [C]C [C]D [C]8 [C]6 S-protein 
co-stimulated [C]c [C]o [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
we [C]w [C]e O 
used [C]u [C]s [C]e [C]d O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_line 
T [C]T I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
transfected [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
luciferase [C]l [C]u [C]c [C]i [C]f [C]e [C]r [C]a [C]s [C]e B-DNA 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r I-DNA 
gene [C]g [C]e [C]n [C]e I-DNA 
constructs [C]c [C]o [C]n [C]s [C]t [C]r [C]u [C]c [C]t [C]s E-DNA 
. [C]. O 

CD80 [C]C [C]D [C]8 [C]0 S-protein 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
-enhancer [C]- [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
CD86 [C]C [C]D [C]8 [C]6 S-protein 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
the [C]t [C]h [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
regulating [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter-enhancer [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]- [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r I-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n B-protein 
protein-1 [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]1 E-protein 
, [C], O 
CD28 [C]C [C]D [C]2 [C]8 B-DNA 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e I-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
and [C]a [C]n [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
kappaB [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
were [C]w [C]e [C]r [C]e O 
4-8 [C]4 [C]- [C]8 O 
times [C]t [C]i [C]m [C]e [C]s O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
after [C]a [C]f [C]t [C]e [C]r O 
CD80 [C]C [C]D [C]8 [C]0 S-protein 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
CD86 [C]C [C]D [C]8 [C]6 S-protein 
ligation [C]l [C]i [C]g [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Our [C]O [C]u [C]r O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
eventual [C]e [C]v [C]e [C]n [C]t [C]u [C]a [C]l O 
appearance [C]a [C]p [C]p [C]e [C]a [C]r [C]a [C]n [C]c [C]e O 
of [C]o [C]f O 
CD80 [C]C [C]D [C]8 [C]0 S-protein 
on [C]o [C]n O 
recently [C]r [C]e [C]c [C]e [C]n [C]t [C]l [C]y O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
CD86+ [C]C [C]D [C]8 [C]6 [C]+ B-cell_type 
APC [C]A [C]P [C]C E-cell_type 
is [C]i [C]s O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
superinduction [C]s [C]u [C]p [C]e [C]r [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
to [C]t [C]o O 
support [C]s [C]u [C]p [C]p [C]o [C]r [C]t O 
vigorous [C]v [C]i [C]g [C]o [C]r [C]o [C]u [C]s O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Duplication [C]D [C]u [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
DR3 [C]D [C]R [C]3 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
on [C]o [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
chromosome [C]c [C]h [C]r [C]o [C]m [C]o [C]s [C]o [C]m [C]e I-DNA 
1p36 [C]1 [C]p [C]3 [C]6 E-DNA 
and [C]a [C]n [C]d O 
its [C]i [C]t [C]s O 
deletion [C]d [C]e [C]l [C]e [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
neuroblastoma [C]n [C]e [C]u [C]r [C]o [C]b [C]l [C]a [C]s [C]t [C]o [C]m [C]a E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
DR3 [C]D [C]R [C]3 I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
, [C], O 
whose [C]w [C]h [C]o [C]s [C]e O 
product [C]p [C]r [C]o [C]d [C]u [C]c [C]t O 
is [C]i [C]s O 
also [C]a [C]l [C]s [C]o O 
known [C]k [C]n [C]o [C]w [C]n O 
as [C]a [C]s O 
Wsl-1/APO-3/TRAMP/LARD [C]W [C]s [C]l [C]- [C]1 [C]/ [C]A [C]P [C]O [C]- [C]3 [C]/ [C]T [C]R [C]A [C]M [C]P [C]/ [C]L [C]A [C]R [C]D S-protein 
, [C], O 
encodes [C]e [C]n [C]c [C]o [C]d [C]e [C]s O 
a [C]a O 
tumor [C]t [C]u [C]m [C]o [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor-related [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]r [C]e [C]l [C]a [C]t [C]e [C]d I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
primarily [C]p [C]r [C]i [C]m [C]a [C]r [C]i [C]l [C]y O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
of [C]o [C]f O 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
and [C]a [C]n [C]d O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
. [C]. O 

DR3 [C]D [C]R [C]3 S-protein 
is [C]i [C]s O 
capable [C]c [C]a [C]p [C]a [C]b [C]l [C]e O 
of [C]o [C]f O 
inducing [C]i [C]n [C]d [C]u [C]c [C]i [C]n [C]g O 
both [C]b [C]o [C]t [C]h O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
when [C]w [C]h [C]e [C]n O 
overexpressed [C]o [C]v [C]e [C]r [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
mammalian [C]m [C]a [C]m [C]m [C]a [C]l [C]i [C]a [C]n B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
although [C]a [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
its [C]i [C]t [C]s O 
ligand [C]l [C]i [C]g [C]a [C]n [C]d O 
has [C]h [C]a [C]s O 
not [C]n [C]o [C]t O 
yet [C]y [C]e [C]t O 
been [C]b [C]e [C]e [C]n O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
. [C]. O 

We [C]W [C]e O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
here [C]h [C]e [C]r [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
DR3 [C]D [C]R [C]3 B-DNA 
gene [C]g [C]e [C]n [C]e I-DNA 
locus [C]l [C]o [C]c [C]u [C]s E-DNA 
is [C]i [C]s O 
tandemly [C]t [C]a [C]n [C]d [C]e [C]m [C]l [C]y O 
duplicated [C]d [C]u [C]p [C]l [C]i [C]c [C]a [C]t [C]e [C]d O 
on [C]o [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
chromosome [C]c [C]h [C]r [C]o [C]m [C]o [C]s [C]o [C]m [C]e I-DNA 
band [C]b [C]a [C]n [C]d I-DNA 
1p36.2-p36.3 [C]1 [C]p [C]3 [C]6 [C]. [C]2 [C]- [C]p [C]3 [C]6 [C]. [C]3 E-DNA 
and [C]a [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
these [C]t [C]h [C]e [C]s [C]e O 
genes [C]g [C]e [C]n [C]e [C]s O 
are [C]a [C]r [C]e O 
hemizygously [C]h [C]e [C]m [C]i [C]z [C]y [C]g [C]o [C]u [C]s [C]l [C]y O 
deleted [C]d [C]e [C]l [C]e [C]t [C]e [C]d O 
and/or [C]a [C]n [C]d [C]/ [C]o [C]r O 
translocated [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]e [C]d O 
to [C]t [C]o O 
another [C]a [C]n [C]o [C]t [C]h [C]e [C]r O 
chromosome [C]c [C]h [C]r [C]o [C]m [C]o [C]s [C]o [C]m [C]e O 
in [C]i [C]n O 
neuroblastoma [C]n [C]e [C]u [C]r [C]o [C]b [C]l [C]a [C]s [C]t [C]o [C]m [C]a B-cell_line 
( [C]( I-cell_line 
NB [C]N [C]B I-cell_line 
) [C]) I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
with [C]w [C]i [C]t [C]h O 
amplified [C]a [C]m [C]p [C]l [C]i [C]f [C]i [C]e [C]d O 
MYCN [C]M [C]Y [C]C [C]N O 
. [C]. O 

Duplication [C]D [C]u [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
at [C]a [C]t O 
least [C]l [C]e [C]a [C]s [C]t O 
a [C]a O 
portion [C]p [C]o [C]r [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
DR3 [C]D [C]R [C]3 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
extracellular [C]e [C]x [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
and [C]a [C]n [C]d I-protein 
transmembrane [C]t [C]r [C]a [C]n [C]s [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e I-protein 
regions [C]r [C]e [C]g [C]i [C]o [C]n [C]s E-protein 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
the [C]t [C]h [C]e O 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c B-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
, [C], O 
was [C]w [C]a [C]s O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
both [C]b [C]o [C]t [C]h O 
fluorescence [C]f [C]l [C]u [C]o [C]r [C]e [C]s [C]c [C]e [C]n [C]c [C]e O 
in [C]i [C]n O 
situ [C]s [C]i [C]t [C]u O 
hybridization [C]h [C]y [C]b [C]r [C]i [C]d [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
genomic [C]g [C]e [C]n [C]o [C]m [C]i [C]c O 
Southern [C]S [C]o [C]u [C]t [C]h [C]e [C]r [C]n O 
blotting [C]b [C]l [C]o [C]t [C]t [C]i [C]n [C]g O 
. [C]. O 

In [C]I [C]n O 
most [C]m [C]o [C]s [C]t O 
NB [C]N [C]B B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
, [C], O 
both [C]b [C]o [C]t [C]h O 
the [C]t [C]h [C]e O 
DR3 [C]D [C]R [C]3 B-DNA 
and [C]a [C]n [C]d I-DNA 
the [C]t [C]h [C]e I-DNA 
DR3L [C]D [C]R [C]3 [C]L I-DNA 
sequences [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s E-DNA 
are [C]a [C]r [C]e O 
simultaneously [C]s [C]i [C]m [C]u [C]l [C]t [C]a [C]n [C]e [C]o [C]u [C]s [C]l [C]y O 
deleted [C]d [C]e [C]l [C]e [C]t [C]e [C]d O 
and/or [C]a [C]n [C]d [C]/ [C]o [C]r O 
translocated [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]e [C]d O 
to [C]t [C]o O 
another [C]a [C]n [C]o [C]t [C]h [C]e [C]r O 
chromosome [C]c [C]h [C]r [C]o [C]m [C]o [C]s [C]o [C]m [C]e S-DNA 
. [C]. O 

Finally [C]F [C]i [C]n [C]a [C]l [C]l [C]y O 
, [C], O 
DR3/ [C]D [C]R [C]3 [C]/ B-protein 
Wsl-1 [C]W [C]s [C]l [C]- [C]1 I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
is [C]i [C]s O 
quite [C]q [C]u [C]i [C]t [C]e O 
variable [C]v [C]a [C]r [C]i [C]a [C]b [C]l [C]e O 
among [C]a [C]m [C]o [C]n [C]g O 
these [C]t [C]h [C]e [C]s [C]e O 
NB [C]N [C]B B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
, [C], O 
with [C]w [C]i [C]t [C]h O 
very [C]v [C]e [C]r [C]y O 
low [C]l [C]o [C]w O 
or [C]o [C]r O 
undetectable [C]u [C]n [C]d [C]e [C]t [C]e [C]c [C]t [C]a [C]b [C]l [C]e O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
in [C]i [C]n O 
7 [C]7 O 
of [C]o [C]f O 
17 [C]1 [C]7 O 
NB [C]N [C]B B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 

Differential [C]D [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l O 
protection [C]p [C]r [C]o [C]t [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
and [C]a [C]n [C]d I-cell_type 
malignant [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]t I-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d I-cell_type 
progenitors [C]p [C]r [C]o [C]g [C]e [C]n [C]i [C]t [C]o [C]r [C]s E-cell_type 
( [C]( O 
CFU-GM [C]C [C]F [C]U [C]- [C]G [C]M S-cell_type 
) [C]) O 
from [C]f [C]r [C]o [C]m O 
Ara-C [C]A [C]r [C]a [C]- [C]C O 
toxicity [C]t [C]o [C]x [C]i [C]c [C]i [C]t [C]y O 
using [C]u [C]s [C]i [C]n [C]g O 
cycloheximide [C]c [C]y [C]c [C]l [C]o [C]h [C]e [C]x [C]i [C]m [C]i [C]d [C]e O 
. [C]. O 

Cycloheximide [C]C [C]y [C]c [C]l [C]o [C]h [C]e [C]x [C]i [C]m [C]i [C]d [C]e O 
, [C], O 
a [C]a O 
reversible [C]r [C]e [C]v [C]e [C]r [C]s [C]i [C]b [C]l [C]e O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
, [C], O 
is [C]i [C]s O 
thought [C]t [C]h [C]o [C]u [C]g [C]h [C]t O 
to [C]t [C]o O 
block [C]b [C]l [C]o [C]c [C]k O 
DNA [C]D [C]N [C]A O 
replication [C]r [C]e [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
by [C]b [C]y O 
preventing [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]i [C]n [C]g O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
a [C]a O 
labile [C]l [C]a [C]b [C]i [C]l [C]e B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
. [C]. O 

In [C]I [C]n O 
animal [C]a [C]n [C]i [C]m [C]a [C]l O 
systems [C]s [C]y [C]s [C]t [C]e [C]m [C]s O 
, [C], O 
cycloheximide [C]c [C]y [C]c [C]l [C]o [C]h [C]e [C]x [C]i [C]m [C]i [C]d [C]e O 
protects [C]p [C]r [C]o [C]t [C]e [C]c [C]t [C]s O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
cytotoxic [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c O 
S-phase [C]S [C]- [C]p [C]h [C]a [C]s [C]e O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
agents [C]a [C]g [C]e [C]n [C]t [C]s O 
, [C], O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
cytosine [C]c [C]y [C]t [C]o [C]s [C]i [C]n [C]e O 
arabinoside [C]a [C]r [C]a [C]b [C]i [C]n [C]o [C]s [C]i [C]d [C]e O 
( [C]( O 
Ara-C [C]A [C]r [C]a [C]- [C]C O 
) [C]) O 
. [C]. O 

Malignant [C]M [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]t B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
appear [C]a [C]p [C]p [C]e [C]a [C]r O 
not [C]n [C]o [C]t O 
to [C]t [C]o O 
be [C]b [C]e O 
susceptible [C]s [C]u [C]s [C]c [C]e [C]p [C]t [C]i [C]b [C]l [C]e O 
to [C]t [C]o O 
cycloheximide-induced [C]c [C]y [C]c [C]l [C]o [C]h [C]e [C]x [C]i [C]m [C]i [C]d [C]e [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
cycle [C]c [C]y [C]c [C]l [C]e O 
arrest [C]a [C]r [C]r [C]e [C]s [C]t O 
and [C]a [C]n [C]d O 
, [C], O 
subsequently [C]s [C]u [C]b [C]s [C]e [C]q [C]u [C]e [C]n [C]t [C]l [C]y O 
, [C], O 
may [C]m [C]a [C]y O 
not [C]n [C]o [C]t O 
be [C]b [C]e O 
protected [C]p [C]r [C]o [C]t [C]e [C]c [C]t [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
Ara-C [C]A [C]r [C]a [C]- [C]C O 
cytotoxicity [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c [C]i [C]t [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
cycloheximide [C]c [C]y [C]c [C]l [C]o [C]h [C]e [C]x [C]i [C]m [C]i [C]d [C]e O 
on [C]o [C]n O 
granulocyte/macrophage [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e [C]/ [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e B-cell_type 
progenitors [C]p [C]r [C]o [C]g [C]e [C]n [C]i [C]t [C]o [C]r [C]s E-cell_type 
( [C]( O 
CFU-GM [C]C [C]F [C]U [C]- [C]G [C]M S-cell_type 
) [C]) O 
after [C]a [C]f [C]t [C]e [C]r O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
Ara-C [C]A [C]r [C]a [C]- [C]C O 
exposure [C]e [C]x [C]p [C]o [C]s [C]u [C]r [C]e O 
was [C]w [C]a [C]s O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
using [C]u [C]s [C]i [C]n [C]g O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
human [C]h [C]u [C]m [C]a [C]n O 
bone [C]b [C]o [C]n [C]e O 
marrow [C]m [C]a [C]r [C]r [C]o [C]w O 
, [C], O 
malignant [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]t B-cell_type 
progenitors [C]p [C]r [C]o [C]g [C]e [C]n [C]i [C]t [C]o [C]r [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
myelogenous [C]m [C]y [C]e [C]l [C]o [C]g [C]e [C]n [C]o [C]u [C]s O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
( [C]( O 
CML [C]C [C]M [C]L O 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
clonogenic [C]c [C]l [C]o [C]n [C]o [C]g [C]e [C]n [C]i [C]c B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
acute [C]a [C]c [C]u [C]t [C]e I-cell_line 
nonlymphocytic [C]n [C]o [C]n [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]i [C]c I-cell_line 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s I-cell_line 
HL-60 [C]H [C]L [C]- [C]6 [C]0 I-cell_line 
and [C]a [C]n [C]d I-cell_line 
KG-1 [C]K [C]G [C]- [C]1 E-cell_line 
. [C]. O 

Mononuclear [C]M [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_line 
or [C]o [C]r I-cell_line 
clonogenic [C]c [C]l [C]o [C]n [C]o [C]g [C]e [C]n [C]i [C]c I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
were [C]w [C]e [C]r [C]e O 
incubated [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]e [C]d O 
for [C]f [C]o [C]r O 
one [C]o [C]n [C]e O 
hour [C]h [C]o [C]u [C]r O 
with [C]w [C]i [C]t [C]h O 
cycloheximide [C]c [C]y [C]c [C]l [C]o [C]h [C]e [C]x [C]i [C]m [C]i [C]d [C]e O 
, [C], O 
followed [C]f [C]o [C]l [C]l [C]o [C]w [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
for [C]f [C]o [C]r O 
three [C]t [C]h [C]r [C]e [C]e O 
or [C]o [C]r O 
17 [C]1 [C]7 O 
hours [C]h [C]o [C]u [C]r [C]s O 
, [C], O 
of [C]o [C]f O 
Ara-C [C]A [C]r [C]a [C]- [C]C O 
before [C]b [C]e [C]f [C]o [C]r [C]e O 
being [C]b [C]e [C]i [C]n [C]g O 
plated [C]p [C]l [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
a [C]a O 
methylcellulose [C]m [C]e [C]t [C]h [C]y [C]l [C]c [C]e [C]l [C]l [C]u [C]l [C]o [C]s [C]e O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
. [C]. O 

CFU-GM [C]C [C]F [C]U [C]- [C]G [C]M O 
survival [C]s [C]u [C]r [C]v [C]i [C]v [C]a [C]l O 
was [C]w [C]a [C]s O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
if [C]i [C]f O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
cells [C]c [C]e [C]l [C]l [C]s O 
were [C]w [C]e [C]r [C]e O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
cycloheximide [C]c [C]y [C]c [C]l [C]o [C]h [C]e [C]x [C]i [C]m [C]i [C]d [C]e O 
before [C]b [C]e [C]f [C]o [C]r [C]e O 
Ara-C [C]A [C]r [C]a [C]- [C]C O 
exposure [C]e [C]x [C]p [C]o [C]s [C]u [C]r [C]e O 
. [C]. O 

Similar [C]S [C]i [C]m [C]i [C]l [C]a [C]r O 
cycloheximide [C]c [C]y [C]c [C]l [C]o [C]h [C]e [C]x [C]i [C]m [C]i [C]d [C]e O 
pretreatment [C]p [C]r [C]e [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
CML [C]C [C]M [C]L B-cell_type 
progenitors [C]p [C]r [C]o [C]g [C]e [C]n [C]i [C]t [C]o [C]r [C]s E-cell_type 
and [C]a [C]n [C]d O 
clonogenic [C]c [C]l [C]o [C]n [C]o [C]g [C]e [C]n [C]i [C]c B-cell_line 
HL-60 [C]H [C]L [C]- [C]6 [C]0 I-cell_line 
and [C]a [C]n [C]d I-cell_line 
KG-1 [C]K [C]G [C]- [C]1 I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
failed [C]f [C]a [C]i [C]l [C]e [C]d O 
to [C]t [C]o O 
protect [C]p [C]r [C]o [C]t [C]e [C]c [C]t O 
CFU-GM [C]C [C]F [C]U [C]- [C]G [C]M S-cell_type 
from [C]f [C]r [C]o [C]m O 
Ara-C-induced [C]A [C]r [C]a [C]- [C]C [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
cytotoxicity [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c [C]i [C]t [C]y O 
. [C]. O 

Primary [C]P [C]r [C]i [C]m [C]a [C]r [C]y O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
accompanied [C]a [C]c [C]c [C]o [C]m [C]p [C]a [C]n [C]i [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
reduction [C]r [C]e [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
two [C]t [C]w [C]o O 
members [C]m [C]e [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
family [C]f [C]a [C]m [C]i [C]l [C]y O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
describes [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e [C]s O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
of [C]o [C]f O 
a [C]a O 
man [C]m [C]a [C]n O 
suspected [C]s [C]u [C]s [C]p [C]e [C]c [C]t [C]e [C]d O 
of [C]o [C]f O 
having [C]h [C]a [C]v [C]i [C]n [C]g O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
conclusion [C]c [C]o [C]n [C]c [C]l [C]u [C]s [C]i [C]o [C]n O 
is [C]i [C]s O 
based [C]b [C]a [C]s [C]e [C]d O 
on [C]o [C]n O 
his [C]h [C]i [C]s O 
high [C]h [C]i [C]g [C]h O 
plasma [C]p [C]l [C]a [C]s [C]m [C]a O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
and [C]a [C]n [C]d O 
high [C]h [C]i [C]g [C]h O 
24-h [C]2 [C]4 [C]- [C]h O 
urinary [C]u [C]r [C]i [C]n [C]a [C]r [C]y O 
17-hydroxycorticosteroid [C]1 [C]7 [C]- [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
and [C]a [C]n [C]d O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
excretion [C]e [C]x [C]c [C]r [C]e [C]t [C]i [C]o [C]n O 
, [C], O 
plus [C]p [C]l [C]u [C]s O 
the [C]t [C]h [C]e O 
fact [C]f [C]a [C]c [C]t O 
that [C]t [C]h [C]a [C]t O 
he [C]h [C]e O 
had [C]h [C]a [C]d O 
no [C]n [C]o O 
manifestations [C]m [C]a [C]n [C]i [C]f [C]e [C]s [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
Cushing [C]C [C]u [C]s [C]h [C]i [C]n [C]g O 
's [C]' [C]s O 
syndrome [C]s [C]y [C]n [C]d [C]r [C]o [C]m [C]e O 
. [C]. O 

Among [C]A [C]m [C]o [C]n [C]g O 
family [C]f [C]a [C]m [C]i [C]l [C]y O 
members [C]m [C]e [C]m [C]b [C]e [C]r [C]s O 
tested [C]t [C]e [C]s [C]t [C]e [C]d O 
, [C], O 
his [C]h [C]i [C]s O 
mother [C]m [C]o [C]t [C]h [C]e [C]r O 
also [C]a [C]l [C]s [C]o O 
had [C]h [C]a [C]d O 
hypercortisolemia [C]h [C]y [C]p [C]e [C]r [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l [C]e [C]m [C]i [C]a O 
. [C]. O 

Both [C]B [C]o [C]t [C]h O 
mother [C]m [C]o [C]t [C]h [C]e [C]r O 
and [C]a [C]n [C]d O 
son [C]s [C]o [C]n O 
had [C]h [C]a [C]d O 
high [C]h [C]i [C]g [C]h O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
unbound [C]u [C]n [C]b [C]o [C]u [C]n [C]d O 
plasma [C]p [C]l [C]a [C]s [C]m [C]a O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
, [C], O 
but [C]b [C]u [C]t O 
their [C]t [C]h [C]e [C]i [C]r O 
plasma [C]p [C]l [C]a [C]s [C]m [C]a O 
ACTH [C]A [C]C [C]T [C]H O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
were [C]w [C]e [C]r [C]e O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
the [C]t [C]h [C]e O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
range [C]r [C]a [C]n [C]g [C]e O 
. [C]. O 

Both [C]B [C]o [C]t [C]h O 
were [C]w [C]e [C]r [C]e O 
partially [C]p [C]a [C]r [C]t [C]i [C]a [C]l [C]l [C]y O 
resistant [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]t O 
to [C]t [C]o O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
adrenal [C]a [C]d [C]r [C]e [C]n [C]a [C]l O 
suppression [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
both [C]b [C]o [C]t [C]h O 
had [C]h [C]a [C]d O 
mild [C]m [C]i [C]l [C]d O 
hypertension [C]h [C]y [C]p [C]e [C]r [C]t [C]e [C]n [C]s [C]i [C]o [C]n O 
without [C]w [C]i [C]t [C]h [C]o [C]u [C]t O 
hypokalemia [C]h [C]y [C]p [C]o [C]k [C]a [C]l [C]e [C]m [C]i [C]a O 
. [C]. O 

To [C]T [C]o O 
study [C]s [C]t [C]u [C]d [C]y O 
this [C]t [C]h [C]i [C]s O 
apparent [C]a [C]p [C]p [C]a [C]r [C]e [C]n [C]t O 
end-organ [C]e [C]n [C]d [C]- [C]o [C]r [C]g [C]a [C]n O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
to [C]t [C]o O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
, [C], O 
we [C]w [C]e O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
the [C]t [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Using [C]U [C]s [C]i [C]n [C]g O 
whole [C]w [C]h [C]o [C]l [C]e O 
cell [C]c [C]e [C]l [C]l O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
, [C], O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
were [C]w [C]e [C]r [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
have [C]h [C]a [C]v [C]e O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
total [C]t [C]o [C]t [C]a [C]l O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
capacity [C]c [C]a [C]p [C]a [C]c [C]i [C]t [C]y O 
. [C]. O 

We [C]W [C]e O 
conclude [C]c [C]o [C]n [C]c [C]l [C]u [C]d [C]e O 
that [C]t [C]h [C]a [C]t O 
these [C]t [C]h [C]e [C]s [C]e O 
two [C]t [C]w [C]o O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
, [C], O 
members [C]m [C]e [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
family [C]f [C]a [C]m [C]i [C]l [C]y O 
, [C], O 
have [C]h [C]a [C]v [C]e O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
accompanied [C]a [C]c [C]c [C]o [C]m [C]p [C]a [C]n [C]i [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

[ [C][ O 
Glucocorticoid [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
and [C]a [C]n [C]d O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
polychemotherapy [C]p [C]o [C]l [C]y [C]c [C]h [C]e [C]m [C]o [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
in [C]i [C]n O 
acute [C]a [C]c [C]u [C]t [C]e O 
lymphatic [C]l [C]y [C]m [C]p [C]h [C]a [C]t [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
] [C]] O 

Glucocorticoid [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
( [C]( O 
GR [C]G [C]R S-protein 
) [C]) O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
were [C]w [C]e [C]r [C]e O 
quantified [C]q [C]u [C]a [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
in [C]i [C]n O 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c B-cell_type 
blasts [C]b [C]l [C]a [C]s [C]t [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l O 
blood [C]b [C]l [C]o [C]o [C]d O 
of [C]o [C]f O 
86 [C]8 [C]6 O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
acute [C]a [C]c [C]u [C]t [C]e O 
lymphoblastic [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
. [C]. O 

The [C]T [C]h [C]e O 
subsequent [C]s [C]u [C]b [C]s [C]e [C]q [C]u [C]e [C]n [C]t O 
achievement [C]a [C]c [C]h [C]i [C]e [C]v [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
complete [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e O 
remission [C]r [C]e [C]m [C]i [C]s [C]s [C]i [C]o [C]n O 
after [C]a [C]f [C]t [C]e [C]r O 
combination [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
chemotherapy [C]c [C]h [C]e [C]m [C]o [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
was [C]w [C]a [C]s O 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
high [C]h [C]i [C]g [C]h O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
. [C]. O 

Forty-seven [C]F [C]o [C]r [C]t [C]y [C]- [C]s [C]e [C]v [C]e [C]n O 
of [C]o [C]f O 
50 [C]5 [C]0 O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
more [C]m [C]o [C]r [C]e O 
than [C]t [C]h [C]a [C]n O 
6 [C]6 O 
, [C], O 
000 [C]0 [C]0 [C]0 O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
sites [C]s [C]i [C]t [C]e [C]s O 
and [C]a [C]n [C]d O 
22 [C]2 [C]2 O 
of [C]o [C]f O 
36 [C]3 [C]6 O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
cells [C]c [C]e [C]l [C]l [C]s O 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
less [C]l [C]e [C]s [C]s O 
than [C]t [C]h [C]a [C]n O 
6 [C]6 O 
, [C], O 
000 [C]0 [C]0 [C]0 O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
sites [C]s [C]i [C]t [C]e [C]s O 
achieved [C]a [C]c [C]h [C]i [C]e [C]v [C]e [C]d O 
remission [C]r [C]e [C]m [C]i [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
study [C]s [C]t [C]u [C]d [C]y O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
may [C]m [C]a [C]y O 
predict [C]p [C]r [C]e [C]d [C]i [C]c [C]t O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
combination [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
chemotherapy [C]c [C]h [C]e [C]m [C]o [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
in [C]i [C]n O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
acute [C]a [C]c [C]u [C]t [C]e O 
lymphoblastic [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
. [C]. O 

Specific [C]S [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
uptake [C]u [C]p [C]t [C]a [C]k [C]e O 
of [C]o [C]f O 
1 [C]1 O 
, [C], O 
25-dihydroxycholecalciferol [C]2 [C]5 [C]- [C]d [C]i [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]c [C]h [C]o [C]l [C]e [C]c [C]a [C]l [C]c [C]i [C]f [C]e [C]r [C]o [C]l O 
by [C]b [C]y O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c I-cell_type 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d I-cell_type 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
preparations [C]p [C]r [C]e [C]p [C]a [C]r [C]a [C]t [C]i [C]o [C]n [C]s E-cell_line 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
[ [C][ O 
CML [C]C [C]M [C]L O 
] [C]] O 
for [C]f [C]o [C]r O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
and [C]a [C]n [C]d O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
1 [C]1 O 
, [C], O 
25-dihydroxycholecalciferol [C]2 [C]5 [C]- [C]d [C]i [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]c [C]h [C]o [C]l [C]e [C]c [C]a [C]l [C]c [C]i [C]f [C]e [C]r [C]o [C]l O 
[ [C][ O 
1 [C]1 O 
, [C], O 
25- [C]2 [C]5 [C]- O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
] [C]] O 
. [C]. O 

Whole [C]W [C]h [C]o [C]l [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
specifically [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]a [C]l [C]l [C]y O 
took [C]t [C]o [C]o [C]k O 
up [C]u [C]p O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
-1 [C]- [C]1 O 
, [C], O 
25- [C]2 [C]5 [C]- O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
with [C]w [C]i [C]t [C]h O 
high [C]h [C]i [C]g [C]h O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
( [C]( O 
Kd [C]K [C]d O 
3.6 [C]3 [C]. [C]6 O 
X [C]X O 
10 [C]1 [C]0 O 
( [C]( O 
-11 [C]- [C]1 [C]1 O 
) [C]) O 
M [C]M O 
) [C]) O 
and [C]a [C]n [C]d O 
low [C]l [C]o [C]w O 
capacity [C]c [C]a [C]p [C]a [C]c [C]i [C]t [C]y O 
. [C]. O 

Subcellular [C]S [C]u [C]b [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
fractionation [C]f [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
labeled [C]l [C]a [C]b [C]e [C]l [C]e [C]d B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
was [C]w [C]a [C]s O 
restricted [C]r [C]e [C]s [C]t [C]r [C]i [C]c [C]t [C]e [C]d O 
to [C]t [C]o O 
cytosols [C]c [C]y [C]t [C]o [C]s [C]o [C]l [C]s O 
and [C]a [C]n [C]d O 
nuclei [C]n [C]u [C]c [C]l [C]e [C]i O 
. [C]. O 

Sucrose [C]S [C]u [C]c [C]r [C]o [C]s [C]e O 
gradient [C]g [C]r [C]a [C]d [C]i [C]e [C]n [C]t O 
centrifugation [C]c [C]e [C]n [C]t [C]r [C]i [C]f [C]u [C]g [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cells [C]c [C]e [C]l [C]l [C]s O 
preincubated [C]p [C]r [C]e [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
-1 [C]- [C]1 O 
, [C], O 
25- [C]2 [C]5 [C]- O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
a [C]a O 
single [C]s [C]i [C]n [C]g [C]l [C]e O 
3.6S [C]3 [C]. [C]6 [C]S O 
peak [C]p [C]e [C]a [C]k O 
which [C]w [C]h [C]i [C]c [C]h O 
was [C]w [C]a [C]s O 
totally [C]t [C]o [C]t [C]a [C]l [C]l [C]y O 
displaced [C]d [C]i [C]s [C]p [C]l [C]a [C]c [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
100-fold [C]1 [C]0 [C]0 [C]- [C]f [C]o [C]l [C]d O 
excess [C]e [C]x [C]c [C]e [C]s [C]s O 
nonradioactive [C]n [C]o [C]n [C]r [C]a [C]d [C]i [C]o [C]a [C]c [C]t [C]i [C]v [C]e O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
we [C]w [C]e O 
were [C]w [C]e [C]r [C]e O 
unable [C]u [C]n [C]a [C]b [C]l [C]e O 
to [C]t [C]o O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
1 [C]1 O 
, [C], O 
25- [C]2 [C]5 [C]- O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
by [C]b [C]y O 
postlabeling [C]p [C]o [C]s [C]t [C]l [C]a [C]b [C]e [C]l [C]i [C]n [C]g O 
standard [C]s [C]t [C]a [C]n [C]d [C]a [C]r [C]d O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
preparations [C]p [C]r [C]e [C]p [C]a [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
cytosols [C]c [C]y [C]t [C]o [C]s [C]o [C]l [C]s O 
prepared [C]p [C]r [C]e [C]p [C]a [C]r [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
a [C]a O 
mixture [C]m [C]i [C]x [C]t [C]u [C]r [C]e O 
of [C]o [C]f O 
CML [C]C [C]M [C]L B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
and [C]a [C]n [C]d O 
1 [C]1 B-cell_line 
, [C], I-cell_line 
25- [C]2 [C]5 [C]- I-cell_line 
( [C]( I-cell_line 
OH [C]O [C]H I-cell_line 
) [C]) I-cell_line 
2D3 [C]2 [C]D [C]3 I-cell_line 
receptor-positive [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e I-cell_line 
T47D [C]T [C]4 [C]7 [C]D E-cell_line 
( [C]( O 
human [C]h [C]u [C]m [C]a [C]n O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
) [C]) O 
cells [C]c [C]e [C]l [C]l [C]s O 
had [C]h [C]a [C]d O 
less [C]l [C]e [C]s [C]s O 
than [C]t [C]h [C]a [C]n O 
10 [C]1 [C]0 O 
% [C]% O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
in [C]i [C]n O 
T47D [C]T [C]4 [C]7 [C]D S-cell_line 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
alone [C]a [C]l [C]o [C]n [C]e O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
the [C]t [C]h [C]e O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
in [C]i [C]n O 
T47D [C]T [C]4 [C]7 [C]D S-cell_line 
cytosols [C]c [C]y [C]t [C]o [C]s [C]o [C]l [C]s O 
were [C]w [C]e [C]r [C]e O 
not [C]n [C]o [C]t O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
if [C]i [C]f O 
the [C]t [C]h [C]e O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
were [C]w [C]e [C]r [C]e O 
occupied [C]o [C]c [C]c [C]u [C]p [C]i [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
-1 [C]- [C]1 O 
, [C], O 
25- [C]2 [C]5 [C]- O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
prior [C]p [C]r [C]i [C]o [C]r O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
CML [C]C [C]M [C]L S-cell_line 
cytosols [C]c [C]y [C]t [C]o [C]s [C]o [C]l [C]s O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
CML [C]C [C]M [C]L B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
appear [C]a [C]p [C]p [C]e [C]a [C]r O 
to [C]t [C]o O 
contain [C]c [C]o [C]n [C]t [C]a [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
the [C]t [C]h [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
for [C]f [C]o [C]r O 
1 [C]1 O 
, [C], O 
25- [C]2 [C]5 [C]- O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
and [C]a [C]n [C]d O 
an [C]a [C]n O 
unknown [C]u [C]n [C]k [C]n [C]o [C]w [C]n O 
substance [C]s [C]u [C]b [C]s [C]t [C]a [C]n [C]c [C]e O 
which [C]w [C]h [C]i [C]c [C]h O 
prevents [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]s O 
its [C]i [C]t [C]s O 
detection [C]d [C]e [C]t [C]e [C]c [C]t [C]i [C]o [C]n O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
preparation [C]p [C]r [C]e [C]p [C]a [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
. [C]. O 

Cells [C]C [C]e [C]l [C]l [C]s O 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
CML [C]C [C]M [C]L O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
phase [C]p [C]h [C]a [C]s [C]e O 
specifically [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]a [C]l [C]l [C]y O 
bound [C]b [C]o [C]u [C]n [C]d O 
more [C]m [C]o [C]r [C]e O 
1 [C]1 O 
, [C], O 
25- [C]2 [C]5 [C]- O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
[ [C][ O 
18.0 [C]1 [C]8 [C]. [C]0 O 
+/- [C]+ [C]/ [C]- O 
3.2 [C]3 [C]. [C]2 O 
( [C]( O 
S.E. [C]S [C]. [C]E [C]. O 
) [C]) O 
fmol/10 [C]f [C]m [C]o [C]l [C]/ [C]1 [C]0 O 
( [C]( O 
7 [C]7 O 
) [C]) O 
cells [C]c [C]e [C]l [C]l [C]s O 
] [C]] O 
than [C]t [C]h [C]a [C]n O 
did [C]d [C]i [C]d O 
those [C]t [C]h [C]o [C]s [C]e O 
in [C]i [C]n O 
acute [C]a [C]c [C]u [C]t [C]e O 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d O 
transformation [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
[ [C][ O 
7.2 [C]7 [C]. [C]2 O 
+/- [C]+ [C]/ [C]- O 
1.5 [C]1 [C]. [C]5 O 
] [C]] O 
or [C]o [C]r O 
than [C]t [C]h [C]a [C]n O 
did [C]d [C]i [C]d O 
cells [C]c [C]e [C]l [C]l [C]s O 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
acute [C]a [C]c [C]u [C]t [C]e O 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
[ [C][ O 
2.6 [C]2 [C]. [C]6 O 
+/- [C]+ [C]/ [C]- O 
0.8 [C]0 [C]. [C]8 O 
] [C]] O 
. [C]. O 

Only [C]O [C]n [C]l [C]y O 
cells [C]c [C]e [C]l [C]l [C]s O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
first [C]f [C]i [C]r [C]s [C]t O 
group [C]g [C]r [C]o [C]u [C]p O 
of [C]o [C]f O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
responded [C]r [C]e [C]s [C]p [C]o [C]n [C]d [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
1 [C]1 O 
, [C], O 
25- [C]2 [C]5 [C]- O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
by [C]b [C]y O 
differentiating [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]n [C]g O 
along [C]a [C]l [C]o [C]n [C]g O 
the [C]t [C]h [C]e O 
monocyte-macrophage [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]- [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
. [C]. O 

We [C]W [C]e O 
conclude [C]c [C]o [C]n [C]c [C]l [C]u [C]d [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
differentiation-induction [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n [C]- [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
1 [C]1 O 
, [C], O 
25- [C]2 [C]5 [C]- O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
is [C]i [C]s O 
likely [C]l [C]i [C]k [C]e [C]l [C]y O 
to [C]t [C]o O 
depend [C]d [C]e [C]p [C]e [C]n [C]d O 
on [C]o [C]n O 
adequate [C]a [C]d [C]e [C]q [C]u [C]a [C]t [C]e O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
and [C]a [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
intact [C]i [C]n [C]t [C]a [C]c [C]t B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
rather [C]r [C]a [C]t [C]h [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
preparations [C]p [C]r [C]e [C]p [C]a [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
should [C]s [C]h [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
before [C]b [C]e [C]f [C]o [C]r [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
of [C]o [C]f O 
a [C]a O 
particular [C]p [C]a [C]r [C]t [C]i [C]c [C]u [C]l [C]a [C]r O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
are [C]a [C]r [C]e O 
designated [C]d [C]e [C]s [C]i [C]g [C]n [C]a [C]t [C]e [C]d O 
as [C]a [C]s O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
. [C]. O 

Effect [C]E [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
cell [C]c [C]e [C]l [C]l O 
cycle [C]c [C]y [C]c [C]l [C]e O 
position [C]p [C]o [C]s [C]i [C]t [C]i [C]o [C]n O 
on [C]o [C]n O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
by [C]b [C]y O 
mouse [C]m [C]o [C]u [C]s [C]e B-cell_line 
and [C]a [C]n [C]d I-cell_line 
human [C]h [C]u [C]m [C]a [C]n I-cell_line 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
: [C]: O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
an [C]a [C]n O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
S [C]S O 
phase [C]p [C]h [C]a [C]s [C]e O 
and [C]a [C]n [C]d O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

We [C]W [C]e O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
the [C]t [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
cell [C]c [C]e [C]l [C]l O 
cycle [C]c [C]y [C]c [C]l [C]e O 
position [C]p [C]o [C]s [C]i [C]t [C]i [C]o [C]n O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
amount [C]a [C]m [C]o [C]u [C]n [C]t O 
of [C]o [C]f O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
that [C]t [C]h [C]a [C]t O 
was [C]w [C]a [C]s O 
specifically [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]a [C]l [C]l [C]y O 
bound [C]b [C]o [C]u [C]n [C]d O 
by [C]b [C]y O 
mouse [C]m [C]o [C]u [C]s [C]e B-cell_line 
and [C]a [C]n [C]d I-cell_line 
human [C]h [C]u [C]m [C]a [C]n I-cell_line 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
. [C]. O 

Cell [C]C [C]e [C]l [C]l B-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
that [C]t [C]h [C]a [C]t O 
were [C]w [C]e [C]r [C]e O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
sensitive [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
or [C]o [C]r O 
resistant [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]t O 
to [C]t [C]o O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
were [C]w [C]e [C]r [C]e O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
. [C]. O 

Exponentially [C]E [C]x [C]p [C]o [C]n [C]e [C]n [C]t [C]i [C]a [C]l [C]l [C]y B-cell_type 
growing [C]g [C]r [C]o [C]w [C]i [C]n [C]g I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
separated [C]s [C]e [C]p [C]a [C]r [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
centrifugal [C]c [C]e [C]n [C]t [C]r [C]i [C]f [C]u [C]g [C]a [C]l O 
elutriation [C]e [C]l [C]u [C]t [C]r [C]i [C]a [C]t [C]i [C]o [C]n O 
into [C]i [C]n [C]t [C]o O 
fractions [C]f [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
that [C]t [C]h [C]a [C]t O 
corresponded [C]c [C]o [C]r [C]r [C]e [C]s [C]p [C]o [C]n [C]d [C]e [C]d O 
to [C]t [C]o O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
positions [C]p [C]o [C]s [C]i [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
cell [C]c [C]e [C]l [C]l O 
cycle [C]c [C]y [C]c [C]l [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
cell [C]c [C]e [C]l [C]l O 
cycle [C]c [C]y [C]c [C]l [C]e O 
phase [C]p [C]h [C]a [C]s [C]e O 
distribution [C]d [C]i [C]s [C]t [C]r [C]i [C]b [C]u [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
each [C]e [C]a [C]c [C]h O 
fraction [C]f [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
estimated [C]e [C]s [C]t [C]i [C]m [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
flow [C]f [C]l [C]o [C]w O 
cytometry [C]c [C]y [C]t [C]o [C]m [C]e [C]t [C]r [C]y O 
and [C]a [C]n [C]d O 
autoradiography [C]a [C]u [C]t [C]o [C]r [C]a [C]d [C]i [C]o [C]g [C]r [C]a [C]p [C]h [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
amount [C]a [C]m [C]o [C]u [C]n [C]t O 
of [C]o [C]f O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
bound [C]b [C]o [C]u [C]n [C]d O 
per [C]p [C]e [C]r O 
cell [C]c [C]e [C]l [C]l O 
in [C]i [C]n O 
each [C]e [C]a [C]c [C]h O 
fraction [C]f [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
whole [C]w [C]h [C]o [C]l [C]e O 
cell [C]c [C]e [C]l [C]l O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
assay [C]a [C]s [C]s [C]a [C]y O 
. [C]. O 

In [C]I [C]n O 
three [C]t [C]h [C]r [C]e [C]e O 
dexamethasone-sensitive [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e [C]- [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
( [C]( O 
two [C]t [C]w [C]o O 
mouse [C]m [C]o [C]u [C]s [C]e O 
and [C]a [C]n [C]d O 
one [C]o [C]n [C]e O 
human [C]h [C]u [C]m [C]a [C]n O 
) [C]) O 
, [C], O 
we [C]w [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
amount [C]a [C]m [C]o [C]u [C]n [C]t O 
of [C]o [C]f O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
bound [C]b [C]o [C]u [C]n [C]d O 
per [C]p [C]e [C]r O 
cell [C]c [C]e [C]l [C]l O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
2-4-fold [C]2 [C]- [C]4 [C]- [C]f [C]o [C]l [C]d O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
G1 [C]G [C]1 O 
phase [C]p [C]h [C]a [C]s [C]e O 
and [C]a [C]n [C]d O 
S [C]S O 
phase [C]p [C]h [C]a [C]s [C]e O 
, [C], O 
and [C]a [C]n [C]d O 
then [C]t [C]h [C]e [C]n O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
G2/M [C]G [C]2 [C]/ [C]M O 
phase [C]p [C]h [C]a [C]s [C]e O 
. [C]. O 

Results [C]R [C]e [C]s [C]u [C]l [C]t [C]s O 
were [C]w [C]e [C]r [C]e O 
the [C]t [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
when [C]w [C]h [C]e [C]n O 
the [C]t [C]h [C]e O 
amount [C]a [C]m [C]o [C]u [C]n [C]t O 
of [C]o [C]f O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
bound [C]b [C]o [C]u [C]n [C]d O 
per [C]p [C]e [C]r O 
milligram [C]m [C]i [C]l [C]l [C]i [C]g [C]r [C]a [C]m O 
of [C]o [C]f O 
cell [C]c [C]e [C]l [C]l B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
was [C]w [C]a [C]s O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
. [C]. O 

Binding [C]B [C]i [C]n [C]d [C]i [C]n [C]g O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
was [C]w [C]a [C]s O 
the [C]t [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
G1 [C]G [C]1 O 
phase [C]p [C]h [C]a [C]s [C]e O 
and [C]a [C]n [C]d O 
S [C]S O 
phase [C]p [C]h [C]a [C]s [C]e O 
, [C], O 
but [C]b [C]u [C]t O 
the [C]t [C]h [C]e O 
proportion [C]p [C]r [C]o [C]p [C]o [C]r [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
bound [C]b [C]o [C]u [C]n [C]d O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
that [C]t [C]h [C]a [C]t O 
translocated [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
nucleus [C]n [C]u [C]c [C]l [C]e [C]u [C]s O 
was [C]w [C]a [C]s O 
greater [C]g [C]r [C]e [C]a [C]t [C]e [C]r O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
S [C]S O 
phase [C]p [C]h [C]a [C]s [C]e O 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
we [C]w [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
amount [C]a [C]m [C]o [C]u [C]n [C]t O 
of [C]o [C]f O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
bound [C]b [C]o [C]u [C]n [C]d O 
per [C]p [C]e [C]r O 
cell [C]c [C]e [C]l [C]l O 
by [C]b [C]y O 
three [C]t [C]h [C]r [C]e [C]e O 
dexamethasone-resistant [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e [C]- [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]t B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
( [C]( O 
two [C]t [C]w [C]o O 
mouse [C]m [C]o [C]u [C]s [C]e O 
and [C]a [C]n [C]d O 
one [C]o [C]n [C]e O 
human [C]h [C]u [C]m [C]a [C]n O 
) [C]) O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
S [C]S O 
phase [C]p [C]h [C]a [C]s [C]e O 
. [C]. O 

Our [C]O [C]u [C]r O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
cell [C]c [C]e [C]l [C]l O 
cycle [C]c [C]y [C]c [C]l [C]e O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
in [C]i [C]n O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
are [C]a [C]r [C]e O 
not [C]n [C]o [C]t O 
simply [C]s [C]i [C]m [C]p [C]l [C]y O 
related [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
to [C]t [C]o O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
in [C]i [C]n O 
cell [C]c [C]e [C]l [C]l B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
or [C]o [C]r O 
cell [C]c [C]e [C]l [C]l O 
volume [C]v [C]o [C]l [C]u [C]m [C]e O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
cell [C]c [C]e [C]l [C]l O 
cycle [C]c [C]y [C]c [C]l [C]e O 
. [C]. O 

An [C]A [C]n O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
S [C]S O 
phase [C]p [C]h [C]a [C]s [C]e O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
to [C]t [C]o O 
inhibit [C]i [C]n [C]h [C]i [C]b [C]i [C]t O 
cell [C]c [C]e [C]l [C]l O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
, [C], O 
and [C]a [C]n [C]d O 
a [C]a O 
failure [C]f [C]a [C]i [C]l [C]u [C]r [C]e O 
of [C]o [C]f O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
S [C]S O 
phase [C]p [C]h [C]a [C]s [C]e O 
might [C]m [C]i [C]g [C]h [C]t O 
represent [C]r [C]e [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
a [C]a O 
new [C]n [C]e [C]w O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
of [C]o [C]f O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
in [C]i [C]n O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Presence [C]P [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
and [C]a [C]n [C]d O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
inducibility [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
glutamine [C]g [C]l [C]u [C]t [C]a [C]m [C]i [C]n [C]e B-protein 
synthetase [C]s [C]y [C]n [C]t [C]h [C]e [C]t [C]a [C]s [C]e E-protein 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Glutamine [C]G [C]l [C]u [C]t [C]a [C]m [C]i [C]n [C]e B-protein 
synthetase [C]s [C]y [C]n [C]t [C]h [C]e [C]t [C]a [C]s [C]e E-protein 
( [C]( O 
EC [C]E [C]C O 
6.3.1.2 [C]6 [C]. [C]3 [C]. [C]1 [C]. [C]2 O 
; [C]; O 
GS [C]G [C]S O 
) [C]) O 
is [C]i [C]s O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
in [C]i [C]n O 
lymphoblasts [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]s S-cell_type 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
acute [C]a [C]c [C]u [C]t [C]e O 
lymphoblastic [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
( [C]( O 
ALL [C]A [C]L [C]L O 
) [C]) O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

In [C]I [C]n O 
16 [C]1 [C]6 O 
out [C]o [C]u [C]t O 
of [C]o [C]f O 
20 [C]2 [C]0 O 
ALL [C]A [C]L [C]L O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
exposure [C]e [C]x [C]p [C]o [C]s [C]u [C]r [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
to [C]t [C]o O 
physiological [C]p [C]h [C]y [C]s [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
enzyme [C]e [C]n [C]z [C]y [C]m [C]e S-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
above [C]a [C]b [C]o [C]v [C]e O 
the [C]t [C]h [C]e O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
was [C]w [C]a [C]s O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
for [C]f [C]o [C]r O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
ligands [C]l [C]i [C]g [C]a [C]n [C]d [C]s O 
. [C]. O 

A [C]A O 
direct [C]d [C]i [C]r [C]e [C]c [C]t O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
magnitude [C]m [C]a [C]g [C]n [C]i [C]t [C]u [C]d [C]e O 
of [C]o [C]f O 
glucocorticoid-mediated [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
of [C]o [C]f O 
GS [C]G [C]S O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
assayed [C]a [C]s [C]s [C]a [C]y [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
cell [C]c [C]e [C]l [C]l B-cell_type 
specimen [C]s [C]p [C]e [C]c [C]i [C]m [C]e [C]n E-cell_type 
. [C]. O 

Moreover [C]M [C]o [C]r [C]e [C]o [C]v [C]e [C]r O 
, [C], O 
the [C]t [C]h [C]e O 
basal [C]b [C]a [C]s [C]a [C]l O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
enzyme [C]e [C]n [C]z [C]y [C]m [C]e S-protein 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
in [C]i [C]n O 
cells [C]c [C]e [C]l [C]l [C]s O 
prior [C]p [C]r [C]i [C]o [C]r O 
to [C]t [C]o O 
exposure [C]e [C]x [C]p [C]o [C]s [C]u [C]r [C]e O 
to [C]t [C]o O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
negatively [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e [C]l [C]y O 
with [C]w [C]i [C]t [C]h O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
density [C]d [C]e [C]n [C]s [C]i [C]t [C]y O 
. [C]. O 

It [C]I [C]t O 
is [C]i [C]s O 
suggested [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
steroid-inducible [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]- [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e B-protein 
GS [C]G [C]S E-protein 
in [C]i [C]n O 
ALL [C]A [C]L [C]L B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
may [C]m [C]a [C]y O 
prove [C]p [C]r [C]o [C]v [C]e O 
to [C]t [C]o O 
be [C]b [C]e O 
a [C]a O 
marker [C]m [C]a [C]r [C]k [C]e [C]r O 
for [C]f [C]o [C]r O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
sites [C]s [C]i [C]t [C]e [C]s E-protein 
. [C]. O 

Binding [C]B [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
progestins [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]i [C]n [C]s O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
. [C]. O 

Correlation [C]C [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
to [C]t [C]o O 
their [C]t [C]h [C]e [C]i [C]r O 
glucocorticoid-like [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]l [C]i [C]k [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
on [C]o [C]n O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
functions [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

A [C]A O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
physiological [C]p [C]h [C]y [C]s [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
and [C]a [C]n [C]d O 
synthetic [C]s [C]y [C]n [C]t [C]h [C]e [C]t [C]i [C]c O 
progestins [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]i [C]n [C]s O 
were [C]w [C]e [C]r [C]e O 
tested [C]t [C]e [C]s [C]t [C]e [C]d O 
for [C]f [C]o [C]r O 
their [C]t [C]h [C]e [C]i [C]r O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
to [C]t [C]o O 
compete [C]c [C]o [C]m [C]p [C]e [C]t [C]e O 
with [C]w [C]i [C]t [C]h O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
their [C]t [C]h [C]e [C]i [C]r O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
to [C]t [C]o O 
elicit [C]e [C]l [C]i [C]c [C]i [C]t O 
glucocorticoid-like [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]l [C]i [C]k [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
. [C]. O 

As [C]A [C]s O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
reference [C]r [C]e [C]f [C]e [C]r [C]e [C]n [C]c [C]e O 
compound [C]c [C]o [C]m [C]p [C]o [C]u [C]n [C]d O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
( [C]( O 
relative [C]r [C]e [C]l [C]a [C]t [C]i [C]v [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
defined [C]d [C]e [C]f [C]i [C]n [C]e [C]d O 
as [C]a [C]s O 
100 [C]1 [C]0 [C]0 O 
% [C]% O 
) [C]) O 
, [C], O 
two [C]t [C]w [C]o O 
potent [C]p [C]o [C]t [C]e [C]n [C]t O 
synthetic [C]s [C]y [C]n [C]t [C]h [C]e [C]t [C]i [C]c O 
progestins [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]i [C]n [C]s O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
pregnane-type [C]p [C]r [C]e [C]g [C]n [C]a [C]n [C]e [C]- [C]t [C]y [C]p [C]e O 
structure [C]s [C]t [C]r [C]u [C]c [C]t [C]u [C]r [C]e O 
, [C], O 
megestrol [C]m [C]e [C]g [C]e [C]s [C]t [C]r [C]o [C]l O 
acetate [C]a [C]c [C]e [C]t [C]a [C]t [C]e O 
and [C]a [C]n [C]d O 
medroxyprogesterone [C]m [C]e [C]d [C]r [C]o [C]x [C]y [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
acetate [C]a [C]c [C]e [C]t [C]a [C]t [C]e O 
, [C], O 
were [C]w [C]e [C]r [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
display [C]d [C]i [C]s [C]p [C]l [C]a [C]y O 
a [C]a O 
considerable [C]c [C]o [C]n [C]s [C]i [C]d [C]e [C]r [C]a [C]b [C]l [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
towards [C]t [C]o [C]w [C]a [C]r [C]d [C]s O 
the [C]t [C]h [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
( [C]( O 
46 [C]4 [C]6 O 
and [C]a [C]n [C]d O 
42 [C]4 [C]2 O 
% [C]% O 
, [C], O 
respectively [C]r [C]e [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
relative [C]r [C]e [C]l [C]a [C]t [C]i [C]v [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
naturally [C]n [C]a [C]t [C]u [C]r [C]a [C]l [C]l [C]y O 
occurring [C]o [C]c [C]c [C]u [C]r [C]r [C]i [C]n [C]g O 
ligand [C]l [C]i [C]g [C]a [C]n [C]d O 
, [C], O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
, [C], O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
was [C]w [C]a [C]s O 
clearly [C]c [C]l [C]e [C]a [C]r [C]l [C]y O 
lower [C]l [C]o [C]w [C]e [C]r O 
( [C]( O 
25 [C]2 [C]5 O 
% [C]% O 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
effective [C]e [C]f [C]f [C]e [C]c [C]t [C]i [C]v [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
medroxyprogesterone [C]m [C]e [C]d [C]r [C]o [C]x [C]y [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
acetate [C]a [C]c [C]e [C]t [C]a [C]t [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
was [C]w [C]a [C]s O 
confirmed [C]c [C]o [C]n [C]f [C]i [C]r [C]m [C]e [C]d O 
by [C]b [C]y O 
direct [C]d [C]i [C]r [C]e [C]c [C]t O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
utilizing [C]u [C]t [C]i [C]l [C]i [C]z [C]i [C]n [C]g O 
a [C]a O 
tritiated [C]t [C]r [C]i [C]t [C]i [C]a [C]t [C]e [C]d O 
derivative [C]d [C]e [C]r [C]i [C]v [C]a [C]t [C]i [C]v [C]e O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
. [C]. O 

No [C]N [C]o O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
existence [C]e [C]x [C]i [C]s [C]t [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
a [C]a O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
progesterone [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]e [C]r [C]o [C]n [C]e B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
was [C]w [C]a [C]s O 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
as [C]a [C]s O 
judged [C]j [C]u [C]d [C]g [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
of [C]o [C]f O 
competition [C]c [C]o [C]m [C]p [C]e [C]t [C]i [C]t [C]i [C]o [C]n O 
experiments [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]s O 
where [C]w [C]h [C]e [C]r [C]e O 
a [C]a O 
progesterone [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
receptor-specific [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
ligand [C]l [C]i [C]g [C]a [C]n [C]d O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
Org [C]O [C]r [C]g O 
2058 [C]2 [C]0 [C]5 [C]8 O 
was [C]w [C]a [C]s O 
used [C]u [C]s [C]e [C]d O 
. [C]. O 

Medroxyprogesterone [C]M [C]e [C]d [C]r [C]o [C]x [C]y [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
acetate [C]a [C]c [C]e [C]t [C]a [C]t [C]e O 
and [C]a [C]n [C]d O 
megestrol [C]m [C]e [C]g [C]e [C]s [C]t [C]r [C]o [C]l O 
acetate [C]a [C]c [C]e [C]t [C]a [C]t [C]e O 
also [C]a [C]l [C]s [C]o O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
glucocorticoid-like [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]l [C]i [C]k [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e S-cell_type 
functions [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
included [C]i [C]n [C]c [C]l [C]u [C]d [C]e [C]d O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
proliferative [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l B-protein 
mitogens [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]s E-protein 
concanavalin [C]c [C]o [C]n [C]c [C]a [C]n [C]a [C]v [C]a [C]l [C]i [C]n B-protein 
A [C]A E-protein 
and [C]a [C]n [C]d O 
phytohaemagglutinin [C]p [C]h [C]y [C]t [C]o [C]h [C]a [C]e [C]m [C]a [C]g [C]g [C]l [C]u [C]t [C]i [C]n [C]i [C]n S-protein 
and [C]a [C]n [C]d O 
an [C]a [C]n O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
accumulation [C]a [C]c [C]c [C]u [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n B-cell_type 
secreting [C]s [C]e [C]c [C]r [C]e [C]t [C]i [C]n [C]g I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
pokeweed [C]p [C]o [C]k [C]e [C]w [C]e [C]e [C]d B-cell_line 
mitogen-stimulated [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d I-cell_line 
cultures [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]s E-cell_line 
. [C]. O 

The [C]T [C]h [C]e O 
progestin [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]i [C]n O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
appears [C]a [C]p [C]p [C]e [C]a [C]r [C]s O 
to [C]t [C]o O 
be [C]b [C]e O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
a [C]a O 
radiosensitive [C]r [C]a [C]d [C]i [C]o [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
( [C]( O 
suppressor [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]o [C]r O 
) [C]) O 
subpopulation [C]s [C]u [C]b [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
T [C]T B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
the [C]t [C]h [C]e O 
synthetic [C]s [C]y [C]n [C]t [C]h [C]e [C]t [C]i [C]c O 
progestins [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]i [C]n [C]s O 
related [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
structurally [C]s [C]t [C]r [C]u [C]c [C]t [C]u [C]r [C]a [C]l [C]l [C]y O 
to [C]t [C]o O 
19-nortestosterone [C]1 [C]9 [C]- [C]n [C]o [C]r [C]t [C]e [C]s [C]t [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
, [C], O 
norethisterone [C]n [C]o [C]r [C]e [C]t [C]h [C]i [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
and [C]a [C]n [C]d O 
d-norgestrel [C]d [C]- [C]n [C]o [C]r [C]g [C]e [C]s [C]t [C]r [C]e [C]l O 
, [C], O 
were [C]w [C]e [C]r [C]e O 
virtually [C]v [C]i [C]r [C]t [C]u [C]a [C]l [C]l [C]y O 
devoid [C]d [C]e [C]v [C]o [C]i [C]d O 
of [C]o [C]f O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
towards [C]t [C]o [C]w [C]a [C]r [C]d [C]s O 
the [C]t [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
nor [C]n [C]o [C]r O 
did [C]d [C]i [C]d O 
they [C]t [C]h [C]e [C]y O 
measurably [C]m [C]e [C]a [C]s [C]u [C]r [C]a [C]b [C]l [C]y O 
influence [C]i [C]n [C]f [C]l [C]u [C]e [C]n [C]c [C]e O 
the [C]t [C]h [C]e O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e S-cell_type 
functions [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
certain [C]c [C]e [C]r [C]t [C]a [C]i [C]n O 
progestins [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]i [C]n [C]s O 
in [C]i [C]n O 
common [C]c [C]o [C]m [C]m [C]o [C]n O 
clinical [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
use [C]u [C]s [C]e O 
probably [C]p [C]r [C]o [C]b [C]a [C]b [C]l [C]y O 
possess [C]p [C]o [C]s [C]s [C]e [C]s [C]s O 
inherent [C]i [C]n [C]h [C]e [C]r [C]e [C]n [C]t O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
side [C]s [C]i [C]d [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
attributable [C]a [C]t [C]t [C]r [C]i [C]b [C]u [C]t [C]a [C]b [C]l [C]e O 
to [C]t [C]o O 
this [C]t [C]h [C]i [C]s O 
character [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r O 
( [C]( O 
e.g. [C]e [C]. [C]g [C]. O 
suppression [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
pituitary-adrenal [C]p [C]i [C]t [C]u [C]i [C]t [C]a [C]r [C]y [C]- [C]a [C]d [C]r [C]e [C]n [C]a [C]l O 
axis [C]a [C]x [C]i [C]s O 
) [C]) O 
might [C]m [C]i [C]g [C]h [C]t O 
be [C]b [C]e O 
expected [C]e [C]x [C]p [C]e [C]c [C]t [C]e [C]d O 
when [C]w [C]h [C]e [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
compounds [C]c [C]o [C]m [C]p [C]o [C]u [C]n [C]d [C]s O 
are [C]a [C]r [C]e O 
used [C]u [C]s [C]e [C]d O 
in [C]i [C]n O 
pharmacological [C]p [C]h [C]a [C]r [C]m [C]a [C]c [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
doses [C]d [C]o [C]s [C]e [C]s O 
. [C]. O 

Metabolic [C]M [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]c O 
and [C]a [C]n [C]d O 
ultrastructural [C]u [C]l [C]t [C]r [C]a [C]s [C]t [C]r [C]u [C]c [C]t [C]u [C]r [C]a [C]l O 
aspects [C]a [C]s [C]p [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
lysis [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c B-cell_type 
lymphocytic [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]i [C]c I-cell_type 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
by [C]b [C]y O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
. [C]. O 

Human [C]H [C]u [C]m [C]a [C]n B-cell_type 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c I-cell_type 
lymphocytic [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]i [C]c I-cell_type 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a I-cell_type 
( [C]( I-cell_type 
CLL [C]C [C]L [C]L I-cell_type 
) [C]) I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
like [C]l [C]i [C]k [C]e O 
prothymocytes [C]p [C]r [C]o [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
and [C]a [C]n [C]d O 
immunoactivated [C]i [C]m [C]m [C]u [C]n [C]o [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-cell_type 
T-lymphocytes [C]T [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
are [C]a [C]r [C]e O 
readily [C]r [C]e [C]a [C]d [C]i [C]l [C]y O 
lysed [C]l [C]y [C]s [C]e [C]d O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
by [C]b [C]y O 
pharmacological [C]p [C]h [C]a [C]r [C]m [C]a [C]c [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
are [C]a [C]r [C]e O 
unaffected [C]u [C]n [C]a [C]f [C]f [C]e [C]c [C]t [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e S-protein 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
, [C], O 
metabolic [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]c O 
and [C]a [C]n [C]d O 
ultrastructural [C]u [C]l [C]t [C]r [C]a [C]s [C]t [C]r [C]u [C]c [C]t [C]u [C]r [C]a [C]l O 
aspects [C]a [C]s [C]p [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cortisol-induced [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
killing [C]k [C]i [C]l [C]l [C]i [C]n [C]g O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
of [C]o [C]f O 
CLL [C]C [C]L [C]L B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
are [C]a [C]r [C]e O 
recorded [C]r [C]e [C]c [C]o [C]r [C]d [C]e [C]d O 
. [C]. O 

In [C]I [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
lysis [C]l [C]y [C]s [C]i [C]s O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
temperature [C]t [C]e [C]m [C]p [C]e [C]r [C]a [C]t [C]u [C]r [C]e O 
dependent [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
was [C]w [C]a [C]s O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
only [C]o [C]n [C]l [C]y O 
after [C]a [C]f [C]t [C]e [C]r O 
6 [C]6 O 
to [C]t [C]o O 
8 [C]8 O 
hr [C]h [C]r O 
incubation [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
by [C]b [C]y O 
means [C]m [C]e [C]a [C]n [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
trypan [C]t [C]r [C]y [C]p [C]a [C]n O 
blue [C]b [C]l [C]u [C]e O 
exclusion [C]e [C]x [C]c [C]l [C]u [C]s [C]i [C]o [C]n O 
test [C]t [C]e [C]s [C]t O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
30 [C]3 [C]0 O 
min [C]m [C]i [C]n O 
of [C]o [C]f O 
incubation [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
at [C]a [C]t O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
37 [C]3 [C]7 O 
degrees [C]d [C]e [C]g [C]r [C]e [C]e [C]s O 
or [C]o [C]r O 
4 [C]4 O 
degrees [C]d [C]e [C]g [C]r [C]e [C]e [C]s O 
followed [C]f [C]o [C]l [C]l [C]o [C]w [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
removal [C]r [C]e [C]m [C]o [C]v [C]a [C]l O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e S-protein 
was [C]w [C]a [C]s O 
still [C]s [C]t [C]i [C]l [C]l O 
sufficient [C]s [C]u [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
to [C]t [C]o O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
the [C]t [C]h [C]e O 
lytic [C]l [C]y [C]t [C]i [C]c O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
. [C]. O 

Ultrastructural [C]U [C]l [C]t [C]r [C]a [C]s [C]t [C]r [C]u [C]c [C]t [C]u [C]r [C]a [C]l O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
sequential [C]s [C]e [C]q [C]u [C]e [C]n [C]t [C]i [C]a [C]l O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
cytoplasm [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m O 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
swelling [C]s [C]w [C]e [C]l [C]l [C]i [C]n [C]g O 
of [C]o [C]f O 
mitochondria [C]m [C]i [C]t [C]o [C]c [C]h [C]o [C]n [C]d [C]r [C]i [C]a O 
and [C]a [C]n [C]d O 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c O 
decompartmentalization [C]d [C]e [C]c [C]o [C]m [C]p [C]a [C]r [C]t [C]m [C]e [C]n [C]t [C]a [C]l [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
followed [C]f [C]o [C]l [C]l [C]o [C]w [C]e [C]d O 
by [C]b [C]y O 
loss [C]l [C]o [C]s [C]s O 
of [C]o [C]f O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
microvilli [C]m [C]i [C]c [C]r [C]o [C]v [C]i [C]l [C]l [C]i O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
appearance [C]a [C]p [C]p [C]e [C]a [C]r [C]a [C]n [C]c [C]e O 
of [C]o [C]f O 
`` [C]` [C]` O 
holes [C]h [C]o [C]l [C]e [C]s O 
'' [C]' [C]' O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
cell [C]c [C]e [C]l [C]l O 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
, [C], O 
and [C]a [C]n [C]d O 
subsequent [C]s [C]u [C]b [C]s [C]e [C]q [C]u [C]e [C]n [C]t O 
condensation [C]c [C]o [C]n [C]d [C]e [C]n [C]s [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-DNA 
chromatin [C]c [C]h [C]r [C]o [C]m [C]a [C]t [C]i [C]n E-DNA 
. [C]. O 

The [C]T [C]h [C]e O 
large [C]l [C]a [C]r [C]g [C]e O 
holes [C]h [C]o [C]l [C]e [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
appearing [C]a [C]p [C]p [C]e [C]a [C]r [C]i [C]n [C]g O 
after [C]a [C]f [C]t [C]e [C]r O 
6 [C]6 O 
hr [C]h [C]r O 
of [C]o [C]f O 
incubation [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e S-protein 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
the [C]t [C]h [C]e O 
cause [C]c [C]a [C]u [C]s [C]e O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
penetration [C]p [C]e [C]n [C]e [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
viable [C]v [C]i [C]a [C]b [C]l [C]e O 
stain [C]s [C]t [C]a [C]i [C]n O 
into [C]i [C]n [C]t [C]o O 
the [C]t [C]h [C]e O 
dead [C]d [C]e [C]a [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
as [C]a [C]s O 
seen [C]s [C]e [C]e [C]n O 
by [C]b [C]y O 
light [C]l [C]i [C]g [C]h [C]t O 
microscopy [C]m [C]i [C]c [C]r [C]o [C]s [C]c [C]o [C]p [C]y O 
. [C]. O 

Addition [C]A [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
metabolic [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]c O 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
actinomycin [C]a [C]c [C]t [C]i [C]n [C]o [C]m [C]y [C]c [C]i [C]n O 
D [C]D O 
, [C], O 
puromycin [C]p [C]u [C]r [C]o [C]m [C]y [C]c [C]i [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
cycloheximide [C]c [C]y [C]c [C]l [C]o [C]h [C]e [C]x [C]i [C]m [C]i [C]d [C]e O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
administration [C]a [C]d [C]m [C]i [C]n [C]i [C]s [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cell [C]c [C]e [C]l [C]l O 
lysis [C]l [C]y [C]s [C]i [C]s O 
. [C]. O 

An [C]A [C]n O 
excess [C]e [C]x [C]c [C]e [C]s [C]s O 
of [C]o [C]f O 
an [C]a [C]n O 
antagonist [C]a [C]n [C]t [C]a [C]g [C]o [C]n [C]i [C]s [C]t O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
cortexolone [C]c [C]o [C]r [C]t [C]e [C]x [C]o [C]l [C]o [C]n [C]e O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
inhibit [C]i [C]n [C]h [C]i [C]b [C]i [C]t O 
the [C]t [C]h [C]e O 
cortisol-induced [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
cytolysis [C]c [C]y [C]t [C]o [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
CLL [C]C [C]L [C]L B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

It [C]I [C]t O 
is [C]i [C]s O 
suggested [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
glucocorticoid-induced [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
lysis [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
CLL [C]C [C]L [C]L I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
is [C]i [C]s O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
phenomenon [C]p [C]h [C]e [C]n [C]o [C]m [C]e [C]n [C]o [C]n O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
rat [C]r [C]a [C]t B-cell_type 
or [C]o [C]r I-cell_type 
murine [C]m [C]u [C]r [C]i [C]n [C]e I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
resulting [C]r [C]e [C]s [C]u [C]l [C]t [C]i [C]n [C]g O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
appears [C]a [C]p [C]p [C]e [C]a [C]r [C]s O 
to [C]t [C]o O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
gene [C]g [C]e [C]n [C]e S-DNA 
( [C]( O 
s [C]s O 
) [C]) O 
the [C]t [C]h [C]e O 
products [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]s O 
of [C]o [C]f O 
which [C]w [C]h [C]i [C]c [C]h O 
eventually [C]e [C]v [C]e [C]n [C]t [C]u [C]a [C]l [C]l [C]y O 
cause [C]c [C]a [C]u [C]s [C]e O 
cytolysis [C]c [C]y [C]t [C]o [C]l [C]y [C]s [C]i [C]s O 
. [C]. O 

Glucocorticoid [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d O 
tumors [C]t [C]u [C]m [C]o [C]r [C]s O 
. [C]. O 

There [C]T [C]h [C]e [C]r [C]e O 
is [C]i [C]s O 
a [C]a O 
range [C]r [C]a [C]n [C]g [C]e O 
of [C]o [C]f O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
numbers [C]n [C]u [C]m [C]b [C]e [C]r [C]s O 
seen [C]s [C]e [C]e [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
subclasses [C]s [C]u [C]b [C]c [C]l [C]a [C]s [C]s [C]e [C]s O 
of [C]o [C]f O 
acute [C]a [C]c [C]u [C]t [C]e O 
lymphatic [C]l [C]y [C]m [C]p [C]h [C]a [C]t [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
( [C]( O 
ALL [C]A [C]L [C]L O 
) [C]) O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
variability [C]v [C]a [C]r [C]i [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
can [C]c [C]a [C]n O 
not [C]n [C]o [C]t O 
be [C]b [C]e O 
explained [C]e [C]x [C]p [C]l [C]a [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
known [C]k [C]n [C]o [C]w [C]n O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
cell [C]c [C]e [C]l [C]l O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
an [C]a [C]n O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
, [C], O 
since [C]s [C]i [C]n [C]c [C]e O 
the [C]t [C]h [C]e O 
tumors [C]t [C]u [C]m [C]o [C]r [C]s O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
highest [C]h [C]i [C]g [C]h [C]e [C]s [C]t O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
fraction [C]f [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
( [C]( O 
i.e. [C]i [C]. [C]e [C]. O 
, [C], O 
Burkitt [C]B [C]u [C]r [C]k [C]i [C]t [C]t O 
's [C]' [C]s O 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a O 
and [C]a [C]n [C]d O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
) [C]) O 
tend [C]t [C]e [C]n [C]d O 
to [C]t [C]o O 
have [C]h [C]a [C]v [C]e O 
lower [C]l [C]o [C]w [C]e [C]r O 
average [C]a [C]v [C]e [C]r [C]a [C]g [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
numbers [C]n [C]u [C]m [C]b [C]e [C]r [C]s O 
than [C]t [C]h [C]a [C]n O 
do [C]d [C]o O 
tumors [C]t [C]u [C]m [C]o [C]r [C]s O 
with [C]w [C]i [C]t [C]h O 
lower [C]l [C]o [C]w [C]e [C]r O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
fractions [C]f [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
common [C]c [C]o [C]m [C]m [C]o [C]n O 
ALL [C]A [C]L [C]L O 
. [C]. O 

All [C]A [C]l [C]l O 
clinical [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
specimens [C]s [C]p [C]e [C]c [C]i [C]m [C]e [C]n [C]s O 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
lymphatic [C]l [C]y [C]m [C]p [C]h [C]a [C]t [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
have [C]h [C]a [C]v [C]e O 
some [C]s [C]o [C]m [C]e O 
measurable [C]m [C]e [C]a [C]s [C]u [C]r [C]a [C]b [C]l [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
; [C]; O 
therefore [C]t [C]h [C]e [C]r [C]e [C]f [C]o [C]r [C]e O 
, [C], O 
the [C]t [C]h [C]e O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
seen [C]s [C]e [C]e [C]n O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
can [C]c [C]a [C]n O 
not [C]n [C]o [C]t O 
be [C]b [C]e O 
explained [C]e [C]x [C]p [C]l [C]a [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
lack [C]l [C]a [C]c [C]k O 
of [C]o [C]f O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
there [C]t [C]h [C]e [C]r [C]e O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
a [C]a O 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
in [C]i [C]n O 
our [C]o [C]u [C]r O 
hands [C]h [C]a [C]n [C]d [C]s O 
, [C], O 
with [C]w [C]i [C]t [C]h O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
level [C]l [C]e [C]v [C]e [C]l O 
and [C]a [C]n [C]d O 
prognosis [C]p [C]r [C]o [C]g [C]n [C]o [C]s [C]i [C]s O 
. [C]. O 

On [C]O [C]n O 
the [C]t [C]h [C]e O 
basis [C]b [C]a [C]s [C]i [C]s O 
of [C]o [C]f O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
models [C]m [C]o [C]d [C]e [C]l [C]s O 
, [C], O 
it [C]i [C]t O 
is [C]i [C]s O 
proposed [C]p [C]r [C]o [C]p [C]o [C]s [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
perhaps [C]p [C]e [C]r [C]h [C]a [C]p [C]s O 
the [C]t [C]h [C]e O 
high [C]h [C]i [C]g [C]h B-cell_line 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
( [C]( O 
i.e. [C]i [C]. [C]e [C]. O 
, [C], O 
common [C]c [C]o [C]m [C]m [C]o [C]n O 
ALL [C]A [C]L [C]L O 
of [C]o [C]f O 
childhood [C]c [C]h [C]i [C]l [C]d [C]h [C]o [C]o [C]d O 
) [C]) O 
have [C]h [C]a [C]v [C]e O 
relative [C]r [C]e [C]l [C]a [C]t [C]i [C]v [C]e O 
stability [C]s [C]t [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
their [C]t [C]h [C]e [C]i [C]r O 
genetic [C]g [C]e [C]n [C]e [C]t [C]i [C]c O 
material [C]m [C]a [C]t [C]e [C]r [C]i [C]a [C]l O 
making [C]m [C]a [C]k [C]i [C]n [C]g O 
glucocorticoid-resistant [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]t O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
less [C]l [C]e [C]s [C]s O 
likely [C]l [C]i [C]k [C]e [C]l [C]y O 
to [C]t [C]o O 
occur [C]o [C]c [C]c [C]u [C]r O 
in [C]i [C]n O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
these [C]t [C]h [C]e [C]s [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
than [C]t [C]h [C]a [C]n O 
in [C]i [C]n O 
low-receptor [C]l [C]o [C]w [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
( [C]( O 
i.e. [C]i [C]. [C]e [C]. O 
, [C], O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
) [C]) O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
greater [C]g [C]r [C]e [C]a [C]t [C]e [C]r O 
genetic [C]g [C]e [C]n [C]e [C]t [C]i [C]c O 
variability [C]v [C]a [C]r [C]i [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
low-receptor [C]l [C]o [C]w [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r B-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
could [C]c [C]o [C]u [C]l [C]d O 
account [C]a [C]c [C]c [C]o [C]u [C]n [C]t O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
earlier [C]e [C]a [C]r [C]l [C]i [C]e [C]r O 
emergence [C]e [C]m [C]e [C]r [C]g [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
clinical [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
in [C]i [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

[ [C][ O 
Tumor [C]T [C]u [C]m [C]o [C]r O 
histology [C]h [C]i [C]s [C]t [C]o [C]l [C]o [C]g [C]y O 
and [C]a [C]n [C]d O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
carcinoma [C]c [C]a [C]r [C]c [C]i [C]n [C]o [C]m [C]a O 
] [C]] O 

In [C]I [C]n O 
Specimens [C]S [C]p [C]e [C]c [C]i [C]m [C]e [C]n [C]s O 
of [C]o [C]f O 
115 [C]1 [C]1 [C]5 O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
4 [C]4 O 
tumorparameters [C]t [C]u [C]m [C]o [C]r [C]p [C]a [C]r [C]a [C]m [C]e [C]t [C]e [C]r [C]s O 
( [C]( O 
tumorsize [C]t [C]u [C]m [C]o [C]r [C]s [C]i [C]z [C]e O 
, [C], O 
tumorboder [C]t [C]u [C]m [C]o [C]r [C]b [C]o [C]d [C]e [C]r O 
, [C], O 
nucleargrade [C]n [C]u [C]c [C]l [C]e [C]a [C]r [C]g [C]r [C]a [C]d [C]e O 
, [C], O 
lymphocytic [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]i [C]c O 
stromal [C]s [C]t [C]r [C]o [C]m [C]a [C]l O 
reaction [C]r [C]e [C]a [C]c [C]t [C]i [C]o [C]n O 
) [C]) O 
3 [C]3 O 
features [C]f [C]e [C]a [C]t [C]u [C]r [C]e [C]s O 
of [C]o [C]f O 
regional [C]r [C]e [C]g [C]i [C]o [C]n [C]a [C]l O 
lymphnodes [C]l [C]y [C]m [C]p [C]h [C]n [C]o [C]d [C]e [C]s O 
( [C]( O 
sinushistiocytosis [C]s [C]i [C]n [C]u [C]s [C]h [C]i [C]s [C]t [C]i [C]o [C]c [C]y [C]t [C]o [C]s [C]i [C]s O 
, [C], O 
T-cellreaction [C]T [C]- [C]c [C]e [C]l [C]l [C]r [C]e [C]a [C]c [C]t [C]i [C]o [C]n O 
, [C], O 
lymphnode [C]l [C]y [C]m [C]p [C]h [C]n [C]o [C]d [C]e O 
metastases [C]m [C]e [C]t [C]a [C]s [C]t [C]a [C]s [C]e [C]s O 
) [C]) O 
and [C]a [C]n [C]d O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n B-protein 
and [C]a [C]n [C]d I-protein 
progesteron [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]e [C]r [C]o [C]n I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
were [C]w [C]e [C]r [C]e O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
. [C]. O 

A [C]A O 
strong [C]s [C]t [C]r [C]o [C]n [C]g O 
sinushistiocytosis [C]s [C]i [C]n [C]u [C]s [C]h [C]i [C]s [C]t [C]i [C]o [C]c [C]y [C]t [C]o [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
T-cellreaction [C]T [C]- [C]c [C]e [C]l [C]l [C]r [C]e [C]a [C]c [C]t [C]i [C]o [C]n O 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
verified [C]v [C]e [C]r [C]i [C]f [C]i [C]e [C]d O 
mainly [C]m [C]a [C]i [C]n [C]l [C]y O 
in [C]i [C]n O 
metastases [C]m [C]e [C]t [C]a [C]s [C]t [C]a [C]s [C]e [C]s O 
in [C]i [C]n O 
free [C]f [C]r [C]e [C]e O 
lymphnodes [C]l [C]y [C]m [C]p [C]h [C]n [C]o [C]d [C]e [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
does [C]d [C]o [C]e [C]s O 
not [C]n [C]o [C]t O 
correlate [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e O 
with [C]w [C]i [C]t [C]h O 
histological [C]h [C]i [C]s [C]t [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
parameters [C]p [C]a [C]r [C]a [C]m [C]e [C]t [C]e [C]r [C]s O 

Aldosterone-receptor [C]A [C]l [C]d [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r S-protein 
deficiency [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
in [C]i [C]n O 
pseudohypoaldosteronism [C]p [C]s [C]e [C]u [C]d [C]o [C]h [C]y [C]p [C]o [C]a [C]l [C]d [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]i [C]s [C]m O 
. [C]. O 

Pseudohypoaldosteronism [C]P [C]s [C]e [C]u [C]d [C]o [C]h [C]y [C]p [C]o [C]a [C]l [C]d [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]i [C]s [C]m O 
, [C], O 
a [C]a O 
syndrome [C]s [C]y [C]n [C]d [C]r [C]o [C]m [C]e O 
characterized [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]d O 
by [C]b [C]y O 
salt [C]s [C]a [C]l [C]t O 
wasting [C]w [C]a [C]s [C]t [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
failure [C]f [C]a [C]i [C]l [C]u [C]r [C]e O 
to [C]t [C]o O 
thrive [C]t [C]h [C]r [C]i [C]v [C]e O 
, [C], O 
usually [C]u [C]s [C]u [C]a [C]l [C]l [C]y O 
presents [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]s O 
in [C]i [C]n O 
infancy [C]i [C]n [C]f [C]a [C]n [C]c [C]y O 
as [C]a [C]s O 
high [C]h [C]i [C]g [C]h O 
urinary [C]u [C]r [C]i [C]n [C]a [C]r [C]y O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
sodium [C]s [C]o [C]d [C]i [C]u [C]m O 
despite [C]d [C]e [C]s [C]p [C]i [C]t [C]e O 
hyponatremia [C]h [C]y [C]p [C]o [C]n [C]a [C]t [C]r [C]e [C]m [C]i [C]a O 
, [C], O 
hyperkalemia [C]h [C]y [C]p [C]e [C]r [C]k [C]a [C]l [C]e [C]m [C]i [C]a O 
, [C], O 
hyperreninemia [C]h [C]y [C]p [C]e [C]r [C]r [C]e [C]n [C]i [C]n [C]e [C]m [C]i [C]a O 
, [C], O 
and [C]a [C]n [C]d O 
elevated [C]e [C]l [C]e [C]v [C]a [C]t [C]e [C]d O 
aldosterone [C]a [C]l [C]d [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
this [C]t [C]h [C]i [C]s O 
syndrome [C]s [C]y [C]n [C]d [C]r [C]o [C]m [C]e O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
possibility [C]p [C]o [C]s [C]s [C]i [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
abnormal [C]a [C]b [C]n [C]o [C]r [C]m [C]a [C]l B-protein 
Type [C]T [C]y [C]p [C]e I-protein 
I [C]I E-protein 
or [C]o [C]r O 
`` [C]` [C]` B-protein 
mineralocorticoid-like [C]m [C]i [C]n [C]e [C]r [C]a [C]l [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]l [C]i [C]k [C]e I-protein 
'' [C]' [C]' I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
have [C]h [C]a [C]v [C]e O 
intrinsic [C]i [C]n [C]t [C]r [C]i [C]n [C]s [C]i [C]c O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
specificity [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]i [C]t [C]y O 
indistinguishable [C]i [C]n [C]d [C]i [C]s [C]t [C]i [C]n [C]g [C]u [C]i [C]s [C]h [C]a [C]b [C]l [C]e O 
from [C]f [C]r [C]o [C]m O 
that [C]t [C]h [C]a [C]t O 
of [C]o [C]f O 
renal [C]r [C]e [C]n [C]a [C]l B-protein 
mineralocorticoid [C]m [C]i [C]n [C]e [C]r [C]a [C]l [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
and [C]a [C]n [C]d O 
are [C]a [C]r [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
many [C]m [C]a [C]n [C]y O 
tissues [C]t [C]i [C]s [C]s [C]u [C]e [C]s O 
and [C]a [C]n [C]d O 
cells [C]c [C]e [C]l [C]l [C]s S-cell_type 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_type 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
three [C]t [C]h [C]r [C]e [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
pseudohypoaldosteronism [C]p [C]s [C]e [C]u [C]d [C]o [C]h [C]y [C]p [C]o [C]a [C]l [C]d [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]i [C]s [C]m O 
: [C]: O 
the [C]t [C]h [C]e O 
28-year-old [C]2 [C]8 [C]- [C]y [C]e [C]a [C]r [C]- [C]o [C]l [C]d O 
index [C]i [C]n [C]d [C]e [C]x O 
case [C]c [C]a [C]s [C]e O 
in [C]i [C]n O 
Melbourne [C]M [C]e [C]l [C]b [C]o [C]u [C]r [C]n [C]e O 
( [C]( O 
Patient [C]P [C]a [C]t [C]i [C]e [C]n [C]t O 
1 [C]1 O 
) [C]) O 
and [C]a [C]n [C]d O 
two [C]t [C]w [C]o O 
siblings [C]s [C]i [C]b [C]l [C]i [C]n [C]g [C]s O 
in [C]i [C]n O 
Munich [C]M [C]u [C]n [C]i [C]c [C]h O 
, [C], O 
eight [C]e [C]i [C]g [C]h [C]t O 
and [C]a [C]n [C]d O 
two [C]t [C]w [C]o O 
years [C]y [C]e [C]a [C]r [C]s O 
of [C]o [C]f O 
age [C]a [C]g [C]e O 
( [C]( O 
Patients [C]P [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
2 [C]2 O 
and [C]a [C]n [C]d O 
3 [C]3 O 
) [C]) O 
; [C]; O 
clinically [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l [C]l [C]y O 
, [C], O 
Patient [C]P [C]a [C]t [C]i [C]e [C]n [C]t O 
3 [C]3 O 
had [C]h [C]a [C]d O 
a [C]a O 
less [C]l [C]e [C]s [C]s O 
severe [C]s [C]e [C]v [C]e [C]r [C]e O 
case [C]c [C]a [C]s [C]e O 
than [C]t [C]h [C]a [C]n O 
his [C]h [C]i [C]s O 
sister [C]s [C]i [C]s [C]t [C]e [C]r O 
. [C]. O 

Percoll-separated [C]P [C]e [C]r [C]c [C]o [C]l [C]l [C]- [C]s [C]e [C]p [C]a [C]r [C]a [C]t [C]e [C]d B-cell_type 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l I-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
bound [C]b [C]o [C]u [C]n [C]d O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
aldosterone [C]a [C]l [C]d [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
with [C]w [C]i [C]t [C]h O 
high [C]h [C]i [C]g [C]h O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
( [C]( O 
Kd [C]K [C]d O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
3 [C]3 O 
nM [C]n [C]M O 
) [C]) O 
and [C]a [C]n [C]d O 
limited [C]l [C]i [C]m [C]i [C]t [C]e [C]d O 
capacity [C]c [C]a [C]p [C]a [C]c [C]i [C]t [C]y O 
( [C]( O 
150 [C]1 [C]5 [C]0 O 
to [C]t [C]o O 
600 [C]6 [C]0 [C]0 O 
sites [C]s [C]i [C]t [C]e [C]s O 
per [C]p [C]e [C]r O 
cell [C]c [C]e [C]l [C]l O 
) [C]) O 
. [C]. O 

On [C]O [C]n O 
repeated [C]r [C]e [C]p [C]e [C]a [C]t [C]e [C]d O 
examination [C]e [C]x [C]a [C]m [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
no [C]n [C]o O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
aldosterone [C]a [C]l [C]d [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
from [C]f [C]r [C]o [C]m O 
Patients [C]P [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
1 [C]1 O 
and [C]a [C]n [C]d O 
2 [C]2 O 
; [C]; O 
in [C]i [C]n O 
Patient [C]P [C]a [C]t [C]i [C]e [C]n [C]t O 
3 [C]3 O 
, [C], O 
the [C]t [C]h [C]e O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
were [C]w [C]e [C]r [C]e O 
62 [C]6 [C]2 O 
sites [C]s [C]i [C]t [C]e [C]s O 
per [C]p [C]e [C]r O 
cell [C]c [C]e [C]l [C]l O 
, [C], O 
more [C]m [C]o [C]r [C]e O 
than [C]t [C]h [C]a [C]n O 
2 [C]2 O 
S.D. [C]S [C]. [C]D [C]. O 
below [C]b [C]e [C]l [C]o [C]w O 
those [C]t [C]h [C]o [C]s [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
. [C]. O 

Levels [C]L [C]e [C]v [C]e [C]l [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
parents [C]p [C]a [C]r [C]e [C]n [C]t [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Munich [C]M [C]u [C]n [C]i [C]c [C]h O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
( [C]( O 
first [C]f [C]i [C]r [C]s [C]t O 
cousins [C]c [C]o [C]u [C]s [C]i [C]n [C]s O 
) [C]) O 
were [C]w [C]e [C]r [C]e O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
. [C]. O 

It [C]I [C]t O 
appears [C]a [C]p [C]p [C]e [C]a [C]r [C]s O 
that [C]t [C]h [C]a [C]t O 
pseudohypoaldosteronism [C]p [C]s [C]e [C]u [C]d [C]o [C]h [C]y [C]p [C]o [C]a [C]l [C]d [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]i [C]s [C]m O 
is [C]i [C]s O 
caused [C]c [C]a [C]u [C]s [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
Type [C]T [C]y [C]p [C]e O 
I [C]I O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
defect [C]d [C]e [C]f [C]e [C]c [C]t O 
, [C], O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
defect [C]d [C]e [C]f [C]e [C]c [C]t O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
complete [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e O 
or [C]o [C]r O 
partial [C]p [C]a [C]r [C]t [C]i [C]a [C]l O 
, [C], O 
that [C]t [C]h [C]a [C]t O 
transmission [C]t [C]r [C]a [C]n [C]s [C]m [C]i [C]s [C]s [C]i [C]o [C]n O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
autosomal [C]a [C]u [C]t [C]o [C]s [C]o [C]m [C]a [C]l O 
recessive [C]r [C]e [C]c [C]e [C]s [C]s [C]i [C]v [C]e O 
, [C], O 
and [C]a [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
study [C]s [C]t [C]u [C]d [C]y O 
of [C]o [C]f O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
pseudohypoaldosteronism [C]p [C]s [C]e [C]u [C]d [C]o [C]h [C]y [C]p [C]o [C]a [C]l [C]d [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]i [C]s [C]m O 
may [C]m [C]a [C]y O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
physiologic [C]p [C]h [C]y [C]s [C]i [C]o [C]l [C]o [C]g [C]i [C]c O 
roles [C]r [C]o [C]l [C]e [C]s O 
for [C]f [C]o [C]r O 
Type [C]T [C]y [C]p [C]e B-protein 
I [C]I I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
nonepithelial [C]n [C]o [C]n [C]e [C]p [C]i [C]t [C]h [C]e [C]l [C]i [C]a [C]l O 
tissues [C]t [C]i [C]s [C]s [C]u [C]e [C]s O 
. [C]. O 

Glucocorticoid [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
urokinase-like [C]u [C]r [C]o [C]k [C]i [C]n [C]a [C]s [C]e [C]- [C]l [C]i [C]k [C]e B-protein 
plasminogen [C]p [C]l [C]a [C]s [C]m [C]i [C]n [C]o [C]g [C]e [C]n I-protein 
activators [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
cultured [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]d B-cell_line 
human [C]h [C]u [C]m [C]a [C]n I-cell_line 
lymphoblasts [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]s E-cell_line 
. [C]. O 

Two [C]T [C]w [C]o O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
lymphoblast [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
, [C], O 
LICR-LON-HMy2 [C]L [C]I [C]C [C]R [C]- [C]L [C]O [C]N [C]- [C]H [C]M [C]y [C]2 S-cell_line 
( [C]( O 
HMy2 [C]H [C]M [C]y [C]2 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
) [C]) O 
and [C]a [C]n [C]d O 
GM4672A [C]G [C]M [C]4 [C]6 [C]7 [C]2 [C]A B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
, [C], O 
are [C]a [C]r [C]e O 
moderately [C]m [C]o [C]d [C]e [C]r [C]a [C]t [C]e [C]l [C]y O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
by [C]b [C]y O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
( [C]( O 
1 [C]1 O 
, [C], O 
4-pregnadien-9-fluoro-16 [C]4 [C]- [C]p [C]r [C]e [C]g [C]n [C]a [C]d [C]i [C]e [C]n [C]- [C]9 [C]- [C]f [C]l [C]u [C]o [C]r [C]o [C]- [C]1 [C]6 O 
alpha-methyl-11 [C]a [C]l [C]p [C]h [C]a [C]- [C]m [C]e [C]t [C]h [C]y [C]l [C]- [C]1 [C]1 O 
beta [C]b [C]e [C]t [C]a O 
, [C], O 
17 [C]1 [C]7 O 
alpha [C]a [C]l [C]p [C]h [C]a O 
, [C], O 
21-triol-3 [C]2 [C]1 [C]- [C]t [C]r [C]i [C]o [C]l [C]- [C]3 O 
, [C], O 
20-dione [C]2 [C]0 [C]- [C]d [C]i [C]o [C]n [C]e O 
) [C]) O 
( [C]( O 
Dex [C]D [C]e [C]x O 
) [C]) O 
. [C]. O 

Both [C]B [C]o [C]t [C]h O 
cell [C]c [C]e [C]l [C]l O 
types [C]t [C]y [C]p [C]e [C]s O 
secrete [C]s [C]e [C]c [C]r [C]e [C]t [C]e O 
a [C]a O 
urokinase [C]u [C]r [C]o [C]k [C]i [C]n [C]a [C]s [C]e B-protein 
( [C]( I-protein 
UK [C]U [C]K I-protein 
) [C]) I-protein 
-like [C]- [C]l [C]i [C]k [C]e I-protein 
plasminogen [C]p [C]l [C]a [C]s [C]m [C]i [C]n [C]o [C]g [C]e [C]n I-protein 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r E-protein 
( [C]( O 
PA [C]P [C]A S-protein 
) [C]) O 
. [C]. O 

Treatment [C]T [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
HMy2 [C]H [C]M [C]y [C]2 B-cell_line 
and [C]a [C]n [C]d I-cell_line 
GM4672A [C]G [C]M [C]4 [C]6 [C]7 [C]2 [C]A I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
with [C]w [C]i [C]t [C]h O 
Dex [C]D [C]e [C]x O 
for [C]f [C]o [C]r O 
1-4 [C]1 [C]- [C]4 O 
days [C]d [C]a [C]y [C]s O 
inhibits [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]s O 
extracellular [C]e [C]x [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
PA [C]P [C]A S-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
a [C]a O 
concentration-dependent [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
manner [C]m [C]a [C]n [C]n [C]e [C]r O 
, [C], O 
being [C]b [C]e [C]i [C]n [C]g O 
half-maximal [C]h [C]a [C]l [C]f [C]- [C]m [C]a [C]x [C]i [C]m [C]a [C]l O 
at [C]a [C]t O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
1 [C]1 O 
X [C]X O 
10 [C]1 [C]0 O 
( [C]( O 
-9 [C]- [C]9 O 
) [C]) O 
M [C]M O 
. [C]. O 

Inhibition [C]I [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
PA [C]P [C]A S-protein 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
cell [C]c [C]e [C]l [C]l O 
types [C]t [C]y [C]p [C]e [C]s O 
is [C]i [C]s O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
for [C]f [C]o [C]r O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
this [C]t [C]h [C]i [C]s O 
specificity [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]i [C]t [C]y O 
parallels [C]p [C]a [C]r [C]a [C]l [C]l [C]e [C]l [C]s O 
the [C]t [C]h [C]e O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
steroids [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]s O 
to [C]t [C]o O 
bind [C]b [C]i [C]n [C]d O 
to [C]t [C]o O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

HMy2 [C]H [C]M [C]y [C]2 B-cell_line 
cell [C]c [C]e [C]l [C]l E-cell_line 
PA [C]P [C]A S-protein 
is [C]i [C]s O 
fully [C]f [C]u [C]l [C]l [C]y O 
suppressible [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]b [C]l [C]e O 
by [C]b [C]y O 
Dex [C]D [C]e [C]x O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
up [C]u [C]p O 
to [C]t [C]o O 
one [C]o [C]n [C]e O 
third [C]t [C]h [C]i [C]r [C]d O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
by [C]b [C]y O 
GM4672A [C]G [C]M [C]4 [C]6 [C]7 [C]2 [C]A B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
is [C]i [C]s O 
resistant [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]t O 
to [C]t [C]o O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
. [C]. O 

Mixing [C]M [C]i [C]x [C]i [C]n [C]g O 
experiments [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]s O 
using [C]u [C]s [C]i [C]n [C]g O 
a [C]a O 
UK [C]U [C]K O 
standard [C]s [C]t [C]a [C]n [C]d [C]a [C]r [C]d O 
and [C]a [C]n [C]d O 
conditioned [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n [C]e [C]d O 
media [C]m [C]e [C]d [C]i [C]a O 
from [C]f [C]r [C]o [C]m O 
Dex-treated [C]D [C]e [C]x [C]- [C]t [C]r [C]e [C]a [C]t [C]e [C]d B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
an [C]a [C]n O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
glucocorticoid-inducible [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e B-protein 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s E-protein 
to [C]t [C]o O 
UK [C]U [C]K S-protein 
or [C]o [C]r O 
plasmin [C]p [C]l [C]a [C]s [C]m [C]i [C]n S-protein 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
cell [C]c [C]e [C]l [C]l O 
types [C]t [C]y [C]p [C]e [C]s O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
conditioned [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n [C]e [C]d O 
media [C]m [C]e [C]d [C]i [C]a O 
from [C]f [C]r [C]o [C]m O 
Dex-treated [C]D [C]e [C]x [C]- [C]t [C]r [C]e [C]a [C]t [C]e [C]d B-cell_line 
GM4672A [C]G [C]M [C]4 [C]6 [C]7 [C]2 [C]A I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
inhibits [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]s O 
a [C]a O 
portion [C]p [C]o [C]r [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
homologous [C]h [C]o [C]m [C]o [C]l [C]o [C]g [C]o [C]u [C]s O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r O 
in [C]i [C]n O 
conditioned [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n [C]e [C]d O 
media [C]m [C]e [C]d [C]i [C]a O 
from [C]f [C]r [C]o [C]m O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
GM4672A [C]G [C]M [C]4 [C]6 [C]7 [C]2 [C]A B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
low [C]l [C]o [C]w O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
glucocorticoid-inducible [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e B-protein 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s E-protein 
may [C]m [C]a [C]y O 
contribute [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e O 
to [C]t [C]o O 
, [C], O 
but [C]b [C]u [C]t O 
can [C]c [C]a [C]n O 
not [C]n [C]o [C]t O 
fully [C]f [C]u [C]l [C]l [C]y O 
account [C]a [C]c [C]c [C]o [C]u [C]n [C]t O 
for [C]f [C]o [C]r O 
, [C], O 
Dex [C]D [C]e [C]x O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
GM4672A [C]G [C]M [C]4 [C]6 [C]7 [C]2 [C]A B-protein 
PA [C]P [C]A E-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

Glucocorticoid-inducible [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e B-protein 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
HMy2 [C]H [C]M [C]y [C]2 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
are [C]a [C]r [C]e O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
totally [C]t [C]o [C]t [C]a [C]l [C]l [C]y O 
absent [C]a [C]b [C]s [C]e [C]n [C]t O 
or [C]o [C]r O 
are [C]a [C]r [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
at [C]a [C]t O 
undetectable [C]u [C]n [C]d [C]e [C]t [C]e [C]c [C]t [C]a [C]b [C]l [C]e O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
UK-like [C]U [C]K [C]- [C]l [C]i [C]k [C]e B-protein 
PAs [C]P [C]A [C]s E-protein 
in [C]i [C]n O 
HMy2 [C]H [C]M [C]y [C]2 B-cell_line 
and [C]a [C]n [C]d I-cell_line 
GM4672A [C]G [C]M [C]4 [C]6 [C]7 [C]2 [C]A I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
differs [C]d [C]i [C]f [C]f [C]e [C]r [C]s O 
with [C]w [C]i [C]t [C]h O 
respect [C]r [C]e [C]s [C]p [C]e [C]c [C]t O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
extent [C]e [C]x [C]t [C]e [C]n [C]t O 
to [C]t [C]o O 
which [C]w [C]h [C]i [C]c [C]h O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
inhibit [C]i [C]n [C]h [C]i [C]b [C]i [C]t O 
constitutively [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y B-protein 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d I-protein 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r E-protein 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
, [C], O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
the [C]t [C]h [C]e O 
possible [C]p [C]o [C]s [C]s [C]i [C]b [C]l [C]e O 
contribution [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
glucocorticoid-inducible [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e B-protein 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s E-protein 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
in [C]i [C]n O 
GM4672A [C]G [C]M [C]4 [C]6 [C]7 [C]2 [C]A B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

Characterization [C]C [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
aldosterone [C]a [C]l [C]d [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
sites [C]s [C]i [C]t [C]e [C]s O 
in [C]i [C]n O 
circulating [C]c [C]i [C]r [C]c [C]u [C]l [C]a [C]t [C]i [C]n [C]g B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

Aldosterone [C]A [C]l [C]d [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
sites [C]s [C]i [C]t [C]e [C]s O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_line 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s E-cell_line 
were [C]w [C]e [C]r [C]e O 
characterized [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]d O 
after [C]a [C]f [C]t [C]e [C]r O 
separation [C]s [C]e [C]p [C]a [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cells [C]c [C]e [C]l [C]l [C]s O 
from [C]f [C]r [C]o [C]m O 
blood [C]b [C]l [C]o [C]o [C]d O 
by [C]b [C]y O 
a [C]a O 
Percoll [C]P [C]e [C]r [C]c [C]o [C]l [C]l O 
gradient [C]g [C]r [C]a [C]d [C]i [C]e [C]n [C]t O 
. [C]. O 

After [C]A [C]f [C]t [C]e [C]r O 
washing [C]w [C]a [C]s [C]h [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
resuspension [C]r [C]e [C]s [C]u [C]s [C]p [C]e [C]n [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
RPMI-1640 [C]R [C]P [C]M [C]I [C]- [C]1 [C]6 [C]4 [C]0 O 
medium [C]m [C]e [C]d [C]i [C]u [C]m O 
, [C], O 
cells [C]c [C]e [C]l [C]l [C]s O 
were [C]w [C]e [C]r [C]e O 
incubated [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]e [C]d O 
at [C]a [C]t O 
37 [C]3 [C]7 O 
degrees [C]d [C]e [C]g [C]r [C]e [C]e [C]s O 
C [C]C O 
for [C]f [C]o [C]r O 
1 [C]1 O 
h [C]h O 
with [C]w [C]i [C]t [C]h O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
aldosterone [C]a [C]l [C]d [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
plus [C]p [C]l [C]u [C]s O 
a [C]a O 
100-fold [C]1 [C]0 [C]0 [C]- [C]f [C]o [C]l [C]d O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
RU-26988 [C]R [C]U [C]- [C]2 [C]6 [C]9 [C]8 [C]8 O 
( [C]( O 
11 [C]1 [C]1 O 
alpha [C]a [C]l [C]p [C]h [C]a O 
, [C], O 
17 [C]1 [C]7 O 
alpha-dihydroxy-17 [C]a [C]l [C]p [C]h [C]a [C]- [C]d [C]i [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]- [C]1 [C]7 O 
beta-propynylandrost-1 [C]b [C]e [C]t [C]a [C]- [C]p [C]r [C]o [C]p [C]y [C]n [C]y [C]l [C]a [C]n [C]d [C]r [C]o [C]s [C]t [C]- [C]1 O 
, [C], O 
4 [C]4 O 
, [C], O 
6-trien-3-one [C]6 [C]- [C]t [C]r [C]i [C]e [C]n [C]- [C]3 [C]- [C]o [C]n [C]e O 
) [C]) O 
, [C], O 
with [C]w [C]i [C]t [C]h O 
or [C]o [C]r O 
without [C]w [C]i [C]t [C]h [C]o [C]u [C]t O 
an [C]a [C]n O 
excess [C]e [C]x [C]c [C]e [C]s [C]s O 
of [C]o [C]f O 
unlabeled [C]u [C]n [C]l [C]a [C]b [C]e [C]l [C]e [C]d O 
aldosterone [C]a [C]l [C]d [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
. [C]. O 

Aldosterone [C]A [C]l [C]d [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
binds [C]b [C]i [C]n [C]d [C]s O 
to [C]t [C]o O 
a [C]a O 
single [C]s [C]i [C]n [C]g [C]l [C]e O 
class [C]c [C]l [C]a [C]s [C]s O 
of [C]o [C]f O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
with [C]w [C]i [C]t [C]h O 
an [C]a [C]n O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
of [C]o [C]f O 
2.7 [C]2 [C]. [C]7 O 
+/- [C]+ [C]/ [C]- O 
0.5 [C]0 [C]. [C]5 O 
nM [C]n [C]M O 
( [C]( O 
means [C]m [C]e [C]a [C]n [C]s O 
+/- [C]+ [C]/ [C]- O 
SD [C]S [C]D O 
, [C], O 
n [C]n O 
= [C]= O 
14 [C]1 [C]4 O 
) [C]) O 
and [C]a [C]n [C]d O 
a [C]a O 
capacity [C]c [C]a [C]p [C]a [C]c [C]i [C]t [C]y O 
of [C]o [C]f O 
290 [C]2 [C]9 [C]0 O 
+/- [C]+ [C]/ [C]- O 
108 [C]1 [C]0 [C]8 O 
sites/cell [C]s [C]i [C]t [C]e [C]s [C]/ [C]c [C]e [C]l [C]l O 
( [C]( O 
n [C]n O 
= [C]= O 
14 [C]1 [C]4 O 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
specificity [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]i [C]t [C]y O 
data [C]d [C]a [C]t [C]a O 
show [C]s [C]h [C]o [C]w O 
a [C]a O 
hierarchy [C]h [C]i [C]e [C]r [C]a [C]r [C]c [C]h [C]y O 
of [C]o [C]f O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
of [C]o [C]f O 
desoxycorticosterone [C]d [C]e [C]s [C]o [C]x [C]y [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
= [C]= O 
corticosterone [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
= [C]= O 
aldosterone [C]a [C]l [C]d [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
greater [C]g [C]r [C]e [C]a [C]t [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
hydrocortisone [C]h [C]y [C]d [C]r [C]o [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]n [C]e O 
greater [C]g [C]r [C]e [C]a [C]t [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_type 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
useful [C]u [C]s [C]e [C]f [C]u [C]l O 
for [C]f [C]o [C]r O 
studying [C]s [C]t [C]u [C]d [C]y [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
physiological [C]p [C]h [C]y [C]s [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
significance [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]c [C]e O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
mineralocorticoid [C]m [C]i [C]n [C]e [C]r [C]a [C]l [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
and [C]a [C]n [C]d O 
their [C]t [C]h [C]e [C]i [C]r O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
humans [C]h [C]u [C]m [C]a [C]n [C]s O 
. [C]. O 

Mineralocorticoid [C]M [C]i [C]n [C]e [C]r [C]a [C]l [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
and [C]a [C]n [C]d I-protein 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
circulating [C]c [C]i [C]r [C]c [C]u [C]l [C]a [C]t [C]i [C]n [C]g B-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
of [C]o [C]f O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y O 
hyperaldosteronism [C]h [C]y [C]p [C]e [C]r [C]a [C]l [C]d [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]i [C]s [C]m O 
. [C]. O 

Mineralocorticoid [C]M [C]i [C]n [C]e [C]r [C]a [C]l [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
and [C]a [C]n [C]d I-protein 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
were [C]w [C]e [C]r [C]e O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
in [C]i [C]n O 
circulating [C]c [C]i [C]r [C]c [C]u [C]l [C]a [C]t [C]i [C]n [C]g B-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
in [C]i [C]n O 
5 [C]5 O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
affected [C]a [C]f [C]f [C]e [C]c [C]t [C]e [C]d O 
by [C]b [C]y O 
Conn [C]C [C]o [C]n [C]n O 
's [C]' [C]s O 
syndrome [C]s [C]y [C]n [C]d [C]r [C]o [C]m [C]e O 
( [C]( O 
3 [C]3 O 
cases [C]c [C]a [C]s [C]e [C]s O 
of [C]o [C]f O 
bilateral [C]b [C]i [C]l [C]a [C]t [C]e [C]r [C]a [C]l O 
adrenal [C]a [C]d [C]r [C]e [C]n [C]a [C]l O 
hyperplasia [C]h [C]y [C]p [C]e [C]r [C]p [C]l [C]a [C]s [C]i [C]a O 
and [C]a [C]n [C]d O 
2 [C]2 O 
cases [C]c [C]a [C]s [C]e [C]s O 
of [C]o [C]f O 
adenoma [C]a [C]d [C]e [C]n [C]o [C]m [C]a O 
plus [C]p [C]l [C]u [C]s O 
unilateral [C]u [C]n [C]i [C]l [C]a [C]t [C]e [C]r [C]a [C]l O 
hyperplasia [C]h [C]y [C]p [C]e [C]r [C]p [C]l [C]a [C]s [C]i [C]a O 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
sites [C]s [C]i [C]t [C]e [C]s O 
per [C]p [C]e [C]r O 
cell [C]c [C]e [C]l [C]l O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
lower [C]l [C]o [C]w [C]e [C]r O 
( [C]( O 
189 [C]1 [C]8 [C]9 O 
+/- [C]+ [C]/ [C]- O 
114 [C]1 [C]1 [C]4 O 
, [C], O 
mean [C]m [C]e [C]a [C]n O 
+/- [C]+ [C]/ [C]- O 
SD [C]S [C]D O 
) [C]) O 
, [C], O 
as [C]a [C]s O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
( [C]( O 
298 [C]2 [C]9 [C]8 O 
+/- [C]+ [C]/ [C]- O 
105 [C]1 [C]0 [C]5 O 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
of [C]o [C]f O 
aldosterone [C]a [C]l [C]d [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
not [C]n [C]o [C]t O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
than [C]t [C]h [C]a [C]n O 
that [C]t [C]h [C]a [C]t O 
of [C]o [C]f O 
healthy [C]h [C]e [C]a [C]l [C]t [C]h [C]y O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
capacity [C]c [C]a [C]p [C]a [C]c [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
of [C]o [C]f O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
for [C]f [C]o [C]r O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
ranged [C]r [C]a [C]n [C]g [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
values [C]v [C]a [C]l [C]u [C]e [C]s O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
a [C]a O 
possible [C]p [C]o [C]s [C]s [C]i [C]b [C]l [C]e O 
down-regulation [C]d [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
mineralocorticoid [C]m [C]i [C]n [C]e [C]r [C]a [C]l [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
humans [C]h [C]u [C]m [C]a [C]n [C]s O 
. [C]. O 

Short-term [C]S [C]h [C]o [C]r [C]t [C]- [C]t [C]e [C]r [C]m O 
and [C]a [C]n [C]d O 
long-term [C]l [C]o [C]n [C]g [C]- [C]t [C]e [C]r [C]m O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n O 
on [C]o [C]n O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d O 
tissues [C]t [C]i [C]s [C]s [C]u [C]e [C]s O 
and [C]a [C]n [C]d O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
with [C]w [C]i [C]t [C]h O 
some [C]s [C]o [C]m [C]e O 
remarks [C]r [C]e [C]m [C]a [C]r [C]k [C]s O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
significance [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]c [C]e O 
for [C]f [C]o [C]r O 
carcinogenesis [C]c [C]a [C]r [C]c [C]i [C]n [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
. [C]. O 

Estrogens [C]E [C]s [C]t [C]r [C]o [C]g [C]e [C]n [C]s O 
have [C]h [C]a [C]v [C]e O 
long [C]l [C]o [C]n [C]g O 
been [C]b [C]e [C]e [C]n O 
thought [C]t [C]h [C]o [C]u [C]g [C]h [C]t O 
to [C]t [C]o O 
play [C]p [C]l [C]a [C]y O 
a [C]a O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
regulating [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
. [C]. O 

The [C]T [C]h [C]e O 
difference [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e O 
in [C]i [C]n O 
some [C]s [C]o [C]m [C]e O 
types [C]t [C]y [C]p [C]e [C]s O 
of [C]o [C]f O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
males [C]m [C]a [C]l [C]e [C]s O 
and [C]a [C]n [C]d O 
females [C]f [C]e [C]m [C]a [C]l [C]e [C]s O 
is [C]i [C]s O 
well-known [C]w [C]e [C]l [C]l [C]- [C]k [C]n [C]o [C]w [C]n O 
, [C], O 
as [C]a [C]s O 
is [C]i [C]s O 
the [C]t [C]h [C]e O 
pronounced [C]p [C]r [C]o [C]n [C]o [C]u [C]n [C]c [C]e [C]d O 
thymic [C]t [C]h [C]y [C]m [C]i [C]c O 
involution [C]i [C]n [C]v [C]o [C]l [C]u [C]t [C]i [C]o [C]n O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
exogenous [C]e [C]x [C]o [C]g [C]e [C]n [C]o [C]u [C]s O 
estrogens [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n [C]s O 
. [C]. O 

Estrogens [C]E [C]s [C]t [C]r [C]o [C]g [C]e [C]n [C]s O 
stimulate [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e O 
some [C]s [C]o [C]m [C]e O 
aspects [C]a [C]s [C]p [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e S-cell_type 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
, [C], O 
depending [C]d [C]e [C]p [C]e [C]n [C]d [C]i [C]n [C]g O 
on [C]o [C]n O 
dose [C]d [C]o [C]s [C]e O 
and [C]a [C]n [C]d O 
mitogen [C]m [C]i [C]t [C]o [C]g [C]e [C]n S-protein 
, [C], O 
inhibit [C]i [C]n [C]h [C]i [C]b [C]i [C]t O 
or [C]o [C]r O 
stimulate [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e O 
proliferative [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
. [C]. O 

Another [C]A [C]n [C]o [C]t [C]h [C]e [C]r O 
example [C]e [C]x [C]a [C]m [C]p [C]l [C]e O 
is [C]i [C]s O 
the [C]t [C]h [C]e O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
delayed [C]d [C]e [C]l [C]a [C]y [C]e [C]d O 
type [C]t [C]y [C]p [C]e O 
hypersensitivity [C]h [C]y [C]p [C]e [C]r [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
. [C]. O 

A [C]A O 
broad [C]b [C]r [C]o [C]a [C]d O 
review [C]r [C]e [C]v [C]i [C]e [C]w O 
is [C]i [C]s O 
given [C]g [C]i [C]v [C]e [C]n O 
of [C]o [C]f O 
such [C]s [C]u [C]c [C]h O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
on [C]o [C]n O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d B-cell_type 
tissue [C]t [C]i [C]s [C]s [C]u [C]e E-cell_type 
and [C]a [C]n [C]d O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
. [C]. O 

Most [C]M [C]o [C]s [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
published [C]p [C]u [C]b [C]l [C]i [C]s [C]h [C]e [C]d O 
so [C]s [C]o O 
far [C]f [C]a [C]r O 
are [C]a [C]r [C]e O 
phenomenological [C]p [C]h [C]e [C]n [C]o [C]m [C]e [C]n [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
the [C]t [C]h [C]e O 
recent [C]r [C]e [C]c [C]e [C]n [C]t O 
description [C]d [C]e [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
thymus [C]t [C]h [C]y [C]m [C]u [C]s O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
some [C]s [C]o [C]m [C]e O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e B-cell_line 
subpopulations [C]s [C]u [C]b [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n [C]s E-cell_line 
, [C], O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
a [C]a O 
deeper [C]d [C]e [C]e [C]p [C]e [C]r O 
understanding [C]u [C]n [C]d [C]e [C]r [C]s [C]t [C]a [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
regulating [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
, [C], O 
open [C]o [C]p [C]e [C]n O 
the [C]t [C]h [C]e O 
possibility [C]p [C]o [C]s [C]s [C]i [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
a [C]a O 
more [C]m [C]o [C]r [C]e O 
detailed [C]d [C]e [C]t [C]a [C]i [C]l [C]e [C]d O 
understanding [C]u [C]n [C]d [C]e [C]r [C]s [C]t [C]a [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
of [C]o [C]f O 
interference [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]e [C]n [C]c [C]e O 
. [C]. O 

Estrogen [C]E [C]s [C]t [C]r [C]o [C]g [C]e [C]n O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
in [C]i [C]n O 
adults [C]a [C]d [C]u [C]l [C]t [C]s O 
are [C]a [C]r [C]e O 
reversible [C]r [C]e [C]v [C]e [C]r [C]s [C]i [C]b [C]l [C]e O 
. [C]. O 

After [C]A [C]f [C]t [C]e [C]r O 
treating [C]t [C]r [C]e [C]a [C]t [C]i [C]n [C]g O 
neonatal [C]n [C]e [C]o [C]n [C]a [C]t [C]a [C]l O 
mice [C]m [C]i [C]c [C]e O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
synthetic [C]s [C]y [C]n [C]t [C]h [C]e [C]t [C]i [C]c O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n O 
diethylstilbestrol [C]d [C]i [C]e [C]t [C]h [C]y [C]l [C]s [C]t [C]i [C]l [C]b [C]e [C]s [C]t [C]r [C]o [C]l O 
( [C]( O 
DES [C]D [C]E [C]S O 
) [C]) O 
, [C], O 
disturbances [C]d [C]i [C]s [C]t [C]u [C]r [C]b [C]a [C]n [C]c [C]e [C]s O 
are [C]a [C]r [C]e O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
in [C]i [C]n O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e B-cell_line 
populations [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n [C]s E-cell_line 
and [C]a [C]n [C]d O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e S-cell_type 
functions [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]s O 
which [C]w [C]h [C]i [C]c [C]h O 
are [C]a [C]r [C]e O 
permanent [C]p [C]e [C]r [C]m [C]a [C]n [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
irreversible [C]i [C]r [C]r [C]e [C]v [C]e [C]r [C]s [C]i [C]b [C]l [C]e O 
. [C]. O 

Lymphocytes [C]L [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
from [C]f [C]r [C]o [C]m O 
adult [C]a [C]d [C]u [C]l [C]t O 
, [C], O 
neonatally [C]n [C]e [C]o [C]n [C]a [C]t [C]a [C]l [C]l [C]y O 
DES-treated [C]D [C]E [C]S [C]- [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
female [C]f [C]e [C]m [C]a [C]l [C]e O 
mice [C]m [C]i [C]c [C]e O 
have [C]h [C]a [C]v [C]e O 
a [C]a O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
mitogen [C]m [C]i [C]t [C]o [C]g [C]e [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
ConA [C]C [C]o [C]n [C]A S-protein 
and [C]a [C]n [C]d O 
LPS [C]L [C]P [C]S S-protein 
( [C]( O 
T [C]T B-protein 
and [C]a [C]n [C]d I-protein 
B [C]B I-protein 
cell [C]c [C]e [C]l [C]l I-protein 
mitogen [C]m [C]i [C]t [C]o [C]g [C]e [C]n E-protein 
) [C]) O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
delayed [C]d [C]e [C]l [C]a [C]y [C]e [C]d O 
type [C]t [C]y [C]p [C]e O 
hypersensitivity [C]h [C]y [C]p [C]e [C]r [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
is [C]i [C]s O 
depressed [C]d [C]e [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
. [C]. O 

A [C]A O 
detailed [C]d [C]e [C]t [C]a [C]i [C]l [C]e [C]d O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
a [C]a O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
T [C]T B-cell_type 
helper [C]h [C]e [C]l [C]p [C]e [C]r I-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
population [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
Natural [C]N [C]a [C]t [C]u [C]r [C]a [C]l B-cell_type 
Killer [C]K [C]i [C]l [C]l [C]e [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
is [C]i [C]s O 
permanently [C]p [C]e [C]r [C]m [C]a [C]n [C]e [C]n [C]t [C]l [C]y O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
and [C]a [C]n [C]d O 
this [C]t [C]h [C]i [C]s O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
impairment [C]i [C]m [C]p [C]a [C]i [C]r [C]m [C]e [C]n [C]t O 
is [C]i [C]s O 
related [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
to [C]t [C]o O 
a [C]a O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
, [C], O 
in [C]i [C]n O 
turn [C]t [C]u [C]r [C]n O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
bone [C]b [C]o [C]n [C]e O 
marrow [C]m [C]a [C]r [C]r [C]o [C]w O 
level [C]l [C]e [C]v [C]e [C]l O 
. [C]. O 

The [C]T [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
animals [C]a [C]n [C]i [C]m [C]a [C]l [C]s O 
have [C]h [C]a [C]v [C]e O 
an [C]a [C]n O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
to [C]t [C]o O 
chemical [C]c [C]h [C]e [C]m [C]i [C]c [C]a [C]l O 
carcinogens [C]c [C]a [C]r [C]c [C]i [C]n [C]o [C]g [C]e [C]n [C]s O 
( [C]( O 
methylcholanthrene [C]m [C]e [C]t [C]h [C]y [C]l [C]c [C]h [C]o [C]l [C]a [C]n [C]t [C]h [C]r [C]e [C]n [C]e O 
) [C]) O 
and [C]a [C]n [C]d O 
they [C]t [C]h [C]e [C]y O 
spontaneously [C]s [C]p [C]o [C]n [C]t [C]a [C]n [C]e [C]o [C]u [C]s [C]l [C]y O 
develop [C]d [C]e [C]v [C]e [C]l [C]o [C]p O 
epithelial [C]e [C]p [C]i [C]t [C]h [C]e [C]l [C]i [C]a [C]l O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
uterine [C]u [C]t [C]e [C]r [C]i [C]n [C]e O 
cervix [C]c [C]e [C]r [C]v [C]i [C]x O 
which [C]w [C]h [C]i [C]c [C]h O 
morphologically [C]m [C]o [C]r [C]p [C]h [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l [C]l [C]y O 
are [C]a [C]r [C]e O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
to [C]t [C]o O 
adenocarcinoma [C]a [C]d [C]e [C]n [C]o [C]c [C]a [C]r [C]c [C]i [C]n [C]o [C]m [C]a O 
. [C]. O 

The [C]T [C]h [C]e O 
association [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
estrogen-associated [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n [C]- [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
malignancy [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]c [C]y O 
and [C]a [C]n [C]d O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
in [C]i [C]n O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e S-cell_type 
functions [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]s O 
deserves [C]d [C]e [C]s [C]e [C]r [C]v [C]e [C]s O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
study [C]s [C]t [C]u [C]d [C]y O 
. [C]. O 

Drugs [C]D [C]r [C]u [C]g [C]s O 
affecting [C]a [C]f [C]f [C]e [C]c [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
hormonal [C]h [C]o [C]r [C]m [C]o [C]n [C]a [C]l O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
of [C]o [C]f O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
and [C]a [C]n [C]d I-cell_type 
leukaemic [C]l [C]e [C]u [C]k [C]a [C]e [C]m [C]i [C]c I-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
leucocytes [C]l [C]e [C]u [C]c [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
authors [C]a [C]u [C]t [C]h [C]o [C]r [C]s O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
behaviour [C]b [C]e [C]h [C]a [C]v [C]i [C]o [C]u [C]r O 
of [C]o [C]f O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e O 
uptake [C]u [C]p [C]t [C]a [C]k [C]e O 
in [C]i [C]n O 
leukaemic [C]l [C]e [C]u [C]k [C]a [C]e [C]m [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
CML [C]C [C]M [C]L S-cell_line 
, [C], O 
CLL [C]C [C]L [C]L S-cell_line 
, [C], O 
AML [C]A [C]M [C]L S-cell_line 
, [C], O 
ALL [C]A [C]L [C]L S-cell_line 
) [C]) O 
, [C], O 
in [C]i [C]n O 
basal [C]b [C]a [C]s [C]a [C]l O 
conditions [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n [C]s O 
and [C]a [C]n [C]d O 
after [C]a [C]f [C]t [C]e [C]r O 
incubation [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
drugs [C]d [C]r [C]u [C]g [C]s O 
which [C]w [C]h [C]i [C]c [C]h O 
modify [C]m [C]o [C]d [C]i [C]f [C]y O 
the [C]t [C]h [C]e O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cAMP [C]c [C]A [C]M [C]P O 
, [C], O 
PGE [C]P [C]G [C]E O 
and [C]a [C]n [C]d O 
PGF [C]P [C]G [C]F O 
. [C]. O 

The [C]T [C]h [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
in [C]i [C]n O 
leukaemic [C]l [C]e [C]u [C]k [C]a [C]e [C]m [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
of [C]o [C]f O 
an [C]a [C]n O 
alteration [C]a [C]l [C]t [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
incorporation [C]i [C]n [C]c [C]o [C]r [C]p [C]o [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
hormones [C]h [C]o [C]r [C]m [C]o [C]n [C]e [C]s O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
alteration [C]a [C]l [C]t [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
scarcely [C]s [C]c [C]a [C]r [C]c [C]e [C]l [C]y O 
modified [C]m [C]o [C]d [C]i [C]f [C]i [C]e [C]d O 
by [C]b [C]y O 
incubation [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
theophylline [C]t [C]h [C]e [C]o [C]p [C]h [C]y [C]l [C]l [C]i [C]n [C]e S-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
increases [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cAMP [C]c [C]A [C]M [C]P O 
. [C]. O 

On [C]O [C]n O 
the [C]t [C]h [C]e O 
other [C]o [C]t [C]h [C]e [C]r O 
hand [C]h [C]a [C]n [C]d O 
, [C], O 
it [C]i [C]t O 
was [C]w [C]a [C]s O 
moderately [C]m [C]o [C]d [C]e [C]r [C]a [C]t [C]e [C]l [C]y O 
counteracted [C]c [C]o [C]u [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]e [C]d O 
by [C]b [C]y O 
thioproline [C]t [C]h [C]i [C]o [C]p [C]r [C]o [C]l [C]i [C]n [C]e O 
and [C]a [C]n [C]d O 
was [C]w [C]a [C]s O 
evidently [C]e [C]v [C]i [C]d [C]e [C]n [C]t [C]l [C]y O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
by [C]b [C]y O 
flurbiprofen [C]f [C]l [C]u [C]r [C]b [C]i [C]p [C]r [C]o [C]f [C]e [C]n O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
also [C]a [C]l [C]s [C]o O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
prostaglandins [C]p [C]r [C]o [C]s [C]t [C]a [C]g [C]l [C]a [C]n [C]d [C]i [C]n [C]s O 
, [C], O 
particularly [C]p [C]a [C]r [C]t [C]i [C]c [C]u [C]l [C]a [C]r [C]l [C]y O 
PGE2 [C]P [C]G [C]E [C]2 O 
, [C], O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
exception [C]e [C]x [C]c [C]e [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
PGF2 [C]P [C]G [C]F [C]2 O 
which [C]w [C]h [C]i [C]c [C]h O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
a [C]a O 
poor [C]p [C]o [C]o [C]r O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
. [C]. O 

Differences [C]D [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
behavior [C]b [C]e [C]h [C]a [C]v [C]i [C]o [C]r O 
of [C]o [C]f O 
hormonal [C]h [C]o [C]r [C]m [C]o [C]n [C]a [C]l O 
uptake [C]u [C]p [C]t [C]a [C]k [C]e O 
of [C]o [C]f O 
CML [C]C [C]M [C]L S-cell_line 
, [C], O 
in [C]i [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
to [C]t [C]o O 
that [C]t [C]h [C]a [C]t O 
of [C]o [C]f O 
AML [C]A [C]M [C]L B-cell_line 
, [C], I-cell_line 
CLL [C]C [C]L [C]L I-cell_line 
and [C]a [C]n [C]d I-cell_line 
ALL [C]A [C]L [C]L I-cell_line 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_line 
leucocytes [C]l [C]e [C]u [C]c [C]o [C]c [C]y [C]t [C]e [C]s E-cell_line 
. [C]. O 

Human [C]H [C]u [C]m [C]a [C]n O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
and [C]a [C]n [C]d O 
impaired [C]i [C]m [C]p [C]a [C]i [C]r [C]e [C]d O 
NK [C]N [C]K B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

Recent [C]R [C]e [C]c [C]e [C]n [C]t O 
advances [C]a [C]d [C]v [C]a [C]n [C]c [C]e [C]s O 
in [C]i [C]n O 
tumor [C]t [C]u [C]m [C]o [C]r O 
immunology [C]i [C]m [C]m [C]u [C]n [C]o [C]l [C]o [C]g [C]y O 
have [C]h [C]a [C]v [C]e O 
led [C]l [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
discovery [C]d [C]i [C]s [C]c [C]o [C]v [C]e [C]r [C]y O 
of [C]o [C]f O 
a [C]a O 
new [C]n [C]e [C]w O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
with [C]w [C]i [C]t [C]h O 
unique [C]u [C]n [C]i [C]q [C]u [C]e O 
antitumor [C]a [C]n [C]t [C]i [C]t [C]u [C]m [C]o [C]r O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

Natural [C]N [C]a [C]t [C]u [C]r [C]a [C]l B-cell_type 
killer [C]k [C]i [C]l [C]l [C]e [C]r I-cell_type 
( [C]( I-cell_type 
NK [C]N [C]K I-cell_type 
) [C]) I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
form [C]f [C]o [C]r [C]m O 
an [C]a [C]n O 
antitumor [C]a [C]n [C]t [C]i [C]t [C]u [C]m [C]o [C]r O 
surveillance [C]s [C]u [C]r [C]v [C]e [C]i [C]l [C]l [C]a [C]n [C]c [C]e O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
and [C]a [C]n [C]d O 
appear [C]a [C]p [C]p [C]e [C]a [C]r O 
to [C]t [C]o O 
be [C]b [C]e O 
vital [C]v [C]i [C]t [C]a [C]l O 
in [C]i [C]n O 
preventing [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]i [C]n [C]g O 
tumor [C]t [C]u [C]m [C]o [C]r O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
and [C]a [C]n [C]d O 
metastasis [C]m [C]e [C]t [C]a [C]s [C]t [C]a [C]s [C]i [C]s O 
in [C]i [C]n O 
animal [C]a [C]n [C]i [C]m [C]a [C]l O 
models [C]m [C]o [C]d [C]e [C]l [C]s O 
. [C]. O 

We [C]W [C]e O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
NK [C]N [C]K S-cell_type 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
benign [C]b [C]e [C]n [C]i [C]g [C]n O 
and [C]a [C]n [C]d O 
malignant [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]t O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
, [C], O 
using [C]u [C]s [C]i [C]n [C]g O 
a [C]a O 
chromium-51 [C]c [C]h [C]r [C]o [C]m [C]i [C]u [C]m [C]- [C]5 [C]1 O 
release [C]r [C]e [C]l [C]e [C]a [C]s [C]e O 
microtiter [C]m [C]i [C]c [C]r [C]o [C]t [C]i [C]t [C]e [C]r O 
cytotoxicity [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c [C]i [C]t [C]y O 
assay [C]a [C]s [C]s [C]a [C]y O 
with [C]w [C]i [C]t [C]h O 
K562 [C]K [C]5 [C]6 [C]2 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
as [C]a [C]s O 
targets [C]t [C]a [C]r [C]g [C]e [C]t [C]s O 
. [C]. O 

Compared [C]C [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
benign [C]b [C]e [C]n [C]i [C]g [C]n O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
, [C], O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
malignancies [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]c [C]i [C]e [C]s O 
had [C]h [C]a [C]d O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
depressed [C]d [C]e [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
NK [C]N [C]K S-cell_type 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
lysis [C]l [C]y [C]s [C]i [C]s O 
( [C]( O 
P [C]P O 
less [C]l [C]e [C]s [C]s O 
than [C]t [C]h [C]a [C]n O 
0.01 [C]0 [C]. [C]0 [C]1 O 
) [C]) O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
lysis [C]l [C]y [C]s [C]i [C]s O 
in [C]i [C]n O 
those [C]t [C]h [C]o [C]s [C]e O 
with [C]w [C]i [C]t [C]h O 
advanced [C]a [C]d [C]v [C]a [C]n [C]c [C]e [C]d O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
( [C]( O 
stages [C]s [C]t [C]a [C]g [C]e [C]s O 
II [C]I [C]I O 
, [C], O 
III [C]I [C]I [C]I O 
, [C], O 
and [C]a [C]n [C]d O 
IV [C]I [C]V O 
) [C]) O 
was [C]w [C]a [C]s O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
less [C]l [C]e [C]s [C]s O 
than [C]t [C]h [C]a [C]n O 
in [C]i [C]n O 
those [C]t [C]h [C]o [C]s [C]e O 
with [C]w [C]i [C]t [C]h O 
limited [C]l [C]i [C]m [C]i [C]t [C]e [C]d O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
( [C]( O 
stage [C]s [C]t [C]a [C]g [C]e O 
I [C]I O 
) [C]) O 
( [C]( O 
P [C]P O 
less [C]l [C]e [C]s [C]s O 
than [C]t [C]h [C]a [C]n O 
0.01 [C]0 [C]. [C]0 [C]1 O 
) [C]) O 
. [C]. O 

NK [C]N [C]K S-cell_type 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
to [C]t [C]o O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n O 
or [C]o [C]r O 
progesterone [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
states [C]s [C]t [C]a [C]t [C]e [C]s O 
. [C]. O 

Positive [C]P [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
depressed [C]d [C]e [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
natural [C]n [C]a [C]t [C]u [C]r [C]a [C]l O 
killer [C]k [C]i [C]l [C]l [C]e [C]r O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
extent [C]e [C]x [C]t [C]e [C]n [C]t O 
of [C]o [C]f O 
tumor [C]t [C]u [C]m [C]o [C]r O 
spread [C]s [C]p [C]r [C]e [C]a [C]d O 
supports [C]s [C]u [C]p [C]p [C]o [C]r [C]t [C]s O 
the [C]t [C]h [C]e O 
concept [C]c [C]o [C]n [C]c [C]e [C]p [C]t O 
of [C]o [C]f O 
an [C]a [C]n O 
NK [C]N [C]K B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
surveillance [C]s [C]u [C]r [C]v [C]e [C]i [C]l [C]l [C]a [C]n [C]c [C]e O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
in [C]i [C]n O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
and [C]a [C]n [C]d O 
emphasizes [C]e [C]m [C]p [C]h [C]a [C]s [C]i [C]z [C]e [C]s O 
its [C]i [C]t [C]s O 
importance [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]c [C]e O 
in [C]i [C]n O 
this [C]t [C]h [C]i [C]s O 
malignancy [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]c [C]y O 
. [C]. O 

Immunosuppressive [C]I [C]m [C]m [C]u [C]n [C]o [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]v [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
serum [C]s [C]e [C]r [C]u [C]m O 
progesterone [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
pregnancy [C]p [C]r [C]e [C]g [C]n [C]a [C]n [C]c [C]y O 
depends [C]d [C]e [C]p [C]e [C]n [C]d [C]s O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
progesterone [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
capacity [C]c [C]a [C]p [C]a [C]c [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
. [C]. O 

Cytotoxic [C]C [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
progesterone [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
capacity [C]c [C]a [C]p [C]a [C]c [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
, [C], O 
together [C]t [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
with [C]w [C]i [C]t [C]h O 
serum [C]s [C]e [C]r [C]u [C]m O 
progesterone [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
, [C], O 
were [C]w [C]e [C]r [C]e O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
in [C]i [C]n O 
women [C]w [C]o [C]m [C]e [C]n O 
with [C]w [C]i [C]t [C]h O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
pregnancy [C]p [C]r [C]e [C]g [C]n [C]a [C]n [C]c [C]y O 
or [C]o [C]r O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
clinical [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
diagnosis [C]d [C]i [C]a [C]g [C]n [C]o [C]s [C]i [C]s O 
of [C]o [C]f O 
threatened [C]t [C]h [C]r [C]e [C]a [C]t [C]e [C]n [C]e [C]d O 
abortion [C]a [C]b [C]o [C]r [C]t [C]i [C]o [C]n O 
or [C]o [C]r O 
threatened [C]t [C]h [C]r [C]e [C]a [C]t [C]e [C]n [C]e [C]d O 
premature [C]p [C]r [C]e [C]m [C]a [C]t [C]u [C]r [C]e O 
labour [C]l [C]a [C]b [C]o [C]u [C]r O 
. [C]. O 

The [C]T [C]h [C]e O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s O 
of [C]o [C]f O 
women [C]w [C]o [C]m [C]e [C]n O 
with [C]w [C]i [C]t [C]h O 
threatened [C]t [C]h [C]r [C]e [C]a [C]t [C]e [C]n [C]e [C]d O 
abortion [C]a [C]b [C]o [C]r [C]t [C]i [C]o [C]n O 
or [C]o [C]r O 
threatened [C]t [C]h [C]r [C]e [C]a [C]t [C]e [C]n [C]e [C]d O 
premature [C]p [C]r [C]e [C]m [C]a [C]t [C]u [C]r [C]e O 
labour [C]l [C]a [C]b [C]o [C]u [C]r O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
cytotoxic [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
( [C]( O 
P [C]P O 
less [C]l [C]e [C]s [C]s O 
than [C]t [C]h [C]a [C]n O 
0.001 [C]0 [C]. [C]0 [C]0 [C]1 O 
) [C]) O 
and [C]a [C]n [C]d O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
lower [C]l [C]o [C]w [C]e [C]r O 
progesterone [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
capacity [C]c [C]a [C]p [C]a [C]c [C]i [C]t [C]y O 
( [C]( O 
P [C]P O 
less [C]l [C]e [C]s [C]s O 
than [C]t [C]h [C]a [C]n O 
0.001 [C]0 [C]. [C]0 [C]0 [C]1 O 
) [C]) O 
than [C]t [C]h [C]a [C]n O 
did [C]d [C]i [C]d O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
healthy [C]h [C]e [C]a [C]l [C]t [C]h [C]y O 
pregnant [C]p [C]r [C]e [C]g [C]n [C]a [C]n [C]t O 
women [C]w [C]o [C]m [C]e [C]n O 
. [C]. O 

Significant [C]S [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
inverse [C]i [C]n [C]v [C]e [C]r [C]s [C]e O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
progesterone [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
capacity [C]c [C]a [C]p [C]a [C]c [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
cytotoxic [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
( [C]( O 
P [C]P O 
less [C]l [C]e [C]s [C]s O 
than [C]t [C]h [C]a [C]n O 
0.001 [C]0 [C]. [C]0 [C]0 [C]1 O 
) [C]) O 
, [C], O 
but [C]b [C]u [C]t O 
the [C]t [C]h [C]e O 
progesterone [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
pregnancy [C]p [C]r [C]e [C]g [C]n [C]a [C]n [C]c [C]y O 
serum [C]s [C]e [C]r [C]u [C]m O 
appeared [C]a [C]p [C]p [C]e [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
have [C]h [C]a [C]v [C]e O 
no [C]n [C]o O 
influence [C]i [C]n [C]f [C]l [C]u [C]e [C]n [C]c [C]e O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
other [C]o [C]t [C]h [C]e [C]r O 
two [C]t [C]w [C]o O 
parameters [C]p [C]a [C]r [C]a [C]m [C]e [C]t [C]e [C]r [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
intact [C]i [C]n [C]t [C]a [C]c [C]t O 
progesterone [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
capacity [C]c [C]a [C]p [C]a [C]c [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
is [C]i [C]s O 
an [C]a [C]n O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
manifestation [C]m [C]a [C]n [C]i [C]f [C]e [C]s [C]t [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
blocking [C]b [C]l [C]o [C]c [C]k [C]i [C]n [C]g O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
exerted [C]e [C]x [C]e [C]r [C]t [C]e [C]d O 
by [C]b [C]y O 
pregnancy [C]p [C]r [C]e [C]g [C]n [C]a [C]n [C]c [C]y O 
serum [C]s [C]e [C]r [C]u [C]m O 
on [C]o [C]n O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e S-cell_type 
cytotoxicity [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c [C]i [C]t [C]y O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
. [C]. O 

Serum [C]S [C]e [C]r [C]u [C]m O 
sex [C]s [C]e [C]x O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
and [C]a [C]n [C]d O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
endometrial [C]e [C]n [C]d [C]o [C]m [C]e [C]t [C]r [C]i [C]a [C]l O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n O 
and [C]a [C]n [C]d O 
progestin [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]i [C]n O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
administration [C]a [C]d [C]m [C]i [C]n [C]i [C]s [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-protein 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e I-protein 
interferon [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n E-protein 
. [C]. O 

Five [C]F [C]i [C]v [C]e O 
normally [C]n [C]o [C]r [C]m [C]a [C]l [C]l [C]y O 
cycling [C]c [C]y [C]c [C]l [C]i [C]n [C]g O 
healthy [C]h [C]e [C]a [C]l [C]t [C]h [C]y O 
women [C]w [C]o [C]m [C]e [C]n O 
were [C]w [C]e [C]r [C]e O 
given [C]g [C]i [C]v [C]e [C]n O 
daily [C]d [C]a [C]i [C]l [C]y O 
subcutaneous [C]s [C]u [C]b [C]c [C]u [C]t [C]a [C]n [C]e [C]o [C]u [C]s O 
injections [C]i [C]n [C]j [C]e [C]c [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-protein 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e I-protein 
interferon [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n E-protein 
( [C]( O 
3 [C]3 O 
X [C]X O 
10 [C]1 [C]0 O 
( [C]( O 
6 [C]6 O 
) [C]) O 
units/day [C]u [C]n [C]i [C]t [C]s [C]/ [C]d [C]a [C]y O 
) [C]) O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
3rd [C]3 [C]r [C]d O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
23rd [C]2 [C]3 [C]r [C]d O 
day [C]d [C]a [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
menstrual [C]m [C]e [C]n [C]s [C]t [C]r [C]u [C]a [C]l O 
cycle [C]c [C]y [C]c [C]l [C]e O 
, [C], O 
and [C]a [C]n [C]d O 
serum [C]s [C]e [C]r [C]u [C]m O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
and [C]a [C]n [C]d O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
monitored [C]m [C]o [C]n [C]i [C]t [C]o [C]r [C]e [C]d O 
at [C]a [C]t O 
3-day [C]3 [C]- [C]d [C]a [C]y O 
intervals [C]i [C]n [C]t [C]e [C]r [C]v [C]a [C]l [C]s O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
preceding [C]p [C]r [C]e [C]c [C]e [C]d [C]i [C]n [C]g O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
cycle [C]c [C]y [C]c [C]l [C]e O 
. [C]. O 

Concentrations [C]C [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l B-protein 
and [C]a [C]n [C]d I-protein 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-protein 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
( [C]( O 
ERC [C]E [C]R [C]C S-protein 
and [C]a [C]n [C]d O 
ERN [C]E [C]R [C]N S-protein 
, [C], O 
respectively [C]r [C]e [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
) [C]) O 
and [C]a [C]n [C]d O 
progestin [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]i [C]n B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
( [C]( O 
PRC [C]P [C]R [C]C S-protein 
and [C]a [C]n [C]d O 
PRN [C]P [C]R [C]N S-protein 
) [C]) O 
were [C]w [C]e [C]r [C]e O 
also [C]a [C]l [C]s [C]o O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
endometrial [C]e [C]n [C]d [C]o [C]m [C]e [C]t [C]r [C]i [C]a [C]l O 
biopsies [C]b [C]i [C]o [C]p [C]s [C]i [C]e [C]s O 
taken [C]t [C]a [C]k [C]e [C]n O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
24th [C]2 [C]4 [C]t [C]h O 
day [C]d [C]a [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
and [C]a [C]n [C]d O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
cycle [C]c [C]y [C]c [C]l [C]e O 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
an [C]a [C]n O 
extensive [C]e [C]x [C]t [C]e [C]n [C]s [C]i [C]v [C]e O 
monitoring [C]m [C]o [C]n [C]i [C]t [C]o [C]r [C]i [C]n [C]g O 
of [C]o [C]f O 
clinical [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
chemical [C]c [C]h [C]e [C]m [C]i [C]c [C]a [C]l O 
and [C]a [C]n [C]d O 
hematological [C]h [C]e [C]m [C]a [C]t [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
tests [C]t [C]e [C]s [C]t [C]s O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
blood [C]b [C]l [C]o [C]o [C]d O 
samples [C]s [C]a [C]m [C]p [C]l [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
performed [C]p [C]e [C]r [C]f [C]o [C]r [C]m [C]e [C]d O 
. [C]. O 

Serum [C]S [C]e [C]r [C]u [C]m O 
estradiol [C]e [C]s [C]t [C]r [C]a [C]d [C]i [C]o [C]l O 
and [C]a [C]n [C]d O 
progesterone [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
were [C]w [C]e [C]r [C]e O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
cycle [C]c [C]y [C]c [C]l [C]e O 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
interferon [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n S-protein 
interacts [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]s O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
FSH [C]F [C]S [C]H O 
and [C]a [C]n [C]d O 
LH [C]L [C]H O 
. [C]. O 

No [C]N [C]o O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
serum [C]s [C]e [C]r [C]u [C]m O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
( [C]( O 
FSH [C]F [C]S [C]H O 
, [C], O 
LH [C]L [C]H O 
, [C], O 
prolactin [C]p [C]r [C]o [C]l [C]a [C]c [C]t [C]i [C]n O 
, [C], O 
insulin [C]i [C]n [C]s [C]u [C]l [C]i [C]n O 
, [C], O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e O 
and [C]a [C]n [C]d O 
TSH [C]T [C]S [C]H O 
) [C]) O 
; [C]; O 
neither [C]n [C]e [C]i [C]t [C]h [C]e [C]r O 
were [C]w [C]e [C]r [C]e O 
the [C]t [C]h [C]e O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
endometrial [C]e [C]n [C]d [C]o [C]m [C]e [C]t [C]r [C]i [C]a [C]l B-protein 
ERC [C]E [C]R [C]C I-protein 
, [C], I-protein 
ERN [C]E [C]R [C]N I-protein 
, [C], I-protein 
PRC [C]P [C]R [C]C I-protein 
and [C]a [C]n [C]d I-protein 
PRN [C]P [C]R [C]N E-protein 
affected [C]a [C]f [C]f [C]e [C]c [C]t [C]e [C]d O 
by [C]b [C]y O 
interferon [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n S-protein 
administration [C]a [C]d [C]m [C]i [C]n [C]i [C]s [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

As [C]A [C]s O 
expected [C]e [C]x [C]p [C]e [C]c [C]t [C]e [C]d O 
, [C], O 
interferon [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n S-protein 
administration [C]a [C]d [C]m [C]i [C]n [C]i [C]s [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e S-cell_type 
counts [C]c [C]o [C]u [C]n [C]t [C]s O 
. [C]. O 

Moreover [C]M [C]o [C]r [C]e [C]o [C]v [C]e [C]r O 
, [C], O 
an [C]a [C]n O 
increasing [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]i [C]n [C]g O 
tendency [C]t [C]e [C]n [C]d [C]e [C]n [C]c [C]y O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
activities [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]i [C]e [C]s O 
of [C]o [C]f O 
serum [C]s [C]e [C]r [C]u [C]m B-protein 
alkaline [C]a [C]l [C]k [C]a [C]l [C]i [C]n [C]e I-protein 
phosphatase [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]a [C]s [C]e E-protein 
and [C]a [C]n [C]d O 
gamma-glutamyltransferase [C]g [C]a [C]m [C]m [C]a [C]- [C]g [C]l [C]u [C]t [C]a [C]m [C]y [C]l [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]r [C]a [C]s [C]e S-protein 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
interferon [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n S-protein 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
shows [C]s [C]h [C]o [C]w [C]s O 
that [C]t [C]h [C]a [C]t O 
interferon [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n S-protein 
may [C]m [C]a [C]y O 
slightly [C]s [C]l [C]i [C]g [C]h [C]t [C]l [C]y O 
interfere [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]e O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
liver [C]l [C]i [C]v [C]e [C]r O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
one [C]o [C]n [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
by [C]b [C]y O 
which [C]w [C]h [C]i [C]c [C]h O 
interferon [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n S-protein 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
may [C]m [C]a [C]y O 
affect [C]a [C]f [C]f [C]e [C]c [C]t O 
the [C]t [C]h [C]e O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
of [C]o [C]f O 
hormone-dependent [C]h [C]o [C]r [C]m [C]o [C]n [C]e [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
neoplasms [C]n [C]e [C]o [C]p [C]l [C]a [C]s [C]m [C]s O 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
the [C]t [C]h [C]e O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
and/or [C]a [C]n [C]d [C]/ [C]o [C]r O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
circulating [C]c [C]i [C]r [C]c [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
hormonal [C]h [C]o [C]r [C]m [C]o [C]n [C]a [C]l O 
compounds [C]c [C]o [C]m [C]p [C]o [C]u [C]n [C]d [C]s O 
. [C]. O 

[ [C][ O 
Glucocorticoid [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
level [C]l [C]e [C]v [C]e [C]l O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
blood [C]b [C]l [C]o [C]o [C]d B-cell_type 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
in [C]i [C]n O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
acute [C]a [C]c [C]u [C]t [C]e O 
diseases [C]d [C]i [C]s [C]e [C]a [C]s [C]e [C]s O 
] [C]] O 

Content [C]C [C]o [C]n [C]t [C]e [C]n [C]t O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
of [C]o [C]f O 
blood [C]b [C]l [C]o [C]o [C]d B-cell_type 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
, [C], O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
and [C]a [C]n [C]d O 
amount [C]a [C]m [C]o [C]u [C]n [C]t O 
of [C]o [C]f O 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
in [C]i [C]n O 
blood [C]b [C]l [C]o [C]o [C]d O 
were [C]w [C]e [C]r [C]e O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
in [C]i [C]n O 
20 [C]2 [C]0 O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
acute [C]a [C]c [C]u [C]t [C]e O 
impairments [C]i [C]m [C]p [C]a [C]i [C]r [C]m [C]e [C]n [C]t [C]s O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
the [C]t [C]h [C]e O 
second [C]s [C]e [C]c [C]o [C]n [C]d O 
day [C]d [C]a [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
. [C]. O 

Content [C]C [C]o [C]n [C]t [C]e [C]n [C]t O 
of [C]o [C]f O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
in [C]i [C]n O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
of [C]o [C]f O 
blood [C]b [C]l [C]o [C]o [C]d O 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s O 
was [C]w [C]a [C]s O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
using [C]u [C]s [C]i [C]n [C]g O 
3H-triamcinolone [C]3 [C]H [C]- [C]t [C]r [C]i [C]a [C]m [C]c [C]i [C]n [C]o [C]l [C]o [C]n [C]e O 
acetonide [C]a [C]c [C]e [C]t [C]o [C]n [C]i [C]d [C]e O 
. [C]. O 

Distinct [C]D [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
amount [C]a [C]m [C]o [C]u [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e B-protein 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
poisoning [C]p [C]o [C]i [C]s [C]o [C]n [C]i [C]n [C]g O 
by [C]b [C]y O 
dichlorethane [C]d [C]i [C]c [C]h [C]l [C]o [C]r [C]e [C]t [C]h [C]a [C]n [C]e O 
and [C]a [C]n [C]d O 
hypnotic [C]h [C]y [C]p [C]n [C]o [C]t [C]i [C]c O 
drugs [C]d [C]r [C]u [C]g [C]s O 
under [C]u [C]n [C]d [C]e [C]r O 
conditions [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
acute [C]a [C]c [C]u [C]t [C]e O 
myocardial [C]m [C]y [C]o [C]c [C]a [C]r [C]d [C]i [C]a [C]l O 
infarction [C]i [C]n [C]f [C]a [C]r [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

In [C]I [C]n O 
acute [C]a [C]c [C]u [C]t [C]e O 
pancreatitis [C]p [C]a [C]n [C]c [C]r [C]e [C]a [C]t [C]i [C]t [C]i [C]s O 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
altered [C]a [C]l [C]t [C]e [C]r [C]e [C]d O 
as [C]a [C]s O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
. [C]. O 

Concentration [C]C [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
endogenous [C]e [C]n [C]d [C]o [C]g [C]e [C]n [C]o [C]u [C]s O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
was [C]w [C]a [C]s O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
in [C]i [C]n O 
blood [C]b [C]l [C]o [C]o [C]d O 
of [C]o [C]f O 
all [C]a [C]l [C]l O 
the [C]t [C]h [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
, [C], O 
except [C]e [C]x [C]c [C]e [C]p [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cases [C]c [C]a [C]s [C]e [C]s O 
of [C]o [C]f O 
acetate [C]a [C]c [C]e [C]t [C]a [C]t [C]e O 
intoxication [C]i [C]n [C]t [C]o [C]x [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Reverse [C]R [C]e [C]v [C]e [C]r [C]s [C]e O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
in [C]i [C]n O 
blood [C]b [C]l [C]o [C]o [C]d O 
and [C]a [C]n [C]d O 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
in [C]i [C]n O 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
. [C]. O 

But [C]B [C]u [C]t O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
acute [C]a [C]c [C]u [C]t [C]e O 
pancreatitis [C]p [C]a [C]n [C]c [C]r [C]e [C]a [C]t [C]i [C]t [C]i [C]s O 
the [C]t [C]h [C]e O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
of [C]o [C]f O 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e B-protein 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
although [C]a [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
there [C]t [C]h [C]e [C]r [C]e O 
was [C]w [C]a [C]s O 
an [C]a [C]n O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
blood [C]b [C]l [C]o [C]o [C]d O 
. [C]. O 

The [C]T [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
immunological [C]i [C]m [C]m [C]u [C]n [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
processes [C]p [C]r [C]o [C]c [C]e [C]s [C]s [C]e [C]s O 
under [C]u [C]n [C]d [C]e [C]r O 
conditions [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
purulent [C]p [C]u [C]r [C]u [C]l [C]e [C]n [C]t O 
complications [C]c [C]o [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n [C]s O 
and [C]a [C]n [C]d O 
possibility [C]p [C]o [C]s [C]s [C]i [C]b [C]i [C]l [C]i [C]t [C]y O 
to [C]t [C]o O 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
metabolism [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]s [C]m O 
in [C]i [C]n O 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 

Therapeutic [C]T [C]h [C]e [C]r [C]a [C]p [C]e [C]u [C]t [C]i [C]c O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
suppress [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s O 
the [C]t [C]h [C]e O 
antimicrobial [C]a [C]n [C]t [C]i [C]m [C]i [C]c [C]r [C]o [C]b [C]i [C]a [C]l O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s E-cell_type 
without [C]w [C]i [C]t [C]h [C]o [C]u [C]t O 
impairing [C]i [C]m [C]p [C]a [C]i [C]r [C]i [C]n [C]g O 
their [C]t [C]h [C]e [C]i [C]r O 
responsiveness [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e [C]n [C]e [C]s [C]s O 
to [C]t [C]o O 
gamma [C]g [C]a [C]m [C]m [C]a B-protein 
interferon [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n E-protein 
. [C]. O 

By [C]B [C]y O 
exposing [C]e [C]x [C]p [C]o [C]s [C]i [C]n [C]g O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
blood-derived [C]b [C]l [C]o [C]o [C]d [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d I-cell_type 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s I-cell_type 
and [C]a [C]n [C]d I-cell_type 
alveolar [C]a [C]l [C]v [C]e [C]o [C]l [C]a [C]r I-cell_type 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s E-cell_type 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
to [C]t [C]o O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
, [C], O 
we [C]w [C]e O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
in [C]i [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
that [C]t [C]h [C]a [C]t O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
markedly [C]m [C]a [C]r [C]k [C]e [C]d [C]l [C]y O 
suppress [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s O 
the [C]t [C]h [C]e O 
antimicrobial [C]a [C]n [C]t [C]i [C]m [C]i [C]c [C]r [C]o [C]b [C]i [C]a [C]l O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_type 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e S-cell_type 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
lymphokines [C]l [C]y [C]m [C]p [C]h [C]o [C]k [C]i [C]n [C]e [C]s S-cell_type 
. [C]. O 

As [C]A [C]s O 
little [C]l [C]i [C]t [C]t [C]l [C]e O 
as [C]a [C]s O 
2.5 [C]2 [C]. [C]5 O 
X [C]X O 
10 [C]1 [C]0 O 
( [C]( O 
-8 [C]- [C]8 O 
) [C]) O 
mol/liter [C]m [C]o [C]l [C]/ [C]l [C]i [C]t [C]e [C]r O 
of [C]o [C]f O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
prevented [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]e [C]d O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_type 
from [C]f [C]r [C]o [C]m O 
inhibiting [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]n [C]g O 
germination [C]g [C]e [C]r [C]m [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Aspergillus [C]A [C]s [C]p [C]e [C]r [C]g [C]i [C]l [C]l [C]u [C]s O 
spores [C]s [C]p [C]o [C]r [C]e [C]s O 
or [C]o [C]r O 
from [C]f [C]r [C]o [C]m O 
eliminating [C]e [C]l [C]i [C]m [C]i [C]n [C]a [C]t [C]i [C]n [C]g O 
ingested [C]i [C]n [C]g [C]e [C]s [C]t [C]e [C]d O 
bacteria [C]b [C]a [C]c [C]t [C]e [C]r [C]i [C]a O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
Listeria [C]L [C]i [C]s [C]t [C]e [C]r [C]i [C]a O 
, [C], O 
Nocardia [C]N [C]o [C]c [C]a [C]r [C]d [C]i [C]a O 
, [C], O 
or [C]o [C]r O 
Salmonella [C]S [C]a [C]l [C]m [C]o [C]n [C]e [C]l [C]l [C]a O 
. [C]. O 

Damage [C]D [C]a [C]m [C]a [C]g [C]e O 
to [C]t [C]o O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e S-cell_type 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
by [C]b [C]y O 
progesterone [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
and [C]a [C]n [C]d O 
appeared [C]a [C]p [C]p [C]e [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
receptor-mediated [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
. [C]. O 

In [C]I [C]n O 
accordance [C]a [C]c [C]c [C]o [C]r [C]d [C]a [C]n [C]c [C]e O 
with [C]w [C]i [C]t [C]h O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
observations [C]o [C]b [C]s [C]e [C]r [C]v [C]a [C]t [C]i [C]o [C]n [C]s O 
, [C], O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
24-36 [C]2 [C]4 [C]- [C]3 [C]6 O 
h [C]h O 
to [C]t [C]o O 
suppress [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s O 
antimicrobial [C]a [C]n [C]t [C]i [C]m [C]i [C]c [C]r [C]o [C]b [C]i [C]a [C]l O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

While [C]W [C]h [C]i [C]l [C]e O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
interfered [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
base-line [C]b [C]a [C]s [C]e [C]- [C]l [C]i [C]n [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_type 
, [C], O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
comparable [C]c [C]o [C]m [C]p [C]a [C]r [C]a [C]b [C]l [C]e O 
to [C]t [C]o O 
drug [C]d [C]r [C]u [C]g O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
in [C]i [C]n O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
had [C]h [C]a [C]d O 
no [C]n [C]o O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e S-cell_type 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Proliferating [C]P [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]n [C]g O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
and [C]a [C]n [C]d O 
gamma-interferon [C]g [C]a [C]m [C]m [C]a [C]- [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n S-protein 
thus [C]t [C]h [C]u [C]s O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
antimicrobial [C]a [C]n [C]t [C]i [C]m [C]i [C]c [C]r [C]o [C]b [C]i [C]a [C]l O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
phagocytes [C]p [C]h [C]a [C]g [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
exposed [C]e [C]x [C]p [C]o [C]s [C]e [C]d O 
to [C]t [C]o O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
over [C]o [C]v [C]e [C]r O 
that [C]t [C]h [C]a [C]t O 
of [C]o [C]f O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
cells [C]c [C]e [C]l [C]l [C]s O 
. [C]. O 

Macrophage [C]M [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
correction [C]c [C]o [C]r [C]r [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
by [C]b [C]y O 
gamma-interferon [C]g [C]a [C]m [C]m [C]a [C]- [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n S-protein 
, [C], O 
however [C]h [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
was [C]w [C]a [C]s O 
dependent [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
pathogen [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
lymphokine [C]l [C]y [C]m [C]p [C]h [C]o [C]k [C]i [C]n [C]e S-protein 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
the [C]t [C]h [C]e O 
antimicrobial [C]a [C]n [C]t [C]i [C]m [C]i [C]c [C]r [C]o [C]b [C]i [C]a [C]l O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
dexamethasone-treated [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e [C]- [C]t [C]r [C]e [C]a [C]t [C]e [C]d B-cell_line 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s E-cell_line 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
Listeria [C]L [C]i [C]s [C]t [C]e [C]r [C]i [C]a O 
and [C]a [C]n [C]d O 
Salmonella [C]S [C]a [C]l [C]m [C]o [C]n [C]e [C]l [C]l [C]a O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
Aspergillus [C]A [C]s [C]p [C]e [C]r [C]g [C]i [C]l [C]l [C]u [C]s O 
or [C]o [C]r O 
Nocardia [C]N [C]o [C]c [C]a [C]r [C]d [C]i [C]a O 
. [C]. O 

Dexamethasone-induced [C]D [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
damage [C]d [C]a [C]m [C]a [C]g [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
antimicrobial [C]a [C]n [C]t [C]i [C]m [C]i [C]c [C]r [C]o [C]b [C]i [C]a [C]l O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s E-cell_type 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
parallels [C]p [C]a [C]r [C]a [C]l [C]l [C]e [C]l [C]s O 
observations [C]o [C]b [C]s [C]e [C]r [C]v [C]a [C]t [C]i [C]o [C]n [C]s O 
that [C]t [C]h [C]a [C]t O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
render [C]r [C]e [C]n [C]d [C]e [C]r O 
laboratory [C]l [C]a [C]b [C]o [C]r [C]a [C]t [C]o [C]r [C]y O 
animals [C]a [C]n [C]i [C]m [C]a [C]l [C]s O 
susceptible [C]s [C]u [C]s [C]c [C]e [C]p [C]t [C]i [C]b [C]l [C]e O 
to [C]t [C]o O 
listeriosis [C]l [C]i [C]s [C]t [C]e [C]r [C]i [C]o [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
aspergillosis [C]a [C]s [C]p [C]e [C]r [C]g [C]i [C]l [C]l [C]o [C]s [C]i [C]s O 
by [C]b [C]y O 
damaging [C]d [C]a [C]m [C]a [C]g [C]i [C]n [C]g O 
resident [C]r [C]e [C]s [C]i [C]d [C]e [C]n [C]t O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_line 
. [C]. O 

Suppression [C]S [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e S-cell_type 
antimicrobial [C]a [C]n [C]t [C]i [C]m [C]i [C]c [C]r [C]o [C]b [C]i [C]a [C]l O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
should [C]s [C]h [C]o [C]u [C]l [C]d O 
thus [C]t [C]h [C]u [C]s O 
be [C]b [C]e O 
considered [C]c [C]o [C]n [C]s [C]i [C]d [C]e [C]r [C]e [C]d O 
when [C]w [C]h [C]e [C]n O 
treating [C]t [C]r [C]e [C]a [C]t [C]i [C]n [C]g O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
; [C]; O 
its [C]i [C]t [C]s O 
prevention [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
gamma-interferon [C]g [C]a [C]m [C]m [C]a [C]- [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n S-protein 
might [C]m [C]i [C]g [C]h [C]t O 
be [C]b [C]e O 
beneficial [C]b [C]e [C]n [C]e [C]f [C]i [C]c [C]i [C]a [C]l O 
for [C]f [C]o [C]r O 
some [C]s [C]o [C]m [C]e O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
all [C]a [C]l [C]l O 
pathogens [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]s O 
. [C]. O 

Interleukin [C]I [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n B-protein 
2 [C]2 I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
( [C]( O 
Tac [C]T [C]a [C]c B-protein 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n E-protein 
) [C]) O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
HTLV-I-associated [C]H [C]T [C]L [C]V [C]- [C]I [C]- [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
adult [C]a [C]d [C]u [C]l [C]t O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l S-cell_type 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
. [C]. O 

Interleukin-2 [C]I [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]2 S-protein 
( [C]( O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
) [C]) O 
is [C]i [C]s O 
a [C]a O 
lymphokine [C]l [C]y [C]m [C]p [C]h [C]o [C]k [C]i [C]n [C]e S-protein 
synthesized [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]z [C]e [C]d O 
by [C]b [C]y O 
some [C]s [C]o [C]m [C]e O 
T-cells [C]T [C]- [C]c [C]e [C]l [C]l [C]s S-cell_type 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Resting [C]R [C]e [C]s [C]t [C]i [C]n [C]g O 
T-cells [C]T [C]- [C]c [C]e [C]l [C]l [C]s S-cell_type 
do [C]d [C]o O 
not [C]n [C]o [C]t O 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
IL-2 [C]I [C]L [C]- [C]2 B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
, [C], O 
but [C]b [C]u [C]t O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
are [C]a [C]r [C]e O 
rapidly [C]r [C]a [C]p [C]i [C]d [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
on [C]o [C]n O 
T-cells [C]T [C]- [C]c [C]e [C]l [C]l [C]s S-cell_type 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
antigens [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]s O 
, [C], O 
mitogens [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]s O 
, [C], O 
or [C]o [C]r O 
monoclonal [C]m [C]o [C]n [C]o [C]c [C]l [C]o [C]n [C]a [C]l B-protein 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s E-protein 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
antigen-specific [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-protein 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
. [C]. O 

Using [C]U [C]s [C]i [C]n [C]g O 
anti-Tac [C]a [C]n [C]t [C]i [C]- [C]T [C]a [C]c S-protein 
, [C], O 
a [C]a O 
monoclonal [C]m [C]o [C]n [C]o [C]c [C]l [C]o [C]n [C]a [C]l B-protein 
antibody [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y E-protein 
that [C]t [C]h [C]a [C]t O 
recognizes [C]r [C]e [C]c [C]o [C]g [C]n [C]i [C]z [C]e [C]s O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
, [C], O 
the [C]t [C]h [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d O 
and [C]a [C]n [C]d O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
be [C]b [C]e O 
a [C]a O 
Mr [C]M [C]r O 
33 [C]3 [C]3 O 
, [C], O 
000 [C]0 [C]0 [C]0 O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
posttranslationally [C]p [C]o [C]s [C]t [C]t [C]r [C]a [C]n [C]s [C]l [C]a [C]t [C]i [C]o [C]n [C]a [C]l [C]l [C]y O 
glycosylated [C]g [C]l [C]y [C]c [C]o [C]s [C]y [C]l [C]a [C]t [C]e [C]d O 
to [C]t [C]o O 
a [C]a O 
Mr [C]M [C]r O 
55 [C]5 [C]5 O 
, [C], O 
000 [C]0 [C]0 [C]0 O 
mature [C]m [C]a [C]t [C]u [C]r [C]e O 
form [C]f [C]o [C]r [C]m O 
. [C]. O 

Normal [C]N [C]o [C]r [C]m [C]a [C]l O 
resting [C]r [C]e [C]s [C]t [C]i [C]n [C]g O 
T-cells [C]T [C]- [C]c [C]e [C]l [C]l [C]s S-cell_type 
and [C]a [C]n [C]d O 
most [C]m [C]o [C]s [C]t O 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c B-cell_line 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l I-cell_line 
populations [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n [C]s E-cell_line 
do [C]d [C]o O 
not [C]n [C]o [C]t O 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
IL-2 [C]I [C]L [C]- [C]2 B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
; [C]; O 
however [C]h [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
the [C]t [C]h [C]e O 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
11 [C]1 [C]1 O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
who [C]w [C]h [C]o O 
had [C]h [C]a [C]d O 
human [C]h [C]u [C]m [C]a [C]n O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
lymphotropic [C]l [C]y [C]m [C]p [C]h [C]o [C]t [C]r [C]o [C]p [C]i [C]c O 
virus-associated [C]v [C]i [C]r [C]u [C]s [C]- [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
adult [C]a [C]d [C]u [C]l [C]t O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
Tac [C]T [C]a [C]c B-protein 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n E-protein 
. [C]. O 

In [C]I [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l I-cell_type 
lymphotropic [C]l [C]y [C]m [C]p [C]h [C]o [C]t [C]r [C]o [C]p [C]i [C]c I-cell_type 
virus-I [C]v [C]i [C]r [C]u [C]s [C]- [C]I I-cell_type 
infected [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
the [C]t [C]h [C]e O 
Mr [C]M [C]r O 
42 [C]4 [C]2 O 
, [C], O 
000 [C]0 [C]0 [C]0 O 
long [C]l [C]o [C]n [C]g O 
open [C]o [C]p [C]e [C]n B-protein 
reading [C]r [C]e [C]a [C]d [C]i [C]n [C]g I-protein 
frame [C]f [C]r [C]a [C]m [C]e I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
encoded [C]e [C]n [C]c [C]o [C]d [C]e [C]d O 
in [C]i [C]n O 
part [C]p [C]a [C]r [C]t O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
pX [C]p [C]X B-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
virus [C]v [C]i [C]r [C]u [C]s O 
may [C]m [C]a [C]y O 
act [C]a [C]c [C]t O 
as [C]a [C]s O 
a [C]a O 
transacting [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]n [C]g B-protein 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l I-protein 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r E-protein 
that [C]t [C]h [C]a [C]t O 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
, [C], O 
thus [C]t [C]h [C]u [C]s O 
providing [C]p [C]r [C]o [C]v [C]i [C]d [C]i [C]n [C]g O 
an [C]a [C]n O 
explanation [C]e [C]x [C]p [C]l [C]a [C]n [C]a [C]t [C]i [C]o [C]n O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
constant [C]c [C]o [C]n [C]s [C]t [C]a [C]n [C]t O 
association [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-2 [C]I [C]L [C]- [C]2 B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
adult [C]a [C]d [C]u [C]l [C]t O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
lymphotropic [C]l [C]y [C]m [C]p [C]h [C]o [C]t [C]r [C]o [C]p [C]i [C]c O 
virus-I [C]v [C]i [C]r [C]u [C]s [C]- [C]I O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
constant [C]c [C]o [C]n [C]s [C]t [C]a [C]n [C]t O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
large [C]l [C]a [C]r [C]g [C]e O 
numbers [C]n [C]u [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
IL-2 [C]I [C]L [C]- [C]2 B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
which [C]w [C]h [C]i [C]c [C]h O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
aberrant [C]a [C]b [C]e [C]r [C]r [C]a [C]n [C]t O 
may [C]m [C]a [C]y O 
play [C]p [C]l [C]a [C]y O 
a [C]a O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
uncontrolled [C]u [C]n [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]l [C]e [C]d O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
of [C]o [C]f O 
adult [C]a [C]d [C]u [C]l [C]t B-cell_type 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l I-cell_type 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Two [C]T [C]w [C]o O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
Tac-positive [C]T [C]a [C]c [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
adult [C]a [C]d [C]u [C]l [C]t O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
anti-Tac [C]a [C]n [C]t [C]i [C]- [C]T [C]a [C]c S-protein 
. [C]. O 

One [C]O [C]n [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
had [C]h [C]a [C]d O 
6- [C]6 [C]- O 
and [C]a [C]n [C]d O 
3-mo [C]3 [C]- [C]m [C]o O 
remissions [C]r [C]e [C]m [C]i [C]s [C]s [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
his [C]h [C]i [C]s O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
two [C]t [C]w [C]o O 
courses [C]c [C]o [C]u [C]r [C]s [C]e [C]s O 
of [C]o [C]f O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
with [C]w [C]i [C]t [C]h O 
this [C]t [C]h [C]i [C]s O 
monoclonal [C]m [C]o [C]n [C]o [C]c [C]l [C]o [C]n [C]a [C]l B-protein 
antibody [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y E-protein 
directed [C]d [C]i [C]r [C]e [C]c [C]t [C]e [C]d O 
toward [C]t [C]o [C]w [C]a [C]r [C]d O 
this [C]t [C]h [C]i [C]s O 
growth [C]g [C]r [C]o [C]w [C]t [C]h B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
. [C]. O 

Lymphocyte [C]L [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e S-cell_type 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
in [C]i [C]n O 
depressed [C]d [C]e [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
hypercortisolemia [C]h [C]y [C]p [C]e [C]r [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l [C]e [C]m [C]i [C]a O 
. [C]. O 

Despite [C]D [C]e [C]s [C]p [C]i [C]t [C]e O 
elevated [C]e [C]l [C]e [C]v [C]a [C]t [C]e [C]d O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
serum [C]s [C]e [C]r [C]u [C]m O 
and [C]a [C]n [C]d O 
urinary [C]u [C]r [C]i [C]n [C]a [C]r [C]y O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
, [C], O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
depressive [C]d [C]e [C]p [C]r [C]e [C]s [C]s [C]i [C]v [C]e O 
illness [C]i [C]l [C]l [C]n [C]e [C]s [C]s O 
manifest [C]m [C]a [C]n [C]i [C]f [C]e [C]s [C]t O 
none [C]n [C]o [C]n [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
clinical [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
stigmata [C]s [C]t [C]i [C]g [C]m [C]a [C]t [C]a O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
excess [C]e [C]x [C]c [C]e [C]s [C]s O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
hypercortisolemia [C]h [C]y [C]p [C]e [C]r [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l [C]e [C]m [C]i [C]a O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
clinical [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
suggests [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]s O 
a [C]a O 
state [C]s [C]t [C]a [C]t [C]e O 
of [C]o [C]f O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
and [C]a [C]n [C]d O 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
alterations [C]a [C]l [C]t [C]e [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
. [C]. O 

Earlier [C]E [C]a [C]r [C]l [C]i [C]e [C]r O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
have [C]h [C]a [C]v [C]e O 
shown [C]s [C]h [C]o [C]w [C]n O 
that [C]t [C]h [C]a [C]t O 
small [C]s [C]m [C]a [C]l [C]l O 
doses [C]d [C]o [C]s [C]e [C]s O 
of [C]o [C]f O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
cause [C]c [C]a [C]u [C]s [C]e O 
a [C]a O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

White [C]W [C]h [C]i [C]t [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
from [C]f [C]r [C]o [C]m O 
depressed [C]d [C]e [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
hypercortisolemia [C]h [C]y [C]p [C]e [C]r [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l [C]e [C]m [C]i [C]a O 
would [C]w [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
expected [C]e [C]x [C]p [C]e [C]c [C]t [C]e [C]d O 
to [C]t [C]o O 
show [C]s [C]h [C]o [C]w O 
a [C]a O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
change [C]c [C]h [C]a [C]n [C]g [C]e O 
in [C]i [C]n O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
if [C]i [C]f O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l O 
tissues [C]t [C]i [C]s [C]s [C]u [C]e [C]s O 
are [C]a [C]r [C]e O 
adequately [C]a [C]d [C]e [C]q [C]u [C]a [C]t [C]e [C]l [C]y O 
exposed [C]e [C]x [C]p [C]o [C]s [C]e [C]d O 
to [C]t [C]o O 
and [C]a [C]n [C]d O 
sensitive [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e O 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
we [C]w [C]e O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
the [C]t [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
to [C]t [C]o O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
from [C]f [C]r [C]o [C]m O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
and [C]a [C]n [C]d O 
depressed [C]d [C]e [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
hypercortisolemia [C]h [C]y [C]p [C]e [C]r [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l [C]e [C]m [C]i [C]a O 
. [C]. O 

Lymphocytes [C]L [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
from [C]f [C]r [C]o [C]m O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
had [C]h [C]a [C]d O 
a [C]a O 
mean [C]m [C]e [C]a [C]n O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
10.2 [C]1 [C]0 [C]. [C]2 O 
+/- [C]+ [C]/ [C]- O 
0.66 [C]0 [C]. [C]6 [C]6 O 
fm/10 [C]f [C]m [C]/ [C]1 [C]0 O 
( [C]( O 
6 [C]6 O 
) [C]) O 
cells [C]c [C]e [C]l [C]l [C]s O 
( [C]( O 
S.E.M. [C]S [C]. [C]E [C]. [C]M [C]. O 
) [C]) O 
and [C]a [C]n [C]d O 
a [C]a O 
dissociation [C]d [C]i [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
constant [C]c [C]o [C]n [C]s [C]t [C]a [C]n [C]t O 
of [C]o [C]f O 
4.8 [C]4 [C]. [C]8 O 
+/- [C]+ [C]/ [C]- O 
0.47 [C]0 [C]. [C]4 [C]7 O 
nM [C]n [C]M O 
. [C]. O 

Lymphocytes [C]L [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
from [C]f [C]r [C]o [C]m O 
depressed [C]d [C]e [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
abnormal [C]a [C]b [C]n [C]o [C]r [C]m [C]a [C]l O 
0800 [C]0 [C]8 [C]0 [C]0 O 
h [C]h O 
serum [C]s [C]e [C]r [C]u [C]m O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
after [C]a [C]f [C]t [C]e [C]r O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
had [C]h [C]a [C]d O 
a [C]a O 
mean [C]m [C]e [C]a [C]n O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
8.8 [C]8 [C]. [C]8 O 
+/- [C]+ [C]/ [C]- O 
0.75 [C]0 [C]. [C]7 [C]5 O 
fm/10 [C]f [C]m [C]/ [C]1 [C]0 O 
( [C]( O 
6 [C]6 O 
) [C]) O 
cells [C]c [C]e [C]l [C]l [C]s O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
from [C]f [C]r [C]o [C]m O 
that [C]t [C]h [C]a [C]t O 
in [C]i [C]n O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
from [C]f [C]r [C]o [C]m O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
or [C]o [C]r O 
from [C]f [C]r [C]o [C]m O 
depressed [C]d [C]e [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
post-dexamethasone [C]p [C]o [C]s [C]t [C]- [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
( [C]( O 
9.4 [C]9 [C]. [C]4 O 
+/- [C]+ [C]/ [C]- O 
0.95 [C]0 [C]. [C]9 [C]5 O 
fm/10 [C]f [C]m [C]/ [C]1 [C]0 O 
( [C]( O 
6 [C]6 O 
) [C]) O 
cells [C]c [C]e [C]l [C]l [C]s O 
) [C]) O 
. [C]. O 

Lymphocytes [C]L [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
from [C]f [C]r [C]o [C]m O 
depressed [C]d [C]e [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
elevated [C]e [C]l [C]e [C]v [C]a [C]t [C]e [C]d O 
urinary [C]u [C]r [C]i [C]n [C]a [C]r [C]y O 
free [C]f [C]r [C]e [C]e O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
excretion [C]e [C]x [C]c [C]r [C]e [C]t [C]i [C]o [C]n O 
( [C]( O 
UFC [C]U [C]F [C]C O 
) [C]) O 
also [C]a [C]l [C]s [C]o O 
had [C]h [C]a [C]d O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
for [C]f [C]o [C]r O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
lack [C]l [C]a [C]c [C]k O 
of [C]o [C]f O 
a [C]a O 
change [C]c [C]h [C]a [C]n [C]g [C]e O 
in [C]i [C]n O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e S-cell_type 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
excess [C]e [C]x [C]c [C]e [C]s [C]s O 
suggests [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]s O 
the [C]t [C]h [C]e O 
possibility [C]p [C]o [C]s [C]s [C]i [C]b [C]i [C]l [C]i [C]t [C]y O 
that [C]t [C]h [C]a [C]t O 
hypercortisolemia [C]h [C]y [C]p [C]e [C]r [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l [C]e [C]m [C]i [C]a O 
in [C]i [C]n O 
depressive [C]d [C]e [C]p [C]r [C]e [C]s [C]s [C]i [C]v [C]e O 
illness [C]i [C]l [C]l [C]n [C]e [C]s [C]s O 
represents [C]r [C]e [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]s O 
a [C]a O 
state [C]s [C]t [C]a [C]t [C]e O 
of [C]o [C]f O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
. [C]. O 

Structure [C]S [C]t [C]r [C]u [C]c [C]t [C]u [C]r [C]e O 
and [C]a [C]n [C]d O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
is [C]i [C]s O 
an [C]a [C]n O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
which [C]w [C]h [C]i [C]c [C]h O 
possesses [C]p [C]o [C]s [C]s [C]e [C]s [C]s [C]e [C]s O 
three [C]t [C]h [C]r [C]e [C]e O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
domains [C]d [C]o [C]m [C]a [C]i [C]n [C]s O 
, [C], O 
one [C]o [C]n [C]e O 
that [C]t [C]h [C]a [C]t O 
binds [C]b [C]i [C]n [C]d [C]s O 
agonist [C]a [C]g [C]o [C]n [C]i [C]s [C]t O 
and [C]a [C]n [C]d O 
antagonist [C]a [C]n [C]t [C]a [C]g [C]o [C]n [C]i [C]s [C]t O 
steroids [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]s O 
, [C], O 
one [C]o [C]n [C]e O 
that [C]t [C]h [C]a [C]t O 
binds [C]b [C]i [C]n [C]d [C]s O 
DNA [C]D [C]N [C]A O 
, [C], O 
and [C]a [C]n [C]d O 
one [C]o [C]n [C]e O 
that [C]t [C]h [C]a [C]t O 
binds [C]b [C]i [C]n [C]d [C]s O 
anti-receptor [C]a [C]n [C]t [C]i [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r B-protein 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s E-protein 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
modulation [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

In [C]I [C]n O 
intact [C]i [C]n [C]t [C]a [C]c [C]t O 
cells [C]c [C]e [C]l [C]l [C]s O 
, [C], O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
, [C], O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
can [C]c [C]a [C]n O 
change [C]c [C]h [C]a [C]n [C]g [C]e O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
that [C]t [C]h [C]a [C]t O 
bind [C]b [C]i [C]n [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
, [C], O 
or [C]o [C]r O 
that [C]t [C]h [C]a [C]t O 
act [C]a [C]c [C]t O 
indirectly [C]i [C]n [C]d [C]i [C]r [C]e [C]c [C]t [C]l [C]y O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
ill-defined [C]i [C]l [C]l [C]- [C]d [C]e [C]f [C]i [C]n [C]e [C]d O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
which [C]w [C]h [C]i [C]c [C]h O 
may [C]m [C]a [C]y O 
include [C]i [C]n [C]c [C]l [C]u [C]d [C]e O 
resumption [C]r [C]e [C]s [C]u [C]m [C]p [C]t [C]i [C]o [C]n O 
or [C]o [C]r O 
arrest [C]a [C]r [C]r [C]e [C]s [C]t O 
of [C]o [C]f O 
cell [C]c [C]e [C]l [C]l O 
cycling [C]c [C]y [C]c [C]l [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
variations [C]v [C]a [C]r [C]i [C]a [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
calcium [C]c [C]a [C]l [C]c [C]i [C]u [C]m O 
ion [C]i [C]o [C]n O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

Some [C]S [C]o [C]m [C]e O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
appear [C]a [C]p [C]p [C]e [C]a [C]r O 
to [C]t [C]o O 
exert [C]e [C]x [C]e [C]r [C]t O 
their [C]t [C]h [C]e [C]i [C]r O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
by [C]b [C]y O 
controlling [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]l [C]i [C]n [C]g O 
critical [C]c [C]r [C]i [C]t [C]i [C]c [C]a [C]l O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
properties [C]p [C]r [C]o [C]p [C]e [C]r [C]t [C]i [C]e [C]s O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
ATP-dependent [C]A [C]T [C]P [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
integrity [C]i [C]n [C]t [C]e [C]g [C]r [C]i [C]t [C]y O 
of [C]o [C]f O 
thiol [C]t [C]h [C]i [C]o [C]l B-protein 
groups [C]g [C]r [C]o [C]u [C]p [C]s E-protein 
, [C], O 
and [C]a [C]n [C]d O 
exposure [C]e [C]x [C]p [C]o [C]s [C]u [C]r [C]e O 
of [C]o [C]f O 
key [C]k [C]e [C]y B-protein 
amino [C]a [C]m [C]i [C]n [C]o I-protein 
acid [C]a [C]c [C]i [C]d I-protein 
residues [C]r [C]e [C]s [C]i [C]d [C]u [C]e [C]s E-protein 
. [C]. O 

Glucocorticoid [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
agonists [C]a [C]g [C]o [C]n [C]i [C]s [C]t [C]s O 
promote [C]p [C]r [C]o [C]m [C]o [C]t [C]e O 
the [C]t [C]h [C]e O 
'transformation [C]' [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
' [C]' O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
into [C]i [C]n [C]t [C]o O 
the [C]t [C]h [C]e O 
DNA-binding [C]D [C]N [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
state [C]s [C]t [C]a [C]t [C]e O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
competent [C]c [C]o [C]m [C]p [C]e [C]t [C]e [C]n [C]t O 
for [C]f [C]o [C]r O 
modulating [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Glucocorticoid [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
antagonists [C]a [C]n [C]t [C]a [C]g [C]o [C]n [C]i [C]s [C]t [C]s O 
are [C]a [C]r [C]e O 
steroids [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]s O 
that [C]t [C]h [C]a [C]t O 
interact [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
but [C]b [C]u [C]t O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
fail [C]f [C]a [C]i [C]l O 
to [C]t [C]o O 
produce [C]p [C]r [C]o [C]d [C]u [C]c [C]e O 
a [C]a O 
stable [C]s [C]t [C]a [C]b [C]l [C]e B-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
or [C]o [C]r O 
produce [C]p [C]r [C]o [C]d [C]u [C]c [C]e O 
a [C]a O 
stable [C]s [C]t [C]a [C]b [C]l [C]e B-protein 
but [C]b [C]u [C]t I-protein 
inefficient [C]i [C]n [C]e [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t I-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
substituent [C]s [C]u [C]b [C]s [C]t [C]i [C]t [C]u [C]e [C]n [C]t O 
groups [C]g [C]r [C]o [C]u [C]p [C]s O 
that [C]t [C]h [C]a [C]t O 
confer [C]c [C]o [C]n [C]f [C]e [C]r O 
agonist [C]a [C]g [C]o [C]n [C]i [C]s [C]t O 
or [C]o [C]r O 
antagonist [C]a [C]n [C]t [C]a [C]g [C]o [C]n [C]i [C]s [C]t O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
, [C], O 
the [C]t [C]h [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
determinants [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]n [C]t [C]s O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
difference [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
level [C]l [C]e [C]v [C]e [C]l O 
remain [C]r [C]e [C]m [C]a [C]i [C]n O 
unknown [C]u [C]n [C]k [C]n [C]o [C]w [C]n O 
. [C]. O 

Most [C]M [C]o [C]s [C]t O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
data [C]d [C]a [C]t [C]a O 
on [C]o [C]n O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
can [C]c [C]a [C]n O 
be [C]b [C]e O 
accommodated [C]a [C]c [C]c [C]o [C]m [C]m [C]o [C]d [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
postulating [C]p [C]o [C]s [C]t [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
existence [C]e [C]x [C]i [C]s [C]t [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
an [C]a [C]n O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
cycle [C]c [C]y [C]c [C]l [C]e O 
that [C]t [C]h [C]a [C]t O 
involves [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]s O 
five [C]f [C]i [C]v [C]e O 
states [C]s [C]t [C]a [C]t [C]e [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
. [C]. O 

The [C]T [C]h [C]e O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
free [C]f [C]r [C]e [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
is [C]i [C]s O 
phosphorylated [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]e [C]d O 
, [C], O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
, [C], O 
and [C]a [C]n [C]d O 
presumably [C]p [C]r [C]e [C]s [C]u [C]m [C]a [C]b [C]l [C]y O 
oligomeric [C]o [C]l [C]i [C]g [C]o [C]m [C]e [C]r [C]i [C]c O 
( [C]( O 
state [C]s [C]t [C]a [C]t [C]e O 
A [C]A O 
) [C]) O 
. [C]. O 

Following [C]F [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
an [C]a [C]n O 
agonist [C]a [C]g [C]o [C]n [C]i [C]s [C]t O 
( [C]( O 
state [C]s [C]t [C]a [C]t [C]e O 
B [C]B O 
) [C]) O 
, [C], O 
it [C]i [C]t O 
can [C]c [C]a [C]n O 
become [C]b [C]e [C]c [C]o [C]m [C]e O 
transformed [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]e [C]d O 
by [C]b [C]y O 
dissociation [C]d [C]i [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
into [C]i [C]n [C]t [C]o O 
its [C]i [C]t [C]s O 
subunits [C]s [C]u [C]b [C]u [C]n [C]i [C]t [C]s O 
and [C]a [C]n [C]d O 
dephosphorylation [C]d [C]e [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
( [C]( O 
state [C]s [C]t [C]a [C]t [C]e O 
C [C]C O 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
transformed [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]e [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
then [C]t [C]h [C]e [C]n O 
interacts [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
chromatin [C]c [C]h [C]r [C]o [C]m [C]a [C]t [C]i [C]n S-DNA 
( [C]( O 
state [C]s [C]t [C]a [C]t [C]e O 
D [C]D O 
) [C]) O 
. [C]. O 

Dissociation [C]D [C]i [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
and [C]a [C]n [C]d O 
oxidation [C]o [C]x [C]i [C]d [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r B-protein 
thiol [C]t [C]h [C]i [C]o [C]l I-protein 
group [C]g [C]r [C]o [C]u [C]p E-protein 
( [C]( O 
s [C]s O 
) [C]) O 
lead [C]l [C]e [C]a [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
inactive [C]i [C]n [C]a [C]c [C]t [C]i [C]v [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
form [C]f [C]o [C]r [C]m O 
( [C]( O 
state [C]s [C]t [C]a [C]t [C]e O 
E [C]E O 
) [C]) O 
. [C]. O 

Reduction [C]R [C]e [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
rephosphorylation [C]r [C]e [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
enable [C]e [C]n [C]a [C]b [C]l [C]e O 
it [C]i [C]t O 
to [C]t [C]o O 
bind [C]b [C]i [C]n [C]d O 
steroids [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]s O 
again [C]a [C]g [C]a [C]i [C]n O 
so [C]s [C]o O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
cycle [C]c [C]y [C]c [C]l [C]e O 
is [C]i [C]s O 
closed [C]c [C]l [C]o [C]s [C]e [C]d O 
. [C]. O 

Thermodynamics [C]T [C]h [C]e [C]r [C]m [C]o [C]d [C]y [C]n [C]a [C]m [C]i [C]c [C]s O 
of [C]o [C]f O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-protein 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
thermodynamics [C]t [C]h [C]e [C]r [C]m [C]o [C]d [C]y [C]n [C]a [C]m [C]i [C]c [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
with [C]w [C]i [C]t [C]h O 
their [C]t [C]h [C]e [C]i [C]r O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
were [C]w [C]e [C]r [C]e O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
in [C]i [C]n O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
from [C]f [C]r [C]o [C]m O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
lymphoblastoid [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]o [C]i [C]d I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
rate [C]r [C]a [C]t [C]e O 
and [C]a [C]n [C]d O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
constants [C]c [C]o [C]n [C]s [C]t [C]a [C]n [C]t [C]s O 
of [C]o [C]f O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
and [C]a [C]n [C]d O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
0 [C]0 O 
degree [C]d [C]e [C]g [C]r [C]e [C]e O 
and [C]a [C]n [C]d O 
25 [C]2 [C]5 O 
degrees [C]d [C]e [C]g [C]r [C]e [C]e [C]s O 
C [C]C O 
were [C]w [C]e [C]r [C]e O 
calculated [C]c [C]a [C]l [C]c [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
curve-fitting [C]c [C]u [C]r [C]v [C]e [C]- [C]f [C]i [C]t [C]t [C]i [C]n [C]g O 
from [C]f [C]r [C]o [C]m O 
time-course [C]t [C]i [C]m [C]e [C]- [C]c [C]o [C]u [C]r [C]s [C]e O 
and [C]a [C]n [C]d O 
equilibrium [C]e [C]q [C]u [C]i [C]l [C]i [C]b [C]r [C]i [C]u [C]m O 
kinetics [C]k [C]i [C]n [C]e [C]t [C]i [C]c [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
data [C]d [C]a [C]t [C]a O 
were [C]w [C]e [C]r [C]e O 
consistent [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
simple [C]s [C]i [C]m [C]p [C]l [C]e O 
reversible [C]r [C]e [C]v [C]e [C]r [C]s [C]i [C]b [C]l [C]e O 
bimolecular [C]b [C]i [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

Arrhenius [C]A [C]r [C]r [C]h [C]e [C]n [C]i [C]u [C]s O 
and [C]a [C]n [C]d O 
Va [C]V [C]a O 
n't [C]n [C]' [C]t O 
Hoff [C]H [C]o [C]f [C]f O 
plots [C]p [C]l [C]o [C]t [C]s O 
were [C]w [C]e [C]r [C]e O 
curvilinear [C]c [C]u [C]r [C]v [C]i [C]l [C]i [C]n [C]e [C]a [C]r O 
for [C]f [C]o [C]r O 
both [C]b [C]o [C]t [C]h O 
steroids [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]s O 
. [C]. O 

At [C]A [C]t O 
equilibrium [C]e [C]q [C]u [C]i [C]l [C]i [C]b [C]r [C]i [C]u [C]m O 
, [C], O 
the [C]t [C]h [C]e O 
solution [C]s [C]o [C]l [C]u [C]t [C]i [C]o [C]n O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
equation [C]e [C]q [C]u [C]a [C]t [C]i [C]o [C]n O 
delta [C]d [C]e [C]l [C]t [C]a O 
G [C]G O 
= [C]= O 
delta [C]d [C]e [C]l [C]t [C]a O 
H [C]H O 
- [C]- O 
T [C]T O 
X [C]X O 
delta [C]d [C]e [C]l [C]t [C]a O 
S [C]S O 
( [C]( O 
eqn. [C]e [C]q [C]n [C]. O 
1 [C]1 O 
) [C]) O 
was [C]w [C]a [C]s O 
( [C]( O 
in [C]i [C]n O 
kJ [C]k [C]J O 
X [C]X O 
mol-1 [C]m [C]o [C]l [C]- [C]1 O 
) [C]) O 
-47 [C]- [C]4 [C]7 O 
= [C]= O 
36 [C]3 [C]6 O 
- [C]- O 
83 [C]8 [C]3 O 
( [C]( O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
) [C]) O 
and [C]a [C]n [C]d O 
-42 [C]- [C]4 [C]2 O 
= [C]= O 
-9 [C]- [C]9 O 
- [C]- O 
33 [C]3 [C]3 O 
( [C]( O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
) [C]) O 
at [C]a [C]t O 
0 [C]0 O 
degree [C]d [C]e [C]g [C]r [C]e [C]e O 
C [C]C O 
. [C]. O 

Enthalpy [C]E [C]n [C]t [C]h [C]a [C]l [C]p [C]y O 
and [C]a [C]n [C]d O 
entropy [C]e [C]n [C]t [C]r [C]o [C]p [C]y O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
quasi-linearly [C]q [C]u [C]a [C]s [C]i [C]- [C]l [C]i [C]n [C]e [C]a [C]r [C]l [C]y O 
with [C]w [C]i [C]t [C]h O 
temperature [C]t [C]e [C]m [C]p [C]e [C]r [C]a [C]t [C]u [C]r [C]e O 
such [C]s [C]u [C]c [C]h O 
that [C]t [C]h [C]a [C]t O 
, [C], O 
at [C]a [C]t O 
25 [C]2 [C]5 O 
degrees [C]d [C]e [C]g [C]r [C]e [C]e [C]s O 
C [C]C O 
, [C], O 
the [C]t [C]h [C]e O 
respective [C]r [C]e [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e O 
values [C]v [C]a [C]l [C]u [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
-50 [C]- [C]5 [C]0 O 
= [C]= O 
-75 [C]- [C]7 [C]5 O 
+ [C]+ O 
25 [C]2 [C]5 O 
and [C]a [C]n [C]d O 
-43 [C]- [C]4 [C]3 O 
= [C]= O 
-48 [C]- [C]4 [C]8 O 
+ [C]+ O 
5 [C]5 O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
for [C]f [C]o [C]r O 
both [C]b [C]o [C]t [C]h O 
steroids [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]s O 
, [C], O 
the [C]t [C]h [C]e O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
entropy-driven [C]e [C]n [C]t [C]r [C]o [C]p [C]y [C]- [C]d [C]r [C]i [C]v [C]e [C]n O 
at [C]a [C]t O 
low [C]l [C]o [C]w O 
temperature [C]t [C]e [C]m [C]p [C]e [C]r [C]a [C]t [C]u [C]r [C]e O 
and [C]a [C]n [C]d O 
became [C]b [C]e [C]c [C]a [C]m [C]e O 
entirely [C]e [C]n [C]t [C]i [C]r [C]e [C]l [C]y O 
enthalpy-driven [C]e [C]n [C]t [C]h [C]a [C]l [C]p [C]y [C]- [C]d [C]r [C]i [C]v [C]e [C]n O 
at [C]a [C]t O 
20 [C]2 [C]0 O 
degrees [C]d [C]e [C]g [C]r [C]e [C]e [C]s O 
C [C]C O 
. [C]. O 

Thermodynamic [C]T [C]h [C]e [C]r [C]m [C]o [C]d [C]y [C]n [C]a [C]m [C]i [C]c O 
values [C]v [C]a [C]l [C]u [C]e [C]s O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
transition [C]t [C]r [C]a [C]n [C]s [C]i [C]t [C]i [C]o [C]n O 
state [C]s [C]t [C]a [C]t [C]e O 
were [C]w [C]e [C]r [C]e O 
calculated [C]c [C]a [C]l [C]c [C]u [C]l [C]a [C]t [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
rate [C]r [C]a [C]t [C]e O 
constants [C]c [C]o [C]n [C]s [C]t [C]a [C]n [C]t [C]s O 
. [C]. O 

For [C]F [C]o [C]r O 
the [C]t [C]h [C]e O 
forward [C]f [C]o [C]r [C]w [C]a [C]r [C]d O 
reaction [C]r [C]e [C]a [C]c [C]t [C]i [C]o [C]n O 
, [C], O 
eqn. [C]e [C]q [C]n [C]. O 
( [C]( O 
1 [C]1 O 
) [C]) O 
gave [C]g [C]a [C]v [C]e O 
45 [C]4 [C]5 O 
= [C]= O 
84 [C]8 [C]4 O 
- [C]- O 
39 [C]3 [C]9 O 
( [C]( O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
) [C]) O 
and [C]a [C]n [C]d O 
46 [C]4 [C]6 O 
= [C]= O 
60 [C]6 [C]0 O 
- [C]- O 
14 [C]1 [C]4 O 
( [C]( O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
) [C]) O 
at [C]a [C]t O 
0 [C]0 O 
degree [C]d [C]e [C]g [C]r [C]e [C]e O 
C [C]C O 
, [C], O 
and [C]a [C]n [C]d O 
44 [C]4 [C]4 O 
= [C]= O 
24 [C]2 [C]4 O 
+ [C]+ O 
20 [C]2 [C]0 O 
( [C]( O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
) [C]) O 
and [C]a [C]n [C]d O 
46 [C]4 [C]6 O 
= [C]= O 
28 [C]2 [C]8 O 
+ [C]+ O 
18 [C]1 [C]8 O 
( [C]( O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
) [C]) O 
at [C]a [C]t O 
25 [C]2 [C]5 O 
degrees [C]d [C]e [C]g [C]r [C]e [C]e [C]s O 
C [C]C O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
fit [C]f [C]i [C]t O 
quite [C]q [C]u [C]i [C]t [C]e O 
well [C]w [C]e [C]l [C]l O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
two-step [C]t [C]w [C]o [C]- [C]s [C]t [C]e [C]p O 
model [C]m [C]o [C]d [C]e [C]l O 
[ [C][ O 
Ross [C]R [C]o [C]s [C]s O 
& [C]& O 
Subramanian [C]S [C]u [C]b [C]r [C]a [C]m [C]a [C]n [C]i [C]a [C]n O 
( [C]( O 
1981 [C]1 [C]9 [C]8 [C]1 O 
) [C]) O 
Biochemistry [C]B [C]i [C]o [C]c [C]h [C]e [C]m [C]i [C]s [C]t [C]r [C]y O 
20 [C]2 [C]0 O 
, [C], O 
3096-3102 [C]3 [C]0 [C]9 [C]6 [C]- [C]3 [C]1 [C]0 [C]2 O 
] [C]] O 
proposed [C]p [C]r [C]o [C]p [C]o [C]s [C]e [C]d O 
for [C]f [C]o [C]r O 
ligand-protein [C]l [C]i [C]g [C]a [C]n [C]d [C]- [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
interactions [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
involves [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]s O 
a [C]a O 
partial [C]p [C]a [C]r [C]t [C]i [C]a [C]l O 
immobilization [C]i [C]m [C]m [C]o [C]b [C]i [C]l [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
reacting [C]r [C]e [C]a [C]c [C]t [C]i [C]n [C]g O 
species [C]s [C]p [C]e [C]c [C]i [C]e [C]s O 
governed [C]g [C]o [C]v [C]e [C]r [C]n [C]e [C]d O 
by [C]b [C]y O 
hydrophobic [C]h [C]y [C]d [C]r [C]o [C]p [C]h [C]o [C]b [C]i [C]c O 
forces [C]f [C]o [C]r [C]c [C]e [C]s O 
, [C], O 
followed [C]f [C]o [C]l [C]l [C]o [C]w [C]e [C]d O 
by [C]b [C]y O 
stabilization [C]s [C]t [C]a [C]b [C]i [C]l [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
by [C]b [C]y O 
short-range [C]s [C]h [C]o [C]r [C]t [C]- [C]r [C]a [C]n [C]g [C]e O 
interactions [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

On [C]O [C]n O 
the [C]t [C]h [C]e O 
basis [C]b [C]a [C]s [C]i [C]s O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
model [C]m [C]o [C]d [C]e [C]l O 
, [C], O 
an [C]a [C]n O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
transition-state [C]t [C]r [C]a [C]n [C]s [C]i [C]t [C]i [C]o [C]n [C]- [C]s [C]t [C]a [C]t [C]e O 
thermodynamics [C]t [C]h [C]e [C]r [C]m [C]o [C]d [C]y [C]n [C]a [C]m [C]i [C]c [C]s O 
led [C]l [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
conclusion [C]c [C]o [C]n [C]c [C]l [C]u [C]s [C]i [C]o [C]n O 
that [C]t [C]h [C]a [C]t O 
no [C]n [C]o O 
more [C]m [C]o [C]r [C]e O 
than [C]t [C]h [C]a [C]n O 
half [C]h [C]a [C]l [C]f O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
area [C]a [C]r [C]e [C]a O 
is [C]i [C]s O 
engaged [C]e [C]n [C]g [C]a [C]g [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
. [C]. O 

Cell [C]C [C]e [C]l [C]l O 
cycle-related [C]c [C]y [C]c [C]l [C]e [C]- [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
in [C]i [C]n O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
T-lymphocyte [C]T [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
for [C]f [C]o [C]r O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
and [C]a [C]n [C]d O 
insulin [C]i [C]n [C]s [C]u [C]l [C]i [C]n O 
. [C]. O 

Enriched [C]E [C]n [C]r [C]i [C]c [C]h [C]e [C]d O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
T-lymphocytes [C]T [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
PHA [C]P [C]H [C]A O 
and [C]a [C]n [C]d O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
for [C]f [C]o [C]r O 
variations [C]v [C]a [C]r [C]i [C]a [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
insulin [C]i [C]n [C]s [C]u [C]l [C]i [C]n O 
and [C]a [C]n [C]d O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
( [C]( O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
) [C]) O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
numbers [C]n [C]u [C]m [C]b [C]e [C]r [C]s O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
early [C]e [C]a [C]r [C]l [C]y O 
phases [C]p [C]h [C]a [C]s [C]e [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cell [C]c [C]e [C]l [C]l O 
cycle [C]c [C]y [C]c [C]l [C]e O 
. [C]. O 

Cells [C]C [C]e [C]l [C]l [C]s O 
in [C]i [C]n O 
G0 [C]G [C]0 O 
, [C], O 
G1a [C]G [C]1 [C]a O 
and [C]a [C]n [C]d O 
G1b [C]G [C]1 [C]b O 
phases [C]p [C]h [C]a [C]s [C]e [C]s O 
, [C], O 
where [C]w [C]h [C]e [C]r [C]e O 
the [C]t [C]h [C]e O 
G1a [C]G [C]1 [C]a O 
- [C]- O 
G1b [C]G [C]1 [C]b O 
transition [C]t [C]r [C]a [C]n [C]s [C]i [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
an [C]a [C]n O 
Interleukin [C]I [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n B-protein 
2 [C]2 E-protein 
dependent [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
event [C]e [C]v [C]e [C]n [C]t O 
, [C], O 
were [C]w [C]e [C]r [C]e O 
quantitated [C]q [C]u [C]a [C]n [C]t [C]i [C]t [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
flow [C]f [C]l [C]o [C]w O 
cytometry [C]c [C]y [C]t [C]o [C]m [C]e [C]t [C]r [C]y O 
. [C]. O 

Few [C]F [C]e [C]w O 
but [C]b [C]u [C]t O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
numbers [C]n [C]u [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
( [C]( O 
2700/cell [C]2 [C]7 [C]0 [C]0 [C]/ [C]c [C]e [C]l [C]l O 
) [C]) O 
and [C]a [C]n [C]d O 
no [C]n [C]o O 
insulin [C]i [C]n [C]s [C]u [C]l [C]i [C]n B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
( [C]( O 
-1/cell [C]- [C]1 [C]/ [C]c [C]e [C]l [C]l O 
) [C]) O 
were [C]w [C]e [C]r [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
resting [C]r [C]e [C]s [C]t [C]i [C]n [C]g O 
( [C]( O 
G0 [C]G [C]0 O 
) [C]) O 
phase [C]p [C]h [C]a [C]s [C]e O 
. [C]. O 

As [C]A [C]s O 
cells [C]c [C]e [C]l [C]l [C]s O 
entered [C]e [C]n [C]t [C]e [C]r [C]e [C]d O 
the [C]t [C]h [C]e O 
G1a [C]G [C]1 [C]a O 
phase [C]p [C]h [C]a [C]s [C]e O 
the [C]t [C]h [C]e O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
and [C]a [C]n [C]d O 
of [C]o [C]f O 
insulin [C]i [C]n [C]s [C]u [C]l [C]i [C]n O 
took [C]t [C]o [C]o [C]k O 
place [C]p [C]l [C]a [C]c [C]e O 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
as [C]a [C]s O 
T-cells [C]T [C]- [C]c [C]e [C]l [C]l [C]s S-cell_type 
entered [C]e [C]n [C]t [C]e [C]r [C]e [C]d O 
the [C]t [C]h [C]e O 
G1b [C]G [C]1 [C]b O 
phase [C]p [C]h [C]a [C]s [C]e O 
( [C]( O 
as [C]a [C]s O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
at [C]a [C]t O 
44 [C]4 [C]4 O 
h [C]h O 
of [C]o [C]f O 
incubation [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
using [C]u [C]s [C]i [C]n [C]g O 
hydroxyurea-treated [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]u [C]r [C]e [C]a [C]- [C]t [C]r [C]e [C]a [C]t [C]e [C]d B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
) [C]) O 
, [C], O 
the [C]t [C]h [C]e O 
major [C]m [C]a [C]j [C]o [C]r O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
took [C]t [C]o [C]o [C]k O 
place [C]p [C]l [C]a [C]c [C]e O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
period [C]p [C]e [C]r [C]i [C]o [C]d O 
16 [C]1 [C]6 O 
- [C]- O 
20 [C]2 [C]0 O 
h [C]h O 
after [C]a [C]f [C]t [C]e [C]r O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Based [C]B [C]a [C]s [C]e [C]d O 
on [C]o [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
, [C], O 
it [C]i [C]t O 
is [C]i [C]s O 
concluded [C]c [C]o [C]n [C]c [C]l [C]u [C]d [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
both [C]b [C]o [C]t [C]h O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
types [C]t [C]y [C]p [C]e [C]s O 
( [C]( O 
cell [C]c [C]e [C]l [C]l B-protein 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e I-protein 
and [C]a [C]n [C]d I-protein 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
) [C]) O 
are [C]a [C]r [C]e O 
being [C]b [C]e [C]i [C]n [C]g O 
formed [C]f [C]o [C]r [C]m [C]e [C]d O 
and [C]a [C]n [C]d O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
at [C]a [C]t O 
G1 [C]G [C]1 O 
phase [C]p [C]h [C]a [C]s [C]e O 
prior [C]p [C]r [C]i [C]o [C]r O 
to [C]t [C]o O 
cell [C]c [C]e [C]l [C]l O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
indicating [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
importance [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]c [C]e O 
of [C]o [C]f O 
G1 [C]G [C]1 O 
phase [C]p [C]h [C]a [C]s [C]e O 
in [C]i [C]n O 
immunoregulation [C]i [C]m [C]m [C]u [C]n [C]o [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Glucocorticoid [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
and [C]a [C]n [C]d O 
cortico-sensitivity [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]- [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
a [C]a O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
clonal [C]c [C]l [C]o [C]n [C]a [C]l I-cell_line 
monocytic [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]i [C]c I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
, [C], O 
CM-SM [C]C [C]M [C]- [C]S [C]M S-cell_line 
. [C]. O 

CM-SM [C]C [C]M [C]- [C]S [C]M S-cell_line 
is [C]i [C]s O 
a [C]a O 
clonal [C]c [C]l [C]o [C]n [C]a [C]l B-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
precursor [C]p [C]r [C]e [C]c [C]u [C]r [C]s [C]o [C]r I-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
phagocytes [C]p [C]h [C]a [C]g [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
inducible [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
to [C]t [C]o O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e S-cell_type 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
tumor [C]t [C]u [C]m [C]o [C]r O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
phorbol [C]p [C]h [C]o [C]r [C]b [C]o [C]l O 
ester [C]e [C]s [C]t [C]e [C]r O 
12-O-tetradecanoyl-phorbol-13-acetate [C]1 [C]2 [C]- [C]O [C]- [C]t [C]e [C]t [C]r [C]a [C]d [C]e [C]c [C]a [C]n [C]o [C]y [C]l [C]- [C]p [C]h [C]o [C]r [C]b [C]o [C]l [C]- [C]1 [C]3 [C]- [C]a [C]c [C]e [C]t [C]a [C]t [C]e O 
( [C]( O 
TPA [C]T [C]P [C]A O 
) [C]) O 
. [C]. O 

Untreated [C]U [C]n [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
CM-SM [C]C [C]M [C]- [C]S [C]M O 
cells [C]c [C]e [C]l [C]l [C]s O 
contain [C]c [C]o [C]n [C]t [C]a [C]i [C]n O 
single [C]s [C]i [C]n [C]g [C]l [C]e O 
class [C]c [C]l [C]a [C]s [C]s O 
, [C], O 
high-affinity [C]h [C]i [C]g [C]h [C]- [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
( [C]( O 
KD [C]K [C]D O 
= [C]= O 
4.0 [C]4 [C]. [C]0 O 
X [C]X O 
10 [C]1 [C]0 O 
( [C]( O 
-9 [C]- [C]9 O 
) [C]) O 
M [C]M O 
) [C]) O 
glucocorticoid-specific [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
sites [C]s [C]i [C]t [C]e [C]s O 
( [C]( O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
60 [C]6 [C]0 O 
, [C], O 
000 [C]0 [C]0 [C]0 O 
per [C]p [C]e [C]r O 
cell [C]c [C]e [C]l [C]l O 
) [C]) O 
, [C], O 
as [C]a [C]s O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
whole [C]w [C]h [C]o [C]l [C]e O 
cell [C]c [C]e [C]l [C]l O 
assay [C]a [C]s [C]s [C]a [C]y O 
, [C], O 
at [C]a [C]t O 
37 [C]3 [C]7 O 
degrees [C]d [C]e [C]g [C]r [C]e [C]e [C]s O 
C [C]C O 
, [C], O 
using [C]u [C]s [C]i [C]n [C]g O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
triamcinolone [C]t [C]r [C]i [C]a [C]m [C]c [C]i [C]n [C]o [C]l [C]o [C]n [C]e O 
acetonide [C]a [C]c [C]e [C]t [C]o [C]n [C]i [C]d [C]e O 
( [C]( O 
TA [C]T [C]A O 
) [C]) O 
. [C]. O 

Exposure [C]E [C]x [C]p [C]o [C]s [C]u [C]r [C]e O 
of [C]o [C]f O 
CM-SM [C]C [C]M [C]- [C]S [C]M S-cell_line 
to [C]t [C]o O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
( [C]( O 
DEX [C]D [C]E [C]X O 
) [C]) O 
produced [C]p [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
a [C]a O 
progressive [C]p [C]r [C]o [C]g [C]r [C]e [C]s [C]s [C]i [C]v [C]e O 
, [C], O 
dose- [C]d [C]o [C]s [C]e [C]- O 
and [C]a [C]n [C]d O 
time-related [C]t [C]i [C]m [C]e [C]- [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
series [C]s [C]e [C]r [C]i [C]e [C]s O 
of [C]o [C]f O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
in [C]i [C]n O 
CM-SM [C]C [C]M [C]- [C]S [C]M S-cell_line 
cell [C]c [C]e [C]l [C]l O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
, [C], O 
saturation [C]s [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
density [C]d [C]e [C]n [C]s [C]i [C]t [C]y O 
, [C], O 
morphology [C]m [C]o [C]r [C]p [C]h [C]o [C]l [C]o [C]g [C]y O 
, [C], O 
and [C]a [C]n [C]d O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
properties [C]p [C]r [C]o [C]p [C]e [C]r [C]t [C]i [C]e [C]s O 
, [C], O 
with [C]w [C]i [C]t [C]h O 
half-maximal [C]h [C]a [C]l [C]f [C]- [C]m [C]a [C]x [C]i [C]m [C]a [C]l O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
at [C]a [C]t O 
about [C]a [C]b [C]o [C]u [C]t O 
10 [C]1 [C]0 O 
( [C]( O 
-9 [C]- [C]9 O 
) [C]) O 
M [C]M O 
for [C]f [C]o [C]r O 
DEX [C]D [C]E [C]X O 
. [C]. O 

TA-receptor [C]T [C]A [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
sites [C]s [C]i [C]t [C]e [C]s O 
rapidly [C]r [C]a [C]p [C]i [C]d [C]l [C]y O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
( [C]( O 
about [C]a [C]b [C]o [C]u [C]t O 
70 [C]7 [C]0 O 
% [C]% O 
) [C]) O 
after [C]a [C]f [C]t [C]e [C]r O 
DEX [C]D [C]E [C]X O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
, [C], O 
without [C]w [C]i [C]t [C]h [C]o [C]u [C]t O 
any [C]a [C]n [C]y O 
apparent [C]a [C]p [C]p [C]a [C]r [C]e [C]n [C]t O 
change [C]c [C]h [C]a [C]n [C]g [C]e O 
in [C]i [C]n O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
specificity [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
. [C]. O 

After [C]A [C]f [C]t [C]e [C]r O 
5 [C]5 O 
days [C]d [C]a [C]y [C]s O 
in [C]i [C]n O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
saturating [C]s [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]n [C]g O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
( [C]( O 
3.6 [C]3 [C]. [C]6 O 
X [C]X O 
10 [C]1 [C]0 O 
( [C]( O 
-8 [C]- [C]8 O 
) [C]) O 
M [C]M O 
) [C]) O 
of [C]o [C]f O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e O 
, [C], O 
the [C]t [C]h [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
reached [C]r [C]e [C]a [C]c [C]h [C]e [C]d O 
a [C]a O 
saturation [C]s [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
density [C]d [C]e [C]n [C]s [C]i [C]t [C]y O 
of [C]o [C]f O 
about [C]a [C]b [C]o [C]u [C]t O 
9.0 [C]9 [C]. [C]0 O 
X [C]X O 
10 [C]1 [C]0 O 
( [C]( O 
6 [C]6 O 
) [C]) O 
viable [C]v [C]i [C]a [C]b [C]l [C]e O 
cells/ml [C]c [C]e [C]l [C]l [C]s [C]/ [C]m [C]l O 
( [C]( O 
about [C]a [C]b [C]o [C]u [C]t O 
4.0 [C]4 [C]. [C]0 O 
X [C]X O 
10 [C]1 [C]0 O 
( [C]( O 
6 [C]6 O 
) [C]) O 
viable [C]v [C]i [C]a [C]b [C]l [C]e O 
cells/ml [C]c [C]e [C]l [C]l [C]s [C]/ [C]m [C]l O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
) [C]) O 
, [C], O 
while [C]w [C]h [C]i [C]l [C]e O 
the [C]t [C]h [C]e O 
modal [C]m [C]o [C]d [C]a [C]l O 
volume [C]v [C]o [C]l [C]u [C]m [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
resulting [C]r [C]e [C]s [C]u [C]l [C]t [C]i [C]n [C]g O 
cell [C]c [C]e [C]l [C]l B-cell_line 
population [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n E-cell_line 
was [C]w [C]a [C]s O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
60 [C]6 [C]0 O 
% [C]% O 
, [C], O 
as [C]a [C]s O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
volume [C]v [C]o [C]l [C]u [C]m [C]e O 
of [C]o [C]f O 
untreated [C]u [C]n [C]t [C]r [C]e [C]a [C]t [C]e [C]d B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

DEX-treated [C]D [C]E [C]X [C]- [C]t [C]r [C]e [C]a [C]t [C]e [C]d B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
appeared [C]a [C]p [C]p [C]e [C]a [C]r [C]e [C]d O 
less [C]l [C]e [C]s [C]s O 
differentiated [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]e [C]d O 
than [C]t [C]h [C]a [C]n O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
, [C], O 
as [C]a [C]s O 
assessed [C]a [C]s [C]s [C]e [C]s [C]s [C]e [C]d O 
by [C]b [C]y O 
combined [C]c [C]o [C]m [C]b [C]i [C]n [C]e [C]d O 
morphologic [C]m [C]o [C]r [C]p [C]h [C]o [C]l [C]o [C]g [C]i [C]c O 
, [C], O 
antigenic [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]i [C]c O 
, [C], O 
and [C]a [C]n [C]d O 
cytoenzymatic [C]c [C]y [C]t [C]o [C]e [C]n [C]z [C]y [C]m [C]a [C]t [C]i [C]c O 
analyses [C]a [C]n [C]a [C]l [C]y [C]s [C]e [C]s O 
. [C]. O 

DEX [C]D [C]E [C]X O 
almost [C]a [C]l [C]m [C]o [C]s [C]t O 
completely [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e [C]l [C]y O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
TPA [C]T [C]P [C]A O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e S-cell_type 
functions [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]s O 
: [C]: O 
adherency [C]a [C]d [C]h [C]e [C]r [C]e [C]n [C]c [C]y O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
plate [C]p [C]l [C]a [C]t [C]e O 
, [C], O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
lysosomal [C]l [C]y [C]s [C]o [C]s [C]o [C]m [C]a [C]l B-protein 
enzymes [C]e [C]n [C]z [C]y [C]m [C]e [C]s E-protein 
, [C], O 
Fc [C]F [C]c B-protein 
and [C]a [C]n [C]d I-protein 
C3 [C]C [C]3 I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
, [C], O 
and [C]a [C]n [C]d O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
phagocytosis [C]p [C]h [C]a [C]g [C]o [C]c [C]y [C]t [C]o [C]s [C]i [C]s O 
. [C]. O 

After [C]A [C]f [C]t [C]e [C]r O 
removal [C]r [C]e [C]m [C]o [C]v [C]a [C]l O 
of [C]o [C]f O 
DEX [C]D [C]E [C]X O 
, [C], O 
the [C]t [C]h [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
, [C], O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
a [C]a O 
few [C]f [C]e [C]w O 
passages [C]p [C]a [C]s [C]s [C]a [C]g [C]e [C]s O 
, [C], O 
returned [C]r [C]e [C]t [C]u [C]r [C]n [C]e [C]d O 
to [C]t [C]o O 
a [C]a O 
state [C]s [C]t [C]a [C]t [C]e O 
apparently [C]a [C]p [C]p [C]a [C]r [C]e [C]n [C]t [C]l [C]y O 
identical [C]i [C]d [C]e [C]n [C]t [C]i [C]c [C]a [C]l O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
untreated [C]u [C]n [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
and [C]a [C]n [C]d O 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
to [C]t [C]o O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e S-cell_type 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
TPA [C]T [C]P [C]A O 
. [C]. O 

Acute [C]A [C]c [C]u [C]t [C]e O 
lymphoblastic [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
in [C]i [C]n O 
children [C]c [C]h [C]i [C]l [C]d [C]r [C]e [C]n O 
: [C]: O 
current [C]c [C]u [C]r [C]r [C]e [C]n [C]t O 
status [C]s [C]t [C]a [C]t [C]u [C]s O 
, [C], O 
controversies [C]c [C]o [C]n [C]t [C]r [C]o [C]v [C]e [C]r [C]s [C]i [C]e [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
future [C]f [C]u [C]t [C]u [C]r [C]e O 
perspective [C]p [C]e [C]r [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e O 
. [C]. O 

Disease-free [C]D [C]i [C]s [C]e [C]a [C]s [C]e [C]- [C]f [C]r [C]e [C]e O 
survival [C]s [C]u [C]r [C]v [C]i [C]v [C]a [C]l O 
( [C]( O 
DFS [C]D [C]F [C]S O 
) [C]) O 
in [C]i [C]n O 
childhood [C]c [C]h [C]i [C]l [C]d [C]h [C]o [C]o [C]d O 
ALL [C]A [C]L [C]L O 
is [C]i [C]s O 
60 [C]6 [C]0 O 
% [C]% O 
, [C], O 
and [C]a [C]n [C]d O 
survival [C]s [C]u [C]r [C]v [C]i [C]v [C]a [C]l O 
in [C]i [C]n O 
good [C]g [C]o [C]o [C]d O 
, [C], O 
average [C]a [C]v [C]e [C]r [C]a [C]g [C]e O 
, [C], O 
and [C]a [C]n [C]d O 
poor [C]p [C]o [C]o [C]r O 
prognostic [C]p [C]r [C]o [C]g [C]n [C]o [C]s [C]t [C]i [C]c O 
groups [C]g [C]r [C]o [C]u [C]p [C]s O 
defined [C]d [C]e [C]f [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
initial [C]i [C]n [C]i [C]t [C]i [C]a [C]l O 
WBC [C]W [C]B [C]C O 
and [C]a [C]n [C]d O 
age [C]a [C]g [C]e O 
is [C]i [C]s O 
90 [C]9 [C]0 O 
, [C], O 
60 [C]6 [C]0 O 
, [C], O 
and [C]a [C]n [C]d O 
45 [C]4 [C]5 O 
% [C]% O 
, [C], O 
respectively [C]r [C]e [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
. [C]. O 

Additional [C]A [C]d [C]d [C]i [C]t [C]i [C]o [C]n [C]a [C]l O 
immunological [C]i [C]m [C]m [C]u [C]n [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
, [C], O 
morphological [C]m [C]o [C]r [C]p [C]h [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
, [C], O 
biochemical [C]b [C]i [C]o [C]c [C]h [C]e [C]m [C]i [C]c [C]a [C]l O 
, [C], O 
cytokinetic [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]t [C]i [C]c O 
, [C], O 
and [C]a [C]n [C]d O 
cytogenetic [C]c [C]y [C]t [C]o [C]g [C]e [C]n [C]e [C]t [C]i [C]c O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
, [C], O 
illustrating [C]i [C]l [C]l [C]u [C]s [C]t [C]r [C]a [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
heterogeneity [C]h [C]e [C]t [C]e [C]r [C]o [C]g [C]e [C]n [C]e [C]i [C]t [C]y O 
of [C]o [C]f O 
ALL [C]A [C]L [C]L O 
and [C]a [C]n [C]d O 
its [C]i [C]t [C]s O 
derivation [C]d [C]e [C]r [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
from [C]f [C]r [C]o [C]m O 
malignant [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]t B-cell_line 
clones [C]c [C]l [C]o [C]n [C]e [C]s E-cell_line 
at [C]a [C]t O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
stages [C]s [C]t [C]a [C]g [C]e [C]s O 
of [C]o [C]f O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
with [C]w [C]i [C]t [C]h O 
varying [C]v [C]a [C]r [C]y [C]i [C]n [C]g O 
rates [C]r [C]a [C]t [C]e [C]s O 
of [C]o [C]f O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Of [C]O [C]f O 
biologic [C]b [C]i [C]o [C]l [C]o [C]g [C]i [C]c O 
importance [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]c [C]e O 
, [C], O 
these [C]t [C]h [C]e [C]s [C]e O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
may [C]m [C]a [C]y O 
refine [C]r [C]e [C]f [C]i [C]n [C]e O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
the [C]t [C]h [C]e O 
characteristic [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]s [C]t [C]i [C]c O 
features [C]f [C]e [C]a [C]t [C]u [C]r [C]e [C]s O 
of [C]o [C]f O 
clinically-determined [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l [C]l [C]y [C]- [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
prognostic [C]p [C]r [C]o [C]g [C]n [C]o [C]s [C]t [C]i [C]c O 
groups [C]g [C]r [C]o [C]u [C]p [C]s O 
. [C]. O 

Multivariate [C]M [C]u [C]l [C]t [C]i [C]v [C]a [C]r [C]i [C]a [C]t [C]e O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
large [C]l [C]a [C]r [C]g [C]e O 
prospective [C]p [C]r [C]o [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e O 
trials [C]t [C]r [C]i [C]a [C]l [C]s O 
with [C]w [C]i [C]t [C]h O 
homogeneous [C]h [C]o [C]m [C]o [C]g [C]e [C]n [C]e [C]o [C]u [C]s O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
will [C]w [C]i [C]l [C]l O 
be [C]b [C]e O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
to [C]t [C]o O 
determine [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e O 
the [C]t [C]h [C]e O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
prognostic [C]p [C]r [C]o [C]g [C]n [C]o [C]s [C]t [C]i [C]c O 
importance [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]c [C]e O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
. [C]. O 

Current [C]C [C]u [C]r [C]r [C]e [C]n [C]t O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
strategies [C]s [C]t [C]r [C]a [C]t [C]e [C]g [C]i [C]e [C]s O 
in [C]i [C]n O 
ALL [C]A [C]L [C]L O 
include [C]i [C]n [C]c [C]l [C]u [C]d [C]e O 
( [C]( O 
1 [C]1 O 
) [C]) O 
tailoring [C]t [C]a [C]i [C]l [C]o [C]r [C]i [C]n [C]g O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
and [C]a [C]n [C]d O 
its [C]i [C]t [C]s O 
intensity [C]i [C]n [C]t [C]e [C]n [C]s [C]i [C]t [C]y O 
to [C]t [C]o O 
prognostic [C]p [C]r [C]o [C]g [C]n [C]o [C]s [C]t [C]i [C]c O 
groups [C]g [C]r [C]o [C]u [C]p [C]s O 
; [C]; O 
( [C]( O 
2 [C]2 O 
) [C]) O 
multiple-drug [C]m [C]u [C]l [C]t [C]i [C]p [C]l [C]e [C]- [C]d [C]r [C]u [C]g O 
combinations [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
; [C]; O 
( [C]( O 
3 [C]3 O 
) [C]) O 
early [C]e [C]a [C]r [C]l [C]y O 
use [C]u [C]s [C]e O 
of [C]o [C]f O 
intrathecal [C]i [C]n [C]t [C]r [C]a [C]t [C]h [C]e [C]c [C]a [C]l O 
( [C]( O 
IT [C]I [C]T O 
) [C]) O 
methotrexate [C]m [C]e [C]t [C]h [C]o [C]t [C]r [C]e [C]x [C]a [C]t [C]e O 
( [C]( O 
MTX [C]M [C]T [C]X O 
) [C]) O 
; [C]; O 
( [C]( O 
4 [C]4 O 
) [C]) O 
CNS [C]C [C]N [C]S O 
prophylaxis [C]p [C]r [C]o [C]p [C]h [C]y [C]l [C]a [C]x [C]i [C]s O 
with [C]w [C]i [C]t [C]h O 
IT [C]I [C]T O 
MTX [C]M [C]T [C]X O 
alone [C]a [C]l [C]o [C]n [C]e O 
in [C]i [C]n O 
good [C]g [C]o [C]o [C]d O 
prognosis [C]p [C]r [C]o [C]g [C]n [C]o [C]s [C]i [C]s O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
and [C]a [C]n [C]d O 
combined [C]c [C]o [C]m [C]b [C]i [C]n [C]e [C]d O 
cranial [C]c [C]r [C]a [C]n [C]i [C]a [C]l O 
radiation [C]r [C]a [C]d [C]i [C]a [C]t [C]i [C]o [C]n O 
( [C]( O 
CXRT [C]C [C]X [C]R [C]T O 
) [C]) O 
, [C], O 
1800 [C]1 [C]8 [C]0 [C]0 O 
rads [C]r [C]a [C]d [C]s O 
plus [C]p [C]l [C]u [C]s O 
IT [C]I [C]T O 
MTX [C]M [C]T [C]X O 
, [C], O 
in [C]i [C]n O 
average [C]a [C]v [C]e [C]r [C]a [C]g [C]e O 
and [C]a [C]n [C]d O 
poor [C]p [C]o [C]o [C]r O 
prognosis [C]p [C]r [C]o [C]g [C]n [C]o [C]s [C]i [C]s O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

Current [C]C [C]u [C]r [C]r [C]e [C]n [C]t O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
show [C]s [C]h [C]o [C]w O 
a [C]a O 
CNS [C]C [C]N [C]S O 
relapse [C]r [C]e [C]l [C]a [C]p [C]s [C]e O 
rate [C]r [C]a [C]t [C]e O 
of [C]o [C]f O 
5 [C]5 O 
% [C]% O 
in [C]i [C]n O 
all [C]a [C]l [C]l O 
prognostic [C]p [C]r [C]o [C]g [C]n [C]o [C]s [C]t [C]i [C]c O 
groups [C]g [C]r [C]o [C]u [C]p [C]s O 
. [C]. O 

Late [C]L [C]a [C]t [C]e O 
neuropsychological [C]n [C]e [C]u [C]r [C]o [C]p [C]s [C]y [C]c [C]h [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
defects [C]d [C]e [C]f [C]e [C]c [C]t [C]s O 
caused [C]c [C]a [C]u [C]s [C]e [C]d O 
by [C]b [C]y O 
cranial [C]c [C]r [C]a [C]n [C]i [C]a [C]l O 
XRT [C]X [C]R [C]T O 
and [C]a [C]n [C]d O 
IT [C]I [C]T O 
MTX [C]M [C]T [C]X O 
have [C]h [C]a [C]v [C]e O 
prompted [C]p [C]r [C]o [C]m [C]p [C]t [C]e [C]d O 
programs [C]p [C]r [C]o [C]g [C]r [C]a [C]m [C]s O 
designed [C]d [C]e [C]s [C]i [C]g [C]n [C]e [C]d O 
to [C]t [C]o O 
reduce [C]r [C]e [C]d [C]u [C]c [C]e O 
the [C]t [C]h [C]e O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
late [C]l [C]a [C]t [C]e O 
toxicity [C]t [C]o [C]x [C]i [C]c [C]i [C]t [C]y O 
of [C]o [C]f O 
CNS [C]C [C]N [C]S O 
prophylaxis [C]p [C]r [C]o [C]p [C]h [C]y [C]l [C]a [C]x [C]i [C]s O 
. [C]. O 

More [C]M [C]o [C]r [C]e O 
pronounced [C]p [C]r [C]o [C]n [C]o [C]u [C]n [C]c [C]e [C]d O 
in [C]i [C]n O 
younger [C]y [C]o [C]u [C]n [C]g [C]e [C]r O 
children [C]c [C]h [C]i [C]l [C]d [C]r [C]e [C]n O 
, [C], O 
these [C]t [C]h [C]e [C]s [C]e O 
abnormalities [C]a [C]b [C]n [C]o [C]r [C]m [C]a [C]l [C]i [C]t [C]i [C]e [C]s O 
include [C]i [C]n [C]c [C]l [C]u [C]d [C]e O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
IQ [C]I [C]Q O 
, [C], O 
visual-motor [C]v [C]i [C]s [C]u [C]a [C]l [C]- [C]m [C]o [C]t [C]o [C]r O 
incoordination [C]i [C]n [C]c [C]o [C]o [C]r [C]d [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
poor [C]p [C]o [C]o [C]r O 
performance [C]p [C]e [C]r [C]f [C]o [C]r [C]m [C]a [C]n [C]c [C]e O 
in [C]i [C]n O 
mathematics [C]m [C]a [C]t [C]h [C]e [C]m [C]a [C]t [C]i [C]c [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
memory [C]m [C]e [C]m [C]o [C]r [C]y O 
dysfunction [C]d [C]y [C]s [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

Until [C]U [C]n [C]t [C]i [C]l O 
1980 [C]1 [C]9 [C]8 [C]0 O 
, [C], O 
more [C]m [C]o [C]r [C]e O 
intensive [C]i [C]n [C]t [C]e [C]n [C]s [C]i [C]v [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
, [C], O 
consolidation [C]c [C]o [C]n [C]s [C]o [C]l [C]i [C]d [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
maintenance [C]m [C]a [C]i [C]n [C]t [C]e [C]n [C]a [C]n [C]c [C]e O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
had [C]h [C]a [C]d O 
failed [C]f [C]a [C]i [C]l [C]e [C]d O 
to [C]t [C]o O 
prolong [C]p [C]r [C]o [C]l [C]o [C]n [C]g O 
DFS [C]D [C]F [C]S O 
in [C]i [C]n O 
children [C]c [C]h [C]i [C]l [C]d [C]r [C]e [C]n O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
poor [C]p [C]o [C]o [C]r O 
prognosis [C]p [C]r [C]o [C]g [C]n [C]o [C]s [C]i [C]s O 
. [C]. O 

In [C]I [C]n O 
West [C]W [C]e [C]s [C]t O 
Germany [C]G [C]e [C]r [C]m [C]a [C]n [C]y O 
( [C]( O 
Berlin-Frankfurt-Muenster [C]B [C]e [C]r [C]l [C]i [C]n [C]- [C]F [C]r [C]a [C]n [C]k [C]f [C]u [C]r [C]t [C]- [C]M [C]u [C]e [C]n [C]s [C]t [C]e [C]r O 
protocol [C]p [C]r [C]o [C]t [C]o [C]c [C]o [C]l O 
) [C]) O 
a [C]a O 
70 [C]7 [C]0 O 
to [C]t [C]o O 
75 [C]7 [C]5 O 
% [C]% O 
DFS [C]D [C]F [C]S O 
is [C]i [C]s O 
seen [C]s [C]e [C]e [C]n O 
in [C]i [C]n O 
all [C]a [C]l [C]l O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
regardless [C]r [C]e [C]g [C]a [C]r [C]d [C]l [C]e [C]s [C]s O 
of [C]o [C]f O 
initial [C]i [C]n [C]i [C]t [C]i [C]a [C]l O 
WBC [C]W [C]B [C]C O 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
effective [C]e [C]f [C]f [C]e [C]c [C]t [C]i [C]v [C]e O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
will [C]w [C]i [C]l [C]l O 
override [C]o [C]v [C]e [C]r [C]r [C]i [C]d [C]e O 
prognostic [C]p [C]r [C]o [C]g [C]n [C]o [C]s [C]t [C]i [C]c O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
. [C]. O 

Ultra-high-dose [C]U [C]l [C]t [C]r [C]a [C]- [C]h [C]i [C]g [C]h [C]- [C]d [C]o [C]s [C]e O 
MTX [C]M [C]T [C]X O 
, [C], O 
without [C]w [C]i [C]t [C]h [C]o [C]u [C]t O 
cranial [C]c [C]r [C]a [C]n [C]i [C]a [C]l O 
radiation [C]r [C]a [C]d [C]i [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
is [C]i [C]s O 
also [C]a [C]l [C]s [C]o O 
showing [C]s [C]h [C]o [C]w [C]i [C]n [C]g O 
promise [C]p [C]r [C]o [C]m [C]i [C]s [C]e O 
in [C]i [C]n O 
poor [C]p [C]o [C]o [C]r O 
prognosis [C]p [C]r [C]o [C]g [C]n [C]o [C]s [C]i [C]s O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

Other [C]O [C]t [C]h [C]e [C]r O 
issues [C]i [C]s [C]s [C]u [C]e [C]s O 
include [C]i [C]n [C]c [C]l [C]u [C]d [C]e O 
the [C]t [C]h [C]e O 
optimal [C]o [C]p [C]t [C]i [C]m [C]a [C]l O 
duration [C]d [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
, [C], O 
the [C]t [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
testicular [C]t [C]e [C]s [C]t [C]i [C]c [C]u [C]l [C]a [C]r O 
biopsies [C]b [C]i [C]o [C]p [C]s [C]i [C]e [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
prophylactic [C]p [C]r [C]o [C]p [C]h [C]y [C]l [C]a [C]c [C]t [C]i [C]c O 
testicular [C]t [C]e [C]s [C]t [C]i [C]c [C]u [C]l [C]a [C]r O 
radiation [C]r [C]a [C]d [C]i [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Recent [C]R [C]e [C]c [C]e [C]n [C]t O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
prognostic [C]p [C]r [C]o [C]g [C]n [C]o [C]s [C]t [C]i [C]c O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
lose [C]l [C]o [C]s [C]e O 
their [C]t [C]h [C]e [C]i [C]r O 
significance [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]c [C]e O 
after [C]a [C]f [C]t [C]e [C]r O 
2 [C]2 O 
years [C]y [C]e [C]a [C]r [C]s O 
of [C]o [C]f O 
continuous [C]c [C]o [C]n [C]t [C]i [C]n [C]u [C]o [C]u [C]s O 
complete [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e O 
remission [C]r [C]e [C]m [C]i [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
2 [C]2 O 
years [C]y [C]e [C]a [C]r [C]s O 
of [C]o [C]f O 
maintenance [C]m [C]a [C]i [C]n [C]t [C]e [C]n [C]a [C]n [C]c [C]e O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
is [C]i [C]s O 
adequate [C]a [C]d [C]e [C]q [C]u [C]a [C]t [C]e O 
. [C]. O 

Bilateral [C]B [C]i [C]l [C]a [C]t [C]e [C]r [C]a [C]l O 
open-wedge [C]o [C]p [C]e [C]n [C]- [C]w [C]e [C]d [C]g [C]e O 
testicular [C]t [C]e [C]s [C]t [C]i [C]c [C]u [C]l [C]a [C]r O 
biopsies [C]b [C]i [C]o [C]p [C]s [C]i [C]e [C]s O 
have [C]h [C]a [C]v [C]e O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
occult [C]o [C]c [C]c [C]u [C]l [C]t O 
testicular [C]t [C]e [C]s [C]t [C]i [C]c [C]u [C]l [C]a [C]r O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
8 [C]8 O 
to [C]t [C]o O 
10 [C]1 [C]0 O 
% [C]% O 
of [C]o [C]f O 
males [C]m [C]a [C]l [C]e [C]s O 
. [C]. O 

A [C]A O 
unified [C]u [C]n [C]i [C]f [C]i [C]e [C]d O 
approach [C]a [C]p [C]p [C]r [C]o [C]a [C]c [C]h O 
to [C]t [C]o O 
children [C]c [C]h [C]i [C]l [C]d [C]r [C]e [C]n O 
with [C]w [C]i [C]t [C]h O 
leukemia/lymphoma [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a [C]/ [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a O 
, [C], O 
a [C]a O 
group [C]g [C]r [C]o [C]u [C]p O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
particularly [C]p [C]a [C]r [C]t [C]i [C]c [C]u [C]l [C]a [C]r [C]l [C]y O 
poor [C]p [C]o [C]o [C]r O 
prognosis [C]p [C]r [C]o [C]g [C]n [C]o [C]s [C]i [C]s O 
, [C], O 
utilizing [C]u [C]t [C]i [C]l [C]i [C]z [C]i [C]n [C]g O 
NHL-type [C]N [C]H [C]L [C]- [C]t [C]y [C]p [C]e O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
more [C]m [C]o [C]r [C]e O 
effective [C]e [C]f [C]f [C]e [C]c [C]t [C]i [C]v [C]e O 
than [C]t [C]h [C]a [C]n O 
conventional [C]c [C]o [C]n [C]v [C]e [C]n [C]t [C]i [C]o [C]n [C]a [C]l O 
ALL [C]A [C]L [C]L O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
. [C]. O 

( [C]( O 
ABSTRACT [C]A [C]B [C]S [C]T [C]R [C]A [C]C [C]T O 
TRUNCATED [C]T [C]R [C]U [C]N [C]C [C]A [C]T [C]E [C]D O 
AT [C]A [C]T O 
400 [C]4 [C]0 [C]0 O 
WORDS [C]W [C]O [C]R [C]D [C]S O 
) [C]) O 

Glucocorticoid [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
to [C]t [C]o O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
hormones [C]h [C]o [C]r [C]m [C]o [C]n [C]e [C]s O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n O 
lymphoproliferative [C]l [C]y [C]m [C]p [C]h [C]o [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
diseases [C]d [C]i [C]s [C]e [C]a [C]s [C]e [C]s O 
and [C]a [C]n [C]d O 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
. [C]. O 

The [C]T [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
( [C]( O 
GR [C]G [C]R S-protein 
) [C]) O 
quantitation [C]q [C]u [C]a [C]n [C]t [C]i [C]t [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
a [C]a O 
whole-cell [C]w [C]h [C]o [C]l [C]e [C]- [C]c [C]e [C]l [C]l O 
assay [C]a [C]s [C]s [C]a [C]y O 
and/or [C]a [C]n [C]d [C]/ [C]o [C]r O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
technique [C]t [C]e [C]c [C]h [C]n [C]i [C]q [C]u [C]e O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
to [C]t [C]o O 
steroids [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]s O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
assessed [C]a [C]s [C]s [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
donors [C]d [C]o [C]n [C]o [C]r [C]s O 
and [C]a [C]n [C]d O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
lymphatic [C]l [C]y [C]m [C]p [C]h [C]a [C]t [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
( [C]( O 
CLL [C]C [C]L [C]L O 
) [C]) O 
, [C], O 
acute [C]a [C]c [C]u [C]t [C]e O 
lymphoblastic [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
( [C]( O 
ALL [C]A [C]L [C]L O 
) [C]) O 
, [C], O 
lymphosarcoma [C]l [C]y [C]m [C]p [C]h [C]o [C]s [C]a [C]r [C]c [C]o [C]m [C]a O 
cell [C]c [C]e [C]l [C]l O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
( [C]( O 
LSCL [C]L [C]S [C]C [C]L O 
) [C]) O 
, [C], O 
acute [C]a [C]c [C]u [C]t [C]e O 
nonlymphatic [C]n [C]o [C]n [C]l [C]y [C]m [C]p [C]h [C]a [C]t [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
( [C]( O 
ANLL [C]A [C]N [C]L [C]L O 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
( [C]( O 
CML [C]C [C]M [C]L O 
) [C]) O 
. [C]. O 

Within [C]W [C]i [C]t [C]h [C]i [C]n O 
the [C]t [C]h [C]e O 
lymphoproliferative [C]l [C]y [C]m [C]p [C]h [C]o [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
diseases [C]d [C]i [C]s [C]e [C]a [C]s [C]e [C]s O 
, [C], O 
ALL [C]A [C]L [C]L B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
exhibited [C]e [C]x [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
highest [C]h [C]i [C]g [C]h [C]e [C]s [C]t O 
GR [C]G [C]R S-protein 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
( [C]( O 
regardless [C]r [C]e [C]g [C]a [C]r [C]d [C]l [C]e [C]s [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
method [C]m [C]e [C]t [C]h [C]o [C]d O 
used [C]u [C]s [C]e [C]d O 
) [C]) O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
highest [C]h [C]i [C]g [C]h [C]e [C]s [C]t O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
spontaneous [C]s [C]p [C]o [C]n [C]t [C]a [C]n [C]e [C]o [C]u [C]s O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
thymidine [C]t [C]h [C]y [C]m [C]i [C]d [C]i [C]n [C]e O 
( [C]( O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
TdR [C]T [C]d [C]R O 
) [C]) O 
uptake [C]u [C]p [C]t [C]a [C]k [C]e O 
by [C]b [C]y O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
. [C]. O 

A [C]A O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
relationship [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n [C]s [C]h [C]i [C]p O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
GR [C]G [C]R S-protein 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
( [C]( O 
whole-cell [C]w [C]h [C]o [C]l [C]e [C]- [C]c [C]e [C]l [C]l O 
assay [C]a [C]s [C]s [C]a [C]y O 
) [C]) O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
to [C]t [C]o O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
found [C]f [C]o [C]u [C]n [C]d O 
. [C]. O 

On [C]O [C]n O 
the [C]t [C]h [C]e O 
contrary [C]c [C]o [C]n [C]t [C]r [C]a [C]r [C]y O 
, [C], O 
CLL [C]C [C]L [C]L B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
presented [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
highest [C]h [C]i [C]g [C]h [C]e [C]s [C]t O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
to [C]t [C]o O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
in [C]i [C]n O 
PHA-stimulated [C]P [C]H [C]A [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
cultures [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]s E-cell_line 
. [C]. O 

Cells [C]C [C]e [C]l [C]l [C]s O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
only [C]o [C]n [C]l [C]y O 
two [C]t [C]w [C]o O 
ALL [C]A [C]L [C]L O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
who [C]w [C]h [C]o O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
undergo [C]u [C]n [C]d [C]e [C]r [C]g [C]o O 
a [C]a O 
remission [C]r [C]e [C]m [C]i [C]s [C]s [C]i [C]o [C]n O 
after [C]a [C]f [C]t [C]e [C]r O 
glucocorticoid-inclusive [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]i [C]n [C]c [C]l [C]u [C]s [C]i [C]v [C]e O 
chemotherapy [C]c [C]h [C]e [C]m [C]o [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
had [C]h [C]a [C]d O 
both [C]b [C]o [C]t [C]h O 
the [C]t [C]h [C]e O 
lowest [C]l [C]o [C]w [C]e [C]s [C]t O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
to [C]t [C]o O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
lowest [C]l [C]o [C]w [C]e [C]s [C]t O 
GR [C]G [C]R O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
whole-cell [C]w [C]h [C]o [C]l [C]e [C]- [C]c [C]e [C]l [C]l O 
assay [C]a [C]s [C]s [C]a [C]y O 
. [C]. O 

Concerning [C]C [C]o [C]n [C]c [C]e [C]r [C]n [C]i [C]n [C]g O 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
, [C], O 
ANLL [C]A [C]N [C]L [C]L O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
had [C]h [C]a [C]d O 
GR [C]G [C]R S-protein 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
slightly [C]s [C]l [C]i [C]g [C]h [C]t [C]l [C]y O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
those [C]t [C]h [C]o [C]s [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
ALL [C]A [C]L [C]L O 
group [C]g [C]r [C]o [C]u [C]p O 
but [C]b [C]u [C]t O 
exhibited [C]e [C]x [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
lowest [C]l [C]o [C]w [C]e [C]s [C]t O 
degree [C]d [C]e [C]g [C]r [C]e [C]e O 
of [C]o [C]f O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
spontaneous [C]s [C]p [C]o [C]n [C]t [C]a [C]n [C]e [C]o [C]u [C]s O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
TdR [C]T [C]d [C]R O 
uptake [C]u [C]p [C]t [C]a [C]k [C]e O 
by [C]b [C]y O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
( [C]( O 
stimulatory [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
occurred [C]o [C]c [C]c [C]u [C]r [C]r [C]e [C]d O 
in [C]i [C]n O 
some [C]s [C]o [C]m [C]e O 
cases [C]c [C]a [C]s [C]e [C]s O 
) [C]) O 
. [C]. O 

CML [C]C [C]M [C]L B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
exhibited [C]e [C]x [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
an [C]a [C]n O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
degree [C]d [C]e [C]g [C]r [C]e [C]e O 
by [C]b [C]y O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
that [C]t [C]h [C]a [C]t O 
of [C]o [C]f O 
ANLL [C]A [C]N [C]L [C]L B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
from [C]f [C]r [C]o [C]m O 
that [C]t [C]h [C]a [C]t O 
of [C]o [C]f O 
lymphoproliferative [C]l [C]y [C]m [C]p [C]h [C]o [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
diseases [C]d [C]i [C]s [C]e [C]a [C]s [C]e [C]s O 
. [C]. O 

No [C]N [C]o O 
clear [C]c [C]l [C]e [C]a [C]r O 
relationship [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n [C]s [C]h [C]i [C]p O 
among [C]a [C]m [C]o [C]n [C]g O 
GR [C]G [C]R O 
pattern [C]p [C]a [C]t [C]t [C]e [C]r [C]n O 
, [C], O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
cell [C]c [C]e [C]l [C]l O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
to [C]t [C]o O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
clinicohematologic [C]c [C]l [C]i [C]n [C]i [C]c [C]o [C]h [C]e [C]m [C]a [C]t [C]o [C]l [C]o [C]g [C]i [C]c O 
parameters [C]p [C]a [C]r [C]a [C]m [C]e [C]t [C]e [C]r [C]s O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d O 
leukemia-bearing [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a [C]- [C]b [C]e [C]a [C]r [C]i [C]n [C]g O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

Glucocorticoid [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
corticosensitivity [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
peanut-positive [C]p [C]e [C]a [C]n [C]u [C]t [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e B-cell_line 
and [C]a [C]n [C]d I-cell_line 
peanut-negative [C]p [C]e [C]a [C]n [C]u [C]t [C]- [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e I-cell_line 
human [C]h [C]u [C]m [C]a [C]n I-cell_line 
thymocyte [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e I-cell_line 
subpopulations [C]s [C]u [C]b [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n [C]s E-cell_line 
. [C]. O 

In [C]I [C]n O 
6 [C]6 O 
human [C]h [C]u [C]m [C]a [C]n O 
thymus [C]t [C]h [C]y [C]m [C]u [C]s O 
glands [C]g [C]l [C]a [C]n [C]d [C]s O 
, [C], O 
the [C]t [C]h [C]e O 
immature [C]i [C]m [C]m [C]a [C]t [C]u [C]r [C]e O 
subset [C]s [C]u [C]b [C]s [C]e [C]t O 
of [C]o [C]f O 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
was [C]w [C]a [C]s O 
separated [C]s [C]e [C]p [C]a [C]r [C]a [C]t [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
more [C]m [C]o [C]r [C]e O 
mature [C]m [C]a [C]t [C]u [C]r [C]e O 
one [C]o [C]n [C]e O 
, [C], O 
by [C]b [C]y O 
differential [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l O 
peanut [C]p [C]e [C]a [C]n [C]u [C]t O 
lectin [C]l [C]e [C]c [C]t [C]i [C]n O 
agglutination [C]a [C]g [C]g [C]l [C]u [C]t [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
2 [C]2 O 
cell [C]c [C]e [C]l [C]l O 
subpopulations [C]s [C]u [C]b [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n [C]s O 
were [C]w [C]e [C]r [C]e O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
for [C]f [C]o [C]r O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
by [C]b [C]y O 
using [C]u [C]s [C]i [C]n [C]g O 
a [C]a O 
whole [C]w [C]h [C]o [C]l [C]e O 
cell [C]c [C]e [C]l [C]l O 
assay [C]a [C]s [C]s [C]a [C]y O 
, [C], O 
with [C]w [C]i [C]t [C]h O 
( [C]( O 
3H [C]3 [C]H O 
) [C]) O 
-triamcinolone [C]- [C]t [C]r [C]i [C]a [C]m [C]c [C]i [C]n [C]o [C]l [C]o [C]n [C]e O 
acetonide [C]a [C]c [C]e [C]t [C]o [C]n [C]i [C]d [C]e O 
as [C]a [C]s O 
tracer [C]t [C]r [C]a [C]c [C]e [C]r O 
. [C]. O 

The [C]T [C]h [C]e O 
unagglutinated [C]u [C]n [C]a [C]g [C]g [C]l [C]u [C]t [C]i [C]n [C]a [C]t [C]e [C]d B-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
( [C]( O 
peanut [C]p [C]e [C]a [C]n [C]u [C]t O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
) [C]) O 
contained [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]e [C]d O 
about [C]a [C]b [C]o [C]u [C]t O 
2 [C]2 O 
times [C]t [C]i [C]m [C]e [C]s O 
more [C]m [C]o [C]r [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
sites [C]s [C]i [C]t [C]e [C]s O 
per [C]p [C]e [C]r O 
cell [C]c [C]e [C]l [C]l O 
than [C]t [C]h [C]a [C]n O 
agglutinated [C]a [C]g [C]g [C]l [C]u [C]t [C]i [C]n [C]a [C]t [C]e [C]d O 
( [C]( O 
peanut [C]p [C]e [C]a [C]n [C]u [C]t O 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
) [C]) O 
ones [C]o [C]n [C]e [C]s O 
( [C]( O 
7650 [C]7 [C]6 [C]5 [C]0 O 
+/- [C]+ [C]/ [C]- O 
1550 [C]1 [C]5 [C]5 [C]0 O 
S.D. [C]S [C]. [C]D [C]. O 
verus [C]v [C]e [C]r [C]u [C]s O 
3195 [C]3 [C]1 [C]9 [C]5 O 
+/- [C]+ [C]/ [C]- O 
896 [C]8 [C]9 [C]6 O 
S.D. [C]S [C]. [C]D [C]. O 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
for [C]f [C]o [C]r O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
was [C]w [C]a [C]s O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
cell [C]c [C]e [C]l [C]l O 
subsets [C]s [C]u [C]b [C]s [C]e [C]t [C]s O 
, [C], O 
as [C]a [C]s O 
was [C]w [C]a [C]s O 
the [C]t [C]h [C]e O 
stereospecificity [C]s [C]t [C]e [C]r [C]e [C]o [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]i [C]t [C]y O 
for [C]f [C]o [C]r O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
, [C], O 
the [C]t [C]h [C]e O 
time-course [C]t [C]i [C]m [C]e [C]- [C]c [C]o [C]u [C]r [C]s [C]e O 
of [C]o [C]f O 
steroid-receptor [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
association [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c O 
to [C]t [C]o O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
translocation [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Despite [C]D [C]e [C]s [C]p [C]i [C]t [C]e O 
the [C]t [C]h [C]e O 
greater [C]g [C]r [C]e [C]a [C]t [C]e [C]r O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
sites [C]s [C]i [C]t [C]e [C]s O 
, [C], O 
the [C]t [C]h [C]e O 
peanut-negative [C]p [C]e [C]a [C]n [C]u [C]t [C]- [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e B-cell_line 
thymocyte [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e I-cell_line 
subpopulation [C]s [C]u [C]b [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n E-cell_line 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
differ [C]d [C]i [C]f [C]f [C]e [C]r O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
peanut-positive [C]p [C]e [C]a [C]n [C]u [C]t [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e S-cell_line 
one [C]o [C]n [C]e O 
in [C]i [C]n O 
its [C]i [C]t [C]s O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
triamcinolone [C]t [C]r [C]i [C]a [C]m [C]c [C]i [C]n [C]o [C]l [C]o [C]n [C]e O 
acetonide [C]a [C]c [C]e [C]t [C]o [C]n [C]i [C]d [C]e O 
, [C], O 
as [C]a [C]s O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
measurements [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]m [C]e [C]n [C]t [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
incorporation [C]i [C]n [C]c [C]o [C]r [C]p [C]o [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
radiolabeled [C]r [C]a [C]d [C]i [C]o [C]l [C]a [C]b [C]e [C]l [C]e [C]d O 
precursors [C]p [C]r [C]e [C]c [C]u [C]r [C]s [C]o [C]r [C]s O 
of [C]o [C]f O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
and [C]a [C]n [C]d O 
DNA [C]D [C]N [C]A O 
. [C]. O 

Moreover [C]M [C]o [C]r [C]e [C]o [C]v [C]e [C]r O 
, [C], O 
the [C]t [C]h [C]e O 
peanut-negative [C]p [C]e [C]a [C]n [C]u [C]t [C]- [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e B-cell_line 
subset [C]s [C]u [C]b [C]s [C]e [C]t E-cell_line 
appeared [C]a [C]p [C]p [C]e [C]a [C]r [C]e [C]d O 
more [C]m [C]o [C]r [C]e O 
resistant [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]t O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
steroid-induced [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
cell [C]c [C]e [C]l [C]l O 
lysis [C]l [C]y [C]s [C]i [C]s O 
as [C]a [C]s O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
peanut-positive [C]p [C]e [C]a [C]n [C]u [C]t [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e S-cell_line 
one [C]o [C]n [C]e O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
our [C]o [C]u [C]r O 
data [C]d [C]a [C]t [C]a O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
density [C]d [C]e [C]n [C]s [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
corticosensitivity [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
are [C]a [C]r [C]e O 
not [C]n [C]o [C]t O 
directly [C]d [C]i [C]r [C]e [C]c [C]t [C]l [C]y O 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
and [C]a [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
sites [C]s [C]i [C]t [C]e [C]s O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
dependent [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
degree [C]d [C]e [C]g [C]r [C]e [C]e O 
of [C]o [C]f O 
immunologic [C]i [C]m [C]m [C]u [C]n [C]o [C]l [C]o [C]g [C]i [C]c O 
maturation [C]m [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 

Defective [C]D [C]e [C]f [C]e [C]c [C]t [C]i [C]v [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
1 [C]1 B-protein 
, [C], I-protein 
25-dihydroxyvitamin [C]2 [C]5 [C]- [C]d [C]i [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]v [C]i [C]t [C]a [C]m [C]i [C]n I-protein 
D3 [C]D [C]3 I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
of [C]o [C]f O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
end-organ [C]e [C]n [C]d [C]- [C]o [C]r [C]g [C]a [C]n O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
to [C]t [C]o O 
1 [C]1 O 
, [C], O 
25-dihydroxyvitamin [C]2 [C]5 [C]- [C]d [C]i [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]v [C]i [C]t [C]a [C]m [C]i [C]n O 
D [C]D O 
. [C]. O 

Lectin-induced [C]L [C]e [C]c [C]t [C]i [C]n [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
DNA [C]D [C]N [C]A O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
by [C]b [C]y O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
17 [C]1 [C]7 O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
donors [C]d [C]o [C]n [C]o [C]r [C]s O 
was [C]w [C]a [C]s O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
( [C]( O 
40-60 [C]4 [C]0 [C]- [C]6 [C]0 O 
% [C]% O 
) [C]) O 
by [C]b [C]y O 
1 [C]1 O 
, [C], O 
25-dihydroxyvitamin [C]2 [C]5 [C]- [C]d [C]i [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]v [C]i [C]t [C]a [C]m [C]i [C]n O 
D3 [C]D [C]3 O 
( [C]( O 
1 [C]1 O 
, [C], O 
25 [C]2 [C]5 O 
[ [C][ O 
OH [C]O [C]H O 
] [C]] O 
2D3 [C]2 [C]D [C]3 O 
) [C]) O 
at [C]a [C]t O 
physiological [C]p [C]h [C]y [C]s [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
( [C]( O 
10 [C]1 [C]0 O 
( [C]( O 
-10 [C]- [C]1 [C]0 O 
) [C]) O 
-10 [C]- [C]1 [C]0 O 
( [C]( O 
-9 [C]- [C]9 O 
) [C]) O 
M [C]M O 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
acquire [C]a [C]c [C]q [C]u [C]i [C]r [C]e O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
for [C]f [C]o [C]r O 
1 [C]1 O 
, [C], O 
25 [C]2 [C]5 O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
upon [C]u [C]p [C]o [C]n O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
lectins [C]l [C]e [C]c [C]t [C]i [C]n [C]s S-protein 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
precedes [C]p [C]r [C]e [C]c [C]e [C]d [C]e [C]s O 
the [C]t [C]h [C]e O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
1 [C]1 O 
, [C], O 
25 [C]2 [C]5 O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
. [C]. O 

We [C]W [C]e O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
from [C]f [C]r [C]o [C]m O 
six [C]s [C]i [C]x O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
from [C]f [C]r [C]o [C]m O 
four [C]f [C]o [C]u [C]r O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
kindreds [C]k [C]i [C]n [C]d [C]r [C]e [C]d [C]s O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
syndrome [C]s [C]y [C]n [C]d [C]r [C]o [C]m [C]e O 
of [C]o [C]f O 
hereditary [C]h [C]e [C]r [C]e [C]d [C]i [C]t [C]a [C]r [C]y O 
end-organ [C]e [C]n [C]d [C]- [C]o [C]r [C]g [C]a [C]n O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
to [C]t [C]o O 
1 [C]1 O 
, [C], O 
25 [C]2 [C]5 O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D [C]2 [C]D O 
( [C]( O 
the [C]t [C]h [C]e O 
so-called [C]s [C]o [C]- [C]c [C]a [C]l [C]l [C]e [C]d O 
vitamin [C]v [C]i [C]t [C]a [C]m [C]i [C]n O 
D-dependent [C]D [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
rickets [C]r [C]i [C]c [C]k [C]e [C]t [C]s O 
type [C]t [C]y [C]p [C]e O 
II [C]I [C]I O 
) [C]) O 
. [C]. O 

In [C]I [C]n O 
five [C]f [C]i [C]v [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
( [C]( O 
three [C]t [C]h [C]r [C]e [C]e O 
kindreds [C]k [C]i [C]n [C]d [C]r [C]e [C]d [C]s O 
) [C]) O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
acquire [C]a [C]c [C]q [C]u [C]i [C]r [C]e O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
for [C]f [C]o [C]r O 
1 [C]1 O 
, [C], O 
25 [C]2 [C]5 O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
upon [C]u [C]p [C]o [C]n O 
phytohemagglutinin-induced [C]p [C]h [C]y [C]t [C]o [C]h [C]e [C]m [C]a [C]g [C]g [C]l [C]u [C]t [C]i [C]n [C]i [C]n [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Moreover [C]M [C]o [C]r [C]e [C]o [C]v [C]e [C]r O 
, [C], O 
in [C]i [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
to [C]t [C]o O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
, [C], O 
the [C]t [C]h [C]e O 
mitogenic [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]i [C]c O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
' [C]' O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
by [C]b [C]y O 
phytohemagglutinin [C]p [C]h [C]y [C]t [C]o [C]h [C]e [C]m [C]a [C]g [C]g [C]l [C]u [C]t [C]i [C]n [C]i [C]n S-protein 
and [C]a [C]n [C]d O 
concanavalin [C]c [C]o [C]n [C]c [C]a [C]n [C]a [C]v [C]a [C]l [C]i [C]n O 
A [C]A O 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
by [C]b [C]y O 
1 [C]1 O 
, [C], O 
25 [C]2 [C]5 O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
. [C]. O 

Activated [C]A [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
sixth [C]s [C]i [C]x [C]t [C]h O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
from [C]f [C]r [C]o [C]m O 
a [C]a O 
fourth [C]f [C]o [C]u [C]r [C]t [C]h O 
kindred [C]k [C]i [C]n [C]d [C]r [C]e [C]d O 
exhibited [C]e [C]x [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
1 [C]1 O 
, [C], O 
25 [C]2 [C]5 O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
but [C]b [C]u [C]t O 
the [C]t [C]h [C]e O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e O 
failed [C]f [C]a [C]i [C]l [C]e [C]d O 
to [C]t [C]o O 
inhibit [C]i [C]n [C]h [C]i [C]b [C]i [C]t O 
the [C]t [C]h [C]e O 
mitogenic [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]i [C]c O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

A [C]A O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
pattern [C]p [C]a [C]t [C]t [C]e [C]r [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
vitamin [C]v [C]i [C]t [C]a [C]m [C]i [C]n O 
D [C]D O 
effector [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
was [C]w [C]a [C]s O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
fibroblasts [C]f [C]i [C]b [C]r [C]o [C]b [C]l [C]a [C]s [C]t [C]s O 
cultured [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
skin [C]s [C]k [C]i [C]n O 
biopsies [C]b [C]i [C]o [C]p [C]s [C]i [C]e [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
group [C]g [C]r [C]o [C]u [C]p O 
of [C]o [C]f O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
conclusions [C]c [C]o [C]n [C]c [C]l [C]u [C]s [C]i [C]o [C]n [C]s O 
from [C]f [C]r [C]o [C]m O 
these [C]t [C]h [C]e [C]s [C]e O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
are [C]a [C]r [C]e O 
: [C]: O 
( [C]( O 
a [C]a O 
) [C]) O 
the [C]t [C]h [C]e O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
mitogenic [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]i [C]c O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
1 [C]1 O 
, [C], O 
25 [C]2 [C]5 O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
is [C]i [C]s O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-protein 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e O 
; [C]; O 
and [C]a [C]n [C]d O 
( [C]( O 
b [C]b O 
) [C]) O 
the [C]t [C]h [C]e O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
for [C]f [C]o [C]r O 
1 [C]1 O 
, [C], O 
25 [C]2 [C]5 O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
in [C]i [C]n O 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
are [C]a [C]r [C]e O 
probably [C]p [C]r [C]o [C]b [C]a [C]b [C]l [C]y O 
controlled [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]l [C]e [C]d O 
genetically [C]g [C]e [C]n [C]e [C]t [C]i [C]c [C]a [C]l [C]l [C]y O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
as [C]a [C]s O 
the [C]t [C]h [C]e O 
effector [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
in [C]i [C]n O 
well-characterized [C]w [C]e [C]l [C]l [C]- [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]d O 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
organs [C]o [C]r [C]g [C]a [C]n [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e O 
, [C], O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
intestine [C]i [C]n [C]t [C]e [C]s [C]t [C]i [C]n [C]e O 
and [C]a [C]n [C]d O 
kidney [C]k [C]i [C]d [C]n [C]e [C]y O 
. [C]. O 

Glucocorticoid [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
of [C]o [C]f O 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_type 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
myasthenia [C]m [C]y [C]a [C]s [C]t [C]h [C]e [C]n [C]i [C]a O 
gravis [C]g [C]r [C]a [C]v [C]i [C]s O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
study [C]s [C]t [C]u [C]d [C]y O 
was [C]w [C]a [C]s O 
performed [C]p [C]e [C]r [C]f [C]o [C]r [C]m [C]e [C]d O 
to [C]t [C]o O 
analyse [C]a [C]n [C]a [C]l [C]y [C]s [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
( [C]( O 
GR [C]G [C]R S-protein 
) [C]) O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
in [C]i [C]n O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
( [C]( O 
MNL [C]M [C]N [C]L S-cell_type 
) [C]) O 
from [C]f [C]r [C]o [C]m O 
39 [C]3 [C]9 O 
myasthenia [C]m [C]y [C]a [C]s [C]t [C]h [C]e [C]n [C]i [C]a O 
gravis [C]g [C]r [C]a [C]v [C]i [C]s O 
( [C]( O 
MG [C]M [C]G O 
) [C]) O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
( [C]( O 
unoperated [C]u [C]n [C]o [C]p [C]e [C]r [C]a [C]t [C]e [C]d O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
( [C]( O 
n [C]n O 
= [C]= O 
13 [C]1 [C]3 O 
) [C]) O 
, [C], O 
thymectomized [C]t [C]h [C]y [C]m [C]e [C]c [C]t [C]o [C]m [C]i [C]z [C]e [C]d O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
( [C]( O 
n [C]n O 
= [C]= O 
14 [C]1 [C]4 O 
) [C]) O 
and [C]a [C]n [C]d O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
receiving [C]r [C]e [C]c [C]e [C]i [C]v [C]i [C]n [C]g O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
: [C]: O 
thymectomized [C]t [C]h [C]y [C]m [C]e [C]c [C]t [C]o [C]m [C]i [C]z [C]e [C]d O 
( [C]( O 
n [C]n O 
= [C]= O 
11 [C]1 [C]1 O 
) [C]) O 
and [C]a [C]n [C]d O 
unoperated [C]u [C]n [C]o [C]p [C]e [C]r [C]a [C]t [C]e [C]d O 
( [C]( O 
n [C]n O 
= [C]= O 
6 [C]6 O 
] [C]] O 
. [C]. O 

A [C]A O 
whole [C]w [C]h [C]o [C]l [C]e O 
cell [C]c [C]e [C]l [C]l O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
assay [C]a [C]s [C]s [C]a [C]y O 
with [C]w [C]i [C]t [C]h O 
3 [C]3 O 
( [C]( O 
H [C]H O 
) [C]) O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
was [C]w [C]a [C]s O 
used [C]u [C]s [C]e [C]d O 
. [C]. O 

GR [C]G [C]R S-protein 
mean [C]m [C]e [C]a [C]n O 
values [C]v [C]a [C]l [C]u [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
MNL [C]M [C]N [C]L S-cell_type 
of [C]o [C]f O 
MG [C]M [C]G O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
( [C]( O 
thymectomized [C]t [C]h [C]y [C]m [C]e [C]c [C]t [C]o [C]m [C]i [C]z [C]e [C]d O 
or [C]o [C]r O 
not [C]n [C]o [C]t O 
) [C]) O 
not [C]n [C]o [C]t O 
receiving [C]r [C]e [C]c [C]e [C]i [C]v [C]i [C]n [C]g O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
than [C]t [C]h [C]a [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
MNL [C]M [C]N [C]L S-cell_type 
of [C]o [C]f O 
healthy [C]h [C]e [C]a [C]l [C]t [C]h [C]y O 
donors [C]d [C]o [C]n [C]o [C]r [C]s O 
. [C]. O 

Affinity [C]A [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
was [C]w [C]a [C]s O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
the [C]t [C]h [C]e O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
range [C]r [C]a [C]n [C]g [C]e O 
. [C]. O 

Sex [C]S [C]e [C]x O 
, [C], O 
age [C]a [C]g [C]e O 
or [C]o [C]r O 
clinical [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
forms [C]f [C]o [C]r [C]m [C]s O 
of [C]o [C]f O 
illness [C]i [C]l [C]l [C]n [C]e [C]s [C]s O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
influence [C]i [C]n [C]f [C]l [C]u [C]e [C]n [C]c [C]e O 
the [C]t [C]h [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
. [C]. O 

In [C]I [C]n O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
receiving [C]r [C]e [C]c [C]e [C]i [C]v [C]i [C]n [C]g O 
prednisone [C]p [C]r [C]e [C]d [C]n [C]i [C]s [C]o [C]n [C]e O 
( [C]( O 
Pd [C]P [C]d O 
) [C]) O 
the [C]t [C]h [C]e O 
GR [C]G [C]R S-protein 
values [C]v [C]a [C]l [C]u [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
lower [C]l [C]o [C]w [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
in [C]i [C]n O 
MG [C]M [C]G O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
without [C]w [C]i [C]t [C]h [C]o [C]u [C]t O 
Pd [C]P [C]d O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
, [C], O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
of [C]o [C]f O 
Pd [C]P [C]d O 
dose [C]d [C]o [C]s [C]e O 
or [C]o [C]r O 
time [C]t [C]i [C]m [C]e O 
of [C]o [C]f O 
administration [C]a [C]d [C]m [C]i [C]n [C]i [C]s [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

No [C]N [C]o O 
differences [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e [C]s O 
in [C]i [C]n O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
and [C]a [C]n [C]d O 
MG [C]M [C]G O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
receiving [C]r [C]e [C]c [C]e [C]i [C]v [C]i [C]n [C]g O 
Pd [C]P [C]d O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
found [C]f [C]o [C]u [C]n [C]d O 
. [C]. O 

Immunological [C]I [C]m [C]m [C]u [C]n [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
interference [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
high [C]h [C]i [C]g [C]h O 
dose [C]d [C]o [C]s [C]e O 
corticosteroids [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]s O 
. [C]. O 

High-dose [C]H [C]i [C]g [C]h [C]- [C]d [C]o [C]s [C]e O 
corticosteroids [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]s O 
( [C]( O 
HDC [C]H [C]D [C]C O 
) [C]) O 
will [C]w [C]i [C]l [C]l O 
influence [C]i [C]n [C]f [C]l [C]u [C]e [C]n [C]c [C]e O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
humoral [C]h [C]u [C]m [C]o [C]r [C]a [C]l O 
participants [C]p [C]a [C]r [C]t [C]i [C]c [C]i [C]p [C]a [C]n [C]t [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
will [C]w [C]i [C]l [C]l O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
size [C]s [C]i [C]z [C]e O 
and [C]a [C]n [C]d O 
weight [C]w [C]e [C]i [C]g [C]h [C]t O 
after [C]a [C]f [C]t [C]e [C]r O 
prolonged [C]p [C]r [C]o [C]l [C]o [C]n [C]g [C]e [C]d O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
HDC [C]H [C]D [C]C O 
. [C]. O 

Lymphocyte [C]L [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e O 
functions [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]s O 
will [C]w [C]i [C]l [C]l O 
be [C]b [C]e O 
impaired [C]i [C]m [C]p [C]a [C]i [C]r [C]e [C]d O 
. [C]. O 

Reduced [C]R [C]e [C]d [C]u [C]c [C]e [C]d O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
B- [C]B [C]- B-cell_type 
as [C]a [C]s I-cell_type 
well [C]w [C]e [C]l [C]l I-cell_type 
as [C]a [C]s I-cell_type 
T-lymphocytes [C]T [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
will [C]w [C]i [C]l [C]l O 
be [C]b [C]e O 
seen [C]s [C]e [C]e [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l S-cell_type 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
can [C]c [C]a [C]n O 
be [C]b [C]e O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
both [C]b [C]o [C]t [C]h O 
as [C]a [C]s O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
serum [C]s [C]e [C]r [C]u [C]m O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
immunoglobulins [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n [C]s S-protein 
and [C]a [C]n [C]d O 
as [C]a [C]s O 
impaired [C]i [C]m [C]p [C]a [C]i [C]r [C]e [C]d O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s S-protein 
and [C]a [C]n [C]d O 
complement [C]c [C]o [C]m [C]p [C]l [C]e [C]m [C]e [C]n [C]t O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
. [C]. O 

Reduced [C]R [C]e [C]d [C]u [C]c [C]e [C]d O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l S-cell_type 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
indicated [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
impaired [C]i [C]m [C]p [C]a [C]i [C]r [C]e [C]d O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
PHA [C]P [C]H [C]A S-protein 
and [C]a [C]n [C]d O 
porkweed [C]p [C]o [C]r [C]k [C]w [C]e [C]e [C]d S-protein 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
by [C]b [C]y O 
impaired [C]i [C]m [C]p [C]a [C]i [C]r [C]e [C]d O 
lymphokinin [C]l [C]y [C]m [C]p [C]h [C]o [C]k [C]i [C]n [C]i [C]n O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
on [C]o [C]n O 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e S-cell_type 
migration [C]m [C]i [C]g [C]r [C]a [C]t [C]i [C]o [C]n O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
reported [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]d O 
. [C]. O 

Reduced [C]R [C]e [C]d [C]u [C]c [C]e [C]d O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e O 
adherence [C]a [C]d [C]h [C]e [C]r [C]e [C]n [C]c [C]e O 
to [C]t [C]o O 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n O 
and [C]a [C]n [C]d O 
suppressed [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e O 
reaction [C]r [C]e [C]a [C]c [C]t [C]i [C]o [C]n O 
have [C]h [C]a [C]v [C]e O 
also [C]a [C]l [C]s [C]o O 
been [C]b [C]e [C]e [C]n O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
. [C]. O 

Humoral [C]H [C]u [C]m [C]o [C]r [C]a [C]l O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
chemotaxis [C]c [C]h [C]e [C]m [C]o [C]t [C]a [C]x [C]i [C]s O 
, [C], O 
opsonisation [C]o [C]p [C]s [C]o [C]n [C]i [C]s [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
phagocytosis [C]p [C]h [C]a [C]g [C]o [C]c [C]y [C]t [C]o [C]s [C]i [C]s O 
, [C], O 
vascular [C]v [C]a [C]s [C]c [C]u [C]l [C]a [C]r O 
permeability [C]p [C]e [C]r [C]m [C]e [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
leading [C]l [C]e [C]a [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
leakage [C]l [C]e [C]a [C]k [C]a [C]g [C]e O 
of [C]o [C]f O 
fluid [C]f [C]l [C]u [C]i [C]d O 
and [C]a [C]n [C]d O 
cells [C]c [C]e [C]l [C]l [C]s O 
and [C]a [C]n [C]d O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
lysis [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
antigens [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]s O 
are [C]a [C]r [C]e O 
impaired [C]i [C]m [C]p [C]a [C]i [C]r [C]e [C]d O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
can [C]c [C]a [C]n O 
be [C]b [C]e O 
explained [C]e [C]x [C]p [C]l [C]a [C]i [C]n [C]e [C]d O 
partly [C]p [C]a [C]r [C]t [C]l [C]y O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
complement [C]c [C]o [C]m [C]p [C]l [C]e [C]m [C]e [C]n [C]t O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
via [C]v [C]i [C]a O 
the [C]t [C]h [C]e O 
alternative [C]a [C]l [C]t [C]e [C]r [C]n [C]a [C]t [C]i [C]v [C]e O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
the [C]t [C]h [C]e O 
classical [C]c [C]l [C]a [C]s [C]s [C]i [C]c [C]a [C]l O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
in [C]i [C]n O 
association [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
HDC [C]H [C]D [C]C O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
. [C]. O 

Acute [C]A [C]c [C]u [C]t [C]e O 
processes [C]p [C]r [C]o [C]c [C]e [C]s [C]s [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
vascular [C]v [C]a [C]s [C]c [C]u [C]l [C]a [C]r O 
permeability [C]p [C]e [C]r [C]m [C]e [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
accumulation [C]a [C]c [C]c [C]u [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
as [C]a [C]s O 
impairing [C]i [C]m [C]p [C]a [C]i [C]r [C]i [C]n [C]g O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
influenced [C]i [C]n [C]f [C]l [C]u [C]e [C]n [C]c [C]e [C]d O 
beneficially [C]b [C]e [C]n [C]e [C]f [C]i [C]c [C]i [C]a [C]l [C]l [C]y O 
by [C]b [C]y O 
HDC [C]H [C]D [C]C O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
can [C]c [C]a [C]n O 
be [C]b [C]e O 
seen [C]s [C]e [C]e [C]n O 
in [C]i [C]n O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
septic [C]s [C]e [C]p [C]t [C]i [C]c O 
shock [C]s [C]h [C]o [C]c [C]k O 
or [C]o [C]r O 
rejection [C]r [C]e [C]j [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
transplant [C]t [C]r [C]a [C]n [C]s [C]p [C]l [C]a [C]n [C]t O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
if [C]i [C]f O 
sepsis [C]s [C]e [C]p [C]s [C]i [C]s O 
or [C]o [C]r O 
rejection [C]r [C]e [C]j [C]e [C]c [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
not [C]n [C]o [C]t O 
rapidly [C]r [C]a [C]p [C]i [C]d [C]l [C]y O 
reversed [C]r [C]e [C]v [C]e [C]r [C]s [C]e [C]d O 
, [C], O 
complications [C]c [C]o [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n [C]s O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
multisystem [C]m [C]u [C]l [C]t [C]i [C]s [C]y [C]s [C]t [C]e [C]m O 
organ [C]o [C]r [C]g [C]a [C]n O 
failure [C]f [C]a [C]i [C]l [C]u [C]r [C]e O 
and [C]a [C]n [C]d O 
bacteremia [C]b [C]a [C]c [C]t [C]e [C]r [C]e [C]m [C]i [C]a O 
are [C]a [C]r [C]e O 
prone [C]p [C]r [C]o [C]n [C]e O 
to [C]t [C]o O 
appear [C]a [C]p [C]p [C]e [C]a [C]r O 
. [C]. O 

Identification [C]I [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-protein 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c I-protein 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
using [C]u [C]s [C]i [C]n [C]g O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
labeling [C]l [C]a [C]b [C]e [C]l [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
anti-human [C]a [C]n [C]t [C]i [C]- [C]h [C]u [C]m [C]a [C]n B-protein 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s E-protein 
. [C]. O 

Antisera [C]A [C]n [C]t [C]i [C]s [C]e [C]r [C]a O 
raised [C]r [C]a [C]i [C]s [C]e [C]d O 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
human [C]h [C]u [C]m [C]a [C]n B-protein 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d I-protein 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
were [C]w [C]e [C]r [C]e O 
used [C]u [C]s [C]e [C]d O 
in [C]i [C]n O 
combination [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
label [C]l [C]a [C]b [C]e [C]l O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
21-mesylate [C]2 [C]1 [C]- [C]m [C]e [C]s [C]y [C]l [C]a [C]t [C]e O 
[ [C][ O 
( [C]( O 
3H [C]3 [C]H O 
] [C]] O 
DM [C]D [C]M O 
) [C]) O 
to [C]t [C]o O 
identify [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]y O 
the [C]t [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
B-lymphoblastoid [C]B [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]o [C]i [C]d I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
IM-9 [C]I [C]M [C]- [C]9 S-cell_line 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l I-cell_line 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
CEM-C7 [C]C [C]E [C]M [C]- [C]C [C]7 S-cell_line 
. [C]. O 

Antisera [C]A [C]n [C]t [C]i [C]s [C]e [C]r [C]a O 
were [C]w [C]e [C]r [C]e O 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
immunization [C]i [C]m [C]m [C]u [C]n [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
New [C]N [C]e [C]w O 
Zealand [C]Z [C]e [C]a [C]l [C]a [C]n [C]d O 
White [C]W [C]h [C]i [C]t [C]e O 
rabbits [C]r [C]a [C]b [C]b [C]i [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
[ [C][ B-protein 
3H [C]3 [C]H I-protein 
] [C]] I-protein 
triamcinolone [C]t [C]r [C]i [C]a [C]m [C]c [C]i [C]n [C]o [C]l [C]o [C]n [C]e I-protein 
acetonide [C]a [C]c [C]e [C]t [C]o [C]n [C]i [C]d [C]e I-protein 
[ [C][ I-protein 
( [C]( I-protein 
3H [C]3 [C]H I-protein 
] [C]] I-protein 
TA [C]T [C]A I-protein 
) [C]) I-protein 
-glucocorticoid [C]- [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
partially [C]p [C]a [C]r [C]t [C]i [C]a [C]l [C]l [C]y O 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d O 
by [C]b [C]y O 
two-stage [C]t [C]w [C]o [C]- [C]s [C]t [C]a [C]g [C]e O 
DNA-cellulose [C]D [C]N [C]A [C]- [C]c [C]e [C]l [C]l [C]u [C]l [C]o [C]s [C]e O 
chromatography [C]c [C]h [C]r [C]o [C]m [C]a [C]t [C]o [C]g [C]r [C]a [C]p [C]h [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
anti-human [C]a [C]n [C]t [C]i [C]- [C]h [C]u [C]m [C]a [C]n B-protein 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s E-protein 
was [C]w [C]a [C]s O 
verified [C]v [C]e [C]r [C]i [C]f [C]i [C]e [C]d O 
by [C]b [C]y O 
: [C]: O 
( [C]( O 
a [C]a O 
) [C]) O 
adsorption [C]a [C]d [C]s [C]o [C]r [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
[ [C][ B-protein 
3H [C]3 [C]H I-protein 
] [C]] I-protein 
TA-receptor-antibody [C]T [C]A [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]- [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y I-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
to [C]t [C]o O 
Protein [C]P [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
A [C]A E-protein 
; [C]; O 
( [C]( O 
b [C]b O 
) [C]) O 
a [C]a O 
shift [C]s [C]h [C]i [C]f [C]t O 
to [C]t [C]o O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
apparent [C]a [C]p [C]p [C]a [C]r [C]e [C]n [C]t O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
weight [C]w [C]e [C]i [C]g [C]h [C]t O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
elution [C]e [C]l [C]u [C]t [C]i [C]o [C]n O 
position [C]p [C]o [C]s [C]i [C]t [C]i [C]o [C]n O 
from [C]f [C]r [C]o [C]m O 
Sephacryl [C]S [C]e [C]p [C]h [C]a [C]c [C]r [C]y [C]l O 
S300 [C]S [C]3 [C]0 [C]0 O 
of [C]o [C]f O 
[ [C][ B-protein 
3H [C]3 [C]H I-protein 
] [C]] I-protein 
TA-receptor [C]T [C]A [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
incubated [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
serum [C]s [C]e [C]r [C]u [C]m O 
; [C]; O 
and [C]a [C]n [C]d O 
( [C]( O 
c [C]c O 
) [C]) O 
the [C]t [C]h [C]e O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
serum [C]s [C]e [C]r [C]u [C]m O 
to [C]t [C]o O 
displace [C]d [C]i [C]s [C]p [C]l [C]a [C]c [C]e O 
[ [C][ B-protein 
3H [C]3 [C]H I-protein 
] [C]] I-protein 
TA-receptor [C]T [C]A [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
on [C]o [C]n O 
sucrose [C]s [C]u [C]c [C]r [C]o [C]s [C]e O 
gradients [C]g [C]r [C]a [C]d [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s S-protein 
also [C]a [C]l [C]s [C]o O 
recognized [C]r [C]e [C]c [C]o [C]g [C]n [C]i [C]z [C]e [C]d O 
rat [C]r [C]a [C]t O 
liver [C]l [C]i [C]v [C]e [C]r O 
and [C]a [C]n [C]d O 
murine [C]m [C]u [C]r [C]i [C]n [C]e B-protein 
S49 [C]S [C]4 [C]9 I-protein 
cell [C]c [C]e [C]l [C]l I-protein 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

Sodium [C]S [C]o [C]d [C]i [C]u [C]m O 
dodecyl [C]d [C]o [C]d [C]e [C]c [C]y [C]l O 
sulfate-polyacrylamide [C]s [C]u [C]l [C]f [C]a [C]t [C]e [C]- [C]p [C]o [C]l [C]y [C]a [C]c [C]r [C]y [C]l [C]a [C]m [C]i [C]d [C]e O 
gel [C]g [C]e [C]l O 
electrophoresis [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
DM-labeled [C]D [C]M [C]- [C]l [C]a [C]b [C]e [C]l [C]e [C]d O 
IM-9 [C]I [C]M [C]- [C]9 O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
a [C]a O 
major [C]m [C]a [C]j [C]o [C]r O 
competable [C]c [C]o [C]m [C]p [C]e [C]t [C]a [C]b [C]l [C]e O 
band [C]b [C]a [C]n [C]d O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
weight [C]w [C]e [C]i [C]g [C]h [C]t O 
of [C]o [C]f O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
90 [C]9 [C]0 O 
, [C], O 
000 [C]0 [C]0 [C]0 O 
, [C], O 
three [C]t [C]h [C]r [C]e [C]e O 
minor [C]m [C]i [C]n [C]o [C]r O 
competable [C]c [C]o [C]m [C]p [C]e [C]t [C]a [C]b [C]l [C]e O 
components [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
weights [C]w [C]e [C]i [C]g [C]h [C]t [C]s O 
of [C]o [C]f O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
78 [C]7 [C]8 O 
, [C], O 
000 [C]0 [C]0 [C]0 O 
, [C], O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
51 [C]5 [C]1 O 
, [C], O 
000 [C]0 [C]0 [C]0 O 
, [C], O 
and [C]a [C]n [C]d O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
38 [C]3 [C]8 O 
, [C], O 
500 [C]5 [C]0 [C]0 O 
, [C], O 
and [C]a [C]n [C]d O 
at [C]a [C]t O 
least [C]l [C]e [C]a [C]s [C]t O 
21 [C]2 [C]1 O 
other [C]o [C]t [C]h [C]e [C]r O 
noncompetable [C]n [C]o [C]n [C]c [C]o [C]m [C]p [C]e [C]t [C]a [C]b [C]l [C]e O 
components [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t [C]s O 
. [C]. O 

Following [C]F [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
immunoprecipitation [C]i [C]m [C]m [C]u [C]n [C]o [C]p [C]r [C]e [C]c [C]i [C]p [C]i [C]t [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
DM-labeled [C]D [C]M [C]- [C]l [C]a [C]b [C]e [C]l [C]e [C]d O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
with [C]w [C]i [C]t [C]h O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
serum [C]s [C]e [C]r [C]u [C]m O 
, [C], O 
only [C]o [C]n [C]l [C]y O 
the [C]t [C]h [C]e O 
Mr [C]M [C]r O 
90 [C]9 [C]0 O 
, [C], O 
000 [C]0 [C]0 [C]0 O 
and [C]a [C]n [C]d O 
78 [C]7 [C]8 O 
, [C], O 
000 [C]0 [C]0 [C]0 O 
components [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t [C]s O 
were [C]w [C]e [C]r [C]e O 
seen [C]s [C]e [C]e [C]n O 
. [C]. O 

Sodium [C]S [C]o [C]d [C]i [C]u [C]m O 
dodecyl [C]d [C]o [C]d [C]e [C]c [C]y [C]l O 
sulfate-polyacrylamide [C]s [C]u [C]l [C]f [C]a [C]t [C]e [C]- [C]p [C]o [C]l [C]y [C]a [C]c [C]r [C]y [C]l [C]a [C]m [C]i [C]d [C]e O 
gel [C]g [C]e [C]l O 
electrophoresis [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
DM-labeled [C]D [C]M [C]- [C]l [C]a [C]b [C]e [C]l [C]e [C]d O 
CEM-C7 [C]C [C]E [C]M [C]- [C]C [C]7 O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
a [C]a O 
larger [C]l [C]a [C]r [C]g [C]e [C]r O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
DM-labeled [C]D [C]M [C]- [C]l [C]a [C]b [C]e [C]l [C]e [C]d O 
components [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t [C]s O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
after [C]a [C]f [C]t [C]e [C]r O 
immunoprecipitation [C]i [C]m [C]m [C]u [C]n [C]o [C]p [C]r [C]e [C]c [C]i [C]p [C]i [C]t [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
DM-labeled [C]D [C]M [C]- [C]l [C]a [C]b [C]e [C]l [C]e [C]d O 
CEM-C7 [C]C [C]E [C]M [C]- [C]C [C]7 O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
, [C], O 
a [C]a O 
predominant [C]p [C]r [C]e [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t O 
competable [C]c [C]o [C]m [C]p [C]e [C]t [C]a [C]b [C]l [C]e O 
component [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
weight [C]w [C]e [C]i [C]g [C]h [C]t O 
of [C]o [C]f O 
90 [C]9 [C]0 O 
, [C], O 
000 [C]0 [C]0 [C]0 O 
was [C]w [C]a [C]s O 
easily [C]e [C]a [C]s [C]i [C]l [C]y O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
component [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t O 
was [C]w [C]a [C]s O 
markedly [C]m [C]a [C]r [C]k [C]e [C]d [C]l [C]y O 
diminished [C]d [C]i [C]m [C]i [C]n [C]i [C]s [C]h [C]e [C]d O 
when [C]w [C]h [C]e [C]n O 
cytosols [C]c [C]y [C]t [C]o [C]s [C]o [C]l [C]s O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-cell_line 
receptor-deficient [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]- [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
ICR-27 [C]I [C]C [C]R [C]- [C]2 [C]7 S-cell_line 
were [C]w [C]e [C]r [C]e O 
used [C]u [C]s [C]e [C]d O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
the [C]t [C]h [C]e O 
combination [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
labeling [C]l [C]a [C]b [C]e [C]l [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
anti-human [C]a [C]n [C]t [C]i [C]- [C]h [C]u [C]m [C]a [C]n B-protein 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s E-protein 
is [C]i [C]s O 
capable [C]c [C]a [C]p [C]a [C]b [C]l [C]e O 
of [C]o [C]f O 
providing [C]p [C]r [C]o [C]v [C]i [C]d [C]i [C]n [C]g O 
direct [C]d [C]i [C]r [C]e [C]c [C]t O 
physical [C]p [C]h [C]y [C]s [C]i [C]c [C]a [C]l O 
identification [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-protein 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d I-protein 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

Effect [C]E [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
thymosin [C]t [C]h [C]y [C]m [C]o [C]s [C]i [C]n O 
on [C]o [C]n O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

Incubation [C]I [C]n [C]c [C]u [C]b [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
thymosin [C]t [C]h [C]y [C]m [C]o [C]s [C]i [C]n O 
fraction [C]f [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
5 [C]5 O 
, [C], O 
( [C]( O 
TMS [C]T [C]M [C]S O 
F5 [C]F [C]5 O 
at [C]a [C]t O 
300 [C]3 [C]0 [C]0 O 
micrograms/ml [C]m [C]i [C]c [C]r [C]o [C]g [C]r [C]a [C]m [C]s [C]/ [C]m [C]l O 
) [C]) O 
a [C]a O 
partially [C]p [C]a [C]r [C]t [C]i [C]a [C]l [C]l [C]y O 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d O 
thymic [C]t [C]h [C]y [C]m [C]i [C]c O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
, [C], O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
the [C]t [C]h [C]e O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
infant [C]i [C]n [C]f [C]a [C]n [C]t I-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
9.6 [C]9 [C]. [C]6 O 
+/- [C]+ [C]/ [C]- O 
2.1 [C]2 [C]. [C]1 O 
fmole/ml [C]f [C]m [C]o [C]l [C]e [C]/ [C]m [C]l O 
to [C]t [C]o O 
5.0 [C]5 [C]. [C]0 O 
+/- [C]+ [C]/ [C]- O 
2.0 [C]2 [C]. [C]0 O 
fmole/ml [C]f [C]m [C]o [C]l [C]e [C]/ [C]m [C]l O 
. [C]. O 

The [C]T [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
infant [C]i [C]n [C]f [C]a [C]n [C]t O 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
2 [C]2 O 
, [C], O 
146 [C]1 [C]4 [C]6 O 
+/- [C]+ [C]/ [C]- O 
726 [C]7 [C]2 [C]6 O 
( [C]( O 
s.d. [C]s [C]. [C]d [C]. O 
) [C]) O 
sites [C]s [C]i [C]t [C]e [C]s O 
per [C]p [C]e [C]r O 
cell [C]c [C]e [C]l [C]l O 
with [C]w [C]i [C]t [C]h O 
dissociation [C]d [C]i [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
constant [C]c [C]o [C]n [C]s [C]t [C]a [C]n [C]t O 
of [C]o [C]f O 
1.4 [C]1 [C]. [C]4 O 
+/- [C]+ [C]/ [C]- O 
0.6 [C]0 [C]. [C]6 O 
X [C]X O 
10 [C]1 [C]0 O 
( [C]( O 
-8 [C]- [C]8 O 
) [C]) O 
M [C]M O 
. [C]. O 

TMS [C]T [C]M [C]S O 
F5 [C]F [C]5 O 
also [C]a [C]l [C]s [C]o O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n O 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
cytolytic [C]c [C]y [C]t [C]o [C]l [C]y [C]t [C]i [C]c O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
( [C]( O 
2.5 [C]2 [C]. [C]5 O 
X [C]X O 
10 [C]1 [C]0 O 
( [C]( O 
-8 [C]- [C]8 O 
) [C]) O 
M [C]M O 
) [C]) O 
to [C]t [C]o O 
168.6 [C]1 [C]6 [C]8 [C]. [C]6 O 
+/- [C]+ [C]/ [C]- O 
30.2 [C]3 [C]0 [C]. [C]2 O 
% [C]% O 
of [C]o [C]f O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
( [C]( O 
P [C]P O 
less [C]l [C]e [C]s [C]s O 
than [C]t [C]h [C]a [C]n O 
0.01 [C]0 [C]. [C]0 [C]1 O 
) [C]) O 
. [C]. O 

In [C]I [C]n O 
animals [C]a [C]n [C]i [C]m [C]a [C]l [C]s O 
, [C], O 
medullary [C]m [C]e [C]d [C]u [C]l [C]l [C]a [C]r [C]y B-cell_type 
and [C]a [C]n [C]d I-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
are [C]a [C]r [C]e O 
more [C]m [C]o [C]r [C]e O 
resistant [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]t O 
to [C]t [C]o O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
than [C]t [C]h [C]a [C]n O 
immature [C]i [C]m [C]m [C]a [C]t [C]u [C]r [C]e B-cell_type 
thymic [C]t [C]h [C]y [C]m [C]i [C]c I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
thymosin [C]t [C]h [C]y [C]m [C]o [C]s [C]i [C]n O 
can [C]c [C]a [C]n O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
consistent [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
are [C]a [C]r [C]e O 
consistent [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
physiological [C]p [C]h [C]y [C]s [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
thymosin [C]t [C]h [C]y [C]m [C]o [C]s [C]i [C]n O 
in [C]i [C]n O 
intrathymic [C]i [C]n [C]t [C]r [C]a [C]t [C]h [C]y [C]m [C]i [C]c O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
maturation [C]m [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
man [C]m [C]a [C]n O 
. [C]. O 

Incubation [C]I [C]n [C]c [C]u [C]b [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
malignant [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]t I-cell_line 
thymus [C]t [C]h [C]y [C]m [C]u [C]s I-cell_line 
derived [C]d [C]e [C]r [C]i [C]v [C]e [C]d I-cell_line 
T [C]T I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
( [C]( O 
MOLT [C]M [C]O [C]L [C]T B-cell_line 
3 [C]3 E-cell_line 
) [C]) O 
with [C]w [C]i [C]t [C]h O 
TMS [C]T [C]M [C]S O 
F5 [C]F [C]5 O 
also [C]a [C]l [C]s [C]o O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
a [C]a O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
reduction [C]r [C]e [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
sites [C]s [C]i [C]t [C]e [C]s O 
to [C]t [C]o O 
44.2 [C]4 [C]4 [C]. [C]2 O 
+/- [C]+ [C]/ [C]- O 
15.3 [C]1 [C]5 [C]. [C]3 O 
% [C]% O 
of [C]o [C]f O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
( [C]( O 
P [C]P O 
less [C]l [C]e [C]s [C]s O 
than [C]t [C]h [C]a [C]n O 
0.05 [C]0 [C]. [C]0 [C]5 O 
) [C]) O 
, [C], O 
but [C]b [C]u [C]t O 
TMS [C]T [C]M [C]S O 
F5 [C]F [C]5 O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
reduce [C]r [C]e [C]d [C]u [C]c [C]e O 
the [C]t [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
MOLT [C]M [C]O [C]L [C]T B-cell_line 
3 [C]3 I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

Specific [C]S [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-protein 
high-affinity [C]h [C]i [C]g [C]h [C]- [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
for [C]f [C]o [C]r O 
1 [C]1 O 
, [C], O 
25-dihydroxyvitamin [C]2 [C]5 [C]- [C]d [C]i [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]v [C]i [C]t [C]a [C]m [C]i [C]n O 
D3 [C]D [C]3 O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
: [C]: O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
in [C]i [C]n O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
and [C]a [C]n [C]d O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
T [C]T B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Human [C]H [C]u [C]m [C]a [C]n B-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
have [C]h [C]a [C]v [C]e O 
high [C]h [C]i [C]g [C]h O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
sites [C]s [C]i [C]t [C]e [C]s O 
for [C]f [C]o [C]r O 
1 [C]1 O 
, [C], O 
25- [C]2 [C]5 [C]- O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
( [C]( O 
Kd [C]K [C]d O 
0.14 [C]0 [C]. [C]1 [C]4 O 
nM [C]n [C]M O 
, [C], O 
sedimentation [C]s [C]e [C]d [C]i [C]m [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
coefficient [C]c [C]o [C]e [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
3.7S [C]3 [C]. [C]7 [C]S O 
) [C]) O 
. [C]. O 

Resting [C]R [C]e [C]s [C]t [C]i [C]n [C]g B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
, [C], O 
however [C]h [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
do [C]d [C]o O 
not [C]n [C]o [C]t O 
have [C]h [C]a [C]v [C]e O 
a [C]a O 
demonstrable [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]b [C]l [C]e O 
1 [C]1 B-protein 
, [C], I-protein 
25- [C]2 [C]5 [C]- I-protein 
( [C]( I-protein 
OH [C]O [C]H I-protein 
) [C]) I-protein 
2D3 [C]2 [C]D [C]3 I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
. [C]. O 

After [C]A [C]f [C]t [C]e [C]r O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
phytohemagglutinin [C]p [C]h [C]y [C]t [C]o [C]h [C]e [C]m [C]a [C]g [C]g [C]l [C]u [C]t [C]i [C]n [C]i [C]n S-protein 
the [C]t [C]h [C]e O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
exhibit [C]e [C]x [C]h [C]i [C]b [C]i [C]t O 
the [C]t [C]h [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
24 [C]2 [C]4 O 
h [C]h O 
, [C], O 
and [C]a [C]n [C]d O 
this [C]t [C]h [C]i [C]s O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
is [C]i [C]s O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
by [C]b [C]y O 
cycloheximide [C]c [C]y [C]c [C]l [C]o [C]h [C]e [C]x [C]i [C]m [C]i [C]d [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
in [C]i [C]n O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
has [C]h [C]a [C]s O 
a [C]a O 
sedimentation [C]s [C]e [C]d [C]i [C]m [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
coefficient [C]c [C]o [C]e [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
of [C]o [C]f O 
3.7S [C]3 [C]. [C]7 [C]S O 
and [C]a [C]n [C]d O 
a [C]a O 
high [C]h [C]i [C]g [C]h O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
( [C]( O 
Kd [C]K [C]d O 
0.10 [C]0 [C]. [C]1 [C]0 O 
nM [C]n [C]M O 
) [C]) O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
ligand [C]l [C]i [C]g [C]a [C]n [C]d O 
. [C]. O 

Effects [C]E [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
excess [C]e [C]x [C]c [C]e [C]s [C]s O 
in [C]i [C]n O 
man [C]m [C]a [C]n O 
on [C]o [C]n O 
insulin [C]i [C]n [C]s [C]u [C]l [C]i [C]n O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
circulating [C]c [C]i [C]r [C]c [C]u [C]l [C]a [C]t [C]i [C]n [C]g B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
: [C]: O 
differences [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e [C]s O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
endogenous [C]e [C]n [C]d [C]o [C]g [C]e [C]n [C]o [C]u [C]s O 
and [C]a [C]n [C]d O 
exogenous [C]e [C]x [C]o [C]g [C]e [C]n [C]o [C]u [C]s O 
hypercorticism [C]h [C]y [C]p [C]e [C]r [C]c [C]o [C]r [C]t [C]i [C]c [C]i [C]s [C]m O 
. [C]. O 

We [C]W [C]e O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
[ [C][ O 
125I [C]1 [C]2 [C]5 [C]I O 
] [C]] O 
insulin [C]i [C]n [C]s [C]u [C]l [C]i [C]n O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
circulating [C]c [C]i [C]r [C]c [C]u [C]l [C]a [C]t [C]i [C]n [C]g B-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s I-cell_type 
or [C]o [C]r I-cell_type 
erythrocytes [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
16 [C]1 [C]6 O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
excess [C]e [C]x [C]c [C]e [C]s [C]s O 
, [C], O 
9 [C]9 O 
chronically [C]c [C]h [C]r [C]o [C]n [C]i [C]c [C]a [C]l [C]l [C]y O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
prednisone [C]p [C]r [C]e [C]d [C]n [C]i [C]s [C]o [C]n [C]e O 
and [C]a [C]n [C]d O 
7 [C]7 O 
with [C]w [C]i [C]t [C]h O 
adrenocortical [C]a [C]d [C]r [C]e [C]n [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]a [C]l O 
hyperfunction [C]h [C]y [C]p [C]e [C]r [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

With [C]W [C]i [C]t [C]h O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
, [C], O 
[ [C][ O 
125I [C]1 [C]2 [C]5 [C]I O 
] [C]] O 
insulin [C]i [C]n [C]s [C]u [C]l [C]i [C]n O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
was [C]w [C]a [C]s O 
iincreased [C]i [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
in [C]i [C]n O 
all [C]a [C]l [C]l O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

Analysis [C]A [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
data [C]d [C]a [C]t [C]a O 
indicated [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
in [C]i [C]n O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
prednisone [C]p [C]r [C]e [C]d [C]n [C]i [C]s [C]o [C]n [C]e O 
was [C]w [C]a [C]s O 
due [C]d [C]u [C]e O 
to [C]t [C]o O 
an [C]a [C]n O 
ncrease [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
in [C]i [C]n O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
adrenocortical [C]a [C]d [C]r [C]e [C]n [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]a [C]l O 
hyperfunction [C]h [C]y [C]p [C]e [C]r [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
, [C], O 
it [C]i [C]t O 
was [C]w [C]a [C]s O 
due [C]d [C]u [C]e O 
to [C]t [C]o O 
an [C]a [C]n O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
. [C]. O 

With [C]W [C]i [C]t [C]h O 
erythrocytes [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]c [C]y [C]t [C]e [C]s O 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
adrenocortical [C]a [C]d [C]r [C]e [C]n [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]a [C]l O 
hyperfunction [C]h [C]y [C]p [C]e [C]r [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
there [C]t [C]h [C]e [C]r [C]e O 
was [C]w [C]a [C]s O 
an [C]a [C]n O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
a [C]a O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
so [C]s [C]o O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
[ [C][ O 
125I [C]1 [C]2 [C]5 [C]I O 
] [C]] O 
insulin [C]i [C]n [C]s [C]u [C]l [C]i [C]n O 
was [C]w [C]a [C]s O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
. [C]. O 

The [C]T [C]h [C]e O 
disparity [C]d [C]i [C]s [C]p [C]a [C]r [C]i [C]t [C]y O 
of [C]o [C]f O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
endogenous [C]e [C]n [C]d [C]o [C]g [C]e [C]n [C]o [C]u [C]s O 
and [C]a [C]n [C]d O 
exogenous [C]e [C]x [C]o [C]g [C]e [C]n [C]o [C]u [C]s O 
hypercorticism [C]h [C]y [C]p [C]e [C]r [C]c [C]o [C]r [C]t [C]i [C]c [C]i [C]s [C]m O 
, [C], O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
two [C]t [C]w [C]o O 
cell [C]c [C]e [C]l [C]l O 
types [C]t [C]y [C]p [C]e [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
and [C]a [C]n [C]d O 
previous [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
excess [C]e [C]x [C]c [C]e [C]s [C]s O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
insulin [C]i [C]n [C]s [C]u [C]l [C]i [C]n B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
are [C]a [C]r [C]e O 
extremely [C]e [C]x [C]t [C]r [C]e [C]m [C]e [C]l [C]y O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
and [C]a [C]n [C]d O 
wide-ranging [C]w [C]i [C]d [C]e [C]- [C]r [C]a [C]n [C]g [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
in [C]i [C]n O 
this [C]t [C]h [C]i [C]s O 
condition [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
extrapolations [C]e [C]x [C]t [C]r [C]a [C]p [C]o [C]l [C]a [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
humans [C]h [C]u [C]m [C]a [C]n [C]s O 
from [C]f [C]r [C]o [C]m O 
data [C]d [C]a [C]t [C]a O 
with [C]w [C]i [C]t [C]h O 
circulating [C]c [C]i [C]r [C]c [C]u [C]l [C]a [C]t [C]i [C]n [C]g B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
to [C]t [C]o O 
liver [C]l [C]i [C]v [C]e [C]r O 
and [C]a [C]n [C]d O 
muscle [C]m [C]u [C]s [C]c [C]l [C]e O 
may [C]m [C]a [C]y O 
not [C]n [C]o [C]t O 
be [C]b [C]e O 
appropriate [C]a [C]p [C]p [C]r [C]o [C]p [C]r [C]i [C]a [C]t [C]e O 
. [C]. O 

Reduced [C]R [C]e [C]d [C]u [C]c [C]e [C]d O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
anorexia [C]a [C]n [C]o [C]r [C]e [C]x [C]i [C]a O 
nervosa [C]n [C]e [C]r [C]v [C]o [C]s [C]a O 
. [C]. O 

Specific [C]S [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
were [C]w [C]e [C]r [C]e O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
in [C]i [C]n O 
circulating [C]c [C]i [C]r [C]c [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_type 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
12 [C]1 [C]2 O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
anorexia [C]a [C]n [C]o [C]r [C]e [C]x [C]i [C]a O 
nervosa [C]n [C]e [C]r [C]v [C]o [C]s [C]a O 
and [C]a [C]n [C]d O 
21 [C]2 [C]1 O 
healthy [C]h [C]e [C]a [C]l [C]t [C]h [C]y O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
. [C]. O 

Cells [C]C [C]e [C]l [C]l [C]s O 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
were [C]w [C]e [C]r [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
contain [C]c [C]o [C]n [C]t [C]a [C]i [C]n O 
a [C]a O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
( [C]( O 
p [C]p O 
less [C]l [C]e [C]s [C]s O 
than [C]t [C]h [C]a [C]n O 
0.01 [C]0 [C]. [C]0 [C]1 O 
) [C]) O 
lower [C]l [C]o [C]w [C]e [C]r O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
( [C]( O 
3830 [C]3 [C]8 [C]3 [C]0 O 
+/- [C]+ [C]/ [C]- O 
210 [C]2 [C]1 [C]0 O 
sites/cell [C]s [C]i [C]t [C]e [C]s [C]/ [C]c [C]e [C]l [C]l O 
, [C], O 
mean [C]m [C]e [C]a [C]n O 
+/- [C]+ [C]/ [C]- O 
SE [C]S [C]E O 
) [C]) O 
than [C]t [C]h [C]a [C]n O 
those [C]t [C]h [C]o [C]s [C]e O 
from [C]f [C]r [C]o [C]m O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
( [C]( O 
4930 [C]4 [C]9 [C]3 [C]0 O 
+/- [C]+ [C]/ [C]- O 
250 [C]2 [C]5 [C]0 O 
sites/cell [C]s [C]i [C]t [C]e [C]s [C]/ [C]c [C]e [C]l [C]l O 
) [C]) O 
. [C]. O 

A [C]A O 
partial [C]p [C]a [C]r [C]t [C]i [C]a [C]l O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
defect [C]d [C]e [C]f [C]e [C]c [C]t O 
may [C]m [C]a [C]y O 
well [C]w [C]e [C]l [C]l O 
explain [C]e [C]x [C]p [C]l [C]a [C]i [C]n O 
the [C]t [C]h [C]e O 
abnormal [C]a [C]b [C]n [C]o [C]r [C]m [C]a [C]l O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
metabolism [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]s [C]m O 
and [C]a [C]n [C]d O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
commonly [C]c [C]o [C]m [C]m [C]o [C]n [C]l [C]y O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
anorexia [C]a [C]n [C]o [C]r [C]e [C]x [C]i [C]a O 
nervosa [C]n [C]e [C]r [C]v [C]o [C]s [C]a O 
. [C]. O 

Regulation [C]R [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
a [C]a O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
is [C]i [C]s O 
well [C]w [C]e [C]l [C]l O 
established [C]e [C]s [C]t [C]a [C]b [C]l [C]i [C]s [C]h [C]e [C]d O 
, [C], O 
but [C]b [C]u [C]t O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
affecting [C]a [C]f [C]f [C]e [C]c [C]t [C]i [C]n [C]g O 
its [C]i [C]t [C]s O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
have [C]h [C]a [C]v [C]e O 
not [C]n [C]o [C]t O 
been [C]b [C]e [C]e [C]n O 
described [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
. [C]. O 

Using [C]U [C]s [C]i [C]n [C]g O 
a [C]a O 
competitive [C]c [C]o [C]m [C]p [C]e [C]t [C]i [C]t [C]i [C]v [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
whole [C]w [C]h [C]o [C]l [C]e O 
cell [C]c [C]e [C]l [C]l O 
assay [C]a [C]s [C]s [C]a [C]y O 
, [C], O 
we [C]w [C]e O 
have [C]h [C]a [C]v [C]e O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
the [C]t [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
-dexamethasone [C]- [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
at [C]a [C]t O 
24 [C]2 [C]4 O 
and [C]a [C]n [C]d O 
37 [C]3 [C]7 O 
degrees [C]d [C]e [C]g [C]r [C]e [C]e [C]s O 
C [C]C O 
in [C]i [C]n O 
untreated [C]u [C]n [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
healthy [C]h [C]e [C]a [C]l [C]t [C]h [C]y O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
taking [C]t [C]a [C]k [C]i [C]n [C]g O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
preparations [C]p [C]r [C]e [C]p [C]a [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

At [C]A [C]t O 
24 [C]2 [C]4 O 
degrees [C]d [C]e [C]g [C]r [C]e [C]e [C]s O 
C [C]C O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
had [C]h [C]a [C]d O 
6000 [C]6 [C]0 [C]0 [C]0 O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
sites/cell [C]s [C]i [C]t [C]e [C]s [C]/ [C]c [C]e [C]l [C]l O 
and [C]a [C]n [C]d O 
a [C]a O 
dissociation [C]d [C]i [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
constant [C]c [C]o [C]n [C]s [C]t [C]a [C]n [C]t O 
of [C]o [C]f O 
4 [C]4 O 
x [C]x O 
10 [C]1 [C]0 O 
( [C]( O 
-9 [C]- [C]9 O 
) [C]) O 
M [C]M O 
. [C]. O 

The [C]T [C]h [C]e O 
administration [C]a [C]d [C]m [C]i [C]n [C]i [C]s [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
1 [C]1 O 
mg [C]m [C]g O 
of [C]o [C]f O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
, [C], O 
5 [C]5 O 
mg [C]m [C]g O 
of [C]o [C]f O 
prednisone [C]p [C]r [C]e [C]d [C]n [C]i [C]s [C]o [C]n [C]e O 
, [C], O 
and [C]a [C]n [C]d O 
37.5 [C]3 [C]7 [C]. [C]5 O 
mg [C]m [C]g O 
of [C]o [C]f O 
cortisone [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]n [C]e O 
acetate [C]a [C]c [C]e [C]t [C]a [C]t [C]e O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
a [C]a O 
30 [C]3 [C]0 O 
% [C]% O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
sites [C]s [C]i [C]t [C]e [C]s O 
after [C]a [C]f [C]t [C]e [C]r O 
1 [C]1 O 
week [C]w [C]e [C]e [C]k O 
with [C]w [C]i [C]t [C]h O 
no [C]n [C]o O 
change [C]c [C]h [C]a [C]n [C]g [C]e O 
in [C]i [C]n O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
. [C]. O 

No [C]N [C]o O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
sites [C]s [C]i [C]t [C]e [C]s O 
was [C]w [C]a [C]s O 
noted [C]n [C]o [C]t [C]e [C]d O 
before [C]b [C]e [C]f [C]o [C]r [C]e O 
1 [C]1 O 
week [C]w [C]e [C]e [C]k O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
diminished [C]d [C]i [C]m [C]i [C]n [C]i [C]s [C]h [C]e [C]d O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
persisted [C]p [C]e [C]r [C]s [C]i [C]s [C]t [C]e [C]d O 
for [C]f [C]o [C]r O 
1 [C]1 O 
week [C]w [C]e [C]e [C]k O 
after [C]a [C]f [C]t [C]e [C]r O 
discontinuation [C]d [C]i [C]s [C]c [C]o [C]n [C]t [C]i [C]n [C]u [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
. [C]. O 

Lymphocytes [C]L [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
from [C]f [C]r [C]o [C]m O 
hospitalized [C]h [C]o [C]s [C]p [C]i [C]t [C]a [C]l [C]i [C]z [C]e [C]d O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
taking [C]t [C]a [C]k [C]i [C]n [C]g O 
40-60 [C]4 [C]0 [C]- [C]6 [C]0 O 
mg [C]m [C]g O 
of [C]o [C]f O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
daily [C]d [C]a [C]i [C]l [C]y O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
change [C]c [C]h [C]a [C]n [C]g [C]e O 
in [C]i [C]n O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
sites [C]s [C]i [C]t [C]e [C]s O 
that [C]t [C]h [C]a [C]t O 
was [C]w [C]a [C]s O 
seen [C]s [C]e [C]e [C]n O 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
taking [C]t [C]a [C]k [C]i [C]n [C]g O 
1 [C]1 O 
mg [C]m [C]g O 
of [C]o [C]f O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
. [C]. O 

When [C]W [C]h [C]e [C]n O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
were [C]w [C]e [C]r [C]e O 
carried [C]c [C]a [C]r [C]r [C]i [C]e [C]d O 
out [C]o [C]u [C]t O 
at [C]a [C]t O 
physiologic [C]p [C]h [C]y [C]s [C]i [C]o [C]l [C]o [C]g [C]i [C]c O 
temperature [C]t [C]e [C]m [C]p [C]e [C]r [C]a [C]t [C]u [C]r [C]e O 
there [C]t [C]h [C]e [C]r [C]e O 
was [C]w [C]a [C]s O 
the [C]t [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
sites [C]s [C]i [C]t [C]e [C]s O 
after [C]a [C]f [C]t [C]e [C]r O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
administration [C]a [C]d [C]m [C]i [C]n [C]i [C]s [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
there [C]t [C]h [C]e [C]r [C]e O 
was [C]w [C]a [C]s O 
a [C]a O 
two-fold [C]t [C]w [C]o [C]- [C]f [C]o [C]l [C]d O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
. [C]. O 

Glucocorticoid [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
administration [C]a [C]d [C]m [C]i [C]n [C]i [C]s [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
in [C]i [C]n O 
a [C]a O 
time-dependent [C]t [C]i [C]m [C]e [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
sites [C]s [C]i [C]t [C]e [C]s O 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
type [C]t [C]y [C]p [C]e O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
administered [C]a [C]d [C]m [C]i [C]n [C]i [C]s [C]t [C]e [C]r [C]e [C]d O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
is [C]i [C]s O 
the [C]t [C]h [C]e O 
first [C]f [C]i [C]r [C]s [C]t O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
demonstration [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
that [C]t [C]h [C]a [C]t O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
modulate [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]e O 
their [C]t [C]h [C]e [C]i [C]r O 
own [C]o [C]w [C]n O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
in [C]i [C]n O 
man [C]m [C]a [C]n O 
. [C]. O 

Immunoglobulin [C]I [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n O 
localization [C]l [C]o [C]c [C]a [C]l [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
benign [C]b [C]e [C]n [C]i [C]g [C]n O 
and [C]a [C]n [C]d O 
malignant [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]t O 
lesions [C]l [C]e [C]s [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n O 
mammary [C]m [C]a [C]m [C]m [C]a [C]r [C]y O 
gland [C]g [C]l [C]a [C]n [C]d O 
. [C]. O 

Using [C]U [C]s [C]i [C]n [C]g O 
direct [C]d [C]i [C]r [C]e [C]c [C]t O 
imunofluorescence [C]i [C]m [C]u [C]n [C]o [C]f [C]l [C]u [C]o [C]r [C]e [C]s [C]c [C]e [C]n [C]c [C]e O 
, [C], O 
lesions [C]l [C]e [C]s [C]i [C]o [C]n [C]s O 
from [C]f [C]r [C]o [C]m O 
266 [C]2 [C]6 [C]6 O 
human [C]h [C]u [C]m [C]a [C]n O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
specimens [C]s [C]p [C]e [C]c [C]i [C]m [C]e [C]n [C]s O 
were [C]w [C]e [C]r [C]e O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
IgA [C]I [C]g [C]A O 
, [C], O 
IgM [C]I [C]g [C]M O 
, [C], O 
or [C]o [C]r O 
IgG [C]I [C]g [C]G O 
localization [C]l [C]o [C]c [C]a [C]l [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
lesions [C]l [C]e [C]s [C]i [C]o [C]n [C]s O 
included [C]i [C]n [C]c [C]l [C]u [C]d [C]e [C]d O 
benign [C]b [C]e [C]n [C]i [C]g [C]n O 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s O 
from [C]f [C]r [C]o [C]m O 
66 [C]6 [C]6 O 
subcutaneous [C]s [C]u [C]b [C]c [C]u [C]t [C]a [C]n [C]e [C]o [C]u [C]s O 
mastectomy [C]m [C]a [C]s [C]t [C]e [C]c [C]t [C]o [C]m [C]y O 
specimens [C]s [C]p [C]e [C]c [C]i [C]m [C]e [C]n [C]s O 
in [C]i [C]n O 
which [C]w [C]h [C]i [C]c [C]h O 
the [C]t [C]h [C]e O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
simultaneous [C]s [C]i [C]m [C]u [C]l [C]t [C]a [C]n [C]e [C]o [C]u [C]s O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
malignancy [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]c [C]y O 
was [C]w [C]a [C]s O 
documented [C]d [C]o [C]c [C]u [C]m [C]e [C]n [C]t [C]e [C]d O 
, [C], O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
carcinomas [C]c [C]a [C]r [C]c [C]i [C]n [C]o [C]m [C]a [C]s O 
from [C]f [C]r [C]o [C]m O 
153 [C]1 [C]5 [C]3 O 
mastectomy [C]m [C]a [C]s [C]t [C]e [C]c [C]t [C]o [C]m [C]y O 
specimens [C]s [C]p [C]e [C]c [C]i [C]m [C]e [C]n [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
47 [C]4 [C]7 O 
biopsies [C]b [C]i [C]o [C]p [C]s [C]i [C]e [C]s O 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
metastatic [C]m [C]e [C]t [C]a [C]s [C]t [C]a [C]t [C]i [C]c O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
. [C]. O 

A [C]A O 
statistically [C]s [C]t [C]a [C]t [C]i [C]s [C]t [C]i [C]c [C]a [C]l [C]l [C]y O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
association [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IgA [C]I [C]g [C]A S-protein 
and [C]a [C]n [C]d O 
IgM [C]I [C]g [C]M S-protein 
with [C]w [C]i [C]t [C]h O 
benign [C]b [C]e [C]n [C]i [C]g [C]n O 
lesions [C]l [C]e [C]s [C]i [C]o [C]n [C]s O 
was [C]w [C]a [C]s O 
contrasted [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
association [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IgG [C]I [C]g [C]G S-protein 
with [C]w [C]i [C]t [C]h O 
malignant [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]t O 
lesions [C]l [C]e [C]s [C]i [C]o [C]n [C]s O 
. [C]. O 

In [C]I [C]n O 
both [C]b [C]o [C]t [C]h O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y O 
and [C]a [C]n [C]d O 
metastatic [C]m [C]e [C]t [C]a [C]s [C]t [C]a [C]t [C]i [C]c O 
lesions [C]l [C]e [C]s [C]i [C]o [C]n [C]s O 
, [C], O 
IgG [C]I [C]g [C]G S-protein 
localization [C]l [C]o [C]c [C]a [C]l [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
estrogen-receptor-poor [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]- [C]p [C]o [C]o [C]r O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y O 
cancers [C]c [C]a [C]n [C]c [C]e [C]r [C]s O 
as [C]a [C]s O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
estrogen-receptor-rich [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]- [C]r [C]i [C]c [C]h O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y O 
cancers [C]c [C]a [C]n [C]c [C]e [C]r [C]s O 
. [C]. O 

Among [C]A [C]m [C]o [C]n [C]g O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
, [C], O 
IgG [C]I [C]g [C]G S-protein 
localization [C]l [C]o [C]c [C]a [C]l [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
tumor [C]t [C]u [C]m [C]o [C]r O 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
relative [C]r [C]e [C]l [C]a [C]t [C]i [C]v [C]e O 
lymphopenia [C]l [C]y [C]m [C]p [C]h [C]o [C]p [C]e [C]n [C]i [C]a O 
. [C]. O 

A [C]A O 
shorter [C]s [C]h [C]o [C]r [C]t [C]e [C]r O 
disease-free [C]d [C]i [C]s [C]e [C]a [C]s [C]e [C]- [C]f [C]r [C]e [C]e O 
interval [C]i [C]n [C]t [C]e [C]r [C]v [C]a [C]l O 
was [C]w [C]a [C]s O 
noted [C]n [C]o [C]t [C]e [C]d O 
in [C]i [C]n O 
association [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
IgG [C]I [C]g [C]G S-protein 
localization [C]l [C]o [C]c [C]a [C]l [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
among [C]a [C]m [C]o [C]n [C]g O 
the [C]t [C]h [C]e O 
metastatic [C]m [C]e [C]t [C]a [C]s [C]t [C]a [C]t [C]i [C]c O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
lesions [C]l [C]e [C]s [C]i [C]o [C]n [C]s O 
. [C]. O 

No [C]N [C]o O 
statistically [C]s [C]t [C]a [C]t [C]i [C]s [C]t [C]i [C]c [C]a [C]l [C]l [C]y O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
association [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
stage [C]s [C]t [C]a [C]g [C]e O 
of [C]o [C]f O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
and [C]a [C]n [C]d O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
was [C]w [C]a [C]s O 
demonstrable [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]b [C]l [C]e O 
. [C]. O 

Moderate-to-severe [C]M [C]o [C]d [C]e [C]r [C]a [C]t [C]e [C]- [C]t [C]o [C]- [C]s [C]e [C]v [C]e [C]r [C]e O 
intraductal [C]i [C]n [C]t [C]r [C]a [C]d [C]u [C]c [C]t [C]a [C]l O 
epithelial [C]e [C]p [C]i [C]t [C]h [C]e [C]l [C]i [C]a [C]l O 
hyperplasias [C]h [C]y [C]p [C]e [C]r [C]p [C]l [C]a [C]s [C]i [C]a [C]s O 
were [C]w [C]e [C]r [C]e O 
more [C]m [C]o [C]r [C]e O 
often [C]o [C]f [C]t [C]e [C]n O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n B-protein 
G [C]G E-protein 
localization [C]l [C]o [C]c [C]a [C]l [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
that [C]t [C]h [C]a [C]t O 
were [C]w [C]e [C]r [C]e O 
other [C]o [C]t [C]h [C]e [C]r O 
benign [C]b [C]e [C]n [C]i [C]g [C]n O 
lesions [C]l [C]e [C]s [C]i [C]o [C]n [C]s O 

Correlation [C]C [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
with [C]w [C]i [C]t [C]h O 
histologic [C]h [C]i [C]s [C]t [C]o [C]l [C]o [C]g [C]i [C]c O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
mammary [C]m [C]a [C]m [C]m [C]a [C]r [C]y O 
carcinoma [C]c [C]a [C]r [C]c [C]i [C]n [C]o [C]m [C]a O 
. [C]. O 

A [C]A O 
Singapore [C]S [C]i [C]n [C]g [C]a [C]p [C]o [C]r [C]e O 
experience [C]e [C]x [C]p [C]e [C]r [C]i [C]e [C]n [C]c [C]e O 
. [C]. O 

Cancer [C]C [C]a [C]n [C]c [C]e [C]r O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
is [C]i [C]s O 
the [C]t [C]h [C]e O 
most [C]m [C]o [C]s [C]t O 
common [C]c [C]o [C]m [C]m [C]o [C]n O 
tumor [C]t [C]u [C]m [C]o [C]r O 
in [C]i [C]n O 
females [C]f [C]e [C]m [C]a [C]l [C]e [C]s O 
in [C]i [C]n O 
Singapore [C]S [C]i [C]n [C]g [C]a [C]p [C]o [C]r [C]e O 
, [C], O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
rate [C]r [C]a [C]t [C]e O 
of [C]o [C]f O 
20.7 [C]2 [C]0 [C]. [C]7 O 
per [C]p [C]e [C]r O 
100 [C]1 [C]0 [C]0 O 
, [C], O 
000 [C]0 [C]0 [C]0 O 
per [C]p [C]e [C]r O 
year [C]y [C]e [C]a [C]r O 
( [C]( O 
1977 [C]1 [C]9 [C]7 [C]7 O 
estimate [C]e [C]s [C]t [C]i [C]m [C]a [C]t [C]e O 
) [C]) O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
predicted [C]p [C]r [C]e [C]d [C]i [C]c [C]t [C]e [C]d O 
to [C]t [C]o O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
to [C]t [C]o O 
29.8 [C]2 [C]9 [C]. [C]8 O 
per [C]p [C]e [C]r O 
100 [C]1 [C]0 [C]0 O 
, [C], O 
000 [C]0 [C]0 [C]0 O 
women [C]w [C]o [C]m [C]e [C]n O 
per [C]p [C]e [C]r O 
year [C]y [C]e [C]a [C]r O 
by [C]b [C]y O 
1995 [C]1 [C]9 [C]9 [C]5 O 
. [C]. O 

A [C]A O 
detailed [C]d [C]e [C]t [C]a [C]i [C]l [C]e [C]d O 
histopathologic [C]h [C]i [C]s [C]t [C]o [C]p [C]a [C]t [C]h [C]o [C]l [C]o [C]g [C]i [C]c O 
review [C]r [C]e [C]v [C]i [C]e [C]w O 
of [C]o [C]f O 
50 [C]5 [C]0 O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
tumors [C]t [C]u [C]m [C]o [C]r [C]s O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
for [C]f [C]o [C]r O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
( [C]( O 
ER [C]E [C]R S-protein 
) [C]) O 
level [C]l [C]e [C]v [C]e [C]l O 
was [C]w [C]a [C]s O 
carried [C]c [C]a [C]r [C]r [C]i [C]e [C]d O 
out [C]o [C]u [C]t O 
and [C]a [C]n [C]d O 
a [C]a O 
variety [C]v [C]a [C]r [C]i [C]e [C]t [C]y O 
of [C]o [C]f O 
morphologic [C]m [C]o [C]r [C]p [C]h [C]o [C]l [C]o [C]g [C]i [C]c O 
features [C]f [C]e [C]a [C]t [C]u [C]r [C]e [C]s O 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
ER [C]E [C]R S-protein 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
to [C]t [C]o O 
identify [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]y O 
any [C]a [C]n [C]y O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
that [C]t [C]h [C]a [C]t O 
will [C]w [C]i [C]l [C]l O 
improve [C]i [C]m [C]p [C]r [C]o [C]v [C]e O 
the [C]t [C]h [C]e O 
management [C]m [C]a [C]n [C]a [C]g [C]e [C]m [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
prognosis [C]p [C]r [C]o [C]g [C]n [C]o [C]s [C]i [C]s O 
for [C]f [C]o [C]r O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
. [C]. O 

Cytosol [C]C [C]y [C]t [C]o [C]s [C]o [C]l O 
was [C]w [C]a [C]s O 
incubated [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
3H-estradiol [C]3 [C]H [C]- [C]e [C]s [C]t [C]r [C]a [C]d [C]i [C]o [C]l O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
and [C]a [C]n [C]d O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
cold [C]c [C]o [C]l [C]d O 
diethylstilbestrol [C]d [C]i [C]e [C]t [C]h [C]y [C]l [C]s [C]t [C]i [C]l [C]b [C]e [C]s [C]t [C]r [C]o [C]l O 
, [C], O 
and [C]a [C]n [C]d O 
bound [C]b [C]o [C]u [C]n [C]d O 
and [C]a [C]n [C]d O 
free [C]f [C]r [C]e [C]e O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e O 
were [C]w [C]e [C]r [C]e O 
separated [C]s [C]e [C]p [C]a [C]r [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
Dextran-coated [C]D [C]e [C]x [C]t [C]r [C]a [C]n [C]- [C]c [C]o [C]a [C]t [C]e [C]d O 
charcoal [C]c [C]h [C]a [C]r [C]c [C]o [C]a [C]l O 
method [C]m [C]e [C]t [C]h [C]o [C]d O 
. [C]. O 

Tumors [C]T [C]u [C]m [C]o [C]r [C]s O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
more [C]m [C]o [C]r [C]e O 
than [C]t [C]h [C]a [C]n O 
5 [C]5 O 
fmol/mg [C]f [C]m [C]o [C]l [C]/ [C]m [C]g O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
were [C]w [C]e [C]r [C]e O 
classified [C]c [C]l [C]a [C]s [C]s [C]i [C]f [C]i [C]e [C]d O 
as [C]a [C]s O 
ER [C]E [C]R S-protein 
-positive [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
. [C]. O 

Progesterone [C]P [C]r [C]o [C]g [C]e [C]s [C]t [C]e [C]r [C]o [C]n [C]e B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
( [C]( O 
PR [C]P [C]R S-protein 
) [C]) O 
level [C]l [C]e [C]v [C]e [C]l O 
was [C]w [C]a [C]s O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
in [C]i [C]n O 
some [C]s [C]o [C]m [C]e O 
specimens [C]s [C]p [C]e [C]c [C]i [C]m [C]e [C]n [C]s O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
use [C]u [C]s [C]e O 
of [C]o [C]f O 
a [C]a O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
method [C]m [C]e [C]t [C]h [C]o [C]d O 
. [C]. O 

Most [C]M [C]o [C]s [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
were [C]w [C]e [C]r [C]e O 
Chinese [C]C [C]h [C]i [C]n [C]e [C]s [C]e O 
( [C]( O 
90 [C]9 [C]0 O 
% [C]% O 
) [C]) O 
. [C]. O 

Three [C]T [C]h [C]r [C]e [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
were [C]w [C]e [C]r [C]e O 
Malays [C]M [C]a [C]l [C]a [C]y [C]s O 
, [C], O 
one [C]o [C]n [C]e O 
was [C]w [C]a [C]s O 
Indian [C]I [C]n [C]d [C]i [C]a [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
one [C]o [C]n [C]e O 
was [C]w [C]a [C]s O 
European [C]E [C]u [C]r [C]o [C]p [C]e [C]a [C]n O 
in [C]i [C]n O 
this [C]t [C]h [C]i [C]s O 
series [C]s [C]e [C]r [C]i [C]e [C]s O 
. [C]. O 

Results [C]R [C]e [C]s [C]u [C]l [C]t [C]s O 
indicated [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
there [C]t [C]h [C]e [C]r [C]e O 
was [C]w [C]a [C]s O 
strong [C]s [C]t [C]r [C]o [C]n [C]g O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
ER [C]E [C]R S-protein 
level [C]l [C]e [C]v [C]e [C]l O 
, [C], O 
age [C]a [C]g [C]e O 
, [C], O 
and [C]a [C]n [C]d O 
histologic [C]h [C]i [C]s [C]t [C]o [C]l [C]o [C]g [C]i [C]c O 
grade [C]g [C]r [C]a [C]d [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
tumors [C]t [C]u [C]m [C]o [C]r [C]s O 
. [C]. O 

No [C]N [C]o O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
existed [C]e [C]x [C]i [C]s [C]t [C]e [C]d O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
or [C]o [C]r O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
lymph [C]l [C]y [C]m [C]p [C]h O 
node [C]n [C]o [C]d [C]e O 
metastases [C]m [C]e [C]t [C]a [C]s [C]t [C]a [C]s [C]e [C]s O 
and [C]a [C]n [C]d O 
ER [C]E [C]R S-protein 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
there [C]t [C]h [C]e [C]r [C]e O 
was [C]w [C]a [C]s O 
a [C]a O 
trend [C]t [C]r [C]e [C]n [C]d O 
for [C]f [C]o [C]r O 
ER [C]E [C]R S-protein 
-positive [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
tumors [C]t [C]u [C]m [C]o [C]r [C]s O 
to [C]t [C]o O 
have [C]h [C]a [C]v [C]e O 
a [C]a O 
low-grade [C]l [C]o [C]w [C]- [C]g [C]r [C]a [C]d [C]e O 
lymphocytic [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]i [C]c O 
infiltration [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
the [C]t [C]h [C]e O 
difference [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e O 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
statistically [C]s [C]t [C]a [C]t [C]i [C]s [C]t [C]i [C]c [C]a [C]l [C]l [C]y O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
. [C]. O 

Mononuclear [C]M [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
infiltrating [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]n [C]g O 
human [C]h [C]u [C]m [C]a [C]n O 
mammary [C]m [C]a [C]m [C]m [C]a [C]r [C]y O 
carcinomas [C]c [C]a [C]r [C]c [C]i [C]n [C]o [C]m [C]a [C]s O 
: [C]: O 
immunohistochemical [C]i [C]m [C]m [C]u [C]n [C]o [C]h [C]i [C]s [C]t [C]o [C]c [C]h [C]e [C]m [C]i [C]c [C]a [C]l O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
with [C]w [C]i [C]t [C]h O 
monoclonal [C]m [C]o [C]n [C]o [C]c [C]l [C]o [C]n [C]a [C]l B-protein 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s E-protein 
. [C]. O 

Breast [C]B [C]r [C]e [C]a [C]s [C]t O 
carcinomas [C]c [C]a [C]r [C]c [C]i [C]n [C]o [C]m [C]a [C]s O 
were [C]w [C]e [C]r [C]e O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
immunoperoxidase [C]i [C]m [C]m [C]u [C]n [C]o [C]p [C]e [C]r [C]o [C]x [C]i [C]d [C]a [C]s [C]e O 
technique [C]t [C]e [C]c [C]h [C]n [C]i [C]q [C]u [C]e O 
using [C]u [C]s [C]i [C]n [C]g O 
antisera [C]a [C]n [C]t [C]i [C]s [C]e [C]r [C]a O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
for [C]f [C]o [C]r O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e B-cell_type 
subsets [C]s [C]u [C]b [C]s [C]e [C]t [C]s E-cell_type 
, [C], O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
, [C], O 
NK [C]N [C]K B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
major [C]m [C]a [C]j [C]o [C]r B-protein 
histocompatibility [C]h [C]i [C]s [C]t [C]o [C]c [C]o [C]m [C]p [C]a [C]t [C]i [C]b [C]i [C]l [C]i [C]t [C]y I-protein 
antigens [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]s E-protein 
( [C]( O 
HLA-A [C]H [C]L [C]A [C]- [C]A S-protein 
, [C], O 
-B [C]- [C]B S-protein 
, [C], O 
-C [C]- [C]C O 
; [C]; O 
Ia-like [C]I [C]a [C]- [C]l [C]i [C]k [C]e S-protein 
) [C]) O 
. [C]. O 

Sixty-four [C]S [C]i [C]x [C]t [C]y [C]- [C]f [C]o [C]u [C]r O 
per [C]p [C]e [C]r O 
cent [C]c [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
had [C]h [C]a [C]d O 
a [C]a O 
moderate [C]m [C]o [C]d [C]e [C]r [C]a [C]t [C]e O 
or [C]o [C]r O 
strong [C]s [C]t [C]r [C]o [C]n [C]g O 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
cell [C]c [C]e [C]l [C]l O 
infiltration [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
77 [C]7 [C]7 O 
% [C]% O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
without [C]w [C]i [C]t [C]h [C]o [C]u [C]t O 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
infiltration [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
had [C]h [C]a [C]d O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
for [C]f [C]o [C]r O 
estrogens [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n [C]s O 
as [C]a [C]s O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
51 [C]5 [C]1 O 
% [C]% O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
infiltration [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
majority [C]m [C]a [C]j [C]o [C]r [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
infiltrating [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]n [C]g B-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
; [C]; O 
generally [C]g [C]e [C]n [C]e [C]r [C]a [C]l [C]l [C]y O 
the [C]t [C]h [C]e O 
OKT8 [C]O [C]K [C]T [C]8 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
were [C]w [C]e [C]r [C]e O 
predominant [C]p [C]r [C]e [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t O 
. [C]. O 

The [C]T [C]h [C]e O 
Leu [C]L [C]e [C]u O 
3A/OKT8 [C]3 [C]A [C]/ [C]O [C]K [C]T [C]8 O 
cell [C]c [C]e [C]l [C]l O 
ratio [C]r [C]a [C]t [C]i [C]o O 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
related [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
to [C]t [C]o O 
histological [C]h [C]i [C]s [C]t [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
type [C]t [C]y [C]p [C]e O 
, [C], O 
tumor [C]t [C]u [C]m [C]o [C]r O 
size [C]s [C]i [C]z [C]e O 
, [C], O 
age [C]a [C]g [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
or [C]o [C]r O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
metastases [C]m [C]e [C]t [C]a [C]s [C]t [C]a [C]s [C]e [C]s O 
. [C]. O 

Some [C]S [C]o [C]m [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
T [C]T O 
cells [C]c [C]e [C]l [C]l [C]s O 
had [C]h [C]a [C]d O 
the [C]t [C]h [C]e O 
Ia [C]I [C]a B-protein 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n E-protein 
and [C]a [C]n [C]d O 
were [C]w [C]e [C]r [C]e O 
thus [C]t [C]h [C]u [C]s O 
probably [C]p [C]r [C]o [C]b [C]a [C]b [C]l [C]y O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
. [C]. O 

The [C]T [C]h [C]e O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
absent [C]a [C]b [C]s [C]e [C]n [C]t O 
or [C]o [C]r O 
less [C]l [C]e [C]s [C]s O 
numerous [C]n [C]u [C]m [C]e [C]r [C]o [C]u [C]s O 
than [C]t [C]h [C]a [C]n O 
the [C]t [C]h [C]e O 
T [C]T O 
cells [C]c [C]e [C]l [C]l [C]s O 
. [C]. O 

There [C]T [C]h [C]e [C]r [C]e O 
was [C]w [C]a [C]s O 
no [C]n [C]o O 
relation [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
their [C]t [C]h [C]e [C]i [C]r O 
distribution [C]d [C]i [C]s [C]t [C]r [C]i [C]b [C]u [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
parameters [C]p [C]a [C]r [C]a [C]m [C]e [C]t [C]e [C]r [C]s O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
. [C]. O 

A [C]A O 
few [C]f [C]e [C]w O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
were [C]w [C]e [C]r [C]e O 
heterogeneous [C]h [C]e [C]t [C]e [C]r [C]o [C]g [C]e [C]n [C]e [C]o [C]u [C]s O 
according [C]a [C]c [C]c [C]o [C]r [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
their [C]t [C]h [C]e [C]i [C]r O 
markers [C]m [C]a [C]r [C]k [C]e [C]r [C]s O 
( [C]( O 
OKM [C]O [C]K [C]M B-protein 
I [C]I E-protein 
and [C]a [C]n [C]d O 
acid [C]a [C]c [C]i [C]d O 
phosphatase [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]a [C]s [C]e O 
) [C]) O 
. [C]. O 

In [C]I [C]n O 
6 [C]6 O 
cases [C]c [C]a [C]s [C]e [C]s O 
only [C]o [C]n [C]l [C]y O 
there [C]t [C]h [C]e [C]r [C]e O 
was [C]w [C]a [C]s O 
a [C]a O 
strong [C]s [C]t [C]r [C]o [C]n [C]g O 
infiltration [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
for [C]f [C]o [C]r O 
acid [C]a [C]c [C]i [C]d B-protein 
phosphatase [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]a [C]s [C]e E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
natural [C]n [C]a [C]t [C]u [C]r [C]a [C]l B-cell_type 
killer [C]k [C]i [C]l [C]l [C]e [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
low [C]l [C]o [C]w O 
. [C]. O 

Only [C]O [C]n [C]l [C]y O 
a [C]a O 
few [C]f [C]e [C]w O 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
infiltrating [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]n [C]g O 
cells [C]c [C]e [C]l [C]l [C]s O 
had [C]h [C]a [C]d O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
for [C]f [C]o [C]r O 
transferrin [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]r [C]r [C]i [C]n O 
. [C]. O 

There [C]T [C]h [C]e [C]r [C]e O 
was [C]w [C]a [C]s O 
a [C]a O 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
infiltration [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
HLA [C]H [C]L [C]A B-protein 
class-I [C]c [C]l [C]a [C]s [C]s [C]- [C]I I-protein 
antigens [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]s E-protein 
on [C]o [C]n O 
tumor [C]t [C]u [C]m [C]o [C]r B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
s [C]s O 
. [C]. O 

Some [C]S [C]o [C]m [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
antisera [C]a [C]n [C]t [C]i [C]s [C]e [C]r [C]a O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
for [C]f [C]o [C]r O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e B-cell_type 
subsets [C]s [C]u [C]b [C]s [C]e [C]t [C]s E-cell_type 
also [C]a [C]l [C]s [C]o O 
stained [C]s [C]t [C]a [C]i [C]n [C]e [C]d O 
the [C]t [C]h [C]e O 
breast [C]b [C]r [C]e [C]a [C]s [C]t B-cell_type 
carcinoma [C]c [C]a [C]r [C]c [C]i [C]n [C]o [C]m [C]a I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
great [C]g [C]r [C]e [C]a [C]t O 
variations [C]v [C]a [C]r [C]i [C]a [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
subsets [C]s [C]u [C]b [C]s [C]e [C]t [C]s O 
of [C]o [C]f O 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
carcinomas [C]c [C]a [C]r [C]c [C]i [C]n [C]o [C]m [C]a [C]s O 
may [C]m [C]a [C]y O 
correspond [C]c [C]o [C]r [C]r [C]e [C]s [C]p [C]o [C]n [C]d O 
to [C]t [C]o O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
systems [C]s [C]y [C]s [C]t [C]e [C]m [C]s O 
of [C]o [C]f O 
defense [C]d [C]e [C]f [C]e [C]n [C]s [C]e O 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
neoplasm [C]n [C]e [C]o [C]p [C]l [C]a [C]s [C]m O 
. [C]. O 

A [C]A O 
case [C]c [C]a [C]s [C]e O 
of [C]o [C]f O 
male [C]m [C]a [C]l [C]e O 
pseudohermaphroditism [C]p [C]s [C]e [C]u [C]d [C]o [C]h [C]e [C]r [C]m [C]a [C]p [C]h [C]r [C]o [C]d [C]i [C]t [C]i [C]s [C]m O 
with [C]w [C]i [C]t [C]h O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
androgen [C]a [C]n [C]d [C]r [C]o [C]g [C]e [C]n B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
47 [C]4 [C]7 O 
, [C], O 
XYY [C]X [C]Y [C]Y O 
karyotype [C]k [C]a [C]r [C]y [C]o [C]t [C]y [C]p [C]e O 
. [C]. O 

A [C]A O 
case [C]c [C]a [C]s [C]e O 
of [C]o [C]f O 
male [C]m [C]a [C]l [C]e O 
pseudohermaphroditism [C]p [C]s [C]e [C]u [C]d [C]o [C]h [C]e [C]r [C]m [C]a [C]p [C]h [C]r [C]o [C]d [C]i [C]t [C]i [C]s [C]m O 
with [C]w [C]i [C]t [C]h O 
47 [C]4 [C]7 O 
, [C], O 
XYY [C]X [C]Y [C]Y O 
karyotype [C]k [C]a [C]r [C]y [C]o [C]t [C]y [C]p [C]e O 
in [C]i [C]n O 
blood [C]b [C]l [C]o [C]o [C]d O 
and [C]a [C]n [C]d O 
cutaneous [C]c [C]u [C]t [C]a [C]n [C]e [C]o [C]u [C]s B-cell_type 
fibroblasts [C]f [C]i [C]b [C]r [C]o [C]b [C]l [C]a [C]s [C]t [C]s E-cell_type 
is [C]i [C]s O 
described [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
. [C]. O 

The [C]T [C]h [C]e O 
plasma [C]p [C]l [C]a [C]s [C]m [C]a O 
testosterone [C]t [C]e [C]s [C]t [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
HCG [C]H [C]C [C]G O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
slightly [C]s [C]l [C]i [C]g [C]h [C]t [C]l [C]y O 
below [C]b [C]e [C]l [C]o [C]w O 
the [C]t [C]h [C]e O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
range [C]r [C]a [C]n [C]g [C]e O 
on [C]o [C]n O 
two [C]t [C]w [C]o O 
occasions [C]o [C]c [C]c [C]a [C]s [C]i [C]o [C]n [C]s O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
a [C]a O 
deficit [C]d [C]e [C]f [C]i [C]c [C]i [C]t O 
of [C]o [C]f O 
gonadal [C]g [C]o [C]n [C]a [C]d [C]a [C]l O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

A [C]A O 
study [C]s [C]t [C]u [C]d [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
for [C]f [C]o [C]r O 
dihydrotestosterone [C]d [C]i [C]h [C]y [C]d [C]r [C]o [C]t [C]e [C]s [C]t [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
in [C]i [C]n O 
fibroblasts [C]f [C]i [C]b [C]r [C]o [C]b [C]l [C]a [C]s [C]t [C]s S-cell_type 
of [C]o [C]f O 
genital [C]g [C]e [C]n [C]i [C]t [C]a [C]l O 
and [C]a [C]n [C]d O 
nongenital [C]n [C]o [C]n [C]g [C]e [C]n [C]i [C]t [C]a [C]l O 
skin [C]s [C]k [C]i [C]n O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
a [C]a O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
in [C]i [C]n O 
genital [C]g [C]e [C]n [C]i [C]t [C]a [C]l O 
skin [C]s [C]k [C]i [C]n O 
; [C]; O 
5-alpha-reductase [C]5 [C]- [C]a [C]l [C]p [C]h [C]a [C]- [C]r [C]e [C]d [C]u [C]c [C]t [C]a [C]s [C]e S-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
fibroblasts [C]f [C]i [C]b [C]r [C]o [C]b [C]l [C]a [C]s [C]t [C]s S-cell_type 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
genital [C]g [C]e [C]n [C]i [C]t [C]a [C]l O 
skin [C]s [C]k [C]i [C]n O 
was [C]w [C]a [C]s O 
low [C]l [C]o [C]w O 
, [C], O 
but [C]b [C]u [C]t O 
the [C]t [C]h [C]e O 
plasma [C]p [C]l [C]a [C]s [C]m [C]a O 
relationship [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n [C]s [C]h [C]i [C]p O 
testosterone/dihydrotestosterone [C]t [C]e [C]s [C]t [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e [C]/ [C]d [C]i [C]h [C]y [C]d [C]r [C]o [C]t [C]e [C]s [C]t [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
under [C]u [C]n [C]d [C]e [C]r O 
HCG [C]H [C]C [C]G O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
. [C]. O 

The [C]T [C]h [C]e O 
diagnostic [C]d [C]i [C]a [C]g [C]n [C]o [C]s [C]t [C]i [C]c O 
possibility [C]p [C]o [C]s [C]s [C]i [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
a [C]a O 
complete [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e O 
testicular [C]t [C]e [C]s [C]t [C]i [C]c [C]u [C]l [C]a [C]r O 
feminization [C]f [C]e [C]m [C]i [C]n [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
syndrome [C]s [C]y [C]n [C]d [C]r [C]o [C]m [C]e O 
with [C]w [C]i [C]t [C]h O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
for [C]f [C]o [C]r O 
dihydrotestosterone [C]d [C]i [C]h [C]y [C]d [C]r [C]o [C]t [C]e [C]s [C]t [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
is [C]i [C]s O 
commented [C]c [C]o [C]m [C]m [C]e [C]n [C]t [C]e [C]d O 
on [C]o [C]n O 
. [C]. O 

1 [C]1 O 
, [C], O 
25-Dihydroxyvitamin [C]2 [C]5 [C]- [C]D [C]i [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]v [C]i [C]t [C]a [C]m [C]i [C]n O 
D3 [C]D [C]3 O 
inhibits [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]s O 
antigen-induced [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
proliferative [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
of [C]o [C]f O 
murine [C]m [C]u [C]r [C]i [C]n [C]e B-cell_type 
spleen [C]s [C]p [C]l [C]e [C]e [C]n I-cell_type 
and [C]a [C]n [C]d I-cell_type 
thymus [C]t [C]h [C]y [C]m [C]u [C]s I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
to [C]t [C]o O 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n S-protein 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
to [C]t [C]o O 
lectin [C]l [C]e [C]c [C]t [C]i [C]n S-protein 
was [C]w [C]a [C]s O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
metabolite [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]t [C]e O 
of [C]o [C]f O 
vitamin [C]v [C]i [C]t [C]a [C]m [C]i [C]n O 
D3 [C]D [C]3 O 
, [C], O 
1 [C]1 O 
, [C], O 
25- [C]2 [C]5 [C]- O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
. [C]. O 

To [C]T [C]o O 
directly [C]d [C]i [C]r [C]e [C]c [C]t [C]l [C]y O 
examine [C]e [C]x [C]a [C]m [C]i [C]n [C]e O 
the [C]t [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
1 [C]1 O 
, [C], O 
25- [C]2 [C]5 [C]- O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
on [C]o [C]n O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
other [C]o [C]t [C]h [C]e [C]r O 
complicating [C]c [C]o [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]n [C]g O 
interactions [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
, [C], O 
we [C]w [C]e O 
utilized [C]u [C]t [C]i [C]l [C]i [C]z [C]e [C]d O 
a [C]a O 
panel [C]p [C]a [C]n [C]e [C]l O 
of [C]o [C]f O 
cloned [C]c [C]l [C]o [C]n [C]e [C]d O 
Ia-restricted [C]I [C]a [C]- [C]r [C]e [C]s [C]t [C]r [C]i [C]c [C]t [C]e [C]d B-cell_line 
T [C]T I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
hybridomas [C]h [C]y [C]b [C]r [C]i [C]d [C]o [C]m [C]a [C]s E-cell_line 
that [C]t [C]h [C]a [C]t O 
secrete [C]s [C]e [C]c [C]r [C]e [C]t [C]e O 
IL [C]I [C]L B-protein 
2 [C]2 E-protein 
on [C]o [C]n O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
cloned [C]c [C]l [C]o [C]n [C]e [C]d O 
Ia-bearing [C]I [C]a [C]- [C]b [C]e [C]a [C]r [C]i [C]n [C]g B-cell_type 
stimulator [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]o [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
TA3 [C]T [C]A [C]3 S-cell_type 
) [C]) O 
or [C]o [C]r O 
when [C]w [C]h [C]e [C]n O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
mitogen [C]m [C]i [C]t [C]o [C]g [C]e [C]n O 
. [C]. O 

Physiologic [C]P [C]h [C]y [C]s [C]i [C]o [C]l [C]o [C]g [C]i [C]c O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
1 [C]1 O 
, [C], O 
25- [C]2 [C]5 [C]- O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
( [C]( O 
0.01 [C]0 [C]. [C]0 [C]1 O 
to [C]t [C]o O 
0.1 [C]0 [C]. [C]1 O 
nm [C]n [C]m O 
) [C]) O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
antigen-induced [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
secretion [C]s [C]e [C]c [C]r [C]e [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL [C]I [C]L O 
2 [C]2 O 
by [C]b [C]y O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
T [C]T B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
hybridomas [C]h [C]y [C]b [C]r [C]i [C]d [C]o [C]m [C]a [C]s E-cell_line 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
dependent [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
free [C]f [C]r [C]e [C]e O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e O 
and [C]a [C]n [C]d O 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
overcome [C]o [C]v [C]e [C]r [C]c [C]o [C]m [C]e O 
by [C]b [C]y O 
increasing [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
Ia-bearing [C]I [C]a [C]- [C]b [C]e [C]a [C]r [C]i [C]n [C]g B-cell_line 
stimulator [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]o [C]r I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
used [C]u [C]s [C]e [C]d O 
. [C]. O 

Pretreatment [C]P [C]r [C]e [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
T [C]T B-cell_line 
hybridoma [C]h [C]y [C]b [C]r [C]i [C]d [C]o [C]m [C]a E-cell_line 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
the [C]t [C]h [C]e O 
TA3 [C]T [C]A [C]3 B-cell_line 
stimulator [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]o [C]r I-cell_line 
cell [C]c [C]e [C]l [C]l E-cell_line 
with [C]w [C]i [C]t [C]h O 
1 [C]1 O 
, [C], O 
25- [C]2 [C]5 [C]- O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
are [C]a [C]r [C]e O 
consistent [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
finding [C]f [C]i [C]n [C]d [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
1 [C]1 B-protein 
, [C], I-protein 
25- [C]2 [C]5 [C]- I-protein 
( [C]( I-protein 
OH [C]O [C]H I-protein 
) [C]) I-protein 
2D3 [C]2 [C]D [C]3 I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
are [C]a [C]r [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
hybridomas [C]h [C]y [C]b [C]r [C]i [C]d [C]o [C]m [C]a [C]s O 
but [C]b [C]u [C]t O 
are [C]a [C]r [C]e O 
lacking [C]l [C]a [C]c [C]k [C]i [C]n [C]g O 
in [C]i [C]n O 
TA3 [C]T [C]A [C]3 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

1 [C]1 O 
, [C], O 
25- [C]2 [C]5 [C]- O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
failed [C]f [C]a [C]i [C]l [C]e [C]d O 
, [C], O 
however [C]h [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
to [C]t [C]o O 
inhibit [C]i [C]n [C]h [C]i [C]b [C]i [C]t O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
T [C]T B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
hybridomas [C]h [C]y [C]b [C]r [C]i [C]d [C]o [C]m [C]a [C]s E-cell_line 
by [C]b [C]y O 
lectin [C]l [C]e [C]c [C]t [C]i [C]n S-protein 
or [C]o [C]r O 
by [C]b [C]y O 
an [C]a [C]n O 
anti-Thy-1 [C]a [C]n [C]t [C]i [C]- [C]T [C]h [C]y [C]- [C]1 B-protein 
antibody [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y E-protein 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
1 [C]1 O 
, [C], O 
25- [C]2 [C]5 [C]- O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
interfering [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]i [C]n [C]g O 
with [C]w [C]i [C]t [C]h O 
early [C]e [C]a [C]r [C]l [C]y O 
events [C]e [C]v [C]e [C]n [C]t [C]s O 
of [C]o [C]f O 
antigen-induced [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
perhaps [C]p [C]e [C]r [C]h [C]a [C]p [C]s O 
by [C]b [C]y O 
hindering [C]h [C]i [C]n [C]d [C]e [C]r [C]i [C]n [C]g O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
recognition [C]r [C]e [C]c [C]o [C]g [C]n [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
relevant [C]r [C]e [C]l [C]e [C]v [C]a [C]n [C]t O 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n O 
on [C]o [C]n O 
stimulator [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]o [C]r O 
cell [C]c [C]e [C]l [C]l O 
surfaces [C]s [C]u [C]r [C]f [C]a [C]c [C]e [C]s O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
should [C]s [C]h [C]o [C]u [C]l [C]d O 
prove [C]p [C]r [C]o [C]v [C]e O 
useful [C]u [C]s [C]e [C]f [C]u [C]l O 
in [C]i [C]n O 
studying [C]s [C]t [C]u [C]d [C]y [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
by [C]b [C]y O 
which [C]w [C]h [C]i [C]c [C]h O 
1 [C]1 O 
, [C], O 
25- [C]2 [C]5 [C]- O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
acts [C]a [C]c [C]t [C]s O 
to [C]t [C]o O 
inhibit [C]i [C]n [C]h [C]i [C]b [C]i [C]t O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
subsequent [C]s [C]u [C]b [C]s [C]e [C]q [C]u [C]e [C]n [C]t O 
IL [C]I [C]L B-protein 
2 [C]2 E-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

Glucocorticoid [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
and [C]a [C]n [C]d O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
and [C]a [C]n [C]d O 
neoplastic [C]n [C]e [C]o [C]p [C]l [C]a [C]s [C]t [C]i [C]c O 
human [C]h [C]u [C]m [C]a [C]n O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d O 
tissues [C]t [C]i [C]s [C]s [C]u [C]e [C]s O 
: [C]: O 
a [C]a O 
review [C]r [C]e [C]v [C]i [C]e [C]w O 
. [C]. O 

The [C]T [C]h [C]e O 
determination [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n B-protein 
and [C]a [C]n [C]d I-protein 
progesterone [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]e [C]r [C]o [C]n [C]e I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
be [C]b [C]e O 
useful [C]u [C]s [C]e [C]f [C]u [C]l O 
in [C]i [C]n O 
predicting [C]p [C]r [C]e [C]d [C]i [C]c [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
endocrine [C]e [C]n [C]d [C]o [C]c [C]r [C]i [C]n [C]e O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
. [C]. O 

Given [C]G [C]i [C]v [C]e [C]n O 
their [C]t [C]h [C]e [C]i [C]r O 
well-known [C]w [C]e [C]l [C]l [C]- [C]k [C]n [C]o [C]w [C]n O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
on [C]o [C]n O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
, [C], O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
used [C]u [C]s [C]e [C]d O 
widely [C]w [C]i [C]d [C]e [C]l [C]y O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
. [C]. O 

Given [C]G [C]i [C]v [C]e [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
facts [C]f [C]a [C]c [C]t [C]s O 
, [C], O 
over [C]o [C]v [C]e [C]r O 
the [C]t [C]h [C]e O 
last [C]l [C]a [C]s [C]t O 
10 [C]1 [C]0 O 
years [C]y [C]e [C]a [C]r [C]s O 
, [C], O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
investigators [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]o [C]r [C]s O 
have [C]h [C]a [C]v [C]e O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
the [C]t [C]h [C]e O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
and [C]a [C]n [C]d O 
neoplastic [C]n [C]e [C]o [C]p [C]l [C]a [C]s [C]t [C]i [C]c O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
to [C]t [C]o O 
see [C]s [C]e [C]e O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
their [C]t [C]h [C]e [C]i [C]r O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
responsiveness [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e [C]n [C]e [C]s [C]s O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
or [C]o [C]r O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
. [C]. O 

No [C]N [C]o O 
clear [C]c [C]l [C]e [C]a [C]r O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
established [C]e [C]s [C]t [C]a [C]b [C]l [C]i [C]s [C]h [C]e [C]d O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
action [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
steroids [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]s O 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
and [C]a [C]n [C]d O 
neoplastic [C]n [C]e [C]o [C]p [C]l [C]a [C]s [C]t [C]i [C]c O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
attempts [C]a [C]t [C]t [C]e [C]m [C]p [C]t [C]s O 
to [C]t [C]o O 
correlate [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
in [C]i [C]n O 
acute [C]a [C]c [C]u [C]t [C]e O 
lymphocytic [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
to [C]t [C]o O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
responsiveness [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e [C]n [C]e [C]s [C]s O 
and [C]a [C]n [C]d O 
immunological [C]i [C]m [C]m [C]u [C]n [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
type [C]t [C]y [C]p [C]e O 
using [C]u [C]s [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
whole-cell-binding [C]w [C]h [C]o [C]l [C]e [C]- [C]c [C]e [C]l [C]l [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
assay [C]a [C]s [C]s [C]a [C]y O 
for [C]f [C]o [C]r O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
determination [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
selecting [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
according [C]a [C]c [C]c [C]o [C]r [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
age [C]a [C]g [C]e O 
and [C]a [C]n [C]d O 
immunological [C]i [C]m [C]m [C]u [C]n [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
criteria [C]c [C]r [C]i [C]t [C]e [C]r [C]i [C]a O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
more [C]m [C]o [C]r [C]e O 
successful [C]s [C]u [C]c [C]c [C]e [C]s [C]s [C]f [C]u [C]l O 
. [C]. O 

[ [C][ O 
Glucocorticoid [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
] [C]] O 

Glucocorticoid [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-cell_type 
( [C]( I-cell_type 
GC [C]G [C]C I-cell_type 
) [C]) I-cell_type 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
in [C]i [C]n O 
intact [C]i [C]n [C]t [C]a [C]c [C]t O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
from [C]f [C]r [C]o [C]m O 
11 [C]1 [C]1 O 
donors [C]d [C]o [C]n [C]o [C]r [C]s O 
. [C]. O 

GC [C]G [C]C O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
parameters [C]p [C]a [C]r [C]a [C]m [C]e [C]t [C]e [C]r [C]s O 
were [C]w [C]e [C]r [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
highly [C]h [C]i [C]g [C]h [C]l [C]y O 
reproducible [C]r [C]e [C]p [C]r [C]o [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
in [C]i [C]n O 
repeated [C]r [C]e [C]p [C]e [C]a [C]t [C]e [C]d O 
experiments [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
. [C]. O 

It [C]I [C]t O 
was [C]w [C]a [C]s O 
shown [C]s [C]h [C]o [C]w [C]n O 
that [C]t [C]h [C]a [C]t O 
GC [C]G [C]C B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
donors [C]d [C]o [C]n [C]o [C]r [C]s O 
' [C]' O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
distributed [C]d [C]i [C]s [C]t [C]r [C]i [C]b [C]u [C]t [C]e [C]d O 
into [C]i [C]n [C]t [C]o O 
two [C]t [C]w [C]o O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
classes [C]c [C]l [C]a [C]s [C]s [C]e [C]s O 
similarly [C]s [C]i [C]m [C]i [C]l [C]a [C]r [C]l [C]y O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
pattern [C]p [C]a [C]t [C]t [C]e [C]r [C]n O 
seen [C]s [C]e [C]e [C]n O 
in [C]i [C]n O 
skin [C]s [C]k [C]i [C]n B-cell_type 
fibroblasts [C]f [C]i [C]b [C]r [C]o [C]b [C]l [C]a [C]s [C]t [C]s E-cell_type 
. [C]. O 

Human [C]H [C]u [C]m [C]a [C]n B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
are [C]a [C]r [C]e O 
an [C]a [C]n O 
adequate [C]a [C]d [C]e [C]q [C]u [C]a [C]t [C]e O 
object [C]o [C]b [C]j [C]e [C]c [C]t O 
for [C]f [C]o [C]r O 
studying [C]s [C]t [C]u [C]d [C]y [C]i [C]n [C]g O 
genetically [C]g [C]e [C]n [C]e [C]t [C]i [C]c [C]a [C]l [C]l [C]y O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
variability [C]v [C]a [C]r [C]i [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
GC [C]G [C]C B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
and [C]a [C]n [C]d O 
its [C]i [C]t [C]s O 
clinical [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
importance [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]c [C]e O 
. [C]. O 

Specific [C]S [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n B-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
sites [C]s [C]i [C]t [C]e [C]s E-protein 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
thymic [C]t [C]h [C]y [C]m [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n O 
in [C]i [C]n O 
preparations [C]p [C]r [C]e [C]p [C]a [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s I-cell_type 
, [C], E-cell_type 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
by [C]b [C]y O 
splenic [C]s [C]p [C]l [C]e [C]n [C]i [C]c B-cell_type 
and [C]a [C]n [C]d I-cell_type 
thymic [C]t [C]h [C]y [C]m [C]i [C]c I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
is [C]i [C]s O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
three [C]t [C]h [C]r [C]e [C]e O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
approaches [C]a [C]p [C]p [C]r [C]o [C]a [C]c [C]h [C]e [C]s O 
( [C]( O 
Dextran-coated [C]D [C]e [C]x [C]t [C]r [C]a [C]n [C]- [C]c [C]o [C]a [C]t [C]e [C]d O 
charcoal [C]c [C]h [C]a [C]r [C]c [C]o [C]a [C]l O 
method [C]m [C]e [C]t [C]h [C]o [C]d O 
, [C], O 
whole [C]w [C]h [C]o [C]l [C]e O 
cell [C]c [C]e [C]l [C]l O 
assay [C]a [C]s [C]s [C]a [C]y O 
, [C], O 
and [C]a [C]n [C]d O 
gel [C]g [C]e [C]l O 
filtration [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
on [C]o [C]n O 
a [C]a O 
sepharose [C]s [C]e [C]p [C]h [C]a [C]r [C]o [C]s [C]e O 
4B [C]4 [C]B O 
column [C]c [C]o [C]l [C]u [C]m [C]n O 
) [C]) O 
. [C]. O 

Scatchard [C]S [C]c [C]a [C]t [C]c [C]h [C]a [C]r [C]d O 
's [C]' [C]s O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
-moxestrol [C]- [C]m [C]o [C]x [C]e [C]s [C]t [C]r [C]o [C]l O 
( [C]( O 
R2858 [C]R [C]2 [C]8 [C]5 [C]8 O 
) [C]) O 
and [C]a [C]n [C]d O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
-estradiol [C]- [C]e [C]s [C]t [C]r [C]a [C]d [C]i [C]o [C]l O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
proves [C]p [C]r [C]o [C]v [C]e [C]s O 
the [C]t [C]h [C]e O 
existence [C]e [C]x [C]i [C]s [C]t [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
a [C]a O 
single [C]s [C]i [C]n [C]g [C]l [C]e O 
class [C]c [C]l [C]a [C]s [C]s O 
of [C]o [C]f O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r B-protein 
sites [C]s [C]i [C]t [C]e [C]s E-protein 
having [C]h [C]a [C]v [C]i [C]n [C]g O 
a [C]a O 
dissociation [C]d [C]i [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
constant [C]c [C]o [C]n [C]s [C]t [C]a [C]n [C]t O 
of [C]o [C]f O 
0.18-2.4 [C]0 [C]. [C]1 [C]8 [C]- [C]2 [C]. [C]4 O 
X [C]X O 
10 [C]1 [C]0 O 
( [C]( O 
-9 [C]- [C]9 O 
) [C]) O 
M [C]M O 
. [C]. O 

Physicochemical [C]P [C]h [C]y [C]s [C]i [C]c [C]o [C]c [C]h [C]e [C]m [C]i [C]c [C]a [C]l O 
properties [C]p [C]r [C]o [C]p [C]e [C]r [C]t [C]i [C]e [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
binder [C]b [C]i [C]n [C]d [C]e [C]r O 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
capacity [C]c [C]a [C]p [C]a [C]c [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
specificity [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]i [C]t [C]y O 
, [C], O 
are [C]a [C]r [C]e O 
quite [C]q [C]u [C]i [C]t [C]e O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
to [C]t [C]o O 
those [C]t [C]h [C]o [C]s [C]e O 
reported [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]d O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
thymus [C]t [C]h [C]y [C]m [C]u [C]s O 
of [C]o [C]f O 
small [C]s [C]m [C]a [C]l [C]l O 
mammalian [C]m [C]a [C]m [C]m [C]a [C]l [C]i [C]a [C]n O 
species [C]s [C]p [C]e [C]c [C]i [C]e [C]s O 
or [C]o [C]r O 
human [C]h [C]u [C]m [C]a [C]n O 
thymoma [C]t [C]h [C]y [C]m [C]o [C]m [C]a O 
. [C]. O 

Administration [C]A [C]d [C]m [C]i [C]n [C]i [C]s [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
fibroblast [C]f [C]i [C]b [C]r [C]o [C]b [C]l [C]a [C]s [C]t B-protein 
interferon [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n E-protein 
to [C]t [C]o O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
advanced [C]a [C]d [C]v [C]a [C]n [C]c [C]e [C]d O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
: [C]: O 
possible [C]p [C]o [C]s [C]s [C]i [C]b [C]l [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
on [C]o [C]n O 
skin [C]s [C]k [C]i [C]n O 
metastasis [C]m [C]e [C]t [C]a [C]s [C]t [C]a [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
on [C]o [C]n O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

Eleven [C]E [C]l [C]e [C]v [C]e [C]n O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
metastasized [C]m [C]e [C]t [C]a [C]s [C]t [C]a [C]s [C]i [C]z [C]e [C]d O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
received [C]r [C]e [C]c [C]e [C]i [C]v [C]e [C]d O 
8 [C]8 O 
intramuscular [C]i [C]n [C]t [C]r [C]a [C]m [C]u [C]s [C]c [C]u [C]l [C]a [C]r O 
injections [C]i [C]n [C]j [C]e [C]c [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
6 [C]6 O 
x [C]x O 
10 [C]1 [C]0 O 
( [C]( O 
6 [C]6 O 
) [C]) O 
units [C]u [C]n [C]i [C]t [C]s O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-protein 
fibroblast [C]f [C]i [C]b [C]r [C]o [C]b [C]l [C]a [C]s [C]t I-protein 
interferon [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n E-protein 
over [C]o [C]v [C]e [C]r O 
a [C]a O 
period [C]p [C]e [C]r [C]i [C]o [C]d O 
of [C]o [C]f O 
40 [C]4 [C]0 O 
days [C]d [C]a [C]y [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
injections [C]i [C]n [C]j [C]e [C]c [C]t [C]i [C]o [C]n [C]s O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
cause [C]c [C]a [C]u [C]s [C]e O 
local [C]l [C]o [C]c [C]a [C]l O 
irritation [C]i [C]r [C]r [C]i [C]t [C]a [C]t [C]i [C]o [C]n O 
or [C]o [C]r O 
inflammation [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Fever [C]F [C]e [C]v [C]e [C]r O 
occurred [C]o [C]c [C]c [C]u [C]r [C]r [C]e [C]d O 
in [C]i [C]n O 
only [C]o [C]n [C]l [C]y O 
1 [C]1 O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
11 [C]1 [C]1 O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
types [C]t [C]y [C]p [C]e [C]s O 
of [C]o [C]f O 
metastases [C]m [C]e [C]t [C]a [C]s [C]t [C]a [C]s [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
monitored [C]m [C]o [C]n [C]i [C]t [C]o [C]r [C]e [C]d O 
, [C], O 
only [C]o [C]n [C]l [C]y O 
skin [C]s [C]k [C]i [C]n O 
nodules [C]n [C]o [C]d [C]u [C]l [C]e [C]s O 
consistently [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]t [C]l [C]y O 
( [C]( O 
10 [C]1 [C]0 O 
out [C]o [C]u [C]t O 
of [C]o [C]f O 
11 [C]1 [C]1 O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
) [C]) O 
exhibited [C]e [C]x [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
that [C]t [C]h [C]a [C]t O 
were [C]w [C]e [C]r [C]e O 
suggestive [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]v [C]e O 
of [C]o [C]f O 
a [C]a O 
therapeutic [C]t [C]h [C]e [C]r [C]a [C]p [C]e [C]u [C]t [C]i [C]c O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
regimen [C]r [C]e [C]g [C]i [C]m [C]e [C]n O 
: [C]: O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
a [C]a O 
simple [C]s [C]i [C]m [C]p [C]l [C]e O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
size [C]s [C]i [C]z [C]e O 
of [C]o [C]f O 
some [C]s [C]o [C]m [C]e O 
nodules [C]n [C]o [C]d [C]u [C]l [C]e [C]s O 
or [C]o [C]r O 
central [C]c [C]e [C]n [C]t [C]r [C]a [C]l O 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s O 
accompanied [C]a [C]c [C]c [C]o [C]m [C]p [C]a [C]n [C]i [C]e [C]d O 
by [C]b [C]y O 
an [C]a [C]n O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
reaction [C]r [C]e [C]a [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

NK-activity [C]N [C]K [C]- [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
was [C]w [C]a [C]s O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
after [C]a [C]f [C]t [C]e [C]r O 
administration [C]a [C]d [C]m [C]i [C]n [C]i [C]s [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
first [C]f [C]i [C]r [C]s [C]t O 
dose [C]d [C]o [C]s [C]e O 
; [C]; O 
the [C]t [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
subsequent [C]s [C]u [C]b [C]s [C]e [C]q [C]u [C]e [C]n [C]t O 
injections [C]i [C]n [C]j [C]e [C]c [C]t [C]i [C]o [C]n [C]s O 
was [C]w [C]a [C]s O 
less [C]l [C]e [C]s [C]s O 
clear [C]c [C]l [C]e [C]a [C]r O 
. [C]. O 

Receptors [C]R [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
for [C]f [C]o [C]r O 
estrogens [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n [C]s O 
and [C]a [C]n [C]d O 
progestogens [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]o [C]g [C]e [C]n [C]s O 
were [C]w [C]e [C]r [C]e O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
tumor [C]t [C]u [C]m [C]o [C]r O 
biopsies [C]b [C]i [C]o [C]p [C]s [C]i [C]e [C]s O 
of [C]o [C]f O 
2 [C]2 O 
out [C]o [C]u [C]t O 
of [C]o [C]f O 
2 [C]2 O 
and [C]a [C]n [C]d O 
5 [C]5 O 
out [C]o [C]u [C]t O 
of [C]o [C]f O 
6 [C]6 O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
tested [C]t [C]e [C]s [C]t [C]e [C]d O 
respectively [C]r [C]e [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
. [C]. O 

Decreased [C]D [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
in [C]i [C]n O 
adrenal [C]a [C]d [C]r [C]e [C]n [C]a [C]l O 
insufficiency [C]i [C]n [C]s [C]u [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
. [C]. O 

To [C]T [C]o O 
examine [C]e [C]x [C]a [C]m [C]i [C]n [C]e O 
the [C]t [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
deficiency [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
, [C], O 
we [C]w [C]e O 
examine [C]e [C]x [C]a [C]m [C]i [C]n [C]e O 
the [C]t [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
to [C]t [C]o O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
and [C]a [C]n [C]d O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
adrenal [C]a [C]d [C]r [C]e [C]n [C]a [C]l O 
insufficiency [C]i [C]n [C]s [C]u [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
before [C]b [C]e [C]f [C]o [C]r [C]e O 
and [C]a [C]n [C]d O 
after [C]a [C]f [C]t [C]e [C]r O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
replacement [C]r [C]e [C]p [C]l [C]a [C]c [C]e [C]m [C]e [C]n [C]t O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
. [C]. O 

Using [C]U [C]s [C]i [C]n [C]g O 
a [C]a O 
whole [C]w [C]h [C]o [C]l [C]e O 
cell [C]c [C]e [C]l [C]l O 
competitive [C]c [C]o [C]m [C]p [C]e [C]t [C]i [C]t [C]i [C]v [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
assay [C]a [C]s [C]s [C]a [C]y O 
, [C], O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
had [C]h [C]a [C]d O 
5977 [C]5 [C]9 [C]7 [C]7 O 
+/- [C]+ [C]/ [C]- O 
1487 [C]1 [C]4 [C]8 [C]7 O 
( [C]( O 
mean [C]m [C]e [C]a [C]n O 
+/- [C]+ [C]/ [C]- O 
SD [C]S [C]D O 
) [C]) O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
sites/cell [C]s [C]i [C]t [C]e [C]s [C]/ [C]c [C]e [C]l [C]l O 
and [C]a [C]n [C]d O 
a [C]a O 
dissociation [C]d [C]i [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
constant [C]c [C]o [C]n [C]s [C]t [C]a [C]n [C]t O 
of [C]o [C]f O 
10 [C]1 [C]0 O 
+/- [C]+ [C]/ [C]- O 
2 [C]2 O 
nM [C]n [C]M O 
. [C]. O 

Lymphocytes [C]L [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
untreated [C]u [C]n [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
adrenal [C]a [C]d [C]r [C]e [C]n [C]a [C]l O 
insufficiency [C]i [C]n [C]s [C]u [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
had [C]h [C]a [C]d O 
fewer [C]f [C]e [C]w [C]e [C]r O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
sites [C]s [C]i [C]t [C]e [C]s E-protein 
( [C]( O 
3364 [C]3 [C]3 [C]6 [C]4 O 
+/-322 [C]+ [C]/ [C]- [C]3 [C]2 [C]2 O 
) [C]) O 
and [C]a [C]n [C]d O 
a [C]a O 
2-fold [C]2 [C]- [C]f [C]o [C]l [C]d O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
( [C]( O 
5.4 [C]5 [C]. [C]4 O 
+/- [C]+ [C]/ [C]- O 
0.9 [C]0 [C]. [C]9 O 
mM [C]m [C]M O 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
administration [C]a [C]d [C]m [C]i [C]n [C]i [C]s [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
conventional [C]c [C]o [C]n [C]v [C]e [C]n [C]t [C]i [C]o [C]n [C]a [C]l O 
replacement [C]r [C]e [C]p [C]l [C]a [C]c [C]e [C]m [C]e [C]n [C]t O 
doses [C]d [C]o [C]s [C]e [C]s O 
of [C]o [C]f O 
cortisone [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]n [C]e O 
acetate [C]a [C]c [C]e [C]t [C]a [C]t [C]e O 
for [C]f [C]o [C]r O 
6 [C]6 O 
months [C]m [C]o [C]n [C]t [C]h [C]s O 
caused [C]c [C]a [C]u [C]s [C]e [C]d O 
no [C]n [C]o O 
change [C]c [C]h [C]a [C]n [C]g [C]e O 
in [C]i [C]n O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
, [C], O 
but [C]b [C]u [C]t O 
was [C]w [C]a [C]s O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
toward [C]t [C]o [C]w [C]a [C]r [C]d O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
. [C]. O 

After [C]A [C]f [C]t [C]e [C]r O 
long [C]l [C]o [C]n [C]g O 
term [C]t [C]e [C]r [C]m O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
replacement [C]r [C]e [C]p [C]l [C]a [C]c [C]e [C]m [C]e [C]n [C]t O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
, [C], O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
parameters [C]p [C]a [C]r [C]a [C]m [C]e [C]t [C]e [C]r [C]s O 
were [C]w [C]e [C]r [C]e O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
to [C]t [C]o O 
those [C]t [C]h [C]o [C]s [C]e O 
in [C]i [C]n O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
before [C]b [C]e [C]f [C]o [C]r [C]e O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
. [C]. O 

The [C]T [C]h [C]e O 
physiological [C]p [C]h [C]y [C]s [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
implications [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
and [C]a [C]n [C]d O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
in [C]i [C]n O 
adrenal [C]a [C]d [C]r [C]e [C]n [C]a [C]l O 
insufficiency [C]i [C]n [C]s [C]u [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
remain [C]r [C]e [C]m [C]a [C]i [C]n O 
to [C]t [C]o O 
be [C]b [C]e O 
elucidated [C]e [C]l [C]u [C]c [C]i [C]d [C]a [C]t [C]e [C]d O 
. [C]. O 

Glucocorticoid [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
and [C]a [C]n [C]d O 
terminal [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l O 
transferase [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]r [C]a [C]s [C]e S-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
as [C]a [C]s O 
indicators [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]o [C]r [C]s O 
of [C]o [C]f O 
prognosis [C]p [C]r [C]o [C]g [C]n [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
acute [C]a [C]c [C]u [C]t [C]e O 
non-lymphocytic [C]n [C]o [C]n [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]i [C]c O 
leukaemia [C]l [C]e [C]u [C]k [C]a [C]e [C]m [C]i [C]a O 
. [C]. O 

Activity [C]A [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
terminal [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l B-protein 
deoxynucleotidyl [C]d [C]e [C]o [C]x [C]y [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]y [C]l I-protein 
transferase [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]r [C]a [C]s [C]e E-protein 
( [C]( O 
TdT [C]T [C]d [C]T S-protein 
) [C]) O 
, [C], O 
adenosine [C]a [C]d [C]e [C]n [C]o [C]s [C]i [C]n [C]e B-protein 
deaminase [C]d [C]e [C]a [C]m [C]i [C]n [C]a [C]s [C]e E-protein 
, [C], O 
and [C]a [C]n [C]d O 
5'nucleotidase [C]5 [C]' [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]a [C]s [C]e S-protein 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
( [C]( I-protein 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e I-protein 
) [C]) I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
were [C]w [C]e [C]r [C]e O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
in [C]i [C]n O 
25 [C]2 [C]5 O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
acute [C]a [C]c [C]u [C]t [C]e O 
non-lymphocytic [C]n [C]o [C]n [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]i [C]c O 
leukaemia [C]l [C]e [C]u [C]k [C]a [C]e [C]m [C]i [C]a O 
. [C]. O 

All [C]A [C]l [C]l O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
were [C]w [C]e [C]r [C]e O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
according [C]a [C]c [C]c [C]o [C]r [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
a [C]a O 
common [C]c [C]o [C]m [C]m [C]o [C]n O 
protocol [C]p [C]r [C]o [C]t [C]o [C]c [C]o [C]l O 
. [C]. O 

Increased [C]I [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
TdT [C]T [C]d [C]T S-protein 
( [C]( O 
greater [C]g [C]r [C]e [C]a [C]t [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
0.1 [C]0 [C]. [C]1 O 
unit/microgram [C]u [C]n [C]i [C]t [C]/ [C]m [C]i [C]c [C]r [C]o [C]g [C]r [C]a [C]m O 
DNA [C]D [C]N [C]A O 
) [C]) O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
11 [C]1 [C]1 O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
group [C]g [C]r [C]o [C]u [C]p O 
of [C]o [C]f O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
was [C]w [C]a [C]s O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
have [C]h [C]a [C]v [C]e O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
remission [C]r [C]e [C]m [C]i [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
survival [C]s [C]u [C]r [C]v [C]i [C]v [C]a [C]l O 
rates [C]r [C]a [C]t [C]e [C]s O 
( [C]( O 
p [C]p O 
= [C]= O 
0.06 [C]0 [C]. [C]0 [C]6 O 
) [C]) O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
low [C]l [C]o [C]w O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
TdT [C]T [C]d [C]T O 
. [C]. O 

The [C]T [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
leukaemic [C]l [C]e [C]u [C]k [C]a [C]e [C]m [C]i [C]c B-cell_type 
blast [C]b [C]l [C]a [C]s [C]t I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
ranged [C]r [C]a [C]n [C]g [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
0 [C]0 O 
to [C]t [C]o O 
0.94 [C]0 [C]. [C]9 [C]4 O 
fmol/microgram [C]f [C]m [C]o [C]l [C]/ [C]m [C]i [C]c [C]r [C]o [C]g [C]r [C]a [C]m O 
DNA [C]D [C]N [C]A O 
. [C]. O 

Thirteen [C]T [C]h [C]i [C]r [C]t [C]e [C]e [C]n O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
had [C]h [C]a [C]d O 
blast [C]b [C]l [C]a [C]s [C]t B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
over [C]o [C]v [C]e [C]r O 
0.22 [C]0 [C]. [C]2 [C]2 O 
fmol/microgram [C]f [C]m [C]o [C]l [C]/ [C]m [C]i [C]c [C]r [C]o [C]g [C]r [C]a [C]m O 
DNA [C]D [C]N [C]A O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
had [C]h [C]a [C]d O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
remission [C]r [C]e [C]m [C]i [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
survival [C]s [C]u [C]r [C]v [C]i [C]v [C]a [C]l O 
rates [C]r [C]a [C]t [C]e [C]s O 
( [C]( O 
p [C]p O 
= [C]= O 
0.006 [C]0 [C]. [C]0 [C]0 [C]6 O 
) [C]) O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
those [C]t [C]h [C]o [C]s [C]e O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
low [C]l [C]o [C]w O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
finding [C]f [C]i [C]n [C]d [C]i [C]n [C]g O 
can [C]c [C]a [C]n O 
not [C]n [C]o [C]t O 
be [C]b [C]e O 
explained [C]e [C]x [C]p [C]l [C]a [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
difference [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e O 
in [C]i [C]n O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
to [C]t [C]o O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
since [C]s [C]i [C]n [C]c [C]e O 
these [C]t [C]h [C]e [C]s [C]e O 
were [C]w [C]e [C]r [C]e O 
not [C]n [C]o [C]t O 
used [C]u [C]s [C]e [C]d O 
as [C]a [C]s O 
therapeutic [C]t [C]h [C]e [C]r [C]a [C]p [C]e [C]u [C]t [C]i [C]c O 
agents [C]a [C]g [C]e [C]n [C]t [C]s O 
. [C]. O 

Adenosine [C]A [C]d [C]e [C]n [C]o [C]s [C]i [C]n [C]e B-protein 
deaminase [C]d [C]e [C]a [C]m [C]i [C]n [C]a [C]s [C]e E-protein 
and [C]a [C]n [C]d O 
5'nucleotidase [C]5 [C]' [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]a [C]s [C]e S-protein 
activities [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]i [C]e [C]s O 
both [C]b [C]o [C]t [C]h O 
varied [C]v [C]a [C]r [C]i [C]e [C]d O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
two [C]t [C]w [C]o O 
orders [C]o [C]r [C]d [C]e [C]r [C]s O 
of [C]o [C]f O 
magnitude [C]m [C]a [C]g [C]n [C]i [C]t [C]u [C]d [C]e O 
. [C]. O 

No [C]N [C]o O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
activities [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]i [C]e [C]s O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
enzymes [C]e [C]n [C]z [C]y [C]m [C]e [C]s O 
and [C]a [C]n [C]d O 
remission [C]r [C]e [C]m [C]i [C]s [C]s [C]i [C]o [C]n O 
or [C]o [C]r O 
survival [C]s [C]u [C]r [C]v [C]i [C]v [C]a [C]l O 
rate [C]r [C]a [C]t [C]e O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
measurements [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]m [C]e [C]n [C]t [C]s O 
of [C]o [C]f O 
TdT [C]T [C]d [C]T S-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
yield [C]y [C]i [C]e [C]l [C]d O 
valuable [C]v [C]a [C]l [C]u [C]a [C]b [C]l [C]e O 
prognostic [C]p [C]r [C]o [C]g [C]n [C]o [C]s [C]t [C]i [C]c O 
information [C]i [C]n [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
acute [C]a [C]c [C]u [C]t [C]e O 
non-lymphocytic [C]n [C]o [C]n [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]i [C]c O 
leukaemia [C]l [C]e [C]u [C]k [C]a [C]e [C]m [C]i [C]a O 

[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
cortivazol [C]c [C]o [C]r [C]t [C]i [C]v [C]a [C]z [C]o [C]l O 
: [C]: O 
a [C]a O 
unique [C]u [C]n [C]i [C]q [C]u [C]e O 
high [C]h [C]i [C]g [C]h O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
ligand [C]l [C]i [C]g [C]a [C]n [C]d O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
. [C]. O 

Cortivazol [C]C [C]o [C]r [C]t [C]i [C]v [C]a [C]z [C]o [C]l O 
( [C]( O 
CVZ [C]C [C]V [C]Z O 
) [C]) O 
and [C]a [C]n [C]d O 
deacylcortivazol [C]d [C]e [C]a [C]c [C]y [C]l [C]c [C]o [C]r [C]t [C]i [C]v [C]a [C]z [C]o [C]l O 
( [C]( O 
DAC [C]D [C]A [C]C O 
) [C]) O 
are [C]a [C]r [C]e O 
pyrazolosteroids [C]p [C]y [C]r [C]a [C]z [C]o [C]l [C]o [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]s O 
with [C]w [C]i [C]t [C]h O 
potent [C]p [C]o [C]t [C]e [C]n [C]t O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

In [C]I [C]n O 
previous [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s O 
work [C]w [C]o [C]r [C]k O 
we [C]w [C]e O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
DAC [C]D [C]A [C]C O 
is [C]i [C]s O 
40-fold [C]4 [C]0 [C]- [C]f [C]o [C]l [C]d O 
more [C]m [C]o [C]r [C]e O 
potent [C]p [C]o [C]t [C]e [C]n [C]t O 
than [C]t [C]h [C]a [C]n O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
( [C]( O 
DEX [C]D [C]E [C]X O 
) [C]) O 
in [C]i [C]n O 
lysing [C]l [C]y [C]s [C]i [C]n [C]g O 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c B-cell_type 
lymphoblasts [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]s E-cell_type 
. [C]. O 

To [C]T [C]o O 
assess [C]a [C]s [C]s [C]e [C]s [C]s O 
the [C]t [C]h [C]e O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
atypical [C]a [C]t [C]y [C]p [C]i [C]c [C]a [C]l O 
steroids [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]s O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
, [C], O 
we [C]w [C]e O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
the [C]t [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
CVZ [C]C [C]V [C]Z O 
to [C]t [C]o O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
from [C]f [C]r [C]o [C]m O 
glucocorticoid-sensitive [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e B-cell_line 
and [C]a [C]n [C]d I-cell_line 
-resistant [C]- [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]t I-cell_line 
variants [C]v [C]a [C]r [C]i [C]a [C]n [C]t [C]s E-cell_line 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
CEM [C]C [C]E [C]M B-cell_line 
C7 [C]C [C]7 E-cell_line 
. [C]. O 

In [C]I [C]n O 
glucocorticoid-sensitive [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
CVZ [C]C [C]V [C]Z O 
causes [C]c [C]a [C]u [C]s [C]e [C]s O 
a [C]a O 
2-fold [C]2 [C]- [C]f [C]o [C]l [C]d O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
glutamine [C]g [C]l [C]u [C]t [C]a [C]m [C]i [C]n [C]e B-protein 
synthetase [C]s [C]y [C]n [C]t [C]h [C]e [C]t [C]a [C]s [C]e E-protein 
and [C]a [C]n [C]d O 
binds [C]b [C]i [C]n [C]d [C]s O 
to [C]t [C]o O 
a [C]a O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
4.6 [C]4 [C]. [C]6 O 
S [C]S O 
region [C]r [C]e [C]g [C]i [C]o [C]n O 
of [C]o [C]f O 
high [C]h [C]i [C]g [C]h O 
salt [C]s [C]a [C]l [C]t O 
sucrose [C]s [C]u [C]c [C]r [C]o [C]s [C]e O 
gradients [C]g [C]r [C]a [C]d [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

On [C]O [C]n O 
DEAE-cellulose [C]D [C]E [C]A [C]E [C]- [C]c [C]e [C]l [C]l [C]u [C]l [C]o [C]s [C]e O 
chromatography [C]c [C]h [C]r [C]o [C]m [C]a [C]t [C]o [C]g [C]r [C]a [C]p [C]h [C]y O 
, [C], O 
[ [C][ B-protein 
3H [C]3 [C]H I-protein 
] [C]] I-protein 
CVZ-receptor [C]C [C]V [C]Z [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
show [C]s [C]h [C]o [C]w O 
a [C]a O 
shift [C]s [C]h [C]i [C]f [C]t O 
from [C]f [C]r [C]o [C]m O 
high [C]h [C]i [C]g [C]h O 
( [C]( O 
0.25 [C]0 [C]. [C]2 [C]5 O 
M [C]M O 
KP [C]K [C]P O 
) [C]) O 
to [C]t [C]o O 
low [C]l [C]o [C]w O 
salt [C]s [C]a [C]l [C]t O 
( [C]( O 
0.09 [C]0 [C]. [C]0 [C]9 O 
M [C]M O 
KP [C]K [C]P O 
) [C]) O 
eluting [C]e [C]l [C]u [C]t [C]i [C]n [C]g O 
forms [C]f [C]o [C]r [C]m [C]s O 
upon [C]u [C]p [C]o [C]n O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

CVZ [C]C [C]V [C]Z O 
competes [C]c [C]o [C]m [C]p [C]e [C]t [C]e [C]s O 
for [C]f [C]o [C]r O 
a [C]a O 
97 [C]9 [C]7 O 
, [C], O 
000-dalton [C]0 [C]0 [C]0 [C]- [C]d [C]a [C]l [C]t [C]o [C]n O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
labeled [C]l [C]a [C]b [C]e [C]l [C]e [C]d O 
by [C]b [C]y O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
mesylate [C]m [C]e [C]s [C]y [C]l [C]a [C]t [C]e O 
. [C]. O 

Scatchard [C]S [C]c [C]a [C]t [C]c [C]h [C]a [C]r [C]d O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
CVZ [C]C [C]V [C]Z O 
in [C]i [C]n O 
glucocorticoid-sensitive [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
a [C]a O 
curvilinear [C]c [C]u [C]r [C]v [C]i [C]l [C]i [C]n [C]e [C]a [C]r O 
plot [C]p [C]l [C]o [C]t O 
which [C]w [C]h [C]i [C]c [C]h O 
resolved [C]r [C]e [C]s [C]o [C]l [C]v [C]e [C]d O 
into [C]i [C]n [C]t [C]o O 
high [C]h [C]i [C]g [C]h O 
( [C]( O 
0.4 [C]0 [C]. [C]4 O 
nM [C]n [C]M O 
) [C]) O 
and [C]a [C]n [C]d O 
low [C]l [C]o [C]w O 
( [C]( O 
11 [C]1 [C]1 O 
nM [C]n [C]M O 
) [C]) O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
components [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
low [C]l [C]o [C]w O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
site [C]s [C]i [C]t [C]e O 
( [C]( O 
0.30 [C]0 [C]. [C]3 [C]0 O 
pmol/mg [C]p [C]m [C]o [C]l [C]/ [C]m [C]g O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
) [C]) O 
was [C]w [C]a [C]s O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
twice [C]t [C]w [C]i [C]c [C]e O 
that [C]t [C]h [C]a [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
high [C]h [C]i [C]g [C]h B-protein 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y I-protein 
site [C]s [C]i [C]t [C]e E-protein 
( [C]( O 
0.14 [C]0 [C]. [C]1 [C]4 O 
pmol/mg [C]p [C]m [C]o [C]l [C]/ [C]m [C]g O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
) [C]) O 
. [C]. O 

Dissociation [C]D [C]i [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
experiments [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
dilution [C]d [C]i [C]l [C]u [C]t [C]i [C]o [C]n O 
and/or [C]a [C]n [C]d [C]/ [C]o [C]r O 
excess [C]e [C]x [C]c [C]e [C]s [C]s O 
unlabeled [C]u [C]n [C]l [C]a [C]b [C]e [C]l [C]e [C]d O 
CVZ [C]C [C]V [C]Z O 
supported [C]s [C]u [C]p [C]p [C]o [C]r [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
sites [C]s [C]i [C]t [C]e [C]s O 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
the [C]t [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
DEX [C]D [C]E [C]X O 
to [C]t [C]o O 
C7 [C]C [C]7 O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
a [C]a O 
single [C]s [C]i [C]n [C]g [C]l [C]e O 
class [C]c [C]l [C]a [C]s [C]s O 
of [C]o [C]f O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
sites [C]s [C]i [C]t [C]e [C]s O 
( [C]( O 
Kd [C]K [C]d O 
= [C]= O 
1.9 [C]1 [C]. [C]9 O 
nM [C]n [C]M O 
; [C]; O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
0.46 [C]0 [C]. [C]4 [C]6 O 
pmol/mg [C]p [C]m [C]o [C]l [C]/ [C]m [C]g O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
) [C]) O 
. [C]. O 

Examination [C]E [C]x [C]a [C]m [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
CVZ [C]C [C]V [C]Z O 
using [C]u [C]s [C]i [C]n [C]g O 
10 [C]1 [C]0 O 
( [C]( O 
-5 [C]- [C]5 O 
) [C]) O 
M [C]M O 
DEX [C]D [C]E [C]X O 
as [C]a [C]s O 
the [C]t [C]h [C]e O 
competing [C]c [C]o [C]m [C]p [C]e [C]t [C]i [C]n [C]g O 
ligand [C]l [C]i [C]g [C]a [C]n [C]d O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
DEX [C]D [C]E [C]X O 
binds [C]b [C]i [C]n [C]d [C]s O 
only [C]o [C]n [C]l [C]y O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
low [C]l [C]o [C]w O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
site [C]s [C]i [C]t [C]e O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
by [C]b [C]y O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
CVZ [C]C [C]V [C]Z O 
. [C]. O 

In [C]I [C]n O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
from [C]f [C]r [C]o [C]m O 
a [C]a O 
glucocorticoid-resistant [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]t B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
with [C]w [C]i [C]t [C]h O 
virtually [C]v [C]i [C]r [C]t [C]u [C]a [C]l [C]l [C]y O 
no [C]n [C]o O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
DEX [C]D [C]E [C]X O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
, [C], O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
CVZ [C]C [C]V [C]Z O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
a [C]a O 
single [C]s [C]i [C]n [C]g [C]l [C]e O 
high [C]h [C]i [C]g [C]h B-protein 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
site [C]s [C]i [C]t [C]e E-protein 
that [C]t [C]h [C]a [C]t O 
was [C]w [C]a [C]s O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
in [C]i [C]n O 
dissociation [C]d [C]i [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
constant [C]c [C]o [C]n [C]s [C]t [C]a [C]n [C]t O 
( [C]( O 
0.8 [C]0 [C]. [C]8 O 
nM [C]n [C]M O 
) [C]) O 
and [C]a [C]n [C]d O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
( [C]( O 
0.13 [C]0 [C]. [C]1 [C]3 O 
pmol/mg [C]p [C]m [C]o [C]l [C]/ [C]m [C]g O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
) [C]) O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
high [C]h [C]i [C]g [C]h B-protein 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y I-protein 
site [C]s [C]i [C]t [C]e E-protein 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
glucocorticoid-sensitive [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
C7 [C]C [C]7 S-cell_line 
. [C]. O 

A [C]A O 
controlled [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]l [C]e [C]d O 
pore [C]p [C]o [C]r [C]e O 
glass [C]g [C]l [C]a [C]s [C]s O 
bead [C]b [C]e [C]a [C]d O 
assay [C]a [C]s [C]s [C]a [C]y O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
measurement [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c B-protein 
and [C]a [C]n [C]d I-protein 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-protein 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

An [C]A [C]n O 
assay [C]a [C]s [C]s [C]a [C]y O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
quantitation [C]q [C]u [C]a [C]n [C]t [C]i [C]t [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c B-protein 
and [C]a [C]n [C]d I-protein 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-protein 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
developed [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]e [C]d O 
using [C]u [C]s [C]i [C]n [C]g O 
controlled [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]l [C]e [C]d O 
pore [C]p [C]o [C]r [C]e O 
glass [C]g [C]l [C]a [C]s [C]s O 
( [C]( O 
CPG [C]C [C]P [C]G O 
) [C]) O 
beads [C]b [C]e [C]a [C]d [C]s O 
. [C]. O 

Soluble [C]S [C]o [C]l [C]u [C]b [C]l [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r B-protein 
-- [C]- [C]- I-protein 
3H-steroid [C]3 [C]H [C]- [C]s [C]t [C]e [C]r [C]o [C]i [C]d I-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
( [C]( O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
or [C]o [C]r O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
extract [C]e [C]x [C]t [C]r [C]a [C]c [C]t O 
) [C]) O 
is [C]i [C]s O 
adsorbed [C]a [C]d [C]s [C]o [C]r [C]b [C]e [C]d O 
quantitatively [C]q [C]u [C]a [C]n [C]t [C]i [C]t [C]a [C]t [C]i [C]v [C]e [C]l [C]y O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
the [C]t [C]h [C]e O 
crevasses [C]c [C]r [C]e [C]v [C]a [C]s [C]s [C]e [C]s O 
of [C]o [C]f O 
porous [C]p [C]o [C]r [C]o [C]u [C]s O 
glass [C]g [C]l [C]a [C]s [C]s O 
beads [C]b [C]e [C]a [C]d [C]s O 
. [C]. O 

Excess [C]E [C]x [C]c [C]e [C]s [C]s O 
labeled [C]l [C]a [C]b [C]e [C]l [C]e [C]d O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
most [C]m [C]o [C]s [C]t O 
non-specifically [C]n [C]o [C]n [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]a [C]l [C]l [C]y O 
bound [C]b [C]o [C]u [C]n [C]d O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
is [C]i [C]s O 
easily [C]e [C]a [C]s [C]i [C]l [C]y O 
washed [C]w [C]a [C]s [C]h [C]e [C]d O 
away [C]a [C]w [C]a [C]y O 
, [C], O 
leaving [C]l [C]e [C]a [C]v [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
hormone-receptor [C]h [C]o [C]r [C]m [C]o [C]n [C]e [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r B-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
retained [C]r [C]e [C]t [C]a [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
beads [C]b [C]e [C]a [C]d [C]s O 
. [C]. O 

Bound [C]B [C]o [C]u [C]n [C]d O 
3H-steroid [C]3 [C]H [C]- [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
is [C]i [C]s O 
eluted [C]e [C]l [C]u [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
ethanol [C]e [C]t [C]h [C]a [C]n [C]o [C]l O 
and [C]a [C]n [C]d O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
radioactivity [C]r [C]a [C]d [C]i [C]o [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
procedure [C]p [C]r [C]o [C]c [C]e [C]d [C]u [C]r [C]e O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
simple [C]s [C]i [C]m [C]p [C]l [C]e O 
, [C], O 
rapid [C]r [C]a [C]p [C]i [C]d O 
, [C], O 
and [C]a [C]n [C]d O 
highly [C]h [C]i [C]g [C]h [C]l [C]y O 
reproducible [C]r [C]e [C]p [C]r [C]o [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
is [C]i [C]s O 
carried [C]c [C]a [C]r [C]r [C]i [C]e [C]d O 
out [C]o [C]u [C]t O 
using [C]u [C]s [C]i [C]n [C]g O 
frozen [C]f [C]r [C]o [C]z [C]e [C]n O 
samples [C]s [C]a [C]m [C]p [C]l [C]e [C]s O 
( [C]( O 
stable [C]s [C]t [C]a [C]b [C]l [C]e O 
for [C]f [C]o [C]r O 
many [C]m [C]a [C]n [C]y O 
months [C]m [C]o [C]n [C]t [C]h [C]s O 
) [C]) O 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
as [C]a [C]s O 
few [C]f [C]e [C]w O 
as [C]a [C]s O 
1 [C]1 O 
X [C]X O 
10 [C]1 [C]0 O 
( [C]( O 
7 [C]7 O 
) [C]) O 
cells [C]c [C]e [C]l [C]l [C]s O 
. [C]. O 

A [C]A O 
comparison [C]c [C]o [C]m [C]p [C]a [C]r [C]i [C]s [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
CPG [C]C [C]P [C]G O 
assay [C]a [C]s [C]s [C]a [C]y O 
to [C]t [C]o O 
dextran [C]d [C]e [C]x [C]t [C]r [C]a [C]n O 
coated [C]c [C]o [C]a [C]t [C]e [C]d O 
charcoal [C]c [C]h [C]a [C]r [C]c [C]o [C]a [C]l O 
and [C]a [C]n [C]d O 
a [C]a O 
whole [C]w [C]h [C]o [C]l [C]e O 
cell [C]c [C]e [C]l [C]l O 
assay [C]a [C]s [C]s [C]a [C]y O 
demonstrates [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]s O 
that [C]t [C]h [C]a [C]t O 
CPG [C]C [C]P [C]G O 
and [C]a [C]n [C]d O 
dextran [C]d [C]e [C]x [C]t [C]r [C]a [C]n O 
coated [C]c [C]o [C]a [C]t [C]e [C]d O 
charcoal [C]c [C]h [C]a [C]r [C]c [C]o [C]a [C]l O 
give [C]g [C]i [C]v [C]e O 
equivalent [C]e [C]q [C]u [C]i [C]v [C]a [C]l [C]e [C]n [C]t O 
measurements [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]m [C]e [C]n [C]t [C]s O 
of [C]o [C]f O 
cytosolic [C]c [C]y [C]t [C]o [C]s [C]o [C]l [C]i [C]c B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
while [C]w [C]h [C]i [C]l [C]e O 
the [C]t [C]h [C]e O 
CPG [C]C [C]P [C]G O 
and [C]a [C]n [C]d O 
whole [C]w [C]h [C]o [C]l [C]e O 
cell [C]c [C]e [C]l [C]l O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
provide [C]p [C]r [C]o [C]v [C]i [C]d [C]e O 
equivalent [C]e [C]q [C]u [C]i [C]v [C]a [C]l [C]e [C]n [C]t O 
values [C]v [C]a [C]l [C]u [C]e [C]s O 
for [C]f [C]o [C]r O 
total [C]t [C]o [C]t [C]a [C]l O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
. [C]. O 

Plasmacytoid [C]P [C]l [C]a [C]s [C]m [C]a [C]c [C]y [C]t [C]o [C]i [C]d O 
blast [C]b [C]l [C]a [C]s [C]t O 
crisis [C]c [C]r [C]i [C]s [C]i [C]s O 
in [C]i [C]n O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l S-cell_type 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
lymphocytic [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
: [C]: O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
estradiol [C]e [C]s [C]t [C]r [C]a [C]d [C]i [C]o [C]l O 
on [C]o [C]n O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
and [C]a [C]n [C]d O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
. [C]. O 

Evolution [C]E [C]v [C]o [C]l [C]u [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
case [C]c [C]a [C]s [C]e O 
of [C]o [C]f O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
lymphocytic [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
( [C]( O 
CLL [C]C [C]L [C]L O 
) [C]) O 
into [C]i [C]n [C]t [C]o O 
blast [C]b [C]l [C]a [C]s [C]t O 
crisis [C]c [C]r [C]i [C]s [C]i [C]s O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
characterized [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]d O 
by [C]b [C]y O 
three [C]t [C]h [C]r [C]e [C]e O 
unusual [C]u [C]n [C]u [C]s [C]u [C]a [C]l O 
features [C]f [C]e [C]a [C]t [C]u [C]r [C]e [C]s O 
( [C]( O 
1 [C]1 O 
) [C]) O 
the [C]t [C]h [C]e O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
emerging [C]e [C]m [C]e [C]r [C]g [C]i [C]n [C]g B-cell_type 
blast [C]b [C]l [C]a [C]s [C]t I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
was [C]w [C]a [C]s O 
that [C]t [C]h [C]a [C]t O 
of [C]o [C]f O 
pre-plasmacytoid [C]p [C]r [C]e [C]- [C]p [C]l [C]a [C]s [C]m [C]a [C]c [C]y [C]t [C]o [C]i [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
as [C]a [C]s O 
shown [C]s [C]h [C]o [C]w [C]n O 
by [C]b [C]y O 
plasma [C]p [C]l [C]a [C]s [C]m [C]a O 
cell [C]c [C]e [C]l [C]l O 
morphology [C]m [C]o [C]r [C]p [C]h [C]o [C]l [C]o [C]g [C]y O 
and [C]a [C]n [C]d O 
an [C]a [C]n O 
immunological [C]i [C]m [C]m [C]u [C]n [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
corresponding [C]c [C]o [C]r [C]r [C]e [C]s [C]p [C]o [C]n [C]d [C]i [C]n [C]g O 
partially [C]p [C]a [C]r [C]t [C]i [C]a [C]l [C]l [C]y O 
with [C]w [C]i [C]t [C]h O 
CLL- [C]C [C]L [C]L [C]- B-cell_type 
or [C]o [C]r I-cell_type 
intermediate [C]i [C]n [C]t [C]e [C]r [C]m [C]e [C]d [C]i [C]a [C]t [C]e I-cell_type 
B-cells [C]B [C]- [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
partially [C]p [C]a [C]r [C]t [C]i [C]a [C]l [C]l [C]y O 
with [C]w [C]i [C]t [C]h O 
plasma [C]p [C]l [C]a [C]s [C]m [C]a B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
terminal [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l B-protein 
transferase [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]r [C]a [C]s [C]e E-protein 
- [C]- O 
, [C], O 
common [C]c [C]o [C]m [C]m [C]o [C]n O 
acute [C]a [C]c [C]u [C]t [C]e B-protein 
lymphocytic [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]i [C]c I-protein 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a I-protein 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n E-protein 
- [C]- O 
, [C], O 
Ia+ [C]I [C]a [C]+ S-protein 
, [C], O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e B-protein 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n I-protein 
heavy [C]h [C]e [C]a [C]v [C]y I-protein 
chains [C]c [C]h [C]a [C]i [C]n [C]s E-protein 
- [C]- O 
, [C], O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
light [C]l [C]i [C]g [C]h [C]t I-protein 
chains [C]c [C]h [C]a [C]i [C]n [C]s E-protein 
+ [C]+ O 
, [C], O 
intracytoplasmic [C]i [C]n [C]t [C]r [C]a [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c B-protein 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n I-protein 
A+ [C]A [C]+ I-protein 
and [C]a [C]n [C]d I-protein 
G+ [C]G [C]+ E-protein 
, [C], O 
BA-1+ [C]B [C]A [C]- [C]1 [C]+ S-protein 
, [C], O 
polyclonal [C]p [C]o [C]l [C]y [C]c [C]l [C]o [C]n [C]a [C]l O 
gammaglobulin [C]g [C]a [C]m [C]m [C]a [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
) [C]) O 
; [C]; O 
( [C]( O 
2 [C]2 O 
) [C]) O 
cytogenetic [C]c [C]y [C]t [C]o [C]g [C]e [C]n [C]e [C]t [C]i [C]c O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
spontaneous [C]s [C]p [C]o [C]n [C]t [C]a [C]n [C]e [C]o [C]u [C]s O 
metaphases [C]m [C]e [C]t [C]a [C]p [C]h [C]a [C]s [C]e [C]s O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
in [C]i [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
typical [C]t [C]y [C]p [C]i [C]c [C]a [C]l O 
CLL [C]C [C]L [C]L O 
abnormality [C]a [C]b [C]n [C]o [C]r [C]m [C]a [C]l [C]i [C]t [C]y O 
, [C], O 
trisomy [C]t [C]r [C]i [C]s [C]o [C]m [C]y O 
12 [C]1 [C]2 O 
, [C], O 
in [C]i [C]n O 
all [C]a [C]l [C]l O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
, [C], O 
an [C]a [C]n O 
additional [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n [C]a [C]l O 
translocation [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
chromosomes [C]c [C]h [C]r [C]o [C]m [C]o [C]s [C]o [C]m [C]e [C]s B-DNA 
14 [C]1 [C]4 I-DNA 
and [C]a [C]n [C]d I-DNA 
17 [C]1 [C]7 E-DNA 
was [C]w [C]a [C]s O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
in [C]i [C]n O 
40 [C]4 [C]0 O 
% [C]% O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
presumptive [C]p [C]r [C]e [C]s [C]u [C]m [C]p [C]t [C]i [C]v [C]e O 
breakpoint [C]b [C]r [C]e [C]a [C]k [C]p [C]o [C]i [C]n [C]t O 
on [C]o [C]n O 
chromosome [C]c [C]h [C]r [C]o [C]m [C]o [C]s [C]o [C]m [C]e B-DNA 
14 [C]1 [C]4 E-DNA 
( [C]( O 
q12-3 [C]q [C]1 [C]2 [C]- [C]3 O 
) [C]) O 
never [C]n [C]e [C]v [C]e [C]r O 
described [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
before [C]b [C]e [C]f [C]o [C]r [C]e O 
( [C]( O 
commonly [C]c [C]o [C]m [C]m [C]o [C]n [C]l [C]y O 
q32 [C]q [C]3 [C]2 O 
) [C]) O 
and [C]a [C]n [C]d O 
( [C]( O 
3 [C]3 O 
) [C]) O 
the [C]t [C]h [C]e O 
progression [C]p [C]r [C]o [C]g [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
was [C]w [C]a [C]s O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
striking [C]s [C]t [C]r [C]i [C]k [C]i [C]n [C]g O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
transformed [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]e [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
of [C]o [C]f O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
sites [C]s [C]i [C]t [C]e [C]s O 
for [C]f [C]o [C]r O 
estradiol [C]e [C]s [C]t [C]r [C]a [C]d [C]i [C]o [C]l O 
( [C]( O 
E2 [C]E [C]2 O 
) [C]) O 
due [C]d [C]u [C]e O 
to [C]t [C]o O 
an [C]a [C]n O 
actual [C]a [C]c [C]t [C]u [C]a [C]l O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
total [C]t [C]o [C]t [C]a [C]l O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
and [C]a [C]n [C]d O 
not [C]n [C]o [C]t O 
to [C]t [C]o O 
a [C]a O 
change [C]c [C]h [C]a [C]n [C]g [C]e O 
in [C]i [C]n O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
for [C]f [C]o [C]r O 
E2 [C]E [C]2 O 
. [C]. O 

The [C]T [C]h [C]e O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
status [C]s [C]t [C]a [C]t [C]u [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
was [C]w [C]a [C]s O 
confirmed [C]c [C]o [C]n [C]f [C]i [C]r [C]m [C]e [C]d O 
by [C]b [C]y O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
transfer [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]r O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c B-protein 
hormone-receptor [C]h [C]o [C]r [C]m [C]o [C]n [C]e [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
upon [C]u [C]p [C]o [C]n O 
temperature [C]t [C]e [C]m [C]p [C]e [C]r [C]a [C]t [C]u [C]r [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Since [C]S [C]i [C]n [C]c [C]e O 
the [C]t [C]h [C]e O 
rise [C]r [C]i [C]s [C]e O 
in [C]i [C]n O 
E2-receptor [C]E [C]2 [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r S-protein 
display [C]d [C]i [C]s [C]p [C]l [C]a [C]y O 
paralleled [C]p [C]a [C]r [C]a [C]l [C]l [C]e [C]l [C]e [C]d O 
a [C]a O 
large [C]l [C]a [C]r [C]g [C]e O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
proliferative [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
a [C]a O 
change [C]c [C]h [C]a [C]n [C]g [C]e O 
in [C]i [C]n O 
their [C]t [C]h [C]e [C]i [C]r O 
maturation [C]m [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
status [C]s [C]t [C]a [C]t [C]u [C]s O 
the [C]t [C]h [C]e O 
question [C]q [C]u [C]e [C]s [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
raised [C]r [C]a [C]i [C]s [C]e [C]d O 
as [C]a [C]s O 
to [C]t [C]o O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
the [C]t [C]h [C]e O 
E2-receptor [C]E [C]2 [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r S-protein 
should [C]s [C]h [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
considered [C]c [C]o [C]n [C]s [C]i [C]d [C]e [C]r [C]e [C]d O 
as [C]a [C]s O 
a [C]a O 
physiological [C]p [C]h [C]y [C]s [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
marker [C]m [C]a [C]r [C]k [C]e [C]r O 
of [C]o [C]f O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
rate [C]r [C]a [C]t [C]e O 
or [C]o [C]r O 
of [C]o [C]f O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Exposure [C]E [C]x [C]p [C]o [C]s [C]u [C]r [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
's [C]' [C]s O 
blast [C]b [C]l [C]a [C]s [C]t B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
to [C]t [C]o O 
E2 [C]E [C]2 O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
cessation [C]c [C]e [C]s [C]s [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cell [C]c [C]e [C]l [C]l O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
at [C]a [C]t O 
least [C]l [C]e [C]a [C]s [C]t O 
one [C]o [C]n [C]e O 
mitosis [C]m [C]i [C]t [C]o [C]s [C]i [C]s O 
after [C]a [C]f [C]t [C]e [C]r O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
inducer [C]i [C]n [C]d [C]u [C]c [C]e [C]r O 
as [C]a [C]s O 
seen [C]s [C]e [C]e [C]n O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
replacement [C]r [C]e [C]p [C]l [C]a [C]c [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
large [C]l [C]a [C]r [C]g [C]e B-cell_type 
blasts [C]b [C]l [C]a [C]s [C]t [C]s E-cell_type 
by [C]b [C]y O 
small [C]s [C]m [C]a [C]l [C]l O 
CLL-like [C]C [C]L [C]L [C]- [C]l [C]i [C]k [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
without [C]w [C]i [C]t [C]h [C]o [C]u [C]t O 
definite [C]d [C]e [C]f [C]i [C]n [C]i [C]t [C]e O 
signs [C]s [C]i [C]g [C]n [C]s O 
of [C]o [C]f O 
alteration [C]a [C]l [C]t [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
status [C]s [C]t [C]a [C]t [C]u [C]s O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
suggests [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]s O 
the [C]t [C]h [C]e O 
association [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
E2-receptor [C]E [C]2 [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
of [C]o [C]f O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
rather [C]r [C]a [C]t [C]h [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
cell [C]c [C]e [C]l [C]l O 
maturation [C]m [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Multiple [C]M [C]u [C]l [C]t [C]i [C]p [C]l [C]e O 
forms [C]f [C]o [C]r [C]m [C]s O 
and [C]a [C]n [C]d O 
fragments [C]f [C]r [C]a [C]g [C]m [C]e [C]n [C]t [C]s O 
of [C]o [C]f O 
cytosolic [C]c [C]y [C]t [C]o [C]s [C]o [C]l [C]i [C]c B-protein 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
from [C]f [C]r [C]o [C]m O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

Therapy [C]T [C]h [C]e [C]r [C]a [C]p [C]y O 
with [C]w [C]i [C]t [C]h O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
is [C]i [C]s O 
generally [C]g [C]e [C]n [C]e [C]r [C]a [C]l [C]l [C]y O 
more [C]m [C]o [C]r [C]e O 
effective [C]e [C]f [C]f [C]e [C]c [C]t [C]i [C]v [C]e O 
in [C]i [C]n O 
acute [C]a [C]c [C]u [C]t [C]e O 
lymphoblastic [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
than [C]t [C]h [C]a [C]n O 
in [C]i [C]n O 
other [C]o [C]t [C]h [C]e [C]r O 
types [C]t [C]y [C]p [C]e [C]s O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
. [C]. O 

Previous [C]P [C]r [C]e [C]v [C]i [C]o [C]u [C]s O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
, [C], O 
however [C]h [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
have [C]h [C]a [C]v [C]e O 
not [C]n [C]o [C]t O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
any [C]a [C]n [C]y O 
consistent [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
relationship [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n [C]s [C]h [C]i [C]p O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
clinical [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
responsiveness [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e [C]n [C]e [C]s [C]s O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
or [C]o [C]r O 
cytosolic [C]c [C]y [C]t [C]o [C]s [C]o [C]l [C]i [C]c O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
glucocorticoid-binding [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
sites [C]s [C]i [C]t [C]e [C]s E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
objectives [C]o [C]b [C]j [C]e [C]c [C]t [C]i [C]v [C]e [C]s O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
were [C]w [C]e [C]r [C]e O 
to [C]t [C]o O 
determine [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
there [C]t [C]h [C]e [C]r [C]e O 
are [C]a [C]r [C]e O 
intrinsic [C]i [C]n [C]t [C]r [C]i [C]n [C]s [C]i [C]c O 
structural [C]s [C]t [C]r [C]u [C]c [C]t [C]u [C]r [C]a [C]l O 
differences [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e [C]s O 
among [C]a [C]m [C]o [C]n [C]g O 
the [C]t [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
types [C]t [C]y [C]p [C]e [C]s O 
of [C]o [C]f O 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
to [C]t [C]o O 
investigate [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
endogenous [C]e [C]n [C]d [C]o [C]g [C]e [C]n [C]o [C]u [C]s B-protein 
peptidases [C]p [C]e [C]p [C]t [C]i [C]d [C]a [C]s [C]e [C]s E-protein 
in [C]i [C]n O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Cytosols [C]C [C]y [C]t [C]o [C]s [C]o [C]l [C]s O 
were [C]w [C]e [C]r [C]e O 
prepared [C]p [C]r [C]e [C]p [C]a [C]r [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
fresh [C]f [C]r [C]e [C]s [C]h B-cell_type 
or [C]o [C]r I-cell_type 
rapidly [C]r [C]a [C]p [C]i [C]d [C]l [C]y I-cell_type 
frozen [C]f [C]r [C]o [C]z [C]e [C]n I-cell_type 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
6 [C]6 O 
healthy [C]h [C]e [C]a [C]l [C]t [C]h [C]y O 
adults [C]a [C]d [C]u [C]l [C]t [C]s O 
and [C]a [C]n [C]d O 
35 [C]3 [C]5 O 
high-risk [C]h [C]i [C]g [C]h [C]- [C]r [C]i [C]s [C]k O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
( [C]( O 
median [C]m [C]e [C]d [C]i [C]a [C]n O 
white [C]w [C]h [C]i [C]t [C]e O 
blood [C]b [C]l [C]o [C]o [C]d O 
cell [C]c [C]e [C]l [C]l O 
count [C]c [C]o [C]u [C]n [C]t O 
, [C], O 
150 [C]1 [C]5 [C]0 O 
, [C], O 
000 [C]0 [C]0 [C]0 O 
cells/microliter [C]c [C]e [C]l [C]l [C]s [C]/ [C]m [C]i [C]c [C]r [C]o [C]l [C]i [C]t [C]e [C]r O 
; [C]; O 
median [C]m [C]e [C]d [C]i [C]a [C]n O 
age [C]a [C]g [C]e O 
, [C], O 
13 [C]1 [C]3 O 
years [C]y [C]e [C]a [C]r [C]s O 
) [C]) O 
. [C]. O 

Receptors [C]R [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
were [C]w [C]e [C]r [C]e O 
labeled [C]l [C]a [C]b [C]e [C]l [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
triamcinolone [C]t [C]r [C]i [C]a [C]m [C]c [C]i [C]n [C]o [C]l [C]o [C]n [C]e O 
acetonide [C]a [C]c [C]e [C]t [C]o [C]n [C]i [C]d [C]e O 
and [C]a [C]n [C]d O 
quantitated [C]q [C]u [C]a [C]n [C]t [C]i [C]t [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
charcoal-dextran [C]c [C]h [C]a [C]r [C]c [C]o [C]a [C]l [C]- [C]d [C]e [C]x [C]t [C]r [C]a [C]n O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
or [C]o [C]r O 
Sephadex [C]S [C]e [C]p [C]h [C]a [C]d [C]e [C]x O 
LH-20 [C]L [C]H [C]- [C]2 [C]0 O 
chromatography [C]c [C]h [C]r [C]o [C]m [C]a [C]t [C]o [C]g [C]r [C]a [C]p [C]h [C]y O 
. [C]. O 

Mean [C]M [C]e [C]a [C]n O 
and [C]a [C]n [C]d O 
median [C]m [C]e [C]d [C]i [C]a [C]n O 
cytosolic [C]c [C]y [C]t [C]o [C]s [C]o [C]l [C]i [C]c O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
12 [C]1 [C]2 O 
acute [C]a [C]c [C]u [C]t [C]e O 
lymphoblastic [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
specimens [C]s [C]p [C]e [C]c [C]i [C]m [C]e [C]n [C]s O 
lacking [C]l [C]a [C]c [C]k [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
standard [C]s [C]t [C]a [C]n [C]d [C]a [C]r [C]d O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l O 
or [C]o [C]r O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
markers [C]m [C]a [C]r [C]k [C]e [C]r [C]s O 
( [C]( O 
`` [C]` [C]` O 
null [C]n [C]u [C]l [C]l O 
cells [C]c [C]e [C]l [C]l [C]s O 
'' [C]' [C]' O 
) [C]) O 
were [C]w [C]e [C]r [C]e O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
4-fold [C]4 [C]- [C]f [C]o [C]l [C]d O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
in [C]i [C]n O 
23 [C]2 [C]3 O 
other [C]o [C]t [C]h [C]e [C]r O 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c B-cell_type 
cell [C]c [C]e [C]l [C]l I-cell_type 
specimens [C]s [C]p [C]e [C]c [C]i [C]m [C]e [C]n [C]s E-cell_type 
. [C]. O 

No [C]N [C]o O 
other [C]o [C]t [C]h [C]e [C]r O 
consistent [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
differences [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e [C]s O 
in [C]i [C]n O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
were [C]w [C]e [C]r [C]e O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
. [C]. O 

Agarose [C]A [C]g [C]a [C]r [C]o [C]s [C]e O 
filtration [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
ultracentrifugation [C]u [C]l [C]t [C]r [C]a [C]c [C]e [C]n [C]t [C]r [C]i [C]f [C]u [C]g [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
hypotonic [C]h [C]y [C]p [C]o [C]t [C]o [C]n [C]i [C]c O 
buffers [C]b [C]u [C]f [C]f [C]e [C]r [C]s O 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
20 [C]2 [C]0 O 
mM [C]m [C]M O 
Na2MoO4 [C]N [C]a [C]2 [C]M [C]o [C]O [C]4 O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s O 
of [C]o [C]f O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
size [C]s [C]i [C]z [C]e O 
and [C]a [C]n [C]d O 
shape [C]s [C]h [C]a [C]p [C]e O 
in [C]i [C]n O 
all [C]a [C]l [C]l O 
clinical [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
specimens [C]s [C]p [C]e [C]c [C]i [C]m [C]e [C]n [C]s O 
tested [C]t [C]e [C]s [C]t [C]e [C]d O 
and [C]a [C]n [C]d O 
two [C]t [C]w [C]o O 
established [C]e [C]s [C]t [C]a [C]b [C]l [C]i [C]s [C]h [C]e [C]d O 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
. [C]. O 

They [C]T [C]h [C]e [C]y O 
had [C]h [C]a [C]d O 
Stokes [C]S [C]t [C]o [C]k [C]e [C]s O 
radii [C]r [C]a [C]d [C]i [C]i O 
( [C]( O 
Rs [C]R [C]s O 
) [C]) O 
of [C]o [C]f O 
8.1 [C]8 [C]. [C]1 O 
+/- [C]+ [C]/ [C]- O 
0.5 [C]0 [C]. [C]5 O 
( [C]( O 
S.D. [C]S [C]. [C]D [C]. O 
) [C]) O 
nm [C]n [C]m O 
( [C]( O 
n [C]n O 
= [C]= O 
50 [C]5 [C]0 O 
) [C]) O 
, [C], O 
sedimentation [C]s [C]e [C]d [C]i [C]m [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
coefficients [C]c [C]o [C]e [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t [C]s O 
of [C]o [C]f O 
9.5 [C]9 [C]. [C]5 O 
+/- [C]+ [C]/ [C]- O 
0.3S [C]0 [C]. [C]3 [C]S O 
( [C]( O 
n [C]n O 
= [C]= O 
40 [C]4 [C]0 O 
) [C]) O 
, [C], O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
weights [C]w [C]e [C]i [C]g [C]h [C]t [C]s O 
of [C]o [C]f O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
330 [C]3 [C]3 [C]0 O 
, [C], O 
000 [C]0 [C]0 [C]0 O 
, [C], O 
and [C]a [C]n [C]d O 
axial [C]a [C]x [C]i [C]a [C]l O 
ratios [C]r [C]a [C]t [C]i [C]o [C]s O 
( [C]( O 
a/b [C]a [C]/ [C]b O 
) [C]) O 
of [C]o [C]f O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
12 [C]1 [C]2 O 
. [C]. O 

In [C]I [C]n O 
hypertonic [C]h [C]y [C]p [C]e [C]r [C]t [C]o [C]n [C]i [C]c O 
, [C], O 
molybdate-free [C]m [C]o [C]l [C]y [C]b [C]d [C]a [C]t [C]e [C]- [C]f [C]r [C]e [C]e O 
buffer [C]b [C]u [C]f [C]f [C]e [C]r O 
, [C], O 
these [C]t [C]h [C]e [C]s [C]e O 
oligomeric [C]o [C]l [C]i [C]g [C]o [C]m [C]e [C]r [C]i [C]c B-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
were [C]w [C]e [C]r [C]e O 
dissociated [C]d [C]i [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
into [C]i [C]n [C]t [C]o O 
subunits [C]s [C]u [C]b [C]u [C]n [C]i [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
Rs [C]R [C]s O 
of [C]o [C]f O 
5.9 [C]5 [C]. [C]9 O 
+/- [C]+ [C]/ [C]- O 
0.3 [C]0 [C]. [C]3 O 
nm [C]n [C]m O 
( [C]( O 
n [C]n O 
= [C]= O 
12 [C]1 [C]2 O 
) [C]) O 
and [C]a [C]n [C]d O 
a/b [C]a [C]/ [C]b O 
of [C]o [C]f O 
11 [C]1 [C]1 O 
to [C]t [C]o O 
12 [C]1 [C]2 O 
, [C], O 
as [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
for [C]f [C]o [C]r O 
other [C]o [C]t [C]h [C]e [C]r O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
. [C]. O 

Fragmentation [C]F [C]r [C]a [C]g [C]m [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
oligomer [C]o [C]l [C]i [C]g [C]o [C]m [C]e [C]r S-protein 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
subunit [C]s [C]u [C]b [C]u [C]n [C]i [C]t S-protein 
was [C]w [C]a [C]s O 
evident [C]e [C]v [C]i [C]d [C]e [C]n [C]t O 
in [C]i [C]n O 
some [C]s [C]o [C]m [C]e O 
cytosols [C]c [C]y [C]t [C]o [C]s [C]o [C]l [C]s O 
. [C]. O 

High [C]H [C]i [C]g [C]h O 
activities [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]i [C]e [C]s O 
of [C]o [C]f O 
peptidases [C]p [C]e [C]p [C]t [C]i [C]d [C]a [C]s [C]e [C]s S-protein 
of [C]o [C]f O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
specificities [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]i [C]t [C]i [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
in [C]i [C]n O 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c O 
cell [C]c [C]e [C]l [C]l O 
cytosols [C]c [C]y [C]t [C]o [C]s [C]o [C]l [C]s O 
, [C], O 
as [C]a [C]s O 
in [C]i [C]n O 
other [C]o [C]t [C]h [C]e [C]r O 
cytosols [C]c [C]y [C]t [C]o [C]s [C]o [C]l [C]s O 
, [C], O 
by [C]b [C]y O 
fluorometric [C]f [C]l [C]u [C]o [C]r [C]o [C]m [C]e [C]t [C]r [C]i [C]c O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
with [C]w [C]i [C]t [C]h O 
derivatives [C]d [C]e [C]r [C]i [C]v [C]a [C]t [C]i [C]v [C]e [C]s O 
of [C]o [C]f O 
7-amino-4-methylcoumarin [C]7 [C]- [C]a [C]m [C]i [C]n [C]o [C]- [C]4 [C]- [C]m [C]e [C]t [C]h [C]y [C]l [C]c [C]o [C]u [C]m [C]a [C]r [C]i [C]n O 
. [C]. O 

Receptor [C]R [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
cleavage [C]c [C]l [C]e [C]a [C]v [C]a [C]g [C]e O 
by [C]b [C]y O 
these [C]t [C]h [C]e [C]s [C]e O 
and [C]a [C]n [C]d O 
other [C]o [C]t [C]h [C]e [C]r O 
endogenous [C]e [C]n [C]d [C]o [C]g [C]e [C]n [C]o [C]u [C]s B-protein 
enzymes [C]e [C]n [C]z [C]y [C]m [C]e [C]s E-protein 
may [C]m [C]a [C]y O 
account [C]a [C]c [C]c [C]o [C]u [C]n [C]t O 
for [C]f [C]o [C]r O 
previous [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s O 
observations [C]o [C]b [C]s [C]e [C]r [C]v [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
`` [C]` [C]` O 
abnormal [C]a [C]b [C]n [C]o [C]r [C]m [C]a [C]l O 
'' [C]' [C]' O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
in [C]i [C]n O 
cytosols [C]c [C]y [C]t [C]o [C]s [C]o [C]l [C]s O 
from [C]f [C]r [C]o [C]m O 
some [C]s [C]o [C]m [C]e O 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c B-cell_type 
specimens [C]s [C]p [C]e [C]c [C]i [C]m [C]e [C]n [C]s E-cell_type 
. [C]. O 

We [C]W [C]e O 
conclude [C]c [C]o [C]n [C]c [C]l [C]u [C]d [C]e O 
that [C]t [C]h [C]a [C]t O 
intrinsic [C]i [C]n [C]t [C]r [C]i [C]n [C]s [C]i [C]c O 
structural [C]s [C]t [C]r [C]u [C]c [C]t [C]u [C]r [C]a [C]l O 
defects [C]d [C]e [C]f [C]e [C]c [C]t [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
are [C]a [C]r [C]e O 
unlikely [C]u [C]n [C]l [C]i [C]k [C]e [C]l [C]y O 
explanations [C]e [C]x [C]p [C]l [C]a [C]n [C]a [C]t [C]i [C]o [C]n [C]s O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
unresponsiveness [C]u [C]n [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e [C]n [C]e [C]s [C]s O 
of [C]o [C]f O 
some [C]s [C]o [C]m [C]e O 
types [C]t [C]y [C]p [C]e [C]s O 
of [C]o [C]f O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
to [C]t [C]o O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
. [C]. O 

Glucocorticoid [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
and [C]a [C]n [C]d O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
water [C]w [C]a [C]t [C]e [C]r O 
space [C]s [C]p [C]a [C]c [C]e O 
. [C]. O 

In [C]I [C]n O 
order [C]o [C]r [C]d [C]e [C]r O 
to [C]t [C]o O 
elucidate [C]e [C]l [C]u [C]c [C]i [C]d [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
relationship [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n [C]s [C]h [C]i [C]p O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
cell [C]c [C]e [C]l [C]l O 
water [C]w [C]a [C]t [C]e [C]r O 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
, [C], O 
eleven [C]e [C]l [C]e [C]v [C]e [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
and [C]a [C]n [C]d O 
malignant [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]t B-cell_type 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d I-cell_type 
or [C]o [C]r I-cell_type 
myelomonocytic [C]m [C]y [C]e [C]l [C]o [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]i [C]c I-cell_type 
cell [C]c [C]e [C]l [C]l I-cell_type 
types [C]t [C]y [C]p [C]e [C]s E-cell_type 
originating [C]o [C]r [C]i [C]g [C]i [C]n [C]a [C]t [C]i [C]n [C]g O 
from [C]f [C]r [C]o [C]m O 
mouse [C]m [C]o [C]u [C]s [C]e O 
, [C], O 
rat [C]r [C]a [C]t O 
and [C]a [C]n [C]d O 
man [C]m [C]a [C]n O 
were [C]w [C]e [C]r [C]e O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
. [C]. O 

The [C]T [C]h [C]e O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
water [C]w [C]a [C]t [C]e [C]r O 
space [C]s [C]p [C]a [C]c [C]e O 
was [C]w [C]a [C]s O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
3H2O [C]3 [C]H [C]2 [C]O O 
, [C], O 
and [C]a [C]n [C]d O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
was [C]w [C]a [C]s O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
in [C]i [C]n O 
a [C]a O 
whole-cell [C]w [C]h [C]o [C]l [C]e [C]- [C]c [C]e [C]l [C]l O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
assay [C]a [C]s [C]s [C]a [C]y O 
with [C]w [C]i [C]t [C]h O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
at [C]a [C]t O 
30 [C]3 [C]0 O 
and [C]a [C]n [C]d O 
37 [C]3 [C]7 O 
degrees [C]d [C]e [C]g [C]r [C]e [C]e [C]s O 
C [C]C O 
. [C]. O 

The [C]T [C]h [C]e O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
water [C]w [C]a [C]t [C]e [C]r O 
phase [C]p [C]h [C]a [C]s [C]e O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
( [C]( O 
around [C]a [C]r [C]o [C]u [C]n [C]d O 
40 [C]4 [C]0 O 
nmol/l [C]n [C]m [C]o [C]l [C]/ [C]l O 
cell [C]c [C]e [C]l [C]l O 
water [C]w [C]a [C]t [C]e [C]r O 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
dependence [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
on [C]o [C]n O 
temperature [C]t [C]e [C]m [C]p [C]e [C]r [C]a [C]t [C]u [C]r [C]e O 
were [C]w [C]e [C]r [C]e O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
and [C]a [C]n [C]d I-cell_type 
malignant [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]t I-cell_type 
rodent [C]r [C]o [C]d [C]e [C]n [C]t I-cell_type 
and [C]a [C]n [C]d I-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

It [C]I [C]t O 
is [C]i [C]s O 
concluded [C]c [C]o [C]n [C]c [C]l [C]u [C]d [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
comparisons [C]c [C]o [C]m [C]p [C]a [C]r [C]i [C]s [C]o [C]n [C]s O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
are [C]a [C]r [C]e O 
best [C]b [C]e [C]s [C]t O 
made [C]m [C]a [C]d [C]e O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
basis [C]b [C]a [C]s [C]i [C]s O 
of [C]o [C]f O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

Covalent [C]C [C]o [C]v [C]a [C]l [C]e [C]n [C]t O 
labeling [C]l [C]a [C]b [C]e [C]l [C]i [C]n [C]g O 
of [C]o [C]f O 
rat [C]r [C]a [C]t B-cell_type 
thymocyte [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e E-cell_type 
and [C]a [C]n [C]d O 
human [C]h [C]u [C]m [C]a [C]n B-protein 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d I-protein 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
. [C]. O 

Lymphoid [C]L [C]y [C]m [C]p [C]h [C]o [C]i [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
contain [C]c [C]o [C]n [C]t [C]a [C]i [C]n O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s S-protein 
for [C]f [C]o [C]r O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
used [C]u [C]s [C]e [C]d O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
dexamethasone-21-mesylate [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e [C]- [C]2 [C]1 [C]- [C]m [C]e [C]s [C]y [C]l [C]a [C]t [C]e O 
to [C]t [C]o O 
label [C]l [C]a [C]b [C]e [C]l O 
covalently [C]c [C]o [C]v [C]a [C]l [C]e [C]n [C]t [C]l [C]y O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
rat [C]r [C]a [C]t B-cell_type 
thymic [C]t [C]h [C]y [C]m [C]i [C]c I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
neoplastic [C]n [C]e [C]o [C]p [C]l [C]a [C]s [C]t [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
acute [C]a [C]c [C]u [C]t [C]e O 
lymphoblastic [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
and [C]a [C]n [C]d O 
malignant [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]t O 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a O 
. [C]. O 

The [C]T [C]h [C]e O 
covalently [C]c [C]o [C]v [C]a [C]l [C]e [C]n [C]t [C]l [C]y O 
labeled [C]l [C]a [C]b [C]e [C]l [C]e [C]d O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
were [C]w [C]e [C]r [C]e O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
by [C]b [C]y O 
polyacrylamide [C]p [C]o [C]l [C]y [C]a [C]c [C]r [C]y [C]l [C]a [C]m [C]i [C]d [C]e O 
gel [C]g [C]e [C]l O 
electrophoresis [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]s [C]i [C]s O 
( [C]( O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
0.1 [C]0 [C]. [C]1 O 
% [C]% O 
sodium [C]s [C]o [C]d [C]i [C]u [C]m O 
dodecyl [C]d [C]o [C]d [C]e [C]c [C]y [C]l O 
sulfate [C]s [C]u [C]l [C]f [C]a [C]t [C]e O 
) [C]) O 
. [C]. O 

In [C]I [C]n O 
cytosolic [C]c [C]y [C]t [C]o [C]s [C]o [C]l [C]i [C]c O 
fractions [C]f [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
prepared [C]p [C]r [C]e [C]p [C]a [C]r [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
rat [C]r [C]a [C]t B-cell_type 
thymic [C]t [C]h [C]y [C]m [C]i [C]c I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
, [C], O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
-dexamethasone-21-mesylate [C]- [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e [C]- [C]2 [C]1 [C]- [C]m [C]e [C]s [C]y [C]l [C]a [C]t [C]e O 
labels [C]l [C]a [C]b [C]e [C]l [C]s O 
a [C]a O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
( [C]( O 
Mr [C]M [C]r O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
equal [C]e [C]q [C]u [C]a [C]l O 
to [C]t [C]o O 
95 [C]9 [C]5 O 
, [C], O 
000 [C]0 [C]0 [C]0 O 
) [C]) O 
which [C]w [C]h [C]i [C]c [C]h O 
was [C]w [C]a [C]s O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
as [C]a [C]s O 
the [C]t [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
criteria [C]c [C]r [C]i [C]t [C]e [C]r [C]i [C]a O 
: [C]: O 
( [C]( O 
a [C]a O 
) [C]) O 
labeling [C]l [C]a [C]b [C]e [C]l [C]i [C]n [C]g O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
moiety [C]m [C]o [C]i [C]e [C]t [C]y O 
is [C]i [C]s O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
by [C]b [C]y O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
100-fold [C]1 [C]0 [C]0 [C]- [C]f [C]o [C]l [C]d O 
molar [C]m [C]o [C]l [C]a [C]r O 
excess [C]e [C]x [C]c [C]e [C]s [C]s O 
of [C]o [C]f O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
, [C], O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
and [C]a [C]n [C]d O 
triamcinolone [C]t [C]r [C]i [C]a [C]m [C]c [C]i [C]n [C]o [C]l [C]o [C]n [C]e O 
acetonide [C]a [C]c [C]e [C]t [C]o [C]n [C]i [C]d [C]e O 
; [C]; O 
and [C]a [C]n [C]d O 
( [C]( O 
b [C]b O 
) [C]) O 
the [C]t [C]h [C]e O 
covalently [C]c [C]o [C]v [C]a [C]l [C]e [C]n [C]t [C]l [C]y O 
labeled [C]l [C]a [C]b [C]e [C]l [C]e [C]d O 
Mr [C]M [C]r O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
equal [C]e [C]q [C]u [C]a [C]l O 
to [C]t [C]o O 
95 [C]9 [C]5 O 
, [C], O 
000 [C]0 [C]0 [C]0 O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
is [C]i [C]s O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
( [C]( O 
by [C]b [C]y O 
heating [C]h [C]e [C]a [C]t [C]i [C]n [C]g O 
at [C]a [C]t O 
20 [C]2 [C]0 O 
degrees [C]d [C]e [C]g [C]r [C]e [C]e [C]s O 
for [C]f [C]o [C]r O 
30 [C]3 [C]0 O 
min [C]m [C]i [C]n O 
) [C]) O 
to [C]t [C]o O 
a [C]a O 
form [C]f [C]o [C]r [C]m O 
that [C]t [C]h [C]a [C]t O 
binds [C]b [C]i [C]n [C]d [C]s O 
to [C]t [C]o O 
DNA-cellulose [C]D [C]N [C]A [C]- [C]c [C]e [C]l [C]l [C]u [C]l [C]o [C]s [C]e O 
. [C]. O 

When [C]W [C]h [C]e [C]n O 
intact [C]i [C]n [C]t [C]a [C]c [C]t B-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
are [C]a [C]r [C]e O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
dexamethasone-21-mesylate [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e [C]- [C]2 [C]1 [C]- [C]m [C]e [C]s [C]y [C]l [C]a [C]t [C]e O 
, [C], O 
an [C]a [C]n O 
Mr [C]M [C]r O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
equal [C]e [C]q [C]u [C]a [C]l O 
to [C]t [C]o O 
95 [C]9 [C]5 O 
, [C], O 
000 [C]0 [C]0 [C]0 O 
moiety [C]m [C]o [C]i [C]e [C]t [C]y O 
is [C]i [C]s O 
also [C]a [C]l [C]s [C]o O 
labeled [C]l [C]a [C]b [C]e [C]l [C]e [C]d O 
covalently [C]c [C]o [C]v [C]a [C]l [C]e [C]n [C]t [C]l [C]y O 
. [C]. O 

Approximately [C]A [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
35 [C]3 [C]5 O 
% [C]% O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
can [C]c [C]a [C]n O 
be [C]b [C]e O 
labeled [C]l [C]a [C]b [C]e [C]l [C]e [C]d O 
covalently [C]c [C]o [C]v [C]a [C]l [C]e [C]n [C]t [C]l [C]y O 
when [C]w [C]h [C]e [C]n O 
intact [C]i [C]n [C]t [C]a [C]c [C]t O 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
are [C]a [C]r [C]e O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
100 [C]1 [C]0 [C]0 O 
nM [C]n [C]M O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
dexamethasone-21-mesylate [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e [C]- [C]2 [C]1 [C]- [C]m [C]e [C]s [C]y [C]l [C]a [C]t [C]e O 
for [C]f [C]o [C]r O 
30 [C]3 [C]0 O 
min [C]m [C]i [C]n O 
at [C]a [C]t O 
4 [C]4 O 
degrees [C]d [C]e [C]g [C]r [C]e [C]e [C]s O 
. [C]. O 

Neoplastic [C]N [C]e [C]o [C]p [C]l [C]a [C]s [C]t [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
acute [C]a [C]c [C]u [C]t [C]e O 
lymphoblastic [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
and [C]a [C]n [C]d O 
malignant [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]t O 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a O 
were [C]w [C]e [C]r [C]e O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
dexamethasone-21-mesylate [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e [C]- [C]2 [C]1 [C]- [C]m [C]e [C]s [C]y [C]l [C]a [C]t [C]e O 
. [C]. O 

In [C]I [C]n O 
all [C]a [C]l [C]l O 
samples [C]s [C]a [C]m [C]p [C]l [C]e [C]s O 
, [C], O 
an [C]a [C]n O 
Mr [C]M [C]r O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
equal [C]e [C]q [C]u [C]a [C]l O 
to [C]t [C]o O 
95 [C]9 [C]5 O 
, [C], O 
000 [C]0 [C]0 [C]0 O 
moiety [C]m [C]o [C]i [C]e [C]t [C]y O 
was [C]w [C]a [C]s O 
labeled [C]l [C]a [C]b [C]e [C]l [C]e [C]d O 
covalently [C]c [C]o [C]v [C]a [C]l [C]e [C]n [C]t [C]l [C]y O 
; [C]; O 
labeling [C]l [C]a [C]b [C]e [C]l [C]i [C]n [C]g O 
was [C]w [C]a [C]s O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
by [C]b [C]y O 
excess [C]e [C]x [C]c [C]e [C]s [C]s O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
. [C]. O 

Smaller [C]S [C]m [C]a [C]l [C]l [C]e [C]r B-protein 
moieties [C]m [C]o [C]i [C]e [C]t [C]i [C]e [C]s E-protein 
were [C]w [C]e [C]r [C]e O 
also [C]a [C]l [C]s [C]o O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
by [C]b [C]y O 
competition [C]c [C]o [C]m [C]p [C]e [C]t [C]i [C]t [C]i [C]o [C]n O 
experiments [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]s O 
; [C]; O 
these [C]t [C]h [C]e [C]s [C]e O 
may [C]m [C]a [C]y O 
represent [C]r [C]e [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
proteolytic [C]p [C]r [C]o [C]t [C]e [C]o [C]l [C]y [C]t [C]i [C]c B-protein 
fragments [C]f [C]r [C]a [C]g [C]m [C]e [C]n [C]t [C]s E-protein 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Mr [C]M [C]r O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
equal [C]e [C]q [C]u [C]a [C]l O 
to [C]t [C]o O 
95 [C]9 [C]5 O 
, [C], O 
000 [C]0 [C]0 [C]0 O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
in [C]i [C]n O 
rat [C]r [C]a [C]t B-cell_type 
and [C]a [C]n [C]d I-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
dexamethasone-21-mesylate [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e [C]- [C]2 [C]1 [C]- [C]m [C]e [C]s [C]y [C]l [C]a [C]t [C]e O 
can [C]c [C]a [C]n O 
be [C]b [C]e O 
used [C]u [C]s [C]e [C]d O 
to [C]t [C]o O 
label [C]l [C]a [C]b [C]e [C]l O 
covalently [C]c [C]o [C]v [C]a [C]l [C]e [C]n [C]t [C]l [C]y O 
the [C]t [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
association [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
oestrogen [C]o [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n B-protein 
and [C]a [C]n [C]d I-protein 
progesterone [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]e [C]r [C]o [C]n [C]e I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
with [C]w [C]i [C]t [C]h O 
histological [C]h [C]i [C]s [C]t [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
features [C]f [C]e [C]a [C]t [C]u [C]r [C]e [C]s O 
of [C]o [C]f O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
and [C]a [C]n [C]d O 
early [C]e [C]a [C]r [C]l [C]y O 
recurrence [C]r [C]e [C]c [C]u [C]r [C]r [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
. [C]. O 

Two [C]T [C]w [C]o O 
hundred [C]h [C]u [C]n [C]d [C]r [C]e [C]d O 
and [C]a [C]n [C]d O 
eighty-eight [C]e [C]i [C]g [C]h [C]t [C]y [C]- [C]e [C]i [C]g [C]h [C]t O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
tumours [C]t [C]u [C]m [C]o [C]u [C]r [C]s O 
were [C]w [C]e [C]r [C]e O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
or [C]o [C]r O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
oestrogen [C]o [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n B-protein 
( [C]( I-protein 
REc [C]R [C]E [C]c I-protein 
) [C]) I-protein 
and [C]a [C]n [C]d I-protein 
progesterone [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]e [C]r [C]o [C]n [C]e I-protein 
( [C]( I-protein 
RPc [C]R [C]P [C]c I-protein 
) [C]) I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

Analysis [C]A [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
has [C]h [C]a [C]s O 
shown [C]s [C]h [C]o [C]w [C]n O 
a [C]a O 
relative [C]r [C]e [C]l [C]a [C]t [C]i [C]v [C]e O 
interdependence [C]i [C]n [C]t [C]e [C]r [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]c [C]e O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
status [C]s [C]t [C]a [C]t [C]u [C]s O 
of [C]o [C]f O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
and [C]a [C]n [C]d O 
other [C]o [C]t [C]h [C]e [C]r O 
prognostic [C]p [C]r [C]o [C]g [C]n [C]o [C]s [C]t [C]i [C]c O 
variables [C]v [C]a [C]r [C]i [C]a [C]b [C]l [C]e [C]s O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
histological [C]h [C]i [C]s [C]t [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
grade [C]g [C]r [C]a [C]d [C]e O 
, [C], O 
lymphocytic [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]i [C]c O 
infiltration [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
tumour [C]t [C]u [C]m [C]o [C]u [C]r O 
elastosis [C]e [C]l [C]a [C]s [C]t [C]o [C]s [C]i [C]s O 
. [C]. O 

There [C]T [C]h [C]e [C]r [C]e O 
were [C]w [C]e [C]r [C]e O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
associations [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n [C]s O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
epithelial [C]e [C]p [C]i [C]t [C]h [C]e [C]l [C]i [C]a [C]l O 
cellularity [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r [C]i [C]t [C]y O 
, [C], O 
stromal [C]s [C]t [C]r [C]o [C]m [C]a [C]l O 
fibrosis [C]f [C]i [C]b [C]r [C]o [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
value [C]v [C]a [C]l [C]u [C]e O 
of [C]o [C]f O 
REc [C]R [C]E [C]c S-protein 
in [C]i [C]n O 
those [C]t [C]h [C]o [C]s [C]e O 
tumours [C]t [C]u [C]m [C]o [C]u [C]r [C]s O 
in [C]i [C]n O 
which [C]w [C]h [C]i [C]c [C]h O 
the [C]t [C]h [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
was [C]w [C]a [C]s O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
. [C]. O 

Cellularity [C]C [C]e [C]l [C]l [C]u [C]l [C]a [C]r [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
fibrosis [C]f [C]i [C]b [C]r [C]o [C]s [C]i [C]s O 
were [C]w [C]e [C]r [C]e O 
unrelated [C]u [C]n [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
or [C]o [C]r O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
oestrogen [C]o [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
. [C]. O 

By [C]B [C]y O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
neither [C]n [C]e [C]i [C]t [C]h [C]e [C]r O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
or [C]o [C]r O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
nor [C]n [C]o [C]r O 
the [C]t [C]h [C]e O 
value [C]v [C]a [C]l [C]u [C]e O 
of [C]o [C]f O 
RPc [C]R [C]P [C]c S-protein 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
related [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
to [C]t [C]o O 
cellularity [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r [C]i [C]t [C]y O 
or [C]o [C]r O 
fibrosis [C]f [C]i [C]b [C]r [C]o [C]s [C]i [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
value [C]v [C]a [C]l [C]u [C]e O 
of [C]o [C]f O 
REc [C]R [C]E [C]c S-protein 
and [C]a [C]n [C]d O 
RPc [C]R [C]P [C]c S-protein 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
as [C]a [C]s O 
an [C]a [C]n O 
indicator [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]o [C]r O 
of [C]o [C]f O 
prognosis [C]p [C]r [C]o [C]g [C]n [C]o [C]s [C]i [C]s O 
was [C]w [C]a [C]s O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
in [C]i [C]n O 
a [C]a O 
sub-group [C]s [C]u [C]b [C]- [C]g [C]r [C]o [C]u [C]p O 
of [C]o [C]f O 
175 [C]1 [C]7 [C]5 O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
receiving [C]r [C]e [C]c [C]e [C]i [C]v [C]i [C]n [C]g O 
no [C]n [C]o O 
additional [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n [C]a [C]l O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
mastectomy [C]m [C]a [C]s [C]t [C]e [C]c [C]t [C]o [C]m [C]y O 
. [C]. O 

Overall [C]O [C]v [C]e [C]r [C]a [C]l [C]l O 
relapse-free [C]r [C]e [C]l [C]a [C]p [C]s [C]e [C]- [C]f [C]r [C]e [C]e O 
survival [C]s [C]u [C]r [C]v [C]i [C]v [C]a [C]l O 
( [C]( O 
RFS [C]R [C]F [C]S O 
) [C]) O 
was [C]w [C]a [C]s O 
no [C]n [C]o O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
for [C]f [C]o [C]r O 
those [C]t [C]h [C]o [C]s [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
those [C]t [C]h [C]o [C]s [C]e O 
without [C]w [C]i [C]t [C]h [C]o [C]u [C]t O 
them [C]t [C]h [C]e [C]m O 
( [C]( O 
REc [C]R [C]E [C]c S-protein 
P [C]P O 
= [C]= O 
0.11 [C]0 [C]. [C]1 [C]1 O 
, [C], O 
RPc [C]R [C]P [C]c O 
P [C]P O 
= [C]= O 
0.7 [C]0 [C]. [C]7 O 
) [C]) O 
. [C]. O 

There [C]T [C]h [C]e [C]r [C]e O 
was [C]w [C]a [C]s O 
no [C]n [C]o O 
difference [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e O 
in [C]i [C]n O 
RFS [C]R [C]F [C]S O 
of [C]o [C]f O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
and [C]a [C]n [C]d O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
tumours [C]t [C]u [C]m [C]o [C]u [C]r [C]s O 
when [C]w [C]h [C]e [C]n O 
the [C]t [C]h [C]e O 
axillary [C]a [C]x [C]i [C]l [C]l [C]a [C]r [C]y O 
node [C]n [C]o [C]d [C]e O 
status [C]s [C]t [C]a [C]t [C]u [C]s O 
was [C]w [C]a [C]s O 
taken [C]t [C]a [C]k [C]e [C]n O 
into [C]i [C]n [C]t [C]o O 
account [C]a [C]c [C]c [C]o [C]u [C]n [C]t O 
. [C]. O 

Clinical [C]C [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
implications [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
. [C]. O 

Normal [C]N [C]o [C]r [C]m [C]a [C]l B-cell_type 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
contain [C]c [C]o [C]n [C]t [C]a [C]i [C]n O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
. [C]. O 

A [C]A O 
variety [C]v [C]a [C]r [C]i [C]e [C]t [C]y O 
of [C]o [C]f O 
stimuli [C]s [C]t [C]i [C]m [C]u [C]l [C]i O 
that [C]t [C]h [C]a [C]t O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
these [C]t [C]h [C]e [C]s [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
also [C]a [C]l [C]s [C]o O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
increases [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
in [C]i [C]n O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Similar [C]S [C]i [C]m [C]i [C]l [C]a [C]r O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
can [C]c [C]a [C]n O 
be [C]b [C]e O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
in [C]i [C]n O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
acute [C]a [C]c [C]u [C]t [C]e O 
lymphoblastic [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
( [C]( O 
ALL [C]A [C]L [C]L O 
) [C]) O 
. [C]. O 

Absence [C]A [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
( [C]( O 
usually [C]u [C]s [C]u [C]a [C]l [C]l [C]y O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
) [C]) O 
predicts [C]p [C]r [C]e [C]d [C]i [C]c [C]t [C]s O 
lack [C]l [C]a [C]c [C]k O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
responsiveness [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e [C]n [C]e [C]s [C]s O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
in [C]i [C]n O 
our [C]o [C]u [C]r O 
hands [C]h [C]a [C]n [C]d [C]s O 
, [C], O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
correlate [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
duration [C]d [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
complete [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e O 
remission [C]r [C]e [C]m [C]i [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
ALL [C]A [C]L [C]L O 
( [C]( O 
though [C]t [C]h [C]o [C]u [C]g [C]h O 
not [C]n [C]o [C]t O 
in [C]i [C]n O 
other [C]o [C]t [C]h [C]e [C]r O 
forms [C]f [C]o [C]r [C]m [C]s O 
of [C]o [C]f O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
) [C]) O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
association [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
of [C]o [C]f O 
cell [C]c [C]e [C]l [C]l O 
type [C]t [C]y [C]p [C]e O 
, [C], O 
age [C]a [C]g [C]e O 
, [C], O 
sex [C]s [C]e [C]x O 
, [C], O 
or [C]o [C]r O 
initial [C]i [C]n [C]i [C]t [C]i [C]a [C]l O 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e S-cell_type 
count [C]c [C]o [C]u [C]n [C]t O 
. [C]. O 

The [C]T [C]h [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
shows [C]s [C]h [C]o [C]w [C]s O 
a [C]a O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
increasing [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]i [C]n [C]g O 
aggressiveness [C]a [C]g [C]g [C]r [C]e [C]s [C]s [C]i [C]v [C]e [C]n [C]e [C]s [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
tumor [C]t [C]u [C]m [C]o [C]r O 
( [C]( O 
null-cell [C]n [C]u [C]l [C]l [C]- [C]c [C]e [C]l [C]l O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
greater [C]g [C]r [C]e [C]a [C]t [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
greater [C]g [C]r [C]e [C]a [C]t [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
Burkitt [C]B [C]u [C]r [C]k [C]i [C]t [C]t O 
's [C]' [C]s O 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a O 
) [C]) O 
. [C]. O 

Corticosteroid-mediated [C]C [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
immunoregulation [C]i [C]m [C]m [C]u [C]n [C]o [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
man [C]m [C]a [C]n O 
. [C]. O 

Glucocorticoids [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
have [C]h [C]a [C]v [C]e O 
profound [C]p [C]r [C]o [C]f [C]o [C]u [C]n [C]d O 
and [C]a [C]n [C]d O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
the [C]t [C]h [C]e O 
precise [C]p [C]r [C]e [C]c [C]i [C]s [C]e O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
corticosteroid-induced [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
immunoregulation [C]i [C]m [C]m [C]u [C]n [C]o [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
man [C]m [C]a [C]n O 
have [C]h [C]a [C]v [C]e O 
not [C]n [C]o [C]t O 
been [C]b [C]e [C]e [C]n O 
precisely [C]p [C]r [C]e [C]c [C]i [C]s [C]e [C]l [C]y O 
defined [C]d [C]e [C]f [C]i [C]n [C]e [C]d O 
. [C]. O 

Intracytoplasmic [C]I [C]n [C]t [C]r [C]a [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c B-protein 
corticosteroid-specific [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
appear [C]a [C]p [C]p [C]e [C]a [C]r O 
to [C]t [C]o O 
be [C]b [C]e O 
an [C]a [C]n O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
common [C]c [C]o [C]m [C]m [C]o [C]n O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
for [C]f [C]o [C]r O 
steroid-induced [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
, [C], O 
but [C]b [C]u [C]t O 
variations [C]v [C]a [C]r [C]i [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
parameters [C]p [C]a [C]r [C]a [C]m [C]e [C]t [C]e [C]r [C]s O 
do [C]d [C]o O 
not [C]n [C]o [C]t O 
account [C]a [C]c [C]c [C]o [C]u [C]n [C]t O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
multifaceted [C]m [C]u [C]l [C]t [C]i [C]f [C]a [C]c [C]e [C]t [C]e [C]d O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
. [C]. O 

Human [C]H [C]u [C]m [C]a [C]n B-cell_type 
circulating [C]c [C]i [C]r [C]c [C]u [C]l [C]a [C]t [C]i [C]n [C]g I-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
redistribute [C]r [C]e [C]d [C]i [C]s [C]t [C]r [C]i [C]b [C]u [C]t [C]e O 
out [C]o [C]u [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
intravascular [C]i [C]n [C]t [C]r [C]a [C]v [C]a [C]s [C]c [C]u [C]l [C]a [C]r O 
compartment [C]c [C]o [C]m [C]p [C]a [C]r [C]t [C]m [C]e [C]n [C]t O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
corticosteroids [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]s O 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
certain [C]c [C]e [C]r [C]t [C]a [C]i [C]n O 
components [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t [C]s O 
at [C]a [C]t O 
this [C]t [C]h [C]i [C]s O 
redistribution [C]r [C]e [C]d [C]i [C]s [C]t [C]r [C]i [C]b [C]u [C]t [C]i [C]o [C]n O 
phenomenon [C]p [C]h [C]e [C]n [C]o [C]m [C]e [C]n [C]o [C]n O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
well-characterized [C]w [C]e [C]l [C]l [C]- [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]d O 
, [C], O 
the [C]t [C]h [C]e O 
importance [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]c [C]e O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
compartmental [C]c [C]o [C]m [C]p [C]a [C]r [C]t [C]m [C]e [C]n [C]t [C]a [C]l O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
shift [C]s [C]h [C]i [C]f [C]t O 
with [C]w [C]i [C]t [C]h O 
respect [C]r [C]e [C]s [C]p [C]e [C]c [C]t O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
of [C]o [C]f O 
corticosteroid-induced [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
immunoregulation [C]i [C]m [C]m [C]u [C]n [C]o [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
are [C]a [C]r [C]e O 
less [C]l [C]e [C]s [C]s O 
well-defined [C]w [C]e [C]l [C]l [C]- [C]d [C]e [C]f [C]i [C]n [C]e [C]d O 
. [C]. O 

Recent [C]R [C]e [C]c [C]e [C]n [C]t O 
observations [C]o [C]b [C]s [C]e [C]r [C]v [C]a [C]t [C]i [C]o [C]n [C]s O 
that [C]t [C]h [C]a [C]t O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
sensitive [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
lytic [C]l [C]y [C]t [C]i [C]c O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
under [C]u [C]n [C]d [C]e [C]r O 
certain [C]c [C]e [C]r [C]t [C]a [C]i [C]n O 
situations [C]s [C]i [C]t [C]u [C]a [C]t [C]i [C]o [C]n [C]s O 
the [C]t [C]h [C]e O 
elimination [C]e [C]l [C]i [C]m [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
selected [C]s [C]e [C]l [C]e [C]c [C]t [C]e [C]d O 
subsets [C]s [C]u [C]b [C]s [C]e [C]t [C]s O 
of [C]o [C]f O 
cells [C]c [C]e [C]l [C]l [C]s O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
a [C]a O 
relevant [C]r [C]e [C]l [C]e [C]v [C]a [C]n [C]t O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
of [C]o [C]f O 
corticosteroid-mediated [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
immunoregulation [C]i [C]m [C]m [C]u [C]n [C]o [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
man [C]m [C]a [C]n O 
. [C]. O 

Corticosteroid-mediated [C]C [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
on [C]o [C]n O 
monocyte [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e S-cell_type 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
an [C]a [C]n O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
of [C]o [C]f O 
drug-induced [C]d [C]r [C]u [C]g [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d B-cell_type 
immunoregulation [C]i [C]m [C]m [C]u [C]n [C]o [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n E-cell_type 
in [C]i [C]n O 
monocyte-dependent [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t B-cell_type 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s E-cell_type 
. [C]. O 

In [C]I [C]n O 
some [C]s [C]o [C]m [C]e O 
experimental [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]a [C]l O 
conditions [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n [C]s O 
, [C], O 
corticosteroids [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]s O 
inhibit [C]i [C]n [C]h [C]i [C]b [C]i [C]t O 
Interleukin [C]I [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n B-protein 
1 [C]1 E-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
immunoregulatory [C]i [C]m [C]m [C]u [C]n [C]o [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
corticosteroids [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]s O 
on [C]o [C]n O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e S-cell_type 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
are [C]a [C]r [C]e O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
. [C]. O 

In [C]I [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
corticosteroids [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]s O 
appear [C]a [C]p [C]p [C]e [C]a [C]r O 
to [C]t [C]o O 
selectively [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
affect [C]a [C]f [C]f [C]e [C]c [C]t O 
early [C]e [C]a [C]r [C]l [C]y O 
immunoregulatory [C]i [C]m [C]m [C]u [C]n [C]o [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
events [C]e [C]v [C]e [C]n [C]t [C]s O 
as [C]a [C]s O 
opposed [C]o [C]p [C]p [C]o [C]s [C]e [C]d O 
to [C]t [C]o O 
altering [C]a [C]l [C]t [C]e [C]r [C]i [C]n [C]g O 
an [C]a [C]n O 
established [C]e [C]s [C]t [C]a [C]b [C]l [C]i [C]s [C]h [C]e [C]d O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
. [C]. O 

Multiple [C]M [C]u [C]l [C]t [C]i [C]p [C]l [C]e O 
sites [C]s [C]i [C]t [C]e [C]s O 
of [C]o [C]f O 
steroid-induced [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
modulations [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
B [C]B I-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
defined [C]d [C]e [C]f [C]i [C]n [C]e [C]d O 
. [C]. O 

Human [C]H [C]u [C]m [C]a [C]n B-cell_line 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
and [C]a [C]n [C]d O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
: [C]: O 
II [C]I [C]I O 
. [C]. O 

Whole [C]W [C]h [C]o [C]l [C]e O 
cell [C]c [C]e [C]l [C]l O 
and [C]a [C]n [C]d O 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
properties [C]p [C]r [C]o [C]p [C]e [C]r [C]t [C]i [C]e [C]s O 
of [C]o [C]f O 
lymphoblastoid [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]o [C]i [C]d B-cell_line 
, [C], I-cell_line 
leukaemia [C]l [C]e [C]u [C]k [C]a [C]e [C]m [C]i [C]a I-cell_line 
and [C]a [C]n [C]d I-cell_line 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
. [C]. O 

The [C]T [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
properties [C]p [C]r [C]o [C]p [C]e [C]r [C]t [C]i [C]e [C]s O 
of [C]o [C]f O 
18 [C]1 [C]8 O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
( [C]( O 
HLCL [C]H [C]L [C]C [C]L S-cell_line 
) [C]) O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
. [C]. O 

The [C]T [C]h [C]e O 
specificity [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]i [C]t [C]y O 
of [C]o [C]f O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
was [C]w [C]a [C]s O 
confirmed [C]c [C]o [C]n [C]f [C]i [C]r [C]m [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
agonists [C]a [C]g [C]o [C]n [C]i [C]s [C]t [C]s O 
and [C]a [C]n [C]d O 
antagonists [C]a [C]n [C]t [C]a [C]g [C]o [C]n [C]i [C]s [C]t [C]s O 
. [C]. O 

A [C]A O 
gradation [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
whole [C]w [C]h [C]o [C]l [C]e O 
cell [C]c [C]e [C]l [C]l O 
and [C]a [C]n [C]d O 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
capacity [C]c [C]a [C]p [C]a [C]c [C]i [C]t [C]y O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
cell [C]c [C]e [C]l [C]l O 
line [C]l [C]i [C]n [C]e O 
types [C]t [C]y [C]p [C]e [C]s O 
: [C]: O 
lymphoblastoid [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]o [C]i [C]d S-cell_line 
greater [C]g [C]r [C]e [C]a [C]t [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a S-cell_line 
greater [C]g [C]r [C]e [C]a [C]t [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
leukaemia [C]l [C]e [C]u [C]k [C]a [C]e [C]m [C]i [C]a S-cell_line 
. [C]. O 

The [C]T [C]h [C]e O 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
of [C]o [C]f O 
leukaemia [C]l [C]e [C]u [C]k [C]a [C]e [C]m [C]i [C]a B-cell_line 
and [C]a [C]n [C]d I-cell_line 
lymphoblastoid [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]o [C]i [C]d I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
appeared [C]a [C]p [C]p [C]e [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
contain [C]c [C]o [C]n [C]t [C]a [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
proteinaceous [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]a [C]c [C]e [C]o [C]u [C]s O 
and [C]a [C]n [C]d O 
phospholipid [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]l [C]i [C]p [C]i [C]d O 
components [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t [C]s O 
. [C]. O 

Cytoplasmic [C]C [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c B-protein 
steroid-receptor [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
exhibited [C]e [C]x [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
a [C]a O 
wide [C]w [C]i [C]d [C]e O 
range [C]r [C]a [C]n [C]g [C]e O 
of [C]o [C]f O 
sedimentation [C]s [C]e [C]d [C]i [C]m [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
coefficients [C]c [C]o [C]e [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t [C]s O 
( [C]( O 
8.5-11.3S [C]8 [C]. [C]5 [C]- [C]1 [C]1 [C]. [C]3 [C]S O 
) [C]) O 
in [C]i [C]n O 
low [C]l [C]o [C]w O 
ionic [C]i [C]o [C]n [C]i [C]c O 
strength [C]s [C]t [C]r [C]e [C]n [C]g [C]t [C]h O 
buffer [C]b [C]u [C]f [C]f [C]e [C]r O 
but [C]b [C]u [C]t O 
there [C]t [C]h [C]e [C]r [C]e O 
was [C]w [C]a [C]s O 
no [C]n [C]o O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
cell [C]c [C]e [C]l [C]l O 
line [C]l [C]i [C]n [C]e O 
type [C]t [C]y [C]p [C]e O 
or [C]o [C]r O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

Activation [C]A [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s O 
by [C]b [C]y O 
heat [C]h [C]e [C]a [C]t O 
( [C]( O 
37 [C]3 [C]7 O 
degrees [C]d [C]e [C]g [C]r [C]e [C]e [C]s O 
C [C]C O 
) [C]) O 
or [C]o [C]r O 
exposure [C]e [C]x [C]p [C]o [C]s [C]u [C]r [C]e O 
to [C]t [C]o O 
high [C]h [C]i [C]g [C]h O 
ionic [C]i [C]o [C]n [C]i [C]c O 
strength [C]s [C]t [C]r [C]e [C]n [C]g [C]t [C]h O 
buffer [C]b [C]u [C]f [C]f [C]e [C]r O 
( [C]( O 
0.3 [C]0 [C]. [C]3 O 
M [C]M O 
NaCl [C]N [C]a [C]C [C]l O 
) [C]) O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
but [C]b [C]u [C]t O 
only [C]o [C]n [C]l [C]y O 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s O 
in [C]i [C]n O 
high [C]h [C]i [C]g [C]h O 
ionic [C]i [C]o [C]n [C]i [C]c O 
strength [C]s [C]t [C]r [C]e [C]n [C]g [C]t [C]h O 
buffer [C]b [C]u [C]f [C]f [C]e [C]r O 
manifested [C]m [C]a [C]n [C]i [C]f [C]e [C]s [C]t [C]e [C]d O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
in [C]i [C]n O 
sedimentation [C]s [C]e [C]d [C]i [C]m [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
coefficient [C]c [C]o [C]e [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
. [C]. O 

No [C]N [C]o O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
or [C]o [C]r O 
nature [C]n [C]a [C]t [C]u [C]r [C]e O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
cytolethal [C]c [C]y [C]t [C]o [C]l [C]e [C]t [C]h [C]a [C]l O 
or [C]o [C]r O 
cytostatic [C]c [C]y [C]t [C]o [C]s [C]t [C]a [C]t [C]i [C]c O 
responsiveness [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e [C]n [C]e [C]s [C]s O 
of [C]o [C]f O 
HLCL [C]H [C]L [C]C [C]L S-cell_line 
to [C]t [C]o O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
. [C]. O 

The [C]T [C]h [C]e O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
to [C]t [C]o O 
cytolethal [C]c [C]y [C]t [C]o [C]l [C]e [C]t [C]h [C]a [C]l O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
can [C]c [C]a [C]n O 
not [C]n [C]o [C]t O 
be [C]b [C]e O 
ascribed [C]a [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
to [C]t [C]o O 
a [C]a O 
failure [C]f [C]a [C]i [C]l [C]u [C]r [C]e O 
of [C]o [C]f O 
cells [C]c [C]e [C]l [C]l [C]s O 
to [C]t [C]o O 
take [C]t [C]a [C]k [C]e O 
up [C]u [C]p O 
and [C]a [C]n [C]d O 
bind [C]b [C]i [C]n [C]d O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
or [C]o [C]r O 
to [C]t [C]o O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
differences [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
species [C]s [C]p [C]e [C]c [C]i [C]e [C]s O 
of [C]o [C]f O 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
. [C]. O 

The [C]T [C]h [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
by [C]b [C]y O 
which [C]w [C]h [C]i [C]c [C]h O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
achieve [C]a [C]c [C]h [C]i [C]e [C]v [C]e O 
cytolethal [C]c [C]y [C]t [C]o [C]l [C]e [C]t [C]h [C]a [C]l O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 

CD28 [C]C [C]D [C]2 [C]8 S-protein 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
CD45RA+ [C]C [C]D [C]4 [C]5 [C]R [C]A [C]+ B-cell_type 
and [C]a [C]n [C]d I-cell_type 
CD45RO+ [C]C [C]D [C]4 [C]5 [C]R [C]O [C]+ I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
: [C]: O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
reactive [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]e O 
oxygen [C]o [C]x [C]y [C]g [C]e [C]n O 
intermediates [C]i [C]n [C]t [C]e [C]r [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]s O 
and [C]a [C]n [C]d O 
c-Rel [C]c [C]- [C]R [C]e [C]l S-protein 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
translocation [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
CD45RA+ [C]C [C]D [C]4 [C]5 [C]R [C]A [C]+ B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
the [C]t [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
complete [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
( [C]( O 
anti-CD3 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]3 S-protein 
plus [C]p [C]l [C]u [C]s O 
anti-CD28 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]2 [C]8 S-protein 
) [C]) O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
in [C]i [C]n O 
CD45RA+ [C]C [C]D [C]4 [C]5 [C]R [C]A [C]+ B-cell_type 
( [C]( I-cell_type 
naive [C]n [C]a [C]i [C]v [C]e I-cell_type 
) [C]) I-cell_type 
and [C]a [C]n [C]d I-cell_type 
CD45RO+ [C]C [C]D [C]4 [C]5 [C]R [C]O [C]+ I-cell_type 
( [C]( I-cell_type 
memory/effector [C]m [C]e [C]m [C]o [C]r [C]y [C]/ [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r I-cell_type 
) [C]) I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Long [C]L [C]o [C]n [C]g O 
exposure [C]e [C]x [C]p [C]o [C]s [C]u [C]r [C]e O 
( [C]( O 
24 [C]2 [C]4 O 
h [C]h O 
) [C]) O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
stronger [C]s [C]t [C]r [C]o [C]n [C]g [C]e [C]r O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
in [C]i [C]n O 
CD45RA+ [C]C [C]D [C]4 [C]5 [C]R [C]A [C]+ B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
than [C]t [C]h [C]a [C]n O 
in [C]i [C]n O 
CD45RO+ [C]C [C]D [C]4 [C]5 [C]R [C]O [C]+ B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Analysis [C]A [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
c-Rel [C]c [C]- [C]R [C]e [C]l I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
indicated [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
after [C]a [C]f [C]t [C]e [C]r O 
anti-CD3+anti-CD28 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]3 [C]+ [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]2 [C]8 O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
the [C]t [C]h [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
c-Rel [C]c [C]- [C]R [C]e [C]l S-protein 
was [C]w [C]a [C]s O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
in [C]i [C]n O 
CD45RA+ [C]C [C]D [C]4 [C]5 [C]R [C]A [C]+ B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Analysis [C]A [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
IkappaBalpha [C]I [C]k [C]a [C]p [C]p [C]a [C]B [C]a [C]l [C]p [C]h [C]a S-protein 
indicated [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
anti-CD3+anti-CD28 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]3 [C]+ [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]2 [C]8 O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
a [C]a O 
long-lasting [C]l [C]o [C]n [C]g [C]- [C]l [C]a [C]s [C]t [C]i [C]n [C]g O 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
CD45RA+ [C]C [C]D [C]4 [C]5 [C]R [C]A [C]+ B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
but [C]b [C]u [C]t O 
in [C]i [C]n O 
CD45RO+ [C]C [C]D [C]4 [C]5 [C]R [C]O [C]+ B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
the [C]t [C]h [C]e O 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
was [C]w [C]a [C]s O 
more [C]m [C]o [C]r [C]e O 
rapid [C]r [C]a [C]p [C]i [C]d O 
. [C]. O 

Because [C]B [C]e [C]c [C]a [C]u [C]s [C]e O 
the [C]t [C]h [C]e O 
CD28 [C]C [C]D [C]2 [C]8 O 
costimulus [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]u [C]s O 
is [C]i [C]s O 
known [C]k [C]n [C]o [C]w [C]n O 
to [C]t [C]o O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
the [C]t [C]h [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
reactive [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]e O 
oxygen [C]o [C]x [C]y [C]g [C]e [C]n O 
intermediates [C]i [C]n [C]t [C]e [C]r [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]s O 
( [C]( O 
ROIs [C]R [C]O [C]I [C]s O 
) [C]) O 
, [C], O 
the [C]t [C]h [C]e O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
ROI [C]R [C]O [C]I O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
in [C]i [C]n O 
CD45RA+ [C]C [C]D [C]4 [C]5 [C]R [C]A [C]+ B-cell_type 
and [C]a [C]n [C]d I-cell_type 
CD45RO+ [C]C [C]D [C]4 [C]5 [C]R [C]O [C]+ I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
by [C]b [C]y O 
flow [C]f [C]l [C]o [C]w O 
cytometry [C]c [C]y [C]t [C]o [C]m [C]e [C]t [C]r [C]y O 
. [C]. O 

ROIs [C]R [C]O [C]I [C]s O 
were [C]w [C]e [C]r [C]e O 
produced [C]p [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
cell [C]c [C]e [C]l [C]l O 
types [C]t [C]y [C]p [C]e [C]s O 
, [C], O 
but [C]b [C]u [C]t O 
more [C]m [C]o [C]r [C]e O 
strongly [C]s [C]t [C]r [C]o [C]n [C]g [C]l [C]y O 
in [C]i [C]n O 
CD45RA+ [C]C [C]D [C]4 [C]5 [C]R [C]A [C]+ B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
data [C]d [C]a [C]t [C]a O 
presented [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]e [C]d O 
in [C]i [C]n O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
emphasize [C]e [C]m [C]p [C]h [C]a [C]s [C]i [C]z [C]e O 
the [C]t [C]h [C]e O 
differences [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e [C]s O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
CD45RA+ [C]C [C]D [C]4 [C]5 [C]R [C]A [C]+ B-cell_type 
and [C]a [C]n [C]d I-cell_type 
CD45RO+ [C]C [C]D [C]4 [C]5 [C]R [C]O [C]+ I-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
in [C]i [C]n O 
ROI-dependent [C]R [C]O [C]I [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
. [C]. O 

Ikaros [C]I [C]k [C]a [C]r [C]o [C]s S-protein 
in [C]i [C]n O 
hemopoietic [C]h [C]e [C]m [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c B-cell_line 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e E-cell_line 
determination [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
homeostasis [C]h [C]o [C]m [C]e [C]o [C]s [C]t [C]a [C]s [C]i [C]s O 
. [C]. O 

Studies [C]S [C]t [C]u [C]d [C]i [C]e [C]s O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
that [C]t [C]h [C]a [C]t O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
hemopoietic [C]h [C]e [C]m [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
have [C]h [C]a [C]v [C]e O 
focused [C]f [C]o [C]c [C]u [C]s [C]e [C]d O 
on [C]o [C]n O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
cascades [C]c [C]a [C]s [C]c [C]a [C]d [C]e [C]s O 
and [C]a [C]n [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
effectors [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r [C]s O 
that [C]t [C]h [C]a [C]t O 
drive [C]d [C]r [C]i [C]v [C]e O 
this [C]t [C]h [C]i [C]s O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
developmental [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t [C]a [C]l O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
in [C]i [C]n O 
a [C]a O 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
fashion [C]f [C]a [C]s [C]h [C]i [C]o [C]n O 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
we [C]w [C]e O 
review [C]r [C]e [C]v [C]i [C]e [C]w O 
the [C]t [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
Ikaros [C]I [C]k [C]a [C]r [C]o [C]s S-protein 
, [C], O 
the [C]t [C]h [C]e O 
founding [C]f [C]o [C]u [C]n [C]d [C]i [C]n [C]g O 
member [C]m [C]e [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
a [C]a O 
unique [C]u [C]n [C]i [C]q [C]u [C]e O 
family [C]f [C]a [C]m [C]i [C]l [C]y O 
of [C]o [C]f O 
zinc [C]z [C]i [C]n [C]c B-protein 
finger [C]f [C]i [C]n [C]g [C]e [C]r I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
this [C]t [C]h [C]i [C]s O 
developmental [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t [C]a [C]l O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
. [C]. O 

Studies [C]S [C]t [C]u [C]d [C]i [C]e [C]s O 
on [C]o [C]n O 
an [C]a [C]n O 
Ikaros [C]I [C]k [C]a [C]r [C]o [C]s S-protein 
null [C]n [C]u [C]l [C]l O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
have [C]h [C]a [C]v [C]e O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
an [C]a [C]n O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
role [C]r [C]o [C]l [C]e O 
for [C]f [C]o [C]r O 
this [C]t [C]h [C]i [C]s O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
in [C]i [C]n O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
fate [C]f [C]a [C]t [C]e O 
determination [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
at [C]a [C]t O 
subsequent [C]s [C]u [C]b [C]s [C]e [C]q [C]u [C]e [C]n [C]t O 
branch [C]b [C]r [C]a [C]n [C]c [C]h O 
points [C]p [C]o [C]i [C]n [C]t [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
. [C]. O 

Differences [C]D [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
phenotypes [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e [C]s O 
of [C]o [C]f O 
a [C]a O 
null [C]n [C]u [C]l [C]l O 
and [C]a [C]n [C]d O 
a [C]a O 
dominant [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
( [C]( O 
DN [C]D [C]N O 
) [C]) O 
Ikaros [C]I [C]k [C]a [C]r [C]o [C]s O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
provide [C]p [C]r [C]o [C]v [C]i [C]d [C]e O 
insight [C]i [C]n [C]s [C]i [C]g [C]h [C]t O 
into [C]i [C]n [C]t [C]o O 
a [C]a O 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
network [C]n [C]e [C]t [C]w [C]o [C]r [C]k O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
which [C]w [C]h [C]i [C]c [C]h O 
Ikaros [C]I [C]k [C]a [C]r [C]o [C]s B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
exert [C]e [C]x [C]e [C]r [C]t O 
their [C]t [C]h [C]e [C]i [C]r O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
in [C]i [C]n O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
a [C]a O 
comparative [C]c [C]o [C]m [C]p [C]a [C]r [C]a [C]t [C]i [C]v [C]e O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
hemopoietic [C]h [C]e [C]m [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c B-cell_type 
stem [C]s [C]t [C]e [C]m I-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
and [C]a [C]n [C]d O 
precursor [C]p [C]r [C]e [C]c [C]u [C]r [C]s [C]o [C]r O 
compartment [C]c [C]o [C]m [C]p [C]a [C]r [C]t [C]m [C]e [C]n [C]t O 
resulting [C]r [C]e [C]s [C]u [C]l [C]t [C]i [C]n [C]g O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
two [C]t [C]w [C]o O 
Ikaros [C]I [C]k [C]a [C]r [C]o [C]s S-protein 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
reveals [C]r [C]e [C]v [C]e [C]a [C]l [C]s O 
a [C]a O 
profound [C]p [C]r [C]o [C]f [C]o [C]u [C]n [C]d O 
yet [C]y [C]e [C]t O 
not [C]n [C]o [C]t O 
absolute [C]a [C]b [C]s [C]o [C]l [C]u [C]t [C]e O 
requirement [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]m [C]e [C]n [C]t O 
for [C]f [C]o [C]r O 
Ikaros [C]I [C]k [C]a [C]r [C]o [C]s S-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
populations [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

Overexpression [C]O [C]v [C]e [C]r [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
p65 [C]p [C]6 [C]5 O 
and [C]a [C]n [C]d O 
c-Jun [C]c [C]- [C]J [C]u [C]n O 
substitutes [C]s [C]u [C]b [C]s [C]t [C]i [C]t [C]u [C]t [C]e [C]s O 
for [C]f [C]o [C]r O 
B7-1 [C]B [C]7 [C]- [C]1 O 
costimulation [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
targeting [C]t [C]a [C]r [C]g [C]e [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
CD28RE [C]C [C]D [C]2 [C]8 [C]R [C]E S-DNA 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

The [C]T [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
Rel [C]R [C]e [C]l S-protein 
and [C]a [C]n [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n B-protein 
protein-1 [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]1 E-protein 
( [C]( O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
) [C]) O 
in [C]i [C]n O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
B7-1- [C]B [C]7 [C]- [C]1 [C]- B-cell_type 
and [C]a [C]n [C]d I-cell_type 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e I-cell_type 
function-associated [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]- [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d I-cell_type 
Ag-3 [C]A [C]g [C]- [C]3 I-cell_type 
( [C]( I-cell_type 
LFA. [C]L [C]F [C]A [C]. I-cell_type 
3 [C]3 I-cell_type 
) [C]) I-cell_type 
-costimulated [C]- [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
evaluated [C]e [C]v [C]a [C]l [C]u [C]a [C]t [C]e [C]d O 
. [C]. O 

We [C]W [C]e O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
overexpression [C]o [C]v [C]e [C]r [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
c-Jun [C]c [C]- [C]J [C]u [C]n S-protein 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
c-Fos [C]c [C]- [C]F [C]o [C]s S-protein 
increases [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
B7-1- [C]B [C]7 [C]- [C]1 [C]- B-cell_type 
and [C]a [C]n [C]d I-cell_type 
LFA-3-costimulated [C]L [C]F [C]A [C]- [C]3 [C]- [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d I-cell_type 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Cotransfection [C]C [C]o [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
c-Jun [C]c [C]- [C]J [C]u [C]n O 
and [C]a [C]n [C]d O 
c-Fos [C]c [C]- [C]F [C]o [C]s O 
substitutes [C]s [C]u [C]b [C]s [C]t [C]i [C]t [C]u [C]t [C]e [C]s O 
for [C]f [C]o [C]r O 
B7-1 [C]B [C]7 [C]- [C]1 O 
costimulation [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
driving [C]d [C]r [C]i [C]v [C]i [C]n [C]g O 
an [C]a [C]n O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n B-DNA 
protein-1 [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]1 I-DNA 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e I-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

Overexpression [C]O [C]v [C]e [C]r [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
Rel [C]R [C]e [C]l B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
p65-expressing [C]p [C]6 [C]5 [C]- [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]n [C]g B-cell_line 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
transcribed [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
equally [C]e [C]q [C]u [C]a [C]l [C]l [C]y O 
well [C]w [C]e [C]l [C]l O 
a [C]a O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-DNA 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-DNA 
kappabeta [C]k [C]a [C]p [C]p [C]a [C]b [C]e [C]t [C]a I-DNA 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r I-DNA 
construct [C]c [C]o [C]n [C]s [C]t [C]r [C]u [C]c [C]t E-DNA 
when [C]w [C]h [C]e [C]n O 
costimulated [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
B7-1 [C]B [C]7 [C]- [C]1 S-protein 
or [C]o [C]r O 
LFA-3 [C]L [C]F [C]A [C]- [C]3 S-protein 
, [C], O 
but [C]b [C]u [C]t O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
or [C]o [C]r O 
CD28 [C]C [C]D [C]2 [C]8 B-DNA 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e I-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t I-DNA 
( [C]( I-DNA 
CD28RE [C]C [C]D [C]2 [C]8 [C]R [C]E I-DNA 
) [C]) I-DNA 
-driven [C]- [C]d [C]r [C]i [C]v [C]e [C]n I-DNA 
reporters [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r [C]s E-DNA 
was [C]w [C]a [C]s O 
superior [C]s [C]u [C]p [C]e [C]r [C]i [C]o [C]r O 
in [C]i [C]n O 
B7-1-costimulated [C]B [C]7 [C]- [C]1 [C]- [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

Combined [C]C [C]o [C]m [C]b [C]i [C]n [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
c-Jun [C]c [C]- [C]J [C]u [C]n S-protein 
and [C]a [C]n [C]d O 
p65 [C]p [C]6 [C]5 S-protein 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
vigorous [C]v [C]i [C]g [C]o [C]r [C]o [C]u [C]s O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter- [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]- I-DNA 
and [C]a [C]n [C]d I-DNA 
CD28RE-driven [C]C [C]D [C]2 [C]8 [C]R [C]E [C]- [C]d [C]r [C]i [C]v [C]e [C]n I-DNA 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r I-DNA 
constructs [C]c [C]o [C]n [C]s [C]t [C]r [C]u [C]c [C]t [C]s E-DNA 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
LFA-3- [C]L [C]F [C]A [C]- [C]3 [C]- B-cell_type 
and [C]a [C]n [C]d I-cell_type 
B7-1-costimulated [C]B [C]7 [C]- [C]1 [C]- [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d I-cell_type 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Mutating [C]M [C]u [C]t [C]a [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
CD28RE [C]C [C]D [C]2 [C]8 [C]R [C]E S-DNA 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
the [C]t [C]h [C]e O 
upstream [C]u [C]p [C]s [C]t [C]r [C]e [C]a [C]m B-DNA 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-DNA 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-DNA 
kappabeta-binding [C]k [C]a [C]p [C]p [C]a [C]b [C]e [C]t [C]a [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
B7-1 [C]B [C]7 [C]- [C]1 S-protein 
-driven [C]- [C]d [C]r [C]i [C]v [C]e [C]n O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
> [C]> O 
90 [C]9 [C]0 O 
% [C]% O 
. [C]. O 

The [C]T [C]h [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
implicates [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]e [C]s O 
a [C]a O 
major [C]m [C]a [C]j [C]o [C]r O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
CD28RE [C]C [C]D [C]2 [C]8 [C]R [C]E S-DNA 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
integration [C]i [C]n [C]t [C]e [C]g [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
p65 [C]p [C]6 [C]5 S-protein 
/ [C]/ O 
c-Jun [C]c [C]- [C]J [C]u [C]n S-protein 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

We [C]W [C]e O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
transition [C]t [C]r [C]a [C]n [C]s [C]i [C]t [C]i [C]o [C]n O 
from [C]f [C]r [C]o [C]m O 
an [C]a [C]n O 
autocrine [C]a [C]u [C]t [C]o [C]c [C]r [C]i [C]n [C]e O 
LFA-3 [C]L [C]F [C]A [C]- [C]3 S-protein 
-driven [C]- [C]d [C]r [C]i [C]v [C]e [C]n O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
a [C]a O 
B7 [C]B [C]7 O 
-- [C]- [C]- O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
paracrine [C]p [C]a [C]r [C]a [C]c [C]r [C]i [C]n [C]e O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
involves [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]s O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
c-Jun [C]c [C]- [C]J [C]u [C]n S-protein 
and [C]a [C]n [C]d O 
p65 [C]p [C]6 [C]5 S-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
the [C]t [C]h [C]e O 
CD28RE [C]C [C]D [C]2 [C]8 [C]R [C]E S-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

Defects [C]D [C]e [C]f [C]e [C]c [C]t [C]s O 
in [C]i [C]n O 
actin-cap [C]a [C]c [C]t [C]i [C]n [C]- [C]c [C]a [C]p O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
Vav-deficient [C]V [C]a [C]v [C]- [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
mice [C]m [C]i [C]c [C]e O 
implicate [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]e O 
an [C]a [C]n O 
actin [C]a [C]c [C]t [C]i [C]n O 
requirement [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]m [C]e [C]n [C]t O 
for [C]f [C]o [C]r O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

BACKGROUND [C]B [C]A [C]C [C]K [C]G [C]R [C]O [C]U [C]N [C]D O 
: [C]: O 
Antigen-receptor [C]A [C]n [C]t [C]i [C]g [C]e [C]n [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
interactions [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
on [C]o [C]n O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
result [C]r [C]e [C]s [C]u [C]l [C]t O 
in [C]i [C]n O 
local [C]l [C]o [C]c [C]a [C]l O 
clustering [C]c [C]l [C]u [C]s [C]t [C]e [C]r [C]i [C]n [C]g O 
of [C]o [C]f O 
actin [C]a [C]c [C]t [C]i [C]n S-protein 
, [C], O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
and [C]a [C]n [C]d O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
molecules [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]s O 
into [C]i [C]n [C]t [C]o O 
an [C]a [C]n O 
asymmetric [C]a [C]s [C]y [C]m [C]m [C]e [C]t [C]r [C]i [C]c O 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
structure [C]s [C]t [C]r [C]u [C]c [C]t [C]u [C]r [C]e O 
termed [C]t [C]e [C]r [C]m [C]e [C]d O 
a [C]a O 
cap [C]c [C]a [C]p O 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
actin [C]a [C]c [C]t [C]i [C]n O 
polymerization [C]p [C]o [C]l [C]y [C]m [C]e [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
known [C]k [C]n [C]o [C]w [C]n O 
to [C]t [C]o O 
be [C]b [C]e O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
, [C], O 
the [C]t [C]h [C]e O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
underlying [C]u [C]n [C]d [C]e [C]r [C]l [C]y [C]i [C]n [C]g O 
cap [C]c [C]a [C]p O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
are [C]a [C]r [C]e O 
unclear [C]u [C]n [C]c [C]l [C]e [C]a [C]r O 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
the [C]t [C]h [C]e O 
events [C]e [C]v [C]e [C]n [C]t [C]s O 
underlying [C]u [C]n [C]d [C]e [C]r [C]l [C]y [C]i [C]n [C]g O 
cap [C]c [C]a [C]p O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
using [C]u [C]s [C]i [C]n [C]g O 
mice [C]m [C]i [C]c [C]e O 
bearing [C]b [C]e [C]a [C]r [C]i [C]n [C]g O 
a [C]a O 
null [C]n [C]u [C]l [C]l O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
vav [C]v [C]a [C]v S-DNA 
( [C]( O 
vav [C]v [C]a [C]v S-DNA 
-/- [C]- [C]/ [C]- O 
) [C]) O 
, [C], O 
a [C]a O 
gene [C]g [C]e [C]n [C]e O 
that [C]t [C]h [C]a [C]t O 
encodes [C]e [C]n [C]c [C]o [C]d [C]e [C]s O 
a [C]a O 
guanine-nucleotide [C]g [C]u [C]a [C]n [C]i [C]n [C]e [C]- [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e B-protein 
exchange [C]e [C]x [C]c [C]h [C]a [C]n [C]g [C]e I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
GTPase [C]G [C]T [C]P [C]a [C]s [C]e B-protein 
Rac [C]R [C]a [C]c E-protein 
. [C]. O 

RESULTS [C]R [C]E [C]S [C]U [C]L [C]T [C]S O 
: [C]: O 
Lymphocytes [C]L [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
from [C]f [C]r [C]o [C]m O 
vav [C]v [C]a [C]v S-DNA 
-/- [C]- [C]/ [C]- O 
mice [C]m [C]i [C]c [C]e O 
failed [C]f [C]a [C]i [C]l [C]e [C]d O 
to [C]t [C]o O 
form [C]f [C]o [C]r [C]m O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
caps [C]c [C]a [C]p [C]s O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
had [C]h [C]a [C]d O 
a [C]a O 
defective [C]d [C]e [C]f [C]e [C]c [C]t [C]i [C]v [C]e O 
actin [C]a [C]c [C]t [C]i [C]n O 
cytoskeleton [C]c [C]y [C]t [C]o [C]s [C]k [C]e [C]l [C]e [C]t [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
vav-/- [C]v [C]a [C]v [C]- [C]/ [C]- B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
deficient [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
in [C]i [C]n O 
interleukin-2 [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]2 O 
( [C]( O 
IL-2 [C]I [C]L [C]- [C]2 O 
) [C]) O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
peak [C]p [C]e [C]a [C]k O 
of [C]o [C]f O 
Ca2+ [C]C [C]a [C]2 [C]+ O 
mobilization [C]m [C]o [C]b [C]i [C]l [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
although [C]a [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
of [C]o [C]f O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
duration [C]d [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Activation [C]A [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Jun [C]J [C]u [C]n B-protein 
N-terminal [C]N [C]- [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
or [C]o [C]r O 
stress-activated [C]s [C]t [C]r [C]e [C]s [C]s [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
( [C]( O 
JNK [C]J [C]N [C]K S-protein 
or [C]o [C]r O 
SAPK [C]S [C]A [C]P [C]K S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
mitogen-activated [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
( [C]( O 
MAPK [C]M [C]A [C]P [C]K S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
NF-ATc1 [C]N [C]F [C]- [C]A [C]T [C]c [C]1 B-DNA 
and [C]a [C]n [C]d I-DNA 
egr-1 [C]e [C]g [C]r [C]- [C]1 I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
was [C]w [C]a [C]s O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
. [C]. O 

Despite [C]D [C]e [C]s [C]p [C]i [C]t [C]e O 
the [C]t [C]h [C]e O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
Ca2+ [C]C [C]a [C]2 [C]+ O 
mobilization [C]m [C]o [C]b [C]i [C]l [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
translocation [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c B-protein 
NF-ATc [C]N [C]F [C]- [C]A [C]T [C]c E-protein 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
nucleus [C]n [C]u [C]c [C]l [C]e [C]u [C]s O 
was [C]w [C]a [C]s O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
, [C], O 
reflecting [C]r [C]e [C]f [C]l [C]e [C]c [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
lower [C]l [C]o [C]w [C]e [C]r O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
Ca2+ [C]C [C]a [C]2 [C]+ O 
in [C]i [C]n O 
vav-/- [C]v [C]a [C]v [C]- [C]/ [C]- B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
still [C]s [C]t [C]i [C]l [C]l O 
sufficient [C]s [C]u [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
to [C]t [C]o O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
calcineurin [C]c [C]a [C]l [C]c [C]i [C]n [C]e [C]u [C]r [C]i [C]n S-protein 
. [C]. O 

Treatment [C]T [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
with [C]w [C]i [C]t [C]h O 
cytochalasin [C]c [C]y [C]t [C]o [C]c [C]h [C]a [C]l [C]a [C]s [C]i [C]n O 
D [C]D O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
blocks [C]b [C]l [C]o [C]c [C]k [C]s O 
actin [C]a [C]c [C]t [C]i [C]n O 
polymerization [C]p [C]o [C]l [C]y [C]m [C]e [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
cap [C]c [C]a [C]p O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
produced [C]p [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
defects [C]d [C]e [C]f [C]e [C]c [C]t [C]s O 
in [C]i [C]n O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
IL-2 [C]I [C]L [C]- [C]2 O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
antigen-receptor [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
were [C]w [C]e [C]r [C]e O 
nearly [C]n [C]e [C]a [C]r [C]l [C]y O 
identical [C]i [C]d [C]e [C]n [C]t [C]i [C]c [C]a [C]l O 
to [C]t [C]o O 
those [C]t [C]h [C]o [C]s [C]e O 
seen [C]s [C]e [C]e [C]n O 
in [C]i [C]n O 
vav-/- [C]v [C]a [C]v [C]- [C]/ [C]- B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

In [C]I [C]n O 
transfection [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
, [C], O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
constitutively [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
Vav [C]V [C]a [C]v S-protein 
or [C]o [C]r O 
Rac [C]R [C]a [C]c S-protein 
could [C]c [C]o [C]u [C]l [C]d O 
complement [C]c [C]o [C]m [C]p [C]l [C]e [C]m [C]e [C]n [C]t O 
constitutively [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
calcineurin [C]c [C]a [C]l [C]c [C]i [C]n [C]e [C]u [C]r [C]i [C]n S-protein 
to [C]t [C]o O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
NF-AT-dependent [C]N [C]F [C]- [C]A [C]T [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
. [C]. O 

CONCLUSIONS [C]C [C]O [C]N [C]C [C]L [C]U [C]S [C]I [C]O [C]N [C]S O 
: [C]: O 
These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
Vav [C]V [C]a [C]v S-protein 
is [C]i [C]s O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
cap [C]c [C]a [C]p O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
the [C]t [C]h [C]e O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
cap [C]c [C]a [C]p O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
IL-2 [C]I [C]L [C]- [C]2 O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
supports [C]s [C]u [C]p [C]p [C]o [C]r [C]t [C]s O 
the [C]t [C]h [C]e O 
hypothesis [C]h [C]y [C]p [C]o [C]t [C]h [C]e [C]s [C]i [C]s O 
that [C]t [C]h [C]a [C]t O 
an [C]a [C]n O 
actin-dependent [C]a [C]c [C]t [C]i [C]n [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
is [C]i [C]s O 
a [C]a O 
source [C]s [C]o [C]u [C]r [C]c [C]e O 
of [C]o [C]f O 
specialized [C]s [C]p [C]e [C]c [C]i [C]a [C]l [C]i [C]z [C]e [C]d O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
. [C]. O 

CD14 [C]C [C]D [C]1 [C]4 S-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
endothelial [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
by [C]b [C]y O 
Bacteroides [C]B [C]a [C]c [C]t [C]e [C]r [C]o [C]i [C]d [C]e [C]s O 
fragilis [C]f [C]r [C]a [C]g [C]i [C]l [C]i [C]s O 
outer [C]o [C]u [C]t [C]e [C]r O 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
. [C]. O 

We [C]W [C]e O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
the [C]t [C]h [C]e O 
capacity [C]c [C]a [C]p [C]a [C]c [C]i [C]t [C]y O 
of [C]o [C]f O 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d O 
Bacteriodes [C]B [C]a [C]c [C]t [C]e [C]r [C]i [C]o [C]d [C]e [C]s O 
fragilis [C]f [C]r [C]a [C]g [C]i [C]l [C]i [C]s O 
outer [C]o [C]u [C]t [C]e [C]r O 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
, [C], O 
B. [C]B [C]. O 
fragilis [C]f [C]r [C]a [C]g [C]i [C]l [C]i [C]s O 
NCTC9343 [C]N [C]C [C]T [C]C [C]9 [C]3 [C]4 [C]3 O 
lipopolysaccharide [C]l [C]i [C]p [C]o [C]p [C]o [C]l [C]y [C]s [C]a [C]c [C]c [C]h [C]a [C]r [C]i [C]d [C]e O 
( [C]( O 
LPS [C]L [C]P [C]S O 
; [C]; O 
endotoxin [C]e [C]n [C]d [C]o [C]t [C]o [C]x [C]i [C]n O 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
B. [C]B [C]. O 
fragilis [C]f [C]r [C]a [C]g [C]i [C]l [C]i [C]s O 
NCTC9343 [C]N [C]C [C]T [C]C [C]9 [C]3 [C]4 [C]3 O 
capsular [C]c [C]a [C]p [C]s [C]u [C]l [C]a [C]r O 
polysaccharides [C]p [C]o [C]l [C]y [C]s [C]a [C]c [C]c [C]h [C]a [C]r [C]i [C]d [C]e [C]s O 
to [C]t [C]o O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
human [C]h [C]u [C]m [C]a [C]n O 
umbilical [C]u [C]m [C]b [C]i [C]l [C]i [C]c [C]a [C]l O 
vein [C]v [C]e [C]i [C]n O 
endothelial [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l O 
cell [C]c [C]e [C]l [C]l O 
( [C]( O 
HUVEC [C]H [C]U [C]V [C]E [C]C O 
) [C]) O 
monolayers [C]m [C]o [C]n [C]o [C]l [C]a [C]y [C]e [C]r [C]s O 
. [C]. O 

To [C]T [C]o O 
assess [C]a [C]s [C]s [C]e [C]s [C]s O 
HUVEC [C]H [C]U [C]V [C]E [C]C O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
E-selectin [C]E [C]- [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]n S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
by [C]b [C]y O 
enzyme-linked [C]e [C]n [C]z [C]y [C]m [C]e [C]- [C]l [C]i [C]n [C]k [C]e [C]d O 
immunosorbent [C]i [C]m [C]m [C]u [C]n [C]o [C]s [C]o [C]r [C]b [C]e [C]n [C]t O 
assay [C]a [C]s [C]s [C]a [C]y O 
( [C]( O 
ELISA [C]E [C]L [C]I [C]S [C]A O 
) [C]) O 
, [C], O 
Northern [C]N [C]o [C]r [C]t [C]h [C]e [C]r [C]n O 
blot [C]b [C]l [C]o [C]t O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
for [C]f [C]o [C]r O 
E-selectin-specific [C]E [C]- [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]n [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
, [C], O 
and [C]a [C]n [C]d O 
electrophoretic [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c O 
gel [C]g [C]e [C]l O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
assay [C]a [C]s [C]s [C]a [C]y O 
( [C]( O 
EMSA [C]E [C]M [C]S [C]A O 
) [C]) O 
for [C]f [C]o [C]r O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
, [C], O 
a [C]a O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
necessary [C]n [C]e [C]c [C]e [C]s [C]s [C]a [C]r [C]y O 
for [C]f [C]o [C]r O 
E-selectin [C]E [C]- [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]n B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Exposure [C]E [C]x [C]p [C]o [C]s [C]u [C]r [C]e O 
of [C]o [C]f O 
HUVECs [C]H [C]U [C]V [C]E [C]C [C]s S-cell_type 
to [C]t [C]o O 
B. [C]B [C]. O 
fragilis [C]f [C]r [C]a [C]g [C]i [C]l [C]i [C]s O 
outer [C]o [C]u [C]t [C]e [C]r O 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
fractions [C]f [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
, [C], O 
separated [C]s [C]e [C]p [C]a [C]r [C]a [C]t [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
other [C]o [C]t [C]h [C]e [C]r O 
components [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
B. [C]B [C]. O 
fragilis [C]f [C]r [C]a [C]g [C]i [C]l [C]i [C]s O 
cell [C]c [C]e [C]l [C]l O 
wall [C]w [C]a [C]l [C]l O 
by [C]b [C]y O 
isopycnic [C]i [C]s [C]o [C]p [C]y [C]c [C]n [C]i [C]c O 
, [C], O 
sucrose [C]s [C]u [C]c [C]r [C]o [C]s [C]e O 
gradient [C]g [C]r [C]a [C]d [C]i [C]e [C]n [C]t O 
centrifugation [C]c [C]e [C]n [C]t [C]r [C]i [C]f [C]u [C]g [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
E-selectin [C]E [C]- [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]n S-protein 
and [C]a [C]n [C]d O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
endothelial [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
. [C]. O 

B. [C]B [C]. O 
fragilis [C]f [C]r [C]a [C]g [C]i [C]l [C]i [C]s O 
outer [C]o [C]u [C]t [C]e [C]r O 
membranes [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e [C]s O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
translocation [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
to [C]t [C]o O 
HUVEC [C]H [C]U [C]V [C]E [C]C O 
nuclei [C]n [C]u [C]c [C]l [C]e [C]i O 
and [C]a [C]n [C]d O 
accumulation [C]a [C]c [C]c [C]u [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
E-selectin [C]E [C]- [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]n B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
in [C]i [C]n O 
HUVEC [C]H [C]U [C]V [C]E [C]C O 
cytoplasm [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m O 
. [C]. O 

E-selectin [C]E [C]- [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
B. [C]B [C]. O 
fragilis [C]f [C]r [C]a [C]g [C]i [C]l [C]i [C]s O 
outer [C]o [C]u [C]t [C]e [C]r O 
membranes [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e [C]s O 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
by [C]b [C]y O 
polymixin [C]p [C]o [C]l [C]y [C]m [C]i [C]x [C]i [C]n O 
B [C]B O 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
E-selectin [C]E [C]- [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
outer [C]o [C]u [C]t [C]e [C]r O 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
fractions [C]f [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
E. [C]E [C]. O 
coli [C]c [C]o [C]l [C]i O 
was [C]w [C]a [C]s O 
competitively [C]c [C]o [C]m [C]p [C]e [C]t [C]i [C]t [C]i [C]v [C]e [C]l [C]y O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
by [C]b [C]y O 
polymixin [C]p [C]o [C]l [C]y [C]m [C]i [C]x [C]i [C]n O 
B [C]B O 
. [C]. O 

Neither [C]N [C]e [C]i [C]t [C]h [C]e [C]r O 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d O 
B. [C]B [C]. O 
fragilis [C]f [C]r [C]a [C]g [C]i [C]l [C]i [C]s O 
LPS [C]L [C]P [C]S O 
, [C], O 
a [C]a O 
prominent [C]p [C]r [C]o [C]m [C]i [C]n [C]e [C]n [C]t O 
constituent [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
outer [C]o [C]u [C]t [C]e [C]r O 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
, [C], O 
nor [C]n [C]o [C]r O 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d O 
B. [C]B [C]. O 
fragilis [C]f [C]r [C]a [C]g [C]i [C]l [C]i [C]s O 
capsular [C]c [C]a [C]p [C]s [C]u [C]l [C]a [C]r O 
polysaccharides [C]p [C]o [C]l [C]y [C]s [C]a [C]c [C]c [C]h [C]a [C]r [C]i [C]d [C]e [C]s O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
HUVEC [C]H [C]U [C]V [C]E [C]C O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Two [C]T [C]w [C]o O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
monoclonal [C]m [C]o [C]n [C]o [C]c [C]l [C]o [C]n [C]a [C]l B-protein 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s E-protein 
directed [C]d [C]i [C]r [C]e [C]c [C]t [C]e [C]d O 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
human [C]h [C]u [C]m [C]a [C]n B-protein 
CD14 [C]C [C]D [C]1 [C]4 E-protein 
completely [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e [C]l [C]y O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
B. [C]B [C]. O 
fragilis [C]f [C]r [C]a [C]g [C]i [C]l [C]i [C]s O 
outer [C]o [C]u [C]t [C]e [C]r O 
membrane-induced [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
E-selectin [C]E [C]- [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]n O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
E-selectin [C]E [C]- [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]n O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

We [C]W [C]e O 
conclude [C]c [C]o [C]n [C]c [C]l [C]u [C]d [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
outer [C]o [C]u [C]t [C]e [C]r O 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
component [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
B. [C]B [C]. O 
fragilis [C]f [C]r [C]a [C]g [C]i [C]l [C]i [C]s O 
cell [C]c [C]e [C]l [C]l O 
wall [C]w [C]a [C]l [C]l O 
contains [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]s O 
a [C]a O 
proinflammatory [C]p [C]r [C]o [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
( [C]( O 
s [C]s O 
) [C]) O 
, [C], O 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
not [C]n [C]o [C]t O 
LPS [C]L [C]P [C]S O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
endothelial [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l I-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
a [C]a O 
soluble [C]s [C]o [C]l [C]u [C]b [C]l [C]e O 
CD14 [C]C [C]D [C]1 [C]4 S-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
. [C]. O 

NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
protects [C]p [C]r [C]o [C]t [C]e [C]c [C]t [C]s O 
HIV-1-infected [C]H [C]I [C]V [C]- [C]1 [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
. [C]. O 

HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y B-cell_type 
monocytic [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]i [C]c I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
in [C]i [C]n O 
sustained [C]s [C]u [C]s [C]t [C]a [C]i [C]n [C]e [C]d O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Recently [C]R [C]e [C]c [C]e [C]n [C]t [C]l [C]y O 
, [C], O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
play [C]p [C]l [C]a [C]y O 
a [C]a O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
protecting [C]p [C]r [C]o [C]t [C]e [C]c [C]t [C]i [C]n [C]g O 
cells [C]c [C]e [C]l [C]l [C]s O 
from [C]f [C]r [C]o [C]m O 
programmed [C]p [C]r [C]o [C]g [C]r [C]a [C]m [C]m [C]e [C]d O 
cell [C]c [C]e [C]l [C]l O 
death [C]d [C]e [C]a [C]t [C]h O 
. [C]. O 

In [C]I [C]n O 
the [C]t [C]h [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
study [C]s [C]t [C]u [C]d [C]y O 
, [C], O 
we [C]w [C]e O 
sought [C]s [C]o [C]u [C]g [C]h [C]t O 
to [C]t [C]o O 
investigate [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
constitutive [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
chronically [C]c [C]h [C]r [C]o [C]n [C]i [C]c [C]a [C]l [C]l [C]y O 
HIV-1-infected [C]H [C]I [C]V [C]- [C]1 [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
promonocytic [C]p [C]r [C]o [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]i [C]c B-cell_line 
U937 [C]U [C]9 [C]3 [C]7 I-cell_line 
( [C]( I-cell_line 
U9-IIIB [C]U [C]9 [C]- [C]I [C]I [C]I [C]B I-cell_line 
) [C]) I-cell_line 
and [C]a [C]n [C]d I-cell_line 
myeloblastic [C]m [C]y [C]e [C]l [C]o [C]b [C]l [C]a [C]s [C]t [C]i [C]c I-cell_line 
PLB-985 [C]P [C]L [C]B [C]- [C]9 [C]8 [C]5 I-cell_line 
( [C]( I-cell_line 
PLB-IIIB [C]P [C]L [C]B [C]- [C]I [C]I [C]I [C]B I-cell_line 
) [C]) I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
affects [C]a [C]f [C]f [C]e [C]c [C]t [C]s O 
apoptotic [C]a [C]p [C]o [C]p [C]t [C]o [C]t [C]i [C]c O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
. [C]. O 

TNFalpha [C]T [C]N [C]F [C]a [C]l [C]p [C]h [C]a S-protein 
and [C]a [C]n [C]d O 
cycloheximide [C]c [C]y [C]c [C]l [C]o [C]h [C]e [C]x [C]i [C]m [C]i [C]d [C]e O 
caused [C]c [C]a [C]u [C]s [C]e [C]d O 
infected [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
cells [C]c [C]e [C]l [C]l [C]s O 
to [C]t [C]o O 
undergo [C]u [C]n [C]d [C]e [C]r [C]g [C]o O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
more [C]m [C]o [C]r [C]e O 
rapidly [C]r [C]a [C]p [C]i [C]d [C]l [C]y O 
than [C]t [C]h [C]a [C]n O 
parental [C]p [C]a [C]r [C]e [C]n [C]t [C]a [C]l B-cell_line 
U937 [C]U [C]9 [C]3 [C]7 E-cell_line 
and [C]a [C]n [C]d O 
PLB-985 [C]P [C]L [C]B [C]- [C]9 [C]8 [C]5 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

Inhibition [C]I [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
TNFalpha [C]T [C]N [C]F [C]a [C]l [C]p [C]h [C]a S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
using [C]u [C]s [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
antioxidant [C]a [C]n [C]t [C]i [C]o [C]x [C]i [C]d [C]a [C]n [C]t O 
N-acetylcysteine [C]N [C]- [C]a [C]c [C]e [C]t [C]y [C]l [C]c [C]y [C]s [C]t [C]e [C]i [C]n [C]e O 
( [C]( O 
NAC [C]N [C]A [C]C O 
) [C]) O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
U937 [C]U [C]9 [C]3 [C]7 B-cell_line 
and [C]a [C]n [C]d I-cell_line 
U9-IIIB [C]U [C]9 [C]- [C]I [C]I [C]I [C]B I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
, [C], O 
while [C]w [C]h [C]i [C]l [C]e O 
preactivation [C]p [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
non-apoptotic [C]n [C]o [C]n [C]- [C]a [C]p [C]o [C]p [C]t [C]o [C]t [C]i [C]c B-protein 
inducer [C]i [C]n [C]d [C]u [C]c [C]e [C]r I-protein 
IL-1beta [C]I [C]L [C]- [C]1 [C]b [C]e [C]t [C]a E-protein 
caused [C]c [C]a [C]u [C]s [C]e [C]d O 
a [C]a O 
relative [C]r [C]e [C]l [C]a [C]t [C]i [C]v [C]e O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
. [C]. O 

Inhibition [C]I [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
constitutive [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
U9-IIIB [C]U [C]9 [C]- [C]I [C]I [C]I [C]B B-cell_line 
and [C]a [C]n [C]d I-cell_line 
PLB-IIIB [C]P [C]L [C]B [C]- [C]I [C]I [C]I [C]B I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
also [C]a [C]l [C]s [C]o O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B B-cell_type 
protects [C]p [C]r [C]o [C]t [C]e [C]c [C]t [C]s I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
a [C]a O 
persistent [C]p [C]e [C]r [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
apoptotic [C]a [C]p [C]o [C]p [C]t [C]o [C]t [C]i [C]c O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
. [C]. O 

TNFalpha [C]T [C]N [C]F [C]a [C]l [C]p [C]h [C]a S-protein 
plus [C]p [C]l [C]u [C]s O 
NAC [C]N [C]A [C]C O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
a [C]a O 
marked [C]m [C]a [C]r [C]k [C]e [C]d O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
Bcl-2 [C]B [C]c [C]l [C]- [C]2 B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
in [C]i [C]n O 
HIV-1-infected [C]H [C]I [C]V [C]- [C]1 [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
coupled [C]c [C]o [C]u [C]p [C]l [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
an [C]a [C]n O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
Bax [C]B [C]a [C]x B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
uninfected [C]u [C]n [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
cells [C]c [C]e [C]l [C]l [C]s O 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
difference [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e O 
in [C]i [C]n O 
susceptibility [C]s [C]u [C]s [C]c [C]e [C]p [C]t [C]i [C]b [C]i [C]l [C]i [C]t [C]y O 
to [C]t [C]o O 
TNFalpha [C]T [C]N [C]F [C]a [C]l [C]p [C]h [C]a S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
may [C]m [C]a [C]y O 
relate [C]r [C]e [C]l [C]a [C]t [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
differences [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e [C]s O 
in [C]i [C]n O 
relative [C]r [C]e [C]l [C]a [C]t [C]i [C]v [C]e O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
Bcl-2 [C]B [C]c [C]l [C]- [C]2 S-protein 
and [C]a [C]n [C]d O 
Bax [C]B [C]a [C]x S-protein 
. [C]. O 

The [C]T [C]h [C]e O 
protective [C]p [C]r [C]o [C]t [C]e [C]c [C]t [C]i [C]v [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
in [C]i [C]n O 
blocking [C]b [C]l [C]o [C]c [C]k [C]i [C]n [C]g O 
TNFalpha- [C]T [C]N [C]F [C]a [C]l [C]p [C]h [C]a [C]- O 
and [C]a [C]n [C]d O 
HIV-1-induced [C]H [C]I [C]V [C]- [C]1 [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
was [C]w [C]a [C]s O 
supported [C]s [C]u [C]p [C]p [C]o [C]r [C]t [C]e [C]d O 
by [C]b [C]y O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
in [C]i [C]n O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_line 
T [C]T I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
engineered [C]e [C]n [C]g [C]i [C]n [C]e [C]e [C]r [C]e [C]d O 
to [C]t [C]o O 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
IkappaB [C]I [C]k [C]a [C]p [C]p [C]a [C]B B-protein 
alpha [C]a [C]l [C]p [C]h [C]a I-protein 
repressor [C]r [C]e [C]p [C]r [C]e [C]s [C]s [C]o [C]r I-protein 
mutants [C]m [C]u [C]t [C]a [C]n [C]t [C]s E-protein 
( [C]( O 
TD-IkappaB [C]T [C]D [C]- [C]I [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
) [C]) O 
under [C]u [C]n [C]d [C]e [C]r O 
the [C]t [C]h [C]e O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
of [C]o [C]f O 
a [C]a O 
tetracycline-responsive [C]t [C]e [C]t [C]r [C]a [C]c [C]y [C]c [C]l [C]i [C]n [C]e [C]- [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

Cells [C]C [C]e [C]l [C]l [C]s O 
underwent [C]u [C]n [C]d [C]e [C]r [C]w [C]e [C]n [C]t O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
TNFalpha [C]T [C]N [C]F [C]a [C]l [C]p [C]h [C]a S-protein 
only [C]o [C]n [C]l [C]y O 
when [C]w [C]h [C]e [C]n O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
by [C]b [C]y O 
TD-IkappaB [C]T [C]D [C]- [C]I [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

As [C]A [C]s O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
U9-IIIB [C]U [C]9 [C]- [C]I [C]I [C]I [C]B B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
, [C], O 
TNFalpha [C]T [C]N [C]F [C]a [C]l [C]p [C]h [C]a S-protein 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
also [C]a [C]l [C]s [C]o O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
a [C]a O 
marked [C]m [C]a [C]r [C]k [C]e [C]d O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
Bcl-2 [C]B [C]c [C]l [C]- [C]2 B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
in [C]i [C]n O 
TD-IkappaB [C]T [C]D [C]- [C]I [C]k [C]a [C]p [C]p [C]a [C]B B-cell_type 
expressing [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]n [C]g I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
experiments [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]s O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
apoptotic [C]a [C]p [C]o [C]p [C]t [C]o [C]t [C]i [C]c O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
is [C]i [C]s O 
perturbed [C]p [C]e [C]r [C]t [C]u [C]r [C]b [C]e [C]d O 
in [C]i [C]n O 
HIV-1-infected [C]H [C]I [C]V [C]- [C]1 [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
U9-IIIB [C]U [C]9 [C]- [C]I [C]I [C]I [C]B B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
and [C]a [C]n [C]d O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
may [C]m [C]a [C]y O 
play [C]p [C]l [C]a [C]y O 
an [C]a [C]n O 
additional [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n [C]a [C]l O 
protective [C]p [C]r [C]o [C]t [C]e [C]c [C]t [C]i [C]v [C]e O 
role [C]r [C]o [C]l [C]e O 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
HIV-1-induced [C]H [C]I [C]V [C]- [C]1 [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Human [C]H [C]u [C]m [C]a [C]n B-cell_type 
normal [C]n [C]o [C]r [C]m [C]a [C]l I-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
B-lymphocytes [C]B [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
are [C]a [C]r [C]e O 
deficient [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
in [C]i [C]n O 
DNA-dependent [C]D [C]N [C]A [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
due [C]d [C]u [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
variant [C]v [C]a [C]r [C]i [C]a [C]n [C]t O 
form [C]f [C]o [C]r [C]m O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Ku86 [C]K [C]u [C]8 [C]6 B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
heterodimeric [C]h [C]e [C]t [C]e [C]r [C]o [C]d [C]i [C]m [C]e [C]r [C]i [C]c O 
Ku [C]K [C]u B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
comprises [C]c [C]o [C]m [C]p [C]r [C]i [C]s [C]e [C]s O 
a [C]a O 
86 [C]8 [C]6 B-protein 
kDa [C]k [C]D [C]a I-protein 
( [C]( I-protein 
Ku86 [C]K [C]u [C]8 [C]6 I-protein 
) [C]) E-protein 
amd [C]a [C]m [C]d O 
a [C]a O 
70 [C]7 [C]0 B-protein 
kDa [C]k [C]D [C]a I-protein 
( [C]( I-protein 
Ku70 [C]K [C]u [C]7 [C]0 I-protein 
) [C]) I-protein 
subunits [C]s [C]u [C]b [C]u [C]n [C]i [C]t [C]s E-protein 
, [C], O 
is [C]i [C]s O 
an [C]a [C]n O 
abundant [C]a [C]b [C]u [C]n [C]d [C]a [C]n [C]t O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
DNA-binding [C]D [C]N [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
which [C]w [C]h [C]i [C]c [C]h O 
binds [C]b [C]i [C]n [C]d [C]s O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
to [C]t [C]o O 
DNA [C]D [C]N [C]A B-DNA 
termini [C]t [C]e [C]r [C]m [C]i [C]n [C]i E-DNA 
without [C]w [C]i [C]t [C]h [C]o [C]u [C]t O 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
specificity [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]i [C]t [C]y O 
. [C]. O 

Ku [C]K [C]u S-protein 
is [C]i [C]s O 
the [C]t [C]h [C]e O 
DNA-targeting [C]D [C]N [C]A [C]- [C]t [C]a [C]r [C]g [C]e [C]t [C]i [C]n [C]g B-protein 
component [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t E-protein 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
large [C]l [C]a [C]r [C]g [C]e O 
catalytic [C]c [C]a [C]t [C]a [C]l [C]y [C]t [C]i [C]c B-protein 
sub-unit [C]s [C]u [C]b [C]- [C]u [C]n [C]i [C]t E-protein 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
DNA-dependent [C]D [C]N [C]A [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
( [C]( O 
DNA-PK [C]D [C]N [C]A [C]- [C]P [C]K B-protein 
[ [C][ I-protein 
CS [C]C [C]S I-protein 
] [C]] E-protein 
) [C]) O 
, [C], O 
that [C]t [C]h [C]a [C]t O 
plays [C]p [C]l [C]a [C]y [C]s O 
a [C]a O 
critical [C]c [C]r [C]i [C]t [C]i [C]c [C]a [C]l O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
mammalian [C]m [C]a [C]m [C]m [C]a [C]l [C]i [C]a [C]n O 
double-strand [C]d [C]o [C]u [C]b [C]l [C]e [C]- [C]s [C]t [C]r [C]a [C]n [C]d O 
break [C]b [C]r [C]e [C]a [C]k O 
repair [C]r [C]e [C]p [C]a [C]i [C]r O 
and [C]a [C]n [C]d O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d O 
V [C]V O 
( [C]( O 
D [C]D O 
) [C]) O 
J [C]J O 
recombination [C]r [C]e [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

By [C]B [C]y O 
using [C]u [C]s [C]i [C]n [C]g O 
electrophoretic [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
, [C], O 
we [C]w [C]e O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
in [C]i [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
major [C]m [C]a [C]j [C]o [C]r B-protein 
Ku [C]K [C]u I-protein 
x [C]x I-protein 
DNA [C]D [C]N [C]A I-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
usually [C]u [C]s [C]u [C]a [C]l [C]l [C]y O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
in [C]i [C]n O 
cell [C]c [C]e [C]l [C]l O 
line [C]l [C]i [C]n [C]e O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
, [C], O 
a [C]a O 
second [C]s [C]e [C]c [C]o [C]n [C]d O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
with [C]w [C]i [C]t [C]h O 
faster [C]f [C]a [C]s [C]t [C]e [C]r O 
electrophoretic [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
( [C]( O 
PBL [C]P [C]B [C]L S-cell_type 
) [C]) O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
faster [C]f [C]a [C]s [C]t [C]e [C]r B-protein 
migrating [C]m [C]i [C]g [C]r [C]a [C]t [C]i [C]n [C]g I-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
was [C]w [C]a [C]s O 
restricted [C]r [C]e [C]s [C]t [C]r [C]i [C]c [C]t [C]e [C]d O 
to [C]t [C]o O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
among [C]a [C]m [C]o [C]n [C]g O 
the [C]t [C]h [C]e O 
circulating [C]c [C]i [C]r [C]c [C]u [C]l [C]a [C]t [C]i [C]n [C]g B-cell_type 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e I-cell_type 
population [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n E-cell_type 
. [C]. O 

Western [C]W [C]e [C]s [C]t [C]e [C]r [C]n O 
blot [C]b [C]l [C]o [C]t O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
a [C]a O 
variant [C]v [C]a [C]r [C]i [C]a [C]n [C]t O 
form [C]f [C]o [C]r [C]m O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Ku86 [C]K [C]u [C]8 [C]6 B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
with [C]w [C]i [C]t [C]h O 
an [C]a [C]n O 
apparent [C]a [C]p [C]p [C]a [C]r [C]e [C]n [C]t O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
weight [C]w [C]e [C]i [C]g [C]h [C]t O 
of [C]o [C]f O 
69 [C]6 [C]9 O 
kDa [C]k [C]D [C]a O 
, [C], O 
and [C]a [C]n [C]d O 
not [C]n [C]o [C]t O 
the [C]t [C]h [C]e O 
86 [C]8 [C]6 B-protein 
kDa- [C]k [C]D [C]a [C]- I-protein 
full-length [C]f [C]u [C]l [C]l [C]- [C]l [C]e [C]n [C]g [C]t [C]h I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
heterodimer [C]h [C]e [C]t [C]e [C]r [C]o [C]d [C]i [C]m [C]e [C]r B-protein 
Ku70/variant-Ku86 [C]K [C]u [C]7 [C]0 [C]/ [C]v [C]a [C]r [C]i [C]a [C]n [C]t [C]- [C]K [C]u [C]8 [C]6 E-protein 
binds [C]b [C]i [C]n [C]d [C]s O 
to [C]t [C]o O 
DNA-ends [C]D [C]N [C]A [C]- [C]e [C]n [C]d [C]s S-DNA 
, [C], O 
this [C]t [C]h [C]i [C]s O 
altered [C]a [C]l [C]t [C]e [C]r [C]e [C]d O 
form [C]f [C]o [C]r [C]m O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Ku [C]K [C]u B-protein 
heterodimer [C]h [C]e [C]t [C]e [C]r [C]o [C]d [C]i [C]m [C]e [C]r E-protein 
has [C]h [C]a [C]s O 
a [C]a O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
to [C]t [C]o O 
recruit [C]r [C]e [C]c [C]r [C]u [C]i [C]t O 
the [C]t [C]h [C]e O 
catalytic [C]c [C]a [C]t [C]a [C]l [C]y [C]t [C]i [C]c B-protein 
component [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t E-protein 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
, [C], O 
DNA-PK [C]D [C]N [C]A [C]- [C]P [C]K B-protein 
( [C]( I-protein 
CS [C]C [C]S I-protein 
) [C]) E-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
contributes [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e [C]s O 
to [C]t [C]o O 
an [C]a [C]n O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
detectable [C]d [C]e [C]t [C]e [C]c [C]t [C]a [C]b [C]l [C]e O 
DNA-PK [C]D [C]N [C]A [C]- [C]P [C]K O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
provide [C]p [C]r [C]o [C]v [C]i [C]d [C]e O 
a [C]a O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
basis [C]b [C]a [C]s [C]i [C]s O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
to [C]t [C]o O 
ionizing [C]i [C]o [C]n [C]i [C]z [C]i [C]n [C]g O 
radiation [C]r [C]a [C]d [C]i [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
identify [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]y O 
a [C]a O 
new [C]n [C]e [C]w O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
of [C]o [C]f O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
DNA-PK [C]D [C]N [C]A [C]- [C]P [C]K O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
that [C]t [C]h [C]a [C]t O 
operates [C]o [C]p [C]e [C]r [C]a [C]t [C]e [C]s O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
. [C]. O 

Co-stimulation [C]C [C]o [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
with [C]w [C]i [C]t [C]h O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
and [C]a [C]n [C]d O 
anti-CD3 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]3 B-protein 
monoclonal [C]m [C]o [C]n [C]o [C]c [C]l [C]o [C]n [C]a [C]l I-protein 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s E-protein 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CREB [C]C [C]R [C]E [C]B S-protein 
. [C]. O 

Phosphorylation [C]P [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cAMP-response [C]c [C]A [C]M [C]P [C]- [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e B-protein 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
CREB [C]C [C]R [C]E [C]B E-protein 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
1 [C]1 O 
h [C]h O 
of [C]o [C]f O 
CD2 [C]C [C]D [C]2 S-protein 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
CD3 [C]C [C]D [C]3 S-protein 
cross-linking [C]c [C]r [C]o [C]s [C]s [C]- [C]l [C]i [C]n [C]k [C]i [C]n [C]g O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
PBMC [C]P [C]B [C]M [C]C E-cell_type 
was [C]w [C]a [C]s O 
recently [C]r [C]e [C]c [C]e [C]n [C]t [C]l [C]y O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
. [C]. O 

The [C]T [C]h [C]e O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
P-CREB [C]P [C]- [C]C [C]R [C]E [C]B S-protein 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
CD3 [C]C [C]D [C]3 O 
cross-linking [C]c [C]r [C]o [C]s [C]s [C]- [C]l [C]i [C]n [C]k [C]i [C]n [C]g O 
was [C]w [C]a [C]s O 
unexpected [C]u [C]n [C]e [C]x [C]p [C]e [C]c [C]t [C]e [C]d O 
, [C], O 
as [C]a [C]s O 
other [C]o [C]t [C]h [C]e [C]r O 
laboratories [C]l [C]a [C]b [C]o [C]r [C]a [C]t [C]o [C]r [C]i [C]e [C]s O 
reported [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]d O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CREB [C]C [C]R [C]E [C]B S-protein 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
CD3 [C]C [C]D [C]3 O 
cross-linking [C]c [C]r [C]o [C]s [C]s [C]- [C]l [C]i [C]n [C]k [C]i [C]n [C]g O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_line 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
. [C]. O 

Due [C]D [C]u [C]e O 
to [C]t [C]o O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_line 
T-cells [C]T [C]- [C]c [C]e [C]l [C]l [C]s E-cell_line 
being [C]b [C]e [C]i [C]n [C]g O 
IL-2-independent [C]I [C]L [C]- [C]2 [C]- [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
, [C], O 
it [C]i [C]t O 
was [C]w [C]a [C]s O 
postulated [C]p [C]o [C]s [C]t [C]u [C]l [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
might [C]m [C]i [C]g [C]h [C]t O 
provide [C]p [C]r [C]o [C]v [C]i [C]d [C]e O 
a [C]a O 
necessary [C]n [C]e [C]c [C]e [C]s [C]s [C]a [C]r [C]y O 
co-stimulus [C]c [C]o [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]u [C]s O 
for [C]f [C]o [C]r O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CREB [C]C [C]R [C]E [C]B S-protein 
in [C]i [C]n O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

Therefore [C]T [C]h [C]e [C]r [C]e [C]f [C]o [C]r [C]e O 
, [C], O 
P-CREB [C]P [C]- [C]C [C]R [C]E [C]B S-protein 
was [C]w [C]a [C]s O 
evaluated [C]e [C]v [C]a [C]l [C]u [C]a [C]t [C]e [C]d O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
co-stimulation [C]c [C]o [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
PBMC [C]P [C]B [C]M [C]C E-cell_type 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-protein 
and [C]a [C]n [C]d I-protein 
CD2 [C]C [C]D [C]2 I-protein 
or [C]o [C]r I-protein 
CD3 [C]C [C]D [C]3 I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

IL-2 [C]I [C]L [C]- [C]2 S-protein 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
augment [C]a [C]u [C]g [C]m [C]e [C]n [C]t O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CREB [C]C [C]R [C]E [C]B S-protein 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
CD2 [C]C [C]D [C]2 O 
cross-linking [C]c [C]r [C]o [C]s [C]s [C]- [C]l [C]i [C]n [C]k [C]i [C]n [C]g O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
while [C]w [C]h [C]i [C]l [C]e O 
neither [C]n [C]e [C]i [C]t [C]h [C]e [C]r O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
nor [C]n [C]o [C]r O 
CD3 [C]C [C]D [C]3 O 
cross-linking [C]c [C]r [C]o [C]s [C]s [C]- [C]l [C]i [C]n [C]k [C]i [C]n [C]g O 
alone [C]a [C]l [C]o [C]n [C]e O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
P-CREB [C]P [C]- [C]C [C]R [C]E [C]B S-protein 
, [C], O 
a [C]a O 
4.5-fold [C]4 [C]. [C]5 [C]- [C]f [C]o [C]l [C]d O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CREB [C]C [C]R [C]E [C]B S-protein 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
1 [C]1 O 
h [C]h O 
of [C]o [C]f O 
IL-2/CD3 [C]I [C]L [C]- [C]2 [C]/ [C]C [C]D [C]3 O 
co-stimulation [C]c [C]o [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
. [C]. O 

Phosphorylation [C]P [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cAMP [C]c [C]A [C]M [C]P O 
, [C], O 
and [C]a [C]n [C]d O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
PKA [C]P [C]K [C]A O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
had [C]h [C]a [C]d O 
no [C]n [C]o O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
P-CREB [C]P [C]- [C]C [C]R [C]E [C]B S-protein 
. [C]. O 

Consistent [C]C [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
p56lck [C]p [C]5 [C]6 [C]l [C]c [C]k S-protein 
or [C]o [C]r O 
p59fyn [C]p [C]5 [C]9 [C]f [C]y [C]n S-protein 
, [C], O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
PTK [C]P [C]T [C]K O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
50 [C]5 [C]0 O 
% [C]% O 
. [C]. O 

Interestingly [C]I [C]n [C]t [C]e [C]r [C]e [C]s [C]t [C]i [C]n [C]g [C]l [C]y O 
, [C], O 
inhibiting [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]n [C]g O 
PKC [C]P [C]K [C]C O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
with [C]w [C]i [C]t [C]h O 
calphostin [C]c [C]a [C]l [C]p [C]h [C]o [C]s [C]t [C]i [C]n O 
C [C]C O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
P-CREB [C]P [C]- [C]C [C]R [C]E [C]B O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
3-fold [C]3 [C]- [C]f [C]o [C]l [C]d O 
over [C]o [C]v [C]e [C]r O 
that [C]t [C]h [C]a [C]t O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
IL-2/CD3 [C]I [C]L [C]- [C]2 [C]/ [C]C [C]D [C]3 B-cell_type 
co-stimulated [C]c [C]o [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
not [C]n [C]o [C]t O 
pretreated [C]p [C]r [C]e [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
PKC [C]P [C]K [C]C O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
to [C]t [C]o O 
previous [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
performed [C]p [C]e [C]r [C]f [C]o [C]r [C]m [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
exogenous [C]e [C]x [C]o [C]g [C]e [C]n [C]o [C]u [C]s B-protein 
IL-2 [C]I [C]L [C]- [C]2 E-protein 
, [C], O 
no [C]n [C]o O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
CREB [C]C [C]R [C]E [C]B S-protein 
to [C]t [C]o O 
a [C]a O 
32P-labeled [C]3 [C]2 [C]P [C]- [C]l [C]a [C]b [C]e [C]l [C]e [C]d O 
oligonucleotide [C]o [C]l [C]i [C]g [C]o [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e O 
probe [C]p [C]r [C]o [C]b [C]e O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
by [C]b [C]y O 
electrophoretic [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
assay [C]a [C]s [C]s [C]a [C]y O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
and [C]a [C]n [C]d O 
CD3 [C]C [C]D [C]3 S-protein 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
provide [C]p [C]r [C]o [C]v [C]i [C]d [C]e O 
a [C]a O 
necessary [C]n [C]e [C]c [C]e [C]s [C]s [C]a [C]r [C]y O 
and [C]a [C]n [C]d O 
co-operative [C]c [C]o [C]- [C]o [C]p [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
stimulus [C]s [C]t [C]i [C]m [C]u [C]l [C]u [C]s O 
promoting [C]p [C]r [C]o [C]m [C]o [C]t [C]i [C]n [C]g O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CREB [C]C [C]R [C]E [C]B S-protein 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
cross-linking [C]c [C]r [C]o [C]s [C]s [C]- [C]l [C]i [C]n [C]k [C]i [C]n [C]g O 
. [C]. O 

HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
a [C]a O 
selective [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e O 
reduction [C]r [C]e [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
STAT5 [C]S [C]T [C]A [C]T [C]5 O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
accompanied [C]a [C]c [C]c [C]o [C]m [C]p [C]a [C]n [C]i [C]e [C]d O 
by [C]b [C]y O 
qualitative [C]q [C]u [C]a [C]l [C]i [C]t [C]a [C]t [C]i [C]v [C]e O 
and [C]a [C]n [C]d O 
quantitative [C]q [C]u [C]a [C]n [C]t [C]i [C]t [C]a [C]t [C]i [C]v [C]e O 
defects [C]d [C]e [C]f [C]e [C]c [C]t [C]s O 
in [C]i [C]n O 
CD4+ [C]C [C]D [C]4 [C]+ B-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

Loss [C]L [C]o [C]s [C]s O 
of [C]o [C]f O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
HIV [C]H [C]I [C]V O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
is [C]i [C]s O 
usually [C]u [C]s [C]u [C]a [C]l [C]l [C]y O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
profound [C]p [C]r [C]o [C]f [C]o [C]u [C]n [C]d O 
dysregulation [C]d [C]y [C]s [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e S-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

To [C]T [C]o O 
investigate [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e S-protein 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
defects [C]d [C]e [C]f [C]e [C]c [C]t [C]s O 
occur [C]o [C]c [C]c [C]u [C]r O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
HIV [C]H [C]I [C]V O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
, [C], O 
PHA [C]P [C]H [C]A B-cell_type 
blasts [C]b [C]l [C]a [C]s [C]t [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
healthy [C]h [C]e [C]a [C]l [C]t [C]h [C]y O 
human [C]h [C]u [C]m [C]a [C]n O 
donors [C]d [C]o [C]n [C]o [C]r [C]s O 
were [C]w [C]e [C]r [C]e O 
infected [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
two [C]t [C]w [C]o O 
strains [C]s [C]t [C]r [C]a [C]i [C]n [C]s O 
of [C]o [C]f O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
and [C]a [C]n [C]d O 
screened [C]s [C]c [C]r [C]e [C]e [C]n [C]e [C]d O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
STAT [C]S [C]T [C]A [C]T B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
used [C]u [C]s [C]e [C]d O 
in [C]i [C]n O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e S-protein 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
. [C]. O 

A [C]A O 
selective [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
STAT5B [C]S [C]T [C]A [C]T [C]5 [C]B S-protein 
was [C]w [C]a [C]s O 
seen [C]s [C]e [C]e [C]n O 
8 [C]8 O 
days [C]d [C]a [C]y [C]s O 
after [C]a [C]f [C]t [C]e [C]r O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
BZ167 [C]B [C]Z [C]1 [C]6 [C]7 O 
dual-tropic [C]d [C]u [C]a [C]l [C]- [C]t [C]r [C]o [C]p [C]i [C]c O 
HIV [C]H [C]I [C]V O 
isolate [C]i [C]s [C]o [C]l [C]a [C]t [C]e O 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
Ba-L [C]B [C]a [C]- [C]L O 
, [C], O 
M-tropic [C]M [C]- [C]t [C]r [C]o [C]p [C]i [C]c O 
strain [C]s [C]t [C]r [C]a [C]i [C]n O 
. [C]. O 

Based [C]B [C]a [C]s [C]e [C]d O 
on [C]o [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
, [C], O 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
HIV-infected [C]H [C]I [C]V [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
in [C]i [C]n O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
stages [C]s [C]t [C]a [C]g [C]e [C]s O 
of [C]o [C]f O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
were [C]w [C]e [C]r [C]e O 
also [C]a [C]l [C]s [C]o O 
tested [C]t [C]e [C]s [C]t [C]e [C]d O 
for [C]f [C]o [C]r O 
STAT [C]S [C]T [C]A [C]T O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
; [C]; O 
decreases [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
in [C]i [C]n O 
STAT5A [C]S [C]T [C]A [C]T [C]5 [C]A S-protein 
, [C], O 
STAT5B [C]S [C]T [C]A [C]T [C]5 [C]B S-protein 
, [C], O 
and [C]a [C]n [C]d O 
STAT1alpha [C]S [C]T [C]A [C]T [C]1 [C]a [C]l [C]p [C]h [C]a S-protein 
were [C]w [C]e [C]r [C]e O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
all [C]a [C]l [C]l O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
reduction [C]r [C]e [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
STATs [C]S [C]T [C]A [C]T [C]s S-protein 
seen [C]s [C]e [C]e [C]n O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
after [C]a [C]f [C]t [C]e [C]r O 
HIV [C]H [C]I [C]V O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
may [C]m [C]a [C]y O 
contribute [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
loss [C]l [C]o [C]s [C]s O 
of [C]o [C]f O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
HIV [C]H [C]I [C]V O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
. [C]. O 

Transcription [C]T [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
that [C]t [C]h [C]a [C]t O 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
monocyte [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e S-cell_type 
/ [C]/ O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e S-cell_type 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
all [C]a [C]l [C]l O 
the [C]t [C]h [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
in [C]i [C]n O 
an [C]a [C]n O 
organism [C]o [C]r [C]g [C]a [C]n [C]i [C]s [C]m O 
contain [C]c [C]o [C]n [C]t [C]a [C]i [C]n O 
the [C]t [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
genetic [C]g [C]e [C]n [C]e [C]t [C]i [C]c O 
information [C]i [C]n [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
differences [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
cell [C]c [C]e [C]l [C]l O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
arise [C]a [C]r [C]i [C]s [C]e O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
lineage-specific [C]l [C]i [C]n [C]e [C]a [C]g [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
. [C]. O 

During [C]D [C]u [C]r [C]i [C]n [C]g O 
myelopoiesis [C]m [C]y [C]e [C]l [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
, [C], O 
external [C]e [C]x [C]t [C]e [C]r [C]n [C]a [C]l O 
differentiating [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]n [C]g O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
set [C]s [C]e [C]t O 
of [C]o [C]f O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
combined [C]c [C]o [C]m [C]b [C]i [C]n [C]e [C]d O 
action [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
subsequently [C]s [C]u [C]b [C]s [C]e [C]q [C]u [C]e [C]n [C]t [C]l [C]y O 
determines [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]s O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
myeloid-specific [C]m [C]y [C]e [C]l [C]o [C]i [C]d [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
generation [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
and [C]a [C]n [C]d O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_type 
. [C]. O 

In [C]I [C]n O 
particular [C]p [C]a [C]r [C]t [C]i [C]c [C]u [C]l [C]a [C]r O 
, [C], O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
PU.1 [C]P [C]U [C]. [C]1 E-protein 
has [C]h [C]a [C]s O 
a [C]a O 
critical [C]c [C]r [C]i [C]t [C]i [C]c [C]a [C]l O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
this [C]t [C]h [C]i [C]s O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
. [C]. O 

We [C]W [C]e O 
review [C]r [C]e [C]v [C]i [C]e [C]w O 
the [C]t [C]h [C]e O 
contribution [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
of [C]o [C]f O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e S-cell_type 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 

Transcription [C]T [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
LKLF [C]L [C]K [C]L [C]F E-protein 
is [C]i [C]s O 
sufficient [C]s [C]u [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
to [C]t [C]o O 
program [C]p [C]r [C]o [C]g [C]r [C]a [C]m O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
quiescence [C]q [C]u [C]i [C]e [C]s [C]c [C]e [C]n [C]c [C]e O 
via [C]v [C]i [C]a O 
a [C]a O 
c-Myc [C]c [C]- [C]M [C]y [C]c O 
-- [C]- [C]- O 
dependent [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
. [C]. O 

T [C]T B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
circulate [C]c [C]i [C]r [C]c [C]u [C]l [C]a [C]t [C]e O 
in [C]i [C]n O 
a [C]a O 
quiescent [C]q [C]u [C]i [C]e [C]s [C]c [C]e [C]n [C]t O 
state [C]s [C]t [C]a [C]t [C]e O 
until [C]u [C]n [C]t [C]i [C]l O 
they [C]t [C]h [C]e [C]y O 
encounter [C]e [C]n [C]c [C]o [C]u [C]n [C]t [C]e [C]r O 
cognate [C]c [C]o [C]g [C]n [C]a [C]t [C]e B-protein 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n E-protein 
bound [C]b [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
of [C]o [C]f O 
an [C]a [C]n O 
antigen-presenting [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]- [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]i [C]n [C]g B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
that [C]t [C]h [C]a [C]t O 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
quiescence [C]q [C]u [C]i [C]e [C]s [C]c [C]e [C]n [C]c [C]e O 
remain [C]r [C]e [C]m [C]a [C]i [C]n O 
largely [C]l [C]a [C]r [C]g [C]e [C]l [C]y O 
unknown [C]u [C]n [C]k [C]n [C]o [C]w [C]n O 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
we [C]w [C]e O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
forced [C]f [C]o [C]r [C]c [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
lung [C]l [C]u [C]n [C]g B-protein 
Kruppel-like [C]K [C]r [C]u [C]p [C]p [C]e [C]l [C]- [C]l [C]i [C]k [C]e I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
( [C]( O 
LKLF [C]L [C]K [C]L [C]F S-protein 
) [C]) O 
in [C]i [C]n O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_line 
T [C]T I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
is [C]i [C]s O 
sufficient [C]s [C]u [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
to [C]t [C]o O 
program [C]p [C]r [C]o [C]g [C]r [C]a [C]m O 
a [C]a O 
quiescent [C]q [C]u [C]i [C]e [C]s [C]c [C]e [C]n [C]t O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
characterized [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]d O 
by [C]b [C]y O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
cell [C]c [C]e [C]l [C]l O 
size [C]s [C]i [C]z [C]e O 
and [C]a [C]n [C]d O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
markers [C]m [C]a [C]r [C]k [C]e [C]r [C]s O 
. [C]. O 

Conversely [C]C [C]o [C]n [C]v [C]e [C]r [C]s [C]e [C]l [C]y O 
, [C], O 
LKLF-deficient [C]L [C]K [C]L [C]F [C]- [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t B-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
produced [C]p [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
gene [C]g [C]e [C]n [C]e O 
targeting [C]t [C]a [C]r [C]g [C]e [C]t [C]i [C]n [C]g O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
cell [C]c [C]e [C]l [C]l O 
size [C]s [C]i [C]z [C]e O 
and [C]a [C]n [C]d O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
markers [C]m [C]a [C]r [C]k [C]e [C]r [C]s O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
. [C]. O 

LKLF [C]L [C]K [C]L [C]F S-protein 
appeared [C]a [C]p [C]p [C]e [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
, [C], O 
at [C]a [C]t O 
least [C]l [C]e [C]a [C]s [C]t O 
in [C]i [C]n O 
part [C]p [C]a [C]r [C]t O 
, [C], O 
by [C]b [C]y O 
decreasing [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]i [C]n [C]g O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
proto-oncogene [C]p [C]r [C]o [C]t [C]o [C]- [C]o [C]n [C]c [C]o [C]g [C]e [C]n [C]e S-DNA 
encoding [C]e [C]n [C]c [C]o [C]d [C]i [C]n [C]g O 
c-Myc [C]c [C]- [C]M [C]y [C]c S-protein 
. [C]. O 

Forced [C]F [C]o [C]r [C]c [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
LKLF [C]L [C]K [C]L [C]F S-protein 
was [C]w [C]a [C]s O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
markedly [C]m [C]a [C]r [C]k [C]e [C]d [C]l [C]y O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
c-Myc [C]c [C]- [C]M [C]y [C]c S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
many [C]m [C]a [C]n [C]y O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
LKLF [C]L [C]K [C]L [C]F S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
were [C]w [C]e [C]r [C]e O 
mimicked [C]m [C]i [C]m [C]i [C]c [C]k [C]e [C]d O 
by [C]b [C]y O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
dominant-negative [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t [C]- [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e B-protein 
MadMyc [C]M [C]a [C]d [C]M [C]y [C]c I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
and [C]a [C]n [C]d O 
rescued [C]r [C]e [C]s [C]c [C]u [C]e [C]d O 
by [C]b [C]y O 
overexpression [C]o [C]v [C]e [C]r [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
c-Myc [C]c [C]- [C]M [C]y [C]c S-protein 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
LKLF [C]L [C]K [C]L [C]F S-protein 
is [C]i [C]s O 
both [C]b [C]o [C]t [C]h O 
necessary [C]n [C]e [C]c [C]e [C]s [C]s [C]a [C]r [C]y O 
and [C]a [C]n [C]d O 
sufficient [C]s [C]u [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
to [C]t [C]o O 
program [C]p [C]r [C]o [C]g [C]r [C]a [C]m O 
quiescence [C]q [C]u [C]i [C]e [C]s [C]c [C]e [C]n [C]c [C]e O 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
functions [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]s O 
, [C], O 
in [C]i [C]n O 
part [C]p [C]a [C]r [C]t O 
, [C], O 
by [C]b [C]y O 
negatively [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e [C]l [C]y O 
regulating [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
a [C]a O 
c-Myc [C]c [C]- [C]M [C]y [C]c O 
-- [C]- [C]- O 
dependent [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
. [C]. O 

HTLV-1 [C]H [C]T [C]L [C]V [C]- [C]1 B-protein 
p12 [C]p [C]1 [C]2 I-protein 
( [C]( I-protein 
I [C]I I-protein 
) [C]) I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
enhances [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]s O 
STAT5 [C]S [C]T [C]A [C]T [C]5 O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
decreases [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
the [C]t [C]h [C]e O 
interleukin-2 [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]2 S-protein 
requirement [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]m [C]e [C]n [C]t O 
for [C]f [C]o [C]r O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
p12 [C]p [C]1 [C]2 B-protein 
( [C]( I-protein 
I [C]I I-protein 
) [C]) I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
, [C], O 
encoded [C]e [C]n [C]c [C]o [C]d [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
pX [C]p [C]X B-DNA 
open [C]o [C]p [C]e [C]n I-DNA 
reading [C]r [C]e [C]a [C]d [C]i [C]n [C]g I-DNA 
frame [C]f [C]r [C]a [C]m [C]e I-DNA 
I [C]I E-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n O 
T-lymphotropic [C]T [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]t [C]r [C]o [C]p [C]i [C]c O 
virus [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
1 [C]1 O 
( [C]( O 
HTLV-1 [C]H [C]T [C]L [C]V [C]- [C]1 O 
) [C]) O 
, [C], O 
is [C]i [C]s O 
a [C]a O 
hydrophobic [C]h [C]y [C]d [C]r [C]o [C]p [C]h [C]o [C]b [C]i [C]c B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
that [C]t [C]h [C]a [C]t O 
localizes [C]l [C]o [C]c [C]a [C]l [C]i [C]z [C]e [C]s O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
endoplasmic [C]e [C]n [C]d [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c O 
reticulum [C]r [C]e [C]t [C]i [C]c [C]u [C]l [C]u [C]m O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
Golgi [C]G [C]o [C]l [C]g [C]i O 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
p12 [C]p [C]1 [C]2 B-protein 
( [C]( I-protein 
I [C]I I-protein 
) [C]) E-protein 
contains [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]s O 
4 [C]4 O 
minimal [C]m [C]i [C]n [C]i [C]m [C]a [C]l O 
proline-rich [C]p [C]r [C]o [C]l [C]i [C]n [C]e [C]- [C]r [C]i [C]c [C]h O 
, [C], O 
src [C]s [C]r [C]c B-protein 
homology [C]h [C]o [C]m [C]o [C]l [C]o [C]g [C]y I-protein 
3-binding [C]3 [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
motifs [C]m [C]o [C]t [C]i [C]f [C]s E-protein 
( [C]( O 
PXXP [C]P [C]X [C]X [C]P S-protein 
) [C]) O 
, [C], O 
a [C]a O 
characteristic [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]s [C]t [C]i [C]c O 
commonly [C]c [C]o [C]m [C]m [C]o [C]n [C]l [C]y O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
, [C], O 
it [C]i [C]t O 
has [C]h [C]a [C]s O 
not [C]n [C]o [C]t O 
been [C]b [C]e [C]e [C]n O 
known [C]k [C]n [C]o [C]w [C]n O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
p12 [C]p [C]1 [C]2 B-protein 
( [C]( I-protein 
I [C]I I-protein 
) [C]) E-protein 
has [C]h [C]a [C]s O 
a [C]a O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
modulating [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
p12 [C]p [C]1 [C]2 B-protein 
( [C]( I-protein 
I [C]I I-protein 
) [C]) E-protein 
binds [C]b [C]i [C]n [C]d [C]s O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c B-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
interleukin-2 [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]2 B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
( [C]( I-protein 
IL-2R [C]I [C]L [C]- [C]2 [C]R I-protein 
) [C]) I-protein 
beta [C]b [C]e [C]t [C]a I-protein 
chain [C]c [C]h [C]a [C]i [C]n E-protein 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
recruitment [C]r [C]e [C]c [C]r [C]u [C]i [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Jak1 [C]J [C]a [C]k [C]1 B-protein 
and [C]a [C]n [C]d I-protein 
Jak3 [C]J [C]a [C]k [C]3 I-protein 
kinases [C]k [C]i [C]n [C]a [C]s [C]e [C]s E-protein 
. [C]. O 

As [C]A [C]s O 
a [C]a O 
result [C]r [C]e [C]s [C]u [C]l [C]t O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
, [C], O 
p12 [C]p [C]1 [C]2 B-protein 
( [C]( I-protein 
I [C]I I-protein 
) [C]) E-protein 
increases [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
signal [C]s [C]i [C]g [C]n [C]a [C]l B-protein 
transducers [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]e [C]r [C]s I-protein 
and [C]a [C]n [C]d I-protein 
activators [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r [C]s I-protein 
of [C]o [C]f I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
5 [C]5 E-protein 
( [C]( O 
STAT5 [C]S [C]T [C]A [C]T [C]5 S-protein 
) [C]) O 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
this [C]t [C]h [C]i [C]s O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
depends [C]d [C]e [C]p [C]e [C]n [C]d [C]s O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
IL-2R [C]I [C]L [C]- [C]2 [C]R B-protein 
beta [C]b [C]e [C]t [C]a I-protein 
and [C]a [C]n [C]d I-protein 
gamma [C]g [C]a [C]m [C]m [C]a I-protein 
( [C]( I-protein 
c [C]c I-protein 
) [C]) I-protein 
chains [C]c [C]h [C]a [C]i [C]n [C]s E-protein 
and [C]a [C]n [C]d O 
Jak3 [C]J [C]a [C]k [C]3 S-protein 
. [C]. O 

Transduction [C]T [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y B-cell_line 
human [C]h [C]u [C]m [C]a [C]n I-cell_line 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_line 
blood [C]b [C]l [C]o [C]o [C]d I-cell_line 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
( [C]( O 
PBMCs [C]P [C]B [C]M [C]C [C]s S-cell_type 
) [C]) O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y I-DNA 
virus [C]v [C]i [C]r [C]u [C]s I-DNA 
type [C]t [C]y [C]p [C]e I-DNA 
1-based [C]1 [C]- [C]b [C]a [C]s [C]e [C]d I-DNA 
retroviral [C]r [C]e [C]t [C]r [C]o [C]v [C]i [C]r [C]a [C]l I-DNA 
vector [C]v [C]e [C]c [C]t [C]o [C]r E-DNA 
expressing [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]n [C]g O 
p12 [C]p [C]1 [C]2 B-protein 
( [C]( I-protein 
I [C]I I-protein 
) [C]) E-protein 
also [C]a [C]l [C]s [C]o O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
STAT5 [C]S [C]T [C]A [C]T [C]5 S-protein 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
p12 [C]p [C]1 [C]2 B-protein 
( [C]( I-protein 
I [C]I I-protein 
) [C]) E-protein 
could [C]c [C]o [C]u [C]l [C]d O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
PBMCs [C]P [C]B [C]M [C]C [C]s E-cell_type 
only [C]o [C]n [C]l [C]y O 
after [C]a [C]f [C]t [C]e [C]r O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
by [C]b [C]y O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
cells [C]c [C]e [C]l [C]l [C]s O 
with [C]w [C]i [C]t [C]h O 
low [C]l [C]o [C]w O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
alphaCD3 [C]a [C]l [C]p [C]h [C]a [C]C [C]D [C]3 B-protein 
and [C]a [C]n [C]d I-protein 
alphaCD28 [C]a [C]l [C]p [C]h [C]a [C]C [C]D [C]2 [C]8 I-protein 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s E-protein 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
the [C]t [C]h [C]e O 
proliferative [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
advantage [C]a [C]d [C]v [C]a [C]n [C]t [C]a [C]g [C]e O 
of [C]o [C]f O 
p12 [C]p [C]1 [C]2 B-cell_type 
( [C]( I-cell_type 
I [C]I I-cell_type 
) [C]) I-cell_type 
-transduced [C]- [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]e [C]d I-cell_type 
PBMCs [C]P [C]B [C]M [C]C [C]s E-cell_type 
was [C]w [C]a [C]s O 
evident [C]e [C]v [C]i [C]d [C]e [C]n [C]t O 
mainly [C]m [C]a [C]i [C]n [C]l [C]y O 
at [C]a [C]t O 
low [C]l [C]o [C]w O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
. [C]. O 

Together [C]T [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
, [C], O 
these [C]t [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
p12 [C]p [C]1 [C]2 B-protein 
( [C]( I-protein 
I [C]I I-protein 
) [C]) E-protein 
may [C]m [C]a [C]y O 
confer [C]c [C]o [C]n [C]f [C]e [C]r O 
a [C]a O 
proliferative [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
advantage [C]a [C]d [C]v [C]a [C]n [C]t [C]a [C]g [C]e O 
on [C]o [C]n O 
HTLV-1-infected [C]H [C]T [C]L [C]V [C]- [C]1 [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
suboptimal [C]s [C]u [C]b [C]o [C]p [C]t [C]i [C]m [C]a [C]l O 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
this [C]t [C]h [C]i [C]s O 
event [C]e [C]v [C]e [C]n [C]t O 
may [C]m [C]a [C]y O 
account [C]a [C]c [C]c [C]o [C]u [C]n [C]t O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
clonal [C]c [C]l [C]o [C]n [C]a [C]l O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
infected [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
. [C]. O 

( [C]( O 
Blood. [C]B [C]l [C]o [C]o [C]d [C]. O 
2001 [C]2 [C]0 [C]0 [C]1 O 
; [C]; O 
98 [C]9 [C]8 O 
: [C]: O 
823-829 [C]8 [C]2 [C]3 [C]- [C]8 [C]2 [C]9 O 
) [C]) O 

Single [C]S [C]i [C]n [C]g [C]l [C]e O 
dose [C]d [C]o [C]s [C]e O 
intranasal [C]i [C]n [C]t [C]r [C]a [C]n [C]a [C]s [C]a [C]l O 
administration [C]a [C]d [C]m [C]i [C]n [C]i [C]s [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
retinal [C]r [C]e [C]t [C]i [C]n [C]a [C]l B-protein 
autoantigen [C]a [C]u [C]t [C]o [C]a [C]n [C]t [C]i [C]g [C]e [C]n E-protein 
generates [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]e [C]s O 
a [C]a O 
rapid [C]r [C]a [C]p [C]i [C]d O 
accumulation [C]a [C]c [C]c [C]u [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
cell [C]c [C]e [C]l [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
draining [C]d [C]r [C]a [C]i [C]n [C]i [C]n [C]g O 
lymph [C]l [C]y [C]m [C]p [C]h O 
node [C]n [C]o [C]d [C]e O 
and [C]a [C]n [C]d O 
spleen [C]s [C]p [C]l [C]e [C]e [C]n O 
: [C]: O 
implications [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n [C]s O 
for [C]f [C]o [C]r O 
tolerance [C]t [C]o [C]l [C]e [C]r [C]a [C]n [C]c [C]e O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
. [C]. O 

BACKGROUND/AIMS [C]B [C]A [C]C [C]K [C]G [C]R [C]O [C]U [C]N [C]D [C]/ [C]A [C]I [C]M [C]S O 
: [C]: O 
A [C]A O 
single [C]s [C]i [C]n [C]g [C]l [C]e O 
intranasal [C]i [C]n [C]t [C]r [C]a [C]n [C]a [C]s [C]a [C]l O 
delivery [C]d [C]e [C]l [C]i [C]v [C]e [C]r [C]y O 
of [C]o [C]f O 
retinal [C]r [C]e [C]t [C]i [C]n [C]a [C]l B-protein 
autoantigen [C]a [C]u [C]t [C]o [C]a [C]n [C]t [C]i [C]g [C]e [C]n E-protein 
suppresses [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]e [C]s O 
effectively [C]e [C]f [C]f [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
experimental [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]a [C]l O 
autoimmune [C]a [C]u [C]t [C]o [C]i [C]m [C]m [C]u [C]n [C]e O 
uveoretinitis [C]u [C]v [C]e [C]o [C]r [C]e [C]t [C]i [C]n [C]i [C]t [C]i [C]s O 
( [C]( O 
EAU [C]E [C]A [C]U O 
) [C]) O 
. [C]. O 

To [C]T [C]o O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
unravel [C]u [C]n [C]r [C]a [C]v [C]e [C]l O 
underlying [C]u [C]n [C]d [C]e [C]r [C]l [C]y [C]i [C]n [C]g O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
the [C]t [C]h [C]e O 
authors [C]a [C]u [C]t [C]h [C]o [C]r [C]s O 
wished [C]w [C]i [C]s [C]h [C]e [C]d O 
to [C]t [C]o O 
determine [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e O 
, [C], O 
firstly [C]f [C]i [C]r [C]s [C]t [C]l [C]y O 
, [C], O 
the [C]t [C]h [C]e O 
kinetics [C]k [C]i [C]n [C]e [C]t [C]i [C]c [C]s O 
of [C]o [C]f O 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n O 
delivery [C]d [C]e [C]l [C]i [C]v [C]e [C]r [C]y O 
and [C]a [C]n [C]d O 
, [C], O 
secondly [C]s [C]e [C]c [C]o [C]n [C]d [C]l [C]y O 
, [C], O 
the [C]t [C]h [C]e O 
early [C]e [C]a [C]r [C]l [C]y O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
initial [C]i [C]n [C]i [C]t [C]i [C]a [C]l O 
stages [C]s [C]t [C]a [C]g [C]e [C]s O 
of [C]o [C]f O 
nasal [C]n [C]a [C]s [C]a [C]l O 
mucosal [C]m [C]u [C]c [C]o [C]s [C]a [C]l O 
tolerance [C]t [C]o [C]l [C]e [C]r [C]a [C]n [C]c [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

METHODS [C]M [C]E [C]T [C]H [C]O [C]D [C]S O 
: [C]: O 
Flow [C]F [C]l [C]o [C]w O 
cytometry [C]c [C]y [C]t [C]o [C]m [C]e [C]t [C]r [C]y O 
, [C], O 
cell [C]c [C]e [C]l [C]l O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
microscopy [C]m [C]i [C]c [C]r [C]o [C]s [C]c [C]o [C]p [C]y O 
were [C]w [C]e [C]r [C]e O 
used [C]u [C]s [C]e [C]d O 
to [C]t [C]o O 
track [C]t [C]r [C]a [C]c [C]k O 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n S-protein 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
a [C]a O 
single [C]s [C]i [C]n [C]g [C]l [C]e O 
, [C], O 
intranasal [C]i [C]n [C]t [C]r [C]a [C]n [C]a [C]s [C]a [C]l O 
dose [C]d [C]o [C]s [C]e O 
of [C]o [C]f O 
Alexa-488 [C]A [C]l [C]e [C]x [C]a [C]- [C]4 [C]8 [C]8 B-protein 
labelled [C]l [C]a [C]b [C]e [C]l [C]l [C]e [C]d I-protein 
retinal [C]r [C]e [C]t [C]i [C]n [C]a [C]l I-protein 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n E-protein 
. [C]. O 

RESULTS [C]R [C]E [C]S [C]U [C]L [C]T [C]S O 
: [C]: O 
A [C]A O 
rapid [C]r [C]a [C]p [C]i [C]d O 
accumulation [C]a [C]c [C]c [C]u [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n S-protein 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
superficial [C]s [C]u [C]p [C]e [C]r [C]f [C]i [C]c [C]i [C]a [C]l O 
cervical [C]c [C]e [C]r [C]v [C]i [C]c [C]a [C]l O 
lymph [C]l [C]y [C]m [C]p [C]h O 
nodes [C]n [C]o [C]d [C]e [C]s O 
( [C]( O 
SCLN [C]S [C]C [C]L [C]N O 
) [C]) O 
and [C]a [C]n [C]d O 
spleen [C]s [C]p [C]l [C]e [C]e [C]n O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
after [C]a [C]f [C]t [C]e [C]r O 
30 [C]3 [C]0 O 
minutes [C]m [C]i [C]n [C]u [C]t [C]e [C]s O 
. [C]. O 

Significant [C]S [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
proliferative [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
to [C]t [C]o O 
IRBP [C]I [C]R [C]B [C]P O 
were [C]w [C]e [C]r [C]e O 
elicited [C]e [C]l [C]i [C]c [C]i [C]t [C]e [C]d O 
by [C]b [C]y O 
48 [C]4 [C]8 O 
hours [C]h [C]o [C]u [C]r [C]s O 
indicating [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
systemic [C]s [C]y [C]s [C]t [C]e [C]m [C]i [C]c O 
priming [C]p [C]r [C]i [C]m [C]i [C]n [C]g O 
of [C]o [C]f O 
naive [C]n [C]a [C]i [C]v [C]e B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
to [C]t [C]o O 
retinal [C]r [C]e [C]t [C]i [C]n [C]a [C]l B-protein 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n E-protein 
had [C]h [C]a [C]d O 
occurred [C]o [C]c [C]c [C]u [C]r [C]r [C]e [C]d O 
. [C]. O 

Cell [C]C [C]e [C]l [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
confirmed [C]c [C]o [C]n [C]f [C]i [C]r [C]m [C]e [C]d O 
by [C]b [C]y O 
immunoprecipitation [C]i [C]m [C]m [C]u [C]n [C]o [C]p [C]r [C]e [C]c [C]i [C]p [C]i [C]t [C]a [C]t [C]i [C]o [C]n O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
STAT4 [C]S [C]T [C]A [C]T [C]4 S-protein 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
STAT6 [C]S [C]T [C]A [C]T [C]6 S-protein 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
lymph [C]l [C]y [C]m [C]p [C]h O 
nodes [C]n [C]o [C]d [C]e [C]s O 
and [C]a [C]n [C]d O 
spleen [C]s [C]p [C]l [C]e [C]e [C]n O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
at [C]a [C]t O 
24 [C]2 [C]4 O 
hours [C]h [C]o [C]u [C]r [C]s O 
, [C], O 
STAT4 [C]S [C]T [C]A [C]T [C]4 O 
heterodimerisation [C]h [C]e [C]t [C]e [C]r [C]o [C]d [C]i [C]m [C]e [C]r [C]i [C]s [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
STAT [C]S [C]T [C]A [C]T B-protein 
3 [C]3 E-protein 
was [C]w [C]a [C]s O 
only [C]o [C]n [C]l [C]y O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
spleen [C]s [C]p [C]l [C]e [C]e [C]n O 
. [C]. O 

CONCLUSIONS [C]C [C]O [C]N [C]C [C]L [C]U [C]S [C]I [C]O [C]N [C]S O 
: [C]: O 
The [C]T [C]h [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
provide [C]p [C]r [C]o [C]v [C]i [C]d [C]e O 
novel [C]n [C]o [C]v [C]e [C]l O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
that [C]t [C]h [C]a [C]t O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
a [C]a O 
single [C]s [C]i [C]n [C]g [C]l [C]e O 
intranasal [C]i [C]n [C]t [C]r [C]a [C]n [C]a [C]s [C]a [C]l O 
application [C]a [C]p [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
rapid [C]r [C]a [C]p [C]i [C]d O 
transfer [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]r O 
of [C]o [C]f O 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n S-protein 
occurs [C]o [C]c [C]c [C]u [C]r [C]s O 
. [C]. O 

Resulting [C]R [C]e [C]s [C]u [C]l [C]t [C]i [C]n [C]g O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
develops [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]s O 
consequent [C]c [C]o [C]n [C]s [C]e [C]q [C]u [C]e [C]n [C]t O 
to [C]t [C]o O 
differential [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l O 
cell [C]c [C]e [C]l [C]l O 
signalling [C]s [C]i [C]g [C]n [C]a [C]l [C]l [C]i [C]n [C]g O 
in [C]i [C]n O 
SCLN [C]S [C]C [C]L [C]N O 
and [C]a [C]n [C]d O 
spleen [C]s [C]p [C]l [C]e [C]e [C]n O 
. [C]. O 

Further [C]F [C]u [C]r [C]t [C]h [C]e [C]r O 
understanding [C]u [C]n [C]d [C]e [C]r [C]s [C]t [C]a [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
underlying [C]u [C]n [C]d [C]e [C]r [C]l [C]y [C]i [C]n [C]g O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
, [C], O 
in [C]i [C]n O 
particular [C]p [C]a [C]r [C]t [C]i [C]c [C]u [C]l [C]a [C]r O 
as [C]a [C]s O 
is [C]i [C]s O 
inferred [C]i [C]n [C]f [C]e [C]r [C]r [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
the [C]t [C]h [C]e O 
contribution [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
local [C]l [C]o [C]c [C]a [C]l O 
versus [C]v [C]e [C]r [C]s [C]u [C]s O 
systemic [C]s [C]y [C]s [C]t [C]e [C]m [C]i [C]c O 
tolerance [C]t [C]o [C]l [C]e [C]r [C]a [C]n [C]c [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
, [C], O 
may [C]m [C]a [C]y O 
assist [C]a [C]s [C]s [C]i [C]s [C]t O 
in [C]i [C]n O 
strategies [C]s [C]t [C]r [C]a [C]t [C]e [C]g [C]i [C]e [C]s O 
to [C]t [C]o O 
clinically [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l [C]l [C]y O 
apply [C]a [C]p [C]p [C]l [C]y O 
mucosal [C]m [C]u [C]c [C]o [C]s [C]a [C]l O 
tolerance [C]t [C]o [C]l [C]e [C]r [C]a [C]n [C]c [C]e O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
successfully [C]s [C]u [C]c [C]c [C]e [C]s [C]s [C]f [C]u [C]l [C]l [C]y O 
. [C]. O 

Regulation [C]R [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
interleukin [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n B-protein 
( [C]( I-protein 
IL [C]I [C]L I-protein 
) [C]) I-protein 
-18 [C]- [C]1 [C]8 I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
alpha [C]a [C]l [C]p [C]h [C]a I-protein 
chain [C]c [C]h [C]a [C]i [C]n E-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
on [C]o [C]n O 
CD4 [C]C [C]D [C]4 B-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
T [C]T O 
helper [C]h [C]e [C]l [C]p [C]e [C]r O 
( [C]( O 
Th [C]T [C]h O 
) [C]) O 
1/Th2 [C]1 [C]/ [C]T [C]h [C]2 O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Critical [C]C [C]r [C]i [C]t [C]i [C]c [C]a [C]l O 
downregulatory [C]d [C]o [C]w [C]n [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
. [C]. O 

Interleukin [C]I [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n B-protein 
( [C]( I-protein 
IL [C]I [C]L I-protein 
) [C]) I-protein 
-18 [C]- [C]1 [C]8 E-protein 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
well [C]w [C]e [C]l [C]l O 
characterized [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]d O 
as [C]a [C]s O 
a [C]a O 
costimulatory [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]o [C]r [C]y B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-12-mediated [C]I [C]L [C]- [C]1 [C]2 [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d B-protein 
interferon [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n I-protein 
( [C]( I-protein 
IFN [C]I [C]F [C]N I-protein 
) [C]) I-protein 
-gamma [C]- [C]g [C]a [C]m [C]m [C]a E-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
T [C]T B-cell_type 
helper [C]h [C]e [C]l [C]p [C]e [C]r I-cell_type 
( [C]( I-cell_type 
Th [C]T [C]h I-cell_type 
) [C]) I-cell_type 
1 [C]1 I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
but [C]b [C]u [C]t O 
also [C]a [C]l [C]s [C]o O 
can [C]c [C]a [C]n O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
IL-4 [C]I [C]L [C]- [C]4 O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
thus [C]t [C]h [C]u [C]s O 
facilitate [C]f [C]a [C]c [C]i [C]l [C]i [C]t [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Th2 [C]T [C]h [C]2 B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

To [C]T [C]o O 
determine [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e O 
the [C]t [C]h [C]e O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
by [C]b [C]y O 
which [C]w [C]h [C]i [C]c [C]h O 
IL-18 [C]I [C]L [C]- [C]1 [C]8 S-protein 
might [C]m [C]i [C]g [C]h [C]t O 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
these [C]t [C]h [C]e [C]s [C]e O 
diametrically [C]d [C]i [C]a [C]m [C]e [C]t [C]r [C]i [C]c [C]a [C]l [C]l [C]y O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
, [C], O 
we [C]w [C]e O 
have [C]h [C]a [C]v [C]e O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
the [C]t [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-18 [C]I [C]L [C]- [C]1 [C]8 B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
alpha [C]a [C]l [C]p [C]h [C]a I-protein 
chain [C]c [C]h [C]a [C]i [C]n E-protein 
( [C]( O 
IL-18Ralpha [C]I [C]L [C]- [C]1 [C]8 [C]R [C]a [C]l [C]p [C]h [C]a S-protein 
) [C]) O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
majority [C]m [C]a [C]j [C]o [C]r [C]i [C]t [C]y O 
of [C]o [C]f O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
CD4 [C]C [C]D [C]4 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
constitutively [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
IL-18Ralpha [C]I [C]L [C]- [C]1 [C]8 [C]R [C]a [C]l [C]p [C]h [C]a S-protein 
. [C]. O 

Upon [C]U [C]p [C]o [C]n O 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
IL-12 [C]I [C]L [C]- [C]1 [C]2 S-protein 
, [C], O 
marked [C]m [C]a [C]r [C]k [C]e [C]d O 
enhancement [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
IL-18Ralpha [C]I [C]L [C]- [C]1 [C]8 [C]R [C]a [C]l [C]p [C]h [C]a S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
. [C]. O 

IL-12 [C]I [C]L [C]- [C]1 [C]2 S-protein 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
upregulation [C]u [C]p [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-18Ralpha [C]I [C]L [C]- [C]1 [C]8 [C]R [C]a [C]l [C]p [C]h [C]a S-protein 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
. [C]. O 

Activated [C]A [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-cell_type 
CD4 [C]C [C]D [C]4 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
that [C]t [C]h [C]a [C]t O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
low [C]l [C]o [C]w O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
IL-18Ralpha [C]I [C]L [C]- [C]1 [C]8 [C]R [C]a [C]l [C]p [C]h [C]a S-protein 
could [C]c [C]o [C]u [C]l [C]d O 
produce [C]p [C]r [C]o [C]d [C]u [C]c [C]e O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
when [C]w [C]h [C]e [C]n O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
combination [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-12 [C]I [C]L [C]- [C]1 [C]2 S-protein 
and [C]a [C]n [C]d O 
IL-18 [C]I [C]L [C]- [C]1 [C]8 S-protein 
, [C], O 
while [C]w [C]h [C]i [C]l [C]e O 
CD4 [C]C [C]D [C]4 B-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
which [C]w [C]h [C]i [C]c [C]h O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
high [C]h [C]i [C]g [C]h O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
IL-18Ralpha [C]I [C]L [C]- [C]1 [C]8 [C]R [C]a [C]l [C]p [C]h [C]a S-protein 
could [C]c [C]o [C]u [C]l [C]d O 
respond [C]r [C]e [C]s [C]p [C]o [C]n [C]d O 
to [C]t [C]o O 
IL-18 [C]I [C]L [C]- [C]1 [C]8 S-protein 
alone [C]a [C]l [C]o [C]n [C]e O 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
a [C]a O 
downregulation [C]d [C]o [C]w [C]n [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-18Ralpha [C]I [C]L [C]- [C]1 [C]8 [C]R [C]a [C]l [C]p [C]h [C]a S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Both [C]B [C]o [C]t [C]h O 
IL-4 [C]I [C]L [C]- [C]4 B-cell_type 
( [C]( I-cell_type 
-/ [C]- [C]/ I-cell_type 
) [C]) I-cell_type 
- [C]- I-cell_type 
and [C]a [C]n [C]d I-cell_type 
signal [C]s [C]i [C]g [C]n [C]a [C]l I-cell_type 
transducer [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]e [C]r I-cell_type 
and [C]a [C]n [C]d I-cell_type 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r I-cell_type 
of [C]o [C]f I-cell_type 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-cell_type 
( [C]( I-cell_type 
Stat [C]S [C]t [C]a [C]t I-cell_type 
) [C]) I-cell_type 
6 [C]6 I-cell_type 
( [C]( I-cell_type 
-/ [C]- [C]/ I-cell_type 
) [C]) I-cell_type 
- [C]- I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
IL-18Ralpha [C]I [C]L [C]- [C]1 [C]8 [C]R [C]a [C]l [C]p [C]h [C]a S-protein 
after [C]a [C]f [C]t [C]e [C]r O 
TCR [C]T [C]C [C]R O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
Stat6 [C]S [C]t [C]a [C]t [C]6 O 
( [C]( O 
-/ [C]- [C]/ O 
) [C]) O 
- [C]- O 
mice [C]m [C]i [C]c [C]e O 
produced [C]p [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
more [C]m [C]o [C]r [C]e O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
IL-18 [C]I [C]L [C]- [C]1 [C]8 S-protein 
than [C]t [C]h [C]a [C]n O 
wild-type [C]w [C]i [C]l [C]d [C]- [C]t [C]y [C]p [C]e O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
positive/negative [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e [C]/ [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IL-18Ralpha [C]I [C]L [C]- [C]1 [C]8 [C]R [C]a [C]l [C]p [C]h [C]a S-protein 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
major [C]m [C]a [C]j [C]o [C]r O 
inductive [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]v [C]e O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
( [C]( O 
IL-12 [C]I [C]L [C]- [C]1 [C]2 S-protein 
and [C]a [C]n [C]d O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
) [C]) O 
determines [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]s O 
the [C]t [C]h [C]e O 
capacity [C]c [C]a [C]p [C]a [C]c [C]i [C]t [C]y O 
of [C]o [C]f O 
IL-18 [C]I [C]L [C]- [C]1 [C]8 S-protein 
to [C]t [C]o O 
polarize [C]p [C]o [C]l [C]a [C]r [C]i [C]z [C]e O 
an [C]a [C]n O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
. [C]. O 

Glucocorticoid-regulated [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

Glucocorticoids [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
are [C]a [C]r [C]e O 
the [C]t [C]h [C]e O 
most [C]m [C]o [C]s [C]t O 
effective [C]e [C]f [C]f [C]e [C]c [C]t [C]i [C]v [C]e O 
antiinflammatory [C]a [C]n [C]t [C]i [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
drugs [C]d [C]r [C]u [C]g [C]s O 
used [C]u [C]s [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
asthma [C]a [C]s [C]t [C]h [C]m [C]a O 
. [C]. O 

They [C]T [C]h [C]e [C]y O 
act [C]a [C]c [C]t O 
by [C]b [C]y O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
a [C]a O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
( [C]( O 
GR [C]G [C]R S-protein 
) [C]) O 
that [C]t [C]h [C]a [C]t O 
, [C], O 
upon [C]u [C]p [C]o [C]n O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
translocates [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]e [C]s O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
nucleus [C]n [C]u [C]c [C]l [C]e [C]u [C]s O 
and [C]a [C]n [C]d O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
increases [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
( [C]( O 
transactivates [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]s O 
) [C]) O 
or [C]o [C]r O 
decreases [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
( [C]( O 
transrepresses [C]t [C]r [C]a [C]n [C]s [C]r [C]e [C]p [C]r [C]e [C]s [C]s [C]e [C]s O 
) [C]) O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Inhibition [C]I [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
pro-inflammatory [C]p [C]r [C]o [C]- [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
( [C]( I-protein 
AP [C]A [C]P I-protein 
) [C]) I-protein 
-1 [C]- [C]1 E-protein 
, [C], O 
signal [C]s [C]i [C]g [C]n [C]a [C]l B-protein 
transducers [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]e [C]r [C]s I-protein 
and [C]a [C]n [C]d I-protein 
activators [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r [C]s I-protein 
of [C]o [C]f I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n E-protein 
( [C]( O 
STATs [C]S [C]T [C]A [C]T [C]s S-protein 
) [C]) O 
, [C], O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
of [C]o [C]f I-protein 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d I-protein 
T [C]T I-protein 
cells [C]c [C]e [C]l [C]l [C]s E-protein 
( [C]( O 
NFAT [C]N [C]F [C]A [C]T S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
( [C]( I-protein 
NF [C]N [C]F I-protein 
) [C]) I-protein 
-kappa [C]- [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
is [C]i [C]s O 
thought [C]t [C]h [C]o [C]u [C]g [C]h [C]t O 
to [C]t [C]o O 
be [C]b [C]e O 
a [C]a O 
major [C]m [C]a [C]j [C]o [C]r O 
action [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
. [C]. O 

Acetylation [C]A [C]c [C]e [C]t [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
histones [C]h [C]i [C]s [C]t [C]o [C]n [C]e [C]s S-protein 
allows [C]a [C]l [C]l [C]o [C]w [C]s O 
unwinding [C]u [C]n [C]w [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
local [C]l [C]o [C]c [C]a [C]l B-DNA 
DNA [C]D [C]N [C]A I-DNA 
structure [C]s [C]t [C]r [C]u [C]c [C]t [C]u [C]r [C]e E-DNA 
and [C]a [C]n [C]d O 
enables [C]e [C]n [C]a [C]b [C]l [C]e [C]s O 
RNA [C]R [C]N [C]A B-protein 
polymerase [C]p [C]o [C]l [C]y [C]m [C]e [C]r [C]a [C]s [C]e I-protein 
II [C]I [C]I E-protein 
to [C]t [C]o O 
enhance [C]e [C]n [C]h [C]a [C]n [C]c [C]e O 
gene [C]g [C]e [C]n [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
. [C]. O 

Histone [C]H [C]i [C]s [C]t [C]o [C]n [C]e O 
acetylation [C]a [C]c [C]e [C]t [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
balance [C]b [C]a [C]l [C]a [C]n [C]c [C]e O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
histone [C]h [C]i [C]s [C]t [C]o [C]n [C]e B-protein 
acetyltransferases [C]a [C]c [C]e [C]t [C]y [C]l [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]r [C]a [C]s [C]e [C]s E-protein 
( [C]( O 
HATs [C]H [C]A [C]T [C]s S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
histone [C]h [C]i [C]s [C]t [C]o [C]n [C]e B-protein 
deacetylases [C]d [C]e [C]a [C]c [C]e [C]t [C]y [C]l [C]a [C]s [C]e [C]s E-protein 
( [C]( O 
HDACs [C]H [C]D [C]A [C]C [C]s S-protein 
) [C]) O 
. [C]. O 

GR [C]G [C]R S-protein 
acts [C]a [C]c [C]t [C]s O 
as [C]a [C]s O 
a [C]a O 
direct [C]d [C]i [C]r [C]e [C]c [C]t O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a O 
B-induced [C]B [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
HAT [C]H [C]A [C]T O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
also [C]a [C]l [C]s [C]o O 
by [C]b [C]y O 
recruiting [C]r [C]e [C]c [C]r [C]u [C]i [C]t [C]i [C]n [C]g O 
HDAC2 [C]H [C]D [C]A [C]C [C]2 S-protein 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B/HAT [C]B [C]/ [C]H [C]A [C]T I-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
. [C]. O 

A [C]A O 
sub-group [C]s [C]u [C]b [C]- [C]g [C]r [C]o [C]u [C]p O 
of [C]o [C]f O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
glucocorticoid-insensitive [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]i [C]n [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
asthma [C]a [C]s [C]t [C]h [C]m [C]a O 
have [C]h [C]a [C]v [C]e O 
an [C]a [C]n O 
inability [C]i [C]n [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
to [C]t [C]o O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
histone [C]h [C]i [C]s [C]t [C]o [C]n [C]e O 
acetylation [C]a [C]c [C]e [C]t [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
GR-specific [C]G [C]R [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-protein 
HAT [C]H [C]A [C]T E-protein 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
suggests [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]s O 
that [C]t [C]h [C]a [C]t O 
pharmacological [C]p [C]h [C]a [C]r [C]m [C]a [C]c [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
manipulation [C]m [C]a [C]n [C]i [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
histone [C]h [C]i [C]s [C]t [C]o [C]n [C]e O 
acetylation [C]a [C]c [C]e [C]t [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
status [C]s [C]t [C]a [C]t [C]u [C]s O 
is [C]i [C]s O 
a [C]a O 
potentially [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l [C]l [C]y O 
useful [C]u [C]s [C]e [C]f [C]u [C]l O 
approach [C]a [C]p [C]p [C]r [C]o [C]a [C]c [C]h O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
diseases [C]d [C]i [C]s [C]e [C]a [C]s [C]e [C]s O 
. [C]. O 

Identification [C]I [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
precise [C]p [C]r [C]e [C]c [C]i [C]s [C]e O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
by [C]b [C]y O 
which [C]w [C]h [C]i [C]c [C]h O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-protein 
GR [C]G [C]R E-protein 
recruits [C]r [C]e [C]c [C]r [C]u [C]i [C]t [C]s O 
HDAC2 [C]H [C]D [C]A [C]C [C]2 S-protein 
may [C]m [C]a [C]y O 
reveal [C]r [C]e [C]v [C]e [C]a [C]l O 
new [C]n [C]e [C]w O 
targets [C]t [C]a [C]r [C]g [C]e [C]t [C]s O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
drugs [C]d [C]r [C]u [C]g [C]s O 
that [C]t [C]h [C]a [C]t O 
may [C]m [C]a [C]y O 
dissociate [C]d [C]i [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
antiinflammatory [C]a [C]n [C]t [C]i [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
actions [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
from [C]f [C]r [C]o [C]m O 
their [C]t [C]h [C]e [C]i [C]r O 
side [C]s [C]i [C]d [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
that [C]t [C]h [C]a [C]t O 
are [C]a [C]r [C]e O 
largely [C]l [C]a [C]r [C]g [C]e [C]l [C]y O 
due [C]d [C]u [C]e O 
to [C]t [C]o O 
gene [C]g [C]e [C]n [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

Copyright [C]C [C]o [C]p [C]y [C]r [C]i [C]g [C]h [C]t O 
Academic [C]A [C]c [C]a [C]d [C]e [C]m [C]i [C]c O 
Press [C]P [C]r [C]e [C]s [C]s O 
. [C]. O 

Differential [C]D [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l O 
ultraviolet-B-induced [C]u [C]l [C]t [C]r [C]a [C]v [C]i [C]o [C]l [C]e [C]t [C]- [C]B [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
immunomodulation [C]i [C]m [C]m [C]u [C]n [C]o [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
XPA [C]X [C]P [C]A O 
, [C], O 
XPC [C]X [C]P [C]C O 
, [C], O 
and [C]a [C]n [C]d O 
CSB [C]C [C]S [C]B O 
DNA [C]D [C]N [C]A O 
repair-deficient [C]r [C]e [C]p [C]a [C]i [C]r [C]- [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
mice [C]m [C]i [C]c [C]e O 
. [C]. O 

Ultraviolet [C]U [C]l [C]t [C]r [C]a [C]v [C]i [C]o [C]l [C]e [C]t O 
B [C]B O 
irradiation [C]i [C]r [C]r [C]a [C]d [C]i [C]a [C]t [C]i [C]o [C]n O 
has [C]h [C]a [C]s O 
serious [C]s [C]e [C]r [C]i [C]o [C]u [C]s O 
consequences [C]c [C]o [C]n [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s O 
for [C]f [C]o [C]r O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
immunity [C]i [C]m [C]m [C]u [C]n [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
can [C]c [C]a [C]n O 
suppress [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s O 
the [C]t [C]h [C]e O 
rejection [C]r [C]e [C]j [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
skin [C]s [C]k [C]i [C]n O 
tumors [C]t [C]u [C]m [C]o [C]r [C]s O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
to [C]t [C]o O 
infectious [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]u [C]s O 
diseases [C]d [C]i [C]s [C]e [C]a [C]s [C]e [C]s O 
. [C]. O 

DNA [C]D [C]N [C]A O 
damage [C]d [C]a [C]m [C]a [C]g [C]e O 
plays [C]p [C]l [C]a [C]y [C]s O 
a [C]a O 
crucial [C]c [C]r [C]u [C]c [C]i [C]a [C]l O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
immunomodulatory [C]i [C]m [C]m [C]u [C]n [C]o [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
ultraviolet [C]u [C]l [C]t [C]r [C]a [C]v [C]i [C]o [C]l [C]e [C]t O 
B [C]B O 
, [C], O 
as [C]a [C]s O 
impaired [C]i [C]m [C]p [C]a [C]i [C]r [C]e [C]d O 
repair [C]r [C]e [C]p [C]a [C]i [C]r O 
of [C]o [C]f O 
ultraviolet-B-induced [C]u [C]l [C]t [C]r [C]a [C]v [C]i [C]o [C]l [C]e [C]t [C]- [C]B [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
DNA [C]D [C]N [C]A O 
damage [C]d [C]a [C]m [C]a [C]g [C]e O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
cause [C]c [C]a [C]u [C]s [C]e O 
suppression [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
immunity [C]i [C]m [C]m [C]u [C]n [C]i [C]t [C]y O 
. [C]. O 

Ultraviolet-B-induced [C]U [C]l [C]t [C]r [C]a [C]v [C]i [C]o [C]l [C]e [C]t [C]- [C]B [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
DNA [C]D [C]N [C]A O 
damage [C]d [C]a [C]m [C]a [C]g [C]e O 
is [C]i [C]s O 
repaired [C]r [C]e [C]p [C]a [C]i [C]r [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
nucleotide [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e O 
excision [C]e [C]x [C]c [C]i [C]s [C]i [C]o [C]n O 
repair [C]r [C]e [C]p [C]a [C]i [C]r O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
very [C]v [C]e [C]r [C]y O 
efficiently [C]e [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t [C]l [C]y O 
. [C]. O 

Nucleotide [C]N [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e O 
excision [C]e [C]x [C]c [C]i [C]s [C]i [C]o [C]n O 
repair [C]r [C]e [C]p [C]a [C]i [C]r O 
comprises [C]c [C]o [C]m [C]p [C]r [C]i [C]s [C]e [C]s O 
two [C]t [C]w [C]o O 
subpathways [C]s [C]u [C]b [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
: [C]: O 
transcription-coupled [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]- [C]c [C]o [C]u [C]p [C]l [C]e [C]d O 
and [C]a [C]n [C]d O 
global [C]g [C]l [C]o [C]b [C]a [C]l O 
genome [C]g [C]e [C]n [C]o [C]m [C]e O 
repair [C]r [C]e [C]p [C]a [C]i [C]r O 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
the [C]t [C]h [C]e O 
immunologic [C]i [C]m [C]m [C]u [C]n [C]o [C]l [C]o [C]g [C]i [C]c O 
consequences [C]c [C]o [C]n [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s O 
of [C]o [C]f O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
nucleotide [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e O 
excision [C]e [C]x [C]c [C]i [C]s [C]i [C]o [C]n O 
repair [C]r [C]e [C]p [C]a [C]i [C]r O 
defects [C]d [C]e [C]f [C]e [C]c [C]t [C]s O 
in [C]i [C]n O 
three [C]t [C]h [C]r [C]e [C]e O 
mouse [C]m [C]o [C]u [C]s [C]e O 
models [C]m [C]o [C]d [C]e [C]l [C]s O 
, [C], O 
XPA [C]X [C]P [C]A O 
, [C], O 
XPC [C]X [C]P [C]C O 
, [C], O 
and [C]a [C]n [C]d O 
CSB [C]C [C]S [C]B O 
mutant [C]m [C]u [C]t [C]a [C]n [C]t O 
mice [C]m [C]i [C]c [C]e O 
, [C], O 
were [C]w [C]e [C]r [C]e O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
. [C]. O 

XPA [C]X [C]P [C]A O 
mice [C]m [C]i [C]c [C]e O 
carry [C]c [C]a [C]r [C]r [C]y O 
a [C]a O 
total [C]t [C]o [C]t [C]a [C]l O 
nucleotide [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e O 
excision [C]e [C]x [C]c [C]i [C]s [C]i [C]o [C]n O 
repair [C]r [C]e [C]p [C]a [C]i [C]r O 
defect [C]d [C]e [C]f [C]e [C]c [C]t O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
XPC [C]X [C]P [C]C O 
and [C]a [C]n [C]d O 
CSB [C]C [C]S [C]B O 
mice [C]m [C]i [C]c [C]e O 
only [C]o [C]n [C]l [C]y O 
lack [C]l [C]a [C]c [C]k O 
global [C]g [C]l [C]o [C]b [C]a [C]l O 
genome [C]g [C]e [C]n [C]o [C]m [C]e O 
and [C]a [C]n [C]d O 
transcription-coupled [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]- [C]c [C]o [C]u [C]p [C]l [C]e [C]d O 
nucleotide [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e O 
excision [C]e [C]x [C]c [C]i [C]s [C]i [C]o [C]n O 
repair [C]r [C]e [C]p [C]a [C]i [C]r O 
, [C], O 
respectively [C]r [C]e [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
. [C]. O 

Our [C]O [C]u [C]r O 
data [C]d [C]a [C]t [C]a O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
parameters [C]p [C]a [C]r [C]a [C]m [C]e [C]t [C]e [C]r [C]s O 
in [C]i [C]n O 
XPA [C]X [C]P [C]A O 
, [C], O 
XPC [C]X [C]P [C]C O 
, [C], O 
and [C]a [C]n [C]d O 
CSB [C]C [C]S [C]B O 
mice [C]m [C]i [C]c [C]e O 
are [C]a [C]r [C]e O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
their [C]t [C]h [C]e [C]i [C]r O 
wild-type [C]w [C]i [C]l [C]d [C]- [C]t [C]y [C]p [C]e O 
( [C]( O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
) [C]) O 
littermates [C]l [C]i [C]t [C]t [C]e [C]r [C]m [C]a [C]t [C]e [C]s O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
may [C]m [C]a [C]y O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
reported [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]d O 
altered [C]a [C]l [C]t [C]e [C]r [C]e [C]d O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
in [C]i [C]n O 
xeroderma [C]x [C]e [C]r [C]o [C]d [C]e [C]r [C]m [C]a O 
pigmentosum [C]p [C]i [C]g [C]m [C]e [C]n [C]t [C]o [C]s [C]u [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
are [C]a [C]r [C]e O 
not [C]n [C]o [C]t O 
constitutive [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
but [C]b [C]u [C]t O 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
due [C]d [C]u [C]e O 
to [C]t [C]o O 
external [C]e [C]x [C]t [C]e [C]r [C]n [C]a [C]l O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
, [C], O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
ultraviolet [C]u [C]l [C]t [C]r [C]a [C]v [C]i [C]o [C]l [C]e [C]t O 
B [C]B O 
. [C]. O 

Upon [C]U [C]p [C]o [C]n O 
exposure [C]e [C]x [C]p [C]o [C]s [C]u [C]r [C]e O 
to [C]t [C]o O 
ultraviolet [C]u [C]l [C]t [C]r [C]a [C]v [C]i [C]o [C]l [C]e [C]t O 
B [C]B O 
, [C], O 
only [C]o [C]n [C]l [C]y O 
XPA [C]X [C]P [C]A O 
mice [C]m [C]i [C]c [C]e O 
are [C]a [C]r [C]e O 
very [C]v [C]e [C]r [C]y O 
sensitive [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
to [C]t [C]o O 
ultraviolet-B-induced [C]u [C]l [C]t [C]r [C]a [C]v [C]i [C]o [C]l [C]e [C]t [C]- [C]B [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Th1-mediated [C]T [C]h [C]1 [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
contact [C]c [C]o [C]n [C]t [C]a [C]c [C]t O 
hypersensitivity [C]h [C]y [C]p [C]e [C]r [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
and [C]a [C]n [C]d O 
interferon-gamma [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
skin [C]s [C]k [C]i [C]n O 
draining [C]d [C]r [C]a [C]i [C]n [C]i [C]n [C]g O 
lymph [C]l [C]y [C]m [C]p [C]h O 
nodes [C]n [C]o [C]d [C]e [C]s O 
. [C]. O 

Lipopolysaccharide-stimulated [C]L [C]i [C]p [C]o [C]p [C]o [C]l [C]y [C]s [C]a [C]c [C]c [C]h [C]a [C]r [C]i [C]d [C]e [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
tumor [C]t [C]u [C]m [C]o [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
and [C]a [C]n [C]d O 
interleukin-10 [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]1 [C]0 S-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
are [C]a [C]r [C]e O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
augmented [C]a [C]u [C]g [C]m [C]e [C]n [C]t [C]e [C]d O 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
XPA [C]X [C]P [C]A O 
and [C]a [C]n [C]d O 
CSB [C]C [C]S [C]B O 
mice [C]m [C]i [C]c [C]e O 
after [C]a [C]f [C]t [C]e [C]r O 
ultraviolet [C]u [C]l [C]t [C]r [C]a [C]v [C]i [C]o [C]l [C]e [C]t O 
B [C]B O 
exposure [C]e [C]x [C]p [C]o [C]s [C]u [C]r [C]e O 
. [C]. O 

Lymph [C]L [C]y [C]m [C]p [C]h O 
node [C]n [C]o [C]d [C]e O 
cell [C]c [C]e [C]l [C]l O 
numbers [C]n [C]u [C]m [C]b [C]e [C]r [C]s O 
were [C]w [C]e [C]r [C]e O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
very [C]v [C]e [C]r [C]y O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
in [C]i [C]n O 
XPA [C]X [C]P [C]A O 
, [C], O 
mildly [C]m [C]i [C]l [C]d [C]l [C]y O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
in [C]i [C]n O 
CSB [C]C [C]S [C]B O 
, [C], O 
and [C]a [C]n [C]d O 
not [C]n [C]o [C]t O 
in [C]i [C]n O 
XPC [C]X [C]P [C]C O 
mice [C]m [C]i [C]c [C]e O 
. [C]. O 

In [C]I [C]n O 
general [C]g [C]e [C]n [C]e [C]r [C]a [C]l O 
XPC [C]X [C]P [C]C O 
mice [C]m [C]i [C]c [C]e O 
do [C]d [C]o O 
not [C]n [C]o [C]t O 
exhibit [C]e [C]x [C]h [C]i [C]b [C]i [C]t O 
any [C]a [C]n [C]y O 
indication [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
ultraviolet [C]u [C]l [C]t [C]r [C]a [C]v [C]i [C]o [C]l [C]e [C]t O 
B [C]B O 
susceptibility [C]s [C]u [C]s [C]c [C]e [C]p [C]t [C]i [C]b [C]i [C]l [C]i [C]t [C]y O 
with [C]w [C]i [C]t [C]h O 
regard [C]r [C]e [C]g [C]a [C]r [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
parameters [C]p [C]a [C]r [C]a [C]m [C]e [C]t [C]e [C]r [C]s O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
both [C]b [C]o [C]t [C]h O 
global [C]g [C]l [C]o [C]b [C]a [C]l O 
genome [C]g [C]e [C]n [C]o [C]m [C]e O 
repair [C]r [C]e [C]p [C]a [C]i [C]r O 
and [C]a [C]n [C]d O 
transcription-coupled [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]- [C]c [C]o [C]u [C]p [C]l [C]e [C]d O 
repair [C]r [C]e [C]p [C]a [C]i [C]r O 
are [C]a [C]r [C]e O 
needed [C]n [C]e [C]e [C]d [C]e [C]d O 
to [C]t [C]o O 
prevent [C]p [C]r [C]e [C]v [C]e [C]n [C]t O 
immunomodulation [C]i [C]m [C]m [C]u [C]n [C]o [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
ultraviolet [C]u [C]l [C]t [C]r [C]a [C]v [C]i [C]o [C]l [C]e [C]t O 
B [C]B O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
transcription-coupled [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]- [C]c [C]o [C]u [C]p [C]l [C]e [C]d O 
repair [C]r [C]e [C]p [C]a [C]i [C]r O 
is [C]i [C]s O 
the [C]t [C]h [C]e O 
major [C]m [C]a [C]j [C]o [C]r O 
DNA [C]D [C]N [C]A O 
repair [C]r [C]e [C]p [C]a [C]i [C]r O 
subpathway [C]s [C]u [C]b [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
of [C]o [C]f O 
nucleotide [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e O 
excision [C]e [C]x [C]c [C]i [C]s [C]i [C]o [C]n O 
repair [C]r [C]e [C]p [C]a [C]i [C]r O 
that [C]t [C]h [C]a [C]t O 
prevents [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]s O 
the [C]t [C]h [C]e O 
acute [C]a [C]c [C]u [C]t [C]e O 
ultraviolet-B-induced [C]u [C]l [C]t [C]r [C]a [C]v [C]i [C]o [C]l [C]e [C]t [C]- [C]B [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
erythema [C]e [C]r [C]y [C]t [C]h [C]e [C]m [C]a O 
. [C]. O 

Biomechanical [C]B [C]i [C]o [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]c [C]a [C]l O 
strain [C]s [C]t [C]r [C]a [C]i [C]n O 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
class [C]c [C]l [C]a [C]s [C]s O 
a [C]a O 
scavenger [C]s [C]c [C]a [C]v [C]e [C]n [C]g [C]e [C]r B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
monocyte/macrophages [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]/ [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
THP-1 [C]T [C]H [C]P [C]- [C]1 B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
: [C]: O 
a [C]a O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
of [C]o [C]f O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
atherosclerosis [C]a [C]t [C]h [C]e [C]r [C]o [C]s [C]c [C]l [C]e [C]r [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
hypertension [C]h [C]y [C]p [C]e [C]r [C]t [C]e [C]n [C]s [C]i [C]o [C]n O 
. [C]. O 

BACKGROUND [C]B [C]A [C]C [C]K [C]G [C]R [C]O [C]U [C]N [C]D O 
: [C]: O 
Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
hypertension [C]h [C]y [C]p [C]e [C]r [C]t [C]e [C]n [C]s [C]i [C]o [C]n O 
is [C]i [C]s O 
an [C]a [C]n O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
risk [C]r [C]i [C]s [C]k O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
atherosclerosis [C]a [C]t [C]h [C]e [C]r [C]o [C]s [C]c [C]l [C]e [C]r [C]o [C]s [C]i [C]s O 
, [C], O 
the [C]t [C]h [C]e O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
for [C]f [C]o [C]r O 
this [C]t [C]h [C]i [C]s O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
are [C]a [C]r [C]e O 
incompletely [C]i [C]n [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e [C]l [C]y O 
described [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
. [C]. O 

Previous [C]P [C]r [C]e [C]v [C]i [C]o [C]u [C]s O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
have [C]h [C]a [C]v [C]e O 
suggested [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
biomechanical [C]b [C]i [C]o [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]c [C]a [C]l O 
strain [C]s [C]t [C]r [C]a [C]i [C]n O 
regulates [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]s O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
. [C]. O 

We [C]W [C]e O 
tested [C]t [C]e [C]s [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
hypothesis [C]h [C]y [C]p [C]o [C]t [C]h [C]e [C]s [C]i [C]s O 
that [C]t [C]h [C]a [C]t O 
biomechanical [C]b [C]i [C]o [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]c [C]a [C]l O 
strain [C]s [C]t [C]r [C]a [C]i [C]n O 
can [C]c [C]a [C]n O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
class [C]c [C]l [C]a [C]s [C]s B-protein 
A [C]A I-protein 
scavenger [C]s [C]c [C]a [C]v [C]e [C]n [C]g [C]e [C]r I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
( [C]( O 
SRA [C]S [C]R [C]A S-protein 
) [C]) O 
, [C], O 
an [C]a [C]n O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
lipoprotein [C]l [C]i [C]p [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
in [C]i [C]n O 
atherogenesis [C]a [C]t [C]h [C]e [C]r [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
. [C]. O 

METHODS [C]M [C]E [C]T [C]H [C]O [C]D [C]S O 
AND [C]A [C]N [C]D O 
RESULTS [C]R [C]E [C]S [C]U [C]L [C]T [C]S O 
: [C]: O 
Human [C]H [C]u [C]m [C]a [C]n B-cell_type 
monocyte/macrophages [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]/ [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s E-cell_type 
or [C]o [C]r O 
THP-1 [C]T [C]H [C]P [C]- [C]1 B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
cultured [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]d O 
in [C]i [C]n O 
a [C]a O 
device [C]d [C]e [C]v [C]i [C]c [C]e O 
that [C]t [C]h [C]a [C]t O 
imposes [C]i [C]m [C]p [C]o [C]s [C]e [C]s O 
uniform [C]u [C]n [C]i [C]f [C]o [C]r [C]m O 
biaxial [C]b [C]i [C]a [C]x [C]i [C]a [C]l O 
cyclic [C]c [C]y [C]c [C]l [C]i [C]c O 
1-Hz [C]1 [C]- [C]H [C]z O 
strains [C]s [C]t [C]r [C]a [C]i [C]n [C]s O 
of [C]o [C]f O 
0 [C]0 O 
% [C]% O 
, [C], O 
1 [C]1 O 
% [C]% O 
, [C], O 
2 [C]2 O 
% [C]% O 
, [C], O 
or [C]o [C]r O 
3 [C]3 O 
% [C]% O 
, [C], O 
and [C]a [C]n [C]d O 
SRA [C]S [C]R [C]A S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
. [C]. O 

Mechanical [C]M [C]e [C]c [C]h [C]a [C]n [C]i [C]c [C]a [C]l O 
strains [C]s [C]t [C]r [C]a [C]i [C]n [C]s O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
SRA [C]S [C]R [C]A B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
( [C]( O 
3.5+/-0.6-fold [C]3 [C]. [C]5 [C]+ [C]/ [C]- [C]0 [C]. [C]6 [C]- [C]f [C]o [C]l [C]d O 
at [C]a [C]t O 
3 [C]3 O 
% [C]% O 
strain [C]s [C]t [C]r [C]a [C]i [C]n O 
for [C]f [C]o [C]r O 
48 [C]4 [C]8 O 
hours [C]h [C]o [C]u [C]r [C]s O 
, [C], O 
P [C]P O 
< [C]< O 
0.01 [C]0 [C]. [C]0 [C]1 O 
) [C]) O 
and [C]a [C]n [C]d O 
SRA [C]S [C]R [C]A B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
in [C]i [C]n O 
THP-1 [C]T [C]H [C]P [C]- [C]1 B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
an [C]a [C]n O 
amplitude-dependent [C]a [C]m [C]p [C]l [C]i [C]t [C]u [C]d [C]e [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
manner [C]m [C]a [C]n [C]n [C]e [C]r O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
accompanied [C]a [C]c [C]c [C]o [C]m [C]p [C]a [C]n [C]i [C]e [C]d O 
by [C]b [C]y O 
augmented [C]a [C]u [C]g [C]m [C]e [C]n [C]t [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
class [C]c [C]l [C]a [C]s [C]s B-protein 
B [C]B I-protein 
scavenger [C]s [C]c [C]a [C]v [C]e [C]n [C]g [C]e [C]r I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
CD36 [C]C [C]D [C]3 [C]6 E-protein 
( [C]( O 
2.8+/-0.3-fold [C]2 [C]. [C]8 [C]+ [C]/ [C]- [C]0 [C]. [C]3 [C]- [C]f [C]o [C]l [C]d O 
, [C], O 
P [C]P O 
< [C]< O 
0.001 [C]0 [C]. [C]0 [C]0 [C]1 O 
) [C]) O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
by [C]b [C]y O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
peroxisome [C]p [C]e [C]r [C]o [C]x [C]i [C]s [C]o [C]m [C]e B-protein 
proliferator-activated [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]o [C]r [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d I-protein 
receptor-gamma [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]- [C]g [C]a [C]m [C]m [C]a E-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

To [C]T [C]o O 
evaluate [C]e [C]v [C]a [C]l [C]u [C]a [C]t [C]e O 
this [C]t [C]h [C]i [C]s O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
, [C], O 
apolipoprotein [C]a [C]p [C]o [C]l [C]i [C]p [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
E [C]E O 
( [C]( O 
-/- [C]- [C]/ [C]- O 
) [C]) O 
mice [C]m [C]i [C]c [C]e O 
were [C]w [C]e [C]r [C]e O 
randomly [C]r [C]a [C]n [C]d [C]o [C]m [C]l [C]y O 
assigned [C]a [C]s [C]s [C]i [C]g [C]n [C]e [C]d O 
to [C]t [C]o O 
receive [C]r [C]e [C]c [C]e [C]i [C]v [C]e O 
standard [C]s [C]t [C]a [C]n [C]d [C]a [C]r [C]d O 
chow [C]c [C]h [C]o [C]w O 
, [C], O 
a [C]a O 
high-cholesterol [C]h [C]i [C]g [C]h [C]- [C]c [C]h [C]o [C]l [C]e [C]s [C]t [C]e [C]r [C]o [C]l O 
diet [C]d [C]i [C]e [C]t O 
, [C], O 
or [C]o [C]r O 
a [C]a O 
high-cholesterol [C]h [C]i [C]g [C]h [C]- [C]c [C]h [C]o [C]l [C]e [C]s [C]t [C]e [C]r [C]o [C]l O 
diet [C]d [C]i [C]e [C]t O 
with [C]w [C]i [C]t [C]h O 
hypertension [C]h [C]y [C]p [C]e [C]r [C]t [C]e [C]n [C]s [C]i [C]o [C]n O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
angiotensin [C]a [C]n [C]g [C]i [C]o [C]t [C]e [C]n [C]s [C]i [C]n O 
II [C]I [C]I O 
infusion [C]i [C]n [C]f [C]u [C]s [C]i [C]o [C]n O 
for [C]f [C]o [C]r O 
8 [C]8 O 
weeks [C]w [C]e [C]e [C]k [C]s O 
. [C]. O 

Immunohistochemistry [C]I [C]m [C]m [C]u [C]n [C]o [C]h [C]i [C]s [C]t [C]o [C]c [C]h [C]e [C]m [C]i [C]s [C]t [C]r [C]y O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
among [C]a [C]m [C]o [C]n [C]g O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_type 
in [C]i [C]n O 
atherosclerotic [C]a [C]t [C]h [C]e [C]r [C]o [C]s [C]c [C]l [C]e [C]r [C]o [C]t [C]i [C]c O 
lesions [C]l [C]e [C]s [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
aorta [C]a [C]o [C]r [C]t [C]a O 
, [C], O 
the [C]t [C]h [C]e O 
proportion [C]p [C]r [C]o [C]p [C]o [C]r [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_type 
with [C]w [C]i [C]t [C]h O 
SRA [C]S [C]R [C]A S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
highest [C]h [C]i [C]g [C]h [C]e [C]s [C]t O 
in [C]i [C]n O 
hypertensive [C]h [C]y [C]p [C]e [C]r [C]t [C]e [C]n [C]s [C]i [C]v [C]e O 
animals [C]a [C]n [C]i [C]m [C]a [C]l [C]s O 
on [C]o [C]n O 
a [C]a O 
high-cholesterol [C]h [C]i [C]g [C]h [C]- [C]c [C]h [C]o [C]l [C]e [C]s [C]t [C]e [C]r [C]o [C]l O 
diet [C]d [C]i [C]e [C]t O 
( [C]( O 
43.9+/-0.7 [C]4 [C]3 [C]. [C]9 [C]+ [C]/ [C]- [C]0 [C]. [C]7 O 
% [C]% O 
, [C], O 
versus [C]v [C]e [C]r [C]s [C]u [C]s O 
12.0+/-2.0 [C]1 [C]2 [C]. [C]0 [C]+ [C]/ [C]- [C]2 [C]. [C]0 O 
% [C]% O 
for [C]f [C]o [C]r O 
normotensive [C]n [C]o [C]r [C]m [C]o [C]t [C]e [C]n [C]s [C]i [C]v [C]e O 
animals [C]a [C]n [C]i [C]m [C]a [C]l [C]s O 
on [C]o [C]n O 
a [C]a O 
high-cholesterol [C]h [C]i [C]g [C]h [C]- [C]c [C]h [C]o [C]l [C]e [C]s [C]t [C]e [C]r [C]o [C]l O 
diet [C]d [C]i [C]e [C]t O 
and [C]a [C]n [C]d O 
4.7+/-4.7 [C]4 [C]. [C]7 [C]+ [C]/ [C]- [C]4 [C]. [C]7 O 
% [C]% O 
for [C]f [C]o [C]r O 
animals [C]a [C]n [C]i [C]m [C]a [C]l [C]s O 
on [C]o [C]n O 
standard [C]s [C]t [C]a [C]n [C]d [C]a [C]r [C]d O 
chow [C]c [C]h [C]o [C]w O 
; [C]; O 
P [C]P O 
< [C]< O 
0.001 [C]0 [C]. [C]0 [C]0 [C]1 O 
) [C]) O 
. [C]. O 

CONCLUSIONS [C]C [C]O [C]N [C]C [C]L [C]U [C]S [C]I [C]O [C]N [C]S O 
: [C]: O 
Biomechanical [C]B [C]i [C]o [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]c [C]a [C]l O 
strain [C]s [C]t [C]r [C]a [C]i [C]n O 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
SRA [C]S [C]R [C]A S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
by [C]b [C]y O 
monocyte/macrophages [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]/ [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_type 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
for [C]f [C]o [C]r O 
promotion [C]p [C]r [C]o [C]m [C]o [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
atherosclerosis [C]a [C]t [C]h [C]e [C]r [C]o [C]s [C]c [C]l [C]e [C]r [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
hypertensive [C]h [C]y [C]p [C]e [C]r [C]t [C]e [C]n [C]s [C]i [C]v [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

High [C]H [C]i [C]g [C]h O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
MCP-1 [C]M [C]C [C]P [C]- [C]1 O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
partly [C]p [C]a [C]r [C]t [C]l [C]y O 
via [C]v [C]i [C]a O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
kinase-AP-1 [C]k [C]i [C]n [C]a [C]s [C]e [C]- [C]A [C]P [C]- [C]1 O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
in [C]i [C]n O 
peritoneal [C]p [C]e [C]r [C]i [C]t [C]o [C]n [C]e [C]a [C]l B-cell_type 
mesothelial [C]m [C]e [C]s [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

BACKGROUND [C]B [C]A [C]C [C]K [C]G [C]R [C]O [C]U [C]N [C]D O 
: [C]: O 
High [C]H [C]i [C]g [C]h O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
in [C]i [C]n O 
peritoneal [C]p [C]e [C]r [C]i [C]t [C]o [C]n [C]e [C]a [C]l O 
dialysis [C]d [C]i [C]a [C]l [C]y [C]s [C]i [C]s O 
solutions [C]s [C]o [C]l [C]u [C]t [C]i [C]o [C]n [C]s O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
implicated [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
pathogenesis [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
peritoneal [C]p [C]e [C]r [C]i [C]t [C]o [C]n [C]e [C]a [C]l O 
fibrosis [C]f [C]i [C]b [C]r [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
ambulatory [C]a [C]m [C]b [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
peritoneal [C]p [C]e [C]r [C]i [C]t [C]o [C]n [C]e [C]a [C]l O 
dialysis [C]d [C]i [C]a [C]l [C]y [C]s [C]i [C]s O 
( [C]( O 
CAPD [C]C [C]A [C]P [C]D O 
) [C]) O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
the [C]t [C]h [C]e O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
are [C]a [C]r [C]e O 
not [C]n [C]o [C]t O 
very [C]v [C]e [C]r [C]y O 
clear [C]c [C]l [C]e [C]a [C]r O 
. [C]. O 

Peritoneal [C]P [C]e [C]r [C]i [C]t [C]o [C]n [C]e [C]a [C]l B-cell_type 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s E-cell_type 
seem [C]s [C]e [C]e [C]m O 
to [C]t [C]o O 
participate [C]p [C]a [C]r [C]t [C]i [C]c [C]i [C]p [C]a [C]t [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
of [C]o [C]f O 
peritoneal [C]p [C]e [C]r [C]i [C]t [C]o [C]n [C]e [C]a [C]l O 
fibrosis [C]f [C]i [C]b [C]r [C]o [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
monocyte [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e B-protein 
chemoattractant [C]c [C]h [C]e [C]m [C]o [C]a [C]t [C]t [C]r [C]a [C]c [C]t [C]a [C]n [C]t I-protein 
protein-1 [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]1 E-protein 
( [C]( O 
MCP-1 [C]M [C]C [C]P [C]- [C]1 S-protein 
) [C]) O 
plays [C]p [C]l [C]a [C]y [C]s O 
a [C]a O 
key [C]k [C]e [C]y O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
recruitment [C]r [C]e [C]c [C]r [C]u [C]i [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
toward [C]t [C]o [C]w [C]a [C]r [C]d O 
the [C]t [C]h [C]e O 
peritoneal [C]p [C]e [C]r [C]i [C]t [C]o [C]n [C]e [C]a [C]l O 
cavity [C]c [C]a [C]v [C]i [C]t [C]y O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
little [C]l [C]i [C]t [C]t [C]l [C]e O 
is [C]i [C]s O 
known [C]k [C]n [C]o [C]w [C]n O 
about [C]a [C]b [C]o [C]u [C]t O 
the [C]t [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
high [C]h [C]i [C]g [C]h O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
on [C]o [C]n O 
MCP-1 [C]M [C]C [C]P [C]- [C]1 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
its [C]i [C]t [C]s O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
peritoneal [C]p [C]e [C]r [C]i [C]t [C]o [C]n [C]e [C]a [C]l I-cell_type 
mesothelial [C]m [C]e [C]s [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

METHODS [C]M [C]E [C]T [C]H [C]O [C]D [C]S O 
: [C]: O 
Mesothelial [C]M [C]e [C]s [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
cultured [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
( [C]( O 
5 [C]5 O 
to [C]t [C]o O 
100 [C]1 [C]0 [C]0 O 
mmol/L [C]m [C]m [C]o [C]l [C]/ [C]L O 
) [C]) O 
or [C]o [C]r O 
mannitol [C]m [C]a [C]n [C]n [C]i [C]t [C]o [C]l O 
chronically [C]c [C]h [C]r [C]o [C]n [C]i [C]c [C]a [C]l [C]l [C]y O 
for [C]f [C]o [C]r O 
up [C]u [C]p O 
to [C]t [C]o O 
seven [C]s [C]e [C]v [C]e [C]n O 
days [C]d [C]a [C]y [C]s O 
. [C]. O 

MCP-1 [C]M [C]C [C]P [C]- [C]1 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
mRNA [C]m [C]R [C]N [C]A O 
and [C]a [C]n [C]d O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
was [C]w [C]a [C]s O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
by [C]b [C]y O 
Northern [C]N [C]o [C]r [C]t [C]h [C]e [C]r [C]n O 
blot [C]b [C]l [C]o [C]t O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
enzyme-linked [C]e [C]n [C]z [C]y [C]m [C]e [C]- [C]l [C]i [C]n [C]k [C]e [C]d O 
immunosorbent [C]i [C]m [C]m [C]u [C]n [C]o [C]s [C]o [C]r [C]b [C]e [C]n [C]t O 
assay [C]a [C]s [C]s [C]a [C]y O 
( [C]( O 
ELISA [C]E [C]L [C]I [C]S [C]A O 
) [C]) O 
. [C]. O 

Chemotactic [C]C [C]h [C]e [C]m [C]o [C]t [C]a [C]c [C]t [C]i [C]c O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
high-glucose-conditioned [C]h [C]i [C]g [C]h [C]- [C]g [C]l [C]u [C]c [C]o [C]s [C]e [C]- [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n [C]e [C]d O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
supernatant [C]s [C]u [C]p [C]e [C]r [C]n [C]a [C]t [C]a [C]n [C]t O 
was [C]w [C]a [C]s O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
by [C]b [C]y O 
chemotactic [C]c [C]h [C]e [C]m [C]o [C]t [C]a [C]c [C]t [C]i [C]c O 
assay [C]a [C]s [C]s [C]a [C]y O 
. [C]. O 

To [C]T [C]o O 
examine [C]e [C]x [C]a [C]m [C]i [C]n [C]e O 
the [C]t [C]h [C]e O 
roles [C]r [C]o [C]l [C]e [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r B-protein 
protein-1 [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]1 E-protein 
( [C]( O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor-kappaB [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
( [C]( O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
) [C]) O 
, [C], O 
electrophoretic [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
assay [C]a [C]s [C]s [C]a [C]y O 
( [C]( O 
EMSA [C]E [C]M [C]S [C]A O 
) [C]) O 
was [C]w [C]a [C]s O 
performed [C]p [C]e [C]r [C]f [C]o [C]r [C]m [C]e [C]d O 
. [C]. O 

RESULTS [C]R [C]E [C]S [C]U [C]L [C]T [C]S O 
: [C]: O 
Glucose [C]G [C]l [C]u [C]c [C]o [C]s [C]e O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
MCP-1 [C]M [C]C [C]P [C]- [C]1 B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
a [C]a O 
time- [C]t [C]i [C]m [C]e [C]- O 
and [C]a [C]n [C]d O 
dose-dependent [C]d [C]o [C]s [C]e [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
manner [C]m [C]a [C]n [C]n [C]e [C]r O 
. [C]. O 

MCP-1 [C]M [C]C [C]P [C]- [C]1 B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
in [C]i [C]n O 
cell [C]c [C]e [C]l [C]l O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
supernant [C]s [C]u [C]p [C]e [C]r [C]n [C]a [C]n [C]t O 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
. [C]. O 

Equivalent [C]E [C]q [C]u [C]i [C]v [C]a [C]l [C]e [C]n [C]t O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
mannitol [C]m [C]a [C]n [C]n [C]i [C]t [C]o [C]l O 
had [C]h [C]a [C]d O 
no [C]n [C]o O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
. [C]. O 

High-glucose-conditioned [C]H [C]i [C]g [C]h [C]- [C]g [C]l [C]u [C]c [C]o [C]s [C]e [C]- [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n [C]e [C]d O 
supernatant [C]s [C]u [C]p [C]e [C]r [C]n [C]a [C]t [C]a [C]n [C]t O 
possessed [C]p [C]o [C]s [C]s [C]e [C]s [C]s [C]e [C]d O 
an [C]a [C]n O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
chemotactic [C]c [C]h [C]e [C]m [C]o [C]t [C]a [C]c [C]t [C]i [C]c O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
for [C]f [C]o [C]r O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
was [C]w [C]a [C]s O 
neutralized [C]n [C]e [C]u [C]t [C]r [C]a [C]l [C]i [C]z [C]e [C]d O 
by [C]b [C]y O 
anti-MCP-1 [C]a [C]n [C]t [C]i [C]- [C]M [C]C [C]P [C]- [C]1 B-protein 
antibody [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y E-protein 
. [C]. O 

EMSA [C]E [C]M [C]S [C]A O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
a [C]a O 
time- [C]t [C]i [C]m [C]e [C]- O 
and [C]a [C]n [C]d O 
dose-dependent [C]d [C]o [C]s [C]e [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
manner [C]m [C]a [C]n [C]n [C]e [C]r O 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
. [C]. O 

Curcumin [C]C [C]u [C]r [C]c [C]u [C]m [C]i [C]n O 
, [C], O 
an [C]a [C]n O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
of [C]o [C]f O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
, [C], O 
dose-dependently [C]d [C]o [C]s [C]e [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t [C]l [C]y O 
suppressed [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
MCP-1 [C]M [C]C [C]P [C]- [C]1 B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
by [C]b [C]y O 
high [C]h [C]i [C]g [C]h O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
. [C]. O 

Tyrosine [C]T [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
genistein [C]g [C]e [C]n [C]i [C]s [C]t [C]e [C]i [C]n O 
( [C]( O 
12.5 [C]1 [C]2 [C]. [C]5 O 
to [C]t [C]o O 
50 [C]5 [C]0 O 
micromol/L [C]m [C]i [C]c [C]r [C]o [C]m [C]o [C]l [C]/ [C]L O 
) [C]) O 
and [C]a [C]n [C]d O 
herbimycin [C]h [C]e [C]r [C]b [C]i [C]m [C]y [C]c [C]i [C]n O 
A [C]A O 
( [C]( O 
0.1 [C]0 [C]. [C]1 O 
to [C]t [C]o O 
1 [C]1 O 
micromol/L [C]m [C]i [C]c [C]r [C]o [C]m [C]o [C]l [C]/ [C]L O 
) [C]) O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
high-glucose-induced [C]h [C]i [C]g [C]h [C]- [C]g [C]l [C]u [C]c [C]o [C]s [C]e [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
MCP-1 [C]M [C]C [C]P [C]- [C]1 B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
a [C]a O 
dose-dependent [C]d [C]o [C]s [C]e [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
manner [C]m [C]a [C]n [C]n [C]e [C]r O 
, [C], O 
and [C]a [C]n [C]d O 
also [C]a [C]l [C]s [C]o O 
suppressed [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
high-glucose-induced [C]h [C]i [C]g [C]h [C]- [C]g [C]l [C]u [C]c [C]o [C]s [C]e [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

CONCLUSIONS [C]C [C]O [C]N [C]C [C]L [C]U [C]S [C]I [C]O [C]N [C]S O 
: [C]: O 
: [C]: O 
High [C]H [C]i [C]g [C]h O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
mesothelial [C]m [C]e [C]s [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l O 
MCP-1 [C]M [C]C [C]P [C]- [C]1 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
partly [C]p [C]a [C]r [C]t [C]l [C]y O 
via [C]v [C]i [C]a O 
the [C]t [C]h [C]e O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
kinase- [C]k [C]i [C]n [C]a [C]s [C]e [C]- O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
. [C]. O 

Signal [C]S [C]i [C]g [C]n [C]a [C]l O 
thresholds [C]t [C]h [C]r [C]e [C]s [C]h [C]o [C]l [C]d [C]s O 
and [C]a [C]n [C]d O 
modular [C]m [C]o [C]d [C]u [C]l [C]a [C]r O 
synergy [C]s [C]y [C]n [C]e [C]r [C]g [C]y O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
costimulatory [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
molecules [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]s O 
in [C]i [C]n O 
B [C]B B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

We [C]W [C]e O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
modulating [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
densities [C]d [C]e [C]n [C]s [C]i [C]t [C]i [C]e [C]s O 
of [C]o [C]f O 
CD80 [C]C [C]D [C]8 [C]0 S-protein 
and [C]a [C]n [C]d O 
CD86 [C]C [C]D [C]8 [C]6 S-protein 
in [C]i [C]n O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
ligation [C]l [C]i [C]g [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Ag [C]A [C]g B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
, [C], O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n B-protein 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e E-protein 
CD54 [C]C [C]D [C]5 [C]4 S-protein 
. [C]. O 

Whereas [C]W [C]h [C]e [C]r [C]e [C]a [C]s O 
B [C]B B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
Ag [C]A [C]g I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
( [C]( O 
BCR [C]B [C]C [C]R S-protein 
) [C]) O 
cross-linking [C]c [C]r [C]o [C]s [C]s [C]- [C]l [C]i [C]n [C]k [C]i [C]n [C]g O 
alone [C]a [C]l [C]o [C]n [C]e O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
CD86 [C]C [C]D [C]8 [C]6 S-protein 
, [C], O 
up-regulation [C]u [C]p [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CD80 [C]C [C]D [C]8 [C]0 S-protein 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
dual [C]d [C]u [C]a [C]l O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
anti-IgM [C]a [C]n [C]t [C]i [C]- [C]I [C]g [C]M S-protein 
and [C]a [C]n [C]d O 
anti-CD54 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]5 [C]4 S-protein 
. [C]. O 

The [C]T [C]h [C]e O 
principal [C]p [C]r [C]i [C]n [C]c [C]i [C]p [C]a [C]l O 
downstream [C]d [C]o [C]w [C]n [C]s [C]t [C]r [C]e [C]a [C]m O 
component [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t O 
contributed [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e [C]d O 
by [C]b [C]y O 
BCR [C]B [C]C [C]R S-protein 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
, [C], O 
toward [C]t [C]o [C]w [C]a [C]r [C]d O 
both [C]b [C]o [C]t [C]h O 
CD80 [C]C [C]D [C]8 [C]0 S-protein 
and [C]a [C]n [C]d O 
CD86 [C]C [C]D [C]8 [C]6 S-protein 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
, [C], O 
was [C]w [C]a [C]s O 
the [C]t [C]h [C]e O 
elevated [C]e [C]l [C]e [C]v [C]a [C]t [C]e [C]d O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
free [C]f [C]r [C]e [C]e O 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c O 
Ca [C]C [C]a O 
( [C]( O 
2+ [C]2 [C]+ O 
) [C]) O 
, [C], O 
recruited [C]r [C]e [C]c [C]r [C]u [C]i [C]t [C]e [C]d O 
by [C]b [C]y O 
way [C]w [C]a [C]y O 
of [C]o [C]f O 
capacitative [C]c [C]a [C]p [C]a [C]c [C]i [C]t [C]a [C]t [C]i [C]v [C]e O 
influx [C]i [C]n [C]f [C]l [C]u [C]x O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
alone [C]a [C]l [C]o [C]n [C]e O 
was [C]w [C]a [C]s O 
sufficient [C]s [C]u [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
to [C]t [C]o O 
generate [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]e O 
an [C]a [C]n O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
CD86 [C]C [C]D [C]8 [C]6 S-protein 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
CD80 [C]C [C]D [C]8 [C]0 S-protein 
enhancement [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]m [C]e [C]n [C]t O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
the [C]t [C]h [C]e O 
concerted [C]c [C]o [C]n [C]c [C]e [C]r [C]t [C]e [C]d O 
action [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
Ca [C]C [C]a O 
( [C]( O 
2+ [C]2 [C]+ O 
) [C]) O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
CD54-initiated [C]C [C]D [C]5 [C]4 [C]- [C]i [C]n [C]i [C]t [C]i [C]a [C]t [C]e [C]d O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
nexus [C]n [C]e [C]x [C]u [C]s O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
anti-IgM [C]a [C]n [C]t [C]i [C]- [C]I [C]g [C]M O 
and [C]a [C]n [C]d O 
anti-CD54 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]5 [C]4 O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
context [C]c [C]o [C]n [C]t [C]e [C]x [C]t O 
of [C]o [C]f O 
CD80 [C]C [C]D [C]8 [C]0 S-protein 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
was [C]w [C]a [C]s O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
to [C]t [C]o O 
involve [C]i [C]n [C]v [C]o [C]l [C]v [C]e O 
a [C]a O 
self-propagating [C]s [C]e [C]l [C]f [C]- [C]p [C]r [C]o [C]p [C]a [C]g [C]a [C]t [C]i [C]n [C]g O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
of [C]o [C]f O 
sequential [C]s [C]e [C]q [C]u [C]e [C]n [C]t [C]i [C]a [C]l O 
synergy [C]s [C]y [C]n [C]e [C]r [C]g [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
first [C]f [C]i [C]r [C]s [C]t O 
step [C]s [C]t [C]e [C]p O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
amplified [C]a [C]m [C]p [C]l [C]i [C]f [C]i [C]e [C]d O 
accumulation [C]a [C]c [C]c [C]u [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
cAMP [C]c [C]A [C]M [C]P O 
, [C], O 
as [C]a [C]s O 
a [C]a O 
result [C]r [C]e [C]s [C]u [C]l [C]t O 
of [C]o [C]f O 
cross-talk [C]c [C]r [C]o [C]s [C]s [C]- [C]t [C]a [C]l [C]k O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
BCR [C]B [C]C [C]R S-protein 
-mobilized [C]- [C]m [C]o [C]b [C]i [C]l [C]i [C]z [C]e [C]d O 
Ca [C]C [C]a O 
( [C]( O 
2+ [C]2 [C]+ O 
) [C]) O 
and [C]a [C]n [C]d O 
CD54-derived [C]C [C]D [C]5 [C]4 [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
then [C]t [C]h [C]e [C]n O 
facilitated [C]f [C]a [C]c [C]i [C]l [C]i [C]t [C]a [C]t [C]e [C]d O 
a [C]a O 
second [C]s [C]e [C]c [C]o [C]n [C]d O 
synergistic [C]s [C]y [C]n [C]e [C]r [C]g [C]i [C]s [C]t [C]i [C]c O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
Ca [C]C [C]a O 
( [C]( O 
2+ [C]2 [C]+ O 
) [C]) O 
and [C]a [C]n [C]d O 
cAMP [C]c [C]A [C]M [C]P O 
, [C], O 
culminating [C]c [C]u [C]l [C]m [C]i [C]n [C]a [C]t [C]i [C]n [C]g O 
in [C]i [C]n O 
CD80 [C]C [C]D [C]8 [C]0 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Our [C]O [C]u [C]r O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
of [C]o [C]f O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transducer [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]e [C]r O 
requirements [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]m [C]e [C]n [C]t [C]s O 
, [C], O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
added [C]a [C]d [C]d [C]e [C]d O 
consequences [C]c [C]o [C]n [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s O 
of [C]o [C]f O 
cross-talk [C]c [C]r [C]o [C]s [C]s [C]- [C]t [C]a [C]l [C]k O 
, [C], O 
offers [C]o [C]f [C]f [C]e [C]r [C]s O 
an [C]a [C]n O 
explanation [C]e [C]x [C]p [C]l [C]a [C]n [C]a [C]t [C]i [C]o [C]n O 
for [C]f [C]o [C]r O 
variable [C]v [C]a [C]r [C]i [C]a [C]b [C]l [C]e O 
modulation [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
costimulatory [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
diverse [C]d [C]i [C]v [C]e [C]r [C]s [C]e O 
physiological [C]p [C]h [C]y [C]s [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
stimuli [C]s [C]t [C]i [C]m [C]u [C]l [C]i O 
. [C]. O 

Importantly [C]I [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t [C]l [C]y O 
, [C], O 
these [C]t [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
also [C]a [C]l [C]s [C]o O 
reveal [C]r [C]e [C]v [C]e [C]a [C]l O 
how [C]h [C]o [C]w O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
threshold [C]t [C]h [C]r [C]e [C]s [C]h [C]o [C]l [C]d O 
barriers [C]b [C]a [C]r [C]r [C]i [C]e [C]r [C]s O 
for [C]f [C]o [C]r O 
recruitment [C]r [C]e [C]c [C]r [C]u [C]i [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
individual [C]i [C]n [C]d [C]i [C]v [C]i [C]d [C]u [C]a [C]l O 
second [C]s [C]e [C]c [C]o [C]n [C]d O 
messengers [C]m [C]e [C]s [C]s [C]e [C]n [C]g [C]e [C]r [C]s O 
can [C]c [C]a [C]n O 
be [C]b [C]e O 
overcome [C]o [C]v [C]e [C]r [C]c [C]o [C]m [C]e O 
by [C]b [C]y O 
constructive [C]c [C]o [C]n [C]s [C]t [C]r [C]u [C]c [C]t [C]i [C]v [C]e O 
convergence [C]c [C]o [C]n [C]v [C]e [C]r [C]g [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
modules [C]m [C]o [C]d [C]u [C]l [C]e [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
Epstein-Barr [C]E [C]p [C]s [C]t [C]e [C]i [C]n [C]- [C]B [C]a [C]r [C]r O 
virus [C]v [C]i [C]r [C]u [C]s O 
in [C]i [C]n O 
neoplastic [C]n [C]e [C]o [C]p [C]l [C]a [C]s [C]t [C]i [C]c O 
transformation [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
review [C]r [C]e [C]v [C]i [C]e [C]w O 
, [C], O 
we [C]w [C]e O 
focus [C]f [C]o [C]c [C]u [C]s O 
on [C]o [C]n O 
new [C]n [C]e [C]w O 
data [C]d [C]a [C]t [C]a O 
from [C]f [C]r [C]o [C]m O 
basic [C]b [C]a [C]s [C]i [C]c O 
, [C], O 
translational [C]t [C]r [C]a [C]n [C]s [C]l [C]a [C]t [C]i [C]o [C]n [C]a [C]l O 
and [C]a [C]n [C]d O 
clinical [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
research [C]r [C]e [C]s [C]e [C]a [C]r [C]c [C]h O 
relating [C]r [C]e [C]l [C]a [C]t [C]i [C]n [C]g O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
Epstein-Barr [C]E [C]p [C]s [C]t [C]e [C]i [C]n [C]- [C]B [C]a [C]r [C]r O 
virus [C]v [C]i [C]r [C]u [C]s O 
( [C]( O 
EBV [C]E [C]B [C]V O 
) [C]) O 
. [C]. O 

Beside [C]B [C]e [C]s [C]i [C]d [C]e O 
its [C]i [C]t [C]s O 
well-known [C]w [C]e [C]l [C]l [C]- [C]k [C]n [C]o [C]w [C]n O 
tropism [C]t [C]r [C]o [C]p [C]i [C]s [C]m O 
for [C]f [C]o [C]r O 
B [C]B B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
epithelial [C]e [C]p [C]i [C]t [C]h [C]e [C]l [C]i [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
EBV [C]E [C]B [C]V O 
also [C]a [C]l [C]s [C]o O 
infects [C]i [C]n [C]f [C]e [C]c [C]t [C]s O 
T [C]T B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
, [C], O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
and [C]a [C]n [C]d O 
granulocytes [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
. [C]. O 

After [C]A [C]f [C]t [C]e [C]r O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
, [C], O 
EBV [C]E [C]B [C]V O 
persists [C]p [C]e [C]r [C]s [C]i [C]s [C]t [C]s O 
throughout [C]t [C]h [C]r [C]o [C]u [C]g [C]h [C]o [C]u [C]t O 
the [C]t [C]h [C]e O 
life [C]l [C]i [C]f [C]e O 
span [C]s [C]p [C]a [C]n O 
in [C]i [C]n O 
resting [C]r [C]e [C]s [C]t [C]i [C]n [C]g B-cell_type 
memory [C]m [C]e [C]m [C]o [C]r [C]y I-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
from [C]f [C]r [C]o [C]m O 
where [C]w [C]h [C]e [C]r [C]e O 
it [C]i [C]t O 
is [C]i [C]s O 
reactivated [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
upon [C]u [C]p [C]o [C]n O 
breakdown [C]b [C]r [C]e [C]a [C]k [C]d [C]o [C]w [C]n O 
of [C]o [C]f O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
immunity [C]i [C]m [C]m [C]u [C]n [C]i [C]t [C]y O 
. [C]. O 

In [C]I [C]n O 
the [C]t [C]h [C]e O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
of [C]o [C]f O 
neoplastic [C]n [C]e [C]o [C]p [C]l [C]a [C]s [C]t [C]i [C]c O 
transformation [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
the [C]t [C]h [C]e O 
EBV-encoded [C]E [C]B [C]V [C]- [C]e [C]n [C]c [C]o [C]d [C]e [C]d B-DNA 
latent [C]l [C]a [C]t [C]e [C]n [C]t I-DNA 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e I-DNA 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-DNA 
1 [C]1 I-DNA 
( [C]( I-DNA 
LMP1 [C]L [C]M [C]P [C]1 I-DNA 
) [C]) I-DNA 
oncogene [C]o [C]n [C]c [C]o [C]g [C]e [C]n [C]e E-DNA 
represents [C]r [C]e [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]s O 
the [C]t [C]h [C]e O 
major [C]m [C]a [C]j [C]o [C]r O 
driving [C]d [C]r [C]i [C]v [C]i [C]n [C]g O 
force [C]f [C]o [C]r [C]c [C]e O 
. [C]. O 

LMP1 [C]L [C]M [C]P [C]1 S-protein 
acts [C]a [C]c [C]t [C]s O 
like [C]l [C]i [C]k [C]e O 
a [C]a O 
constitutively [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y B-protein 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
tumor [C]t [C]u [C]m [C]o [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y E-protein 
and [C]a [C]n [C]d O 
allows [C]a [C]l [C]l [C]o [C]w [C]s O 
the [C]t [C]h [C]e O 
amplification [C]a [C]m [C]p [C]l [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
or [C]o [C]r O 
bypassing [C]b [C]y [C]p [C]a [C]s [C]s [C]i [C]n [C]g O 
of [C]o [C]f O 
physiological [C]p [C]h [C]y [C]s [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
direct [C]d [C]i [C]r [C]e [C]c [C]t O 
and [C]a [C]n [C]d O 
indirect [C]i [C]n [C]d [C]i [C]r [C]e [C]c [C]t O 
interactions [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
with [C]w [C]i [C]t [C]h O 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
tumor [C]t [C]u [C]m [C]o [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
receptor-associated [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]- [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
( [C]( I-protein 
TRAF [C]T [C]R [C]A [C]F I-protein 
) [C]) I-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y E-protein 
. [C]. O 

TRAF2 [C]T [C]R [C]A [C]F [C]2 S-protein 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
JAK3 [C]J [C]A [C]K [C]3 S-protein 
/ [C]/ O 
STAT [C]S [C]T [C]A [C]T S-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
may [C]m [C]a [C]y O 
result [C]r [C]e [C]s [C]u [C]l [C]t O 
in [C]i [C]n O 
sustained [C]s [C]u [C]s [C]t [C]a [C]i [C]n [C]e [C]d O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
leading [C]l [C]e [C]a [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a S-cell_line 
. [C]. O 

The [C]T [C]h [C]e O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
LMP1 [C]L [C]M [C]P [C]1 S-protein 
to [C]t [C]o O 
suppress [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s O 
germinal [C]g [C]e [C]r [C]m [C]i [C]n [C]a [C]l O 
center [C]c [C]e [C]n [C]t [C]e [C]r O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
its [C]i [C]t [C]s O 
capacity [C]c [C]a [C]p [C]a [C]c [C]i [C]t [C]y O 
to [C]t [C]o O 
mediate [C]m [C]e [C]d [C]i [C]a [C]t [C]e O 
its [C]i [C]t [C]s O 
own [C]o [C]w [C]n O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
shed [C]s [C]h [C]e [C]d O 
new [C]n [C]e [C]w O 
light [C]l [C]i [C]g [C]h [C]t O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
pathogenesis [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
EBV-associated [C]E [C]B [C]V [C]- [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
latency [C]l [C]a [C]t [C]e [C]n [C]c [C]y O 
type [C]t [C]y [C]p [C]e O 
II [C]I [C]I O 
lymphoproliferations [C]l [C]y [C]m [C]p [C]h [C]o [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
like [C]l [C]i [C]k [C]e O 
Hodgkin [C]H [C]o [C]d [C]g [C]k [C]i [C]n O 
's [C]' [C]s O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
and [C]a [C]n [C]d O 
angioimmunoblastic [C]a [C]n [C]g [C]i [C]o [C]i [C]m [C]m [C]u [C]n [C]o [C]b [C]l [C]a [C]s [C]t [C]i [C]c O 
lymphadenopathy [C]l [C]y [C]m [C]p [C]h [C]a [C]d [C]e [C]n [C]o [C]p [C]a [C]t [C]h [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
carboxy [C]c [C]a [C]r [C]b [C]o [C]x [C]y B-protein 
terminus [C]t [C]e [C]r [C]m [C]i [C]n [C]u [C]s E-protein 
of [C]o [C]f O 
LMP1 [C]L [C]M [C]P [C]1 S-protein 
is [C]i [C]s O 
also [C]a [C]l [C]s [C]o O 
a [C]a O 
reliable [C]r [C]e [C]l [C]i [C]a [C]b [C]l [C]e O 
marker [C]m [C]a [C]r [C]k [C]e [C]r O 
for [C]f [C]o [C]r O 
individual [C]i [C]n [C]d [C]i [C]v [C]i [C]d [C]u [C]a [C]l O 
EBV [C]E [C]B [C]V O 
strain [C]s [C]t [C]r [C]a [C]i [C]n O 
identification [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
thus [C]t [C]h [C]u [C]s O 
offers [C]o [C]f [C]f [C]e [C]r [C]s O 
new [C]n [C]e [C]w O 
possibilities [C]p [C]o [C]s [C]s [C]i [C]b [C]i [C]l [C]i [C]t [C]i [C]e [C]s O 
in [C]i [C]n O 
tracing [C]t [C]r [C]a [C]c [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
events [C]e [C]v [C]e [C]n [C]t [C]s O 
leading [C]l [C]e [C]a [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
posttransplant [C]p [C]o [C]s [C]t [C]t [C]r [C]a [C]n [C]s [C]p [C]l [C]a [C]n [C]t O 
lymphoproliferative [C]l [C]y [C]m [C]p [C]h [C]o [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
disorders [C]d [C]i [C]s [C]o [C]r [C]d [C]e [C]r [C]s O 
( [C]( O 
PTLDs [C]P [C]T [C]L [C]D [C]s O 
) [C]) O 
. [C]. O 

Cytotoxic [C]C [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c B-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
directed [C]d [C]i [C]r [C]e [C]c [C]t [C]e [C]d O 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
well-characterized [C]w [C]e [C]l [C]l [C]- [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]d O 
epitopes [C]e [C]p [C]i [C]t [C]o [C]p [C]e [C]s O 
of [C]o [C]f O 
EBV [C]E [C]B [C]V B-DNA 
latency [C]l [C]a [C]t [C]e [C]n [C]c [C]y I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
represent [C]r [C]e [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
an [C]a [C]n O 
already [C]a [C]l [C]r [C]e [C]a [C]d [C]y O 
successful [C]s [C]u [C]c [C]c [C]e [C]s [C]s [C]f [C]u [C]l O 
and [C]a [C]n [C]d O 
promising [C]p [C]r [C]o [C]m [C]i [C]s [C]i [C]n [C]g O 
therapeutic [C]t [C]h [C]e [C]r [C]a [C]p [C]e [C]u [C]t [C]i [C]c O 
approach [C]a [C]p [C]p [C]r [C]o [C]a [C]c [C]h O 
to [C]t [C]o O 
EBV-associated [C]E [C]B [C]V [C]- [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d B-cell_line 
lymphomas [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a [C]s E-cell_line 
, [C], O 
in [C]i [C]n O 
particular [C]p [C]a [C]r [C]t [C]i [C]c [C]u [C]l [C]a [C]r O 
PTLDs [C]P [C]T [C]L [C]D [C]s O 

Interferon-alpha [C]I [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
drives [C]d [C]r [C]i [C]v [C]e [C]s O 
T [C]T O 
cell-mediated [C]c [C]e [C]l [C]l [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
immunopathology [C]i [C]m [C]m [C]u [C]n [C]o [C]p [C]a [C]t [C]h [C]o [C]l [C]o [C]g [C]y O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
intestine [C]i [C]n [C]t [C]e [C]s [C]t [C]i [C]n [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
interferon [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n B-protein 
( [C]( I-protein 
IFN [C]I [C]F [C]N I-protein 
) [C]) I-protein 
-alpha [C]- [C]a [C]l [C]p [C]h [C]a E-protein 
to [C]t [C]o O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
autoimmunity [C]a [C]u [C]t [C]o [C]i [C]m [C]m [C]u [C]n [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
exacerbate [C]e [C]x [C]a [C]c [C]e [C]r [C]b [C]a [C]t [C]e O 
Th1 [C]T [C]h [C]1 O 
diseases [C]d [C]i [C]s [C]e [C]a [C]s [C]e [C]s O 
is [C]i [C]s O 
well [C]w [C]e [C]l [C]l O 
known [C]k [C]n [C]o [C]w [C]n O 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
recently [C]r [C]e [C]c [C]e [C]n [C]t [C]l [C]y O 
described [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
IFN-alpha [C]I [C]F [C]N [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
mucosa [C]m [C]u [C]c [C]o [C]s [C]a O 
of [C]o [C]f O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
celiac [C]c [C]e [C]l [C]i [C]a [C]c O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
( [C]( O 
CD [C]C [C]D O 
) [C]) O 
, [C], O 
a [C]a O 
gluten-sensitive [C]g [C]l [C]u [C]t [C]e [C]n [C]- [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
Th1-mediated [C]T [C]h [C]1 [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
enteropathy [C]e [C]n [C]t [C]e [C]r [C]o [C]p [C]a [C]t [C]h [C]y O 
, [C], O 
characterized [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]d O 
by [C]b [C]y O 
villous [C]v [C]i [C]l [C]l [C]o [C]u [C]s O 
atrophy [C]a [C]t [C]r [C]o [C]p [C]h [C]y O 
and [C]a [C]n [C]d O 
crypt [C]c [C]r [C]y [C]p [C]t O 
cell [C]c [C]e [C]l [C]l O 
hyperplasia [C]h [C]y [C]p [C]e [C]r [C]p [C]l [C]a [C]s [C]i [C]a O 
. [C]. O 

Previous [C]P [C]r [C]e [C]v [C]i [C]o [C]u [C]s O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
from [C]f [C]r [C]o [C]m O 
this [C]t [C]h [C]i [C]s O 
laboratory [C]l [C]a [C]b [C]o [C]r [C]a [C]t [C]o [C]r [C]y O 
have [C]h [C]a [C]v [C]e O 
shown [C]s [C]h [C]o [C]w [C]n O 
that [C]t [C]h [C]a [C]t O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
explant [C]e [C]x [C]p [C]l [C]a [C]n [C]t O 
cultures [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]s O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n O 
fetal [C]f [C]e [C]t [C]a [C]l O 
gut [C]g [C]u [C]t O 
can [C]c [C]a [C]n O 
also [C]a [C]l [C]s [C]o O 
result [C]r [C]e [C]s [C]u [C]l [C]t O 
in [C]i [C]n O 
villous [C]v [C]i [C]l [C]l [C]o [C]u [C]s O 
atrophy [C]a [C]t [C]r [C]o [C]p [C]h [C]y O 
and [C]a [C]n [C]d O 
crypt [C]c [C]r [C]y [C]p [C]t O 
cell [C]c [C]e [C]l [C]l O 
hyperplasia [C]h [C]y [C]p [C]e [C]r [C]p [C]l [C]a [C]s [C]i [C]a O 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
, [C], O 
therefore [C]t [C]h [C]e [C]r [C]e [C]f [C]o [C]r [C]e O 
, [C], O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
that [C]t [C]h [C]a [C]t O 
take [C]t [C]a [C]k [C]e O 
place [C]p [C]l [C]a [C]c [C]e O 
in [C]i [C]n O 
explant [C]e [C]x [C]p [C]l [C]a [C]n [C]t O 
cultures [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]s O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n O 
fetal [C]f [C]e [C]t [C]a [C]l O 
gut [C]g [C]u [C]t O 
after [C]a [C]f [C]t [C]e [C]r O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
with [C]w [C]i [C]t [C]h O 
anti-CD3 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]3 S-protein 
and/or [C]a [C]n [C]d [C]/ [C]o [C]r O 
IFN-alpha [C]I [C]F [C]N [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
. [C]. O 

We [C]W [C]e O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
with [C]w [C]i [C]t [C]h O 
anti-CD3 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]3 S-protein 
alone [C]a [C]l [C]o [C]n [C]e O 
elicits [C]e [C]l [C]i [C]c [C]i [C]t [C]s O 
a [C]a O 
small [C]s [C]m [C]a [C]l [C]l O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
and [C]a [C]n [C]d O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
with [C]w [C]i [C]t [C]h O 
no [C]n [C]o O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
injury [C]i [C]n [C]j [C]u [C]r [C]y O 
. [C]. O 

Similarly [C]S [C]i [C]m [C]i [C]l [C]a [C]r [C]l [C]y O 
, [C], O 
no [C]n [C]o O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
are [C]a [C]r [C]e O 
seen [C]s [C]e [C]e [C]n O 
in [C]i [C]n O 
explants [C]e [C]x [C]p [C]l [C]a [C]n [C]t [C]s O 
cultured [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
IFN-alpha [C]I [C]F [C]N [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
alone [C]a [C]l [C]o [C]n [C]e O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IFN-alpha [C]I [C]F [C]N [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
with [C]w [C]i [C]t [C]h O 
anti-CD3 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]3 S-protein 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
in [C]i [C]n O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
Th1 [C]T [C]h [C]1 O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
and [C]a [C]n [C]d O 
crypt [C]c [C]r [C]y [C]p [C]t O 
cell [C]c [C]e [C]l [C]l O 
hyperplasia [C]h [C]y [C]p [C]e [C]r [C]p [C]l [C]a [C]s [C]i [C]a O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
is [C]i [C]s O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
STAT1 [C]S [C]T [C]A [C]T [C]1 S-protein 
, [C], O 
STAT3 [C]S [C]T [C]A [C]T [C]3 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
Fyn [C]F [C]y [C]n B-protein 
, [C], I-protein 
a [C]a I-protein 
Src [C]S [C]r [C]c I-protein 
homology [C]h [C]o [C]m [C]o [C]l [C]o [C]g [C]y I-protein 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
interacts [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
both [C]b [C]o [C]t [C]h O 
TCR [C]T [C]C [C]R O 
and [C]a [C]n [C]d O 
IFN-alpha [C]I [C]F [C]N [C]- [C]a [C]l [C]p [C]h [C]a O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
components [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t [C]s O 
. [C]. O 

Together [C]T [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
these [C]t [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
IFN-alpha [C]I [C]F [C]N [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
can [C]c [C]a [C]n O 
facilitate [C]f [C]a [C]c [C]i [C]l [C]i [C]t [C]a [C]t [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Th1-reactive [C]T [C]h [C]1 [C]- [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
gut [C]g [C]u [C]t O 
and [C]a [C]n [C]d O 
drive [C]d [C]r [C]i [C]v [C]e O 
immunopathology [C]i [C]m [C]m [C]u [C]n [C]o [C]p [C]a [C]t [C]h [C]o [C]l [C]o [C]g [C]y O 
. [C]. O 

Suppression [C]S [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
tumor [C]t [C]u [C]m [C]o [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
cAMP [C]c [C]A [C]M [C]P O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
: [C]: O 
dissociation [C]d [C]i [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
mRNA [C]m [C]R [C]N [C]A O 
level [C]l [C]e [C]v [C]e [C]l O 
and [C]a [C]n [C]d O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
of [C]o [C]f O 
interleukin-10 [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]1 [C]0 S-protein 
. [C]. O 

BACKGROUND [C]B [C]A [C]C [C]K [C]G [C]R [C]O [C]U [C]N [C]D O 
: [C]: O 
Elevation [C]E [C]l [C]e [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
cAMP [C]c [C]A [C]M [C]P O 
inhibits [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]s O 
lipopolysaccharide [C]l [C]i [C]p [C]o [C]p [C]o [C]l [C]y [C]s [C]a [C]c [C]c [C]h [C]a [C]r [C]i [C]d [C]e O 
( [C]( O 
LPS [C]L [C]P [C]S O 
) [C]) O 
-stimulated [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
tumor [C]t [C]u [C]m [C]o [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
( [C]( O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
) [C]) O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
increases [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
interleukin [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n B-protein 
( [C]( I-protein 
IL [C]I [C]L I-protein 
) [C]) I-protein 
-10 [C]- [C]1 [C]0 E-protein 
in [C]i [C]n O 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
obligates [C]o [C]b [C]l [C]i [C]g [C]a [C]t [C]e [C]s O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
kappaB [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
( [C]( O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
) [C]) O 
. [C]. O 

Exogenous [C]E [C]x [C]o [C]g [C]e [C]n [C]o [C]u [C]s O 
IL-10 [C]I [C]L [C]- [C]1 [C]0 S-protein 
inhibits [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]s O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
in [C]i [C]n O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
and [C]a [C]n [C]d O 
thus [C]t [C]h [C]u [C]s O 
attenuates [C]a [C]t [C]t [C]e [C]n [C]u [C]a [C]t [C]e [C]s O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

We [C]W [C]e O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
the [C]t [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
endogenous [C]e [C]n [C]d [C]o [C]g [C]e [C]n [C]o [C]u [C]s O 
IL-10 [C]I [C]L [C]- [C]1 [C]0 S-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
by [C]b [C]y O 
cAMP [C]c [C]A [C]M [C]P O 
. [C]. O 

METHODS [C]M [C]E [C]T [C]H [C]O [C]D [C]S O 
: [C]: O 
Human [C]H [C]u [C]m [C]a [C]n B-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
Escherichia [C]E [C]s [C]c [C]h [C]e [C]r [C]i [C]c [C]h [C]i [C]a O 
coli [C]c [C]o [C]l [C]i O 
LPS [C]L [C]P [C]S O 
( [C]( O 
100 [C]1 [C]0 [C]0 O 
ng/ml [C]n [C]g [C]/ [C]m [C]l O 
) [C]) O 
with [C]w [C]i [C]t [C]h O 
and [C]a [C]n [C]d O 
without [C]w [C]i [C]t [C]h [C]o [C]u [C]t O 
forskolin [C]f [C]o [C]r [C]s [C]k [C]o [C]l [C]i [C]n O 
( [C]( O 
FSK [C]F [C]S [C]K O 
, [C], O 
50 [C]5 [C]0 O 
microM [C]m [C]i [C]c [C]r [C]o [C]M O 
) [C]) O 
or [C]o [C]r O 
dibutyryl [C]d [C]i [C]b [C]u [C]t [C]y [C]r [C]y [C]l O 
cyclic [C]c [C]y [C]c [C]l [C]i [C]c O 
AMP [C]A [C]M [C]P O 
( [C]( O 
dbcAMP [C]d [C]b [C]c [C]A [C]M [C]P O 
, [C], O 
100 [C]1 [C]0 [C]0 O 
microM [C]m [C]i [C]c [C]r [C]o [C]M O 
) [C]) O 
. [C]. O 

Cytokine [C]C [C]y [C]t [C]o [C]k [C]i [C]n [C]e S-protein 
( [C]( O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
and [C]a [C]n [C]d O 
IL-10 [C]I [C]L [C]- [C]1 [C]0 S-protein 
) [C]) O 
release [C]r [C]e [C]l [C]e [C]a [C]s [C]e O 
was [C]w [C]a [C]s O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
by [C]b [C]y O 
immunoassay [C]i [C]m [C]m [C]u [C]n [C]o [C]a [C]s [C]s [C]a [C]y O 
. [C]. O 

TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
was [C]w [C]a [C]s O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
by [C]b [C]y O 
reverse [C]r [C]e [C]v [C]e [C]r [C]s [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
polymerase [C]p [C]o [C]l [C]y [C]m [C]e [C]r [C]a [C]s [C]e O 
chain [C]c [C]h [C]a [C]i [C]n O 
reaction [C]r [C]e [C]a [C]c [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
was [C]w [C]a [C]s O 
assessed [C]a [C]s [C]s [C]e [C]s [C]s [C]e [C]d O 
by [C]b [C]y O 
gel [C]g [C]e [C]l O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
assay [C]a [C]s [C]s [C]a [C]y O 
. [C]. O 

RESULTS [C]R [C]E [C]S [C]U [C]L [C]T [C]S O 
: [C]: O 
cAMP-elevating [C]c [C]A [C]M [C]P [C]- [C]e [C]l [C]e [C]v [C]a [C]t [C]i [C]n [C]g O 
agents [C]a [C]g [C]e [C]n [C]t [C]s O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
LPS-stimulated [C]L [C]P [C]S [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
release [C]r [C]e [C]l [C]e [C]a [C]s [C]e O 
( [C]( O 
0.77 [C]0 [C]. [C]7 [C]7 O 
+/- [C]+ [C]/ [C]- O 
0.13 [C]0 [C]. [C]1 [C]3 O 
ng/10 [C]n [C]g [C]/ [C]1 [C]0 O 
( [C]( O 
6 [C]6 O 
) [C]) O 
cells [C]c [C]e [C]l [C]l [C]s O 
in [C]i [C]n O 
LPS [C]L [C]P [C]S O 
+ [C]+ O 
dbcAMP [C]d [C]b [C]c [C]A [C]M [C]P O 
and [C]a [C]n [C]d O 
0.68 [C]0 [C]. [C]6 [C]8 O 
+/- [C]+ [C]/ [C]- O 
0.19 [C]0 [C]. [C]1 [C]9 O 
ng/10 [C]n [C]g [C]/ [C]1 [C]0 O 
( [C]( O 
6 [C]6 O 
) [C]) O 
cells [C]c [C]e [C]l [C]l [C]s O 
in [C]i [C]n O 
LPS [C]L [C]P [C]S O 
+ [C]+ O 
FSK [C]F [C]S [C]K O 
, [C], O 
both [C]b [C]o [C]t [C]h O 
P [C]P O 
< [C]< O 
0.05 [C]0 [C]. [C]0 [C]5 O 
vs [C]v [C]s O 
1.61 [C]1 [C]. [C]6 [C]1 O 
+/- [C]+ [C]/ [C]- O 
0.34 [C]0 [C]. [C]3 [C]4 O 
ng/10 [C]n [C]g [C]/ [C]1 [C]0 O 
( [C]( O 
6 [C]6 O 
) [C]) O 
cells [C]c [C]e [C]l [C]l [C]s O 
in [C]i [C]n O 
LPS [C]L [C]P [C]S O 
alone [C]a [C]l [C]o [C]n [C]e O 
) [C]) O 
. [C]. O 

Conversely [C]C [C]o [C]n [C]v [C]e [C]r [C]s [C]e [C]l [C]y O 
, [C], O 
cAMP [C]c [C]A [C]M [C]P O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
LPS-stimulated [C]L [C]P [C]S [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
IL-10 [C]I [C]L [C]- [C]1 [C]0 S-protein 
release [C]r [C]e [C]l [C]e [C]a [C]s [C]e O 
( [C]( O 
100 [C]1 [C]0 [C]0 O 
+/- [C]+ [C]/ [C]- O 
21.5 [C]2 [C]1 [C]. [C]5 O 
pg/10 [C]p [C]g [C]/ [C]1 [C]0 O 
( [C]( O 
6 [C]6 O 
) [C]) O 
cells [C]c [C]e [C]l [C]l [C]s O 
in [C]i [C]n O 
LPS [C]L [C]P [C]S O 
+ [C]+ O 
dbcAMP [C]d [C]b [C]c [C]A [C]M [C]P O 
and [C]a [C]n [C]d O 
110 [C]1 [C]1 [C]0 O 
+/- [C]+ [C]/ [C]- O 
25.2 [C]2 [C]5 [C]. [C]2 O 
pg/10 [C]p [C]g [C]/ [C]1 [C]0 O 
( [C]( O 
6 [C]6 O 
) [C]) O 
cells [C]c [C]e [C]l [C]l [C]s O 
in [C]i [C]n O 
LPS [C]L [C]P [C]S O 
+ [C]+ O 
FSK [C]F [C]S [C]K O 
, [C], O 
both [C]b [C]o [C]t [C]h O 
P [C]P O 
< [C]< O 
0.05 [C]0 [C]. [C]0 [C]5 O 
vs [C]v [C]s O 
53.3 [C]5 [C]3 [C]. [C]3 O 
+/- [C]+ [C]/ [C]- O 
12.8 [C]1 [C]2 [C]. [C]8 O 
pg/10 [C]p [C]g [C]/ [C]1 [C]0 O 
( [C]( O 
6 [C]6 O 
) [C]) O 
cells [C]c [C]e [C]l [C]l [C]s O 
in [C]i [C]n O 
LPS [C]L [C]P [C]S O 
alone [C]a [C]l [C]o [C]n [C]e O 
) [C]) O 
. [C]. O 

Neither [C]N [C]e [C]i [C]t [C]h [C]e [C]r O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
nor [C]n [C]o [C]r O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
LPS [C]L [C]P [C]S O 
was [C]w [C]a [C]s O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
cAMP-elevating [C]c [C]A [C]M [C]P [C]- [C]e [C]l [C]e [C]v [C]a [C]t [C]i [C]n [C]g O 
agents [C]a [C]g [C]e [C]n [C]t [C]s O 
. [C]. O 

Neutralization [C]N [C]e [C]u [C]t [C]r [C]a [C]l [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-10 [C]I [C]L [C]- [C]1 [C]0 S-protein 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
antibody [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y S-protein 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
attenuate [C]a [C]t [C]t [C]e [C]n [C]u [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
cAMP-elevating [C]c [C]A [C]M [C]P [C]- [C]e [C]l [C]e [C]v [C]a [C]t [C]i [C]n [C]g O 
agents [C]a [C]g [C]e [C]n [C]t [C]s O 
on [C]o [C]n O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

CONCLUSION [C]C [C]O [C]N [C]C [C]L [C]U [C]S [C]I [C]O [C]N O 
: [C]: O 
The [C]T [C]h [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
cAMP [C]c [C]A [C]M [C]P O 
inhibits [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]s O 
LPS-stimulated [C]L [C]P [C]S [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
a [C]a O 
posttranscriptional [C]p [C]o [C]s [C]t [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
of [C]o [C]f O 
endogenous [C]e [C]n [C]d [C]o [C]g [C]e [C]n [C]o [C]u [C]s O 
IL-10 [C]I [C]L [C]- [C]1 [C]0 S-protein 
. [C]. O 

Copyright [C]C [C]o [C]p [C]y [C]r [C]i [C]g [C]h [C]t O 
2001 [C]2 [C]0 [C]0 [C]1 O 
Academic [C]A [C]c [C]a [C]d [C]e [C]m [C]i [C]c O 
Press [C]P [C]r [C]e [C]s [C]s O 
. [C]. O 

Activation [C]A [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
p21 [C]p [C]2 [C]1 B-DNA 
( [C]( I-DNA 
CIP1/WAF1 [C]C [C]I [C]P [C]1 [C]/ [C]W [C]A [C]F [C]1 I-DNA 
) [C]) I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
by [C]b [C]y O 
bone [C]b [C]o [C]n [C]e B-protein 
morphogenetic [C]m [C]o [C]r [C]p [C]h [C]o [C]g [C]e [C]n [C]e [C]t [C]i [C]c I-protein 
protein-2 [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]2 E-protein 
in [C]i [C]n O 
mouse [C]m [C]o [C]u [C]s [C]e O 
B [C]B B-cell_line 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

BMPs [C]B [C]M [C]P [C]s S-protein 
exert [C]e [C]x [C]e [C]r [C]t O 
a [C]a O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
types [C]t [C]y [C]p [C]e [C]s O 
of [C]o [C]f O 
cells [C]c [C]e [C]l [C]l [C]s O 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
reported [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
BMP-2 [C]B [C]M [C]P [C]- [C]2 S-protein 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
of [C]o [C]f O 
HS-72 [C]H [C]S [C]- [C]7 [C]2 B-cell_line 
mouse [C]m [C]o [C]u [C]s [C]e I-cell_line 
hybridoma [C]h [C]y [C]b [C]r [C]i [C]d [C]o [C]m [C]a I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
by [C]b [C]y O 
inducing [C]i [C]n [C]d [C]u [C]c [C]i [C]n [C]g O 
p21 [C]p [C]2 [C]1 O 
( [C]( O 
CIP1/WAF1 [C]C [C]I [C]P [C]1 [C]/ [C]W [C]A [C]F [C]1 O 
) [C]) O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

In [C]I [C]n O 
the [C]t [C]h [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
study [C]s [C]t [C]u [C]d [C]y O 
, [C], O 
we [C]w [C]e O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
BMP-2 [C]B [C]M [C]P [C]- [C]2 S-protein 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
mouse [C]m [C]o [C]u [C]s [C]e O 
p21 [C]p [C]2 [C]1 B-DNA 
( [C]( I-DNA 
CIP1/WAF1 [C]C [C]I [C]P [C]1 [C]/ [C]W [C]A [C]F [C]1 I-DNA 
) [C]) I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
in [C]i [C]n O 
HS-72 [C]H [C]S [C]- [C]7 [C]2 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
, [C], O 
and [C]a [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
a [C]a O 
29-base [C]2 [C]9 [C]- [C]b [C]a [C]s [C]e B-DNA 
pair [C]p [C]a [C]i [C]r I-DNA 
( [C]( I-DNA 
b [C]b I-DNA 
) [C]) I-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
( [C]( O 
-1928/-1900 [C]- [C]1 [C]9 [C]2 [C]8 [C]/ [C]- [C]1 [C]9 [C]0 [C]0 O 
relative [C]r [C]e [C]l [C]a [C]t [C]i [C]v [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
TATA [C]T [C]A [C]T [C]A B-DNA 
box [C]b [C]o [C]x E-DNA 
) [C]) O 
, [C], O 
conserved [C]c [C]o [C]n [C]s [C]e [C]r [C]v [C]e [C]d O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
mice [C]m [C]i [C]c [C]e O 
and [C]a [C]n [C]d O 
humans [C]h [C]u [C]m [C]a [C]n [C]s O 
, [C], O 
was [C]w [C]a [C]s O 
responsive [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e O 
to [C]t [C]o O 
BMP-2 [C]B [C]M [C]P [C]- [C]2 S-protein 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
Smad1 [C]S [C]m [C]a [C]d [C]1 S-protein 
, [C], O 
Smad4 [C]S [C]m [C]a [C]d [C]4 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
constitutively [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
mutants [C]m [C]u [C]t [C]a [C]n [C]t [C]s O 
of [C]o [C]f O 
BMP [C]B [C]M [C]P B-protein 
type [C]t [C]y [C]p [C]e I-protein 
I [C]I I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
an [C]a [C]n O 
oligonucleotide [C]o [C]l [C]i [C]g [C]o [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e O 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
29-b [C]2 [C]9 [C]- [C]b B-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
Smad4 [C]S [C]m [C]a [C]d [C]4 S-protein 
and [C]a [C]n [C]d O 
phosphorylated [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]e [C]d B-protein 
Smad1 [C]S [C]m [C]a [C]d [C]1 E-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
extract [C]e [C]x [C]t [C]r [C]a [C]c [C]t O 
of [C]o [C]f O 
BMP-2 [C]B [C]M [C]P [C]- [C]2 S-protein 
-stimulated [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
HS-72 [C]H [C]S [C]- [C]7 [C]2 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggested [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
BMP-2 [C]B [C]M [C]P [C]- [C]2 S-protein 
might [C]m [C]i [C]g [C]h [C]t O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
p21 [C]p [C]2 [C]1 O 
( [C]( O 
CIP1/WAF1 [C]C [C]I [C]P [C]1 [C]/ [C]W [C]A [C]F [C]1 O 
) [C]) O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
inducing [C]i [C]n [C]d [C]u [C]c [C]i [C]n [C]g O 
a [C]a O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
Smad4 [C]S [C]m [C]a [C]d [C]4 S-protein 
and [C]a [C]n [C]d O 
Smad1 [C]S [C]m [C]a [C]d [C]1 S-protein 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
29-b [C]2 [C]9 [C]- [C]b B-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
in [C]i [C]n O 
HS-72 [C]H [C]S [C]- [C]7 [C]2 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

Dendritic [C]D [C]e [C]n [C]d [C]r [C]i [C]t [C]i [C]c B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
from [C]f [C]r [C]o [C]m O 
common [C]c [C]o [C]m [C]m [C]o [C]n O 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d B-cell_type 
progenitors [C]p [C]r [C]o [C]g [C]e [C]n [C]i [C]t [C]o [C]r [C]s E-cell_type 
. [C]. O 

Dendritic [C]D [C]e [C]n [C]d [C]r [C]i [C]t [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
DCs [C]D [C]C [C]s S-cell_type 
) [C]) O 
are [C]a [C]r [C]e O 
professional [C]p [C]r [C]o [C]f [C]e [C]s [C]s [C]i [C]o [C]n [C]a [C]l O 
antigen-presenting [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]- [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]i [C]n [C]g B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
which [C]w [C]h [C]i [C]c [C]h O 
both [C]b [C]o [C]t [C]h O 
initiate [C]i [C]n [C]i [C]t [C]i [C]a [C]t [C]e O 
adaptive [C]a [C]d [C]a [C]p [C]t [C]i [C]v [C]e O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
and [C]a [C]n [C]d O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
tolerance [C]t [C]o [C]l [C]e [C]r [C]a [C]n [C]c [C]e O 
to [C]t [C]o O 
self-antigens [C]s [C]e [C]l [C]f [C]- [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]s S-protein 
. [C]. O 

It [C]I [C]t O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
suggested [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
these [C]t [C]h [C]e [C]s [C]e O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
on [C]o [C]n O 
responder [C]r [C]e [C]s [C]p [C]o [C]n [C]d [C]e [C]r O 
cells [C]c [C]e [C]l [C]l [C]s O 
depend [C]d [C]e [C]p [C]e [C]n [C]d O 
on [C]o [C]n O 
subsets [C]s [C]u [C]b [C]s [C]e [C]t [C]s O 
of [C]o [C]f O 
DCs [C]D [C]C [C]s S-cell_type 
arising [C]a [C]r [C]i [C]s [C]i [C]n [C]g O 
from [C]f [C]r [C]o [C]m O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d O 
or [C]o [C]r O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d O 
hematopoietic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c O 
origins [C]o [C]r [C]i [C]g [C]i [C]n [C]s O 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
model [C]m [C]o [C]d [C]e [C]l O 
, [C], O 
CD8 [C]C [C]D [C]8 B-cell_type 
alpha+ [C]a [C]l [C]p [C]h [C]a [C]+ I-cell_type 
Mac-1- [C]M [C]a [C]c [C]- [C]1 [C]- I-cell_type 
DCs [C]D [C]C [C]s E-cell_type 
are [C]a [C]r [C]e O 
supposed [C]s [C]u [C]p [C]p [C]o [C]s [C]e [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
of [C]o [C]f O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d O 
while [C]w [C]h [C]i [C]l [C]e O 
CD8 [C]C [C]D [C]8 B-cell_type 
alpha- [C]a [C]l [C]p [C]h [C]a [C]- I-cell_type 
Mac-1+ [C]M [C]a [C]c [C]- [C]1 [C]+ I-cell_type 
DCs [C]D [C]C [C]s E-cell_type 
are [C]a [C]r [C]e O 
supposed [C]s [C]u [C]p [C]p [C]o [C]s [C]e [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
of [C]o [C]f O 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d O 
origin [C]o [C]r [C]i [C]g [C]i [C]n O 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
we [C]w [C]e O 
summarize [C]s [C]u [C]m [C]m [C]a [C]r [C]i [C]z [C]e O 
our [C]o [C]u [C]r O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
that [C]t [C]h [C]a [C]t O 
both [C]b [C]o [C]t [C]h O 
CD8 [C]C [C]D [C]8 B-cell_type 
alpha+ [C]a [C]l [C]p [C]h [C]a [C]+ I-cell_type 
and [C]a [C]n [C]d I-cell_type 
CD8 [C]C [C]D [C]8 I-cell_type 
alpha- [C]a [C]l [C]p [C]h [C]a [C]- I-cell_type 
DCs [C]D [C]C [C]s E-cell_type 
can [C]c [C]a [C]n O 
arise [C]a [C]r [C]i [C]s [C]e O 
from [C]f [C]r [C]o [C]m O 
clonogenic [C]c [C]l [C]o [C]n [C]o [C]g [C]e [C]n [C]i [C]c B-cell_type 
common [C]c [C]o [C]m [C]m [C]o [C]n I-cell_type 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d I-cell_type 
progenitors [C]p [C]r [C]o [C]g [C]e [C]n [C]i [C]t [C]o [C]r [C]s E-cell_type 
( [C]( O 
CMPs [C]C [C]M [C]P [C]s S-cell_type 
) [C]) O 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
thymus [C]t [C]h [C]y [C]m [C]u [C]s O 
and [C]a [C]n [C]d O 
spleen [C]s [C]p [C]l [C]e [C]e [C]n O 
. [C]. O 

Therefore [C]T [C]h [C]e [C]r [C]e [C]f [C]o [C]r [C]e O 
CD8 [C]C [C]D [C]8 B-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
DCs [C]D [C]C [C]s S-cell_type 
does [C]d [C]o [C]e [C]s O 
not [C]n [C]o [C]t O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
a [C]a O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d O 
origin [C]o [C]r [C]i [C]g [C]i [C]n O 
and [C]a [C]n [C]d O 
differences [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e [C]s O 
among [C]a [C]m [C]o [C]n [C]g O 
CD8 [C]C [C]D [C]8 B-cell_type 
alpha+ [C]a [C]l [C]p [C]h [C]a [C]+ I-cell_type 
and [C]a [C]n [C]d I-cell_type 
CD8 [C]C [C]D [C]8 I-cell_type 
alpha- [C]a [C]l [C]p [C]h [C]a [C]- I-cell_type 
DCs [C]D [C]C [C]s E-cell_type 
might [C]m [C]i [C]g [C]h [C]t O 
rather [C]r [C]a [C]t [C]h [C]e [C]r O 
reflect [C]r [C]e [C]f [C]l [C]e [C]c [C]t O 
maturation [C]m [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
status [C]s [C]t [C]a [C]t [C]u [C]s O 
than [C]t [C]h [C]a [C]n O 
ontogeny [C]o [C]n [C]t [C]o [C]g [C]e [C]n [C]y O 
. [C]. O 

On [C]O [C]n O 
the [C]t [C]h [C]e O 
basis [C]b [C]a [C]s [C]i [C]s O 
of [C]o [C]f O 
transplantation [C]t [C]r [C]a [C]n [C]s [C]p [C]l [C]a [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
, [C], O 
it [C]i [C]t O 
seems [C]s [C]e [C]e [C]m [C]s O 
likely [C]l [C]i [C]k [C]e [C]l [C]y O 
that [C]t [C]h [C]a [C]t O 
most [C]m [C]o [C]s [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
DCs [C]D [C]C [C]s S-cell_type 
in [C]i [C]n O 
secondary [C]s [C]e [C]c [C]o [C]n [C]d [C]a [C]r [C]y O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d O 
organs [C]o [C]r [C]g [C]a [C]n [C]s O 
and [C]a [C]n [C]d O 
a [C]a O 
substantial [C]s [C]u [C]b [C]s [C]t [C]a [C]n [C]t [C]i [C]a [C]l O 
fraction [C]f [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
thymic [C]t [C]h [C]y [C]m [C]i [C]c B-cell_type 
DCs [C]D [C]C [C]s E-cell_type 
are [C]a [C]r [C]e O 
myeloid-derived [C]m [C]y [C]e [C]l [C]o [C]i [C]d [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
. [C]. O 

Macrophage [C]M [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
Murabutide [C]M [C]u [C]r [C]a [C]b [C]u [C]t [C]i [C]d [C]e O 
, [C], O 
an [C]a [C]n O 
HIV-suppressive [C]H [C]I [C]V [C]- [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]v [C]e O 
muramyl [C]m [C]u [C]r [C]a [C]m [C]y [C]l O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
derivative [C]d [C]e [C]r [C]i [C]v [C]a [C]t [C]i [C]v [C]e O 
, [C], O 
selectively [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
activates [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]s O 
extracellular [C]e [C]x [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
signal-regulated [C]s [C]i [C]g [C]n [C]a [C]l [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d I-protein 
kinases [C]k [C]i [C]n [C]a [C]s [C]e [C]s I-protein 
1 [C]1 I-protein 
and [C]a [C]n [C]d I-protein 
2 [C]2 E-protein 
, [C], O 
C/EBPbeta [C]C [C]/ [C]E [C]B [C]P [C]b [C]e [C]t [C]a S-protein 
and [C]a [C]n [C]d O 
STAT1 [C]S [C]T [C]A [C]T [C]1 S-protein 
: [C]: O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
CD14 [C]C [C]D [C]1 [C]4 S-protein 
and [C]a [C]n [C]d O 
Toll-like [C]T [C]o [C]l [C]l [C]- [C]l [C]i [C]k [C]e B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s I-protein 
2 [C]2 I-protein 
and [C]a [C]n [C]d I-protein 
4 [C]4 E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
smallest [C]s [C]m [C]a [C]l [C]l [C]e [C]s [C]t O 
unit [C]u [C]n [C]i [C]t O 
of [C]o [C]f O 
bacterial [C]b [C]a [C]c [C]t [C]e [C]r [C]i [C]a [C]l O 
peptidoglycans [C]p [C]e [C]p [C]t [C]i [C]d [C]o [C]g [C]l [C]y [C]c [C]a [C]n [C]s O 
known [C]k [C]n [C]o [C]w [C]n O 
to [C]t [C]o O 
be [C]b [C]e O 
endowed [C]e [C]n [C]d [C]o [C]w [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
biological [C]b [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
activities [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]i [C]e [C]s O 
is [C]i [C]s O 
muramyl [C]m [C]u [C]r [C]a [C]m [C]y [C]l O 
dipeptide [C]d [C]i [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
( [C]( O 
MDP [C]M [C]D [C]P O 
) [C]) O 
. [C]. O 

A [C]A O 
clinically [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l [C]l [C]y O 
acceptable [C]a [C]c [C]c [C]e [C]p [C]t [C]a [C]b [C]l [C]e O 
synthetic [C]s [C]y [C]n [C]t [C]h [C]e [C]t [C]i [C]c O 
derivative [C]d [C]e [C]r [C]i [C]v [C]a [C]t [C]i [C]v [C]e O 
of [C]o [C]f O 
MDP [C]M [C]D [C]P O 
, [C], O 
namely [C]n [C]a [C]m [C]e [C]l [C]y O 
murabutide [C]m [C]u [C]r [C]a [C]b [C]u [C]t [C]i [C]d [C]e O 
( [C]( O 
MB [C]M [C]B O 
) [C]) O 
, [C], O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
interesting [C]i [C]n [C]t [C]e [C]r [C]e [C]s [C]t [C]i [C]n [C]g O 
pharmacological [C]p [C]h [C]a [C]r [C]m [C]a [C]c [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
properties [C]p [C]r [C]o [C]p [C]e [C]r [C]t [C]i [C]e [C]s O 
and [C]a [C]n [C]d O 
to [C]t [C]o O 
suppress [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
replication [C]r [C]e [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
monocyte-derived [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d B-cell_type 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s E-cell_type 
( [C]( O 
MDM [C]M [C]D [C]M S-cell_type 
) [C]) O 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
addressed [C]a [C]d [C]d [C]r [C]e [C]s [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
events [C]e [C]v [C]e [C]n [C]t [C]s O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
MDM [C]M [C]D [C]M S-cell_type 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
MB [C]M [C]B O 
or [C]o [C]r O 
the [C]t [C]h [C]e O 
potent [C]p [C]o [C]t [C]e [C]n [C]t O 
immunostimulant [C]i [C]m [C]m [C]u [C]n [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]n [C]t O 
LPS [C]L [C]P [C]S O 
. [C]. O 

We [C]W [C]e O 
also [C]a [C]l [C]s [C]o O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
by [C]b [C]y O 
muramyl [C]m [C]u [C]r [C]a [C]m [C]y [C]l O 
peptides [C]p [C]e [C]p [C]t [C]i [C]d [C]e [C]s O 
involves [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]s O 
the [C]t [C]h [C]e O 
use [C]u [C]s [C]e O 
of [C]o [C]f O 
cell [C]c [C]e [C]l [C]l B-protein 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
CD14 [C]C [C]D [C]1 [C]4 S-protein 
and [C]a [C]n [C]d O 
Toll-like [C]T [C]o [C]l [C]l [C]- [C]l [C]i [C]k [C]e B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
2 [C]2 E-protein 
( [C]( O 
TLR2 [C]T [C]L [C]R [C]2 S-protein 
) [C]) O 
or [C]o [C]r O 
TLR4 [C]T [C]L [C]R [C]4 S-protein 
that [C]t [C]h [C]a [C]t O 
are [C]a [C]r [C]e O 
known [C]k [C]n [C]o [C]w [C]n O 
to [C]t [C]o O 
be [C]b [C]e O 
signal-transducing [C]s [C]i [C]g [C]n [C]a [C]l [C]- [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]i [C]n [C]g B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
for [C]f [C]o [C]r O 
other [C]o [C]t [C]h [C]e [C]r O 
bacterial [C]b [C]a [C]c [C]t [C]e [C]r [C]i [C]a [C]l O 
cell [C]c [C]e [C]l [C]l O 
wall [C]w [C]a [C]l [C]l O 
components [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t [C]s O 
. [C]. O 

We [C]W [C]e O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
, [C], O 
unlike [C]u [C]n [C]l [C]i [C]k [C]e O 
LPS [C]L [C]P [C]S O 
, [C], O 
the [C]t [C]h [C]e O 
safe [C]s [C]a [C]f [C]e O 
immunomodulator [C]i [C]m [C]m [C]u [C]n [C]o [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]o [C]r O 
MB [C]M [C]B O 
selectively [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
activates [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]s O 
extracellular [C]e [C]x [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
signal-regulated [C]s [C]i [C]g [C]n [C]a [C]l [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d I-protein 
kinases [C]k [C]i [C]n [C]a [C]s [C]e [C]s I-protein 
( [C]( I-protein 
Erk [C]E [C]r [C]k I-protein 
) [C]) I-protein 
1/2 [C]1 [C]/ [C]2 E-protein 
, [C], O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
detectable [C]d [C]e [C]t [C]e [C]c [C]t [C]a [C]b [C]l [C]e O 
Jun [C]J [C]u [C]n B-protein 
N-terminal [C]N [C]- [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
( [C]( O 
JNK [C]J [C]N [C]K S-protein 
) [C]) O 
or [C]o [C]r O 
p38 [C]p [C]3 [C]8 B-protein 
mitogen-activated [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
STAT1 [C]S [C]T [C]A [C]T [C]1 S-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
but [C]b [C]u [C]t O 
weak [C]w [C]e [C]a [C]k O 
or [C]o [C]r O 
no [C]n [C]o O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
STAT3 [C]S [C]T [C]A [C]T [C]3 S-protein 
or [C]o [C]r O 
STAT5 [C]S [C]T [C]A [C]T [C]5 S-protein 
respectively [C]r [C]e [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
, [C], O 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
in [C]i [C]n O 
MB-stimulated [C]M [C]B [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_type 
MDM [C]M [C]D [C]M E-cell_type 
. [C]. O 

Using [C]U [C]s [C]i [C]n [C]g O 
MonoMac6 [C]M [C]o [C]n [C]o [C]M [C]a [C]c [C]6 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
, [C], O 
we [C]w [C]e O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
high [C]h [C]i [C]g [C]h O 
C/EBPbeta [C]C [C]/ [C]E [C]B [C]P [C]b [C]e [C]t [C]a S-protein 
and [C]a [C]n [C]d O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
but [C]b [C]u [C]t O 
weaker [C]w [C]e [C]a [C]k [C]e [C]r O 
and [C]a [C]n [C]d O 
transient [C]t [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
MB [C]M [C]B O 
. [C]. O 

Moreover [C]M [C]o [C]r [C]e [C]o [C]v [C]e [C]r O 
, [C], O 
the [C]t [C]h [C]e O 
truncated [C]t [C]r [C]u [C]n [C]c [C]a [C]t [C]e [C]d O 
form [C]f [C]o [C]r [C]m O 
of [C]o [C]f O 
C/EBPbeta [C]C [C]/ [C]E [C]B [C]P [C]b [C]e [C]t [C]a S-protein 
, [C], O 
known [C]k [C]n [C]o [C]w [C]n O 
to [C]t [C]o O 
repress [C]r [C]e [C]p [C]r [C]e [C]s [C]s O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
, [C], O 
was [C]w [C]a [C]s O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
in [C]i [C]n O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
from [C]f [C]r [C]o [C]m O 
MB-treated [C]M [C]B [C]- [C]t [C]r [C]e [C]a [C]t [C]e [C]d B-cell_line 
THP-1 [C]T [C]H [C]P [C]- [C]1 I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

Surprisingly [C]S [C]u [C]r [C]p [C]r [C]i [C]s [C]i [C]n [C]g [C]l [C]y O 
, [C], O 
neither [C]n [C]e [C]i [C]t [C]h [C]e [C]r O 
MB [C]M [C]B O 
nor [C]n [C]o [C]r O 
MDP [C]M [C]D [C]P O 
were [C]w [C]e [C]r [C]e O 
able [C]a [C]b [C]l [C]e O 
to [C]t [C]o O 
transduce [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]e O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
via [C]v [C]i [C]a O 
CD14 [C]C [C]D [C]1 [C]4 S-protein 
and [C]a [C]n [C]d O 
TLR2 [C]T [C]L [C]R [C]2 B-protein 
or [C]o [C]r I-protein 
4 [C]4 E-protein 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
major [C]m [C]a [C]j [C]o [C]r O 
differences [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
early [C]e [C]a [C]r [C]l [C]y O 
cell [C]c [C]e [C]l [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
LPS [C]L [C]P [C]S O 
and [C]a [C]n [C]d O 
muramyl [C]m [C]u [C]r [C]a [C]m [C]y [C]l O 
peptides [C]p [C]e [C]p [C]t [C]i [C]d [C]e [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
strongly [C]s [C]t [C]r [C]o [C]n [C]g [C]l [C]y O 
argue [C]a [C]r [C]g [C]u [C]e O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
implication [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
co-receptors [C]c [C]o [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s S-protein 
other [C]o [C]t [C]h [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
TLR2 [C]T [C]L [C]R [C]2 S-protein 
and [C]a [C]n [C]d O 
TLR4 [C]T [C]L [C]R [C]4 S-protein 
in [C]i [C]n O 
mediating [C]m [C]e [C]d [C]i [C]a [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
events [C]e [C]v [C]e [C]n [C]t [C]s O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
defined [C]d [C]e [C]f [C]i [C]n [C]e [C]d O 
subunits [C]s [C]u [C]b [C]u [C]n [C]i [C]t [C]s O 
of [C]o [C]f O 
bacterial [C]b [C]a [C]c [C]t [C]e [C]r [C]i [C]a [C]l O 
peptidoglycans [C]p [C]e [C]p [C]t [C]i [C]d [C]o [C]g [C]l [C]y [C]c [C]a [C]n [C]s O 
. [C]. O 

Nuclear [C]N [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
peroxisome [C]p [C]e [C]r [C]o [C]x [C]i [C]s [C]o [C]m [C]e I-protein 
proliferator-activated [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]o [C]r [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s I-protein 
alpha [C]a [C]l [C]p [C]h [C]a I-protein 
and [C]a [C]n [C]d I-protein 
gamma [C]g [C]a [C]m [C]m [C]a E-protein 
have [C]h [C]a [C]v [C]e O 
opposing [C]o [C]p [C]p [C]o [C]s [C]i [C]n [C]g O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
on [C]o [C]n O 
monocyte [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e O 
chemotaxis [C]c [C]h [C]e [C]m [C]o [C]t [C]a [C]x [C]i [C]s O 
in [C]i [C]n O 
endometriosis [C]e [C]n [C]d [C]o [C]m [C]e [C]t [C]r [C]i [C]o [C]s [C]i [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
peroxisome [C]p [C]e [C]r [C]o [C]x [C]i [C]s [C]o [C]m [C]e B-protein 
proliferator-activated [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]o [C]r [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s I-protein 
( [C]( I-protein 
PPARs [C]P [C]P [C]A [C]R [C]s I-protein 
) [C]) I-protein 
alpha [C]a [C]l [C]p [C]h [C]a I-protein 
and [C]a [C]n [C]d I-protein 
gamma [C]g [C]a [C]m [C]m [C]a E-protein 
are [C]a [C]r [C]e O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
that [C]t [C]h [C]a [C]t O 
play [C]p [C]l [C]a [C]y O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
roles [C]r [C]o [C]l [C]e [C]s O 
in [C]i [C]n O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
diseases [C]d [C]i [C]s [C]e [C]a [C]s [C]e [C]s O 
like [C]l [C]i [C]k [C]e O 
ulcerative [C]u [C]l [C]c [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
colitis [C]c [C]o [C]l [C]i [C]t [C]i [C]s O 
and [C]a [C]n [C]d O 
arthritis [C]a [C]r [C]t [C]h [C]r [C]i [C]t [C]i [C]s O 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
, [C], O 
we [C]w [C]e O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
the [C]t [C]h [C]e O 
possible [C]p [C]o [C]s [C]s [C]i [C]b [C]l [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
PPARs [C]P [C]P [C]A [C]R [C]s S-protein 
in [C]i [C]n O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e O 
attraction [C]a [C]t [C]t [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
into [C]i [C]n [C]t [C]o O 
the [C]t [C]h [C]e O 
peritoneal [C]p [C]e [C]r [C]i [C]t [C]o [C]n [C]e [C]a [C]l O 
cavity [C]c [C]a [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
endometriosis [C]e [C]n [C]d [C]o [C]m [C]e [C]t [C]r [C]i [C]o [C]s [C]i [C]s O 
. [C]. O 

We [C]W [C]e O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
PPAR-alpha [C]P [C]P [C]A [C]R [C]- [C]a [C]l [C]p [C]h [C]a B-RNA 
and [C]a [C]n [C]d I-RNA 
-gamma [C]- [C]g [C]a [C]m [C]m [C]a E-RNA 
messenger [C]m [C]e [C]s [C]s [C]e [C]n [C]g [C]e [C]r O 
RNA [C]R [C]N [C]A O 
by [C]b [C]y O 
RT-PCR [C]R [C]T [C]- [C]P [C]C [C]R O 
and [C]a [C]n [C]d O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
by [C]b [C]y O 
immunoblotting [C]i [C]m [C]m [C]u [C]n [C]o [C]b [C]l [C]o [C]t [C]t [C]i [C]n [C]g O 
of [C]o [C]f O 
lysates [C]l [C]y [C]s [C]a [C]t [C]e [C]s O 
of [C]o [C]f O 
peritoneal [C]p [C]e [C]r [C]i [C]t [C]o [C]n [C]e [C]a [C]l B-cell_type 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
monocytic [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]i [C]c B-cell_line 
U937 [C]U [C]9 [C]3 [C]7 I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

Using [C]U [C]s [C]i [C]n [C]g O 
immunocytochemistry [C]i [C]m [C]m [C]u [C]n [C]o [C]c [C]y [C]t [C]o [C]c [C]h [C]e [C]m [C]i [C]s [C]t [C]r [C]y O 
, [C], O 
we [C]w [C]e O 
localized [C]l [C]o [C]c [C]a [C]l [C]i [C]z [C]e [C]d O 
PPAR-alpha [C]P [C]P [C]A [C]R [C]- [C]a [C]l [C]p [C]h [C]a B-protein 
and [C]a [C]n [C]d I-protein 
-gamma [C]- [C]g [C]a [C]m [C]m [C]a E-protein 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
the [C]t [C]h [C]e O 
nuclei [C]n [C]u [C]c [C]l [C]e [C]i O 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
cell [C]c [C]e [C]l [C]l O 
types [C]t [C]y [C]p [C]e [C]s O 
. [C]. O 

Monocyte [C]M [C]o [C]n [C]o [C]c [C]y [C]t [C]e O 
chemotactic [C]c [C]h [C]e [C]m [C]o [C]t [C]a [C]c [C]t [C]i [C]c O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
peritoneal [C]p [C]e [C]r [C]i [C]t [C]o [C]n [C]e [C]a [C]l O 
fluid [C]f [C]l [C]u [C]i [C]d O 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
endometriosis [C]e [C]n [C]d [C]o [C]m [C]e [C]t [C]r [C]i [C]o [C]s [C]i [C]s O 
was [C]w [C]a [C]s O 
quantified [C]q [C]u [C]a [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
in [C]i [C]n O 
Boyden [C]B [C]o [C]y [C]d [C]e [C]n O 
chambers [C]c [C]h [C]a [C]m [C]b [C]e [C]r [C]s O 
. [C]. O 

Migration [C]M [C]i [C]g [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
U937 [C]U [C]9 [C]3 [C]7 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
was [C]w [C]a [C]s O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
by [C]b [C]y O 
WY [C]W [C]Y O 
14643 [C]1 [C]4 [C]6 [C]4 [C]3 O 
and [C]a [C]n [C]d O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
rosiglitazone [C]r [C]o [C]s [C]i [C]g [C]l [C]i [C]t [C]a [C]z [C]o [C]n [C]e O 
. [C]. O 

Peritoneal [C]P [C]e [C]r [C]i [C]t [C]o [C]n [C]e [C]a [C]l O 
fluid [C]f [C]l [C]u [C]i [C]d O 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
endometriosis [C]e [C]n [C]d [C]o [C]m [C]e [C]t [C]r [C]i [C]o [C]s [C]i [C]s O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
U937 [C]U [C]9 [C]3 [C]7 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
transiently [C]t [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t [C]l [C]y O 
transfected [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
PPAR-alpha/GAL4 [C]P [C]P [C]A [C]R [C]- [C]a [C]l [C]p [C]h [C]a [C]/ [C]G [C]A [C]L [C]4 B-DNA 
luciferase [C]l [C]u [C]c [C]i [C]f [C]e [C]r [C]a [C]s [C]e I-DNA 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r E-DNA 
. [C]. O 

By [C]B [C]y O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
peritoneal [C]p [C]e [C]r [C]i [C]t [C]o [C]n [C]e [C]a [C]l O 
fluid [C]f [C]l [C]u [C]i [C]d O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
cause [C]c [C]a [C]u [C]s [C]e O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
PPAR-gamma/GAL4 [C]P [C]P [C]A [C]R [C]- [C]g [C]a [C]m [C]m [C]a [C]/ [C]G [C]A [C]L [C]4 B-DNA 
constructs [C]c [C]o [C]n [C]s [C]t [C]r [C]u [C]c [C]t [C]s E-DNA 
. [C]. O 

The [C]T [C]h [C]e O 
U937 [C]U [C]9 [C]3 [C]7 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
transiently [C]t [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t [C]l [C]y O 
transfected [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
PPAR [C]P [C]P [C]A [C]R B-DNA 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e I-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t I-DNA 
luciferase [C]l [C]u [C]c [C]i [C]f [C]e [C]r [C]a [C]s [C]e I-DNA 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r E-DNA 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
stage-dependent [C]s [C]t [C]a [C]g [C]e [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
up-regulation [C]u [C]p [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
when [C]w [C]h [C]e [C]n O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
peritoneal [C]p [C]e [C]r [C]i [C]t [C]o [C]n [C]e [C]a [C]l O 
fluid [C]f [C]l [C]u [C]i [C]d O 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
endometriosis [C]e [C]n [C]d [C]o [C]m [C]e [C]t [C]r [C]i [C]o [C]s [C]i [C]s O 
. [C]. O 

Treatment [C]T [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
peritoneal [C]p [C]e [C]r [C]i [C]t [C]o [C]n [C]e [C]a [C]l O 
fluid [C]f [C]l [C]u [C]i [C]d O 
from [C]f [C]r [C]o [C]m O 
healthy [C]h [C]e [C]a [C]l [C]t [C]h [C]y O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
down-regulated [C]d [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
PPAR [C]P [C]P [C]A [C]R O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t O 
transactivation [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

We [C]W [C]e O 
conclude [C]c [C]o [C]n [C]c [C]l [C]u [C]d [C]e O 
that [C]t [C]h [C]a [C]t O 
peritoneal [C]p [C]e [C]r [C]i [C]t [C]o [C]n [C]e [C]a [C]l O 
fluid [C]f [C]l [C]u [C]i [C]d O 
of [C]o [C]f O 
endometriosis [C]e [C]n [C]d [C]o [C]m [C]e [C]t [C]r [C]i [C]o [C]s [C]i [C]s O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
contains [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]s O 
activators [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r [C]s O 
of [C]o [C]f O 
PPAR-alpha [C]P [C]P [C]A [C]R [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
that [C]t [C]h [C]a [C]t O 
stimulate [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e O 
chemotaxis [C]c [C]h [C]e [C]m [C]o [C]t [C]a [C]x [C]i [C]s O 
. [C]. O 

Inhibitors [C]I [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
of [C]o [C]f O 
PPAR-alpha [C]P [C]P [C]A [C]R [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
or [C]o [C]r O 
activators [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r [C]s O 
of [C]o [C]f O 
PPAR-gamma [C]P [C]P [C]A [C]R [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
developed [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]e [C]d O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
inflammation [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]i [C]o [C]n O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
endometriosis [C]e [C]n [C]d [C]o [C]m [C]e [C]t [C]r [C]i [C]o [C]s [C]i [C]s O 
. [C]. O 

Long-term-impaired [C]L [C]o [C]n [C]g [C]- [C]t [C]e [C]r [C]m [C]- [C]i [C]m [C]p [C]a [C]i [C]r [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor-kappa [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
and [C]a [C]n [C]d O 
I [C]I B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B I-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
in [C]i [C]n O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
of [C]o [C]f O 
trauma [C]t [C]r [C]a [C]u [C]m [C]a O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

Nuclear [C]N [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
( [C]( I-protein 
NF [C]N [C]F I-protein 
) [C]) I-protein 
-kappa [C]- [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
dimer [C]d [C]i [C]m [C]e [C]r O 
characteristics [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]s [C]t [C]i [C]c [C]s O 
were [C]w [C]e [C]r [C]e O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
in [C]i [C]n O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
PBMCs [C]P [C]B [C]M [C]C [C]s S-cell_type 
) [C]) O 
of [C]o [C]f O 
major-trauma [C]m [C]a [C]j [C]o [C]r [C]- [C]t [C]r [C]a [C]u [C]m [C]a O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
and [C]a [C]n [C]d O 
healthy [C]h [C]e [C]a [C]l [C]t [C]h [C]y O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
. [C]. O 

Analysis [C]A [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
PBMCs [C]P [C]B [C]M [C]C [C]s S-cell_type 
on [C]o [C]n O 
days [C]d [C]a [C]y [C]s O 
1 [C]1 O 
, [C], O 
3 [C]3 O 
, [C], O 
5 [C]5 O 
, [C], O 
and [C]a [C]n [C]d O 
10 [C]1 [C]0 O 
after [C]a [C]f [C]t [C]e [C]r O 
trauma [C]t [C]r [C]a [C]u [C]m [C]a O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
p65p50 [C]p [C]6 [C]5 [C]p [C]5 [C]0 B-protein 
heterodimers [C]h [C]e [C]t [C]e [C]r [C]o [C]d [C]i [C]m [C]e [C]r [C]s E-protein 
and [C]a [C]n [C]d O 
p50p50 [C]p [C]5 [C]0 [C]p [C]5 [C]0 B-protein 
homodimers [C]h [C]o [C]m [C]o [C]d [C]i [C]m [C]e [C]r [C]s E-protein 
was [C]w [C]a [C]s O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
that [C]t [C]h [C]a [C]t O 
in [C]i [C]n O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
. [C]. O 

In [C]I [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
lipopolysaccharide [C]l [C]i [C]p [C]o [C]p [C]o [C]l [C]y [C]s [C]a [C]c [C]c [C]h [C]a [C]r [C]i [C]d [C]e O 
( [C]( O 
LPS [C]L [C]P [C]S O 
) [C]) O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
PBMCs [C]P [C]B [C]M [C]C [C]s S-cell_type 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a O 
B [C]B O 
translocation [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
throughout [C]t [C]h [C]r [C]o [C]u [C]g [C]h [C]o [C]u [C]t O 
the [C]t [C]h [C]e O 
survey [C]s [C]u [C]r [C]v [C]e [C]y O 
, [C], O 
p65p50 [C]p [C]6 [C]5 [C]p [C]5 [C]0 O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
remained [C]r [C]e [C]m [C]a [C]i [C]n [C]e [C]d O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
lower [C]l [C]o [C]w [C]e [C]r O 
in [C]i [C]n O 
trauma [C]t [C]r [C]a [C]u [C]m [C]a O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
than [C]t [C]h [C]a [C]n O 
in [C]i [C]n O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
. [C]. O 

After [C]A [C]f [C]t [C]e [C]r O 
LPS [C]L [C]P [C]S O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
, [C], O 
the [C]t [C]h [C]e O 
p65p50/p50p50 [C]p [C]6 [C]5 [C]p [C]5 [C]0 [C]/ [C]p [C]5 [C]0 [C]p [C]5 [C]0 O 
ratio [C]r [C]a [C]t [C]i [C]o O 
was [C]w [C]a [C]s O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
lower [C]l [C]o [C]w [C]e [C]r O 
in [C]i [C]n O 
PBMCs [C]P [C]B [C]M [C]C [C]s S-cell_type 
from [C]f [C]r [C]o [C]m O 
trauma [C]t [C]r [C]a [C]u [C]m [C]a O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
than [C]t [C]h [C]a [C]n O 
from [C]f [C]r [C]o [C]m O 
healthy [C]h [C]e [C]a [C]l [C]t [C]h [C]y O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
ex [C]e [C]x O 
vivo [C]v [C]i [C]v [C]o O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
I [C]I B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B I-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
was [C]w [C]a [C]s O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
in [C]i [C]n O 
PBMCs [C]P [C]B [C]M [C]C [C]s S-cell_type 
of [C]o [C]f O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
than [C]t [C]h [C]a [C]n O 
of [C]o [C]f O 
trauma [C]t [C]r [C]a [C]u [C]m [C]a O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

LPS [C]L [C]P [C]S O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
I [C]I O 
kappa [C]k [C]a [C]p [C]p [C]a O 
B [C]B O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
PBMCs [C]P [C]B [C]M [C]C [C]s S-cell_type 
from [C]f [C]r [C]o [C]m O 
trauma [C]t [C]r [C]a [C]u [C]m [C]a O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
, [C], O 
but [C]b [C]u [C]t O 
strong [C]s [C]t [C]r [C]o [C]n [C]g O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
staphylococci [C]s [C]t [C]a [C]p [C]h [C]y [C]l [C]o [C]c [C]o [C]c [C]c [C]i O 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
this [C]t [C]h [C]i [C]s O 
defect [C]d [C]e [C]f [C]e [C]c [C]t O 
is [C]i [C]s O 
not [C]n [C]o [C]t O 
universal [C]u [C]n [C]i [C]v [C]e [C]r [C]s [C]a [C]l O 
and [C]a [C]n [C]d O 
depends [C]d [C]e [C]p [C]e [C]n [C]d [C]s O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
nature [C]n [C]a [C]t [C]u [C]r [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
activating [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]n [C]g O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
no [C]n [C]o O 
direct [C]d [C]i [C]r [C]e [C]c [C]t O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
interleukin-10 [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]1 [C]0 S-protein 
or [C]o [C]r O 
transforming [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]i [C]n [C]g B-protein 
growth [C]g [C]r [C]o [C]w [C]t [C]h I-protein 
factor-beta [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]b [C]e [C]t [C]a E-protein 
and [C]a [C]n [C]d O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
, [C], O 
these [C]t [C]h [C]e [C]s [C]e O 
immunosuppressive [C]i [C]m [C]m [C]u [C]n [C]o [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]v [C]e B-protein 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s E-protein 
were [C]w [C]e [C]r [C]e O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
elevated [C]e [C]l [C]e [C]v [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
trauma [C]t [C]r [C]a [C]u [C]m [C]a O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
by [C]b [C]y O 
10 [C]1 [C]0 O 
days [C]d [C]a [C]y [C]s O 
after [C]a [C]f [C]t [C]e [C]r O 
admission [C]a [C]d [C]m [C]i [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
long-term [C]l [C]o [C]n [C]g [C]- [C]t [C]e [C]r [C]m O 
low-basal [C]l [C]o [C]w [C]- [C]b [C]a [C]s [C]a [C]l O 
and [C]a [C]n [C]d O 
LPS-induced [C]L [C]P [C]S [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
translocation [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
recalled [C]r [C]e [C]c [C]a [C]l [C]l [C]e [C]d O 
long-term [C]l [C]o [C]n [C]g [C]- [C]t [C]e [C]r [C]m O 
immunoparalysis [C]i [C]m [C]m [C]u [C]n [C]o [C]p [C]a [C]r [C]a [C]l [C]y [C]s [C]i [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
severe [C]s [C]e [C]v [C]e [C]r [C]e O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
stress [C]s [C]t [C]r [C]e [C]s [C]s O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
trauma [C]t [C]r [C]a [C]u [C]m [C]a O 
. [C]. O 

Hepatic [C]H [C]e [C]p [C]a [C]t [C]i [C]c O 
ischemia-reperfusion [C]i [C]s [C]c [C]h [C]e [C]m [C]i [C]a [C]- [C]r [C]e [C]p [C]e [C]r [C]f [C]u [C]s [C]i [C]o [C]n O 
injury [C]i [C]n [C]j [C]u [C]r [C]y O 
. [C]. O 

BACKGROUND [C]B [C]A [C]C [C]K [C]G [C]R [C]O [C]U [C]N [C]D O 
: [C]: O 
The [C]T [C]h [C]e O 
morbidity [C]m [C]o [C]r [C]b [C]i [C]d [C]i [C]t [C]y O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
liver [C]l [C]i [C]v [C]e [C]r O 
transplantation [C]t [C]r [C]a [C]n [C]s [C]p [C]l [C]a [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
major [C]m [C]a [C]j [C]o [C]r O 
hepatic [C]h [C]e [C]p [C]a [C]t [C]i [C]c O 
resections [C]r [C]e [C]s [C]e [C]c [C]t [C]i [C]o [C]n [C]s O 
is [C]i [C]s O 
partly [C]p [C]a [C]r [C]t [C]l [C]y O 
a [C]a O 
result [C]r [C]e [C]s [C]u [C]l [C]t O 
of [C]o [C]f O 
ischemia-reperfusion [C]i [C]s [C]c [C]h [C]e [C]m [C]i [C]a [C]- [C]r [C]e [C]p [C]e [C]r [C]f [C]u [C]s [C]i [C]o [C]n O 
injury [C]i [C]n [C]j [C]u [C]r [C]y O 
. [C]. O 

DATA [C]D [C]A [C]T [C]A O 
SOURCES [C]S [C]O [C]U [C]R [C]C [C]E [C]S O 
: [C]: O 
The [C]T [C]h [C]e O 
entire [C]e [C]n [C]t [C]i [C]r [C]e O 
world [C]w [C]o [C]r [C]l [C]d O 
literature [C]l [C]i [C]t [C]e [C]r [C]a [C]t [C]u [C]r [C]e O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
subject [C]s [C]u [C]b [C]j [C]e [C]c [C]t O 
was [C]w [C]a [C]s O 
searched [C]s [C]e [C]a [C]r [C]c [C]h [C]e [C]d O 
via [C]v [C]i [C]a O 
Medline [C]M [C]e [C]d [C]l [C]i [C]n [C]e O 
. [C]. O 

Keywords [C]K [C]e [C]y [C]w [C]o [C]r [C]d [C]s O 
included [C]i [C]n [C]c [C]l [C]u [C]d [C]e [C]d O 
reperfusion [C]r [C]e [C]p [C]e [C]r [C]f [C]u [C]s [C]i [C]o [C]n O 
injury [C]i [C]n [C]j [C]u [C]r [C]y O 
, [C], O 
transplantation [C]t [C]r [C]a [C]n [C]s [C]p [C]l [C]a [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
liver [C]l [C]i [C]v [C]e [C]r O 
resection [C]r [C]e [C]s [C]e [C]c [C]t [C]i [C]o [C]n O 
, [C], O 
nitric [C]n [C]i [C]t [C]r [C]i [C]c O 
oxide [C]o [C]x [C]i [C]d [C]e O 
, [C], O 
endothelin [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]n O 
, [C], O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
, [C], O 
Kupffer [C]K [C]u [C]p [C]f [C]f [C]e [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
ischemic/ischaemic [C]i [C]s [C]c [C]h [C]e [C]m [C]i [C]c [C]/ [C]i [C]s [C]c [C]h [C]a [C]e [C]m [C]i [C]c O 
preconditioning [C]p [C]r [C]e [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n [C]i [C]n [C]g O 
, [C], O 
and [C]a [C]n [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor-kappa [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
. [C]. O 

CONCLUSIONS [C]C [C]O [C]N [C]C [C]L [C]U [C]S [C]I [C]O [C]N [C]S O 
: [C]: O 
An [C]A [C]n O 
imbalance [C]i [C]m [C]b [C]a [C]l [C]a [C]n [C]c [C]e O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
endothelin [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]n O 
and [C]a [C]n [C]d O 
nitric [C]n [C]i [C]t [C]r [C]i [C]c O 
oxide [C]o [C]x [C]i [C]d [C]e O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
in [C]i [C]n O 
failure [C]f [C]a [C]i [C]l [C]u [C]r [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
hepatic [C]h [C]e [C]p [C]a [C]t [C]i [C]c O 
microcirculation [C]m [C]i [C]c [C]r [C]o [C]c [C]i [C]r [C]c [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
onset [C]o [C]n [C]s [C]e [C]t O 
of [C]o [C]f O 
reperfusion [C]r [C]e [C]p [C]e [C]r [C]f [C]u [C]s [C]i [C]o [C]n O 
. [C]. O 

Activation [C]A [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor-kappa [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
liver [C]l [C]i [C]v [C]e [C]r O 
promotes [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]s O 
proinflammatory [C]p [C]r [C]o [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y B-protein 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e E-protein 
and [C]a [C]n [C]d O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n B-protein 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e E-protein 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
result [C]r [C]e [C]s [C]u [C]l [C]t O 
in [C]i [C]n O 
oxygen-derived [C]o [C]x [C]y [C]g [C]e [C]n [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
free [C]f [C]r [C]e [C]e O 
radical [C]r [C]a [C]d [C]i [C]c [C]a [C]l O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
neutrophil [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]h [C]i [C]l O 
recruitment [C]r [C]e [C]c [C]r [C]u [C]i [C]t [C]m [C]e [C]n [C]t O 
, [C], O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
contributing [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]i [C]n [C]g O 
to [C]t [C]o O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
injury [C]i [C]n [C]j [C]u [C]r [C]y O 
. [C]. O 

Various [C]V [C]a [C]r [C]i [C]o [C]u [C]s O 
therapeutic [C]t [C]h [C]e [C]r [C]a [C]p [C]e [C]u [C]t [C]i [C]c O 
modalities [C]m [C]o [C]d [C]a [C]l [C]i [C]t [C]i [C]e [C]s O 
acting [C]a [C]c [C]t [C]i [C]n [C]g O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
above [C]a [C]b [C]o [C]v [C]e O 
mediators [C]m [C]e [C]d [C]i [C]a [C]t [C]o [C]r [C]s O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
successfully [C]s [C]u [C]c [C]c [C]e [C]s [C]s [C]f [C]u [C]l [C]l [C]y O 
used [C]u [C]s [C]e [C]d O 
to [C]t [C]o O 
attenuate [C]a [C]t [C]t [C]e [C]n [C]u [C]a [C]t [C]e O 
reperfusion [C]r [C]e [C]p [C]e [C]r [C]f [C]u [C]s [C]i [C]o [C]n O 
injury [C]i [C]n [C]j [C]u [C]r [C]y O 
in [C]i [C]n O 
animal [C]a [C]n [C]i [C]m [C]a [C]l O 
models [C]m [C]o [C]d [C]e [C]l [C]s O 
of [C]o [C]f O 
hepatic [C]h [C]e [C]p [C]a [C]t [C]i [C]c O 
transplantation [C]t [C]r [C]a [C]n [C]s [C]p [C]l [C]a [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
resection [C]r [C]e [C]s [C]e [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

Application [C]A [C]p [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
knowledge [C]k [C]n [C]o [C]w [C]l [C]e [C]d [C]g [C]e O 
gained [C]g [C]a [C]i [C]n [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
animal [C]a [C]n [C]i [C]m [C]a [C]l O 
models [C]m [C]o [C]d [C]e [C]l [C]s O 
of [C]o [C]f O 
hepatic [C]h [C]e [C]p [C]a [C]t [C]i [C]c O 
ischemia-reperfusion [C]i [C]s [C]c [C]h [C]e [C]m [C]i [C]a [C]- [C]r [C]e [C]p [C]e [C]r [C]f [C]u [C]s [C]i [C]o [C]n O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
clinical [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
setting [C]s [C]e [C]t [C]t [C]i [C]n [C]g O 
will [C]w [C]i [C]l [C]l O 
improve [C]i [C]m [C]p [C]r [C]o [C]v [C]e O 
the [C]t [C]h [C]e O 
outcome [C]o [C]u [C]t [C]c [C]o [C]m [C]e O 
of [C]o [C]f O 
hepatic [C]h [C]e [C]p [C]a [C]t [C]i [C]c O 
surgery [C]s [C]u [C]r [C]g [C]e [C]r [C]y O 
. [C]. O 

Down-regulation [C]D [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-12 [C]I [C]L [C]- [C]1 [C]2 B-DNA 
p40 [C]p [C]4 [C]0 I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
in [C]i [C]n O 
Plasmodium [C]P [C]l [C]a [C]s [C]m [C]o [C]d [C]i [C]u [C]m O 
berghei-infected [C]b [C]e [C]r [C]g [C]h [C]e [C]i [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
mice [C]m [C]i [C]c [C]e O 
. [C]. O 

We [C]W [C]e O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
the [C]t [C]h [C]e O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
that [C]t [C]h [C]a [C]t O 
causes [C]c [C]a [C]u [C]s [C]e [C]s O 
suppression [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-12 [C]I [C]L [C]- [C]1 [C]2 B-DNA 
p40 [C]p [C]4 [C]0 I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
Plasmodium [C]P [C]l [C]a [C]s [C]m [C]o [C]d [C]i [C]u [C]m O 
berghei [C]b [C]e [C]r [C]g [C]h [C]e [C]i O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
IL-12 [C]I [C]L [C]- [C]1 [C]2 S-protein 
together [C]t [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
with [C]w [C]i [C]t [C]h O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
plays [C]p [C]l [C]a [C]y [C]s O 
an [C]a [C]n O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
protection [C]p [C]r [C]o [C]t [C]e [C]c [C]t [C]i [C]o [C]n O 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
pathogenic [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]i [C]c O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
, [C], O 
the [C]t [C]h [C]e O 
IL-12 [C]I [C]L [C]- [C]1 [C]2 B-protein 
p70 [C]p [C]7 [C]0 I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
infected [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d B-cell_type 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s E-cell_type 
is [C]i [C]s O 
lower [C]l [C]o [C]w [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
that [C]t [C]h [C]a [C]t O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
uninfected [C]u [C]n [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d B-cell_type 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s E-cell_type 
. [C]. O 

We [C]W [C]e O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
study [C]s [C]t [C]u [C]d [C]y O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-12 [C]I [C]L [C]- [C]1 [C]2 B-DNA 
p40 [C]p [C]4 [C]0 I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
IL-12 [C]I [C]L [C]- [C]1 [C]2 B-DNA 
p35 [C]p [C]3 [C]5 I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
in [C]i [C]n O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_type 
of [C]o [C]f O 
P. [C]P [C]. O 
berghei-infected [C]b [C]e [C]r [C]g [C]h [C]e [C]i [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
mice [C]m [C]i [C]c [C]e O 
was [C]w [C]a [C]s O 
profoundly [C]p [C]r [C]o [C]f [C]o [C]u [C]n [C]d [C]l [C]y O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
. [C]. O 

The [C]T [C]h [C]e O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_type 
that [C]t [C]h [C]a [C]t O 
had [C]h [C]a [C]d O 
contacted [C]c [C]o [C]n [C]t [C]a [C]c [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
P. [C]P [C]. B-cell_type 
berghei-infected [C]b [C]e [C]r [C]g [C]h [C]e [C]i [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d I-cell_type 
erythrocytes [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
was [C]w [C]a [C]s O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
soluble [C]s [C]o [C]l [C]u [C]b [C]l [C]e O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
, [C], O 
IL-10 [C]I [C]L [C]- [C]1 [C]0 S-protein 
. [C]. O 

There [C]T [C]h [C]e [C]r [C]e O 
was [C]w [C]a [C]s O 
comparable [C]c [C]o [C]m [C]p [C]a [C]r [C]a [C]b [C]l [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
in [C]i [C]n O 
uninfected [C]u [C]n [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d B-cell_type 
and [C]a [C]n [C]d I-cell_type 
infected [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IFN-regulatory [C]I [C]F [C]N [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y B-DNA 
factor-1 [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]1 I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
was [C]w [C]a [C]s O 
comparable [C]c [C]o [C]m [C]p [C]a [C]r [C]a [C]b [C]l [C]e O 
in [C]i [C]n O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
level [C]l [C]e [C]v [C]e [C]l O 
in [C]i [C]n O 
uninfected [C]u [C]n [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d B-cell_type 
and [C]a [C]n [C]d I-cell_type 
infected [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
while [C]w [C]h [C]i [C]l [C]e O 
the [C]t [C]h [C]e O 
unidentified [C]u [C]n [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IFN-regulatory [C]I [C]F [C]N [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y B-protein 
factor-1 [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]1 E-protein 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
infected [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Therefore [C]T [C]h [C]e [C]r [C]e [C]f [C]o [C]r [C]e O 
, [C], O 
the [C]t [C]h [C]e O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IL-12 [C]I [C]L [C]- [C]1 [C]2 B-DNA 
p40 [C]p [C]4 [C]0 I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
appeared [C]a [C]p [C]p [C]e [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
at [C]a [C]t O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
gene [C]g [C]e [C]n [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
Friend [C]F [C]r [C]i [C]e [C]n [C]d B-protein 
of [C]o [C]f I-protein 
GATA [C]G [C]A [C]T [C]A I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
U-shaped [C]U [C]- [C]s [C]h [C]a [C]p [C]e [C]d O 
, [C], O 
FOG-1 [C]F [C]O [C]G [C]- [C]1 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
FOG-2 [C]F [C]O [C]G [C]- [C]2 S-protein 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
as [C]a [C]s O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
regulators [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]s O 
of [C]o [C]f O 
blood [C]b [C]l [C]o [C]o [C]d O 
, [C], O 
heart [C]h [C]e [C]a [C]r [C]t O 
, [C], O 
and [C]a [C]n [C]d O 
eye [C]e [C]y [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
in [C]i [C]n O 
Drosophila [C]D [C]r [C]o [C]s [C]o [C]p [C]h [C]i [C]l [C]a O 
. [C]. O 

Friend [C]F [C]r [C]i [C]e [C]n [C]d B-protein 
of [C]o [C]f I-protein 
GATA [C]G [C]A [C]T [C]A I-protein 
( [C]( I-protein 
FOG [C]F [C]O [C]G I-protein 
) [C]) I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
GATA [C]G [C]A [C]T [C]A O 
factor-activated [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
gene [C]g [C]e [C]n [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
. [C]. O 

During [C]D [C]u [C]r [C]i [C]n [C]g O 
vertebrate [C]v [C]e [C]r [C]t [C]e [C]b [C]r [C]a [C]t [C]e O 
hematopoiesis [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
, [C], O 
FOG [C]F [C]O [C]G B-protein 
and [C]a [C]n [C]d I-protein 
GATA [C]G [C]A [C]T [C]A I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
cooperate [C]c [C]o [C]o [C]p [C]e [C]r [C]a [C]t [C]e O 
to [C]t [C]o O 
promote [C]p [C]r [C]o [C]m [C]o [C]t [C]e O 
erythrocyte [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]c [C]y [C]t [C]e O 
and [C]a [C]n [C]d O 
megakaryocyte [C]m [C]e [C]g [C]a [C]k [C]a [C]r [C]y [C]o [C]c [C]y [C]t [C]e O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
Drosophila [C]D [C]r [C]o [C]s [C]o [C]p [C]h [C]i [C]l [C]a B-protein 
FOG [C]F [C]O [C]G I-protein 
homologue [C]h [C]o [C]m [C]o [C]l [C]o [C]g [C]u [C]e I-protein 
U-shaped [C]U [C]- [C]s [C]h [C]a [C]p [C]e [C]d E-protein 
( [C]( O 
Ush [C]U [C]s [C]h S-protein 
) [C]) O 
is [C]i [C]s O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
similarly [C]s [C]i [C]m [C]i [C]l [C]a [C]r [C]l [C]y O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
blood [C]b [C]l [C]o [C]o [C]d O 
cell [C]c [C]e [C]l [C]l O 
anlage [C]a [C]n [C]l [C]a [C]g [C]e O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
embryogenesis [C]e [C]m [C]b [C]r [C]y [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
. [C]. O 

During [C]D [C]u [C]r [C]i [C]n [C]g O 
hematopoiesis [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
, [C], O 
the [C]t [C]h [C]e O 
acute [C]a [C]c [C]u [C]t [C]e O 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
1 [C]1 O 
homologue [C]h [C]o [C]m [C]o [C]l [C]o [C]g [C]u [C]e O 
Lozenge [C]L [C]o [C]z [C]e [C]n [C]g [C]e B-cell_type 
and [C]a [C]n [C]d I-cell_type 
Glial [C]G [C]l [C]i [C]a [C]l I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
missing [C]m [C]i [C]s [C]s [C]i [C]n [C]g O 
are [C]a [C]r [C]e O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
crystal [C]c [C]r [C]y [C]s [C]t [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
plasmatocytes [C]p [C]l [C]a [C]s [C]m [C]a [C]t [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
, [C], O 
respectively [C]r [C]e [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
additional [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n [C]a [C]l O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
predicted [C]p [C]r [C]e [C]d [C]i [C]c [C]t [C]e [C]d O 
to [C]t [C]o O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
crystal [C]c [C]r [C]y [C]s [C]t [C]a [C]l O 
cell [C]c [C]e [C]l [C]l O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
, [C], O 
we [C]w [C]e O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
Ush [C]U [C]s [C]h S-protein 
is [C]i [C]s O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
hemocyte [C]h [C]e [C]m [C]o [C]c [C]y [C]t [C]e B-cell_type 
precursors [C]p [C]r [C]e [C]c [C]u [C]r [C]s [C]o [C]r [C]s E-cell_type 
and [C]a [C]n [C]d O 
plasmatocytes [C]p [C]l [C]a [C]s [C]m [C]a [C]t [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
throughout [C]t [C]h [C]r [C]o [C]u [C]g [C]h [C]o [C]u [C]t O 
embryogenesis [C]e [C]m [C]b [C]r [C]y [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
larval [C]l [C]a [C]r [C]v [C]a [C]l O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
, [C], O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
GATA [C]G [C]A [C]T [C]A B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
Serpent [C]S [C]e [C]r [C]p [C]e [C]n [C]t E-protein 
is [C]i [C]s O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
for [C]f [C]o [C]r O 
Ush [C]U [C]s [C]h S-protein 
embryonic [C]e [C]m [C]b [C]r [C]y [C]o [C]n [C]i [C]c O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
loss [C]l [C]o [C]s [C]s O 
of [C]o [C]f O 
ush [C]u [C]s [C]h O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
in [C]i [C]n O 
an [C]a [C]n O 
overproduction [C]o [C]v [C]e [C]r [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
crystal [C]c [C]r [C]y [C]s [C]t [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
forced [C]f [C]o [C]r [C]c [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
Ush [C]U [C]s [C]h S-protein 
reduces [C]r [C]e [C]d [C]u [C]c [C]e [C]s O 
this [C]t [C]h [C]i [C]s O 
cell [C]c [C]e [C]l [C]l O 
population [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Murine [C]M [C]u [C]r [C]i [C]n [C]e B-protein 
FOG-1 [C]F [C]O [C]G [C]- [C]1 I-protein 
and [C]a [C]n [C]d I-protein 
FOG-2 [C]F [C]O [C]G [C]- [C]2 E-protein 
also [C]a [C]l [C]s [C]o O 
can [C]c [C]a [C]n O 
repress [C]r [C]e [C]p [C]r [C]e [C]s [C]s O 
crystal [C]c [C]r [C]y [C]s [C]t [C]a [C]l O 
cell [C]c [C]e [C]l [C]l O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
, [C], O 
but [C]b [C]u [C]t O 
a [C]a O 
mutant [C]m [C]u [C]t [C]a [C]n [C]t O 
version [C]v [C]e [C]r [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
FOG-2 [C]F [C]O [C]G [C]- [C]2 S-protein 
lacking [C]l [C]a [C]c [C]k [C]i [C]n [C]g O 
a [C]a O 
conserved [C]c [C]o [C]n [C]s [C]e [C]r [C]v [C]e [C]d O 
motif [C]m [C]o [C]t [C]i [C]f O 
that [C]t [C]h [C]a [C]t O 
binds [C]b [C]i [C]n [C]d [C]s O 
the [C]t [C]h [C]e O 
corepressor [C]c [C]o [C]r [C]e [C]p [C]r [C]e [C]s [C]s [C]o [C]r B-protein 
C-terminal [C]C [C]- [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
fails [C]f [C]a [C]i [C]l [C]s O 
to [C]t [C]o O 
affect [C]a [C]f [C]f [C]e [C]c [C]t O 
the [C]t [C]h [C]e O 
cell [C]c [C]e [C]l [C]l O 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
GATA [C]G [C]A [C]T [C]A B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
Pannier [C]P [C]a [C]n [C]n [C]i [C]e [C]r E-protein 
( [C]( O 
Pnr [C]P [C]n [C]r S-protein 
) [C]) O 
is [C]i [C]s O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
eye [C]e [C]y [C]e O 
and [C]a [C]n [C]d O 
heart [C]h [C]e [C]a [C]r [C]t O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
in [C]i [C]n O 
Drosophila [C]D [C]r [C]o [C]s [C]o [C]p [C]h [C]i [C]l [C]a O 
. [C]. O 

When [C]W [C]h [C]e [C]n O 
Ush [C]U [C]s [C]h S-protein 
, [C], O 
FOG-1 [C]F [C]O [C]G [C]- [C]1 S-protein 
, [C], O 
FOG-2 [C]F [C]O [C]G [C]- [C]2 S-protein 
, [C], O 
or [C]o [C]r O 
mutant [C]m [C]u [C]t [C]a [C]n [C]t B-protein 
FOG-2 [C]F [C]O [C]G [C]- [C]2 E-protein 
is [C]i [C]s O 
coexpressed [C]c [C]o [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
Pnr [C]P [C]n [C]r S-protein 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
these [C]t [C]h [C]e [C]s [C]e O 
developmental [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t [C]a [C]l O 
processes [C]p [C]r [C]o [C]c [C]e [C]s [C]s [C]e [C]s O 
, [C], O 
severe [C]s [C]e [C]v [C]e [C]r [C]e O 
eye [C]e [C]y [C]e O 
and [C]a [C]n [C]d O 
heart [C]h [C]e [C]a [C]r [C]t O 
phenotypes [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e [C]s O 
result [C]r [C]e [C]s [C]u [C]l [C]t O 
, [C], O 
consistent [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
conserved [C]c [C]o [C]n [C]s [C]e [C]r [C]v [C]e [C]d O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Pnr [C]P [C]n [C]r S-protein 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
fly [C]f [C]l [C]y O 
and [C]a [C]n [C]d O 
mouse [C]m [C]o [C]u [C]s [C]e O 
FOG [C]F [C]O [C]G B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
similarly [C]s [C]i [C]m [C]i [C]l [C]a [C]r [C]l [C]y O 
in [C]i [C]n O 
three [C]t [C]h [C]r [C]e [C]e O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
contexts [C]c [C]o [C]n [C]t [C]e [C]x [C]t [C]s O 
in [C]i [C]n O 
Drosophila [C]D [C]r [C]o [C]s [C]o [C]p [C]h [C]i [C]l [C]a O 
, [C], O 
but [C]b [C]u [C]t O 
may [C]m [C]a [C]y O 
use [C]u [C]s [C]e O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
to [C]t [C]o O 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
genetic [C]g [C]e [C]n [C]e [C]t [C]i [C]c O 
events [C]e [C]v [C]e [C]n [C]t [C]s O 
in [C]i [C]n O 
blood [C]b [C]l [C]o [C]o [C]d O 
vs [C]v [C]s O 
. [C]. O 
cardial [C]c [C]a [C]r [C]d [C]i [C]a [C]l B-cell_line 
or [C]o [C]r I-cell_line 
eye [C]e [C]y [C]e I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lineages [C]l [C]i [C]n [C]e [C]a [C]g [C]e [C]s E-cell_line 

The [C]T [C]h [C]e O 
RING [C]R [C]I [C]N [C]G B-protein 
finger [C]f [C]i [C]n [C]g [C]e [C]r I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
Siah-1 [C]S [C]i [C]a [C]h [C]- [C]1 S-protein 
regulates [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]s O 
the [C]t [C]h [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l B-protein 
coactivator [C]c [C]o [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r E-protein 
OBF-1 [C]O [C]B [C]F [C]- [C]1 S-protein 
. [C]. O 

The [C]T [C]h [C]e O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l B-protein 
coactivator [C]c [C]o [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r E-protein 
OBF-1 [C]O [C]B [C]F [C]- [C]1 S-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
interacts [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
Oct-1 [C]O [C]c [C]t [C]- [C]1 S-protein 
and [C]a [C]n [C]d O 
Oct-2 [C]O [C]c [C]t [C]- [C]2 S-protein 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
octamer [C]o [C]c [C]t [C]a [C]m [C]e [C]r B-DNA 
site [C]s [C]i [C]t [C]e I-DNA 
DNA [C]D [C]N [C]A E-DNA 
, [C], O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
be [C]b [C]e O 
critical [C]c [C]r [C]i [C]t [C]i [C]c [C]a [C]l O 
for [C]f [C]o [C]r O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
a [C]a O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
germinal [C]g [C]e [C]r [C]m [C]i [C]n [C]a [C]l O 
centers [C]c [C]e [C]n [C]t [C]e [C]r [C]s O 
in [C]i [C]n O 
secondary [C]s [C]e [C]c [C]o [C]n [C]d [C]a [C]r [C]y O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d O 
organs [C]o [C]r [C]g [C]a [C]n [C]s O 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
we [C]w [C]e O 
have [C]h [C]a [C]v [C]e O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
the [C]t [C]h [C]e O 
RING [C]R [C]I [C]N [C]G B-protein 
finger [C]f [C]i [C]n [C]g [C]e [C]r I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
Siah-1 [C]S [C]i [C]a [C]h [C]- [C]1 S-protein 
as [C]a [C]s O 
a [C]a O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
interacting [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]n [C]g O 
specifically [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]a [C]l [C]l [C]y O 
with [C]w [C]i [C]t [C]h O 
OBF-1 [C]O [C]B [C]F [C]- [C]1 S-protein 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
C-terminal [C]C [C]- [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l S-protein 
part [C]p [C]a [C]r [C]t O 
of [C]o [C]f O 
Siah-1 [C]S [C]i [C]a [C]h [C]- [C]1 S-protein 
and [C]a [C]n [C]d O 
by [C]b [C]y O 
residues [C]r [C]e [C]s [C]i [C]d [C]u [C]e [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
N-terminus [C]N [C]- [C]t [C]e [C]r [C]m [C]i [C]n [C]u [C]s S-protein 
of [C]o [C]f O 
OBF-1 [C]O [C]B [C]F [C]- [C]1 S-protein 
, [C], O 
partly [C]p [C]a [C]r [C]t [C]l [C]y O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
residues [C]r [C]e [C]s [C]i [C]d [C]u [C]e [C]s O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
Oct [C]O [C]c [C]t B-protein 
POU [C]P [C]O [C]U I-protein 
domains [C]d [C]o [C]m [C]a [C]i [C]n [C]s E-protein 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
DNA [C]D [C]N [C]A O 
. [C]. O 

Interaction [C]I [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
Siah-1 [C]S [C]i [C]a [C]h [C]- [C]1 S-protein 
and [C]a [C]n [C]d O 
OBF-1 [C]O [C]B [C]F [C]- [C]1 S-protein 
leads [C]l [C]e [C]a [C]d [C]s O 
to [C]t [C]o O 
downregulation [C]d [C]o [C]w [C]n [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
OBF-1 [C]O [C]B [C]F [C]- [C]1 O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
level [C]l [C]e [C]v [C]e [C]l O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
mRNA [C]m [C]R [C]N [C]A O 
, [C], O 
and [C]a [C]n [C]d O 
to [C]t [C]o O 
a [C]a O 
corresponding [C]c [C]o [C]r [C]r [C]e [C]s [C]p [C]o [C]n [C]d [C]i [C]n [C]g O 
reduction [C]r [C]e [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
octamer [C]o [C]c [C]t [C]a [C]m [C]e [C]r O 
site-dependent [C]s [C]i [C]t [C]e [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Inhibition [C]I [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
ubiquitin-proteasome [C]u [C]b [C]i [C]q [C]u [C]i [C]t [C]i [C]n [C]- [C]p [C]r [C]o [C]t [C]e [C]a [C]s [C]o [C]m [C]e O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
in [C]i [C]n O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
leads [C]l [C]e [C]a [C]d [C]s O 
to [C]t [C]o O 
elevated [C]e [C]l [C]e [C]v [C]a [C]t [C]e [C]d O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
OBF-1 [C]O [C]B [C]F [C]- [C]1 B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
in [C]i [C]n O 
immunized [C]i [C]m [C]m [C]u [C]n [C]i [C]z [C]e [C]d O 
mice [C]m [C]i [C]c [C]e O 
, [C], O 
OBF-1 [C]O [C]B [C]F [C]- [C]1 B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
amounts [C]a [C]m [C]o [C]u [C]n [C]t [C]s O 
are [C]a [C]r [C]e O 
dramatically [C]d [C]r [C]a [C]m [C]a [C]t [C]i [C]c [C]a [C]l [C]l [C]y O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
in [C]i [C]n O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y B-cell_type 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d I-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
without [C]w [C]i [C]t [C]h [C]o [C]u [C]t O 
concomitant [C]c [C]o [C]n [C]c [C]o [C]m [C]i [C]t [C]a [C]n [C]t O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
OBF-1 [C]O [C]B [C]F [C]- [C]1 B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
Siah-1 [C]S [C]i [C]a [C]h [C]- [C]1 S-protein 
is [C]i [C]s O 
part [C]p [C]a [C]r [C]t O 
of [C]o [C]f O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
loop [C]l [C]o [C]o [C]p O 
controlling [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]l [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
OBF-1 [C]O [C]B [C]F [C]- [C]1 B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
in [C]i [C]n O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
beta-catenin [C]b [C]e [C]t [C]a [C]- [C]c [C]a [C]t [C]e [C]n [C]i [C]n O 
-- [C]- [C]- O 
TCF-1 [C]T [C]C [C]F [C]- [C]1 O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
ensures [C]e [C]n [C]s [C]u [C]r [C]e [C]s O 
CD4 [C]C [C]D [C]4 B-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
CD8 [C]C [C]D [C]8 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
thymocyte [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e E-cell_type 
survival [C]s [C]u [C]r [C]v [C]i [C]v [C]a [C]l O 
. [C]. O 

The [C]T [C]h [C]e O 
association [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
trans-acting [C]t [C]r [C]a [C]n [C]s [C]- [C]a [C]c [C]t [C]i [C]n [C]g B-protein 
T [C]T I-protein 
cell [C]c [C]e [C]l [C]l I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
( [C]( O 
TCFs [C]T [C]C [C]F [C]s S-protein 
) [C]) O 
or [C]o [C]r O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d B-protein 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
1 [C]1 E-protein 
( [C]( O 
LEF-1 [C]L [C]E [C]F [C]- [C]1 S-protein 
) [C]) O 
with [C]w [C]i [C]t [C]h O 
their [C]t [C]h [C]e [C]i [C]r O 
coactivator [C]c [C]o [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r O 
beta-catenin [C]b [C]e [C]t [C]a [C]- [C]c [C]a [C]t [C]e [C]n [C]i [C]n O 
mediates [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]s O 
transient [C]t [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
to [C]t [C]o O 
extracellular [C]e [C]x [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
Wnt [C]W [C]n [C]t O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
. [C]. O 

We [C]W [C]e O 
show [C]s [C]h [C]o [C]w O 
here [C]h [C]e [C]r [C]e O 
that [C]t [C]h [C]a [C]t O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
maturation [C]m [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
depends [C]d [C]e [C]p [C]e [C]n [C]d [C]s O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
beta-catenin [C]b [C]e [C]t [C]a [C]- [C]c [C]a [C]t [C]e [C]n [C]i [C]n B-protein 
-- [C]- [C]- I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
in [C]i [C]n O 
TCF-1 [C]T [C]C [C]F [C]- [C]1 S-protein 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
domain [C]d [C]o [C]m [C]a [C]i [C]n O 
is [C]i [C]s O 
necessary [C]n [C]e [C]c [C]e [C]s [C]s [C]a [C]r [C]y O 
to [C]t [C]o O 
mediate [C]m [C]e [C]d [C]i [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
survival [C]s [C]u [C]r [C]v [C]i [C]v [C]a [C]l O 
of [C]o [C]f O 
immature [C]i [C]m [C]m [C]a [C]t [C]u [C]r [C]e O 
CD4 [C]C [C]D [C]4 B-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
CD8 [C]C [C]D [C]8 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
double-positive [C]d [C]o [C]u [C]b [C]l [C]e [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e I-cell_type 
( [C]( I-cell_type 
DP [C]D [C]P I-cell_type 
) [C]) I-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

Accelerated [C]A [C]c [C]c [C]e [C]l [C]e [C]r [C]a [C]t [C]e [C]d O 
spontaneous [C]s [C]p [C]o [C]n [C]t [C]a [C]n [C]e [C]o [C]u [C]s O 
thymocyte [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e O 
death [C]d [C]e [C]a [C]t [C]h O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
TCF-1 [C]T [C]C [C]F [C]- [C]1 S-protein 
correlates [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
aberrantly [C]a [C]b [C]e [C]r [C]r [C]a [C]n [C]t [C]l [C]y O 
low [C]l [C]o [C]w O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
anti-apoptotic [C]a [C]n [C]t [C]i [C]- [C]a [C]p [C]o [C]p [C]t [C]o [C]t [C]i [C]c B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
Bcl-x [C]B [C]c [C]l [C]- [C]x B-protein 
( [C]( I-protein 
L [C]L I-protein 
) [C]) E-protein 
. [C]. O 

Increasing [C]I [C]n [C]c [C]r [C]e [C]a [C]s [C]i [C]n [C]g O 
anti-apoptotic [C]a [C]n [C]t [C]i [C]- [C]a [C]p [C]o [C]p [C]t [C]o [C]t [C]i [C]c O 
effectors [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r [C]s O 
in [C]i [C]n O 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
use [C]u [C]s [C]e O 
of [C]o [C]f O 
a [C]a O 
Bcl-2 [C]B [C]c [C]l [C]- [C]2 B-DNA 
transgene [C]t [C]r [C]a [C]n [C]s [C]g [C]e [C]n [C]e E-DNA 
rescued [C]r [C]e [C]s [C]c [C]u [C]e [C]d O 
TCF-1-deficient [C]T [C]C [C]F [C]- [C]1 [C]- [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t B-cell_type 
DP [C]D [C]P I-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
TCF-1 [C]T [C]C [C]F [C]- [C]1 S-protein 
, [C], O 
upon [C]u [C]p [C]o [C]n O 
association [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
beta-catenin [C]b [C]e [C]t [C]a [C]- [C]c [C]a [C]t [C]e [C]n [C]i [C]n O 
, [C], O 
transiently [C]t [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t [C]l [C]y O 
ensures [C]e [C]n [C]s [C]u [C]r [C]e [C]s O 
the [C]t [C]h [C]e O 
survival [C]s [C]u [C]r [C]v [C]i [C]v [C]a [C]l O 
of [C]o [C]f O 
immature [C]i [C]m [C]m [C]a [C]t [C]u [C]r [C]e B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
enables [C]e [C]n [C]a [C]b [C]l [C]e [C]s O 
them [C]t [C]h [C]e [C]m O 
to [C]t [C]o O 
generate [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]e O 
and [C]a [C]n [C]d O 
edit [C]e [C]d [C]i [C]t O 
T [C]T B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
( [C]( I-protein 
TCR [C]T [C]C [C]R I-protein 
) [C]) I-protein 
alpha [C]a [C]l [C]p [C]h [C]a I-protein 
chains [C]c [C]h [C]a [C]i [C]n [C]s E-protein 
and [C]a [C]n [C]d O 
attempt [C]a [C]t [C]t [C]e [C]m [C]p [C]t O 
TCR [C]T [C]C [C]R S-protein 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
selection [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

TRAIL/Apo2L [C]T [C]R [C]A [C]I [C]L [C]/ [C]A [C]p [C]o [C]2 [C]L B-protein 
ligand [C]l [C]i [C]g [C]a [C]n [C]d E-protein 
selectively [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
overcomes [C]o [C]v [C]e [C]r [C]c [C]o [C]m [C]e [C]s O 
drug [C]d [C]r [C]u [C]g O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
in [C]i [C]n O 
multiple [C]m [C]u [C]l [C]t [C]i [C]p [C]l [C]e O 
myeloma [C]m [C]y [C]e [C]l [C]o [C]m [C]a O 
: [C]: O 
therapeutic [C]t [C]h [C]e [C]r [C]a [C]p [C]e [C]u [C]t [C]i [C]c O 
applications [C]a [C]p [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

Multiple [C]M [C]u [C]l [C]t [C]i [C]p [C]l [C]e O 
myeloma [C]m [C]y [C]e [C]l [C]o [C]m [C]a O 
( [C]( O 
MM [C]M [C]M O 
) [C]) O 
remains [C]r [C]e [C]m [C]a [C]i [C]n [C]s O 
incurable [C]i [C]n [C]c [C]u [C]r [C]a [C]b [C]l [C]e O 
and [C]a [C]n [C]d O 
novel [C]n [C]o [C]v [C]e [C]l O 
treatments [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t [C]s O 
are [C]a [C]r [C]e O 
urgently [C]u [C]r [C]g [C]e [C]n [C]t [C]l [C]y O 
needed [C]n [C]e [C]e [C]d [C]e [C]d O 
. [C]. O 

Preclinical [C]P [C]r [C]e [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
evaluations [C]e [C]v [C]a [C]l [C]u [C]a [C]t [C]i [C]o [C]n [C]s O 
were [C]w [C]e [C]r [C]e O 
performed [C]p [C]e [C]r [C]f [C]o [C]r [C]m [C]e [C]d O 
to [C]t [C]o O 
assess [C]a [C]s [C]s [C]e [C]s [C]s O 
the [C]t [C]h [C]e O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
therapeutic [C]t [C]h [C]e [C]r [C]a [C]p [C]e [C]u [C]t [C]i [C]c O 
applications [C]a [C]p [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n O 
recombinant [C]r [C]e [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]n [C]t O 
tumor [C]t [C]u [C]m [C]o [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
( [C]( I-protein 
TNF [C]T [C]N [C]F I-protein 
) [C]) I-protein 
-related [C]- [C]r [C]e [C]l [C]a [C]t [C]e [C]d I-protein 
apoptosis-inducing [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s [C]- [C]i [C]n [C]d [C]u [C]c [C]i [C]n [C]g I-protein 
ligand/Apo2 [C]l [C]i [C]g [C]a [C]n [C]d [C]/ [C]A [C]p [C]o [C]2 I-protein 
ligand [C]l [C]i [C]g [C]a [C]n [C]d E-protein 
( [C]( O 
TRAIL/Apo2L [C]T [C]R [C]A [C]I [C]L [C]/ [C]A [C]p [C]o [C]2 [C]L S-protein 
) [C]) O 
in [C]i [C]n O 
MM [C]M [C]M O 
. [C]. O 

TRAIL/Apo2L [C]T [C]R [C]A [C]I [C]L [C]/ [C]A [C]p [C]o [C]2 [C]L S-protein 
potently [C]p [C]o [C]t [C]e [C]n [C]t [C]l [C]y O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
of [C]o [C]f O 
MM [C]M [C]M B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
majority [C]m [C]a [C]j [C]o [C]r [C]i [C]t [C]y O 
of [C]o [C]f O 
MM [C]M [C]M B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
cells [C]c [C]e [C]l [C]l [C]s O 
sensitive [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
or [C]o [C]r O 
resistant [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]t O 
to [C]t [C]o O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
( [C]( O 
Dex [C]D [C]e [C]x O 
) [C]) O 
, [C], O 
doxorubicin [C]d [C]o [C]x [C]o [C]r [C]u [C]b [C]i [C]c [C]i [C]n O 
( [C]( O 
Dox [C]D [C]o [C]x O 
) [C]) O 
, [C], O 
melphalan [C]m [C]e [C]l [C]p [C]h [C]a [C]l [C]a [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
mitoxantrone [C]m [C]i [C]t [C]o [C]x [C]a [C]n [C]t [C]r [C]o [C]n [C]e O 
. [C]. O 

TRAIL/Apo2L [C]T [C]R [C]A [C]I [C]L [C]/ [C]A [C]p [C]o [C]2 [C]L S-protein 
also [C]a [C]l [C]s [C]o O 
overcame [C]o [C]v [C]e [C]r [C]c [C]a [C]m [C]e O 
the [C]t [C]h [C]e O 
survival [C]s [C]u [C]r [C]v [C]i [C]v [C]a [C]l O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
interleukin [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n B-protein 
6 [C]6 E-protein 
on [C]o [C]n O 
MM [C]M [C]M B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
affect [C]a [C]f [C]f [C]e [C]c [C]t O 
the [C]t [C]h [C]e O 
survival [C]s [C]u [C]r [C]v [C]i [C]v [C]a [C]l O 
of [C]o [C]f O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
and [C]a [C]n [C]d I-cell_type 
bone [C]b [C]o [C]n [C]e I-cell_type 
marrow [C]m [C]a [C]r [C]r [C]o [C]w I-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
healthy [C]h [C]e [C]a [C]l [C]t [C]h [C]y O 
donors [C]d [C]o [C]n [C]o [C]r [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
status [C]s [C]t [C]a [C]t [C]u [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
TRAIL [C]T [C]R [C]A [C]I [C]L B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
( [C]( O 
assessed [C]a [C]s [C]s [C]e [C]s [C]s [C]e [C]d O 
by [C]b [C]y O 
immunoblotting [C]i [C]m [C]m [C]u [C]n [C]o [C]b [C]l [C]o [C]t [C]t [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
flow [C]f [C]l [C]o [C]w O 
cytometry [C]c [C]y [C]t [C]o [C]m [C]e [C]t [C]r [C]y O 
) [C]) O 
could [C]c [C]o [C]u [C]l [C]d O 
not [C]n [C]o [C]t O 
predict [C]p [C]r [C]e [C]d [C]i [C]c [C]t O 
TRAIL [C]T [C]R [C]A [C]I [C]L O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
MM [C]M [C]M B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
anti-MM [C]a [C]n [C]t [C]i [C]- [C]M [C]M O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
TRAIL/Apo2L [C]T [C]R [C]A [C]I [C]L [C]/ [C]A [C]p [C]o [C]2 [C]L S-protein 
was [C]w [C]a [C]s O 
confirmed [C]c [C]o [C]n [C]f [C]i [C]r [C]m [C]e [C]d O 
in [C]i [C]n O 
nu/xid/bg [C]n [C]u [C]/ [C]x [C]i [C]d [C]/ [C]b [C]g O 
mice [C]m [C]i [C]c [C]e O 
xenografted [C]x [C]e [C]n [C]o [C]g [C]r [C]a [C]f [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
MM [C]M [C]M I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
; [C]; O 
TRAIL [C]T [C]R [C]A [C]I [C]L S-protein 
( [C]( O 
500 [C]5 [C]0 [C]0 O 
microg [C]m [C]i [C]c [C]r [C]o [C]g O 
intraperitoneally [C]i [C]n [C]t [C]r [C]a [C]p [C]e [C]r [C]i [C]t [C]o [C]n [C]e [C]a [C]l [C]l [C]y O 
daily [C]d [C]a [C]i [C]l [C]y O 
for [C]f [C]o [C]r O 
14 [C]1 [C]4 O 
days [C]d [C]a [C]y [C]s O 
) [C]) O 
was [C]w [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
tolerated [C]t [C]o [C]l [C]e [C]r [C]a [C]t [C]e [C]d O 
and [C]a [C]n [C]d O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
suppressed [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
of [C]o [C]f O 
plasmacytomas [C]p [C]l [C]a [C]s [C]m [C]a [C]c [C]y [C]t [C]o [C]m [C]a [C]s S-cell_type 
. [C]. O 

Dox [C]D [C]o [C]x O 
up-regulated [C]u [C]p [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
TRAIL [C]T [C]R [C]A [C]I [C]L B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
death [C]d [C]e [C]a [C]t [C]h B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
5 [C]5 E-protein 
( [C]( O 
DR5 [C]D [C]R [C]5 S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
synergistically [C]s [C]y [C]n [C]e [C]r [C]g [C]i [C]s [C]t [C]i [C]c [C]a [C]l [C]l [C]y O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
the [C]t [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
TRAIL [C]T [C]R [C]A [C]I [C]L S-protein 
not [C]n [C]o [C]t O 
only [C]o [C]n [C]l [C]y O 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
MM [C]M [C]M B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
sensitive [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
to [C]t [C]o O 
, [C], O 
but [C]b [C]u [C]t O 
also [C]a [C]l [C]s [C]o O 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
those [C]t [C]h [C]o [C]s [C]e O 
resistant [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]t O 
to [C]t [C]o O 
, [C], O 
Dex- [C]D [C]e [C]x [C]- O 
or [C]o [C]r O 
Dox-induced [C]D [C]o [C]x [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
. [C]. O 

Nuclear [C]N [C]u [C]c [C]l [C]e [C]a [C]r O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
( [C]( O 
NF [C]N [C]F O 
) [C]) O 
-kappaB [C]- [C]k [C]a [C]p [C]p [C]a [C]B O 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
, [C], O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
SN50 [C]S [C]N [C]5 [C]0 O 
( [C]( O 
a [C]a O 
cell-permeable [C]c [C]e [C]l [C]l [C]- [C]p [C]e [C]r [C]m [C]e [C]a [C]b [C]l [C]e O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
translocation [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
) [C]) O 
or [C]o [C]r O 
the [C]t [C]h [C]e O 
proteasome [C]p [C]r [C]o [C]t [C]e [C]a [C]s [C]o [C]m [C]e O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
PS-341 [C]P [C]S [C]- [C]3 [C]4 [C]1 O 
, [C], O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
the [C]t [C]h [C]e O 
proapoptotic [C]p [C]r [C]o [C]a [C]p [C]o [C]p [C]t [C]o [C]t [C]i [C]c O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
TRAIL/Apo2L [C]T [C]R [C]A [C]I [C]L [C]/ [C]A [C]p [C]o [C]2 [C]L S-protein 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
TRAIL-sensitive [C]T [C]R [C]A [C]I [C]L [C]- [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e B-cell_type 
MM [C]M [C]M I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
SN50 [C]S [C]N [C]5 [C]0 O 
reversed [C]r [C]e [C]v [C]e [C]r [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
TRAIL [C]T [C]R [C]A [C]I [C]L O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
of [C]o [C]f O 
ARH-77 [C]A [C]R [C]H [C]- [C]7 [C]7 B-cell_type 
and [C]a [C]n [C]d I-cell_type 
IM-9 [C]I [C]M [C]- [C]9 I-cell_type 
MM [C]M [C]M I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Importantly [C]I [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t [C]l [C]y O 
, [C], O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
B [C]B I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
not [C]n [C]o [C]t O 
sensitized [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]z [C]e [C]d O 
to [C]t [C]o O 
TRAIL [C]T [C]R [C]A [C]I [C]L S-protein 
by [C]b [C]y O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
Dox [C]D [C]o [C]x O 
, [C], O 
SN50 [C]S [C]N [C]5 [C]0 O 
, [C], O 
or [C]o [C]r O 
PS-341 [C]P [C]S [C]- [C]3 [C]4 [C]1 O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
preclinical [C]p [C]r [C]e [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
TRAIL/Apo2L [C]T [C]R [C]A [C]I [C]L [C]/ [C]A [C]p [C]o [C]2 [C]L S-protein 
can [C]c [C]a [C]n O 
overcome [C]o [C]v [C]e [C]r [C]c [C]o [C]m [C]e O 
conventional [C]c [C]o [C]n [C]v [C]e [C]n [C]t [C]i [C]o [C]n [C]a [C]l O 
drug [C]d [C]r [C]u [C]g O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
and [C]a [C]n [C]d O 
provide [C]p [C]r [C]o [C]v [C]i [C]d [C]e O 
the [C]t [C]h [C]e O 
basis [C]b [C]a [C]s [C]i [C]s O 
for [C]f [C]o [C]r O 
clinical [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
trials [C]t [C]r [C]i [C]a [C]l [C]s O 
of [C]o [C]f O 
TRAIL [C]T [C]R [C]A [C]I [C]L S-protein 
-based [C]- [C]b [C]a [C]s [C]e [C]d O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
regimens [C]r [C]e [C]g [C]i [C]m [C]e [C]n [C]s O 
to [C]t [C]o O 
improve [C]i [C]m [C]p [C]r [C]o [C]v [C]e O 
outcome [C]o [C]u [C]t [C]c [C]o [C]m [C]e O 
in [C]i [C]n O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
MM [C]M [C]M O 
. [C]. O 

( [C]( O 
Blood. [C]B [C]l [C]o [C]o [C]d [C]. O 
2001 [C]2 [C]0 [C]0 [C]1 O 
; [C]; O 
98 [C]9 [C]8 O 
: [C]: O 
795-804 [C]7 [C]9 [C]5 [C]- [C]8 [C]0 [C]4 O 
) [C]) O 

CD28 [C]C [C]D [C]2 [C]8 S-protein 
costimulation [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
not [C]n [C]o [C]t O 
only [C]o [C]n [C]l [C]y O 
to [C]t [C]o O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
IL-12 [C]I [C]L [C]- [C]1 [C]2 B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
but [C]b [C]u [C]t O 
also [C]a [C]l [C]s [C]o O 
to [C]t [C]o O 
render [C]r [C]e [C]n [C]d [C]e [C]r O 
janus [C]j [C]a [C]n [C]u [C]s B-protein 
kinases/STAT4 [C]k [C]i [C]n [C]a [C]s [C]e [C]s [C]/ [C]S [C]T [C]A [C]T [C]4 E-protein 
responsive [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e O 
to [C]t [C]o O 
IL-12 [C]I [C]L [C]- [C]1 [C]2 S-protein 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
TCR-triggered [C]T [C]C [C]R [C]- [C]t [C]r [C]i [C]g [C]g [C]e [C]r [C]e [C]d B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
resting [C]r [C]e [C]s [C]t [C]i [C]n [C]g B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
acquisition [C]a [C]c [C]q [C]u [C]i [C]s [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
functions [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]s O 
depends [C]d [C]e [C]p [C]e [C]n [C]d [C]s O 
on [C]o [C]n O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
CD28 [C]C [C]D [C]2 [C]8 O 
costimulatory [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
are [C]a [C]r [C]e O 
provided [C]p [C]r [C]o [C]v [C]i [C]d [C]e [C]d O 
upon [C]u [C]p [C]o [C]n O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
, [C], O 
we [C]w [C]e O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
how [C]h [C]o [C]w O 
CD28 [C]C [C]D [C]2 [C]8 O 
costimulation [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
functions [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]s O 
to [C]t [C]o O 
allow [C]a [C]l [C]l [C]o [C]w O 
TCR [C]T [C]C [C]R S-protein 
-triggered [C]- [C]t [C]r [C]i [C]g [C]g [C]e [C]r [C]e [C]d O 
resting [C]r [C]e [C]s [C]t [C]i [C]n [C]g B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
to [C]t [C]o O 
acquire [C]a [C]c [C]q [C]u [C]i [C]r [C]e O 
IL-12 [C]I [C]L [C]- [C]1 [C]2 S-protein 
responsiveness [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e [C]n [C]e [C]s [C]s O 
. [C]. O 

When [C]W [C]h [C]e [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
are [C]a [C]r [C]e O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
low [C]l [C]o [C]w O 
doses [C]d [C]o [C]s [C]e [C]s O 
of [C]o [C]f O 
anti-CD3 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]3 B-protein 
mAb [C]m [C]A [C]b E-protein 
, [C], O 
CD28 [C]C [C]D [C]2 [C]8 O 
costimulation [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
optimal [C]o [C]p [C]t [C]i [C]m [C]a [C]l O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
IL-12 [C]I [C]L [C]- [C]1 [C]2 B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
( [C]( O 
IL-12R [C]I [C]L [C]- [C]1 [C]2 [C]R S-protein 
) [C]) O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
with [C]w [C]i [C]t [C]h O 
high [C]h [C]i [C]g [C]h O 
doses [C]d [C]o [C]s [C]e [C]s O 
of [C]o [C]f O 
anti-CD3 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]3 S-protein 
alone [C]a [C]l [C]o [C]n [C]e O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
comparable [C]c [C]o [C]m [C]p [C]a [C]r [C]a [C]b [C]l [C]e O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
IL-12R [C]I [C]L [C]- [C]1 [C]2 [C]R S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
to [C]t [C]o O 
those [C]t [C]h [C]o [C]s [C]e O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
upon [C]u [C]p [C]o [C]n O 
CD28 [C]C [C]D [C]2 [C]8 O 
costimulation [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Nevertheless [C]N [C]e [C]v [C]e [C]r [C]t [C]h [C]e [C]l [C]e [C]s [C]s O 
, [C], O 
there [C]t [C]h [C]e [C]r [C]e O 
was [C]w [C]a [C]s O 
a [C]a O 
substantial [C]s [C]u [C]b [C]s [C]t [C]a [C]n [C]t [C]i [C]a [C]l O 
difference [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e O 
in [C]i [C]n O 
IL-12 [C]I [C]L [C]- [C]1 [C]2 S-protein 
responsiveness [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e [C]n [C]e [C]s [C]s O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
two [C]t [C]w [C]o O 
groups [C]g [C]r [C]o [C]u [C]p [C]s O 
of [C]o [C]f O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
: [C]: O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
anti-CD28-costimulated [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]2 [C]8 [C]- [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
that [C]t [C]h [C]a [C]t O 
were [C]w [C]e [C]r [C]e O 
not [C]n [C]o [C]t O 
costimulated [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
anti-CD28 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]2 [C]8 S-protein 
exhibited [C]e [C]x [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
Janus [C]J [C]a [C]n [C]u [C]s B-protein 
kinases [C]k [C]i [C]n [C]a [C]s [C]e [C]s E-protein 
( [C]( O 
JAK [C]J [C]A [C]K S-protein 
) [C]) O 
JAK2/TYK2 [C]J [C]A [C]K [C]2 [C]/ [C]T [C]Y [C]K [C]2 S-protein 
and [C]a [C]n [C]d O 
STAT4 [C]S [C]T [C]A [C]T [C]4 S-protein 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
IFN-y [C]I [C]F [C]N [C]- [C]y O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
IL-12 [C]I [C]L [C]- [C]1 [C]2 S-protein 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Importantly [C]I [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t [C]l [C]y O 
, [C], O 
STAT6 [C]S [C]T [C]A [C]T [C]6 O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
IL-4 [C]I [C]L [C]- [C]4 O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
in [C]i [C]n O 
anti-CD28-uncostimulated [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]2 [C]8 [C]- [C]u [C]n [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
resutls [C]r [C]e [C]s [C]u [C]t [C]l [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
CD28 [C]C [C]D [C]2 [C]8 O 
costimulation [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
not [C]n [C]o [C]t O 
only [C]o [C]n [C]l [C]y O 
contributes [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e [C]s O 
to [C]t [C]o O 
up-regulating [C]u [C]p [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
IL-12R [C]I [C]L [C]- [C]1 [C]2 [C]R S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
but [C]b [C]u [C]t O 
is [C]i [C]s O 
also [C]a [C]l [C]s [C]o O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
to [C]t [C]o O 
render [C]r [C]e [C]n [C]d [C]e [C]r O 
JAKs/STAT4 [C]J [C]A [C]K [C]s [C]/ [C]S [C]T [C]A [C]T [C]4 S-protein 
responsive [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e O 
to [C]t [C]o O 
IL-12 [C]I [C]L [C]- [C]1 [C]2 S-protein 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Constitutively [C]C [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
Akt-1 [C]A [C]k [C]t [C]- [C]1 S-protein 
is [C]i [C]s O 
vital [C]v [C]i [C]t [C]a [C]l O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
survival [C]s [C]u [C]r [C]v [C]i [C]v [C]a [C]l O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
monocyte-differentiated [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]- [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]e [C]d I-cell_type 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s E-cell_type 
. [C]. O 

Role [C]R [C]o [C]l [C]e O 
of [C]o [C]f O 
Mcl-1 [C]M [C]c [C]l [C]- [C]1 S-protein 
, [C], O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
of [C]o [C]f O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
( [C]( I-protein 
NF [C]N [C]F I-protein 
) [C]) I-protein 
-kappaB [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
, [C], O 
Bad [C]B [C]a [C]d S-protein 
, [C], O 
or [C]o [C]r O 
caspase [C]c [C]a [C]s [C]p [C]a [C]s [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Recent [C]R [C]e [C]c [C]e [C]n [C]t O 
data [C]d [C]a [C]t [C]a O 
from [C]f [C]r [C]o [C]m O 
mice [C]m [C]i [C]c [C]e O 
deficient [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
for [C]f [C]o [C]r O 
phosphatase [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]a [C]s [C]e S-protein 
and [C]a [C]n [C]d O 
tensin [C]t [C]e [C]n [C]s [C]i [C]n B-DNA 
homologue [C]h [C]o [C]m [C]o [C]l [C]o [C]g [C]u [C]e E-DNA 
deleted [C]d [C]e [C]l [C]e [C]t [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
chromosome [C]c [C]h [C]r [C]o [C]m [C]o [C]s [C]o [C]m [C]e B-DNA 
10 [C]1 [C]0 E-DNA 
or [C]o [C]r O 
src [C]s [C]r [C]c B-protein 
homology [C]h [C]o [C]m [C]o [C]l [C]o [C]g [C]y I-protein 
2 [C]2 I-protein 
domain-containing [C]d [C]o [C]m [C]a [C]i [C]n [C]- [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g I-protein 
5 [C]5 I-protein 
' [C]' I-protein 
inositol [C]i [C]n [C]o [C]s [C]i [C]t [C]o [C]l I-protein 
phosphatase [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]a [C]s [C]e E-protein 
, [C], O 
phosphatases [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]a [C]s [C]e [C]s S-protein 
that [C]t [C]h [C]a [C]t O 
negatively [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e [C]l [C]y O 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
phosphatidylinositol [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]i [C]d [C]y [C]l [C]i [C]n [C]o [C]s [C]i [C]t [C]o [C]l B-protein 
3-kinase [C]3 [C]- [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
( [C]( O 
PI3K [C]P [C]I [C]3 [C]K S-protein 
) [C]) O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
, [C], O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
an [C]a [C]n O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_type 
in [C]i [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
animals [C]a [C]n [C]i [C]m [C]a [C]l [C]s O 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
an [C]a [C]n O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
role [C]r [C]o [C]l [C]e O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
PI3K [C]P [C]I [C]3 [C]K S-protein 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
for [C]f [C]o [C]r O 
macro-phage [C]m [C]a [C]c [C]r [C]o [C]- [C]p [C]h [C]a [C]g [C]e S-cell_type 
survival [C]s [C]u [C]r [C]v [C]i [C]v [C]a [C]l O 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
, [C], O 
we [C]w [C]e O 
focused [C]f [C]o [C]c [C]u [C]s [C]e [C]d O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
PI3K-regulated [C]P [C]I [C]3 [C]K [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d B-protein 
serine/threonine [C]s [C]e [C]r [C]i [C]n [C]e [C]/ [C]t [C]h [C]r [C]e [C]o [C]n [C]i [C]n [C]e I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
Akt-1 [C]A [C]k [C]t [C]- [C]1 S-protein 
in [C]i [C]n O 
modulating [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e S-cell_type 
survival [C]s [C]u [C]r [C]v [C]i [C]v [C]a [C]l O 
. [C]. O 

Akt-1 [C]A [C]k [C]t [C]- [C]1 S-protein 
was [C]w [C]a [C]s O 
constitutively [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
PI3K [C]P [C]I [C]3 [C]K S-protein 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
, [C], O 
LY294002 [C]L [C]Y [C]2 [C]9 [C]4 [C]0 [C]0 [C]2 O 
, [C], O 
suppressed [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Akt-1 [C]A [C]k [C]t [C]- [C]1 S-protein 
and [C]a [C]n [C]d O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
cell [C]c [C]e [C]l [C]l O 
death [C]d [C]e [C]a [C]t [C]h O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
suppression [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
Akt-1 [C]A [C]k [C]t [C]- [C]1 S-protein 
by [C]b [C]y O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
PI3K [C]P [C]I [C]3 [C]K S-protein 
or [C]o [C]r O 
a [C]a O 
dominant [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t B-protein 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e I-protein 
( [C]( I-protein 
DN [C]D [C]N I-protein 
) [C]) I-protein 
Akt-1 [C]A [C]k [C]t [C]- [C]1 E-protein 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
loss [C]l [C]o [C]s [C]s O 
of [C]o [C]f O 
mitochondrial [C]m [C]i [C]t [C]o [C]c [C]h [C]o [C]n [C]d [C]r [C]i [C]a [C]l O 
transmembrane [C]t [C]r [C]a [C]n [C]s [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
, [C], O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
caspases-9 [C]c [C]a [C]s [C]p [C]a [C]s [C]e [C]s [C]- [C]9 B-protein 
and [C]a [C]n [C]d I-protein 
-3 [C]- [C]3 E-protein 
, [C], O 
and [C]a [C]n [C]d O 
DNA [C]D [C]N [C]A O 
fragmentation [C]f [C]r [C]a [C]g [C]m [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
PI3K [C]P [C]I [C]3 [C]K S-protein 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
were [C]w [C]e [C]r [C]e O 
reversed [C]r [C]e [C]v [C]e [C]r [C]s [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
ectopic [C]e [C]c [C]t [C]o [C]p [C]i [C]c O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
constitutively [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
Akt-1 [C]A [C]k [C]t [C]- [C]1 S-protein 
or [C]o [C]r O 
Bcl-x [C]B [C]c [C]l [C]- [C]x B-protein 
( [C]( I-protein 
L [C]L I-protein 
) [C]) E-protein 
. [C]. O 

Inhibition [C]I [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
PI3K [C]P [C]I [C]3 [C]K S-protein 
/Akt-1 [C]/ [C]A [C]k [C]t [C]- [C]1 O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
by [C]b [C]y O 
LY294002 [C]L [C]Y [C]2 [C]9 [C]4 [C]0 [C]0 [C]2 O 
or [C]o [C]r O 
DN [C]D [C]N B-protein 
Akt-1 [C]A [C]k [C]t [C]- [C]1 E-protein 
had [C]h [C]a [C]d O 
no [C]n [C]o O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
constitutive [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
or [C]o [C]r O 
inducible [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
( [C]( I-protein 
NF [C]N [C]F I-protein 
) [C]) I-protein 
-kappaB [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s E-cell_type 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
after [C]a [C]f [C]t [C]e [C]r O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
PI3K [C]P [C]I [C]3 [C]K S-protein 
/ [C]/ O 
Akt-1 [C]A [C]k [C]t [C]- [C]1 S-protein 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
, [C], O 
a [C]a O 
marked [C]m [C]a [C]r [C]k [C]e [C]d O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
antiapoptotic [C]a [C]n [C]t [C]i [C]a [C]p [C]o [C]p [C]t [C]o [C]t [C]i [C]c B-protein 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e E-protein 
Mcl-1 [C]M [C]c [C]l [C]- [C]1 S-protein 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
other [C]o [C]t [C]h [C]e [C]r O 
Bcl-2 [C]B [C]c [C]l [C]- [C]2 B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y I-protein 
members [C]m [C]e [C]m [C]b [C]e [C]r [C]s E-protein 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
, [C], O 
and [C]a [C]n [C]d O 
Mcl-1 [C]M [C]c [C]l [C]- [C]1 S-protein 
rescued [C]r [C]e [C]s [C]c [C]u [C]e [C]d O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_type 
from [C]f [C]r [C]o [C]m O 
LY294002-induced [C]L [C]Y [C]2 [C]9 [C]4 [C]0 [C]0 [C]2 [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
cell [C]c [C]e [C]l [C]l O 
death [C]d [C]e [C]a [C]t [C]h O 
. [C]. O 

Further [C]F [C]u [C]r [C]t [C]h [C]e [C]r O 
, [C], O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Mcl-1 [C]M [C]c [C]l [C]- [C]1 S-protein 
by [C]b [C]y O 
antisense [C]a [C]n [C]t [C]i [C]s [C]e [C]n [C]s [C]e O 
oligonucleotides [C]o [C]l [C]i [C]g [C]o [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e [C]s O 
, [C], O 
also [C]a [C]l [C]s [C]o O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e S-cell_type 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
our [C]o [C]u [C]r O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
constitutive [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Akt-1 [C]A [C]k [C]t [C]- [C]1 S-protein 
regulates [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]s O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e S-cell_type 
survival [C]s [C]u [C]r [C]v [C]i [C]v [C]a [C]l O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
Mcl-1 [C]M [C]c [C]l [C]- [C]1 S-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
of [C]o [C]f O 
caspases [C]c [C]a [C]s [C]p [C]a [C]s [C]e [C]s S-protein 
, [C], O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
, [C], O 
or [C]o [C]r O 
Bad [C]B [C]a [C]d S-protein 
. [C]. O 

GRbeta [C]G [C]R [C]b [C]e [C]t [C]a O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
nasal [C]n [C]a [C]s [C]a [C]l B-cell_type 
polyp [C]p [C]o [C]l [C]y [C]p I-cell_type 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
its [C]i [C]t [C]s O 
relationship [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n [C]s [C]h [C]i [C]p O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
anti-inflammatory [C]a [C]n [C]t [C]i [C]- [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
intranasal [C]i [C]n [C]t [C]r [C]a [C]n [C]a [C]s [C]a [C]l O 
fluticasone [C]f [C]l [C]u [C]t [C]i [C]c [C]a [C]s [C]o [C]n [C]e O 
. [C]. O 

BACKGROUND [C]B [C]A [C]C [C]K [C]G [C]R [C]O [C]U [C]N [C]D O 
: [C]: O 
Nasal [C]N [C]a [C]s [C]a [C]l O 
polyposis [C]p [C]o [C]l [C]y [C]p [C]o [C]s [C]i [C]s O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
is [C]i [C]s O 
an [C]a [C]n O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
disorder [C]d [C]i [C]s [C]o [C]r [C]d [C]e [C]r O 
with [C]w [C]i [C]t [C]h O 
intense [C]i [C]n [C]t [C]e [C]n [C]s [C]e O 
eosinophilic [C]e [C]o [C]s [C]i [C]n [C]o [C]p [C]h [C]i [C]l [C]i [C]c O 
infiltration [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
respiratory [C]r [C]e [C]s [C]p [C]i [C]r [C]a [C]t [C]o [C]r [C]y O 
mucosa [C]m [C]u [C]c [C]o [C]s [C]a O 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
often [C]o [C]f [C]t [C]e [C]n O 
difficult [C]d [C]i [C]f [C]f [C]i [C]c [C]u [C]l [C]t O 
to [C]t [C]o O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
with [C]w [C]i [C]t [C]h O 
topical [C]t [C]o [C]p [C]i [C]c [C]a [C]l O 
steroids [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]s O 
. [C]. O 

Recent [C]R [C]e [C]c [C]e [C]n [C]t O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
suggests [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]s O 
that [C]t [C]h [C]a [C]t O 
overexpression [C]o [C]v [C]e [C]r [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
splice [C]s [C]p [C]l [C]i [C]c [C]e I-protein 
variant [C]v [C]a [C]r [C]i [C]a [C]n [C]t E-protein 
GRbeta [C]G [C]R [C]b [C]e [C]t [C]a S-protein 
in [C]i [C]n O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
might [C]m [C]i [C]g [C]h [C]t O 
contribute [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e O 
to [C]t [C]o O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
insensitivity [C]i [C]n [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
diseases [C]d [C]i [C]s [C]e [C]a [C]s [C]e [C]s O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
asthma [C]a [C]s [C]t [C]h [C]m [C]a O 
. [C]. O 

OBJECTIVE [C]O [C]B [C]J [C]E [C]C [C]T [C]I [C]V [C]E O 
: [C]: O 
The [C]T [C]h [C]e O 
purposes [C]p [C]u [C]r [C]p [C]o [C]s [C]e [C]s O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
investigation [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]i [C]o [C]n O 
were [C]w [C]e [C]r [C]e O 
to [C]t [C]o O 
determine [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
nasal [C]n [C]a [C]s [C]a [C]l B-cell_type 
polyp [C]p [C]o [C]l [C]y [C]p I-cell_type 
( [C]( I-cell_type 
NP [C]N [C]P I-cell_type 
) [C]) I-cell_type 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
overexpress [C]o [C]v [C]e [C]r [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
GRbeta [C]G [C]R [C]b [C]e [C]t [C]a S-protein 
and [C]a [C]n [C]d O 
to [C]t [C]o O 
examine [C]e [C]x [C]a [C]m [C]i [C]n [C]e O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
GRbeta [C]G [C]R [C]b [C]e [C]t [C]a S-protein 
overexpression [C]o [C]v [C]e [C]r [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
is [C]i [C]s O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
insensitivity [C]i [C]n [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
potent [C]p [C]o [C]t [C]e [C]n [C]t O 
topical [C]t [C]o [C]p [C]i [C]c [C]a [C]l O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
fluticasone [C]f [C]l [C]u [C]t [C]i [C]c [C]a [C]s [C]o [C]n [C]e O 
propionate [C]p [C]r [C]o [C]p [C]i [C]o [C]n [C]a [C]t [C]e O 
( [C]( O 
FP [C]F [C]P O 
) [C]) O 
. [C]. O 

METHODS [C]M [C]E [C]T [C]H [C]O [C]D [C]S O 
: [C]: O 
Biopsies [C]B [C]i [C]o [C]p [C]s [C]i [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
10 [C]1 [C]0 O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
NPs [C]N [C]P [C]s O 
before [C]b [C]e [C]f [C]o [C]r [C]e O 
and [C]a [C]n [C]d O 
4 [C]4 O 
weeks [C]w [C]e [C]e [C]k [C]s O 
after [C]a [C]f [C]t [C]e [C]r O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
intranasal [C]i [C]n [C]t [C]r [C]a [C]n [C]a [C]s [C]a [C]l O 
FP [C]F [C]P O 
. [C]. O 

Middle [C]M [C]i [C]d [C]d [C]l [C]e O 
turbinates [C]t [C]u [C]r [C]b [C]i [C]n [C]a [C]t [C]e [C]s O 
biopsies [C]b [C]i [C]o [C]p [C]s [C]i [C]e [C]s O 
from [C]f [C]r [C]o [C]m O 
6 [C]6 O 
healthy [C]h [C]e [C]a [C]l [C]t [C]h [C]y O 
, [C], O 
nonallergic [C]n [C]o [C]n [C]a [C]l [C]l [C]e [C]r [C]g [C]i [C]c O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
served [C]s [C]e [C]r [C]v [C]e [C]d O 
as [C]a [C]s O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
. [C]. O 

Biopsies [C]B [C]i [C]o [C]p [C]s [C]i [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
immunostained [C]i [C]m [C]m [C]u [C]n [C]o [C]s [C]t [C]a [C]i [C]n [C]e [C]d O 
for [C]f [C]o [C]r O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
cell [C]c [C]e [C]l [C]l O 
markers [C]m [C]a [C]r [C]k [C]e [C]r [C]s O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
GRbeta [C]G [C]R [C]b [C]e [C]t [C]a S-protein 
and [C]a [C]n [C]d O 
probed [C]p [C]r [C]o [C]b [C]e [C]d O 
for [C]f [C]o [C]r O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
. [C]. O 

The [C]T [C]h [C]e O 
anti-inflammatory [C]a [C]n [C]t [C]i [C]- [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
FP [C]F [C]P O 
was [C]w [C]a [C]s O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
in [C]i [C]n O 
relation [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
to [C]t [C]o O 
pretreatment [C]p [C]r [C]e [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
GRbeta [C]G [C]R [C]b [C]e [C]t [C]a O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

RESULTS [C]R [C]E [C]S [C]U [C]L [C]T [C]S O 
: [C]: O 
The [C]T [C]h [C]e O 
total [C]t [C]o [C]t [C]a [C]l O 
numbers [C]n [C]u [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
in [C]i [C]n O 
NPs [C]N [C]P [C]s S-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
percentage [C]p [C]e [C]r [C]c [C]e [C]n [C]t [C]a [C]g [C]e O 
of [C]o [C]f O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
expressing [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]n [C]g O 
GRbeta [C]G [C]R [C]b [C]e [C]t [C]a S-protein 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
( [C]( O 
40.5 [C]4 [C]0 [C]. [C]5 O 
% [C]% O 
+/- [C]+ [C]/ [C]- O 
19.2 [C]1 [C]9 [C]. [C]2 O 
% [C]% O 
vs [C]v [C]s O 
16.1 [C]1 [C]6 [C]. [C]1 O 
% [C]% O 
+/- [C]+ [C]/ [C]- O 
4.0 [C]4 [C]. [C]0 O 
% [C]% O 
, [C], O 
P [C]P O 
=.009 [C]= [C]. [C]0 [C]0 [C]9 O 
) [C]) O 
. [C]. O 

GRbeta [C]G [C]R [C]b [C]e [C]t [C]a S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
NPs [C]N [C]P [C]s S-cell_type 
was [C]w [C]a [C]s O 
almost [C]a [C]l [C]m [C]o [C]s [C]t O 
exclusive [C]e [C]x [C]c [C]l [C]u [C]s [C]i [C]v [C]e O 
to [C]t [C]o O 
T [C]T B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
, [C], O 
eosinophils [C]e [C]o [C]s [C]i [C]n [C]o [C]p [C]h [C]i [C]l [C]s S-cell_type 
, [C], O 
and [C]a [C]n [C]d O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_type 
. [C]. O 

An [C]A [C]n O 
inverse [C]i [C]n [C]v [C]e [C]r [C]s [C]e O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
baseline [C]b [C]a [C]s [C]e [C]l [C]i [C]n [C]e O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
cell [C]c [C]e [C]l [C]l O 
GRbeta [C]G [C]R [C]b [C]e [C]t [C]a S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
reduction [C]r [C]e [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
after [C]a [C]f [C]t [C]e [C]r O 
FP [C]F [C]P O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
in [C]i [C]n O 
EG2-positive [C]E [C]G [C]2 [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e B-cell_type 
eosinophils [C]e [C]o [C]s [C]i [C]n [C]o [C]p [C]h [C]i [C]l [C]s E-cell_type 
, [C], O 
CD4-positive [C]C [C]D [C]4 [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e B-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
, [C], O 
endothelial [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l O 
VCAM-1 [C]V [C]C [C]A [C]M [C]- [C]1 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
IL-4 [C]I [C]L [C]- [C]4 B-cell_type 
mRNA-positive [C]m [C]R [C]N [C]A [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

NPs [C]N [C]P [C]s S-cell_type 
that [C]t [C]h [C]a [C]t O 
were [C]w [C]e [C]r [C]e O 
`` [C]` [C]` O 
FP-insensitive [C]F [C]P [C]- [C]i [C]n [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
'' [C]' [C]' O 
in [C]i [C]n O 
terms [C]t [C]e [C]r [C]m [C]s O 
of [C]o [C]f O 
suppression [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
eosinophil [C]e [C]o [C]s [C]i [C]n [C]o [C]p [C]h [C]i [C]l S-cell_type 
numbers [C]n [C]u [C]m [C]b [C]e [C]r [C]s O 
( [C]( O 
major [C]m [C]a [C]j [C]o [C]r B-protein 
basic [C]b [C]a [C]s [C]i [C]c I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
-positive [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
) [C]) O 
had [C]h [C]a [C]d O 
a [C]a O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
greater [C]g [C]r [C]e [C]a [C]t [C]e [C]r O 
percentage [C]p [C]e [C]r [C]c [C]e [C]n [C]t [C]a [C]g [C]e O 
of [C]o [C]f O 
GRbeta-positive [C]G [C]R [C]b [C]e [C]t [C]a [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e B-cell_type 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
a [C]a O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
ratio [C]r [C]a [C]t [C]i [C]o O 
of [C]o [C]f O 
GRbeta-positive/GRalpha-positive [C]G [C]R [C]b [C]e [C]t [C]a [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e [C]/ [C]G [C]R [C]a [C]l [C]p [C]h [C]a [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
and [C]a [C]n [C]d O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
numbers [C]n [C]u [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
GRbeta-positive [C]G [C]R [C]b [C]e [C]t [C]a [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e B-cell_type 
eosinophils [C]e [C]o [C]s [C]i [C]n [C]o [C]p [C]h [C]i [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_type 
in [C]i [C]n O 
comparison [C]c [C]o [C]m [C]p [C]a [C]r [C]i [C]s [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
those [C]t [C]h [C]o [C]s [C]e O 
that [C]t [C]h [C]a [C]t O 
were [C]w [C]e [C]r [C]e O 
`` [C]` [C]` O 
FP-sensitive. [C]F [C]P [C]- [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e [C]. O 
'' [C]' [C]' O 

`` [C]` [C]` B-cell_type 
FP-insensitive [C]F [C]P [C]- [C]i [C]n [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e I-cell_type 
'' [C]' [C]' I-cell_type 
NPs [C]N [C]P [C]s E-cell_type 
also [C]a [C]l [C]s [C]o O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
a [C]a O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
percentage [C]p [C]e [C]r [C]c [C]e [C]n [C]t [C]a [C]g [C]e O 
of [C]o [C]f O 
IL-5-positive [C]I [C]L [C]- [C]5 [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e B-cell_type 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
expressing [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]n [C]g O 
GRbeta [C]G [C]R [C]b [C]e [C]t [C]a S-protein 
before [C]b [C]e [C]f [C]o [C]r [C]e O 
and [C]a [C]n [C]d O 
after [C]a [C]f [C]t [C]e [C]r O 
FP [C]F [C]P O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
. [C]. O 

CONCLUSION [C]C [C]O [C]N [C]C [C]L [C]U [C]S [C]I [C]O [C]N O 
: [C]: O 
GRbeta [C]G [C]R [C]b [C]e [C]t [C]a S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
appears [C]a [C]p [C]p [C]e [C]a [C]r [C]s O 
to [C]t [C]o O 
be [C]b [C]e O 
a [C]a O 
marker [C]m [C]a [C]r [C]k [C]e [C]r O 
of [C]o [C]f O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
insensitivity [C]i [C]n [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
NPs [C]N [C]P [C]s S-cell_type 
. [C]. O 

Expression [C]E [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
GRbeta [C]G [C]R [C]b [C]e [C]t [C]a S-protein 
by [C]b [C]y O 
NP [C]N [C]P B-cell_type 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
particularly [C]p [C]a [C]r [C]t [C]i [C]c [C]u [C]l [C]a [C]r [C]l [C]y O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
eosinophils [C]e [C]o [C]s [C]i [C]n [C]o [C]p [C]h [C]i [C]l [C]s S-cell_type 
, [C], O 
might [C]m [C]i [C]g [C]h [C]t O 
render [C]r [C]e [C]n [C]d [C]e [C]r O 
them [C]t [C]h [C]e [C]m O 
resistant [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]t O 
to [C]t [C]o O 
suppression [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
by [C]b [C]y O 
topical [C]t [C]o [C]p [C]i [C]c [C]a [C]l O 
steroids [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]s O 
and [C]a [C]n [C]d O 
thereby [C]t [C]h [C]e [C]r [C]e [C]b [C]y O 
contribute [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e O 
to [C]t [C]o O 
persistent [C]p [C]e [C]r [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
NP [C]N [C]P S-cell_type 
inflammation [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Transcriptional [C]T [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
galectin-10 [C]g [C]a [C]l [C]e [C]c [C]t [C]i [C]n [C]- [C]1 [C]0 S-protein 
( [C]( O 
eosinophil [C]e [C]o [C]s [C]i [C]n [C]o [C]p [C]h [C]i [C]l B-protein 
Charcot-Leyden [C]C [C]h [C]a [C]r [C]c [C]o [C]t [C]- [C]L [C]e [C]y [C]d [C]e [C]n I-protein 
crystal [C]c [C]r [C]y [C]s [C]t [C]a [C]l I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
) [C]) O 
: [C]: O 
a [C]a O 
GC [C]G [C]C B-DNA 
box [C]b [C]o [C]x E-DNA 
( [C]( O 
-44 [C]- [C]4 [C]4 O 
to [C]t [C]o O 
-50 [C]- [C]5 [C]0 O 
) [C]) O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
butyric [C]b [C]u [C]t [C]y [C]r [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Galectin-10 [C]G [C]a [C]l [C]e [C]c [C]t [C]i [C]n [C]- [C]1 [C]0 S-protein 
( [C]( O 
gal-10 [C]g [C]a [C]l [C]- [C]1 [C]0 S-protein 
, [C], O 
also [C]a [C]l [C]s [C]o O 
known [C]k [C]n [C]o [C]w [C]n O 
as [C]a [C]s O 
Charcot-Leyden [C]C [C]h [C]a [C]r [C]c [C]o [C]t [C]- [C]L [C]e [C]y [C]d [C]e [C]n B-protein 
crystal [C]c [C]r [C]y [C]s [C]t [C]a [C]l I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
) [C]) O 
is [C]i [C]s O 
a [C]a O 
member [C]m [C]e [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
galectin [C]g [C]a [C]l [C]e [C]c [C]t [C]i [C]n B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y E-protein 
of [C]o [C]f O 
beta-galactoside [C]b [C]e [C]t [C]a [C]- [C]g [C]a [C]l [C]a [C]c [C]t [C]o [C]s [C]i [C]d [C]e B-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
uniquely [C]u [C]n [C]i [C]q [C]u [C]e [C]l [C]y O 
in [C]i [C]n O 
eosinophilic [C]e [C]o [C]s [C]i [C]n [C]o [C]p [C]h [C]i [C]l [C]i [C]c B-cell_type 
and [C]a [C]n [C]d I-cell_type 
basophilic [C]b [C]a [C]s [C]o [C]p [C]h [C]i [C]l [C]i [C]c I-cell_type 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

To [C]T [C]o O 
gain [C]g [C]a [C]i [C]n O 
a [C]a O 
better [C]b [C]e [C]t [C]t [C]e [C]r O 
understanding [C]u [C]n [C]d [C]e [C]r [C]s [C]t [C]a [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
galectin [C]g [C]a [C]l [C]e [C]c [C]t [C]i [C]n O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
we [C]w [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
an [C]a [C]n O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
gene [C]g [C]e [C]n [C]e O 
encoding [C]e [C]n [C]c [C]o [C]d [C]i [C]n [C]g O 
gal-10 [C]g [C]a [C]l [C]- [C]1 [C]0 S-protein 
. [C]. O 

Analysis [C]A [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
minimal [C]m [C]i [C]n [C]i [C]m [C]a [C]l B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
nine [C]n [C]i [C]n [C]e O 
consensus-binding [C]c [C]o [C]n [C]s [C]e [C]n [C]s [C]u [C]s [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
for [C]f [C]o [C]r O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
that [C]t [C]h [C]a [C]t O 
are [C]a [C]r [C]e O 
also [C]a [C]l [C]s [C]o O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
minimal [C]m [C]i [C]n [C]i [C]m [C]a [C]l B-DNA 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s E-DNA 
of [C]o [C]f O 
galectins [C]g [C]a [C]l [C]e [C]c [C]t [C]i [C]n [C]s B-DNA 
-1 [C]- [C]1 I-DNA 
, [C], I-DNA 
-2 [C]- [C]2 I-DNA 
, [C], I-DNA 
and [C]a [C]n [C]d I-DNA 
-3 [C]- [C]3 E-DNA 
. [C]. O 

The [C]T [C]h [C]e O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
gal-10 [C]g [C]a [C]l [C]- [C]1 [C]0 O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
after [C]a [C]f [C]t [C]e [C]r O 
disruption [C]d [C]i [C]s [C]r [C]u [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
the [C]t [C]h [C]e O 
GC [C]G [C]C B-DNA 
box [C]b [C]o [C]x E-DNA 
( [C]( O 
-44 [C]- [C]4 [C]4 O 
to [C]t [C]o O 
-50 [C]- [C]5 [C]0 O 
) [C]) O 
or [C]o [C]r O 
the [C]t [C]h [C]e O 
Oct [C]O [C]c [C]t B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
( [C]( O 
-255 [C]- [C]2 [C]5 [C]5 O 
to [C]t [C]o O 
-261 [C]- [C]2 [C]6 [C]1 O 
) [C]) O 
suggests [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]s O 
that [C]t [C]h [C]a [C]t O 
these [C]t [C]h [C]e [C]s [C]e O 
sites [C]s [C]i [C]t [C]e [C]s O 
, [C], O 
along [C]a [C]l [C]o [C]n [C]g O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
characterized [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]d O 
GATA [C]G [C]A [C]T [C]A B-DNA 
and [C]a [C]n [C]d I-DNA 
EoTF [C]E [C]o [C]T [C]F I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
, [C], O 
are [C]a [C]r [C]e O 
necessary [C]n [C]e [C]c [C]e [C]s [C]s [C]a [C]r [C]y O 
for [C]f [C]o [C]r O 
full [C]f [C]u [C]l [C]l O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

By [C]B [C]y O 
supershift [C]s [C]u [C]p [C]e [C]r [C]s [C]h [C]i [C]f [C]t O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
, [C], O 
we [C]w [C]e O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
Sp1 [C]S [C]p [C]1 S-protein 
and [C]a [C]n [C]d O 
Oct1 [C]O [C]c [C]t [C]1 S-protein 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
consensus [C]c [C]o [C]n [C]s [C]e [C]n [C]s [C]u [C]s B-DNA 
GC [C]G [C]C I-DNA 
box [C]b [C]o [C]x E-DNA 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
Oct [C]O [C]c [C]t B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
, [C], O 
respectively [C]r [C]e [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
. [C]. O 

Similar [C]S [C]i [C]m [C]i [C]l [C]a [C]r O 
to [C]t [C]o O 
gal-1 [C]g [C]a [C]l [C]- [C]1 S-DNA 
, [C], O 
gal-10 [C]g [C]a [C]l [C]- [C]1 [C]0 O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
is [C]i [C]s O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
butyric [C]b [C]u [C]t [C]y [C]r [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
, [C], O 
an [C]a [C]n O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
lost [C]l [C]o [C]s [C]t O 
upon [C]u [C]p [C]o [C]n O 
ablation [C]a [C]b [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
GC [C]G [C]C B-DNA 
box [C]b [C]o [C]x E-DNA 
. [C]. O 

Additionally [C]A [C]d [C]d [C]i [C]t [C]i [C]o [C]n [C]a [C]l [C]l [C]y O 
, [C], O 
we [C]w [C]e O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
AML3 [C]A [C]M [C]L [C]3 O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
consensus [C]c [C]o [C]n [C]s [C]e [C]n [C]s [C]u [C]s B-DNA 
AML [C]A [C]M [C]L I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
and [C]a [C]n [C]d O 
YY1 [C]Y [C]Y [C]1 B-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g E-protein 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
Inr [C]I [C]n [C]r B-DNA 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e E-DNA 
, [C], O 
both [C]b [C]o [C]t [C]h O 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s O 
functioning [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]i [C]n [C]g O 
as [C]a [C]s O 
silencers [C]s [C]i [C]l [C]e [C]n [C]c [C]e [C]r [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
gal-10 [C]g [C]a [C]l [C]- [C]1 [C]0 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

Tumour-stromal [C]T [C]u [C]m [C]o [C]u [C]r [C]- [C]s [C]t [C]r [C]o [C]m [C]a [C]l O 
interactions [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

Role [C]R [C]o [C]l [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
stroma [C]s [C]t [C]r [C]o [C]m [C]a O 
in [C]i [C]n O 
mammary [C]m [C]a [C]m [C]m [C]a [C]r [C]y O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
. [C]. O 

Mammary [C]M [C]a [C]m [C]m [C]a [C]r [C]y O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
depends [C]d [C]e [C]p [C]e [C]n [C]d [C]s O 
on [C]o [C]n O 
branching [C]b [C]r [C]a [C]n [C]c [C]h [C]i [C]n [C]g O 
morphogenesis [C]m [C]o [C]r [C]p [C]h [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
, [C], O 
namely [C]n [C]a [C]m [C]e [C]l [C]y O 
the [C]t [C]h [C]e O 
bifurcation [C]b [C]i [C]f [C]u [C]r [C]c [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
extension [C]e [C]x [C]t [C]e [C]n [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
ductal [C]d [C]u [C]c [C]t [C]a [C]l O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
points [C]p [C]o [C]i [C]n [C]t [C]s O 
( [C]( O 
end [C]e [C]n [C]d O 
buds [C]b [C]u [C]d [C]s O 
) [C]) O 
and [C]a [C]n [C]d O 
secretory [C]s [C]e [C]c [C]r [C]e [C]t [C]o [C]r [C]y O 
lobules [C]l [C]o [C]b [C]u [C]l [C]e [C]s O 
into [C]i [C]n [C]t [C]o O 
a [C]a O 
more [C]m [C]o [C]r [C]e O 
or [C]o [C]r O 
less [C]l [C]e [C]s [C]s O 
fatty [C]f [C]a [C]t [C]t [C]y O 
stroma [C]s [C]t [C]r [C]o [C]m [C]a O 
. [C]. O 

Because [C]B [C]e [C]c [C]a [C]u [C]s [C]e O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
carcinomas [C]c [C]a [C]r [C]c [C]i [C]n [C]o [C]m [C]a [C]s O 
are [C]a [C]r [C]e O 
overwhelmingly [C]o [C]v [C]e [C]r [C]w [C]h [C]e [C]l [C]m [C]i [C]n [C]g [C]l [C]y O 
ductal [C]d [C]u [C]c [C]t [C]a [C]l O 
in [C]i [C]n O 
origin [C]o [C]r [C]i [C]g [C]i [C]n O 
, [C], O 
this [C]t [C]h [C]i [C]s O 
review [C]r [C]e [C]v [C]i [C]e [C]w O 
focuses [C]f [C]o [C]c [C]u [C]s [C]e [C]s O 
on [C]o [C]n O 
stromal [C]s [C]t [C]r [C]o [C]m [C]a [C]l O 
influences [C]i [C]n [C]f [C]l [C]u [C]e [C]n [C]c [C]e [C]s O 
guiding [C]g [C]u [C]i [C]d [C]i [C]n [C]g O 
postnatal [C]p [C]o [C]s [C]t [C]n [C]a [C]t [C]a [C]l O 
ductal [C]d [C]u [C]c [C]t [C]a [C]l O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
there [C]t [C]h [C]e [C]r [C]e O 
is [C]i [C]s O 
only [C]o [C]n [C]l [C]y O 
the [C]t [C]h [C]e O 
briefest [C]b [C]r [C]i [C]e [C]f [C]e [C]s [C]t O 
account [C]a [C]c [C]c [C]o [C]u [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
embryonic [C]e [C]m [C]b [C]r [C]y [C]o [C]n [C]i [C]c O 
stroma [C]s [C]t [C]r [C]o [C]m [C]a O 
( [C]( O 
mesenchyme [C]m [C]e [C]s [C]e [C]n [C]c [C]h [C]y [C]m [C]e O 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
stroma [C]s [C]t [C]r [C]o [C]m [C]a O 
as [C]a [C]s O 
the [C]t [C]h [C]e O 
necessary [C]n [C]e [C]c [C]e [C]s [C]s [C]a [C]r [C]y O 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
for [C]f [C]o [C]r O 
endocrine [C]e [C]n [C]d [C]o [C]c [C]r [C]i [C]n [C]e O 
mammogens [C]m [C]a [C]m [C]m [C]o [C]g [C]e [C]n [C]s O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
source [C]s [C]o [C]u [C]r [C]c [C]e O 
of [C]o [C]f O 
stimulatory [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
is [C]i [C]s O 
described [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
importance [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]c [C]e O 
of [C]o [C]f O 
mammary [C]m [C]a [C]m [C]m [C]a [C]r [C]y O 
epithelium-induced [C]e [C]p [C]i [C]t [C]h [C]e [C]l [C]i [C]u [C]m [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
modifications [C]m [C]o [C]d [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
periductal [C]p [C]e [C]r [C]i [C]d [C]u [C]c [C]t [C]a [C]l O 
stroma [C]s [C]t [C]r [C]o [C]m [C]a O 
is [C]i [C]s O 
emphasized [C]e [C]m [C]p [C]h [C]a [C]s [C]i [C]z [C]e [C]d O 
. [C]. O 

Evidence [C]E [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
is [C]i [C]s O 
presented [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
if [C]i [C]f O 
they [C]t [C]h [C]e [C]y O 
are [C]a [C]r [C]e O 
to [C]t [C]o O 
grow [C]g [C]r [C]o [C]w O 
, [C], O 
end [C]e [C]n [C]d O 
buds [C]b [C]u [C]d [C]s O 
must [C]m [C]u [C]s [C]t O 
condition [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n O 
proximal [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]l O 
fatty [C]f [C]a [C]t [C]t [C]y O 
stroma [C]s [C]t [C]r [C]o [C]m [C]a O 
by [C]b [C]y O 
recruiting [C]r [C]e [C]c [C]r [C]u [C]i [C]t [C]i [C]n [C]g O 
white [C]w [C]h [C]i [C]t [C]e B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
inducing [C]i [C]n [C]d [C]u [C]c [C]i [C]n [C]g O 
stromal [C]s [C]t [C]r [C]o [C]m [C]a [C]l O 
cell [C]c [C]e [C]l [C]l O 
division [C]d [C]i [C]v [C]i [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
, [C], O 
possibly [C]p [C]o [C]s [C]s [C]i [C]b [C]l [C]y O 
, [C], O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
fibrous [C]f [C]i [C]b [C]r [C]o [C]u [C]s O 
stromal [C]s [C]t [C]r [C]o [C]m [C]a [C]l O 
tunic [C]t [C]u [C]n [C]i [C]c O 
around [C]a [C]r [C]o [C]u [C]n [C]d O 
the [C]t [C]h [C]e O 
end [C]e [C]n [C]d O 
bud [C]b [C]u [C]d O 
is [C]i [C]s O 
described [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
and [C]a [C]n [C]d O 
its [C]i [C]t [C]s O 
likely [C]l [C]i [C]k [C]e [C]l [C]y O 
role [C]r [C]o [C]l [C]e O 
as [C]a [C]s O 
a [C]a O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
ductal [C]d [C]u [C]c [C]t [C]a [C]l O 
morphogen [C]m [C]o [C]r [C]p [C]h [C]o [C]g [C]e [C]n O 
is [C]i [C]s O 
discussed [C]d [C]i [C]s [C]c [C]u [C]s [C]s [C]e [C]d O 
; [C]; O 
a [C]a O 
possible [C]p [C]o [C]s [C]s [C]i [C]b [C]l [C]e O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
also [C]a [C]l [C]s [C]o O 
considered [C]c [C]o [C]n [C]s [C]i [C]d [C]e [C]r [C]e [C]d O 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
governing [C]g [C]o [C]v [C]e [C]r [C]n [C]i [C]n [C]g O 
fibrotic [C]f [C]i [C]b [C]r [C]o [C]t [C]i [C]c O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
, [C], O 
ductal [C]d [C]u [C]c [C]t [C]a [C]l O 
morphogenesis [C]m [C]o [C]r [C]p [C]h [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
are [C]a [C]r [C]e O 
unknown [C]u [C]n [C]k [C]n [C]o [C]w [C]n O 
, [C], O 
a [C]a O 
role [C]r [C]o [C]l [C]e O 
for [C]f [C]o [C]r O 
transforming [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]i [C]n [C]g O 
growth [C]g [C]r [C]o [C]w [C]t [C]h B-protein 
factor-beta [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]b [C]e [C]t [C]a E-protein 
is [C]i [C]s O 
highly [C]h [C]i [C]g [C]h [C]l [C]y O 
likely [C]l [C]i [C]k [C]e [C]l [C]y O 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
discussed [C]d [C]i [C]s [C]c [C]u [C]s [C]s [C]e [C]d O 
. [C]. O 

Finally [C]F [C]i [C]n [C]a [C]l [C]l [C]y O 
, [C], O 
a [C]a O 
need [C]n [C]e [C]e [C]d O 
for [C]f [C]o [C]r O 
new [C]n [C]e [C]w O 
conceptual [C]c [C]o [C]n [C]c [C]e [C]p [C]t [C]u [C]a [C]l O 
and [C]a [C]n [C]d O 
experimental [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]a [C]l O 
approaches [C]a [C]p [C]p [C]r [C]o [C]a [C]c [C]h [C]e [C]s O 
to [C]t [C]o O 
understanding [C]u [C]n [C]d [C]e [C]r [C]s [C]t [C]a [C]n [C]d [C]i [C]n [C]g O 
stromal-epithelial [C]s [C]t [C]r [C]o [C]m [C]a [C]l [C]- [C]e [C]p [C]i [C]t [C]h [C]e [C]l [C]i [C]a [C]l O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
is [C]i [C]s O 
discussed [C]d [C]i [C]s [C]c [C]u [C]s [C]s [C]e [C]d O 
. [C]. O 

Adipophilin [C]A [C]d [C]i [C]p [C]o [C]p [C]h [C]i [C]l [C]i [C]n S-protein 
is [C]i [C]s O 
a [C]a O 
sensitive [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
marker [C]m [C]a [C]r [C]k [C]e [C]r O 
for [C]f [C]o [C]r O 
lipid [C]l [C]i [C]p [C]i [C]d O 
loading [C]l [C]o [C]a [C]d [C]i [C]n [C]g O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

Adipophilin [C]A [C]d [C]i [C]p [C]o [C]p [C]h [C]i [C]l [C]i [C]n S-protein 
, [C], O 
a [C]a O 
marker [C]m [C]a [C]r [C]k [C]e [C]r O 
of [C]o [C]f O 
lipid [C]l [C]i [C]p [C]i [C]d O 
accumulation [C]a [C]c [C]c [C]u [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
initially [C]i [C]n [C]i [C]t [C]i [C]a [C]l [C]l [C]y O 
described [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
in [C]i [C]n O 
adipocytes [C]a [C]d [C]i [C]p [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
, [C], O 
was [C]w [C]a [C]s O 
recently [C]r [C]e [C]c [C]e [C]n [C]t [C]l [C]y O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
be [C]b [C]e O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
in [C]i [C]n O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e B-cell_type 
foam [C]f [C]o [C]a [C]m I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

We [C]W [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
even [C]e [C]v [C]e [C]n O 
freshly [C]f [C]r [C]e [C]s [C]h [C]l [C]y B-cell_type 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d I-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
adipophilin [C]a [C]d [C]i [C]p [C]o [C]p [C]h [C]i [C]l [C]i [C]n S-protein 
and [C]a [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
amount [C]a [C]m [C]o [C]u [C]n [C]t O 
of [C]o [C]f O 
adipophilin [C]a [C]d [C]i [C]p [C]o [C]p [C]h [C]i [C]l [C]i [C]n B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
is [C]i [C]s O 
variable [C]v [C]a [C]r [C]i [C]a [C]b [C]l [C]e O 
in [C]i [C]n O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
from [C]f [C]r [C]o [C]m O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
healthy [C]h [C]e [C]a [C]l [C]t [C]h [C]y O 
individuals [C]i [C]n [C]d [C]i [C]v [C]i [C]d [C]u [C]a [C]l [C]s O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
the [C]t [C]h [C]e O 
physiological [C]p [C]h [C]y [C]s [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
adipophilin [C]a [C]d [C]i [C]p [C]o [C]p [C]h [C]i [C]l [C]i [C]n S-protein 
does [C]d [C]o [C]e [C]s O 
not [C]n [C]o [C]t O 
correlate [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
free [C]f [C]r [C]e [C]e O 
fatty [C]f [C]a [C]t [C]t [C]y O 
acids [C]a [C]c [C]i [C]d [C]s O 
, [C], O 
cholesterylesters [C]c [C]h [C]o [C]l [C]e [C]s [C]t [C]e [C]r [C]y [C]l [C]e [C]s [C]t [C]e [C]r [C]s O 
or [C]o [C]r O 
free [C]f [C]r [C]e [C]e O 
cholesterol [C]c [C]h [C]o [C]l [C]e [C]s [C]t [C]e [C]r [C]o [C]l O 
. [C]. O 

Enzymatically [C]E [C]n [C]z [C]y [C]m [C]a [C]t [C]i [C]c [C]a [C]l [C]l [C]y B-protein 
modified [C]m [C]o [C]d [C]i [C]f [C]i [C]e [C]d I-protein 
low-density [C]l [C]o [C]w [C]- [C]d [C]e [C]n [C]s [C]i [C]t [C]y I-protein 
lipoprotein [C]l [C]i [C]p [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
( [C]( O 
E-LDL [C]E [C]- [C]L [C]D [C]L S-protein 
) [C]) O 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
rapid [C]r [C]a [C]p [C]i [C]d O 
foam [C]f [C]o [C]a [C]m O 
cell [C]c [C]e [C]l [C]l O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
and [C]a [C]n [C]d O 
upregulates [C]u [C]p [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]s O 
adipophilin [C]a [C]d [C]i [C]p [C]o [C]p [C]h [C]i [C]l [C]i [C]n S-protein 
mRNA [C]m [C]R [C]N [C]A O 
and [C]a [C]n [C]d O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
2 [C]2 O 
h [C]h O 
of [C]o [C]f O 
incubation [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
rapid [C]r [C]a [C]p [C]i [C]d O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
adipophilin [C]a [C]d [C]i [C]p [C]o [C]p [C]h [C]i [C]l [C]i [C]n S-protein 
is [C]i [C]s O 
accompanied [C]a [C]c [C]c [C]o [C]m [C]p [C]a [C]n [C]i [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
of [C]o [C]f O 
free [C]f [C]r [C]e [C]e O 
fatty [C]f [C]a [C]t [C]t [C]y O 
acids [C]a [C]c [C]i [C]d [C]s O 
in [C]i [C]n O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
incubated [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
E-LDL [C]E [C]- [C]L [C]D [C]L S-protein 
. [C]. O 

Adipophilin [C]A [C]d [C]i [C]p [C]o [C]p [C]h [C]i [C]l [C]i [C]n S-protein 
facilitates [C]f [C]a [C]c [C]i [C]l [C]i [C]t [C]a [C]t [C]e [C]s O 
the [C]t [C]h [C]e O 
uptake [C]u [C]p [C]t [C]a [C]k [C]e O 
of [C]o [C]f O 
free [C]f [C]r [C]e [C]e O 
fatty [C]f [C]a [C]t [C]t [C]y O 
acids [C]a [C]c [C]i [C]d [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
here [C]h [C]e [C]r [C]e O 
we [C]w [C]e O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
free [C]f [C]r [C]e [C]e O 
fatty [C]f [C]a [C]t [C]t [C]y O 
acids [C]a [C]c [C]i [C]d [C]s O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
is [C]i [C]s O 
related [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
early [C]e [C]a [C]r [C]l [C]y O 
upregulation [C]u [C]p [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
adipophilin [C]a [C]d [C]i [C]p [C]o [C]p [C]h [C]i [C]l [C]i [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
blood [C]b [C]l [C]o [C]o [C]d B-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

Fatty [C]F [C]a [C]t [C]t [C]y O 
acids [C]a [C]c [C]i [C]d [C]s O 
are [C]a [C]r [C]e O 
ligands [C]l [C]i [C]g [C]a [C]n [C]d [C]s O 
for [C]f [C]o [C]r O 
peroxisome [C]p [C]e [C]r [C]o [C]x [C]i [C]s [C]o [C]m [C]e B-protein 
proliferator-activated [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]o [C]r [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d I-protein 
receptor-gamma [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]- [C]g [C]a [C]m [C]m [C]a E-protein 
( [C]( O 
PPARgamma [C]P [C]P [C]A [C]R [C]g [C]a [C]m [C]m [C]a S-protein 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
upregulation [C]u [C]p [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
adipophilin [C]a [C]d [C]i [C]p [C]o [C]p [C]h [C]i [C]l [C]i [C]n B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
by [C]b [C]y O 
PPARgamma [C]P [C]P [C]A [C]R [C]g [C]a [C]m [C]m [C]a S-protein 
agonists [C]a [C]g [C]o [C]n [C]i [C]s [C]t [C]s O 
like [C]l [C]i [C]k [C]e O 
15d-PGJ [C]1 [C]5 [C]d [C]- [C]P [C]G [C]J O 
( [C]( O 
2 [C]2 O 
) [C]) O 
and [C]a [C]n [C]d O 
ciglitazone [C]c [C]i [C]g [C]l [C]i [C]t [C]a [C]z [C]o [C]n [C]e O 
indicates [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e [C]s O 
that [C]t [C]h [C]a [C]t O 
PPARgamma [C]P [C]P [C]A [C]R [C]g [C]a [C]m [C]m [C]a S-protein 
may [C]m [C]a [C]y O 
mediate [C]m [C]e [C]d [C]i [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
adipophilin [C]a [C]d [C]i [C]p [C]o [C]p [C]h [C]i [C]l [C]i [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

Constitutive [C]C [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
MHC [C]M [C]H [C]C B-DNA 
class [C]c [C]l [C]a [C]s [C]s I-DNA 
II [C]I [C]I I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
in [C]i [C]n O 
melanoma [C]m [C]e [C]l [C]a [C]n [C]o [C]m [C]a B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
class [C]c [C]l [C]a [C]s [C]s B-DNA 
II [C]I [C]I I-DNA 
transactivator [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r E-DNA 
abnormally [C]a [C]b [C]n [C]o [C]r [C]m [C]a [C]l [C]l [C]y O 
initiated [C]i [C]n [C]i [C]t [C]i [C]a [C]t [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
its [C]i [C]t [C]s O 
B [C]B B-DNA 
cell-specific [C]c [C]e [C]l [C]l [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

In [C]I [C]n O 
melanoma [C]m [C]e [C]l [C]a [C]n [C]o [C]m [C]a B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
, [C], O 
two [C]t [C]w [C]o O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
patterns [C]p [C]a [C]t [C]t [C]e [C]r [C]n [C]s O 
of [C]o [C]f O 
MHC [C]M [C]H [C]C O 
class [C]c [C]l [C]a [C]s [C]s O 
II [C]I [C]I O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
described [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
, [C], O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
an [C]a [C]n O 
IFN [C]I [C]F [C]N O 
gamma-inducible [C]g [C]a [C]m [C]m [C]a [C]- [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
HLA-DR [C]H [C]L [C]A [C]- [C]D [C]R S-DNA 
and [C]a [C]n [C]d O 
HLA-DP [C]H [C]L [C]A [C]- [C]D [C]P S-DNA 
, [C], O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
faint [C]f [C]a [C]i [C]n [C]t O 
or [C]o [C]r O 
null [C]n [C]u [C]l [C]l O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
HLA-DQ [C]H [C]L [C]A [C]- [C]D [C]Q S-DNA 
, [C], O 
resembling [C]r [C]e [C]s [C]e [C]m [C]b [C]l [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
described [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
for [C]f [C]o [C]r O 
melanocytes [C]m [C]e [C]l [C]a [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
, [C], O 
or [C]o [C]r O 
a [C]a O 
constitutive [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
i.e. [C]i [C]. [C]e [C]. O 
, [C], O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
, [C], O 
of [C]o [C]f O 
all [C]a [C]l [C]l O 
three [C]t [C]h [C]r [C]e [C]e O 
HLA-D [C]H [C]L [C]A [C]- [C]D B-DNA 
isotypes [C]i [C]s [C]o [C]t [C]y [C]p [C]e [C]s E-DNA 
. [C]. O 

As [C]A [C]s O 
this [C]t [C]h [C]i [C]s O 
latter [C]l [C]a [C]t [C]t [C]e [C]r O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
more [C]m [C]o [C]r [C]e O 
rapid [C]r [C]a [C]p [C]i [C]d O 
progression [C]p [C]r [C]o [C]g [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
melanoma [C]m [C]e [C]l [C]a [C]n [C]o [C]m [C]a O 
tumors [C]t [C]u [C]m [C]o [C]r [C]s O 
, [C], O 
we [C]w [C]e O 
have [C]h [C]a [C]v [C]e O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
in [C]i [C]n O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
melanoma [C]m [C]e [C]l [C]a [C]n [C]o [C]m [C]a B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
the [C]t [C]h [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
leading [C]l [C]e [C]a [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
this [C]t [C]h [C]i [C]s O 
abnormal [C]a [C]b [C]n [C]o [C]r [C]m [C]a [C]l O 
pattern [C]p [C]a [C]t [C]t [C]e [C]r [C]n O 
of [C]o [C]f O 
MHC [C]M [C]H [C]C O 
class [C]c [C]l [C]a [C]s [C]s O 
II [C]I [C]I O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

In [C]I [C]n O 
agreement [C]a [C]g [C]r [C]e [C]e [C]m [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
a [C]a O 
coordinate [C]c [C]o [C]o [C]r [C]d [C]i [C]n [C]a [C]t [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
HLA-D [C]H [C]L [C]A [C]- [C]D B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
in [C]i [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
cell [C]c [C]e [C]l [C]l O 
lines [C]l [C]i [C]n [C]e [C]s O 
, [C], O 
we [C]w [C]e O 
have [C]h [C]a [C]v [C]e O 
shown [C]s [C]h [C]o [C]w [C]n O 
the [C]t [C]h [C]e O 
constitutive [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
CIITA [C]C [C]I [C]I [C]T [C]A B-RNA 
( [C]( I-RNA 
class [C]c [C]l [C]a [C]s [C]s I-RNA 
II [C]I [C]I I-RNA 
transactivator [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r I-RNA 
) [C]) I-RNA 
transcripts [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]s E-RNA 
, [C], O 
CIITA [C]C [C]I [C]I [C]T [C]A S-protein 
being [C]b [C]e [C]i [C]n [C]g O 
known [C]k [C]n [C]o [C]w [C]n O 
as [C]a [C]s O 
the [C]t [C]h [C]e O 
master [C]m [C]a [C]s [C]t [C]e [C]r O 
switch [C]s [C]w [C]i [C]t [C]c [C]h O 
of [C]o [C]f O 
MHC [C]M [C]H [C]C O 
class [C]c [C]l [C]a [C]s [C]s O 
II [C]I [C]I O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Unexpectedly [C]U [C]n [C]e [C]x [C]p [C]e [C]c [C]t [C]e [C]d [C]l [C]y O 
, [C], O 
these [C]t [C]h [C]e [C]s [C]e O 
transcripts [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]s O 
initiate [C]i [C]n [C]i [C]t [C]i [C]a [C]t [C]e O 
from [C]f [C]r [C]o [C]m O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r B-DNA 
III [C]I [C]I [C]I E-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
CIITA [C]C [C]I [C]I [C]T [C]A B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
, [C], O 
a [C]a O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
mainly [C]m [C]a [C]i [C]n [C]l [C]y O 
used [C]u [C]s [C]e [C]d O 
constitutively [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y O 
in [C]i [C]n O 
B [C]B B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
occur [C]o [C]c [C]c [C]u [C]r O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
( [C]( O 
s [C]s O 
) [C]) O 
acting [C]a [C]c [C]t [C]i [C]n [C]g O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r O 
located [C]l [C]o [C]c [C]a [C]t [C]e [C]d O 
upstream [C]u [C]p [C]s [C]t [C]r [C]e [C]a [C]m O 
of [C]o [C]f O 
CIITA [C]C [C]I [C]I [C]T [C]A B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r I-DNA 
III [C]I [C]I [C]I E-DNA 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
was [C]w [C]a [C]s O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
described [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
in [C]i [C]n O 
epithelioid [C]e [C]p [C]i [C]t [C]h [C]e [C]l [C]i [C]o [C]i [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
as [C]a [C]s O 
an [C]a [C]n O 
IFN-gamma-response [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a [C]- [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
hypothesis [C]h [C]y [C]p [C]o [C]t [C]h [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
a [C]a O 
general [C]g [C]e [C]n [C]e [C]r [C]a [C]l O 
abnormality [C]a [C]b [C]n [C]o [C]r [C]m [C]a [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
was [C]w [C]a [C]s O 
dismissed [C]d [C]i [C]s [C]m [C]i [C]s [C]s [C]e [C]d O 
. [C]. O 

Constitutive [C]C [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CIITA [C]C [C]I [C]I [C]T [C]A S-DNA 
from [C]f [C]r [C]o [C]m O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r B-DNA 
III [C]I [C]I [C]I E-DNA 
having [C]h [C]a [C]v [C]i [C]n [C]g O 
been [C]b [C]e [C]e [C]n O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
unrelated [C]u [C]n [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
melanoma [C]m [C]e [C]l [C]a [C]n [C]o [C]m [C]a B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
, [C], O 
we [C]w [C]e O 
propose [C]p [C]r [C]o [C]p [C]o [C]s [C]e O 
the [C]t [C]h [C]e O 
hypothesis [C]h [C]y [C]p [C]o [C]t [C]h [C]e [C]s [C]i [C]s O 
that [C]t [C]h [C]a [C]t O 
this [C]t [C]h [C]i [C]s O 
phenomenon [C]p [C]h [C]e [C]n [C]o [C]m [C]e [C]n [C]o [C]n O 
might [C]m [C]i [C]g [C]h [C]t O 
not [C]n [C]o [C]t O 
be [C]b [C]e O 
a [C]a O 
random [C]r [C]a [C]n [C]d [C]o [C]m O 
event [C]e [C]v [C]e [C]n [C]t O 
, [C], O 
but [C]b [C]u [C]t O 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
linked [C]l [C]i [C]n [C]k [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
neoplasic [C]n [C]e [C]o [C]p [C]l [C]a [C]s [C]i [C]c O 
state [C]s [C]t [C]a [C]t [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
melanoma [C]m [C]e [C]l [C]a [C]n [C]o [C]m [C]a B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 

Caspase [C]C [C]a [C]s [C]p [C]a [C]s [C]e S-protein 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
calcineurin [C]c [C]a [C]l [C]c [C]i [C]n [C]e [C]u [C]r [C]i [C]n O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
contributes [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e [C]s O 
to [C]t [C]o O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
release [C]r [C]e [C]l [C]e [C]a [C]s [C]e O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Calcineurin [C]C [C]a [C]l [C]c [C]i [C]n [C]e [C]u [C]r [C]i [C]n S-protein 
, [C], O 
a [C]a O 
Ca [C]C [C]a B-protein 
( [C]( I-protein 
2+ [C]2 [C]+ I-protein 
) [C]) I-protein 
/calmodulin-dependent [C]/ [C]c [C]a [C]l [C]m [C]o [C]d [C]u [C]l [C]i [C]n [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t I-protein 
Ser/Thr [C]S [C]e [C]r [C]/ [C]T [C]h [C]r I-protein 
phosphatase [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]a [C]s [C]e I-protein 
( [C]( I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
phosphatase [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]a [C]s [C]e I-protein 
2B [C]2 [C]B I-protein 
) [C]) E-protein 
, [C], O 
plays [C]p [C]l [C]a [C]y [C]s O 
a [C]a O 
critical [C]c [C]r [C]i [C]t [C]i [C]c [C]a [C]l O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
IL-2 [C]I [C]L [C]- [C]2 O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

It [C]I [C]t O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
reported [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
release [C]r [C]e [C]l [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_line 
T [C]T E-cell_line 
requires [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]s O 
caspase-like [C]c [C]a [C]s [C]p [C]a [C]s [C]e [C]- [C]l [C]i [C]k [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
( [C]( O 
Posmantur [C]P [C]o [C]s [C]m [C]a [C]n [C]t [C]u [C]r O 
et [C]e [C]t O 
al. [C]a [C]l [C]. O 
( [C]( O 
1998 [C]1 [C]9 [C]9 [C]8 O 
) [C]) O 
Exp. [C]E [C]x [C]p [C]. O 
Cell. [C]C [C]e [C]l [C]l [C]. O 
Res. [C]R [C]e [C]s [C]. O 
244 [C]2 [C]4 [C]4 O 
, [C], O 
302-309 [C]3 [C]0 [C]2 [C]- [C]3 [C]0 [C]9 O 
) [C]) O 
. [C]. O 

We [C]W [C]e O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
here [C]h [C]e [C]r [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
60-kDa [C]6 [C]0 [C]- [C]k [C]D [C]a B-protein 
catalytic [C]c [C]a [C]t [C]a [C]l [C]y [C]t [C]i [C]c I-protein 
subunit [C]s [C]u [C]b [C]u [C]n [C]i [C]t E-protein 
of [C]o [C]f O 
calcineurin [C]c [C]a [C]l [C]c [C]i [C]n [C]e [C]u [C]r [C]i [C]n B-protein 
A [C]A E-protein 
( [C]( O 
Cn [C]C [C]n B-protein 
A [C]A E-protein 
) [C]) O 
was [C]w [C]a [C]s O 
partially [C]p [C]a [C]r [C]t [C]i [C]a [C]l [C]l [C]y O 
cleaved [C]c [C]l [C]e [C]a [C]v [C]e [C]d O 
to [C]t [C]o O 
a [C]a O 
45-kDa [C]4 [C]5 [C]- [C]k [C]D [C]a S-protein 
form [C]f [C]o [C]r [C]m O 
in [C]i [C]n O 
phytohemagglutinin [C]p [C]h [C]y [C]t [C]o [C]h [C]e [C]m [C]a [C]g [C]g [C]l [C]u [C]t [C]i [C]n [C]i [C]n O 
A [C]A O 
( [C]( O 
PHA [C]P [C]H [C]A O 
) [C]) O 
or [C]o [C]r O 
phorbol [C]p [C]h [C]o [C]r [C]b [C]o [C]l O 
ester [C]e [C]s [C]t [C]e [C]r O 
+ [C]+ O 
ionomycin [C]i [C]o [C]n [C]o [C]m [C]y [C]c [C]i [C]n O 
( [C]( O 
P [C]P O 
+ [C]+ O 
I [C]I O 
) [C]) O 
-activated [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

In [C]I [C]n O 
parallel [C]p [C]a [C]r [C]a [C]l [C]l [C]e [C]l O 
, [C], O 
proteolytic [C]p [C]r [C]o [C]t [C]e [C]o [C]l [C]y [C]t [C]i [C]c O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
upstream [C]u [C]p [C]s [C]t [C]r [C]e [C]a [C]m O 
caspases [C]c [C]a [C]s [C]p [C]a [C]s [C]e [C]s S-protein 
( [C]( O 
caspase-8 [C]c [C]a [C]s [C]p [C]a [C]s [C]e [C]- [C]8 O 
and [C]a [C]n [C]d O 
-9 [C]- [C]9 O 
) [C]) O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
effector [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r B-protein 
caspase-3 [C]c [C]a [C]s [C]p [C]a [C]s [C]e [C]- [C]3 E-protein 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
. [C]. O 

Cn [C]C [C]n B-protein 
A [C]A E-protein 
cleavage [C]c [C]l [C]e [C]a [C]v [C]a [C]g [C]e O 
was [C]w [C]a [C]s O 
caspase [C]c [C]a [C]s [C]p [C]a [C]s [C]e O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
, [C], O 
since [C]s [C]i [C]n [C]c [C]e O 
it [C]i [C]t O 
was [C]w [C]a [C]s O 
inhibitable [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]a [C]b [C]l [C]e O 
by [C]b [C]y O 
pan-caspase [C]p [C]a [C]n [C]- [C]c [C]a [C]s [C]p [C]a [C]s [C]e O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
Cbz-Asp-CH [C]C [C]b [C]z [C]- [C]A [C]s [C]p [C]- [C]C [C]H O 
( [C]( O 
2 [C]2 O 
) [C]) O 
OC [C]O [C]C O 
( [C]( O 
O [C]O O 
) [C]) O 
-2 [C]- [C]2 O 
, [C], O 
6-dichlorobenzene [C]6 [C]- [C]d [C]i [C]c [C]h [C]l [C]o [C]r [C]o [C]b [C]e [C]n [C]z [C]e [C]n [C]e O 
( [C]( O 
Z-D-DCB [C]Z [C]- [C]D [C]- [C]D [C]C [C]B O 
) [C]) O 
. [C]. O 

Cn [C]C [C]n B-protein 
A [C]A E-protein 
cleavage [C]c [C]l [C]e [C]a [C]v [C]a [C]g [C]e O 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
when [C]w [C]h [C]e [C]n O 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d O 
calcineurin [C]c [C]a [C]l [C]c [C]i [C]n [C]e [C]u [C]r [C]i [C]n S-protein 
was [C]w [C]a [C]s O 
digested [C]d [C]i [C]g [C]e [C]s [C]t [C]e [C]d O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
with [C]w [C]i [C]t [C]h O 
caspase-3 [C]c [C]a [C]s [C]p [C]a [C]s [C]e [C]- [C]3 S-protein 
. [C]. O 

Truncated [C]T [C]r [C]u [C]n [C]c [C]a [C]t [C]e [C]d B-protein 
Cn [C]C [C]n I-protein 
A [C]A E-protein 
was [C]w [C]a [C]s O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
phosphatase [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]a [C]s [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
calmodulin [C]c [C]a [C]l [C]m [C]o [C]d [C]u [C]l [C]i [C]n O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
in [C]i [C]n O 
PHA [C]P [C]H [C]A O 
or [C]o [C]r O 
P [C]P O 
+ [C]+ O 
I-activated [C]I [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
, [C], O 
dephosphorylation [C]d [C]e [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
calcineurin [C]c [C]a [C]l [C]c [C]i [C]n [C]e [C]u [C]r [C]i [C]n S-protein 
substrate [C]s [C]u [C]b [C]s [C]t [C]r [C]a [C]t [C]e O 
NFATc [C]N [C]F [C]A [C]T [C]c S-protein 
( [C]( O 
a [C]a O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
known [C]k [C]n [C]o [C]w [C]n O 
to [C]t [C]o O 
be [C]b [C]e O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
transactivation [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
) [C]) O 
, [C], O 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
suppressed [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
by [C]b [C]y O 
Z-D-DCB [C]Z [C]- [C]D [C]- [C]D [C]C [C]B O 
. [C]. O 

Taken [C]T [C]a [C]k [C]e [C]n O 
together [C]t [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
, [C], O 
our [C]o [C]u [C]r O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
caspase-mediated [C]c [C]a [C]s [C]p [C]a [C]s [C]e [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
cleavage [C]c [C]l [C]e [C]a [C]v [C]a [C]g [C]e O 
of [C]o [C]f O 
Cn [C]C [C]n B-protein 
A [C]A E-protein 
contributes [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e [C]s O 
to [C]t [C]o O 
IL-2 [C]I [C]L [C]- [C]2 O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Copyright [C]C [C]o [C]p [C]y [C]r [C]i [C]g [C]h [C]t O 
2001 [C]2 [C]0 [C]0 [C]1 O 
Academic [C]A [C]c [C]a [C]d [C]e [C]m [C]i [C]c O 
Press [C]P [C]r [C]e [C]s [C]s O 
. [C]. O 

Maturation [C]M [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
dendritic [C]d [C]e [C]n [C]d [C]r [C]i [C]t [C]i [C]c I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
as [C]a [C]s O 
sulfasalazine [C]s [C]u [C]l [C]f [C]a [C]s [C]a [C]l [C]a [C]z [C]i [C]n [C]e O 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
. [C]. O 

AIM [C]A [C]I [C]M O 
: [C]: O 
Sulfasalazine [C]S [C]u [C]l [C]f [C]a [C]s [C]a [C]l [C]a [C]z [C]i [C]n [C]e O 
, [C], O 
a [C]a O 
nonsteroidal [C]n [C]o [C]n [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]a [C]l O 
anti-inflammatory [C]a [C]n [C]t [C]i [C]- [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
drug [C]d [C]r [C]u [C]g O 
, [C], O 
is [C]i [C]s O 
effective [C]e [C]f [C]f [C]e [C]c [C]t [C]i [C]v [C]e O 
in [C]i [C]n O 
treating [C]t [C]r [C]e [C]a [C]t [C]i [C]n [C]g O 
some [C]s [C]o [C]m [C]e O 
autoimmune [C]a [C]u [C]t [C]o [C]i [C]m [C]m [C]u [C]n [C]e O 
diseases [C]d [C]i [C]s [C]e [C]a [C]s [C]e [C]s O 
, [C], O 
but [C]b [C]u [C]t O 
its [C]i [C]t [C]s O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
of [C]o [C]f O 
action [C]a [C]c [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
unclear [C]u [C]n [C]c [C]l [C]e [C]a [C]r O 
. [C]. O 

To [C]T [C]o O 
determine [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
dendritic [C]d [C]e [C]n [C]d [C]r [C]i [C]t [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
a [C]a O 
possible [C]p [C]o [C]s [C]s [C]i [C]b [C]l [C]e O 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
drug [C]d [C]r [C]u [C]g O 
, [C], O 
we [C]w [C]e O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
the [C]t [C]h [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
sulfasalazine [C]s [C]u [C]l [C]f [C]a [C]s [C]a [C]l [C]a [C]z [C]i [C]n [C]e O 
and [C]a [C]n [C]d O 
its [C]i [C]t [C]s O 
metabolites [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]t [C]e [C]s O 
, [C], O 
aminosalicylate [C]a [C]m [C]i [C]n [C]o [C]s [C]a [C]l [C]i [C]c [C]y [C]l [C]a [C]t [C]e O 
and [C]a [C]n [C]d O 
sulfapyridine [C]s [C]u [C]l [C]f [C]a [C]p [C]y [C]r [C]i [C]d [C]i [C]n [C]e O 
, [C], O 
on [C]o [C]n O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
maturation [C]m [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
( [C]( O 
terminal [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
) [C]) O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d I-cell_type 
dendritic [C]d [C]e [C]n [C]d [C]r [C]i [C]t [C]i [C]c I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

METHODS [C]M [C]E [C]T [C]H [C]O [C]D [C]S O 
: [C]: O 
We [C]W [C]e O 
prepared [C]p [C]r [C]e [C]p [C]a [C]r [C]e [C]d O 
immature [C]i [C]m [C]m [C]a [C]t [C]u [C]r [C]e B-cell_type 
dendritic [C]d [C]e [C]n [C]d [C]r [C]i [C]t [C]i [C]c I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
by [C]b [C]y O 
incubating [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]i [C]n [C]g O 
CD14-positive [C]C [C]D [C]1 [C]4 [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
granulocyte- [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e [C]- B-protein 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e I-protein 
colony-stimulating [C]c [C]o [C]l [C]o [C]n [C]y [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]n [C]g I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
and [C]a [C]n [C]d O 
interleukin [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n B-protein 
( [C]( I-protein 
IL [C]I [C]L I-protein 
) [C]) I-protein 
-4 [C]- [C]4 E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
were [C]w [C]e [C]r [C]e O 
matured [C]m [C]a [C]t [C]u [C]r [C]e [C]d O 
by [C]b [C]y O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
tumor [C]t [C]u [C]m [C]o [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
( [C]( I-protein 
TNF [C]T [C]N [C]F I-protein 
) [C]) I-protein 
-a [C]- [C]a E-protein 
, [C], O 
IL-1 [C]I [C]L [C]- [C]1 B-protein 
beta [C]b [C]e [C]t [C]a E-protein 
, [C], O 
and [C]a [C]n [C]d O 
prostaglandin [C]p [C]r [C]o [C]s [C]t [C]a [C]g [C]l [C]a [C]n [C]d [C]i [C]n B-protein 
E2 [C]E [C]2 E-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
sulfasalazine [C]s [C]u [C]l [C]f [C]a [C]s [C]a [C]l [C]a [C]z [C]i [C]n [C]e O 
or [C]o [C]r O 
its [C]i [C]t [C]s O 
metabolites [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]t [C]e [C]s O 
-- [C]- [C]- O 
aminosalicylate [C]a [C]m [C]i [C]n [C]o [C]s [C]a [C]l [C]i [C]c [C]y [C]l [C]a [C]t [C]e O 
and [C]a [C]n [C]d O 
sulfapyridine [C]s [C]u [C]l [C]f [C]a [C]p [C]y [C]r [C]i [C]d [C]i [C]n [C]e O 
, [C], O 
or [C]o [C]r O 
their [C]t [C]h [C]e [C]i [C]r O 
combinations [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

We [C]W [C]e O 
quantified [C]q [C]u [C]a [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
the [C]t [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
drugs [C]d [C]r [C]u [C]g [C]s O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
dendritic [C]d [C]e [C]n [C]d [C]r [C]i [C]t [C]i [C]c O 
cell [C]c [C]e [C]l [C]l O 
characteristics [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]s [C]t [C]i [C]c [C]s O 
, [C], O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
autologous [C]a [C]u [C]t [C]o [C]l [C]o [C]g [C]o [C]u [C]s O 
and [C]a [C]n [C]d O 
allogeneic [C]a [C]l [C]l [C]o [C]g [C]e [C]n [C]e [C]i [C]c O 
pan-T [C]p [C]a [C]n [C]- [C]T O 
cell [C]c [C]e [C]l [C]l O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
marker [C]m [C]a [C]r [C]k [C]e [C]r O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
, [C], O 
IL-12 [C]I [C]L [C]- [C]1 [C]2 O 
p40 [C]p [C]4 [C]0 O 
subunit [C]s [C]u [C]b [C]u [C]n [C]i [C]t O 
secretion [C]s [C]e [C]c [C]r [C]e [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
( [C]( I-protein 
NF [C]N [C]F I-protein 
) [C]) I-protein 
-kappa [C]- [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
. [C]. O 

RESULTS [C]R [C]E [C]S [C]U [C]L [C]T [C]S O 
: [C]: O 
Dendritic [C]D [C]e [C]n [C]d [C]r [C]i [C]t [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
sulfasalazine [C]s [C]u [C]l [C]f [C]a [C]s [C]a [C]l [C]a [C]z [C]i [C]n [C]e O 
( [C]( O 
1.25 [C]1 [C]. [C]2 [C]5 O 
micromol/L [C]m [C]i [C]c [C]r [C]o [C]m [C]o [C]l [C]/ [C]L O 
or [C]o [C]r O 
2.5 [C]2 [C]. [C]5 O 
micromol/L [C]m [C]i [C]c [C]r [C]o [C]m [C]o [C]l [C]/ [C]L O 
) [C]) O 
could [C]c [C]o [C]u [C]l [C]d O 
not [C]n [C]o [C]t O 
stimulate [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
p [C]p O 
< [C]< O 
0.028 [C]0 [C]. [C]0 [C]2 [C]8 O 
, [C], O 
two-sided [C]t [C]w [C]o [C]- [C]s [C]i [C]d [C]e [C]d O 
paired [C]p [C]a [C]i [C]r [C]e [C]d O 
t-test [C]t [C]- [C]t [C]e [C]s [C]t O 
) [C]) O 
. [C]. O 

In [C]I [C]n O 
distinction [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t [C]i [C]o [C]n O 
to [C]t [C]o O 
drug-free [C]d [C]r [C]u [C]g [C]- [C]f [C]r [C]e [C]e O 
maturing [C]m [C]a [C]t [C]u [C]r [C]i [C]n [C]g O 
dendritic [C]d [C]e [C]n [C]d [C]r [C]i [C]t [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
2.5 [C]2 [C]. [C]5 O 
micromol/L [C]m [C]i [C]c [C]r [C]o [C]m [C]o [C]l [C]/ [C]L O 
sulfasalazine [C]s [C]u [C]l [C]f [C]a [C]s [C]a [C]l [C]a [C]z [C]i [C]n [C]e O 
upregulated [C]u [C]p [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
CD14 [C]C [C]D [C]1 [C]4 S-protein 
and [C]a [C]n [C]d O 
CD68 [C]C [C]D [C]6 [C]8 S-protein 
and [C]a [C]n [C]d O 
downregulated [C]d [C]o [C]w [C]n [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
CD40 [C]C [C]D [C]4 [C]0 S-protein 
, [C], O 
CD80 [C]C [C]D [C]8 [C]0 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
CD83 [C]C [C]D [C]8 [C]3 S-protein 
( [C]( O 
for [C]f [C]o [C]r O 
all [C]a [C]l [C]l O 
CD [C]C [C]D O 
markers [C]m [C]a [C]r [C]k [C]e [C]r [C]s O 
, [C], O 
p [C]p O 
< [C]< O 
0.03 [C]0 [C]. [C]0 [C]3 O 
for [C]f [C]o [C]r O 
difference [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
measurements [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]m [C]e [C]n [C]t [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
sulfasalazine [C]s [C]u [C]l [C]f [C]a [C]s [C]a [C]l [C]a [C]z [C]i [C]n [C]e O 
) [C]) O 
. [C]. O 

From [C]F [C]r [C]o [C]m O 
concentration-dependent [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
in [C]i [C]n O 
CD83 [C]C [C]D [C]8 [C]3 O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
we [C]w [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
an [C]a [C]n O 
apparent [C]a [C]p [C]p [C]a [C]r [C]e [C]n [C]t O 
ID50 [C]I [C]D [C]5 [C]0 O 
> [C]> O 
> [C]> O 
1.5 [C]1 [C]. [C]5 O 
micromol/L [C]m [C]i [C]c [C]r [C]o [C]m [C]o [C]l [C]/ [C]L O 
sulfasalazine [C]s [C]u [C]l [C]f [C]a [C]s [C]a [C]l [C]a [C]z [C]i [C]n [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
apparent [C]a [C]p [C]p [C]a [C]r [C]e [C]n [C]t O 
ID50 [C]I [C]D [C]5 [C]0 O 
value [C]v [C]a [C]l [C]u [C]e O 
for [C]f [C]o [C]r O 
aminosalicylate-inhibited [C]a [C]m [C]i [C]n [C]o [C]s [C]a [C]l [C]i [C]c [C]y [C]l [C]a [C]t [C]e [C]- [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
maturation [C]m [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
4 [C]4 O 
micromol/L [C]m [C]i [C]c [C]r [C]o [C]m [C]o [C]l [C]/ [C]L O 
. [C]. O 

Sulfapyridine [C]S [C]u [C]l [C]f [C]a [C]p [C]y [C]r [C]i [C]d [C]i [C]n [C]e O 
had [C]h [C]a [C]d O 
no [C]n [C]o O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
. [C]. O 

At [C]A [C]t O 
1.25 [C]1 [C]. [C]2 [C]5 O 
micromol/L [C]m [C]i [C]c [C]r [C]o [C]m [C]o [C]l [C]/ [C]L O 
, [C], O 
sulfasalazine [C]s [C]u [C]l [C]f [C]a [C]s [C]a [C]l [C]a [C]z [C]i [C]n [C]e O 
largely [C]l [C]a [C]r [C]g [C]e [C]l [C]y O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
NF-kB [C]N [C]F [C]- [C]k [C]B O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
dendritic [C]d [C]e [C]n [C]d [C]r [C]i [C]t [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

CONCLUSION [C]C [C]O [C]N [C]C [C]L [C]U [C]S [C]I [C]O [C]N O 
: [C]: O 
Maturing [C]M [C]a [C]t [C]u [C]r [C]i [C]n [C]g B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
dendritic [C]d [C]e [C]n [C]d [C]r [C]i [C]t [C]i [C]c I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
are [C]a [C]r [C]e O 
hundred-fold [C]h [C]u [C]n [C]d [C]r [C]e [C]d [C]- [C]f [C]o [C]l [C]d O 
more [C]m [C]o [C]r [C]e O 
sensitive [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
to [C]t [C]o O 
sulfasalazine [C]s [C]u [C]l [C]f [C]a [C]s [C]a [C]l [C]a [C]z [C]i [C]n [C]e O 
than [C]t [C]h [C]a [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
NK [C]N [C]K B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
most [C]m [C]o [C]s [C]t O 
sensitive [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
human [C]h [C]u [C]m [C]a [C]n O 
cells [C]c [C]e [C]l [C]l [C]s O 
described [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
so [C]s [C]o O 
far [C]f [C]a [C]r O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
dendritic [C]d [C]e [C]n [C]d [C]r [C]i [C]t [C]i [C]c O 
cell [C]c [C]e [C]l [C]l O 
maturation [C]m [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
an [C]a [C]n O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
of [C]o [C]f O 
sulfasalazine [C]s [C]u [C]l [C]f [C]a [C]s [C]a [C]l [C]a [C]z [C]i [C]n [C]e O 
. [C]. O 

Because [C]B [C]e [C]c [C]a [C]u [C]s [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
dendritic [C]d [C]e [C]n [C]d [C]r [C]i [C]t [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
( [C]( O 
auto [C]a [C]u [C]t [C]o O 
) [C]) O 
immunity [C]i [C]m [C]m [C]u [C]n [C]i [C]t [C]y O 
, [C], O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
their [C]t [C]h [C]e [C]i [C]r O 
maturation [C]m [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
might [C]m [C]i [C]g [C]h [C]t O 
provide [C]p [C]r [C]o [C]v [C]i [C]d [C]e O 
a [C]a O 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
for [C]f [C]o [C]r O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
optimization [C]o [C]p [C]t [C]i [C]m [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
sulfasalazine [C]s [C]u [C]l [C]f [C]a [C]s [C]a [C]l [C]a [C]z [C]i [C]n [C]e O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
. [C]. O 

Defective [C]D [C]e [C]f [C]e [C]c [C]t [C]i [C]v [C]e O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
proteasome [C]p [C]r [C]o [C]t [C]e [C]a [C]s [C]o [C]m [C]e S-protein 
in [C]i [C]n O 
autoimmunity [C]a [C]u [C]t [C]o [C]i [C]m [C]m [C]u [C]n [C]i [C]t [C]y O 
: [C]: O 
involvement [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
impaired [C]i [C]m [C]p [C]a [C]i [C]r [C]e [C]d O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Type [C]T [C]y [C]p [C]e O 
1 [C]1 O 
diabetes [C]d [C]i [C]a [C]b [C]e [C]t [C]e [C]s O 
( [C]( O 
also [C]a [C]l [C]s [C]o O 
known [C]k [C]n [C]o [C]w [C]n O 
as [C]a [C]s O 
insulin-dependent [C]i [C]n [C]s [C]u [C]l [C]i [C]n [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
diabetes [C]d [C]i [C]a [C]b [C]e [C]t [C]e [C]s O 
mellitus [C]m [C]e [C]l [C]l [C]i [C]t [C]u [C]s O 
or [C]o [C]r O 
juvenile-onset [C]j [C]u [C]v [C]e [C]n [C]i [C]l [C]e [C]- [C]o [C]n [C]s [C]e [C]t O 
diabetes [C]d [C]i [C]a [C]b [C]e [C]t [C]e [C]s O 
) [C]) O 
is [C]i [C]s O 
usually [C]u [C]s [C]u [C]a [C]l [C]l [C]y O 
caused [C]c [C]a [C]u [C]s [C]e [C]d O 
by [C]b [C]y O 
T [C]T O 
cell-mediated [C]c [C]e [C]l [C]l [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
autoimmunity [C]a [C]u [C]t [C]o [C]i [C]m [C]m [C]u [C]n [C]i [C]t [C]y O 
, [C], O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
prediabetic [C]p [C]r [C]e [C]d [C]i [C]a [C]b [C]e [C]t [C]i [C]c O 
state [C]s [C]t [C]a [C]t [C]e O 
characterized [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
autoantibodies [C]a [C]u [C]t [C]o [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s S-protein 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
for [C]f [C]o [C]r O 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
by [C]b [C]y O 
pancreatic [C]p [C]a [C]n [C]c [C]r [C]e [C]a [C]t [C]i [C]c B-cell_type 
beta [C]b [C]e [C]t [C]a I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
nonobese [C]n [C]o [C]n [C]o [C]b [C]e [C]s [C]e O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
diabetes [C]d [C]i [C]a [C]b [C]e [C]t [C]e [C]s O 
( [C]( O 
NOD [C]N [C]O [C]D O 
) [C]) O 
mouse [C]m [C]o [C]u [C]s [C]e O 
is [C]i [C]s O 
a [C]a O 
spontaneous [C]s [C]p [C]o [C]n [C]t [C]a [C]n [C]e [C]o [C]u [C]s O 
model [C]m [C]o [C]d [C]e [C]l O 
of [C]o [C]f O 
type [C]t [C]y [C]p [C]e O 
1 [C]1 O 
diabetes [C]d [C]i [C]a [C]b [C]e [C]t [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
strong [C]s [C]t [C]r [C]o [C]n [C]g O 
genetic [C]g [C]e [C]n [C]e [C]t [C]i [C]c O 
component [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t O 
that [C]t [C]h [C]a [C]t O 
maps [C]m [C]a [C]p [C]s O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
major [C]m [C]a [C]j [C]o [C]r B-DNA 
histocompatibility [C]h [C]i [C]s [C]t [C]o [C]c [C]o [C]m [C]p [C]a [C]t [C]i [C]b [C]i [C]l [C]i [C]t [C]y I-DNA 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x I-DNA 
( [C]( I-DNA 
MHC [C]M [C]H [C]C I-DNA 
) [C]) I-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
genome [C]g [C]e [C]n [C]o [C]m [C]e S-DNA 
. [C]. O 

A [C]A O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
proteasome [C]p [C]r [C]o [C]t [C]e [C]a [C]s [C]o [C]m [C]e S-protein 
defect [C]d [C]e [C]f [C]e [C]c [C]t O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
in [C]i [C]n O 
NOD [C]N [C]O [C]D O 
mouse [C]m [C]o [C]u [C]s [C]e O 
in [C]i [C]n O 
select [C]s [C]e [C]l [C]e [C]c [C]t O 
lymphocytic [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]i [C]c B-cell_line 
and [C]a [C]n [C]d I-cell_line 
monocytic [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]i [C]c I-cell_line 
lineages [C]l [C]i [C]n [C]e [C]a [C]g [C]e [C]s E-cell_line 
that [C]t [C]h [C]a [C]t O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
from [C]f [C]r [C]o [C]m O 
down-regulation [C]d [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
proteasome [C]p [C]r [C]o [C]t [C]e [C]a [C]s [C]o [C]m [C]e B-protein 
subunit [C]s [C]u [C]b [C]u [C]n [C]i [C]t I-protein 
LMP2 [C]L [C]M [C]P [C]2 E-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
encoded [C]e [C]n [C]c [C]o [C]d [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
gene [C]g [C]e [C]n [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
MHC [C]M [C]H [C]C B-DNA 
genomic [C]g [C]e [C]n [C]o [C]m [C]i [C]c I-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
defect [C]d [C]e [C]f [C]e [C]c [C]t O 
prevents [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]s O 
the [C]t [C]h [C]e O 
proteolytic [C]p [C]r [C]o [C]t [C]e [C]o [C]l [C]y [C]t [C]i [C]c O 
processing [C]p [C]r [C]o [C]c [C]e [C]s [C]s [C]i [C]n [C]g O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-protein 
factor-kappaB [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
( [C]( O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
) [C]) O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
plays [C]p [C]l [C]a [C]y [C]s O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
roles [C]r [C]o [C]l [C]e [C]s O 
in [C]i [C]n O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
and [C]a [C]n [C]d O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
, [C], O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
increases [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
the [C]t [C]h [C]e O 
susceptibility [C]s [C]u [C]s [C]c [C]e [C]p [C]t [C]i [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
affected [C]a [C]f [C]f [C]e [C]c [C]t [C]e [C]d O 
cells [C]c [C]e [C]l [C]l [C]s O 
to [C]t [C]o O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
tumor [C]t [C]u [C]m [C]o [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor-alpha [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]a [C]l [C]p [C]h [C]a E-protein 
( [C]( O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
novel [C]n [C]o [C]v [C]e [C]l O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
proteasome [C]p [C]r [C]o [C]t [C]e [C]a [C]s [C]o [C]m [C]e S-protein 
in [C]i [C]n O 
dysfunction [C]d [C]y [C]s [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
autoimmunity [C]a [C]u [C]t [C]o [C]i [C]m [C]m [C]u [C]n [C]i [C]t [C]y O 
is [C]i [C]s O 
presented [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]e [C]d O 
and [C]a [C]n [C]d O 
documented [C]d [C]o [C]c [C]u [C]m [C]e [C]n [C]t [C]e [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
both [C]b [C]o [C]t [C]h O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
and [C]a [C]n [C]d O 
developmental [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t [C]a [C]l O 
stage [C]s [C]t [C]a [C]g [C]e O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
. [C]. O 

We [C]W [C]e O 
propose [C]p [C]r [C]o [C]p [C]o [C]s [C]e O 
a [C]a O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
proteasome [C]p [C]r [C]o [C]t [C]e [C]a [C]s [C]o [C]m [C]e S-protein 
as [C]a [C]s O 
a [C]a O 
step [C]s [C]t [C]e [C]p O 
in [C]i [C]n O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
pathogenesis [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
targeting [C]t [C]a [C]r [C]g [C]e [C]t [C]i [C]n [C]g O 
. [C]. O 

Down-regulation [C]D [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
TDT [C]T [C]D [C]T O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
CD4 [C]C [C]D [C]4 B-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
CD8 [C]C [C]D [C]8 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
by [C]b [C]y O 
Ikaros [C]I [C]k [C]a [C]r [C]o [C]s B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
in [C]i [C]n O 
direct [C]d [C]i [C]r [C]e [C]c [C]t O 
competition [C]c [C]o [C]m [C]p [C]e [C]t [C]i [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
an [C]a [C]n O 
Ets [C]E [C]t [C]s B-protein 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r E-protein 
. [C]. O 

Ikaros [C]I [C]k [C]a [C]r [C]o [C]s S-protein 
is [C]i [C]s O 
a [C]a O 
unique [C]u [C]n [C]i [C]q [C]u [C]e O 
regulator [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r O 
of [C]o [C]f O 
lymphopoiesis [C]l [C]y [C]m [C]p [C]h [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
that [C]t [C]h [C]a [C]t O 
associates [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
pericentromeric [C]p [C]e [C]r [C]i [C]c [C]e [C]n [C]t [C]r [C]o [C]m [C]e [C]r [C]i [C]c B-DNA 
heterochromatin [C]h [C]e [C]t [C]e [C]r [C]o [C]c [C]h [C]r [C]o [C]m [C]a [C]t [C]i [C]n E-DNA 
and [C]a [C]n [C]d O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
implicated [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
heritable [C]h [C]e [C]r [C]i [C]t [C]a [C]b [C]l [C]e O 
gene [C]g [C]e [C]n [C]e O 
inactivation [C]i [C]n [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Binding [C]B [C]i [C]n [C]d [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
competition [C]c [C]o [C]m [C]p [C]e [C]t [C]i [C]t [C]i [C]o [C]n O 
experiments [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]s O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
Ikaros [C]I [C]k [C]a [C]r [C]o [C]s B-protein 
dimers [C]d [C]i [C]m [C]e [C]r [C]s E-protein 
compete [C]c [C]o [C]m [C]p [C]e [C]t [C]e O 
with [C]w [C]i [C]t [C]h O 
an [C]a [C]n O 
Ets [C]E [C]t [C]s B-protein 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r E-protein 
for [C]f [C]o [C]r O 
occupancy [C]o [C]c [C]c [C]u [C]p [C]a [C]n [C]c [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
lymphocyte-specific [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-DNA 
TdT [C]T [C]d [C]T I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

Mutations [C]M [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
that [C]t [C]h [C]a [C]t O 
selectively [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
disrupt [C]d [C]i [C]s [C]r [C]u [C]p [C]t O 
Ikaros [C]I [C]k [C]a [C]r [C]o [C]s O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
an [C]a [C]n O 
integrated [C]i [C]n [C]t [C]e [C]g [C]r [C]a [C]t [C]e [C]d B-DNA 
TdT [C]T [C]d [C]T I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
had [C]h [C]a [C]d O 
no [C]n [C]o O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
a [C]a O 
CD4 [C]C [C]D [C]4 B-cell_line 
( [C]( I-cell_line 
+ [C]+ I-cell_line 
) [C]) I-cell_line 
CD8 [C]C [C]D [C]8 I-cell_line 
( [C]( I-cell_line 
+ [C]+ I-cell_line 
) [C]) I-cell_line 
thymocyte [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
these [C]t [C]h [C]e [C]s [C]e O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
abolished [C]a [C]b [C]o [C]l [C]i [C]s [C]h [C]e [C]d O 
down-regulation [C]d [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
on [C]o [C]n O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
providing [C]p [C]r [C]o [C]v [C]i [C]d [C]i [C]n [C]g O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
that [C]t [C]h [C]a [C]t O 
Ikaros [C]I [C]k [C]a [C]r [C]o [C]s S-protein 
plays [C]p [C]l [C]a [C]y [C]s O 
a [C]a O 
direct [C]d [C]i [C]r [C]e [C]c [C]t O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
repression [C]r [C]e [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Reduced [C]R [C]e [C]d [C]u [C]c [C]e [C]d O 
access [C]a [C]c [C]c [C]e [C]s [C]s O 
to [C]t [C]o O 
restriction [C]r [C]e [C]s [C]t [C]r [C]i [C]c [C]t [C]i [C]o [C]n O 
enzyme [C]e [C]n [C]z [C]y [C]m [C]e O 
cleavage [C]c [C]l [C]e [C]a [C]v [C]a [C]g [C]e O 
suggested [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
chromatin [C]c [C]h [C]r [C]o [C]m [C]a [C]t [C]i [C]n O 
alterations [C]a [C]l [C]t [C]e [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
accompany [C]a [C]c [C]c [C]o [C]m [C]p [C]a [C]n [C]y O 
down-regulation [C]d [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
Ikaros-dependent [C]I [C]k [C]a [C]r [C]o [C]s [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
down-regulation [C]d [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
event [C]e [C]v [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
chromatin [C]c [C]h [C]r [C]o [C]m [C]a [C]t [C]i [C]n O 
alterations [C]a [C]l [C]t [C]e [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
appear [C]a [C]p [C]p [C]e [C]a [C]r O 
to [C]t [C]o O 
precede [C]p [C]r [C]e [C]c [C]e [C]d [C]e O 
pericentromeric [C]p [C]e [C]r [C]i [C]c [C]e [C]n [C]t [C]r [C]o [C]m [C]e [C]r [C]i [C]c O 
repositioning [C]r [C]e [C]p [C]o [C]s [C]i [C]t [C]i [C]o [C]n [C]i [C]n [C]g O 
. [C]. O 

Current [C]C [C]u [C]r [C]r [C]e [C]n [C]t O 
models [C]m [C]o [C]d [C]e [C]l [C]s O 
propose [C]p [C]r [C]o [C]p [C]o [C]s [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
functions [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
Ikaros [C]I [C]k [C]a [C]r [C]o [C]s S-protein 
should [C]s [C]h [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
disrupted [C]d [C]i [C]s [C]r [C]u [C]p [C]t [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
small [C]s [C]m [C]a [C]l [C]l O 
isoform [C]i [C]s [C]o [C]f [C]o [C]r [C]m S-protein 
that [C]t [C]h [C]a [C]t O 
retains [C]r [C]e [C]t [C]a [C]i [C]n [C]s O 
the [C]t [C]h [C]e O 
dimerization [C]d [C]i [C]m [C]e [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n B-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
and [C]a [C]n [C]d O 
lacks [C]l [C]a [C]c [C]k [C]s O 
the [C]t [C]h [C]e O 
DNA-binding [C]D [C]N [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
. [C]. O 

Surprisingly [C]S [C]u [C]r [C]p [C]r [C]i [C]s [C]i [C]n [C]g [C]l [C]y O 
, [C], O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
CD4 [C]C [C]D [C]4 B-cell_line 
( [C]( I-cell_line 
+ [C]+ I-cell_line 
) [C]) I-cell_line 
CD8 [C]C [C]D [C]8 I-cell_line 
( [C]( I-cell_line 
+ [C]+ I-cell_line 
) [C]) I-cell_line 
thymocyte [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
, [C], O 
overexpression [C]o [C]v [C]e [C]r [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
small [C]s [C]m [C]a [C]l [C]l B-protein 
Ikaros [C]I [C]k [C]a [C]r [C]o [C]s I-protein 
isoform [C]i [C]s [C]o [C]f [C]o [C]r [C]m E-protein 
had [C]h [C]a [C]d O 
no [C]n [C]o O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
or [C]o [C]r O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
pericentromeric [C]p [C]e [C]r [C]i [C]c [C]e [C]n [C]t [C]r [C]o [C]m [C]e [C]r [C]i [C]c O 
targeting [C]t [C]a [C]r [C]g [C]e [C]t [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
DNA-binding [C]D [C]N [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
properties [C]p [C]r [C]o [C]p [C]e [C]r [C]t [C]i [C]e [C]s O 
of [C]o [C]f O 
Ikaros [C]I [C]k [C]a [C]r [C]o [C]s S-protein 
. [C]. O 

Rather [C]R [C]a [C]t [C]h [C]e [C]r O 
, [C], O 
the [C]t [C]h [C]e O 
small [C]s [C]m [C]a [C]l [C]l O 
isoform [C]i [C]s [C]o [C]f [C]o [C]r [C]m S-protein 
assembled [C]a [C]s [C]s [C]e [C]m [C]b [C]l [C]e [C]d O 
into [C]i [C]n [C]t [C]o O 
multimeric [C]m [C]u [C]l [C]t [C]i [C]m [C]e [C]r [C]i [C]c B-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
with [C]w [C]i [C]t [C]h O 
DNA-bound [C]D [C]N [C]A [C]- [C]b [C]o [C]u [C]n [C]d B-protein 
Ikaros [C]I [C]k [C]a [C]r [C]o [C]s E-protein 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
pericentromeric [C]p [C]e [C]r [C]i [C]c [C]e [C]n [C]t [C]r [C]o [C]m [C]e [C]r [C]i [C]c O 
foci [C]f [C]o [C]c [C]i O 
. [C]. O 

The [C]T [C]h [C]e O 
capacity [C]c [C]a [C]p [C]a [C]c [C]i [C]t [C]y O 
for [C]f [C]o [C]r O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
multimer [C]m [C]u [C]l [C]t [C]i [C]m [C]e [C]r O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
suggests [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]s O 
that [C]t [C]h [C]a [C]t O 
interactions [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
Ikaros [C]I [C]k [C]a [C]r [C]o [C]s B-protein 
dimers [C]d [C]i [C]m [C]e [C]r [C]s E-protein 
bound [C]b [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
TdT [C]T [C]d [C]T B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
and [C]a [C]n [C]d O 
those [C]t [C]h [C]o [C]s [C]e O 
bound [C]b [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
pericentromeric [C]p [C]e [C]r [C]i [C]c [C]e [C]n [C]t [C]r [C]o [C]m [C]e [C]r [C]i [C]c B-DNA 
repeat [C]r [C]e [C]p [C]e [C]a [C]t I-DNA 
sequences [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s E-DNA 
may [C]m [C]a [C]y O 
contribute [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
pericentromeric [C]p [C]e [C]r [C]i [C]c [C]e [C]n [C]t [C]r [C]o [C]m [C]e [C]r [C]i [C]c O 
repositioning [C]r [C]e [C]p [C]o [C]s [C]i [C]t [C]i [C]o [C]n [C]i [C]n [C]g O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
inactive [C]i [C]n [C]a [C]c [C]t [C]i [C]v [C]e B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
. [C]. O 

Type [C]T [C]y [C]p [C]e B-protein 
I [C]I I-protein 
interferons [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n [C]s E-protein 
and [C]a [C]n [C]d O 
IL-12 [C]I [C]L [C]- [C]1 [C]2 S-protein 
: [C]: O 
convergence [C]c [C]o [C]n [C]v [C]e [C]r [C]g [C]e [C]n [C]c [C]e O 
and [C]a [C]n [C]d O 
cross-regulation [C]c [C]r [C]o [C]s [C]s [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
among [C]a [C]m [C]o [C]n [C]g O 
mediators [C]m [C]e [C]d [C]i [C]a [C]t [C]o [C]r [C]s O 
of [C]o [C]f O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
immunity [C]i [C]m [C]m [C]u [C]n [C]i [C]t [C]y O 
. [C]. O 

Therapeutic [C]T [C]h [C]e [C]r [C]a [C]p [C]e [C]u [C]t [C]i [C]c O 
use [C]u [C]s [C]e O 
of [C]o [C]f O 
type [C]t [C]y [C]p [C]e B-protein 
I [C]I I-protein 
IFN [C]I [C]F [C]N E-protein 
( [C]( O 
IFN-alpha/beta [C]I [C]F [C]N [C]- [C]a [C]l [C]p [C]h [C]a [C]/ [C]b [C]e [C]t [C]a S-protein 
) [C]) O 
has [C]h [C]a [C]s O 
become [C]b [C]e [C]c [C]o [C]m [C]e O 
common [C]c [C]o [C]m [C]m [C]o [C]n O 
. [C]. O 

Many [C]M [C]a [C]n [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
diverse [C]d [C]i [C]v [C]e [C]r [C]s [C]e O 
diseases [C]d [C]i [C]s [C]e [C]a [C]s [C]e [C]s O 
targeted [C]t [C]a [C]r [C]g [C]e [C]t [C]e [C]d O 
are [C]a [C]r [C]e O 
marked [C]m [C]a [C]r [C]k [C]e [C]d O 
by [C]b [C]y O 
pathogenetic [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]e [C]t [C]i [C]c O 
abnormalities [C]a [C]b [C]n [C]o [C]r [C]m [C]a [C]l [C]i [C]t [C]i [C]e [C]s O 
in [C]i [C]n O 
cell-mediated [C]c [C]e [C]l [C]l [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
immunity [C]i [C]m [C]m [C]u [C]n [C]i [C]t [C]y O 
( [C]( O 
CMI [C]C [C]M [C]I O 
) [C]) O 
, [C], O 
these [C]t [C]h [C]e [C]s [C]e O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
causing [C]c [C]a [C]u [C]s [C]i [C]n [C]g O 
injury [C]i [C]n [C]j [C]u [C]r [C]y O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
host [C]h [C]o [C]s [C]t O 
, [C], O 
lacking [C]l [C]a [C]c [C]k [C]i [C]n [C]g O 
sufficient [C]s [C]u [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
vigor [C]v [C]i [C]g [C]o [C]r O 
for [C]f [C]o [C]r O 
virus [C]v [C]i [C]r [C]u [C]s O 
or [C]o [C]r O 
tumor [C]t [C]u [C]m [C]o [C]r O 
clearance [C]c [C]l [C]e [C]a [C]r [C]a [C]n [C]c [C]e O 
, [C], O 
or [C]o [C]r O 
both [C]b [C]o [C]t [C]h O 
. [C]. O 

In [C]I [C]n O 
general [C]g [C]e [C]n [C]e [C]r [C]a [C]l O 
, [C], O 
therapeutic [C]t [C]h [C]e [C]r [C]a [C]p [C]e [C]u [C]t [C]i [C]c O 
efficacy [C]e [C]f [C]f [C]i [C]c [C]a [C]c [C]y O 
is [C]i [C]s O 
limited [C]l [C]i [C]m [C]i [C]t [C]e [C]d O 
. [C]. O 

It [C]I [C]t O 
is [C]i [C]s O 
thus [C]t [C]h [C]u [C]s O 
notable [C]n [C]o [C]t [C]a [C]b [C]l [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
pleiotropic [C]p [C]l [C]e [C]i [C]o [C]t [C]r [C]o [C]p [C]i [C]c O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
type [C]t [C]y [C]p [C]e B-protein 
I [C]I I-protein 
IFN [C]I [C]F [C]N E-protein 
on [C]o [C]n O 
CMI [C]C [C]M [C]I O 
remain [C]r [C]e [C]m [C]a [C]i [C]n O 
poorly [C]p [C]o [C]o [C]r [C]l [C]y O 
understood [C]u [C]n [C]d [C]e [C]r [C]s [C]t [C]o [C]o [C]d O 
. [C]. O 

We [C]W [C]e O 
characterized [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]d O 
the [C]t [C]h [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
type [C]t [C]y [C]p [C]e B-protein 
I [C]I I-protein 
IFN [C]I [C]F [C]N E-protein 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-12 [C]I [C]L [C]- [C]1 [C]2 S-protein 
, [C], O 
the [C]t [C]h [C]e O 
central [C]c [C]e [C]n [C]t [C]r [C]a [C]l B-protein 
immunoregulatory [C]i [C]m [C]m [C]u [C]n [C]o [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y I-protein 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e E-protein 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
CD4 [C]C [C]D [C]4 B-protein 
( [C]( I-protein 
+ [C]+ I-protein 
) [C]) I-protein 
T [C]T I-protein 
cell [C]c [C]e [C]l [C]l I-protein 
arm [C]a [C]r [C]m E-protein 
of [C]o [C]f O 
CMI [C]C [C]M [C]I O 
. [C]. O 

We [C]W [C]e O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
type [C]t [C]y [C]p [C]e B-protein 
I [C]I I-protein 
IFN [C]I [C]F [C]N E-protein 
are [C]a [C]r [C]e O 
potent [C]p [C]o [C]t [C]e [C]n [C]t O 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
of [C]o [C]f O 
IL-12 [C]I [C]L [C]- [C]1 [C]2 O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
monocytes/macrophages [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s [C]/ [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
underlying [C]u [C]n [C]d [C]e [C]r [C]l [C]y [C]i [C]n [C]g O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
involves [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]s O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IL-12p40 [C]I [C]L [C]- [C]1 [C]2 [C]p [C]4 [C]0 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
, [C], O 
marked [C]m [C]a [C]r [C]k [C]e [C]d O 
by [C]b [C]y O 
down-regulation [C]d [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
PU.1 [C]P [C]U [C]. [C]1 O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
upstream [C]u [C]p [C]s [C]t [C]r [C]e [C]a [C]m B-DNA 
Ets [C]E [C]t [C]s I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IL-12p40 [C]I [C]L [C]- [C]1 [C]2 [C]p [C]4 [C]0 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

Type [C]T [C]y [C]p [C]e B-protein 
I [C]I I-protein 
IFN [C]I [C]F [C]N E-protein 
have [C]h [C]a [C]v [C]e O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
been [C]b [C]e [C]e [C]n O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
be [C]b [C]e O 
able [C]a [C]b [C]l [C]e O 
to [C]t [C]o O 
substitute [C]s [C]u [C]b [C]s [C]t [C]i [C]t [C]u [C]t [C]e O 
for [C]f [C]o [C]r O 
IL-12 [C]I [C]L [C]- [C]1 [C]2 S-protein 
in [C]i [C]n O 
driving [C]d [C]r [C]i [C]v [C]i [C]n [C]g O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
from [C]f [C]r [C]o [C]m O 
T [C]T B-cell_type 
and [C]a [C]n [C]d I-cell_type 
NK [C]N [C]K I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
IFN-alpha/beta [C]I [C]F [C]N [C]- [C]a [C]l [C]p [C]h [C]a [C]/ [C]b [C]e [C]t [C]a S-protein 
to [C]t [C]o O 
suppress [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s O 
IL-12 [C]I [C]L [C]- [C]1 [C]2 O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
while [C]w [C]h [C]i [C]l [C]e O 
up-regulating [C]u [C]p [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
suggests [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]s O 
a [C]a O 
possible [C]p [C]o [C]s [C]s [C]i [C]b [C]l [C]e O 
mechanistic [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]t [C]i [C]c O 
basis [C]b [C]a [C]s [C]i [C]s O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
difficulties [C]d [C]i [C]f [C]f [C]i [C]c [C]u [C]l [C]t [C]i [C]e [C]s O 
of [C]o [C]f O 
employing [C]e [C]m [C]p [C]l [C]o [C]y [C]i [C]n [C]g O 
these [C]t [C]h [C]e [C]s [C]e O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
in [C]i [C]n O 
diseases [C]d [C]i [C]s [C]e [C]a [C]s [C]e [C]s O 
involving [C]i [C]n [C]v [C]o [C]l [C]v [C]i [C]n [C]g O 
abnormalities [C]a [C]b [C]n [C]o [C]r [C]m [C]a [C]l [C]i [C]t [C]i [C]e [C]s O 
of [C]o [C]f O 
CMI [C]C [C]M [C]I O 
. [C]. O 

Nuclear [C]N [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor-kappaB [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
suppressive [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]v [C]e O 
and [C]a [C]n [C]d O 
inhibitor-kappaB [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
stimulatory [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
troglitazone [C]t [C]r [C]o [C]g [C]l [C]i [C]t [C]a [C]z [C]o [C]n [C]e O 
in [C]i [C]n O 
obese [C]o [C]b [C]e [C]s [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
type [C]t [C]y [C]p [C]e O 
2 [C]2 O 
diabetes [C]d [C]i [C]a [C]b [C]e [C]t [C]e [C]s O 
: [C]: O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
an [C]a [C]n O 
antiinflammatory [C]a [C]n [C]t [C]i [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
action [C]a [C]c [C]t [C]i [C]o [C]n O 
? [C]? O 

It [C]I [C]t O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
shown [C]s [C]h [C]o [C]w [C]n O 
recently [C]r [C]e [C]c [C]e [C]n [C]t [C]l [C]y O 
that [C]t [C]h [C]a [C]t O 
troglitazone [C]t [C]r [C]o [C]g [C]l [C]i [C]t [C]a [C]z [C]o [C]n [C]e O 
exerts [C]e [C]x [C]e [C]r [C]t [C]s O 
an [C]a [C]n O 
anti-inflammatory [C]a [C]n [C]t [C]i [C]- [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
, [C], O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
, [C], O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
experimental [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]a [C]l O 
animals [C]a [C]n [C]i [C]m [C]a [C]l [C]s O 
. [C]. O 

To [C]T [C]o O 
test [C]t [C]e [C]s [C]t O 
these [C]t [C]h [C]e [C]s [C]e O 
properties [C]p [C]r [C]o [C]p [C]e [C]r [C]t [C]i [C]e [C]s O 
in [C]i [C]n O 
humans [C]h [C]u [C]m [C]a [C]n [C]s O 
, [C], O 
we [C]w [C]e O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
troglitazone [C]t [C]r [C]o [C]g [C]l [C]i [C]t [C]a [C]z [C]o [C]n [C]e O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
proinflammatory [C]p [C]r [C]o [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-protein 
factor-kappaB [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
and [C]a [C]n [C]d O 
its [C]i [C]t [C]s O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
IkappaB [C]I [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
in [C]i [C]n O 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
MNC [C]M [C]N [C]C S-cell_type 
) [C]) O 
and [C]a [C]n [C]d O 
plasma [C]p [C]l [C]a [C]s [C]m [C]a B-protein 
soluble [C]s [C]o [C]l [C]u [C]b [C]l [C]e I-protein 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r I-protein 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n I-protein 
molecule-1 [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]- [C]1 E-protein 
, [C], O 
monocyte [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e B-protein 
chemoattractant [C]c [C]h [C]e [C]m [C]o [C]a [C]t [C]t [C]r [C]a [C]c [C]t [C]a [C]n [C]t I-protein 
protein-1 [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]1 E-protein 
, [C], O 
plasminogen [C]p [C]l [C]a [C]s [C]m [C]i [C]n [C]o [C]g [C]e [C]n B-protein 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r I-protein 
inhibitor-1 [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]- [C]1 E-protein 
, [C], O 
and [C]a [C]n [C]d O 
C-reactive [C]C [C]- [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]e B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
. [C]. O 

We [C]W [C]e O 
also [C]a [C]l [C]s [C]o O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
the [C]t [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
troglitazone [C]t [C]r [C]o [C]g [C]l [C]i [C]t [C]a [C]z [C]o [C]n [C]e O 
on [C]o [C]n O 
reactive [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]e O 
oxygen [C]o [C]x [C]y [C]g [C]e [C]n O 
species [C]s [C]p [C]e [C]c [C]i [C]e [C]s O 
generation [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
p47 [C]p [C]4 [C]7 O 
( [C]( O 
phox [C]p [C]h [C]o [C]x O 
) [C]) O 
subunit [C]s [C]u [C]b [C]u [C]n [C]i [C]t O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
9-hydroxyoctadecadienoic [C]9 [C]- [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]o [C]c [C]t [C]a [C]d [C]e [C]c [C]a [C]d [C]i [C]e [C]n [C]o [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
( [C]( O 
9-HODE [C]9 [C]- [C]H [C]O [C]D [C]E O 
) [C]) O 
, [C], O 
13-HODE [C]1 [C]3 [C]- [C]H [C]O [C]D [C]E O 
, [C], O 
o-tyrosine [C]o [C]- [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
, [C], O 
and [C]a [C]n [C]d O 
m-tyrosine [C]m [C]- [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
in [C]i [C]n O 
obese [C]o [C]b [C]e [C]s [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
type [C]t [C]y [C]p [C]e O 
2 [C]2 O 
diabetes [C]d [C]i [C]a [C]b [C]e [C]t [C]e [C]s O 
. [C]. O 

Seven [C]S [C]e [C]v [C]e [C]n O 
obese [C]o [C]b [C]e [C]s [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
type [C]t [C]y [C]p [C]e O 
2 [C]2 O 
diabetes [C]d [C]i [C]a [C]b [C]e [C]t [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
troglitazone [C]t [C]r [C]o [C]g [C]l [C]i [C]t [C]a [C]z [C]o [C]n [C]e O 
( [C]( O 
400 [C]4 [C]0 [C]0 O 
mg/day [C]m [C]g [C]/ [C]d [C]a [C]y O 
) [C]) O 
for [C]f [C]o [C]r O 
4 [C]4 O 
weeks [C]w [C]e [C]e [C]k [C]s O 
. [C]. O 

Blood [C]B [C]l [C]o [C]o [C]d O 
samples [C]s [C]a [C]m [C]p [C]l [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
at [C]a [C]t O 
weekly [C]w [C]e [C]e [C]k [C]l [C]y O 
intervals [C]i [C]n [C]t [C]e [C]r [C]v [C]a [C]l [C]s O 
. [C]. O 

Nuclear [C]N [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor-kappaB [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
MNC [C]M [C]N [C]C S-cell_type 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
was [C]w [C]a [C]s O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
after [C]a [C]f [C]t [C]e [C]r O 
troglitazone [C]t [C]r [C]o [C]g [C]l [C]i [C]t [C]a [C]z [C]o [C]n [C]e O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
at [C]a [C]t O 
week [C]w [C]e [C]e [C]k O 
1 [C]1 O 
and [C]a [C]n [C]d O 
continued [C]c [C]o [C]n [C]t [C]i [C]n [C]u [C]e [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
up [C]u [C]p O 
to [C]t [C]o O 
week [C]w [C]e [C]e [C]k O 
4 [C]4 O 
. [C]. O 

On [C]O [C]n O 
the [C]t [C]h [C]e O 
other [C]o [C]t [C]h [C]e [C]r O 
hand [C]h [C]a [C]n [C]d O 
, [C], O 
IkappaB [C]I [C]k [C]a [C]p [C]p [C]a [C]B O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
after [C]a [C]f [C]t [C]e [C]r O 
troglitazone [C]t [C]r [C]o [C]g [C]l [C]i [C]t [C]a [C]z [C]o [C]n [C]e O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
at [C]a [C]t O 
week [C]w [C]e [C]e [C]k O 
1 [C]1 O 
, [C], O 
and [C]a [C]n [C]d O 
this [C]t [C]h [C]i [C]s O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
persisted [C]p [C]e [C]r [C]s [C]i [C]s [C]t [C]e [C]d O 
throughout [C]t [C]h [C]r [C]o [C]u [C]g [C]h [C]o [C]u [C]t O 
the [C]t [C]h [C]e O 
study [C]s [C]t [C]u [C]d [C]y O 
. [C]. O 

Plasma [C]P [C]l [C]a [C]s [C]m [C]a B-protein 
monocyte [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e I-protein 
chemoattractant [C]c [C]h [C]e [C]m [C]o [C]a [C]t [C]t [C]r [C]a [C]c [C]t [C]a [C]n [C]t I-protein 
protein-1 [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]1 E-protein 
and [C]a [C]n [C]d O 
soluble [C]s [C]o [C]l [C]u [C]b [C]l [C]e B-protein 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r I-protein 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n I-protein 
molecule-1 [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]- [C]1 E-protein 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
after [C]a [C]f [C]t [C]e [C]r O 
troglitazone [C]t [C]r [C]o [C]g [C]l [C]i [C]t [C]a [C]z [C]o [C]n [C]e O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
, [C], O 
although [C]a [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
there [C]t [C]h [C]e [C]r [C]e O 
was [C]w [C]a [C]s O 
a [C]a O 
trend [C]t [C]r [C]e [C]n [C]d O 
toward [C]t [C]o [C]w [C]a [C]r [C]d O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
. [C]. O 

Reactive [C]R [C]e [C]a [C]c [C]t [C]i [C]v [C]e O 
oxygen [C]o [C]x [C]y [C]g [C]e [C]n O 
species [C]s [C]p [C]e [C]c [C]i [C]e [C]s O 
generation [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
polymorphonuclear [C]p [C]o [C]l [C]y [C]m [C]o [C]r [C]p [C]h [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
MNC [C]M [C]N [C]C S-cell_type 
, [C], O 
p47 [C]p [C]4 [C]7 B-protein 
( [C]( I-protein 
phox [C]p [C]h [C]o [C]x I-protein 
) [C]) I-protein 
subunit [C]s [C]u [C]b [C]u [C]n [C]i [C]t I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
quantities [C]q [C]u [C]a [C]n [C]t [C]i [C]t [C]i [C]e [C]s O 
, [C], O 
plasminogen [C]p [C]l [C]a [C]s [C]m [C]i [C]n [C]o [C]g [C]e [C]n B-protein 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r I-protein 
inhibitor-1 [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]- [C]1 E-protein 
, [C], O 
and [C]a [C]n [C]d O 
C-reactive [C]C [C]- [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]e B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
after [C]a [C]f [C]t [C]e [C]r O 
troglitazone [C]t [C]r [C]o [C]g [C]l [C]i [C]t [C]a [C]z [C]o [C]n [C]e O 
intake [C]i [C]n [C]t [C]a [C]k [C]e O 
. [C]. O 

13-HODE/linoleic [C]1 [C]3 [C]- [C]H [C]O [C]D [C]E [C]/ [C]l [C]i [C]n [C]o [C]l [C]e [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
and [C]a [C]n [C]d O 
9-HODE/linoleic [C]9 [C]- [C]H [C]O [C]D [C]E [C]/ [C]l [C]i [C]n [C]o [C]l [C]e [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
ratios [C]r [C]a [C]t [C]i [C]o [C]s O 
also [C]a [C]l [C]s [C]o O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
after [C]a [C]f [C]t [C]e [C]r O 
troglitazone [C]t [C]r [C]o [C]g [C]l [C]i [C]t [C]a [C]z [C]o [C]n [C]e O 
intake [C]i [C]n [C]t [C]a [C]k [C]e O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
o-tyrosine/phenylalanine [C]o [C]- [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e [C]/ [C]p [C]h [C]e [C]n [C]y [C]l [C]a [C]l [C]a [C]n [C]i [C]n [C]e O 
and [C]a [C]n [C]d O 
m-tyrosine/phenylalanine [C]m [C]- [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e [C]/ [C]p [C]h [C]e [C]n [C]y [C]l [C]a [C]l [C]a [C]n [C]i [C]n [C]e O 
ratios [C]r [C]a [C]t [C]i [C]o [C]s O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
change [C]c [C]h [C]a [C]n [C]g [C]e O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
troglitazone [C]t [C]r [C]o [C]g [C]l [C]i [C]t [C]a [C]z [C]o [C]n [C]e O 
has [C]h [C]a [C]s O 
profound [C]p [C]r [C]o [C]f [C]o [C]u [C]n [C]d O 
antiinflammatory [C]a [C]n [C]t [C]i [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
in [C]i [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
to [C]t [C]o O 
antioxidant [C]a [C]n [C]t [C]i [C]o [C]x [C]i [C]d [C]a [C]n [C]t O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
in [C]i [C]n O 
obese [C]o [C]b [C]e [C]s [C]e O 
type [C]t [C]y [C]p [C]e O 
2 [C]2 O 
diabetics [C]d [C]i [C]a [C]b [C]e [C]t [C]i [C]c [C]s O 
; [C]; O 
these [C]t [C]h [C]e [C]s [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
relevant [C]r [C]e [C]l [C]e [C]v [C]a [C]n [C]t O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
recently [C]r [C]e [C]c [C]e [C]n [C]t [C]l [C]y O 
described [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
beneficial [C]b [C]e [C]n [C]e [C]f [C]i [C]c [C]i [C]a [C]l O 
antiatherosclerotic [C]a [C]n [C]t [C]i [C]a [C]t [C]h [C]e [C]r [C]o [C]s [C]c [C]l [C]e [C]r [C]o [C]t [C]i [C]c O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
troglitazone [C]t [C]r [C]o [C]g [C]l [C]i [C]t [C]a [C]z [C]o [C]n [C]e O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
vascular [C]v [C]a [C]s [C]c [C]u [C]l [C]a [C]r O 
level [C]l [C]e [C]v [C]e [C]l O 
. [C]. O 

OX40 [C]O [C]X [C]4 [C]0 O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
gp34/OX40 [C]g [C]p [C]3 [C]4 [C]/ [C]O [C]X [C]4 [C]0 B-protein 
ligand [C]l [C]i [C]g [C]a [C]n [C]d E-protein 
enhances [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]s O 
productive [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]v [C]e O 
human [C]h [C]u [C]m [C]a [C]n O 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
virus [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
1 [C]1 O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

OX40 [C]O [C]X [C]4 [C]0 S-protein 
is [C]i [C]s O 
a [C]a O 
member [C]m [C]e [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
tumor [C]t [C]u [C]m [C]o [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
( [C]( I-protein 
TNF [C]T [C]N [C]F I-protein 
) [C]) I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
superfamily [C]s [C]u [C]p [C]e [C]r [C]f [C]a [C]m [C]i [C]l [C]y E-protein 
and [C]a [C]n [C]d O 
known [C]k [C]n [C]o [C]w [C]n O 
to [C]t [C]o O 
be [C]b [C]e O 
an [C]a [C]n O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
costimulatory [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]o [C]r [C]y B-protein 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e E-protein 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
on [C]o [C]n O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

To [C]T [C]o O 
investigate [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
costimulation [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
OX40 [C]O [C]X [C]4 [C]0 S-protein 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n O 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
virus [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
1 [C]1 O 
( [C]( O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
) [C]) O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
its [C]i [C]t [C]s O 
natural [C]n [C]a [C]t [C]u [C]r [C]a [C]l O 
ligand [C]l [C]i [C]g [C]a [C]n [C]d O 
, [C], O 
gp34 [C]g [C]p [C]3 [C]4 S-protein 
, [C], O 
the [C]t [C]h [C]e O 
OX40-transfected [C]O [C]X [C]4 [C]0 [C]- [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]e [C]d B-cell_line 
ACH-2 [C]A [C]C [C]H [C]- [C]2 I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e I-cell_line 
, [C], I-cell_line 
ACH-2/OX40 [C]A [C]C [C]H [C]- [C]2 [C]/ [C]O [C]X [C]4 [C]0 E-cell_line 
, [C], O 
chronically [C]c [C]h [C]r [C]o [C]n [C]i [C]c [C]a [C]l [C]l [C]y O 
infected [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
, [C], O 
was [C]w [C]a [C]s O 
cocultured [C]c [C]o [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
paraformaldehyde [C]p [C]a [C]r [C]a [C]f [C]o [C]r [C]m [C]a [C]l [C]d [C]e [C]h [C]y [C]d [C]e O 
( [C]( O 
PFA [C]P [C]F [C]A O 
) [C]) O 
-fixed [C]- [C]f [C]i [C]x [C]e [C]d O 
gp34-transfected [C]g [C]p [C]3 [C]4 [C]- [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]e [C]d B-cell_line 
mouse [C]m [C]o [C]u [C]s [C]e I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e I-cell_line 
, [C], I-cell_line 
SV-T2/gp34 [C]S [C]V [C]- [C]T [C]2 [C]/ [C]g [C]p [C]3 [C]4 E-cell_line 
. [C]. O 

The [C]T [C]h [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
strongly [C]s [C]t [C]r [C]o [C]n [C]g [C]l [C]y O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
was [C]w [C]a [C]s O 
followed [C]f [C]o [C]l [C]l [C]o [C]w [C]e [C]d O 
by [C]b [C]y O 
apparent [C]a [C]p [C]p [C]a [C]r [C]e [C]n [C]t O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
both [C]b [C]o [C]t [C]h O 
processes [C]p [C]r [C]o [C]c [C]e [C]s [C]s [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
specifically [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]a [C]l [C]l [C]y O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
gp34 [C]g [C]p [C]3 [C]4 S-protein 
-specific [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
neutralizing [C]n [C]e [C]u [C]t [C]r [C]a [C]l [C]i [C]z [C]i [C]n [C]g B-protein 
monoclonal [C]m [C]o [C]n [C]o [C]c [C]l [C]o [C]n [C]a [C]l I-protein 
antibody [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y I-protein 
5A8 [C]5 [C]A [C]8 E-protein 
. [C]. O 

Endogenous [C]E [C]n [C]d [C]o [C]g [C]e [C]n [C]o [C]u [C]s O 
TNF [C]T [C]N [C]F B-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
( [C]( O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
TNF-beta [C]T [C]N [C]F [C]- [C]b [C]e [C]t [C]a S-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
were [C]w [C]e [C]r [C]e O 
not [C]n [C]o [C]t O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
gp34 [C]g [C]p [C]3 [C]4 S-protein 
-stimulated [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
ACH-2/OX40 [C]A [C]C [C]H [C]- [C]2 [C]/ [C]O [C]X [C]4 [C]0 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
was [C]w [C]a [C]s O 
dependent [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
kappa [C]k [C]a [C]p [C]p [C]a B-DNA 
B [C]B I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 B-DNA 
long [C]l [C]o [C]n [C]g I-DNA 
terminal [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l I-DNA 
repeat [C]r [C]e [C]p [C]e [C]a [C]t E-DNA 
, [C], O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
OX40-gp34 [C]O [C]X [C]4 [C]0 [C]- [C]g [C]p [C]3 [C]4 O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
consisting [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]i [C]n [C]g O 
of [C]o [C]f O 
p50 [C]p [C]5 [C]0 B-protein 
and [C]a [C]n [C]d I-protein 
p65 [C]p [C]6 [C]5 I-protein 
subunits [C]s [C]u [C]b [C]u [C]n [C]i [C]t [C]s E-protein 
. [C]. O 

When [C]W [C]h [C]e [C]n O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
CD4 [C]C [C]D [C]4 B-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
acutely [C]a [C]c [C]u [C]t [C]e [C]l [C]y O 
infected [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
( [C]( O 
NL4-3 [C]N [C]L [C]4 [C]- [C]3 O 
) [C]) O 
( [C]( O 
CXCR4-using [C]C [C]X [C]C [C]R [C]4 [C]- [C]u [C]s [C]i [C]n [C]g B-cell_line 
T-cell-line-tropic [C]T [C]- [C]c [C]e [C]l [C]l [C]- [C]l [C]i [C]n [C]e [C]- [C]t [C]r [C]o [C]p [C]i [C]c E-cell_line 
) [C]) O 
were [C]w [C]e [C]r [C]e O 
cocultured [C]c [C]o [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
PFA-fixed [C]P [C]F [C]A [C]- [C]f [C]i [C]x [C]e [C]d O 
gp34 [C]g [C]p [C]3 [C]4 B-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l E-cell_type 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
virus [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
1-bearing [C]1 [C]- [C]b [C]e [C]a [C]r [C]i [C]n [C]g O 
MT-2 [C]M [C]T [C]- [C]2 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
or [C]o [C]r O 
SV-T2/gp34 [C]S [C]V [C]- [C]T [C]2 [C]/ [C]g [C]p [C]3 [C]4 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
, [C], O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
markedly [C]m [C]a [C]r [C]k [C]e [C]d [C]l [C]y O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
. [C]. O 

The [C]T [C]h [C]e O 
enhancement [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]m [C]e [C]n [C]t O 
was [C]w [C]a [C]s O 
again [C]a [C]g [C]a [C]i [C]n O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
by [C]b [C]y O 
5A8 [C]5 [C]A [C]8 S-protein 
. [C]. O 

The [C]T [C]h [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
study [C]s [C]t [C]u [C]d [C]y O 
first [C]f [C]i [C]r [C]s [C]t O 
shows [C]s [C]h [C]o [C]w [C]s O 
that [C]t [C]h [C]a [C]t O 
OX40-gp34 [C]O [C]X [C]4 [C]0 [C]- [C]g [C]p [C]3 [C]4 O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
stimulates [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]s O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
suggests [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]s O 
that [C]t [C]h [C]a [C]t O 
OX40 [C]O [C]X [C]4 [C]0 O 
triggering [C]t [C]r [C]i [C]g [C]g [C]e [C]r [C]i [C]n [C]g O 
by [C]b [C]y O 
gp34 [C]g [C]p [C]3 [C]4 S-protein 
may [C]m [C]a [C]y O 
play [C]p [C]l [C]a [C]y O 
an [C]a [C]n O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
enhancing [C]e [C]n [C]h [C]a [C]n [C]c [C]i [C]n [C]g O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
acutely [C]a [C]c [C]u [C]t [C]e [C]l [C]y O 
and [C]a [C]n [C]d O 
latently [C]l [C]a [C]t [C]e [C]n [C]t [C]l [C]y O 
infected [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
CD4 [C]C [C]D [C]4 B-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
. [C]. O 

Troglitazone [C]T [C]r [C]o [C]g [C]l [C]i [C]t [C]a [C]z [C]o [C]n [C]e O 
, [C], O 
a [C]a O 
PPARgamma [C]P [C]P [C]A [C]R [C]g [C]a [C]m [C]m [C]a O 
ligand [C]l [C]i [C]g [C]a [C]n [C]d O 
, [C], O 
inhibits [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]s O 
osteopontin [C]o [C]s [C]t [C]e [C]o [C]p [C]o [C]n [C]t [C]i [C]n O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
monocytes/macrophage [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s [C]/ [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e I-cell_type 
THP-1 [C]T [C]H [C]P [C]- [C]1 I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Peroxizome [C]P [C]e [C]r [C]o [C]x [C]i [C]z [C]o [C]m [C]e B-protein 
proliferator-activated [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]o [C]r [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d I-protein 
receptor-gamma [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]- [C]g [C]a [C]m [C]m [C]a E-protein 
( [C]( O 
PPARgamma [C]P [C]P [C]A [C]R [C]g [C]a [C]m [C]m [C]a S-protein 
) [C]) O 
is [C]i [C]s O 
a [C]a O 
member [C]m [C]e [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y E-protein 
of [C]o [C]f O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
that [C]t [C]h [C]a [C]t O 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
adipocyte [C]a [C]d [C]i [C]p [C]o [C]c [C]y [C]t [C]e O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Recent [C]R [C]e [C]c [C]e [C]n [C]t O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
liganded [C]l [C]i [C]g [C]a [C]n [C]d [C]e [C]d B-protein 
PPARgamma [C]P [C]P [C]A [C]R [C]g [C]a [C]m [C]m [C]a E-protein 
not [C]n [C]o [C]t O 
only [C]o [C]n [C]l [C]y O 
promotes [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]s O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
but [C]b [C]u [C]t O 
also [C]a [C]l [C]s [C]o O 
inhibits [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]s O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_type 
. [C]. O 

Osteopontin [C]O [C]s [C]t [C]e [C]o [C]p [C]o [C]n [C]t [C]i [C]n S-protein 
, [C], O 
a [C]a O 
component [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t O 
of [C]o [C]f O 
extracellular [C]e [C]x [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
matrix [C]m [C]a [C]t [C]r [C]i [C]x O 
, [C], O 
is [C]i [C]s O 
synthesized [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]z [C]e [C]d O 
by [C]b [C]y O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_type 
in [C]i [C]n O 
atherosclerotic [C]a [C]t [C]h [C]e [C]r [C]o [C]s [C]c [C]l [C]e [C]r [C]o [C]t [C]i [C]c O 
plaques [C]p [C]l [C]a [C]q [C]u [C]e [C]s O 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
, [C], O 
we [C]w [C]e O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
PPARgamma [C]P [C]P [C]A [C]R [C]g [C]a [C]m [C]m [C]a S-protein 
ligand [C]l [C]i [C]g [C]a [C]n [C]d O 
regulates [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]s O 
osteopontin [C]o [C]s [C]t [C]e [C]o [C]p [C]o [C]n [C]t [C]i [C]n O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
THP-1 [C]T [C]H [C]P [C]- [C]1 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
, [C], O 
a [C]a O 
cell [C]c [C]e [C]l [C]l O 
line [C]l [C]i [C]n [C]e O 
derived [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
monocytic [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]i [C]c I-cell_type 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
which [C]w [C]h [C]i [C]c [C]h O 
can [C]c [C]a [C]n O 
differentiate [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]e O 
to [C]t [C]o O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e S-cell_type 
upon [C]u [C]p [C]o [C]n O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
phorbol [C]p [C]h [C]o [C]r [C]b [C]o [C]l O 
ester [C]e [C]s [C]t [C]e [C]r O 
PMA [C]P [C]M [C]A O 
. [C]. O 

Northern [C]N [C]o [C]r [C]t [C]h [C]e [C]r [C]n O 
blot [C]b [C]l [C]o [C]t O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
osteopontin [C]o [C]s [C]t [C]e [C]o [C]p [C]o [C]n [C]t [C]i [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
is [C]i [C]s O 
markedly [C]m [C]a [C]r [C]k [C]e [C]d [C]l [C]y O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
PMA [C]P [C]M [C]A O 
. [C]. O 

Troglitazone [C]T [C]r [C]o [C]g [C]l [C]i [C]t [C]a [C]z [C]o [C]n [C]e O 
, [C], O 
a [C]a O 
PPARgamma [C]P [C]P [C]A [C]R [C]g [C]a [C]m [C]m [C]a S-protein 
ligand [C]l [C]i [C]g [C]a [C]n [C]d O 
, [C], O 
dramatically [C]d [C]r [C]a [C]m [C]a [C]t [C]i [C]c [C]a [C]l [C]l [C]y O 
attenuated [C]a [C]t [C]t [C]e [C]n [C]u [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
PMA-induced [C]P [C]M [C]A [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
osteopontin [C]o [C]s [C]t [C]e [C]o [C]p [C]o [C]n [C]t [C]i [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Transient [C]T [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t O 
transfection [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
osteopontin [C]o [C]s [C]t [C]e [C]o [C]p [C]o [C]n [C]t [C]i [C]n I-DNA 
promoter/luciferase [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]/ [C]l [C]u [C]c [C]i [C]f [C]e [C]r [C]a [C]s [C]e I-DNA 
construct [C]c [C]o [C]n [C]s [C]t [C]r [C]u [C]c [C]t E-DNA 
which [C]w [C]h [C]i [C]c [C]h O 
contains [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]s O 
a [C]a O 
5'-flanking [C]5 [C]' [C]- [C]f [C]l [C]a [C]n [C]k [C]i [C]n [C]g B-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
-1500 [C]- [C]1 [C]5 [C]0 [C]0 O 
and [C]a [C]n [C]d O 
+87 [C]+ [C]8 [C]7 O 
relative [C]r [C]e [C]l [C]a [C]t [C]i [C]v [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-DNA 
start [C]s [C]t [C]a [C]r [C]t I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
troglitazone [C]t [C]r [C]o [C]g [C]l [C]i [C]t [C]a [C]z [C]o [C]n [C]e O 
or [C]o [C]r O 
cotransfection [C]c [C]o [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
PPARgamma [C]P [C]P [C]A [C]R [C]g [C]a [C]m [C]m [C]a B-DNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n I-DNA 
vector [C]v [C]e [C]c [C]t [C]o [C]r E-DNA 
inhibits [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]s O 
osteopontin [C]o [C]s [C]t [C]e [C]o [C]p [C]o [C]n [C]t [C]i [C]n O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
troglitazone [C]t [C]r [C]o [C]g [C]l [C]i [C]t [C]a [C]z [C]o [C]n [C]e O 
reduces [C]r [C]e [C]d [C]u [C]c [C]e [C]s O 
osteopontin [C]o [C]s [C]t [C]e [C]o [C]p [C]o [C]n [C]t [C]i [C]n O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
at [C]a [C]t O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
level [C]l [C]e [C]v [C]e [C]l O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
PPARgamma [C]P [C]P [C]A [C]R [C]g [C]a [C]m [C]m [C]a S-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
the [C]t [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
troglitazone [C]t [C]r [C]o [C]g [C]l [C]i [C]t [C]a [C]z [C]o [C]n [C]e O 
in [C]i [C]n O 
inhibiting [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_type 
to [C]t [C]o O 
produce [C]p [C]r [C]o [C]d [C]u [C]c [C]e O 
extracellular [C]e [C]x [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
matrix [C]m [C]a [C]t [C]r [C]i [C]x O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
particularly [C]p [C]a [C]r [C]t [C]i [C]c [C]u [C]l [C]a [C]r [C]l [C]y O 
relevant [C]r [C]e [C]l [C]e [C]v [C]a [C]n [C]t O 
to [C]t [C]o O 
atherosclerotic [C]a [C]t [C]h [C]e [C]r [C]o [C]s [C]c [C]l [C]e [C]r [C]o [C]t [C]i [C]c O 
plaque [C]p [C]l [C]a [C]q [C]u [C]e O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Transcription [C]T [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
regulates [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]s O 
Ig [C]I [C]g B-protein 
lambda [C]l [C]a [C]m [C]b [C]d [C]a E-protein 
light [C]l [C]i [C]g [C]h [C]t O 
chain [C]c [C]h [C]a [C]i [C]n O 
gene [C]g [C]e [C]n [C]e O 
rearrangement [C]r [C]e [C]a [C]r [C]r [C]a [C]n [C]g [C]e [C]m [C]e [C]n [C]t O 
. [C]. O 

The [C]T [C]h [C]e O 
tissue- [C]t [C]i [C]s [C]s [C]u [C]e [C]- O 
and [C]a [C]n [C]d O 
stage-specific [C]s [C]t [C]a [C]g [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
assembly [C]a [C]s [C]s [C]e [C]m [C]b [C]l [C]y O 
of [C]o [C]f O 
Ig [C]I [C]g B-DNA 
and [C]a [C]n [C]d I-DNA 
TCR [C]T [C]C [C]R I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
is [C]i [C]s O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
common [C]c [C]o [C]m [C]m [C]o [C]n O 
V [C]V B-protein 
( [C]( I-protein 
D [C]D I-protein 
) [C]) I-protein 
J [C]J I-protein 
recombinase [C]r [C]e [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]s [C]e I-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
in [C]i [C]n O 
precursor [C]p [C]r [C]e [C]c [C]u [C]r [C]s [C]o [C]r B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

Directed [C]D [C]i [C]r [C]e [C]c [C]t [C]e [C]d O 
alterations [C]a [C]l [C]t [C]e [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
accessibility [C]a [C]c [C]c [C]e [C]s [C]s [C]i [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
V [C]V B-DNA 
, [C], I-DNA 
D [C]D I-DNA 
, [C], I-DNA 
and [C]a [C]n [C]d I-DNA 
J [C]J I-DNA 
gene [C]g [C]e [C]n [C]e I-DNA 
segments [C]s [C]e [C]g [C]m [C]e [C]n [C]t [C]s E-DNA 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
the [C]t [C]h [C]e O 
recombinase [C]r [C]e [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]s [C]e S-protein 
to [C]t [C]o O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
Ag [C]A [C]g B-DNA 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-DNA 
loci [C]l [C]o [C]c [C]i E-DNA 
. [C]. O 

Accessibility [C]A [C]c [C]c [C]e [C]s [C]s [C]i [C]b [C]i [C]l [C]i [C]t [C]y O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
a [C]a O 
given [C]g [C]i [C]v [C]e [C]n O 
locus [C]l [C]o [C]c [C]u [C]s S-DNA 
is [C]i [C]s O 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
with [C]w [C]i [C]t [C]h O 
cognate [C]c [C]o [C]g [C]n [C]a [C]t [C]e B-DNA 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r I-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
and [C]a [C]n [C]d O 
correlates [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
unrearranged [C]u [C]n [C]r [C]e [C]a [C]r [C]r [C]a [C]n [C]g [C]e [C]d O 
gene [C]g [C]e [C]n [C]e B-DNA 
segments [C]s [C]e [C]g [C]m [C]e [C]n [C]t [C]s E-DNA 
. [C]. O 

As [C]A [C]s O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
our [C]o [C]u [C]r O 
prior [C]p [C]r [C]i [C]o [C]r O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
, [C], O 
rearrangement [C]r [C]e [C]a [C]r [C]r [C]a [C]n [C]g [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Igkappa [C]I [C]g [C]k [C]a [C]p [C]p [C]a B-DNA 
locus [C]l [C]o [C]c [C]u [C]s E-DNA 
is [C]i [C]s O 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
inducible [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
Igkappa [C]I [C]g [C]k [C]a [C]p [C]p [C]a B-DNA 
locus [C]l [C]o [C]c [C]u [C]s E-DNA 
, [C], O 
known [C]k [C]n [C]o [C]w [C]n O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l B-DNA 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l I-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
Iglambda [C]I [C]g [C]l [C]a [C]m [C]b [C]d [C]a B-DNA 
locus [C]l [C]o [C]c [C]u [C]s E-DNA 
lack [C]l [C]a [C]c [C]k O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B B-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
. [C]. O 

Consistent [C]C [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
this [C]t [C]h [C]i [C]s O 
observation [C]o [C]b [C]s [C]e [C]r [C]v [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
assembled [C]a [C]s [C]s [C]e [C]m [C]b [C]l [C]e [C]d O 
Iglambda [C]I [C]g [C]l [C]a [C]m [C]b [C]d [C]a B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
in [C]i [C]n O 
mature [C]m [C]a [C]t [C]u [C]r [C]e B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
be [C]b [C]e O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
. [C]. O 

Nonetheless [C]N [C]o [C]n [C]e [C]t [C]h [C]e [C]l [C]e [C]s [C]s O 
, [C], O 
we [C]w [C]e O 
now [C]n [C]o [C]w O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
repression [C]r [C]e [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
inhibits [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]s O 
germline [C]g [C]e [C]r [C]m [C]l [C]i [C]n [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
recombination [C]r [C]e [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Iglambda [C]I [C]g [C]l [C]a [C]m [C]b [C]d [C]a B-DNA 
gene [C]g [C]e [C]n [C]e I-DNA 
segments [C]s [C]e [C]g [C]m [C]e [C]n [C]t [C]s E-DNA 
in [C]i [C]n O 
precursor [C]p [C]r [C]e [C]c [C]u [C]r [C]s [C]o [C]r B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Molecular [C]M [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
analyses [C]a [C]n [C]a [C]l [C]y [C]s [C]e [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
block [C]b [C]l [C]o [C]c [C]k O 
in [C]i [C]n O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
impairs [C]i [C]m [C]p [C]a [C]i [C]r [C]s O 
Iglambda [C]I [C]g [C]l [C]a [C]m [C]b [C]d [C]a O 
rearrangement [C]r [C]e [C]a [C]r [C]r [C]a [C]n [C]g [C]e [C]m [C]e [C]n [C]t O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
recombinase [C]r [C]e [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]s [C]e S-protein 
accessibility [C]a [C]c [C]c [C]e [C]s [C]s [C]i [C]b [C]i [C]l [C]i [C]t [C]y O 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
the [C]t [C]h [C]e O 
activities [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]i [C]e [C]s O 
of [C]o [C]f O 
known [C]k [C]n [C]o [C]w [C]n O 
Iglambda [C]I [C]g [C]l [C]a [C]m [C]b [C]d [C]a B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
and [C]a [C]n [C]d O 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r B-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
are [C]a [C]r [C]e O 
unaffected [C]u [C]n [C]a [C]f [C]f [C]e [C]c [C]t [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
background [C]b [C]a [C]c [C]k [C]g [C]r [C]o [C]u [C]n [C]d O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
expand [C]e [C]x [C]p [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
range [C]r [C]a [C]n [C]g [C]e O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
action [C]a [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
precursor [C]p [C]r [C]e [C]c [C]u [C]r [C]s [C]o [C]r B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
beyond [C]b [C]e [C]y [C]o [C]n [C]d O 
Igkappa [C]I [C]g [C]k [C]a [C]p [C]p [C]a S-protein 
to [C]t [C]o O 
include [C]i [C]n [C]c [C]l [C]u [C]d [C]e O 
the [C]t [C]h [C]e O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
of [C]o [C]f O 
recombinational [C]r [C]e [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n [C]a [C]l O 
accessibility [C]a [C]c [C]c [C]e [C]s [C]s [C]i [C]b [C]i [C]l [C]i [C]t [C]y O 
at [C]a [C]t O 
both [C]b [C]o [C]t [C]h O 
L [C]L B-DNA 
chain [C]c [C]h [C]a [C]i [C]n I-DNA 
loci [C]l [C]o [C]c [C]i E-DNA 
. [C]. O 

Moreover [C]M [C]o [C]r [C]e [C]o [C]v [C]e [C]r O 
, [C], O 
our [C]o [C]u [C]r O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
strongly [C]s [C]t [C]r [C]o [C]n [C]g [C]l [C]y O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
the [C]t [C]h [C]e O 
existence [C]e [C]x [C]i [C]s [C]t [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
Iglambda [C]I [C]g [C]l [C]a [C]m [C]b [C]d [C]a B-DNA 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y I-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
directly [C]d [C]i [C]r [C]e [C]c [C]t [C]l [C]y O 
or [C]o [C]r O 
indirectly [C]i [C]n [C]d [C]i [C]r [C]e [C]c [C]t [C]l [C]y O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
early [C]e [C]a [C]r [C]l [C]y O 
stages [C]s [C]t [C]a [C]g [C]e [C]s O 
of [C]o [C]f O 
B [C]B O 
cell [C]c [C]e [C]l [C]l O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
. [C]. O 

Transcription [C]T [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
STAT5A [C]S [C]T [C]A [C]T [C]5 [C]A S-protein 
is [C]i [C]s O 
a [C]a O 
substrate [C]s [C]u [C]b [C]s [C]t [C]r [C]a [C]t [C]e O 
of [C]o [C]f O 
Bruton [C]B [C]r [C]u [C]t [C]o [C]n B-protein 
's [C]' [C]s I-protein 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
in [C]i [C]n O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

STAT5A [C]S [C]T [C]A [C]T [C]5 [C]A S-protein 
is [C]i [C]s O 
a [C]a O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
regulator [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r O 
of [C]o [C]f O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
lymphohematopoietic [C]l [C]y [C]m [C]p [C]h [C]o [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
we [C]w [C]e O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
STAT5A [C]S [C]T [C]A [C]T [C]5 [C]A S-protein 
can [C]c [C]a [C]n O 
serve [C]s [C]e [C]r [C]v [C]e O 
as [C]a [C]s O 
a [C]a O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
substrate [C]s [C]u [C]b [C]s [C]t [C]r [C]a [C]t [C]e O 
of [C]o [C]f O 
Bruton [C]B [C]r [C]u [C]t [C]o [C]n B-protein 
's [C]' [C]s I-protein 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
( [C]( O 
BTK [C]B [C]T [C]K S-protein 
) [C]) O 
. [C]. O 

Purified [C]P [C]u [C]r [C]i [C]f [C]i [C]e [C]d B-protein 
recombinant [C]r [C]e [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]n [C]t I-protein 
BTK [C]B [C]T [C]K E-protein 
was [C]w [C]a [C]s O 
capable [C]c [C]a [C]p [C]a [C]b [C]l [C]e O 
of [C]o [C]f O 
directly [C]d [C]i [C]r [C]e [C]c [C]t [C]l [C]y O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d B-protein 
recombinant [C]r [C]e [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]n [C]t I-protein 
STAT5A [C]S [C]T [C]A [C]T [C]5 [C]A E-protein 
with [C]w [C]i [C]t [C]h O 
high [C]h [C]i [C]g [C]h O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
( [C]( O 
K [C]K O 
( [C]( O 
d [C]d O 
) [C]) O 
= [C]= O 
44 [C]4 [C]4 O 
nm [C]n [C]m O 
) [C]) O 
, [C], O 
as [C]a [C]s O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
plasmon [C]p [C]l [C]a [C]s [C]m [C]o [C]n O 
resonance [C]r [C]e [C]s [C]o [C]n [C]a [C]n [C]c [C]e O 
using [C]u [C]s [C]i [C]n [C]g O 
a [C]a O 
BIAcore [C]B [C]I [C]A [C]c [C]o [C]r [C]e O 
biosensor [C]b [C]i [C]o [C]s [C]e [C]n [C]s [C]o [C]r O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
. [C]. O 

BTK [C]B [C]T [C]K S-protein 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
capable [C]c [C]a [C]p [C]a [C]b [C]l [C]e O 
of [C]o [C]f O 
tyrosine-phosphorylating [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e [C]- [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]n [C]g O 
ectopically [C]e [C]c [C]t [C]o [C]p [C]i [C]c [C]a [C]l [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
recombinant [C]r [C]e [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]n [C]t B-protein 
STAT5A [C]S [C]T [C]A [C]T [C]5 [C]A E-protein 
on [C]o [C]n O 
Tyr [C]T [C]y [C]r O 
( [C]( O 
694 [C]6 [C]9 [C]4 O 
) [C]) O 
both [C]b [C]o [C]t [C]h O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
in [C]i [C]n O 
a [C]a O 
Janus [C]J [C]a [C]n [C]u [C]s B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
3 [C]3 E-protein 
-independent [C]- [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
fashion [C]f [C]a [C]s [C]h [C]i [C]o [C]n O 
. [C]. O 

BTK [C]B [C]T [C]K S-protein 
phosphorylated [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
Y665F [C]Y [C]6 [C]6 [C]5 [C]F B-protein 
, [C], I-protein 
Y668F [C]Y [C]6 [C]6 [C]8 [C]F I-protein 
, [C], I-protein 
and [C]a [C]n [C]d I-protein 
Y682F [C]Y [C]6 [C]8 [C]2 [C]F I-protein 
, [C], I-protein 
Y683F [C]Y [C]6 [C]8 [C]3 [C]F I-protein 
mutants [C]m [C]u [C]t [C]a [C]n [C]t [C]s E-protein 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
the [C]t [C]h [C]e O 
Y694F [C]Y [C]6 [C]9 [C]4 [C]F B-protein 
mutant [C]m [C]u [C]t [C]a [C]n [C]t E-protein 
of [C]o [C]f O 
STAT5A [C]S [C]T [C]A [C]T [C]5 [C]A S-protein 
. [C]. O 

STAT5A [C]S [C]T [C]A [C]T [C]5 [C]A O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
Src [C]S [C]r [C]c B-protein 
homology [C]h [C]o [C]m [C]o [C]l [C]o [C]g [C]y I-protein 
2 [C]2 I-protein 
( [C]( I-protein 
SH2 [C]S [C]H [C]2 I-protein 
) [C]) I-protein 
and [C]a [C]n [C]d I-protein 
SH3 [C]S [C]H [C]3 I-protein 
domains [C]d [C]o [C]m [C]a [C]i [C]n [C]s E-protein 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
alter [C]a [C]l [C]t [C]e [C]r O 
the [C]t [C]h [C]e O 
BTK [C]B [C]T [C]K S-protein 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Recombinant [C]R [C]e [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]n [C]t B-protein 
BTK [C]B [C]T [C]K I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
with [C]w [C]i [C]t [C]h O 
mutant [C]m [C]u [C]t [C]a [C]n [C]t O 
pleckstrin [C]p [C]l [C]e [C]c [C]k [C]s [C]t [C]r [C]i [C]n O 
homology [C]h [C]o [C]m [C]o [C]l [C]o [C]g [C]y O 
, [C], O 
SH2 [C]S [C]H [C]2 B-protein 
, [C], I-protein 
or [C]o [C]r I-protein 
SH3 [C]S [C]H [C]3 I-protein 
domains [C]d [C]o [C]m [C]a [C]i [C]n [C]s E-protein 
were [C]w [C]e [C]r [C]e O 
capable [C]c [C]a [C]p [C]a [C]b [C]l [C]e O 
of [C]o [C]f O 
phosphorylating [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]n [C]g O 
STAT5A [C]S [C]T [C]A [C]T [C]5 [C]A S-protein 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
recombinant [C]r [C]e [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]n [C]t B-protein 
BTK [C]B [C]T [C]K I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
with [C]w [C]i [C]t [C]h O 
SH1/kinase [C]S [C]H [C]1 [C]/ [C]k [C]i [C]n [C]a [C]s [C]e O 
domain [C]d [C]o [C]m [C]a [C]i [C]n O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
were [C]w [C]e [C]r [C]e O 
not [C]n [C]o [C]t O 
. [C]. O 

In [C]I [C]n O 
pull-down [C]p [C]u [C]l [C]l [C]- [C]d [C]o [C]w [C]n O 
experiments [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]s O 
, [C], O 
only [C]o [C]n [C]l [C]y O 
full-length [C]f [C]u [C]l [C]l [C]- [C]l [C]e [C]n [C]g [C]t [C]h B-protein 
BTK [C]B [C]T [C]K E-protein 
and [C]a [C]n [C]d O 
its [C]i [C]t [C]s O 
SH1/kinase [C]S [C]H [C]1 [C]/ [C]k [C]i [C]n [C]a [C]s [C]e B-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
( [C]( O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
the [C]t [C]h [C]e O 
pleckstrin [C]p [C]l [C]e [C]c [C]k [C]s [C]t [C]r [C]i [C]n O 
homology [C]h [C]o [C]m [C]o [C]l [C]o [C]g [C]y O 
, [C], O 
SH2 [C]S [C]H [C]2 B-protein 
, [C], I-protein 
or [C]o [C]r I-protein 
SH3 [C]S [C]H [C]3 I-protein 
domains [C]d [C]o [C]m [C]a [C]i [C]n [C]s E-protein 
) [C]) O 
were [C]w [C]e [C]r [C]e O 
capable [C]c [C]a [C]p [C]a [C]b [C]l [C]e O 
of [C]o [C]f O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
STAT5A [C]S [C]T [C]A [C]T [C]5 [C]A S-protein 
. [C]. O 

Ectopically [C]E [C]c [C]t [C]o [C]p [C]i [C]c [C]a [C]l [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
BTK [C]B [C]T [C]K B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
was [C]w [C]a [C]s O 
capable [C]c [C]a [C]p [C]a [C]b [C]l [C]e O 
of [C]o [C]f O 
tyrosine-phosphorylating [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e [C]- [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]n [C]g O 
STAT5A [C]S [C]T [C]A [C]T [C]5 [C]A S-protein 
both [C]b [C]o [C]t [C]h O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
. [C]. O 

BTK [C]B [C]T [C]K S-protein 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
ectopically [C]e [C]c [C]t [C]o [C]p [C]i [C]c [C]a [C]l [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
wild [C]w [C]i [C]l [C]d O 
type [C]t [C]y [C]p [C]e O 
( [C]( O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
Tyr [C]T [C]y [C]r B-protein 
( [C]( I-protein 
694 [C]6 [C]9 [C]4 I-protein 
) [C]) I-protein 
mutant [C]m [C]u [C]t [C]a [C]n [C]t E-protein 
) [C]) O 
STAT5A [C]S [C]T [C]A [C]T [C]5 [C]A S-protein 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
its [C]i [C]t [C]s O 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

In [C]I [C]n O 
BTK [C]B [C]T [C]K S-protein 
-competent [C]- [C]c [C]o [C]m [C]p [C]e [C]t [C]e [C]n [C]t O 
chicken [C]c [C]h [C]i [C]c [C]k [C]e [C]n O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
anti-IgM-stimulated [C]a [C]n [C]t [C]i [C]- [C]I [C]g [C]M [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
STAT5 [C]S [C]T [C]A [C]T [C]5 B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
was [C]w [C]a [C]s O 
prevented [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]e [C]d O 
by [C]b [C]y O 
pretreatment [C]p [C]r [C]e [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
BTK [C]B [C]T [C]K S-protein 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
LFM-A13 [C]L [C]F [C]M [C]- [C]A [C]1 [C]3 O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
by [C]b [C]y O 
pretreatment [C]p [C]r [C]e [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
JAK3 [C]J [C]A [C]K [C]3 O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
HI-P131 [C]H [C]I [C]- [C]P [C]1 [C]3 [C]1 O 
. [C]. O 

B [C]B O 
cell [C]c [C]e [C]l [C]l O 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
ligation [C]l [C]i [C]g [C]a [C]t [C]i [C]o [C]n O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
STAT5 [C]S [C]T [C]A [C]T [C]5 S-protein 
in [C]i [C]n O 
BTK [C]B [C]T [C]K S-protein 
-deficient [C]- [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
chicken [C]c [C]h [C]i [C]c [C]k [C]e [C]n O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
reconstituted [C]r [C]e [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
wild [C]w [C]i [C]l [C]d B-protein 
type [C]t [C]y [C]p [C]e I-protein 
human [C]h [C]u [C]m [C]a [C]n I-protein 
BTK [C]B [C]T [C]K E-protein 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
in [C]i [C]n O 
BTK [C]B [C]T [C]K S-protein 
-deficient [C]- [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
chicken [C]c [C]h [C]i [C]c [C]k [C]e [C]n O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
reconstituted [C]r [C]e [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
kinase-inactive [C]k [C]i [C]n [C]a [C]s [C]e [C]- [C]i [C]n [C]a [C]c [C]t [C]i [C]v [C]e B-protein 
mutant [C]m [C]u [C]t [C]a [C]n [C]t I-protein 
BTK [C]B [C]T [C]K E-protein 
. [C]. O 

Similarly [C]S [C]i [C]m [C]i [C]l [C]a [C]r [C]l [C]y O 
, [C], O 
anti-IgM [C]a [C]n [C]t [C]i [C]- [C]I [C]g [C]M O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
STAT5A [C]S [C]T [C]A [C]T [C]5 [C]A S-protein 
in [C]i [C]n O 
BTK [C]B [C]T [C]K S-protein 
-competent [C]- [C]c [C]o [C]m [C]p [C]e [C]t [C]e [C]n [C]t O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
wild [C]w [C]i [C]l [C]d O 
type [C]t [C]y [C]p [C]e O 
mice [C]m [C]i [C]c [C]e O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
in [C]i [C]n O 
BTK [C]B [C]T [C]K S-protein 
-deficient [C]- [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
XID [C]X [C]I [C]D O 
mice [C]m [C]i [C]c [C]e O 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
to [C]t [C]o O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
XID [C]X [C]I [C]D O 
mice [C]m [C]i [C]c [C]e O 
, [C], O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
JAK3 [C]J [C]A [C]K [C]3 O 
knockout [C]k [C]n [C]o [C]c [C]k [C]o [C]u [C]t O 
mice [C]m [C]i [C]c [C]e O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
a [C]a O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
STAT5A [C]S [C]T [C]A [C]T [C]5 [C]A O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
anti-IgM [C]a [C]n [C]t [C]i [C]- [C]I [C]g [C]M O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
provide [C]p [C]r [C]o [C]v [C]i [C]d [C]e O 
unprecedented [C]u [C]n [C]p [C]r [C]e [C]c [C]e [C]d [C]e [C]n [C]t [C]e [C]d O 
experimental [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]a [C]l O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
that [C]t [C]h [C]a [C]t O 
BTK [C]B [C]T [C]K S-protein 
plays [C]p [C]l [C]a [C]y [C]s O 
a [C]a O 
nonredundant [C]n [C]o [C]n [C]r [C]e [C]d [C]u [C]n [C]d [C]a [C]n [C]t O 
and [C]a [C]n [C]d O 
pivotal [C]p [C]i [C]v [C]o [C]t [C]a [C]l O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
B [C]B O 
cell [C]c [C]e [C]l [C]l O 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n O 
receptor-mediated [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
STAT5A [C]S [C]T [C]A [C]T [C]5 [C]A O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 

Role [C]R [C]o [C]l [C]e O 
of [C]o [C]f O 
T-bet [C]T [C]- [C]b [C]e [C]t S-protein 
in [C]i [C]n O 
commitment [C]c [C]o [C]m [C]m [C]i [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
TH1 [C]T [C]H [C]1 B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
before [C]b [C]e [C]f [C]o [C]r [C]e O 
IL-12 [C]I [C]L [C]- [C]1 [C]2 S-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
selection [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

How [C]H [C]o [C]w O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
helper [C]h [C]e [C]l [C]p [C]e [C]r B-cell_type 
T [C]T I-cell_type 
( [C]( I-cell_type 
TH [C]T [C]H I-cell_type 
) [C]) I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
is [C]i [C]s O 
controversial [C]c [C]o [C]n [C]t [C]r [C]o [C]v [C]e [C]r [C]s [C]i [C]a [C]l O 
. [C]. O 

We [C]W [C]e O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
T-bet [C]T [C]- [C]b [C]e [C]t S-protein 
, [C], O 
without [C]w [C]i [C]t [C]h [C]o [C]u [C]t O 
apparent [C]a [C]p [C]p [C]a [C]r [C]e [C]n [C]t O 
assistance [C]a [C]s [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
from [C]f [C]r [C]o [C]m O 
interleukin [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n B-protein 
12 [C]1 [C]2 I-protein 
( [C]( I-protein 
IL-12 [C]I [C]L [C]- [C]1 [C]2 I-protein 
) [C]) E-protein 
/ [C]/ O 
STAT4 [C]S [C]T [C]A [C]T [C]4 S-protein 
, [C], O 
specifies [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]e [C]s O 
TH1 [C]T [C]H [C]1 S-cell_type 
effector [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r O 
fate [C]f [C]a [C]t [C]e O 
by [C]b [C]y O 
targeting [C]t [C]a [C]r [C]g [C]e [C]t [C]i [C]n [C]g O 
chromatin [C]c [C]h [C]r [C]o [C]m [C]a [C]t [C]i [C]n O 
remodeling [C]r [C]e [C]m [C]o [C]d [C]e [C]l [C]i [C]n [C]g O 
to [C]t [C]o O 
individual [C]i [C]n [C]d [C]i [C]v [C]i [C]d [C]u [C]a [C]l O 
interferon-gamma [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n [C]- [C]g [C]a [C]m [C]m [C]a B-DNA 
( [C]( I-DNA 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a I-DNA 
) [C]) I-DNA 
alleles [C]a [C]l [C]l [C]e [C]l [C]e [C]s E-DNA 
and [C]a [C]n [C]d O 
by [C]b [C]y O 
inducing [C]i [C]n [C]d [C]u [C]c [C]i [C]n [C]g O 
IL-12 [C]I [C]L [C]- [C]1 [C]2 B-DNA 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-DNA 
beta2 [C]b [C]e [C]t [C]a [C]2 E-DNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Subsequently [C]S [C]u [C]b [C]s [C]e [C]q [C]u [C]e [C]n [C]t [C]l [C]y O 
, [C], O 
it [C]i [C]t O 
appears [C]a [C]p [C]p [C]e [C]a [C]r [C]s O 
that [C]t [C]h [C]a [C]t O 
IL-12 [C]I [C]L [C]- [C]1 [C]2 S-protein 
/ [C]/ O 
STAT4 [C]S [C]T [C]A [C]T [C]4 S-protein 
serves [C]s [C]e [C]r [C]v [C]e [C]s O 
two [C]t [C]w [C]o O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
functions [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
TH1 [C]T [C]H [C]1 B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
: [C]: O 
as [C]a [C]s O 
growth [C]g [C]r [C]o [C]w [C]t [C]h B-protein 
signal [C]s [C]i [C]g [C]n [C]a [C]l E-protein 
, [C], O 
inducing [C]i [C]n [C]d [C]u [C]c [C]i [C]n [C]g O 
survival [C]s [C]u [C]r [C]v [C]i [C]v [C]a [C]l O 
and [C]a [C]n [C]d O 
cell [C]c [C]e [C]l [C]l O 
division [C]d [C]i [C]v [C]i [C]s [C]i [C]o [C]n O 
; [C]; O 
and [C]a [C]n [C]d O 
as [C]a [C]s O 
trans-activator [C]t [C]r [C]a [C]n [C]s [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r S-protein 
, [C], O 
prolonging [C]p [C]r [C]o [C]l [C]o [C]n [C]g [C]i [C]n [C]g O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
a [C]a O 
genetic [C]g [C]e [C]n [C]e [C]t [C]i [C]c O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
coactivator [C]c [C]o [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r S-protein 
, [C], O 
CREB-binding [C]C [C]R [C]E [C]B [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
a [C]a O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e S-protein 
does [C]d [C]o [C]e [C]s O 
not [C]n [C]o [C]t O 
simply [C]s [C]i [C]m [C]p [C]l [C]y O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
TH [C]T [C]H O 
fate [C]f [C]a [C]t [C]e O 
choice [C]c [C]h [C]o [C]i [C]c [C]e O 
but [C]b [C]u [C]t O 
instead [C]i [C]n [C]s [C]t [C]e [C]a [C]d O 
may [C]m [C]a [C]y O 
act [C]a [C]c [C]t O 
as [C]a [C]s O 
an [C]a [C]n O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
secondary [C]s [C]e [C]c [C]o [C]n [C]d [C]a [C]r [C]y O 
stimulus [C]s [C]t [C]i [C]m [C]u [C]l [C]u [C]s O 
that [C]t [C]h [C]a [C]t O 
mediates [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]s O 
selective [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e O 
survival [C]s [C]u [C]r [C]v [C]i [C]v [C]a [C]l O 
of [C]o [C]f O 
a [C]a O 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e O 
. [C]. O 

Stat6 [C]S [C]t [C]a [C]t [C]6 S-protein 
is [C]i [C]s O 
necessary [C]n [C]e [C]c [C]e [C]s [C]s [C]a [C]r [C]y O 
and [C]a [C]n [C]d O 
sufficient [C]s [C]u [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
for [C]f [C]o [C]r O 
IL-4 [C]I [C]L [C]- [C]4 O 
's [C]' [C]s O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
Th2 [C]T [C]h [C]2 O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
cell [C]c [C]e [C]l [C]l O 
expansion [C]e [C]x [C]p [C]a [C]n [C]s [C]i [C]o [C]n O 
. [C]. O 

IL-4 [C]I [C]L [C]- [C]4 S-protein 
plays [C]p [C]l [C]a [C]y [C]s O 
a [C]a O 
critical [C]c [C]r [C]i [C]t [C]i [C]c [C]a [C]l O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
T [C]T O 
CR-stimulated [C]C [C]R [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_type 
naive [C]n [C]a [C]i [C]v [C]e I-cell_type 
CD4 [C]C [C]D [C]4 I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
Th2 [C]T [C]h [C]2 O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
. [C]. O 

In [C]I [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
, [C], O 
the [C]t [C]h [C]e O 
IL-4R [C]I [C]L [C]- [C]4 [C]R S-protein 
activates [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]s O 
a [C]a O 
set [C]s [C]e [C]t O 
of [C]o [C]f O 
phosphotyrosine [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e B-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
domain-containing [C]d [C]o [C]m [C]a [C]i [C]n [C]- [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
insulin [C]i [C]n [C]s [C]u [C]l [C]i [C]n B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
substrate [C]s [C]u [C]b [C]s [C]t [C]r [C]a [C]t [C]e I-protein 
1/2 [C]1 [C]/ [C]2 E-protein 
, [C], O 
Shc [C]S [C]h [C]c S-protein 
, [C], O 
and [C]a [C]n [C]d O 
IL-4R [C]I [C]L [C]- [C]4 [C]R B-protein 
interacting [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
, [C], O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
Stat6 [C]S [C]t [C]a [C]t [C]6 S-protein 
. [C]. O 

Stat6 [C]S [C]t [C]a [C]t [C]6 S-protein 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
be [C]b [C]e O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
Th2 [C]T [C]h [C]2 O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

To [C]T [C]o O 
determine [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e O 
the [C]t [C]h [C]e O 
roles [C]r [C]o [C]l [C]e [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
phosphotyrosine [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e B-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
adaptors [C]a [C]d [C]a [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
Th2 [C]T [C]h [C]2 O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
we [C]w [C]e O 
prepared [C]p [C]r [C]e [C]p [C]a [C]r [C]e [C]d O 
a [C]a O 
retrovirus [C]r [C]e [C]t [C]r [C]o [C]v [C]i [C]r [C]u [C]s O 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
a [C]a O 
mutant [C]m [C]u [C]t [C]a [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-protein 
( [C]( I-protein 
h [C]h I-protein 
) [C]) I-protein 
IL-4R [C]I [C]L [C]- [C]4 [C]R I-protein 
alpha-chain [C]a [C]l [C]p [C]h [C]a [C]- [C]c [C]h [C]a [C]i [C]n E-protein 
, [C], O 
Y497F [C]Y [C]4 [C]9 [C]7 [C]F S-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
unable [C]u [C]n [C]a [C]b [C]l [C]e O 
to [C]t [C]o O 
recruit [C]r [C]e [C]c [C]r [C]u [C]i [C]t O 
these [C]t [C]h [C]e [C]s [C]e O 
adaptors [C]a [C]d [C]a [C]p [C]t [C]o [C]r [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
mutant [C]m [C]u [C]t [C]a [C]n [C]t B-protein 
hIL-4Ralpha [C]h [C]I [C]L [C]- [C]4 [C]R [C]a [C]l [C]p [C]h [C]a E-protein 
, [C], O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
the [C]t [C]h [C]e O 
wild-type [C]w [C]i [C]l [C]d [C]- [C]t [C]y [C]p [C]e B-protein 
( [C]( I-protein 
WT [C]W [C]T I-protein 
) [C]) I-protein 
hIL-4Ralpha [C]h [C]I [C]L [C]- [C]4 [C]R [C]a [C]l [C]p [C]h [C]a E-protein 
, [C], O 
was [C]w [C]a [C]s O 
introduced [C]i [C]n [C]t [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
into [C]i [C]n [C]t [C]o O 
naive [C]n [C]a [C]i [C]v [C]e B-cell_type 
CD4 [C]C [C]D [C]4 I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Upon [C]U [C]p [C]o [C]n O 
hIL-4 [C]h [C]I [C]L [C]- [C]4 O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
Y497F [C]Y [C]4 [C]9 [C]7 [C]F S-protein 
worked [C]w [C]o [C]r [C]k [C]e [C]d O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
the [C]t [C]h [C]e O 
WT [C]W [C]T B-protein 
hIL-4Ralpha [C]h [C]I [C]L [C]- [C]4 [C]R [C]a [C]l [C]p [C]h [C]a E-protein 
in [C]i [C]n O 
driving [C]d [C]r [C]i [C]v [C]i [C]n [C]g O 
Th2 [C]T [C]h [C]2 O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
as [C]a [C]s O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
by [C]b [C]y O 
Gata3 [C]G [C]a [C]t [C]a [C]3 O 
up-regulation [C]u [C]p [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
IL-4 [C]I [C]L [C]- [C]4 O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
IL-4-driven [C]I [C]L [C]- [C]4 [C]- [C]d [C]r [C]i [C]v [C]e [C]n O 
cell [C]c [C]e [C]l [C]l O 
expansion [C]e [C]x [C]p [C]a [C]n [C]s [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
infected [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
Y497F [C]Y [C]4 [C]9 [C]7 [C]F S-protein 
, [C], O 
although [C]a [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
cells [C]c [C]e [C]l [C]l [C]s O 
infected [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
Y497F [C]Y [C]4 [C]9 [C]7 [C]F S-protein 
were [C]w [C]e [C]r [C]e O 
not [C]n [C]o [C]t O 
capable [C]c [C]a [C]p [C]a [C]b [C]l [C]e O 
of [C]o [C]f O 
phosphorylating [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]n [C]g O 
insulin [C]i [C]n [C]s [C]u [C]l [C]i [C]n B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
substrate [C]s [C]u [C]b [C]s [C]t [C]r [C]a [C]t [C]e I-protein 
2 [C]2 E-protein 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
Y497 [C]Y [C]4 [C]9 [C]7 S-protein 
is [C]i [C]s O 
dispensable [C]d [C]i [C]s [C]p [C]e [C]n [C]s [C]a [C]b [C]l [C]e O 
for [C]f [C]o [C]r O 
both [C]b [C]o [C]t [C]h O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
-driven [C]- [C]d [C]r [C]i [C]v [C]e [C]n O 
Th2 [C]T [C]h [C]2 O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
cell [C]c [C]e [C]l [C]l O 
expansion [C]e [C]x [C]p [C]a [C]n [C]s [C]i [C]o [C]n O 
. [C]. O 

Both [C]B [C]o [C]t [C]h O 
WT [C]W [C]T B-protein 
and [C]a [C]n [C]d I-protein 
Y497F [C]Y [C]4 [C]9 [C]7 [C]F I-protein 
hIL-4Ralpha [C]h [C]I [C]L [C]- [C]4 [C]R [C]a [C]l [C]p [C]h [C]a E-protein 
lose [C]l [C]o [C]s [C]e O 
the [C]t [C]h [C]e O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
to [C]t [C]o O 
drive [C]d [C]r [C]i [C]v [C]e O 
Th2 [C]T [C]h [C]2 O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
cell [C]c [C]e [C]l [C]l O 
expansion [C]e [C]x [C]p [C]a [C]n [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
Stat6-knockout [C]S [C]t [C]a [C]t [C]6 [C]- [C]k [C]n [C]o [C]c [C]k [C]o [C]u [C]t B-cell_type 
CD4 [C]C [C]D [C]4 I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

A [C]A O 
constitutively [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
form [C]f [C]o [C]r [C]m O 
of [C]o [C]f O 
Stat6 [C]S [C]t [C]a [C]t [C]6 S-protein 
introduced [C]i [C]n [C]t [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
into [C]i [C]n [C]t [C]o O 
CD4 [C]C [C]D [C]4 B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
Th2 [C]T [C]h [C]2 O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
cell [C]c [C]e [C]l [C]l O 
expansion [C]e [C]x [C]p [C]a [C]n [C]s [C]i [C]o [C]n O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-protein 
Stat6 [C]S [C]t [C]a [C]t [C]6 E-protein 
is [C]i [C]s O 
necessary [C]n [C]e [C]c [C]e [C]s [C]s [C]a [C]r [C]y O 
and [C]a [C]n [C]d O 
sufficient [C]s [C]u [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
to [C]t [C]o O 
mediate [C]m [C]e [C]d [C]i [C]a [C]t [C]e O 
both [C]b [C]o [C]t [C]h O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
-driven [C]- [C]d [C]r [C]i [C]v [C]e [C]n O 
Th2 [C]T [C]h [C]2 O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
cell [C]c [C]e [C]l [C]l O 
expansion [C]e [C]x [C]p [C]a [C]n [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
CD4 [C]C [C]D [C]4 B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 B-protein 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
on [C]o [C]n O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
genes [C]g [C]e [C]n [C]e [C]s O 
: [C]: O 
derepression [C]d [C]e [C]r [C]e [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
by [C]b [C]y O 
Tat [C]T [C]a [C]t S-protein 
. [C]. O 

In [C]I [C]n O 
HIV-infected [C]H [C]I [C]V [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
individuals [C]i [C]n [C]d [C]i [C]v [C]i [C]d [C]u [C]a [C]l [C]s O 
dysregulation [C]d [C]y [C]s [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
is [C]i [C]s O 
characterized [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]d O 
by [C]b [C]y O 
severe [C]s [C]e [C]v [C]e [C]r [C]e O 
disorders [C]d [C]i [C]s [C]o [C]r [C]d [C]e [C]r [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
network [C]n [C]e [C]t [C]w [C]o [C]r [C]k O 
. [C]. O 

Increase [C]I [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
secretion [C]s [C]e [C]c [C]r [C]e [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
, [C], O 
the [C]t [C]h [C]e O 
major [C]m [C]a [C]j [C]o [C]r O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
and [C]a [C]n [C]d O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e S-protein 
, [C], O 
may [C]m [C]a [C]y O 
play [C]p [C]l [C]a [C]y O 
a [C]a O 
decisive [C]d [C]e [C]c [C]i [C]s [C]i [C]v [C]e O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
sensitization [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
for [C]f [C]o [C]r O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
indirect [C]i [C]n [C]d [C]i [C]r [C]e [C]c [C]t O 
death [C]d [C]e [C]a [C]t [C]h O 
of [C]o [C]f O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
augmented [C]a [C]u [C]g [C]m [C]e [C]n [C]t [C]e [C]d O 
virus [C]v [C]i [C]r [C]u [C]s O 
replication [C]r [C]e [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

We [C]W [C]e O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
cause [C]c [C]a [C]u [C]s [C]e O 
of [C]o [C]f O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
IL-2 [C]I [C]L [C]- [C]2 O 
secretion [C]s [C]e [C]c [C]r [C]e [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
HIV [C]H [C]I [C]V B-protein 
Tat [C]T [C]a [C]t E-protein 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
this [C]t [C]h [C]i [C]s O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
. [C]. O 

We [C]W [C]e O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
IL-2 [C]I [C]L [C]- [C]2 O 
secretion [C]s [C]e [C]c [C]r [C]e [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
due [C]d [C]u [C]e O 
to [C]t [C]o O 
Tat [C]T [C]a [C]t S-protein 
-enhanced [C]- [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Tat [C]T [C]a [C]t S-protein 
derepresses [C]d [C]e [C]r [C]e [C]p [C]r [C]e [C]s [C]s [C]e [C]s O 
and [C]a [C]n [C]d O 
activates [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]s O 
the [C]t [C]h [C]e O 
distal [C]d [C]i [C]s [C]t [C]a [C]l B-DNA 
AP-1 [C]A [C]P [C]- [C]1 I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
( [C]( O 
position [C]p [C]o [C]s [C]i [C]t [C]i [C]o [C]n B-DNA 
-185 [C]- [C]1 [C]8 [C]5 I-DNA 
to [C]t [C]o I-DNA 
-177 [C]- [C]1 [C]7 [C]7 E-DNA 
) [C]) O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

In [C]I [C]n O 
nonstimulated [C]n [C]o [C]n [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
a [C]a O 
repressor [C]r [C]e [C]p [C]r [C]e [C]s [C]s [C]o [C]r O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
NF-IL6 [C]N [C]F [C]- [C]I [C]L [C]6 S-protein 
, [C], O 
JunB [C]J [C]u [C]n [C]B S-protein 
, [C], O 
c-Fos [C]c [C]- [C]F [C]o [C]s S-protein 
and [C]a [C]n [C]d O 
Fra-1 [C]F [C]r [C]a [C]- [C]1 S-protein 
is [C]i [C]s O 
formed [C]f [C]o [C]r [C]m [C]e [C]d O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
AP-1 [C]A [C]P [C]- [C]1 B-DNA 
( [C]( I-DNA 
IL-2/d [C]I [C]L [C]- [C]2 [C]/ [C]d I-DNA 
) [C]) I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
and [C]a [C]n [C]d O 
represses [C]r [C]e [C]p [C]r [C]e [C]s [C]s [C]e [C]s O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

After [C]A [C]f [C]t [C]e [C]r O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
a [C]a O 
heterodimeric [C]h [C]e [C]t [C]e [C]r [C]o [C]d [C]i [C]m [C]e [C]r [C]i [C]c B-protein 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r E-protein 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
p65 [C]p [C]6 [C]5 S-protein 
and [C]a [C]n [C]d O 
c-Jun [C]c [C]- [C]J [C]u [C]n S-protein 
binds [C]b [C]i [C]n [C]d [C]s O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
AP-1 [C]A [C]P [C]- [C]1 B-DNA 
( [C]( I-DNA 
IL-2/d [C]I [C]L [C]- [C]2 [C]/ [C]d I-DNA 
) [C]) I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
. [C]. O 

HIV [C]H [C]I [C]V B-protein 
Tat [C]T [C]a [C]t E-protein 
enhances [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]s O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
and [C]a [C]n [C]d O 
consequently [C]c [C]o [C]n [C]s [C]e [C]q [C]u [C]e [C]n [C]t [C]l [C]y O 
, [C], O 
activates [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]s O 
the [C]t [C]h [C]e O 
AP-1 [C]A [C]P [C]- [C]1 B-DNA 
( [C]( I-DNA 
IL-2/d [C]I [C]L [C]- [C]2 [C]/ [C]d I-DNA 
) [C]) I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
. [C]. O 

Our [C]O [C]u [C]r O 
data [C]d [C]a [C]t [C]a O 
provide [C]p [C]r [C]o [C]v [C]i [C]d [C]e O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
for [C]f [C]o [C]r O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
by [C]b [C]y O 
which [C]w [C]h [C]i [C]c [C]h O 
HIV [C]H [C]I [C]V B-protein 
Tat [C]T [C]a [C]t E-protein 
dysregulates [C]d [C]y [C]s [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]s O 
IL-2 [C]I [C]L [C]- [C]2 O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
therefore [C]t [C]h [C]e [C]r [C]e [C]f [C]o [C]r [C]e O 
may [C]m [C]a [C]y O 
contribute [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
a [C]a O 
way [C]w [C]a [C]y O 
yet [C]y [C]e [C]t O 
to [C]t [C]o O 
be [C]b [C]e O 
clarified [C]c [C]l [C]a [C]r [C]i [C]f [C]i [C]e [C]d O 
. [C]. O 

Transforming [C]T [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]i [C]n [C]g B-protein 
growth [C]g [C]r [C]o [C]w [C]t [C]h I-protein 
factor-beta1 [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]b [C]e [C]t [C]a [C]1 E-protein 
interferes [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
thrombopoietin-induced [C]t [C]h [C]r [C]o [C]m [C]b [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]n [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
megakaryoblastic [C]m [C]e [C]g [C]a [C]k [C]a [C]r [C]y [C]o [C]b [C]l [C]a [C]s [C]t [C]i [C]c B-cell_type 
and [C]a [C]n [C]d I-cell_type 
erythroleukemic [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

OBJECTIVE [C]O [C]B [C]J [C]E [C]C [C]T [C]I [C]V [C]E O 
: [C]: O 
Thrombopoietin [C]T [C]h [C]r [C]o [C]m [C]b [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]n S-protein 
( [C]( O 
TPO [C]T [C]P [C]O S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
transforming [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]i [C]n [C]g B-protein 
growth [C]g [C]r [C]o [C]w [C]t [C]h I-protein 
factor-beta [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]b [C]e [C]t [C]a I-protein 
( [C]( I-protein 
1 [C]1 I-protein 
) [C]) E-protein 
( [C]( O 
TGF-beta [C]T [C]G [C]F [C]- [C]b [C]e [C]t [C]a B-protein 
( [C]( I-protein 
1 [C]1 I-protein 
) [C]) E-protein 
) [C]) O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
exert [C]e [C]x [C]e [C]r [C]t O 
opposite [C]o [C]p [C]p [C]o [C]s [C]i [C]t [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
on [C]o [C]n O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
megakaryocytic [C]m [C]e [C]g [C]a [C]k [C]a [C]r [C]y [C]o [C]c [C]y [C]t [C]i [C]c O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
hematopoietic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

To [C]T [C]o O 
determine [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
TGF-beta [C]T [C]G [C]F [C]- [C]b [C]e [C]t [C]a B-protein 
( [C]( I-protein 
1 [C]1 I-protein 
) [C]) E-protein 
interferes [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]e [C]s O 
directly [C]d [C]i [C]r [C]e [C]c [C]t [C]l [C]y O 
with [C]w [C]i [C]t [C]h O 
TPO [C]T [C]P [C]O S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
hematopoietic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
we [C]w [C]e O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
the [C]t [C]h [C]e O 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
TPO [C]T [C]P [C]O S-protein 
-responsive [C]- [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e O 
cell [C]c [C]e [C]l [C]l O 
lines [C]l [C]i [C]n [C]e [C]s O 
Mo-7e [C]M [C]o [C]- [C]7 [C]e O 
and [C]a [C]n [C]d O 
HEL [C]H [C]E [C]L O 
. [C]. O 

MATERIALS [C]M [C]A [C]T [C]E [C]R [C]I [C]A [C]L [C]S O 
AND [C]A [C]N [C]D O 
METHODS [C]M [C]E [C]T [C]H [C]O [C]D [C]S O 
: [C]: O 
The [C]T [C]h [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
were [C]w [C]e [C]r [C]e O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
100 [C]1 [C]0 [C]0 O 
ng/mL [C]n [C]g [C]/ [C]m [C]L O 
TPO [C]T [C]P [C]O S-protein 
and/or [C]a [C]n [C]d [C]/ [C]o [C]r O 
100 [C]1 [C]0 [C]0 O 
ng/mL [C]n [C]g [C]/ [C]m [C]L O 
TGF-beta1 [C]T [C]G [C]F [C]- [C]b [C]e [C]t [C]a [C]1 S-protein 
and [C]a [C]n [C]d O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
for [C]f [C]o [C]r O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
( [C]( O 
3H [C]3 [C]H O 
thymidine [C]t [C]h [C]y [C]m [C]i [C]d [C]i [C]n [C]e O 
incorporation [C]i [C]n [C]c [C]o [C]r [C]p [C]o [C]r [C]a [C]t [C]i [C]o [C]n O 
) [C]) O 
, [C], O 
viability [C]v [C]i [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
( [C]( O 
trypan [C]t [C]r [C]y [C]p [C]a [C]n O 
blue [C]b [C]l [C]u [C]e O 
exclusion [C]e [C]x [C]c [C]l [C]u [C]s [C]i [C]o [C]n O 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
( [C]( O 
Western [C]W [C]e [C]s [C]t [C]e [C]r [C]n O 
blot [C]b [C]l [C]o [C]t O 
) [C]) O 
. [C]. O 

RESULTS [C]R [C]E [C]S [C]U [C]L [C]T [C]S O 
: [C]: O 
TPO [C]T [C]P [C]O S-protein 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
the [C]t [C]h [C]e O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Mo-7e [C]M [C]o [C]- [C]7 [C]e B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
as [C]a [C]s O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
3H-thymidine [C]3 [C]H [C]- [C]t [C]h [C]y [C]m [C]i [C]d [C]i [C]n [C]e O 
incorporation [C]i [C]n [C]c [C]o [C]r [C]p [C]o [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
TGF-beta1 [C]T [C]G [C]F [C]- [C]b [C]e [C]t [C]a [C]1 S-protein 
suppressed [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
baseline [C]b [C]a [C]s [C]e [C]l [C]i [C]n [C]e O 
cell [C]c [C]e [C]l [C]l O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
and [C]a [C]n [C]d O 
antagonized [C]a [C]n [C]t [C]a [C]g [C]o [C]n [C]i [C]z [C]e [C]d O 
the [C]t [C]h [C]e O 
proliferative [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
TPO [C]T [C]P [C]O S-protein 
. [C]. O 

TPO [C]T [C]P [C]O S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
also [C]a [C]l [C]s [C]o O 
was [C]w [C]a [C]s O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
mitogen-activated [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
( [C]( O 
MAPK [C]M [C]A [C]P [C]K S-protein 
) [C]) O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
( [C]( O 
PD098059 [C]P [C]D [C]0 [C]9 [C]8 [C]0 [C]5 [C]9 O 
) [C]) O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
inhibits [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]s O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
MAPK [C]M [C]A [C]P [C]K B-protein 
extracellular [C]e [C]x [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r I-protein 
signal-regulated [C]s [C]i [C]g [C]n [C]a [C]l [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d I-protein 
kinases [C]k [C]i [C]n [C]a [C]s [C]e [C]s E-protein 
( [C]( O 
ERK [C]E [C]R [C]K S-protein 
) [C]) O 
ERK1 [C]E [C]R [C]K [C]1 S-protein 
and [C]a [C]n [C]d O 
ERK2 [C]E [C]R [C]K [C]2 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
AG490 [C]A [C]G [C]4 [C]9 [C]0 O 
, [C], O 
an [C]a [C]n O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
of [C]o [C]f O 
Janus [C]J [C]a [C]n [C]u [C]s B-protein 
kinase-2 [C]k [C]i [C]n [C]a [C]s [C]e [C]- [C]2 E-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
completely [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e [C]l [C]y O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
TPO [C]T [C]P [C]O S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

As [C]A [C]s O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
Western [C]W [C]e [C]s [C]t [C]e [C]r [C]n O 
blotting [C]b [C]l [C]o [C]t [C]t [C]i [C]n [C]g O 
, [C], O 
TGF-beta1 [C]T [C]G [C]F [C]- [C]b [C]e [C]t [C]a [C]1 S-protein 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
the [C]t [C]h [C]e O 
TPO [C]T [C]P [C]O S-protein 
-stimulated [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
ERK1 [C]E [C]R [C]K [C]1 S-protein 
/ [C]/ O 
ERK2 [C]E [C]R [C]K [C]2 S-protein 
and [C]a [C]n [C]d O 
STAT5 [C]S [C]T [C]A [C]T [C]5 O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
Mo-7e [C]M [C]o [C]- [C]7 [C]e B-cell_line 
and [C]a [C]n [C]d I-cell_line 
HEL [C]H [C]E [C]L I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
was [C]w [C]a [C]s O 
completely [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e [C]l [C]y O 
reversed [C]r [C]e [C]v [C]e [C]r [C]s [C]e [C]d O 
by [C]b [C]y O 
preincubation [C]p [C]r [C]e [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
phosphatase [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]a [C]s [C]e O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
( [C]( O 
Na3VO4 [C]N [C]a [C]3 [C]V [C]O [C]4 O 
) [C]) O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
suggests [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]s O 
that [C]t [C]h [C]a [C]t O 
TGF-beta1 [C]T [C]G [C]F [C]- [C]b [C]e [C]t [C]a [C]1 S-protein 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
a [C]a O 
phosphatase [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]a [C]s [C]e S-protein 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
STAT3 [C]S [C]T [C]A [C]T [C]3 S-protein 
also [C]a [C]l [C]s [C]o O 
was [C]w [C]a [C]s O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
TPO [C]T [C]P [C]O S-protein 
, [C], O 
STAT3 [C]S [C]T [C]A [C]T [C]3 S-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
remained [C]r [C]e [C]m [C]a [C]i [C]n [C]e [C]d O 
unaltered [C]u [C]n [C]a [C]l [C]t [C]e [C]r [C]e [C]d O 
by [C]b [C]y O 
TGF-beta1 [C]T [C]G [C]F [C]- [C]b [C]e [C]t [C]a [C]1 S-protein 
. [C]. O 

CONCLUSION [C]C [C]O [C]N [C]C [C]L [C]U [C]S [C]I [C]O [C]N O 
: [C]: O 
Taken [C]T [C]a [C]k [C]e [C]n O 
together [C]t [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
, [C], O 
these [C]t [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
TGF-beta1 [C]T [C]G [C]F [C]- [C]b [C]e [C]t [C]a [C]1 S-protein 
modulates [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]e [C]s O 
TPO [C]T [C]P [C]O S-protein 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
on [C]o [C]n O 
megakaryocytic [C]m [C]e [C]g [C]a [C]k [C]a [C]r [C]y [C]o [C]c [C]y [C]t [C]i [C]c O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
interfering [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]i [C]n [C]g O 
with [C]w [C]i [C]t [C]h O 
TPO [C]T [C]P [C]O S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
, [C], O 
particularly [C]p [C]a [C]r [C]t [C]i [C]c [C]u [C]l [C]a [C]r [C]l [C]y O 
by [C]b [C]y O 
reducing [C]r [C]e [C]d [C]u [C]c [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
activities [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]i [C]e [C]s O 
of [C]o [C]f O 
MAPK [C]M [C]A [C]P [C]K B-protein 
ERK1/ERK2 [C]E [C]R [C]K [C]1 [C]/ [C]E [C]R [C]K [C]2 I-protein 
and [C]a [C]n [C]d I-protein 
STAT5 [C]S [C]T [C]A [C]T [C]5 E-protein 
. [C]. O 

Invariant [C]I [C]n [C]v [C]a [C]r [C]i [C]a [C]n [C]t B-protein 
chain [C]c [C]h [C]a [C]i [C]n E-protein 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
B [C]B O 
cell [C]c [C]e [C]l [C]l O 
maturation [C]m [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
activating [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]n [C]g O 
a [C]a O 
TAF [C]T [C]A [C]F B-protein 
( [C]( I-protein 
II [C]I [C]I I-protein 
) [C]) I-protein 
105-NF-kappaB [C]1 [C]0 [C]5 [C]- [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
program [C]p [C]r [C]o [C]g [C]r [C]a [C]m O 
. [C]. O 

Early [C]E [C]a [C]r [C]l [C]y O 
stages [C]s [C]t [C]a [C]g [C]e [C]s O 
of [C]o [C]f O 
B [C]B O 
cell [C]c [C]e [C]l [C]l O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
occur [C]o [C]c [C]c [C]u [C]r O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
bone [C]b [C]o [C]n [C]e O 
marrow [C]m [C]a [C]r [C]r [C]o [C]w O 
, [C], O 
resulting [C]r [C]e [C]s [C]u [C]l [C]t [C]i [C]n [C]g O 
in [C]i [C]n O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
immature [C]i [C]m [C]m [C]a [C]t [C]u [C]r [C]e B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

From [C]F [C]r [C]o [C]m O 
there [C]t [C]h [C]e [C]r [C]e O 
these [C]t [C]h [C]e [C]s [C]e O 
immature [C]i [C]m [C]m [C]a [C]t [C]u [C]r [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
migrate [C]m [C]i [C]g [C]r [C]a [C]t [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
spleen [C]s [C]p [C]l [C]e [C]e [C]n O 
where [C]w [C]h [C]e [C]r [C]e O 
they [C]t [C]h [C]e [C]y O 
differentiate [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]e O 
to [C]t [C]o O 
mature [C]m [C]a [C]t [C]u [C]r [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
final [C]f [C]i [C]n [C]a [C]l O 
maturation [C]m [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
step [C]s [C]t [C]e [C]p O 
is [C]i [C]s O 
crucial [C]c [C]r [C]u [C]c [C]i [C]a [C]l O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
to [C]t [C]o O 
become [C]b [C]e [C]c [C]o [C]m [C]e O 
responsive [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e O 
to [C]t [C]o O 
antigens [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]s S-protein 
and [C]a [C]n [C]d O 
to [C]t [C]o O 
participate [C]p [C]a [C]r [C]t [C]i [C]c [C]i [C]p [C]a [C]t [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
. [C]. O 

Recently [C]R [C]e [C]c [C]e [C]n [C]t [C]l [C]y O 
, [C], O 
invariant [C]i [C]n [C]v [C]a [C]r [C]i [C]a [C]n [C]t B-protein 
chain [C]c [C]h [C]a [C]i [C]n E-protein 
( [C]( O 
Ii [C]I [C]i S-protein 
) [C]) O 
, [C], O 
a [C]a O 
major [C]m [C]a [C]j [C]o [C]r B-protein 
histocompatibility [C]h [C]i [C]s [C]t [C]o [C]c [C]o [C]m [C]p [C]a [C]t [C]i [C]b [C]i [C]l [C]i [C]t [C]y I-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x I-protein 
class [C]c [C]l [C]a [C]s [C]s I-protein 
II [C]I [C]I I-protein 
chaperone [C]c [C]h [C]a [C]p [C]e [C]r [C]o [C]n [C]e E-protein 
, [C], O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
c-Rel [C]c [C]- [C]R [C]e [C]l S-protein 
and [C]a [C]n [C]d O 
p65/RelA [C]p [C]6 [C]5 [C]/ [C]R [C]e [C]l [C]A S-protein 
, [C], O 
were [C]w [C]e [C]r [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
play [C]p [C]l [C]a [C]y O 
a [C]a O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
final [C]f [C]i [C]n [C]a [C]l O 
antigen-independent [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]- [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
stage [C]s [C]t [C]a [C]g [C]e O 
of [C]o [C]f O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
spleen [C]s [C]p [C]l [C]e [C]e [C]n O 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
, [C], O 
we [C]w [C]e O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
a [C]a O 
possible [C]p [C]o [C]s [C]s [C]i [C]b [C]l [C]e O 
link [C]l [C]i [C]n [C]k O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
Ii [C]I [C]i S-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
B [C]B O 
cell [C]c [C]e [C]l [C]l O 
maturation [C]m [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
. [C]. O 

Our [C]O [C]u [C]r O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
Ii [C]I [C]i S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
B [C]B O 
cell [C]c [C]e [C]l [C]l O 
maturation [C]m [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
involves [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]s O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B B-protein 
p65/RelA [C]p [C]6 [C]5 [C]/ [C]R [C]e [C]l [C]A I-protein 
homodimer [C]h [C]o [C]m [C]o [C]d [C]i [C]m [C]e [C]r E-protein 
and [C]a [C]n [C]d O 
requires [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]s O 
the [C]t [C]h [C]e O 
B [C]B B-protein 
cell-enriched [C]c [C]e [C]l [C]l [C]- [C]e [C]n [C]r [C]i [C]c [C]h [C]e [C]d I-protein 
coactivator [C]c [C]o [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r E-protein 
TBP-associated [C]T [C]B [C]P [C]- [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
( [C]( I-protein 
II [C]I [C]I I-protein 
) [C]) I-protein 
105 [C]1 [C]0 [C]5 E-protein 
. [C]. O 

Androgens [C]A [C]n [C]d [C]r [C]o [C]g [C]e [C]n [C]s O 
indirectly [C]i [C]n [C]d [C]i [C]r [C]e [C]c [C]t [C]l [C]y O 
accelerate [C]a [C]c [C]c [C]e [C]l [C]e [C]r [C]a [C]t [C]e O 
thymocyte [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e S-cell_type 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
. [C]. O 

Apoptotic [C]A [C]p [C]o [C]p [C]t [C]o [C]t [C]i [C]c O 
processes [C]p [C]r [C]o [C]c [C]e [C]s [C]s [C]e [C]s O 
, [C], O 
or [C]o [C]r O 
the [C]t [C]h [C]e O 
disturbance [C]d [C]i [C]s [C]t [C]u [C]r [C]b [C]a [C]n [C]c [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
natural [C]n [C]a [C]t [C]u [C]r [C]a [C]l O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
processes [C]p [C]r [C]o [C]c [C]e [C]s [C]s [C]e [C]s O 
, [C], O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
pathogenesis [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
autoimmune [C]a [C]u [C]t [C]o [C]i [C]m [C]m [C]u [C]n [C]e O 
diseases [C]d [C]i [C]s [C]e [C]a [C]s [C]e [C]s O 
( [C]( O 
AID [C]A [C]I [C]D O 
) [C]) O 
. [C]. O 

Women [C]W [C]o [C]m [C]e [C]n O 
are [C]a [C]r [C]e O 
, [C], O 
in [C]i [C]n O 
general [C]g [C]e [C]n [C]e [C]r [C]a [C]l O 
, [C], O 
more [C]m [C]o [C]r [C]e O 
susceptible [C]s [C]u [C]s [C]c [C]e [C]p [C]t [C]i [C]b [C]l [C]e O 
than [C]t [C]h [C]a [C]n O 
men [C]m [C]e [C]n O 
to [C]t [C]o O 
develop [C]d [C]e [C]v [C]e [C]l [C]o [C]p O 
AID [C]A [C]I [C]D O 
like [C]l [C]i [C]k [C]e O 
rheumatoid [C]r [C]h [C]e [C]u [C]m [C]a [C]t [C]o [C]i [C]d O 
arthritis [C]a [C]r [C]t [C]h [C]r [C]i [C]t [C]i [C]s O 
. [C]. O 

Androgens [C]A [C]n [C]d [C]r [C]o [C]g [C]e [C]n [C]s O 
and [C]a [C]n [C]d O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
, [C], O 
in [C]i [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
to [C]t [C]o O 
oestrogens [C]o [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n [C]s O 
, [C], O 
have [C]h [C]a [C]v [C]e O 
favourable [C]f [C]a [C]v [C]o [C]u [C]r [C]a [C]b [C]l [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
in [C]i [C]n O 
AID [C]A [C]I [C]D O 
models [C]m [C]o [C]d [C]e [C]l [C]s O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n O 
AID [C]A [C]I [C]D O 
. [C]. O 

It [C]I [C]t O 
is [C]i [C]s O 
known [C]k [C]n [C]o [C]w [C]n O 
that [C]t [C]h [C]a [C]t O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
( [C]( O 
GC [C]G [C]C O 
) [C]) O 
, [C], O 
used [C]u [C]s [C]e [C]d O 
for [C]f [C]o [C]r O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
AID [C]A [C]I [C]D O 
, [C], O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
thymus [C]t [C]h [C]y [C]m [C]u [C]s O 
resulting [C]r [C]e [C]s [C]u [C]l [C]t [C]i [C]n [C]g O 
in [C]i [C]n O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
numbers [C]n [C]u [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
CD4+ [C]C [C]D [C]4 [C]+ B-cell_type 
CD8+ [C]C [C]D [C]8 [C]+ I-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

It [C]I [C]t O 
was [C]w [C]a [C]s O 
asked [C]a [C]s [C]k [C]e [C]d O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
androgens [C]a [C]n [C]d [C]r [C]o [C]g [C]e [C]n [C]s O 
, [C], O 
in [C]i [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
to [C]t [C]o O 
oestrogens [C]o [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n [C]s O 
, [C], O 
exert [C]e [C]x [C]e [C]r [C]t O 
their [C]t [C]h [C]e [C]i [C]r O 
favourable [C]f [C]a [C]v [C]o [C]u [C]r [C]a [C]b [C]l [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
AID [C]A [C]I [C]D O 
by [C]b [C]y O 
a [C]a O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
comparable [C]c [C]o [C]m [C]p [C]a [C]r [C]a [C]b [C]l [C]e O 
to [C]t [C]o O 
that [C]t [C]h [C]a [C]t O 
described [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
for [C]f [C]o [C]r O 
GC [C]G [C]C O 
by [C]b [C]y O 
eliminating [C]e [C]l [C]i [C]m [C]i [C]n [C]a [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
prone [C]p [C]r [C]o [C]n [C]e O 
CD4+ [C]C [C]D [C]4 [C]+ B-cell_type 
CD8+ [C]C [C]D [C]8 [C]+ I-cell_type 
population [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n E-cell_type 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
thymus [C]t [C]h [C]y [C]m [C]u [C]s O 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
both [C]b [C]o [C]t [C]h O 
androgens [C]a [C]n [C]d [C]r [C]o [C]g [C]e [C]n [C]s O 
and [C]a [C]n [C]d O 
oestrogens [C]o [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n [C]s O 
proved [C]p [C]r [C]o [C]v [C]e [C]d O 
thymolytic [C]t [C]h [C]y [C]m [C]o [C]l [C]y [C]t [C]i [C]c O 
, [C], O 
a [C]a O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
percentage [C]p [C]e [C]r [C]c [C]e [C]n [C]t [C]a [C]g [C]e O 
of [C]o [C]f O 
CD4+ [C]C [C]D [C]4 [C]+ B-cell_type 
CD8+ [C]C [C]D [C]8 [C]+ I-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
by [C]b [C]y O 
flow [C]f [C]l [C]o [C]w O 
cytometry [C]c [C]y [C]t [C]o [C]m [C]e [C]t [C]r [C]y O 
after [C]a [C]f [C]t [C]e [C]r O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
mice [C]m [C]i [C]c [C]e O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
androgen [C]a [C]n [C]d [C]r [C]o [C]g [C]e [C]n O 
methyltestosterone [C]m [C]e [C]t [C]h [C]y [C]l [C]t [C]e [C]s [C]t [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
oestrogen [C]o [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n O 
ethinylestradiol [C]e [C]t [C]h [C]i [C]n [C]y [C]l [C]e [C]s [C]t [C]r [C]a [C]d [C]i [C]o [C]l O 
. [C]. O 

To [C]T [C]o O 
investigate [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
the [C]t [C]h [C]e O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
thymolytic [C]t [C]h [C]y [C]m [C]o [C]l [C]y [C]t [C]i [C]c O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
were [C]w [C]e [C]r [C]e O 
due [C]d [C]u [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
on [C]o [C]n O 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
, [C], O 
cells [C]c [C]e [C]l [C]l [C]s O 
were [C]w [C]e [C]r [C]e O 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
thymus [C]t [C]h [C]y [C]m [C]u [C]s O 
and [C]a [C]n [C]d O 
incubated [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
androgens [C]a [C]n [C]d [C]r [C]o [C]g [C]e [C]n [C]s O 
or [C]o [C]r O 
oestrogens [C]o [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n [C]s O 
to [C]t [C]o O 
measure [C]m [C]e [C]a [C]s [C]u [C]r [C]e O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
. [C]. O 

Several [C]S [C]e [C]v [C]e [C]r [C]a [C]l O 
techniques [C]t [C]e [C]c [C]h [C]n [C]i [C]q [C]u [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
used [C]u [C]s [C]e [C]d O 
to [C]t [C]o O 
determine [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e O 
thymocyte [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e S-cell_type 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
, [C], O 
but [C]b [C]u [C]t O 
no [C]n [C]o O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
apoptotic [C]a [C]p [C]o [C]p [C]t [C]o [C]t [C]i [C]c O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
. [C]. O 

Using [C]U [C]s [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
very [C]v [C]e [C]r [C]y O 
sensitive [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
TUNEL [C]T [C]U [C]N [C]E [C]L O 
assay [C]a [C]s [C]s [C]a [C]y O 
, [C], O 
no [C]n [C]o O 
direct [C]d [C]i [C]r [C]e [C]c [C]t O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
androgens [C]a [C]n [C]d [C]r [C]o [C]g [C]e [C]n [C]s O 
on [C]o [C]n O 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
is [C]i [C]s O 
in [C]i [C]n O 
sharp [C]s [C]h [C]a [C]r [C]p O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
high [C]h [C]i [C]g [C]h O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
GC [C]G [C]C O 
. [C]. O 

Therefore [C]T [C]h [C]e [C]r [C]e [C]f [C]o [C]r [C]e O 
, [C], O 
upon [C]u [C]p [C]o [C]n O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
androgen [C]a [C]n [C]d [C]r [C]o [C]g [C]e [C]n O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
, [C], O 
other [C]o [C]t [C]h [C]e [C]r O 
cells [C]c [C]e [C]l [C]l [C]s O 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
androgen [C]a [C]n [C]d [C]r [C]o [C]g [C]e [C]n B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
than [C]t [C]h [C]a [C]n O 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
are [C]a [C]r [C]e O 
probably [C]p [C]r [C]o [C]b [C]a [C]b [C]l [C]y O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
inducing [C]i [C]n [C]d [C]u [C]c [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
thymic [C]t [C]h [C]y [C]m [C]i [C]c O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
. [C]. O 

To [C]T [C]o O 
study [C]s [C]t [C]u [C]d [C]y O 
the [C]t [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
androgen [C]a [C]n [C]d [C]r [C]o [C]g [C]e [C]n B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
on [C]o [C]n O 
thymocyte [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e S-cell_type 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
, [C], O 
androgen [C]a [C]n [C]d [C]r [C]o [C]g [C]e [C]n B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
mutant [C]m [C]u [C]t [C]a [C]n [C]t O 
( [C]( O 
Tfm/Y [C]T [C]f [C]m [C]/ [C]Y O 
) [C]) O 
mice [C]m [C]i [C]c [C]e O 
were [C]w [C]e [C]r [C]e O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
androgens [C]a [C]n [C]d [C]r [C]o [C]g [C]e [C]n [C]s O 
. [C]. O 

No [C]N [C]o O 
alterations [C]a [C]l [C]t [C]e [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
thymocyte [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e B-cell_type 
subpopulations [C]s [C]u [C]b [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
seen [C]s [C]e [C]e [C]n O 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
percentage [C]p [C]e [C]r [C]c [C]e [C]n [C]t [C]a [C]g [C]e O 
of [C]o [C]f O 
CD4+ [C]C [C]D [C]4 [C]+ B-cell_type 
CD8+ [C]C [C]D [C]8 [C]+ I-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
after [C]a [C]f [C]t [C]e [C]r O 
administration [C]a [C]d [C]m [C]i [C]n [C]i [C]s [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
androgens [C]a [C]n [C]d [C]r [C]o [C]g [C]e [C]n [C]s O 
depend [C]d [C]e [C]p [C]e [C]n [C]d O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
androgen [C]a [C]n [C]d [C]r [C]o [C]g [C]e [C]n B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
it [C]i [C]t O 
is [C]i [C]s O 
concluded [C]c [C]o [C]n [C]c [C]l [C]u [C]d [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
androgens [C]a [C]n [C]d [C]r [C]o [C]g [C]e [C]n [C]s O 
indirectly [C]i [C]n [C]d [C]i [C]r [C]e [C]c [C]t [C]l [C]y O 
accelerate [C]a [C]c [C]c [C]e [C]l [C]e [C]r [C]a [C]t [C]e O 
thymocyte [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e S-cell_type 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
. [C]. O 

Inhibition [C]I [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
and [C]a [C]n [C]d O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
in [C]i [C]n O 
CD4 [C]C [C]D [C]4 B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
by [C]b [C]y O 
peroxisome [C]p [C]e [C]r [C]o [C]x [C]i [C]s [C]o [C]m [C]e B-protein 
proliferator-activated [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]o [C]r [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
gamma [C]g [C]a [C]m [C]m [C]a I-protein 
ligands [C]l [C]i [C]g [C]a [C]n [C]d [C]s E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
peroxisome [C]p [C]e [C]r [C]o [C]x [C]i [C]s [C]o [C]m [C]e B-protein 
proliferator-activated [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]o [C]r [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
gamma [C]g [C]a [C]m [C]m [C]a E-protein 
( [C]( O 
PPARgamma [C]P [C]P [C]A [C]R [C]g [C]a [C]m [C]m [C]a S-protein 
) [C]) O 
, [C], O 
a [C]a O 
member [C]m [C]e [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
superfamily [C]s [C]u [C]p [C]e [C]r [C]f [C]a [C]m [C]i [C]l [C]y E-protein 
, [C], O 
is [C]i [C]s O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
for [C]f [C]o [C]r O 
adipocyte [C]a [C]d [C]i [C]p [C]o [C]c [C]y [C]t [C]e O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
homeostasis [C]h [C]o [C]m [C]e [C]o [C]s [C]t [C]a [C]s [C]i [C]s O 
. [C]. O 

PPARgamma [C]P [C]P [C]A [C]R [C]g [C]a [C]m [C]m [C]a S-protein 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
found [C]f [C]o [C]u [C]n [C]d O 
recently [C]r [C]e [C]c [C]e [C]n [C]t [C]l [C]y O 
to [C]t [C]o O 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
mitogens [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]s S-protein 
and [C]a [C]n [C]d O 
inflammation [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Our [C]O [C]u [C]r O 
study [C]s [C]t [C]u [C]d [C]y O 
shows [C]s [C]h [C]o [C]w [C]s O 
PPARgamma [C]P [C]P [C]A [C]R [C]g [C]a [C]m [C]m [C]a S-protein 
to [C]t [C]o O 
be [C]b [C]e O 
preferentially [C]p [C]r [C]e [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
nuclei [C]n [C]u [C]c [C]l [C]e [C]i O 
of [C]o [C]f O 
resting [C]r [C]e [C]s [C]t [C]i [C]n [C]g B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
to [C]t [C]o O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
upon [C]u [C]p [C]o [C]n O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
by [C]b [C]y O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
anti-CD3 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]3 S-protein 
and [C]a [C]n [C]d O 
anti-CD28 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]2 [C]8 S-protein 
or [C]o [C]r O 
phorbol [C]p [C]h [C]o [C]r [C]b [C]o [C]l O 
myristyl [C]m [C]y [C]r [C]i [C]s [C]t [C]y [C]l O 
acetate [C]a [C]c [C]e [C]t [C]a [C]t [C]e O 
( [C]( O 
PMA [C]P [C]M [C]A O 
) [C]) O 
. [C]. O 

We [C]W [C]e O 
also [C]a [C]l [C]s [C]o O 
found [C]f [C]o [C]u [C]n [C]d O 
the [C]t [C]h [C]e O 
PPARgamma [C]P [C]P [C]A [C]R [C]g [C]a [C]m [C]m [C]a B-protein 
ligand [C]l [C]i [C]g [C]a [C]n [C]d E-protein 
ciglitizone [C]c [C]i [C]g [C]l [C]i [C]t [C]i [C]z [C]o [C]n [C]e O 
to [C]t [C]o O 
attenuate [C]a [C]t [C]t [C]e [C]n [C]u [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
by [C]b [C]y O 
inhibiting [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]n [C]g O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
anti-CD3 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]3 S-protein 
and [C]a [C]n [C]d O 
anti-CD28 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]2 [C]8 S-protein 
or [C]o [C]r O 
PMA-induced [C]P [C]M [C]A [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
proliferative [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
. [C]. O 

Inhibition [C]I [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
the [C]t [C]h [C]e O 
proliferative [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
and [C]a [C]n [C]d O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
CD4 [C]C [C]D [C]4 B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
was [C]w [C]a [C]s O 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
suppression [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
AP1 [C]A [C]P [C]1 S-protein 
and [C]a [C]n [C]d O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
. [C]. O 

PPARgamma [C]P [C]P [C]A [C]R [C]g [C]a [C]m [C]m [C]a B-protein 
ligands [C]l [C]i [C]g [C]a [C]n [C]d [C]s E-protein 
also [C]a [C]l [C]s [C]o O 
strongly [C]s [C]t [C]r [C]o [C]n [C]g [C]l [C]y O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
SEA-induced [C]S [C]E [C]A [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
Vbeta3 [C]V [C]b [C]e [C]t [C]a [C]3 O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
, [C], O 
together [C]t [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
with [C]w [C]i [C]t [C]h O 
previous [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
PPARgamma [C]P [C]P [C]A [C]R [C]g [C]a [C]m [C]m [C]a B-protein 
ligands [C]l [C]i [C]g [C]a [C]n [C]d [C]s E-protein 
on [C]o [C]n O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-cell_type 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s E-cell_type 
, [C], O 
provide [C]p [C]r [C]o [C]v [C]i [C]d [C]e O 
clear [C]c [C]l [C]e [C]a [C]r O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
for [C]f [C]o [C]r O 
PPARgamma [C]P [C]P [C]A [C]R [C]g [C]a [C]m [C]m [C]a S-protein 
as [C]a [C]s O 
a [C]a O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e B-protein 
regulator [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r E-protein 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e S-cell_type 
and [C]a [C]n [C]d O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

PPARgamma [C]P [C]P [C]A [C]R [C]g [C]a [C]m [C]m [C]a S-protein 
may [C]m [C]a [C]y O 
thus [C]t [C]h [C]u [C]s O 
be [C]b [C]e O 
a [C]a O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
therapeutic [C]t [C]h [C]e [C]r [C]a [C]p [C]e [C]u [C]t [C]i [C]c O 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
autoimmunity [C]a [C]u [C]t [C]o [C]i [C]m [C]m [C]u [C]n [C]i [C]t [C]y O 
. [C]. O 

A [C]A O 
prominent [C]p [C]r [C]o [C]m [C]i [C]n [C]e [C]n [C]t O 
role [C]r [C]o [C]l [C]e O 
for [C]f [C]o [C]r O 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r B-protein 
protein-1 [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]1 E-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
2B4 [C]2 [C]B [C]4 I-DNA 
( [C]( I-DNA 
CD244 [C]C [C]D [C]2 [C]4 [C]4 I-DNA 
) [C]) I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
in [C]i [C]n O 
NK [C]N [C]K B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
cell [C]c [C]e [C]l [C]l B-protein 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e I-protein 
glycoprotein [C]g [C]l [C]y [C]c [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
2B4 [C]2 [C]B [C]4 E-protein 
( [C]( O 
CD244 [C]C [C]D [C]2 [C]4 [C]4 S-protein 
) [C]) O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Ig [C]I [C]g B-protein 
superfamily [C]s [C]u [C]p [C]e [C]r [C]f [C]a [C]m [C]i [C]l [C]y E-protein 
is [C]i [C]s O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NK [C]N [C]K S-cell_type 
and [C]a [C]n [C]d O 
T [C]T B-cell_type 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e E-cell_type 
functions [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
recently [C]r [C]e [C]c [C]e [C]n [C]t [C]l [C]y O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
CD48 [C]C [C]D [C]4 [C]8 S-protein 
as [C]a [C]s O 
the [C]t [C]h [C]e O 
high [C]h [C]i [C]g [C]h B-protein 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y I-protein 
counterreceptor [C]c [C]o [C]u [C]n [C]t [C]e [C]r [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
for [C]f [C]o [C]r O 
2B4 [C]2 [C]B [C]4 S-protein 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
mice [C]m [C]i [C]c [C]e O 
and [C]a [C]n [C]d O 
humans [C]h [C]u [C]m [C]a [C]n [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c B-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
of [C]o [C]f O 
2B4 [C]2 [C]B [C]4 S-protein 
associates [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
src [C]s [C]r [C]c B-protein 
homology [C]h [C]o [C]m [C]o [C]l [C]o [C]g [C]y I-protein 
2 [C]2 I-protein 
domain-containing [C]d [C]o [C]m [C]a [C]i [C]n [C]- [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
or [C]o [C]r O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g B-protein 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e I-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n I-protein 
molecule-associated [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]- [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
, [C], O 
whose [C]w [C]h [C]o [C]s [C]e O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
the [C]t [C]h [C]e O 
underlying [C]u [C]n [C]d [C]e [C]r [C]l [C]y [C]i [C]n [C]g O 
genetic [C]g [C]e [C]n [C]e [C]t [C]i [C]c O 
defect [C]d [C]e [C]f [C]e [C]c [C]t O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
X-linked [C]X [C]- [C]l [C]i [C]n [C]k [C]e [C]d O 
lymphoproliferative [C]l [C]y [C]m [C]p [C]h [C]o [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
syndrome [C]s [C]y [C]n [C]d [C]r [C]o [C]m [C]e O 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
, [C], O 
we [C]w [C]e O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
the [C]t [C]h [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
cloning [C]c [C]l [C]o [C]n [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
characterization [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
2B4 [C]2 [C]B [C]4 I-DNA 
( [C]( I-DNA 
h2B4 [C]h [C]2 [C]B [C]4 I-DNA 
) [C]) I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

Through [C]T [C]h [C]r [C]o [C]u [C]g [C]h O 
primer [C]p [C]r [C]i [C]m [C]e [C]r O 
extension [C]e [C]x [C]t [C]e [C]n [C]s [C]i [C]o [C]n O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
, [C], O 
we [C]w [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
h2B4 [C]h [C]2 [C]B [C]4 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
initiates [C]i [C]n [C]i [C]t [C]i [C]a [C]t [C]e [C]s O 
at [C]a [C]t O 
multiple [C]m [C]u [C]l [C]t [C]i [C]p [C]l [C]e O 
start [C]s [C]t [C]a [C]r [C]t O 
sites [C]s [C]i [C]t [C]e [C]s O 
. [C]. O 

We [C]W [C]e O 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d O 
h2B4 [C]h [C]2 [C]B [C]4 B-DNA 
genomic [C]g [C]e [C]n [C]o [C]m [C]i [C]c I-DNA 
clones [C]c [C]l [C]o [C]n [C]e [C]s E-DNA 
and [C]a [C]n [C]d O 
PCR [C]P [C]C [C]R O 
amplified [C]a [C]m [C]p [C]l [C]i [C]f [C]i [C]e [C]d O 
the [C]t [C]h [C]e O 
5 [C]5 B-DNA 
' [C]' I-DNA 
untranslated [C]u [C]n [C]t [C]r [C]a [C]n [C]s [C]l [C]a [C]t [C]e [C]d I-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r B-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
a [C]a O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
AP-1 [C]A [C]P [C]- [C]1 B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
that [C]t [C]h [C]a [C]t O 
lies [C]l [C]i [C]e [C]s O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
( [C]( O 
-106 [C]- [C]1 [C]0 [C]6 O 
to [C]t [C]o O 
-100 [C]- [C]1 [C]0 [C]0 O 
) [C]) O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
transient [C]t [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t O 
transfection [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
in [C]i [C]n O 
YT [C]Y [C]T B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
, [C], O 
a [C]a O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
NK [C]N [C]K I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
. [C]. O 

EMSAs [C]E [C]M [C]S [C]A [C]s O 
with [C]w [C]i [C]t [C]h O 
Abs [C]A [C]b [C]s S-protein 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
for [C]f [C]o [C]r O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
AP-1 [C]A [C]P [C]- [C]1 B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y E-protein 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
multiple [C]m [C]u [C]l [C]t [C]i [C]p [C]l [C]e O 
members [C]m [C]e [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Jun [C]J [C]u [C]n B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y E-protein 
are [C]a [C]r [C]e O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
h2B4 [C]h [C]2 [C]B [C]4 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
. [C]. O 

Mutation [C]M [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
AP-1 [C]A [C]P [C]- [C]1 B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
not [C]n [C]o [C]t O 
only [C]o [C]n [C]l [C]y O 
abolishes [C]a [C]b [C]o [C]l [C]i [C]s [C]h [C]e [C]s O 
protein/DNA [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]/ [C]D [C]N [C]A O 
interactions [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
but [C]b [C]u [C]t O 
also [C]a [C]l [C]s [C]o O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
a [C]a O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
role [C]r [C]o [C]l [C]e O 
for [C]f [C]o [C]r O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
h2B4 [C]h [C]2 [C]B [C]4 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
. [C]. O 

Functional [C]F [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
correction [C]c [C]o [C]r [C]r [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
FA-C [C]F [C]A [C]- [C]C B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
with [C]w [C]i [C]t [C]h O 
FANCC [C]F [C]A [C]N [C]C [C]C S-protein 
suppresses [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]e [C]s O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
interferon [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n B-DNA 
gamma-inducible [C]g [C]a [C]m [C]m [C]a [C]- [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
. [C]. O 

Because [C]B [C]e [C]c [C]a [C]u [C]s [C]e O 
hematopoietic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
derived [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
Fanconi [C]F [C]a [C]n [C]c [C]o [C]n [C]i O 
anemia [C]a [C]n [C]e [C]m [C]i [C]a O 
( [C]( O 
FA [C]F [C]A O 
) [C]) O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
C-complementation [C]C [C]- [C]c [C]o [C]m [C]p [C]l [C]e [C]m [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
group [C]g [C]r [C]o [C]u [C]p O 
( [C]( O 
FA-C [C]F [C]A [C]- [C]C O 
) [C]) O 
are [C]a [C]r [C]e O 
hypersensitive [C]h [C]y [C]p [C]e [C]r [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
interferon [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n B-protein 
gamma [C]g [C]a [C]m [C]m [C]a E-protein 
( [C]( O 
IFNgamma [C]I [C]F [C]N [C]g [C]a [C]m [C]m [C]a S-protein 
) [C]) O 
, [C], O 
the [C]t [C]h [C]e O 
products [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]s O 
of [C]o [C]f O 
certain [C]c [C]e [C]r [C]t [C]a [C]i [C]n O 
IFNgamma-inducible [C]I [C]F [C]N [C]g [C]a [C]m [C]m [C]a [C]- [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
known [C]k [C]n [C]o [C]w [C]n O 
to [C]t [C]o O 
influence [C]i [C]n [C]f [C]l [C]u [C]e [C]n [C]c [C]e O 
hematopoietic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c O 
cell [C]c [C]e [C]l [C]l O 
survival [C]s [C]u [C]r [C]v [C]i [C]v [C]a [C]l O 
were [C]w [C]e [C]r [C]e O 
quantified [C]q [C]u [C]a [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
. [C]. O 

High [C]H [C]i [C]g [C]h O 
constitutive [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IFNgamma-inducible [C]I [C]F [C]N [C]g [C]a [C]m [C]m [C]a [C]- [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
, [C], O 
IFN-stimulated [C]I [C]F [C]N [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-protein 
gene [C]g [C]e [C]n [C]e I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
3 [C]3 I-protein 
gamma [C]g [C]a [C]m [C]m [C]a I-protein 
subunit [C]s [C]u [C]b [C]u [C]n [C]i [C]t E-protein 
( [C]( O 
ISGF3gamma [C]I [C]S [C]G [C]F [C]3 [C]g [C]a [C]m [C]m [C]a S-protein 
) [C]) O 
, [C], O 
IFN [C]I [C]F [C]N B-protein 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y I-protein 
factor-1 [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]1 E-protein 
( [C]( O 
IRF-1 [C]I [C]R [C]F [C]- [C]1 S-protein 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
cyclin-dependent [C]c [C]y [C]c [C]l [C]i [C]n [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r I-protein 
p21 [C]p [C]2 [C]1 E-protein 
( [C]( O 
WAF1 [C]W [C]A [C]F [C]1 S-protein 
) [C]) O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
FANCC [C]F [C]A [C]N [C]C [C]C S-protein 
mutant [C]m [C]u [C]t [C]a [C]n [C]t O 
B [C]B B-cell_type 
lymphoblasts [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]s E-cell_type 
, [C], O 
low-density [C]l [C]o [C]w [C]- [C]d [C]e [C]n [C]s [C]i [C]t [C]y B-cell_type 
bone [C]b [C]o [C]n [C]e I-cell_type 
marrow [C]m [C]a [C]r [C]r [C]o [C]w I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
and [C]a [C]n [C]d O 
murine [C]m [C]u [C]r [C]i [C]n [C]e B-cell_type 
embryonic [C]e [C]m [C]b [C]r [C]y [C]o [C]n [C]i [C]c I-cell_type 
fibroblasts [C]f [C]i [C]b [C]r [C]o [C]b [C]l [C]a [C]s [C]t [C]s E-cell_type 
. [C]. O 

Paradoxically [C]P [C]a [C]r [C]a [C]d [C]o [C]x [C]i [C]c [C]a [C]l [C]l [C]y O 
, [C], O 
these [C]t [C]h [C]e [C]s [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
do [C]d [C]o O 
not [C]n [C]o [C]t O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e B-protein 
signal [C]s [C]i [C]g [C]n [C]a [C]l I-protein 
transducer [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]e [C]r I-protein 
and [C]a [C]n [C]d I-protein 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r I-protein 
of [C]o [C]f I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
( [C]( I-protein 
STAT [C]S [C]T [C]A [C]T I-protein 
) [C]) I-protein 
1 [C]1 E-protein 
properly [C]p [C]r [C]o [C]p [C]e [C]r [C]l [C]y O 
. [C]. O 

In [C]I [C]n O 
an [C]a [C]n O 
attempt [C]a [C]t [C]t [C]e [C]m [C]p [C]t O 
to [C]t [C]o O 
clarify [C]c [C]l [C]a [C]r [C]i [C]f [C]y O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
by [C]b [C]y O 
which [C]w [C]h [C]i [C]c [C]h O 
FA-C [C]F [C]A [C]- [C]C B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
overexpress [C]o [C]v [C]e [C]r [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
IFNgamma-inducible [C]I [C]F [C]N [C]g [C]a [C]m [C]m [C]a [C]- [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
face [C]f [C]a [C]c [C]e O 
of [C]o [C]f O 
defective [C]d [C]e [C]f [C]e [C]c [C]t [C]i [C]v [C]e O 
STAT1 [C]S [C]T [C]A [C]T [C]1 O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
it [C]i [C]t O 
was [C]w [C]a [C]s O 
reasoned [C]r [C]e [C]a [C]s [C]o [C]n [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-protein 
STAT1 [C]S [C]T [C]A [C]T [C]1 E-protein 
might [C]m [C]i [C]g [C]h [C]t O 
result [C]r [C]e [C]s [C]u [C]l [C]t O 
in [C]i [C]n O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
hematopoietic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c B-protein 
IFNgamma-responsive [C]I [C]F [C]N [C]g [C]a [C]m [C]m [C]a [C]- [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
that [C]t [C]h [C]a [C]t O 
normally [C]n [C]o [C]r [C]m [C]a [C]l [C]l [C]y O 
modulates [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]e [C]s O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
other [C]o [C]t [C]h [C]e [C]r O 
IFNgamma-responsive [C]I [C]F [C]N [C]g [C]a [C]m [C]m [C]a [C]- [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
. [C]. O 

Levels [C]L [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IFNgamma [C]I [C]F [C]N [C]g [C]a [C]m [C]m [C]a S-protein 
-inducible [C]- [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
IFN [C]I [C]F [C]N B-protein 
consensus [C]c [C]o [C]n [C]s [C]e [C]n [C]s [C]u [C]s I-protein 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
( [C]( O 
ICSBP [C]I [C]C [C]S [C]B [C]P S-protein 
) [C]) O 
, [C], O 
a [C]a O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e B-protein 
trans-acting [C]t [C]r [C]a [C]n [C]s [C]- [C]a [C]c [C]t [C]i [C]n [C]g I-protein 
regulator [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r E-protein 
of [C]o [C]f O 
some [C]s [C]o [C]m [C]e O 
IFNgamma-inducible [C]I [C]F [C]N [C]g [C]a [C]m [C]m [C]a [C]- [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
, [C], O 
were [C]w [C]e [C]r [C]e O 
quantified [C]q [C]u [C]a [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
. [C]. O 

ICSBP [C]I [C]C [C]S [C]B [C]P S-protein 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
were [C]w [C]e [C]r [C]e O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
in [C]i [C]n O 
FA-C [C]F [C]A [C]- [C]C B-cell_type 
B [C]B I-cell_type 
lymphoblasts [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]s E-cell_type 
and [C]a [C]n [C]d O 
MEFs [C]M [C]E [C]F [C]s S-cell_type 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
enforced [C]e [C]n [C]f [C]o [C]r [C]c [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
ICSBP [C]I [C]C [C]S [C]B [C]P S-protein 
failed [C]f [C]a [C]i [C]l [C]e [C]d O 
to [C]t [C]o O 
down-regulate [C]d [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
IRF-1 [C]I [C]R [C]F [C]- [C]1 S-protein 
, [C], O 
ISGF3gamma [C]I [C]S [C]G [C]F [C]3 [C]g [C]a [C]m [C]m [C]a S-protein 
, [C], O 
and [C]a [C]n [C]d O 
p21 [C]p [C]2 [C]1 B-protein 
( [C]( I-protein 
WAF1 [C]W [C]A [C]F [C]1 I-protein 
) [C]) E-protein 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
the [C]t [C]h [C]e O 
FANCC [C]F [C]A [C]N [C]C [C]C B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
functions [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]s O 
to [C]t [C]o O 
modulate [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
family [C]f [C]a [C]m [C]i [C]l [C]y O 
of [C]o [C]f O 
genes [C]g [C]e [C]n [C]e [C]s O 
that [C]t [C]h [C]a [C]t O 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
cells [C]c [C]e [C]l [C]l [C]s O 
are [C]a [C]r [C]e O 
inducible [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
only [C]o [C]n [C]l [C]y O 
by [C]b [C]y O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
environmental [C]e [C]n [C]v [C]i [C]r [C]o [C]n [C]m [C]e [C]n [C]t [C]a [C]l O 
cues [C]c [C]u [C]e [C]s O 
for [C]f [C]o [C]r O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
or [C]o [C]r O 
mitogenic [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]i [C]c O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
but [C]b [C]u [C]t O 
it [C]i [C]t O 
does [C]d [C]o [C]e [C]s O 
so [C]s [C]o O 
independently [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t [C]l [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
classic [C]c [C]l [C]a [C]s [C]s [C]i [C]c O 
IFN-STAT1 [C]I [C]F [C]N [C]- [C]S [C]T [C]A [C]T [C]1 O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
not [C]n [C]o [C]t O 
the [C]t [C]h [C]e O 
direct [C]d [C]i [C]r [C]e [C]c [C]t O 
result [C]r [C]e [C]s [C]u [C]l [C]t O 
of [C]o [C]f O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
ICSBP [C]I [C]C [C]S [C]B [C]P S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

A [C]A O 
genetic [C]g [C]e [C]n [C]e [C]t [C]i [C]c O 
investigation [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
E2A [C]E [C]2 [C]A O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
. [C]. O 

Lymphocytes [C]L [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
are [C]a [C]r [C]e O 
derived [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
hematopoietic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c B-cell_type 
stem [C]s [C]t [C]e [C]m I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
HSC [C]H [C]S [C]C S-cell_type 
) [C]) O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
a [C]a O 
series [C]s [C]e [C]r [C]i [C]e [C]s O 
of [C]o [C]f O 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
events [C]e [C]v [C]e [C]n [C]t [C]s O 
. [C]. O 

Multipotent [C]M [C]u [C]l [C]t [C]i [C]p [C]o [C]t [C]e [C]n [C]t B-cell_type 
HSCs [C]H [C]S [C]C [C]s E-cell_type 
become [C]b [C]e [C]c [C]o [C]m [C]e O 
committed [C]c [C]o [C]m [C]m [C]i [C]t [C]t [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
B [C]B B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e E-cell_line 
in [C]i [C]n O 
bone [C]b [C]o [C]n [C]e O 
marrow [C]m [C]a [C]r [C]r [C]o [C]w O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
T [C]T B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e E-cell_line 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
thymus [C]t [C]h [C]y [C]m [C]u [C]s O 
after [C]a [C]f [C]t [C]e [C]r O 
receiving [C]r [C]e [C]c [C]e [C]i [C]v [C]i [C]n [C]g O 
appropriate [C]a [C]p [C]p [C]r [C]o [C]p [C]r [C]i [C]a [C]t [C]e O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
corresponding [C]c [C]o [C]r [C]r [C]e [C]s [C]p [C]o [C]n [C]d [C]i [C]n [C]g O 
microenvironment [C]m [C]i [C]c [C]r [C]o [C]e [C]n [C]v [C]i [C]r [C]o [C]n [C]m [C]e [C]n [C]t O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
committed [C]c [C]o [C]m [C]m [C]i [C]t [C]t [C]e [C]d O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
must [C]m [C]u [C]s [C]t O 
then [C]t [C]h [C]e [C]n O 
undergo [C]u [C]n [C]d [C]e [C]r [C]g [C]o O 
V [C]V O 
( [C]( O 
D [C]D O 
) [C]) O 
J [C]J O 
recombination [C]r [C]e [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
or [C]o [C]r O 
T [C]T B-DNA 
cell [C]c [C]e [C]l [C]l I-DNA 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-DNA 
gene [C]g [C]e [C]n [C]e I-DNA 
locus [C]l [C]o [C]c [C]u [C]s E-DNA 
resulting [C]r [C]e [C]s [C]u [C]l [C]t [C]i [C]n [C]g O 
in [C]i [C]n O 
clonal [C]c [C]l [C]o [C]n [C]a [C]l O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
B [C]B B-cell_type 
or [C]o [C]r I-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
, [C], O 
respectively [C]r [C]e [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
. [C]. O 

Lymphocyte [C]L [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e O 
commitment [C]c [C]o [C]m [C]m [C]i [C]t [C]m [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
are [C]a [C]r [C]e O 
accompanied [C]a [C]c [C]c [C]o [C]m [C]p [C]a [C]n [C]i [C]e [C]d O 
by [C]b [C]y O 
programmed [C]p [C]r [C]o [C]g [C]r [C]a [C]m [C]m [C]e [C]d O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
or [C]o [C]r O 
repression [C]r [C]e [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
events [C]e [C]v [C]e [C]n [C]t [C]s O 
which [C]w [C]h [C]i [C]c [C]h O 
are [C]a [C]r [C]e O 
driven [C]d [C]r [C]i [C]v [C]e [C]n O 
by [C]b [C]y O 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e B-protein 
and [C]a [C]n [C]d I-protein 
stage [C]s [C]t [C]a [C]g [C]e I-protein 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
basic-helix-loop-helix [C]b [C]a [C]s [C]i [C]c [C]- [C]h [C]e [C]l [C]i [C]x [C]- [C]l [C]o [C]o [C]p [C]- [C]h [C]e [C]l [C]i [C]x B-protein 
( [C]( I-protein 
bHLH [C]b [C]H [C]L [C]H I-protein 
) [C]) I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
encoded [C]e [C]n [C]c [C]o [C]d [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
E2A [C]E [C]2 [C]A B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
are [C]a [C]r [C]e O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
events [C]e [C]v [C]e [C]n [C]t [C]s O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
B [C]B O 
and [C]a [C]n [C]d O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e O 
commitment [C]c [C]o [C]m [C]m [C]i [C]t [C]m [C]e [C]n [C]t O 
, [C], O 
initiation [C]i [C]n [C]i [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
V [C]V O 
( [C]( O 
D [C]D O 
) [C]) O 
J [C]J O 
recombination [C]r [C]e [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Several [C]S [C]e [C]v [C]e [C]r [C]a [C]l O 
recent [C]r [C]e [C]c [C]e [C]n [C]t O 
reviews [C]r [C]e [C]v [C]i [C]e [C]w [C]s O 
have [C]h [C]a [C]v [C]e O 
provided [C]p [C]r [C]o [C]v [C]i [C]d [C]e [C]d O 
a [C]a O 
comprehensive [C]c [C]o [C]m [C]p [C]r [C]e [C]h [C]e [C]n [C]s [C]i [C]v [C]e O 
discussion [C]d [C]i [C]s [C]c [C]u [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
biochemical [C]b [C]i [C]o [C]c [C]h [C]e [C]m [C]i [C]c [C]a [C]l O 
, [C], O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
, [C], O 
and [C]a [C]n [C]d O 
genetic [C]g [C]e [C]n [C]e [C]t [C]i [C]c O 
research [C]r [C]e [C]s [C]e [C]a [C]r [C]c [C]h O 
on [C]o [C]n O 
E2A [C]E [C]2 [C]A O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
( [C]( O 
1 [C]1 O 
, [C], O 
2 [C]2 O 
) [C]) O 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
, [C], O 
we [C]w [C]e O 
only [C]o [C]n [C]l [C]y O 
discuss [C]d [C]i [C]s [C]c [C]u [C]s [C]s O 
some [C]s [C]o [C]m [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
genetic [C]g [C]e [C]n [C]e [C]t [C]i [C]c O 
approaches [C]a [C]p [C]p [C]r [C]o [C]a [C]c [C]h [C]e [C]s O 
our [C]o [C]u [C]r O 
laboratory [C]l [C]a [C]b [C]o [C]r [C]a [C]t [C]o [C]r [C]y O 
( [C]( O 
except [C]e [C]x [C]c [C]e [C]p [C]t O 
where [C]w [C]h [C]e [C]r [C]e O 
it [C]i [C]t O 
is [C]i [C]s O 
noted [C]n [C]o [C]t [C]e [C]d O 
) [C]) O 
has [C]h [C]a [C]s O 
undertaken [C]u [C]n [C]d [C]e [C]r [C]t [C]a [C]k [C]e [C]n O 
to [C]t [C]o O 
investigate [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
E2A [C]E [C]2 [C]A B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 

D609 [C]D [C]6 [C]0 [C]9 O 
inhibits [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]s O 
ionizing [C]i [C]o [C]n [C]i [C]z [C]i [C]n [C]g O 
radiation-induced [C]r [C]a [C]d [C]i [C]a [C]t [C]i [C]o [C]n [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
oxidative [C]o [C]x [C]i [C]d [C]a [C]t [C]i [C]v [C]e O 
damage [C]d [C]a [C]m [C]a [C]g [C]e O 
by [C]b [C]y O 
acting [C]a [C]c [C]t [C]i [C]n [C]g O 
as [C]a [C]s O 
a [C]a O 
potent [C]p [C]o [C]t [C]e [C]n [C]t O 
antioxidant [C]a [C]n [C]t [C]i [C]o [C]x [C]i [C]d [C]a [C]n [C]t O 
. [C]. O 

Tricyclodecan-9-yl-xanthogenate [C]T [C]r [C]i [C]c [C]y [C]c [C]l [C]o [C]d [C]e [C]c [C]a [C]n [C]- [C]9 [C]- [C]y [C]l [C]- [C]x [C]a [C]n [C]t [C]h [C]o [C]g [C]e [C]n [C]a [C]t [C]e O 
( [C]( O 
D609 [C]D [C]6 [C]0 [C]9 O 
) [C]) O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
extensively [C]e [C]x [C]t [C]e [C]n [C]s [C]i [C]v [C]e [C]l [C]y O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
in [C]i [C]n O 
biological [C]b [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
systems [C]s [C]y [C]s [C]t [C]e [C]m [C]s O 
and [C]a [C]n [C]d O 
exhibits [C]e [C]x [C]h [C]i [C]b [C]i [C]t [C]s O 
a [C]a O 
variety [C]v [C]a [C]r [C]i [C]e [C]t [C]y O 
of [C]o [C]f O 
biological [C]b [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
functions [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]s O 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
antiviral [C]a [C]n [C]t [C]i [C]v [C]i [C]r [C]a [C]l O 
, [C], O 
antitumor [C]a [C]n [C]t [C]i [C]t [C]u [C]m [C]o [C]r O 
, [C], O 
and [C]a [C]n [C]d O 
anti-inflammatory [C]a [C]n [C]t [C]i [C]- [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
activities [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]i [C]e [C]s O 
. [C]. O 

Most [C]M [C]o [C]s [C]t O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
activities [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]i [C]e [C]s O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
largely [C]l [C]a [C]r [C]g [C]e [C]l [C]y O 
attributed [C]a [C]t [C]t [C]r [C]i [C]b [C]u [C]t [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
D609 [C]D [C]6 [C]0 [C]9 O 
on [C]o [C]n O 
phosphatidylcholine-specific [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]i [C]d [C]y [C]l [C]c [C]h [C]o [C]l [C]i [C]n [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
phospholipase [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]l [C]i [C]p [C]a [C]s [C]e B-protein 
C [C]C E-protein 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
as [C]a [C]s O 
a [C]a O 
xanthate [C]x [C]a [C]n [C]t [C]h [C]a [C]t [C]e O 
derivative [C]d [C]e [C]r [C]i [C]v [C]a [C]t [C]i [C]v [C]e O 
, [C], O 
D609 [C]D [C]6 [C]0 [C]9 O 
is [C]i [C]s O 
a [C]a O 
strong [C]s [C]t [C]r [C]o [C]n [C]g O 
electrolyte [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]l [C]y [C]t [C]e O 
and [C]a [C]n [C]d O 
readily [C]r [C]e [C]a [C]d [C]i [C]l [C]y O 
dissociates [C]d [C]i [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]s O 
to [C]t [C]o O 
xanthate [C]x [C]a [C]n [C]t [C]h [C]a [C]t [C]e O 
anions [C]a [C]n [C]i [C]o [C]n [C]s O 
and [C]a [C]n [C]d O 
cations [C]c [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
alkali [C]a [C]l [C]k [C]a [C]l [C]i O 
metals [C]m [C]e [C]t [C]a [C]l [C]s O 
in [C]i [C]n O 
solution [C]s [C]o [C]l [C]u [C]t [C]i [C]o [C]n O 
. [C]. O 

Xanthate [C]X [C]a [C]n [C]t [C]h [C]a [C]t [C]e O 
anions [C]a [C]n [C]i [C]o [C]n [C]s O 
and [C]a [C]n [C]d O 
protonated [C]p [C]r [C]o [C]t [C]o [C]n [C]a [C]t [C]e [C]d O 
xanthic [C]x [C]a [C]n [C]t [C]h [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
contain [C]c [C]o [C]n [C]t [C]a [C]i [C]n O 
a [C]a O 
free [C]f [C]r [C]e [C]e O 
thiol [C]t [C]h [C]i [C]o [C]l O 
moiety [C]m [C]o [C]i [C]e [C]t [C]y O 
and [C]a [C]n [C]d O 
are [C]a [C]r [C]e O 
highly [C]h [C]i [C]g [C]h [C]l [C]y O 
reductive [C]r [C]e [C]d [C]u [C]c [C]t [C]i [C]v [C]e O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
implies [C]i [C]m [C]p [C]l [C]i [C]e [C]s O 
that [C]t [C]h [C]a [C]t O 
D609 [C]D [C]6 [C]0 [C]9 O 
and [C]a [C]n [C]d O 
other [C]o [C]t [C]h [C]e [C]r O 
xanthate [C]x [C]a [C]n [C]t [C]h [C]a [C]t [C]e O 
derivatives [C]d [C]e [C]r [C]i [C]v [C]a [C]t [C]i [C]v [C]e [C]s O 
may [C]m [C]a [C]y O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
as [C]a [C]s O 
potent [C]p [C]o [C]t [C]e [C]n [C]t O 
antioxidants [C]a [C]n [C]t [C]i [C]o [C]x [C]i [C]d [C]a [C]n [C]t [C]s O 
. [C]. O 

Indeed [C]I [C]n [C]d [C]e [C]e [C]d O 
, [C], O 
we [C]w [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
D609 [C]D [C]6 [C]0 [C]9 O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
Fenton [C]F [C]e [C]n [C]t [C]o [C]n O 
reaction-induced [C]r [C]e [C]a [C]c [C]t [C]i [C]o [C]n [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
oxidation [C]o [C]x [C]i [C]d [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
dihydrorhodamine [C]d [C]i [C]h [C]y [C]d [C]r [C]o [C]r [C]h [C]o [C]d [C]a [C]m [C]i [C]n [C]e O 
123 [C]1 [C]2 [C]3 O 
in [C]i [C]n O 
a [C]a O 
dose-dependent [C]d [C]o [C]s [C]e [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
manner [C]m [C]a [C]n [C]n [C]e [C]r O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
to [C]t [C]o O 
that [C]t [C]h [C]a [C]t O 
of [C]o [C]f O 
pyrrolidinedithiocarbamate [C]p [C]y [C]r [C]r [C]o [C]l [C]i [C]d [C]i [C]n [C]e [C]d [C]i [C]t [C]h [C]i [C]o [C]c [C]a [C]r [C]b [C]a [C]m [C]a [C]t [C]e O 
, [C], O 
a [C]a O 
well [C]w [C]e [C]l [C]l O 
known [C]k [C]n [C]o [C]w [C]n O 
antioxidant [C]a [C]n [C]t [C]i [C]o [C]x [C]i [C]d [C]a [C]n [C]t O 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
D609 [C]D [C]6 [C]0 [C]9 O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
alpha-phenyl-tert-butylnitrone-free [C]a [C]l [C]p [C]h [C]a [C]- [C]p [C]h [C]e [C]n [C]y [C]l [C]- [C]t [C]e [C]r [C]t [C]- [C]b [C]u [C]t [C]y [C]l [C]n [C]i [C]t [C]r [C]o [C]n [C]e [C]- [C]f [C]r [C]e [C]e O 
radical [C]r [C]a [C]d [C]i [C]c [C]a [C]l O 
spin [C]s [C]p [C]i [C]n O 
adducts [C]a [C]d [C]d [C]u [C]c [C]t [C]s O 
and [C]a [C]n [C]d O 
lipid [C]l [C]i [C]p [C]i [C]d O 
peroxidation [C]p [C]e [C]r [C]o [C]x [C]i [C]d [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
synaptosomal [C]s [C]y [C]n [C]a [C]p [C]t [C]o [C]s [C]o [C]m [C]a [C]l O 
membranes [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e [C]s O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
Fenton [C]F [C]e [C]n [C]t [C]o [C]n O 
reagents [C]r [C]e [C]a [C]g [C]e [C]n [C]t [C]s O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
preincubation [C]p [C]r [C]e [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
with [C]w [C]i [C]t [C]h O 
D609 [C]D [C]6 [C]0 [C]9 O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
a [C]a O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
diminution [C]d [C]i [C]m [C]i [C]n [C]u [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
ionizing [C]i [C]o [C]n [C]i [C]z [C]i [C]n [C]g O 
radiation [C]r [C]a [C]d [C]i [C]a [C]t [C]i [C]o [C]n O 
( [C]( O 
IR [C]I [C]R O 
) [C]) O 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
1 [C]1 O 
) [C]) O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
reactive [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]e O 
oxygen [C]o [C]x [C]y [C]g [C]e [C]n O 
species [C]s [C]p [C]e [C]c [C]i [C]e [C]s O 
; [C]; O 
2 [C]2 O 
) [C]) O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
glutathione [C]g [C]l [C]u [C]t [C]a [C]t [C]h [C]i [C]o [C]n [C]e O 
; [C]; O 
3 [C]3 O 
) [C]) O 
oxidative [C]o [C]x [C]i [C]d [C]a [C]t [C]i [C]v [C]e O 
damage [C]d [C]a [C]m [C]a [C]g [C]e O 
to [C]t [C]o O 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s O 
and [C]a [C]n [C]d O 
lipids [C]l [C]i [C]p [C]i [C]d [C]s O 
; [C]; O 
and [C]a [C]n [C]d O 
4 [C]4 O 
) [C]) O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor-kappaB [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
. [C]. O 

Moreover [C]M [C]o [C]r [C]e [C]o [C]v [C]e [C]r O 
, [C], O 
when [C]w [C]h [C]e [C]n O 
D609 [C]D [C]6 [C]0 [C]9 O 
( [C]( O 
50 [C]5 [C]0 O 
mg/kg [C]m [C]g [C]/ [C]k [C]g O 
i.v. [C]i [C]. [C]v [C]. O 
) [C]) O 
was [C]w [C]a [C]s O 
administered [C]a [C]d [C]m [C]i [C]n [C]i [C]s [C]t [C]e [C]r [C]e [C]d O 
to [C]t [C]o O 
mice [C]m [C]i [C]c [C]e O 
10 [C]1 [C]0 O 
min [C]m [C]i [C]n O 
prior [C]p [C]r [C]i [C]o [C]r O 
to [C]t [C]o O 
total [C]t [C]o [C]t [C]a [C]l O 
body [C]b [C]o [C]d [C]y O 
IR [C]I [C]R O 
( [C]( O 
6.5 [C]6 [C]. [C]5 O 
and [C]a [C]n [C]d O 
8.5 [C]8 [C]. [C]5 O 
Gy [C]G [C]y O 
) [C]) O 
, [C], O 
it [C]i [C]t O 
protected [C]p [C]r [C]o [C]t [C]e [C]c [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
mice [C]m [C]i [C]c [C]e O 
from [C]f [C]r [C]o [C]m O 
IR-induced [C]I [C]R [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
lethality [C]l [C]e [C]t [C]h [C]a [C]l [C]i [C]t [C]y O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
these [C]t [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
D609 [C]D [C]6 [C]0 [C]9 O 
is [C]i [C]s O 
a [C]a O 
potent [C]p [C]o [C]t [C]e [C]n [C]t O 
antioxidant [C]a [C]n [C]t [C]i [C]o [C]x [C]i [C]d [C]a [C]n [C]t O 
and [C]a [C]n [C]d O 
has [C]h [C]a [C]s O 
the [C]t [C]h [C]e O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
to [C]t [C]o O 
inhibit [C]i [C]n [C]h [C]i [C]b [C]i [C]t O 
IR-induced [C]I [C]R [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
oxidative [C]o [C]x [C]i [C]d [C]a [C]t [C]i [C]v [C]e O 
stress [C]s [C]t [C]r [C]e [C]s [C]s O 
. [C]. O 

Inhibition [C]I [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
glucocorticoid-inducible [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
GILZ [C]G [C]I [C]L [C]Z E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
immunosuppressive [C]i [C]m [C]m [C]u [C]n [C]o [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]v [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
arise [C]a [C]r [C]i [C]s [C]e O 
largely [C]l [C]a [C]r [C]g [C]e [C]l [C]y O 
by [C]b [C]y O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
ascribed [C]a [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
to [C]t [C]o O 
interference [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]e [C]n [C]c [C]e O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
and [C]a [C]n [C]d O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
and [C]a [C]n [C]d O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
by [C]b [C]y O 
competition [C]c [C]o [C]m [C]p [C]e [C]t [C]i [C]t [C]i [C]o [C]n O 
for [C]f [C]o [C]r O 
common [C]c [C]o [C]m [C]m [C]o [C]n O 
coactivators [C]c [C]o [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r [C]s O 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
we [C]w [C]e O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
glucocorticoid-induced [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
interleukin-2 [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]2 O 
mRNA [C]m [C]R [C]N [C]A O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-cell_type 
normal [C]n [C]o [C]r [C]m [C]a [C]l I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
new [C]n [C]e [C]w O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
this [C]t [C]h [C]i [C]s O 
phenomenon [C]p [C]h [C]e [C]n [C]o [C]m [C]e [C]n [C]o [C]n O 
is [C]i [C]s O 
secondary [C]s [C]e [C]c [C]o [C]n [C]d [C]a [C]r [C]y O 
to [C]t [C]o O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
glucocorticoid-regulated [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
genes [C]g [C]e [C]n [C]e [C]s S-DNA 
. [C]. O 

One [C]O [C]n [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
most [C]m [C]o [C]s [C]t O 
prominent [C]p [C]r [C]o [C]m [C]i [C]n [C]e [C]n [C]t O 
glucocorticoid-induced [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
genes [C]g [C]e [C]n [C]e [C]s S-DNA 
is [C]i [C]s O 
glucocorticoid-induced [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d B-DNA 
leucine [C]l [C]e [C]u [C]c [C]i [C]n [C]e I-DNA 
zipper [C]z [C]i [C]p [C]p [C]e [C]r E-DNA 
( [C]( O 
GILZ [C]G [C]I [C]L [C]Z S-DNA 
) [C]) O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
reported [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]d O 
to [C]t [C]o O 
inhibit [C]i [C]n [C]h [C]i [C]b [C]i [C]t O 
activation-induced [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
up-regulation [C]u [C]p [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Fas [C]F [C]a [C]s B-RNA 
ligand [C]l [C]i [C]g [C]a [C]n [C]d I-RNA 
( [C]( I-RNA 
FasL [C]F [C]a [C]s [C]L I-RNA 
) [C]) I-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
. [C]. O 

Indeed [C]I [C]n [C]d [C]e [C]e [C]d O 
, [C], O 
transient [C]t [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
GILZ [C]G [C]I [C]L [C]Z S-DNA 
in [C]i [C]n O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_line 
T [C]T I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r B-DNA 
construct [C]c [C]o [C]n [C]s [C]t [C]r [C]u [C]c [C]t E-DNA 
driven [C]d [C]r [C]i [C]v [C]e [C]n O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
FasL [C]F [C]a [C]s [C]L B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
accounted [C]a [C]c [C]c [C]o [C]u [C]n [C]t [C]e [C]d O 
for [C]f [C]o [C]r O 
by [C]b [C]y O 
GILZ [C]G [C]I [C]L [C]Z S-protein 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Egr-2 [C]E [C]g [C]r [C]- [C]2 S-protein 
and [C]a [C]n [C]d O 
Egr-3 [C]E [C]g [C]r [C]- [C]3 S-protein 
, [C], O 
NFAT/AP-1 [C]N [C]F [C]A [C]T [C]/ [C]A [C]P [C]- [C]1 S-protein 
-inducible [C]- [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
that [C]t [C]h [C]a [C]t O 
bind [C]b [C]i [C]n [C]d O 
a [C]a O 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y B-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
FasL [C]F [C]a [C]s [C]L B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
and [C]a [C]n [C]d O 
up-regulate [C]u [C]p [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
FasL [C]F [C]a [C]s [C]L O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

GILZ [C]G [C]I [C]L [C]Z S-protein 
also [C]a [C]l [C]s [C]o O 
potently [C]p [C]o [C]t [C]e [C]n [C]t [C]l [C]y O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
AP-1-driven [C]A [C]P [C]- [C]1 [C]- [C]d [C]r [C]i [C]v [C]e [C]n B-DNA 
and [C]a [C]n [C]d I-DNA 
IL-2 [C]I [C]L [C]- [C]2 I-DNA 
promoter-driven [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]- [C]d [C]r [C]i [C]v [C]e [C]n I-DNA 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r I-DNA 
constructs [C]c [C]o [C]n [C]s [C]t [C]r [C]u [C]c [C]t [C]s E-DNA 
, [C], O 
and [C]a [C]n [C]d O 
recombinant [C]r [C]e [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]n [C]t O 
GILZ [C]G [C]I [C]L [C]Z S-protein 
specifically [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]a [C]l [C]l [C]y O 
interacted [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
c-Fos [C]c [C]- [C]F [C]o [C]s S-protein 
and [C]a [C]n [C]d O 
c-Jun [C]c [C]- [C]J [C]u [C]n S-protein 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
and [C]a [C]n [C]d O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
active [C]a [C]c [C]t [C]i [C]v [C]e B-protein 
AP-1 [C]A [C]P [C]- [C]1 E-protein 
to [C]t [C]o O 
its [C]i [C]t [C]s O 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
DNA [C]D [C]N [C]A O 
. [C]. O 

Whereas [C]W [C]h [C]e [C]r [C]e [C]a [C]s O 
homodimerization [C]h [C]o [C]m [C]o [C]d [C]i [C]m [C]e [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
GILZ [C]G [C]I [C]L [C]Z S-protein 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
its [C]i [C]t [C]s O 
leucine [C]l [C]e [C]u [C]c [C]i [C]n [C]e B-protein 
zipper [C]z [C]i [C]p [C]p [C]e [C]r E-protein 
, [C], O 
the [C]t [C]h [C]e O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
c-Fos [C]c [C]- [C]F [C]o [C]s S-protein 
and [C]a [C]n [C]d O 
c-Jun [C]c [C]- [C]J [C]u [C]n S-protein 
occurred [C]o [C]c [C]c [C]u [C]r [C]r [C]e [C]d O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
N-terminal [C]N [C]- [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l S-protein 
60-amino [C]6 [C]0 [C]- [C]a [C]m [C]i [C]n [C]o B-protein 
acid [C]a [C]c [C]i [C]d I-protein 
region [C]r [C]e [C]g [C]i [C]o [C]n E-protein 
of [C]o [C]f O 
GILZ [C]G [C]I [C]L [C]Z S-protein 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
GILZ [C]G [C]I [C]L [C]Z S-protein 
represents [C]r [C]e [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]s O 
a [C]a O 
glucocorticoid-induced [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
gene [C]g [C]e [C]n [C]e O 
product [C]p [C]r [C]o [C]d [C]u [C]c [C]t O 
that [C]t [C]h [C]a [C]t O 
can [C]c [C]a [C]n O 
inhibit [C]i [C]n [C]h [C]i [C]b [C]i [C]t O 
a [C]a O 
variety [C]v [C]a [C]r [C]i [C]e [C]t [C]y O 
of [C]o [C]f O 
activation-induced [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
events [C]e [C]v [C]e [C]n [C]t [C]s O 
, [C], O 
at [C]a [C]t O 
least [C]l [C]e [C]a [C]s [C]t O 
in [C]i [C]n O 
part [C]p [C]a [C]r [C]t O 
by [C]b [C]y O 
direct [C]d [C]i [C]r [C]e [C]c [C]t O 
interference [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]e [C]n [C]c [C]e O 
with [C]w [C]i [C]t [C]h O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
therefore [C]t [C]h [C]e [C]r [C]e [C]f [C]o [C]r [C]e O 
a [C]a O 
candidate [C]c [C]a [C]n [C]d [C]i [C]d [C]a [C]t [C]e O 
for [C]f [C]o [C]r O 
a [C]a O 
mediator [C]m [C]e [C]d [C]i [C]a [C]t [C]o [C]r O 
of [C]o [C]f O 
glucocorticoid-induced [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
immunosuppression [C]i [C]m [C]m [C]u [C]n [C]o [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Pharmacokinetic [C]P [C]h [C]a [C]r [C]m [C]a [C]c [C]o [C]k [C]i [C]n [C]e [C]t [C]i [C]c O 
differences [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e [C]s O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
a [C]a O 
T [C]T O 
cell-tolerizing [C]c [C]e [C]l [C]l [C]- [C]t [C]o [C]l [C]e [C]r [C]i [C]z [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
a [C]a O 
T [C]T O 
cell-activating [C]c [C]e [C]l [C]l [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]n [C]g O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
. [C]. O 

Vaccination [C]V [C]a [C]c [C]c [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
representing [C]r [C]e [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]i [C]n [C]g O 
a [C]a O 
CTL [C]C [C]T [C]L O 
epitope [C]e [C]p [C]i [C]t [C]o [C]p [C]e O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n O 
papillomavirus [C]p [C]a [C]p [C]i [C]l [C]l [C]o [C]m [C]a [C]v [C]i [C]r [C]u [C]s O 
( [C]( O 
HPV [C]H [C]P [C]V O 
) [C]) O 
16 [C]1 [C]6 O 
E7 [C]E [C]7 B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
a [C]a O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
CTL [C]C [C]T [C]L O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
that [C]t [C]h [C]a [C]t O 
prevents [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]s O 
the [C]t [C]h [C]e O 
outgrowth [C]o [C]u [C]t [C]g [C]r [C]o [C]w [C]t [C]h O 
of [C]o [C]f O 
HPV16 [C]H [C]P [C]V [C]1 [C]6 O 
E7-expressing [C]E [C]7 [C]- [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]n [C]g O 
tumors [C]t [C]u [C]m [C]o [C]r [C]s O 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
vaccination [C]v [C]a [C]c [C]c [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
encoding [C]e [C]n [C]c [C]o [C]d [C]i [C]n [C]g O 
an [C]a [C]n O 
adenovirus [C]a [C]d [C]e [C]n [C]o [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
5 [C]5 O 
( [C]( O 
Ad5 [C]A [C]d [C]5 O 
) [C]) O 
E1A [C]E [C]1 [C]A O 
CTL [C]C [C]T [C]L O 
epitope [C]e [C]p [C]i [C]t [C]o [C]p [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
in [C]i [C]n O 
CTL [C]C [C]T [C]L O 
tolerance [C]t [C]o [C]l [C]e [C]r [C]a [C]n [C]c [C]e O 
and [C]a [C]n [C]d O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
of [C]o [C]f O 
an [C]a [C]n O 
Ad5 [C]A [C]d [C]5 O 
E1A-expressing [C]E [C]1 [C]A [C]- [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]n [C]g O 
tumor [C]t [C]u [C]m [C]o [C]r O 
. [C]. O 

It [C]I [C]t O 
is [C]i [C]s O 
unclear [C]u [C]n [C]c [C]l [C]e [C]a [C]r O 
why [C]w [C]h [C]y O 
these [C]t [C]h [C]e [C]s [C]e O 
peptides [C]p [C]e [C]p [C]t [C]i [C]d [C]e [C]s O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
such [C]s [C]u [C]c [C]h O 
opposite [C]o [C]p [C]p [C]o [C]s [C]i [C]t [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
. [C]. O 

To [C]T [C]o O 
determine [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
a [C]a O 
difference [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e O 
in [C]i [C]n O 
pharmacokinetics [C]p [C]h [C]a [C]r [C]m [C]a [C]c [C]o [C]k [C]i [C]n [C]e [C]t [C]i [C]c [C]s O 
can [C]c [C]a [C]n O 
explain [C]e [C]x [C]p [C]l [C]a [C]i [C]n O 
the [C]t [C]h [C]e O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
contrasts [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t [C]s O 
, [C], O 
tritiated [C]t [C]r [C]i [C]t [C]i [C]a [C]t [C]e [C]d O 
Ad5 [C]A [C]d [C]5 O 
E1A [C]E [C]1 [C]A O 
and [C]a [C]n [C]d O 
HPV16 [C]H [C]P [C]V [C]1 [C]6 O 
E7 [C]E [C]7 O 
peptides [C]p [C]e [C]p [C]t [C]i [C]d [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
injected [C]i [C]n [C]j [C]e [C]c [C]t [C]e [C]d O 
into [C]i [C]n [C]t [C]o O 
mice [C]m [C]i [C]c [C]e O 
. [C]. O 

Results [C]R [C]e [C]s [C]u [C]l [C]t [C]s O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
tolerizing [C]t [C]o [C]l [C]e [C]r [C]i [C]z [C]i [C]n [C]g O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
spread [C]s [C]p [C]r [C]e [C]a [C]d O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
body [C]b [C]o [C]d [C]y O 
16 [C]1 [C]6 O 
times [C]t [C]i [C]m [C]e [C]s O 
faster [C]f [C]a [C]s [C]t [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
the [C]t [C]h [C]e O 
activating [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]n [C]g O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
and [C]a [C]n [C]d O 
was [C]w [C]a [C]s O 
cleared [C]c [C]l [C]e [C]a [C]r [C]e [C]d O 
at [C]a [C]t O 
least [C]l [C]e [C]a [C]s [C]t O 
2 [C]2 O 
times [C]t [C]i [C]m [C]e [C]s O 
faster [C]f [C]a [C]s [C]t [C]e [C]r O 
. [C]. O 

The [C]T [C]h [C]e O 
HPV16 [C]H [C]P [C]V [C]1 [C]6 O 
E7 [C]E [C]7 O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
kinetics [C]k [C]i [C]n [C]e [C]t [C]i [C]c [C]s O 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
kinetics [C]k [C]i [C]n [C]e [C]t [C]i [C]c [C]s O 
of [C]o [C]f O 
HPV16 [C]H [C]P [C]V [C]1 [C]6 B-protein 
E7 [C]E [C]7 E-protein 
-specific [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
CTL [C]C [C]T [C]L O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
Ad5 [C]A [C]d [C]5 O 
E1A [C]E [C]1 [C]A O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
injection [C]i [C]n [C]j [C]e [C]c [C]t [C]i [C]o [C]n O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
physical [C]p [C]h [C]y [C]s [C]i [C]c [C]a [C]l O 
deletion [C]d [C]e [C]l [C]e [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
preexisting [C]p [C]r [C]e [C]e [C]x [C]i [C]s [C]t [C]i [C]n [C]g O 
Ad5 [C]A [C]d [C]5 B-protein 
E1A [C]E [C]1 [C]A E-protein 
-specific [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
CTLs [C]C [C]T [C]L [C]s S-protein 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
24 [C]2 [C]4 O 
h [C]h O 
after [C]a [C]f [C]t [C]e [C]r O 
injection [C]i [C]n [C]j [C]e [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
tolerization [C]t [C]o [C]l [C]e [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
occurred [C]o [C]c [C]c [C]u [C]r [C]r [C]e [C]d O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
time [C]t [C]i [C]m [C]e O 
when [C]w [C]h [C]e [C]n O 
the [C]t [C]h [C]e O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
reached [C]r [C]e [C]a [C]c [C]h [C]e [C]d O 
its [C]i [C]t [C]s O 
maximum [C]m [C]a [C]x [C]i [C]m [C]u [C]m O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
organs [C]o [C]r [C]g [C]a [C]n [C]s O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
ubiquitous [C]u [C]b [C]i [C]q [C]u [C]i [C]t [C]o [C]u [C]s O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
tolerizing [C]t [C]o [C]l [C]e [C]r [C]i [C]z [C]i [C]n [C]g O 
Ad5 [C]A [C]d [C]5 O 
E1A [C]E [C]1 [C]A O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
a [C]a O 
short [C]s [C]h [C]o [C]r [C]t O 
period [C]p [C]e [C]r [C]i [C]o [C]d O 
of [C]o [C]f O 
time [C]t [C]i [C]m [C]e O 
causes [C]c [C]a [C]u [C]s [C]e [C]s O 
activation-induced [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
cell [C]c [C]e [C]l [C]l O 
death [C]d [C]e [C]a [C]t [C]h O 
of [C]o [C]f O 
Ad5 [C]A [C]d [C]5 B-protein 
E1A [C]E [C]1 [C]A E-protein 
-specific [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
CTLs [C]C [C]T [C]L [C]s S-protein 
. [C]. O 

Therefore [C]T [C]h [C]e [C]r [C]e [C]f [C]o [C]r [C]e O 
, [C], O 
information [C]i [C]n [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
pharmacokinetics [C]p [C]h [C]a [C]r [C]m [C]a [C]c [C]o [C]k [C]i [C]n [C]e [C]t [C]i [C]c [C]s O 
of [C]o [C]f O 
peptides [C]p [C]e [C]p [C]t [C]i [C]d [C]e [C]s O 
is [C]i [C]s O 
vital [C]v [C]i [C]t [C]a [C]l O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
safety [C]s [C]a [C]f [C]e [C]t [C]y O 
and [C]a [C]n [C]d O 
efficacy [C]e [C]f [C]f [C]i [C]c [C]a [C]c [C]y O 
of [C]o [C]f O 
peptide-based [C]p [C]e [C]p [C]t [C]i [C]d [C]e [C]- [C]b [C]a [C]s [C]e [C]d O 
vaccines [C]v [C]a [C]c [C]c [C]i [C]n [C]e [C]s O 
. [C]. O 

Smad3 [C]S [C]m [C]a [C]d [C]3 S-protein 
and [C]a [C]n [C]d O 
Smad4 [C]S [C]m [C]a [C]d [C]4 S-protein 
mediate [C]m [C]e [C]d [C]i [C]a [C]t [C]e O 
transforming [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]i [C]n [C]g B-protein 
growth [C]g [C]r [C]o [C]w [C]t [C]h I-protein 
factor-beta1 [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]b [C]e [C]t [C]a [C]1 E-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
IgA [C]I [C]g [C]A O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
murine [C]m [C]u [C]r [C]i [C]n [C]e B-cell_type 
B [C]B I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

Transforming [C]T [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]i [C]n [C]g B-protein 
growth [C]g [C]r [C]o [C]w [C]t [C]h I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
( [C]( I-protein 
TGF [C]T [C]G [C]F I-protein 
) [C]) I-protein 
-beta1 [C]- [C]b [C]e [C]t [C]a [C]1 E-protein 
is [C]i [C]s O 
well [C]w [C]e [C]l [C]l O 
established [C]e [C]s [C]t [C]a [C]b [C]l [C]i [C]s [C]h [C]e [C]d O 
as [C]a [C]s O 
a [C]a O 
critical [C]c [C]r [C]i [C]t [C]i [C]c [C]a [C]l O 
IgA [C]I [C]g [C]A B-protein 
isotype [C]i [C]s [C]o [C]t [C]y [C]p [C]e I-protein 
switching [C]s [C]w [C]i [C]t [C]c [C]h [C]i [C]n [C]g I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
and [C]a [C]n [C]d O 
Smad [C]S [C]m [C]a [C]d B-protein 
molecules [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]s E-protein 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
reported [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]d O 
to [C]t [C]o O 
act [C]a [C]c [C]t O 
as [C]a [C]s O 
transducers [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]e [C]r [C]s S-protein 
and [C]a [C]n [C]d O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
TGF-beta1 [C]T [C]G [C]F [C]- [C]b [C]e [C]t [C]a [C]1 S-protein 
-targeted [C]- [C]t [C]a [C]r [C]g [C]e [C]t [C]e [C]d O 
genes [C]g [C]e [C]n [C]e [C]s S-DNA 
. [C]. O 

We [C]W [C]e O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
the [C]t [C]h [C]e O 
involvement [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
Smad [C]S [C]m [C]a [C]d B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
in [C]i [C]n O 
TGF-beta1 [C]T [C]G [C]F [C]- [C]b [C]e [C]t [C]a [C]1 S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
IgA [C]I [C]g [C]A O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

First [C]F [C]i [C]r [C]s [C]t O 
, [C], O 
we [C]w [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
TGF-beta1 [C]T [C]G [C]F [C]- [C]b [C]e [C]t [C]a [C]1 S-protein 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
increases [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
endogenous [C]e [C]n [C]d [C]o [C]g [C]e [C]n [C]o [C]u [C]s B-RNA 
germ-line [C]g [C]e [C]r [C]m [C]- [C]l [C]i [C]n [C]e I-RNA 
( [C]( I-RNA 
GL [C]G [C]L I-RNA 
) [C]) I-RNA 
alpha [C]a [C]l [C]p [C]h [C]a I-RNA 
transcripts [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]s E-RNA 
by [C]b [C]y O 
LPS-stimulated [C]L [C]P [C]S [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
CH12.LX.4933 [C]C [C]H [C]1 [C]2 [C]. [C]L [C]X [C]. [C]4 [C]9 [C]3 [C]3 B-cell_line 
( [C]( I-cell_line 
mu [C]m [C]u I-cell_line 
( [C]( I-cell_line 
+ [C]+ I-cell_line 
) [C]) I-cell_line 
) [C]) I-cell_line 
B [C]B I-cell_line 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

To [C]T [C]o O 
investigate [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e O 
its [C]i [C]t [C]s O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
, [C], O 
the [C]t [C]h [C]e O 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
was [C]w [C]a [C]s O 
transfected [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
pFL3 [C]p [C]F [C]L [C]3 S-DNA 
that [C]t [C]h [C]a [C]t O 
contains [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]s O 
the [C]t [C]h [C]e O 
TGF-beta-responsive [C]T [C]G [C]F [C]- [C]b [C]e [C]t [C]a [C]- [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e B-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
GLalpha [C]G [C]L [C]a [C]l [C]p [C]h [C]a B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
, [C], O 
and [C]a [C]n [C]d O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
TGF-beta1 [C]T [C]G [C]F [C]- [C]b [C]e [C]t [C]a [C]1 S-protein 
. [C]. O 

Similar [C]S [C]i [C]m [C]i [C]l [C]a [C]r O 
to [C]t [C]o O 
endogenous [C]e [C]n [C]d [C]o [C]g [C]e [C]n [C]o [C]u [C]s B-RNA 
GLalpha [C]G [C]L [C]a [C]l [C]p [C]h [C]a I-RNA 
transcripts [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]s E-RNA 
, [C], O 
TGF-beta1 [C]T [C]G [C]F [C]- [C]b [C]e [C]t [C]a [C]1 S-protein 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
GLalpha [C]G [C]L [C]a [C]l [C]p [C]h [C]a B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
overexpression [C]o [C]v [C]e [C]r [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
Smad3 [C]S [C]m [C]a [C]d [C]3 S-protein 
markedly [C]m [C]a [C]r [C]k [C]e [C]d [C]l [C]y O 
enhances [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]s O 
the [C]t [C]h [C]e O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
is [C]i [C]s O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
augmented [C]a [C]u [C]g [C]m [C]e [C]n [C]t [C]e [C]d O 
by [C]b [C]y O 
cotransfected [C]c [C]o [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]e [C]d B-protein 
Smad4 [C]S [C]m [C]a [C]d [C]4 E-protein 
. [C]. O 

On [C]O [C]n O 
the [C]t [C]h [C]e O 
other [C]o [C]t [C]h [C]e [C]r O 
hand [C]h [C]a [C]n [C]d O 
, [C], O 
Smad7 [C]S [C]m [C]a [C]d [C]7 S-protein 
substantially [C]s [C]u [C]b [C]s [C]t [C]a [C]n [C]t [C]i [C]a [C]l [C]l [C]y O 
abrogates [C]a [C]b [C]r [C]o [C]g [C]a [C]t [C]e [C]s O 
the [C]t [C]h [C]e O 
synergistic [C]s [C]y [C]n [C]e [C]r [C]g [C]i [C]s [C]t [C]i [C]c O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
Smad3/4 [C]S [C]m [C]a [C]d [C]3 [C]/ [C]4 S-protein 
on [C]o [C]n O 
GLalpha [C]G [C]L [C]a [C]l [C]p [C]h [C]a B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
overexpression [C]o [C]v [C]e [C]r [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
Smad3/4 [C]S [C]m [C]a [C]d [C]3 [C]/ [C]4 S-protein 
enhances [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]s O 
TGF-beta1 [C]T [C]G [C]F [C]- [C]b [C]e [C]t [C]a [C]1 S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
endogenous [C]e [C]n [C]d [C]o [C]g [C]e [C]n [C]o [C]u [C]s B-RNA 
GLalpha [C]G [C]L [C]a [C]l [C]p [C]h [C]a I-RNA 
transcripts [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]s E-RNA 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
spleen [C]s [C]p [C]l [C]e [C]e [C]n I-cell_type 
B [C]B I-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
s [C]s O 
. [C]. O 

Finally [C]F [C]i [C]n [C]a [C]l [C]l [C]y O 
, [C], O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
TGF-beta1 [C]T [C]G [C]F [C]- [C]b [C]e [C]t [C]a [C]1 S-protein 
, [C], O 
overexpression [C]o [C]v [C]e [C]r [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
Smad3/4 [C]S [C]m [C]a [C]d [C]3 [C]/ [C]4 S-protein 
selectively [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
increases [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
both [C]b [C]o [C]t [C]h O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
IgA [C]I [C]g [C]A O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
IgA [C]I [C]g [C]A O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
study [C]s [C]t [C]u [C]d [C]y O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
Smad3 [C]S [C]m [C]a [C]d [C]3 S-protein 
, [C], O 
Smad4 [C]S [C]m [C]a [C]d [C]4 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
Smad7 [C]S [C]m [C]a [C]d [C]7 S-protein 
, [C], O 
at [C]a [C]t O 
least [C]l [C]e [C]a [C]s [C]t O 
in [C]i [C]n O 
part [C]p [C]a [C]r [C]t O 
, [C], O 
serve [C]s [C]e [C]r [C]v [C]e O 
as [C]a [C]s O 
mediators [C]m [C]e [C]d [C]i [C]a [C]t [C]o [C]r [C]s O 
linking [C]l [C]i [C]n [C]k [C]i [C]n [C]g O 
TGF-beta1 [C]T [C]G [C]F [C]- [C]b [C]e [C]t [C]a [C]1 S-protein 
to [C]t [C]o O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IgA [C]I [C]g [C]A B-DNA 
switching [C]s [C]w [C]i [C]t [C]c [C]h [C]i [C]n [C]g I-DNA 
related [C]r [C]e [C]l [C]a [C]t [C]e [C]d I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
and [C]a [C]n [C]d O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IgA [C]I [C]g [C]A O 
class [C]c [C]l [C]a [C]s [C]s O 
switching [C]s [C]w [C]i [C]t [C]c [C]h [C]i [C]n [C]g O 
. [C]. O 

The [C]T [C]h [C]e O 
translesion [C]t [C]r [C]a [C]n [C]s [C]l [C]e [C]s [C]i [C]o [C]n B-protein 
DNA [C]D [C]N [C]A I-protein 
polymerase [C]p [C]o [C]l [C]y [C]m [C]e [C]r [C]a [C]s [C]e I-protein 
zeta [C]z [C]e [C]t [C]a E-protein 
plays [C]p [C]l [C]a [C]y [C]s O 
a [C]a O 
major [C]m [C]a [C]j [C]o [C]r O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
Ig [C]I [C]g O 
and [C]a [C]n [C]d O 
bcl-6 [C]b [C]c [C]l [C]- [C]6 O 
somatic [C]s [C]o [C]m [C]a [C]t [C]i [C]c O 
hypermutation [C]h [C]y [C]p [C]e [C]r [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Ig [C]I [C]g O 
somatic [C]s [C]o [C]m [C]a [C]t [C]i [C]c O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
would [C]w [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
introduced [C]i [C]n [C]t [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
polymerase [C]p [C]o [C]l [C]y [C]m [C]e [C]r [C]a [C]s [C]e S-protein 
( [C]( O 
pol [C]p [C]o [C]l S-protein 
) [C]) O 
while [C]w [C]h [C]i [C]l [C]e O 
repairing [C]r [C]e [C]p [C]a [C]i [C]r [C]i [C]n [C]g O 
DNA [C]D [C]N [C]A O 
outside [C]o [C]u [C]t [C]s [C]i [C]d [C]e O 
main [C]m [C]a [C]i [C]n O 
DNA [C]D [C]N [C]A O 
replication [C]r [C]e [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

We [C]W [C]e O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
constitutively [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y O 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
the [C]t [C]h [C]e O 
translesion [C]t [C]r [C]a [C]n [C]s [C]l [C]e [C]s [C]i [C]o [C]n B-protein 
pol [C]p [C]o [C]l I-protein 
zeta [C]z [C]e [C]t [C]a E-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
effectively [C]e [C]f [C]f [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
extends [C]e [C]x [C]t [C]e [C]n [C]d [C]s O 
DNA [C]D [C]N [C]A O 
past [C]p [C]a [C]s [C]t O 
mismatched [C]m [C]i [C]s [C]m [C]a [C]t [C]c [C]h [C]e [C]d O 
bases [C]b [C]a [C]s [C]e [C]s O 
( [C]( O 
mispair [C]m [C]i [C]s [C]p [C]a [C]i [C]r O 
extender [C]e [C]x [C]t [C]e [C]n [C]d [C]e [C]r O 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
pol [C]p [C]o [C]l B-protein 
eta [C]e [C]t [C]a E-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
bypasses [C]b [C]y [C]p [C]a [C]s [C]s [C]e [C]s O 
DNA [C]D [C]N [C]A O 
lesions [C]l [C]e [C]s [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
an [C]a [C]n O 
error-free [C]e [C]r [C]r [C]o [C]r [C]- [C]f [C]r [C]e [C]e O 
fashion [C]f [C]a [C]s [C]h [C]i [C]o [C]n O 
. [C]. O 

Upon [C]U [C]p [C]o [C]n O 
B [C]B B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
( [C]( O 
BCR [C]B [C]C [C]R S-protein 
) [C]) O 
engagement [C]e [C]n [C]g [C]a [C]g [C]e [C]m [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
coculture [C]c [C]o [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
with [C]w [C]i [C]t [C]h O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-cell_type 
CD4+ [C]C [C]D [C]4 [C]+ I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
these [C]t [C]h [C]e [C]s [C]e O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
upregulated [C]u [C]p [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
pol [C]p [C]o [C]l B-protein 
zeta [C]z [C]e [C]t [C]a E-protein 
, [C], O 
downregulated [C]d [C]o [C]w [C]n [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
pol [C]p [C]o [C]l B-protein 
eta [C]e [C]t [C]a E-protein 
, [C], O 
and [C]a [C]n [C]d O 
mutated [C]m [C]u [C]t [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
Ig [C]I [C]g B-DNA 
and [C]a [C]n [C]d I-DNA 
bcl-6 [C]b [C]c [C]l [C]- [C]6 I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
. [C]. O 

Inhibition [C]I [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
pol [C]p [C]o [C]l B-protein 
zeta [C]z [C]e [C]t [C]a E-protein 
REV3 [C]R [C]E [C]V [C]3 B-protein 
catalytic [C]c [C]a [C]t [C]a [C]l [C]y [C]t [C]i [C]c I-protein 
subunit [C]s [C]u [C]b [C]u [C]n [C]i [C]t E-protein 
by [C]b [C]y O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
phosphorothioate-modified [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]o [C]t [C]h [C]i [C]o [C]a [C]t [C]e [C]- [C]m [C]o [C]d [C]i [C]f [C]i [C]e [C]d O 
oligonucleotides [C]o [C]l [C]i [C]g [C]o [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e [C]s O 
impaired [C]i [C]m [C]p [C]a [C]i [C]r [C]e [C]d O 
Ig [C]I [C]g O 
and [C]a [C]n [C]d O 
bcl-6 [C]b [C]c [C]l [C]- [C]6 O 
hypermutation [C]h [C]y [C]p [C]e [C]r [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
UV [C]U [C]V O 
damage-induced [C]d [C]a [C]m [C]a [C]g [C]e [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
DNA [C]D [C]N [C]A O 
mutagenesis [C]m [C]u [C]t [C]a [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
, [C], O 
without [C]w [C]i [C]t [C]h [C]o [C]u [C]t O 
affecting [C]a [C]f [C]f [C]e [C]c [C]t [C]i [C]n [C]g O 
cell [C]c [C]e [C]l [C]l O 
cycle [C]c [C]y [C]c [C]l [C]e O 
or [C]o [C]r O 
viability [C]v [C]i [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
pol [C]p [C]o [C]l B-protein 
zeta [C]z [C]e [C]t [C]a E-protein 
plays [C]p [C]l [C]a [C]y [C]s O 
a [C]a O 
critical [C]c [C]r [C]i [C]t [C]i [C]c [C]a [C]l O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
Ig [C]I [C]g O 
and [C]a [C]n [C]d O 
bcl-6 [C]b [C]c [C]l [C]- [C]6 O 
hypermutation [C]h [C]y [C]p [C]e [C]r [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
perhaps [C]p [C]e [C]r [C]h [C]a [C]p [C]s O 
facilitated [C]f [C]a [C]c [C]i [C]l [C]i [C]t [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
downregulation [C]d [C]o [C]w [C]n [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
pol [C]p [C]o [C]l B-protein 
eta [C]e [C]t [C]a E-protein 
. [C]. O 

Molecular [C]M [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
of [C]o [C]f O 
cell [C]c [C]e [C]l [C]l O 
cycle [C]c [C]y [C]c [C]l [C]e O 
progression [C]p [C]r [C]o [C]g [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
oncogene [C]o [C]n [C]c [C]o [C]g [C]e [C]n [C]e B-protein 
product [C]p [C]r [C]o [C]d [C]u [C]c [C]t I-protein 
Tax [C]T [C]a [C]x E-protein 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
virus [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
I [C]I O 
. [C]. O 

The [C]T [C]h [C]e O 
trans-activator [C]t [C]r [C]a [C]n [C]s [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
Tax [C]T [C]a [C]x E-protein 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
virus [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
I [C]I O 
( [C]( O 
HTLV-I [C]H [C]T [C]L [C]V [C]- [C]I O 
) [C]) O 
plays [C]p [C]l [C]a [C]y [C]s O 
an [C]a [C]n O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
adult [C]a [C]d [C]u [C]l [C]t O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
, [C], O 
at [C]a [C]t O 
least [C]l [C]e [C]a [C]s [C]t O 
in [C]i [C]n O 
part [C]p [C]a [C]r [C]t O 
, [C], O 
its [C]i [C]t [C]s O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
to [C]t [C]o O 
stimulate [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e O 
cell [C]c [C]e [C]l [C]l O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
. [C]. O 

We [C]W [C]e O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
reported [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
Tax [C]T [C]a [C]x S-protein 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
cell [C]c [C]e [C]l [C]l O 
cycle [C]c [C]y [C]c [C]l [C]e O 
progression [C]p [C]r [C]o [C]g [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
from [C]f [C]r [C]o [C]m O 
G0/G1 [C]G [C]0 [C]/ [C]G [C]1 O 
phase [C]p [C]h [C]a [C]s [C]e O 
to [C]t [C]o O 
S [C]S O 
and [C]a [C]n [C]d O 
G2/M [C]G [C]2 [C]/ [C]M O 
phases [C]p [C]h [C]a [C]s [C]e [C]s O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e I-cell_line 
Kit [C]K [C]i [C]t I-cell_line 
225 [C]2 [C]2 [C]5 I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

To [C]T [C]o O 
elucidate [C]e [C]l [C]u [C]c [C]i [C]d [C]a [C]t [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
of [C]o [C]f O 
Tax [C]T [C]a [C]x S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
cell [C]c [C]e [C]l [C]l O 
cycle [C]c [C]y [C]c [C]l [C]e O 
progression [C]p [C]r [C]o [C]g [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
we [C]w [C]e O 
systematically [C]s [C]y [C]s [C]t [C]e [C]m [C]a [C]t [C]i [C]c [C]a [C]l [C]l [C]y O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
the [C]t [C]h [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
Tax [C]T [C]a [C]x S-protein 
on [C]o [C]n O 
biochemical [C]b [C]i [C]o [C]c [C]h [C]e [C]m [C]i [C]c [C]a [C]l O 
events [C]e [C]v [C]e [C]n [C]t [C]s O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
cell [C]c [C]e [C]l [C]l O 
cycle [C]c [C]y [C]c [C]l [C]e O 
progression [C]p [C]r [C]o [C]g [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Introduction [C]I [C]n [C]t [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Tax [C]T [C]a [C]x S-protein 
into [C]i [C]n [C]t [C]o O 
resting [C]r [C]e [C]s [C]t [C]i [C]n [C]g B-cell_line 
Kit [C]K [C]i [C]t I-cell_line 
225 [C]2 [C]2 [C]5 I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
G1/S [C]G [C]1 [C]/ [C]S O 
transition [C]t [C]r [C]a [C]n [C]s [C]i [C]t [C]i [C]o [C]n O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
cascade [C]c [C]a [C]s [C]c [C]a [C]d [C]e O 
consisting [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]i [C]n [C]g O 
of [C]o [C]f O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cyclin [C]c [C]y [C]c [C]l [C]i [C]n B-protein 
dependent [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
2 [C]2 E-protein 
( [C]( O 
CDK2 [C]C [C]D [C]K [C]2 S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
CDK4 [C]C [C]D [C]K [C]4 S-protein 
, [C], O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Rb [C]R [C]b B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
and [C]a [C]n [C]d O 
an [C]a [C]n O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
free [C]f [C]r [C]e [C]e O 
E2F [C]E [C]2 [C]F S-protein 
. [C]. O 

The [C]T [C]h [C]e O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
result [C]r [C]e [C]s [C]u [C]l [C]t O 
from [C]f [C]r [C]o [C]m O 
Tax [C]T [C]a [C]x S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
genes [C]g [C]e [C]n [C]e [C]s O 
for [C]f [C]o [C]r O 
cell [C]c [C]e [C]l [C]l B-protein 
cycle [C]c [C]y [C]c [C]l [C]e I-protein 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y I-protein 
molecules [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]s E-protein 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
cyclin [C]c [C]y [C]c [C]l [C]i [C]n B-protein 
D2 [C]D [C]2 E-protein 
, [C], O 
cyclin [C]c [C]y [C]c [C]l [C]i [C]n B-protein 
E [C]E E-protein 
, [C], O 
E2F1 [C]E [C]2 [C]F [C]1 S-protein 
, [C], O 
CDK2 [C]C [C]D [C]K [C]2 S-protein 
, [C], O 
CDK4 [C]C [C]D [C]K [C]4 S-protein 
and [C]a [C]n [C]d O 
CDK6 [C]C [C]D [C]K [C]6 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
Tax [C]T [C]a [C]x S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
reduction [C]r [C]e [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CDK [C]C [C]D [C]K B-protein 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s I-protein 
p19 [C]p [C]1 [C]9 E-protein 
( [C]( O 
INK4d [C]I [C]N [C]K [C]4 [C]d S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
p27 [C]p [C]2 [C]7 B-protein 
( [C]( I-protein 
Kip1 [C]K [C]i [C]p [C]1 I-protein 
) [C]) E-protein 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
modulations [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]i [C]o [C]n [C]s O 
by [C]b [C]y O 
Tax [C]T [C]a [C]x S-protein 
always [C]a [C]l [C]w [C]a [C]y [C]s O 
paralleled [C]p [C]a [C]r [C]a [C]l [C]l [C]e [C]l [C]e [C]d O 
the [C]t [C]h [C]e O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
Tax [C]T [C]a [C]x S-protein 
to [C]t [C]o O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
Tax [C]T [C]a [C]x S-protein 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
trans-activation [C]t [C]r [C]a [C]n [C]s [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
genes [C]g [C]e [C]n [C]e [C]s O 
for [C]f [C]o [C]r O 
cell [C]c [C]e [C]l [C]l B-protein 
cycle [C]c [C]y [C]c [C]l [C]e I-protein 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y I-protein 
molecules [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]s E-protein 
in [C]i [C]n O 
Tax [C]T [C]a [C]x S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
cell [C]c [C]e [C]l [C]l O 
cycle [C]c [C]y [C]c [C]l [C]e O 
progression [C]p [C]r [C]o [C]g [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Cot [C]C [C]o [C]t B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
cyclooxygenase-2 [C]c [C]y [C]c [C]l [C]o [C]o [C]x [C]y [C]g [C]e [C]n [C]a [C]s [C]e [C]- [C]2 O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
of [C]o [C]f I-protein 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d I-protein 
T [C]T I-protein 
cells [C]c [C]e [C]l [C]l [C]s E-protein 
. [C]. O 

Cyclooxygenase-2 [C]C [C]y [C]c [C]l [C]o [C]o [C]x [C]y [C]g [C]e [C]n [C]a [C]s [C]e [C]- [C]2 S-protein 
( [C]( O 
COX-2 [C]C [C]O [C]X [C]- [C]2 S-protein 
) [C]) O 
is [C]i [C]s O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
upon [C]u [C]p [C]o [C]n O 
T [C]T B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
triggering [C]t [C]r [C]i [C]g [C]g [C]e [C]r [C]i [C]n [C]g O 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
we [C]w [C]e O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
that [C]t [C]h [C]a [C]t O 
Cot [C]C [C]o [C]t B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
, [C], O 
a [C]a O 
mitogen-activated [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
up-regulates [C]u [C]p [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]s O 
COX-2 [C]C [C]O [C]X [C]- [C]2 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_line 
T [C]T I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

Induction [C]I [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
COX-2 [C]C [C]O [C]X [C]- [C]2 O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
by [C]b [C]y O 
Cot [C]C [C]o [C]t B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
occurred [C]o [C]c [C]c [C]u [C]r [C]r [C]e [C]d O 
mainly [C]m [C]a [C]i [C]n [C]l [C]y O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
of [C]o [C]f I-protein 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d I-protein 
T [C]T I-protein 
cells [C]c [C]e [C]l [C]l [C]s E-protein 
( [C]( O 
NFAT [C]N [C]F [C]A [C]T S-protein 
) [C]) O 
. [C]. O 

Mutation [C]M [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
distal [C]d [C]i [C]s [C]t [C]a [C]l B-DNA 
( [C]( I-DNA 
-105/-97 [C]- [C]1 [C]0 [C]5 [C]/ [C]- [C]9 [C]7 I-DNA 
) [C]) E-DNA 
and [C]a [C]n [C]d O 
proximal [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]l B-DNA 
( [C]( I-DNA 
-76/-61 [C]- [C]7 [C]6 [C]/ [C]- [C]6 [C]1 I-DNA 
) [C]) E-DNA 
NFAT [C]N [C]F [C]A [C]T B-DNA 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e I-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
COX-2 [C]C [C]O [C]X [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
abolished [C]a [C]b [C]o [C]l [C]i [C]s [C]h [C]e [C]d O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
Cot [C]C [C]o [C]t B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
. [C]. O 

Even [C]E [C]v [C]e [C]n O 
more [C]m [C]o [C]r [C]e O 
, [C], O 
coexpression [C]c [C]o [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
dominant [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
version [C]v [C]e [C]r [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
NFAT [C]N [C]F [C]A [C]T S-protein 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
Cot [C]C [C]o [C]t B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
COX-2 [C]C [C]O [C]X [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
cotransfection [C]c [C]o [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
constitutively [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
version [C]v [C]e [C]r [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
calcium-dependent [C]c [C]a [C]l [C]c [C]i [C]u [C]m [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t B-protein 
phosphatase [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]a [C]s [C]e I-protein 
calcineurin [C]c [C]a [C]l [C]c [C]i [C]n [C]e [C]u [C]r [C]i [C]n E-protein 
synergizes [C]s [C]y [C]n [C]e [C]r [C]g [C]i [C]z [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
Cot [C]C [C]o [C]t B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
up-regulation [C]u [C]p [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
COX-2 [C]C [C]O [C]X [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
-driven [C]- [C]d [C]r [C]i [C]v [C]e [C]n O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
. [C]. O 

Strikingly [C]S [C]t [C]r [C]i [C]k [C]i [C]n [C]g [C]l [C]y O 
, [C], O 
Cot [C]C [C]o [C]t B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
transactivation [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
GAL4-NFAT [C]G [C]A [C]L [C]4 [C]- [C]N [C]F [C]A [C]T B-protein 
fusion [C]f [C]u [C]s [C]i [C]o [C]n I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
N-terminal [C]N [C]- [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l B-protein 
transactivation [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n I-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
of [C]o [C]f O 
NFATp [C]N [C]F [C]A [C]T [C]p S-protein 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
to [C]t [C]o O 
phorbol [C]p [C]h [C]o [C]r [C]b [C]o [C]l O 
ester [C]e [C]s [C]t [C]e [C]r O 
plus [C]p [C]l [C]u [C]s O 
calcium [C]c [C]a [C]l [C]c [C]i [C]u [C]m O 
ionophore [C]i [C]o [C]n [C]o [C]p [C]h [C]o [C]r [C]e O 
A23187 [C]A [C]2 [C]3 [C]1 [C]8 [C]7 O 
, [C], O 
Cot [C]C [C]o [C]t B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
increases [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
both [C]b [C]o [C]t [C]h O 
COX-2 [C]C [C]O [C]X [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
NFAT [C]N [C]F [C]A [C]T S-protein 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
transactivation [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
a [C]a O 
cyclosporin [C]c [C]y [C]c [C]l [C]o [C]s [C]p [C]o [C]r [C]i [C]n O 
A-independent [C]A [C]- [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
manner [C]m [C]a [C]n [C]n [C]e [C]r O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
Cot [C]C [C]o [C]t B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
up-regulates [C]u [C]p [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]s O 
COX-2 [C]C [C]O [C]X [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
-driven [C]- [C]d [C]r [C]i [C]v [C]e [C]n O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
NFAT [C]N [C]F [C]A [C]T B-DNA 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e I-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
, [C], O 
being [C]b [C]e [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
Cot [C]C [C]o [C]t B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
NFAT [C]N [C]F [C]A [C]T S-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
transactivation [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
presumably [C]p [C]r [C]e [C]s [C]u [C]m [C]a [C]b [C]l [C]y O 
implicated [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
this [C]t [C]h [C]i [C]s O 
up-regulation [C]u [C]p [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Positive [C]P [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
and [C]a [C]n [C]d O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
roles [C]r [C]o [C]l [C]e [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
trans-acting [C]t [C]r [C]a [C]n [C]s [C]- [C]a [C]c [C]t [C]i [C]n [C]g B-protein 
T [C]T I-protein 
cell [C]c [C]e [C]l [C]l I-protein 
factor-1 [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]1 E-protein 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
acquisition [C]a [C]c [C]q [C]u [C]i [C]s [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
Ly-49 [C]L [C]y [C]- [C]4 [C]9 B-protein 
MHC [C]M [C]H [C]C I-protein 
class [C]c [C]l [C]a [C]s [C]s I-protein 
I [C]I I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
by [C]b [C]y O 
NK [C]N [C]K B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Members [C]M [C]e [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Ly-49 [C]L [C]y [C]- [C]4 [C]9 B-DNA 
gene [C]g [C]e [C]n [C]e I-DNA 
family [C]f [C]a [C]m [C]i [C]l [C]y E-DNA 
code [C]c [C]o [C]d [C]e O 
for [C]f [C]o [C]r O 
class [C]c [C]l [C]a [C]s [C]s B-protein 
I [C]I I-protein 
MHC-specific [C]M [C]H [C]C [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
that [C]t [C]h [C]a [C]t O 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
NK [C]N [C]K O 
cell [C]c [C]e [C]l [C]l O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

Due [C]D [C]u [C]e O 
to [C]t [C]o O 
a [C]a O 
combinatorial [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]o [C]r [C]i [C]a [C]l O 
distribution [C]d [C]i [C]s [C]t [C]r [C]i [C]b [C]u [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Ly-49 [C]L [C]y [C]- [C]4 [C]9 B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
, [C], O 
NK [C]N [C]K B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
display [C]d [C]i [C]s [C]p [C]l [C]a [C]y O 
considerable [C]c [C]o [C]n [C]s [C]i [C]d [C]e [C]r [C]a [C]b [C]l [C]e O 
clonal [C]c [C]l [C]o [C]n [C]a [C]l O 
heterogeneity [C]h [C]e [C]t [C]e [C]r [C]o [C]g [C]e [C]n [C]e [C]i [C]t [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
acquisition [C]a [C]c [C]q [C]u [C]i [C]s [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
one [C]o [C]n [C]e O 
Ly-49 [C]L [C]y [C]- [C]4 [C]9 B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
, [C], O 
Ly-49A [C]L [C]y [C]- [C]4 [C]9 [C]A S-protein 
is [C]i [C]s O 
strictly [C]s [C]t [C]r [C]i [C]c [C]t [C]l [C]y O 
dependent [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l B-protein 
trans-acting [C]t [C]r [C]a [C]n [C]s [C]- [C]a [C]c [C]t [C]i [C]n [C]g I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
T [C]T B-protein 
cell-specific [C]c [C]e [C]l [C]l [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-protein 
factor-1 [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]1 E-protein 
( [C]( O 
TCF-1 [C]T [C]C [C]F [C]- [C]1 S-protein 
) [C]) O 
. [C]. O 

Indeed [C]I [C]n [C]d [C]e [C]e [C]d O 
, [C], O 
TCF-1 [C]T [C]C [C]F [C]- [C]1 S-protein 
binds [C]b [C]i [C]n [C]d [C]s O 
to [C]t [C]o O 
two [C]t [C]w [C]o O 
sites [C]s [C]i [C]t [C]e [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
Ly-49a [C]L [C]y [C]- [C]4 [C]9 [C]a B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
and [C]a [C]n [C]d O 
regulates [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]s O 
its [C]i [C]t [C]s O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
Ly-49a [C]L [C]y [C]- [C]4 [C]9 [C]a B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
is [C]i [C]s O 
a [C]a O 
direct [C]d [C]i [C]r [C]e [C]c [C]t O 
TCF-1 [C]T [C]C [C]F [C]- [C]1 S-protein 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
. [C]. O 

TCF-1 [C]T [C]C [C]F [C]- [C]1 S-protein 
deficiency [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
altered [C]a [C]l [C]t [C]e [C]r [C]e [C]d O 
usage [C]u [C]s [C]a [C]g [C]e O 
of [C]o [C]f O 
additional [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n [C]a [C]l O 
Ly-49 [C]L [C]y [C]- [C]4 [C]9 B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

We [C]W [C]e O 
show [C]s [C]h [C]o [C]w O 
in [C]i [C]n O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
, [C], O 
using [C]u [C]s [C]i [C]n [C]g O 
TCF-1 [C]T [C]C [C]F [C]- [C]1 B-protein 
beta [C]b [C]e [C]t [C]a I-protein 
( [C]( I-protein 
2 [C]2 I-protein 
) [C]) I-protein 
-microglobulin [C]- [C]m [C]i [C]c [C]r [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n E-protein 
double-deficient [C]d [C]o [C]u [C]b [C]l [C]e [C]- [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
mice [C]m [C]i [C]c [C]e O 
, [C], O 
that [C]t [C]h [C]a [C]t O 
these [C]t [C]h [C]e [C]s [C]e O 
repertoire [C]r [C]e [C]p [C]e [C]r [C]t [C]o [C]i [C]r [C]e O 
alterations [C]a [C]l [C]t [C]e [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
are [C]a [C]r [C]e O 
not [C]n [C]o [C]t O 
due [C]d [C]u [C]e O 
to [C]t [C]o O 
Ly-49/MHC [C]L [C]y [C]- [C]4 [C]9 [C]/ [C]M [C]H [C]C O 
class [C]c [C]l [C]a [C]s [C]s O 
I [C]I O 
interactions [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

Our [C]O [C]u [C]r O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
rather [C]r [C]a [C]t [C]h [C]e [C]r O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
a [C]a O 
TCF-1 [C]T [C]C [C]F [C]- [C]1 S-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
, [C], O 
cell [C]c [C]e [C]l [C]l O 
autonomous [C]a [C]u [C]t [C]o [C]n [C]o [C]m [C]o [C]u [C]s O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
acquisition [C]a [C]c [C]q [C]u [C]i [C]s [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
multiple [C]m [C]u [C]l [C]t [C]i [C]p [C]l [C]e O 
Ly-49 [C]L [C]y [C]- [C]4 [C]9 B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

Besides [C]B [C]e [C]s [C]i [C]d [C]e [C]s O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
usage [C]u [C]s [C]a [C]g [C]e O 
( [C]( O 
Ly-49A [C]L [C]y [C]- [C]4 [C]9 [C]A B-protein 
and [C]a [C]n [C]d I-protein 
D [C]D E-protein 
) [C]) O 
, [C], O 
we [C]w [C]e O 
also [C]a [C]l [C]s [C]o O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
no [C]n [C]o O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
( [C]( O 
Ly-49C [C]L [C]y [C]- [C]4 [C]9 [C]C S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
expanded [C]e [C]x [C]p [C]a [C]n [C]d [C]e [C]d O 
( [C]( O 
Ly-49G [C]L [C]y [C]- [C]4 [C]9 [C]G B-protein 
and [C]a [C]n [C]d I-protein 
I [C]I E-protein 
) [C]) O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
usage [C]u [C]s [C]a [C]g [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
TCF-1 [C]T [C]C [C]F [C]- [C]1 S-protein 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
in [C]i [C]n O 
all [C]a [C]l [C]l O 
cases [C]c [C]a [C]s [C]e [C]s O 
correlate [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
TCF [C]T [C]C [C]F B-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
respective [C]r [C]e [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e O 
proximal [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]l B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

Therefore [C]T [C]h [C]e [C]r [C]e [C]f [C]o [C]r [C]e O 
, [C], O 
besides [C]b [C]e [C]s [C]i [C]d [C]e [C]s O 
TCF-1 [C]T [C]C [C]F [C]- [C]1 S-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
proximal [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]l B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
, [C], O 
Ly-49 [C]L [C]y [C]- [C]4 [C]9 O 
acquisition [C]a [C]c [C]q [C]u [C]i [C]s [C]i [C]t [C]i [C]o [C]n O 
may [C]m [C]a [C]y O 
also [C]a [C]l [C]s [C]o O 
be [C]b [C]e O 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
TCF-1 [C]T [C]C [C]F [C]- [C]1 S-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
more [C]m [C]o [C]r [C]e O 
distant [C]d [C]i [C]s [C]t [C]a [C]n [C]t O 
cis-acting [C]c [C]i [C]s [C]- [C]a [C]c [C]t [C]i [C]n [C]g B-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
and/or [C]a [C]n [C]d [C]/ [C]o [C]r O 
by [C]b [C]y O 
regulating [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
additional [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n [C]a [C]l O 
trans-acting [C]t [C]r [C]a [C]n [C]s [C]- [C]a [C]c [C]t [C]i [C]n [C]g B-DNA 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-DNA 
. [C]. O 

Consistent [C]C [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
differential [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l O 
, [C], O 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
or [C]o [C]r O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
TCF-1 [C]T [C]C [C]F [C]- [C]1 S-protein 
for [C]f [C]o [C]r O 
Ly-49 [C]L [C]y [C]- [C]4 [C]9 B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
acquisition [C]a [C]c [C]q [C]u [C]i [C]s [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r O 
gene [C]g [C]e [C]n [C]e O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
an [C]a [C]n O 
inducing [C]i [C]n [C]d [C]u [C]c [C]i [C]n [C]g O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
a [C]a O 
repressing [C]r [C]e [C]p [C]r [C]e [C]s [C]s [C]i [C]n [C]g O 
TCF [C]T [C]C [C]F B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
in [C]i [C]n O 
certain [C]c [C]e [C]r [C]t [C]a [C]i [C]n O 
proximal [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]l O 
Ly-49 [C]L [C]y [C]- [C]4 [C]9 B-DNA 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s E-DNA 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
reveal [C]r [C]e [C]v [C]e [C]a [C]l O 
an [C]a [C]n O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
TCF-1 [C]T [C]C [C]F [C]- [C]1 S-protein 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
NK [C]N [C]K B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
repertoire [C]r [C]e [C]p [C]e [C]r [C]t [C]o [C]i [C]r [C]e O 
. [C]. O 

Ligation [C]L [C]i [C]g [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CD11b [C]C [C]D [C]1 [C]1 [C]b S-protein 
and [C]a [C]n [C]d O 
CD11c [C]C [C]D [C]1 [C]1 [C]c B-protein 
beta [C]b [C]e [C]t [C]a I-protein 
( [C]( I-protein 
2 [C]2 I-protein 
) [C]) E-protein 
integrins [C]i [C]n [C]t [C]e [C]g [C]r [C]i [C]n [C]s S-protein 
by [C]b [C]y O 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s S-protein 
or [C]o [C]r O 
soluble [C]s [C]o [C]l [C]u [C]b [C]l [C]e B-protein 
CD23 [C]C [C]D [C]2 [C]3 E-protein 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e B-protein 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
1alpha [C]1 [C]a [C]l [C]p [C]h [C]a E-protein 
( [C]( O 
MIP-1alpha [C]M [C]I [C]P [C]- [C]1 [C]a [C]l [C]p [C]h [C]a S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
MIP-1beta [C]M [C]I [C]P [C]- [C]1 [C]b [C]e [C]t [C]a S-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
a [C]a O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
dependent [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
on [C]o [C]n O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor-kappaB [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
. [C]. O 

Chemokines [C]C [C]h [C]e [C]m [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
and [C]a [C]n [C]d O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n B-protein 
molecules [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]s E-protein 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
integrins [C]i [C]n [C]t [C]e [C]g [C]r [C]i [C]n [C]s S-protein 
play [C]p [C]l [C]a [C]y O 
a [C]a O 
major [C]m [C]a [C]j [C]o [C]r O 
part [C]p [C]a [C]r [C]t O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
trafficking [C]t [C]r [C]a [C]f [C]f [C]i [C]c [C]k [C]i [C]n [C]g O 
, [C], O 
extravasation [C]e [C]x [C]t [C]r [C]a [C]v [C]a [C]s [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
recruitment [C]r [C]e [C]c [C]r [C]u [C]i [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
to [C]t [C]o O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
sites [C]s [C]i [C]t [C]e [C]s O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
beta [C]b [C]e [C]t [C]a O 
( [C]( O 
2 [C]2 O 
) [C]) O 
integrin [C]i [C]n [C]t [C]e [C]g [C]r [C]i [C]n O 
engagement [C]e [C]n [C]g [C]a [C]g [C]e [C]m [C]e [C]n [C]t O 
on [C]o [C]n O 
chemokine [C]c [C]h [C]e [C]m [C]o [C]k [C]i [C]n [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
freshly [C]f [C]r [C]e [C]s [C]h [C]l [C]y B-cell_type 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d I-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

We [C]W [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
ligation [C]l [C]i [C]g [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CD11b [C]C [C]D [C]1 [C]1 [C]b S-protein 
or [C]o [C]r O 
CD11c [C]C [C]D [C]1 [C]1 [C]c S-protein 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
CD11a [C]C [C]D [C]1 [C]1 [C]a B-protein 
alpha [C]a [C]l [C]p [C]h [C]a I-protein 
chains [C]c [C]h [C]a [C]i [C]n [C]s E-protein 
of [C]o [C]f O 
beta [C]b [C]e [C]t [C]a B-protein 
( [C]( I-protein 
2 [C]2 I-protein 
) [C]) I-protein 
integrins [C]i [C]n [C]t [C]e [C]g [C]r [C]i [C]n [C]s E-protein 
by [C]b [C]y O 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s S-protein 
or [C]o [C]r O 
soluble [C]s [C]o [C]l [C]u [C]b [C]l [C]e B-protein 
CD23 [C]C [C]D [C]2 [C]3 I-protein 
( [C]( I-protein 
sCD23 [C]s [C]C [C]D [C]2 [C]3 I-protein 
) [C]) I-protein 
fusion [C]f [C]u [C]s [C]i [C]o [C]n I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
rapidly [C]r [C]a [C]p [C]i [C]d [C]l [C]y O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
secretion [C]s [C]e [C]c [C]r [C]e [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
interleukin [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n B-protein 
8 [C]8 E-protein 
, [C], O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e B-protein 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
( [C]( I-protein 
MIP [C]M [C]I [C]P I-protein 
) [C]) I-protein 
1alpha [C]1 [C]a [C]l [C]p [C]h [C]a E-protein 
, [C], O 
and [C]a [C]n [C]d O 
MIP-1beta [C]M [C]I [C]P [C]- [C]1 [C]b [C]e [C]t [C]a S-protein 
. [C]. O 

Because [C]B [C]e [C]c [C]a [C]u [C]s [C]e O 
the [C]t [C]h [C]e O 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s S-DNA 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
chemokine [C]c [C]h [C]e [C]m [C]o [C]k [C]i [C]n [C]e B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
contain [C]c [C]o [C]n [C]t [C]a [C]i [C]n O 
kappaB [C]k [C]a [C]p [C]p [C]a [C]B B-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
, [C], O 
we [C]w [C]e O 
assessed [C]a [C]s [C]s [C]e [C]s [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
possible [C]p [C]o [C]s [C]s [C]i [C]b [C]l [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor-kappaB [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
( [C]( O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
) [C]) O 
in [C]i [C]n O 
controlling [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]l [C]i [C]n [C]g O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
genes [C]g [C]e [C]n [C]e [C]s O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
beta [C]b [C]e [C]t [C]a O 
( [C]( O 
2 [C]2 O 
) [C]) O 
integrin [C]i [C]n [C]t [C]e [C]g [C]r [C]i [C]n O 
engagement [C]e [C]n [C]g [C]a [C]g [C]e [C]m [C]e [C]n [C]t O 
. [C]. O 

Electrophoretic [C]E [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
sCD23 [C]s [C]C [C]D [C]2 [C]3 S-protein 
or [C]o [C]r O 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s S-protein 
to [C]t [C]o O 
CD11b [C]C [C]D [C]1 [C]1 [C]b S-protein 
or [C]o [C]r O 
to [C]t [C]o O 
CD11c [C]C [C]D [C]1 [C]1 [C]c S-protein 
up-regulated [C]u [C]p [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
DNA-binding [C]D [C]N [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
. [C]. O 

Activation [C]A [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
was [C]w [C]a [C]s O 
accompanied [C]a [C]c [C]c [C]o [C]m [C]p [C]a [C]n [C]i [C]e [C]d O 
by [C]b [C]y O 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
its [C]i [C]t [C]s O 
cytosolic [C]c [C]y [C]t [C]o [C]s [C]o [C]l [C]i [C]c B-protein 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r I-protein 
IkappaB-alpha [C]I [C]k [C]a [C]p [C]p [C]a [C]B [C]- [C]a [C]l [C]p [C]h [C]a E-protein 
. [C]. O 

Blockade [C]B [C]l [C]o [C]c [C]k [C]a [C]d [C]e O 
of [C]o [C]f O 
depletion [C]d [C]e [C]p [C]l [C]e [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IkappaB-alpha [C]I [C]k [C]a [C]p [C]p [C]a [C]B [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
by [C]b [C]y O 
proteasome [C]p [C]r [C]o [C]t [C]e [C]a [C]s [C]o [C]m [C]e O 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
( [C]( O 
proteasome [C]p [C]r [C]o [C]t [C]e [C]a [C]s [C]o [C]m [C]e O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
I [C]I O 
or [C]o [C]r O 
acetyl-leucinyl-leucinyl-norleucinal [C]a [C]c [C]e [C]t [C]y [C]l [C]- [C]l [C]e [C]u [C]c [C]i [C]n [C]y [C]l [C]- [C]l [C]e [C]u [C]c [C]i [C]n [C]y [C]l [C]- [C]n [C]o [C]r [C]l [C]e [C]u [C]c [C]i [C]n [C]a [C]l O 
) [C]) O 
led [C]l [C]e [C]d O 
to [C]t [C]o O 
concomitant [C]c [C]o [C]n [C]c [C]o [C]m [C]i [C]t [C]a [C]n [C]t O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B O 
DNA-binding [C]D [C]N [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
MIP-1alpha [C]M [C]I [C]P [C]- [C]1 [C]a [C]l [C]p [C]h [C]a B-RNA 
and [C]a [C]n [C]d I-RNA 
MIP-1beta [C]M [C]I [C]P [C]- [C]1 [C]b [C]e [C]t [C]a I-RNA 
messenger [C]m [C]e [C]s [C]s [C]e [C]n [C]g [C]e [C]r I-RNA 
RNA [C]R [C]N [C]A E-RNA 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
beta [C]b [C]e [C]t [C]a O 
( [C]( O 
2 [C]2 O 
) [C]) O 
integrin [C]i [C]n [C]t [C]e [C]g [C]r [C]i [C]n O 
ligation [C]l [C]i [C]g [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
triggering [C]t [C]r [C]i [C]g [C]g [C]e [C]r [C]i [C]n [C]g O 
of [C]o [C]f O 
CD11b [C]C [C]D [C]1 [C]1 [C]b S-protein 
or [C]o [C]r O 
CD11c [C]C [C]D [C]1 [C]1 [C]c B-protein 
beta [C]b [C]e [C]t [C]a I-protein 
( [C]( I-protein 
2 [C]2 I-protein 
) [C]) E-protein 
integrin [C]i [C]n [C]t [C]e [C]g [C]r [C]i [C]n O 
on [C]o [C]n O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
provides [C]p [C]r [C]o [C]v [C]i [C]d [C]e [C]s O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
leading [C]l [C]e [C]a [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
translocation [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
and [C]a [C]n [C]d O 
subsequent [C]s [C]u [C]b [C]s [C]e [C]q [C]u [C]e [C]n [C]t O 
secretion [C]s [C]e [C]c [C]r [C]e [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
MIP-1alpha [C]M [C]I [C]P [C]- [C]1 [C]a [C]l [C]p [C]h [C]a S-protein 
and [C]a [C]n [C]d O 
MIP-1beta [C]M [C]I [C]P [C]- [C]1 [C]b [C]e [C]t [C]a S-protein 
that [C]t [C]h [C]a [C]t O 
may [C]m [C]a [C]y O 
have [C]h [C]a [C]v [C]e O 
an [C]a [C]n O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
recruitment [C]r [C]e [C]c [C]r [C]u [C]i [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
other [C]o [C]t [C]h [C]e [C]r O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
initiation [C]i [C]n [C]i [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
an [C]a [C]n O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 

Synergistic [C]S [C]y [C]n [C]e [C]r [C]g [C]i [C]s [C]t [C]i [C]c O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
Acyl-coenzyme [C]A [C]c [C]y [C]l [C]- [C]c [C]o [C]e [C]n [C]z [C]y [C]m [C]e I-DNA 
A [C]A I-DNA 
: [C]: I-DNA 
cholesterol [C]c [C]h [C]o [C]l [C]e [C]s [C]t [C]e [C]r [C]o [C]l I-DNA 
acyltransterase-1 [C]a [C]c [C]y [C]l [C]t [C]r [C]a [C]n [C]s [C]t [C]e [C]r [C]a [C]s [C]e [C]- [C]1 I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
by [C]b [C]y O 
interferon-gamma [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
and [C]a [C]n [C]d O 
all-trans-retinoic [C]a [C]l [C]l [C]- [C]t [C]r [C]a [C]n [C]s [C]- [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
THP-1 [C]T [C]H [C]P [C]- [C]1 B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Acyl-coenzyme [C]A [C]c [C]y [C]l [C]- [C]c [C]o [C]e [C]n [C]z [C]y [C]m [C]e B-protein 
A [C]A I-protein 
: [C]: I-protein 
cholesterol [C]c [C]h [C]o [C]l [C]e [C]s [C]t [C]e [C]r [C]o [C]l I-protein 
acyltransferase [C]a [C]c [C]y [C]l [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]r [C]a [C]s [C]e E-protein 
( [C]( O 
ACAT [C]A [C]C [C]A [C]T S-protein 
) [C]) O 
is [C]i [C]s O 
an [C]a [C]n O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
enzyme [C]e [C]n [C]z [C]y [C]m [C]e E-protein 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
cholesterol [C]c [C]h [C]o [C]l [C]e [C]s [C]t [C]e [C]r [C]o [C]l O 
homeostasis [C]h [C]o [C]m [C]e [C]o [C]s [C]t [C]a [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
atherosclerotic [C]a [C]t [C]h [C]e [C]r [C]o [C]s [C]c [C]l [C]e [C]r [C]o [C]t [C]i [C]c O 
foam [C]f [C]o [C]a [C]m O 
cell [C]c [C]e [C]l [C]l O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Human [C]H [C]u [C]m [C]a [C]n B-DNA 
ACAT-1 [C]A [C]C [C]A [C]T [C]- [C]1 I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
contains [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]s O 
two [C]t [C]w [C]o O 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s S-DNA 
( [C]( O 
P1 [C]P [C]1 S-DNA 
and [C]a [C]n [C]d O 
P7 [C]P [C]7 S-DNA 
) [C]) O 
, [C], O 
each [C]e [C]a [C]c [C]h O 
located [C]l [C]o [C]c [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
a [C]a O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
chromosome [C]c [C]h [C]r [C]o [C]m [C]o [C]s [C]o [C]m [C]e B-DNA 
( [C]( I-DNA 
1 [C]1 I-DNA 
and [C]a [C]n [C]d I-DNA 
7 [C]7 I-DNA 
) [C]) E-DNA 
( [C]( O 
Li [C]L [C]i O 
, [C], O 
B. [C]B [C]. O 
L. [C]L [C]. O 
, [C], O 
Li [C]L [C]i O 
, [C], O 
X. [C]X [C]. O 
L. [C]L [C]. O 
, [C], O 
Duan [C]D [C]u [C]a [C]n O 
, [C], O 
Z. [C]Z [C]. O 
J. [C]J [C]. O 
, [C], O 
Lee [C]L [C]e [C]e O 
, [C], O 
O. [C]O [C]. O 
, [C], O 
Lin [C]L [C]i [C]n O 
, [C], O 
S. [C]S [C]. O 
, [C], O 
Ma [C]M [C]a O 
, [C], O 
Z. [C]Z [C]. O 
M. [C]M [C]. O 
, [C], O 
Chang [C]C [C]h [C]a [C]n [C]g O 
, [C], O 
C. [C]C [C]. O 
C. [C]C [C]. O 
, [C], O 
Yang [C]Y [C]a [C]n [C]g O 
, [C], O 
X. [C]X [C]. O 
Y. [C]Y [C]. O 
, [C], O 
Park [C]P [C]a [C]r [C]k O 
, [C], O 
J. [C]J [C]. O 
P. [C]P [C]. O 
, [C], O 
Mohandas [C]M [C]o [C]h [C]a [C]n [C]d [C]a [C]s O 
, [C], O 
T. [C]T [C]. O 
K. [C]K [C]. O 
, [C], O 
Noll [C]N [C]o [C]l [C]l O 
, [C], O 
W. [C]W [C]. O 
, [C], O 
Chan [C]C [C]h [C]a [C]n O 
, [C], O 
L. [C]L [C]. O 
, [C], O 
and [C]a [C]n [C]d O 
Chang [C]C [C]h [C]a [C]n [C]g O 
, [C], O 
T. [C]T [C]. O 
Y. [C]Y [C]. O 
( [C]( O 
1999 [C]1 [C]9 [C]9 [C]9 O 
) [C]) O 
J. [C]J [C]. O 
Biol [C]B [C]i [C]o [C]l O 
Chem. [C]C [C]h [C]e [C]m [C]. O 
274 [C]2 [C]7 [C]4 O 
, [C], O 
11060-11071 [C]1 [C]1 [C]0 [C]6 [C]0 [C]- [C]1 [C]1 [C]0 [C]7 [C]1 O 
) [C]) O 
. [C]. O 

Interferon-gamma [C]I [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
( [C]( O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
) [C]) O 
, [C], O 
a [C]a O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e S-protein 
that [C]t [C]h [C]a [C]t O 
exerts [C]e [C]x [C]e [C]r [C]t [C]s O 
many [C]m [C]a [C]n [C]y O 
pro-atherosclerotic [C]p [C]r [C]o [C]- [C]a [C]t [C]h [C]e [C]r [C]o [C]s [C]c [C]l [C]e [C]r [C]o [C]t [C]i [C]c O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
, [C], O 
causes [C]c [C]a [C]u [C]s [C]e [C]s O 
up-regulation [C]u [C]p [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
ACAT-1 [C]A [C]C [C]A [C]T [C]- [C]1 B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
monocyte-derived [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d I-cell_type 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
macrophage-like [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]- [C]l [C]i [C]k [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
in [C]i [C]n O 
other [C]o [C]t [C]h [C]e [C]r O 
cell [C]c [C]e [C]l [C]l O 
types [C]t [C]y [C]p [C]e [C]s O 
. [C]. O 

To [C]T [C]o O 
examine [C]e [C]x [C]a [C]m [C]i [C]n [C]e O 
the [C]t [C]h [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
nature [C]n [C]a [C]t [C]u [C]r [C]e O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
observation [C]o [C]b [C]s [C]e [C]r [C]v [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
we [C]w [C]e O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
the [C]t [C]h [C]e O 
ACAT-1 [C]A [C]C [C]A [C]T [C]- [C]1 B-DNA 
P1 [C]P [C]1 I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
a [C]a O 
159-base [C]1 [C]5 [C]9 [C]- [C]b [C]a [C]s [C]e B-DNA 
pair [C]p [C]a [C]i [C]r I-DNA 
core [C]c [C]o [C]r [C]e I-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
region [C]r [C]e [C]g [C]i [C]o [C]n O 
contains [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]s O 
4 [C]4 O 
Sp1 [C]S [C]p [C]1 B-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
and [C]a [C]n [C]d O 
an [C]a [C]n O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a B-DNA 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d I-DNA 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e E-DNA 
( [C]( O 
GAS [C]G [C]A [C]S S-DNA 
) [C]) O 
that [C]t [C]h [C]a [C]t O 
overlaps [C]o [C]v [C]e [C]r [C]l [C]a [C]p [C]s O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
second [C]s [C]e [C]c [C]o [C]n [C]d O 
Sp1 [C]S [C]p [C]1 B-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
. [C]. O 

In [C]I [C]n O 
the [C]t [C]h [C]e O 
monocytic [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]i [C]c B-cell_type 
cell [C]c [C]e [C]l [C]l I-cell_type 
line [C]l [C]i [C]n [C]e I-cell_type 
THP-1 [C]T [C]H [C]P [C]- [C]1 I-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
, [C], O 
the [C]t [C]h [C]e O 
combination [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
and [C]a [C]n [C]d O 
all-trans-retinoic [C]a [C]l [C]l [C]- [C]t [C]r [C]a [C]n [C]s [C]- [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
( [C]( O 
a [C]a O 
known [C]k [C]n [C]o [C]w [C]n O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
agent [C]a [C]g [C]e [C]n [C]t O 
) [C]) O 
enhances [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]s O 
the [C]t [C]h [C]e O 
ACAT-1 [C]A [C]C [C]A [C]T [C]- [C]1 B-DNA 
P1 [C]P [C]1 I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
the [C]t [C]h [C]e O 
P7 [C]P [C]7 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

Additional [C]A [C]d [C]d [C]i [C]t [C]i [C]o [C]n [C]a [C]l O 
experiments [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]s O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
all-trans-retinoic [C]a [C]l [C]l [C]- [C]t [C]r [C]a [C]n [C]s [C]- [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
causes [C]c [C]a [C]u [C]s [C]e [C]s O 
large [C]l [C]a [C]r [C]g [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
STAT1 [C]S [C]T [C]A [C]T [C]1 E-protein 
, [C], O 
while [C]w [C]h [C]i [C]l [C]e O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
causes [C]c [C]a [C]u [C]s [C]e [C]s O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
STAT1 [C]S [C]T [C]A [C]T [C]1 S-protein 
such [C]s [C]u [C]c [C]h O 
that [C]t [C]h [C]a [C]t O 
it [C]i [C]t O 
binds [C]b [C]i [C]n [C]d [C]s O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
GAS/Sp1 [C]G [C]A [C]S [C]/ [C]S [C]p [C]1 B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
ACAT-1 [C]A [C]C [C]A [C]T [C]- [C]1 B-DNA 
P1 [C]P [C]1 I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

Our [C]O [C]u [C]r O 
work [C]w [C]o [C]r [C]k O 
provides [C]p [C]r [C]o [C]v [C]i [C]d [C]e [C]s O 
a [C]a O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
to [C]t [C]o O 
account [C]a [C]c [C]c [C]o [C]u [C]n [C]t O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
in [C]i [C]n O 
causing [C]c [C]a [C]u [C]s [C]i [C]n [C]g O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
ACAT-1 [C]A [C]C [C]A [C]T [C]- [C]1 S-protein 
in [C]i [C]n O 
macrophage-like [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]- [C]l [C]i [C]k [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Inhaled [C]I [C]n [C]h [C]a [C]l [C]e [C]d O 
nitric [C]n [C]i [C]t [C]r [C]i [C]c O 
oxide [C]o [C]x [C]i [C]d [C]e O 
down-regulates [C]d [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]s O 
intrapulmonary [C]i [C]n [C]t [C]r [C]a [C]p [C]u [C]l [C]m [C]o [C]n [C]a [C]r [C]y O 
nitric [C]n [C]i [C]t [C]r [C]i [C]c O 
oxide [C]o [C]x [C]i [C]d [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
lipopolysaccharide-induced [C]l [C]i [C]p [C]o [C]p [C]o [C]l [C]y [C]s [C]a [C]c [C]c [C]h [C]a [C]r [C]i [C]d [C]e [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
acute [C]a [C]c [C]u [C]t [C]e O 
lung [C]l [C]u [C]n [C]g O 
injury [C]i [C]n [C]j [C]u [C]r [C]y O 
. [C]. O 

OBJECTIVE [C]O [C]B [C]J [C]E [C]C [C]T [C]I [C]V [C]E O 
: [C]: O 
To [C]T [C]o O 
examine [C]e [C]x [C]a [C]m [C]i [C]n [C]e O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
inhaled [C]i [C]n [C]h [C]a [C]l [C]e [C]d O 
nitric [C]n [C]i [C]t [C]r [C]i [C]c O 
oxide [C]o [C]x [C]i [C]d [C]e O 
( [C]( O 
NO [C]N [C]O O 
) [C]) O 
affected [C]a [C]f [C]f [C]e [C]c [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
intrapulmonary [C]i [C]n [C]t [C]r [C]a [C]p [C]u [C]l [C]m [C]o [C]n [C]a [C]r [C]y O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NO [C]N [C]O O 
, [C], O 
reactive [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]e O 
oxygen [C]o [C]x [C]y [C]g [C]e [C]n O 
species [C]s [C]p [C]e [C]c [C]i [C]e [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor-kappaB [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
in [C]i [C]n O 
a [C]a O 
lipopolysaccharide [C]l [C]i [C]p [C]o [C]p [C]o [C]l [C]y [C]s [C]a [C]c [C]c [C]h [C]a [C]r [C]i [C]d [C]e O 
( [C]( O 
LPS [C]L [C]P [C]S O 
) [C]) O 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
model [C]m [C]o [C]d [C]e [C]l O 
of [C]o [C]f O 
acute [C]a [C]c [C]u [C]t [C]e O 
lung [C]l [C]u [C]n [C]g O 
injury [C]i [C]n [C]j [C]u [C]r [C]y O 
. [C]. O 

DESIGN [C]D [C]E [C]S [C]I [C]G [C]N O 
: [C]: O 
Prospective [C]P [C]r [C]o [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e O 
, [C], O 
randomized [C]r [C]a [C]n [C]d [C]o [C]m [C]i [C]z [C]e [C]d O 
, [C], O 
laboratory [C]l [C]a [C]b [C]o [C]r [C]a [C]t [C]o [C]r [C]y O 
study [C]s [C]t [C]u [C]d [C]y O 
. [C]. O 

SETTING [C]S [C]E [C]T [C]T [C]I [C]N [C]G O 
: [C]: O 
Experimental [C]E [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]a [C]l O 
laboratory [C]l [C]a [C]b [C]o [C]r [C]a [C]t [C]o [C]r [C]y O 
at [C]a [C]t O 
a [C]a O 
biomedical [C]b [C]i [C]o [C]m [C]e [C]d [C]i [C]c [C]a [C]l O 
institute [C]i [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]e O 
. [C]. O 

SUBJECTS [C]S [C]U [C]B [C]J [C]E [C]C [C]T [C]S O 
: [C]: O 
Twenty [C]T [C]w [C]e [C]n [C]t [C]y O 
male [C]m [C]a [C]l [C]e O 
rabbits [C]r [C]a [C]b [C]b [C]i [C]t [C]s O 
weighing [C]w [C]e [C]i [C]g [C]h [C]i [C]n [C]g O 
2.5-3.5 [C]2 [C]. [C]5 [C]- [C]3 [C]. [C]5 O 
kg [C]k [C]g O 
. [C]. O 

INTERVENTIONS [C]I [C]N [C]T [C]E [C]R [C]V [C]E [C]N [C]T [C]I [C]O [C]N [C]S O 
: [C]: O 
Saline [C]S [C]a [C]l [C]i [C]n [C]e O 
or [C]o [C]r O 
LPS [C]L [C]P [C]S O 
( [C]( O 
5 [C]5 O 
mg/kg [C]m [C]g [C]/ [C]k [C]g O 
of [C]o [C]f O 
body [C]b [C]o [C]d [C]y O 
weight [C]w [C]e [C]i [C]g [C]h [C]t O 
) [C]) O 
was [C]w [C]a [C]s O 
administered [C]a [C]d [C]m [C]i [C]n [C]i [C]s [C]t [C]e [C]r [C]e [C]d O 
intravenously [C]i [C]n [C]t [C]r [C]a [C]v [C]e [C]n [C]o [C]u [C]s [C]l [C]y O 
with [C]w [C]i [C]t [C]h O 
or [C]o [C]r O 
without [C]w [C]i [C]t [C]h [C]o [C]u [C]t O 
NO [C]N [C]O O 
inhalation [C]i [C]n [C]h [C]a [C]l [C]a [C]t [C]i [C]o [C]n O 
( [C]( O 
10 [C]1 [C]0 O 
ppm [C]p [C]p [C]m O 
) [C]) O 
in [C]i [C]n O 
each [C]e [C]a [C]c [C]h O 
group [C]g [C]r [C]o [C]u [C]p O 
of [C]o [C]f O 
five [C]f [C]i [C]v [C]e O 
rabbits [C]r [C]a [C]b [C]b [C]i [C]t [C]s O 
. [C]. O 

MEASUREMENTS [C]M [C]E [C]A [C]S [C]U [C]R [C]E [C]M [C]E [C]N [C]T [C]S O 
AND [C]A [C]N [C]D O 
MAIN [C]M [C]A [C]I [C]N O 
RESULTS [C]R [C]E [C]S [C]U [C]L [C]T [C]S O 
: [C]: O 
LPS [C]L [C]P [C]S O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
lung [C]l [C]u [C]n [C]g O 
leak [C]l [C]e [C]a [C]k O 
index [C]i [C]n [C]d [C]e [C]x O 
, [C], O 
the [C]t [C]h [C]e O 
neutrophils [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]h [C]i [C]l [C]s S-cell_type 
and [C]a [C]n [C]d O 
NO [C]N [C]O O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
in [C]i [C]n O 
bronchoalveolar [C]b [C]r [C]o [C]n [C]c [C]h [C]o [C]a [C]l [C]v [C]e [C]o [C]l [C]a [C]r O 
lavage [C]l [C]a [C]v [C]a [C]g [C]e O 
fluid [C]f [C]l [C]u [C]i [C]d O 
, [C], O 
and [C]a [C]n [C]d O 
NO [C]N [C]O O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
produced [C]p [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
resting [C]r [C]e [C]s [C]t [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
alveolar [C]a [C]l [C]v [C]e [C]o [C]l [C]a [C]r B-cell_type 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s E-cell_type 
. [C]. O 

Inhaled [C]I [C]n [C]h [C]a [C]l [C]e [C]d O 
NO [C]N [C]O O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
lung [C]l [C]u [C]n [C]g O 
leak [C]l [C]e [C]a [C]k O 
index [C]i [C]n [C]d [C]e [C]x O 
, [C], O 
the [C]t [C]h [C]e O 
neutrophils [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]h [C]i [C]l [C]s S-cell_type 
and [C]a [C]n [C]d O 
NO [C]N [C]O O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
as [C]a [C]s O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
by [C]b [C]y O 
nitrite [C]n [C]i [C]t [C]r [C]i [C]t [C]e O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
lavage [C]l [C]a [C]v [C]a [C]g [C]e O 
fluid [C]f [C]l [C]u [C]i [C]d O 
, [C], O 
and [C]a [C]n [C]d O 
NO [C]N [C]O O 
produced [C]p [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
resting [C]r [C]e [C]s [C]t [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
alveolar [C]a [C]l [C]v [C]e [C]o [C]l [C]a [C]r B-cell_type 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s E-cell_type 
. [C]. O 

Inhaled [C]I [C]n [C]h [C]a [C]l [C]e [C]d O 
NO [C]N [C]O O 
also [C]a [C]l [C]s [C]o O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
the [C]t [C]h [C]e O 
activities [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]i [C]e [C]s O 
of [C]o [C]f O 
reactive [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]e O 
oxygen [C]o [C]x [C]y [C]g [C]e [C]n O 
species [C]s [C]p [C]e [C]c [C]i [C]e [C]s O 
and [C]a [C]n [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor-kappaB [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
DNA [C]D [C]N [C]A O 
in [C]i [C]n O 
lavage [C]l [C]a [C]v [C]a [C]g [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
alveolar [C]a [C]l [C]v [C]e [C]o [C]l [C]a [C]r B-cell_type 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s E-cell_type 
. [C]. O 

CONCLUSION [C]C [C]O [C]N [C]C [C]L [C]U [C]S [C]I [C]O [C]N O 
: [C]: O 
Inhaled [C]I [C]n [C]h [C]a [C]l [C]e [C]d O 
NO [C]N [C]O O 
attenuates [C]a [C]t [C]t [C]e [C]n [C]u [C]a [C]t [C]e [C]s O 
LPS-induced [C]L [C]P [C]S [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
acute [C]a [C]c [C]u [C]t [C]e O 
lung [C]l [C]u [C]n [C]g O 
injury [C]i [C]n [C]j [C]u [C]r [C]y O 
, [C], O 
possibly [C]p [C]o [C]s [C]s [C]i [C]b [C]l [C]y O 
by [C]b [C]y O 
decreasing [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]i [C]n [C]g O 
NO [C]N [C]O O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
lungs [C]l [C]u [C]n [C]g [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
of [C]o [C]f O 
reducing [C]r [C]e [C]d [C]u [C]c [C]i [C]n [C]g O 
NO [C]N [C]O O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
resulting [C]r [C]e [C]s [C]u [C]l [C]t [C]i [C]n [C]g O 
from [C]f [C]r [C]o [C]m O 
inhaled [C]i [C]n [C]h [C]a [C]l [C]e [C]d O 
NO [C]N [C]O O 
may [C]m [C]a [C]y O 
involve [C]i [C]n [C]v [C]o [C]l [C]v [C]e O 
, [C], O 
in [C]i [C]n O 
part [C]p [C]a [C]r [C]t O 
, [C], O 
the [C]t [C]h [C]e O 
activities [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]i [C]e [C]s O 
of [C]o [C]f O 
reactive [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]e O 
oxygen [C]o [C]x [C]y [C]g [C]e [C]n O 
species [C]s [C]p [C]e [C]c [C]i [C]e [C]s O 
and/or [C]a [C]n [C]d [C]/ [C]o [C]r O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor-kappaB [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
. [C]. O 

Treatment [C]T [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
allergic [C]a [C]l [C]l [C]e [C]r [C]g [C]i [C]c O 
airway [C]a [C]i [C]r [C]w [C]a [C]y O 
inflammation [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
hyperresponsiveness [C]h [C]y [C]p [C]e [C]r [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e [C]n [C]e [C]s [C]s O 
by [C]b [C]y O 
antisense-induced [C]a [C]n [C]t [C]i [C]s [C]e [C]n [C]s [C]e [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
local [C]l [C]o [C]c [C]a [C]l O 
blockade [C]b [C]l [C]o [C]c [C]k [C]a [C]d [C]e O 
of [C]o [C]f O 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 S-DNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Recent [C]R [C]e [C]c [C]e [C]n [C]t O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
in [C]i [C]n O 
transgenic [C]t [C]r [C]a [C]n [C]s [C]g [C]e [C]n [C]i [C]c O 
mice [C]m [C]i [C]c [C]e O 
have [C]h [C]a [C]v [C]e O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
dominant [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
form [C]f [C]o [C]r [C]m O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 E-protein 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
can [C]c [C]a [C]n O 
prevent [C]p [C]r [C]e [C]v [C]e [C]n [C]t O 
T [C]T B-cell_type 
helper [C]h [C]e [C]l [C]p [C]e [C]r I-cell_type 
cell [C]c [C]e [C]l [C]l I-cell_type 
type [C]t [C]y [C]p [C]e I-cell_type 
2 [C]2 E-cell_type 
( [C]( O 
Th2 [C]T [C]h [C]2 S-cell_type 
) [C]) O 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
allergic [C]a [C]l [C]l [C]e [C]r [C]g [C]i [C]c O 
airway [C]a [C]i [C]r [C]w [C]a [C]y O 
inflammation [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
mice [C]m [C]i [C]c [C]e O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
it [C]i [C]t O 
remains [C]r [C]e [C]m [C]a [C]i [C]n [C]s O 
unclear [C]u [C]n [C]c [C]l [C]e [C]a [C]r O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 S-protein 
plays [C]p [C]l [C]a [C]y [C]s O 
a [C]a O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
effector [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r O 
phase [C]p [C]h [C]a [C]s [C]e O 
of [C]o [C]f O 
allergic [C]a [C]l [C]l [C]e [C]r [C]g [C]i [C]c O 
airway [C]a [C]i [C]r [C]w [C]a [C]y O 
inflammation [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
antagonizing [C]a [C]n [C]t [C]a [C]g [C]o [C]n [C]i [C]z [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and/or [C]a [C]n [C]d [C]/ [C]o [C]r O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 S-DNA 
can [C]c [C]a [C]n O 
be [C]b [C]e O 
used [C]u [C]s [C]e [C]d O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
of [C]o [C]f O 
allergic [C]a [C]l [C]l [C]e [C]r [C]g [C]i [C]c O 
airway [C]a [C]i [C]r [C]w [C]a [C]y O 
inflammation [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
hyperresponsiveness [C]h [C]y [C]p [C]e [C]r [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e [C]n [C]e [C]s [C]s O 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
, [C], O 
we [C]w [C]e O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
the [C]t [C]h [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
locally [C]l [C]o [C]c [C]a [C]l [C]l [C]y O 
antagonizing [C]a [C]n [C]t [C]a [C]g [C]o [C]n [C]i [C]z [C]i [C]n [C]g O 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 S-protein 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
a [C]a O 
murine [C]m [C]u [C]r [C]i [C]n [C]e O 
model [C]m [C]o [C]d [C]e [C]l O 
of [C]o [C]f O 
asthma [C]a [C]s [C]t [C]h [C]m [C]a O 
. [C]. O 

We [C]W [C]e O 
could [C]c [C]o [C]u [C]l [C]d O 
suppress [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s O 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
interleukin [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n B-protein 
( [C]( I-protein 
IL [C]I [C]L I-protein 
) [C]) I-protein 
-4 [C]- [C]4 E-protein 
-producing [C]- [C]p [C]r [C]o [C]d [C]u [C]c [C]i [C]n [C]g O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
by [C]b [C]y O 
an [C]a [C]n O 
antisense [C]a [C]n [C]t [C]i [C]s [C]e [C]n [C]s [C]e O 
phosphorothioate [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]o [C]t [C]h [C]i [C]o [C]a [C]t [C]e O 
oligonucleotide [C]o [C]l [C]i [C]g [C]o [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e O 
overlapping [C]o [C]v [C]e [C]r [C]l [C]a [C]p [C]p [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
translation [C]t [C]r [C]a [C]n [C]s [C]l [C]a [C]t [C]i [C]o [C]n B-DNA 
start [C]s [C]t [C]a [C]r [C]t I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
of [C]o [C]f O 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 S-DNA 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
nonsense [C]n [C]o [C]n [C]s [C]e [C]n [C]s [C]e O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
oligonucleotides [C]o [C]l [C]i [C]g [C]o [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
virtually [C]v [C]i [C]r [C]t [C]u [C]a [C]l [C]l [C]y O 
inactive [C]i [C]n [C]a [C]c [C]t [C]i [C]v [C]e O 
. [C]. O 

In [C]I [C]n O 
a [C]a O 
murine [C]m [C]u [C]r [C]i [C]n [C]e O 
model [C]m [C]o [C]d [C]e [C]l O 
of [C]o [C]f O 
asthma [C]a [C]s [C]t [C]h [C]m [C]a O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
allergic [C]a [C]l [C]l [C]e [C]r [C]g [C]i [C]c O 
pulmonary [C]p [C]u [C]l [C]m [C]o [C]n [C]a [C]r [C]y O 
inflammation [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
hyperresponsiveness [C]h [C]y [C]p [C]e [C]r [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e [C]n [C]e [C]s [C]s O 
in [C]i [C]n O 
ovalbumin [C]o [C]v [C]a [C]l [C]b [C]u [C]m [C]i [C]n O 
( [C]( O 
OVA [C]O [C]V [C]A O 
) [C]) O 
-sensitized [C]- [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]z [C]e [C]d O 
mice [C]m [C]i [C]c [C]e O 
, [C], O 
local [C]l [C]o [C]c [C]a [C]l O 
intranasal [C]i [C]n [C]t [C]r [C]a [C]n [C]a [C]s [C]a [C]l O 
administration [C]a [C]d [C]m [C]i [C]n [C]i [C]s [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
fluorescein [C]f [C]l [C]u [C]o [C]r [C]e [C]s [C]c [C]e [C]i [C]n O 
isothiocyanate-labeled [C]i [C]s [C]o [C]t [C]h [C]i [C]o [C]c [C]y [C]a [C]n [C]a [C]t [C]e [C]- [C]l [C]a [C]b [C]e [C]l [C]e [C]d O 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 O 
antisense [C]a [C]n [C]t [C]i [C]s [C]e [C]n [C]s [C]e O 
oligonucleotides [C]o [C]l [C]i [C]g [C]o [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e [C]s O 
led [C]l [C]e [C]d O 
to [C]t [C]o O 
DNA [C]D [C]N [C]A O 
uptake [C]u [C]p [C]t [C]a [C]k [C]e O 
in [C]i [C]n O 
lung [C]l [C]u [C]n [C]g B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
reduction [C]r [C]e [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Such [C]S [C]u [C]c [C]h O 
intrapulmonary [C]i [C]n [C]t [C]r [C]a [C]p [C]u [C]l [C]m [C]o [C]n [C]a [C]r [C]y O 
blockade [C]b [C]l [C]o [C]c [C]k [C]a [C]d [C]e O 
of [C]o [C]f O 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
caused [C]c [C]a [C]u [C]s [C]e [C]d O 
an [C]a [C]n O 
abrogation [C]a [C]b [C]r [C]o [C]g [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
signs [C]s [C]i [C]g [C]n [C]s O 
of [C]o [C]f O 
lung [C]l [C]u [C]n [C]g O 
inflammation [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]i [C]o [C]n O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
infiltration [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
eosinophils [C]e [C]o [C]s [C]i [C]n [C]o [C]p [C]h [C]i [C]l [C]s S-cell_type 
and [C]a [C]n [C]d O 
Th2 [C]T [C]h [C]2 S-cell_type 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
antisense [C]a [C]n [C]t [C]i [C]s [C]e [C]n [C]s [C]e O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
nonsense [C]n [C]o [C]n [C]s [C]e [C]n [C]s [C]e O 
oligonucleotides [C]o [C]l [C]i [C]g [C]o [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e [C]s O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
a [C]a O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
reduction [C]r [C]e [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
airway [C]a [C]i [C]r [C]w [C]a [C]y O 
hyperresponsiveness [C]h [C]y [C]p [C]e [C]r [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e [C]n [C]e [C]s [C]s O 
in [C]i [C]n O 
OVA-sensitized [C]O [C]V [C]A [C]- [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]z [C]e [C]d O 
mice [C]m [C]i [C]c [C]e O 
to [C]t [C]o O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
comparable [C]c [C]o [C]m [C]p [C]a [C]r [C]a [C]b [C]l [C]e O 
to [C]t [C]o O 
saline-treated [C]s [C]a [C]l [C]i [C]n [C]e [C]- [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
mice [C]m [C]i [C]c [C]e O 
, [C], O 
as [C]a [C]s O 
assessed [C]a [C]s [C]s [C]e [C]s [C]s [C]e [C]d O 
by [C]b [C]y O 
both [C]b [C]o [C]t [C]h O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
pause [C]p [C]a [C]u [C]s [C]e O 
( [C]( O 
PenH [C]P [C]e [C]n [C]H O 
) [C]) O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
and [C]a [C]n [C]d O 
pulmonary [C]p [C]u [C]l [C]m [C]o [C]n [C]a [C]r [C]y O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
body [C]b [C]o [C]d [C]y O 
plethysmography [C]p [C]l [C]e [C]t [C]h [C]y [C]s [C]m [C]o [C]g [C]r [C]a [C]p [C]h [C]y O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
a [C]a O 
critical [C]c [C]r [C]i [C]t [C]i [C]c [C]a [C]l O 
role [C]r [C]o [C]l [C]e O 
for [C]f [C]o [C]r O 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 S-DNA 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
effector [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r O 
phase [C]p [C]h [C]a [C]s [C]e O 
of [C]o [C]f O 
a [C]a O 
murine [C]m [C]u [C]r [C]i [C]n [C]e O 
asthma [C]a [C]s [C]t [C]h [C]m [C]a O 
model [C]m [C]o [C]d [C]e [C]l O 
and [C]a [C]n [C]d O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
local [C]l [C]o [C]c [C]a [C]l O 
delivery [C]d [C]e [C]l [C]i [C]v [C]e [C]r [C]y O 
of [C]o [C]f O 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 O 
antisense [C]a [C]n [C]t [C]i [C]s [C]e [C]n [C]s [C]e O 
oligonucleotides [C]o [C]l [C]i [C]g [C]o [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e [C]s O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
approach [C]a [C]p [C]p [C]r [C]o [C]a [C]c [C]h O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
airway [C]a [C]i [C]r [C]w [C]a [C]y O 
hyperresponsiveness [C]h [C]y [C]p [C]e [C]r [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e [C]n [C]e [C]s [C]s O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
in [C]i [C]n O 
asthma [C]a [C]s [C]t [C]h [C]m [C]a O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
approach [C]a [C]p [C]p [C]r [C]o [C]a [C]c [C]h O 
has [C]h [C]a [C]s O 
the [C]t [C]h [C]e O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
advantage [C]a [C]d [C]v [C]a [C]n [C]t [C]a [C]g [C]e O 
of [C]o [C]f O 
suppressing [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
proinflammatory [C]p [C]r [C]o [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y B-protein 
Th2 [C]T [C]h [C]2 I-protein 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s E-protein 
simultaneously [C]s [C]i [C]m [C]u [C]l [C]t [C]a [C]n [C]e [C]o [C]u [C]s [C]l [C]y O 
rather [C]r [C]a [C]t [C]h [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
suppressing [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
a [C]a O 
single [C]s [C]i [C]n [C]g [C]l [C]e O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e S-protein 
. [C]. O 

T [C]T O 
helper-cell [C]h [C]e [C]l [C]p [C]e [C]r [C]- [C]c [C]e [C]l [C]l O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
regulates [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]s O 
atherosclerosis [C]a [C]t [C]h [C]e [C]r [C]o [C]s [C]c [C]l [C]e [C]r [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
mice [C]m [C]i [C]c [C]e O 
under [C]u [C]n [C]d [C]e [C]r O 
conditions [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
mild [C]m [C]i [C]l [C]d O 
hypercholesterolemia [C]h [C]y [C]p [C]e [C]r [C]c [C]h [C]o [C]l [C]e [C]s [C]t [C]e [C]r [C]o [C]l [C]e [C]m [C]i [C]a O 
. [C]. O 

BACKGROUND [C]B [C]A [C]C [C]K [C]G [C]R [C]O [C]U [C]N [C]D O 
: [C]: O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
are [C]a [C]r [C]e O 
implicated [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
atherosclerosis [C]a [C]t [C]h [C]e [C]r [C]o [C]s [C]c [C]l [C]e [C]r [C]o [C]s [C]i [C]s O 
, [C], O 
but [C]b [C]u [C]t O 
little [C]l [C]i [C]t [C]t [C]l [C]e O 
is [C]i [C]s O 
known [C]k [C]n [C]o [C]w [C]n O 
about [C]a [C]b [C]o [C]u [C]t O 
the [C]t [C]h [C]e O 
genetic [C]g [C]e [C]n [C]e [C]t [C]i [C]c O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
or [C]o [C]r O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
, [C], O 
especially [C]e [C]s [C]p [C]e [C]c [C]i [C]a [C]l [C]l [C]y O 
under [C]u [C]n [C]d [C]e [C]r O 
conditions [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
mild [C]m [C]i [C]l [C]d O 
hypercholesterolemia [C]h [C]y [C]p [C]e [C]r [C]c [C]h [C]o [C]l [C]e [C]s [C]t [C]e [C]r [C]o [C]l [C]e [C]m [C]i [C]a O 
. [C]. O 

METHODS [C]M [C]E [C]T [C]H [C]O [C]D [C]S O 
AND [C]A [C]N [C]D O 
RESULTS [C]R [C]E [C]S [C]U [C]L [C]T [C]S O 
: [C]: O 
BALB/c [C]B [C]A [C]L [C]B [C]/ [C]c O 
mice [C]m [C]i [C]c [C]e O 
, [C], O 
making [C]m [C]a [C]k [C]i [C]n [C]g O 
a [C]a O 
CD4+ [C]C [C]D [C]4 [C]+ O 
Th2 [C]T [C]h [C]2 O 
( [C]( O 
IL-4+ [C]I [C]L [C]- [C]4 [C]+ O 
) [C]) O 
cell [C]c [C]e [C]l [C]l O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
, [C], O 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
both [C]b [C]o [C]t [C]h O 
MHC [C]M [C]H [C]C B-protein 
class [C]c [C]l [C]a [C]s [C]s I-protein 
II [C]I [C]I I-protein 
antigens [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]s E-protein 
( [C]( O 
IA [C]I [C]A B-protein 
( [C]( I-protein 
d [C]d I-protein 
) [C]) E-protein 
, [C], O 
IE [C]I [C]E B-protein 
( [C]( I-protein 
d [C]d I-protein 
) [C]) E-protein 
) [C]) O 
and [C]a [C]n [C]d O 
are [C]a [C]r [C]e O 
atherosclerosis-resistant [C]a [C]t [C]h [C]e [C]r [C]o [C]s [C]c [C]l [C]e [C]r [C]o [C]s [C]i [C]s [C]- [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]t O 
. [C]. O 

C57Bl/6 [C]C [C]5 [C]7 [C]B [C]l [C]/ [C]6 O 
mice [C]m [C]i [C]c [C]e O 
produce [C]p [C]r [C]o [C]d [C]u [C]c [C]e O 
a [C]a O 
CD4+ [C]C [C]D [C]4 [C]+ O 
Th1 [C]T [C]h [C]1 O 
( [C]( O 
interferon [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n O 
[ [C][ O 
IFN [C]I [C]F [C]N O 
] [C]] O 
gamma+ [C]g [C]a [C]m [C]m [C]a [C]+ O 
) [C]) O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
, [C], O 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
IA [C]I [C]A B-protein 
( [C]( I-protein 
b [C]b I-protein 
) [C]) E-protein 
but [C]b [C]u [C]t O 
no [C]n [C]o O 
IE [C]I [C]E S-protein 
, [C], O 
and [C]a [C]n [C]d O 
are [C]a [C]r [C]e O 
atherosclerosis-prone [C]a [C]t [C]h [C]e [C]r [C]o [C]s [C]c [C]l [C]e [C]r [C]o [C]s [C]i [C]s [C]- [C]p [C]r [C]o [C]n [C]e O 
. [C]. O 

To [C]T [C]o O 
evaluate [C]e [C]v [C]a [C]l [C]u [C]a [C]t [C]e O 
T [C]T O 
helper-cell [C]h [C]e [C]l [C]p [C]e [C]r [C]- [C]c [C]e [C]l [C]l O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
in [C]i [C]n O 
fatty [C]f [C]a [C]t [C]t [C]y O 
streak [C]s [C]t [C]r [C]e [C]a [C]k O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
wild-type [C]w [C]i [C]l [C]d [C]- [C]t [C]y [C]p [C]e O 
C57Bl/6 [C]C [C]5 [C]7 [C]B [C]l [C]/ [C]6 O 
mice [C]m [C]i [C]c [C]e O 
( [C]( O 
IA [C]I [C]A O 
( [C]( O 
b [C]b O 
) [C]) O 
+IE- [C]+ [C]I [C]E [C]- O 
) [C]) O 
and [C]a [C]n [C]d O 
transgenic [C]t [C]r [C]a [C]n [C]s [C]g [C]e [C]n [C]i [C]c O 
mice [C]m [C]i [C]c [C]e O 
, [C], O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
AB [C]A [C]B O 
( [C]( O 
o [C]o O 
) [C]) O 
, [C], O 
IA [C]I [C]A O 
( [C]( O 
b [C]b O 
) [C]) O 
-IE- [C]- [C]I [C]E [C]- O 
; [C]; O 
ABEalpha [C]A [C]B [C]E [C]a [C]l [C]p [C]h [C]a O 
, [C], O 
IA-IE [C]I [C]A [C]- [C]I [C]E O 
( [C]( O 
k [C]k O 
) [C]) O 
+ [C]+ O 
; [C]; O 
or [C]o [C]r O 
BL [C]B [C]L O 
: [C]: O 
TG [C]T [C]G O 
: [C]: O 
Ealpha [C]E [C]a [C]l [C]p [C]h [C]a O 
, [C], O 
IA [C]I [C]A O 
( [C]( O 
b [C]b O 
) [C]) O 
+IE [C]+ [C]I [C]E O 
( [C]( O 
k [C]k O 
) [C]) O 
+ [C]+ O 
, [C], O 
were [C]w [C]e [C]r [C]e O 
fed [C]f [C]e [C]d O 
a [C]a O 
high-cholesterol [C]h [C]i [C]g [C]h [C]- [C]c [C]h [C]o [C]l [C]e [C]s [C]t [C]e [C]r [C]o [C]l O 
diet [C]d [C]i [C]e [C]t O 
for [C]f [C]o [C]r O 
16 [C]1 [C]6 O 
weeks [C]w [C]e [C]e [C]k [C]s O 
and [C]a [C]n [C]d O 
evaluated [C]e [C]v [C]a [C]l [C]u [C]a [C]t [C]e [C]d O 
histomorphometrically [C]h [C]i [C]s [C]t [C]o [C]m [C]o [C]r [C]p [C]h [C]o [C]m [C]e [C]t [C]r [C]i [C]c [C]a [C]l [C]l [C]y O 
for [C]f [C]o [C]r O 
aortic [C]a [C]o [C]r [C]t [C]i [C]c O 
lesions [C]l [C]e [C]s [C]i [C]o [C]n [C]s O 
. [C]. O 

Lesion [C]L [C]e [C]s [C]i [C]o [C]n O 
size [C]s [C]i [C]z [C]e O 
in [C]i [C]n O 
AB [C]A [C]B O 
( [C]( O 
o [C]o O 
) [C]) O 
, [C], O 
ABEalpha [C]A [C]B [C]E [C]a [C]l [C]p [C]h [C]a O 
, [C], O 
and [C]a [C]n [C]d O 
BL [C]B [C]L O 
: [C]: O 
TG [C]T [C]G O 
: [C]: O 
Ealpha [C]E [C]a [C]l [C]p [C]h [C]a O 
strains [C]s [C]t [C]r [C]a [C]i [C]n [C]s O 
was [C]w [C]a [C]s O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
by [C]b [C]y O 
54 [C]5 [C]4 O 
% [C]% O 
, [C], O 
79 [C]7 [C]9 O 
% [C]% O 
, [C], O 
and [C]a [C]n [C]d O 
82 [C]8 [C]2 O 
% [C]% O 
, [C], O 
respectively [C]r [C]e [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
, [C], O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
wild-type [C]w [C]i [C]l [C]d [C]- [C]t [C]y [C]p [C]e O 
, [C], O 
correlating [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]n [C]g O 
with [C]w [C]i [C]t [C]h O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
Th1 [C]T [C]h [C]1 S-cell_type 
and [C]a [C]n [C]d O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
Th2 [C]T [C]h [C]2 S-cell_type 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
T [C]T O 
helper-cell [C]h [C]e [C]l [C]p [C]e [C]r [C]- [C]c [C]e [C]l [C]l O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
is [C]i [C]s O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
in [C]i [C]n O 
fatty [C]f [C]a [C]t [C]t [C]y O 
lesion [C]l [C]e [C]s [C]i [C]o [C]n O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
. [C]. O 

Decreasing [C]D [C]e [C]c [C]r [C]e [C]a [C]s [C]i [C]n [C]g O 
Th1 [C]T [C]h [C]1 B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
by [C]b [C]y O 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s S-protein 
( [C]( O 
alpha-CD4 [C]a [C]l [C]p [C]h [C]a [C]- [C]C [C]D [C]4 S-protein 
) [C]) O 
or [C]o [C]r O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
( [C]( O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
) [C]) O 
also [C]a [C]l [C]s [C]o O 
caused [C]c [C]a [C]u [C]s [C]e [C]d O 
> [C]> O 
/=80 [C]/ [C]= [C]8 [C]0 O 
% [C]% O 
reductions [C]r [C]e [C]d [C]u [C]c [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
lesion [C]l [C]e [C]s [C]i [C]o [C]n O 
size [C]s [C]i [C]z [C]e O 
. [C]. O 

Immunohistology [C]I [C]m [C]m [C]u [C]n [C]o [C]h [C]i [C]s [C]t [C]o [C]l [C]o [C]g [C]y O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
, [C], O 
colocalized [C]c [C]o [C]l [C]o [C]c [C]a [C]l [C]i [C]z [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_type 
. [C]. O 

Confirming [C]C [C]o [C]n [C]f [C]i [C]r [C]m [C]i [C]n [C]g O 
these [C]t [C]h [C]e [C]s [C]e O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
in [C]i [C]n O 
a [C]a O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
mouse [C]m [C]o [C]u [C]s [C]e O 
strain [C]s [C]t [C]r [C]a [C]i [C]n O 
, [C], O 
BALB/c [C]B [C]A [C]L [C]B [C]/ [C]c O 
Stat [C]S [C]t [C]a [C]t O 
6 [C]6 O 
knockout [C]k [C]n [C]o [C]c [C]k [C]o [C]u [C]t O 
mice [C]m [C]i [C]c [C]e O 
( [C]( O 
Th2 [C]T [C]h [C]2 O 
cell-deficient [C]c [C]e [C]l [C]l [C]- [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
) [C]) O 
developed [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]e [C]d O 
aortic [C]a [C]o [C]r [C]t [C]i [C]c O 
lesions [C]l [C]e [C]s [C]i [C]o [C]n [C]s O 
comparable [C]c [C]o [C]m [C]p [C]a [C]r [C]a [C]b [C]l [C]e O 
to [C]t [C]o O 
C57Bl/6 [C]C [C]5 [C]7 [C]B [C]l [C]/ [C]6 O 
mice [C]m [C]i [C]c [C]e O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
diet [C]d [C]i [C]e [C]t O 
. [C]. O 

CONCLUSIONS [C]C [C]O [C]N [C]C [C]L [C]U [C]S [C]I [C]O [C]N [C]S O 
: [C]: O 
In [C]I [C]n O 
mildly [C]m [C]i [C]l [C]d [C]l [C]y O 
hypercholesterolemic [C]h [C]y [C]p [C]e [C]r [C]c [C]h [C]o [C]l [C]e [C]s [C]t [C]e [C]r [C]o [C]l [C]e [C]m [C]i [C]c O 
C57Bl/6 [C]C [C]5 [C]7 [C]B [C]l [C]/ [C]6 O 
mice [C]m [C]i [C]c [C]e O 
, [C], O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
IA [C]I [C]A B-protein 
( [C]( I-protein 
b [C]b I-protein 
) [C]) E-protein 
and [C]a [C]n [C]d O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
IE [C]I [C]E S-protein 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
CD4+ [C]C [C]D [C]4 [C]+ O 
T [C]T O 
helper-cell [C]h [C]e [C]l [C]p [C]e [C]r [C]- [C]c [C]e [C]l [C]l O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
; [C]; O 
fatty [C]f [C]a [C]t [C]t [C]y O 
lesions [C]l [C]e [C]s [C]i [C]o [C]n [C]s O 
were [C]w [C]e [C]r [C]e O 
proportional [C]p [C]r [C]o [C]p [C]o [C]r [C]t [C]i [C]o [C]n [C]a [C]l O 
to [C]t [C]o O 
IFNgamma+ [C]I [C]F [C]N [C]g [C]a [C]m [C]m [C]a [C]+ B-cell_type 
Th1 [C]T [C]h [C]1 I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
C57Bl/6 [C]C [C]5 [C]7 [C]B [C]l [C]/ [C]6 O 
and [C]a [C]n [C]d O 
BALB/c [C]B [C]A [C]L [C]B [C]/ [C]c O 
strains [C]s [C]t [C]r [C]a [C]i [C]n [C]s O 
. [C]. O 

IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
may [C]m [C]a [C]y O 
participate [C]p [C]a [C]r [C]t [C]i [C]c [C]i [C]p [C]a [C]t [C]e O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
may [C]m [C]a [C]y O 
act [C]a [C]c [C]t O 
to [C]t [C]o O 
limit [C]l [C]i [C]m [C]i [C]t O 
Th1-cell [C]T [C]h [C]1 [C]- [C]c [C]e [C]l [C]l O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
. [C]. O 

Requirement [C]R [C]e [C]q [C]u [C]i [C]r [C]e [C]m [C]e [C]n [C]t O 
for [C]f [C]o [C]r O 
p38 [C]p [C]3 [C]8 S-protein 
and [C]a [C]n [C]d O 
p44/p42 [C]p [C]4 [C]4 [C]/ [C]p [C]4 [C]2 S-protein 
mitogen-activated [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
kinases [C]k [C]i [C]n [C]a [C]s [C]e [C]s E-protein 
in [C]i [C]n O 
RAGE [C]R [C]A [C]G [C]E S-protein 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor-kappaB [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
secretion [C]s [C]e [C]c [C]r [C]e [C]t [C]i [C]o [C]n O 
. [C]. O 

Advanced [C]A [C]d [C]v [C]a [C]n [C]c [C]e [C]d O 
glycation [C]g [C]l [C]y [C]c [C]a [C]t [C]i [C]o [C]n O 
end [C]e [C]n [C]d O 
product [C]p [C]r [C]o [C]d [C]u [C]c [C]t O 
( [C]( O 
AGE [C]A [C]G [C]E O 
) [C]) O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
signal-transducing [C]s [C]i [C]g [C]n [C]a [C]l [C]- [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]i [C]n [C]g B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
for [C]f [C]o [C]r I-protein 
AGE [C]A [C]G [C]E E-protein 
( [C]( O 
RAGE [C]R [C]A [C]G [C]E S-protein 
) [C]) O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
linked [C]l [C]i [C]n [C]k [C]e [C]d O 
to [C]t [C]o O 
a [C]a O 
proinflammatory [C]p [C]r [C]o [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
phenotypic [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]i [C]c O 
change [C]c [C]h [C]a [C]n [C]g [C]e O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
cells [C]c [C]e [C]l [C]l [C]s O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
the [C]t [C]h [C]e O 
precise [C]p [C]r [C]e [C]c [C]i [C]s [C]e O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
have [C]h [C]a [C]v [C]e O 
not [C]n [C]o [C]t O 
been [C]b [C]e [C]e [C]n O 
elucidated [C]e [C]l [C]u [C]c [C]i [C]d [C]a [C]t [C]e [C]d O 
. [C]. O 

We [C]W [C]e O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
here [C]h [C]e [C]r [C]e O 
that [C]t [C]h [C]a [C]t O 
human [C]h [C]u [C]m [C]a [C]n O 
serum [C]s [C]e [C]r [C]u [C]m O 
albumin [C]a [C]l [C]b [C]u [C]m [C]i [C]n O 
modified [C]m [C]o [C]d [C]i [C]f [C]i [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
N [C]N O 
( [C]( O 
varepsilon [C]v [C]a [C]r [C]e [C]p [C]s [C]i [C]l [C]o [C]n O 
) [C]) O 
- [C]- O 
( [C]( O 
carboxymethyl [C]c [C]a [C]r [C]b [C]o [C]x [C]y [C]m [C]e [C]t [C]h [C]y [C]l O 
) [C]) O 
lysine [C]l [C]y [C]s [C]i [C]n [C]e O 
( [C]( O 
CML [C]C [C]M [C]L O 
) [C]) O 
, [C], O 
a [C]a O 
major [C]m [C]a [C]j [C]o [C]r O 
AGE [C]A [C]G [C]E O 
adduct [C]a [C]d [C]d [C]u [C]c [C]t O 
that [C]t [C]h [C]a [C]t O 
progressively [C]p [C]r [C]o [C]g [C]r [C]e [C]s [C]s [C]i [C]v [C]e [C]l [C]y O 
accumulates [C]a [C]c [C]c [C]u [C]m [C]u [C]l [C]a [C]t [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
aging [C]a [C]g [C]i [C]n [C]g O 
, [C], O 
diabetes [C]d [C]i [C]a [C]b [C]e [C]t [C]e [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
renal [C]r [C]e [C]n [C]a [C]l O 
failure [C]f [C]a [C]i [C]l [C]u [C]r [C]e O 
, [C], O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
( [C]( I-protein 
NF [C]N [C]F I-protein 
) [C]) I-protein 
-kappaB [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
-driven [C]- [C]d [C]r [C]i [C]v [C]e [C]n O 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
monocytic [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]i [C]c I-cell_type 
THP-1 [C]T [C]H [C]P [C]- [C]1 I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
was [C]w [C]a [C]s O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
synthetic [C]s [C]y [C]n [C]t [C]h [C]e [C]t [C]i [C]c O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
corresponding [C]c [C]o [C]r [C]r [C]e [C]s [C]p [C]o [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
putative [C]p [C]u [C]t [C]a [C]t [C]i [C]v [C]e B-protein 
ligand-binding [C]l [C]i [C]g [C]a [C]n [C]d [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
of [C]o [C]f O 
RAGE [C]R [C]A [C]G [C]E S-protein 
, [C], O 
with [C]w [C]i [C]t [C]h O 
anti- [C]a [C]n [C]t [C]i [C]- O 
RAGE [C]R [C]A [C]G [C]E S-protein 
antiserum [C]a [C]n [C]t [C]i [C]s [C]e [C]r [C]u [C]m O 
, [C], O 
and [C]a [C]n [C]d O 
by [C]b [C]y O 
coexpression [C]c [C]o [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
truncated [C]t [C]r [C]u [C]n [C]c [C]a [C]t [C]e [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
lacking [C]l [C]a [C]c [C]k [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
. [C]. O 

Signal [C]S [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
from [C]f [C]r [C]o [C]m O 
RAGE [C]R [C]A [C]G [C]E S-protein 
to [C]t [C]o O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
the [C]t [C]h [C]e O 
generation [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
reactive [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]e O 
oxygen [C]o [C]x [C]y [C]g [C]e [C]n O 
species [C]s [C]p [C]e [C]c [C]i [C]e [C]s O 
, [C], O 
since [C]s [C]i [C]n [C]c [C]e O 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
antioxidant [C]a [C]n [C]t [C]i [C]o [C]x [C]i [C]d [C]a [C]n [C]t O 
N-acetyl-L-cysteine [C]N [C]- [C]a [C]c [C]e [C]t [C]y [C]l [C]- [C]L [C]- [C]c [C]y [C]s [C]t [C]e [C]i [C]n [C]e O 
. [C]. O 

CML-modified [C]C [C]M [C]L [C]- [C]m [C]o [C]d [C]i [C]f [C]i [C]e [C]d B-protein 
albumin [C]a [C]l [C]b [C]u [C]m [C]i [C]n E-protein 
produced [C]p [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
rapid [C]r [C]a [C]p [C]i [C]d O 
transient [C]t [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
extracellular [C]e [C]x [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
signal-regulated [C]s [C]i [C]g [C]n [C]a [C]l [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
1 [C]1 I-protein 
and [C]a [C]n [C]d I-protein 
2 [C]2 E-protein 
, [C], O 
and [C]a [C]n [C]d O 
p38 [C]p [C]3 [C]8 B-protein 
mitogen-activated [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
( [C]( O 
MAPK [C]M [C]A [C]P [C]K S-protein 
) [C]) O 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
c-Jun [C]c [C]- [C]J [C]u [C]n B-protein 
NH [C]N [C]H I-protein 
( [C]( I-protein 
2 [C]2 I-protein 
) [C]) I-protein 
-terminal [C]- [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
. [C]. O 

RAGE [C]R [C]A [C]G [C]E S-protein 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
suppressed [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
selective [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e O 
p38 [C]p [C]3 [C]8 B-protein 
MAPK [C]M [C]A [C]P [C]K E-protein 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
SB203580 [C]S [C]B [C]2 [C]0 [C]3 [C]5 [C]8 [C]0 O 
and [C]a [C]n [C]d O 
by [C]b [C]y O 
coexpression [C]c [C]o [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
kinase-dead [C]k [C]i [C]n [C]a [C]s [C]e [C]- [C]d [C]e [C]a [C]d O 
p38 [C]p [C]3 [C]8 O 
dominant-negative [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t [C]- [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
mutant [C]m [C]u [C]t [C]a [C]n [C]t O 
. [C]. O 

Activation [C]A [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
by [C]b [C]y O 
CML-modified [C]C [C]M [C]L [C]- [C]m [C]o [C]d [C]i [C]f [C]i [C]e [C]d B-protein 
albumin [C]a [C]l [C]b [C]u [C]m [C]i [C]n E-protein 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
secretion [C]s [C]e [C]c [C]r [C]e [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
proinflammatory [C]p [C]r [C]o [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y B-protein 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s E-protein 
( [C]( O 
tumor [C]t [C]u [C]m [C]o [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor-alpha [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]a [C]l [C]p [C]h [C]a E-protein 
, [C], O 
interleukin-1beta [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]1 [C]b [C]e [C]t [C]a S-protein 
, [C], O 
and [C]a [C]n [C]d O 
monocyte [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e B-protein 
chemoattractant [C]c [C]h [C]e [C]m [C]o [C]a [C]t [C]t [C]r [C]a [C]c [C]t [C]a [C]n [C]t I-protein 
protein-1 [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]1 E-protein 
) [C]) O 
severalfold [C]s [C]e [C]v [C]e [C]r [C]a [C]l [C]f [C]o [C]l [C]d O 
, [C], O 
and [C]a [C]n [C]d O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
p38 [C]p [C]3 [C]8 B-protein 
MAPK [C]M [C]A [C]P [C]K E-protein 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
these [C]t [C]h [C]e [C]s [C]e O 
increases [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
p38 [C]p [C]3 [C]8 B-protein 
MAPK [C]M [C]A [C]P [C]K E-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
mediates [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]s O 
RAGE [C]R [C]A [C]G [C]E S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
secretion [C]s [C]e [C]c [C]r [C]e [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
proinflammatory [C]p [C]r [C]o [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y B-protein 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s E-protein 
and [C]a [C]n [C]d O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
accelerated [C]a [C]c [C]c [C]e [C]l [C]e [C]r [C]a [C]t [C]e [C]d O 
inflammation [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]i [C]o [C]n O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
a [C]a O 
consequence [C]c [C]o [C]n [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
this [C]t [C]h [C]i [C]s O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
. [C]. O 

Antigen-receptor [C]A [C]n [C]t [C]i [C]g [C]e [C]n [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
cross-linking [C]c [C]r [C]o [C]s [C]s [C]- [C]l [C]i [C]n [C]k [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
lipopolysaccharide [C]l [C]i [C]p [C]o [C]p [C]o [C]l [C]y [C]s [C]a [C]c [C]c [C]h [C]a [C]r [C]i [C]d [C]e O 
trigger [C]t [C]r [C]i [C]g [C]g [C]e [C]r O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
phosphoinositide [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]i [C]n [C]o [C]s [C]i [C]t [C]i [C]d [C]e B-protein 
3-kinase [C]3 [C]- [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
to [C]t [C]o O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a O 
B [C]B O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
NF-kappaB/Rel [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B [C]/ [C]R [C]e [C]l B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
play [C]p [C]l [C]a [C]y O 
an [C]a [C]n O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
genes [C]g [C]e [C]n [C]e [C]s O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
B [C]B O 
cell [C]c [C]e [C]l [C]l O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
, [C], O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

Nuclear [C]N [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
is [C]i [C]s O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
in [C]i [C]n O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
by [C]b [C]y O 
engagement [C]e [C]n [C]g [C]a [C]g [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
the [C]t [C]h [C]e O 
BCR [C]B [C]C [C]R S-protein 
or [C]o [C]r O 
CD40 [C]C [C]D [C]4 [C]0 S-protein 
or [C]o [C]r O 
by [C]b [C]y O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
lipopolysaccharide [C]l [C]i [C]p [C]o [C]p [C]o [C]l [C]y [C]s [C]a [C]c [C]c [C]h [C]a [C]r [C]i [C]d [C]e O 
( [C]( O 
LPS [C]L [C]P [C]S O 
) [C]) O 
. [C]. O 

Despite [C]D [C]e [C]s [C]p [C]i [C]t [C]e O 
the [C]t [C]h [C]e O 
importance [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]c [C]e O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
to [C]t [C]o O 
B [C]B O 
cell [C]c [C]e [C]l [C]l O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
, [C], O 
little [C]l [C]i [C]t [C]t [C]l [C]e O 
is [C]i [C]s O 
known [C]k [C]n [C]o [C]w [C]n O 
about [C]a [C]b [C]o [C]u [C]t O 
the [C]t [C]h [C]e O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
leading [C]l [C]e [C]a [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
we [C]w [C]e O 
address [C]a [C]d [C]d [C]r [C]e [C]s [C]s O 
the [C]t [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
phosphoinositide [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]i [C]n [C]o [C]s [C]i [C]t [C]i [C]d [C]e B-protein 
3'-kinase [C]3 [C]' [C]- [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
( [C]( O 
PI [C]P [C]I B-protein 
3-kinase [C]3 [C]- [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
) [C]) O 
in [C]i [C]n O 
BCR [C]B [C]C [C]R S-protein 
- [C]- O 
and [C]a [C]n [C]d O 
LPS-induced [C]L [C]P [C]S [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
using [C]u [C]s [C]i [C]n [C]g O 
populations [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y B-cell_type 
murine [C]m [C]u [C]r [C]i [C]n [C]e I-cell_type 
resting [C]r [C]e [C]s [C]t [C]i [C]n [C]g I-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Using [C]U [C]s [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
pharmacological [C]p [C]h [C]a [C]r [C]m [C]a [C]c [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
of [C]o [C]f O 
PI [C]P [C]I B-protein 
3-kinase [C]3 [C]- [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
, [C], O 
Wortmannin [C]W [C]o [C]r [C]t [C]m [C]a [C]n [C]n [C]i [C]n O 
and [C]a [C]n [C]d O 
LY294002 [C]L [C]Y [C]2 [C]9 [C]4 [C]0 [C]0 [C]2 O 
, [C], O 
we [C]w [C]e O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
PI [C]P [C]I B-protein 
3-kinase [C]3 [C]- [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
is [C]i [C]s O 
vital [C]v [C]i [C]t [C]a [C]l O 
for [C]f [C]o [C]r O 
BCR [C]B [C]C [C]R S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
DNA-binding [C]D [C]N [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
we [C]w [C]e O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
this [C]t [C]h [C]i [C]s O 
is [C]i [C]s O 
achieved [C]a [C]c [C]h [C]i [C]e [C]v [C]e [C]d O 
via [C]v [C]i [C]a O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
C [C]C E-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IkappaBalpha [C]I [C]k [C]a [C]p [C]p [C]a [C]B [C]a [C]l [C]p [C]h [C]a S-protein 
. [C]. O 

Similar [C]S [C]i [C]m [C]i [C]l [C]a [C]r O 
analyses [C]a [C]n [C]a [C]l [C]y [C]s [C]e [C]s O 
reveal [C]r [C]e [C]v [C]e [C]a [C]l O 
that [C]t [C]h [C]a [C]t O 
PI [C]P [C]I B-protein 
3-kinase [C]3 [C]- [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
is [C]i [C]s O 
also [C]a [C]l [C]s [C]o O 
critical [C]c [C]r [C]i [C]t [C]i [C]c [C]a [C]l O 
in [C]i [C]n O 
triggering [C]t [C]r [C]i [C]g [C]g [C]e [C]r [C]i [C]n [C]g O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
DNA-binding [C]D [C]N [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
IkappaBalpha [C]I [C]k [C]a [C]p [C]p [C]a [C]B [C]a [C]l [C]p [C]h [C]a S-protein 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
LPS [C]L [C]P [C]S O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Interestingly [C]I [C]n [C]t [C]e [C]r [C]e [C]s [C]t [C]i [C]n [C]g [C]l [C]y O 
, [C], O 
a [C]a O 
PKC [C]P [C]K [C]C O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
which [C]w [C]h [C]i [C]c [C]h O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
the [C]t [C]h [C]e O 
BCR [C]B [C]C [C]R S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
IkappaBalpha [C]I [C]k [C]a [C]p [C]p [C]a [C]B [C]a [C]l [C]p [C]h [C]a S-protein 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
had [C]h [C]a [C]d O 
no [C]n [C]o O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IkappaBalpha [C]I [C]k [C]a [C]p [C]p [C]a [C]B [C]a [C]l [C]p [C]h [C]a S-protein 
after [C]a [C]f [C]t [C]e [C]r O 
LPS [C]L [C]P [C]S O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Taken [C]T [C]a [C]k [C]e [C]n O 
together [C]t [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
, [C], O 
our [C]o [C]u [C]r O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
involvement [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
PI [C]P [C]I B-protein 
3-kinase [C]3 [C]- [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
in [C]i [C]n O 
at [C]a [C]t O 
least [C]l [C]e [C]a [C]s [C]t O 
two [C]t [C]w [C]o O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
leading [C]l [C]e [C]a [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
in [C]i [C]n O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Tetramer-guided [C]T [C]e [C]t [C]r [C]a [C]m [C]e [C]r [C]- [C]g [C]u [C]i [C]d [C]e [C]d O 
epitope [C]e [C]p [C]i [C]t [C]o [C]p [C]e O 
mapping [C]m [C]a [C]p [C]p [C]i [C]n [C]g O 
: [C]: O 
rapid [C]r [C]a [C]p [C]i [C]d O 
identification [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
characterization [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
immunodominant [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t B-cell_type 
CD4+ [C]C [C]D [C]4 [C]+ I-cell_type 
T [C]T I-cell_type 
cell [C]c [C]e [C]l [C]l I-cell_type 
epitopes [C]e [C]p [C]i [C]t [C]o [C]p [C]e [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
antigens [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]s S-protein 
. [C]. O 

T [C]T O 
cell [C]c [C]e [C]l [C]l O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
to [C]t [C]o O 
Ags [C]A [C]g [C]s S-protein 
involve [C]i [C]n [C]v [C]o [C]l [C]v [C]e O 
recognition [C]r [C]e [C]c [C]o [C]g [C]n [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
selected [C]s [C]e [C]l [C]e [C]c [C]t [C]e [C]d O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e B-protein 
epitopes [C]e [C]p [C]i [C]t [C]o [C]p [C]e [C]s E-protein 
contained [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]e [C]d O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
the [C]t [C]h [C]e O 
antigenic [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]i [C]c B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
, [C], O 
we [C]w [C]e O 
describe [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e O 
a [C]a O 
new [C]n [C]e [C]w O 
approach [C]a [C]p [C]p [C]r [C]o [C]a [C]c [C]h O 
for [C]f [C]o [C]r O 
direct [C]d [C]i [C]r [C]e [C]c [C]t O 
identification [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CD4+ [C]C [C]D [C]4 [C]+ B-cell_type 
T [C]T I-cell_type 
cell [C]c [C]e [C]l [C]l I-cell_type 
epitopes [C]e [C]p [C]i [C]t [C]o [C]p [C]e [C]s E-cell_type 
of [C]o [C]f O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
Ags [C]A [C]g [C]s S-protein 
that [C]t [C]h [C]a [C]t O 
uses [C]u [C]s [C]e [C]s O 
human [C]h [C]u [C]m [C]a [C]n B-protein 
class [C]c [C]l [C]a [C]s [C]s I-protein 
II [C]I [C]I I-protein 
tetramers [C]t [C]e [C]t [C]r [C]a [C]m [C]e [C]r [C]s E-protein 
to [C]t [C]o O 
identify [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]y O 
reactive [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
. [C]. O 

With [C]W [C]i [C]t [C]h O 
a [C]a O 
panel [C]p [C]a [C]n [C]e [C]l O 
of [C]o [C]f O 
60 [C]6 [C]0 O 
overlapping [C]o [C]v [C]e [C]r [C]l [C]a [C]p [C]p [C]i [C]n [C]g O 
peptides [C]p [C]e [C]p [C]t [C]i [C]d [C]e [C]s O 
covering [C]c [C]o [C]v [C]e [C]r [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
entire [C]e [C]n [C]t [C]i [C]r [C]e O 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
VP16 [C]V [C]P [C]1 [C]6 B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
, [C], O 
a [C]a O 
major [C]m [C]a [C]j [C]o [C]r O 
Ag [C]A [C]g S-protein 
for [C]f [C]o [C]r O 
HSV-2 [C]H [C]S [C]V [C]- [C]2 O 
, [C], O 
we [C]w [C]e O 
generated [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]e [C]d O 
a [C]a O 
panel [C]p [C]a [C]n [C]e [C]l O 
of [C]o [C]f O 
class [C]c [C]l [C]a [C]s [C]s B-protein 
II [C]I [C]I I-protein 
MHC [C]M [C]H [C]C I-protein 
tetramers [C]t [C]e [C]t [C]r [C]a [C]m [C]e [C]r [C]s E-protein 
loaded [C]l [C]o [C]a [C]d [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
pools [C]p [C]o [C]o [C]l [C]s O 
that [C]t [C]h [C]a [C]t O 
were [C]w [C]e [C]r [C]e O 
used [C]u [C]s [C]e [C]d O 
to [C]t [C]o O 
stain [C]s [C]t [C]a [C]i [C]n O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
of [C]o [C]f O 
an [C]a [C]n O 
HSV-2 [C]H [C]S [C]V [C]- [C]2 O 
infected [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
individual [C]i [C]n [C]d [C]i [C]v [C]i [C]d [C]u [C]a [C]l O 
. [C]. O 

With [C]W [C]i [C]t [C]h O 
this [C]t [C]h [C]i [C]s O 
approach [C]a [C]p [C]p [C]r [C]o [C]a [C]c [C]h O 
, [C], O 
we [C]w [C]e O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
four [C]f [C]o [C]u [C]r O 
new [C]n [C]e [C]w O 
DRA1*0101/DRB1*0401- [C]D [C]R [C]A [C]1 [C]* [C]0 [C]1 [C]0 [C]1 [C]/ [C]D [C]R [C]B [C]1 [C]* [C]0 [C]4 [C]0 [C]1 [C]- O 
and [C]a [C]n [C]d O 
two [C]t [C]w [C]o O 
DRA1*0101/DRB1*0404-restricted [C]D [C]R [C]A [C]1 [C]* [C]0 [C]1 [C]0 [C]1 [C]/ [C]D [C]R [C]B [C]1 [C]* [C]0 [C]4 [C]0 [C]4 [C]- [C]r [C]e [C]s [C]t [C]r [C]i [C]c [C]t [C]e [C]d O 
, [C], O 
VP16-specific [C]V [C]P [C]1 [C]6 [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-protein 
epitopes [C]e [C]p [C]i [C]t [C]o [C]p [C]e [C]s E-protein 
. [C]. O 

By [C]B [C]y O 
using [C]u [C]s [C]i [C]n [C]g O 
tetramers [C]t [C]e [C]t [C]r [C]a [C]m [C]e [C]r [C]s S-protein 
to [C]t [C]o O 
sort [C]s [C]o [C]r [C]t O 
individual [C]i [C]n [C]d [C]i [C]v [C]i [C]d [C]u [C]a [C]l O 
cells [C]c [C]e [C]l [C]l [C]s O 
, [C], O 
we [C]w [C]e O 
easily [C]e [C]a [C]s [C]i [C]l [C]y O 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
a [C]a O 
large [C]l [C]a [C]r [C]g [C]e O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
clones [C]c [C]l [C]o [C]n [C]e [C]s O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
to [C]t [C]o O 
these [C]t [C]h [C]e [C]s [C]e O 
epitopes [C]e [C]p [C]i [C]t [C]o [C]p [C]e [C]s S-protein 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
DRA1*0101/DRB1*0401 [C]D [C]R [C]A [C]1 [C]* [C]0 [C]1 [C]0 [C]1 [C]/ [C]D [C]R [C]B [C]1 [C]* [C]0 [C]4 [C]0 [C]1 O 
and [C]a [C]n [C]d O 
DRA1*0101/DRB1*0404 [C]D [C]R [C]A [C]1 [C]* [C]0 [C]1 [C]0 [C]1 [C]/ [C]D [C]R [C]B [C]1 [C]* [C]0 [C]4 [C]0 [C]4 O 
are [C]a [C]r [C]e O 
structurally [C]s [C]t [C]r [C]u [C]c [C]t [C]u [C]r [C]a [C]l [C]l [C]y O 
very [C]v [C]e [C]r [C]y O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
, [C], O 
nonoverlapping [C]n [C]o [C]n [C]o [C]v [C]e [C]r [C]l [C]a [C]p [C]p [C]i [C]n [C]g O 
VP16 [C]V [C]P [C]1 [C]6 B-protein 
epitopes [C]e [C]p [C]i [C]t [C]o [C]p [C]e [C]s E-protein 
were [C]w [C]e [C]r [C]e O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
, [C], O 
illustrating [C]i [C]l [C]l [C]u [C]s [C]t [C]r [C]a [C]t [C]i [C]n [C]g O 
high [C]h [C]i [C]g [C]h O 
selectivity [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
individual [C]i [C]n [C]d [C]i [C]v [C]i [C]d [C]u [C]a [C]l O 
allele [C]a [C]l [C]l [C]e [C]l [C]e O 
polymorphisms [C]p [C]o [C]l [C]y [C]m [C]o [C]r [C]p [C]h [C]i [C]s [C]m [C]s O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
common [C]c [C]o [C]m [C]m [C]o [C]n O 
MHC [C]M [C]H [C]C O 
variants [C]v [C]a [C]r [C]i [C]a [C]n [C]t [C]s O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
rapid [C]r [C]a [C]p [C]i [C]d O 
approach [C]a [C]p [C]p [C]r [C]o [C]a [C]c [C]h O 
to [C]t [C]o O 
detecting [C]d [C]e [C]t [C]e [C]c [C]t [C]i [C]n [C]g O 
CD4+ [C]C [C]D [C]4 [C]+ B-cell_type 
T [C]T I-cell_type 
cell [C]c [C]e [C]l [C]l I-cell_type 
epitopes [C]e [C]p [C]i [C]t [C]o [C]p [C]e [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
Ags [C]A [C]g [C]s S-protein 
can [C]c [C]a [C]n O 
be [C]b [C]e O 
applied [C]a [C]p [C]p [C]l [C]i [C]e [C]d O 
to [C]t [C]o O 
any [C]a [C]n [C]y O 
known [C]k [C]n [C]o [C]w [C]n O 
Ag [C]A [C]g S-protein 
that [C]t [C]h [C]a [C]t O 
gives [C]g [C]i [C]v [C]e [C]s O 
a [C]a O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
. [C]. O 

Localized [C]L [C]o [C]c [C]a [C]l [C]i [C]z [C]e [C]d O 
pancreatic [C]p [C]a [C]n [C]c [C]r [C]e [C]a [C]t [C]i [C]c O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
in [C]i [C]n O 
taurocholate-induced [C]t [C]a [C]u [C]r [C]o [C]c [C]h [C]o [C]l [C]a [C]t [C]e [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
pancreatitis [C]p [C]a [C]n [C]c [C]r [C]e [C]a [C]t [C]i [C]t [C]i [C]s O 
. [C]. O 

Transcription [C]T [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-protein 
factor-kappaB [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
( [C]( O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
) [C]) O 
is [C]i [C]s O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
cerulein [C]c [C]e [C]r [C]u [C]l [C]e [C]i [C]n O 
pancreatitis [C]p [C]a [C]n [C]c [C]r [C]e [C]a [C]t [C]i [C]t [C]i [C]s O 
and [C]a [C]n [C]d O 
mediates [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]s O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
other [C]o [C]t [C]h [C]e [C]r O 
models [C]m [C]o [C]d [C]e [C]l [C]s O 
of [C]o [C]f O 
pancreatitis [C]p [C]a [C]n [C]c [C]r [C]e [C]a [C]t [C]i [C]t [C]i [C]s O 
has [C]h [C]a [C]s O 
not [C]n [C]o [C]t O 
been [C]b [C]e [C]e [C]n O 
established [C]e [C]s [C]t [C]a [C]b [C]l [C]i [C]s [C]h [C]e [C]d O 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
we [C]w [C]e O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
upregulation [C]u [C]p [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
and [C]a [C]n [C]d O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y B-protein 
molecules [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]s E-protein 
, [C], O 
and [C]a [C]n [C]d O 
their [C]t [C]h [C]e [C]i [C]r O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
local [C]l [C]o [C]c [C]a [C]l O 
pancreatic [C]p [C]a [C]n [C]c [C]r [C]e [C]a [C]t [C]i [C]c O 
injury [C]i [C]n [C]j [C]u [C]r [C]y O 
, [C], O 
in [C]i [C]n O 
a [C]a O 
model [C]m [C]o [C]d [C]e [C]l O 
of [C]o [C]f O 
severe [C]s [C]e [C]v [C]e [C]r [C]e O 
pancreatitis [C]p [C]a [C]n [C]c [C]r [C]e [C]a [C]t [C]i [C]t [C]i [C]s O 
. [C]. O 

Rats [C]R [C]a [C]t [C]s O 
received [C]r [C]e [C]c [C]e [C]i [C]v [C]e [C]d O 
intraductal [C]i [C]n [C]t [C]r [C]a [C]d [C]u [C]c [C]t [C]a [C]l O 
infusion [C]i [C]n [C]f [C]u [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
taurocholate [C]t [C]a [C]u [C]r [C]o [C]c [C]h [C]o [C]l [C]a [C]t [C]e O 
or [C]o [C]r O 
saline [C]s [C]a [C]l [C]i [C]n [C]e O 
, [C], O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
pancreatic [C]p [C]a [C]n [C]c [C]r [C]e [C]a [C]t [C]i [C]c O 
head [C]h [C]e [C]a [C]d O 
and [C]a [C]n [C]d O 
tail [C]t [C]a [C]i [C]l O 
were [C]w [C]e [C]r [C]e O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
separately [C]s [C]e [C]p [C]a [C]r [C]a [C]t [C]e [C]l [C]y O 
. [C]. O 

NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
and [C]a [C]n [C]d O 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r B-protein 
protein-1 [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]1 E-protein 
( [C]( O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
) [C]) O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
were [C]w [C]e [C]r [C]e O 
assessed [C]a [C]s [C]s [C]e [C]s [C]s [C]e [C]d O 
by [C]b [C]y O 
gel [C]g [C]e [C]l O 
shift [C]s [C]h [C]i [C]f [C]t O 
assay [C]a [C]s [C]s [C]a [C]y O 
, [C], O 
and [C]a [C]n [C]d O 
mRNA [C]m [C]R [C]N [C]A O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
interleukin-6 [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]6 S-RNA 
, [C], O 
tumor [C]t [C]u [C]m [C]o [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor-alpha [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]a [C]l [C]p [C]h [C]a E-protein 
, [C], O 
KC [C]K [C]C O 
, [C], O 
monocyte [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e B-protein 
chemoattractant [C]c [C]h [C]e [C]m [C]o [C]a [C]t [C]t [C]r [C]a [C]c [C]t [C]a [C]n [C]t I-protein 
protein-1 [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]1 E-protein 
, [C], O 
and [C]a [C]n [C]d O 
inducible [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e B-protein 
nitric [C]n [C]i [C]t [C]r [C]i [C]c I-protein 
oxide [C]o [C]x [C]i [C]d [C]e I-protein 
synthase [C]s [C]y [C]n [C]t [C]h [C]a [C]s [C]e E-protein 
was [C]w [C]a [C]s O 
assessed [C]a [C]s [C]s [C]e [C]s [C]s [C]e [C]d O 
by [C]b [C]y O 
semiquantitative [C]s [C]e [C]m [C]i [C]q [C]u [C]a [C]n [C]t [C]i [C]t [C]a [C]t [C]i [C]v [C]e O 
RT-PCR [C]R [C]T [C]- [C]P [C]C [C]R O 
. [C]. O 

Morphological [C]M [C]o [C]r [C]p [C]h [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
damage [C]d [C]a [C]m [C]a [C]g [C]e O 
and [C]a [C]n [C]d O 
trypsin [C]t [C]r [C]y [C]p [C]s [C]i [C]n O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
were [C]w [C]e [C]r [C]e O 
much [C]m [C]u [C]c [C]h O 
greater [C]g [C]r [C]e [C]a [C]t [C]e [C]r O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
pancreatic [C]p [C]a [C]n [C]c [C]r [C]e [C]a [C]t [C]i [C]c O 
head [C]h [C]e [C]a [C]d O 
than [C]t [C]h [C]a [C]n O 
tail [C]t [C]a [C]i [C]l O 
, [C], O 
in [C]i [C]n O 
parallel [C]p [C]a [C]r [C]a [C]l [C]l [C]e [C]l O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
stronger [C]s [C]t [C]r [C]o [C]n [C]g [C]e [C]r O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B B-RNA 
and [C]a [C]n [C]d I-RNA 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e I-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
. [C]. O 

Saline [C]S [C]a [C]l [C]i [C]n [C]e O 
infusion [C]i [C]n [C]f [C]u [C]s [C]i [C]o [C]n O 
mildly [C]m [C]i [C]l [C]d [C]l [C]y O 
affected [C]a [C]f [C]f [C]e [C]c [C]t [C]e [C]d O 
these [C]t [C]h [C]e [C]s [C]e O 
parameters [C]p [C]a [C]r [C]a [C]m [C]e [C]t [C]e [C]r [C]s O 
. [C]. O 

AP-1 [C]A [C]P [C]- [C]1 S-protein 
was [C]w [C]a [C]s O 
strongly [C]s [C]t [C]r [C]o [C]n [C]g [C]l [C]y O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
pancreatic [C]p [C]a [C]n [C]c [C]r [C]e [C]a [C]t [C]i [C]c O 
segments [C]s [C]e [C]g [C]m [C]e [C]n [C]t [C]s O 
after [C]a [C]f [C]t [C]e [C]r O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
taurocholate [C]t [C]a [C]u [C]r [C]o [C]c [C]h [C]o [C]l [C]a [C]t [C]e O 
or [C]o [C]r O 
saline [C]s [C]a [C]l [C]i [C]n [C]e O 
infusion [C]i [C]n [C]f [C]u [C]s [C]i [C]o [C]n O 
. [C]. O 

NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
N-acetylcysteine [C]N [C]- [C]a [C]c [C]e [C]t [C]y [C]l [C]c [C]y [C]s [C]t [C]e [C]i [C]n [C]e O 
ameliorated [C]a [C]m [C]e [C]l [C]i [C]o [C]r [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
local [C]l [C]o [C]c [C]a [C]l O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
. [C]. O 

Correlation [C]C [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
localized [C]l [C]o [C]c [C]a [C]l [C]i [C]z [C]e [C]d O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
upregulation [C]u [C]p [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
damage [C]d [C]a [C]m [C]a [C]g [C]e O 
suggests [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]s O 
a [C]a O 
key [C]k [C]e [C]y O 
role [C]r [C]o [C]l [C]e O 
for [C]f [C]o [C]r O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
of [C]o [C]f O 
acute [C]a [C]c [C]u [C]t [C]e O 
pancreatitis [C]p [C]a [C]n [C]c [C]r [C]e [C]a [C]t [C]i [C]t [C]i [C]s O 
. [C]. O 

CD45 [C]C [C]D [C]4 [C]5 B-protein 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e I-protein 
phosphatase [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]a [C]s [C]e E-protein 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
common [C]c [C]o [C]m [C]m [C]o [C]n O 
gamma-chain [C]g [C]a [C]m [C]m [C]a [C]- [C]c [C]h [C]a [C]i [C]n B-protein 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e E-protein 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
STAT [C]S [C]T [C]A [C]T S-protein 
and [C]a [C]n [C]d O 
extracellular [C]e [C]x [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
signal-related [C]s [C]i [C]g [C]n [C]a [C]l [C]- [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
lymphoblasts [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]s E-cell_type 
: [C]: O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
without [C]w [C]i [C]t [C]h [C]o [C]u [C]t O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
objective [C]o [C]b [C]j [C]e [C]c [C]t [C]i [C]v [C]e O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
was [C]w [C]a [C]s O 
to [C]t [C]o O 
test [C]t [C]e [C]s [C]t O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
CD45 [C]C [C]D [C]4 [C]5 O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
can [C]c [C]a [C]n O 
influence [C]i [C]n [C]f [C]l [C]u [C]e [C]n [C]c [C]e O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
processes [C]p [C]r [C]o [C]c [C]e [C]s [C]s [C]e [C]s O 
in [C]i [C]n O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
lymphoblasts [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]s E-cell_type 
. [C]. O 

To [C]T [C]o O 
this [C]t [C]h [C]i [C]s O 
end [C]e [C]n [C]d O 
, [C], O 
we [C]w [C]e O 
generated [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]e [C]d O 
lymphoblasts [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]s S-cell_type 
which [C]w [C]h [C]i [C]c [C]h O 
proliferate [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]e O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
common [C]c [C]o [C]m [C]m [C]o [C]n O 
gamma-chain [C]g [C]a [C]m [C]m [C]a [C]- [C]c [C]h [C]a [C]i [C]n B-protein 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s E-protein 
, [C], O 
but [C]b [C]u [C]t O 
readily [C]r [C]e [C]a [C]d [C]i [C]l [C]y O 
undergo [C]u [C]n [C]d [C]e [C]r [C]g [C]o O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
after [C]a [C]f [C]t [C]e [C]r O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
withdrawal [C]w [C]i [C]t [C]h [C]d [C]r [C]a [C]w [C]a [C]l O 
. [C]. O 

In [C]I [C]n O 
experiments [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
CD45R0 [C]C [C]D [C]4 [C]5 [C]R [C]0 B-protein 
mAb [C]m [C]A [C]b I-protein 
UCHL-1 [C]U [C]C [C]H [C]L [C]- [C]1 E-protein 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l B-protein 
CD45 [C]C [C]D [C]4 [C]5 I-protein 
mAbs [C]m [C]A [C]b [C]s E-protein 
, [C], O 
we [C]w [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Interestingly [C]I [C]n [C]t [C]e [C]r [C]e [C]s [C]t [C]i [C]n [C]g [C]l [C]y O 
, [C], O 
the [C]t [C]h [C]e O 
pan-CD45 [C]p [C]a [C]n [C]- [C]C [C]D [C]4 [C]5 B-protein 
mAb [C]m [C]A [C]b I-protein 
GAP8.3 [C]G [C]A [C]P [C]8 [C]. [C]3 E-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
most [C]m [C]o [C]s [C]t O 
effective [C]e [C]f [C]f [C]e [C]c [C]t [C]i [C]v [C]e O 
in [C]i [C]n O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
OKT-3-mediated [C]O [C]K [C]T [C]- [C]3 [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
quiescent [C]q [C]u [C]i [C]e [C]s [C]c [C]e [C]n [C]t B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
, [C], O 
was [C]w [C]a [C]s O 
ineffective [C]i [C]n [C]e [C]f [C]f [C]e [C]c [C]t [C]i [C]v [C]e O 
in [C]i [C]n O 
lymphoblasts [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]s S-cell_type 
. [C]. O 

Addition [C]A [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CD3 [C]C [C]D [C]3 B-protein 
mAb [C]m [C]A [C]b I-protein 
OKT-3 [C]O [C]K [C]T [C]- [C]3 E-protein 
had [C]h [C]a [C]d O 
no [C]n [C]o O 
influence [C]i [C]n [C]f [C]l [C]u [C]e [C]n [C]c [C]e O 
on [C]o [C]n O 
IL-2-mediated [C]I [C]L [C]- [C]2 [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
( [C]( O 
with [C]w [C]i [C]t [C]h O 
or [C]o [C]r O 
without [C]w [C]i [C]t [C]h [C]o [C]u [C]t O 
UCHL-1 [C]U [C]C [C]H [C]L [C]- [C]1 S-protein 
) [C]) O 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
after [C]a [C]f [C]t [C]e [C]r O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
OKT-3 [C]O [C]K [C]T [C]- [C]3 S-protein 
to [C]t [C]o O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
- [C]- O 
and [C]a [C]n [C]d O 
IL-7 [C]I [C]L [C]- [C]7 S-protein 
-stimulated [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
, [C], O 
UCHL-1 [C]U [C]C [C]H [C]L [C]- [C]1 S-protein 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
could [C]c [C]o [C]u [C]l [C]d O 
not [C]n [C]o [C]t O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
alter [C]a [C]l [C]t [C]e [C]r O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

We [C]W [C]e O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
find [C]f [C]i [C]n [C]d O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
CD45R0 [C]C [C]D [C]4 [C]5 [C]R [C]0 O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
. [C]. O 

In [C]I [C]n O 
Western [C]W [C]e [C]s [C]t [C]e [C]r [C]n O 
blots [C]b [C]l [C]o [C]t [C]s O 
using [C]u [C]s [C]i [C]n [C]g O 
mAbs [C]m [C]A [C]b [C]s S-protein 
detecting [C]d [C]e [C]t [C]e [C]c [C]t [C]i [C]n [C]g O 
phosphorylated [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]e [C]d B-protein 
STAT-3 [C]S [C]T [C]A [C]T [C]- [C]3 I-protein 
, [C], I-protein 
STAT-5 [C]S [C]T [C]A [C]T [C]- [C]5 I-protein 
, [C], I-protein 
STAT-6 [C]S [C]T [C]A [C]T [C]- [C]6 E-protein 
, [C], O 
or [C]o [C]r O 
extracellular [C]e [C]x [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
signal-related [C]s [C]i [C]g [C]n [C]a [C]l [C]- [C]r [C]e [C]l [C]a [C]t [C]e [C]d I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
1/2 [C]1 [C]/ [C]2 E-protein 
, [C], O 
we [C]w [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
CD45R0 [C]C [C]D [C]4 [C]5 [C]R [C]0 O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
could [C]c [C]o [C]u [C]l [C]d O 
effectively [C]e [C]f [C]f [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
diminish [C]d [C]i [C]m [C]i [C]n [C]i [C]s [C]h O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
components [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t [C]s O 
. [C]. O 

Using [C]U [C]s [C]i [C]n [C]g O 
RT-PCR [C]R [C]T [C]- [C]P [C]C [C]R O 
, [C], O 
we [C]w [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
CD45R0 [C]C [C]D [C]4 [C]5 [C]R [C]0 O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
IL-2 [C]I [C]L [C]- [C]2 O 
mRNA [C]m [C]R [C]N [C]A O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
without [C]w [C]i [C]t [C]h [C]o [C]u [C]t O 
major [C]m [C]a [C]j [C]o [C]r O 
influence [C]i [C]n [C]f [C]l [C]u [C]e [C]n [C]c [C]e O 
on [C]o [C]n O 
IL-13 [C]I [C]L [C]- [C]1 [C]3 S-protein 
, [C], O 
IL-5 [C]I [C]L [C]- [C]5 S-protein 
, [C], O 
or [C]o [C]r O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
. [C]. O 

Costimulation [C]C [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
OKT-3 [C]O [C]K [C]T [C]- [C]3 S-protein 
and [C]a [C]n [C]d O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
optimally [C]o [C]p [C]t [C]i [C]m [C]a [C]l [C]l [C]y O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
secretion [C]s [C]e [C]c [C]r [C]e [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
, [C], O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
, [C], O 
and [C]a [C]n [C]d O 
IL-5 [C]I [C]L [C]- [C]5 S-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
by [C]b [C]y O 
CD45 [C]C [C]D [C]4 [C]5 O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
. [C]. O 

In [C]I [C]n O 
conclusion [C]c [C]o [C]n [C]c [C]l [C]u [C]s [C]i [C]o [C]n O 
, [C], O 
we [C]w [C]e O 
illustrate [C]i [C]l [C]l [C]u [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
CD45R0 [C]C [C]D [C]4 [C]5 [C]R [C]0 O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
early [C]e [C]a [C]r [C]l [C]y O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
receptor-associated [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]- [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
processes [C]p [C]r [C]o [C]c [C]e [C]s [C]s [C]e [C]s O 
and [C]a [C]n [C]d O 
mRNA [C]m [C]R [C]N [C]A O 
and [C]a [C]n [C]d O 
DNA [C]D [C]N [C]A O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
in [C]i [C]n O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
lymphoblasts [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]s E-cell_type 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
we [C]w [C]e O 
show [C]s [C]h [C]o [C]w O 
the [C]t [C]h [C]e O 
existence [C]e [C]x [C]i [C]s [C]t [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
CD45 [C]C [C]D [C]4 [C]5 B-protein 
epitopes [C]e [C]p [C]i [C]t [C]o [C]p [C]e [C]s E-protein 
( [C]( O 
GAP8.3 [C]G [C]A [C]P [C]8 [C]. [C]3 S-protein 
) [C]) O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
are [C]a [C]r [C]e O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
and [C]a [C]n [C]d O 
critical [C]c [C]r [C]i [C]t [C]i [C]c [C]a [C]l O 
for [C]f [C]o [C]r O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
in [C]i [C]n O 
quiescent [C]q [C]u [C]i [C]e [C]s [C]c [C]e [C]n [C]t B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
, [C], O 
but [C]b [C]u [C]t O 
are [C]a [C]r [C]e O 
nonfunctional [C]n [C]o [C]n [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
in [C]i [C]n O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
lymphoblasts [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]s E-cell_type 
. [C]. O 

Pax5 [C]P [C]a [C]x [C]5 S-DNA 
determines [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]s O 
the [C]t [C]h [C]e O 
identity [C]i [C]d [C]e [C]n [C]t [C]i [C]t [C]y O 
of [C]o [C]f O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
beginning [C]b [C]e [C]g [C]i [C]n [C]n [C]i [C]n [C]g O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
end [C]e [C]n [C]d O 
of [C]o [C]f O 
B-lymphopoiesis [C]B [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
. [C]. O 

Despite [C]D [C]e [C]s [C]p [C]i [C]t [C]e O 
being [C]b [C]e [C]i [C]n [C]g O 
one [C]o [C]n [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
most [C]m [C]o [C]s [C]t O 
intensively [C]i [C]n [C]t [C]e [C]n [C]s [C]i [C]v [C]e [C]l [C]y O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
cell [C]c [C]e [C]l [C]l O 
types [C]t [C]y [C]p [C]e [C]s O 
, [C], O 
the [C]t [C]h [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
basis [C]b [C]a [C]s [C]i [C]s O 
of [C]o [C]f O 
B [C]B O 
cell [C]c [C]e [C]l [C]l O 
specification [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
largely [C]l [C]a [C]r [C]g [C]e [C]l [C]y O 
unknown [C]u [C]n [C]k [C]n [C]o [C]w [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
Pax5 [C]P [C]a [C]x [C]5 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
encoding [C]e [C]n [C]c [C]o [C]d [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
BSAP [C]B [C]S [C]A [C]P E-protein 
is [C]i [C]s O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
progression [C]p [C]r [C]o [C]g [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
B-lymphopoiesis [C]B [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
beyond [C]b [C]e [C]y [C]o [C]n [C]d O 
the [C]t [C]h [C]e O 
pro-B [C]p [C]r [C]o [C]- [C]B O 
cell [C]c [C]e [C]l [C]l O 
stage [C]s [C]t [C]a [C]g [C]e O 
. [C]. O 

Pax5-deficient [C]P [C]a [C]x [C]5 [C]- [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t B-cell_type 
pro-B [C]p [C]r [C]o [C]- [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
are [C]a [C]r [C]e O 
, [C], O 
however [C]h [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
not [C]n [C]o [C]t O 
yet [C]y [C]e [C]t O 
committed [C]c [C]o [C]m [C]m [C]i [C]t [C]t [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
B-lymphoid [C]B [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d B-cell_type 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e E-cell_type 
, [C], O 
but [C]b [C]u [C]t O 
instead [C]i [C]n [C]s [C]t [C]e [C]a [C]d O 
have [C]h [C]a [C]v [C]e O 
a [C]a O 
broad [C]b [C]r [C]o [C]a [C]d O 
lymphomyeloid [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]y [C]e [C]l [C]o [C]i [C]d O 
developmental [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t [C]a [C]l O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
. [C]. O 

Pax5 [C]P [C]a [C]x [C]5 S-DNA 
appears [C]a [C]p [C]p [C]e [C]a [C]r [C]s O 
to [C]t [C]o O 
mediate [C]m [C]e [C]d [C]i [C]a [C]t [C]e O 
B-lineage [C]B [C]- [C]l [C]i [C]n [C]e [C]a [C]g [C]e O 
commitment [C]c [C]o [C]m [C]m [C]i [C]t [C]m [C]e [C]n [C]t O 
by [C]b [C]y O 
repressing [C]r [C]e [C]p [C]r [C]e [C]s [C]s [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
non-B-lymphoid [C]n [C]o [C]n [C]- [C]B [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
and [C]a [C]n [C]d O 
by [C]b [C]y O 
simultaneously [C]s [C]i [C]m [C]u [C]l [C]t [C]a [C]n [C]e [C]o [C]u [C]s [C]l [C]y O 
activating [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
B-lineage-specific [C]B [C]- [C]l [C]i [C]n [C]e [C]a [C]g [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
. [C]. O 

Pax5 [C]P [C]a [C]x [C]5 S-DNA 
thus [C]t [C]h [C]u [C]s O 
functions [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]s O 
both [C]b [C]o [C]t [C]h O 
as [C]a [C]s O 
a [C]a O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
repressor [C]r [C]e [C]p [C]r [C]e [C]s [C]s [C]o [C]r O 
and [C]a [C]n [C]d O 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r O 
, [C], O 
depending [C]d [C]e [C]p [C]e [C]n [C]d [C]i [C]n [C]g O 
on [C]o [C]n O 
its [C]i [C]t [C]s O 
interactions [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
with [C]w [C]i [C]t [C]h O 
corepressors [C]c [C]o [C]r [C]e [C]p [C]r [C]e [C]s [C]s [C]o [C]r [C]s S-protein 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Groucho [C]G [C]r [C]o [C]u [C]c [C]h [C]o B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y E-protein 
or [C]o [C]r O 
with [C]w [C]i [C]t [C]h O 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
regulators [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]s O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
the [C]t [C]h [C]e O 
TATA-binding [C]T [C]A [C]T [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
. [C]. O 

Once [C]O [C]n [C]c [C]e O 
committed [C]c [C]o [C]m [C]m [C]i [C]t [C]t [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
B-lineage [C]B [C]- [C]l [C]i [C]n [C]e [C]a [C]g [C]e S-cell_type 
, [C], O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
require [C]r [C]e [C]q [C]u [C]i [C]r [C]e O 
Pax5 [C]P [C]a [C]x [C]5 S-DNA 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
to [C]t [C]o O 
maintain [C]m [C]a [C]i [C]n [C]t [C]a [C]i [C]n O 
their [C]t [C]h [C]e [C]i [C]r O 
B-lymphoid [C]B [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d O 
identity [C]i [C]d [C]e [C]n [C]t [C]i [C]t [C]y O 
throughout [C]t [C]h [C]r [C]o [C]u [C]g [C]h [C]o [C]u [C]t O 
B [C]B O 
cell [C]c [C]e [C]l [C]l O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 

Partners [C]P [C]a [C]r [C]t [C]n [C]e [C]r [C]s O 
in [C]i [C]n O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
: [C]: O 
NFAT [C]N [C]F [C]A [C]T S-protein 
and [C]a [C]n [C]d O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
. [C]. O 

Combinatorial [C]C [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]o [C]r [C]i [C]a [C]l O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
a [C]a O 
powerful [C]p [C]o [C]w [C]e [C]r [C]f [C]u [C]l O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
that [C]t [C]h [C]a [C]t O 
enables [C]e [C]n [C]a [C]b [C]l [C]e [C]s O 
tight [C]t [C]i [C]g [C]h [C]t O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
of [C]o [C]f O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
via [C]v [C]i [C]a O 
integration [C]i [C]n [C]t [C]e [C]g [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
multiple [C]m [C]u [C]l [C]t [C]i [C]p [C]l [C]e O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
that [C]t [C]h [C]a [C]t O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
enhanceosome [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]o [C]s [C]o [C]m [C]e O 
assembly [C]a [C]s [C]s [C]e [C]m [C]b [C]l [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
four [C]f [C]o [C]u [C]r O 
calcium-regulated [C]c [C]a [C]l [C]c [C]i [C]u [C]m [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
NFAT [C]N [C]F [C]A [C]T B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y E-protein 
act [C]a [C]c [C]t O 
synergistically [C]s [C]y [C]n [C]e [C]r [C]g [C]i [C]s [C]t [C]i [C]c [C]a [C]l [C]l [C]y O 
with [C]w [C]i [C]t [C]h O 
AP-1 [C]A [C]P [C]- [C]1 B-protein 
( [C]( I-protein 
Fos/Jun [C]F [C]o [C]s [C]/ [C]J [C]u [C]n I-protein 
) [C]) I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
on [C]o [C]n O 
composite [C]c [C]o [C]m [C]p [C]o [C]s [C]i [C]t [C]e O 
DNA [C]D [C]N [C]A O 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s O 
which [C]w [C]h [C]i [C]c [C]h O 
contain [C]c [C]o [C]n [C]t [C]a [C]i [C]n O 
adjacent [C]a [C]d [C]j [C]a [C]c [C]e [C]n [C]t O 
NFAT [C]N [C]F [C]A [C]T B-DNA 
and [C]a [C]n [C]d I-DNA 
AP-1 [C]A [C]P [C]- [C]1 I-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
, [C], O 
where [C]w [C]h [C]e [C]r [C]e O 
they [C]t [C]h [C]e [C]y O 
form [C]f [C]o [C]r [C]m O 
highly [C]h [C]i [C]g [C]h [C]l [C]y O 
stable [C]s [C]t [C]a [C]b [C]l [C]e O 
ternary [C]t [C]e [C]r [C]n [C]a [C]r [C]y O 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s O 
to [C]t [C]o O 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
diverse [C]d [C]i [C]v [C]e [C]r [C]s [C]e O 
inducible [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
genes [C]g [C]e [C]n [C]e [C]s O 
. [C]. O 

Concomitant [C]C [C]o [C]n [C]c [C]o [C]m [C]i [C]t [C]a [C]n [C]t O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NFAT [C]N [C]F [C]A [C]T S-protein 
and [C]a [C]n [C]d O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
requires [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]s O 
concerted [C]c [C]o [C]n [C]c [C]e [C]r [C]t [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
two [C]t [C]w [C]o O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
: [C]: O 
calcium/calcineurin [C]c [C]a [C]l [C]c [C]i [C]u [C]m [C]/ [C]c [C]a [C]l [C]c [C]i [C]n [C]e [C]u [C]r [C]i [C]n O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
promotes [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]s O 
NFAT [C]N [C]F [C]A [C]T O 
dephosphorylation [C]d [C]e [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
translocation [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
; [C]; O 
and [C]a [C]n [C]d O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
C [C]C I-protein 
( [C]( I-protein 
PKC [C]P [C]K [C]C I-protein 
) [C]) I-protein 
/Ras [C]/ [C]R [C]a [C]s E-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
promotes [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]s O 
the [C]t [C]h [C]e O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
, [C], O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
members [C]m [C]e [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Fos [C]F [C]o [C]s B-protein 
and [C]a [C]n [C]d I-protein 
Jun [C]J [C]u [C]n I-protein 
families [C]f [C]a [C]m [C]i [C]l [C]i [C]e [C]s E-protein 
of [C]o [C]f O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

A [C]A O 
fifth [C]f [C]i [C]f [C]t [C]h O 
member [C]m [C]e [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
NFAT [C]N [C]F [C]A [C]T B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y E-protein 
, [C], O 
NFAT5 [C]N [C]F [C]A [C]T [C]5 S-protein 
, [C], O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
the [C]t [C]h [C]e O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
osmotic [C]o [C]s [C]m [C]o [C]t [C]i [C]c O 
stress [C]s [C]t [C]r [C]e [C]s [C]s O 
, [C], O 
by [C]b [C]y O 
a [C]a O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
that [C]t [C]h [C]a [C]t O 
requires [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]s O 
dimer [C]d [C]i [C]m [C]e [C]r O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
of [C]o [C]f O 
calcineurin [C]c [C]a [C]l [C]c [C]i [C]n [C]e [C]u [C]r [C]i [C]n S-protein 
or [C]o [C]r O 
of [C]o [C]f O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
. [C]. O 

Pharmacological [C]P [C]h [C]a [C]r [C]m [C]a [C]c [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
interference [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]e [C]n [C]c [C]e O 
with [C]w [C]i [C]t [C]h O 
theNFAT [C]t [C]h [C]e [C]N [C]F [C]A [C]T O 
: [C]: O 
AP-1 [C]A [C]P [C]- [C]1 O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
useful [C]u [C]s [C]e [C]f [C]u [C]l O 
in [C]i [C]n O 
selective [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e O 
manipulation [C]m [C]a [C]n [C]i [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
. [C]. O 

Balanced [C]B [C]a [C]l [C]a [C]n [C]c [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NFAT [C]N [C]F [C]A [C]T S-protein 
and [C]a [C]n [C]d O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
is [C]i [C]s O 
known [C]k [C]n [C]o [C]w [C]n O 
to [C]t [C]o O 
be [C]b [C]e O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
productive [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]v [C]e O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
, [C], O 
but [C]b [C]u [C]t O 
the [C]t [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
NFAT [C]N [C]F [C]A [C]T O 
: [C]: O 
AP-1 [C]A [C]P [C]- [C]1 O 
interactions [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
other [C]o [C]t [C]h [C]e [C]r O 
cell [C]c [C]e [C]l [C]l O 
types [C]t [C]y [C]p [C]e [C]s O 
and [C]a [C]n [C]d O 
biological [C]b [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
processes [C]p [C]r [C]o [C]c [C]e [C]s [C]s [C]e [C]s O 
remains [C]r [C]e [C]m [C]a [C]i [C]n [C]s O 
to [C]t [C]o O 
be [C]b [C]e O 
understood [C]u [C]n [C]d [C]e [C]r [C]s [C]t [C]o [C]o [C]d O 
. [C]. O 

Cytokine [C]C [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
Vgamma [C]V [C]g [C]a [C]m [C]m [C]a B-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
-T-cell [C]- [C]T [C]- [C]c [C]e [C]l [C]l I-cell_type 
subsets [C]s [C]u [C]b [C]s [C]e [C]t [C]s E-cell_type 
is [C]i [C]s O 
an [C]a [C]n O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
determining [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]i [C]n [C]g O 
CD4 [C]C [C]D [C]4 O 
( [C]( O 
+ [C]+ O 
) [C]) O 
-Th-cell [C]- [C]T [C]h [C]- [C]c [C]e [C]l [C]l O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
and [C]a [C]n [C]d O 
susceptibility [C]s [C]u [C]s [C]c [C]e [C]p [C]t [C]i [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
BALB/c [C]B [C]A [C]L [C]B [C]/ [C]c O 
mice [C]m [C]i [C]c [C]e O 
to [C]t [C]o O 
coxsackievirus [C]c [C]o [C]x [C]s [C]a [C]c [C]k [C]i [C]e [C]v [C]i [C]r [C]u [C]s O 
B3-induced [C]B [C]3 [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
myocarditis [C]m [C]y [C]o [C]c [C]a [C]r [C]d [C]i [C]t [C]i [C]s O 
. [C]. O 

Two [C]T [C]w [C]o O 
coxsackievirus [C]c [C]o [C]x [C]s [C]a [C]c [C]k [C]i [C]e [C]v [C]i [C]r [C]u [C]s O 
B3 [C]B [C]3 O 
( [C]( O 
CVB3 [C]C [C]V [C]B [C]3 O 
) [C]) O 
variants [C]v [C]a [C]r [C]i [C]a [C]n [C]t [C]s O 
( [C]( O 
H3 [C]H [C]3 O 
and [C]a [C]n [C]d O 
H310A1 [C]H [C]3 [C]1 [C]0 [C]A [C]1 O 
) [C]) O 
differ [C]d [C]i [C]f [C]f [C]e [C]r O 
by [C]b [C]y O 
a [C]a O 
single [C]s [C]i [C]n [C]g [C]l [C]e O 
amino [C]a [C]m [C]i [C]n [C]o O 
acid [C]a [C]c [C]i [C]d O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
VP2 [C]V [C]P [C]2 B-protein 
capsid [C]c [C]a [C]p [C]s [C]i [C]d I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
. [C]. O 

H3 [C]H [C]3 O 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
severe [C]s [C]e [C]v [C]e [C]r [C]e O 
myocarditis [C]m [C]y [C]o [C]c [C]a [C]r [C]d [C]i [C]t [C]i [C]s O 
in [C]i [C]n O 
BALB/c [C]B [C]A [C]L [C]B [C]/ [C]c O 
mice [C]m [C]i [C]c [C]e O 
, [C], O 
but [C]b [C]u [C]t O 
H310A1 [C]H [C]3 [C]1 [C]0 [C]A [C]1 O 
is [C]i [C]s O 
amyocarditic [C]a [C]m [C]y [C]o [C]c [C]a [C]r [C]d [C]i [C]t [C]i [C]c O 
. [C]. O 

Infection [C]I [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
H3 [C]H [C]3 O 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
H310A1 [C]H [C]3 [C]1 [C]0 [C]A [C]1 O 
, [C], O 
preferentially [C]p [C]r [C]e [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l [C]l [C]y O 
activates [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]s O 
Vgamma4 [C]V [C]g [C]a [C]m [C]m [C]a [C]4 B-cell_type 
Vdelta4 [C]V [C]d [C]e [C]l [C]t [C]a [C]4 I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
are [C]a [C]r [C]e O 
strongly [C]s [C]t [C]r [C]o [C]n [C]g [C]l [C]y O 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
for [C]f [C]o [C]r O 
gamma [C]g [C]a [C]m [C]m [C]a B-protein 
interferon [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n E-protein 
( [C]( O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
) [C]) O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
Vgamma1 [C]V [C]g [C]a [C]m [C]m [C]a [C]1 B-cell_type 
Vdelta4 [C]V [C]d [C]e [C]l [C]t [C]a [C]4 I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
are [C]a [C]r [C]e O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
H3 [C]H [C]3 O 
and [C]a [C]n [C]d O 
H310A1 [C]H [C]3 [C]1 [C]0 [C]A [C]1 O 
virus-infected [C]v [C]i [C]r [C]u [C]s [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
animals [C]a [C]n [C]i [C]m [C]a [C]l [C]s O 
. [C]. O 

Depletion [C]D [C]e [C]p [C]l [C]e [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Vgamma1 [C]V [C]g [C]a [C]m [C]m [C]a [C]1 B-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
using [C]u [C]s [C]i [C]n [C]g O 
monoclonal [C]m [C]o [C]n [C]o [C]c [C]l [C]o [C]n [C]a [C]l B-protein 
anti-Vgamma1 [C]a [C]n [C]t [C]i [C]- [C]V [C]g [C]a [C]m [C]m [C]a [C]1 I-protein 
antibody [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y E-protein 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
myocarditis [C]m [C]y [C]o [C]c [C]a [C]r [C]d [C]i [C]t [C]i [C]s O 
and [C]a [C]n [C]d O 
CD4 [C]C [C]D [C]4 O 
( [C]( O 
+ [C]+ O 
) [C]) O 
- [C]- O 
, [C], O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
( [C]( O 
+ [C]+ O 
) [C]) O 
-cell [C]- [C]c [C]e [C]l [C]l O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
H3- [C]H [C]3 [C]- O 
and [C]a [C]n [C]d O 
H310A1-infected [C]H [C]3 [C]1 [C]0 [C]A [C]1 [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
mice [C]m [C]i [C]c [C]e O 
yet [C]y [C]e [C]t O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
CD4 [C]C [C]D [C]4 O 
( [C]( O 
+ [C]+ O 
) [C]) O 
- [C]- O 
, [C], O 
IL-4 [C]I [C]L [C]- [C]4 O 
( [C]( O 
+ [C]+ O 
) [C]) O 
-cell [C]- [C]c [C]e [C]l [C]l O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
. [C]. O 

Depleting [C]D [C]e [C]p [C]l [C]e [C]t [C]i [C]n [C]g O 
Vgamma4 [C]V [C]g [C]a [C]m [C]m [C]a [C]4 B-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
suppressed [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
myocarditis [C]m [C]y [C]o [C]c [C]a [C]r [C]d [C]i [C]t [C]i [C]s O 
and [C]a [C]n [C]d O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
CD4 [C]C [C]D [C]4 B-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
but [C]b [C]u [C]t O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
CD4 [C]C [C]D [C]4 B-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
IL-4 [C]I [C]L [C]- [C]4 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
Vgamma1 [C]V [C]g [C]a [C]m [C]m [C]a [C]1 B-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
and [C]a [C]n [C]d I-cell_type 
Vgamma4 [C]V [C]g [C]a [C]m [C]m [C]a [C]4 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
was [C]w [C]a [C]s O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
adoptively [C]a [C]d [C]o [C]p [C]t [C]i [C]v [C]e [C]l [C]y O 
transferring [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]r [C]r [C]i [C]n [C]g O 
these [C]t [C]h [C]e [C]s [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
H3-infected [C]H [C]3 [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
BALB/c [C]B [C]A [C]L [C]B [C]/ [C]c O 
Stat4 [C]S [C]t [C]a [C]t [C]4 O 
knockout [C]k [C]n [C]o [C]c [C]k [C]o [C]u [C]t O 
( [C]( O 
Stat4ko [C]S [C]t [C]a [C]t [C]4 [C]k [C]o O 
) [C]) O 
( [C]( O 
defective [C]d [C]e [C]f [C]e [C]c [C]t [C]i [C]v [C]e O 
in [C]i [C]n O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
) [C]) O 
or [C]o [C]r O 
BALB/c [C]B [C]A [C]L [C]B [C]/ [C]c O 
Stat6ko [C]S [C]t [C]a [C]t [C]6 [C]k [C]o O 
( [C]( O 
defective [C]d [C]e [C]f [C]e [C]c [C]t [C]i [C]v [C]e O 
in [C]i [C]n O 
IL-4 [C]I [C]L [C]- [C]4 O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
) [C]) O 
mice [C]m [C]i [C]c [C]e O 
into [C]i [C]n [C]t [C]o O 
H3 [C]H [C]3 O 
virus-infected [C]v [C]i [C]r [C]u [C]s [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
wild-type [C]w [C]i [C]l [C]d [C]- [C]t [C]y [C]p [C]e O 
BALB/c [C]B [C]A [C]L [C]B [C]/ [C]c O 
recipients [C]r [C]e [C]c [C]i [C]p [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

Vgamma4 [C]V [C]g [C]a [C]m [C]m [C]a [C]4 B-cell_type 
and [C]a [C]n [C]d I-cell_type 
Vgamma1 [C]V [C]g [C]a [C]m [C]m [C]a [C]1 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
Stat4ko [C]S [C]t [C]a [C]t [C]4 [C]k [C]o O 
mice [C]m [C]i [C]c [C]e O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
but [C]b [C]u [C]t O 
no [C]n [C]o O 
or [C]o [C]r O 
minimal [C]m [C]i [C]n [C]i [C]m [C]a [C]l O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
these [C]t [C]h [C]e [C]s [C]e O 
cell [C]c [C]e [C]l [C]l O 
populations [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n [C]s O 
derived [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
Stat6ko [C]S [C]t [C]a [C]t [C]6 [C]k [C]o O 
mice [C]m [C]i [C]c [C]e O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
but [C]b [C]u [C]t O 
no [C]n [C]o O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
. [C]. O 

Stat4ko [C]S [C]t [C]a [C]t [C]4 [C]k [C]o B-cell_type 
Vgamma1 [C]V [C]g [C]a [C]m [C]m [C]a [C]1 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s I-cell_type 
( [C]( I-cell_type 
IL-4 [C]I [C]L [C]- [C]4 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) E-cell_type 
) [C]) O 
suppress [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s O 
myocarditis [C]m [C]y [C]o [C]c [C]a [C]r [C]d [C]i [C]t [C]i [C]s O 
. [C]. O 

Stat6ko [C]S [C]t [C]a [C]t [C]6 [C]k [C]o B-cell_type 
Vgamma1 [C]V [C]g [C]a [C]m [C]m [C]a [C]1 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s I-cell_type 
( [C]( I-cell_type 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
) [C]) E-cell_type 
were [C]w [C]e [C]r [C]e O 
not [C]n [C]o [C]t O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y O 
. [C]. O 

Stat6ko [C]S [C]t [C]a [C]t [C]6 [C]k [C]o B-cell_type 
Vgamma4 [C]V [C]g [C]a [C]m [C]m [C]a [C]4 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s I-cell_type 
( [C]( I-cell_type 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
) [C]) E-cell_type 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
myocarditis [C]m [C]y [C]o [C]c [C]a [C]r [C]d [C]i [C]t [C]i [C]s O 
. [C]. O 

Stat4ko [C]S [C]t [C]a [C]t [C]4 [C]k [C]o B-cell_type 
Vgamma4 [C]V [C]g [C]a [C]m [C]m [C]a [C]4 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s I-cell_type 
( [C]( I-cell_type 
IL-4 [C]I [C]L [C]- [C]4 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
) [C]) E-cell_type 
neither [C]n [C]e [C]i [C]t [C]h [C]e [C]r O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
nor [C]n [C]o [C]r O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
gammadelta-T-cell [C]g [C]a [C]m [C]m [C]a [C]d [C]e [C]l [C]t [C]a [C]- [C]T [C]- [C]c [C]e [C]l [C]l B-cell_type 
subsets [C]s [C]u [C]b [C]s [C]e [C]t [C]s E-cell_type 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
myocarditis [C]m [C]y [C]o [C]c [C]a [C]r [C]d [C]i [C]t [C]i [C]s O 
susceptibility [C]s [C]u [C]s [C]c [C]e [C]p [C]t [C]i [C]b [C]i [C]l [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
bias [C]b [C]i [C]a [C]s O 
the [C]t [C]h [C]e O 
CD4 [C]C [C]D [C]4 B-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
-Th-cell [C]- [C]T [C]h [C]- [C]c [C]e [C]l [C]l E-cell_type 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
produced [C]p [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
Vgamma [C]V [C]g [C]a [C]m [C]m [C]a B-cell_type 
subpopulation [C]s [C]u [C]b [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n E-cell_type 
have [C]h [C]a [C]v [C]e O 
a [C]a O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
influence [C]i [C]n [C]f [C]l [C]u [C]e [C]n [C]c [C]e O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
CD4 [C]C [C]D [C]4 S-protein 
( [C]( O 
+ [C]+ O 
) [C]) O 
-Th-cell [C]- [C]T [C]h [C]- [C]c [C]e [C]l [C]l O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
. [C]. O 

Plasmin [C]P [C]l [C]a [C]s [C]m [C]i [C]n S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
and [C]a [C]n [C]d O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
involves [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]s O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
and [C]a [C]n [C]d O 
IKKbeta [C]I [C]K [C]K [C]b [C]e [C]t [C]a S-protein 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

It [C]I [C]t O 
was [C]w [C]a [C]s O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
shown [C]s [C]h [C]o [C]w [C]n O 
that [C]t [C]h [C]a [C]t O 
plasmin [C]p [C]l [C]a [C]s [C]m [C]i [C]n S-protein 
activates [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]s O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
in [C]i [C]n O 
terms [C]t [C]e [C]r [C]m [C]s O 
of [C]o [C]f O 
lipid [C]l [C]i [C]p [C]i [C]d O 
mediator [C]m [C]e [C]d [C]i [C]a [C]t [C]o [C]r O 
release [C]r [C]e [C]l [C]e [C]a [C]s [C]e O 
and [C]a [C]n [C]d O 
chemotactic [C]c [C]h [C]e [C]m [C]o [C]t [C]a [C]c [C]t [C]i [C]c O 
migration [C]m [C]i [C]g [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
it [C]i [C]t O 
is [C]i [C]s O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
plasmin [C]p [C]l [C]a [C]s [C]m [C]i [C]n S-protein 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
proinflammatory [C]p [C]r [C]o [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y B-protein 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e E-protein 
release [C]r [C]e [C]l [C]e [C]a [C]s [C]e O 
and [C]a [C]n [C]d O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
( [C]( O 
TF [C]T [C]F S-protein 
) [C]) O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
by [C]b [C]y O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
. [C]. O 

Plasmin [C]P [C]l [C]a [C]s [C]m [C]i [C]n S-protein 
0.043 [C]0 [C]. [C]0 [C]4 [C]3 O 
to [C]t [C]o O 
1.43 [C]1 [C]. [C]4 [C]3 O 
CTA [C]C [C]T [C]A O 
U/mL [C]U [C]/ [C]m [C]L O 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
active [C]a [C]c [C]t [C]i [C]v [C]e B-protein 
site-blocked [C]s [C]i [C]t [C]e [C]- [C]b [C]l [C]o [C]c [C]k [C]e [C]d I-protein 
plasmin [C]p [C]l [C]a [C]s [C]m [C]i [C]n E-protein 
, [C], O 
triggered [C]t [C]r [C]i [C]g [C]g [C]e [C]r [C]e [C]d O 
concentration-dependent [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
mRNA [C]m [C]R [C]N [C]A O 
for [C]f [C]o [C]r O 
interleukin-1alpha [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]1 [C]a [C]l [C]p [C]h [C]a S-protein 
( [C]( O 
IL-1alpha [C]I [C]L [C]- [C]1 [C]a [C]l [C]p [C]h [C]a S-protein 
) [C]) O 
, [C], O 
IL-1beta [C]I [C]L [C]- [C]1 [C]b [C]e [C]t [C]a S-protein 
, [C], O 
tumor [C]t [C]u [C]m [C]o [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor-alpha [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]a [C]l [C]p [C]h [C]a E-protein 
( [C]( O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
TF [C]T [C]F S-protein 
with [C]w [C]i [C]t [C]h O 
maximum [C]m [C]a [C]x [C]i [C]m [C]u [C]m O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
after [C]a [C]f [C]t [C]e [C]r O 
4 [C]4 O 
hours [C]h [C]o [C]u [C]r [C]s O 
. [C]. O 

Plasmin [C]P [C]l [C]a [C]s [C]m [C]i [C]n S-protein 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
mRNA [C]m [C]R [C]N [C]A O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
in [C]i [C]n O 
a [C]a O 
concentration-dependent [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
manner [C]m [C]a [C]n [C]n [C]e [C]r O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
lysine [C]l [C]y [C]s [C]i [C]n [C]e O 
analogue [C]a [C]n [C]a [C]l [C]o [C]g [C]u [C]e O 
trans-4- [C]t [C]r [C]a [C]n [C]s [C]- [C]4 [C]- O 
( [C]( O 
aminomethyl [C]a [C]m [C]i [C]n [C]o [C]m [C]e [C]t [C]h [C]y [C]l O 
) [C]) O 
cyclohexane-1-carboxylic [C]c [C]y [C]c [C]l [C]o [C]h [C]e [C]x [C]a [C]n [C]e [C]- [C]1 [C]- [C]c [C]a [C]r [C]b [C]o [C]x [C]y [C]l [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
( [C]( O 
t-AMCA [C]t [C]- [C]A [C]M [C]C [C]A O 
) [C]) O 
. [C]. O 

Increases [C]I [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
in [C]i [C]n O 
mRNA [C]m [C]R [C]N [C]A O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
were [C]w [C]e [C]r [C]e O 
followed [C]f [C]o [C]l [C]l [C]o [C]w [C]e [C]d O 
by [C]b [C]y O 
concentration- [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]- O 
and [C]a [C]n [C]d O 
time-dependent [C]t [C]i [C]m [C]e [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
release [C]r [C]e [C]l [C]e [C]a [C]s [C]e O 
of [C]o [C]f O 
IL-1alpha [C]I [C]L [C]- [C]1 [C]a [C]l [C]p [C]h [C]a S-protein 
, [C], O 
IL-1beta [C]I [C]L [C]- [C]1 [C]b [C]e [C]t [C]a S-protein 
and [C]a [C]n [C]d O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
and [C]a [C]n [C]d O 
by [C]b [C]y O 
TF [C]T [C]F S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
on [C]o [C]n O 
monocyte [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e O 
surfaces [C]s [C]u [C]r [C]f [C]a [C]c [C]e [C]s O 
. [C]. O 

Neither [C]N [C]e [C]i [C]t [C]h [C]e [C]r O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
nor [C]n [C]o [C]r O 
TF [C]T [C]F S-protein 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
when [C]w [C]h [C]e [C]n O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
were [C]w [C]e [C]r [C]e O 
preincubated [C]p [C]r [C]e [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
actinomycin [C]a [C]c [C]t [C]i [C]n [C]o [C]m [C]y [C]c [C]i [C]n O 
D [C]D O 
or [C]o [C]r O 
cycloheximide [C]c [C]y [C]c [C]l [C]o [C]h [C]e [C]x [C]i [C]m [C]i [C]d [C]e O 
. [C]. O 

Electrophoretic [C]E [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
indicated [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e [C]d O 
plasmin [C]p [C]l [C]a [C]s [C]m [C]i [C]n S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
; [C]; O 
DNA-binding [C]D [C]N [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
were [C]w [C]e [C]r [C]e O 
composed [C]c [C]o [C]m [C]p [C]o [C]s [C]e [C]d O 
of [C]o [C]f O 
p50 [C]p [C]5 [C]0 S-protein 
, [C], O 
p65 [C]p [C]6 [C]5 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
c-Rel [C]c [C]- [C]R [C]e [C]l S-protein 
, [C], O 
as [C]a [C]s O 
shown [C]s [C]h [C]o [C]w [C]n O 
by [C]b [C]y O 
supershift [C]s [C]u [C]p [C]e [C]r [C]s [C]h [C]i [C]f [C]t O 
experiments [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]s O 
. [C]. O 

Nuclear [C]N [C]u [C]c [C]l [C]e [C]a [C]r O 
translocation [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappaB/Rel [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B [C]/ [C]R [C]e [C]l B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
coincided [C]c [C]o [C]i [C]n [C]c [C]i [C]d [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
IkappaBalpha [C]I [C]k [C]a [C]p [C]p [C]a [C]B [C]a [C]l [C]p [C]h [C]a O 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

At [C]A [C]t O 
variance [C]v [C]a [C]r [C]i [C]a [C]n [C]c [C]e O 
with [C]w [C]i [C]t [C]h O 
endotoxic [C]e [C]n [C]d [C]o [C]t [C]o [C]x [C]i [C]c O 
lipopolysaccharide [C]l [C]i [C]p [C]o [C]p [C]o [C]l [C]y [C]s [C]a [C]c [C]c [C]h [C]a [C]r [C]i [C]d [C]e O 
, [C], O 
plasmin [C]p [C]l [C]a [C]s [C]m [C]i [C]n S-protein 
elicited [C]e [C]l [C]i [C]c [C]i [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
rapid [C]r [C]a [C]p [C]i [C]d O 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
another [C]a [C]n [C]o [C]t [C]h [C]e [C]r O 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c B-protein 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B I-protein 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r I-protein 
, [C], I-protein 
p105 [C]p [C]1 [C]0 [C]5 E-protein 
. [C]. O 

Proteolysis [C]P [C]r [C]o [C]t [C]e [C]o [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B O 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
was [C]w [C]a [C]s O 
apparently [C]a [C]p [C]p [C]a [C]r [C]e [C]n [C]t [C]l [C]y O 
due [C]d [C]u [C]e O 
to [C]t [C]o O 
transient [C]t [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IkappaB [C]I [C]k [C]a [C]p [C]p [C]a [C]B B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
( [C]( I-protein 
IKK [C]I [C]K [C]K I-protein 
) [C]) I-protein 
beta [C]b [C]e [C]t [C]a E-protein 
that [C]t [C]h [C]a [C]t O 
reached [C]r [C]e [C]a [C]c [C]h [C]e [C]d O 
maximum [C]m [C]a [C]x [C]i [C]m [C]u [C]m O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
at [C]a [C]t O 
1 [C]1 O 
hour [C]h [C]o [C]u [C]r O 
after [C]a [C]f [C]t [C]e [C]r O 
plasmin [C]p [C]l [C]a [C]s [C]m [C]i [C]n S-protein 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
AP-1 [C]A [C]P [C]- [C]1 O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
was [C]w [C]a [C]s O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
in [C]i [C]n O 
plasmin [C]p [C]l [C]a [C]s [C]m [C]i [C]n S-protein 
-treated [C]- [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
, [C], O 
with [C]w [C]i [C]t [C]h O 
most [C]m [C]o [C]s [C]t O 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s O 
composed [C]c [C]o [C]m [C]p [C]o [C]s [C]e [C]d O 
of [C]o [C]f O 
JunD [C]J [C]u [C]n [C]D S-protein 
, [C], O 
c-Fos [C]c [C]- [C]F [C]o [C]s S-protein 
, [C], O 
and [C]a [C]n [C]d O 
FosB [C]F [C]o [C]s [C]B S-protein 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
substantiate [C]s [C]u [C]b [C]s [C]t [C]a [C]n [C]t [C]i [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
plasmin [C]p [C]l [C]a [C]s [C]m [C]i [C]n S-protein 
as [C]a [C]s O 
a [C]a O 
proinflammatory [C]p [C]r [C]o [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
reveal [C]r [C]e [C]v [C]e [C]a [C]l O 
an [C]a [C]n O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
new [C]n [C]e [C]w O 
link [C]l [C]i [C]n [C]k O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
plasminogen-plasmin [C]p [C]l [C]a [C]s [C]m [C]i [C]n [C]o [C]g [C]e [C]n [C]- [C]p [C]l [C]a [C]s [C]m [C]i [C]n O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
and [C]a [C]n [C]d O 
inflammation [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

( [C]( O 
Blood. [C]B [C]l [C]o [C]o [C]d [C]. O 
2001 [C]2 [C]0 [C]0 [C]1 O 
; [C]; O 
97 [C]9 [C]7 O 
: [C]: O 
3941-3950 [C]3 [C]9 [C]4 [C]1 [C]- [C]3 [C]9 [C]5 [C]0 O 
) [C]) O 

STAT3 [C]S [C]T [C]A [C]T [C]3 S-protein 
is [C]i [C]s O 
constitutively [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
in [C]i [C]n O 
some [C]s [C]o [C]m [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
Polycythemia [C]P [C]o [C]l [C]y [C]c [C]y [C]t [C]h [C]e [C]m [C]i [C]a O 
rubra [C]r [C]u [C]b [C]r [C]a O 
vera [C]v [C]e [C]r [C]a O 
. [C]. O 

OBJECTIVE [C]O [C]B [C]J [C]E [C]C [C]T [C]I [C]V [C]E O 
: [C]: O 
Polycythemia [C]P [C]o [C]l [C]y [C]c [C]y [C]t [C]h [C]e [C]m [C]i [C]a O 
vera [C]v [C]e [C]r [C]a O 
is [C]i [C]s O 
a [C]a O 
clonal [C]c [C]l [C]o [C]n [C]a [C]l O 
stem [C]s [C]t [C]e [C]m O 
cell [C]c [C]e [C]l [C]l O 
disorder [C]d [C]i [C]s [C]o [C]r [C]d [C]e [C]r O 
characterized [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]d O 
by [C]b [C]y O 
hyperproliferation [C]h [C]y [C]p [C]e [C]r [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d B-cell_type 
, [C], I-cell_type 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d I-cell_type 
, [C], I-cell_type 
and [C]a [C]n [C]d I-cell_type 
megakaryocytic [C]m [C]e [C]g [C]a [C]k [C]a [C]r [C]y [C]o [C]c [C]y [C]t [C]i [C]c I-cell_type 
lineages [C]l [C]i [C]n [C]e [C]a [C]g [C]e [C]s E-cell_type 
. [C]. O 

While [C]W [C]h [C]i [C]l [C]e O 
it [C]i [C]t O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
shown [C]s [C]h [C]o [C]w [C]n O 
that [C]t [C]h [C]a [C]t O 
progenitor [C]p [C]r [C]o [C]g [C]e [C]n [C]i [C]t [C]o [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
of [C]o [C]f O 
P. [C]P [C]. O 
vera [C]v [C]e [C]r [C]a O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
are [C]a [C]r [C]e O 
hypersensitive [C]h [C]y [C]p [C]e [C]r [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
to [C]t [C]o O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
erythropoietin [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]n S-protein 
, [C], O 
insulin-like [C]i [C]n [C]s [C]u [C]l [C]i [C]n [C]- [C]l [C]i [C]k [C]e B-protein 
growth [C]g [C]r [C]o [C]w [C]t [C]h I-protein 
factor-1 [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]1 E-protein 
, [C], O 
thrombopoietin [C]t [C]h [C]r [C]o [C]m [C]b [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]n S-protein 
, [C], O 
interleukin-3 [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]3 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
granulocyte/monocyte [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e [C]/ [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e B-protein 
colony-stimulating [C]c [C]o [C]l [C]o [C]n [C]y [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]n [C]g I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
, [C], O 
the [C]t [C]h [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
pathogenesis [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
remains [C]r [C]e [C]m [C]a [C]i [C]n [C]s O 
unknown [C]u [C]n [C]k [C]n [C]o [C]w [C]n O 
. [C]. O 

Growth [C]G [C]r [C]o [C]w [C]t [C]h O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
hypersensitivity [C]h [C]y [C]p [C]e [C]r [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
in [C]i [C]n O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
. [C]. O 

We [C]W [C]e O 
therefore [C]t [C]h [C]e [C]r [C]e [C]f [C]o [C]r [C]e O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
a [C]a O 
common [C]c [C]o [C]m [C]m [C]o [C]n O 
downstream [C]d [C]o [C]w [C]n [C]s [C]t [C]r [C]e [C]a [C]m O 
effector [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r O 
of [C]o [C]f O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
, [C], O 
the [C]t [C]h [C]e O 
signal [C]s [C]i [C]g [C]n [C]a [C]l B-protein 
transducers [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]e [C]r [C]s I-protein 
and [C]a [C]n [C]d I-protein 
activators [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r [C]s I-protein 
of [C]o [C]f I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n E-protein 
( [C]( O 
STATs [C]S [C]T [C]A [C]T [C]s S-protein 
) [C]) O 
. [C]. O 

A [C]A O 
constitutive [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
STAT [C]S [C]T [C]A [C]T B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
could [C]c [C]o [C]u [C]l [C]d O 
explain [C]e [C]x [C]p [C]l [C]a [C]i [C]n O 
the [C]t [C]h [C]e O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
P. [C]P [C]. B-cell_type 
vera [C]v [C]e [C]r [C]a I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
even [C]e [C]v [C]e [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

METHODS [C]M [C]E [C]T [C]H [C]O [C]D [C]S O 
: [C]: O 
Peripheral [C]P [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
granulocytes [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
P. [C]P [C]. O 
vera [C]v [C]e [C]r [C]a O 
and [C]a [C]n [C]d O 
from [C]f [C]r [C]o [C]m O 
healthy [C]h [C]e [C]a [C]l [C]t [C]h [C]y O 
volunteers [C]v [C]o [C]l [C]u [C]n [C]t [C]e [C]e [C]r [C]s O 
were [C]w [C]e [C]r [C]e O 
assayed [C]a [C]s [C]s [C]a [C]y [C]e [C]d O 
for [C]f [C]o [C]r O 
STAT1 [C]S [C]T [C]A [C]T [C]1 B-protein 
, [C], I-protein 
3 [C]3 I-protein 
, [C], I-protein 
and [C]a [C]n [C]d I-protein 
5 [C]5 E-protein 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
by [C]b [C]y O 
electrophoretic [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
assay [C]a [C]s [C]s [C]a [C]y O 
. [C]. O 

RESULTS [C]R [C]E [C]S [C]U [C]L [C]T [C]S O 
: [C]: O 
Four [C]F [C]o [C]u [C]r O 
of [C]o [C]f O 
14 [C]1 [C]4 O 
P. [C]P [C]. O 
vera [C]v [C]e [C]r [C]a O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
constitutive [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
STAT3 [C]S [C]T [C]A [C]T [C]3 O 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
in [C]i [C]n O 
unstimulated [C]u [C]n [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
granulocytes [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
, [C], O 
while [C]w [C]h [C]i [C]l [C]e O 
none [C]n [C]o [C]n [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
17 [C]1 [C]7 O 
healthy [C]h [C]e [C]a [C]l [C]t [C]h [C]y O 
volunteers [C]v [C]o [C]l [C]u [C]n [C]t [C]e [C]e [C]r [C]s O 
tested [C]t [C]e [C]s [C]t [C]e [C]d O 
did [C]d [C]i [C]d O 
. [C]. O 

None [C]N [C]o [C]n [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
constitutive [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
STAT1 [C]S [C]T [C]A [C]T [C]1 S-protein 
or [C]o [C]r O 
STAT5 [C]S [C]T [C]A [C]T [C]5 S-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

Western [C]W [C]e [C]s [C]t [C]e [C]r [C]n O 
blotting [C]b [C]l [C]o [C]t [C]t [C]i [C]n [C]g O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
, [C], O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
three [C]t [C]h [C]r [C]e [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
, [C], O 
STAT3 [C]S [C]T [C]A [C]T [C]3 S-protein 
is [C]i [C]s O 
constitutively [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y O 
phosphorylated [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]e [C]d O 
on [C]o [C]n O 
Tyr [C]T [C]y [C]r O 
705 [C]7 [C]0 [C]5 O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
it [C]i [C]t O 
is [C]i [C]s O 
unphosphorylated [C]u [C]n [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
other [C]o [C]t [C]h [C]e [C]r O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
. [C]. O 

Interestingly [C]I [C]n [C]t [C]e [C]r [C]e [C]s [C]t [C]i [C]n [C]g [C]l [C]y O 
, [C], O 
constitutive [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
STAT3 [C]S [C]T [C]A [C]T [C]3 S-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
correlate [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
duration [C]d [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
or [C]o [C]r O 
the [C]t [C]h [C]e O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
regimen [C]r [C]e [C]g [C]i [C]m [C]e [C]n O 
. [C]. O 

It [C]I [C]t O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
a [C]a O 
recently [C]r [C]e [C]c [C]e [C]n [C]t [C]l [C]y O 
diagnosed [C]d [C]i [C]a [C]g [C]n [C]o [C]s [C]e [C]d O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
two [C]t [C]w [C]o O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
only [C]o [C]n [C]l [C]y O 
with [C]w [C]i [C]t [C]h O 
phlebotomy [C]p [C]h [C]l [C]e [C]b [C]o [C]t [C]o [C]m [C]y O 
. [C]. O 

CONCLUSION [C]C [C]O [C]N [C]C [C]L [C]U [C]S [C]I [C]O [C]N O 
: [C]: O 
Our [C]O [C]u [C]r O 
data [C]d [C]a [C]t [C]a O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
constitutive [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
STAT3 [C]S [C]T [C]A [C]T [C]3 S-protein 
is [C]i [C]s O 
not [C]n [C]o [C]t O 
a [C]a O 
secondary [C]s [C]e [C]c [C]o [C]n [C]d [C]a [C]r [C]y O 
event [C]e [C]v [C]e [C]n [C]t O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
mutagenizing [C]m [C]u [C]t [C]a [C]g [C]e [C]n [C]i [C]z [C]i [C]n [C]g O 
agents [C]a [C]g [C]e [C]n [C]t [C]s O 
or [C]o [C]r O 
by [C]b [C]y O 
prolonged [C]p [C]r [C]o [C]l [C]o [C]n [C]g [C]e [C]d O 
hyperproliferation [C]h [C]y [C]p [C]e [C]r [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
hematopoietic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
but [C]b [C]u [C]t O 
rather [C]r [C]a [C]t [C]h [C]e [C]r O 
represents [C]r [C]e [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]s O 
a [C]a O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
aberration [C]a [C]b [C]e [C]r [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Constitutively [C]C [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y B-protein 
active [C]a [C]c [C]t [C]i [C]v [C]e I-protein 
STAT3 [C]S [C]T [C]A [C]T [C]3 E-protein 
may [C]m [C]a [C]y O 
contribute [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
hypersensitivity [C]h [C]y [C]p [C]e [C]r [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
P. [C]P [C]. B-cell_type 
vera [C]v [C]e [C]r [C]a I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Identification [C]I [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n B-protein 
sites [C]s [C]i [C]t [C]e [C]s E-protein 
for [C]f [C]o [C]r O 
Bruton [C]B [C]r [C]u [C]t [C]o [C]n B-protein 
's [C]' [C]s I-protein 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
the [C]t [C]h [C]e O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l B-protein 
regulator [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r I-protein 
BAP/TFII-I [C]B [C]A [C]P [C]/ [C]T [C]F [C]I [C]I [C]- [C]I E-protein 
. [C]. O 

Bruton [C]B [C]r [C]u [C]t [C]o [C]n B-protein 
's [C]' [C]s I-protein 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
( [C]( O 
Btk [C]B [C]t [C]k S-protein 
) [C]) O 
, [C], O 
a [C]a O 
member [C]m [C]e [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Tec [C]T [C]e [C]c B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y I-protein 
of [C]o [C]f I-protein 
cytosolic [C]c [C]y [C]t [C]o [C]s [C]o [C]l [C]i [C]c I-protein 
kinases [C]k [C]i [C]n [C]a [C]s [C]e [C]s E-protein 
, [C], O 
is [C]i [C]s O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
for [C]f [C]o [C]r O 
B [C]B B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

BAP/TFII-I [C]B [C]A [C]P [C]/ [C]T [C]F [C]I [C]I [C]- [C]I S-protein 
, [C], O 
a [C]a O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
implicated [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
is [C]i [C]s O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
Btk [C]B [C]t [C]k S-protein 
in [C]i [C]n O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
transiently [C]t [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t [C]l [C]y O 
phosphorylated [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]e [C]d O 
on [C]o [C]n O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
B [C]B B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
engagement [C]e [C]n [C]g [C]a [C]g [C]e [C]m [C]e [C]n [C]t O 
. [C]. O 

BAP/TFII-I [C]B [C]A [C]P [C]/ [C]T [C]F [C]I [C]I [C]- [C]I S-protein 
is [C]i [C]s O 
a [C]a O 
substrate [C]s [C]u [C]b [C]s [C]t [C]r [C]a [C]t [C]e O 
for [C]f [C]o [C]r O 
Btk [C]B [C]t [C]k S-protein 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
hyperphosphorylated [C]h [C]y [C]p [C]e [C]r [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]e [C]d O 
on [C]o [C]n O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
upon [C]u [C]p [C]o [C]n O 
coexpression [C]c [C]o [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
Btk [C]B [C]t [C]k S-protein 
in [C]i [C]n O 
mammalian [C]m [C]a [C]m [C]m [C]a [C]l [C]i [C]a [C]n B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

In [C]I [C]n O 
an [C]a [C]n O 
effort [C]e [C]f [C]f [C]o [C]r [C]t O 
to [C]t [C]o O 
understand [C]u [C]n [C]d [C]e [C]r [C]s [C]t [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
physiologic [C]p [C]h [C]y [C]s [C]i [C]o [C]l [C]o [C]g [C]i [C]c O 
consequences [C]c [C]o [C]n [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s O 
of [C]o [C]f O 
BAP/TFII-I [C]B [C]A [C]P [C]/ [C]T [C]F [C]I [C]I [C]- [C]I S-protein 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
B [C]B O 
cell [C]c [C]e [C]l [C]l O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
site-directed [C]s [C]i [C]t [C]e [C]- [C]d [C]i [C]r [C]e [C]c [C]t [C]e [C]d O 
mutagenesis [C]m [C]u [C]t [C]a [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
phosphopeptide [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
mapping [C]m [C]a [C]p [C]p [C]i [C]n [C]g O 
were [C]w [C]e [C]r [C]e O 
used [C]u [C]s [C]e [C]d O 
to [C]t [C]o O 
locate [C]l [C]o [C]c [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
predominant [C]p [C]r [C]e [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t O 
sites [C]s [C]i [C]t [C]e [C]s O 
of [C]o [C]f O 
BAP/TFII-I [C]B [C]A [C]P [C]/ [C]T [C]F [C]I [C]I [C]- [C]I S-protein 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
Btk [C]B [C]t [C]k S-protein 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
residues [C]r [C]e [C]s [C]i [C]d [C]u [C]e [C]s O 
, [C], O 
Tyr248 [C]T [C]y [C]r [C]2 [C]4 [C]8 O 
, [C], O 
Tyr357 [C]T [C]y [C]r [C]3 [C]5 [C]7 O 
, [C], O 
and [C]a [C]n [C]d O 
Tyr462 [C]T [C]y [C]r [C]4 [C]6 [C]2 O 
, [C], O 
were [C]w [C]e [C]r [C]e O 
also [C]a [C]l [C]s [C]o O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
the [C]t [C]h [C]e O 
major [C]m [C]a [C]j [C]o [C]r O 
sites [C]s [C]i [C]t [C]e [C]s O 
for [C]f [C]o [C]r O 
Btk [C]B [C]t [C]k S-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
BAP/TFII-I [C]B [C]A [C]P [C]/ [C]T [C]F [C]I [C]I [C]- [C]I S-protein 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
. [C]. O 

Residues [C]R [C]e [C]s [C]i [C]d [C]u [C]e [C]s O 
Tyr357 [C]T [C]y [C]r [C]3 [C]5 [C]7 O 
and [C]a [C]n [C]d O 
Tyr462 [C]T [C]y [C]r [C]4 [C]6 [C]2 O 
are [C]a [C]r [C]e O 
contained [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]e [C]d O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
the [C]t [C]h [C]e O 
loop [C]l [C]o [C]o [C]p B-protein 
regions [C]r [C]e [C]g [C]i [C]o [C]n [C]s E-protein 
of [C]o [C]f O 
adjacent [C]a [C]d [C]j [C]a [C]c [C]e [C]n [C]t O 
helix-loop-helix-like [C]h [C]e [C]l [C]i [C]x [C]- [C]l [C]o [C]o [C]p [C]- [C]h [C]e [C]l [C]i [C]x [C]- [C]l [C]i [C]k [C]e B-protein 
repeats [C]r [C]e [C]p [C]e [C]a [C]t [C]s E-protein 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
BAP/TFII-I [C]B [C]A [C]P [C]/ [C]T [C]F [C]I [C]I [C]- [C]I S-protein 
. [C]. O 

Mutation [C]M [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
Tyr248 [C]T [C]y [C]r [C]2 [C]4 [C]8 O 
, [C], O 
Tyr357 [C]T [C]y [C]r [C]3 [C]5 [C]7 O 
, [C], O 
or [C]o [C]r O 
Tyr462 [C]T [C]y [C]r [C]4 [C]6 [C]2 O 
to [C]t [C]o O 
phenylalanine [C]p [C]h [C]e [C]n [C]y [C]l [C]a [C]l [C]a [C]n [C]i [C]n [C]e O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
from [C]f [C]r [C]o [C]m O 
a [C]a O 
c-fos [C]c [C]- [C]f [C]o [C]s B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
relative [C]r [C]e [C]l [C]a [C]t [C]i [C]v [C]e O 
to [C]t [C]o O 
wild-type [C]w [C]i [C]l [C]d [C]- [C]t [C]y [C]p [C]e B-DNA 
BAP/TFII-I [C]B [C]A [C]P [C]/ [C]T [C]F [C]I [C]I [C]- [C]I E-DNA 
in [C]i [C]n O 
transfected [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]e [C]d O 
COS-7 [C]C [C]O [C]S [C]- [C]7 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
, [C], O 
consistent [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
interpretation [C]i [C]n [C]t [C]e [C]r [C]p [C]r [C]e [C]t [C]a [C]t [C]i [C]o [C]n O 
that [C]t [C]h [C]a [C]t O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
at [C]a [C]t O 
these [C]t [C]h [C]e [C]s [C]e O 
sites [C]s [C]i [C]t [C]e [C]s O 
contributes [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e [C]s O 
to [C]t [C]o O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Phosphorylation [C]P [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
BAP/TFII-I [C]B [C]A [C]P [C]/ [C]T [C]F [C]I [C]I [C]- [C]I S-protein 
by [C]b [C]y O 
Btk [C]B [C]t [C]k S-protein 
may [C]m [C]a [C]y O 
link [C]l [C]i [C]n [C]k O 
engagement [C]e [C]n [C]g [C]a [C]g [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n S-protein 
to [C]t [C]o O 
modulation [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Expression [C]E [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
interferon [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n B-protein 
consensus [C]c [C]o [C]n [C]s [C]e [C]n [C]s [C]u [C]s I-protein 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
potent [C]p [C]o [C]t [C]e [C]n [C]t O 
immunity [C]i [C]m [C]m [C]u [C]n [C]i [C]t [C]y O 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
BCR/ABL-induced [C]B [C]C [C]R [C]/ [C]A [C]B [C]L [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
. [C]. O 

Mice [C]M [C]i [C]c [C]e O 
deficient [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
interferon [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n B-protein 
consensus [C]c [C]o [C]n [C]s [C]e [C]n [C]s [C]u [C]s I-protein 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
( [C]( O 
ICSBP [C]I [C]C [C]S [C]B [C]P S-protein 
) [C]) O 
develop [C]d [C]e [C]v [C]e [C]l [C]o [C]p O 
a [C]a O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
resembling [C]r [C]e [C]s [C]e [C]m [C]b [C]l [C]i [C]n [C]g O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
( [C]( O 
CML [C]C [C]M [C]L O 
) [C]) O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
in [C]i [C]n O 
humans [C]h [C]u [C]m [C]a [C]n [C]s O 
is [C]i [C]s O 
caused [C]c [C]a [C]u [C]s [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
BCR/ABL [C]B [C]C [C]R [C]/ [C]A [C]B [C]L B-protein 
oncoprotein [C]o [C]n [C]c [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
. [C]. O 

Interferon-alpha [C]I [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
( [C]( O 
IFN-alpha [C]I [C]F [C]N [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
) [C]) O 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
ICSBP [C]I [C]C [C]S [C]B [C]P S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
an [C]a [C]n O 
effective [C]e [C]f [C]f [C]e [C]c [C]t [C]i [C]v [C]e O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
for [C]f [C]o [C]r O 
CML [C]C [C]M [C]L O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
enforced [C]e [C]n [C]f [C]o [C]r [C]c [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
ICSBP [C]I [C]C [C]S [C]B [C]P S-protein 
might [C]m [C]i [C]g [C]h [C]t O 
antagonize [C]a [C]n [C]t [C]a [C]g [C]o [C]n [C]i [C]z [C]e O 
BCR/ABL-induced [C]B [C]C [C]R [C]/ [C]A [C]B [C]L [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
; [C]; O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
ICSBP-modified [C]I [C]C [C]S [C]B [C]P [C]- [C]m [C]o [C]d [C]i [C]f [C]i [C]e [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
generated [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]e [C]d O 
a [C]a O 
protective [C]p [C]r [C]o [C]t [C]e [C]c [C]t [C]i [C]v [C]e O 
CD8 [C]C [C]D [C]8 O 
( [C]( O 
+ [C]+ O 
) [C]) O 
cytotoxic [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
BCR/ABL-transformed [C]B [C]C [C]R [C]/ [C]A [C]B [C]L [C]- [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]e [C]d B-cell_type 
BaF3 [C]B [C]a [C]F [C]3 I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
a [C]a O 
murine [C]m [C]u [C]r [C]i [C]n [C]e O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
model [C]m [C]o [C]d [C]e [C]l O 
. [C]. O 

ICSBP [C]I [C]C [C]S [C]B [C]P S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
represents [C]r [C]e [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]s O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
means [C]m [C]e [C]a [C]n [C]s O 
of [C]o [C]f O 
stimulating [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
a [C]a O 
host [C]h [C]o [C]s [C]t O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
BCR/ABL [C]B [C]C [C]R [C]/ [C]A [C]B [C]L B-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
a [C]a O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
strategy [C]s [C]t [C]r [C]a [C]t [C]e [C]g [C]y O 
for [C]f [C]o [C]r O 
immunotherapy [C]i [C]m [C]m [C]u [C]n [C]o [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
of [C]o [C]f O 
CML [C]C [C]M [C]L O 
. [C]. O 

( [C]( O 
Blood. [C]B [C]l [C]o [C]o [C]d [C]. O 
2001 [C]2 [C]0 [C]0 [C]1 O 
; [C]; O 
97 [C]9 [C]7 O 
: [C]: O 
3491-3497 [C]3 [C]4 [C]9 [C]1 [C]- [C]3 [C]4 [C]9 [C]7 O 
) [C]) O 

A [C]A O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
block [C]b [C]l [C]o [C]c [C]k O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
-150 [C]- [C]1 [C]5 [C]0 B-DNA 
AP-1 [C]A [C]P [C]- [C]1 I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
in [C]i [C]n O 
effector [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r B-cell_type 
CD8+ [C]C [C]D [C]8 [C]+ I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Both [C]B [C]o [C]t [C]h O 
CD4+ [C]C [C]D [C]4 [C]+ B-cell_type 
and [C]a [C]n [C]d I-cell_type 
CD8+ [C]C [C]D [C]8 [C]+ I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
that [C]t [C]h [C]a [C]t O 
produce [C]p [C]r [C]o [C]d [C]u [C]c [C]e O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
Ag [C]A [C]g O 
recognition [C]r [C]e [C]c [C]o [C]g [C]n [C]i [C]t [C]i [C]o [C]n O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
most [C]m [C]o [C]s [C]t O 
effector [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r B-cell_type 
CD8+ [C]C [C]D [C]8 [C]+ I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
recovered [C]r [C]e [C]c [C]o [C]v [C]e [C]r [C]e [C]d O 
after [C]a [C]f [C]t [C]e [C]r O 
exposure [C]e [C]x [C]p [C]o [C]s [C]u [C]r [C]e O 
to [C]t [C]o O 
Ag [C]A [C]g S-protein 
do [C]d [C]o O 
not [C]n [C]o [C]t O 
produce [C]p [C]r [C]o [C]d [C]u [C]c [C]e O 
sufficient [C]s [C]u [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
to [C]t [C]o O 
sustain [C]s [C]u [C]s [C]t [C]a [C]i [C]n O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
, [C], O 
and [C]a [C]n [C]d O 
depend [C]d [C]e [C]p [C]e [C]n [C]d O 
on [C]o [C]n O 
CD4+ [C]C [C]D [C]4 [C]+ B-cell_type 
T [C]T I-cell_type 
helper [C]h [C]e [C]l [C]p [C]e [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
for [C]f [C]o [C]r O 
this [C]t [C]h [C]i [C]s O 
obligate [C]o [C]b [C]l [C]i [C]g [C]a [C]t [C]e O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
. [C]. O 

IL-2 [C]I [C]L [C]- [C]2 O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
CD4+ [C]C [C]D [C]4 [C]+ B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
is [C]i [C]s O 
primarily [C]p [C]r [C]i [C]m [C]a [C]r [C]i [C]l [C]y O 
controlled [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]l [C]e [C]d O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
, [C], O 
but [C]b [C]u [C]t O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
restricting [C]r [C]e [C]s [C]t [C]r [C]i [C]c [C]t [C]i [C]n [C]g O 
IL-2 [C]I [C]L [C]- [C]2 O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
CD8+ [C]C [C]D [C]8 [C]+ B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
have [C]h [C]a [C]v [C]e O 
not [C]n [C]o [C]t O 
been [C]b [C]e [C]e [C]n O 
elucidated [C]e [C]l [C]u [C]c [C]i [C]d [C]a [C]t [C]e [C]d O 
. [C]. O 

To [C]T [C]o O 
evaluate [C]e [C]v [C]a [C]l [C]u [C]a [C]t [C]e O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
in [C]i [C]n O 
CD8+ [C]C [C]D [C]8 [C]+ B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
we [C]w [C]e O 
stably [C]s [C]t [C]a [C]b [C]l [C]y O 
transfected [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]e [C]d O 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
into [C]i [C]n [C]t [C]o O 
Ag [C]A [C]g S-protein 
-specific [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
CD8+ [C]C [C]D [C]8 [C]+ B-cell_line 
T [C]T I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
clones [C]c [C]l [C]o [C]n [C]e [C]s E-cell_line 
. [C]. O 

CD28+ [C]C [C]D [C]2 [C]8 [C]+ B-cell_type 
CD8 [C]C [C]D [C]8 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
unable [C]u [C]n [C]a [C]b [C]l [C]e O 
to [C]t [C]o O 
transcribe [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]b [C]e O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
antigenic [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]i [C]c O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
had [C]h [C]a [C]d O 
a [C]a O 
block [C]b [C]l [C]o [C]c [C]k O 
in [C]i [C]n O 
transactivation [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
-150 [C]- [C]1 [C]5 [C]0 B-DNA 
CD28 [C]C [C]D [C]2 [C]8 I-DNA 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e I-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t I-DNA 
( [C]( I-DNA 
CD28RE [C]C [C]D [C]2 [C]8 [C]R [C]E I-DNA 
) [C]) I-DNA 
/AP-1 [C]/ [C]A [C]P [C]- [C]1 I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
, [C], O 
but [C]b [C]u [C]t O 
did [C]d [C]i [C]d O 
transactivate [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
composite [C]c [C]o [C]m [C]p [C]o [C]s [C]i [C]t [C]e O 
NFAT/AP-1 [C]N [C]F [C]A [C]T [C]/ [C]A [C]P [C]- [C]1 B-DNA 
and [C]a [C]n [C]d I-DNA 
OCT/AP-1 [C]O [C]C [C]T [C]/ [C]A [C]P [C]- [C]1 I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
, [C], O 
and [C]a [C]n [C]d O 
a [C]a O 
consensus [C]c [C]o [C]n [C]s [C]e [C]n [C]s [C]u [C]s B-DNA 
AP-1 [C]A [C]P [C]- [C]1 I-DNA 
motif [C]m [C]o [C]t [C]i [C]f E-DNA 
. [C]. O 

Mutation [C]M [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
nonconsensus [C]n [C]o [C]n [C]c [C]o [C]n [C]s [C]e [C]n [C]s [C]u [C]s B-DNA 
-150 [C]- [C]1 [C]5 [C]0 I-DNA 
AP-1 [C]A [C]P [C]- [C]1 I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
to [C]t [C]o O 
a [C]a O 
consensus [C]c [C]o [C]n [C]s [C]e [C]n [C]s [C]u [C]s B-DNA 
AP-1 [C]A [C]P [C]- [C]1 I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
, [C], O 
or [C]o [C]r O 
insertion [C]i [C]n [C]s [C]e [C]r [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
CD28RE/AP-1 [C]C [C]D [C]2 [C]8 [C]R [C]E [C]/ [C]A [C]P [C]- [C]1 B-DNA 
consensus [C]c [C]o [C]n [C]s [C]e [C]n [C]s [C]u [C]s I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
upstream [C]u [C]p [C]s [C]t [C]r [C]e [C]a [C]m O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
native [C]n [C]a [C]t [C]i [C]v [C]e O 
-150 [C]- [C]1 [C]5 [C]0 B-DNA 
CD28RE/AP-1 [C]C [C]D [C]2 [C]8 [C]R [C]E [C]/ [C]A [C]P [C]- [C]1 I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
restored [C]r [C]e [C]s [C]t [C]o [C]r [C]e [C]d O 
transactivation [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
altered [C]a [C]l [C]t [C]e [C]r [C]e [C]d O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r S-DNA 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
defect [C]d [C]e [C]f [C]e [C]c [C]t O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
-150 [C]- [C]1 [C]5 [C]0 B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
may [C]m [C]a [C]y O 
reflect [C]r [C]e [C]f [C]l [C]e [C]c [C]t O 
the [C]t [C]h [C]e O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
or [C]o [C]r O 
inactivity [C]i [C]n [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
a [C]a O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
rather [C]r [C]a [C]t [C]h [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
repression [C]r [C]e [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

Stem [C]S [C]t [C]e [C]m B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
and [C]a [C]n [C]d O 
interleukin-3 [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]3 S-protein 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
stepwise [C]s [C]t [C]e [C]p [C]w [C]i [C]s [C]e O 
generation [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d B-cell_type 
precursor [C]p [C]r [C]e [C]c [C]u [C]r [C]s [C]o [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
a [C]a O 
basic [C]b [C]a [C]s [C]i [C]c O 
fibroblast [C]f [C]i [C]b [C]r [C]o [C]b [C]l [C]a [C]s [C]t B-protein 
growth [C]g [C]r [C]o [C]w [C]t [C]h I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
hematopoietic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c B-cell_line 
stem [C]s [C]t [C]e [C]m I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e I-cell_line 
, [C], I-cell_line 
A-6 [C]A [C]- [C]6 E-cell_line 
. [C]. O 

A [C]A O 
m [C]m O 
ultipotent [C]u [C]l [C]t [C]i [C]p [C]o [C]t [C]e [C]n [C]t B-cell_type 
immature [C]i [C]m [C]m [C]a [C]t [C]u [C]r [C]e I-cell_type 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d I-cell_type 
cell [C]c [C]e [C]l [C]l I-cell_type 
population [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n E-cell_type 
was [C]w [C]a [C]s O 
produced [C]p [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
a [C]a O 
basic [C]b [C]a [C]s [C]i [C]c B-protein 
fibroblast [C]f [C]i [C]b [C]r [C]o [C]b [C]l [C]a [C]s [C]t I-protein 
growth [C]g [C]r [C]o [C]w [C]t [C]h I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
( [C]( O 
bFGF [C]b [C]F [C]G [C]F S-protein 
) [C]) O 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
hematopoietic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c B-cell_line 
stem [C]s [C]t [C]e [C]m I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e I-cell_line 
, [C], I-cell_line 
A-6 [C]A [C]- [C]6 E-cell_line 
, [C], O 
when [C]w [C]h [C]e [C]n O 
cultured [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
stem [C]s [C]t [C]e [C]m B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
( [C]( O 
SCF [C]S [C]C [C]F S-protein 
) [C]) O 
replacing [C]r [C]e [C]p [C]l [C]a [C]c [C]i [C]n [C]g O 
bFGF [C]b [C]F [C]G [C]F S-protein 
. [C]. O 

Those [C]T [C]h [C]o [C]s [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
were [C]w [C]e [C]r [C]e O 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
for [C]f [C]o [C]r O 
stem [C]s [C]t [C]e [C]m B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
markers [C]m [C]a [C]r [C]k [C]e [C]r [C]s E-protein 
, [C], O 
c-kit [C]c [C]- [C]k [C]i [C]t S-protein 
and [C]a [C]n [C]d O 
CD34 [C]C [C]D [C]3 [C]4 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
a [C]a O 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
marker [C]m [C]a [C]r [C]k [C]e [C]r I-protein 
, [C], I-protein 
F4/80 [C]F [C]4 [C]/ [C]8 [C]0 E-protein 
. [C]. O 

Some [C]S [C]o [C]m [C]e O 
cell [C]c [C]e [C]l [C]l O 
fractions [C]f [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
were [C]w [C]e [C]r [C]e O 
also [C]a [C]l [C]s [C]o O 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
for [C]f [C]o [C]r O 
Mac-1 [C]M [C]a [C]c [C]- [C]1 B-protein 
, [C], I-protein 
a [C]a I-protein 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e I-protein 
marker [C]m [C]a [C]r [C]k [C]e [C]r E-protein 
or [C]o [C]r O 
Gr-1 [C]G [C]r [C]- [C]1 B-protein 
, [C], I-protein 
a [C]a I-protein 
granulocytic [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]i [C]c I-protein 
maker [C]m [C]a [C]k [C]e [C]r E-protein 
, [C], O 
but [C]b [C]u [C]t O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
for [C]f [C]o [C]r O 
an [C]a [C]n O 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d B-protein 
marker [C]m [C]a [C]r [C]k [C]e [C]r I-protein 
TER119 [C]T [C]E [C]R [C]1 [C]1 [C]9 E-protein 
. [C]. O 

They [C]T [C]h [C]e [C]y O 
also [C]a [C]l [C]s [C]o O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
mRNA [C]m [C]R [C]N [C]A O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
myeloid-specific [C]m [C]y [C]e [C]l [C]o [C]i [C]d [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-protein 
PU.1 [C]P [C]U [C]. [C]1 E-protein 
but [C]b [C]u [C]t O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
that [C]t [C]h [C]a [C]t O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
erythroid-specific [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-protein 
GATA-1 [C]G [C]A [C]T [C]A [C]- [C]1 E-protein 
. [C]. O 

Among [C]A [C]m [C]o [C]n [C]g O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
, [C], O 
interleukin-3 [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]3 S-protein 
( [C]( O 
IL-3 [C]I [C]L [C]- [C]3 S-protein 
) [C]) O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d B-cell_type 
precursor [C]p [C]r [C]e [C]c [C]u [C]r [C]s [C]o [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
that [C]t [C]h [C]a [C]t O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
erythroid-specific [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-protein 
GATA-1 [C]G [C]A [C]T [C]A [C]- [C]1 E-protein 
and [C]a [C]n [C]d O 
beta-major [C]b [C]e [C]t [C]a [C]- [C]m [C]a [C]j [C]o [C]r B-protein 
globin [C]g [C]l [C]o [C]b [C]i [C]n E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
quantitative [C]q [C]u [C]a [C]n [C]t [C]i [C]t [C]a [C]t [C]i [C]v [C]e O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d B-cell_type 
precursor [C]p [C]r [C]e [C]c [C]u [C]r [C]s [C]o [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
newly [C]n [C]e [C]w [C]l [C]y O 
produced [C]p [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
immature [C]i [C]m [C]m [C]a [C]t [C]u [C]r [C]e B-cell_type 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
by [C]b [C]y O 
cultivation [C]c [C]u [C]l [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
IL-3 [C]I [C]L [C]- [C]3 S-protein 
. [C]. O 

SCF [C]S [C]C [C]F S-protein 
and [C]a [C]n [C]d O 
IL-3 [C]I [C]L [C]- [C]3 S-protein 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
stepwise [C]s [C]t [C]e [C]p [C]w [C]i [C]s [C]e O 
generation [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d B-cell_type 
precursor [C]p [C]r [C]e [C]c [C]u [C]r [C]s [C]o [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
an [C]a [C]n O 
A-6 [C]A [C]- [C]6 B-cell_line 
hematopoietic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c I-cell_line 
stem [C]s [C]t [C]e [C]m I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
. [C]. O 

Copyright [C]C [C]o [C]p [C]y [C]r [C]i [C]g [C]h [C]t O 
2001 [C]2 [C]0 [C]0 [C]1 O 
Academic [C]A [C]c [C]a [C]d [C]e [C]m [C]i [C]c O 
Press [C]P [C]r [C]e [C]s [C]s O 
. [C]. O 

Distinct [C]D [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
BMI-1 [C]B [C]M [C]I [C]- [C]1 S-protein 
and [C]a [C]n [C]d O 
EZH2 [C]E [C]Z [C]H [C]2 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
patterns [C]p [C]a [C]t [C]t [C]e [C]r [C]n [C]s O 
in [C]i [C]n O 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
and [C]a [C]n [C]d O 
mature [C]m [C]a [C]t [C]u [C]r [C]e B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
a [C]a O 
role [C]r [C]o [C]l [C]e O 
for [C]f [C]o [C]r O 
Polycomb [C]P [C]o [C]l [C]y [C]c [C]o [C]m [C]b B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

BMI-1 [C]B [C]M [C]I [C]- [C]1 S-protein 
and [C]a [C]n [C]d O 
EZH2 [C]E [C]Z [C]H [C]2 S-protein 
Polycomb-group [C]P [C]o [C]l [C]y [C]c [C]o [C]m [C]b [C]- [C]g [C]r [C]o [C]u [C]p B-protein 
( [C]( I-protein 
PcG [C]P [C]c [C]G I-protein 
) [C]) I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
belong [C]b [C]e [C]l [C]o [C]n [C]g O 
to [C]t [C]o O 
two [C]t [C]w [C]o O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
hematopoiesis [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
. [C]. O 

Using [C]U [C]s [C]i [C]n [C]g O 
unique [C]u [C]n [C]i [C]q [C]u [C]e O 
PcG-specific [C]P [C]c [C]G [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
antisera [C]a [C]n [C]t [C]i [C]s [C]e [C]r [C]a O 
and [C]a [C]n [C]d O 
triple [C]t [C]r [C]i [C]p [C]l [C]e O 
immunofluorescence [C]i [C]m [C]m [C]u [C]n [C]o [C]f [C]l [C]u [C]o [C]r [C]e [C]s [C]c [C]e [C]n [C]c [C]e O 
, [C], O 
we [C]w [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
mature [C]m [C]a [C]t [C]u [C]r [C]e B-cell_type 
resting [C]r [C]e [C]s [C]t [C]i [C]n [C]g I-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
BMI-1 [C]B [C]M [C]I [C]- [C]1 S-protein 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
dividing [C]d [C]i [C]v [C]i [C]d [C]i [C]n [C]g B-cell_type 
blasts [C]b [C]l [C]a [C]s [C]t [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
EZH2 [C]E [C]Z [C]H [C]2 O 
( [C]( O 
+ [C]+ O 
) [C]) O 
. [C]. O 

By [C]B [C]y O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
subcapsular [C]s [C]u [C]b [C]c [C]a [C]p [C]s [C]u [C]l [C]a [C]r B-cell_type 
immature [C]i [C]m [C]m [C]a [C]t [C]u [C]r [C]e I-cell_type 
double-negative [C]d [C]o [C]u [C]b [C]l [C]e [C]- [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e I-cell_type 
( [C]( I-cell_type 
DN [C]D [C]N I-cell_type 
) [C]) I-cell_type 
( [C]( I-cell_type 
CD4 [C]C [C]D [C]4 I-cell_type 
( [C]( I-cell_type 
- [C]- I-cell_type 
) [C]) I-cell_type 
/CD8 [C]/ [C]C [C]D [C]8 I-cell_type 
( [C]( I-cell_type 
- [C]- I-cell_type 
) [C]) I-cell_type 
) [C]) I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
thymus [C]t [C]h [C]y [C]m [C]u [C]s O 
coexpressed [C]c [C]o [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
BMI-1 [C]B [C]M [C]I [C]- [C]1 S-protein 
and [C]a [C]n [C]d O 
EZH2 [C]E [C]Z [C]H [C]2 S-protein 
or [C]o [C]r O 
were [C]w [C]e [C]r [C]e O 
BMI-1 [C]B [C]M [C]I [C]- [C]1 O 
single [C]s [C]i [C]n [C]g [C]l [C]e O 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
. [C]. O 

Their [C]T [C]h [C]e [C]i [C]r O 
descendants [C]d [C]e [C]s [C]c [C]e [C]n [C]d [C]a [C]n [C]t [C]s O 
, [C], O 
double-positive [C]d [C]o [C]u [C]b [C]l [C]e [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e B-cell_type 
( [C]( I-cell_type 
DP [C]D [C]P I-cell_type 
; [C]; I-cell_type 
CD4 [C]C [C]D [C]4 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
/CD8 [C]/ [C]C [C]D [C]8 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
) [C]) I-cell_type 
cortical [C]c [C]o [C]r [C]t [C]i [C]c [C]a [C]l I-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
, [C], O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
EZH2 [C]E [C]Z [C]H [C]2 S-protein 
without [C]w [C]i [C]t [C]h [C]o [C]u [C]t O 
BMI-1 [C]B [C]M [C]I [C]- [C]1 S-protein 
. [C]. O 

Most [C]M [C]o [C]s [C]t O 
EZH2 [C]E [C]Z [C]H [C]2 B-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
DN [C]D [C]N I-cell_type 
and [C]a [C]n [C]d I-cell_type 
DP [C]D [C]P I-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
dividing [C]d [C]i [C]v [C]i [C]d [C]i [C]n [C]g O 
, [C], O 
while [C]w [C]h [C]i [C]l [C]e O 
DN [C]D [C]N B-cell_type 
BMI-1 [C]B [C]M [C]I [C]- [C]1 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
/EZH2 [C]/ [C]E [C]Z [C]H [C]2 I-cell_type 
( [C]( I-cell_type 
- [C]- I-cell_type 
) [C]) I-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
resting [C]r [C]e [C]s [C]t [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
occasionally [C]o [C]c [C]c [C]a [C]s [C]i [C]o [C]n [C]a [C]l [C]l [C]y O 
noted [C]n [C]o [C]t [C]e [C]d O 
in [C]i [C]n O 
DN [C]D [C]N B-cell_type 
BMI-1 [C]B [C]M [C]I [C]- [C]1 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
/EZH2 [C]/ [C]E [C]Z [C]H [C]2 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Maturation [C]M [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
DP [C]D [C]P B-cell_type 
cortical [C]c [C]o [C]r [C]t [C]i [C]c [C]a [C]l I-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
to [C]t [C]o O 
single-positive [C]s [C]i [C]n [C]g [C]l [C]e [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e B-cell_type 
( [C]( I-cell_type 
CD4 [C]C [C]D [C]4 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
/CD8 [C]/ [C]C [C]D [C]8 I-cell_type 
( [C]( I-cell_type 
- [C]- I-cell_type 
) [C]) E-cell_type 
or [C]o [C]r O 
CD8 [C]C [C]D [C]8 B-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
/CD4 [C]/ [C]C [C]D [C]4 I-cell_type 
( [C]( I-cell_type 
- [C]- I-cell_type 
) [C]) I-cell_type 
) [C]) I-cell_type 
medullar [C]m [C]e [C]d [C]u [C]l [C]l [C]a [C]r I-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
detectability [C]d [C]e [C]t [C]e [C]c [C]t [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
EZH2 [C]E [C]Z [C]H [C]2 S-protein 
and [C]a [C]n [C]d O 
continued [C]c [C]o [C]n [C]t [C]i [C]n [C]u [C]e [C]d O 
relative [C]r [C]e [C]l [C]a [C]t [C]i [C]v [C]e O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
BMI-1 [C]B [C]M [C]I [C]- [C]1 S-protein 
. [C]. O 

Our [C]O [C]u [C]r O 
data [C]d [C]a [C]t [C]a O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
BMI-1 [C]B [C]M [C]I [C]- [C]1 S-protein 
and [C]a [C]n [C]d O 
EZH2 [C]E [C]Z [C]H [C]2 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
mature [C]m [C]a [C]t [C]u [C]r [C]e B-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
is [C]i [C]s O 
mutually [C]m [C]u [C]t [C]u [C]a [C]l [C]l [C]y O 
exclusive [C]e [C]x [C]c [C]l [C]u [C]s [C]i [C]v [C]e O 
and [C]a [C]n [C]d O 
linked [C]l [C]i [C]n [C]k [C]e [C]d O 
to [C]t [C]o O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
status [C]s [C]t [C]a [C]t [C]u [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
this [C]t [C]h [C]i [C]s O 
pattern [C]p [C]a [C]t [C]t [C]e [C]r [C]n O 
is [C]i [C]s O 
not [C]n [C]o [C]t O 
yet [C]y [C]e [C]t O 
established [C]e [C]s [C]t [C]a [C]b [C]l [C]i [C]s [C]h [C]e [C]d O 
in [C]i [C]n O 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cortex [C]c [C]o [C]r [C]t [C]e [C]x O 
and [C]a [C]n [C]d O 
medulla [C]m [C]e [C]d [C]u [C]l [C]l [C]a O 
. [C]. O 

T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
stage-specific [C]s [C]t [C]a [C]g [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
PcG [C]P [C]c [C]G O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
profiles [C]p [C]r [C]o [C]f [C]i [C]l [C]e [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
PcG [C]P [C]c [C]G B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
contribute [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e O 
to [C]t [C]o O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

They [C]T [C]h [C]e [C]y O 
probably [C]p [C]r [C]o [C]b [C]a [C]b [C]l [C]y O 
reflect [C]r [C]e [C]f [C]l [C]e [C]c [C]t O 
stabilization [C]s [C]t [C]a [C]b [C]i [C]l [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cell [C]c [C]e [C]l [C]l O 
type-specific [C]t [C]y [C]p [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
irreversibility [C]i [C]r [C]r [C]e [C]v [C]e [C]r [C]s [C]i [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e O 
choice [C]c [C]h [C]o [C]i [C]c [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
difference [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e O 
in [C]i [C]n O 
PcG [C]P [C]c [C]G O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
medullar [C]m [C]e [C]d [C]u [C]l [C]l [C]a [C]r B-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
mature [C]m [C]a [C]t [C]u [C]r [C]e B-cell_type 
interfollicular [C]i [C]n [C]t [C]e [C]r [C]f [C]o [C]l [C]l [C]i [C]c [C]u [C]l [C]a [C]r I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
indicates [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e [C]s O 
that [C]t [C]h [C]a [C]t O 
additional [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n [C]a [C]l O 
maturation [C]m [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
processes [C]p [C]r [C]o [C]c [C]e [C]s [C]s [C]e [C]s O 
occur [C]o [C]c [C]c [C]u [C]r O 
after [C]a [C]f [C]t [C]e [C]r O 
thymocyte [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e O 
transportation [C]t [C]r [C]a [C]n [C]s [C]p [C]o [C]r [C]t [C]a [C]t [C]i [C]o [C]n O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
thymus [C]t [C]h [C]y [C]m [C]u [C]s O 
. [C]. O 

Stepwise [C]S [C]t [C]e [C]p [C]w [C]i [C]s [C]e O 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e O 
restriction [C]r [C]e [C]s [C]t [C]r [C]i [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
progenitors [C]p [C]r [C]o [C]g [C]e [C]n [C]i [C]t [C]o [C]r [C]s S-cell_type 
in [C]i [C]n O 
lympho-myelopoiesis [C]l [C]y [C]m [C]p [C]h [C]o [C]- [C]m [C]y [C]e [C]l [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
. [C]. O 

It [C]I [C]t O 
has [C]h [C]a [C]s O 
long [C]l [C]o [C]n [C]g O 
been [C]b [C]e [C]e [C]n O 
controversial [C]c [C]o [C]n [C]t [C]r [C]o [C]v [C]e [C]r [C]s [C]i [C]a [C]l O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
hematopoiesis [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
progresses [C]p [C]r [C]o [C]g [C]r [C]e [C]s [C]s [C]e [C]s O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
ordered [C]o [C]r [C]d [C]e [C]r [C]e [C]d O 
stages [C]s [C]t [C]a [C]g [C]e [C]s O 
of [C]o [C]f O 
determination [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
as [C]a [C]s O 
in [C]i [C]n O 
embryonic [C]e [C]m [C]b [C]r [C]y [C]o [C]n [C]i [C]c O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
is [C]i [C]s O 
due [C]d [C]u [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
a [C]a O 
methodology [C]m [C]e [C]t [C]h [C]o [C]d [C]o [C]l [C]o [C]g [C]y O 
capable [C]c [C]a [C]p [C]a [C]b [C]l [C]e O 
of [C]o [C]f O 
exactly [C]e [C]x [C]a [C]c [C]t [C]l [C]y O 
determining [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
developmental [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t [C]a [C]l O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
of [C]o [C]f O 
hematopoietic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c B-cell_type 
stem/progenitor [C]s [C]t [C]e [C]m [C]/ [C]p [C]r [C]o [C]g [C]e [C]n [C]i [C]t [C]o [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
multilineage [C]m [C]u [C]l [C]t [C]i [C]l [C]i [C]n [C]e [C]a [C]g [C]e O 
progenitor [C]p [C]r [C]o [C]g [C]e [C]n [C]i [C]t [C]o [C]r O 
( [C]( O 
MLP [C]M [C]L [C]P O 
) [C]) O 
assay [C]a [C]s [C]s [C]a [C]y O 
enabled [C]e [C]n [C]a [C]b [C]l [C]e [C]d O 
us [C]u [C]s O 
to [C]t [C]o O 
discriminate [C]d [C]i [C]s [C]c [C]r [C]i [C]m [C]i [C]n [C]a [C]t [C]e O 
among [C]a [C]m [C]o [C]n [C]g O 
seven [C]s [C]e [C]v [C]e [C]n O 
types [C]t [C]y [C]p [C]e [C]s O 
of [C]o [C]f O 
hematopoietic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c O 
progenitors [C]p [C]r [C]o [C]g [C]e [C]n [C]i [C]t [C]o [C]r [C]s O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
are [C]a [C]r [C]e O 
multipotent [C]m [C]u [C]l [C]t [C]i [C]p [C]o [C]t [C]e [C]n [C]t O 
progenitor [C]p [C]r [C]o [C]g [C]e [C]n [C]i [C]t [C]o [C]r O 
p-MTB [C]p [C]- [C]M [C]T [C]B O 
( [C]( O 
capable [C]c [C]a [C]p [C]a [C]b [C]l [C]e O 
of [C]o [C]f O 
generating [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]i [C]n [C]g O 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d B-cell_type 
, [C], I-cell_type 
T [C]T I-cell_type 
and [C]a [C]n [C]d I-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
) [C]) O 
, [C], O 
bipotent [C]b [C]i [C]p [C]o [C]t [C]e [C]n [C]t O 
progenitors [C]p [C]r [C]o [C]g [C]e [C]n [C]i [C]t [C]o [C]r [C]s O 
p-MT [C]p [C]- [C]M [C]T O 
, [C], O 
p-MB [C]p [C]- [C]M [C]B O 
and [C]a [C]n [C]d O 
p-TB [C]p [C]- [C]T [C]B O 
, [C], O 
and [C]a [C]n [C]d O 
unipotent [C]u [C]n [C]i [C]p [C]o [C]t [C]e [C]n [C]t O 
progenitors [C]p [C]r [C]o [C]g [C]e [C]n [C]i [C]t [C]o [C]r [C]s O 
p-M [C]p [C]- [C]M O 
, [C], O 
p-T [C]p [C]- [C]T O 
and [C]a [C]n [C]d O 
p-B [C]p [C]- [C]B O 
. [C]. O 

Among [C]A [C]m [C]o [C]n [C]g O 
these [C]t [C]h [C]e [C]s [C]e O 
seven [C]s [C]e [C]v [C]e [C]n O 
types [C]t [C]y [C]p [C]e [C]s O 
, [C], O 
the [C]t [C]h [C]e O 
p-TB [C]p [C]- [C]T [C]B O 
type [C]t [C]y [C]p [C]e O 
progenitor [C]p [C]r [C]o [C]g [C]e [C]n [C]i [C]t [C]o [C]r O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
absent [C]a [C]b [C]s [C]e [C]n [C]t O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
of [C]o [C]f O 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e O 
commitment [C]c [C]o [C]m [C]m [C]i [C]t [C]m [C]e [C]n [C]t O 
proceeds [C]p [C]r [C]o [C]c [C]e [C]e [C]d [C]s O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
an [C]a [C]n O 
ordered [C]o [C]r [C]d [C]e [C]r [C]e [C]d O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
random [C]r [C]a [C]n [C]d [C]o [C]m O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
. [C]. O 

By [C]B [C]y O 
extending [C]e [C]x [C]t [C]e [C]n [C]d [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
area [C]a [C]r [C]e [C]a O 
of [C]o [C]f O 
investigation [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]i [C]o [C]n O 
to [C]t [C]o O 
include [C]i [C]n [C]c [C]l [C]u [C]d [C]e O 
the [C]t [C]h [C]e O 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d B-cell_type 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e E-cell_type 
, [C], O 
more [C]m [C]o [C]r [C]e O 
convincing [C]c [C]o [C]n [C]v [C]i [C]n [C]c [C]i [C]n [C]g O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
ordered [C]o [C]r [C]d [C]e [C]r [C]e [C]d O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
was [C]w [C]a [C]s O 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
. [C]. O 

Detailed [C]D [C]e [C]t [C]a [C]i [C]l [C]e [C]d O 
and [C]a [C]n [C]d O 
exact [C]e [C]x [C]a [C]c [C]t O 
illustration [C]i [C]l [C]l [C]u [C]s [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
of [C]o [C]f O 
hematopoiesis [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
will [C]w [C]i [C]l [C]l O 
provide [C]p [C]r [C]o [C]v [C]i [C]d [C]e O 
an [C]a [C]n O 
opportunity [C]o [C]p [C]p [C]o [C]r [C]t [C]u [C]n [C]i [C]t [C]y O 
to [C]t [C]o O 
revive [C]r [C]e [C]v [C]i [C]v [C]e O 
hematopoiesis [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
as [C]a [C]s O 
one [C]o [C]n [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
most [C]m [C]o [C]s [C]t O 
fascinating [C]f [C]a [C]s [C]c [C]i [C]n [C]a [C]t [C]i [C]n [C]g O 
targets [C]t [C]a [C]r [C]g [C]e [C]t [C]s O 
of [C]o [C]f O 
research [C]r [C]e [C]s [C]e [C]a [C]r [C]c [C]h O 
in [C]i [C]n O 
developmental [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t [C]a [C]l O 
biology [C]b [C]i [C]o [C]l [C]o [C]g [C]y O 

Epstein-Barr [C]E [C]p [C]s [C]t [C]e [C]i [C]n [C]- [C]B [C]a [C]r [C]r O 
Virus [C]V [C]i [C]r [C]u [C]s O 
and [C]a [C]n [C]d O 
its [C]i [C]t [C]s O 
glycoprotein-350 [C]g [C]l [C]y [C]c [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]3 [C]5 [C]0 S-protein 
upregulate [C]u [C]p [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
IL-6 [C]I [C]L [C]- [C]6 S-protein 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
B-lymphocytes [C]B [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
via [C]v [C]i [C]a O 
CD21 [C]C [C]D [C]2 [C]1 S-protein 
, [C], O 
involving [C]i [C]n [C]v [C]o [C]l [C]v [C]i [C]n [C]g O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
and [C]a [C]n [C]d O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
. [C]. O 

Epstein-Barr [C]E [C]p [C]s [C]t [C]e [C]i [C]n [C]- [C]B [C]a [C]r [C]r O 
virus [C]v [C]i [C]r [C]u [C]s O 
( [C]( O 
EBV [C]E [C]B [C]V O 
) [C]) O 
is [C]i [C]s O 
a [C]a O 
ubiquitous [C]u [C]b [C]i [C]q [C]u [C]i [C]t [C]o [C]u [C]s O 
and [C]a [C]n [C]d O 
highly [C]h [C]i [C]g [C]h [C]l [C]y O 
immunotropic [C]i [C]m [C]m [C]u [C]n [C]o [C]t [C]r [C]o [C]p [C]i [C]c O 
gamma [C]g [C]a [C]m [C]m [C]a O 
herpesvirus [C]h [C]e [C]r [C]p [C]e [C]s [C]v [C]i [C]r [C]u [C]s O 
that [C]t [C]h [C]a [C]t O 
infects [C]i [C]n [C]f [C]e [C]c [C]t [C]s O 
more [C]m [C]o [C]r [C]e O 
than [C]t [C]h [C]a [C]n O 
90 [C]9 [C]0 O 
% [C]% O 
of [C]o [C]f O 
humans [C]h [C]u [C]m [C]a [C]n [C]s O 
worldwide [C]w [C]o [C]r [C]l [C]d [C]w [C]i [C]d [C]e O 
. [C]. O 

Its [C]I [C]t [C]s O 
pathogenicity [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]i [C]c [C]i [C]t [C]y O 
leads [C]l [C]e [C]a [C]d [C]s O 
to [C]t [C]o O 
a [C]a O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
diseases [C]d [C]i [C]s [C]e [C]a [C]s [C]e [C]s O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
tumors [C]t [C]u [C]m [C]o [C]r [C]s O 
that [C]t [C]h [C]a [C]t O 
result [C]r [C]e [C]s [C]u [C]l [C]t O 
from [C]f [C]r [C]o [C]m O 
EBV [C]E [C]B [C]V O 
's [C]' [C]s O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
to [C]t [C]o O 
readily [C]r [C]e [C]a [C]d [C]i [C]l [C]y O 
transform [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m O 
B-lymphocytes [C]B [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
and [C]a [C]n [C]d O 
, [C], O 
to [C]t [C]o O 
a [C]a O 
lesser [C]l [C]e [C]s [C]s [C]e [C]r O 
extent [C]e [C]x [C]t [C]e [C]n [C]t O 
, [C], O 
epithelial [C]e [C]p [C]i [C]t [C]h [C]e [C]l [C]i [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

EBV [C]E [C]B [C]V O 
utilizes [C]u [C]t [C]i [C]l [C]i [C]z [C]e [C]s O 
CD21/CR2 [C]C [C]D [C]2 [C]1 [C]/ [C]C [C]R [C]2 S-protein 
as [C]a [C]s O 
its [C]i [C]t [C]s O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
on [C]o [C]n O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
to [C]t [C]o O 
initiate [C]i [C]n [C]i [C]t [C]i [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
. [C]. O 

EBV [C]E [C]B [C]V O 
binds [C]b [C]i [C]n [C]d [C]s O 
to [C]t [C]o O 
CR2 [C]C [C]R [C]2 S-protein 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
its [C]i [C]t [C]s O 
major [C]m [C]a [C]j [C]o [C]r B-protein 
envelope [C]e [C]n [C]v [C]e [C]l [C]o [C]p [C]e I-protein 
glycoprotein-350 [C]g [C]l [C]y [C]c [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]3 [C]5 [C]0 E-protein 
( [C]( O 
gp350 [C]g [C]p [C]3 [C]5 [C]0 S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
also [C]a [C]l [C]s [C]o O 
a [C]a O 
remarkable [C]r [C]e [C]m [C]a [C]r [C]k [C]a [C]b [C]l [C]e O 
immunomodulating [C]i [C]m [C]m [C]u [C]n [C]o [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
agent [C]a [C]g [C]e [C]n [C]t O 
. [C]. O 

We [C]W [C]e O 
had [C]h [C]a [C]d O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
shown [C]s [C]h [C]o [C]w [C]n O 
that [C]t [C]h [C]a [C]t O 
EBV [C]E [C]B [C]V O 
is [C]i [C]s O 
capable [C]c [C]a [C]p [C]a [C]b [C]l [C]e O 
of [C]o [C]f O 
modulating [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
a [C]a O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
. [C]. O 

We [C]W [C]e O 
now [C]n [C]o [C]w O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
while [C]w [C]h [C]i [C]l [C]e O 
both [C]b [C]o [C]t [C]h O 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d O 
recombinant [C]r [C]e [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]n [C]t B-protein 
gp350 [C]g [C]p [C]3 [C]5 [C]0 E-protein 
( [C]( O 
rgp350 [C]r [C]g [C]p [C]3 [C]5 [C]0 S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
EBV [C]E [C]B [C]V O 
upregulate [C]u [C]p [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
IL-6 [C]I [C]L [C]- [C]6 B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
in [C]i [C]n O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
EBV-induced [C]E [C]B [C]V [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
IL-6 [C]I [C]L [C]- [C]6 O 
gene [C]g [C]e [C]n [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
occurs [C]o [C]c [C]c [C]u [C]r [C]s O 
for [C]f [C]o [C]r O 
a [C]a O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
longer [C]l [C]o [C]n [C]g [C]e [C]r O 
period [C]p [C]e [C]r [C]i [C]o [C]d O 
of [C]o [C]f O 
time [C]t [C]i [C]m [C]e O 
( [C]( O 
i.e. [C]i [C]. [C]e [C]. O 
12 [C]1 [C]2 O 
hours [C]h [C]o [C]u [C]r [C]s O 
for [C]f [C]o [C]r O 
EBV [C]E [C]B [C]V O 
as [C]a [C]s O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
6 [C]6 O 
hours [C]h [C]o [C]u [C]r [C]s O 
for [C]f [C]o [C]r O 
rgp350 [C]r [C]g [C]p [C]3 [C]5 [C]0 S-protein 
) [C]) O 
. [C]. O 

Moreover [C]M [C]o [C]r [C]e [C]o [C]v [C]e [C]r O 
, [C], O 
the [C]t [C]h [C]e O 
half-life [C]h [C]a [C]l [C]f [C]- [C]l [C]i [C]f [C]e O 
of [C]o [C]f O 
EBV-induced [C]E [C]B [C]V [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
IL-6 [C]I [C]L [C]- [C]6 B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
longer [C]l [C]o [C]n [C]g [C]e [C]r O 
( [C]( O 
10 [C]1 [C]0 O 
hours [C]h [C]o [C]u [C]r [C]s O 
) [C]) O 
than [C]t [C]h [C]a [C]n O 
that [C]t [C]h [C]a [C]t O 
of [C]o [C]f O 
mRNA [C]m [C]R [C]N [C]A O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
rgp350 [C]r [C]g [C]p [C]3 [C]5 [C]0 S-protein 
( [C]( O 
about [C]a [C]b [C]o [C]u [C]t O 
6 [C]6 O 
hours [C]h [C]o [C]u [C]r [C]s O 
) [C]) O 
. [C]. O 

Both [C]B [C]o [C]t [C]h O 
EBV [C]E [C]B [C]V O 
and [C]a [C]n [C]d O 
gp350 [C]g [C]p [C]3 [C]5 [C]0 S-protein 
enhance [C]e [C]n [C]h [C]a [C]n [C]c [C]e O 
the [C]t [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
, [C], O 
as [C]a [C]s O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
band-shift [C]b [C]a [C]n [C]d [C]- [C]s [C]h [C]i [C]f [C]t O 
and [C]a [C]n [C]d O 
augment [C]a [C]u [C]g [C]m [C]e [C]n [C]t O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
CAT [C]C [C]A [C]T B-DNA 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r I-DNA 
plasmid [C]p [C]l [C]a [C]s [C]m [C]i [C]d E-DNA 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
we [C]w [C]e O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
while [C]w [C]h [C]i [C]l [C]e O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-6 [C]I [C]L [C]- [C]6 O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
by [C]b [C]y O 
gp350 [C]g [C]p [C]3 [C]5 [C]0 S-protein 
is [C]i [C]s O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
primarily [C]p [C]r [C]i [C]m [C]a [C]r [C]i [C]l [C]y O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
C [C]C O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
, [C], O 
EBV [C]E [C]B [C]V O 
can [C]c [C]a [C]n O 
mediate [C]m [C]e [C]d [C]i [C]a [C]t [C]e O 
its [C]i [C]t [C]s O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
multiple [C]m [C]u [C]l [C]t [C]i [C]p [C]l [C]e O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
. [C]. O 

To [C]T [C]o O 
our [C]o [C]u [C]r O 
knowledge [C]k [C]n [C]o [C]w [C]l [C]e [C]d [C]g [C]e O 
this [C]t [C]h [C]i [C]s O 
is [C]i [C]s O 
the [C]t [C]h [C]e O 
first [C]f [C]i [C]r [C]s [C]t O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
showing [C]s [C]h [C]o [C]w [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
a [C]a O 
herpesvirus [C]h [C]e [C]r [C]p [C]e [C]s [C]v [C]i [C]r [C]u [C]s B-protein 
envelope [C]e [C]n [C]v [C]e [C]l [C]o [C]p [C]e I-protein 
glycoprotein [C]g [C]l [C]y [C]c [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
to [C]t [C]o O 
CR2 [C]C [C]R [C]2 S-protein 
on [C]o [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
leading [C]l [C]e [C]a [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
upregulation [C]u [C]p [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-6 [C]I [C]L [C]- [C]6 O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
. [C]. O 

Copyright [C]C [C]o [C]p [C]y [C]r [C]i [C]g [C]h [C]t O 
2001 [C]2 [C]0 [C]0 [C]1 O 
Academic [C]A [C]c [C]a [C]d [C]e [C]m [C]i [C]c O 
Press [C]P [C]r [C]e [C]s [C]s O 
. [C]. O 

Gene- [C]G [C]e [C]n [C]e [C]- O 
and [C]a [C]n [C]d O 
tissue-specificity [C]t [C]i [C]s [C]s [C]u [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]i [C]t [C]y O 
of [C]o [C]f O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
Big [C]B [C]i [C]g O 
Blue [C]B [C]l [C]u [C]e O 
rats [C]r [C]a [C]t [C]s O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
hepatocarcinogen [C]h [C]e [C]p [C]a [C]t [C]o [C]c [C]a [C]r [C]c [C]i [C]n [C]o [C]g [C]e [C]n O 
N-hydroxy-2-acetylaminofluorene [C]N [C]- [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]- [C]2 [C]- [C]a [C]c [C]e [C]t [C]y [C]l [C]a [C]m [C]i [C]n [C]o [C]f [C]l [C]u [C]o [C]r [C]e [C]n [C]e O 
. [C]. O 

In [C]I [C]n O 
a [C]a O 
previous [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
, [C], O 
we [C]w [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
treating [C]t [C]r [C]e [C]a [C]t [C]i [C]n [C]g O 
transgenic [C]t [C]r [C]a [C]n [C]s [C]g [C]e [C]n [C]i [C]c O 
Big [C]B [C]i [C]g O 
Blue [C]B [C]l [C]u [C]e O 
rats [C]r [C]a [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
hepatocarcinogen [C]h [C]e [C]p [C]a [C]t [C]o [C]c [C]a [C]r [C]c [C]i [C]n [C]o [C]g [C]e [C]n O 
N-hydroxy-2-acetylaminofluorene [C]N [C]- [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]- [C]2 [C]- [C]a [C]c [C]e [C]t [C]y [C]l [C]a [C]m [C]i [C]n [C]o [C]f [C]l [C]u [C]o [C]r [C]e [C]n [C]e O 
( [C]( O 
N-OH-AAF [C]N [C]- [C]O [C]H [C]- [C]A [C]A [C]F O 
) [C]) O 
produced [C]p [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
the [C]t [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
major [C]m [C]a [C]j [C]o [C]r O 
DNA [C]D [C]N [C]A O 
adduct [C]a [C]d [C]d [C]u [C]c [C]t O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
liver [C]l [C]i [C]v [C]e [C]r O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
nontarget [C]n [C]o [C]n [C]t [C]a [C]r [C]g [C]e [C]t B-cell_type 
spleen [C]s [C]p [C]l [C]e [C]e [C]n I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
bone [C]b [C]o [C]n [C]e B-cell_type 
marrow [C]m [C]a [C]r [C]r [C]o [C]w I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
lacI [C]l [C]a [C]c [C]I B-cell_type 
mutants [C]m [C]u [C]t [C]a [C]n [C]t [C]s E-cell_type 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
liver [C]l [C]i [C]v [C]e [C]r O 
, [C], O 
and [C]a [C]n [C]d O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
much [C]m [C]u [C]c [C]h O 
lower [C]l [C]o [C]w [C]e [C]r O 
frequencies [C]f [C]r [C]e [C]q [C]u [C]e [C]n [C]c [C]i [C]e [C]s O 
of [C]o [C]f O 
l [C]l O 
acI [C]a [C]c [C]I B-cell_type 
and [C]a [C]n [C]d I-cell_type 
hprt [C]h [C]p [C]r [C]t I-cell_type 
mutants [C]m [C]u [C]t [C]a [C]n [C]t [C]s E-cell_type 
in [C]i [C]n O 
spleen [C]s [C]p [C]l [C]e [C]e [C]n B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

In [C]I [C]n O 
the [C]t [C]h [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
study [C]s [C]t [C]u [C]d [C]y O 
, [C], O 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
was [C]w [C]a [C]s O 
conducted [C]c [C]o [C]n [C]d [C]u [C]c [C]t [C]e [C]d O 
on [C]o [C]n O 
lacI [C]l [C]a [C]c [C]I B-DNA 
DNA [C]D [C]N [C]A E-DNA 
and [C]a [C]n [C]d O 
hprt [C]h [C]p [C]r [C]t B-DNA 
cDNA [C]c [C]D [C]N [C]A E-DNA 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
mutants [C]m [C]u [C]t [C]a [C]n [C]t [C]s O 
, [C], O 
to [C]t [C]o O 
determine [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e O 
the [C]t [C]h [C]e O 
mutational [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]a [C]l O 
specificity [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]i [C]t [C]y O 
of [C]o [C]f O 
N-OH-AAF [C]N [C]- [C]O [C]H [C]- [C]A [C]A [C]F O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
rat [C]r [C]a [C]t O 
. [C]. O 

All [C]A [C]l [C]l O 
the [C]t [C]h [C]e O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
spectra [C]s [C]p [C]e [C]c [C]t [C]r [C]a O 
from [C]f [C]r [C]o [C]m O 
N-OH-AAF-treated [C]N [C]- [C]O [C]H [C]- [C]A [C]A [C]F [C]- [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
rats [C]r [C]a [C]t [C]s O 
differed [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]d O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
from [C]f [C]r [C]o [C]m O 
corresponding [C]c [C]o [C]r [C]r [C]e [C]s [C]p [C]o [C]n [C]d [C]i [C]n [C]g O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
profiles [C]p [C]r [C]o [C]f [C]i [C]l [C]e [C]s O 
from [C]f [C]r [C]o [C]m O 
untreated [C]u [C]n [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
animals [C]a [C]n [C]i [C]m [C]a [C]l [C]s O 
( [C]( O 
P [C]P O 
= [C]= O 
0.02 [C]0 [C]. [C]0 [C]2 O 
to [C]t [C]o O 
P [C]P O 
< [C]< O 
0.0001 [C]0 [C]. [C]0 [C]0 [C]0 [C]1 O 
) [C]) O 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
there [C]t [C]h [C]e [C]r [C]e O 
were [C]w [C]e [C]r [C]e O 
similarities [C]s [C]i [C]m [C]i [C]l [C]a [C]r [C]i [C]t [C]i [C]e [C]s O 
among [C]a [C]m [C]o [C]n [C]g O 
the [C]t [C]h [C]e O 
mutational [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]a [C]l O 
patterns [C]p [C]a [C]t [C]t [C]e [C]r [C]n [C]s O 
derived [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
N-OH-AAF-treated [C]N [C]- [C]O [C]H [C]- [C]A [C]A [C]F [C]- [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
rats [C]r [C]a [C]t [C]s O 
( [C]( O 
e.g. [C]e [C]. [C]g [C]. O 
, [C], O 
G [C]G O 
: [C]: O 
C [C]C O 
-- [C]- [C]- O 
> [C]> O 
T [C]T O 
: [C]: O 
A [C]A O 
transversion [C]t [C]r [C]a [C]n [C]s [C]v [C]e [C]r [C]s [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
the [C]t [C]h [C]e O 
most [C]m [C]o [C]s [C]t O 
common [C]c [C]o [C]m [C]m [C]o [C]n O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
all [C]a [C]l [C]l O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
sets [C]s [C]e [C]t [C]s O 
) [C]) O 
, [C], O 
there [C]t [C]h [C]e [C]r [C]e O 
were [C]w [C]e [C]r [C]e O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
differences [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
patterns [C]p [C]a [C]t [C]t [C]e [C]r [C]n [C]s O 
of [C]o [C]f O 
basepair [C]b [C]a [C]s [C]e [C]p [C]a [C]i [C]r O 
substitution [C]s [C]u [C]b [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
frameshift [C]f [C]r [C]a [C]m [C]e [C]s [C]h [C]i [C]f [C]t O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
liver [C]l [C]i [C]v [C]e [C]r O 
and [C]a [C]n [C]d O 
spleen [C]s [C]p [C]l [C]e [C]e [C]n B-cell_type 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e I-cell_type 
lacI [C]l [C]a [C]c [C]I I-cell_type 
mutants [C]m [C]u [C]t [C]a [C]n [C]t [C]s E-cell_type 
( [C]( O 
P [C]P O 
= [C]= O 
0.02 [C]0 [C]. [C]0 [C]2 O 
) [C]) O 
and [C]a [C]n [C]d O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
spleen [C]s [C]p [C]l [C]e [C]e [C]n B-cell_type 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e E-cell_type 
lacI [C]l [C]a [C]c [C]I B-cell_type 
and [C]a [C]n [C]d I-cell_type 
hprt [C]h [C]p [C]r [C]t I-cell_type 
mutants [C]m [C]u [C]t [C]a [C]n [C]t [C]s E-cell_type 
( [C]( O 
P [C]P O 
= [C]= O 
0.04 [C]0 [C]. [C]0 [C]4 O 
) [C]) O 
. [C]. O 

Also [C]A [C]l [C]s [C]o O 
, [C], O 
multiplex [C]m [C]u [C]l [C]t [C]i [C]p [C]l [C]e [C]x O 
PCR [C]P [C]C [C]R O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
genomic [C]g [C]e [C]n [C]o [C]m [C]i [C]c B-DNA 
DNA [C]D [C]N [C]A E-DNA 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
hprt [C]h [C]p [C]r [C]t B-cell_type 
mutants [C]m [C]u [C]t [C]a [C]n [C]t [C]s E-cell_type 
indicated [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
12 [C]1 [C]2 O 
% [C]% O 
of [C]o [C]f O 
mutants [C]m [C]u [C]t [C]a [C]n [C]t [C]s O 
from [C]f [C]r [C]o [C]m O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
rats [C]r [C]a [C]t [C]s O 
had [C]h [C]a [C]d O 
major [C]m [C]a [C]j [C]o [C]r O 
deletions [C]d [C]e [C]l [C]e [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
hprt [C]h [C]p [C]r [C]t B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
; [C]; O 
no [C]n [C]o O 
corresponding [C]c [C]o [C]r [C]r [C]e [C]s [C]p [C]o [C]n [C]d [C]i [C]n [C]g O 
incidence [C]i [C]n [C]c [C]i [C]d [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
large [C]l [C]a [C]r [C]g [C]e O 
deletions [C]d [C]e [C]l [C]e [C]t [C]i [C]o [C]n [C]s O 
was [C]w [C]a [C]s O 
evident [C]e [C]v [C]i [C]d [C]e [C]n [C]t O 
among [C]a [C]m [C]o [C]n [C]g O 
lacI [C]l [C]a [C]c [C]I O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

All [C]A [C]l [C]l O 
the [C]t [C]h [C]e O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
profiles [C]p [C]r [C]o [C]f [C]i [C]l [C]e [C]s O 
reflect [C]r [C]e [C]f [C]l [C]e [C]c [C]t O 
the [C]t [C]h [C]e O 
general [C]g [C]e [C]n [C]e [C]r [C]a [C]l O 
mutational [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]a [C]l O 
specificity [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
major [C]m [C]a [C]j [C]o [C]r O 
DNA [C]D [C]N [C]A O 
adduct [C]a [C]d [C]d [C]u [C]c [C]t O 
formed [C]f [C]o [C]r [C]m [C]e [C]d O 
by [C]b [C]y O 
N-OH-AAF [C]N [C]- [C]O [C]H [C]- [C]A [C]A [C]F O 
. [C]. O 

The [C]T [C]h [C]e O 
differences [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e [C]s O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
N-OH-AAF [C]N [C]- [C]O [C]H [C]- [C]A [C]A [C]F O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
endogenous [C]e [C]n [C]d [C]o [C]g [C]e [C]n [C]o [C]u [C]s B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
and [C]a [C]n [C]d O 
transgene [C]t [C]r [C]a [C]n [C]s [C]g [C]e [C]n [C]e S-DNA 
can [C]c [C]a [C]n O 
be [C]b [C]e O 
partially [C]p [C]a [C]r [C]t [C]i [C]a [C]l [C]l [C]y O 
explained [C]e [C]x [C]p [C]l [C]a [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
structures [C]s [C]t [C]r [C]u [C]c [C]t [C]u [C]r [C]e [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
two [C]t [C]w [C]o O 
genes [C]g [C]e [C]n [C]e [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
tissue-specificity [C]t [C]i [C]s [C]s [C]u [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
spectra [C]s [C]p [C]e [C]c [C]t [C]r [C]a O 
may [C]m [C]a [C]y O 
contribute [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e O 
to [C]t [C]o O 
targeting [C]t [C]a [C]r [C]g [C]e [C]t [C]i [C]n [C]g O 
tumor [C]t [C]u [C]m [C]o [C]r O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
liver [C]l [C]i [C]v [C]e [C]r O 
. [C]. O 

Environ. [C]E [C]n [C]v [C]i [C]r [C]o [C]n [C]. O 
Mol. [C]M [C]o [C]l [C]. O 
Mutagen. [C]M [C]u [C]t [C]a [C]g [C]e [C]n [C]. O 
37 [C]3 [C]7 O 
: [C]: O 
203-214 [C]2 [C]0 [C]3 [C]- [C]2 [C]1 [C]4 O 
, [C], O 
2001 [C]2 [C]0 [C]0 [C]1 O 
. [C]. O 

Published [C]P [C]u [C]b [C]l [C]i [C]s [C]h [C]e [C]d O 
2001 [C]2 [C]0 [C]0 [C]1 O 
Wiley-Liss [C]W [C]i [C]l [C]e [C]y [C]- [C]L [C]i [C]s [C]s O 
, [C], O 
Inc [C]I [C]n [C]c O 
. [C]. O 

Caspase [C]C [C]a [C]s [C]p [C]a [C]s [C]e S-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
cleavage [C]c [C]l [C]e [C]a [C]v [C]a [C]g [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
hematopoietic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c B-protein 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-protein 
adaptor [C]a [C]d [C]a [C]p [C]t [C]o [C]r I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
Gads [C]G [C]a [C]d [C]s E-protein 
alters [C]a [C]l [C]t [C]e [C]r [C]s O 
signalling [C]s [C]i [C]g [C]n [C]a [C]l [C]l [C]i [C]n [C]g O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
T [C]T B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
. [C]. O 

Gads [C]G [C]a [C]d [C]s S-protein 
is [C]i [C]s O 
a [C]a O 
SH2 [C]S [C]H [C]2 B-protein 
and [C]a [C]n [C]d I-protein 
SH3 [C]S [C]H [C]3 I-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
-containing [C]- [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
, [C], O 
hematopoietic-specific [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-protein 
adaptor [C]a [C]d [C]a [C]p [C]t [C]o [C]r I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
that [C]t [C]h [C]a [C]t O 
functions [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
signalling [C]s [C]i [C]g [C]n [C]a [C]l [C]l [C]i [C]n [C]g O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
T [C]T B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
. [C]. O 

Gads [C]G [C]a [C]d [C]s S-protein 
acts [C]a [C]c [C]t [C]s O 
by [C]b [C]y O 
linking [C]l [C]i [C]n [C]k [C]i [C]n [C]g O 
SLP-76 [C]S [C]L [C]P [C]- [C]7 [C]6 S-protein 
, [C], O 
bound [C]b [C]o [C]u [C]n [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
carboxy-terminal [C]c [C]a [C]r [C]b [C]o [C]x [C]y [C]- [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l B-protein 
Gads [C]G [C]a [C]d [C]s I-protein 
SH3 [C]S [C]H [C]3 I-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
, [C], O 
to [C]t [C]o O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e B-protein 
phosphorylated [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]e [C]d I-protein 
LAT [C]L [C]A [C]T E-protein 
which [C]w [C]h [C]i [C]c [C]h O 
contains [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]s O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
sites [C]s [C]i [C]t [C]e [C]s O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
Gads [C]G [C]a [C]d [C]s B-protein 
SH2 [C]S [C]H [C]2 I-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
. [C]. O 

Gads [C]G [C]a [C]d [C]s S-protein 
is [C]i [C]s O 
distinguished [C]d [C]i [C]s [C]t [C]i [C]n [C]g [C]u [C]i [C]s [C]h [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
Grb2 [C]G [C]r [C]b [C]2 S-protein 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
closely [C]c [C]l [C]o [C]s [C]e [C]l [C]y O 
related [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
Grap [C]G [C]r [C]a [C]p B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
a [C]a O 
120 [C]1 [C]2 [C]0 B-protein 
amino [C]a [C]m [C]i [C]n [C]o I-protein 
acid [C]a [C]c [C]i [C]d I-protein 
unique [C]u [C]n [C]i [C]q [C]u [C]e I-protein 
region [C]r [C]e [C]g [C]i [C]o [C]n E-protein 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
SH2 [C]S [C]H [C]2 B-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
carboxy [C]c [C]a [C]r [C]b [C]o [C]x [C]y B-protein 
terminal [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l I-protein 
SH3 [C]S [C]H [C]3 I-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
we [C]w [C]e O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
unique [C]u [C]n [C]i [C]q [C]u [C]e O 
region [C]r [C]e [C]g [C]i [C]o [C]n O 
of [C]o [C]f O 
Gads [C]G [C]a [C]d [C]s S-protein 
contains [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]s O 
a [C]a O 
capase [C]c [C]a [C]p [C]a [C]s [C]e B-protein 
cleavage [C]c [C]l [C]e [C]a [C]v [C]a [C]g [C]e I-protein 
site [C]s [C]i [C]t [C]e E-protein 
. [C]. O 

Induction [C]I [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
in [C]i [C]n O 
detectable [C]d [C]e [C]t [C]e [C]c [C]t [C]a [C]b [C]l [C]e O 
Gads [C]G [C]a [C]d [C]s S-protein 
cleavage [C]c [C]l [C]e [C]a [C]v [C]a [C]g [C]e O 
by [C]b [C]y O 
60 [C]6 [C]0 O 
min [C]m [C]i [C]n O 
. [C]. O 

Gads [C]G [C]a [C]d [C]s S-protein 
cleavage [C]c [C]l [C]e [C]a [C]v [C]a [C]g [C]e O 
is [C]i [C]s O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
by [C]b [C]y O 
treating [C]t [C]r [C]e [C]a [C]t [C]i [C]n [C]g O 
cells [C]c [C]e [C]l [C]l [C]s O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
caspase [C]c [C]a [C]s [C]p [C]a [C]s [C]e O 
3 [C]3 O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
. [C]. O 

A [C]A O 
putative [C]p [C]u [C]t [C]a [C]t [C]i [C]v [C]e B-protein 
caspase [C]c [C]a [C]s [C]p [C]a [C]s [C]e I-protein 
3 [C]3 I-protein 
cleavage [C]c [C]l [C]e [C]a [C]v [C]a [C]g [C]e I-protein 
site [C]s [C]i [C]t [C]e E-protein 
was [C]w [C]a [C]s O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
the [C]t [C]h [C]e O 
unique [C]u [C]n [C]i [C]q [C]u [C]e O 
region [C]r [C]e [C]g [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
site [C]s [C]i [C]t [C]e O 
prevented [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]e [C]d O 
Gads [C]G [C]a [C]d [C]s S-protein 
cleavage [C]c [C]l [C]e [C]a [C]v [C]a [C]g [C]e O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
, [C], O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
. [C]. O 

The [C]T [C]h [C]e O 
Gads [C]G [C]a [C]d [C]s S-protein 
cleavage [C]c [C]l [C]e [C]a [C]v [C]a [C]g [C]e O 
products [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]s O 
retained [C]r [C]e [C]t [C]a [C]i [C]n [C]e [C]d O 
the [C]t [C]h [C]e O 
predicted [C]p [C]r [C]e [C]d [C]i [C]c [C]t [C]e [C]d O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
specificity [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]i [C]t [C]y O 
for [C]f [C]o [C]r O 
SLP-76 [C]S [C]L [C]P [C]- [C]7 [C]6 S-protein 
and [C]a [C]n [C]d O 
LAT [C]L [C]A [C]T S-protein 
. [C]. O 

Expression [C]E [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Gads [C]G [C]a [C]d [C]s S-protein 
cleavage [C]c [C]l [C]e [C]a [C]v [C]a [C]g [C]e O 
products [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]s O 
in [C]i [C]n O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_line 
T [C]T I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
NFAT [C]N [C]F [C]A [C]T O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
TCR [C]T [C]C [C]R O 
cross [C]c [C]r [C]o [C]s [C]s O 
linking [C]l [C]i [C]n [C]k [C]i [C]n [C]g O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
cleavage [C]c [C]l [C]e [C]a [C]v [C]a [C]g [C]e O 
of [C]o [C]f O 
Gads [C]G [C]a [C]d [C]s S-protein 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
could [C]c [C]o [C]u [C]l [C]d O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
to [C]t [C]o O 
alter [C]a [C]l [C]t [C]e [C]r O 
signalling [C]s [C]i [C]g [C]n [C]a [C]l [C]l [C]i [C]n [C]g O 
downstream [C]d [C]o [C]w [C]n [C]s [C]t [C]r [C]e [C]a [C]m O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
T [C]T B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
by [C]b [C]y O 
disrupting [C]d [C]i [C]s [C]r [C]u [C]p [C]t [C]i [C]n [C]g O 
cross [C]c [C]r [C]o [C]s [C]s O 
talk [C]t [C]a [C]l [C]k O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
SLP-76 [C]S [C]L [C]P [C]- [C]7 [C]6 S-protein 
and [C]a [C]n [C]d O 
LAT [C]L [C]A [C]T S-protein 
. [C]. O 

Targeting [C]T [C]a [C]r [C]g [C]e [C]t [C]i [C]n [C]g O 
of [C]o [C]f O 
p300 [C]p [C]3 [C]0 [C]0 S-protein 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
interleukin-2 [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
via [C]v [C]i [C]a O 
CREB-Rel [C]C [C]R [C]E [C]B [C]- [C]R [C]e [C]l O 
cross-talk [C]c [C]r [C]o [C]s [C]s [C]- [C]t [C]a [C]l [C]k O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
mitogen [C]m [C]i [C]t [C]o [C]g [C]e [C]n S-protein 
and [C]a [C]n [C]d O 
oncogenic [C]o [C]n [C]c [C]o [C]g [C]e [C]n [C]i [C]c O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
in [C]i [C]n O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-cell_type 
T-cells [C]T [C]- [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
, [C], O 
we [C]w [C]e O 
explore [C]e [C]x [C]p [C]l [C]o [C]r [C]e O 
the [C]t [C]h [C]e O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
of [C]o [C]f O 
targeting [C]t [C]a [C]r [C]g [C]e [C]t [C]i [C]n [C]g O 
of [C]o [C]f O 
p300 [C]p [C]3 [C]0 [C]0 S-protein 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
interleukin-2 [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]2 B-DNA 
( [C]( I-DNA 
IL-2 [C]I [C]L [C]- [C]2 I-DNA 
) [C]) I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
mitogenic [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]i [C]c O 
and [C]a [C]n [C]d O 
oncogenic [C]o [C]n [C]c [C]o [C]g [C]e [C]n [C]i [C]c O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
. [C]. O 

Recruitment [C]R [C]e [C]c [C]r [C]u [C]i [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
p300 [C]p [C]3 [C]0 [C]0 S-protein 
by [C]b [C]y O 
cAMP-responsive [C]c [C]A [C]M [C]P [C]- [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e B-protein 
element-binding [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein-Rel [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]R [C]e [C]l E-protein 
cross-talk [C]c [C]r [C]o [C]s [C]s [C]- [C]t [C]a [C]l [C]k O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
composite [C]c [C]o [C]m [C]p [C]o [C]s [C]i [C]t [C]e B-protein 
CD28 [C]C [C]D [C]2 [C]8 I-protein 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e I-protein 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-protein 
( [C]( O 
CD28RE [C]C [C]D [C]2 [C]8 [C]R [C]E S-protein 
) [C]) O 
- [C]- O 
TRE [C]T [C]R [C]E B-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
is [C]i [C]s O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
for [C]f [C]o [C]r O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
inducibility [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]i [C]l [C]i [C]t [C]y O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
CD28RE-TRE [C]C [C]D [C]2 [C]8 [C]R [C]E [C]- [C]T [C]R [C]E S-DNA 
is [C]i [C]s O 
the [C]t [C]h [C]e O 
exclusive [C]e [C]x [C]c [C]l [C]u [C]s [C]i [C]v [C]e O 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l E-cell_type 
lymphotropic [C]l [C]y [C]m [C]p [C]h [C]o [C]t [C]r [C]o [C]p [C]i [C]c O 
virus [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
I [C]I O 
oncoprotein [C]o [C]n [C]c [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
Tax [C]T [C]a [C]x E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
intrinsic [C]i [C]n [C]t [C]r [C]i [C]n [C]s [C]i [C]c O 
histone [C]h [C]i [C]s [C]t [C]o [C]n [C]e O 
acetyltransferase [C]a [C]c [C]e [C]t [C]y [C]l [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]r [C]a [C]s [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
p300 [C]p [C]3 [C]0 [C]0 S-protein 
is [C]i [C]s O 
dispensable [C]d [C]i [C]s [C]p [C]e [C]n [C]s [C]a [C]b [C]l [C]e O 
for [C]f [C]o [C]r O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
, [C], O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
N-terminal [C]N [C]- [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l B-protein 
743 [C]7 [C]4 [C]3 I-protein 
residues [C]r [C]e [C]s [C]i [C]d [C]u [C]e [C]s E-protein 
contain [C]c [C]o [C]n [C]t [C]a [C]i [C]n O 
the [C]t [C]h [C]e O 
minimal [C]m [C]i [C]n [C]i [C]m [C]a [C]l O 
structural [C]s [C]t [C]r [C]u [C]c [C]t [C]u [C]r [C]a [C]l O 
requirements [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]m [C]e [C]n [C]t [C]s O 
for [C]f [C]o [C]r O 
synergistic [C]s [C]y [C]n [C]e [C]r [C]g [C]i [C]s [C]t [C]i [C]c O 
transactivation [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
CD28RE-TRE [C]C [C]D [C]2 [C]8 [C]R [C]E [C]- [C]T [C]R [C]E S-DNA 
, [C], O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
, [C], O 
and [C]a [C]n [C]d O 
endogenous [C]e [C]n [C]d [C]o [C]g [C]e [C]n [C]o [C]u [C]s O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Mutational [C]M [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]a [C]l O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
p300 [C]p [C]3 [C]0 [C]0 S-protein 
reveals [C]r [C]e [C]v [C]e [C]a [C]l [C]s O 
differential [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l O 
structural [C]s [C]t [C]r [C]u [C]c [C]t [C]u [C]r [C]a [C]l O 
requirements [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]m [C]e [C]n [C]t [C]s O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
N-terminal [C]N [C]- [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l O 
p300 [C]p [C]3 [C]0 [C]0 O 
module [C]m [C]o [C]d [C]u [C]l [C]e O 
by [C]b [C]y O 
individual [C]i [C]n [C]d [C]i [C]v [C]i [C]d [C]u [C]a [C]l O 
cis-elements [C]c [C]i [C]s [C]- [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s S-DNA 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
provide [C]p [C]r [C]o [C]v [C]i [C]d [C]e O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
that [C]t [C]h [C]a [C]t O 
p300 [C]p [C]3 [C]0 [C]0 S-protein 
assembles [C]a [C]s [C]s [C]e [C]m [C]b [C]l [C]e [C]s O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
to [C]t [C]o O 
form [C]f [C]o [C]r [C]m O 
an [C]a [C]n O 
enhanceosome-like [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]o [C]s [C]o [C]m [C]e [C]- [C]l [C]i [C]k [C]e O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
centrally [C]c [C]e [C]n [C]t [C]r [C]a [C]l [C]l [C]y O 
integrated [C]i [C]n [C]t [C]e [C]g [C]r [C]a [C]t [C]e [C]d O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
CD28RE-TRE [C]C [C]D [C]2 [C]8 [C]R [C]E [C]- [C]T [C]R [C]E B-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
module-targeted [C]m [C]o [C]d [C]u [C]l [C]e [C]- [C]t [C]a [C]r [C]g [C]e [C]t [C]e [C]d O 
associations [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-cell_type 
T-cells [C]T [C]- [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Regulation [C]R [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l S-cell_type 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
to [C]t [C]o O 
inhalant [C]i [C]n [C]h [C]a [C]l [C]a [C]n [C]t O 
allergen [C]a [C]l [C]l [C]e [C]r [C]g [C]e [C]n O 
: [C]: O 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
distinguishes [C]d [C]i [C]s [C]t [C]i [C]n [C]g [C]u [C]i [C]s [C]h [C]e [C]s O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
Th1- [C]T [C]h [C]1 [C]- O 
and [C]a [C]n [C]d O 
Th2-polarized [C]T [C]h [C]2 [C]- [C]p [C]o [C]l [C]a [C]r [C]i [C]z [C]e [C]d O 
immunity [C]i [C]m [C]m [C]u [C]n [C]i [C]t [C]y O 
. [C]. O 

BACKGROUND [C]B [C]A [C]C [C]K [C]G [C]R [C]O [C]U [C]N [C]D O 
: [C]: O 
The [C]T [C]h [C]e O 
precise [C]p [C]r [C]e [C]c [C]i [C]s [C]e O 
nature [C]n [C]a [C]t [C]u [C]r [C]e O 
of [C]o [C]f O 
allergen-specific [C]a [C]l [C]l [C]e [C]r [C]g [C]e [C]n [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
in [C]i [C]n O 
atopics [C]a [C]t [C]o [C]p [C]i [C]c [C]s O 
versus [C]v [C]e [C]r [C]s [C]u [C]s O 
non-atopics [C]n [C]o [C]n [C]- [C]a [C]t [C]o [C]p [C]i [C]c [C]s O 
, [C], O 
in [C]i [C]n O 
particular [C]p [C]a [C]r [C]t [C]i [C]c [C]u [C]l [C]a [C]r O 
the [C]t [C]h [C]e O 
'Th1 [C]' [C]T [C]h [C]1 O 
polarity [C]p [C]o [C]l [C]a [C]r [C]i [C]t [C]y O 
' [C]' O 
of [C]o [C]f O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
in [C]i [C]n O 
non-atopics [C]n [C]o [C]n [C]- [C]a [C]t [C]o [C]p [C]i [C]c [C]s O 
, [C], O 
remains [C]r [C]e [C]m [C]a [C]i [C]n [C]s O 
controversial [C]c [C]o [C]n [C]t [C]r [C]o [C]v [C]e [C]r [C]s [C]i [C]a [C]l O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
is [C]i [C]s O 
due [C]d [C]u [C]e O 
in [C]i [C]n O 
part [C]p [C]a [C]r [C]t O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
relative [C]r [C]e [C]l [C]a [C]t [C]i [C]v [C]e O 
insensitivity [C]i [C]n [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
detection [C]d [C]e [C]t [C]e [C]c [C]t [C]i [C]o [C]n O 
systems [C]s [C]y [C]s [C]t [C]e [C]m [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
variations [C]v [C]a [C]r [C]i [C]a [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
kinetics [C]k [C]i [C]n [C]e [C]t [C]i [C]c [C]s O 
of [C]o [C]f O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
catabolism [C]c [C]a [C]t [C]a [C]b [C]o [C]l [C]i [C]s [C]m O 
in [C]i [C]n O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
systems [C]s [C]y [C]s [C]t [C]e [C]m [C]s O 
. [C]. O 

As [C]A [C]s O 
an [C]a [C]n O 
alternative [C]a [C]l [C]t [C]e [C]r [C]n [C]a [C]t [C]i [C]v [C]e O 
to [C]t [C]o O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
measurement [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]m [C]e [C]n [C]t O 
, [C], O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
focuses [C]f [C]o [C]c [C]u [C]s [C]e [C]s O 
on [C]o [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 E-protein 
for [C]f [C]o [C]r O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
allergen-specific [C]a [C]l [C]l [C]e [C]r [C]g [C]e [C]n [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
Th [C]T [C]h O 
cell [C]c [C]e [C]l [C]l O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
. [C]. O 

METHODS [C]M [C]E [C]T [C]H [C]O [C]D [C]S O 
: [C]: O 
Cord [C]C [C]o [C]r [C]d B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
Th1- [C]T [C]h [C]1 [C]- O 
or [C]o [C]r O 
Th2-polarized [C]T [C]h [C]2 [C]- [C]p [C]o [C]l [C]a [C]r [C]i [C]z [C]e [C]d O 
by [C]b [C]y O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
in [C]i [C]n O 
IL-12- [C]I [C]L [C]- [C]1 [C]2 [C]- O 
or [C]o [C]r O 
IL-4-employing [C]I [C]L [C]- [C]4 [C]- [C]e [C]m [C]p [C]l [C]o [C]y [C]i [C]n [C]g O 
established [C]e [C]s [C]t [C]a [C]b [C]l [C]i [C]s [C]h [C]e [C]d O 
methods [C]m [C]e [C]t [C]h [C]o [C]d [C]s O 
; [C]; O 
PBMC [C]P [C]B [C]M [C]C S-cell_type 
from [C]f [C]r [C]o [C]m O 
house [C]h [C]o [C]u [C]s [C]e O 
dust [C]d [C]u [C]s [C]t O 
mite [C]m [C]i [C]t [C]e O 
( [C]( O 
HDM [C]H [C]D [C]M O 
) [C]) O 
-sensitive [C]- [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
atopics [C]a [C]t [C]o [C]p [C]i [C]c [C]s O 
and [C]a [C]n [C]d O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
were [C]w [C]e [C]r [C]e O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
overnight [C]o [C]v [C]e [C]r [C]n [C]i [C]g [C]h [C]t O 
with [C]w [C]i [C]t [C]h O 
HDM [C]H [C]D [C]M O 
; [C]; O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
by [C]b [C]y O 
ELISA [C]E [C]L [C]I [C]S [C]A O 
and [C]a [C]n [C]d O 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
by [C]b [C]y O 
PCR [C]P [C]C [C]R O 
. [C]. O 

RESULTS [C]R [C]E [C]S [C]U [C]L [C]T [C]S O 
: [C]: O 
Cytokine [C]C [C]y [C]t [C]o [C]k [C]i [C]n [C]e S-protein 
-driven [C]- [C]d [C]r [C]i [C]v [C]e [C]n O 
Th2 [C]T [C]h [C]2 O 
polarization [C]p [C]o [C]l [C]a [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
naive [C]n [C]a [C]i [C]v [C]e B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
is [C]i [C]s O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
marked [C]m [C]a [C]r [C]k [C]e [C]d O 
upregulation [C]u [C]p [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
a [C]a O 
reciprocal [C]r [C]e [C]c [C]i [C]p [C]r [C]o [C]c [C]a [C]l O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
pattern [C]p [C]a [C]t [C]t [C]e [C]r [C]n O 
accompanies [C]a [C]c [C]c [C]o [C]m [C]p [C]a [C]n [C]i [C]e [C]s O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
towards [C]t [C]o [C]w [C]a [C]r [C]d [C]s O 
the [C]t [C]h [C]e O 
Th1 [C]T [C]h [C]1 O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
. [C]. O 

In [C]I [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
HDM [C]H [C]D [C]M O 
skin [C]s [C]k [C]i [C]n O 
prick [C]p [C]r [C]i [C]c [C]k O 
test-positive [C]t [C]e [C]s [C]t [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
( [C]( O 
HDM-SPT+/HDM-IgE+ [C]H [C]D [C]M [C]- [C]S [C]P [C]T [C]+ [C]/ [C]H [C]D [C]M [C]- [C]I [C]g [C]E [C]+ O 
) [C]) O 
volunteers [C]v [C]o [C]l [C]u [C]n [C]t [C]e [C]e [C]r [C]s O 
, [C], O 
overnight [C]o [C]v [C]e [C]r [C]n [C]i [C]g [C]h [C]t O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
in [C]i [C]n O 
marked [C]m [C]a [C]r [C]k [C]e [C]d O 
upregulation [C]u [C]p [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
an [C]a [C]n O 
equally [C]e [C]q [C]u [C]a [C]l [C]l [C]y O 
marked [C]m [C]a [C]r [C]k [C]e [C]d O 
downregulation [C]d [C]o [C]w [C]n [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
SPT-/IgE- [C]S [C]P [C]T [C]- [C]/ [C]I [C]g [C]E [C]- O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
. [C]. O 

In [C]I [C]n O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
who [C]w [C]h [C]o O 
are [C]a [C]r [C]e O 
HDM-SPT+ [C]H [C]D [C]M [C]- [C]S [C]P [C]T [C]+ O 
but [C]b [C]u [C]t O 
IgE- [C]I [C]g [C]E [C]- O 
, [C], O 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
remained [C]r [C]e [C]m [C]a [C]i [C]n [C]e [C]d O 
relatively [C]r [C]e [C]l [C]a [C]t [C]i [C]v [C]e [C]l [C]y O 
stable [C]s [C]t [C]a [C]b [C]l [C]e O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
with [C]w [C]i [C]t [C]h O 
HDM [C]H [C]D [C]M O 
. [C]. O 

CONCLUSIONS [C]C [C]O [C]N [C]C [C]L [C]U [C]S [C]I [C]O [C]N [C]S O 
: [C]: O 
Upregulation [C]U [C]p [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
PBMC [C]P [C]B [C]M [C]C S-cell_type 
is [C]i [C]s O 
a [C]a O 
hallmark [C]h [C]a [C]l [C]l [C]m [C]a [C]r [C]k O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
early [C]e [C]a [C]r [C]l [C]y O 
phase [C]p [C]h [C]a [C]s [C]e O 
of [C]o [C]f O 
Th2 [C]T [C]h [C]2 O 
recall [C]r [C]e [C]c [C]a [C]l [C]l O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
to [C]t [C]o O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
allergen [C]a [C]l [C]l [C]e [C]r [C]g [C]e [C]n O 
in [C]i [C]n O 
atopics [C]a [C]t [C]o [C]p [C]i [C]c [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
reciprocal [C]r [C]e [C]c [C]i [C]p [C]r [C]o [C]c [C]a [C]l O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
pattern [C]p [C]a [C]t [C]t [C]e [C]r [C]n O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
HDM-specific [C]H [C]D [C]M [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
recall [C]r [C]e [C]c [C]a [C]l [C]l O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
of [C]o [C]f O 
non-atopics [C]n [C]o [C]n [C]- [C]a [C]t [C]o [C]p [C]i [C]c [C]s O 
provides [C]p [C]r [C]o [C]v [C]i [C]d [C]e [C]s O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
confirmation [C]c [C]o [C]n [C]f [C]i [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
underlying [C]u [C]n [C]d [C]e [C]r [C]l [C]y [C]i [C]n [C]g O 
Th1-like [C]T [C]h [C]1 [C]- [C]l [C]i [C]k [C]e O 
immunity [C]i [C]m [C]m [C]u [C]n [C]i [C]t [C]y O 
in [C]i [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
parallel [C]p [C]a [C]r [C]a [C]l [C]l [C]e [C]l O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
in [C]i [C]n O 
neonatal [C]n [C]e [C]o [C]n [C]a [C]t [C]a [C]l B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
approach [C]a [C]p [C]p [C]r [C]o [C]a [C]c [C]h O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
utilized [C]u [C]t [C]i [C]l [C]i [C]z [C]e [C]d O 
for [C]f [C]o [C]r O 
monitoring [C]m [C]o [C]n [C]i [C]t [C]o [C]r [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
progress [C]p [C]r [C]o [C]g [C]r [C]e [C]s [C]s O 
of [C]o [C]f O 
allergen-specific [C]a [C]l [C]l [C]e [C]r [C]g [C]e [C]n [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
Th1/Th2 [C]T [C]h [C]1 [C]/ [C]T [C]h [C]2 O 
memory [C]m [C]e [C]m [C]o [C]r [C]y O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
early [C]e [C]a [C]r [C]l [C]y O 
childhood [C]c [C]h [C]i [C]l [C]d [C]h [C]o [C]o [C]d O 
, [C], O 
and [C]a [C]n [C]d O 
hence [C]h [C]e [C]n [C]c [C]e O 
in [C]i [C]n O 
assessment [C]a [C]s [C]s [C]e [C]s [C]s [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
risk [C]r [C]i [C]s [C]k O 
for [C]f [C]o [C]r O 
future [C]f [C]u [C]t [C]u [C]r [C]e O 
allergic [C]a [C]l [C]l [C]e [C]r [C]g [C]i [C]c O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
. [C]. O 

Copyright [C]C [C]o [C]p [C]y [C]r [C]i [C]g [C]h [C]t O 
2001 [C]2 [C]0 [C]0 [C]1 O 
S. [C]S [C]. O 
Karger [C]K [C]a [C]r [C]g [C]e [C]r O 
AG [C]A [C]G O 
, [C], O 
Basel [C]B [C]a [C]s [C]e [C]l O 

The [C]T [C]h [C]e O 
heat [C]h [C]e [C]a [C]t O 
shock [C]s [C]h [C]o [C]c [C]k O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
reduces [C]r [C]e [C]d [C]u [C]c [C]e [C]s O 
myelin [C]m [C]y [C]e [C]l [C]i [C]n B-protein 
oligodendrocyte [C]o [C]l [C]i [C]g [C]o [C]d [C]e [C]n [C]d [C]r [C]o [C]c [C]y [C]t [C]e I-protein 
glycoprotein [C]g [C]l [C]y [C]c [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
experimental [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]a [C]l O 
autoimmune [C]a [C]u [C]t [C]o [C]i [C]m [C]m [C]u [C]n [C]e O 
encephalomyelitis [C]e [C]n [C]c [C]e [C]p [C]h [C]a [C]l [C]o [C]m [C]y [C]e [C]l [C]i [C]t [C]i [C]s O 
in [C]i [C]n O 
mice [C]m [C]i [C]c [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
stress [C]s [C]t [C]r [C]e [C]s [C]s O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
( [C]( O 
SR [C]S [C]R O 
) [C]) O 
can [C]c [C]a [C]n O 
block [C]b [C]l [C]o [C]c [C]k O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
by [C]b [C]y O 
preventing [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]i [C]n [C]g O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor-kappa [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
( [C]( O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
) [C]) O 
. [C]. O 

As [C]A [C]s O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
contributes [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e [C]s O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
pathogenesis [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
demyelinating [C]d [C]e [C]m [C]y [C]e [C]l [C]i [C]n [C]a [C]t [C]i [C]n [C]g O 
diseases [C]d [C]i [C]s [C]e [C]a [C]s [C]e [C]s O 
, [C], O 
we [C]w [C]e O 
tested [C]t [C]e [C]s [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
SR [C]S [C]R O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
progression [C]p [C]r [C]o [C]g [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
demyelinating [C]d [C]e [C]m [C]y [C]e [C]l [C]i [C]n [C]a [C]t [C]i [C]n [C]g O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
experimental [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]a [C]l O 
autoimmune [C]a [C]u [C]t [C]o [C]i [C]m [C]m [C]u [C]n [C]e O 
encephalomyelitis [C]e [C]n [C]c [C]e [C]p [C]h [C]a [C]l [C]o [C]m [C]y [C]e [C]l [C]i [C]t [C]i [C]s O 
( [C]( O 
EAE [C]E [C]A [C]E O 
) [C]) O 
. [C]. O 

EAE [C]E [C]A [C]E O 
was [C]w [C]a [C]s O 
actively [C]a [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
in [C]i [C]n O 
C57BL/6 [C]C [C]5 [C]7 [C]B [C]L [C]/ [C]6 O 
mice [C]m [C]i [C]c [C]e O 
using [C]u [C]s [C]i [C]n [C]g O 
an [C]a [C]n O 
encephalitogenic [C]e [C]n [C]c [C]e [C]p [C]h [C]a [C]l [C]i [C]t [C]o [C]g [C]e [C]n [C]i [C]c O 
myelin [C]m [C]y [C]e [C]l [C]i [C]n B-protein 
oligodendrocyte [C]o [C]l [C]i [C]g [C]o [C]d [C]e [C]n [C]d [C]r [C]o [C]c [C]y [C]t [C]e I-protein 
glycoprotein [C]g [C]l [C]y [C]c [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
( [C]( O 
MOG [C]M [C]O [C]G B-protein 
( [C]( I-protein 
35-55 [C]3 [C]5 [C]- [C]5 [C]5 I-protein 
) [C]) E-protein 
) [C]) O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
. [C]. O 

Whole [C]W [C]h [C]o [C]l [C]e O 
body [C]b [C]o [C]d [C]y O 
hyperthermia [C]h [C]y [C]p [C]e [C]r [C]t [C]h [C]e [C]r [C]m [C]i [C]a O 
was [C]w [C]a [C]s O 
used [C]u [C]s [C]e [C]d O 
to [C]t [C]o O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
a [C]a O 
heat [C]h [C]e [C]a [C]t O 
shock [C]s [C]h [C]o [C]c [C]k O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
( [C]( O 
HSR [C]H [C]S [C]R O 
) [C]) O 
in [C]i [C]n O 
immunized [C]i [C]m [C]m [C]u [C]n [C]i [C]z [C]e [C]d O 
mice [C]m [C]i [C]c [C]e O 
2 [C]2 O 
days [C]d [C]a [C]y [C]s O 
after [C]a [C]f [C]t [C]e [C]r O 
the [C]t [C]h [C]e O 
booster [C]b [C]o [C]o [C]s [C]t [C]e [C]r O 
MOG [C]M [C]O [C]G O 
( [C]( O 
35-55 [C]3 [C]5 [C]- [C]5 [C]5 O 
) [C]) O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
injection [C]i [C]n [C]j [C]e [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
HSR [C]H [C]S [C]R O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
the [C]t [C]h [C]e O 
incidence [C]i [C]n [C]c [C]i [C]d [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
EAE [C]E [C]A [C]E O 
by [C]b [C]y O 
70 [C]7 [C]0 O 
% [C]% O 
, [C], O 
delayed [C]d [C]e [C]l [C]a [C]y [C]e [C]d O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
onset [C]o [C]n [C]s [C]e [C]t O 
by [C]b [C]y O 
6 [C]6 O 
days [C]d [C]a [C]y [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
attenuated [C]a [C]t [C]t [C]e [C]n [C]u [C]a [C]t [C]e [C]d O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
severity [C]s [C]e [C]v [C]e [C]r [C]i [C]t [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
HSR [C]H [C]S [C]R O 
attenuated [C]a [C]t [C]t [C]e [C]n [C]u [C]a [C]t [C]e [C]d O 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e S-cell_type 
infiltration [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
into [C]i [C]n [C]t [C]o O 
CNS [C]C [C]N [C]S O 
assessed [C]a [C]s [C]s [C]e [C]s [C]s [C]e [C]d O 
by [C]b [C]y O 
quantitation [C]q [C]u [C]a [C]n [C]t [C]i [C]t [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
perivascular [C]p [C]e [C]r [C]i [C]v [C]a [C]s [C]c [C]u [C]l [C]a [C]r O 
infiltrates [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]e [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
by [C]b [C]y O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
staining [C]s [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
for [C]f [C]o [C]r O 
CD4 [C]C [C]D [C]4 S-protein 
and [C]a [C]n [C]d O 
CD25 [C]C [C]D [C]2 [C]5 S-protein 
immunopositive [C]i [C]m [C]m [C]u [C]n [C]o [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
T-cells [C]T [C]- [C]c [C]e [C]l [C]l [C]s S-cell_type 
. [C]. O 

T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
assessed [C]a [C]s [C]s [C]e [C]s [C]s [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
interferon [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n B-protein 
gamma [C]g [C]a [C]m [C]m [C]a E-protein 
( [C]( O 
IFNgamma [C]I [C]F [C]N [C]g [C]a [C]m [C]m [C]a S-protein 
) [C]) O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
MOG [C]M [C]O [C]G B-protein 
( [C]( I-protein 
35-55 [C]3 [C]5 [C]- [C]5 [C]5 I-protein 
) [C]) E-protein 
, [C], O 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
HSR [C]H [C]S [C]R O 
. [C]. O 

The [C]T [C]h [C]e O 
HSR [C]H [C]S [C]R O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
brain [C]b [C]r [C]a [C]i [C]n O 
that [C]t [C]h [C]a [C]t O 
normally [C]n [C]o [C]r [C]m [C]a [C]l [C]l [C]y O 
occurs [C]o [C]c [C]c [C]u [C]r [C]s O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
EAE [C]E [C]A [C]E O 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
early [C]e [C]a [C]r [C]l [C]y O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
RANTES [C]R [C]A [C]N [C]T [C]E [C]S S-protein 
( [C]( O 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d B-protein 
on [C]o [C]n I-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n I-protein 
of [C]o [C]f I-protein 
normal [C]n [C]o [C]r [C]m [C]a [C]l I-protein 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l I-protein 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d I-protein 
and [C]a [C]n [C]d I-protein 
secreted [C]s [C]e [C]c [C]r [C]e [C]t [C]e [C]d E-protein 
) [C]) O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
later [C]l [C]a [C]t [C]e [C]r O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
inducible [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
form [C]f [C]o [C]r [C]m O 
of [C]o [C]f O 
nitric [C]n [C]i [C]t [C]r [C]i [C]c B-protein 
oxide [C]o [C]x [C]i [C]d [C]e I-protein 
synthase [C]s [C]y [C]n [C]t [C]h [C]a [C]s [C]e E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
early [C]e [C]a [C]r [C]l [C]y O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
HSR [C]H [C]S [C]R O 
. [C]. O 

The [C]T [C]h [C]e O 
finding [C]f [C]i [C]n [C]d [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
SR [C]S [C]R O 
reduces [C]r [C]e [C]d [C]u [C]c [C]e [C]s O 
inflammation [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
brain [C]b [C]r [C]a [C]i [C]n O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
clinical [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
severity [C]s [C]e [C]v [C]e [C]r [C]i [C]t [C]y O 
of [C]o [C]f O 
EAE [C]E [C]A [C]E O 
opens [C]o [C]p [C]e [C]n [C]s O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
therapeutic [C]t [C]h [C]e [C]r [C]a [C]p [C]e [C]u [C]t [C]i [C]c O 
approach [C]a [C]p [C]p [C]r [C]o [C]a [C]c [C]h O 
for [C]f [C]o [C]r O 
prevention [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
autoimmune [C]a [C]u [C]t [C]o [C]i [C]m [C]m [C]u [C]n [C]e O 
diseases [C]d [C]i [C]s [C]e [C]a [C]s [C]e [C]s O 
. [C]. O 

In [C]I [C]n O 
vivo [C]v [C]i [C]v [C]o O 
detection [C]d [C]e [C]t [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
in [C]i [C]n O 
developing [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]i [C]n [C]g O 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
. [C]. O 

Information [C]I [C]n [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
regarding [C]r [C]e [C]g [C]a [C]r [C]d [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
processes [C]p [C]r [C]o [C]c [C]e [C]s [C]s [C]e [C]s O 
that [C]t [C]h [C]a [C]t O 
occur [C]o [C]c [C]c [C]u [C]r O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
has [C]h [C]a [C]s O 
largely [C]l [C]a [C]r [C]g [C]e [C]l [C]y O 
been [C]b [C]e [C]e [C]n O 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
use [C]u [C]s [C]e O 
of [C]o [C]f O 
transgenic [C]t [C]r [C]a [C]n [C]s [C]g [C]e [C]n [C]i [C]c O 
mouse [C]m [C]o [C]u [C]s [C]e O 
models [C]m [C]o [C]d [C]e [C]l [C]s O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
although [C]a [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
providing [C]p [C]r [C]o [C]v [C]i [C]d [C]i [C]n [C]g O 
invaluable [C]i [C]n [C]v [C]a [C]l [C]u [C]a [C]b [C]l [C]e O 
information [C]i [C]n [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
are [C]a [C]r [C]e O 
time [C]t [C]i [C]m [C]e O 
consuming [C]c [C]o [C]n [C]s [C]u [C]m [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
costly [C]c [C]o [C]s [C]t [C]l [C]y O 
. [C]. O 

To [C]T [C]o O 
this [C]t [C]h [C]i [C]s O 
end [C]e [C]n [C]d O 
, [C], O 
we [C]w [C]e O 
have [C]h [C]a [C]v [C]e O 
developed [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]e [C]d O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
that [C]t [C]h [C]a [C]t O 
facilitates [C]f [C]a [C]c [C]i [C]l [C]i [C]t [C]a [C]t [C]e [C]s O 
the [C]t [C]h [C]e O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
T-lymphocyte [C]T [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e S-cell_type 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
approach [C]a [C]p [C]p [C]r [C]o [C]a [C]c [C]h O 
uses [C]u [C]s [C]e [C]s O 
reporter-plasmids [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r [C]- [C]p [C]l [C]a [C]s [C]m [C]i [C]d [C]s S-DNA 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
detection [C]d [C]e [C]t [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
mitogen-activated [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
or [C]o [C]r O 
cyclic [C]c [C]y [C]c [C]l [C]i [C]c B-protein 
AMP-dependent [C]A [C]M [C]P [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
. [C]. O 

Reporter-plasmids [C]R [C]e [C]p [C]o [C]r [C]t [C]e [C]r [C]- [C]p [C]l [C]a [C]s [C]m [C]i [C]d [C]s S-DNA 
are [C]a [C]r [C]e O 
transfected [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]e [C]d O 
into [C]i [C]n [C]t [C]o O 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
in [C]i [C]n O 
fetal [C]f [C]e [C]t [C]a [C]l O 
thymic [C]t [C]h [C]y [C]m [C]i [C]c O 
organ [C]o [C]r [C]g [C]a [C]n O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
by [C]b [C]y O 
accelerated [C]a [C]c [C]c [C]e [C]l [C]e [C]r [C]a [C]t [C]e [C]d O 
DNA/particle [C]D [C]N [C]A [C]/ [C]p [C]a [C]r [C]t [C]i [C]c [C]l [C]e O 
bombardment [C]b [C]o [C]m [C]b [C]a [C]r [C]d [C]m [C]e [C]n [C]t O 
( [C]( O 
gene [C]g [C]e [C]n [C]e O 
gun [C]g [C]u [C]n O 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
is [C]i [C]s O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
form [C]f [C]o [C]r [C]m O 
of [C]o [C]f O 
a [C]a O 
standard [C]s [C]t [C]a [C]n [C]d [C]a [C]r [C]d O 
luciferase [C]l [C]u [C]c [C]i [C]f [C]e [C]r [C]a [C]s [C]e O 
assay [C]a [C]s [C]s [C]a [C]y O 
. [C]. O 

Importantly [C]I [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t [C]l [C]y O 
, [C], O 
this [C]t [C]h [C]i [C]s O 
powerful [C]p [C]o [C]w [C]e [C]r [C]f [C]u [C]l O 
technique [C]t [C]e [C]c [C]h [C]n [C]i [C]q [C]u [C]e O 
preserves [C]p [C]r [C]e [C]s [C]e [C]r [C]v [C]e [C]s O 
the [C]t [C]h [C]e O 
structural [C]s [C]t [C]r [C]u [C]c [C]t [C]u [C]r [C]a [C]l O 
integrity [C]i [C]n [C]t [C]e [C]g [C]r [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
thymus [C]t [C]h [C]y [C]m [C]u [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
will [C]w [C]i [C]l [C]l O 
provide [C]p [C]r [C]o [C]v [C]i [C]d [C]e O 
an [C]a [C]n O 
invaluable [C]i [C]n [C]v [C]a [C]l [C]u [C]a [C]b [C]l [C]e O 
tool [C]t [C]o [C]o [C]l O 
to [C]t [C]o O 
study [C]s [C]t [C]u [C]d [C]y O 
how [C]h [C]o [C]w O 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
respond [C]r [C]e [C]s [C]p [C]o [C]n [C]d O 
to [C]t [C]o O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
environmental [C]e [C]n [C]v [C]i [C]r [C]o [C]n [C]m [C]e [C]n [C]t [C]a [C]l O 
stimuli [C]s [C]t [C]i [C]m [C]u [C]l [C]i O 
encountered [C]e [C]n [C]c [C]o [C]u [C]n [C]t [C]e [C]r [C]e [C]d O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
the [C]t [C]h [C]e O 
thymic [C]t [C]h [C]y [C]m [C]i [C]c O 
milieu [C]m [C]i [C]l [C]i [C]e [C]u O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
this [C]t [C]h [C]i [C]s O 
method [C]m [C]e [C]t [C]h [C]o [C]d O 
allows [C]a [C]l [C]l [C]o [C]w [C]s O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
monitoring [C]m [C]o [C]n [C]i [C]t [C]o [C]r [C]i [C]n [C]g O 
of [C]o [C]f O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
that [C]t [C]h [C]a [C]t O 
occur [C]o [C]c [C]c [C]u [C]r O 
in [C]i [C]n O 
a [C]a O 
biological [C]b [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
time [C]t [C]i [C]m [C]e O 
frame [C]f [C]r [C]a [C]m [C]e O 
, [C], O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
the [C]t [C]h [C]e O 
natural [C]n [C]a [C]t [C]u [C]r [C]a [C]l O 
environment [C]e [C]n [C]v [C]i [C]r [C]o [C]n [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
differentiating [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]n [C]g B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Core-binding [C]C [C]o [C]r [C]e [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
beta [C]b [C]e [C]t [C]a E-protein 
( [C]( O 
CBFbeta [C]C [C]B [C]F [C]b [C]e [C]t [C]a S-protein 
) [C]) O 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
CBFbeta-smooth [C]C [C]B [C]F [C]b [C]e [C]t [C]a [C]- [C]s [C]m [C]o [C]o [C]t [C]h B-protein 
muscle [C]m [C]u [C]s [C]c [C]l [C]e I-protein 
myosin [C]m [C]y [C]o [C]s [C]i [C]n I-protein 
heavy [C]h [C]e [C]a [C]v [C]y I-protein 
chain [C]c [C]h [C]a [C]i [C]n E-protein 
, [C], O 
rescues [C]r [C]e [C]s [C]c [C]u [C]e [C]s O 
definitive [C]d [C]e [C]f [C]i [C]n [C]i [C]t [C]i [C]v [C]e O 
hematopoiesis [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
in [C]i [C]n O 
CBFbeta [C]C [C]B [C]F [C]b [C]e [C]t [C]a S-protein 
-deficient [C]- [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
embryonic [C]e [C]m [C]b [C]r [C]y [C]o [C]n [C]i [C]c B-cell_type 
stem [C]s [C]t [C]e [C]m I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Core-binding [C]C [C]o [C]r [C]e [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
beta [C]b [C]e [C]t [C]a E-protein 
( [C]( O 
CBFbeta [C]C [C]B [C]F [C]b [C]e [C]t [C]a S-protein 
) [C]) O 
is [C]i [C]s O 
the [C]t [C]h [C]e O 
non-DNA-binding [C]n [C]o [C]n [C]- [C]D [C]N [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
subunit [C]s [C]u [C]b [C]u [C]n [C]i [C]t E-protein 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
heterodimeric [C]h [C]e [C]t [C]e [C]r [C]o [C]d [C]i [C]m [C]e [C]r [C]i [C]c B-protein 
CBFs [C]C [C]B [C]F [C]s E-protein 
. [C]. O 

Genes [C]G [C]e [C]n [C]e [C]s B-DNA 
encoding [C]e [C]n [C]c [C]o [C]d [C]i [C]n [C]g I-DNA 
CBFbeta [C]C [C]B [C]F [C]b [C]e [C]t [C]a E-DNA 
( [C]( O 
CBFB [C]C [C]B [C]F [C]B S-DNA 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
one [C]o [C]n [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
DNA-binding [C]D [C]N [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
CBFalpha [C]C [C]B [C]F [C]a [C]l [C]p [C]h [C]a I-protein 
subunits [C]s [C]u [C]b [C]u [C]n [C]i [C]t [C]s I-protein 
, [C], I-protein 
Runx1 [C]R [C]u [C]n [C]x [C]1 E-protein 
( [C]( O 
also [C]a [C]l [C]s [C]o O 
known [C]k [C]n [C]o [C]w [C]n O 
as [C]a [C]s O 
CBFalpha2 [C]C [C]B [C]F [C]a [C]l [C]p [C]h [C]a [C]2 S-protein 
, [C], O 
AML1 [C]A [C]M [C]L [C]1 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
PEBP2alphaB [C]P [C]E [C]B [C]P [C]2 [C]a [C]l [C]p [C]h [C]a [C]B S-protein 
) [C]) O 
, [C], O 
are [C]a [C]r [C]e O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
hematopoiesis [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
are [C]a [C]r [C]e O 
also [C]a [C]l [C]s [C]o O 
frequent [C]f [C]r [C]e [C]q [C]u [C]e [C]n [C]t O 
targets [C]t [C]a [C]r [C]g [C]e [C]t [C]s O 
of [C]o [C]f O 
chromosomal [C]c [C]h [C]r [C]o [C]m [C]o [C]s [C]o [C]m [C]a [C]l O 
translocations [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
acute [C]a [C]c [C]u [C]t [C]e O 
leukemias [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a [C]s O 
in [C]i [C]n O 
humans [C]h [C]u [C]m [C]a [C]n [C]s O 
. [C]. O 

Homozygous [C]H [C]o [C]m [C]o [C]z [C]y [C]g [C]o [C]u [C]s O 
disruption [C]d [C]i [C]s [C]r [C]u [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
the [C]t [C]h [C]e O 
Runx1 [C]R [C]u [C]n [C]x [C]1 B-DNA 
or [C]o [C]r I-DNA 
Cbfb [C]C [C]b [C]f [C]b I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
in [C]i [C]n O 
mice [C]m [C]i [C]c [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
in [C]i [C]n O 
embryonic [C]e [C]m [C]b [C]r [C]y [C]o [C]n [C]i [C]c O 
lethality [C]l [C]e [C]t [C]h [C]a [C]l [C]i [C]t [C]y O 
at [C]a [C]t O 
midgestation [C]m [C]i [C]d [C]g [C]e [C]s [C]t [C]a [C]t [C]i [C]o [C]n O 
due [C]d [C]u [C]e O 
to [C]t [C]o O 
hemorrhaging [C]h [C]e [C]m [C]o [C]r [C]r [C]h [C]a [C]g [C]i [C]n [C]g O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
central [C]c [C]e [C]n [C]t [C]r [C]a [C]l O 
nervous [C]n [C]e [C]r [C]v [C]o [C]u [C]s O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
, [C], O 
and [C]a [C]n [C]d O 
severely [C]s [C]e [C]v [C]e [C]r [C]e [C]l [C]y O 
impairs [C]i [C]m [C]p [C]a [C]i [C]r [C]s O 
fetal [C]f [C]e [C]t [C]a [C]l O 
liver [C]l [C]i [C]v [C]e [C]r O 
hematopoiesis [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
. [C]. O 

Results [C]R [C]e [C]s [C]u [C]l [C]t [C]s O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
Cbfb-deficient [C]C [C]b [C]f [C]b [C]- [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
mouse [C]m [C]o [C]u [C]s [C]e O 
embryonic [C]e [C]m [C]b [C]r [C]y [C]o [C]n [C]i [C]c B-cell_type 
stem [C]s [C]t [C]e [C]m I-cell_type 
( [C]( I-cell_type 
ES [C]E [C]S I-cell_type 
) [C]) I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
can [C]c [C]a [C]n O 
differentiate [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]e O 
into [C]i [C]n [C]t [C]o O 
primitive [C]p [C]r [C]i [C]m [C]i [C]t [C]i [C]v [C]e B-cell_type 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d I-cell_type 
colonies [C]c [C]o [C]l [C]o [C]n [C]i [C]e [C]s E-cell_type 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
, [C], O 
but [C]b [C]u [C]t O 
are [C]a [C]r [C]e O 
impaired [C]i [C]m [C]p [C]a [C]i [C]r [C]e [C]d O 
in [C]i [C]n O 
their [C]t [C]h [C]e [C]i [C]r O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
to [C]t [C]o O 
produce [C]p [C]r [C]o [C]d [C]u [C]c [C]e O 
definitive [C]d [C]e [C]f [C]i [C]n [C]i [C]t [C]i [C]v [C]e O 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d B-cell_type 
and [C]a [C]n [C]d I-cell_type 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d I-cell_type 
colonies [C]c [C]o [C]l [C]o [C]n [C]i [C]e [C]s E-cell_type 
, [C], O 
mimicking [C]m [C]i [C]m [C]i [C]c [C]k [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
defect [C]d [C]e [C]f [C]e [C]c [C]t O 
. [C]. O 

Definitive [C]D [C]e [C]f [C]i [C]n [C]i [C]t [C]i [C]v [C]e O 
hematopoiesis [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
is [C]i [C]s O 
restored [C]r [C]e [C]s [C]t [C]o [C]r [C]e [C]d O 
by [C]b [C]y O 
ectopic [C]e [C]c [C]t [C]o [C]p [C]i [C]c O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
full-length [C]f [C]u [C]l [C]l [C]- [C]l [C]e [C]n [C]g [C]t [C]h B-DNA 
Cbfb [C]C [C]b [C]f [C]b I-DNA 
transgenes [C]t [C]r [C]a [C]n [C]s [C]g [C]e [C]n [C]e [C]s E-DNA 
, [C], O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
by [C]b [C]y O 
a [C]a O 
transgene [C]t [C]r [C]a [C]n [C]s [C]g [C]e [C]n [C]e O 
encoding [C]e [C]n [C]c [C]o [C]d [C]i [C]n [C]g O 
only [C]o [C]n [C]l [C]y O 
the [C]t [C]h [C]e O 
heterodimerization [C]h [C]e [C]t [C]e [C]r [C]o [C]d [C]i [C]m [C]e [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n B-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
of [C]o [C]f O 
CBFbeta [C]C [C]B [C]F [C]b [C]e [C]t [C]a S-protein 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
the [C]t [C]h [C]e O 
CBFbeta [C]C [C]B [C]F [C]b [C]e [C]t [C]a S-protein 
- [C]- O 
smooth [C]s [C]m [C]o [C]o [C]t [C]h B-protein 
muscle [C]m [C]u [C]s [C]c [C]l [C]e I-protein 
myosin [C]m [C]y [C]o [C]s [C]i [C]n I-protein 
heavy [C]h [C]e [C]a [C]v [C]y I-protein 
chain [C]c [C]h [C]a [C]i [C]n I-protein 
( [C]( I-protein 
SMMHC [C]S [C]M [C]M [C]H [C]C I-protein 
) [C]) I-protein 
fusion [C]f [C]u [C]s [C]i [C]o [C]n I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
generated [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
inv [C]i [C]n [C]v B-protein 
( [C]( I-protein 
16 [C]1 [C]6 I-protein 
) [C]) E-protein 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
acute [C]a [C]c [C]u [C]t [C]e B-cell_line 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d I-cell_line 
leukemias [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a [C]s E-cell_line 
( [C]( O 
M4Eo [C]M [C]4 [C]E [C]o S-cell_line 
) [C]) O 
can [C]c [C]a [C]n O 
not [C]n [C]o [C]t O 
rescue [C]r [C]e [C]s [C]c [C]u [C]e O 
definitive [C]d [C]e [C]f [C]i [C]n [C]i [C]t [C]i [C]v [C]e O 
hematopoiesis [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
by [C]b [C]y O 
Cbfb-deficient [C]C [C]b [C]f [C]b [C]- [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t B-cell_type 
ES [C]E [C]S I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Sequences [C]S [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s O 
responsible [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]b [C]l [C]e O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
inability [C]i [C]n [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
CBFbeta [C]C [C]B [C]F [C]b [C]e [C]t [C]a S-protein 
-SMMHC [C]- [C]S [C]M [C]M [C]H [C]C O 
to [C]t [C]o O 
rescue [C]r [C]e [C]s [C]c [C]u [C]e O 
definitive [C]d [C]e [C]f [C]i [C]n [C]i [C]t [C]i [C]v [C]e O 
hematopoiesis [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
reside [C]r [C]e [C]s [C]i [C]d [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
SMMHC [C]S [C]M [C]M [C]H [C]C B-protein 
portion [C]p [C]o [C]r [C]t [C]i [C]o [C]n E-protein 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
fusion [C]f [C]u [C]s [C]i [C]o [C]n B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
. [C]. O 

Results [C]R [C]e [C]s [C]u [C]l [C]t [C]s O 
also [C]a [C]l [C]s [C]o O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
CBFbeta-SMMHC [C]C [C]B [C]F [C]b [C]e [C]t [C]a [C]- [C]S [C]M [C]M [C]H [C]C B-protein 
fusion [C]f [C]u [C]s [C]i [C]o [C]n I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
transdominantly [C]t [C]r [C]a [C]n [C]s [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t [C]l [C]y O 
inhibits [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]s O 
definitive [C]d [C]e [C]f [C]i [C]n [C]i [C]t [C]i [C]v [C]e O 
hematopoiesis [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
extent [C]e [C]x [C]t [C]e [C]n [C]t O 
as [C]a [C]s O 
homozygous [C]h [C]o [C]m [C]o [C]z [C]y [C]g [C]o [C]u [C]s O 
loss [C]l [C]o [C]s [C]s O 
of [C]o [C]f O 
Runx1 [C]R [C]u [C]n [C]x [C]1 S-protein 
or [C]o [C]r O 
Cbfb [C]C [C]b [C]f [C]b S-protein 
. [C]. O 

CBFbeta-SMMHC [C]C [C]B [C]F [C]b [C]e [C]t [C]a [C]- [C]S [C]M [C]M [C]H [C]C S-protein 
preferentially [C]p [C]r [C]e [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l [C]l [C]y O 
inhibits [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]s O 
the [C]t [C]h [C]e O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d B-cell_type 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
while [C]w [C]h [C]i [C]l [C]e O 
increasing [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
blastlike [C]b [C]l [C]a [C]s [C]t [C]l [C]i [C]k [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
latency [C]l [C]a [C]t [C]e [C]n [C]c [C]y O 
pattern [C]p [C]a [C]t [C]t [C]e [C]r [C]n O 
of [C]o [C]f O 
Epstein-Barr [C]E [C]p [C]s [C]t [C]e [C]i [C]n [C]- [C]B [C]a [C]r [C]r O 
virus [C]v [C]i [C]r [C]u [C]s O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
viral [C]v [C]i [C]r [C]a [C]l O 
IL-10 [C]I [C]L [C]- [C]1 [C]0 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
cutaneous [C]c [C]u [C]t [C]a [C]n [C]e [C]o [C]u [C]s B-cell_type 
natural [C]n [C]a [C]t [C]u [C]r [C]a [C]l I-cell_type 
killer/T-cell [C]k [C]i [C]l [C]l [C]e [C]r [C]/ [C]T [C]- [C]c [C]e [C]l [C]l I-cell_type 
lymphomas [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
nasal [C]n [C]a [C]s [C]a [C]l B-cell_type 
type [C]t [C]y [C]p [C]e I-cell_type 
, [C], I-cell_type 
extranodal [C]e [C]x [C]t [C]r [C]a [C]n [C]o [C]d [C]a [C]l I-cell_type 
natural [C]n [C]a [C]t [C]u [C]r [C]a [C]l I-cell_type 
killer [C]k [C]i [C]l [C]l [C]e [C]r I-cell_type 
or [C]o [C]r I-cell_type 
T [C]T I-cell_type 
( [C]( I-cell_type 
NK/T [C]N [C]K [C]/ [C]T I-cell_type 
) [C]) I-cell_type 
-cell [C]- [C]c [C]e [C]l [C]l I-cell_type 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a E-cell_type 
is [C]i [C]s O 
usually [C]u [C]s [C]u [C]a [C]l [C]l [C]y O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
latent [C]l [C]a [C]t [C]e [C]n [C]t O 
Epstein-Barr [C]E [C]p [C]s [C]t [C]e [C]i [C]n [C]- [C]B [C]a [C]r [C]r O 
virus [C]v [C]i [C]r [C]u [C]s O 
( [C]( O 
EBV [C]E [C]B [C]V O 
) [C]) O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

In [C]I [C]n O 
order [C]o [C]r [C]d [C]e [C]r O 
to [C]t [C]o O 
elucidate [C]e [C]l [C]u [C]c [C]i [C]d [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
EBV [C]E [C]B [C]V O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
patterns [C]p [C]a [C]t [C]t [C]e [C]r [C]n [C]s O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
, [C], O 
we [C]w [C]e O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
eight [C]e [C]i [C]g [C]h [C]t O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
cutaneous [C]c [C]u [C]t [C]a [C]n [C]e [C]o [C]u [C]s O 
EBV-related [C]E [C]B [C]V [C]- [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
NK/T-cell [C]N [C]K [C]/ [C]T [C]- [C]c [C]e [C]l [C]l O 
lymphomas [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a [C]s O 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
six [C]s [C]i [C]x O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
NK-cell [C]N [C]K [C]- [C]c [C]e [C]l [C]l O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
and [C]a [C]n [C]d O 
two [C]t [C]w [C]o O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
implication [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
EBV [C]E [C]B [C]V O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
skin [C]s [C]k [C]i [C]n O 
lesions [C]l [C]e [C]s [C]i [C]o [C]n [C]s O 
was [C]w [C]a [C]s O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
EBV-DNA [C]E [C]B [C]V [C]- [C]D [C]N [C]A S-DNA 
, [C], O 
EBV-encoded [C]E [C]B [C]V [C]- [C]e [C]n [C]c [C]o [C]d [C]e [C]d B-RNA 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-RNA 
RNA [C]R [C]N [C]A E-RNA 
( [C]( O 
EBER [C]E [C]B [C]E [C]R S-RNA 
) [C]) O 
and [C]a [C]n [C]d O 
a [C]a O 
clonality [C]c [C]l [C]o [C]n [C]a [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
EBV-DNA [C]E [C]B [C]V [C]- [C]D [C]N [C]A B-DNA 
fragments [C]f [C]r [C]a [C]g [C]m [C]e [C]n [C]t [C]s E-DNA 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
terminal [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l B-DNA 
repeats [C]r [C]e [C]p [C]e [C]a [C]t [C]s E-DNA 
. [C]. O 

Transcripts [C]T [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]s O 
of [C]o [C]f O 
EBV-encoded [C]E [C]B [C]V [C]- [C]e [C]n [C]c [C]o [C]d [C]e [C]d B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
were [C]w [C]e [C]r [C]e O 
screened [C]s [C]c [C]r [C]e [C]e [C]n [C]e [C]d O 
by [C]b [C]y O 
reverse [C]r [C]e [C]v [C]e [C]r [C]s [C]e O 
transcription- [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]- O 
polymerase [C]p [C]o [C]l [C]y [C]m [C]e [C]r [C]a [C]s [C]e O 
chain [C]c [C]h [C]a [C]i [C]n O 
reaction [C]r [C]e [C]a [C]c [C]t [C]i [C]o [C]n O 
( [C]( O 
RT-PCR [C]R [C]T [C]- [C]P [C]C [C]R O 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
confirmed [C]c [C]o [C]n [C]f [C]i [C]r [C]m [C]e [C]d O 
by [C]b [C]y O 
Southern [C]S [C]o [C]u [C]t [C]h [C]e [C]r [C]n O 
blot [C]b [C]l [C]o [C]t O 
hybridization [C]h [C]y [C]b [C]r [C]i [C]d [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
EBV-related [C]E [C]B [C]V [C]- [C]r [C]e [C]l [C]a [C]t [C]e [C]d B-protein 
antigens [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]s E-protein 
was [C]w [C]a [C]s O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
immunostaining [C]i [C]m [C]m [C]u [C]n [C]o [C]s [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
using [C]u [C]s [C]i [C]n [C]g O 
paraffin-embedded [C]p [C]a [C]r [C]a [C]f [C]f [C]i [C]n [C]- [C]e [C]m [C]b [C]e [C]d [C]d [C]e [C]d O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
sections [C]s [C]e [C]c [C]t [C]i [C]o [C]n [C]s O 
and [C]a [C]n [C]d O 
cell [C]c [C]e [C]l [C]l O 
pellets [C]p [C]e [C]l [C]l [C]e [C]t [C]s O 
of [C]o [C]f O 
EBV-positive [C]E [C]B [C]V [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
. [C]. O 

Our [C]O [C]u [C]r O 
study [C]s [C]t [C]u [C]d [C]y O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
all [C]a [C]l [C]l O 
samples [C]s [C]a [C]m [C]p [C]l [C]e [C]s O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
contained [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]e [C]d O 
EBV [C]E [C]B [C]V B-RNA 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-RNA 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n I-RNA 
( [C]( I-RNA 
EBNA [C]E [C]B [C]N [C]A I-RNA 
) [C]) I-RNA 
-1 [C]- [C]1 I-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
which [C]w [C]h [C]i [C]c [C]h O 
was [C]w [C]a [C]s O 
transcribed [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
using [C]u [C]s [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
Q [C]Q B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
both [C]b [C]o [C]t [C]h O 
the [C]t [C]h [C]e O 
Q [C]Q B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
and [C]a [C]n [C]d O 
another [C]a [C]n [C]o [C]t [C]h [C]e [C]r O 
upstream [C]u [C]p [C]s [C]t [C]r [C]e [C]a [C]m B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
( [C]( O 
Cp/Wp [C]C [C]p [C]/ [C]W [C]p S-DNA 
) [C]) O 
were [C]w [C]e [C]r [C]e O 
used [C]u [C]s [C]e [C]d O 
in [C]i [C]n O 
EBV-positive [C]E [C]B [C]V [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
, [C], O 
B95.8 [C]B [C]9 [C]5 [C]. [C]8 S-cell_line 
, [C], O 
Raji [C]R [C]a [C]j [C]i S-cell_line 
and [C]a [C]n [C]d O 
Jiyoye [C]J [C]i [C]y [C]o [C]y [C]e S-cell_line 
. [C]. O 

Latent [C]L [C]a [C]t [C]e [C]n [C]t B-RNA 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e I-RNA 
protein-1 [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]1 I-RNA 
( [C]( I-RNA 
LMP-1 [C]L [C]M [C]P [C]- [C]1 I-RNA 
) [C]) I-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
was [C]w [C]a [C]s O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
in [C]i [C]n O 
seven [C]s [C]e [C]v [C]e [C]n O 
of [C]o [C]f O 
eight [C]e [C]i [C]g [C]h [C]t O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
and [C]a [C]n [C]d O 
all [C]a [C]l [C]l O 
cell [C]c [C]e [C]l [C]l B-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
EBNA-2 [C]E [C]B [C]N [C]A [C]- [C]2 B-RNA 
transcripts [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]s E-RNA 
were [C]w [C]e [C]r [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
only [C]o [C]n [C]l [C]y O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
cell [C]c [C]e [C]l [C]l B-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
. [C]. O 

Immunostaining [C]I [C]m [C]m [C]u [C]n [C]o [C]s [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
no [C]n [C]o O 
LMP-1 [C]L [C]M [C]P [C]- [C]1 B-protein 
, [C], I-protein 
EBNA-2 [C]E [C]B [C]N [C]A [C]- [C]2 I-protein 
or [C]o [C]r I-protein 
ZEBRA [C]Z [C]E [C]B [C]R [C]A I-protein 
antigens [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]s E-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
paraffin-embedded [C]p [C]a [C]r [C]a [C]f [C]f [C]i [C]n [C]- [C]e [C]m [C]b [C]e [C]d [C]d [C]e [C]d O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
sections [C]s [C]e [C]c [C]t [C]i [C]o [C]n [C]s O 
, [C], O 
although [C]a [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
they [C]t [C]h [C]e [C]y O 
were [C]w [C]e [C]r [C]e O 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
cell [C]c [C]e [C]l [C]l B-cell_line 
line [C]l [C]i [C]n [C]e I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

Latent [C]L [C]a [C]t [C]e [C]n [C]t B-RNA 
BHRF1 [C]B [C]H [C]R [C]F [C]1 I-RNA 
transcripts [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]s E-RNA 
encoding [C]e [C]n [C]c [C]o [C]d [C]i [C]n [C]g O 
bcl-2 [C]b [C]c [C]l [C]- [C]2 B-RNA 
homologue [C]h [C]o [C]m [C]o [C]l [C]o [C]g [C]u [C]e E-RNA 
and [C]a [C]n [C]d O 
BCRF1 [C]B [C]C [C]R [C]F [C]1 B-RNA 
transcripts [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]s E-RNA 
encoding [C]e [C]n [C]c [C]o [C]d [C]i [C]n [C]g O 
viral [C]v [C]i [C]r [C]a [C]l B-protein 
interleukin [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n I-protein 
( [C]( I-protein 
vIL [C]v [C]I [C]L I-protein 
) [C]) I-protein 
-10 [C]- [C]1 [C]0 E-protein 
were [C]w [C]e [C]r [C]e O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
in [C]i [C]n O 
one [C]o [C]n [C]e O 
and [C]a [C]n [C]d O 
two [C]t [C]w [C]o O 
of [C]o [C]f O 
eight [C]e [C]i [C]g [C]h [C]t O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
, [C], O 
respectively [C]r [C]e [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
. [C]. O 

A [C]A O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
NK-cell [C]N [C]K [C]- [C]c [C]e [C]l [C]l O 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a O 
expressing [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]n [C]g O 
both [C]b [C]o [C]t [C]h O 
transcripts [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]s O 
died [C]d [C]i [C]e [C]d O 
of [C]o [C]f O 
rapid [C]r [C]a [C]p [C]i [C]d O 
progression [C]p [C]r [C]o [C]g [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
illness [C]i [C]l [C]l [C]n [C]e [C]s [C]s O 
. [C]. O 

Our [C]O [C]u [C]r O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
restricted [C]r [C]e [C]s [C]t [C]r [C]i [C]c [C]t [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
latency-associated [C]l [C]a [C]t [C]e [C]n [C]c [C]y [C]- [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d B-DNA 
EBV [C]E [C]B [C]V I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
vIL-10 [C]v [C]I [C]L [C]- [C]1 [C]0 B-RNA 
and [C]a [C]n [C]d I-RNA 
bcl-2 [C]b [C]c [C]l [C]- [C]2 I-RNA 
homologue [C]h [C]o [C]m [C]o [C]l [C]o [C]g [C]u [C]e E-RNA 
may [C]m [C]a [C]y O 
favour [C]f [C]a [C]v [C]o [C]u [C]r O 
tumour [C]t [C]u [C]m [C]o [C]u [C]r O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
, [C], O 
evading [C]e [C]v [C]a [C]d [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
host [C]h [C]o [C]s [C]t O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
surveillance [C]s [C]u [C]r [C]v [C]e [C]i [C]l [C]l [C]a [C]n [C]c [C]e O 
. [C]. O 

Copyright [C]C [C]o [C]p [C]y [C]r [C]i [C]g [C]h [C]t O 
2001 [C]2 [C]0 [C]0 [C]1 O 
Cancer [C]C [C]a [C]n [C]c [C]e [C]r O 
Research [C]R [C]e [C]s [C]e [C]a [C]r [C]c [C]h O 
Campaign [C]C [C]a [C]m [C]p [C]a [C]i [C]g [C]n O 
. [C]. O 

Oxidized [C]O [C]x [C]i [C]d [C]i [C]z [C]e [C]d O 
alkyl [C]a [C]l [C]k [C]y [C]l O 
phospholipids [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]l [C]i [C]p [C]i [C]d [C]s O 
are [C]a [C]r [C]e O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
, [C], O 
high [C]h [C]i [C]g [C]h O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
peroxisome [C]p [C]e [C]r [C]o [C]x [C]i [C]s [C]o [C]m [C]e O 
proliferator-activated [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]o [C]r [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
gamma [C]g [C]a [C]m [C]m [C]a O 
ligands [C]l [C]i [C]g [C]a [C]n [C]d [C]s O 
and [C]a [C]n [C]d O 
agonists [C]a [C]g [C]o [C]n [C]i [C]s [C]t [C]s O 
. [C]. O 

Synthetic [C]S [C]y [C]n [C]t [C]h [C]e [C]t [C]i [C]c O 
high [C]h [C]i [C]g [C]h O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
peroxisome [C]p [C]e [C]r [C]o [C]x [C]i [C]s [C]o [C]m [C]e O 
proliferator-activated [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]o [C]r [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
( [C]( O 
PPAR [C]P [C]P [C]A [C]R O 
) [C]) O 
agonists [C]a [C]g [C]o [C]n [C]i [C]s [C]t [C]s O 
are [C]a [C]r [C]e O 
known [C]k [C]n [C]o [C]w [C]n O 
, [C], O 
but [C]b [C]u [C]t O 
biologic [C]b [C]i [C]o [C]l [C]o [C]g [C]i [C]c O 
ligands [C]l [C]i [C]g [C]a [C]n [C]d [C]s O 
are [C]a [C]r [C]e O 
of [C]o [C]f O 
low [C]l [C]o [C]w O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
. [C]. O 

Oxidized [C]O [C]x [C]i [C]d [C]i [C]z [C]e [C]d B-protein 
low [C]l [C]o [C]w I-protein 
density [C]d [C]e [C]n [C]s [C]i [C]t [C]y I-protein 
lipoprotein [C]l [C]i [C]p [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
( [C]( O 
oxLDL [C]o [C]x [C]L [C]D [C]L S-protein 
) [C]) O 
is [C]i [C]s O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
and [C]a [C]n [C]d O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
PPARs [C]P [C]P [C]A [C]R [C]s S-protein 
. [C]. O 

We [C]W [C]e O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
, [C], O 
by [C]b [C]y O 
phospholipase [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]l [C]i [C]p [C]a [C]s [C]e O 
A [C]A O 
( [C]( O 
1 [C]1 O 
) [C]) O 
digestion [C]d [C]i [C]g [C]e [C]s [C]t [C]i [C]o [C]n O 
, [C], O 
that [C]t [C]h [C]a [C]t O 
PPARgamma [C]P [C]P [C]A [C]R [C]g [C]a [C]m [C]m [C]a O 
agonists [C]a [C]g [C]o [C]n [C]i [C]s [C]t [C]s O 
in [C]i [C]n O 
oxLDL [C]o [C]x [C]L [C]D [C]L S-protein 
arise [C]a [C]r [C]i [C]s [C]e O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
small [C]s [C]m [C]a [C]l [C]l O 
pool [C]p [C]o [C]o [C]l O 
of [C]o [C]f O 
alkyl [C]a [C]l [C]k [C]y [C]l O 
phosphatidylcholines [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]i [C]d [C]y [C]l [C]c [C]h [C]o [C]l [C]i [C]n [C]e [C]s O 
in [C]i [C]n O 
LDL [C]L [C]D [C]L S-protein 
. [C]. O 

We [C]W [C]e O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
an [C]a [C]n O 
abundant [C]a [C]b [C]u [C]n [C]d [C]a [C]n [C]t O 
oxidatively [C]o [C]x [C]i [C]d [C]a [C]t [C]i [C]v [C]e [C]l [C]y O 
fragmented [C]f [C]r [C]a [C]g [C]m [C]e [C]n [C]t [C]e [C]d O 
alkyl [C]a [C]l [C]k [C]y [C]l O 
phospholipid [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]l [C]i [C]p [C]i [C]d O 
in [C]i [C]n O 
oxLDL [C]o [C]x [C]L [C]D [C]L S-protein 
, [C], O 
hexadecyl [C]h [C]e [C]x [C]a [C]d [C]e [C]c [C]y [C]l O 
azelaoyl [C]a [C]z [C]e [C]l [C]a [C]o [C]y [C]l O 
phosphatidylcholine [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]i [C]d [C]y [C]l [C]c [C]h [C]o [C]l [C]i [C]n [C]e O 
( [C]( O 
azPC [C]a [C]z [C]P [C]C O 
) [C]) O 
, [C], O 
as [C]a [C]s O 
a [C]a O 
high [C]h [C]i [C]g [C]h O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
ligand [C]l [C]i [C]g [C]a [C]n [C]d O 
and [C]a [C]n [C]d O 
agonist [C]a [C]g [C]o [C]n [C]i [C]s [C]t O 
for [C]f [C]o [C]r O 
PPARgamma [C]P [C]P [C]A [C]R [C]g [C]a [C]m [C]m [C]a S-protein 
. [C]. O 

[ [C][ O 
( [C]( O 
3 [C]3 O 
) [C]) O 
H [C]H O 
] [C]] O 
azPC [C]a [C]z [C]P [C]C O 
bound [C]b [C]o [C]u [C]n [C]d O 
recombinant [C]r [C]e [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]n [C]t B-protein 
PPARgamma [C]P [C]P [C]A [C]R [C]g [C]a [C]m [C]m [C]a E-protein 
with [C]w [C]i [C]t [C]h O 
an [C]a [C]n O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
( [C]( O 
K [C]K O 
( [C]( O 
d [C]d O 
) [C]) O 
( [C]( O 
( [C]( O 
app [C]a [C]p [C]p O 
) [C]) O 
) [C]) O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
40 [C]4 [C]0 O 
nm [C]n [C]m O 
) [C]) O 
that [C]t [C]h [C]a [C]t O 
was [C]w [C]a [C]s O 
equivalent [C]e [C]q [C]u [C]i [C]v [C]a [C]l [C]e [C]n [C]t O 
to [C]t [C]o O 
rosiglitazone [C]r [C]o [C]s [C]i [C]g [C]l [C]i [C]t [C]a [C]z [C]o [C]n [C]e O 
( [C]( O 
BRL49653 [C]B [C]R [C]L [C]4 [C]9 [C]6 [C]5 [C]3 O 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
competition [C]c [C]o [C]m [C]p [C]e [C]t [C]i [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
rosiglitazone [C]r [C]o [C]s [C]i [C]g [C]l [C]i [C]t [C]a [C]z [C]o [C]n [C]e O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
occurred [C]o [C]c [C]c [C]u [C]r [C]r [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
ligand-binding [C]l [C]i [C]g [C]a [C]n [C]d [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
pocket [C]p [C]o [C]c [C]k [C]e [C]t E-protein 
. [C]. O 

azPC [C]a [C]z [C]P [C]C O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
PPRE [C]P [C]P [C]R [C]E O 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
as [C]a [C]s O 
did [C]d [C]i [C]d O 
rosiglitazone [C]r [C]o [C]s [C]i [C]g [C]l [C]i [C]t [C]a [C]z [C]o [C]n [C]e O 
, [C], O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
half-maximal [C]h [C]a [C]l [C]f [C]- [C]m [C]a [C]x [C]i [C]m [C]a [C]l O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
at [C]a [C]t O 
100 [C]1 [C]0 [C]0 O 
nm [C]n [C]m O 
. [C]. O 

Overexpression [C]O [C]v [C]e [C]r [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
PPARalpha [C]P [C]P [C]A [C]R [C]a [C]l [C]p [C]h [C]a S-protein 
or [C]o [C]r O 
PPARgamma [C]P [C]P [C]A [C]R [C]g [C]a [C]m [C]m [C]a S-protein 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
azPC [C]a [C]z [C]P [C]C O 
was [C]w [C]a [C]s O 
a [C]a O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
PPARgamma [C]P [C]P [C]A [C]R [C]g [C]a [C]m [C]m [C]a O 
agonist [C]a [C]g [C]o [C]n [C]i [C]s [C]t O 
. [C]. O 

The [C]T [C]h [C]e O 
scavenger [C]s [C]c [C]a [C]v [C]e [C]n [C]g [C]e [C]r B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
CD36 [C]C [C]D [C]3 [C]6 E-protein 
is [C]i [C]s O 
encoded [C]e [C]n [C]c [C]o [C]d [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
PPRE-responsive [C]P [C]P [C]R [C]E [C]- [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
, [C], O 
and [C]a [C]n [C]d O 
azPC [C]a [C]z [C]P [C]C O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
CD36 [C]C [C]D [C]3 [C]6 S-protein 
in [C]i [C]n O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

We [C]W [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
anti-CD36 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]3 [C]6 S-protein 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
azPC [C]a [C]z [C]P [C]C O 
uptake [C]u [C]p [C]t [C]a [C]k [C]e O 
, [C], O 
and [C]a [C]n [C]d O 
it [C]i [C]t O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
PPRE [C]P [C]P [C]R [C]E O 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

Results [C]R [C]e [C]s [C]u [C]l [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
small [C]s [C]m [C]a [C]l [C]l O 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e O 
phospholipid [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]l [C]i [C]p [C]i [C]d B-protein 
flippase [C]f [C]l [C]i [C]p [C]p [C]a [C]s [C]e I-protein 
mimetic [C]m [C]i [C]m [C]e [C]t [C]i [C]c E-protein 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
azPC [C]a [C]z [C]P [C]C O 
acts [C]a [C]c [C]t [C]s O 
intracellularly [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r [C]l [C]y O 
and [C]a [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
azPC [C]a [C]z [C]P [C]C O 
accumulation [C]a [C]c [C]c [C]u [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
efficient [C]e [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
certain [C]c [C]e [C]r [C]t [C]a [C]i [C]n O 
alkyl [C]a [C]l [C]k [C]y [C]l O 
phospholipid [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]l [C]i [C]p [C]i [C]d O 
oxidation [C]o [C]x [C]i [C]d [C]a [C]t [C]i [C]o [C]n O 
products [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]s O 
in [C]i [C]n O 
oxLDL [C]o [C]x [C]L [C]D [C]L S-protein 
are [C]a [C]r [C]e O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
, [C], O 
high [C]h [C]i [C]g [C]h O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
extracellular [C]e [C]x [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
ligands [C]l [C]i [C]g [C]a [C]n [C]d [C]s O 
and [C]a [C]n [C]d O 
agonists [C]a [C]g [C]o [C]n [C]i [C]s [C]t [C]s O 
for [C]f [C]o [C]r O 
PPARgamma [C]P [C]P [C]A [C]R [C]g [C]a [C]m [C]m [C]a S-protein 
that [C]t [C]h [C]a [C]t O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
PPAR-responsive [C]P [C]P [C]A [C]R [C]- [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 

Regulation [C]R [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
MAT2B [C]M [C]A [C]T [C]2 [C]B I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
encoding [C]e [C]n [C]c [C]o [C]d [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y B-protein 
beta [C]b [C]e [C]t [C]a I-protein 
subunit [C]s [C]u [C]b [C]u [C]n [C]i [C]t E-protein 
of [C]o [C]f O 
methionine [C]m [C]e [C]t [C]h [C]i [C]o [C]n [C]i [C]n [C]e B-protein 
adenosyltransferase [C]a [C]d [C]e [C]n [C]o [C]s [C]y [C]l [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]r [C]a [C]s [C]e E-protein 
, [C], O 
MAT [C]M [C]A [C]T B-protein 
II [C]I [C]I E-protein 
. [C]. O 

Methionine [C]M [C]e [C]t [C]h [C]i [C]o [C]n [C]i [C]n [C]e B-protein 
adenosyltransferase [C]a [C]d [C]e [C]n [C]o [C]s [C]y [C]l [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]r [C]a [C]s [C]e E-protein 
( [C]( O 
MAT [C]M [C]A [C]T S-protein 
) [C]) O 
catalyzes [C]c [C]a [C]t [C]a [C]l [C]y [C]z [C]e [C]s O 
the [C]t [C]h [C]e O 
biosynthesis [C]b [C]i [C]o [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
S-adenosylmethionine [C]S [C]- [C]a [C]d [C]e [C]n [C]o [C]s [C]y [C]l [C]m [C]e [C]t [C]h [C]i [C]o [C]n [C]i [C]n [C]e S-protein 
( [C]( O 
AdoMet [C]A [C]d [C]o [C]M [C]e [C]t S-protein 
) [C]) O 
, [C], O 
a [C]a O 
key [C]k [C]e [C]y O 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e O 
in [C]i [C]n O 
transmethylation [C]t [C]r [C]a [C]n [C]s [C]m [C]e [C]t [C]h [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
reactions [C]r [C]e [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
and [C]a [C]n [C]d O 
polyamine [C]p [C]o [C]l [C]y [C]a [C]m [C]i [C]n [C]e O 
biosynthesis [C]b [C]i [C]o [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
MAT [C]M [C]A [C]T B-protein 
II [C]I [C]I I-protein 
isozyme [C]i [C]s [C]o [C]z [C]y [C]m [C]e E-protein 
consists [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]s O 
of [C]o [C]f O 
a [C]a O 
catalytic [C]c [C]a [C]t [C]a [C]l [C]y [C]t [C]i [C]c B-protein 
alpha2 [C]a [C]l [C]p [C]h [C]a [C]2 I-protein 
and [C]a [C]n [C]d I-protein 
a [C]a I-protein 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y I-protein 
beta [C]b [C]e [C]t [C]a I-protein 
subunit [C]s [C]u [C]b [C]u [C]n [C]i [C]t E-protein 
. [C]. O 

Down-regulation [C]D [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
MAT [C]M [C]A [C]T B-protein 
II [C]I [C]I I-protein 
beta [C]b [C]e [C]t [C]a I-protein 
subunit [C]s [C]u [C]b [C]u [C]n [C]i [C]t E-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
causes [C]c [C]a [C]u [C]s [C]e [C]s O 
a [C]a O 
6-10-fold [C]6 [C]- [C]1 [C]0 [C]- [C]f [C]o [C]l [C]d O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
AdoMet [C]A [C]d [C]o [C]M [C]e [C]t S-protein 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
. [C]. O 

To [C]T [C]o O 
understand [C]u [C]n [C]d [C]e [C]r [C]s [C]t [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
by [C]b [C]y O 
which [C]w [C]h [C]i [C]c [C]h O 
the [C]t [C]h [C]e O 
beta [C]b [C]e [C]t [C]a B-protein 
subunit [C]s [C]u [C]b [C]u [C]n [C]i [C]t E-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
is [C]i [C]s O 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
, [C], O 
we [C]w [C]e O 
cloned [C]c [C]l [C]o [C]n [C]e [C]d O 
the [C]t [C]h [C]e O 
MAT2B [C]M [C]A [C]T [C]2 [C]B B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
, [C], O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
its [C]i [C]t [C]s O 
organization [C]o [C]r [C]g [C]a [C]n [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
characterized [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]d O 
its [C]i [C]t [C]s O 
5'-flanking [C]5 [C]' [C]- [C]f [C]l [C]a [C]n [C]k [C]i [C]n [C]g B-DNA 
sequences [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s E-DNA 
, [C], O 
and [C]a [C]n [C]d O 
elucidated [C]e [C]l [C]u [C]c [C]i [C]d [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
its [C]i [C]t [C]s O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r S-DNA 
. [C]. O 

Transcription [C]T [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
MAT2B [C]M [C]A [C]T [C]2 [C]B B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
initiates [C]i [C]n [C]i [C]t [C]i [C]a [C]t [C]e [C]s O 
at [C]a [C]t O 
position [C]p [C]o [C]s [C]i [C]t [C]i [C]o [C]n O 
-203 [C]- [C]2 [C]0 [C]3 O 
relative [C]r [C]e [C]l [C]a [C]t [C]i [C]v [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
translation [C]t [C]r [C]a [C]n [C]s [C]l [C]a [C]t [C]i [C]o [C]n B-DNA 
start [C]s [C]t [C]a [C]r [C]t I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
. [C]. O 

Promoter [C]P [C]r [C]o [C]m [C]o [C]t [C]e [C]r B-DNA 
deletion [C]d [C]e [C]l [C]e [C]t [C]i [C]o [C]n I-DNA 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s E-DNA 
defined [C]d [C]e [C]f [C]i [C]n [C]e [C]d O 
a [C]a O 
minimal [C]m [C]i [C]n [C]i [C]m [C]a [C]l B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
positions [C]p [C]o [C]s [C]i [C]t [C]i [C]o [C]n [C]s B-DNA 
+52 [C]+ [C]5 [C]2 I-DNA 
and [C]a [C]n [C]d I-DNA 
+93 [C]+ [C]9 [C]3 E-DNA 
base [C]b [C]a [C]s [C]e O 
pairs [C]p [C]a [C]i [C]r [C]s O 
, [C], O 
a [C]a O 
GC-rich [C]G [C]C [C]- [C]r [C]i [C]c [C]h B-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
. [C]. O 

Inclusion [C]I [C]n [C]c [C]l [C]u [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
sequences [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
-4 [C]- [C]4 O 
and [C]a [C]n [C]d O 
+52 [C]+ [C]5 [C]2 O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
; [C]; O 
this [C]t [C]h [C]i [C]s O 
was [C]w [C]a [C]s O 
primarily [C]p [C]r [C]i [C]m [C]a [C]r [C]i [C]l [C]y O 
because [C]b [C]e [C]c [C]a [C]u [C]s [C]e O 
of [C]o [C]f O 
an [C]a [C]n O 
Sp1 [C]S [C]p [C]1 B-DNA 
recognition [C]r [C]e [C]c [C]o [C]g [C]n [C]i [C]t [C]i [C]o [C]n I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
at [C]a [C]t O 
+9/+15 [C]+ [C]9 [C]/ [C]+ [C]1 [C]5 O 
. [C]. O 

The [C]T [C]h [C]e O 
inclusion [C]i [C]n [C]c [C]l [C]u [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
sequences [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s O 
up [C]u [C]p O 
to [C]t [C]o O 
position [C]p [C]o [C]s [C]i [C]t [C]i [C]o [C]n O 
-115 [C]- [C]1 [C]1 [C]5 O 
provided [C]p [C]r [C]o [C]v [C]i [C]d [C]e [C]d O 
full [C]f [C]u [C]l [C]l O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
; [C]; O 
this [C]t [C]h [C]i [C]s O 
was [C]w [C]a [C]s O 
attributed [C]a [C]t [C]t [C]r [C]i [C]b [C]u [C]t [C]e [C]d O 
to [C]t [C]o O 
a [C]a O 
TATA [C]T [C]A [C]T [C]A S-DNA 
at [C]a [C]t O 
-32 [C]- [C]3 [C]2 O 
. [C]. O 

The [C]T [C]h [C]e O 
Sp1 [C]S [C]p [C]1 B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
at [C]a [C]t O 
position [C]p [C]o [C]s [C]i [C]t [C]i [C]o [C]n O 
+9 [C]+ [C]9 O 
was [C]w [C]a [C]s O 
key [C]k [C]e [C]y O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
protein.DNA [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]. [C]D [C]N [C]A O 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s O 
. [C]. O 

Mutation [C]M [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
the [C]t [C]h [C]e O 
Sp1 [C]S [C]p [C]1 B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
at [C]a [C]t O 
+9 [C]+ [C]9 O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
TATA [C]T [C]A [C]T [C]A S-DNA 
at [C]a [C]t O 
-32 [C]- [C]3 [C]2 O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
to [C]t [C]o O 
its [C]i [C]t [C]s O 
minimal [C]m [C]i [C]n [C]i [C]m [C]a [C]l O 
level [C]l [C]e [C]v [C]e [C]l O 
. [C]. O 

Supershift [C]S [C]u [C]p [C]e [C]r [C]s [C]h [C]i [C]f [C]t O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
no [C]n [C]o O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
anti-Sp1 [C]a [C]n [C]t [C]i [C]- [C]S [C]p [C]1 B-protein 
antibody [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y E-protein 
on [C]o [C]n O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
the [C]t [C]h [C]e O 
anti-Sp3 [C]a [C]n [C]t [C]i [C]- [C]S [C]p [C]3 B-protein 
antibody [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y E-protein 
had [C]h [C]a [C]d O 
a [C]a O 
strong [C]s [C]t [C]r [C]o [C]n [C]g O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
protein.DNA [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]. [C]D [C]N [C]A O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
Sp3 [C]S [C]p [C]3 S-protein 
is [C]i [C]s O 
one [C]o [C]n [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
main [C]m [C]a [C]i [C]n O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
this [C]t [C]h [C]i [C]s O 
Sp1 [C]S [C]p [C]1 B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
. [C]. O 

Chromatin [C]C [C]h [C]r [C]o [C]m [C]a [C]t [C]i [C]n O 
immunoprecipitation [C]i [C]m [C]m [C]u [C]n [C]o [C]p [C]r [C]e [C]c [C]i [C]p [C]i [C]t [C]a [C]t [C]i [C]o [C]n O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
supported [C]s [C]u [C]p [C]p [C]o [C]r [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
involvement [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
Sp1 [C]S [C]p [C]1 S-protein 
and [C]a [C]n [C]d O 
Sp3 [C]S [C]p [C]3 S-protein 
in [C]i [C]n O 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s O 
formed [C]f [C]o [C]r [C]m [C]e [C]d O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
MAT2B [C]M [C]A [C]T [C]2 [C]B B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

The [C]T [C]h [C]e O 
data [C]d [C]a [C]t [C]a O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
5'-untranslated [C]5 [C]' [C]- [C]u [C]n [C]t [C]r [C]a [C]n [C]s [C]l [C]a [C]t [C]e [C]d B-DNA 
sequences [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s E-DNA 
play [C]p [C]l [C]a [C]y O 
an [C]a [C]n O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
regulating [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
MAT2B [C]M [C]A [C]T [C]2 [C]B B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
and [C]a [C]n [C]d O 
identifies [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]s O 
the [C]t [C]h [C]e O 
Sp1 [C]S [C]p [C]1 B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
at [C]a [C]t O 
+9 [C]+ [C]9 O 
as [C]a [C]s O 
a [C]a O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
for [C]f [C]o [C]r O 
modulating [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
MAT2B [C]M [C]A [C]T [C]2 [C]B O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
a [C]a O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
that [C]t [C]h [C]a [C]t O 
can [C]c [C]a [C]n O 
have [C]h [C]a [C]v [C]e O 
a [C]a O 
major [C]m [C]a [C]j [C]o [C]r O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
AdoMet [C]A [C]d [C]o [C]M [C]e [C]t S-protein 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
. [C]. O 

Molecular [C]M [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
pathogenesis [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
influenza [C]i [C]n [C]f [C]l [C]u [C]e [C]n [C]z [C]a O 
A [C]A O 
virus [C]v [C]i [C]r [C]u [C]s O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
virus-induced [C]v [C]i [C]r [C]u [C]s [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Despite [C]D [C]e [C]s [C]p [C]i [C]t [C]e O 
vaccines [C]v [C]a [C]c [C]c [C]i [C]n [C]e [C]s O 
and [C]a [C]n [C]d O 
antiviral [C]a [C]n [C]t [C]i [C]v [C]i [C]r [C]a [C]l O 
substances [C]s [C]u [C]b [C]s [C]t [C]a [C]n [C]c [C]e [C]s O 
influenza [C]i [C]n [C]f [C]l [C]u [C]e [C]n [C]z [C]a O 
still [C]s [C]t [C]i [C]l [C]l O 
causes [C]c [C]a [C]u [C]s [C]e [C]s O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
morbidity [C]m [C]o [C]r [C]b [C]i [C]d [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
mortality [C]m [C]o [C]r [C]t [C]a [C]l [C]i [C]t [C]y O 
world [C]w [C]o [C]r [C]l [C]d O 
wide [C]w [C]i [C]d [C]e O 
. [C]. O 

Better [C]B [C]e [C]t [C]t [C]e [C]r O 
understanding [C]u [C]n [C]d [C]e [C]r [C]s [C]t [C]a [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
of [C]o [C]f O 
influenza [C]i [C]n [C]f [C]l [C]u [C]e [C]n [C]z [C]a O 
virus [C]v [C]i [C]r [C]u [C]s O 
replication [C]r [C]e [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
pathogenesis [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
host [C]h [C]o [C]s [C]t O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
is [C]i [C]s O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
more [C]m [C]o [C]r [C]e O 
efficient [C]e [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
means [C]m [C]e [C]a [C]n [C]s O 
of [C]o [C]f O 
prevention [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
influenza [C]i [C]n [C]f [C]l [C]u [C]e [C]n [C]z [C]a O 
. [C]. O 

Influenza [C]I [C]n [C]f [C]l [C]u [C]e [C]n [C]z [C]a O 
A [C]A O 
virus [C]v [C]i [C]r [C]u [C]s O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
replicates [C]r [C]e [C]p [C]l [C]i [C]c [C]a [C]t [C]e [C]s O 
in [C]i [C]n O 
epithelial [C]e [C]p [C]i [C]t [C]h [C]e [C]l [C]i [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
, [C], O 
regulates [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]s O 
host [C]h [C]o [C]s [C]t O 
cell [C]c [C]e [C]l [C]l O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
and [C]a [C]n [C]d O 
translational [C]t [C]r [C]a [C]n [C]s [C]l [C]a [C]t [C]i [C]o [C]n [C]a [C]l O 
systems [C]s [C]y [C]s [C]t [C]e [C]m [C]s O 
and [C]a [C]n [C]d O 
activates [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]s O 
, [C], O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
downregulates [C]d [C]o [C]w [C]n [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]s O 
apoptotic [C]a [C]p [C]o [C]p [C]t [C]o [C]t [C]i [C]c O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
. [C]. O 

Influenza [C]I [C]n [C]f [C]l [C]u [C]e [C]n [C]z [C]a O 
A [C]A O 
virus [C]v [C]i [C]r [C]u [C]s O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
chemotactic [C]c [C]h [C]e [C]m [C]o [C]t [C]a [C]c [C]t [C]i [C]c O 
( [C]( O 
RANTES [C]R [C]A [C]N [C]T [C]E [C]S S-protein 
, [C], O 
MIP-1 [C]M [C]I [C]P [C]- [C]1 B-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
, [C], O 
MCP-1 [C]M [C]C [C]P [C]- [C]1 S-protein 
, [C], O 
MCP-3 [C]M [C]C [C]P [C]- [C]3 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
IP-10 [C]I [C]P [C]- [C]1 [C]0 S-protein 
) [C]) O 
, [C], O 
pro-inflammatory [C]p [C]r [C]o [C]- [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
( [C]( O 
IL-1 [C]I [C]L [C]- [C]1 B-protein 
beta [C]b [C]e [C]t [C]a E-protein 
, [C], O 
IL-6 [C]I [C]L [C]- [C]6 S-protein 
, [C], O 
IL-18 [C]I [C]L [C]- [C]1 [C]8 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
antiviral [C]a [C]n [C]t [C]i [C]v [C]i [C]r [C]a [C]l B-protein 
( [C]( I-protein 
IFN-alpha/beta [C]I [C]F [C]N [C]- [C]a [C]l [C]p [C]h [C]a [C]/ [C]b [C]e [C]t [C]a I-protein 
) [C]) I-protein 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s E-protein 
. [C]. O 

Cytokine [C]C [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
is [C]i [C]s O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
, [C], O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
, [C], O 
STAT [C]S [C]T [C]A [C]T S-protein 
and [C]a [C]n [C]d O 
IRF [C]I [C]R [C]F B-protein 
signal [C]s [C]i [C]g [C]n [C]a [C]l I-protein 
transducing [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]i [C]n [C]g I-protein 
molecules [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]s E-protein 
in [C]i [C]n O 
influenza [C]i [C]n [C]f [C]l [C]u [C]e [C]n [C]z [C]a O 
A [C]A O 
virus-infected [C]v [C]i [C]r [C]u [C]s [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
cells [C]c [C]e [C]l [C]l [C]s O 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
upregulating [C]u [C]p [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
influenza [C]i [C]n [C]f [C]l [C]u [C]e [C]n [C]z [C]a O 
A [C]A O 
virus [C]v [C]i [C]r [C]u [C]s O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
activates [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]s O 
caspase-1 [C]c [C]a [C]s [C]p [C]a [C]s [C]e [C]- [C]1 B-protein 
enzyme [C]e [C]n [C]z [C]y [C]m [C]e E-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
proteolytic [C]p [C]r [C]o [C]t [C]e [C]o [C]l [C]y [C]t [C]i [C]c O 
processing [C]p [C]r [C]o [C]c [C]e [C]s [C]s [C]i [C]n [C]g O 
of [C]o [C]f O 
proIL-1 [C]p [C]r [C]o [C]I [C]L [C]- [C]1 B-protein 
beta [C]b [C]e [C]t [C]a E-protein 
and [C]a [C]n [C]d O 
proIL-18 [C]p [C]r [C]o [C]I [C]L [C]- [C]1 [C]8 S-protein 
into [C]i [C]n [C]t [C]o O 
their [C]t [C]h [C]e [C]i [C]r O 
biologically [C]b [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l [C]l [C]y O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
forms [C]f [C]o [C]r [C]m [C]s O 
. [C]. O 

Influenza [C]I [C]n [C]f [C]l [C]u [C]e [C]n [C]z [C]a O 
A [C]A O 
virus-induced [C]v [C]i [C]r [C]u [C]s [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
IFN-alpha/beta [C]I [C]F [C]N [C]- [C]a [C]l [C]p [C]h [C]a [C]/ [C]b [C]e [C]t [C]a S-protein 
is [C]i [C]s O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
in [C]i [C]n O 
host [C]h [C]o [C]s [C]t O 
's [C]' [C]s O 
antiviral [C]a [C]n [C]t [C]i [C]v [C]i [C]r [C]a [C]l O 
defence [C]d [C]e [C]f [C]e [C]n [C]c [C]e O 
by [C]b [C]y O 
activating [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
antiviral [C]a [C]n [C]t [C]i [C]v [C]i [C]r [C]a [C]l B-DNA 
Mx [C]M [C]x E-DNA 
, [C], O 
PKR [C]P [C]K [C]R B-DNA 
and [C]a [C]n [C]d I-DNA 
oligoadenylate [C]o [C]l [C]i [C]g [C]o [C]a [C]d [C]e [C]n [C]y [C]l [C]a [C]t [C]e I-DNA 
synthetase [C]s [C]y [C]n [C]t [C]h [C]e [C]t [C]a [C]s [C]e I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
. [C]. O 

IFN-alpha/beta [C]I [C]F [C]N [C]- [C]a [C]l [C]p [C]h [C]a [C]/ [C]b [C]e [C]t [C]a S-protein 
also [C]a [C]l [C]s [C]o O 
prolongs [C]p [C]r [C]o [C]l [C]o [C]n [C]g [C]s O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
survival [C]s [C]u [C]r [C]v [C]i [C]v [C]a [C]l O 
, [C], O 
upregulates [C]u [C]p [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]s O 
IL-12 [C]I [C]L [C]- [C]1 [C]2 O 
and [C]a [C]n [C]d O 
IL-18 [C]I [C]L [C]- [C]1 [C]8 O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
together [C]t [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
with [C]w [C]i [C]t [C]h O 
IL-18 [C]I [C]L [C]- [C]1 [C]8 S-protein 
stimulates [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]s O 
NK [C]N [C]K B-cell_type 
and [C]a [C]n [C]d I-cell_type 
T [C]T I-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
Th1-type [C]T [C]h [C]1 [C]- [C]t [C]y [C]p [C]e O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
. [C]. O 

Comparison [C]C [C]o [C]m [C]p [C]a [C]r [C]i [C]s [C]o [C]n O 
of [C]o [C]f O 
hprt [C]h [C]p [C]r [C]t O 
and [C]a [C]n [C]d O 
lacI [C]l [C]a [C]c [C]I O 
mutant [C]m [C]u [C]t [C]a [C]n [C]t O 
frequency [C]f [C]r [C]e [C]q [C]u [C]e [C]n [C]c [C]y O 
with [C]w [C]i [C]t [C]h O 
DNA [C]D [C]N [C]A O 
adduct [C]a [C]d [C]d [C]u [C]c [C]t O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
N-hydroxy-2-acetylaminofluorene-treated [C]N [C]- [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]- [C]2 [C]- [C]a [C]c [C]e [C]t [C]y [C]l [C]a [C]m [C]i [C]n [C]o [C]f [C]l [C]u [C]o [C]r [C]e [C]n [C]e [C]- [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
Big [C]B [C]i [C]g O 
Blue [C]B [C]l [C]u [C]e O 
rats [C]r [C]a [C]t [C]s O 
. [C]. O 

N-Hydroxy-2-acetylaminofluorene [C]N [C]- [C]H [C]y [C]d [C]r [C]o [C]x [C]y [C]- [C]2 [C]- [C]a [C]c [C]e [C]t [C]y [C]l [C]a [C]m [C]i [C]n [C]o [C]f [C]l [C]u [C]o [C]r [C]e [C]n [C]e O 
( [C]( O 
N-OH-AAF [C]N [C]- [C]O [C]H [C]- [C]A [C]A [C]F O 
) [C]) O 
is [C]i [C]s O 
the [C]t [C]h [C]e O 
proximate [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e O 
carcinogenic [C]c [C]a [C]r [C]c [C]i [C]n [C]o [C]g [C]e [C]n [C]i [C]c O 
metabolite [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]t [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
powerful [C]p [C]o [C]w [C]e [C]r [C]f [C]u [C]l O 
rat [C]r [C]a [C]t O 
liver [C]l [C]i [C]v [C]e [C]r O 
carcinogen [C]c [C]a [C]r [C]c [C]i [C]n [C]o [C]g [C]e [C]n O 
2-acetylaminofluorene [C]2 [C]- [C]a [C]c [C]e [C]t [C]y [C]l [C]a [C]m [C]i [C]n [C]o [C]f [C]l [C]u [C]o [C]r [C]e [C]n [C]e O 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
, [C], O 
transgenic [C]t [C]r [C]a [C]n [C]s [C]g [C]e [C]n [C]i [C]c O 
Big [C]B [C]i [C]g O 
Blue [C]B [C]l [C]u [C]e O 
( [C]( O 
R [C]R O 
) [C]) O 
rats [C]r [C]a [C]t [C]s O 
were [C]w [C]e [C]r [C]e O 
used [C]u [C]s [C]e [C]d O 
to [C]t [C]o O 
examine [C]e [C]x [C]a [C]m [C]i [C]n [C]e O 
the [C]t [C]h [C]e O 
relationship [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n [C]s [C]h [C]i [C]p O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
mutagenicity [C]m [C]u [C]t [C]a [C]g [C]e [C]n [C]i [C]c [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
DNA [C]D [C]N [C]A O 
adduct [C]a [C]d [C]d [C]u [C]c [C]t O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
N-OH-AAF [C]N [C]- [C]O [C]H [C]- [C]A [C]A [C]F O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
liver [C]l [C]i [C]v [C]e [C]r O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
that [C]t [C]h [C]a [C]t O 
in [C]i [C]n O 
nontarget [C]n [C]o [C]n [C]t [C]a [C]r [C]g [C]e [C]t O 
tissues [C]t [C]i [C]s [C]s [C]u [C]e [C]s O 
. [C]. O 

Male [C]M [C]a [C]l [C]e O 
rats [C]r [C]a [C]t [C]s O 
were [C]w [C]e [C]r [C]e O 
given [C]g [C]i [C]v [C]e [C]n O 
one [C]o [C]n [C]e O 
, [C], O 
two [C]t [C]w [C]o O 
, [C], O 
or [C]o [C]r O 
four [C]f [C]o [C]u [C]r O 
doses [C]d [C]o [C]s [C]e [C]s O 
of [C]o [C]f O 
25 [C]2 [C]5 O 
mg [C]m [C]g O 
N-OH-AAF/kg [C]N [C]- [C]O [C]H [C]- [C]A [C]A [C]F [C]/ [C]k [C]g O 
body [C]b [C]o [C]d [C]y O 
weight [C]w [C]e [C]i [C]g [C]h [C]t O 
by [C]b [C]y O 
i.p. [C]i [C]. [C]p [C]. O 
injection [C]i [C]n [C]j [C]e [C]c [C]t [C]i [C]o [C]n O 
at [C]a [C]t O 
4-day [C]4 [C]- [C]d [C]a [C]y O 
intervals [C]i [C]n [C]t [C]e [C]r [C]v [C]a [C]l [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
groups [C]g [C]r [C]o [C]u [C]p [C]s O 
of [C]o [C]f O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
and [C]a [C]n [C]d O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
rats [C]r [C]a [C]t [C]s O 
were [C]w [C]e [C]r [C]e O 
euthanized [C]e [C]u [C]t [C]h [C]a [C]n [C]i [C]z [C]e [C]d O 
up [C]u [C]p O 
to [C]t [C]o O 
10 [C]1 [C]0 O 
weeks [C]w [C]e [C]e [C]k [C]s O 
after [C]a [C]f [C]t [C]e [C]r O 
beginning [C]b [C]e [C]g [C]i [C]n [C]n [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
dosing [C]d [C]o [C]s [C]i [C]n [C]g O 
. [C]. O 

Mutant [C]M [C]u [C]t [C]a [C]n [C]t O 
frequencies [C]f [C]r [C]e [C]q [C]u [C]e [C]n [C]c [C]i [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
spleen [C]s [C]p [C]l [C]e [C]e [C]n B-DNA 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e I-DNA 
hprt [C]h [C]p [C]r [C]t I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
, [C], O 
and [C]a [C]n [C]d O 
lacI [C]l [C]a [C]c [C]I O 
mutant [C]m [C]u [C]t [C]a [C]n [C]t O 
frequencies [C]f [C]r [C]e [C]q [C]u [C]e [C]n [C]c [C]i [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
liver [C]l [C]i [C]v [C]e [C]r O 
and [C]a [C]n [C]d O 
spleen [C]s [C]p [C]l [C]e [C]e [C]n O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
. [C]. O 

At [C]A [C]t O 
6 [C]6 O 
weeks [C]w [C]e [C]e [C]k [C]s O 
after [C]a [C]f [C]t [C]e [C]r O 
beginning [C]b [C]e [C]g [C]i [C]n [C]n [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
dosing [C]d [C]o [C]s [C]i [C]n [C]g O 
, [C], O 
the [C]t [C]h [C]e O 
hprt [C]h [C]p [C]r [C]t O 
mutant [C]m [C]u [C]t [C]a [C]n [C]t O 
frequency [C]f [C]r [C]e [C]q [C]u [C]e [C]n [C]c [C]y O 
in [C]i [C]n O 
spleen [C]s [C]p [C]l [C]e [C]e [C]n B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
four-dose [C]f [C]o [C]u [C]r [C]- [C]d [C]o [C]s [C]e O 
group [C]g [C]r [C]o [C]u [C]p O 
was [C]w [C]a [C]s O 
16.5 [C]1 [C]6 [C]. [C]5 O 
x [C]x O 
10 [C]1 [C]0 O 
( [C]( O 
-6 [C]- [C]6 O 
) [C]) O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
3.2 [C]3 [C]. [C]2 O 
x [C]x O 
10 [C]1 [C]0 O 
( [C]( O 
-6 [C]- [C]6 O 
) [C]) O 
in [C]i [C]n O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
animals [C]a [C]n [C]i [C]m [C]a [C]l [C]s O 
. [C]. O 

Also [C]A [C]l [C]s [C]o O 
at [C]a [C]t O 
6 [C]6 O 
weeks [C]w [C]e [C]e [C]k [C]s O 
, [C], O 
rats [C]r [C]a [C]t [C]s O 
given [C]g [C]i [C]v [C]e [C]n O 
one [C]o [C]n [C]e O 
, [C], O 
two [C]t [C]w [C]o O 
, [C], O 
or [C]o [C]r O 
four [C]f [C]o [C]u [C]r O 
doses [C]d [C]o [C]s [C]e [C]s O 
of [C]o [C]f O 
N-OH-AAF [C]N [C]- [C]O [C]H [C]- [C]A [C]A [C]F O 
had [C]h [C]a [C]d O 
lacI [C]l [C]a [C]c [C]I O 
mutant [C]m [C]u [C]t [C]a [C]n [C]t O 
frequencies [C]f [C]r [C]e [C]q [C]u [C]e [C]n [C]c [C]i [C]e [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
liver [C]l [C]i [C]v [C]e [C]r O 
of [C]o [C]f O 
97.6 [C]9 [C]7 [C]. [C]6 O 
, [C], O 
155.6 [C]1 [C]5 [C]5 [C]. [C]6 O 
, [C], O 
and [C]a [C]n [C]d O 
406.8 [C]4 [C]0 [C]6 [C]. [C]8 O 
x [C]x O 
10 [C]1 [C]0 O 
( [C]( O 
-6 [C]- [C]6 O 
) [C]) O 
, [C], O 
respectively [C]r [C]e [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
, [C], O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
frequency [C]f [C]r [C]e [C]q [C]u [C]e [C]n [C]c [C]y O 
of [C]o [C]f O 
25.7 [C]2 [C]5 [C]. [C]7 O 
x [C]x O 
10 [C]1 [C]0 O 
( [C]( O 
-6 [C]- [C]6 O 
) [C]) O 
; [C]; O 
rats [C]r [C]a [C]t [C]s O 
given [C]g [C]i [C]v [C]e [C]n O 
four [C]f [C]o [C]u [C]r O 
doses [C]d [C]o [C]s [C]e [C]s O 
had [C]h [C]a [C]d O 
lacI [C]l [C]a [C]c [C]I O 
mutant [C]m [C]u [C]t [C]a [C]n [C]t O 
frequencies [C]f [C]r [C]e [C]q [C]u [C]e [C]n [C]c [C]i [C]e [C]s O 
in [C]i [C]n O 
spleen [C]s [C]p [C]l [C]e [C]e [C]n B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
of [C]o [C]f O 
55.8 [C]5 [C]5 [C]. [C]8 O 
x [C]x O 
10 [C]1 [C]0 O 
( [C]( O 
-6 [C]- [C]6 O 
) [C]) O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
frequency [C]f [C]r [C]e [C]q [C]u [C]e [C]n [C]c [C]y O 
of [C]o [C]f O 
20.4 [C]2 [C]0 [C]. [C]4 O 
x [C]x O 
10 [C]1 [C]0 O 
( [C]( O 
-6 [C]- [C]6 O 
) [C]) O 
. [C]. O 

Additional [C]A [C]d [C]d [C]i [C]t [C]i [C]o [C]n [C]a [C]l O 
rats [C]r [C]a [C]t [C]s O 
were [C]w [C]e [C]r [C]e O 
evaluated [C]e [C]v [C]a [C]l [C]u [C]a [C]t [C]e [C]d O 
for [C]f [C]o [C]r O 
DNA [C]D [C]N [C]A O 
adduct [C]a [C]d [C]d [C]u [C]c [C]t O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
liver [C]l [C]i [C]v [C]e [C]r O 
, [C], O 
spleen [C]s [C]p [C]l [C]e [C]e [C]n B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
, [C], O 
and [C]a [C]n [C]d O 
bone [C]b [C]o [C]n [C]e O 
marrow [C]m [C]a [C]r [C]r [C]o [C]w O 
by [C]b [C]y O 
( [C]( O 
32 [C]3 [C]2 O 
) [C]) O 
P-postlabeling [C]P [C]- [C]p [C]o [C]s [C]t [C]l [C]a [C]b [C]e [C]l [C]i [C]n [C]g O 
. [C]. O 

Adduct [C]A [C]d [C]d [C]u [C]c [C]t O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
was [C]w [C]a [C]s O 
conducted [C]c [C]o [C]n [C]d [C]u [C]c [C]t [C]e [C]d O 
1 [C]1 O 
day [C]d [C]a [C]y O 
after [C]a [C]f [C]t [C]e [C]r O 
one [C]o [C]n [C]e O 
, [C], O 
two [C]t [C]w [C]o O 
, [C], O 
and [C]a [C]n [C]d O 
four [C]f [C]o [C]u [C]r O 
treatments [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
N-OH-AAF [C]N [C]- [C]O [C]H [C]- [C]A [C]A [C]F O 
, [C], O 
5 [C]5 O 
days [C]d [C]a [C]y [C]s O 
after [C]a [C]f [C]t [C]e [C]r O 
one [C]o [C]n [C]e O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
, [C], O 
and [C]a [C]n [C]d O 
9 [C]9 O 
days [C]d [C]a [C]y [C]s O 
after [C]a [C]f [C]t [C]e [C]r O 
two [C]t [C]w [C]o O 
treatments [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t [C]s O 
. [C]. O 

N- [C]N [C]- O 
( [C]( O 
Deoxyguanosin-8-yl [C]D [C]e [C]o [C]x [C]y [C]g [C]u [C]a [C]n [C]o [C]s [C]i [C]n [C]- [C]8 [C]- [C]y [C]l O 
) [C]) O 
-2-aminofluorene [C]- [C]2 [C]- [C]a [C]m [C]i [C]n [C]o [C]f [C]l [C]u [C]o [C]r [C]e [C]n [C]e O 
was [C]w [C]a [C]s O 
the [C]t [C]h [C]e O 
major [C]m [C]a [C]j [C]o [C]r O 
DNA [C]D [C]N [C]A O 
adduct [C]a [C]d [C]d [C]u [C]c [C]t O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
in [C]i [C]n O 
all [C]a [C]l [C]l O 
the [C]t [C]h [C]e O 
tissues [C]t [C]i [C]s [C]s [C]u [C]e [C]s O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
. [C]. O 

Adduct [C]A [C]d [C]d [C]u [C]c [C]t O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
total [C]t [C]o [C]t [C]a [C]l O 
dose [C]d [C]o [C]s [C]e O 
to [C]t [C]o O 
maximum [C]m [C]a [C]x [C]i [C]m [C]u [C]m O 
values [C]v [C]a [C]l [C]u [C]e [C]s O 
in [C]i [C]n O 
samples [C]s [C]a [C]m [C]p [C]l [C]e [C]s O 
taken [C]t [C]a [C]k [C]e [C]n O 
1 [C]1 O 
day [C]d [C]a [C]y O 
after [C]a [C]f [C]t [C]e [C]r O 
two [C]t [C]w [C]o O 
doses [C]d [C]o [C]s [C]e [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
remained [C]r [C]e [C]m [C]a [C]i [C]n [C]e [C]d O 
essentially [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l [C]l [C]y O 
the [C]t [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
after [C]a [C]f [C]t [C]e [C]r O 
four [C]f [C]o [C]u [C]r O 
doses [C]d [C]o [C]s [C]e [C]s O 
. [C]. O 

In [C]I [C]n O 
samples [C]s [C]a [C]m [C]p [C]l [C]e [C]s O 
taken [C]t [C]a [C]k [C]e [C]n O 
after [C]a [C]f [C]t [C]e [C]r O 
four [C]f [C]o [C]u [C]r O 
doses [C]d [C]o [C]s [C]e [C]s O 
, [C], O 
adduct [C]a [C]d [C]d [C]u [C]c [C]t O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
were [C]w [C]e [C]r [C]e O 
103 [C]1 [C]0 [C]3 O 
, [C], O 
28 [C]2 [C]8 O 
, [C], O 
and [C]a [C]n [C]d O 
7 [C]7 O 
fmol/microg [C]f [C]m [C]o [C]l [C]/ [C]m [C]i [C]c [C]r [C]o [C]g O 
of [C]o [C]f O 
DNA [C]D [C]N [C]A O 
in [C]i [C]n O 
liver [C]l [C]i [C]v [C]e [C]r O 
, [C], O 
spleen [C]s [C]p [C]l [C]e [C]e [C]n B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
, [C], O 
and [C]a [C]n [C]d O 
bone [C]b [C]o [C]n [C]e O 
marrow [C]m [C]a [C]r [C]r [C]o [C]w O 
, [C], O 
respectively [C]r [C]e [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
extent [C]e [C]x [C]t [C]e [C]n [C]t O 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
DNA [C]D [C]N [C]A O 
adduct [C]a [C]d [C]d [C]u [C]c [C]t O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
mutant [C]m [C]u [C]t [C]a [C]n [C]t O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
correlates [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
organ [C]o [C]r [C]g [C]a [C]n O 
specificity [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]i [C]t [C]y O 
for [C]f [C]o [C]r O 
N-OH-AAF [C]N [C]- [C]O [C]H [C]- [C]A [C]A [C]F O 
carcinogenesis [C]c [C]a [C]r [C]c [C]i [C]n [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
rat [C]r [C]a [C]t O 
. [C]. O 

Environ. [C]E [C]n [C]v [C]i [C]r [C]o [C]n [C]. O 
Mol. [C]M [C]o [C]l [C]. O 
Mutagen. [C]M [C]u [C]t [C]a [C]g [C]e [C]n [C]. O 
37 [C]3 [C]7 O 
: [C]: O 
195-202 [C]1 [C]9 [C]5 [C]- [C]2 [C]0 [C]2 O 
, [C], O 
2001 [C]2 [C]0 [C]0 [C]1 O 
. [C]. O 

Published [C]P [C]u [C]b [C]l [C]i [C]s [C]h [C]e [C]d O 
2001 [C]2 [C]0 [C]0 [C]1 O 
Wiley-Liss [C]W [C]i [C]l [C]e [C]y [C]- [C]L [C]i [C]s [C]s O 
, [C], O 
Inc [C]I [C]n [C]c O 
. [C]. O 

Expression [C]E [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
Mad1 [C]M [C]a [C]d [C]1 S-protein 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
leads [C]l [C]e [C]a [C]d [C]s O 
to [C]t [C]o O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
thymic [C]t [C]h [C]y [C]m [C]i [C]c O 
cellularity [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
impaired [C]i [C]m [C]p [C]a [C]i [C]r [C]e [C]d O 
mitogen-induced [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

To [C]T [C]o O 
investigate [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e O 
Mad1 [C]M [C]a [C]d [C]1 S-protein 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
, [C], O 
transgenic [C]t [C]r [C]a [C]n [C]s [C]g [C]e [C]n [C]i [C]c O 
mice [C]m [C]i [C]c [C]e O 
were [C]w [C]e [C]r [C]e O 
generated [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
a [C]a O 
Mad1 [C]M [C]a [C]d [C]1 B-DNA 
transgene [C]t [C]r [C]a [C]n [C]s [C]g [C]e [C]n [C]e E-DNA 
in [C]i [C]n O 
T [C]T B-cell_type 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
under [C]u [C]n [C]d [C]e [C]r O 
the [C]t [C]h [C]e O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
proximal [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]l B-DNA 
lck [C]l [C]c [C]k I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

Thymus [C]T [C]h [C]y [C]m [C]u [C]s O 
size [C]s [C]i [C]z [C]e O 
in [C]i [C]n O 
lck-Mad1 [C]l [C]c [C]k [C]- [C]M [C]a [C]d [C]1 O 
transgenic [C]t [C]r [C]a [C]n [C]s [C]g [C]e [C]n [C]i [C]c O 
mice [C]m [C]i [C]c [C]e O 
is [C]i [C]s O 
drastically [C]d [C]r [C]a [C]s [C]t [C]i [C]c [C]a [C]l [C]l [C]y O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
although [C]a [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
representation [C]r [C]e [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
thymocyte [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e B-cell_type 
sub [C]s [C]u [C]b I-cell_type 
populations [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n [C]s E-cell_type 
appears [C]a [C]p [C]p [C]e [C]a [C]r [C]s O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
. [C]. O 

To [C]T [C]o O 
investigate [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e O 
more [C]m [C]o [C]r [C]e O 
closely [C]c [C]l [C]o [C]s [C]e [C]l [C]y O 
any [C]a [C]n [C]y O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
Mad1 [C]M [C]a [C]d [C]1 O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
on [C]o [C]n O 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
, [C], O 
we [C]w [C]e O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
thymic [C]t [C]h [C]y [C]m [C]i [C]c O 
selection [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]o [C]n O 
using [C]u [C]s [C]i [C]n [C]g O 
MHC [C]M [C]H [C]C O 
class [C]c [C]l [C]a [C]s [C]s O 
I-restricted [C]I [C]- [C]r [C]e [C]s [C]t [C]r [C]i [C]c [C]t [C]e [C]d O 
H-Y-TCR [C]H [C]- [C]Y [C]- [C]T [C]C [C]R O 
transgenic [C]t [C]r [C]a [C]n [C]s [C]g [C]e [C]n [C]i [C]c O 
mice [C]m [C]i [C]c [C]e O 
. [C]. O 

Mad1 [C]M [C]a [C]d [C]1 O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
reduces [C]r [C]e [C]d [C]u [C]c [C]e [C]s O 
the [C]t [C]h [C]e O 
efficiency [C]e [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
of [C]o [C]f O 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
selection [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
and [C]a [C]n [C]d O 
splenic [C]s [C]p [C]l [C]e [C]n [C]i [C]c B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
lck-Mad1 [C]l [C]c [C]k [C]- [C]M [C]a [C]d [C]1 O 
transgenic [C]t [C]r [C]a [C]n [C]s [C]g [C]e [C]n [C]i [C]c O 
mice [C]m [C]i [C]c [C]e O 
display [C]d [C]i [C]s [C]p [C]l [C]a [C]y O 
a [C]a O 
profound [C]p [C]r [C]o [C]f [C]o [C]u [C]n [C]d O 
proliferative [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
defect [C]d [C]e [C]f [C]e [C]c [C]t O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
PMA/Ionomycin [C]P [C]M [C]A [C]/ [C]I [C]o [C]n [C]o [C]m [C]y [C]c [C]i [C]n O 
or [C]o [C]r O 
immobilized [C]i [C]m [C]m [C]o [C]b [C]i [C]l [C]i [C]z [C]e [C]d B-protein 
anti-CD3/CD28 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]3 [C]/ [C]C [C]D [C]2 [C]8 I-protein 
antibody [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y E-protein 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
proliferative [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
defect [C]d [C]e [C]f [C]e [C]c [C]t O 
is [C]i [C]s O 
not [C]n [C]o [C]t O 
reversed [C]r [C]e [C]v [C]e [C]r [C]s [C]e [C]d O 
by [C]b [C]y O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
exogenous [C]e [C]x [C]o [C]g [C]e [C]n [C]o [C]u [C]s B-protein 
IL-2 [C]I [C]L [C]- [C]2 E-protein 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
p53-independent [C]p [C]5 [C]3 [C]- [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
. [C]. O 

The [C]T [C]h [C]e O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
caused [C]c [C]a [C]u [C]s [C]e [C]d O 
by [C]b [C]y O 
Mad1 [C]M [C]a [C]d [C]1 S-protein 
is [C]i [C]s O 
overcome [C]o [C]v [C]e [C]r [C]c [C]o [C]m [C]e O 
by [C]b [C]y O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
active [C]a [C]c [C]t [C]i [C]v [C]e B-protein 
c-Myc [C]c [C]- [C]M [C]y [C]c E-protein 
. [C]. O 

Differential [C]D [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l O 
requirement [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]m [C]e [C]n [C]t O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
PU.1 [C]P [C]U [C]. [C]1 E-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
generation [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
natural [C]n [C]a [C]t [C]u [C]r [C]a [C]l B-cell_type 
killer [C]k [C]i [C]l [C]l [C]e [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
versus [C]v [C]e [C]r [C]s [C]u [C]s O 
B [C]B B-cell_type 
and [C]a [C]n [C]d I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

PU.1 [C]P [C]U [C]. [C]1 S-protein 
is [C]i [C]s O 
a [C]a O 
member [C]m [C]e [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Ets [C]E [C]t [C]s B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y I-protein 
of [C]o [C]f I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d B-cell_line 
and [C]a [C]n [C]d I-cell_line 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lineages [C]l [C]i [C]n [C]e [C]a [C]g [C]e [C]s E-cell_line 
, [C], O 
but [C]b [C]u [C]t O 
its [C]i [C]t [C]s O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
natural [C]n [C]a [C]t [C]u [C]r [C]a [C]l B-cell_type 
killer [C]k [C]i [C]l [C]l [C]e [C]r I-cell_type 
( [C]( I-cell_type 
NK [C]N [C]K I-cell_type 
) [C]) I-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
is [C]i [C]s O 
not [C]n [C]o [C]t O 
known [C]k [C]n [C]o [C]w [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
study [C]s [C]t [C]u [C]d [C]y O 
shows [C]s [C]h [C]o [C]w [C]s O 
that [C]t [C]h [C]a [C]t O 
PU.1 [C]P [C]U [C]. [C]1 S-protein 
is [C]i [C]s O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
NK [C]N [C]K B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
, [C], O 
on [C]o [C]n O 
cell [C]c [C]e [C]l [C]l O 
transfer [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]r O 
into [C]i [C]n [C]t [C]o O 
alymphoid [C]a [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d O 
Rag2/gammac [C]R [C]a [C]g [C]2 [C]/ [C]g [C]a [C]m [C]m [C]a [C]c O 
( [C]( O 
-/- [C]- [C]/ [C]- O 
) [C]) O 
mice [C]m [C]i [C]c [C]e O 
, [C], O 
hematopoietic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c B-cell_type 
progenitors [C]p [C]r [C]o [C]g [C]e [C]n [C]i [C]t [C]o [C]r [C]s E-cell_type 
of [C]o [C]f O 
PU.1 [C]P [C]U [C]. [C]1 B-cell_type 
( [C]( I-cell_type 
-/- [C]- [C]/ [C]- I-cell_type 
) [C]) I-cell_type 
fetal [C]f [C]e [C]t [C]a [C]l I-cell_type 
liver [C]l [C]i [C]v [C]e [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
could [C]c [C]o [C]u [C]l [C]d O 
generate [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]e O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
NK [C]N [C]K B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
B [C]B B-cell_type 
or [C]o [C]r I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Nevertheless [C]N [C]e [C]v [C]e [C]r [C]t [C]h [C]e [C]l [C]e [C]s [C]s O 
, [C], O 
the [C]t [C]h [C]e O 
numbers [C]n [C]u [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
bone [C]b [C]o [C]n [C]e B-cell_type 
marrow [C]m [C]a [C]r [C]r [C]o [C]w I-cell_type 
NK [C]N [C]K I-cell_type 
cell [C]c [C]e [C]l [C]l I-cell_type 
precursors [C]p [C]r [C]e [C]c [C]u [C]r [C]s [C]o [C]r [C]s E-cell_type 
and [C]a [C]n [C]d O 
splenic [C]s [C]p [C]l [C]e [C]n [C]i [C]c B-cell_type 
mature [C]m [C]a [C]t [C]u [C]r [C]e I-cell_type 
NK [C]N [C]K I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
. [C]. O 

Moreover [C]M [C]o [C]r [C]e [C]o [C]v [C]e [C]r O 
, [C], O 
PU.1 [C]P [C]U [C]. [C]1 B-cell_type 
( [C]( I-cell_type 
-/- [C]- [C]/ [C]- I-cell_type 
) [C]) I-cell_type 
NK [C]N [C]K I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
displayed [C]d [C]i [C]s [C]p [C]l [C]a [C]y [C]e [C]d O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
for [C]f [C]o [C]r O 
stem [C]s [C]t [C]e [C]m B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
and [C]a [C]n [C]d O 
interleukin [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n B-protein 
( [C]( I-protein 
IL [C]I [C]L I-protein 
) [C]) I-protein 
-7 [C]- [C]7 E-protein 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
a [C]a O 
nonredundant [C]n [C]o [C]n [C]r [C]e [C]d [C]u [C]n [C]d [C]a [C]n [C]t O 
role [C]r [C]o [C]l [C]e O 
for [C]f [C]o [C]r O 
PU.1 [C]P [C]U [C]. [C]1 S-protein 
in [C]i [C]n O 
regulating [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e B-DNA 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
NK [C]N [C]K O 
cell [C]c [C]e [C]l [C]l O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
. [C]. O 

PU.1 [C]P [C]U [C]. [C]1 B-cell_type 
( [C]( I-cell_type 
-/- [C]- [C]/ [C]- I-cell_type 
) [C]) I-cell_type 
NK [C]N [C]K I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
also [C]a [C]l [C]s [C]o O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
defective [C]d [C]e [C]f [C]e [C]c [C]t [C]i [C]v [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y O 
and [C]a [C]n [C]d O 
activating [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]n [C]g O 
members [C]m [C]e [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Ly49 [C]L [C]y [C]4 [C]9 B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y E-protein 
and [C]a [C]n [C]d O 
failed [C]f [C]a [C]i [C]l [C]e [C]d O 
to [C]t [C]o O 
proliferate [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]e O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
and [C]a [C]n [C]d O 
IL-12 [C]I [C]L [C]- [C]1 [C]2 S-protein 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
despite [C]d [C]e [C]s [C]p [C]i [C]t [C]e O 
the [C]t [C]h [C]e O 
less [C]l [C]e [C]s [C]s O 
stringent [C]s [C]t [C]r [C]i [C]n [C]g [C]e [C]n [C]t O 
requirement [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]m [C]e [C]n [C]t O 
for [C]f [C]o [C]r O 
PU.1 [C]P [C]U [C]. [C]1 S-protein 
in [C]i [C]n O 
NK [C]N [C]K O 
cell [C]c [C]e [C]l [C]l O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
B [C]B B-cell_type 
and [C]a [C]n [C]d I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
PU.1 [C]P [C]U [C]. [C]1 S-protein 
regulates [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]s O 
NK [C]N [C]K O 
cell [C]c [C]e [C]l [C]l O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
homeostasis [C]h [C]o [C]m [C]e [C]o [C]s [C]t [C]a [C]s [C]i [C]s O 
. [C]. O 

Benzene-extracted [C]B [C]e [C]n [C]z [C]e [C]n [C]e [C]- [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]e [C]d O 
components [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t [C]s O 
are [C]a [C]r [C]e O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
major [C]m [C]a [C]j [C]o [C]r O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
diesel [C]d [C]i [C]e [C]s [C]e [C]l O 
exhaust [C]e [C]x [C]h [C]a [C]u [C]s [C]t O 
particles [C]p [C]a [C]r [C]t [C]i [C]c [C]l [C]e [C]s O 
: [C]: O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
interleukin-8 [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]8 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
bronchial [C]b [C]r [C]o [C]n [C]c [C]h [C]i [C]a [C]l I-cell_type 
epithelial [C]e [C]p [C]i [C]t [C]h [C]e [C]l [C]i [C]a [C]l I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Epidemiologic [C]E [C]p [C]i [C]d [C]e [C]m [C]i [C]o [C]l [C]o [C]g [C]i [C]c O 
and [C]a [C]n [C]d O 
experimental [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]a [C]l O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
diesel [C]d [C]i [C]e [C]s [C]e [C]l O 
exhaust [C]e [C]x [C]h [C]a [C]u [C]s [C]t O 
particles [C]p [C]a [C]r [C]t [C]i [C]c [C]l [C]e [C]s O 
( [C]( O 
DEPs [C]D [C]E [C]P [C]s O 
) [C]) O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
related [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
to [C]t [C]o O 
increasing [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]i [C]n [C]g O 
respiratory [C]r [C]e [C]s [C]p [C]i [C]r [C]a [C]t [C]o [C]r [C]y O 
mortality [C]m [C]o [C]r [C]t [C]a [C]l [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
morbidity [C]m [C]o [C]r [C]b [C]i [C]d [C]i [C]t [C]y O 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
shown [C]s [C]h [C]o [C]w [C]n O 
that [C]t [C]h [C]a [C]t O 
DEPs [C]D [C]E [C]P [C]s O 
augmented [C]a [C]u [C]g [C]m [C]e [C]n [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y B-protein 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s E-protein 
by [C]b [C]y O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
airway [C]a [C]i [C]r [C]w [C]a [C]y I-cell_type 
epithelial [C]e [C]p [C]i [C]t [C]h [C]e [C]l [C]i [C]a [C]l I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
. [C]. O 

To [C]T [C]o O 
better [C]b [C]e [C]t [C]t [C]e [C]r O 
understand [C]u [C]n [C]d [C]e [C]r [C]s [C]t [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
of [C]o [C]f O 
their [C]t [C]h [C]e [C]i [C]r O 
proinflammatory [C]p [C]r [C]o [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
activities [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]i [C]e [C]s O 
, [C], O 
we [C]w [C]e O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
the [C]t [C]h [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
components [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t [C]s O 
extracted [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
DEPs [C]D [C]E [C]P [C]s O 
on [C]o [C]n O 
interleukin [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n O 
( [C]( O 
IL [C]I [C]L O 
) [C]) O 
-8 [C]- [C]8 O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
bronchial [C]b [C]r [C]o [C]n [C]c [C]h [C]i [C]a [C]l I-cell_line 
epithelial [C]e [C]p [C]i [C]t [C]h [C]e [C]l [C]i [C]a [C]l I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e I-cell_line 
BEAS-2B [C]B [C]E [C]A [C]S [C]- [C]2 [C]B E-cell_line 
and [C]a [C]n [C]d O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
airway [C]a [C]i [C]r [C]w [C]a [C]y I-cell_type 
epithelial [C]e [C]p [C]i [C]t [C]h [C]e [C]l [C]i [C]a [C]l I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
very [C]v [C]e [C]r [C]y O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l O 
airways [C]a [C]i [C]r [C]w [C]a [C]y [C]s O 
by [C]b [C]y O 
an [C]a [C]n O 
ultrathin [C]u [C]l [C]t [C]r [C]a [C]t [C]h [C]i [C]n O 
bronchoscope [C]b [C]r [C]o [C]n [C]c [C]h [C]o [C]s [C]c [C]o [C]p [C]e O 
. [C]. O 

We [C]W [C]e O 
used [C]u [C]s [C]e [C]d O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
agents [C]a [C]g [C]e [C]n [C]t [C]s O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
on [C]o [C]n O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
in [C]i [C]n O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
the [C]t [C]h [C]e O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
C [C]C O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
staurosporin [C]s [C]t [C]a [C]u [C]r [C]o [C]s [C]p [C]o [C]r [C]i [C]n O 
, [C], O 
antioxidant [C]a [C]n [C]t [C]i [C]o [C]x [C]i [C]d [C]a [C]n [C]t O 
agents [C]a [C]g [C]e [C]n [C]t [C]s O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
N-acetyl [C]N [C]- [C]a [C]c [C]e [C]t [C]y [C]l O 
cysteine [C]c [C]y [C]s [C]t [C]e [C]i [C]n [C]e O 
( [C]( O 
NAC [C]N [C]A [C]C O 
) [C]) O 
and [C]a [C]n [C]d O 
pyrrolidine [C]p [C]y [C]r [C]r [C]o [C]l [C]i [C]d [C]i [C]n [C]e O 
dithiocarbamate [C]d [C]i [C]t [C]h [C]i [C]o [C]c [C]a [C]r [C]b [C]a [C]m [C]a [C]t [C]e O 
( [C]( O 
PDTC [C]P [C]D [C]T [C]C O 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
p38 [C]p [C]3 [C]8 B-protein 
mitogen-activated [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
( [C]( O 
MAPK [C]M [C]A [C]P [C]K S-protein 
) [C]) O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
SB203580 [C]S [C]B [C]2 [C]0 [C]3 [C]5 [C]8 [C]0 O 
. [C]. O 

Benzene-extracted [C]B [C]e [C]n [C]z [C]e [C]n [C]e [C]- [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]e [C]d O 
components [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t [C]s O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
mimicking [C]m [C]i [C]m [C]i [C]c [C]k [C]i [C]n [C]g O 
DEPs [C]D [C]E [C]P [C]s O 
on [C]o [C]n O 
IL-8 [C]I [C]L [C]- [C]8 O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
release [C]r [C]e [C]l [C]e [C]a [C]s [C]e O 
of [C]o [C]f O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
( [C]( O 
IL-8 [C]I [C]L [C]- [C]8 S-protein 
; [C]; O 
granulocyte [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e B-protein 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e I-protein 
colony-stimulating [C]c [C]o [C]l [C]o [C]n [C]y [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]n [C]g I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
; [C]; O 
and [C]a [C]n [C]d O 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
on [C]o [C]n O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
and [C]a [C]n [C]d O 
secreted [C]s [C]e [C]c [C]r [C]e [C]t [C]e [C]d O 
) [C]) O 
and [C]a [C]n [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
( [C]( O 
NF [C]N [C]F O 
) [C]) O 
-kappa [C]- [C]k [C]a [C]p [C]p [C]a O 
B [C]B O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

We [C]W [C]e O 
also [C]a [C]l [C]s [C]o O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
NAC [C]N [C]A [C]C O 
, [C], O 
PDTC [C]P [C]D [C]T [C]C O 
, [C], O 
and [C]a [C]n [C]d O 
SB203580 [C]S [C]B [C]2 [C]0 [C]3 [C]5 [C]8 [C]0 O 
suppressed [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
activities [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]i [C]e [C]s O 
of [C]o [C]f O 
DEPs [C]D [C]E [C]P [C]s O 
and [C]a [C]n [C]d O 
their [C]t [C]h [C]e [C]i [C]r O 
benzene [C]b [C]e [C]n [C]z [C]e [C]n [C]e O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
roles [C]r [C]o [C]l [C]e [C]s O 
of [C]o [C]f O 
oxidants-mediated [C]o [C]x [C]i [C]d [C]a [C]n [C]t [C]s [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a O 
B [C]B O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
p38MAPK [C]p [C]3 [C]8 [C]M [C]A [C]P [C]K S-protein 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
. [C]. O 

Finally [C]F [C]i [C]n [C]a [C]l [C]l [C]y O 
, [C], O 
benzo [C]b [C]e [C]n [C]z [C]o O 
[ [C][ O 
a [C]a O 
] [C]] O 
pyrene [C]p [C]y [C]r [C]e [C]n [C]e O 
, [C], O 
one [C]o [C]n [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
compounds [C]c [C]o [C]m [C]p [C]o [C]u [C]n [C]d [C]s O 
included [C]i [C]n [C]c [C]l [C]u [C]d [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
benzene [C]b [C]e [C]n [C]z [C]e [C]n [C]e O 
component [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t O 
, [C], O 
replicated [C]r [C]e [C]p [C]l [C]i [C]c [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
activities [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]i [C]e [C]s O 
shown [C]s [C]h [C]o [C]w [C]n O 
by [C]b [C]y O 
DEPs [C]D [C]E [C]P [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
PPAR [C]P [C]P [C]A [C]R I-protein 
gamma [C]g [C]a [C]m [C]m [C]a E-protein 
is [C]i [C]s O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
by [C]b [C]y O 
mouse [C]m [C]o [C]u [C]s [C]e B-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
PPAR [C]P [C]P [C]A [C]R O 
gamma [C]g [C]a [C]m [C]m [C]a O 
agonists [C]a [C]g [C]o [C]n [C]i [C]s [C]t [C]s O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
. [C]. O 

Peroxisome [C]P [C]e [C]r [C]o [C]x [C]i [C]s [C]o [C]m [C]e B-protein 
proliferator-activated [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]o [C]r [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
( [C]( I-protein 
PPAR [C]P [C]P [C]A [C]R I-protein 
) [C]) I-protein 
-gamma [C]- [C]g [C]a [C]m [C]m [C]a E-protein 
is [C]i [C]s O 
a [C]a O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
that [C]t [C]h [C]a [C]t O 
serves [C]s [C]e [C]r [C]v [C]e [C]s O 
as [C]a [C]s O 
a [C]a O 
trans [C]t [C]r [C]a [C]n [C]s O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
to [C]t [C]o O 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
lipid [C]l [C]i [C]p [C]i [C]d O 
metabolism [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]s [C]m O 
. [C]. O 

Intense [C]I [C]n [C]t [C]e [C]n [C]s [C]e O 
interest [C]i [C]n [C]t [C]e [C]r [C]e [C]s [C]t O 
is [C]i [C]s O 
focused [C]f [C]o [C]c [C]u [C]s [C]e [C]d O 
on [C]o [C]n O 
PPAR-gamma [C]P [C]P [C]A [C]R [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
and [C]a [C]n [C]d O 
its [C]i [C]t [C]s O 
ligands [C]l [C]i [C]g [C]a [C]n [C]d [C]s O 
owing [C]o [C]w [C]i [C]n [C]g O 
to [C]t [C]o O 
its [C]i [C]t [C]s O 
putative [C]p [C]u [C]t [C]a [C]t [C]i [C]v [C]e O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
adipocyte [C]a [C]d [C]i [C]p [C]o [C]c [C]y [C]t [C]e O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Little [C]L [C]i [C]t [C]t [C]l [C]e O 
is [C]i [C]s O 
known [C]k [C]n [C]o [C]w [C]n O 
, [C], O 
however [C]h [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
about [C]a [C]b [C]o [C]u [C]t O 
the [C]t [C]h [C]e O 
functions [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
PPAR-gamma [C]P [C]P [C]A [C]R [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
, [C], O 
especially [C]e [C]s [C]p [C]e [C]c [C]i [C]a [C]l [C]l [C]y O 
in [C]i [C]n O 
T [C]T B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

We [C]W [C]e O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
both [C]b [C]o [C]t [C]h O 
naive [C]n [C]a [C]i [C]v [C]e B-cell_type 
and [C]a [C]n [C]d I-cell_type 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d I-cell_type 
ovalbumin-specific [C]o [C]v [C]a [C]l [C]b [C]u [C]m [C]i [C]n [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
DO11.10-transgenic [C]D [C]O [C]1 [C]1 [C]. [C]1 [C]0 [C]- [C]t [C]r [C]a [C]n [C]s [C]g [C]e [C]n [C]i [C]c O 
mice [C]m [C]i [C]c [C]e O 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
PPAR-gamma [C]P [C]P [C]A [C]R [C]- [C]g [C]a [C]m [C]m [C]a S-RNA 
mRNA [C]m [C]R [C]N [C]A O 
and [C]a [C]n [C]d O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
. [C]. O 

In [C]I [C]n O 
order [C]o [C]r [C]d [C]e [C]r O 
to [C]t [C]o O 
determine [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e O 
the [C]t [C]h [C]e O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
PPAR-gamma [C]P [C]P [C]A [C]R [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
, [C], O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
phorbol [C]p [C]h [C]o [C]r [C]b [C]o [C]l O 
12-myristate [C]1 [C]2 [C]- [C]m [C]y [C]r [C]i [C]s [C]t [C]a [C]t [C]e O 
13-acetate [C]1 [C]3 [C]- [C]a [C]c [C]e [C]t [C]a [C]t [C]e O 
and [C]a [C]n [C]d O 
ionomycin [C]i [C]o [C]n [C]o [C]m [C]y [C]c [C]i [C]n O 
or [C]o [C]r O 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n O 
and [C]a [C]n [C]d O 
antigen-presenting [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]- [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]i [C]n [C]g B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Simultaneous [C]S [C]i [C]m [C]u [C]l [C]t [C]a [C]n [C]e [C]o [C]u [C]s O 
exposure [C]e [C]x [C]p [C]o [C]s [C]u [C]r [C]e O 
to [C]t [C]o O 
PPAR-gamma [C]P [C]P [C]A [C]R [C]- [C]g [C]a [C]m [C]m [C]a O 
ligands [C]l [C]i [C]g [C]a [C]n [C]d [C]s O 
( [C]( O 
e.g. [C]e [C]. [C]g [C]. O 
15-deoxy-Delta [C]1 [C]5 [C]- [C]d [C]e [C]o [C]x [C]y [C]- [C]D [C]e [C]l [C]t [C]a O 
( [C]( O 
12 [C]1 [C]2 O 
, [C], O 
14 [C]1 [C]4 O 
) [C]) O 
-prostaglandin [C]- [C]p [C]r [C]o [C]s [C]t [C]a [C]g [C]l [C]a [C]n [C]d [C]i [C]n O 
J [C]J O 
( [C]( O 
2 [C]2 O 
) [C]) O 
, [C], O 
troglitazone [C]t [C]r [C]o [C]g [C]l [C]i [C]t [C]a [C]z [C]o [C]n [C]e O 
) [C]) O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
drastic [C]d [C]r [C]a [C]s [C]t [C]i [C]c O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
decreases [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
in [C]i [C]n O 
cell [C]c [C]e [C]l [C]l O 
viability [C]v [C]i [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
cell [C]c [C]e [C]l [C]l O 
viability [C]v [C]i [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
was [C]w [C]a [C]s O 
due [C]d [C]u [C]e O 
to [C]t [C]o O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
T [C]T B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
, [C], O 
and [C]a [C]n [C]d O 
occurred [C]o [C]c [C]c [C]u [C]r [C]r [C]e [C]d O 
only [C]o [C]n [C]l [C]y O 
when [C]w [C]h [C]e [C]n O 
cells [C]c [C]e [C]l [C]l [C]s O 
were [C]w [C]e [C]r [C]e O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
PPAR-gamma [C]P [C]P [C]A [C]R [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
, [C], O 
and [C]a [C]n [C]d O 
not [C]n [C]o [C]t O 
PPAR-alpha [C]P [C]P [C]A [C]R [C]- [C]a [C]l [C]p [C]h [C]a O 
agonists [C]a [C]g [C]o [C]n [C]i [C]s [C]t [C]s O 
, [C], O 
revealing [C]r [C]e [C]v [C]e [C]a [C]l [C]i [C]n [C]g O 
specificity [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]i [C]t [C]y O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
for [C]f [C]o [C]r O 
PPAR-gamma [C]P [C]P [C]A [C]R [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
observations [C]o [C]b [C]s [C]e [C]r [C]v [C]a [C]t [C]i [C]o [C]n [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
PPAR-gamma [C]P [C]P [C]A [C]R [C]- [C]g [C]a [C]m [C]m [C]a O 
agonists [C]a [C]g [C]o [C]n [C]i [C]s [C]t [C]s O 
play [C]p [C]l [C]a [C]y O 
an [C]a [C]n O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
regulating [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
T [C]T O 
cell-mediated [C]c [C]e [C]l [C]l [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
by [C]b [C]y O 
inducing [C]i [C]n [C]d [C]u [C]c [C]i [C]n [C]g O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
. [C]. O 

T [C]T O 
cell [C]c [C]e [C]l [C]l O 
death [C]d [C]e [C]a [C]t [C]h O 
via [C]v [C]i [C]a O 
PPAR-gamma [C]P [C]P [C]A [C]R [C]- [C]g [C]a [C]m [C]m [C]a O 
ligation [C]l [C]i [C]g [C]a [C]t [C]i [C]o [C]n O 
may [C]m [C]a [C]y O 
act [C]a [C]c [C]t O 
as [C]a [C]s O 
a [C]a O 
potent [C]p [C]o [C]t [C]e [C]n [C]t O 
anti-inflammatory [C]a [C]n [C]t [C]i [C]- [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
, [C], O 
and [C]a [C]n [C]d O 
ligands [C]l [C]i [C]g [C]a [C]n [C]d [C]s O 
could [C]c [C]o [C]u [C]l [C]d O 
possibly [C]p [C]o [C]s [C]s [C]i [C]b [C]l [C]y O 
be [C]b [C]e O 
used [C]u [C]s [C]e [C]d O 
to [C]t [C]o O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
disorders [C]d [C]i [C]s [C]o [C]r [C]d [C]e [C]r [C]s O 
in [C]i [C]n O 
which [C]w [C]h [C]i [C]c [C]h O 
excessive [C]e [C]x [C]c [C]e [C]s [C]s [C]i [C]v [C]e O 
inflammation [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]i [C]o [C]n O 
occurs [C]o [C]c [C]c [C]u [C]r [C]s O 
. [C]. O 

Suppression [C]S [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
lung [C]l [C]u [C]n [C]g O 
inflammation [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
rats [C]r [C]a [C]t [C]s O 
by [C]b [C]y O 
prevention [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
liver [C]l [C]i [C]v [C]e [C]r O 
. [C]. O 

Activation [C]A [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
and [C]a [C]n [C]d O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
chemokines [C]c [C]h [C]e [C]m [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
are [C]a [C]r [C]e O 
thought [C]t [C]h [C]o [C]u [C]g [C]h [C]t O 
to [C]t [C]o O 
be [C]b [C]e O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
pathogenesis [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
neutrophilic [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]h [C]i [C]l [C]i [C]c O 
lung [C]l [C]u [C]n [C]g O 
inflammation [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Calpain-1 [C]C [C]a [C]l [C]p [C]a [C]i [C]n [C]- [C]1 O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
( [C]( O 
CI-1 [C]C [C]I [C]- [C]1 O 
) [C]) O 
blocks [C]b [C]l [C]o [C]c [C]k [C]s O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
by [C]b [C]y O 
preventing [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]i [C]n [C]g O 
proteolysis [C]p [C]r [C]o [C]t [C]e [C]o [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
IkappaB-alpha [C]I [C]k [C]a [C]p [C]p [C]a [C]B [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
ubiquitin/proteasome [C]u [C]b [C]i [C]q [C]u [C]i [C]t [C]i [C]n [C]/ [C]p [C]r [C]o [C]t [C]e [C]a [C]s [C]o [C]m [C]e O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
. [C]. O 

We [C]W [C]e O 
hypothesized [C]h [C]y [C]p [C]o [C]t [C]h [C]e [C]s [C]i [C]z [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
proteasome [C]p [C]r [C]o [C]t [C]e [C]a [C]s [C]o [C]m [C]e O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
CI-1 [C]C [C]I [C]- [C]1 O 
would [C]w [C]o [C]u [C]l [C]d O 
block [C]b [C]l [C]o [C]c [C]k O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
after [C]a [C]f [C]t [C]e [C]r O 
intraperitoneal [C]i [C]n [C]t [C]r [C]a [C]p [C]e [C]r [C]i [C]t [C]o [C]n [C]e [C]a [C]l O 
( [C]( O 
i.p. [C]i [C]. [C]p [C]. O 
) [C]) O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
bacterial [C]b [C]a [C]c [C]t [C]e [C]r [C]i [C]a [C]l O 
lipopolysaccharide [C]l [C]i [C]p [C]o [C]p [C]o [C]l [C]y [C]s [C]a [C]c [C]c [C]h [C]a [C]r [C]i [C]d [C]e O 
( [C]( O 
LPS [C]L [C]P [C]S O 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
would [C]w [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
suppression [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
chemokine [C]c [C]h [C]e [C]m [C]o [C]k [C]i [C]n [C]e O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
attenuation [C]a [C]t [C]t [C]e [C]n [C]u [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
neutrophilic [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]h [C]i [C]l [C]i [C]c O 
alveolitis [C]a [C]l [C]v [C]e [C]o [C]l [C]i [C]t [C]i [C]s O 
. [C]. O 

We [C]W [C]e O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
rats [C]r [C]a [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
single [C]s [C]i [C]n [C]g [C]l [C]e O 
i.p. [C]i [C]. [C]p [C]. O 
injection [C]i [C]n [C]j [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CI-1 [C]C [C]I [C]- [C]1 O 
( [C]( O 
10 [C]1 [C]0 O 
mg/kg [C]m [C]g [C]/ [C]k [C]g O 
) [C]) O 
two [C]t [C]w [C]o O 
hours [C]h [C]o [C]u [C]r [C]s O 
prior [C]p [C]r [C]i [C]o [C]r O 
to [C]t [C]o O 
i.p. [C]i [C]. [C]p [C]. O 
LPS [C]L [C]P [C]S O 
( [C]( O 
7 [C]7 O 
mg/kg [C]m [C]g [C]/ [C]k [C]g O 
) [C]) O 
. [C]. O 

Treatment [C]T [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
Cl-1 [C]C [C]l [C]- [C]1 O 
prevented [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]e [C]d O 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IkappaB-alpha [C]I [C]k [C]a [C]p [C]p [C]a [C]B [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
and [C]a [C]n [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
liver [C]l [C]i [C]v [C]e [C]r O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
LPS [C]L [C]P [C]S O 
; [C]; O 
however [C]h [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
Cl-1 [C]C [C]l [C]- [C]1 O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
had [C]h [C]a [C]d O 
no [C]n [C]o O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
lung [C]l [C]u [C]n [C]g O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
. [C]. O 

CI-1 [C]C [C]I [C]- [C]1 O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
prior [C]p [C]r [C]i [C]o [C]r O 
to [C]t [C]o O 
LPS [C]L [C]P [C]S O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
40 [C]4 [C]0 O 
% [C]% O 
lower [C]l [C]o [C]w [C]e [C]r O 
MIP-2 [C]M [C]I [C]P [C]- [C]2 O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
lung [C]l [C]u [C]n [C]g O 
lavage [C]l [C]a [C]v [C]a [C]g [C]e O 
fluid [C]f [C]l [C]u [C]i [C]d O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
rats [C]r [C]a [C]t [C]s O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
vehicle [C]v [C]e [C]h [C]i [C]c [C]l [C]e O 
prior [C]p [C]r [C]i [C]o [C]r O 
to [C]t [C]o O 
LPS [C]L [C]P [C]S O 
( [C]( O 
502 [C]5 [C]0 [C]2 O 
+/- [C]+ [C]/ [C]- O 
112 [C]1 [C]1 [C]2 O 
pg/ml [C]p [C]g [C]/ [C]m [C]l O 
vs. [C]v [C]s [C]. O 
859 [C]8 [C]5 [C]9 O 
+/-144 [C]+ [C]/ [C]- [C]1 [C]4 [C]4 O 
pg/ml [C]p [C]g [C]/ [C]m [C]l O 
, [C], O 
P [C]P O 
< [C]< O 
0.05 [C]0 [C]. [C]0 [C]5 O 
) [C]) O 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
CI-1 [C]C [C]I [C]- [C]1 O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
substantially [C]s [C]u [C]b [C]s [C]t [C]a [C]n [C]t [C]i [C]a [C]l [C]l [C]y O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
LPS-induced [C]L [C]P [C]S [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
neutrophilic [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]h [C]i [C]l [C]i [C]c O 
alveolitis [C]a [C]l [C]v [C]e [C]o [C]l [C]i [C]t [C]i [C]s O 
( [C]( O 
2.7+ [C]2 [C]. [C]7 [C]+ O 
/- [C]/ [C]- O 
1.2 [C]1 [C]. [C]2 O 
x [C]x O 
10 [C]1 [C]0 O 
( [C]( O 
5 [C]5 O 
) [C]) O 
vs. [C]v [C]s [C]. O 
43.7 [C]4 [C]3 [C]. [C]7 O 
+/- [C]+ [C]/ [C]- O 
12.2 [C]1 [C]2 [C]. [C]2 O 
x [C]x O 
10 [C]1 [C]0 O 
( [C]( O 
5 [C]5 O 
) [C]) O 
lung [C]l [C]u [C]n [C]g B-cell_type 
lavage [C]l [C]a [C]v [C]a [C]g [C]e I-cell_type 
neutrophils [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]h [C]i [C]l [C]s E-cell_type 
, [C], O 
P [C]P O 
< [C]< O 
0.01 [C]0 [C]. [C]0 [C]1 O 
) [C]) O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
liver [C]l [C]i [C]v [C]e [C]r O 
can [C]c [C]a [C]n O 
alter [C]a [C]l [C]t [C]e [C]r O 
lung [C]l [C]u [C]n [C]g O 
inflammation [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]i [C]o [C]n O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
systemic [C]s [C]y [C]s [C]t [C]e [C]m [C]i [C]c O 
LPS [C]L [C]P [C]S O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
a [C]a O 
liver-lung [C]l [C]i [C]v [C]e [C]r [C]- [C]l [C]u [C]n [C]g O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
contributes [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e [C]s O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
lung [C]l [C]u [C]n [C]g O 
. [C]. O 

Notch1 [C]N [C]o [C]t [C]c [C]h [C]1 S-protein 
regulates [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]s O 
maturation [C]m [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CD4+ [C]C [C]D [C]4 [C]+ B-cell_type 
and [C]a [C]n [C]d I-cell_type 
CD8+ [C]C [C]D [C]8 [C]+ I-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
by [C]b [C]y O 
modulating [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
TCR [C]T [C]C [C]R O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
strength [C]s [C]t [C]r [C]e [C]n [C]g [C]t [C]h O 
. [C]. O 

Notch [C]N [C]o [C]t [C]c [C]h O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
regulates [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]s O 
cell [C]c [C]e [C]l [C]l O 
fate [C]f [C]a [C]t [C]e O 
decisions [C]d [C]e [C]c [C]i [C]s [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
multiple [C]m [C]u [C]l [C]t [C]i [C]p [C]l [C]e O 
lineages [C]l [C]i [C]n [C]e [C]a [C]g [C]e [C]s O 
. [C]. O 

We [C]W [C]e O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
in [C]i [C]n O 
this [C]t [C]h [C]i [C]s O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
that [C]t [C]h [C]a [C]t O 
retroviral [C]r [C]e [C]t [C]r [C]o [C]v [C]i [C]r [C]a [C]l O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
Notch1 [C]N [C]o [C]t [C]c [C]h [C]1 S-protein 
in [C]i [C]n O 
mouse [C]m [C]o [C]u [C]s [C]e B-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
abrogates [C]a [C]b [C]r [C]o [C]g [C]a [C]t [C]e [C]s O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
immature [C]i [C]m [C]m [C]a [C]t [C]u [C]r [C]e B-cell_type 
CD4+CD8+ [C]C [C]D [C]4 [C]+ [C]C [C]D [C]8 [C]+ I-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
into [C]i [C]n [C]t [C]o O 
both [C]b [C]o [C]t [C]h O 
CD4 [C]C [C]D [C]4 B-cell_type 
and [C]a [C]n [C]d I-cell_type 
CD8 [C]C [C]D [C]8 I-cell_type 
mature [C]m [C]a [C]t [C]u [C]r [C]e I-cell_type 
single-positive [C]s [C]i [C]n [C]g [C]l [C]e [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
Notch1 [C]N [C]o [C]t [C]c [C]h [C]1 S-protein 
to [C]t [C]o O 
inhibit [C]i [C]n [C]h [C]i [C]b [C]i [C]t O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
with [C]w [C]i [C]t [C]h O 
both [C]b [C]o [C]t [C]h O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
and [C]a [C]n [C]d I-cell_type 
TCR [C]T [C]C [C]R I-cell_type 
transgenic [C]t [C]r [C]a [C]n [C]s [C]g [C]e [C]n [C]i [C]c I-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

Notch1 [C]N [C]o [C]t [C]c [C]h [C]1 S-protein 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
developmental [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t [C]a [C]l O 
arrest [C]a [C]r [C]r [C]e [C]s [C]t O 
was [C]w [C]a [C]s O 
dose [C]d [C]o [C]s [C]e O 
dependent [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
was [C]w [C]a [C]s O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
impaired [C]i [C]m [C]p [C]a [C]i [C]r [C]e [C]d O 
thymocyte [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
to [C]t [C]o O 
TCR [C]T [C]C [C]R O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Notch1 [C]N [C]o [C]t [C]c [C]h [C]1 S-protein 
also [C]a [C]l [C]s [C]o O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
TCR-mediated [C]T [C]C [C]R [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
in [C]i [C]n O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_line 
T [C]T I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
constitutively [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
Notch1 [C]N [C]o [C]t [C]c [C]h [C]1 S-protein 
abrogates [C]a [C]b [C]r [C]o [C]g [C]a [C]t [C]e [C]s O 
CD4+ [C]C [C]D [C]4 [C]+ O 
and [C]a [C]n [C]d O 
CD8+ [C]C [C]D [C]8 [C]+ O 
maturation [C]m [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
interfering [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]i [C]n [C]g O 
with [C]w [C]i [C]t [C]h O 
TCR [C]T [C]C [C]R O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
strength [C]s [C]t [C]r [C]e [C]n [C]g [C]t [C]h O 
and [C]a [C]n [C]d O 
provide [C]p [C]r [C]o [C]v [C]i [C]d [C]e O 
an [C]a [C]n O 
explanation [C]e [C]x [C]p [C]l [C]a [C]n [C]a [C]t [C]i [C]o [C]n O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
physiological [C]p [C]h [C]y [C]s [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Notch [C]N [C]o [C]t [C]c [C]h O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
thymocyte [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
. [C]. O 

Expression [C]E [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
SART3 [C]S [C]A [C]R [C]T [C]3 B-protein 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n E-protein 
and [C]a [C]n [C]d O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CTLs [C]C [C]T [C]L [C]s S-cell_type 
by [C]b [C]y O 
SART3-derived [C]S [C]A [C]R [C]T [C]3 [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
peptides [C]p [C]e [C]p [C]t [C]i [C]d [C]e [C]s O 
in [C]i [C]n O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

We [C]W [C]e O 
recently [C]r [C]e [C]c [C]e [C]n [C]t [C]l [C]y O 
reported [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
SART3 [C]S [C]A [C]R [C]T [C]3 B-protein 
tumour-rejection [C]t [C]u [C]m [C]o [C]u [C]r [C]- [C]r [C]e [C]j [C]e [C]c [C]t [C]i [C]o [C]n I-protein 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n E-protein 
as [C]a [C]s O 
possessing [C]p [C]o [C]s [C]s [C]e [C]s [C]s [C]i [C]n [C]g O 
tumour [C]t [C]u [C]m [C]o [C]u [C]r O 
epitopes [C]e [C]p [C]i [C]t [C]o [C]p [C]e [C]s O 
capable [C]c [C]a [C]p [C]a [C]b [C]l [C]e O 
of [C]o [C]f O 
inducing [C]i [C]n [C]d [C]u [C]c [C]i [C]n [C]g O 
HLA-class [C]H [C]L [C]A [C]- [C]c [C]l [C]a [C]s [C]s B-cell_type 
I-restricted [C]I [C]- [C]r [C]e [C]s [C]t [C]r [C]i [C]c [C]t [C]e [C]d I-cell_type 
cytotoxic [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c I-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
( [C]( O 
CTLs [C]C [C]T [C]L [C]s S-cell_type 
) [C]) O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
SART3 [C]S [C]A [C]R [C]T [C]3 B-protein 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n E-protein 
in [C]i [C]n O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
to [C]t [C]o O 
explore [C]e [C]x [C]p [C]l [C]o [C]r [C]e O 
an [C]a [C]n O 
appropriate [C]a [C]p [C]p [C]r [C]o [C]p [C]r [C]i [C]a [C]t [C]e O 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e O 
for [C]f [C]o [C]r O 
use [C]u [C]s [C]e O 
in [C]i [C]n O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
immunotherapy [C]i [C]m [C]m [C]u [C]n [C]o [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
of [C]o [C]f O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
SART3 [C]S [C]A [C]R [C]T [C]3 B-protein 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n E-protein 
was [C]w [C]a [C]s O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
in [C]i [C]n O 
all [C]a [C]l [C]l O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
breast [C]b [C]r [C]e [C]a [C]s [C]t B-cell_line 
cancer [C]c [C]a [C]n [C]c [C]e [C]r I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
tested [C]t [C]e [C]s [C]t [C]e [C]d O 
, [C], O 
30 [C]3 [C]0 O 
of [C]o [C]f O 
40 [C]4 [C]0 O 
( [C]( O 
75 [C]7 [C]5 O 
% [C]% O 
) [C]) O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
samples [C]s [C]a [C]m [C]p [C]l [C]e [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
0 [C]0 O 
of [C]o [C]f O 
3 [C]3 O 
non-tumourous [C]n [C]o [C]n [C]- [C]t [C]u [C]m [C]o [C]u [C]r [C]o [C]u [C]s O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
samples [C]s [C]a [C]m [C]p [C]l [C]e [C]s O 
. [C]. O 

SART3 [C]S [C]A [C]R [C]T [C]3 O 
derived [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
peptides [C]p [C]e [C]p [C]t [C]i [C]d [C]e [C]s O 
at [C]a [C]t O 
positions [C]p [C]o [C]s [C]i [C]t [C]i [C]o [C]n [C]s B-DNA 
109-118 [C]1 [C]0 [C]9 [C]- [C]1 [C]1 [C]8 I-DNA 
and [C]a [C]n [C]d I-DNA 
315-323 [C]3 [C]1 [C]5 [C]- [C]3 [C]2 [C]3 E-DNA 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
HLA-A24 [C]H [C]L [C]A [C]- [C]A [C]2 [C]4 O 
restricted [C]r [C]e [C]s [C]t [C]r [C]i [C]c [C]t [C]e [C]d O 
CTLs [C]C [C]T [C]L [C]s S-cell_type 
that [C]t [C]h [C]a [C]t O 
reacted [C]r [C]e [C]a [C]c [C]t [C]e [C]d O 
to [C]t [C]o O 
breast [C]b [C]r [C]e [C]a [C]s [C]t B-cell_type 
cancer [C]c [C]a [C]n [C]c [C]e [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
PBMCs [C]P [C]B [C]M [C]C [C]s S-cell_type 
) [C]) O 
of [C]o [C]f O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

Therefore [C]T [C]h [C]e [C]r [C]e [C]f [C]o [C]r [C]e O 
, [C], O 
the [C]t [C]h [C]e O 
SART3 [C]S [C]A [C]R [C]T [C]3 B-protein 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n E-protein 
and [C]a [C]n [C]d O 
its [C]i [C]t [C]s O 
peptides [C]p [C]e [C]p [C]t [C]i [C]d [C]e [C]s O 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
an [C]a [C]n O 
appropriate [C]a [C]p [C]p [C]r [C]o [C]p [C]r [C]i [C]a [C]t [C]e O 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e O 
for [C]f [C]o [C]r O 
use [C]u [C]s [C]e O 
in [C]i [C]n O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
immunotherapy [C]i [C]m [C]m [C]u [C]n [C]o [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
majority [C]m [C]a [C]j [C]o [C]r [C]i [C]t [C]y O 
of [C]o [C]f O 
HLA-A24-positive [C]H [C]L [C]A [C]- [C]A [C]2 [C]4 [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 

Autostimulation [C]A [C]u [C]t [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Epstein-Barr [C]E [C]p [C]s [C]t [C]e [C]i [C]n [C]- [C]B [C]a [C]r [C]r O 
virus [C]v [C]i [C]r [C]u [C]s O 
BRLF1 [C]B [C]R [C]L [C]F [C]1 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
is [C]i [C]s O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
consensus [C]c [C]o [C]n [C]s [C]e [C]n [C]s [C]u [C]s O 
Sp1 [C]S [C]p [C]1 B-DNA 
and [C]a [C]n [C]d I-DNA 
Sp3 [C]S [C]p [C]3 I-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
. [C]. O 

As [C]A [C]s O 
an [C]a [C]n O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
step [C]s [C]t [C]e [C]p O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
lytic [C]l [C]y [C]t [C]i [C]c O 
cascade [C]c [C]a [C]s [C]c [C]a [C]d [C]e O 
, [C], O 
the [C]t [C]h [C]e O 
Rta [C]R [C]t [C]a O 
homologues [C]h [C]o [C]m [C]o [C]l [C]o [C]g [C]u [C]e [C]s O 
of [C]o [C]f O 
gammaherpesviruses [C]g [C]a [C]m [C]m [C]a [C]h [C]e [C]r [C]p [C]e [C]s [C]v [C]i [C]r [C]u [C]s [C]e [C]s O 
all [C]a [C]l [C]l O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
their [C]t [C]h [C]e [C]i [C]r O 
own [C]o [C]w [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Consistent [C]C [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
this [C]t [C]h [C]i [C]s O 
biologic [C]b [C]i [C]o [C]l [C]o [C]g [C]i [C]c O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
, [C], O 
the [C]t [C]h [C]e O 
Epstein-Barr [C]E [C]p [C]s [C]t [C]e [C]i [C]n [C]- [C]B [C]a [C]r [C]r O 
virus [C]v [C]i [C]r [C]u [C]s O 
( [C]( O 
EBV [C]E [C]B [C]V O 
) [C]) O 
Rta [C]R [C]t [C]a B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
powerfully [C]p [C]o [C]w [C]e [C]r [C]f [C]u [C]l [C]l [C]y O 
stimulates [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]s O 
the [C]t [C]h [C]e O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r S-DNA 
of [C]o [C]f O 
its [C]i [C]t [C]s O 
own [C]o [C]w [C]n O 
gene [C]g [C]e [C]n [C]e O 
, [C], O 
Rp [C]R [C]p S-DNA 
, [C], O 
in [C]i [C]n O 
EBV-positive [C]E [C]B [C]V [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
transient-transfection [C]t [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t [C]- [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
reporter-based [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r [C]- [C]b [C]a [C]s [C]e [C]d O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
. [C]. O 

We [C]W [C]e O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
the [C]t [C]h [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
RpCAT [C]R [C]p [C]C [C]A [C]T S-DNA 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
Rta [C]R [C]t [C]a S-protein 
by [C]b [C]y O 
deletional [C]d [C]e [C]l [C]e [C]t [C]i [C]o [C]n [C]a [C]l O 
and [C]a [C]n [C]d O 
site-directed [C]s [C]i [C]t [C]e [C]- [C]d [C]i [C]r [C]e [C]c [C]t [C]e [C]d O 
mutagenesis [C]m [C]u [C]t [C]a [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
. [C]. O 

Two [C]T [C]w [C]o O 
cognate [C]c [C]o [C]g [C]n [C]a [C]t [C]e B-DNA 
Sp1 [C]S [C]p [C]1 I-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
located [C]l [C]o [C]c [C]a [C]t [C]e [C]d O 
at [C]a [C]t O 
-279 [C]- [C]2 [C]7 [C]9 O 
and [C]a [C]n [C]d O 
-45 [C]- [C]4 [C]5 O 
relative [C]r [C]e [C]l [C]a [C]t [C]i [C]v [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l B-DNA 
start [C]s [C]t [C]a [C]r [C]t I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
proved [C]p [C]r [C]o [C]v [C]e [C]d O 
crucial [C]c [C]r [C]u [C]c [C]i [C]a [C]l O 
for [C]f [C]o [C]r O 
Rta-mediated [C]R [C]t [C]a [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Previously [C]P [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
described [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
sites [C]s [C]i [C]t [C]e [C]s O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
Zif268 [C]Z [C]i [C]f [C]2 [C]6 [C]8 E-protein 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
viral [C]v [C]i [C]r [C]a [C]l B-protein 
transactivator [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r I-protein 
ZEBRA [C]Z [C]E [C]B [C]R [C]A E-protein 
were [C]w [C]e [C]r [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
dispensable [C]d [C]i [C]s [C]p [C]e [C]n [C]s [C]a [C]b [C]l [C]e O 
for [C]f [C]o [C]r O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
RpCAT [C]R [C]p [C]C [C]A [C]T S-DNA 
by [C]b [C]y O 
Rta [C]R [C]t [C]a S-protein 
. [C]. O 

Gel [C]G [C]e [C]l O 
shift [C]s [C]h [C]i [C]f [C]t O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
, [C], O 
using [C]u [C]s [C]i [C]n [C]g O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
of [C]o [C]f O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
latency [C]l [C]a [C]t [C]e [C]n [C]c [C]y O 
or [C]o [C]r O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
into [C]i [C]n [C]t [C]o O 
the [C]t [C]h [C]e O 
lytic [C]l [C]y [C]t [C]i [C]c O 
cycle [C]c [C]y [C]c [C]l [C]e O 
, [C], O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
Sp1 [C]S [C]p [C]1 S-protein 
and [C]a [C]n [C]d O 
Sp3 [C]S [C]p [C]3 S-protein 
as [C]a [C]s O 
the [C]t [C]h [C]e O 
predominant [C]p [C]r [C]e [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
bound [C]b [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
Rp [C]R [C]p S-DNA 
near [C]n [C]e [C]a [C]r O 
-45 [C]- [C]4 [C]5 O 
. [C]. O 

During [C]D [C]u [C]r [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
lytic [C]l [C]y [C]t [C]i [C]c O 
cycle [C]c [C]y [C]c [C]l [C]e O 
, [C], O 
ZEBRA [C]Z [C]E [C]B [C]R [C]A S-protein 
bound [C]b [C]o [C]u [C]n [C]d O 
Rp [C]R [C]p S-DNA 
near [C]n [C]e [C]a [C]r O 
the [C]t [C]h [C]e O 
Sp1/Sp3 [C]S [C]p [C]1 [C]/ [C]S [C]p [C]3 B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
. [C]. O 

The [C]T [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
Sp1 [C]S [C]p [C]1 S-protein 
and [C]a [C]n [C]d O 
Sp3 [C]S [C]p [C]3 S-protein 
to [C]t [C]o O 
Rp [C]R [C]p S-DNA 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r O 
activities [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]i [C]e [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
mutagenesis [C]m [C]u [C]t [C]a [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
, [C], O 
establishing [C]e [C]s [C]t [C]a [C]b [C]l [C]i [C]s [C]h [C]i [C]n [C]g O 
a [C]a O 
direct [C]d [C]i [C]r [C]e [C]c [C]t O 
link [C]l [C]i [C]n [C]k O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Rp [C]R [C]p S-DNA 
by [C]b [C]y O 
Rta [C]R [C]t [C]a S-protein 
and [C]a [C]n [C]d O 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
by [C]b [C]y O 
Sp1 [C]S [C]p [C]1 S-protein 
and/or [C]a [C]n [C]d [C]/ [C]o [C]r O 
Sp3 [C]S [C]p [C]3 S-protein 
. [C]. O 

The [C]T [C]h [C]e O 
relative [C]r [C]e [C]l [C]a [C]t [C]i [C]v [C]e O 
abundance [C]a [C]b [C]u [C]n [C]d [C]a [C]n [C]c [C]e O 
or [C]o [C]r O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
state [C]s [C]t [C]a [C]t [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
Sp1 [C]S [C]p [C]1 S-protein 
and [C]a [C]n [C]d O 
Sp3 [C]S [C]p [C]3 S-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
altered [C]a [C]l [C]t [C]e [C]r [C]e [C]d O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
stimuli [C]s [C]t [C]i [C]m [C]u [C]l [C]i O 
that [C]t [C]h [C]a [C]t O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
the [C]t [C]h [C]e O 
BRLF1 [C]B [C]R [C]L [C]F [C]1 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
and [C]a [C]n [C]d O 
thereby [C]t [C]h [C]e [C]r [C]e [C]b [C]y O 
contribute [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
viral [C]v [C]i [C]r [C]a [C]l O 
lytic [C]l [C]y [C]t [C]i [C]c O 
cycle [C]c [C]y [C]c [C]l [C]e O 
. [C]. O 

Gene [C]G [C]e [C]n [C]e O 
transfer [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]r O 
of [C]o [C]f O 
antisense [C]a [C]n [C]t [C]i [C]s [C]e [C]n [C]s [C]e O 
hypoxia [C]h [C]y [C]p [C]o [C]x [C]i [C]a B-protein 
inducible [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e I-protein 
factor-1 [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]1 I-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
enhances [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]s O 
the [C]t [C]h [C]e O 
therapeutic [C]t [C]h [C]e [C]r [C]a [C]p [C]e [C]u [C]t [C]i [C]c O 
efficacy [C]e [C]f [C]f [C]i [C]c [C]a [C]c [C]y O 
of [C]o [C]f O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
immunotherapy [C]i [C]m [C]m [C]u [C]n [C]o [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
. [C]. O 

Solid [C]S [C]o [C]l [C]i [C]d O 
tumors [C]t [C]u [C]m [C]o [C]r [C]s O 
meet [C]m [C]e [C]e [C]t O 
their [C]t [C]h [C]e [C]i [C]r O 
demands [C]d [C]e [C]m [C]a [C]n [C]d [C]s O 
for [C]f [C]o [C]r O 
nascent [C]n [C]a [C]s [C]c [C]e [C]n [C]t O 
blood [C]b [C]l [C]o [C]o [C]d O 
vessels [C]v [C]e [C]s [C]s [C]e [C]l [C]s O 
and [C]a [C]n [C]d O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
glycolysis [C]g [C]l [C]y [C]c [C]o [C]l [C]y [C]s [C]i [C]s O 
, [C], O 
to [C]t [C]o O 
combat [C]c [C]o [C]m [C]b [C]a [C]t O 
hypoxia [C]h [C]y [C]p [C]o [C]x [C]i [C]a O 
, [C], O 
by [C]b [C]y O 
activating [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]n [C]g O 
multiple [C]m [C]u [C]l [C]t [C]i [C]p [C]l [C]e O 
genes [C]g [C]e [C]n [C]e [C]s O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
angiogenesis [C]a [C]n [C]g [C]i [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
metabolism [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]s [C]m O 
. [C]. O 

Hypoxia [C]H [C]y [C]p [C]o [C]x [C]i [C]a B-protein 
inducible [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e I-protein 
factor-1 [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]1 E-protein 
( [C]( O 
HIF-1 [C]H [C]I [C]F [C]- [C]1 S-protein 
) [C]) O 
is [C]i [C]s O 
a [C]a O 
constitutively [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
basic [C]b [C]a [C]s [C]i [C]c O 
helix-loop-helix [C]h [C]e [C]l [C]i [C]x [C]- [C]l [C]o [C]o [C]p [C]- [C]h [C]e [C]l [C]i [C]x B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
, [C], O 
formed [C]f [C]o [C]r [C]m [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
assembly [C]a [C]s [C]s [C]e [C]m [C]b [C]l [C]y O 
of [C]o [C]f O 
HIF-1alpha [C]H [C]I [C]F [C]- [C]1 [C]a [C]l [C]p [C]h [C]a S-protein 
and [C]a [C]n [C]d O 
HIF-1beta [C]H [C]I [C]F [C]- [C]1 [C]b [C]e [C]t [C]a S-protein 
( [C]( O 
Arnt [C]A [C]r [C]n [C]t S-protein 
) [C]) O 
, [C], O 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
stablized [C]s [C]t [C]a [C]b [C]l [C]i [C]z [C]e [C]d O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
hypoxia [C]h [C]y [C]p [C]o [C]x [C]i [C]a O 
, [C], O 
and [C]a [C]n [C]d O 
rapidly [C]r [C]a [C]p [C]i [C]d [C]l [C]y O 
degraded [C]d [C]e [C]g [C]r [C]a [C]d [C]e [C]d O 
under [C]u [C]n [C]d [C]e [C]r O 
normoxic [C]n [C]o [C]r [C]m [C]o [C]x [C]i [C]c O 
conditions [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

It [C]I [C]t O 
activates [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]s O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
genes [C]g [C]e [C]n [C]e [C]s O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
for [C]f [C]o [C]r O 
maintaining [C]m [C]a [C]i [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
oxygen [C]o [C]x [C]y [C]g [C]e [C]n O 
homeostasis [C]h [C]o [C]m [C]e [C]o [C]s [C]t [C]a [C]s [C]i [C]s O 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
, [C], O 
we [C]w [C]e O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
engineered [C]e [C]n [C]g [C]i [C]n [C]e [C]e [C]r [C]e [C]d O 
down-regulation [C]d [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
HIF-1alpha [C]H [C]I [C]F [C]- [C]1 [C]a [C]l [C]p [C]h [C]a S-protein 
by [C]b [C]y O 
intratumoral [C]i [C]n [C]t [C]r [C]a [C]t [C]u [C]m [C]o [C]r [C]a [C]l O 
gene [C]g [C]e [C]n [C]e O 
transfer [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]r O 
of [C]o [C]f O 
an [C]a [C]n O 
antisense [C]a [C]n [C]t [C]i [C]s [C]e [C]n [C]s [C]e B-DNA 
HIF-1alpha [C]H [C]I [C]F [C]- [C]1 [C]a [C]l [C]p [C]h [C]a I-DNA 
plasmid [C]p [C]l [C]a [C]s [C]m [C]i [C]d E-DNA 
leads [C]l [C]e [C]a [C]d [C]s O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
down-regulation [C]d [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
VEGF [C]V [C]E [C]G [C]F S-DNA 
, [C], O 
and [C]a [C]n [C]d O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
tumor [C]t [C]u [C]m [C]o [C]r O 
microvessel [C]m [C]i [C]c [C]r [C]o [C]v [C]e [C]s [C]s [C]e [C]l O 
density [C]d [C]e [C]n [C]s [C]i [C]t [C]y O 
. [C]. O 

Antisense [C]A [C]n [C]t [C]i [C]s [C]e [C]n [C]s [C]e O 
HIF-1alpha [C]H [C]I [C]F [C]- [C]1 [C]a [C]l [C]p [C]h [C]a O 
monotherapy [C]m [C]o [C]n [C]o [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
complete [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e O 
and [C]a [C]n [C]d O 
permanent [C]p [C]e [C]r [C]m [C]a [C]n [C]e [C]n [C]t O 
rejection [C]r [C]e [C]j [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
small [C]s [C]m [C]a [C]l [C]l O 
( [C]( O 
0.1 [C]0 [C]. [C]1 O 
cm [C]c [C]m O 
in [C]i [C]n O 
diameter [C]d [C]i [C]a [C]m [C]e [C]t [C]e [C]r O 
) [C]) O 
EL-4 [C]E [C]L [C]- [C]4 O 
tumors [C]t [C]u [C]m [C]o [C]r [C]s O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
unusual [C]u [C]n [C]u [C]s [C]u [C]a [C]l O 
for [C]f [C]o [C]r O 
an [C]a [C]n O 
anti-angiogenic [C]a [C]n [C]t [C]i [C]- [C]a [C]n [C]g [C]i [C]o [C]g [C]e [C]n [C]i [C]c O 
agent [C]a [C]g [C]e [C]n [C]t O 
where [C]w [C]h [C]e [C]r [C]e O 
transient [C]t [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t O 
suppression [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
tumor [C]t [C]u [C]m [C]o [C]r O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
is [C]i [C]s O 
the [C]t [C]h [C]e O 
norm [C]n [C]o [C]r [C]m O 
. [C]. O 

It [C]I [C]t O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
NK [C]N [C]K B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
rejection [C]r [C]e [C]j [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
tumors [C]t [C]u [C]m [C]o [C]r [C]s O 
, [C], O 
but [C]b [C]u [C]t O 
failed [C]f [C]a [C]i [C]l [C]e [C]d O 
to [C]t [C]o O 
stimulate [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e O 
systemic [C]s [C]y [C]s [C]t [C]e [C]m [C]i [C]c O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
anti-tumor [C]a [C]n [C]t [C]i [C]- [C]t [C]u [C]m [C]o [C]r O 
immunity [C]i [C]m [C]m [C]u [C]n [C]i [C]t [C]y O 
, [C], O 
and [C]a [C]n [C]d O 
synergized [C]s [C]y [C]n [C]e [C]r [C]g [C]i [C]z [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
B7-1-mediated [C]B [C]7 [C]- [C]1 [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
immunotherapy [C]i [C]m [C]m [C]u [C]n [C]o [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
to [C]t [C]o O 
cause [C]c [C]a [C]u [C]s [C]e O 
the [C]t [C]h [C]e O 
NK [C]N [C]K B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
and [C]a [C]n [C]d O 
CD8 [C]C [C]D [C]8 B-cell_type 
T [C]T I-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
rejection [C]r [C]e [C]j [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
larger [C]l [C]a [C]r [C]g [C]e [C]r O 
EL-4 [C]E [C]L [C]- [C]4 O 
tumors [C]t [C]u [C]m [C]o [C]r [C]s O 
( [C]( O 
0.4 [C]0 [C]. [C]4 O 
cm [C]c [C]m O 
in [C]i [C]n O 
diameter [C]d [C]i [C]a [C]m [C]e [C]t [C]e [C]r O 
) [C]) O 
that [C]t [C]h [C]a [C]t O 
were [C]w [C]e [C]r [C]e O 
refractory [C]r [C]e [C]f [C]r [C]a [C]c [C]t [C]o [C]r [C]y O 
to [C]t [C]o O 
monotherapies [C]m [C]o [C]n [C]o [C]t [C]h [C]e [C]r [C]a [C]p [C]i [C]e [C]s O 
. [C]. O 

Mice [C]M [C]i [C]c [C]e O 
cured [C]c [C]u [C]r [C]e [C]d O 
of [C]o [C]f O 
their [C]t [C]h [C]e [C]i [C]r O 
tumors [C]t [C]u [C]m [C]o [C]r [C]s O 
by [C]b [C]y O 
combination [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
resisted [C]r [C]e [C]s [C]i [C]s [C]t [C]e [C]d O 
a [C]a O 
rechallenge [C]r [C]e [C]c [C]h [C]a [C]l [C]l [C]e [C]n [C]g [C]e O 
with [C]w [C]i [C]t [C]h O 
parental [C]p [C]a [C]r [C]e [C]n [C]t [C]a [C]l B-cell_type 
tumor [C]t [C]u [C]m [C]o [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
indicating [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]i [C]n [C]g O 
systemic [C]s [C]y [C]s [C]t [C]e [C]m [C]i [C]c O 
antitumor [C]a [C]n [C]t [C]i [C]t [C]u [C]m [C]o [C]r O 
immunity [C]i [C]m [C]m [C]u [C]n [C]i [C]t [C]y O 
had [C]h [C]a [C]d O 
been [C]b [C]e [C]e [C]n O 
achieved [C]a [C]c [C]h [C]i [C]e [C]v [C]e [C]d O 
. [C]. O 

In [C]I [C]n O 
summary [C]s [C]u [C]m [C]m [C]a [C]r [C]y O 
, [C], O 
whilst [C]w [C]h [C]i [C]l [C]s [C]t O 
intensive [C]i [C]n [C]t [C]e [C]n [C]s [C]i [C]v [C]e O 
investigations [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]i [C]o [C]n [C]s O 
are [C]a [C]r [C]e O 
in [C]i [C]n O 
progress [C]p [C]r [C]o [C]g [C]r [C]e [C]s [C]s O 
to [C]t [C]o O 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
the [C]t [C]h [C]e O 
many [C]m [C]a [C]n [C]y O 
HIF-1 [C]H [C]I [C]F [C]- [C]1 S-protein 
effectors [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r [C]s O 
, [C], O 
the [C]t [C]h [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
herein [C]h [C]e [C]r [C]e [C]i [C]n O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
blocking [C]b [C]l [C]o [C]c [C]k [C]i [C]n [C]g O 
hypoxia-inducible [C]h [C]y [C]p [C]o [C]x [C]i [C]a [C]- [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
and [C]a [C]n [C]d O 
enhancing [C]e [C]n [C]h [C]a [C]n [C]c [C]i [C]n [C]g O 
NK-mediated [C]N [C]K [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
antitumor [C]a [C]n [C]t [C]i [C]t [C]u [C]m [C]o [C]r O 
immunity [C]i [C]m [C]m [C]u [C]n [C]i [C]t [C]y O 
by [C]b [C]y O 
targeting [C]t [C]a [C]r [C]g [C]e [C]t [C]i [C]n [C]g O 
HIF-1 [C]H [C]I [C]F [C]- [C]1 S-protein 
itself [C]i [C]t [C]s [C]e [C]l [C]f O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
advantageous [C]a [C]d [C]v [C]a [C]n [C]t [C]a [C]g [C]e [C]o [C]u [C]s O 
, [C], O 
especially [C]e [C]s [C]p [C]e [C]c [C]i [C]a [C]l [C]l [C]y O 
when [C]w [C]h [C]e [C]n O 
combined [C]c [C]o [C]m [C]b [C]i [C]n [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
immunotherapy [C]i [C]m [C]m [C]u [C]n [C]o [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
. [C]. O 

Runx2 [C]R [C]u [C]n [C]x [C]2 S-DNA 
: [C]: O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
oncogenic [C]o [C]n [C]c [C]o [C]g [C]e [C]n [C]i [C]c O 
effector [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
by [C]b [C]y O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
complementation [C]c [C]o [C]m [C]p [C]l [C]e [C]m [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
retroviral [C]r [C]e [C]t [C]r [C]o [C]v [C]i [C]r [C]a [C]l O 
tagging [C]t [C]a [C]g [C]g [C]i [C]n [C]g O 
. [C]. O 

The [C]T [C]h [C]e O 
Runx2 [C]R [C]u [C]n [C]x [C]2 S-DNA 
( [C]( O 
Cbfa1 [C]C [C]b [C]f [C]a [C]1 S-DNA 
, [C], O 
Pebp2alphaA [C]P [C]e [C]b [C]p [C]2 [C]a [C]l [C]p [C]h [C]a [C]A S-DNA 
, [C], O 
Aml3 [C]A [C]m [C]l [C]3 S-DNA 
) [C]) O 
gene [C]g [C]e [C]n [C]e O 
was [C]w [C]a [C]s O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
as [C]a [C]s O 
a [C]a O 
frequent [C]f [C]r [C]e [C]q [C]u [C]e [C]n [C]t O 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
for [C]f [C]o [C]r O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
proviral [C]p [C]r [C]o [C]v [C]i [C]r [C]a [C]l O 
insertion [C]i [C]n [C]s [C]e [C]r [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
lymphomas [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a [C]s O 
of [C]o [C]f O 
CD2-MYC [C]C [C]D [C]2 [C]- [C]M [C]Y [C]C O 
transgenic [C]t [C]r [C]a [C]n [C]s [C]g [C]e [C]n [C]i [C]c O 
mice [C]m [C]i [C]c [C]e O 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
recently [C]r [C]e [C]c [C]e [C]n [C]t [C]l [C]y O 
shown [C]s [C]h [C]o [C]w [C]n O 
that [C]t [C]h [C]a [C]t O 
over-expression [C]o [C]v [C]e [C]r [C]- [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
full-length [C]f [C]u [C]l [C]l [C]- [C]l [C]e [C]n [C]g [C]t [C]h O 
, [C], O 
most [C]m [C]o [C]s [C]t O 
highly [C]h [C]i [C]g [C]h [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
Runx2 [C]R [C]u [C]n [C]x [C]2 S-DNA 
isoform [C]i [C]s [C]o [C]f [C]o [C]r [C]m O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
thymus [C]t [C]h [C]y [C]m [C]u [C]s O 
perturbs [C]p [C]e [C]r [C]t [C]u [C]r [C]b [C]s O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
, [C], O 
leads [C]l [C]e [C]a [C]d [C]s O 
to [C]t [C]o O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
spontaneous [C]s [C]p [C]o [C]n [C]t [C]a [C]n [C]e [C]o [C]u [C]s O 
lymphomas [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a [C]s O 
at [C]a [C]t O 
low [C]l [C]o [C]w O 
frequency [C]f [C]r [C]e [C]q [C]u [C]e [C]n [C]c [C]y O 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
strongly [C]s [C]t [C]r [C]o [C]n [C]g [C]l [C]y O 
synergistic [C]s [C]y [C]n [C]e [C]r [C]g [C]i [C]s [C]t [C]i [C]c O 
with [C]w [C]i [C]t [C]h O 
Myc [C]M [C]y [C]c S-protein 
. [C]. O 

To [C]T [C]o O 
gain [C]g [C]a [C]i [C]n O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
insight [C]i [C]n [C]s [C]i [C]g [C]h [C]t O 
into [C]i [C]n [C]t [C]o O 
the [C]t [C]h [C]e O 
relationship [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n [C]s [C]h [C]i [C]p O 
of [C]o [C]f O 
Runx2 [C]R [C]u [C]n [C]x [C]2 S-DNA 
to [C]t [C]o O 
other [C]o [C]t [C]h [C]e [C]r O 
lymphomagenic [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a [C]g [C]e [C]n [C]i [C]c O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
, [C], O 
we [C]w [C]e O 
tested [C]t [C]e [C]s [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
combining [C]c [C]o [C]m [C]b [C]i [C]n [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
CD2-Runx2 [C]C [C]D [C]2 [C]- [C]R [C]u [C]n [C]x [C]2 B-DNA 
transgene [C]t [C]r [C]a [C]n [C]s [C]g [C]e [C]n [C]e E-DNA 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
Pim1 [C]P [C]i [C]m [C]1 B-DNA 
transgene [C]t [C]r [C]a [C]n [C]s [C]g [C]e [C]n [C]e E-DNA 
( [C]( O 
E [C]E B-DNA 
( [C]( I-DNA 
mu [C]m [C]u I-DNA 
) [C]) I-DNA 
-Pim1 [C]- [C]P [C]i [C]m [C]1 E-DNA 
) [C]) O 
or [C]o [C]r O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
p53 [C]p [C]5 [C]3 S-DNA 
null [C]n [C]u [C]l [C]l O 
genotype [C]g [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
, [C], O 
as [C]a [C]s O 
each [C]e [C]a [C]c [C]h O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
displays [C]d [C]i [C]s [C]p [C]l [C]a [C]y [C]s O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
synergy [C]s [C]y [C]n [C]e [C]r [C]g [C]y O 
with [C]w [C]i [C]t [C]h O 
Myc [C]M [C]y [C]c S-protein 
. [C]. O 

In [C]I [C]n O 
both [C]b [C]o [C]t [C]h O 
cases [C]c [C]a [C]s [C]e [C]s O 
we [C]w [C]e O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
synergistic [C]s [C]y [C]n [C]e [C]r [C]g [C]i [C]s [C]t [C]i [C]c O 
tumour [C]t [C]u [C]m [C]o [C]u [C]r O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
Runx2 [C]R [C]u [C]n [C]x [C]2 S-protein 
appeared [C]a [C]p [C]p [C]e [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
have [C]h [C]a [C]v [C]e O 
a [C]a O 
dominant [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
tumour [C]t [C]u [C]m [C]o [C]u [C]r O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
in [C]i [C]n O 
each [C]e [C]a [C]c [C]h O 
case [C]c [C]a [C]s [C]e O 
, [C], O 
with [C]w [C]i [C]t [C]h O 
most [C]m [C]o [C]s [C]t O 
tumours [C]t [C]u [C]m [C]o [C]u [C]r [C]s O 
conforming [C]c [C]o [C]n [C]f [C]o [C]r [C]m [C]i [C]n [C]g O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
CD3 [C]C [C]D [C]3 O 
( [C]( O 
+ [C]+ O 
) [C]) O 
, [C], O 
CD8 [C]C [C]D [C]8 O 
( [C]( O 
+ [C]+ O 
) [C]) O 
, [C], O 
CD4 [C]C [C]D [C]4 O 
( [C]( O 
+/- [C]+ [C]/ [C]- O 
) [C]) O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
seen [C]s [C]e [C]e [C]n O 
in [C]i [C]n O 
CD2-Runx2 [C]C [C]D [C]2 [C]- [C]R [C]u [C]n [C]x [C]2 O 
mice [C]m [C]i [C]c [C]e O 
. [C]. O 

Neonatal [C]N [C]e [C]o [C]n [C]a [C]t [C]a [C]l O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CD2-Runx2 [C]C [C]D [C]2 [C]- [C]R [C]u [C]n [C]x [C]2 O 
mice [C]m [C]i [C]c [C]e O 
with [C]w [C]i [C]t [C]h O 
Moloney [C]M [C]o [C]l [C]o [C]n [C]e [C]y O 
murine [C]m [C]u [C]r [C]i [C]n [C]e O 
leukaemia [C]l [C]e [C]u [C]k [C]a [C]e [C]m [C]i [C]a O 
virus [C]v [C]i [C]r [C]u [C]s O 
( [C]( O 
Moloney [C]M [C]o [C]l [C]o [C]n [C]e [C]y O 
MLV [C]M [C]L [C]V O 
) [C]) O 
also [C]a [C]l [C]s [C]o O 
led [C]l [C]e [C]d O 
to [C]t [C]o O 
a [C]a O 
dramatic [C]d [C]r [C]a [C]m [C]a [C]t [C]i [C]c O 
acceleration [C]a [C]c [C]c [C]e [C]l [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
tumour [C]t [C]u [C]m [C]o [C]u [C]r O 
onset [C]o [C]n [C]s [C]e [C]t O 
. [C]. O 

Analysis [C]A [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
known [C]k [C]n [C]o [C]w [C]n O 
Moloney [C]M [C]o [C]l [C]o [C]n [C]e [C]y B-DNA 
MLV [C]M [C]L [C]V I-DNA 
target [C]t [C]a [C]r [C]g [C]e [C]t I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
in [C]i [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
lymphomas [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a [C]s O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
a [C]a O 
high [C]h [C]i [C]g [C]h O 
frequency [C]f [C]r [C]e [C]q [C]u [C]e [C]n [C]c [C]y O 
of [C]o [C]f O 
rearrangement [C]r [C]e [C]a [C]r [C]r [C]a [C]n [C]g [C]e [C]m [C]e [C]n [C]t O 
at [C]a [C]t O 
c-Myc [C]c [C]- [C]M [C]y [C]c S-DNA 
or [C]o [C]r O 
N-Myc [C]N [C]- [C]M [C]y [C]c S-DNA 
( [C]( O 
82 [C]8 [C]2 O 
% [C]% O 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
a [C]a O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
at [C]a [C]t O 
Pim1 [C]P [C]i [C]m [C]1 S-DNA 
or [C]o [C]r O 
Pim2 [C]P [C]i [C]m [C]2 S-DNA 
( [C]( O 
23 [C]2 [C]3 O 
% [C]% O 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
at [C]a [C]t O 
Pal1/Gfi1 [C]P [C]a [C]l [C]1 [C]/ [C]G [C]f [C]i [C]1 S-DNA 
( [C]( O 
18 [C]1 [C]8 O 
% [C]% O 
) [C]) O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
Runx2 [C]R [C]u [C]n [C]x [C]2 S-protein 
makes [C]m [C]a [C]k [C]e [C]s O 
a [C]a O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
contribution [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]i [C]o [C]n O 
to [C]t [C]o O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
which [C]w [C]h [C]i [C]c [C]h O 
does [C]d [C]o [C]e [C]s O 
not [C]n [C]o [C]t O 
coincide [C]c [C]o [C]i [C]n [C]c [C]i [C]d [C]e O 
with [C]w [C]i [C]t [C]h O 
any [C]a [C]n [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
oncogene [C]o [C]n [C]c [C]o [C]g [C]e [C]n [C]e O 
complementation [C]c [C]o [C]m [C]p [C]l [C]e [C]m [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
groups [C]g [C]r [C]o [C]u [C]p [C]s O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
by [C]b [C]y O 
retroviral [C]r [C]e [C]t [C]r [C]o [C]v [C]i [C]r [C]a [C]l O 
tagging [C]t [C]a [C]g [C]g [C]i [C]n [C]g O 
. [C]. O 

The [C]T [C]h [C]e O 
involvement [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
-related [C]- [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
apoptosis-inducing [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s [C]- [C]i [C]n [C]d [C]u [C]c [C]i [C]n [C]g O 
ligand [C]l [C]i [C]g [C]a [C]n [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
cytotoxicity [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c [C]i [C]t [C]y O 
of [C]o [C]f O 
IFN-beta [C]I [C]F [C]N [C]- [C]b [C]e [C]t [C]a S-protein 
-stimulated [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
dendritic [C]d [C]e [C]n [C]d [C]r [C]i [C]t [C]i [C]c I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
to [C]t [C]o O 
tumor [C]t [C]u [C]m [C]o [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
-related [C]- [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
apoptosis-inducing [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s [C]- [C]i [C]n [C]d [C]u [C]c [C]i [C]n [C]g O 
ligand [C]l [C]i [C]g [C]a [C]n [C]d O 
( [C]( O 
TRAIL [C]T [C]R [C]A [C]I [C]L O 
) [C]) O 
is [C]i [C]s O 
characterized [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]d O 
by [C]b [C]y O 
its [C]i [C]t [C]s O 
preferential [C]p [C]r [C]e [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
of [C]o [C]f O 
tumor [C]t [C]u [C]m [C]o [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Dendritic [C]D [C]e [C]n [C]d [C]r [C]i [C]t [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
DCs [C]D [C]C [C]s S-cell_type 
) [C]) O 
, [C], O 
besides [C]b [C]e [C]s [C]i [C]d [C]e [C]s O 
their [C]t [C]h [C]e [C]i [C]r O 
role [C]r [C]o [C]l [C]e O 
as [C]a [C]s O 
APCs [C]A [C]P [C]C [C]s O 
, [C], O 
now [C]n [C]o [C]w O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
to [C]t [C]o O 
exert [C]e [C]x [C]e [C]r [C]t O 
cytotoxicity [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c [C]i [C]t [C]y O 
or [C]o [C]r O 
cytostasis [C]c [C]y [C]t [C]o [C]s [C]t [C]a [C]s [C]i [C]s O 
on [C]o [C]n O 
some [C]s [C]o [C]m [C]e O 
tumor [C]t [C]u [C]m [C]o [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
, [C], O 
we [C]w [C]e O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
that [C]t [C]h [C]a [C]t O 
both [C]b [C]o [C]t [C]h O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
CD34 [C]C [C]D [C]3 [C]4 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
stem [C]s [C]t [C]e [C]m I-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
-derived [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
DCs [C]D [C]C [C]s S-cell_type 
( [C]( O 
CD34DCs [C]C [C]D [C]3 [C]4 [C]D [C]C [C]s S-cell_type 
) [C]) O 
and [C]a [C]n [C]d O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
CD14 [C]C [C]D [C]1 [C]4 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
monocyte [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e E-cell_type 
-derived [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
DCs [C]D [C]C [C]s S-cell_type 
( [C]( O 
MoDCs [C]M [C]o [C]D [C]C [C]s S-cell_type 
) [C]) O 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
TRAIL [C]T [C]R [C]A [C]I [C]L O 
and [C]a [C]n [C]d O 
exhibit [C]e [C]x [C]h [C]i [C]b [C]i [C]t O 
cytotoxicity [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c [C]i [C]t [C]y O 
to [C]t [C]o O 
some [C]s [C]o [C]m [C]e O 
types [C]t [C]y [C]p [C]e [C]s O 
of [C]o [C]f O 
tumor [C]t [C]u [C]m [C]o [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
partially [C]p [C]a [C]r [C]t [C]i [C]a [C]l [C]l [C]y O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
TRAIL [C]T [C]R [C]A [C]I [C]L O 
. [C]. O 

Moderate [C]M [C]o [C]d [C]e [C]r [C]a [C]t [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
TRAIL [C]T [C]R [C]A [C]I [C]L O 
appeared [C]a [C]p [C]p [C]e [C]a [C]r [C]e [C]d O 
on [C]o [C]n O 
CD34DCs [C]C [C]D [C]3 [C]4 [C]D [C]C [C]s S-cell_type 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
8th [C]8 [C]t [C]h O 
day [C]d [C]a [C]y O 
of [C]o [C]f O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
and [C]a [C]n [C]d O 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
seen [C]s [C]e [C]e [C]n O 
on [C]o [C]n O 
freshly [C]f [C]r [C]e [C]s [C]h [C]l [C]y B-cell_type 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d I-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
TRAIL [C]T [C]R [C]A [C]I [C]L O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
remained [C]r [C]e [C]m [C]a [C]i [C]n [C]e [C]d O 
constant [C]c [C]o [C]n [C]s [C]t [C]a [C]n [C]t O 
until [C]u [C]n [C]t [C]i [C]l O 
DC [C]D [C]C O 
maturation [C]m [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

TRAIL [C]T [C]R [C]A [C]I [C]L O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
on [C]o [C]n O 
immature [C]i [C]m [C]m [C]a [C]t [C]u [C]r [C]e B-cell_type 
CD34DCs [C]C [C]D [C]3 [C]4 [C]D [C]C [C]s E-cell_type 
or [C]o [C]r O 
MoDCs [C]M [C]o [C]D [C]C [C]s S-cell_type 
was [C]w [C]a [C]s O 
greatly [C]g [C]r [C]e [C]a [C]t [C]l [C]y O 
up-regulated [C]u [C]p [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
after [C]a [C]f [C]t [C]e [C]r O 
IFN-beta [C]I [C]F [C]N [C]- [C]b [C]e [C]t [C]a S-protein 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Moreover [C]M [C]o [C]r [C]e [C]o [C]v [C]e [C]r O 
, [C], O 
IFN-beta [C]I [C]F [C]N [C]- [C]b [C]e [C]t [C]a S-protein 
could [C]c [C]o [C]u [C]l [C]d O 
strikingly [C]s [C]t [C]r [C]i [C]k [C]i [C]n [C]g [C]l [C]y O 
enhance [C]e [C]n [C]h [C]a [C]n [C]c [C]e O 
the [C]t [C]h [C]e O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
CD34DCs [C]C [C]D [C]3 [C]4 [C]D [C]C [C]s S-cell_type 
or [C]o [C]r O 
MoDCs [C]M [C]o [C]D [C]C [C]s S-cell_type 
to [C]t [C]o O 
kill [C]k [C]i [C]l [C]l O 
TRAIL-sensitive [C]T [C]R [C]A [C]I [C]L [C]- [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
tumor [C]t [C]u [C]m [C]o [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
but [C]b [C]u [C]t O 
LPS [C]L [C]P [C]S O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
have [C]h [C]a [C]v [C]e O 
such [C]s [C]u [C]c [C]h O 
an [C]a [C]n O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
. [C]. O 

The [C]T [C]h [C]e O 
up-regulation [C]u [C]p [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
TRAIL [C]T [C]R [C]A [C]I [C]L O 
on [C]o [C]n O 
IFN-beta [C]I [C]F [C]N [C]- [C]b [C]e [C]t [C]a S-protein 
-stimulated [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
DCs [C]D [C]C [C]s S-cell_type 
partially [C]p [C]a [C]r [C]t [C]i [C]a [C]l [C]l [C]y O 
contributed [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
cytotoxicity [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c [C]i [C]t [C]y O 
of [C]o [C]f O 
DCS [C]D [C]C [C]S S-cell_type 
: [C]: O 
Pretreatment [C]P [C]r [C]e [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
TRAIL-sensitive [C]T [C]R [C]A [C]I [C]L [C]- [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
tumor [C]t [C]u [C]m [C]o [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
with [C]w [C]i [C]t [C]h O 
caspase-3 [C]c [C]a [C]s [C]p [C]a [C]s [C]e [C]- [C]3 O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
could [C]c [C]o [C]u [C]l [C]d O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
their [C]t [C]h [C]e [C]i [C]r O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
cytotoxicity [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c [C]i [C]t [C]y O 
of [C]o [C]f O 
IFN-beta [C]I [C]F [C]N [C]- [C]b [C]e [C]t [C]a S-protein 
-stimulated [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
DCS [C]D [C]C [C]S S-cell_type 
: [C]: O 
In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
could [C]c [C]o [C]u [C]l [C]d O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
the [C]t [C]h [C]e O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
tumor [C]t [C]u [C]m [C]o [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
killing [C]k [C]i [C]l [C]l [C]i [C]n [C]g O 
by [C]b [C]y O 
nonstimulated [C]n [C]o [C]n [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
or [C]o [C]r O 
LPS-stimulated [C]L [C]P [C]S [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
DCS [C]D [C]C [C]S S-cell_type 
: [C]: O 
Our [C]O [C]u [C]r O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
IFN-beta [C]I [C]F [C]N [C]- [C]b [C]e [C]t [C]a S-protein 
-stimulated [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
DCs [C]D [C]C [C]s S-cell_type 
are [C]a [C]r [C]e O 
functionally [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l [C]l [C]y O 
cytotoxic [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
an [C]a [C]n O 
innate [C]i [C]n [C]n [C]a [C]t [C]e O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
of [C]o [C]f O 
DC-mediated [C]D [C]C [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
antitumor [C]a [C]n [C]t [C]i [C]t [C]u [C]m [C]o [C]r O 
immunity [C]i [C]m [C]m [C]u [C]n [C]i [C]t [C]y O 
might [C]m [C]i [C]g [C]h [C]t O 
exist [C]e [C]x [C]i [C]s [C]t O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
in [C]i [C]n O 
which [C]w [C]h [C]i [C]c [C]h O 
DCs [C]D [C]C [C]s S-cell_type 
act [C]a [C]c [C]t O 
as [C]a [C]s O 
effectors [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r [C]s O 
to [C]t [C]o O 
directly [C]d [C]i [C]r [C]e [C]c [C]t [C]l [C]y O 
kill [C]k [C]i [C]l [C]l O 
tumor [C]t [C]u [C]m [C]o [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
partially [C]p [C]a [C]r [C]t [C]i [C]a [C]l [C]l [C]y O 
via [C]v [C]i [C]a O 
TRAIL [C]T [C]R [C]A [C]I [C]L O 
. [C]. O 

Subsequently [C]S [C]u [C]b [C]s [C]e [C]q [C]u [C]e [C]n [C]t [C]l [C]y O 
, [C], O 
DCs [C]D [C]C [C]s S-cell_type 
act [C]a [C]c [C]t O 
as [C]a [C]s O 
APCs [C]A [C]P [C]C [C]s O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
uptake [C]u [C]p [C]t [C]a [C]k [C]e O 
, [C], O 
processing [C]p [C]r [C]o [C]c [C]e [C]s [C]s [C]i [C]n [C]g O 
, [C], O 
and [C]a [C]n [C]d O 
presentation [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
apoptotic [C]a [C]p [C]o [C]p [C]t [C]o [C]t [C]i [C]c B-protein 
tumor [C]t [C]u [C]m [C]o [C]r I-protein 
Ags [C]A [C]g [C]s E-protein 
to [C]t [C]o O 
cross-prime [C]c [C]r [C]o [C]s [C]s [C]- [C]p [C]r [C]i [C]m [C]e O 
CD8 [C]C [C]D [C]8 B-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
CTL [C]C [C]T [C]L I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Tumor [C]T [C]u [C]m [C]o [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
lytic [C]l [C]y [C]t [C]i [C]c O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
tumor-specific [C]t [C]u [C]m [C]o [C]r [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-cell_type 
cytotoxic [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c I-cell_type 
t [C]t I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
by [C]b [C]y O 
modulating [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y O 
natural [C]n [C]a [C]t [C]u [C]r [C]a [C]l O 
killer [C]k [C]i [C]l [C]l [C]e [C]r O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

Tumor-infiltrating [C]T [C]u [C]m [C]o [C]r [C]- [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]n [C]g B-cell_type 
p58+ [C]p [C]5 [C]8 [C]+ I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
a [C]a O 
renal [C]r [C]e [C]n [C]a [C]l O 
tumor [C]t [C]u [C]m [C]o [C]r O 
were [C]w [C]e [C]r [C]e O 
specifically [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]a [C]l [C]l [C]y O 
expanded [C]e [C]x [C]p [C]a [C]n [C]d [C]e [C]d O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
tumor [C]t [C]u [C]m [C]o [C]r O 
cell [C]c [C]e [C]l [C]l O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
cloned [C]c [C]l [C]o [C]n [C]e [C]d O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
p58+ [C]p [C]5 [C]8 [C]+ B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
a [C]a O 
memory [C]m [C]e [C]m [C]o [C]r [C]y B-cell_type 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e E-cell_type 
and [C]a [C]n [C]d O 
corresponded [C]c [C]o [C]r [C]r [C]e [C]s [C]p [C]o [C]n [C]d [C]e [C]d O 
to [C]t [C]o O 
clonal [C]c [C]l [C]o [C]n [C]a [C]l O 
TCRBV3 [C]T [C]C [C]R [C]B [C]V [C]3 O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
expansion [C]e [C]x [C]p [C]a [C]n [C]s [C]i [C]o [C]n O 
. [C]. O 

Functionally [C]F [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l [C]l [C]y O 
, [C], O 
p58 [C]p [C]5 [C]8 B-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
CTLs [C]C [C]T [C]L [C]s E-cell_type 
displayed [C]d [C]i [C]s [C]p [C]l [C]a [C]y [C]e [C]d O 
a [C]a O 
low [C]l [C]o [C]w O 
lytic [C]l [C]y [C]t [C]i [C]c O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
for [C]f [C]o [C]r O 
HLA-A2 [C]H [C]L [C]A [C]- [C]A [C]2 B-cell_type 
tumor [C]t [C]u [C]m [C]o [C]r I-cell_type 
and [C]a [C]n [C]d I-cell_type 
normal [C]n [C]o [C]r [C]m [C]a [C]l I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
this [C]t [C]h [C]i [C]s O 
lytic [C]l [C]y [C]t [C]i [C]c O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
was [C]w [C]a [C]s O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
after [C]a [C]f [C]t [C]e [C]r O 
blockade [C]b [C]l [C]o [C]c [C]k [C]a [C]d [C]e O 
of [C]o [C]f O 
p58 [C]p [C]5 [C]8 S-protein 
with [C]w [C]i [C]t [C]h O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
monoclonal [C]m [C]o [C]n [C]o [C]c [C]l [C]o [C]n [C]a [C]l B-protein 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s E-protein 
. [C]. O 

Interestingly [C]I [C]n [C]t [C]e [C]r [C]e [C]s [C]t [C]i [C]n [C]g [C]l [C]y O 
, [C], O 
we [C]w [C]e O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
tumor [C]t [C]u [C]m [C]o [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
was [C]w [C]a [C]s O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
to [C]t [C]o O 
trigger [C]t [C]r [C]i [C]g [C]g [C]e [C]r O 
the [C]t [C]h [C]e O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
p58 [C]p [C]5 [C]8 S-protein 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
lytic [C]l [C]y [C]t [C]i [C]c O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
antigen-specific [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-cell_type 
CTLs [C]C [C]T [C]L [C]s E-cell_type 
and [C]a [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
p58 [C]p [C]5 [C]8 S-protein 
by [C]b [C]y O 
tumor [C]t [C]u [C]m [C]o [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
an [C]a [C]n O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
factor-kappaB [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a [C]B O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
p58+ [C]p [C]5 [C]8 [C]+ B-cell_type 
tumor-specific [C]t [C]u [C]m [C]o [C]r [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-cell_type 
CTLS [C]C [C]T [C]L [C]S E-cell_type 
. [C]. O 

T-cell [C]T [C]- [C]c [C]e [C]l [C]l B-protein 
factor-1 [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]1 E-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
natural [C]n [C]a [C]t [C]u [C]r [C]a [C]l I-cell_type 
killer [C]k [C]i [C]l [C]l [C]e [C]r I-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
circulating [C]c [C]i [C]r [C]c [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
CD56 [C]C [C]D [C]5 [C]6 B-protein 
( [C]( I-protein 
+ [C]+ I-protein 
) [C]) E-protein 
bright [C]b [C]r [C]i [C]g [C]h [C]t O 
natural [C]n [C]a [C]t [C]u [C]r [C]a [C]l B-cell_type 
killer [C]k [C]i [C]l [C]l [C]e [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Transcription [C]T [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
are [C]a [C]r [C]e O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
to [C]t [C]o O 
govern [C]g [C]o [C]v [C]e [C]r [C]n O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
along [C]a [C]l [C]o [C]n [C]g O 
the [C]t [C]h [C]e O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d B-cell_type 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e E-cell_type 
from [C]f [C]r [C]o [C]m O 
uncommitted [C]u [C]n [C]c [C]o [C]m [C]m [C]i [C]t [C]t [C]e [C]d B-cell_type 
hematopoietic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c I-cell_type 
stem [C]s [C]t [C]e [C]m I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
many [C]m [C]a [C]n [C]y O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
have [C]h [C]a [C]v [C]e O 
putative [C]p [C]u [C]t [C]a [C]t [C]i [C]v [C]e O 
roles [C]r [C]o [C]l [C]e [C]s O 
based [C]b [C]a [C]s [C]e [C]d O 
on [C]o [C]n O 
murine [C]m [C]u [C]r [C]i [C]n [C]e O 
knockout [C]k [C]n [C]o [C]c [C]k [C]o [C]u [C]t O 
experiments [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]s O 
, [C], O 
their [C]t [C]h [C]e [C]i [C]r O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
is [C]i [C]s O 
less [C]l [C]e [C]s [C]s O 
known [C]k [C]n [C]o [C]w [C]n O 
and [C]a [C]n [C]d O 
was [C]w [C]a [C]s O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
. [C]. O 

Transcription [C]T [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
fresh [C]f [C]r [C]e [C]s [C]h O 
and [C]a [C]n [C]d O 
cultured [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]d O 
adult [C]a [C]d [C]u [C]l [C]t B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
bone [C]b [C]o [C]n [C]e I-cell_type 
marrow [C]m [C]a [C]r [C]r [C]o [C]w I-cell_type 
and [C]a [C]n [C]d I-cell_type 
umbilical [C]u [C]m [C]b [C]i [C]l [C]i [C]c [C]a [C]l I-cell_type 
cord [C]c [C]o [C]r [C]d I-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
progenitors [C]p [C]r [C]o [C]g [C]e [C]n [C]i [C]t [C]o [C]r [C]s E-cell_type 
was [C]w [C]a [C]s O 
evaluated [C]e [C]v [C]a [C]l [C]u [C]a [C]t [C]e [C]d O 
. [C]. O 

We [C]W [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
fresh [C]f [C]r [C]e [C]s [C]h B-cell_type 
CD34 [C]C [C]D [C]3 [C]4 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
Lin [C]L [C]i [C]n I-cell_type 
( [C]( I-cell_type 
- [C]- I-cell_type 
) [C]) I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
that [C]t [C]h [C]a [C]t O 
are [C]a [C]r [C]e O 
human [C]h [C]u [C]m [C]a [C]n O 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e O 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n O 
( [C]( O 
HLA [C]H [C]L [C]A O 
) [C]) O 
-DR [C]- [C]D [C]R O 
( [C]( O 
- [C]- O 
) [C]) O 
or [C]o [C]r O 
CD38 [C]C [C]D [C]3 [C]8 O 
( [C]( O 
- [C]- O 
) [C]) O 
constitutively [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y O 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 S-protein 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l B-protein 
factor-1 [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]1 E-protein 
( [C]( O 
TCF-1 [C]T [C]C [C]F [C]- [C]1 S-protein 
) [C]) O 
or [C]o [C]r O 
Id-3 [C]I [C]d [C]- [C]3 S-protein 
. [C]. O 

Culture [C]C [C]u [C]l [C]t [C]u [C]r [C]e O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
murine [C]m [C]u [C]r [C]i [C]n [C]e B-cell_line 
fetal [C]f [C]e [C]t [C]a [C]l I-cell_line 
liver [C]l [C]i [C]v [C]e [C]r I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e I-cell_line 
AFT024 [C]A [C]F [C]T [C]0 [C]2 [C]4 E-cell_line 
and [C]a [C]n [C]d O 
defined [C]d [C]e [C]f [C]i [C]n [C]e [C]d O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
was [C]w [C]a [C]s O 
capable [C]c [C]a [C]p [C]a [C]b [C]l [C]e O 
of [C]o [C]f O 
inducing [C]i [C]n [C]d [C]u [C]c [C]i [C]n [C]g O 
TCF-1 [C]T [C]C [C]F [C]- [C]1 B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
no [C]n [C]o O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l B-DNA 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
rearrangement [C]r [C]e [C]a [C]r [C]r [C]a [C]n [C]g [C]e [C]m [C]e [C]n [C]t O 
was [C]w [C]a [C]s O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
in [C]i [C]n O 
cultured [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]d O 
progeny [C]p [C]r [C]o [C]g [C]e [C]n [C]y O 
. [C]. O 

Id-3 [C]I [C]d [C]- [C]3 S-protein 
, [C], O 
a [C]a O 
basic [C]b [C]a [C]s [C]i [C]c B-protein 
helix [C]h [C]e [C]l [C]i [C]x I-protein 
loop [C]l [C]o [C]o [C]p I-protein 
helix [C]h [C]e [C]l [C]i [C]x I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
with [C]w [C]i [C]t [C]h O 
dominant [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
for [C]f [C]o [C]r O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
, [C], O 
also [C]a [C]l [C]s [C]o O 
was [C]w [C]a [C]s O 
upregulated [C]u [C]p [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
and [C]a [C]n [C]d O 
may [C]m [C]a [C]y O 
explain [C]e [C]x [C]p [C]l [C]a [C]i [C]n O 
unsuccessful [C]u [C]n [C]s [C]u [C]c [C]c [C]e [C]s [C]s [C]f [C]u [C]l O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
maturation [C]m [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

To [C]T [C]o O 
better [C]b [C]e [C]t [C]t [C]e [C]r O 
understand [C]u [C]n [C]d [C]e [C]r [C]s [C]t [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
developmental [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t [C]a [C]l O 
link [C]l [C]i [C]n [C]k O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
natural [C]n [C]a [C]t [C]u [C]r [C]a [C]l B-cell_type 
killer [C]k [C]i [C]l [C]l [C]e [C]r I-cell_type 
( [C]( I-cell_type 
NK [C]N [C]K I-cell_type 
) [C]) I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
derived [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
progenitors [C]p [C]r [C]o [C]g [C]e [C]n [C]i [C]t [C]o [C]r [C]s S-cell_type 
, [C], O 
we [C]w [C]e O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
NK [C]N [C]K B-cell_type 
cell [C]c [C]e [C]l [C]l I-cell_type 
subsets [C]s [C]u [C]b [C]s [C]e [C]t [C]s E-cell_type 
circulating [C]c [C]i [C]r [C]c [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
in [C]i [C]n O 
blood [C]b [C]l [C]o [C]o [C]d O 
. [C]. O 

CD56 [C]C [C]D [C]5 [C]6 B-cell_type 
( [C]( I-cell_type 
+bright [C]+ [C]b [C]r [C]i [C]g [C]h [C]t I-cell_type 
) [C]) E-cell_type 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
CD56 [C]C [C]D [C]5 [C]6 B-cell_type 
( [C]( I-cell_type 
+dim [C]+ [C]d [C]i [C]m I-cell_type 
) [C]) E-cell_type 
, [C], O 
NK [C]N [C]K B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
constitutively [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y O 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
TCF-1 [C]T [C]C [C]F [C]- [C]1 S-protein 
by [C]b [C]y O 
reverse [C]r [C]e [C]v [C]e [C]r [C]s [C]e O 
transcriptase [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]a [C]s [C]e O 
polymerase [C]p [C]o [C]l [C]y [C]m [C]e [C]r [C]a [C]s [C]e O 
chain [C]c [C]h [C]a [C]i [C]n O 
reaction [C]r [C]e [C]a [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
Western [C]W [C]e [C]s [C]t [C]e [C]r [C]n O 
blot [C]b [C]l [C]o [C]t O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
TCF-1 [C]T [C]C [C]F [C]- [C]1 B-protein 
isoform [C]i [C]s [C]o [C]f [C]o [C]r [C]m E-protein 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
CD56 [C]C [C]D [C]5 [C]6 B-cell_type 
( [C]( I-cell_type 
+bright [C]+ [C]b [C]r [C]i [C]g [C]h [C]t I-cell_type 
) [C]) I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
lectin [C]l [C]e [C]c [C]t [C]i [C]n S-protein 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n B-protein 
class [C]c [C]l [C]a [C]s [C]s I-protein 
I [C]I E-protein 
recognizing [C]r [C]e [C]c [C]o [C]g [C]n [C]i [C]z [C]i [C]n [C]g O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
, [C], O 
was [C]w [C]a [C]s O 
identical [C]i [C]d [C]e [C]n [C]t [C]i [C]c [C]a [C]l O 
to [C]t [C]o O 
that [C]t [C]h [C]a [C]t O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
in [C]i [C]n O 
NK [C]N [C]K O 
cell [C]c [C]e [C]l [C]l O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
and [C]a [C]n [C]d O 
was [C]w [C]a [C]s O 
distinctly [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t [C]l [C]y O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
from [C]f [C]r [C]o [C]m O 
isoforms [C]i [C]s [C]o [C]f [C]o [C]r [C]m [C]s O 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
TCF-1 [C]T [C]C [C]F [C]- [C]1 S-protein 
does [C]d [C]o [C]e [C]s O 
not [C]n [C]o [C]t O 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
killer [C]k [C]i [C]l [C]l [C]e [C]r I-DNA 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n I-DNA 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
, [C], O 
TCF-1 [C]T [C]C [C]F [C]- [C]1 S-protein 
is [C]i [C]s O 
uniquely [C]u [C]n [C]i [C]q [C]u [C]e [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
circulating [C]c [C]i [C]r [C]c [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
CD56 [C]C [C]D [C]5 [C]6 B-cell_type 
( [C]( I-cell_type 
+bright [C]+ [C]b [C]r [C]i [C]g [C]h [C]t I-cell_type 
) [C]) I-cell_type 
NK [C]N [C]K I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
and [C]a [C]n [C]d O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
TCF-1 [C]T [C]C [C]F [C]- [C]1 B-protein 
isoforms [C]i [C]s [C]o [C]f [C]o [C]r [C]m [C]s E-protein 
may [C]m [C]a [C]y O 
play [C]p [C]l [C]a [C]y O 
an [C]a [C]n O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
regulating [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
NK [C]N [C]K O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
from [C]f [C]r [C]o [C]m O 
a [C]a O 
common [C]c [C]o [C]m [C]m [C]o [C]n O 
NK/T-cell [C]N [C]K [C]/ [C]T [C]- [C]c [C]e [C]l [C]l B-cell_type 
progenitor [C]p [C]r [C]o [C]g [C]e [C]n [C]i [C]t [C]o [C]r E-cell_type 
. [C]. O 

Transcriptional [C]T [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
a [C]a O 
matrix [C]m [C]a [C]t [C]r [C]i [C]x B-protein 
associating [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]n [C]g I-protein 
region-binding [C]r [C]e [C]g [C]i [C]o [C]n [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
. [C]. O 

contextual [C]c [C]o [C]n [C]t [C]e [C]x [C]t [C]u [C]a [C]l O 
requirements [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]m [C]e [C]n [C]t [C]s O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
bright [C]b [C]r [C]i [C]g [C]h [C]t S-protein 
. [C]. O 

Bright [C]B [C]r [C]i [C]g [C]h [C]t S-protein 
( [C]( O 
B [C]B B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
regulator [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r I-protein 
of [C]o [C]f I-protein 
IgH [C]I [C]g [C]H I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n E-protein 
) [C]) O 
is [C]i [C]s O 
a [C]a O 
B [C]B B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
-specific [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
, [C], O 
matrix [C]m [C]a [C]t [C]r [C]i [C]x B-protein 
associating [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]n [C]g I-protein 
region-binding [C]r [C]e [C]g [C]i [C]o [C]n [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
that [C]t [C]h [C]a [C]t O 
transactivates [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]s O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
IgH [C]I [C]g [C]H B-DNA 
intronic [C]i [C]n [C]t [C]r [C]o [C]n [C]i [C]c I-DNA 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r E-DNA 
( [C]( O 
E [C]E B-DNA 
mu [C]m [C]u E-DNA 
) [C]) O 
. [C]. O 

We [C]W [C]e O 
show [C]s [C]h [C]o [C]w O 
here [C]h [C]e [C]r [C]e O 
that [C]t [C]h [C]a [C]t O 
Bright [C]B [C]r [C]i [C]g [C]h [C]t S-protein 
has [C]h [C]a [C]s O 
multiple [C]m [C]u [C]l [C]t [C]i [C]p [C]l [C]e O 
contextual [C]c [C]o [C]n [C]t [C]e [C]x [C]t [C]u [C]a [C]l O 
requirements [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]m [C]e [C]n [C]t [C]s O 
to [C]t [C]o O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
as [C]a [C]s O 
a [C]a O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l B-protein 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r E-protein 
. [C]. O 

Bright [C]B [C]r [C]i [C]g [C]h [C]t S-protein 
can [C]c [C]a [C]n O 
not [C]n [C]o [C]t O 
transactivate [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
via [C]v [C]i [C]a O 
out [C]o [C]u [C]t O 
of [C]o [C]f O 
context [C]c [C]o [C]n [C]t [C]e [C]x [C]t O 
, [C], O 
concatenated [C]c [C]o [C]n [C]c [C]a [C]t [C]e [C]n [C]a [C]t [C]e [C]d B-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
sites [C]s [C]i [C]t [C]e [C]s E-protein 
. [C]. O 

Transactivation [C]T [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
maximal [C]m [C]a [C]x [C]i [C]m [C]a [C]l O 
on [C]o [C]n O 
integrated [C]i [C]n [C]t [C]e [C]g [C]r [C]a [C]t [C]e [C]d O 
substrates [C]s [C]u [C]b [C]s [C]t [C]r [C]a [C]t [C]e [C]s O 
. [C]. O 

Two [C]T [C]w [C]o O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
three [C]t [C]h [C]r [C]e [C]e O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
in [C]i [C]n O 
E [C]E B-DNA 
mu [C]m [C]u E-DNA 
are [C]a [C]r [C]e O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
full [C]f [C]u [C]l [C]l O 
Bright [C]B [C]r [C]i [C]g [C]h [C]t S-protein 
transactivation [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
Bright [C]B [C]r [C]i [C]g [C]h [C]t B-protein 
DNA [C]D [C]N [C]A I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
defined [C]d [C]e [C]f [C]i [C]n [C]e [C]d O 
a [C]a O 
new [C]n [C]e [C]w O 
family [C]f [C]a [C]m [C]i [C]l [C]y O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
includes [C]i [C]n [C]c [C]l [C]u [C]d [C]e [C]s O 
SWI1 [C]S [C]W [C]I [C]1 S-protein 
, [C], O 
a [C]a O 
component [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
SWI.SNF [C]S [C]W [C]I [C]. [C]S [C]N [C]F B-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
have [C]h [C]a [C]v [C]e O 
high [C]h [C]i [C]g [C]h O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
group-like [C]g [C]r [C]o [C]u [C]p [C]- [C]l [C]i [C]k [C]e O 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
characteristics [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]s [C]t [C]i [C]c [C]s O 
. [C]. O 

Similar [C]S [C]i [C]m [C]i [C]l [C]a [C]r O 
to [C]t [C]o O 
one [C]o [C]n [C]e O 
group [C]g [C]r [C]o [C]u [C]p O 
of [C]o [C]f O 
high [C]h [C]i [C]g [C]h B-protein 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y I-protein 
group [C]g [C]r [C]o [C]u [C]p I-protein 
box [C]b [C]o [C]x I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
, [C], O 
Bright [C]B [C]r [C]i [C]g [C]h [C]t S-protein 
distorts [C]d [C]i [C]s [C]t [C]o [C]r [C]t [C]s O 
E [C]E B-DNA 
mu [C]m [C]u I-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
-containing [C]- [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
DNA [C]D [C]N [C]A O 
on [C]o [C]n O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
, [C], O 
supporting [C]s [C]u [C]p [C]p [C]o [C]r [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
concept [C]c [C]o [C]n [C]c [C]e [C]p [C]t O 
that [C]t [C]h [C]a [C]t O 
it [C]i [C]t O 
mediates [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]s O 
E [C]E B-DNA 
mu [C]m [C]u E-DNA 
remodeling [C]r [C]e [C]m [C]o [C]d [C]e [C]l [C]i [C]n [C]g O 
. [C]. O 

Transfection [C]T [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
implicate [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]e O 
Bright [C]B [C]r [C]i [C]g [C]h [C]t S-protein 
in [C]i [C]n O 
facilitating [C]f [C]a [C]c [C]i [C]l [C]i [C]t [C]a [C]t [C]i [C]n [C]g O 
spatially [C]s [C]p [C]a [C]t [C]i [C]a [C]l [C]l [C]y O 
separated [C]s [C]e [C]p [C]a [C]r [C]a [C]t [C]e [C]d O 
promoter-enhancer [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]- [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r O 
interactions [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
transient [C]t [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
stable [C]s [C]t [C]a [C]b [C]l [C]e O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
. [C]. O 

Finally [C]F [C]i [C]n [C]a [C]l [C]l [C]y O 
, [C], O 
we [C]w [C]e O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
overexpression [C]o [C]v [C]e [C]r [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
Bright [C]B [C]r [C]i [C]g [C]h [C]t S-protein 
leads [C]l [C]e [C]a [C]d [C]s O 
to [C]t [C]o O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
DNase [C]D [C]N [C]a [C]s [C]e O 
I [C]I O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
endogenous [C]e [C]n [C]d [C]o [C]g [C]e [C]n [C]o [C]u [C]s O 
E [C]E B-DNA 
mu [C]m [C]u E-DNA 
matrix [C]m [C]a [C]t [C]r [C]i [C]x O 
associating [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]n [C]g O 
regions [C]r [C]e [C]g [C]i [C]o [C]n [C]s O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
Bright [C]B [C]r [C]i [C]g [C]h [C]t S-protein 
may [C]m [C]a [C]y O 
contribute [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e O 
to [C]t [C]o O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
by [C]b [C]y O 
remodeling [C]r [C]e [C]m [C]o [C]d [C]e [C]l [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n B-DNA 
locus [C]l [C]o [C]c [C]u [C]s E-DNA 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
B [C]B B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
. [C]. O 

Analysis [C]A [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
BCL-6 [C]B [C]C [C]L [C]- [C]6 O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
classic [C]c [C]l [C]a [C]s [C]s [C]i [C]c O 
Hodgkin [C]H [C]o [C]d [C]g [C]k [C]i [C]n O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
B- [C]B [C]- B-cell_type 
and [C]a [C]n [C]d I-cell_type 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l I-cell_type 
type [C]t [C]y [C]p [C]e E-cell_type 
. [C]. O 

BCL-6 [C]B [C]C [C]L [C]- [C]6 S-DNA 
is [C]i [C]s O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
for [C]f [C]o [C]r O 
germinal [C]g [C]e [C]r [C]m [C]i [C]n [C]a [C]l O 
center [C]c [C]e [C]n [C]t [C]e [C]r O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
thus [C]t [C]h [C]u [C]s O 
for [C]f [C]o [C]r O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
maturation [C]m [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n B-DNA 
( [C]( I-DNA 
Ig [C]I [C]g I-DNA 
) [C]) I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
by [C]b [C]y O 
somatic [C]s [C]o [C]m [C]a [C]t [C]i [C]c O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
5'-noncoding [C]5 [C]' [C]- [C]n [C]o [C]n [C]c [C]o [C]d [C]i [C]n [C]g B-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
BCL-6 [C]B [C]C [C]L [C]- [C]6 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
is [C]i [C]s O 
even [C]e [C]v [C]e [C]n O 
a [C]a O 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
machinery [C]m [C]a [C]c [C]h [C]i [C]n [C]e [C]r [C]y O 
. [C]. O 

Translocations [C]T [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
BCL-6 [C]B [C]C [C]L [C]- [C]6 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
to [C]t [C]o O 
heterologous [C]h [C]e [C]t [C]e [C]r [C]o [C]l [C]o [C]g [C]o [C]u [C]s B-DNA 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s E-DNA 
and [C]a [C]n [C]d O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
its [C]i [C]t [C]s O 
5'-noncoding [C]5 [C]' [C]- [C]n [C]o [C]n [C]c [C]o [C]d [C]i [C]n [C]g B-DNA 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y I-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
were [C]w [C]e [C]r [C]e O 
reported [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
for [C]f [C]o [C]r O 
deregulating [C]d [C]e [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
BCL-6 [C]B [C]C [C]L [C]- [C]6 S-DNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
for [C]f [C]o [C]r O 
playing [C]p [C]l [C]a [C]y [C]i [C]n [C]g O 
a [C]a O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
genesis [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
non-Hodgkin [C]n [C]o [C]n [C]- [C]H [C]o [C]d [C]g [C]k [C]i [C]n O 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a O 
. [C]. O 

In [C]I [C]n O 
line [C]l [C]i [C]n [C]e O 
with [C]w [C]i [C]t [C]h O 
this [C]t [C]h [C]i [C]s O 
hypothesis [C]h [C]y [C]p [C]o [C]t [C]h [C]e [C]s [C]i [C]s O 
is [C]i [C]s O 
the [C]t [C]h [C]e O 
observation [C]o [C]b [C]s [C]e [C]r [C]v [C]a [C]t [C]i [C]o [C]n O 
that [C]t [C]h [C]a [C]t O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l O 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a O 
with [C]w [C]i [C]t [C]h O 
somatic [C]s [C]o [C]m [C]a [C]t [C]i [C]c O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
, [C], O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
diffuse [C]d [C]i [C]f [C]f [C]u [C]s [C]e O 
large [C]l [C]a [C]r [C]g [C]e O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l O 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a O 
and [C]a [C]n [C]d O 
follicular [C]f [C]o [C]l [C]l [C]i [C]c [C]u [C]l [C]a [C]r O 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a O 
, [C], O 
also [C]a [C]l [C]s [C]o O 
carry [C]c [C]a [C]r [C]r [C]y O 
BCL-6 [C]B [C]C [C]L [C]- [C]6 O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
, [C], O 
some [C]s [C]o [C]m [C]e O 
of [C]o [C]f O 
which [C]w [C]h [C]i [C]c [C]h O 
are [C]a [C]r [C]e O 
recurrently [C]r [C]e [C]c [C]u [C]r [C]r [C]e [C]n [C]t [C]l [C]y O 
detectable [C]d [C]e [C]t [C]e [C]c [C]t [C]a [C]b [C]l [C]e O 
. [C]. O 

Classic [C]C [C]l [C]a [C]s [C]s [C]i [C]c O 
Hodgkin [C]H [C]o [C]d [C]g [C]k [C]i [C]n O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
( [C]( O 
cHD [C]c [C]H [C]D O 
) [C]) O 
is [C]i [C]s O 
also [C]a [C]l [C]s [C]o O 
derived [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
with [C]w [C]i [C]t [C]h O 
high [C]h [C]i [C]g [C]h O 
loads [C]l [C]o [C]a [C]d [C]s O 
of [C]o [C]f O 
somatic [C]s [C]o [C]m [C]a [C]t [C]i [C]c O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
and [C]a [C]n [C]d O 
thus [C]t [C]h [C]u [C]s O 
a [C]a O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
candidate [C]c [C]a [C]n [C]d [C]i [C]d [C]a [C]t [C]e O 
for [C]f [C]o [C]r O 
BCL-6 [C]B [C]C [C]L [C]- [C]6 O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

To [C]T [C]o O 
determine [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
and [C]a [C]n [C]d O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
BCL-6 [C]B [C]C [C]L [C]- [C]6 O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
cHD [C]c [C]H [C]D O 
, [C], O 
the [C]t [C]h [C]e O 
5'-noncoding [C]5 [C]' [C]- [C]n [C]o [C]n [C]c [C]o [C]d [C]i [C]n [C]g B-DNA 
BCL-6 [C]B [C]C [C]L [C]- [C]6 E-DNA 
proportion [C]p [C]r [C]o [C]p [C]o [C]r [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
single [C]s [C]i [C]n [C]g [C]l [C]e B-cell_type 
Hodgkin [C]H [C]o [C]d [C]g [C]k [C]i [C]n I-cell_type 
and [C]a [C]n [C]d I-cell_type 
Reed-Sternberg [C]R [C]e [C]e [C]d [C]- [C]S [C]t [C]e [C]r [C]n [C]b [C]e [C]r [C]g I-cell_type 
( [C]( I-cell_type 
HRS [C]H [C]R [C]S I-cell_type 
) [C]) I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
6 [C]6 O 
cases [C]c [C]a [C]s [C]e [C]s O 
of [C]o [C]f O 
cHD [C]c [C]H [C]D O 
and [C]a [C]n [C]d O 
6 [C]6 O 
cases [C]c [C]a [C]s [C]e [C]s O 
of [C]o [C]f O 
HD-derived [C]H [C]D [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
was [C]w [C]a [C]s O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
. [C]. O 

All [C]A [C]l [C]l O 
B-cell-derived [C]B [C]- [C]c [C]e [C]l [C]l [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
HD [C]H [C]D O 
cases [C]c [C]a [C]s [C]e [C]s O 
and [C]a [C]n [C]d O 
cell [C]c [C]e [C]l [C]l O 
lines [C]l [C]i [C]n [C]e [C]s O 
harbored [C]h [C]a [C]r [C]b [C]o [C]r [C]e [C]d O 
BCL-6 [C]B [C]C [C]L [C]- [C]6 O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
both [C]b [C]o [C]t [C]h O 
T-cell-derived [C]T [C]- [C]c [C]e [C]l [C]l [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
HD [C]H [C]D O 
cases [C]c [C]a [C]s [C]e [C]s O 
and [C]a [C]n [C]d O 
cell [C]c [C]e [C]l [C]l O 
lines [C]l [C]i [C]n [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
devoid [C]d [C]e [C]v [C]o [C]i [C]d O 
of [C]o [C]f O 
BCL-6 [C]B [C]C [C]L [C]- [C]6 O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

With [C]W [C]i [C]t [C]h O 
only [C]o [C]n [C]l [C]y O 
one [C]o [C]n [C]e O 
exception [C]e [C]x [C]c [C]e [C]p [C]t [C]i [C]o [C]n O 
, [C], O 
there [C]t [C]h [C]e [C]r [C]e O 
were [C]w [C]e [C]r [C]e O 
no [C]n [C]o O 
lymphoma-specific [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
recurrent [C]r [C]e [C]c [C]u [C]r [C]r [C]e [C]n [C]t O 
BCL-6 [C]B [C]C [C]L [C]- [C]6 O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
, [C], O 
and [C]a [C]n [C]d O 
BCL-6 [C]B [C]C [C]L [C]- [C]6 B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
was [C]w [C]a [C]s O 
absent [C]a [C]b [C]s [C]e [C]n [C]t O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
HRS [C]H [C]R [C]S B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
of [C]o [C]f O 
most [C]m [C]o [C]s [C]t O 
cases [C]c [C]a [C]s [C]e [C]s O 
. [C]. O 

In [C]I [C]n O 
conclusion [C]c [C]o [C]n [C]c [C]l [C]u [C]s [C]i [C]o [C]n O 
, [C], O 
( [C]( O 
1 [C]1 O 
) [C]) O 
somatic [C]s [C]o [C]m [C]a [C]t [C]i [C]c O 
BCL-6 [C]B [C]C [C]L [C]- [C]6 O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
are [C]a [C]r [C]e O 
restricted [C]r [C]e [C]s [C]t [C]r [C]i [C]c [C]t [C]e [C]d O 
to [C]t [C]o O 
cHD [C]c [C]H [C]D O 
cases [C]c [C]a [C]s [C]e [C]s O 
of [C]o [C]f O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l S-cell_type 
origin [C]o [C]r [C]i [C]g [C]i [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
( [C]( O 
2 [C]2 O 
) [C]) O 
the [C]t [C]h [C]e O 
BCL-6 [C]B [C]C [C]L [C]- [C]6 O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
represent [C]r [C]e [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
mostly [C]m [C]o [C]s [C]t [C]l [C]y O 
irrelevant [C]i [C]r [C]r [C]e [C]l [C]e [C]v [C]a [C]n [C]t O 
somatic [C]s [C]o [C]m [C]a [C]t [C]i [C]c O 
base [C]b [C]a [C]s [C]e O 
substitutions [C]s [C]u [C]b [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]o [C]n [C]s O 
without [C]w [C]i [C]t [C]h [C]o [C]u [C]t O 
consequences [C]c [C]o [C]n [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s O 
for [C]f [C]o [C]r O 
BCL-6 [C]B [C]C [C]L [C]- [C]6 B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
pathogenesis [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
cHD [C]c [C]H [C]D O 
. [C]. O 

Gadd45gamma [C]G [C]a [C]d [C]d [C]4 [C]5 [C]g [C]a [C]m [C]m [C]a S-DNA 
is [C]i [C]s O 
dispensable [C]d [C]i [C]s [C]p [C]e [C]n [C]s [C]a [C]b [C]l [C]e O 
for [C]f [C]o [C]r O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
mouse [C]m [C]o [C]u [C]s [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Gadd45gamma [C]G [C]a [C]d [C]d [C]4 [C]5 [C]g [C]a [C]m [C]m [C]a S-DNA 
, [C], O 
a [C]a O 
family [C]f [C]a [C]m [C]i [C]l [C]y O 
member [C]m [C]e [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
growth [C]g [C]r [C]o [C]w [C]t [C]h B-DNA 
arrest [C]a [C]r [C]r [C]e [C]s [C]t I-DNA 
and [C]a [C]n [C]d I-DNA 
DNA [C]D [C]N [C]A I-DNA 
damage-inducible [C]d [C]a [C]m [C]a [C]g [C]e [C]- [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e I-DNA 
gene [C]g [C]e [C]n [C]e I-DNA 
family [C]f [C]a [C]m [C]i [C]l [C]y I-DNA 
45 [C]4 [C]5 E-DNA 
( [C]( O 
Gadd45 [C]G [C]a [C]d [C]d [C]4 [C]5 S-DNA 
) [C]) O 
, [C], O 
is [C]i [C]s O 
strongly [C]s [C]t [C]r [C]o [C]n [C]g [C]l [C]y O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
interleukin-2 [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]2 S-protein 
( [C]( O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
) [C]) O 
in [C]i [C]n O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

While [C]W [C]h [C]i [C]l [C]e O 
in [C]i [C]n O 
most [C]m [C]o [C]s [C]t O 
tissues [C]t [C]i [C]s [C]s [C]u [C]e [C]s O 
all [C]a [C]l [C]l O 
Gadd45 [C]G [C]a [C]d [C]d [C]4 [C]5 B-DNA 
family [C]f [C]a [C]m [C]i [C]l [C]y I-DNA 
members [C]m [C]e [C]m [C]b [C]e [C]r [C]s E-DNA 
are [C]a [C]r [C]e O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
, [C], O 
Gadd45gamma [C]G [C]a [C]d [C]d [C]4 [C]5 [C]g [C]a [C]m [C]m [C]a S-DNA 
is [C]i [C]s O 
the [C]t [C]h [C]e O 
only [C]o [C]n [C]l [C]y O 
member [C]m [C]e [C]m [C]b [C]e [C]r O 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
we [C]w [C]e O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
Gadd45gamma [C]G [C]a [C]d [C]d [C]4 [C]5 [C]g [C]a [C]m [C]m [C]a S-DNA 
is [C]i [C]s O 
dependent [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
on [C]o [C]n O 
a [C]a O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
Jak3 [C]J [C]a [C]k [C]3 E-protein 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
Stat5a [C]S [C]t [C]a [C]t [C]5 [C]a S-protein 
and [C]a [C]n [C]d O 
Stat5b [C]S [C]t [C]a [C]t [C]5 [C]b S-protein 
( [C]( O 
signal [C]s [C]i [C]g [C]n [C]a [C]l B-protein 
transducer [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]e [C]r I-protein 
and [C]a [C]n [C]d I-protein 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r I-protein 
of [C]o [C]f I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n E-protein 
) [C]) O 
. [C]. O 

Previous [C]P [C]r [C]e [C]v [C]i [C]o [C]u [C]s O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
ectopically [C]e [C]c [C]t [C]o [C]p [C]i [C]c [C]a [C]l [C]l [C]y O 
overexpressed [C]o [C]v [C]e [C]r [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
Gadd45gamma [C]G [C]a [C]d [C]d [C]4 [C]5 [C]g [C]a [C]m [C]m [C]a S-DNA 
in [C]i [C]n O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
cell [C]c [C]e [C]l [C]l O 
lines [C]l [C]i [C]n [C]e [C]s O 
implicated [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]e [C]d O 
its [C]i [C]t [C]s O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
. [C]. O 

To [C]T [C]o O 
analyze [C]a [C]n [C]a [C]l [C]y [C]z [C]e O 
the [C]t [C]h [C]e O 
physiological [C]p [C]h [C]y [C]s [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
Gadd45gamma [C]G [C]a [C]d [C]d [C]4 [C]5 [C]g [C]a [C]m [C]m [C]a S-DNA 
we [C]w [C]e O 
used [C]u [C]s [C]e [C]d O 
homologous [C]h [C]o [C]m [C]o [C]l [C]o [C]g [C]o [C]u [C]s O 
recombination [C]r [C]e [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
to [C]t [C]o O 
generate [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]e O 
mice [C]m [C]i [C]c [C]e O 
lacking [C]l [C]a [C]c [C]k [C]i [C]n [C]g O 
Gadd45gamma [C]G [C]a [C]d [C]d [C]4 [C]5 [C]g [C]a [C]m [C]m [C]a S-DNA 
. [C]. O 

Gadd45gamma [C]G [C]a [C]d [C]d [C]4 [C]5 [C]g [C]a [C]m [C]m [C]a S-DNA 
-deficient [C]- [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
mice [C]m [C]i [C]c [C]e O 
develop [C]d [C]e [C]v [C]e [C]l [C]o [C]p O 
normally [C]n [C]o [C]r [C]m [C]a [C]l [C]l [C]y O 
, [C], O 
are [C]a [C]r [C]e O 
indistinguishable [C]i [C]n [C]d [C]i [C]s [C]t [C]i [C]n [C]g [C]u [C]i [C]s [C]h [C]a [C]b [C]l [C]e O 
from [C]f [C]r [C]o [C]m O 
their [C]t [C]h [C]e [C]i [C]r O 
littermates [C]l [C]i [C]t [C]t [C]e [C]r [C]m [C]a [C]t [C]e [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
are [C]a [C]r [C]e O 
fertile [C]f [C]e [C]r [C]t [C]i [C]l [C]e O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
hematopoiesis [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
in [C]i [C]n O 
mice [C]m [C]i [C]c [C]e O 
lacking [C]l [C]a [C]c [C]k [C]i [C]n [C]g O 
Gadd45gamma [C]G [C]a [C]d [C]d [C]4 [C]5 [C]g [C]a [C]m [C]m [C]a S-DNA 
is [C]i [C]s O 
not [C]n [C]o [C]t O 
impaired [C]i [C]m [C]p [C]a [C]i [C]r [C]e [C]d O 
and [C]a [C]n [C]d O 
Gadd45gamma [C]G [C]a [C]d [C]d [C]4 [C]5 [C]g [C]a [C]m [C]m [C]a S-DNA 
-deficient [C]- [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
T [C]T B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
show [C]s [C]h [C]o [C]w O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
to [C]t [C]o O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
Gadd45gamma [C]G [C]a [C]d [C]d [C]4 [C]5 [C]g [C]a [C]m [C]m [C]a S-DNA 
is [C]i [C]s O 
not [C]n [C]o [C]t O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
for [C]f [C]o [C]r O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
mouse [C]m [C]o [C]u [C]s [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
hematopoiesis [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
, [C], O 
possibly [C]p [C]o [C]s [C]s [C]i [C]b [C]l [C]y O 
due [C]d [C]u [C]e O 
to [C]t [C]o O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
redundancy [C]r [C]e [C]d [C]u [C]n [C]d [C]a [C]n [C]c [C]y O 
among [C]a [C]m [C]o [C]n [C]g O 
the [C]t [C]h [C]e O 
Gadd45 [C]G [C]a [C]d [C]d [C]4 [C]5 B-DNA 
family [C]f [C]a [C]m [C]i [C]l [C]y I-DNA 
members [C]m [C]e [C]m [C]b [C]e [C]r [C]s E-DNA 
. [C]. O 

Gadd45gamma [C]G [C]a [C]d [C]d [C]4 [C]5 [C]g [C]a [C]m [C]m [C]a S-DNA 
is [C]i [C]s O 
also [C]a [C]l [C]s [C]o O 
dispensable [C]d [C]i [C]s [C]p [C]e [C]n [C]s [C]a [C]b [C]l [C]e O 
for [C]f [C]o [C]r O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Decreased [C]D [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
c-myc [C]c [C]- [C]m [C]y [C]c B-DNA 
family [C]f [C]a [C]m [C]i [C]l [C]y I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
in [C]i [C]n O 
thymuses [C]t [C]h [C]y [C]m [C]u [C]s [C]e [C]s O 
from [C]f [C]r [C]o [C]m O 
myasthenia [C]m [C]y [C]a [C]s [C]t [C]h [C]e [C]n [C]i [C]a O 
gravis [C]g [C]r [C]a [C]v [C]i [C]s O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
thymus [C]t [C]h [C]y [C]m [C]u [C]s O 
is [C]i [C]s O 
a [C]a O 
critical [C]c [C]r [C]i [C]t [C]i [C]c [C]a [C]l O 
organ [C]o [C]r [C]g [C]a [C]n O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
elimination [C]e [C]l [C]i [C]m [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
autoreactive [C]a [C]u [C]t [C]o [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]e B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
by [C]b [C]y O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
. [C]. O 

We [C]W [C]e O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
apoptosis-associated [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s [C]- [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
genes [C]g [C]e [C]n [C]e [C]s O 
, [C], O 
bcl-xL [C]b [C]c [C]l [C]- [C]x [C]L S-DNA 
, [C], O 
bad [C]b [C]a [C]d S-DNA 
, [C], O 
caspase-3 [C]c [C]a [C]s [C]p [C]a [C]s [C]e [C]- [C]3 S-DNA 
, [C], O 
and [C]a [C]n [C]d O 
c-myc [C]c [C]- [C]m [C]y [C]c B-DNA 
family [C]f [C]a [C]m [C]i [C]l [C]y I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
in [C]i [C]n O 
myasthenia [C]m [C]y [C]a [C]s [C]t [C]h [C]e [C]n [C]i [C]a O 
gravis [C]g [C]r [C]a [C]v [C]i [C]s O 
( [C]( O 
MG [C]M [C]G O 
) [C]) O 
thymuses [C]t [C]h [C]y [C]m [C]u [C]s [C]e [C]s O 
. [C]. O 

We [C]W [C]e O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
mRNA [C]m [C]R [C]N [C]A O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
myc [C]m [C]y [C]c B-DNA 
family [C]f [C]a [C]m [C]i [C]l [C]y I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
, [C], O 
c-myc [C]c [C]- [C]m [C]y [C]c S-DNA 
and [C]a [C]n [C]d O 
max [C]m [C]a [C]x S-DNA 
, [C], O 
were [C]w [C]e [C]r [C]e O 
markedly [C]m [C]a [C]r [C]k [C]e [C]d [C]l [C]y O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
in [C]i [C]n O 
MG [C]M [C]G O 
thymuses [C]t [C]h [C]y [C]m [C]u [C]s [C]e [C]s O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
c-myc [C]c [C]- [C]m [C]y [C]c S-DNA 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
is [C]i [C]s O 
abnormal [C]a [C]b [C]n [C]o [C]r [C]m [C]a [C]l O 
in [C]i [C]n O 
MG [C]M [C]G O 
thymuses [C]t [C]h [C]y [C]m [C]u [C]s [C]e [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
molecules [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]s O 
whose [C]w [C]h [C]o [C]s [C]e O 
expressions [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n [C]s O 
are [C]a [C]r [C]e O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
myc [C]m [C]y [C]c S-DNA 
, [C], O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
STAM [C]S [C]T [C]A [C]M S-protein 
, [C], O 
prothymosin-alpha [C]p [C]r [C]o [C]t [C]h [C]y [C]m [C]o [C]s [C]i [C]n [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
, [C], O 
and [C]a [C]n [C]d O 
NFkappaB [C]N [C]F [C]k [C]a [C]p [C]p [C]a [C]B S-protein 

Immunohistochemical [C]I [C]m [C]m [C]u [C]n [C]o [C]h [C]i [C]s [C]t [C]o [C]c [C]h [C]e [C]m [C]i [C]c [C]a [C]l O 
detection [C]d [C]e [C]t [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
interferon-gamma-producing [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n [C]- [C]g [C]a [C]m [C]m [C]a [C]- [C]p [C]r [C]o [C]d [C]u [C]c [C]i [C]n [C]g B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
dermatophytosis [C]d [C]e [C]r [C]m [C]a [C]t [C]o [C]p [C]h [C]y [C]t [C]o [C]s [C]i [C]s O 
. [C]. O 

Skin [C]S [C]k [C]i [C]n O 
lesions [C]l [C]e [C]s [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
dermatophytosis [C]d [C]e [C]r [C]m [C]a [C]t [C]o [C]p [C]h [C]y [C]t [C]o [C]s [C]i [C]s O 
are [C]a [C]r [C]e O 
thought [C]t [C]h [C]o [C]u [C]g [C]h [C]t O 
to [C]t [C]o O 
be [C]b [C]e O 
a [C]a O 
result [C]r [C]e [C]s [C]u [C]l [C]t O 
of [C]o [C]f O 
a [C]a O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
. [C]. O 

We [C]W [C]e O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
IFN-gamma-positive [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
as [C]a [C]s O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
Th1 [C]T [C]h [C]1 S-cell_type 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
) [C]) O 
were [C]w [C]e [C]r [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
skin [C]s [C]k [C]i [C]n O 
lesions [C]l [C]e [C]s [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
dermatophytosis [C]d [C]e [C]r [C]m [C]a [C]t [C]o [C]p [C]h [C]y [C]t [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
situ [C]s [C]i [C]t [C]u O 
by [C]b [C]y O 
immunohistochemical [C]i [C]m [C]m [C]u [C]n [C]o [C]h [C]i [C]s [C]t [C]o [C]c [C]h [C]e [C]m [C]i [C]c [C]a [C]l O 
techniques [C]t [C]e [C]c [C]h [C]n [C]i [C]q [C]u [C]e [C]s O 
. [C]. O 

Mixtures [C]M [C]i [C]x [C]t [C]u [C]r [C]e [C]s O 
of [C]o [C]f O 
CD4-positive [C]C [C]D [C]4 [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
CD8-positive [C]C [C]D [C]8 [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
dermal [C]d [C]e [C]r [C]m [C]a [C]l O 
infiltrates [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]e [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
lesions [C]l [C]e [C]s [C]i [C]o [C]n [C]s O 
. [C]. O 

Considerable [C]C [C]o [C]n [C]s [C]i [C]d [C]e [C]r [C]a [C]b [C]l [C]e O 
numbers [C]n [C]u [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
CD1a-positive [C]C [C]D [C]1 [C]a [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
upper [C]u [C]p [C]p [C]e [C]r O 
dermis [C]d [C]e [C]r [C]m [C]i [C]s O 
and [C]a [C]n [C]d O 
epidermis [C]e [C]p [C]i [C]d [C]e [C]r [C]m [C]i [C]s O 
. [C]. O 

A [C]A O 
marked [C]m [C]a [C]r [C]k [C]e [C]d O 
accumulation [C]a [C]c [C]c [C]u [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CD68-positive [C]C [C]D [C]6 [C]8 [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
upper [C]u [C]p [C]p [C]e [C]r O 
dermis [C]d [C]e [C]r [C]m [C]i [C]s O 
. [C]. O 

IFN-gamma-positive [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
upper [C]u [C]p [C]p [C]e [C]r O 
dermis [C]d [C]e [C]r [C]m [C]i [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
lesions [C]l [C]e [C]s [C]i [C]o [C]n [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
pattern [C]p [C]a [C]t [C]t [C]e [C]r [C]n O 
of [C]o [C]f O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
staining [C]s [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
appeared [C]a [C]p [C]p [C]e [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
in [C]i [C]n O 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_type 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
staining [C]s [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
was [C]w [C]a [C]s O 
considered [C]c [C]o [C]n [C]s [C]i [C]d [C]e [C]r [C]e [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
highly [C]h [C]i [C]g [C]h [C]l [C]y O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
because [C]b [C]e [C]c [C]a [C]u [C]s [C]e O 
it [C]i [C]t O 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
completely [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e [C]l [C]y O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
by [C]b [C]y O 
preabsorption [C]p [C]r [C]e [C]a [C]b [C]s [C]o [C]r [C]p [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
recombinant [C]r [C]e [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]n [C]t B-protein 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a E-protein 
. [C]. O 

Our [C]O [C]u [C]r O 
data [C]d [C]a [C]t [C]a O 
support [C]s [C]u [C]p [C]p [C]o [C]r [C]t O 
the [C]t [C]h [C]e O 
hypothesis [C]h [C]y [C]p [C]o [C]t [C]h [C]e [C]s [C]i [C]s O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
skin [C]s [C]k [C]i [C]n O 
lesions [C]l [C]e [C]s [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
dermatophytosis [C]d [C]e [C]r [C]m [C]a [C]t [C]o [C]p [C]h [C]y [C]t [C]o [C]s [C]i [C]s O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
Th1 [C]T [C]h [C]1 S-cell_type 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
. [C]. O 

Th1 [C]T [C]h [C]1 S-cell_type 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
characterized [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]d O 
by [C]b [C]y O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
release [C]r [C]e [C]l [C]e [C]a [C]s [C]e O 
, [C], O 
is [C]i [C]s O 
thought [C]t [C]h [C]o [C]u [C]g [C]h [C]t O 
to [C]t [C]o O 
be [C]b [C]e O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
host [C]h [C]o [C]s [C]t O 
defense [C]d [C]e [C]f [C]e [C]n [C]s [C]e O 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
dermatophytes [C]d [C]e [C]r [C]m [C]a [C]t [C]o [C]p [C]h [C]y [C]t [C]e [C]s O 
and [C]a [C]n [C]d O 
to [C]t [C]o O 
reflect [C]r [C]e [C]f [C]l [C]e [C]c [C]t O 
cutaneous [C]c [C]u [C]t [C]a [C]n [C]e [C]o [C]u [C]s O 
reaction [C]r [C]e [C]a [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
dermatophytosis [C]d [C]e [C]r [C]m [C]a [C]t [C]o [C]p [C]h [C]y [C]t [C]o [C]s [C]i [C]s O 
. [C]. O 

Regulation [C]R [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
helix-loop-helix [C]h [C]e [C]l [C]i [C]x [C]- [C]l [C]o [C]o [C]p [C]- [C]h [C]e [C]l [C]i [C]x B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
, [C], O 
E2A [C]E [C]2 [C]A S-protein 
and [C]a [C]n [C]d O 
Id3 [C]I [C]d [C]3 S-protein 
, [C], O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
Ras [C]R [C]a [C]s S-protein 
- [C]- O 
ERK [C]E [C]R [C]K S-protein 
MAPK [C]M [C]A [C]P [C]K S-protein 
cascade [C]c [C]a [C]s [C]c [C]a [C]d [C]e O 
. [C]. O 

Activation [C]A [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
mitogen-activated [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
( [C]( O 
MAPK [C]M [C]A [C]P [C]K S-protein 
) [C]) O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
leads [C]l [C]e [C]a [C]d [C]s O 
to [C]t [C]o O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
and/or [C]a [C]n [C]d [C]/ [C]o [C]r O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
a [C]a O 
wide [C]w [C]i [C]d [C]e O 
variety [C]v [C]a [C]r [C]i [C]e [C]t [C]y O 
of [C]o [C]f O 
cell [C]c [C]e [C]l [C]l O 
types [C]t [C]y [C]p [C]e [C]s O 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
developing [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]i [C]n [C]g B-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
basic [C]b [C]a [C]s [C]i [C]c B-protein 
helix-loop-helix [C]h [C]e [C]l [C]i [C]x [C]- [C]l [C]o [C]o [C]p [C]- [C]h [C]e [C]l [C]i [C]x I-protein 
( [C]( I-protein 
bHLH [C]b [C]H [C]L [C]H I-protein 
) [C]) I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
E12 [C]E [C]1 [C]2 S-protein 
and [C]a [C]n [C]d O 
E47 [C]E [C]4 [C]7 S-protein 
and [C]a [C]n [C]d O 
an [C]a [C]n O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r B-protein 
HLH [C]H [C]L [C]H I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
, [C], O 
Id3 [C]I [C]d [C]3 S-protein 
, [C], O 
play [C]p [C]l [C]a [C]y O 
key [C]k [C]e [C]y O 
roles [C]r [C]o [C]l [C]e [C]s O 
in [C]i [C]n O 
thymocyte [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

We [C]W [C]e O 
show [C]s [C]h [C]o [C]w O 
here [C]h [C]e [C]r [C]e O 
that [C]t [C]h [C]a [C]t O 
E2A [C]E [C]2 [C]A S-protein 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
is [C]i [C]s O 
lowered [C]l [C]o [C]w [C]e [C]r [C]e [C]d O 
in [C]i [C]n O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y B-cell_type 
immature [C]i [C]m [C]m [C]a [C]t [C]u [C]r [C]e I-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
consequent [C]c [C]o [C]n [C]s [C]e [C]q [C]u [C]e [C]n [C]t O 
to [C]t [C]o O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
( [C]( O 
TCR [C]T [C]C [C]R O 
) [C]) O 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
ligation [C]l [C]i [C]g [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Whereas [C]W [C]h [C]e [C]r [C]e [C]a [C]s O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
E2A [C]E [C]2 [C]A O 
mRNA [C]m [C]R [C]N [C]A O 
and [C]a [C]n [C]d O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
are [C]a [C]r [C]e O 
unaltered [C]u [C]n [C]a [C]l [C]t [C]e [C]r [C]e [C]d O 
, [C], O 
Id3 [C]I [C]d [C]3 B-RNA 
transcripts [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]s E-RNA 
are [C]a [C]r [C]e O 
rapidly [C]r [C]a [C]p [C]i [C]d [C]l [C]y O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
upon [C]u [C]p [C]o [C]n O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
TCR [C]T [C]C [C]R S-protein 
. [C]. O 

Activation [C]A [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Id3 [C]I [C]d [C]3 O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
a [C]a O 
dose-dependent [C]d [C]o [C]s [C]e [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
manner [C]m [C]a [C]n [C]n [C]e [C]r O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
extracellular [C]e [C]x [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
signal-regulated [C]s [C]i [C]g [C]n [C]a [C]l [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
( [C]( O 
ERK [C]E [C]R [C]K S-protein 
) [C]) O 
MAPK [C]M [C]A [C]P [C]K S-protein 
module [C]m [C]o [C]d [C]u [C]l [C]e O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
observations [C]o [C]b [C]s [C]e [C]r [C]v [C]a [C]t [C]i [C]o [C]n [C]s O 
directly [C]d [C]i [C]r [C]e [C]c [C]t [C]l [C]y O 
connect [C]c [C]o [C]n [C]n [C]e [C]c [C]t O 
the [C]t [C]h [C]e O 
ERK [C]E [C]R [C]K S-protein 
MAPK [C]M [C]A [C]P [C]K S-protein 
cascade [C]c [C]a [C]s [C]c [C]a [C]d [C]e O 
and [C]a [C]n [C]d O 
HLH [C]H [C]L [C]H B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
in [C]i [C]n O 
a [C]a O 
linear [C]l [C]i [C]n [C]e [C]a [C]r O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
. [C]. O 

Retinoic [C]R [C]e [C]t [C]i [C]n [C]o [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
up-regulates [C]u [C]p [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]s O 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d O 
ICAM-3 [C]I [C]C [C]A [C]M [C]- [C]3 O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
a [C]a O 
cell-specific [C]c [C]e [C]l [C]l [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
fashion [C]f [C]a [C]s [C]h [C]i [C]o [C]n O 
-- [C]- [C]- O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
for [C]f [C]o [C]r O 
retinoid [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]d O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
mast [C]m [C]a [C]s [C]t B-cell_type 
cell [C]c [C]e [C]l [C]l I-cell_type 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e E-cell_type 
. [C]. O 

Investigation [C]I [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
mast [C]m [C]a [C]s [C]t O 
cell [C]c [C]e [C]l [C]l O 
responsiveness [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e [C]n [C]e [C]s [C]s O 
toward [C]t [C]o [C]w [C]a [C]r [C]d O 
retinoic [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
( [C]( O 
RA [C]R [C]A O 
) [C]) O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
selective [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e O 
promotion [C]p [C]r [C]o [C]m [C]o [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
ICAM-3 [C]I [C]C [C]A [C]M [C]- [C]3 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
mast [C]m [C]a [C]s [C]t I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e I-cell_line 
HMC-1 [C]H [C]M [C]C [C]- [C]1 E-cell_line 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
was [C]w [C]a [C]s O 
dose- [C]d [C]o [C]s [C]e [C]- O 
and [C]a [C]n [C]d O 
time-dependent [C]t [C]i [C]m [C]e [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
detectable [C]d [C]e [C]t [C]e [C]c [C]t [C]a [C]b [C]l [C]e O 
by [C]b [C]y O 
flow [C]f [C]l [C]o [C]w O 
cytometry [C]c [C]y [C]t [C]o [C]m [C]e [C]t [C]r [C]y O 
, [C], O 
Western [C]W [C]e [C]s [C]t [C]e [C]r [C]n O 
blot [C]b [C]l [C]o [C]t O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
, [C], O 
ELISA [C]E [C]L [C]I [C]S [C]A O 
, [C], O 
and [C]a [C]n [C]d O 
Northern [C]N [C]o [C]r [C]t [C]h [C]e [C]r [C]n O 
blot [C]b [C]l [C]o [C]t O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
. [C]. O 

ICAM-3 [C]I [C]C [C]A [C]M [C]- [C]3 S-protein 
modulation [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
cell-type [C]c [C]e [C]l [C]l [C]- [C]t [C]y [C]p [C]e O 
dependent [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
, [C], O 
detectable [C]d [C]e [C]t [C]e [C]c [C]t [C]a [C]b [C]l [C]e O 
also [C]a [C]l [C]s [C]o O 
for [C]f [C]o [C]r O 
HL-60 [C]H [C]L [C]- [C]6 [C]0 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
and [C]a [C]n [C]d O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
U-937 [C]U [C]- [C]9 [C]3 [C]7 S-cell_line 
and [C]a [C]n [C]d O 
only [C]o [C]n [C]l [C]y O 
weakly [C]w [C]e [C]a [C]k [C]l [C]y O 
for [C]f [C]o [C]r O 
KU812 [C]K [C]U [C]8 [C]1 [C]2 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

Terminally [C]T [C]e [C]r [C]m [C]i [C]n [C]a [C]l [C]l [C]y B-cell_type 
differentiated [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]e [C]d I-cell_type 
skin [C]s [C]k [C]i [C]n I-cell_type 
mast [C]m [C]a [C]s [C]t I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
also [C]a [C]l [C]s [C]o O 
failed [C]f [C]a [C]i [C]l [C]e [C]d O 
to [C]t [C]o O 
up-modulate [C]u [C]p [C]- [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]e O 
their [C]t [C]h [C]e [C]i [C]r O 
ICAM-3 [C]I [C]C [C]A [C]M [C]- [C]3 S-protein 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
requirement [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]m [C]e [C]n [C]t O 
for [C]f [C]o [C]r O 
some [C]s [C]o [C]m [C]e O 
degree [C]d [C]e [C]g [C]r [C]e [C]e O 
of [C]o [C]f O 
immaturity [C]i [C]m [C]m [C]a [C]t [C]u [C]r [C]i [C]t [C]y O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
. [C]. O 

RA-mediated [C]R [C]A [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
on [C]o [C]n O 
ICAM-1 [C]I [C]C [C]A [C]M [C]- [C]1 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
in [C]i [C]n O 
parallel [C]p [C]a [C]r [C]a [C]l [C]l [C]e [C]l O 
, [C], O 
were [C]w [C]e [C]r [C]e O 
clearly [C]c [C]l [C]e [C]a [C]r [C]l [C]y O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
from [C]f [C]r [C]o [C]m O 
those [C]t [C]h [C]o [C]s [C]e O 
on [C]o [C]n O 
ICAM-3 [C]I [C]C [C]A [C]M [C]- [C]3 S-protein 
. [C]. O 

Investigation [C]I [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
retinoid [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
known [C]k [C]n [C]o [C]w [C]n O 
to [C]t [C]o O 
mediate [C]m [C]e [C]d [C]i [C]a [C]t [C]e O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
RA [C]R [C]A O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
, [C], O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
RAR [C]R [C]A [C]R B-RNA 
alpha [C]a [C]l [C]p [C]h [C]a I-RNA 
, [C], I-RNA 
RAR [C]R [C]A [C]R I-RNA 
gamma [C]g [C]a [C]m [C]m [C]a I-RNA 
, [C], I-RNA 
RXR [C]R [C]X [C]R I-RNA 
beta [C]b [C]e [C]t [C]a I-RNA 
, [C], I-RNA 
and [C]a [C]n [C]d I-RNA 
RXR [C]R [C]X [C]R I-RNA 
gamma [C]g [C]a [C]m [C]m [C]a I-RNA 
transcripts [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]s E-RNA 
in [C]i [C]n O 
all [C]a [C]l [C]l O 
cell [C]c [C]e [C]l [C]l O 
lines [C]l [C]i [C]n [C]e [C]s O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
, [C], O 
and [C]a [C]n [C]d O 
HMC-1 [C]H [C]M [C]C [C]- [C]1 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
were [C]w [C]e [C]r [C]e O 
the [C]t [C]h [C]e O 
only [C]o [C]n [C]l [C]y O 
line [C]l [C]i [C]n [C]e O 
lacking [C]l [C]a [C]c [C]k [C]i [C]n [C]g O 
RXR [C]R [C]X [C]R B-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
. [C]. O 

RAR [C]R [C]A [C]R B-protein 
beta [C]b [C]e [C]t [C]a E-protein 
, [C], O 
not [C]n [C]o [C]t O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
at [C]a [C]t O 
baseline [C]b [C]a [C]s [C]e [C]l [C]i [C]n [C]e O 
, [C], O 
was [C]w [C]a [C]s O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
RA [C]R [C]A O 
in [C]i [C]n O 
a [C]a O 
fashion [C]f [C]a [C]s [C]h [C]i [C]o [C]n O 
obviously [C]o [C]b [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
correlating [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]n [C]g O 
with [C]w [C]i [C]t [C]h O 
ICAM-3 [C]I [C]C [C]A [C]M [C]- [C]3 S-protein 
up-regulation [C]u [C]p [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Increased [C]I [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
ICAM-3 [C]I [C]C [C]A [C]M [C]- [C]3 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
of [C]o [C]f O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
significance [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]c [C]e O 
, [C], O 
such [C]s [C]u [C]c [C]h O 
that [C]t [C]h [C]a [C]t O 
processes [C]p [C]r [C]o [C]c [C]e [C]s [C]s [C]e [C]s O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
or [C]o [C]r O 
co-stimulated [C]c [C]o [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
via [C]v [C]i [C]a O 
ICAM-3 [C]I [C]C [C]A [C]M [C]- [C]3 S-protein 
( [C]( O 
homotypic [C]h [C]o [C]m [C]o [C]t [C]y [C]p [C]i [C]c O 
aggregation [C]a [C]g [C]g [C]r [C]e [C]g [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
IL-8 [C]I [C]L [C]- [C]8 O 
secretion [C]s [C]e [C]c [C]r [C]e [C]t [C]i [C]o [C]n O 
) [C]) O 
were [C]w [C]e [C]r [C]e O 
clearly [C]c [C]l [C]e [C]a [C]r [C]l [C]y O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
upon [C]u [C]p [C]o [C]n O 
RA [C]R [C]A O 
pretreatment [C]p [C]r [C]e [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
RA [C]R [C]A O 
may [C]m [C]a [C]y O 
contribute [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e O 
via [C]v [C]i [C]a O 
hitherto [C]h [C]i [C]t [C]h [C]e [C]r [C]t [C]o O 
unrecognized [C]u [C]n [C]r [C]e [C]c [C]o [C]g [C]n [C]i [C]z [C]e [C]d O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
to [C]t [C]o O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
host [C]h [C]o [C]s [C]t O 
defense [C]d [C]e [C]f [C]e [C]n [C]s [C]e O 
. [C]. O 

CD28 [C]C [C]D [C]2 [C]8 S-protein 
and [C]a [C]n [C]d O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
co-stimulation [C]c [C]o [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Over [C]O [C]v [C]e [C]r O 
the [C]t [C]h [C]e O 
last [C]l [C]a [C]s [C]t O 
decade [C]d [C]e [C]c [C]a [C]d [C]e O 
the [C]t [C]h [C]e O 
concept [C]c [C]o [C]n [C]c [C]e [C]p [C]t O 
of [C]o [C]f O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
co-stimulation [C]c [C]o [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
has [C]h [C]a [C]s O 
emerged [C]e [C]m [C]e [C]r [C]g [C]e [C]d O 
to [C]t [C]o O 
take [C]t [C]a [C]k [C]e O 
a [C]a O 
central [C]c [C]e [C]n [C]t [C]r [C]a [C]l O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
of [C]o [C]f O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
the [C]t [C]h [C]e O 
exact [C]e [C]x [C]a [C]c [C]t O 
definition [C]d [C]e [C]f [C]i [C]n [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
co-stimulation [C]c [C]o [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
still [C]s [C]t [C]i [C]l [C]l O 
unclear [C]u [C]n [C]c [C]l [C]e [C]a [C]r O 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
review [C]r [C]e [C]v [C]i [C]e [C]w O 
, [C], O 
we [C]w [C]e O 
re-examine [C]r [C]e [C]- [C]e [C]x [C]a [C]m [C]i [C]n [C]e O 
the [C]t [C]h [C]e O 
concept [C]c [C]o [C]n [C]c [C]e [C]p [C]t O 
of [C]o [C]f O 
co-stimulation [C]c [C]o [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

We [C]W [C]e O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
while [C]w [C]h [C]i [C]l [C]e O 
co-stimulation [C]c [C]o [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
, [C], O 
there [C]t [C]h [C]e [C]r [C]e O 
is [C]i [C]s O 
little [C]l [C]i [C]t [C]t [C]l [C]e O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
to [C]t [C]o O 
link [C]l [C]i [C]n [C]k O 
co-stimulation [C]c [C]o [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
anergy [C]a [C]n [C]e [C]r [C]g [C]y O 
. [C]. O 

We [C]W [C]e O 
then [C]t [C]h [C]e [C]n O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
a [C]a O 
framework [C]f [C]r [C]a [C]m [C]e [C]w [C]o [C]r [C]k O 
for [C]f [C]o [C]r O 
studying [C]s [C]t [C]u [C]d [C]y [C]i [C]n [C]g O 
co-stimulation [C]c [C]o [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Focusing [C]F [C]o [C]c [C]u [C]s [C]i [C]n [C]g O 
on [C]o [C]n O 
recent [C]r [C]e [C]c [C]e [C]n [C]t O 
advances [C]a [C]d [C]v [C]a [C]n [C]c [C]e [C]s O 
in [C]i [C]n O 
our [C]o [C]u [C]r O 
understanding [C]u [C]n [C]d [C]e [C]r [C]s [C]t [C]a [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
CD28 [C]C [C]D [C]2 [C]8 S-protein 
, [C], O 
we [C]w [C]e O 
discuss [C]d [C]i [C]s [C]c [C]u [C]s [C]s O 
four [C]f [C]o [C]u [C]r O 
areas [C]a [C]r [C]e [C]a [C]s O 
of [C]o [C]f O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
where [C]w [C]h [C]e [C]r [C]e O 
co-stimulation [C]c [C]o [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
may [C]m [C]a [C]y O 
play [C]p [C]l [C]a [C]y O 
a [C]a O 
role [C]r [C]o [C]l [C]e O 
. [C]. O 

Regulation [C]R [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r B-protein 
protein-1 [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]1 E-protein 
and [C]a [C]n [C]d O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
in [C]i [C]n O 
CD8+ [C]C [C]D [C]8 [C]+ B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
exposed [C]e [C]x [C]p [C]o [C]s [C]e [C]d O 
to [C]t [C]o O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-protein 
self-antigens [C]s [C]e [C]l [C]f [C]- [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]s E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
events [C]e [C]v [C]e [C]n [C]t [C]s O 
that [C]t [C]h [C]a [C]t O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
tolerance [C]t [C]o [C]l [C]e [C]r [C]a [C]n [C]c [C]e O 
to [C]t [C]o O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-protein 
self [C]s [C]e [C]l [C]f I-protein 
Ags [C]A [C]g [C]s E-protein 
are [C]a [C]r [C]e O 
still [C]s [C]t [C]i [C]l [C]l O 
unknown [C]u [C]n [C]k [C]n [C]o [C]w [C]n O 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
, [C], O 
we [C]w [C]e O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
the [C]t [C]h [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
- [C]- O 
and [C]a [C]n [C]d O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
tolerance [C]t [C]o [C]l [C]e [C]r [C]a [C]n [C]c [C]e O 
to [C]t [C]o O 
a [C]a O 
self [C]s [C]e [C]l [C]f B-protein 
Ag [C]A [C]g E-protein 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
exclusively [C]e [C]x [C]c [C]l [C]u [C]s [C]i [C]v [C]e [C]l [C]y O 
on [C]o [C]n O 
hepatocytes [C]h [C]e [C]p [C]a [C]t [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
. [C]. O 

Naive [C]N [C]a [C]i [C]v [C]e B-cell_type 
CD8 [C]C [C]D [C]8 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
Desire [C]D [C]e [C]s [C]i [C]r [C]e I-cell_type 
( [C]( I-cell_type 
Des [C]D [C]e [C]s I-cell_type 
) [C]) I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
Des [C]D [C]e [C]s O 
TCR-transgenic [C]T [C]C [C]R [C]- [C]t [C]r [C]a [C]n [C]s [C]g [C]e [C]n [C]i [C]c O 
mice [C]m [C]i [C]c [C]e O 
that [C]t [C]h [C]a [C]t O 
are [C]a [C]r [C]e O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
H-2K [C]H [C]- [C]2 [C]K B-protein 
( [C]( I-protein 
b [C]b I-protein 
) [C]) I-protein 
class [C]c [C]l [C]a [C]s [C]s I-protein 
I [C]I I-protein 
Ag [C]A [C]g E-protein 
were [C]w [C]e [C]r [C]e O 
transferred [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]r [C]r [C]e [C]d O 
into [C]i [C]n [C]t [C]o O 
Alb-K [C]A [C]l [C]b [C]- [C]K O 
( [C]( O 
b [C]b O 
) [C]) O 
-transgenic [C]- [C]t [C]r [C]a [C]n [C]s [C]g [C]e [C]n [C]i [C]c O 
mice [C]m [C]i [C]c [C]e O 
that [C]t [C]h [C]a [C]t O 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
the [C]t [C]h [C]e O 
H-2K [C]H [C]- [C]2 [C]K B-protein 
( [C]( I-protein 
b [C]b I-protein 
) [C]) I-protein 
Ag [C]A [C]g E-protein 
on [C]o [C]n O 
hepatocytes [C]h [C]e [C]p [C]a [C]t [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
only [C]o [C]n [C]l [C]y O 
. [C]. O 

Tolerance [C]T [C]o [C]l [C]e [C]r [C]a [C]n [C]c [C]e O 
develops [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]s O 
in [C]i [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
mice [C]m [C]i [C]c [C]e O 
. [C]. O 

We [C]W [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
self-reactive [C]s [C]e [C]l [C]f [C]- [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]e B-cell_type 
CD8 [C]C [C]D [C]8 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
Des [C]D [C]e [C]s I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
transiently [C]t [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t [C]l [C]y O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
, [C], O 
then [C]t [C]h [C]e [C]n O 
became [C]b [C]e [C]c [C]a [C]m [C]e O 
unresponsive [C]u [C]n [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e O 
and [C]a [C]n [C]d O 
were [C]w [C]e [C]r [C]e O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
deleted [C]d [C]e [C]l [C]e [C]t [C]e [C]d O 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
to [C]t [C]o O 
CD8 [C]C [C]D [C]8 B-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
Des [C]D [C]e [C]s I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
with [C]w [C]i [C]t [C]h O 
APCs [C]A [C]P [C]C [C]s O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
high [C]h [C]i [C]g [C]h O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
and [C]a [C]n [C]d O 
high [C]h [C]i [C]g [C]h O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
, [C], O 
the [C]t [C]h [C]e O 
unresponsive [C]u [C]n [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e O 
CD8 [C]C [C]D [C]8 B-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
Des [C]D [C]e [C]s I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
no [C]n [C]o O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
and [C]a [C]n [C]d O 
only [C]o [C]n [C]l [C]y O 
weak [C]w [C]e [C]a [C]k O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
differences [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e [C]s O 
in [C]i [C]n O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
generation [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B I-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
. [C]. O 

Indeed [C]I [C]n [C]d [C]e [C]e [C]d O 
, [C], O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
primed [C]p [C]r [C]i [C]m [C]e [C]d B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
predominantly [C]p [C]r [C]e [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t [C]l [C]y O 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
p50/p50 [C]p [C]5 [C]0 [C]/ [C]p [C]5 [C]0 B-protein 
and [C]a [C]n [C]d I-protein 
p65/p50 [C]p [C]6 [C]5 [C]/ [C]p [C]5 [C]0 I-protein 
dimers [C]d [C]i [C]m [C]e [C]r [C]s E-protein 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
these [C]t [C]h [C]e [C]s [C]e O 
p50-containing [C]p [C]5 [C]0 [C]- [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g B-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
are [C]a [C]r [C]e O 
barely [C]b [C]a [C]r [C]e [C]l [C]y O 
detectable [C]d [C]e [C]t [C]e [C]c [C]t [C]a [C]b [C]l [C]e O 
in [C]i [C]n O 
tolerant [C]t [C]o [C]l [C]e [C]r [C]a [C]n [C]t B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
that [C]t [C]h [C]a [C]t O 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
p65- [C]p [C]6 [C]5 [C]- B-protein 
and [C]a [C]n [C]d I-protein 
c-Rel-containing [C]c [C]- [C]R [C]e [C]l [C]- [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g I-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
observations [C]o [C]b [C]s [C]e [C]r [C]v [C]a [C]t [C]i [C]o [C]n [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
fine [C]f [C]i [C]n [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B I-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
may [C]m [C]a [C]y O 
determine [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
fate [C]f [C]a [C]t [C]e O 
. [C]. O 

Transcriptional [C]T [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
. [C]. O 

Lymphocytes [C]L [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
used [C]u [C]s [C]e [C]d O 
to [C]t [C]o O 
investigate [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e O 
many [C]m [C]a [C]n [C]y O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
processes [C]p [C]r [C]o [C]c [C]e [C]s [C]s [C]e [C]s O 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e O 
commitment [C]c [C]o [C]m [C]m [C]i [C]t [C]m [C]e [C]n [C]t O 
, [C], O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
that [C]t [C]h [C]a [C]t O 
mediate [C]m [C]e [C]d [C]i [C]a [C]t [C]e O 
these [C]t [C]h [C]e [C]s [C]e O 
processes [C]p [C]r [C]o [C]c [C]e [C]s [C]s [C]e [C]s O 
are [C]a [C]r [C]e O 
often [C]o [C]f [C]t [C]e [C]n O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
broadly [C]b [C]r [C]o [C]a [C]d [C]l [C]y O 
in [C]i [C]n O 
many [C]m [C]a [C]n [C]y O 
cell [C]c [C]e [C]l [C]l O 
types [C]t [C]y [C]p [C]e [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
emerging [C]e [C]m [C]e [C]r [C]g [C]i [C]n [C]g O 
theme [C]t [C]h [C]e [C]m [C]e O 
is [C]i [C]s O 
one [C]o [C]n [C]e O 
of [C]o [C]f O 
cell-type-specific [C]c [C]e [C]l [C]l [C]- [C]t [C]y [C]p [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
affecting [C]a [C]f [C]f [C]e [C]c [C]t [C]i [C]n [C]g O 
not [C]n [C]o [C]t O 
only [C]o [C]n [C]l [C]y O 
the [C]t [C]h [C]e O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
but [C]b [C]u [C]t O 
also [C]a [C]l [C]s [C]o O 
their [C]t [C]h [C]e [C]i [C]r O 
access [C]a [C]c [C]c [C]e [C]s [C]s O 
to [C]t [C]o O 
appropriate [C]a [C]p [C]p [C]r [C]o [C]p [C]r [C]i [C]a [C]t [C]e O 
regions [C]r [C]e [C]g [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
DNA [C]D [C]N [C]A O 
. [C]. O 

Existence [C]E [C]x [C]i [C]s [C]t [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
retinoic [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]c B-protein 
acid-receptor [C]a [C]c [C]i [C]d [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
-independent [C]- [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
retinoid [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]d B-protein 
X-receptor [C]X [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
in [C]i [C]n O 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

We [C]W [C]e O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
reported [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
ER-27191 [C]E [C]R [C]- [C]2 [C]7 [C]1 [C]9 [C]1 O 
( [C]( O 
4- [C]4 [C]- O 
[ [C][ O 
4 [C]4 O 
, [C], O 
5 [C]5 O 
, [C], O 
7 [C]7 O 
, [C], O 
8 [C]8 O 
, [C], O 
9 [C]9 O 
, [C], O 
10-hexahydro-7 [C]1 [C]0 [C]- [C]h [C]e [C]x [C]a [C]h [C]y [C]d [C]r [C]o [C]- [C]7 O 
, [C], O 
7 [C]7 O 
, [C], O 
10 [C]1 [C]0 O 
, [C], O 
10-tetramethyl-1- [C]1 [C]0 [C]- [C]t [C]e [C]t [C]r [C]a [C]m [C]e [C]t [C]h [C]y [C]l [C]- [C]1 [C]- O 
( [C]( O 
3-pyridylmethyl [C]3 [C]- [C]p [C]y [C]r [C]i [C]d [C]y [C]l [C]m [C]e [C]t [C]h [C]y [C]l O 
) [C]) O 
anthra [C]a [C]n [C]t [C]h [C]r [C]a O 
[ [C][ O 
1 [C]1 O 
, [C], O 
2-b [C]2 [C]- [C]b O 
] [C]] O 
pyrrol-3-yl [C]p [C]y [C]r [C]r [C]o [C]l [C]- [C]3 [C]- [C]y [C]l O 
] [C]] O 
benzoic [C]b [C]e [C]n [C]z [C]o [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
) [C]) O 
is [C]i [C]s O 
a [C]a O 
potent [C]p [C]o [C]t [C]e [C]n [C]t O 
antagonist [C]a [C]n [C]t [C]a [C]g [C]o [C]n [C]i [C]s [C]t O 
of [C]o [C]f O 
retinoic [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]c B-protein 
acid [C]a [C]c [C]i [C]d I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
( [C]( O 
RAR [C]R [C]A [C]R S-protein 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
ER-35795 [C]E [C]R [C]- [C]3 [C]5 [C]7 [C]9 [C]5 O 
( [C]( O 
( [C]( O 
2E [C]2 [C]E O 
, [C], O 
4E [C]4 [C]E O 
, [C], O 
6E [C]6 [C]E O 
) [C]) O 
-7- [C]- [C]7 [C]- O 
[ [C][ O 
1- [C]1 [C]- O 
( [C]( O 
1-methylethyl [C]1 [C]- [C]m [C]e [C]t [C]h [C]y [C]l [C]e [C]t [C]h [C]y [C]l O 
) [C]) O 
-8-chloro-1 [C]- [C]8 [C]- [C]c [C]h [C]l [C]o [C]r [C]o [C]- [C]1 O 
, [C], O 
2 [C]2 O 
, [C], O 
3 [C]3 O 
, [C], O 
4-tetrahydroquinolin-6-yl [C]4 [C]- [C]t [C]e [C]t [C]r [C]a [C]h [C]y [C]d [C]r [C]o [C]q [C]u [C]i [C]n [C]o [C]l [C]i [C]n [C]- [C]6 [C]- [C]y [C]l O 
] [C]] O 
-6-fluoro-3-methyl-2 [C]- [C]6 [C]- [C]f [C]l [C]u [C]o [C]r [C]o [C]- [C]3 [C]- [C]m [C]e [C]t [C]h [C]y [C]l [C]- [C]2 O 
, [C], O 
4 [C]4 O 
, [C], O 
6-nonatrienoic [C]6 [C]- [C]n [C]o [C]n [C]a [C]t [C]r [C]i [C]e [C]n [C]o [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
) [C]) O 
is [C]i [C]s O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
retinoid [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]d B-protein 
X [C]X I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
( [C]( O 
RXR [C]R [C]X [C]R S-protein 
) [C]) O 
-specific [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
agonist [C]a [C]g [C]o [C]n [C]i [C]s [C]t O 
. [C]. O 

By [C]B [C]y O 
using [C]u [C]s [C]i [C]n [C]g O 
these [C]t [C]h [C]e [C]s [C]e O 
compounds [C]c [C]o [C]m [C]p [C]o [C]u [C]n [C]d [C]s O 
, [C], O 
we [C]w [C]e O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
RAR [C]R [C]A [C]R S-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
RXR [C]R [C]X [C]R S-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
operate [C]o [C]p [C]e [C]r [C]a [C]t [C]e O 
to [C]t [C]o O 
mediate [C]m [C]e [C]d [C]i [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
diverse [C]d [C]i [C]v [C]e [C]r [C]s [C]e O 
activities [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]i [C]e [C]s O 
of [C]o [C]f O 
retinoids [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]d [C]s O 
, [C], O 
particularly [C]p [C]a [C]r [C]t [C]i [C]c [C]u [C]l [C]a [C]r [C]l [C]y O 
, [C], O 
the [C]t [C]h [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
RXR [C]R [C]X [C]R S-protein 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
on [C]o [C]n O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

ER-27191 [C]E [C]R [C]- [C]2 [C]7 [C]1 [C]9 [C]1 O 
completely [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e [C]l [C]y O 
antagonized [C]a [C]n [C]t [C]a [C]g [C]o [C]n [C]i [C]z [C]e [C]d O 
HL60 [C]H [C]L [C]6 [C]0 B-cell_line 
cell [C]c [C]e [C]l [C]l E-cell_line 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
all-trans-retinoic [C]a [C]l [C]l [C]- [C]t [C]r [C]a [C]n [C]s [C]- [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
( [C]( O 
atRA [C]a [C]t [C]R [C]A O 
) [C]) O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
the [C]t [C]h [C]e O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
ER-35795 [C]E [C]R [C]- [C]3 [C]5 [C]7 [C]9 [C]5 O 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
antagonized [C]a [C]n [C]t [C]a [C]g [C]o [C]n [C]i [C]z [C]e [C]d O 
at [C]a [C]t O 
all [C]a [C]l [C]l O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
RAR [C]R [C]A [C]R S-protein 
antagonist [C]a [C]n [C]t [C]a [C]g [C]o [C]n [C]i [C]s [C]t O 
, [C], O 
but [C]b [C]u [C]t O 
was [C]w [C]a [C]s O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
by [C]b [C]y O 
an [C]a [C]n O 
RXR [C]R [C]X [C]R B-protein 
homodimer [C]h [C]o [C]m [C]o [C]d [C]i [C]m [C]e [C]r E-protein 
antagonist [C]a [C]n [C]t [C]a [C]g [C]o [C]n [C]i [C]s [C]t O 
( [C]( O 
LGD100754 [C]L [C]G [C]D [C]1 [C]0 [C]0 [C]7 [C]5 [C]4 O 
, [C], O 
( [C]( O 
2E [C]2 [C]E O 
, [C], O 
4E [C]4 [C]E O 
, [C], O 
6Z [C]6 [C]Z O 
) [C]) O 
-7- [C]- [C]7 [C]- O 
( [C]( O 
3-n-propoxy-5 [C]3 [C]- [C]n [C]- [C]p [C]r [C]o [C]p [C]o [C]x [C]y [C]- [C]5 O 
, [C], O 
6 [C]6 O 
, [C], O 
7 [C]7 O 
, [C], O 
8-tetrahydro-5 [C]8 [C]- [C]t [C]e [C]t [C]r [C]a [C]h [C]y [C]d [C]r [C]o [C]- [C]5 O 
, [C], O 
5 [C]5 O 
, [C], O 
8 [C]8 O 
, [C], O 
8-tetramethylnaphthalen-2-yl [C]8 [C]- [C]t [C]e [C]t [C]r [C]a [C]m [C]e [C]t [C]h [C]y [C]l [C]n [C]a [C]p [C]h [C]t [C]h [C]a [C]l [C]e [C]n [C]- [C]2 [C]- [C]y [C]l O 
) [C]) O 
-3-methylocta-2 [C]- [C]3 [C]- [C]m [C]e [C]t [C]h [C]y [C]l [C]o [C]c [C]t [C]a [C]- [C]2 O 
, [C], O 
4 [C]4 O 
, [C], O 
6-trienoic [C]6 [C]- [C]t [C]r [C]i [C]e [C]n [C]o [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
) [C]) O 
. [C]. O 

Its [C]I [C]t [C]s O 
agonistic [C]a [C]g [C]o [C]n [C]i [C]s [C]t [C]i [C]c O 
action [C]a [C]c [C]t [C]i [C]o [C]n O 
on [C]o [C]n O 
RXR/RAR [C]R [C]X [C]R [C]/ [C]R [C]A [C]R B-protein 
heterodimer [C]h [C]e [C]t [C]e [C]r [C]o [C]d [C]i [C]m [C]e [C]r E-protein 
, [C], O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
other [C]o [C]t [C]h [C]e [C]r O 
hand [C]h [C]a [C]n [C]d O 
, [C], O 
was [C]w [C]a [C]s O 
neutralized [C]n [C]e [C]u [C]t [C]r [C]a [C]l [C]i [C]z [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
RAR [C]R [C]A [C]R S-protein 
antagonist [C]a [C]n [C]t [C]a [C]g [C]o [C]n [C]i [C]s [C]t O 
. [C]. O 

During [C]D [C]u [C]r [C]i [C]n [C]g O 
HL60 [C]H [C]L [C]6 [C]0 B-cell_line 
cell [C]c [C]e [C]l [C]l E-cell_line 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
atRA [C]a [C]t [C]R [C]A O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
RARbeta [C]R [C]A [C]R [C]b [C]e [C]t [C]a B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
, [C], O 
while [C]w [C]h [C]i [C]l [C]e O 
the [C]t [C]h [C]e O 
RXR [C]R [C]X [C]R S-protein 
had [C]h [C]a [C]d O 
no [C]n [C]o O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
. [C]. O 

Interestingly [C]I [C]n [C]t [C]e [C]r [C]e [C]s [C]t [C]i [C]n [C]g [C]l [C]y O 
, [C], O 
a [C]a O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
RXR [C]R [C]X [C]R S-protein 
-pathway [C]- [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
seen [C]s [C]e [C]e [C]n O 
in [C]i [C]n O 
lipopolysaccharide-induced [C]l [C]i [C]p [C]o [C]p [C]o [C]l [C]y [C]s [C]a [C]c [C]c [C]h [C]a [C]r [C]i [C]d [C]e [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
mouse [C]m [C]o [C]u [C]s [C]e B-cell_type 
splenocyte [C]s [C]p [C]l [C]e [C]n [C]o [C]c [C]y [C]t [C]e E-cell_type 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
strongly [C]s [C]t [C]r [C]o [C]n [C]g [C]l [C]y O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
the [C]t [C]h [C]e O 
existence [C]e [C]x [C]i [C]s [C]t [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
a [C]a O 
pharmacological [C]p [C]h [C]a [C]r [C]m [C]a [C]c [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
RXR [C]R [C]X [C]R S-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
ligand [C]l [C]i [C]g [C]a [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
can [C]c [C]a [C]n O 
bind [C]b [C]i [C]n [C]d O 
to [C]t [C]o O 
RXR [C]R [C]X [C]R S-protein 
. [C]. O 

Targeting [C]T [C]a [C]r [C]g [C]e [C]t [C]i [C]n [C]g O 
Src [C]S [C]r [C]c B-protein 
homology [C]h [C]o [C]m [C]o [C]l [C]o [C]g [C]y I-protein 
2 [C]2 I-protein 
domain-containing [C]d [C]o [C]m [C]a [C]i [C]n [C]- [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g I-protein 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e I-protein 
phosphatase [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]a [C]s [C]e E-protein 
( [C]( O 
SHP-1 [C]S [C]H [C]P [C]- [C]1 S-protein 
) [C]) O 
into [C]i [C]n [C]t [C]o O 
lipid [C]l [C]i [C]p [C]i [C]d O 
rafts [C]r [C]a [C]f [C]t [C]s O 
inhibits [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]s O 
CD3 [C]C [C]D [C]3 S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

To [C]T [C]o O 
study [C]s [C]t [C]u [C]d [C]y O 
the [C]t [C]h [C]e O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
by [C]b [C]y O 
which [C]w [C]h [C]i [C]c [C]h O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e I-protein 
phosphatases [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]a [C]s [C]e [C]s E-protein 
( [C]( O 
PTPs [C]P [C]T [C]P [C]s S-protein 
) [C]) O 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
CD3 [C]C [C]D [C]3 S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
we [C]w [C]e O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
distribution [C]d [C]i [C]s [C]t [C]r [C]i [C]b [C]u [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
PTPs [C]P [C]T [C]P [C]s S-protein 
in [C]i [C]n O 
subdomains [C]s [C]u [C]b [C]d [C]o [C]m [C]a [C]i [C]n [C]s O 
of [C]o [C]f O 
plasma [C]p [C]l [C]a [C]s [C]m [C]a O 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
. [C]. O 

We [C]W [C]e O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
here [C]h [C]e [C]r [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
bulk [C]b [C]u [C]l [C]k O 
PTP [C]P [C]T [C]P S-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
is [C]i [C]s O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
outside [C]o [C]u [C]t [C]s [C]i [C]d [C]e O 
the [C]t [C]h [C]e O 
lipid [C]l [C]i [C]p [C]i [C]d O 
rafts [C]r [C]a [C]f [C]t [C]s O 
, [C], O 
as [C]a [C]s O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
sucrose [C]s [C]u [C]c [C]r [C]o [C]s [C]e O 
density [C]d [C]e [C]n [C]s [C]i [C]t [C]y O 
gradient [C]g [C]r [C]a [C]d [C]i [C]e [C]n [C]t O 
sedimentation [C]s [C]e [C]d [C]i [C]m [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

In [C]I [C]n O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_line 
T [C]T I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
, [C], O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
5 [C]5 O 
-- [C]- [C]- O 
10 [C]1 [C]0 O 
% [C]% O 
of [C]o [C]f O 
Src [C]S [C]r [C]c B-protein 
homology [C]h [C]o [C]m [C]o [C]l [C]o [C]g [C]y I-protein 
2 [C]2 I-protein 
domain-containing [C]d [C]o [C]m [C]a [C]i [C]n [C]- [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g I-protein 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e I-protein 
phosphatase [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]a [C]s [C]e E-protein 
( [C]( O 
SHP-1 [C]S [C]H [C]P [C]- [C]1 S-protein 
) [C]) O 
is [C]i [C]s O 
constitutively [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
plasma [C]p [C]l [C]a [C]s [C]m [C]a O 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
, [C], O 
and [C]a [C]n [C]d O 
nearly [C]n [C]e [C]a [C]r [C]l [C]y O 
50 [C]5 [C]0 O 
% [C]% O 
of [C]o [C]f O 
SHP-2 [C]S [C]H [C]P [C]- [C]2 S-protein 
is [C]i [C]s O 
translocated [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]e [C]d O 
to [C]t [C]o O 
plasma [C]p [C]l [C]a [C]s [C]m [C]a O 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
after [C]a [C]f [C]t [C]e [C]r O 
vanadate [C]v [C]a [C]n [C]a [C]d [C]a [C]t [C]e O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
. [C]. O 

Similar [C]S [C]i [C]m [C]i [C]l [C]a [C]r O 
to [C]t [C]o O 
transmembrane [C]t [C]r [C]a [C]n [C]s [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e B-protein 
PTP [C]P [C]T [C]P E-protein 
, [C], O 
CD45 [C]C [C]D [C]4 [C]5 S-protein 
, [C], O 
the [C]t [C]h [C]e O 
membrane-associated [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e [C]- [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
populations [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
SHP-1 [C]S [C]H [C]P [C]- [C]1 S-protein 
and [C]a [C]n [C]d O 
SHP-2 [C]S [C]H [C]P [C]- [C]2 S-protein 
are [C]a [C]r [C]e O 
essentially [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l [C]l [C]y O 
excluded [C]e [C]x [C]c [C]l [C]u [C]d [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
lipid [C]l [C]i [C]p [C]i [C]d O 
rafts [C]r [C]a [C]f [C]t [C]s O 
, [C], O 
where [C]w [C]h [C]e [C]r [C]e O 
other [C]o [C]t [C]h [C]e [C]r O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g B-protein 
molecules [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]s E-protein 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
Lck [C]L [C]c [C]k B-protein 
, [C], I-protein 
linker [C]l [C]i [C]n [C]k [C]e [C]r I-protein 
for [C]f [C]o [C]r I-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n I-protein 
of [C]o [C]f I-protein 
T [C]T I-protein 
cells [C]c [C]e [C]l [C]l [C]s E-protein 
, [C], O 
and [C]a [C]n [C]d O 
CD3 [C]C [C]D [C]3 B-protein 
zeta [C]z [C]e [C]t [C]a E-protein 
are [C]a [C]r [C]e O 
enriched [C]e [C]n [C]r [C]i [C]c [C]h [C]e [C]d O 
. [C]. O 

We [C]W [C]e O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
CD3 [C]C [C]D [C]3 S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
substrates [C]s [C]u [C]b [C]s [C]t [C]r [C]a [C]t [C]e [C]s O 
is [C]i [C]s O 
largely [C]l [C]a [C]r [C]g [C]e [C]l [C]y O 
restricted [C]r [C]e [C]s [C]t [C]r [C]i [C]c [C]t [C]e [C]d O 
to [C]t [C]o O 
lipid [C]l [C]i [C]p [C]i [C]d O 
rafts [C]r [C]a [C]f [C]t [C]s O 
, [C], O 
unless [C]u [C]n [C]l [C]e [C]s [C]s O 
PTPs [C]P [C]T [C]P [C]s S-protein 
are [C]a [C]r [C]e O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
. [C]. O 

It [C]I [C]t O 
suggests [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]s O 
that [C]t [C]h [C]a [C]t O 
a [C]a O 
restricted [C]r [C]e [C]s [C]t [C]r [C]i [C]c [C]t [C]e [C]d O 
partition [C]p [C]a [C]r [C]t [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
PTPs [C]P [C]T [C]P [C]s S-protein 
among [C]a [C]m [C]o [C]n [C]g O 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
subdomains [C]s [C]u [C]b [C]d [C]o [C]m [C]a [C]i [C]n [C]s O 
may [C]m [C]a [C]y O 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
. [C]. O 

To [C]T [C]o O 
test [C]t [C]e [C]s [C]t O 
this [C]t [C]h [C]i [C]s O 
hypothesis [C]h [C]y [C]p [C]o [C]t [C]h [C]e [C]s [C]i [C]s O 
, [C], O 
we [C]w [C]e O 
targeted [C]t [C]a [C]r [C]g [C]e [C]t [C]e [C]d O 
SHP-1 [C]S [C]H [C]P [C]- [C]1 S-protein 
into [C]i [C]n [C]t [C]o O 
lipid [C]l [C]i [C]p [C]i [C]d O 
rafts [C]r [C]a [C]f [C]t [C]s O 
by [C]b [C]y O 
using [C]u [C]s [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
N-terminal [C]N [C]- [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l B-protein 
region [C]r [C]e [C]g [C]i [C]o [C]n I-protein 
of [C]o [C]f I-protein 
Lck [C]L [C]c [C]k E-protein 
( [C]( O 
residues [C]r [C]e [C]s [C]i [C]d [C]u [C]e [C]s B-protein 
1 [C]1 I-protein 
-- [C]- [C]- I-protein 
14 [C]1 [C]4 E-protein 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
Lck/SHP-1 [C]L [C]c [C]k [C]/ [C]S [C]H [C]P [C]- [C]1 B-protein 
chimera [C]c [C]h [C]i [C]m [C]e [C]r [C]a E-protein 
inside [C]i [C]n [C]s [C]i [C]d [C]e O 
lipid [C]l [C]i [C]p [C]i [C]d O 
rafts [C]r [C]a [C]f [C]t [C]s O 
profoundly [C]p [C]r [C]o [C]f [C]o [C]u [C]n [C]d [C]l [C]y O 
inhibits [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]s O 
CD3 [C]C [C]D [C]3 S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CD3 [C]C [C]D [C]3 B-protein 
zeta/epsilon [C]z [C]e [C]t [C]a [C]/ [C]e [C]p [C]s [C]i [C]l [C]o [C]n E-protein 
, [C], O 
IL-2 [C]I [C]L [C]- [C]2 O 
generation [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
mobilization [C]m [C]o [C]b [C]i [C]l [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-AT [C]N [C]F [C]- [C]A [C]T S-protein 
. [C]. O 

Collectively [C]C [C]o [C]l [C]l [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
, [C], O 
these [C]t [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
exclusion [C]e [C]x [C]c [C]l [C]u [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
PTPs [C]P [C]T [C]P [C]s S-protein 
from [C]f [C]r [C]o [C]m O 
lipid [C]l [C]i [C]p [C]i [C]d O 
rafts [C]r [C]a [C]f [C]t [C]s O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
a [C]a O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
that [C]t [C]h [C]a [C]t O 
potentiates [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]t [C]e [C]s O 
TCR [C]T [C]C [C]R S-protein 
/ [C]/ O 
CD3 [C]C [C]D [C]3 S-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 

An [C]A [C]n O 
instructive [C]i [C]n [C]s [C]t [C]r [C]u [C]c [C]t [C]i [C]v [C]e O 
component [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t O 
in [C]i [C]n O 
T [C]T B-cell_type 
helper [C]h [C]e [C]l [C]p [C]e [C]r I-cell_type 
cell [C]c [C]e [C]l [C]l I-cell_type 
type [C]t [C]y [C]p [C]e I-cell_type 
2 [C]2 E-cell_type 
( [C]( O 
Th2 [C]T [C]h [C]2 S-cell_type 
) [C]) O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 S-protein 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
interleukin [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n B-protein 
( [C]( I-protein 
IL [C]I [C]L I-protein 
) [C]) I-protein 
-12 [C]- [C]1 [C]2 E-protein 
and [C]a [C]n [C]d O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
polarize [C]p [C]o [C]l [C]a [C]r [C]i [C]z [C]e O 
naive [C]n [C]a [C]i [C]v [C]e B-cell_type 
CD4 [C]C [C]D [C]4 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
toward [C]t [C]o [C]w [C]a [C]r [C]d O 
T [C]T O 
helper [C]h [C]e [C]l [C]p [C]e [C]r O 
cell [C]c [C]e [C]l [C]l O 
type [C]t [C]y [C]p [C]e O 
1 [C]1 O 
( [C]( O 
Th1 [C]T [C]h [C]1 O 
) [C]) O 
or [C]o [C]r O 
Th2 [C]T [C]h [C]2 O 
phenotypes [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e [C]s O 
, [C], O 
it [C]i [C]t O 
is [C]i [C]s O 
not [C]n [C]o [C]t O 
known [C]k [C]n [C]o [C]w [C]n O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
instruct [C]i [C]n [C]s [C]t [C]r [C]u [C]c [C]t O 
the [C]t [C]h [C]e O 
developmental [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t [C]a [C]l O 
fate [C]f [C]a [C]t [C]e O 
in [C]i [C]n O 
uncommitted [C]u [C]n [C]c [C]o [C]m [C]m [C]i [C]t [C]t [C]e [C]d B-cell_type 
progenitors [C]p [C]r [C]o [C]g [C]e [C]n [C]i [C]t [C]o [C]r [C]s E-cell_type 
or [C]o [C]r O 
select [C]s [C]e [C]l [C]e [C]c [C]t O 
for [C]f [C]o [C]r O 
outgrowth [C]o [C]u [C]t [C]g [C]r [C]o [C]w [C]t [C]h O 
of [C]o [C]f O 
cells [C]c [C]e [C]l [C]l [C]s O 
that [C]t [C]h [C]a [C]t O 
have [C]h [C]a [C]v [C]e O 
stochastically [C]s [C]t [C]o [C]c [C]h [C]a [C]s [C]t [C]i [C]c [C]a [C]l [C]l [C]y O 
committed [C]c [C]o [C]m [C]m [C]i [C]t [C]t [C]e [C]d O 
to [C]t [C]o O 
a [C]a O 
particular [C]p [C]a [C]r [C]t [C]i [C]c [C]u [C]l [C]a [C]r O 
fate [C]f [C]a [C]t [C]e O 
. [C]. O 

To [C]T [C]o O 
distinguish [C]d [C]i [C]s [C]t [C]i [C]n [C]g [C]u [C]i [C]s [C]h O 
these [C]t [C]h [C]e [C]s [C]e O 
instructive [C]i [C]n [C]s [C]t [C]r [C]u [C]c [C]t [C]i [C]v [C]e O 
and [C]a [C]n [C]d O 
selective [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e O 
models [C]m [C]o [C]d [C]e [C]l [C]s O 
, [C], O 
we [C]w [C]e O 
used [C]u [C]s [C]e [C]d O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
matrix [C]m [C]a [C]t [C]r [C]i [C]x O 
technology [C]t [C]e [C]c [C]h [C]n [C]o [C]l [C]o [C]g [C]y O 
to [C]t [C]o O 
isolate [C]i [C]s [C]o [C]l [C]a [C]t [C]e O 
committed [C]c [C]o [C]m [C]m [C]i [C]t [C]t [C]e [C]d B-cell_type 
progenitors [C]p [C]r [C]o [C]g [C]e [C]n [C]i [C]t [C]o [C]r [C]s E-cell_type 
based [C]b [C]a [C]s [C]e [C]d O 
on [C]o [C]n O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
secretion [C]s [C]e [C]c [C]r [C]e [C]t [C]i [C]o [C]n O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
and [C]a [C]n [C]d O 
developed [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]e [C]d O 
retroviral-based [C]r [C]e [C]t [C]r [C]o [C]v [C]i [C]r [C]a [C]l [C]- [C]b [C]a [C]s [C]e [C]d O 
tagging [C]t [C]a [C]g [C]g [C]i [C]n [C]g O 
approaches [C]a [C]p [C]p [C]r [C]o [C]a [C]c [C]h [C]e [C]s O 
to [C]t [C]o O 
directly [C]d [C]i [C]r [C]e [C]c [C]t [C]l [C]y O 
monitor [C]m [C]o [C]n [C]i [C]t [C]o [C]r O 
individual [C]i [C]n [C]d [C]i [C]v [C]i [C]d [C]u [C]a [C]l O 
progenitor [C]p [C]r [C]o [C]g [C]e [C]n [C]i [C]t [C]o [C]r O 
fate [C]f [C]a [C]t [C]e O 
decisions [C]d [C]e [C]c [C]i [C]s [C]i [C]o [C]n [C]s O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
clonal [C]c [C]l [C]o [C]n [C]a [C]l O 
and [C]a [C]n [C]d O 
population [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
. [C]. O 

We [C]W [C]e O 
observe [C]o [C]b [C]s [C]e [C]r [C]v [C]e O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
redirection [C]r [C]e [C]d [C]i [C]r [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
in [C]i [C]n O 
cells [C]c [C]e [C]l [C]l [C]s O 
that [C]t [C]h [C]a [C]t O 
have [C]h [C]a [C]v [C]e O 
already [C]a [C]l [C]r [C]e [C]a [C]d [C]y O 
committed [C]c [C]o [C]m [C]m [C]i [C]t [C]t [C]e [C]d O 
to [C]t [C]o O 
a [C]a O 
non-IL-4-producing [C]n [C]o [C]n [C]- [C]I [C]L [C]- [C]4 [C]- [C]p [C]r [C]o [C]d [C]u [C]c [C]i [C]n [C]g O 
fate [C]f [C]a [C]t [C]e O 
, [C], O 
inconsistent [C]i [C]n [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
predictions [C]p [C]r [C]e [C]d [C]i [C]c [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
selective [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e O 
model [C]m [C]o [C]d [C]e [C]l O 
. [C]. O 

Further [C]F [C]u [C]r [C]t [C]h [C]e [C]r O 
, [C], O 
retroviral [C]r [C]e [C]t [C]r [C]o [C]v [C]i [C]r [C]a [C]l O 
tagging [C]t [C]a [C]g [C]g [C]i [C]n [C]g O 
of [C]o [C]f O 
naive [C]n [C]a [C]i [C]v [C]e B-cell_type 
progenitors [C]p [C]r [C]o [C]g [C]e [C]n [C]i [C]t [C]o [C]r [C]s E-cell_type 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
Th2-specific [C]T [C]h [C]2 [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 E-protein 
provided [C]p [C]r [C]o [C]v [C]i [C]d [C]e [C]d O 
direct [C]d [C]i [C]r [C]e [C]c [C]t O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
for [C]f [C]o [C]r O 
instructive [C]i [C]n [C]s [C]t [C]r [C]u [C]c [C]t [C]i [C]v [C]e O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
no [C]n [C]o O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
selective [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e O 
outgrowth [C]o [C]u [C]t [C]g [C]r [C]o [C]w [C]t [C]h O 
of [C]o [C]f O 
cells [C]c [C]e [C]l [C]l [C]s O 
committed [C]c [C]o [C]m [C]m [C]i [C]t [C]t [C]e [C]d O 
to [C]t [C]o O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
the [C]t [C]h [C]e O 
Th1 [C]T [C]h [C]1 O 
or [C]o [C]r O 
Th2 [C]T [C]h [C]2 O 
fate [C]f [C]a [C]t [C]e O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
would [C]w [C]o [C]u [C]l [C]d O 
seem [C]s [C]e [C]e [C]m O 
to [C]t [C]o O 
exclude [C]e [C]x [C]c [C]l [C]u [C]d [C]e O 
selection [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]o [C]n O 
as [C]a [C]s O 
an [C]a [C]n O 
exclusive [C]e [C]x [C]c [C]l [C]u [C]s [C]i [C]v [C]e O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
in [C]i [C]n O 
Th1 [C]T [C]h [C]1 S-cell_type 
/ [C]/ O 
Th2 [C]T [C]h [C]2 S-cell_type 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
support [C]s [C]u [C]p [C]p [C]o [C]r [C]t O 
an [C]a [C]n O 
instructive [C]i [C]n [C]s [C]t [C]r [C]u [C]c [C]t [C]i [C]v [C]e O 
model [C]m [C]o [C]d [C]e [C]l O 
of [C]o [C]f O 
cytokine-driven [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]- [C]d [C]r [C]i [C]v [C]e [C]n O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
programming [C]p [C]r [C]o [C]g [C]r [C]a [C]m [C]m [C]i [C]n [C]g O 
of [C]o [C]f O 
cell [C]c [C]e [C]l [C]l O 
fate [C]f [C]a [C]t [C]e O 
decisions [C]d [C]e [C]c [C]i [C]s [C]i [C]o [C]n [C]s O 
. [C]. O 

In [C]I [C]n O 
vitro-activated [C]v [C]i [C]t [C]r [C]o [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
lupus [C]l [C]u [C]p [C]u [C]s I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
which [C]w [C]h [C]i [C]c [C]h O 
bind [C]b [C]i [C]n [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n B-protein 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e I-protein 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-protein 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
shown [C]s [C]h [C]o [C]w [C]n O 
that [C]t [C]h [C]a [C]t O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
( [C]( O 
ERalpha [C]E [C]R [C]a [C]l [C]p [C]h [C]a S-protein 
, [C], O 
ERbeta [C]E [C]R [C]b [C]e [C]t [C]a S-protein 
) [C]) O 
transcripts [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]s O 
are [C]a [C]r [C]e O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
SLE [C]S [C]L [C]E B-cell_type 
and [C]a [C]n [C]d I-cell_type 
normal [C]n [C]o [C]r [C]m [C]a [C]l I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
, [C], O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
from [C]f [C]r [C]o [C]m O 
female [C]f [C]e [C]m [C]a [C]l [C]e O 
lupus [C]l [C]u [C]p [C]u [C]s O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
and [C]a [C]n [C]d O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
donors [C]d [C]o [C]n [C]o [C]r [C]s O 
were [C]w [C]e [C]r [C]e O 
tested [C]t [C]e [C]s [C]t [C]e [C]d O 
for [C]f [C]o [C]r O 
biologically [C]b [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l [C]l [C]y O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
ER [C]E [C]R B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
capable [C]c [C]a [C]p [C]a [C]b [C]l [C]e O 
of [C]o [C]f O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n I-DNA 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e I-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
( [C]( O 
hERE [C]h [C]E [C]R [C]E S-DNA 
) [C]) O 
by [C]b [C]y O 
electrophoretic [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
. [C]. O 

When [C]W [C]h [C]e [C]n O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
17beta-estradiol [C]1 [C]7 [C]b [C]e [C]t [C]a [C]- [C]e [C]s [C]t [C]r [C]a [C]d [C]i [C]o [C]l O 
( [C]( O 
E2 [C]E [C]2 O 
) [C]) O 
, [C], O 
PMA [C]P [C]M [C]A O 
and [C]a [C]n [C]d O 
ionomycin [C]i [C]o [C]n [C]o [C]m [C]y [C]c [C]i [C]n O 
, [C], O 
two [C]t [C]w [C]o O 
major [C]m [C]a [C]j [C]o [C]r O 
retarded [C]r [C]e [C]t [C]a [C]r [C]d [C]e [C]d O 
bands [C]b [C]a [C]n [C]d [C]s O 
in [C]i [C]n O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
exhibited [C]e [C]x [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
a [C]a O 
migration [C]m [C]i [C]g [C]r [C]a [C]t [C]i [C]o [C]n O 
pattern [C]p [C]a [C]t [C]t [C]e [C]r [C]n O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
to [C]t [C]o O 
slow [C]s [C]l [C]o [C]w O 
migrating [C]m [C]i [C]g [C]r [C]a [C]t [C]i [C]n [C]g O 
protein-ERE [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]E [C]R [C]E B-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
cell [C]c [C]e [C]l [C]l O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
. [C]. O 

T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
cultured [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]d O 
only [C]o [C]n [C]l [C]y O 
with [C]w [C]i [C]t [C]h O 
E2 [C]E [C]2 O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
have [C]h [C]a [C]v [C]e O 
these [C]t [C]h [C]e [C]s [C]e O 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s O 
was [C]w [C]a [C]s O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
by [C]b [C]y O 
competition [C]c [C]o [C]m [C]p [C]e [C]t [C]i [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
hERE [C]h [C]E [C]R [C]E O 
cold [C]c [C]o [C]l [C]d O 
oligonucleotide [C]o [C]l [C]i [C]g [C]o [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e O 
and [C]a [C]n [C]d O 
partially [C]p [C]a [C]r [C]t [C]i [C]a [C]l [C]l [C]y O 
with [C]w [C]i [C]t [C]h O 
anti-ERalpha [C]a [C]n [C]t [C]i [C]- [C]E [C]R [C]a [C]l [C]p [C]h [C]a B-protein 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s E-protein 
. [C]. O 

There [C]T [C]h [C]e [C]r [C]e O 
was [C]w [C]a [C]s O 
no [C]n [C]o O 
notable [C]n [C]o [C]t [C]a [C]b [C]l [C]e O 
difference [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
migration [C]m [C]i [C]g [C]r [C]a [C]t [C]i [C]o [C]n O 
pattern [C]p [C]a [C]t [C]t [C]e [C]r [C]n O 
of [C]o [C]f O 
ERE-binding [C]E [C]R [C]E [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
SLE [C]S [C]L [C]E O 
and [C]a [C]n [C]d O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
. [C]. O 

Together [C]T [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
, [C], O 
these [C]t [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
lupus-derived [C]l [C]u [C]p [C]u [C]s [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
or [C]o [C]r O 
normal-derived [C]n [C]o [C]r [C]m [C]a [C]l [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
, [C], O 
contain [C]c [C]o [C]n [C]t [C]a [C]i [C]n O 
biologically [C]b [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l [C]l [C]y O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
ERalpha [C]E [C]R [C]a [C]l [C]p [C]h [C]a B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
. [C]. O 

Other [C]O [C]t [C]h [C]e [C]r O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
responsible [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]b [C]l [C]e O 
for [C]f [C]o [C]r O 
differential [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
lupus [C]l [C]u [C]p [C]u [C]s B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
to [C]t [C]o O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n O 
. [C]. O 

Mechanism [C]M [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
protease [C]p [C]r [C]o [C]t [C]e [C]a [C]s [C]e O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
on [C]o [C]n O 
tumor [C]t [C]u [C]m [C]o [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
. [C]. O 

If [C]I [C]f O 
the [C]t [C]h [C]e O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
becomes [C]b [C]e [C]c [C]o [C]m [C]e [C]s O 
excessive [C]e [C]x [C]c [C]e [C]s [C]s [C]i [C]v [C]e O 
or [C]o [C]r O 
uncontrolled [C]u [C]n [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]l [C]e [C]d O 
by [C]b [C]y O 
some [C]s [C]o [C]m [C]e O 
stimuli [C]s [C]t [C]i [C]m [C]u [C]l [C]i O 
, [C], O 
inappropriate [C]i [C]n [C]a [C]p [C]p [C]r [C]o [C]p [C]r [C]i [C]a [C]t [C]e O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
occur [C]o [C]c [C]c [C]u [C]r O 
. [C]. O 

Monocytes [C]M [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
are [C]a [C]r [C]e O 
extremely [C]e [C]x [C]t [C]r [C]e [C]m [C]e [C]l [C]y O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
cells [C]c [C]e [C]l [C]l [C]s O 
for [C]f [C]o [C]r O 
regulating [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
network [C]n [C]e [C]t [C]w [C]o [C]r [C]k O 
and [C]a [C]n [C]d O 
tumor [C]t [C]u [C]m [C]o [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
( [C]( O 
TNFalpha [C]T [C]N [C]F [C]a [C]l [C]p [C]h [C]a S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
interleukin- [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- B-protein 
( [C]( I-protein 
IL [C]I [C]L I-protein 
) [C]) I-protein 
10 [C]1 [C]0 E-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
are [C]a [C]r [C]e O 
mainly [C]m [C]a [C]i [C]n [C]l [C]y O 
synthesized [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]z [C]e [C]d O 
by [C]b [C]y O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
, [C], O 
are [C]a [C]r [C]e O 
representative [C]r [C]e [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]a [C]t [C]i [C]v [C]e O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
that [C]t [C]h [C]a [C]t O 
play [C]p [C]l [C]a [C]y O 
a [C]a O 
central [C]c [C]e [C]n [C]t [C]r [C]a [C]l O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
network [C]n [C]e [C]t [C]w [C]o [C]r [C]k O 
. [C]. O 

Protease [C]P [C]r [C]o [C]t [C]e [C]a [C]s [C]e O 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
gabexate [C]g [C]a [C]b [C]e [C]x [C]a [C]t [C]e O 
mesilate [C]m [C]e [C]s [C]i [C]l [C]a [C]t [C]e O 
( [C]( O 
GM [C]G [C]M O 
) [C]) O 
and [C]a [C]n [C]d O 
ulinastatin [C]u [C]l [C]i [C]n [C]a [C]s [C]t [C]a [C]t [C]i [C]n O 
( [C]( O 
UTI [C]U [C]T [C]I O 
) [C]) O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
have [C]h [C]a [C]v [C]e O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
beneficial [C]b [C]e [C]n [C]e [C]f [C]i [C]c [C]i [C]a [C]l O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
by [C]b [C]y O 
inhibiting [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
, [C], O 
but [C]b [C]u [C]t O 
the [C]t [C]h [C]e O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
for [C]f [C]o [C]r O 
this [C]t [C]h [C]i [C]s O 
has [C]h [C]a [C]s O 
yet [C]y [C]e [C]t O 
to [C]t [C]o O 
be [C]b [C]e O 
fully [C]f [C]u [C]l [C]l [C]y O 
elucidated [C]e [C]l [C]u [C]c [C]i [C]d [C]a [C]t [C]e [C]d O 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
we [C]w [C]e O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
protease [C]p [C]r [C]o [C]t [C]e [C]a [C]s [C]e O 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
proinflammatory [C]p [C]r [C]o [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
lipopolysaccharide- [C]l [C]i [C]p [C]o [C]p [C]o [C]l [C]y [C]s [C]a [C]c [C]c [C]h [C]a [C]r [C]i [C]d [C]e [C]- O 
( [C]( O 
LPS [C]L [C]P [C]S O 
) [C]) O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
. [C]. O 

LPS-stimulated [C]L [C]P [C]S [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
were [C]w [C]e [C]r [C]e O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
GM [C]G [C]M O 
or [C]o [C]r O 
UTI [C]U [C]T [C]I O 
. [C]. O 

The [C]T [C]h [C]e O 
value [C]v [C]a [C]l [C]u [C]e O 
of [C]o [C]f O 
TNFalpha [C]T [C]N [C]F [C]a [C]l [C]p [C]h [C]a S-protein 
and [C]a [C]n [C]d O 
IL-10 [C]I [C]L [C]- [C]1 [C]0 S-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
medium [C]m [C]e [C]d [C]i [C]u [C]m O 
of [C]o [C]f O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
was [C]w [C]a [C]s O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
and [C]a [C]n [C]d O 
each [C]e [C]a [C]c [C]h O 
mRNA [C]m [C]R [C]N [C]A O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
assayed [C]a [C]s [C]s [C]a [C]y [C]e [C]d O 
. [C]. O 

The [C]T [C]h [C]e O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
protease [C]p [C]r [C]o [C]t [C]e [C]a [C]s [C]e O 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
C [C]C E-protein 
( [C]( O 
PKC [C]P [C]K [C]C S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
( [C]( O 
NFkappaB [C]N [C]F [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
) [C]) O 
were [C]w [C]e [C]r [C]e O 
also [C]a [C]l [C]s [C]o O 
evaluated [C]e [C]v [C]a [C]l [C]u [C]a [C]t [C]e [C]d O 
. [C]. O 

GM [C]G [C]M O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
TNFalpha [C]T [C]N [C]F [C]a [C]l [C]p [C]h [C]a S-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
LPS-stimulated [C]L [C]P [C]S [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
as [C]a [C]s O 
shown [C]s [C]h [C]o [C]w [C]n O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
mRNA [C]m [C]R [C]N [C]A O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
IL-10 [C]I [C]L [C]- [C]1 [C]0 S-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
LPS-stimulated [C]L [C]P [C]S [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
. [C]. O 

GM [C]G [C]M O 
also [C]a [C]l [C]s [C]o O 
suppressed [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
NFkappaB [C]N [C]F [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
LPS-stimulated [C]L [C]P [C]S [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
. [C]. O 

UTI [C]U [C]T [C]I O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
TNFalpha [C]T [C]N [C]F [C]a [C]l [C]p [C]h [C]a S-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
LPS-stimulated [C]L [C]P [C]S [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
, [C], O 
but [C]b [C]u [C]t O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
inhibit [C]i [C]n [C]h [C]i [C]b [C]i [C]t O 
the [C]t [C]h [C]e O 
TNFalpha [C]T [C]N [C]F [C]a [C]l [C]p [C]h [C]a B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
study [C]s [C]t [C]u [C]d [C]y O 
shows [C]s [C]h [C]o [C]w [C]s O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
GM [C]G [C]M O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
TNFalpha [C]T [C]N [C]F [C]a [C]l [C]p [C]h [C]a S-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
is [C]i [C]s O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
suppression [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
NFkappaB [C]N [C]F [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
while [C]w [C]h [C]i [C]l [C]e O 
the [C]t [C]h [C]e O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
of [C]o [C]f O 
UTI [C]U [C]T [C]I O 
inhibiting [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]n [C]g O 
TNFalpha [C]T [C]N [C]F [C]a [C]l [C]p [C]h [C]a S-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
due [C]d [C]u [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
the [C]t [C]h [C]e O 
translation [C]t [C]r [C]a [C]n [C]s [C]l [C]a [C]t [C]i [C]o [C]n O 
or [C]o [C]r O 
secretion [C]s [C]e [C]c [C]r [C]e [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
TNFalpha [C]T [C]N [C]F [C]a [C]l [C]p [C]h [C]a S-protein 
. [C]. O 

Homocysteine [C]H [C]o [C]m [C]o [C]c [C]y [C]s [C]t [C]e [C]i [C]n [C]e O 
stimulates [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]s O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
monocyte [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e B-protein 
chemoattractant [C]c [C]h [C]e [C]m [C]o [C]a [C]t [C]t [C]r [C]a [C]c [C]t [C]a [C]n [C]t I-protein 
protein-1 [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]1 E-protein 
in [C]i [C]n O 
endothelial [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
leading [C]l [C]e [C]a [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
monocyte [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e O 
chemotaxis [C]c [C]h [C]e [C]m [C]o [C]t [C]a [C]x [C]i [C]s O 
. [C]. O 

Hyperhomocysteinemia [C]H [C]y [C]p [C]e [C]r [C]h [C]o [C]m [C]o [C]c [C]y [C]s [C]t [C]e [C]i [C]n [C]e [C]m [C]i [C]a O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
as [C]a [C]s O 
an [C]a [C]n O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
risk [C]r [C]i [C]s [C]k O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
for [C]f [C]o [C]r O 
atherosclerosis [C]a [C]t [C]h [C]e [C]r [C]o [C]s [C]c [C]l [C]e [C]r [C]o [C]s [C]i [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
infiltration [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
into [C]i [C]n [C]t [C]o O 
the [C]t [C]h [C]e O 
arterial [C]a [C]r [C]t [C]e [C]r [C]i [C]a [C]l O 
wall [C]w [C]a [C]l [C]l O 
is [C]i [C]s O 
one [C]o [C]n [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
key [C]k [C]e [C]y O 
events [C]e [C]v [C]e [C]n [C]t [C]s O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
atherogenesis [C]a [C]t [C]h [C]e [C]r [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
. [C]. O 

Monocyte [C]M [C]o [C]n [C]o [C]c [C]y [C]t [C]e B-protein 
chemoattractant [C]c [C]h [C]e [C]m [C]o [C]a [C]t [C]t [C]r [C]a [C]c [C]t [C]a [C]n [C]t I-protein 
protein-1 [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]1 E-protein 
( [C]( O 
MCP-1 [C]M [C]C [C]P [C]- [C]1 S-protein 
) [C]) O 
is [C]i [C]s O 
a [C]a O 
potent [C]p [C]o [C]t [C]e [C]n [C]t O 
chemokine [C]c [C]h [C]e [C]m [C]o [C]k [C]i [C]n [C]e S-protein 
that [C]t [C]h [C]a [C]t O 
stimulates [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]s O 
the [C]t [C]h [C]e O 
migration [C]m [C]i [C]g [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
into [C]i [C]n [C]t [C]o O 
the [C]t [C]h [C]e O 
intima [C]i [C]n [C]t [C]i [C]m [C]a O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
arterial [C]a [C]r [C]t [C]e [C]r [C]i [C]a [C]l O 
wall [C]w [C]a [C]l [C]l O 
. [C]. O 

The [C]T [C]h [C]e O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
by [C]b [C]y O 
which [C]w [C]h [C]i [C]c [C]h O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
monocyte [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e O 
infiltration [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
occurs [C]o [C]c [C]c [C]u [C]r [C]s O 
in [C]i [C]n O 
atherosclerotic [C]a [C]t [C]h [C]e [C]r [C]o [C]s [C]c [C]l [C]e [C]r [C]o [C]t [C]i [C]c O 
lesions [C]l [C]e [C]s [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
hyperhomocysteinemia [C]h [C]y [C]p [C]e [C]r [C]h [C]o [C]m [C]o [C]c [C]y [C]s [C]t [C]e [C]i [C]n [C]e [C]m [C]i [C]a O 
has [C]h [C]a [C]s O 
not [C]n [C]o [C]t O 
been [C]b [C]e [C]e [C]n O 
delineated [C]d [C]e [C]l [C]i [C]n [C]e [C]a [C]t [C]e [C]d O 
. [C]. O 

The [C]T [C]h [C]e O 
objective [C]o [C]b [C]j [C]e [C]c [C]t [C]i [C]v [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
study [C]s [C]t [C]u [C]d [C]y O 
was [C]w [C]a [C]s O 
to [C]t [C]o O 
investigate [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
homocysteine [C]h [C]o [C]m [C]o [C]c [C]y [C]s [C]t [C]e [C]i [C]n [C]e O 
on [C]o [C]n O 
MCP-1 [C]M [C]C [C]P [C]- [C]1 S-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
endothelial [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Cells [C]C [C]e [C]l [C]l [C]s O 
were [C]w [C]e [C]r [C]e O 
incubated [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
homocysteine [C]h [C]o [C]m [C]o [C]c [C]y [C]s [C]t [C]e [C]i [C]n [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
secretion [C]s [C]e [C]c [C]r [C]e [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
MCP-1 [C]M [C]C [C]P [C]- [C]1 B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
was [C]w [C]a [C]s O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
( [C]( O 
195 [C]1 [C]9 [C]5 O 
% [C]% O 
as [C]a [C]s O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
) [C]) O 
in [C]i [C]n O 
cells [C]c [C]e [C]l [C]l [C]s O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
pathological [C]p [C]a [C]t [C]h [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
homocysteine [C]h [C]o [C]m [C]o [C]c [C]y [C]s [C]t [C]e [C]i [C]n [C]e O 
. [C]. O 

Such [C]S [C]u [C]c [C]h O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
was [C]w [C]a [C]s O 
accompanied [C]a [C]c [C]c [C]o [C]m [C]p [C]a [C]n [C]i [C]e [C]d O 
by [C]b [C]y O 
an [C]a [C]n O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
MCP-1 [C]M [C]C [C]P [C]- [C]1 B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
( [C]( O 
176 [C]1 [C]7 [C]6 O 
% [C]% O 
as [C]a [C]s O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
) [C]) O 
in [C]i [C]n O 
endothelial [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
which [C]w [C]h [C]i [C]c [C]h O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
monocyte [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e O 
chemotaxis [C]c [C]h [C]e [C]m [C]o [C]t [C]a [C]x [C]i [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
p38 [C]p [C]3 [C]8 B-protein 
MAP [C]M [C]A [C]P I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
other [C]o [C]t [C]h [C]e [C]r O 
members [C]m [C]e [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
p38 [C]p [C]3 [C]8 O 
MAP [C]M [C]A [C]P O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
MKK3 [C]M [C]K [C]K [C]3 S-protein 
, [C], O 
MKK6 [C]M [C]K [C]K [C]6 S-protein 
, [C], O 
ATF-2 [C]A [C]T [C]F [C]- [C]2 S-protein 
and [C]a [C]n [C]d O 
Elk-1 [C]E [C]l [C]k [C]- [C]1 S-protein 
, [C], O 
were [C]w [C]e [C]r [C]e O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
homocysteine-treated [C]h [C]o [C]m [C]o [C]c [C]y [C]s [C]t [C]e [C]i [C]n [C]e [C]- [C]t [C]r [C]e [C]a [C]t [C]e [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Homocysteine-induced [C]H [C]o [C]m [C]o [C]c [C]y [C]s [C]t [C]e [C]i [C]n [C]e [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
MCP-1 [C]M [C]C [C]P [C]- [C]1 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
subsequent [C]s [C]u [C]b [C]s [C]e [C]q [C]u [C]e [C]n [C]t O 
monocyte [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e O 
chemotaxis [C]c [C]h [C]e [C]m [C]o [C]t [C]a [C]x [C]i [C]s O 
were [C]w [C]e [C]r [C]e O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
p38 [C]p [C]3 [C]8 B-protein 
MAP [C]M [C]A [C]P I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
( [C]( O 
SB203580 [C]S [C]B [C]2 [C]0 [C]3 [C]5 [C]8 [C]0 O 
) [C]) O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
p38 [C]p [C]3 [C]8 B-protein 
MAP [C]M [C]A [C]P I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
might [C]m [C]i [C]g [C]h [C]t O 
be [C]b [C]e O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
homocysteine-induced [C]h [C]o [C]m [C]o [C]c [C]y [C]s [C]t [C]e [C]i [C]n [C]e [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
MCP-1 [C]M [C]C [C]P [C]- [C]1 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
endothelial [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
staurosporine [C]s [C]t [C]a [C]u [C]r [C]o [C]s [C]p [C]o [C]r [C]i [C]n [C]e O 
, [C], O 
a [C]a O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
C [C]C E-protein 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
, [C], O 
had [C]h [C]a [C]d O 
no [C]n [C]o O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
homocysteine-induced [C]h [C]o [C]m [C]o [C]c [C]y [C]s [C]t [C]e [C]i [C]n [C]e [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
MCP-1 [C]M [C]C [C]P [C]- [C]1 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

In [C]I [C]n O 
conclusion [C]c [C]o [C]n [C]c [C]l [C]u [C]s [C]i [C]o [C]n O 
, [C], O 
our [C]o [C]u [C]r O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
homocysteine [C]h [C]o [C]m [C]o [C]c [C]y [C]s [C]t [C]e [C]i [C]n [C]e O 
stimulates [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]s O 
MCP-1 [C]M [C]C [C]P [C]- [C]1 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
endothelial [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
leading [C]l [C]e [C]a [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
monocyte [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e O 
chemotaxis [C]c [C]h [C]e [C]m [C]o [C]t [C]a [C]x [C]i [C]s O 
. [C]. O 

Inducible [C]I [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
to [C]t [C]o O 
Fas-mediated [C]F [C]a [C]s [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Apoptosis [C]A [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
produced [C]p [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
in [C]i [C]n O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
Fas [C]F [C]a [C]s S-protein 
( [C]( O 
APO-1 [C]A [C]P [C]O [C]- [C]1 S-protein 
, [C], O 
CD95 [C]C [C]D [C]9 [C]5 S-protein 
) [C]) O 
triggering [C]t [C]r [C]i [C]g [C]g [C]e [C]r [C]i [C]n [C]g O 
is [C]i [C]s O 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
derived [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
other [C]o [C]t [C]h [C]e [C]r O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
: [C]: O 
CD40 [C]C [C]D [C]4 [C]0 O 
engagement [C]e [C]n [C]g [C]a [C]g [C]e [C]m [C]e [C]n [C]t O 
produces [C]p [C]r [C]o [C]d [C]u [C]c [C]e [C]s O 
upregulation [C]u [C]p [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Fas [C]F [C]a [C]s S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
marked [C]m [C]a [C]r [C]k [C]e [C]d O 
susceptibility [C]s [C]u [C]s [C]c [C]e [C]p [C]t [C]i [C]b [C]i [C]l [C]i [C]t [C]y O 
to [C]t [C]o O 
Fas [C]F [C]a [C]s S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
cell [C]c [C]e [C]l [C]l O 
death [C]d [C]e [C]a [C]t [C]h O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
engagement [C]e [C]n [C]g [C]a [C]g [C]e [C]m [C]e [C]n [C]t O 
, [C], O 
or [C]o [C]r O 
IL-4R [C]I [C]L [C]- [C]4 [C]R O 
engagement [C]e [C]n [C]g [C]a [C]g [C]e [C]m [C]e [C]n [C]t O 
, [C], O 
inhibits [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]s O 
Fas [C]F [C]a [C]s S-protein 
killing [C]k [C]i [C]l [C]l [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
so [C]s [C]o O 
doing [C]d [C]o [C]i [C]n [C]g O 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
a [C]a O 
state [C]s [C]t [C]a [C]t [C]e O 
of [C]o [C]f O 
Fas [C]F [C]a [C]s S-protein 
-resistance [C]- [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
, [C], O 
even [C]e [C]v [C]e [C]n O 
in [C]i [C]n O 
otherwise [C]o [C]t [C]h [C]e [C]r [C]w [C]i [C]s [C]e O 
sensitive [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
, [C], O 
CD40 [C]C [C]D [C]4 [C]0 S-protein 
-stimulated [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
targets [C]t [C]a [C]r [C]g [C]e [C]t [C]s O 
. [C]. O 

Surface [C]S [C]u [C]r [C]f [C]a [C]c [C]e B-protein 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n E-protein 
and [C]a [C]n [C]d O 
IL-4R [C]I [C]L [C]- [C]4 [C]R S-protein 
utilize [C]u [C]t [C]i [C]l [C]i [C]z [C]e O 
at [C]a [C]t O 
least [C]l [C]e [C]a [C]s [C]t O 
partially [C]p [C]a [C]r [C]t [C]i [C]a [C]l [C]l [C]y O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
to [C]t [C]o O 
produce [C]p [C]r [C]o [C]d [C]u [C]c [C]e O 
Fas [C]F [C]a [C]s S-protein 
-resistance [C]- [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
that [C]t [C]h [C]a [C]t O 
differentially [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l [C]l [C]y O 
depend [C]d [C]e [C]p [C]e [C]n [C]d O 
on [C]o [C]n O 
PKC [C]P [C]K [C]C S-protein 
and [C]a [C]n [C]d O 
STAT6 [C]S [C]T [C]A [C]T [C]6 S-protein 
, [C], O 
respectively [C]r [C]e [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
. [C]. O 

Further [C]F [C]u [C]r [C]t [C]h [C]e [C]r O 
, [C], O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
for [C]f [C]o [C]r O 
inducible [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
Fas [C]F [C]a [C]s S-protein 
-resistance [C]- [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
bypasses [C]b [C]y [C]p [C]a [C]s [C]s [C]e [C]s O 
Btk [C]B [C]t [C]k S-protein 
, [C], O 
requires [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]s O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
, [C], O 
and [C]a [C]n [C]d O 
entails [C]e [C]n [C]t [C]a [C]i [C]l [C]s O 
new [C]n [C]e [C]w O 
macromolecular [C]m [C]a [C]c [C]r [C]o [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
. [C]. O 

Terminal [C]T [C]e [C]r [C]m [C]i [C]n [C]a [C]l O 
effectors [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r [C]s O 
of [C]o [C]f O 
B [C]B B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
Fas [C]F [C]a [C]s S-protein 
-resistance [C]- [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
include [C]i [C]n [C]c [C]l [C]u [C]d [C]e O 
the [C]t [C]h [C]e O 
known [C]k [C]n [C]o [C]w [C]n O 
anti-apoptotic [C]a [C]n [C]t [C]i [C]- [C]a [C]p [C]o [C]p [C]t [C]o [C]t [C]i [C]c B-protein 
gene [C]g [C]e [C]n [C]e I-protein 
products [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]s E-protein 
, [C], O 
Bcl-xL [C]B [C]c [C]l [C]- [C]x [C]L S-protein 
and [C]a [C]n [C]d O 
FLIP [C]F [C]L [C]I [C]P S-protein 
, [C], O 
and [C]a [C]n [C]d O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
anti-apoptotic [C]a [C]n [C]t [C]i [C]- [C]a [C]p [C]o [C]p [C]t [C]o [C]t [C]i [C]c B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
that [C]t [C]h [C]a [C]t O 
encodes [C]e [C]n [C]c [C]o [C]d [C]e [C]s O 
FAIM [C]F [C]A [C]I [C]M S-protein 
( [C]( O 
Fas [C]F [C]a [C]s B-protein 
Apoptosis [C]A [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s I-protein 
Inhibitory [C]I [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y I-protein 
Molecule [C]M [C]o [C]l [C]e [C]c [C]u [C]l [C]e E-protein 
) [C]) O 
. [C]. O 

faim [C]f [C]a [C]i [C]m S-protein 
was [C]w [C]a [C]s O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
by [C]b [C]y O 
differential [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l O 
display [C]d [C]i [C]s [C]p [C]l [C]a [C]y O 
and [C]a [C]n [C]d O 
exists [C]e [C]x [C]i [C]s [C]t [C]s O 
in [C]i [C]n O 
two [C]t [C]w [C]o O 
alternatively [C]a [C]l [C]t [C]e [C]r [C]n [C]a [C]t [C]i [C]v [C]e [C]l [C]y O 
spliced [C]s [C]p [C]l [C]i [C]c [C]e [C]d O 
forms [C]f [C]o [C]r [C]m [C]s O 
; [C]; O 
faim-S [C]f [C]a [C]i [C]m [C]- [C]S S-protein 
is [C]i [C]s O 
broadly [C]b [C]r [C]o [C]a [C]d [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
, [C], O 
but [C]b [C]u [C]t O 
faim-L [C]f [C]a [C]i [C]m [C]- [C]L O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
is [C]i [C]s O 
tissue-specific [C]t [C]i [C]s [C]s [C]u [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
. [C]. O 

The [C]T [C]h [C]e O 
FAIM [C]F [C]A [C]I [C]M B-DNA 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e E-DNA 
is [C]i [C]s O 
highly [C]h [C]i [C]g [C]h [C]l [C]y O 
evolu- [C]e [C]v [C]o [C]l [C]u [C]- O 
tionarily [C]t [C]i [C]o [C]n [C]a [C]r [C]i [C]l [C]y O 
conserved [C]c [C]o [C]n [C]s [C]e [C]r [C]v [C]e [C]d O 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
an [C]a [C]n O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
role [C]r [C]o [C]l [C]e O 
for [C]f [C]o [C]r O 
this [C]t [C]h [C]i [C]s O 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e O 
throughout [C]t [C]h [C]r [C]o [C]u [C]g [C]h [C]o [C]u [C]t O 
phylogeny [C]p [C]h [C]y [C]l [C]o [C]g [C]e [C]n [C]y O 
. [C]. O 

Inducible [C]I [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
to [C]t [C]o O 
Fas [C]F [C]a [C]s S-protein 
killing [C]k [C]i [C]l [C]l [C]i [C]n [C]g O 
is [C]i [C]s O 
hypothesized [C]h [C]y [C]p [C]o [C]t [C]h [C]e [C]s [C]i [C]z [C]e [C]d O 
to [C]t [C]o O 
protect [C]p [C]r [C]o [C]t [C]e [C]c [C]t O 
foreign [C]f [C]o [C]r [C]e [C]i [C]g [C]n O 
antigen-specific [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
potentially [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l [C]l [C]y O 
hazardous [C]h [C]a [C]z [C]a [C]r [C]d [C]o [C]u [C]s O 
interactions [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
with [C]w [C]i [C]t [C]h O 
FasL-bearing [C]F [C]a [C]s [C]L [C]- [C]b [C]e [C]a [C]r [C]i [C]n [C]g B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
autoreactive [C]a [C]u [C]t [C]o [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]e B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
fail [C]f [C]a [C]i [C]l O 
to [C]t [C]o O 
become [C]b [C]e [C]c [C]o [C]m [C]e O 
Fas [C]F [C]a [C]s S-protein 
-resistant [C]- [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]t O 
and [C]a [C]n [C]d O 
are [C]a [C]r [C]e O 
deleted [C]d [C]e [C]l [C]e [C]t [C]e [C]d O 
via [C]v [C]i [C]a O 
Fas [C]F [C]a [C]s S-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
cytotoxicity [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c [C]i [C]t [C]y O 
. [C]. O 

Inadvertent [C]I [C]n [C]a [C]d [C]v [C]e [C]r [C]t [C]e [C]n [C]t O 
or [C]o [C]r O 
aberrant [C]a [C]b [C]e [C]r [C]r [C]a [C]n [C]t O 
acquisition [C]a [C]c [C]q [C]u [C]i [C]s [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Fas [C]F [C]a [C]s S-protein 
-resistance [C]- [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
may [C]m [C]a [C]y O 
permit [C]p [C]e [C]r [C]m [C]i [C]t O 
autoreactive [C]a [C]u [C]t [C]o [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]e B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
to [C]t [C]o O 
escape [C]e [C]s [C]c [C]a [C]p [C]e O 
Fas [C]F [C]a [C]s S-protein 
deletion [C]d [C]e [C]l [C]e [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
malignant [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]t B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
to [C]t [C]o O 
impede [C]i [C]m [C]p [C]e [C]d [C]e O 
anti-tumor [C]a [C]n [C]t [C]i [C]- [C]t [C]u [C]m [C]o [C]r O 
immunity [C]i [C]m [C]m [C]u [C]n [C]i [C]t [C]y O 
. [C]. O 

Stromal [C]S [C]t [C]r [C]o [C]m [C]a [C]l B-protein 
cell-derived [C]c [C]e [C]l [C]l [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
1 [C]1 I-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
chemotaxis [C]c [C]h [C]e [C]m [C]o [C]t [C]a [C]x [C]i [C]s O 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
is [C]i [C]s O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
nitric [C]n [C]i [C]t [C]r [C]i [C]c O 
oxide [C]o [C]x [C]i [C]d [C]e O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
. [C]. O 

Stromal [C]S [C]t [C]r [C]o [C]m [C]a [C]l B-protein 
cell-derived [C]c [C]e [C]l [C]l [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
1 [C]1 I-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
( [C]( O 
SDF1 [C]S [C]D [C]F [C]1 B-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
) [C]) O 
and [C]a [C]n [C]d O 
its [C]i [C]t [C]s O 
cognate [C]c [C]o [C]g [C]n [C]a [C]t [C]e O 
chemokine [C]c [C]h [C]e [C]m [C]o [C]k [C]i [C]n [C]e B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
CXCR4 [C]C [C]X [C]C [C]R [C]4 E-protein 
act [C]a [C]c [C]t O 
as [C]a [C]s O 
potent [C]p [C]o [C]t [C]e [C]n [C]t O 
chemoattractants [C]c [C]h [C]e [C]m [C]o [C]a [C]t [C]t [C]r [C]a [C]c [C]t [C]a [C]n [C]t [C]s O 
and [C]a [C]n [C]d O 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
trafficking [C]t [C]r [C]a [C]f [C]f [C]i [C]c [C]k [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
homing [C]h [C]o [C]m [C]i [C]n [C]g O 
of [C]o [C]f O 
hematopoietic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c B-cell_type 
progenitor [C]p [C]r [C]o [C]g [C]e [C]n [C]i [C]t [C]o [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
the [C]t [C]h [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
regulating [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
SDF1 [C]S [C]D [C]F [C]1 B-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
-driven [C]- [C]d [C]r [C]i [C]v [C]e [C]n O 
cell [C]c [C]e [C]l [C]l O 
migration [C]m [C]i [C]g [C]r [C]a [C]t [C]i [C]o [C]n O 
are [C]a [C]r [C]e O 
not [C]n [C]o [C]t O 
well [C]w [C]e [C]l [C]l O 
defined [C]d [C]e [C]f [C]i [C]n [C]e [C]d O 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
, [C], O 
we [C]w [C]e O 
have [C]h [C]a [C]v [C]e O 
explored [C]e [C]x [C]p [C]l [C]o [C]r [C]e [C]d O 
the [C]t [C]h [C]e O 
roles [C]r [C]o [C]l [C]e [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
second [C]s [C]e [C]c [C]o [C]n [C]d O 
messenger [C]m [C]e [C]s [C]s [C]e [C]n [C]g [C]e [C]r O 
NO [C]N [C]O O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
in [C]i [C]n O 
SDF1 [C]S [C]D [C]F [C]1 B-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
migration [C]m [C]i [C]g [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

SDF1 [C]S [C]D [C]F [C]1 B-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_line 
T [C]T I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
NO [C]N [C]O B-protein 
synthase [C]s [C]y [C]n [C]t [C]h [C]a [C]s [C]e E-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
catalyzes [C]c [C]a [C]t [C]a [C]l [C]y [C]z [C]e [C]s O 
the [C]t [C]h [C]e O 
generation [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NO [C]N [C]O O 
. [C]. O 

We [C]W [C]e O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
pretreatment [C]p [C]r [C]e [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
or [C]o [C]r O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
PBLs [C]P [C]B [C]L [C]s S-cell_type 
with [C]w [C]i [C]t [C]h O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
NO [C]N [C]O O 
donors [C]d [C]o [C]n [C]o [C]r [C]s O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
the [C]t [C]h [C]e O 
SDF1 [C]S [C]D [C]F [C]1 B-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
migration [C]m [C]i [C]g [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
of [C]o [C]f O 
NO [C]N [C]O B-protein 
synthase [C]s [C]y [C]n [C]t [C]h [C]a [C]s [C]e E-protein 
markedly [C]m [C]a [C]r [C]k [C]e [C]d [C]l [C]y O 
abrogated [C]a [C]b [C]r [C]o [C]g [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
chemotactic [C]c [C]h [C]e [C]m [C]o [C]t [C]a [C]c [C]t [C]i [C]c O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
in [C]i [C]n O 
a [C]a O 
concentration-dependent [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
manner [C]m [C]a [C]n [C]n [C]e [C]r O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
we [C]w [C]e O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
linked [C]l [C]i [C]n [C]k [C]e [C]d O 
to [C]t [C]o O 
NO [C]N [C]O O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
, [C], O 
also [C]a [C]l [C]s [C]o O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
the [C]t [C]h [C]e O 
SDF1 [C]S [C]D [C]F [C]1 B-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
chemotactic [C]c [C]h [C]e [C]m [C]o [C]t [C]a [C]c [C]t [C]i [C]c O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
these [C]t [C]h [C]e [C]s [C]e O 
compounds [C]c [C]o [C]m [C]p [C]o [C]u [C]n [C]d [C]s O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
have [C]h [C]a [C]v [C]e O 
a [C]a O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
SDF1 [C]S [C]D [C]F [C]1 B-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
mitogen-activated [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
the [C]t [C]h [C]e O 
MAP/Erk [C]M [C]A [C]P [C]/ [C]E [C]r [C]k O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
PD98059 [C]P [C]D [C]9 [C]8 [C]0 [C]5 [C]9 O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
abrogate [C]a [C]b [C]r [C]o [C]g [C]a [C]t [C]e O 
SDF1 [C]S [C]D [C]F [C]1 B-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
chemotaxis [C]c [C]h [C]e [C]m [C]o [C]t [C]a [C]x [C]i [C]s O 
. [C]. O 

AKT [C]A [C]K [C]T S-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
mediate [C]m [C]e [C]d [C]i [C]a [C]t [C]e O 
NO [C]N [C]O O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
, [C], O 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
phosphorylated [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]e [C]d O 
upon [C]u [C]p [C]o [C]n O 
SDF1 [C]S [C]D [C]F [C]1 B-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
NO-related [C]N [C]O [C]- [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
may [C]m [C]a [C]y O 
mediate [C]m [C]e [C]d [C]i [C]a [C]t [C]e O 
SDF1 [C]S [C]D [C]F [C]1 B-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
chemotaxis [C]c [C]h [C]e [C]m [C]o [C]t [C]a [C]x [C]i [C]s O 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
mitogen-activated [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
lack [C]l [C]a [C]c [C]k O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a O 
B [C]B O 
transactivation [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
PKC [C]P [C]K [C]C O 
epsilon [C]e [C]p [C]s [C]i [C]l [C]o [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
CD4 [C]C [C]D [C]4 B-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
CD8 [C]C [C]D [C]8 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
correlates [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
selection [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

Deletion [C]D [C]e [C]l [C]e [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
autoreactive [C]a [C]u [C]t [C]o [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]e B-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
DP [C]D [C]P O 
stage [C]s [C]t [C]a [C]g [C]e O 
is [C]i [C]s O 
the [C]t [C]h [C]e O 
basis [C]b [C]a [C]s [C]i [C]s O 
for [C]f [C]o [C]r O 
tolerance [C]t [C]o [C]l [C]e [C]r [C]a [C]n [C]c [C]e O 
to [C]t [C]o O 
thymus-expressed [C]t [C]h [C]y [C]m [C]u [C]s [C]- [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d B-protein 
self [C]s [C]e [C]l [C]f I-protein 
antigens [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]s E-protein 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
we [C]w [C]e O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
signalling [C]s [C]i [C]g [C]n [C]a [C]l [C]l [C]i [C]n [C]g O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
are [C]a [C]r [C]e O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
in [C]i [C]n O 
DP [C]D [C]P B-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
as [C]a [C]s O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
mature [C]m [C]a [C]t [C]u [C]r [C]e B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
upon [C]u [C]p [C]o [C]n O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n O 
. [C]. O 

Using [C]U [C]s [C]i [C]n [C]g O 
triple [C]t [C]r [C]i [C]p [C]l [C]e O 
transgenic [C]t [C]r [C]a [C]n [C]s [C]g [C]e [C]n [C]i [C]c O 
mice [C]m [C]i [C]c [C]e O 
expressing [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]n [C]g O 
a [C]a O 
TCR [C]T [C]C [C]R B-DNA 
transgene [C]t [C]r [C]a [C]n [C]s [C]g [C]e [C]n [C]e E-DNA 
, [C], O 
dominant [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t B-protein 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e I-protein 
ras/Mek [C]r [C]a [C]s [C]/ [C]M [C]e [C]k I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
and [C]a [C]n [C]d O 
a [C]a O 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r B-DNA 
gene [C]g [C]e [C]n [C]e I-DNA 
construct [C]c [C]o [C]n [C]s [C]t [C]r [C]u [C]c [C]t E-DNA 
with [C]w [C]i [C]t [C]h O 
AP-1 [C]A [C]P [C]- [C]1 B-DNA 
or [C]o [C]r I-DNA 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a I-DNA 
B [C]B I-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
, [C], O 
we [C]w [C]e O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
a [C]a O 
complete [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e O 
lack [C]l [C]a [C]c [C]k O 
of [C]o [C]f O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
in [C]i [C]n O 
DP [C]D [C]P B-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
both [C]b [C]o [C]t [C]h O 
were [C]w [C]e [C]r [C]e O 
transcriptionally [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l [C]l [C]y O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
in [C]i [C]n O 
mature [C]m [C]a [C]t [C]u [C]r [C]e B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
after [C]a [C]f [C]t [C]e [C]r O 
antigenic [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]i [C]c O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Lack [C]L [C]a [C]c [C]k O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
death [C]d [C]e [C]a [C]t [C]h O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n S-protein 
. [C]. O 

AP-1 [C]A [C]P [C]- [C]1 S-protein 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
dependent [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
integrity [C]i [C]n [C]t [C]e [C]g [C]r [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
ras/Mek [C]r [C]a [C]s [C]/ [C]M [C]e [C]k O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
indicating [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
this [C]t [C]h [C]i [C]s O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
was [C]w [C]a [C]s O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
DP [C]D [C]P B-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
we [C]w [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
a [C]a O 
complete [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e O 
lack [C]l [C]a [C]c [C]k O 
of [C]o [C]f O 
constitutive [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
epsilon [C]e [C]p [C]s [C]i [C]l [C]o [C]n B-protein 
isoform [C]i [C]s [C]o [C]f [C]o [C]r [C]m I-protein 
of [C]o [C]f I-protein 
Protein [C]P [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
Kinase [C]K [C]i [C]n [C]a [C]s [C]e I-protein 
C [C]C E-protein 
( [C]( O 
PKC [C]P [C]K [C]C S-protein 
) [C]) O 
in [C]i [C]n O 
DP [C]D [C]P B-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
, [C], O 
although [C]a [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
it [C]i [C]t O 
was [C]w [C]a [C]s O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
in [C]i [C]n O 
mature [C]m [C]a [C]t [C]u [C]r [C]e B-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Taken [C]T [C]a [C]k [C]e [C]n O 
together [C]t [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
the [C]t [C]h [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
lack [C]l [C]a [C]c [C]k O 
of [C]o [C]f O 
PKC [C]P [C]K [C]C B-protein 
epsilon [C]e [C]p [C]s [C]i [C]l [C]o [C]n E-protein 
in [C]i [C]n O 
DP [C]D [C]P B-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
could [C]c [C]o [C]u [C]l [C]d O 
lead [C]l [C]e [C]a [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
after [C]a [C]f [C]t [C]e [C]r O 
antigenic [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]i [C]c O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
contributing [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]i [C]n [C]g O 
to [C]t [C]o O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
selection [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

Cell [C]C [C]e [C]l [C]l O 
Death [C]D [C]e [C]a [C]t [C]h O 
and [C]a [C]n [C]d O 
Differentiation [C]D [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
( [C]( O 
2000 [C]2 [C]0 [C]0 [C]0 O 
) [C]) O 
7 [C]7 O 
, [C], O 
1253 [C]1 [C]2 [C]5 [C]3 O 
- [C]- O 
1262 [C]1 [C]2 [C]6 [C]2 O 
. [C]. O 

CD2 [C]C [C]D [C]2 O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
leads [C]l [C]e [C]a [C]d [C]s O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
delayed [C]d [C]e [C]l [C]a [C]y [C]e [C]d O 
and [C]a [C]n [C]d O 
prolonged [C]p [C]r [C]o [C]l [C]o [C]n [C]g [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
STAT1 [C]S [C]T [C]A [C]T [C]1 S-protein 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
NK [C]N [C]K B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

OBJECTIVE [C]O [C]B [C]J [C]E [C]C [C]T [C]I [C]V [C]E O 
: [C]: O 
T [C]T B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
can [C]c [C]a [C]n O 
be [C]b [C]e O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
soluble [C]s [C]o [C]l [C]u [C]b [C]l [C]e O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
or [C]o [C]r O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
direct [C]d [C]i [C]r [C]e [C]c [C]t O 
cell-cell [C]c [C]e [C]l [C]l [C]- [C]c [C]e [C]l [C]l O 
interactions [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
are [C]a [C]r [C]e O 
known [C]k [C]n [C]o [C]w [C]n O 
to [C]t [C]o O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
STAT [C]S [C]T [C]A [C]T B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
, [C], O 
the [C]t [C]h [C]e O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
by [C]b [C]y O 
which [C]w [C]h [C]i [C]c [C]h O 
other [C]o [C]t [C]h [C]e [C]r O 
cell-surface [C]c [C]e [C]l [C]l [C]- [C]s [C]u [C]r [C]f [C]a [C]c [C]e B-protein 
molecules [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]s E-protein 
, [C], O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
CD2 [C]C [C]D [C]2 S-protein 
, [C], O 
transduce [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]e O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
is [C]i [C]s O 
unclear [C]u [C]n [C]c [C]l [C]e [C]a [C]r O 
. [C]. O 

The [C]T [C]h [C]e O 
goal [C]g [C]o [C]a [C]l O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
was [C]w [C]a [C]s O 
to [C]t [C]o O 
determine [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
CD2 [C]C [C]D [C]2 S-protein 
recapitulates [C]r [C]e [C]c [C]a [C]p [C]i [C]t [C]u [C]l [C]a [C]t [C]e [C]s O 
aspects [C]a [C]s [C]p [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
use [C]u [C]s [C]e O 
of [C]o [C]f O 
STAT [C]S [C]T [C]A [C]T B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

MATERIALS [C]M [C]A [C]T [C]E [C]R [C]I [C]A [C]L [C]S O 
AND [C]A [C]N [C]D O 
METHODS [C]M [C]E [C]T [C]H [C]O [C]D [C]S O 
: [C]: O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
anti-CD2 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]2 B-protein 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s E-protein 
or [C]o [C]r O 
cells [C]c [C]e [C]l [C]l [C]s O 
bearing [C]b [C]e [C]a [C]r [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
natural [C]n [C]a [C]t [C]u [C]r [C]a [C]l O 
CD2 [C]C [C]D [C]2 B-protein 
ligand [C]l [C]i [C]g [C]a [C]n [C]d I-protein 
CD58 [C]C [C]D [C]5 [C]8 E-protein 
, [C], O 
after [C]a [C]f [C]t [C]e [C]r O 
which [C]w [C]h [C]i [C]c [C]h O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
STAT [C]S [C]T [C]A [C]T B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
was [C]w [C]a [C]s O 
assessed [C]a [C]s [C]s [C]e [C]s [C]s [C]e [C]d O 
. [C]. O 

RESULTS [C]R [C]E [C]S [C]U [C]L [C]T [C]S O 
: [C]: O 
Stimulation [C]S [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CD2 [C]C [C]D [C]2 S-protein 
on [C]o [C]n O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y B-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
leads [C]l [C]e [C]a [C]d [C]s O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
translocation [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
STAT1 [C]S [C]T [C]A [C]T [C]1 S-protein 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
to [C]t [C]o O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
, [C], O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
STAT1 [C]S [C]T [C]A [C]T [C]1 S-protein 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
CD2 [C]C [C]D [C]2 O 
ligation [C]l [C]i [C]g [C]a [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
delayed [C]d [C]e [C]l [C]a [C]y [C]e [C]d O 
and [C]a [C]n [C]d O 
does [C]d [C]o [C]e [C]s O 
not [C]n [C]o [C]t O 
involve [C]i [C]n [C]v [C]o [C]l [C]v [C]e O 
Jak [C]J [C]a [C]k B-protein 
kinases [C]k [C]i [C]n [C]a [C]s [C]e [C]s E-protein 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
while [C]w [C]h [C]i [C]l [C]e O 
STAT [C]S [C]T [C]A [C]T O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
is [C]i [C]s O 
generally [C]g [C]e [C]n [C]e [C]r [C]a [C]l [C]l [C]y O 
transient [C]t [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t O 
, [C], O 
STAT1 [C]S [C]T [C]A [C]T [C]1 O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
CD2 [C]C [C]D [C]2 O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
persists [C]p [C]e [C]r [C]s [C]i [C]s [C]t [C]s O 
for [C]f [C]o [C]r O 
a [C]a O 
period [C]p [C]e [C]r [C]i [C]o [C]d O 
of [C]o [C]f O 
days [C]d [C]a [C]y [C]s O 
. [C]. O 

Transcription [C]T [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
key [C]k [C]e [C]y O 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
genes [C]g [C]e [C]n [C]e [C]s O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
IRF1 [C]I [C]R [C]F [C]1 S-DNA 
and [C]a [C]n [C]d O 
c-fos [C]c [C]- [C]f [C]o [C]s S-DNA 
proceeds [C]p [C]r [C]o [C]c [C]e [C]e [C]d [C]s O 
with [C]w [C]i [C]t [C]h O 
delayed [C]d [C]e [C]l [C]a [C]y [C]e [C]d O 
kinetics [C]k [C]i [C]n [C]e [C]t [C]i [C]c [C]s O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
CD2 [C]C [C]D [C]2 O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
this [C]t [C]h [C]i [C]s O 
unique [C]u [C]n [C]i [C]q [C]u [C]e O 
pattern [C]p [C]a [C]t [C]t [C]e [C]r [C]n O 
of [C]o [C]f O 
STAT [C]S [C]T [C]A [C]T O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
may [C]m [C]a [C]y O 
lead [C]l [C]e [C]a [C]d O 
to [C]t [C]o O 
a [C]a O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
CD2 [C]C [C]D [C]2 O 
ligation [C]l [C]i [C]g [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
appears [C]a [C]p [C]p [C]e [C]a [C]r [C]s O 
to [C]t [C]o O 
be [C]b [C]e O 
restricted [C]r [C]e [C]s [C]t [C]r [C]i [C]c [C]t [C]e [C]d O 
to [C]t [C]o O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
as [C]a [C]s O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CD2 [C]C [C]D [C]2 S-protein 
on [C]o [C]n O 
NK [C]N [C]K B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
does [C]d [C]o [C]e [C]s O 
not [C]n [C]o [C]t O 
lead [C]l [C]e [C]a [C]d O 
to [C]t [C]o O 
STAT1 [C]S [C]T [C]A [C]T [C]1 O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

CONCLUSION [C]C [C]O [C]N [C]C [C]L [C]U [C]S [C]I [C]O [C]N O 
: [C]: O 
Stimulation [C]S [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
cell-surface [C]c [C]e [C]l [C]l [C]- [C]s [C]u [C]r [C]f [C]a [C]c [C]e B-protein 
molecules [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]s E-protein 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
CD2 [C]C [C]D [C]2 S-protein 
involves [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]s O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
STAT [C]S [C]T [C]A [C]T B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
, [C], O 
thus [C]t [C]h [C]u [C]s O 
recapitulating [C]r [C]e [C]c [C]a [C]p [C]i [C]t [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s O 
of [C]o [C]f O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
. [C]. O 

NFATc1 [C]N [C]F [C]A [C]T [C]c [C]1 S-protein 
and [C]a [C]n [C]d O 
NFATc2 [C]N [C]F [C]A [C]T [C]c [C]2 S-protein 
together [C]t [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
both [C]b [C]o [C]t [C]h O 
T [C]T O 
and [C]a [C]n [C]d O 
B [C]B O 
cell [C]c [C]e [C]l [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

NFAT [C]N [C]F [C]A [C]T B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
play [C]p [C]l [C]a [C]y O 
critical [C]c [C]r [C]i [C]t [C]i [C]c [C]a [C]l O 
roles [C]r [C]o [C]l [C]e [C]s O 
in [C]i [C]n O 
gene [C]g [C]e [C]n [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
. [C]. O 

To [C]T [C]o O 
investigate [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
the [C]t [C]h [C]e O 
two [C]t [C]w [C]o O 
most [C]m [C]o [C]s [C]t O 
prominent [C]p [C]r [C]o [C]m [C]i [C]n [C]e [C]n [C]t O 
NFAT [C]N [C]F [C]A [C]T B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y I-protein 
members [C]m [C]e [C]m [C]b [C]e [C]r [C]s E-protein 
, [C], O 
NFATc1 [C]N [C]F [C]A [C]T [C]c [C]1 S-protein 
and [C]a [C]n [C]d O 
NFATc2 [C]N [C]F [C]A [C]T [C]c [C]2 S-protein 
, [C], O 
we [C]w [C]e O 
generated [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]e [C]d O 
mice [C]m [C]i [C]c [C]e O 
bearing [C]b [C]e [C]a [C]r [C]i [C]n [C]g O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d O 
systems [C]s [C]y [C]s [C]t [C]e [C]m [C]s O 
devoid [C]d [C]e [C]v [C]o [C]i [C]d O 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
. [C]. O 

Doubly [C]D [C]o [C]u [C]b [C]l [C]y O 
deficient [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
displayed [C]d [C]i [C]s [C]p [C]l [C]a [C]y [C]e [C]d O 
cell [C]c [C]e [C]l [C]l O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
markers [C]m [C]a [C]r [C]k [C]e [C]r [C]s O 
of [C]o [C]f O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
yet [C]y [C]e [C]t O 
were [C]w [C]e [C]r [C]e O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
deficient [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
multiple [C]m [C]u [C]l [C]t [C]i [C]p [C]l [C]e O 
effector [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r O 
functions [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]s O 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
Th [C]T [C]h B-protein 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e E-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
, [C], O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e B-protein 
effector [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r I-protein 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e E-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
cytolytic [C]c [C]y [C]t [C]o [C]l [C]y [C]t [C]i [C]c O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

Nevertheless [C]N [C]e [C]v [C]e [C]r [C]t [C]h [C]e [C]l [C]e [C]s [C]s O 
, [C], O 
doubly [C]d [C]o [C]u [C]b [C]l [C]y B-cell_type 
deficient [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t I-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
hyperactivated [C]h [C]y [C]p [C]e [C]r [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
, [C], O 
as [C]a [C]s O 
evidenced [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e [C]d O 
by [C]b [C]y O 
extremely [C]e [C]x [C]t [C]r [C]e [C]m [C]e [C]l [C]y O 
elevated [C]e [C]l [C]e [C]v [C]a [C]t [C]e [C]d O 
serum [C]s [C]e [C]r [C]u [C]m O 
IgG1 [C]I [C]g [C]G [C]1 S-protein 
and [C]a [C]n [C]d O 
IgE [C]I [C]g [C]E S-protein 
, [C], O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
plasma [C]p [C]l [C]a [C]s [C]m [C]a B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
expansion [C]e [C]x [C]p [C]a [C]n [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
infiltration [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
end [C]e [C]n [C]d O 
organs [C]o [C]r [C]g [C]a [C]n [C]s O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
NFATc1 [C]N [C]F [C]A [C]T [C]c [C]1 S-protein 
and [C]a [C]n [C]d O 
NFATc2 [C]N [C]F [C]A [C]T [C]c [C]2 S-protein 
are [C]a [C]r [C]e O 
dispensable [C]d [C]i [C]s [C]p [C]e [C]n [C]s [C]a [C]b [C]l [C]e O 
for [C]f [C]o [C]r O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
reactivity [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
but [C]b [C]u [C]t O 
are [C]a [C]r [C]e O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
effector [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
while [C]w [C]h [C]i [C]l [C]e O 
in [C]i [C]n O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
NFATs [C]N [C]F [C]A [C]T [C]s S-protein 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
both [C]b [C]o [C]t [C]h O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
homeostasis [C]h [C]o [C]m [C]e [C]o [C]s [C]t [C]a [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Epstein-barr [C]E [C]p [C]s [C]t [C]e [C]i [C]n [C]- [C]b [C]a [C]r [C]r O 
virus [C]v [C]i [C]r [C]u [C]s O 
immediate-early [C]i [C]m [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]- [C]e [C]a [C]r [C]l [C]y B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
BZLF1 [C]B [C]Z [C]L [C]F [C]1 E-protein 
is [C]i [C]s O 
SUMO-1 [C]S [C]U [C]M [C]O [C]- [C]1 O 
modified [C]m [C]o [C]d [C]i [C]f [C]i [C]e [C]d O 
and [C]a [C]n [C]d O 
disrupts [C]d [C]i [C]s [C]r [C]u [C]p [C]t [C]s O 
promyelocytic [C]p [C]r [C]o [C]m [C]y [C]e [C]l [C]o [C]c [C]y [C]t [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
bodies [C]b [C]o [C]d [C]i [C]e [C]s O 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
immediate-early [C]i [C]m [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]- [C]e [C]a [C]r [C]l [C]y B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
herpes [C]h [C]e [C]r [C]p [C]e [C]s O 
simplex [C]s [C]i [C]m [C]p [C]l [C]e [C]x O 
virus [C]v [C]i [C]r [C]u [C]s O 
( [C]( O 
HSV [C]H [C]S [C]V O 
) [C]) O 
and [C]a [C]n [C]d O 
cytomegalovirus [C]c [C]y [C]t [C]o [C]m [C]e [C]g [C]a [C]l [C]o [C]v [C]i [C]r [C]u [C]s O 
( [C]( O 
CMV [C]C [C]M [C]V O 
) [C]) O 
are [C]a [C]r [C]e O 
known [C]k [C]n [C]o [C]w [C]n O 
to [C]t [C]o O 
modify [C]m [C]o [C]d [C]i [C]f [C]y O 
promyelocytic [C]p [C]r [C]o [C]m [C]y [C]e [C]l [C]o [C]c [C]y [C]t [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
( [C]( O 
PML [C]P [C]M [C]L O 
) [C]) O 
( [C]( O 
ND10 [C]N [C]D [C]1 [C]0 O 
) [C]) O 
bodies [C]b [C]o [C]d [C]i [C]e [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
nucleus [C]n [C]u [C]c [C]l [C]e [C]u [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
host [C]h [C]o [C]s [C]t O 
cell [C]c [C]e [C]l [C]l O 
, [C], O 
it [C]i [C]t O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
unclear [C]u [C]n [C]c [C]l [C]e [C]a [C]r O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
lytic [C]l [C]y [C]t [C]i [C]c O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
gamma [C]g [C]a [C]m [C]m [C]a O 
herpesviruses [C]h [C]e [C]r [C]p [C]e [C]s [C]v [C]i [C]r [C]u [C]s [C]e [C]s O 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
a [C]a O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
. [C]. O 

The [C]T [C]h [C]e O 
PML [C]P [C]M [C]L B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
is [C]i [C]s O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
interferon [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n S-protein 
, [C], O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
major [C]m [C]a [C]j [C]o [C]r B-protein 
histocompatibility [C]h [C]i [C]s [C]t [C]o [C]c [C]o [C]m [C]p [C]a [C]t [C]i [C]b [C]i [C]l [C]i [C]t [C]y I-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x I-protein 
class [C]c [C]l [C]a [C]s [C]s I-protein 
I [C]I E-protein 
presentation [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
necessary [C]n [C]e [C]c [C]e [C]s [C]s [C]a [C]r [C]y O 
for [C]f [C]o [C]r O 
certain [C]c [C]e [C]r [C]t [C]a [C]i [C]n O 
types [C]t [C]y [C]p [C]e [C]s O 
of [C]o [C]f O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
. [C]. O 

Therefore [C]T [C]h [C]e [C]r [C]e [C]f [C]o [C]r [C]e O 
, [C], O 
it [C]i [C]t O 
is [C]i [C]s O 
likely [C]l [C]i [C]k [C]e [C]l [C]y O 
that [C]t [C]h [C]a [C]t O 
PML [C]P [C]M [C]L O 
bodies [C]b [C]o [C]d [C]i [C]e [C]s O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
an [C]a [C]n O 
antiviral [C]a [C]n [C]t [C]i [C]v [C]i [C]r [C]a [C]l O 
capacity [C]c [C]a [C]p [C]a [C]c [C]i [C]t [C]y O 
. [C]. O 

SUMO-1 [C]S [C]U [C]M [C]O [C]- [C]1 O 
modification [C]m [C]o [C]d [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
PML [C]P [C]M [C]L S-protein 
is [C]i [C]s O 
known [C]k [C]n [C]o [C]w [C]n O 
to [C]t [C]o O 
be [C]b [C]e O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
PML [C]P [C]M [C]L O 
bodies [C]b [C]o [C]d [C]i [C]e [C]s O 
. [C]. O 

To [C]T [C]o O 
examine [C]e [C]x [C]a [C]m [C]i [C]n [C]e O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
Epstein-Barr [C]E [C]p [C]s [C]t [C]e [C]i [C]n [C]- [C]B [C]a [C]r [C]r O 
virus [C]v [C]i [C]r [C]u [C]s O 
( [C]( O 
EBV [C]E [C]B [C]V O 
) [C]) O 
lytic [C]l [C]y [C]t [C]i [C]c O 
replication [C]r [C]e [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
interferes [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
PML [C]P [C]M [C]L O 
bodies [C]b [C]o [C]d [C]i [C]e [C]s O 
, [C], O 
we [C]w [C]e O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
EBV [C]E [C]B [C]V B-DNA 
immediate-early [C]i [C]m [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]- [C]e [C]a [C]r [C]l [C]y I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
BZLF1 [C]B [C]Z [C]L [C]F [C]1 B-DNA 
( [C]( I-DNA 
Z [C]Z I-DNA 
) [C]) E-DNA 
and [C]a [C]n [C]d O 
BRLF1 [C]B [C]R [C]L [C]F [C]1 B-DNA 
( [C]( I-DNA 
R [C]R I-DNA 
) [C]) E-DNA 
in [C]i [C]n O 
EBV-positive [C]E [C]B [C]V [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
and [C]a [C]n [C]d O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
PML [C]P [C]M [C]L S-protein 
localization [C]l [C]o [C]c [C]a [C]l [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Both [C]B [C]o [C]t [C]h O 
Z [C]Z O 
and [C]a [C]n [C]d O 
R [C]R O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
PML [C]P [C]M [C]L S-protein 
dispersion [C]d [C]i [C]s [C]p [C]e [C]r [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
EBV-positive [C]E [C]B [C]V [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Z [C]Z O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
R [C]R O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
is [C]i [C]s O 
sufficient [C]s [C]u [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
to [C]t [C]o O 
disrupt [C]d [C]i [C]s [C]r [C]u [C]p [C]t O 
PML [C]P [C]M [C]L O 
bodies [C]b [C]o [C]d [C]i [C]e [C]s O 
in [C]i [C]n O 
EBV-negative [C]E [C]B [C]V [C]- [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
. [C]. O 

We [C]W [C]e O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
dispersion [C]d [C]i [C]s [C]p [C]e [C]r [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
PML [C]P [C]M [C]L O 
bodies [C]b [C]o [C]d [C]i [C]e [C]s O 
by [C]b [C]y O 
Z [C]Z S-DNA 
requires [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]s O 
a [C]a O 
portion [C]p [C]o [C]r [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l B-DNA 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n I-DNA 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-DNA 
of [C]o [C]f O 
Z [C]Z S-DNA 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
the [C]t [C]h [C]e O 
DNA-binding [C]D [C]N [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

As [C]A [C]s O 
was [C]w [C]a [C]s O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
reported [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]d O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
HSV-1 [C]H [C]S [C]V [C]- [C]1 B-protein 
ICP0 [C]I [C]C [C]P [C]0 I-protein 
and [C]a [C]n [C]d I-protein 
CMV [C]C [C]M [C]V I-protein 
IE1 [C]I [C]E [C]1 I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
, [C], O 
Z [C]Z S-DNA 
reduces [C]r [C]e [C]d [C]u [C]c [C]e [C]s O 
the [C]t [C]h [C]e O 
amount [C]a [C]m [C]o [C]u [C]n [C]t O 
of [C]o [C]f O 
SUMO-1-modified [C]S [C]U [C]M [C]O [C]- [C]1 [C]- [C]m [C]o [C]d [C]i [C]f [C]i [C]e [C]d B-protein 
PML [C]P [C]M [C]L E-protein 
. [C]. O 

We [C]W [C]e O 
also [C]a [C]l [C]s [C]o O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
Z [C]Z S-DNA 
itself [C]i [C]t [C]s [C]e [C]l [C]f O 
is [C]i [C]s O 
SUMO-1 [C]S [C]U [C]M [C]O [C]- [C]1 O 
modified [C]m [C]o [C]d [C]i [C]f [C]i [C]e [C]d O 
( [C]( O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
amino [C]a [C]m [C]i [C]n [C]o O 
acid [C]a [C]c [C]i [C]d O 
12 [C]1 [C]2 O 
) [C]) O 
and [C]a [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
Z [C]Z S-DNA 
competes [C]c [C]o [C]m [C]p [C]e [C]t [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
PML [C]P [C]M [C]L S-protein 
for [C]f [C]o [C]r O 
limiting [C]l [C]i [C]m [C]i [C]t [C]i [C]n [C]g O 
amounts [C]a [C]m [C]o [C]u [C]n [C]t [C]s O 
of [C]o [C]f O 
SUMO-1 [C]S [C]U [C]M [C]O [C]- [C]1 S-protein 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
disruption [C]d [C]i [C]s [C]r [C]u [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
PML [C]P [C]M [C]L O 
bodies [C]b [C]o [C]d [C]i [C]e [C]s O 
is [C]i [C]s O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
for [C]f [C]o [C]r O 
efficient [C]e [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
lytic [C]l [C]y [C]t [C]i [C]c O 
replication [C]r [C]e [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
EBV [C]E [C]B [C]V O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
Z [C]Z S-DNA 
may [C]m [C]a [C]y O 
potentially [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l [C]l [C]y O 
alter [C]a [C]l [C]t [C]e [C]r O 
the [C]t [C]h [C]e O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
variety [C]v [C]a [C]r [C]i [C]e [C]t [C]y O 
of [C]o [C]f O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s O 
by [C]b [C]y O 
inhibiting [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]n [C]g O 
SUMO-1 [C]S [C]U [C]M [C]O [C]- [C]1 O 
modification [C]m [C]o [C]d [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 

Suppression [C]S [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor-kappaB [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
and [C]a [C]n [C]d O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r B-protein 
kappaB [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
by [C]b [C]y O 
troglitazone [C]t [C]r [C]o [C]g [C]l [C]i [C]t [C]a [C]z [C]o [C]n [C]e O 
: [C]: O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
for [C]f [C]o [C]r O 
an [C]a [C]n O 
anti-inflammatory [C]a [C]n [C]t [C]i [C]- [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
and [C]a [C]n [C]d O 
a [C]a O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
antiatherosclerotic [C]a [C]n [C]t [C]i [C]a [C]t [C]h [C]e [C]r [C]o [C]s [C]c [C]l [C]e [C]r [C]o [C]t [C]i [C]c O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
obese [C]o [C]b [C]e [C]s [C]e O 
. [C]. O 

To [C]T [C]o O 
elucidate [C]e [C]l [C]u [C]c [C]i [C]d [C]a [C]t [C]e O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
troglitazone [C]t [C]r [C]o [C]g [C]l [C]i [C]t [C]a [C]z [C]o [C]n [C]e O 
exerts [C]e [C]x [C]e [C]r [C]t [C]s O 
an [C]a [C]n O 
antiinflammatory [C]a [C]n [C]t [C]i [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
in [C]i [C]n O 
humans [C]h [C]u [C]m [C]a [C]n [C]s O 
, [C], O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
, [C], O 
we [C]w [C]e O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
suppression [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
kappaB [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
( [C]( O 
NFkappaB [C]N [C]F [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
) [C]) O 
in [C]i [C]n O 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s I-cell_type 
( [C]( I-cell_type 
MNC [C]M [C]N [C]C I-cell_type 
) [C]) E-cell_type 
by [C]b [C]y O 
this [C]t [C]h [C]i [C]s O 
drug [C]d [C]r [C]u [C]g O 
. [C]. O 

We [C]W [C]e O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
intranuclear [C]i [C]n [C]t [C]r [C]a [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
NFkappaB [C]N [C]F [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
, [C], O 
total [C]t [C]o [C]t [C]a [C]l O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
NFkappaB [C]N [C]F [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
, [C], O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r B-protein 
kappaB [C]k [C]a [C]p [C]p [C]a [C]B I-protein 
( [C]( I-protein 
IkappaB [C]I [C]k [C]a [C]p [C]p [C]a [C]B I-protein 
) [C]) I-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
, [C], O 
reactive [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]e O 
oxygen [C]o [C]x [C]y [C]g [C]e [C]n O 
species [C]s [C]p [C]e [C]c [C]i [C]e [C]s O 
( [C]( O 
ROS [C]R [C]O [C]S O 
) [C]) O 
generation [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
p47 [C]p [C]4 [C]7 B-protein 
( [C]( I-protein 
phox [C]p [C]h [C]o [C]x I-protein 
) [C]) I-protein 
subunit [C]s [C]u [C]b [C]u [C]n [C]i [C]t E-protein 
( [C]( O 
a [C]a O 
key [C]k [C]e [C]y O 
component [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
of [C]o [C]f O 
nicotinamide [C]n [C]i [C]c [C]o [C]t [C]i [C]n [C]a [C]m [C]i [C]d [C]e B-protein 
adenine [C]a [C]d [C]e [C]n [C]i [C]n [C]e I-protein 
dinucleotide [C]d [C]i [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e I-protein 
phosphate [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]e I-protein 
oxidase [C]o [C]x [C]i [C]d [C]a [C]s [C]e E-protein 
) [C]) O 
in [C]i [C]n O 
MNC [C]M [C]N [C]C S-cell_type 
. [C]. O 

Plasma [C]P [C]l [C]a [C]s [C]m [C]a B-protein 
tumor [C]t [C]u [C]m [C]o [C]r I-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
( [C]( I-protein 
TNF [C]T [C]N [C]F I-protein 
) [C]) I-protein 
-alpha [C]- [C]a [C]l [C]p [C]h [C]a E-protein 
, [C], O 
soluble [C]s [C]o [C]l [C]u [C]b [C]l [C]e B-protein 
intercellular [C]i [C]n [C]t [C]e [C]r [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r I-protein 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n I-protein 
molecule-1 [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]- [C]1 E-protein 
( [C]( O 
sICAM-1 [C]s [C]I [C]C [C]A [C]M [C]- [C]1 S-protein 
) [C]) O 
, [C], O 
monocyte [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e B-protein 
chemoattractant [C]c [C]h [C]e [C]m [C]o [C]a [C]t [C]t [C]r [C]a [C]c [C]t [C]a [C]n [C]t I-protein 
protein-1 [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]1 I-protein 
( [C]( I-protein 
MCP-1 [C]M [C]C [C]P [C]- [C]1 I-protein 
) [C]) E-protein 
, [C], O 
plasminogen [C]p [C]l [C]a [C]s [C]m [C]i [C]n [C]o [C]g [C]e [C]n B-protein 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r I-protein 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r I-protein 
type [C]t [C]y [C]p [C]e I-protein 
1 [C]1 E-protein 
( [C]( O 
PAI-1 [C]P [C]A [C]I [C]- [C]1 S-protein 
) [C]) O 
, [C], O 
C-reactive [C]C [C]- [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]e B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
( [C]( I-protein 
CRP [C]C [C]R [C]P I-protein 
) [C]) E-protein 
, [C], O 
and [C]a [C]n [C]d O 
interleukin [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n B-protein 
( [C]( I-protein 
IL [C]I [C]L I-protein 
) [C]) I-protein 
-10 [C]- [C]1 [C]0 E-protein 
( [C]( O 
antiinflammatory [C]a [C]n [C]t [C]i [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y B-protein 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e E-protein 
) [C]) O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
were [C]w [C]e [C]r [C]e O 
also [C]a [C]l [C]s [C]o O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
as [C]a [C]s O 
mediators [C]m [C]e [C]d [C]i [C]a [C]t [C]o [C]r [C]s O 
of [C]o [C]f O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
that [C]t [C]h [C]a [C]t O 
are [C]a [C]r [C]e O 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
proinflammatory [C]p [C]r [C]o [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
NFkappaB [C]N [C]F [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
. [C]. O 

Seven [C]S [C]e [C]v [C]e [C]n O 
nondiabetic [C]n [C]o [C]n [C]d [C]i [C]a [C]b [C]e [C]t [C]i [C]c O 
obese [C]o [C]b [C]e [C]s [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
were [C]w [C]e [C]r [C]e O 
given [C]g [C]i [C]v [C]e [C]n O 
400 [C]4 [C]0 [C]0 O 
mg [C]m [C]g O 
troglitazone [C]t [C]r [C]o [C]g [C]l [C]i [C]t [C]a [C]z [C]o [C]n [C]e O 
daily [C]d [C]a [C]i [C]l [C]y O 
for [C]f [C]o [C]r O 
4 [C]4 O 
weeks [C]w [C]e [C]e [C]k [C]s O 
. [C]. O 

Blood [C]B [C]l [C]o [C]o [C]d O 
samples [C]s [C]a [C]m [C]p [C]l [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
collected [C]c [C]o [C]l [C]l [C]e [C]c [C]t [C]e [C]d O 
before [C]b [C]e [C]f [C]o [C]r [C]e O 
and [C]a [C]n [C]d O 
at [C]a [C]t O 
weekly [C]w [C]e [C]e [C]k [C]l [C]y O 
intervals [C]i [C]n [C]t [C]e [C]r [C]v [C]a [C]l [C]s O 
thereafter [C]t [C]h [C]e [C]r [C]e [C]a [C]f [C]t [C]e [C]r O 
. [C]. O 

MNC [C]M [C]N [C]C S-cell_type 
were [C]w [C]e [C]r [C]e O 
separated [C]s [C]e [C]p [C]a [C]r [C]a [C]t [C]e [C]d O 
; [C]; O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
intranuclear [C]i [C]n [C]t [C]r [C]a [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
NFkappaB [C]N [C]F [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
, [C], O 
total [C]t [C]o [C]t [C]a [C]l O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
NFkappaB [C]N [C]F [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
, [C], O 
IkappaBalpha [C]I [C]k [C]a [C]p [C]p [C]a [C]B [C]a [C]l [C]p [C]h [C]a S-protein 
, [C], O 
and [C]a [C]n [C]d O 
p47 [C]p [C]4 [C]7 B-protein 
( [C]( I-protein 
phox [C]p [C]h [C]o [C]x I-protein 
) [C]) I-protein 
subunit [C]s [C]u [C]b [C]u [C]n [C]i [C]t E-protein 
and [C]a [C]n [C]d O 
ROS [C]R [C]O [C]S O 
generation [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
were [C]w [C]e [C]r [C]e O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
. [C]. O 

Plasma [C]P [C]l [C]a [C]s [C]m [C]a O 
was [C]w [C]a [C]s O 
used [C]u [C]s [C]e [C]d O 
to [C]t [C]o O 
measure [C]m [C]e [C]a [C]s [C]u [C]r [C]e O 
insulin [C]i [C]n [C]s [C]u [C]l [C]i [C]n O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
, [C], O 
TNFalpha [C]T [C]N [C]F [C]a [C]l [C]p [C]h [C]a S-protein 
, [C], O 
sICAM [C]s [C]I [C]C [C]A [C]M S-protein 
, [C], O 
MCP-1 [C]M [C]C [C]P [C]- [C]1 S-protein 
, [C], O 
PAI-1 [C]P [C]A [C]I [C]- [C]1 S-protein 
, [C], O 
CRP [C]C [C]R [C]P S-protein 
, [C], O 
and [C]a [C]n [C]d O 
IL-10 [C]I [C]L [C]- [C]1 [C]0 S-protein 
. [C]. O 

Plasma [C]P [C]l [C]a [C]s [C]m [C]a O 
insulin [C]i [C]n [C]s [C]u [C]l [C]i [C]n O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
fell [C]f [C]e [C]l [C]l O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
at [C]a [C]t O 
week [C]w [C]e [C]e [C]k O 
1 [C]1 O 
, [C], O 
from [C]f [C]r [C]o [C]m O 
31.2 [C]3 [C]1 [C]. [C]2 O 
+/- [C]+ [C]/ [C]- O 
29.1 [C]2 [C]9 [C]. [C]1 O 
to [C]t [C]o O 
14.2 [C]1 [C]4 [C]. [C]2 O 
+/- [C]+ [C]/ [C]- O 
11.4 [C]1 [C]1 [C]. [C]4 O 
mU/L [C]m [C]U [C]/ [C]L O 
( [C]( O 
P [C]P O 
< [C]< O 
0.01 [C]0 [C]. [C]0 [C]1 O 
) [C]) O 
and [C]a [C]n [C]d O 
remained [C]r [C]e [C]m [C]a [C]i [C]n [C]e [C]d O 
low [C]l [C]o [C]w O 
throughout [C]t [C]h [C]r [C]o [C]u [C]g [C]h [C]o [C]u [C]t O 
4 [C]4 O 
weeks [C]w [C]e [C]e [C]k [C]s O 
. [C]. O 

Plasma [C]P [C]l [C]a [C]s [C]m [C]a O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
alter [C]a [C]l [C]t [C]e [C]r O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
. [C]. O 

There [C]T [C]h [C]e [C]r [C]e O 
was [C]w [C]a [C]s O 
a [C]a O 
fall [C]f [C]a [C]l [C]l O 
in [C]i [C]n O 
intranuclear [C]i [C]n [C]t [C]r [C]a [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
NFkappaB [C]N [C]F [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
, [C], O 
total [C]t [C]o [C]t [C]a [C]l O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
NFkappaB [C]N [C]F [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
, [C], O 
and [C]a [C]n [C]d O 
p47 [C]p [C]4 [C]7 B-protein 
( [C]( I-protein 
phox [C]p [C]h [C]o [C]x I-protein 
) [C]) I-protein 
subunit [C]s [C]u [C]b [C]u [C]n [C]i [C]t E-protein 
, [C], O 
with [C]w [C]i [C]t [C]h O 
an [C]a [C]n O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
IkappaBalpha [C]I [C]k [C]a [C]p [C]p [C]a [C]B [C]a [C]l [C]p [C]h [C]a S-protein 
at [C]a [C]t O 
week [C]w [C]e [C]e [C]k O 
2 [C]2 O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
persisted [C]p [C]e [C]r [C]s [C]i [C]s [C]t [C]e [C]d O 
until [C]u [C]n [C]t [C]i [C]l O 
week [C]w [C]e [C]e [C]k O 
4 [C]4 O 
. [C]. O 

There [C]T [C]h [C]e [C]r [C]e O 
was [C]w [C]a [C]s O 
a [C]a O 
parallel [C]p [C]a [C]r [C]a [C]l [C]l [C]e [C]l O 
fall [C]f [C]a [C]l [C]l O 
in [C]i [C]n O 
ROS [C]R [C]O [C]S O 
generation [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
MNC [C]M [C]N [C]C S-cell_type 
at [C]a [C]t O 
week [C]w [C]e [C]e [C]k O 
1 [C]1 O 
; [C]; O 
this [C]t [C]h [C]i [C]s O 
progressed [C]p [C]r [C]o [C]g [C]r [C]e [C]s [C]s [C]e [C]d O 
and [C]a [C]n [C]d O 
persisted [C]p [C]e [C]r [C]s [C]i [C]s [C]t [C]e [C]d O 
until [C]u [C]n [C]t [C]i [C]l O 
week [C]w [C]e [C]e [C]k O 
4 [C]4 O 
( [C]( O 
P [C]P O 
< [C]< O 
0.001 [C]0 [C]. [C]0 [C]0 [C]1 O 
) [C]) O 
. [C]. O 

Plasma [C]P [C]l [C]a [C]s [C]m [C]a O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
, [C], O 
sICAM-1 [C]s [C]I [C]C [C]A [C]M [C]- [C]1 S-protein 
, [C], O 
MCP-1 [C]M [C]C [C]P [C]- [C]1 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
PAI-1 [C]P [C]A [C]I [C]- [C]1 S-protein 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
fell [C]f [C]e [C]l [C]l O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
at [C]a [C]t O 
week [C]w [C]e [C]e [C]k O 
4 [C]4 O 
. [C]. O 

Plasma [C]P [C]l [C]a [C]s [C]m [C]a O 
IL-10 [C]I [C]L [C]- [C]1 [C]0 S-protein 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
plasma [C]p [C]l [C]a [C]s [C]m [C]a B-protein 
CRP [C]C [C]R [C]P E-protein 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
. [C]. O 

We [C]W [C]e O 
conclude [C]c [C]o [C]n [C]c [C]l [C]u [C]d [C]e O 
that [C]t [C]h [C]a [C]t O 
troglitazone [C]t [C]r [C]o [C]g [C]l [C]i [C]t [C]a [C]z [C]o [C]n [C]e O 
has [C]h [C]a [C]s O 
an [C]a [C]n O 
antiinflammatory [C]a [C]n [C]t [C]i [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
action [C]a [C]c [C]t [C]i [C]o [C]n O 
that [C]t [C]h [C]a [C]t O 
may [C]m [C]a [C]y O 
contribute [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e O 
to [C]t [C]o O 
its [C]i [C]t [C]s O 
putative [C]p [C]u [C]t [C]a [C]t [C]i [C]v [C]e O 
antiatherosclerotic [C]a [C]n [C]t [C]i [C]a [C]t [C]h [C]e [C]r [C]o [C]s [C]c [C]l [C]e [C]r [C]o [C]t [C]i [C]c O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
. [C]. O 

Tyrosine [C]T [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
phosphorylation-dependent [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
. [C]. O 

Requirement [C]R [C]e [C]q [C]u [C]i [C]r [C]e [C]m [C]e [C]n [C]t O 
for [C]f [C]o [C]r O 
p56 [C]p [C]5 [C]6 B-protein 
LCK [C]L [C]C [C]K I-protein 
and [C]a [C]n [C]d I-protein 
ZAP-70 [C]Z [C]A [C]P [C]- [C]7 [C]0 I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e I-protein 
kinases [C]k [C]i [C]n [C]a [C]s [C]e [C]s E-protein 
. [C]. O 

Phosphorylation [C]P [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
N-terminal [C]N [C]- [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l B-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
of [C]o [C]f O 
I [C]I B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B I-protein 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y I-protein 
subunits [C]s [C]u [C]b [C]u [C]n [C]i [C]t [C]s E-protein 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
serine [C]s [C]e [C]r [C]i [C]n [C]e O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
ubiquitination [C]u [C]b [C]i [C]q [C]u [C]i [C]t [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
subsequent [C]s [C]u [C]b [C]s [C]e [C]q [C]u [C]e [C]n [C]t O 
proteasome-mediated [C]p [C]r [C]o [C]t [C]e [C]a [C]s [C]o [C]m [C]e [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
I [C]I B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B-alpha [C]B [C]- [C]a [C]l [C]p [C]h [C]a E-protein 
, [C], O 
little [C]l [C]i [C]t [C]t [C]l [C]e O 
is [C]i [C]s O 
known [C]k [C]n [C]o [C]w [C]n O 
about [C]a [C]b [C]o [C]u [C]t O 
the [C]t [C]h [C]e O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
that [C]t [C]h [C]a [C]t O 
lead [C]l [C]e [C]a [C]d O 
to [C]t [C]o O 
release [C]r [C]e [C]l [C]e [C]a [C]s [C]e O 
of [C]o [C]f O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
as [C]a [C]s O 
a [C]a O 
consequence [C]c [C]o [C]n [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
I [C]I B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B-alpha [C]B [C]- [C]a [C]l [C]p [C]h [C]a E-protein 
[ [C][ O 
Imbert [C]I [C]m [C]b [C]e [C]r [C]t O 
, [C], O 
V. [C]V [C]. O 
, [C], O 
Rupec [C]R [C]u [C]p [C]e [C]c O 
, [C], O 
R.A. [C]R [C]. [C]A [C]. O 
, [C], O 
Livolsi [C]L [C]i [C]v [C]o [C]l [C]s [C]i O 
, [C], O 
A. [C]A [C]. O 
, [C], O 
Pahl [C]P [C]a [C]h [C]l O 
, [C], O 
H.L. [C]H [C]. [C]L [C]. O 
, [C], O 
Traenckner [C]T [C]r [C]a [C]e [C]n [C]c [C]k [C]n [C]e [C]r O 
, [C], O 
B.M. [C]B [C]. [C]M [C]. O 
, [C], O 
Mueller-Dieckmann [C]M [C]u [C]e [C]l [C]l [C]e [C]r [C]- [C]D [C]i [C]e [C]c [C]k [C]m [C]a [C]n [C]n O 
, [C], O 
C. [C]C [C]. O 
, [C], O 
Farahifar [C]F [C]a [C]r [C]a [C]h [C]i [C]f [C]a [C]r O 
, [C], O 
D. [C]D [C]. O 
, [C], O 
Rossi [C]R [C]o [C]s [C]s [C]i O 
, [C], O 
B. [C]B [C]. O 
, [C], O 
Auberger [C]A [C]u [C]b [C]e [C]r [C]g [C]e [C]r O 
, [C], O 
P. [C]P [C]. O 
, [C], O 
Baeuerle [C]B [C]a [C]e [C]u [C]e [C]r [C]l [C]e O 
, [C], O 
P. [C]P [C]. O 
& [C]& O 
Peyron [C]P [C]e [C]y [C]r [C]o [C]n O 
, [C], O 
J.F. [C]J [C]. [C]F [C]. O 
( [C]( O 
1996 [C]1 [C]9 [C]9 [C]6 O 
) [C]) O 
Cell [C]C [C]e [C]l [C]l O 
86 [C]8 [C]6 O 
, [C], O 
787 [C]7 [C]8 [C]7 O 
-- [C]- [C]- O 
798 [C]7 [C]9 [C]8 O 
] [C]] O 
. [C]. O 

The [C]T [C]h [C]e O 
involvement [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e B-protein 
kinases [C]k [C]i [C]n [C]a [C]s [C]e [C]s E-protein 
p56 [C]p [C]5 [C]6 B-protein 
( [C]( I-protein 
lck [C]l [C]c [C]k I-protein 
) [C]) E-protein 
and [C]a [C]n [C]d O 
ZAP-70 [C]Z [C]A [C]P [C]- [C]7 [C]0 S-protein 
in [C]i [C]n O 
this [C]t [C]h [C]i [C]s O 
reaction [C]r [C]e [C]a [C]c [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
here [C]h [C]e [C]r [C]e O 
using [C]u [C]s [C]i [C]n [C]g O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
pharmacological [C]p [C]h [C]a [C]r [C]m [C]a [C]c [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
and [C]a [C]n [C]d O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_line 
mutants [C]m [C]u [C]t [C]a [C]n [C]t [C]s E-cell_line 
unable [C]u [C]n [C]a [C]b [C]l [C]e O 
to [C]t [C]o O 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
these [C]t [C]h [C]e [C]s [C]e O 
kinases [C]k [C]i [C]n [C]a [C]s [C]e [C]s S-protein 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
prevented [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]e [C]d O 
both [C]b [C]o [C]t [C]h O 
pervanadate-induced [C]p [C]e [C]r [C]v [C]a [C]n [C]a [C]d [C]a [C]t [C]e [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
I [C]I B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B-alpha [C]B [C]- [C]a [C]l [C]p [C]h [C]a E-protein 
on [C]o [C]n O 
Tyr42 [C]T [C]y [C]r [C]4 [C]2 O 
and [C]a [C]n [C]d O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
we [C]w [C]e O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
, [C], O 
in [C]i [C]n O 
p56 [C]p [C]5 [C]6 B-cell_line 
( [C]( I-cell_line 
lck [C]l [C]c [C]k I-cell_line 
) [C]) I-cell_line 
-deficient [C]- [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t I-cell_line 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t I-cell_line 
mutants [C]m [C]u [C]t [C]a [C]n [C]t [C]s E-cell_line 
, [C], O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
could [C]c [C]o [C]u [C]l [C]d O 
still [C]s [C]t [C]i [C]l [C]l O 
associate [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e O 
with [C]w [C]i [C]t [C]h O 
I [C]I B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B-alpha [C]B [C]- [C]a [C]l [C]p [C]h [C]a E-protein 
despite [C]d [C]e [C]s [C]p [C]i [C]t [C]e O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
on [C]o [C]n O 
Tyr42 [C]T [C]y [C]r [C]4 [C]2 O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
the [C]t [C]h [C]e O 
SH2 [C]S [C]H [C]2 B-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
of [C]o [C]f O 
p56 [C]p [C]5 [C]6 B-protein 
( [C]( I-protein 
lck [C]l [C]c [C]k I-protein 
) [C]) E-protein 
appeared [C]a [C]p [C]p [C]e [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
pervanadate-induced [C]p [C]e [C]r [C]v [C]a [C]n [C]a [C]d [C]a [C]t [C]e [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
for [C]f [C]o [C]r O 
Tyr42 [C]T [C]y [C]r [C]4 [C]2 O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
p56 [C]p [C]5 [C]6 B-protein 
( [C]( I-protein 
lck [C]l [C]c [C]k I-protein 
) [C]) E-protein 
and [C]a [C]n [C]d O 
ZAP-70 [C]Z [C]A [C]P [C]- [C]7 [C]0 S-protein 
are [C]a [C]r [C]e O 
key [C]k [C]e [C]y O 
components [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
that [C]t [C]h [C]a [C]t O 
leads [C]l [C]e [C]a [C]d [C]s O 
to [C]t [C]o O 
phosphotyrosine-dependent [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
confirm [C]c [C]o [C]n [C]f [C]i [C]r [C]m O 
that [C]t [C]h [C]a [C]t O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e B-protein 
kinases [C]k [C]i [C]n [C]a [C]s [C]e [C]s E-protein 
must [C]m [C]u [C]s [C]t O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
at [C]a [C]t O 
least [C]l [C]e [C]a [C]s [C]t O 
two [C]t [C]w [C]o O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
steps [C]s [C]t [C]e [C]p [C]s O 
to [C]t [C]o O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
. [C]. O 

Finally [C]F [C]i [C]n [C]a [C]l [C]l [C]y O 
, [C], O 
we [C]w [C]e O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
H [C]H O 
( [C]( O 
2 [C]2 O 
) [C]) O 
O [C]O O 
( [C]( O 
2 [C]2 O 
) [C]) O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
stimulates [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]s O 
p56 [C]p [C]5 [C]6 B-protein 
( [C]( I-protein 
lck [C]l [C]c [C]k I-protein 
) [C]) E-protein 
and [C]a [C]n [C]d O 
ZAP-70 [C]Z [C]A [C]P [C]- [C]7 [C]0 S-protein 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
is [C]i [C]s O 
an [C]a [C]n O 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
I [C]I B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B-alpha [C]B [C]- [C]a [C]l [C]p [C]h [C]a E-protein 
. [C]. O 

Specific [C]S [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
missense [C]m [C]i [C]s [C]s [C]e [C]n [C]s [C]e O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
NEMO [C]N [C]E [C]M [C]O S-DNA 
result [C]r [C]e [C]s [C]u [C]l [C]t O 
in [C]i [C]n O 
hyper-IgM [C]h [C]y [C]p [C]e [C]r [C]- [C]I [C]g [C]M O 
syndrome [C]s [C]y [C]n [C]d [C]r [C]o [C]m [C]e O 
with [C]w [C]i [C]t [C]h O 
hypohydrotic [C]h [C]y [C]p [C]o [C]h [C]y [C]d [C]r [C]o [C]t [C]i [C]c O 
ectodermal [C]e [C]c [C]t [C]o [C]d [C]e [C]r [C]m [C]a [C]l O 
dysplasia [C]d [C]y [C]s [C]p [C]l [C]a [C]s [C]i [C]a O 
. [C]. O 

The [C]T [C]h [C]e O 
gene [C]g [C]e [C]n [C]e O 
that [C]t [C]h [C]a [C]t O 
encodes [C]e [C]n [C]c [C]o [C]d [C]e [C]s O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-DNA 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-DNA 
kappaB [C]k [C]a [C]p [C]p [C]a [C]B I-DNA 
( [C]( I-DNA 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B I-DNA 
) [C]) I-DNA 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l I-DNA 
modulator [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]o [C]r E-DNA 
( [C]( O 
or [C]o [C]r O 
NEMO [C]N [C]E [C]M [C]O S-DNA 
, [C], O 
also [C]a [C]l [C]s [C]o O 
known [C]k [C]n [C]o [C]w [C]n O 
as [C]a [C]s O 
IKKgamma [C]I [C]K [C]K [C]g [C]a [C]m [C]m [C]a S-DNA 
) [C]) O 
is [C]i [C]s O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
. [C]. O 

We [C]W [C]e O 
describe [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
putative [C]p [C]u [C]t [C]a [C]t [C]i [C]v [C]e B-protein 
zinc-finger [C]z [C]i [C]n [C]c [C]- [C]f [C]i [C]n [C]g [C]e [C]r I-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
of [C]o [C]f O 
NEMO [C]N [C]E [C]M [C]O S-protein 
that [C]t [C]h [C]a [C]t O 
result [C]r [C]e [C]s [C]u [C]l [C]t O 
in [C]i [C]n O 
an [C]a [C]n O 
X-linked [C]X [C]- [C]l [C]i [C]n [C]k [C]e [C]d O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y O 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
characterized [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]d O 
by [C]b [C]y O 
hyper-IgM [C]h [C]y [C]p [C]e [C]r [C]- [C]I [C]g [C]M O 
syndrome [C]s [C]y [C]n [C]d [C]r [C]o [C]m [C]e O 
and [C]a [C]n [C]d O 
hypohydrotic [C]h [C]y [C]p [C]o [C]h [C]y [C]d [C]r [C]o [C]t [C]i [C]c O 
ectodermal [C]e [C]c [C]t [C]o [C]d [C]e [C]r [C]m [C]a [C]l O 
dysplasia [C]d [C]y [C]s [C]p [C]l [C]a [C]s [C]i [C]a O 
( [C]( O 
XHM-ED [C]X [C]H [C]M [C]- [C]E [C]D O 
) [C]) O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
prevent [C]p [C]r [C]e [C]v [C]e [C]n [C]t O 
CD40 [C]C [C]D [C]4 [C]0 B-protein 
ligand [C]l [C]i [C]g [C]a [C]n [C]d E-protein 
( [C]( O 
CD40L [C]C [C]D [C]4 [C]0 [C]L S-protein 
) [C]) O 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B B-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
( [C]( O 
IkappaB-alpha [C]I [C]k [C]a [C]p [C]p [C]a [C]B [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
account [C]a [C]c [C]c [C]o [C]u [C]n [C]t O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
observations [C]o [C]b [C]s [C]e [C]r [C]v [C]a [C]t [C]i [C]o [C]n [C]s O 
: [C]: O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
XHM-ED [C]X [C]H [C]M [C]- [C]E [C]D O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
are [C]a [C]r [C]e O 
unable [C]u [C]n [C]a [C]b [C]l [C]e O 
to [C]t [C]o O 
undergo [C]u [C]n [C]d [C]e [C]r [C]g [C]o O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n O 
class-switch [C]c [C]l [C]a [C]s [C]s [C]- [C]s [C]w [C]i [C]t [C]c [C]h O 
recombination [C]r [C]e [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
antigen-presenting [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]- [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]i [C]n [C]g B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
APCs [C]A [C]P [C]C [C]s S-cell_type 
) [C]) O 
are [C]a [C]r [C]e O 
unable [C]u [C]n [C]a [C]b [C]l [C]e O 
to [C]t [C]o O 
synthesize [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]z [C]e O 
the [C]t [C]h [C]e O 
NF-kappaB-regulated [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d B-protein 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s E-protein 
interleukin [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n B-protein 
12 [C]1 [C]2 E-protein 
( [C]( O 
IL-12 [C]I [C]L [C]- [C]1 [C]2 S-protein 
) [C]) O 
or [C]o [C]r O 
tumor [C]t [C]u [C]m [C]o [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
( [C]( O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
) [C]) O 
when [C]w [C]h [C]e [C]n O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
CD40L [C]C [C]D [C]4 [C]0 [C]L S-protein 
. [C]. O 

Nevertheless [C]N [C]e [C]v [C]e [C]r [C]t [C]h [C]e [C]l [C]e [C]s [C]s O 
, [C], O 
innate [C]i [C]n [C]n [C]a [C]t [C]e O 
immunity [C]i [C]m [C]m [C]u [C]n [C]i [C]t [C]y O 
is [C]i [C]s O 
preserved [C]p [C]r [C]e [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
XHM-ED [C]X [C]H [C]M [C]- [C]E [C]D O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
because [C]b [C]e [C]c [C]a [C]u [C]s [C]e O 
APCs [C]A [C]P [C]C [C]s S-cell_type 
retain [C]r [C]e [C]t [C]a [C]i [C]n O 
the [C]t [C]h [C]e O 
capacity [C]c [C]a [C]p [C]a [C]c [C]i [C]t [C]y O 
to [C]t [C]o O 
respond [C]r [C]e [C]s [C]p [C]o [C]n [C]d O 
to [C]t [C]o O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
lipopolysaccharide [C]l [C]i [C]p [C]o [C]p [C]o [C]l [C]y [C]s [C]a [C]c [C]c [C]h [C]a [C]r [C]i [C]d [C]e O 
or [C]o [C]r O 
Staphylococcus [C]S [C]t [C]a [C]p [C]h [C]y [C]l [C]o [C]c [C]o [C]c [C]c [C]u [C]s B-protein 
aureus [C]a [C]u [C]r [C]e [C]u [C]s I-protein 
Cowan [C]C [C]o [C]w [C]a [C]n I-protein 
's [C]' [C]s I-protein 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n E-protein 
( [C]( O 
SAC [C]S [C]A [C]C S-protein 
) [C]) O 
. [C]. O 

Overall [C]O [C]v [C]e [C]r [C]a [C]l [C]l O 
, [C], O 
the [C]t [C]h [C]e O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
XHM-ED [C]X [C]H [C]M [C]- [C]E [C]D O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
shows [C]s [C]h [C]o [C]w [C]s O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
putative [C]p [C]u [C]t [C]a [C]t [C]i [C]v [C]e B-protein 
zinc-finger [C]z [C]i [C]n [C]c [C]- [C]f [C]i [C]n [C]g [C]e [C]r I-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
of [C]o [C]f O 
NEMO [C]N [C]E [C]M [C]O S-protein 
has [C]h [C]a [C]s O 
a [C]a O 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
demonstrates [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]s O 
the [C]t [C]h [C]e O 
definite [C]d [C]e [C]f [C]i [C]n [C]i [C]t [C]e O 
requirement [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
CD40 [C]C [C]D [C]4 [C]0 S-protein 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
for [C]f [C]o [C]r O 
B [C]B B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n O 
class-switching [C]c [C]l [C]a [C]s [C]s [C]- [C]s [C]w [C]i [C]t [C]c [C]h [C]i [C]n [C]g O 
. [C]. O 

Granulocytic [C]G [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]i [C]c O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
NB4 [C]N [C]B [C]4 I-cell_type 
promyelocytic [C]p [C]r [C]o [C]m [C]y [C]e [C]l [C]o [C]c [C]y [C]t [C]i [C]c I-cell_type 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
all-trans [C]a [C]l [C]l [C]- [C]t [C]r [C]a [C]n [C]s O 
retinoic [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
metabolites [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]t [C]e [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
metabolism [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]s [C]m O 
of [C]o [C]f O 
all-trans [C]a [C]l [C]l [C]- [C]t [C]r [C]a [C]n [C]s O 
retinoic [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
( [C]( O 
ATRA [C]A [C]T [C]R [C]A O 
) [C]) O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
reported [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
partly [C]p [C]a [C]r [C]t [C]l [C]y O 
responsible [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]b [C]l [C]e O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
to [C]t [C]o O 
ATRA [C]A [C]T [C]R [C]A O 
seen [C]s [C]e [C]e [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n O 
acute [C]a [C]c [C]u [C]t [C]e O 
promyelocytic [C]p [C]r [C]o [C]m [C]y [C]e [C]l [C]o [C]c [C]y [C]t [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
( [C]( O 
APL [C]A [C]P [C]L O 
) [C]) O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
ATRA [C]A [C]T [C]R [C]A O 
metabolism [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]s [C]m O 
appears [C]a [C]p [C]p [C]e [C]a [C]r [C]s O 
to [C]t [C]o O 
be [C]b [C]e O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
. [C]. O 

The [C]T [C]h [C]e O 
purpose [C]p [C]u [C]r [C]p [C]o [C]s [C]e O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
was [C]w [C]a [C]s O 
to [C]t [C]o O 
evaluate [C]e [C]v [C]a [C]l [C]u [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
principal [C]p [C]r [C]i [C]n [C]c [C]i [C]p [C]a [C]l O 
metabolites [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]t [C]e [C]s O 
of [C]o [C]f O 
ATRA [C]A [C]T [C]R [C]A O 
[ [C][ O 
4-hydroxy-retinoic [C]4 [C]- [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]- [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
( [C]( O 
4-OH-RA [C]4 [C]- [C]O [C]H [C]- [C]R [C]A O 
) [C]) O 
, [C], O 
18-hydroxy-retinoic [C]1 [C]8 [C]- [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]- [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
( [C]( O 
18-OH-RA [C]1 [C]8 [C]- [C]O [C]H [C]- [C]R [C]A O 
) [C]) O 
, [C], O 
4-oxo-retinoic [C]4 [C]- [C]o [C]x [C]o [C]- [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
( [C]( O 
4-oxo-RA [C]4 [C]- [C]o [C]x [C]o [C]- [C]R [C]A O 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
5 [C]5 O 
, [C], O 
6-epoxy-retinoic [C]6 [C]- [C]e [C]p [C]o [C]x [C]y [C]- [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
( [C]( O 
5 [C]5 O 
, [C], O 
6-epoxy-RA [C]6 [C]- [C]e [C]p [C]o [C]x [C]y [C]- [C]R [C]A O 
) [C]) O 
] [C]] O 
in [C]i [C]n O 
NB4 [C]N [C]B [C]4 B-cell_line 
, [C], I-cell_line 
a [C]a I-cell_line 
human [C]h [C]u [C]m [C]a [C]n I-cell_line 
promyelocytic [C]p [C]r [C]o [C]m [C]y [C]e [C]l [C]o [C]c [C]y [C]t [C]i [C]c I-cell_line 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
that [C]t [C]h [C]a [C]t O 
exhibits [C]e [C]x [C]h [C]i [C]b [C]i [C]t [C]s O 
the [C]t [C]h [C]e O 
APL [C]A [C]P [C]L O 
diagnostic [C]d [C]i [C]a [C]g [C]n [C]o [C]s [C]t [C]i [C]c O 
t [C]t O 
( [C]( O 
15 [C]1 [C]5 O 
; [C]; O 
17 [C]1 [C]7 O 
) [C]) O 
chromosomal [C]c [C]h [C]r [C]o [C]m [C]o [C]s [C]o [C]m [C]a [C]l O 
translocation [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
expresses [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]s O 
the [C]t [C]h [C]e O 
PML-RAR [C]P [C]M [C]L [C]- [C]R [C]A [C]R B-protein 
alpha [C]a [C]l [C]p [C]h [C]a I-protein 
fusion [C]f [C]u [C]s [C]i [C]o [C]n I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
. [C]. O 

We [C]W [C]e O 
established [C]e [C]s [C]t [C]a [C]b [C]l [C]i [C]s [C]h [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
four [C]f [C]o [C]u [C]r O 
ATRA [C]A [C]T [C]R [C]A O 
metabolites [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]t [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
indeed [C]i [C]n [C]d [C]e [C]e [C]d O 
formed [C]f [C]o [C]r [C]m [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
NB4 [C]N [C]B [C]4 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
. [C]. O 

NB4 [C]N [C]B [C]4 O 
cell [C]c [C]e [C]l [C]l O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
was [C]w [C]a [C]s O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
( [C]( O 
69-78 [C]6 [C]9 [C]- [C]7 [C]8 O 
% [C]% O 
at [C]a [C]t O 
120 [C]1 [C]2 [C]0 O 
h [C]h O 
) [C]) O 
and [C]a [C]n [C]d O 
cell [C]c [C]e [C]l [C]l O 
cycle [C]c [C]y [C]c [C]l [C]e O 
progression [C]p [C]r [C]o [C]g [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
G1 [C]G [C]1 O 
phase [C]p [C]h [C]a [C]s [C]e O 
( [C]( O 
82-85 [C]8 [C]2 [C]- [C]8 [C]5 O 
% [C]% O 
at [C]a [C]t O 
120 [C]1 [C]2 [C]0 O 
h [C]h O 
) [C]) O 
was [C]w [C]a [C]s O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
by [C]b [C]y O 
ATRA [C]A [C]T [C]R [C]A O 
and [C]a [C]n [C]d O 
all [C]a [C]l [C]l O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
metabolites [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]t [C]e [C]s O 
at [C]a [C]t O 
1 [C]1 O 
microM [C]m [C]i [C]c [C]r [C]o [C]M O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

ATRA [C]A [C]T [C]R [C]A O 
and [C]a [C]n [C]d O 
its [C]i [C]t [C]s O 
metabolites [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]t [C]e [C]s O 
could [C]c [C]o [C]u [C]l [C]d O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
NB4 [C]N [C]B [C]4 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
, [C], O 
as [C]a [C]s O 
evaluated [C]e [C]v [C]a [C]l [C]u [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
cell [C]c [C]e [C]l [C]l O 
morphology [C]m [C]o [C]r [C]p [C]h [C]o [C]l [C]o [C]g [C]y O 
, [C], O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
nitroblue [C]n [C]i [C]t [C]r [C]o [C]b [C]l [C]u [C]e O 
tetrazolium [C]t [C]e [C]t [C]r [C]a [C]z [C]o [C]l [C]i [C]u [C]m O 
reduction [C]r [C]e [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
test [C]t [C]e [C]s [C]t O 
( [C]( O 
82-88 [C]8 [C]2 [C]- [C]8 [C]8 O 
% [C]% O 
at [C]a [C]t O 
120 [C]1 [C]2 [C]0 O 
h [C]h O 
) [C]) O 
or [C]o [C]r O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
maturation [C]m [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]o [C]n B-protein 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-protein 
cell [C]c [C]e [C]l [C]l I-protein 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e I-protein 
marker [C]m [C]a [C]r [C]k [C]e [C]r I-protein 
CD11c [C]C [C]D [C]1 [C]1 [C]c E-protein 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
body [C]b [C]o [C]d [C]y O 
reorganization [C]r [C]e [C]o [C]r [C]g [C]a [C]n [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
to [C]t [C]o O 
macropunctated [C]m [C]a [C]c [C]r [C]o [C]p [C]u [C]n [C]c [C]t [C]a [C]t [C]e [C]d O 
structures [C]s [C]t [C]r [C]u [C]c [C]t [C]u [C]r [C]e [C]s O 
, [C], O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
the [C]t [C]h [C]e O 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
PML-RAR [C]P [C]M [C]L [C]- [C]R [C]A [C]R B-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
, [C], O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
for [C]f [C]o [C]r O 
ATRA [C]A [C]T [C]R [C]A O 
and [C]a [C]n [C]d O 
all [C]a [C]l [C]l O 
of [C]o [C]f O 
its [C]i [C]t [C]s O 
metabolites [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]t [C]e [C]s O 
. [C]. O 

Comparison [C]C [C]o [C]m [C]p [C]a [C]r [C]i [C]s [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
relative [C]r [C]e [C]l [C]a [C]t [C]i [C]v [C]e O 
potency [C]p [C]o [C]t [C]e [C]n [C]c [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
retinoids [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]d [C]s O 
using [C]u [C]s [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
nitroblue [C]n [C]i [C]t [C]r [C]o [C]b [C]l [C]u [C]e O 
tetrazolium [C]t [C]e [C]t [C]r [C]a [C]z [C]o [C]l [C]i [C]u [C]m O 
reduction [C]r [C]e [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
test [C]t [C]e [C]s [C]t O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
effective [C]e [C]f [C]f [C]e [C]c [C]t [C]i [C]v [C]e O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
to [C]t [C]o O 
differentiate [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]e O 
50 [C]5 [C]0 O 
% [C]% O 
of [C]o [C]f O 
cells [C]c [C]e [C]l [C]l [C]s O 
in [C]i [C]n O 
72 [C]7 [C]2 O 
h [C]h O 
as [C]a [C]s O 
follows [C]f [C]o [C]l [C]l [C]o [C]w [C]s O 
: [C]: O 
ATRA [C]A [C]T [C]R [C]A O 
, [C], O 
15.8 [C]1 [C]5 [C]. [C]8 O 
+/- [C]+ [C]/ [C]- O 
1.7 [C]1 [C]. [C]7 O 
nM [C]n [C]M O 
; [C]; O 
4-oxo-RA [C]4 [C]- [C]o [C]x [C]o [C]- [C]R [C]A O 
, [C], O 
38.3 [C]3 [C]8 [C]. [C]3 O 
+/- [C]+ [C]/ [C]- O 
1.3 [C]1 [C]. [C]3 O 
nM [C]n [C]M O 
; [C]; O 
18-OH-RA [C]1 [C]8 [C]- [C]O [C]H [C]- [C]R [C]A O 
, [C], O 
55.5 [C]5 [C]5 [C]. [C]5 O 
+/- [C]+ [C]/ [C]- O 
1.8 [C]1 [C]. [C]8 O 
nM [C]n [C]M O 
; [C]; O 
4-OH-RA [C]4 [C]- [C]O [C]H [C]- [C]R [C]A O 
, [C], O 
79.8 [C]7 [C]9 [C]. [C]8 O 
+/- [C]+ [C]/ [C]- O 
1.8 [C]1 [C]. [C]8 O 
nM [C]n [C]M O 
; [C]; O 
and [C]a [C]n [C]d O 
5 [C]5 O 
, [C], O 
6-epoxy-RA [C]6 [C]- [C]e [C]p [C]o [C]x [C]y [C]- [C]R [C]A O 
, [C], O 
99.5 [C]9 [C]9 [C]. [C]5 O 
+/- [C]+ [C]/ [C]- O 
1.5 [C]1 [C]. [C]5 O 
nM [C]n [C]M O 
. [C]. O 

The [C]T [C]h [C]e O 
ATRA [C]A [C]T [C]R [C]A O 
metabolites [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]t [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
exert [C]e [C]x [C]e [C]r [C]t O 
their [C]t [C]h [C]e [C]i [C]r O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
via [C]v [C]i [C]a O 
the [C]t [C]h [C]e O 
RAR [C]R [C]A [C]R B-protein 
alpha [C]a [C]l [C]p [C]h [C]a I-protein 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
, [C], O 
because [C]b [C]e [C]c [C]a [C]u [C]s [C]e O 
the [C]t [C]h [C]e O 
RAR [C]R [C]A [C]R O 
alpha-specific [C]a [C]l [C]p [C]h [C]a [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
antagonist [C]a [C]n [C]t [C]a [C]g [C]o [C]n [C]i [C]s [C]t O 
BMS614 [C]B [C]M [C]S [C]6 [C]1 [C]4 O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
metabolite-induced [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]t [C]e [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
CD11c [C]C [C]D [C]1 [C]1 [C]c O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
NB4 [C]N [C]B [C]4 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
principal [C]p [C]r [C]i [C]n [C]c [C]i [C]p [C]a [C]l O 
ATRA [C]A [C]T [C]R [C]A O 
Phase [C]P [C]h [C]a [C]s [C]e O 
1 [C]1 O 
metabolites [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]t [C]e [C]s O 
can [C]c [C]a [C]n O 
elicit [C]e [C]l [C]i [C]c [C]i [C]t O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
RAR [C]R [C]A [C]R O 
alpha [C]a [C]l [C]p [C]h [C]a O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
, [C], O 
and [C]a [C]n [C]d O 
they [C]t [C]h [C]e [C]y O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
these [C]t [C]h [C]e [C]s [C]e O 
metabolites [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]t [C]e [C]s O 
may [C]m [C]a [C]y O 
play [C]p [C]l [C]a [C]y O 
a [C]a O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
ATRA [C]A [C]T [C]R [C]A O 
antileukemic [C]a [C]n [C]t [C]i [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
. [C]. O 

Expression [C]E [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
oestrogen [C]o [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n B-protein 
and [C]a [C]n [C]d I-protein 
progesterone [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]e [C]r [C]o [C]n [C]e I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
by [C]b [C]y O 
mast [C]m [C]a [C]s [C]t B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
alone [C]a [C]l [C]o [C]n [C]e O 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
, [C], O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_type 
or [C]o [C]r O 
other [C]o [C]t [C]h [C]e [C]r O 
immune [C]i [C]m [C]m [C]u [C]n [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n O 
upper [C]u [C]p [C]p [C]e [C]r O 
airways [C]a [C]i [C]r [C]w [C]a [C]y [C]s O 
. [C]. O 

BACKGROUND [C]B [C]A [C]C [C]K [C]G [C]R [C]O [C]U [C]N [C]D O 
: [C]: O 
Nasal [C]N [C]a [C]s [C]a [C]l O 
polyposis [C]p [C]o [C]l [C]y [C]p [C]o [C]s [C]i [C]s O 
often [C]o [C]f [C]t [C]e [C]n O 
coexists [C]c [C]o [C]e [C]x [C]i [C]s [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
asthma [C]a [C]s [C]t [C]h [C]m [C]a O 
in [C]i [C]n O 
airway [C]a [C]i [C]r [C]w [C]a [C]y O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
conditions [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n [C]s O 
characterised [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]s [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
infiltration [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
range [C]r [C]a [C]n [C]g [C]e O 
of [C]o [C]f O 
immune [C]i [C]m [C]m [C]u [C]n [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

A [C]A O 
potentially [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l [C]l [C]y O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
role [C]r [C]o [C]l [C]e O 
for [C]f [C]o [C]r O 
ovarian [C]o [C]v [C]a [C]r [C]i [C]a [C]n O 
hormones [C]h [C]o [C]r [C]m [C]o [C]n [C]e [C]s O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
implicated [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
airway [C]a [C]i [C]r [C]w [C]a [C]y O 
inflammation [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]i [C]o [C]n O 
but [C]b [C]u [C]t O 
the [C]t [C]h [C]e O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
for [C]f [C]o [C]r O 
such [C]s [C]u [C]c [C]h O 
action [C]a [C]c [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
not [C]n [C]o [C]t O 
known [C]k [C]n [C]o [C]w [C]n O 
. [C]. O 

METHODS [C]M [C]E [C]T [C]H [C]O [C]D [C]S O 
: [C]: O 
Expression [C]E [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
oestrogen [C]o [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
( [C]( O 
ER [C]E [C]R S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
progesterone [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]e [C]r [C]o [C]n [C]e B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
( [C]( O 
PR [C]P [C]R S-protein 
) [C]) O 
was [C]w [C]a [C]s O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
using [C]u [C]s [C]i [C]n [C]g O 
immunohistochemistry [C]i [C]m [C]m [C]u [C]n [C]o [C]h [C]i [C]s [C]t [C]o [C]c [C]h [C]e [C]m [C]i [C]s [C]t [C]r [C]y O 
in [C]i [C]n O 
formalin [C]f [C]o [C]r [C]m [C]a [C]l [C]i [C]n O 
fixed [C]f [C]i [C]x [C]e [C]d O 
nasal [C]n [C]a [C]s [C]a [C]l O 
polyp [C]p [C]o [C]l [C]y [C]p O 
tissues [C]t [C]i [C]s [C]s [C]u [C]e [C]s O 
from [C]f [C]r [C]o [C]m O 
47 [C]4 [C]7 O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
for [C]f [C]o [C]r O 
ER [C]E [C]R S-protein 
or [C]o [C]r O 
PR [C]P [C]R S-protein 
were [C]w [C]e [C]r [C]e O 
confirmed [C]c [C]o [C]n [C]f [C]i [C]r [C]m [C]e [C]d O 
by [C]b [C]y O 
spatial [C]s [C]p [C]a [C]t [C]i [C]a [C]l O 
location [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
dual [C]d [C]u [C]a [C]l O 
immunolabelling [C]i [C]m [C]m [C]u [C]n [C]o [C]l [C]a [C]b [C]e [C]l [C]l [C]i [C]n [C]g O 
, [C], O 
and [C]a [C]n [C]d O 
histochemical [C]h [C]i [C]s [C]t [C]o [C]c [C]h [C]e [C]m [C]i [C]c [C]a [C]l O 
staining [C]s [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
. [C]. O 

RESULTS [C]R [C]E [C]S [C]U [C]L [C]T [C]S O 
: [C]: O 
Consistent [C]C [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
known [C]k [C]n [C]o [C]w [C]n O 
features [C]f [C]e [C]a [C]t [C]u [C]r [C]e [C]s O 
of [C]o [C]f O 
nasal [C]n [C]a [C]s [C]a [C]l O 
polyps [C]p [C]o [C]l [C]y [C]p [C]s O 
, [C], O 
CD4+ [C]C [C]D [C]4 [C]+ B-cell_type 
( [C]( I-cell_type 
T [C]T I-cell_type 
helper/inducer [C]h [C]e [C]l [C]p [C]e [C]r [C]/ [C]i [C]n [C]d [C]u [C]c [C]e [C]r I-cell_type 
) [C]) E-cell_type 
, [C], O 
CD8+ [C]C [C]D [C]8 [C]+ B-cell_type 
( [C]( I-cell_type 
cytotoxic/suppressor [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c [C]/ [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]o [C]r I-cell_type 
) [C]) E-cell_type 
, [C], O 
CD68+ [C]C [C]D [C]6 [C]8 [C]+ S-cell_type 
( [C]( O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_type 
) [C]) O 
, [C], O 
mast [C]m [C]a [C]s [C]t B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
eosinophils [C]e [C]o [C]s [C]i [C]n [C]o [C]p [C]h [C]i [C]l [C]s S-cell_type 
and [C]a [C]n [C]d O 
neutrophils [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]h [C]i [C]l [C]s S-cell_type 
were [C]w [C]e [C]r [C]e O 
all [C]a [C]l [C]l O 
clearly [C]c [C]l [C]e [C]a [C]r [C]l [C]y O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
by [C]b [C]y O 
their [C]t [C]h [C]e [C]i [C]r O 
relevant [C]r [C]e [C]l [C]e [C]v [C]a [C]n [C]t O 
monoclonal [C]m [C]o [C]n [C]o [C]c [C]l [C]o [C]n [C]a [C]l B-protein 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s E-protein 
or [C]o [C]r O 
appropriate [C]a [C]p [C]p [C]r [C]o [C]p [C]r [C]i [C]a [C]t [C]e O 
histochemical [C]h [C]i [C]s [C]t [C]o [C]c [C]h [C]e [C]m [C]i [C]c [C]a [C]l O 
staining [C]s [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
, [C], O 
but [C]b [C]u [C]t O 
only [C]o [C]n [C]l [C]y O 
mast [C]m [C]a [C]s [C]t B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
tested [C]t [C]e [C]s [C]t [C]e [C]d O 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
for [C]f [C]o [C]r O 
ER [C]E [C]R S-protein 
/PR [C]/ [C]P [C]R O 
labelling [C]l [C]a [C]b [C]e [C]l [C]l [C]i [C]n [C]g O 
with [C]w [C]i [C]t [C]h O 
their [C]t [C]h [C]e [C]i [C]r O 
polyclonal [C]p [C]o [C]l [C]y [C]c [C]l [C]o [C]n [C]a [C]l B-protein 
and [C]a [C]n [C]d I-protein 
monoclonal [C]m [C]o [C]n [C]o [C]c [C]l [C]o [C]n [C]a [C]l I-protein 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
frequencies [C]f [C]r [C]e [C]q [C]u [C]e [C]n [C]c [C]i [C]e [C]s O 
for [C]f [C]o [C]r O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
were [C]w [C]e [C]r [C]e O 
61.7 [C]6 [C]1 [C]. [C]7 O 
% [C]% O 
for [C]f [C]o [C]r O 
ER [C]E [C]R B-cell_type 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e E-cell_type 
and [C]a [C]n [C]d O 
59.6 [C]5 [C]9 [C]. [C]6 O 
% [C]% O 
for [C]f [C]o [C]r O 
PR [C]P [C]R B-cell_type 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
ER [C]E [C]R S-protein 
/ [C]/ O 
PR [C]P [C]R S-protein 
was [C]w [C]a [C]s O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
of [C]o [C]f O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
sex [C]s [C]e [C]x O 
and [C]a [C]n [C]d O 
age [C]a [C]g [C]e O 
but [C]b [C]u [C]t O 
was [C]w [C]a [C]s O 
highly [C]h [C]i [C]g [C]h [C]l [C]y O 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
numbers [C]n [C]u [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
mast [C]m [C]a [C]s [C]t B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
r [C]r O 
= [C]= O 
0.973 [C]0 [C]. [C]9 [C]7 [C]3 O 
, [C], O 
p [C]p O 
< [C]< O 
0.001 [C]0 [C]. [C]0 [C]0 [C]1 O 
for [C]f [C]o [C]r O 
ER [C]E [C]R S-protein 
; [C]; O 
r [C]r O 
= [C]= O 
0.955 [C]0 [C]. [C]9 [C]5 [C]5 O 
, [C], O 
p [C]p O 
< [C]< O 
0.001 [C]0 [C]. [C]0 [C]0 [C]1 O 
for [C]f [C]o [C]r O 
PR [C]P [C]R S-protein 
) [C]) O 
. [C]. O 

Fewer [C]F [C]e [C]w [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
5 [C]5 O 
% [C]% O 
of [C]o [C]f O 
mast [C]m [C]a [C]s [C]t B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
for [C]f [C]o [C]r O 
ER [C]E [C]R S-protein 
/ [C]/ O 
PR [C]P [C]R S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

CONCLUSIONS [C]C [C]O [C]N [C]C [C]L [C]U [C]S [C]I [C]O [C]N [C]S O 
: [C]: O 
Mast [C]M [C]a [C]s [C]t B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
alone [C]a [C]l [C]o [C]n [C]e O 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
, [C], O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_type 
, [C], O 
or [C]o [C]r O 
other [C]o [C]t [C]h [C]e [C]r O 
immune [C]i [C]m [C]m [C]u [C]n [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
ER [C]E [C]R S-protein 
/ [C]/ O 
PR [C]P [C]R S-protein 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n O 
upper [C]u [C]p [C]p [C]e [C]r O 
airways [C]a [C]i [C]r [C]w [C]a [C]y [C]s O 
. [C]. O 

Numerous [C]N [C]u [C]m [C]e [C]r [C]o [C]u [C]s O 
ER/PR [C]E [C]R [C]/ [C]P [C]R B-cell_type 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e I-cell_type 
mast [C]m [C]a [C]s [C]t I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
exist [C]e [C]x [C]i [C]s [C]t O 
in [C]i [C]n O 
nasal [C]n [C]a [C]s [C]a [C]l O 
polyps [C]p [C]o [C]l [C]y [C]p [C]s O 
, [C], O 
indicating [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
this [C]t [C]h [C]i [C]s O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
a [C]a O 
major [C]m [C]a [C]j [C]o [C]r O 
route [C]r [C]o [C]u [C]t [C]e O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
involvement [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
sex [C]s [C]e [C]x O 
hormones [C]h [C]o [C]r [C]m [C]o [C]n [C]e [C]s O 
in [C]i [C]n O 
airway [C]a [C]i [C]r [C]w [C]a [C]y O 
inflammation [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]i [C]o [C]n O 
when [C]w [C]h [C]e [C]n O 
exposed [C]e [C]x [C]p [C]o [C]s [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
and [C]a [C]n [C]d O 
varying [C]v [C]a [C]r [C]y [C]i [C]n [C]g O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
oestrogen [C]o [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n O 
and [C]a [C]n [C]d O 
progesterone [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
characteristic [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]s [C]t [C]i [C]c O 
of [C]o [C]f O 
females [C]f [C]e [C]m [C]a [C]l [C]e [C]s O 
. [C]. O 

NF [C]N [C]F O 
kappa [C]k [C]a [C]p [C]p [C]a O 
b [C]b O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
in [C]i [C]n O 
posthypoxic [C]p [C]o [C]s [C]t [C]h [C]y [C]p [C]o [C]x [C]i [C]c B-cell_type 
endothelial [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
: [C]: O 
relevance [C]r [C]e [C]l [C]e [C]v [C]a [C]n [C]c [C]e O 
to [C]t [C]o O 
E-selectin [C]E [C]- [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
neutrophil [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]h [C]i [C]l O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
. [C]. O 

Our [C]O [C]u [C]r O 
previous [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
have [C]h [C]a [C]v [C]e O 
implicated [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
kappa [C]k [C]a [C]p [C]p [C]a O 
B [C]B O 
( [C]( O 
NF [C]N [C]F B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
) [C]) O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n B-protein 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e E-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
endothelial [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
exposed [C]e [C]x [C]p [C]o [C]s [C]e [C]d O 
to [C]t [C]o O 
anoxia-reoxygenation [C]a [C]n [C]o [C]x [C]i [C]a [C]- [C]r [C]e [C]o [C]x [C]y [C]g [C]e [C]n [C]a [C]t [C]i [C]o [C]n O 
( [C]( O 
A/R [C]A [C]/ [C]R O 
) [C]) O 
or [C]o [C]r O 
a [C]a O 
redox [C]r [C]e [C]d [C]o [C]x O 
imbalance [C]i [C]m [C]b [C]a [C]l [C]a [C]n [C]c [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
objectives [C]o [C]b [C]j [C]e [C]c [C]t [C]i [C]v [C]e [C]s O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
were [C]w [C]e [C]r [C]e O 
( [C]( O 
1 [C]1 O 
) [C]) O 
to [C]t [C]o O 
define [C]d [C]e [C]f [C]i [C]n [C]e O 
the [C]t [C]h [C]e O 
kinetics [C]k [C]i [C]n [C]e [C]t [C]i [C]c [C]s O 
of [C]o [C]f O 
NF [C]N [C]F B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
examining [C]e [C]x [C]a [C]m [C]i [C]n [C]i [C]n [C]g O 
I [C]I O 
kappa [C]k [C]a [C]p [C]p [C]a O 
B [C]B O 
alpha [C]a [C]l [C]p [C]h [C]a O 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
translocation [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
p65 [C]p [C]6 [C]5 S-protein 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
A/R [C]A [C]/ [C]R O 
or [C]o [C]r O 
redox [C]r [C]e [C]d [C]o [C]x O 
imbalance [C]i [C]m [C]b [C]a [C]l [C]a [C]n [C]c [C]e O 
( [C]( O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
cells [C]c [C]e [C]l [C]l [C]s O 
with [C]w [C]i [C]t [C]h O 
diamide [C]d [C]i [C]a [C]m [C]i [C]d [C]e O 
and [C]a [C]n [C]d O 
buthionine [C]b [C]u [C]t [C]h [C]i [C]o [C]n [C]i [C]n [C]e O 
sulfoximine [C]s [C]u [C]l [C]f [C]o [C]x [C]i [C]m [C]i [C]n [C]e O 
) [C]) O 
and [C]a [C]n [C]d O 
( [C]( O 
2 [C]2 O 
) [C]) O 
to [C]t [C]o O 
determine [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
the [C]t [C]h [C]e O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
for [C]f [C]o [C]r O 
I [C]I O 
kappa [C]k [C]a [C]p [C]p [C]a O 
B [C]B O 
alpha [C]a [C]l [C]p [C]h [C]a O 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
translocation [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
p65 [C]p [C]6 [C]5 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
E-selectin [C]E [C]- [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]n S-protein 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
neutrophil [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]h [C]i [C]l O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
is [C]i [C]s O 
related [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
( [C]( O 
PTK [C]P [C]T [C]K S-protein 
) [C]) O 
, [C], O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e I-protein 
phosphatase [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]a [C]s [C]e E-protein 
( [C]( O 
PTPase [C]P [C]T [C]P [C]a [C]s [C]e S-protein 
) [C]) O 
and/or [C]a [C]n [C]d [C]/ [C]o [C]r O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
C [C]C E-protein 
( [C]( O 
PKC [C]P [C]K [C]C S-protein 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
both [C]b [C]o [C]t [C]h O 
A/R [C]A [C]/ [C]R O 
and [C]a [C]n [C]d O 
redox [C]r [C]e [C]d [C]o [C]x O 
imbalance [C]i [C]m [C]b [C]a [C]l [C]a [C]n [C]c [C]e O 
led [C]l [C]e [C]d O 
to [C]t [C]o O 
I [C]I O 
kappa [C]k [C]a [C]p [C]p [C]a O 
B [C]B O 
alpha [C]a [C]l [C]p [C]h [C]a O 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
30 [C]3 [C]0 O 
min [C]m [C]i [C]n O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
concomitant [C]c [C]o [C]n [C]c [C]o [C]m [C]i [C]t [C]a [C]n [C]t O 
appearance [C]a [C]p [C]p [C]e [C]a [C]r [C]a [C]n [C]c [C]e O 
of [C]o [C]f O 
p65 [C]p [C]6 [C]5 S-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
nucleus [C]n [C]u [C]c [C]l [C]e [C]u [C]s O 
, [C], O 
consistent [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
rapid [C]r [C]a [C]p [C]i [C]d O 
cytosolic [C]c [C]y [C]t [C]o [C]s [C]o [C]l [C]i [C]c O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF [C]N [C]F B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
and [C]a [C]n [C]d O 
subsequent [C]s [C]u [C]b [C]s [C]e [C]q [C]u [C]e [C]n [C]t O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
translocation [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-protein 
p65 [C]p [C]6 [C]5 I-protein 
subunit [C]s [C]u [C]b [C]u [C]n [C]i [C]t E-protein 
. [C]. O 

Inhibition [C]I [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
PKC [C]P [C]K [C]C S-protein 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
I [C]I B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B I-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
p65 [C]p [C]6 [C]5 S-protein 
translocation [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
A/R-challenged [C]A [C]/ [C]R [C]- [C]c [C]h [C]a [C]l [C]l [C]e [C]n [C]g [C]e [C]d O 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
redox-altered [C]r [C]e [C]d [C]o [C]x [C]- [C]a [C]l [C]t [C]e [C]r [C]e [C]d O 
, [C], O 
endothelial [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
both [C]b [C]o [C]t [C]h O 
A/R- [C]A [C]/ [C]R [C]- O 
and [C]a [C]n [C]d O 
redox-induced [C]r [C]e [C]d [C]o [C]x [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
NF [C]N [C]F O 
kappa [C]k [C]a [C]p [C]p [C]a O 
B [C]B O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
by [C]b [C]y O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
PTK [C]P [C]T [C]K S-protein 
. [C]. O 

Similarly [C]S [C]i [C]m [C]i [C]l [C]a [C]r [C]l [C]y O 
, [C], O 
A/R-induced [C]A [C]/ [C]R [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
E-selectin [C]E [C]- [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
neutrophil-endothelial [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]h [C]i [C]l [C]- [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l O 
cell [C]c [C]e [C]l [C]l O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
were [C]w [C]e [C]r [C]e O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
by [C]b [C]y O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
PKC [C]P [C]K [C]C S-protein 
or [C]o [C]r O 
PTK [C]P [C]T [C]K S-protein 
, [C], O 
while [C]w [C]h [C]i [C]l [C]e O 
only [C]o [C]n [C]l [C]y O 
PTK [C]P [C]T [C]K S-protein 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
redox-induced [C]r [C]e [C]d [C]o [C]x [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
. [C]. O 

Pretreatment [C]P [C]r [C]e [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
cells [C]c [C]e [C]l [C]l [C]s O 
with [C]w [C]i [C]t [C]h O 
N-acetyl [C]N [C]- [C]a [C]c [C]e [C]t [C]y [C]l O 
cysteine [C]c [C]y [C]s [C]t [C]e [C]i [C]n [C]e O 
effectively [C]e [C]f [C]f [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
A/R- [C]A [C]/ [C]R [C]- O 
or [C]o [C]r O 
redox-induced [C]r [C]e [C]d [C]o [C]x [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
I [C]I O 
kappa [C]k [C]a [C]p [C]p [C]a O 
B [C]B O 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
attenuated [C]a [C]t [C]t [C]e [C]n [C]u [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
respective [C]r [C]e [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e O 
neutrophil [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]h [C]i [C]l O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
. [C]. O 

Collectively [C]C [C]o [C]l [C]l [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
, [C], O 
these [C]t [C]h [C]e [C]s [C]e O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
A/R-induced [C]A [C]/ [C]R [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
E-selectin [C]E [C]- [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
neutrophil-endothelial [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]h [C]i [C]l [C]- [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l O 
cell [C]c [C]e [C]l [C]l O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
are [C]a [C]r [C]e O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
both [C]b [C]o [C]t [C]h O 
PKC [C]P [C]K [C]C S-protein 
and [C]a [C]n [C]d O 
PTK [C]P [C]T [C]K S-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
rapid [C]r [C]a [C]p [C]i [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF [C]N [C]F B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
A/R-induced [C]A [C]/ [C]R [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
NF [C]N [C]F B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
appears [C]a [C]p [C]p [C]e [C]a [C]r [C]s O 
to [C]t [C]o O 
be [C]b [C]e O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
, [C], O 
at [C]a [C]t O 
least [C]l [C]e [C]a [C]s [C]t O 
in [C]i [C]n O 
part [C]p [C]a [C]r [C]t O 
, [C], O 
by [C]b [C]y O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
redox [C]r [C]e [C]d [C]o [C]x O 
imbalance [C]i [C]m [C]b [C]a [C]l [C]a [C]n [C]c [C]e O 
. [C]. O 

Copyright [C]C [C]o [C]p [C]y [C]r [C]i [C]g [C]h [C]t O 
2001 [C]2 [C]0 [C]0 [C]1 O 
S. [C]S [C]. O 
Karger [C]K [C]a [C]r [C]g [C]e [C]r O 
AG [C]A [C]G O 
, [C], O 
Basel [C]B [C]a [C]s [C]e [C]l O 

Induction [C]I [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
herbicide [C]h [C]e [C]r [C]b [C]i [C]c [C]i [C]d [C]e O 
2 [C]2 O 
, [C], O 
4-dichlorophenoxyacetic [C]4 [C]- [C]d [C]i [C]c [C]h [C]l [C]o [C]r [C]o [C]p [C]h [C]e [C]n [C]o [C]x [C]y [C]a [C]c [C]e [C]t [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
. [C]. O 

Dimethylammonium [C]D [C]i [C]m [C]e [C]t [C]h [C]y [C]l [C]a [C]m [C]m [C]o [C]n [C]i [C]u [C]m O 
salt [C]s [C]a [C]l [C]t O 
of [C]o [C]f O 
2 [C]2 O 
, [C], O 
4-dichlorophenoxyacetic [C]4 [C]- [C]d [C]i [C]c [C]h [C]l [C]o [C]r [C]o [C]p [C]h [C]e [C]n [C]o [C]x [C]y [C]a [C]c [C]e [C]t [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
( [C]( O 
DMA-2 [C]D [C]M [C]A [C]- [C]2 O 
, [C], O 
4-D [C]4 [C]- [C]D O 
) [C]) O 
is [C]i [C]s O 
a [C]a O 
widely [C]w [C]i [C]d [C]e [C]l [C]y O 
used [C]u [C]s [C]e [C]d O 
herbicide [C]h [C]e [C]r [C]b [C]i [C]c [C]i [C]d [C]e O 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
considered [C]c [C]o [C]n [C]s [C]i [C]d [C]e [C]r [C]e [C]d O 
moderately [C]m [C]o [C]d [C]e [C]r [C]a [C]t [C]e [C]l [C]y O 
toxic [C]t [C]o [C]x [C]i [C]c O 
. [C]. O 

In [C]I [C]n O 
the [C]t [C]h [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
study [C]s [C]t [C]u [C]d [C]y O 
we [C]w [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
DMA-2 [C]D [C]M [C]A [C]- [C]2 O 
, [C], O 
4-D [C]4 [C]- [C]D O 
is [C]i [C]s O 
able [C]a [C]b [C]l [C]e O 
to [C]t [C]o O 
cause [C]c [C]a [C]u [C]s [C]e O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
of [C]o [C]f O 
healthy [C]h [C]e [C]a [C]l [C]t [C]h [C]y O 
individuals [C]i [C]n [C]d [C]i [C]v [C]i [C]d [C]u [C]a [C]l [C]s O 
and [C]a [C]n [C]d O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_line 
T [C]T I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

Apoptosis [C]A [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
DMA-2 [C]D [C]M [C]A [C]- [C]2 O 
, [C], O 
4-D [C]4 [C]- [C]D O 
was [C]w [C]a [C]s O 
dose [C]d [C]o [C]s [C]e O 
and [C]a [C]n [C]d O 
time [C]t [C]i [C]m [C]e O 
dependent [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
, [C], O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
of [C]o [C]f O 
Fas [C]F [C]a [C]s S-protein 
, [C], O 
TNF [C]T [C]N [C]F B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
1 [C]1 E-protein 
or [C]o [C]r O 
the [C]t [C]h [C]e O 
aromatic [C]a [C]r [C]o [C]m [C]a [C]t [C]i [C]c B-protein 
hydrocarbon [C]h [C]y [C]d [C]r [C]o [C]c [C]a [C]r [C]b [C]o [C]n I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
, [C], O 
and [C]a [C]n [C]d O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
disruption [C]d [C]i [C]s [C]r [C]u [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
mitochondrial [C]m [C]i [C]t [C]o [C]c [C]h [C]o [C]n [C]d [C]r [C]i [C]a [C]l O 
transmembrane [C]t [C]r [C]a [C]n [C]s [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
and [C]a [C]n [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
caspase-9 [C]c [C]a [C]s [C]p [C]a [C]s [C]e [C]- [C]9 S-protein 
. [C]. O 

ZVAD-FMK [C]Z [C]V [C]A [C]D [C]- [C]F [C]M [C]K O 
, [C], O 
a [C]a O 
broad-spectrum [C]b [C]r [C]o [C]a [C]d [C]- [C]s [C]p [C]e [C]c [C]t [C]r [C]u [C]m O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
of [C]o [C]f O 
caspases [C]c [C]a [C]s [C]p [C]a [C]s [C]e [C]s S-protein 
, [C], O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
DMA-2 [C]D [C]M [C]A [C]- [C]2 O 
, [C], O 
4-D-induced [C]4 [C]- [C]D [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
completely [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e [C]l [C]y O 
. [C]. O 

While [C]W [C]h [C]i [C]l [C]e O 
an [C]a [C]n O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
of [C]o [C]f O 
caspase-9 [C]c [C]a [C]s [C]p [C]a [C]s [C]e [C]- [C]9 S-protein 
, [C], O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
caspase-9 [C]c [C]a [C]s [C]p [C]a [C]s [C]e [C]- [C]9 S-protein 
and [C]a [C]n [C]d O 
caspase-3 [C]c [C]a [C]s [C]p [C]a [C]s [C]e [C]- [C]3 O 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
in [C]i [C]n O 
combination [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
strongly [C]s [C]t [C]r [C]o [C]n [C]g [C]l [C]y O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
DMA-2 [C]D [C]M [C]A [C]- [C]2 O 
, [C], O 
4-D-induced [C]4 [C]- [C]D [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
, [C], O 
an [C]a [C]n O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
of [C]o [C]f O 
caspase-3 [C]c [C]a [C]s [C]p [C]a [C]s [C]e [C]- [C]3 S-protein 
had [C]h [C]a [C]d O 
a [C]a O 
moderate [C]m [C]o [C]d [C]e [C]r [C]a [C]t [C]e O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
. [C]. O 

Unlike [C]U [C]n [C]l [C]i [C]k [C]e O 
Fas [C]F [C]a [C]s S-protein 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
, [C], O 
the [C]t [C]h [C]e O 
initiator [C]i [C]n [C]i [C]t [C]i [C]a [C]t [C]o [C]r B-protein 
caspase [C]c [C]a [C]s [C]p [C]a [C]s [C]e E-protein 
, [C], O 
caspase-8 [C]c [C]a [C]s [C]p [C]a [C]s [C]e [C]- [C]8 S-protein 
, [C], O 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
DMA-2 [C]D [C]M [C]A [C]- [C]2 O 
, [C], O 
4-D-induced [C]4 [C]- [C]D [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
. [C]. O 

Transfection [C]T [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
with [C]w [C]i [C]t [C]h O 
Bcl-2 [C]B [C]c [C]l [C]- [C]2 S-protein 
prevented [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]e [C]d O 
DMA-2 [C]D [C]M [C]A [C]- [C]2 O 
, [C], O 
4-D-induced [C]4 [C]- [C]D [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
disruption [C]d [C]i [C]s [C]r [C]u [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
mitochondrial [C]m [C]i [C]t [C]o [C]c [C]h [C]o [C]n [C]d [C]r [C]i [C]a [C]l O 
transmembrane [C]t [C]r [C]a [C]n [C]s [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
and [C]a [C]n [C]d O 
led [C]l [C]e [C]d O 
to [C]t [C]o O 
a [C]a O 
complete [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e O 
blockage [C]b [C]l [C]o [C]c [C]k [C]a [C]g [C]e O 
of [C]o [C]f O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
. [C]. O 

Our [C]O [C]u [C]r O 
data [C]d [C]a [C]t [C]a O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
DMA-2 [C]D [C]M [C]A [C]- [C]2 O 
, [C], O 
4-D [C]4 [C]- [C]D O 
kills [C]k [C]i [C]l [C]l [C]s O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
by [C]b [C]y O 
initiating [C]i [C]n [C]i [C]t [C]i [C]a [C]t [C]i [C]n [C]g O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
via [C]v [C]i [C]a O 
a [C]a O 
direct [C]d [C]i [C]r [C]e [C]c [C]t O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
mitochondria [C]m [C]i [C]t [C]o [C]c [C]h [C]o [C]n [C]d [C]r [C]i [C]a O 
. [C]. O 

The [C]T [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
caspases [C]c [C]a [C]s [C]p [C]a [C]s [C]e [C]s S-protein 
occurs [C]o [C]c [C]c [C]u [C]r [C]s O 
downstream [C]d [C]o [C]w [C]n [C]s [C]t [C]r [C]e [C]a [C]m O 
of [C]o [C]f O 
mitochondrial [C]m [C]i [C]t [C]o [C]c [C]h [C]o [C]n [C]d [C]r [C]i [C]a [C]l O 
damage [C]d [C]a [C]m [C]a [C]g [C]e O 
, [C], O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
dysfunction [C]d [C]y [C]s [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
mitochondria [C]m [C]i [C]t [C]o [C]c [C]h [C]o [C]n [C]d [C]r [C]i [C]a O 
appears [C]a [C]p [C]p [C]e [C]a [C]r [C]s O 
to [C]t [C]o O 
be [C]b [C]e O 
sufficient [C]s [C]u [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
for [C]f [C]o [C]r O 
triggering [C]t [C]r [C]i [C]g [C]g [C]e [C]r [C]i [C]n [C]g O 
all [C]a [C]l [C]l O 
downstream [C]d [C]o [C]w [C]n [C]s [C]t [C]r [C]e [C]a [C]m O 
events [C]e [C]v [C]e [C]n [C]t [C]s O 
leading [C]l [C]e [C]a [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
. [C]. O 

Inhibition [C]I [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Th1 [C]T [C]h [C]1 O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
IL-6 [C]I [C]L [C]- [C]6 S-protein 
is [C]i [C]s O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
SOCS1 [C]S [C]O [C]C [C]S [C]1 S-protein 
. [C]. O 

Interleukin [C]I [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n B-protein 
6 [C]6 E-protein 
( [C]( O 
IL-6 [C]I [C]L [C]- [C]6 S-protein 
) [C]) O 
is [C]i [C]s O 
a [C]a O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e S-protein 
produced [C]p [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
immune [C]i [C]m [C]m [C]u [C]n [C]e B-cell_type 
and [C]a [C]n [C]d I-cell_type 
nonimmune [C]n [C]o [C]n [C]i [C]m [C]m [C]u [C]n [C]e I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
exhibits [C]e [C]x [C]h [C]i [C]b [C]i [C]t [C]s O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
pleiotropy [C]p [C]l [C]e [C]i [C]o [C]t [C]r [C]o [C]p [C]y O 
and [C]a [C]n [C]d O 
redundancy [C]r [C]e [C]d [C]u [C]n [C]d [C]a [C]n [C]c [C]y O 
. [C]. O 

IL-6 [C]I [C]L [C]- [C]6 S-protein 
plays [C]p [C]l [C]a [C]y [C]s O 
an [C]a [C]n O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
cell [C]c [C]e [C]l [C]l O 
types [C]t [C]y [C]p [C]e [C]s O 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
, [C], O 
we [C]w [C]e O 
describe [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-6 [C]I [C]L [C]- [C]6 S-protein 
: [C]: O 
the [C]t [C]h [C]e O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CD4 [C]C [C]D [C]4 S-protein 
+ [C]+ O 
Th1 [C]T [C]h [C]1 O 
cell [C]c [C]e [C]l [C]l O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

While [C]W [C]h [C]i [C]l [C]e O 
IL-6 [C]I [C]L [C]- [C]6 S-protein 
-directed [C]- [C]d [C]i [C]r [C]e [C]c [C]t [C]e [C]d O 
CD4 [C]C [C]D [C]4 S-protein 
+ [C]+ O 
Th2 [C]T [C]h [C]2 O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
, [C], O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Th1 [C]T [C]h [C]1 O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
IL-6 [C]I [C]L [C]- [C]6 S-protein 
is [C]i [C]s O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
of [C]o [C]f O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
. [C]. O 

IL-6 [C]I [C]L [C]- [C]6 S-protein 
upregulates [C]u [C]p [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]s O 
suppressor [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]o [C]r B-protein 
of [C]o [C]f I-protein 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e I-protein 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g I-protein 
1 [C]1 E-protein 
( [C]( O 
SOCS1 [C]S [C]O [C]C [C]S [C]1 S-protein 
) [C]) O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-cell_type 
CD4+ [C]C [C]D [C]4 [C]+ I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
thereby [C]t [C]h [C]e [C]r [C]e [C]b [C]y O 
interfering [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]i [C]n [C]g O 
with [C]w [C]i [C]t [C]h O 
signal [C]s [C]i [C]g [C]n [C]a [C]l B-protein 
transducer [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]e [C]r I-protein 
and [C]a [C]n [C]d I-protein 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r I-protein 
of [C]o [C]f I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
1 [C]1 E-protein 
( [C]( O 
STAT1 [C]S [C]T [C]A [C]T [C]1 S-protein 
) [C]) O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
interferon [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n B-protein 
gamma [C]g [C]a [C]m [C]m [C]a E-protein 
( [C]( O 
IFNgamma [C]I [C]F [C]N [C]g [C]a [C]m [C]m [C]a S-protein 
) [C]) O 
. [C]. O 

Inhibition [C]I [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IFNgamma [C]I [C]F [C]N [C]g [C]a [C]m [C]m [C]a S-protein 
receptor-mediated [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
by [C]b [C]y O 
IL-6 [C]I [C]L [C]- [C]6 S-protein 
prevents [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]s O 
autoregulation [C]a [C]u [C]t [C]o [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IFNgamma [C]I [C]F [C]N [C]g [C]a [C]m [C]m [C]a B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
by [C]b [C]y O 
IFNgamma [C]I [C]F [C]N [C]g [C]a [C]m [C]m [C]a S-protein 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
CD4+ [C]C [C]D [C]4 [C]+ B-cell_type 
T [C]T I-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
thereby [C]t [C]h [C]e [C]r [C]e [C]b [C]y O 
preventing [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]i [C]n [C]g O 
Th1 [C]T [C]h [C]1 O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
IL-6 [C]I [C]L [C]- [C]6 S-protein 
promotes [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]s O 
CD4 [C]C [C]D [C]4 S-protein 
+ [C]+ O 
Th2 [C]T [C]h [C]2 O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
inhibits [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]s O 
Th1 [C]T [C]h [C]1 O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
two [C]t [C]w [C]o O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
. [C]. O 

Interaction [C]I [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
CCAAT/enhancer [C]C [C]C [C]A [C]A [C]T [C]/ [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r B-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
and [C]a [C]n [C]d O 
cyclic [C]c [C]y [C]c [C]l [C]i [C]c B-protein 
AMP [C]A [C]M [C]P I-protein 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e I-protein 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
1 [C]1 E-protein 
regulates [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]s O 
human [C]h [C]u [C]m [C]a [C]n O 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
virus [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
1 [C]1 O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
cells [C]c [C]e [C]l [C]l [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
monocyte/macrophage [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]/ [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e B-cell_type 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e E-cell_type 
. [C]. O 

Recent [C]R [C]e [C]c [C]e [C]n [C]t O 
observations [C]o [C]b [C]s [C]e [C]r [C]v [C]a [C]t [C]i [C]o [C]n [C]s O 
have [C]h [C]a [C]v [C]e O 
shown [C]s [C]h [C]o [C]w [C]n O 
two [C]t [C]w [C]o O 
CCAAT/enhancer [C]C [C]C [C]A [C]A [C]T [C]/ [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r B-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-DNA 
( [C]( I-DNA 
C/EBP [C]C [C]/ [C]E [C]B [C]P I-DNA 
) [C]) I-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
to [C]t [C]o O 
be [C]b [C]e O 
critically [C]c [C]r [C]i [C]t [C]i [C]c [C]a [C]l [C]l [C]y O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
for [C]f [C]o [C]r O 
efficient [C]e [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
human [C]h [C]u [C]m [C]a [C]n O 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
virus [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
1 [C]1 O 
( [C]( O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
) [C]) O 
replication [C]r [C]e [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
cells [C]c [C]e [C]l [C]l [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
monocyte/macrophage [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]/ [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e B-cell_type 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e E-cell_type 
, [C], O 
a [C]a O 
cell [C]c [C]e [C]l [C]l O 
type [C]t [C]y [C]p [C]e O 
likely [C]l [C]i [C]k [C]e [C]l [C]y O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
transport [C]t [C]r [C]a [C]n [C]s [C]p [C]o [C]r [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
virus [C]v [C]i [C]r [C]u [C]s O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
brain [C]b [C]r [C]a [C]i [C]n O 
. [C]. O 

Additionally [C]A [C]d [C]d [C]i [C]t [C]i [C]o [C]n [C]a [C]l [C]l [C]y O 
, [C], O 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
variation [C]v [C]a [C]r [C]i [C]a [C]t [C]i [C]o [C]n O 
at [C]a [C]t O 
C/EBP [C]C [C]/ [C]E [C]B [C]P B-DNA 
site [C]s [C]i [C]t [C]e I-DNA 
I [C]I E-DNA 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
lies [C]l [C]i [C]e [C]s O 
immediately [C]i [C]m [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]l [C]y O 
upstream [C]u [C]p [C]s [C]t [C]r [C]e [C]a [C]m O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
distal [C]d [C]i [C]s [C]t [C]a [C]l B-DNA 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-DNA 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-DNA 
kappa [C]k [C]a [C]p [C]p [C]a I-DNA 
B [C]B I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
and [C]a [C]n [C]d O 
immediately [C]i [C]m [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]l [C]y O 
downstream [C]d [C]o [C]w [C]n [C]s [C]t [C]r [C]e [C]a [C]m O 
of [C]o [C]f O 
a [C]a O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
site [C]s [C]i [C]t [C]e O 
for [C]f [C]o [C]r O 
activating [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]n [C]g B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
( [C]( O 
ATF [C]A [C]T [C]F S-protein 
) [C]) O 
/ [C]/ O 
cyclic [C]c [C]y [C]c [C]l [C]i [C]c B-protein 
AMP [C]A [C]M [C]P I-protein 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e I-protein 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
( [C]( O 
CREB [C]C [C]R [C]E [C]B S-protein 
) [C]) O 
, [C], O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
affect [C]a [C]f [C]f [C]e [C]c [C]t O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 B-DNA 
long [C]l [C]o [C]n [C]g I-DNA 
terminal [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l I-DNA 
repeat [C]r [C]e [C]p [C]e [C]a [C]t E-DNA 
( [C]( O 
LTR [C]L [C]T [C]R S-DNA 
) [C]) O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

Given [C]G [C]i [C]v [C]e [C]n O 
that [C]t [C]h [C]a [C]t O 
C/EBP [C]C [C]/ [C]E [C]B [C]P B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
interact [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t O 
with [C]w [C]i [C]t [C]h O 
many [C]m [C]a [C]n [C]y O 
other [C]o [C]t [C]h [C]e [C]r O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
members [C]m [C]e [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
ATF/CREB [C]A [C]T [C]F [C]/ [C]C [C]R [C]E [C]B B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y E-protein 
, [C], O 
we [C]w [C]e O 
proceeded [C]p [C]r [C]o [C]c [C]e [C]e [C]d [C]e [C]d O 
to [C]t [C]o O 
determine [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
an [C]a [C]n O 
adjacent [C]a [C]d [C]j [C]a [C]c [C]e [C]n [C]t O 
ATF/CREB [C]A [C]T [C]F [C]/ [C]C [C]R [C]E [C]B B-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
could [C]c [C]o [C]u [C]l [C]d O 
affect [C]a [C]f [C]f [C]e [C]c [C]t O 
C/EBP [C]C [C]/ [C]E [C]B [C]P B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
C/EBP [C]C [C]/ [C]E [C]B [C]P B-DNA 
site [C]s [C]i [C]t [C]e I-DNA 
I [C]I E-DNA 
. [C]. O 

Electrophoretic [C]E [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
analyses [C]a [C]n [C]a [C]l [C]y [C]s [C]e [C]s O 
indicated [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
selected [C]s [C]e [C]l [C]e [C]c [C]t [C]e [C]d O 
ATF/CREB [C]A [C]T [C]F [C]/ [C]C [C]R [C]E [C]B B-DNA 
site [C]s [C]i [C]t [C]e I-DNA 
variants [C]v [C]a [C]r [C]i [C]a [C]n [C]t [C]s E-DNA 
assisted [C]a [C]s [C]s [C]i [C]s [C]t [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
recruitment [C]r [C]e [C]c [C]r [C]u [C]i [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
C/EBP [C]C [C]/ [C]E [C]B [C]P B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
to [C]t [C]o O 
an [C]a [C]n O 
adjacent [C]a [C]d [C]j [C]a [C]c [C]e [C]n [C]t O 
, [C], O 
naturally [C]n [C]a [C]t [C]u [C]r [C]a [C]l [C]l [C]y O 
occurring [C]o [C]c [C]c [C]u [C]r [C]r [C]i [C]n [C]g O 
, [C], O 
low-affinity [C]l [C]o [C]w [C]- [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
C/EBP [C]C [C]/ [C]E [C]B [C]P B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
biophysical [C]b [C]i [C]o [C]p [C]h [C]y [C]s [C]i [C]c [C]a [C]l O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
appears [C]a [C]p [C]p [C]e [C]a [C]r [C]s O 
to [C]t [C]o O 
occur [C]o [C]c [C]c [C]u [C]r O 
via [C]v [C]i [C]a O 
at [C]a [C]t O 
least [C]l [C]e [C]a [C]s [C]t O 
two [C]t [C]w [C]o O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
. [C]. O 

First [C]F [C]i [C]r [C]s [C]t O 
, [C], O 
low [C]l [C]o [C]w O 
amounts [C]a [C]m [C]o [C]u [C]n [C]t [C]s O 
of [C]o [C]f O 
CREB-1 [C]C [C]R [C]E [C]B [C]- [C]1 S-protein 
and [C]a [C]n [C]d O 
C/EBP [C]C [C]/ [C]E [C]B [C]P S-protein 
appear [C]a [C]p [C]p [C]e [C]a [C]r O 
to [C]t [C]o O 
heterodimerize [C]h [C]e [C]t [C]e [C]r [C]o [C]d [C]i [C]m [C]e [C]r [C]i [C]z [C]e O 
and [C]a [C]n [C]d O 
bind [C]b [C]i [C]n [C]d O 
to [C]t [C]o O 
a [C]a O 
site [C]s [C]i [C]t [C]e O 
consisting [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]i [C]n [C]g O 
of [C]o [C]f O 
a [C]a O 
half [C]h [C]a [C]l [C]f O 
site [C]s [C]i [C]t [C]e O 
from [C]f [C]r [C]o [C]m O 
both [C]b [C]o [C]t [C]h O 
the [C]t [C]h [C]e O 
ATF/CREB [C]A [C]T [C]F [C]/ [C]C [C]R [C]E [C]B B-DNA 
and [C]a [C]n [C]d I-DNA 
C/EBP [C]C [C]/ [C]E [C]B [C]P I-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
CREB-1 [C]C [C]R [C]E [C]B [C]- [C]1 B-protein 
homodimers [C]h [C]o [C]m [C]o [C]d [C]i [C]m [C]e [C]r [C]s E-protein 
bind [C]b [C]i [C]n [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
ATF/CREB [C]A [C]T [C]F [C]/ [C]C [C]R [C]E [C]B B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
and [C]a [C]n [C]d O 
recruit [C]r [C]e [C]c [C]r [C]u [C]i [C]t O 
C/EBP [C]C [C]/ [C]E [C]B [C]P B-protein 
dimers [C]d [C]i [C]m [C]e [C]r [C]s E-protein 
to [C]t [C]o O 
their [C]t [C]h [C]e [C]i [C]r O 
cognate [C]c [C]o [C]g [C]n [C]a [C]t [C]e O 
weak [C]w [C]e [C]a [C]k B-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
reciprocal [C]r [C]e [C]c [C]i [C]p [C]r [C]o [C]c [C]a [C]l O 
, [C], O 
since [C]s [C]i [C]n [C]c [C]e O 
C/EBP [C]C [C]/ [C]E [C]B [C]P B-protein 
dimer [C]d [C]i [C]m [C]e [C]r E-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
a [C]a O 
strong [C]s [C]t [C]r [C]o [C]n [C]g O 
C/EBP [C]C [C]/ [C]E [C]B [C]P B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
leads [C]l [C]e [C]a [C]d [C]s O 
to [C]t [C]o O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
CREB-1 [C]C [C]R [C]E [C]B [C]- [C]1 S-protein 
recruitment [C]r [C]e [C]c [C]r [C]u [C]i [C]t [C]m [C]e [C]n [C]t O 
to [C]t [C]o O 
ATF/CREB [C]A [C]T [C]F [C]/ [C]C [C]R [C]E [C]B B-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
that [C]t [C]h [C]a [C]t O 
are [C]a [C]r [C]e O 
weakly [C]w [C]e [C]a [C]k [C]l [C]y O 
bound [C]b [C]o [C]u [C]n [C]d O 
by [C]b [C]y O 
CREB [C]C [C]R [C]E [C]B S-protein 
. [C]. O 

Sequence [C]S [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
variation [C]v [C]a [C]r [C]i [C]a [C]t [C]i [C]o [C]n O 
at [C]a [C]t O 
both [C]b [C]o [C]t [C]h O 
C/EBP [C]C [C]/ [C]E [C]B [C]P B-DNA 
and [C]a [C]n [C]d I-DNA 
ATF/CREB [C]A [C]T [C]F [C]/ [C]C [C]R [C]E [C]B I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
affects [C]a [C]f [C]f [C]e [C]c [C]t [C]s O 
the [C]t [C]h [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
interactions [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
mediating [C]m [C]e [C]d [C]i [C]a [C]t [C]i [C]n [C]g O 
both [C]b [C]o [C]t [C]h O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
. [C]. O 

Most [C]M [C]o [C]s [C]t O 
importantly [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t [C]l [C]y O 
, [C], O 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
variation [C]v [C]a [C]r [C]i [C]a [C]t [C]i [C]o [C]n O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
ATF/CREB [C]A [C]T [C]F [C]/ [C]C [C]R [C]E [C]B B-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
affected [C]a [C]f [C]f [C]e [C]c [C]t [C]e [C]d O 
basal [C]b [C]a [C]s [C]a [C]l O 
LTR [C]L [C]T [C]R S-DNA 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
LTR [C]L [C]T [C]R S-DNA 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
interleukin-6 [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]6 S-protein 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
a [C]a O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
that [C]t [C]h [C]a [C]t O 
leads [C]l [C]e [C]a [C]d [C]s O 
to [C]t [C]o O 
increases [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
in [C]i [C]n O 
C/EBP [C]C [C]/ [C]E [C]B [C]P O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 B-DNA 
LTR [C]L [C]T [C]R E-DNA 
ATF/CREB [C]A [C]T [C]F [C]/ [C]C [C]R [C]E [C]B B-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
variation [C]v [C]a [C]r [C]i [C]a [C]t [C]i [C]o [C]n O 
may [C]m [C]a [C]y O 
modulate [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]e O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
viral [C]v [C]i [C]r [C]a [C]l B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
C/EBP [C]C [C]/ [C]E [C]B [C]P O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 

Selective [C]S [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
interleukin-4 [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]4 O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
by [C]b [C]y O 
aspirin [C]a [C]s [C]p [C]i [C]r [C]i [C]n O 
. [C]. O 

Previous [C]P [C]r [C]e [C]v [C]i [C]o [C]u [C]s O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
indicated [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
aspirin [C]a [C]s [C]p [C]i [C]r [C]i [C]n O 
( [C]( O 
acetylsalicylic [C]a [C]c [C]e [C]t [C]y [C]l [C]s [C]a [C]l [C]i [C]c [C]y [C]l [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
[ [C][ O 
ASA [C]A [C]S [C]A O 
] [C]] O 
) [C]) O 
can [C]c [C]a [C]n O 
have [C]h [C]a [C]v [C]e O 
profound [C]p [C]r [C]o [C]f [C]o [C]u [C]n [C]d O 
immunomodulatory [C]i [C]m [C]m [C]u [C]n [C]o [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
by [C]b [C]y O 
regulating [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
types [C]t [C]y [C]p [C]e [C]s O 
of [C]o [C]f O 
cells [C]c [C]e [C]l [C]l [C]s O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
is [C]i [C]s O 
the [C]t [C]h [C]e O 
first [C]f [C]i [C]r [C]s [C]t O 
in [C]i [C]n O 
which [C]w [C]h [C]i [C]c [C]h O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
ASA [C]A [C]S [C]A O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
therapeutic [C]t [C]h [C]e [C]r [C]a [C]p [C]e [C]u [C]t [C]i [C]c O 
range [C]r [C]a [C]n [C]g [C]e O 
were [C]w [C]e [C]r [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
reduce [C]r [C]e [C]d [C]u [C]c [C]e O 
interleukin [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n B-protein 
( [C]( I-protein 
IL [C]I [C]L I-protein 
) [C]) I-protein 
-4 [C]- [C]4 E-protein 
secretion [C]s [C]e [C]c [C]r [C]e [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
RNA [C]R [C]N [C]A O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
freshly [C]f [C]r [C]e [C]s [C]h [C]l [C]y B-cell_type 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d I-cell_type 
and [C]a [C]n [C]d I-cell_type 
mitogen-primed [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]p [C]r [C]i [C]m [C]e [C]d I-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
CD4+ [C]C [C]D [C]4 [C]+ I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
ASA [C]A [C]S [C]A O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
affect [C]a [C]f [C]f [C]e [C]c [C]t O 
IL-13 [C]I [C]L [C]- [C]1 [C]3 S-protein 
, [C], O 
interferon-gamma [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
, [C], O 
and [C]a [C]n [C]d O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

ASA [C]A [C]S [C]A O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
, [C], O 
promoter-driven [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]- [C]d [C]r [C]i [C]v [C]e [C]n O 
chloramphenicol [C]c [C]h [C]l [C]o [C]r [C]a [C]m [C]p [C]h [C]e [C]n [C]i [C]c [C]o [C]l O 
acetyltransferase [C]a [C]c [C]e [C]t [C]y [C]l [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]r [C]a [C]s [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
transiently [C]t [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t [C]l [C]y O 
transfected [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]e [C]d O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_line 
T [C]T I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

The [C]T [C]h [C]e O 
structurally [C]s [C]t [C]r [C]u [C]c [C]t [C]u [C]r [C]a [C]l [C]l [C]y O 
unrelated [C]u [C]n [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
nonsteroidal [C]n [C]o [C]n [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]a [C]l O 
anti-inflammatory [C]a [C]n [C]t [C]i [C]- [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
drugs [C]d [C]r [C]u [C]g [C]s O 
indomethacin [C]i [C]n [C]d [C]o [C]m [C]e [C]t [C]h [C]a [C]c [C]i [C]n O 
and [C]a [C]n [C]d O 
flurbiprofen [C]f [C]l [C]u [C]r [C]b [C]i [C]p [C]r [C]o [C]f [C]e [C]n O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
affect [C]a [C]f [C]f [C]e [C]c [C]t O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
the [C]t [C]h [C]e O 
weak [C]w [C]e [C]a [C]k O 
cyclo-oxygenase [C]c [C]y [C]c [C]l [C]o [C]- [C]o [C]x [C]y [C]g [C]e [C]n [C]a [C]s [C]e O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
salicylic [C]s [C]a [C]l [C]i [C]c [C]y [C]l [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
was [C]w [C]a [C]s O 
at [C]a [C]t O 
least [C]l [C]e [C]a [C]s [C]t O 
as [C]a [C]s O 
effective [C]e [C]f [C]f [C]e [C]c [C]t [C]i [C]v [C]e O 
as [C]a [C]s O 
ASA [C]A [C]S [C]A O 
in [C]i [C]n O 
inhibiting [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]n [C]g O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
ASA [C]A [C]S [C]A O 
on [C]o [C]n O 
IL-4 [C]I [C]L [C]- [C]4 O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
known [C]k [C]n [C]o [C]w [C]n O 
salicylate [C]s [C]a [C]l [C]i [C]c [C]y [C]l [C]a [C]t [C]e B-protein 
target [C]t [C]a [C]r [C]g [C]e [C]t I-protein 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
( [C]( I-protein 
NF [C]N [C]F I-protein 
) [C]) I-protein 
-kappaB [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
and [C]a [C]n [C]d O 
was [C]w [C]a [C]s O 
accompanied [C]a [C]c [C]c [C]o [C]m [C]p [C]a [C]n [C]i [C]e [C]d O 
by [C]b [C]y O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
an [C]a [C]n O 
inducible [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
to [C]t [C]o O 
an [C]a [C]n O 
IL-4 [C]I [C]L [C]- [C]4 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r I-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
upstream [C]u [C]p [C]s [C]t [C]r [C]e [C]a [C]m O 
of [C]o [C]f O 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
overlapping [C]o [C]v [C]e [C]r [C]l [C]a [C]p [C]p [C]i [C]n [C]g O 
, [C], O 
the [C]t [C]h [C]e O 
NF [C]N [C]F B-DNA 
of [C]o [C]f I-DNA 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d I-DNA 
T [C]T I-DNA 
cells- [C]c [C]e [C]l [C]l [C]s [C]- I-DNA 
and [C]a [C]n [C]d I-DNA 
NF-kappaB-binding [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
P1 [C]P [C]1 I-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
. [C]. O 

It [C]I [C]t O 
is [C]i [C]s O 
concluded [C]c [C]o [C]n [C]c [C]l [C]u [C]d [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
anti-inflammatory [C]a [C]n [C]t [C]i [C]- [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
salicylates [C]s [C]a [C]l [C]i [C]c [C]y [C]l [C]a [C]t [C]e [C]s O 
, [C], O 
by [C]b [C]y O 
means [C]m [C]e [C]a [C]n [C]s O 
of [C]o [C]f O 
a [C]a O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
unrecognized [C]u [C]n [C]r [C]e [C]c [C]o [C]g [C]n [C]i [C]z [C]e [C]d O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
of [C]o [C]f O 
action [C]a [C]c [C]t [C]i [C]o [C]n O 
, [C], O 
can [C]c [C]a [C]n O 
influence [C]i [C]n [C]f [C]l [C]u [C]e [C]n [C]c [C]e O 
the [C]t [C]h [C]e O 
nature [C]n [C]a [C]t [C]u [C]r [C]e O 
of [C]o [C]f O 
adaptive [C]a [C]d [C]a [C]p [C]t [C]i [C]v [C]e O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
by [C]b [C]y O 
selectively [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
inhibiting [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
, [C], O 
a [C]a O 
critical [C]c [C]r [C]i [C]t [C]i [C]c [C]a [C]l O 
effector [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
, [C], O 
in [C]i [C]n O 
CD4+ [C]C [C]D [C]4 [C]+ B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Molecular [C]M [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
and [C]a [C]n [C]d O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
mediators [C]m [C]e [C]d [C]i [C]a [C]t [C]o [C]r [C]s O 
of [C]o [C]f O 
interleukin-1 [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]1 S-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
acute [C]a [C]c [C]u [C]t [C]e O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
arthritis [C]a [C]r [C]t [C]h [C]r [C]i [C]t [C]i [C]s O 
. [C]. O 

OBJECTIVE [C]O [C]B [C]J [C]E [C]C [C]T [C]I [C]V [C]E O 
: [C]: O 
To [C]T [C]o O 
examine [C]e [C]x [C]a [C]m [C]i [C]n [C]e O 
the [C]t [C]h [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
and [C]a [C]n [C]d O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
in [C]i [C]n O 
a [C]a O 
model [C]m [C]o [C]d [C]e [C]l O 
of [C]o [C]f O 
acute [C]a [C]c [C]u [C]t [C]e O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
monarticular [C]m [C]o [C]n [C]a [C]r [C]t [C]i [C]c [C]u [C]l [C]a [C]r O 
arthritis [C]a [C]r [C]t [C]h [C]r [C]i [C]t [C]i [C]s O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
methylated [C]m [C]e [C]t [C]h [C]y [C]l [C]a [C]t [C]e [C]d B-protein 
bovine [C]b [C]o [C]v [C]i [C]n [C]e I-protein 
serum [C]s [C]e [C]r [C]u [C]m I-protein 
albumin [C]a [C]l [C]b [C]u [C]m [C]i [C]n E-protein 
( [C]( O 
mBSA [C]m [C]B [C]S [C]A S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
interleukin-1 [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]1 S-protein 
( [C]( O 
IL-1 [C]I [C]L [C]- [C]1 S-protein 
) [C]) O 
. [C]. O 

METHODS [C]M [C]E [C]T [C]H [C]O [C]D [C]S O 
: [C]: O 
Mice [C]M [C]i [C]c [C]e O 
were [C]w [C]e [C]r [C]e O 
injected [C]i [C]n [C]j [C]e [C]c [C]t [C]e [C]d O 
intraarticularly [C]i [C]n [C]t [C]r [C]a [C]a [C]r [C]t [C]i [C]c [C]u [C]l [C]a [C]r [C]l [C]y O 
with [C]w [C]i [C]t [C]h O 
mBSA [C]m [C]B [C]S [C]A S-protein 
on [C]o [C]n O 
day [C]d [C]a [C]y O 
0 [C]0 O 
and [C]a [C]n [C]d O 
subcutaneously [C]s [C]u [C]b [C]c [C]u [C]t [C]a [C]n [C]e [C]o [C]u [C]s [C]l [C]y O 
with [C]w [C]i [C]t [C]h O 
recombinant [C]r [C]e [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]n [C]t B-protein 
human [C]h [C]u [C]m [C]a [C]n I-protein 
IL-1beta [C]I [C]L [C]- [C]1 [C]b [C]e [C]t [C]a E-protein 
on [C]o [C]n O 
days [C]d [C]a [C]y [C]s O 
0-2 [C]0 [C]- [C]2 O 
. [C]. O 

At [C]A [C]t O 
day [C]d [C]a [C]y O 
7 [C]7 O 
, [C], O 
knee [C]k [C]n [C]e [C]e O 
joints [C]j [C]o [C]i [C]n [C]t [C]s O 
were [C]w [C]e [C]r [C]e O 
removed [C]r [C]e [C]m [C]o [C]v [C]e [C]d O 
and [C]a [C]n [C]d O 
assessed [C]a [C]s [C]s [C]e [C]s [C]s [C]e [C]d O 
histologically [C]h [C]i [C]s [C]t [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l [C]l [C]y O 
. [C]. O 

Flow [C]F [C]l [C]o [C]w O 
cytometry [C]c [C]y [C]t [C]o [C]m [C]e [C]t [C]r [C]y O 
and [C]a [C]n [C]d O 
RNase [C]R [C]N [C]a [C]s [C]e O 
protection [C]p [C]r [C]o [C]t [C]e [C]c [C]t [C]i [C]o [C]n O 
were [C]w [C]e [C]r [C]e O 
used [C]u [C]s [C]e [C]d O 
to [C]t [C]o O 
analyze [C]a [C]n [C]a [C]l [C]y [C]z [C]e O 
IL-1 [C]I [C]L [C]- [C]1 S-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
events [C]e [C]v [C]e [C]n [C]t [C]s O 
. [C]. O 

RESULTS [C]R [C]E [C]S [C]U [C]L [C]T [C]S O 
: [C]: O 
C57BL/6 [C]C [C]5 [C]7 [C]B [C]L [C]/ [C]6 O 
( [C]( O 
B6 [C]B [C]6 O 
) [C]) O 
, [C], O 
129/Sv [C]1 [C]2 [C]9 [C]/ [C]S [C]v O 
, [C], O 
and [C]a [C]n [C]d O 
( [C]( O 
B6 [C]B [C]6 O 
x [C]x O 
129/ [C]1 [C]2 [C]9 [C]/ O 
Sv [C]S [C]v O 
) [C]) O 
F1 [C]F [C]1 O 
hybrid [C]h [C]y [C]b [C]r [C]i [C]d O 
mice [C]m [C]i [C]c [C]e O 
, [C], O 
all [C]a [C]l [C]l O 
H-2b [C]H [C]- [C]2 [C]b O 
strains [C]s [C]t [C]r [C]a [C]i [C]n [C]s O 
, [C], O 
were [C]w [C]e [C]r [C]e O 
susceptible [C]s [C]u [C]s [C]c [C]e [C]p [C]t [C]i [C]b [C]l [C]e O 
to [C]t [C]o O 
mBSA [C]m [C]B [C]S [C]A S-protein 
/IL-1-induced [C]/ [C]I [C]L [C]- [C]1 [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
arthritis [C]a [C]r [C]t [C]h [C]r [C]i [C]t [C]i [C]s O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
C3H/HeJ [C]C [C]3 [C]H [C]/ [C]H [C]e [C]J O 
( [C]( O 
H-2k [C]H [C]- [C]2 [C]k O 
) [C]) O 
mice [C]m [C]i [C]c [C]e O 
were [C]w [C]e [C]r [C]e O 
not [C]n [C]o [C]t O 
. [C]. O 

B6 [C]B [C]6 O 
mice [C]m [C]i [C]c [C]e O 
lacking [C]l [C]a [C]c [C]k [C]i [C]n [C]g O 
T [C]T B-cell_type 
and [C]a [C]n [C]d I-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
RAG1-/- [C]R [C]A [C]G [C]1 [C]- [C]/ [C]- O 
) [C]) O 
or [C]o [C]r O 
major [C]m [C]a [C]j [C]o [C]r B-protein 
histocompatibility [C]h [C]i [C]s [C]t [C]o [C]c [C]o [C]m [C]p [C]a [C]t [C]i [C]b [C]i [C]l [C]i [C]t [C]y I-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x I-protein 
( [C]( I-protein 
MHC [C]M [C]H [C]C I-protein 
) [C]) I-protein 
class [C]c [C]l [C]a [C]s [C]s I-protein 
II [C]I [C]I I-protein 
antigens [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]s E-protein 
( [C]( O 
MHCII-/- [C]M [C]H [C]C [C]I [C]I [C]- [C]/ [C]- O 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
B6 [C]B [C]6 O 
mice [C]m [C]i [C]c [C]e O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
CD4+ [C]C [C]D [C]4 [C]+ B-protein 
T [C]T I-protein 
cell-depleting [C]c [C]e [C]l [C]l [C]- [C]d [C]e [C]p [C]l [C]e [C]t [C]i [C]n [C]g I-protein 
monoclonal [C]m [C]o [C]n [C]o [C]c [C]l [C]o [C]n [C]a [C]l I-protein 
antibody [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y E-protein 
, [C], O 
were [C]w [C]e [C]r [C]e O 
resistant [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]t O 
to [C]t [C]o O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
B [C]B O 
cell-deficient [C]c [C]e [C]l [C]l [C]- [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
( [C]( O 
muMT/ [C]m [C]u [C]M [C]T [C]/ O 
muMT [C]m [C]u [C]M [C]T O 
) [C]) O 
mice [C]m [C]i [C]c [C]e O 
developed [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]e [C]d O 
arthritis [C]a [C]r [C]t [C]h [C]r [C]i [C]t [C]i [C]s O 
at [C]a [C]t O 
an [C]a [C]n O 
incidence [C]i [C]n [C]c [C]i [C]d [C]e [C]n [C]c [C]e O 
and [C]a [C]n [C]d O 
severity [C]s [C]e [C]v [C]e [C]r [C]i [C]t [C]y O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
to [C]t [C]o O 
that [C]t [C]h [C]a [C]t O 
of [C]o [C]f O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
. [C]. O 

RelB-deficient [C]R [C]e [C]l [C]B [C]- [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
( [C]( O 
RelB-/- [C]R [C]e [C]l [C]B [C]- [C]/ [C]- O 
) [C]) O 
bone [C]b [C]o [C]n [C]e O 
marrow [C]m [C]a [C]r [C]r [C]o [C]w O 
chimeric [C]c [C]h [C]i [C]m [C]e [C]r [C]i [C]c O 
mice [C]m [C]i [C]c [C]e O 
had [C]h [C]a [C]d O 
arthritis [C]a [C]r [C]t [C]h [C]r [C]i [C]t [C]i [C]s O 
that [C]t [C]h [C]a [C]t O 
was [C]w [C]a [C]s O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
in [C]i [C]n O 
incidence [C]i [C]n [C]c [C]i [C]d [C]e [C]n [C]c [C]e O 
and [C]a [C]n [C]d O 
severity [C]s [C]e [C]v [C]e [C]r [C]i [C]t [C]y O 
. [C]. O 

In [C]I [C]n O 
B6 [C]B [C]6 O 
mice [C]m [C]i [C]c [C]e O 
, [C], O 
flow [C]f [C]l [C]o [C]w O 
cytometry [C]c [C]y [C]t [C]o [C]m [C]e [C]t [C]r [C]y O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
an [C]a [C]n O 
IL-1-dependent [C]I [C]L [C]- [C]1 [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t B-cell_type 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e E-cell_type 
infiltration [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
into [C]i [C]n [C]t [C]o O 
the [C]t [C]h [C]e O 
synovial [C]s [C]y [C]n [C]o [C]v [C]i [C]a [C]l O 
compartment [C]c [C]o [C]m [C]p [C]a [C]r [C]t [C]m [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
RNase [C]R [C]N [C]a [C]s [C]e O 
protection [C]p [C]r [C]o [C]t [C]e [C]c [C]t [C]i [C]o [C]n O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
messenger [C]m [C]e [C]s [C]s [C]e [C]n [C]g [C]e [C]r B-RNA 
RNA [C]R [C]N [C]A E-RNA 
( [C]( O 
mRNA [C]m [C]R [C]N [C]A S-RNA 
) [C]) O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
chemokines [C]c [C]h [C]e [C]m [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
monocyte [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e B-protein 
chemoattractant [C]c [C]h [C]e [C]m [C]o [C]a [C]t [C]t [C]r [C]a [C]c [C]t [C]a [C]n [C]t I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
1 [C]1 E-protein 
, [C], O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e B-protein 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
2 [C]2 E-protein 
( [C]( O 
MIP-2 [C]M [C]I [C]P [C]- [C]2 S-protein 
) [C]) O 
, [C], O 
RANTES [C]R [C]A [C]N [C]T [C]E [C]S S-protein 
, [C], O 
MIP-1alpha [C]M [C]I [C]P [C]- [C]1 [C]a [C]l [C]p [C]h [C]a S-protein 
, [C], O 
and [C]a [C]n [C]d O 
MIP-1beta [C]M [C]I [C]P [C]- [C]1 [C]b [C]e [C]t [C]a S-protein 
, [C], O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
. [C]. O 

CONCLUSION [C]C [C]O [C]N [C]C [C]L [C]U [C]S [C]I [C]O [C]N O 
: [C]: O 
Arthritis [C]A [C]r [C]t [C]h [C]r [C]i [C]t [C]i [C]s O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
mBSA [C]m [C]B [C]S [C]A S-protein 
/ [C]/ O 
IL-1 [C]I [C]L [C]- [C]1 S-protein 
is [C]i [C]s O 
strain [C]s [C]t [C]r [C]a [C]i [C]n O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
and [C]a [C]n [C]d O 
dependent [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
on [C]o [C]n O 
CD4+ [C]C [C]D [C]4 [C]+ B-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
at [C]a [C]t O 
least [C]l [C]e [C]a [C]s [C]t O 
partially [C]p [C]a [C]r [C]t [C]i [C]a [C]l [C]l [C]y O 
on [C]o [C]n O 
RelB [C]R [C]e [C]l [C]B S-protein 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
on [C]o [C]n O 
B [C]B B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
or [C]o [C]r O 
antibody [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y S-protein 
. [C]. O 

IL-1 [C]I [C]L [C]- [C]1 S-protein 
contributes [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e [C]s O 
to [C]t [C]o O 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e O 
recruitment [C]r [C]e [C]c [C]r [C]u [C]i [C]t [C]m [C]e [C]n [C]t O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
synovium [C]s [C]y [C]n [C]o [C]v [C]i [C]u [C]m O 
and [C]a [C]n [C]d O 
directly [C]d [C]i [C]r [C]e [C]c [C]t [C]l [C]y O 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
chemokine [C]c [C]h [C]e [C]m [C]o [C]k [C]i [C]n [C]e O 
mRNA [C]m [C]R [C]N [C]A O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
synovial [C]s [C]y [C]n [C]o [C]v [C]i [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
model [C]m [C]o [C]d [C]e [C]l O 
of [C]o [C]f O 
acute [C]a [C]c [C]u [C]t [C]e O 
monarticular [C]m [C]o [C]n [C]a [C]r [C]t [C]i [C]c [C]u [C]l [C]a [C]r O 
arthritis [C]a [C]r [C]t [C]h [C]r [C]i [C]t [C]i [C]s O 
is [C]i [C]s O 
particularly [C]p [C]a [C]r [C]t [C]i [C]c [C]u [C]l [C]a [C]r [C]l [C]y O 
suitable [C]s [C]u [C]i [C]t [C]a [C]b [C]l [C]e O 
for [C]f [C]o [C]r O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
investigations [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]i [C]o [C]n [C]s O 
into [C]i [C]n [C]t [C]o O 
cell-mediated [C]c [C]e [C]l [C]l [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
immunity [C]i [C]m [C]m [C]u [C]n [C]i [C]t [C]y O 
in [C]i [C]n O 
arthritis [C]a [C]r [C]t [C]h [C]r [C]i [C]t [C]i [C]s O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
IL-1 [C]I [C]L [C]- [C]1 S-protein 
. [C]. O 

Positive [C]P [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
and [C]a [C]n [C]d O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
granulopoiesis [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
by [C]b [C]y O 
endogenous [C]e [C]n [C]d [C]o [C]g [C]e [C]n [C]o [C]u [C]s B-protein 
RARalpha [C]R [C]A [C]R [C]a [C]l [C]p [C]h [C]a E-protein 
. [C]. O 

Acute [C]A [C]c [C]u [C]t [C]e O 
promyelocytic [C]p [C]r [C]o [C]m [C]y [C]e [C]l [C]o [C]c [C]y [C]t [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
( [C]( O 
APL [C]A [C]P [C]L O 
) [C]) O 
is [C]i [C]s O 
always [C]a [C]l [C]w [C]a [C]y [C]s O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
chromosomal [C]c [C]h [C]r [C]o [C]m [C]o [C]s [C]o [C]m [C]a [C]l O 
translocations [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n [C]s O 
that [C]t [C]h [C]a [C]t O 
disrupt [C]d [C]i [C]s [C]r [C]u [C]p [C]t O 
the [C]t [C]h [C]e O 
retinoic [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]c B-DNA 
acid [C]a [C]c [C]i [C]d I-DNA 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-DNA 
alpha [C]a [C]l [C]p [C]h [C]a I-DNA 
( [C]( I-DNA 
RARalpha [C]R [C]A [C]R [C]a [C]l [C]p [C]h [C]a I-DNA 
) [C]) I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
. [C]. O 

Whether [C]W [C]h [C]e [C]t [C]h [C]e [C]r O 
these [C]t [C]h [C]e [C]s [C]e O 
translocations [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n [C]s O 
relate [C]r [C]e [C]l [C]a [C]t [C]e O 
to [C]t [C]o O 
a [C]a O 
role [C]r [C]o [C]l [C]e O 
for [C]f [C]o [C]r O 
endogenous [C]e [C]n [C]d [C]o [C]g [C]e [C]n [C]o [C]u [C]s B-protein 
RARalpha [C]R [C]A [C]R [C]a [C]l [C]p [C]h [C]a E-protein 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
granulopoiesis [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
remains [C]r [C]e [C]m [C]a [C]i [C]n [C]s O 
uncertain [C]u [C]n [C]c [C]e [C]r [C]t [C]a [C]i [C]n O 
because [C]b [C]e [C]c [C]a [C]u [C]s [C]e O 
most [C]m [C]o [C]s [C]t O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
addressing [C]a [C]d [C]d [C]r [C]e [C]s [C]s [C]i [C]n [C]g O 
this [C]t [C]h [C]i [C]s O 
question [C]q [C]u [C]e [C]s [C]t [C]i [C]o [C]n O 
have [C]h [C]a [C]v [C]e O 
used [C]u [C]s [C]e [C]d O 
non-physiological [C]n [C]o [C]n [C]- [C]p [C]h [C]y [C]s [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
overexpression [C]o [C]v [C]e [C]r [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
systems [C]s [C]y [C]s [C]t [C]e [C]m [C]s O 
. [C]. O 

Granulocyte [C]G [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
cells [C]c [C]e [C]l [C]l [C]s O 
derived [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
RARalpha-deficient [C]R [C]A [C]R [C]a [C]l [C]p [C]h [C]a [C]- [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
( [C]( O 
RARalpha [C]R [C]A [C]R [C]a [C]l [C]p [C]h [C]a O 
( [C]( O 
-/- [C]- [C]/ [C]- O 
) [C]) O 
) [C]) O 
mice [C]m [C]i [C]c [C]e O 
was [C]w [C]a [C]s O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
and [C]a [C]n [C]d O 
evaluated [C]e [C]v [C]a [C]l [C]u [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
context [C]c [C]o [C]n [C]t [C]e [C]x [C]t O 
of [C]o [C]f O 
agonist-bound [C]a [C]g [C]o [C]n [C]i [C]s [C]t [C]- [C]b [C]o [C]u [C]n [C]d B-protein 
and [C]a [C]n [C]d I-protein 
ligand-free [C]l [C]i [C]g [C]a [C]n [C]d [C]- [C]f [C]r [C]e [C]e I-protein 
RARalpha [C]R [C]A [C]R [C]a [C]l [C]p [C]h [C]a E-protein 
. [C]. O 

Our [C]O [C]u [C]r O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
RARalpha [C]R [C]A [C]R [C]a [C]l [C]p [C]h [C]a S-protein 
is [C]i [C]s O 
dispensable [C]d [C]i [C]s [C]p [C]e [C]n [C]s [C]a [C]b [C]l [C]e O 
for [C]f [C]o [C]r O 
granulopoiesis [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
, [C], O 
as [C]a [C]s O 
RARalpha [C]R [C]A [C]R [C]a [C]l [C]p [C]h [C]a O 
( [C]( O 
-/- [C]- [C]/ [C]- O 
) [C]) O 
mice [C]m [C]i [C]c [C]e O 
have [C]h [C]a [C]v [C]e O 
a [C]a O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
granulocyte [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e I-cell_type 
population [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n E-cell_type 
despite [C]d [C]e [C]s [C]p [C]i [C]t [C]e O 
an [C]a [C]n O 
impaired [C]i [C]m [C]p [C]a [C]i [C]r [C]e [C]d O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
to [C]t [C]o O 
respond [C]r [C]e [C]s [C]p [C]o [C]n [C]d O 
to [C]t [C]o O 
retinoids [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]d [C]s O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
although [C]a [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
it [C]i [C]t O 
is [C]i [C]s O 
not [C]n [C]o [C]t O 
absolutely [C]a [C]b [C]s [C]o [C]l [C]u [C]t [C]e [C]l [C]y O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
, [C], O 
RARalpha [C]R [C]A [C]R [C]a [C]l [C]p [C]h [C]a S-protein 
can [C]c [C]a [C]n O 
bidirectionally [C]b [C]i [C]d [C]i [C]r [C]e [C]c [C]t [C]i [C]o [C]n [C]a [C]l [C]l [C]y O 
modulate [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]e O 
granulopoiesis [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
. [C]. O 

RARalpha [C]R [C]A [C]R [C]a [C]l [C]p [C]h [C]a S-protein 
stimulates [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]s O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
exogenous [C]e [C]x [C]o [C]g [C]e [C]n [C]o [C]u [C]s O 
retinoic [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
endogenous [C]e [C]n [C]d [C]o [C]g [C]e [C]n [C]o [C]u [C]s O 
retinoids [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]d [C]s O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
granulopoiesis [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
, [C], O 
as [C]a [C]s O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
vitamin [C]v [C]i [C]t [C]a [C]m [C]i [C]n O 
A-deficient [C]A [C]- [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
mice [C]m [C]i [C]c [C]e O 
or [C]o [C]r O 
animals [C]a [C]n [C]i [C]m [C]a [C]l [C]s O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
an [C]a [C]n O 
RAR [C]R [C]A [C]R O 
antagonist [C]a [C]n [C]t [C]a [C]g [C]o [C]n [C]i [C]s [C]t O 
accumulate [C]a [C]c [C]c [C]u [C]m [C]u [C]l [C]a [C]t [C]e O 
more [C]m [C]o [C]r [C]e O 
immature [C]i [C]m [C]m [C]a [C]t [C]u [C]r [C]e B-cell_type 
granulocytes [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
in [C]i [C]n O 
their [C]t [C]h [C]e [C]i [C]r O 
bone [C]b [C]o [C]n [C]e O 
marrow [C]m [C]a [C]r [C]r [C]o [C]w O 
. [C]. O 

Conversely [C]C [C]o [C]n [C]v [C]e [C]r [C]s [C]e [C]l [C]y O 
, [C], O 
RARalpha [C]R [C]A [C]R [C]a [C]l [C]p [C]h [C]a S-protein 
acts [C]a [C]c [C]t [C]s O 
to [C]t [C]o O 
limit [C]l [C]i [C]m [C]i [C]t O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
ligand [C]l [C]i [C]g [C]a [C]n [C]d S-protein 
because [C]b [C]e [C]c [C]a [C]u [C]s [C]e O 
granulocyte [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e B-cell_type 
precursors [C]p [C]r [C]e [C]c [C]u [C]r [C]s [C]o [C]r [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
RARalpha [C]R [C]A [C]R [C]a [C]l [C]p [C]h [C]a O 
( [C]( O 
-/- [C]- [C]/ [C]- O 
) [C]) O 
mice [C]m [C]i [C]c [C]e O 
differentiate [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]e O 
earlier [C]e [C]a [C]r [C]l [C]i [C]e [C]r O 
in [C]i [C]n O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
the [C]t [C]h [C]e O 
block [C]b [C]l [C]o [C]c [C]k O 
in [C]i [C]n O 
granulopoiesis [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
exerted [C]e [C]x [C]e [C]r [C]t [C]e [C]d O 
by [C]b [C]y O 
RARalpha [C]R [C]A [C]R [C]a [C]l [C]p [C]h [C]a S-protein 
fusion [C]f [C]u [C]s [C]i [C]o [C]n B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
APL [C]A [C]P [C]L B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
may [C]m [C]a [C]y O 
correspond [C]c [C]o [C]r [C]r [C]e [C]s [C]p [C]o [C]n [C]d O 
to [C]t [C]o O 
an [C]a [C]n O 
amplification [C]a [C]m [C]p [C]l [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
unliganded [C]u [C]n [C]l [C]i [C]g [C]a [C]n [C]d [C]e [C]d B-protein 
RARalpha [C]R [C]A [C]R [C]a [C]l [C]p [C]h [C]a E-protein 
. [C]. O 

Expression [C]E [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
stem [C]s [C]t [C]e [C]m B-DNA 
cell [C]c [C]e [C]l [C]l I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
murine [C]m [C]u [C]r [C]i [C]n [C]e B-DNA 
CBFalpha2 [C]C [C]B [C]F [C]a [C]l [C]p [C]h [C]a [C]2 I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
: [C]: O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
roles [C]r [C]o [C]l [C]e [C]s O 
and [C]a [C]n [C]d O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
natural [C]n [C]a [C]t [C]u [C]r [C]a [C]l B-cell_type 
killer [C]k [C]i [C]l [C]l [C]e [C]r I-cell_type 
and [C]a [C]n [C]d I-cell_type 
T [C]T I-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
. [C]. O 

The [C]T [C]h [C]e O 
Runt [C]R [C]u [C]n [C]t B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
CBFalpha2 [C]C [C]B [C]F [C]a [C]l [C]p [C]h [C]a [C]2 S-protein 
( [C]( O 
AML1 [C]A [C]M [C]L [C]1 S-protein 
, [C], O 
PEBP2alphaB [C]P [C]E [C]B [C]P [C]2 [C]a [C]l [C]p [C]h [C]a [C]B S-protein 
, [C], O 
or [C]o [C]r O 
Runx1 [C]R [C]u [C]n [C]x [C]1 S-protein 
) [C]) O 
is [C]i [C]s O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
by [C]b [C]y O 
hematopoietic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c B-cell_type 
stem [C]s [C]t [C]e [C]m I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
at [C]a [C]t O 
high [C]h [C]i [C]g [C]h O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
in [C]i [C]n O 
T-lineage [C]T [C]- [C]l [C]i [C]n [C]e [C]a [C]g [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

In [C]I [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
CBFalpha2 [C]C [C]B [C]F [C]a [C]l [C]p [C]h [C]a [C]2 S-protein 
is [C]i [C]s O 
usually [C]u [C]s [C]u [C]a [C]l [C]l [C]y O 
transcribed [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
a [C]a O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
( [C]( O 
distal [C]d [C]i [C]s [C]t [C]a [C]l B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
) [C]) O 
than [C]t [C]h [C]a [C]n O 
in [C]i [C]n O 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
proximal [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]l B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
) [C]) O 
, [C], O 
but [C]b [C]u [C]t O 
the [C]t [C]h [C]e O 
developmental [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t [C]a [C]l O 
and [C]a [C]n [C]d O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
significance [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]c [C]e O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
switch [C]s [C]w [C]i [C]t [C]c [C]h O 
has [C]h [C]a [C]s O 
not [C]n [C]o [C]t O 
been [C]b [C]e [C]e [C]n O 
known [C]k [C]n [C]o [C]w [C]n O 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
, [C], O 
we [C]w [C]e O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
that [C]t [C]h [C]a [C]t O 
both [C]b [C]o [C]t [C]h O 
coding [C]c [C]o [C]d [C]i [C]n [C]g B-DNA 
and [C]a [C]n [C]d I-DNA 
noncoding [C]n [C]o [C]n [C]c [C]o [C]d [C]i [C]n [C]g I-DNA 
sequences [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s E-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
distal [C]d [C]i [C]s [C]t [C]a [C]l B-DNA 
5 [C]5 I-DNA 
' [C]' I-DNA 
end [C]e [C]n [C]d E-DNA 
are [C]a [C]r [C]e O 
highly [C]h [C]i [C]g [C]h [C]l [C]y O 
conserved [C]c [C]o [C]n [C]s [C]e [C]r [C]v [C]e [C]d O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
and [C]a [C]n [C]d I-DNA 
the [C]t [C]h [C]e I-DNA 
murine [C]m [C]u [C]r [C]i [C]n [C]e I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
, [C], O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
distal [C]d [C]i [C]s [C]t [C]a [C]l B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
is [C]i [C]s O 
responsible [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]b [C]l [C]e O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
overwhelming [C]o [C]v [C]e [C]r [C]w [C]h [C]e [C]l [C]m [C]i [C]n [C]g O 
majority [C]m [C]a [C]j [C]o [C]r [C]i [C]t [C]y O 
of [C]o [C]f O 
CBFalpha2 [C]C [C]B [C]F [C]a [C]l [C]p [C]h [C]a [C]2 O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
murine [C]m [C]u [C]r [C]i [C]n [C]e O 
hematopoietic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c B-cell_type 
stem [C]s [C]t [C]e [C]m I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Distal [C]D [C]i [C]s [C]t [C]a [C]l O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
is [C]i [C]s O 
maintained [C]m [C]a [C]i [C]n [C]t [C]a [C]i [C]n [C]e [C]d O 
throughout [C]t [C]h [C]r [C]o [C]u [C]g [C]h [C]o [C]u [C]t O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
at [C]a [C]t O 
lower [C]l [C]o [C]w [C]e [C]r O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
in [C]i [C]n O 
B [C]B O 
cell [C]c [C]e [C]l [C]l O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
, [C], O 
but [C]b [C]u [C]t O 
downregulated [C]d [C]o [C]w [C]n [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
natural [C]n [C]a [C]t [C]u [C]r [C]a [C]l O 
killer [C]k [C]i [C]l [C]l [C]e [C]r O 
cell [C]c [C]e [C]l [C]l O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
. [C]. O 

The [C]T [C]h [C]e O 
distal [C]d [C]i [C]s [C]t [C]a [C]l B-DNA 
N-terminal [C]N [C]- [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l I-DNA 
isoform [C]i [C]s [C]o [C]f [C]o [C]r [C]m E-DNA 
binds [C]b [C]i [C]n [C]d [C]s O 
to [C]t [C]o O 
functionally [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l [C]l [C]y O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y B-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
from [C]f [C]r [C]o [C]m O 
known [C]k [C]n [C]o [C]w [C]n O 
target [C]t [C]a [C]r [C]g [C]e [C]t B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
with [C]w [C]i [C]t [C]h O 
two- [C]t [C]w [C]o [C]- O 
to [C]t [C]o O 
threefold [C]t [C]h [C]r [C]e [C]e [C]f [C]o [C]l [C]d O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
than [C]t [C]h [C]a [C]n O 
the [C]t [C]h [C]e O 
proximal [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]l B-DNA 
N-terminal [C]N [C]- [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l I-DNA 
isoform [C]i [C]s [C]o [C]f [C]o [C]r [C]m E-DNA 
. [C]. O 

Neither [C]N [C]e [C]i [C]t [C]h [C]e [C]r O 
full-length [C]f [C]u [C]l [C]l [C]- [C]l [C]e [C]n [C]g [C]t [C]h B-DNA 
isoform [C]i [C]s [C]o [C]f [C]o [C]r [C]m E-DNA 
alters [C]a [C]l [C]t [C]e [C]r [C]s O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
of [C]o [C]f O 
a [C]a O 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
under [C]u [C]n [C]d [C]e [C]r O 
nondifferentiating [C]n [C]o [C]n [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]n [C]g O 
conditions [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n [C]s O 
, [C], O 
but [C]b [C]u [C]t O 
the [C]t [C]h [C]e O 
proximal [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]l B-DNA 
isoform [C]i [C]s [C]o [C]f [C]o [C]r [C]m E-DNA 
selectively [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
delays [C]d [C]e [C]l [C]a [C]y [C]s O 
mitotic [C]m [C]i [C]t [C]o [C]t [C]i [C]c O 
arrest [C]a [C]r [C]r [C]e [C]s [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cell [C]c [C]e [C]l [C]l O 
line [C]l [C]i [C]n [C]e O 
under [C]u [C]n [C]d [C]e [C]r O 
differentiating [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]n [C]g O 
conditions [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n [C]s O 
, [C], O 
resulting [C]r [C]e [C]s [C]u [C]l [C]t [C]i [C]n [C]g O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
generation [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
greater [C]g [C]r [C]e [C]a [C]t [C]e [C]r O 
numbers [C]n [C]u [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
neutrophils [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]h [C]i [C]l [C]s S-cell_type 
. [C]. O 

Constitutive [C]C [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
PI3-K [C]P [C]I [C]3 [C]- [C]K O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
is [C]i [C]s O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
for [C]f [C]o [C]r O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
survival [C]s [C]u [C]r [C]v [C]i [C]v [C]a [C]l O 
, [C], O 
of [C]o [C]f O 
Theileria [C]T [C]h [C]e [C]i [C]l [C]e [C]r [C]i [C]a B-cell_type 
parva-transformed [C]p [C]a [C]r [C]v [C]a [C]- [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]e [C]d I-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Theileria [C]T [C]h [C]e [C]i [C]l [C]e [C]r [C]i [C]a O 
is [C]i [C]s O 
an [C]a [C]n O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
parasite [C]p [C]a [C]r [C]a [C]s [C]i [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
causes [C]c [C]a [C]u [C]s [C]e [C]s O 
lymphoproliferative [C]l [C]y [C]m [C]p [C]h [C]o [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
disorders [C]d [C]i [C]s [C]o [C]r [C]d [C]e [C]r [C]s O 
in [C]i [C]n O 
cattle [C]c [C]a [C]t [C]t [C]l [C]e O 
, [C], O 
and [C]a [C]n [C]d O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
leucocytes [C]l [C]e [C]u [C]c [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
a [C]a O 
transformed [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]e [C]d O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
to [C]t [C]o O 
tumour [C]t [C]u [C]m [C]o [C]u [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
but [C]b [C]u [C]t O 
the [C]t [C]h [C]e O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
by [C]b [C]y O 
which [C]w [C]h [C]i [C]c [C]h O 
the [C]t [C]h [C]e O 
parasite [C]p [C]a [C]r [C]a [C]s [C]i [C]t [C]e O 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
this [C]t [C]h [C]i [C]s O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
are [C]a [C]r [C]e O 
not [C]n [C]o [C]t O 
understood [C]u [C]n [C]d [C]e [C]r [C]s [C]t [C]o [C]o [C]d O 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
, [C], O 
we [C]w [C]e O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
infected [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d B-cell_type 
B [C]B I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
display [C]d [C]i [C]s [C]p [C]l [C]a [C]y O 
constitutive [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
phosphoinositide [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]i [C]n [C]o [C]s [C]i [C]t [C]i [C]d [C]e O 
3-kinase [C]3 [C]- [C]k [C]i [C]n [C]a [C]s [C]e O 
( [C]( O 
PI3-K [C]P [C]I [C]3 [C]- [C]K O 
) [C]) O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
appears [C]a [C]p [C]p [C]e [C]a [C]r [C]s O 
to [C]t [C]o O 
be [C]b [C]e O 
necessary [C]n [C]e [C]c [C]e [C]s [C]s [C]a [C]r [C]y O 
for [C]f [C]o [C]r O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
survival [C]s [C]u [C]r [C]v [C]i [C]v [C]a [C]l O 
. [C]. O 

Importantly [C]I [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t [C]l [C]y O 
, [C], O 
we [C]w [C]e O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
one [C]o [C]n [C]e O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
by [C]b [C]y O 
which [C]w [C]h [C]i [C]c [C]h O 
PI3-K [C]P [C]I [C]3 [C]- [C]K S-protein 
mediates [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]s O 
the [C]t [C]h [C]e O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
infected [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d B-cell_type 
B [C]B I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
is [C]i [C]s O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
granulocyte-monocyte [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e [C]- [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e B-protein 
colony-stimulating [C]c [C]o [C]l [C]o [C]n [C]y [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]n [C]g I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
( [C]( O 
GM-CSF [C]G [C]M [C]- [C]C [C]S [C]F S-protein 
) [C]) O 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
autocrine [C]a [C]u [C]t [C]o [C]c [C]r [C]i [C]n [C]e O 
loop [C]l [C]o [C]o [C]p O 
. [C]. O 

PI3-K [C]P [C]I [C]3 [C]- [C]K S-protein 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
GM-CSF [C]G [C]M [C]- [C]C [C]S [C]F S-protein 
appears [C]a [C]p [C]p [C]e [C]a [C]r [C]s O 
to [C]t [C]o O 
be [C]b [C]e O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
level [C]l [C]e [C]v [C]e [C]l O 
and [C]a [C]n [C]d O 
, [C], O 
consistently [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]t [C]l [C]y O 
, [C], O 
we [C]w [C]e O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
PI3-K [C]P [C]I [C]3 [C]- [C]K S-protein 
is [C]i [C]s O 
also [C]a [C]l [C]s [C]o O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
constitutive [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
and [C]a [C]n [C]d O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
characterizes [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]s O 
Theileria-infected [C]T [C]h [C]e [C]i [C]l [C]e [C]r [C]i [C]a [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
leucocytes [C]l [C]e [C]u [C]c [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
. [C]. O 

Taken [C]T [C]a [C]k [C]e [C]n O 
together [C]t [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
, [C], O 
our [C]o [C]u [C]r O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
highlight [C]h [C]i [C]g [C]h [C]l [C]i [C]g [C]h [C]t O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
strategy [C]s [C]t [C]r [C]a [C]t [C]e [C]g [C]y O 
exploited [C]e [C]x [C]p [C]l [C]o [C]i [C]t [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
parasite [C]p [C]a [C]r [C]a [C]s [C]i [C]t [C]e O 
Theileria [C]T [C]h [C]e [C]i [C]l [C]e [C]r [C]i [C]a O 
to [C]t [C]o O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
continued [C]c [C]o [C]n [C]t [C]i [C]n [C]u [C]e [C]d O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
its [C]i [C]t [C]s O 
host [C]h [C]o [C]s [C]t B-cell_type 
leucocyte [C]l [C]e [C]u [C]c [C]o [C]c [C]y [C]t [C]e E-cell_type 
. [C]. O 

Lymphokine [C]L [C]y [C]m [C]p [C]h [C]o [C]k [C]i [C]n [C]e S-protein 
dependence [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
STAT3 [C]S [C]T [C]A [C]T [C]3 O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
produced [C]p [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n O 
cross-linking [C]c [C]r [C]o [C]s [C]s [C]- [C]l [C]i [C]n [C]k [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
by [C]b [C]y O 
phorbol [C]p [C]h [C]o [C]r [C]b [C]o [C]l O 
ester [C]e [C]s [C]t [C]e [C]r O 
plus [C]p [C]l [C]u [C]s O 
calcium [C]c [C]a [C]l [C]c [C]i [C]u [C]m O 
ionophore [C]i [C]o [C]n [C]o [C]p [C]h [C]o [C]r [C]e O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
in [C]i [C]n O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Stimulation [C]S [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
by [C]b [C]y O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e B-protein 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n E-protein 
( [C]( O 
sIg [C]s [C]I [C]g S-protein 
) [C]) O 
triggering [C]t [C]r [C]i [C]g [C]g [C]e [C]r [C]i [C]n [C]g O 
, [C], O 
or [C]o [C]r O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
mitogenic [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]i [C]c O 
combination [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
phorbol [C]p [C]h [C]o [C]r [C]b [C]o [C]l O 
ester [C]e [C]s [C]t [C]e [C]r O 
and [C]a [C]n [C]d O 
calcium [C]c [C]a [C]l [C]c [C]i [C]u [C]m O 
ionophore [C]i [C]o [C]n [C]o [C]p [C]h [C]o [C]r [C]e O 
, [C], O 
is [C]i [C]s O 
accompanied [C]a [C]c [C]c [C]o [C]m [C]p [C]a [C]n [C]i [C]e [C]d O 
by [C]b [C]y O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
STAT [C]S [C]T [C]A [C]T B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
responsible [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]b [C]l [C]e O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
delayed [C]d [C]e [C]l [C]a [C]y [C]e [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
accumulation [C]a [C]c [C]c [C]u [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
phosphorylated [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]e [C]d B-protein 
STAT3 [C]S [C]T [C]A [C]T [C]3 E-protein 
was [C]w [C]a [C]s O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
in [C]i [C]n O 
detail [C]d [C]e [C]t [C]a [C]i [C]l O 
, [C], O 
focusing [C]f [C]o [C]c [C]u [C]s [C]i [C]n [C]g O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
B [C]B B-protein 
cell-derived [C]c [C]e [C]l [C]l [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d I-protein 
lymphokines [C]l [C]y [C]m [C]p [C]h [C]o [C]k [C]i [C]n [C]e [C]s E-protein 
. [C]. O 

sIg [C]s [C]I [C]g S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
STAT3 [C]S [C]T [C]A [C]T [C]3 S-protein 
was [C]w [C]a [C]s O 
partially [C]p [C]a [C]r [C]t [C]i [C]a [C]l [C]l [C]y O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
in [C]i [C]n O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
IL-6- [C]I [C]L [C]- [C]6 [C]- O 
or [C]o [C]r O 
IL-10-deficient [C]I [C]L [C]- [C]1 [C]0 [C]- [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
mice [C]m [C]i [C]c [C]e O 
, [C], O 
and [C]a [C]n [C]d O 
was [C]w [C]a [C]s O 
partially [C]p [C]a [C]r [C]t [C]i [C]a [C]l [C]l [C]y O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
by [C]b [C]y O 
neutralizing [C]n [C]e [C]u [C]t [C]r [C]a [C]l [C]i [C]z [C]i [C]n [C]g B-protein 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s E-protein 
directed [C]d [C]i [C]r [C]e [C]c [C]t [C]e [C]d O 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
lymphokines [C]l [C]y [C]m [C]p [C]h [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
. [C]. O 

sIg [C]s [C]I [C]g S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
STAT3 [C]S [C]T [C]A [C]T [C]3 O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
completely [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e [C]l [C]y O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
by [C]b [C]y O 
combining [C]c [C]o [C]m [C]b [C]i [C]n [C]i [C]n [C]g O 
IL-6- [C]I [C]L [C]- [C]6 [C]- B-protein 
and [C]a [C]n [C]d I-protein 
IL-10-specific [C]I [C]L [C]- [C]1 [C]0 [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-protein 
neutralizing [C]n [C]e [C]u [C]t [C]r [C]a [C]l [C]i [C]z [C]i [C]n [C]g I-protein 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s E-protein 
, [C], O 
or [C]o [C]r O 
by [C]b [C]y O 
adding [C]a [C]d [C]d [C]i [C]n [C]g O 
individual [C]i [C]n [C]d [C]i [C]v [C]i [C]d [C]u [C]a [C]l O 
neutralizing [C]n [C]e [C]u [C]t [C]r [C]a [C]l [C]i [C]z [C]i [C]n [C]g B-protein 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s E-protein 
to [C]t [C]o O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
lymphokine-deficient [C]l [C]y [C]m [C]p [C]h [C]o [C]k [C]i [C]n [C]e [C]- [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
animals [C]a [C]n [C]i [C]m [C]a [C]l [C]s O 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
IL-10 [C]I [C]L [C]- [C]1 [C]0 S-protein 
alone [C]a [C]l [C]o [C]n [C]e O 
appeared [C]a [C]p [C]p [C]e [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
account [C]a [C]c [C]c [C]o [C]u [C]n [C]t O 
for [C]f [C]o [C]r O 
STAT3 [C]S [C]T [C]A [C]T [C]3 O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
resulting [C]r [C]e [C]s [C]u [C]l [C]t [C]i [C]n [C]g O 
from [C]f [C]r [C]o [C]m O 
B [C]B O 
cell [C]c [C]e [C]l [C]l O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
phorbol [C]p [C]h [C]o [C]r [C]b [C]o [C]l O 
ester [C]e [C]s [C]t [C]e [C]r O 
and [C]a [C]n [C]d O 
calcium [C]c [C]a [C]l [C]c [C]i [C]u [C]m O 
ionophore [C]i [C]o [C]n [C]o [C]p [C]h [C]o [C]r [C]e O 
. [C]. O 

In [C]I [C]n O 
keeping [C]k [C]e [C]e [C]p [C]i [C]n [C]g O 
with [C]w [C]i [C]t [C]h O 
these [C]t [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
, [C], O 
soluble [C]s [C]o [C]l [C]u [C]b [C]l [C]e O 
IL-6 [C]I [C]L [C]- [C]6 S-protein 
and [C]a [C]n [C]d O 
IL-10 [C]I [C]L [C]- [C]1 [C]0 S-protein 
were [C]w [C]e [C]r [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
supernatant [C]s [C]u [C]p [C]e [C]r [C]n [C]a [C]t [C]a [C]n [C]t O 
fluid [C]f [C]l [C]u [C]i [C]d O 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
work [C]w [C]o [C]r [C]k O 
indicates [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e [C]s O 
that [C]t [C]h [C]a [C]t O 
a [C]a O 
lymphokine [C]l [C]y [C]m [C]p [C]h [C]o [C]k [C]i [C]n [C]e O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
is [C]i [C]s O 
responsible [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]b [C]l [C]e O 
for [C]f [C]o [C]r O 
STAT3 [C]S [C]T [C]A [C]T [C]3 O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
that [C]t [C]h [C]a [C]t O 
occurs [C]o [C]c [C]c [C]u [C]r [C]s O 
late [C]l [C]a [C]t [C]e O 
after [C]a [C]f [C]t [C]e [C]r O 
B [C]B O 
cell [C]c [C]e [C]l [C]l O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
points [C]p [C]o [C]i [C]n [C]t [C]s O 
out [C]o [C]u [C]t O 
differences [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e [C]s O 
in [C]i [C]n O 
B [C]B O 
cell [C]c [C]e [C]l [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
that [C]t [C]h [C]a [C]t O 
result [C]r [C]e [C]s [C]u [C]l [C]t O 
from [C]f [C]r [C]o [C]m O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
and [C]a [C]n [C]d O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
pharmacological [C]p [C]h [C]a [C]r [C]m [C]a [C]c [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
mimicry [C]m [C]i [C]m [C]i [C]c [C]r [C]y O 
of [C]o [C]f O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g B-protein 
mediators [C]m [C]e [C]d [C]i [C]a [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

Transcription [C]T [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
AP-4 [C]A [C]P [C]- [C]4 E-protein 
is [C]i [C]s O 
a [C]a O 
ligand [C]l [C]i [C]g [C]a [C]n [C]d S-protein 
for [C]f [C]o [C]r O 
immunoglobulin-kappa [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n [C]- [C]k [C]a [C]p [C]p [C]a B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r I-DNA 
E-box [C]E [C]- [C]b [C]o [C]x I-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
. [C]. O 

Immunoglobulin [C]I [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n B-DNA 
( [C]( I-DNA 
Ig [C]I [C]g I-DNA 
) [C]) I-DNA 
-kappa [C]- [C]k [C]a [C]p [C]p [C]a I-DNA 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s E-DNA 
from [C]f [C]r [C]o [C]m O 
humans [C]h [C]u [C]m [C]a [C]n [C]s O 
and [C]a [C]n [C]d O 
mice [C]m [C]i [C]c [C]e O 
share [C]s [C]h [C]a [C]r [C]e O 
conserved [C]c [C]o [C]n [C]s [C]e [C]r [C]v [C]e [C]d B-DNA 
sequences [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s E-DNA 
. [C]. O 

The [C]T [C]h [C]e O 
octamer [C]o [C]c [C]t [C]a [C]m [C]e [C]r B-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
is [C]i [C]s O 
common [C]c [C]o [C]m [C]m [C]o [C]n O 
to [C]t [C]o O 
all [C]a [C]l [C]l O 
Ig [C]I [C]g B-DNA 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s E-DNA 
and [C]a [C]n [C]d O 
pivotal [C]p [C]i [C]v [C]o [C]t [C]a [C]l O 
for [C]f [C]o [C]r O 
their [C]t [C]h [C]e [C]i [C]r O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
other [C]o [C]t [C]h [C]e [C]r O 
conserved [C]c [C]o [C]n [C]s [C]e [C]r [C]v [C]e [C]d B-DNA 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e I-DNA 
motifs [C]m [C]o [C]t [C]i [C]f [C]s E-DNA 
, [C], O 
that [C]t [C]h [C]a [C]t O 
differ [C]d [C]i [C]f [C]f [C]e [C]r O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
Ig [C]I [C]g B-DNA 
variable [C]v [C]a [C]r [C]i [C]a [C]b [C]l [C]e I-DNA 
gene [C]g [C]e [C]n [C]e I-DNA 
families [C]f [C]a [C]m [C]i [C]l [C]i [C]e [C]s E-DNA 
, [C], O 
are [C]a [C]r [C]e O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
conserved [C]c [C]o [C]n [C]s [C]e [C]r [C]v [C]e [C]d O 
motifs [C]m [C]o [C]t [C]i [C]f [C]s O 
do [C]d [C]o O 
not [C]n [C]o [C]t O 
stimulate [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
an [C]a [C]n O 
octamer [C]o [C]c [C]t [C]a [C]m [C]e [C]r S-DNA 
. [C]. O 

One [C]O [C]n [C]e O 
example [C]e [C]x [C]a [C]m [C]p [C]l [C]e O 
is [C]i [C]s O 
an [C]a [C]n O 
E-box [C]E [C]- [C]b [C]o [C]x S-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
E47/E12 [C]E [C]4 [C]7 [C]/ [C]E [C]1 [C]2 B-DNA 
type [C]t [C]y [C]p [C]e I-DNA 
( [C]( I-DNA 
5'-CAGCTG-3 [C]5 [C]' [C]- [C]C [C]A [C]G [C]C [C]T [C]G [C]- [C]3 I-DNA 
' [C]' I-DNA 
) [C]) E-DNA 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
all [C]a [C]l [C]l O 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
and [C]a [C]n [C]d I-DNA 
murine [C]m [C]u [C]r [C]i [C]n [C]e I-DNA 
Ig-kappa [C]I [C]g [C]- [C]k [C]a [C]p [C]p [C]a I-DNA 
gene [C]g [C]e [C]n [C]e I-DNA 
subgroups/families [C]s [C]u [C]b [C]g [C]r [C]o [C]u [C]p [C]s [C]/ [C]f [C]a [C]m [C]i [C]l [C]i [C]e [C]s E-DNA 
, [C], O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
exception [C]e [C]x [C]c [C]e [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
subgroups [C]s [C]u [C]b [C]g [C]r [C]o [C]u [C]p [C]s O 
II [C]I [C]I O 
and [C]a [C]n [C]d O 
VI [C]V [C]I O 
and [C]a [C]n [C]d O 
their [C]t [C]h [C]e [C]i [C]r O 
related [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
murine [C]m [C]u [C]r [C]i [C]n [C]e B-DNA 
families [C]f [C]a [C]m [C]i [C]l [C]i [C]e [C]s E-DNA 
. [C]. O 

In [C]I [C]n O 
the [C]t [C]h [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
study [C]s [C]t [C]u [C]d [C]y O 
we [C]w [C]e O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
ubiquitously [C]u [C]b [C]i [C]q [C]u [C]i [C]t [C]o [C]u [C]s [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
AP-4 [C]A [C]P [C]- [C]4 E-protein 
, [C], O 
and [C]a [C]n [C]d O 
not [C]n [C]o [C]t O 
E47 [C]E [C]4 [C]7 S-protein 
, [C], O 
interacts [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]s O 
specifically [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]a [C]l [C]l [C]y O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
kappa [C]k [C]a [C]p [C]p [C]a B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r I-DNA 
E-boxes [C]E [C]- [C]b [C]o [C]x [C]e [C]s E-DNA 
when [C]w [C]h [C]e [C]n O 
tested [C]t [C]e [C]s [C]t [C]e [C]d O 
in [C]i [C]n O 
electrophoretic [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c O 
mobility-shift [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y [C]- [C]s [C]h [C]i [C]f [C]t O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
using [C]u [C]s [C]i [C]n [C]g O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
derived [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
and [C]a [C]n [C]d I-cell_line 
murine [C]m [C]u [C]r [C]i [C]n [C]e I-cell_line 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
AP-4 [C]A [C]P [C]- [C]4 S-protein 
, [C], O 
unlike [C]u [C]n [C]l [C]i [C]k [C]e O 
E47 [C]E [C]4 [C]7 S-protein 
, [C], O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
act [C]a [C]c [C]t O 
as [C]a [C]s O 
a [C]a O 
transactivator [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r S-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
in [C]i [C]n O 
agreement [C]a [C]g [C]r [C]e [C]e [C]m [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
previous [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
on [C]o [C]n O 
intact [C]i [C]n [C]t [C]a [C]c [C]t O 
kappa [C]k [C]a [C]p [C]p [C]a B-DNA 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s E-DNA 
, [C], O 
showing [C]s [C]h [C]o [C]w [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
absent [C]a [C]b [C]s [C]e [C]n [C]t O 
when [C]w [C]h [C]e [C]n O 
the [C]t [C]h [C]e O 
octamer [C]o [C]c [C]t [C]a [C]m [C]e [C]r B-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
mutated [C]m [C]u [C]t [C]a [C]t [C]e [C]d O 
. [C]. O 

Based [C]B [C]a [C]s [C]e [C]d O 
on [C]o [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
, [C], O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
conservation [C]c [C]o [C]n [C]s [C]e [C]r [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
5'-CAGCTG-3 [C]5 [C]' [C]- [C]C [C]A [C]G [C]C [C]T [C]G [C]- [C]3 B-DNA 
' [C]' I-DNA 
motif [C]m [C]o [C]t [C]i [C]f E-DNA 
among [C]a [C]m [C]o [C]n [C]g O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
and [C]a [C]n [C]d I-DNA 
murine [C]m [C]u [C]r [C]i [C]n [C]e I-DNA 
kappa [C]k [C]a [C]p [C]p [C]a I-DNA 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s E-DNA 
, [C], O 
we [C]w [C]e O 
propose [C]p [C]r [C]o [C]p [C]o [C]s [C]e O 
that [C]t [C]h [C]a [C]t O 
AP-4 [C]A [C]P [C]- [C]4 S-protein 
is [C]i [C]s O 
the [C]t [C]h [C]e O 
major [C]m [C]a [C]j [C]o [C]r B-protein 
ligand [C]l [C]i [C]g [C]a [C]n [C]d E-protein 
for [C]f [C]o [C]r O 
Ig-kappa [C]I [C]g [C]- [C]k [C]a [C]p [C]p [C]a B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r I-DNA 
E-boxes [C]E [C]- [C]b [C]o [C]x [C]e [C]s E-DNA 
. [C]. O 

A [C]A O 
16-mer [C]1 [C]6 [C]- [C]m [C]e [C]r O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
( [C]( O 
RQIKIWFQNRRMKWKK [C]R [C]Q [C]I [C]K [C]I [C]W [C]F [C]Q [C]N [C]R [C]R [C]M [C]K [C]W [C]K [C]K O 
) [C]) O 
from [C]f [C]r [C]o [C]m O 
antennapedia [C]a [C]n [C]t [C]e [C]n [C]n [C]a [C]p [C]e [C]d [C]i [C]a O 
preferentially [C]p [C]r [C]e [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l [C]l [C]y O 
targets [C]t [C]a [C]r [C]g [C]e [C]t [C]s O 
the [C]t [C]h [C]e O 
Class [C]C [C]l [C]a [C]s [C]s O 
I [C]I O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
. [C]. O 

Translocation [C]T [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
antigenic [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]i [C]c O 
peptides [C]p [C]e [C]p [C]t [C]i [C]d [C]e [C]s O 
into [C]i [C]n [C]t [C]o O 
the [C]t [C]h [C]e O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
of [C]o [C]f O 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n B-cell_type 
presenting [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]i [C]n [C]g I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
facilitates [C]f [C]a [C]c [C]i [C]l [C]i [C]t [C]a [C]t [C]e [C]s O 
proteosomal [C]p [C]r [C]o [C]t [C]e [C]o [C]s [C]o [C]m [C]a [C]l O 
processing [C]p [C]r [C]o [C]c [C]e [C]s [C]s [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
loading [C]l [C]o [C]a [C]d [C]i [C]n [C]g O 
into [C]i [C]n [C]t [C]o O 
Class [C]C [C]l [C]a [C]s [C]s B-protein 
I [C]I I-protein 
molecules [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]s E-protein 
for [C]f [C]o [C]r O 
MHC [C]M [C]H [C]C O 
presentation [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
cell [C]c [C]e [C]l [C]l O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
DNA [C]D [C]N [C]A B-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Drosophila [C]D [C]r [C]o [C]s [C]o [C]p [C]h [C]i [C]l [C]a B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
( [C]( O 
Antennapedia [C]A [C]n [C]t [C]e [C]n [C]n [C]a [C]p [C]e [C]d [C]i [C]a S-protein 
) [C]) O 
, [C], O 
a [C]a O 
60 [C]6 [C]0 B-protein 
amino [C]a [C]m [C]i [C]n [C]o I-protein 
acid [C]a [C]c [C]i [C]d I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
, [C], O 
is [C]i [C]s O 
rapidly [C]r [C]a [C]p [C]i [C]d [C]l [C]y O 
taken [C]t [C]a [C]k [C]e [C]n O 
up [C]u [C]p O 
by [C]b [C]y O 
cells [C]c [C]e [C]l [C]l [C]s O 
and [C]a [C]n [C]d O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
fused [C]f [C]u [C]s [C]e [C]d O 
to [C]t [C]o O 
selected [C]s [C]e [C]l [C]e [C]c [C]t [C]e [C]d O 
antigens [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]s S-protein 
to [C]t [C]o O 
enhance [C]e [C]n [C]h [C]a [C]n [C]c [C]e O 
their [C]t [C]h [C]e [C]i [C]r O 
immunogenicity [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]e [C]n [C]i [C]c [C]i [C]t [C]y O 
. [C]. O 

We [C]W [C]e O 
now [C]n [C]o [C]w O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
a [C]a O 
16 [C]1 [C]6 O 
amino [C]a [C]m [C]i [C]n [C]o O 
acid [C]a [C]c [C]i [C]d O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
from [C]f [C]r [C]o [C]m O 
antennapedia [C]a [C]n [C]t [C]e [C]n [C]n [C]a [C]p [C]e [C]d [C]i [C]a O 
can [C]c [C]a [C]n O 
facilitate [C]f [C]a [C]c [C]i [C]l [C]i [C]t [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c O 
uptake [C]u [C]p [C]t [C]a [C]k [C]e O 
of [C]o [C]f O 
CTL [C]C [C]T [C]L O 
epitope [C]e [C]p [C]i [C]t [C]o [C]p [C]e O 
9-mer [C]9 [C]- [C]m [C]e [C]r O 
peptides [C]p [C]e [C]p [C]t [C]i [C]d [C]e [C]s O 
. [C]. O 

Synthetic [C]S [C]y [C]n [C]t [C]h [C]e [C]t [C]i [C]c O 
peptides [C]p [C]e [C]p [C]t [C]i [C]d [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
made [C]m [C]a [C]d [C]e O 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
16-mer [C]1 [C]6 [C]- [C]m [C]e [C]r O 
antennapedia [C]a [C]n [C]t [C]e [C]n [C]n [C]a [C]p [C]e [C]d [C]i [C]a O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
linked [C]l [C]i [C]n [C]k [C]e [C]d O 
in [C]i [C]n O 
tandem [C]t [C]a [C]n [C]d [C]e [C]m O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
ovalbumin [C]o [C]v [C]a [C]l [C]b [C]u [C]m [C]i [C]n O 
SIINFEKL [C]S [C]I [C]I [C]N [C]F [C]E [C]K [C]L O 
CTL [C]C [C]T [C]L O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
was [C]w [C]a [C]s O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
rapidly [C]r [C]a [C]p [C]i [C]d [C]l [C]y O 
internalise [C]i [C]n [C]t [C]e [C]r [C]n [C]a [C]l [C]i [C]s [C]e O 
into [C]i [C]n [C]t [C]o O 
APCs [C]A [C]P [C]C [C]s S-cell_type 
by [C]b [C]y O 
confocal [C]c [C]o [C]n [C]f [C]o [C]c [C]a [C]l O 
microscopy [C]m [C]i [C]c [C]r [C]o [C]s [C]c [C]o [C]p [C]y O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
CTL [C]C [C]T [C]L S-cell_type 
in [C]i [C]n O 
C57BL/6 [C]C [C]5 [C]7 [C]B [C]L [C]/ [C]6 O 
mice [C]m [C]i [C]c [C]e O 
and [C]a [C]n [C]d O 
protected [C]p [C]r [C]o [C]t [C]e [C]c [C]t [C]e [C]d O 
them [C]t [C]h [C]e [C]m O 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
of [C]o [C]f O 
an [C]a [C]n O 
ovalbumin [C]o [C]v [C]a [C]l [C]b [C]u [C]m [C]i [C]n B-cell_line 
expressing [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]n [C]g I-cell_line 
tumour [C]t [C]u [C]m [C]o [C]u [C]r I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
( [C]( O 
E.G7-OVA [C]E [C]. [C]G [C]7 [C]- [C]O [C]V [C]A S-cell_line 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
hybrid [C]h [C]y [C]b [C]r [C]i [C]d O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
to [C]t [C]o O 
be [C]b [C]e O 
processed [C]p [C]r [C]o [C]c [C]e [C]s [C]s [C]e [C]d O 
and [C]a [C]n [C]d O 
presented [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]e [C]d O 
by [C]b [C]y O 
APCs [C]A [C]P [C]C [C]s S-cell_type 
was [C]w [C]a [C]s O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
, [C], O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
the [C]t [C]h [C]e O 
SIINFEKL [C]S [C]I [C]I [C]N [C]F [C]E [C]K [C]L O 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
was [C]w [C]a [C]s O 
appended [C]a [C]p [C]p [C]e [C]n [C]d [C]e [C]d O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
C-terminus [C]C [C]- [C]t [C]e [C]r [C]m [C]i [C]n [C]u [C]s S-protein 
or [C]o [C]r O 
N-terminus [C]N [C]- [C]t [C]e [C]r [C]m [C]i [C]n [C]u [C]s S-protein 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Antennapedia [C]A [C]n [C]t [C]e [C]n [C]n [C]a [C]p [C]e [C]d [C]i [C]a O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
synthetic [C]s [C]y [C]n [C]t [C]h [C]e [C]t [C]i [C]c O 
peptides [C]p [C]e [C]p [C]t [C]i [C]d [C]e [C]s O 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
other [C]o [C]t [C]h [C]e [C]r O 
CTL [C]C [C]T [C]L O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
epitopes [C]e [C]p [C]i [C]t [C]o [C]p [C]e [C]s O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
useful [C]u [C]s [C]e [C]f [C]u [C]l O 
for [C]f [C]o [C]r O 
priming [C]p [C]r [C]i [C]m [C]i [C]n [C]g O 
CTLs [C]C [C]T [C]L [C]s S-cell_type 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 

Bone [C]B [C]o [C]n [C]e B-cell_type 
marrow [C]m [C]a [C]r [C]r [C]o [C]w I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
promote [C]p [C]r [C]o [C]m [C]o [C]t [C]e O 
TH2 [C]T [C]H [C]2 O 
polarization [C]p [C]o [C]l [C]a [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
inhibit [C]i [C]n [C]h [C]i [C]b [C]i [C]t O 
virus-specific [C]v [C]i [C]r [C]u [C]s [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
CTL [C]C [C]T [C]L O 
generation [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
laboratory [C]l [C]a [C]b [C]o [C]r [C]a [C]t [C]o [C]r [C]y O 
recently [C]r [C]e [C]c [C]e [C]n [C]t [C]l [C]y O 
reported [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
bone [C]b [C]o [C]n [C]e I-cell_type 
marrow [C]m [C]a [C]r [C]r [C]o [C]w I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
BMC [C]B [C]M [C]C S-cell_type 
) [C]) O 
inhibit [C]i [C]n [C]h [C]i [C]b [C]i [C]t O 
the [C]t [C]h [C]e O 
generation [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
virus-specific [C]v [C]i [C]r [C]u [C]s [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-cell_type 
CTL [C]C [C]T [C]L E-cell_type 
in [C]i [C]n O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
supernatants [C]s [C]u [C]p [C]e [C]r [C]n [C]a [C]t [C]a [C]n [C]t [C]s O 
contained [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]e [C]d O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
prostaglandin [C]p [C]r [C]o [C]s [C]t [C]a [C]g [C]l [C]a [C]n [C]d [C]i [C]n B-protein 
E [C]E I-protein 
( [C]( I-protein 
2 [C]2 I-protein 
) [C]) I-protein 
( [C]( I-protein 
PGE [C]P [C]G [C]E I-protein 
( [C]( I-protein 
2 [C]2 I-protein 
) [C]) I-protein 
) [C]) E-protein 
( [C]( O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
favor [C]f [C]a [C]v [C]o [C]r O 
TH2 [C]T [C]H [C]2 O 
cell [C]c [C]e [C]l [C]l O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
) [C]) O 
and [C]a [C]n [C]d O 
also [C]a [C]l [C]s [C]o O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
EBV-CTL [C]E [C]B [C]V [C]- [C]C [C]T [C]L O 
effector [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r O 
cell [C]c [C]e [C]l [C]l O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
, [C], O 
we [C]w [C]e O 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
PBL [C]P [C]B [C]L S-cell_type 
from [C]f [C]r [C]o [C]m O 
Epstein-Barr [C]E [C]p [C]s [C]t [C]e [C]i [C]n [C]- [C]B [C]a [C]r [C]r O 
virus [C]v [C]i [C]r [C]u [C]s O 
( [C]( O 
EBV [C]E [C]B [C]V O 
) [C]) O 
IgG [C]I [C]g [C]G B-protein 
antibody [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y E-protein 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
kidney [C]k [C]i [C]d [C]n [C]e [C]y O 
transplant [C]t [C]r [C]a [C]n [C]s [C]p [C]l [C]a [C]n [C]t O 
recipients [C]r [C]e [C]c [C]i [C]p [C]i [C]e [C]n [C]t [C]s O 
( [C]( O 
R [C]R O 
) [C]) O 
and [C]a [C]n [C]d O 
their [C]t [C]h [C]e [C]i [C]r O 
living-related [C]l [C]i [C]v [C]i [C]n [C]g [C]- [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
donors [C]d [C]o [C]n [C]o [C]r [C]s O 
( [C]( O 
LRD [C]L [C]R [C]D O 
) [C]) O 
one [C]o [C]n [C]e O 
year [C]y [C]e [C]a [C]r O 
after [C]a [C]f [C]t [C]e [C]r O 
renal [C]r [C]e [C]n [C]a [C]l O 
transplantation [C]t [C]r [C]a [C]n [C]s [C]p [C]l [C]a [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

EBV-specific [C]E [C]B [C]V [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-cell_type 
CTL [C]C [C]T [C]L E-cell_type 
were [C]w [C]e [C]r [C]e O 
then [C]t [C]h [C]e [C]n O 
generated [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
by [C]b [C]y O 
stimulating [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
PBL [C]P [C]B [C]L S-cell_type 
with [C]w [C]i [C]t [C]h O 
autologous [C]a [C]u [C]t [C]o [C]l [C]o [C]g [C]o [C]u [C]s O 
EBV-transformed [C]E [C]B [C]V [C]- [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]e [C]d B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
EBV-B [C]E [C]B [C]V [C]- [C]B S-cell_type 
) [C]) O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
or [C]o [C]r O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
autologous [C]a [C]u [C]t [C]o [C]l [C]o [C]g [C]o [C]u [C]s B-cell_type 
BMC [C]B [C]M [C]C E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
BMC [C]B [C]M [C]C S-cell_type 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
EBV-CTL [C]E [C]B [C]V [C]- [C]C [C]T [C]L B-cell_type 
generation [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]i [C]o [C]n I-cell_type 
cultures [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]s E-cell_type 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
CD3+ [C]C [C]D [C]3 [C]+ B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
of [C]o [C]f O 
IL-4 [C]I [C]L [C]- [C]4 B-protein 
, [C], I-protein 
-5 [C]- [C]5 I-protein 
, [C], I-protein 
-6 [C]- [C]6 I-protein 
, [C], I-protein 
-10 [C]- [C]1 [C]0 I-protein 
, [C], I-protein 
and [C]a [C]n [C]d I-protein 
-13 [C]- [C]1 [C]3 E-protein 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
CD3+ [C]C [C]D [C]3 [C]+ B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
also [C]a [C]l [C]s [C]o O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
TH2 [C]T [C]H [C]2 B-protein 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
CCR3 [C]C [C]C [C]R [C]3 E-protein 
. [C]. O 

Inhibition [C]I [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
even [C]e [C]v [C]e [C]n O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
by [C]b [C]y O 
preparing [C]p [C]r [C]e [C]p [C]a [C]r [C]i [C]n [C]g O 
EBV-CTL [C]E [C]B [C]V [C]- [C]C [C]T [C]L B-cell_type 
generating [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]i [C]n [C]g I-cell_type 
cultures [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]s E-cell_type 
in [C]i [C]n O 
trans-wells [C]t [C]r [C]a [C]n [C]s [C]- [C]w [C]e [C]l [C]l [C]s O 
that [C]t [C]h [C]a [C]t O 
separated [C]s [C]e [C]p [C]a [C]r [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
autologous [C]a [C]u [C]t [C]o [C]l [C]o [C]g [C]o [C]u [C]s B-cell_type 
BMC [C]B [C]M [C]C E-cell_type 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
PBL [C]P [C]B [C]L S-cell_type 
+ [C]+ O 
EBV-B [C]E [C]B [C]V [C]- [C]B S-cell_type 
. [C]. O 

It [C]I [C]t O 
was [C]w [C]a [C]s O 
then [C]t [C]h [C]e [C]n O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
CD3+ [C]C [C]D [C]3 [C]+ B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
after [C]a [C]f [C]t [C]e [C]r O 
7 [C]7 O 
days [C]d [C]a [C]y [C]s O 
of [C]o [C]f O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
autologous [C]a [C]u [C]t [C]o [C]l [C]o [C]g [C]o [C]u [C]s B-cell_type 
BMC [C]B [C]M [C]C E-cell_type 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
used [C]u [C]s [C]e [C]d O 
as [C]a [C]s O 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
of [C]o [C]f O 
EBV-CTL [C]E [C]B [C]V [C]- [C]C [C]T [C]L O 
generation [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Protein [C]P [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
Kinase [C]K [C]i [C]n [C]a [C]s [C]e I-protein 
A [C]A E-protein 
( [C]( O 
PKA [C]P [C]K [C]A S-protein 
) [C]) O 
, [C], O 
a [C]a O 
cAMP [C]c [C]A [C]M [C]P B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
upregulation [C]u [C]p [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
TH2 [C]T [C]H [C]2 B-protein 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e E-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
, [C], O 
was [C]w [C]a [C]s O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
in [C]i [C]n O 
EBV-CTL [C]E [C]B [C]V [C]- [C]C [C]T [C]L B-cell_type 
cultures [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]s E-cell_type 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
BMC [C]B [C]M [C]C S-cell_type 
. [C]. O 

Additionally [C]A [C]d [C]d [C]i [C]t [C]i [C]o [C]n [C]a [C]l [C]l [C]y O 
, [C], O 
IL-4-mediated [C]I [C]L [C]- [C]4 [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
( [C]( O 
STAT-6 [C]S [C]T [C]A [C]T [C]- [C]6 S-protein 
) [C]) O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
slightly [C]s [C]l [C]i [C]g [C]h [C]t [C]l [C]y O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
BMC [C]B [C]M [C]C S-cell_type 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
soluble [C]s [C]o [C]l [C]u [C]b [C]l [C]e B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
( [C]( O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
cell-cell [C]c [C]e [C]l [C]l [C]- [C]c [C]e [C]l [C]l O 
contact [C]c [C]o [C]n [C]t [C]a [C]c [C]t O 
in [C]i [C]n O 
this [C]t [C]h [C]i [C]s O 
autologous [C]a [C]u [C]t [C]o [C]l [C]o [C]g [C]o [C]u [C]s O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
is [C]i [C]s O 
not [C]n [C]o [C]t O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
, [C], O 
so [C]s [C]o O 
that [C]t [C]h [C]a [C]t O 
BMC [C]B [C]M [C]C S-cell_type 
( [C]( O 
at [C]a [C]t O 
least [C]l [C]e [C]a [C]s [C]t O 
partially [C]p [C]a [C]r [C]t [C]i [C]a [C]l [C]l [C]y O 
, [C], O 
via [C]v [C]i [C]a O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
) [C]) O 
promote [C]p [C]r [C]o [C]m [C]o [C]t [C]e O 
TH2 [C]T [C]H [C]2 O 
polarization [C]p [C]o [C]l [C]a [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
. [C]. O 

Moreover [C]M [C]o [C]r [C]e [C]o [C]v [C]e [C]r O 
, [C], O 
TH2 [C]T [C]H [C]2 B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
culturing [C]c [C]u [C]l [C]t [C]u [C]r [C]i [C]n [C]g O 
with [C]w [C]i [C]t [C]h O 
autologous [C]a [C]u [C]t [C]o [C]l [C]o [C]g [C]o [C]u [C]s B-cell_type 
BMC [C]B [C]M [C]C E-cell_type 
directly [C]d [C]i [C]r [C]e [C]c [C]t [C]l [C]y O 
inhibit [C]i [C]n [C]h [C]i [C]b [C]i [C]t O 
EBV-CTL [C]E [C]B [C]V [C]- [C]C [C]T [C]L O 
generation [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
TH2 [C]T [C]H [C]2 S-protein 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
PKA [C]P [C]K [C]A S-protein 
, [C], O 
CCR3 [C]C [C]C [C]R [C]3 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
STAT-6 [C]S [C]T [C]A [C]T [C]- [C]6 S-protein 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
are [C]a [C]r [C]e O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
by [C]b [C]y O 
BMC [C]B [C]M [C]C S-cell_type 
. [C]. O 

Reduction [C]R [C]e [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
Pax-5a [C]P [C]a [C]x [C]- [C]5 [C]a S-protein 
in [C]i [C]n O 
B [C]B B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
of [C]o [C]f O 
aged [C]a [C]g [C]e [C]d O 
mice [C]m [C]i [C]c [C]e O 
. [C]. O 

Aging [C]A [C]g [C]i [C]n [C]g O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
intrinsic [C]i [C]n [C]t [C]r [C]i [C]n [C]s [C]i [C]c O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
humoral [C]h [C]u [C]m [C]o [C]r [C]a [C]l O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
may [C]m [C]a [C]y O 
lead [C]l [C]e [C]a [C]d O 
to [C]t [C]o O 
an [C]a [C]n O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
occurrence [C]o [C]c [C]c [C]u [C]r [C]r [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
autoimmune [C]a [C]u [C]t [C]o [C]i [C]m [C]m [C]u [C]n [C]e O 
disorders [C]d [C]i [C]s [C]o [C]r [C]d [C]e [C]r [C]s O 
and [C]a [C]n [C]d O 
pathogenic [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]i [C]c O 
susceptibility [C]s [C]u [C]s [C]c [C]e [C]p [C]t [C]i [C]b [C]i [C]l [C]i [C]t [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
Pax-5 [C]P [C]a [C]x [C]- [C]5 S-protein 
is [C]i [C]s O 
a [C]a O 
key [C]k [C]e [C]y O 
regulator [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r O 
of [C]o [C]f O 
B [C]B O 
cell [C]c [C]e [C]l [C]l O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
. [C]. O 

Pax-5a/B [C]P [C]a [C]x [C]- [C]5 [C]a [C]/ [C]B B-protein 
cell-specific [C]c [C]e [C]l [C]l [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-protein 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
and [C]a [C]n [C]d O 
an [C]a [C]n O 
alternatively [C]a [C]l [C]t [C]e [C]r [C]n [C]a [C]t [C]i [C]v [C]e [C]l [C]y B-protein 
spliced [C]s [C]p [C]l [C]i [C]c [C]e [C]d I-protein 
isoform [C]i [C]s [C]o [C]f [C]o [C]r [C]m I-protein 
, [C], I-protein 
Pax-5d [C]P [C]a [C]x [C]- [C]5 [C]d E-protein 
, [C], O 
may [C]m [C]a [C]y O 
have [C]h [C]a [C]v [C]e O 
opposing [C]o [C]p [C]p [C]o [C]s [C]i [C]n [C]g O 
functions [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
due [C]d [C]u [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
lack [C]l [C]a [C]c [C]k O 
of [C]o [C]f O 
a [C]a O 
transactivation [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n B-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
in [C]i [C]n O 
Pax-5d [C]P [C]a [C]x [C]- [C]5 [C]d S-protein 
. [C]. O 

To [C]T [C]o O 
study [C]s [C]t [C]u [C]d [C]y O 
B [C]B B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
-specific [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
that [C]t [C]h [C]a [C]t O 
occur [C]o [C]c [C]c [C]u [C]r O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
aging [C]a [C]g [C]i [C]n [C]g O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
, [C], O 
we [C]w [C]e O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
patterns [C]p [C]a [C]t [C]t [C]e [C]r [C]n [C]s O 
of [C]o [C]f O 
Pax-5a [C]P [C]a [C]x [C]- [C]5 [C]a B-protein 
and [C]a [C]n [C]d I-protein 
5d [C]5 [C]d E-protein 
in [C]i [C]n O 
mature [C]m [C]a [C]t [C]u [C]r [C]e B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
of [C]o [C]f O 
young [C]y [C]o [C]u [C]n [C]g O 
and [C]a [C]n [C]d O 
aged [C]a [C]g [C]e [C]d O 
mice [C]m [C]i [C]c [C]e O 
. [C]. O 

RNase [C]R [C]N [C]a [C]s [C]e O 
protection [C]p [C]r [C]o [C]t [C]e [C]c [C]t [C]i [C]o [C]n O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
a [C]a O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
pattern [C]p [C]a [C]t [C]t [C]e [C]r [C]n O 
for [C]f [C]o [C]r O 
both [C]b [C]o [C]t [C]h O 
age [C]a [C]g [C]e O 
groups [C]g [C]r [C]o [C]u [C]p [C]s O 
that [C]t [C]h [C]a [C]t O 
indicates [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e [C]s O 
that [C]t [C]h [C]a [C]t O 
aging [C]a [C]g [C]i [C]n [C]g O 
has [C]h [C]a [C]s O 
no [C]n [C]o O 
affect [C]a [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
initiation [C]i [C]n [C]i [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
or [C]o [C]r O 
alternative [C]a [C]l [C]t [C]e [C]r [C]n [C]a [C]t [C]i [C]v [C]e O 
splicing [C]s [C]p [C]l [C]i [C]c [C]i [C]n [C]g O 
for [C]f [C]o [C]r O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
isoform [C]i [C]s [C]o [C]f [C]o [C]r [C]m S-protein 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
a [C]a O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
reduction [C]r [C]e [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
Pax-5a [C]P [C]a [C]x [C]- [C]5 [C]a S-protein 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
Pax-5d [C]P [C]a [C]x [C]- [C]5 [C]d S-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
aged [C]a [C]g [C]e [C]d B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
, [C], O 
while [C]w [C]h [C]i [C]l [C]e O 
Western [C]W [C]e [C]s [C]t [C]e [C]r [C]n O 
blot [C]b [C]l [C]o [C]t O 
analyses [C]a [C]n [C]a [C]l [C]y [C]s [C]e [C]s O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
Pax-5a [C]P [C]a [C]x [C]- [C]5 [C]a B-protein 
and [C]a [C]n [C]d I-protein 
5d [C]5 [C]d E-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s O 
were [C]w [C]e [C]r [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
age [C]a [C]g [C]e O 
groups [C]g [C]r [C]o [C]u [C]p [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
Pax-5a [C]P [C]a [C]x [C]- [C]5 [C]a S-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
in [C]i [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
two [C]t [C]w [C]o O 
Pax-5 [C]P [C]a [C]x [C]- [C]5 B-DNA 
target [C]t [C]a [C]r [C]g [C]e [C]t I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
in [C]i [C]n O 
aged [C]a [C]g [C]e [C]d B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Expression [C]E [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Ig [C]I [C]g B-protein 
J [C]J I-protein 
chain [C]c [C]h [C]a [C]i [C]n E-protein 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
secreted [C]s [C]e [C]c [C]r [C]e [C]t [C]e [C]d O 
form [C]f [C]o [C]r [C]m O 
of [C]o [C]f O 
Ig [C]I [C]g B-protein 
mu [C]m [C]u E-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
are [C]a [C]r [C]e O 
both [C]b [C]o [C]t [C]h O 
known [C]k [C]n [C]o [C]w [C]n O 
to [C]t [C]o O 
be [C]b [C]e O 
suppressed [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
by [C]b [C]y O 
Pax-5a [C]P [C]a [C]x [C]- [C]5 [C]a S-protein 
in [C]i [C]n O 
mature [C]m [C]a [C]t [C]u [C]r [C]e B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
were [C]w [C]e [C]r [C]e O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
in [C]i [C]n O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
of [C]o [C]f O 
aged [C]a [C]g [C]e [C]d O 
mice [C]m [C]i [C]c [C]e O 
. [C]. O 

Together [C]T [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
, [C], O 
our [C]o [C]u [C]r O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
aging [C]a [C]g [C]i [C]n [C]g O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
cause [C]c [C]a [C]u [C]s [C]e O 
posttranslational [C]p [C]o [C]s [C]t [C]t [C]r [C]a [C]n [C]s [C]l [C]a [C]t [C]i [C]o [C]n [C]a [C]l O 
modification [C]m [C]o [C]d [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
( [C]( O 
s [C]s O 
) [C]) O 
of [C]o [C]f O 
Pax-5a [C]P [C]a [C]x [C]- [C]5 [C]a S-protein 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
Pax-5d [C]P [C]a [C]x [C]- [C]5 [C]d S-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
may [C]m [C]a [C]y O 
lead [C]l [C]e [C]a [C]d O 
to [C]t [C]o O 
an [C]a [C]n O 
abnormal [C]a [C]b [C]n [C]o [C]r [C]m [C]a [C]l O 
B [C]B O 
cell [C]c [C]e [C]l [C]l O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
in [C]i [C]n O 
aged [C]a [C]g [C]e [C]d O 
mice [C]m [C]i [C]c [C]e O 
, [C], O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
elevated [C]e [C]l [C]e [C]v [C]a [C]t [C]e [C]d O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
J [C]J B-protein 
chain [C]c [C]h [C]a [C]i [C]n E-protein 
, [C], O 
and [C]a [C]n [C]d O 
secretion [C]s [C]e [C]c [C]r [C]e [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IgM [C]I [C]g [C]M S-protein 

NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B/Rel [C]B [C]/ [C]R [C]e [C]l E-protein 
participation [C]p [C]a [C]r [C]t [C]i [C]c [C]i [C]p [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
lymphokine-dependent [C]l [C]y [C]m [C]p [C]h [C]o [C]k [C]i [C]n [C]e [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
T [C]T B-cell_type 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Proliferative [C]P [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
of [C]o [C]f O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
to [C]t [C]o O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
and [C]a [C]n [C]d O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
depend [C]d [C]e [C]p [C]e [C]n [C]d O 
on [C]o [C]n O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
, [C], O 
but [C]b [C]u [C]t O 
the [C]t [C]h [C]e O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
( [C]( O 
s [C]s O 
) [C]) O 
by [C]b [C]y O 
which [C]w [C]h [C]i [C]c [C]h O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
enhances [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]s O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
competence [C]c [C]o [C]m [C]p [C]e [C]t [C]e [C]n [C]c [C]e O 
to [C]t [C]o O 
respond [C]r [C]e [C]s [C]p [C]o [C]n [C]d O 
to [C]t [C]o O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
is [C]i [C]s O 
not [C]n [C]o [C]t O 
fully [C]f [C]u [C]l [C]l [C]y O 
understood [C]u [C]n [C]d [C]e [C]r [C]s [C]t [C]o [C]o [C]d O 
. [C]. O 

The [C]T [C]h [C]e O 
NF-kappaB/Rel [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B [C]/ [C]R [C]e [C]l B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y E-protein 
represents [C]r [C]e [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]s O 
one [C]o [C]n [C]e O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
such [C]s [C]u [C]c [C]h O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

We [C]W [C]e O 
show [C]s [C]h [C]o [C]w O 
in [C]i [C]n O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
that [C]t [C]h [C]a [C]t O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
an [C]a [C]n O 
IkappaBalpha [C]I [C]k [C]a [C]p [C]p [C]a [C]B [C]a [C]l [C]p [C]h [C]a S-protein 
( [C]( O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
that [C]t [C]h [C]a [C]t O 
dissociates [C]d [C]i [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]s O 
from [C]f [C]r [C]o [C]m O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
) [C]) O 
mutant [C]m [C]u [C]t [C]a [C]n [C]t O 
refractory [C]r [C]e [C]f [C]r [C]a [C]c [C]t [C]o [C]r [C]y O 
to [C]t [C]o O 
signal-induced [C]s [C]i [C]g [C]n [C]a [C]l [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
( [C]( O 
IkappaBalpha [C]I [C]k [C]a [C]p [C]p [C]a [C]B [C]a [C]l [C]p [C]h [C]a B-protein 
( [C]( I-protein 
DeltaN [C]D [C]e [C]l [C]t [C]a [C]N I-protein 
) [C]) E-protein 
) [C]) O 
interfered [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
acquisition [C]a [C]c [C]q [C]u [C]i [C]s [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
competence [C]c [C]o [C]m [C]p [C]e [C]t [C]e [C]n [C]c [C]e O 
to [C]t [C]o O 
proliferate [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]e O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
. [C]. O 

Thymocytes [C]T [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
and [C]a [C]n [C]d O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
IkappaBalpha [C]I [C]k [C]a [C]p [C]p [C]a [C]B [C]a [C]l [C]p [C]h [C]a B-protein 
( [C]( I-protein 
DeltaN [C]D [C]e [C]l [C]t [C]a [C]N I-protein 
) [C]) E-protein 
transgenic [C]t [C]r [C]a [C]n [C]s [C]g [C]e [C]n [C]i [C]c O 
mice [C]m [C]i [C]c [C]e O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
IL-2R [C]I [C]L [C]- [C]2 [C]R B-protein 
subunits [C]s [C]u [C]b [C]u [C]n [C]i [C]t [C]s E-protein 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
transgenic [C]t [C]r [C]a [C]n [C]s [C]g [C]e [C]n [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
exhibited [C]e [C]x [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
a [C]a O 
dramatic [C]d [C]r [C]a [C]m [C]a [C]t [C]i [C]c O 
defect [C]d [C]e [C]f [C]e [C]c [C]t O 
in [C]i [C]n O 
Stat5A [C]S [C]t [C]a [C]t [C]5 [C]A O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
a [C]a O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
defect [C]d [C]e [C]f [C]e [C]c [C]t O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
for [C]f [C]o [C]r O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
Stat5 [C]S [C]t [C]a [C]t [C]5 S-protein 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
T [C]T B-cell_type 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
with [C]w [C]i [C]t [C]h O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
insulin [C]i [C]n [C]s [C]u [C]l [C]i [C]n O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
substrate-2 [C]s [C]u [C]b [C]s [C]t [C]r [C]a [C]t [C]e [C]- [C]2 O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
only [C]o [C]n [C]l [C]y O 
a [C]a O 
modest [C]m [C]o [C]d [C]e [C]s [C]t O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
Stat6 [C]S [C]t [C]a [C]t [C]6 O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
insulin [C]i [C]n [C]s [C]u [C]l [C]i [C]n O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
substrate-1 [C]s [C]u [C]b [C]s [C]t [C]r [C]a [C]t [C]e [C]- [C]1 O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
after [C]a [C]f [C]t [C]e [C]r O 
IL-4 [C]I [C]L [C]- [C]4 O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
NF-kappaB/Rel/IkappaBalpha [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B [C]/ [C]R [C]e [C]l [C]/ [C]I [C]k [C]a [C]p [C]p [C]a [C]B [C]a [C]l [C]p [C]h [C]a O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
can [C]c [C]a [C]n O 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
capacitation [C]c [C]a [C]p [C]a [C]c [C]i [C]t [C]a [C]t [C]i [C]o [C]n O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
downstream [C]d [C]o [C]w [C]n [C]s [C]t [C]r [C]e [C]a [C]m O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
Stat [C]S [C]t [C]a [C]t B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y E-protein 
. [C]. O 

BMS-189453 [C]B [C]M [C]S [C]- [C]1 [C]8 [C]9 [C]4 [C]5 [C]3 O 
, [C], O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
retinoid [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]d O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
antagonist [C]a [C]n [C]t [C]a [C]g [C]o [C]n [C]i [C]s [C]t O 
, [C], O 
is [C]i [C]s O 
a [C]a O 
potent [C]p [C]o [C]t [C]e [C]n [C]t O 
testicular [C]t [C]e [C]s [C]t [C]i [C]c [C]u [C]l [C]a [C]r O 
toxin [C]t [C]o [C]x [C]i [C]n O 
. [C]. O 

BMS-189453 [C]B [C]M [C]S [C]- [C]1 [C]8 [C]9 [C]4 [C]5 [C]3 O 
is [C]i [C]s O 
a [C]a O 
synthetic [C]s [C]y [C]n [C]t [C]h [C]e [C]t [C]i [C]c O 
retinoid [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]d O 
that [C]t [C]h [C]a [C]t O 
acts [C]a [C]c [C]t [C]s O 
as [C]a [C]s O 
an [C]a [C]n O 
antagonist [C]a [C]n [C]t [C]a [C]g [C]o [C]n [C]i [C]s [C]t O 
at [C]a [C]t O 
retinoic [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]c B-protein 
acid [C]a [C]c [C]i [C]d I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s I-protein 
alpha [C]a [C]l [C]p [C]h [C]a I-protein 
, [C], I-protein 
beta [C]b [C]e [C]t [C]a I-protein 
, [C], I-protein 
and [C]a [C]n [C]d I-protein 
gamma [C]g [C]a [C]m [C]m [C]a E-protein 
. [C]. O 

In [C]I [C]n O 
Sprague [C]S [C]p [C]r [C]a [C]g [C]u [C]e O 
Dawley [C]D [C]a [C]w [C]l [C]e [C]y O 
rats [C]r [C]a [C]t [C]s O 
at [C]a [C]t O 
daily [C]d [C]a [C]i [C]l [C]y O 
oral [C]o [C]r [C]a [C]l O 
doses [C]d [C]o [C]s [C]e [C]s O 
of [C]o [C]f O 
15 [C]1 [C]5 O 
, [C], O 
60 [C]6 [C]0 O 
, [C], O 
or [C]o [C]r O 
240 [C]2 [C]4 [C]0 O 
mg/kg [C]m [C]g [C]/ [C]k [C]g O 
for [C]f [C]o [C]r O 
1 [C]1 O 
month [C]m [C]o [C]n [C]t [C]h O 
, [C], O 
BMS-189453 [C]B [C]M [C]S [C]- [C]1 [C]8 [C]9 [C]4 [C]5 [C]3 O 
produced [C]p [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
increases [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
in [C]i [C]n O 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e S-cell_type 
counts [C]c [C]o [C]u [C]n [C]t [C]s O 
, [C], O 
alkaline [C]a [C]l [C]k [C]a [C]l [C]i [C]n [C]e B-protein 
phosphatase [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]a [C]s [C]e E-protein 
and [C]a [C]n [C]d O 
alanine [C]a [C]l [C]a [C]n [C]i [C]n [C]e B-protein 
aminotransferase [C]a [C]m [C]i [C]n [C]o [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]r [C]a [C]s [C]e E-protein 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
marked [C]m [C]a [C]r [C]k [C]e [C]d O 
testicular [C]t [C]e [C]s [C]t [C]i [C]c [C]u [C]l [C]a [C]r O 
degeneration [C]d [C]e [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
atrophy [C]a [C]t [C]r [C]o [C]p [C]h [C]y O 
at [C]a [C]t O 
all [C]a [C]l [C]l O 
doses [C]d [C]o [C]s [C]e [C]s O 
. [C]. O 

Significant [C]S [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
overt [C]o [C]v [C]e [C]r [C]t O 
signs [C]s [C]i [C]g [C]n [C]s O 
of [C]o [C]f O 
toxicity [C]t [C]o [C]x [C]i [C]c [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
deaths [C]d [C]e [C]a [C]t [C]h [C]s O 
occurred [C]o [C]c [C]c [C]u [C]r [C]r [C]e [C]d O 
at [C]a [C]t O 
240 [C]2 [C]4 [C]0 O 
mg/kg [C]m [C]g [C]/ [C]k [C]g O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
body-weight [C]b [C]o [C]d [C]y [C]- [C]w [C]e [C]i [C]g [C]h [C]t O 
and [C]a [C]n [C]d O 
food-consumption [C]f [C]o [C]o [C]d [C]- [C]c [C]o [C]n [C]s [C]u [C]m [C]p [C]t [C]i [C]o [C]n O 
decreases [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
occurred [C]o [C]c [C]c [C]u [C]r [C]r [C]e [C]d O 
at [C]a [C]t O 
60 [C]6 [C]0 O 
and [C]a [C]n [C]d O 
240 [C]2 [C]4 [C]0 O 
mg/kg [C]m [C]g [C]/ [C]k [C]g O 
. [C]. O 

When [C]W [C]h [C]e [C]n O 
BMS-189453 [C]B [C]M [C]S [C]- [C]1 [C]8 [C]9 [C]4 [C]5 [C]3 O 
was [C]w [C]a [C]s O 
administered [C]a [C]d [C]m [C]i [C]n [C]i [C]s [C]t [C]e [C]r [C]e [C]d O 
to [C]t [C]o O 
male [C]m [C]a [C]l [C]e O 
rats [C]r [C]a [C]t [C]s O 
at [C]a [C]t O 
daily [C]d [C]a [C]i [C]l [C]y O 
doses [C]d [C]o [C]s [C]e [C]s O 
ranging [C]r [C]a [C]n [C]g [C]i [C]n [C]g O 
from [C]f [C]r [C]o [C]m O 
12.5 [C]1 [C]2 [C]. [C]5 O 
to [C]t [C]o O 
100 [C]1 [C]0 [C]0 O 
mg/kg [C]m [C]g [C]/ [C]k [C]g O 
for [C]f [C]o [C]r O 
1 [C]1 O 
week [C]w [C]e [C]e [C]k O 
, [C], O 
only [C]o [C]n [C]l [C]y O 
minimal [C]m [C]i [C]n [C]i [C]m [C]a [C]l O 
testicular [C]t [C]e [C]s [C]t [C]i [C]c [C]u [C]l [C]a [C]r O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
occurred [C]o [C]c [C]c [C]u [C]r [C]r [C]e [C]d O 
at [C]a [C]t O 
all [C]a [C]l [C]l O 
doses [C]d [C]o [C]s [C]e [C]s O 
, [C], O 
shortly [C]s [C]h [C]o [C]r [C]t [C]l [C]y O 
after [C]a [C]f [C]t [C]e [C]r O 
the [C]t [C]h [C]e O 
dosing [C]d [C]o [C]s [C]i [C]n [C]g O 
period [C]p [C]e [C]r [C]i [C]o [C]d O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
after [C]a [C]f [C]t [C]e [C]r O 
a [C]a O 
1-month [C]1 [C]- [C]m [C]o [C]n [C]t [C]h O 
drug-free [C]d [C]r [C]u [C]g [C]- [C]f [C]r [C]e [C]e O 
observation [C]o [C]b [C]s [C]e [C]r [C]v [C]a [C]t [C]i [C]o [C]n O 
period [C]p [C]e [C]r [C]i [C]o [C]d O 
, [C], O 
marked [C]m [C]a [C]r [C]k [C]e [C]d O 
testicular [C]t [C]e [C]s [C]t [C]i [C]c [C]u [C]l [C]a [C]r O 
atrophy [C]a [C]t [C]r [C]o [C]p [C]h [C]y O 
was [C]w [C]a [C]s O 
evident [C]e [C]v [C]i [C]d [C]e [C]n [C]t O 
at [C]a [C]t O 
all [C]a [C]l [C]l O 
doses [C]d [C]o [C]s [C]e [C]s O 
. [C]. O 

BMS-189453 [C]B [C]M [C]S [C]- [C]1 [C]8 [C]9 [C]4 [C]5 [C]3 O 
was [C]w [C]a [C]s O 
then [C]t [C]h [C]e [C]n O 
administered [C]a [C]d [C]m [C]i [C]n [C]i [C]s [C]t [C]e [C]r [C]e [C]d O 
at [C]a [C]t O 
doses [C]d [C]o [C]s [C]e [C]s O 
of [C]o [C]f O 
2 [C]2 O 
, [C], O 
10 [C]1 [C]0 O 
, [C], O 
or [C]o [C]r O 
50 [C]5 [C]0 O 
mg/kg [C]m [C]g [C]/ [C]k [C]g O 
to [C]t [C]o O 
male [C]m [C]a [C]l [C]e O 
rats [C]r [C]a [C]t [C]s O 
for [C]f [C]o [C]r O 
1 [C]1 O 
, [C], O 
3 [C]3 O 
, [C], O 
or [C]o [C]r O 
7 [C]7 O 
consecutive [C]c [C]o [C]n [C]s [C]e [C]c [C]u [C]t [C]i [C]v [C]e O 
days [C]d [C]a [C]y [C]s O 
. [C]. O 

Dose- [C]D [C]o [C]s [C]e [C]- O 
and [C]a [C]n [C]d O 
duration-dependent [C]d [C]u [C]r [C]a [C]t [C]i [C]o [C]n [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
testicular [C]t [C]e [C]s [C]t [C]i [C]c [C]u [C]l [C]a [C]r O 
toxicity [C]t [C]o [C]x [C]i [C]c [C]i [C]t [C]y O 
that [C]t [C]h [C]a [C]t O 
occurred [C]o [C]c [C]c [C]u [C]r [C]r [C]e [C]d O 
after [C]a [C]f [C]t [C]e [C]r O 
a [C]a O 
1-month [C]1 [C]- [C]m [C]o [C]n [C]t [C]h O 
observation [C]o [C]b [C]s [C]e [C]r [C]v [C]a [C]t [C]i [C]o [C]n O 
period [C]p [C]e [C]r [C]i [C]o [C]d O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
recover [C]r [C]e [C]c [C]o [C]v [C]e [C]r O 
, [C], O 
and [C]a [C]n [C]d O 
, [C], O 
in [C]i [C]n O 
some [C]s [C]o [C]m [C]e O 
cases [C]c [C]a [C]s [C]e [C]s O 
, [C], O 
was [C]w [C]a [C]s O 
more [C]m [C]o [C]r [C]e O 
severe [C]s [C]e [C]v [C]e [C]r [C]e O 
4 [C]4 O 
months [C]m [C]o [C]n [C]t [C]h [C]s O 
after [C]a [C]f [C]t [C]e [C]r O 
the [C]t [C]h [C]e O 
last [C]l [C]a [C]s [C]t O 
dose [C]d [C]o [C]s [C]e O 
. [C]. O 

In [C]I [C]n O 
rabbits [C]r [C]a [C]b [C]b [C]i [C]t [C]s O 
administered [C]a [C]d [C]m [C]i [C]n [C]i [C]s [C]t [C]e [C]r [C]e [C]d O 
BMS-189453 [C]B [C]M [C]S [C]- [C]1 [C]8 [C]9 [C]4 [C]5 [C]3 O 
at [C]a [C]t O 
oral [C]o [C]r [C]a [C]l O 
doses [C]d [C]o [C]s [C]e [C]s O 
of [C]o [C]f O 
2 [C]2 O 
, [C], O 
10 [C]1 [C]0 O 
, [C], O 
or [C]o [C]r O 
50 [C]5 [C]0 O 
mg/kg [C]m [C]g [C]/ [C]k [C]g O 
for [C]f [C]o [C]r O 
1 [C]1 O 
week [C]w [C]e [C]e [C]k O 
, [C], O 
testicular [C]t [C]e [C]s [C]t [C]i [C]c [C]u [C]l [C]a [C]r O 
degeneration [C]d [C]e [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
atrophy [C]a [C]t [C]r [C]o [C]p [C]h [C]y O 
were [C]w [C]e [C]r [C]e O 
evident [C]e [C]v [C]i [C]d [C]e [C]n [C]t O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
high-dose [C]h [C]i [C]g [C]h [C]- [C]d [C]o [C]s [C]e O 
group [C]g [C]r [C]o [C]u [C]p O 
at [C]a [C]t O 
1 [C]1 O 
month [C]m [C]o [C]n [C]t [C]h O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
retinoid [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]d O 
antagonists [C]a [C]n [C]t [C]a [C]g [C]o [C]n [C]i [C]s [C]t [C]s O 
can [C]c [C]a [C]n O 
selectively [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
produce [C]p [C]r [C]o [C]d [C]u [C]c [C]e O 
progressive [C]p [C]r [C]o [C]g [C]r [C]e [C]s [C]s [C]i [C]v [C]e O 
and [C]a [C]n [C]d O 
prolonged [C]p [C]r [C]o [C]l [C]o [C]n [C]g [C]e [C]d O 
testicular [C]t [C]e [C]s [C]t [C]i [C]c [C]u [C]l [C]a [C]r O 
toxicity [C]t [C]o [C]x [C]i [C]c [C]i [C]t [C]y O 
after [C]a [C]f [C]t [C]e [C]r O 
single [C]s [C]i [C]n [C]g [C]l [C]e O 
or [C]o [C]r O 
repeated [C]r [C]e [C]p [C]e [C]a [C]t [C]e [C]d O 
oral [C]o [C]r [C]a [C]l O 
doses [C]d [C]o [C]s [C]e [C]s O 
that [C]t [C]h [C]a [C]t O 
are [C]a [C]r [C]e O 
otherwise [C]o [C]t [C]h [C]e [C]r [C]w [C]i [C]s [C]e O 
well [C]w [C]e [C]l [C]l O 
tolerated [C]t [C]o [C]l [C]e [C]r [C]a [C]t [C]e [C]d O 
. [C]. O 

Sequential [C]S [C]e [C]q [C]u [C]e [C]n [C]t [C]i [C]a [C]l O 
involvement [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
NFAT [C]N [C]F [C]A [C]T S-protein 
and [C]a [C]n [C]d O 
Egr [C]E [C]g [C]r S-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
FasL [C]F [C]a [C]s [C]L O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
critical [C]c [C]r [C]i [C]t [C]i [C]c [C]a [C]l O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NFAT [C]N [C]F [C]A [C]T B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
in [C]i [C]n O 
maintaining [C]m [C]a [C]i [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d O 
homeostasis [C]h [C]o [C]m [C]e [C]o [C]s [C]t [C]a [C]s [C]i [C]s O 
was [C]w [C]a [C]s O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
in [C]i [C]n O 
mice [C]m [C]i [C]c [C]e O 
lacking [C]l [C]a [C]c [C]k [C]i [C]n [C]g O 
both [C]b [C]o [C]t [C]h O 
NFATp [C]N [C]F [C]A [C]T [C]p S-protein 
and [C]a [C]n [C]d O 
NFAT4 [C]N [C]F [C]A [C]T [C]4 S-protein 
( [C]( O 
DKO [C]D [C]K [C]O O 
) [C]) O 
. [C]. O 

DKO [C]D [C]K [C]O O 
mice [C]m [C]i [C]c [C]e O 
exhibit [C]e [C]x [C]h [C]i [C]b [C]i [C]t O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
lymphoproliferation [C]l [C]y [C]m [C]p [C]h [C]o [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
activation-induced [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
cell [C]c [C]e [C]l [C]l O 
death [C]d [C]e [C]a [C]t [C]h O 
, [C], O 
and [C]a [C]n [C]d O 
impaired [C]i [C]m [C]p [C]a [C]i [C]r [C]e [C]d O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
FasL [C]F [C]a [C]s [C]L S-protein 
. [C]. O 

The [C]T [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
Egr2 [C]E [C]g [C]r [C]2 S-protein 
and [C]a [C]n [C]d O 
Egr3 [C]E [C]g [C]r [C]3 S-protein 
are [C]a [C]r [C]e O 
potent [C]p [C]o [C]t [C]e [C]n [C]t O 
activators [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r [C]s O 
of [C]o [C]f O 
FasL [C]F [C]a [C]s [C]L O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
we [C]w [C]e O 
find [C]f [C]i [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
Egr2 [C]E [C]g [C]r [C]2 S-DNA 
and [C]a [C]n [C]d O 
Egr3 [C]E [C]g [C]r [C]3 S-DNA 
are [C]a [C]r [C]e O 
NFAT [C]N [C]F [C]A [C]T B-DNA 
target [C]t [C]a [C]r [C]g [C]e [C]t I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
. [C]. O 

Activation [C]A [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
FasL [C]F [C]a [C]s [C]L S-protein 
occurs [C]o [C]c [C]c [C]u [C]r [C]s O 
via [C]v [C]i [C]a O 
the [C]t [C]h [C]e O 
NFAT [C]N [C]F [C]A [C]T S-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Egr3 [C]E [C]g [C]r [C]3 S-DNA 
, [C], O 
as [C]a [C]s O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
exogenously [C]e [C]x [C]o [C]g [C]e [C]n [C]o [C]u [C]s [C]l [C]y O 
provided [C]p [C]r [C]o [C]v [C]i [C]d [C]e [C]d O 
NFATp [C]N [C]F [C]A [C]T [C]p S-protein 
to [C]t [C]o O 
restore [C]r [C]e [C]s [C]t [C]o [C]r [C]e O 
Egr [C]E [C]g [C]r S-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
FasL [C]F [C]a [C]s [C]L O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
DKO [C]D [C]K [C]O B-cell_type 
lymph [C]l [C]y [C]m [C]p [C]h I-cell_type 
node [C]n [C]o [C]d [C]e I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Further [C]F [C]u [C]r [C]t [C]h [C]e [C]r O 
, [C], O 
Egr3 [C]E [C]g [C]r [C]3 S-DNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
is [C]i [C]s O 
enriched [C]e [C]n [C]r [C]i [C]c [C]h [C]e [C]d O 
in [C]i [C]n O 
Th1 [C]T [C]h [C]1 B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
a [C]a O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
basis [C]b [C]a [C]s [C]i [C]s O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
known [C]k [C]n [C]o [C]w [C]n O 
preferential [C]p [C]r [C]e [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
FasL [C]F [C]a [C]s [C]L S-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
Th1 [C]T [C]h [C]1 O 
versus [C]v [C]e [C]r [C]s [C]u [C]s O 
Th2 [C]T [C]h [C]2 O 
subset [C]s [C]u [C]b [C]s [C]e [C]t O 
. [C]. O 

Mechanisms [C]M [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
and [C]a [C]n [C]d O 
clinical [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
relevance [C]r [C]e [C]l [C]e [C]v [C]a [C]n [C]c [C]e O 
of [C]o [C]f O 
nongenomic [C]n [C]o [C]n [C]g [C]e [C]n [C]o [C]m [C]i [C]c O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
actions [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

Glucocorticoids [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
have [C]h [C]a [C]v [C]e O 
profound [C]p [C]r [C]o [C]f [C]o [C]u [C]n [C]d O 
anti-inflammatory [C]a [C]n [C]t [C]i [C]- [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
and [C]a [C]n [C]d O 
immunosuppressive [C]i [C]m [C]m [C]u [C]n [C]o [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]v [C]e O 
actions [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
when [C]w [C]h [C]e [C]n O 
used [C]u [C]s [C]e [C]d O 
therapeutically [C]t [C]h [C]e [C]r [C]a [C]p [C]e [C]u [C]t [C]i [C]c [C]a [C]l [C]l [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
therapeutic [C]t [C]h [C]e [C]r [C]a [C]p [C]e [C]u [C]t [C]i [C]c O 
dose [C]d [C]o [C]s [C]e O 
is [C]i [C]s O 
quite [C]q [C]u [C]i [C]t [C]e O 
variable [C]v [C]a [C]r [C]i [C]a [C]b [C]l [C]e O 
and [C]a [C]n [C]d O 
depends [C]d [C]e [C]p [C]e [C]n [C]d [C]s O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
, [C], O 
but [C]b [C]u [C]t O 
ranges [C]r [C]a [C]n [C]g [C]e [C]s O 
from [C]f [C]r [C]o [C]m O 
very [C]v [C]e [C]r [C]y O 
low [C]l [C]o [C]w O 
to [C]t [C]o O 
extremely [C]e [C]x [C]t [C]r [C]e [C]m [C]e [C]l [C]y O 
high [C]h [C]i [C]g [C]h O 
. [C]. O 

The [C]T [C]h [C]e O 
rationale [C]r [C]a [C]t [C]i [C]o [C]n [C]a [C]l [C]e O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
use [C]u [C]s [C]e O 
of [C]o [C]f O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
dosage [C]d [C]o [C]s [C]a [C]g [C]e O 
regimens [C]r [C]e [C]g [C]i [C]m [C]e [C]n [C]s O 
for [C]f [C]o [C]r O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
clinical [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
indications [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]i [C]o [C]n [C]s O 
is [C]i [C]s O 
the [C]t [C]h [C]e O 
existence [C]e [C]x [C]i [C]s [C]t [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
three [C]t [C]h [C]r [C]e [C]e O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
, [C], O 
therapeutically [C]t [C]h [C]e [C]r [C]a [C]p [C]e [C]u [C]t [C]i [C]c [C]a [C]l [C]l [C]y O 
relevant [C]r [C]e [C]l [C]e [C]v [C]a [C]n [C]t O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
: [C]: O 
genomic [C]g [C]e [C]n [C]o [C]m [C]i [C]c O 
, [C], O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
nongenomic [C]n [C]o [C]n [C]g [C]e [C]n [C]o [C]m [C]i [C]c O 
and [C]a [C]n [C]d O 
unspecific [C]u [C]n [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
nongenomic [C]n [C]o [C]n [C]g [C]e [C]n [C]o [C]m [C]i [C]c O 
. [C]. O 

Genomic [C]G [C]e [C]n [C]o [C]m [C]i [C]c O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
are [C]a [C]r [C]e O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
cytosolic [C]c [C]y [C]t [C]o [C]s [C]o [C]l [C]i [C]c B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
that [C]t [C]h [C]a [C]t O 
alter [C]a [C]l [C]t [C]e [C]r O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
genes [C]g [C]e [C]n [C]e [C]s O 
. [C]. O 

Specific [C]S [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
nongenomic [C]n [C]o [C]n [C]g [C]e [C]n [C]o [C]m [C]i [C]c O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
occur [C]o [C]c [C]c [C]u [C]r O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
a [C]a O 
few [C]f [C]e [C]w O 
minutes [C]m [C]i [C]n [C]u [C]t [C]e [C]s O 
and [C]a [C]n [C]d O 
are [C]a [C]r [C]e O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
steroid-selective [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]- [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e B-protein 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

Unspecific [C]U [C]n [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
nongenomic [C]n [C]o [C]n [C]g [C]e [C]n [C]o [C]m [C]i [C]c O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
occur [C]o [C]c [C]c [C]u [C]r O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
seconds [C]s [C]e [C]c [C]o [C]n [C]d [C]s O 
, [C], O 
but [C]b [C]u [C]t O 
only [C]o [C]n [C]l [C]y O 
at [C]a [C]t O 
high [C]h [C]i [C]g [C]h O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
dosages [C]d [C]o [C]s [C]a [C]g [C]e [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
seem [C]s [C]e [C]e [C]m O 
to [C]t [C]o O 
result [C]r [C]e [C]s [C]u [C]l [C]t O 
from [C]f [C]r [C]o [C]m O 
direct [C]d [C]i [C]r [C]e [C]c [C]t O 
interactions [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
with [C]w [C]i [C]t [C]h O 
biological [C]b [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
membranes [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e [C]s O 
. [C]. O 

For [C]F [C]o [C]r O 
unspecific [C]u [C]n [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
nongenomic [C]n [C]o [C]n [C]g [C]e [C]n [C]o [C]m [C]i [C]c O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
, [C], O 
methylprednisolone [C]m [C]e [C]t [C]h [C]y [C]l [C]p [C]r [C]e [C]d [C]n [C]i [C]s [C]o [C]l [C]o [C]n [C]e O 
and [C]a [C]n [C]d O 
other [C]o [C]t [C]h [C]e [C]r O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
inhibit [C]i [C]n [C]h [C]i [C]b [C]i [C]t O 
cation [C]c [C]a [C]t [C]i [C]o [C]n O 
cycling [C]c [C]y [C]c [C]l [C]i [C]n [C]g O 
across [C]a [C]c [C]r [C]o [C]s [C]s O 
the [C]t [C]h [C]e O 
plasma [C]p [C]l [C]a [C]s [C]m [C]a O 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
, [C], O 
but [C]b [C]u [C]t O 
to [C]t [C]o O 
have [C]h [C]a [C]v [C]e O 
little [C]l [C]i [C]t [C]t [C]l [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
could [C]c [C]o [C]u [C]l [C]d O 
diminish [C]d [C]i [C]m [C]i [C]n [C]i [C]s [C]h O 
or [C]o [C]r O 
prevent [C]p [C]r [C]e [C]v [C]e [C]n [C]t O 
the [C]t [C]h [C]e O 
acute [C]a [C]c [C]u [C]t [C]e O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
by [C]b [C]y O 
interfering [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]i [C]n [C]g O 
with [C]w [C]i [C]t [C]h O 
processes [C]p [C]r [C]o [C]c [C]e [C]s [C]s [C]e [C]s O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
the [C]t [C]h [C]e O 
rise [C]r [C]i [C]s [C]e O 
in [C]i [C]n O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
Ca2+ [C]C [C]a [C]2 [C]+ O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

It [C]I [C]t O 
is [C]i [C]s O 
proposed [C]p [C]r [C]o [C]p [C]o [C]s [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
additional [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n [C]a [C]l O 
therapeutic [C]t [C]h [C]e [C]r [C]a [C]p [C]e [C]u [C]t [C]i [C]c O 
benefit [C]b [C]e [C]n [C]e [C]f [C]i [C]t O 
of [C]o [C]f O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
doses [C]d [C]o [C]s [C]e [C]s O 
is [C]i [C]s O 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
via [C]v [C]i [C]a O 
these [C]t [C]h [C]e [C]s [C]e O 
nongenomic [C]n [C]o [C]n [C]g [C]e [C]n [C]o [C]m [C]i [C]c O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
. [C]. O 

High [C]H [C]i [C]g [C]h O 
glucose-induced [C]g [C]l [C]u [C]c [C]o [C]s [C]e [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
intercellular [C]i [C]n [C]t [C]e [C]r [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n I-protein 
molecule-1 [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]- [C]1 E-protein 
( [C]( O 
ICAM-1 [C]I [C]C [C]A [C]M [C]- [C]1 S-protein 
) [C]) O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
an [C]a [C]n O 
osmotic [C]o [C]s [C]m [C]o [C]t [C]i [C]c O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
in [C]i [C]n O 
rat [C]r [C]a [C]t B-cell_type 
mesangial [C]m [C]e [C]s [C]a [C]n [C]g [C]i [C]a [C]l I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
is [C]i [C]s O 
PKC-NF-kappa [C]P [C]K [C]C [C]- [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a O 
B-dependent [C]B [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
. [C]. O 

AIMS/HYPOTHESIS [C]A [C]I [C]M [C]S [C]/ [C]H [C]Y [C]P [C]O [C]T [C]H [C]E [C]S [C]I [C]S O 
: [C]: O 
Infiltration [C]I [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
glomerular [C]g [C]l [C]o [C]m [C]e [C]r [C]u [C]l [C]a [C]r O 
enlargement [C]e [C]n [C]l [C]a [C]r [C]g [C]e [C]m [C]e [C]n [C]t O 
accompanied [C]a [C]c [C]c [C]o [C]m [C]p [C]a [C]n [C]i [C]e [C]d O 
by [C]b [C]y O 
glomerular [C]g [C]l [C]o [C]m [C]e [C]r [C]u [C]l [C]a [C]r B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
are [C]a [C]r [C]e O 
very [C]v [C]e [C]r [C]y O 
early [C]e [C]a [C]r [C]l [C]y O 
characteristics [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]s [C]t [C]i [C]c [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
pathophysiology [C]p [C]a [C]t [C]h [C]o [C]p [C]h [C]y [C]s [C]i [C]o [C]l [C]o [C]g [C]y O 
of [C]o [C]f O 
diabetes [C]d [C]i [C]a [C]b [C]e [C]t [C]e [C]s O 
. [C]. O 

To [C]T [C]o O 
clarify [C]c [C]l [C]a [C]r [C]i [C]f [C]y O 
the [C]t [C]h [C]e O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
of [C]o [C]f O 
early [C]e [C]a [C]r [C]l [C]y O 
diabetic [C]d [C]i [C]a [C]b [C]e [C]t [C]i [C]c O 
nephropathy [C]n [C]e [C]p [C]h [C]r [C]o [C]p [C]a [C]t [C]h [C]y O 
, [C], O 
we [C]w [C]e O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
-thymidine [C]- [C]t [C]h [C]y [C]m [C]i [C]d [C]i [C]n [C]e O 
incorporation [C]i [C]n [C]c [C]o [C]r [C]p [C]o [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
cell [C]c [C]e [C]l [C]l O 
numbers [C]n [C]u [C]m [C]b [C]e [C]r [C]s O 
to [C]t [C]o O 
show [C]s [C]h [C]o [C]w O 
the [C]t [C]h [C]e O 
influence [C]i [C]n [C]f [C]l [C]u [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
a [C]a O 
high [C]h [C]i [C]g [C]h O 
ambient [C]a [C]m [C]b [C]i [C]e [C]n [C]t O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
osmotic [C]o [C]s [C]m [C]o [C]t [C]i [C]c O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
rat [C]r [C]a [C]t B-cell_type 
mesangial [C]m [C]e [C]s [C]a [C]n [C]g [C]i [C]a [C]l I-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

We [C]W [C]e O 
also [C]a [C]l [C]s [C]o O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
the [C]t [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
high [C]h [C]i [C]g [C]h O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
intercellular [C]i [C]n [C]t [C]e [C]r [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n I-protein 
molecule-1 [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]- [C]1 E-protein 
and [C]a [C]n [C]d O 
vascular [C]v [C]a [C]s [C]c [C]u [C]l [C]a [C]r B-protein 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n I-protein 
molecule-1 [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]- [C]1 E-protein 
by [C]b [C]y O 
flow [C]f [C]l [C]o [C]w O 
cytometry [C]c [C]y [C]t [C]o [C]m [C]e [C]t [C]r [C]y O 
and [C]a [C]n [C]d O 
semiquantitative [C]s [C]e [C]m [C]i [C]q [C]u [C]a [C]n [C]t [C]i [C]t [C]a [C]t [C]i [C]v [C]e O 
RT-PCR [C]R [C]T [C]- [C]P [C]C [C]R O 
in [C]i [C]n O 
mesangial [C]m [C]e [C]s [C]a [C]n [C]g [C]i [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
to [C]t [C]o O 
mesangial [C]m [C]e [C]s [C]a [C]n [C]g [C]i [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

METHODS/RESULTS [C]M [C]E [C]T [C]H [C]O [C]D [C]S [C]/ [C]R [C]E [C]S [C]U [C]L [C]T [C]S O 
: [C]: O 
Cells [C]C [C]e [C]l [C]l [C]s O 
exposed [C]e [C]x [C]p [C]o [C]s [C]e [C]d O 
to [C]t [C]o O 
high [C]h [C]i [C]g [C]h O 
D-glucose [C]D [C]- [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
( [C]( O 
30 [C]3 [C]0 O 
mmol/l [C]m [C]m [C]o [C]l [C]/ [C]l O 
) [C]) O 
caused [C]c [C]a [C]u [C]s [C]e [C]d O 
an [C]a [C]n O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
-thymidine [C]- [C]t [C]h [C]y [C]m [C]i [C]d [C]i [C]n [C]e O 
incorporation [C]i [C]n [C]c [C]o [C]r [C]p [C]o [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
cell [C]c [C]e [C]l [C]l O 
numbers [C]n [C]u [C]m [C]b [C]e [C]r [C]s O 
at [C]a [C]t O 
24 [C]2 [C]4 O 
and [C]a [C]n [C]d O 
48 [C]4 [C]8 O 
h [C]h O 
and [C]a [C]n [C]d O 
normalized [C]n [C]o [C]r [C]m [C]a [C]l [C]i [C]z [C]e [C]d O 
at [C]a [C]t O 
72 [C]7 [C]2 O 
h [C]h O 
( [C]( O 
p [C]p O 
< [C]< O 
0.05 [C]0 [C]. [C]0 [C]5 O 
) [C]) O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
these [C]t [C]h [C]e [C]s [C]e O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
not [C]n [C]o [C]t O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
high [C]h [C]i [C]g [C]h O 
mannitol [C]m [C]a [C]n [C]n [C]i [C]t [C]o [C]l O 
( [C]( O 
30 [C]3 [C]0 O 
mmol/l [C]m [C]m [C]o [C]l [C]/ [C]l O 
) [C]) O 
, [C], O 
IL-1 [C]I [C]L [C]- [C]1 B-protein 
beta [C]b [C]e [C]t [C]a E-protein 
, [C], O 
or [C]o [C]r O 
TNF [C]T [C]N [C]F B-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
-stimulated [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
mesangial [C]m [C]e [C]s [C]a [C]n [C]g [C]i [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Cells [C]C [C]e [C]l [C]l [C]s O 
exposed [C]e [C]x [C]p [C]o [C]s [C]e [C]d O 
to [C]t [C]o O 
high-glucose [C]h [C]i [C]g [C]h [C]- [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
( [C]( O 
15 [C]1 [C]5 O 
, [C], O 
30 [C]3 [C]0 O 
, [C], O 
or [C]o [C]r O 
60 [C]6 [C]0 O 
mmol/l [C]m [C]m [C]o [C]l [C]/ [C]l O 
) [C]) O 
or [C]o [C]r O 
osmotic [C]o [C]s [C]m [C]o [C]t [C]i [C]c O 
agents [C]a [C]g [C]e [C]n [C]t [C]s O 
( [C]( O 
L-glucose [C]L [C]- [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
, [C], O 
raffinose [C]r [C]a [C]f [C]f [C]i [C]n [C]o [C]s [C]e O 
and [C]a [C]n [C]d O 
mannitol [C]m [C]a [C]n [C]n [C]i [C]t [C]o [C]l O 
) [C]) O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
intercellular [C]i [C]n [C]t [C]e [C]r [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n I-protein 
molecule-1 [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]- [C]1 E-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
began [C]b [C]e [C]g [C]a [C]n O 
to [C]t [C]o O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
after [C]a [C]f [C]t [C]e [C]r O 
24 [C]2 [C]4 O 
h [C]h O 
, [C], O 
reached [C]r [C]e [C]a [C]c [C]h [C]e [C]d O 
its [C]i [C]t [C]s O 
maximum [C]m [C]a [C]x [C]i [C]m [C]u [C]m O 
at [C]a [C]t O 
24 [C]2 [C]4 O 
and [C]a [C]n [C]d O 
48 [C]4 [C]8 O 
h [C]h O 
and [C]a [C]n [C]d O 
gradually [C]g [C]r [C]a [C]d [C]u [C]a [C]l [C]l [C]y O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
afterwards [C]a [C]f [C]t [C]e [C]r [C]w [C]a [C]r [C]d [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
stimulatory [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
high [C]h [C]i [C]g [C]h O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
and [C]a [C]n [C]d O 
high [C]h [C]i [C]g [C]h O 
mannitol [C]m [C]a [C]n [C]n [C]i [C]t [C]o [C]l O 
on [C]o [C]n O 
mRNA [C]m [C]R [C]N [C]A O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
were [C]w [C]e [C]r [C]e O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
as [C]a [C]s O 
early [C]e [C]a [C]r [C]l [C]y O 
as [C]a [C]s O 
6 [C]6 O 
h [C]h O 
and [C]a [C]n [C]d O 
reached [C]r [C]e [C]a [C]c [C]h [C]e [C]d O 
its [C]i [C]t [C]s O 
maximum [C]m [C]a [C]x [C]i [C]m [C]u [C]m O 
at [C]a [C]t O 
12 [C]1 [C]2 O 
h [C]h O 
. [C]. O 

Up-regulation [C]U [C]p [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
ICAM-1 [C]I [C]C [C]A [C]M [C]- [C]1 S-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
and [C]a [C]n [C]d O 
mRNA [C]m [C]R [C]N [C]A O 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
IL-1-beta [C]I [C]L [C]- [C]1 [C]- [C]b [C]e [C]t [C]a S-protein 
and [C]a [C]n [C]d O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
-stimulated [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
mesangial [C]m [C]e [C]s [C]a [C]n [C]g [C]i [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Neither [C]N [C]e [C]i [C]t [C]h [C]e [C]r O 
vascular [C]v [C]a [C]s [C]c [C]u [C]l [C]a [C]r B-protein 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n I-protein 
molecule-1 [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]- [C]1 E-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
nor [C]n [C]o [C]r O 
mRNA [C]m [C]R [C]N [C]A O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
, [C], O 
however [C]h [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
affected [C]a [C]f [C]f [C]e [C]c [C]t [C]e [C]d O 
by [C]b [C]y O 
high [C]h [C]i [C]g [C]h O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
and [C]a [C]n [C]d O 
high [C]h [C]i [C]g [C]h O 
mannitol [C]m [C]a [C]n [C]n [C]i [C]t [C]o [C]l O 
. [C]. O 

Notably [C]N [C]o [C]t [C]a [C]b [C]l [C]y O 
, [C], O 
the [C]t [C]h [C]e O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
C [C]C O 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
calphostin [C]c [C]a [C]l [C]p [C]h [C]o [C]s [C]t [C]i [C]n O 
C [C]C O 
and [C]a [C]n [C]d O 
staurosporine [C]s [C]t [C]a [C]u [C]r [C]o [C]s [C]p [C]o [C]r [C]i [C]n [C]e O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
high [C]h [C]i [C]g [C]h O 
glucose- [C]g [C]l [C]u [C]c [C]o [C]s [C]e [C]- O 
or [C]o [C]r O 
high [C]h [C]i [C]g [C]h O 
mannitol-induced [C]m [C]a [C]n [C]n [C]i [C]t [C]o [C]l [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
intercellular [C]i [C]n [C]t [C]e [C]r [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-RNA 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n I-RNA 
molecule-1 [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]- [C]1 E-RNA 
mRNA [C]m [C]R [C]N [C]A O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
high [C]h [C]i [C]g [C]h O 
glucose-induced [C]g [C]l [C]u [C]c [C]o [C]s [C]e [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
the [C]t [C]h [C]e O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a O 
B [C]B O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
N-tosyl-L-phenylalanine [C]N [C]- [C]t [C]o [C]s [C]y [C]l [C]- [C]L [C]- [C]p [C]h [C]e [C]n [C]y [C]l [C]a [C]l [C]a [C]n [C]i [C]n [C]e O 
chloromethyl [C]c [C]h [C]l [C]o [C]r [C]o [C]m [C]e [C]t [C]h [C]y [C]l O 
ketone [C]k [C]e [C]t [C]o [C]n [C]e O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
high [C]h [C]i [C]g [C]h O 
glucose- [C]g [C]l [C]u [C]c [C]o [C]s [C]e [C]- O 
or [C]o [C]r O 
high [C]h [C]i [C]g [C]h O 
mannitol-induced [C]m [C]a [C]n [C]n [C]i [C]t [C]o [C]l [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
intercellular [C]i [C]n [C]t [C]e [C]r [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-RNA 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n I-RNA 
molecule-1 [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]- [C]1 E-RNA 
mRNA [C]m [C]R [C]N [C]A O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
high [C]h [C]i [C]g [C]h O 
glucose-induced [C]g [C]l [C]u [C]c [C]o [C]s [C]e [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Results [C]R [C]e [C]s [C]u [C]l [C]t [C]s O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
high [C]h [C]i [C]g [C]h O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
( [C]( O 
15 [C]1 [C]5 O 
, [C], O 
30 [C]3 [C]0 O 
mmol/l [C]m [C]m [C]o [C]l [C]/ [C]l O 
) [C]) O 
or [C]o [C]r O 
high [C]h [C]i [C]g [C]h O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
osmotic [C]o [C]s [C]m [C]o [C]t [C]i [C]c O 
agents [C]a [C]g [C]e [C]n [C]t [C]s O 
remarkably [C]r [C]e [C]m [C]a [C]r [C]k [C]a [C]b [C]l [C]y O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
adherent [C]a [C]d [C]h [C]e [C]r [C]e [C]n [C]t O 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
to [C]t [C]o O 
mesangial [C]m [C]e [C]s [C]a [C]n [C]g [C]i [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
p [C]p O 
< [C]< O 
0.01 [C]0 [C]. [C]0 [C]1 O 
) [C]) O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
5 [C]5 O 
mmol/l [C]m [C]m [C]o [C]l [C]/ [C]l O 
D-glucose [C]D [C]- [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
) [C]) O 
. [C]. O 

Functional [C]F [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
blocking [C]b [C]l [C]o [C]c [C]k [C]i [C]n [C]g O 
of [C]o [C]f O 
intercellular [C]i [C]n [C]t [C]e [C]r [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n I-protein 
molecule-1 [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]- [C]1 E-protein 
on [C]o [C]n O 
mesangial [C]m [C]e [C]s [C]a [C]n [C]g [C]i [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
with [C]w [C]i [C]t [C]h O 
rat [C]r [C]a [C]t B-protein 
intercellular [C]i [C]n [C]t [C]e [C]r [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r I-protein 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n I-protein 
molecule-1 [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]- [C]1 I-protein 
monoclonal [C]m [C]o [C]n [C]o [C]c [C]l [C]o [C]n [C]a [C]l I-protein 
antibody [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y E-protein 
, [C], O 
calphostin [C]c [C]a [C]l [C]p [C]h [C]o [C]s [C]t [C]i [C]n O 
C [C]C O 
, [C], O 
staurosporine [C]s [C]t [C]a [C]u [C]r [C]o [C]s [C]p [C]o [C]r [C]i [C]n [C]e O 
, [C], O 
or [C]o [C]r O 
N-tosyl-L-phenylalanine [C]N [C]- [C]t [C]o [C]s [C]y [C]l [C]- [C]L [C]- [C]p [C]h [C]e [C]n [C]y [C]l [C]a [C]l [C]a [C]n [C]i [C]n [C]e O 
chloromethyl [C]c [C]h [C]l [C]o [C]r [C]o [C]m [C]e [C]t [C]h [C]y [C]l O 
ketone [C]k [C]e [C]t [C]o [C]n [C]e O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
high [C]h [C]i [C]g [C]h O 
glucose- [C]g [C]l [C]u [C]c [C]o [C]s [C]e [C]- O 
or [C]o [C]r O 
high [C]h [C]i [C]g [C]h O 
mannitol-induced [C]m [C]a [C]n [C]n [C]i [C]t [C]o [C]l [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
( [C]( O 
p [C]p O 
< [C]< O 
< [C]< O 
0.05 [C]0 [C]. [C]0 [C]5 O 
) [C]) O 
. [C]. O 

CONCLUSION/INTERPRETATION [C]C [C]O [C]N [C]C [C]L [C]U [C]S [C]I [C]O [C]N [C]/ [C]I [C]N [C]T [C]E [C]R [C]P [C]R [C]E [C]T [C]A [C]T [C]I [C]O [C]N O 
: [C]: O 
These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
high [C]h [C]i [C]g [C]h O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
can [C]c [C]a [C]n O 
upregulate [C]u [C]p [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
intercellular [C]i [C]n [C]t [C]e [C]r [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n I-protein 
molecule-1 [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]- [C]1 E-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
and [C]a [C]n [C]d O 
mRNA [C]m [C]R [C]N [C]A O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
vascular [C]v [C]a [C]s [C]c [C]u [C]l [C]a [C]r O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
molecule-1 [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]- [C]1 O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
mesangial [C]m [C]e [C]s [C]a [C]n [C]g [C]i [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
promote [C]p [C]r [C]o [C]m [C]o [C]t [C]e O 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
up-regulation [C]u [C]p [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
intercellular [C]i [C]n [C]t [C]e [C]r [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n I-protein 
molecule-1 [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]- [C]1 E-protein 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
osmotic [C]o [C]s [C]m [C]o [C]t [C]i [C]c O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
, [C], O 
possibly [C]p [C]o [C]s [C]s [C]i [C]b [C]l [C]y O 
depending [C]d [C]e [C]p [C]e [C]n [C]d [C]i [C]n [C]g O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
C [C]C E-protein 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor-kappa [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
( [C]( O 
PKC [C]P [C]K [C]C S-protein 
- [C]- O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
) [C]) O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
. [C]. O 

High [C]H [C]i [C]g [C]h O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
itself [C]i [C]t [C]s [C]e [C]l [C]f O 
can [C]c [C]a [C]n O 
also [C]a [C]l [C]s [C]o O 
promote [C]p [C]r [C]o [C]m [C]o [C]t [C]e O 
mesangial [C]m [C]e [C]s [C]a [C]n [C]g [C]i [C]a [C]l O 
cell [C]c [C]e [C]l [C]l O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
PKC-NF-kappa [C]P [C]K [C]C [C]- [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a O 
B [C]B O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
. [C]. O 

We [C]W [C]e O 
conclude [C]c [C]o [C]n [C]c [C]l [C]u [C]d [C]e O 
that [C]t [C]h [C]a [C]t O 
hyperglycaemia [C]h [C]y [C]p [C]e [C]r [C]g [C]l [C]y [C]c [C]a [C]e [C]m [C]i [C]a O 
in [C]i [C]n O 
itself [C]i [C]t [C]s [C]e [C]l [C]f O 
seems [C]s [C]e [C]e [C]m [C]s O 
to [C]t [C]o O 
be [C]b [C]e O 
an [C]a [C]n O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
early [C]e [C]a [C]r [C]l [C]y O 
diabetic [C]d [C]i [C]a [C]b [C]e [C]t [C]i [C]c O 
nephropathy [C]n [C]e [C]p [C]h [C]r [C]o [C]p [C]a [C]t [C]h [C]y O 
. [C]. O 

Combined [C]C [C]o [C]m [C]b [C]i [C]n [C]e [C]d O 
corticosteroid/ [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]/ O 
granulocyte [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e B-protein 
colony-stimulating [C]c [C]o [C]l [C]o [C]n [C]y [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]n [C]g I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
( [C]( O 
G-CSF [C]G [C]- [C]C [C]S [C]F S-protein 
) [C]) O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
severe [C]s [C]e [C]v [C]e [C]r [C]e O 
congenital [C]c [C]o [C]n [C]g [C]e [C]n [C]i [C]t [C]a [C]l O 
neutropenia [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]e [C]n [C]i [C]a O 
unresponsive [C]u [C]n [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e O 
to [C]t [C]o O 
G-CSF [C]G [C]- [C]C [C]S [C]F S-protein 
: [C]: O 
Activated [C]A [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
synergize [C]s [C]y [C]n [C]e [C]r [C]g [C]i [C]z [C]e O 
with [C]w [C]i [C]t [C]h O 
G-CSF [C]G [C]- [C]C [C]S [C]F S-protein 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
. [C]. O 

More [C]M [C]o [C]r [C]e O 
than [C]t [C]h [C]a [C]n O 
90 [C]9 [C]0 O 
% [C]% O 
of [C]o [C]f O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
severe [C]s [C]e [C]v [C]e [C]r [C]e O 
congenital [C]c [C]o [C]n [C]g [C]e [C]n [C]i [C]t [C]a [C]l O 
neutropenia [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]e [C]n [C]i [C]a O 
( [C]( O 
SCN [C]S [C]C [C]N O 
) [C]) O 
respond [C]r [C]e [C]s [C]p [C]o [C]n [C]d O 
to [C]t [C]o O 
granulocyte [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e B-protein 
colony-stimulating [C]c [C]o [C]l [C]o [C]n [C]y [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]n [C]g I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
( [C]( O 
G-CSF [C]G [C]- [C]C [C]S [C]F S-protein 
) [C]) O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
basis [C]b [C]a [C]s [C]i [C]s O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
refractory [C]r [C]e [C]f [C]r [C]a [C]c [C]t [C]o [C]r [C]y O 
state [C]s [C]t [C]a [C]t [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
remaining [C]r [C]e [C]m [C]a [C]i [C]n [C]i [C]n [C]g O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
is [C]i [C]s O 
unknown [C]u [C]n [C]k [C]n [C]o [C]w [C]n O 
. [C]. O 

To [C]T [C]o O 
address [C]a [C]d [C]d [C]r [C]e [C]s [C]s O 
this [C]t [C]h [C]i [C]s O 
issue [C]i [C]s [C]s [C]u [C]e O 
, [C], O 
we [C]w [C]e O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
a [C]a O 
child [C]c [C]h [C]i [C]l [C]d O 
with [C]w [C]i [C]t [C]h O 
SCN [C]S [C]C [C]N O 
who [C]w [C]h [C]o O 
was [C]w [C]a [C]s O 
totally [C]t [C]o [C]t [C]a [C]l [C]l [C]y O 
unresponsive [C]u [C]n [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e O 
to [C]t [C]o O 
G-CSF [C]G [C]- [C]C [C]S [C]F S-protein 
and [C]a [C]n [C]d O 
had [C]h [C]a [C]d O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
point [C]p [C]o [C]i [C]n [C]t O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
extracellular [C]e [C]x [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
G-CSF [C]G [C]- [C]C [C]S [C]F B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
( [C]( O 
GCSF-R [C]G [C]C [C]S [C]F [C]- [C]R S-protein 
) [C]) O 
. [C]. O 

Marrow [C]M [C]a [C]r [C]r [C]o [C]w O 
stromal [C]s [C]t [C]r [C]o [C]m [C]a [C]l O 
support [C]s [C]u [C]p [C]p [C]o [C]r [C]t O 
of [C]o [C]f O 
granulopoiesis [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
was [C]w [C]a [C]s O 
evaluated [C]e [C]v [C]a [C]l [C]u [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
plating [C]p [C]l [C]a [C]t [C]i [C]n [C]g O 
CD34 [C]C [C]D [C]3 [C]4 B-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
on [C]o [C]n O 
preformed [C]p [C]r [C]e [C]f [C]o [C]r [C]m [C]e [C]d O 
stromal [C]s [C]t [C]r [C]o [C]m [C]a [C]l O 
layers [C]l [C]a [C]y [C]e [C]r [C]s O 
. [C]. O 

Nonadherent [C]N [C]o [C]n [C]a [C]d [C]h [C]e [C]r [C]e [C]n [C]t B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
harvested [C]h [C]a [C]r [C]v [C]e [C]s [C]t [C]e [C]d O 
and [C]a [C]n [C]d O 
assayed [C]a [C]s [C]s [C]a [C]y [C]e [C]d O 
in [C]i [C]n O 
clonogenic [C]c [C]l [C]o [C]n [C]o [C]g [C]e [C]n [C]i [C]c O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
for [C]f [C]o [C]r O 
granulocytic [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]i [C]c O 
colony [C]c [C]o [C]l [C]o [C]n [C]y O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
G-CSF [C]G [C]- [C]C [C]S [C]F S-protein 
and [C]a [C]n [C]d O 
corticosteroids [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]s O 
on [C]o [C]n O 
granulopoiesis [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
was [C]w [C]a [C]s O 
evaluated [C]e [C]v [C]a [C]l [C]u [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
clonogenic [C]c [C]l [C]o [C]n [C]o [C]g [C]e [C]n [C]i [C]c O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
of [C]o [C]f O 
marrow [C]m [C]a [C]r [C]r [C]o [C]w B-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
by [C]b [C]y O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
murine [C]m [C]u [C]r [C]i [C]n [C]e B-cell_line 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e I-cell_line 
32D [C]3 [C]2 [C]D E-cell_line 
expressing [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
's [C]' [C]s O 
mutated [C]m [C]u [C]t [C]a [C]t [C]e [C]d B-protein 
G-CSFR [C]G [C]- [C]C [C]S [C]F [C]R E-protein 
, [C], O 
and [C]a [C]n [C]d O 
by [C]b [C]y O 
measuring [C]m [C]e [C]a [C]s [C]u [C]r [C]i [C]n [C]g O 
STAT5 [C]S [C]T [C]A [C]T [C]5 O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
from [C]f [C]r [C]o [C]m O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Patient [C]P [C]a [C]t [C]i [C]e [C]n [C]t O 
's [C]' [C]s O 
stroma [C]s [C]t [C]r [C]o [C]m [C]a O 
supported [C]s [C]u [C]p [C]p [C]o [C]r [C]t [C]e [C]d O 
granulopoiesis [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
derived [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
marrow [C]m [C]a [C]r [C]r [C]o [C]w B-cell_type 
CD34 [C]C [C]D [C]3 [C]4 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
a [C]a O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
manner [C]m [C]a [C]n [C]n [C]e [C]r O 
. [C]. O 

Normal [C]N [C]o [C]r [C]m [C]a [C]l O 
stroma [C]s [C]t [C]r [C]o [C]m [C]a O 
, [C], O 
however [C]h [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
failed [C]f [C]a [C]i [C]l [C]e [C]d O 
to [C]t [C]o O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
granulopoiesis [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
from [C]f [C]r [C]o [C]m O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
's [C]' [C]s O 
CD34 [C]C [C]D [C]3 [C]4 B-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Clonogenic [C]C [C]l [C]o [C]n [C]o [C]g [C]e [C]n [C]i [C]c O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
's [C]' [C]s O 
marrow [C]m [C]a [C]r [C]r [C]o [C]w B-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
incorporating [C]i [C]n [C]c [C]o [C]r [C]p [C]o [C]r [C]a [C]t [C]i [C]n [C]g O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
G-CSF [C]G [C]- [C]C [C]S [C]F S-protein 
or [C]o [C]r O 
hydrocortisone [C]h [C]y [C]d [C]r [C]o [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]n [C]e O 
produced [C]p [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
little [C]l [C]i [C]t [C]t [C]l [C]e O 
neutrophil [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]h [C]i [C]l O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
inclusion [C]i [C]n [C]c [C]l [C]u [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
G-CSF [C]G [C]- [C]C [C]S [C]F S-protein 
and [C]a [C]n [C]d O 
hydrocortisone [C]h [C]y [C]d [C]r [C]o [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]n [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e B-protein 
`` [C]` [C]` I-protein 
cocktail [C]c [C]o [C]c [C]k [C]t [C]a [C]i [C]l I-protein 
'' [C]' [C]' E-protein 
markedly [C]m [C]a [C]r [C]k [C]e [C]d [C]l [C]y O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
neutrophil [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]h [C]i [C]l O 
numbers [C]n [C]u [C]m [C]b [C]e [C]r [C]s O 
. [C]. O 

Proliferation [C]P [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
32D [C]3 [C]2 [C]D B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
expressing [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
mutated [C]m [C]u [C]t [C]a [C]t [C]e [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
and [C]a [C]n [C]d O 
STAT5 [C]S [C]T [C]A [C]T [C]5 O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
were [C]w [C]e [C]r [C]e O 
improved [C]i [C]m [C]p [C]r [C]o [C]v [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
combination [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
G-CSF [C]G [C]- [C]C [C]S [C]F S-protein 
and [C]a [C]n [C]d O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
. [C]. O 

When [C]W [C]h [C]e [C]n O 
small [C]s [C]m [C]a [C]l [C]l O 
daily [C]d [C]a [C]i [C]l [C]y O 
doses [C]d [C]o [C]s [C]e [C]s O 
of [C]o [C]f O 
oral [C]o [C]r [C]a [C]l O 
prednisone [C]p [C]r [C]e [C]d [C]n [C]i [C]s [C]o [C]n [C]e O 
were [C]w [C]e [C]r [C]e O 
then [C]t [C]h [C]e [C]n O 
administered [C]a [C]d [C]m [C]i [C]n [C]i [C]s [C]t [C]e [C]r [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
conventional [C]c [C]o [C]n [C]v [C]e [C]n [C]t [C]i [C]o [C]n [C]a [C]l O 
doses [C]d [C]o [C]s [C]e [C]s O 
of [C]o [C]f O 
subcutaneous [C]s [C]u [C]b [C]c [C]u [C]t [C]a [C]n [C]e [C]o [C]u [C]s B-protein 
G-CSF [C]G [C]- [C]C [C]S [C]F E-protein 
, [C], O 
the [C]t [C]h [C]e O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
responded [C]r [C]e [C]s [C]p [C]o [C]n [C]d [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
neutrophil [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]h [C]i [C]l O 
numbers [C]n [C]u [C]m [C]b [C]e [C]r [C]s O 
and [C]a [C]n [C]d O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
complete [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e O 
reversal [C]r [C]e [C]v [C]e [C]r [C]s [C]a [C]l O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
infectious [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]u [C]s O 
problems [C]p [C]r [C]o [C]b [C]l [C]e [C]m [C]s O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
provide [C]p [C]r [C]o [C]v [C]i [C]d [C]e O 
insight [C]i [C]n [C]s [C]i [C]g [C]h [C]t O 
into [C]i [C]n [C]t [C]o O 
SCN [C]S [C]C [C]N O 
unresponsive [C]u [C]n [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e O 
to [C]t [C]o O 
standard [C]s [C]t [C]a [C]n [C]d [C]a [C]r [C]d O 
G-CSF [C]G [C]- [C]C [C]S [C]F S-protein 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
corrective [C]c [C]o [C]r [C]r [C]e [C]c [C]t [C]i [C]v [C]e O 
action [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
combined [C]c [C]o [C]m [C]b [C]i [C]n [C]e [C]d O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
G-CSF [C]G [C]- [C]C [C]S [C]F S-protein 
and [C]a [C]n [C]d O 
corticosteroids [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]s O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
synergistic [C]s [C]y [C]n [C]e [C]r [C]g [C]i [C]s [C]t [C]i [C]c O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
STAT5 [C]S [C]T [C]A [C]T [C]5 S-protein 
. [C]. O 

Human [C]H [C]u [C]m [C]a [C]n B-cell_type 
renal [C]r [C]e [C]n [C]a [C]l I-cell_type 
mesangial [C]m [C]e [C]s [C]a [C]n [C]g [C]i [C]a [C]l I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
are [C]a [C]r [C]e O 
a [C]a O 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
anti-inflammatory [C]a [C]n [C]t [C]i [C]- [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
action [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
9-cis [C]9 [C]- [C]c [C]i [C]s O 
retinoic [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
. [C]. O 

Mesangial [C]M [C]e [C]s [C]a [C]n [C]g [C]i [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
play [C]p [C]l [C]a [C]y O 
an [C]a [C]n O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
glomerular [C]g [C]l [C]o [C]m [C]e [C]r [C]u [C]l [C]a [C]r O 
injury [C]i [C]n [C]j [C]u [C]r [C]y O 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
in [C]i [C]n O 
cultured [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]d B-cell_line 
human [C]h [C]u [C]m [C]a [C]n I-cell_line 
mesangial [C]m [C]e [C]s [C]a [C]n [C]g [C]i [C]a [C]l I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
( [C]( O 
CHMC [C]C [C]H [C]M [C]C S-cell_line 
) [C]) O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
9-cis [C]9 [C]- [C]c [C]i [C]s O 
retinoic [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
( [C]( O 
9-cRA [C]9 [C]- [C]c [C]R [C]A O 
) [C]) O 
, [C], O 
an [C]a [C]n O 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r O 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
retinoic [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]c B-protein 
acid [C]a [C]c [C]i [C]d I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
( [C]( O 
RARs [C]R [C]A [C]R [C]s S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
retinoid [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]d B-protein 
X [C]X I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
( [C]( O 
RXRs [C]R [C]X [C]R [C]s S-protein 
) [C]) O 
. [C]. O 

9-cRA [C]9 [C]- [C]c [C]R [C]A O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
foetal [C]f [C]o [C]e [C]t [C]a [C]l O 
calf [C]c [C]a [C]l [C]f O 
serum-induced [C]s [C]e [C]r [C]u [C]m [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
CHMC [C]C [C]H [C]M [C]C S-cell_line 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

It [C]I [C]t O 
also [C]a [C]l [C]s [C]o O 
prevented [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]e [C]d O 
CHMC [C]C [C]H [C]M [C]C S-cell_line 
death [C]d [C]e [C]a [C]t [C]h O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
mediator [C]m [C]e [C]d [C]i [C]a [C]t [C]o [C]r O 
H [C]H O 
( [C]( O 
2 [C]2 O 
) [C]) O 
O [C]O O 
( [C]( O 
2 [C]2 O 
) [C]) O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
preventive [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]i [C]v [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
due [C]d [C]u [C]e O 
to [C]t [C]o O 
any [C]a [C]n [C]y O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
H [C]H O 
( [C]( O 
2 [C]2 O 
) [C]) O 
O [C]O O 
( [C]( O 
2 [C]2 O 
) [C]) O 
catabolism [C]c [C]a [C]t [C]a [C]b [C]o [C]l [C]i [C]s [C]m O 
and [C]a [C]n [C]d O 
it [C]i [C]t O 
persisted [C]p [C]e [C]r [C]s [C]i [C]s [C]t [C]e [C]d O 
even [C]e [C]v [C]e [C]n O 
when [C]w [C]h [C]e [C]n O 
both [C]b [C]o [C]t [C]h O 
catalase [C]c [C]a [C]t [C]a [C]l [C]a [C]s [C]e O 
and [C]a [C]n [C]d O 
glutathione [C]g [C]l [C]u [C]t [C]a [C]t [C]h [C]i [C]o [C]n [C]e O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
were [C]w [C]e [C]r [C]e O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
. [C]. O 

Finally [C]F [C]i [C]n [C]a [C]l [C]l [C]y O 
, [C], O 
9-cRA [C]9 [C]- [C]c [C]R [C]A O 
diminished [C]d [C]i [C]m [C]i [C]n [C]i [C]s [C]h [C]e [C]d O 
monocyte [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
to [C]t [C]o O 
FCS-stimulated [C]F [C]C [C]S [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_line 
CHMC [C]C [C]H [C]M [C]C E-cell_line 
. [C]. O 

Interestingly [C]I [C]n [C]t [C]e [C]r [C]e [C]s [C]t [C]i [C]n [C]g [C]l [C]y O 
, [C], O 
the [C]t [C]h [C]e O 
retinoid [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]d O 
also [C]a [C]l [C]s [C]o O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
in [C]i [C]n O 
FCS-stimulated [C]F [C]C [C]S [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
the [C]t [C]h [C]e O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
two [C]t [C]w [C]o O 
mesangial [C]m [C]e [C]s [C]a [C]n [C]g [C]i [C]a [C]l B-protein 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n I-protein 
molecules [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]s E-protein 
, [C], O 
fibronectin [C]f [C]i [C]b [C]r [C]o [C]n [C]e [C]c [C]t [C]i [C]n S-protein 
and [C]a [C]n [C]d O 
osteopontin [C]o [C]s [C]t [C]e [C]o [C]p [C]o [C]n [C]t [C]i [C]n S-protein 
, [C], O 
but [C]b [C]u [C]t O 
it [C]i [C]t O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
modify [C]m [C]o [C]d [C]i [C]f [C]y O 
the [C]t [C]h [C]e O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
intercellular [C]i [C]n [C]t [C]e [C]r [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n I-protein 
molecule-1 [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]- [C]1 E-protein 
and [C]a [C]n [C]d O 
vascular [C]v [C]a [C]s [C]c [C]u [C]l [C]a [C]r B-protein 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n I-protein 
molecule-1 [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]- [C]1 E-protein 
. [C]. O 

All [C]A [C]l [C]l O 
major [C]m [C]a [C]j [C]o [C]r O 
RARs [C]R [C]A [C]R [C]s B-protein 
and [C]a [C]n [C]d I-protein 
RXRs [C]R [C]X [C]R [C]s I-protein 
isotypes [C]i [C]s [C]o [C]t [C]y [C]p [C]e [C]s E-protein 
were [C]w [C]e [C]r [C]e O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
CHMC [C]C [C]H [C]M [C]C S-cell_line 
regardless [C]r [C]e [C]g [C]a [C]r [C]d [C]l [C]e [C]s [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
or [C]o [C]r O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
9-cRA [C]9 [C]- [C]c [C]R [C]A O 
. [C]. O 

Transcripts [C]T [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]s O 
to [C]t [C]o O 
RAR-alpha [C]R [C]A [C]R [C]- [C]a [C]l [C]p [C]h [C]a S-RNA 
, [C], O 
RAR-beta [C]R [C]A [C]R [C]- [C]b [C]e [C]t [C]a S-RNA 
and [C]a [C]n [C]d O 
RXR-alpha [C]R [C]X [C]R [C]- [C]a [C]l [C]p [C]h [C]a S-RNA 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
after [C]a [C]f [C]t [C]e [C]r O 
incubation [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
9-cRA [C]9 [C]- [C]c [C]R [C]A O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
RXR-gamma [C]R [C]X [C]R [C]- [C]g [C]a [C]m [C]m [C]a S-RNA 
was [C]w [C]a [C]s O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
a [C]a O 
major [C]m [C]a [C]j [C]o [C]r O 
role [C]r [C]o [C]l [C]e O 
for [C]f [C]o [C]r O 
RARs [C]R [C]A [C]R [C]s S-protein 
and [C]a [C]n [C]d O 
RXRs [C]R [C]X [C]R [C]s S-protein 
in [C]i [C]n O 
9-cRA-anti-inflammatory [C]9 [C]- [C]c [C]R [C]A [C]- [C]a [C]n [C]t [C]i [C]- [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
. [C]. O 

9-cRA [C]9 [C]- [C]c [C]R [C]A O 
was [C]w [C]a [C]s O 
toxic [C]t [C]o [C]x [C]i [C]c O 
only [C]o [C]n [C]l [C]y O 
at [C]a [C]t O 
50 [C]5 [C]0 O 
microM [C]m [C]i [C]c [C]r [C]o [C]M O 
( [C]( O 
a [C]a O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
50 [C]5 [C]0 O 
- [C]- O 
5000 [C]5 [C]0 [C]0 [C]0 O 
times [C]t [C]i [C]m [C]e [C]s O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
above [C]a [C]b [C]o [C]v [C]e O 
) [C]) O 
. [C]. O 

Cell [C]C [C]e [C]l [C]l O 
death [C]d [C]e [C]a [C]t [C]h O 
occurred [C]o [C]c [C]c [C]u [C]r [C]r [C]e [C]d O 
by [C]b [C]y O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
, [C], O 
whose [C]w [C]h [C]o [C]s [C]e O 
onset [C]o [C]n [C]s [C]e [C]t O 
was [C]w [C]a [C]s O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
pronounced [C]p [C]r [C]o [C]n [C]o [C]u [C]n [C]c [C]e [C]d O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
catalase [C]c [C]a [C]t [C]a [C]l [C]a [C]s [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
glutathione [C]g [C]l [C]u [C]t [C]a [C]t [C]h [C]i [C]o [C]n [C]e O 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
, [C], O 
being [C]b [C]e [C]i [C]n [C]g O 
more [C]m [C]o [C]r [C]e O 
effectively [C]e [C]f [C]f [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
all-trans [C]a [C]l [C]l [C]- [C]t [C]r [C]a [C]n [C]s O 
retinoic [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
. [C]. O 

Modulation [C]M [C]o [C]d [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
oxidant/antioxidant [C]o [C]x [C]i [C]d [C]a [C]n [C]t [C]/ [C]a [C]n [C]t [C]i [C]o [C]x [C]i [C]d [C]a [C]n [C]t O 
balance [C]b [C]a [C]l [C]a [C]n [C]c [C]e O 
failed [C]f [C]a [C]i [C]l [C]e [C]d O 
to [C]t [C]o O 
inhibit [C]i [C]n [C]h [C]i [C]b [C]i [C]t O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
. [C]. O 

We [C]W [C]e O 
conclude [C]c [C]o [C]n [C]c [C]l [C]u [C]d [C]e O 
that [C]t [C]h [C]a [C]t O 
mesangial [C]m [C]e [C]s [C]a [C]n [C]g [C]i [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
might [C]m [C]i [C]g [C]h [C]t O 
be [C]b [C]e O 
a [C]a O 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
glomerulopathies [C]g [C]l [C]o [C]m [C]e [C]r [C]u [C]l [C]o [C]p [C]a [C]t [C]h [C]i [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
9-cRA [C]9 [C]- [C]c [C]R [C]A O 
. [C]. O 

Expression [C]E [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
mammalian [C]m [C]a [C]m [C]m [C]a [C]l [C]i [C]a [C]n B-DNA 
defensin [C]d [C]e [C]f [C]e [C]n [C]s [C]i [C]n I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
. [C]. O 

Antimicrobial [C]A [C]n [C]t [C]i [C]m [C]i [C]c [C]r [C]o [C]b [C]i [C]a [C]l O 
peptides [C]p [C]e [C]p [C]t [C]i [C]d [C]e [C]s O 
are [C]a [C]r [C]e O 
a [C]a O 
prevalent [C]p [C]r [C]e [C]v [C]a [C]l [C]e [C]n [C]t O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
of [C]o [C]f O 
host [C]h [C]o [C]s [C]t O 
defense [C]d [C]e [C]f [C]e [C]n [C]s [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
throughout [C]t [C]h [C]r [C]o [C]u [C]g [C]h [C]o [C]u [C]t O 
nature [C]n [C]a [C]t [C]u [C]r [C]e O 
. [C]. O 

In [C]I [C]n O 
mammals [C]m [C]a [C]m [C]m [C]a [C]l [C]s O 
, [C], O 
defensins [C]d [C]e [C]f [C]e [C]n [C]s [C]i [C]n [C]s S-protein 
are [C]a [C]r [C]e O 
among [C]a [C]m [C]o [C]n [C]g O 
the [C]t [C]h [C]e O 
most [C]m [C]o [C]s [C]t O 
abundant [C]a [C]b [C]u [C]n [C]d [C]a [C]n [C]t O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
broad-spectrum [C]b [C]r [C]o [C]a [C]d [C]- [C]s [C]p [C]e [C]c [C]t [C]r [C]u [C]m O 
antibiotics [C]a [C]n [C]t [C]i [C]b [C]i [C]o [C]t [C]i [C]c [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
are [C]a [C]r [C]e O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
epithelial [C]e [C]p [C]i [C]t [C]h [C]e [C]l [C]i [C]a [C]l B-cell_type 
and [C]a [C]n [C]d I-cell_type 
hematopoietic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
defensin [C]d [C]e [C]f [C]e [C]n [C]s [C]i [C]n O 
peptides [C]p [C]e [C]p [C]t [C]i [C]d [C]e [C]s O 
are [C]a [C]r [C]e O 
especially [C]e [C]s [C]p [C]e [C]c [C]i [C]a [C]l [C]l [C]y O 
abundant [C]a [C]b [C]u [C]n [C]d [C]a [C]n [C]t O 
in [C]i [C]n O 
neutrophils [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]h [C]i [C]l [C]s S-cell_type 
; [C]; O 
however [C]h [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
is [C]i [C]s O 
limited [C]l [C]i [C]m [C]i [C]t [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
promyelocyte [C]p [C]r [C]o [C]m [C]y [C]e [C]l [C]o [C]c [C]y [C]t [C]e O 
stage [C]s [C]t [C]a [C]g [C]e O 
. [C]. O 

In [C]I [C]n O 
epithelial [C]e [C]p [C]i [C]t [C]h [C]e [C]l [C]i [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
defensin [C]d [C]e [C]f [C]e [C]n [C]s [C]i [C]n B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
are [C]a [C]r [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
as [C]a [C]s O 
both [C]b [C]o [C]t [C]h O 
constitutively [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
and [C]a [C]n [C]d O 
inducible [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
. [C]. O 

Induction [C]I [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
by [C]b [C]y O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
bacterial [C]b [C]a [C]c [C]t [C]e [C]r [C]i [C]a [C]l O 
lipopolysaccharide [C]l [C]i [C]p [C]o [C]p [C]o [C]l [C]y [C]s [C]a [C]c [C]c [C]h [C]a [C]r [C]i [C]d [C]e O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
mediators [C]m [C]e [C]d [C]i [C]a [C]t [C]o [C]r [C]s O 
. [C]. O 

In [C]I [C]n O 
vivo [C]v [C]i [C]v [C]o O 
, [C], O 
up-regulation [C]u [C]p [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
defensin [C]d [C]e [C]f [C]e [C]n [C]s [C]i [C]n B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
occurs [C]o [C]c [C]c [C]u [C]r [C]s O 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
infectious [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]u [C]s O 
and [C]a [C]n [C]d O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
states [C]s [C]t [C]a [C]t [C]e [C]s O 
. [C]. O 

Gene [C]G [C]e [C]n [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
occurs [C]o [C]c [C]c [C]u [C]r [C]s O 
via [C]v [C]i [C]a O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
common [C]c [C]o [C]m [C]m [C]o [C]n O 
to [C]t [C]o O 
other [C]o [C]t [C]h [C]e [C]r O 
innate [C]i [C]n [C]n [C]a [C]t [C]e O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
, [C], O 
utilizing [C]u [C]t [C]i [C]l [C]i [C]z [C]i [C]n [C]g O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
( [C]( I-protein 
NF [C]N [C]F I-protein 
) [C]) I-protein 
-kappaB [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
and [C]a [C]n [C]d O 
NF [C]N [C]F B-protein 
interleukin-6 [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]6 E-protein 
. [C]. O 

Together [C]T [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
, [C], O 
the [C]t [C]h [C]e O 
data [C]d [C]a [C]t [C]a O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
a [C]a O 
broad-based [C]b [C]r [C]o [C]a [C]d [C]- [C]b [C]a [C]s [C]e [C]d O 
innate [C]i [C]n [C]n [C]a [C]t [C]e O 
host [C]h [C]o [C]s [C]t O 
defense [C]d [C]e [C]f [C]e [C]n [C]s [C]e O 
whereby [C]w [C]h [C]e [C]r [C]e [C]b [C]y O 
potent [C]p [C]o [C]t [C]e [C]n [C]t O 
antimicrobial [C]a [C]n [C]t [C]i [C]m [C]i [C]c [C]r [C]o [C]b [C]i [C]a [C]l O 
peptides [C]p [C]e [C]p [C]t [C]i [C]d [C]e [C]s O 
are [C]a [C]r [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
to [C]t [C]o O 
prevent [C]p [C]r [C]e [C]v [C]e [C]n [C]t O 
initial [C]i [C]n [C]i [C]t [C]i [C]a [C]l O 
colonization [C]c [C]o [C]l [C]o [C]n [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
pathogenic [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]i [C]c O 
microorganisms [C]m [C]i [C]c [C]r [C]o [C]o [C]r [C]g [C]a [C]n [C]i [C]s [C]m [C]s O 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
the [C]t [C]h [C]e O 
recognition [C]r [C]e [C]c [C]o [C]g [C]n [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
bacteria [C]b [C]a [C]c [C]t [C]e [C]r [C]i [C]a O 
coupled [C]c [C]o [C]u [C]p [C]l [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
nascent [C]n [C]a [C]s [C]c [C]e [C]n [C]t O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
can [C]c [C]a [C]n O 
bolster [C]b [C]o [C]l [C]s [C]t [C]e [C]r O 
this [C]t [C]h [C]i [C]s O 
defense [C]d [C]e [C]f [C]e [C]n [C]s [C]e O 
by [C]b [C]y O 
a [C]a O 
coordinated [C]c [C]o [C]o [C]r [C]d [C]i [C]n [C]a [C]t [C]e [C]d O 
up-regulation [C]u [C]p [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
peptides [C]p [C]e [C]p [C]t [C]i [C]d [C]e [C]s O 
. [C]. O 

Multiple [C]M [C]u [C]l [C]t [C]i [C]p [C]l [C]e O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
cyclic [C]c [C]y [C]c [C]l [C]i [C]c B-protein 
AMP-responsive [C]A [C]M [C]P [C]- [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e I-protein 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
( [C]( O 
CREB [C]C [C]R [C]E [C]B S-protein 
) [C]) O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
CD3/CD28 [C]C [C]D [C]3 [C]/ [C]C [C]D [C]2 [C]8 O 
costimulation [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
optimal [C]o [C]p [C]t [C]i [C]m [C]a [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cAMP-responsive [C]c [C]A [C]M [C]P [C]- [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e B-protein 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
( [C]( O 
CREB [C]C [C]R [C]E [C]B S-protein 
) [C]) O 
, [C], O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
full [C]f [C]u [C]l [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
T [C]T B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
, [C], O 
requires [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]s O 
the [C]t [C]h [C]e O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
CD3 [C]C [C]D [C]3 S-protein 
and [C]a [C]n [C]d O 
CD28 [C]C [C]D [C]2 [C]8 S-protein 
. [C]. O 

Using [C]U [C]s [C]i [C]n [C]g O 
a [C]a O 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
to [C]t [C]o O 
detect [C]d [C]e [C]t [C]e [C]c [C]t O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CREB [C]C [C]R [C]E [C]B S-protein 
and [C]a [C]n [C]d O 
CREB-binding [C]C [C]R [C]E [C]B [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
( [C]( O 
CBP [C]C [C]B [C]P S-protein 
) [C]) O 
, [C], O 
in [C]i [C]n O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
we [C]w [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
CREB [C]C [C]R [C]E [C]B S-protein 
binds [C]b [C]i [C]n [C]d [C]s O 
to [C]t [C]o O 
CBP [C]C [C]B [C]P S-protein 
only [C]o [C]n [C]l [C]y O 
by [C]b [C]y O 
engagement [C]e [C]n [C]g [C]a [C]g [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
CD3 [C]C [C]D [C]3 S-protein 
and [C]a [C]n [C]d O 
CD28 [C]C [C]D [C]2 [C]8 S-protein 
. [C]. O 

CD3/CD28 [C]C [C]D [C]3 [C]/ [C]C [C]D [C]2 [C]8 S-protein 
-promoted [C]- [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]d O 
CREB [C]C [C]R [C]E [C]B S-protein 
- [C]- O 
CBP [C]C [C]B [C]P S-protein 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
dependent [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
on [C]o [C]n O 
p38 [C]p [C]3 [C]8 B-protein 
mitogen-activated [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
( [C]( O 
MAPK [C]M [C]A [C]P [C]K S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
calcium/calmodulin-dependent [C]c [C]a [C]l [C]c [C]i [C]u [C]m [C]/ [C]c [C]a [C]l [C]m [C]o [C]d [C]u [C]l [C]i [C]n [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
( [C]( I-protein 
CaMK [C]C [C]a [C]M [C]K I-protein 
) [C]) I-protein 
IV [C]I [C]V E-protein 
in [C]i [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
extracellular [C]e [C]x [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
signal-regulated [C]s [C]i [C]g [C]n [C]a [C]l [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
. [C]. O 

Extracellular [C]E [C]x [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
signal-regulated [C]s [C]i [C]g [C]n [C]a [C]l [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
, [C], I-protein 
CaMKIV [C]C [C]a [C]M [C]K [C]I [C]V E-protein 
, [C], O 
and [C]a [C]n [C]d O 
p38 [C]p [C]3 [C]8 B-protein 
MAPK [C]M [C]A [C]P [C]K E-protein 
were [C]w [C]e [C]r [C]e O 
also [C]a [C]l [C]s [C]o O 
the [C]t [C]h [C]e O 
kinases [C]k [C]i [C]n [C]a [C]s [C]e [C]s O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
CREB [C]C [C]R [C]E [C]B S-protein 
Ser [C]S [C]e [C]r O 
( [C]( O 
133 [C]1 [C]3 [C]3 O 
) [C]) O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
CD3/CD28 [C]C [C]D [C]3 [C]/ [C]C [C]D [C]2 [C]8 S-protein 
. [C]. O 

A [C]A O 
reconstitution [C]r [C]e [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]o [C]n O 
experiment [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t O 
illustrated [C]i [C]l [C]l [C]u [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
optimum [C]o [C]p [C]t [C]i [C]m [C]u [C]m O 
CREB [C]C [C]R [C]E [C]B S-protein 
- [C]- O 
CBP [C]C [C]B [C]P S-protein 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
CREB [C]C [C]R [C]E [C]B S-protein 
trans-activation [C]t [C]r [C]a [C]n [C]s [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
were [C]w [C]e [C]r [C]e O 
attained [C]a [C]t [C]t [C]a [C]i [C]n [C]e [C]d O 
when [C]w [C]h [C]e [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
three [C]t [C]h [C]r [C]e [C]e O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
were [C]w [C]e [C]r [C]e O 
simultaneously [C]s [C]i [C]m [C]u [C]l [C]t [C]a [C]n [C]e [C]o [C]u [C]s [C]l [C]y O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Our [C]O [C]u [C]r O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
coordinated [C]c [C]o [C]o [C]r [C]d [C]i [C]n [C]a [C]t [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
kinases [C]k [C]i [C]n [C]a [C]s [C]e [C]s S-protein 
leads [C]l [C]e [C]a [C]d [C]s O 
to [C]t [C]o O 
full [C]f [C]u [C]l [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CREB [C]C [C]R [C]E [C]B S-protein 
. [C]. O 

Notably [C]N [C]o [C]t [C]a [C]b [C]l [C]y O 
, [C], O 
CD28 [C]C [C]D [C]2 [C]8 O 
ligation [C]l [C]i [C]g [C]a [C]t [C]i [C]o [C]n O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
p38 [C]p [C]3 [C]8 B-protein 
MAPK [C]M [C]A [C]P [C]K E-protein 
and [C]a [C]n [C]d O 
CaMKIV [C]C [C]a [C]M [C]K [C]I [C]V S-protein 
, [C], O 
the [C]t [C]h [C]e O 
kinases [C]k [C]i [C]n [C]a [C]s [C]e [C]s S-protein 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
CD3 [C]C [C]D [C]3 O 
engagement [C]e [C]n [C]g [C]a [C]g [C]e [C]m [C]e [C]n [C]t O 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
CD28 [C]C [C]D [C]2 [C]8 S-protein 
acts [C]a [C]c [C]t [C]s O 
by [C]b [C]y O 
increasing [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
extent [C]e [C]x [C]t [C]e [C]n [C]t O 
of [C]o [C]f O 
p38 [C]p [C]3 [C]8 B-protein 
MAPK [C]M [C]A [C]P [C]K E-protein 
and [C]a [C]n [C]d O 
CaMKIV [C]C [C]a [C]M [C]K [C]I [C]V S-protein 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
support [C]s [C]u [C]p [C]p [C]o [C]r [C]t O 
the [C]t [C]h [C]e O 
model [C]m [C]o [C]d [C]e [C]l O 
of [C]o [C]f O 
a [C]a O 
minimum [C]m [C]i [C]n [C]i [C]m [C]u [C]m O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
threshold [C]t [C]h [C]r [C]e [C]s [C]h [C]o [C]l [C]d O 
for [C]f [C]o [C]r O 
CREB [C]C [C]R [C]E [C]B S-protein 
- [C]- O 
CBP [C]C [C]B [C]P S-protein 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
that [C]t [C]h [C]a [C]t O 
can [C]c [C]a [C]n O 
be [C]b [C]e O 
reached [C]r [C]e [C]a [C]c [C]h [C]e [C]d O 
only [C]o [C]n [C]l [C]y O 
when [C]w [C]h [C]e [C]n O 
both [C]b [C]o [C]t [C]h O 
CD3 [C]C [C]D [C]3 S-protein 
and [C]a [C]n [C]d O 
CD28 [C]C [C]D [C]2 [C]8 S-protein 
are [C]a [C]r [C]e O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
. [C]. O 

The [C]T [C]h [C]e O 
murine [C]m [C]u [C]r [C]i [C]n [C]e B-DNA 
IL-2 [C]I [C]L [C]- [C]2 I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
contains [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]s O 
distal [C]d [C]i [C]s [C]t [C]a [C]l B-DNA 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y I-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
responsive [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
Ah [C]A [C]h B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
, [C], O 
a [C]a O 
member [C]m [C]e [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
evolutionarily [C]e [C]v [C]o [C]l [C]u [C]t [C]i [C]o [C]n [C]a [C]r [C]i [C]l [C]y O 
conserved [C]c [C]o [C]n [C]s [C]e [C]r [C]v [C]e [C]d O 
bHLH-PAS [C]b [C]H [C]L [C]H [C]- [C]P [C]A [C]S B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y E-protein 
. [C]. O 

Signaling [C]S [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
TCR [C]T [C]C [C]R S-protein 
and [C]a [C]n [C]d O 
costimulatory [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
primarily [C]p [C]r [C]i [C]m [C]a [C]r [C]i [C]l [C]y O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
in [C]i [C]n O 
naive [C]n [C]a [C]i [C]v [C]e B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
minimal [C]m [C]i [C]n [C]i [C]m [C]a [C]l B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
necessary [C]n [C]e [C]c [C]e [C]s [C]s [C]a [C]r [C]y O 
for [C]f [C]o [C]r O 
this [C]t [C]h [C]i [C]s O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
lies [C]l [C]i [C]e [C]s O 
proximal [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]l O 
, [C], O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
-300 [C]- [C]3 [C]0 [C]0 O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-DNA 
start [C]s [C]t [C]a [C]r [C]t I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
. [C]. O 

We [C]W [C]e O 
had [C]h [C]a [C]d O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
shown [C]s [C]h [C]o [C]w [C]n O 
that [C]t [C]h [C]a [C]t O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
arylhydrocarbon [C]a [C]r [C]y [C]l [C]h [C]y [C]d [C]r [C]o [C]c [C]a [C]r [C]b [C]o [C]n B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
( [C]( O 
AHR [C]A [C]H [C]R S-protein 
) [C]) O 
, [C], O 
a [C]a O 
member [C]m [C]e [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
bHLH-PAS [C]b [C]H [C]L [C]H [C]- [C]P [C]A [C]S B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y I-protein 
of [C]o [C]f I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
, [C], O 
leads [C]l [C]e [C]a [C]d [C]s O 
to [C]t [C]o O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
mRNA [C]m [C]R [C]N [C]A O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-2 [C]I [C]L [C]- [C]2 S-RNA 
in [C]i [C]n O 
murine [C]m [C]u [C]r [C]i [C]n [C]e B-cell_type 
fetal [C]f [C]e [C]t [C]a [C]l I-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
AHR [C]A [C]H [C]R S-protein 
is [C]i [C]s O 
abundant [C]a [C]b [C]u [C]n [C]d [C]a [C]n [C]t O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
thymus [C]t [C]h [C]y [C]m [C]u [C]s O 
and [C]a [C]n [C]d O 
may [C]m [C]a [C]y O 
play [C]p [C]l [C]a [C]y O 
a [C]a O 
role [C]r [C]o [C]l [C]e O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
. [C]. O 

Moreover [C]M [C]o [C]r [C]e [C]o [C]v [C]e [C]r O 
, [C], O 
its [C]i [C]t [C]s O 
overactivation [C]o [C]v [C]e [C]r [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
chemicals [C]c [C]h [C]e [C]m [C]i [C]c [C]a [C]l [C]s O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
dioxins [C]d [C]i [C]o [C]x [C]i [C]n [C]s O 
leads [C]l [C]e [C]a [C]d [C]s O 
to [C]t [C]o O 
immunosuppression [C]i [C]m [C]m [C]u [C]n [C]o [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
thymic [C]t [C]h [C]y [C]m [C]i [C]c O 
involution [C]i [C]n [C]v [C]o [C]l [C]u [C]t [C]i [C]o [C]n O 
. [C]. O 

Binding [C]B [C]i [C]n [C]d [C]i [C]n [C]g O 
motifs [C]m [C]o [C]t [C]i [C]f [C]s O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
liganded [C]l [C]i [C]g [C]a [C]n [C]d [C]e [C]d B-protein 
AHR [C]A [C]H [C]R E-protein 
can [C]c [C]a [C]n O 
be [C]b [C]e O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
distal [C]d [C]i [C]s [C]t [C]a [C]l B-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n I-DNA 
-1300 [C]- [C]1 [C]3 [C]0 [C]0 I-DNA 
to [C]t [C]o I-DNA 
-800 [C]- [C]8 [C]0 [C]0 E-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
mouse [C]m [C]o [C]u [C]s [C]e B-DNA 
IL-2 [C]I [C]L [C]- [C]2 I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

We [C]W [C]e O 
show [C]s [C]h [C]o [C]w O 
here [C]h [C]e [C]r [C]e O 
that [C]t [C]h [C]a [C]t O 
these [C]t [C]h [C]e [C]s [C]e O 
DNA [C]D [C]N [C]A B-DNA 
motifs [C]m [C]o [C]t [C]i [C]f [C]s E-DNA 
, [C], O 
the [C]t [C]h [C]e O 
so-called [C]s [C]o [C]- [C]c [C]a [C]l [C]l [C]e [C]d O 
dioxin [C]d [C]i [C]o [C]x [C]i [C]n B-DNA 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e I-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
, [C], O 
after [C]a [C]f [C]t [C]e [C]r O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
liganded [C]l [C]i [C]g [C]a [C]n [C]d [C]e [C]d B-protein 
AHR [C]A [C]H [C]R E-protein 
are [C]a [C]r [C]e O 
sufficient [C]s [C]u [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
to [C]t [C]o O 
transactivate [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
luciferase [C]l [C]u [C]c [C]i [C]f [C]e [C]r [C]a [C]s [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
a [C]a O 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r O 
gene [C]g [C]e [C]n [C]e O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
. [C]. O 

The [C]T [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
can [C]c [C]a [C]n O 
be [C]b [C]e O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
AHR [C]A [C]H [C]R S-protein 
also [C]a [C]l [C]s [C]o O 
in [C]i [C]n O 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
after [C]a [C]f [C]t [C]e [C]r O 
injection [C]i [C]n [C]j [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
2 [C]2 O 
, [C], O 
3 [C]3 O 
, [C], O 
7 [C]7 O 
, [C], O 
8-tetrachlorodibenzo-p-dioxin [C]8 [C]- [C]t [C]e [C]t [C]r [C]a [C]c [C]h [C]l [C]o [C]r [C]o [C]d [C]i [C]b [C]e [C]n [C]z [C]o [C]- [C]p [C]- [C]d [C]i [C]o [C]x [C]i [C]n O 
, [C], O 
a [C]a O 
potent [C]p [C]o [C]t [C]e [C]n [C]t O 
ligand [C]l [C]i [C]g [C]a [C]n [C]d O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
AHR [C]A [C]H [C]R S-protein 
. [C]. O 

The [C]T [C]h [C]e O 
AHR [C]A [C]H [C]R S-protein 
mediates [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]s O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
as [C]a [C]s O 
shown [C]s [C]h [C]o [C]w [C]n O 
with [C]w [C]i [C]t [C]h O 
AHR [C]A [C]H [C]R S-protein 
-deficient [C]- [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
mice [C]m [C]i [C]c [C]e O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
in [C]i [C]n O 
spleen [C]s [C]p [C]l [C]e [C]e [C]n B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
costimulation [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
via [C]v [C]i [C]a O 
the [C]t [C]h [C]e O 
TCR [C]T [C]C [C]R S-protein 
is [C]i [C]s O 
necessary [C]n [C]e [C]c [C]e [C]s [C]s [C]a [C]r [C]y O 
for [C]f [C]o [C]r O 
optimal [C]o [C]p [C]t [C]i [C]m [C]a [C]l O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r I-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
contains [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]s O 
novel [C]n [C]o [C]v [C]e [C]l O 
distal [C]d [C]i [C]s [C]t [C]a [C]l B-DNA 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y I-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
that [C]t [C]h [C]a [C]t O 
can [C]c [C]a [C]n O 
be [C]b [C]e O 
addressed [C]a [C]d [C]d [C]r [C]e [C]s [C]s [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
AHR [C]A [C]H [C]R S-protein 
to [C]t [C]o O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
IL-2 [C]I [C]L [C]- [C]2 S-DNA 
and [C]a [C]n [C]d O 
can [C]c [C]a [C]n O 
cooperate [C]c [C]o [C]o [C]p [C]e [C]r [C]a [C]t [C]e O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
proximal [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]l B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 

Visualization [C]V [C]i [C]s [C]u [C]a [C]l [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Syk-antigen [C]S [C]y [C]k [C]- [C]a [C]n [C]t [C]i [C]g [C]e [C]n B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
interactions [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
using [C]u [C]s [C]i [C]n [C]g O 
green [C]g [C]r [C]e [C]e [C]n B-protein 
fluorescent [C]f [C]l [C]u [C]o [C]r [C]e [C]s [C]c [C]e [C]n [C]t I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
: [C]: O 
differential [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l O 
roles [C]r [C]o [C]l [C]e [C]s O 
for [C]f [C]o [C]r O 
Syk [C]S [C]y [C]k S-protein 
and [C]a [C]n [C]d O 
Lyn [C]L [C]y [C]n S-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
capping [C]c [C]a [C]p [C]p [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
internalization [C]i [C]n [C]t [C]e [C]r [C]n [C]a [C]l [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
cross-linking [C]c [C]r [C]o [C]s [C]s [C]- [C]l [C]i [C]n [C]k [C]i [C]n [C]g O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
B [C]B B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
Ag [C]A [C]g I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
( [C]( O 
BCR [C]B [C]C [C]R S-protein 
) [C]) O 
is [C]i [C]s O 
coupled [C]c [C]o [C]u [C]p [C]l [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
multiple [C]m [C]u [C]l [C]t [C]i [C]p [C]l [C]e O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
cascades [C]c [C]a [C]s [C]c [C]a [C]d [C]e [C]s O 
via [C]v [C]i [C]a O 
receptor-associated [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]- [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
, [C], O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e I-protein 
kinases [C]k [C]i [C]n [C]a [C]s [C]e [C]s E-protein 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
the [C]t [C]h [C]e O 
Src [C]S [C]r [C]c B-protein 
and [C]a [C]n [C]d I-protein 
Syk [C]S [C]y [C]k I-protein 
families [C]f [C]a [C]m [C]i [C]l [C]i [C]e [C]s E-protein 
. [C]. O 

To [C]T [C]o O 
monitor [C]m [C]o [C]n [C]i [C]t [C]o [C]r O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
subcellular [C]s [C]u [C]b [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
distribution [C]d [C]i [C]s [C]t [C]r [C]i [C]b [C]u [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Syk [C]S [C]y [C]k S-protein 
in [C]i [C]n O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
responding [C]r [C]e [C]s [C]p [C]o [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
BCR [C]B [C]C [C]R S-protein 
cross-linking [C]c [C]r [C]o [C]s [C]s [C]- [C]l [C]i [C]n [C]k [C]i [C]n [C]g O 
, [C], O 
we [C]w [C]e O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
Syk [C]S [C]y [C]k S-protein 
-deficient [C]- [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
DT40 [C]D [C]T [C]4 [C]0 B-cell_line 
B [C]B I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
a [C]a O 
fusion [C]f [C]u [C]s [C]i [C]o [C]n B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
consisting [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]i [C]n [C]g O 
of [C]o [C]f O 
Syk [C]S [C]y [C]k S-protein 
coupled [C]c [C]o [C]u [C]p [C]l [C]e [C]d O 
to [C]t [C]o O 
green [C]g [C]r [C]e [C]e [C]n B-protein 
fluorescent [C]f [C]l [C]u [C]o [C]r [C]e [C]s [C]c [C]e [C]n [C]t I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
. [C]. O 

Treatment [C]T [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
with [C]w [C]i [C]t [C]h O 
anti-IgM [C]a [C]n [C]t [C]i [C]- [C]I [C]g [C]M B-protein 
Abs [C]A [C]b [C]s E-protein 
leads [C]l [C]e [C]a [C]d [C]s O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
recruitment [C]r [C]e [C]c [C]r [C]u [C]i [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e S-protein 
from [C]f [C]r [C]o [C]m O 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c O 
and [C]a [C]n [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
compartments [C]c [C]o [C]m [C]p [C]a [C]r [C]t [C]m [C]e [C]n [C]t [C]s O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
site [C]s [C]i [C]t [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cross-linked [C]c [C]r [C]o [C]s [C]s [C]- [C]l [C]i [C]n [C]k [C]e [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
plasma [C]p [C]l [C]a [C]s [C]m [C]a O 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
Syk-receptor [C]S [C]y [C]k [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r B-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
aggregate [C]a [C]g [C]g [C]r [C]e [C]g [C]a [C]t [C]e O 
into [C]i [C]n [C]t [C]o O 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
patches [C]p [C]a [C]t [C]c [C]h [C]e [C]s O 
that [C]t [C]h [C]a [C]t O 
redistribute [C]r [C]e [C]d [C]i [C]s [C]t [C]r [C]i [C]b [C]u [C]t [C]e O 
to [C]t [C]o O 
form [C]f [C]o [C]r [C]m O 
a [C]a O 
cap [C]c [C]a [C]p O 
at [C]a [C]t O 
one [C]o [C]n [C]e O 
pole [C]p [C]o [C]l [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cell [C]c [C]e [C]l [C]l O 
. [C]. O 

Syk [C]S [C]y [C]k S-protein 
is [C]i [C]s O 
not [C]n [C]o [C]t O 
demonstrably [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]b [C]l [C]y O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
internalized [C]i [C]n [C]t [C]e [C]r [C]n [C]a [C]l [C]i [C]z [C]e [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
. [C]. O 

Catalytically [C]C [C]a [C]t [C]a [C]l [C]y [C]t [C]i [C]c [C]a [C]l [C]l [C]y O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
Syk [C]S [C]y [C]k S-protein 
promotes [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]s O 
and [C]a [C]n [C]d O 
stabilizes [C]s [C]t [C]a [C]b [C]i [C]l [C]i [C]z [C]e [C]s O 
the [C]t [C]h [C]e O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
tightly [C]t [C]i [C]g [C]h [C]t [C]l [C]y B-protein 
capped [C]c [C]a [C]p [C]p [C]e [C]d I-protein 
BCR [C]B [C]C [C]R I-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
plasma [C]p [C]l [C]a [C]s [C]m [C]a O 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
. [C]. O 

Lyn [C]L [C]y [C]n S-protein 
is [C]i [C]s O 
not [C]n [C]o [C]t O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
recruitment [C]r [C]e [C]c [C]r [C]u [C]i [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
Syk [C]S [C]y [C]k S-protein 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
cross-linked [C]c [C]r [C]o [C]s [C]s [C]- [C]l [C]i [C]n [C]k [C]e [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
, [C], O 
but [C]b [C]u [C]t O 
is [C]i [C]s O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
internalization [C]i [C]n [C]t [C]e [C]r [C]n [C]a [C]l [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
clustered [C]c [C]l [C]u [C]s [C]t [C]e [C]r [C]e [C]d O 
BCR [C]B [C]C [C]R B-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
. [C]. O 

In [C]I [C]n O 
the [C]t [C]h [C]e O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
Lyn [C]L [C]y [C]n S-protein 
, [C], O 
receptor-Syk [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]- [C]S [C]y [C]k B-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
plasma [C]p [C]l [C]a [C]s [C]m [C]a O 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
are [C]a [C]r [C]e O 
long [C]l [C]o [C]n [C]g O 
lived [C]l [C]i [C]v [C]e [C]d O 
, [C], O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
receptor-mediated [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
NF-AT [C]N [C]F [C]- [C]A [C]T B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
is [C]i [C]s O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
Lyn [C]L [C]y [C]n S-protein 
appears [C]a [C]p [C]p [C]e [C]a [C]r [C]s O 
to [C]t [C]o O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
to [C]t [C]o O 
negatively [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e [C]l [C]y O 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
aspects [C]a [C]s [C]p [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
BCR [C]B [C]C [C]R S-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
by [C]b [C]y O 
stimulating [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
internalization [C]i [C]n [C]t [C]e [C]r [C]n [C]a [C]l [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
down-regulation [C]d [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Renal [C]R [C]e [C]n [C]a [C]l O 
interstitial [C]i [C]n [C]t [C]e [C]r [C]s [C]t [C]i [C]t [C]i [C]a [C]l O 
fibrosis [C]f [C]i [C]b [C]r [C]o [C]s [C]i [C]s O 
is [C]i [C]s O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
in [C]i [C]n O 
angiotensin [C]a [C]n [C]g [C]i [C]o [C]t [C]e [C]n [C]s [C]i [C]n B-protein 
II [C]I [C]I I-protein 
type [C]t [C]y [C]p [C]e I-protein 
1a [C]1 [C]a I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
-deficient [C]- [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
mice [C]m [C]i [C]c [C]e O 
. [C]. O 

Unilateral [C]U [C]n [C]i [C]l [C]a [C]t [C]e [C]r [C]a [C]l O 
ureteral [C]u [C]r [C]e [C]t [C]e [C]r [C]a [C]l O 
obstruction [C]o [C]b [C]s [C]t [C]r [C]u [C]c [C]t [C]i [C]o [C]n O 
( [C]( O 
UUO [C]U [C]U [C]O O 
) [C]) O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
in [C]i [C]n O 
tubulointerstitial [C]t [C]u [C]b [C]u [C]l [C]o [C]i [C]n [C]t [C]e [C]r [C]s [C]t [C]i [C]t [C]i [C]a [C]l O 
fibrosis [C]f [C]i [C]b [C]r [C]o [C]s [C]i [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
affected [C]a [C]f [C]f [C]e [C]c [C]t [C]e [C]d O 
kidney [C]k [C]i [C]d [C]n [C]e [C]y O 
by [C]b [C]y O 
stimulating [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
renin-angiotensin [C]r [C]e [C]n [C]i [C]n [C]- [C]a [C]n [C]g [C]i [C]o [C]t [C]e [C]n [C]s [C]i [C]n O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
established [C]e [C]s [C]t [C]a [C]b [C]l [C]i [C]s [C]h [C]e [C]d O 
a [C]a O 
UUO [C]U [C]U [C]O O 
model [C]m [C]o [C]d [C]e [C]l O 
in [C]i [C]n O 
angiotensin [C]a [C]n [C]g [C]i [C]o [C]t [C]e [C]n [C]s [C]i [C]n B-protein 
type [C]t [C]y [C]p [C]e I-protein 
1a [C]1 [C]a I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
( [C]( O 
AT1a [C]A [C]T [C]1 [C]a S-protein 
) [C]) O 
deficient [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
( [C]( O 
mutant [C]m [C]u [C]t [C]a [C]n [C]t O 
) [C]) O 
mice [C]m [C]i [C]c [C]e O 
to [C]t [C]o O 
elucidate [C]e [C]l [C]u [C]c [C]i [C]d [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
angiotensin [C]a [C]n [C]g [C]i [C]o [C]t [C]e [C]n [C]s [C]i [C]n B-protein 
II [C]I [C]I E-protein 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
AT1a [C]A [C]T [C]1 [C]a S-protein 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
fibrosis [C]f [C]i [C]b [C]r [C]o [C]s [C]i [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
obstructed [C]o [C]b [C]s [C]t [C]r [C]u [C]c [C]t [C]e [C]d O 
kidney [C]k [C]i [C]d [C]n [C]e [C]y O 
( [C]( O 
OBK [C]O [C]B [C]K O 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
relative [C]r [C]e [C]l [C]a [C]t [C]i [C]v [C]e O 
volume [C]v [C]o [C]l [C]u [C]m [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
tubulointerstitium [C]t [C]u [C]b [C]u [C]l [C]o [C]i [C]n [C]t [C]e [C]r [C]s [C]t [C]i [C]t [C]i [C]u [C]m O 
was [C]w [C]a [C]s O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
by [C]b [C]y O 
an [C]a [C]n O 
image [C]i [C]m [C]a [C]g [C]e O 
analyzer [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]r O 
; [C]; O 
deposition [C]d [C]e [C]p [C]o [C]s [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
collagen [C]c [C]o [C]l [C]l [C]a [C]g [C]e [C]n B-protein 
types [C]t [C]y [C]p [C]e [C]s I-protein 
III [C]I [C]I [C]I I-protein 
and [C]a [C]n [C]d I-protein 
IV [C]I [C]V E-protein 
and [C]a [C]n [C]d O 
monocyte [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e S-cell_type 
/ [C]/ O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e S-cell_type 
infiltration [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
were [C]w [C]e [C]r [C]e O 
histologically [C]h [C]i [C]s [C]t [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l [C]l [C]y O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
using [C]u [C]s [C]i [C]n [C]g O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-protein 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s E-protein 
. [C]. O 

Also [C]A [C]l [C]s [C]o O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
were [C]w [C]e [C]r [C]e O 
the [C]t [C]h [C]e O 
mRNA [C]m [C]R [C]N [C]A O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
transforming [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]i [C]n [C]g B-protein 
growth [C]g [C]r [C]o [C]w [C]t [C]h I-protein 
factor-beta [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]b [C]e [C]t [C]a E-protein 
by [C]b [C]y O 
Northern [C]N [C]o [C]r [C]t [C]h [C]e [C]r [C]n O 
blot [C]b [C]l [C]o [C]t O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
. [C]. O 

Nuclear [C]N [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor-kappaB [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
was [C]w [C]a [C]s O 
assessed [C]a [C]s [C]s [C]e [C]s [C]s [C]e [C]d O 
by [C]b [C]y O 
gel [C]g [C]e [C]l O 
shift [C]s [C]h [C]i [C]f [C]t O 
assay [C]a [C]s [C]s [C]a [C]y O 
. [C]. O 

UUO [C]U [C]U [C]O O 
in [C]i [C]n O 
wild [C]w [C]i [C]l [C]d O 
mice [C]m [C]i [C]c [C]e O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
a [C]a O 
marked [C]m [C]a [C]r [C]k [C]e [C]d O 
expansion [C]e [C]x [C]p [C]a [C]n [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
relative [C]r [C]e [C]l [C]a [C]t [C]i [C]v [C]e O 
volume [C]v [C]o [C]l [C]u [C]m [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
tubulointerstitium [C]t [C]u [C]b [C]u [C]l [C]o [C]i [C]n [C]t [C]e [C]r [C]s [C]t [C]i [C]t [C]i [C]u [C]m O 
, [C], O 
together [C]t [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
with [C]w [C]i [C]t [C]h O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
deposition [C]d [C]e [C]p [C]o [C]s [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
collagen [C]c [C]o [C]l [C]l [C]a [C]g [C]e [C]n B-protein 
types [C]t [C]y [C]p [C]e [C]s I-protein 
III [C]I [C]I [C]I I-protein 
and [C]a [C]n [C]d I-protein 
IV [C]I [C]V E-protein 
and [C]a [C]n [C]d O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
infiltrated [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]e [C]d O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
/ [C]/ O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_type 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
interstitium [C]i [C]n [C]t [C]e [C]r [C]s [C]t [C]i [C]t [C]i [C]u [C]m O 
, [C], O 
relative [C]r [C]e [C]l [C]a [C]t [C]i [C]v [C]e O 
to [C]t [C]o O 
sham-operated [C]s [C]h [C]a [C]m [C]- [C]o [C]p [C]e [C]r [C]a [C]t [C]e [C]d O 
mice [C]m [C]i [C]c [C]e O 
. [C]. O 

In [C]I [C]n O 
comparison [C]c [C]o [C]m [C]p [C]a [C]r [C]i [C]s [C]o [C]n O 
, [C], O 
these [C]t [C]h [C]e [C]s [C]e O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
lower [C]l [C]o [C]w [C]e [C]r O 
in [C]i [C]n O 
mutant [C]m [C]u [C]t [C]a [C]n [C]t O 
mice [C]m [C]i [C]c [C]e O 
with [C]w [C]i [C]t [C]h O 
UUO [C]U [C]U [C]O O 
. [C]. O 

The [C]T [C]h [C]e O 
mRNA [C]m [C]R [C]N [C]A O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
transforming [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]i [C]n [C]g B-protein 
growth [C]g [C]r [C]o [C]w [C]t [C]h I-protein 
factor-beta [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]b [C]e [C]t [C]a E-protein 
was [C]w [C]a [C]s O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
OBK [C]O [C]B [C]K O 
of [C]o [C]f O 
wild [C]w [C]i [C]l [C]d O 
mice [C]m [C]i [C]c [C]e O 
with [C]w [C]i [C]t [C]h O 
UUO [C]U [C]U [C]O O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
sham-operated [C]s [C]h [C]a [C]m [C]- [C]o [C]p [C]e [C]r [C]a [C]t [C]e [C]d O 
mice [C]m [C]i [C]c [C]e O 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
the [C]t [C]h [C]e O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
mRNA [C]m [C]R [C]N [C]A O 
level [C]l [C]e [C]v [C]e [C]l O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
OBK [C]O [C]B [C]K O 
of [C]o [C]f O 
mutant [C]m [C]u [C]t [C]a [C]n [C]t O 
mice [C]m [C]i [C]c [C]e O 
was [C]w [C]a [C]s O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
less [C]l [C]e [C]s [C]s O 
than [C]t [C]h [C]a [C]n O 
in [C]i [C]n O 
wild [C]w [C]i [C]l [C]d O 
mice [C]m [C]i [C]c [C]e O 
. [C]. O 

Finally [C]F [C]i [C]n [C]a [C]l [C]l [C]y O 
, [C], O 
UUO [C]U [C]U [C]O O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor-kappaB [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
in [C]i [C]n O 
wild [C]w [C]i [C]l [C]d O 
mice [C]m [C]i [C]c [C]e O 
but [C]b [C]u [C]t O 
was [C]w [C]a [C]s O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
OBK [C]O [C]B [C]K O 
of [C]o [C]f O 
mutant [C]m [C]u [C]t [C]a [C]n [C]t O 
mice [C]m [C]i [C]c [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
provide [C]p [C]r [C]o [C]v [C]i [C]d [C]e O 
direct [C]d [C]i [C]r [C]e [C]c [C]t O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
that [C]t [C]h [C]a [C]t O 
angiotensin [C]a [C]n [C]g [C]i [C]o [C]t [C]e [C]n [C]s [C]i [C]n B-protein 
II [C]I [C]I E-protein 
acting [C]a [C]c [C]t [C]i [C]n [C]g O 
via [C]v [C]i [C]a O 
the [C]t [C]h [C]e O 
AT1a [C]A [C]T [C]1 [C]a S-protein 
plays [C]p [C]l [C]a [C]y [C]s O 
a [C]a O 
pivotal [C]p [C]i [C]v [C]o [C]t [C]a [C]l O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
tubulointerstitial [C]t [C]u [C]b [C]u [C]l [C]o [C]i [C]n [C]t [C]e [C]r [C]s [C]t [C]i [C]t [C]i [C]a [C]l O 
fibrosis [C]f [C]i [C]b [C]r [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
UUO [C]U [C]U [C]O O 
. [C]. O 

HLA-DQ [C]H [C]L [C]A [C]- [C]D [C]Q B-protein 
tetramers [C]t [C]e [C]t [C]r [C]a [C]m [C]e [C]r [C]s E-protein 
identify [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]y O 
epitope-specific [C]e [C]p [C]i [C]t [C]o [C]p [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l O 
blood [C]b [C]l [C]o [C]o [C]d O 
of [C]o [C]f O 
herpes [C]h [C]e [C]r [C]p [C]e [C]s O 
simplex [C]s [C]i [C]m [C]p [C]l [C]e [C]x O 
virus [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
2-infected [C]2 [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
individuals [C]i [C]n [C]d [C]i [C]v [C]i [C]d [C]u [C]a [C]l [C]s O 
: [C]: O 
direct [C]d [C]i [C]r [C]e [C]c [C]t O 
detection [C]d [C]e [C]t [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
immunodominant [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t B-cell_type 
antigen-responsive [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]- [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Ag-specific [C]A [C]g [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-cell_type 
CD4+ [C]C [C]D [C]4 [C]+ I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
are [C]a [C]r [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
in [C]i [C]n O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l O 
blood [C]b [C]l [C]o [C]o [C]d O 
in [C]i [C]n O 
low [C]l [C]o [C]w O 
frequency [C]f [C]r [C]e [C]q [C]u [C]e [C]n [C]c [C]y O 
, [C], O 
where [C]w [C]h [C]e [C]r [C]e O 
they [C]t [C]h [C]e [C]y O 
undergo [C]u [C]n [C]d [C]e [C]r [C]g [C]o O 
recruitment [C]r [C]e [C]c [C]r [C]u [C]i [C]t [C]m [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
expansion [C]e [C]x [C]p [C]a [C]n [C]s [C]i [C]o [C]n O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
pathogenesis [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
numerous [C]n [C]u [C]m [C]e [C]r [C]o [C]u [C]s O 
autoimmune [C]a [C]u [C]t [C]o [C]i [C]m [C]m [C]u [C]n [C]e O 
diseases [C]d [C]i [C]s [C]e [C]a [C]s [C]e [C]s O 
. [C]. O 

MHC [C]M [C]H [C]C B-protein 
tetramers [C]t [C]e [C]t [C]r [C]a [C]m [C]e [C]r [C]s E-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
constitute [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]e O 
a [C]a O 
labeled [C]l [C]a [C]b [C]e [C]l [C]e [C]d B-protein 
MHC-peptide [C]M [C]H [C]C [C]- [C]p [C]e [C]p [C]t [C]i [C]d [C]e I-protein 
ligand [C]l [C]i [C]g [C]a [C]n [C]d E-protein 
suitable [C]s [C]u [C]i [C]t [C]a [C]b [C]l [C]e O 
for [C]f [C]o [C]r O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
Ag-specific [C]A [C]g [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
on [C]o [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
provide [C]p [C]r [C]o [C]v [C]i [C]d [C]e O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
approach [C]a [C]p [C]p [C]r [C]o [C]a [C]c [C]h O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
detection [C]d [C]e [C]t [C]e [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
characterization [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
such [C]s [C]u [C]c [C]h O 
rare [C]r [C]a [C]r [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
, [C], O 
we [C]w [C]e O 
utilized [C]u [C]t [C]i [C]l [C]i [C]z [C]e [C]d O 
this [C]t [C]h [C]i [C]s O 
technology [C]t [C]e [C]c [C]h [C]n [C]o [C]l [C]o [C]g [C]y O 
to [C]t [C]o O 
identify [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]y O 
HLA [C]H [C]L [C]A B-protein 
DQ [C]D [C]Q E-protein 
-restricted [C]- [C]r [C]e [C]s [C]t [C]r [C]i [C]c [C]t [C]e [C]d O 
Ag-specific [C]A [C]g [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l O 
blood [C]b [C]l [C]o [C]o [C]d O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
and [C]a [C]n [C]d O 
to [C]t [C]o O 
identify [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]y O 
immunodominant [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t O 
epitopes [C]e [C]p [C]i [C]t [C]o [C]p [C]e [C]s O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
viral [C]v [C]i [C]r [C]a [C]l O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

Peptides [C]P [C]e [C]p [C]t [C]i [C]d [C]e [C]s O 
representing [C]r [C]e [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]i [C]n [C]g O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
epitope [C]e [C]p [C]i [C]t [C]o [C]p [C]e B-protein 
regions [C]r [C]e [C]g [C]i [C]o [C]n [C]s E-protein 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
VP16 [C]V [C]P [C]1 [C]6 B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
from [C]f [C]r [C]o [C]m O 
HSV-2 [C]H [C]S [C]V [C]- [C]2 O 
were [C]w [C]e [C]r [C]e O 
loaded [C]l [C]o [C]a [C]d [C]e [C]d O 
onto [C]o [C]n [C]t [C]o O 
recombinant [C]r [C]e [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]n [C]t B-protein 
DQ0602 [C]D [C]Q [C]0 [C]6 [C]0 [C]2 I-protein 
molecules [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]s E-protein 
to [C]t [C]o O 
generate [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]e O 
a [C]a O 
panel [C]p [C]a [C]n [C]e [C]l O 
of [C]o [C]f O 
Ag-specific [C]A [C]g [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-protein 
DQ0602 [C]D [C]Q [C]0 [C]6 [C]0 [C]2 I-protein 
tetramers [C]t [C]e [C]t [C]r [C]a [C]m [C]e [C]r [C]s E-protein 
. [C]. O 

VP16 [C]V [C]P [C]1 [C]6 B-protein 
Ag [C]A [C]g E-protein 
-specific [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
DQ-restricted [C]D [C]Q [C]- [C]r [C]e [C]s [C]t [C]r [C]i [C]c [C]t [C]e [C]d B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
and [C]a [C]n [C]d O 
expanded [C]e [C]x [C]p [C]a [C]n [C]d [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l O 
blood [C]b [C]l [C]o [C]o [C]d O 
of [C]o [C]f O 
HSV-2-infected [C]H [C]S [C]V [C]- [C]2 [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
individuals [C]i [C]n [C]d [C]i [C]v [C]i [C]d [C]u [C]a [C]l [C]s O 
, [C], O 
representing [C]r [C]e [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]i [C]n [C]g O 
two [C]t [C]w [C]o O 
predominant [C]p [C]r [C]e [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t O 
epitope [C]e [C]p [C]i [C]t [C]o [C]p [C]e O 
specificities [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]i [C]t [C]i [C]e [C]s O 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
VP16 [C]V [C]P [C]1 [C]6 O 
369-380 [C]3 [C]6 [C]9 [C]- [C]3 [C]8 [C]0 O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
has [C]h [C]a [C]s O 
a [C]a O 
lower [C]l [C]o [C]w [C]e [C]r O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
for [C]f [C]o [C]r O 
DQ0602 [C]D [C]Q [C]0 [C]6 [C]0 [C]2 B-protein 
molecules [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]s E-protein 
than [C]t [C]h [C]a [C]n O 
the [C]t [C]h [C]e O 
VP16 [C]V [C]P [C]1 [C]6 O 
33-52 [C]3 [C]3 [C]- [C]5 [C]2 O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
, [C], O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
that [C]t [C]h [C]a [C]t O 
recognized [C]r [C]e [C]c [C]o [C]g [C]n [C]i [C]z [C]e [C]d O 
the [C]t [C]h [C]e O 
VP16 [C]V [C]P [C]1 [C]6 O 
369-380 [C]3 [C]6 [C]9 [C]- [C]3 [C]8 [C]0 O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
occurred [C]o [C]c [C]c [C]u [C]r [C]r [C]e [C]d O 
at [C]a [C]t O 
a [C]a O 
much [C]m [C]u [C]c [C]h O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
frequency [C]f [C]r [C]e [C]q [C]u [C]e [C]n [C]c [C]y O 
than [C]t [C]h [C]a [C]n O 
those [C]t [C]h [C]o [C]s [C]e O 
that [C]t [C]h [C]a [C]t O 
were [C]w [C]e [C]r [C]e O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
VP16 [C]V [C]P [C]1 [C]6 O 
33-52 [C]3 [C]3 [C]- [C]5 [C]2 O 
peptide [C]p [C]e [C]p [C]t [C]i [C]d [C]e O 
. [C]. O 

Down-regulation [C]D [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
BOB.1/OBF.1 [C]B [C]O [C]B [C]. [C]1 [C]/ [C]O [C]B [C]F [C]. [C]1 S-protein 
and [C]a [C]n [C]d O 
Oct2 [C]O [C]c [C]t [C]2 S-protein 
in [C]i [C]n O 
classical [C]c [C]l [C]a [C]s [C]s [C]i [C]c [C]a [C]l O 
Hodgkin [C]H [C]o [C]d [C]g [C]k [C]i [C]n O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
in [C]i [C]n O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e O 
predominant [C]p [C]r [C]e [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t O 
Hodgkin [C]H [C]o [C]d [C]g [C]k [C]i [C]n O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
correlates [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
tumor [C]t [C]u [C]m [C]o [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
L [C]L B-cell_type 
& [C]& I-cell_type 
H [C]H I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
) [C]) O 
of [C]o [C]f O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e O 
predominant [C]p [C]r [C]e [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t O 
Hodgkin [C]H [C]o [C]d [C]g [C]k [C]i [C]n O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
( [C]( O 
LPHD [C]L [C]P [C]H [C]D O 
) [C]) O 
, [C], O 
Hodgkin [C]H [C]o [C]d [C]g [C]k [C]i [C]n B-cell_type 
and [C]a [C]n [C]d I-cell_type 
Reed-Sternberg [C]R [C]e [C]e [C]d [C]- [C]S [C]t [C]e [C]r [C]n [C]b [C]e [C]r [C]g I-cell_type 
( [C]( I-cell_type 
HRS [C]H [C]R [C]S I-cell_type 
) [C]) I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
of [C]o [C]f O 
classical [C]c [C]l [C]a [C]s [C]s [C]i [C]c [C]a [C]l O 
Hodgkin [C]H [C]o [C]d [C]g [C]k [C]i [C]n O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
( [C]( O 
cHD [C]c [C]H [C]D O 
) [C]) O 
are [C]a [C]r [C]e O 
unable [C]u [C]n [C]a [C]b [C]l [C]e O 
to [C]t [C]o O 
transcribe [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]b [C]e O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n S-protein 
, [C], O 
despite [C]d [C]e [C]s [C]p [C]i [C]t [C]e O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
rearranged [C]r [C]e [C]a [C]r [C]r [C]a [C]n [C]g [C]e [C]d B-DNA 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
initial [C]i [C]n [C]i [C]t [C]i [C]a [C]l O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
have [C]h [C]a [C]v [C]e O 
suggested [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]e [C]d O 
crippling [C]c [C]r [C]i [C]p [C]p [C]l [C]i [C]n [C]g O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n O 
gene [C]g [C]e [C]n [C]e O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
to [C]t [C]o O 
be [C]b [C]e O 
the [C]t [C]h [C]e O 
cause [C]c [C]a [C]u [C]s [C]e O 
of [C]o [C]f O 
absent [C]a [C]b [C]s [C]e [C]n [C]t O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
cHD [C]c [C]H [C]D O 
, [C], O 
recent [C]r [C]e [C]c [C]e [C]n [C]t O 
work [C]w [C]o [C]r [C]k O 
of [C]o [C]f O 
our [C]o [C]u [C]r O 
group [C]g [C]r [C]o [C]u [C]p O 
has [C]h [C]a [C]s O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
an [C]a [C]n O 
impaired [C]i [C]m [C]p [C]a [C]i [C]r [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
as [C]a [C]s O 
a [C]a O 
superior [C]s [C]u [C]p [C]e [C]r [C]i [C]o [C]r O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
. [C]. O 

As [C]A [C]s O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
mainly [C]m [C]a [C]i [C]n [C]l [C]y O 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
Oct2 [C]O [C]c [C]t [C]2 S-protein 
and [C]a [C]n [C]d O 
BOB.1/OBF.1 [C]B [C]O [C]B [C]. [C]1 [C]/ [C]O [C]B [C]F [C]. [C]1 S-protein 
, [C], O 
we [C]w [C]e O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
35 [C]3 [C]5 O 
cases [C]c [C]a [C]s [C]e [C]s O 
of [C]o [C]f O 
LPHD [C]L [C]P [C]H [C]D O 
, [C], O 
32 [C]3 [C]2 O 
cases [C]c [C]a [C]s [C]e [C]s O 
of [C]o [C]f O 
cHD [C]c [C]H [C]D O 
, [C], O 
and [C]a [C]n [C]d O 
2 [C]2 O 
Hodgkin [C]H [C]o [C]d [C]g [C]k [C]i [C]n B-cell_line 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
and [C]a [C]n [C]d O 
also [C]a [C]l [C]s [C]o O 
in [C]i [C]n O 
parallel [C]p [C]a [C]r [C]a [C]l [C]l [C]e [C]l O 
for [C]f [C]o [C]r O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Our [C]O [C]u [C]r O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
an [C]a [C]n O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
Oct2 [C]O [C]c [C]t [C]2 S-protein 
and/or [C]a [C]n [C]d [C]/ [C]o [C]r O 
BOB.1/OBF.1 [C]B [C]O [C]B [C]. [C]1 [C]/ [C]O [C]B [C]F [C]. [C]1 S-protein 
in [C]i [C]n O 
cHD [C]c [C]H [C]D O 
and [C]a [C]n [C]d O 
a [C]a O 
striking [C]s [C]t [C]r [C]i [C]k [C]i [C]n [C]g O 
overexpression [C]o [C]v [C]e [C]r [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
Oct2 [C]O [C]c [C]t [C]2 S-protein 
in [C]i [C]n O 
LPHD [C]L [C]P [C]H [C]D O 
. [C]. O 

Immunoglobulin [C]I [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
lacking [C]l [C]a [C]c [C]k [C]i [C]n [C]g O 
in [C]i [C]n O 
cHD [C]c [C]H [C]D O 
but [C]b [C]u [C]t O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
in [C]i [C]n O 
LPHD [C]L [C]P [C]H [C]D O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
the [C]t [C]h [C]e O 
reintroduction [C]r [C]e [C]i [C]n [C]t [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
BOB.1/OBF.1 [C]B [C]O [C]B [C]. [C]1 [C]/ [C]O [C]B [C]F [C]. [C]1 S-protein 
and [C]a [C]n [C]d O 
Oct2 [C]O [C]c [C]t [C]2 S-protein 
into [C]i [C]n [C]t [C]o O 
cultured [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]d O 
HRS [C]H [C]R [C]S B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
restored [C]r [C]e [C]s [C]t [C]o [C]r [C]e [C]d O 
the [C]t [C]h [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
cotransduced [C]c [C]o [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]e [C]d O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r I-DNA 
constructs [C]c [C]o [C]n [C]s [C]t [C]r [C]u [C]c [C]t [C]s E-DNA 
. [C]. O 

Our [C]O [C]u [C]r O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
dismiss [C]d [C]i [C]s [C]m [C]i [C]s [C]s O 
the [C]t [C]h [C]e O 
concept [C]c [C]o [C]n [C]c [C]e [C]p [C]t O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
cHD [C]c [C]H [C]D O 
and [C]a [C]n [C]d O 
LPHD [C]L [C]P [C]H [C]D O 
is [C]i [C]s O 
due [C]d [C]u [C]e O 
to [C]t [C]o O 
disrupting [C]d [C]i [C]s [C]r [C]u [C]p [C]t [C]i [C]n [C]g O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n B-DNA 
V [C]V I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
in [C]i [C]n O 
cHD [C]c [C]H [C]D O 
but [C]b [C]u [C]t O 
is [C]i [C]s O 
most [C]m [C]o [C]s [C]t O 
likely [C]l [C]i [C]k [C]e [C]l [C]y O 
due [C]d [C]u [C]e O 
to [C]t [C]o O 
a [C]a O 
down-regulation [C]d [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Oct2 [C]O [C]c [C]t [C]2 S-protein 
and/or [C]a [C]n [C]d [C]/ [C]o [C]r O 
BOB.1/OBF.1 [C]B [C]O [C]B [C]. [C]1 [C]/ [C]O [C]B [C]F [C]. [C]1 S-protein 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
Oct2 [C]O [C]c [C]t [C]2 S-protein 
as [C]a [C]s O 
a [C]a O 
new [C]n [C]e [C]w O 
and [C]a [C]n [C]d O 
valuable [C]v [C]a [C]l [C]u [C]a [C]b [C]l [C]e O 
marker [C]m [C]a [C]r [C]k [C]e [C]r O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
identification [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
L [C]L B-cell_type 
& [C]& I-cell_type 
H [C]H I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
their [C]t [C]h [C]e [C]i [C]r O 
distinction [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t [C]i [C]o [C]n O 
from [C]f [C]r [C]o [C]m O 
HRS [C]H [C]R [C]S B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
impairment [C]i [C]m [C]p [C]a [C]i [C]r [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
down-regulated [C]d [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
Oct2 [C]O [C]c [C]t [C]2 S-protein 
and [C]a [C]n [C]d O 
BOB.1/OBF.1 [C]B [C]O [C]B [C]. [C]1 [C]/ [C]O [C]B [C]F [C]. [C]1 S-protein 
is [C]i [C]s O 
the [C]t [C]h [C]e O 
first [C]f [C]i [C]r [C]s [C]t O 
established [C]e [C]s [C]t [C]a [C]b [C]l [C]i [C]s [C]h [C]e [C]d O 
general [C]g [C]e [C]n [C]e [C]r [C]a [C]l O 
recurrent [C]r [C]e [C]c [C]u [C]r [C]r [C]e [C]n [C]t O 
defect [C]d [C]e [C]f [C]e [C]c [C]t O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
HRS [C]H [C]R [C]S B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Constitutive [C]C [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
is [C]i [C]s O 
a [C]a O 
characteristic [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]s [C]t [C]i [C]c O 
feature [C]f [C]e [C]a [C]t [C]u [C]r [C]e O 
of [C]o [C]f O 
mycosis [C]m [C]y [C]c [C]o [C]s [C]i [C]s O 
fungoides [C]f [C]u [C]n [C]g [C]o [C]i [C]d [C]e [C]s O 
: [C]: O 
implications [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n [C]s O 
for [C]f [C]o [C]r O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
resistance [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]c [C]e O 
and [C]a [C]n [C]d O 
pathogenesis [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B I-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y I-protein 
of [C]o [C]f I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
is [C]i [C]s O 
an [C]a [C]n O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
regulator [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r O 
of [C]o [C]f O 
genes [C]g [C]e [C]n [C]e [C]s O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
, [C], O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n O 
( [C]( O 
Ig [C]I [C]g O 
) [C]) O 
class [C]c [C]l [C]a [C]s [C]s O 
switching [C]s [C]w [C]i [C]t [C]c [C]h [C]i [C]n [C]g O 
, [C], O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
. [C]. O 

Recently [C]R [C]e [C]c [C]e [C]n [C]t [C]l [C]y O 
, [C], O 
members [C]m [C]e [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y E-protein 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
p65 [C]p [C]6 [C]5 B-protein 
( [C]( I-protein 
Rel [C]R [C]e [C]l I-protein 
A [C]A I-protein 
) [C]) E-protein 
, [C], O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
implicated [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
promoting [C]p [C]r [C]o [C]m [C]o [C]t [C]i [C]n [C]g O 
survival [C]s [C]u [C]r [C]v [C]i [C]v [C]a [C]l O 
of [C]o [C]f O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
hematopoeitic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]e [C]i [C]t [C]i [C]c O 
neoplasms [C]n [C]e [C]o [C]p [C]l [C]a [C]s [C]m [C]s O 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
malignancies [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]c [C]i [C]e [C]s O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
adult [C]a [C]d [C]u [C]l [C]t O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
leukemia-lymphoma [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a O 
. [C]. O 

We [C]W [C]e O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
active [C]a [C]c [C]t [C]i [C]v [C]e B-protein 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B I-protein 
p65 [C]p [C]6 [C]5 I-protein 
( [C]( I-protein 
Rel [C]R [C]e [C]l I-protein 
A [C]A I-protein 
) [C]) E-protein 
in [C]i [C]n O 
cases [C]c [C]a [C]s [C]e [C]s O 
of [C]o [C]f O 
mycosis [C]m [C]y [C]c [C]o [C]s [C]i [C]s O 
fungoides [C]f [C]u [C]n [C]g [C]o [C]i [C]d [C]e [C]s O 
( [C]( O 
MF [C]M [C]F O 
) [C]) O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
chemical [C]c [C]h [C]e [C]m [C]i [C]c [C]a [C]l O 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
on [C]o [C]n O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
cutaneous [C]c [C]u [C]t [C]a [C]n [C]e [C]o [C]u [C]s B-cell_line 
T [C]T I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a I-cell_line 
( [C]( I-cell_line 
CTCL [C]C [C]T [C]C [C]L I-cell_line 
) [C]) I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
. [C]. O 

Paraffin-embedded [C]P [C]a [C]r [C]a [C]f [C]f [C]i [C]n [C]- [C]e [C]m [C]b [C]e [C]d [C]d [C]e [C]d O 
tissues [C]t [C]i [C]s [C]s [C]u [C]e [C]s O 
from [C]f [C]r [C]o [C]m O 
23 [C]2 [C]3 O 
cutaneous [C]c [C]u [C]t [C]a [C]n [C]e [C]o [C]u [C]s O 
lesions [C]l [C]e [C]s [C]i [C]o [C]n [C]s O 
and [C]a [C]n [C]d O 
a [C]a O 
single [C]s [C]i [C]n [C]g [C]l [C]e O 
lymph [C]l [C]y [C]m [C]p [C]h O 
node [C]n [C]o [C]d [C]e O 
biopsy [C]b [C]i [C]o [C]p [C]s [C]y O 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
diagnosed [C]d [C]i [C]a [C]g [C]n [C]o [C]s [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
MF [C]M [C]F O 
were [C]w [C]e [C]r [C]e O 
evaluated [C]e [C]v [C]a [C]l [C]u [C]a [C]t [C]e [C]d O 
for [C]f [C]o [C]r O 
p65 [C]p [C]6 [C]5 O 
( [C]( O 
Rel [C]R [C]e [C]l O 
A [C]A O 
) [C]) O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
by [C]b [C]y O 
using [C]u [C]s [C]i [C]n [C]g O 
a [C]a O 
monoclonal [C]m [C]o [C]n [C]o [C]c [C]l [C]o [C]n [C]a [C]l B-protein 
mouse [C]m [C]o [C]u [C]s [C]e I-protein 
antibody [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y E-protein 
that [C]t [C]h [C]a [C]t O 
detects [C]d [C]e [C]t [C]e [C]c [C]t [C]s O 
the [C]t [C]h [C]e O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
form [C]f [C]o [C]r [C]m O 
of [C]o [C]f O 
p65 [C]p [C]6 [C]5 B-protein 
( [C]( I-protein 
Rel [C]R [C]e [C]l I-protein 
A [C]A I-protein 
) [C]) E-protein 
. [C]. O 

Apoptosis [C]A [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
after [C]a [C]f [C]t [C]e [C]r O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a O 
B [C]B O 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
gliotoxin [C]g [C]l [C]i [C]o [C]t [C]o [C]x [C]i [C]n O 
, [C], O 
MG132 [C]M [C]G [C]1 [C]3 [C]2 O 
, [C], O 
BAY [C]B [C]A [C]Y O 
11-7082 [C]1 [C]1 [C]- [C]7 [C]0 [C]8 [C]2 O 
, [C], O 
and [C]a [C]n [C]d O 
BAY [C]B [C]A [C]Y O 
11-7085 [C]1 [C]1 [C]- [C]7 [C]0 [C]8 [C]5 O 
was [C]w [C]a [C]s O 
quantitatively [C]q [C]u [C]a [C]n [C]t [C]i [C]t [C]a [C]t [C]i [C]v [C]e [C]l [C]y O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
CTCL [C]C [C]T [C]C [C]L B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s I-cell_line 
HuT-78 [C]H [C]u [C]T [C]- [C]7 [C]8 I-cell_line 
and [C]a [C]n [C]d I-cell_line 
HH [C]H [C]H E-cell_line 
by [C]b [C]y O 
propidium [C]p [C]r [C]o [C]p [C]i [C]d [C]i [C]u [C]m O 
iodide [C]i [C]o [C]d [C]i [C]d [C]e O 
( [C]( O 
PI [C]P [C]I O 
) [C]) O 
/cell [C]/ [C]c [C]e [C]l [C]l O 
cycle [C]c [C]y [C]c [C]l [C]e O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
for [C]f [C]o [C]r O 
detection [C]d [C]e [C]t [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
hypodiploid [C]h [C]y [C]p [C]o [C]d [C]i [C]p [C]l [C]o [C]i [C]d O 
( [C]( O 
sub-G [C]s [C]u [C]b [C]- [C]G O 
( [C]( O 
0 [C]0 O 
) [C]) O 
) [C]) O 
population [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
by [C]b [C]y O 
determination [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
Annexin [C]A [C]n [C]n [C]e [C]x [C]i [C]n O 
V/7-amino-actinomycin [C]V [C]/ [C]7 [C]- [C]a [C]m [C]i [C]n [C]o [C]- [C]a [C]c [C]t [C]i [C]n [C]o [C]m [C]y [C]c [C]i [C]n O 
D [C]D O 
( [C]( O 
7-AAD [C]7 [C]- [C]A [C]A [C]D O 
) [C]) O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Nuclear [C]N [C]u [C]c [C]l [C]e [C]a [C]r O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
from [C]f [C]r [C]o [C]m O 
CTCL [C]C [C]T [C]C [C]L B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
before [C]b [C]e [C]f [C]o [C]r [C]e O 
and [C]a [C]n [C]d O 
after [C]a [C]f [C]t [C]e [C]r O 
chemical [C]c [C]h [C]e [C]m [C]i [C]c [C]a [C]l O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
were [C]w [C]e [C]r [C]e O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
for [C]f [C]o [C]r O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a O 
B [C]B O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
DNA-binding [C]D [C]N [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
by [C]b [C]y O 
electrophoretic [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
assay [C]a [C]s [C]s [C]a [C]y O 
( [C]( O 
EMSA [C]E [C]M [C]S [C]A O 
) [C]) O 
with [C]w [C]i [C]t [C]h O 
quantitative [C]q [C]u [C]a [C]n [C]t [C]i [C]t [C]a [C]t [C]i [C]v [C]e O 
densitometry [C]d [C]e [C]n [C]s [C]i [C]t [C]o [C]m [C]e [C]t [C]r [C]y O 
. [C]. O 

Nuclear [C]N [C]u [C]c [C]l [C]e [C]a [C]r O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
p65 [C]p [C]6 [C]5 B-protein 
( [C]( I-protein 
Rel [C]R [C]e [C]l I-protein 
A [C]A I-protein 
) [C]) E-protein 
before [C]b [C]e [C]f [C]o [C]r [C]e O 
and [C]a [C]n [C]d O 
after [C]a [C]f [C]t [C]e [C]r O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y O 
compounds [C]c [C]o [C]m [C]p [C]o [C]u [C]n [C]d [C]s O 
was [C]w [C]a [C]s O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
by [C]b [C]y O 
immunofluorescence [C]i [C]m [C]m [C]u [C]n [C]o [C]f [C]l [C]u [C]o [C]r [C]e [C]s [C]c [C]e [C]n [C]c [C]e O 
staining [C]s [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
in [C]i [C]n O 
each [C]e [C]a [C]c [C]h O 
CTCL [C]C [C]T [C]C [C]L B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
. [C]. O 

Neoplastic [C]N [C]e [C]o [C]p [C]l [C]a [C]s [C]t [C]i [C]c B-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
22 [C]2 [C]2 O 
of [C]o [C]f O 
24 [C]2 [C]4 O 
cases [C]c [C]a [C]s [C]e [C]s O 
of [C]o [C]f O 
MF [C]M [C]F O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
strong [C]s [C]t [C]r [C]o [C]n [C]g O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
and [C]a [C]n [C]d O 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
active [C]a [C]c [C]t [C]i [C]v [C]e B-protein 
p65 [C]p [C]6 [C]5 I-protein 
( [C]( I-protein 
Rel [C]R [C]e [C]l I-protein 
A [C]A I-protein 
) [C]) E-protein 
. [C]. O 

Compared [C]C [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
untreated [C]u [C]n [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
a [C]a O 
marked [C]m [C]a [C]r [C]k [C]e [C]d O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
, [C], O 
a [C]a O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a O 
B [C]B O 
DNA-binding [C]D [C]N [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
, [C], O 
and [C]a [C]n [C]d O 
a [C]a O 
marked [C]m [C]a [C]r [C]k [C]e [C]d O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
p65 [C]p [C]6 [C]5 O 
( [C]( O 
Rel [C]R [C]e [C]l O 
A [C]A O 
) [C]) O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
were [C]w [C]e [C]r [C]e O 
seen [C]s [C]e [C]e [C]n O 
in [C]i [C]n O 
cells [C]c [C]e [C]l [C]l [C]s O 
from [C]f [C]r [C]o [C]m O 
both [C]b [C]o [C]t [C]h O 
CTCL [C]C [C]T [C]C [C]L B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
after [C]a [C]f [C]t [C]e [C]r O 
chemical [C]c [C]h [C]e [C]m [C]i [C]c [C]a [C]l O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a O 
B [C]B O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
form [C]f [C]o [C]r [C]m O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B I-protein 
p65 [C]p [C]6 [C]5 I-protein 
( [C]( I-protein 
Rel [C]R [C]e [C]l I-protein 
A [C]A I-protein 
) [C]) E-protein 
is [C]i [C]s O 
commonly [C]c [C]o [C]m [C]m [C]o [C]n [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
neoplastic [C]n [C]e [C]o [C]p [C]l [C]a [C]s [C]t [C]i [C]c B-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
in [C]i [C]n O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
MF [C]M [C]F O 
. [C]. O 

In [C]I [C]n O 
CTCL [C]C [C]T [C]C [C]L B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
, [C], O 
the [C]t [C]h [C]e O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a O 
B [C]B O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
marked [C]m [C]a [C]r [C]k [C]e [C]d O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
spontaneous [C]s [C]p [C]o [C]n [C]t [C]a [C]n [C]e [C]o [C]u [C]s O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
caused [C]c [C]a [C]u [C]s [C]e [C]d O 
by [C]b [C]y O 
chemical [C]c [C]h [C]e [C]m [C]i [C]c [C]a [C]l O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a O 
B [C]B O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
a [C]a O 
critical [C]c [C]r [C]i [C]t [C]i [C]c [C]a [C]l O 
role [C]r [C]o [C]l [C]e O 
for [C]f [C]o [C]r O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
pathogenesis [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
tumor [C]t [C]u [C]m [C]o [C]r O 
cell [C]c [C]e [C]l [C]l O 
maintenance [C]m [C]a [C]i [C]n [C]t [C]e [C]n [C]a [C]n [C]c [C]e O 
of [C]o [C]f O 
CTCLs [C]C [C]T [C]C [C]L [C]s O 
. [C]. O 

HUM [C]H [C]U [C]M O 
PATHOL [C]P [C]A [C]T [C]H [C]O [C]L O 
31 [C]3 [C]1 O 
: [C]: O 
1482-1490 [C]1 [C]4 [C]8 [C]2 [C]- [C]1 [C]4 [C]9 [C]0 O 
. [C]. O 

Human [C]H [C]u [C]m [C]a [C]n O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
virus [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
1 [C]1 O 
tax [C]t [C]a [C]x B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
activates [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]s O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
AP-1 [C]A [C]P [C]- [C]1 B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
by [C]b [C]y O 
inducing [C]i [C]n [C]d [C]u [C]c [C]i [C]n [C]g O 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Human [C]H [C]u [C]m [C]a [C]n O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
virus [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
1 [C]1 O 
( [C]( O 
HTLV-1 [C]H [C]T [C]L [C]V [C]- [C]1 O 
) [C]) O 
Tax [C]T [C]a [C]x B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
family [C]f [C]a [C]m [C]i [C]l [C]y O 
members [C]m [C]e [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
AP-1 [C]A [C]P [C]- [C]1 E-protein 
, [C], O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
c-Jun [C]c [C]- [C]J [C]u [C]n S-protein 
, [C], O 
JunD [C]J [C]u [C]n [C]D S-protein 
, [C], O 
c-Fos [C]c [C]- [C]F [C]o [C]s S-protein 
, [C], O 
and [C]a [C]n [C]d O 
Fra-1 [C]F [C]r [C]a [C]- [C]1 S-protein 
, [C], O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
RNA [C]R [C]N [C]A O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

We [C]W [C]e O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
the [C]t [C]h [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
Tax [C]T [C]a [C]x S-protein 
in [C]i [C]n O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
AP-1-binding [C]A [C]P [C]- [C]1 [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
( [C]( O 
AP-1 [C]A [C]P [C]- [C]1 B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
) [C]) O 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Transient [C]T [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t O 
transfection [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
Tax [C]T [C]a [C]x S-protein 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
luciferase [C]l [C]u [C]c [C]i [C]f [C]e [C]r [C]a [C]s [C]e B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
two [C]t [C]w [C]o O 
copies [C]c [C]o [C]p [C]i [C]e [C]s O 
of [C]o [C]f O 
an [C]a [C]n O 
AP-1 [C]A [C]P [C]- [C]1 B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t I-cell_line 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
. [C]. O 

Tax [C]T [C]a [C]x S-protein 
activates [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]s O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
viral [C]v [C]i [C]r [C]a [C]l B-DNA 
and [C]a [C]n [C]d I-DNA 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
two [C]t [C]w [C]o O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
enhancers [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r [C]s O 
: [C]: O 
a [C]a O 
cAMP-responsive [C]c [C]A [C]M [C]P [C]- [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e B-DNA 
( [C]( I-DNA 
CRE [C]C [C]R [C]E I-DNA 
) [C]) I-DNA 
-like [C]- [C]l [C]i [C]k [C]e I-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
and [C]a [C]n [C]d O 
a [C]a O 
kappaB [C]k [C]a [C]p [C]p [C]a [C]B B-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
. [C]. O 

Two [C]T [C]w [C]o O 
Tax [C]T [C]a [C]x B-protein 
mutants [C]m [C]u [C]t [C]a [C]n [C]t [C]s E-protein 
differentially [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l [C]l [C]y O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
two [C]t [C]w [C]o O 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s O 
. [C]. O 

Tax703 [C]T [C]a [C]x [C]7 [C]0 [C]3 S-protein 
preferentially [C]p [C]r [C]e [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l [C]l [C]y O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
kappaB [C]k [C]a [C]p [C]p [C]a [C]B B-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
the [C]t [C]h [C]e O 
CRE-like [C]C [C]R [C]E [C]- [C]l [C]i [C]k [C]e O 
one [C]o [C]n [C]e O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
TaxM22 [C]T [C]a [C]x [C]M [C]2 [C]2 S-protein 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
the [C]t [C]h [C]e O 
reverse [C]r [C]e [C]v [C]e [C]r [C]s [C]e O 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
Tax703 [C]T [C]a [C]x [C]7 [C]0 [C]3 S-protein 
and [C]a [C]n [C]d O 
Tax [C]T [C]a [C]x S-protein 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
TaxM22 [C]T [C]a [C]x [C]M [C]2 [C]2 S-protein 
, [C], O 
converted [C]c [C]o [C]n [C]v [C]e [C]r [C]t [C]e [C]d O 
cell [C]c [C]e [C]l [C]l O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
of [C]o [C]f O 
a [C]a O 
mouse [C]m [C]o [C]u [C]s [C]e B-cell_line 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
from [C]f [C]r [C]o [C]m O 
being [C]b [C]e [C]i [C]n [C]g O 
interleukin [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n O 
( [C]( O 
IL [C]I [C]L O 
) [C]) O 
-2-dependent [C]- [C]2 [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
to [C]t [C]o O 
being [C]b [C]e [C]i [C]n [C]g O 
IL-2-independent [C]I [C]L [C]- [C]2 [C]- [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
. [C]. O 

Unlike [C]U [C]n [C]l [C]i [C]k [C]e O 
the [C]t [C]h [C]e O 
wild-type [C]w [C]i [C]l [C]d [C]- [C]t [C]y [C]p [C]e B-protein 
Tax [C]T [C]a [C]x E-protein 
, [C], O 
Tax703 [C]T [C]a [C]x [C]7 [C]0 [C]3 S-protein 
and [C]a [C]n [C]d O 
TaxM22 [C]T [C]a [C]x [C]M [C]2 [C]2 S-protein 
only [C]o [C]n [C]l [C]y O 
weakly [C]w [C]e [C]a [C]k [C]l [C]y O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
AP-1 [C]A [C]P [C]- [C]1 B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l B-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
Tax [C]T [C]a [C]x S-protein 
seems [C]s [C]e [C]e [C]m [C]s O 
to [C]t [C]o O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
AP-1 [C]A [C]P [C]- [C]1 B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
via [C]v [C]i [C]a O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
from [C]f [C]r [C]o [C]m O 
those [C]t [C]h [C]o [C]s [C]e O 
of [C]o [C]f O 
kappaB [C]k [C]a [C]p [C]p [C]a [C]B B-DNA 
or [C]o [C]r I-DNA 
CRE-like [C]C [C]R [C]E [C]- [C]l [C]i [C]k [C]e I-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
, [C], O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
AP-1 [C]A [C]P [C]- [C]1 B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
is [C]i [C]s O 
dispensable [C]d [C]i [C]s [C]p [C]e [C]n [C]s [C]a [C]b [C]l [C]e O 
for [C]f [C]o [C]r O 
IL-2-independent [C]I [C]L [C]- [C]2 [C]- [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
of [C]o [C]f O 
CTLL-2 [C]C [C]T [C]L [C]L [C]- [C]2 O 
. [C]. O 

Electrophoretic [C]E [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
Tax [C]T [C]a [C]x S-protein 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
strong [C]s [C]t [C]r [C]o [C]n [C]g O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
to [C]t [C]o O 
an [C]a [C]n O 
AP-1 [C]A [C]P [C]- [C]1 B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
in [C]i [C]n O 
CTLL-2 [C]C [C]T [C]L [C]L [C]- [C]2 O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
Tax703 [C]T [C]a [C]x [C]7 [C]0 [C]3 S-protein 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
, [C], O 
indicating [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
AP-1 [C]A [C]P [C]- [C]1 B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
is [C]i [C]s O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
Tax [C]T [C]a [C]x S-protein 
. [C]. O 

The [C]T [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
Tax [C]T [C]a [C]x S-protein 
in [C]i [C]n O 
CTLL-2 [C]C [C]T [C]L [C]L [C]- [C]2 O 
contained [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]e [C]d O 
JunD [C]J [C]u [C]n [C]D S-protein 
and [C]a [C]n [C]d O 
Fra-2 [C]F [C]r [C]a [C]- [C]2 S-protein 
. [C]. O 

Other [C]O [C]t [C]h [C]e [C]r O 
AP-1 [C]A [C]P [C]- [C]1 B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
were [C]w [C]e [C]r [C]e O 
undetectable [C]u [C]n [C]d [C]e [C]t [C]e [C]c [C]t [C]a [C]b [C]l [C]e O 
. [C]. O 

Activation [C]A [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
AP-1 [C]A [C]P [C]- [C]1 B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
in [C]i [C]n O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
by [C]b [C]y O 
JunD [C]J [C]u [C]n [C]D S-protein 
and/or [C]a [C]n [C]d [C]/ [C]o [C]r O 
Fra-2 [C]F [C]r [C]a [C]- [C]2 S-protein 
was [C]w [C]a [C]s O 
weak [C]w [C]e [C]a [C]k O 
. [C]. O 

c-Jun [C]c [C]- [C]J [C]u [C]n S-protein 
, [C], O 
JunB [C]J [C]u [C]n [C]B S-protein 
, [C], O 
and [C]a [C]n [C]d O 
c-Fos [C]c [C]- [C]F [C]o [C]s S-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
greater [C]g [C]r [C]e [C]a [C]t [C]e [C]r O 
, [C], O 
although [C]a [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
was [C]w [C]a [C]s O 
still [C]s [C]t [C]i [C]l [C]l O 
less [C]l [C]e [C]s [C]s O 
than [C]t [C]h [C]a [C]n O 
that [C]t [C]h [C]a [C]t O 
with [C]w [C]i [C]t [C]h O 
Tax [C]T [C]a [C]x S-protein 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
the [C]t [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
AP-1 [C]A [C]P [C]- [C]1 B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
by [C]b [C]y O 
Tax [C]T [C]a [C]x S-protein 
may [C]m [C]a [C]y O 
not [C]n [C]o [C]t O 
be [C]b [C]e O 
sufficient [C]s [C]u [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
for [C]f [C]o [C]r O 
a [C]a O 
complete [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
AP-1 [C]A [C]P [C]- [C]1 B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
by [C]b [C]y O 
Tax [C]T [C]a [C]x S-protein 
. [C]. O 

Our [C]O [C]u [C]r O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
Tax [C]T [C]a [C]x S-protein 
activates [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]s O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
with [C]w [C]i [C]t [C]h O 
AP-1 [C]A [C]P [C]- [C]1 B-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
by [C]b [C]y O 
inducing [C]i [C]n [C]d [C]u [C]c [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
DNA-binding [C]D [C]N [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
AP-1 [C]A [C]P [C]- [C]1 B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
a [C]a O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
from [C]f [C]r [C]o [C]m O 
those [C]t [C]h [C]o [C]s [C]e O 
of [C]o [C]f O 
CRE-like [C]C [C]R [C]E [C]- [C]l [C]i [C]k [C]e B-DNA 
and [C]a [C]n [C]d I-DNA 
kappaB [C]k [C]a [C]p [C]p [C]a [C]B I-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
. [C]. O 

Copyright [C]C [C]o [C]p [C]y [C]r [C]i [C]g [C]h [C]t O 
2001 [C]2 [C]0 [C]0 [C]1 O 
Academic [C]A [C]c [C]a [C]d [C]e [C]m [C]i [C]c O 
Press [C]P [C]r [C]e [C]s [C]s O 
. [C]. O 

Strict [C]S [C]t [C]r [C]i [C]c [C]t O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n O 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
virus [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
1 [C]1 O 
replication [C]r [C]e [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
a [C]a O 
genetic [C]g [C]e [C]n [C]e [C]t [C]i [C]c O 
switch [C]s [C]w [C]i [C]t [C]c [C]h O 
: [C]: O 
Tet [C]T [C]e [C]t O 
for [C]f [C]o [C]r O 
Tat [C]T [C]a [C]t O 
. [C]. O 

Live-attenuated [C]L [C]i [C]v [C]e [C]- [C]a [C]t [C]t [C]e [C]n [C]u [C]a [C]t [C]e [C]d O 
human [C]h [C]u [C]m [C]a [C]n O 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
virus [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
1 [C]1 O 
( [C]( O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
) [C]) O 
variants [C]v [C]a [C]r [C]i [C]a [C]n [C]t [C]s O 
have [C]h [C]a [C]v [C]e O 
shown [C]s [C]h [C]o [C]w [C]n O 
great [C]g [C]r [C]e [C]a [C]t O 
promise [C]p [C]r [C]o [C]m [C]i [C]s [C]e O 
as [C]a [C]s O 
AIDS [C]A [C]I [C]D [C]S O 
vaccines [C]v [C]a [C]c [C]c [C]i [C]n [C]e [C]s O 
, [C], O 
but [C]b [C]u [C]t O 
continued [C]c [C]o [C]n [C]t [C]i [C]n [C]u [C]e [C]d O 
replication [C]r [C]e [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
can [C]c [C]a [C]n O 
lead [C]l [C]e [C]a [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
selection [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
faster-replicating [C]f [C]a [C]s [C]t [C]e [C]r [C]- [C]r [C]e [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]n [C]g O 
variants [C]v [C]a [C]r [C]i [C]a [C]n [C]t [C]s O 
that [C]t [C]h [C]a [C]t O 
are [C]a [C]r [C]e O 
pathogenic [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]i [C]c O 
. [C]. O 

We [C]W [C]e O 
therefore [C]t [C]h [C]e [C]r [C]e [C]f [C]o [C]r [C]e O 
designed [C]d [C]e [C]s [C]i [C]g [C]n [C]e [C]d O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 B-DNA 
genomes [C]g [C]e [C]n [C]o [C]m [C]e [C]s E-DNA 
that [C]t [C]h [C]a [C]t O 
replicate [C]r [C]e [C]p [C]l [C]i [C]c [C]a [C]t [C]e O 
exclusively [C]e [C]x [C]c [C]l [C]u [C]s [C]i [C]v [C]e [C]l [C]y O 
upon [C]u [C]p [C]o [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
nontoxic [C]n [C]o [C]n [C]t [C]o [C]x [C]i [C]c O 
effector [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r O 
doxycycline [C]d [C]o [C]x [C]y [C]c [C]y [C]c [C]l [C]i [C]n [C]e O 
( [C]( O 
dox [C]d [C]o [C]x O 
) [C]) O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
was [C]w [C]a [C]s O 
achieved [C]a [C]c [C]h [C]i [C]e [C]v [C]e [C]d O 
by [C]b [C]y O 
replacement [C]r [C]e [C]p [C]l [C]a [C]c [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
viral [C]v [C]i [C]r [C]a [C]l O 
TAR-Tat [C]T [C]A [C]R [C]- [C]T [C]a [C]t O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
for [C]f [C]o [C]r O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
Escherichia [C]E [C]s [C]c [C]h [C]e [C]r [C]i [C]c [C]h [C]i [C]a O 
coli-derived [C]c [C]o [C]l [C]i [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
Tet [C]T [C]e [C]t O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
for [C]f [C]o [C]r O 
inducible [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
designer [C]d [C]e [C]s [C]i [C]g [C]n [C]e [C]r O 
`` [C]` [C]` O 
HIV-rtTA [C]H [C]I [C]V [C]- [C]r [C]t [C]T [C]A O 
'' [C]' [C]' O 
viruses [C]v [C]i [C]r [C]u [C]s [C]e [C]s O 
replicate [C]r [C]e [C]p [C]l [C]i [C]c [C]a [C]t [C]e O 
in [C]i [C]n O 
a [C]a O 
strictly [C]s [C]t [C]r [C]i [C]c [C]t [C]l [C]y O 
dox-dependent [C]d [C]o [C]x [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
manner [C]m [C]a [C]n [C]n [C]e [C]r O 
both [C]b [C]o [C]t [C]h O 
in [C]i [C]n O 
a [C]a O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l B-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
rate [C]r [C]a [C]t [C]e O 
of [C]o [C]f O 
replication [C]r [C]e [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
can [C]c [C]a [C]n O 
be [C]b [C]e O 
fine-tuned [C]f [C]i [C]n [C]e [C]- [C]t [C]u [C]n [C]e [C]d O 
by [C]b [C]y O 
simple [C]s [C]i [C]m [C]p [C]l [C]e O 
variation [C]v [C]a [C]r [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
dox [C]d [C]o [C]x O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
HIV-rtTA [C]H [C]I [C]V [C]- [C]r [C]t [C]T [C]A O 
viruses [C]v [C]i [C]r [C]u [C]s [C]e [C]s O 
provide [C]p [C]r [C]o [C]v [C]i [C]d [C]e O 
a [C]a O 
tool [C]t [C]o [C]o [C]l O 
to [C]t [C]o O 
perform [C]p [C]e [C]r [C]f [C]o [C]r [C]m O 
genetics [C]g [C]e [C]n [C]e [C]t [C]i [C]c [C]s O 
, [C], O 
e.g. [C]e [C]. [C]g [C]. O 
, [C], O 
selection [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
optimization [C]o [C]p [C]t [C]i [C]m [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
experiments [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]s O 
, [C], O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
E. [C]E [C]. O 
coli-derived [C]c [C]o [C]l [C]i [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
Tet [C]T [C]e [C]t O 
reagents [C]r [C]e [C]a [C]g [C]e [C]n [C]t [C]s O 
in [C]i [C]n O 
a [C]a O 
eukaryotic [C]e [C]u [C]k [C]a [C]r [C]y [C]o [C]t [C]i [C]c O 
background [C]b [C]a [C]c [C]k [C]g [C]r [C]o [C]u [C]n [C]d O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
such [C]s [C]u [C]c [C]h O 
viruses [C]v [C]i [C]r [C]u [C]s [C]e [C]s O 
may [C]m [C]a [C]y O 
represent [C]r [C]e [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
improved [C]i [C]m [C]p [C]r [C]o [C]v [C]e [C]d O 
vaccine [C]v [C]a [C]c [C]c [C]i [C]n [C]e O 
candidates [C]c [C]a [C]n [C]d [C]i [C]d [C]a [C]t [C]e [C]s O 
because [C]b [C]e [C]c [C]a [C]u [C]s [C]e O 
their [C]t [C]h [C]e [C]i [C]r O 
replication [C]r [C]e [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
can [C]c [C]a [C]n O 
be [C]b [C]e O 
turned [C]t [C]u [C]r [C]n [C]e [C]d O 
on [C]o [C]n O 
and [C]a [C]n [C]d O 
off [C]o [C]f [C]f O 
at [C]a [C]t O 
will [C]w [C]i [C]l [C]l O 
. [C]. O 

Synovial [C]S [C]y [C]n [C]o [C]v [C]i [C]a [C]l O 
fluid [C]f [C]l [C]u [C]i [C]d O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor-kappaB [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
in [C]i [C]n O 
a [C]a O 
monocytic [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]i [C]c B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
. [C]. O 

OBJECTIVE [C]O [C]B [C]J [C]E [C]C [C]T [C]I [C]V [C]E O 
: [C]: O 
To [C]T [C]o O 
determine [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e O 
the [C]t [C]h [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
synovial [C]s [C]y [C]n [C]o [C]v [C]i [C]a [C]l O 
fluids [C]f [C]l [C]u [C]i [C]d [C]s O 
( [C]( O 
SF [C]S [C]F O 
) [C]) O 
on [C]o [C]n O 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor-kappaB [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
( [C]( O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
) [C]) O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
Mono [C]M [C]o [C]n [C]o B-cell_line 
Mac [C]M [C]a [C]c I-cell_line 
6 [C]6 I-cell_line 
monocytic/macrophage [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]i [C]c [C]/ [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
as [C]a [C]s O 
a [C]a O 
model [C]m [C]o [C]d [C]e [C]l O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
SF [C]S [C]F O 
and [C]a [C]n [C]d O 
synovial [C]s [C]y [C]n [C]o [C]v [C]i [C]a [C]l B-cell_type 
tissue [C]t [C]i [C]s [C]s [C]u [C]e I-cell_type 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s E-cell_type 
in [C]i [C]n O 
arthritis [C]a [C]r [C]t [C]h [C]r [C]i [C]t [C]i [C]s O 
. [C]. O 

METHODS [C]M [C]E [C]T [C]H [C]O [C]D [C]S O 
: [C]: O 
Mono [C]M [C]o [C]n [C]o B-cell_line 
Mac [C]M [C]a [C]c I-cell_line 
6 [C]6 I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
were [C]w [C]e [C]r [C]e O 
incubated [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
SF [C]S [C]F O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
knee [C]k [C]n [C]e [C]e O 
joints [C]j [C]o [C]i [C]n [C]t [C]s O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
rheumatoid [C]r [C]h [C]e [C]u [C]m [C]a [C]t [C]o [C]i [C]d O 
arthritis [C]a [C]r [C]t [C]h [C]r [C]i [C]t [C]i [C]s O 
( [C]( O 
RA [C]R [C]A O 
) [C]) O 
, [C], O 
undifferentiated [C]u [C]n [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]e [C]d O 
seronegative [C]s [C]e [C]r [C]o [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
oligoarthritis [C]o [C]l [C]i [C]g [C]o [C]a [C]r [C]t [C]h [C]r [C]i [C]t [C]i [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
osteoarthritis [C]o [C]s [C]t [C]e [C]o [C]a [C]r [C]t [C]h [C]r [C]i [C]t [C]i [C]s O 
( [C]( O 
OA [C]O [C]A O 
) [C]) O 
. [C]. O 

Nuclear [C]N [C]u [C]c [C]l [C]e [C]a [C]r O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
prepared [C]p [C]r [C]e [C]p [C]a [C]r [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
Mono [C]M [C]o [C]n [C]o B-cell_line 
Mac [C]M [C]a [C]c I-cell_line 
6 [C]6 I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
and [C]a [C]n [C]d O 
RA [C]R [C]A O 
synovial [C]s [C]y [C]n [C]o [C]v [C]i [C]a [C]l O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
were [C]w [C]e [C]r [C]e O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
by [C]b [C]y O 
electrophoretic [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
( [C]( O 
EMSA [C]E [C]M [C]S [C]A O 
) [C]) O 
for [C]f [C]o [C]r O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B B-protein 
DNA [C]D [C]N [C]A I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
. [C]. O 

RESULTS [C]R [C]E [C]S [C]U [C]L [C]T [C]S O 
: [C]: O 
Induction [C]I [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
p65 [C]p [C]6 [C]5 B-protein 
( [C]( I-protein 
RelA [C]R [C]e [C]l [C]A I-protein 
) [C]) I-protein 
/p50 [C]/ [C]p [C]5 [C]0 I-protein 
heterodimer [C]h [C]e [C]t [C]e [C]r [C]o [C]d [C]i [C]m [C]e [C]r E-protein 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
incubation [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Mono [C]M [C]o [C]n [C]o B-cell_line 
Mac [C]M [C]a [C]c I-cell_line 
6 [C]6 I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
with [C]w [C]i [C]t [C]h O 
SF [C]S [C]F O 
( [C]( O 
20 [C]2 [C]0 O 
% [C]% O 
in [C]i [C]n O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
medium [C]m [C]e [C]d [C]i [C]u [C]m O 
) [C]) O 
from [C]f [C]r [C]o [C]m O 
5 [C]5 O 
of [C]o [C]f O 
8 [C]8 O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
RA [C]R [C]A O 
, [C], O 
4 [C]4 O 
of [C]o [C]f O 
5 [C]5 O 
with [C]w [C]i [C]t [C]h O 
OA [C]O [C]A O 
, [C], O 
and [C]a [C]n [C]d O 
none [C]n [C]o [C]n [C]e O 
of [C]o [C]f O 
3 [C]3 O 
with [C]w [C]i [C]t [C]h O 
undifferentiated [C]u [C]n [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]e [C]d O 
seronegative [C]s [C]e [C]r [C]o [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
oligoarthritis [C]o [C]l [C]i [C]g [C]o [C]a [C]r [C]t [C]h [C]r [C]i [C]t [C]i [C]s O 
. [C]. O 

Incubation [C]I [C]n [C]c [C]u [C]b [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
SF [C]S [C]F O 
with [C]w [C]i [C]t [C]h O 
neutralizing [C]n [C]e [C]u [C]t [C]r [C]a [C]l [C]i [C]z [C]i [C]n [C]g B-protein 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s E-protein 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
tumor [C]t [C]u [C]m [C]o [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor-alpha [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]a [C]l [C]p [C]h [C]a I-protein 
( [C]( I-protein 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a I-protein 
) [C]) E-protein 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s S-protein 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
interleukin [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n B-protein 
6 [C]6 I-protein 
( [C]( I-protein 
IL-6 [C]I [C]L [C]- [C]6 I-protein 
) [C]) E-protein 
, [C], O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
the [C]t [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
p65/p50 [C]p [C]6 [C]5 [C]/ [C]p [C]5 [C]0 O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
SF [C]S [C]F O 
from [C]f [C]r [C]o [C]m O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
RA [C]R [C]A O 
and [C]a [C]n [C]d O 
OA [C]O [C]A O 
. [C]. O 

Unexpectedly [C]U [C]n [C]e [C]x [C]p [C]e [C]c [C]t [C]e [C]d [C]l [C]y O 
, [C], O 
a [C]a O 
slowly [C]s [C]l [C]o [C]w [C]l [C]y O 
migrating [C]m [C]i [C]g [C]r [C]a [C]t [C]i [C]n [C]g O 
SF [C]S [C]F O 
inducible [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
-binding [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
EMSA [C]E [C]M [C]S [C]A O 
of [C]o [C]f O 
Mono [C]M [C]o [C]n [C]o B-cell_line 
Mac [C]M [C]a [C]c I-cell_line 
6 [C]6 I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
after [C]a [C]f [C]t [C]e [C]r O 
incubation [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
SF [C]S [C]F O 
from [C]f [C]r [C]o [C]m O 
5 [C]5 O 
of [C]o [C]f O 
8 [C]8 O 
RA [C]R [C]A O 
and [C]a [C]n [C]d O 
2 [C]2 O 
of [C]o [C]f O 
5 [C]5 O 
OA [C]O [C]A O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
by [C]b [C]y O 
SF [C]S [C]F O 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
affected [C]a [C]f [C]f [C]e [C]c [C]t [C]e [C]d O 
by [C]b [C]y O 
neutralization [C]n [C]e [C]u [C]t [C]r [C]a [C]l [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
or [C]o [C]r O 
IL-6 [C]I [C]L [C]- [C]6 S-protein 
in [C]i [C]n O 
SF [C]S [C]F O 
, [C], O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
inducible [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
by [C]b [C]y O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
, [C], O 
IL-1beta [C]I [C]L [C]- [C]1 [C]b [C]e [C]t [C]a O 
, [C], O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
/ [C]/ O 
IL-1beta [C]I [C]L [C]- [C]1 [C]b [C]e [C]t [C]a S-protein 
, [C], O 
IL-6 [C]I [C]L [C]- [C]6 S-protein 
, [C], O 
platelet [C]p [C]l [C]a [C]t [C]e [C]l [C]e [C]t B-protein 
derived [C]d [C]e [C]r [C]i [C]v [C]e [C]d I-protein 
growth [C]g [C]r [C]o [C]w [C]t [C]h I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
, [C], O 
lipopolysaccharide [C]l [C]i [C]p [C]o [C]p [C]o [C]l [C]y [C]s [C]a [C]c [C]c [C]h [C]a [C]r [C]i [C]d [C]e O 
, [C], O 
or [C]o [C]r O 
tetradecanoyl [C]t [C]e [C]t [C]r [C]a [C]d [C]e [C]c [C]a [C]n [C]o [C]y [C]l O 
phorbol [C]p [C]h [C]o [C]r [C]b [C]o [C]l O 
acetate [C]a [C]c [C]e [C]t [C]a [C]t [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
slowly [C]s [C]l [C]o [C]w [C]l [C]y O 
migrating [C]m [C]i [C]g [C]r [C]a [C]t [C]i [C]n [C]g B-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
could [C]c [C]o [C]u [C]l [C]d O 
not [C]n [C]o [C]t O 
be [C]b [C]e O 
supershifted [C]s [C]u [C]p [C]e [C]r [C]s [C]h [C]i [C]f [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s S-protein 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
, [C], O 
Jun [C]J [C]u [C]n S-protein 
, [C], O 
or [C]o [C]r O 
the [C]t [C]h [C]e O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
coactivators [C]c [C]o [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r [C]s O 
p300 [C]p [C]3 [C]0 [C]0 S-protein 
or [C]o [C]r O 
CBP [C]C [C]B [C]P S-protein 
. [C]. O 

A [C]A O 
NF-kappaB-binding [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
with [C]w [C]i [C]t [C]h O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
slow [C]s [C]l [C]o [C]w O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
prepared [C]p [C]r [C]e [C]p [C]a [C]r [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
fresh [C]f [C]r [C]e [C]s [C]h O 
human [C]h [C]u [C]m [C]a [C]n O 
RA [C]R [C]A O 
synovial [C]s [C]y [C]n [C]o [C]v [C]i [C]a [C]l O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
. [C]. O 

CONCLUSION [C]C [C]O [C]N [C]C [C]L [C]U [C]S [C]I [C]O [C]N O 
: [C]: O 
Biological [C]B [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
in [C]i [C]n O 
SF [C]S [C]F O 
from [C]f [C]r [C]o [C]m O 
RA [C]R [C]A O 
and [C]a [C]n [C]d O 
OA [C]O [C]A O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
is [C]i [C]s O 
capable [C]c [C]a [C]p [C]a [C]b [C]l [C]e O 
of [C]o [C]f O 
inducing [C]i [C]n [C]d [C]u [C]c [C]i [C]n [C]g O 
p65/p50 [C]p [C]6 [C]5 [C]/ [C]p [C]5 [C]0 B-protein 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_type 
. [C]. O 

A [C]A O 
property [C]p [C]r [C]o [C]p [C]e [C]r [C]t [C]y O 
of [C]o [C]f O 
SF [C]S [C]F O 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
of [C]o [C]f O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
and [C]a [C]n [C]d O 
other [C]o [C]t [C]h [C]e [C]r O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
is [C]i [C]s O 
responsible [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]b [C]l [C]e O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
slowly [C]s [C]l [C]o [C]w [C]l [C]y O 
migrating [C]m [C]i [C]g [C]r [C]a [C]t [C]i [C]n [C]g O 
NF-kappaB-binding [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
. [C]. O 

Soluble [C]S [C]o [C]l [C]u [C]b [C]l [C]e O 
mediators [C]m [C]e [C]d [C]i [C]a [C]t [C]o [C]r [C]s O 
in [C]i [C]n O 
SF [C]S [C]F O 
of [C]o [C]f O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
RA [C]R [C]A O 
and [C]a [C]n [C]d O 
OA [C]O [C]A O 
can [C]c [C]a [C]n O 
therefore [C]t [C]h [C]e [C]r [C]e [C]f [C]o [C]r [C]e O 
modulate [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B B-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
site [C]s [C]i [C]t [C]e E-protein 
in [C]i [C]n O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_type 
and [C]a [C]n [C]d O 
may [C]m [C]a [C]y O 
play [C]p [C]l [C]a [C]y O 
a [C]a O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
arthritis [C]a [C]r [C]t [C]h [C]r [C]i [C]t [C]i [C]s O 
. [C]. O 

Peroxisome [C]P [C]e [C]r [C]o [C]x [C]i [C]s [C]o [C]m [C]e B-protein 
proliferator [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]o [C]r I-protein 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r I-protein 
receptor-gamma [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]- [C]g [C]a [C]m [C]m [C]a E-protein 
agonists [C]a [C]g [C]o [C]n [C]i [C]s [C]t [C]s O 
and [C]a [C]n [C]d O 
15-deoxy-Delta [C]1 [C]5 [C]- [C]d [C]e [C]o [C]x [C]y [C]- [C]D [C]e [C]l [C]t [C]a O 
( [C]( O 
12 [C]1 [C]2 O 
, [C], O 
14 [C]1 [C]4 O 
) [C]) O 
( [C]( O 
12 [C]1 [C]2 O 
, [C], O 
14 [C]1 [C]4 O 
) [C]) O 
-PGJ [C]- [C]P [C]G [C]J O 
( [C]( O 
2 [C]2 O 
) [C]) O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
and [C]a [C]n [C]d O 
malignant [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]t O 
B-lineage [C]B [C]- [C]l [C]i [C]n [C]e [C]a [C]g [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
research [C]r [C]e [C]s [C]e [C]a [C]r [C]c [C]h O 
described [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
herein [C]h [C]e [C]r [C]e [C]i [C]n O 
evaluates [C]e [C]v [C]a [C]l [C]u [C]a [C]t [C]e [C]s O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
significance [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]c [C]e O 
of [C]o [C]f O 
peroxisome [C]p [C]e [C]r [C]o [C]x [C]i [C]s [C]o [C]m [C]e B-protein 
proliferator [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]o [C]r I-protein 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r I-protein 
receptor-gamma [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]- [C]g [C]a [C]m [C]m [C]a I-protein 
( [C]( I-protein 
PPAR-gamma [C]P [C]P [C]A [C]R [C]- [C]g [C]a [C]m [C]m [C]a I-protein 
) [C]) E-protein 
on [C]o [C]n O 
B-lineage [C]B [C]- [C]l [C]i [C]n [C]e [C]a [C]g [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Normal [C]N [C]o [C]r [C]m [C]a [C]l B-cell_type 
mouse [C]m [C]o [C]u [C]s [C]e I-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
a [C]a O 
variety [C]v [C]a [C]r [C]i [C]e [C]t [C]y O 
of [C]o [C]f O 
B [C]B B-cell_type 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
reflective [C]r [C]e [C]f [C]l [C]e [C]c [C]t [C]i [C]v [C]e O 
of [C]o [C]f O 
stages [C]s [C]t [C]a [C]g [C]e [C]s O 
of [C]o [C]f O 
B [C]B O 
cell [C]c [C]e [C]l [C]l O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
( [C]( O 
e.g. [C]e [C]. [C]g [C]. O 
, [C], O 
70Z/3 [C]7 [C]0 [C]Z [C]/ [C]3 O 
, [C], O 
CH31 [C]C [C]H [C]3 [C]1 O 
, [C], O 
WEHI-231 [C]W [C]E [C]H [C]I [C]- [C]2 [C]3 [C]1 O 
, [C], O 
CH12 [C]C [C]H [C]1 [C]2 O 
, [C], O 
and [C]a [C]n [C]d O 
J558 [C]J [C]5 [C]5 [C]8 O 
) [C]) O 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
PPAR-gamma [C]P [C]P [C]A [C]R [C]- [C]g [C]a [C]m [C]m [C]a B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
and [C]a [C]n [C]d O 
, [C], O 
by [C]b [C]y O 
Western [C]W [C]e [C]s [C]t [C]e [C]r [C]n O 
blot [C]b [C]l [C]o [C]t O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
, [C], O 
the [C]t [C]h [C]e O 
67-kDa [C]6 [C]7 [C]- [C]k [C]D [C]a B-protein 
PPAR-gamma [C]P [C]P [C]A [C]R [C]- [C]g [C]a [C]m [C]m [C]a I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
. [C]. O 

15-Deoxy-Delta [C]1 [C]5 [C]- [C]D [C]e [C]o [C]x [C]y [C]- [C]D [C]e [C]l [C]t [C]a O 
( [C]( O 
12 [C]1 [C]2 O 
, [C], O 
14 [C]1 [C]4 O 
) [C]) O 
-PGJ [C]- [C]P [C]G [C]J O 
( [C]( O 
2 [C]2 O 
) [C]) O 
( [C]( O 
15d-PGJ [C]1 [C]5 [C]d [C]- [C]P [C]G [C]J O 
( [C]( O 
2 [C]2 O 
) [C]) O 
) [C]) O 
, [C], O 
a [C]a O 
PPAR-gamma [C]P [C]P [C]A [C]R [C]- [C]g [C]a [C]m [C]m [C]a O 
agonist [C]a [C]g [C]o [C]n [C]i [C]s [C]t O 
, [C], O 
has [C]h [C]a [C]s O 
a [C]a O 
dose-dependent [C]d [C]o [C]s [C]e [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
antiproliferative [C]a [C]n [C]t [C]i [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
and [C]a [C]n [C]d O 
cytotoxic [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
and [C]a [C]n [C]d I-cell_type 
malignant [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]t I-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
as [C]a [C]s O 
shown [C]s [C]h [C]o [C]w [C]n O 
by [C]b [C]y O 
[ [C][ O 
( [C]( O 
3 [C]3 O 
) [C]) O 
H [C]H O 
] [C]] O 
thymidine [C]t [C]h [C]y [C]m [C]i [C]d [C]i [C]n [C]e O 
and [C]a [C]n [C]d O 
3- [C]3 [C]- O 
[ [C][ O 
4 [C]4 O 
, [C], O 
5-dimethylthiazol-2-yl [C]5 [C]- [C]d [C]i [C]m [C]e [C]t [C]h [C]y [C]l [C]t [C]h [C]i [C]a [C]z [C]o [C]l [C]- [C]2 [C]- [C]y [C]l O 
] [C]] O 
-2 [C]- [C]2 O 
, [C], O 
5-diphenyltetrazolium [C]5 [C]- [C]d [C]i [C]p [C]h [C]e [C]n [C]y [C]l [C]t [C]e [C]t [C]r [C]a [C]z [C]o [C]l [C]i [C]u [C]m O 
bromide [C]b [C]r [C]o [C]m [C]i [C]d [C]e O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
. [C]. O 

Only [C]O [C]n [C]l [C]y O 
PPAR-gamma [C]P [C]P [C]A [C]R [C]- [C]g [C]a [C]m [C]m [C]a O 
agonists [C]a [C]g [C]o [C]n [C]i [C]s [C]t [C]s O 
( [C]( O 
thiazolidinediones [C]t [C]h [C]i [C]a [C]z [C]o [C]l [C]i [C]d [C]i [C]n [C]e [C]d [C]i [C]o [C]n [C]e [C]s O 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
not [C]n [C]o [C]t O 
PPAR-alpha [C]P [C]P [C]A [C]R [C]- [C]a [C]l [C]p [C]h [C]a O 
agonists [C]a [C]g [C]o [C]n [C]i [C]s [C]t [C]s O 
, [C], O 
mimicked [C]m [C]i [C]m [C]i [C]c [C]k [C]e [C]d O 
the [C]t [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
15d-PGJ [C]1 [C]5 [C]d [C]- [C]P [C]G [C]J O 
( [C]( O 
2 [C]2 O 
) [C]) O 
on [C]o [C]n O 
B-lineage [C]B [C]- [C]l [C]i [C]n [C]e [C]a [C]g [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
indicating [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
by [C]b [C]y O 
which [C]w [C]h [C]i [C]c [C]h O 
15d-PGJ [C]1 [C]5 [C]d [C]- [C]P [C]G [C]J O 
( [C]( O 
2 [C]2 O 
) [C]) O 
negatively [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e [C]l [C]y O 
affects [C]a [C]f [C]f [C]e [C]c [C]t [C]s O 
B-lineage [C]B [C]- [C]l [C]i [C]n [C]e [C]a [C]g [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
involves [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]s O 
in [C]i [C]n O 
part [C]p [C]a [C]r [C]t O 
PPAR-gamma [C]P [C]P [C]A [C]R [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
. [C]. O 

The [C]T [C]h [C]e O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
by [C]b [C]y O 
which [C]w [C]h [C]i [C]c [C]h O 
PPAR-gamma [C]P [C]P [C]A [C]R [C]- [C]g [C]a [C]m [C]m [C]a O 
agonists [C]a [C]g [C]o [C]n [C]i [C]s [C]t [C]s O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
cytotoxicity [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c [C]i [C]t [C]y O 
is [C]i [C]s O 
via [C]v [C]i [C]a O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
, [C], O 
as [C]a [C]s O 
shown [C]s [C]h [C]o [C]w [C]n O 
by [C]b [C]y O 
annexin [C]a [C]n [C]n [C]e [C]x [C]i [C]n O 
V [C]V O 
staining [C]s [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
as [C]a [C]s O 
confirmed [C]c [C]o [C]n [C]f [C]i [C]r [C]m [C]e [C]d O 
by [C]b [C]y O 
DNA [C]D [C]N [C]A O 
fragmentation [C]f [C]r [C]a [C]g [C]m [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
using [C]u [C]s [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
TUNEL [C]T [C]U [C]N [C]E [C]L O 
assay [C]a [C]s [C]s [C]a [C]y O 
. [C]. O 

Interestingly [C]I [C]n [C]t [C]e [C]r [C]e [C]s [C]t [C]i [C]n [C]g [C]l [C]y O 
, [C], O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
PGF [C]P [C]G [C]F O 
( [C]( O 
2alpha [C]2 [C]a [C]l [C]p [C]h [C]a O 
) [C]) O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
known [C]k [C]n [C]o [C]w [C]n O 
to [C]t [C]o O 
affect [C]a [C]f [C]f [C]e [C]c [C]t O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
, [C], O 
dramatically [C]d [C]r [C]a [C]m [C]a [C]t [C]i [C]c [C]a [C]l [C]l [C]y O 
attenuated [C]a [C]t [C]t [C]e [C]n [C]u [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
deleterious [C]d [C]e [C]l [C]e [C]t [C]e [C]r [C]i [C]o [C]u [C]s O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
PPAR-gamma [C]P [C]P [C]A [C]R [C]- [C]g [C]a [C]m [C]m [C]a O 
agonists [C]a [C]g [C]o [C]n [C]i [C]s [C]t [C]s O 
on [C]o [C]n O 
B [C]B B-cell_type 
lymphomas [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a [C]s E-cell_type 
. [C]. O 

Surprisingly [C]S [C]u [C]r [C]p [C]r [C]i [C]s [C]i [C]n [C]g [C]l [C]y O 
, [C], O 
15d-PGJ [C]1 [C]5 [C]d [C]- [C]P [C]G [C]J O 
( [C]( O 
2 [C]2 O 
) [C]) O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
a [C]a O 
massive [C]m [C]a [C]s [C]s [C]i [C]v [C]e O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
mitogen-activated [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
pretreatment [C]p [C]r [C]e [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
PGF [C]P [C]G [C]F O 
( [C]( O 
2alpha [C]2 [C]a [C]l [C]p [C]h [C]a O 
) [C]) O 
blunted [C]b [C]l [C]u [C]n [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
mitogen-activated [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
is [C]i [C]s O 
the [C]t [C]h [C]e O 
first [C]f [C]i [C]r [C]s [C]t O 
study [C]s [C]t [C]u [C]d [C]y O 
evaluating [C]e [C]v [C]a [C]l [C]u [C]a [C]t [C]i [C]n [C]g O 
PPAR-gamma [C]P [C]P [C]A [C]R [C]- [C]g [C]a [C]m [C]m [C]a O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
its [C]i [C]t [C]s O 
significance [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]c [C]e O 
on [C]o [C]n O 
B [C]B B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

PPAR-gamma [C]P [C]P [C]A [C]R [C]- [C]g [C]a [C]m [C]m [C]a O 
agonists [C]a [C]g [C]o [C]n [C]i [C]s [C]t [C]s O 
may [C]m [C]a [C]y O 
serve [C]s [C]e [C]r [C]v [C]e O 
as [C]a [C]s O 
a [C]a O 
counterbalance [C]c [C]o [C]u [C]n [C]t [C]e [C]r [C]b [C]a [C]l [C]a [C]n [C]c [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
stimulating [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
other [C]o [C]t [C]h [C]e [C]r O 
PGs [C]P [C]G [C]s O 
, [C], O 
namely [C]n [C]a [C]m [C]e [C]l [C]y O 
PGE [C]P [C]G [C]E O 
( [C]( O 
2 [C]2 O 
) [C]) O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
promotes [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]s O 
B [C]B O 
cell [C]c [C]e [C]l [C]l O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Finally [C]F [C]i [C]n [C]a [C]l [C]l [C]y O 
, [C], O 
the [C]t [C]h [C]e O 
use [C]u [C]s [C]e O 
of [C]o [C]f O 
PGs [C]P [C]G [C]s O 
, [C], O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
15d-PGJ [C]1 [C]5 [C]d [C]- [C]P [C]G [C]J O 
( [C]( O 
2 [C]2 O 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
synthetic [C]s [C]y [C]n [C]t [C]h [C]e [C]t [C]i [C]c O 
PPAR-gamma [C]P [C]P [C]A [C]R [C]- [C]g [C]a [C]m [C]m [C]a O 
agonists [C]a [C]g [C]o [C]n [C]i [C]s [C]t [C]s O 
to [C]t [C]o O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
B-lineage [C]B [C]- [C]l [C]i [C]n [C]e [C]a [C]g [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
may [C]m [C]a [C]y O 
lead [C]l [C]e [C]a [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
novel [C]n [C]o [C]v [C]e [C]l O 
therapies [C]t [C]h [C]e [C]r [C]a [C]p [C]i [C]e [C]s O 
for [C]f [C]o [C]r O 
fatal [C]f [C]a [C]t [C]a [C]l B-cell_type 
B [C]B I-cell_type 
lymphomas [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a [C]s E-cell_type 

Inhibition [C]I [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
STAT3 [C]S [C]T [C]A [C]T [C]3 O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
leads [C]l [C]e [C]a [C]d [C]s O 
to [C]t [C]o O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
of [C]o [C]f O 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c B-cell_type 
large [C]l [C]a [C]r [C]g [C]e I-cell_type 
granular [C]g [C]r [C]a [C]n [C]u [C]l [C]a [C]r I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
Mcl-1 [C]M [C]c [C]l [C]- [C]1 O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Large [C]L [C]a [C]r [C]g [C]e O 
granular [C]g [C]r [C]a [C]n [C]u [C]l [C]a [C]r O 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e O 
( [C]( O 
LGL [C]L [C]G [C]L O 
) [C]) O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
is [C]i [C]s O 
characterized [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
expansion [C]e [C]x [C]p [C]a [C]n [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
antigen-activated [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-cell_type 
cytotoxic [C]c [C]y [C]t [C]o [C]t [C]o [C]x [C]i [C]c I-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
are [C]a [C]r [C]e O 
resistant [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]t O 
to [C]t [C]o O 
Fas-mediated [C]F [C]a [C]s [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
despite [C]d [C]e [C]s [C]p [C]i [C]t [C]e O 
expressing [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]n [C]g O 
high [C]h [C]i [C]g [C]h O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
Fas [C]F [C]a [C]s S-protein 
. [C]. O 

We [C]W [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c B-cell_type 
LGL [C]L [C]G [C]L E-cell_type 
from [C]f [C]r [C]o [C]m O 
19 [C]1 [C]9 O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
displayed [C]d [C]i [C]s [C]p [C]l [C]a [C]y [C]e [C]d O 
high [C]h [C]i [C]g [C]h O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-protein 
STAT3 [C]S [C]T [C]A [C]T [C]3 E-protein 
. [C]. O 

Treatment [C]T [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c B-cell_type 
LGL [C]L [C]G [C]L E-cell_type 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
JAK-selective [C]J [C]A [C]K [C]- [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
AG-490 [C]A [C]G [C]- [C]4 [C]9 [C]0 O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
corresponding [C]c [C]o [C]r [C]r [C]e [C]s [C]p [C]o [C]n [C]d [C]i [C]n [C]g O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
STAT [C]S [C]T [C]A [C]T S-protein 
-DNA [C]- [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

Moreover [C]M [C]o [C]r [C]e [C]o [C]v [C]e [C]r O 
, [C], O 
using [C]u [C]s [C]i [C]n [C]g O 
an [C]a [C]n O 
antisense [C]a [C]n [C]t [C]i [C]s [C]e [C]n [C]s [C]e O 
oligonucleotide [C]o [C]l [C]i [C]g [C]o [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e O 
approach [C]a [C]p [C]p [C]r [C]o [C]a [C]c [C]h O 
to [C]t [C]o O 
diminish [C]d [C]i [C]m [C]i [C]n [C]i [C]s [C]h O 
STAT3 [C]S [C]T [C]A [C]T [C]3 O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
we [C]w [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
Fas [C]F [C]a [C]s O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
was [C]w [C]a [C]s O 
restored [C]r [C]e [C]s [C]t [C]o [C]r [C]e [C]d O 
in [C]i [C]n O 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c B-cell_type 
LGL [C]L [C]G [C]L E-cell_type 
. [C]. O 

AG-490-induced [C]A [C]G [C]- [C]4 [C]9 [C]0 [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c B-cell_type 
LGL [C]L [C]G [C]L E-cell_type 
was [C]w [C]a [C]s O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
of [C]o [C]f O 
Bcl-xL [C]B [C]c [C]l [C]- [C]x [C]L O 
or [C]o [C]r O 
Bcl-2 [C]B [C]c [C]l [C]- [C]2 O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
we [C]w [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
Bcl-2-family [C]B [C]c [C]l [C]- [C]2 [C]- [C]f [C]a [C]m [C]i [C]l [C]y B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
Mcl-1 [C]M [C]c [C]l [C]- [C]1 E-protein 
was [C]w [C]a [C]s O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
AG-490 [C]A [C]G [C]- [C]4 [C]9 [C]0 O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
. [C]. O 

Activated [C]A [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-protein 
STAT3 [C]S [C]T [C]A [C]T [C]3 E-protein 
was [C]w [C]a [C]s O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
bind [C]b [C]i [C]n [C]d O 
an [C]a [C]n O 
SIE-related [C]S [C]I [C]E [C]- [C]r [C]e [C]l [C]a [C]t [C]e [C]d B-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
murine [C]m [C]u [C]r [C]i [C]n [C]e B-DNA 
mcl-1 [C]m [C]c [C]l [C]- [C]1 I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

Using [C]U [C]s [C]i [C]n [C]g O 
a [C]a O 
luciferase [C]l [C]u [C]c [C]i [C]f [C]e [C]r [C]a [C]s [C]e O 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r O 
assay [C]a [C]s [C]s [C]a [C]y O 
, [C], O 
we [C]w [C]e O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
v-src [C]v [C]- [C]s [C]r [C]c O 
overexpression [C]o [C]v [C]e [C]r [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
NIH3T3 [C]N [C]I [C]H [C]3 [C]T [C]3 O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
STAT3 [C]S [C]T [C]A [C]T [C]3 S-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
mcl-1 [C]m [C]c [C]l [C]- [C]1 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
and [C]a [C]n [C]d O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
endogenous [C]e [C]n [C]d [C]o [C]g [C]e [C]n [C]o [C]u [C]s O 
Mcl-1 [C]M [C]c [C]l [C]- [C]1 O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
. [C]. O 

We [C]W [C]e O 
conclude [C]c [C]o [C]n [C]c [C]l [C]u [C]d [C]e O 
that [C]t [C]h [C]a [C]t O 
STAT3 [C]S [C]T [C]A [C]T [C]3 S-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
contributed [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e [C]d O 
to [C]t [C]o O 
accumulation [C]a [C]c [C]c [C]u [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c B-cell_type 
LGL [C]L [C]G [C]L I-cell_type 
clones [C]c [C]l [C]o [C]n [C]e [C]s E-cell_type 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
investigation [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]i [C]o [C]n O 
should [C]s [C]h [C]o [C]u [C]l [C]d O 
focus [C]f [C]o [C]c [C]u [C]s O 
on [C]o [C]n O 
novel [C]n [C]o [C]v [C]e [C]l O 
strategies [C]s [C]t [C]r [C]a [C]t [C]e [C]g [C]i [C]e [C]s O 
targeting [C]t [C]a [C]r [C]g [C]e [C]t [C]i [C]n [C]g O 
STAT3 [C]S [C]T [C]A [C]T [C]3 S-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
LGL [C]L [C]G [C]L O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
. [C]. O 

Decreased [C]D [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
immediate [C]i [C]m [C]m [C]e [C]d [C]i [C]a [C]t [C]e O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
activating [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]n [C]g B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor-2 [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]2 E-protein 
mutant [C]m [C]u [C]t [C]a [C]n [C]t O 
mice [C]m [C]i [C]c [C]e O 
. [C]. O 

Transcription [C]T [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
activating [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]n [C]g I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
( [C]( I-protein 
ATF [C]A [C]T [C]F I-protein 
) [C]) I-protein 
-2 [C]- [C]2 E-protein 
is [C]i [C]s O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
transduced [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
JNK [C]J [C]N [C]K O 
and [C]a [C]n [C]d O 
p38 [C]p [C]3 [C]8 O 
MAP [C]M [C]A [C]P O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
. [C]. O 

To [C]T [C]o O 
better [C]b [C]e [C]t [C]t [C]e [C]r O 
define [C]d [C]e [C]f [C]i [C]n [C]e O 
the [C]t [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
ATF-2 [C]A [C]T [C]F [C]- [C]2 S-protein 
in [C]i [C]n O 
inflammation [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
adult [C]a [C]d [C]u [C]l [C]t O 
mice [C]m [C]i [C]c [C]e O 
expressing [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]n [C]g O 
small [C]s [C]m [C]a [C]l [C]l O 
amounts [C]a [C]m [C]o [C]u [C]n [C]t [C]s O 
of [C]o [C]f O 
a [C]a O 
mutant [C]m [C]u [C]t [C]a [C]n [C]t B-protein 
ATF-2 [C]A [C]T [C]F [C]- [C]2 I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
were [C]w [C]e [C]r [C]e O 
challenged [C]c [C]h [C]a [C]l [C]l [C]e [C]n [C]g [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
lipopolysaccharide [C]l [C]i [C]p [C]o [C]p [C]o [C]l [C]y [C]s [C]a [C]c [C]c [C]h [C]a [C]r [C]i [C]d [C]e O 
( [C]( O 
LPS [C]L [C]P [C]S O 
) [C]) O 
, [C], O 
anti-CD3 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]3 B-protein 
antibody [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y E-protein 
or [C]o [C]r O 
virus [C]v [C]i [C]r [C]u [C]s O 
. [C]. O 

Within [C]W [C]i [C]t [C]h [C]i [C]n O 
3 [C]3 O 
h [C]h O 
of [C]o [C]f O 
challenge [C]c [C]h [C]a [C]l [C]l [C]e [C]n [C]g [C]e O 
by [C]b [C]y O 
LPS [C]L [C]P [C]S O 
, [C], O 
ATF-2 [C]A [C]T [C]F [C]- [C]2 O 
mutant [C]m [C]u [C]t [C]a [C]n [C]t O 
mice [C]m [C]i [C]c [C]e O 
had [C]h [C]a [C]d O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n B-protein 
molecules [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]s E-protein 
E-selectin [C]E [C]- [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]n S-protein 
, [C], O 
P-selectin [C]P [C]- [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]n S-protein 
and [C]a [C]n [C]d O 
VCAM-1 [C]V [C]C [C]A [C]M [C]- [C]1 S-protein 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
the [C]t [C]h [C]e O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
tumor [C]t [C]u [C]m [C]o [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor-alpha [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]a [C]l [C]p [C]h [C]a E-protein 
, [C], O 
IL-1beta [C]I [C]L [C]- [C]1 [C]b [C]e [C]t [C]a S-protein 
and [C]a [C]n [C]d O 
IL-6 [C]I [C]L [C]- [C]6 S-protein 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
mice [C]m [C]i [C]c [C]e O 
. [C]. O 

Stimulation [C]S [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
T [C]T B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
by [C]b [C]y O 
anti-CD3 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]3 B-protein 
antibody [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y E-protein 
also [C]a [C]l [C]s [C]o O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
less [C]l [C]e [C]s [C]s O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-1 [C]I [C]L [C]- [C]1 S-protein 
and [C]a [C]n [C]d O 
IL-6 [C]I [C]L [C]- [C]6 S-protein 
in [C]i [C]n O 
ATF-2 [C]A [C]T [C]F [C]- [C]2 O 
mutant [C]m [C]u [C]t [C]a [C]n [C]t O 
tissues [C]t [C]i [C]s [C]s [C]u [C]e [C]s O 
. [C]. O 

ATF-2 [C]A [C]T [C]F [C]- [C]2 B-cell_type 
mutant [C]m [C]u [C]t [C]a [C]n [C]t I-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
anti-CD3 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]3 B-protein 
antibody [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y E-protein 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
c-Jun [C]c [C]- [C]J [C]u [C]n S-protein 
, [C], O 
JunB [C]J [C]u [C]n [C]B S-protein 
, [C], O 
JunD [C]J [C]u [C]n [C]D S-protein 
and [C]a [C]n [C]d O 
Fra-2 [C]F [C]r [C]a [C]- [C]2 S-protein 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
to [C]t [C]o O 
what [C]w [C]h [C]a [C]t O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
after [C]a [C]f [C]t [C]e [C]r O 
p38 [C]p [C]3 [C]8 O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
mice [C]m [C]i [C]c [C]e O 
, [C], O 
relative [C]r [C]e [C]l [C]a [C]t [C]i [C]v [C]e O 
ATF-2 [C]A [C]T [C]F [C]- [C]2 O 
deficiency [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
prevent [C]p [C]r [C]e [C]v [C]e [C]n [C]t O 
the [C]t [C]h [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
a [C]a O 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
infiltrate [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
week [C]w [C]e [C]e [C]k O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
an [C]a [C]n O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
stimulus [C]s [C]t [C]i [C]m [C]u [C]l [C]u [C]s O 
. [C]. O 

ATF-2 [C]A [C]T [C]F [C]- [C]2 O 
mutant [C]m [C]u [C]t [C]a [C]n [C]t O 
mice [C]m [C]i [C]c [C]e O 
proved [C]p [C]r [C]o [C]v [C]e [C]d O 
more [C]m [C]o [C]r [C]e O 
susceptible [C]s [C]u [C]s [C]c [C]e [C]p [C]t [C]i [C]b [C]l [C]e O 
to [C]t [C]o O 
death [C]d [C]e [C]a [C]t [C]h O 
than [C]t [C]h [C]a [C]n O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
mice [C]m [C]i [C]c [C]e O 
from [C]f [C]r [C]o [C]m O 
LPS [C]L [C]P [C]S O 
plus [C]p [C]l [C]u [C]s O 
D-galactosamine [C]D [C]- [C]g [C]a [C]l [C]a [C]c [C]t [C]o [C]s [C]a [C]m [C]i [C]n [C]e O 
injection [C]i [C]n [C]j [C]e [C]c [C]t [C]i [C]o [C]n O 
or [C]o [C]r O 
Coxsackievirus [C]C [C]o [C]x [C]s [C]a [C]c [C]k [C]i [C]e [C]v [C]i [C]r [C]u [C]s O 
B3 [C]B [C]3 O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
had [C]h [C]a [C]d O 
a [C]a O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
incidence [C]i [C]n [C]c [C]i [C]d [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
pulmonary [C]p [C]u [C]l [C]m [C]o [C]n [C]a [C]r [C]y O 
infiltrates [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]e [C]s O 
after [C]a [C]f [C]t [C]e [C]r O 
exposure [C]e [C]x [C]p [C]o [C]s [C]u [C]r [C]e O 
to [C]t [C]o O 
Herpes [C]H [C]e [C]r [C]p [C]e [C]s O 
simplex [C]s [C]i [C]m [C]p [C]l [C]e [C]x O 
virus-1 [C]v [C]i [C]r [C]u [C]s [C]- [C]1 O 
. [C]. O 

ATF-2 [C]A [C]T [C]F [C]- [C]2 S-protein 
is [C]i [C]s O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
for [C]f [C]o [C]r O 
maximal [C]m [C]a [C]x [C]i [C]m [C]a [C]l O 
immediate [C]i [C]m [C]m [C]e [C]d [C]i [C]a [C]t [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n B-protein 
molecules [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]s E-protein 
and [C]a [C]n [C]d O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
, [C], O 
but [C]b [C]u [C]t O 
at [C]a [C]t O 
later [C]l [C]a [C]t [C]e [C]r O 
time [C]t [C]i [C]m [C]e O 
points [C]p [C]o [C]i [C]n [C]t [C]s O 
may [C]m [C]a [C]y O 
even [C]e [C]v [C]e [C]n O 
protect [C]p [C]r [C]o [C]t [C]e [C]c [C]t O 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
overactive [C]o [C]v [C]e [C]r [C]a [C]c [C]t [C]i [C]v [C]e O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
. [C]. O 

LIGHT [C]L [C]I [C]G [C]H [C]T S-protein 
, [C], O 
a [C]a O 
TNF-like [C]T [C]N [C]F [C]- [C]l [C]i [C]k [C]e B-protein 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e E-protein 
, [C], O 
costimulates [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]s O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
dendritic [C]d [C]e [C]n [C]d [C]r [C]i [C]t [C]i [C]c B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
allogeneic [C]a [C]l [C]l [C]o [C]g [C]e [C]n [C]e [C]i [C]c O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
. [C]. O 

LIGHT [C]L [C]I [C]G [C]H [C]T S-protein 
is [C]i [C]s O 
a [C]a O 
recently [C]r [C]e [C]c [C]e [C]n [C]t [C]l [C]y O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
member [C]m [C]e [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
TNF [C]T [C]N [C]F B-protein 
superfamily [C]s [C]u [C]p [C]e [C]r [C]f [C]a [C]m [C]i [C]l [C]y E-protein 
and [C]a [C]n [C]d O 
its [C]i [C]t [C]s O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
, [C], O 
herpesvirus [C]h [C]e [C]r [C]p [C]e [C]s [C]v [C]i [C]r [C]u [C]s B-protein 
entry [C]e [C]n [C]t [C]r [C]y I-protein 
mediator [C]m [C]e [C]d [C]i [C]a [C]t [C]o [C]r E-protein 
and [C]a [C]n [C]d O 
lymphotoxin [C]l [C]y [C]m [C]p [C]h [C]o [C]t [C]o [C]x [C]i [C]n B-protein 
beta [C]b [C]e [C]t [C]a I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
, [C], O 
are [C]a [C]r [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
stromal [C]s [C]t [C]r [C]o [C]m [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
, [C], O 
we [C]w [C]e O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
LIGHT [C]L [C]I [C]G [C]H [C]T S-protein 
is [C]i [C]s O 
selectively [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
on [C]o [C]n O 
immature [C]i [C]m [C]m [C]a [C]t [C]u [C]r [C]e B-cell_type 
dendritic [C]d [C]e [C]n [C]d [C]r [C]i [C]t [C]i [C]c I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
DCs [C]D [C]C [C]s S-cell_type 
) [C]) O 
generated [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
PBMCs [C]P [C]B [C]M [C]C [C]s E-cell_type 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
LIGHT [C]L [C]I [C]G [C]H [C]T S-protein 
is [C]i [C]s O 
not [C]n [C]o [C]t O 
detectable [C]d [C]e [C]t [C]e [C]c [C]t [C]a [C]b [C]l [C]e O 
in [C]i [C]n O 
DCs [C]D [C]C [C]s S-cell_type 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
freshly [C]f [C]r [C]e [C]s [C]h [C]l [C]y O 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
PBMCs [C]P [C]B [C]M [C]C [C]s S-cell_type 
or [C]o [C]r O 
rendered [C]r [C]e [C]n [C]d [C]e [C]r [C]e [C]d O 
mature [C]m [C]a [C]t [C]u [C]r [C]e O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
by [C]b [C]y O 
LPS [C]L [C]P [C]S O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
. [C]. O 

Blockade [C]B [C]l [C]o [C]c [C]k [C]a [C]d [C]e O 
of [C]o [C]f O 
LIGHT [C]L [C]I [C]G [C]H [C]T S-protein 
by [C]b [C]y O 
its [C]i [C]t [C]s O 
soluble [C]s [C]o [C]l [C]u [C]b [C]l [C]e B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
, [C], O 
lymphotoxin [C]l [C]y [C]m [C]p [C]h [C]o [C]t [C]o [C]x [C]i [C]n B-protein 
beta [C]b [C]e [C]t [C]a I-protein 
receptor-Ig [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]- [C]I [C]g E-protein 
or [C]o [C]r O 
HVEM-Ig [C]H [C]V [C]E [C]M [C]- [C]I [C]g S-protein 
, [C], O 
inhibits [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]s O 
the [C]t [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
DC [C]D [C]C S-cell_type 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y O 
allogeneic [C]a [C]l [C]l [C]o [C]g [C]e [C]n [C]e [C]i [C]c O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
engagement [C]e [C]n [C]g [C]a [C]g [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
LIGHT [C]L [C]I [C]G [C]H [C]T S-protein 
costimulates [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]s O 
human [C]h [C]u [C]m [C]a [C]n O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
amplifies [C]a [C]m [C]p [C]l [C]i [C]f [C]i [C]e [C]s O 
the [C]t [C]h [C]e O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
, [C], O 
and [C]a [C]n [C]d O 
preferentially [C]p [C]r [C]e [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l [C]l [C]y O 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
the [C]t [C]h [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
, [C], O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
an [C]a [C]n O 
antigenic [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]i [C]c O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
. [C]. O 

Our [C]O [C]u [C]r O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
LIGHT [C]L [C]I [C]G [C]H [C]T S-protein 
is [C]i [C]s O 
a [C]a O 
costimulatory [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]o [C]r [C]y B-protein 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e E-protein 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
DC [C]D [C]C S-cell_type 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
. [C]. O 

Suppression [C]S [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
HIV [C]H [C]I [C]V O 
type [C]t [C]y [C]p [C]e O 
1 [C]1 O 
replication [C]r [C]e [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
a [C]a O 
dominant-negative [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t [C]- [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e B-protein 
Ets-1 [C]E [C]t [C]s [C]- [C]1 I-protein 
mutant [C]m [C]u [C]t [C]a [C]n [C]t E-protein 
. [C]. O 

Activity [C]A [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
distal [C]d [C]i [C]s [C]t [C]a [C]l B-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n O 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
virus [C]v [C]i [C]r [C]u [C]s O 
( [C]( O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
) [C]) O 
long [C]l [C]o [C]n [C]g B-DNA 
terminal [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l I-DNA 
repeat [C]r [C]e [C]p [C]e [C]a [C]t E-DNA 
( [C]( O 
LTR [C]L [C]T [C]R S-DNA 
) [C]) O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
contains [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]s O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
Ets-1 [C]E [C]t [C]s [C]- [C]1 B-protein 
and [C]a [C]n [C]d I-protein 
USF-1 [C]U [C]S [C]F [C]- [C]1 I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
, [C], O 
is [C]i [C]s O 
integral [C]i [C]n [C]t [C]e [C]g [C]r [C]a [C]l O 
for [C]f [C]o [C]r O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
replication [C]r [C]e [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
Ets-1 [C]E [C]t [C]s [C]- [C]1 B-protein 
and [C]a [C]n [C]d I-protein 
USF-1 [C]U [C]S [C]F [C]- [C]1 I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
play [C]p [C]l [C]a [C]y O 
a [C]a O 
critical [C]c [C]r [C]i [C]t [C]i [C]c [C]a [C]l O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 B-DNA 
LTR [C]L [C]T [C]R I-DNA 
distal [C]d [C]i [C]s [C]t [C]a [C]l I-DNA 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r I-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
, [C], O 
as [C]a [C]s O 
indicated [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
potent [C]p [C]o [C]t [C]e [C]n [C]t O 
dominant [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
a [C]a O 
mutant [C]m [C]u [C]t [C]a [C]n [C]t B-DNA 
Ets-1 [C]E [C]t [C]s [C]- [C]1 I-DNA 
lacking [C]l [C]a [C]c [C]k [C]i [C]n [C]g I-DNA 
trans-activation [C]t [C]r [C]a [C]n [C]s [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n I-DNA 
domains [C]d [C]o [C]m [C]a [C]i [C]n [C]s E-DNA 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
LTR [C]L [C]T [C]R S-DNA 
. [C]. O 

To [C]T [C]o O 
determine [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e O 
the [C]t [C]h [C]e O 
biological [C]b [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
relevance [C]r [C]e [C]l [C]e [C]v [C]a [C]n [C]c [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Ets-1 [C]E [C]t [C]s [C]- [C]1 B-protein 
and [C]a [C]n [C]d I-protein 
USF-1 [C]U [C]S [C]F [C]- [C]1 I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
in [C]i [C]n O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
replication [C]r [C]e [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
we [C]w [C]e O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
the [C]t [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
dominant-negative [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t [C]- [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
mutant [C]m [C]u [C]t [C]a [C]n [C]t O 
of [C]o [C]f O 
Ets-1 [C]E [C]t [C]s [C]- [C]1 S-DNA 
( [C]( O 
dnEts-1 [C]d [C]n [C]E [C]t [C]s [C]- [C]1 S-DNA 
) [C]) O 
on [C]o [C]n O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

We [C]W [C]e O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
dnEts [C]d [C]n [C]E [C]t [C]s S-DNA 
markedly [C]m [C]a [C]r [C]k [C]e [C]d [C]l [C]y O 
suppressed [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
T [C]T B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
finding [C]f [C]i [C]n [C]d [C]i [C]n [C]g O 
indicates [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e [C]s O 
that [C]t [C]h [C]a [C]t O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
transcriptionaly [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l [C]y B-protein 
active [C]a [C]c [C]t [C]i [C]v [C]e I-protein 
USF-1/Ets-1 [C]U [C]S [C]F [C]- [C]1 [C]/ [C]E [C]t [C]s [C]- [C]1 I-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
is [C]i [C]s O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
productive [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]v [C]e O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cells [C]c [C]e [C]l [C]l [C]s O 
by [C]b [C]y O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
, [C], O 
and [C]a [C]n [C]d O 
suggests [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]s O 
that [C]t [C]h [C]a [C]t O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
USF-1 [C]U [C]S [C]F [C]- [C]1 S-protein 
and [C]a [C]n [C]d O 
Ets-1 [C]E [C]t [C]s [C]- [C]1 S-protein 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 B-DNA 
LTR [C]L [C]T [C]R E-DNA 
may [C]m [C]a [C]y O 
provide [C]p [C]r [C]o [C]v [C]i [C]d [C]e O 
a [C]a O 
new [C]n [C]e [C]w O 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
for [C]f [C]o [C]r O 
anti-HIV-1 [C]a [C]n [C]t [C]i [C]- [C]H [C]I [C]V [C]- [C]1 O 
gene [C]g [C]e [C]n [C]e O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
. [C]. O 

Human [C]H [C]u [C]m [C]a [C]n B-cell_type 
eosinophils [C]e [C]o [C]s [C]i [C]n [C]o [C]p [C]h [C]i [C]l [C]s E-cell_type 
constitutively [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y O 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
of [C]o [C]f I-protein 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d I-protein 
T [C]T I-protein 
cells [C]c [C]e [C]l [C]l [C]s I-protein 
p [C]p I-protein 
and [C]a [C]n [C]d I-protein 
c [C]c E-protein 
. [C]. O 

BACKGROUND [C]B [C]A [C]C [C]K [C]G [C]R [C]O [C]U [C]N [C]D O 
: [C]: O 
Eosinophils [C]E [C]o [C]s [C]i [C]n [C]o [C]p [C]h [C]i [C]l [C]s S-cell_type 
are [C]a [C]r [C]e O 
now [C]n [C]o [C]w O 
known [C]k [C]n [C]o [C]w [C]n O 
to [C]t [C]o O 
produce [C]p [C]r [C]o [C]d [C]u [C]c [C]e O 
a [C]a O 
variety [C]v [C]a [C]r [C]i [C]e [C]t [C]y O 
of [C]o [C]f O 
proinflammatory [C]p [C]r [C]o [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y B-protein 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s E-protein 
, [C], O 
although [C]a [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
that [C]t [C]h [C]a [C]t O 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
their [C]t [C]h [C]e [C]i [C]r O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
are [C]a [C]r [C]e O 
poorly [C]p [C]o [C]o [C]r [C]l [C]y O 
understood [C]u [C]n [C]d [C]e [C]r [C]s [C]t [C]o [C]o [C]d O 
. [C]. O 

The [C]T [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
almost [C]a [C]l [C]m [C]o [C]s [C]t O 
all [C]a [C]l [C]l O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
produced [C]p [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
eosinophils [C]e [C]o [C]s [C]i [C]n [C]o [C]p [C]h [C]i [C]l [C]s S-cell_type 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
proallergic [C]p [C]r [C]o [C]a [C]l [C]l [C]e [C]r [C]g [C]i [C]c B-protein 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e I-protein 
IL-4 [C]I [C]L [C]- [C]4 E-protein 
, [C], O 
is [C]i [C]s O 
now [C]n [C]o [C]w O 
known [C]k [C]n [C]o [C]w [C]n O 
to [C]t [C]o O 
be [C]b [C]e O 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
members [C]m [C]e [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
of [C]o [C]f I-protein 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d I-protein 
T [C]T I-protein 
cells [C]c [C]e [C]l [C]l [C]s E-protein 
( [C]( O 
NFAT [C]N [C]F [C]A [C]T S-protein 
) [C]) O 
family [C]f [C]a [C]m [C]i [C]l [C]y O 
of [C]o [C]f O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
. [C]. O 

OBJECTIVE [C]O [C]B [C]J [C]E [C]C [C]T [C]I [C]V [C]E O 
: [C]: O 
We [C]W [C]e O 
sought [C]s [C]o [C]u [C]g [C]h [C]t O 
to [C]t [C]o O 
characterize [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
NFAT [C]N [C]F [C]A [C]T B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
in [C]i [C]n O 
resting [C]r [C]e [C]s [C]t [C]i [C]n [C]g B-cell_type 
and [C]a [C]n [C]d I-cell_type 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d I-cell_type 
eosinophils [C]e [C]o [C]s [C]i [C]n [C]o [C]p [C]h [C]i [C]l [C]s E-cell_type 
. [C]. O 

METHODS [C]M [C]E [C]T [C]H [C]O [C]D [C]S O 
: [C]: O 
Nuclear [C]N [C]u [C]c [C]l [C]e [C]a [C]r O 
and [C]a [C]n [C]d O 
whole [C]w [C]h [C]o [C]l [C]e O 
cell [C]c [C]e [C]l [C]l O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
were [C]w [C]e [C]r [C]e O 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
both [C]b [C]o [C]t [C]h O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
eosinophils [C]e [C]o [C]s [C]i [C]n [C]o [C]p [C]h [C]i [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
those [C]t [C]h [C]o [C]s [C]e O 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
bronchoalveolar [C]b [C]r [C]o [C]n [C]c [C]h [C]o [C]a [C]l [C]v [C]e [C]o [C]l [C]a [C]r O 
lavage [C]l [C]a [C]v [C]a [C]g [C]e O 
fluid [C]f [C]l [C]u [C]i [C]d O 
of [C]o [C]f O 
asthmatic [C]a [C]s [C]t [C]h [C]m [C]a [C]t [C]i [C]c O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
after [C]a [C]f [C]t [C]e [C]r O 
endobronchial [C]e [C]n [C]d [C]o [C]b [C]r [C]o [C]n [C]c [C]h [C]i [C]a [C]l O 
allergen [C]a [C]l [C]l [C]e [C]r [C]g [C]e [C]n O 
challenge [C]c [C]h [C]a [C]l [C]l [C]e [C]n [C]g [C]e O 
. [C]. O 

NFAT [C]N [C]F [C]A [C]T S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
using [C]u [C]s [C]i [C]n [C]g O 
immunoprecipitation [C]i [C]m [C]m [C]u [C]n [C]o [C]p [C]r [C]e [C]c [C]i [C]p [C]i [C]t [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
Western [C]W [C]e [C]s [C]t [C]e [C]r [C]n O 
blot [C]b [C]l [C]o [C]t O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
, [C], O 
DNA-binding [C]D [C]N [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
RT-PCR [C]R [C]T [C]- [C]P [C]C [C]R O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
eosinophil [C]e [C]o [C]s [C]i [C]n [C]o [C]p [C]h [C]i [C]l B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
. [C]. O 

RESULTS [C]R [C]E [C]S [C]U [C]L [C]T [C]S O 
: [C]: O 
Both [C]B [C]o [C]t [C]h O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
and [C]a [C]n [C]d I-cell_type 
bronchoalveolar [C]b [C]r [C]o [C]n [C]c [C]h [C]o [C]a [C]l [C]v [C]e [C]o [C]l [C]a [C]r I-cell_type 
lavage [C]l [C]a [C]v [C]a [C]g [C]e I-cell_type 
fluid [C]f [C]l [C]u [C]i [C]d I-cell_type 
eosinophils [C]e [C]o [C]s [C]i [C]n [C]o [C]p [C]h [C]i [C]l [C]s E-cell_type 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
NFATp [C]N [C]F [C]A [C]T [C]p B-protein 
and [C]a [C]n [C]d I-protein 
NFATc [C]N [C]F [C]A [C]T [C]c I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
. [C]. O 

Unlike [C]U [C]n [C]l [C]i [C]k [C]e O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
multiple [C]m [C]u [C]l [C]t [C]i [C]p [C]l [C]e O 
NFATc [C]N [C]F [C]A [C]T [C]c O 
isoforms [C]i [C]s [C]o [C]f [C]o [C]r [C]m [C]s O 
, [C], O 
eosinophils [C]e [C]o [C]s [C]i [C]n [C]o [C]p [C]h [C]i [C]l [C]s S-cell_type 
preferentially [C]p [C]r [C]e [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l [C]l [C]y O 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
the [C]t [C]h [C]e O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
85-kd [C]8 [C]5 [C]- [C]k [C]d O 
isoform [C]i [C]s [C]o [C]f [C]o [C]r [C]m O 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
eosinophils [C]e [C]o [C]s [C]i [C]n [C]o [C]p [C]h [C]i [C]l [C]s S-cell_type 
were [C]w [C]e [C]r [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
constitutively [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y O 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
NFATc [C]N [C]F [C]A [C]T [C]c B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
. [C]. O 

A [C]A O 
brief [C]b [C]r [C]i [C]e [C]f O 
incubation [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
T [C]T B-protein 
( [C]( I-protein 
H [C]H I-protein 
) [C]) I-protein 
2 [C]2 I-protein 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s E-protein 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
and [C]a [C]n [C]d O 
IL-5 [C]I [C]L [C]- [C]5 S-protein 
was [C]w [C]a [C]s O 
sufficient [C]s [C]u [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
to [C]t [C]o O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
the [C]t [C]h [C]e O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
translocation [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NFATc [C]N [C]F [C]A [C]T [C]c S-protein 
. [C]. O 

Eosinophil [C]E [C]o [C]s [C]i [C]n [C]o [C]p [C]h [C]i [C]l O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
contain [C]c [C]o [C]n [C]t [C]a [C]i [C]n O 
multiple [C]m [C]u [C]l [C]t [C]i [C]p [C]l [C]e O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
that [C]t [C]h [C]a [C]t O 
can [C]c [C]a [C]n O 
specifically [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]a [C]l [C]l [C]y O 
recognize [C]r [C]e [C]c [C]o [C]g [C]n [C]i [C]z [C]e O 
the [C]t [C]h [C]e O 
IL-4 [C]I [C]L [C]- [C]4 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r I-DNA 
P1 [C]P [C]1 I-DNA 
NFAT [C]N [C]F [C]A [C]T I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
in [C]i [C]n O 
DNA-binding [C]D [C]N [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
NFATp [C]N [C]F [C]A [C]T [C]p S-protein 
. [C]. O 

CONCLUSION [C]C [C]O [C]N [C]C [C]L [C]U [C]S [C]I [C]O [C]N O 
: [C]: O 
NFATp [C]N [C]F [C]A [C]T [C]p S-protein 
and [C]a [C]n [C]d O 
NFATc [C]N [C]F [C]A [C]T [C]c S-protein 
can [C]c [C]a [C]n O 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
and [C]a [C]n [C]d O 
other [C]o [C]t [C]h [C]e [C]r O 
genes [C]g [C]e [C]n [C]e [C]s O 
in [C]i [C]n O 
eosinophils [C]e [C]o [C]s [C]i [C]n [C]o [C]p [C]h [C]i [C]l [C]s S-cell_type 
but [C]b [C]u [C]t O 
appear [C]a [C]p [C]p [C]e [C]a [C]r O 
to [C]t [C]o O 
be [C]b [C]e O 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
in [C]i [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
. [C]. O 

BLyS [C]B [C]L [C]y [C]S S-protein 
BINDS [C]B [C]I [C]N [C]D [C]S O 
TO [C]T [C]O O 
B [C]B B-cell_type 
CELLS [C]C [C]E [C]L [C]L [C]S E-cell_type 
WITH [C]W [C]I [C]T [C]H O 
HIGH [C]H [C]I [C]G [C]H O 
AFFINITY [C]A [C]F [C]F [C]I [C]N [C]I [C]T [C]Y O 
AND [C]A [C]N [C]D O 
INDUCES [C]I [C]N [C]D [C]U [C]C [C]E [C]S O 
ACTIVATION [C]A [C]C [C]T [C]I [C]V [C]A [C]T [C]I [C]O [C]N O 
OF [C]O [C]F O 
THE [C]T [C]H [C]E O 
TRANSCRIPTION [C]T [C]R [C]A [C]N [C]S [C]C [C]R [C]I [C]P [C]T [C]I [C]O [C]N B-protein 
FACTORS [C]F [C]A [C]C [C]T [C]O [C]R [C]S E-protein 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
AND [C]A [C]N [C]D O 
ELF-1 [C]E [C]L [C]F [C]- [C]1 S-protein 
. [C]. O 

B [C]B B-protein 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e I-protein 
stimulator [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]o [C]r E-protein 
( [C]( O 
BLyS [C]B [C]L [C]y [C]S S-protein 
) [C]) O 
is [C]i [C]s O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
member [C]m [C]e [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
TNF [C]T [C]N [C]F B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y I-protein 
of [C]o [C]f I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
by [C]b [C]y O 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
as [C]a [C]s O 
membrane-bound [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e [C]- [C]b [C]o [C]u [C]n [C]d O 
and [C]a [C]n [C]d O 
soluble [C]s [C]o [C]l [C]u [C]b [C]l [C]e O 
forms [C]f [C]o [C]r [C]m [C]s O 
. [C]. O 

BLyS [C]B [C]L [C]y [C]S S-protein 
was [C]w [C]a [C]s O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
act [C]a [C]c [C]t O 
specifically [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]a [C]l [C]l [C]y O 
on [C]o [C]n O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
inducing [C]i [C]n [C]d [C]u [C]c [C]i [C]n [C]g O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
both [C]b [C]o [C]t [C]h O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
. [C]. O 

The [C]T [C]h [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
study [C]s [C]t [C]u [C]d [C]y O 
was [C]w [C]a [C]s O 
undertaken [C]u [C]n [C]d [C]e [C]r [C]t [C]a [C]k [C]e [C]n O 
to [C]t [C]o O 
characterize [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
radiolabeled [C]r [C]a [C]d [C]i [C]o [C]l [C]a [C]b [C]e [C]l [C]e [C]d B-protein 
BLyS [C]B [C]L [C]y [C]S E-protein 
to [C]t [C]o O 
its [C]i [C]t [C]s O 
cognate [C]c [C]o [C]g [C]n [C]a [C]t [C]e B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
on [C]o [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
B [C]B I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
examine [C]e [C]x [C]a [C]m [C]i [C]n [C]e O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
events [C]e [C]v [C]e [C]n [C]t [C]s O 
initiated [C]i [C]n [C]i [C]t [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
BLyS [C]B [C]L [C]y [C]S S-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
. [C]. O 

Similar [C]S [C]i [C]m [C]i [C]l [C]a [C]r O 
to [C]t [C]o O 
other [C]o [C]t [C]h [C]e [C]r O 
TNF [C]T [C]N [C]F B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y I-protein 
members [C]m [C]e [C]m [C]b [C]e [C]r [C]s E-protein 
, [C], O 
BLyS [C]B [C]L [C]y [C]S S-protein 
is [C]i [C]s O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
in [C]i [C]n O 
solution [C]s [C]o [C]l [C]u [C]t [C]i [C]o [C]n O 
as [C]a [C]s O 
a [C]a O 
homotrimer [C]h [C]o [C]m [C]o [C]t [C]r [C]i [C]m [C]e [C]r S-protein 
as [C]a [C]s O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
gel [C]g [C]e [C]l O 
filtration [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
chromatography [C]c [C]h [C]r [C]o [C]m [C]a [C]t [C]o [C]g [C]r [C]a [C]p [C]h [C]y O 
and [C]a [C]n [C]d O 
light [C]l [C]i [C]g [C]h [C]t O 
scattering [C]s [C]c [C]a [C]t [C]t [C]e [C]r [C]i [C]n [C]g O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
. [C]. O 

BLyS [C]B [C]L [C]y [C]S S-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
is [C]i [C]s O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
as [C]a [C]s O 
other [C]o [C]t [C]h [C]e [C]r O 
TNF [C]T [C]N [C]F B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y I-protein 
members [C]m [C]e [C]m [C]b [C]e [C]r [C]s E-protein 
tested [C]t [C]e [C]s [C]t [C]e [C]d O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
compete [C]c [C]o [C]m [C]p [C]e [C]t [C]e O 
for [C]f [C]o [C]r O 
( [C]( O 
125 [C]1 [C]2 [C]5 O 
) [C]) O 
I- [C]I [C]- O 
BLyS [C]B [C]L [C]y [C]S S-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
. [C]. O 

Analysis [C]A [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
equilibrium [C]e [C]q [C]u [C]i [C]l [C]i [C]b [C]r [C]i [C]u [C]m O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
( [C]( B-protein 
125 [C]1 [C]2 [C]5 I-protein 
) [C]) I-protein 
I-labeled [C]I [C]- [C]l [C]a [C]b [C]e [C]l [C]e [C]d I-protein 
BLyS [C]B [C]L [C]y [C]S E-protein 
to [C]t [C]o O 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
tonsillar [C]t [C]o [C]n [C]s [C]i [C]l [C]l [C]a [C]r I-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
saturable [C]s [C]a [C]t [C]u [C]r [C]a [C]b [C]l [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
. [C]. O 

Scatchard [C]S [C]c [C]a [C]t [C]c [C]h [C]a [C]r [C]d O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
data [C]d [C]a [C]t [C]a O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
a [C]a O 
single [C]s [C]i [C]n [C]g [C]l [C]e O 
class [C]c [C]l [C]a [C]s [C]s O 
of [C]o [C]f O 
high-affinity [C]h [C]i [C]g [C]h [C]- [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
on [C]o [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
with [C]w [C]i [C]t [C]h O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
2600 [C]2 [C]6 [C]0 [C]0 O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
sites [C]s [C]i [C]t [C]e [C]s O 
per [C]p [C]e [C]r O 
cell [C]c [C]e [C]l [C]l O 
and [C]a [C]n [C]d O 
an [C]a [C]n O 
apparent [C]a [C]p [C]p [C]a [C]r [C]e [C]n [C]t O 
dissociation [C]d [C]i [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
constant [C]c [C]o [C]n [C]s [C]t [C]a [C]n [C]t O 
( [C]( O 
K [C]K O 
( [C]( O 
D [C]D O 
) [C]) O 
) [C]) O 
of [C]o [C]f O 
about [C]a [C]b [C]o [C]u [C]t O 
0.1 [C]0 [C]. [C]1 O 
nM [C]n [C]M O 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
we [C]w [C]e O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
that [C]t [C]h [C]a [C]t O 
BLyS [C]B [C]L [C]y [C]S S-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
Ets [C]E [C]t [C]s B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
, [C], O 
ELF-1 [C]E [C]L [C]F [C]- [C]1 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
mRNA [C]m [C]R [C]N [C]A O 
for [C]f [C]o [C]r O 
Polo-like [C]P [C]o [C]l [C]o [C]- [C]l [C]i [C]k [C]e B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
( [C]( O 
PLK [C]P [C]L [C]K S-protein 
) [C]) O 
. [C]. O 

Copyright [C]C [C]o [C]p [C]y [C]r [C]i [C]g [C]h [C]t O 
2001 [C]2 [C]0 [C]0 [C]1 O 
Academic [C]A [C]c [C]a [C]d [C]e [C]m [C]i [C]c O 
Press [C]P [C]r [C]e [C]s [C]s O 
. [C]. O 

Design [C]D [C]e [C]s [C]i [C]g [C]n O 
and [C]a [C]n [C]d O 
use [C]u [C]s [C]e O 
of [C]o [C]f O 
an [C]a [C]n O 
inducibly [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]y O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
human [C]h [C]u [C]m [C]a [C]n O 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
virus [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
1 [C]1 O 
Nef [C]N [C]e [C]f S-protein 
to [C]t [C]o O 
study [C]s [C]t [C]u [C]d [C]y O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
modulation [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
Nef [C]N [C]e [C]f B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n O 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
virus [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
1 [C]1 O 
( [C]( O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
) [C]) O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
enhance [C]e [C]n [C]h [C]a [C]n [C]c [C]e O 
the [C]t [C]h [C]e O 
infectivity [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
virus [C]v [C]i [C]r [C]u [C]s O 
particles [C]p [C]a [C]r [C]t [C]i [C]c [C]l [C]e [C]s O 
, [C], O 
downmodulate [C]d [C]o [C]w [C]n [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]e O 
cell [C]c [C]e [C]l [C]l B-protein 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
, [C], O 
and [C]a [C]n [C]d O 
associate [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e O 
with [C]w [C]i [C]t [C]h O 
many [C]m [C]a [C]n [C]y O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
that [C]t [C]h [C]a [C]t O 
are [C]a [C]r [C]e O 
thought [C]t [C]h [C]o [C]u [C]g [C]h [C]t O 
to [C]t [C]o O 
facilitate [C]f [C]a [C]c [C]i [C]l [C]i [C]t [C]a [C]t [C]e O 
HIV [C]H [C]I [C]V O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

One [C]O [C]n [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
challenges [C]c [C]h [C]a [C]l [C]l [C]e [C]n [C]g [C]e [C]s O 
in [C]i [C]n O 
defining [C]d [C]e [C]f [C]i [C]n [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
events [C]e [C]v [C]e [C]n [C]t [C]s O 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
Nef [C]N [C]e [C]f S-protein 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
obtaining [C]o [C]b [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
good [C]g [C]o [C]o [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
Nef [C]N [C]e [C]f B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
attributed [C]a [C]t [C]t [C]r [C]i [C]b [C]u [C]t [C]e [C]d O 
to [C]t [C]o O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
Nef [C]N [C]e [C]f S-protein 
on [C]o [C]n O 
cell [C]c [C]e [C]l [C]l O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
designed [C]d [C]e [C]s [C]i [C]g [C]n [C]e [C]d O 
a [C]a O 
Nef [C]N [C]e [C]f B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
readily [C]r [C]e [C]a [C]d [C]i [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l B-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
and [C]a [C]n [C]d O 
whose [C]w [C]h [C]o [C]s [C]e O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
inducibly [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]y O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
. [C]. O 

It [C]I [C]t O 
is [C]i [C]s O 
composed [C]c [C]o [C]m [C]p [C]o [C]s [C]e [C]d O 
of [C]o [C]f O 
a [C]a O 
fusion [C]f [C]u [C]s [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
full-length [C]f [C]u [C]l [C]l [C]- [C]l [C]e [C]n [C]g [C]t [C]h B-protein 
Nef [C]N [C]e [C]f E-protein 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
hormone-binding [C]h [C]o [C]r [C]m [C]o [C]n [C]e [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
( [C]( O 
Nef-ER [C]N [C]e [C]f [C]- [C]E [C]R S-protein 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
Nef-ER [C]N [C]e [C]f [C]- [C]E [C]R S-protein 
is [C]i [C]s O 
kept [C]k [C]e [C]p [C]t O 
in [C]i [C]n O 
an [C]a [C]n O 
inactive [C]i [C]n [C]a [C]c [C]t [C]i [C]v [C]e O 
state [C]s [C]t [C]a [C]t [C]e O 
due [C]d [C]u [C]e O 
to [C]t [C]o O 
steric [C]s [C]t [C]e [C]r [C]i [C]c O 
hindrance [C]h [C]i [C]n [C]d [C]r [C]a [C]n [C]c [C]e O 
, [C], O 
and [C]a [C]n [C]d O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
membrane-permeable [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e [C]- [C]p [C]e [C]r [C]m [C]e [C]a [C]b [C]l [C]e O 
drug [C]d [C]r [C]u [C]g O 
4-hydroxytamoxifen [C]4 [C]- [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]t [C]a [C]m [C]o [C]x [C]i [C]f [C]e [C]n O 
( [C]( O 
4-HT [C]4 [C]- [C]H [C]T O 
) [C]) O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
binds [C]b [C]i [C]n [C]d [C]s O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
ER [C]E [C]R B-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
, [C], O 
leads [C]l [C]e [C]a [C]d [C]s O 
to [C]t [C]o O 
inducible [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Nef-ER [C]N [C]e [C]f [C]- [C]E [C]R S-protein 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
cells [C]c [C]e [C]l [C]l [C]s O 
. [C]. O 

We [C]W [C]e O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
Nef-ER [C]N [C]e [C]f [C]- [C]E [C]R S-protein 
inducibly [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]y O 
associates [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
62-kDa [C]6 [C]2 [C]- [C]k [C]D [C]a B-protein 
Ser/Thr [C]S [C]e [C]r [C]/ [C]T [C]h [C]r I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
localized [C]l [C]o [C]c [C]a [C]l [C]i [C]z [C]e [C]d O 
to [C]t [C]o O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
microdomains [C]m [C]i [C]c [C]r [C]o [C]d [C]o [C]m [C]a [C]i [C]n [C]s O 
( [C]( O 
lipid [C]l [C]i [C]p [C]i [C]d O 
rafts [C]r [C]a [C]f [C]t [C]s O 
) [C]) O 
only [C]o [C]n [C]l [C]y O 
after [C]a [C]f [C]t [C]e [C]r O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Using [C]U [C]s [C]i [C]n [C]g O 
this [C]t [C]h [C]i [C]s O 
inducible [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
Nef [C]N [C]e [C]f S-protein 
, [C], O 
we [C]w [C]e O 
also [C]a [C]l [C]s [C]o O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
the [C]t [C]h [C]e O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
requirements [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]m [C]e [C]n [C]t [C]s O 
for [C]f [C]o [C]r O 
CD4 [C]C [C]D [C]4 S-protein 
and [C]a [C]n [C]d O 
HLA-A2 [C]H [C]L [C]A [C]- [C]A [C]2 S-protein 
downmodulation [C]d [C]o [C]w [C]n [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
a [C]a O 
SupT1 [C]S [C]u [C]p [C]T [C]1 B-cell_line 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
. [C]. O 

Half-maximal [C]H [C]a [C]l [C]f [C]- [C]m [C]a [C]x [C]i [C]m [C]a [C]l O 
downmodulation [C]d [C]o [C]w [C]n [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cell [C]c [C]e [C]l [C]l B-protein 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e I-protein 
CD4 [C]C [C]D [C]4 E-protein 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
very [C]v [C]e [C]r [C]y O 
little [C]l [C]i [C]t [C]t [C]l [C]e O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
Nef-ER [C]N [C]e [C]f [C]- [C]E [C]R S-protein 
and [C]a [C]n [C]d O 
occurred [C]o [C]c [C]c [C]u [C]r [C]r [C]e [C]d O 
as [C]a [C]s O 
early [C]e [C]a [C]r [C]l [C]y O 
as [C]a [C]s O 
4 [C]4 O 
h [C]h O 
after [C]a [C]f [C]t [C]e [C]r O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
4-HT [C]4 [C]- [C]H [C]T O 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
50 [C]5 [C]0 O 
% [C]% O 
downmodulation [C]d [C]o [C]w [C]n [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
HLA-A2 [C]H [C]L [C]A [C]- [C]A [C]2 S-protein 
by [C]b [C]y O 
Nef [C]N [C]e [C]f S-protein 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
16 [C]1 [C]6 O 
to [C]t [C]o O 
24 [C]2 [C]4 O 
h [C]h O 
and [C]a [C]n [C]d O 
about [C]a [C]b [C]o [C]u [C]t O 
50- [C]5 [C]0 [C]- O 
to [C]t [C]o O 
100-fold-greater [C]1 [C]0 [C]0 [C]- [C]f [C]o [C]l [C]d [C]- [C]g [C]r [C]e [C]a [C]t [C]e [C]r O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
4-HT [C]4 [C]- [C]H [C]T O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
HLA-A2 [C]H [C]L [C]A [C]- [C]A [C]2 S-protein 
downmodulation [C]d [C]o [C]w [C]n [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
may [C]m [C]a [C]y O 
require [C]r [C]e [C]q [C]u [C]i [C]r [C]e O 
certain [C]c [C]e [C]r [C]t [C]a [C]i [C]n O 
threshold [C]t [C]h [C]r [C]e [C]s [C]h [C]o [C]l [C]d O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
Nef [C]N [C]e [C]f S-protein 
. [C]. O 

The [C]T [C]h [C]e O 
differential [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l O 
timing [C]t [C]i [C]m [C]i [C]n [C]g O 
of [C]o [C]f O 
CD4 [C]C [C]D [C]4 S-protein 
and [C]a [C]n [C]d O 
HLA-A2 [C]H [C]L [C]A [C]- [C]A [C]2 S-protein 
downmodulation [C]d [C]o [C]w [C]n [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
may [C]m [C]a [C]y O 
have [C]h [C]a [C]v [C]e O 
implications [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n [C]s O 
for [C]f [C]o [C]r O 
HIV [C]H [C]I [C]V O 
pathogenesis [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
evasion [C]e [C]v [C]a [C]s [C]i [C]o [C]n O 
. [C]. O 

Regulation [C]R [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
chemokine [C]c [C]h [C]e [C]m [C]o [C]k [C]i [C]n [C]e O 
mRNA [C]m [C]R [C]N [C]A O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
a [C]a O 
rat [C]r [C]a [C]t O 
model [C]m [C]o [C]d [C]e [C]l O 
of [C]o [C]f O 
vanadium-induced [C]v [C]a [C]n [C]a [C]d [C]i [C]u [C]m [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
pulmonary [C]p [C]u [C]l [C]m [C]o [C]n [C]a [C]r [C]y O 
inflammation [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Environmental [C]E [C]n [C]v [C]i [C]r [C]o [C]n [C]m [C]e [C]n [C]t [C]a [C]l O 
and [C]a [C]n [C]d O 
occupational [C]o [C]c [C]c [C]u [C]p [C]a [C]t [C]i [C]o [C]n [C]a [C]l O 
exposure [C]e [C]x [C]p [C]o [C]s [C]u [C]r [C]e O 
to [C]t [C]o O 
vanadium [C]v [C]a [C]n [C]a [C]d [C]i [C]u [C]m O 
dusts [C]d [C]u [C]s [C]t [C]s O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
in [C]i [C]n O 
toxic [C]t [C]o [C]x [C]i [C]c O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
mainly [C]m [C]a [C]i [C]n [C]l [C]y O 
confined [C]c [C]o [C]n [C]f [C]i [C]n [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
respiratory [C]r [C]e [C]s [C]p [C]i [C]r [C]a [C]t [C]o [C]r [C]y O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
. [C]. O 

Using [C]U [C]s [C]i [C]n [C]g O 
a [C]a O 
rat [C]r [C]a [C]t O 
model [C]m [C]o [C]d [C]e [C]l O 
of [C]o [C]f O 
acute [C]a [C]c [C]u [C]t [C]e O 
lung [C]l [C]u [C]n [C]g O 
inflammation [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]i [C]o [C]n O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
intratracheal [C]i [C]n [C]t [C]r [C]a [C]t [C]r [C]a [C]c [C]h [C]e [C]a [C]l O 
instillation [C]i [C]n [C]s [C]t [C]i [C]l [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
sodium [C]s [C]o [C]d [C]i [C]u [C]m O 
metavanadate [C]m [C]e [C]t [C]a [C]v [C]a [C]n [C]a [C]d [C]a [C]t [C]e O 
( [C]( O 
NaVO3 [C]N [C]a [C]V [C]O [C]3 O 
) [C]) O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
dose [C]d [C]o [C]s [C]e O 
of [C]o [C]f O 
200 [C]2 [C]0 [C]0 O 
microg [C]m [C]i [C]c [C]r [C]o [C]g O 
V/kg [C]V [C]/ [C]k [C]g O 
, [C], O 
we [C]w [C]e O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
relationship [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n [C]s [C]h [C]i [C]p O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
cytologic [C]c [C]y [C]t [C]o [C]l [C]o [C]g [C]i [C]c O 
characterization [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
pulmonary [C]p [C]u [C]l [C]m [C]o [C]n [C]a [C]r [C]y O 
inflammation [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
chemokine [C]c [C]h [C]e [C]m [C]o [C]k [C]i [C]n [C]e B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
. [C]. O 

Significant [C]S [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
polymorphonuclear [C]p [C]o [C]l [C]y [C]m [C]o [C]r [C]p [C]h [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_type 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e E-cell_type 
( [C]( O 
PMN [C]P [C]M [C]N S-cell_type 
) [C]) O 
influx [C]i [C]n [C]f [C]l [C]u [C]x O 
( [C]( O 
P [C]P O 
< [C]< O 
0.01 [C]0 [C]. [C]0 [C]1 O 
) [C]) O 
into [C]i [C]n [C]t [C]o O 
the [C]t [C]h [C]e O 
lung [C]l [C]u [C]n [C]g O 
was [C]w [C]a [C]s O 
noted [C]n [C]o [C]t [C]e [C]d O 
4 [C]4 O 
h [C]h O 
after [C]a [C]f [C]t [C]e [C]r O 
NaVO3 [C]N [C]a [C]V [C]O [C]3 O 
instillation [C]i [C]n [C]s [C]t [C]i [C]l [C]l [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
alveolar [C]a [C]l [C]v [C]e [C]o [C]l [C]a [C]r B-cell_type 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s E-cell_type 
( [C]( O 
AMs [C]A [C]M [C]s S-cell_type 
) [C]) O 
in [C]i [C]n O 
bronchoalveolar [C]b [C]r [C]o [C]n [C]c [C]h [C]o [C]a [C]l [C]v [C]e [C]o [C]l [C]a [C]r B-cell_type 
lavage [C]l [C]a [C]v [C]a [C]g [C]e I-cell_type 
( [C]( I-cell_type 
BAL [C]B [C]A [C]L I-cell_type 
) [C]) I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
appeared [C]a [C]p [C]p [C]e [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
neither [C]n [C]e [C]i [C]t [C]h [C]e [C]r O 
PMNs [C]P [C]M [C]N [C]s S-cell_type 
nor [C]n [C]o [C]r O 
AMs [C]A [C]M [C]s S-cell_type 
changed [C]c [C]h [C]a [C]n [C]g [C]e [C]d O 
substantially [C]s [C]u [C]b [C]s [C]t [C]a [C]n [C]t [C]i [C]a [C]l [C]l [C]y O 
1 [C]1 O 
h [C]h O 
after [C]a [C]f [C]t [C]e [C]r O 
NaVO3 [C]N [C]a [C]V [C]O [C]3 O 
instillation [C]i [C]n [C]s [C]t [C]i [C]l [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

By [C]B [C]y O 
Northern [C]N [C]o [C]r [C]t [C]h [C]e [C]r [C]n O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
, [C], O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e B-RNA 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y I-RNA 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-RNA 
( [C]( I-RNA 
MIP [C]M [C]I [C]P I-RNA 
) [C]) I-RNA 
-2 [C]- [C]2 I-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
in [C]i [C]n O 
BAL [C]B [C]A [C]L B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
markedly [C]m [C]a [C]r [C]k [C]e [C]d [C]l [C]y O 
1 [C]1 O 
h [C]h O 
after [C]a [C]f [C]t [C]e [C]r O 
NaVO3 [C]N [C]a [C]V [C]O [C]3 O 
instillation [C]i [C]n [C]s [C]t [C]i [C]l [C]l [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
a [C]a O 
little [C]l [C]i [C]t [C]t [C]l [C]e O 
bit [C]b [C]i [C]t O 
at [C]a [C]t O 
4 [C]4 O 
h [C]h O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
MIP-1alpha [C]M [C]I [C]P [C]- [C]1 [C]a [C]l [C]p [C]h [C]a B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
in [C]i [C]n O 
BAL [C]B [C]A [C]L B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
was [C]w [C]a [C]s O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
relatively [C]r [C]e [C]l [C]a [C]t [C]i [C]v [C]e [C]l [C]y O 
high [C]h [C]i [C]g [C]h O 
1 [C]1 O 
h [C]h O 
after [C]a [C]f [C]t [C]e [C]r O 
NaVO3 [C]N [C]a [C]V [C]O [C]3 O 
instillation [C]i [C]n [C]s [C]t [C]i [C]l [C]l [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
although [C]a [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
a [C]a O 
basal [C]b [C]a [C]s [C]a [C]l O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
in [C]i [C]n O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
group [C]g [C]r [C]o [C]u [C]p O 
, [C], O 
and [C]a [C]n [C]d O 
returned [C]r [C]e [C]t [C]u [C]r [C]n [C]e [C]d O 
rapidly [C]r [C]a [C]p [C]i [C]d [C]l [C]y O 
nearly [C]n [C]e [C]a [C]r [C]l [C]y O 
to [C]t [C]o O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
level [C]l [C]e [C]v [C]e [C]l O 
at [C]a [C]t O 
4 [C]4 O 
h [C]h O 
. [C]. O 

Since [C]S [C]i [C]n [C]c [C]e O 
MIP-2 [C]M [C]I [C]P [C]- [C]2 S-protein 
is [C]i [C]s O 
a [C]a O 
potent [C]p [C]o [C]t [C]e [C]n [C]t O 
PMN [C]P [C]M [C]N S-cell_type 
chemoattractant [C]c [C]h [C]e [C]m [C]o [C]a [C]t [C]t [C]r [C]a [C]c [C]t [C]a [C]n [C]t O 
and [C]a [C]n [C]d O 
MIP-1alpha [C]M [C]I [C]P [C]- [C]1 [C]a [C]l [C]p [C]h [C]a S-protein 
is [C]i [C]s O 
a [C]a O 
potent [C]p [C]o [C]t [C]e [C]n [C]t O 
macrophage/monocyte [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]/ [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e O 
chemoattractant [C]c [C]h [C]e [C]m [C]o [C]a [C]t [C]t [C]r [C]a [C]c [C]t [C]a [C]n [C]t O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
well [C]w [C]e [C]l [C]l O 
known [C]k [C]n [C]o [C]w [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
facts [C]f [C]a [C]c [C]t [C]s O 
that [C]t [C]h [C]a [C]t O 
PMN [C]P [C]M [C]N S-cell_type 
influx [C]i [C]n [C]f [C]l [C]u [C]x O 
was [C]w [C]a [C]s O 
preceded [C]p [C]r [C]e [C]c [C]e [C]d [C]e [C]d O 
by [C]b [C]y O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
MIP-2 [C]M [C]I [C]P [C]- [C]2 O 
mRNA [C]m [C]R [C]N [C]A O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
MIP-2 [C]M [C]I [C]P [C]- [C]2 S-protein 
is [C]i [C]s O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
NaVO3-induced [C]N [C]a [C]V [C]O [C]3 [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
pulmonary [C]p [C]u [C]l [C]m [C]o [C]n [C]a [C]r [C]y O 
inflammation [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
MIP-1alpha [C]M [C]I [C]P [C]- [C]1 [C]a [C]l [C]p [C]h [C]a B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
followed [C]f [C]o [C]l [C]l [C]o [C]w [C]e [C]d O 
by [C]b [C]y O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
AMs [C]A [C]M [C]s S-cell_type 
in [C]i [C]n O 
BAL [C]B [C]A [C]L B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
AMs [C]A [C]M [C]s S-cell_type 
might [C]m [C]i [C]g [C]h [C]t O 
be [C]b [C]e O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
MIP-1alpha [C]M [C]I [C]P [C]- [C]1 [C]a [C]l [C]p [C]h [C]a S-protein 
, [C], O 
adherent [C]a [C]d [C]h [C]e [C]r [C]e [C]n [C]t O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
lining [C]l [C]i [C]n [C]i [C]n [C]g O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
airways [C]a [C]i [C]r [C]w [C]a [C]y [C]s O 
and [C]a [C]n [C]d O 
then [C]t [C]h [C]e [C]n O 
resistant [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]t O 
to [C]t [C]o O 
be [C]b [C]e O 
washed [C]w [C]a [C]s [C]h [C]e [C]d O 
out [C]o [C]u [C]t O 
. [C]. O 

To [C]T [C]o O 
delineate [C]d [C]e [C]l [C]i [C]n [C]e [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
of [C]o [C]f O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
we [C]w [C]e O 
recently [C]r [C]e [C]c [C]e [C]n [C]t [C]l [C]y O 
cloned [C]c [C]l [C]o [C]n [C]e [C]d O 
the [C]t [C]h [C]e O 
5'-flanking [C]5 [C]' [C]- [C]f [C]l [C]a [C]n [C]k [C]i [C]n [C]g B-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
MIP-2 [C]M [C]I [C]P [C]- [C]2 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
. [C]. O 

The [C]T [C]h [C]e O 
promotor [C]p [C]r [C]o [C]m [C]o [C]t [C]o [C]r B-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
contains [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]s O 
consensus [C]c [C]o [C]n [C]s [C]e [C]n [C]s [C]u [C]s B-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
for [C]f [C]o [C]r O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
kappaB [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
( [C]( O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r B-protein 
protein-1 [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]1 E-protein 
( [C]( O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
) [C]) O 
. [C]. O 

Using [C]U [C]s [C]i [C]n [C]g O 
electrophoretic [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
assay [C]a [C]s [C]s [C]a [C]y O 
, [C], O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
, [C], O 
not [C]n [C]o [C]t O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
, [C], O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
was [C]w [C]a [C]s O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
1 [C]1 O 
h [C]h O 
after [C]a [C]f [C]t [C]e [C]r O 
NaVO3 [C]N [C]a [C]V [C]O [C]3 O 
instillation [C]i [C]n [C]s [C]t [C]i [C]l [C]l [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
MIP-2 [C]M [C]I [C]P [C]- [C]2 B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
. [C]. O 

p65 [C]p [C]6 [C]5 B-protein 
( [C]( I-protein 
Rel [C]R [C]e [C]l I-protein 
A [C]A I-protein 
) [C]) E-protein 
and [C]a [C]n [C]d O 
p50 [C]p [C]5 [C]0 B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
appears [C]a [C]p [C]p [C]e [C]a [C]r [C]s O 
to [C]t [C]o O 
be [C]b [C]e O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
MIP-2 [C]M [C]I [C]P [C]- [C]2 O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
. [C]. O 

Taken [C]T [C]a [C]k [C]e [C]n O 
together [C]t [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
, [C], O 
our [C]o [C]u [C]r O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
MIP-2 [C]M [C]I [C]P [C]- [C]2 S-protein 
is [C]i [C]s O 
an [C]a [C]n O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
mediator [C]m [C]e [C]d [C]i [C]a [C]t [C]o [C]r O 
of [C]o [C]f O 
NaVO3-induced [C]N [C]a [C]V [C]O [C]3 [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
pulmonary [C]p [C]u [C]l [C]m [C]o [C]n [C]a [C]r [C]y O 
inflammation [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
rat [C]r [C]a [C]t O 
model [C]m [C]o [C]d [C]e [C]l O 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
elevated [C]e [C]l [C]e [C]v [C]a [C]t [C]e [C]d O 
MIP-2 [C]M [C]I [C]P [C]- [C]2 B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
are [C]a [C]r [C]e O 
accompanied [C]a [C]c [C]c [C]o [C]m [C]p [C]a [C]n [C]i [C]e [C]d O 
by [C]b [C]y O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
BAL [C]B [C]A [C]L B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
possible [C]p [C]o [C]s [C]s [C]i [C]b [C]l [C]e O 
MIP-2 [C]M [C]I [C]P [C]- [C]2 S-protein 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
. [C]. O 

Activation [C]A [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
healthy [C]h [C]e [C]a [C]l [C]t [C]h [C]y B-cell_type 
lymphomonocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
exposed [C]e [C]x [C]p [C]o [C]s [C]e [C]d O 
to [C]t [C]o O 
bystander [C]b [C]y [C]s [C]t [C]a [C]n [C]d [C]e [C]r O 
HIV-1-infected [C]H [C]I [C]V [C]- [C]1 [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Persistent [C]P [C]e [C]r [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
is [C]i [C]s O 
one [C]o [C]n [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
hallmarks [C]h [C]a [C]l [C]l [C]m [C]a [C]r [C]k [C]s O 
of [C]o [C]f O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
we [C]w [C]e O 
analysed [C]a [C]n [C]a [C]l [C]y [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
, [C], O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
STAT [C]S [C]T [C]A [C]T B-protein 
1 [C]1 I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
and [C]a [C]n [C]d O 
IRF-1 [C]I [C]R [C]F [C]- [C]1 B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
, [C], O 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
PBMC [C]P [C]B [C]M [C]C S-cell_type 
) [C]) O 
exposed [C]e [C]x [C]p [C]o [C]s [C]e [C]d O 
to [C]t [C]o O 
HIV-infected [C]H [C]I [C]V [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
. [C]. O 

Western [C]W [C]e [C]s [C]t [C]e [C]r [C]n O 
blot [C]b [C]l [C]o [C]t O 
analyses [C]a [C]n [C]a [C]l [C]y [C]s [C]e [C]s O 
and [C]a [C]n [C]d O 
reverse [C]r [C]e [C]v [C]e [C]r [C]s [C]e O 
transcriptase-polymerase [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]a [C]s [C]e [C]- [C]p [C]o [C]l [C]y [C]m [C]e [C]r [C]a [C]s [C]e O 
chain [C]c [C]h [C]a [C]i [C]n O 
reaction [C]r [C]e [C]a [C]c [C]t [C]i [C]o [C]n O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
both [C]b [C]o [C]t [C]h O 
cells [C]c [C]e [C]l [C]l [C]s O 
infected [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
X4 [C]X [C]4 O 
strain [C]s [C]t [C]r [C]a [C]i [C]n O 
and [C]a [C]n [C]d O 
cells [C]c [C]e [C]l [C]l [C]s O 
infected [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
R5 [C]R [C]5 O 
strain [C]s [C]t [C]r [C]a [C]i [C]n O 
are [C]a [C]r [C]e O 
able [C]a [C]b [C]l [C]e O 
to [C]t [C]o O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
STAT [C]S [C]T [C]A [C]T B-protein 
1alpha [C]1 [C]a [C]l [C]p [C]h [C]a I-protein 
and [C]a [C]n [C]d I-protein 
beta [C]b [C]e [C]t [C]a E-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
IRF-1 [C]I [C]R [C]F [C]- [C]1 B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
was [C]w [C]a [C]s O 
prevented [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]e [C]d O 
by [C]b [C]y O 
neutralizing [C]n [C]e [C]u [C]t [C]r [C]a [C]l [C]i [C]z [C]i [C]n [C]g O 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s O 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
interferon-alpha [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
( [C]( O 
IFN-alpha [C]I [C]F [C]N [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
) [C]) O 
. [C]. O 

HIV-1-infected [C]H [C]I [C]V [C]- [C]1 [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
dose-dependently [C]d [C]o [C]s [C]e [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t [C]l [C]y O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
apoptotic [C]a [C]p [C]o [C]p [C]t [C]o [C]t [C]i [C]c O 
commitment [C]c [C]o [C]m [C]m [C]i [C]t [C]m [C]e [C]n [C]t O 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
PBMC [C]P [C]B [C]M [C]C E-cell_type 
, [C], O 
as [C]a [C]s O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
by [C]b [C]y O 
DNA [C]D [C]N [C]A O 
fragmentation [C]f [C]r [C]a [C]g [C]m [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
, [C], O 
but [C]b [C]u [C]t O 
this [C]t [C]h [C]i [C]s O 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
accompanied [C]a [C]c [C]c [C]o [C]m [C]p [C]a [C]n [C]i [C]e [C]d O 
by [C]b [C]y O 
an [C]a [C]n O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
of [C]o [C]f O 
caspase-3 [C]c [C]a [C]s [C]p [C]a [C]s [C]e [C]- [C]3 O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
, [C], O 
even [C]e [C]v [C]e [C]n O 
if [C]i [C]f O 
a [C]a O 
slight [C]s [C]l [C]i [C]g [C]h [C]t O 
up-regulation [C]u [C]p [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-1beta-converting [C]I [C]L [C]- [C]1 [C]b [C]e [C]t [C]a [C]- [C]c [C]o [C]n [C]v [C]e [C]r [C]t [C]i [C]n [C]g B-RNA 
enzyme [C]e [C]n [C]z [C]y [C]m [C]e I-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
was [C]w [C]a [C]s O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
. [C]. O 

Apoptosis [C]A [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
abrogated [C]a [C]b [C]r [C]o [C]g [C]a [C]t [C]e [C]d O 
mainly [C]m [C]a [C]i [C]n [C]l [C]y O 
by [C]b [C]y O 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s S-protein 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
tumour [C]t [C]u [C]m [C]o [C]u [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor-alpha [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]a [C]l [C]p [C]h [C]a E-protein 
( [C]( O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
, [C], O 
to [C]t [C]o O 
a [C]a O 
lesser [C]l [C]e [C]s [C]s [C]e [C]r O 
extent [C]e [C]x [C]t [C]e [C]n [C]t O 
, [C], O 
by [C]b [C]y O 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s S-protein 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
. [C]. O 

All [C]A [C]l [C]l O 
these [C]t [C]h [C]e [C]s [C]e O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
uninfected [C]u [C]n [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d B-cell_type 
PBMC [C]P [C]B [C]M [C]C E-cell_type 
can [C]c [C]a [C]n O 
undergo [C]u [C]n [C]d [C]e [C]r [C]g [C]o O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
after [C]a [C]f [C]t [C]e [C]r O 
exposure [C]e [C]x [C]p [C]o [C]s [C]u [C]r [C]e O 
to [C]t [C]o O 
bystander [C]b [C]y [C]s [C]t [C]a [C]n [C]d [C]e [C]r O 
HIV-infected [C]H [C]I [C]V [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
subsequent [C]s [C]u [C]b [C]s [C]e [C]q [C]u [C]e [C]n [C]t O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
IFNs [C]I [C]F [C]N [C]s S-protein 
and [C]a [C]n [C]d O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
. [C]. O 

The [C]T [C]h [C]e O 
physical [C]p [C]h [C]y [C]s [C]i [C]c [C]a [C]l O 
association [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
C [C]C I-protein 
theta [C]t [C]h [C]e [C]t [C]a E-protein 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
lipid [C]l [C]i [C]p [C]i [C]d O 
raft-associated [C]r [C]a [C]f [C]t [C]- [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
of [C]o [C]f O 
kappa [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
( [C]( I-protein 
IKK [C]I [C]K [C]K I-protein 
) [C]) I-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
plays [C]p [C]l [C]a [C]y [C]s O 
a [C]a O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a O 
B [C]B O 
cascade [C]c [C]a [C]s [C]c [C]a [C]d [C]e O 
by [C]b [C]y O 
TCR [C]T [C]C [C]R S-protein 
and [C]a [C]n [C]d O 
CD28 [C]C [C]D [C]2 [C]8 S-protein 
. [C]. O 

We [C]W [C]e O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
C [C]C I-protein 
theta [C]t [C]h [C]e [C]t [C]a E-protein 
( [C]( O 
PKCtheta [C]P [C]K [C]C [C]t [C]h [C]e [C]t [C]a S-protein 
) [C]) O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
cascade [C]c [C]a [C]s [C]c [C]a [C]d [C]e O 
in [C]i [C]n O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
CD4 [C]C [C]D [C]4 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

Among [C]A [C]m [C]o [C]n [C]g O 
six [C]s [C]i [C]x O 
or [C]o [C]r O 
so [C]s [C]o O 
PKC [C]P [C]K [C]C B-protein 
isoforms [C]i [C]s [C]o [C]f [C]o [C]r [C]m [C]s E-protein 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
only [C]o [C]n [C]l [C]y O 
PKCtheta [C]P [C]K [C]C [C]t [C]h [C]e [C]t [C]a S-protein 
participates [C]p [C]a [C]r [C]t [C]i [C]c [C]i [C]p [C]a [C]t [C]e [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
assembly [C]a [C]s [C]s [C]e [C]m [C]b [C]l [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
supramolecular [C]s [C]u [C]p [C]r [C]a [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
clusters [C]c [C]l [C]u [C]s [C]t [C]e [C]r [C]s O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
contact [C]c [C]o [C]n [C]t [C]a [C]c [C]t O 
site [C]s [C]i [C]t [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
TCR [C]T [C]C [C]R S-protein 
with [C]w [C]i [C]t [C]h O 
Ag [C]A [C]g S-protein 
. [C]. O 

Signaling [C]S [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
via [C]v [C]i [C]a O 
both [C]b [C]o [C]t [C]h O 
the [C]t [C]h [C]e O 
TCR [C]T [C]C [C]R S-protein 
and [C]a [C]n [C]d O 
CD28 [C]C [C]D [C]2 [C]8 S-protein 
is [C]i [C]s O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
optimal [C]o [C]p [C]t [C]i [C]m [C]a [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
multisubunit [C]m [C]u [C]l [C]t [C]i [C]s [C]u [C]b [C]u [C]n [C]i [C]t B-protein 
IkappaB [C]I [C]k [C]a [C]p [C]p [C]a [C]B I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
( [C]( I-protein 
IKK [C]I [C]K [C]K I-protein 
) [C]) I-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
in [C]i [C]n O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
; [C]; O 
this [C]t [C]h [C]i [C]s O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
Ca [C]C [C]a O 
( [C]( O 
2+ [C]2 [C]+ O 
) [C]) O 
-independent [C]- [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
PKC [C]P [C]K [C]C O 
isoform [C]i [C]s [C]o [C]f [C]o [C]r [C]m O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
, [C], O 
rottlerin [C]r [C]o [C]t [C]t [C]l [C]e [C]r [C]i [C]n O 
. [C]. O 

Moreover [C]M [C]o [C]r [C]e [C]o [C]v [C]e [C]r O 
, [C], O 
endogenous [C]e [C]n [C]d [C]o [C]g [C]e [C]n [C]o [C]u [C]s O 
PKCtheta [C]P [C]K [C]C [C]t [C]h [C]e [C]t [C]a S-protein 
physically [C]p [C]h [C]y [C]s [C]i [C]c [C]a [C]l [C]l [C]y O 
associates [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
IKK [C]I [C]K [C]K B-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
in [C]i [C]n O 
CD3/CD28-costimulated [C]C [C]D [C]3 [C]/ [C]C [C]D [C]2 [C]8 [C]- [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_type 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y I-cell_type 
CD4 [C]C [C]D [C]4 I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
set [C]s [C]e [C]t O 
of [C]o [C]f O 
stimuli [C]s [C]t [C]i [C]m [C]u [C]l [C]i O 
also [C]a [C]l [C]s [C]o O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
relocation [C]r [C]e [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
endogenous [C]e [C]n [C]d [C]o [C]g [C]e [C]n [C]o [C]u [C]s O 
PKCtheta [C]P [C]K [C]C [C]t [C]h [C]e [C]t [C]a S-protein 
and [C]a [C]n [C]d O 
IKKs [C]I [C]K [C]K [C]s S-protein 
to [C]t [C]o O 
a [C]a O 
GM1 [C]G [C]M [C]1 O 
ganglioside-enriched [C]g [C]a [C]n [C]g [C]l [C]i [C]o [C]s [C]i [C]d [C]e [C]- [C]e [C]n [C]r [C]i [C]c [C]h [C]e [C]d O 
, [C], O 
detergent-insoluble [C]d [C]e [C]t [C]e [C]r [C]g [C]e [C]n [C]t [C]- [C]i [C]n [C]s [C]o [C]l [C]u [C]b [C]l [C]e O 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
compartment [C]c [C]o [C]m [C]p [C]a [C]r [C]t [C]m [C]e [C]n [C]t O 
in [C]i [C]n O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

IKKs [C]I [C]K [C]K [C]s S-protein 
recruited [C]r [C]e [C]c [C]r [C]u [C]i [C]t [C]e [C]d O 
to [C]t [C]o O 
these [C]t [C]h [C]e [C]s [C]e O 
lipid [C]l [C]i [C]p [C]i [C]d O 
rafts [C]r [C]a [C]f [C]t [C]s O 
were [C]w [C]e [C]r [C]e O 
capable [C]c [C]a [C]p [C]a [C]b [C]l [C]e O 
of [C]o [C]f O 
phosphorylating [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]n [C]g O 
a [C]a O 
recombinant [C]r [C]e [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]n [C]t O 
IkappaBalpha [C]I [C]k [C]a [C]p [C]p [C]a [C]B [C]a [C]l [C]p [C]h [C]a O 
sustrate [C]s [C]u [C]s [C]t [C]r [C]a [C]t [C]e O 
. [C]. O 

Confocal [C]C [C]o [C]n [C]f [C]o [C]c [C]a [C]l O 
microscopy [C]m [C]i [C]c [C]r [C]o [C]s [C]c [C]o [C]p [C]y O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
exogenously [C]e [C]x [C]o [C]g [C]e [C]n [C]o [C]u [C]s [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
PKCtheta [C]P [C]K [C]C [C]t [C]h [C]e [C]t [C]a S-protein 
and [C]a [C]n [C]d O 
IKKss [C]I [C]K [C]K [C]s [C]s S-protein 
colocalize [C]c [C]o [C]l [C]o [C]c [C]a [C]l [C]i [C]z [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
of [C]o [C]f O 
CD3/CD28-costimulated [C]C [C]D [C]3 [C]/ [C]C [C]D [C]2 [C]8 [C]- [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_line 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t I-cell_line 
T [C]T I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

Constitutively [C]C [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
kinase-inactive [C]k [C]i [C]n [C]a [C]s [C]e [C]- [C]i [C]n [C]a [C]c [C]t [C]i [C]v [C]e B-protein 
PKCtheta [C]P [C]K [C]C [C]t [C]h [C]e [C]t [C]a E-protein 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
IKKbeta [C]I [C]K [C]K [C]b [C]e [C]t [C]a S-protein 
in [C]i [C]n O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_line 
T [C]T I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

Expression [C]E [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
dominant-active [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t [C]- [C]a [C]c [C]t [C]i [C]v [C]e B-protein 
PKCtheta [C]P [C]K [C]C [C]t [C]h [C]e [C]t [C]a E-protein 
also [C]a [C]l [C]s [C]o O 
had [C]h [C]a [C]d O 
stimulatory [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
CD28 [C]C [C]D [C]2 [C]8 B-DNA 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e I-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

Taken [C]T [C]a [C]k [C]e [C]n O 
together [C]t [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
, [C], O 
these [C]t [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
PKCtheta [C]P [C]K [C]C [C]t [C]h [C]e [C]t [C]a S-protein 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
TCR [C]T [C]C [C]R S-protein 
and [C]a [C]n [C]d O 
CD28 [C]C [C]D [C]2 [C]8 S-protein 
plays [C]p [C]l [C]a [C]y [C]s O 
an [C]a [C]n O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
assembly [C]a [C]s [C]s [C]e [C]m [C]b [C]l [C]y O 
and [C]a [C]n [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IKK [C]I [C]K [C]K B-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 

T-cell [C]T [C]- [C]c [C]e [C]l [C]l S-cell_type 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
osteoclastogenesis [C]o [C]s [C]t [C]e [C]o [C]c [C]l [C]a [C]s [C]t [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
by [C]b [C]y O 
signalling [C]s [C]i [C]g [C]n [C]a [C]l [C]l [C]i [C]n [C]g O 
cross-talk [C]c [C]r [C]o [C]s [C]s [C]- [C]t [C]a [C]l [C]k O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
RANKL [C]R [C]A [C]N [C]K [C]L S-protein 
and [C]a [C]n [C]d O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
. [C]. O 

Bone [C]B [C]o [C]n [C]e O 
resorption [C]r [C]e [C]s [C]o [C]r [C]p [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
, [C], O 
where [C]w [C]h [C]e [C]r [C]e O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l S-cell_type 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
RANKL [C]R [C]A [C]N [C]K [C]L S-protein 
( [C]( O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r B-protein 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r I-protein 
of [C]o [C]f I-protein 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
( [C]( I-protein 
NF [C]N [C]F I-protein 
) [C]) I-protein 
-kappaB [C]- [C]k [C]a [C]p [C]p [C]a [C]B I-protein 
ligand [C]l [C]i [C]g [C]a [C]n [C]d E-protein 
) [C]) O 
, [C], O 
a [C]a O 
member [C]m [C]e [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
tumour-necrosis [C]t [C]u [C]m [C]o [C]u [C]r [C]- [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y E-protein 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
for [C]f [C]o [C]r O 
osteoclastogenesis [C]o [C]s [C]t [C]e [C]o [C]c [C]l [C]a [C]s [C]t [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
, [C], O 
may [C]m [C]a [C]y O 
contribute [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e O 
to [C]t [C]o O 
pathological [C]p [C]a [C]t [C]h [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
conditions [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n [C]s O 
, [C], O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
autoimmune [C]a [C]u [C]t [C]o [C]i [C]m [C]m [C]u [C]n [C]e O 
arthritis [C]a [C]r [C]t [C]h [C]r [C]i [C]t [C]i [C]s O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
maintain [C]m [C]a [C]i [C]n [C]t [C]a [C]i [C]n O 
bone [C]b [C]o [C]n [C]e O 
homeostasis [C]h [C]o [C]m [C]e [C]o [C]s [C]t [C]a [C]s [C]i [C]s O 
by [C]b [C]y O 
counterbalancing [C]c [C]o [C]u [C]n [C]t [C]e [C]r [C]b [C]a [C]l [C]a [C]n [C]c [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
action [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
RANKL [C]R [C]A [C]N [C]K [C]L S-protein 
remains [C]r [C]e [C]m [C]a [C]i [C]n [C]s O 
unknown [C]u [C]n [C]k [C]n [C]o [C]w [C]n O 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
we [C]w [C]e O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l S-cell_type 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
interferon [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n B-protein 
( [C]( I-protein 
IFN [C]I [C]F [C]N I-protein 
) [C]) I-protein 
-gamma [C]- [C]g [C]a [C]m [C]m [C]a E-protein 
strongly [C]s [C]t [C]r [C]o [C]n [C]g [C]l [C]y O 
suppresses [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]e [C]s O 
osteoclastogenesis [C]o [C]s [C]t [C]e [C]o [C]c [C]l [C]a [C]s [C]t [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
by [C]b [C]y O 
interfering [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]i [C]n [C]g O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
RANKL [C]R [C]A [C]N [C]K [C]L S-protein 
-RANK [C]- [C]R [C]A [C]N [C]K O 
signalling [C]s [C]i [C]g [C]n [C]a [C]l [C]l [C]i [C]n [C]g O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
. [C]. O 

IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
rapid [C]r [C]a [C]p [C]i [C]d O 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
RANK [C]R [C]A [C]N [C]K B-protein 
adapter [C]a [C]d [C]a [C]p [C]t [C]e [C]r I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
, [C], O 
TRAF6 [C]T [C]R [C]A [C]F [C]6 S-protein 
( [C]( O 
tumour [C]t [C]u [C]m [C]o [C]u [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
receptor-associated [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]- [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
6 [C]6 E-protein 
) [C]) O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
in [C]i [C]n O 
strong [C]s [C]t [C]r [C]o [C]n [C]g O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
RANKL [C]R [C]A [C]N [C]K [C]L S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
and [C]a [C]n [C]d O 
JNK [C]J [C]N [C]K S-protein 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
osteoclastogenesis [C]o [C]s [C]t [C]e [C]o [C]c [C]l [C]a [C]s [C]t [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
is [C]i [C]s O 
rescued [C]r [C]e [C]s [C]c [C]u [C]e [C]d O 
by [C]b [C]y O 
overexpressing [C]o [C]v [C]e [C]r [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]n [C]g O 
TRAF6 [C]T [C]R [C]A [C]F [C]6 S-protein 
in [C]i [C]n O 
precursor [C]p [C]r [C]e [C]c [C]u [C]r [C]s [C]o [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
indicates [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e [C]s O 
that [C]t [C]h [C]a [C]t O 
TRAF6 [C]T [C]R [C]A [C]F [C]6 S-protein 
is [C]i [C]s O 
the [C]t [C]h [C]e O 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
critical [C]c [C]r [C]i [C]t [C]i [C]c [C]a [C]l O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
action [C]a [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
we [C]w [C]e O 
provide [C]p [C]r [C]o [C]v [C]i [C]d [C]e O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
accelerated [C]a [C]c [C]c [C]e [C]l [C]e [C]r [C]a [C]t [C]e [C]d O 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
TRAF6 [C]T [C]R [C]A [C]F [C]6 S-protein 
requires [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]s O 
both [C]b [C]o [C]t [C]h O 
its [C]i [C]t [C]s O 
ubiquitination [C]u [C]b [C]i [C]q [C]u [C]i [C]t [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
initiated [C]i [C]n [C]i [C]t [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
RANKL [C]R [C]A [C]N [C]K [C]L S-protein 
, [C], O 
and [C]a [C]n [C]d O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
ubiquitin-proteasome [C]u [C]b [C]i [C]q [C]u [C]i [C]t [C]i [C]n [C]- [C]p [C]r [C]o [C]t [C]e [C]a [C]s [C]o [C]m [C]e O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
. [C]. O 

Our [C]O [C]u [C]r O 
study [C]s [C]t [C]u [C]d [C]y O 
shows [C]s [C]h [C]o [C]w [C]s O 
that [C]t [C]h [C]a [C]t O 
there [C]t [C]h [C]e [C]r [C]e O 
is [C]i [C]s O 
cross-talk [C]c [C]r [C]o [C]s [C]s [C]- [C]t [C]a [C]l [C]k O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
tumour [C]t [C]u [C]m [C]o [C]u [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
and [C]a [C]n [C]d O 
IFN [C]I [C]F [C]N B-protein 
families [C]f [C]a [C]m [C]i [C]l [C]i [C]e [C]s E-protein 
of [C]o [C]f O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
, [C], O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
which [C]w [C]h [C]i [C]c [C]h O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
provides [C]p [C]r [C]o [C]v [C]i [C]d [C]e [C]s O 
a [C]a O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
link [C]l [C]i [C]n [C]k O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l S-cell_type 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
bone [C]b [C]o [C]n [C]e O 
resorption [C]r [C]e [C]s [C]o [C]r [C]p [C]t [C]i [C]o [C]n O 
. [C]. O 

Our [C]O [C]u [C]r O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
may [C]m [C]a [C]y O 
offer [C]o [C]f [C]f [C]e [C]r O 
a [C]a O 
therapeutic [C]t [C]h [C]e [C]r [C]a [C]p [C]e [C]u [C]t [C]i [C]c O 
approach [C]a [C]p [C]p [C]r [C]o [C]a [C]c [C]h O 
to [C]t [C]o O 
treat [C]t [C]r [C]e [C]a [C]t O 
the [C]t [C]h [C]e O 
inflammation-induced [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]i [C]o [C]n [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
breakdown [C]b [C]r [C]e [C]a [C]k [C]d [C]o [C]w [C]n O 
. [C]. O 

Stromal-derived [C]S [C]t [C]r [C]o [C]m [C]a [C]l [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
1 [C]1 E-protein 
and [C]a [C]n [C]d O 
thrombopoietin [C]t [C]h [C]r [C]o [C]m [C]b [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]n S-protein 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
aspects [C]a [C]s [C]p [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n O 
megakaryopoiesis [C]m [C]e [C]g [C]a [C]k [C]a [C]r [C]y [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
chemokine [C]c [C]h [C]e [C]m [C]o [C]k [C]i [C]n [C]e S-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
stromal-derived [C]s [C]t [C]r [C]o [C]m [C]a [C]l [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
1 [C]1 E-protein 
( [C]( O 
SDF-1 [C]S [C]D [C]F [C]- [C]1 S-protein 
) [C]) O 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
human [C]h [C]u [C]m [C]a [C]n O 
megakaryopoiesis [C]m [C]e [C]g [C]a [C]k [C]a [C]r [C]y [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
and [C]a [C]n [C]d O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
and [C]a [C]n [C]d O 
its [C]i [C]t [C]s O 
comparison [C]c [C]o [C]m [C]p [C]a [C]r [C]i [C]s [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
that [C]t [C]h [C]a [C]t O 
of [C]o [C]f O 
thrombopoietin [C]t [C]h [C]r [C]o [C]m [C]b [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]n S-protein 
( [C]( O 
TPO [C]T [C]P [C]O S-protein 
) [C]) O 
have [C]h [C]a [C]v [C]e O 
not [C]n [C]o [C]t O 
been [C]b [C]e [C]e [C]n O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
it [C]i [C]t O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
SDF-1 [C]S [C]D [C]F [C]- [C]1 S-protein 
, [C], O 
unlike [C]u [C]n [C]l [C]i [C]k [C]e O 
TPO [C]T [C]P [C]O S-protein 
, [C], O 
does [C]d [C]o [C]e [C]s O 
not [C]n [C]o [C]t O 
stimulate [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e O 
alpha [C]a [C]l [C]p [C]h [C]a O 
( [C]( O 
IIb [C]I [C]I [C]b O 
) [C]) O 
beta [C]b [C]e [C]t [C]a O 
( [C]( O 
3 [C]3 O 
) [C]) O 
( [C]( O 
+ [C]+ O 
) [C]) O 
cell [C]c [C]e [C]l [C]l O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
or [C]o [C]r O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
or [C]o [C]r O 
have [C]h [C]a [C]v [C]e O 
an [C]a [C]n O 
antiapoptotic [C]a [C]n [C]t [C]i [C]a [C]p [C]o [C]p [C]t [C]o [C]t [C]i [C]c O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
it [C]i [C]t O 
does [C]d [C]o [C]e [C]s O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
chemotaxis [C]c [C]h [C]e [C]m [C]o [C]t [C]a [C]x [C]i [C]s O 
, [C], O 
trans-Matrigel [C]t [C]r [C]a [C]n [C]s [C]- [C]M [C]a [C]t [C]r [C]i [C]g [C]e [C]l O 
migration [C]m [C]i [C]g [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
secretion [C]s [C]e [C]c [C]r [C]e [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
matrix [C]m [C]a [C]t [C]r [C]i [C]x O 
metalloproteinase [C]m [C]e [C]t [C]a [C]l [C]l [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]a [C]s [C]e B-protein 
9 [C]9 E-protein 
( [C]( O 
MMP-9 [C]M [C]M [C]P [C]- [C]9 S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
vascular [C]v [C]a [C]s [C]c [C]u [C]l [C]a [C]r B-protein 
endothelial [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l I-protein 
growth [C]g [C]r [C]o [C]w [C]t [C]h I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
( [C]( O 
VEGF [C]V [C]E [C]G [C]F S-protein 
) [C]) O 
by [C]b [C]y O 
these [C]t [C]h [C]e [C]s [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
both [C]b [C]o [C]t [C]h O 
SDF-1 [C]S [C]D [C]F [C]- [C]1 S-protein 
and [C]a [C]n [C]d O 
TPO [C]T [C]P [C]O S-protein 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
the [C]t [C]h [C]e O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
alpha [C]a [C]l [C]p [C]h [C]a B-cell_type 
( [C]( I-cell_type 
IIb [C]I [C]I [C]b I-cell_type 
) [C]) I-cell_type 
beta [C]b [C]e [C]t [C]a I-cell_type 
( [C]( I-cell_type 
3 [C]3 I-cell_type 
) [C]) I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
to [C]t [C]o O 
fibrinogen [C]f [C]i [C]b [C]r [C]i [C]n [C]o [C]g [C]e [C]n S-protein 
and [C]a [C]n [C]d O 
vitronectin [C]v [C]i [C]t [C]r [C]o [C]n [C]e [C]c [C]t [C]i [C]n S-protein 
. [C]. O 

Investigating [C]I [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
SDF-1 [C]S [C]D [C]F [C]- [C]1 S-protein 
and [C]a [C]n [C]d O 
TPO [C]T [C]P [C]O S-protein 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
some [C]s [C]o [C]m [C]e O 
overlapping [C]o [C]v [C]e [C]r [C]l [C]a [C]p [C]p [C]i [C]n [C]g O 
patterns [C]p [C]a [C]t [C]t [C]e [C]r [C]n [C]s O 
of [C]o [C]f O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
phosphorylation/activation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n [C]/ [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
( [C]( O 
mitogen-activated [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
[ [C][ I-protein 
MAPK [C]M [C]A [C]P [C]K I-protein 
] [C]] I-protein 
p42/44 [C]p [C]4 [C]2 [C]/ [C]4 [C]4 E-protein 
, [C], O 
MAPK [C]M [C]A [C]P [C]K B-protein 
p38 [C]p [C]3 [C]8 E-protein 
, [C], O 
and [C]a [C]n [C]d O 
AKT [C]A [C]K [C]T B-protein 
[ [C][ I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
B [C]B I-protein 
] [C]] E-protein 
) [C]) O 
and [C]a [C]n [C]d O 
some [C]s [C]o [C]m [C]e O 
that [C]t [C]h [C]a [C]t O 
were [C]w [C]e [C]r [C]e O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
for [C]f [C]o [C]r O 
TPO [C]T [C]P [C]O S-protein 
( [C]( O 
eg [C]e [C]g O 
, [C], O 
JAK-STAT [C]J [C]A [C]K [C]- [C]S [C]T [C]A [C]T S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
for [C]f [C]o [C]r O 
SDF-1 [C]S [C]D [C]F [C]- [C]1 S-protein 
( [C]( O 
eg [C]e [C]g O 
, [C], O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
) [C]) O 
. [C]. O 

It [C]I [C]t O 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
though [C]t [C]h [C]o [C]u [C]g [C]h O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
phosphatidyl-inositol [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]i [C]d [C]y [C]l [C]- [C]i [C]n [C]o [C]s [C]i [C]t [C]o [C]l B-protein 
3-kinase [C]3 [C]- [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
( [C]( O 
PI-3K [C]P [C]I [C]- [C]3 [C]K S-protein 
) [C]) O 
by [C]b [C]y O 
LY294002 [C]L [C]Y [C]2 [C]9 [C]4 [C]0 [C]0 [C]2 O 
in [C]i [C]n O 
alpha [C]a [C]l [C]p [C]h [C]a B-cell_type 
( [C]( I-cell_type 
IIb [C]I [C]I [C]b I-cell_type 
) [C]) I-cell_type 
beta [C]b [C]e [C]t [C]a I-cell_type 
( [C]( I-cell_type 
3 [C]3 I-cell_type 
) [C]) I-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
chemotaxis [C]c [C]h [C]e [C]m [C]o [C]t [C]a [C]x [C]i [C]s O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
secretion [C]s [C]e [C]c [C]r [C]e [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
MMP-9 [C]M [C]M [C]P [C]- [C]9 S-protein 
and [C]a [C]n [C]d O 
VEGF [C]V [C]E [C]G [C]F S-protein 
, [C], O 
the [C]t [C]h [C]e O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
MAPK [C]M [C]A [C]P [C]K B-protein 
p42/44 [C]p [C]4 [C]2 [C]/ [C]4 [C]4 E-protein 
( [C]( O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
MEK [C]M [C]E [C]K O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
U0126 [C]U [C]0 [C]1 [C]2 [C]6 O 
) [C]) O 
had [C]h [C]a [C]d O 
no [C]n [C]o O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
survival [C]s [C]u [C]r [C]v [C]i [C]v [C]a [C]l O 
, [C], O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
migration [C]m [C]i [C]g [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
. [C]. O 

Hence [C]H [C]e [C]n [C]c [C]e O 
, [C], O 
it [C]i [C]t O 
is [C]i [C]s O 
suggested [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
proliferative [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
TPO [C]T [C]P [C]O S-protein 
is [C]i [C]s O 
more [C]m [C]o [C]r [C]e O 
related [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
to [C]t [C]o O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
JAK-STAT [C]J [C]A [C]K [C]- [C]S [C]T [C]A [C]T O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
( [C]( O 
unique [C]u [C]n [C]i [C]q [C]u [C]e O 
to [C]t [C]o O 
TPO [C]T [C]P [C]O S-protein 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
PI-3K-AKT [C]P [C]I [C]- [C]3 [C]K [C]- [C]A [C]K [C]T O 
axis [C]a [C]x [C]i [C]s O 
is [C]i [C]s O 
differentially [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l [C]l [C]y O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
TPO- [C]T [C]P [C]O [C]- O 
and [C]a [C]n [C]d O 
SDF-1-dependent [C]S [C]D [C]F [C]- [C]1 [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
. [C]. O 

Accordingly [C]A [C]c [C]c [C]o [C]r [C]d [C]i [C]n [C]g [C]l [C]y O 
, [C], O 
PI-3K [C]P [C]I [C]- [C]3 [C]K S-protein 
is [C]i [C]s O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
TPO [C]T [C]P [C]O S-protein 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
, [C], O 
TPO- [C]T [C]P [C]O [C]- O 
and [C]a [C]n [C]d O 
SDF-1-regulated [C]S [C]D [C]F [C]- [C]1 [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
to [C]t [C]o O 
fibrinogen [C]f [C]i [C]b [C]r [C]i [C]n [C]o [C]g [C]e [C]n S-protein 
and [C]a [C]n [C]d O 
vitronectin [C]v [C]i [C]t [C]r [C]o [C]n [C]e [C]c [C]t [C]i [C]n S-protein 
, [C], O 
and [C]a [C]n [C]d O 
SDF-1 [C]S [C]D [C]F [C]- [C]1 S-protein 
-mediated [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
migration [C]m [C]i [C]g [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
expands [C]e [C]x [C]p [C]a [C]n [C]d [C]s O 
the [C]t [C]h [C]e O 
understanding [C]u [C]n [C]d [C]e [C]r [C]s [C]t [C]a [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
SDF-1 [C]S [C]D [C]F [C]- [C]1 S-protein 
and [C]a [C]n [C]d O 
TPO [C]T [C]P [C]O S-protein 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
human [C]h [C]u [C]m [C]a [C]n O 
megakaryopoiesis [C]m [C]e [C]g [C]a [C]k [C]a [C]r [C]y [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
indicates [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e [C]s O 
the [C]t [C]h [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
basis [C]b [C]a [C]s [C]i [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
differences [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e [C]s O 
in [C]i [C]n O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
. [C]. O 

( [C]( O 
Blood. [C]B [C]l [C]o [C]o [C]d [C]. O 
2000 [C]2 [C]0 [C]0 [C]0 O 
; [C]; O 
96 [C]9 [C]6 O 
: [C]: O 
4142-4151 [C]4 [C]1 [C]4 [C]2 [C]- [C]4 [C]1 [C]5 [C]1 O 
) [C]) O 

Adhesion [C]A [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
immature [C]i [C]m [C]m [C]a [C]t [C]u [C]r [C]e B-cell_type 
and [C]a [C]n [C]d I-cell_type 
mature [C]m [C]a [C]t [C]u [C]r [C]e I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
thymic [C]t [C]h [C]y [C]m [C]i [C]c I-cell_type 
epithelial [C]e [C]p [C]i [C]t [C]h [C]e [C]l [C]i [C]a [C]l I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
TEC [C]T [C]E [C]C S-cell_type 
) [C]) O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-6 [C]I [C]L [C]- [C]6 B-protein 
gene [C]g [C]e [C]n [C]e I-protein 
trascription [C]t [C]r [C]a [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
( [C]( O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
and [C]a [C]n [C]d O 
NF-IL6 [C]N [C]F [C]- [C]I [C]L [C]6 S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
IL-6 [C]I [C]L [C]- [C]6 O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
: [C]: O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
alpha3beta1 [C]a [C]l [C]p [C]h [C]a [C]3 [C]b [C]e [C]t [C]a [C]1 B-protein 
and [C]a [C]n [C]d I-protein 
alpha6beta4 [C]a [C]l [C]p [C]h [C]a [C]6 [C]b [C]e [C]t [C]a [C]4 I-protein 
integrins [C]i [C]n [C]t [C]e [C]g [C]r [C]i [C]n [C]s E-protein 
. [C]. O 

T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l I-cell_type 
precursors [C]p [C]r [C]e [C]c [C]u [C]r [C]s [C]o [C]r [C]s E-cell_type 
homed [C]h [C]o [C]m [C]e [C]d O 
to [C]t [C]o O 
thymus [C]t [C]h [C]y [C]m [C]u [C]s O 
develop [C]d [C]e [C]v [C]e [C]l [C]o [C]p O 
in [C]i [C]n O 
close [C]c [C]l [C]o [C]s [C]e O 
contact [C]c [C]o [C]n [C]t [C]a [C]c [C]t O 
with [C]w [C]i [C]t [C]h O 
stromal [C]s [C]t [C]r [C]o [C]m [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Among [C]A [C]m [C]o [C]n [C]g O 
them [C]t [C]h [C]e [C]m O 
, [C], O 
thymic [C]t [C]h [C]y [C]m [C]i [C]c B-cell_type 
epithelial [C]e [C]p [C]i [C]t [C]h [C]e [C]l [C]i [C]a [C]l I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
TEC [C]T [C]E [C]C S-cell_type 
) [C]) O 
are [C]a [C]r [C]e O 
known [C]k [C]n [C]o [C]w [C]n O 
to [C]t [C]o O 
exert [C]e [C]x [C]e [C]r [C]t O 
dominant [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t O 
roles [C]r [C]o [C]l [C]e [C]s O 
in [C]i [C]n O 
their [C]t [C]h [C]e [C]i [C]r O 
survival [C]s [C]u [C]r [C]v [C]i [C]v [C]a [C]l O 
and [C]a [C]n [C]d O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
shaping [C]s [C]h [C]a [C]p [C]i [C]n [C]g O 
. [C]. O 

Key [C]K [C]e [C]y O 
molecules [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]s O 
mediating [C]m [C]e [C]d [C]i [C]a [C]t [C]i [C]n [C]g O 
TEC [C]T [C]E [C]C S-cell_type 
/ [C]/ O 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
interactions [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
include [C]i [C]n [C]c [C]l [C]u [C]d [C]e O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
and [C]a [C]n [C]d O 
growth [C]g [C]r [C]o [C]w [C]t [C]h B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
secreted [C]s [C]e [C]c [C]r [C]e [C]t [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
two [C]t [C]w [C]o O 
cell [C]c [C]e [C]l [C]l O 
types [C]t [C]y [C]p [C]e [C]s O 
and [C]a [C]n [C]d O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
mediating [C]m [C]e [C]d [C]i [C]a [C]t [C]i [C]n [C]g O 
cell [C]c [C]e [C]l [C]l O 
contact [C]c [C]o [C]n [C]t [C]a [C]c [C]t O 
. [C]. O 

Signaling [C]S [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
events [C]e [C]v [C]e [C]n [C]t [C]s O 
triggered [C]t [C]r [C]i [C]g [C]g [C]e [C]r [C]e [C]d O 
in [C]i [C]n O 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
by [C]b [C]y O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
to [C]t [C]o O 
epithelial [C]e [C]p [C]i [C]t [C]h [C]e [C]l [C]i [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
extensively [C]e [C]x [C]t [C]e [C]n [C]s [C]i [C]v [C]e [C]l [C]y O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
little [C]l [C]i [C]t [C]t [C]l [C]e O 
is [C]i [C]s O 
known [C]k [C]n [C]o [C]w [C]n O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
opposite [C]o [C]p [C]p [C]o [C]s [C]i [C]t [C]e O 
phenomenon [C]p [C]h [C]e [C]n [C]o [C]m [C]e [C]n [C]o [C]n O 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
this [C]t [C]h [C]i [C]s O 
issue [C]i [C]s [C]s [C]u [C]e O 
in [C]i [C]n O 
a [C]a O 
co-culture [C]c [C]o [C]- [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
composed [C]c [C]o [C]m [C]p [C]o [C]s [C]e [C]d O 
of [C]o [C]f O 
TEC [C]T [C]E [C]C B-cell_type 
cultures [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]s E-cell_type 
derived [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
human [C]h [C]u [C]m [C]a [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
thymus [C]t [C]h [C]y [C]m [C]u [C]s O 
and [C]a [C]n [C]d O 
heterologous [C]h [C]e [C]t [C]e [C]r [C]o [C]l [C]o [C]g [C]o [C]u [C]s B-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

We [C]W [C]e O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
adhere [C]a [C]d [C]h [C]e [C]r [C]e O 
to [C]t [C]o O 
TEC [C]T [C]E [C]C S-cell_type 
involving [C]i [C]n [C]v [C]o [C]l [C]v [C]i [C]n [C]g O 
beta1 [C]b [C]e [C]t [C]a [C]1 B-protein 
and [C]a [C]n [C]d I-protein 
beta4 [C]b [C]e [C]t [C]a [C]4 I-protein 
integrins [C]i [C]n [C]t [C]e [C]g [C]r [C]i [C]n [C]s E-protein 
and [C]a [C]n [C]d O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
the [C]t [C]h [C]e O 
clustering [C]c [C]l [C]u [C]s [C]t [C]e [C]r [C]i [C]n [C]g O 
of [C]o [C]f O 
alpha3beta1 [C]a [C]l [C]p [C]h [C]a [C]3 [C]b [C]e [C]t [C]a [C]1 B-protein 
and [C]a [C]n [C]d I-protein 
alpha6beta4 [C]a [C]l [C]p [C]h [C]a [C]6 [C]b [C]e [C]t [C]a [C]4 I-protein 
heterodimers [C]h [C]e [C]t [C]e [C]r [C]o [C]d [C]i [C]m [C]e [C]r [C]s E-protein 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
TEC [C]T [C]E [C]C O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
thymocyte [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
followed [C]f [C]o [C]l [C]l [C]o [C]w [C]e [C]d O 
by [C]b [C]y O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
and [C]a [C]n [C]d O 
NF-IL6 [C]N [C]F [C]- [C]I [C]L [C]6 S-protein 
gene [C]g [C]e [C]n [C]e B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
and [C]a [C]n [C]d O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
IL-6 [C]I [C]L [C]- [C]6 O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
two [C]t [C]w [C]o O 
latter [C]l [C]a [C]t [C]t [C]e [C]r O 
phenomena [C]p [C]h [C]e [C]n [C]o [C]m [C]e [C]n [C]a O 
were [C]w [C]e [C]r [C]e O 
reproduced [C]r [C]e [C]p [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
cross-linking [C]c [C]r [C]o [C]s [C]s [C]- [C]l [C]i [C]n [C]k [C]i [C]n [C]g O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
alpha3 [C]a [C]l [C]p [C]h [C]a [C]3 S-protein 
, [C], O 
alpha6 [C]a [C]l [C]p [C]h [C]a [C]6 S-protein 
, [C], O 
beta1 [C]b [C]e [C]t [C]a [C]1 B-protein 
and [C]a [C]n [C]d I-protein 
beta4 [C]b [C]e [C]t [C]a [C]4 I-protein 
integrins [C]i [C]n [C]t [C]e [C]g [C]r [C]i [C]n [C]s E-protein 
, [C], O 
thus [C]t [C]h [C]u [C]s O 
implying [C]i [C]m [C]p [C]l [C]y [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
alpha3beta1 [C]a [C]l [C]p [C]h [C]a [C]3 [C]b [C]e [C]t [C]a [C]1 B-protein 
and [C]a [C]n [C]d I-protein 
alpha6beta4 [C]a [C]l [C]p [C]h [C]a [C]6 [C]b [C]e [C]t [C]a [C]4 I-protein 
heterodimers [C]h [C]e [C]t [C]e [C]r [C]o [C]d [C]i [C]m [C]e [C]r [C]s E-protein 
can [C]c [C]a [C]n O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
thymocyte [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
extended [C]e [C]x [C]t [C]e [C]n [C]d [C]e [C]d O 
our [C]o [C]u [C]r O 
previous [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s O 
work [C]w [C]o [C]r [C]k O 
investigating [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]i [C]n [C]g O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
experimental [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]a [C]l O 
setting [C]s [C]e [C]t [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
inducing [C]i [C]n [C]d [C]u [C]c [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
non [C]n [C]o [C]n O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
or [C]o [C]r O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
policlonal [C]p [C]o [C]l [C]i [C]c [C]l [C]o [C]n [C]a [C]l B-cell_type 
or [C]o [C]r I-cell_type 
clonal [C]c [C]l [C]o [C]n [C]a [C]l I-cell_type 
mature [C]m [C]a [C]t [C]u [C]r [C]e I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
as [C]a [C]s O 
representative [C]r [C]e [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]a [C]t [C]i [C]v [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
more [C]m [C]o [C]r [C]e O 
mature [C]m [C]a [C]t [C]u [C]r [C]e B-cell_type 
thymocyte [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e I-cell_type 
subset [C]s [C]u [C]b [C]s [C]e [C]t E-cell_type 
. [C]. O 

We [C]W [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
unstimulated [C]u [C]n [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_type 
T [C]T I-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
i [C]i O 
) [C]) O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
beta1 [C]b [C]e [C]t [C]a [C]1 O 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
beta4 [C]b [C]e [C]t [C]a [C]4 O 
integrin [C]i [C]n [C]t [C]e [C]g [C]r [C]i [C]n O 
functions [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]s O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
ii [C]i [C]i O 
) [C]) O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
the [C]t [C]h [C]e O 
clustering [C]c [C]l [C]u [C]s [C]t [C]e [C]r [C]i [C]n [C]g O 
of [C]o [C]f O 
alpha3beta1 [C]a [C]l [C]p [C]h [C]a [C]3 [C]b [C]e [C]t [C]a [C]1 S-protein 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
alpha2beta1 [C]a [C]l [C]p [C]h [C]a [C]2 [C]b [C]e [C]t [C]a [C]1 B-protein 
heterodimers [C]h [C]e [C]t [C]e [C]r [C]o [C]d [C]i [C]m [C]e [C]r [C]s E-protein 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
TEC [C]T [C]E [C]C O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
and [C]a [C]n [C]d O 
iii [C]i [C]i [C]i O 
) [C]) O 
up-regulated [C]u [C]p [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
IL-6 [C]I [C]L [C]- [C]6 O 
secretion [C]s [C]e [C]c [C]r [C]e [C]t [C]i [C]o [C]n O 
. [C]. O 

We [C]W [C]e O 
propose [C]p [C]r [C]o [C]p [C]o [C]s [C]e O 
that [C]t [C]h [C]a [C]t O 
alpha3beta1 [C]a [C]l [C]p [C]h [C]a [C]3 [C]b [C]e [C]t [C]a [C]1 B-protein 
and [C]a [C]n [C]d I-protein 
alpha6beta4 [C]a [C]l [C]p [C]h [C]a [C]6 [C]b [C]e [C]t [C]a [C]4 I-protein 
heterodimers [C]h [C]e [C]t [C]e [C]r [C]o [C]d [C]i [C]m [C]e [C]r [C]s E-protein 
are [C]a [C]r [C]e O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
to [C]t [C]o O 
cluster [C]c [C]l [C]u [C]s [C]t [C]e [C]r O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
TEC [C]T [C]E [C]C O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
recognizing [C]r [C]e [C]c [C]o [C]g [C]n [C]i [C]z [C]i [C]n [C]g O 
yet [C]y [C]e [C]t O 
unknown [C]u [C]n [C]k [C]n [C]o [C]w [C]n O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
ligands [C]l [C]i [C]g [C]a [C]n [C]d [C]s E-protein 
differentially [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
. [C]. O 

Identification [C]I [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
characterization [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
SKAT-2 [C]S [C]K [C]A [C]T [C]- [C]2 S-DNA 
, [C], O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
Th2-specific [C]T [C]h [C]2 [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-DNA 
zinc [C]z [C]i [C]n [C]c I-DNA 
finger [C]f [C]i [C]n [C]g [C]e [C]r I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
Kruppel-type [C]K [C]r [C]u [C]p [C]p [C]e [C]l [C]- [C]t [C]y [C]p [C]e B-DNA 
zinc [C]z [C]i [C]n [C]c I-DNA 
finger [C]f [C]i [C]n [C]g [C]e [C]r I-DNA 
( [C]( I-DNA 
ZF [C]Z [C]F I-DNA 
) [C]) I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
, [C], O 
SKAT-2 [C]S [C]K [C]A [C]T [C]- [C]2 S-DNA 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
selectively [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
by [C]b [C]y O 
murine [C]m [C]u [C]r [C]i [C]n [C]e B-cell_type 
Th2 [C]T [C]h [C]2 I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
encoded [C]e [C]n [C]c [C]o [C]d [C]e [C]d O 
by [C]b [C]y O 
this [C]t [C]h [C]i [C]s O 
gene [C]g [C]e [C]n [C]e O 
has [C]h [C]a [C]s O 
14 [C]1 [C]4 O 
C2H2-type [C]C [C]2 [C]H [C]2 [C]- [C]t [C]y [C]p [C]e O 
ZF [C]Z [C]F O 
tandemly [C]t [C]a [C]n [C]d [C]e [C]m [C]l [C]y O 
arrayed [C]a [C]r [C]r [C]a [C]y [C]e [C]d O 
at [C]a [C]t O 
its [C]i [C]t [C]s O 
C [C]C B-DNA 
terminus [C]t [C]e [C]r [C]m [C]i [C]n [C]u [C]s E-DNA 
and [C]a [C]n [C]d O 
N-terminal [C]N [C]- [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l S-DNA 
SCAN [C]S [C]C [C]A [C]N B-DNA 
box [C]b [C]o [C]x E-DNA 
and [C]a [C]n [C]d O 
KRAB [C]K [C]R [C]A [C]B B-DNA 
domains [C]d [C]o [C]m [C]a [C]i [C]n [C]s E-DNA 
. [C]. O 

SKAT-2 [C]S [C]K [C]A [C]T [C]- [C]2 S-DNA 
is [C]i [C]s O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
restricted [C]r [C]e [C]s [C]t [C]r [C]i [C]c [C]t [C]e [C]d O 
in [C]i [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
RNA [C]R [C]N [C]A O 
level [C]l [C]e [C]v [C]e [C]l O 
, [C], O 
detectable [C]d [C]e [C]t [C]e [C]c [C]t [C]a [C]b [C]l [C]e O 
only [C]o [C]n [C]l [C]y O 
in [C]i [C]n O 
brain [C]b [C]r [C]a [C]i [C]n O 
and [C]a [C]n [C]d O 
at [C]a [C]t O 
low [C]l [C]o [C]w O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
in [C]i [C]n O 
kidney [C]k [C]i [C]d [C]n [C]e [C]y O 
and [C]a [C]n [C]d O 
spleen [C]s [C]p [C]l [C]e [C]e [C]n O 
and [C]a [C]n [C]d O 
few [C]f [C]e [C]w O 
hematopoietic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
. [C]. O 

By [C]B [C]y O 
in [C]i [C]n O 
situ [C]s [C]i [C]t [C]u O 
hybridization [C]h [C]y [C]b [C]r [C]i [C]d [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
SKAT-2 [C]S [C]K [C]A [C]T [C]- [C]2 S-DNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
peak [C]p [C]e [C]a [C]k O 
in [C]i [C]n O 
antigen-stimulated [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
CD4 [C]C [C]D [C]4 B-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
after [C]a [C]f [C]t [C]e [C]r O 
2-3 [C]2 [C]- [C]3 O 
days [C]d [C]a [C]y [C]s O 
of [C]o [C]f O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
under [C]u [C]n [C]d [C]e [C]r O 
Th2 [C]T [C]h [C]2 O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
Th1 [C]T [C]h [C]1 O 
biasing [C]b [C]i [C]a [C]s [C]i [C]n [C]g O 
conditions [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
pattern [C]p [C]a [C]t [C]t [C]e [C]r [C]n O 
of [C]o [C]f O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
closely [C]c [C]l [C]o [C]s [C]e [C]l [C]y O 
mirrored [C]m [C]i [C]r [C]r [C]o [C]r [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
of [C]o [C]f O 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 S-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
. [C]. O 

In [C]I [C]n O 
transient [C]t [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t O 
transfection [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
experiments [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]s O 
in [C]i [C]n O 
phorbol [C]p [C]h [C]o [C]r [C]b [C]o [C]l O 
12-myristate [C]1 [C]2 [C]- [C]m [C]y [C]r [C]i [C]s [C]t [C]a [C]t [C]e O 
13-acetate/ionomycin-stimulated [C]1 [C]3 [C]- [C]a [C]c [C]e [C]t [C]a [C]t [C]e [C]/ [C]i [C]o [C]n [C]o [C]m [C]y [C]c [C]i [C]n [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
EL4 [C]E [C]L [C]4 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
, [C], O 
SKAT-2 [C]S [C]K [C]A [C]T [C]- [C]2 S-DNA 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
up-regulate [C]u [C]p [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IL-4 [C]I [C]L [C]- [C]4 B-DNA 
but [C]b [C]u [C]t I-DNA 
not [C]n [C]o [C]t I-DNA 
the [C]t [C]h [C]e I-DNA 
IL-5 [C]I [C]L [C]- [C]5 I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
, [C], O 
contrasting [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t [C]i [C]n [C]g O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 S-protein 
to [C]t [C]o O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
both [C]b [C]o [C]t [C]h O 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s S-DNA 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
result [C]r [C]e [C]s [C]u [C]l [C]t O 
was [C]w [C]a [C]s O 
confirmed [C]c [C]o [C]n [C]f [C]i [C]r [C]m [C]e [C]d O 
using [C]u [C]s [C]i [C]n [C]g O 
clones [C]c [C]l [C]o [C]n [C]e [C]s O 
of [C]o [C]f O 
EL4 [C]E [C]L [C]4 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
stably [C]s [C]t [C]a [C]b [C]l [C]y O 
expressing [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]n [C]g O 
an [C]a [C]n O 
inducible [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
form [C]f [C]o [C]r [C]m O 
of [C]o [C]f O 
SKAT-2 [C]S [C]K [C]A [C]T [C]- [C]2 S-DNA 
, [C], O 
thus [C]t [C]h [C]u [C]s O 
SKAT-2 [C]S [C]K [C]A [C]T [C]- [C]2 S-DNA 
is [C]i [C]s O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
Th2-specific [C]T [C]h [C]2 [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
that [C]t [C]h [C]a [C]t O 
may [C]m [C]a [C]y O 
play [C]p [C]l [C]a [C]y O 
a [C]a O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
selective [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

hsp70 [C]h [C]s [C]p [C]7 [C]0 B-protein 
interacting [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
Hip [C]H [C]i [C]p E-protein 
does [C]d [C]o [C]e [C]s O 
not [C]n [C]o [C]t O 
affect [C]a [C]f [C]f [C]e [C]c [C]t O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
folding [C]f [C]o [C]l [C]d [C]i [C]n [C]g O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
hsp90-based [C]h [C]s [C]p [C]9 [C]0 [C]- [C]b [C]a [C]s [C]e [C]d O 
chaperone [C]c [C]h [C]a [C]p [C]e [C]r [C]o [C]n [C]e O 
machinery [C]m [C]a [C]c [C]h [C]i [C]n [C]e [C]r [C]y O 
except [C]e [C]x [C]c [C]e [C]p [C]t O 
to [C]t [C]o O 
oppose [C]o [C]p [C]p [C]o [C]s [C]e O 
the [C]t [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
BAG-1 [C]B [C]A [C]G [C]- [C]1 S-protein 
. [C]. O 

Reticulocyte [C]R [C]e [C]t [C]i [C]c [C]u [C]l [C]o [C]c [C]y [C]t [C]e O 
lysate [C]l [C]y [C]s [C]a [C]t [C]e O 
contains [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]s O 
a [C]a O 
chaperone [C]c [C]h [C]a [C]p [C]e [C]r [C]o [C]n [C]e O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
that [C]t [C]h [C]a [C]t O 
assembles [C]a [C]s [C]s [C]e [C]m [C]b [C]l [C]e [C]s O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
( [C]( I-protein 
GR [C]G [C]R I-protein 
) [C]) I-protein 
.hsp90 [C]. [C]h [C]s [C]p [C]9 [C]0 I-protein 
heterocomplexes [C]h [C]e [C]t [C]e [C]r [C]o [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
. [C]. O 

Using [C]U [C]s [C]i [C]n [C]g O 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
, [C], O 
we [C]w [C]e O 
have [C]h [C]a [C]v [C]e O 
prepared [C]p [C]r [C]e [C]p [C]a [C]r [C]e [C]d O 
a [C]a O 
five-protein [C]f [C]i [C]v [C]e [C]- [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
heterocomplex [C]h [C]e [C]t [C]e [C]r [C]o [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
assembly [C]a [C]s [C]s [C]e [C]m [C]b [C]l [C]y O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
consisting [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]i [C]n [C]g O 
of [C]o [C]f O 
two [C]t [C]w [C]o O 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
for [C]f [C]o [C]r O 
heterocomplex [C]h [C]e [C]t [C]e [C]r [C]o [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
assembly- [C]a [C]s [C]s [C]e [C]m [C]b [C]l [C]y [C]- O 
hsp90 [C]h [C]s [C]p [C]9 [C]0 S-protein 
and [C]a [C]n [C]d O 
hsp70 [C]h [C]s [C]p [C]7 [C]0 S-protein 
-and [C]- [C]a [C]n [C]d O 
three [C]t [C]h [C]r [C]e [C]e O 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s O 
that [C]t [C]h [C]a [C]t O 
act [C]a [C]c [C]t O 
as [C]a [C]s O 
co-chaperones [C]c [C]o [C]- [C]c [C]h [C]a [C]p [C]e [C]r [C]o [C]n [C]e [C]s O 
to [C]t [C]o O 
enhance [C]e [C]n [C]h [C]a [C]n [C]c [C]e O 
assembly- [C]a [C]s [C]s [C]e [C]m [C]b [C]l [C]y [C]- O 
Hop [C]H [C]o [C]p S-protein 
, [C], O 
hsp40 [C]h [C]s [C]p [C]4 [C]0 S-protein 
, [C], O 
p23 [C]p [C]2 [C]3 S-protein 
[ [C][ O 
Morishima [C]M [C]o [C]r [C]i [C]s [C]h [C]i [C]m [C]a O 
, [C], O 
Y. [C]Y [C]. O 
, [C], O 
Kanelakis [C]K [C]a [C]n [C]e [C]l [C]a [C]k [C]i [C]s O 
, [C], O 
K. [C]K [C]. O 
C. [C]C [C]. O 
, [C], O 
Silverstein [C]S [C]i [C]l [C]v [C]e [C]r [C]s [C]t [C]e [C]i [C]n O 
, [C], O 
A. [C]A [C]. O 
M. [C]M [C]. O 
, [C], O 
Dittmar [C]D [C]i [C]t [C]t [C]m [C]a [C]r O 
, [C], O 
K. [C]K [C]. O 
D. [C]D [C]. O 
, [C], O 
Estrada [C]E [C]s [C]t [C]r [C]a [C]d [C]a O 
, [C], O 
L. [C]L [C]. O 
, [C], O 
and [C]a [C]n [C]d O 
Pratt [C]P [C]r [C]a [C]t [C]t O 
, [C], O 
W. [C]W [C]. O 
B. [C]B [C]. O 
( [C]( O 
2000 [C]2 [C]0 [C]0 [C]0 O 
) [C]) O 
J. [C]J [C]. O 
Biol. [C]B [C]i [C]o [C]l [C]. O 
Chem. [C]C [C]h [C]e [C]m [C]. O 
275 [C]2 [C]7 [C]5 O 
, [C], O 
6894-6900 [C]6 [C]8 [C]9 [C]4 [C]- [C]6 [C]9 [C]0 [C]0 O 
] [C]] O 
. [C]. O 

The [C]T [C]h [C]e O 
hsp70 [C]h [C]s [C]p [C]7 [C]0 B-protein 
co-chaperone [C]c [C]o [C]- [C]c [C]h [C]a [C]p [C]e [C]r [C]o [C]n [C]e I-protein 
Hip [C]H [C]i [C]p E-protein 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
recovered [C]r [C]e [C]c [C]o [C]v [C]e [C]r [C]e [C]d O 
in [C]i [C]n O 
receptor.hsp90 [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]. [C]h [C]s [C]p [C]9 [C]0 B-protein 
heterocomplexes [C]h [C]e [C]t [C]e [C]r [C]o [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
at [C]a [C]t O 
an [C]a [C]n O 
intermediate [C]i [C]n [C]t [C]e [C]r [C]m [C]e [C]d [C]i [C]a [C]t [C]e O 
stage [C]s [C]t [C]a [C]g [C]e O 
of [C]o [C]f O 
assembly [C]a [C]s [C]s [C]e [C]m [C]b [C]l [C]y O 
in [C]i [C]n O 
reticulocyte [C]r [C]e [C]t [C]i [C]c [C]u [C]l [C]o [C]c [C]y [C]t [C]e O 
lysate [C]l [C]y [C]s [C]a [C]t [C]e O 
, [C], O 
and [C]a [C]n [C]d O 
Hip [C]H [C]i [C]p S-protein 
is [C]i [C]s O 
also [C]a [C]l [C]s [C]o O 
thought [C]t [C]h [C]o [C]u [C]g [C]h [C]t O 
to [C]t [C]o O 
be [C]b [C]e O 
an [C]a [C]n O 
intrinsic [C]i [C]n [C]t [C]r [C]i [C]n [C]s [C]i [C]c O 
component [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
assembly [C]a [C]s [C]s [C]e [C]m [C]b [C]l [C]y O 
machinery [C]m [C]a [C]c [C]h [C]i [C]n [C]e [C]r [C]y O 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
we [C]w [C]e O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
immunodepletion [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]p [C]l [C]e [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Hip [C]H [C]i [C]p S-protein 
from [C]f [C]r [C]o [C]m O 
reticulocyte [C]r [C]e [C]t [C]i [C]c [C]u [C]l [C]o [C]c [C]y [C]t [C]e O 
lysate [C]l [C]y [C]s [C]a [C]t [C]e O 
or [C]o [C]r O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
high [C]h [C]i [C]g [C]h O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
Hip [C]H [C]i [C]p S-protein 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d O 
five-protein [C]f [C]i [C]v [C]e [C]- [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
does [C]d [C]o [C]e [C]s O 
not [C]n [C]o [C]t O 
affect [C]a [C]f [C]f [C]e [C]c [C]t O 
GR.hsp90 [C]G [C]R [C]. [C]h [C]s [C]p [C]9 [C]0 O 
heterocomplex [C]h [C]e [C]t [C]e [C]r [C]o [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
assembly [C]a [C]s [C]s [C]e [C]m [C]b [C]l [C]y O 
or [C]o [C]r O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
that [C]t [C]h [C]a [C]t O 
occurs [C]o [C]c [C]c [C]u [C]r [C]s O 
with [C]w [C]i [C]t [C]h O 
assembly [C]a [C]s [C]s [C]e [C]m [C]b [C]l [C]y O 
. [C]. O 

Despite [C]D [C]e [C]s [C]p [C]i [C]t [C]e O 
the [C]t [C]h [C]e O 
fact [C]f [C]a [C]c [C]t O 
that [C]t [C]h [C]a [C]t O 
Hip [C]H [C]i [C]p S-protein 
does [C]d [C]o [C]e [C]s O 
not [C]n [C]o [C]t O 
affect [C]a [C]f [C]f [C]e [C]c [C]t O 
assembly [C]a [C]s [C]s [C]e [C]m [C]b [C]l [C]y O 
, [C], O 
it [C]i [C]t O 
is [C]i [C]s O 
recovered [C]r [C]e [C]c [C]o [C]v [C]e [C]r [C]e [C]d O 
in [C]i [C]n O 
GR.hsp90 [C]G [C]R [C]. [C]h [C]s [C]p [C]9 [C]0 B-protein 
heterocomplexes [C]h [C]e [C]t [C]e [C]r [C]o [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
assembled [C]a [C]s [C]s [C]e [C]m [C]b [C]l [C]e [C]d O 
by [C]b [C]y O 
both [C]b [C]o [C]t [C]h O 
systems [C]s [C]y [C]s [C]t [C]e [C]m [C]s O 
. [C]. O 

In [C]I [C]n O 
the [C]t [C]h [C]e O 
five-protein [C]f [C]i [C]v [C]e [C]- [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
, [C], O 
Hip [C]H [C]i [C]p S-protein 
prevents [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]s O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
assembly [C]a [C]s [C]s [C]e [C]m [C]b [C]l [C]y O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
hsp70 [C]h [C]s [C]p [C]7 [C]0 B-protein 
co-chaperone [C]c [C]o [C]- [C]c [C]h [C]a [C]p [C]e [C]r [C]o [C]n [C]e I-protein 
BAG-1 [C]B [C]A [C]G [C]- [C]1 E-protein 
, [C], O 
and [C]a [C]n [C]d O 
cotransfection [C]c [C]o [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Hip [C]H [C]i [C]p S-protein 
with [C]w [C]i [C]t [C]h O 
BAG-1 [C]B [C]A [C]G [C]- [C]1 S-protein 
opposes [C]o [C]p [C]p [C]o [C]s [C]e [C]s O 
BAG-1 [C]B [C]A [C]G [C]- [C]1 S-protein 
reduction [C]r [C]e [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
COS [C]C [C]O [C]S B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

We [C]W [C]e O 
conclude [C]c [C]o [C]n [C]c [C]l [C]u [C]d [C]e O 
that [C]t [C]h [C]a [C]t O 
Hip [C]H [C]i [C]p S-protein 
is [C]i [C]s O 
not [C]n [C]o [C]t O 
a [C]a O 
component [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
assembly [C]a [C]s [C]s [C]e [C]m [C]b [C]l [C]y O 
machinery [C]m [C]a [C]c [C]h [C]i [C]n [C]e [C]r [C]y O 
but [C]b [C]u [C]t O 
that [C]t [C]h [C]a [C]t O 
it [C]i [C]t O 
could [C]c [C]o [C]u [C]l [C]d O 
play [C]p [C]l [C]a [C]y O 
a [C]a O 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
opposition [C]o [C]p [C]p [C]o [C]s [C]i [C]t [C]i [C]o [C]n O 
to [C]t [C]o O 
BAG-1 [C]B [C]A [C]G [C]- [C]1 S-protein 
. [C]. O 

Cutting [C]C [C]u [C]t [C]t [C]i [C]n [C]g O 
edge [C]e [C]d [C]g [C]e O 
: [C]: O 
STAT6-deficient [C]S [C]T [C]A [C]T [C]6 [C]- [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
mice [C]m [C]i [C]c [C]e O 
have [C]h [C]a [C]v [C]e O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
tumor [C]t [C]u [C]m [C]o [C]r O 
immunity [C]i [C]m [C]m [C]u [C]n [C]i [C]t [C]y O 
to [C]t [C]o O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y O 
and [C]a [C]n [C]d O 
metastatic [C]m [C]e [C]t [C]a [C]s [C]t [C]a [C]t [C]i [C]c O 
mammary [C]m [C]a [C]m [C]m [C]a [C]r [C]y O 
carcinoma [C]c [C]a [C]r [C]c [C]i [C]n [C]o [C]m [C]a O 
. [C]. O 

STAT4 [C]S [C]T [C]A [C]T [C]4 S-protein 
and [C]a [C]n [C]d O 
STAT6 [C]S [C]T [C]A [C]T [C]6 S-protein 
are [C]a [C]r [C]e O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
CD4 [C]C [C]D [C]4 O 
( [C]( O 
+ [C]+ O 
) [C]) O 
Th1 [C]T [C]h [C]1 O 
and [C]a [C]n [C]d O 
Th2 [C]T [C]h [C]2 O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
, [C], O 
respectively [C]r [C]e [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
. [C]. O 

Tumor [C]T [C]u [C]m [C]o [C]r O 
immunologists [C]i [C]m [C]m [C]u [C]n [C]o [C]l [C]o [C]g [C]i [C]s [C]t [C]s O 
have [C]h [C]a [C]v [C]e O 
hypothesized [C]h [C]y [C]p [C]o [C]t [C]h [C]e [C]s [C]i [C]z [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
Th1 [C]T [C]h [C]1 B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
are [C]a [C]r [C]e O 
critical [C]c [C]r [C]i [C]t [C]i [C]c [C]a [C]l O 
in [C]i [C]n O 
tumor [C]t [C]u [C]m [C]o [C]r O 
immunity [C]i [C]m [C]m [C]u [C]n [C]i [C]t [C]y O 
because [C]b [C]e [C]c [C]a [C]u [C]s [C]e O 
they [C]t [C]h [C]e [C]y O 
facilitate [C]f [C]a [C]c [C]i [C]l [C]i [C]t [C]a [C]t [C]e O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
CD8 [C]C [C]D [C]8 B-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
are [C]a [C]r [C]e O 
potent [C]p [C]o [C]t [C]e [C]n [C]t O 
anti-tumor [C]a [C]n [C]t [C]i [C]- [C]t [C]u [C]m [C]o [C]r B-cell_type 
effectors [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r [C]s E-cell_type 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
used [C]u [C]s [C]e [C]d O 
STAT4 [C]S [C]T [C]A [C]T [C]4 O 
( [C]( O 
-/- [C]- [C]/ [C]- O 
) [C]) O 
and [C]a [C]n [C]d O 
STAT6 [C]S [C]T [C]A [C]T [C]6 O 
( [C]( O 
-/- [C]- [C]/ [C]- O 
) [C]) O 
mice [C]m [C]i [C]c [C]e O 
to [C]t [C]o O 
test [C]t [C]e [C]s [C]t O 
this [C]t [C]h [C]i [C]s O 
hypothesis [C]h [C]y [C]p [C]o [C]t [C]h [C]e [C]s [C]i [C]s O 
. [C]. O 

BALB/c [C]B [C]A [C]L [C]B [C]/ [C]c O 
and [C]a [C]n [C]d O 
knockout [C]k [C]n [C]o [C]c [C]k [C]o [C]u [C]t O 
mice [C]m [C]i [C]c [C]e O 
were [C]w [C]e [C]r [C]e O 
challenged [C]c [C]h [C]a [C]l [C]l [C]e [C]n [C]g [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
mammary [C]m [C]a [C]m [C]m [C]a [C]r [C]y O 
gland [C]g [C]l [C]a [C]n [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
highly [C]h [C]i [C]g [C]h [C]l [C]y O 
malignant [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]t O 
and [C]a [C]n [C]d O 
spontaneously [C]s [C]p [C]o [C]n [C]t [C]a [C]n [C]e [C]o [C]u [C]s [C]l [C]y O 
metastatic [C]m [C]e [C]t [C]a [C]s [C]t [C]a [C]t [C]i [C]c O 
BALB/c-derived [C]B [C]A [C]L [C]B [C]/ [C]c [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
4T1 [C]4 [C]T [C]1 O 
mammary [C]m [C]a [C]m [C]m [C]a [C]r [C]y O 
carcinoma [C]c [C]a [C]r [C]c [C]i [C]n [C]o [C]m [C]a O 
. [C]. O 

Primary [C]P [C]r [C]i [C]m [C]a [C]r [C]y O 
tumor [C]t [C]u [C]m [C]o [C]r O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
and [C]a [C]n [C]d O 
metastatic [C]m [C]e [C]t [C]a [C]s [C]t [C]a [C]t [C]i [C]c O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
are [C]a [C]r [C]e O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
in [C]i [C]n O 
STAT6 [C]S [C]T [C]A [C]T [C]6 O 
( [C]( O 
-/- [C]- [C]/ [C]- O 
) [C]) O 
mice [C]m [C]i [C]c [C]e O 
relative [C]r [C]e [C]l [C]a [C]t [C]i [C]v [C]e O 
to [C]t [C]o O 
BALB/c [C]B [C]A [C]L [C]B [C]/ [C]c O 
and [C]a [C]n [C]d O 
STAT4 [C]S [C]T [C]A [C]T [C]4 O 
( [C]( O 
-/- [C]- [C]/ [C]- O 
) [C]) O 
mice [C]m [C]i [C]c [C]e O 
. [C]. O 

Ab [C]A [C]b O 
depletions [C]d [C]e [C]p [C]l [C]e [C]t [C]i [C]o [C]n [C]s O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
is [C]i [C]s O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
CD8 [C]C [C]D [C]8 B-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
and [C]a [C]n [C]d O 
immunized [C]i [C]m [C]m [C]u [C]n [C]i [C]z [C]e [C]d O 
STAT6 [C]S [C]T [C]A [C]T [C]6 O 
( [C]( O 
-/- [C]- [C]/ [C]- O 
) [C]) O 
mice [C]m [C]i [C]c [C]e O 
have [C]h [C]a [C]v [C]e O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
4T1-specific [C]4 [C]T [C]1 [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-cell_type 
CTL [C]C [C]T [C]L E-cell_type 
than [C]t [C]h [C]a [C]n O 
BALB/c [C]B [C]A [C]L [C]B [C]/ [C]c O 
or [C]o [C]r O 
STAT4 [C]S [C]T [C]A [C]T [C]4 O 
( [C]( O 
-/- [C]- [C]/ [C]- O 
) [C]) O 
mice [C]m [C]i [C]c [C]e O 
. [C]. O 

Surprisingly [C]S [C]u [C]r [C]p [C]r [C]i [C]s [C]i [C]n [C]g [C]l [C]y O 
, [C], O 
Th1 [C]T [C]h [C]1 B-cell_type 
or [C]o [C]r I-cell_type 
Th2 [C]T [C]h [C]2 I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
are [C]a [C]r [C]e O 
not [C]n [C]o [C]t O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
, [C], O 
because [C]b [C]e [C]c [C]a [C]u [C]s [C]e O 
CD4 [C]C [C]D [C]4 O 
depletion [C]d [C]e [C]p [C]l [C]e [C]t [C]i [C]o [C]n O 
does [C]d [C]o [C]e [C]s O 
not [C]n [C]o [C]t O 
diminish [C]d [C]i [C]m [C]i [C]n [C]i [C]s [C]h O 
the [C]t [C]h [C]e O 
anti-tumor [C]a [C]n [C]t [C]i [C]- [C]t [C]u [C]m [C]o [C]r O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
. [C]. O 

Therefore [C]T [C]h [C]e [C]r [C]e [C]f [C]o [C]r [C]e O 
, [C], O 
deletion [C]d [C]e [C]l [C]e [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
STAT6 [C]S [C]T [C]A [C]T [C]6 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
facilitates [C]f [C]a [C]c [C]i [C]l [C]i [C]t [C]a [C]t [C]e [C]s O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
potent [C]p [C]o [C]t [C]e [C]n [C]t O 
anti-tumor [C]a [C]n [C]t [C]i [C]- [C]t [C]u [C]m [C]o [C]r O 
immunity [C]i [C]m [C]m [C]u [C]n [C]i [C]t [C]y O 
via [C]v [C]i [C]a O 
a [C]a O 
CD4 [C]C [C]D [C]4 O 
( [C]( O 
+ [C]+ O 
) [C]) O 
-independent [C]- [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
. [C]. O 

Activation [C]A [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
oncogenic [C]o [C]n [C]c [C]o [C]g [C]e [C]n [C]i [C]c B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
AP-1 [C]A [C]P [C]- [C]1 E-protein 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
infected [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
human [C]h [C]u [C]m [C]a [C]n O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
virus [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
1 [C]1 O 
. [C]. O 

Human [C]H [C]u [C]m [C]a [C]n O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
virus [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
1 [C]1 O 
( [C]( O 
HTLV-1 [C]H [C]T [C]L [C]V [C]- [C]1 O 
) [C]) O 
Tax [C]T [C]a [C]x B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
transforms [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]s O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
. [C]. O 

We [C]W [C]e O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
Tax [C]T [C]a [C]x S-protein 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
family [C]f [C]a [C]m [C]i [C]l [C]y O 
members [C]m [C]e [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
AP-1 [C]A [C]P [C]- [C]1 E-protein 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
c-Jun [C]c [C]- [C]J [C]u [C]n S-protein 
, [C], O 
JunD [C]J [C]u [C]n [C]D S-protein 
, [C], O 
c-Fos [C]c [C]- [C]F [C]o [C]s S-protein 
, [C], O 
and [C]a [C]n [C]d O 
Fra-1 [C]F [C]r [C]a [C]- [C]1 S-protein 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
mRNA [C]m [C]R [C]N [C]A O 
level [C]l [C]e [C]v [C]e [C]l O 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
, [C], O 
we [C]w [C]e O 
have [C]h [C]a [C]v [C]e O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
the [C]t [C]h [C]e O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
Tax [C]T [C]a [C]x S-protein 
to [C]t [C]o O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
AP-1-binding [C]A [C]P [C]- [C]1 [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
( [C]( O 
AP-1 [C]A [C]P [C]- [C]1 B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
) [C]) O 
. [C]. O 

A [C]A O 
transient [C]t [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t O 
transfection [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
study [C]s [C]t [C]u [C]d [C]y O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
Tax [C]T [C]a [C]x S-protein 
can [C]c [C]a [C]n O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
AP-1-binding [C]A [C]P [C]- [C]1 [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
in [C]i [C]n O 
a [C]a O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
T [C]T I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
any [C]a [C]n [C]y O 
combination [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
AP-1 [C]A [C]P [C]- [C]1 B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
did [C]d [C]i [C]d O 
so [C]s [C]o O 
much [C]m [C]u [C]c [C]h O 
less [C]l [C]e [C]s [C]s O 
than [C]t [C]h [C]a [C]n O 
Tax [C]T [C]a [C]x S-protein 
, [C], O 
indicating [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
AP-1 [C]A [C]P [C]- [C]1 B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
by [C]b [C]y O 
Tax [C]T [C]a [C]x S-protein 
may [C]m [C]a [C]y O 
require [C]r [C]e [C]q [C]u [C]i [C]r [C]e O 
a [C]a O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
other [C]o [C]t [C]h [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
the [C]t [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
AP-1 [C]A [C]P [C]- [C]1 B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
. [C]. O 

Fresh [C]F [C]r [C]e [C]s [C]h B-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
of [C]o [C]f O 
all [C]a [C]l [C]l O 
surveyed [C]s [C]u [C]r [C]v [C]e [C]y [C]e [C]d O 
ATL [C]A [C]T [C]L O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
displayed [C]d [C]i [C]s [C]p [C]l [C]a [C]y [C]e [C]d O 
constitutive [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
AP-1 [C]A [C]P [C]- [C]1 O 
DNA-binding [C]D [C]N [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
no [C]n [C]o O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
individuals [C]i [C]n [C]d [C]i [C]v [C]i [C]d [C]u [C]a [C]l [C]s O 
did [C]d [C]i [C]d O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
the [C]t [C]h [C]e O 
HTLV-1 [C]H [C]T [C]L [C]V [C]- [C]1 B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
tax [C]t [C]a [C]x S-DNA 
, [C], O 
are [C]a [C]r [C]e O 
not [C]n [C]o [C]t O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
fresh [C]f [C]r [C]e [C]s [C]h O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
ATL [C]A [C]T [C]L O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

Our [C]O [C]u [C]r O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
occurs [C]o [C]c [C]c [C]u [C]r [C]s O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
Tax-dependent [C]T [C]a [C]x [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
-independent [C]- [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
in [C]i [C]n O 
HTLV-1-infected [C]H [C]T [C]L [C]V [C]- [C]1 [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
may [C]m [C]a [C]y O 
play [C]p [C]l [C]a [C]y O 
some [C]s [C]o [C]m [C]e O 
roles [C]r [C]o [C]l [C]e [C]s O 
in [C]i [C]n O 
dysregulated [C]d [C]y [C]s [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
phenotypes [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e [C]s O 
of [C]o [C]f O 
HTLV-1-infected [C]H [C]T [C]L [C]V [C]- [C]1 [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

2 [C]2 O 
, [C], O 
2 [C]2 O 
' [C]' O 
, [C], O 
4 [C]4 O 
, [C], O 
6 [C]6 O 
, [C], O 
6'-pentachlorobiphenyl [C]6 [C]' [C]- [C]p [C]e [C]n [C]t [C]a [C]c [C]h [C]l [C]o [C]r [C]o [C]b [C]i [C]p [C]h [C]e [C]n [C]y [C]l O 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
monocytic [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]i [C]c I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Polychlorinatedbiphenyls [C]P [C]o [C]l [C]y [C]c [C]h [C]l [C]o [C]r [C]i [C]n [C]a [C]t [C]e [C]d [C]b [C]i [C]p [C]h [C]e [C]n [C]y [C]l [C]s O 
( [C]( O 
PCBs [C]P [C]C [C]B [C]s O 
) [C]) O 
are [C]a [C]r [C]e O 
a [C]a O 
group [C]g [C]r [C]o [C]u [C]p O 
of [C]o [C]f O 
persistent [C]p [C]e [C]r [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
widely [C]w [C]i [C]d [C]e [C]l [C]y O 
dispersed [C]d [C]i [C]s [C]p [C]e [C]r [C]s [C]e [C]d O 
environmental [C]e [C]n [C]v [C]i [C]r [C]o [C]n [C]m [C]e [C]n [C]t [C]a [C]l O 
pollutants [C]p [C]o [C]l [C]l [C]u [C]t [C]a [C]n [C]t [C]s O 
, [C], O 
some [C]s [C]o [C]m [C]e O 
of [C]o [C]f O 
which [C]w [C]h [C]i [C]c [C]h O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
immunotoxic [C]i [C]m [C]m [C]u [C]n [C]o [C]t [C]o [C]x [C]i [C]c O 
. [C]. O 

In [C]I [C]n O 
the [C]t [C]h [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
study [C]s [C]t [C]u [C]d [C]y O 
, [C], O 
we [C]w [C]e O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
PCBs [C]P [C]C [C]B [C]s O 
on [C]o [C]n O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
by [C]b [C]y O 
assessing [C]a [C]s [C]s [C]e [C]s [C]s [C]i [C]n [C]g O 
apoptotic [C]a [C]p [C]o [C]p [C]t [C]o [C]t [C]i [C]c O 
cell [C]c [C]e [C]l [C]l O 
death [C]d [C]e [C]a [C]t [C]h O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
monocytic [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]i [C]c I-cell_line 
U937 [C]U [C]9 [C]3 [C]7 I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

Among [C]A [C]m [C]o [C]n [C]g O 
the [C]t [C]h [C]e O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
congeners [C]c [C]o [C]n [C]g [C]e [C]n [C]e [C]r [C]s O 
tested [C]t [C]e [C]s [C]t [C]e [C]d O 
, [C], O 
2 [C]2 O 
, [C], O 
2 [C]2 O 
' [C]' O 
, [C], O 
4 [C]4 O 
, [C], O 
6 [C]6 O 
, [C], O 
6'-pentachlorobiphenyl [C]6 [C]' [C]- [C]p [C]e [C]n [C]t [C]a [C]c [C]h [C]l [C]o [C]r [C]o [C]b [C]i [C]p [C]h [C]e [C]n [C]y [C]l O 
( [C]( O 
PeCB [C]P [C]e [C]C [C]B O 
) [C]) O 
, [C], O 
a [C]a O 
highly [C]h [C]i [C]g [C]h [C]l [C]y O 
ortho-substituted [C]o [C]r [C]t [C]h [C]o [C]- [C]s [C]u [C]b [C]s [C]t [C]i [C]t [C]u [C]t [C]e [C]d O 
congener [C]c [C]o [C]n [C]g [C]e [C]n [C]e [C]r O 
, [C], O 
specifically [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]a [C]l [C]l [C]y O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
DNA [C]D [C]N [C]A O 
fragmentation [C]f [C]r [C]a [C]g [C]m [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
a [C]a O 
hallmark [C]h [C]a [C]l [C]l [C]m [C]a [C]r [C]k O 
of [C]o [C]f O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
, [C], O 
while [C]w [C]h [C]i [C]l [C]e O 
the [C]t [C]h [C]e O 
other [C]o [C]t [C]h [C]e [C]r O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
di- [C]d [C]i [C]- O 
, [C], O 
tri- [C]t [C]r [C]i [C]- O 
, [C], O 
tetra- [C]t [C]e [C]t [C]r [C]a [C]- O 
, [C], O 
and [C]a [C]n [C]d O 
pentachlorobiphenyls [C]p [C]e [C]n [C]t [C]a [C]c [C]h [C]l [C]o [C]r [C]o [C]b [C]i [C]p [C]h [C]e [C]n [C]y [C]l [C]s O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
. [C]. O 

To [C]T [C]o O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
study [C]s [C]t [C]u [C]d [C]y O 
the [C]t [C]h [C]e O 
2 [C]2 O 
, [C], O 
2 [C]2 O 
' [C]' O 
, [C], O 
4 [C]4 O 
, [C], O 
6 [C]6 O 
, [C], O 
6'-PeCB-induced [C]6 [C]' [C]- [C]P [C]e [C]C [C]B [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
cell [C]c [C]e [C]l [C]l O 
death [C]d [C]e [C]a [C]t [C]h O 
, [C], O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
features [C]f [C]e [C]a [C]t [C]u [C]r [C]e [C]s O 
of [C]o [C]f O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
were [C]w [C]e [C]r [C]e O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
. [C]. O 

2 [C]2 O 
, [C], O 
2 [C]2 O 
' [C]' O 
, [C], O 
4 [C]4 O 
, [C], O 
6 [C]6 O 
, [C], O 
6'-PeCB [C]6 [C]' [C]- [C]P [C]e [C]C [C]B O 
caused [C]c [C]a [C]u [C]s [C]e [C]d O 
a [C]a O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
cell [C]c [C]e [C]l [C]l O 
viability [C]v [C]i [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
morphologic [C]m [C]o [C]r [C]p [C]h [C]o [C]l [C]o [C]g [C]i [C]c O 
features [C]f [C]e [C]a [C]t [C]u [C]r [C]e [C]s O 
characteristic [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]s [C]t [C]i [C]c O 
of [C]o [C]f O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
chromatin [C]c [C]h [C]r [C]o [C]m [C]a [C]t [C]i [C]n O 
aggregation [C]a [C]g [C]g [C]r [C]e [C]g [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
apoptotic [C]a [C]p [C]o [C]p [C]t [C]o [C]t [C]i [C]c O 
bodies [C]b [C]o [C]d [C]i [C]e [C]s O 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
caspase-3 [C]c [C]a [C]s [C]p [C]a [C]s [C]e [C]- [C]3 S-protein 
, [C], O 
an [C]a [C]n O 
executioner [C]e [C]x [C]e [C]c [C]u [C]t [C]i [C]o [C]n [C]e [C]r O 
of [C]o [C]f O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
, [C], O 
was [C]w [C]a [C]s O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
and [C]a [C]n [C]d O 
its [C]i [C]t [C]s O 
substrate [C]s [C]u [C]b [C]s [C]t [C]r [C]a [C]t [C]e O 
, [C], O 
poly [C]p [C]o [C]l [C]y B-protein 
( [C]( I-protein 
ADP-ribose [C]A [C]D [C]P [C]- [C]r [C]i [C]b [C]o [C]s [C]e I-protein 
) [C]) I-protein 
polymerase [C]p [C]o [C]l [C]y [C]m [C]e [C]r [C]a [C]s [C]e E-protein 
( [C]( O 
PARP [C]P [C]A [C]R [C]P S-protein 
) [C]) O 
, [C], O 
was [C]w [C]a [C]s O 
cleaved [C]c [C]l [C]e [C]a [C]v [C]e [C]d O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
2 [C]2 O 
, [C], O 
2 [C]2 O 
' [C]' O 
, [C], O 
4 [C]4 O 
, [C], O 
6 [C]6 O 
, [C], O 
6'-PeCB-induced [C]6 [C]' [C]- [C]P [C]e [C]C [C]B [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
3 [C]3 O 
, [C], O 
3 [C]3 O 
' [C]' O 
, [C], O 
4 [C]4 O 
, [C], O 
4 [C]4 O 
' [C]' O 
, [C], O 
5-PeCB [C]5 [C]- [C]P [C]e [C]C [C]B O 
, [C], O 
a [C]a O 
congener [C]c [C]o [C]n [C]g [C]e [C]n [C]e [C]r O 
of [C]o [C]f O 
coplanar [C]c [C]o [C]p [C]l [C]a [C]n [C]a [C]r O 
structure [C]s [C]t [C]r [C]u [C]c [C]t [C]u [C]r [C]e O 
, [C], O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
2 [C]2 O 
, [C], O 
3 [C]3 O 
, [C], O 
7 [C]7 O 
, [C], O 
8-TCDD [C]8 [C]- [C]T [C]C [C]D [C]D O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
monocytic [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]i [C]c I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
although [C]a [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
they [C]t [C]h [C]e [C]y O 
potently [C]p [C]o [C]t [C]e [C]n [C]t [C]l [C]y O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
CYP [C]C [C]Y [C]P B-protein 
1A1 [C]1 [C]A [C]1 E-protein 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
hepatoma [C]h [C]e [C]p [C]a [C]t [C]o [C]m [C]a I-cell_line 
Hep [C]H [C]e [C]p I-cell_line 
G2 [C]G [C]2 I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

Taken [C]T [C]a [C]k [C]e [C]n O 
together [C]t [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
, [C], O 
the [C]t [C]h [C]e O 
data [C]d [C]a [C]t [C]a O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
2 [C]2 O 
, [C], O 
2 [C]2 O 
' [C]' O 
, [C], O 
4 [C]4 O 
, [C], O 
6 [C]6 O 
, [C], O 
6'-PeCB [C]6 [C]' [C]- [C]P [C]e [C]C [C]B O 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
monocytic [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]i [C]c I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
a [C]a O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
arylhydrocarbon [C]a [C]r [C]y [C]l [C]h [C]y [C]d [C]r [C]o [C]c [C]a [C]r [C]b [C]o [C]n B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
suggests [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]s O 
a [C]a O 
possibly [C]p [C]o [C]s [C]s [C]i [C]b [C]l [C]y O 
separate [C]s [C]e [C]p [C]a [C]r [C]a [C]t [C]e O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
by [C]b [C]y O 
which [C]w [C]h [C]i [C]c [C]h O 
PCBs [C]P [C]C [C]B [C]s O 
cause [C]c [C]a [C]u [C]s [C]e O 
immunosuppression [C]i [C]m [C]m [C]u [C]n [C]o [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Effects [C]E [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
deregulated [C]d [C]e [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
Raf [C]R [C]a [C]f O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
on [C]o [C]n O 
integrin [C]i [C]n [C]t [C]e [C]g [C]r [C]i [C]n S-protein 
, [C], O 
cytokine-receptor [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
hematopoietic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
deregulated [C]d [C]e [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
Raf [C]R [C]a [C]f O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
and [C]a [C]n [C]d O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
hematopoietic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
. [C]. O 

The [C]T [C]h [C]e O 
cytokine-dependent [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t B-cell_line 
murine [C]m [C]u [C]r [C]i [C]n [C]e I-cell_line 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d I-cell_line 
FDC-P1 [C]F [C]D [C]C [C]- [C]P [C]1 E-cell_line 
and [C]a [C]n [C]d O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
erythroleukemic [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c I-cell_line 
TF-1 [C]T [C]F [C]- [C]1 I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
were [C]w [C]e [C]r [C]e O 
transformed [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]e [C]d O 
to [C]t [C]o O 
grow [C]g [C]r [C]o [C]w O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
deregulated [C]d [C]e [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
Raf [C]R [C]a [C]f O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
exogenous [C]e [C]x [C]o [C]g [C]e [C]n [C]o [C]u [C]s B-protein 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
conditionally [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n [C]a [C]l [C]l [C]y O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
Raf [C]R [C]a [C]f B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
were [C]w [C]e [C]r [C]e O 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
beta-estradiol [C]b [C]e [C]t [C]a [C]- [C]e [C]s [C]t [C]r [C]a [C]d [C]i [C]o [C]l O 
as [C]a [C]s O 
cDNAs [C]c [C]D [C]N [C]A [C]s S-DNA 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
Raf [C]R [C]a [C]f B-protein 
catalytic [C]c [C]a [C]t [C]a [C]l [C]y [C]t [C]i [C]c E-protein 
, [C], O 
but [C]b [C]u [C]t O 
lacking [C]l [C]a [C]c [C]k [C]i [C]n [C]g O 
negative-regulatory [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y B-protein 
domains [C]d [C]o [C]m [C]a [C]i [C]n [C]s E-protein 
, [C], O 
were [C]w [C]e [C]r [C]e O 
ligated [C]l [C]i [C]g [C]a [C]t [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e B-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
( [C]( O 
deltaRaf [C]d [C]e [C]l [C]t [C]a [C]R [C]a [C]f B-protein 
: [C]: I-protein 
ER [C]E [C]R E-protein 
) [C]) O 
. [C]. O 

Continuous [C]C [C]o [C]n [C]t [C]i [C]n [C]u [C]o [C]u [C]s O 
deltaRaf [C]d [C]e [C]l [C]t [C]a [C]R [C]a [C]f S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
prevented [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]e [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
exogenous [C]e [C]x [C]o [C]g [C]e [C]n [C]o [C]u [C]s B-protein 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s E-protein 
and [C]a [C]n [C]d O 
altered [C]a [C]l [C]t [C]e [C]r [C]e [C]d O 
the [C]t [C]h [C]e O 
morphology [C]m [C]o [C]r [C]p [C]h [C]o [C]l [C]o [C]g [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
FD/deltaRaf [C]F [C]D [C]/ [C]d [C]e [C]l [C]t [C]a [C]R [C]a [C]f B-cell_type 
: [C]: I-cell_type 
ER [C]E [C]R I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
as [C]a [C]s O 
they [C]t [C]h [C]e [C]y O 
grew [C]g [C]r [C]e [C]w O 
in [C]i [C]n O 
large [C]l [C]a [C]r [C]g [C]e O 
aggregated [C]a [C]g [C]g [C]r [C]e [C]g [C]a [C]t [C]e [C]d O 
masses [C]m [C]a [C]s [C]s [C]e [C]s O 
( [C]( O 
> [C]> O 
100 [C]1 [C]0 [C]0 O 
cells [C]c [C]e [C]l [C]l [C]s O 
) [C]) O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
the [C]t [C]h [C]e O 
parental [C]p [C]a [C]r [C]e [C]n [C]t [C]a [C]l B-cell_line 
cytokine-dependent [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t I-cell_line 
FDC-P1 [C]F [C]D [C]C [C]- [C]P [C]1 I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
grew [C]g [C]r [C]e [C]w O 
in [C]i [C]n O 
smaller [C]s [C]m [C]a [C]l [C]l [C]e [C]r O 
grape-like [C]g [C]r [C]a [C]p [C]e [C]- [C]l [C]i [C]k [C]e O 
clusters [C]c [C]l [C]u [C]s [C]t [C]e [C]r [C]s O 
( [C]( O 
< [C]< O 
10 [C]1 [C]0 O 
cells [C]c [C]e [C]l [C]l [C]s O 
) [C]) O 
. [C]. O 

FD/deltaRaf-1 [C]F [C]D [C]/ [C]d [C]e [C]l [C]t [C]a [C]R [C]a [C]f [C]- [C]1 B-cell_line 
: [C]: I-cell_line 
ER [C]E [C]R I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
growing [C]g [C]r [C]o [C]w [C]i [C]n [C]g O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
Raf [C]R [C]a [C]f O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
displayed [C]d [C]i [C]s [C]p [C]l [C]a [C]y [C]e [C]d O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Mac-2 [C]M [C]a [C]c [C]- [C]2 B-protein 
and [C]a [C]n [C]d I-protein 
Mac-3 [C]M [C]a [C]c [C]- [C]3 I-protein 
molecules [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]s E-protein 
on [C]o [C]n O 
their [C]t [C]h [C]e [C]i [C]r O 
cell [C]c [C]e [C]l [C]l B-cell_type 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e E-cell_type 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
when [C]w [C]h [C]e [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
were [C]w [C]e [C]r [C]e O 
cultured [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]d O 
in [C]i [C]n O 
IL-3 [C]I [C]L [C]- [C]3 S-protein 
, [C], O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n B-protein 
molecules [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]s E-protein 
were [C]w [C]e [C]r [C]e O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
. [C]. O 

Expression [C]E [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
Raf [C]R [C]a [C]f B-protein 
oncoproteins [C]o [C]n [C]c [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
also [C]a [C]l [C]s [C]o O 
abrogated [C]a [C]b [C]r [C]o [C]g [C]a [C]t [C]e [C]d O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
dependency [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]c [C]y O 
and [C]a [C]n [C]d O 
prevented [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]e [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
of [C]o [C]f O 
TF-1 [C]T [C]F [C]- [C]1 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

Moreover [C]M [C]o [C]r [C]e [C]o [C]v [C]e [C]r O 
, [C], O 
the [C]t [C]h [C]e O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
status [C]s [C]t [C]a [C]t [C]u [C]s O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
Raf-responsive [C]R [C]a [C]f [C]- [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
was [C]w [C]a [C]s O 
more [C]m [C]o [C]r [C]e O 
immature [C]i [C]m [C]m [C]a [C]t [C]u [C]r [C]e O 
upon [C]u [C]p [C]o [C]n O 
Raf [C]R [C]a [C]f O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
as [C]a [C]s O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
differentiation-inducing [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n [C]- [C]i [C]n [C]d [C]u [C]c [C]i [C]n [C]g O 
agent [C]a [C]g [C]e [C]n [C]t O 
phorbol [C]p [C]h [C]o [C]r [C]b [C]o [C]l O 
12 [C]1 [C]2 O 
myristate [C]m [C]y [C]r [C]i [C]s [C]t [C]a [C]t [C]e O 
13-acetate [C]1 [C]3 [C]- [C]a [C]c [C]e [C]t [C]a [C]t [C]e O 
( [C]( O 
PMA [C]P [C]M [C]A O 
) [C]) O 
and [C]a [C]n [C]d O 
beta-estradiol [C]b [C]e [C]t [C]a [C]- [C]e [C]s [C]t [C]r [C]a [C]d [C]i [C]o [C]l O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
CD11b [C]C [C]D [C]1 [C]1 [C]b B-protein 
and [C]a [C]n [C]d I-protein 
CD18 [C]C [C]D [C]1 [C]8 I-protein 
integrin [C]i [C]n [C]t [C]e [C]g [C]r [C]i [C]n I-protein 
molecules [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]s E-protein 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
cell [C]c [C]e [C]l [C]l B-cell_type 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e E-cell_type 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
when [C]w [C]h [C]e [C]n O 
the [C]t [C]h [C]e O 
Raf-responsive [C]R [C]a [C]f [C]- [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
to [C]t [C]o O 
differentiate [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]e O 
with [C]w [C]i [C]t [C]h O 
PMA [C]P [C]M [C]A O 
and [C]a [C]n [C]d O 
GM-CSF [C]G [C]M [C]- [C]C [C]S [C]F S-protein 
, [C], O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
deltaRaf [C]d [C]e [C]l [C]t [C]a [C]R [C]a [C]f B-protein 
: [C]: I-protein 
ER [C]E [C]R E-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
CD11b [C]C [C]D [C]1 [C]1 [C]b B-protein 
and [C]a [C]n [C]d I-protein 
CD18 [C]C [C]D [C]1 [C]8 I-protein 
molecules [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]s E-protein 
were [C]w [C]e [C]r [C]e O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
. [C]. O 

Retinoic [C]R [C]e [C]t [C]i [C]n [C]o [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
( [C]( O 
RA [C]R [C]A O 
) [C]) O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
3H-thymidine [C]3 [C]H [C]- [C]t [C]h [C]y [C]m [C]i [C]d [C]i [C]n [C]e O 
incorporation [C]i [C]n [C]c [C]o [C]r [C]p [C]o [C]r [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
GM-CSF [C]G [C]M [C]- [C]C [C]S [C]F S-protein 
. [C]. O 

Interestingly [C]I [C]n [C]t [C]e [C]r [C]e [C]s [C]t [C]i [C]n [C]g [C]l [C]y O 
, [C], O 
Raf [C]R [C]a [C]f O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
counterbalanced [C]c [C]o [C]u [C]n [C]t [C]e [C]r [C]b [C]a [C]l [C]a [C]n [C]c [C]e [C]d O 
the [C]t [C]h [C]e O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
DNA [C]D [C]N [C]A O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
caused [C]c [C]a [C]u [C]s [C]e [C]d O 
by [C]b [C]y O 
RA [C]R [C]A O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
PMA [C]P [C]M [C]A O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
deregulated [C]d [C]e [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
Raf [C]R [C]a [C]f O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
can [C]c [C]a [C]n O 
alter [C]a [C]l [C]t [C]e [C]r O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
dependency [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]c [C]y O 
, [C], O 
integrin [C]i [C]n [C]t [C]e [C]g [C]r [C]i [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
stage [C]s [C]t [C]a [C]g [C]e O 
of [C]o [C]f O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
Raf-responsive [C]R [C]a [C]f [C]- [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
will [C]w [C]i [C]l [C]l O 
be [C]b [C]e O 
useful [C]u [C]s [C]e [C]f [C]u [C]l O 
in [C]i [C]n O 
elucidating [C]e [C]l [C]u [C]c [C]i [C]d [C]a [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
roles [C]r [C]o [C]l [C]e [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
MAP [C]M [C]A [C]P O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
cascade [C]c [C]a [C]s [C]c [C]a [C]d [C]e O 
on [C]o [C]n O 
hematopoietic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
malignant [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]t O 
transformation [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 

Cyclic [C]C [C]y [C]c [C]l [C]i [C]c O 
AMP [C]A [C]M [C]P O 
activates [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]s O 
p38 [C]p [C]3 [C]8 B-protein 
mitogen-activated [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
in [C]i [C]n O 
Th2 [C]T [C]h [C]2 B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
: [C]: O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 S-protein 
and [C]a [C]n [C]d O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Th2 [C]T [C]h [C]2 S-cell_type 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

cAMP [C]c [C]A [C]M [C]P O 
is [C]i [C]s O 
an [C]a [C]n O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
second [C]s [C]e [C]c [C]o [C]n [C]d O 
messenger [C]m [C]e [C]s [C]s [C]e [C]n [C]g [C]e [C]r O 
with [C]w [C]i [C]t [C]h O 
immunomodulatory [C]i [C]m [C]m [C]u [C]n [C]o [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
properties [C]p [C]r [C]o [C]p [C]e [C]r [C]t [C]i [C]e [C]s O 
. [C]. O 

Elevation [C]E [C]l [C]e [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
cAMP [C]c [C]A [C]M [C]P O 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
agents [C]a [C]g [C]e [C]n [C]t [C]s O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
IL-1alpha [C]I [C]L [C]- [C]1 [C]a [C]l [C]p [C]h [C]a S-protein 
or [C]o [C]r O 
PGs [C]P [C]G [C]s S-protein 
, [C], O 
inhibits [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]s O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

In [C]I [C]n O 
effector [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
an [C]a [C]n O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
cAMP [C]c [C]A [C]M [C]P O 
inhibits [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]s O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e S-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
Th1 [C]T [C]h [C]1 B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
but [C]b [C]u [C]t O 
stimulates [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]s O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e S-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
Th2 [C]T [C]h [C]2 B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
we [C]w [C]e O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
that [C]t [C]h [C]a [C]t O 
cAMP-induced [C]c [C]A [C]M [C]P [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
in [C]i [C]n O 
Th2 [C]T [C]h [C]2 B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
occur [C]o [C]c [C]c [C]u [C]r O 
independently [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t [C]l [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
A [C]A E-protein 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
the [C]t [C]h [C]e O 
major [C]m [C]a [C]j [C]o [C]r O 
mediator [C]m [C]e [C]d [C]i [C]a [C]t [C]o [C]r O 
of [C]o [C]f O 
cAMP-induced [C]c [C]A [C]M [C]P [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
events [C]e [C]v [C]e [C]n [C]t [C]s O 
in [C]i [C]n O 
most [C]m [C]o [C]s [C]t O 
cell [C]c [C]e [C]l [C]l O 
types [C]t [C]y [C]p [C]e [C]s O 
. [C]. O 

Instead [C]I [C]n [C]s [C]t [C]e [C]a [C]d O 
, [C], O 
cAMP [C]c [C]A [C]M [C]P O 
stimulates [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]s O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
p38 [C]p [C]3 [C]8 B-protein 
mitogen-activated [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
in [C]i [C]n O 
Th2 [C]T [C]h [C]2 B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
appears [C]a [C]p [C]p [C]e [C]a [C]r [C]s O 
to [C]t [C]o O 
be [C]b [C]e O 
a [C]a O 
Th2 [C]T [C]h [C]2 S-cell_type 
-selective [C]- [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e O 
event [C]e [C]v [C]e [C]n [C]t O 
because [C]b [C]e [C]c [C]a [C]u [C]s [C]e O 
cAMP [C]c [C]A [C]M [C]P O 
barely [C]b [C]a [C]r [C]e [C]l [C]y O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
p38 [C]p [C]3 [C]8 S-protein 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
Th1 [C]T [C]h [C]1 B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

We [C]W [C]e O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
in [C]i [C]n O 
Th2 [C]T [C]h [C]2 B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
cAMP [C]c [C]A [C]M [C]P O 
promotes [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]s O 
the [C]t [C]h [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
IL-5 [C]I [C]L [C]- [C]5 S-protein 
and [C]a [C]n [C]d O 
IL-13 [C]I [C]L [C]- [C]1 [C]3 S-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
play [C]p [C]l [C]a [C]y O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
but [C]b [C]u [C]t O 
critical [C]c [C]r [C]i [C]t [C]i [C]c [C]a [C]l O 
roles [C]r [C]o [C]l [C]e [C]s O 
in [C]i [C]n O 
asthma [C]a [C]s [C]t [C]h [C]m [C]a O 
pathogenesis [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
. [C]. O 

Our [C]O [C]u [C]r O 
data [C]d [C]a [C]t [C]a O 
also [C]a [C]l [C]s [C]o O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
cAMP [C]c [C]A [C]M [C]P O 
causes [C]c [C]a [C]u [C]s [C]e [C]s O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 E-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
we [C]w [C]e O 
have [C]h [C]a [C]v [C]e O 
shown [C]s [C]h [C]o [C]w [C]n O 
is [C]i [C]s O 
a [C]a O 
critical [C]c [C]r [C]i [C]t [C]i [C]c [C]a [C]l O 
regulator [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r O 
of [C]o [C]f O 
Th2 [C]T [C]h [C]2 S-cell_type 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
, [C], O 
in [C]i [C]n O 
turn [C]t [C]u [C]r [C]n O 
, [C], O 
of [C]o [C]f O 
airway [C]a [C]i [C]r [C]w [C]a [C]y O 
inflammation [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
mice [C]m [C]i [C]c [C]e O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
Th2 [C]T [C]h [C]2 S-cell_type 
-specific [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
p38 [C]p [C]3 [C]8 B-protein 
mitogen-activated [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
together [C]t [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
provide [C]p [C]r [C]o [C]v [C]i [C]d [C]e O 
a [C]a O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
basis [C]b [C]a [C]s [C]i [C]s O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
differential [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
cAMP [C]c [C]A [C]M [C]P O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
two [C]t [C]w [C]o O 
T [C]T B-cell_type 
helper [C]h [C]e [C]l [C]p [C]e [C]r I-cell_type 
cell [C]c [C]e [C]l [C]l I-cell_type 
subsets [C]s [C]u [C]b [C]s [C]e [C]t [C]s E-cell_type 
. [C]. O 

Characterization [C]C [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
and [C]a [C]n [C]d O 
IL-13 [C]I [C]L [C]- [C]1 [C]3 S-protein 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
dependent [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-protein 
IL-13 [C]I [C]L [C]- [C]1 [C]3 I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
alpha [C]a [C]l [C]p [C]h [C]a I-protein 
chain [C]c [C]h [C]a [C]i [C]n I-protein 
1 [C]1 E-protein 
: [C]: O 
redundancy [C]r [C]e [C]d [C]u [C]n [C]d [C]a [C]n [C]c [C]y O 
of [C]o [C]f O 
requirement [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
residue [C]r [C]e [C]s [C]i [C]d [C]u [C]e O 
for [C]f [C]o [C]r O 
STAT3 [C]S [C]T [C]A [C]T [C]3 O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

IL-4 [C]I [C]L [C]- [C]4 S-protein 
and [C]a [C]n [C]d O 
IL-13 [C]I [C]L [C]- [C]1 [C]3 S-protein 
are [C]a [C]r [C]e O 
pleiotropic [C]p [C]l [C]e [C]i [C]o [C]t [C]r [C]o [C]p [C]i [C]c B-protein 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s E-protein 
whose [C]w [C]h [C]o [C]s [C]e O 
biological [C]b [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
activities [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]i [C]e [C]s O 
overlap [C]o [C]v [C]e [C]r [C]l [C]a [C]p O 
with [C]w [C]i [C]t [C]h O 
each [C]e [C]a [C]c [C]h O 
other [C]o [C]t [C]h [C]e [C]r O 
. [C]. O 

IL-13 [C]I [C]L [C]- [C]1 [C]3 B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
alpha [C]a [C]l [C]p [C]h [C]a I-protein 
chain [C]c [C]h [C]a [C]i [C]n I-protein 
1 [C]1 E-protein 
( [C]( O 
IL-13R [C]I [C]L [C]- [C]1 [C]3 [C]R B-protein 
alpha [C]a [C]l [C]p [C]h [C]a I-protein 
1 [C]1 E-protein 
) [C]) O 
is [C]i [C]s O 
necessary [C]n [C]e [C]c [C]e [C]s [C]s [C]a [C]r [C]y O 
for [C]f [C]o [C]r O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
IL-13 [C]I [C]L [C]- [C]1 [C]3 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
heterodimer [C]h [C]e [C]t [C]e [C]r [C]o [C]d [C]i [C]m [C]e [C]r O 
composed [C]c [C]o [C]m [C]p [C]o [C]s [C]e [C]d O 
of [C]o [C]f O 
IL-13R [C]I [C]L [C]- [C]1 [C]3 [C]R B-protein 
alpha [C]a [C]l [C]p [C]h [C]a I-protein 
1 [C]1 E-protein 
and [C]a [C]n [C]d O 
IL-4R [C]I [C]L [C]- [C]4 [C]R B-protein 
alpha [C]a [C]l [C]p [C]h [C]a I-protein 
chain [C]c [C]h [C]a [C]i [C]n E-protein 
transduces [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]e [C]s O 
IL-13 [C]I [C]L [C]- [C]1 [C]3 S-protein 
and [C]a [C]n [C]d O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
; [C]; O 
however [C]h [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
the [C]t [C]h [C]e O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
mapping [C]m [C]a [C]p [C]p [C]i [C]n [C]g O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
of [C]o [C]f O 
IL-13R [C]I [C]L [C]- [C]1 [C]3 [C]R B-protein 
alpha [C]a [C]l [C]p [C]h [C]a I-protein 
1 [C]1 E-protein 
is [C]i [C]s O 
not [C]n [C]o [C]t O 
fully [C]f [C]u [C]l [C]l [C]y O 
understood [C]u [C]n [C]d [C]e [C]r [C]s [C]t [C]o [C]o [C]d O 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
, [C], O 
we [C]w [C]e O 
constructed [C]c [C]o [C]n [C]s [C]t [C]r [C]u [C]c [C]t [C]e [C]d O 
wild [C]w [C]i [C]l [C]d O 
and [C]a [C]n [C]d O 
mutated [C]m [C]u [C]t [C]a [C]t [C]e [C]d O 
types [C]t [C]y [C]p [C]e [C]s O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-protein 
IL-13R [C]I [C]L [C]- [C]1 [C]3 [C]R I-protein 
alpha [C]a [C]l [C]p [C]h [C]a I-protein 
1 [C]1 E-protein 
, [C], O 
and [C]a [C]n [C]d O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
and [C]a [C]n [C]d O 
IL-13 [C]I [C]L [C]- [C]1 [C]3 S-protein 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
using [C]u [C]s [C]i [C]n [C]g O 
an [C]a [C]n O 
IL-13R [C]I [C]L [C]- [C]1 [C]3 [C]R B-protein 
alpha [C]a [C]l [C]p [C]h [C]a I-protein 
1 [C]1 E-protein 
-transfected [C]- [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]e [C]d O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
B [C]B I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
. [C]. O 

Expression [C]E [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-13R [C]I [C]L [C]- [C]1 [C]3 [C]R B-protein 
alpha [C]a [C]l [C]p [C]h [C]a I-protein 
1 [C]1 E-protein 
evoked [C]e [C]v [C]o [C]k [C]e [C]d O 
STAT3 [C]S [C]T [C]A [C]T [C]3 S-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
and [C]a [C]n [C]d O 
IL-13 [C]I [C]L [C]- [C]1 [C]3 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
on [C]o [C]n O 
which [C]w [C]h [C]i [C]c [C]h O 
IL-13R [C]I [C]L [C]- [C]1 [C]3 [C]R B-protein 
alpha [C]a [C]l [C]p [C]h [C]a I-protein 
1 [C]1 E-protein 
was [C]w [C]a [C]s O 
highly [C]h [C]i [C]g [C]h [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
, [C], O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
and [C]a [C]n [C]d O 
IL-13 [C]I [C]L [C]- [C]1 [C]3 S-protein 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
STAT3 [C]S [C]T [C]A [C]T [C]3 S-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Replacement [C]R [C]e [C]p [C]l [C]a [C]c [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
two [C]t [C]w [C]o O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
residues [C]r [C]e [C]s [C]i [C]d [C]u [C]e [C]s O 
completely [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e [C]l [C]y O 
abolished [C]a [C]b [C]o [C]l [C]i [C]s [C]h [C]e [C]d O 
STAT3 [C]S [C]T [C]A [C]T [C]3 S-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
although [C]a [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
replacing [C]r [C]e [C]p [C]l [C]a [C]c [C]i [C]n [C]g O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
residue [C]r [C]e [C]s [C]i [C]d [C]u [C]e O 
alone [C]a [C]l [C]o [C]n [C]e O 
retained [C]r [C]e [C]t [C]a [C]i [C]n [C]e [C]d O 
it [C]i [C]t O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
we [C]w [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
Box1 [C]B [C]o [C]x [C]1 B-protein 
region [C]r [C]e [C]g [C]i [C]o [C]n E-protein 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
C-terminal [C]C [C]- [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l B-protein 
tail [C]t [C]a [C]i [C]l E-protein 
of [C]o [C]f O 
IL-13R [C]I [C]L [C]- [C]1 [C]3 [C]R B-protein 
alpha [C]a [C]l [C]p [C]h [C]a I-protein 
1 [C]1 E-protein 
were [C]w [C]e [C]r [C]e O 
critical [C]c [C]r [C]i [C]t [C]i [C]c [C]a [C]l O 
for [C]f [C]o [C]r O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
Tyk2 [C]T [C]y [C]k [C]2 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Jak1 [C]J [C]a [C]k [C]1 S-protein 
, [C], O 
Tyk2 [C]T [C]y [C]k [C]2 S-protein 
, [C], O 
the [C]t [C]h [C]e O 
insulin [C]i [C]n [C]s [C]u [C]l [C]i [C]n B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
substrate-1 [C]s [C]u [C]b [C]s [C]t [C]r [C]a [C]t [C]e [C]- [C]1 E-protein 
and [C]a [C]n [C]d O 
STAT6 [C]S [C]T [C]A [C]T [C]6 S-protein 
respectively [C]r [C]e [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
STAT3 [C]S [C]T [C]A [C]T [C]3 S-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
and [C]a [C]n [C]d O 
IL-13 [C]I [C]L [C]- [C]1 [C]3 S-protein 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
along [C]a [C]l [C]o [C]n [C]g O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
STAT6 [C]S [C]T [C]A [C]T [C]6 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
there [C]t [C]h [C]e [C]r [C]e O 
is [C]i [C]s O 
a [C]a O 
unique [C]u [C]n [C]i [C]q [C]u [C]e O 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
in [C]i [C]n O 
IL-13R [C]I [C]L [C]- [C]1 [C]3 [C]R B-protein 
alpha [C]a [C]l [C]p [C]h [C]a I-protein 
1 [C]1 E-protein 
to [C]t [C]o O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
STAT3 [C]S [C]T [C]A [C]T [C]3 S-protein 
. [C]. O 

Functional [C]F [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
uncoupling [C]u [C]n [C]c [C]o [C]u [C]p [C]l [C]i [C]n [C]g O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Janus [C]J [C]a [C]n [C]u [C]s O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
3-Stat5 [C]3 [C]- [C]S [C]t [C]a [C]t [C]5 O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
in [C]i [C]n O 
malignant [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]t O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
virus [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
1-transformed [C]1 [C]- [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]e [C]d O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Human [C]H [C]u [C]m [C]a [C]n O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
virus [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
1 [C]1 O 
( [C]( O 
HTLV-1 [C]H [C]T [C]L [C]V [C]- [C]1 O 
) [C]) O 
transforms [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]s O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e S-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
T [C]T B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
causes [C]c [C]a [C]u [C]s [C]e [C]s O 
adult [C]a [C]d [C]u [C]l [C]t O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
. [C]. O 

Janus [C]J [C]a [C]n [C]u [C]s B-protein 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
( [C]( I-protein 
Jak [C]J [C]a [C]k I-protein 
) [C]) I-protein 
3 [C]3 E-protein 
and [C]a [C]n [C]d O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
Stat5a [C]S [C]t [C]a [C]t [C]5 [C]a S-protein 
and [C]a [C]n [C]d O 
Stat5b [C]S [C]t [C]a [C]t [C]5 [C]b S-protein 
are [C]a [C]r [C]e O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
are [C]a [C]r [C]e O 
constitutively [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y O 
hyperactivated [C]h [C]y [C]p [C]e [C]r [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
HTLV-1-transformed [C]H [C]T [C]L [C]V [C]- [C]1 [C]- [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]e [C]d B-cell_line 
human [C]h [C]u [C]m [C]a [C]n I-cell_line 
T [C]T I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
and [C]a [C]n [C]d O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
HTLV-1-infected [C]H [C]T [C]L [C]V [C]- [C]1 [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
; [C]; O 
therefore [C]t [C]h [C]e [C]r [C]e [C]f [C]o [C]r [C]e O 
, [C], O 
a [C]a O 
critical [C]c [C]r [C]i [C]t [C]i [C]c [C]a [C]l O 
role [C]r [C]o [C]l [C]e O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
Jak3-Stat5 [C]J [C]a [C]k [C]3 [C]- [C]S [C]t [C]a [C]t [C]5 O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
progression [C]p [C]r [C]o [C]g [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
postulated [C]p [C]o [C]s [C]t [C]u [C]l [C]a [C]t [C]e [C]d O 
. [C]. O 

We [C]W [C]e O 
recently [C]r [C]e [C]c [C]e [C]n [C]t [C]l [C]y O 
reported [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
tyrphostin [C]t [C]y [C]r [C]p [C]h [C]o [C]s [C]t [C]i [C]n O 
AG-490 [C]A [C]G [C]- [C]4 [C]9 [C]0 O 
selectively [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
IL-2 [C]I [C]L [C]- [C]2 O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Jak3/Stat5 [C]J [C]a [C]k [C]3 [C]/ [C]S [C]t [C]a [C]t [C]5 S-protein 
and [C]a [C]n [C]d O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
of [C]o [C]f O 
murine [C]m [C]u [C]r [C]i [C]n [C]e B-cell_line 
T [C]T I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
we [C]w [C]e O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
disruption [C]d [C]i [C]s [C]r [C]u [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Jak3/Stat5a/b [C]J [C]a [C]k [C]3 [C]/ [C]S [C]t [C]a [C]t [C]5 [C]a [C]/ [C]b O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
with [C]w [C]i [C]t [C]h O 
AG-490 [C]A [C]G [C]- [C]4 [C]9 [C]0 O 
( [C]( O 
50 [C]5 [C]0 O 
& [C]& O 
mgr [C]m [C]g [C]r O 
; [C]; O 
M [C]M O 
) [C]) O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
the [C]t [C]h [C]e O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
, [C], O 
but [C]b [C]u [C]t O 
paradoxically [C]p [C]a [C]r [C]a [C]d [C]o [C]x [C]i [C]c [C]a [C]l [C]l [C]y O 
failed [C]f [C]a [C]i [C]l [C]e [C]d O 
to [C]t [C]o O 
inhibit [C]i [C]n [C]h [C]i [C]b [C]i [C]t O 
the [C]t [C]h [C]e O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
HTLV-1-transformed [C]H [C]T [C]L [C]V [C]- [C]1 [C]- [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]e [C]d B-cell_line 
human [C]h [C]u [C]m [C]a [C]n I-cell_line 
T [C]T I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
, [C], O 
HuT-102 [C]H [C]u [C]T [C]- [C]1 [C]0 [C]2 S-cell_line 
and [C]a [C]n [C]d O 
MT-2 [C]M [C]T [C]- [C]2 S-cell_line 
. [C]. O 

Structural [C]S [C]t [C]r [C]u [C]c [C]t [C]u [C]r [C]a [C]l O 
homologues [C]h [C]o [C]m [C]o [C]l [C]o [C]g [C]u [C]e [C]s O 
of [C]o [C]f O 
AG-490 [C]A [C]G [C]- [C]4 [C]9 [C]0 O 
also [C]a [C]l [C]s [C]o O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
HTLV-1-infected [C]H [C]T [C]L [C]V [C]- [C]1 [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Disruption [C]D [C]i [C]s [C]r [C]u [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
constitutive [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
Jak3/Stat5 [C]J [C]a [C]k [C]3 [C]/ [C]S [C]t [C]a [C]t [C]5 O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
AG-490 [C]A [C]G [C]- [C]4 [C]9 [C]0 O 
was [C]w [C]a [C]s O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
1 [C]1 O 
) [C]) O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Jak3 [C]J [C]a [C]k [C]3 S-protein 
, [C], O 
Stat5a [C]S [C]t [C]a [C]t [C]5 [C]a S-protein 
( [C]( O 
Tyr [C]T [C]y [C]r O 
( [C]( O 
694 [C]6 [C]9 [C]4 O 
) [C]) O 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
Stat5b [C]S [C]t [C]a [C]t [C]5 [C]b S-protein 
( [C]( O 
Tyr [C]T [C]y [C]r O 
( [C]( O 
699 [C]6 [C]9 [C]9 O 
) [C]) O 
) [C]) O 
; [C]; O 
2 [C]2 O 
) [C]) O 
serine [C]s [C]e [C]r [C]i [C]n [C]e O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Stat5a [C]S [C]t [C]a [C]t [C]5 [C]a S-protein 
( [C]( O 
Ser [C]S [C]e [C]r O 
( [C]( O 
726 [C]7 [C]2 [C]6 O 
) [C]) O 
) [C]) O 
as [C]a [C]s O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
phosphospecific [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-protein 
Ab [C]A [C]b E-protein 
; [C]; O 
and [C]a [C]n [C]d O 
3 [C]3 O 
) [C]) O 
Stat5a/b [C]S [C]t [C]a [C]t [C]5 [C]a [C]/ [C]b O 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
Stat5-responsive [C]S [C]t [C]a [C]t [C]5 [C]- [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e B-DNA 
beta-casein [C]b [C]e [C]t [C]a [C]- [C]c [C]a [C]s [C]e [C]i [C]n I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
AG-490 [C]A [C]G [C]- [C]4 [C]9 [C]0 O 
had [C]h [C]a [C]d O 
no [C]n [C]o O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
by [C]b [C]y O 
p50/p65 [C]p [C]5 [C]0 [C]/ [C]p [C]6 [C]5 B-protein 
components [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t [C]s E-protein 
of [C]o [C]f O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
, [C], O 
a [C]a O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
HTLV-1-encoded [C]H [C]T [C]L [C]V [C]- [C]1 [C]- [C]e [C]n [C]c [C]o [C]d [C]e [C]d B-protein 
phosphoprotein [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
, [C], I-protein 
Tax [C]T [C]a [C]x E-protein 
. [C]. O 

Collectively [C]C [C]o [C]l [C]l [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
, [C], O 
these [C]t [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
Jak3-Stat5 [C]J [C]a [C]k [C]3 [C]- [C]S [C]t [C]a [C]t [C]5 O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
in [C]i [C]n O 
HTLV-1-transformed [C]H [C]T [C]L [C]V [C]- [C]1 [C]- [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]e [C]d B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
has [C]h [C]a [C]s O 
become [C]b [C]e [C]c [C]o [C]m [C]e O 
functionally [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l [C]l [C]y O 
redundant [C]r [C]e [C]d [C]u [C]n [C]d [C]a [C]n [C]t O 
for [C]f [C]o [C]r O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Reversal [C]R [C]e [C]v [C]e [C]r [C]s [C]a [C]l O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
uncoupling [C]u [C]n [C]c [C]o [C]u [C]p [C]l [C]i [C]n [C]g O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
before [C]b [C]e [C]f [C]o [C]r [C]e O 
Jak3/Stat5 [C]J [C]a [C]k [C]3 [C]/ [C]S [C]t [C]a [C]t [C]5 O 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
will [C]w [C]i [C]l [C]l O 
be [C]b [C]e O 
useful [C]u [C]s [C]e [C]f [C]u [C]l O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
malignancy [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]c [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
Epstein-Barr [C]E [C]p [C]s [C]t [C]e [C]i [C]n [C]- [C]B [C]a [C]r [C]r B-DNA 
virus [C]v [C]i [C]r [C]u [C]s I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
initiating [C]i [C]n [C]i [C]t [C]i [C]a [C]t [C]i [C]n [C]g O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l O 
transformation [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
RFX [C]R [C]F [C]X B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
B-cell-specific [C]B [C]- [C]c [C]e [C]l [C]l [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-protein 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
BSAP/Pax5 [C]B [C]S [C]A [C]P [C]/ [C]P [C]a [C]x [C]5 E-protein 
. [C]. O 

Epstein-Barr [C]E [C]p [C]s [C]t [C]e [C]i [C]n [C]- [C]B [C]a [C]r [C]r O 
virus [C]v [C]i [C]r [C]u [C]s O 
( [C]( O 
EBV [C]E [C]B [C]V O 
) [C]) O 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l S-cell_type 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
transformation [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
a [C]a O 
central [C]c [C]e [C]n [C]t [C]r [C]a [C]l O 
feature [C]f [C]e [C]a [C]t [C]u [C]r [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
virus [C]v [C]i [C]r [C]u [C]s O 
' [C]' O 
strategy [C]s [C]t [C]r [C]a [C]t [C]e [C]g [C]y O 
for [C]f [C]o [C]r O 
colonizing [C]c [C]o [C]l [C]o [C]n [C]i [C]z [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
, [C], O 
requires [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]s O 
full [C]f [C]u [C]l [C]l O 
virus [C]v [C]i [C]r [C]u [C]s O 
latent [C]l [C]a [C]t [C]e [C]n [C]t O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
initiated [C]i [C]n [C]i [C]t [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
viral [C]v [C]i [C]r [C]a [C]l B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r I-DNA 
Wp [C]W [C]p E-DNA 
. [C]. O 

Interestingly [C]I [C]n [C]t [C]e [C]r [C]e [C]s [C]t [C]i [C]n [C]g [C]l [C]y O 
, [C], O 
when [C]w [C]h [C]e [C]n O 
EBV [C]E [C]B [C]V O 
accesses [C]a [C]c [C]c [C]e [C]s [C]s [C]e [C]s O 
other [C]o [C]t [C]h [C]e [C]r O 
cell [C]c [C]e [C]l [C]l O 
types [C]t [C]y [C]p [C]e [C]s O 
, [C], O 
this [C]t [C]h [C]i [C]s O 
growth-transforming [C]g [C]r [C]o [C]w [C]t [C]h [C]- [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]i [C]n [C]g O 
program [C]p [C]r [C]o [C]g [C]r [C]a [C]m O 
is [C]i [C]s O 
not [C]n [C]o [C]t O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
. [C]. O 

The [C]T [C]h [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
work [C]w [C]o [C]r [C]k O 
focuses [C]f [C]o [C]c [C]u [C]s [C]e [C]s O 
on [C]o [C]n O 
a [C]a O 
region [C]r [C]e [C]g [C]i [C]o [C]n O 
of [C]o [C]f O 
Wp [C]W [C]p S-DNA 
which [C]w [C]h [C]i [C]c [C]h O 
in [C]i [C]n O 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
confers [C]c [C]o [C]n [C]f [C]e [C]r [C]s O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l S-cell_type 
-specific [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

Bandshift [C]B [C]a [C]n [C]d [C]s [C]h [C]i [C]f [C]t O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
this [C]t [C]h [C]i [C]s O 
region [C]r [C]e [C]g [C]i [C]o [C]n O 
contains [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]s O 
three [C]t [C]h [C]r [C]e [C]e O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
sites [C]s [C]i [C]t [C]e [C]s O 
, [C], O 
termed [C]t [C]e [C]r [C]m [C]e [C]d O 
sites [C]s [C]i [C]t [C]e [C]s B-DNA 
B [C]B I-DNA 
, [C], I-DNA 
C [C]C I-DNA 
, [C], I-DNA 
and [C]a [C]n [C]d I-DNA 
D [C]D E-DNA 
, [C], O 
in [C]i [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
to [C]t [C]o O 
a [C]a O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
characterized [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]d O 
CREB [C]C [C]R [C]E [C]B B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
we [C]w [C]e O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
site [C]s [C]i [C]t [C]e B-DNA 
C [C]C E-DNA 
binds [C]b [C]i [C]n [C]d [C]s O 
members [C]m [C]e [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
ubiquitously [C]u [C]b [C]i [C]q [C]u [C]i [C]t [C]o [C]u [C]s [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
RFX [C]R [C]F [C]X B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y I-protein 
of [C]o [C]f I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
, [C], O 
notably [C]n [C]o [C]t [C]a [C]b [C]l [C]y O 
RFX1 [C]R [C]F [C]X [C]1 S-protein 
, [C], O 
RFX3 [C]R [C]F [C]X [C]3 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
MIBP1 [C]M [C]I [C]B [C]P [C]1 S-protein 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
sites [C]s [C]i [C]t [C]e [C]s B-DNA 
B [C]B I-DNA 
and [C]a [C]n [C]d I-DNA 
D [C]D E-DNA 
both [C]b [C]o [C]t [C]h O 
bind [C]b [C]i [C]n [C]d O 
the [C]t [C]h [C]e O 
B-cell-specific [C]B [C]- [C]c [C]e [C]l [C]l [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-protein 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
BSAP/Pax5 [C]B [C]S [C]A [C]P [C]/ [C]P [C]a [C]x [C]5 E-protein 
. [C]. O 

In [C]I [C]n O 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
with [C]w [C]i [C]t [C]h O 
mutant [C]m [C]u [C]t [C]a [C]n [C]t B-DNA 
Wp [C]W [C]p I-DNA 
constructs [C]c [C]o [C]n [C]s [C]t [C]r [C]u [C]c [C]t [C]s E-DNA 
, [C], O 
the [C]t [C]h [C]e O 
loss [C]l [C]o [C]s [C]s O 
of [C]o [C]f O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
any [C]a [C]n [C]y O 
one [C]o [C]n [C]e O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
sites [C]s [C]i [C]t [C]e [C]s O 
severely [C]s [C]e [C]v [C]e [C]r [C]e [C]l [C]y O 
impaired [C]i [C]m [C]p [C]a [C]i [C]r [C]e [C]d O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
while [C]w [C]h [C]i [C]l [C]e O 
the [C]t [C]h [C]e O 
wild-type [C]w [C]i [C]l [C]d [C]- [C]t [C]y [C]p [C]e B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
non-B [C]n [C]o [C]n [C]- [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
by [C]b [C]y O 
ectopic [C]e [C]c [C]t [C]o [C]p [C]i [C]c O 
BSAP [C]B [C]S [C]A [C]P O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

We [C]W [C]e O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
Wp [C]W [C]p S-DNA 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
BSAP [C]B [C]S [C]A [C]P S-protein 
helps [C]h [C]e [C]l [C]p [C]s O 
to [C]t [C]o O 
ensure [C]e [C]n [C]s [C]u [C]r [C]e O 
the [C]t [C]h [C]e O 
B-cell [C]B [C]- [C]c [C]e [C]l [C]l S-cell_type 
specificity [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]i [C]t [C]y O 
of [C]o [C]f O 
EBV [C]E [C]B [C]V O 
's [C]' [C]s O 
growth-transforming [C]g [C]r [C]o [C]w [C]t [C]h [C]- [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]i [C]n [C]g O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

Activation [C]A [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Lck [C]L [C]c [C]k B-protein 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
Herpesvirus [C]H [C]e [C]r [C]p [C]e [C]s [C]v [C]i [C]r [C]u [C]s O 
saimiri [C]s [C]a [C]i [C]m [C]i [C]r [C]i O 
tip [C]t [C]i [C]p B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
involves [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]s O 
two [C]t [C]w [C]o O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
interactions [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
Tip [C]T [C]i [C]p B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
of [C]o [C]f O 
Herpesvirus [C]H [C]e [C]r [C]p [C]e [C]s [C]v [C]i [C]r [C]u [C]s O 
saimiri [C]s [C]a [C]i [C]m [C]i [C]r [C]i O 
strain [C]s [C]t [C]r [C]a [C]i [C]n O 
484C [C]4 [C]8 [C]4 [C]C O 
binds [C]b [C]i [C]n [C]d [C]s O 
to [C]t [C]o O 
and [C]a [C]n [C]d O 
activates [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]s O 
the [C]t [C]h [C]e O 
Lck [C]L [C]c [C]k B-protein 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
. [C]. O 

Two [C]T [C]w [C]o O 
sequences [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
Tip [C]T [C]i [C]p B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
were [C]w [C]e [C]r [C]e O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
be [C]b [C]e O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
Lck [C]L [C]c [C]k S-protein 
. [C]. O 

A [C]A O 
proline-rich [C]p [C]r [C]o [C]l [C]i [C]n [C]e [C]- [C]r [C]i [C]c [C]h B-protein 
region [C]r [C]e [C]g [C]i [C]o [C]n E-protein 
, [C], O 
residues [C]r [C]e [C]s [C]i [C]d [C]u [C]e [C]s O 
132-141 [C]1 [C]3 [C]2 [C]- [C]1 [C]4 [C]1 O 
, [C], O 
binds [C]b [C]i [C]n [C]d [C]s O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
SH3 [C]S [C]H [C]3 B-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Lck [C]L [C]c [C]k B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
. [C]. O 

We [C]W [C]e O 
show [C]s [C]h [C]o [C]w O 
here [C]h [C]e [C]r [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
other [C]o [C]t [C]h [C]e [C]r O 
Lck-binding [C]L [C]c [C]k [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
, [C], O 
residues [C]r [C]e [C]s [C]i [C]d [C]u [C]e [C]s O 
104-113 [C]1 [C]0 [C]4 [C]- [C]1 [C]1 [C]3 O 
, [C], O 
binds [C]b [C]i [C]n [C]d [C]s O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
carboxyl-terminal [C]c [C]a [C]r [C]b [C]o [C]x [C]y [C]l [C]- [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l B-protein 
half [C]h [C]a [C]l [C]f E-protein 
of [C]o [C]f O 
Lck [C]L [C]c [C]k S-protein 
and [C]a [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
this [C]t [C]h [C]i [C]s O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
does [C]d [C]o [C]e [C]s O 
not [C]n [C]o [C]t O 
require [C]r [C]e [C]q [C]u [C]i [C]r [C]e O 
the [C]t [C]h [C]e O 
Lck [C]L [C]c [C]k B-protein 
SH3 [C]S [C]H [C]3 I-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
. [C]. O 

Mutated [C]M [C]u [C]t [C]a [C]t [C]e [C]d O 
Tip [C]T [C]i [C]p S-protein 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
only [C]o [C]n [C]l [C]y O 
one [C]o [C]n [C]e O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
Lck-binding [C]L [C]c [C]k [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
can [C]c [C]a [C]n O 
bind [C]b [C]i [C]n [C]d O 
stably [C]s [C]t [C]a [C]b [C]l [C]y O 
to [C]t [C]o O 
Lck [C]L [C]c [C]k S-protein 
, [C], O 
although [C]a [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
not [C]n [C]o [C]t O 
as [C]a [C]s O 
strongly [C]s [C]t [C]r [C]o [C]n [C]g [C]l [C]y O 
as [C]a [C]s O 
wild-type [C]w [C]i [C]l [C]d [C]- [C]t [C]y [C]p [C]e B-protein 
Tip [C]T [C]i [C]p E-protein 
. [C]. O 

Interaction [C]I [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Tip [C]T [C]i [C]p S-protein 
with [C]w [C]i [C]t [C]h O 
Lck [C]L [C]c [C]k S-protein 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
Lck-binding [C]L [C]c [C]k [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
increases [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
the [C]t [C]h [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
Lck [C]L [C]c [C]k S-protein 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
. [C]. O 

Simultaneous [C]S [C]i [C]m [C]u [C]l [C]t [C]a [C]n [C]e [C]o [C]u [C]s O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
domains [C]d [C]o [C]m [C]a [C]i [C]n [C]s O 
is [C]i [C]s O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
maximal [C]m [C]a [C]x [C]i [C]m [C]a [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Lck [C]L [C]c [C]k S-protein 
. [C]. O 

The [C]T [C]h [C]e O 
transient [C]t [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
Tip [C]T [C]i [C]p S-protein 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
stimulate [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e O 
both [C]b [C]o [C]t [C]h O 
Stat3 [C]S [C]t [C]a [C]t [C]3 S-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
NF-AT [C]N [C]F [C]- [C]A [C]T S-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
. [C]. O 

Mutant [C]M [C]u [C]t [C]a [C]n [C]t O 
forms [C]f [C]o [C]r [C]m [C]s O 
of [C]o [C]f O 
Tip [C]T [C]i [C]p S-protein 
lacking [C]l [C]a [C]c [C]k [C]i [C]n [C]g O 
one [C]o [C]n [C]e O 
or [C]o [C]r O 
the [C]t [C]h [C]e O 
other [C]o [C]t [C]h [C]e [C]r O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
two [C]t [C]w [C]o O 
Lck-binding [C]L [C]c [C]k [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
domains [C]d [C]o [C]m [C]a [C]i [C]n [C]s E-protein 
retained [C]r [C]e [C]t [C]a [C]i [C]n [C]e [C]d O 
the [C]t [C]h [C]e O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
to [C]t [C]o O 
stimulate [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e O 
Stat3 [C]S [C]t [C]a [C]t [C]3 S-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
. [C]. O 

Tip [C]T [C]i [C]p S-protein 
lacking [C]l [C]a [C]c [C]k [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
proline-rich [C]p [C]r [C]o [C]l [C]i [C]n [C]e [C]- [C]r [C]i [C]c [C]h O 
Lck-binding [C]L [C]c [C]k [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
exhibited [C]e [C]x [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
almost [C]a [C]l [C]m [C]o [C]s [C]t O 
wild-type [C]w [C]i [C]l [C]d [C]- [C]t [C]y [C]p [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
this [C]t [C]h [C]i [C]s O 
assay [C]a [C]s [C]s [C]a [C]y O 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
ablation [C]a [C]b [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
Lck-binding [C]L [C]c [C]k [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
abolished [C]a [C]b [C]o [C]l [C]i [C]s [C]h [C]e [C]d O 
the [C]t [C]h [C]e O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
Tip [C]T [C]i [C]p S-protein 
to [C]t [C]o O 
stimulate [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e O 
NF-AT [C]N [C]F [C]- [C]A [C]T S-protein 
-dependent [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
. [C]. O 

Full [C]F [C]u [C]l [C]l O 
biological [C]b [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
Tip [C]T [C]i [C]p S-protein 
, [C], O 
therefore [C]t [C]h [C]e [C]r [C]e [C]f [C]o [C]r [C]e O 
, [C], O 
appears [C]a [C]p [C]p [C]e [C]a [C]r [C]s O 
to [C]t [C]o O 
require [C]r [C]e [C]q [C]u [C]i [C]r [C]e O 
both [C]b [C]o [C]t [C]h O 
Lck-binding [C]L [C]c [C]k [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
domains [C]d [C]o [C]m [C]a [C]i [C]n [C]s E-protein 
. [C]. O 

Accumulation [C]A [C]c [C]c [C]u [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
RXR [C]R [C]X [C]R B-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cycling [C]c [C]y [C]c [C]l [C]i [C]n [C]g O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
: [C]: O 
modulation [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
RXRE [C]R [C]X [C]R [C]E O 
transactivation [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
mitogen-activated [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
reported [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
resting [C]r [C]e [C]s [C]t [C]i [C]n [C]g O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
immature [C]i [C]m [C]m [C]a [C]t [C]u [C]r [C]e I-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
T [C]T I-cell_type 
( [C]( I-cell_type 
PBT [C]P [C]B [C]T I-cell_type 
) [C]) I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
is [C]i [C]s O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
loss [C]l [C]o [C]s [C]s O 
of [C]o [C]f O 
retinoid [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]d B-protein 
X [C]X I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
( [C]( O 
RXRalpha [C]R [C]X [C]R [C]a [C]l [C]p [C]h [C]a S-protein 
) [C]) O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

In [C]I [C]n O 
the [C]t [C]h [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
study [C]s [C]t [C]u [C]d [C]y O 
, [C], O 
we [C]w [C]e O 
have [C]h [C]a [C]v [C]e O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
, [C], O 
unlike [C]u [C]n [C]l [C]i [C]k [C]e O 
resting [C]r [C]e [C]s [C]t [C]i [C]n [C]g O 
cells [C]c [C]e [C]l [C]l [C]s O 
, [C], O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cycling [C]c [C]y [C]c [C]l [C]i [C]n [C]g B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
mature [C]m [C]a [C]t [C]u [C]r [C]e I-cell_type 
PBT [C]P [C]B [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
, [C], O 
and [C]a [C]n [C]d O 
T [C]T B-cell_line 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e I-cell_line 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
is [C]i [C]s O 
accompanied [C]a [C]c [C]c [C]o [C]m [C]p [C]a [C]n [C]i [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
accumulation [C]a [C]c [C]c [C]u [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
RXRalpha [C]R [C]X [C]R [C]a [C]l [C]p [C]h [C]a S-protein 
mRNA [C]m [C]R [C]N [C]A O 
and [C]a [C]n [C]d O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
. [C]. O 

Interestingly [C]I [C]n [C]t [C]e [C]r [C]e [C]s [C]t [C]i [C]n [C]g [C]l [C]y O 
, [C], O 
cyclosporin [C]c [C]y [C]c [C]l [C]o [C]s [C]p [C]o [C]r [C]i [C]n O 
A [C]A O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
augmented [C]a [C]u [C]g [C]m [C]e [C]n [C]t [C]e [C]d O 
RXRalpha [C]R [C]X [C]R [C]a [C]l [C]p [C]h [C]a S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
indicating [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
involvement [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
calcineurin [C]c [C]a [C]l [C]c [C]i [C]n [C]e [C]u [C]r [C]i [C]n O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
. [C]. O 

9-cis [C]9 [C]- [C]c [C]i [C]s O 
retinoic [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
accumulation [C]a [C]c [C]c [C]u [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
retinoids [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]d [C]s O 
can [C]c [C]a [C]n O 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
their [C]t [C]h [C]e [C]i [C]r O 
own [C]o [C]w [C]n O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Transfection [C]T [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
in [C]i [C]n O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
, [C], O 
using [C]u [C]s [C]i [C]n [C]g O 
RXRE-dependent [C]R [C]X [C]R [C]E [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
, [C], O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
RXRalpha [C]R [C]X [C]R [C]a [C]l [C]p [C]h [C]a S-protein 
accumulated [C]a [C]c [C]c [C]u [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
transcriptionally [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l [C]l [C]y O 
inactive [C]i [C]n [C]a [C]c [C]t [C]i [C]v [C]e O 
. [C]. O 

To [C]T [C]o O 
investigate [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
of [C]o [C]f O 
such [C]s [C]u [C]c [C]h O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
the [C]t [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
two [C]t [C]w [C]o O 
mitogen-activated [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
, [C], O 
c-Jun [C]c [C]- [C]J [C]u [C]n B-protein 
N-terminal [C]N [C]- [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
( [C]( O 
JNK [C]J [C]N [C]K S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
extracellular [C]e [C]x [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
signal-regulated [C]s [C]i [C]g [C]n [C]a [C]l [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
( [C]( O 
ERK [C]E [C]R [C]K S-protein 
) [C]) O 
, [C], O 
in [C]i [C]n O 
modulating [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
RXRE-dependent [C]R [C]X [C]R [C]E [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
, [C], O 
was [C]w [C]a [C]s O 
explored [C]e [C]x [C]p [C]l [C]o [C]r [C]e [C]d O 
. [C]. O 

The [C]T [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
constitutively [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
MAP/ERK [C]M [C]A [C]P [C]/ [C]E [C]R [C]K B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
1 [C]1 E-protein 
( [C]( O 
MEKK1 [C]M [C]E [C]K [C]K [C]1 S-protein 
) [C]) O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
RXRE-dependent [C]R [C]X [C]R [C]E [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
dominant [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t B-protein 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e I-protein 
MEKK1 [C]M [C]E [C]K [C]K [C]1 E-protein 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
, [C], O 
indicating [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
involvement [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
JNK [C]J [C]N [C]K S-protein 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
constitutively [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y B-protein 
active [C]a [C]c [C]t [C]i [C]v [C]e I-protein 
MEK1 [C]M [C]E [C]K [C]1 E-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
activates [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]s O 
ERK [C]E [C]R [C]K S-protein 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
, [C], O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
RXRE-dependent [C]R [C]X [C]R [C]E [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

When [C]W [C]h [C]e [C]n O 
both [C]b [C]o [C]t [C]h O 
were [C]w [C]e [C]r [C]e O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
simultaneously [C]s [C]i [C]m [C]u [C]l [C]t [C]a [C]n [C]e [C]o [C]u [C]s [C]l [C]y O 
, [C], O 
JNK [C]J [C]N [C]K S-protein 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
was [C]w [C]a [C]s O 
dominant [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t O 
over [C]o [C]v [C]e [C]r O 
ERK [C]E [C]R [C]K S-protein 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
and [C]a [C]n [C]d O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
RXRE-mediated [C]R [C]X [C]R [C]E [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
a [C]a O 
dual [C]d [C]u [C]a [C]l O 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
of [C]o [C]f O 
RXRalpha [C]R [C]X [C]R [C]a [C]l [C]p [C]h [C]a S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
resting [C]r [C]e [C]s [C]t [C]i [C]n [C]g B-cell_type 
and [C]a [C]n [C]d I-cell_type 
cycling [C]c [C]y [C]c [C]l [C]i [C]n [C]g I-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
a [C]a O 
dynamic [C]d [C]y [C]n [C]a [C]m [C]i [C]c O 
balance [C]b [C]a [C]l [C]a [C]n [C]c [C]e O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
JNK [C]J [C]N [C]K O 
and [C]a [C]n [C]d O 
ERK [C]E [C]R [C]K O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
in [C]i [C]n O 
modulating [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
RXRE-mediated [C]R [C]X [C]R [C]E [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
transactivation [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
proteasome [C]p [C]r [C]o [C]t [C]e [C]a [C]s [C]o [C]m [C]e S-protein 
regulates [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]s O 
receptor-mediated [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
endocytosis [C]e [C]n [C]d [C]o [C]c [C]y [C]t [C]o [C]s [C]i [C]s O 
of [C]o [C]f O 
interleukin-2 [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]2 S-protein 
. [C]. O 

Recent [C]R [C]e [C]c [C]e [C]n [C]t O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
have [C]h [C]a [C]v [C]e O 
increasingly [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]i [C]n [C]g [C]l [C]y O 
implicated [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
proteasome [C]p [C]r [C]o [C]t [C]e [C]a [C]s [C]o [C]m [C]e S-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cell [C]c [C]e [C]l [C]l B-protein 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

In [C]I [C]n O 
the [C]t [C]h [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
study [C]s [C]t [C]u [C]d [C]y O 
, [C], O 
we [C]w [C]e O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
proteasome [C]p [C]r [C]o [C]t [C]e [C]a [C]s [C]o [C]m [C]e S-protein 
for [C]f [C]o [C]r O 
ligand-dependent [C]l [C]i [C]g [C]a [C]n [C]d [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
endocytosis [C]e [C]n [C]d [C]o [C]c [C]y [C]t [C]o [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
interleukin-2 [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]2 B-protein 
( [C]( I-protein 
IL-2 [C]I [C]L [C]- [C]2 I-protein 
) [C]) I-protein 
-interleukin-2 [C]- [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]2 I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
( [C]( I-protein 
IL-2R [C]I [C]L [C]- [C]2 [C]R I-protein 
) [C]) I-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
. [C]. O 

Proteasome [C]P [C]r [C]o [C]t [C]e [C]a [C]s [C]o [C]m [C]e O 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
impaired [C]i [C]m [C]p [C]a [C]i [C]r [C]e [C]d O 
internalization [C]i [C]n [C]t [C]e [C]r [C]n [C]a [C]l [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-2.IL-2R [C]I [C]L [C]- [C]2 [C]. [C]I [C]L [C]- [C]2 [C]R S-protein 
and [C]a [C]n [C]d O 
prevented [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
lysosomal [C]l [C]y [C]s [C]o [C]s [C]o [C]m [C]a [C]l O 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e S-protein 
. [C]. O 

Based [C]B [C]a [C]s [C]e [C]d O 
on [C]o [C]n O 
time-course [C]t [C]i [C]m [C]e [C]- [C]c [C]o [C]u [C]r [C]s [C]e O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
, [C], O 
proteasome [C]p [C]r [C]o [C]t [C]e [C]a [C]s [C]o [C]m [C]e S-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
is [C]i [C]s O 
primarily [C]p [C]r [C]i [C]m [C]a [C]r [C]i [C]l [C]y O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
after [C]a [C]f [C]t [C]e [C]r O 
initial [C]i [C]n [C]i [C]t [C]i [C]a [C]l O 
endocytosis [C]e [C]n [C]d [C]o [C]c [C]y [C]t [C]o [C]s [C]i [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IL-2.IL-2R [C]I [C]L [C]- [C]2 [C]. [C]I [C]L [C]- [C]2 [C]R S-protein 
. [C]. O 

Proteasome [C]P [C]r [C]o [C]t [C]e [C]a [C]s [C]o [C]m [C]e O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
necessary [C]n [C]e [C]c [C]e [C]s [C]s [C]a [C]r [C]y O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
lysosomal [C]l [C]y [C]s [C]o [C]s [C]o [C]m [C]a [C]l O 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
internalized [C]i [C]n [C]t [C]e [C]r [C]n [C]a [C]l [C]i [C]z [C]e [C]d O 
by [C]b [C]y O 
IL-2R [C]I [C]L [C]- [C]2 [C]R S-protein 
that [C]t [C]h [C]a [C]t O 
were [C]w [C]e [C]r [C]e O 
comprised [C]c [C]o [C]m [C]p [C]r [C]i [C]s [C]e [C]d O 
of [C]o [C]f O 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c B-protein 
tailless [C]t [C]a [C]i [C]l [C]l [C]e [C]s [C]s E-protein 
beta- [C]b [C]e [C]t [C]a [C]- B-protein 
or [C]o [C]r I-protein 
gamma [C]g [C]a [C]m [C]m [C]a I-protein 
c-subunits [C]c [C]- [C]s [C]u [C]b [C]u [C]n [C]i [C]t [C]s E-protein 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
proteasome [C]p [C]r [C]o [C]t [C]e [C]a [C]s [C]o [C]m [C]e S-protein 
is [C]i [C]s O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
of [C]o [C]f O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
the [C]t [C]h [C]e O 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c B-protein 
tail [C]t [C]a [C]i [C]l E-protein 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IL-2R [C]I [C]L [C]- [C]2 [C]R S-protein 
beta- [C]b [C]e [C]t [C]a [C]- B-protein 
or [C]o [C]r I-protein 
gamma [C]g [C]a [C]m [C]m [C]a I-protein 
c-subunits [C]c [C]- [C]s [C]u [C]b [C]u [C]n [C]i [C]t [C]s E-protein 
and [C]a [C]n [C]d O 
their [C]t [C]h [C]e [C]i [C]r O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
components [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t [C]s O 
. [C]. O 

Therefore [C]T [C]h [C]e [C]r [C]e [C]f [C]o [C]r [C]e O 
, [C], O 
a [C]a O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
proteasome [C]p [C]r [C]o [C]t [C]e [C]a [C]s [C]o [C]m [C]e S-protein 
is [C]i [C]s O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
optimal [C]o [C]p [C]t [C]i [C]m [C]a [C]l O 
endocytosis [C]e [C]n [C]d [C]o [C]c [C]y [C]t [C]o [C]s [C]i [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IL-2R/ligand [C]I [C]L [C]- [C]2 [C]R [C]/ [C]l [C]i [C]g [C]a [C]n [C]d B-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
subsequent [C]s [C]u [C]b [C]s [C]e [C]q [C]u [C]e [C]n [C]t O 
lysosomal [C]l [C]y [C]s [C]o [C]s [C]o [C]m [C]a [C]l O 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
, [C], O 
possibly [C]p [C]o [C]s [C]s [C]i [C]b [C]l [C]y O 
by [C]b [C]y O 
regulating [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
trafficking [C]t [C]r [C]a [C]f [C]f [C]i [C]c [C]k [C]i [C]n [C]g O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
lysosome [C]l [C]y [C]s [C]o [C]s [C]o [C]m [C]e O 
. [C]. O 

Functional [C]F [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
characterization [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
two [C]t [C]w [C]o O 
alternative [C]a [C]l [C]t [C]e [C]r [C]n [C]a [C]t [C]i [C]v [C]e O 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
p45 [C]p [C]4 [C]5 I-DNA 
NF-E2 [C]N [C]F [C]- [C]E [C]2 I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
. [C]. O 

OBJECTIVE [C]O [C]B [C]J [C]E [C]C [C]T [C]I [C]V [C]E O 
: [C]: O 
The [C]T [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
NF-E2 [C]N [C]F [C]- [C]E [C]2 E-protein 
, [C], O 
a [C]a O 
heterodimeric [C]h [C]e [C]t [C]e [C]r [C]o [C]d [C]i [C]m [C]e [C]r [C]i [C]c B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
composed [C]c [C]o [C]m [C]p [C]o [C]s [C]e [C]d O 
of [C]o [C]f O 
p45 [C]p [C]4 [C]5 S-protein 
and [C]a [C]n [C]d O 
small [C]s [C]m [C]a [C]l [C]l O 
Maf [C]M [C]a [C]f B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
, [C], O 
is [C]i [C]s O 
considered [C]c [C]o [C]n [C]s [C]i [C]d [C]e [C]r [C]e [C]d O 
crucial [C]c [C]r [C]u [C]c [C]i [C]a [C]l O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
proper [C]p [C]r [C]o [C]p [C]e [C]r O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
erythrocytes [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
and [C]a [C]n [C]d O 
megakaryocytes [C]m [C]e [C]g [C]a [C]k [C]a [C]r [C]y [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
. [C]. O 

We [C]W [C]e O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
the [C]t [C]h [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
of [C]o [C]f O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
aimed [C]a [C]i [C]m [C]e [C]d O 
at [C]a [C]t O 
understanding [C]u [C]n [C]d [C]e [C]r [C]s [C]t [C]a [C]n [C]d [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
controlling [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]l [C]i [C]n [C]g O 
p45 [C]p [C]4 [C]5 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

MATERIALS [C]M [C]A [C]T [C]E [C]R [C]I [C]A [C]L [C]S O 
AND [C]A [C]N [C]D O 
METHODS [C]M [C]E [C]T [C]H [C]O [C]D [C]S O 
: [C]: O 
Human [C]H [C]u [C]m [C]a [C]n B-RNA 
p45 [C]p [C]4 [C]5 I-RNA 
mRNAs [C]m [C]R [C]N [C]A [C]s E-RNA 
have [C]h [C]a [C]v [C]e O 
two [C]t [C]w [C]o O 
alternative [C]a [C]l [C]t [C]e [C]r [C]n [C]a [C]t [C]i [C]v [C]e O 
isoforms [C]i [C]s [C]o [C]f [C]o [C]r [C]m [C]s O 
, [C], O 
aNF-E2 [C]a [C]N [C]F [C]- [C]E [C]2 S-RNA 
and [C]a [C]n [C]d O 
fNF-E2 [C]f [C]N [C]F [C]- [C]E [C]2 S-RNA 
, [C], O 
and [C]a [C]n [C]d O 
these [C]t [C]h [C]e [C]s [C]e O 
isoforms [C]i [C]s [C]o [C]f [C]o [C]r [C]m [C]s O 
are [C]a [C]r [C]e O 
transcribed [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
alternative [C]a [C]l [C]t [C]e [C]r [C]n [C]a [C]t [C]i [C]v [C]e B-DNA 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s E-DNA 
. [C]. O 

We [C]W [C]e O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
lineage-specific [C]l [C]i [C]n [C]e [C]a [C]g [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
isomers [C]i [C]s [C]o [C]m [C]e [C]r [C]s O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n O 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d B-cell_type 
and [C]a [C]n [C]d I-cell_type 
megakaryocytic [C]m [C]e [C]g [C]a [C]k [C]a [C]r [C]y [C]o [C]c [C]y [C]t [C]i [C]c I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
by [C]b [C]y O 
reverse [C]r [C]e [C]v [C]e [C]r [C]s [C]e O 
transcriptase [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]a [C]s [C]e O 
polymerase [C]p [C]o [C]l [C]y [C]m [C]e [C]r [C]a [C]s [C]e O 
chain [C]c [C]h [C]a [C]i [C]n O 
reaction [C]r [C]e [C]a [C]c [C]t [C]i [C]o [C]n O 
or [C]o [C]r O 
Northern [C]N [C]o [C]r [C]t [C]h [C]e [C]r [C]n O 
blot [C]b [C]l [C]o [C]t O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
. [C]. O 

For [C]F [C]o [C]r O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
characterization [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s O 
, [C], O 
plasmids [C]p [C]l [C]a [C]s [C]m [C]i [C]d [C]s O 
in [C]i [C]n O 
which [C]w [C]h [C]i [C]c [C]h O 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
were [C]w [C]e [C]r [C]e O 
placed [C]p [C]l [C]a [C]c [C]e [C]d O 
under [C]u [C]n [C]d [C]e [C]r O 
the [C]t [C]h [C]e O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
of [C]o [C]f O 
a [C]a O 
series [C]s [C]e [C]r [C]i [C]e [C]s O 
of [C]o [C]f O 
truncated [C]t [C]r [C]u [C]n [C]c [C]a [C]t [C]e [C]d O 
or [C]o [C]r O 
mutated [C]m [C]u [C]t [C]a [C]t [C]e [C]d O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r B-DNA 
fragments [C]f [C]r [C]a [C]g [C]m [C]e [C]n [C]t [C]s E-DNA 
were [C]w [C]e [C]r [C]e O 
transfected [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]e [C]d O 
to [C]t [C]o O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
hematopoietic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
. [C]. O 

RESULTS [C]R [C]E [C]S [C]U [C]L [C]T [C]S O 
: [C]: O 
When [C]W [C]h [C]e [C]n O 
CD34 [C]C [C]D [C]3 [C]4 B-cell_type 
( [C]( I-cell_type 
+ [C]+ I-cell_type 
) [C]) I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
human [C]h [C]u [C]m [C]a [C]n O 
cord [C]c [C]o [C]r [C]d O 
blood [C]b [C]l [C]o [C]o [C]d O 
were [C]w [C]e [C]r [C]e O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
to [C]t [C]o O 
unilineage [C]u [C]n [C]i [C]l [C]i [C]n [C]e [C]a [C]g [C]e O 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d O 
or [C]o [C]r O 
megakaryocytic [C]m [C]e [C]g [C]a [C]k [C]a [C]r [C]y [C]o [C]c [C]y [C]t [C]i [C]c O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
liquid [C]l [C]i [C]q [C]u [C]i [C]d O 
suspension [C]s [C]u [C]s [C]p [C]e [C]n [C]s [C]i [C]o [C]n O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
, [C], O 
both [C]b [C]o [C]t [C]h O 
transcripts [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]s O 
, [C], O 
although [C]a [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
barely [C]b [C]a [C]r [C]e [C]l [C]y O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
at [C]a [C]t O 
day [C]d [C]a [C]y O 
0 [C]0 O 
, [C], O 
were [C]w [C]e [C]r [C]e O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d O 
and [C]a [C]n [C]d O 
megakaryocytic [C]m [C]e [C]g [C]a [C]k [C]a [C]r [C]y [C]o [C]c [C]y [C]t [C]i [C]c O 
cultures [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]s O 
. [C]. O 

fNF-E2 [C]f [C]N [C]F [C]- [C]E [C]2 B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
more [C]m [C]o [C]r [C]e O 
abundant [C]a [C]b [C]u [C]n [C]d [C]a [C]n [C]t O 
in [C]i [C]n O 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
than [C]t [C]h [C]a [C]n O 
megakaryocytic [C]m [C]e [C]g [C]a [C]k [C]a [C]r [C]y [C]o [C]c [C]y [C]t [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
at [C]a [C]t O 
day [C]d [C]a [C]y O 
7 [C]7 O 
of [C]o [C]f O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
both [C]b [C]o [C]t [C]h O 
isomers [C]i [C]s [C]o [C]m [C]e [C]r [C]s O 
were [C]w [C]e [C]r [C]e O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
erythroid-megakaryocytic [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d [C]- [C]m [C]e [C]g [C]a [C]k [C]a [C]r [C]y [C]o [C]c [C]y [C]t [C]i [C]c I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
, [C], O 
megakaryocytic [C]m [C]e [C]g [C]a [C]k [C]a [C]r [C]y [C]o [C]c [C]y [C]t [C]i [C]c O 
maturation [C]m [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
loss [C]l [C]o [C]s [C]s O 
of [C]o [C]f O 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
phorbol [C]p [C]h [C]o [C]r [C]b [C]o [C]l O 
12-myristate [C]1 [C]2 [C]- [C]m [C]y [C]r [C]i [C]s [C]t [C]a [C]t [C]e O 
13-acetate [C]1 [C]3 [C]- [C]a [C]c [C]e [C]t [C]a [C]t [C]e O 
( [C]( O 
PMA [C]P [C]M [C]A O 
) [C]) O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
exclusive [C]e [C]x [C]c [C]l [C]u [C]s [C]i [C]v [C]e O 
downregulation [C]d [C]o [C]w [C]n [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
fNF-E2 [C]f [C]N [C]F [C]- [C]E [C]2 S-RNA 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
fNF-E2 [C]f [C]N [C]F [C]- [C]E [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
is [C]i [C]s O 
more [C]m [C]o [C]r [C]e O 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
. [C]. O 

Functional [C]F [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
fNF-E2 [C]f [C]N [C]F [C]- [C]E [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
is [C]i [C]s O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
only [C]o [C]n [C]l [C]y O 
in [C]i [C]n O 
erythroid-megakaryocytic [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d [C]- [C]m [C]e [C]g [C]a [C]k [C]a [C]r [C]y [C]o [C]c [C]y [C]t [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
double [C]d [C]o [C]u [C]b [C]l [C]e B-DNA 
GATA [C]G [C]A [C]T [C]A I-DNA 
sit [C]s [C]i [C]t E-DNA 
e [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
proximal [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]l O 
region [C]r [C]e [C]g [C]i [C]o [C]n O 
is [C]i [C]s O 
necessary [C]n [C]e [C]c [C]e [C]s [C]s [C]a [C]r [C]y O 
for [C]f [C]o [C]r O 
its [C]i [C]t [C]s O 
efficient [C]e [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

CONCLUSION [C]C [C]O [C]N [C]C [C]L [C]U [C]S [C]I [C]O [C]N O 
: [C]: O 
These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
GATA [C]G [C]A [C]T [C]A B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
govern [C]g [C]o [C]v [C]e [C]r [C]n O 
the [C]t [C]h [C]e O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d B-cell_type 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
are [C]a [C]r [C]e O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
full [C]f [C]u [C]l [C]l O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
p45 [C]p [C]4 [C]5 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
. [C]. O 

Transcriptional [C]T [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
heme [C]h [C]e [C]m [C]e B-DNA 
oxygenase-1 [C]o [C]x [C]y [C]g [C]e [C]n [C]a [C]s [C]e [C]- [C]1 E-DNA 
and [C]a [C]n [C]d O 
its [C]i [C]t [C]s O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
significance [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]c [C]e O 
in [C]i [C]n O 
acetaminophen-induced [C]a [C]c [C]e [C]t [C]a [C]m [C]i [C]n [C]o [C]p [C]h [C]e [C]n [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
hepatitis [C]h [C]e [C]p [C]a [C]t [C]i [C]t [C]i [C]s O 
and [C]a [C]n [C]d O 
hepatocellular [C]h [C]e [C]p [C]a [C]t [C]o [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
injury [C]i [C]n [C]j [C]u [C]r [C]y O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
rat [C]r [C]a [C]t O 
. [C]. O 

BACKGROUND/AIM [C]B [C]A [C]C [C]K [C]G [C]R [C]O [C]U [C]N [C]D [C]/ [C]A [C]I [C]M O 
: [C]: O 
Glutathione [C]G [C]l [C]u [C]t [C]a [C]t [C]h [C]i [C]o [C]n [C]e O 
depletion [C]d [C]e [C]p [C]l [C]e [C]t [C]i [C]o [C]n O 
contributes [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e [C]s O 
to [C]t [C]o O 
acetaminophen [C]a [C]c [C]e [C]t [C]a [C]m [C]i [C]n [C]o [C]p [C]h [C]e [C]n O 
hepatotoxicity [C]h [C]e [C]p [C]a [C]t [C]o [C]t [C]o [C]x [C]i [C]c [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
known [C]k [C]n [C]o [C]w [C]n O 
to [C]t [C]o O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
the [C]t [C]h [C]e O 
oxidative [C]o [C]x [C]i [C]d [C]a [C]t [C]i [C]v [C]e O 
stress [C]s [C]t [C]r [C]e [C]s [C]s O 
reactant [C]r [C]e [C]a [C]c [C]t [C]a [C]n [C]t O 
heme [C]h [C]e [C]m [C]e B-protein 
oxygenase-1 [C]o [C]x [C]y [C]g [C]e [C]n [C]a [C]s [C]e [C]- [C]1 E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
metabolites [C]m [C]e [C]t [C]a [C]b [C]o [C]l [C]i [C]t [C]e [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
heme [C]h [C]e [C]m [C]e O 
oxygenase [C]o [C]x [C]y [C]g [C]e [C]n [C]a [C]s [C]e O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
, [C], O 
biliverdin [C]b [C]i [C]l [C]i [C]v [C]e [C]r [C]d [C]i [C]n O 
, [C], O 
carbon [C]c [C]a [C]r [C]b [C]o [C]n O 
monoxide [C]m [C]o [C]n [C]o [C]x [C]i [C]d [C]e O 
, [C], O 
and [C]a [C]n [C]d O 
iron [C]i [C]r [C]o [C]n O 
may [C]m [C]a [C]y O 
modulate [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]e O 
acetaminophen [C]a [C]c [C]e [C]t [C]a [C]m [C]i [C]n [C]o [C]p [C]h [C]e [C]n O 
toxicity [C]t [C]o [C]x [C]i [C]c [C]i [C]t [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
aim [C]a [C]i [C]m O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
study [C]s [C]t [C]u [C]d [C]y O 
was [C]w [C]a [C]s O 
to [C]t [C]o O 
assess [C]a [C]s [C]s [C]e [C]s [C]s O 
cell-type [C]c [C]e [C]l [C]l [C]- [C]t [C]y [C]p [C]e O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
heme [C]h [C]e [C]m [C]e B-DNA 
oxygenase-1 [C]o [C]x [C]y [C]g [C]e [C]n [C]a [C]s [C]e [C]- [C]1 E-DNA 
and [C]a [C]n [C]d O 
its [C]i [C]t [C]s O 
impact [C]i [C]m [C]p [C]a [C]c [C]t O 
on [C]o [C]n O 
liver [C]l [C]i [C]v [C]e [C]r O 
injury [C]i [C]n [C]j [C]u [C]r [C]y O 
and [C]a [C]n [C]d O 
microcirculatory [C]m [C]i [C]c [C]r [C]o [C]c [C]i [C]r [C]c [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
disturbances [C]d [C]i [C]s [C]t [C]u [C]r [C]b [C]a [C]n [C]c [C]e [C]s O 
in [C]i [C]n O 
a [C]a O 
model [C]m [C]o [C]d [C]e [C]l O 
of [C]o [C]f O 
acetaminophen-induced [C]a [C]c [C]e [C]t [C]a [C]m [C]i [C]n [C]o [C]p [C]h [C]e [C]n [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
hepatitis [C]h [C]e [C]p [C]a [C]t [C]i [C]t [C]i [C]s O 
. [C]. O 

METHODS [C]M [C]E [C]T [C]H [C]O [C]D [C]S O 
: [C]: O 
Gene [C]G [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
heme [C]h [C]e [C]m [C]e B-DNA 
oxygenase-1 [C]o [C]x [C]y [C]g [C]e [C]n [C]a [C]s [C]e [C]- [C]1 E-DNA 
was [C]w [C]a [C]s O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
by [C]b [C]y O 
Northern- [C]N [C]o [C]r [C]t [C]h [C]e [C]r [C]n [C]- O 
and [C]a [C]n [C]d O 
Western [C]W [C]e [C]s [C]t [C]e [C]r [C]n O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
immunohistochemistry [C]i [C]m [C]m [C]u [C]n [C]o [C]h [C]i [C]s [C]t [C]o [C]c [C]h [C]e [C]m [C]i [C]s [C]t [C]r [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
time [C]t [C]i [C]m [C]e O 
course [C]c [C]o [C]u [C]r [C]s [C]e O 
of [C]o [C]f O 
heme [C]h [C]e [C]m [C]e B-protein 
oxygenase-1 [C]o [C]x [C]y [C]g [C]e [C]n [C]a [C]s [C]e [C]- [C]1 I-protein 
and [C]a [C]n [C]d I-protein 
-2 [C]- [C]2 E-protein 
, [C], O 
cytokine-induced [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d B-protein 
neutrophil [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]h [C]i [C]l I-protein 
chemoattractant-1 [C]c [C]h [C]e [C]m [C]o [C]a [C]t [C]t [C]r [C]a [C]c [C]t [C]a [C]n [C]t [C]- [C]1 E-protein 
, [C], O 
and [C]a [C]n [C]d O 
intercellular [C]i [C]n [C]t [C]e [C]r [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n I-protein 
molecule-1 [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]- [C]1 E-protein 
was [C]w [C]a [C]s O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
by [C]b [C]y O 
Northern [C]N [C]o [C]r [C]t [C]h [C]e [C]r [C]n O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
. [C]. O 

DNA-binding [C]D [C]N [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor-kappaB [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
was [C]w [C]a [C]s O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
electrophoretic [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
assay [C]a [C]s [C]s [C]a [C]y O 
. [C]. O 

Sinusoidal [C]S [C]i [C]n [C]u [C]s [C]o [C]i [C]d [C]a [C]l O 
perfusion [C]p [C]e [C]r [C]f [C]u [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
leukocyte-endothelial [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]- [C]e [C]n [C]d [C]o [C]t [C]h [C]e [C]l [C]i [C]a [C]l O 
interactions [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
were [C]w [C]e [C]r [C]e O 
assessed [C]a [C]s [C]s [C]e [C]s [C]s [C]e [C]d O 
by [C]b [C]y O 
intravital [C]i [C]n [C]t [C]r [C]a [C]v [C]i [C]t [C]a [C]l O 
microscopy [C]m [C]i [C]c [C]r [C]o [C]s [C]c [C]o [C]p [C]y O 
. [C]. O 

RESULTS [C]R [C]E [C]S [C]U [C]L [C]T [C]S O 
: [C]: O 
Acetaminophen [C]A [C]c [C]e [C]t [C]a [C]m [C]i [C]n [C]o [C]p [C]h [C]e [C]n O 
caused [C]c [C]a [C]u [C]s [C]e [C]d O 
a [C]a O 
moderate [C]m [C]o [C]d [C]e [C]r [C]a [C]t [C]e O 
sinusoidal [C]s [C]i [C]n [C]u [C]s [C]o [C]i [C]d [C]a [C]l O 
perfusion [C]p [C]e [C]r [C]f [C]u [C]s [C]i [C]o [C]n O 
failure [C]f [C]a [C]i [C]l [C]u [C]r [C]e O 
( [C]( O 
-15 [C]- [C]1 [C]5 O 
% [C]% O 
) [C]) O 
and [C]a [C]n [C]d O 
infiltration [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
neutrophils [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]h [C]i [C]l [C]s S-cell_type 
along [C]a [C]l [C]o [C]n [C]g O 
with [C]w [C]i [C]t [C]h O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor-kappaB [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
and [C]a [C]n [C]d O 
intercellular [C]i [C]n [C]t [C]e [C]r [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n I-protein 
molecule-1 [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]- [C]1 E-protein 
and [C]a [C]n [C]d O 
cytokine-induced [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d B-protein 
neutrophil [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]h [C]i [C]l I-protein 
chemoattractant-1 [C]c [C]h [C]e [C]m [C]o [C]a [C]t [C]t [C]r [C]a [C]c [C]t [C]a [C]n [C]t [C]- [C]1 E-protein 
mRNAs [C]m [C]R [C]N [C]A [C]s O 
. [C]. O 

Induction [C]I [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
heme [C]h [C]e [C]m [C]e B-protein 
oxygenase-1 [C]o [C]x [C]y [C]g [C]e [C]n [C]a [C]s [C]e [C]- [C]1 E-protein 
mRNA [C]m [C]R [C]N [C]A O 
and [C]a [C]n [C]d O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
( [C]( O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
30-fold [C]3 [C]0 [C]- [C]f [C]o [C]l [C]d O 
) [C]) O 
in [C]i [C]n O 
hepatocytes [C]h [C]e [C]p [C]a [C]t [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
and [C]a [C]n [C]d O 
non-parenchymal [C]n [C]o [C]n [C]- [C]p [C]a [C]r [C]e [C]n [C]c [C]h [C]y [C]m [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
paralleled [C]p [C]a [C]r [C]a [C]l [C]l [C]e [C]l [C]e [C]d O 
the [C]t [C]h [C]e O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
. [C]. O 

Blockade [C]B [C]l [C]o [C]c [C]k [C]a [C]d [C]e O 
of [C]o [C]f O 
heme [C]h [C]e [C]m [C]e O 
oxygenase [C]o [C]x [C]y [C]g [C]e [C]n [C]a [C]s [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
with [C]w [C]i [C]t [C]h O 
tin-protoporphyrin-IX [C]t [C]i [C]n [C]- [C]p [C]r [C]o [C]t [C]o [C]p [C]o [C]r [C]p [C]h [C]y [C]r [C]i [C]n [C]- [C]I [C]X O 
abrogated [C]a [C]b [C]r [C]o [C]g [C]a [C]t [C]e [C]d O 
acetaminophen-induced [C]a [C]c [C]e [C]t [C]a [C]m [C]i [C]n [C]o [C]p [C]h [C]e [C]n [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
hepatic [C]h [C]e [C]p [C]a [C]t [C]i [C]c B-cell_type 
neutrophil [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]h [C]i [C]l E-cell_type 
accumulation [C]a [C]c [C]c [C]u [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor-kappaB [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
but [C]b [C]u [C]t O 
failed [C]f [C]a [C]i [C]l [C]e [C]d O 
to [C]t [C]o O 
affect [C]a [C]f [C]f [C]e [C]c [C]t O 
sinusoidal [C]s [C]i [C]n [C]u [C]s [C]o [C]i [C]d [C]a [C]l O 
perfusion [C]p [C]e [C]r [C]f [C]u [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
liver [C]l [C]i [C]v [C]e [C]r O 
injury [C]i [C]n [C]j [C]u [C]r [C]y O 
. [C]. O 

CONCLUSIONS [C]C [C]O [C]N [C]C [C]L [C]U [C]S [C]I [C]O [C]N [C]S O 
: [C]: O 
The [C]T [C]h [C]e O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
acetaminophen [C]a [C]c [C]e [C]t [C]a [C]m [C]i [C]n [C]o [C]p [C]h [C]e [C]n O 
hepatotoxicity [C]h [C]e [C]p [C]a [C]t [C]o [C]t [C]o [C]x [C]i [C]c [C]i [C]t [C]y O 
is [C]i [C]s O 
modulated [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
parallel [C]p [C]a [C]r [C]a [C]l [C]l [C]e [C]l O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
heme [C]h [C]e [C]m [C]e B-DNA 
oxygenase-1 [C]o [C]x [C]y [C]g [C]e [C]n [C]a [C]s [C]e [C]- [C]1 I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
heme [C]h [C]e [C]m [C]e B-DNA 
oxygenase-1 [C]o [C]x [C]y [C]g [C]e [C]n [C]a [C]s [C]e [C]- [C]1 E-DNA 
has [C]h [C]a [C]s O 
no [C]n [C]o O 
permissive [C]p [C]e [C]r [C]m [C]i [C]s [C]s [C]i [C]v [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
sinusoidal [C]s [C]i [C]n [C]u [C]s [C]o [C]i [C]d [C]a [C]l O 
perfusion [C]p [C]e [C]r [C]f [C]u [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
does [C]d [C]o [C]e [C]s O 
not [C]n [C]o [C]t O 
affect [C]a [C]f [C]f [C]e [C]c [C]t O 
liver [C]l [C]i [C]v [C]e [C]r O 
injury [C]i [C]n [C]j [C]u [C]r [C]y O 
in [C]i [C]n O 
this [C]t [C]h [C]i [C]s O 
model [C]m [C]o [C]d [C]e [C]l O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
argue [C]a [C]r [C]g [C]u [C]e O 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
a [C]a O 
central [C]c [C]e [C]n [C]t [C]r [C]a [C]l O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor-kappaB [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a [C]B E-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
neutrophil [C]n [C]e [C]u [C]t [C]r [C]o [C]p [C]h [C]i [C]l O 
infiltration [C]i [C]n [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
as [C]a [C]s O 
perpetuating [C]p [C]e [C]r [C]p [C]e [C]t [C]u [C]a [C]t [C]i [C]n [C]g O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
of [C]o [C]f O 
liver [C]l [C]i [C]v [C]e [C]r O 
injury [C]i [C]n [C]j [C]u [C]r [C]y O 
in [C]i [C]n O 
acetaminophen [C]a [C]c [C]e [C]t [C]a [C]m [C]i [C]n [C]o [C]p [C]h [C]e [C]n O 
toxicity [C]t [C]o [C]x [C]i [C]c [C]i [C]t [C]y O 
. [C]. O 

Tumor [C]T [C]u [C]m [C]o [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor-alpha [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]a [C]l [C]p [C]h [C]a E-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
requires [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]s O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
granulocyte-macrophage [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e [C]- [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e B-protein 
colony-stimulating [C]c [C]o [C]l [C]o [C]n [C]y [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]n [C]g I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
. [C]. O 

OBJECTIVE [C]O [C]B [C]J [C]E [C]C [C]T [C]I [C]V [C]E O 
: [C]: O 
Tumor [C]T [C]u [C]m [C]o [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor- [C]f [C]a [C]c [C]t [C]o [C]r [C]- I-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
( [C]( O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
) [C]) O 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
a [C]a O 
variety [C]v [C]a [C]r [C]i [C]e [C]t [C]y O 
of [C]o [C]f O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
, [C], O 
some [C]s [C]o [C]m [C]e O 
of [C]o [C]f O 
them [C]t [C]h [C]e [C]m O 
being [C]b [C]e [C]i [C]n [C]g O 
at [C]a [C]t O 
least [C]l [C]e [C]a [C]s [C]t O 
seemingly [C]s [C]e [C]e [C]m [C]i [C]n [C]g [C]l [C]y O 
contradictory [C]c [C]o [C]n [C]t [C]r [C]a [C]d [C]i [C]c [C]t [C]o [C]r [C]y O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
we [C]w [C]e O 
set [C]s [C]e [C]t O 
out [C]o [C]u [C]t O 
to [C]t [C]o O 
find [C]f [C]i [C]n [C]d O 
differences [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
modes [C]m [C]o [C]d [C]e [C]s O 
of [C]o [C]f O 
proliferative [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
and [C]a [C]n [C]d O 
apoptotic [C]a [C]p [C]o [C]p [C]t [C]o [C]t [C]i [C]c O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
to [C]t [C]o O 
TNF- [C]T [C]N [C]F [C]- B-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
. [C]. O 

MATERIALS [C]M [C]A [C]T [C]E [C]R [C]I [C]A [C]L [C]S O 
AND [C]A [C]N [C]D O 
METHODS [C]M [C]E [C]T [C]H [C]O [C]D [C]S O 
: [C]: O 
We [C]W [C]e O 
screened [C]s [C]c [C]r [C]e [C]e [C]n [C]e [C]d O 
a [C]a O 
panel [C]p [C]a [C]n [C]e [C]l O 
of [C]o [C]f O 
acute [C]a [C]c [C]u [C]t [C]e B-cell_line 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d I-cell_line 
leukemia-derived [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a [C]- [C]d [C]e [C]r [C]i [C]v [C]e [C]d I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
for [C]f [C]o [C]r O 
TNF- [C]T [C]N [C]F [C]- B-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
-responsiveness [C]- [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e [C]n [C]e [C]s [C]s O 
. [C]. O 

In [C]I [C]n O 
two [C]t [C]w [C]o O 
lines [C]l [C]i [C]n [C]e [C]s O 
( [C]( O 
OCI-AML-1 [C]O [C]C [C]I [C]- [C]A [C]M [C]L [C]- [C]1 S-cell_line 
, [C], O 
OCI-AML-11 [C]O [C]C [C]I [C]- [C]A [C]M [C]L [C]- [C]1 [C]1 S-cell_line 
) [C]) O 
, [C], O 
TNF- [C]T [C]N [C]F [C]- B-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
acted [C]a [C]c [C]t [C]e [C]d O 
as [C]a [C]s O 
an [C]a [C]n O 
apoptotic [C]a [C]p [C]o [C]p [C]t [C]o [C]t [C]i [C]c O 
agent [C]a [C]g [C]e [C]n [C]t O 
; [C]; O 
in [C]i [C]n O 
others [C]o [C]t [C]h [C]e [C]r [C]s O 
( [C]( O 
HU-3 [C]H [C]U [C]- [C]3 S-cell_line 
, [C], O 
M-07e [C]M [C]- [C]0 [C]7 [C]e S-cell_line 
, [C], O 
TF-1 [C]T [C]F [C]- [C]1 S-cell_line 
) [C]) O 
, [C], O 
it [C]i [C]t O 
had [C]h [C]a [C]d O 
the [C]t [C]h [C]e O 
opposite [C]o [C]p [C]p [C]o [C]s [C]i [C]t [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
, [C], O 
preventing [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]i [C]n [C]g O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
inducing [C]i [C]n [C]d [C]u [C]c [C]i [C]n [C]g O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Direct [C]D [C]i [C]r [C]e [C]c [C]t O 
and [C]a [C]n [C]d O 
indirect [C]i [C]n [C]d [C]i [C]r [C]e [C]c [C]t O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
, [C], O 
were [C]w [C]e [C]r [C]e O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
. [C]. O 

RESULTS [C]R [C]E [C]S [C]U [C]L [C]T [C]S O 
: [C]: O 
All [C]A [C]l [C]l O 
cell [C]c [C]e [C]l [C]l O 
lines [C]l [C]i [C]n [C]e [C]s O 
tested [C]t [C]e [C]s [C]t [C]e [C]d O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
TNF- [C]T [C]N [C]F [C]- B-protein 
alpha [C]a [C]l [C]p [C]h [C]a I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s I-protein 
I [C]I I-protein 
and [C]a [C]n [C]d I-protein 
II [C]I [C]I E-protein 
and [C]a [C]n [C]d O 
responded [C]r [C]e [C]s [C]p [C]o [C]n [C]d [C]e [C]d O 
to [C]t [C]o O 
TNF- [C]T [C]N [C]F [C]- B-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
by [C]b [C]y O 
upregulation [C]u [C]p [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
intercellular [C]i [C]n [C]t [C]e [C]r [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n I-protein 
molecule-1 [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]- [C]1 E-protein 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
to [C]t [C]o O 
granulocyte-macrophage [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e [C]- [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e B-protein 
colony-stimulating [C]c [C]o [C]l [C]o [C]n [C]y [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]n [C]g I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
( [C]( O 
GM-CSF [C]G [C]M [C]- [C]C [C]S [C]F S-protein 
) [C]) O 
, [C], O 
TNF- [C]T [C]N [C]F [C]- B-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
MAP [C]M [C]A [C]P B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
and [C]a [C]n [C]d O 
p70S6 [C]p [C]7 [C]0 [C]S [C]6 O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
. [C]. O 

Nevertheless [C]N [C]e [C]v [C]e [C]r [C]t [C]h [C]e [C]l [C]e [C]s [C]s O 
, [C], O 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
clearly [C]c [C]l [C]e [C]a [C]r [C]l [C]y O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
the [C]t [C]h [C]e O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
cell [C]c [C]e [C]l [C]l O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
, [C], O 
indicating [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
TNF- [C]T [C]N [C]F [C]- B-cell_type 
alpha-proliferative [C]a [C]l [C]p [C]h [C]a [C]- [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]v [C]e I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
produced [C]p [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
a [C]a O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
that [C]t [C]h [C]a [C]t O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
upon [C]u [C]p [C]o [C]n O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
above [C]a [C]b [C]o [C]v [C]e O 
pathways [C]p [C]a [C]t [C]h [C]w [C]a [C]y [C]s O 
. [C]. O 

Anti-GM-CSF [C]A [C]n [C]t [C]i [C]- [C]G [C]M [C]- [C]C [C]S [C]F B-protein 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s E-protein 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
an [C]a [C]n O 
autocrine [C]a [C]u [C]t [C]o [C]c [C]r [C]i [C]n [C]e O 
loop [C]l [C]o [C]o [C]p O 
for [C]f [C]o [C]r O 
cell [C]c [C]e [C]l [C]l O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
GM-CSF [C]G [C]M [C]- [C]C [C]S [C]F S-protein 
. [C]. O 

Supporting [C]S [C]u [C]p [C]p [C]o [C]r [C]t [C]i [C]n [C]g O 
this [C]t [C]h [C]i [C]s O 
notion [C]n [C]o [C]t [C]i [C]o [C]n O 
, [C], O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
upregulation [C]u [C]p [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
GM-CSF [C]G [C]M [C]- [C]C [C]S [C]F B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
and [C]a [C]n [C]d O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
secretion [C]s [C]e [C]c [C]r [C]e [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
-proliferative [C]- [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
TNF-alpha-apoptotic [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a [C]- [C]a [C]p [C]o [C]p [C]t [C]o [C]t [C]i [C]c B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
. [C]. O 

CONCLUSION [C]C [C]O [C]N [C]C [C]L [C]U [C]S [C]I [C]O [C]N O 
: [C]: O 
These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
identify [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]y O 
GM-CSF [C]G [C]M [C]- [C]C [C]S [C]F S-protein 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
as [C]a [C]s O 
an [C]a [C]n O 
early [C]e [C]a [C]r [C]l [C]y O 
and [C]a [C]n [C]d O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
step [C]s [C]t [C]e [C]p O 
in [C]i [C]n O 
TNF- [C]T [C]N [C]F [C]- O 
alpha-induced [C]a [C]l [C]p [C]h [C]a [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

We [C]W [C]e O 
show [C]s [C]h [C]o [C]w O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
first [C]f [C]i [C]r [C]s [C]t O 
time [C]t [C]i [C]m [C]e O 
that [C]t [C]h [C]a [C]t O 
TNF-alpha-treated [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a [C]- [C]t [C]r [C]e [C]a [C]t [C]e [C]d B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
producing [C]p [C]r [C]o [C]d [C]u [C]c [C]i [C]n [C]g O 
no [C]n [C]o O 
or [C]o [C]r O 
only [C]o [C]n [C]l [C]y O 
minimal [C]m [C]i [C]n [C]i [C]m [C]a [C]l O 
amounts [C]a [C]m [C]o [C]u [C]n [C]t [C]s O 
of [C]o [C]f O 
GM-CSF [C]G [C]M [C]- [C]C [C]S [C]F S-protein 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
an [C]a [C]n O 
apoptotic [C]a [C]p [C]o [C]p [C]t [C]o [C]t [C]i [C]c O 
phenotype [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e O 
, [C], O 
while [C]w [C]h [C]i [C]l [C]e O 
cell [C]c [C]e [C]l [C]l O 
lines [C]l [C]i [C]n [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
high [C]h [C]i [C]g [C]h O 
GM-CSF [C]G [C]M [C]- [C]C [C]S [C]F S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
rates [C]r [C]a [C]t [C]e [C]s O 
can [C]c [C]a [C]n O 
escape [C]e [C]s [C]c [C]a [C]p [C]e O 
from [C]f [C]r [C]o [C]m O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
arrest [C]a [C]r [C]r [C]e [C]s [C]t O 
or [C]o [C]r O 
even [C]e [C]v [C]e [C]n O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
context [C]c [C]o [C]n [C]t [C]e [C]x [C]t O 
, [C], O 
we [C]w [C]e O 
discuss [C]d [C]i [C]s [C]c [C]u [C]s [C]s O 
arguments [C]a [C]r [C]g [C]u [C]m [C]e [C]n [C]t [C]s O 
pointing [C]p [C]o [C]i [C]n [C]t [C]i [C]n [C]g O 
at [C]a [C]t O 
NF-kappaB [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a [C]B S-protein 
as [C]a [C]s O 
regulator [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r O 
of [C]o [C]f O 
GM-CSF [C]G [C]M [C]- [C]C [C]S [C]F S-protein 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
thus [C]t [C]h [C]u [C]s O 
indirectly [C]i [C]n [C]d [C]i [C]r [C]e [C]c [C]t [C]l [C]y O 
as [C]a [C]s O 
regulator [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
escape [C]e [C]s [C]c [C]a [C]p [C]e O 
of [C]o [C]f O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
apoptosis [C]a [C]p [C]o [C]p [C]t [C]o [C]s [C]i [C]s O 

Glucocorticoid [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
of [C]o [C]f O 
T [C]T B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
: [C]: O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
for [C]f [C]o [C]r O 
heterogeneity [C]h [C]e [C]t [C]e [C]r [C]o [C]g [C]e [C]n [C]e [C]i [C]t [C]y O 
. [C]. O 

Glucocorticoid [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
were [C]w [C]e [C]r [C]e O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
in [C]i [C]n O 
T [C]T B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
that [C]t [C]h [C]a [C]t O 
were [C]w [C]e [C]r [C]e O 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l O 
blood [C]b [C]l [C]o [C]o [C]d O 
by [C]b [C]y O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
nylon [C]n [C]y [C]l [C]o [C]n O 
wool [C]w [C]o [C]o [C]l O 
filtration [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
or [C]o [C]r O 
E-rosette [C]E [C]- [C]r [C]o [C]s [C]e [C]t [C]t [C]e O 
sedimentation [C]s [C]e [C]d [C]i [C]m [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
nylon [C]n [C]y [C]l [C]o [C]n O 
wool [C]w [C]o [C]o [C]l O 
filtration [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
specifically [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]a [C]l [C]l [C]y O 
bind [C]b [C]i [C]n [C]d O 
6.7 [C]6 [C]. [C]7 O 
+/- [C]+ [C]/ [C]- O 
0.2 [C]0 [C]. [C]2 O 
fmol [C]f [C]m [C]o [C]l O 
of [C]o [C]f O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
per [C]p [C]e [C]r O 
million [C]m [C]i [C]l [C]l [C]i [C]o [C]n O 
cells [C]c [C]e [C]l [C]l [C]s O 
( [C]( O 
equivalent [C]e [C]q [C]u [C]i [C]v [C]a [C]l [C]e [C]n [C]t O 
to [C]t [C]o O 
4000 [C]4 [C]0 [C]0 [C]0 O 
+/- [C]+ [C]/ [C]- O 
200 [C]2 [C]0 [C]0 O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
per [C]p [C]e [C]r O 
cell [C]c [C]e [C]l [C]l O 
) [C]) O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
E-rosette [C]E [C]- [C]r [C]o [C]s [C]e [C]t [C]t [C]e O 
sedimentation [C]s [C]e [C]d [C]i [C]m [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
bind [C]b [C]i [C]n [C]d O 
12.0 [C]1 [C]2 [C]. [C]0 O 
+/- [C]+ [C]/ [C]- O 
0.7 [C]0 [C]. [C]7 O 
fmol [C]f [C]m [C]o [C]l O 
of [C]o [C]f O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
per [C]p [C]e [C]r O 
million [C]m [C]i [C]l [C]l [C]i [C]o [C]n O 
cells [C]c [C]e [C]l [C]l [C]s O 
( [C]( O 
equivalent [C]e [C]q [C]u [C]i [C]v [C]a [C]l [C]e [C]n [C]t O 
to [C]t [C]o O 
7200 [C]7 [C]2 [C]0 [C]0 O 
+/- [C]+ [C]/ [C]- O 
400 [C]4 [C]0 [C]0 O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
per [C]p [C]e [C]r O 
cell [C]c [C]e [C]l [C]l O 
) [C]) O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
difference [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
amount [C]a [C]m [C]o [C]u [C]n [C]t O 
of [C]o [C]f O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
bound [C]b [C]o [C]u [C]n [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
two [C]t [C]w [C]o O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
preparations [C]p [C]r [C]e [C]p [C]a [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
was [C]w [C]a [C]s O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
( [C]( O 
p [C]p O 
less [C]l [C]e [C]s [C]s O 
than [C]t [C]h [C]a [C]n O 
.001 [C]. [C]0 [C]0 [C]1 O 
) [C]) O 
and [C]a [C]n [C]d O 
was [C]w [C]a [C]s O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
immediately [C]i [C]m [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]l [C]y O 
after [C]a [C]f [C]t [C]e [C]r O 
cell [C]c [C]e [C]l [C]l O 
isolation [C]i [C]s [C]o [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
affinities [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]i [C]e [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
T [C]T B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
preparations [C]p [C]r [C]e [C]p [C]a [C]r [C]a [C]t [C]i [C]o [C]n [C]s E-cell_line 
for [C]f [C]o [C]r O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
were [C]w [C]e [C]r [C]e O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
. [C]. O 

T [C]T O 
cells [C]c [C]e [C]l [C]l [C]s O 
that [C]t [C]h [C]a [C]t O 
are [C]a [C]r [C]e O 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
combination [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
nylon [C]n [C]y [C]l [C]o [C]n O 
wool [C]w [C]o [C]o [C]l O 
filtration [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
followed [C]f [C]o [C]l [C]l [C]o [C]w [C]e [C]d O 
by [C]b [C]y O 
E-rosette [C]E [C]- [C]r [C]o [C]s [C]e [C]t [C]t [C]e O 
sedimentation [C]s [C]e [C]d [C]i [C]m [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
bind [C]b [C]i [C]n [C]d O 
the [C]t [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
amount [C]a [C]m [C]o [C]u [C]n [C]t O 
of [C]o [C]f O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
as [C]a [C]s O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
nylon [C]n [C]y [C]l [C]o [C]n O 
wool [C]w [C]o [C]o [C]l O 
filtration [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
alone [C]a [C]l [C]o [C]n [C]e O 
. [C]. O 

T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
combination [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
E-rosette [C]E [C]- [C]r [C]o [C]s [C]e [C]t [C]t [C]e O 
sedimentation [C]s [C]e [C]d [C]i [C]m [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
by [C]b [C]y O 
nylon [C]n [C]y [C]l [C]o [C]n O 
wool [C]w [C]o [C]o [C]l O 
filtration [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
bind [C]b [C]i [C]n [C]d O 
less [C]l [C]e [C]s [C]s O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
than [C]t [C]h [C]a [C]n O 
do [C]d [C]o O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
E-rosette [C]E [C]- [C]r [C]o [C]s [C]e [C]t [C]t [C]e O 
sedimentation [C]s [C]e [C]d [C]i [C]m [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
alone [C]a [C]l [C]o [C]n [C]e O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
are [C]a [C]r [C]e O 
heterogeneous [C]h [C]e [C]t [C]e [C]r [C]o [C]g [C]e [C]n [C]e [C]o [C]u [C]s O 
with [C]w [C]i [C]t [C]h O 
respect [C]r [C]e [C]s [C]p [C]e [C]c [C]t O 
to [C]t [C]o O 
their [C]t [C]h [C]e [C]i [C]r O 
quantity [C]q [C]u [C]a [C]n [C]t [C]i [C]t [C]y O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

Isolation [C]I [C]s [C]o [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
by [C]b [C]y O 
E-rosette [C]E [C]- [C]r [C]o [C]s [C]e [C]t [C]t [C]e O 
sedimentation [C]s [C]e [C]d [C]i [C]m [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
enriches [C]e [C]n [C]r [C]i [C]c [C]h [C]e [C]s O 
for [C]f [C]o [C]r O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
that [C]t [C]h [C]a [C]t O 
have [C]h [C]a [C]v [C]e O 
a [C]a O 
greater [C]g [C]r [C]e [C]a [C]t [C]e [C]r O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
, [C], O 
and [C]a [C]n [C]d O 
isolation [C]i [C]s [C]o [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
by [C]b [C]y O 
nylon [C]n [C]y [C]l [C]o [C]n O 
wool [C]w [C]o [C]o [C]l O 
filtration [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
enriches [C]e [C]n [C]r [C]i [C]c [C]h [C]e [C]s O 
for [C]f [C]o [C]r O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
that [C]t [C]h [C]a [C]t O 
have [C]h [C]a [C]v [C]e O 
a [C]a O 
lesser [C]l [C]e [C]s [C]s [C]e [C]r O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

Glucocorticoid [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
and [C]a [C]n [C]d O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
established [C]e [C]s [C]t [C]a [C]b [C]l [C]i [C]s [C]h [C]e [C]d O 
optimal [C]o [C]p [C]t [C]i [C]m [C]a [C]l O 
conditions [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n [C]s O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
measurement [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
( [C]( O 
GR [C]G [C]R S-protein 
) [C]) O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
white [C]w [C]h [C]i [C]t [C]e I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
using [C]u [C]s [C]i [C]n [C]g O 
a [C]a O 
whole-cell [C]w [C]h [C]o [C]l [C]e [C]- [C]c [C]e [C]l [C]l O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
assay [C]a [C]s [C]s [C]a [C]y O 
with [C]w [C]i [C]t [C]h O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
as [C]a [C]s O 
the [C]t [C]h [C]e O 
ligand [C]l [C]i [C]g [C]a [C]n [C]d O 
, [C], O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
subsequent [C]s [C]u [C]b [C]s [C]e [C]q [C]u [C]e [C]n [C]t O 
determination [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
GR [C]G [C]R S-protein 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
of [C]o [C]f O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
forms [C]f [C]o [C]r [C]m [C]s O 
of [C]o [C]f O 
acute [C]a [C]c [C]u [C]t [C]e O 
and [C]a [C]n [C]d O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
. [C]. O 

A [C]A O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
in [C]i [C]n O 
continuous [C]c [C]o [C]n [C]t [C]i [C]n [C]u [C]o [C]u [C]s O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
were [C]w [C]e [C]r [C]e O 
also [C]a [C]l [C]s [C]o O 
subjected [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
GR [C]G [C]R S-protein 
assay [C]a [C]s [C]s [C]a [C]y O 
, [C], O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
were [C]w [C]e [C]r [C]e O 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
cell [C]c [C]e [C]l [C]l B-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
to [C]t [C]o O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
steroids [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]s O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
. [C]. O 

The [C]T [C]h [C]e O 
GR [C]G [C]R S-protein 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
of [C]o [C]f O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
amounted [C]a [C]m [C]o [C]u [C]n [C]t [C]e [C]d O 
to [C]t [C]o O 
4 [C]4 O 
, [C], O 
850 [C]8 [C]5 [C]0 O 
+/- [C]+ [C]/ [C]- O 
1 [C]1 O 
, [C], O 
340 [C]3 [C]4 [C]0 O 
( [C]( O 
mean [C]m [C]e [C]a [C]n O 
+/- [C]+ [C]/ [C]- O 
SD [C]S [C]D O 
) [C]) O 
receptors/cell [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s [C]/ [C]c [C]e [C]l [C]l O 
. [C]. O 

The [C]T [C]h [C]e O 
mean [C]m [C]e [C]a [C]n O 
equilibrium [C]e [C]q [C]u [C]i [C]l [C]i [C]b [C]r [C]i [C]u [C]m O 
dissociation [C]d [C]i [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
constant [C]c [C]o [C]n [C]s [C]t [C]a [C]n [C]t O 
( [C]( O 
KD [C]K [C]D O 
) [C]) O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
GR [C]G [C]R S-protein 
was [C]w [C]a [C]s O 
1.2 [C]1 [C]. [C]2 O 
x [C]x O 
10 [C]1 [C]0 O 
( [C]( O 
-8 [C]- [C]8 O 
) [C]) O 
M [C]M O 
. [C]. O 

Steroidal [C]S [C]t [C]e [C]r [C]o [C]i [C]d [C]a [C]l O 
compounds [C]c [C]o [C]m [C]p [C]o [C]u [C]n [C]d [C]s O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
known [C]k [C]n [C]o [C]w [C]n O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
potency [C]p [C]o [C]t [C]e [C]n [C]c [C]y O 
effectively [C]e [C]f [C]f [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
competed [C]c [C]o [C]m [C]p [C]e [C]t [C]e [C]d O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
steroids [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]s O 
devoid [C]d [C]e [C]v [C]o [C]i [C]d O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
( [C]( O 
e.g. [C]e [C]. [C]g [C]. O 
estradiol-17 [C]e [C]s [C]t [C]r [C]a [C]d [C]i [C]o [C]l [C]- [C]1 [C]7 O 
beta [C]b [C]e [C]t [C]a O 
and [C]a [C]n [C]d O 
testosterone [C]t [C]e [C]s [C]t [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
) [C]) O 
were [C]w [C]e [C]r [C]e O 
ineffective [C]i [C]n [C]e [C]f [C]f [C]e [C]c [C]t [C]i [C]v [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
GR [C]G [C]R S-protein 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
blast [C]b [C]l [C]a [C]s [C]t B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
eight [C]e [C]i [C]g [C]h [C]t O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
suffering [C]s [C]u [C]f [C]f [C]e [C]r [C]i [C]n [C]g O 
from [C]f [C]r [C]o [C]m O 
acute [C]a [C]c [C]u [C]t [C]e O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
and [C]a [C]n [C]d O 
four [C]f [C]o [C]u [C]r O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
blast [C]b [C]l [C]a [C]s [C]t O 
crisis [C]c [C]r [C]i [C]s [C]i [C]s O 
of [C]o [C]f O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
myelocytic [C]m [C]y [C]e [C]l [C]o [C]c [C]y [C]t [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
highly [C]h [C]i [C]g [C]h [C]l [C]y O 
variable [C]v [C]a [C]r [C]i [C]a [C]b [C]l [C]e O 
( [C]( O 
3 [C]3 O 
, [C], O 
230-29 [C]2 [C]3 [C]0 [C]- [C]2 [C]9 O 
, [C], O 
900 [C]9 [C]0 [C]0 O 
receptors/cell [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s [C]/ [C]c [C]e [C]l [C]l O 
) [C]) O 
, [C], O 
while [C]w [C]h [C]i [C]l [C]e O 
the [C]t [C]h [C]e O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
of [C]o [C]f O 
six [C]s [C]i [C]x O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
lymphatic [C]l [C]y [C]m [C]p [C]h [C]a [C]t [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
contained [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]e [C]d O 
a [C]a O 
rather [C]r [C]a [C]t [C]h [C]e [C]r O 
stable [C]s [C]t [C]a [C]b [C]l [C]e O 
GR [C]G [C]R S-protein 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
( [C]( O 
2 [C]2 O 
, [C], O 
930-5 [C]9 [C]3 [C]0 [C]- [C]5 O 
, [C], O 
120 [C]1 [C]2 [C]0 O 
receptors/cell [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s [C]/ [C]c [C]e [C]l [C]l O 
) [C]) O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
was [C]w [C]a [C]s O 
comparable [C]c [C]o [C]m [C]p [C]a [C]r [C]a [C]b [C]l [C]e O 
with [C]w [C]i [C]t [C]h O 
that [C]t [C]h [C]a [C]t O 
of [C]o [C]f O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

GR [C]G [C]R S-protein 
was [C]w [C]a [C]s O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
in [C]i [C]n O 
all [C]a [C]l [C]l O 
the [C]t [C]h [C]e O 
12 [C]1 [C]2 O 
malignant [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]t B-cell_line 
continuous [C]c [C]o [C]n [C]t [C]i [C]n [C]u [C]o [C]u [C]s I-cell_line 
white [C]w [C]h [C]i [C]t [C]e I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
. [C]. O 

Large [C]L [C]a [C]r [C]g [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
contained [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]e [C]d O 
more [C]m [C]o [C]r [C]e O 
GR [C]G [C]R S-protein 
than [C]t [C]h [C]a [C]n O 
the [C]t [C]h [C]e O 
smaller [C]s [C]m [C]a [C]l [C]l [C]e [C]r O 
ones [C]o [C]n [C]e [C]s O 
. [C]. O 

There [C]T [C]h [C]e [C]r [C]e O 
was [C]w [C]a [C]s O 
no [C]n [C]o O 
apparent [C]a [C]p [C]p [C]a [C]r [C]e [C]n [C]t O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
GR [C]G [C]R S-protein 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
to [C]t [C]o O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
as [C]a [C]s O 
judged [C]j [C]u [C]d [C]g [C]e [C]d O 
by [C]b [C]y O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
thymidine [C]t [C]h [C]y [C]m [C]i [C]d [C]i [C]n [C]e O 
incorporation [C]i [C]n [C]c [C]o [C]r [C]p [C]o [C]r [C]a [C]t [C]i [C]o [C]n O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
. [C]. O 

Distribution [C]D [C]i [C]s [C]t [C]r [C]i [C]b [C]u [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
markers [C]m [C]a [C]r [C]k [C]e [C]r [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
relate [C]r [C]e [C]l [C]a [C]t [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
GR [C]G [C]R S-protein 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

We [C]W [C]e O 
conclude [C]c [C]o [C]n [C]c [C]l [C]u [C]d [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
GR [C]G [C]R S-protein 
is [C]i [C]s O 
probably [C]p [C]r [C]o [C]b [C]a [C]b [C]l [C]y O 
a [C]a O 
universal [C]u [C]n [C]i [C]v [C]e [C]r [C]s [C]a [C]l O 
feature [C]f [C]e [C]a [C]t [C]u [C]r [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
and [C]a [C]n [C]d O 
, [C], O 
from [C]f [C]r [C]o [C]m O 
a [C]a O 
clinical [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
standpoint [C]s [C]t [C]a [C]n [C]d [C]p [C]o [C]i [C]n [C]t O 
, [C], O 
probably [C]p [C]r [C]o [C]b [C]a [C]b [C]l [C]y O 
does [C]d [C]o [C]e [C]s O 
not [C]n [C]o [C]t O 
alone [C]a [C]l [C]o [C]n [C]e O 
imply [C]i [C]m [C]p [C]l [C]y O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
responsiveness [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e [C]n [C]e [C]s [C]s O 
. [C]. O 

Evidence [C]E [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
for [C]f [C]o [C]r O 
a [C]a O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
in [C]i [C]n O 
rheumatoid [C]r [C]h [C]e [C]u [C]m [C]a [C]t [C]o [C]i [C]d B-cell_type 
synovial [C]s [C]y [C]n [C]o [C]v [C]i [C]a [C]l I-cell_type 
tissue [C]t [C]i [C]s [C]s [C]u [C]e I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

One [C]O [C]n [C]e O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
by [C]b [C]y O 
which [C]w [C]h [C]i [C]c [C]h O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
could [C]c [C]o [C]u [C]l [C]d O 
exert [C]e [C]x [C]e [C]r [C]t O 
their [C]t [C]h [C]e [C]i [C]r O 
anti-inflammatory [C]a [C]n [C]t [C]i [C]- [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
action [C]a [C]c [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
via [C]v [C]i [C]a O 
rapidly [C]r [C]a [C]p [C]i [C]d [C]l [C]y O 
saturable [C]s [C]a [C]t [C]u [C]r [C]a [C]b [C]l [C]e O 
, [C], O 
stereo-specific [C]s [C]t [C]e [C]r [C]e [C]o [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-protein 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
is [C]i [C]s O 
of [C]o [C]f O 
an [C]a [C]n O 
investigation [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]i [C]o [C]n O 
into [C]i [C]n [C]t [C]o O 
such [C]s [C]u [C]c [C]h O 
a [C]a O 
possibility [C]p [C]o [C]s [C]s [C]i [C]b [C]i [C]l [C]i [C]t [C]y O 
in [C]i [C]n O 
synovial [C]s [C]y [C]n [C]o [C]v [C]i [C]a [C]l B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Synovium [C]S [C]y [C]n [C]o [C]v [C]i [C]u [C]m O 
, [C], O 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
knee [C]k [C]n [C]e [C]e O 
joints [C]j [C]o [C]i [C]n [C]t [C]s O 
of [C]o [C]f O 
rheumatoid [C]r [C]h [C]e [C]u [C]m [C]a [C]t [C]o [C]i [C]d O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
undergoing [C]u [C]n [C]d [C]e [C]r [C]g [C]o [C]i [C]n [C]g O 
surgery [C]s [C]u [C]r [C]g [C]e [C]r [C]y O 
, [C], O 
was [C]w [C]a [C]s O 
incubated [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
clostridiopeptidase [C]c [C]l [C]o [C]s [C]t [C]r [C]i [C]d [C]i [C]o [C]p [C]e [C]p [C]t [C]i [C]d [C]a [C]s [C]e B-protein 
A [C]A E-protein 
and [C]a [C]n [C]d O 
trypsin-EDTA [C]t [C]r [C]y [C]p [C]s [C]i [C]n [C]- [C]E [C]D [C]T [C]A S-protein 
to [C]t [C]o O 
obtain [C]o [C]b [C]t [C]a [C]i [C]n O 
cell [C]c [C]e [C]l [C]l O 
suspensions [C]s [C]u [C]s [C]p [C]e [C]n [C]s [C]i [C]o [C]n [C]s O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
, [C], O 
together [C]t [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
with [C]w [C]i [C]t [C]h O 
cells [C]c [C]e [C]l [C]l [C]s O 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
synovial [C]s [C]y [C]n [C]o [C]v [C]i [C]a [C]l O 
fluid [C]f [C]l [C]u [C]i [C]d O 
aspirated [C]a [C]s [C]p [C]i [C]r [C]a [C]t [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
rheumatoid [C]r [C]h [C]e [C]u [C]m [C]a [C]t [C]o [C]i [C]d O 
arthritis [C]a [C]r [C]t [C]h [C]r [C]i [C]t [C]i [C]s O 
, [C], O 
were [C]w [C]e [C]r [C]e O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
by [C]b [C]y O 
electron [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]n O 
microscopy [C]m [C]i [C]c [C]r [C]o [C]s [C]c [C]o [C]p [C]y O 
. [C]. O 

Duplicate [C]D [C]u [C]p [C]l [C]i [C]c [C]a [C]t [C]e O 
samples [C]s [C]a [C]m [C]p [C]l [C]e [C]s O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
cell [C]c [C]e [C]l [C]l O 
suspensions [C]s [C]u [C]s [C]p [C]e [C]n [C]s [C]i [C]o [C]n [C]s O 
were [C]w [C]e [C]r [C]e O 
incubated [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
increasing [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]i [C]n [C]g O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
H3Dexamethasone [C]H [C]3 [C]D [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
( [C]( O 
1 [C]1 O 
x [C]x O 
10 [C]1 [C]0 O 
( [C]( O 
-10 [C]- [C]1 [C]0 O 
) [C]) O 
M-1 [C]M [C]- [C]1 O 
x [C]x O 
10 [C]1 [C]0 O 
( [C]( O 
-9 [C]- [C]9 O 
) [C]) O 
M [C]M O 
) [C]) O 
for [C]f [C]o [C]r O 
30 [C]3 [C]0 O 
minutes [C]m [C]i [C]n [C]u [C]t [C]e [C]s O 
at [C]a [C]t O 
37 [C]3 [C]7 O 
degrees [C]d [C]e [C]g [C]r [C]e [C]e [C]s O 
C [C]C O 
. [C]. O 

Analysis [C]A [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
proportion [C]p [C]r [C]o [C]p [C]o [C]r [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
bound [C]b [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
whole [C]w [C]h [C]o [C]l [C]e B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
for [C]f [C]o [C]r O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
, [C], O 
rapidly [C]r [C]a [C]p [C]i [C]d [C]l [C]y O 
saturable [C]s [C]a [C]t [C]u [C]r [C]a [C]b [C]l [C]e O 
, [C], O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
synovial [C]s [C]y [C]n [C]o [C]v [C]i [C]a [C]l O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
, [C], O 
but [C]b [C]u [C]t O 
this [C]t [C]h [C]i [C]s O 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
synovial [C]s [C]y [C]n [C]o [C]v [C]i [C]a [C]l B-cell_type 
fluid [C]f [C]l [C]u [C]i [C]d I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Electron [C]E [C]l [C]e [C]c [C]t [C]r [C]o [C]n O 
micrographs [C]m [C]i [C]c [C]r [C]o [C]g [C]r [C]a [C]p [C]h [C]s O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
cells [C]c [C]e [C]l [C]l [C]s O 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
synovial [C]s [C]y [C]n [C]o [C]v [C]i [C]a [C]l O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
consisted [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]d O 
of [C]o [C]f O 
synovial [C]s [C]y [C]n [C]o [C]v [C]i [C]a [C]l B-cell_type 
fibroblast [C]f [C]i [C]b [C]r [C]o [C]b [C]l [C]a [C]s [C]t E-cell_type 
- [C]- O 
and [C]a [C]n [C]d O 
macrophage-types [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]- [C]t [C]y [C]p [C]e [C]s S-cell_type 
, [C], O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
, [C], O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
and [C]a [C]n [C]d O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_type 
. [C]. O 

Polymorphonuclear [C]P [C]o [C]l [C]y [C]m [C]o [C]r [C]p [C]h [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_type 
leucocytes [C]l [C]e [C]u [C]c [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
appeared [C]a [C]p [C]p [C]e [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
absent [C]a [C]b [C]s [C]e [C]n [C]t O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
in [C]i [C]n O 
synovial [C]s [C]y [C]n [C]o [C]v [C]i [C]a [C]l B-cell_type 
fluid [C]f [C]l [C]u [C]i [C]d I-cell_type 
cell [C]c [C]e [C]l [C]l I-cell_type 
type [C]t [C]y [C]p [C]e I-cell_type 
polymorphonuclear [C]p [C]o [C]l [C]y [C]m [C]o [C]r [C]p [C]h [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
leucocytes [C]l [C]e [C]u [C]c [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
the [C]t [C]h [C]e O 
predominant [C]p [C]r [C]e [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t O 
cell [C]c [C]e [C]l [C]l O 
type [C]t [C]y [C]p [C]e O 
. [C]. O 

We [C]W [C]e O 
concluded [C]c [C]o [C]n [C]c [C]l [C]u [C]d [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
this [C]t [C]h [C]i [C]s O 
, [C], O 
that [C]t [C]h [C]a [C]t O 
one [C]o [C]n [C]e O 
or [C]o [C]r O 
more [C]m [C]o [C]r [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cell [C]c [C]e [C]l [C]l O 
types [C]t [C]y [C]p [C]e [C]s O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
in [C]i [C]n O 
synovial [C]s [C]y [C]n [C]o [C]v [C]i [C]a [C]l O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
contain [C]c [C]o [C]n [C]t [C]a [C]i [C]n O 
a [C]a O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-protein 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
, [C], O 
but [C]b [C]u [C]t O 
that [C]t [C]h [C]a [C]t O 
this [C]t [C]h [C]i [C]s O 
is [C]i [C]s O 
lacking [C]l [C]a [C]c [C]k [C]i [C]n [C]g O 
in [C]i [C]n O 
synovial [C]s [C]y [C]n [C]o [C]v [C]i [C]a [C]l B-cell_type 
fluid [C]f [C]l [C]u [C]i [C]d I-cell_type 
polymorphonuclear [C]p [C]o [C]l [C]y [C]m [C]o [C]r [C]p [C]h [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
leucocytes [C]l [C]e [C]u [C]c [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

Clinical [C]C [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
implications [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
. [C]. O 

Glucorticoid [C]G [C]l [C]u [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
were [C]w [C]e [C]r [C]e O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
in [C]i [C]n O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
populations [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c B-cell_type 
lymphoblasts [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]s E-cell_type 
. [C]. O 

Normal [C]N [C]o [C]r [C]m [C]a [C]l B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
contain [C]c [C]o [C]n [C]t [C]a [C]i [C]n O 
low [C]l [C]o [C]w O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
( [C]( O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
2 [C]2 O 
, [C], O 
500 [C]5 [C]0 [C]0 O 
sites/cell [C]s [C]i [C]t [C]e [C]s [C]/ [C]c [C]e [C]l [C]l O 
) [C]) O 
which [C]w [C]h [C]i [C]c [C]h O 
are [C]a [C]r [C]e O 
identical [C]i [C]d [C]e [C]n [C]t [C]i [C]c [C]a [C]l O 
in [C]i [C]n O 
T- [C]T [C]- O 
and [C]a [C]n [C]d O 
non-T-fractions [C]n [C]o [C]n [C]- [C]T [C]- [C]f [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

Phytohemagglutinin [C]P [C]h [C]y [C]t [C]o [C]h [C]e [C]m [C]a [C]g [C]g [C]l [C]u [C]t [C]i [C]n [C]i [C]n S-protein 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
increases [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
about [C]a [C]b [C]o [C]u [C]t O 
3-fold [C]3 [C]- [C]f [C]o [C]l [C]d O 
. [C]. O 

Leukemic [C]L [C]e [C]u [C]k [C]e [C]m [C]i [C]c B-cell_type 
lymphoblasts [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]s E-cell_type 
contain [C]c [C]o [C]n [C]t [C]a [C]i [C]n O 
larger [C]l [C]a [C]r [C]g [C]e [C]r O 
numbers [C]n [C]u [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
sites [C]s [C]i [C]t [C]e [C]s O 
. [C]. O 

Presence [C]P [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
is [C]i [C]s O 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
sensitivitiy [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]i [C]y O 
to [C]t [C]o O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
. [C]. O 

Quantity [C]Q [C]u [C]a [C]n [C]t [C]i [C]t [C]y O 
of [C]o [C]f O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
is [C]i [C]s O 
also [C]a [C]l [C]s [C]o O 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
complete [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e O 
remission [C]r [C]e [C]m [C]i [C]s [C]s [C]i [C]o [C]n O 
duration [C]d [C]u [C]r [C]a [C]t [C]i [C]o [C]n O 
independently [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t [C]l [C]y O 
of [C]o [C]f O 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c B-cell_type 
cell [C]c [C]e [C]l [C]l I-cell_type 
type [C]t [C]y [C]p [C]e E-cell_type 
( [C]( O 
T [C]T O 
or [C]o [C]r O 
null [C]n [C]u [C]l [C]l O 
) [C]) O 
, [C], O 
initial [C]i [C]n [C]i [C]t [C]i [C]a [C]l O 
WBC [C]W [C]B [C]C S-cell_type 
, [C], O 
or [C]o [C]r O 
age [C]a [C]g [C]e O 
of [C]o [C]f O 
patient [C]p [C]a [C]t [C]i [C]e [C]n [C]t O 
. [C]. O 

Quantitative [C]Q [C]u [C]a [C]n [C]t [C]i [C]t [C]a [C]t [C]i [C]v [C]e O 
determination [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
in [C]i [C]n O 
acute [C]a [C]c [C]u [C]t [C]e O 
lymphoblastic [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
of [C]o [C]f O 
value [C]v [C]a [C]l [C]u [C]e O 
both [C]b [C]o [C]t [C]h O 
as [C]a [C]s O 
an [C]a [C]n O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
prognostic [C]p [C]r [C]o [C]g [C]n [C]o [C]s [C]t [C]i [C]c O 
variable [C]v [C]a [C]r [C]i [C]a [C]b [C]l [C]e O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
which [C]w [C]h [C]i [C]c [C]h O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
should [C]s [C]h [C]o [C]u [C]l [C]d O 
receive [C]r [C]e [C]c [C]e [C]i [C]v [C]e O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
. [C]. O 

Functional [C]F [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
and [C]a [C]n [C]d O 
physical [C]p [C]h [C]y [C]s [C]i [C]c [C]a [C]l O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
protein-tyrosine [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e B-protein 
kinases [C]k [C]i [C]n [C]a [C]s [C]e [C]s I-protein 
Fyn [C]F [C]y [C]n I-protein 
and [C]a [C]n [C]d I-protein 
Csk [C]C [C]s [C]k E-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
. [C]. O 

The [C]T [C]h [C]e O 
Src-like [C]S [C]r [C]c [C]- [C]l [C]i [C]k [C]e B-protein 
protein-tyrosine [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
Fyn [C]F [C]y [C]n S-protein 
is [C]i [C]s O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l B-protein 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
. [C]. O 

Transient [C]T [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
actively [C]a [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
mutated [C]m [C]u [C]t [C]a [C]t [C]e [C]d O 
Fyn [C]F [C]y [C]n S-protein 
, [C], O 
having [C]h [C]a [C]v [C]i [C]n [C]g O 
Phe-528 [C]P [C]h [C]e [C]- [C]5 [C]2 [C]8 O 
instead [C]i [C]n [C]s [C]t [C]e [C]a [C]d O 
of [C]o [C]f O 
Tyr-528 [C]T [C]y [C]r [C]- [C]5 [C]2 [C]8 O 
or [C]o [C]r O 
Thr-338 [C]T [C]h [C]r [C]- [C]3 [C]3 [C]8 O 
instead [C]i [C]n [C]s [C]t [C]e [C]a [C]d O 
of [C]o [C]f O 
Ile-338 [C]I [C]l [C]e [C]- [C]3 [C]3 [C]8 O 
, [C], O 
in [C]i [C]n O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_type 
T-cells [C]T [C]- [C]c [C]e [C]l [C]l [C]s E-cell_type 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-DNA 
the [C]t [C]h [C]e I-DNA 
serum [C]s [C]e [C]r [C]u [C]m I-DNA 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e I-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
( [C]( O 
SRE [C]S [C]R [C]E S-DNA 
) [C]) O 
, [C], O 
12-O-tetradecanoyl-phorbol-13-acetate [C]1 [C]2 [C]- [C]O [C]- [C]t [C]e [C]t [C]r [C]a [C]d [C]e [C]c [C]a [C]n [C]o [C]y [C]l [C]- [C]p [C]h [C]o [C]r [C]b [C]o [C]l [C]- [C]1 [C]3 [C]- [C]a [C]c [C]e [C]t [C]a [C]t [C]e B-DNA 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e I-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
, [C], O 
cyclic [C]c [C]y [C]c [C]l [C]i [C]c B-DNA 
AMP [C]A [C]M [C]P I-DNA 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e I-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
, [C], O 
and [C]a [C]n [C]d O 
c-fos [C]c [C]- [C]f [C]o [C]s B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

The [C]T [C]h [C]e O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
SRE [C]S [C]R [C]E S-DNA 
was [C]w [C]a [C]s O 
particularly [C]p [C]a [C]r [C]t [C]i [C]c [C]u [C]l [C]a [C]r [C]l [C]y O 
prominent [C]p [C]r [C]o [C]m [C]i [C]n [C]e [C]n [C]t O 
not [C]n [C]o [C]t O 
only [C]o [C]n [C]l [C]y O 
with [C]w [C]i [C]t [C]h O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
Fyn [C]F [C]y [C]n S-protein 
but [C]b [C]u [C]t O 
also [C]a [C]l [C]s [C]o O 
with [C]w [C]i [C]t [C]h O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-protein 
( [C]( I-protein 
wild-type [C]w [C]i [C]l [C]d [C]- [C]t [C]y [C]p [C]e I-protein 
) [C]) I-protein 
Fyn [C]F [C]y [C]n E-protein 
. [C]. O 

SRE [C]S [C]R [C]E S-DNA 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
both [C]b [C]o [C]t [C]h O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-protein 
and [C]a [C]n [C]d I-protein 
active [C]a [C]c [C]t [C]i [C]v [C]e I-protein 
Lck [C]L [C]c [C]k E-protein 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-protein 
and [C]a [C]n [C]d I-protein 
active [C]a [C]c [C]t [C]i [C]v [C]e I-protein 
Fyn [C]F [C]y [C]n E-protein 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
gene [C]g [C]e [C]n [C]e I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
when [C]w [C]h [C]e [C]n O 
transfected [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]e [C]d O 
cells [C]c [C]e [C]l [C]l [C]s O 
were [C]w [C]e [C]r [C]e O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
concanavalin [C]c [C]o [C]n [C]c [C]a [C]n [C]a [C]v [C]a [C]l [C]i [C]n B-protein 
A [C]A E-protein 
plus [C]p [C]l [C]u [C]s O 
12-O-tetradecanoylphorbol-13-acetate [C]1 [C]2 [C]- [C]O [C]- [C]t [C]e [C]t [C]r [C]a [C]d [C]e [C]c [C]a [C]n [C]o [C]y [C]l [C]p [C]h [C]o [C]r [C]b [C]o [C]l [C]- [C]1 [C]3 [C]- [C]a [C]c [C]e [C]t [C]a [C]t [C]e O 
. [C]. O 

Under [C]U [C]n [C]d [C]e [C]r O 
the [C]t [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
conditions [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n [C]s O 
, [C], O 
Lck [C]L [C]c [C]k S-protein 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
stimulate [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
unless [C]u [C]n [C]l [C]e [C]s [C]s O 
it [C]i [C]t O 
was [C]w [C]a [C]s O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Interestingly [C]I [C]n [C]t [C]e [C]r [C]e [C]s [C]t [C]i [C]n [C]g [C]l [C]y O 
, [C], O 
a [C]a O 
mutant [C]m [C]u [C]t [C]a [C]n [C]t B-protein 
Fyn [C]F [C]y [C]n E-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
has [C]h [C]a [C]s O 
deletions [C]d [C]e [C]l [C]e [C]t [C]i [C]o [C]n [C]s O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
the [C]t [C]h [C]e O 
SH2 [C]S [C]H [C]2 B-protein 
region [C]r [C]e [C]g [C]i [C]o [C]n E-protein 
and [C]a [C]n [C]d O 
so [C]s [C]o O 
is [C]i [C]s O 
able [C]a [C]b [C]l [C]e O 
to [C]t [C]o O 
transform [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m O 
chicken [C]c [C]h [C]i [C]c [C]k [C]e [C]n B-cell_type 
embryo [C]e [C]m [C]b [C]r [C]y [C]o I-cell_type 
fibroblasts [C]f [C]i [C]b [C]r [C]o [C]b [C]l [C]a [C]s [C]t [C]s E-cell_type 
, [C], O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
stimulate [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
the [C]t [C]h [C]e O 
c-fos [C]c [C]- [C]f [C]o [C]s B-DNA 
or [C]o [C]r I-DNA 
IL-2 [C]I [C]L [C]- [C]2 I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
importance [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]c [C]e O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
region [C]r [C]e [C]g [C]i [C]o [C]n O 
in [C]i [C]n O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l S-cell_type 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
. [C]. O 

Csk [C]C [C]s [C]k S-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
phosphorylates [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]e [C]s O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
residues [C]r [C]e [C]s [C]i [C]d [C]u [C]e [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
sites [C]s [C]i [C]t [C]e [C]s O 
of [C]o [C]f O 
Src [C]S [C]r [C]c B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y I-protein 
kinases [C]k [C]i [C]n [C]a [C]s [C]e [C]s E-protein 
, [C], O 
down-regulated [C]d [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
Fyn- [C]F [C]y [C]n [C]- O 
and [C]a [C]n [C]d O 
Lck-mediated [C]L [C]c [C]k [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
serum [C]s [C]e [C]r [C]u [C]m B-DNA 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e I-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
and [C]a [C]n [C]d O 
Fyn-mediated [C]F [C]y [C]n [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
enhancement [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
Fyn [C]F [C]y [C]n S-protein 
and [C]a [C]n [C]d O 
Lck [C]L [C]c [C]k S-protein 
, [C], O 
whose [C]w [C]h [C]o [C]s [C]e O 
activities [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]i [C]e [C]s O 
are [C]a [C]r [C]e O 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
Csk [C]C [C]s [C]k S-protein 
, [C], O 
are [C]a [C]r [C]e O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
phases [C]p [C]h [C]a [C]s [C]e [C]s O 
of [C]o [C]f O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l S-cell_type 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

A [C]A O 
novel [C]n [C]o [C]v [C]e [C]l O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B I-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
p65 [C]p [C]6 [C]5 B-protein 
homodimers [C]h [C]o [C]m [C]o [C]d [C]i [C]m [C]e [C]r [C]s E-protein 
: [C]: O 
implications [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n [C]s O 
for [C]f [C]o [C]r O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
subunit [C]s [C]u [C]b [C]u [C]n [C]i [C]t O 
dimerization [C]d [C]i [C]m [C]e [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
predominant [C]p [C]r [C]e [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t O 
inducible [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
form [C]f [C]o [C]r [C]m O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
is [C]i [C]s O 
a [C]a O 
heteromeric [C]h [C]e [C]t [C]e [C]r [C]o [C]m [C]e [C]r [C]i [C]c B-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
two [C]t [C]w [C]o O 
Rel-related [C]R [C]e [C]l [C]- [C]r [C]e [C]l [C]a [C]t [C]e [C]d B-protein 
DNA-binding [C]D [C]N [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
subunits [C]s [C]u [C]b [C]u [C]n [C]i [C]t [C]s E-protein 
, [C], O 
termed [C]t [C]e [C]r [C]m [C]e [C]d B-protein 
p65 [C]p [C]6 [C]5 E-protein 
and [C]a [C]n [C]d O 
p50 [C]p [C]5 [C]0 S-protein 
. [C]. O 

Prior [C]P [C]r [C]i [C]o [C]r O 
transfection [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
have [C]h [C]a [C]v [C]e O 
shown [C]s [C]h [C]o [C]w [C]n O 
that [C]t [C]h [C]a [C]t O 
when [C]w [C]h [C]e [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
p65 [C]p [C]6 [C]5 B-protein 
and [C]a [C]n [C]d I-protein 
p50 [C]p [C]5 [C]0 I-protein 
subunits [C]s [C]u [C]b [C]u [C]n [C]i [C]t [C]s E-protein 
are [C]a [C]r [C]e O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
independently [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t [C]l [C]y O 
as [C]a [C]s O 
stable [C]s [C]t [C]a [C]b [C]l [C]e B-protein 
homodimers [C]h [C]o [C]m [C]o [C]d [C]i [C]m [C]e [C]r [C]s E-protein 
, [C], O 
p65 [C]p [C]6 [C]5 S-protein 
stimulates [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]s O 
kappa [C]k [C]a [C]p [C]p [C]a O 
B-directed [C]B [C]- [C]d [C]i [C]r [C]e [C]c [C]t [C]e [C]d O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
p50 [C]p [C]5 [C]0 S-protein 
functions [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]s O 
as [C]a [C]s O 
a [C]a O 
kappa [C]k [C]a [C]p [C]p [C]a O 
B-specific [C]B [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
repressor [C]r [C]e [C]p [C]r [C]e [C]s [C]s [C]o [C]r O 
. [C]. O 

While [C]W [C]h [C]i [C]l [C]e O 
authentic [C]a [C]u [C]t [C]h [C]e [C]n [C]t [C]i [C]c O 
p50 [C]p [C]5 [C]0 B-protein 
homodimers [C]h [C]o [C]m [C]o [C]d [C]i [C]m [C]e [C]r [C]s E-protein 
( [C]( O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
termed [C]t [C]e [C]r [C]m [C]e [C]d O 
KBF1 [C]K [C]B [C]F [C]1 S-protein 
) [C]) O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
in [C]i [C]n O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
from [C]f [C]r [C]o [C]m O 
nontransfected [C]n [C]o [C]n [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]e [C]d O 
cells [C]c [C]e [C]l [C]l [C]s O 
, [C], O 
experimental [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]a [C]l O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
supporting [C]s [C]u [C]p [C]p [C]o [C]r [C]t [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
existence [C]e [C]x [C]i [C]s [C]t [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
p65 [C]p [C]6 [C]5 B-protein 
homodimers [C]h [C]o [C]m [C]o [C]d [C]i [C]m [C]e [C]r [C]s E-protein 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
was [C]w [C]a [C]s O 
lacking [C]l [C]a [C]c [C]k [C]i [C]n [C]g O 
. [C]. O 

We [C]W [C]e O 
now [C]n [C]o [C]w O 
provide [C]p [C]r [C]o [C]v [C]i [C]d [C]e O 
direct [C]d [C]i [C]r [C]e [C]c [C]t O 
biochemical [C]b [C]i [C]o [C]c [C]h [C]e [C]m [C]i [C]c [C]a [C]l O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
an [C]a [C]n O 
endogenous [C]e [C]n [C]d [C]o [C]g [C]e [C]n [C]o [C]u [C]s O 
pool [C]p [C]o [C]o [C]l O 
of [C]o [C]f O 
inducible [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
p65 [C]p [C]6 [C]5 B-protein 
homodimers [C]h [C]o [C]m [C]o [C]d [C]i [C]m [C]e [C]r [C]s E-protein 
in [C]i [C]n O 
intact [C]i [C]n [C]t [C]a [C]c [C]t O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

As [C]A [C]s O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
prototypical [C]p [C]r [C]o [C]t [C]o [C]t [C]y [C]p [C]i [C]c [C]a [C]l O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B I-protein 
p50-p65 [C]p [C]5 [C]0 [C]- [C]p [C]6 [C]5 I-protein 
heterodimer [C]h [C]e [C]t [C]e [C]r [C]o [C]d [C]i [C]m [C]e [C]r E-protein 
, [C], O 
this [C]t [C]h [C]i [C]s O 
novel [C]n [C]o [C]v [C]e [C]l O 
p65 [C]p [C]6 [C]5 B-protein 
homodimeric [C]h [C]o [C]m [C]o [C]d [C]i [C]m [C]e [C]r [C]i [C]c I-protein 
form [C]f [C]o [C]r [C]m E-protein 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
is [C]i [C]s O 
functionally [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l [C]l [C]y O 
sequestered [C]s [C]e [C]q [C]u [C]e [C]s [C]t [C]e [C]r [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
cytoplasm [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m O 
but [C]b [C]u [C]t O 
rapidly [C]r [C]a [C]p [C]i [C]d [C]l [C]y O 
appears [C]a [C]p [C]p [C]e [C]a [C]r [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
compartment [C]c [C]o [C]m [C]p [C]a [C]r [C]t [C]m [C]e [C]n [C]t O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Site-directed [C]S [C]i [C]t [C]e [C]- [C]d [C]i [C]r [C]e [C]c [C]t [C]e [C]d O 
mutagenesis [C]m [C]u [C]t [C]a [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
homodimerization [C]h [C]o [C]m [C]o [C]d [C]i [C]m [C]e [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
p65 [C]p [C]6 [C]5 S-protein 
is [C]i [C]s O 
dependent [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
upon [C]u [C]p [C]o [C]n O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
cysteine [C]c [C]y [C]s [C]t [C]e [C]i [C]n [C]e O 
216 [C]2 [C]1 [C]6 O 
and [C]a [C]n [C]d O 
a [C]a O 
conserved [C]c [C]o [C]n [C]s [C]e [C]r [C]v [C]e [C]d O 
recognition [C]r [C]e [C]c [C]o [C]g [C]n [C]i [C]t [C]i [C]o [C]n O 
motif [C]m [C]o [C]t [C]i [C]f O 
for [C]f [C]o [C]r O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
A [C]A E-protein 
( [C]( O 
RRPS [C]R [C]R [C]P [C]S S-protein 
; [C]; O 
amino [C]a [C]m [C]i [C]n [C]o O 
acids [C]a [C]c [C]i [C]d [C]s O 
273 [C]2 [C]7 [C]3 O 
to [C]t [C]o O 
276 [C]2 [C]7 [C]6 O 
) [C]) O 
, [C], O 
both [C]b [C]o [C]t [C]h O 
of [C]o [C]f O 
which [C]w [C]h [C]i [C]c [C]h O 
reside [C]r [C]e [C]s [C]i [C]d [C]e O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
a [C]a O 
91-amino-acid [C]9 [C]1 [C]- [C]a [C]m [C]i [C]n [C]o [C]- [C]a [C]c [C]i [C]d O 
segment [C]s [C]e [C]g [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Rel [C]R [C]e [C]l B-protein 
homology [C]h [C]o [C]m [C]o [C]l [C]o [C]g [C]y I-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
that [C]t [C]h [C]a [C]t O 
mediates [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]s O 
self-association [C]s [C]e [C]l [C]f [C]- [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
at [C]a [C]t O 
these [C]t [C]h [C]e [C]s [C]e O 
two [C]t [C]w [C]o O 
sites [C]s [C]i [C]t [C]e [C]s O 
do [C]d [C]o O 
not [C]n [C]o [C]t O 
affect [C]a [C]f [C]f [C]e [C]c [C]t O 
heterodimerization [C]h [C]e [C]t [C]e [C]r [C]o [C]d [C]i [C]m [C]e [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
p65 [C]p [C]6 [C]5 S-protein 
with [C]w [C]i [C]t [C]h O 
p50 [C]p [C]5 [C]0 S-protein 
or [C]o [C]r O 
its [C]i [C]t [C]s O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
I [C]I O 
kappa [C]k [C]a [C]p [C]p [C]a O 
B [C]B O 
alpha [C]a [C]l [C]p [C]h [C]a O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
later [C]l [C]a [C]t [C]e [C]r O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
neither [C]n [C]e [C]i [C]t [C]h [C]e [C]r O 
homo- [C]h [C]o [C]m [C]o [C]- O 
nor [C]n [C]o [C]r O 
heterodimer [C]h [C]e [C]t [C]e [C]r [C]o [C]d [C]i [C]m [C]e [C]r O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
an [C]a [C]n O 
absolute [C]a [C]b [C]s [C]o [C]l [C]u [C]t [C]e O 
prerequisite [C]p [C]r [C]e [C]r [C]e [C]q [C]u [C]i [C]s [C]i [C]t [C]e O 
for [C]f [C]o [C]r O 
I [C]I B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B I-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
recognition [C]r [C]e [C]c [C]o [C]g [C]n [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
p65 [C]p [C]6 [C]5 S-protein 
. [C]. O 

Taken [C]T [C]a [C]k [C]e [C]n O 
together [C]t [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
with [C]w [C]i [C]t [C]h O 
prior [C]p [C]r [C]i [C]o [C]r O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
, [C], O 
these [C]t [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
biological [C]b [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
activities [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]i [C]e [C]s O 
of [C]o [C]f O 
p65 [C]p [C]6 [C]5 B-protein 
and [C]a [C]n [C]d I-protein 
p50 [C]p [C]5 [C]0 I-protein 
homodimers [C]h [C]o [C]m [C]o [C]d [C]i [C]m [C]e [C]r [C]s E-protein 
are [C]a [C]r [C]e O 
independently [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t [C]l [C]y O 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
, [C], O 
thereby [C]t [C]h [C]e [C]r [C]e [C]b [C]y O 
providing [C]p [C]r [C]o [C]v [C]i [C]d [C]i [C]n [C]g O 
an [C]a [C]n O 
integrated [C]i [C]n [C]t [C]e [C]g [C]r [C]a [C]t [C]e [C]d O 
and [C]a [C]n [C]d O 
flexible [C]f [C]l [C]e [C]x [C]i [C]b [C]l [C]e O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
rapid [C]r [C]a [C]p [C]i [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
repression [C]r [C]e [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
/ [C]/ O 
Rel [C]R [C]e [C]l S-protein 
-directed [C]- [C]d [C]i [C]r [C]e [C]c [C]t [C]e [C]d O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Carrier [C]C [C]a [C]r [C]r [C]i [C]e [C]r O 
determination [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
for [C]f [C]o [C]r O 
X-linked [C]X [C]- [C]l [C]i [C]n [C]k [C]e [C]d O 
agammaglobulinemia [C]a [C]g [C]a [C]m [C]m [C]a [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n [C]e [C]m [C]i [C]a O 
using [C]u [C]s [C]i [C]n [C]g O 
X [C]X O 
inactivation [C]i [C]n [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

We [C]W [C]e O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
the [C]t [C]h [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
a [C]a O 
relatively [C]r [C]e [C]l [C]a [C]t [C]i [C]v [C]e [C]l [C]y O 
quick [C]q [C]u [C]i [C]c [C]k O 
and [C]a [C]n [C]d O 
simple [C]s [C]i [C]m [C]p [C]l [C]e O 
method [C]m [C]e [C]t [C]h [C]o [C]d O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
assessment [C]a [C]s [C]s [C]e [C]s [C]s [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
X [C]X O 
inactivation [C]i [C]n [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
status [C]s [C]t [C]a [C]t [C]u [C]s O 
for [C]f [C]o [C]r O 
carrier [C]c [C]a [C]r [C]r [C]i [C]e [C]r O 
determination [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
families [C]f [C]a [C]m [C]i [C]l [C]i [C]e [C]s O 
affected [C]a [C]f [C]f [C]e [C]c [C]t [C]e [C]d O 
by [C]b [C]y O 
X-linked [C]X [C]- [C]l [C]i [C]n [C]k [C]e [C]d O 
agammaglobulinemia [C]a [C]g [C]a [C]m [C]m [C]a [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n [C]e [C]m [C]i [C]a O 
( [C]( O 
XLA [C]X [C]L [C]A O 
) [C]) O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
method [C]m [C]e [C]t [C]h [C]o [C]d O 
utilises [C]u [C]t [C]i [C]l [C]i [C]s [C]e [C]s O 
an [C]a [C]n O 
immunomagnetic [C]i [C]m [C]m [C]u [C]n [C]o [C]m [C]a [C]g [C]n [C]e [C]t [C]i [C]c O 
separation [C]s [C]e [C]p [C]a [C]r [C]a [C]t [C]i [C]o [C]n O 
technique [C]t [C]e [C]c [C]h [C]n [C]i [C]q [C]u [C]e O 
for [C]f [C]o [C]r O 
B [C]B B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
purification [C]p [C]u [C]r [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
a [C]a O 
polymerase [C]p [C]o [C]l [C]y [C]m [C]e [C]r [C]a [C]s [C]e O 
chain [C]c [C]h [C]a [C]i [C]n O 
reaction [C]r [C]e [C]a [C]c [C]t [C]i [C]o [C]n O 
( [C]( O 
PCR [C]P [C]C [C]R O 
) [C]) O 
based [C]b [C]a [C]s [C]e [C]d O 
assay [C]a [C]s [C]s [C]a [C]y O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
determination [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
methylation [C]m [C]e [C]t [C]h [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
status [C]s [C]t [C]a [C]t [C]u [C]s O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
androgen [C]a [C]n [C]d [C]r [C]o [C]g [C]e [C]n B-DNA 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-DNA 
( [C]( I-DNA 
AR [C]A [C]R I-DNA 
) [C]) I-DNA 
gene [C]g [C]e [C]n [C]e I-DNA 
locus [C]l [C]o [C]c [C]u [C]s E-DNA 
to [C]t [C]o O 
assess [C]a [C]s [C]s [C]e [C]s [C]s O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
X [C]X O 
inactivation [C]i [C]n [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
random [C]r [C]a [C]n [C]d [C]o [C]m O 
or [C]o [C]r O 
non-random [C]n [C]o [C]n [C]- [C]r [C]a [C]n [C]d [C]o [C]m O 
at [C]a [C]t O 
this [C]t [C]h [C]i [C]s O 
locus [C]l [C]o [C]c [C]u [C]s O 
. [C]. O 

We [C]W [C]e O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
the [C]t [C]h [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
we [C]w [C]e O 
have [C]h [C]a [C]v [C]e O 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
using [C]u [C]s [C]i [C]n [C]g O 
this [C]t [C]h [C]i [C]s O 
assay [C]a [C]s [C]s [C]a [C]y O 
to [C]t [C]o O 
investigate [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e O 
females [C]f [C]e [C]m [C]a [C]l [C]e [C]s O 
known [C]k [C]n [C]o [C]w [C]n O 
to [C]t [C]o O 
be [C]b [C]e O 
carriers [C]c [C]a [C]r [C]r [C]i [C]e [C]r [C]s O 
of [C]o [C]f O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
X-linked [C]X [C]- [C]l [C]i [C]n [C]k [C]e [C]d O 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
disorders [C]d [C]i [C]s [C]o [C]r [C]d [C]e [C]r [C]s O 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
we [C]w [C]e O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
four [C]f [C]o [C]u [C]r O 
females [C]f [C]e [C]m [C]a [C]l [C]e [C]s O 
from [C]f [C]r [C]o [C]m O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
families [C]f [C]a [C]m [C]i [C]l [C]i [C]e [C]s O 
affected [C]a [C]f [C]f [C]e [C]c [C]t [C]e [C]d O 
by [C]b [C]y O 
XLA [C]X [C]L [C]A O 
, [C], O 
two [C]t [C]w [C]o O 
of [C]o [C]f O 
whom [C]w [C]h [C]o [C]m O 
were [C]w [C]e [C]r [C]e O 
of [C]o [C]f O 
unknown [C]u [C]n [C]k [C]n [C]o [C]w [C]n O 
carrier [C]c [C]a [C]r [C]r [C]i [C]e [C]r O 
status [C]s [C]t [C]a [C]t [C]u [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
we [C]w [C]e O 
discuss [C]d [C]i [C]s [C]c [C]u [C]s [C]s O 
the [C]t [C]h [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
this [C]t [C]h [C]i [C]s O 
and [C]a [C]n [C]d O 
other [C]o [C]t [C]h [C]e [C]r O 
X-inactivation [C]X [C]- [C]i [C]n [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
. [C]. O 

A [C]A O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
assay [C]a [C]s [C]s [C]a [C]y O 
has [C]h [C]a [C]s O 
recently [C]r [C]e [C]c [C]e [C]n [C]t [C]l [C]y O 
been [C]b [C]e [C]e [C]n O 
described [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
by [C]b [C]y O 
Allen [C]A [C]l [C]l [C]e [C]n O 
et [C]e [C]t O 
al. [C]a [C]l [C]. O 
( [C]( O 
1992 [C]1 [C]9 [C]9 [C]2 O 
) [C]) O 
and [C]a [C]n [C]d O 
applied [C]a [C]p [C]p [C]l [C]i [C]e [C]d O 
to [C]t [C]o O 
members [C]m [C]e [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
one [C]o [C]n [C]e O 
family [C]f [C]a [C]m [C]i [C]l [C]y O 
affected [C]a [C]f [C]f [C]e [C]c [C]t [C]e [C]d O 
by [C]b [C]y O 
XLA [C]X [C]L [C]A O 
. [C]. O 

Effects [C]E [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
and [C]a [C]n [C]d O 
Fc [C]F [C]c B-protein 
gamma [C]g [C]a [C]m [C]m [C]a I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
II [C]I [C]I E-protein 
engagement [C]e [C]n [C]g [C]a [C]g [C]e [C]m [C]e [C]n [C]t O 
on [C]o [C]n O 
Egr-1 [C]E [C]g [C]r [C]- [C]1 S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
B [C]B B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
by [C]b [C]y O 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n O 
crosslinking [C]c [C]r [C]o [C]s [C]s [C]l [C]i [C]n [C]k [C]i [C]n [C]g O 
. [C]. O 

Egr-1 [C]E [C]g [C]r [C]- [C]1 S-DNA 
is [C]i [C]s O 
an [C]a [C]n O 
immediate [C]i [C]m [C]m [C]e [C]d [C]i [C]a [C]t [C]e B-DNA 
early [C]e [C]a [C]r [C]l [C]y I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
rapidly [C]r [C]a [C]p [C]i [C]d [C]l [C]y O 
upregulated [C]u [C]p [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
mitogenic [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]i [C]c O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
crosslinking [C]c [C]r [C]o [C]s [C]s [C]l [C]i [C]n [C]k [C]i [C]n [C]g O 
on [C]o [C]n O 
murine [C]m [C]u [C]r [C]i [C]n [C]e B-cell_type 
B [C]B I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

It [C]I [C]t O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
shown [C]s [C]h [C]o [C]w [C]n O 
that [C]t [C]h [C]a [C]t O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
Egr-1 [C]E [C]g [C]r [C]- [C]1 S-DNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
are [C]a [C]r [C]e O 
closely [C]c [C]l [C]o [C]s [C]e [C]l [C]y O 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
B [C]B B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
models [C]m [C]o [C]d [C]e [C]l [C]s O 
of [C]o [C]f O 
B [C]B O 
cell [C]c [C]e [C]l [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
tolerance [C]t [C]o [C]l [C]e [C]r [C]a [C]n [C]c [C]e O 
. [C]. O 

We [C]W [C]e O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
Egr-1 [C]E [C]g [C]r [C]- [C]1 S-DNA 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
B [C]B O 
cell [C]c [C]e [C]l [C]l O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
Fab'2 [C]F [C]a [C]b [C]' [C]2 S-protein 
and [C]a [C]n [C]d O 
IgG [C]I [C]g [C]G B-protein 
anti-immunoglobulin [C]a [C]n [C]t [C]i [C]- [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n E-protein 
( [C]( O 
anti-Ig [C]a [C]n [C]t [C]i [C]- [C]I [C]g S-protein 
) [C]) O 
, [C], O 
since [C]s [C]i [C]n [C]c [C]e O 
it [C]i [C]t O 
is [C]i [C]s O 
known [C]k [C]n [C]o [C]w [C]n O 
that [C]t [C]h [C]a [C]t O 
Fab'2 [C]F [C]a [C]b [C]' [C]2 B-protein 
anti-Ig [C]a [C]n [C]t [C]i [C]- [C]I [C]g E-protein 
is [C]i [C]s O 
mitogenic [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]i [C]c O 
while [C]w [C]h [C]i [C]l [C]e O 
IgG [C]I [C]g [C]G B-protein 
anti-Ig [C]a [C]n [C]t [C]i [C]- [C]I [C]g E-protein 
is [C]i [C]s O 
not [C]n [C]o [C]t O 
, [C], O 
owing [C]o [C]w [C]i [C]n [C]g O 
to [C]t [C]o O 
a [C]a O 
dominant [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
crosslinking [C]c [C]r [C]o [C]s [C]s [C]l [C]i [C]n [C]k [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
B [C]B B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
Fc [C]F [C]c I-protein 
gamma [C]g [C]a [C]m [C]m [C]a I-protein 
RII [C]R [C]I [C]I E-protein 
to [C]t [C]o O 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e B-protein 
Ig [C]I [C]g E-protein 
. [C]. O 

While [C]W [C]h [C]i [C]l [C]e O 
mitogenic [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]i [C]c O 
doses [C]d [C]o [C]s [C]e [C]s O 
of [C]o [C]f O 
Fab'2 [C]F [C]a [C]b [C]' [C]2 B-protein 
anti-Ig [C]a [C]n [C]t [C]i [C]- [C]I [C]g E-protein 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
large [C]l [C]a [C]r [C]g [C]e O 
and [C]a [C]n [C]d O 
rapid [C]r [C]a [C]p [C]i [C]d O 
increases [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
in [C]i [C]n O 
Egr-1 [C]E [C]g [C]r [C]- [C]1 O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
IgG [C]I [C]g [C]G B-protein 
anti-Ig [C]a [C]n [C]t [C]i [C]- [C]I [C]g E-protein 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
in [C]i [C]n O 
smaller [C]s [C]m [C]a [C]l [C]l [C]e [C]r O 
increases [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
in [C]i [C]n O 
Egr-1 [C]E [C]g [C]r [C]- [C]1 B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
, [C], O 
comparable [C]c [C]o [C]m [C]p [C]a [C]r [C]a [C]b [C]l [C]e O 
to [C]t [C]o O 
that [C]t [C]h [C]a [C]t O 
seen [C]s [C]e [C]e [C]n O 
with [C]w [C]i [C]t [C]h O 
submitogenic [C]s [C]u [C]b [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]i [C]c O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
Fab'2 [C]F [C]a [C]b [C]' [C]2 B-protein 
anti-Ig [C]a [C]n [C]t [C]i [C]- [C]I [C]g E-protein 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
the [C]t [C]h [C]e O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
Egr-1 [C]E [C]g [C]r [C]- [C]1 O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
B [C]B O 
cell [C]c [C]e [C]l [C]l O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
breaks [C]b [C]r [C]e [C]a [C]k [C]s O 
down [C]d [C]o [C]w [C]n O 
when [C]w [C]h [C]e [C]n O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
is [C]i [C]s O 
added [C]a [C]d [C]d [C]e [C]d O 
as [C]a [C]s O 
a [C]a O 
co-mitogen [C]c [C]o [C]- [C]m [C]i [C]t [C]o [C]g [C]e [C]n O 
to [C]t [C]o O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
B [C]B O 
cell [C]c [C]e [C]l [C]l O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
IgG [C]I [C]g [C]G B-protein 
anti-Ig [C]a [C]n [C]t [C]i [C]- [C]I [C]g E-protein 
or [C]o [C]r O 
submitogenic [C]s [C]u [C]b [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]i [C]c O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
Fab'2 [C]F [C]a [C]b [C]' [C]2 B-protein 
anti-Ig [C]a [C]n [C]t [C]i [C]- [C]I [C]g E-protein 
. [C]. O 

No [C]N [C]o O 
corresponding [C]c [C]o [C]r [C]r [C]e [C]s [C]p [C]o [C]n [C]d [C]i [C]n [C]g O 
increases [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
in [C]i [C]n O 
Egr-1 [C]E [C]g [C]r [C]- [C]1 B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
are [C]a [C]r [C]e O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
when [C]w [C]h [C]e [C]n O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
is [C]i [C]s O 
added [C]a [C]d [C]d [C]e [C]d O 
. [C]. O 

Therefore [C]T [C]h [C]e [C]r [C]e [C]f [C]o [C]r [C]e O 
, [C], O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
overcomes [C]o [C]v [C]e [C]r [C]c [C]o [C]m [C]e [C]s O 
Fc [C]F [C]c O 
receptor-mediated [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
B [C]B B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
without [C]w [C]i [C]t [C]h [C]o [C]u [C]t O 
affecting [C]a [C]f [C]f [C]e [C]c [C]t [C]i [C]n [C]g O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Egr-1 [C]E [C]g [C]r [C]- [C]1 B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
, [C], O 
as [C]a [C]s O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
earlier [C]e [C]a [C]r [C]l [C]i [C]e [C]r O 
for [C]f [C]o [C]r O 
c-myc [C]c [C]- [C]m [C]y [C]c B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
in [C]i [C]n O 
this [C]t [C]h [C]i [C]s O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
. [C]. O 

Identification [C]I [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
cyclosporin-sensitive [C]c [C]y [C]c [C]l [C]o [C]s [C]p [C]o [C]r [C]i [C]n [C]- [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e B-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
tumor [C]t [C]u [C]m [C]o [C]r I-DNA 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-DNA 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-DNA 
alpha [C]a [C]l [C]p [C]h [C]a I-DNA 
gene [C]g [C]e [C]n [C]e I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

Tumor [C]T [C]u [C]m [C]o [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
( [C]( O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
) [C]) O 
, [C], O 
a [C]a O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e S-protein 
with [C]w [C]i [C]t [C]h O 
pleiotropic [C]p [C]l [C]e [C]i [C]o [C]t [C]r [C]o [C]p [C]i [C]c O 
biological [C]b [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
, [C], O 
is [C]i [C]s O 
produced [C]p [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
variety [C]v [C]a [C]r [C]i [C]e [C]t [C]y O 
of [C]o [C]f O 
cell [C]c [C]e [C]l [C]l O 
types [C]t [C]y [C]p [C]e [C]s O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
diverse [C]d [C]i [C]v [C]e [C]r [C]s [C]e O 
stimuli [C]s [C]t [C]i [C]m [C]u [C]l [C]i O 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
paper [C]p [C]a [C]p [C]e [C]r O 
, [C], O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
is [C]i [C]s O 
shown [C]s [C]h [C]o [C]w [C]n O 
to [C]t [C]o O 
be [C]b [C]e O 
highly [C]h [C]i [C]g [C]h [C]l [C]y O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
in [C]i [C]n O 
a [C]a O 
murine [C]m [C]u [C]r [C]i [C]n [C]e B-cell_line 
T [C]T I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
clone [C]c [C]l [C]o [C]n [C]e E-cell_line 
by [C]b [C]y O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
T [C]T B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
( [C]( O 
TCR [C]T [C]C [C]R S-protein 
) [C]) O 
ligands [C]l [C]i [C]g [C]a [C]n [C]d [C]s O 
or [C]o [C]r O 
by [C]b [C]y O 
calcium [C]c [C]a [C]l [C]c [C]i [C]u [C]m O 
ionophores [C]i [C]o [C]n [C]o [C]p [C]h [C]o [C]r [C]e [C]s O 
alone [C]a [C]l [C]o [C]n [C]e O 
. [C]. O 

Induction [C]I [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
rapid [C]r [C]a [C]p [C]i [C]d O 
, [C], O 
does [C]d [C]o [C]e [C]s O 
not [C]n [C]o [C]t O 
require [C]r [C]e [C]q [C]u [C]i [C]r [C]e O 
de [C]d [C]e O 
novo [C]n [C]o [C]v [C]o O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
completely [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e [C]l [C]y O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
immunosuppressant [C]i [C]m [C]m [C]u [C]n [C]o [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]a [C]n [C]t O 
cyclosporin [C]c [C]y [C]c [C]l [C]o [C]s [C]p [C]o [C]r [C]i [C]n O 
A [C]A O 
( [C]( O 
CsA [C]C [C]s [C]A O 
) [C]) O 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
a [C]a O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r I-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
, [C], O 
kappa [C]k [C]a [C]p [C]p [C]a B-DNA 
3 [C]3 E-DNA 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
plays [C]p [C]l [C]a [C]y [C]s O 
a [C]a O 
key [C]k [C]e [C]y O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
calcium-mediated [C]c [C]a [C]l [C]c [C]i [C]u [C]m [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
inducibility [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]i [C]l [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
CsA [C]C [C]s [C]A O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
gene [C]g [C]e [C]n [C]e O 
. [C]. O 

In [C]I [C]n O 
electrophoretic [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
, [C], O 
an [C]a [C]n O 
oligonucleotide [C]o [C]l [C]i [C]g [C]o [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e O 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
kappa [C]k [C]a [C]p [C]p [C]a B-DNA 
3 [C]3 E-DNA 
forms [C]f [C]o [C]r [C]m [C]s O 
two [C]t [C]w [C]o O 
DNA [C]D [C]N [C]A O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s O 
that [C]t [C]h [C]a [C]t O 
are [C]a [C]r [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
in [C]i [C]n O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
from [C]f [C]r [C]o [C]m O 
unstimulated [C]u [C]n [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s O 
appear [C]a [C]p [C]p [C]e [C]a [C]r O 
in [C]i [C]n O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
only [C]o [C]n [C]l [C]y O 
after [C]a [C]f [C]t [C]e [C]r O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Induction [C]I [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
inducible [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
is [C]i [C]s O 
rapid [C]r [C]a [C]p [C]i [C]d O 
, [C], O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
of [C]o [C]f O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
by [C]b [C]y O 
CsA [C]C [C]s [C]A O 
, [C], O 
and [C]a [C]n [C]d O 
thus [C]t [C]h [C]u [C]s O 
, [C], O 
exactly [C]e [C]x [C]a [C]c [C]t [C]l [C]y O 
parallels [C]p [C]a [C]r [C]a [C]l [C]l [C]e [C]l [C]s O 
the [C]t [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
by [C]b [C]y O 
TCR [C]T [C]C [C]R O 
ligands [C]l [C]i [C]g [C]a [C]n [C]d [C]s O 
or [C]o [C]r O 
by [C]b [C]y O 
calcium [C]c [C]a [C]l [C]c [C]i [C]u [C]m O 
ionophore [C]i [C]o [C]n [C]o [C]p [C]h [C]o [C]r [C]e O 
. [C]. O 

Our [C]O [C]u [C]r O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
kappa [C]k [C]a [C]p [C]p [C]a B-protein 
3 [C]3 I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
resembles [C]r [C]e [C]s [C]e [C]m [C]b [C]l [C]e [C]s O 
the [C]t [C]h [C]e O 
preexisting [C]p [C]r [C]e [C]e [C]x [C]i [C]s [C]t [C]i [C]n [C]g O 
component [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t O 
of [C]o [C]f O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
of [C]o [C]f O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
the [C]t [C]h [C]e O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
is [C]i [C]s O 
an [C]a [C]n O 
immediate [C]i [C]m [C]m [C]e [C]d [C]i [C]a [C]t [C]e O 
early [C]e [C]a [C]r [C]l [C]y O 
gene [C]g [C]e [C]n [C]e O 
in [C]i [C]n O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
provides [C]p [C]r [C]o [C]v [C]i [C]d [C]e [C]s O 
a [C]a O 
new [C]n [C]e [C]w O 
model [C]m [C]o [C]d [C]e [C]l O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
in [C]i [C]n O 
which [C]w [C]h [C]i [C]c [C]h O 
to [C]t [C]o O 
study [C]s [C]t [C]u [C]d [C]y O 
CsA-sensitive [C]C [C]s [C]A [C]- [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Differences [C]D [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e [C]s O 
in [C]i [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
AP-1 [C]A [C]P [C]- [C]1 E-protein 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
promyelocytic [C]p [C]r [C]o [C]m [C]y [C]e [C]l [C]o [C]c [C]y [C]t [C]i [C]c I-cell_line 
HL-60 [C]H [C]L [C]- [C]6 [C]0 I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
towards [C]t [C]o [C]w [C]a [C]r [C]d [C]s O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_type 
versus [C]v [C]e [C]r [C]s [C]u [C]s O 
granulocytes [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
. [C]. O 

Commitment [C]C [C]o [C]m [C]m [C]i [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
HL-60 [C]H [C]L [C]- [C]6 [C]0 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
to [C]t [C]o O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e O 
or [C]o [C]r O 
granulocytic [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]i [C]c O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
achieved [C]a [C]c [C]h [C]i [C]e [C]v [C]e [C]d O 
by [C]b [C]y O 
incubation [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
4 [C]4 O 
beta-phorbol [C]b [C]e [C]t [C]a [C]- [C]p [C]h [C]o [C]r [C]b [C]o [C]l O 
12-myristate [C]1 [C]2 [C]- [C]m [C]y [C]r [C]i [C]s [C]t [C]a [C]t [C]e O 
13-acetate [C]1 [C]3 [C]- [C]a [C]c [C]e [C]t [C]a [C]t [C]e O 
( [C]( O 
PMA [C]P [C]M [C]A O 
) [C]) O 
for [C]f [C]o [C]r O 
30-60 [C]3 [C]0 [C]- [C]6 [C]0 O 
min [C]m [C]i [C]n O 
or [C]o [C]r O 
with [C]w [C]i [C]t [C]h O 
dimethyl [C]d [C]i [C]m [C]e [C]t [C]h [C]y [C]l O 
sulphoxide [C]s [C]u [C]l [C]p [C]h [C]o [C]x [C]i [C]d [C]e O 
( [C]( O 
DMSO [C]D [C]M [C]S [C]O O 
) [C]) O 
for [C]f [C]o [C]r O 
24 [C]2 [C]4 O 
h [C]h O 
respectively [C]r [C]e [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
commitment [C]c [C]o [C]m [C]m [C]i [C]t [C]m [C]e [C]n [C]t O 
stage [C]s [C]t [C]a [C]g [C]e O 
towards [C]t [C]o [C]w [C]a [C]r [C]d [C]s O 
PMA-induced [C]P [C]M [C]A [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
increases [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
in [C]i [C]n O 
jun [C]j [C]u [C]n O 
B [C]B O 
and [C]a [C]n [C]d O 
c-fos [C]c [C]- [C]f [C]o [C]s O 
mRNA [C]m [C]R [C]N [C]A O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
, [C], O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
with [C]w [C]i [C]t [C]h O 
an [C]a [C]n O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
AP-1 [C]A [C]P [C]- [C]1 E-protein 
. [C]. O 

Nevertheless [C]N [C]e [C]v [C]e [C]r [C]t [C]h [C]e [C]l [C]e [C]s [C]s O 
, [C], O 
gel [C]g [C]e [C]l O 
retardation [C]r [C]e [C]t [C]a [C]r [C]d [C]a [C]t [C]i [C]o [C]n O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
indicated [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
in [C]i [C]n O 
untreated [C]u [C]n [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
cells [C]c [C]e [C]l [C]l [C]s O 
was [C]w [C]a [C]s O 
drastically [C]d [C]r [C]a [C]s [C]t [C]i [C]c [C]a [C]l [C]l [C]y O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
commitment [C]c [C]o [C]m [C]m [C]i [C]t [C]m [C]e [C]n [C]t O 
stage [C]s [C]t [C]a [C]g [C]e O 
of [C]o [C]f O 
DMSO-induced [C]D [C]M [C]S [C]O [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
HL-60 [C]H [C]L [C]- [C]6 [C]0 O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
towards [C]t [C]o [C]w [C]a [C]r [C]d [C]s O 
granulocytes [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
. [C]. O 

When [C]W [C]h [C]e [C]n O 
HL-60 [C]H [C]L [C]- [C]6 [C]0 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
were [C]w [C]e [C]r [C]e O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
sodium [C]s [C]o [C]d [C]i [C]u [C]m O 
butyrate [C]b [C]u [C]t [C]y [C]r [C]a [C]t [C]e O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
monocytic [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]i [C]c O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
a [C]a O 
remarkable [C]r [C]e [C]m [C]a [C]r [C]k [C]a [C]b [C]l [C]e O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
AP-1 [C]A [C]P [C]- [C]1 O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
was [C]w [C]a [C]s O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
. [C]. O 

Treatment [C]T [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
HL-60 [C]H [C]L [C]- [C]6 [C]0 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
with [C]w [C]i [C]t [C]h O 
1 [C]1 O 
alpha [C]a [C]l [C]p [C]h [C]a O 
, [C], O 
25-dihydroxyvitamin [C]2 [C]5 [C]- [C]d [C]i [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]v [C]i [C]t [C]a [C]m [C]i [C]n O 
D3 [C]D [C]3 O 
, [C], O 
another [C]a [C]n [C]o [C]t [C]h [C]e [C]r O 
monocytic [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]i [C]c O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
agent [C]a [C]g [C]e [C]n [C]t O 
, [C], O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
a [C]a O 
weak [C]w [C]e [C]a [C]k O 
, [C], O 
but [C]b [C]u [C]t O 
appreciable [C]a [C]p [C]p [C]r [C]e [C]c [C]i [C]a [C]b [C]l [C]e O 
, [C], O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
sodium [C]s [C]o [C]d [C]i [C]u [C]m O 
butyrate [C]b [C]u [C]t [C]y [C]r [C]a [C]t [C]e O 
or [C]o [C]r O 
1 [C]1 O 
alpha [C]a [C]l [C]p [C]h [C]a O 
, [C], O 
25-dihydroxyvitamin [C]2 [C]5 [C]- [C]d [C]i [C]h [C]y [C]d [C]r [C]o [C]x [C]y [C]v [C]i [C]t [C]a [C]m [C]i [C]n O 
D3 [C]D [C]3 O 
to [C]t [C]o O 
HL-60 [C]H [C]L [C]- [C]6 [C]0 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
c-fos [C]c [C]- [C]f [C]o [C]s B-DNA 
, [C], I-DNA 
c-jun [C]c [C]- [C]j [C]u [C]n I-DNA 
, [C], I-DNA 
jun [C]j [C]u [C]n I-DNA 
B [C]B I-DNA 
and [C]a [C]n [C]d I-DNA 
jun [C]j [C]u [C]n I-DNA 
D [C]D I-DNA 
proto-oncogenes [C]p [C]r [C]o [C]t [C]o [C]- [C]o [C]n [C]c [C]o [C]g [C]e [C]n [C]e [C]s E-DNA 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
when [C]w [C]h [C]e [C]n O 
HL-60 [C]H [C]L [C]- [C]6 [C]0 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
were [C]w [C]e [C]r [C]e O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
retinoic [C]r [C]e [C]t [C]i [C]n [C]o [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
, [C], O 
a [C]a O 
granulocytic [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]i [C]c O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
inducer [C]i [C]n [C]d [C]u [C]c [C]e [C]r O 
, [C], O 
no [C]n [C]o O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
AP-1 [C]A [C]P [C]- [C]1 O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
, [C], O 
and [C]a [C]n [C]d O 
only [C]o [C]n [C]l [C]y O 
a [C]a O 
weak [C]w [C]e [C]a [C]k O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
jun [C]j [C]u [C]n B-RNA 
D [C]D I-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
level [C]l [C]e [C]v [C]e [C]l O 
was [C]w [C]a [C]s O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
is [C]i [C]s O 
not [C]n [C]o [C]t O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
HL-60 [C]H [C]L [C]- [C]6 [C]0 S-cell_line 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
towards [C]t [C]o [C]w [C]a [C]r [C]d [C]s O 
granulocytes [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
monocytic [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]i [C]c O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
an [C]a [C]n O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
differential [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]l O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
AP-1 [C]A [C]P [C]- [C]1 S-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
critical [C]c [C]r [C]i [C]t [C]i [C]c [C]a [C]l O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
HL-60 [C]H [C]L [C]- [C]6 [C]0 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
towards [C]t [C]o [C]w [C]a [C]r [C]d [C]s O 
monocytic [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]i [C]c B-cell_type 
or [C]o [C]r I-cell_type 
granulocytic [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]i [C]c I-cell_type 
lineages [C]l [C]i [C]n [C]e [C]a [C]g [C]e [C]s E-cell_type 

Glucocorticoid [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
and [C]a [C]n [C]d O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
leukemias [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a [C]s O 
. [C]. O 

In [C]I [C]n O 
an [C]a [C]n O 
attempt [C]a [C]t [C]t [C]e [C]m [C]p [C]t O 
to [C]t [C]o O 
investigate [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
utility [C]u [C]t [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
determination [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
to [C]t [C]o O 
predict [C]p [C]r [C]e [C]d [C]i [C]c [C]t O 
clinical [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
responsiveness [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e [C]n [C]e [C]s [C]s O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n O 
leukemias [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a [C]s O 
we [C]w [C]e O 
have [C]h [C]a [C]v [C]e O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
from [C]f [C]r [C]o [C]m O 
46 [C]4 [C]6 O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
from [C]f [C]r [C]o [C]m O 
18 [C]1 [C]8 O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
donors [C]d [C]o [C]n [C]o [C]r [C]s O 
. [C]. O 

In [C]I [C]n O 
the [C]t [C]h [C]e O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
there [C]t [C]h [C]e [C]r [C]e O 
were [C]w [C]e [C]r [C]e O 
3 [C]3 O 
, [C], O 
875 [C]8 [C]7 [C]5 O 
( [C]( O 
Median [C]M [C]e [C]d [C]i [C]a [C]n O 
) [C]) O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
sites [C]s [C]i [C]t [C]e [C]s O 
per [C]p [C]e [C]r O 
cell [C]c [C]e [C]l [C]l O 
. [C]. O 

The [C]T [C]h [C]e O 
blasts [C]b [C]l [C]a [C]s [C]t [C]s S-cell_type 
from [C]f [C]r [C]o [C]m O 
17 [C]1 [C]7 O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
ANLL [C]A [C]N [C]L [C]L O 
had [C]h [C]a [C]d O 
on [C]o [C]n O 
average [C]a [C]v [C]e [C]r [C]a [C]g [C]e O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
sites [C]s [C]i [C]t [C]e [C]s E-protein 
per [C]p [C]e [C]r O 
cell [C]c [C]e [C]l [C]l O 
( [C]( O 
Median [C]M [C]e [C]d [C]i [C]a [C]n O 
= [C]= O 
7 [C]7 O 
, [C], O 
250 [C]2 [C]5 [C]0 O 
, [C], O 
range [C]r [C]a [C]n [C]g [C]e O 
: [C]: O 
0 [C]0 O 
to [C]t [C]o O 
15 [C]1 [C]5 O 
, [C], O 
295 [C]2 [C]9 [C]5 O 
) [C]) O 
than [C]t [C]h [C]a [C]n O 
the [C]t [C]h [C]e O 
other [C]o [C]t [C]h [C]e [C]r O 
leukemias [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a [C]s O 
. [C]. O 

Of [C]O [C]f O 
the [C]t [C]h [C]e O 
15 [C]1 [C]5 O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
CLL [C]C [C]L [C]L O 
, [C], O 
six [C]s [C]i [C]x O 
had [C]h [C]a [C]d O 
received [C]r [C]e [C]c [C]e [C]i [C]v [C]e [C]d O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
for [C]f [C]o [C]r O 
3 [C]3 O 
to [C]t [C]o O 
5 [C]5 O 
years [C]y [C]e [C]a [C]r [C]s O 
. [C]. O 

Their [C]T [C]h [C]e [C]i [C]r O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
had [C]h [C]a [C]d O 
lower [C]l [C]o [C]w [C]e [C]r O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
( [C]( O 
Median [C]M [C]e [C]d [C]i [C]a [C]n O 
= [C]= O 
2 [C]2 O 
, [C], O 
000 [C]0 [C]0 [C]0 O 
) [C]) O 
than [C]t [C]h [C]a [C]n O 
the [C]t [C]h [C]e O 
other [C]o [C]t [C]h [C]e [C]r O 
cases [C]c [C]a [C]s [C]e [C]s O 
which [C]w [C]h [C]i [C]c [C]h O 
were [C]w [C]e [C]r [C]e O 
newly [C]n [C]e [C]w [C]l [C]y O 
diagnosed [C]d [C]i [C]a [C]g [C]n [C]o [C]s [C]e [C]d O 
( [C]( O 
Median [C]M [C]e [C]d [C]i [C]a [C]n O 
= [C]= O 
4 [C]4 O 
, [C], O 
500 [C]5 [C]0 [C]0 O 
) [C]) O 
. [C]. O 

Four [C]F [C]o [C]u [C]r O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
had [C]h [C]a [C]d O 
ALL/AUL [C]A [C]L [C]L [C]/ [C]A [C]U [C]L O 
, [C], O 
three [C]t [C]h [C]r [C]e [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
had [C]h [C]a [C]d O 
blast [C]b [C]l [C]a [C]s [C]t O 
crisis [C]c [C]r [C]i [C]s [C]i [C]s O 
as [C]a [C]s O 
terminal [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l O 
phase [C]p [C]h [C]a [C]s [C]e O 
of [C]o [C]f O 
CML [C]C [C]M [C]L O 
, [C], O 
and [C]a [C]n [C]d O 
seven [C]s [C]e [C]v [C]e [C]n O 
had [C]h [C]a [C]d O 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c O 
Non-Hodgkin [C]N [C]o [C]n [C]- [C]H [C]o [C]d [C]g [C]k [C]i [C]n O 
lymphomas [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a [C]s O 
( [C]( O 
Median [C]M [C]e [C]d [C]i [C]a [C]n O 
= [C]= O 
3 [C]3 O 
, [C], O 
500 [C]5 [C]0 [C]0 O 
sites/cell [C]s [C]i [C]t [C]e [C]s [C]/ [C]c [C]e [C]l [C]l O 
) [C]) O 
. [C]. O 

In [C]I [C]n O 
24 [C]2 [C]4 O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
we [C]w [C]e O 
have [C]h [C]a [C]v [C]e O 
also [C]a [C]l [C]s [C]o O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
the [C]t [C]h [C]e O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
to [C]t [C]o O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
. [C]. O 

There [C]T [C]h [C]e [C]r [C]e O 
was [C]w [C]a [C]s O 
no [C]n [C]o O 
marked [C]m [C]a [C]r [C]k [C]e [C]d O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

An [C]A [C]n O 
attempt [C]a [C]t [C]t [C]e [C]m [C]p [C]t O 
to [C]t [C]o O 
correlate [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
with [C]w [C]i [C]t [C]h O 
clinical [C]c [C]l [C]i [C]n [C]i [C]c [C]a [C]l O 
responsiveness [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]i [C]v [C]e [C]n [C]e [C]s [C]s O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
determination [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
might [C]m [C]i [C]g [C]h [C]t O 
be [C]b [C]e O 
of [C]o [C]f O 
value [C]v [C]a [C]l [C]u [C]e O 
in [C]i [C]n O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d O 
malignancies [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]c [C]i [C]e [C]s O 
but [C]b [C]u [C]t O 
probably [C]p [C]r [C]o [C]b [C]a [C]b [C]l [C]y O 
not [C]n [C]o [C]t O 
in [C]i [C]n O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
other [C]o [C]t [C]h [C]e [C]r O 
leukemias [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a [C]s O 
. [C]. O 

'Activation-labile [C]' [C]A [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n [C]- [C]l [C]a [C]b [C]i [C]l [C]e B-protein 
' [C]' I-protein 
glucocorticoid-receptor [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
of [C]o [C]f O 
a [C]a O 
steroid-resistant [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]- [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]t O 
variant [C]v [C]a [C]r [C]i [C]a [C]n [C]t O 
of [C]o [C]f O 
CEM-C7 [C]C [C]E [C]M [C]- [C]C [C]7 B-cell_line 
human [C]h [C]u [C]m [C]a [C]n I-cell_line 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

For [C]F [C]o [C]r O 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c B-protein 
glucocorticoid-receptor [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
to [C]t [C]o O 
enter [C]e [C]n [C]t [C]e [C]r O 
and [C]a [C]n [C]d O 
accumulate [C]a [C]c [C]c [C]u [C]m [C]u [C]l [C]a [C]t [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
nucleus [C]n [C]u [C]c [C]l [C]e [C]u [C]s O 
a [C]a O 
temperature-dependent [C]t [C]e [C]m [C]p [C]e [C]r [C]a [C]t [C]u [C]r [C]e [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
event [C]e [C]v [C]e [C]n [C]t O 
, [C], O 
'activation [C]' [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
' [C]' O 
is [C]i [C]s O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
. [C]. O 

Activation [C]A [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
can [C]c [C]a [C]n O 
be [C]b [C]e O 
achieved [C]a [C]c [C]h [C]i [C]e [C]v [C]e [C]d O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
by [C]b [C]y O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
ionic [C]i [C]o [C]n [C]i [C]c O 
strength [C]s [C]t [C]r [C]e [C]n [C]g [C]t [C]h O 
, [C], O 
dilution [C]d [C]i [C]l [C]u [C]t [C]i [C]o [C]n O 
or [C]o [C]r O 
gel [C]g [C]e [C]l O 
filtration [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
manifested [C]m [C]a [C]n [C]i [C]f [C]e [C]s [C]t [C]e [C]d O 
by [C]b [C]y O 
an [C]a [C]n O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
of [C]o [C]f O 
steroid-receptor [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r B-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
for [C]f [C]o [C]r O 
DNA [C]D [C]N [C]A S-DNA 
and [C]a [C]n [C]d O 
an [C]a [C]n O 
altered [C]a [C]l [C]t [C]e [C]r [C]e [C]d O 
elution [C]e [C]l [C]u [C]t [C]i [C]o [C]n O 
profile [C]p [C]r [C]o [C]f [C]i [C]l [C]e O 
from [C]f [C]r [C]o [C]m O 
ion-exchange [C]i [C]o [C]n [C]- [C]e [C]x [C]c [C]h [C]a [C]n [C]g [C]e O 
resins [C]r [C]e [C]s [C]i [C]n [C]s O 
. [C]. O 

Munck [C]M [C]u [C]n [C]c [C]k O 
and [C]a [C]n [C]d O 
Foley [C]F [C]o [C]l [C]e [C]y O 
have [C]h [C]a [C]v [C]e O 
shown [C]s [C]h [C]o [C]w [C]n O 
that [C]t [C]h [C]a [C]t O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s O 
elute [C]e [C]l [C]u [C]t [C]e O 
from [C]f [C]r [C]o [C]m O 
DEAE-cellulose [C]D [C]E [C]A [C]E [C]- [C]c [C]e [C]l [C]l [C]u [C]l [C]o [C]s [C]e O 
in [C]i [C]n O 
a [C]a O 
manner [C]m [C]a [C]n [C]n [C]e [C]r O 
identical [C]i [C]d [C]e [C]n [C]t [C]i [C]c [C]a [C]l O 
to [C]t [C]o O 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
. [C]. O 

We [C]W [C]e O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
here [C]h [C]e [C]r [C]e O 
that [C]t [C]h [C]a [C]t O 
DEAE-cellulose [C]D [C]E [C]A [C]E [C]- [C]c [C]e [C]l [C]l [C]u [C]l [C]o [C]s [C]e O 
chromatography [C]c [C]h [C]r [C]o [C]m [C]a [C]t [C]o [C]g [C]r [C]a [C]p [C]h [C]y O 
of [C]o [C]f O 
steroid-receptor [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r B-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
from [C]f [C]r [C]o [C]m O 
CEM-C7 [C]C [C]E [C]M [C]- [C]C [C]7 S-cell_line 
, [C], O 
a [C]a O 
cloned [C]c [C]l [C]o [C]n [C]e [C]d B-cell_line 
human [C]h [C]u [C]m [C]a [C]n I-cell_line 
leukaemic [C]l [C]e [C]u [C]k [C]a [C]e [C]m [C]i [C]c I-cell_line 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
sensitive [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
cytolytic [C]c [C]y [C]t [C]o [C]l [C]y [C]t [C]i [C]c O 
action [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
its [C]i [C]t [C]s O 
steroid-resistant [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]- [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]t B-cell_line 
subclone [C]s [C]u [C]b [C]c [C]l [C]o [C]n [C]e I-cell_line 
4R4 [C]4 [C]R [C]4 E-cell_line 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
of [C]o [C]f O 
clone [C]c [C]l [C]o [C]n [C]e B-cell_line 
4R4 [C]4 [C]R [C]4 E-cell_line 
can [C]c [C]a [C]n O 
not [C]n [C]o [C]t O 
form [C]f [C]o [C]r [C]m O 
stable [C]s [C]t [C]a [C]b [C]l [C]e O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
defines [C]d [C]e [C]f [C]i [C]n [C]e [C]s O 
a [C]a O 
new [C]n [C]e [C]w O 
defect [C]d [C]e [C]f [C]e [C]c [C]t O 
in [C]i [C]n O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
action [C]a [C]c [C]t [C]i [C]o [C]n O 
, [C], O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
lability [C]l [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
( [C]( O 
r+act1 [C]r [C]+ [C]a [C]c [C]t [C]1 O 
) [C]) O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
unlike [C]u [C]n [C]l [C]i [C]k [C]e O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
the [C]t [C]h [C]e O 
r- [C]r [C]- B-cell_line 
, [C], I-cell_line 
r+nt- [C]r [C]+ [C]n [C]t [C]- I-cell_line 
, [C], I-cell_line 
or [C]o [C]r I-cell_line 
r+nti [C]r [C]+ [C]n [C]t [C]i I-cell_line 
phenotypes [C]p [C]h [C]e [C]n [C]o [C]t [C]y [C]p [C]e [C]s E-cell_line 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
described [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
for [C]f [C]o [C]r O 
mouse [C]m [C]o [C]u [C]s [C]e B-cell_line 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d I-cell_line 
variants [C]v [C]a [C]r [C]i [C]a [C]n [C]t [C]s E-cell_line 
. [C]. O 

Granulocytes [C]G [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
endometrium [C]e [C]n [C]d [C]o [C]m [C]e [C]t [C]r [C]i [C]u [C]m O 
of [C]o [C]f O 
post-partum [C]p [C]o [C]s [C]t [C]- [C]p [C]a [C]r [C]t [C]u [C]m O 
women [C]w [C]o [C]m [C]e [C]n O 
. [C]. O 

Endometrial [C]E [C]n [C]d [C]o [C]m [C]e [C]t [C]r [C]i [C]a [C]l O 
samples [C]s [C]a [C]m [C]p [C]l [C]e [C]s O 
of [C]o [C]f O 
women [C]w [C]o [C]m [C]e [C]n O 
at [C]a [C]t O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
stages [C]s [C]t [C]a [C]g [C]e [C]s O 
of [C]o [C]f O 
gonadal [C]g [C]o [C]n [C]a [C]d [C]a [C]l O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
after [C]a [C]f [C]t [C]e [C]r O 
parturition [C]p [C]a [C]r [C]t [C]u [C]r [C]i [C]t [C]i [C]o [C]n O 
were [C]w [C]e [C]r [C]e O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
and [C]a [C]n [C]d O 
numbers [C]n [C]u [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
endometrial [C]e [C]n [C]d [C]o [C]m [C]e [C]t [C]r [C]i [C]a [C]l B-cell_type 
granulocytes [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
samples [C]s [C]a [C]m [C]p [C]l [C]e [C]s O 
at [C]a [C]t O 
all [C]a [C]l [C]l O 
the [C]t [C]h [C]e O 
stages [C]s [C]t [C]a [C]g [C]e [C]s O 
contained [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]e [C]d O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
numbers [C]n [C]u [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
granulocytes [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
( [C]( O 
i.e. [C]i [C]. [C]e [C]. O 
greater [C]g [C]r [C]e [C]a [C]t [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
7/high-power [C]7 [C]/ [C]h [C]i [C]g [C]h [C]- [C]p [C]o [C]w [C]e [C]r O 
field [C]f [C]i [C]e [C]l [C]d O 
) [C]) O 
, [C], O 
the [C]t [C]h [C]e O 
100 [C]1 [C]0 [C]0 O 
% [C]% O 
values [C]v [C]a [C]l [C]u [C]e [C]s O 
for [C]f [C]o [C]r O 
late-proliferative [C]l [C]a [C]t [C]e [C]- [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
and [C]a [C]n [C]d O 
adaptation [C]a [C]d [C]a [C]p [C]t [C]a [C]t [C]i [C]o [C]n O 
hyperplasia [C]h [C]y [C]p [C]e [C]r [C]p [C]l [C]a [C]s [C]i [C]a O 
were [C]w [C]e [C]r [C]e O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
the [C]t [C]h [C]e O 
values [C]v [C]a [C]l [C]u [C]e [C]s O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
resting [C]r [C]e [C]s [C]t [C]i [C]n [C]g O 
( [C]( O 
81.8 [C]8 [C]1 [C]. [C]8 O 
% [C]% O 
) [C]) O 
, [C], O 
early [C]e [C]a [C]r [C]l [C]y O 
( [C]( O 
82.4 [C]8 [C]2 [C]. [C]4 O 
% [C]% O 
) [C]) O 
and [C]a [C]n [C]d O 
mid- [C]m [C]i [C]d [C]- O 
( [C]( O 
87.9 [C]8 [C]7 [C]. [C]9 O 
% [C]% O 
) [C]) O 
proliferative [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
and [C]a [C]n [C]d O 
secretory [C]s [C]e [C]c [C]r [C]e [C]t [C]o [C]r [C]y O 
( [C]( O 
83.3 [C]8 [C]3 [C]. [C]3 O 
% [C]% O 
) [C]) O 
phases [C]p [C]h [C]a [C]s [C]e [C]s O 
. [C]. O 

We [C]W [C]e O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
this [C]t [C]h [C]i [C]s O 
correlates [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
suggestion [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]o [C]n O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
granulocytes [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
constitute [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]e O 
a [C]a O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
for [C]f [C]o [C]r O 
oestrogens [C]o [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n [C]s O 
. [C]. O 

Interaction [C]I [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
with [C]w [C]i [C]t [C]h O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_type 
. [C]. O 

Identification [C]I [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
and [C]a [C]n [C]d O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_type 
. [C]. O 

Glucocorticoid [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
was [C]w [C]a [C]s O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
in [C]i [C]n O 
resident [C]r [C]e [C]s [C]i [C]d [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
thioglycollate-elicited [C]t [C]h [C]i [C]o [C]g [C]l [C]y [C]c [C]o [C]l [C]l [C]a [C]t [C]e [C]- [C]e [C]l [C]i [C]c [C]i [C]t [C]e [C]d B-cell_type 
mouse [C]m [C]o [C]u [C]s [C]e I-cell_type 
peritoneal [C]p [C]e [C]r [C]i [C]t [C]o [C]n [C]e [C]a [C]l I-cell_type 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s E-cell_type 
, [C], O 
rabbit [C]r [C]a [C]b [C]b [C]i [C]t B-cell_type 
alveolar [C]a [C]l [C]v [C]e [C]o [C]l [C]a [C]r I-cell_type 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s E-cell_type 
, [C], O 
and [C]a [C]n [C]d O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

Two [C]T [C]w [C]o O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
of [C]o [C]f O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
were [C]w [C]e [C]r [C]e O 
used [C]u [C]s [C]e [C]d O 
-- [C]- [C]- O 
an [C]a [C]n O 
assay [C]a [C]s [C]s [C]a [C]y O 
with [C]w [C]i [C]t [C]h O 
intact [C]i [C]n [C]t [C]a [C]c [C]t B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
suspension [C]s [C]u [C]s [C]p [C]e [C]n [C]s [C]i [C]o [C]n O 
or [C]o [C]r O 
monolayers [C]m [C]o [C]n [C]o [C]l [C]a [C]y [C]e [C]r [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
an [C]a [C]n O 
assay [C]a [C]s [C]s [C]a [C]y O 
of [C]o [C]f O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
and [C]a [C]n [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
forms [C]f [C]o [C]r [C]m [C]s O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_type 
phagocytes [C]p [C]h [C]a [C]g [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
contained [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]e [C]d O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
equal [C]e [C]q [C]u [C]a [C]l O 
to [C]t [C]o O 
4 [C]4 O 
-- [C]- [C]- O 
10 [C]1 [C]0 O 
X [C]X O 
10 [C]1 [C]0 O 
( [C]( O 
3 [C]3 O 
) [C]) O 
high [C]h [C]i [C]g [C]h B-protein 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
sites [C]s [C]i [C]t [C]e [C]s E-protein 
per [C]p [C]e [C]r O 
cell [C]c [C]e [C]l [C]l O 
, [C], O 
with [C]w [C]i [C]t [C]h O 
dissociation [C]d [C]i [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
constants [C]c [C]o [C]n [C]s [C]t [C]a [C]n [C]t [C]s O 
of [C]o [C]f O 
approximately [C]a [C]p [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
equal [C]e [C]q [C]u [C]a [C]l O 
to [C]t [C]o O 
2 [C]2 O 
-- [C]- [C]- O 
8 [C]8 O 
nM [C]n [C]M O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
saturable [C]s [C]a [C]t [C]u [C]r [C]a [C]b [C]l [C]e B-protein 
sites [C]s [C]i [C]t [C]e [C]s E-protein 
was [C]w [C]a [C]s O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
for [C]f [C]o [C]r O 
steroids [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]s O 
with [C]w [C]i [C]t [C]h O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
or [C]o [C]r O 
antiglucocorticoid [C]a [C]n [C]t [C]i [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

Cortisol [C]C [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
, [C], O 
corticosterone [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
, [C], O 
and [C]a [C]n [C]d O 
progesterone [C]p [C]r [C]o [C]g [C]e [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
competed [C]c [C]o [C]m [C]p [C]e [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
for [C]f [C]o [C]r O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
estradiol [C]e [C]s [C]t [C]r [C]a [C]d [C]i [C]o [C]l O 
, [C], O 
dihydrotestosterone [C]d [C]i [C]h [C]y [C]d [C]r [C]o [C]t [C]e [C]s [C]t [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
, [C], O 
and [C]a [C]n [C]d O 
11-epicortisol [C]1 [C]1 [C]- [C]e [C]p [C]i [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
competed [C]c [C]o [C]m [C]p [C]e [C]t [C]e [C]d O 
very [C]v [C]e [C]r [C]y O 
little [C]l [C]i [C]t [C]t [C]l [C]e O 
. [C]. O 

Binding [C]B [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
to [C]t [C]o O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
and [C]a [C]n [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
forms [C]f [C]o [C]r [C]m [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r B-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
and [C]a [C]n [C]d O 
temperature-sensitive [C]t [C]e [C]m [C]p [C]e [C]r [C]a [C]t [C]u [C]r [C]e [C]- [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
translocation [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
forms [C]f [C]o [C]r [C]m [C]s O 
to [C]t [C]o O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
forms [C]f [C]o [C]r [C]m [C]s O 
were [C]w [C]e [C]r [C]e O 
shown [C]s [C]h [C]o [C]w [C]n O 
. [C]. O 

At [C]A [C]t O 
37 [C]3 [C]7 O 
degrees [C]d [C]e [C]g [C]r [C]e [C]e [C]s O 
C [C]C O 
the [C]t [C]h [C]e O 
predominant [C]p [C]r [C]e [C]d [C]o [C]m [C]i [C]n [C]a [C]n [C]t O 
form [C]f [C]o [C]r [C]m O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
hormone-receptor [C]h [C]o [C]r [C]m [C]o [C]n [C]e [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r B-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
was [C]w [C]a [C]s O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
corticosteroids [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]s O 
interact [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t O 
with [C]w [C]i [C]t [C]h O 
macrophages [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]s S-cell_type 
at [C]a [C]t O 
physiological [C]p [C]h [C]y [C]s [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

Nitric [C]N [C]i [C]t [C]r [C]i [C]c O 
oxide [C]o [C]x [C]i [C]d [C]e O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
: [C]: O 
a [C]a O 
possible [C]p [C]o [C]s [C]s [C]i [C]b [C]l [C]e O 
role [C]r [C]o [C]l [C]e O 
for [C]f [C]o [C]r O 
G [C]G B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
reported [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]d O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
inductive [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]v [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
nitric [C]n [C]i [C]t [C]r [C]i [C]c O 
oxide [C]o [C]x [C]i [C]d [C]e O 
on [C]o [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
PBMC [C]P [C]B [C]M [C]C E-cell_type 
. [C]. O 

We [C]W [C]e O 
describe [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
and [C]a [C]n [C]d O 
potentially [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l [C]l [C]y O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
of [C]o [C]f O 
nitric [C]n [C]i [C]t [C]r [C]i [C]c O 
oxide [C]o [C]x [C]i [C]d [C]e O 
signaling-through [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g [C]- [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
direct [C]d [C]i [C]r [C]e [C]c [C]t O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
guanine [C]g [C]u [C]a [C]n [C]i [C]n [C]e B-protein 
nucleotide-binding [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
( [C]( O 
G [C]G B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
) [C]) O 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
nitric [C]n [C]i [C]t [C]r [C]i [C]c O 
oxide [C]o [C]x [C]i [C]d [C]e O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
membranes [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e [C]s O 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
fresh [C]f [C]r [C]e [C]s [C]h B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
PBMC [C]P [C]B [C]M [C]C E-cell_type 
enhances [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]s O 
the [C]t [C]h [C]e O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
membranes [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e [C]s O 
to [C]t [C]o O 
hydrolyze [C]h [C]y [C]d [C]r [C]o [C]l [C]y [C]z [C]e O 
[ [C][ O 
gamma-32P [C]g [C]a [C]m [C]m [C]a [C]- [C]3 [C]2 [C]P O 
] [C]] O 
GTP [C]G [C]T [C]P O 
and [C]a [C]n [C]d O 
bind [C]b [C]i [C]n [C]d O 
[ [C][ O 
gamma-35S [C]g [C]a [C]m [C]m [C]a [C]- [C]3 [C]5 [C]S O 
] [C]] O 
GTP [C]G [C]T [C]P O 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
whole [C]w [C]h [C]o [C]l [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
with [C]w [C]i [C]t [C]h O 
nitric [C]n [C]i [C]t [C]r [C]i [C]c O 
oxide [C]o [C]x [C]i [C]d [C]e O 
yielded [C]y [C]i [C]e [C]l [C]d [C]e [C]d O 
membranes [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
GTPase [C]G [C]T [C]P [C]a [C]s [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
the [C]t [C]h [C]e O 
GTPase [C]G [C]T [C]P [C]a [C]s [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
pure [C]p [C]u [C]r [C]e O 
, [C], O 
recombinant [C]r [C]e [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]n [C]t O 
Gs [C]G [C]s B-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
, [C], O 
Gi [C]G [C]i B-protein 
alpha [C]a [C]l [C]p [C]h [C]a I-protein 
1 [C]1 E-protein 
, [C], O 
and [C]a [C]n [C]d O 
p21ras [C]p [C]2 [C]1 [C]r [C]a [C]s S-protein 
was [C]w [C]a [C]s O 
greatly [C]g [C]r [C]e [C]a [C]t [C]l [C]y O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
by [C]b [C]y O 
nitric [C]n [C]i [C]t [C]r [C]i [C]c O 
oxide [C]o [C]x [C]i [C]d [C]e O 
. [C]. O 

In [C]I [C]n O 
support [C]s [C]u [C]p [C]p [C]o [C]r [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
existence [C]e [C]x [C]i [C]s [C]t [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
in [C]i [C]n O 
whole [C]w [C]h [C]o [C]l [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
, [C], O 
we [C]w [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
G [C]G O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
, [C], O 
GDP-beta-S [C]G [C]D [C]P [C]- [C]b [C]e [C]t [C]a [C]- [C]S O 
, [C], O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
translocation [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
nitric [C]n [C]i [C]t [C]r [C]i [C]c O 
oxide [C]o [C]x [C]i [C]d [C]e O 
or [C]o [C]r O 
LPS [C]L [C]P [C]S O 
in [C]i [C]n O 
permeabilized [C]p [C]e [C]r [C]m [C]e [C]a [C]b [C]i [C]l [C]i [C]z [C]e [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
nitric [C]n [C]i [C]t [C]r [C]i [C]c O 
oxide [C]o [C]x [C]i [C]d [C]e O 
greatly [C]g [C]r [C]e [C]a [C]t [C]l [C]y O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
the [C]t [C]h [C]e O 
pertussis [C]p [C]e [C]r [C]t [C]u [C]s [C]s [C]i [C]s O 
toxin-mediated [C]t [C]o [C]x [C]i [C]n [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
ADP-ribosylation [C]A [C]D [C]P [C]- [C]r [C]i [C]b [C]o [C]s [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
45- [C]4 [C]5 [C]- B-protein 
and [C]a [C]n [C]d I-protein 
41-kDa [C]4 [C]1 [C]- [C]k [C]D [C]a I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
in [C]i [C]n O 
membranes [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e [C]s O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
. [C]. O 

Because [C]B [C]e [C]c [C]a [C]u [C]s [C]e O 
G [C]G B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
play [C]p [C]l [C]a [C]y O 
a [C]a O 
central [C]c [C]e [C]n [C]t [C]r [C]a [C]l O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
many [C]m [C]a [C]n [C]y O 
diverse [C]d [C]i [C]v [C]e [C]r [C]s [C]e O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
systems [C]s [C]y [C]s [C]t [C]e [C]m [C]s O 
, [C], O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
an [C]a [C]n O 
endogenous [C]e [C]n [C]d [C]o [C]g [C]e [C]n [C]o [C]u [C]s O 
and [C]a [C]n [C]d O 
inducible [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
oxidant [C]o [C]x [C]i [C]d [C]a [C]n [C]t O 
may [C]m [C]a [C]y O 
represent [C]r [C]e [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
a [C]a O 
novel [C]n [C]o [C]v [C]e [C]l O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
granulocyte-macrophage [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e [C]- [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e B-DNA 
colony-stimulating [C]c [C]o [C]l [C]o [C]n [C]y [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]n [C]g I-DNA 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r I-DNA 
cis-acting [C]c [C]i [C]s [C]- [C]a [C]c [C]t [C]i [C]n [C]g I-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
CLE0 [C]C [C]L [C]E [C]0 S-DNA 
mediates [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]s O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
recognized [C]r [C]e [C]c [C]o [C]g [C]n [C]i [C]z [C]e [C]d O 
by [C]b [C]y O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
related [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
to [C]t [C]o O 
AP1 [C]A [C]P [C]1 S-protein 
and [C]a [C]n [C]d O 
NFAT [C]N [C]F [C]A [C]T S-protein 
. [C]. O 

Expression [C]E [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
granulocyte-macrophage [C]g [C]r [C]a [C]n [C]u [C]l [C]o [C]c [C]y [C]t [C]e [C]- [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e B-DNA 
colony-stimulating [C]c [C]o [C]l [C]o [C]n [C]y [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]n [C]g I-DNA 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-DNA 
( [C]( I-DNA 
GM-CSF [C]G [C]M [C]- [C]C [C]S [C]F I-DNA 
) [C]) I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
in [C]i [C]n O 
T [C]T O 
cells [C]c [C]e [C]l [C]l [C]s O 
is [C]i [C]s O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
combination [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
phorbol [C]p [C]h [C]o [C]r [C]b [C]o [C]l O 
ester [C]e [C]s [C]t [C]e [C]r O 
( [C]( O 
phorbol [C]p [C]h [C]o [C]r [C]b [C]o [C]l O 
myristate [C]m [C]y [C]r [C]i [C]s [C]t [C]a [C]t [C]e O 
acetate [C]a [C]c [C]e [C]t [C]a [C]t [C]e O 
) [C]) O 
and [C]a [C]n [C]d O 
calcium [C]c [C]a [C]l [C]c [C]i [C]u [C]m O 
ionophore [C]i [C]o [C]n [C]o [C]p [C]h [C]o [C]r [C]e O 
( [C]( O 
A23187 [C]A [C]2 [C]3 [C]1 [C]8 [C]7 O 
) [C]) O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
mimic [C]m [C]i [C]m [C]i [C]c O 
antigen [C]a [C]n [C]t [C]i [C]g [C]e [C]n O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
shown [C]s [C]h [C]o [C]w [C]n O 
that [C]t [C]h [C]a [C]t O 
a [C]a O 
fragment [C]f [C]r [C]a [C]g [C]m [C]e [C]n [C]t O 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
bp [C]b [C]p B-DNA 
-95 [C]- [C]9 [C]5 I-DNA 
to [C]t [C]o I-DNA 
+27 [C]+ [C]2 [C]7 E-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
mouse [C]m [C]o [C]u [C]s [C]e B-DNA 
GM-CSF [C]G [C]M [C]- [C]C [C]S [C]F I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
can [C]c [C]a [C]n O 
confer [C]c [C]o [C]n [C]f [C]e [C]r O 
inducibility [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]i [C]l [C]i [C]t [C]y O 
to [C]t [C]o O 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t I-cell_line 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
we [C]w [C]e O 
use [C]u [C]s [C]e O 
an [C]a [C]n O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
to [C]t [C]o O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
a [C]a O 
cis-acting [C]c [C]i [C]s [C]- [C]a [C]c [C]t [C]i [C]n [C]g B-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
( [C]( O 
positions [C]p [C]o [C]s [C]i [C]t [C]i [C]o [C]n [C]s B-DNA 
-54 [C]- [C]5 [C]4 I-DNA 
to [C]t [C]o I-DNA 
-40 [C]- [C]4 [C]0 E-DNA 
) [C]) O 
, [C], O 
referred [C]r [C]e [C]f [C]e [C]r [C]r [C]e [C]d O 
to [C]t [C]o O 
as [C]a [C]s O 
CLE0 [C]C [C]L [C]E [C]0 S-DNA 
, [C], O 
is [C]i [C]s O 
a [C]a O 
target [C]t [C]a [C]r [C]g [C]e [C]t O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
. [C]. O 

We [C]W [C]e O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
templates [C]t [C]e [C]m [C]p [C]l [C]a [C]t [C]e [C]s O 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
intact [C]i [C]n [C]t [C]a [C]c [C]t O 
CLE0 [C]C [C]L [C]E [C]0 S-DNA 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
with [C]w [C]i [C]t [C]h O 
templates [C]t [C]e [C]m [C]p [C]l [C]a [C]t [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
deleted [C]d [C]e [C]l [C]e [C]t [C]e [C]d B-DNA 
or [C]o [C]r I-DNA 
mutated [C]m [C]u [C]t [C]a [C]t [C]e [C]d I-DNA 
CLE0 [C]C [C]L [C]E [C]0 E-DNA 
. [C]. O 

We [C]W [C]e O 
also [C]a [C]l [C]s [C]o O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
two [C]t [C]w [C]o O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
were [C]w [C]e [C]r [C]e O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
CLE0 [C]C [C]L [C]E [C]0 S-DNA 
, [C], O 
since [C]s [C]i [C]n [C]c [C]e O 
only [C]o [C]n [C]l [C]y O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
from [C]f [C]r [C]o [C]m O 
cells [C]c [C]e [C]l [C]l [C]s O 
treated [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
both [C]b [C]o [C]t [C]h O 
phorbol [C]p [C]h [C]o [C]r [C]b [C]o [C]l O 
myristate [C]m [C]y [C]r [C]i [C]s [C]t [C]a [C]t [C]e O 
acetate [C]a [C]c [C]e [C]t [C]a [C]t [C]e O 
and [C]a [C]n [C]d O 
A23187 [C]A [C]2 [C]3 [C]1 [C]8 [C]7 O 
supported [C]s [C]u [C]p [C]p [C]o [C]r [C]t [C]e [C]d O 
optimal [C]o [C]p [C]t [C]i [C]m [C]a [C]l O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

Stimulation [C]S [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
probably [C]p [C]r [C]o [C]b [C]a [C]b [C]l [C]y O 
was [C]w [C]a [C]s O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
CLE0-binding [C]C [C]L [C]E [C]0 [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
because [C]b [C]e [C]c [C]a [C]u [C]s [C]e O 
depletion [C]d [C]e [C]p [C]l [C]e [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s O 
specifically [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]a [C]l [C]l [C]y O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
GM-CSF [C]G [C]M [C]- [C]C [C]S [C]F S-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
. [C]. O 

One [C]O [C]n [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
possessed [C]p [C]o [C]s [C]s [C]e [C]s [C]s [C]e [C]d O 
biochemical [C]b [C]i [C]o [C]c [C]h [C]e [C]m [C]i [C]c [C]a [C]l O 
and [C]a [C]n [C]d O 
immunological [C]i [C]m [C]m [C]u [C]n [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
features [C]f [C]e [C]a [C]t [C]u [C]r [C]e [C]s O 
identical [C]i [C]d [C]e [C]n [C]t [C]i [C]c [C]a [C]l O 
to [C]t [C]o O 
those [C]t [C]h [C]o [C]s [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
AP1 [C]A [C]P [C]1 E-protein 
. [C]. O 

Another [C]A [C]n [C]o [C]t [C]h [C]e [C]r O 
factor [C]f [C]a [C]c [C]t [C]o [C]r O 
resembled [C]r [C]e [C]s [C]e [C]m [C]b [C]l [C]e [C]d O 
the [C]t [C]h [C]e O 
T-cell-specific [C]T [C]- [C]c [C]e [C]l [C]l [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
NFAT [C]N [C]F [C]A [C]T E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
characteristics [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]s [C]t [C]i [C]c [C]s O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
two [C]t [C]w [C]o O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
are [C]a [C]r [C]e O 
consistent [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
their [C]t [C]h [C]e [C]i [C]r O 
involvement [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]m [C]e [C]n [C]t O 
in [C]i [C]n O 
GM-CSF [C]G [C]M [C]- [C]C [C]S [C]F O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
CLE0-like [C]C [C]L [C]E [C]0 [C]- [C]l [C]i [C]k [C]e B-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
promoters [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]s S-DNA 
of [C]o [C]f O 
interleukin-3 [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]3 B-DNA 
( [C]( I-DNA 
IL-3 [C]I [C]L [C]- [C]3 I-DNA 
) [C]) I-DNA 
, [C], I-DNA 
IL-4 [C]I [C]L [C]- [C]4 I-DNA 
, [C], I-DNA 
IL-5 [C]I [C]L [C]- [C]5 I-DNA 
, [C], I-DNA 
GM-CSF [C]G [C]M [C]- [C]C [C]S [C]F I-DNA 
, [C], I-DNA 
and [C]a [C]n [C]d I-DNA 
NFAT [C]N [C]F [C]A [C]T I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
suggests [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]s O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
we [C]w [C]e O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
, [C], O 
or [C]o [C]r O 
related [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
that [C]t [C]h [C]a [C]t O 
recognize [C]r [C]e [C]c [C]o [C]g [C]n [C]i [C]z [C]e O 
these [C]t [C]h [C]e [C]s [C]e O 
sites [C]s [C]i [C]t [C]e [C]s O 
, [C], O 
may [C]m [C]a [C]y O 
account [C]a [C]c [C]c [C]o [C]u [C]n [C]t O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
coordinate [C]c [C]o [C]o [C]r [C]d [C]i [C]n [C]a [C]t [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
genes [C]g [C]e [C]n [C]e [C]s O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l S-cell_type 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Identification [C]I [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
characterization [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
an [C]a [C]n O 
Alu-containing [C]A [C]l [C]u [C]- [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g B-DNA 
, [C], I-DNA 
T-cell-specific [C]T [C]- [C]c [C]e [C]l [C]l [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-DNA 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r E-DNA 
located [C]l [C]o [C]c [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
last [C]l [C]a [C]s [C]t O 
intron [C]i [C]n [C]t [C]r [C]o [C]n S-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
CD8 [C]C [C]D [C]8 I-DNA 
alpha [C]a [C]l [C]p [C]h [C]a I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
. [C]. O 

Expression [C]E [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
CD8 [C]C [C]D [C]8 I-DNA 
alpha [C]a [C]l [C]p [C]h [C]a I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
is [C]i [C]s O 
restricted [C]r [C]e [C]s [C]t [C]r [C]i [C]c [C]t [C]e [C]d O 
to [C]t [C]o O 
cells [C]c [C]e [C]l [C]l [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d B-cell_type 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e E-cell_type 
and [C]a [C]n [C]d O 
developmentally [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t [C]a [C]l [C]l [C]y O 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
thymopoiesis [C]t [C]h [C]y [C]m [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
. [C]. O 

As [C]A [C]s O 
an [C]a [C]n O 
initial [C]i [C]n [C]i [C]t [C]i [C]a [C]l O 
step [C]s [C]t [C]e [C]p O 
towards [C]t [C]o [C]w [C]a [C]r [C]d [C]s O 
understanding [C]u [C]n [C]d [C]e [C]r [C]s [C]t [C]a [C]n [C]d [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
basis [C]b [C]a [C]s [C]i [C]s O 
for [C]f [C]o [C]r O 
tissue-specific [C]t [C]i [C]s [C]s [C]u [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
gene [C]g [C]e [C]n [C]e O 
, [C], O 
we [C]w [C]e O 
surveyed [C]s [C]u [C]r [C]v [C]e [C]y [C]e [C]d O 
the [C]t [C]h [C]e O 
surrounding [C]s [C]u [C]r [C]r [C]o [C]u [C]n [C]d [C]i [C]n [C]g O 
chromatin [C]c [C]h [C]r [C]o [C]m [C]a [C]t [C]i [C]n O 
structure [C]s [C]t [C]r [C]u [C]c [C]t [C]u [C]r [C]e O 
for [C]f [C]o [C]r O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
cis-acting [C]c [C]i [C]s [C]- [C]a [C]c [C]t [C]i [C]n [C]g B-DNA 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y I-DNA 
regions [C]r [C]e [C]g [C]i [C]o [C]n [C]s E-DNA 
by [C]b [C]y O 
DNase [C]D [C]N [C]a [C]s [C]e B-protein 
I [C]I E-protein 
hypersensitivity [C]h [C]y [C]p [C]e [C]r [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
mapping [C]m [C]a [C]p [C]p [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
found [C]f [C]o [C]u [C]n [C]d O 
four [C]f [C]o [C]u [C]r O 
hypersensitive [C]h [C]y [C]p [C]e [C]r [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
sites [C]s [C]i [C]t [C]e [C]s O 
, [C], O 
three [C]t [C]h [C]r [C]e [C]e O 
of [C]o [C]f O 
which [C]w [C]h [C]i [C]c [C]h O 
were [C]w [C]e [C]r [C]e O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
restricted [C]r [C]e [C]s [C]t [C]r [C]i [C]c [C]t [C]e [C]d O 
. [C]. O 

By [C]B [C]y O 
using [C]u [C]s [C]i [C]n [C]g O 
a [C]a O 
reporter-based [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r [C]- [C]b [C]a [C]s [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
approach [C]a [C]p [C]p [C]r [C]o [C]a [C]c [C]h O 
, [C], O 
a [C]a O 
T-cell-specific [C]T [C]- [C]c [C]e [C]l [C]l [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-DNA 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r E-DNA 
was [C]w [C]a [C]s O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
by [C]b [C]y O 
its [C]i [C]t [C]s O 
close [C]c [C]l [C]o [C]s [C]e O 
association [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
prominent [C]p [C]r [C]o [C]m [C]i [C]n [C]e [C]n [C]t O 
T-cell-restricted [C]T [C]- [C]c [C]e [C]l [C]l [C]- [C]r [C]e [C]s [C]t [C]r [C]i [C]c [C]t [C]e [C]d B-DNA 
hypersensitive [C]h [C]y [C]p [C]e [C]r [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
last [C]l [C]a [C]s [C]t O 
intron [C]i [C]n [C]t [C]r [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
CD8 [C]C [C]D [C]8 B-DNA 
alpha [C]a [C]l [C]p [C]h [C]a I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
. [C]. O 

Deletion [C]D [C]e [C]l [C]e [C]t [C]i [C]o [C]n O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
minimal [C]m [C]i [C]n [C]i [C]m [C]a [C]l O 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r O 
is [C]i [C]s O 
adjacent [C]a [C]d [C]j [C]a [C]c [C]e [C]n [C]t O 
to [C]t [C]o O 
a [C]a O 
negative [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e O 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t O 
. [C]. O 

DNA [C]D [C]N [C]A O 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
minimal [C]m [C]i [C]n [C]i [C]m [C]a [C]l B-DNA 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r E-DNA 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
a [C]a O 
striking [C]s [C]t [C]r [C]i [C]k [C]i [C]n [C]g O 
cluster [C]c [C]l [C]u [C]s [C]t [C]e [C]r O 
of [C]o [C]f O 
consensus [C]c [C]o [C]n [C]s [C]e [C]n [C]s [C]u [C]s B-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
for [C]f [C]o [C]r O 
Ets-1 [C]E [C]t [C]s [C]- [C]1 B-protein 
, [C], I-protein 
TCF-1 [C]T [C]C [C]F [C]- [C]1 I-protein 
, [C], I-protein 
CRE [C]C [C]R [C]E I-protein 
, [C], I-protein 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 I-protein 
, [C], I-protein 
LyF-1 [C]L [C]y [C]F [C]- [C]1 I-protein 
, [C], I-protein 
and [C]a [C]n [C]d I-protein 
bHLH [C]b [C]H [C]L [C]H I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
which [C]w [C]h [C]i [C]c [C]h O 
were [C]w [C]e [C]r [C]e O 
verified [C]v [C]e [C]r [C]i [C]f [C]i [C]e [C]d O 
by [C]b [C]y O 
electrophoretic [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
the [C]t [C]h [C]e O 
5 [C]5 B-DNA 
' [C]' I-DNA 
end [C]e [C]n [C]d E-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r S-DNA 
was [C]w [C]a [C]s O 
composed [C]c [C]o [C]m [C]p [C]o [C]s [C]e [C]d O 
of [C]o [C]f O 
an [C]a [C]n O 
Alu [C]A [C]l [C]u O 
repeat [C]r [C]e [C]p [C]e [C]a [C]t O 
which [C]w [C]h [C]i [C]c [C]h O 
contained [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]e [C]d O 
the [C]t [C]h [C]e O 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 B-DNA 
, [C], I-DNA 
bHLH [C]b [C]H [C]L [C]H I-DNA 
, [C], I-DNA 
and [C]a [C]n [C]d I-DNA 
LyF-1 [C]L [C]y [C]F [C]- [C]1 I-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
. [C]. O 

Site-directed [C]S [C]i [C]t [C]e [C]- [C]d [C]i [C]r [C]e [C]c [C]t [C]e [C]d O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Ets-1 [C]E [C]t [C]s [C]- [C]1 B-DNA 
and [C]a [C]n [C]d I-DNA 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
dramatically [C]d [C]r [C]a [C]m [C]a [C]t [C]i [C]c [C]a [C]l [C]l [C]y O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
importance [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]c [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
other [C]o [C]t [C]h [C]e [C]r O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
sites [C]s [C]i [C]t [C]e [C]s O 
only [C]o [C]n [C]l [C]y O 
became [C]b [C]e [C]c [C]a [C]m [C]e O 
apparent [C]a [C]p [C]p [C]a [C]r [C]e [C]n [C]t O 
when [C]w [C]h [C]e [C]n O 
combinations [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
were [C]w [C]e [C]r [C]e O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
. [C]. O 

Taken [C]T [C]a [C]k [C]e [C]n O 
together [C]t [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
, [C], O 
these [C]t [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
CD8 [C]C [C]D [C]8 I-DNA 
alpha [C]a [C]l [C]p [C]h [C]a I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
is [C]i [C]s O 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
multiple [C]m [C]u [C]l [C]t [C]i [C]p [C]l [C]e O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l B-protein 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r O 
located [C]l [C]o [C]c [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
last [C]l [C]a [C]s [C]t O 
intron [C]i [C]n [C]t [C]r [C]o [C]n S-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
gene [C]g [C]e [C]n [C]e O 
. [C]. O 

Comparison [C]C [C]o [C]m [C]p [C]a [C]r [C]i [C]s [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
CD8 [C]C [C]D [C]8 B-DNA 
alpha [C]a [C]l [C]p [C]h [C]a I-DNA 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r E-DNA 
with [C]w [C]i [C]t [C]h O 
other [C]o [C]t [C]h [C]e [C]r O 
recently [C]r [C]e [C]c [C]e [C]n [C]t [C]l [C]y O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
T-cell-specific [C]T [C]- [C]c [C]e [C]l [C]l [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-DNA 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y I-DNA 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s E-DNA 
suggests [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]s O 
that [C]t [C]h [C]a [C]t O 
a [C]a O 
common [C]c [C]o [C]m [C]m [C]o [C]n O 
set [C]s [C]e [C]t O 
of [C]o [C]f O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
regulates [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]s O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
. [C]. O 

Molecular [C]M [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
IL-3 [C]I [C]L [C]- [C]3 I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
: [C]: O 
inducible [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
T [C]T O 
cell-restricted [C]c [C]e [C]l [C]l [C]- [C]r [C]e [C]s [C]t [C]r [C]i [C]c [C]t [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
requires [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]s O 
intact [C]i [C]n [C]t [C]a [C]c [C]t O 
AP-1 [C]A [C]P [C]- [C]1 B-DNA 
and [C]a [C]n [C]d I-DNA 
Elf-1 [C]E [C]l [C]f [C]- [C]1 I-DNA 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-DNA 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
. [C]. O 

Interleukin [C]I [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n B-protein 
3 [C]3 E-protein 
( [C]( O 
IL-3 [C]I [C]L [C]- [C]3 S-protein 
) [C]) O 
is [C]i [C]s O 
a [C]a O 
hematopoietic [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]t [C]i [C]c B-protein 
stem-cell [C]s [C]t [C]e [C]m [C]- [C]c [C]e [C]l [C]l I-protein 
growth [C]g [C]r [C]o [C]w [C]t [C]h I-protein 
and [C]a [C]n [C]d I-protein 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
solely [C]s [C]o [C]l [C]e [C]l [C]y O 
in [C]i [C]n O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
T [C]T B-cell_type 
and [C]a [C]n [C]d I-cell_type 
NK [C]N [C]K I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Studies [C]S [C]t [C]u [C]d [C]i [C]e [C]s O 
to [C]t [C]o O 
date [C]d [C]a [C]t [C]e O 
have [C]h [C]a [C]v [C]e O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
elements [C]e [C]l [C]e [C]m [C]e [C]n [C]t [C]s O 
5 [C]5 O 
' [C]' O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
IL-3 [C]I [C]L [C]- [C]3 B-DNA 
coding [C]c [C]o [C]d [C]i [C]n [C]g I-DNA 
sequences [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s E-DNA 
that [C]t [C]h [C]a [C]t O 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
its [C]i [C]t [C]s O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
, [C], O 
but [C]b [C]u [C]t O 
the [C]t [C]h [C]e O 
sequences [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s O 
that [C]t [C]h [C]a [C]t O 
confer [C]c [C]o [C]n [C]f [C]e [C]r O 
T [C]T O 
cell-specific [C]c [C]e [C]l [C]l [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
remain [C]r [C]e [C]m [C]a [C]i [C]n O 
to [C]t [C]o O 
be [C]b [C]e O 
clearly [C]c [C]l [C]e [C]a [C]r [C]l [C]y O 
defined [C]d [C]e [C]f [C]i [C]n [C]e [C]d O 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
now [C]n [C]o [C]w O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
DNA [C]D [C]N [C]A B-DNA 
sequences [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s E-DNA 
that [C]t [C]h [C]a [C]t O 
are [C]a [C]r [C]e O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
T [C]T O 
cell-restricted [C]c [C]e [C]l [C]l [C]- [C]r [C]e [C]s [C]t [C]r [C]i [C]c [C]t [C]e [C]d O 
IL-3 [C]I [C]L [C]- [C]3 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
. [C]. O 

A [C]A O 
series [C]s [C]e [C]r [C]i [C]e [C]s O 
of [C]o [C]f O 
transient [C]t [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t O 
transfections [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]i [C]o [C]n [C]s O 
performed [C]p [C]e [C]r [C]f [C]o [C]r [C]m [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
IL-3-chloramphenicol [C]I [C]L [C]- [C]3 [C]- [C]c [C]h [C]l [C]o [C]r [C]a [C]m [C]p [C]h [C]e [C]n [C]i [C]c [C]o [C]l I-DNA 
acetyltransferase [C]a [C]c [C]e [C]t [C]y [C]l [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]r [C]a [C]s [C]e I-DNA 
( [C]( I-DNA 
CAT [C]C [C]A [C]T I-DNA 
) [C]) I-DNA 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r I-DNA 
plasmids [C]p [C]l [C]a [C]s [C]m [C]i [C]d [C]s E-DNA 
in [C]i [C]n O 
T [C]T B-cell_type 
and [C]a [C]n [C]d I-cell_type 
non-T [C]n [C]o [C]n [C]- [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
a [C]a O 
plasmid [C]p [C]l [C]a [C]s [C]m [C]i [C]d S-DNA 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
319 [C]3 [C]1 [C]9 O 
bp [C]b [C]p O 
of [C]o [C]f O 
5 [C]5 B-DNA 
' [C]' I-DNA 
flanking [C]f [C]l [C]a [C]n [C]k [C]i [C]n [C]g I-DNA 
sequences [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s E-DNA 
was [C]w [C]a [C]s O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
exclusively [C]e [C]x [C]c [C]l [C]u [C]s [C]i [C]v [C]e [C]l [C]y O 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Deletion [C]D [C]e [C]l [C]e [C]t [C]i [C]o [C]n O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
specificity [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]i [C]t [C]y O 
was [C]w [C]a [C]s O 
conferred [C]c [C]o [C]n [C]f [C]e [C]r [C]r [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
49-bp [C]4 [C]9 [C]- [C]b [C]p B-DNA 
fragment [C]f [C]r [C]a [C]g [C]m [C]e [C]n [C]t E-DNA 
( [C]( O 
bp [C]b [C]p B-DNA 
-319 [C]- [C]3 [C]1 [C]9 I-DNA 
to [C]t [C]o I-DNA 
-270 [C]- [C]2 [C]7 [C]0 E-DNA 
) [C]) O 
that [C]t [C]h [C]a [C]t O 
included [C]i [C]n [C]c [C]l [C]u [C]d [C]e [C]d O 
a [C]a O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l B-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
for [C]f [C]o [C]r O 
AP-1 [C]A [C]P [C]- [C]1 B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
6 [C]6 O 
bp [C]b [C]p O 
upstream [C]u [C]p [C]s [C]t [C]r [C]e [C]a [C]m O 
of [C]o [C]f O 
a [C]a O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-DNA 
site [C]s [C]i [C]t [C]e I-DNA 
for [C]f [C]o [C]r I-DNA 
Elf-1 [C]E [C]l [C]f [C]- [C]1 E-DNA 
, [C], O 
a [C]a O 
member [C]m [C]e [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Ets [C]E [C]t [C]s B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y E-protein 
of [C]o [C]f O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

DNaseI [C]D [C]N [C]a [C]s [C]e [C]I S-protein 
footprint [C]f [C]o [C]o [C]t [C]p [C]r [C]i [C]n [C]t O 
and [C]a [C]n [C]d O 
electrophoretic [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
assay [C]a [C]s [C]s [C]a [C]y O 
analyses [C]a [C]n [C]a [C]l [C]y [C]s [C]e [C]s O 
performed [C]p [C]e [C]r [C]f [C]o [C]r [C]m [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
MLA-144 [C]M [C]L [C]A [C]- [C]1 [C]4 [C]4 B-cell_line 
T [C]T I-cell_line 
cell [C]c [C]e [C]l [C]l E-cell_line 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
this [C]t [C]h [C]i [C]s O 
49-bp [C]4 [C]9 [C]- [C]b [C]p B-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
contains [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]s O 
a [C]a O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-DNA 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
that [C]t [C]h [C]a [C]t O 
includes [C]i [C]n [C]c [C]l [C]u [C]d [C]e [C]s O 
consensus [C]c [C]o [C]n [C]s [C]e [C]n [C]s [C]u [C]s B-DNA 
AP-1 [C]A [C]P [C]- [C]1 I-DNA 
and [C]a [C]n [C]d I-DNA 
Elf-1 [C]E [C]l [C]f [C]- [C]1 I-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
prepared [C]p [C]r [C]e [C]p [C]a [C]r [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
contained [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]e [C]d O 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s O 
that [C]t [C]h [C]a [C]t O 
bound [C]b [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
synthetic [C]s [C]y [C]n [C]t [C]h [C]e [C]t [C]i [C]c O 
oligonucleotides [C]o [C]l [C]i [C]g [C]o [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e [C]s O 
corresponding [C]c [C]o [C]r [C]r [C]e [C]s [C]p [C]o [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
AP-1 [C]A [C]P [C]- [C]1 B-DNA 
and [C]a [C]n [C]d I-DNA 
Elf-1 [C]E [C]l [C]f [C]- [C]1 I-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
. [C]. O 

In [C]I [C]n O 
vitro-transcribed [C]v [C]i [C]t [C]r [C]o [C]- [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
and [C]a [C]n [C]d O 
-translated [C]- [C]t [C]r [C]a [C]n [C]s [C]l [C]a [C]t [C]e [C]d O 
Elf-1 [C]E [C]l [C]f [C]- [C]1 B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
bound [C]b [C]o [C]u [C]n [C]d O 
specifically [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]a [C]l [C]l [C]y O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
Elf-1 [C]E [C]l [C]f [C]- [C]1 B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
, [C], O 
and [C]a [C]n [C]d O 
Elf-1 [C]E [C]l [C]f [C]- [C]1 O 
antisera [C]a [C]n [C]t [C]i [C]s [C]e [C]r [C]a O 
competed [C]c [C]o [C]m [C]p [C]e [C]t [C]e [C]d O 
and [C]a [C]n [C]d O 
super [C]s [C]u [C]p [C]e [C]r O 
shifted [C]s [C]h [C]i [C]f [C]t [C]e [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
in [C]i [C]n O 
MLA-144 [C]M [C]L [C]A [C]- [C]1 [C]4 [C]4 S-cell_line 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
. [C]. O 

Moreover [C]M [C]o [C]r [C]e [C]o [C]v [C]e [C]r O 
, [C], O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
anti-Jun [C]a [C]n [C]t [C]i [C]- [C]J [C]u [C]n O 
family [C]f [C]a [C]m [C]i [C]l [C]y O 
antiserum [C]a [C]n [C]t [C]i [C]s [C]e [C]r [C]u [C]m O 
in [C]i [C]n O 
electrophoretic [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
assay [C]a [C]s [C]s [C]a [C]y O 
reactions [C]r [C]e [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
completely [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e [C]l [C]y O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
AP-1-related [C]A [C]P [C]- [C]1 [C]- [C]r [C]e [C]l [C]a [C]t [C]e [C]d B-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
. [C]. O 

Transient [C]T [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t O 
transfection [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
in [C]i [C]n O 
MLA-144 [C]M [C]L [C]A [C]- [C]1 [C]4 [C]4 B-cell_line 
T [C]T I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
constructs [C]c [C]o [C]n [C]s [C]t [C]r [C]u [C]c [C]t [C]s O 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
AP-1 [C]A [C]P [C]- [C]1 B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
almost [C]a [C]l [C]m [C]o [C]s [C]t O 
completely [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e [C]l [C]y O 
abolished [C]a [C]b [C]o [C]l [C]i [C]s [C]h [C]e [C]d O 
CAT [C]C [C]A [C]T O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
while [C]w [C]h [C]i [C]l [C]e O 
mutation [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Elf-1 [C]E [C]l [C]f [C]- [C]1 B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
or [C]o [C]r O 
the [C]t [C]h [C]e O 
NF-IL-3 [C]N [C]F [C]- [C]I [C]L [C]- [C]3 B-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
, [C], O 
a [C]a O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
described [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-DNA 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
( [C]( O 
bp. [C]b [C]p [C]. B-DNA 
-155 [C]- [C]1 [C]5 [C]5 I-DNA 
to [C]t [C]o I-DNA 
-148 [C]- [C]1 [C]4 [C]8 E-DNA 
) [C]) O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
IL-3 [C]I [C]L [C]- [C]3 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
, [C], O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
CAT [C]C [C]A [C]T O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
to [C]t [C]o O 
< [C]< O 
25 [C]2 [C]5 O 
% [C]% O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
given [C]g [C]i [C]v [C]e [C]n O 
by [C]b [C]y O 
wild-type [C]w [C]i [C]l [C]d [C]- [C]t [C]y [C]p [C]e O 
constructs [C]c [C]o [C]n [C]s [C]t [C]r [C]u [C]c [C]t [C]s O 
. [C]. O 

We [C]W [C]e O 
conclude [C]c [C]o [C]n [C]c [C]l [C]u [C]d [C]e O 
that [C]t [C]h [C]a [C]t O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
IL-3 [C]I [C]L [C]- [C]3 I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
requires [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]s O 
the [C]t [C]h [C]e O 
AP-1 [C]A [C]P [C]- [C]1 B-DNA 
and [C]a [C]n [C]d I-DNA 
Elf-1 [C]E [C]l [C]f [C]- [C]1 I-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
; [C]; O 
however [C]h [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
unlike [C]u [C]n [C]l [C]i [C]k [C]e O 
other [C]o [C]t [C]h [C]e [C]r O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
characterized [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]d O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
, [C], O 
the [C]t [C]h [C]e O 
AP-1 [C]A [C]P [C]- [C]1 B-protein 
and [C]a [C]n [C]d I-protein 
Elf-1 [C]E [C]l [C]f [C]- [C]1 I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
can [C]c [C]a [C]n O 
bind [C]b [C]i [C]n [C]d O 
independently [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t [C]l [C]y O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
IL-3 [C]I [C]L [C]- [C]3 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
. [C]. O 

( [C]( O 
ABSTRACT [C]A [C]B [C]S [C]T [C]R [C]A [C]C [C]T O 
TRUNCATED [C]T [C]R [C]U [C]N [C]C [C]A [C]T [C]E [C]D O 
AT [C]A [C]T O 
400 [C]4 [C]0 [C]0 O 
WORDS [C]W [C]O [C]R [C]D [C]S O 
) [C]) O 

Combination [C]C [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
and [C]a [C]n [C]d O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
reduces [C]r [C]e [C]d [C]u [C]c [C]e [C]s O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
receptor-binding [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
contributing [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]i [C]n [C]g O 
to [C]t [C]o O 
persistent [C]p [C]e [C]r [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
poor [C]p [C]o [C]o [C]r O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
in [C]i [C]n O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
inflammatory [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]o [C]r [C]y O 
illnesses [C]i [C]l [C]l [C]n [C]e [C]s [C]s [C]e [C]s O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
resistant [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]t O 
( [C]( O 
SR [C]S [C]R O 
) [C]) O 
asthma [C]a [C]s [C]t [C]h [C]m [C]a O 
are [C]a [C]r [C]e O 
poorly [C]p [C]o [C]o [C]r [C]l [C]y O 
defined [C]d [C]e [C]f [C]i [C]n [C]e [C]d O 
. [C]. O 

We [C]W [C]e O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
the [C]t [C]h [C]e O 
possibility [C]p [C]o [C]s [C]s [C]i [C]b [C]i [C]l [C]i [C]t [C]y O 
that [C]t [C]h [C]a [C]t O 
certain [C]c [C]e [C]r [C]t [C]a [C]i [C]n O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s O 
, [C], O 
specifically [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]a [C]l [C]l [C]y O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
and [C]a [C]n [C]d O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
, [C], O 
could [C]c [C]o [C]u [C]l [C]d O 
affect [C]a [C]f [C]f [C]e [C]c [C]t O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
. [C]. O 

A [C]A O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
radioligand-binding [C]r [C]a [C]d [C]i [C]o [C]l [C]i [C]g [C]a [C]n [C]d [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
assay [C]a [C]s [C]s [C]a [C]y O 
was [C]w [C]a [C]s O 
used [C]u [C]s [C]e [C]d O 
to [C]t [C]o O 
measure [C]m [C]e [C]a [C]s [C]u [C]r [C]e O 
the [C]t [C]h [C]e O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
( [C]( O 
GR [C]G [C]R S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
dissociation [C]d [C]i [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
constant [C]c [C]o [C]n [C]s [C]t [C]a [C]n [C]t O 
( [C]( O 
Kd [C]K [C]d O 
) [C]) O 
in [C]i [C]n O 
PBMC [C]P [C]B [C]M [C]C S-cell_type 
from [C]f [C]r [C]o [C]m O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
donors [C]d [C]o [C]n [C]o [C]r [C]s O 
and [C]a [C]n [C]d O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
SR [C]S [C]R O 
asthma [C]a [C]s [C]t [C]h [C]m [C]a O 
, [C], O 
cultured [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
and [C]a [C]n [C]d O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
. [C]. O 

PBMC [C]P [C]B [C]M [C]C O 
from [C]f [C]r [C]o [C]m O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
donors [C]d [C]o [C]n [C]o [C]r [C]s O 
incubated [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]e [C]d O 
for [C]f [C]o [C]r O 
48 [C]4 [C]8 O 
h [C]h O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
combination [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
+ [C]+ O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
had [C]h [C]a [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
GR [C]G [C]R O 
with [C]w [C]i [C]t [C]h O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
( [C]( O 
GR [C]G [C]R O 
Kd [C]K [C]d O 
= [C]= O 
36.1 [C]3 [C]6 [C]. [C]1 O 
+/- [C]+ [C]/ [C]- O 
1.63 [C]1 [C]. [C]6 [C]3 O 
nM [C]n [C]M O 
, [C], O 
mean [C]m [C]e [C]a [C]n O 
+/- [C]+ [C]/ [C]- O 
SEM [C]S [C]E [C]M O 
; [C]; O 
p [C]p O 
= [C]= O 
0.0001 [C]0 [C]. [C]0 [C]0 [C]0 [C]1 O 
) [C]) O 
as [C]a [C]s O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
PBMC [C]P [C]B [C]M [C]C S-cell_type 
incubated [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
medium [C]m [C]e [C]d [C]i [C]u [C]m O 
alone [C]a [C]l [C]o [C]n [C]e O 
( [C]( O 
GR [C]G [C]R O 
Kd [C]K [C]d O 
= [C]= O 
6.74 [C]6 [C]. [C]7 [C]4 O 
+/- [C]+ [C]/ [C]- O 
0.46 [C]0 [C]. [C]4 [C]6 O 
nM [C]n [C]M O 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
cytosolic [C]c [C]y [C]t [C]o [C]s [C]o [C]l [C]i [C]c O 
GR [C]G [C]R O 
Kd [C]K [C]d O 
remained [C]r [C]e [C]m [C]a [C]i [C]n [C]e [C]d O 
unchanged [C]u [C]n [C]c [C]h [C]a [C]n [C]g [C]e [C]d O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
when [C]w [C]h [C]e [C]n O 
PBMC [C]P [C]B [C]M [C]C S-cell_type 
were [C]w [C]e [C]r [C]e O 
incubated [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
alone [C]a [C]l [C]o [C]n [C]e O 
or [C]o [C]r O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
alone [C]a [C]l [C]o [C]n [C]e O 
, [C], O 
no [C]n [C]o O 
change [C]c [C]h [C]a [C]n [C]g [C]e O 
in [C]i [C]n O 
GR-binding [C]G [C]R [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
when [C]w [C]h [C]e [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
non-T [C]n [C]o [C]n [C]- [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
individually [C]i [C]n [C]d [C]i [C]v [C]i [C]d [C]u [C]a [C]l [C]l [C]y O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
combination [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
IL-2 [C]I [C]L [C]- [C]2 O 
+ [C]+ O 
IL-4 [C]I [C]L [C]- [C]4 O 
, [C], O 
a [C]a O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
reduction [C]r [C]e [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
GR-binding [C]G [C]R [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
only [C]o [C]n [C]l [C]y O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l I-cell_type 
population [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n E-cell_type 
( [C]( O 
p [C]p O 
= [C]= O 
0.0001 [C]0 [C]. [C]0 [C]0 [C]0 [C]1 O 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
IL-2 [C]I [C]L [C]- [C]2 O 
+ [C]+ O 
IL-4-induced [C]I [C]L [C]- [C]4 [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
alteration [C]a [C]l [C]t [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
PBMC [C]P [C]B [C]M [C]C O 
GR [C]G [C]R O 
Kd [C]K [C]d O 
was [C]w [C]a [C]s O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
an [C]a [C]n O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
GR [C]G [C]R O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
( [C]( O 
8348 [C]8 [C]3 [C]4 [C]8 O 
+/- [C]+ [C]/ [C]- O 
964 [C]9 [C]6 [C]4 O 
vs [C]v [C]s O 
1710 [C]1 [C]7 [C]1 [C]0 O 
+/- [C]+ [C]/ [C]- O 
228 [C]2 [C]2 [C]8 O 
sites/cell [C]s [C]i [C]t [C]e [C]s [C]/ [C]c [C]e [C]l [C]l O 
; [C]; O 
p [C]p O 
= [C]= O 
0.0003 [C]0 [C]. [C]0 [C]0 [C]0 [C]3 O 
) [C]) O 
. [C]. O 

More [C]M [C]o [C]r [C]e O 
importantly [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t [C]l [C]y O 
, [C], O 
the [C]t [C]h [C]e O 
alteration [C]a [C]l [C]t [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
PBMC [C]P [C]B [C]M [C]C O 
GR-binding [C]G [C]R [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
with [C]w [C]i [C]t [C]h O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
+ [C]+ O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
was [C]w [C]a [C]s O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
change [C]c [C]h [C]a [C]n [C]g [C]e O 
in [C]i [C]n O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
methylprednisolone [C]m [C]e [C]t [C]h [C]y [C]l [C]p [C]r [C]e [C]d [C]n [C]i [C]s [C]o [C]l [C]o [C]n [C]e O 
MPN [C]M [C]P [C]N O 
, [C], O 
i.e. [C]i [C]. [C]e [C]. O 
, [C], O 
a [C]a O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
MPN [C]M [C]P [C]N O 
on [C]o [C]n O 
PMA/ionomycin-induced [C]P [C]M [C]A [C]/ [C]i [C]o [C]n [C]o [C]m [C]y [C]c [C]i [C]n [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
+ [C]+ O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
on [C]o [C]n O 
PBMC [C]P [C]B [C]M [C]C S-cell_type 
GR [C]G [C]R S-protein 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
MPN [C]M [C]P [C]N O 
were [C]w [C]e [C]r [C]e O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
by [C]b [C]y O 
co-incubation [C]c [C]o [C]- [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
. [C]. O 

Freshly [C]F [C]r [C]e [C]s [C]h [C]l [C]y O 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d O 
PBMC [C]P [C]B [C]M [C]C S-cell_type 
from [C]f [C]r [C]o [C]m O 
four [C]f [C]o [C]u [C]r O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
SR [C]S [C]R O 
asthma [C]a [C]s [C]t [C]h [C]m [C]a O 
had [C]h [C]a [C]d O 
a [C]a O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
GR-binding [C]G [C]R [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
( [C]( O 
Kd [C]K [C]d O 
= [C]= O 
40.0 [C]4 [C]0 [C]. [C]0 O 
+/- [C]+ [C]/ [C]- O 
2.68 [C]2 [C]. [C]6 [C]8 O 
nM [C]n [C]M O 
; [C]; O 
p [C]p O 
= [C]= O 
0.0001 [C]0 [C]. [C]0 [C]0 [C]0 [C]1 O 
) [C]) O 
when [C]w [C]h [C]e [C]n O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
seven [C]s [C]e [C]v [C]e [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
( [C]( O 
7.15 [C]7 [C]. [C]1 [C]5 O 
+/- [C]+ [C]/ [C]- O 
0.41 [C]0 [C]. [C]4 [C]1 O 
nM [C]n [C]M O 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
altered [C]a [C]l [C]t [C]e [C]r [C]e [C]d O 
PBMC [C]P [C]B [C]M [C]C O 
GR [C]G [C]R O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
SR [C]S [C]R O 
asthma [C]a [C]s [C]t [C]h [C]m [C]a O 
reversed [C]r [C]e [C]v [C]e [C]r [C]s [C]e [C]d O 
to [C]t [C]o O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
when [C]w [C]h [C]e [C]n O 
incubated [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
medium [C]m [C]e [C]d [C]i [C]u [C]m O 
alone [C]a [C]l [C]o [C]n [C]e O 
, [C], O 
but [C]b [C]u [C]t O 
was [C]w [C]a [C]s O 
sustained [C]s [C]u [C]s [C]t [C]a [C]i [C]n [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
+ [C]+ O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
observations [C]o [C]b [C]s [C]e [C]r [C]v [C]a [C]t [C]i [C]o [C]n [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
with [C]w [C]i [C]t [C]h O 
persistent [C]p [C]e [C]r [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
inflammation [C]i [C]n [C]f [C]l [C]a [C]m [C]m [C]a [C]t [C]i [C]o [C]n O 
certain [C]c [C]e [C]r [C]t [C]a [C]i [C]n O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
may [C]m [C]a [C]y O 
contribute [C]c [C]o [C]n [C]t [C]r [C]i [C]b [C]u [C]t [C]e O 
to [C]t [C]o O 
an [C]a [C]n O 
impaired [C]i [C]m [C]p [C]a [C]i [C]r [C]e [C]d O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
the [C]t [C]h [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
and [C]a [C]n [C]d O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
were [C]w [C]e [C]r [C]e O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
by [C]b [C]y O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
. [C]. O 

Characterization [C]C [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
CD4 [C]C [C]D [C]4 I-DNA 
gene [C]g [C]e [C]n [C]e I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
: [C]: O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
CD4 [C]C [C]D [C]4 B-DNA 
gene [C]g [C]e [C]n [C]e I-DNA 
core [C]c [C]o [C]r [C]e I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
is [C]i [C]s O 
tissue-specific [C]t [C]i [C]s [C]s [C]u [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
Ets [C]E [C]t [C]s B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
. [C]. O 

We [C]W [C]e O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
the [C]t [C]h [C]e O 
5 [C]5 B-DNA 
' [C]' I-DNA 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-DNA 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l I-DNA 
sequences [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s E-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
CD4 [C]C [C]D [C]4 I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
. [C]. O 

We [C]W [C]e O 
located [C]l [C]o [C]c [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-DNA 
initiation [C]i [C]n [C]i [C]t [C]i [C]a [C]t [C]i [C]o [C]n I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
and [C]a [C]n [C]d O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
CD4 [C]C [C]D [C]4 B-DNA 
core [C]c [C]o [C]r [C]e I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
( [C]( O 
positions [C]p [C]o [C]s [C]i [C]t [C]i [C]o [C]n [C]s B-DNA 
-40 [C]- [C]4 [C]0 I-DNA 
to [C]t [C]o I-DNA 
+16 [C]+ [C]1 [C]6 E-DNA 
) [C]) O 
lacks [C]l [C]a [C]c [C]k [C]s O 
a [C]a O 
classical [C]c [C]l [C]a [C]s [C]s [C]i [C]c [C]a [C]l O 
`` [C]` [C]` O 
TATA [C]T [C]A [C]T [C]A O 
'' [C]' [C]' O 
or [C]o [C]r O 
initiator [C]i [C]n [C]i [C]t [C]i [C]a [C]t [C]o [C]r B-DNA 
positioning [C]p [C]o [C]s [C]i [C]t [C]i [C]o [C]n [C]i [C]n [C]g I-DNA 
consensus [C]c [C]o [C]n [C]s [C]e [C]n [C]s [C]u [C]s I-DNA 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e E-DNA 
but [C]b [C]u [C]t O 
directs [C]d [C]i [C]r [C]e [C]c [C]t [C]s O 
precise [C]p [C]r [C]e [C]c [C]i [C]s [C]e O 
and [C]a [C]n [C]d O 
efficient [C]e [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
when [C]w [C]h [C]e [C]n O 
coupled [C]c [C]o [C]u [C]p [C]l [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
ubiquitously [C]u [C]b [C]i [C]q [C]u [C]i [C]t [C]o [C]u [C]s [C]l [C]y O 
active [C]a [C]c [C]t [C]i [C]v [C]e O 
simian [C]s [C]i [C]m [C]i [C]a [C]n B-DNA 
virus [C]v [C]i [C]r [C]u [C]s I-DNA 
40 [C]4 [C]0 I-DNA 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r E-DNA 
. [C]. O 

The [C]T [C]h [C]e O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
CD4 [C]C [C]D [C]4 B-DNA 
gene [C]g [C]e [C]n [C]e I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
CD4 [C]C [C]D [C]4 O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
cell [C]c [C]e [C]l [C]l O 
types [C]t [C]y [C]p [C]e [C]s O 
. [C]. O 

Interestingly [C]I [C]n [C]t [C]e [C]r [C]e [C]s [C]t [C]i [C]n [C]g [C]l [C]y O 
, [C], O 
the [C]t [C]h [C]e O 
CD4 [C]C [C]D [C]4 B-DNA 
core [C]c [C]o [C]r [C]e I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
also [C]a [C]l [C]s [C]o O 
displayed [C]d [C]i [C]s [C]p [C]l [C]a [C]y [C]e [C]d O 
a [C]a O 
tissue-specific [C]t [C]i [C]s [C]s [C]u [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

Within [C]W [C]i [C]t [C]h [C]i [C]n O 
this [C]t [C]h [C]i [C]s O 
fragment [C]f [C]r [C]a [C]g [C]m [C]e [C]n [C]t O 
, [C], O 
three [C]t [C]h [C]r [C]e [C]e O 
nucleic [C]n [C]u [C]c [C]l [C]e [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
sequences [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s O 
are [C]a [C]r [C]e O 
completely [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e [C]l [C]y O 
conserved [C]c [C]o [C]n [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
murine [C]m [C]u [C]r [C]i [C]n [C]e B-DNA 
CD4 [C]C [C]D [C]4 I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
. [C]. O 

One [C]O [C]n [C]e O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
sequences [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s O 
contains [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]s O 
a [C]a O 
perfect [C]p [C]e [C]r [C]f [C]e [C]c [C]t B-DNA 
ETS [C]E [C]T [C]S I-DNA 
consensus [C]c [C]o [C]n [C]s [C]e [C]n [C]s [C]u [C]s I-DNA 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e E-DNA 
. [C]. O 

Another [C]A [C]n [C]o [C]t [C]h [C]e [C]r O 
ETS [C]E [C]T [C]S B-DNA 
consensus [C]c [C]o [C]n [C]s [C]e [C]n [C]s [C]u [C]s I-DNA 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e E-DNA 
is [C]i [C]s O 
located [C]l [C]o [C]c [C]a [C]t [C]e [C]d O 
1060 [C]1 [C]0 [C]6 [C]0 O 
nt [C]n [C]t O 
upstream [C]u [C]p [C]s [C]t [C]r [C]e [C]a [C]m O 
. [C]. O 

Electrophoretic-mobility-shift [C]E [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c [C]- [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y [C]- [C]s [C]h [C]i [C]f [C]t O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
core [C]c [C]o [C]r [C]e O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
ETS [C]E [C]T [C]S O 
motif [C]m [C]o [C]t [C]i [C]f O 
binds [C]b [C]i [C]n [C]d [C]s O 
an [C]a [C]n O 
Ets-related [C]E [C]t [C]s [C]- [C]r [C]e [C]l [C]a [C]t [C]e [C]d B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
specifically [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]a [C]l [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
at [C]a [C]t O 
high [C]h [C]i [C]g [C]h O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
in [C]i [C]n O 
CD4+ [C]C [C]D [C]4 [C]+ B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Moreover [C]M [C]o [C]r [C]e [C]o [C]v [C]e [C]r O 
, [C], O 
in [C]i [C]n O 
CD4- [C]C [C]D [C]4 [C]- B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
overexpression [C]o [C]v [C]e [C]r [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
Ets-1 [C]E [C]t [C]s [C]- [C]1 S-protein 
or [C]o [C]r O 
Ets-2 [C]E [C]t [C]s [C]- [C]2 S-protein 
efficiently [C]e [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t [C]l [C]y O 
and [C]a [C]n [C]d O 
specifically [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]a [C]l [C]l [C]y O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
CD4 [C]C [C]D [C]4 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
and [C]a [C]n [C]d O 
core [C]c [C]o [C]r [C]e B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
Ets [C]E [C]t [C]s B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
play [C]p [C]l [C]a [C]y O 
a [C]a O 
central [C]c [C]e [C]n [C]t [C]r [C]a [C]l O 
role [C]r [C]o [C]l [C]e O 
in [C]i [C]n O 
controlling [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]l [C]i [C]n [C]g O 
CD4 [C]C [C]D [C]4 O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
by [C]b [C]y O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
both [C]b [C]o [C]t [C]h O 
a [C]a O 
classical [C]c [C]l [C]a [C]s [C]s [C]i [C]c [C]a [C]l B-DNA 
remote [C]r [C]e [C]m [C]o [C]t [C]e I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
and [C]a [C]n [C]d O 
an [C]a [C]n O 
unusual [C]u [C]n [C]u [C]s [C]u [C]a [C]l O 
proximal [C]p [C]r [C]o [C]x [C]i [C]m [C]a [C]l B-DNA 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r I-DNA 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e E-DNA 

Glucocorticoid [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
inactivation [C]i [C]n [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
c [C]c O 
ultured [C]u [C]l [C]t [C]u [C]r [C]e [C]d B-cell_line 
human [C]h [C]u [C]m [C]a [C]n I-cell_line 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_line 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
are [C]a [C]r [C]e O 
not [C]n [C]o [C]t O 
cytolytic [C]c [C]y [C]t [C]o [C]l [C]y [C]t [C]i [C]c O 
for [C]f [C]o [C]r O 
and [C]a [C]n [C]d O 
do [C]d [C]o O 
not [C]n [C]o [C]t O 
inhibit [C]i [C]n [C]h [C]i [C]b [C]i [C]t O 
the [C]t [C]h [C]e O 
growth [C]g [C]r [C]o [C]w [C]t [C]h O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IM-9 [C]I [C]M [C]- [C]9 B-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
of [C]o [C]f O 
cultured [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]d B-cell_line 
human [C]h [C]u [C]m [C]a [C]n I-cell_line 
lymphoblasts [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]s E-cell_line 
, [C], O 
these [C]t [C]h [C]e [C]s [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
have [C]h [C]a [C]v [C]e O 
a [C]a O 
high [C]h [C]i [C]g [C]h O 
steroid-binding [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
capacity [C]c [C]a [C]p [C]a [C]c [C]i [C]t [C]y O 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
used [C]u [C]s [C]e [C]d O 
IM-9 [C]I [C]M [C]- [C]9 B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
order [C]o [C]r [C]d [C]e [C]r O 
to [C]t [C]o O 
examine [C]e [C]x [C]a [C]m [C]i [C]n [C]e O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
unoccupied [C]u [C]n [C]o [C]c [C]c [C]u [C]p [C]i [C]e [C]d B-protein 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d I-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
are [C]a [C]r [C]e O 
inactivated [C]i [C]n [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
and [C]a [C]n [C]d O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
intact [C]i [C]n [C]t [C]a [C]c [C]t B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

when [C]w [C]h [C]e [C]n O 
IM-9 [C]I [C]M [C]- [C]9 B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
are [C]a [C]r [C]e O 
incubated [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
glucose-free [C]g [C]l [C]u [C]c [C]o [C]s [C]e [C]- [C]f [C]r [C]e [C]e O 
medium [C]m [C]e [C]d [C]i [C]u [C]m O 
in [C]i [C]n O 
a [C]a O 
nitrogen [C]n [C]i [C]t [C]r [C]o [C]g [C]e [C]n O 
atmosphere [C]a [C]t [C]m [C]o [C]s [C]p [C]h [C]e [C]r [C]e O 
, [C], O 
both [C]b [C]o [C]t [C]h O 
their [C]t [C]h [C]e [C]i [C]r O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
to [C]t [C]o O 
bind [C]b [C]i [C]n [C]d O 
triamcinolone [C]t [C]r [C]i [C]a [C]m [C]c [C]i [C]n [C]o [C]l [C]o [C]n [C]e O 
acetonide [C]a [C]c [C]e [C]t [C]o [C]n [C]i [C]d [C]e O 
and [C]a [C]n [C]d O 
their [C]t [C]h [C]e [C]i [C]r O 
ATP [C]A [C]T [C]P O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
decline [C]d [C]e [C]c [C]l [C]i [C]n [C]e O 
and [C]a [C]n [C]d O 
, [C], O 
when [C]w [C]h [C]e [C]n O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
and [C]a [C]n [C]d O 
oxygen [C]o [C]x [C]y [C]g [C]e [C]n O 
are [C]a [C]r [C]e O 
reintroduced [C]r [C]e [C]i [C]n [C]t [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
, [C], O 
ATP [C]A [C]T [C]P O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
and [C]a [C]n [C]d O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
return [C]r [C]e [C]t [C]u [C]r [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
glucocorticoid-binding [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
prepared [C]p [C]r [C]e [C]p [C]a [C]r [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
cells [C]c [C]e [C]l [C]l [C]s O 
exposed [C]e [C]x [C]p [C]o [C]s [C]e [C]d O 
to [C]t [C]o O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
degrees [C]d [C]e [C]g [C]r [C]e [C]e [C]s O 
of [C]o [C]f O 
energy [C]e [C]n [C]e [C]r [C]g [C]y O 
limitation [C]l [C]i [C]m [C]i [C]t [C]a [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
directly [C]d [C]i [C]r [C]e [C]c [C]t [C]l [C]y O 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
ATP [C]A [C]T [C]P O 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
. [C]. O 

Receptor [C]R [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
intact [C]i [C]n [C]t [C]a [C]c [C]t B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
is [C]i [C]s O 
rapid [C]r [C]a [C]p [C]i [C]d O 
and [C]a [C]n [C]d O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
of [C]o [C]f O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
. [C]. O 

Cytosol [C]C [C]y [C]t [C]o [C]s [C]o [C]l O 
prepared [C]p [C]r [C]e [C]p [C]a [C]r [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
inactivated [C]i [C]n [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
cells [C]c [C]e [C]l [C]l [C]s O 
can [C]c [C]a [C]n O 
not [C]n [C]o [C]t O 
be [C]b [C]e O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
ATP [C]A [C]T [C]P O 
. [C]. O 

The [C]T [C]h [C]e O 
inactivation [C]i [C]n [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
that [C]t [C]h [C]a [C]t O 
occurs [C]o [C]c [C]c [C]u [C]r [C]s O 
when [C]w [C]h [C]e [C]n O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
from [C]f [C]r [C]o [C]m O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
IM-9 [C]I [C]M [C]- [C]9 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
is [C]i [C]s O 
incubated [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]e [C]d O 
at [C]a [C]t O 
25 [C]2 [C]5 O 
degrees [C]d [C]e [C]g [C]r [C]e [C]e [C]s O 
C [C]C O 
is [C]i [C]s O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
by [C]b [C]y O 
molybdate [C]m [C]o [C]l [C]y [C]b [C]d [C]a [C]t [C]e O 
, [C], O 
vanadate [C]v [C]a [C]n [C]a [C]d [C]a [C]t [C]e O 
, [C], O 
fluoride [C]f [C]l [C]u [C]o [C]r [C]i [C]d [C]e O 
, [C], O 
ATP [C]A [C]T [C]P O 
, [C], O 
and [C]a [C]n [C]d O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
other [C]o [C]t [C]h [C]e [C]r O 
nucleotides [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
experiments [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
intact [C]i [C]n [C]t [C]a [C]c [C]t B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
lymphoblasts [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]s E-cell_type 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
of [C]o [C]f O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
glucocorticoid-binding [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
capacity [C]c [C]a [C]p [C]a [C]c [C]i [C]t [C]y O 
do [C]d [C]o O 
not [C]n [C]o [C]t O 
necessarily [C]n [C]e [C]c [C]e [C]s [C]s [C]a [C]r [C]i [C]l [C]y O 
reflect [C]r [C]e [C]f [C]l [C]e [C]c [C]t O 
the [C]t [C]h [C]e O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
of [C]o [C]f O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
. [C]. O 

Glucocorticoids [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
and [C]a [C]n [C]d O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
. [C]. O 

II [C]I [C]I O 
. [C]. O 

Cell [C]C [C]e [C]l [C]l O 
cycle-dependent [C]c [C]y [C]c [C]l [C]e [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
in [C]i [C]n O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
. [C]. O 

To [C]T [C]o O 
study [C]s [C]t [C]u [C]d [C]y O 
variations [C]v [C]a [C]r [C]i [C]a [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
cell [C]c [C]e [C]l [C]l O 
cycle [C]c [C]y [C]c [C]l [C]e O 
, [C], O 
we [C]w [C]e O 
have [C]h [C]a [C]v [C]e O 
separated [C]s [C]e [C]p [C]a [C]r [C]a [C]t [C]e [C]d O 
mitogen-stimulated [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_line 
human [C]h [C]u [C]m [C]a [C]n I-cell_line 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_line 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_line 
and [C]a [C]n [C]d O 
rat [C]r [C]a [C]t B-cell_type 
lymph [C]l [C]y [C]m [C]p [C]h I-cell_type 
node [C]n [C]o [C]d [C]e I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
by [C]b [C]y O 
unit [C]u [C]n [C]i [C]t O 
gravity [C]g [C]r [C]a [C]v [C]i [C]t [C]y O 
sedimentation [C]s [C]e [C]d [C]i [C]m [C]e [C]n [C]t [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
resultant [C]r [C]e [C]s [C]u [C]l [C]t [C]a [C]n [C]t O 
fractions [C]f [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

By [C]B [C]y O 
morphologic [C]m [C]o [C]r [C]p [C]h [C]o [C]l [C]o [C]g [C]i [C]c O 
criteria [C]c [C]r [C]i [C]t [C]e [C]r [C]i [C]a O 
and [C]a [C]n [C]d O 
thymidine [C]t [C]h [C]y [C]m [C]i [C]d [C]i [C]n [C]e O 
incorporation [C]i [C]n [C]c [C]o [C]r [C]p [C]o [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
the [C]t [C]h [C]e O 
fractions [C]f [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
were [C]w [C]e [C]r [C]e O 
separated [C]s [C]e [C]p [C]a [C]r [C]a [C]t [C]e [C]d O 
into [C]i [C]n [C]t [C]o O 
populations [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
G0 [C]G [C]0 B-cell_type 
and [C]a [C]n [C]d I-cell_type 
G1 [C]G [C]1 I-cell_type 
phase [C]p [C]h [C]a [C]s [C]e I-cell_type 
and [C]a [C]n [C]d I-cell_type 
S [C]S I-cell_type 
and [C]a [C]n [C]d I-cell_type 
post-S [C]p [C]o [C]s [C]t [C]- [C]S I-cell_type 
phase [C]p [C]h [C]a [C]s [C]e I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

A [C]A O 
2- [C]2 [C]- O 
to [C]t [C]o O 
3-fold [C]3 [C]- [C]f [C]o [C]l [C]d O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
sites [C]s [C]i [C]t [C]e [C]s O 
per [C]p [C]e [C]r O 
cell [C]c [C]e [C]l [C]l O 
, [C], O 
for [C]f [C]o [C]r O 
cells [C]c [C]e [C]l [C]l [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
S [C]S O 
and [C]a [C]n [C]d O 
post-S [C]p [C]o [C]s [C]t [C]- [C]S O 
phase [C]p [C]h [C]a [C]s [C]e O 
over [C]o [C]v [C]e [C]r O 
those [C]t [C]h [C]o [C]s [C]e O 
in [C]i [C]n O 
G0 [C]G [C]0 O 
and [C]a [C]n [C]d O 
G1 [C]G [C]1 O 
, [C], O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
both [C]b [C]o [C]t [C]h O 
nonstimulated [C]n [C]o [C]n [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_type 
rat [C]r [C]a [C]t I-cell_type 
lymph [C]l [C]y [C]m [C]p [C]h I-cell_type 
node [C]n [C]o [C]d [C]e I-cell_type 
cell [C]c [C]e [C]l [C]l I-cell_type 
suspensions [C]s [C]u [C]s [C]p [C]e [C]n [C]s [C]i [C]o [C]n [C]s E-cell_type 
and [C]a [C]n [C]d O 
concanavalin [C]c [C]o [C]n [C]c [C]a [C]n [C]a [C]v [C]a [C]l [C]i [C]n B-cell_line 
A-stimulated [C]A [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d I-cell_line 
human [C]h [C]u [C]m [C]a [C]n I-cell_line 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_line 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_line 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
observations [C]o [C]b [C]s [C]e [C]r [C]v [C]a [C]t [C]i [C]o [C]n [C]s O 
together [C]t [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
with [C]w [C]i [C]t [C]h O 
those [C]t [C]h [C]o [C]s [C]e O 
from [C]f [C]r [C]o [C]m O 
other [C]o [C]t [C]h [C]e [C]r O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
new [C]n [C]e [C]w O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
near [C]n [C]e [C]a [C]r O 
the [C]t [C]h [C]e O 
S [C]S O 
phase [C]p [C]h [C]a [C]s [C]e O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
a [C]a O 
general [C]g [C]e [C]n [C]e [C]r [C]a [C]l O 
phenomenon [C]p [C]h [C]e [C]n [C]o [C]m [C]e [C]n [C]o [C]n O 
in [C]i [C]n O 
proliferating [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]n [C]g B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

We [C]W [C]e O 
propose [C]p [C]r [C]o [C]p [C]o [C]s [C]e O 
that [C]t [C]h [C]a [C]t O 
this [C]t [C]h [C]i [C]s O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
cell [C]c [C]e [C]l [C]l O 
cycle [C]c [C]y [C]c [C]l [C]e O 
may [C]m [C]a [C]y O 
explain [C]e [C]x [C]p [C]l [C]a [C]i [C]n O 
the [C]t [C]h [C]e O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
mitogen-stimulated [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e S-cell_type 
migration [C]m [C]i [C]g [C]r [C]a [C]t [C]i [C]o [C]n O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
certain [C]c [C]e [C]r [C]t [C]a [C]i [C]n O 
breast [C]b [C]r [C]e [C]a [C]s [C]t B-protein 
cancer-related [C]c [C]a [C]n [C]c [C]e [C]r [C]- [C]r [C]e [C]l [C]a [C]t [C]e [C]d I-protein 
antigens [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]s E-protein 
( [C]( O 
MCF-7 [C]M [C]C [C]F [C]- [C]7 S-protein 
and [C]a [C]n [C]d O 
MuMTV [C]M [C]u [C]M [C]T [C]V S-protein 
) [C]) O 
: [C]: O 
their [C]t [C]h [C]e [C]i [C]r O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
as [C]a [C]s O 
discriminants [C]d [C]i [C]s [C]c [C]r [C]i [C]m [C]i [C]n [C]a [C]n [C]t [C]s O 
. [C]. O 

Certain [C]C [C]e [C]r [C]t [C]a [C]i [C]n O 
oncogenic [C]o [C]n [C]c [C]o [C]g [C]e [C]n [C]i [C]c O 
viruses [C]v [C]i [C]r [C]u [C]s [C]e [C]s O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
implicated [C]i [C]m [C]p [C]l [C]i [C]c [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
murine [C]m [C]u [C]r [C]i [C]n [C]e O 
mammary [C]m [C]a [C]m [C]m [C]a [C]r [C]y O 
tumor [C]t [C]u [C]m [C]o [C]r O 
virus [C]v [C]i [C]r [C]u [C]s O 
( [C]( O 
MuMTV [C]M [C]u [C]M [C]T [C]V O 
) [C]) O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
Mason-Pfizer [C]M [C]a [C]s [C]o [C]n [C]- [C]P [C]f [C]i [C]z [C]e [C]r O 
monkey [C]m [C]o [C]n [C]k [C]e [C]y O 
virus [C]v [C]i [C]r [C]u [C]s O 
( [C]( O 
MPMV [C]M [C]P [C]M [C]V O 
) [C]) O 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
used [C]u [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e O 
migration [C]m [C]i [C]g [C]r [C]a [C]t [C]i [C]o [C]n O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
( [C]( O 
LMI [C]L [C]M [C]I O 
) [C]) O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
assay [C]a [C]s [C]s [C]a [C]y O 
the [C]t [C]h [C]e O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer-related [C]c [C]a [C]n [C]c [C]e [C]r [C]- [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
antigens [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]s O 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
MuMTV [C]M [C]u [C]M [C]T [C]V S-protein 
, [C], O 
MPMV [C]M [C]P [C]M [C]V S-protein 
, [C], O 
and [C]a [C]n [C]d O 
a [C]a O 
breast [C]b [C]r [C]e [C]a [C]s [C]t B-cell_line 
cancer [C]c [C]a [C]n [C]c [C]e [C]r I-cell_line 
cultured [C]c [C]u [C]l [C]t [C]u [C]r [C]e [C]d I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
, [C], O 
MCF-7 [C]M [C]C [C]F [C]- [C]7 S-cell_line 
, [C], O 
in [C]i [C]n O 
96 [C]9 [C]6 O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
, [C], O 
in [C]i [C]n O 
32 [C]3 [C]2 O 
women [C]w [C]o [C]m [C]e [C]n O 
with [C]w [C]i [C]t [C]h O 
benign [C]b [C]e [C]n [C]i [C]g [C]n O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
, [C], O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
67 [C]6 [C]7 O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
women [C]w [C]o [C]m [C]e [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
lowest [C]l [C]o [C]w [C]e [C]s [C]t O 
tenth [C]t [C]e [C]n [C]t [C]h O 
percentile [C]p [C]e [C]r [C]c [C]e [C]n [C]t [C]i [C]l [C]e O 
of [C]o [C]f O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
( [C]( O 
LMI [C]L [C]M [C]I O 
) [C]) O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
was [C]w [C]a [C]s O 
used [C]u [C]s [C]e [C]d O 
as [C]a [C]s O 
the [C]t [C]h [C]e O 
cutoff [C]c [C]u [C]t [C]o [C]f [C]f O 
point [C]p [C]o [C]i [C]n [C]t O 
to [C]t [C]o O 
designate [C]d [C]e [C]s [C]i [C]g [C]n [C]a [C]t [C]e O 
responders [C]r [C]e [C]s [C]p [C]o [C]n [C]d [C]e [C]r [C]s O 
. [C]. O 

Breast [C]B [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
to [C]t [C]o O 
MuMTV [C]M [C]u [C]M [C]T [C]V S-protein 
( [C]( O 
49 [C]4 [C]9 O 
% [C]% O 
and [C]a [C]n [C]d O 
to [C]t [C]o O 
MCF-7 [C]M [C]C [C]F [C]- [C]7 O 
( [C]( O 
50 [C]5 [C]0 O 
% [C]% O 
) [C]) O 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
to [C]t [C]o O 
MPMV [C]M [C]P [C]M [C]V S-protein 
( [C]( O 
29 [C]2 [C]9 O 
% [C]% O 
) [C]) O 
. [C]. O 

In [C]I [C]n O 
a [C]a O 
paired-antigen [C]p [C]a [C]i [C]r [C]e [C]d [C]- [C]a [C]n [C]t [C]i [C]g [C]e [C]n O 
study [C]s [C]t [C]u [C]d [C]y O 
using [C]u [C]s [C]i [C]n [C]g O 
MuMTV [C]M [C]u [C]M [C]T [C]V S-protein 
and [C]a [C]n [C]d O 
MCF-7 [C]M [C]C [C]F [C]- [C]7 S-protein 
, [C], O 
75 [C]7 [C]5 O 
% [C]% O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
responded [C]r [C]e [C]s [C]p [C]o [C]n [C]d [C]e [C]d O 
, [C], O 
versus [C]v [C]e [C]r [C]s [C]u [C]s O 
18 [C]1 [C]8 O 
% [C]% O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
women [C]w [C]o [C]m [C]e [C]n O 
( [C]( O 
P [C]P O 
less [C]l [C]e [C]s [C]s O 
than [C]t [C]h [C]a [C]n O 
0.0050 [C]0 [C]. [C]0 [C]0 [C]5 [C]0 O 
) [C]) O 
. [C]. O 

The [C]T [C]h [C]e O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
for [C]f [C]o [C]r O 
this [C]t [C]h [C]i [C]s O 
assay [C]a [C]s [C]s [C]a [C]y O 
to [C]t [C]o O 
distinguish [C]d [C]i [C]s [C]t [C]i [C]n [C]g [C]u [C]i [C]s [C]h O 
`` [C]` [C]` O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
'' [C]' [C]' O 
from [C]f [C]r [C]o [C]m O 
`` [C]` [C]` O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
'' [C]' [C]' O 
was [C]w [C]a [C]s O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
using [C]u [C]s [C]i [C]n [C]g O 
a [C]a O 
migration [C]m [C]i [C]g [C]r [C]a [C]t [C]i [C]o [C]n O 
index [C]i [C]n [C]d [C]e [C]x O 
derived [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
discriminant [C]d [C]i [C]s [C]c [C]r [C]i [C]m [C]i [C]n [C]a [C]n [C]t O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
assay [C]a [C]s [C]s [C]a [C]y O 
to [C]t [C]o O 
discriminate [C]d [C]i [C]s [C]c [C]r [C]i [C]m [C]i [C]n [C]a [C]t [C]e O 
`` [C]` [C]` O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
'' [C]' [C]' O 
from [C]f [C]r [C]o [C]m O 
`` [C]` [C]` O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
'' [C]' [C]' O 
was [C]w [C]a [C]s O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
( [C]( O 
P [C]P O 
less [C]l [C]e [C]s [C]s O 
than [C]t [C]h [C]a [C]n O 
0.001 [C]0 [C]. [C]0 [C]0 [C]1 O 
) [C]) O 
and [C]a [C]n [C]d O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
a [C]a O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
detecting [C]d [C]e [C]t [C]e [C]c [C]t [C]i [C]n [C]g O 
`` [C]` [C]` O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
'' [C]' [C]' O 
of [C]o [C]f O 
75 [C]7 [C]5 O 
% [C]% O 
. [C]. O 

The [C]T [C]h [C]e O 
overall [C]o [C]v [C]e [C]r [C]a [C]l [C]l O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
to [C]t [C]o O 
MuMTV [C]M [C]u [C]M [C]T [C]V S-protein 
and [C]a [C]n [C]d O 
MCF-7 [C]M [C]C [C]F [C]- [C]7 S-protein 
were [C]w [C]e [C]r [C]e O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
reference [C]r [C]e [C]f [C]e [C]r [C]e [C]n [C]c [C]e O 
to [C]t [C]o O 
certain [C]c [C]e [C]r [C]t [C]a [C]i [C]n O 
prognostic [C]p [C]r [C]o [C]g [C]n [C]o [C]s [C]t [C]i [C]c O 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s O 
, [C], O 
but [C]b [C]u [C]t O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
no [C]n [C]o O 
relation [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
to [C]t [C]o O 
age [C]a [C]g [C]e O 
, [C], O 
menstrual [C]m [C]e [C]n [C]s [C]t [C]r [C]u [C]a [C]l O 
status [C]s [C]t [C]a [C]t [C]u [C]s O 
, [C], O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
status [C]s [C]t [C]a [C]t [C]u [C]s O 
, [C], O 
or [C]o [C]r O 
stage [C]s [C]t [C]a [C]g [C]e O 
of [C]o [C]f O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
above [C]a [C]b [C]o [C]v [C]e O 
reactions [C]r [C]e [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
a [C]a O 
large [C]l [C]a [C]r [C]g [C]e O 
proportion [C]p [C]r [C]o [C]p [C]o [C]r [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
exhibit [C]e [C]x [C]h [C]i [C]b [C]i [C]t O 
presensitization [C]p [C]r [C]e [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
to [C]t [C]o O 
antigenfs [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]f [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
in [C]i [C]n O 
MuMTV [C]M [C]u [C]M [C]T [C]V S-protein 
and [C]a [C]n [C]d O 
MCF-7 [C]M [C]C [C]F [C]- [C]7 S-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
cross-reactive [C]c [C]r [C]o [C]s [C]s [C]- [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]e O 
with [C]w [C]i [C]t [C]h O 
antigens [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
appear [C]a [C]p [C]p [C]e [C]a [C]r O 
to [C]t [C]o O 
be [C]b [C]e O 
independent [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
of [C]o [C]f O 
major [C]m [C]a [C]j [C]o [C]r O 
prognostic [C]p [C]r [C]o [C]g [C]n [C]o [C]s [C]t [C]i [C]c O 
variables [C]v [C]a [C]r [C]i [C]a [C]b [C]l [C]e [C]s O 
. [C]. O 

Further [C]F [C]u [C]r [C]t [C]h [C]e [C]r O 
refinement [C]r [C]e [C]f [C]i [C]n [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
assay [C]a [C]s [C]s [C]a [C]y O 
may [C]m [C]a [C]y O 
yield [C]y [C]i [C]e [C]l [C]d O 
one [C]o [C]n [C]e O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
more [C]m [C]o [C]r [C]e O 
highly [C]h [C]i [C]g [C]h [C]l [C]y O 
discriminating [C]d [C]i [C]s [C]c [C]r [C]i [C]m [C]i [C]n [C]a [C]t [C]i [C]n [C]g O 
for [C]f [C]o [C]r O 
breast [C]b [C]r [C]e [C]a [C]s [C]t O 
cancer [C]c [C]a [C]n [C]c [C]e [C]r O 
. [C]. O 

Chronic [C]C [C]h [C]r [C]o [C]n [C]i [C]c O 
lymphatic [C]l [C]y [C]m [C]p [C]h [C]a [C]t [C]i [C]c O 
leukaemia [C]l [C]e [C]u [C]k [C]a [C]e [C]m [C]i [C]a O 
: [C]: O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
. [C]. O 

Glucocorticoid [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
and [C]a [C]n [C]d O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
nucleic [C]n [C]u [C]c [C]l [C]e [C]i [C]c O 
acid [C]a [C]c [C]i [C]d O 
precursors [C]p [C]r [C]e [C]c [C]u [C]r [C]s [C]o [C]r [C]s O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
in [C]i [C]n O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
from [C]f [C]r [C]o [C]m O 
27 [C]2 [C]7 O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
at [C]a [C]t O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
stages [C]s [C]t [C]a [C]g [C]e [C]s O 
of [C]o [C]f O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
lymphatic [C]l [C]y [C]m [C]p [C]h [C]a [C]t [C]i [C]c O 
leukaemia [C]l [C]e [C]u [C]k [C]a [C]e [C]m [C]i [C]a O 
. [C]. O 

No [C]N [C]o O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
can [C]c [C]a [C]n O 
be [C]b [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
stage [C]s [C]t [C]a [C]g [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
. [C]. O 

On [C]O [C]n O 
the [C]t [C]h [C]e O 
other [C]o [C]t [C]h [C]e [C]r O 
hand [C]h [C]a [C]n [C]d O 
, [C], O 
a [C]a O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
difference [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e O 
( [C]( O 
P [C]P O 
less [C]l [C]e [C]s [C]s O 
than [C]t [C]h [C]a [C]n O 
0.02 [C]0 [C]. [C]0 [C]2 O 
) [C]) O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
stage [C]s [C]t [C]a [C]g [C]e O 
O [C]O O 
and [C]a [C]n [C]d O 
stage [C]s [C]t [C]a [C]g [C]e O 
III/IV [C]I [C]I [C]I [C]/ [C]I [C]V O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
, [C], O 
in [C]i [C]n O 
terms [C]t [C]e [C]r [C]m [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
on [C]o [C]n O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
uridine [C]u [C]r [C]i [C]d [C]i [C]n [C]e O 
incorporation [C]i [C]n [C]c [C]o [C]r [C]p [C]o [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Pyrrolidine [C]P [C]y [C]r [C]r [C]o [C]l [C]i [C]d [C]i [C]n [C]e O 
dithiocarbamate [C]d [C]i [C]t [C]h [C]i [C]o [C]c [C]a [C]r [C]b [C]a [C]m [C]a [C]t [C]e O 
inhibits [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]s O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
mobilization [C]m [C]o [C]b [C]i [C]l [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
TNF [C]T [C]N [C]F O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
TNF [C]T [C]N [C]F I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
contains [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]s O 
four [C]f [C]o [C]u [C]r O 
potential [C]p [C]o [C]t [C]e [C]n [C]t [C]i [C]a [C]l O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-DNA 
factor-kappa [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a I-DNA 
B [C]B I-DNA 
( [C]( I-DNA 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a I-DNA 
B [C]B I-DNA 
) [C]) I-DNA 
-binding [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
, [C], O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
strongest [C]s [C]t [C]r [C]o [C]n [C]g [C]e [C]s [C]t O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
seen [C]s [C]e [C]e [C]n O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
-605 [C]- [C]6 [C]0 [C]5 O 
motif [C]m [C]o [C]t [C]i [C]f O 
. [C]. O 

Nuclear [C]N [C]u [C]c [C]l [C]e [C]a [C]r O 
extracts [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]s O 
from [C]f [C]r [C]o [C]m O 
unstimulated [C]u [C]n [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
monocytic [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]i [C]c I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
, [C], O 
Mono [C]M [C]o [C]n [C]o B-cell_line 
Mac [C]M [C]a [C]c I-cell_line 
6 [C]6 E-cell_line 
, [C], O 
contain [C]c [C]o [C]n [C]t [C]a [C]i [C]n O 
one [C]o [C]n [C]e O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
( [C]( O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x B-protein 
II [C]I [C]I E-protein 
) [C]) O 
, [C], O 
consistent [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
constitutive [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e B-protein 
p50 [C]p [C]5 [C]0 I-protein 
homodimer [C]h [C]o [C]m [C]o [C]d [C]i [C]m [C]e [C]r E-protein 
. [C]. O 

Stimulation [C]S [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
Mono [C]M [C]o [C]n [C]o B-cell_line 
Mac [C]M [C]a [C]c I-cell_line 
6 [C]6 I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
with [C]w [C]i [C]t [C]h O 
LPS [C]L [C]P [C]S O 
will [C]w [C]i [C]l [C]l O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x B-protein 
II [C]I [C]I E-protein 
and [C]a [C]n [C]d O 
will [C]w [C]i [C]l [C]l O 
strongly [C]s [C]t [C]r [C]o [C]n [C]g [C]l [C]y O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
a [C]a O 
second [C]s [C]e [C]c [C]o [C]n [C]d O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x O 
( [C]( O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x B-protein 
I [C]I E-protein 
) [C]) O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
represents [C]r [C]e [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]s O 
the [C]t [C]h [C]e O 
p50/65 [C]p [C]5 [C]0 [C]/ [C]6 [C]5 B-protein 
heterodimer [C]h [C]e [C]t [C]e [C]r [C]o [C]d [C]i [C]m [C]e [C]r E-protein 
. [C]. O 

Treatment [C]T [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
Mono [C]M [C]o [C]n [C]o B-cell_type 
Mac [C]M [C]a [C]c I-cell_type 
6 [C]6 I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
with [C]w [C]i [C]t [C]h O 
pyrrolidine-dithiocarbamate [C]p [C]y [C]r [C]r [C]o [C]l [C]i [C]d [C]i [C]n [C]e [C]- [C]d [C]i [C]t [C]h [C]i [C]o [C]c [C]a [C]r [C]b [C]a [C]m [C]a [C]t [C]e O 
( [C]( O 
PDTC [C]P [C]D [C]T [C]C O 
) [C]) O 
at [C]a [C]t O 
300 [C]3 [C]0 [C]0 O 
microM [C]m [C]i [C]c [C]r [C]o [C]M O 
will [C]w [C]i [C]l [C]l O 
block [C]b [C]l [C]o [C]c [C]k O 
the [C]t [C]h [C]e O 
LPS-induced [C]L [C]P [C]S [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d B-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x I-protein 
I [C]I E-protein 
almost [C]a [C]l [C]m [C]o [C]s [C]t O 
completely [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e [C]l [C]y O 
and [C]a [C]n [C]d O 
will [C]w [C]i [C]l [C]l O 
reduce [C]r [C]e [C]d [C]u [C]c [C]e O 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x B-protein 
II [C]I [C]I E-protein 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
constitutive [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
. [C]. O 

Binding [C]B [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
other [C]o [C]t [C]h [C]e [C]r O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
that [C]t [C]h [C]a [C]t O 
recognize [C]r [C]e [C]c [C]o [C]g [C]n [C]i [C]z [C]e O 
the [C]t [C]h [C]e O 
SP-1 [C]S [C]P [C]- [C]1 O 
and [C]a [C]n [C]d O 
c/EBP [C]c [C]/ [C]E [C]B [C]P O 
motifs [C]m [C]o [C]t [C]i [C]f [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
TNF [C]T [C]N [C]F I-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
is [C]i [C]s O 
not [C]n [C]o [C]t O 
affected [C]a [C]f [C]f [C]e [C]c [C]t [C]e [C]d O 
by [C]b [C]y O 
such [C]s [C]u [C]c [C]h O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
. [C]. O 

Northern [C]N [C]o [C]r [C]t [C]h [C]e [C]r [C]n O 
blot [C]b [C]l [C]o [C]t O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
demonstrates [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]s O 
that [C]t [C]h [C]a [C]t O 
PDTC [C]P [C]D [C]T [C]C O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
will [C]w [C]i [C]l [C]l O 
strongly [C]s [C]t [C]r [C]o [C]n [C]g [C]l [C]y O 
reduce [C]r [C]e [C]d [C]u [C]c [C]e O 
LPS-induced [C]L [C]P [C]S [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d B-protein 
TNF [C]T [C]N [C]F I-protein 
transcripts [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]s E-protein 
. [C]. O 

Secreted [C]S [C]e [C]c [C]r [C]e [C]t [C]e [C]d O 
TNF [C]T [C]N [C]F B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
as [C]a [C]s O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
Wehi [C]W [C]e [C]h [C]i O 
164S/ActD [C]1 [C]6 [C]4 [C]S [C]/ [C]A [C]c [C]t [C]D O 
bioassay [C]b [C]i [C]o [C]a [C]s [C]s [C]a [C]y O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
a [C]a O 
sandwich [C]s [C]a [C]n [C]d [C]w [C]i [C]c [C]h O 
immunoassay [C]i [C]m [C]m [C]u [C]n [C]o [C]a [C]s [C]s [C]a [C]y O 
was [C]w [C]a [C]s O 
similarly [C]s [C]i [C]m [C]i [C]l [C]a [C]r [C]l [C]y O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
PDTC [C]P [C]D [C]T [C]C O 
. [C]. O 

Kinetic [C]K [C]i [C]n [C]e [C]t [C]i [C]c O 
analyses [C]a [C]n [C]a [C]l [C]y [C]s [C]e [C]s O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
after [C]a [C]f [C]t [C]e [C]r O 
LPS [C]L [C]P [C]S O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
will [C]w [C]i [C]l [C]l O 
peak [C]p [C]e [C]a [C]k O 
at [C]a [C]t O 
1 [C]1 O 
h [C]h O 
, [C], O 
TNF [C]T [C]N [C]F O 
transcript [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t O 
prevalence [C]p [C]r [C]e [C]v [C]a [C]l [C]e [C]n [C]c [C]e O 
at [C]a [C]t O 
2 [C]2 O 
h [C]h O 
, [C], O 
and [C]a [C]n [C]d O 
TNF [C]T [C]N [C]F B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
at [C]a [C]t O 
4 [C]4 O 
h [C]h O 
. [C]. O 

PDTC [C]P [C]D [C]T [C]C O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
shift [C]s [C]h [C]i [C]f [C]t O 
this [C]t [C]h [C]i [C]s O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
LPS [C]L [C]P [C]S O 
to [C]t [C]o O 
a [C]a O 
later [C]l [C]a [C]t [C]e [C]r O 
time [C]t [C]i [C]m [C]e O 
, [C], O 
but [C]b [C]u [C]t O 
suppressed [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a O 
B [C]B O 
mobilization [C]m [C]o [C]b [C]i [C]l [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
TNF [C]T [C]N [C]F B-protein 
transcripts [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]s E-protein 
, [C], O 
and [C]a [C]n [C]d O 
TNF [C]T [C]N [C]F B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
over [C]o [C]v [C]e [C]r O 
the [C]t [C]h [C]e O 
entire [C]e [C]n [C]t [C]i [C]r [C]e O 
8-h [C]8 [C]- [C]h O 
observation [C]o [C]b [C]s [C]e [C]r [C]v [C]a [C]t [C]i [C]o [C]n O 
period [C]p [C]e [C]r [C]i [C]o [C]d O 
. [C]. O 

Analysis [C]A [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
freshly [C]f [C]r [C]e [C]s [C]h [C]l [C]y O 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d O 
, [C], O 
LPS-stimulated [C]L [C]P [C]S [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
a [C]a O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
blockade [C]b [C]l [C]o [C]c [C]k [C]a [C]d [C]e O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
in [C]i [C]n O 
these [C]t [C]h [C]e [C]s [C]e O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y O 
cells [C]c [C]e [C]l [C]l [C]s O 
, [C], O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
TNF [C]T [C]N [C]F B-protein 
transcripts [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]s E-protein 
, [C], O 
as [C]a [C]s O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
Northern [C]N [C]o [C]r [C]t [C]h [C]e [C]r [C]n O 
blot [C]b [C]l [C]o [C]t O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
by [C]b [C]y O 
quantitative [C]q [C]u [C]a [C]n [C]t [C]i [C]t [C]a [C]t [C]i [C]v [C]e O 
polymerase [C]p [C]o [C]l [C]y [C]m [C]e [C]r [C]a [C]s [C]e O 
chain [C]c [C]h [C]a [C]i [C]n O 
reaction [C]r [C]e [C]a [C]c [C]t [C]i [C]o [C]n O 
, [C], O 
was [C]w [C]a [C]s O 
prevented [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]e [C]d O 
by [C]b [C]y O 
PDTC [C]P [C]D [C]T [C]C O 
as [C]a [C]s O 
was [C]w [C]a [C]s O 
TNF [C]T [C]N [C]F B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
dithiocarbamates [C]d [C]i [C]t [C]h [C]i [C]o [C]c [C]a [C]r [C]b [C]a [C]m [C]a [C]t [C]e [C]s O 
can [C]c [C]a [C]n O 
profoundly [C]p [C]r [C]o [C]f [C]o [C]u [C]n [C]d [C]l [C]y O 
affect [C]a [C]f [C]f [C]e [C]c [C]t O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
is [C]i [C]s O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
LPS-induced [C]L [C]P [C]S [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
TNF [C]T [C]N [C]F O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

Comparing [C]C [C]o [C]m [C]p [C]a [C]r [C]i [C]n [C]g O 
regions [C]r [C]e [C]g [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Epstein-Barr [C]E [C]p [C]s [C]t [C]e [C]i [C]n [C]- [C]B [C]a [C]r [C]r B-protein 
virus [C]v [C]i [C]r [C]u [C]s I-protein 
ZEBRA [C]Z [C]E [C]B [C]R [C]A I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
which [C]w [C]h [C]i [C]c [C]h O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
as [C]a [C]s O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l B-DNA 
activating [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]n [C]g I-DNA 
sequences [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]s E-DNA 
in [C]i [C]n O 
Saccharomyces [C]S [C]a [C]c [C]c [C]h [C]a [C]r [C]o [C]m [C]y [C]c [C]e [C]s O 
cerevisiae [C]c [C]e [C]r [C]e [C]v [C]i [C]s [C]i [C]a [C]e O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
ZEBRA [C]Z [C]E [C]B [C]R [C]A B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
activates [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]s O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
Epstein-Barr [C]E [C]p [C]s [C]t [C]e [C]i [C]n [C]- [C]B [C]a [C]r [C]r O 
virus [C]v [C]i [C]r [C]u [C]s O 
early-lytic-cycle [C]e [C]a [C]r [C]l [C]y [C]- [C]l [C]y [C]t [C]i [C]c [C]- [C]c [C]y [C]c [C]l [C]e B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
B [C]B I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
it [C]i [C]t O 
is [C]i [C]s O 
shown [C]s [C]h [C]o [C]w [C]n O 
that [C]t [C]h [C]a [C]t O 
ZEBRA [C]Z [C]E [C]B [C]R [C]A S-protein 
also [C]a [C]l [C]s [C]o O 
behaves [C]b [C]e [C]h [C]a [C]v [C]e [C]s O 
as [C]a [C]s O 
a [C]a O 
sequence-specific [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-protein 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l I-protein 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r E-protein 
in [C]i [C]n O 
Saccharomyces [C]S [C]a [C]c [C]c [C]h [C]a [C]r [C]o [C]m [C]y [C]c [C]e [C]s O 
cerevisiae [C]c [C]e [C]r [C]e [C]v [C]i [C]s [C]i [C]a [C]e O 
. [C]. O 

Deletional [C]D [C]e [C]l [C]e [C]t [C]i [C]o [C]n [C]a [C]l O 
mutagenesis [C]m [C]u [C]t [C]a [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
defined [C]d [C]e [C]f [C]i [C]n [C]e [C]d O 
three [C]t [C]h [C]r [C]e [C]e O 
regions [C]r [C]e [C]g [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
ZEBRA [C]Z [C]E [C]B [C]R [C]A S-protein 
that [C]t [C]h [C]a [C]t O 
participate [C]p [C]a [C]r [C]t [C]i [C]c [C]i [C]p [C]a [C]t [C]e O 
in [C]i [C]n O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
S. [C]S [C]. O 
cerevisiae [C]c [C]e [C]r [C]e [C]v [C]i [C]s [C]i [C]a [C]e O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
regions [C]r [C]e [C]g [C]i [C]o [C]n [C]s O 
are [C]a [C]r [C]e O 
designated [C]d [C]e [C]s [C]i [C]g [C]n [C]a [C]t [C]e [C]d O 
YI [C]Y [C]I S-protein 
( [C]( O 
amino [C]a [C]m [C]i [C]n [C]o B-protein 
acids [C]a [C]c [C]i [C]d [C]s I-protein 
[ [C][ I-protein 
aa [C]a [C]a I-protein 
] [C]] I-protein 
1 [C]1 I-protein 
to [C]t [C]o I-protein 
25 [C]2 [C]5 E-protein 
) [C]) O 
, [C], O 
YII [C]Y [C]I [C]I S-protein 
( [C]( O 
aa [C]a [C]a B-protein 
51 [C]5 [C]1 I-protein 
to [C]t [C]o I-protein 
102 [C]1 [C]0 [C]2 E-protein 
) [C]) O 
, [C], O 
and [C]a [C]n [C]d O 
YIII [C]Y [C]I [C]I [C]I S-protein 
( [C]( O 
aa [C]a [C]a B-protein 
228 [C]2 [C]2 [C]8 I-protein 
to [C]t [C]o I-protein 
245 [C]2 [C]4 [C]5 E-protein 
) [C]) O 
. [C]. O 

Two [C]T [C]w [C]o O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
three [C]t [C]h [C]r [C]e [C]e O 
regions [C]r [C]e [C]g [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
native [C]n [C]a [C]t [C]i [C]v [C]e O 
ZEBRA [C]Z [C]E [C]B [C]R [C]A B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
act [C]a [C]c [C]t O 
together [C]t [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
to [C]t [C]o O 
mediate [C]m [C]e [C]d [C]i [C]a [C]t [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
when [C]w [C]h [C]e [C]n O 
assayed [C]a [C]s [C]s [C]a [C]y [C]e [C]d O 
on [C]o [C]n O 
ZEBRA [C]Z [C]E [C]B [C]R [C]A B-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
sites [C]s [C]i [C]t [C]e [C]s E-protein 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
when [C]w [C]h [C]e [C]n O 
fused [C]f [C]u [C]s [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
DNA [C]D [C]N [C]A B-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
of [C]o [C]f O 
GAL [C]G [C]A [C]L S-protein 
4 [C]4 O 
and [C]a [C]n [C]d O 
assayed [C]a [C]s [C]s [C]a [C]y [C]e [C]d O 
on [C]o [C]n O 
GAL4 [C]G [C]A [C]L [C]4 B-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
sites [C]s [C]i [C]t [C]e [C]s E-protein 
, [C], O 
regions [C]r [C]e [C]g [C]i [C]o [C]n [C]s B-protein 
YII [C]Y [C]I [C]I I-protein 
and [C]a [C]n [C]d I-protein 
YIII [C]Y [C]I [C]I [C]I E-protein 
were [C]w [C]e [C]r [C]e O 
each [C]e [C]a [C]c [C]h O 
sufficient [C]s [C]u [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
to [C]t [C]o O 
confer [C]c [C]o [C]n [C]f [C]e [C]r O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
S. [C]S [C]. O 
cerevisiae [C]c [C]e [C]r [C]e [C]v [C]i [C]s [C]i [C]a [C]e O 
. [C]. O 

Regions [C]R [C]e [C]g [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
ZEBRA [C]Z [C]E [C]B [C]R [C]A S-protein 
which [C]w [C]h [C]i [C]c [C]h O 
affected [C]a [C]f [C]f [C]e [C]c [C]t [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
S. [C]S [C]. O 
cerevisiae [C]c [C]e [C]r [C]e [C]v [C]i [C]s [C]i [C]a [C]e O 
were [C]w [C]e [C]r [C]e O 
also [C]a [C]l [C]s [C]o O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
B [C]B I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
amino-terminal [C]a [C]m [C]i [C]n [C]o [C]- [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l B-protein 
region [C]r [C]e [C]g [C]i [C]o [C]n E-protein 
of [C]o [C]f O 
ZEBRA [C]Z [C]E [C]B [C]R [C]A S-protein 
( [C]( O 
aa [C]a [C]a B-protein 
1 [C]1 I-protein 
to [C]t [C]o I-protein 
98 [C]9 [C]8 E-protein 
) [C]) O 
was [C]w [C]a [C]s O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
both [C]b [C]o [C]t [C]h O 
in [C]i [C]n O 
S. [C]S [C]. O 
cerevisiae [C]c [C]e [C]r [C]e [C]v [C]i [C]s [C]i [C]a [C]e O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
; [C]; O 
deletion [C]d [C]e [C]l [C]e [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
carboxy-terminal [C]c [C]a [C]r [C]b [C]o [C]x [C]y [C]- [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l B-protein 
18 [C]1 [C]8 I-protein 
aa [C]a [C]a E-protein 
also [C]a [C]l [C]s [C]o O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
cell [C]c [C]e [C]l [C]l O 
types [C]t [C]y [C]p [C]e [C]s O 
. [C]. O 

Thus [C]T [C]h [C]u [C]s O 
, [C], O 
the [C]t [C]h [C]e O 
behavior [C]b [C]e [C]h [C]a [C]v [C]i [C]o [C]r O 
of [C]o [C]f O 
ZEBRA [C]Z [C]E [C]B [C]R [C]A S-protein 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
B [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
S. [C]S [C]. O 
cerevisiae [C]c [C]e [C]r [C]e [C]v [C]i [C]s [C]i [C]a [C]e O 
suggests [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]s O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
contains [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]s O 
universal [C]u [C]n [C]i [C]v [C]e [C]r [C]s [C]a [C]l B-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n I-protein 
motifs [C]m [C]o [C]t [C]i [C]f [C]s E-protein 
that [C]t [C]h [C]a [C]t O 
interact [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t O 
with [C]w [C]i [C]t [C]h O 
conserved [C]c [C]o [C]n [C]s [C]e [C]r [C]v [C]e [C]d O 
components [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
machinery [C]m [C]a [C]c [C]h [C]i [C]n [C]e [C]r [C]y O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
certain [C]c [C]e [C]r [C]t [C]a [C]i [C]n O 
deletion [C]d [C]e [C]l [C]e [C]t [C]i [C]o [C]n B-protein 
mutants [C]m [C]u [C]t [C]a [C]n [C]t [C]s E-protein 
of [C]o [C]f O 
ZEBRA [C]Z [C]E [C]B [C]R [C]A S-protein 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
mutations [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
N-terminal [C]N [C]- [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l B-protein 
region [C]r [C]e [C]g [C]i [C]o [C]n E-protein 
exhibited [C]e [C]x [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
discordant [C]d [C]i [C]s [C]c [C]o [C]r [C]d [C]a [C]n [C]t O 
behaviors [C]b [C]e [C]h [C]a [C]v [C]i [C]o [C]r [C]s O 
in [C]i [C]n O 
S. [C]S [C]. O 
cerevisiae [C]c [C]e [C]r [C]e [C]v [C]i [C]s [C]i [C]a [C]e O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
B [C]B O 
cells [C]c [C]e [C]l [C]l [C]s O 
. [C]. O 

For [C]F [C]o [C]r O 
example [C]e [C]x [C]a [C]m [C]p [C]l [C]e O 
, [C], O 
deletion [C]d [C]e [C]l [C]e [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
ZEBRA [C]Z [C]E [C]B [C]R [C]A B-protein 
aa [C]a [C]a I-protein 
26 [C]2 [C]6 I-protein 
to [C]t [C]o I-protein 
51 [C]5 [C]1 E-protein 
impaired [C]i [C]m [C]p [C]a [C]i [C]r [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
to [C]t [C]o O 
a [C]a O 
great [C]g [C]r [C]e [C]a [C]t O 
extent [C]e [C]x [C]t [C]e [C]n [C]t O 
in [C]i [C]n O 
B [C]B B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
but [C]b [C]u [C]t O 
had [C]h [C]a [C]d O 
little [C]l [C]i [C]t [C]t [C]l [C]e O 
or [C]o [C]r O 
no [C]n [C]o O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
in [C]i [C]n O 
S. [C]S [C]. O 
cerevisiae [C]c [C]e [C]r [C]e [C]v [C]i [C]s [C]i [C]a [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
discordant [C]d [C]i [C]s [C]c [C]o [C]r [C]d [C]a [C]n [C]t O 
mutants [C]m [C]u [C]t [C]a [C]n [C]t [C]s O 
may [C]m [C]a [C]y O 
reflect [C]r [C]e [C]f [C]l [C]e [C]c [C]t O 
interactions [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
variable [C]v [C]a [C]r [C]i [C]a [C]b [C]l [C]e B-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
of [C]o [C]f O 
a [C]a O 
conserved [C]c [C]o [C]n [C]s [C]e [C]r [C]v [C]e [C]d O 
component [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t O 
or [C]o [C]r O 
unique [C]u [C]n [C]i [C]q [C]u [C]e O 
interactions [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
with [C]w [C]i [C]t [C]h O 
specialized [C]s [C]p [C]e [C]c [C]i [C]a [C]l [C]i [C]z [C]e [C]d O 
components [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
basal [C]b [C]a [C]s [C]a [C]l O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
apparatus [C]a [C]p [C]p [C]a [C]r [C]a [C]t [C]u [C]s O 
in [C]i [C]n O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
cells [C]c [C]e [C]l [C]l [C]s O 
. [C]. O 

Functional [C]F [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
v-Rel [C]v [C]- [C]R [C]e [C]l B-protein 
and [C]a [C]n [C]d I-protein 
c-Rel [C]c [C]- [C]R [C]e [C]l I-protein 
oncoproteins [C]o [C]n [C]c [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
TATA-binding [C]T [C]A [C]T [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
and [C]a [C]n [C]d O 
association [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
IIB [C]I [C]I [C]B E-protein 
. [C]. O 

Rel [C]R [C]e [C]l B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
genes [C]g [C]e [C]n [C]e [C]s O 
linked [C]l [C]i [C]n [C]k [C]e [C]d O 
to [C]t [C]o O 
kappa [C]k [C]a [C]p [C]p [C]a O 
B-binding [C]B [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
motifs [C]m [C]o [C]t [C]i [C]f [C]s O 
. [C]. O 

Little [C]L [C]i [C]t [C]t [C]l [C]e O 
is [C]i [C]s O 
known [C]k [C]n [C]o [C]w [C]n O 
, [C], O 
however [C]h [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
by [C]b [C]y O 
which [C]w [C]h [C]i [C]c [C]h O 
they [C]t [C]h [C]e [C]y O 
enhance [C]e [C]n [C]h [C]a [C]n [C]c [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
v-Rel [C]v [C]- [C]R [C]e [C]l B-protein 
and [C]a [C]n [C]d I-protein 
c-Rel [C]c [C]- [C]R [C]e [C]l I-protein 
oncoproteins [C]o [C]n [C]c [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
to [C]t [C]o O 
interact [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t O 
with [C]w [C]i [C]t [C]h O 
components [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
basal [C]b [C]a [C]s [C]a [C]l O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
machinery [C]m [C]a [C]c [C]h [C]i [C]n [C]e [C]r [C]y O 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
we [C]w [C]e O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
that [C]t [C]h [C]a [C]t O 
both [C]b [C]o [C]t [C]h O 
the [C]t [C]h [C]e O 
acidic [C]a [C]c [C]i [C]d [C]i [C]c O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
domain [C]d [C]o [C]m [C]a [C]i [C]n O 
mapping [C]m [C]a [C]p [C]p [C]i [C]n [C]g O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
unique [C]u [C]n [C]i [C]q [C]u [C]e O 
C [C]C B-protein 
terminus [C]t [C]e [C]r [C]m [C]i [C]n [C]u [C]s E-protein 
of [C]o [C]f O 
chicken [C]c [C]h [C]i [C]c [C]k [C]e [C]n B-protein 
c-Rel [C]c [C]- [C]R [C]e [C]l E-protein 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
F9 [C]F [C]9 B-protein 
cell-specific [C]c [C]e [C]l [C]l [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n I-protein 
region [C]r [C]e [C]g [C]i [C]o [C]n E-protein 
common [C]c [C]o [C]m [C]m [C]o [C]n O 
to [C]t [C]o O 
both [C]b [C]o [C]t [C]h O 
v-Rel [C]v [C]- [C]R [C]e [C]l S-protein 
and [C]a [C]n [C]d O 
c-Rel [C]c [C]- [C]R [C]e [C]l S-protein 
interact [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
TATA-binding [C]T [C]A [C]T [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
( [C]( O 
TBP [C]T [C]B [C]P S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
IIB [C]I [C]I [C]B E-protein 
( [C]( O 
TFIIB [C]T [C]F [C]I [C]I [C]B S-protein 
) [C]) O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
. [C]. O 

We [C]W [C]e O 
also [C]a [C]l [C]s [C]o O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
TPB [C]T [C]P [C]B S-protein 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
Rel [C]R [C]e [C]l B-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n I-protein 
regions [C]r [C]e [C]g [C]i [C]o [C]n [C]s E-protein 
leads [C]l [C]e [C]a [C]d [C]s O 
to [C]t [C]o O 
synergistic [C]s [C]y [C]n [C]e [C]r [C]g [C]i [C]s [C]t [C]i [C]c O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
kappa [C]k [C]a [C]p [C]p [C]a B-DNA 
B-linked [C]B [C]- [C]l [C]i [C]n [C]k [C]e [C]d I-DNA 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
. [C]. O 

Combined [C]C [C]o [C]m [C]b [C]i [C]n [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
observation [C]o [C]b [C]s [C]e [C]r [C]v [C]a [C]t [C]i [C]o [C]n O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
mouse [C]m [C]o [C]u [C]s [C]e B-protein 
c-Rel [C]c [C]- [C]R [C]e [C]l I-protein 
and [C]a [C]n [C]d I-protein 
human [C]h [C]u [C]m [C]a [C]n I-protein 
RelA [C]R [C]e [C]l [C]A I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
also [C]a [C]l [C]s [C]o O 
interact [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t O 
with [C]w [C]i [C]t [C]h O 
TBP [C]T [C]B [C]P S-protein 
and [C]a [C]n [C]d O 
TFIIB [C]T [C]F [C]I [C]I [C]B S-protein 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
, [C], O 
these [C]t [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
association [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
basal [C]b [C]a [C]s [C]a [C]l B-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
is [C]i [C]s O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l O 
activities [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]i [C]e [C]s O 
of [C]o [C]f O 
Rel [C]R [C]e [C]l B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
. [C]. O 

p21ras [C]p [C]2 [C]1 [C]r [C]a [C]s S-protein 
and [C]a [C]n [C]d O 
calcineurin [C]c [C]a [C]l [C]c [C]i [C]n [C]e [C]u [C]r [C]i [C]n O 
synergize [C]s [C]y [C]n [C]e [C]r [C]g [C]i [C]z [C]e O 
to [C]t [C]o O 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
of [C]o [C]f O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

In [C]I [C]n O 
T [C]T B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
, [C], O 
triggering [C]t [C]r [C]i [C]g [C]g [C]e [C]r [C]i [C]n [C]g O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
T [C]T B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
( [C]( O 
TCR [C]T [C]C [C]R S-protein 
) [C]) O 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
cascades [C]c [C]a [C]s [C]c [C]a [C]d [C]e [C]s O 
which [C]w [C]h [C]i [C]c [C]h O 
ultimately [C]u [C]l [C]t [C]i [C]m [C]a [C]t [C]e [C]l [C]y O 
synergize [C]s [C]y [C]n [C]e [C]r [C]g [C]i [C]z [C]e O 
to [C]t [C]o O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
the [C]t [C]h [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
of [C]o [C]f O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
NFAT [C]N [C]F [C]A [C]T S-cell_line 
) [C]) O 
, [C], O 
a [C]a O 
DNA [C]D [C]N [C]A B-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
critical [C]c [C]r [C]i [C]t [C]i [C]c [C]a [C]l O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
inducibility [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]i [C]l [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
specificity [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
T [C]T B-protein 
cell [C]c [C]e [C]l [C]l I-protein 
growth [C]g [C]r [C]o [C]w [C]t [C]h I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
interleukin [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n B-protein 
2 [C]2 E-protein 
. [C]. O 

One [C]O [C]n [C]e O 
immediate [C]i [C]m [C]m [C]e [C]d [C]i [C]a [C]t [C]e O 
consequence [C]c [C]o [C]n [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
via [C]v [C]i [C]a O 
the [C]t [C]h [C]e O 
TCR [C]T [C]C [C]R S-protein 
is [C]i [C]s O 
an [C]a [C]n O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
cytosolic [C]c [C]y [C]t [C]o [C]s [C]o [C]l [C]i [C]c O 
calcium [C]c [C]a [C]l [C]c [C]i [C]u [C]m O 
. [C]. O 

Calcium [C]C [C]a [C]l [C]c [C]i [C]u [C]m O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
are [C]a [C]r [C]e O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
for [C]f [C]o [C]r O 
NFAT [C]N [C]F [C]A [C]T S-cell_line 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
recent [C]r [C]e [C]c [C]e [C]n [C]t O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
have [C]h [C]a [C]v [C]e O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
calcineurin [C]c [C]a [C]l [C]c [C]i [C]n [C]e [C]u [C]r [C]i [C]n S-protein 
, [C], O 
a [C]a O 
calcium-calmodulin [C]c [C]a [C]l [C]c [C]i [C]u [C]m [C]- [C]c [C]a [C]l [C]m [C]o [C]d [C]u [C]l [C]i [C]n B-protein 
dependent [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t I-protein 
serine-threonine [C]s [C]e [C]r [C]i [C]n [C]e [C]- [C]t [C]h [C]r [C]e [C]o [C]n [C]i [C]n [C]e I-protein 
phosphatase [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]a [C]s [C]e E-protein 
, [C], O 
as [C]a [C]s O 
a [C]a O 
prominent [C]p [C]r [C]o [C]m [C]i [C]n [C]e [C]n [C]t O 
component [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
calcium [C]c [C]a [C]l [C]c [C]i [C]u [C]m O 
signaling [C]s [C]i [C]g [C]n [C]a [C]l [C]i [C]n [C]g O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

A [C]A O 
second [C]s [C]e [C]c [C]o [C]n [C]d O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
molecule [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e O 
in [C]i [C]n O 
TCR [C]T [C]C [C]R O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
the [C]t [C]h [C]e O 
guanine [C]g [C]u [C]a [C]n [C]i [C]n [C]e B-protein 
nucleotide [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
, [C], O 
p21ras [C]p [C]2 [C]1 [C]r [C]a [C]s S-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
coupled [C]c [C]o [C]u [C]p [C]l [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
TCR [C]T [C]C [C]R S-protein 
by [C]b [C]y O 
a [C]a O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
dependent [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
. [C]. O 

The [C]T [C]h [C]e O 
experiments [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]s O 
presented [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]e [C]d O 
here [C]h [C]e [C]r [C]e O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
by [C]b [C]y O 
transfection [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
mutationally [C]m [C]u [C]t [C]a [C]t [C]i [C]o [C]n [C]a [C]l [C]l [C]y O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
calcineurin [C]c [C]a [C]l [C]c [C]i [C]n [C]e [C]u [C]r [C]i [C]n S-protein 
or [C]o [C]r O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
p21ras [C]p [C]2 [C]1 [C]r [C]a [C]s S-protein 
alone [C]a [C]l [C]o [C]n [C]e O 
is [C]i [C]s O 
insufficient [C]i [C]n [C]s [C]u [C]f [C]f [C]i [C]c [C]i [C]e [C]n [C]t O 
for [C]f [C]o [C]r O 
NFAT [C]N [C]F [C]A [C]T S-cell_type 
transactivation [C]t [C]r [C]a [C]n [C]s [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
coexpression [C]c [C]o [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
calcineurin [C]c [C]a [C]l [C]c [C]i [C]n [C]e [C]u [C]r [C]i [C]n O 
with [C]w [C]i [C]t [C]h O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
p21ras [C]p [C]2 [C]1 [C]r [C]a [C]s O 
could [C]c [C]o [C]u [C]l [C]d O 
mimic [C]m [C]i [C]m [C]i [C]c O 
TCR [C]T [C]C [C]R O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
in [C]i [C]n O 
NFAT [C]N [C]F [C]A [C]T S-cell_type 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
data [C]d [C]a [C]t [C]a O 
identify [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]y O 
calcineurin [C]c [C]a [C]l [C]c [C]i [C]n [C]e [C]u [C]r [C]i [C]n S-protein 
and [C]a [C]n [C]d O 
p21ras [C]p [C]2 [C]1 [C]r [C]a [C]s S-protein 
as [C]a [C]s O 
cooperative [C]c [C]o [C]o [C]p [C]e [C]r [C]a [C]t [C]i [C]v [C]e O 
partners [C]p [C]a [C]r [C]t [C]n [C]e [C]r [C]s O 
in [C]i [C]n O 
T [C]T B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Expression [C]E [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
chicken [C]c [C]h [C]i [C]c [C]k [C]e [C]n B-protein 
GATA [C]G [C]A [C]T [C]A I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y E-protein 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
early [C]e [C]a [C]r [C]l [C]y O 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
DNA [C]D [C]N [C]A O 
motif [C]m [C]o [C]t [C]i [C]f O 
WGATAR [C]W [C]G [C]A [C]T [C]A [C]R O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l B-DNA 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y I-DNA 
domains [C]d [C]o [C]m [C]a [C]i [C]n [C]s E-DNA 
of [C]o [C]f O 
globin [C]g [C]l [C]o [C]b [C]i [C]n S-DNA 
and [C]a [C]n [C]d O 
other [C]o [C]t [C]h [C]e [C]r O 
erythroid-specific [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
activator [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]o [C]r B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
that [C]t [C]h [C]a [C]t O 
bind [C]b [C]i [C]n [C]d O 
to [C]t [C]o O 
this [C]t [C]h [C]i [C]s O 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y B-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
, [C], O 
the [C]t [C]h [C]e O 
GATA [C]G [C]A [C]T [C]A B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
, [C], O 
belong [C]b [C]e [C]l [C]o [C]n [C]g O 
to [C]t [C]o O 
a [C]a O 
multi-gene [C]m [C]u [C]l [C]t [C]i [C]- [C]g [C]e [C]n [C]e B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y E-protein 
that [C]t [C]h [C]a [C]t O 
is [C]i [C]s O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
chicken [C]c [C]h [C]i [C]c [C]k [C]e [C]n B-cell_type 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
we [C]w [C]e O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
, [C], O 
as [C]a [C]s O 
in [C]i [C]n O 
chickens [C]c [C]h [C]i [C]c [C]k [C]e [C]n [C]s O 
, [C], O 
multiple [C]m [C]u [C]l [C]t [C]i [C]p [C]l [C]e O 
members [C]m [C]e [C]m [C]b [C]e [C]r [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
GATA [C]G [C]A [C]T [C]A B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y E-protein 
are [C]a [C]r [C]e O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
and [C]a [C]n [C]d I-cell_type 
murine [C]m [C]u [C]r [C]i [C]n [C]e I-cell_type 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

During [C]D [C]u [C]r [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
early [C]e [C]a [C]r [C]l [C]y O 
stages [C]s [C]t [C]a [C]g [C]e [C]s O 
of [C]o [C]f O 
chicken [C]c [C]h [C]i [C]c [C]k [C]e [C]n O 
embryogenesis [C]e [C]m [C]b [C]r [C]y [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
( [C]( O 
well [C]w [C]e [C]l [C]l O 
before [C]b [C]e [C]f [C]o [C]r [C]e O 
blood [C]b [C]l [C]o [C]o [C]d O 
island [C]i [C]s [C]l [C]a [C]n [C]d O 
formation [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n O 
) [C]) O 
, [C], O 
each [C]e [C]a [C]c [C]h O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
GATA [C]G [C]A [C]T [C]A B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y I-protein 
members [C]m [C]e [C]m [C]b [C]e [C]r [C]s E-protein 
is [C]i [C]s O 
transcribed [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
unique [C]u [C]n [C]i [C]q [C]u [C]e O 
temporal [C]t [C]e [C]m [C]p [C]o [C]r [C]a [C]l O 
and [C]a [C]n [C]d O 
spatial [C]s [C]p [C]a [C]t [C]i [C]a [C]l O 
pattern [C]p [C]a [C]t [C]t [C]e [C]r [C]n O 
. [C]. O 

In [C]I [C]n O 
the [C]t [C]h [C]e O 
primitive [C]p [C]r [C]i [C]m [C]i [C]t [C]i [C]v [C]e B-cell_type 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d I-cell_type 
lineage [C]l [C]i [C]n [C]e [C]a [C]g [C]e E-cell_type 
, [C], O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
embryonic [C]e [C]m [C]b [C]r [C]y [C]o [C]n [C]i [C]c B-DNA 
epsilon-globin [C]e [C]p [C]s [C]i [C]l [C]o [C]n [C]- [C]g [C]l [C]o [C]b [C]i [C]n I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
parallels [C]p [C]a [C]r [C]a [C]l [C]l [C]e [C]l [C]s O 
GATA-1 [C]G [C]A [C]T [C]A [C]- [C]1 O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
while [C]w [C]h [C]i [C]l [C]e O 
the [C]t [C]h [C]e O 
switch [C]s [C]w [C]i [C]t [C]c [C]h O 
to [C]t [C]o O 
beta-globin [C]b [C]e [C]t [C]a [C]- [C]g [C]l [C]o [C]b [C]i [C]n O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
definitive [C]d [C]e [C]f [C]i [C]n [C]i [C]t [C]i [C]v [C]e B-cell_type 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
is [C]i [C]s O 
directly [C]d [C]i [C]r [C]e [C]c [C]t [C]l [C]y O 
preceded [C]p [C]r [C]e [C]c [C]e [C]d [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
pronounced [C]p [C]r [C]o [C]n [C]o [C]u [C]n [C]c [C]e [C]d O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
GATA-3 [C]G [C]A [C]T [C]A [C]- [C]3 S-protein 
accumulation [C]a [C]c [C]c [C]u [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
timing [C]t [C]i [C]m [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
pattern [C]p [C]a [C]t [C]t [C]e [C]r [C]n O 
of [C]o [C]f O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
mRNAs [C]m [C]R [C]N [C]A [C]s S-RNA 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
avian [C]a [C]v [C]i [C]a [C]n O 
erythroid [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]i [C]d O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
suggests [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]s O 
that [C]t [C]h [C]a [C]t O 
temporally [C]t [C]e [C]m [C]p [C]o [C]r [C]a [C]l [C]l [C]y O 
regulated [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
in [C]i [C]n O 
GATA [C]G [C]A [C]T [C]A B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
are [C]a [C]r [C]e O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
vertebrate [C]v [C]e [C]r [C]t [C]e [C]b [C]r [C]a [C]t [C]e O 
hematopoiesis [C]h [C]e [C]m [C]a [C]t [C]o [C]p [C]o [C]i [C]e [C]s [C]i [C]s O 
. [C]. O 

Molecular [C]M [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-protein 
interleukin [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n I-protein 
2 [C]2 E-protein 
and [C]a [C]n [C]d O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l S-cell_type 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
interleukin [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n B-protein 
4 [C]4 E-protein 
. [C]. O 

Distinct [C]D [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l B-cell_type 
subsets [C]s [C]u [C]b [C]s [C]e [C]t [C]s E-cell_type 
, [C], O 
differing [C]d [C]i [C]f [C]f [C]e [C]r [C]i [C]n [C]g O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
patterns [C]p [C]a [C]t [C]t [C]e [C]r [C]n [C]s O 
of [C]o [C]f O 
lymphokines [C]l [C]y [C]m [C]p [C]h [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
produced [C]p [C]r [C]o [C]d [C]u [C]c [C]e [C]d O 
, [C], O 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
cell-mediated [C]c [C]e [C]l [C]l [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
and [C]a [C]n [C]d O 
humoral [C]h [C]u [C]m [C]o [C]r [C]a [C]l O 
immune [C]i [C]m [C]m [C]u [C]n [C]e O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
. [C]. O 

The [C]T [C]h [C]e O 
two [C]t [C]w [C]o O 
major [C]m [C]a [C]j [C]o [C]r O 
types [C]t [C]y [C]p [C]e [C]s O 
and [C]a [C]n [C]d O 
their [C]t [C]h [C]e [C]i [C]r O 
principal [C]p [C]r [C]i [C]n [C]c [C]i [C]p [C]a [C]l O 
products [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]s O 
, [C], O 
interleukin [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n B-protein 
4 [C]4 E-protein 
and [C]a [C]n [C]d O 
interferon [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n B-protein 
gamma [C]g [C]a [C]m [C]m [C]a E-protein 
( [C]( O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
and [C]a [C]n [C]d O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
) [C]) O 
, [C], O 
are [C]a [C]r [C]e O 
reciprocally [C]r [C]e [C]c [C]i [C]p [C]r [C]o [C]c [C]a [C]l [C]l [C]y O 
negatively [C]n [C]e [C]g [C]a [C]t [C]i [C]v [C]e [C]l [C]y O 
interactive [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]v [C]e O 
. [C]. O 

To [C]T [C]o O 
analyze [C]a [C]n [C]a [C]l [C]y [C]z [C]e O 
the [C]t [C]h [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
of [C]o [C]f O 
IL-4-mediated [C]I [C]L [C]- [C]4 [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
suppression [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
cell-mediated [C]c [C]e [C]l [C]l [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
immunity [C]i [C]m [C]m [C]u [C]n [C]i [C]t [C]y O 
we [C]w [C]e O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
its [C]i [C]t [C]s O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
on [C]o [C]n O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
interleukin [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n B-protein 
2 [C]2 E-protein 
( [C]( O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a S-protein 
. [C]. O 

IL-4 [C]I [C]L [C]- [C]4 S-protein 
pretreatment [C]p [C]r [C]e [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
Jurkat [C]J [C]u [C]r [C]k [C]a [C]t B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
prior [C]p [C]r [C]i [C]o [C]r O 
to [C]t [C]o O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
a [C]a O 
decrease [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IL2 [C]I [C]L [C]2 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
. [C]. O 

IL-4 [C]I [C]L [C]- [C]4 S-protein 
suppressed [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
IL-2 [C]I [C]L [C]- [C]2 O 
and [C]a [C]n [C]d O 
IFN-gamma [C]I [C]F [C]N [C]- [C]g [C]a [C]m [C]m [C]a O 
mRNA [C]m [C]R [C]N [C]A O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
in [C]i [C]n O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
and [C]a [C]n [C]d O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
anti-CD28 [C]a [C]n [C]t [C]i [C]- [C]C [C]D [C]2 [C]8 B-protein 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s E-protein 
relieved [C]r [C]e [C]l [C]i [C]e [C]v [C]e [C]d O 
this [C]t [C]h [C]i [C]s O 
suppression [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

Using [C]U [C]s [C]i [C]n [C]g O 
enhancer-reporter [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r [C]- [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r B-DNA 
constructs [C]c [C]o [C]n [C]s [C]t [C]r [C]u [C]c [C]t [C]s E-DNA 
, [C], O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
specifically [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]a [C]l [C]l [C]y O 
down-regulated [C]d [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
NFIL-2B [C]N [C]F [C]I [C]L [C]- [C]2 [C]B B-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
. [C]. O 

Electrophoretic [C]E [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
using [C]u [C]s [C]i [C]n [C]g O 
a [C]a O 
DNA [C]D [C]N [C]A O 
oligomer [C]o [C]l [C]i [C]g [C]o [C]m [C]e [C]r O 
containing [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
NFIL-2B [C]N [C]F [C]I [C]L [C]- [C]2 [C]B B-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
indicated [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
NFIL-2B [C]N [C]F [C]I [C]L [C]- [C]2 [C]B B-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
and [C]a [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
NFIL-2B [C]N [C]F [C]I [C]L [C]- [C]2 [C]B B-protein 
DNA [C]D [C]N [C]A I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
is [C]i [C]s O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
from [C]f [C]r [C]o [C]m O 
AP- [C]A [C]P [C]- S-protein 
1 [C]1 O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
IL-4 [C]I [C]L [C]- [C]4 S-protein 
may [C]m [C]a [C]y O 
regulate [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
development [C]d [C]e [C]v [C]e [C]l [C]o [C]p [C]m [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
function [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l B-cell_type 
subsets [C]s [C]u [C]b [C]s [C]e [C]t [C]s E-cell_type 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
cell-mediated [C]c [C]e [C]l [C]l [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
immunity [C]i [C]m [C]m [C]u [C]n [C]i [C]t [C]y O 
in [C]i [C]n O 
part [C]p [C]a [C]r [C]t O 
by [C]b [C]y O 
inhibiting [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]n [C]g B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
IL2 [C]I [C]L [C]2 B-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 

Immunochemical [C]I [C]m [C]m [C]u [C]n [C]o [C]c [C]h [C]e [C]m [C]i [C]c [C]a [C]l O 
differences [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e [C]s O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
from [C]f [C]r [C]o [C]m O 
corticoid-sensitive [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e B-cell_type 
and [C]a [C]n [C]d I-cell_type 
-resistant [C]- [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]t I-cell_type 
malignant [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]t I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
explored [C]e [C]x [C]p [C]l [C]o [C]r [C]e [C]d O 
the [C]t [C]h [C]e O 
possibility [C]p [C]o [C]s [C]s [C]i [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
using [C]u [C]s [C]i [C]n [C]g O 
antibodies [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]i [C]e [C]s S-protein 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d O 
rat [C]r [C]a [C]t O 
liver [C]l [C]i [C]v [C]e [C]r O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
to [C]t [C]o O 
study [C]s [C]t [C]u [C]d [C]y O 
the [C]t [C]h [C]e O 
immunochemical [C]i [C]m [C]m [C]u [C]n [C]o [C]c [C]h [C]e [C]m [C]i [C]c [C]a [C]l O 
properties [C]p [C]r [C]o [C]p [C]e [C]r [C]t [C]i [C]e [C]s O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
from [C]f [C]r [C]o [C]m O 
murine [C]m [C]u [C]r [C]i [C]n [C]e B-cell_type 
and [C]a [C]n [C]d I-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
malignant [C]m [C]a [C]l [C]i [C]g [C]n [C]a [C]n [C]t I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

For [C]F [C]o [C]r O 
this [C]t [C]h [C]i [C]s O 
purpose [C]p [C]u [C]r [C]p [C]o [C]s [C]e O 
, [C], O 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d B-protein 
immune [C]i [C]m [C]m [C]u [C]n [C]e I-protein 
immunoglobulin [C]i [C]m [C]m [C]u [C]n [C]o [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n I-protein 
G [C]G E-protein 
was [C]w [C]a [C]s O 
covalently [C]c [C]o [C]v [C]a [C]l [C]e [C]n [C]t [C]l [C]y O 
linked [C]l [C]i [C]n [C]k [C]e [C]d O 
to [C]t [C]o O 
Sepharose [C]S [C]e [C]p [C]h [C]a [C]r [C]o [C]s [C]e B-protein 
CL-4B [C]C [C]L [C]- [C]4 [C]B E-protein 
. [C]. O 

We [C]W [C]e O 
then [C]t [C]h [C]e [C]n O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
the [C]t [C]h [C]e O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
gel [C]g [C]e [C]l O 
to [C]t [C]o O 
recognize [C]r [C]e [C]c [C]o [C]g [C]n [C]i [C]z [C]e O 
cytosolic [C]c [C]y [C]t [C]o [C]s [C]o [C]l [C]i [C]c B-protein 
[ [C][ I-protein 
3H [C]3 [C]H I-protein 
] [C]] I-protein 
triamcinolone [C]t [C]r [C]i [C]a [C]m [C]c [C]i [C]n [C]o [C]l [C]o [C]n [C]e I-protein 
acetonide-receptor [C]a [C]c [C]e [C]t [C]o [C]n [C]i [C]d [C]e [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
corticoid-sensitive [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e B-cell_line 
( [C]( I-cell_line 
CS [C]C [C]S I-cell_line 
) [C]) I-cell_line 
and [C]a [C]n [C]d I-cell_line 
-resistant [C]- [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]t I-cell_line 
strains [C]s [C]t [C]r [C]a [C]i [C]n [C]s I-cell_line 
of [C]o [C]f I-cell_line 
mouse [C]m [C]o [C]u [C]s [C]e I-cell_line 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a I-cell_line 
P1798 [C]P [C]1 [C]7 [C]9 [C]8 E-cell_line 
, [C], O 
from [C]f [C]r [C]o [C]m O 
CS [C]C [C]S B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
of [C]o [C]f O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
lymphatic [C]l [C]y [C]m [C]p [C]h [C]a [C]t [C]i [C]c O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
, [C], O 
and [C]a [C]n [C]d O 
from [C]f [C]r [C]o [C]m O 
a [C]a O 
CS [C]C [C]S B-cell_line 
clone [C]c [C]l [C]o [C]n [C]e E-cell_line 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
leukemic [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]c I-cell_type 
lymphoblasts [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]s E-cell_type 
in [C]i [C]n O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
( [C]( O 
CH6 [C]C [C]H [C]6 S-cell_line 
) [C]) O 
. [C]. O 

Mouse [C]M [C]o [C]u [C]s [C]e O 
thymus [C]t [C]h [C]y [C]m [C]u [C]s O 
was [C]w [C]a [C]s O 
used [C]u [C]s [C]e [C]d O 
as [C]a [C]s O 
a [C]a O 
source [C]s [C]o [C]u [C]r [C]c [C]e O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
from [C]f [C]r [C]o [C]m O 
normal [C]n [C]o [C]r [C]m [C]a [C]l B-cell_type 
CS [C]C [C]S I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

Whereas [C]W [C]h [C]e [C]r [C]e [C]a [C]s O 
the [C]t [C]h [C]e O 
immunoaffinity [C]i [C]m [C]m [C]u [C]n [C]o [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
column [C]c [C]o [C]l [C]u [C]m [C]n O 
retained [C]r [C]e [C]t [C]a [C]i [C]n [C]e [C]d O 
70 [C]7 [C]0 O 
to [C]t [C]o O 
84 [C]8 [C]4 O 
% [C]% O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
58- [C]5 [C]8 [C]- O 
to [C]t [C]o O 
62-A [C]6 [C]2 [C]- [C]A O 
( [C]( O 
Stokes [C]S [C]t [C]o [C]k [C]e [C]s O 
radius [C]r [C]a [C]d [C]i [C]u [C]s O 
) [C]) O 
[ [C][ B-protein 
3H [C]3 [C]H I-protein 
] [C]] I-protein 
triamcinolone [C]t [C]r [C]i [C]a [C]m [C]c [C]i [C]n [C]o [C]l [C]o [C]n [C]e I-protein 
acetonide-receptor [C]a [C]c [C]e [C]t [C]o [C]n [C]i [C]d [C]e [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
characteristic [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]s [C]t [C]i [C]c O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
CS [C]C [C]S B-cell_line 
mouse [C]m [C]o [C]u [C]s [C]e I-cell_line 
and [C]a [C]n [C]d I-cell_line 
human [C]h [C]u [C]m [C]a [C]n I-cell_line 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_line 
, [C], O 
it [C]i [C]t O 
failed [C]f [C]a [C]i [C]l [C]e [C]d O 
to [C]t [C]o O 
recognize [C]r [C]e [C]c [C]o [C]g [C]n [C]i [C]z [C]e O 
the [C]t [C]h [C]e O 
27- [C]2 [C]7 [C]- O 
to [C]t [C]o O 
28-A [C]2 [C]8 [C]- [C]A O 
( [C]( O 
Stokes [C]S [C]t [C]o [C]k [C]e [C]s O 
radius [C]r [C]a [C]d [C]i [C]u [C]s O 
) [C]) O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
in [C]i [C]n O 
corticoid-resistant [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]- [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]t O 
mouse [C]m [C]o [C]u [C]s [C]e B-cell_line 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a I-cell_line 
P1798 [C]P [C]1 [C]7 [C]9 [C]8 I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

Therefore [C]T [C]h [C]e [C]r [C]e [C]f [C]o [C]r [C]e O 
, [C], O 
under [C]u [C]n [C]d [C]e [C]r O 
appropriate [C]a [C]p [C]p [C]r [C]o [C]p [C]r [C]i [C]a [C]t [C]e O 
experimental [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]a [C]l O 
conditions [C]c [C]o [C]n [C]d [C]i [C]t [C]i [C]o [C]n [C]s O 
, [C], O 
it [C]i [C]t O 
was [C]w [C]a [C]s O 
possible [C]p [C]o [C]s [C]s [C]i [C]b [C]l [C]e O 
to [C]t [C]o O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
cross-reactivity [C]c [C]r [C]o [C]s [C]s [C]- [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
antiserum [C]a [C]n [C]t [C]i [C]s [C]e [C]r [C]u [C]m O 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
rat [C]r [C]a [C]t B-protein 
liver [C]l [C]i [C]v [C]e [C]r I-protein 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
58- [C]5 [C]8 [C]- O 
to [C]t [C]o O 
62-A [C]6 [C]2 [C]- [C]A O 
( [C]( O 
Stokes [C]S [C]t [C]o [C]k [C]e [C]s O 
radius [C]r [C]a [C]d [C]i [C]u [C]s O 
) [C]) O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
from [C]f [C]r [C]o [C]m O 
species [C]s [C]p [C]e [C]c [C]i [C]e [C]s O 
as [C]a [C]s O 
diverse [C]d [C]i [C]v [C]e [C]r [C]s [C]e O 
as [C]a [C]s O 
mouse [C]m [C]o [C]u [C]s [C]e O 
and [C]a [C]n [C]d O 
humans [C]h [C]u [C]m [C]a [C]n [C]s O 
. [C]. O 

Heterogeneity [C]H [C]e [C]t [C]e [C]r [C]o [C]g [C]e [C]n [C]e [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
responses [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e [C]s O 
to [C]t [C]o O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
in [C]i [C]n O 
acute [C]a [C]c [C]u [C]t [C]e O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
. [C]. O 

In [C]I [C]n O 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e B-cell_type 
population [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n E-cell_type 
freshly [C]f [C]r [C]e [C]s [C]h [C]l [C]y O 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
blood [C]b [C]l [C]o [C]o [C]d O 
of [C]o [C]f O 
26 [C]2 [C]6 O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
acute [C]a [C]c [C]u [C]t [C]e O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a O 
, [C], O 
we [C]w [C]e O 
have [C]h [C]a [C]v [C]e O 
measured [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]d O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
parameters [C]p [C]a [C]r [C]a [C]m [C]e [C]t [C]e [C]r [C]s O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
, [C], O 
nucleoside [C]n [C]u [C]c [C]l [C]e [C]o [C]s [C]i [C]d [C]e O 
incorporation [C]i [C]n [C]c [C]o [C]r [C]p [C]o [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
percentage [C]p [C]e [C]r [C]c [C]e [C]n [C]t [C]a [C]g [C]e O 
of [C]o [C]f O 
cells [C]c [C]e [C]l [C]l [C]s O 
in [C]i [C]n O 
S [C]S O 
phase [C]p [C]h [C]a [C]s [C]e O 
, [C], O 
and [C]a [C]n [C]d O 
steroid-induced [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
cell [C]c [C]e [C]l [C]l O 
lysis [C]l [C]y [C]s [C]i [C]s O 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
in [C]i [C]n O 
some [C]s [C]o [C]m [C]e O 
cases [C]c [C]a [C]s [C]e [C]s O 
, [C], O 
the [C]t [C]h [C]e O 
short-term [C]s [C]h [C]o [C]r [C]t [C]- [C]t [C]e [C]r [C]m O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
therapy [C]t [C]h [C]e [C]r [C]a [C]p [C]y O 
was [C]w [C]a [C]s O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
, [C], O 
in [C]i [C]n O 
all [C]a [C]l [C]l O 
the [C]t [C]h [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
, [C], O 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
were [C]w [C]e [C]r [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
contain [C]c [C]o [C]n [C]t [C]a [C]i [C]n O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
, [C], O 
we [C]w [C]e O 
failed [C]f [C]a [C]i [C]l [C]e [C]d O 
to [C]t [C]o O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
any [C]a [C]n [C]y O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
sites [C]s [C]i [C]t [C]e [C]s O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
or [C]o [C]r O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
could [C]c [C]o [C]u [C]l [C]d O 
be [C]b [C]e O 
in [C]i [C]n O 
part [C]p [C]a [C]r [C]t O 
explained [C]e [C]x [C]p [C]l [C]a [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
marked [C]m [C]a [C]r [C]k [C]e [C]d O 
heterogeneity [C]h [C]e [C]t [C]e [C]r [C]o [C]g [C]e [C]n [C]e [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
leukocyte [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e O 
subpopulations [C]s [C]u [C]b [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

It [C]I [C]t O 
appears [C]a [C]p [C]p [C]e [C]a [C]r [C]s O 
, [C], O 
however [C]h [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
degree [C]d [C]e [C]g [C]r [C]e [C]e O 
of [C]o [C]f O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
action [C]a [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
the [C]t [C]h [C]e O 
extent [C]e [C]x [C]t [C]e [C]n [C]t O 
of [C]o [C]f O 
spontaneous [C]s [C]p [C]o [C]n [C]t [C]a [C]n [C]e [C]o [C]u [C]s O 
and [C]a [C]n [C]d O 
dexamethasone-induced [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
cell [C]c [C]e [C]l [C]l O 
death [C]d [C]e [C]a [C]t [C]h O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
related [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
cells [C]c [C]e [C]l [C]l [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
S [C]S O 
phase [C]p [C]h [C]a [C]s [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cell [C]c [C]e [C]l [C]l O 
cycle [C]c [C]y [C]c [C]l [C]e O 
. [C]. O 

Glucocorticoid [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
and [C]a [C]n [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
extract [C]e [C]x [C]t [C]r [C]a [C]c [C]t O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

Cortisol [C]C [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
by [C]b [C]y O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
and [C]a [C]n [C]d O 
0.4 [C]0 [C]. [C]4 O 
M [C]M O 
KCl [C]K [C]C [C]l O 
extract [C]e [C]x [C]t [C]r [C]a [C]c [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
fraction [C]f [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
leukocytes [C]l [C]e [C]u [C]k [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
by [C]b [C]y O 
gel [C]g [C]e [C]l O 
chromatography [C]c [C]h [C]r [C]o [C]m [C]a [C]t [C]o [C]g [C]r [C]a [C]p [C]h [C]y O 
and [C]a [C]n [C]d O 
ion [C]i [C]o [C]n O 
exchange [C]e [C]x [C]c [C]h [C]a [C]n [C]g [C]e O 
filtration [C]f [C]i [C]l [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
on [C]o [C]n O 
DEAE [C]D [C]E [C]A [C]E O 
cellulose [C]c [C]e [C]l [C]l [C]u [C]l [C]o [C]s [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c B-protein 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
has [C]h [C]a [C]s O 
a [C]a O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
weight [C]w [C]e [C]i [C]g [C]h [C]t O 
95 [C]9 [C]5 O 
000 [C]0 [C]0 [C]0 O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
soluble [C]s [C]o [C]l [C]u [C]b [C]l [C]e B-protein 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
50 [C]5 [C]0 O 
000 [C]0 [C]0 [C]0 O 
. [C]. O 

The [C]T [C]h [C]e O 
absence [C]a [C]b [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
uptake [C]u [C]p [C]t [C]a [C]k [C]e O 
of [C]o [C]f O 
radioactive [C]r [C]a [C]d [C]i [C]o [C]a [C]c [C]t [C]i [C]v [C]e O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
by [C]b [C]y O 
isolated [C]i [C]s [C]o [C]l [C]a [C]t [C]e [C]d O 
nuclei [C]n [C]u [C]c [C]l [C]e [C]i O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
apparent [C]a [C]p [C]p [C]a [C]r [C]e [C]n [C]t O 
requirement [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
for [C]f [C]o [C]r O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
in [C]i [C]n O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
sites [C]s [C]i [C]t [C]e [C]s O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
. [C]. O 

The [C]T [C]h [C]e O 
association [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
constant [C]c [C]o [C]n [C]s [C]t [C]a [C]n [C]t O 
characterising [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]s [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
to [C]t [C]o O 
cytosol [C]c [C]y [C]t [C]o [C]s [C]o [C]l O 
was [C]w [C]a [C]s O 
KA [C]K [C]A O 
= [C]= O 
3.5 [C]3 [C]. [C]5 O 
. [C]. O 
10 [C]1 [C]0 O 
( [C]( O 
9 [C]9 O 
) [C]) O 
l/mol [C]l [C]/ [C]m [C]o [C]l O 
. [C]. O 

Corticosteroid-induced [C]C [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
lymphopenia [C]l [C]y [C]m [C]p [C]h [C]o [C]p [C]e [C]n [C]i [C]a O 
, [C], O 
immunosuppression [C]i [C]m [C]m [C]u [C]n [C]o [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
body [C]b [C]o [C]d [C]y O 
defense [C]d [C]e [C]f [C]e [C]n [C]s [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
apparent [C]a [C]p [C]p [C]a [C]r [C]e [C]n [C]t O 
paradox [C]p [C]a [C]r [C]a [C]d [C]o [C]x O 
of [C]o [C]f O 
heightened [C]h [C]e [C]i [C]g [C]h [C]t [C]e [C]n [C]e [C]d O 
adrenal [C]a [C]d [C]r [C]e [C]n [C]a [C]l O 
corticosteroid [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
reduction [C]r [C]e [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
competence [C]c [C]o [C]m [C]p [C]e [C]t [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
body [C]b [C]o [C]d [C]y O 
's [C]' [C]s O 
defensive [C]d [C]e [C]f [C]e [C]n [C]s [C]i [C]v [C]e O 
apparatus [C]a [C]p [C]p [C]a [C]r [C]a [C]t [C]u [C]s O 
to [C]t [C]o O 
cope [C]c [C]o [C]p [C]e O 
with [C]w [C]i [C]t [C]h O 
exposure [C]e [C]x [C]p [C]o [C]s [C]u [C]r [C]e O 
to [C]t [C]o O 
new [C]n [C]e [C]w O 
microbial [C]m [C]i [C]c [C]r [C]o [C]b [C]i [C]a [C]l B-protein 
antigens [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]s E-protein 
is [C]i [C]s O 
considered [C]c [C]o [C]n [C]s [C]i [C]d [C]e [C]r [C]e [C]d O 
. [C]. O 

The [C]T [C]h [C]e O 
question [C]q [C]u [C]e [C]s [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
asked [C]a [C]s [C]k [C]e [C]d O 
how [C]h [C]o [C]w O 
this [C]t [C]h [C]i [C]s O 
lowered [C]l [C]o [C]w [C]e [C]r [C]e [C]d O 
defensive [C]d [C]e [C]f [C]e [C]n [C]s [C]i [C]v [C]e O 
capability [C]c [C]a [C]p [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
occurs [C]o [C]c [C]c [C]u [C]r [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
face [C]f [C]a [C]c [C]e O 
of [C]o [C]f O 
a [C]a O 
threat [C]t [C]h [C]r [C]e [C]a [C]t O 
to [C]t [C]o O 
body [C]b [C]o [C]d [C]y O 
integrity [C]i [C]n [C]t [C]e [C]g [C]r [C]i [C]t [C]y O 
, [C], O 
is [C]i [C]s O 
consistent [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
Cannon [C]C [C]a [C]n [C]n [C]o [C]n O 
's [C]' [C]s O 
principals [C]p [C]r [C]i [C]n [C]c [C]i [C]p [C]a [C]l [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
`` [C]` [C]` O 
wisdom [C]w [C]i [C]s [C]d [C]o [C]m O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
body. [C]b [C]o [C]d [C]y [C]. O 
'' [C]' [C]' O 

The [C]T [C]h [C]e O 
suggestion [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
offered [C]o [C]f [C]f [C]e [C]r [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
immunologic [C]i [C]m [C]m [C]u [C]n [C]o [C]l [C]o [C]g [C]i [C]c O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
self-antigens [C]s [C]e [C]l [C]f [C]- [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]s S-protein 
exposed [C]e [C]x [C]p [C]o [C]s [C]e [C]d O 
by [C]b [C]y O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
or [C]o [C]r O 
trauma [C]t [C]r [C]a [C]u [C]m [C]a O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
suppressed [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
by [C]b [C]y O 
corticosteroid [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
to [C]t [C]o O 
offset [C]o [C]f [C]f [C]s [C]e [C]t O 
the [C]t [C]h [C]e O 
likelihood [C]l [C]i [C]k [C]e [C]l [C]i [C]h [C]o [C]o [C]d O 
of [C]o [C]f O 
autoimmune [C]a [C]u [C]t [C]o [C]i [C]m [C]m [C]u [C]n [C]e O 
attack [C]a [C]t [C]t [C]a [C]c [C]k O 
. [C]. O 

Protein [C]P [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e I-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e E-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
lipopolysaccharide [C]l [C]i [C]p [C]o [C]p [C]o [C]l [C]y [C]s [C]a [C]c [C]c [C]h [C]a [C]r [C]i [C]d [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

Bacterial [C]B [C]a [C]c [C]t [C]e [C]r [C]i [C]a [C]l O 
LPS [C]L [C]P [C]S O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
IL-1 [C]I [C]L [C]- [C]1 S-protein 
, [C], O 
IL-6 [C]I [C]L [C]- [C]6 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
TNF [C]T [C]N [C]F S-protein 
in [C]i [C]n O 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-cell_type 
phagocytes [C]p [C]h [C]a [C]g [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
, [C], O 
and [C]a [C]n [C]d O 
this [C]t [C]h [C]i [C]s O 
represents [C]r [C]e [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]s O 
a [C]a O 
central [C]c [C]e [C]n [C]t [C]r [C]a [C]l O 
component [C]c [C]o [C]m [C]p [C]o [C]n [C]e [C]n [C]t O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
pathogenesis [C]p [C]a [C]t [C]h [C]o [C]g [C]e [C]n [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
septic [C]s [C]e [C]p [C]t [C]i [C]c O 
shock [C]s [C]h [C]o [C]c [C]k O 
syndrome [C]s [C]y [C]n [C]d [C]r [C]o [C]m [C]e O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
the [C]t [C]h [C]e O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
by [C]b [C]y O 
which [C]w [C]h [C]i [C]c [C]h O 
LPS [C]L [C]P [C]S O 
activates [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]s O 
these [C]t [C]h [C]e [C]s [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
to [C]t [C]o O 
express [C]e [C]x [C]p [C]r [C]e [C]s [C]s O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
are [C]a [C]r [C]e O 
not [C]n [C]o [C]t O 
completely [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e [C]l [C]y O 
characterized [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]d O 
. [C]. O 

The [C]T [C]h [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
study [C]s [C]t [C]u [C]d [C]y O 
addressed [C]a [C]d [C]d [C]r [C]e [C]s [C]s [C]e [C]d O 
the [C]t [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
kinases [C]k [C]i [C]n [C]a [C]s [C]e [C]s E-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
LPS [C]L [C]P [C]S O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
. [C]. O 

It [C]I [C]t O 
is [C]i [C]s O 
shown [C]s [C]h [C]o [C]w [C]n O 
that [C]t [C]h [C]a [C]t O 
LPS [C]L [C]P [C]S O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
a [C]a O 
12- [C]1 [C]2 [C]- O 
to [C]t [C]o O 
16-fold [C]1 [C]6 [C]- [C]f [C]o [C]l [C]d O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
IL-1 [C]I [C]L [C]- [C]1 O 
beta [C]b [C]e [C]t [C]a O 
, [C], O 
IL-6 [C]I [C]L [C]- [C]6 O 
, [C], O 
and [C]a [C]n [C]d O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a O 
mRNA [C]m [C]R [C]N [C]A O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
, [C], O 
and [C]a [C]n [C]d O 
this [C]t [C]h [C]i [C]s O 
was [C]w [C]a [C]s O 
completely [C]c [C]o [C]m [C]p [C]l [C]e [C]t [C]e [C]l [C]y O 
or [C]o [C]r O 
more [C]m [C]o [C]r [C]e O 
than [C]t [C]h [C]a [C]n O 
80 [C]8 [C]0 O 
% [C]% O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
herbimycin [C]h [C]e [C]r [C]b [C]i [C]m [C]y [C]c [C]i [C]n O 
A [C]A O 
and [C]a [C]n [C]d O 
genistein [C]g [C]e [C]n [C]i [C]s [C]t [C]e [C]i [C]n O 
at [C]a [C]t O 
the [C]t [C]h [C]e O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
1.7 [C]1 [C]. [C]7 O 
and [C]a [C]n [C]d O 
37 [C]3 [C]7 O 
microM [C]m [C]i [C]c [C]r [C]o [C]M O 
, [C], O 
respectively [C]r [C]e [C]s [C]p [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
. [C]. O 

Protein [C]P [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
C [C]C E-protein 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
staurosporine [C]s [C]t [C]a [C]u [C]r [C]o [C]s [C]p [C]o [C]r [C]i [C]n [C]e O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
LPS [C]L [C]P [C]S O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-protein 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
it [C]i [C]t O 
had [C]h [C]a [C]d O 
no [C]n [C]o O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
on [C]o [C]n O 
IL-6 [C]I [C]L [C]- [C]6 S-protein 
and [C]a [C]n [C]d O 
IL-1 [C]I [C]L [C]- [C]1 O 
beta [C]b [C]e [C]t [C]a O 
. [C]. O 

Inhibition [C]I [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
A [C]A E-protein 
by [C]b [C]y O 
H89 [C]H [C]8 [C]9 O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
IL-6 [C]I [C]L [C]- [C]6 B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
but [C]b [C]u [C]t O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
detectably [C]d [C]e [C]t [C]e [C]c [C]t [C]a [C]b [C]l [C]y O 
change [C]c [C]h [C]a [C]n [C]g [C]e O 
IL-1 [C]I [C]L [C]- [C]1 O 
beta [C]b [C]e [C]t [C]a O 
or [C]o [C]r O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a O 
mRNA [C]m [C]R [C]N [C]A O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
. [C]. O 

In [C]I [C]n O 
contrast [C]c [C]o [C]n [C]t [C]r [C]a [C]s [C]t O 
, [C], O 
LPS [C]L [C]P [C]S O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a B-RNA 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y I-RNA 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
was [C]w [C]a [C]s O 
constitutively [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
and [C]a [C]n [C]d O 
not [C]n [C]o [C]t O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
these [C]t [C]h [C]e [C]s [C]e O 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
to [C]t [C]o O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e B-RNA 
mRNA [C]m [C]R [C]N [C]A E-RNA 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
, [C], O 
LPS-induced [C]L [C]P [C]S [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
IL-6 [C]I [C]L [C]- [C]6 O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
and [C]a [C]n [C]d O 
IL-6 [C]I [C]L [C]- [C]6 O 
bioactivity [C]b [C]i [C]o [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
were [C]w [C]e [C]r [C]e O 
also [C]a [C]l [C]s [C]o O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
to [C]t [C]o O 
baseline [C]b [C]a [C]s [C]e [C]l [C]i [C]n [C]e O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
PTK [C]P [C]T [C]K O 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
herbimycin [C]h [C]e [C]r [C]b [C]i [C]m [C]y [C]c [C]i [C]n O 
A [C]A O 
and [C]a [C]n [C]d O 
genistein [C]g [C]e [C]n [C]i [C]s [C]t [C]e [C]i [C]n O 
. [C]. O 

Both [C]B [C]o [C]t [C]h O 
PTK [C]P [C]T [C]K O 
inhibitors [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]s O 
also [C]a [C]l [C]s [C]o O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
the [C]t [C]h [C]e O 
LPS [C]L [C]P [C]S O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
factor-kappa [C]f [C]a [C]c [C]t [C]o [C]r [C]- [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
( [C]( O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
) [C]) O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
a [C]a O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
cytokine [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e B-RNA 
genes [C]g [C]e [C]n [C]e [C]s E-RNA 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
IL-6 [C]I [C]L [C]- [C]6 S-DNA 
and [C]a [C]n [C]d O 
TNF-alpha [C]T [C]N [C]F [C]- [C]a [C]l [C]p [C]h [C]a S-DNA 
. [C]. O 

The [C]T [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
was [C]w [C]a [C]s O 
also [C]a [C]l [C]s [C]o O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
H89 [C]H [C]8 [C]9 O 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
staurosporine [C]s [C]t [C]a [C]u [C]r [C]o [C]s [C]p [C]o [C]r [C]i [C]n [C]e O 
had [C]h [C]a [C]d O 
no [C]n [C]o O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
on [C]o [C]n O 
this [C]t [C]h [C]i [C]s O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
. [C]. O 

In [C]I [C]n O 
summary [C]s [C]u [C]m [C]m [C]a [C]r [C]y O 
, [C], O 
these [C]t [C]h [C]e [C]s [C]e O 
findings [C]f [C]i [C]n [C]d [C]i [C]n [C]g [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
C [C]C E-protein 
and [C]a [C]n [C]d O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
A [C]A E-protein 
appear [C]a [C]p [C]p [C]e [C]a [C]r O 
to [C]t [C]o O 
have [C]h [C]a [C]v [C]e O 
selective [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
LPS [C]L [C]P [C]S O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
, [C], O 
whereas [C]w [C]h [C]e [C]r [C]e [C]a [C]s O 
PTK [C]P [C]T [C]K S-protein 
is [C]i [C]s O 
required [C]r [C]e [C]q [C]u [C]i [C]r [C]e [C]d O 
for [C]f [C]o [C]r O 
LPS [C]L [C]P [C]S O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
broad [C]b [C]r [C]o [C]a [C]d O 
spectrum [C]s [C]p [C]e [C]c [C]t [C]r [C]u [C]m O 
of [C]o [C]f O 
cytokines [C]c [C]y [C]t [C]o [C]k [C]i [C]n [C]e [C]s S-protein 
and [C]a [C]n [C]d O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
. [C]. O 

In [C]I [C]n O 
vivo [C]v [C]i [C]v [C]o O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
I [C]I B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B I-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
is [C]i [C]s O 
stored [C]s [C]t [C]o [C]r [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
cytoplasm [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m O 
in [C]i [C]n O 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
I [C]I I-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B I-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
. [C]. O 

It [C]I [C]t O 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
shown [C]s [C]h [C]o [C]w [C]n O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
that [C]t [C]h [C]a [C]t O 
dissociation [C]d [C]i [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
I [C]I B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B I-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
from [C]f [C]r [C]o [C]m O 
these [C]t [C]h [C]e [C]s [C]e O 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
in [C]i [C]n O 
active [C]a [C]c [C]t [C]i [C]v [C]e B-protein 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
we [C]w [C]e O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
lipopolysaccharide [C]l [C]i [C]p [C]o [C]p [C]o [C]l [C]y [C]s [C]a [C]c [C]c [C]h [C]a [C]r [C]i [C]d [C]e O 
( [C]( O 
LPS [C]L [C]P [C]S O 
) [C]) O 
-induced [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
B [C]B B-cell_type 
or [C]o [C]r I-cell_type 
pre-B [C]p [C]r [C]e [C]- [C]B I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
in [C]i [C]n O 
loss [C]l [C]o [C]s [C]s O 
of [C]o [C]f O 
I [C]I B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B I-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
from [C]f [C]r [C]o [C]m O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B I-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
. [C]. O 

Many [C]M [C]a [C]n [C]y O 
liberated [C]l [C]i [C]b [C]e [C]r [C]a [C]t [C]e [C]d O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B I-protein 
dimers [C]d [C]i [C]m [C]e [C]r [C]s E-protein 
reached [C]r [C]e [C]a [C]c [C]h [C]e [C]d O 
the [C]t [C]h [C]e O 
nucleus [C]n [C]u [C]c [C]l [C]e [C]u [C]s O 
, [C], O 
where [C]w [C]h [C]e [C]r [C]e O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
c-rel [C]c [C]- [C]r [C]e [C]l S-protein 
, [C], O 
p65 [C]p [C]6 [C]5 O 
and [C]a [C]n [C]d O 
p50 [C]p [C]5 [C]0 O 
were [C]w [C]e [C]r [C]e O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
by [C]b [C]y O 
immunoblotting [C]i [C]m [C]m [C]u [C]n [C]o [C]b [C]l [C]o [C]t [C]t [C]i [C]n [C]g O 
and [C]a [C]n [C]d O 
by [C]b [C]y O 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
. [C]. O 

Some [C]S [C]o [C]m [C]e O 
liberated [C]l [C]i [C]b [C]e [C]r [C]a [C]t [C]e [C]d B-protein 
dimers [C]d [C]i [C]m [C]e [C]r [C]s E-protein 
were [C]w [C]e [C]r [C]e O 
retained [C]r [C]e [C]t [C]a [C]i [C]n [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
cytoplasm [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m O 
, [C], O 
however [C]h [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
newly [C]n [C]e [C]w [C]l [C]y O 
synthesized [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]z [C]e [C]d O 
I [C]I B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B I-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
, [C], O 
a [C]a O 
finding [C]f [C]i [C]n [C]d [C]i [C]n [C]g O 
which [C]w [C]h [C]i [C]c [C]h O 
strongly [C]s [C]t [C]r [C]o [C]n [C]g [C]l [C]y O 
suggests [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]s O 
( [C]( O 
i [C]i O 
) [C]) O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
LPS-induced [C]L [C]P [C]S [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
causes [C]c [C]a [C]u [C]s [C]e [C]s O 
dissociation [C]d [C]i [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s O 
rather [C]r [C]a [C]t [C]h [C]e [C]r O 
than [C]t [C]h [C]a [C]n O 
preventing [C]p [C]r [C]e [C]v [C]e [C]n [C]t [C]i [C]n [C]g O 
their [C]t [C]h [C]e [C]i [C]r O 
association [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
( [C]( O 
ii [C]i [C]i O 
) [C]) O 
that [C]t [C]h [C]a [C]t O 
dissociation [C]d [C]i [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
from [C]f [C]r [C]o [C]m O 
modification [C]m [C]o [C]d [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
I [C]I B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B I-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
and [C]a [C]n [C]d O 
not [C]n [C]o [C]t O 
of [C]o [C]f O 
c-rel [C]c [C]- [C]r [C]e [C]l S-protein 
or [C]o [C]r O 
p65 [C]p [C]6 [C]5 S-protein 
. [C]. O 

No [C]N [C]o O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
LPS [C]L [C]P [C]S O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
was [C]w [C]a [C]s O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
on [C]o [C]n O 
p105 [C]p [C]1 [C]0 [C]5 S-protein 
or [C]o [C]r O 
p100 [C]p [C]1 [C]0 [C]0 S-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
also [C]a [C]l [C]s [C]o O 
retain [C]r [C]e [C]t [C]a [C]i [C]n O 
rel [C]r [C]e [C]l B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y I-protein 
members [C]m [C]e [C]m [C]b [C]e [C]r [C]s E-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
cytoplasm [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m O 
. [C]. O 

Quite [C]Q [C]u [C]i [C]t [C]e O 
unexpectedly [C]u [C]n [C]e [C]x [C]p [C]e [C]c [C]t [C]e [C]d [C]l [C]y O 
, [C], O 
we [C]w [C]e O 
also [C]a [C]l [C]s [C]o O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
in [C]i [C]n O 
unstimulated [C]u [C]n [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
there [C]t [C]h [C]e [C]r [C]e O 
is [C]i [C]s O 
a [C]a O 
constant [C]c [C]o [C]n [C]s [C]t [C]a [C]n [C]t O 
ongoing [C]o [C]n [C]g [C]o [C]i [C]n [C]g O 
process [C]p [C]r [C]o [C]c [C]e [C]s [C]s O 
of [C]o [C]f O 
degradation [C]d [C]e [C]g [C]r [C]a [C]d [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
replacement [C]r [C]e [C]p [C]l [C]a [C]c [C]e [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
complexed [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]d B-protein 
I [C]I I-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B I-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
. [C]. O 

We [C]W [C]e O 
propose [C]p [C]r [C]o [C]p [C]o [C]s [C]e O 
that [C]t [C]h [C]a [C]t O 
this [C]t [C]h [C]i [C]s O 
turnover [C]t [C]u [C]r [C]n [C]o [C]v [C]e [C]r O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
low [C]l [C]o [C]w O 
level [C]l [C]e [C]v [C]e [C]l O 
of [C]o [C]f O 
active [C]a [C]c [C]t [C]i [C]v [C]e B-protein 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
presumably [C]p [C]r [C]e [C]s [C]u [C]m [C]a [C]b [C]l [C]y O 
necessary [C]n [C]e [C]c [C]e [C]s [C]s [C]a [C]r [C]y O 
even [C]e [C]v [C]e [C]n O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
unstimulated [C]u [C]n [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
cell [C]c [C]e [C]l [C]l O 
, [C], O 
and [C]a [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
high [C]h [C]i [C]g [C]h O 
rate [C]r [C]a [C]t [C]e O 
of [C]o [C]f O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
I [C]I B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B I-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
provides [C]p [C]r [C]o [C]v [C]i [C]d [C]e [C]s O 
the [C]t [C]h [C]e O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
to [C]t [C]o O 
turn [C]t [C]u [C]r [C]n O 
off [C]o [C]f [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
rapidly [C]r [C]a [C]p [C]i [C]d [C]l [C]y O 
as [C]a [C]s O 
soon [C]s [C]o [C]o [C]n O 
as [C]a [C]s O 
the [C]t [C]h [C]e O 
activating [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]n [C]g O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
ceases [C]c [C]e [C]a [C]s [C]e [C]s O 
. [C]. O 

Identification [C]I [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
killer [C]k [C]i [C]l [C]l [C]e [C]r B-DNA 
cell-specific [C]c [C]e [C]l [C]l [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c I-DNA 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y I-DNA 
element [C]e [C]l [C]e [C]m [C]e [C]n [C]t E-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
mouse [C]m [C]o [C]u [C]s [C]e B-DNA 
perforin [C]p [C]e [C]r [C]f [C]o [C]r [C]i [C]n I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
: [C]: O 
an [C]a [C]n O 
Ets-binding [C]E [C]t [C]s [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
site-homologous [C]s [C]i [C]t [C]e [C]- [C]h [C]o [C]m [C]o [C]l [C]o [C]g [C]o [C]u [C]s O 
motif [C]m [C]o [C]t [C]i [C]f O 
that [C]t [C]h [C]a [C]t O 
interacts [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
Ets-related [C]E [C]t [C]s [C]- [C]r [C]e [C]l [C]a [C]t [C]e [C]d B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
gene [C]g [C]e [C]n [C]e O 
encoding [C]e [C]n [C]c [C]o [C]d [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
cytolytic [C]c [C]y [C]t [C]o [C]l [C]y [C]t [C]i [C]c B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
perforin [C]p [C]e [C]r [C]f [C]o [C]r [C]i [C]n S-protein 
is [C]i [C]s O 
selectively [C]s [C]e [C]l [C]e [C]c [C]t [C]i [C]v [C]e [C]l [C]y O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
by [C]b [C]y O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-cell_type 
killer [C]k [C]i [C]l [C]l [C]e [C]r I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

To [C]T [C]o O 
understand [C]u [C]n [C]d [C]e [C]r [C]s [C]t [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
underlying [C]u [C]n [C]d [C]e [C]r [C]l [C]y [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
cell-type-specific [C]c [C]e [C]l [C]l [C]- [C]t [C]y [C]p [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
gene [C]g [C]e [C]n [C]e O 
, [C], O 
we [C]w [C]e O 
have [C]h [C]a [C]v [C]e O 
characterized [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]d O 
the [C]t [C]h [C]e O 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
functions [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]s O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
DNA-protein [C]D [C]N [C]A [C]- [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
interactions [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
5'-flanking [C]5 [C]' [C]- [C]f [C]l [C]a [C]n [C]k [C]i [C]n [C]g B-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
mouse [C]m [C]o [C]u [C]s [C]e B-DNA 
perforin [C]p [C]e [C]r [C]f [C]o [C]r [C]i [C]n I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
( [C]( O 
Pfp [C]P [C]f [C]p S-DNA 
) [C]) O 
. [C]. O 

A [C]A O 
region [C]r [C]e [C]g [C]i [C]o [C]n O 
extending [C]e [C]x [C]t [C]e [C]n [C]d [C]i [C]n [C]g O 
from [C]f [C]r [C]o [C]m O 
residues [C]r [C]e [C]s [C]i [C]d [C]u [C]e [C]s B-DNA 
+62 [C]+ [C]6 [C]2 I-DNA 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h I-DNA 
-141 [C]- [C]1 [C]4 [C]1 E-DNA 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
possesses [C]p [C]o [C]s [C]s [C]e [C]s [C]s [C]e [C]s O 
the [C]t [C]h [C]e O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
, [C], O 
and [C]a [C]n [C]d O 
regions [C]r [C]e [C]g [C]i [C]o [C]n [C]s O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
upstream [C]u [C]p [C]s [C]t [C]r [C]e [C]a [C]m O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
are [C]a [C]r [C]e O 
able [C]a [C]b [C]l [C]e O 
to [C]t [C]o O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
enhance [C]e [C]n [C]h [C]a [C]n [C]c [C]e O 
or [C]o [C]r O 
suppress [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
were [C]w [C]e [C]r [C]e O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
. [C]. O 

The [C]T [C]h [C]e O 
region [C]r [C]e [C]g [C]i [C]o [C]n O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
residues [C]r [C]e [C]s [C]i [C]d [C]u [C]e [C]s B-DNA 
-411 [C]- [C]4 [C]1 [C]1 I-DNA 
and [C]a [C]n [C]d I-DNA 
-566 [C]- [C]5 [C]6 [C]6 E-DNA 
was [C]w [C]a [C]s O 
chosen [C]c [C]h [C]o [C]s [C]e [C]n O 
for [C]f [C]o [C]r O 
further [C]f [C]u [C]r [C]t [C]h [C]e [C]r O 
characterization [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
since [C]s [C]i [C]n [C]c [C]e O 
it [C]i [C]t O 
contains [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]s O 
an [C]a [C]n O 
enhancer-like [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r [C]- [C]l [C]i [C]k [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
identified [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
a [C]a O 
32-mer [C]3 [C]2 [C]- [C]m [C]e [C]r O 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
( [C]( O 
residues [C]r [C]e [C]s [C]i [C]d [C]u [C]e [C]s B-DNA 
-491 [C]- [C]4 [C]9 [C]1 I-DNA 
to [C]t [C]o I-DNA 
-522 [C]- [C]5 [C]2 [C]2 E-DNA 
) [C]) O 
which [C]w [C]h [C]i [C]c [C]h O 
appeared [C]a [C]p [C]p [C]e [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
capable [C]c [C]a [C]p [C]a [C]b [C]l [C]e O 
of [C]o [C]f O 
enhancing [C]e [C]n [C]h [C]a [C]n [C]c [C]i [C]n [C]g O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
a [C]a O 
killer [C]k [C]i [C]l [C]l [C]e [C]r O 
cell-specific [C]c [C]e [C]l [C]l [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
manner [C]m [C]a [C]n [C]n [C]e [C]r O 
. [C]. O 

Within [C]W [C]i [C]t [C]h [C]i [C]n O 
this [C]t [C]h [C]i [C]s O 
segment [C]s [C]e [C]g [C]m [C]e [C]n [C]t O 
, [C], O 
a [C]a O 
9-mer [C]9 [C]- [C]m [C]e [C]r O 
motif [C]m [C]o [C]t [C]i [C]f O 
( [C]( O 
5'-ACAGGAAGT-3 [C]5 [C]' [C]- [C]A [C]C [C]A [C]G [C]G [C]A [C]A [C]G [C]T [C]- [C]3 O 
' [C]' O 
, [C], O 
residues [C]r [C]e [C]s [C]i [C]d [C]u [C]e [C]s B-DNA 
-505 [C]- [C]5 [C]0 [C]5 I-DNA 
to [C]t [C]o I-DNA 
-497 [C]- [C]4 [C]9 [C]7 E-DNA 
; [C]; O 
designated [C]d [C]e [C]s [C]i [C]g [C]n [C]a [C]t [C]e [C]d O 
NF-P [C]N [C]F [C]- [C]P O 
motif [C]m [C]o [C]t [C]i [C]f O 
) [C]) O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
highly [C]h [C]i [C]g [C]h [C]l [C]y O 
homologous [C]h [C]o [C]m [C]o [C]l [C]o [C]g [C]o [C]u [C]s O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
Ets [C]E [C]t [C]s B-DNA 
proto-oncoprotein-binding [C]p [C]r [C]o [C]t [C]o [C]- [C]o [C]n [C]c [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
, [C], O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
interact [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t O 
with [C]w [C]i [C]t [C]h O 
two [C]t [C]w [C]o O 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s O 
, [C], O 
NF-P1 [C]N [C]F [C]- [C]P [C]1 S-protein 
and [C]a [C]n [C]d O 
NF-P2 [C]N [C]F [C]- [C]P [C]2 S-protein 
. [C]. O 

NF-P2 [C]N [C]F [C]- [C]P [C]2 S-protein 
appears [C]a [C]p [C]p [C]e [C]a [C]r [C]s O 
to [C]t [C]o O 
be [C]b [C]e O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
reagents [C]r [C]e [C]a [C]g [C]e [C]n [C]t [C]s O 
known [C]k [C]n [C]o [C]w [C]n O 
to [C]t [C]o O 
up-regulate [C]u [C]p [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
perforin [C]p [C]e [C]r [C]f [C]o [C]r [C]i [C]n O 
message [C]m [C]e [C]s [C]s [C]a [C]g [C]e O 
level [C]l [C]e [C]v [C]e [C]l O 
and [C]a [C]n [C]d O 
is [C]i [C]s O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
exclusively [C]e [C]x [C]c [C]l [C]u [C]s [C]i [C]v [C]e [C]l [C]y O 
in [C]i [C]n O 
killer [C]k [C]i [C]l [C]l [C]e [C]r B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Electrophoretic [C]E [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
assay [C]a [C]s [C]s [C]a [C]y O 
and [C]a [C]n [C]d O 
UV [C]U [C]V O 
cross-linking [C]c [C]r [C]o [C]s [C]s [C]- [C]l [C]i [C]n [C]k [C]i [C]n [C]g O 
experiments [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]s O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
NF-P1 [C]N [C]F [C]- [C]P [C]1 S-protein 
and [C]a [C]n [C]d O 
NF-P2 [C]N [C]F [C]- [C]P [C]2 S-protein 
may [C]m [C]a [C]y O 
possess [C]p [C]o [C]s [C]s [C]e [C]s [C]s O 
common [C]c [C]o [C]m [C]m [C]o [C]n O 
DNA-binding [C]D [C]N [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
subunits [C]s [C]u [C]b [C]u [C]n [C]i [C]t [C]s E-protein 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
the [C]t [C]h [C]e O 
larger [C]l [C]a [C]r [C]g [C]e [C]r O 
native [C]n [C]a [C]t [C]i [C]v [C]e O 
molecular [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]a [C]r O 
mass [C]m [C]a [C]s [C]s O 
of [C]o [C]f O 
NF-P1 [C]N [C]F [C]- [C]P [C]1 S-protein 
suggests [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]s O 
that [C]t [C]h [C]a [C]t O 
NF-P1 [C]N [C]F [C]- [C]P [C]1 S-protein 
contains [C]c [C]o [C]n [C]t [C]a [C]i [C]n [C]s O 
an [C]a [C]n O 
additional [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n [C]a [C]l O 
non-DNA-binding [C]n [C]o [C]n [C]- [C]D [C]N [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g B-protein 
subunit [C]s [C]u [C]b [C]u [C]n [C]i [C]t E-protein 
( [C]( O 
s [C]s O 
) [C]) O 
. [C]. O 

In [C]I [C]n O 
view [C]v [C]i [C]e [C]w O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
homology [C]h [C]o [C]m [C]o [C]l [C]o [C]g [C]y O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
NF-P [C]N [C]F [C]- [C]P B-protein 
motif [C]m [C]o [C]t [C]i [C]f E-protein 
and [C]a [C]n [C]d O 
other [C]o [C]t [C]h [C]e [C]r O 
Ets [C]E [C]t [C]s B-protein 
proto-oncoprotein-binding [C]p [C]r [C]o [C]t [C]o [C]- [C]o [C]n [C]c [C]o [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
sites [C]s [C]i [C]t [C]e [C]s E-protein 
, [C], O 
it [C]i [C]t O 
is [C]i [C]s O 
postulated [C]p [C]o [C]s [C]t [C]u [C]l [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
NF-P1 [C]N [C]F [C]- [C]P [C]1 S-protein 
and [C]a [C]n [C]d O 
NF-P2 [C]N [C]F [C]- [C]P [C]2 S-protein 
belong [C]b [C]e [C]l [C]o [C]n [C]g O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
Ets [C]E [C]t [C]s B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y E-protein 
. [C]. O 

Results [C]R [C]e [C]s [C]u [C]l [C]t [C]s O 
obtained [C]o [C]b [C]t [C]a [C]i [C]n [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
competition [C]c [C]o [C]m [C]p [C]e [C]t [C]i [C]t [C]i [C]o [C]n O 
assay [C]a [C]s [C]s [C]a [C]y O 
, [C], O 
nevertheless [C]n [C]e [C]v [C]e [C]r [C]t [C]h [C]e [C]l [C]e [C]s [C]s O 
, [C], O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
NF-P1 [C]N [C]F [C]- [C]P [C]1 S-protein 
and [C]a [C]n [C]d O 
NF-P2 [C]N [C]F [C]- [C]P [C]2 S-protein 
are [C]a [C]r [C]e O 
related [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
to [C]t [C]o O 
but [C]b [C]u [C]t O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
from [C]f [C]r [C]o [C]m O 
Ets [C]E [C]t [C]s B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
, [C], O 
e.g. [C]e [C]. [C]g [C]. O 
, [C], O 
Ets-1 [C]E [C]t [C]s [C]- [C]1 S-protein 
, [C], O 
Ets-2 [C]E [C]t [C]s [C]- [C]2 S-protein 
, [C], O 
and [C]a [C]n [C]d O 
NF-AT/Elf-1 [C]N [C]F [C]- [C]A [C]T [C]/ [C]E [C]l [C]f [C]- [C]1 S-protein 
, [C], O 
known [C]k [C]n [C]o [C]w [C]n O 
to [C]t [C]o O 
be [C]b [C]e O 
expressed [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]e [C]d O 
in [C]i [C]n O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-DNA 
B1 [C]B [C]1 I-DNA 
( [C]( I-DNA 
p50/p105 [C]p [C]5 [C]0 [C]/ [C]p [C]1 [C]0 [C]5 I-DNA 
) [C]) I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
T-lymphocytes [C]T [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
via [C]v [C]i [C]a O 
CD2 [C]C [C]D [C]2 B-protein 
and [C]a [C]n [C]d I-protein 
CD28 [C]C [C]D [C]2 [C]8 I-protein 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n I-protein 
molecules [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]s E-protein 
. [C]. O 

Stimulation [C]S [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
primary [C]p [C]r [C]i [C]m [C]a [C]r [C]y B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
T-lymphocytes [C]T [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
via [C]v [C]i [C]a O 
CD2 [C]C [C]D [C]2 B-protein 
and [C]a [C]n [C]d I-protein 
CD28 [C]C [C]D [C]2 [C]8 I-protein 
adhesion [C]a [C]d [C]h [C]e [C]s [C]i [C]o [C]n I-protein 
molecules [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]s E-protein 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
a [C]a O 
long-lasting [C]l [C]o [C]n [C]g [C]- [C]l [C]a [C]s [C]t [C]i [C]n [C]g O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
( [C]( O 
> [C]> O 
3 [C]3 O 
weeks [C]w [C]e [C]e [C]k [C]s O 
) [C]) O 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
potent [C]p [C]o [C]t [C]e [C]n [C]t O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
does [C]d [C]o [C]e [C]s O 
not [C]n [C]o [C]t O 
require [C]r [C]e [C]q [C]u [C]i [C]r [C]e O 
accessory [C]a [C]c [C]c [C]e [C]s [C]s [C]o [C]r [C]y O 
cells [C]c [C]e [C]l [C]l [C]s O 
, [C], O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
, [C], O 
but [C]b [C]u [C]t O 
depends [C]d [C]e [C]p [C]e [C]n [C]d [C]s O 
on [C]o [C]n O 
persistent [C]p [C]e [C]r [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
interleukin [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n B-protein 
2 [C]2 E-protein 
( [C]( O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
) [C]) O 
secretion [C]s [C]e [C]c [C]r [C]e [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
receptivity [C]r [C]e [C]c [C]e [C]p [C]t [C]i [C]v [C]i [C]t [C]y O 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
high [C]h [C]i [C]g [C]h O 
and [C]a [C]n [C]d O 
prolonged [C]p [C]r [C]o [C]l [C]o [C]n [C]g [C]e [C]d O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
inducible [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e O 
CD25/IL-2 [C]C [C]D [C]2 [C]5 [C]/ [C]I [C]L [C]- [C]2 B-DNA 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-DNA 
alpha [C]a [C]l [C]p [C]h [C]a I-DNA 
( [C]( I-DNA 
IL-2R [C]I [C]L [C]- [C]2 [C]R I-DNA 
alpha [C]a [C]l [C]p [C]h [C]a I-DNA 
) [C]) I-DNA 
chain [C]c [C]h [C]a [C]i [C]n I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
. [C]. O 

The [C]T [C]h [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n B-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
participates [C]p [C]a [C]r [C]t [C]i [C]c [C]i [C]p [C]a [C]t [C]e [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
IL-2 [C]I [C]L [C]- [C]2 B-DNA 
and [C]a [C]n [C]d I-DNA 
IL-2R [C]I [C]L [C]- [C]2 [C]R I-DNA 
alpha [C]a [C]l [C]p [C]h [C]a I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
, [C], O 
as [C]a [C]s O 
well [C]w [C]e [C]l [C]l O 
as [C]a [C]s O 
multiple [C]m [C]u [C]l [C]t [C]i [C]p [C]l [C]e B-DNA 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

To [C]T [C]o O 
evaluate [C]e [C]v [C]a [C]l [C]u [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
T-lymphocytes [C]T [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
, [C], O 
we [C]w [C]e O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
analyzed [C]a [C]n [C]a [C]l [C]y [C]z [C]e [C]d O 
the [C]t [C]h [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B-related [C]B [C]- [C]r [C]e [C]l [C]a [C]t [C]e [C]d I-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
CD2+CD28 [C]C [C]D [C]2 [C]+ [C]C [C]D [C]2 [C]8 O 
costimulation [C]c [C]o [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

We [C]W [C]e O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
a [C]a O 
long-term [C]l [C]o [C]n [C]g [C]- [C]t [C]e [C]r [C]m O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
p50/p65 [C]p [C]5 [C]0 [C]/ [C]p [C]6 [C]5 B-protein 
heterodimer [C]h [C]e [C]t [C]e [C]r [C]o [C]d [C]i [C]m [C]e [C]r E-protein 
, [C], O 
a [C]a O 
putative [C]p [C]u [C]t [C]a [C]t [C]i [C]v [C]e B-protein 
p65/c-Rel [C]p [C]6 [C]5 [C]/ [C]c [C]- [C]R [C]e [C]l I-protein 
heterodimer [C]h [C]e [C]t [C]e [C]r [C]o [C]d [C]i [C]m [C]e [C]r E-protein 
, [C], O 
and [C]a [C]n [C]d O 
a [C]a O 
constitutive [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
KBF1/p50 [C]K [C]B [C]F [C]1 [C]/ [C]p [C]5 [C]0 B-protein 
homodimers [C]h [C]o [C]m [C]o [C]d [C]i [C]m [C]e [C]r [C]s I-protein 
. [C]. E-protein 

As [C]A [C]s O 
the [C]t [C]h [C]e O 
role [C]r [C]o [C]l [C]e O 
of [C]o [C]f O 
p50 [C]p [C]5 [C]0 S-protein 
remains [C]r [C]e [C]m [C]a [C]i [C]n [C]s O 
unclear [C]u [C]n [C]c [C]l [C]e [C]a [C]r O 
, [C], O 
we [C]w [C]e O 
focused [C]f [C]o [C]c [C]u [C]s [C]e [C]d O 
our [C]o [C]u [C]r O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
study [C]s [C]t [C]u [C]d [C]y O 
on [C]o [C]n O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B1 [C]B [C]1 E-protein 
( [C]( O 
p50/p105 [C]p [C]5 [C]0 [C]/ [C]p [C]1 [C]0 [C]5 S-protein 
) [C]) O 
gene [C]g [C]e [C]n [C]e O 
regulation [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Using [C]U [C]s [C]i [C]n [C]g O 
electrophoretic [C]e [C]l [C]e [C]c [C]t [C]r [C]o [C]p [C]h [C]o [C]r [C]e [C]t [C]i [C]c O 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y O 
shift [C]s [C]h [C]i [C]f [C]t O 
assays [C]a [C]s [C]s [C]a [C]y [C]s O 
and [C]a [C]n [C]d O 
Western [C]W [C]e [C]s [C]t [C]e [C]r [C]n O 
and [C]a [C]n [C]d O 
Northern [C]N [C]o [C]r [C]t [C]h [C]e [C]r [C]n O 
blot [C]b [C]l [C]o [C]t O 
analyses [C]a [C]n [C]a [C]l [C]y [C]s [C]e [C]s O 
, [C], O 
we [C]w [C]e O 
studied [C]s [C]t [C]u [C]d [C]i [C]e [C]d O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-DNA 
B1 [C]B [C]1 I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
via [C]v [C]i [C]a O 
CD2+CD28 [C]C [C]D [C]2 [C]+ [C]C [C]D [C]2 [C]8 S-protein 
. [C]. O 

We [C]W [C]e O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
a [C]a O 
transient [C]t [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t O 
4- [C]4 [C]- O 
to [C]t [C]o O 
5-fold [C]5 [C]- [C]f [C]o [C]l [C]d O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a O 
B1 [C]B [C]1 O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
at [C]a [C]t O 
both [C]b [C]o [C]t [C]h O 
the [C]t [C]h [C]e O 
mRNA [C]m [C]R [C]N [C]A O 
and [C]a [C]n [C]d O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
, [C], O 
lasting [C]l [C]a [C]s [C]t [C]i [C]n [C]g O 
for [C]f [C]o [C]r O 
at [C]a [C]t O 
least [C]l [C]e [C]a [C]s [C]t O 
24 [C]2 [C]4 O 
h [C]h O 
. [C]. O 

p50 [C]p [C]5 [C]0 O 
DNA-binding [C]D [C]N [C]A [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
apparently [C]a [C]p [C]p [C]a [C]r [C]e [C]n [C]t [C]l [C]y O 
stays [C]s [C]t [C]a [C]y [C]s O 
highly [C]h [C]i [C]g [C]h [C]l [C]y O 
controlled [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]l [C]e [C]d O 
when [C]w [C]h [C]e [C]n O 
p105 [C]p [C]1 [C]0 [C]5 O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
is [C]i [C]s O 
enhanced [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
physiological [C]p [C]h [C]y [C]s [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
stimulus [C]s [C]t [C]i [C]m [C]u [C]l [C]u [C]s O 
of [C]o [C]f O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
T-cells [C]T [C]- [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Partial [C]P [C]a [C]r [C]t [C]i [C]a [C]l O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
p50 [C]p [C]5 [C]0 O 
and [C]a [C]n [C]d O 
p105 [C]p [C]1 [C]0 [C]5 O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
by [C]b [C]y O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B1 [C]B [C]1 E-protein 
antisense [C]a [C]n [C]t [C]i [C]s [C]e [C]n [C]s [C]e O 
oligonucleotides [C]o [C]l [C]i [C]g [C]o [C]n [C]u [C]c [C]l [C]e [C]o [C]t [C]i [C]d [C]e [C]s O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
CD25/IL-2R [C]C [C]D [C]2 [C]5 [C]/ [C]I [C]L [C]- [C]2 [C]R B-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
cell [C]c [C]e [C]l [C]l O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
. [C]. O 

( [C]( O 
ABSTRACT [C]A [C]B [C]S [C]T [C]R [C]A [C]C [C]T O 
TRUNCATED [C]T [C]R [C]U [C]N [C]C [C]A [C]T [C]E [C]D O 
AT [C]A [C]T O 
250 [C]2 [C]5 [C]0 O 
WORDS [C]W [C]O [C]R [C]D [C]S O 
) [C]) O 

Vitamin [C]V [C]i [C]t [C]a [C]m [C]i [C]n B-protein 
D [C]D I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
quantitation [C]q [C]u [C]a [C]n [C]t [C]i [C]t [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
in [C]i [C]n O 
health [C]h [C]e [C]a [C]l [C]t [C]h O 
and [C]a [C]n [C]d O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
. [C]. O 

Vitamin [C]V [C]i [C]t [C]a [C]m [C]i [C]n B-protein 
D [C]D I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
( [C]( O 
VDR [C]V [C]D [C]R O 
) [C]) O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
quantitated [C]q [C]u [C]a [C]n [C]t [C]i [C]t [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
mononuclear [C]m [C]o [C]n [C]o [C]n [C]u [C]c [C]l [C]e [C]a [C]r I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
( [C]( O 
PBMC [C]P [C]B [C]M [C]C S-cell_type 
) [C]) O 
from [C]f [C]r [C]o [C]m O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
absorptive [C]a [C]b [C]s [C]o [C]r [C]p [C]t [C]i [C]v [C]e O 
hypercalciuria [C]h [C]y [C]p [C]e [C]r [C]c [C]a [C]l [C]c [C]i [C]u [C]r [C]i [C]a O 
( [C]( O 
AH [C]A [C]H O 
) [C]) O 
and [C]a [C]n [C]d O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
high [C]h [C]i [C]g [C]h O 
1 [C]1 O 
, [C], O 
25 [C]2 [C]5 O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
due [C]d [C]u [C]e O 
to [C]t [C]o O 
acquired [C]a [C]c [C]q [C]u [C]i [C]r [C]e [C]d O 
or [C]o [C]r O 
transient [C]t [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t O 
disease [C]d [C]i [C]s [C]e [C]a [C]s [C]e O 
states [C]s [C]t [C]a [C]t [C]e [C]s O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
compared [C]c [C]o [C]m [C]p [C]a [C]r [C]e [C]d O 
to [C]t [C]o O 
those [C]t [C]h [C]o [C]s [C]e O 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
subjects [C]s [C]u [C]b [C]j [C]e [C]c [C]t [C]s O 
. [C]. O 

VDR [C]V [C]D [C]R O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
resting [C]r [C]e [C]s [C]t [C]i [C]n [C]g B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
the [C]t [C]h [C]e O 
three [C]t [C]h [C]r [C]e [C]e O 
groups [C]g [C]r [C]o [C]u [C]p [C]s O 
and [C]a [C]n [C]d O 
represented [C]r [C]e [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]e [C]d O 
constitutive [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
. [C]. O 

Following [C]F [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
phytohemagglutinin [C]p [C]h [C]y [C]t [C]o [C]h [C]e [C]m [C]a [C]g [C]g [C]l [C]u [C]t [C]i [C]n [C]i [C]n S-protein 
, [C], O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s S-cell_type 
with [C]w [C]i [C]t [C]h O 
hypercalcitriolemia [C]h [C]y [C]p [C]e [C]r [C]c [C]a [C]l [C]c [C]i [C]t [C]r [C]i [C]o [C]l [C]e [C]m [C]i [C]a O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
greater [C]g [C]r [C]e [C]a [C]t [C]e [C]r O 
VDR [C]V [C]D [C]R O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

Patients [C]P [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
AH [C]A [C]H O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
a [C]a O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
value [C]v [C]a [C]l [C]u [C]e O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
group [C]g [C]r [C]o [C]u [C]p O 
, [C], O 
but [C]b [C]u [C]t O 
6 [C]6 O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
had [C]h [C]a [C]d O 
significantly [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t [C]l [C]y O 
greater [C]g [C]r [C]e [C]a [C]t [C]e [C]r O 
concentrations [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
VDR [C]V [C]D [C]R S-protein 
despite [C]d [C]e [C]s [C]p [C]i [C]t [C]e O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
plasma [C]p [C]l [C]a [C]s [C]m [C]a O 
1 [C]1 O 
, [C], O 
25 [C]2 [C]5 O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
in [C]i [C]n O 
four [C]f [C]o [C]u [C]r O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
. [C]. O 

Proliferation [C]P [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
as [C]a [C]s O 
assessed [C]a [C]s [C]s [C]e [C]s [C]s [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
[ [C][ O 
3H [C]3 [C]H O 
] [C]] O 
thymidine [C]t [C]h [C]y [C]m [C]i [C]d [C]i [C]n [C]e O 
incorporation [C]i [C]n [C]c [C]o [C]r [C]p [C]o [C]r [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
inversely [C]i [C]n [C]v [C]e [C]r [C]s [C]e [C]l [C]y O 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
serum [C]s [C]e [C]r [C]u [C]m O 
1 [C]1 O 
, [C], O 
25 [C]2 [C]5 O 
( [C]( O 
OH [C]O [C]H O 
) [C]) O 
2D3 [C]2 [C]D [C]3 O 
and [C]a [C]n [C]d O 
was [C]w [C]a [C]s O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
( [C]( O 
R [C]R O 
= [C]= O 
-0.299 [C]- [C]0 [C]. [C]2 [C]9 [C]9 O 
, [C], O 
p [C]p O 
= [C]= O 
0.048 [C]0 [C]. [C]0 [C]4 [C]8 O 
) [C]) O 
. [C]. O 

Taken [C]T [C]a [C]k [C]e [C]n O 
together [C]t [C]o [C]g [C]e [C]t [C]h [C]e [C]r O 
, [C], O 
the [C]t [C]h [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
that [C]t [C]h [C]a [C]t O 
PBMC [C]P [C]B [C]M [C]C S-cell_type 
provide [C]p [C]r [C]o [C]v [C]i [C]d [C]e O 
a [C]a O 
useful [C]u [C]s [C]e [C]f [C]u [C]l O 
system [C]s [C]y [C]s [C]t [C]e [C]m O 
for [C]f [C]o [C]r O 
studying [C]s [C]t [C]u [C]d [C]y [C]i [C]n [C]g O 
VDR [C]V [C]D [C]R S-protein 
status [C]s [C]t [C]a [C]t [C]u [C]s O 
in [C]i [C]n O 
transient [C]t [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t O 
or [C]o [C]r O 
acquired [C]a [C]c [C]q [C]u [C]i [C]r [C]e [C]d O 
states [C]s [C]t [C]a [C]t [C]e [C]s O 
of [C]o [C]f O 
hypercalcitriolemia [C]h [C]y [C]p [C]e [C]r [C]c [C]a [C]l [C]c [C]i [C]t [C]r [C]i [C]o [C]l [C]e [C]m [C]i [C]a O 
. [C]. O 

Furthermore [C]F [C]u [C]r [C]t [C]h [C]e [C]r [C]m [C]o [C]r [C]e O 
, [C], O 
the [C]t [C]h [C]e O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
in [C]i [C]n O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
absorptive [C]a [C]b [C]s [C]o [C]r [C]p [C]t [C]i [C]v [C]e O 
hypercalciuria [C]h [C]y [C]p [C]e [C]r [C]c [C]a [C]l [C]c [C]i [C]u [C]r [C]i [C]a O 
disclosed [C]d [C]i [C]s [C]c [C]l [C]o [C]s [C]e [C]d O 
it [C]i [C]t O 
to [C]t [C]o O 
be [C]b [C]e O 
a [C]a O 
heterogeneous [C]h [C]e [C]t [C]e [C]r [C]o [C]g [C]e [C]n [C]e [C]o [C]u [C]s O 
disorder [C]d [C]i [C]s [C]o [C]r [C]d [C]e [C]r O 
, [C], O 
characterized [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e [C]d O 
by [C]b [C]y O 
both [C]b [C]o [C]t [C]h O 
vitamin [C]v [C]i [C]t [C]a [C]m [C]i [C]n O 
D-dependent [C]D [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
and [C]a [C]n [C]d O 
D-independent [C]D [C]- [C]i [C]n [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
forms [C]f [C]o [C]r [C]m [C]s O 
of [C]o [C]f O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
up-regulation [C]u [C]p [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Reactive [C]R [C]e [C]a [C]c [C]t [C]i [C]v [C]e O 
oxygen [C]o [C]x [C]y [C]g [C]e [C]n O 
intermediates [C]i [C]n [C]t [C]e [C]r [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]s O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
in [C]i [C]n O 
a [C]a O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
kinase-dependent [C]k [C]i [C]n [C]a [C]s [C]e [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
combination [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
vanadate [C]v [C]a [C]n [C]a [C]d [C]a [C]t [C]e O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
the [C]t [C]h [C]e O 
p56lck [C]p [C]5 [C]6 [C]l [C]c [C]k B-protein 
and [C]a [C]n [C]d I-protein 
p59fyn [C]p [C]5 [C]9 [C]f [C]y [C]n I-protein 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e I-protein 
kinases [C]k [C]i [C]n [C]a [C]s [C]e [C]s E-protein 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
previously [C]p [C]r [C]e [C]v [C]i [C]o [C]u [C]s [C]l [C]y O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
ionizing [C]i [C]o [C]n [C]i [C]z [C]i [C]n [C]g O 
radiation [C]r [C]a [C]d [C]i [C]a [C]t [C]i [C]o [C]n O 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
B-lymphocyte [C]B [C]- [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e I-cell_type 
precursors [C]p [C]r [C]e [C]c [C]u [C]r [C]s [C]o [C]r [C]s E-cell_type 
by [C]b [C]y O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
unidentified [C]u [C]n [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]i [C]e [C]d O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e B-protein 
kinases [C]k [C]i [C]n [C]a [C]s [C]e [C]s E-protein 
and [C]a [C]n [C]d O 
this [C]t [C]h [C]i [C]s O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
substantially [C]s [C]u [C]b [C]s [C]t [C]a [C]n [C]t [C]i [C]a [C]l [C]l [C]y O 
augmented [C]a [C]u [C]g [C]m [C]e [C]n [C]t [C]e [C]d O 
by [C]b [C]y O 
vanadate [C]v [C]a [C]n [C]a [C]d [C]a [C]t [C]e O 
. [C]. O 

Ionizing [C]I [C]o [C]n [C]i [C]z [C]i [C]n [C]g O 
radiation [C]r [C]a [C]d [C]i [C]a [C]t [C]i [C]o [C]n O 
generates [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]e [C]s O 
reactive [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]e O 
oxygen [C]o [C]x [C]y [C]g [C]e [C]n O 
intermediates [C]i [C]n [C]t [C]e [C]r [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]s O 
( [C]( O 
ROI [C]R [C]O [C]I O 
) [C]) O 
. [C]. O 

Because [C]B [C]e [C]c [C]a [C]u [C]s [C]e O 
H2O2 [C]H [C]2 [C]O [C]2 O 
is [C]i [C]s O 
a [C]a O 
potent [C]p [C]o [C]t [C]e [C]n [C]t O 
ROI [C]R [C]O [C]I O 
generator [C]g [C]e [C]n [C]e [C]r [C]a [C]t [C]o [C]r O 
that [C]t [C]h [C]a [C]t O 
readily [C]r [C]e [C]a [C]d [C]i [C]l [C]y O 
crosses [C]c [C]r [C]o [C]s [C]s [C]e [C]s O 
the [C]t [C]h [C]e O 
plasma [C]p [C]l [C]a [C]s [C]m [C]a O 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
, [C], O 
we [C]w [C]e O 
used [C]u [C]s [C]e [C]d O 
H2O2 [C]H [C]2 [C]O [C]2 O 
to [C]t [C]o O 
examine [C]e [C]x [C]a [C]m [C]i [C]n [C]e O 
the [C]t [C]h [C]e O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
ROI [C]R [C]O [C]I O 
on [C]o [C]n O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

We [C]W [C]e O 
now [C]n [C]o [C]w O 
provide [C]p [C]r [C]o [C]v [C]i [C]d [C]e O 
evidence [C]e [C]v [C]i [C]d [C]e [C]n [C]c [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
herbimycin [C]h [C]e [C]r [C]b [C]i [C]m [C]y [C]c [C]i [C]n O 
A [C]A O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
free [C]f [C]r [C]e [C]e O 
radical [C]r [C]a [C]d [C]i [C]c [C]a [C]l O 
scavenger [C]s [C]c [C]a [C]v [C]e [C]n [C]g [C]e [C]r O 
N-acetyl-cysteine [C]N [C]- [C]a [C]c [C]e [C]t [C]y [C]l [C]- [C]c [C]y [C]s [C]t [C]e [C]i [C]n [C]e O 
inhibit [C]i [C]n [C]h [C]i [C]b [C]i [C]t O 
both [C]b [C]o [C]t [C]h O 
radiation-induced [C]r [C]a [C]d [C]i [C]a [C]t [C]i [C]o [C]n [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
and [C]a [C]n [C]d O 
H2O2-induced [C]H [C]2 [C]O [C]2 [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
, [C], O 
indicating [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
triggered [C]t [C]r [C]i [C]g [C]g [C]e [C]r [C]e [C]d O 
by [C]b [C]y O 
ROI [C]R [C]O [C]I O 
is [C]i [C]s O 
dependent [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
on [C]o [C]n O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
kinase [C]k [C]i [C]n [C]a [C]s [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

H2O2 [C]H [C]2 [C]O [C]2 O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
stimulate [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e O 
Ins-1 [C]I [C]n [C]s [C]- [C]1 B-protein 
, [C], I-protein 
4 [C]4 I-protein 
, [C], I-protein 
5-P3 [C]5 [C]- [C]P [C]3 E-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
a [C]a O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
kinase-dependent [C]k [C]i [C]n [C]a [C]s [C]e [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
manner [C]m [C]a [C]n [C]n [C]e [C]r O 
and [C]a [C]n [C]d O 
to [C]t [C]o O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
calcium [C]c [C]a [C]l [C]c [C]i [C]u [C]m O 
signals [C]s [C]i [C]g [C]n [C]a [C]l [C]s O 
that [C]t [C]h [C]a [C]t O 
were [C]w [C]e [C]r [C]e O 
greatly [C]g [C]r [C]e [C]a [C]t [C]l [C]y O 
augmented [C]a [C]u [C]g [C]m [C]e [C]n [C]t [C]e [C]d O 
by [C]b [C]y O 
vanadate [C]v [C]a [C]n [C]a [C]d [C]a [C]t [C]e O 
. [C]. O 

The [C]T [C]h [C]e O 
synergistic [C]s [C]y [C]n [C]e [C]r [C]g [C]i [C]s [C]t [C]i [C]c O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
H2O2 [C]H [C]2 [C]O [C]2 O 
plus [C]p [C]l [C]u [C]s O 
vanadate [C]v [C]a [C]n [C]a [C]d [C]a [C]t [C]e O 
included [C]i [C]n [C]c [C]l [C]u [C]d [C]e [C]d O 
physiologically [C]p [C]h [C]y [C]s [C]i [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l [C]l [C]y O 
relevant [C]r [C]e [C]l [C]e [C]v [C]a [C]n [C]t O 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s O 
such [C]s [C]u [C]c [C]h O 
as [C]a [C]s O 
PLC [C]P [C]L [C]C B-protein 
gamma [C]g [C]a [C]m [C]m [C]a I-protein 
1 [C]1 E-protein 
. [C]. O 

Although [C]A [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
cells [C]c [C]e [C]l [C]l [C]s O 
with [C]w [C]i [C]t [C]h O 
H2O2 [C]H [C]2 [C]O [C]2 O 
alone [C]a [C]l [C]o [C]n [C]e O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
affect [C]a [C]f [C]f [C]e [C]c [C]t O 
the [C]t [C]h [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
src [C]s [C]r [C]c B-protein 
family [C]f [C]a [C]m [C]i [C]l [C]y I-protein 
kinases [C]k [C]i [C]n [C]a [C]s [C]e [C]s E-protein 
, [C], O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
H2O2 [C]H [C]2 [C]O [C]2 O 
plus [C]p [C]l [C]u [C]s O 
vanadate [C]v [C]a [C]n [C]a [C]d [C]a [C]t [C]e O 
led [C]l [C]e [C]d O 
to [C]t [C]o O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
p56lck [C]p [C]5 [C]6 [C]l [C]c [C]k B-protein 
and [C]a [C]n [C]d I-protein 
p59fyn [C]p [C]5 [C]9 [C]f [C]y [C]n I-protein 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e I-protein 
kinases [C]k [C]i [C]n [C]a [C]s [C]e [C]s E-protein 
. [C]. O 

The [C]T [C]h [C]e O 
combined [C]c [C]o [C]m [C]b [C]i [C]n [C]e [C]d O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
phosphatases [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]a [C]s [C]e [C]s S-protein 
and [C]a [C]n [C]d O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
kinases [C]k [C]i [C]n [C]a [C]s [C]e [C]s S-protein 
provides [C]p [C]r [C]o [C]v [C]i [C]d [C]e [C]s O 
a [C]a O 
potent [C]p [C]o [C]t [C]e [C]n [C]t O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
synergistic [C]s [C]y [C]n [C]e [C]r [C]g [C]i [C]s [C]t [C]i [C]c O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
H2O2 [C]H [C]2 [C]O [C]2 O 
plus [C]p [C]l [C]u [C]s O 
vanadate [C]v [C]a [C]n [C]a [C]d [C]a [C]t [C]e O 
. [C]. O 

Induction [C]I [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
ROI [C]R [C]O [C]I O 
may [C]m [C]a [C]y O 
thus [C]t [C]h [C]u [C]s O 
lead [C]l [C]e [C]a [C]d O 
to [C]t [C]o O 
many [C]m [C]a [C]n [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
pleiotropic [C]p [C]l [C]e [C]i [C]o [C]t [C]r [C]o [C]p [C]i [C]c O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
ROI [C]R [C]O [C]I O 
in [C]i [C]n O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
including [C]i [C]n [C]c [C]l [C]u [C]d [C]i [C]n [C]g O 
downstream [C]d [C]o [C]w [C]n [C]s [C]t [C]r [C]e [C]a [C]m O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
PLC [C]P [C]L [C]C B-protein 
gamma [C]g [C]a [C]m [C]m [C]a I-protein 
1 [C]1 E-protein 
and [C]a [C]n [C]d O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 

Influence [C]I [C]n [C]f [C]l [C]u [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
sex [C]s [C]e [C]x B-protein 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
globulin [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n E-protein 
and [C]a [C]n [C]d O 
serum [C]s [C]e [C]r [C]u [C]m B-protein 
albumin [C]a [C]l [C]b [C]u [C]m [C]i [C]n E-protein 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
conversion [C]c [C]o [C]n [C]v [C]e [C]r [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
androstenedione [C]a [C]n [C]d [C]r [C]o [C]s [C]t [C]e [C]n [C]e [C]d [C]i [C]o [C]n [C]e O 
to [C]t [C]o O 
testosterone [C]t [C]e [C]s [C]t [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
by [C]b [C]y O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
erythrocytes [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
influence [C]i [C]n [C]f [C]l [C]u [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-protein 
serum [C]s [C]e [C]r [C]u [C]m I-protein 
albumin [C]a [C]l [C]b [C]u [C]m [C]i [C]n E-protein 
and [C]a [C]n [C]d O 
sex [C]s [C]e [C]x B-protein 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e I-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-protein 
globulin [C]g [C]l [C]o [C]b [C]u [C]l [C]i [C]n E-protein 
( [C]( O 
SHBG [C]S [C]H [C]B [C]G S-protein 
) [C]) O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
enzymic [C]e [C]n [C]z [C]y [C]m [C]i [C]c O 
conversion [C]c [C]o [C]n [C]v [C]e [C]r [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
androstenedione [C]a [C]n [C]d [C]r [C]o [C]s [C]t [C]e [C]n [C]e [C]d [C]i [C]o [C]n [C]e O 
to [C]t [C]o O 
testosterone [C]t [C]e [C]s [C]t [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
erythrocytes [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
was [C]w [C]a [C]s O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
. [C]. O 

Total [C]T [C]o [C]t [C]a [C]l O 
plasma [C]p [C]l [C]a [C]s [C]m [C]a O 
and [C]a [C]n [C]d O 
albumin [C]a [C]l [C]b [C]u [C]m [C]i [C]n S-protein 
delayed [C]d [C]e [C]l [C]a [C]y [C]e [C]d O 
the [C]t [C]h [C]e O 
conversion [C]c [C]o [C]n [C]v [C]e [C]r [C]s [C]i [C]o [C]n O 
rate [C]r [C]a [C]t [C]e O 
of [C]o [C]f O 
androstenedione [C]a [C]n [C]d [C]r [C]o [C]s [C]t [C]e [C]n [C]e [C]d [C]i [C]o [C]n [C]e O 
, [C], O 
while [C]w [C]h [C]i [C]l [C]e O 
SHBG [C]S [C]H [C]B [C]G S-protein 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
it [C]i [C]t O 
markedly [C]m [C]a [C]r [C]k [C]e [C]d [C]l [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
SHBG [C]S [C]H [C]B [C]G S-protein 
was [C]w [C]a [C]s O 
largely [C]l [C]a [C]r [C]g [C]e [C]l [C]y O 
abolished [C]a [C]b [C]o [C]l [C]i [C]s [C]h [C]e [C]d O 
by [C]b [C]y O 
heating [C]h [C]e [C]a [C]t [C]i [C]n [C]g O 
to [C]t [C]o O 
60 [C]6 [C]0 O 
degrees [C]d [C]e [C]g [C]r [C]e [C]e [C]s O 
C [C]C O 
for [C]f [C]o [C]r O 
1 [C]1 O 
h [C]h O 
and [C]a [C]n [C]d O 
by [C]b [C]y O 
saturating [C]s [C]a [C]t [C]u [C]r [C]a [C]t [C]i [C]n [C]g O 
its [C]i [C]t [C]s O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
sites [C]s [C]i [C]t [C]e [C]s O 
by [C]b [C]y O 
DHT [C]D [C]H [C]T O 
. [C]. O 

The [C]T [C]h [C]e O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
of [C]o [C]f O 
both [C]b [C]o [C]t [C]h O 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
related [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
to [C]t [C]o O 
their [C]t [C]h [C]e [C]i [C]r O 
concentration [C]c [C]o [C]n [C]c [C]e [C]n [C]t [C]r [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

It [C]I [C]t O 
appears [C]a [C]p [C]p [C]e [C]a [C]r [C]s O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
sites [C]s [C]i [C]t [C]e [C]s O 
of [C]o [C]f O 
albumin [C]a [C]l [C]b [C]u [C]m [C]i [C]n S-protein 
provide [C]p [C]r [C]o [C]v [C]i [C]d [C]e O 
a [C]a O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
for [C]f [C]o [C]r O 
retarding [C]r [C]e [C]t [C]a [C]r [C]d [C]i [C]n [C]g O 
androstenedione [C]a [C]n [C]d [C]r [C]o [C]s [C]t [C]e [C]n [C]e [C]d [C]i [C]o [C]n [C]e O 
uptake [C]u [C]p [C]t [C]a [C]k [C]e O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
erythrocytes [C]e [C]r [C]y [C]t [C]h [C]r [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
and [C]a [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
high [C]h [C]i [C]g [C]h O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
of [C]o [C]f O 
SHBG [C]S [C]H [C]B [C]G S-protein 
for [C]f [C]o [C]r O 
testosterone [C]t [C]e [C]s [C]t [C]o [C]s [C]t [C]e [C]r [C]o [C]n [C]e O 
facilitates [C]f [C]a [C]c [C]i [C]l [C]i [C]t [C]a [C]t [C]e [C]s O 
the [C]t [C]h [C]e O 
diffusion [C]d [C]i [C]f [C]f [C]u [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
this [C]t [C]h [C]i [C]s O 
steroid [C]s [C]t [C]e [C]r [C]o [C]i [C]d O 
out [C]o [C]u [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cell [C]c [C]e [C]l [C]l O 
and [C]a [C]n [C]d O 
thus [C]t [C]h [C]u [C]s O 
, [C], O 
displaces [C]d [C]i [C]s [C]p [C]l [C]a [C]c [C]e [C]s O 
the [C]t [C]h [C]e O 
chemical [C]c [C]h [C]e [C]m [C]i [C]c [C]a [C]l O 
equilibrium [C]e [C]q [C]u [C]i [C]l [C]i [C]b [C]r [C]i [C]u [C]m O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
the [C]t [C]h [C]e O 
cell [C]c [C]e [C]l [C]l O 
. [C]. O 

Glucocorticoids [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
and [C]a [C]n [C]d O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
. [C]. O 

I [C]I O 
. [C]. O 

Increased [C]I [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
in [C]i [C]n O 
antigen-stimulated [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_line 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_line 
. [C]. O 

Recently [C]R [C]e [C]c [C]e [C]n [C]t [C]l [C]y O 
a [C]a O 
2- [C]2 [C]- O 
to [C]t [C]o O 
3-fold [C]3 [C]- [C]f [C]o [C]l [C]d O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
has [C]h [C]a [C]s O 
been [C]b [C]e [C]e [C]n O 
noted [C]n [C]o [C]t [C]e [C]d O 
after [C]a [C]f [C]t [C]e [C]r O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
mitogen [C]m [C]i [C]t [C]o [C]g [C]e [C]n O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Here [C]H [C]e [C]r [C]e O 
, [C], O 
we [C]w [C]e O 
extend [C]e [C]x [C]t [C]e [C]n [C]d O 
these [C]t [C]h [C]e [C]s [C]e O 
observations [C]o [C]b [C]s [C]e [C]r [C]v [C]a [C]t [C]i [C]o [C]n [C]s O 
to [C]t [C]o O 
in [C]i [C]n O 
vivo [C]v [C]i [C]v [C]o O 
immunization [C]i [C]m [C]m [C]u [C]n [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

After [C]A [C]f [C]t [C]e [C]r O 
unilateral [C]u [C]n [C]i [C]l [C]a [C]t [C]e [C]r [C]a [C]l O 
immunization [C]i [C]m [C]m [C]u [C]n [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
adrenalectomized [C]a [C]d [C]r [C]e [C]n [C]a [C]l [C]e [C]c [C]t [C]o [C]m [C]i [C]z [C]e [C]d O 
male [C]m [C]a [C]l [C]e O 
rats [C]r [C]a [C]t [C]s O 
, [C], O 
a [C]a O 
50 [C]5 [C]0 O 
% [C]% O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
sites [C]s [C]i [C]t [C]e [C]s O 
per [C]p [C]e [C]r O 
cell [C]c [C]e [C]l [C]l O 
, [C], O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
, [C], O 
was [C]w [C]a [C]s O 
observed [C]o [C]b [C]s [C]e [C]r [C]v [C]e [C]d O 
in [C]i [C]n O 
cell [C]c [C]e [C]l [C]l O 
suspensions [C]s [C]u [C]s [C]p [C]e [C]n [C]s [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
homolateral [C]h [C]o [C]m [C]o [C]l [C]a [C]t [C]e [C]r [C]a [C]l O 
lymph [C]l [C]y [C]m [C]p [C]h O 
nodes [C]n [C]o [C]d [C]e [C]s O 
over [C]o [C]v [C]e [C]r O 
those [C]t [C]h [C]o [C]s [C]e O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
contralateral [C]c [C]o [C]n [C]t [C]r [C]a [C]l [C]a [C]t [C]e [C]r [C]a [C]l O 
nonimmunized [C]n [C]o [C]n [C]i [C]m [C]m [C]u [C]n [C]i [C]z [C]e [C]d O 
side [C]s [C]i [C]d [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
same [C]s [C]a [C]m [C]e O 
animal [C]a [C]n [C]i [C]m [C]a [C]l O 
. [C]. O 

The [C]T [C]h [C]e O 
association [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
constant [C]c [C]o [C]n [C]s [C]t [C]a [C]n [C]t O 
for [C]f [C]o [C]r O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
was [C]w [C]a [C]s O 
similar [C]s [C]i [C]m [C]i [C]l [C]a [C]r O 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
groups [C]g [C]r [C]o [C]u [C]p [C]s O 
, [C], O 
as [C]a [C]s O 
was [C]w [C]a [C]s O 
the [C]t [C]h [C]e O 
stereospecificity [C]s [C]t [C]e [C]r [C]e [C]o [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]i [C]t [C]y O 
for [C]f [C]o [C]r O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
steroids [C]s [C]t [C]e [C]r [C]o [C]i [C]d [C]s O 
, [C], O 
the [C]t [C]h [C]e O 
time [C]t [C]i [C]m [C]e O 
course [C]c [C]o [C]u [C]r [C]s [C]e O 
of [C]o [C]f O 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c O 
and [C]a [C]n [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
association [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
cytoplasmic-to-nuclear [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c [C]- [C]t [C]o [C]- [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
translocation [C]t [C]r [C]a [C]n [C]s [C]l [C]o [C]c [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Despite [C]D [C]e [C]s [C]p [C]i [C]t [C]e O 
a [C]a O 
50 [C]5 [C]0 O 
% [C]% O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
sites [C]s [C]i [C]t [C]e [C]s O 
per [C]p [C]e [C]r O 
cell [C]c [C]e [C]l [C]l O 
, [C], O 
the [C]t [C]h [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
homolateral [C]h [C]o [C]m [C]o [C]l [C]a [C]t [C]e [C]r [C]a [C]l O 
and [C]a [C]n [C]d O 
controlateral [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]a [C]t [C]e [C]r [C]a [C]l O 
lymph [C]l [C]y [C]m [C]p [C]h O 
nodes [C]n [C]o [C]d [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
equally [C]e [C]q [C]u [C]a [C]l [C]l [C]y O 
sensitive [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
inhibitory [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r [C]y O 
effects [C]e [C]f [C]f [C]e [C]c [C]t [C]s O 
of [C]o [C]f O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
, [C], O 
as [C]a [C]s O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
measurements [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]m [C]e [C]n [C]t [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
incorporation [C]i [C]n [C]c [C]o [C]r [C]p [C]o [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
radiolabeled [C]r [C]a [C]d [C]i [C]o [C]l [C]a [C]b [C]e [C]l [C]e [C]d O 
precursors [C]p [C]r [C]e [C]c [C]u [C]r [C]s [C]o [C]r [C]s O 
of [C]o [C]f O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
, [C], O 
RNA [C]R [C]N [C]A O 
, [C], O 
and [C]a [C]n [C]d O 
DNA [C]D [C]N [C]A O 
, [C], O 
or [C]o [C]r O 
measurements [C]m [C]e [C]a [C]s [C]u [C]r [C]e [C]m [C]e [C]n [C]t [C]s O 
of [C]o [C]f O 
in [C]i [C]n O 
vitro [C]v [C]i [C]t [C]r [C]o O 
cell [C]c [C]e [C]l [C]l O 
survival [C]s [C]u [C]r [C]v [C]i [C]v [C]a [C]l O 
. [C]. O 

Glucocorticoid [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
and [C]a [C]n [C]d O 
actions [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
rat [C]r [C]a [C]t B-cell_type 
thymocytes [C]t [C]h [C]y [C]m [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
immunologically [C]i [C]m [C]m [C]u [C]n [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l [C]l [C]y O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

After [C]A [C]f [C]t [C]e [C]r O 
reviewing [C]r [C]e [C]v [C]i [C]e [C]w [C]i [C]n [C]g O 
briefly [C]b [C]r [C]i [C]e [C]f [C]l [C]y O 
our [C]o [C]u [C]r O 
earlier [C]e [C]a [C]r [C]l [C]i [C]e [C]r O 
studies [C]s [C]t [C]u [C]d [C]i [C]e [C]s O 
on [C]o [C]n O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
and [C]a [C]n [C]d O 
mechanisms [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m [C]s O 
in [C]i [C]n O 
thymus [C]t [C]h [C]y [C]m [C]u [C]s B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
we [C]w [C]e O 
have [C]h [C]a [C]v [C]e O 
outlined [C]o [C]u [C]t [C]l [C]i [C]n [C]e [C]d O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
two [C]t [C]w [C]o O 
areas [C]a [C]r [C]e [C]a [C]s O 
of [C]o [C]f O 
current [C]c [C]u [C]r [C]r [C]e [C]n [C]t O 
interest [C]i [C]n [C]t [C]e [C]r [C]e [C]s [C]t O 
in [C]i [C]n O 
our [C]o [C]u [C]r O 
laboratories [C]l [C]a [C]b [C]o [C]r [C]a [C]t [C]o [C]r [C]i [C]e [C]s O 
: [C]: O 
the [C]t [C]h [C]e O 
`` [C]` [C]` O 
life-cycle [C]l [C]i [C]f [C]e [C]- [C]c [C]y [C]c [C]l [C]e O 
'' [C]' [C]' O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
and [C]a [C]n [C]d O 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s O 
in [C]i [C]n O 
thymus [C]t [C]h [C]y [C]m [C]u [C]s B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
and [C]a [C]n [C]d O 
sensitivity [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
immunologically [C]i [C]m [C]m [C]u [C]n [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l [C]l [C]y B-cell_type 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d I-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

Several [C]S [C]e [C]v [C]e [C]r [C]a [C]l O 
of [C]o [C]f O 
our [C]o [C]u [C]r O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
on [C]o [C]n O 
energetics [C]e [C]n [C]e [C]r [C]g [C]e [C]t [C]i [C]c [C]s O 
and [C]a [C]n [C]d O 
kinetics [C]k [C]i [C]n [C]e [C]t [C]i [C]c [C]s O 
of [C]o [C]f O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s E-protein 
in [C]i [C]n O 
rat [C]r [C]a [C]t B-cell_type 
thymus [C]t [C]h [C]y [C]m [C]u [C]s I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
seem [C]s [C]e [C]e [C]m O 
to [C]t [C]o O 
require [C]r [C]e [C]q [C]u [C]i [C]r [C]e O 
extension [C]e [C]x [C]t [C]e [C]n [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
simplest [C]s [C]i [C]m [C]p [C]l [C]e [C]s [C]t O 
model [C]m [C]o [C]d [C]e [C]l O 
of [C]o [C]f O 
hormone-receptor [C]h [C]o [C]r [C]m [C]o [C]n [C]e [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
transformations [C]t [C]r [C]a [C]n [C]s [C]f [C]o [C]r [C]m [C]a [C]t [C]i [C]o [C]n [C]s O 
in [C]i [C]n O 
intact [C]i [C]n [C]t [C]a [C]c [C]t B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

ATP-depletion [C]A [C]T [C]P [C]- [C]d [C]e [C]p [C]l [C]e [C]t [C]i [C]o [C]n O 
experiments [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
the [C]t [C]h [C]e O 
existence [C]e [C]x [C]i [C]s [C]t [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
a [C]a O 
nonbinding [C]n [C]o [C]n [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
form [C]f [C]o [C]r [C]m O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
; [C]; O 
`` [C]` [C]` O 
chase [C]c [C]h [C]a [C]s [C]e O 
'' [C]' [C]' O 
experiments [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]s O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
reaction [C]r [C]e [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
hormone [C]h [C]o [C]r [C]m [C]o [C]n [C]e O 
directly [C]d [C]i [C]r [C]e [C]c [C]t [C]l [C]y O 
with [C]w [C]i [C]t [C]h O 
nuclear-bound [C]n [C]u [C]c [C]l [C]e [C]a [C]r [C]- [C]b [C]o [C]u [C]n [C]d O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
; [C]; O 
experiments [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]s O 
on [C]o [C]n O 
depletion [C]d [C]e [C]p [C]l [C]e [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
replenishment [C]r [C]e [C]p [C]l [C]e [C]n [C]i [C]s [C]h [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
cytoplasmic [C]c [C]y [C]t [C]o [C]p [C]l [C]a [C]s [C]m [C]i [C]c B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
using [C]u [C]s [C]i [C]n [C]g O 
cortisol [C]c [C]o [C]r [C]t [C]i [C]s [C]o [C]l O 
and [C]a [C]n [C]d O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
suggest [C]s [C]u [C]g [C]g [C]e [C]s [C]t O 
the [C]t [C]h [C]e O 
existence [C]e [C]x [C]i [C]s [C]t [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
at [C]a [C]t O 
least [C]l [C]e [C]a [C]s [C]t O 
two [C]t [C]w [C]o O 
subpopulations [C]s [C]u [C]b [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
nuclear-bound [C]n [C]u [C]c [C]l [C]e [C]a [C]r [C]- [C]b [C]o [C]u [C]n [C]d B-protein 
hormone-receptor [C]h [C]o [C]r [C]m [C]o [C]n [C]e [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
that [C]t [C]h [C]a [C]t O 
mitogen [C]m [C]i [C]t [C]o [C]g [C]e [C]n O 
or [C]o [C]r O 
immunologic [C]i [C]m [C]m [C]u [C]n [C]o [C]l [C]o [C]g [C]i [C]c O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
in [C]i [C]n O 
culture [C]c [C]u [C]l [C]t [C]u [C]r [C]e O 
leads [C]l [C]e [C]a [C]d [C]s O 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
24 [C]2 [C]4 O 
h [C]h O 
or [C]o [C]r O 
so [C]s [C]o O 
to [C]t [C]o O 
a [C]a O 
striking [C]s [C]t [C]r [C]i [C]k [C]i [C]n [C]g O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
number [C]n [C]u [C]m [C]b [C]e [C]r O 
of [C]o [C]f O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
sites [C]s [C]i [C]t [C]e [C]s O 
per [C]p [C]e [C]r O 
cell [C]c [C]e [C]l [C]l O 
. [C]. O 

We [C]W [C]e O 
believe [C]b [C]e [C]l [C]i [C]e [C]v [C]e O 
this [C]t [C]h [C]i [C]s O 
increase [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
due [C]d [C]u [C]e O 
to [C]t [C]o O 
partial [C]p [C]a [C]r [C]t [C]i [C]a [C]l O 
synchronization [C]s [C]y [C]n [C]c [C]h [C]r [C]o [C]n [C]i [C]z [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cell [C]c [C]e [C]l [C]l O 
population [C]p [C]o [C]p [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
a [C]a O 
phase [C]p [C]h [C]a [C]s [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
cell [C]c [C]e [C]l [C]l O 
cycle [C]c [C]y [C]c [C]l [C]e O 
in [C]i [C]n O 
which [C]w [C]h [C]i [C]c [C]h O 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
is [C]i [C]s O 
high [C]h [C]i [C]g [C]h O 
. [C]. O 

Contrary [C]C [C]o [C]n [C]t [C]r [C]a [C]r [C]y O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
widely [C]w [C]i [C]d [C]e [C]l [C]y O 
held [C]h [C]e [C]l [C]d O 
view [C]v [C]i [C]e [C]w O 
that [C]t [C]h [C]a [C]t O 
mitogen-stimulated [C]m [C]i [C]t [C]o [C]g [C]e [C]n [C]- [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
become [C]b [C]e [C]c [C]o [C]m [C]e O 
insensitive [C]i [C]n [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
to [C]t [C]o O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
, [C], O 
our [C]o [C]u [C]r O 
experiments [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]s O 
show [C]s [C]h [C]o [C]w O 
that [C]t [C]h [C]a [C]t O 
with [C]w [C]i [C]t [C]h O 
respect [C]r [C]e [C]s [C]p [C]e [C]c [C]t O 
to [C]t [C]o O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
thymidine [C]t [C]h [C]y [C]m [C]i [C]d [C]i [C]n [C]e O 
and [C]a [C]n [C]d O 
uridine [C]u [C]r [C]i [C]d [C]i [C]n [C]e O 
incorporation [C]i [C]n [C]c [C]o [C]r [C]p [C]o [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
glucose [C]g [C]l [C]u [C]c [C]o [C]s [C]e O 
uptake [C]u [C]p [C]t [C]a [C]k [C]e O 
, [C], O 
the [C]t [C]h [C]e O 
cells [C]c [C]e [C]l [C]l [C]s O 
are [C]a [C]r [C]e O 
highly [C]h [C]i [C]g [C]h [C]l [C]y O 
sensitive [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e O 
to [C]t [C]o O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
at [C]a [C]t O 
24 [C]2 [C]4 O 
, [C], O 
48 [C]4 [C]8 O 
, [C], O 
and [C]a [C]n [C]d O 
72 [C]7 [C]2 O 
h [C]h O 
after [C]a [C]f [C]t [C]e [C]r O 
stimulation [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
concanavalin [C]c [C]o [C]n [C]c [C]a [C]n [C]a [C]v [C]a [C]l [C]i [C]n B-protein 
A [C]A E-protein 
. [C]. O 

Nuclear [C]N [C]u [C]c [C]l [C]e [C]a [C]r O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
in [C]i [C]n O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c B-cell_type 
lymphatic [C]l [C]y [C]m [C]p [C]h [C]a [C]t [C]i [C]c I-cell_type 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

A [C]A O 
reliable [C]r [C]e [C]l [C]i [C]a [C]b [C]l [C]e O 
procedure [C]p [C]r [C]o [C]c [C]e [C]d [C]u [C]r [C]e O 
is [C]i [C]s O 
described [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
for [C]f [C]o [C]r O 
isolating [C]i [C]s [C]o [C]l [C]a [C]t [C]i [C]n [C]g O 
3H-triamcinolone [C]3 [C]H [C]- [C]t [C]r [C]i [C]a [C]m [C]c [C]i [C]n [C]o [C]l [C]o [C]n [C]e B-protein 
acetonide [C]a [C]c [C]e [C]t [C]o [C]n [C]i [C]d [C]e I-protein 
( [C]( I-protein 
3H-TA [C]3 [C]H [C]- [C]T [C]A I-protein 
) [C]) I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
from [C]f [C]r [C]o [C]m O 
purified [C]p [C]u [C]r [C]i [C]f [C]i [C]e [C]d O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
lymphatic [C]l [C]y [C]m [C]p [C]h [C]a [C]t [C]i [C]c B-cell_type 
leukemia [C]l [C]e [C]u [C]k [C]e [C]m [C]i [C]a I-cell_type 
( [C]( I-cell_type 
CLL [C]C [C]L [C]L I-cell_type 
) [C]) I-cell_type 
lymphocyte [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e E-cell_type 
nuclei [C]n [C]u [C]c [C]l [C]e [C]i O 
, [C], O 
based [C]b [C]a [C]s [C]e [C]d O 
on [C]o [C]n O 
the [C]t [C]h [C]e O 
use [C]u [C]s [C]e O 
of [C]o [C]f O 
carbobenzoxy-L-phenylalanine [C]c [C]a [C]r [C]b [C]o [C]b [C]e [C]n [C]z [C]o [C]x [C]y [C]- [C]L [C]- [C]p [C]h [C]e [C]n [C]y [C]l [C]a [C]l [C]a [C]n [C]i [C]n [C]e O 
( [C]( O 
CBZ-L-phe [C]C [C]B [C]Z [C]- [C]L [C]- [C]p [C]h [C]e O 
) [C]) O 
to [C]t [C]o O 
prevent [C]p [C]r [C]e [C]v [C]e [C]n [C]t O 
breakdown [C]b [C]r [C]e [C]a [C]k [C]d [C]o [C]w [C]n O 
of [C]o [C]f O 
hormone-receptor [C]h [C]o [C]r [C]m [C]o [C]n [C]e [C]- [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r B-protein 
complexes [C]c [C]o [C]m [C]p [C]l [C]e [C]x [C]e [C]s E-protein 
during [C]d [C]u [C]r [C]i [C]n [C]g O 
extraction [C]e [C]x [C]t [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
nuclei [C]n [C]u [C]c [C]l [C]e [C]i O 
with [C]w [C]i [C]t [C]h O 
0.6M [C]0 [C]. [C]6 [C]M O 
KCl [C]K [C]C [C]l O 
. [C]. O 

Using [C]U [C]s [C]i [C]n [C]g O 
this [C]t [C]h [C]i [C]s O 
method [C]m [C]e [C]t [C]h [C]o [C]d O 
, [C], O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
glucocorticoid [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
was [C]w [C]a [C]s O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
14/14 [C]1 [C]4 [C]/ [C]1 [C]4 O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
untreated [C]u [C]n [C]t [C]r [C]e [C]a [C]t [C]e [C]d O 
CLL [C]C [C]L [C]L O 
. [C]. O 

No [C]N [C]o O 
correlation [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
nuclear-associated [C]n [C]u [C]c [C]l [C]e [C]a [C]r [C]- [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
3H-TA [C]3 [C]H [C]- [C]T [C]A O 
and [C]a [C]n [C]d O 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l O 
white [C]w [C]h [C]i [C]t [C]e O 
blood [C]b [C]l [C]o [C]o [C]d O 
cell [C]c [C]e [C]l [C]l O 
count [C]c [C]o [C]u [C]n [C]t O 
or [C]o [C]r O 
rosetting [C]r [C]o [C]s [C]e [C]t [C]t [C]i [C]n [C]g O 
ability [C]a [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
circulating [C]c [C]i [C]r [C]c [C]u [C]l [C]a [C]t [C]i [C]n [C]g B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

Multiple [C]M [C]u [C]l [C]t [C]i [C]p [C]l [C]e O 
closely-linked [C]c [C]l [C]o [C]s [C]e [C]l [C]y [C]- [C]l [C]i [C]n [C]k [C]e [C]d O 
NFAT/octamer [C]N [C]F [C]A [C]T [C]/ [C]o [C]c [C]t [C]a [C]m [C]e [C]r S-DNA 
and [C]a [C]n [C]d O 
HMG [C]H [C]M [C]G B-DNA 
I [C]I I-DNA 
( [C]( I-DNA 
Y [C]Y I-DNA 
) [C]) I-DNA 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
are [C]a [C]r [C]e O 
part [C]p [C]a [C]r [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
interleukin-4 [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n [C]- [C]4 O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
. [C]. O 

We [C]W [C]e O 
show [C]s [C]h [C]o [C]w O 
here [C]h [C]e [C]r [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
immediate [C]i [C]m [C]m [C]e [C]d [C]i [C]a [C]t [C]e B-DNA 
upstream [C]u [C]p [C]s [C]t [C]r [C]e [C]a [C]m I-DNA 
region [C]r [C]e [C]g [C]i [C]o [C]n E-DNA 
( [C]( O 
from [C]f [C]r [C]o [C]m O 
position [C]p [C]o [C]s [C]i [C]t [C]i [C]o [C]n O 
-12 [C]- [C]1 [C]2 O 
to [C]t [C]o O 
-270 [C]- [C]2 [C]7 [C]0 O 
) [C]) O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
murine [C]m [C]u [C]r [C]i [C]n [C]e B-DNA 
interleukin [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n I-DNA 
4 [C]4 I-DNA 
( [C]( I-DNA 
Il-4 [C]I [C]l [C]- [C]4 I-DNA 
) [C]) I-DNA 
gene [C]g [C]e [C]n [C]e E-DNA 
harbors [C]h [C]a [C]r [C]b [C]o [C]r [C]s O 
a [C]a O 
strong [C]s [C]t [C]r [C]o [C]n [C]g O 
cell-type [C]c [C]e [C]l [C]l [C]- [C]t [C]y [C]p [C]e O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
transcriptional [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l B-DNA 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r E-DNA 
. [C]. O 

In [C]I [C]n O 
T [C]T B-cell_type 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
the [C]t [C]h [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Il-4 [C]I [C]l [C]- [C]4 B-DNA 
promoter/enhancer [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]/ [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r E-DNA 
is [C]i [C]s O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
phorbol [C]p [C]h [C]o [C]r [C]b [C]o [C]l O 
esters [C]e [C]s [C]t [C]e [C]r [C]s O 
, [C], O 
Ca++ [C]C [C]a [C]+ [C]+ O 
ionophores [C]i [C]o [C]n [C]o [C]p [C]h [C]o [C]r [C]e [C]s O 
and [C]a [C]n [C]d O 
agonists [C]a [C]g [C]o [C]n [C]i [C]s [C]t [C]s O 
of [C]o [C]f O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n B-protein 
kinase [C]k [C]i [C]n [C]a [C]s [C]e I-protein 
A [C]A E-protein 
and [C]a [C]n [C]d O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
by [C]b [C]y O 
low [C]l [C]o [C]w O 
doses [C]d [C]o [C]s [C]e [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
immunosuppressant [C]i [C]m [C]m [C]u [C]n [C]o [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]a [C]n [C]t O 
cyclosporin [C]c [C]y [C]c [C]l [C]o [C]s [C]p [C]o [C]r [C]i [C]n O 
A [C]A O 
. [C]. O 

The [C]T [C]h [C]e O 
Il-4 [C]I [C]l [C]- [C]4 B-DNA 
promoter/enhancer [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]/ [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r E-DNA 
is [C]i [C]s O 
transcriptionally [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n [C]a [C]l [C]l [C]y O 
inactive [C]i [C]n [C]a [C]c [C]t [C]i [C]v [C]e O 
in [C]i [C]n O 
B [C]B B-cell_type 
lymphoma [C]l [C]y [C]m [C]p [C]h [C]o [C]m [C]a I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
and [C]a [C]n [C]d O 
HeLa [C]H [C]e [C]L [C]a B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

DNase [C]D [C]N [C]a [C]s [C]e O 
I [C]I O 
footprint [C]f [C]o [C]o [C]t [C]p [C]r [C]i [C]n [C]t O 
protection [C]p [C]r [C]o [C]t [C]e [C]c [C]t [C]i [C]o [C]n O 
experiments [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]s O 
revealed [C]r [C]e [C]v [C]e [C]a [C]l [C]e [C]d O 
six [C]s [C]i [C]x O 
sites [C]s [C]i [C]t [C]e [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Il-4 [C]I [C]l [C]- [C]4 B-DNA 
promoter/enhancer [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r [C]/ [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r E-DNA 
to [C]t [C]o O 
be [C]b [C]e O 
bound [C]b [C]o [C]u [C]n [C]d O 
by [C]b [C]y O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
from [C]f [C]r [C]o [C]m O 
lymphoid [C]l [C]y [C]m [C]p [C]h [C]o [C]i [C]d B-cell_type 
and [C]a [C]n [C]d I-cell_type 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Among [C]A [C]m [C]o [C]n [C]g O 
them [C]t [C]h [C]e [C]m O 
are [C]a [C]r [C]e O 
four [C]f [C]o [C]u [C]r O 
purine [C]p [C]u [C]r [C]i [C]n [C]e O 
boxes [C]b [C]o [C]x [C]e [C]s O 
which [C]w [C]h [C]i [C]c [C]h O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
described [C]d [C]e [C]s [C]c [C]r [C]i [C]b [C]e [C]d O 
to [C]t [C]o O 
be [C]b [C]e O 
important [C]i [C]m [C]p [C]o [C]r [C]t [C]a [C]n [C]t O 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e O 
motifs [C]m [C]o [C]t [C]i [C]f [C]s O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Il-2 [C]I [C]l [C]- [C]2 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
. [C]. O 

They [C]T [C]h [C]e [C]y O 
contain [C]c [C]o [C]n [C]t [C]a [C]i [C]n O 
the [C]t [C]h [C]e O 
motif [C]m [C]o [C]t [C]i [C]f O 
GGAAA [C]G [C]G [C]A [C]A [C]A O 
and [C]a [C]n [C]d O 
are [C]a [C]r [C]e O 
recognized [C]r [C]e [C]c [C]o [C]g [C]n [C]i [C]z [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
inducible [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e B-protein 
and [C]a [C]n [C]d I-protein 
cyclosporin [C]c [C]y [C]c [C]l [C]o [C]s [C]p [C]o [C]r [C]i [C]n I-protein 
A-sensitive [C]A [C]- [C]s [C]e [C]n [C]s [C]i [C]t [C]i [C]v [C]e I-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
NFAT-1 [C]N [C]F [C]A [C]T [C]- [C]1 E-protein 
. [C]. O 

Three [C]T [C]h [C]r [C]e [C]e O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Il-4 [C]I [C]l [C]- [C]4 B-DNA 
NFAT-1 [C]N [C]F [C]A [C]T [C]- [C]1 I-DNA 
sites [C]s [C]i [C]t [C]e [C]s E-DNA 
are [C]a [C]r [C]e O 
closely [C]c [C]l [C]o [C]s [C]e [C]l [C]y O 
linked [C]l [C]i [C]n [C]k [C]e [C]d O 
to [C]t [C]o O 
weak [C]w [C]e [C]a [C]k O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
sites [C]s [C]i [C]t [C]e [C]s O 
of [C]o [C]f O 
Octamer [C]O [C]c [C]t [C]a [C]m [C]e [C]r B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

Several [C]S [C]e [C]v [C]e [C]r [C]a [C]l O 
purine [C]p [C]u [C]r [C]i [C]n [C]e O 
boxes [C]b [C]o [C]x [C]e [C]s O 
and [C]a [C]n [C]d O 
an [C]a [C]n O 
AT-rich [C]A [C]T [C]- [C]r [C]i [C]c [C]h B-DNA 
protein-binding [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g I-DNA 
site [C]s [C]i [C]t [C]e E-DNA 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Il-4 [C]I [C]l [C]- [C]4 O 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r O 
are [C]a [C]r [C]e O 
also [C]a [C]l [C]s [C]o O 
recognized [C]r [C]e [C]c [C]o [C]g [C]n [C]i [C]z [C]e [C]d O 
by [C]b [C]y O 
the [C]t [C]h [C]e O 
high [C]h [C]i [C]g [C]h B-protein 
mobility [C]m [C]o [C]b [C]i [C]l [C]i [C]t [C]y I-protein 
group [C]g [C]r [C]o [C]u [C]p I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
HMG [C]H [C]M [C]G B-protein 
I [C]I I-protein 
( [C]( I-protein 
Y [C]Y E-protein 
) [C]) O 
. [C]. O 

Whereas [C]W [C]h [C]e [C]r [C]e [C]a [C]s O 
the [C]t [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
NFAT-1 [C]N [C]F [C]A [C]T [C]- [C]1 S-protein 
and [C]a [C]n [C]d O 
Octamer [C]O [C]c [C]t [C]a [C]m [C]e [C]r B-protein 
factors [C]f [C]a [C]c [C]t [C]o [C]r [C]s E-protein 
enhance [C]e [C]n [C]h [C]a [C]n [C]c [C]e O 
the [C]t [C]h [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
Il-4 [C]I [C]l [C]- [C]4 B-DNA 
promoter [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]r E-DNA 
, [C], O 
the [C]t [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
HMG [C]H [C]M [C]G O 
I [C]I O 
( [C]( O 
Y [C]Y O 
) [C]) O 
suppresses [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]e [C]s O 
its [C]i [C]t [C]s O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
, [C], O 
therefore [C]t [C]h [C]e [C]r [C]e [C]f [C]o [C]r [C]e O 
, [C], O 
appears [C]a [C]p [C]p [C]e [C]a [C]r [C]s O 
to [C]t [C]o O 
be [C]b [C]e O 
involved [C]i [C]n [C]v [C]o [C]l [C]v [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
suppression [C]s [C]u [C]p [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
Il-4 [C]I [C]l [C]- [C]4 S-protein 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
resting [C]r [C]e [C]s [C]t [C]i [C]n [C]g B-cell_type 
T [C]T I-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

Reversibility [C]R [C]e [C]v [C]e [C]r [C]s [C]i [C]b [C]i [C]l [C]i [C]t [C]y O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
differentiated [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]e [C]d O 
state [C]s [C]t [C]a [C]t [C]e O 
in [C]i [C]n O 
somatic [C]s [C]o [C]m [C]a [C]t [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

Analysis [C]A [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
de [C]d [C]e O 
novo [C]n [C]o [C]v [C]o O 
gene [C]g [C]e [C]n [C]e O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
multinucleated [C]m [C]u [C]l [C]t [C]i [C]n [C]u [C]c [C]l [C]e [C]a [C]t [C]e [C]d B-cell_type 
heterokaryons [C]h [C]e [C]t [C]e [C]r [C]o [C]k [C]a [C]r [C]y [C]o [C]n [C]s E-cell_type 
has [C]h [C]a [C]s O 
shown [C]s [C]h [C]o [C]w [C]n O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
differentiated [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]e [C]d O 
state [C]s [C]t [C]a [C]t [C]e O 
, [C], O 
although [C]a [C]l [C]t [C]h [C]o [C]u [C]g [C]h O 
stable [C]s [C]t [C]a [C]b [C]l [C]e O 
, [C], O 
is [C]i [C]s O 
not [C]n [C]o [C]t O 
irreversible [C]i [C]r [C]r [C]e [C]v [C]e [C]r [C]s [C]i [C]b [C]l [C]e O 
, [C], O 
and [C]a [C]n [C]d O 
can [C]c [C]a [C]n O 
be [C]b [C]e O 
reprogrammed [C]r [C]e [C]p [C]r [C]o [C]g [C]r [C]a [C]m [C]m [C]e [C]d O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
appropriate [C]a [C]p [C]p [C]r [C]o [C]p [C]r [C]i [C]a [C]t [C]e O 
combinations [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
trans-acting [C]t [C]r [C]a [C]n [C]s [C]- [C]a [C]c [C]t [C]i [C]n [C]g B-protein 
regulatory [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]y I-protein 
molecules [C]m [C]o [C]l [C]e [C]c [C]u [C]l [C]e [C]s E-protein 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
properties [C]p [C]r [C]o [C]p [C]e [C]r [C]t [C]i [C]e [C]s O 
have [C]h [C]a [C]v [C]e O 
been [C]b [C]e [C]e [C]n O 
exploited [C]e [C]x [C]p [C]l [C]o [C]i [C]t [C]e [C]d O 
to [C]t [C]o O 
design [C]d [C]e [C]s [C]i [C]g [C]n O 
strategies [C]s [C]t [C]r [C]a [C]t [C]e [C]g [C]i [C]e [C]s O 
for [C]f [C]o [C]r O 
identifying [C]i [C]d [C]e [C]n [C]t [C]i [C]f [C]y [C]i [C]n [C]g O 
novel [C]n [C]o [C]v [C]e [C]l O 
regulators [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]o [C]r [C]s O 
of [C]o [C]f O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
. [C]. O 

Phosphatidylcholine [C]P [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]i [C]d [C]y [C]l [C]c [C]h [C]o [C]l [C]i [C]n [C]e O 
hydrolysis [C]h [C]y [C]d [C]r [C]o [C]l [C]y [C]s [C]i [C]s O 
activates [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]s O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
and [C]a [C]n [C]d O 
increases [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
human [C]h [C]u [C]m [C]a [C]n O 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
virus [C]v [C]i [C]r [C]u [C]s O 
replication [C]r [C]e [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
T [C]T B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
. [C]. O 

We [C]W [C]e O 
have [C]h [C]a [C]v [C]e O 
tested [C]t [C]e [C]s [C]t [C]e [C]d O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
breakdown [C]b [C]r [C]e [C]a [C]k [C]d [C]o [C]w [C]n O 
of [C]o [C]f O 
phosphatidylcholine [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]i [C]d [C]y [C]l [C]c [C]h [C]o [C]l [C]i [C]n [C]e O 
( [C]( O 
PC [C]P [C]C O 
) [C]) O 
initiated [C]i [C]n [C]i [C]t [C]i [C]a [C]t [C]e [C]d O 
by [C]b [C]y O 
exogenous [C]e [C]x [C]o [C]g [C]e [C]n [C]o [C]u [C]s O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
PC-specific [C]P [C]C [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-protein 
phospholipase [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]l [C]i [C]p [C]a [C]s [C]e I-protein 
C [C]C E-protein 
( [C]( O 
PC-PLC [C]P [C]C [C]- [C]P [C]L [C]C S-protein 
) [C]) O 
from [C]f [C]r [C]o [C]m O 
Bacillus [C]B [C]a [C]c [C]i [C]l [C]l [C]u [C]s O 
cereus [C]c [C]e [C]r [C]e [C]u [C]s O 
or [C]o [C]r O 
by [C]b [C]y O 
endogenous [C]e [C]n [C]d [C]o [C]g [C]e [C]n [C]o [C]u [C]s O 
overexpression [C]o [C]v [C]e [C]r [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
PC-PLC [C]P [C]C [C]- [C]P [C]L [C]C S-protein 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
and [C]a [C]n [C]d O 
increases [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]s O 
human [C]h [C]u [C]m [C]a [C]n B-DNA 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y I-DNA 
virus [C]v [C]i [C]r [C]u [C]s I-DNA 
( [C]( I-DNA 
HIV [C]H [C]I [C]V I-DNA 
) [C]) I-DNA 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r E-DNA 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

PC-PLC-activated [C]P [C]C [C]- [C]P [C]L [C]C [C]- [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
hydrolysis [C]h [C]y [C]d [C]r [C]o [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
PC [C]P [C]C O 
was [C]w [C]a [C]s O 
found [C]f [C]o [C]u [C]n [C]d O 
to [C]t [C]o O 
induce [C]i [C]n [C]d [C]u [C]c [C]e O 
bona [C]b [C]o [C]n [C]a O 
fide [C]f [C]i [C]d [C]e O 
p50/p65 [C]p [C]5 [C]0 [C]/ [C]p [C]6 [C]5 B-protein 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B E-protein 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
in [C]i [C]n O 
three [C]t [C]h [C]r [C]e [C]e O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
cell [C]c [C]e [C]l [C]l B-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n O 
or [C]o [C]r O 
murine [C]m [C]u [C]r [C]i [C]n [C]e O 
origin [C]o [C]r [C]i [C]g [C]i [C]n O 
. [C]. O 

No [C]N [C]o O 
significant [C]s [C]i [C]g [C]n [C]i [C]f [C]i [C]c [C]a [C]n [C]t O 
changes [C]c [C]h [C]a [C]n [C]g [C]e [C]s O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
turnover [C]t [C]u [C]r [C]n [C]o [C]v [C]e [C]r O 
of [C]o [C]f O 
other [C]o [C]t [C]h [C]e [C]r O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
phospholipids [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]l [C]i [C]p [C]i [C]d [C]s O 
were [C]w [C]e [C]r [C]e O 
detected [C]d [C]e [C]t [C]e [C]c [C]t [C]e [C]d O 
in [C]i [C]n O 
PC-PLC-treated [C]P [C]C [C]- [C]P [C]L [C]C [C]- [C]t [C]r [C]e [C]a [C]t [C]e [C]d B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

Induction [C]I [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
by [C]b [C]y O 
PC-PLC [C]P [C]C [C]- [C]P [C]L [C]C S-protein 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
depend [C]d [C]e [C]p [C]e [C]n [C]d O 
on [C]o [C]n O 
de [C]d [C]e O 
novo [C]n [C]o [C]v [C]o O 
synthesis [C]s [C]y [C]n [C]t [C]h [C]e [C]s [C]i [C]s O 
of [C]o [C]f O 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s O 
or [C]o [C]r O 
autocrine [C]a [C]u [C]t [C]o [C]c [C]r [C]i [C]n [C]e O 
secretion [C]s [C]e [C]c [C]r [C]e [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
tumor [C]t [C]u [C]m [C]o [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r E-protein 
or [C]o [C]r O 
interleukin [C]i [C]n [C]t [C]e [C]r [C]l [C]e [C]u [C]k [C]i [C]n B-protein 
1 [C]1 E-protein 
. [C]. O 

In [C]I [C]n O 
human [C]h [C]u [C]m [C]a [C]n B-cell_line 
monocytic [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]i [C]c I-cell_line 
and [C]a [C]n [C]d I-cell_line 
lymphoblastoid [C]l [C]y [C]m [C]p [C]h [C]o [C]b [C]l [C]a [C]s [C]t [C]o [C]i [C]d I-cell_line 
T-cell [C]T [C]- [C]c [C]e [C]l [C]l I-cell_line 
lines [C]l [C]i [C]n [C]e [C]s E-cell_line 
, [C], O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B E-protein 
by [C]b [C]y O 
PC-PLC [C]P [C]C [C]- [C]P [C]L [C]C S-protein 
resulted [C]r [C]e [C]s [C]u [C]l [C]t [C]e [C]d O 
in [C]i [C]n O 
clear [C]c [C]l [C]e [C]a [C]r O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
luciferase [C]l [C]u [C]c [C]i [C]f [C]e [C]r [C]a [C]s [C]e S-protein 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
vectors [C]v [C]e [C]c [C]t [C]o [C]r [C]s O 
placed [C]p [C]l [C]a [C]c [C]e [C]d O 
under [C]u [C]n [C]d [C]e [C]r O 
the [C]t [C]h [C]e O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
of [C]o [C]f O 
synthetic [C]s [C]y [C]n [C]t [C]h [C]e [C]t [C]i [C]c B-DNA 
kappa [C]k [C]a [C]p [C]p [C]a I-DNA 
B [C]B I-DNA 
enhancers [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r [C]s E-DNA 
or [C]o [C]r O 
wild [C]w [C]i [C]l [C]d O 
type [C]t [C]y [C]p [C]e O 
, [C], O 
but [C]b [C]u [C]t O 
not [C]n [C]o [C]t O 
kappa [C]k [C]a [C]p [C]p [C]a O 
B-mutated [C]B [C]- [C]m [C]u [C]t [C]a [C]t [C]e [C]d O 
, [C], O 
HIV [C]H [C]I [C]V B-DNA 
long [C]l [C]o [C]n [C]g I-DNA 
terminal [C]t [C]e [C]r [C]m [C]i [C]n [C]a [C]l I-DNA 
repeat [C]r [C]e [C]p [C]e [C]a [C]t I-DNA 
constructs [C]c [C]o [C]n [C]s [C]t [C]r [C]u [C]c [C]t [C]s E-DNA 
. [C]. O 

HIV [C]H [C]I [C]V O 
replication [C]r [C]e [C]p [C]l [C]i [C]c [C]a [C]t [C]i [C]o [C]n O 
was [C]w [C]a [C]s O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
by [C]b [C]y O 
PC-PLC [C]P [C]C [C]- [C]P [C]L [C]C S-protein 
in [C]i [C]n O 
chronically [C]c [C]h [C]r [C]o [C]n [C]i [C]c [C]a [C]l [C]l [C]y O 
infected [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
and [C]a [C]n [C]d O 
T [C]T O 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
. [C]. O 

NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a O 
B [C]B O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
promoted [C]p [C]r [C]o [C]m [C]o [C]t [C]e [C]d O 
by [C]b [C]y O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
exogenous [C]e [C]x [C]o [C]g [C]e [C]n [C]o [C]u [C]s B-protein 
PC-PLC [C]P [C]C [C]- [C]P [C]L [C]C E-protein 
correlated [C]c [C]o [C]r [C]r [C]e [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
an [C]a [C]n O 
intense [C]i [C]n [C]t [C]e [C]n [C]s [C]e O 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
diacylglycerol [C]d [C]i [C]a [C]c [C]y [C]l [C]g [C]l [C]y [C]c [C]e [C]r [C]o [C]l O 
. [C]. O 

However [C]H [C]o [C]w [C]e [C]v [C]e [C]r O 
, [C], O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
a [C]a O 
phosphatidylinositol-specific [C]p [C]h [C]o [C]s [C]p [C]h [C]a [C]t [C]i [C]d [C]y [C]l [C]i [C]n [C]o [C]s [C]i [C]t [C]o [C]l [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-protein 
PLC [C]P [C]L [C]C E-protein 
from [C]f [C]r [C]o [C]m O 
B.cereus [C]B [C]. [C]c [C]e [C]r [C]e [C]u [C]s O 
also [C]a [C]l [C]s [C]o O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
diacylglycerol [C]d [C]i [C]a [C]c [C]y [C]l [C]g [C]l [C]y [C]c [C]e [C]r [C]o [C]l O 
but [C]b [C]u [C]t O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
kappa [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B I-protein 
enhancer-directed [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r [C]- [C]d [C]i [C]r [C]e [C]c [C]t [C]e [C]d I-protein 
vectors [C]v [C]e [C]c [C]t [C]o [C]r [C]s E-protein 
. [C]. O 

PC-PLC-induced [C]P [C]C [C]- [C]P [C]L [C]C [C]- [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a O 
B [C]B O 
activation [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]i [C]o [C]n O 
could [C]c [C]o [C]u [C]l [C]d O 
not [C]n [C]o [C]t O 
be [C]b [C]e O 
blocked [C]b [C]l [C]o [C]c [C]k [C]e [C]d O 
by [C]b [C]y O 
a [C]a O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
inhibitor [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]o [C]r O 
of [C]o [C]f O 
phorbol [C]p [C]h [C]o [C]r [C]b [C]o [C]l B-protein 
ester-inducible [C]e [C]s [C]t [C]e [C]r [C]- [C]i [C]n [C]d [C]u [C]c [C]i [C]b [C]l [C]e I-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n I-protein 
kinases [C]k [C]i [C]n [C]a [C]s [C]e [C]s I-protein 
C [C]C E-protein 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
indicate [C]i [C]n [C]d [C]i [C]c [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
a [C]a O 
cellular [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
, [C], O 
dependent [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
on [C]o [C]n O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
PC [C]P [C]C O 
breakdown [C]b [C]r [C]e [C]a [C]k [C]d [C]o [C]w [C]n O 
, [C], O 
is [C]i [C]s O 
functional [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]a [C]l O 
in [C]i [C]n O 
T [C]T B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
monocytes [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
and [C]a [C]n [C]d O 
may [C]m [C]a [C]y O 
be [C]b [C]e O 
used [C]u [C]s [C]e [C]d O 
by [C]b [C]y O 
various [C]v [C]a [C]r [C]i [C]o [C]u [C]s O 
transmembrane [C]t [C]r [C]a [C]n [C]s [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e O 
receptors [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]s O 
to [C]t [C]o O 
activate [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e O 
HIV [C]H [C]I [C]V O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a O 
B-dependent [C]B [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
HIV [C]H [C]I [C]V B-DNA 
enhancer [C]e [C]n [C]h [C]a [C]n [C]c [C]e [C]r E-DNA 
. [C]. O 

Novel [C]N [C]o [C]v [C]e [C]l O 
mechanism [C]m [C]e [C]c [C]h [C]a [C]n [C]i [C]s [C]m O 
for [C]f [C]o [C]r O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
human [C]h [C]u [C]m [C]a [C]n B-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
by [C]b [C]y O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
. [C]. O 

Glucocorticoids [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
inhibit [C]i [C]n [C]h [C]i [C]b [C]i [C]t O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
IL-2 [C]I [C]L [C]- [C]2 B-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r E-protein 
. [C]. O 

Interaction [C]I [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
with [C]w [C]i [C]t [C]h O 
its [C]i [C]t [C]s O 
high [C]h [C]i [C]g [C]h B-protein 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y I-protein 
membrane [C]m [C]e [C]m [C]b [C]r [C]a [C]n [C]e I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
complex [C]c [C]o [C]m [C]p [C]l [C]e [C]x E-protein 
( [C]( O 
IL-2R [C]I [C]L [C]- [C]2 [C]R S-protein 
) [C]) O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
on [C]o [C]n O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
T [C]T B-cell_type 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
induces [C]i [C]n [C]d [C]u [C]c [C]e [C]s O 
cell [C]c [C]e [C]l [C]l O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
mediates [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]s O 
effector [C]e [C]f [C]f [C]e [C]c [C]t [C]o [C]r O 
functions [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]s O 
. [C]. O 

Glucocorticoids [C]G [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
inhibit [C]i [C]n [C]h [C]i [C]b [C]i [C]t O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
production [C]p [C]r [C]o [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
inhibiting [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]n [C]g O 
TCR-mediated [C]T [C]C [C]R [C]- [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

We [C]W [C]e O 
asked [C]a [C]s [C]k [C]e [C]d O 
whether [C]w [C]h [C]e [C]t [C]h [C]e [C]r O 
they [C]t [C]h [C]e [C]y O 
also [C]a [C]l [C]s [C]o O 
inhibit [C]i [C]n [C]h [C]i [C]b [C]i [C]t O 
the [C]t [C]h [C]e O 
action [C]a [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
by [C]b [C]y O 
inhibiting [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]n [C]g O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
IL-2R [C]I [C]L [C]- [C]2 [C]R S-protein 
. [C]. O 

Human [C]H [C]u [C]m [C]a [C]n B-cell_type 
peripheral [C]p [C]e [C]r [C]i [C]p [C]h [C]e [C]r [C]a [C]l I-cell_type 
blood [C]b [C]l [C]o [C]o [C]d I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
PMA [C]P [C]M [C]A O 
for [C]f [C]o [C]r O 
48 [C]4 [C]8 O 
h [C]h O 
( [C]( O 
PMA [C]P [C]M [C]A B-cell_line 
blasts [C]b [C]l [C]a [C]s [C]t [C]s E-cell_line 
) [C]) O 
, [C], O 
were [C]w [C]e [C]r [C]e O 
incubated [C]i [C]n [C]c [C]u [C]b [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
incremental [C]i [C]n [C]c [C]r [C]e [C]m [C]e [C]n [C]t [C]a [C]l O 
dosages [C]d [C]o [C]s [C]a [C]g [C]e [C]s O 
of [C]o [C]f O 
dexamethasone [C]d [C]e [C]x [C]a [C]m [C]e [C]t [C]h [C]a [C]s [C]o [C]n [C]e O 
( [C]( O 
Dex [C]D [C]e [C]x O 
; [C]; O 
10 [C]1 [C]0 O 
( [C]( O 
-5 [C]- [C]5 O 
) [C]) O 
-10 [C]- [C]1 [C]0 O 
( [C]( O 
-9 [C]- [C]9 O 
) [C]) O 
M [C]M O 
) [C]) O 
. [C]. O 

Dex [C]D [C]e [C]x O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
the [C]t [C]h [C]e O 
IL-2-dependent [C]I [C]L [C]- [C]2 [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
PMA [C]P [C]M [C]A B-cell_line 
blasts [C]b [C]l [C]a [C]s [C]t [C]s E-cell_line 
in [C]i [C]n O 
a [C]a O 
dose-dependent [C]d [C]o [C]s [C]e [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
fashion [C]f [C]a [C]s [C]h [C]i [C]o [C]n O 
( [C]( O 
IC50 [C]I [C]C [C]5 [C]0 O 
, [C], O 
5 [C]5 O 
x [C]x O 
10 [C]1 [C]0 O 
( [C]( O 
-8 [C]- [C]8 O 
) [C]) O 
M [C]M O 
) [C]) O 
. [C]. O 

Cell [C]C [C]e [C]l [C]l O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
IL-2R [C]I [C]L [C]- [C]2 [C]R B-protein 
alpha- [C]a [C]l [C]p [C]h [C]a [C]- I-protein 
and [C]a [C]n [C]d I-protein 
beta-chains [C]b [C]e [C]t [C]a [C]- [C]c [C]h [C]a [C]i [C]n [C]s E-protein 
as [C]a [C]s O 
determined [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e [C]d O 
by [C]b [C]y O 
immunofluorescence [C]i [C]m [C]m [C]u [C]n [C]o [C]f [C]l [C]u [C]o [C]r [C]e [C]s [C]c [C]e [C]n [C]c [C]e O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
affected [C]a [C]f [C]f [C]e [C]c [C]t [C]e [C]d O 
by [C]b [C]y O 
Dex [C]D [C]e [C]x O 
. [C]. O 

In [C]I [C]n O 
addition [C]a [C]d [C]d [C]i [C]t [C]i [C]o [C]n O 
, [C], O 
Scatchard [C]S [C]c [C]a [C]t [C]c [C]h [C]a [C]r [C]d O 
plot [C]p [C]l [C]o [C]t O 
analysis [C]a [C]n [C]a [C]l [C]y [C]s [C]i [C]s O 
of [C]o [C]f O 
125I-labeled [C]1 [C]2 [C]5 [C]I [C]- [C]l [C]a [C]b [C]e [C]l [C]e [C]d B-protein 
IL-2 [C]I [C]L [C]- [C]2 E-protein 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
Dex [C]D [C]e [C]x O 
did [C]d [C]i [C]d O 
not [C]n [C]o [C]t O 
affect [C]a [C]f [C]f [C]e [C]c [C]t O 
the [C]t [C]h [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
IL-2 [C]I [C]L [C]- [C]2 S-protein 
, [C], O 
thus [C]t [C]h [C]u [C]s O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
inhibition [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
is [C]i [C]s O 
due [C]d [C]u [C]e O 
to [C]t [C]o O 
a [C]a O 
postreceptor [C]p [C]o [C]s [C]t [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r O 
effect [C]e [C]f [C]f [C]e [C]c [C]t O 
. [C]. O 

Inhibition [C]I [C]n [C]h [C]i [C]b [C]i [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
T [C]T O 
cell [C]c [C]e [C]l [C]l O 
proliferation [C]p [C]r [C]o [C]l [C]i [C]f [C]e [C]r [C]a [C]t [C]i [C]o [C]n O 
by [C]b [C]y O 
Dex [C]D [C]e [C]x O 
was [C]w [C]a [C]s O 
associated [C]a [C]s [C]s [C]o [C]c [C]i [C]a [C]t [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
IL-2-dependent [C]I [C]L [C]- [C]2 [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
tyrosine [C]t [C]y [C]r [C]o [C]s [C]i [C]n [C]e O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
several [C]s [C]e [C]v [C]e [C]r [C]a [C]l O 
intracellular [C]i [C]n [C]t [C]r [C]a [C]c [C]e [C]l [C]l [C]u [C]l [C]a [C]r B-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
and [C]a [C]n [C]d O 
decreased [C]d [C]e [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
phosphorylation [C]p [C]h [C]o [C]s [C]p [C]h [C]o [C]r [C]y [C]l [C]a [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
retinoblastoma [C]r [C]e [C]t [C]i [C]n [C]o [C]b [C]l [C]a [C]s [C]t [C]o [C]m [C]a B-protein 
gene [C]g [C]e [C]n [C]e I-protein 
product [C]p [C]r [C]o [C]d [C]u [C]c [C]t I-protein 
Rb [C]R [C]b E-protein 
, [C], O 
a [C]a O 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n O 
essential [C]e [C]s [C]s [C]e [C]n [C]t [C]i [C]a [C]l O 
for [C]f [C]o [C]r O 
controlling [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]l [C]i [C]n [C]g O 
the [C]t [C]h [C]e O 
progression [C]p [C]r [C]o [C]g [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
of [C]o [C]f O 
cells [C]c [C]e [C]l [C]l [C]s O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
the [C]t [C]h [C]e O 
cell [C]c [C]e [C]l [C]l O 
cycle [C]c [C]y [C]c [C]l [C]e O 
. [C]. O 

IL-2-dependent [C]I [C]L [C]- [C]2 [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
IL-2R [C]I [C]L [C]- [C]2 [C]R O 
alpha [C]a [C]l [C]p [C]h [C]a O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
PMA [C]P [C]M [C]A B-cell_line 
blasts [C]b [C]l [C]a [C]s [C]t [C]s E-cell_line 
and [C]a [C]n [C]d O 
NF-kB [C]N [C]F [C]- [C]k [C]B S-protein 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
in [C]i [C]n O 
resting [C]r [C]e [C]s [C]t [C]i [C]n [C]g B-cell_type 
human [C]h [C]u [C]m [C]a [C]n I-cell_type 
T [C]T I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
were [C]w [C]e [C]r [C]e O 
also [C]a [C]l [C]s [C]o O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
by [C]b [C]y O 
Dex [C]D [C]e [C]x O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
results [C]r [C]e [C]s [C]u [C]l [C]t [C]s O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
glucocorticoids [C]g [C]l [C]u [C]c [C]o [C]c [C]o [C]r [C]t [C]i [C]c [C]o [C]i [C]d [C]s O 
inhibit [C]i [C]n [C]h [C]i [C]b [C]i [C]t O 
preactivated [C]p [C]r [C]e [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d B-cell_line 
T [C]T I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
by [C]b [C]y O 
down-regulating [C]d [C]o [C]w [C]n [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]i [C]n [C]g O 
signal [C]s [C]i [C]g [C]n [C]a [C]l O 
transduction [C]t [C]r [C]a [C]n [C]s [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
IL-2R [C]I [C]L [C]- [C]2 [C]R S-protein 
. [C]. O 

Chronic [C]C [C]h [C]r [C]o [C]n [C]i [C]c O 
human [C]h [C]u [C]m [C]a [C]n O 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
virus [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
1 [C]1 O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
stimulates [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]s O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a O 
B/rel [C]B [C]/ [C]r [C]e [C]l O 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activities [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]i [C]e [C]s O 
in [C]i [C]n O 
myelomonoblastic [C]m [C]y [C]e [C]l [C]o [C]m [C]o [C]n [C]o [C]b [C]l [C]a [C]s [C]t [C]i [C]c B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

The [C]T [C]h [C]e O 
relationship [C]r [C]e [C]l [C]a [C]t [C]i [C]o [C]n [C]s [C]h [C]i [C]p O 
between [C]b [C]e [C]t [C]w [C]e [C]e [C]n O 
human [C]h [C]u [C]m [C]a [C]n O 
immunodeficiency [C]i [C]m [C]m [C]u [C]n [C]o [C]d [C]e [C]f [C]i [C]c [C]i [C]e [C]n [C]c [C]y O 
virus [C]v [C]i [C]r [C]u [C]s O 
type [C]t [C]y [C]p [C]e O 
1 [C]1 O 
( [C]( O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
) [C]) O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
induction [C]i [C]n [C]d [C]u [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a O 
B [C]B O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
was [C]w [C]a [C]s O 
examined [C]e [C]x [C]a [C]m [C]i [C]n [C]e [C]d O 
in [C]i [C]n O 
a [C]a O 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
model [C]m [C]o [C]d [C]e [C]l E-cell_line 
of [C]o [C]f O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
derived [C]d [C]e [C]r [C]i [C]v [C]e [C]d O 
from [C]f [C]r [C]o [C]m O 
the [C]t [C]h [C]e O 
PLB-985 [C]P [C]L [C]B [C]- [C]9 [C]8 [C]5 B-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
. [C]. O 

Chronic [C]C [C]h [C]r [C]o [C]n [C]i [C]c O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
of [C]o [C]f O 
PLB-985 [C]P [C]L [C]B [C]- [C]9 [C]8 [C]5 B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
led [C]l [C]e [C]d O 
to [C]t [C]o O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
monocyte-specific [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]e [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
surface [C]s [C]u [C]r [C]f [C]a [C]c [C]e O 
marker [C]m [C]a [C]r [C]k [C]e [C]r O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
, [C], O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
c-fms [C]c [C]- [C]f [C]m [C]s O 
gene [C]g [C]e [C]n [C]e O 
transcription [C]t [C]r [C]a [C]n [C]s [C]c [C]r [C]i [C]p [C]t [C]i [C]o [C]n O 
, [C], O 
and [C]a [C]n [C]d O 
morphological [C]m [C]o [C]r [C]p [C]h [C]o [C]l [C]o [C]g [C]i [C]c [C]a [C]l O 
alterations [C]a [C]l [C]t [C]e [C]r [C]a [C]t [C]i [C]o [C]n [C]s O 
consistent [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
differentiation [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t [C]i [C]a [C]t [C]i [C]o [C]n O 
along [C]a [C]l [C]o [C]n [C]g O 
the [C]t [C]h [C]e O 
monocytic [C]m [C]o [C]n [C]o [C]c [C]y [C]t [C]i [C]c O 
pathway [C]p [C]a [C]t [C]h [C]w [C]a [C]y O 
. [C]. O 

PLB-IIIB [C]P [C]L [C]B [C]- [C]I [C]I [C]I [C]B B-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
displayed [C]d [C]i [C]s [C]p [C]l [C]a [C]y [C]e [C]d O 
a [C]a O 
constitutive [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a O 
B-like [C]B [C]- [C]l [C]i [C]k [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
that [C]t [C]h [C]a [C]t O 
was [C]w [C]a [C]s O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
from [C]f [C]r [C]o [C]m O 
that [C]t [C]h [C]a [C]t O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
by [C]b [C]y O 
tumor [C]t [C]u [C]m [C]o [C]r B-protein 
necrosis [C]n [C]e [C]c [C]r [C]o [C]s [C]i [C]s I-protein 
factor [C]f [C]a [C]c [C]t [C]o [C]r I-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
or [C]o [C]r O 
phorbol [C]p [C]h [C]o [C]r [C]b [C]o [C]l O 
12-myristate [C]1 [C]2 [C]- [C]m [C]y [C]r [C]i [C]s [C]t [C]a [C]t [C]e O 
13-acetate [C]1 [C]3 [C]- [C]a [C]c [C]e [C]t [C]a [C]t [C]e O 
treatment [C]t [C]r [C]e [C]a [C]t [C]m [C]e [C]n [C]t O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
parental [C]p [C]a [C]r [C]e [C]n [C]t [C]a [C]l B-cell_line 
PLB-985 [C]P [C]L [C]B [C]- [C]9 [C]8 [C]5 I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
line [C]l [C]i [C]n [C]e E-cell_line 
. [C]. O 

This [C]T [C]h [C]i [C]s O 
unique [C]u [C]n [C]i [C]q [C]u [C]e O 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
consisted [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]d O 
of [C]o [C]f O 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s O 
of [C]o [C]f O 
70 [C]7 [C]0 B-protein 
, [C], I-protein 
90 [C]9 [C]0 I-protein 
, [C], I-protein 
and [C]a [C]n [C]d I-protein 
100 [C]1 [C]0 [C]0 I-protein 
kDa [C]k [C]D [C]a E-protein 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
high [C]h [C]i [C]g [C]h O 
degree [C]d [C]e [C]g [C]r [C]e [C]e O 
of [C]o [C]f O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
specificity [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]i [C]t [C]y O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B I-protein 
site [C]s [C]i [C]t [C]e E-protein 
within [C]w [C]i [C]t [C]h [C]i [C]n O 
the [C]t [C]h [C]e O 
PRDII [C]P [C]R [C]D [C]I [C]I B-protein 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-protein 
of [C]o [C]f O 
beta [C]b [C]e [C]t [C]a B-protein 
interferon [C]i [C]n [C]t [C]e [C]r [C]f [C]e [C]r [C]o [C]n E-protein 
. [C]. O 

In [C]I [C]n O 
this [C]t [C]h [C]i [C]s O 
report [C]r [C]e [C]p [C]o [C]r [C]t O 
, [C], O 
we [C]w [C]e O 
characterize [C]c [C]h [C]a [C]r [C]a [C]c [C]t [C]e [C]r [C]i [C]z [C]e O 
the [C]t [C]h [C]e O 
nature [C]n [C]a [C]t [C]u [C]r [C]e O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s O 
and [C]a [C]n [C]d O 
demonstrate [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e O 
that [C]t [C]h [C]a [C]t O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
these [C]t [C]h [C]e [C]s [C]e O 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s O 
is [C]i [C]s O 
also [C]a [C]l [C]s [C]o O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
following [C]f [C]o [C]l [C]l [C]o [C]w [C]i [C]n [C]g O 
Sendai [C]S [C]e [C]n [C]d [C]a [C]i O 
paramyxovirus [C]p [C]a [C]r [C]a [C]m [C]y [C]x [C]o [C]v [C]i [C]r [C]u [C]s O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

The [C]T [C]h [C]e O 
70-kDa [C]7 [C]0 [C]- [C]k [C]D [C]a B-protein 
protein [C]p [C]r [C]o [C]t [C]e [C]i [C]n E-protein 
corresponds [C]c [C]o [C]r [C]r [C]e [C]s [C]p [C]o [C]n [C]d [C]s O 
to [C]t [C]o O 
the [C]t [C]h [C]e O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B I-protein 
RelA [C]R [C]e [C]l [C]A I-protein 
( [C]( I-protein 
p65 [C]p [C]6 [C]5 I-protein 
) [C]) I-protein 
subunit [C]s [C]u [C]b [C]u [C]n [C]i [C]t E-protein 
, [C], O 
which [C]w [C]h [C]i [C]c [C]h O 
is [C]i [C]s O 
activated [C]a [C]c [C]t [C]i [C]v [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
response [C]r [C]e [C]s [C]p [C]o [C]n [C]s [C]e O 
to [C]t [C]o O 
an [C]a [C]n O 
acute [C]a [C]c [C]u [C]t [C]e O 
paramyxovirus [C]p [C]a [C]r [C]a [C]m [C]y [C]x [C]o [C]v [C]i [C]r [C]u [C]s O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
or [C]o [C]r O 
a [C]a O 
chronic [C]c [C]h [C]r [C]o [C]n [C]i [C]c O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
. [C]. O 

Virus [C]V [C]i [C]r [C]u [C]s O 
infection [C]i [C]n [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
does [C]d [C]o [C]e [C]s O 
not [C]n [C]o [C]t O 
appear [C]a [C]p [C]p [C]e [C]a [C]r O 
to [C]t [C]o O 
alter [C]a [C]l [C]t [C]e [C]r O 
the [C]t [C]h [C]e O 
amount [C]a [C]m [C]o [C]u [C]n [C]t O 
of [C]o [C]f O 
RelA [C]R [C]e [C]l [C]A S-protein 
( [C]( O 
p65 [C]p [C]6 [C]5 S-protein 
) [C]) O 
or [C]o [C]r O 
NFKB1 [C]N [C]F [C]K [C]B [C]1 S-protein 
( [C]( O 
p50 [C]p [C]5 [C]0 S-protein 
) [C]) O 
but [C]b [C]u [C]t O 
rather [C]r [C]a [C]t [C]h [C]e [C]r O 
affects [C]a [C]f [C]f [C]e [C]c [C]t [C]s O 
the [C]t [C]h [C]e O 
capacity [C]c [C]a [C]p [C]a [C]c [C]i [C]t [C]y O 
of [C]o [C]f O 
I [C]I B-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B I-protein 
alpha [C]a [C]l [C]p [C]h [C]a E-protein 
to [C]t [C]o O 
sequester [C]s [C]e [C]q [C]u [C]e [C]s [C]t [C]e [C]r O 
RelA [C]R [C]e [C]l [C]A B-protein 
( [C]( I-protein 
p65 [C]p [C]6 [C]5 I-protein 
) [C]) E-protein 
, [C], O 
therefore [C]t [C]h [C]e [C]r [C]e [C]f [C]o [C]r [C]e O 
leading [C]l [C]e [C]a [C]d [C]i [C]n [C]g O 
to [C]t [C]o O 
constitutive [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
RelA [C]R [C]e [C]l [C]A O 
DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
and [C]a [C]n [C]d O 
to [C]t [C]o O 
increased [C]i [C]n [C]c [C]r [C]e [C]a [C]s [C]e [C]d O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a O 
B-dependent [C]B [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t O 
gene [C]g [C]e [C]n [C]e O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
. [C]. O 

The [C]T [C]h [C]e O 
virally [C]v [C]i [C]r [C]a [C]l [C]l [C]y O 
induced [C]i [C]n [C]d [C]u [C]c [C]e [C]d O 
90- [C]9 [C]0 [C]- B-protein 
to [C]t [C]o I-protein 
100-kDa [C]1 [C]0 [C]0 [C]- [C]k [C]D [C]a I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
have [C]h [C]a [C]v [C]e O 
a [C]a O 
distinct [C]d [C]i [C]s [C]t [C]i [C]n [C]c [C]t O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
specificity [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c [C]i [C]t [C]y O 
for [C]f [C]o [C]r O 
the [C]t [C]h [C]e O 
PRDII [C]P [C]R [C]D [C]I [C]I B-DNA 
domain [C]d [C]o [C]m [C]a [C]i [C]n E-DNA 
and [C]a [C]n [C]d O 
an [C]a [C]n O 
AT-rich [C]A [C]T [C]- [C]r [C]i [C]c [C]h B-DNA 
sequence [C]s [C]e [C]q [C]u [C]e [C]n [C]c [C]e E-DNA 
but [C]b [C]u [C]t O 
do [C]d [C]o O 
not [C]n [C]o [C]t O 
cross-react [C]c [C]r [C]o [C]s [C]s [C]- [C]r [C]e [C]a [C]c [C]t O 
with [C]w [C]i [C]t [C]h O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a O 
B [C]B O 
subunit-specific [C]s [C]u [C]b [C]u [C]n [C]i [C]t [C]- [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
antisera [C]a [C]n [C]t [C]i [C]s [C]e [C]r [C]a O 
directed [C]d [C]i [C]r [C]e [C]c [C]t [C]e [C]d O 
against [C]a [C]g [C]a [C]i [C]n [C]s [C]t O 
NFKB1 [C]N [C]F [C]K [C]B [C]1 S-protein 
( [C]( O 
p105 [C]p [C]1 [C]0 [C]5 S-protein 
or [C]o [C]r O 
p50 [C]p [C]5 [C]0 S-protein 
) [C]) O 
, [C], O 
NFKB2 [C]N [C]F [C]K [C]B [C]2 S-protein 
( [C]( O 
p100 [C]p [C]1 [C]0 [C]0 S-protein 
or [C]o [C]r O 
p52 [C]p [C]5 [C]2 S-protein 
) [C]) O 
, [C], O 
RelA [C]R [C]e [C]l [C]A S-protein 
( [C]( O 
p65 [C]p [C]6 [C]5 S-protein 
) [C]) O 
, [C], O 
or [C]o [C]r O 
c-rel [C]c [C]- [C]r [C]e [C]l S-protein 
. [C]. O 

DNA [C]D [C]N [C]A O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
90- [C]9 [C]0 [C]- B-protein 
to [C]t [C]o I-protein 
100-kDa [C]1 [C]0 [C]0 [C]- [C]k [C]D [C]a I-protein 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s E-protein 
was [C]w [C]a [C]s O 
not [C]n [C]o [C]t O 
inhibited [C]i [C]n [C]h [C]i [C]b [C]i [C]t [C]e [C]d O 
by [C]b [C]y O 
recombinant [C]r [C]e [C]c [C]o [C]m [C]b [C]i [C]n [C]a [C]n [C]t B-protein 
I [C]I I-protein 
kappa [C]k [C]a [C]p [C]p [C]a I-protein 
B [C]B I-protein 
alpha/MAD-3 [C]a [C]l [C]p [C]h [C]a [C]/ [C]M [C]A [C]D [C]- [C]3 E-protein 
and [C]a [C]n [C]d O 
was [C]w [C]a [C]s O 
resistant [C]r [C]e [C]s [C]i [C]s [C]t [C]a [C]n [C]t O 
to [C]t [C]o O 
tryptic [C]t [C]r [C]y [C]p [C]t [C]i [C]c O 
digestion [C]d [C]i [C]g [C]e [C]s [C]t [C]i [C]o [C]n O 
, [C], O 
suggesting [C]s [C]u [C]g [C]g [C]e [C]s [C]t [C]i [C]n [C]g O 
that [C]t [C]h [C]a [C]t O 
these [C]t [C]h [C]e [C]s [C]e O 
proteins [C]p [C]r [C]o [C]t [C]e [C]i [C]n [C]s O 
may [C]m [C]a [C]y O 
not [C]n [C]o [C]t O 
be [C]b [C]e O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a B-protein 
B [C]B I-protein 
related [C]r [C]e [C]l [C]a [C]t [C]e [C]d E-protein 
. [C]. O 

Transient [C]T [C]r [C]a [C]n [C]s [C]i [C]e [C]n [C]t O 
cotransfection [C]c [C]o [C]t [C]r [C]a [C]n [C]s [C]f [C]e [C]c [C]t [C]i [C]o [C]n O 
experiments [C]e [C]x [C]p [C]e [C]r [C]i [C]m [C]e [C]n [C]t [C]s O 
demonstrated [C]d [C]e [C]m [C]o [C]n [C]s [C]t [C]r [C]a [C]t [C]e [C]d O 
that [C]t [C]h [C]a [C]t O 
RelA [C]R [C]e [C]l [C]A O 
and [C]a [C]n [C]d O 
NFKB1 [C]N [C]F [C]K [C]B [C]1 O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
maximally [C]m [C]a [C]x [C]i [C]m [C]a [C]l [C]l [C]y O 
stimulated [C]s [C]t [C]i [C]m [C]u [C]l [C]a [C]t [C]e [C]d O 
HIV-1 [C]H [C]I [C]V [C]- [C]1 B-DNA 
LTR- [C]L [C]T [C]R [C]- I-DNA 
and [C]a [C]n [C]d I-DNA 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a I-DNA 
B-dependent [C]B [C]- [C]d [C]e [C]p [C]e [C]n [C]d [C]e [C]n [C]t I-DNA 
reporter [C]r [C]e [C]p [C]o [C]r [C]t [C]e [C]r I-DNA 
genes [C]g [C]e [C]n [C]e [C]s E-DNA 
; [C]; O 
differences [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]c [C]e [C]s O 
in [C]i [C]n O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a O 
B-like [C]B [C]- [C]l [C]i [C]k [C]e O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
were [C]w [C]e [C]r [C]e O 
also [C]a [C]l [C]s [C]o O 
reflected [C]r [C]e [C]f [C]l [C]e [C]c [C]t [C]e [C]d O 
in [C]i [C]n O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
constitutive [C]c [C]o [C]n [C]s [C]t [C]i [C]t [C]u [C]t [C]i [C]v [C]e O 
levels [C]l [C]e [C]v [C]e [C]l [C]s O 
of [C]o [C]f O 
NF-kappa [C]N [C]F [C]- [C]k [C]a [C]p [C]p [C]a O 
B-regulated [C]B [C]- [C]r [C]e [C]g [C]u [C]l [C]a [C]t [C]e [C]d O 
gene [C]g [C]e [C]n [C]e O 
expression [C]e [C]x [C]p [C]r [C]e [C]s [C]s [C]i [C]o [C]n O 
in [C]i [C]n O 
HIV-1-infected [C]H [C]I [C]V [C]- [C]1 [C]- [C]i [C]n [C]f [C]e [C]c [C]t [C]e [C]d B-cell_line 
myeloid [C]m [C]y [C]e [C]l [C]o [C]i [C]d I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
. [C]. O 

Presence [C]P [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
estrogen-binding [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
sites [C]s [C]i [C]t [C]e [C]s O 
on [C]o [C]n O 
macrophage-like [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]- [C]l [C]i [C]k [C]e B-cell_type 
synoviocytes [C]s [C]y [C]n [C]o [C]v [C]i [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
CD8+ [C]C [C]D [C]8 [C]+ B-cell_line 
, [C], I-cell_line 
CD29+ [C]C [C]D [C]2 [C]9 [C]+ I-cell_line 
, [C], I-cell_line 
CD45RO+ [C]C [C]D [C]4 [C]5 [C]R [C]O [C]+ I-cell_line 
T [C]T I-cell_line 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_line 
in [C]i [C]n O 
normal [C]n [C]o [C]r [C]m [C]a [C]l O 
and [C]a [C]n [C]d O 
rheumatoid [C]r [C]h [C]e [C]u [C]m [C]a [C]t [C]o [C]i [C]d O 
synovium [C]s [C]y [C]n [C]o [C]v [C]i [C]u [C]m O 
. [C]. O 

OBJECTIVE [C]O [C]B [C]J [C]E [C]C [C]T [C]I [C]V [C]E O 
. [C]. O 

To [C]T [C]o O 
study [C]s [C]t [C]u [C]d [C]y O 
the [C]t [C]h [C]e O 
presence [C]p [C]r [C]e [C]s [C]e [C]n [C]c [C]e O 
of [C]o [C]f O 
estrogen-binding [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n [C]- [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
sites [C]s [C]i [C]t [C]e [C]s O 
( [C]( O 
EBS [C]E [C]B [C]S O 
) [C]) O 
in [C]i [C]n O 
the [C]t [C]h [C]e O 
synovial [C]s [C]y [C]n [C]o [C]v [C]i [C]a [C]l O 
tissues [C]t [C]i [C]s [C]s [C]u [C]e [C]s O 
of [C]o [C]f O 
male [C]m [C]a [C]l [C]e O 
and [C]a [C]n [C]d O 
female [C]f [C]e [C]m [C]a [C]l [C]e O 
patients [C]p [C]a [C]t [C]i [C]e [C]n [C]t [C]s O 
with [C]w [C]i [C]t [C]h O 
rheumatoid [C]r [C]h [C]e [C]u [C]m [C]a [C]t [C]o [C]i [C]d O 
arthritis [C]a [C]r [C]t [C]h [C]r [C]i [C]t [C]i [C]s O 
( [C]( O 
RA [C]R [C]A O 
) [C]) O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
age- [C]a [C]g [C]e [C]- O 
and [C]a [C]n [C]d O 
sex-matched [C]s [C]e [C]x [C]- [C]m [C]a [C]t [C]c [C]h [C]e [C]d O 
healthy [C]h [C]e [C]a [C]l [C]t [C]h [C]y O 
controls [C]c [C]o [C]n [C]t [C]r [C]o [C]l [C]s O 
. [C]. O 

METHODS [C]M [C]E [C]T [C]H [C]O [C]D [C]S O 
. [C]. O 

Both [C]B [C]o [C]t [C]h O 
type [C]t [C]y [C]p [C]e O 
1 [C]1 O 
( [C]( O 
high [C]h [C]i [C]g [C]h O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
, [C], O 
low [C]l [C]o [C]w O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
capacity [C]c [C]a [C]p [C]a [C]c [C]i [C]t [C]y O 
) [C]) O 
and [C]a [C]n [C]d O 
type [C]t [C]y [C]p [C]e O 
2 [C]2 O 
( [C]( O 
reduced [C]r [C]e [C]d [C]u [C]c [C]e [C]d O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
, [C], O 
higher [C]h [C]i [C]g [C]h [C]e [C]r O 
binding [C]b [C]i [C]n [C]d [C]i [C]n [C]g O 
capacity [C]c [C]a [C]p [C]a [C]c [C]i [C]t [C]y O 
) [C]) O 
EBS [C]E [C]B [C]S O 
were [C]w [C]e [C]r [C]e O 
investigated [C]i [C]n [C]v [C]e [C]s [C]t [C]i [C]g [C]a [C]t [C]e [C]d O 
in [C]i [C]n O 
both [C]b [C]o [C]t [C]h O 
soluble [C]s [C]o [C]l [C]u [C]b [C]l [C]e O 
and [C]a [C]n [C]d O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
fractions [C]f [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
homogenized [C]h [C]o [C]m [C]o [C]g [C]e [C]n [C]i [C]z [C]e [C]d O 
synovial [C]s [C]y [C]n [C]o [C]v [C]i [C]a [C]l O 
tissue [C]t [C]i [C]s [C]s [C]u [C]e O 
samples [C]s [C]a [C]m [C]p [C]l [C]e [C]s O 
by [C]b [C]y O 
a [C]a O 
dextran-coated [C]d [C]e [C]x [C]t [C]r [C]a [C]n [C]- [C]c [C]o [C]a [C]t [C]e [C]d O 
charcoal [C]c [C]h [C]a [C]r [C]c [C]o [C]a [C]l O 
method [C]m [C]e [C]t [C]h [C]o [C]d O 
. [C]. O 

To [C]T [C]o O 
determine [C]d [C]e [C]t [C]e [C]r [C]m [C]i [C]n [C]e O 
what [C]w [C]h [C]a [C]t O 
type [C]t [C]y [C]p [C]e O 
of [C]o [C]f O 
synovial [C]s [C]y [C]n [C]o [C]v [C]i [C]a [C]l B-cell_type 
cell [C]c [C]e [C]l [C]l E-cell_type 
was [C]w [C]a [C]s O 
positive [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e O 
for [C]f [C]o [C]r O 
EBS [C]E [C]B [C]S O 
, [C], O 
cryosections [C]c [C]r [C]y [C]o [C]s [C]e [C]c [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
synovial [C]s [C]y [C]n [C]o [C]v [C]i [C]a [C]l O 
tissues [C]t [C]i [C]s [C]s [C]u [C]e [C]s O 
were [C]w [C]e [C]r [C]e O 
immunostained [C]i [C]m [C]m [C]u [C]n [C]o [C]s [C]t [C]a [C]i [C]n [C]e [C]d O 
with [C]w [C]i [C]t [C]h O 
a [C]a O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c O 
monoclonal [C]m [C]o [C]n [C]o [C]c [C]l [C]o [C]n [C]a [C]l B-protein 
anti-estrogen [C]a [C]n [C]t [C]i [C]- [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n I-protein 
receptor [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r I-protein 
antibody [C]a [C]n [C]t [C]i [C]b [C]o [C]d [C]y E-protein 
( [C]( O 
anti-ER [C]a [C]n [C]t [C]i [C]- [C]E [C]R B-protein 
MAb [C]M [C]A [C]b E-protein 
) [C]) O 
using [C]u [C]s [C]i [C]n [C]g O 
both [C]b [C]o [C]t [C]h O 
immunofluorescence [C]i [C]m [C]m [C]u [C]n [C]o [C]f [C]l [C]u [C]o [C]r [C]e [C]s [C]c [C]e [C]n [C]c [C]e O 
and [C]a [C]n [C]d O 
immunoperoxidase [C]i [C]m [C]m [C]u [C]n [C]o [C]p [C]e [C]r [C]o [C]x [C]i [C]d [C]a [C]s [C]e O 
techniques [C]t [C]e [C]c [C]h [C]n [C]i [C]q [C]u [C]e [C]s O 
. [C]. O 

Double [C]D [C]o [C]u [C]b [C]l [C]e O 
immunostaining [C]i [C]m [C]m [C]u [C]n [C]o [C]s [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
with [C]w [C]i [C]t [C]h O 
the [C]t [C]h [C]e O 
anti-ER [C]a [C]n [C]t [C]i [C]- [C]E [C]R B-protein 
MAb [C]M [C]A [C]b E-protein 
and [C]a [C]n [C]d O 
with [C]w [C]i [C]t [C]h O 
specific [C]s [C]p [C]e [C]c [C]i [C]f [C]i [C]c B-protein 
MAb [C]M [C]A [C]b E-protein 
to [C]t [C]o O 
detect [C]d [C]e [C]t [C]e [C]c [C]t O 
different [C]d [C]i [C]f [C]f [C]e [C]r [C]e [C]n [C]t O 
macrophage [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e B-protein 
antigens [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]s E-protein 
( [C]( O 
Ber-MAC3 [C]B [C]e [C]r [C]- [C]M [C]A [C]C [C]3 S-protein 
, [C], O 
MAC387 [C]M [C]A [C]C [C]3 [C]8 [C]7 S-protein 
, [C], O 
CD68 [C]C [C]D [C]6 [C]8 S-protein 
) [C]) O 
and [C]a [C]n [C]d O 
CD8+ [C]C [C]D [C]8 [C]+ B-cell_line 
T [C]T I-cell_line 
cell [C]c [C]e [C]l [C]l I-cell_line 
subsets [C]s [C]u [C]b [C]s [C]e [C]t [C]s E-cell_line 
( [C]( O 
CD29+ [C]C [C]D [C]2 [C]9 [C]+ S-cell_line 
, [C], O 
CD45RO+ [C]C [C]D [C]4 [C]5 [C]R [C]O [C]+ S-cell_line 
and [C]a [C]n [C]d O 
CD29- [C]C [C]D [C]2 [C]9 [C]- S-cell_line 
, [C], O 
CD45RO- [C]C [C]D [C]4 [C]5 [C]R [C]O [C]- S-cell_line 
) [C]) O 
was [C]w [C]a [C]s O 
performed [C]p [C]e [C]r [C]f [C]o [C]r [C]m [C]e [C]d O 
. [C]. O 

RESULTS [C]R [C]E [C]S [C]U [C]L [C]T [C]S O 
. [C]. O 

Higher [C]H [C]i [C]g [C]h [C]e [C]r O 
affinity [C]a [C]f [C]f [C]i [C]n [C]i [C]t [C]y O 
EBS [C]E [C]B [C]S O 
were [C]w [C]e [C]r [C]e O 
found [C]f [C]o [C]u [C]n [C]d O 
mostly [C]m [C]o [C]s [C]t [C]l [C]y O 
in [C]i [C]n O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
cell [C]c [C]e [C]l [C]l O 
fractions [C]f [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
of [C]o [C]f O 
either [C]e [C]i [C]t [C]h [C]e [C]r O 
RA [C]R [C]A O 
or [C]o [C]r O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
synovial [C]s [C]y [C]n [C]o [C]v [C]i [C]a [C]l O 
tissues [C]t [C]i [C]s [C]s [C]u [C]e [C]s O 
( [C]( O 
28 [C]2 [C]8 O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
33 [C]3 [C]3 O 
) [C]) O 
. [C]. O 

These [C]T [C]h [C]e [C]s [C]e O 
EBS [C]E [C]B [C]S O 
were [C]w [C]e [C]r [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
to [C]t [C]o O 
a [C]a O 
lesser [C]l [C]e [C]s [C]s [C]e [C]r O 
extent [C]e [C]x [C]t [C]e [C]n [C]t O 
in [C]i [C]n O 
soluble [C]s [C]o [C]l [C]u [C]b [C]l [C]e O 
cell [C]c [C]e [C]l [C]l O 
fractions [C]f [C]r [C]a [C]c [C]t [C]i [C]o [C]n [C]s O 
( [C]( O 
11 [C]1 [C]1 O 
of [C]o [C]f O 
the [C]t [C]h [C]e O 
33 [C]3 [C]3 O 
) [C]) O 
. [C]. O 

Immunostaining [C]I [C]m [C]m [C]u [C]n [C]o [C]s [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
showed [C]s [C]h [C]o [C]w [C]e [C]d O 
the [C]t [C]h [C]e O 
estrogen [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n B-cell_type 
receptor-positive [C]r [C]e [C]c [C]e [C]p [C]t [C]o [C]r [C]- [C]p [C]o [C]s [C]i [C]t [C]i [C]v [C]e I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
to [C]t [C]o O 
be [C]b [C]e O 
the [C]t [C]h [C]e O 
macrophage-like [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]- [C]l [C]i [C]k [C]e B-cell_type 
synoviocytes [C]s [C]y [C]n [C]o [C]v [C]i [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
and [C]a [C]n [C]d O 
the [C]t [C]h [C]e O 
CD8+ [C]C [C]D [C]8 [C]+ S-cell_line 
, [C], O 
CD29+ [C]C [C]D [C]2 [C]9 [C]+ B-cell_line 
T [C]T I-cell_line 
cells [C]c [C]e [C]l [C]l [C]s E-cell_line 
both [C]b [C]o [C]t [C]h O 
in [C]i [C]n O 
RA [C]R [C]A O 
and [C]a [C]n [C]d O 
in [C]i [C]n O 
control [C]c [C]o [C]n [C]t [C]r [C]o [C]l O 
synovial [C]s [C]y [C]n [C]o [C]v [C]i [C]a [C]l O 
tissues [C]t [C]i [C]s [C]s [C]u [C]e [C]s O 
. [C]. O 

Higher [C]H [C]i [C]g [C]h [C]e [C]r O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
content [C]c [C]o [C]n [C]t [C]e [C]n [C]t O 
of [C]o [C]f O 
EBS [C]E [C]B [C]S O 
was [C]w [C]a [C]s O 
consistent [C]c [C]o [C]n [C]s [C]i [C]s [C]t [C]e [C]n [C]t O 
with [C]w [C]i [C]t [C]h O 
more [C]m [C]o [C]r [C]e O 
intense [C]i [C]n [C]t [C]e [C]n [C]s [C]e O 
nuclear [C]n [C]u [C]c [C]l [C]e [C]a [C]r O 
staining [C]s [C]t [C]a [C]i [C]n [C]i [C]n [C]g O 
of [C]o [C]f O 
synoviocytes [C]s [C]y [C]n [C]o [C]v [C]i [C]o [C]c [C]y [C]t [C]e [C]s S-cell_type 
and [C]a [C]n [C]d O 
T [C]T B-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
. [C]. O 

CONCLUSION [C]C [C]O [C]N [C]C [C]L [C]U [C]S [C]I [C]O [C]N O 
. [C]. O 

It [C]I [C]t O 
is [C]i [C]s O 
conceivable [C]c [C]o [C]n [C]c [C]e [C]i [C]v [C]a [C]b [C]l [C]e O 
that [C]t [C]h [C]a [C]t O 
the [C]t [C]h [C]e O 
immunomodulatory [C]i [C]m [C]m [C]u [C]n [C]o [C]m [C]o [C]d [C]u [C]l [C]a [C]t [C]o [C]r [C]y O 
activity [C]a [C]c [C]t [C]i [C]v [C]i [C]t [C]y O 
exerted [C]e [C]x [C]e [C]r [C]t [C]e [C]d O 
by [C]b [C]y O 
estrogens [C]e [C]s [C]t [C]r [C]o [C]g [C]e [C]n [C]s O 
is [C]i [C]s O 
at [C]a [C]t O 
least [C]l [C]e [C]a [C]s [C]t O 
partly [C]p [C]a [C]r [C]t [C]l [C]y O 
mediated [C]m [C]e [C]d [C]i [C]a [C]t [C]e [C]d O 
through [C]t [C]h [C]r [C]o [C]u [C]g [C]h O 
their [C]t [C]h [C]e [C]i [C]r O 
interaction [C]i [C]n [C]t [C]e [C]r [C]a [C]c [C]t [C]i [C]o [C]n O 
with [C]w [C]i [C]t [C]h O 
EBS [C]E [C]B [C]S O 
that [C]t [C]h [C]a [C]t O 
are [C]a [C]r [C]e O 
present [C]p [C]r [C]e [C]s [C]e [C]n [C]t O 
on [C]o [C]n O 
macrophage-like [C]m [C]a [C]c [C]r [C]o [C]p [C]h [C]a [C]g [C]e [C]- [C]l [C]i [C]k [C]e B-cell_type 
synoviocytes [C]s [C]y [C]n [C]o [C]v [C]i [C]o [C]c [C]y [C]t [C]e [C]s E-cell_type 
, [C], O 
functioning [C]f [C]u [C]n [C]c [C]t [C]i [C]o [C]n [C]i [C]n [C]g O 
as [C]a [C]s O 
antigen-processing [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]- [C]p [C]r [C]o [C]c [C]e [C]s [C]s [C]i [C]n [C]g B-cell_type 
and [C]a [C]n [C]d I-cell_type 
antigen-presenting [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]- [C]p [C]r [C]e [C]s [C]e [C]n [C]t [C]i [C]n [C]g I-cell_type 
cells [C]c [C]e [C]l [C]l [C]s E-cell_type 
, [C], O 
and [C]a [C]n [C]d O 
on [C]o [C]n O 
antigen-experienced [C]a [C]n [C]t [C]i [C]g [C]e [C]n [C]- [C]e [C]x [C]p [C]e [C]r [C]i [C]e [C]n [C]c [C]e [C]d B-cell_line 
( [C]( I-cell_line 
memory [C]m [C]e [C]m [C]o [C]r [C]y I-cell_line 
) [C]) I-cell_line 
CD8+ [C]C [C]D [C]8 [C]+ I-cell_line 
T [C]T I-cell_line 
lymphocytes [C]l [C]y [C]m [C]p [C]h [C]o [C]c [C]y [C]t [C]e [C]s E-cell_line 
( [C]( O 
CD29+ [C]C [C]D [C]2 [C]9 [C]+ S-cell_line 
, [C], O 
CD45RO+ [C]C [C]D [C]4 [C]5 [C]R [C]O [C]+ S-cell_line 

